2017-03-24,Ratings Changes Today
2017-03-23,Advanced Accelerator Applications Reports 23% Sales Growth For Fiscal 2016; Continued NETSPOT® Launch Success
2017-03-15,Advanced Accelerator Applications To Announce Full-Year 2016 Financial Results On March 23
2017-03-06,Advanced Accelerator Applications Announces Presentation Of Quality Of Life Findings From NETTER-1 Phase III Study At ENETS
2017-03-01,Advanced Accelerator Applications Announces Addition Of NETSPOT® To National Comprehensive Cancer Network® Guidelines For Evaluation Of NETs
2017-01-12,Advanced Accelerator Applications Announces New England Journal Of Medicine Publication Of Lutathera® NETTER-1 Phase III Results
2017-01-09,Advanced Accelerator Applications CEO Provides Progress Report On Corporate Developments Of 2016; Asserts Confidence In Ability To Address FDA Comments On Lutathera® NDA
2017-01-04,Advanced Accelerator Applications To Present At 35th Annual J.P. Morgan Healthcare Conference
2016-12-21,Advanced Accelerator Applications Receives Complete Response Letter From FDA For Lutathera®, An Investigational Treatment For Neuroendocrine Tumors
2016-12-15,Advanced Accelerator Applications Announces European Commission Approval Of SomaKit TOC™
2016-12-13,Ratings Changes Today
2016-12-08,Advanced Accelerator Applications Announces CMS Pass-Through Reimbursement Code For Its First FDA Approved Drug NETSPOT®
2016-11-28,Advanced Accelerator Applications Reports 15.4% Sales Growth In The Third Quarter Of 2016 And Feedback From The FDA For Lutathera®, An Investigational Treatment For Neuroendocrine Tumors
2016-11-23,Advanced Accelerator Applications To Announce Third Quarter And Nine-Month 2016 Financial Results On November 28
2016-11-02,Advanced Accelerator Applications Announces Swiss Marketing Authorization For Two PET Diagnostic Products
2016-10-17,Advanced Accelerator Applications Announces Positive EMA Opinion On Application For SomaKit TOC
2016-10-11,Advanced Accelerator Applications Announces Presentations On Lutathera® NETTER-1 Phase III And NeoBOMB1 At EANM
2016-10-05,Advanced Accelerator Applications S.A. Announces Pricing Of $150 Million Public Offering Of American Depositary Shares
2016-10-04,Advanced Accelerator Applications S.A. Announces Proposed Public Offering Of American Depositary Shares
2016-09-22,EMA Prematurely Announced Opinion On SomaKit TOC® Kit Application
2016-09-20,Advanced Accelerator Applications Announces Revised EMA Review Timeline For Lutathera®
2016-09-16,Advanced Accelerator Applications Announces Positive EMA Opinion On Application For SomaKit TOC Kit For Radiopharmaceutical Preparation Of Gallium (Ga 68) Edotreotide For Gastroenteropancreatic Neuroendocrine Tumor Detection
2016-09-06,Advanced Accelerator Applications Announces Two Phase II Studies Evaluating 99MrhAnnexin V-128 Imaging In Cardiovascular And Cardio-Oncology Indications At University Of Ottawa Heart Institute And Ottawa Hospital
2016-08-31,Advanced Accelerator Applications Reports 24.4% Sales Growth In The Second Quarter Of 2016
2016-08-03,Advanced Accelerator Applications Announces First Administration Of NETSPOT™ At Holy Name Medical Center
2016-08-02,Advanced Accelerator Applications Announces Clinical Trial Agreement With National Cancer Institute For Study Of Lutathera In Patients With Inoperable Pheochromocytoma And Paraganglioma
2016-07-26,Advanced Accelerator Applications Announces Opening Of First U.S. Manufacturing Facility; Preparation For Anticipated Lutathera Launch
2016-06-27,Advanced Accelerator Applications Announces FDA Priority Review For Lutathera
2016-06-10,Advanced Accelerator Applications Expands U.S. NETSPOT™ Supply Chain With Two Additional Radiopharmacy Networks
2016-06-09,Cardinal Health To Prepare NETSPOT™ Doses For Advanced Accelerator Applications
2016-06-07,Advanced Accelerator Applications Announces Expansion Of Theranostic Pipeline With NeoBOMB1
2016-06-02,Advanced Accelerator Applications Announces FDA Approval Of NETSPOT™ (Somakit-TATE), A Kit For The Preparation Of Gallium Ga 68 Dotatate For Neuroendocrine Tumor Detection
2016-05-31,Advanced Accelerator Applications Reports 29.6% Sales Growth In The First Quarter Of 2016
2016-05-26,Advanced Accelerator Applications Expands Its Presence In Germany With Strategic Acquisition Of Two Production Sites
2016-05-26,Advanced Accelerator Applications Appoints Francois Nader, M.D., To Board Of Directors
2016-05-23,Advanced Accelerator Applications Preparing For Lutathera Launch By Scaling Up Production In Ivrea, Italy
2016-05-18,ITEL Signs Agreement With Advanced Accelerator Applications To Commercialize F-18 Radiopharmaceuticals In Southern Italy
2016-04-29,Advanced Accelerator Applications Reports 26.8% Sales Growth In 2015 And Continues To Show Significant Clinical Progress Across Both Therapeutic And Diagnostic Platforms
2016-04-22,Advanced Accelerator Applications To Announce Fourth Quarter And Year End 2015 Financial Results On April 29, 2016
2016-03-23,Advanced Accelerator Applications Provides Lutathera Update
2016-02-25,Advanced Accelerator Applications Provides Update On Lutathera And Somakit
2016-01-26,Zevacor To Produce SomaKit-TATE Doses For AAA
2016-01-11,Advanced Accelerator Applications Signs Exclusive License Agreement With Johns Hopkins University To Develop PSMA Receptor Ligand In Prostate Cancer
2016-01-10,Advanced Accelerator Applications To Present New Data From Lutathera NETTER-1 Phase 3 Study At 2016 Gastrointestinal Cancer Symposium (ASCO GI)
2016-01-07,Advanced Accelerator Applications Acquires The IDB Group
2015-12-10,Advanced Accelerator Applications Reports 37% Growth In Sales For The Third Quarter Of 2015 And 32% Growth In Sales For The First Nine Months Of 2015
,
,
,
,
2017-03-23,Arbutus Announces Appointment Of Daniel Burgess To Board Of Directors
2017-03-21,Arbutus Announces Year-End 2016 Financial Results
2017-03-16,Arbutus Licenses LNP Delivery Technology To Alexion For Use In Single Messenger RNA Product Candidate
2017-03-06,Arbutus To Participate In Upcoming Investor Conferences
2017-02-09,Arbutus To Participate In Upcoming Investor Conferences
2017-02-08,Arbutus Is Granted A Pre-trial Injunction Restraining Acuitas From Entering Into Agreements Sublicensing Arbutus LNP Technology
2016-12-12,Arbutus Provides Additional Data From The ARB-1467 Phase II Clinical Trial In HBV Patients
2016-11-14,Arbutus Presents HBV Drug Combination Studies At AASLD
2016-11-03,Arbutus Provides Corporate Update And Announces Third Quarter 2016 Financial Results
2016-10-19,Patrick Machado Joins Board Of Directors Of Roivant Sciences
2016-10-03,Arbutus Recognizes Liver Cancer Awareness Month With Grant To Support The Hepatitis B Foundation's Patient Storytelling Campaign
2016-10-01,Arbutus To Present HBV Data At The 2016 AASLD Liver Meeting
2016-09-29,Arbutus Reports Interim Multi-Dose Results From Phase II Clinical Trial Of ARB-1467 In Patients With Chronic HBV Infection
2016-09-13,Arbutus' Chief Scientific Officer, Dr. Michael J. Sofia, Awarded The 2016 Lasker~DeBakey Clinical Medical Research Award
2016-08-10,Arbutus To Present At The 2016 Wedbush PacGrow Healthcare Conference
2016-08-08,Arbutus Announces Issuance Of Broad New US Patent For LNP Delivery Technology
2016-08-04,Arbutus Provides Corporate Update And Announces Second Quarter 2016 Financial Results
2016-07-19,Arbutus Reports Topline Results From TKM-PLK1 HCC Clinical Trial
2016-07-18,Arbutus To Present Data On New LNP Formulations For Delivery Of MRNA At The 2016 Controlled Release Society Conference
2016-07-13,Roivant Sciences Appoints Professor Andrew Lo, PhD As Independent Director
2016-06-30,Arbutus To Present MRNA Delivery Data At The 32nd Annual Meeting Of The Japan Society Of Drug Delivery System
2016-06-03,Arbutus To Participate In Upcoming Investor Conferences
2016-06-01,Arbutus To Present At The 5th Antiviral Drugs Research And Development Conference
2016-05-04,Arbutus Provides Corporate Update And Announces First Quarter 2016 Financial Results
2016-05-03,Arbutus Expands HBV Pipeline
2016-04-29,Arbutus To Provide A Corporate Update And Release First Quarter 2016 Financial Results
2016-04-27,Arbutus To Participate In Upcoming Investor Conferences
2016-04-22,Arbutus Presents Data From Combination Activity Studies Of HBV Drug Candidates
2016-04-21,Arbutus Announces Planned Executive Departure
2016-04-14,Arbutus Presents Data On HBV Capsid Assembly Inhibitor AB-423 At EASL 2016
2016-03-30,Arbutus To Present Preclinical HBV Data At EASL 2016
2016-03-09,Arbutus Announces Year-End 2015 Financial Results
2016-03-08,Arbutus Appoints Dr. Elizabeth Howard Executive Vice President And General Counsel
2016-03-03,Arbutus Biopharma To Participate In Upcoming Investor Conferences
2016-02-04,Arbutus Biopharma To Participate In Upcoming Investor Conferences
2016-01-20,Kuros Biosurgery Holding Ltd. Closes Merger With Cytos Biotechnology Ltd. Which Is Renamed Kuros Biosciences Ltd.
2016-01-10,Arbutus Provides A Corporate Update And Outlines 2016 Milestones
2015-11-05,Arbutus Biopharma Announces Third Quarter 2015 Financial Results
2015-10-28,Arbutus Provides An HBV Pipeline Update
2015-10-15,Dr. Michael J. Sofia, Arbutus' Chief Scientific Officer, Named Economist's 2015 Innovation Award Winner In The Bioscience Category
2015-10-06,Arbutus Biopharma Presents Preclinical Data At The 2015 International Meeting On Molecular Biology Of Hepatitis B Viruses
2015-10-01,Arbutus To Present TKM-HBV Data At The 2015 AASLD Liver Meeting
2015-09-09,Arbutus To Present At The Baird 2015 Healthcare Conference
2015-09-09,Arbutus Biopharma Enters Oversold Territory (ABUS)
2015-09-03,5 Stocks Under $10 Set to Soar
2015-08-25,Arbutus Announces Initiation Of Patient Dosing In The TKM-PLK1 HCC Expansion Cohort
2015-08-07,Arbutus To Present At 2015 Wedbush PacGrow Healthcare Conference
2015-08-06,Arbutus Biopharma Is Now Oversold (ABUS)
2015-08-05,Arbutus Biopharma Announces Second Quarter 2015 Financial Results
,
,
,
,
2017-03-01,4 Smaller Biotech Names Worth Researching
2017-02-28,ACADIA Pharmaceuticals Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2016
2017-02-27,ACADIA Pharmaceuticals To Present At The Cowen And Company 37th Annual Health Care Conference On March 6, 2017
2017-02-21,ACADIA Pharmaceuticals To Announce Fourth Quarter And Full Year 2016 Financial Results On February 28, 2017
2017-02-20,Your Burning Biotech Questions Answered
2017-02-17,Your Burning Biotech Questions Answered
2017-02-17,Sage Therapeutics Leads Biotech Movers on False Takeout Rumors
2017-02-17,Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta
2017-02-15,Biotech Buoyed by Deal Talk
2017-02-10,Welcome to the Small-Cap Biotech Mailbag!
2017-02-03,Acadia Pops on Takeout Rumors, But Don't Buy on M&A Just Yet
2017-01-29,The Next Target in Biotech Land
2017-01-27,The Next Target in Biotech Land
2017-01-23,Allergan, Apple, Facebook: Doug Kass' Views
2017-01-16,Allergan, Citigroup, Apple: Doug Kass' Views
2017-01-10,4 Biotech Names That Could Be M&amp;A Targets
2017-01-05,3 Biotechs Screaming 'Takeover Target'
2017-01-03,Hey, What About the Transports?
2017-01-03,ACADIA Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference On January 10, 2017
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2017-01-02,Starbucks, Allergan, Amazon: Doug Kass' Views
2016-12-20,Acadia Pharmaceuticals Soars After Positive Alzheimer's Disease Study
2016-12-20,Acadia Pharma Takes Low Road to Justify Drug Push Into Alzheimer's Psychosis
2016-12-20,ACADIA Pharmaceuticals Announces Positive Top-Line Results From Phase II Study Of Pimavanserin For Alzheimer's Disease Psychosis
2016-12-19,Allergan, Apple, Oakland Capital: Doug Kass' Views
2016-12-12,This Rally May Not Be Done, but It's Close
2016-12-05,Apple, Starbucks, Cisco: Doug Kass' Views
2016-12-01,ACADIA Pharmaceuticals Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Major Depressive Disorder
2016-11-30,Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield
2016-11-28,Home Depot, Lowe's, Best Buy: Doug Kass' Views
2016-11-25,Apple Continues to Underperform; the Market Is Resistant: Best of Kass
2016-11-25,Biotech Hits an Inflection Point
2016-11-22,4 Promising Small Biotechs to Watch in 2017
2016-11-18,2 Small-Cap Biotech Buyout Targets
2016-11-17,Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios
2016-11-15,ACADIA Pharmaceuticals Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Negative Symptoms Of Schizophrenia
2016-11-08,Acadia Shares Soar as Nuplazid Sales Easily Top Estimates
2016-11-08,Analysts' Actions -- Bank of America, Depomed, Hertz, AT&T and More
2016-11-07,ACADIA Pharmaceuticals Reports Third Quarter 2016 Financial Results
2016-11-07,Cisco, Allergan, Facebook: Doug Kass' Views
2016-11-03,ACADIA Pharmaceuticals Initiates Phase III Trial Of Pimavanserin For Adjunctive Treatment In Patients With Schizophrenia
2016-11-01,Small Biotechs on My Shopping List
2016-11-01,ACADIA Pharmaceuticals To Announce Third Quarter 2016 Financial Results On November 7, 2016
2016-10-31,ACADIA Pharmaceuticals Initiates Phase II Study Of Pimavanserin In Alzheimer's Disease Agitation
2016-10-24,Schlumberger, Amazon, Apple: Doug Kass' Views
2016-10-20,Biotech Bargain Bin Bursts With Bounty
2016-10-11,ACADIA Pharmaceuticals Receives California Life Sciences Association's 2016 Pantheon DiNA Award For Outstanding Therapeutic Product For NUPLAZID™
2016-10-03,J.C.Penney, Wells Fargo, Deutsche Bank: Doug Kass' Views
2016-09-20,ACADIA Pharmaceuticals To Present At The Ladenburg Thalmann 2016 Healthcare Conference On September 27, 2016
2016-09-19,ACADIA Pharmaceuticals Sponsors National Parkinson Foundation's Caregiver Summit
2016-09-14,These 5 Biotech Stocks Are Ready for a Volatility Break
2016-09-11,Don't Be Fooled, There's Still Complacency Here
2016-09-09,5 Stocks to Trade for Big Breakout Gains
2016-09-06,ACADIA Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference On September 12, 2016
2016-08-24,Todd S. Young, Executive Vice President, Chief Financial Officer Of ACADIA Pharmaceuticals (Photo: Business Wire)
2016-08-23,ACADIA Pharmaceuticals Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares
2016-08-15,Tracking Bullish and Bearish Reversals
2016-08-12,Biotech Stock Mailbag: Heron, Acadia, Exact Sciences, Sarepta
2016-08-09,ACADIA Pharmaceuticals Prices Public Offering Of Common Stock
2016-08-08,ACADIA Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2016-08-04,Highlighted Post-Market Laggard: ACADIA Pharmaceuticals (ACAD)
2016-08-04,ACADIA Pharmaceuticals Reports Second Quarter 2016 Financial Results
2016-08-02,Biotech Pop-Up Party in Full Swing
2016-08-02,It's 'All Systems Go' for Biotech
2016-07-29,ACADIA Pharmaceuticals To Announce Second Quarter 2016 Financial Results On August 4, 2016
2016-07-22,Biogen Should Either a Buyer or a Seller Be
2016-07-21,Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal
2016-07-21,Investors Scour Big Pharma M&amp;A Scene for Next Big Takeover
2016-07-20,Strong On High Relative Volume: ACADIA Pharmaceuticals (ACAD)
2016-06-27,ACADIA Pharmaceuticals Added To Large-Cap Russell 1000 Market Index
2016-06-22,Analysts' Actions -- Domino's, McDonald's, Priceline, Tesla and More
2016-06-16,ACADIA Pharmaceuticals To Present At The JMP Securities Life Sciences Conference On June 21, 2016
2016-06-03,Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Post-Market Leader Stock
2016-06-02,4 Possible Acquisition Targets in Biotech
2016-06-01,ACADIA Pharmaceuticals To Present At The Goldman Sachs 37th Annual Global Healthcare Conference On June 8, 2016
2016-05-31,ACADIA Pharmaceuticals Announces NUPLAZID™ (pimavanserin) Is Now Available For The Treatment Of Hallucinations And Delusions Associated With Parkinson's Disease Psychosis
2016-05-26,'Mad Money' Lightning Round: I'm Buying Buffett's Berkshire Hathaway
2016-05-25,Jim Cramer's 'Mad Money' Recap: Own This Rally and Buy These Stocks
2016-05-17,ACADIA Pharmaceuticals (ACAD) Is Today's Storm The Castle Stock
2016-05-17,Biotech Is Showing Some Bargains
2016-05-12,'Mad Money' Lightning Round: I'm Sticking With Panera Forever
2016-05-11,Jim Cramer's 'Mad Money' Recap: These Stocks Have Staying Power
2016-05-09,Acadia Pharmaceutical's Nuplazid Pricing Is Good News for Shareholders
2016-05-05,Acadia (ACAD) Stock Slides in After-Hours Trading on Q1 Financial Results
2016-05-05,ACADIA Pharmaceuticals (ACAD) Lags In Post-Market Trading
2016-05-05,ACADIA Pharmaceuticals Reports First Quarter 2016 Financial Results
2016-05-05,Acadia Drug Approval May Entice Biogen, Teva as Buyers
2016-05-04,Acadia Pharmaceuticals Stock Has Fallen Too Far Recently
2016-05-04,ACADIA Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference On May 11, 2016
2016-05-03,Why Acadia Pharma's First Drug Approval Isn't Moving Stock Higher
2016-05-03,8 Stocks Spiking on Big Volume
2016-05-03,Analysts' Actions -- Amazon, Walmart, Acadia, International Paper and More
2016-05-02,Investors Await Pricing of Acadia's Recently Approved Parkinson's Drug
2016-05-02,ACADIA Pharmaceuticals To Announce First Quarter 2016 Financial Results On May 5, 2016
2016-05-02,4 Possible Biotech M&amp;A Targets
2016-05-02,ACADIA Pharmaceuticals (ACAD) Shows Signs Of Being Water-Logged And Getting Wetter
2016-05-02,ACADIA Pharmaceuticals (ACAD) Stock Down Despite Nuplazid Approval
2016-04-29,NUPLAZID™ (pimavanserin) Bottle (Photo: Business Wire)
2016-04-21,3 Red Flags to Lightly Consider
2016-04-14,ACADIA Pharmaceuticals (ACAD) Flagged As Strong On High Volume
2016-04-11,Facebook, Ford and General Motors: Doug Kass' Views
2016-04-07,'Mad Money' Lightning Round: Take Costco Over Walmart
2016-04-06,Jim Cramer's 'Mad Money' Recap: Maybe the Government Did Some Good After All
2016-04-06,ACADIA Pharmaceuticals To Present At The 15th Annual Needham Healthcare Conference On April 12, 2016
2016-04-03,Biotech Stock Mailbag: Intercept, Acadia, Keryx, Galena
2016-04-01,Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Post-Market Leader Stock
2016-03-31,Buy Acadia, Alkermes, Starbucks and Verizon, Says Mott Capital Portfolio Manager
2016-03-31,Should Acadia, Alkermes Shares be at the Top of Your Buy List?
2016-03-31,Revisiting 3 Promising Small Biotechs
2016-03-31,Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Strong On High Relative Volume Stock
2016-03-31,Acadia's Parkinson's drug Nuplazid clears key hurdle
2016-03-30,Why Acadia (ACAD) Stock is Still Soaring Today
2016-03-30,4 Big-Volume Stocks to Trade for Big Gains
2016-03-30,Acadia (ACAD) Stock Skyrockets, Parkinson's Disease Drug Backed by FDA Advisory Panel
2016-03-29,FDA Advisory Committee Votes 12 To 2 That Benefits Of ACADIA Pharmaceuticals' NUPLAZID™ (Pimavanserin) For The Treatment Of Psychosis Associated With Parkinson's Disease Outweigh The Risks
2016-03-29,Acadia Pharma FDA Advisory Panel Live Blog
2016-03-29,ACADIA Pharmaceuticals Stock Trading Halted Today
2016-03-28,7 Stocks Seeing Big Volume Today -- and How You Should Trade Them Now
2016-03-28,3 Drugs Stocks Driving The Industry Higher
2016-03-28,Acadia Pharmaceuticals (ACAD) Stock Soars Ahead of Tuesday Panel
2016-03-28,ACADIA Pharmaceuticals (ACAD): Heavy Pre-Market Activity
2016-03-28,U.S. Futures Have Strong Start to Week
2016-03-28,Acadia's Parkinson's Drug Hit With Critical FDA Review Ahead of Tuesday Panel
2016-03-24,Biotech Stock Mailbag: How to Spot Red Flags in Clinical Trial Data
2016-03-23,ACADIA Pharmaceuticals (ACAD) Highlighted As Today's Perilous Reversal Stock
2016-03-11,There Are Reasons for Acadia Investors to Be Optimistic About Nuplazid and the Company
2016-03-07,Tesla, Amazon and Netflix: Doug Kass' Views
2016-03-06,Biotech Stock Mailbag: Acadia, Relypsa, Celator
2016-03-04,Small-Cap Friday: ACADIA Pharmaceuticals
2016-03-04,Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's "Perilous Reversal" Stock
2016-03-01,ACADIA Pharmaceuticals (ACAD) Is Today's Dead Cat Bounce Stock
2016-03-01,ACADIA Pharmaceuticals To Present At The Cowen And Company 36th Annual Health Care Conference On March 8, 2016
2016-02-29,ACADIA Pharmaceuticals Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2015
2016-02-23,ACADIA Pharmaceuticals To Announce Fourth Quarter And Full Year 2015 Financial Results On February 29, 2016
2016-02-19,What Carl Icahn Is Doing; Biotech Breakout: Best of Kass
2016-02-15,JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views
2016-02-11,Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Weak On High Relative Volume Stock
2016-02-03,ACADIA Pharmaceuticals To Present At The LEERINK Partners 5th Annual Global Healthcare Conference On February 10, 2016
2016-01-29,ACADIA Pharmaceuticals Announces FDA Advisory Committee Meeting To Review NUPLAZID™ (Pimavanserin) For The Treatment Of Parkinson's Disease Psychosis
2016-01-29,Today's Dead Cat Bounce Stock: ACADIA Pharmaceuticals (ACAD)
2016-01-25,ACADIA Pharmaceuticals Appoints James (Randy) R. Owen, M.D., As Senior Vice President, Clinical Development And Chief Medical Officer
2016-01-22,Strong On High Volume: ACADIA Pharmaceuticals (ACAD)
2016-01-22,Analysts' Actions -- Alaska Air, Avon, Bristol-Myers, Goldman Sachs and More
2016-01-14,Today's Dead Cat Bounce Stock Is ACADIA Pharmaceuticals (ACAD)
2016-01-13,5 Stocks Insiders Love Right Now
2016-01-12,Strong On High Relative Volume: ACADIA Pharmaceuticals (ACAD)
2016-01-11,ACADIA Pharmaceuticals Appoints Jim Daly To Board Of Directors
2016-01-07,ACADIA Pharmaceuticals To Present At The 34th Annual J.P. Morgan Healthcare Conference On January 12, 2016
2016-01-06,ACADIA Pharmaceuticals Prices Public Offering Of Common Stock
2016-01-05,ACADIA Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2015-12-15,ACADIA Pharmaceuticals Appoints Julian C. Baker To Board Of Directors
2015-12-14,ACADIA Pharmaceuticals (ACAD) Is Today's Dead Cat Bounce Stock
2015-11-30,ACADIA Pharmaceuticals Appoints Srdjan (Serge) Stankovic, M.D., M.S.P.H., As Executive Vice President, Head Of Research And Development
2015-11-30,ACADIA Pharmaceuticals Appoints Edmund P. Harrigan, M.D., To Board Of Directors
2015-11-11,Unilever, Visa and NXP Semiconductors Are Superior Stocks, Says Mott Capital Manager
2015-11-11,Visa, Unilever and NXP Semi Are Superior Stocks Says Mott Manager
2015-11-09,Weak On High Volume: ACADIA Pharmaceuticals (ACAD)
2015-11-06,Water-Logged And Getting Wetter: ACADIA Pharmaceuticals (ACAD)
2015-11-05,ACADIA Pharmaceuticals Reports Third Quarter 2015 Financial Results
2015-11-04,ACADIA Pharmaceuticals To Present At The 24th Annual Credit Suisse Healthcare Conference On November 10, 2015
2015-11-02,3 Stocks Spiking on Big Volume
2015-11-02,ACADIA Pharmaceuticals Announces FDA Priority Review Of NUPLAZID™ (Pimavanserin) New Drug Application For Parkinson's Disease Psychosis
2015-10-29,ACADIA Pharmaceuticals To Announce Third Quarter Financial Results On November 5, 2015
2015-10-29,Acadia's New Drug Could Have Potential for Investors
2015-09-24,Interesting ACAD Put And Call Options For November 20th
2015-09-22,ACADIA Pharmaceuticals To Present At The Ladenburg Thalmann 2015 Healthcare Conference On September 29, 2015
2015-09-21,Water-Logged And Getting Wetter: ACADIA Pharmaceuticals (ACAD)
2015-09-09,Perilous Reversal Watch: ACADIA Pharmaceuticals (ACAD)
2015-09-03,Acadia Pharmaceuticals (ACAD) Stock Climbs on Drug Application for Parkinson's Treatment
2015-09-03,Steve Davis, Chief Executive Officer Of ACADIA Pharmaceuticals (Photo: Business Wire)
2015-09-03,ACADIA Pharmaceuticals Submits New Drug Application For NUPLAZID™ For The Treatment Of Parkinson's Disease Psychosis
2015-08-21,Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Post-Market Leader Stock
2015-08-07,Today's Water-Logged And Getting Wetter Stock: ACADIA Pharmaceuticals (ACAD)
2015-08-07,Analysts' Actions -- Intel, Texas Instruments and Viacom
2015-08-06,ACADIA Pharmaceuticals Reports Second Quarter 2015 Financial Results
2015-08-06,ACADIA Pharmaceuticals Announces Publication Of Data From Its -015 Open Label Safety Study In Parkinson's Disease Psychosis In The Journal Of The American Medical Directors Association
2015-08-05,ACADIA Pharmaceuticals Announces Senior Management Appointments In Manufacturing, Quality, Compliance, Access And Reimbursement And Business Development
2015-07-30,ACADIA Pharmaceuticals To Announce Second Quarter Financial Results On August 6, 2015
2015-07-15,ACADIA Pharmaceuticals (ACAD) Strong On High Relative Volume Today
2015-06-17,ACADIA Pharmaceuticals To Present At The JMP Securities Life Sciences Conference On June 24, 2015
2017-03-23,Ratings Changes Today
2017-03-21,USPTO Grants Composition Of Matter Patent To Achillion For Small Molecule Complement Alternative Pathway Factor D Inhibitors
2017-03-02,These 5 Stocks Under $10 Could Explode Up Soon
2017-02-28,Achillion Pharmaceuticals To Support A Natural History Study Of C3 Glomerulopathy, A Rare Renal Disorder, Conducted By Experts At Imperial College London
2017-02-24,Will Insiders Be Tempted To Buy More ACHN At The New 52-Week Low?
2017-02-24,4 Biotech Stocks on the Move
2017-02-24,Biotech Movers: Cempra Flys High On Phase Three Results
2017-02-23,Achillion Reports 2016 Fourth Quarter And Year-End Financial Results
2017-02-13,Achillion To Present At The Leerink Partners 6th Annual Global Healthcare Conference
2017-02-02,Premarket Biotech Movers: Cytokinetics, Achillion, Qiagen
2017-01-25,Notable Wednesday Option Activity: ACHN, RH, AJRD
2017-01-04,Don't Be Complacent About Complacency
2016-12-28,Achillion Announces Clinical Milestone For The Advancement Of JNJ-4178 In Phase 2B Development For Chronic HCV
2016-12-08,These 5 Stocks Under $10 Could Make You a Lot of Money
2016-12-05,Data Presented At American Society Of Hematology Meeting Demonstrate Potential Advantages Of Factor D Inhibition For The Treatment Of Complement Alternative Pathway-Mediated Diseases
2016-11-30,Achillion Announces Initiation Of Patient Dosing By Janssen In A Global, Short Treatment-Duration Phase 2b Study Of JNJ-4178 In Chronic HCV
2016-11-03,Health Sector Down As Report of Industry Price Collusion Surfaces
2016-11-03,The Great 'ASH16' Abstract Drop Mostly Causes Drug Stocks to Do Same
2016-11-03,Achillion Announces Upcoming Presentations Of Novel Research Into Complement Biology At The 58th Annual Meeting Of The American Society Of Hematology
2016-11-03,Achillion Reports Third Quarter 2016 Financial Results And Provides Update On Clinical Programs
2016-11-02,Achillion To Present At The Credit Suisse 25th Annual Healthcare Conference
2016-10-31,Tax-Loss Selling Offers Stock-Picking Opportunities
2016-10-28,Achillion Pharmaceuticals Becomes Oversold (ACHN)
2016-10-25,First Week of ACHN June 2017 Options Trading
2016-09-23,Achillion Announces 100% SVR12 In The 6-Week And 8-Week Cohorts In Janssen's Phase 2 Trial Evaluating The Triple Combination Treatment Regimen Including Odalasvir, AL-335, And Simeprevir For Genotype 1 Treatment-Naive HCV
2016-09-20,Interesting ACHN Put And Call Options For November 18th
2016-09-09,Achillion Announces 100% SVR Reported In Janssen's Phase 2a Trial Evaluating Triple Combination Of Odalasvir, AL-335, And Simeprevir For Genotype 1 Treatment-Naive HCV
2016-09-06,Achillion Presents Novel Research On Factor D Inhibition At The XXVIth International Complement Workshop
2016-09-01,Achillion To Present At Two Upcoming Investor Conferences
2016-08-11,Achillion Announces Upcoming Presentation Of Interim Phase 2a Results From The Janssen Sponsored Trial Of Odalasvir, AL-335 And Simeprevir At The European Association For The Study Of The Liver (EASL) Special Conference
2016-08-09,Achillion To Present At The 2016 Wedbush PacGrow Healthcare Conference
2016-08-04,Achillion Reports Second Quarter 2016 Financial Results
2016-07-07,ACHN August 26th Options Begin Trading
2016-07-07,Achillion Pharmaceuticals (ACHN) Stock Up, JMP Upgrades
2016-07-07,Analysts' Actions -- First Solar, Qualcomm, Red Hat, Zions and More
2016-06-23,Interesting ACHN Put And Call Options For August 5th
2016-06-10,Achillion Presents Interim Phase 1 Results For ACH-4471, A Novel Orally-Administered Factor D Inhibitor, At The 21st Congress Of The European Hematology Association
2016-06-01,Achillion To Present At Three Upcoming Investor Conferences
2016-05-19,Achillion Announces Acceptance Of Late Breaking Abstract For ACH-4471 At The 21st Congress Of The European Hematology Association
2016-05-03,Achillion Reports First Quarter 2016 Financial Results And Provides Update On Clinical Programs
2016-04-28,Achillion To Present At The Deutsche Bank 41st Annual Health Care Conference
2016-03-04,Achillion Pharmaceuticals (ACHN) Weak On High Volume Today
2016-03-03,Achillion To Present At Two Upcoming Investor Conferences
2016-02-25,Achillion Reports 2015 Fourth Quarter And Year-End Financial Results
2016-02-11,Achillion Initiates Phase 1 Study Of ACH-4471, First Orally-Administered Small Molecule Complement Factor D Inhibitor
2016-02-08,Achillion To Present At The Leerink Partners 5th Annual Global Healthcare Conference
2016-02-05,Achillion Pharmaceuticals is Now Oversold (ACHN)
2016-02-03,Achillion Announces Appointments Of Martha Manning As General Counsel And Amy Jennings As Head Of Regulatory Affairs
2016-01-26,Achillion Pharmaceuticals (ACHN) Weak On High Volume
2016-01-08,Achillion Pharmaceuticals (ACHN) Flagged As Strong On High Volume
2016-01-04,Achillion Appoints Dr. Joel Barrish As Chief Scientific Officer
2015-12-30,Trade-Ideas: Achillion Pharmaceuticals (ACHN) Is Today's Strong On High Relative Volume Stock
2015-12-16,Achillion Appoints Dr. Frank Verwiel To Board Of Directors
2015-12-14,Achillion Pharmaceuticals (ACHN) Is Today's Dead Cat Bounce Stock
2015-12-05,Achillion Announces Upcoming Oral Presentation At The 57th Annual Meeting Of The American Society Of Hematology And Nomination Of ACH-4471, A Novel Small Molecule Factor D Inhibitor, For Clinical Development
2015-11-23,Nothing for Bears to Get Excited About
2015-11-17,Lilly's Diabetes Drug Makes It a Turner Medical Fund Pick
2015-11-17,Achillion Pharmaceuticals (ACHN) Stock Has 40% Potential Upside
2015-11-09,Ratings Changes Today
2015-11-05,Achillion Reports Third Quarter And Nine Month 2015 Financial Results
2015-11-05,Achillion Announces Upcoming Oral Presentation At The 57th Annual Meeting Of The American Society Of Hematology Detailing Novel Results With Factor D Inhibitors
2015-11-02,Achillion To Present At The Credit Suisse 24th Annual Healthcare Conference
2015-10-16,Strong On High Relative Volume: Achillion Pharmaceuticals (ACHN)
2015-10-16,Achillion Announces That Janssen Has Initiated A Phase 2a Study To Evaluate The Combination Of AL-335, Odalasvir (ACH-3102), And Simeprevir For The Treatment Of Genotype 1 Chronic HCV
2015-09-18,Achillion Pharmaceuticals (ACHN) Highlighted As Today's Perilous Reversal Stock
2015-09-14,Commit To Purchase Achillion Pharmaceuticals At $7, Earn 36% Annualized Using Options
2015-09-01,Achillion To Present At Two Upcoming Investor Conferences
2015-08-18,Trade-Ideas: Achillion Pharmaceuticals (ACHN) Is Today's "Perilous Reversal" Stock
2015-08-17,Strong On High Volume: Achillion Pharmaceuticals (ACHN)
2015-08-10,Achillion Reports Second Quarter And Six Month 2015 Financial Results
2015-08-06,Achillion Pharmaceuticals Becomes Oversold (ACHN)
2015-08-05,August 5 Premarket Briefing: 10 Things You Should Know
2015-08-03,Achillion Announces That Janssen Has Initiated A Phase I Study To Evaluate The Effect Of Simeprevir And Odalasvir (ACH-3102) On AL-335 Pharmacokinetics
2015-07-14,Achillion Pharmaceuticals Stock Sees Short Interest Expand By 12.4%
2015-07-01,10 Worst Biotech Stocks in the NASDAQ
2015-06-18,Achillion To Present At The JMP Securities Life Sciences Conference 2015
2015-05-30,'Mad Money' Lightning Round: Sell, Sell, Sell Achillion Pharmaceuticals
2015-05-29,Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
2015-05-20,Stocks Struggle to Hold Gains as Market Processes Fed Minutes
2015-05-20,Stocks Rise as Banks Settle With DOJ, Crude Rallies
2015-05-20,Achillion Pharmaceuticals (ACHN) Stock Plummeting Following Ratings Cuts
2015-05-20,Analysts' Actions -- Achillion, Keurig Green Mountain, Lions Gate and More
2015-05-19,Achillion Enters Into Worldwide Collaboration For Hepatitis C With Janssen
2015-05-19,Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest
2015-05-07,Achillion Reports First Quarter 2015 Financial Results
2015-05-05,May 5 Premarket Briefing: 10 Things You Should Know
2015-04-30,Achillion To Present At Two Upcoming Investor Conferences
2015-04-27,Achillion Pharmaceuticals Becomes Oversold
2015-04-25,Achillion Presents Detailed Clinical Results On ACH-3102 And ACH-3422 At The International Liver Congress
2015-04-08,Achillion Announces Upcoming Presentations At The International Liver Congress 2015 (EASL)
2015-03-21,'Mad Money' Lightning Round: Buy, Buy, Buy Whole Foods Markets
2015-03-20,Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
2015-03-05,Achillion Pharmaceuticals (ACHN) Stock Tanking Today on Heavy Volume
2015-03-05,Achillion Pharmaceuticals Shares Cross Below 200 DMA
2015-03-05,Achillion Reports 2014 Fourth Quarter And Year-End Financial Results
2015-02-26,Develop Biotech 'Buy-Sell' Strategy
2015-02-18,Achillion Pharmaceuticals Announces Closing Of Public Offering Of Common Stock
2015-02-11,Achillion Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2015-02-11,Achillion: Hep C Drug Discounting May Hurt Our Market Value, Stock Price
2015-02-11,'Mad Money' Lightning Round: Stop Fretting and Buy, Buy, Buy Sirius XM
2015-02-10,Jim Cramer's 'Mad Money' Recap: No Foreign News Is Great U.S. News
2015-02-10,Achillion Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2015-02-09,Jim Cramer Answers Twitter Questions on Coca-Cola, Yelp, Facebook, and More
2015-02-09,Achillion Achieves 100% SVR12 In Phase 2 Trial Evaluating 6-Week Combination Treatment With ACH-3102
2015-02-06,Achillion To Present At Two Upcoming Investor Conferences
2015-02-06,Biotech Stock Mailbag: Hep C stocks, Bluebird, Advaxis, Hemispherx
2015-01-28,'Mad Money' Lightning Round: I'm Worried About Martin Midstream Partners
2015-01-27,Jim Cramer's 'Mad Money' Recap: Why Own Whiners When You Can Own Winners?
2015-01-06,Jim Cramer's 'Mad Money' Recap: Knowing Where to Look for Bargains
2015-01-02,One Reason Achillion Pharmaceuticals (ACHN) Stock is Rising Today
2015-01-02,Biotech Stocks 2014: The Best, Worst and Fastest-Growing
2014-12-24,February 2015 Options Now Available For Achillion Pharmaceuticals
2014-12-23,Dow Reaches Record Close as Santa Claus Rally Hits Day 5
2014-12-23,Dow, S&P 500 Near Session Highs After GDP Growth Smashes Expectations
2014-12-23,Dow Industrials Top 18,000 but Biopharma Stocks Drag Nasdaq Lower
2014-12-23,Analysts' Actions: Achillion, Avon, Kimberly-Clark, Salesforce.com
2014-12-22,Achillion Pharma Takeout Less Likely Following Subpar Hep C Drug Results
2014-12-22,Achillion Shows Potential For "Best-in-Disease" HCV Regimen - 100% SVR4 Following A Dual 6-Week ACH-3102-Based Regimen And Separately A 4.8 Log10 Reduction With ACH-3422
2014-12-18,Six Biotech and Technology Stocks With Strong Technical Set-Ups
2014-11-28,A Biotech With Enormous Potential
2014-11-26,ACHN January 2015 Options Begin Trading
2014-11-26,December's Essential, Stock-Moving Biotech Events Explained While Eating Turkey
2014-11-25,Achillion To Present At Two Upcoming Investor Conferences
2014-11-20,Two Small-Cap Biotechnology Gems
2014-11-13,5 Momentum Stocks Currently on the Move with More Potential Upside
2014-11-12,Achillion Pharmaceuticals (ACHN) Stock Rises on Positive Hepatitis C Drug Results
2014-11-10,Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
2014-11-08,Achillion Reports 100% SVR12 In A Phase 2 Combination Study With ACH-3102 At The Liver Meeting 2014 (AASLD)
2014-11-06,ACHN December 26th Options Begin Trading
2014-11-06,Achillion Announces Upcoming Poster Presentations Discussing Novel Oral Complement Factor D Inhibitor Platform At The 56th Annual Meeting Of The American Society Of Hematology
2014-11-04,Achillion Pharmaceuticals (ACHN) Stock Falls on Lack of Hepatitis C Drug Data in Quarterly Earnings
2014-11-04,Achillion Reports Third Quarter And Nine Month 2014 Financial Results
2014-11-03,Super Important Biotech and Drug Stock Events for November
2014-10-28,Off the Charts
2014-10-22,Speculating on Achillion's Boom-or-Bust Hep C Drug Study Results
2014-10-17,Must See Charts: 4 Biotech Stocks to Watch in a Market Snapback
2014-10-08,Achillion To Present Updated Clinical HCV Data On ACH-3102 And Preclinical Profile Of ACH-3422 At The American Association For The Study Of Liver Diseases (AASLD) Annual Meeting
2014-10-03,Biotech Stock Mailbag: Seattle Genetics, Achillion, Catalyst Pharma
2014-09-30,Why J&J Expands Antiviral Franchise but Doesn't Buy Achillion, Novavax
2014-09-16,'Fast Money' Recap: How Alibaba Is Hitting Momentum Stocks
2014-09-11,Jim Cramer's 'Mad Money' Recap: Enjoy This Bull Market While It Lasts
2014-09-05,Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte
2014-09-03,'Mad Money' Lightning Round: I'm Taking Verizon Over AT&T
2014-09-02,Jim Cramer's 'Mad Money' Recap: The 2012 Stock Market All Over Again
2014-08-26,Achillion Pharmaceuticals (ACHN) Stock Hits New One-Year High
2014-08-26,'Fast Money' Recap: Next Stop, S&P 2,100?
2014-08-25,Why Achillion Pharmaceuticals (ACHN) Stock Hit a One-Year High Today
2014-08-19,Why Achillion Pharmaceuticals (ACHN) Stock Is Up in After-Hours Trading Today
2014-08-19,Achillion Granted U.S. Patent For ACH-3102 And Structurally Related NS5A Inhibitors
2014-08-18,Playing the New Hepatitis C Drugs
2014-08-18,3 Big Stocks on Traders' Radars
2014-08-18,Why Achillion Pharmaceuticals (ACHN) Stock Hit a One-Year High Today
2014-08-15,Why Achillion Pharmaceuticals (ACHN) Stock Surged to a One-Year High Today
2014-08-15,Achillion Achieves 100 Percent Sustained Virologic Response Rate (SVR4) From An Eight Week Phase 2 Trial Evaluating A Ribavirin-Free Regimen Of ACH-3102 And Sofosbuvir For Genotype 1 HCV ("Proxy Study")
2014-08-12,ACHN November 22nd Options Begin Trading
2014-08-07,Achillion Reports Second Quarter And Six Month 2014 Financial Results
2014-07-25,3 Biotech Stocks Under $10 to Trade for Breakouts
2014-07-01,Achillion Pharmaceuticals Added To The Russell 2000 And Russell Microcap Indexes
2014-06-16,Why Achillion Pharmaceuticals (ACHN) Is Spiking Today
2014-06-11,4 Big Stocks on Traders' Radars
2014-06-11,Achillion Pharmaceuticals (ACHN) Stock Falls After Two Days of Gains
2014-06-11,Achillion To Present At Two Upcoming Investor Conferences
2014-06-10,Why Achillion Pharmaceuticals (ACHN) Stock Is Surging Today (Update)
2014-06-10,A Mixed Finish for Markets With No News to Tip Big Swings
2014-06-10,This Biotech Stock Could Be the Next Big Short Squeeze
2014-06-10,Are Achillion, Inovio Buyout Targets, Like Merck's Idenix?: StockTwits
2014-06-10,Achillion Hep C Drug Update is Well Timed
2014-06-10,Achillion Announces Initiation Of ACH-3422 Dosing In HCV-Infected Patients And Ability To Resume Sovaprevir Clinical Program For The Treatment Of Chronic HCV
2014-06-10,'Fast Money' Recap: Markets Start Another Week on Positive Note
2014-06-09,Why Achillion Pharmaceuticals (ACHN) Stock Is Up Today (Update)
2014-06-09,3 Big Stocks Everyone Is Talking About
2014-06-09,Achillion Pharma Might be Next Hep C Takeout Target
2014-05-07,Achillion Reports First Quarter 2014 Financial Results
2014-05-01,Achillion To Present At Three Upcoming Investor Conferences
2014-04-30,Achillion Advances ACH-3422, Uridine-Analog Nucleotide Inhibitor, Into Clinical Trial; Initiates Phase 2 Pilot Study With ACH-3102, NS5A Inhibitor, For HCV
2014-04-14,First Week of April 19th Options Trading For Achillion Pharmaceuticals (ACHN)
2014-03-26,3 Biotech Stocks Under $10 to Trade
2014-03-14,Achillion Announces Oral Presentations Given At APASL 2014 Detailing Clinical Activity Of ACH-3102, Second-Generation NS5A Inhibitor, Against Genotype 1b HCV
2014-03-07,Achillion Reports 2013 Fourth Quarter And Year-End Financial Results
2014-03-04,Achillion Hasn't Stopped Aching
2017-03-23,Ratings Changes Today
2017-03-21,USPTO Grants Composition Of Matter Patent To Achillion For Small Molecule Complement Alternative Pathway Factor D Inhibitors
2017-03-02,These 5 Stocks Under $10 Could Explode Up Soon
2017-02-28,Achillion Pharmaceuticals To Support A Natural History Study Of C3 Glomerulopathy, A Rare Renal Disorder, Conducted By Experts At Imperial College London
2017-02-24,Will Insiders Be Tempted To Buy More ACHN At The New 52-Week Low?
2017-02-24,4 Biotech Stocks on the Move
2017-02-24,Biotech Movers: Cempra Flys High On Phase Three Results
2017-02-23,Achillion Reports 2016 Fourth Quarter And Year-End Financial Results
2017-02-13,Achillion To Present At The Leerink Partners 6th Annual Global Healthcare Conference
2017-02-02,Premarket Biotech Movers: Cytokinetics, Achillion, Qiagen
2017-01-25,Notable Wednesday Option Activity: ACHN, RH, AJRD
2017-01-04,Don't Be Complacent About Complacency
2016-12-28,Achillion Announces Clinical Milestone For The Advancement Of JNJ-4178 In Phase 2B Development For Chronic HCV
2016-12-08,These 5 Stocks Under $10 Could Make You a Lot of Money
2016-12-05,Data Presented At American Society Of Hematology Meeting Demonstrate Potential Advantages Of Factor D Inhibition For The Treatment Of Complement Alternative Pathway-Mediated Diseases
2016-11-30,Achillion Announces Initiation Of Patient Dosing By Janssen In A Global, Short Treatment-Duration Phase 2b Study Of JNJ-4178 In Chronic HCV
2016-11-03,Health Sector Down As Report of Industry Price Collusion Surfaces
2016-11-03,The Great 'ASH16' Abstract Drop Mostly Causes Drug Stocks to Do Same
2016-11-03,Achillion Announces Upcoming Presentations Of Novel Research Into Complement Biology At The 58th Annual Meeting Of The American Society Of Hematology
2016-11-03,Achillion Reports Third Quarter 2016 Financial Results And Provides Update On Clinical Programs
2016-11-02,Achillion To Present At The Credit Suisse 25th Annual Healthcare Conference
2016-10-31,Tax-Loss Selling Offers Stock-Picking Opportunities
2016-10-28,Achillion Pharmaceuticals Becomes Oversold (ACHN)
2016-10-25,First Week of ACHN June 2017 Options Trading
2016-09-23,Achillion Announces 100% SVR12 In The 6-Week And 8-Week Cohorts In Janssen's Phase 2 Trial Evaluating The Triple Combination Treatment Regimen Including Odalasvir, AL-335, And Simeprevir For Genotype 1 Treatment-Naive HCV
2016-09-20,Interesting ACHN Put And Call Options For November 18th
2016-09-09,Achillion Announces 100% SVR Reported In Janssen's Phase 2a Trial Evaluating Triple Combination Of Odalasvir, AL-335, And Simeprevir For Genotype 1 Treatment-Naive HCV
2016-09-06,Achillion Presents Novel Research On Factor D Inhibition At The XXVIth International Complement Workshop
2016-09-01,Achillion To Present At Two Upcoming Investor Conferences
2016-08-11,Achillion Announces Upcoming Presentation Of Interim Phase 2a Results From The Janssen Sponsored Trial Of Odalasvir, AL-335 And Simeprevir At The European Association For The Study Of The Liver (EASL) Special Conference
2016-08-09,Achillion To Present At The 2016 Wedbush PacGrow Healthcare Conference
2016-08-04,Achillion Reports Second Quarter 2016 Financial Results
2016-07-07,ACHN August 26th Options Begin Trading
2016-07-07,Achillion Pharmaceuticals (ACHN) Stock Up, JMP Upgrades
2016-07-07,Analysts' Actions -- First Solar, Qualcomm, Red Hat, Zions and More
2016-06-23,Interesting ACHN Put And Call Options For August 5th
2016-06-10,Achillion Presents Interim Phase 1 Results For ACH-4471, A Novel Orally-Administered Factor D Inhibitor, At The 21st Congress Of The European Hematology Association
2016-06-01,Achillion To Present At Three Upcoming Investor Conferences
2016-05-19,Achillion Announces Acceptance Of Late Breaking Abstract For ACH-4471 At The 21st Congress Of The European Hematology Association
2016-05-03,Achillion Reports First Quarter 2016 Financial Results And Provides Update On Clinical Programs
2016-04-28,Achillion To Present At The Deutsche Bank 41st Annual Health Care Conference
2016-03-04,Achillion Pharmaceuticals (ACHN) Weak On High Volume Today
2016-03-03,Achillion To Present At Two Upcoming Investor Conferences
2016-02-25,Achillion Reports 2015 Fourth Quarter And Year-End Financial Results
2016-02-11,Achillion Initiates Phase 1 Study Of ACH-4471, First Orally-Administered Small Molecule Complement Factor D Inhibitor
2016-02-08,Achillion To Present At The Leerink Partners 5th Annual Global Healthcare Conference
2016-02-05,Achillion Pharmaceuticals is Now Oversold (ACHN)
2016-02-03,Achillion Announces Appointments Of Martha Manning As General Counsel And Amy Jennings As Head Of Regulatory Affairs
2016-01-26,Achillion Pharmaceuticals (ACHN) Weak On High Volume
2016-01-08,Achillion Pharmaceuticals (ACHN) Flagged As Strong On High Volume
2016-01-04,Achillion Appoints Dr. Joel Barrish As Chief Scientific Officer
2015-12-30,Trade-Ideas: Achillion Pharmaceuticals (ACHN) Is Today's Strong On High Relative Volume Stock
2015-12-16,Achillion Appoints Dr. Frank Verwiel To Board Of Directors
2015-12-14,Achillion Pharmaceuticals (ACHN) Is Today's Dead Cat Bounce Stock
2015-12-05,Achillion Announces Upcoming Oral Presentation At The 57th Annual Meeting Of The American Society Of Hematology And Nomination Of ACH-4471, A Novel Small Molecule Factor D Inhibitor, For Clinical Development
2015-11-23,Nothing for Bears to Get Excited About
2015-11-17,Lilly's Diabetes Drug Makes It a Turner Medical Fund Pick
2015-11-17,Achillion Pharmaceuticals (ACHN) Stock Has 40% Potential Upside
2015-11-09,Ratings Changes Today
2015-11-05,Achillion Reports Third Quarter And Nine Month 2015 Financial Results
2015-11-05,Achillion Announces Upcoming Oral Presentation At The 57th Annual Meeting Of The American Society Of Hematology Detailing Novel Results With Factor D Inhibitors
2015-11-02,Achillion To Present At The Credit Suisse 24th Annual Healthcare Conference
2015-10-16,Strong On High Relative Volume: Achillion Pharmaceuticals (ACHN)
2015-10-16,Achillion Announces That Janssen Has Initiated A Phase 2a Study To Evaluate The Combination Of AL-335, Odalasvir (ACH-3102), And Simeprevir For The Treatment Of Genotype 1 Chronic HCV
2015-09-18,Achillion Pharmaceuticals (ACHN) Highlighted As Today's Perilous Reversal Stock
2015-09-14,Commit To Purchase Achillion Pharmaceuticals At $7, Earn 36% Annualized Using Options
2015-09-01,Achillion To Present At Two Upcoming Investor Conferences
2015-08-18,Trade-Ideas: Achillion Pharmaceuticals (ACHN) Is Today's "Perilous Reversal" Stock
2015-08-17,Strong On High Volume: Achillion Pharmaceuticals (ACHN)
2015-08-10,Achillion Reports Second Quarter And Six Month 2015 Financial Results
2015-08-06,Achillion Pharmaceuticals Becomes Oversold (ACHN)
2015-08-05,August 5 Premarket Briefing: 10 Things You Should Know
2015-08-03,Achillion Announces That Janssen Has Initiated A Phase I Study To Evaluate The Effect Of Simeprevir And Odalasvir (ACH-3102) On AL-335 Pharmacokinetics
2015-07-14,Achillion Pharmaceuticals Stock Sees Short Interest Expand By 12.4%
2015-07-01,10 Worst Biotech Stocks in the NASDAQ
2015-06-18,Achillion To Present At The JMP Securities Life Sciences Conference 2015
2015-05-30,'Mad Money' Lightning Round: Sell, Sell, Sell Achillion Pharmaceuticals
2015-05-29,Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
2015-05-20,Stocks Struggle to Hold Gains as Market Processes Fed Minutes
2015-05-20,Stocks Rise as Banks Settle With DOJ, Crude Rallies
2015-05-20,Achillion Pharmaceuticals (ACHN) Stock Plummeting Following Ratings Cuts
2015-05-20,Analysts' Actions -- Achillion, Keurig Green Mountain, Lions Gate and More
2015-05-19,Achillion Enters Into Worldwide Collaboration For Hepatitis C With Janssen
2015-05-19,Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest
2015-05-07,Achillion Reports First Quarter 2015 Financial Results
2015-05-05,May 5 Premarket Briefing: 10 Things You Should Know
2015-04-30,Achillion To Present At Two Upcoming Investor Conferences
2015-04-27,Achillion Pharmaceuticals Becomes Oversold
2015-04-25,Achillion Presents Detailed Clinical Results On ACH-3102 And ACH-3422 At The International Liver Congress
2015-04-08,Achillion Announces Upcoming Presentations At The International Liver Congress 2015 (EASL)
2015-03-21,'Mad Money' Lightning Round: Buy, Buy, Buy Whole Foods Markets
2015-03-20,Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
2015-03-05,Achillion Pharmaceuticals (ACHN) Stock Tanking Today on Heavy Volume
2015-03-05,Achillion Pharmaceuticals Shares Cross Below 200 DMA
2015-03-05,Achillion Reports 2014 Fourth Quarter And Year-End Financial Results
2015-02-26,Develop Biotech 'Buy-Sell' Strategy
2015-02-18,Achillion Pharmaceuticals Announces Closing Of Public Offering Of Common Stock
2015-02-11,Achillion Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2015-02-11,Achillion: Hep C Drug Discounting May Hurt Our Market Value, Stock Price
2015-02-11,'Mad Money' Lightning Round: Stop Fretting and Buy, Buy, Buy Sirius XM
2015-02-10,Jim Cramer's 'Mad Money' Recap: No Foreign News Is Great U.S. News
2015-02-10,Achillion Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2015-02-09,Jim Cramer Answers Twitter Questions on Coca-Cola, Yelp, Facebook, and More
2015-02-09,Achillion Achieves 100% SVR12 In Phase 2 Trial Evaluating 6-Week Combination Treatment With ACH-3102
2015-02-06,Achillion To Present At Two Upcoming Investor Conferences
2015-02-06,Biotech Stock Mailbag: Hep C stocks, Bluebird, Advaxis, Hemispherx
2015-01-28,'Mad Money' Lightning Round: I'm Worried About Martin Midstream Partners
2015-01-27,Jim Cramer's 'Mad Money' Recap: Why Own Whiners When You Can Own Winners?
2015-01-06,Jim Cramer's 'Mad Money' Recap: Knowing Where to Look for Bargains
2015-01-02,One Reason Achillion Pharmaceuticals (ACHN) Stock is Rising Today
2015-01-02,Biotech Stocks 2014: The Best, Worst and Fastest-Growing
2014-12-24,February 2015 Options Now Available For Achillion Pharmaceuticals
2014-12-23,Dow Reaches Record Close as Santa Claus Rally Hits Day 5
2014-12-23,Dow, S&P 500 Near Session Highs After GDP Growth Smashes Expectations
2014-12-23,Dow Industrials Top 18,000 but Biopharma Stocks Drag Nasdaq Lower
2014-12-23,Analysts' Actions: Achillion, Avon, Kimberly-Clark, Salesforce.com
2014-12-22,Achillion Pharma Takeout Less Likely Following Subpar Hep C Drug Results
2014-12-22,Achillion Shows Potential For "Best-in-Disease" HCV Regimen - 100% SVR4 Following A Dual 6-Week ACH-3102-Based Regimen And Separately A 4.8 Log10 Reduction With ACH-3422
2014-12-18,Six Biotech and Technology Stocks With Strong Technical Set-Ups
2014-11-28,A Biotech With Enormous Potential
2014-11-26,ACHN January 2015 Options Begin Trading
2014-11-26,December's Essential, Stock-Moving Biotech Events Explained While Eating Turkey
2014-11-25,Achillion To Present At Two Upcoming Investor Conferences
2014-11-20,Two Small-Cap Biotechnology Gems
2014-11-13,5 Momentum Stocks Currently on the Move with More Potential Upside
2014-11-12,Achillion Pharmaceuticals (ACHN) Stock Rises on Positive Hepatitis C Drug Results
2014-11-10,Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
2014-11-08,Achillion Reports 100% SVR12 In A Phase 2 Combination Study With ACH-3102 At The Liver Meeting 2014 (AASLD)
2014-11-06,ACHN December 26th Options Begin Trading
2014-11-06,Achillion Announces Upcoming Poster Presentations Discussing Novel Oral Complement Factor D Inhibitor Platform At The 56th Annual Meeting Of The American Society Of Hematology
2014-11-04,Achillion Pharmaceuticals (ACHN) Stock Falls on Lack of Hepatitis C Drug Data in Quarterly Earnings
2014-11-04,Achillion Reports Third Quarter And Nine Month 2014 Financial Results
2014-11-03,Super Important Biotech and Drug Stock Events for November
2014-10-28,Off the Charts
2014-10-22,Speculating on Achillion's Boom-or-Bust Hep C Drug Study Results
2014-10-17,Must See Charts: 4 Biotech Stocks to Watch in a Market Snapback
2014-10-08,Achillion To Present Updated Clinical HCV Data On ACH-3102 And Preclinical Profile Of ACH-3422 At The American Association For The Study Of Liver Diseases (AASLD) Annual Meeting
2014-10-03,Biotech Stock Mailbag: Seattle Genetics, Achillion, Catalyst Pharma
2014-09-30,Why J&J Expands Antiviral Franchise but Doesn't Buy Achillion, Novavax
2014-09-16,'Fast Money' Recap: How Alibaba Is Hitting Momentum Stocks
2014-09-11,Jim Cramer's 'Mad Money' Recap: Enjoy This Bull Market While It Lasts
2014-09-05,Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte
2014-09-03,'Mad Money' Lightning Round: I'm Taking Verizon Over AT&T
2014-09-02,Jim Cramer's 'Mad Money' Recap: The 2012 Stock Market All Over Again
2014-08-26,Achillion Pharmaceuticals (ACHN) Stock Hits New One-Year High
2014-08-26,'Fast Money' Recap: Next Stop, S&P 2,100?
2014-08-25,Why Achillion Pharmaceuticals (ACHN) Stock Hit a One-Year High Today
2014-08-19,Why Achillion Pharmaceuticals (ACHN) Stock Is Up in After-Hours Trading Today
2014-08-19,Achillion Granted U.S. Patent For ACH-3102 And Structurally Related NS5A Inhibitors
2014-08-18,Playing the New Hepatitis C Drugs
2014-08-18,3 Big Stocks on Traders' Radars
2014-08-18,Why Achillion Pharmaceuticals (ACHN) Stock Hit a One-Year High Today
2014-08-15,Why Achillion Pharmaceuticals (ACHN) Stock Surged to a One-Year High Today
2014-08-15,Achillion Achieves 100 Percent Sustained Virologic Response Rate (SVR4) From An Eight Week Phase 2 Trial Evaluating A Ribavirin-Free Regimen Of ACH-3102 And Sofosbuvir For Genotype 1 HCV ("Proxy Study")
2014-08-12,ACHN November 22nd Options Begin Trading
2014-08-07,Achillion Reports Second Quarter And Six Month 2014 Financial Results
2014-07-25,3 Biotech Stocks Under $10 to Trade for Breakouts
2014-07-01,Achillion Pharmaceuticals Added To The Russell 2000 And Russell Microcap Indexes
2014-06-16,Why Achillion Pharmaceuticals (ACHN) Is Spiking Today
2014-06-11,4 Big Stocks on Traders' Radars
2014-06-11,Achillion Pharmaceuticals (ACHN) Stock Falls After Two Days of Gains
2014-06-11,Achillion To Present At Two Upcoming Investor Conferences
2014-06-10,Why Achillion Pharmaceuticals (ACHN) Stock Is Surging Today (Update)
2014-06-10,A Mixed Finish for Markets With No News to Tip Big Swings
2014-06-10,This Biotech Stock Could Be the Next Big Short Squeeze
2014-06-10,Are Achillion, Inovio Buyout Targets, Like Merck's Idenix?: StockTwits
2014-06-10,Achillion Hep C Drug Update is Well Timed
2014-06-10,Achillion Announces Initiation Of ACH-3422 Dosing In HCV-Infected Patients And Ability To Resume Sovaprevir Clinical Program For The Treatment Of Chronic HCV
2014-06-10,'Fast Money' Recap: Markets Start Another Week on Positive Note
2014-06-09,Why Achillion Pharmaceuticals (ACHN) Stock Is Up Today (Update)
2014-06-09,3 Big Stocks Everyone Is Talking About
2014-06-09,Achillion Pharma Might be Next Hep C Takeout Target
2014-05-07,Achillion Reports First Quarter 2014 Financial Results
2014-05-01,Achillion To Present At Three Upcoming Investor Conferences
2014-04-30,Achillion Advances ACH-3422, Uridine-Analog Nucleotide Inhibitor, Into Clinical Trial; Initiates Phase 2 Pilot Study With ACH-3102, NS5A Inhibitor, For HCV
2014-04-14,First Week of April 19th Options Trading For Achillion Pharmaceuticals (ACHN)
2014-03-26,3 Biotech Stocks Under $10 to Trade
2014-03-14,Achillion Announces Oral Presentations Given At APASL 2014 Detailing Clinical Activity Of ACH-3102, Second-Generation NS5A Inhibitor, Against Genotype 1b HCV
2014-03-07,Achillion Reports 2013 Fourth Quarter And Year-End Financial Results
2014-03-04,Achillion Hasn't Stopped Aching
2017-03-13,The MS Awareness Facts Skill Allows Users To Ask Amazon Alexa For An MS Awareness Fact To Learn More About Multiple Sclerosis And Find Helpful Information On MS And Its Symptoms.
2017-03-09,Patent Trials And Appeal Board (PTAB) Upholds Four AMPYRA® Patents
2017-03-09,Acorda Stock Jumps Following Patent Challenge Win
2017-02-27,Acorda To Present At The Cowen And Company 37th Annual Healthcare Conference
2017-02-21,Ratings Changes Today
2017-02-21,Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board Of Directors
2017-02-15,Analysts' Actions -- Acorda, Restoration Hardware, Humana, Merck and More
2017-02-14,Acorda Provides Financial And Pipeline Update For Fourth Quarter And Year End 2016
2017-02-09,Acorda Therapeutics Stock Surges on Clinical Trial Results
2017-02-09,Acorda, Amgen and Regeneron Lead Premarket Biotech Movers
2017-02-09,Acorda Therapeutics Inhaled Drug Reduces Parkinson's Motor Symptoms in Late-Stage Study
2017-02-09,Acorda Announces Positive Phase 3 Clinical Trial Results For CVT-301
2017-02-03,Acorda Therapeutics To Present At Two Investor Conferences In February
2017-01-31,Acorda To Host Conference Call To Discuss Fourth Quarter 2016 On February 14, 2017
2017-01-24,First Week of March 17th Options Trading For Acorda Therapeutics (ACOR)
2017-01-09,Acorda Announces 2016 AMPYRA Net Sales And 2017 Financial Guidance At J.P. Morgan Healthcare Conference
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2016-12-28,Acorda Therapeutics To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-20,First Week of February 2017 Options Trading For Acorda Therapeutics (ACOR)
2016-11-22,Acorda Therapeutics To Present At The 28th Annual Piper Jaffray Healthcare Conference
2016-11-21,In Case You Missed It Monday: Markets Punch Through Record Highs
2016-11-21,Acorda Stroke Study Fails, Dampening Revenue Growth Plans
2016-11-21,Acorda To Discontinue Development Of Dalfampridine For Treatment Of Post-Stroke Walking Difficulties
2016-11-13,Six Thoughts on President Trump and the Durability of the Biotech Stock Rally
2016-11-09,Acorda Therapeutics To Present At The Stifel 2016 Healthcare Conference
2016-10-27,Acorda Provides Financial And Pipeline Update For Third Quarter 2016
2016-10-17,Commit To Purchase Acorda Therapeutics At $7, Earn 15.4% Annualized Using Options
2016-10-17,Acorda To Host Conference Call To Discuss Third Quarter 2016 On October 27, 2016
2016-10-13,Data From Clinical And Preclinical Trials Of CVT-301 For Treatment Of OFF Periods In Parkinson's Disease Published In Science Translational Medicine
2016-10-12,Acorda Therapeutics, Inc. Has Been Named As One Of The 100 Best Medium Workplaces Based On An Independent Survey By Fortune Magazine And Great Place To Work®. (Photo: Business Wire)
2016-10-04,Acorda Announces Departure Of Michael Rogers
2016-09-29,Oversold Conditions For Acorda Therapeutics (ACOR)
2016-09-16,5 Stocks to Trade for Big Breakout Gains
2016-09-15,(Graphic: Business Wire)
2016-07-29,Ratings Changes Today
2016-07-28,Acorda Provides Financial And Pipeline Update For Second Quarter 2016
2016-07-21,Trade-Ideas: Acorda Therapeutics (ACOR) Is Today's "Perilous Reversal" Stock
2016-07-20,Strong On High Volume: Acorda Therapeutics (ACOR)
2016-07-18,September 16th Options Now Available For Acorda Therapeutics (ACOR)
2016-07-07,Acorda To Host Conference Call To Discuss Second Quarter 2016 On July 28, 2016
2016-07-01,Acorda Appoints Burkhard Blank, M.D., As Chief Medical Officer (CMO)
2016-06-13,Biotie Therapies Corp. Announces That The Delisting Of Its American Depositary Shares From NASDAQ Global Select Market Has Become Effective
2016-06-09,Acorda Presents Phase 1 Data On CVT-427 For Acute Treatment Of Migraine At 58th Annual Scientific Meeting Of The American Headache Society
2016-05-31,Acorda Therapeutics To Present At The 37th Annual Goldman Sachs Global Healthcare Conference
2016-05-20,Acorda To Discontinue Development Of PLUMIAZ For Treatment Of Epilepsy Seizure Clusters
2016-05-18,Biotie Therapies Corp. To Delist Its American Depositary Shares From The Nasdaq Global Select Market
2016-05-04,Acorda Therapeutics Named One Of The Best Places To Work For In New York
2016-05-03,Acorda Therapeutics (ACOR) Highlighted As Today's Perilous Reversal Stock
2016-05-02,Acorda Therapeutics (ACOR) Is Today's Dead Cat Bounce Stock
2016-05-02,Final Results Of The Subsequent Offer Period Of Acorda Therapeutics' Tender Offer For All Of The Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp.
2016-04-29,Trade-Ideas: Acorda Therapeutics (ACOR) Is Today's Weak On High Relative Volume Stock
2016-04-29,Acorda Therapeutics To Present At Two Investor Conferences In May
2016-04-28,Acorda Provides Financial And Pipeline Update For First Quarter 2016
2016-04-20,Acorda Announces Results From Phase 2b Clinical Trial Of CVT-301 For Treatment Of OFF Periods In Parkinson's Disease Published In Movement Disorders
2016-04-18,Completion Of Acorda Therapeutics' Voluntary Tender Offer For All Of The Issued And Outstanding Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp. And Matters Related Thereto
2016-04-14,Acorda To Host Conference Call To Discuss First Quarter 2016 On April 28, 2016
2016-04-13,Final Results Of Acorda Therapeutics' Voluntary Tender Offer For All Of The Issued And Outstanding Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp. And Commencement Of A Subsequent Offer Period
2016-04-12,'Mad Money' Lightning Round: UnitedHealth May Be the Dow's Best Stock
2016-04-11,Jim Cramer's 'Mad Money' Recap: These Stocks Are New-High Winners
2016-04-11,Acorda Therapeutics Announces Preliminary Tender Offer Results And Acceptance Of The Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp. Tendered In Tender Offer
2016-04-07,Phase 2b Data On Inhaled Levodopa CVT-301 Featured In Invited Science Session At American Academy Of Neurology (AAN) Annual Meeting
2016-03-22,Acorda Therapeutics Supplements The Tender Offer Document Relating To The Voluntary Public Tender Offer For All Of The Issued And Outstanding Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp. On 22 March 2016
2016-03-21,Acorda Wins Federal Circuit Appeal Allowing AMPYRA® Patent Litigation To Continue In Delaware District Court
2016-03-18,Acorda Therapeutics Supplements Tender Offer Document Relating To The Voluntary Public Tender Offer For All Of The Issued And Outstanding Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies On 18 March 2016
2016-03-11,Acorda Announces Patent Trials And Appeal Board (PTAB) Institutes IPRs Of AMPYRA Patents
2016-03-10,Acorda Therapeutics, Inc. Will Commence The Voluntary Public Tender Offer For All Of The Issued And Outstanding Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp. On 11 March 2016
2016-03-03,Acorda Has Filed Tender Offer Document Relating To Public Tender Offer For Biotie Therapies With Finnish Financial Supervisory Authority
2016-03-01,Acorda Therapeutics To Present At Two Investor Conferences In March
2016-02-17,Acorda Announces Expiration Of The Hart-Scott-Rodino Waiting Period For Its Tender Offer For Biotie Therapies
2016-02-12,Ratings Changes Today
2016-02-11,Acorda Provides Financial And Pipeline Update For Fourth Quarter And Year End 2015
2016-02-04,Acorda Therapeutics To Present At Two Investor Conferences In February
2016-01-28,Acorda To Host Conference Call To Discuss Fourth Quarter And Year End 2015 Results On February 11, 2016
2016-01-26,Acorda Therapeutics (ACOR) Stock: Weak On High Volume Today
2016-01-26,7 Stocks to Trade for Breakouts on Big Volume
2016-01-19,Acorda Acquires Parkinson's Drug Through Biotie Buyout
2016-01-19,European Stocks Follow Asia Higher as China GDP Revives Hopes for Stimulus
2016-01-19,Acorda To Acquire Biotie Therapies
2016-01-11,Acorda Announces 2015 AMPYRA Sales, 2016 Financial Guidance And 2016/2017 Clinical Milestones At J.P. Morgan Healthcare Conference
2015-12-22,Acorda to Present at the 34th Annual J.P. Morgan Healthcare Conference
2015-12-21,Acorda Announces Departure Of Chief Medical Officer (CMO); Company Appoints Burkhard Blank, M.D. As Interim CMO
2015-12-08,Acorda Presents Analyses On Use Of Healthcare Services For Seizure Clusters At American Epilepsy Society Annual Meeting
2015-12-03,Acorda Initiates Phase 1 Clinical Trial Of CVT-427, Inhaled Therapy For Acute Treatment Of Migraines
2015-11-30,Acorda Therapeutics To Present At The Oppenheimer Annual Healthcare Conference
2015-11-19,Ratings Changes Today
2015-11-10,Acorda Therapeutics To Present At Two Investor Conferences In November
2015-10-23,Acorda Therapeutics (ACOR) Strong On High Relative Volume Today
2015-10-22,Acorda Provides Financial And Pipeline Update For 2015 Third Quarter
2015-10-12,Insider Trading Alert - ACOR, CMCT And NUAN Traded By Insiders
2015-10-08,Acorda Therapeutics To Host Conference Call To Discuss Third Quarter Results On October 22, 2015
2015-10-07,Insider Trading Alert - ACOR, TIPT And NUAN Traded By Insiders
2015-10-07,Acorda to Present New rHIgM22 and AMPYRA® (dalfampridine) Data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
2015-10-06,Acorda Therapeutics (ACOR) Is Today's Perilous Reversal Stock
2015-10-02,Acorda Recognized With Legal Media Group 2015 Life Sciences Award
2015-09-30,Acorda Therapeutics (ACOR) Is Today's Strong On High Volume Stock
2015-09-30,Acorda Named One Of The 100 Best Workplaces For Women By Fortune And Great Place To Work
2015-09-28,RSI Alert: Acorda Therapeutics (ACOR) Now Oversold
2015-09-03,Acorda Therapeutics To Present At The Baird 2015 Healthcare Conference
2015-08-28,Interesting ACOR Put And Call Options For April 2016
2015-08-25,Acorda Therapeutics (ACOR) Stock Climbs After Panel Dismisses Patent Challenge
2015-08-25,Pre-Market Activity Shows Heavy Volume And Movement For Acorda Therapeutics (ACOR)
2015-08-24,Acorda Announces Patent Trials And Appeal Board (PTAB) Denies Both IPRs Of AMPYRA Patents
2015-08-24,Ratings Changes Today
2015-08-05,Acorda Therapeutics To Present At The Canaccord Genuity Growth Conference
2015-07-31,Ratings Changes Today
2015-07-30,Acorda Provides Financial And Pipeline Update For 2015 Second Quarter
2015-07-22,Acorda Awarded Grant To Study ARCUS® Technology In Respiratory Distress Syndrome
2015-07-14,Acorda Therapeutics Stock Sees Short Interest Decline 10.7%
2015-06-24,Acorda Data On Inhaled Levodopa Therapy CVT-301 Recognized In Blue Ribbon Highlights Session At International Congress Of Parkinson's Disease And Movement Disorders
2015-06-23,First Week Of August 21st Options Trading For Acorda Therapeutics (ACOR)
2015-06-16,Chart Trends in Airgas, Acorda Therapeutics
2015-06-16,Acorda Presents Data On Inhaled Levodopa Therapy CVT-301 At International Congress Of Parkinson's Disease And Movement Disorders
2015-06-15,Acorda CEO Ron Cohen Named BIO Chairman For 2015-2016 Term
2015-05-26,Acorda Therapeutics To Present At The Jefferies Global Healthcare Conference
2015-05-18,Insider Trading Alert - ROP, GEVO And ACOR Traded By Insiders
2015-05-05,Acorda Therapeutics To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference
2015-05-01,Acorda Therapeutics To Present At The Deutsche Bank 40th Annual Health Care Conference
2015-04-30,Acorda Therapeutics (ACOR) Highlighted As Weak On High Volume
2015-04-30,Acorda Reports First Quarter 2015 Financial Results
2015-04-23,Acorda Therapeutics To Host Conference Call To Discuss First Quarter 2015 Financial Results On April 30, 2015
2015-04-22,Acorda Presents Data On First Clinical Study Of Remyelinating Antibody For Multiple Sclerosis At American Academy Of Neurology Annual Meeting
2015-04-22,Acorda Therapeutics Named One Of The Best Places To Work For In New York 2015
2015-03-24,ACOR Crosses Above Key Moving Average Level
2015-03-18,'Mad Money' Lightning Round: I Don't Like Caterpillar, Buy TG Therapeutics
2015-03-17,Jim Cramer's 'Mad Money' Recap: This Maddening Market Can't Make Up Its Mind
2015-03-16,Acorda Therapeutics Ringing The Opening Bell At The NASDAQ Stock Exchange, March 16, 2015 (Photo: Business Wire)
2015-03-11,Acorda Therapeutics Stock Sees Short Interest Jump 13.3%
2015-03-10,Acorda To Present New Analyses Of Cimaglermin Alfa (GGF2) Data At The 64th Annual ACC Scientific Session
2015-03-04,Acorda Therapeutics To Present At The Barclays Global Healthcare Conference
2015-02-27,Notable Two Hundred Day Moving Average Cross - ACOR
2015-02-23,Acorda Therapeutics To Present At The Cowen 35th Annual Health Care Conference
2015-02-19,'Mad Money' Lightning Round: Don't Gamble on Las Vegas Sands
2015-02-18,Jim Cramer's 'Mad Money' Recap: Forget Buffett, Think for Yourself
2015-02-17,Acorda Therapeutics (ACOR) Downgraded From Buy to Hold
2015-02-17,Acorda Therapeutics To Present At The 2015 RBC Capital Markets' Healthcare Conference
2015-02-13,Ratings Changes Today
2015-02-12,Acorda Therapeutics Reports Fourth Quarter And Full Year 2014 Financial Results
2015-02-11,3 Big-Volume Stocks to Trade for Breakouts: First Solar and More
2015-02-11,Acorda Therapeutics (ACOR) Showing Signs Of A Dead Cat Bounce Today
2015-02-05,Acorda Therapeutics To Present At The 2015 Leerink Global Healthcare Conference
2015-02-05,Acorda Therapeutics To Host Conference Call To Discuss Fourth Quarter And Year End 2014 Financial Results On February 12, 2015
2015-02-02,Acorda Announces Safety And Tolerability Data From First Clinical Trial Of Remyelinating Antibody In Multiple Sclerosis
2015-01-13,Acorda Therapeutics (ACOR) Reaches New Lifetime High Today
2015-01-13,Jim Cramer's Top Stock Picks: ISIS CELG NPSP AA ACOR
2015-01-12,Jim Cramer's 'Mad Money' Recap: Blame Tech, Oil and Retail for Today's Losses
2015-01-12,First Week Of ACOR February 20th Options Trading
2015-01-12,Acorda Provides Corporate Update At J.P. Morgan Healthcare Conference
2015-01-08,Today's Strong And Under The Radar Stock Is Acorda Therapeutics (ACOR)
2015-01-08,Biogen Idec's Critical Nerve Repair Drug is Poised for Big News -- Soon
2015-01-06,Acorda To Present At The 33rd Annual J.P. Morgan Healthcare Conference
2014-12-15,Acorda Announces Initiation Of Phase 3 Clinical Trial For Dalfampridine In Post-Stroke Walking Deficits
2014-12-10,Acorda Announces Initiation Of Phase 3 Trial Of CVT-301 In Parkinson's Disease
2014-12-02,Acorda Therapeutics To Present At The 26th Annual Piper Jaffray Healthcare Conference
2014-11-14,Acorda Therapeutics To Present At The Jefferies 2014 Global Healthcare Conference
2014-11-12,Acorda Therapeutics To Present At The Stifel 2014 Healthcare Conference
2014-11-04,Acorda Therapeutics To Present At The Credit Suisse 2014 Healthcare Conference
2014-10-30,Acorda Therapeutics Reports Third Quarter 2014 Financial Results
2014-10-24,First Week of December 20th Options Trading For Acorda Therapeutics (ACOR)
2014-10-23,Acorda Therapeutics To Host Conference Call To Discuss Third Quarter 2014 Financial Results On October 30, 2014
2014-10-22,Acorda Therapeutics Completes Acquisition Of Civitas Therapeutics
2014-10-20,Insider Trading Alert - IBKR, C And ACOR Traded By Insiders
2014-10-08,Insider Trading Alert - HCN, ACOR And DRII Traded By Insiders
2014-10-03,Jim Cramer's Top Stock Picks: CMG UA TAP ACOR
2014-10-02,Jim Cramer's 'Mad Money' Recap: Are You Ready to Profit From Friday's Panic?
2014-09-25,Perilous Reversal Watch: Acorda Therapeutics (ACOR)
2014-09-25,How to Trade the Market's Most-Active Stocks: KBH, BBBY, ACOR
2014-09-24,Jim Cramer's 'Mad Money' Recap: Why You Can't Get Too Negative in This Market
2014-09-24,Acorda Acquires Civitas Therapeutics for $525M for Parkinson's Treatment
2014-09-24,Why Acorda Therapeutics (ACOR) Stock Is Rising Today
2014-09-24,Acorda Therapeutics (ACOR) Moving On Heavy Pre-Market Trading
2014-09-24,Acorda Therapeutics To Acquire Civitas Therapeutics
2014-09-10,Acorda Therapeutics And HealthCore To Present Real World Health Economics And Outcomes Data On Multiple Sclerosis Therapy AMPYRA
2014-09-04,Acorda Therapeutics To Present At The Aegis Capital 2014 Healthcare And Technology Conference
2014-09-02,Acorda Therapeutics To Present At The Morgan Stanley Global Healthcare Conference
2014-08-27,Acorda Therapeutics To Present At The Baird 2014 Healthcare Conference
2014-08-20,First Week of ACOR April 2015 Options Trading
2014-07-31,Acorda Therapeutics Reports Second Quarter 2014 Financial Results
2014-07-24,Acorda Therapeutics To Host Conference Call To Discuss Second Quarter 2014 Financial Results On July 31, 2014
2014-06-26,Acorda Therapeutics Announces Notification Of ANDA Filing For AMPYRA&#174;
2014-06-19,Acorda Therapeutics (ACOR) Highlighted As Today's Perilous Reversal Stock
2017-03-13,The MS Awareness Facts Skill Allows Users To Ask Amazon Alexa For An MS Awareness Fact To Learn More About Multiple Sclerosis And Find Helpful Information On MS And Its Symptoms.
2017-03-09,Patent Trials And Appeal Board (PTAB) Upholds Four AMPYRA® Patents
2017-03-09,Acorda Stock Jumps Following Patent Challenge Win
2017-02-27,Acorda To Present At The Cowen And Company 37th Annual Healthcare Conference
2017-02-21,Ratings Changes Today
2017-02-21,Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board Of Directors
2017-02-15,Analysts' Actions -- Acorda, Restoration Hardware, Humana, Merck and More
2017-02-14,Acorda Provides Financial And Pipeline Update For Fourth Quarter And Year End 2016
2017-02-09,Acorda Therapeutics Stock Surges on Clinical Trial Results
2017-02-09,Acorda, Amgen and Regeneron Lead Premarket Biotech Movers
2017-02-09,Acorda Therapeutics Inhaled Drug Reduces Parkinson's Motor Symptoms in Late-Stage Study
2017-02-09,Acorda Announces Positive Phase 3 Clinical Trial Results For CVT-301
2017-02-03,Acorda Therapeutics To Present At Two Investor Conferences In February
2017-01-31,Acorda To Host Conference Call To Discuss Fourth Quarter 2016 On February 14, 2017
2017-01-24,First Week of March 17th Options Trading For Acorda Therapeutics (ACOR)
2017-01-09,Acorda Announces 2016 AMPYRA Net Sales And 2017 Financial Guidance At J.P. Morgan Healthcare Conference
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2016-12-28,Acorda Therapeutics To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-20,First Week of February 2017 Options Trading For Acorda Therapeutics (ACOR)
2016-11-22,Acorda Therapeutics To Present At The 28th Annual Piper Jaffray Healthcare Conference
2016-11-21,In Case You Missed It Monday: Markets Punch Through Record Highs
2016-11-21,Acorda Stroke Study Fails, Dampening Revenue Growth Plans
2016-11-21,Acorda To Discontinue Development Of Dalfampridine For Treatment Of Post-Stroke Walking Difficulties
2016-11-13,Six Thoughts on President Trump and the Durability of the Biotech Stock Rally
2016-11-09,Acorda Therapeutics To Present At The Stifel 2016 Healthcare Conference
2016-10-27,Acorda Provides Financial And Pipeline Update For Third Quarter 2016
2016-10-17,Commit To Purchase Acorda Therapeutics At $7, Earn 15.4% Annualized Using Options
2016-10-17,Acorda To Host Conference Call To Discuss Third Quarter 2016 On October 27, 2016
2016-10-13,Data From Clinical And Preclinical Trials Of CVT-301 For Treatment Of OFF Periods In Parkinson's Disease Published In Science Translational Medicine
2016-10-12,Acorda Therapeutics, Inc. Has Been Named As One Of The 100 Best Medium Workplaces Based On An Independent Survey By Fortune Magazine And Great Place To Work®. (Photo: Business Wire)
2016-10-04,Acorda Announces Departure Of Michael Rogers
2016-09-29,Oversold Conditions For Acorda Therapeutics (ACOR)
2016-09-16,5 Stocks to Trade for Big Breakout Gains
2016-09-15,(Graphic: Business Wire)
2016-07-29,Ratings Changes Today
2016-07-28,Acorda Provides Financial And Pipeline Update For Second Quarter 2016
2016-07-21,Trade-Ideas: Acorda Therapeutics (ACOR) Is Today's "Perilous Reversal" Stock
2016-07-20,Strong On High Volume: Acorda Therapeutics (ACOR)
2016-07-18,September 16th Options Now Available For Acorda Therapeutics (ACOR)
2016-07-07,Acorda To Host Conference Call To Discuss Second Quarter 2016 On July 28, 2016
2016-07-01,Acorda Appoints Burkhard Blank, M.D., As Chief Medical Officer (CMO)
2016-06-13,Biotie Therapies Corp. Announces That The Delisting Of Its American Depositary Shares From NASDAQ Global Select Market Has Become Effective
2016-06-09,Acorda Presents Phase 1 Data On CVT-427 For Acute Treatment Of Migraine At 58th Annual Scientific Meeting Of The American Headache Society
2016-05-31,Acorda Therapeutics To Present At The 37th Annual Goldman Sachs Global Healthcare Conference
2016-05-20,Acorda To Discontinue Development Of PLUMIAZ For Treatment Of Epilepsy Seizure Clusters
2016-05-18,Biotie Therapies Corp. To Delist Its American Depositary Shares From The Nasdaq Global Select Market
2016-05-04,Acorda Therapeutics Named One Of The Best Places To Work For In New York
2016-05-03,Acorda Therapeutics (ACOR) Highlighted As Today's Perilous Reversal Stock
2016-05-02,Acorda Therapeutics (ACOR) Is Today's Dead Cat Bounce Stock
2016-05-02,Final Results Of The Subsequent Offer Period Of Acorda Therapeutics' Tender Offer For All Of The Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp.
2016-04-29,Trade-Ideas: Acorda Therapeutics (ACOR) Is Today's Weak On High Relative Volume Stock
2016-04-29,Acorda Therapeutics To Present At Two Investor Conferences In May
2016-04-28,Acorda Provides Financial And Pipeline Update For First Quarter 2016
2016-04-20,Acorda Announces Results From Phase 2b Clinical Trial Of CVT-301 For Treatment Of OFF Periods In Parkinson's Disease Published In Movement Disorders
2016-04-18,Completion Of Acorda Therapeutics' Voluntary Tender Offer For All Of The Issued And Outstanding Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp. And Matters Related Thereto
2016-04-14,Acorda To Host Conference Call To Discuss First Quarter 2016 On April 28, 2016
2016-04-13,Final Results Of Acorda Therapeutics' Voluntary Tender Offer For All Of The Issued And Outstanding Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp. And Commencement Of A Subsequent Offer Period
2016-04-12,'Mad Money' Lightning Round: UnitedHealth May Be the Dow's Best Stock
2016-04-11,Jim Cramer's 'Mad Money' Recap: These Stocks Are New-High Winners
2016-04-11,Acorda Therapeutics Announces Preliminary Tender Offer Results And Acceptance Of The Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp. Tendered In Tender Offer
2016-04-07,Phase 2b Data On Inhaled Levodopa CVT-301 Featured In Invited Science Session At American Academy Of Neurology (AAN) Annual Meeting
2016-03-22,Acorda Therapeutics Supplements The Tender Offer Document Relating To The Voluntary Public Tender Offer For All Of The Issued And Outstanding Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp. On 22 March 2016
2016-03-21,Acorda Wins Federal Circuit Appeal Allowing AMPYRA® Patent Litigation To Continue In Delaware District Court
2016-03-18,Acorda Therapeutics Supplements Tender Offer Document Relating To The Voluntary Public Tender Offer For All Of The Issued And Outstanding Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies On 18 March 2016
2016-03-11,Acorda Announces Patent Trials And Appeal Board (PTAB) Institutes IPRs Of AMPYRA Patents
2016-03-10,Acorda Therapeutics, Inc. Will Commence The Voluntary Public Tender Offer For All Of The Issued And Outstanding Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp. On 11 March 2016
2016-03-03,Acorda Has Filed Tender Offer Document Relating To Public Tender Offer For Biotie Therapies With Finnish Financial Supervisory Authority
2016-03-01,Acorda Therapeutics To Present At Two Investor Conferences In March
2016-02-17,Acorda Announces Expiration Of The Hart-Scott-Rodino Waiting Period For Its Tender Offer For Biotie Therapies
2016-02-12,Ratings Changes Today
2016-02-11,Acorda Provides Financial And Pipeline Update For Fourth Quarter And Year End 2015
2016-02-04,Acorda Therapeutics To Present At Two Investor Conferences In February
2016-01-28,Acorda To Host Conference Call To Discuss Fourth Quarter And Year End 2015 Results On February 11, 2016
2016-01-26,Acorda Therapeutics (ACOR) Stock: Weak On High Volume Today
2016-01-26,7 Stocks to Trade for Breakouts on Big Volume
2016-01-19,Acorda Acquires Parkinson's Drug Through Biotie Buyout
2016-01-19,European Stocks Follow Asia Higher as China GDP Revives Hopes for Stimulus
2016-01-19,Acorda To Acquire Biotie Therapies
2016-01-11,Acorda Announces 2015 AMPYRA Sales, 2016 Financial Guidance And 2016/2017 Clinical Milestones At J.P. Morgan Healthcare Conference
2015-12-22,Acorda to Present at the 34th Annual J.P. Morgan Healthcare Conference
2015-12-21,Acorda Announces Departure Of Chief Medical Officer (CMO); Company Appoints Burkhard Blank, M.D. As Interim CMO
2015-12-08,Acorda Presents Analyses On Use Of Healthcare Services For Seizure Clusters At American Epilepsy Society Annual Meeting
2015-12-03,Acorda Initiates Phase 1 Clinical Trial Of CVT-427, Inhaled Therapy For Acute Treatment Of Migraines
2015-11-30,Acorda Therapeutics To Present At The Oppenheimer Annual Healthcare Conference
2015-11-19,Ratings Changes Today
2015-11-10,Acorda Therapeutics To Present At Two Investor Conferences In November
2015-10-23,Acorda Therapeutics (ACOR) Strong On High Relative Volume Today
2015-10-22,Acorda Provides Financial And Pipeline Update For 2015 Third Quarter
2015-10-12,Insider Trading Alert - ACOR, CMCT And NUAN Traded By Insiders
2015-10-08,Acorda Therapeutics To Host Conference Call To Discuss Third Quarter Results On October 22, 2015
2015-10-07,Insider Trading Alert - ACOR, TIPT And NUAN Traded By Insiders
2015-10-07,Acorda to Present New rHIgM22 and AMPYRA® (dalfampridine) Data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
2015-10-06,Acorda Therapeutics (ACOR) Is Today's Perilous Reversal Stock
2015-10-02,Acorda Recognized With Legal Media Group 2015 Life Sciences Award
2015-09-30,Acorda Therapeutics (ACOR) Is Today's Strong On High Volume Stock
2015-09-30,Acorda Named One Of The 100 Best Workplaces For Women By Fortune And Great Place To Work
2015-09-28,RSI Alert: Acorda Therapeutics (ACOR) Now Oversold
2015-09-03,Acorda Therapeutics To Present At The Baird 2015 Healthcare Conference
2015-08-28,Interesting ACOR Put And Call Options For April 2016
2015-08-25,Acorda Therapeutics (ACOR) Stock Climbs After Panel Dismisses Patent Challenge
2015-08-25,Pre-Market Activity Shows Heavy Volume And Movement For Acorda Therapeutics (ACOR)
2015-08-24,Acorda Announces Patent Trials And Appeal Board (PTAB) Denies Both IPRs Of AMPYRA Patents
2015-08-24,Ratings Changes Today
2015-08-05,Acorda Therapeutics To Present At The Canaccord Genuity Growth Conference
2015-07-31,Ratings Changes Today
2015-07-30,Acorda Provides Financial And Pipeline Update For 2015 Second Quarter
2015-07-22,Acorda Awarded Grant To Study ARCUS® Technology In Respiratory Distress Syndrome
2015-07-14,Acorda Therapeutics Stock Sees Short Interest Decline 10.7%
2015-06-24,Acorda Data On Inhaled Levodopa Therapy CVT-301 Recognized In Blue Ribbon Highlights Session At International Congress Of Parkinson's Disease And Movement Disorders
2015-06-23,First Week Of August 21st Options Trading For Acorda Therapeutics (ACOR)
2015-06-16,Chart Trends in Airgas, Acorda Therapeutics
2015-06-16,Acorda Presents Data On Inhaled Levodopa Therapy CVT-301 At International Congress Of Parkinson's Disease And Movement Disorders
2015-06-15,Acorda CEO Ron Cohen Named BIO Chairman For 2015-2016 Term
2015-05-26,Acorda Therapeutics To Present At The Jefferies Global Healthcare Conference
2015-05-18,Insider Trading Alert - ROP, GEVO And ACOR Traded By Insiders
2015-05-05,Acorda Therapeutics To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference
2015-05-01,Acorda Therapeutics To Present At The Deutsche Bank 40th Annual Health Care Conference
2015-04-30,Acorda Therapeutics (ACOR) Highlighted As Weak On High Volume
2015-04-30,Acorda Reports First Quarter 2015 Financial Results
2015-04-23,Acorda Therapeutics To Host Conference Call To Discuss First Quarter 2015 Financial Results On April 30, 2015
2015-04-22,Acorda Presents Data On First Clinical Study Of Remyelinating Antibody For Multiple Sclerosis At American Academy Of Neurology Annual Meeting
2015-04-22,Acorda Therapeutics Named One Of The Best Places To Work For In New York 2015
2015-03-24,ACOR Crosses Above Key Moving Average Level
2015-03-18,'Mad Money' Lightning Round: I Don't Like Caterpillar, Buy TG Therapeutics
2015-03-17,Jim Cramer's 'Mad Money' Recap: This Maddening Market Can't Make Up Its Mind
2015-03-16,Acorda Therapeutics Ringing The Opening Bell At The NASDAQ Stock Exchange, March 16, 2015 (Photo: Business Wire)
2015-03-11,Acorda Therapeutics Stock Sees Short Interest Jump 13.3%
2015-03-10,Acorda To Present New Analyses Of Cimaglermin Alfa (GGF2) Data At The 64th Annual ACC Scientific Session
2015-03-04,Acorda Therapeutics To Present At The Barclays Global Healthcare Conference
2015-02-27,Notable Two Hundred Day Moving Average Cross - ACOR
2015-02-23,Acorda Therapeutics To Present At The Cowen 35th Annual Health Care Conference
2015-02-19,'Mad Money' Lightning Round: Don't Gamble on Las Vegas Sands
2015-02-18,Jim Cramer's 'Mad Money' Recap: Forget Buffett, Think for Yourself
2015-02-17,Acorda Therapeutics (ACOR) Downgraded From Buy to Hold
2015-02-17,Acorda Therapeutics To Present At The 2015 RBC Capital Markets' Healthcare Conference
2015-02-13,Ratings Changes Today
2015-02-12,Acorda Therapeutics Reports Fourth Quarter And Full Year 2014 Financial Results
2015-02-11,3 Big-Volume Stocks to Trade for Breakouts: First Solar and More
2015-02-11,Acorda Therapeutics (ACOR) Showing Signs Of A Dead Cat Bounce Today
2015-02-05,Acorda Therapeutics To Present At The 2015 Leerink Global Healthcare Conference
2015-02-05,Acorda Therapeutics To Host Conference Call To Discuss Fourth Quarter And Year End 2014 Financial Results On February 12, 2015
2015-02-02,Acorda Announces Safety And Tolerability Data From First Clinical Trial Of Remyelinating Antibody In Multiple Sclerosis
2015-01-13,Acorda Therapeutics (ACOR) Reaches New Lifetime High Today
2015-01-13,Jim Cramer's Top Stock Picks: ISIS CELG NPSP AA ACOR
2015-01-12,Jim Cramer's 'Mad Money' Recap: Blame Tech, Oil and Retail for Today's Losses
2015-01-12,First Week Of ACOR February 20th Options Trading
2015-01-12,Acorda Provides Corporate Update At J.P. Morgan Healthcare Conference
2015-01-08,Today's Strong And Under The Radar Stock Is Acorda Therapeutics (ACOR)
2015-01-08,Biogen Idec's Critical Nerve Repair Drug is Poised for Big News -- Soon
2015-01-06,Acorda To Present At The 33rd Annual J.P. Morgan Healthcare Conference
2014-12-15,Acorda Announces Initiation Of Phase 3 Clinical Trial For Dalfampridine In Post-Stroke Walking Deficits
2014-12-10,Acorda Announces Initiation Of Phase 3 Trial Of CVT-301 In Parkinson's Disease
2014-12-02,Acorda Therapeutics To Present At The 26th Annual Piper Jaffray Healthcare Conference
2014-11-14,Acorda Therapeutics To Present At The Jefferies 2014 Global Healthcare Conference
2014-11-12,Acorda Therapeutics To Present At The Stifel 2014 Healthcare Conference
2014-11-04,Acorda Therapeutics To Present At The Credit Suisse 2014 Healthcare Conference
2014-10-30,Acorda Therapeutics Reports Third Quarter 2014 Financial Results
2014-10-24,First Week of December 20th Options Trading For Acorda Therapeutics (ACOR)
2014-10-23,Acorda Therapeutics To Host Conference Call To Discuss Third Quarter 2014 Financial Results On October 30, 2014
2014-10-22,Acorda Therapeutics Completes Acquisition Of Civitas Therapeutics
2014-10-20,Insider Trading Alert - IBKR, C And ACOR Traded By Insiders
2014-10-08,Insider Trading Alert - HCN, ACOR And DRII Traded By Insiders
2014-10-03,Jim Cramer's Top Stock Picks: CMG UA TAP ACOR
2014-10-02,Jim Cramer's 'Mad Money' Recap: Are You Ready to Profit From Friday's Panic?
2014-09-25,Perilous Reversal Watch: Acorda Therapeutics (ACOR)
2014-09-25,How to Trade the Market's Most-Active Stocks: KBH, BBBY, ACOR
2014-09-24,Jim Cramer's 'Mad Money' Recap: Why You Can't Get Too Negative in This Market
2014-09-24,Acorda Acquires Civitas Therapeutics for $525M for Parkinson's Treatment
2014-09-24,Why Acorda Therapeutics (ACOR) Stock Is Rising Today
2014-09-24,Acorda Therapeutics (ACOR) Moving On Heavy Pre-Market Trading
2014-09-24,Acorda Therapeutics To Acquire Civitas Therapeutics
2014-09-10,Acorda Therapeutics And HealthCore To Present Real World Health Economics And Outcomes Data On Multiple Sclerosis Therapy AMPYRA
2014-09-04,Acorda Therapeutics To Present At The Aegis Capital 2014 Healthcare And Technology Conference
2014-09-02,Acorda Therapeutics To Present At The Morgan Stanley Global Healthcare Conference
2014-08-27,Acorda Therapeutics To Present At The Baird 2014 Healthcare Conference
2014-08-20,First Week of ACOR April 2015 Options Trading
2014-07-31,Acorda Therapeutics Reports Second Quarter 2014 Financial Results
2014-07-24,Acorda Therapeutics To Host Conference Call To Discuss Second Quarter 2014 Financial Results On July 31, 2014
2014-06-26,Acorda Therapeutics Announces Notification Of ANDA Filing For AMPYRA&#174;
2014-06-19,Acorda Therapeutics (ACOR) Highlighted As Today's Perilous Reversal Stock
2017-03-15,Aclaris Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update
2017-02-27,Aclaris Therapeutics Submits New Drug Application For A-101 As A Novel Treatment For Seborrheic Keratosis - A Common Skin Condition
2017-02-23,Aclaris Therapeutics To Announce Fourth Quarter And Full Year 2016 Financial Results On March 15, 2017
2017-02-06,Aclaris Therapeutics is Now Oversold (ACRS)
2017-02-06,Aclaris Therapeutics To Attend Upcoming Investor Conferences
2017-02-06,Skin Lesion Drug Only Scratches the Surface, Says Aclaris CEO
2017-02-06,New Skin Lesion Drug Only Scratches Market's Surface, Says Aclaris CEO
2017-01-26,Aclaris Therapeutics Announces Appointment Of Andrew Powell To Board Of Directors
2017-01-03,Aclaris To Present At 35th Annual J.P. Morgan Healthcare Conference
2016-12-28,Commit To Buy Aclaris Therapeutics At $22.50, Earn 12.2% Annualized Using Options
2016-12-07,Aclaris Therapeutics Initiates Phase 1 Clinical Trial For ATI-50001, An Investigational JAK Inhibitor, For The Treatment Of Alopecia Totalis And Alopecia Universalis
2016-11-22,Aclaris Therapeutics To Attend Upcoming Investor Conferences
2016-11-17,Aclaris Announces Pricing Of Public Offering Of Common Stock
2016-11-16,Aclaris Announces Proposed Public Offering Of Common Stock
2016-11-15,Aclaris Therapeutics Announces Positive Top-Line Phase 3 Results For A-101 In Treating Seborrheic Keratosis, A Common Undertreated Skin Condition
2016-11-03,Aclaris Therapeutics Reports Third Quarter 2016 Financial Results
2016-10-31,Aclaris Therapeutics Submits Investigational New Drug Application For ATI-50001 To Treat Alopecia Universalis And Alopecia Totalis
2016-10-28,Aclaris Therapeutics Honored As One Of The Best Places To Work In Pennsylvania
2016-10-27,Aclaris Therapeutics Becomes Oversold
2016-10-25,Aclaris Therapeutics To Announce Third Quarter 2016 Financial Results On November 3, 2016
2016-10-19,New Observational Study Demonstrates Patient Impact Of Seborrheic Keratosis, A Common, Undertreated Skin Condition Affecting 83.8 Million Americans
2016-09-06,Aclaris Therapeutics To Present At The Morgan Stanley 2016 Healthcare Conference
2016-08-18,Aclaris Therapeutics Announces Positive Results In Phase 2 Clinical Trial Of A-101 For Treatment Of Common Warts  
2016-08-11,Aclaris Therapeutics Reports Second Quarter 2016 Financial Results
2016-08-04,Aclaris Announces Appointment Of Bill Humphries To Board Of Directors
2016-08-02,Aclaris Therapeutics To Announce Second Quarter 2016 Financial Results On August 11, 2016
2016-07-25,Aclaris Therapeutics Completes Enrollment Of Phase 3 Pivotal Trials Of A-101 For The Treatment Of Seborrheic Keratosis (SK); Provides Update On Clinical Programs
2016-07-13,Short Interest Surges 58% For ACRS
2016-07-05,Aclaris Therapeutics To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference
2016-05-31,Aclaris Therapeutics To Present At Upcoming Investor Conferences In June
2016-05-27,Aclaris Therapeutics Announces $20.0 Million Private Placement
2016-05-11,Aclaris Therapeutics Reports First Quarter 2016 Financial Results
2016-05-05,Aclaris Therapeutics, Inc. Appoints Kevin Scott As Vice President Of Sales
2016-05-02,Aclaris Therapeutics To Present At The Bank Of America Merrill Lynch 2016 Healthcare Conference
2016-04-26,Aclaris Therapeutics To Announce First Quarter 2016 Financial Results On May 11, 2016
2016-03-28,Aclaris Therapeutics Acquires Worldwide Rights To Compounds And Key Intellectual Property For Potential Treatment For Hair Loss
2016-03-23,Aclaris Therapeutics Reports Fourth Quarter And Full Year 2015 Operating And Financial Results
2016-03-17,Aclaris Therapeutics Becomes Oversold (ACRS)
2016-03-17,Aclaris Therapeutics To Announce Fourth Quarter And Full Year 2015 Financial Results On March 23, 2016
2016-02-17,Aclaris Therapeutics Enters Oversold Territory
2016-02-05,Aclaris Therapeutics To Present At The 2016 Leerink Partners Annual Global Healthcare Conference
2016-01-19,Aclaris Therapeutics Initiates Phase 3 Clinical Trials Of A-101 For The Treatment Of Seborrheic Keratosis
2015-12-22,Aclaris Therapeutics, Inc. Added To Russell 2000® Index
2015-12-16,Aclaris Therapeutics, Inc. Appoints Brett Fair As Senior Vice President Of Commercial Operations
2015-12-07,Aclaris Therapeutics Initiates Phase 2 Clinical Trial Of A-101 For Treatment Of Common Warts
2015-11-18,Aclaris Therapeutics Reports Third Quarter 2015 Financial Results
2015-11-04,5 Stocks With Big Insider Buying -- Should You Love Them Too?
2015-10-21,5 Stocks Insiders Love Right Now
2015-10-13,Aclaris Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-10-07,Jim Cramer's 'Mad Money' Recap: Watching China Warily, Again
,
,
,
,
2017-03-15,Aclaris Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update
2017-02-27,Aclaris Therapeutics Submits New Drug Application For A-101 As A Novel Treatment For Seborrheic Keratosis - A Common Skin Condition
2017-02-23,Aclaris Therapeutics To Announce Fourth Quarter And Full Year 2016 Financial Results On March 15, 2017
2017-02-06,Aclaris Therapeutics is Now Oversold (ACRS)
2017-02-06,Aclaris Therapeutics To Attend Upcoming Investor Conferences
2017-02-06,Skin Lesion Drug Only Scratches the Surface, Says Aclaris CEO
2017-02-06,New Skin Lesion Drug Only Scratches Market's Surface, Says Aclaris CEO
2017-01-26,Aclaris Therapeutics Announces Appointment Of Andrew Powell To Board Of Directors
2017-01-03,Aclaris To Present At 35th Annual J.P. Morgan Healthcare Conference
2016-12-28,Commit To Buy Aclaris Therapeutics At $22.50, Earn 12.2% Annualized Using Options
2016-12-07,Aclaris Therapeutics Initiates Phase 1 Clinical Trial For ATI-50001, An Investigational JAK Inhibitor, For The Treatment Of Alopecia Totalis And Alopecia Universalis
2016-11-22,Aclaris Therapeutics To Attend Upcoming Investor Conferences
2016-11-17,Aclaris Announces Pricing Of Public Offering Of Common Stock
2016-11-16,Aclaris Announces Proposed Public Offering Of Common Stock
2016-11-15,Aclaris Therapeutics Announces Positive Top-Line Phase 3 Results For A-101 In Treating Seborrheic Keratosis, A Common Undertreated Skin Condition
2016-11-03,Aclaris Therapeutics Reports Third Quarter 2016 Financial Results
2016-10-31,Aclaris Therapeutics Submits Investigational New Drug Application For ATI-50001 To Treat Alopecia Universalis And Alopecia Totalis
2016-10-28,Aclaris Therapeutics Honored As One Of The Best Places To Work In Pennsylvania
2016-10-27,Aclaris Therapeutics Becomes Oversold
2016-10-25,Aclaris Therapeutics To Announce Third Quarter 2016 Financial Results On November 3, 2016
2016-10-19,New Observational Study Demonstrates Patient Impact Of Seborrheic Keratosis, A Common, Undertreated Skin Condition Affecting 83.8 Million Americans
2016-09-06,Aclaris Therapeutics To Present At The Morgan Stanley 2016 Healthcare Conference
2016-08-18,Aclaris Therapeutics Announces Positive Results In Phase 2 Clinical Trial Of A-101 For Treatment Of Common Warts  
2016-08-11,Aclaris Therapeutics Reports Second Quarter 2016 Financial Results
2016-08-04,Aclaris Announces Appointment Of Bill Humphries To Board Of Directors
2016-08-02,Aclaris Therapeutics To Announce Second Quarter 2016 Financial Results On August 11, 2016
2016-07-25,Aclaris Therapeutics Completes Enrollment Of Phase 3 Pivotal Trials Of A-101 For The Treatment Of Seborrheic Keratosis (SK); Provides Update On Clinical Programs
2016-07-13,Short Interest Surges 58% For ACRS
2016-07-05,Aclaris Therapeutics To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference
2016-05-31,Aclaris Therapeutics To Present At Upcoming Investor Conferences In June
2016-05-27,Aclaris Therapeutics Announces $20.0 Million Private Placement
2016-05-11,Aclaris Therapeutics Reports First Quarter 2016 Financial Results
2016-05-05,Aclaris Therapeutics, Inc. Appoints Kevin Scott As Vice President Of Sales
2016-05-02,Aclaris Therapeutics To Present At The Bank Of America Merrill Lynch 2016 Healthcare Conference
2016-04-26,Aclaris Therapeutics To Announce First Quarter 2016 Financial Results On May 11, 2016
2016-03-28,Aclaris Therapeutics Acquires Worldwide Rights To Compounds And Key Intellectual Property For Potential Treatment For Hair Loss
2016-03-23,Aclaris Therapeutics Reports Fourth Quarter And Full Year 2015 Operating And Financial Results
2016-03-17,Aclaris Therapeutics Becomes Oversold (ACRS)
2016-03-17,Aclaris Therapeutics To Announce Fourth Quarter And Full Year 2015 Financial Results On March 23, 2016
2016-02-17,Aclaris Therapeutics Enters Oversold Territory
2016-02-05,Aclaris Therapeutics To Present At The 2016 Leerink Partners Annual Global Healthcare Conference
2016-01-19,Aclaris Therapeutics Initiates Phase 3 Clinical Trials Of A-101 For The Treatment Of Seborrheic Keratosis
2015-12-22,Aclaris Therapeutics, Inc. Added To Russell 2000® Index
2015-12-16,Aclaris Therapeutics, Inc. Appoints Brett Fair As Senior Vice President Of Commercial Operations
2015-12-07,Aclaris Therapeutics Initiates Phase 2 Clinical Trial Of A-101 For Treatment Of Common Warts
2015-11-18,Aclaris Therapeutics Reports Third Quarter 2015 Financial Results
2015-11-04,5 Stocks With Big Insider Buying -- Should You Love Them Too?
2015-10-21,5 Stocks Insiders Love Right Now
2015-10-13,Aclaris Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-10-07,Jim Cramer's 'Mad Money' Recap: Watching China Warily, Again
,
,
,
,
2017-03-17,AcelRx Pharmaceuticals To Participate At Three Upcoming Investor Events In March And April
2017-03-01,AcelRx Pharmaceuticals To Participate At Two Upcoming Investor Events In March
2017-02-27,AcelRx Pharmaceuticals' New Drug Application For DSUVIA Accepted For Filing With PDUFA Date Of October 12, 2017
2017-02-23,AcelRx Pharmaceuticals To Hold Annual 2016 Financial Results Conference Call And Webcast On Thursday, March 2nd, 2017
2017-02-16,AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer
2017-02-07,AcelRx Pharmaceuticals To Participate At Four Upcoming Investor Events In February
2017-01-08,AcelRx Pharmaceuticals Provides Guidance On 2017 Milestones For ARX-04, Now Known As DSUVIA™ In The United States, For The Treatment Of Moderate-to-Severe Acute Pain
2017-01-08,AcelRx Pharmaceuticals Announces DSUVIA™ As Brand Name For ARX-04 In The United States
2016-12-13,AcelRx Pharmaceuticals Submits New Drug Application For ARX-04 For The Treatment Of Moderate-To-Severe Acute Pain
2016-12-06,AcelRx Pharmaceuticals Reports On ARX-04 Market And Landscape Presented At Analyst & Investor Event
2016-11-28,AcelRx Pharmaceuticals Updates Agenda For Analyst & Investor Event Focusing On Innovative Therapies For Treatment Of Acute Pain
2016-11-09,AcelRx Pharmaceuticals To Host Analyst & Investor Event On December 1, 2016
2016-11-08,AcelRx Pharmaceuticals To Participate At Three Upcoming Investor Events In November
2016-10-25,AcelRx Pharmaceuticals To Hold Third Quarter Financial Results Conference Call And Webcast On Tuesday, November 1st, 2016
2016-10-13,ACRX: Insiders vs. Shorts
2016-09-27,AcelRx Initiates Phase 3 Study Of Zalviso® In Patients With Moderate-to-Severe Acute Post-Operative Pain
2016-09-22,AcelRx Pharmaceuticals To Present At The Ladenburg Thalmann 2016 Healthcare Conference
2016-09-15,Here's Why AcelRx Pharmaceuticals (ACRX) Stock Gained Today
2016-09-15,AcelRx Reports Positive Results For ARX-04 (sufentanil Sublingual Tablet, 30 Mcg), Including In Elderly Patients And Patients With Organ Impairment, In Third Phase 3 Registration Trial, SAP303
2016-09-14,AcelRx Pharmaceuticals To Announce Topline Results In Phase 3 Study Of ARX-04 In Patients With Post-Operative Moderate-to-Severe Acute Pain
2016-08-31,AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in September
2016-08-15,AcelRx Pharmaceuticals' ARX-04 Phase 3 Trial Met Its Primary Endpoint, Reduced Pain Intensity In ER Patients With Moderate-to-Severe Acute Pain
2016-07-26,AcelRx Pharmaceuticals To Hold Second Quarter Financial Results Conference Call And Webcast On Thursday, July 28th, 2016
2016-07-06,AcelRx Pharmaceuticals To Present At Cantor Fitzgerald 2nd Annual Healthcare Conference
2016-06-28,AcelRx Pharmaceuticals Completes Patient Enrollment In Remaining Phase 3 Studies Of ARX-04 As A Potential Treatment Of Moderate-to-Severe Acute Pain
2016-06-27,AcelRx Pharmaceuticals Joins Russell 3000 And Russell 2000 Indexes
2016-06-02,AcelRx Pharmaceuticals To Participate In Three Upcoming Healthcare Investor Events In June
2016-05-04,AcelRx Pharmaceuticals To Present At Two Upcoming Investor Events In May
2016-04-28,AcelRx Pharmaceuticals To Hold First Quarter Financial Results Conference Call And Webcast On Monday, May 2nd, 2016
2016-03-29,AcelRx Pharmaceuticals Names Howard B. Rosen As Chief Executive Officer And Provides Update On Clinical Development Activities And Corporate Priorities For 2016
2016-03-25,AcelRx Publishes A Review Of Hospital-Based Opioid Patient-Controlled Analgesia, Risks And Pharmacoeconomics
2016-03-14,AcelRx Pharmaceuticals Advances ARX-04 into Extension Phase of Open-Label Phase 3 Emergency Room Study
2016-03-07,AcelRx Pharmaceuticals Initiates Phase 3 Study Of ARX-04 In Patients With Post-Operative Moderate-to-Severe Acute Pain
2016-03-03,AcelRx Pharmaceuticals To Hold Annual 2015 Financial Results Conference Call And Webcast On Monday, March 7th, 2016.
2016-03-01,AcelRx Pharmaceuticals To Present At Two Upcoming Investor Events In March
2016-02-25,AcelRx Pharmaceuticals' Moderate-to-Severe Acute Pain Candidate ARX-04 Shows Improved Pain Scores In ER Patients In Interim Phase 3 Analysis
2016-02-03,AcelRx Pharmaceuticals To Present At Two Upcoming Investor Events In February
2016-01-27,First Week of ACRX September 16th Options Trading
2016-01-21,AcelRx Pharmaceuticals Announces Presentation Of Phase 3 Sufentanil Sublingual 30 Mcg Tablet (ARX-04) Data At The European Congress Of Ambulatory Surgery
2016-01-10,AcelRx Pharmaceuticals Announces Anticipated 2016 Milestones
2016-01-08,AcelRx Completes Protocol Review With FDA And Plans To Initiate Phase 3 Open-Label Study (IAP312) For Zalviso™ In 1Q 2016
2015-12-23,AcelRx Pharmaceuticals Receives Notice Of Eligibility For Centralized Review Of ARX-04 From European Medicines Agency
2015-12-14,AcelRx Pharmaceuticals Conducts Pre-NDA Meeting with U.S. Food and Drug Administration for ARX-04
2015-12-02,AcelRx Pharmaceuticals (ACRX) Highlighted As Weak On High Volume
2015-11-23,AcelRx Pharmaceuticals To Present At Piper Jaffray 27th Annual Healthcare Conference
2015-11-13,AcelRx Pharmaceuticals (ACRX) Strong On High Relative Volume Today
2015-11-10,AcelRx Pharmaceuticals To Present At Jefferies 2015 Global Healthcare Conference
2015-11-05,AcelRx Pharmaceuticals To Present At Credit Suisse 24th Annual Healthcare Conference
2015-11-04,AcelRx Pharmaceuticals Presents Data From Phase 3 Clinical Trials Evaluating The Safety And Efficacy Of Zalviso In Obese Surgical Patients
2015-10-26,AcelRx Pharmaceuticals To Hold Business Update And Third Quarter Financial Results Conference Call And Webcast On Thursday, Oct 29th, 2015
2015-10-23,AcelRx Pharmaceuticals Announces Presentation Of Phase 3 Data From ARX-04 Sufentanil Sublingual 30 Mcg Program At The American Society Of Anesthesiology Meeting
2015-10-08,AcelRx Pharmaceuticals Provides Regulatory Update On Zalviso
2015-10-06,AcelRx Pharmaceuticals Announces Initiation Of Clinical Study With ARX-04 In Emergency Room Patients With Moderate-to-Severe Acute Pain
2015-10-02,Amicus, Other Biotech CEOs Should Listen More, Talk Less About FDA Matters
2015-10-01,AcelRx Pharmaceuticals Appoints Gina Ford As Vice President Commercial Strategy
2015-09-24,AcelRx Pharmaceuticals To Host Analyst & Investor Event On October 2, 2015
2015-09-22,AcelRx Pharmaceuticals Reports That The European Commission Has Granted Marketing Authorization For Zalviso™ For Treatment Of Acute Moderate-to-Severe Post-Operative Pain In Adult Patients
2015-09-21,PDL BioPharma Acquires A Portion Of AcelRx Pharmaceuticals' Expected Royalties And Commercial Milestones From Zalviso™ For $65 Million
2015-09-21,AcelRx Pharmaceuticals Receives $65 Million From The Partial Sale Of Zalviso™ European Royalties And Commercial Milestones To PDL BioPharma
2015-09-09,AcelRx Pharmaceuticals' ARX-04 Meets All Endpoints In Pivotal Phase 3 Study For Moderate-to-Severe Acute Pain
2015-08-26,AcelRx Pharmaceuticals To Participate At Three Investor Conferences In September
2015-07-29,AcelRx Pharmaceuticals To Hold Business Update And Second Quarter Financial Results Conference Call And Webcast On Monday, Aug. 3rd, 2015.
2015-07-24,5 Stocks Poised for Breakouts
2015-07-24,AcelRx Announces Positive CHMP Opinion For Zalviso In The Management Of Acute Moderate-to-Severe Post-Operative Pain In Adult Patients
2015-07-14,3 Stocks Under $10 to Trade for Breakouts
2015-07-02,Zalviso™ Phase 3 Orthopedic Results Published In Anesthesiology Demonstrate Significant Reductions In Post-Operative Pain
2015-07-01,10 Worst Biotech Stocks in the NASDAQ
2015-05-22,AcelRx Pharmaceuticals To Present At Two Upcoming Investor Conferences In June
2015-05-14,AcelRx Awarded Contract From Department Of Defense To Advance ARX-04
2015-05-08,Insider Trading Alert - LAD, RSE And ACRX Traded By Insiders
2015-05-01,AcelRx Pharmaceuticals To Participate At Upcoming Investor Conferences In May
2015-04-30,AcelRx Pharmaceuticals To Hold First Quarter Financial Results Conference Call And Webcast On Monday, May 4th, 2015
2015-04-24,Insider Trading Alert - STFC, ACRX And CSC Traded By Insiders
2015-03-23,AcelRx Pharmaceuticals: What Went Wrong and What's on the Horizon for the Struggling Biotech?
2015-03-20,AcelRx Appoints Howard B. Rosen As Interim CEO
2015-03-16,AcelRx Pharmaceuticals Announces Initiation Of Pivotal Phase 3 Trial For ARX-04
2015-03-13,INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AcelRx Pharmaceuticals, Inc. (ACRX) To Contact The Firm
2015-03-10,AcelRx Pharmaceuticals (ACRX) Stock Extends Losses Today as Jefferies Downgrades
2015-03-09,EQUITY ALERT: The Rosen Law Firm Announces Investigation Of Securities Claims Against AcelRx Pharmaceuticals, Inc. - ACRX
2015-03-09,AcelRx Pharmaceuticals (ACRX) Stock Tanks Today on FDA Demand For Further Zalviso Trials
2015-03-09,AcelRx Pharmaceuticals Is Now Oversold (ACRX)
2015-03-09,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of AcelRx Pharmaceuticals, Inc. - ACRX
2015-03-09,AcelRx Provides Regulatory Update On Zalviso
2015-03-04,AcelRx Pharmaceuticals To Hold Annual 2014 Financial Results Conference Call And Webcast On Monday, March 9th, 2015
2015-02-20,AcelRx Pharmaceuticals To Participate At Two Upcoming Investor Events
2015-02-04,AcelRx Pharmaceuticals To Present At BIO CEO & Investor Conference
2015-01-15,Will the Second Time be a Charm for Biotech AcelRx After Their FDA Rejection?
2015-01-09,5 Stocks Under $10 Setting Up to Trade Higher: Callon Petroleum and More
2014-12-30,AcelRx Pharmaceuticals (ACRX) Downgraded From Hold to Sell
2014-12-29,Ratings Changes Today
2014-12-02,AcelRx Pharmaceuticals Receives CE Mark Approval For Zalviso
2014-11-20,AcelRx Pharmaceuticals To Participate In Four Upcoming Investor Events
2014-11-19,SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In AcelRx Pharmaceuticals, Inc. To Contact Brower Piven Before The December 1, 2014 Lead Plaintiff Deadline In Class Action Lawsuit
2014-11-17,UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors Of Class Action Against AcelRx Pharmaceuticals, Inc. And Its Board Of Directors And A Lead Plaintiff Deadline Of December 1, 2014
2014-11-12,AcelRx Pharmaceuticals (ACRX) Upgraded From Sell to Hold
2014-11-11,AcelRx Pharmaceuticals (ACRX) Stock Rises After Third-Quarter Earnings Report
2014-11-11,Ratings Changes Today
2014-11-10,AcelRx Pharmaceuticals Receives International Standards Organization (ISO) 13485:2003 Certification Of Its Quality Management System
2014-11-07,AcelRx Pharmaceuticals To Participate In Two Upcoming Investor Events
2014-11-06,INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors Of The Lead Plaintiff Deadline In The Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc.
2014-11-06,AcelRx Pharmaceuticals To Hold Third Quarter Financial Results Conference Call And Webcast On Monday, November 10, 2014
2014-11-05,Acelrx Pharmaceuticals Announces Management Change
2014-10-27,AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentations At The American College Of Surgeons Meeting
2014-10-22,AcelRx Announces Publication Of Zalviso Phase 3 Abdominal Trial Results
2014-10-16,AcelRx Pharmaceuticals Provides Update On Its Patent Portfolio For Zalviso™ And Its Proprietary Platform Technologies
2014-10-15,SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In AcelRx Pharmaceuticals, Inc. To Contact Brower Piven Before The December 1, 2014 Lead Plaintiff Deadline In Class Action Lawsuit
2014-10-07,Harwood Feffer LLP Announces Investigation Of AcelRx Pharmaceuticals, Inc.
2014-10-07,Lifshitz & Miller Law Firm Announces Investigation Of AcelRx Pharmaceuticals, Inc., Ambit Biosciences, Athlon Energy Inc., LipoScience, Inc., Simplicity Bancorp, Inc., And TIBCO Software Inc.
2014-10-07,AcelRx Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors
2014-10-03,INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $50,000 Investing In AcelRx Pharmaceuticals, Inc. (ACRX) To Contact The Firm
2014-10-02,INVESTOR ALERT: Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. Filed By Glancy Binkow & Goldberg LLP
2014-09-29,Strong On High Volume: AcelRx Pharmaceuticals (ACRX)
2014-09-26,Why AcelRx Pharmaceuticals (ACRX) Stock Hit a One-Year Low Today
2014-09-26,AcelRx Pharmaceuticals Provides Regulatory Update On Zalviso™
2014-09-10,AcelRx Announces Publication Of Manuscript Analyzing Cost Of Intravenous Patient-Controlled Analgesia With Opioids
2014-09-04,AcelRx Announces Publication Of Sufentanil Sublingual Tablet System Vs. Intravenous Patient-Controlled Analgesia With Morphine For Postoperative Pain Study Results
2014-08-27,AcelRx Pharmaceuticals To Participate In Two Upcoming Investor Events
2014-08-26,The Best Hedge Fund You've Never Heard Of and Its Top 5 Stock Picks
2014-08-08,AcelRx Pharmaceuticals To Participate In Three Upcoming Investor Events
2014-08-07,AcelRx Pharmaceuticals To Hold Second Quarter Financial Results Conference Call And Webcast On Monday, August 11th, 2014.
2014-08-01,Perilous Reversal Stock: AcelRx Pharmaceuticals (ACRX)
2014-08-01,4 Biotech Stocks Under $10 to Trade for Breakouts
2014-07-29,Today's Dead Cat Bounce Stock: AcelRx Pharmaceuticals (ACRX)
2014-07-28,Why AcelRx Pharmaceuticals (ACRX) Stock Is Plummeting Today
2014-07-28,FDA Rejects AcelRx Painkiller Dispensing Device (Update)
2014-07-28,AcelRx Pharmaceuticals (ACRX) Moving On Heavy Volume In The Pre-Market Hours
2014-07-25,AcelRx Pharmaceuticals Receives Complete Response Letter From FDA For New Drug Application For Zalviso™
2014-07-24,AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date For Zalviso
2014-07-24,4 Biotech Stocks Breaking Out on Big Volume
2014-07-18,Biotech Stock Mailbag: AcelRx, Yellen Aftermath, Nymox
2014-07-14,Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events
2014-07-07,AcelRx And Grunenthal Announce Submission Of European Marketing Authorization Application For ZALVISO™
2014-07-03,5 Stocks Spiking on Unusual Volume
2014-06-25,First Week of August 16th Options Trading For AcelRx Pharmaceuticals (ACRX)
2014-06-19,AcelRx Pharmaceuticals To Present At The JMP Securities Healthcare Conference
2014-06-06,Oversold Conditions For AcelRx Pharmaceuticals (ACRX)
2014-06-03,Results Of Cost Analysis Study Presented At ISPOR Meeting Identify Intravenous Patient-Controlled Analgesia (IV PCA) Costs Of $200 To $240 For Two Days Of Post-Surgical Pain Management
2014-05-29,AcelRx Pharmaceuticals To Present At The Jefferies Global Healthcare Conference
2014-05-19,AcelRx Pharmaceuticals To Present At The UBS Global Healthcare Conference
2014-05-14,AcelRx Pharmaceuticals is Now Oversold (ACRX)
2014-05-02,AcelRx Pharmaceuticals To Hold First Quarter Financial Results Conference Call And Webcast On Thursday, May 8, 2014
2014-05-01,AcelRx Pharmaceuticals Announces Zalviso&#8482; And ARX-04 Data Presentations At The American Pain Society 33rd Annual Scientific Meeting
2014-04-25,First Week of ACRX December 20th Options Trading
2014-04-04,AcelRx Pharmaceuticals To Present At The 13th Annual Needham Healthcare Conference
2014-03-27,Interesting ACRX Put And Call Options For May 17th
2014-03-25,AcelRx Pharmaceuticals Appoints Timothy E. Morris As Chief Financial Officer
2014-03-07,AcelRx Pharmaceuticals To Participate At The 26th Annual Roth Conference
2014-02-24,AcelRx Pharmaceuticals To Hold Fourth Quarter And Annual 2013 Financial Results Conference Call And Webcast On Monday, March 3, 2014
2014-02-05,AcelRx Pharmaceuticals To Participate In Three Upcoming Investor Events
2013-12-30,First Week of ACRX February 2014 Options Trading
2013-12-19,AcelRx Secures $40 Million Credit Facility With Hercules Technology Growth Capital
2013-12-16,AcelRx And Grunenthal Announce Collaboration For EU Commercialization Of ZALVISO&#8482;
2013-12-13,AcelRx Pharmaceuticals Presents ARX-04 Dose-Finding Phase 2 Study Data At Anesthesia Medical Conference
2013-12-11,AcelRx Pharmaceuticals Adds New Board Member
2013-12-02,Zalviso&#8482; New Drug Application Accepted For Filing By FDA
2013-11-26,AcelRx Pharmaceuticals To Present At The 25th Annual Piper Jaffray Healthcare Conference
2013-11-19,First Week Of ACRX January 2014 Options Trading
2013-11-13,5 Stocks With Big Insider Buying
2013-11-13,Top Insider Trades: AGCO VVUS INWK ACRX
2013-11-06,Oversold Conditions For AcelRx Pharmaceuticals (ACRX)
2013-11-05,Top Insider Trades: ACW ZINC ACRX FCX
2013-10-23,First Week Of ACRX June 2014 Options Trading
2013-10-22,AcelRx Pharmaceuticals To Hold Third Quarter 2013 Financial Results Conference Call And Webcast On November 5, 2013
2013-10-15,AcelRx Pharmaceuticals Announces Data Presentations For Zalviso™ At US And International Medical Meetings
2013-10-14,AcelRx Pharmaceuticals Becomes Oversold (ACRX)
2013-10-08,AcelRx Pharmaceuticals Provides Update On Its Patent Portfolio For Zalviso™ And Its Proprietary Platform Technologies
2013-09-30,AcelRx Pharmaceuticals Submits New Drug Application To The FDA For Zalviso™
2013-09-27,5 Stocks Poised for Breakouts
2013-09-04,David H. Chung Joins AcelRx Pharmaceuticals As Chief Commercial Officer
2013-08-30,AcelRx Pharmaceuticals To Present At The Stifel Healthcare Conference 2013
2013-08-05,5 Stocks Ready to Break Out
2013-08-05,AcelRx Pharmaceuticals To Present At Canaccord Genuity 33rd Annual Growth Conference
2013-08-02,AcelRx Pharmaceuticals To Hold Second Quarter 2013 Financial Results Conference Call And Webcast On August 12, 2013
2013-07-31,5 Stocks With Big Insider Buying
2013-07-25,Top Insider Trades: ACRX EBAY RLGY BERY
2013-07-23,AcelRx Pharmaceuticals Announces Closing Of Public Offering And Exercise Of Option To Purchase Additional Shares
2013-07-18,AcelRx Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2013-07-17,AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2013-07-08,5 Stocks Spiking on Unusual Volume
2013-07-02,AcelRx Pharmaceuticals Joins Russell Global And Russell 3000 Indexes
2017-03-17,AcelRx Pharmaceuticals To Participate At Three Upcoming Investor Events In March And April
2017-03-01,AcelRx Pharmaceuticals To Participate At Two Upcoming Investor Events In March
2017-02-27,AcelRx Pharmaceuticals' New Drug Application For DSUVIA Accepted For Filing With PDUFA Date Of October 12, 2017
2017-02-23,AcelRx Pharmaceuticals To Hold Annual 2016 Financial Results Conference Call And Webcast On Thursday, March 2nd, 2017
2017-02-16,AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer
2017-02-07,AcelRx Pharmaceuticals To Participate At Four Upcoming Investor Events In February
2017-01-08,AcelRx Pharmaceuticals Provides Guidance On 2017 Milestones For ARX-04, Now Known As DSUVIA™ In The United States, For The Treatment Of Moderate-to-Severe Acute Pain
2017-01-08,AcelRx Pharmaceuticals Announces DSUVIA™ As Brand Name For ARX-04 In The United States
2016-12-13,AcelRx Pharmaceuticals Submits New Drug Application For ARX-04 For The Treatment Of Moderate-To-Severe Acute Pain
2016-12-06,AcelRx Pharmaceuticals Reports On ARX-04 Market And Landscape Presented At Analyst & Investor Event
2016-11-28,AcelRx Pharmaceuticals Updates Agenda For Analyst & Investor Event Focusing On Innovative Therapies For Treatment Of Acute Pain
2016-11-09,AcelRx Pharmaceuticals To Host Analyst & Investor Event On December 1, 2016
2016-11-08,AcelRx Pharmaceuticals To Participate At Three Upcoming Investor Events In November
2016-10-25,AcelRx Pharmaceuticals To Hold Third Quarter Financial Results Conference Call And Webcast On Tuesday, November 1st, 2016
2016-10-13,ACRX: Insiders vs. Shorts
2016-09-27,AcelRx Initiates Phase 3 Study Of Zalviso® In Patients With Moderate-to-Severe Acute Post-Operative Pain
2016-09-22,AcelRx Pharmaceuticals To Present At The Ladenburg Thalmann 2016 Healthcare Conference
2016-09-15,Here's Why AcelRx Pharmaceuticals (ACRX) Stock Gained Today
2016-09-15,AcelRx Reports Positive Results For ARX-04 (sufentanil Sublingual Tablet, 30 Mcg), Including In Elderly Patients And Patients With Organ Impairment, In Third Phase 3 Registration Trial, SAP303
2016-09-14,AcelRx Pharmaceuticals To Announce Topline Results In Phase 3 Study Of ARX-04 In Patients With Post-Operative Moderate-to-Severe Acute Pain
2016-08-31,AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in September
2016-08-15,AcelRx Pharmaceuticals' ARX-04 Phase 3 Trial Met Its Primary Endpoint, Reduced Pain Intensity In ER Patients With Moderate-to-Severe Acute Pain
2016-07-26,AcelRx Pharmaceuticals To Hold Second Quarter Financial Results Conference Call And Webcast On Thursday, July 28th, 2016
2016-07-06,AcelRx Pharmaceuticals To Present At Cantor Fitzgerald 2nd Annual Healthcare Conference
2016-06-28,AcelRx Pharmaceuticals Completes Patient Enrollment In Remaining Phase 3 Studies Of ARX-04 As A Potential Treatment Of Moderate-to-Severe Acute Pain
2016-06-27,AcelRx Pharmaceuticals Joins Russell 3000 And Russell 2000 Indexes
2016-06-02,AcelRx Pharmaceuticals To Participate In Three Upcoming Healthcare Investor Events In June
2016-05-04,AcelRx Pharmaceuticals To Present At Two Upcoming Investor Events In May
2016-04-28,AcelRx Pharmaceuticals To Hold First Quarter Financial Results Conference Call And Webcast On Monday, May 2nd, 2016
2016-03-29,AcelRx Pharmaceuticals Names Howard B. Rosen As Chief Executive Officer And Provides Update On Clinical Development Activities And Corporate Priorities For 2016
2016-03-25,AcelRx Publishes A Review Of Hospital-Based Opioid Patient-Controlled Analgesia, Risks And Pharmacoeconomics
2016-03-14,AcelRx Pharmaceuticals Advances ARX-04 into Extension Phase of Open-Label Phase 3 Emergency Room Study
2016-03-07,AcelRx Pharmaceuticals Initiates Phase 3 Study Of ARX-04 In Patients With Post-Operative Moderate-to-Severe Acute Pain
2016-03-03,AcelRx Pharmaceuticals To Hold Annual 2015 Financial Results Conference Call And Webcast On Monday, March 7th, 2016.
2016-03-01,AcelRx Pharmaceuticals To Present At Two Upcoming Investor Events In March
2016-02-25,AcelRx Pharmaceuticals' Moderate-to-Severe Acute Pain Candidate ARX-04 Shows Improved Pain Scores In ER Patients In Interim Phase 3 Analysis
2016-02-03,AcelRx Pharmaceuticals To Present At Two Upcoming Investor Events In February
2016-01-27,First Week of ACRX September 16th Options Trading
2016-01-21,AcelRx Pharmaceuticals Announces Presentation Of Phase 3 Sufentanil Sublingual 30 Mcg Tablet (ARX-04) Data At The European Congress Of Ambulatory Surgery
2016-01-10,AcelRx Pharmaceuticals Announces Anticipated 2016 Milestones
2016-01-08,AcelRx Completes Protocol Review With FDA And Plans To Initiate Phase 3 Open-Label Study (IAP312) For Zalviso™ In 1Q 2016
2015-12-23,AcelRx Pharmaceuticals Receives Notice Of Eligibility For Centralized Review Of ARX-04 From European Medicines Agency
2015-12-14,AcelRx Pharmaceuticals Conducts Pre-NDA Meeting with U.S. Food and Drug Administration for ARX-04
2015-12-02,AcelRx Pharmaceuticals (ACRX) Highlighted As Weak On High Volume
2015-11-23,AcelRx Pharmaceuticals To Present At Piper Jaffray 27th Annual Healthcare Conference
2015-11-13,AcelRx Pharmaceuticals (ACRX) Strong On High Relative Volume Today
2015-11-10,AcelRx Pharmaceuticals To Present At Jefferies 2015 Global Healthcare Conference
2015-11-05,AcelRx Pharmaceuticals To Present At Credit Suisse 24th Annual Healthcare Conference
2015-11-04,AcelRx Pharmaceuticals Presents Data From Phase 3 Clinical Trials Evaluating The Safety And Efficacy Of Zalviso In Obese Surgical Patients
2015-10-26,AcelRx Pharmaceuticals To Hold Business Update And Third Quarter Financial Results Conference Call And Webcast On Thursday, Oct 29th, 2015
2015-10-23,AcelRx Pharmaceuticals Announces Presentation Of Phase 3 Data From ARX-04 Sufentanil Sublingual 30 Mcg Program At The American Society Of Anesthesiology Meeting
2015-10-08,AcelRx Pharmaceuticals Provides Regulatory Update On Zalviso
2015-10-06,AcelRx Pharmaceuticals Announces Initiation Of Clinical Study With ARX-04 In Emergency Room Patients With Moderate-to-Severe Acute Pain
2015-10-02,Amicus, Other Biotech CEOs Should Listen More, Talk Less About FDA Matters
2015-10-01,AcelRx Pharmaceuticals Appoints Gina Ford As Vice President Commercial Strategy
2015-09-24,AcelRx Pharmaceuticals To Host Analyst & Investor Event On October 2, 2015
2015-09-22,AcelRx Pharmaceuticals Reports That The European Commission Has Granted Marketing Authorization For Zalviso™ For Treatment Of Acute Moderate-to-Severe Post-Operative Pain In Adult Patients
2015-09-21,PDL BioPharma Acquires A Portion Of AcelRx Pharmaceuticals' Expected Royalties And Commercial Milestones From Zalviso™ For $65 Million
2015-09-21,AcelRx Pharmaceuticals Receives $65 Million From The Partial Sale Of Zalviso™ European Royalties And Commercial Milestones To PDL BioPharma
2015-09-09,AcelRx Pharmaceuticals' ARX-04 Meets All Endpoints In Pivotal Phase 3 Study For Moderate-to-Severe Acute Pain
2015-08-26,AcelRx Pharmaceuticals To Participate At Three Investor Conferences In September
2015-07-29,AcelRx Pharmaceuticals To Hold Business Update And Second Quarter Financial Results Conference Call And Webcast On Monday, Aug. 3rd, 2015.
2015-07-24,5 Stocks Poised for Breakouts
2015-07-24,AcelRx Announces Positive CHMP Opinion For Zalviso In The Management Of Acute Moderate-to-Severe Post-Operative Pain In Adult Patients
2015-07-14,3 Stocks Under $10 to Trade for Breakouts
2015-07-02,Zalviso™ Phase 3 Orthopedic Results Published In Anesthesiology Demonstrate Significant Reductions In Post-Operative Pain
2015-07-01,10 Worst Biotech Stocks in the NASDAQ
2015-05-22,AcelRx Pharmaceuticals To Present At Two Upcoming Investor Conferences In June
2015-05-14,AcelRx Awarded Contract From Department Of Defense To Advance ARX-04
2015-05-08,Insider Trading Alert - LAD, RSE And ACRX Traded By Insiders
2015-05-01,AcelRx Pharmaceuticals To Participate At Upcoming Investor Conferences In May
2015-04-30,AcelRx Pharmaceuticals To Hold First Quarter Financial Results Conference Call And Webcast On Monday, May 4th, 2015
2015-04-24,Insider Trading Alert - STFC, ACRX And CSC Traded By Insiders
2015-03-23,AcelRx Pharmaceuticals: What Went Wrong and What's on the Horizon for the Struggling Biotech?
2015-03-20,AcelRx Appoints Howard B. Rosen As Interim CEO
2015-03-16,AcelRx Pharmaceuticals Announces Initiation Of Pivotal Phase 3 Trial For ARX-04
2015-03-13,INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AcelRx Pharmaceuticals, Inc. (ACRX) To Contact The Firm
2015-03-10,AcelRx Pharmaceuticals (ACRX) Stock Extends Losses Today as Jefferies Downgrades
2015-03-09,EQUITY ALERT: The Rosen Law Firm Announces Investigation Of Securities Claims Against AcelRx Pharmaceuticals, Inc. - ACRX
2015-03-09,AcelRx Pharmaceuticals (ACRX) Stock Tanks Today on FDA Demand For Further Zalviso Trials
2015-03-09,AcelRx Pharmaceuticals Is Now Oversold (ACRX)
2015-03-09,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of AcelRx Pharmaceuticals, Inc. - ACRX
2015-03-09,AcelRx Provides Regulatory Update On Zalviso
2015-03-04,AcelRx Pharmaceuticals To Hold Annual 2014 Financial Results Conference Call And Webcast On Monday, March 9th, 2015
2015-02-20,AcelRx Pharmaceuticals To Participate At Two Upcoming Investor Events
2015-02-04,AcelRx Pharmaceuticals To Present At BIO CEO & Investor Conference
2015-01-15,Will the Second Time be a Charm for Biotech AcelRx After Their FDA Rejection?
2015-01-09,5 Stocks Under $10 Setting Up to Trade Higher: Callon Petroleum and More
2014-12-30,AcelRx Pharmaceuticals (ACRX) Downgraded From Hold to Sell
2014-12-29,Ratings Changes Today
2014-12-02,AcelRx Pharmaceuticals Receives CE Mark Approval For Zalviso
2014-11-20,AcelRx Pharmaceuticals To Participate In Four Upcoming Investor Events
2014-11-19,SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In AcelRx Pharmaceuticals, Inc. To Contact Brower Piven Before The December 1, 2014 Lead Plaintiff Deadline In Class Action Lawsuit
2014-11-17,UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors Of Class Action Against AcelRx Pharmaceuticals, Inc. And Its Board Of Directors And A Lead Plaintiff Deadline Of December 1, 2014
2014-11-12,AcelRx Pharmaceuticals (ACRX) Upgraded From Sell to Hold
2014-11-11,AcelRx Pharmaceuticals (ACRX) Stock Rises After Third-Quarter Earnings Report
2014-11-11,Ratings Changes Today
2014-11-10,AcelRx Pharmaceuticals Receives International Standards Organization (ISO) 13485:2003 Certification Of Its Quality Management System
2014-11-07,AcelRx Pharmaceuticals To Participate In Two Upcoming Investor Events
2014-11-06,INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors Of The Lead Plaintiff Deadline In The Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc.
2014-11-06,AcelRx Pharmaceuticals To Hold Third Quarter Financial Results Conference Call And Webcast On Monday, November 10, 2014
2014-11-05,Acelrx Pharmaceuticals Announces Management Change
2014-10-27,AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentations At The American College Of Surgeons Meeting
2014-10-22,AcelRx Announces Publication Of Zalviso Phase 3 Abdominal Trial Results
2014-10-16,AcelRx Pharmaceuticals Provides Update On Its Patent Portfolio For Zalviso™ And Its Proprietary Platform Technologies
2014-10-15,SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In AcelRx Pharmaceuticals, Inc. To Contact Brower Piven Before The December 1, 2014 Lead Plaintiff Deadline In Class Action Lawsuit
2014-10-07,Harwood Feffer LLP Announces Investigation Of AcelRx Pharmaceuticals, Inc.
2014-10-07,Lifshitz & Miller Law Firm Announces Investigation Of AcelRx Pharmaceuticals, Inc., Ambit Biosciences, Athlon Energy Inc., LipoScience, Inc., Simplicity Bancorp, Inc., And TIBCO Software Inc.
2014-10-07,AcelRx Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors
2014-10-03,INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $50,000 Investing In AcelRx Pharmaceuticals, Inc. (ACRX) To Contact The Firm
2014-10-02,INVESTOR ALERT: Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. Filed By Glancy Binkow & Goldberg LLP
2014-09-29,Strong On High Volume: AcelRx Pharmaceuticals (ACRX)
2014-09-26,Why AcelRx Pharmaceuticals (ACRX) Stock Hit a One-Year Low Today
2014-09-26,AcelRx Pharmaceuticals Provides Regulatory Update On Zalviso™
2014-09-10,AcelRx Announces Publication Of Manuscript Analyzing Cost Of Intravenous Patient-Controlled Analgesia With Opioids
2014-09-04,AcelRx Announces Publication Of Sufentanil Sublingual Tablet System Vs. Intravenous Patient-Controlled Analgesia With Morphine For Postoperative Pain Study Results
2014-08-27,AcelRx Pharmaceuticals To Participate In Two Upcoming Investor Events
2014-08-26,The Best Hedge Fund You've Never Heard Of and Its Top 5 Stock Picks
2014-08-08,AcelRx Pharmaceuticals To Participate In Three Upcoming Investor Events
2014-08-07,AcelRx Pharmaceuticals To Hold Second Quarter Financial Results Conference Call And Webcast On Monday, August 11th, 2014.
2014-08-01,Perilous Reversal Stock: AcelRx Pharmaceuticals (ACRX)
2014-08-01,4 Biotech Stocks Under $10 to Trade for Breakouts
2014-07-29,Today's Dead Cat Bounce Stock: AcelRx Pharmaceuticals (ACRX)
2014-07-28,Why AcelRx Pharmaceuticals (ACRX) Stock Is Plummeting Today
2014-07-28,FDA Rejects AcelRx Painkiller Dispensing Device (Update)
2014-07-28,AcelRx Pharmaceuticals (ACRX) Moving On Heavy Volume In The Pre-Market Hours
2014-07-25,AcelRx Pharmaceuticals Receives Complete Response Letter From FDA For New Drug Application For Zalviso™
2014-07-24,AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date For Zalviso
2014-07-24,4 Biotech Stocks Breaking Out on Big Volume
2014-07-18,Biotech Stock Mailbag: AcelRx, Yellen Aftermath, Nymox
2014-07-14,Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events
2014-07-07,AcelRx And Grunenthal Announce Submission Of European Marketing Authorization Application For ZALVISO™
2014-07-03,5 Stocks Spiking on Unusual Volume
2014-06-25,First Week of August 16th Options Trading For AcelRx Pharmaceuticals (ACRX)
2014-06-19,AcelRx Pharmaceuticals To Present At The JMP Securities Healthcare Conference
2014-06-06,Oversold Conditions For AcelRx Pharmaceuticals (ACRX)
2014-06-03,Results Of Cost Analysis Study Presented At ISPOR Meeting Identify Intravenous Patient-Controlled Analgesia (IV PCA) Costs Of $200 To $240 For Two Days Of Post-Surgical Pain Management
2014-05-29,AcelRx Pharmaceuticals To Present At The Jefferies Global Healthcare Conference
2014-05-19,AcelRx Pharmaceuticals To Present At The UBS Global Healthcare Conference
2014-05-14,AcelRx Pharmaceuticals is Now Oversold (ACRX)
2014-05-02,AcelRx Pharmaceuticals To Hold First Quarter Financial Results Conference Call And Webcast On Thursday, May 8, 2014
2014-05-01,AcelRx Pharmaceuticals Announces Zalviso&#8482; And ARX-04 Data Presentations At The American Pain Society 33rd Annual Scientific Meeting
2014-04-25,First Week of ACRX December 20th Options Trading
2014-04-04,AcelRx Pharmaceuticals To Present At The 13th Annual Needham Healthcare Conference
2014-03-27,Interesting ACRX Put And Call Options For May 17th
2014-03-25,AcelRx Pharmaceuticals Appoints Timothy E. Morris As Chief Financial Officer
2014-03-07,AcelRx Pharmaceuticals To Participate At The 26th Annual Roth Conference
2014-02-24,AcelRx Pharmaceuticals To Hold Fourth Quarter And Annual 2013 Financial Results Conference Call And Webcast On Monday, March 3, 2014
2014-02-05,AcelRx Pharmaceuticals To Participate In Three Upcoming Investor Events
2013-12-30,First Week of ACRX February 2014 Options Trading
2013-12-19,AcelRx Secures $40 Million Credit Facility With Hercules Technology Growth Capital
2013-12-16,AcelRx And Grunenthal Announce Collaboration For EU Commercialization Of ZALVISO&#8482;
2013-12-13,AcelRx Pharmaceuticals Presents ARX-04 Dose-Finding Phase 2 Study Data At Anesthesia Medical Conference
2013-12-11,AcelRx Pharmaceuticals Adds New Board Member
2013-12-02,Zalviso&#8482; New Drug Application Accepted For Filing By FDA
2013-11-26,AcelRx Pharmaceuticals To Present At The 25th Annual Piper Jaffray Healthcare Conference
2013-11-19,First Week Of ACRX January 2014 Options Trading
2013-11-13,5 Stocks With Big Insider Buying
2013-11-13,Top Insider Trades: AGCO VVUS INWK ACRX
2013-11-06,Oversold Conditions For AcelRx Pharmaceuticals (ACRX)
2013-11-05,Top Insider Trades: ACW ZINC ACRX FCX
2013-10-23,First Week Of ACRX June 2014 Options Trading
2013-10-22,AcelRx Pharmaceuticals To Hold Third Quarter 2013 Financial Results Conference Call And Webcast On November 5, 2013
2013-10-15,AcelRx Pharmaceuticals Announces Data Presentations For Zalviso™ At US And International Medical Meetings
2013-10-14,AcelRx Pharmaceuticals Becomes Oversold (ACRX)
2013-10-08,AcelRx Pharmaceuticals Provides Update On Its Patent Portfolio For Zalviso™ And Its Proprietary Platform Technologies
2013-09-30,AcelRx Pharmaceuticals Submits New Drug Application To The FDA For Zalviso™
2013-09-27,5 Stocks Poised for Breakouts
2013-09-04,David H. Chung Joins AcelRx Pharmaceuticals As Chief Commercial Officer
2013-08-30,AcelRx Pharmaceuticals To Present At The Stifel Healthcare Conference 2013
2013-08-05,5 Stocks Ready to Break Out
2013-08-05,AcelRx Pharmaceuticals To Present At Canaccord Genuity 33rd Annual Growth Conference
2013-08-02,AcelRx Pharmaceuticals To Hold Second Quarter 2013 Financial Results Conference Call And Webcast On August 12, 2013
2013-07-31,5 Stocks With Big Insider Buying
2013-07-25,Top Insider Trades: ACRX EBAY RLGY BERY
2013-07-23,AcelRx Pharmaceuticals Announces Closing Of Public Offering And Exercise Of Option To Purchase Additional Shares
2013-07-18,AcelRx Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2013-07-17,AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2013-07-08,5 Stocks Spiking on Unusual Volume
2013-07-02,AcelRx Pharmaceuticals Joins Russell Global And Russell 3000 Indexes
2017-03-07,Alcobra Ltd. To Participate In Upcoming Healthcare Conferences
2017-03-01,INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Alcobra, Ltd. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2017-03-01,Alcobra To Host Investor Forum And Webcast On March 28 In New York City
2017-02-17,Lifshitz & Miller LLP Files Class Action Lawsuit Against Alcobra, Ltd.
2017-02-15,Alcobra Announces Fourth-Quarter And Full-Year 2016 Financial Results And Provides Corporate Update
2017-02-08,Alcobra Ltd. To Release Fiscal 2016 Financial Results And Participate At The BIO CEO & Investor Conference In New York
2017-02-06,Alcobra Reports On Productive FDA Meeting For New Lead Product Candidate For ADHD
2017-02-02,Lifshitz & Miller Law Firm Announces Investigation Of Alcobra Ltd., Egalet Corporation, Sanderson Farms, Inc., Surgical Care Affiliates, Inc., State Street Corporation, Tenet Healthcare Corp., Vista Outdoor Inc. And Zagg Inc.
2017-01-31,IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces An Investigation Of Alcobra, Ltd., And Encourages Investors To Contact The Firm
2017-01-19,SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Alcobra, Ltd. And Encourages Investors With Losses To Contact The Firm
2017-01-19,SHAREHOLDER ALERT: Goldberg Law PC Announces An Investigation Of Alcobra, Ltd. And Advises Investors With Losses To Contact The Firm
2017-01-18,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of Alcobra Ltd.
2017-01-17,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Alcobra Ltd. (ADHD)
2017-01-17,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Alcobra Ltd. - ADHD
2017-01-17,Alcobra Shares Plummet as ADHD Drug Fails
2017-01-17,Alcobra Reports Phase 3 Clinical Trial Of MDX In Adults With ADHD Missed Primary Endpoint
2017-01-09,Alcobra Provides Update On Recent FDA Meeting And Path Forward For MDX Clinical Development Program
2016-12-14,Alcobra Updates On Recent FDA Meeting
2016-11-15,Alcobra Announces Third Quarter 2016 Financial Results And Provides Corporate Update
2016-11-15,Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive
2016-11-07,Alcobra Ltd. To Participate In Upcoming Healthcare Conferences
2016-11-01,Alcobra Ltd. To Release Third Quarter Financial Results And Host Corporate Update Conference Call & Webcast On November 15
2016-10-07,Update From Alcobra On Recent FDA Communications
2016-09-30,Alcobra (ADHD) Stock Sliding, Downgraded After FDA Clinical Hold
2016-09-29,Alcobra (ADHD) Stock Tumbles on FDA Clinical Hold, Cantor Remains Bullish
2016-09-28,Alcobra Announces IND Clinical Hold Affecting The MDX Phase III MEASURE Study
2016-08-30,Alcobra Announces Second Quarter 2016 Financial Results And Provides Corporate Update
2016-08-15,Alcobra Ltd. To Release Second Quarter Financial Results And Host Corporate Update Conference Call & Webcast On Tuesday, August 30
2016-07-19,Alcobra Granted European Orphan Drug Designation For Metadoxine In Fragile X Syndrome
2016-07-05,Alcobra Ltd. To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference
2016-06-01,Alcobra Ltd. To Participate In Upcoming Investment Conferences
2016-05-20,7 Stocks Under $10 Making Big Moves Higher
2016-05-16,Alcobra Announces First Quarter 2016 Financial Results And Provides Corporate Update
2016-05-04,Alcobra Ltd. To Release First Quarter Financial Results And Host Corporate Update Conference Call & Webcast On May 16
2016-03-01,Alcobra Ltd. To Present At Upcoming Investment Conferences
2016-02-17,CORRECTING And REPLACING -- Alcobra Announces Fourth Quarter And Fiscal 2015 Financial Results And Provides Corporate Update
2016-02-17,Alcobra Announces Fourth Quarter And Fiscal 2015 Financial Results And Provides Corporate Update
2016-02-02,Alcobra Ltd. To Release Fourth Quarter And Fiscal Year 2015 Financial Results And Host Corporate Update Conference Call & Webcast On February 17
2016-01-28,Alcobra Ltd. To Present At Upcoming Investment Conferences
2016-01-11,RSI Alert: Alcobra (ADHD) Now Oversold
2015-12-18,Alcobra Enters Oversold Territory (ADHD)
2015-12-17,Alcobra Added To The NASDAQ Biotechnology Index
2015-11-24,Alcobra Ltd. To Participate In Piper Jaffray 27th Annual Healthcare Conference
2015-11-16,Alcobra Ltd. To Present At Upcoming Investment Conferences Company Will Host Corporate Update Conference Call & Webcast On November 17
2015-11-13,Alcobra Ltd. Prices Public Offering Of Ordinary Shares
2015-11-12,Alcobra Ltd. Announces Proposed Public Offering Of Ordinary Shares
2015-11-12,Alcobra Announces Third Quarter 2015 Financial Results And Provides Corporate Update
2015-11-05,Alcobra Ltd. To Release Third Quarter 2015 Financial Results And Host Corporate Update Conference Call & Webcast On November 17
2015-09-21,FDA Grants Fast Track Designation To Alcobra's MDX For Fragile X Syndrome
2015-08-13,Alcobra Announces Second Quarter 2015 Financial Results And Provides Corporate Update
2015-08-03,Alcobra Ltd. To Release Second Quarter 2015 Financial Results And Host Corporate Update Conference Call & Webcast On August 13
2015-07-13,Alcobra Announces Election Of Dr. Joao Siffert To Board Of Directors
2015-07-12,Breadth Is Key Over the Next Few Days
2015-06-24,Alcobra Placebo Beats Drug in Failed Genetic Disease Study
2015-06-24,Alcobra Announces Results From Phase 2 Clinical Trial Of MDX For Fragile X Syndrome
2015-06-23,Alcobra Ltd. To Present Results Of Phase II Fragile X Trial In A Conference Call & Webcast Presentation On Wednesday, June 24
2015-05-28,Alcobra Ltd. To Present At Two Conferences In June
2015-05-06,Alcobra Announces First Quarter 2015 Financial Results And Provides Corporate Update
2015-04-27,Alcobra Ltd. To Participate At Two Conferences In May
2015-04-16,Alcobra Ltd. To Release First Quarter 2015 Financial Results And Host Corporate Update Conference Call & Webcast On May 6
2015-04-06,Alcobra Ltd. To Present At Two CNS Focused Conferences In April
2015-03-10,Alcobra's MDX Meets Primary Endpoint In Phase II Safety And Tolerability Clinical Trial In Adolescents With ADHD
2015-03-03,Alcobra Ltd. To Present At 27th Annual ROTH Conference
2015-02-27,5 Stocks Poised for Big Breakouts: Xoom, Alcobra and More
2015-02-26,5 Stocks Under $10 to Trade for Breakouts: SouFun, Repros and More
2015-02-17,4 Biotech Stocks Under $10 to Trade for Breakouts: Sophiris, Atossa and More
2015-02-12,Alcobra Announces Fourth Quarter And Fiscal Year 2014 Financial Results And Provides Corporate Update
2015-02-02,Alcobra Ltd. To Release Fourth Quarter And Fiscal Year 2014 Financial Results And Host Corporate Update Conference Call & Webcast On February 12
2015-01-29,Alcobra Ltd. To Present At BIO CEO & Investor Conference
2015-01-14,Alcobra Ltd. Announces Closing Of Public Offering Of Ordinary Shares And Full Exercise Of Over-Allotment Option
2015-01-09,UPDATE - UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Notifies Investors Of Class Action Against Alcobra Ltd. And Its Board Of Directors And A Lead Plaintiff Deadline Of January 20, 2015 -- ADHD
2015-01-09,Alcobra Ltd. Prices Public Offering Of Ordinary Shares
2015-01-08,Alcobra Ltd. Announces Commencement Of Public Offering Of Ordinary Shares
2015-01-02,ADHD SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of Class Action Against Alcobra Ltd. And Its Board Of Directors And A Lead Plaintiff Deadline Of January 19, 2015 -- ADHD
2014-12-30,SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Alcobra Ltd. To Contact Brower Piven Before The January 19, 2015 Lead Plaintiff Deadline In Class Action Lawsuit
2014-12-17,Alcobra Ltd. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors
2014-12-08,Law Offices Of Marc S. Henzel Announces Securities Class Action Periods
2014-12-01,SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Alcobra Ltd. To Contact Brower Piven Before The January 19, 2015 Lead Plaintiff Deadline In Class Action Lawsuit
2014-11-26,INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Alcobra Ltd. (ADHD) To Contact The Firm
2014-11-24,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Alcobra Ltd - ADHD
2014-11-24,Alcobra Ltd. To Present At Investor Conferences In December
2014-11-21,SHAREHOLDER ALERT: Investigation On Behalf Of Alcobra, Ltd. Investors Announced By Law Offices Of Howard G. Smith
2014-11-19,SHAREHOLDER ALERT: Class Action Lawsuit Against Alcobra, Ltd. Filed By Glancy Binkow & Goldberg LLP
2014-11-17,Alcobra Announces Third Quarter Financial Results And Provides Corporate Update
2014-11-06,Alcobra Ltd. To Release Third Quarter 2014 Financial Results And Host Corporate Update Conference Call And Webcast On Monday, November 17
2014-11-03,Alcobra Ltd. To Present At Investor Conferences In November
2014-10-31,SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Possible Securities Laws Violations By The Board Of Directors Of Alcobra Ltd.
2014-10-27,Block & Leviton LLP Investigates Alcobra Ltd, Its Officers And Directors For Possible Violations Of The Federal Securities Laws
2014-10-23,Alcobra Applies Revisionist History to ADHD Drug Study Analysis
2014-10-23,Alcobra Announces Presentation Of New Data From Phase III Adult ADHD Study At AACAP Annual Meeting
2014-10-17,5 Stocks Under $10 Set to Soar
2014-10-07,It's True, Small-Cap Biotech Stocks Are Acting Badly These Days
2014-10-06,Why Alcobra (ADHD) Stock Hit a One-Year Low Today
2014-10-06,Alcobra ADHD Drug Fails Key Study Except When Patients Removed From Analysis
2014-10-06,Alcobra Announces Topline Results From Phase III Study Of MDX In Adult ADHD
2014-10-01,Oversold Conditions For Alcobra (ADHD)
2014-09-24,Why Alcobra Investors Are So Nervous About a Coming Drug Study
2014-09-19,Alcobra Announces Completion Of All Patient Visits In Phase III Clinical Trial Of MDX In Adult ADHD
2014-09-05,Alcobra Ltd. To Present At The Aegis Healthcare & Technology Conference
2014-09-02,Alcobra Announces Enrollment Of First Patient In Phase IIb Clinical Trial Of MDX In Adolescents With ADHD
2014-08-27,Why Alcobra (ADHD) Stock Is Declining Today
2014-08-26,Your September Biotech Back-to-School Calendar
2014-08-19,Alcobra Announces Enrollment Of First Patient In Phase IIb Clinical Trial Of MDX In Fragile X Syndrome
2014-08-11,Alcobra Announces Second Quarter Financial Results And Provides Corporate Update
2014-08-08,Alcobra Releases New Neuroimaging Data Supporting Pro-Cognitive Effects Of MDX
2014-08-06,Alcobra Ltd. To Provide Corporate Overview At The Canaccord Genuity 34th Annual Growth Conference
2014-08-01,Alcobra Ltd. To Release Second Quarter 2014 Results And Host Investor Conference Call And Webcast On Monday, August 11
2014-07-17,Alcobra Discusses New Market Research And Updates On Recent Corporate Events At Investor Forum In New York City
2014-07-14,Alcobra Completes Patient Recruitment In Phase III Clinical Trial Of MDX In Adult ADHD
2014-07-10,14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014
2014-07-07,Alcobra To Host Investor Forum And Webcast On July 15 In New York City
2014-07-07,3 Big-Volume Stocks to Trade for Breakouts
2014-07-03,5 Stocks Spiking on Unusual Volume
2014-06-17,Alcobra Ltd. To Provide Corporate Overview At The JMP Securities Healthcare Conference
2014-06-09,Alcobra To Present At The American Society Of Clinical Psychopharmacology Annual Meeting And The BIO International Convention
2014-05-27,Alcobra Ltd. To Provide Corporate Overview At The Jefferies 2014 Global Healthcare Conference
2014-05-23,Alcobra Ltd. To Present At The Gordon Research Conference On Fragile X And Autism-Related Disorders
2014-05-15,Alcobra Announces First Quarter Financial Results And Corporate Update
2014-05-12,Alcobra Ltd. Presents Evidence Of Novel Mechanism Of Action For Metadoxine Extended Release (MDX) In Cognitive Disorders At The Society Of Biological Psychiatry Annual Meeting
2014-05-08,Alcobra Announces FDA Clearance Of Protocol For Phase IIb Study Of Metadoxine Extended Release (MDX) In The Treatment Of Fragile X Syndrome
2014-05-08,Alcobra Ltd. To Provide Corporate Overview At Oppenheimer And BioMed Conferences
2014-05-07,Alcobra Ltd. To Release First Quarter 2014 Results And Host Investor Conference Call On Thursday, May 15, 2014
2014-05-05,Alcobra Ltd. Presents Positive Results From Phase IIb Study Of Metadoxine Extended Release (MDX) In Adults With Predominantly Inattentive ADHD At APA Annual Meeting
2014-05-01,Alcobra Issued New US Patent Covering Metadoxine Use For Cognitive Disorders
2014-04-24,Alcobra Ltd. To Present New Data For Metadoxine Extended Release (MDX) At Upcoming Meetings
2014-04-10,Alcobra Ltd. Submits Protocol To FDA For Phase IIb Clinical Study Of Metadoxine Extended Release (MDX) In The Treatment Of Fragile X Syndrome
2014-04-08,Relative Strength Alert For Alcobra
2014-03-26,Alcobra Announces Shares Uplisted To NASDAQ Global Market
2014-03-18,Alcobra Announces Enrollment Of First Patient In Phase 3 Clinical Trial For MDX In Adult ADHD
2014-03-06,Alcobra Announces FDA Clearance Of IND For Metadoxine Extended Release (MDX)
2014-02-24,Alcobra Ltd. To Discuss Biomarkers In Fragile X And Autism Trials At The Second Annual Autism Investment Conference
2014-02-19,Alcobra Appoints J.P. Morgan Banker Dr. Tomer Berkovitz As Chief Financial Officer
2014-02-13,Alcobra Announces Fourth Quarter And Fiscal Year End 2013 Financial Results And Corporate Update
2014-02-07,Alcobra Announces IND Submission For Extended Release Metadoxine To Treat Adults With ADHD
2014-01-31,Alcobra Ltd. To Provide Corporate Overview At 16th Annual BIO CEO & Investor Conference
2014-01-29,Alcobra Ltd. To Release Fourth Quarter 2013 Results And Host Investor Conference Call On Thursday, February 13, 2014
2014-01-27,Alcobra Announces New Biomarker Finding In A Follow-Up Fragile X Animal Study For MG01CI
2014-01-13,Alcobra Strengthens Management Team With Addition Of Industry Veteran David C. Baker As Chief Commercial Officer
2013-12-18,FDA Grants Orphan Drug Status To Metadoxine In Fragile X Syndrome
2013-12-16,Alcobra Ltd. Announces Highly Statistically Significant Positive Phase IIb Clinical Trial Results In Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder
2013-12-16,5 Stocks Ready to Break Out
2013-12-02,Alcobra To Present At The 25th Annual Piper Jaffray Healthcare Conference
2013-11-22,Alcobra Ltd. Announces New Findings On Diminished Abuse Potential Of Its Proprietary Drug Candidate, MG01CI
2013-11-07,Alcobra Ltd. Reports Third Quarter 2013 Results
2013-11-05,Alcobra Successfully Completes Enrollment In Comparative Phase II Study Of Attention And Cognitive Function Benefits In Patients With PI-ADHD
2013-10-31,Alcobra Ltd. To Host A Third Quarter 2013 Conference Call On November 7th
2013-10-30,Alcobra Ltd. Announces Closing Of Approximately $38 Million Public Offering Of Ordinary Shares
2013-10-29,Alcobra Ltd. Announces Full Exercise Of Over-Allotment Option By Underwriters
2013-10-24,Alcobra Ltd. Prices Public Offering Of $33 Million Of Ordinary Shares
2013-10-23,Biotech Stock Bubble Debate in 14 Charts
2013-10-21,Alcobra Ltd. To Present At AACAP's 60th Annual Meeting On October 24th
2013-10-14,Alcobra Ltd. Announces New Findings On Novel Mechanism Of Action For Its Proprietary Drug, MG01CI, For Treatment Of Cognitive Dysfunctions
2013-10-02,Alcobra Ltd. Selects CNS Clinical Trials Expert Premier Research As CRO For Phase III Clinical Study Of MG01CI As A Treatment For Adults With ADHD
2013-09-25,Alcobra To Present Fragile X Study Results At 2013 FRAXA Investigators Meeting
2013-09-19,Alcobra Ltd. To Present At The Aegis Capital 2013 Annual Healthcare Conference On September 26th In Las Vegas
2013-09-10,Alcobra's Pre-Clinical Fragile X Study For MG01CI Shows Significant Positive Results
2013-09-03,Alcobra Ltd. To Present At The Stifel Nicolaus 2013 Annual Healthcare Conference On September 11th
2013-08-26,Alcobra Enrolls First Patient In Comparative Study Of Executive Function Benefits In Patients With PI-ADHD
2013-08-06,Alcobra Ltd. Reports Second Quarter 2013 Results
2013-07-30,Alcobra Ltd. To Host ADHD Seminar In New York City On August 6, 2013
2013-07-30,Alcobra Ltd. Appoints Dr. Jonathan Rubin As Chief Medical Officer
2013-07-24,Alcobra Ltd. To Provide Second Quarter 2013 Financials And Business Update On August 6th
2013-07-11,Alcobra Plans to Break ADHD Ranks
2013-06-24,Alcobra Ltd. Announces U.S. Patent Issuance
2013-06-03,Alcobra Ltd. To Ring The NASDAQ Stock Market Opening Bell On Thursday, June 6th
2013-05-28,Alcobra Ltd. Announces Closing Of Initial Public Offering
2013-05-28,Alcobra Ltd. To Present At Upcoming Investor Conferences
2017-03-10,Adamas Announces New Employment Inducement Grant
2017-03-01,Adamas To Present At The 37th Annual Cowen Health Care Conference
2017-02-28,Adamas Reports Recent Achievements And Financial Results For The Fourth Quarter And Full-Year 2016
2017-02-28,Adamas Presents Additional Open-Label, Long-Term Safety And Efficacy Data On ADS-5102 At The First Pan American Parkinson's Disease And Movement Disorders Congress
2017-02-17,Adamas To Present New ADS-5102 Data From Phase 2 Trial In Walking Impairment Associated With Multiple Sclerosis At ACTRIMS Forum 2017
2017-01-08,Adamas Outlines Key 2017 Priorities And Highlights 2016 Achievements
2017-01-06,Adamas Announces U.S. FDA Acceptance Of ADS-5102 New Drug Application For The Treatment Of Levodopa-induced Dyskinesia In Patients With Parkinson's Disease
2017-01-03,Adamas Pharmaceuticals Completes Phase 1 Clinical Trial Of ADS-4101 For Treatment Of Partial Onset Seizures In Patients With Epilepsy
2016-11-15,Adamas Pharmaceuticals To Present At The 28th Annual Piper Jaffray Healthcare Conference
2016-11-03,Adamas Reports Third Quarter 2016 Financial Results
2016-11-02,RSI Alert: Adamas Pharmaceuticals (ADMS) Now Oversold
2016-11-01,Adamas Pharmaceuticals To Present At The Stifel 2016 Healthcare Conference
2016-10-27,Adamas Submits New Drug Application To U.S. FDA For ADS-5102 For The Treatment Of Levodopa-induced Dyskinesia In Patients With Parkinson's Disease
2016-10-26,Commit To Buy Adamas Pharmaceuticals At $12.50, Earn 12.5% Annualized Using Options
2016-10-24,Adamas Pharmaceuticals To Present At The 25th Annual Credit Suisse Healthcare Conference
2016-10-20,Biotech Bargain Bin Bursts With Bounty
2016-09-22,Adamas Appoints Michael F. Bigham To Board Of Directors
2016-09-22,Allergan And Adamas Announce U.S. Availability Of New Dosage Strengths For NAMZARIC® (Memantine And Donepezil Hydrochlorides) Extended Release For The Treatment Of Moderate To Severe Alzheimer's Disease
2016-09-20,Adamas Announces Results Of EASE LID 3, A Pivotal Trial Of ADS-5102 For The Treatment Of Levodopa-induced Dyskinesia (LID) In Parkinson's Disease Patients At The 4th World Parkinson Congress
2016-09-14,5 Stocks Insiders Love Right Now
2016-09-12,Adamas Announces Two Data Presentations On ADS-5102 For The Treatment Of Levodopa-induced Dyskinesia (LID) At The 4th World Parkinson Congress
2016-09-09,Adamas Announces New Employment Inducement Grant
2016-08-31,Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC® Patent Litigation
2016-08-25,Adamas Pharmaceuticals Stock Sees Short Interest Make 28.6% Move
2016-08-04,Adamas Reports Second Quarter 2016 Financial Results
2016-07-27,Short Interest Jumps 12.6% For ADMS
2016-07-27,Commit To Purchase Adamas Pharmaceuticals At $12.50, Earn 30.8% Annualized Using Options
2016-07-25,Adamas Pharmaceuticals (ADMS) Is Weak On High Volume Today
2016-07-19,Allergan And Adamas Announce New Expanded Indication For NAMZARIC® (Memantine And Donepezil Hydrochlorides) Extended Release For The Treatment Of Moderate To Severe Alzheimer's Disease
2016-06-29,Adamas Pharmaceuticals To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference
2016-06-29,16 Biopharma Companies Besides Medivation That Are Attractive Targets
2016-06-22,Adamas Pharmaceuticals (ADMS) Weak On High Volume Today
2016-06-22,Adamas Announces Additional ADS-5102 Data For The Treatment Of Levodopa-induced Dyskinesia At The International Congress Of Parkinson's Disease And Movement Disorders
2016-06-13,Adamas Announces Positive Results From Its Phase 2 Proof-of-Concept Study Of ADS-5102 For The Treatment Of Walking Impairment In Multiple Sclerosis (MS) Patients
2016-05-25,Adamas Pharmaceuticals Stock Sees Short Interest Increase 20.4%
2016-05-16,Adamas Announces Two Data Presentations On ADS-5102 For The Treatment Of Levodopa-induced Dyskinesia (LID) At The 20th International Congress Of Parkinson's And Movement Disorders
2016-05-10,Adamas Reports First Quarter 2016 Financial Results
2016-05-06,Adamas Announces New Employment Inducement Grant
2016-04-28,Adamas Announces Positive Top-line Results From Its Phase 3 EASE LID 3 Trial Of ADS-5102 For The Treatment Of Levodopa-induced Dyskinesia (LID) In Patients With Parkinson's Disease
2016-04-27,Adamas To Host Conference Call And Webcast To Provide Company Update
2016-04-19,Adamas Presents Positive Findings From The Phase 3 EASE LID Clinical Trial Of ADS-5102 For The Treatment Of Levodopa-induced Dyskinesia (LID) Associated With Parkinson's Disease At The American Academy Of Neurology Annual Meeting
2016-04-18,Jim Cramer's 'Mad Money' Recap: Here Are Today's Top 10 Winning Stocks
2016-04-14,Adamas Announces Data Update At The 68th American Academy Of Neurology Annual Meeting
2016-04-01,Adamas Pharmaceuticals (ADMS) Flagged As Strong On High Volume
2016-02-23,Adamas Reports Fourth Quarter And Full Year 2015 Financial Results
2016-02-22,Adamas Pharmaceuticals To Present At Two Upcoming Healthcare Conferences
2016-02-22,Ratings Changes Today
2016-01-20,Commit To Buy Adamas Pharmaceuticals At $12.50, Earn 20.1% Annualized Using Options
2016-01-12,Adamas Pharmaceuticals Provides Review Of 2015 And Projected Future Milestones
2016-01-06,Adamas Announces Pricing Of Public Offering Of Common Stock
2016-01-05,Adamas Announces Proposed Public Offering Of Common Stock
2016-01-04,SLTD, WTW, FB, AMZN: Rev Shark's Views
2015-12-28,Adamas Pharmaceuticals (ADMS) Flagged As Strong On High Volume
2015-12-28,Ratings Changes Today
2015-12-24,Perilous Reversal Watch: Adamas Pharmaceuticals (ADMS)
2015-12-23,Adamas Announces Positive Top-Line Phase 3 Results Of ADS-5102 For The Treatment Of Levodopa-induced Dyskinesia In Patients With Parkinson's Disease
2015-12-22,Adamas To Host Conference Call And Webcast To Provide Company Update
2015-12-14,Adamas Completes Enrollment Of Its Phase 3 EASE LID 3 Study Evaluating ADS-5102 For Treatment Of Levodopa-Induced Dyskinesia In Patients With Parkinson's Disease
2015-11-17,Adamas Pharmaceuticals To Present At The 27th Annual Piper Jaffray Healthcare Conference
2015-11-12,Adamas Reports Third Quarter 2015 Financial Results
2015-10-27,Adamas Pharmaceuticals To Present At The 24th Annual Credit Suisse Healthcare Conference
2015-10-13,Ratings Changes Today
2015-10-12,Adamas Presents Nonclinical Findings Supporting The Potential Use Of ADS-5102 For The Treatment Of Multiple Sclerosis Gait
2015-10-05,Adamas Pharmaceuticals Enters Oversold Territory (ADMS)
2015-09-09,Oversold Conditions For Adamas Pharmaceuticals (ADMS)
2015-08-27,Adamas Pharmaceuticals To Present At BioCentury's NewsMakers In The Biotech Industry Conference
2015-08-13,Adamas Pharmaceuticals Enters Oversold Territory (ADMS)
2015-08-11,Adamas Reports Second Quarter 2015 Financial Results
2015-07-09,Adamas Completes Recruitment Of Its Phase 3 EASE LID Study Evaluating ADS-5102 For The Treatment Of Levodopa-induced Dyskinesia Associated With Parkinson's Disease
2015-07-07,Adamas Pharmaceuticals Issued U.S. Patent Relating To ADS-5102 Program
2015-06-24,Adamas Pharmaceuticals To Present At The Cantor Fitzgerald Inaugural Healthcare Conference
2015-06-23,Adamas Pharmaceuticals (ADMS) Weak On High Volume
2015-06-16,Adamas Pharmaceuticals (ADMS) Flagged As Strong On High Volume
2015-06-15,Adamas Announces Additional Findings From Its Phase 2/3 Trial Of ADS-5102 For The Treatment Of Levodopa-induced Dyskinesia (LID) Associated With Parkinson's Disease
2015-06-11,Adamas Begins Phase 2 Clinical Trial Assessing ADS-5102 For Treating Multiple Sclerosis Symptoms In Patients With Walking Impairment
2015-06-09,Adamas Pharmaceuticals To Present At The 2015 JMP Securities Life Science Conference
2015-05-18,Ratings Changes Today
2015-05-18,Actavis Launches NAMZARIC™ (memantine Hydrochloride Extended-release And Donepezil Hydrochloride), A Fixed-Dose Combination Therapy For The Treatment Of Moderate To Severe Alzheimer's Disease
2015-05-13,Adamas Reports First Quarter 2015 Financial Results
2015-04-10,Adamas Pharmaceuticals Receives Orphan Drug Designation For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia Associated With Parkinson's Disease
2015-04-09,Adamas Pharmaceuticals To Present At 2015 Needham Healthcare Conference
2015-03-31,Adamas Pharmaceuticals Issued Patent
2015-03-03,Adamas Reports Fiscal 2014 Financial Results
2015-02-09,Adamas Pharmaceuticals' Phase 2/3 Clinical Study Published In Movement Disorders
2015-01-11,Adamas Pharmaceuticals Provides Review Of 2014 And Previews Upcoming Business Drivers
2015-01-08,Adamas Pharmaceuticals Receives $30 Million Milestone Payment From Actavis
2014-12-24,Market News: Adamas Pharmaceuticals, Virgin America, CalAmp
2014-12-24,Actavis And Adamas Announce FDA Approval Of Namzaric™, A Fixed-Dose Combination Of Memantine Extended-Release And Donepezil Hydrochloride
2014-12-02,Adamas Pharmaceuticals Issued Six Additional U.S. Patents
2014-11-18,Adamas Pharmaceuticals To Present At Piper Jaffray Healthcare Conference
2014-11-05,Adamas Pharmaceuticals To Present At 2014 Credit Suisse Healthcare Conference
2014-11-04,Adamas Reports Third Quarter 2014 Financial Results
2014-10-28,Adamas Pharmaceuticals Expands Its Phase 3 Program With ADS-5102 For The Treatment Of Levodopa-induced Dyskinesia (LID) In Patients With Parkinson's Disease
2014-10-02,5 Big-Volume Stocks to Trade for Big Breakouts
2014-08-13,Adamas Pharmaceuticals Announces Management Changes
2014-08-07,Adamas Reports Second Quarter 2014 Financial Results
2014-08-05,United States Patent Issued To Adamas Pharmaceuticals
2014-06-16,Adamas Pharmaceuticals To Present At JMP Securities Healthcare Conference 2014
2014-06-10,Adamas Pharmaceuticals Announces Rater Training Data On ADS-5102 For Parkinson's Disease Patients With Levodopa-Induced Dyskinesia
2014-06-09,Adamas Pharmaceuticals Initiates Phase 3 Trial For ADS-5102 In Parkinson's Disease Patients With Levodopa-Induced Dyskinesia
2014-06-09,United States Patent Issued To Adamas Pharmaceuticals
2014-05-20,Adamas Pharmaceuticals Receives $25 Million Milestone Payment From Forest Laboratories
2014-04-30,Adamas Pharmaceuticals Provides Data Update On ADS-5102 At The American Academy Of Neurology Annual Meeting
2014-04-23,Adamas Pharmaceuticals Announces Data Update At American Academy Of Neurology Annual Meeting
2014-04-15,Adamas Pharmaceuticals Announces Closing Of Its Initial Public Offering
,
,
2017-03-15,Aduro Biotech To Host Research And Development Day In New York
2017-03-10,Aduro Biotech Awarded East Bay Innovation Award For Its Contributions in Life Sciences And The San Francisco East Bay Community
2017-03-06,Aduro Biotech Announces Upcoming Data Presentations At The 2017 American Association For Cancer Research Annual Meeting
2017-03-02,Aduro Biotech Announces Upcoming Data Presentations At The Keystone Symposia On Cancer Immunology And Immunotherapy Conference
2017-03-01,Aduro Biotech Announces Fourth Quarter And Full Year 2016 Financial Results
2017-02-28,Aduro Biotech To Present At Two Investor Conferences In March
2017-02-17,3 Stocks Setting Up for Major Breakouts
2017-02-10,Aduro Biotech To Present At The Leerink Partners 6th Annual Global Healthcare Conference
2017-01-26,Aduro Biotech Announces Appointment Of Leading Immunotherapy And Oncology Experts To Scientific Advisory Board
2017-01-19,Aduro Biotech Enters Into Exclusive License Agreement For Proprietary Neoantigen Identification Technology
2017-01-09,Aduro Biotech Announces Clinical Collaboration With Merck To Evaluate The Combination Of Aduro's CRS-207 With Merck's KEYTRUDA® (pembrolizumab) For The Treatment Of Gastric Cancer
2016-12-27,Aduro Biotech To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-22,Commit To Purchase Aduro Biotech At $7.50, Earn 20.8% Annualized Using Options
2016-12-07,Trump's Drug Pricing Comment Sends Biotech Stocks Into Free-Fall
2016-12-06,Aduro Biotech Europe's Hans Van Eenennaam, Ph.D. And John Dulos, Ph.D. Honored With The Intellectual Property Owners Education Foundation's 43rd Inventor Of The Year Award for Contributions In The Discovery Of KEYTRUDA® (pembrolizumab)
2016-12-05,Aduro Biotech Announces Anti-CD27 Agonist, An Investigational Anti-Cancer Immunotherapy, Advancing In Collaboration With MSD
2016-12-03,Aduro Biotech Presents Preclinical Data Supporting Clinical Development Of Its Anti-APRIL Antibody, BION-1301, For The Treatment Of Multiple Myeloma
2016-11-21,Partial Clinical Hold Lifted And Enrollment Resumes For Aduro Biotech LADD Clinical Trials
2016-11-12,Aduro Biotech Highlights Positive Clinical Results From Second Cohort Of Phase 1b Mesothelioma Clinical Trial
2016-11-09,Aduro Biotech's Personalized LADD Therapy Featured In An Oral Presentation At SITC's New Cancer Immunotherapy Agents In Development Program
2016-11-07,Aduro Biotech Presents Preclinical Data Demonstrating Acute And Systemic Immune Activation Through STING Pathway Stimulation With ADU-S100
2016-11-03,Aduro Biotech Enters Oversold Territory (ADRO)
2016-11-02,Aduro Biotech Reports Third Quarter 2016 Financial Results
2016-10-24,Aduro Biotech Reports Partial Clinical Hold To Pause Enrollment In LADD Trials
2016-10-23,Aduro Biotech To Host Conference Call
2016-09-29,Aduro Biotech Enters Oversold Territory (ADRO)
2016-09-27,Aduro Biotech Presents Encouraging Preclinical Data Showing Combination Synergy Of Its Immunotherapy And Checkpoint Inhibitors To Increase Antitumor Efficacy
2016-09-26,Aduro Biotech's Stephen T. Isaacs Named 2016 Visionary Leader By Berkeley Chamber Of Commerce
2016-09-22,Aduro Biotech To Present At LEERINK Partners Roundtable Series
2016-09-20,First Week of ADRO November 18th Options Trading
2016-09-06,Aduro Biotech Appoints Oncology Expert And Industry Veteran Natalie Sacks, M.D. As Chief Medical Officer
2016-09-01,Aduro Biotech Announces New Corporate Offices And Laboratory Space
2016-08-04,Aduro Biotech (ADRO) Is Today's Strong On High Volume Stock
2016-08-04,Aduro Biotech To Present At Canaccord Genuity Growth Conference
2016-08-03,Aduro Biotech Reports Second Quarter 2016 Financial Results
2016-06-09,Aduro Biotech To Present At NASDAQ Investor Conference
2016-06-04,Aduro Biotech Presents Encouraging Anti-Tumor Response Data From Ongoing Phase 1b Study In Malignant Pleural Mesothelioma At ASCO
2016-05-17,Ratings Changes Today
2016-05-16,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Into Possible Securities Fraud Violations By Certain Officers And Directors Of Audro BioTech, Inc.
2016-05-16,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Aduro BioTech, Inc. - ADRO
2016-05-16,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Aduro BioTech, Inc. (ADRO)
2016-05-16,Aduro Biotech Becomes Oversold (ADRO)
2016-05-16,Aduro Biotech Pancreatic Cancer Immunotherapy Fails Mid-Stage Study
2016-05-16,Aduro Biotech Announces Phase 2b ECLIPSE Trial Misses Primary Endpoint In Heavily Pretreated Metastatic Pancreatic Cancer
2016-05-15,Aduro Biotech To Host Conference Call
2016-05-12,Aduro Biotech Announces First Patient Dosed In Phase 1 Study Of ADU-S100 For The Treatment Of Cutaneously Accessible Tumors
2016-05-11,Aduro Biotech Announces Management Promotions
2016-05-02,Aduro Biotech Announces First Quarter 2016 Financial Results
2016-04-28,Aduro Biotech Announces Key Preclinical Data Published Highlighting New Approach To Treat Multiple Myeloma
2016-04-27,Aduro Biotech To Present At Two Upcoming Investor Conferences
2016-04-26,7 Stocks Rising on Big Volume -- Here's How to Trade Them Now
2016-04-22,These 5 Stocks Are Poised for Breakouts
2016-04-11,Aduro Biotech Chief Scientific Officer To Highlight The Potential Of STING Activation In Cancer Immunotherapy In A Major Symposium At The 2016 American Association For Cancer Research Annual Meeting
2016-04-01,5 Stocks Poised for Big Breakouts
2016-03-29,Commit To Buy Aduro Biotech At $10, Earn 46.1% Annualized Using Options
2016-03-28,Aduro Biotech And UC Berkeley Launch Industry-Leading Immunotherapeutics And Vaccine Research Initiative
2016-03-24,Aduro Biotech Announces First Patient Dosed In Combination Clinical Trial Of CRS-207 And Epacadostat To Treat Ovarian Cancer
2016-03-08,Aduro Biotech Announces Fourth Quarter And Full Year 2015 Financial Results
2016-03-07,Aduro Biotech To Present At ROTH Conference
2016-02-03,Aduro Biotech To Present At Leerink Partners Global Healthcare Conference
2016-02-01,Aduro Biotech Receives $22.4 Million In Clinical Development Milestone Payments From Janssen
2016-01-25,Aduro Biotech Appoints Aimee Luck Murphy As Vice President Of Clinical Development And Operations
2016-01-11,Oversold Conditions For Aduro Biotech (ADRO)
2016-01-07,Aduro Biotech To Present At JP Morgan Healthcare Conference
2016-01-05,Aduro Biotech Expands Patent Portfolio With Key Newly Issued Composition And Methods Patents
2015-12-21,Aduro Biotech Announces Initiation Of Phase 1 Study Of ADU-741 For The Treatment Of Prostate Cancer
2015-12-16,Aduro Biotech Receives Milestone Payment From Janssen For Acceptance Of Investigational New Drug Application For ADU-741 In Prostate Cancer
2015-12-14,Aduro Biotech Receives Orphan Drug Designation In The European Union For CRS-207 And GVAX Pancreas For The Treatment Of Pancreatic Cancer
2015-12-10,Aduro Biotech Announces First Patient Dosed In Phase 1 Study Of ADU-214 For The Treatment Of Lung Cancer
2015-12-02,Aduro Biotech To Present At Oppenheimer Healthcare Conference
2015-12-01,Analysts' Actions -- CBS, Cummins, Campbell Soup, WhiteWave Foods and More
2015-11-27,Aduro Biotech To Present At NASDAQ Investor Conference
2015-11-24,Aduro Biotech Confirms All Clinical Trials Continue Unaltered And As Planned
2015-11-23,Aduro Biotech Receives Orphan Drug Designation In The European Union For CRS-207 For The Treatment Of Mesothelioma
2015-11-23,Aduro Biotech Announces Third Quarter 2015 Financial Results
2015-11-20,Aduro Biotech Europe's Chief Scientific Officer, Andrea Van Elsas, Ph.D. Featured As Keynote Speaker On Immunomodulatory Antibodies At ESMO Symposium On Immuno-Oncology 2015
2015-11-19,Aduro Biotech Establishes European Subsidiary
2015-11-18,Aduro Biotech Receives Milestone Payment From Janssen For Submission Of Investigational New Drug Application For ADU-741 In Prostate Cancer
2015-11-09,Aduro Biotech Announces Five Poster Presentations At The Society Of Immunotherapy Of Cancer Annual Meeting
2015-11-04,Aduro Biotech To Present At Credit Suisse Healthcare Conference
2015-10-29,Aduro Biotech Receives Milestone Payment From Janssen For Acceptance Of Investigational New Drug Application For ADU-214 In Lung Cancer
2015-10-28,Aduro Biotech And Protein Potential Present Data Demonstrating Novel Vaccine Offers 100% Protection In Malarial Model
2015-10-08,Aduro Biotech Receives Milestone Payment From Janssen For Submission Of Investigational New Drug Application For ADU-214 In Lung Cancer
2015-09-26,Aduro Biotech Announces Phase 1b Mesothelioma Trial Featured In Spotlight Poster At ESMO/ECC
2015-09-24,Aduro Biotech Enters Into Definitive Agreement To Acquire Premier Antibody Portfolio And Engineering Capabilities Through Purchase Of BioNovion
2015-09-23,Aduro Biotech To Participate In Leerink Partners Immuno-Oncology Roundtable
2015-09-21,Aduro Biotech Appoints Blaine Templeman As Executive Vice President, General Counsel And Secretary
2015-09-09,Aduro Biotech Announces Clinical Trial Agreement To Evaluate Combination Of Two Novel Cancer Immunotherapies For The Treatment Of Ovarian Cancer
2015-09-08,Aduro Biotech Completes Enrollment In Phase 2b ECLIPSE Trial In Metastatic Pancreatic Cancer
2015-09-02,Aduro Biotech To Present At BioCentury's NewsMakers In The Biotech Industry Conference
2015-08-20,Sentiment for Advaxis Back to Bullish With Broadfin and Inovio Deal
2015-08-10,Aduro Biotech Announces Second Quarter 2015 Financial Results
2015-08-10,Aduro Biotech Completes Enrollment In Phase 1b Clinical Trial Of CRS-207 Immunotherapy For The Treatment Of Mesothelioma
2015-08-06,Aduro Biotech To Present At The 35th Annual Canaccord Genuity Growth Conference
2015-06-29,Aduro Biotech Announces Immunotherapy Regimen Successfully Passes Futility Analysis In Phase 2b ECLIPSE Trial In Metastatic Pancreatic Cancer
2015-06-26,Aduro Biotech Appoints Industry Veteran, Stephen Sherwin, M.D., To Its Board Of Directors
2015-06-02,Aduro Biotech Appoints Liana Wu As Vice President Of Commercial
2015-06-01,Aduro Biotech Announces ASCO Presentation Of Encouraging Data From Ongoing Phase 1b Clinical Trial Of Its Immunotherapy For The Treatment Of Mesothelioma
2015-05-29,Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
2015-05-28,Aduro Biotech Announces First Quarter 2015 Financial Results
2015-05-07,Aduro Biotech's Preclinical Results For Its STING-Targeted CDN Immuno-Oncology Platform Highlighted In Prestigious Peer-Reviewed Publications
2015-05-06,Aduro Biotech To Present At Bank Of America Merrill Lynch 2015 Health Care Conference
2015-04-20,Aduro Biotech Announces Close Of Initial Public Offering, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares, And Concurrent Private Placement
2015-04-17,IPO Market 'Has Been a Lonely Place' but Pace Is Picking Up
2015-04-15,Cancer Immunotherapy Remains Hot as Aduro Biotech Doubles in Value On IPO Debut
2015-04-14,Advaxis Shares Rise Ahead of Aduro's Rival Cancer Immunotherapy IPO
,
,
2017-03-07,Aerie Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Business Update
2017-03-05,4 Small-Cap Biotech Stars
2017-03-03,4 Small-Cap Biotech Stars
2017-03-02,Aerie Pharmaceuticals To Present At Three Investor Conferences In March
2017-03-01,Aerie Pharmaceuticals Announces Resubmission Of NDA For RhopressaTM (netarsudil Ophthalmic Solution) 0.02%
2017-02-27,Aerie Pharmaceuticals To Announce Fourth Quarter And Year End 2016 Financial Results And Host Conference Call On Tuesday, March 7, 2017
2017-02-15,Aerie Pharmaceuticals To Present At The RBC Capital Markets 2017 Global Healthcare Conference
2017-02-13,Noteworthy Monday Option Activity: AERI, NHTC, SUPN
2017-02-06,Aerie Pharmaceuticals Announces Appointment Of Huan Sheng, M.D., Ph.D., As Director Clinical Research And Drug Safety
2017-02-03,Aerie Pharmaceuticals Announces Appointment Of Barry Ivin As Site Director Of New Manufacturing Plant In Ireland
2017-01-27,Dearth of Momentum Helps Build 'Wall of Worry'
2017-01-23,Aerie Pharmaceuticals Announces Appointment Of Kristine Erickson, O.D., Ph.D., As Vice President Clinical Research
2017-01-23,Allergan, Apple, Facebook: Doug Kass' Views
2017-01-16,Allergan, Citigroup, Apple: Doug Kass' Views
2017-01-09,Aerie Pharmaceuticals Enters Into Lease Agreement For New Manufacturing Plant In Ireland
2017-01-03,Inotek Pharma Shares Plummet Following Negative Glaucoma Trial Results
2017-01-03,Inotek Pharma Glaucoma Drug Suffers Study Setback at Start of New Year
2016-12-23,Aerie Pharmaceuticals Provides Update On Timing Of NDA Filing For RhopressaTM (netarsudil Ophthalmic Solution) 0.02%
2016-12-22,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
2016-12-19,Aerie Pharmaceuticals Announces Appointment Of Judith J. Robertson As Chief Commercial Officer
2016-12-19,Apple, Alphabet, Starbucks: Doug Kass' Views
2016-12-07,Aerie Pharmaceuticals Completes Enrollment Of Mercury 2 Phase 3 Registration Trial Of Roclatan™ (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005%
2016-12-01,Aerie Pharmaceuticals To Participate In Two Investor Conferences In December
2016-11-28,Home Depot, Lowe's, Best Buy: Doug Kass' Views
2016-11-25,Apple Continues to Underperform; the Market Is Resistant: Best of Kass
2016-11-21,Facebook, Home Depot, Disney: Doug Kass' Views
2016-11-16,4 Stocks You Should Watch Because They're Breaking Out Higher
2016-11-07,Cisco, Allergan, Facebook: Doug Kass' Views
2016-11-03,Aerie Pharmaceuticals To Participate In Three Investor Conferences In November
2016-11-02,Aerie Pharmaceuticals Reports Third Quarter 2016 Financial Results And Provides Business Update
2016-10-27,Aerie Pharmaceuticals Reports Positive Topline Efficacy Results Of Rocket 4 Phase 3 Trial Of RhopressaTM (netarsudil Ophthalmic Solution) 0.02%
2016-10-25,Aerie Pharmaceuticals To Announce Third Quarter 2016 Financial Results And Host Conference Call On Wednesday, November 2, 2016
2016-10-24,Schlumberger, Amazon, Apple: Doug Kass' Views
2016-10-03,J.C.Penney, Wells Fargo, Deutsche Bank: Doug Kass' Views
2016-09-28,Aerie Pharmaceuticals To Host Investor Day On October 5, 2016
2016-09-21,Cloudy Outlook for Aerie Pharma's Glaucoma Drug
2016-09-19,Wells Fargo, Citigroup, Apple: Doug Kass' Views
2016-09-16,Notable Friday Option Activity: AERI, AWH, WATT
2016-09-16,Aerie Pharmaceuticals Raises $125 Million In Public Offerings
2016-09-15,Aerie Pharmaceuticals Announces Public Offering Of Common Stock
2016-09-15,Trending Tickers: AAPL, TMUS, FIT, AERI
2016-09-15,Bought Aerie Earlier? Congratulations
2016-09-15,Why Shares of Aerie Pharmaceuticals (AERI) are Soaring Today
2016-09-14,Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005% Phase 3 Topline Efficacy Results
2016-09-14,Fear of Being Left Out Is Lifting Indices
2016-09-09,4 Biotechs Set to Provide a Shot in the Arm
2016-09-09,4 Biotechs Set to Provide a Shot in the Arm
2016-09-06,Aerie Pharmaceuticals Submits New Drug Application To U.S. Food And Drug Administration For Rhopressa™ (netarsudil Ophthalmic Solution) 0.02%
2016-08-30,2 Biotechs to Watch Ahead of the Election
2016-08-25,Aerie Pharmaceuticals Stock Sees Short Interest Decline 17%
2016-08-04,Aerie Pharmaceuticals To Present At The Canaccord Genuity Growth Conference
2016-08-03,Aerie Pharmaceuticals Reports Second Quarter 2016 Financial Results And Provides Business Update
2016-07-27,Aerie Pharmaceuticals To Announce Second Quarter 2016 Financial Results And Host Conference Call On Wednesday, August 3, 2016
2016-07-22,Noteworthy Friday Option Activity: AERI, NAV, CBI
2016-07-06,Aerie Pharmaceuticals To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference
2016-06-27,First Week of February 2017 Options Trading For Aerie Pharmaceuticals (AERI)
2016-06-16,Aerie Pharmaceuticals Completes Enrollment Of Rocket 4 Phase 3 Clinical Trial Of RhopressaTM (netarsudil Ophthalmic Solution) 0.02%
2016-06-02,Aerie Pharmaceuticals To Participate In Two Investor Conferences In June
2016-05-05,Aerie Pharmaceuticals Completes Enrollment Of Mercury 1 Phase 3 Registration Trial Of RoclatanTM (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005%
2016-05-04,Aerie Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference
2016-05-02,Aerie Pharmaceuticals Reports First Quarter 2016 Financial Results And Provides Business Update
2016-04-25,Aerie Pharmaceuticals To Announce First Quarter 2016 Financial Results And Host Conference Call On Monday, May 2, 2016
2016-04-14,Commit To Buy Aerie Pharmaceuticals At $12.50, Earn 38.6% Annualized Using Options
2016-04-05,Aerie Pharmaceuticals To Present At The 15th Annual Needham Healthcare Conference
2016-03-28,Short Interest Moves 18.4% Higher For AERI
2016-03-28,Aerie Pharmaceuticals Initiates Second Phase 3 Registration Trial Of RoclatanTM (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005%
2016-03-17,Aerie Pharmaceuticals Reports Update On Positive Safety Results For RhopressaTM QD (netarsudil Ophthalmic Solution) 0.02%
2016-03-09,Aerie Pharmaceuticals Becomes Oversold (AERI)
2016-03-07,Tesla, Amazon and Netflix: Doug Kass' Views
2016-03-03,Noteworthy Thursday Option Activity: AERI, GB, W
2016-03-03,Aerie Pharma Falls on Glaucoma Eye Drop Safety Concerns
2016-03-03,Aerie Pharmaceuticals Announces Availability On Its Website Of Abstracts To Be Presented At The American Glaucoma Society 26th Annual Meeting
2016-03-01,Aerie Pharmaceuticals Reports Year End 2015 Financial Results And Provides Business Update
2016-02-22,Aerie Pharmaceuticals Announces Four New Abstracts To Be Presented At The American Glaucoma Society 26th Annual Meeting Next Week
2016-02-22,Aerie Pharmaceuticals To Announce Fourth Quarter And Year End 2015 Financial Results And Host Conference Call On Tuesday, March 1, 2016
2016-02-22,Amazon, Berkshire Hathaway and Potash: Doug Kass' Views
2016-02-19,What Carl Icahn Is Doing; Biotech Breakout: Best of Kass
2016-02-18,One Reason Why Aerie Pharmaceuticals (AERI) Stock is Soaring Today
2016-02-17,Aerie Pharmaceuticals Reports Positive RhopressaTM QD (netarsudil Ophthalmic Solution) 0.02% 12 Month Interim Safety Results For Rocket 2
2016-02-16,Aerie Pharmaceuticals To Present At The RBC Capital Markets 2016 Healthcare Conference
2016-02-15,JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views
2016-02-15,General Motors, MetLife and Tesla: Doug Kass' Views
2016-02-02,Aerie Pharmaceuticals Enters Oversold Territory (AERI)
2016-01-11,Aerie Pharmaceuticals Becomes Oversold (AERI)
2015-12-28,Short Interest Moves 14.3% Lower For AERI
2015-12-01,Commit To Buy Aerie Pharmaceuticals At $17.50, Earn 20.7% Annualized Using Options
2015-11-05,Aerie Pharmaceuticals To Participate In Several Conferences In November
2015-11-04,Aerie Pharmaceuticals To Host Investor And Media Briefing During The 2015 American Academy Of Ophthalmology Annual Meeting On November 13, 2015
2015-11-03,Aerie Pharmaceuticals Reports Third Quarter 2015 Financial Results And Provides Business Update
2015-10-20,Aerie Pharmaceuticals To Announce Third Quarter 2015 Financial Results And Host Conference Call On Tuesday, November 3, 2015
2015-10-13,Short Interest Declines 23.2% For AERI
2015-09-24,Aerie Pharmaceuticals Initiates Fourth Phase 3 Clinical Trial Of RhopressaTM
2015-09-21,Aerie Pharmaceuticals Initiates First Phase 3 Registration Trial Of RoclatanTM
2015-09-16,Aerie Pharmaceuticals Reports Positive Rhopressa™ Phase 3 Efficacy Results
2015-09-09,Aerie Pharmaceuticals Announces That Richard A. Lewis, M.D., Has Joined As Chief Medical Officer
2015-09-08,Aerie Pharmaceuticals And Ramot At Tel Aviv University Enter Research Collaboration
2015-08-28,First Week of AERI October 16th Options Trading
2015-08-06,Aerie Pharmaceuticals is Now Oversold (AERI)
2015-08-06,Aerie Pharmaceuticals To Present At The Canaccord Genuity Growth Conference
2015-08-05,Aerie Pharmaceuticals Reports Second Quarter 2015 Financial Results And Provides Business Update
2015-08-05,Aerie Pharmaceuticals And GrayBug Announce Research Collaboration
2015-07-22,Aerie Pharmaceuticals To Announce Second Quarter 2015 Financial Results And Host Conference Call On Wednesday, August 5, 2015
2015-07-01,10 Worst Biotech Stocks in the NASDAQ
2015-07-01,Aerie Pharmaceuticals To Present At The Cantor Fitzgerald 2015 Healthcare Conference
2015-06-29,Commit To Buy Aerie Pharmaceuticals At $12.50, Earn 23% Annualized Using Options
2015-06-29,Aerie Pharmaceuticals Elects Julie McHugh And Michael M. Du Toit To The Company's Board Of Directors
2015-06-19,AERI INVESTOR DEADLINE ALERT: Law Offices Of Howard G. Smith Reminds Investors Of The Lead Plaintiff Deadline In The Class Action Lawsuit Against Aerie Pharmaceuticals, Inc.
2015-06-19,Aerie Pharmaceuticals (AERI) Stock Upgraded by Analysts
2015-06-19,Analysts' Actions -- BioMarin, BP, Micron and More
2015-06-19,Biotech Stock Mailbag: Unstoppable Heron, Aerie Disclosure Fail, Gene Therapy, Hate Mail!
2015-06-18,DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Aerie Pharmaceuticals, Inc. Of Upcoming Deadline
2015-06-16,Market News: Aerie Pharmaceuticals, Coty Inc, NCR Corporation
2015-06-16,Aerie (AERI) Stock Spikes After FDA Lowers Drug Trial's Primary Endpoint
2015-06-15,Aerie Pharmaceuticals Receives Positive Feedback From FDA
2015-06-12,5 Stocks Ready for Breakouts
2015-06-01,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Aerie Pharmaceuticals, Inc. Of Pendency Of Class Action Lawsuit And A Lead Plaintiff Deadline Of June 29, 2015 - AERI
2015-05-27,Aerie Pharmaceuticals To Participate In Two Investor Conferences In June
2015-05-18,Kessler Topaz Meltzer & Check, LLP Announces Shareholder Class Action Against Aerie Pharmaceuticals, Inc. -- AERI
2015-05-15,EQUITY ALERT: The Rosen Law Firm Reminds Aerie Pharmaceuticals, Inc. Investors Of The Important Class Action Deadline
2015-05-11,INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Aerie Pharmaceuticals, Inc. (AERI) To Contact The Firm
2015-05-11,SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Aerie Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2015-05-07,Aerie Pharmaceuticals Reports First Quarter 2015 Financial Results And Provides Business And Strategic Update
2015-05-07,AERIE PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Announces Shareholder Class Action Against Aerie Pharmaceuticals, Inc. -- AERI
2015-05-07,Aerie Pharmaceuticals Elects Richard Croarkin To The Company's Board Of Directors
2015-05-06,SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aerie Pharmaceuticals, Inc.
2015-05-04,4 Big-Volume Stocks to Trade for Breakouts
2015-05-03,Shades of 1990s in Social Media Earnings Misses: Best of Kass
2015-05-01,Robbins Arroyo LLP: Aerie Pharmaceuticals, Inc. (AERI) Misled Shareholders According To A Recently Filed Class Action
2015-04-30,EQUITY ALERT: The Rosen Law Firm Announces The Filing Of A Securities Class Action Against Aerie Pharmaceuticals, Inc.
2015-04-30,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors Of Class Action Against Aerie Pharmaceuticals, Inc. And Lead Plaintiff
2015-04-28,Lifshitz & Miller Law Firm Announces Investigation Of Aerie Pharmaceuticals, Inc., American Science And Engineering, Inc., Associated Estates Realty Corporation, Cadiz Inc., MagnaChip Semiconductor Corporation, Procera Networks, Inc. And Trinity Industries Inc.
2015-04-28,Aerie Pharmaceuticals To Announce First Quarter 2015 Financial Results And Host Conference Call On Thursday, May 7, 2015
2015-04-27,Harwood Feffer LLP Announces Investigation Of Aerie Pharmaceuticals, Inc.
2015-04-27,Aerie Pharmaceuticals (AERI) Stock Hits 52-Week Low on Rhopressa Trial Results
2015-04-27,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Aerie Pharmaceuticals, Inc.
2015-04-24,EQUITY ALERT: The Rosen Law Firm Announces Investigation Of Securities Claims Against Aerie Pharmaceuticals, Inc.
2015-04-24,Investor Alert: Investigation Of Aerie Pharmaceuticals, Inc. Announced By Holzer & Holzer, LLC
2015-04-24,Bernstein Liebhard LLP Investigates Claims On Behalf Of Those Who Invested In Aerie Pharmaceuticals, Inc.
2015-04-23,Aerie Pharmaceuticals Reports Initial RhopressaTM Phase 3 Efficacy Results
2015-04-08,Aerie Pharmaceuticals To Present At The 14th Annual Needham Healthcare Conference
2015-03-31,First Week Of November 20th Options Trading For Aerie Pharmaceuticals (AERI)
2015-03-24,Aerie Pharmaceuticals Completes Enrollment In Second Phase 3 Registration Trial ("Rocket 2") Of Rhopressa™, Novel Triple-Action Product To Lower Intraocular Pressure In Patients With Glaucoma
2015-03-03,Aerie Pharmaceuticals To Participate In Two Investor Conferences In March
2015-03-02,Aerie Pharmaceuticals Reports Fourth Quarter And Full Year 2014 Financial Results And Provides Business And Product Development Update
2015-02-18,4 Stocks Breaking Out on Big Volume: Zillow, Aerie and More
2015-02-18,Aerie Pharmaceuticals Announces Potential Breakthroughs With New Preclinical Research
2015-02-17,Aerie Pharmaceuticals Announces Rhopressa™ Presentation At 2015 Meeting Of The Association For Ocular Pharmacology And Therapeutics
2015-02-17,Aerie Pharmaceuticals To Announce Fourth Quarter And Year End 2014 Financial Results And Host Conference Call On Monday, March 2, 2015
2015-02-03,Aerie Pharmaceuticals To Participate In Two Investor Conferences In February
2015-01-13,Commit To Buy Aerie Pharmaceuticals At $25, Earn 20.9% Annualized Using Options
2015-01-12,Aerie Pharmaceuticals Announces Acceleration Of Expected Timeline For Reporting Efficacy Results From Phase 3 Registration Trial ("Rocket 1") Of RhopressaTM
2014-12-16,Aerie Pharmaceuticals Added To NASDAQ Biotechnology Index (NBI)
2014-12-02,Aerie Pharmaceuticals Completes Enrollment In Phase 3 Registration Trial ("Rocket 1") Of Rhopressa™, Novel Triple-Action Product To Lower Intraocular Pressure In Patients With Glaucoma
2014-11-24,Aerie Pharmaceuticals To Present At The Piper Jaffray 26th Annual Healthcare Conference
2014-11-12,Aerie Pharmaceuticals To Present At The 2014 Stifel Nicolaus Annual Healthcare Conference
2014-11-11,Aerie Pharmaceuticals Reports Third Quarter 2014 Financial Results And Provides Business And Product Development Update
2014-10-28,Aerie Pharmaceuticals To Announce Third Quarter 2014 Financial Results And Host Conference Call On Tuesday, November 11, 2014
2014-10-06,Aerie Pharmaceuticals Elects Benjamin F. McGraw, III To Its Board Of Directors
2014-09-30,Aerie Announces Closing Of $125 Million Convertible Notes Financing
2014-09-09,Aerie Announces $125 Million Convertible Notes
2014-09-04,Aerie Pharmaceuticals To Host Investor Day On September 10, 2014
2014-09-03,Aerie Pharmaceuticals Inc. Initiates Phase 3 Safety-Only Registration Trial In Canada Of RhopressaTM In Patients With Glaucoma
2014-08-07,Aerie Pharmaceuticals To Present At The Canaccord Genuity 34th Annual Growth Conference
2014-08-06,Aerie Pharmaceuticals Reports Second Quarter 2014 Financial Results And Provides Business And Product Development Update
2014-07-24,Aerie Pharmaceuticals, Inc. Receives Health Canada &#8220;No Objection Letter&#8221; To Commence Phase 3 Registration Trial Of RhopressaTM In Patients With Glaucoma In Canada
2014-07-23,Aerie Pharmaceuticals To Announce Second Quarter 2014 Financial Results And Host Conference Call On Wednesday, August 6, 2014
2014-07-14,Aerie Pharmaceuticals Initiates Phase 3 Registration Trials Of RhopressaTM, Novel Triple-Action Product To Lower Intraocular Pressure In Patients With Glaucoma
2014-07-07,Aerie Pharmaceuticals Expands Management Team, Names Michael McCleerey As Vice President, Marketing
2014-06-25,Why Aerie Pharmaceuticals (AERI) Stock Is Soaring Today
2014-06-09,3 Big-Volume Stocks to Trade for Breakouts
2017-03-07,Aerie Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Business Update
2017-03-05,4 Small-Cap Biotech Stars
2017-03-03,4 Small-Cap Biotech Stars
2017-03-02,Aerie Pharmaceuticals To Present At Three Investor Conferences In March
2017-03-01,Aerie Pharmaceuticals Announces Resubmission Of NDA For RhopressaTM (netarsudil Ophthalmic Solution) 0.02%
2017-02-27,Aerie Pharmaceuticals To Announce Fourth Quarter And Year End 2016 Financial Results And Host Conference Call On Tuesday, March 7, 2017
2017-02-15,Aerie Pharmaceuticals To Present At The RBC Capital Markets 2017 Global Healthcare Conference
2017-02-13,Noteworthy Monday Option Activity: AERI, NHTC, SUPN
2017-02-06,Aerie Pharmaceuticals Announces Appointment Of Huan Sheng, M.D., Ph.D., As Director Clinical Research And Drug Safety
2017-02-03,Aerie Pharmaceuticals Announces Appointment Of Barry Ivin As Site Director Of New Manufacturing Plant In Ireland
2017-01-27,Dearth of Momentum Helps Build 'Wall of Worry'
2017-01-23,Aerie Pharmaceuticals Announces Appointment Of Kristine Erickson, O.D., Ph.D., As Vice President Clinical Research
2017-01-23,Allergan, Apple, Facebook: Doug Kass' Views
2017-01-16,Allergan, Citigroup, Apple: Doug Kass' Views
2017-01-09,Aerie Pharmaceuticals Enters Into Lease Agreement For New Manufacturing Plant In Ireland
2017-01-03,Inotek Pharma Shares Plummet Following Negative Glaucoma Trial Results
2017-01-03,Inotek Pharma Glaucoma Drug Suffers Study Setback at Start of New Year
2016-12-23,Aerie Pharmaceuticals Provides Update On Timing Of NDA Filing For RhopressaTM (netarsudil Ophthalmic Solution) 0.02%
2016-12-22,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
2016-12-19,Aerie Pharmaceuticals Announces Appointment Of Judith J. Robertson As Chief Commercial Officer
2016-12-19,Apple, Alphabet, Starbucks: Doug Kass' Views
2016-12-07,Aerie Pharmaceuticals Completes Enrollment Of Mercury 2 Phase 3 Registration Trial Of Roclatan™ (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005%
2016-12-01,Aerie Pharmaceuticals To Participate In Two Investor Conferences In December
2016-11-28,Home Depot, Lowe's, Best Buy: Doug Kass' Views
2016-11-25,Apple Continues to Underperform; the Market Is Resistant: Best of Kass
2016-11-21,Facebook, Home Depot, Disney: Doug Kass' Views
2016-11-16,4 Stocks You Should Watch Because They're Breaking Out Higher
2016-11-07,Cisco, Allergan, Facebook: Doug Kass' Views
2016-11-03,Aerie Pharmaceuticals To Participate In Three Investor Conferences In November
2016-11-02,Aerie Pharmaceuticals Reports Third Quarter 2016 Financial Results And Provides Business Update
2016-10-27,Aerie Pharmaceuticals Reports Positive Topline Efficacy Results Of Rocket 4 Phase 3 Trial Of RhopressaTM (netarsudil Ophthalmic Solution) 0.02%
2016-10-25,Aerie Pharmaceuticals To Announce Third Quarter 2016 Financial Results And Host Conference Call On Wednesday, November 2, 2016
2016-10-24,Schlumberger, Amazon, Apple: Doug Kass' Views
2016-10-03,J.C.Penney, Wells Fargo, Deutsche Bank: Doug Kass' Views
2016-09-28,Aerie Pharmaceuticals To Host Investor Day On October 5, 2016
2016-09-21,Cloudy Outlook for Aerie Pharma's Glaucoma Drug
2016-09-19,Wells Fargo, Citigroup, Apple: Doug Kass' Views
2016-09-16,Notable Friday Option Activity: AERI, AWH, WATT
2016-09-16,Aerie Pharmaceuticals Raises $125 Million In Public Offerings
2016-09-15,Aerie Pharmaceuticals Announces Public Offering Of Common Stock
2016-09-15,Trending Tickers: AAPL, TMUS, FIT, AERI
2016-09-15,Bought Aerie Earlier? Congratulations
2016-09-15,Why Shares of Aerie Pharmaceuticals (AERI) are Soaring Today
2016-09-14,Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005% Phase 3 Topline Efficacy Results
2016-09-14,Fear of Being Left Out Is Lifting Indices
2016-09-09,4 Biotechs Set to Provide a Shot in the Arm
2016-09-09,4 Biotechs Set to Provide a Shot in the Arm
2016-09-06,Aerie Pharmaceuticals Submits New Drug Application To U.S. Food And Drug Administration For Rhopressa™ (netarsudil Ophthalmic Solution) 0.02%
2016-08-30,2 Biotechs to Watch Ahead of the Election
2016-08-25,Aerie Pharmaceuticals Stock Sees Short Interest Decline 17%
2016-08-04,Aerie Pharmaceuticals To Present At The Canaccord Genuity Growth Conference
2016-08-03,Aerie Pharmaceuticals Reports Second Quarter 2016 Financial Results And Provides Business Update
2016-07-27,Aerie Pharmaceuticals To Announce Second Quarter 2016 Financial Results And Host Conference Call On Wednesday, August 3, 2016
2016-07-22,Noteworthy Friday Option Activity: AERI, NAV, CBI
2016-07-06,Aerie Pharmaceuticals To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference
2016-06-27,First Week of February 2017 Options Trading For Aerie Pharmaceuticals (AERI)
2016-06-16,Aerie Pharmaceuticals Completes Enrollment Of Rocket 4 Phase 3 Clinical Trial Of RhopressaTM (netarsudil Ophthalmic Solution) 0.02%
2016-06-02,Aerie Pharmaceuticals To Participate In Two Investor Conferences In June
2016-05-05,Aerie Pharmaceuticals Completes Enrollment Of Mercury 1 Phase 3 Registration Trial Of RoclatanTM (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005%
2016-05-04,Aerie Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference
2016-05-02,Aerie Pharmaceuticals Reports First Quarter 2016 Financial Results And Provides Business Update
2016-04-25,Aerie Pharmaceuticals To Announce First Quarter 2016 Financial Results And Host Conference Call On Monday, May 2, 2016
2016-04-14,Commit To Buy Aerie Pharmaceuticals At $12.50, Earn 38.6% Annualized Using Options
2016-04-05,Aerie Pharmaceuticals To Present At The 15th Annual Needham Healthcare Conference
2016-03-28,Short Interest Moves 18.4% Higher For AERI
2016-03-28,Aerie Pharmaceuticals Initiates Second Phase 3 Registration Trial Of RoclatanTM (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005%
2016-03-17,Aerie Pharmaceuticals Reports Update On Positive Safety Results For RhopressaTM QD (netarsudil Ophthalmic Solution) 0.02%
2016-03-09,Aerie Pharmaceuticals Becomes Oversold (AERI)
2016-03-07,Tesla, Amazon and Netflix: Doug Kass' Views
2016-03-03,Noteworthy Thursday Option Activity: AERI, GB, W
2016-03-03,Aerie Pharma Falls on Glaucoma Eye Drop Safety Concerns
2016-03-03,Aerie Pharmaceuticals Announces Availability On Its Website Of Abstracts To Be Presented At The American Glaucoma Society 26th Annual Meeting
2016-03-01,Aerie Pharmaceuticals Reports Year End 2015 Financial Results And Provides Business Update
2016-02-22,Aerie Pharmaceuticals Announces Four New Abstracts To Be Presented At The American Glaucoma Society 26th Annual Meeting Next Week
2016-02-22,Aerie Pharmaceuticals To Announce Fourth Quarter And Year End 2015 Financial Results And Host Conference Call On Tuesday, March 1, 2016
2016-02-22,Amazon, Berkshire Hathaway and Potash: Doug Kass' Views
2016-02-19,What Carl Icahn Is Doing; Biotech Breakout: Best of Kass
2016-02-18,One Reason Why Aerie Pharmaceuticals (AERI) Stock is Soaring Today
2016-02-17,Aerie Pharmaceuticals Reports Positive RhopressaTM QD (netarsudil Ophthalmic Solution) 0.02% 12 Month Interim Safety Results For Rocket 2
2016-02-16,Aerie Pharmaceuticals To Present At The RBC Capital Markets 2016 Healthcare Conference
2016-02-15,JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views
2016-02-15,General Motors, MetLife and Tesla: Doug Kass' Views
2016-02-02,Aerie Pharmaceuticals Enters Oversold Territory (AERI)
2016-01-11,Aerie Pharmaceuticals Becomes Oversold (AERI)
2015-12-28,Short Interest Moves 14.3% Lower For AERI
2015-12-01,Commit To Buy Aerie Pharmaceuticals At $17.50, Earn 20.7% Annualized Using Options
2015-11-05,Aerie Pharmaceuticals To Participate In Several Conferences In November
2015-11-04,Aerie Pharmaceuticals To Host Investor And Media Briefing During The 2015 American Academy Of Ophthalmology Annual Meeting On November 13, 2015
2015-11-03,Aerie Pharmaceuticals Reports Third Quarter 2015 Financial Results And Provides Business Update
2015-10-20,Aerie Pharmaceuticals To Announce Third Quarter 2015 Financial Results And Host Conference Call On Tuesday, November 3, 2015
2015-10-13,Short Interest Declines 23.2% For AERI
2015-09-24,Aerie Pharmaceuticals Initiates Fourth Phase 3 Clinical Trial Of RhopressaTM
2015-09-21,Aerie Pharmaceuticals Initiates First Phase 3 Registration Trial Of RoclatanTM
2015-09-16,Aerie Pharmaceuticals Reports Positive Rhopressa™ Phase 3 Efficacy Results
2015-09-09,Aerie Pharmaceuticals Announces That Richard A. Lewis, M.D., Has Joined As Chief Medical Officer
2015-09-08,Aerie Pharmaceuticals And Ramot At Tel Aviv University Enter Research Collaboration
2015-08-28,First Week of AERI October 16th Options Trading
2015-08-06,Aerie Pharmaceuticals is Now Oversold (AERI)
2015-08-06,Aerie Pharmaceuticals To Present At The Canaccord Genuity Growth Conference
2015-08-05,Aerie Pharmaceuticals Reports Second Quarter 2015 Financial Results And Provides Business Update
2015-08-05,Aerie Pharmaceuticals And GrayBug Announce Research Collaboration
2015-07-22,Aerie Pharmaceuticals To Announce Second Quarter 2015 Financial Results And Host Conference Call On Wednesday, August 5, 2015
2015-07-01,10 Worst Biotech Stocks in the NASDAQ
2015-07-01,Aerie Pharmaceuticals To Present At The Cantor Fitzgerald 2015 Healthcare Conference
2015-06-29,Commit To Buy Aerie Pharmaceuticals At $12.50, Earn 23% Annualized Using Options
2015-06-29,Aerie Pharmaceuticals Elects Julie McHugh And Michael M. Du Toit To The Company's Board Of Directors
2015-06-19,AERI INVESTOR DEADLINE ALERT: Law Offices Of Howard G. Smith Reminds Investors Of The Lead Plaintiff Deadline In The Class Action Lawsuit Against Aerie Pharmaceuticals, Inc.
2015-06-19,Aerie Pharmaceuticals (AERI) Stock Upgraded by Analysts
2015-06-19,Analysts' Actions -- BioMarin, BP, Micron and More
2015-06-19,Biotech Stock Mailbag: Unstoppable Heron, Aerie Disclosure Fail, Gene Therapy, Hate Mail!
2015-06-18,DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Aerie Pharmaceuticals, Inc. Of Upcoming Deadline
2015-06-16,Market News: Aerie Pharmaceuticals, Coty Inc, NCR Corporation
2015-06-16,Aerie (AERI) Stock Spikes After FDA Lowers Drug Trial's Primary Endpoint
2015-06-15,Aerie Pharmaceuticals Receives Positive Feedback From FDA
2015-06-12,5 Stocks Ready for Breakouts
2015-06-01,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Aerie Pharmaceuticals, Inc. Of Pendency Of Class Action Lawsuit And A Lead Plaintiff Deadline Of June 29, 2015 - AERI
2015-05-27,Aerie Pharmaceuticals To Participate In Two Investor Conferences In June
2015-05-18,Kessler Topaz Meltzer & Check, LLP Announces Shareholder Class Action Against Aerie Pharmaceuticals, Inc. -- AERI
2015-05-15,EQUITY ALERT: The Rosen Law Firm Reminds Aerie Pharmaceuticals, Inc. Investors Of The Important Class Action Deadline
2015-05-11,INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Aerie Pharmaceuticals, Inc. (AERI) To Contact The Firm
2015-05-11,SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Aerie Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2015-05-07,Aerie Pharmaceuticals Reports First Quarter 2015 Financial Results And Provides Business And Strategic Update
2015-05-07,AERIE PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Announces Shareholder Class Action Against Aerie Pharmaceuticals, Inc. -- AERI
2015-05-07,Aerie Pharmaceuticals Elects Richard Croarkin To The Company's Board Of Directors
2015-05-06,SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aerie Pharmaceuticals, Inc.
2015-05-04,4 Big-Volume Stocks to Trade for Breakouts
2015-05-03,Shades of 1990s in Social Media Earnings Misses: Best of Kass
2015-05-01,Robbins Arroyo LLP: Aerie Pharmaceuticals, Inc. (AERI) Misled Shareholders According To A Recently Filed Class Action
2015-04-30,EQUITY ALERT: The Rosen Law Firm Announces The Filing Of A Securities Class Action Against Aerie Pharmaceuticals, Inc.
2015-04-30,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors Of Class Action Against Aerie Pharmaceuticals, Inc. And Lead Plaintiff
2015-04-28,Lifshitz & Miller Law Firm Announces Investigation Of Aerie Pharmaceuticals, Inc., American Science And Engineering, Inc., Associated Estates Realty Corporation, Cadiz Inc., MagnaChip Semiconductor Corporation, Procera Networks, Inc. And Trinity Industries Inc.
2015-04-28,Aerie Pharmaceuticals To Announce First Quarter 2015 Financial Results And Host Conference Call On Thursday, May 7, 2015
2015-04-27,Harwood Feffer LLP Announces Investigation Of Aerie Pharmaceuticals, Inc.
2015-04-27,Aerie Pharmaceuticals (AERI) Stock Hits 52-Week Low on Rhopressa Trial Results
2015-04-27,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Aerie Pharmaceuticals, Inc.
2015-04-24,EQUITY ALERT: The Rosen Law Firm Announces Investigation Of Securities Claims Against Aerie Pharmaceuticals, Inc.
2015-04-24,Investor Alert: Investigation Of Aerie Pharmaceuticals, Inc. Announced By Holzer & Holzer, LLC
2015-04-24,Bernstein Liebhard LLP Investigates Claims On Behalf Of Those Who Invested In Aerie Pharmaceuticals, Inc.
2015-04-23,Aerie Pharmaceuticals Reports Initial RhopressaTM Phase 3 Efficacy Results
2015-04-08,Aerie Pharmaceuticals To Present At The 14th Annual Needham Healthcare Conference
2015-03-31,First Week Of November 20th Options Trading For Aerie Pharmaceuticals (AERI)
2015-03-24,Aerie Pharmaceuticals Completes Enrollment In Second Phase 3 Registration Trial ("Rocket 2") Of Rhopressa™, Novel Triple-Action Product To Lower Intraocular Pressure In Patients With Glaucoma
2015-03-03,Aerie Pharmaceuticals To Participate In Two Investor Conferences In March
2015-03-02,Aerie Pharmaceuticals Reports Fourth Quarter And Full Year 2014 Financial Results And Provides Business And Product Development Update
2015-02-18,4 Stocks Breaking Out on Big Volume: Zillow, Aerie and More
2015-02-18,Aerie Pharmaceuticals Announces Potential Breakthroughs With New Preclinical Research
2015-02-17,Aerie Pharmaceuticals Announces Rhopressa™ Presentation At 2015 Meeting Of The Association For Ocular Pharmacology And Therapeutics
2015-02-17,Aerie Pharmaceuticals To Announce Fourth Quarter And Year End 2014 Financial Results And Host Conference Call On Monday, March 2, 2015
2015-02-03,Aerie Pharmaceuticals To Participate In Two Investor Conferences In February
2015-01-13,Commit To Buy Aerie Pharmaceuticals At $25, Earn 20.9% Annualized Using Options
2015-01-12,Aerie Pharmaceuticals Announces Acceleration Of Expected Timeline For Reporting Efficacy Results From Phase 3 Registration Trial ("Rocket 1") Of RhopressaTM
2014-12-16,Aerie Pharmaceuticals Added To NASDAQ Biotechnology Index (NBI)
2014-12-02,Aerie Pharmaceuticals Completes Enrollment In Phase 3 Registration Trial ("Rocket 1") Of Rhopressa™, Novel Triple-Action Product To Lower Intraocular Pressure In Patients With Glaucoma
2014-11-24,Aerie Pharmaceuticals To Present At The Piper Jaffray 26th Annual Healthcare Conference
2014-11-12,Aerie Pharmaceuticals To Present At The 2014 Stifel Nicolaus Annual Healthcare Conference
2014-11-11,Aerie Pharmaceuticals Reports Third Quarter 2014 Financial Results And Provides Business And Product Development Update
2014-10-28,Aerie Pharmaceuticals To Announce Third Quarter 2014 Financial Results And Host Conference Call On Tuesday, November 11, 2014
2014-10-06,Aerie Pharmaceuticals Elects Benjamin F. McGraw, III To Its Board Of Directors
2014-09-30,Aerie Announces Closing Of $125 Million Convertible Notes Financing
2014-09-09,Aerie Announces $125 Million Convertible Notes
2014-09-04,Aerie Pharmaceuticals To Host Investor Day On September 10, 2014
2014-09-03,Aerie Pharmaceuticals Inc. Initiates Phase 3 Safety-Only Registration Trial In Canada Of RhopressaTM In Patients With Glaucoma
2014-08-07,Aerie Pharmaceuticals To Present At The Canaccord Genuity 34th Annual Growth Conference
2014-08-06,Aerie Pharmaceuticals Reports Second Quarter 2014 Financial Results And Provides Business And Product Development Update
2014-07-24,Aerie Pharmaceuticals, Inc. Receives Health Canada &#8220;No Objection Letter&#8221; To Commence Phase 3 Registration Trial Of RhopressaTM In Patients With Glaucoma In Canada
2014-07-23,Aerie Pharmaceuticals To Announce Second Quarter 2014 Financial Results And Host Conference Call On Wednesday, August 6, 2014
2014-07-14,Aerie Pharmaceuticals Initiates Phase 3 Registration Trials Of RhopressaTM, Novel Triple-Action Product To Lower Intraocular Pressure In Patients With Glaucoma
2014-07-07,Aerie Pharmaceuticals Expands Management Team, Names Michael McCleerey As Vice President, Marketing
2014-06-25,Why Aerie Pharmaceuticals (AERI) Stock Is Soaring Today
2014-06-09,3 Big-Volume Stocks to Trade for Breakouts
2017-03-15,Aeterna Zentaris Reports Fourth Quarter And Full-Year 2016 Financial And Operating Results
2017-03-07,Aeterna Zentaris Announces EMA Pediatric Committee Agreement On The Pediatric Investigation Plan For Macrilen™
2017-03-06,Aeterna Zentaris To Announce Fourth Quarter And Full-Year 2016 Financial And Operating Results On March 15, 2017
2017-03-02,Aeterna Zentaris Announces Presentation Regarding Macrilen™ At 99th Annual Meeting Of The Endocrine Society
2017-02-14,Aeterna Zentaris Announces Zoptrex™ Presentation In Prostate Cancer At 2017 Genitourinary Cancers Symposium
2017-02-13,Aeterna Zentaris Announces Plans To Pursue FDA Registration Of Macrilen™
2017-02-09,Aeterna Zentaris To Present At The 2nd Annual Disruptive Growth & Healthcare Conference
2017-02-07,Aeterna Zentaris To Present At The 2017 BIO CEO And Investor Conference
2017-01-30,Aeterna Zentaris Announces Completion Of Zoptrex™ Pivotal Phase 3 Clinical Trial In Advanced Endometrial Cancer; Expects To Report Top-Line Results In April 2017
2017-01-04,Aeterna Zentaris Announces Top-Line Results Of Confirmatory Phase 3 Trial Of Macrilen™
2016-11-08,Aeterna Zentaris Reports Third Quarter 2016 Financial And Operating Results
2016-11-01,Aeterna Zentaris Announces Closing Of US$7,560,000 Registered Direct Offering Of Common Shares And Warrants
2016-10-28,Aeterna Zentaris To Announce Third Quarter 2016 Financial And Operating Results On November 8, 2016
2016-10-27,Aeterna Zentaris Announces US$7,560,000 Registered Direct Offering Of Common Shares And Warrants
2016-10-26,Aeterna Zentaris Completes Patient Recruitment For Confirmatory Phase 3 Trial Of Macrilen™
2016-10-12,Aeterna Zentaris And Specialised Therapeutics Asia Sign Exclusive License Agreement For The Potential Marketing Of Zoptrex™ In Australia And New Zealand
2016-09-14,Aeterna Zentaris Announces Expiration Of Remaining Series B Warrants
2016-09-12,Aeterna Zentaris To Present At Upcoming Aegis Capital Corp. 2016 Growth Conference In Las Vegas, Nevada
2016-09-06,Aeterna Zentaris To Present At Upcoming Rodman & Renshaw Annual Global Investment Conference In New York
2016-08-09,Aeterna Zentaris Reports Second Quarter 2016 Financial And Operating Results
2016-08-08,Aeterna Zentaris Expands Promotion Of APIFINY® Into Florida
2016-08-01,Aeterna Zentaris And Rafa Laboratories Sign Exclusive License Agreement For Zoptrex™ In Israel
2016-07-27,Aeterna Zentaris To Announce Second Quarter 2016 Financial And Operating Results On August 9, 2016
2016-07-01,Aeterna Zentaris And Orient EuroPharma Co., Ltd. Sign Exclusive License Agreement For Zoptrex™ In Taiwan And Southeast Asia
2016-06-14,Aeterna Zentaris Announces IND Submission By Sinopharm A-Think
2016-06-06,Aeterna Zentaris Reconfirms Commitment To LHRH-receptor Targeting Zoptrex™ During 2016 ASCO Annual Meeting
2016-05-23,Aeterna Zentaris Elects Ms. Carolyn Egbert As Independent Chair Of The Board
2016-05-10,Aeterna Zentaris Announces Election Of Directors At 2016 Shareholders' Meeting
2016-05-09,Aeterna Zentaris Reports First Quarter 2016 Financial And Operating Results
2016-04-27,Aeterna Zentaris Acquires Exclusive U.S. Promotional Rights For APIFINY® Prostate Cancer Blood Test
2016-04-26,Aeterna Zentaris To Announce First Quarter 2016 Financial And Operating Results On May 9, 2016
2016-04-08,Aeterna Zentaris Mails Information Circular In Connection With Annual Meeting Of Shareholders
2016-04-01,Aeterna Zentaris Announces At The Market Issuance Program
2016-03-29,Aeterna Zentaris Reports Fourth Quarter And Full-Year 2015 Financial And Operating Results
2016-03-15,Aeterna Zentaris To Announce Fourth Quarter And Full-Year 2015 Financial And Operating Results On March 29, 2016
2016-03-01,Aeterna Zentaris Reports On Zoptrex™ Development Progress In China
2016-02-26,Company Profile For Aeterna Zentaris Inc.
2016-02-23,Aeterna Zentaris Commences Promotional Activities For APIFINY® Prostate Cancer Blood Test
2016-02-18,Aeterna Zentaris Appoints Geneviève Lemaire As Vice President, Finance And Chief Accounting Officer
2016-02-01,Aeterna Zentaris To Participate In 18th Annual BIO CEO & Investor Conference Seeking Partnering Opportunities
2016-01-29,Aeterna Zentaris Announces Appointments To Board Of Directors
2016-01-26,Aeterna Zentaris Files International Patent Application For Novel Method Of Manufacturing Zoptrex™
2016-01-25,Strong On High Volume: AEterna Zentaris (AEZS)
2016-01-25,Aeterna Zentaris Announces Additional Market Purchases Of Common Shares By Executive Management
2016-01-19,Aeterna Zentaris Concludes Successful Meeting Of Clinical Investigators For Confirmatory Phase 3 Trial Of Macrilen™
2016-01-13,Aeterna Zentaris Affirms Focus On Targeted Oncology During 2016 J.P. Morgan Healthcare Conference
2015-12-30,Aeterna Zentaris Announces Filing Of Preliminary Base Shelf Prospectus
2015-12-14,Aeterna Zentaris Announces Closing Of US$16.65 Million Public Offering Of Common Shares And Warrants
2015-12-09,Aeterna Zentaris Announces Pricing Of US$16.65 Million Public Offering Of Common Shares And Warrants
2015-12-08,Aeterna Zentaris Announces Proposed Public Offering Of Common Shares And Warrants
2015-12-08,Aeterna Zentaris Regains Compliance With NASDAQ $1.00 Minimum Bid Price Rule And Announces 2016 Corporate Objectives
2015-12-04,Today's Dead Cat Bounce Stock Is AEterna Zentaris (AEZS)
2015-12-01,Aeterna Zentaris And Armune BioScience Finalize Co-Marketing Agreement For APIFINY® Prostate Cancer Blood Test
2015-11-27,Trade-Ideas: AEterna Zentaris (AEZS) Is Today's "Perilous Reversal" Stock
2015-11-25,Aeterna Zentaris Affirms Fundamental Strength Of Business
2015-11-25,AEterna Zentaris (AEZS) Showing Signs Of A Dead Cat Bounce Today
2015-11-24,Aeterna Zentaris Confirms No Corporate Developments
2015-11-24,Aeterna Zentaris Announces Exercise Of Last Series B Warrants Covered By November 1, 2015 Agreement
2015-11-24,AEterna Zentaris (AEZS): Heavy Pre-Market Activity
2015-11-19,Aeterna Zentaris Announces First Patient Enrolled For Confirmatory Phase 3 Trial Of Macrilen™ For The Evaluation Of AGHD
2015-11-18,Aeterna Zentaris Announces Details And Implementation Of Share Consolidation To Regain NASDAQ Compliance
2015-11-16,Aeterna Zentaris Announces Shareholder Approval Of Share Consolidation
2015-11-12,Aeterna Zentaris Announces Exercise Of Series B Warrants
2015-11-11,Aeterna Zentaris Urges Shareholders To Vote In Favor Of The Share Consolidation And Highlights Support From ISS And Glass Lewis
2015-11-02,Aeterna Zentaris Announces Agreement To Exercise Substantially All Remaining Series B Warrants
2015-10-27,Leading Independent Advisory Firms ISS And Glass Lewis Recommend Shareholders Of Aeterna Zentaris Vote FOR Share Consolidation
2015-10-23,Aeterna Zentaris To Announce Third Quarter 2015 Financial And Operating Results On November 6, 2015
2015-10-16,Aeterna Zentaris Announces Special Meeting Of Shareholders And Mailing Of Management Information Circular
2015-10-13,Aeterna Zentaris: Data And Safety Monitoring Board Recommends Continuation Of ZoptEC Phase 3 Trial In Advanced Endometrial Cancer
2015-10-12,Aeterna Zentaris Announces Restructuring Of Finance & Accounting Operations And Closure Of Quebec City Office
2015-09-29,Today's Weak On High Volume Stock: AEterna Zentaris (AEZS)
2015-09-28,Aeterna Zentaris' Zoptarelin Doxorubicin Meets Phase 2 Primary Endpoint In Men With Heavily Pretreated Castration And Taxane Resistant Prostate Cancer
2015-09-25,Aeterna Zentaris Announces TSX Approval Of Series B Warrant Amendment
2015-09-24,Aeterna Zentaris Announces Dismissal Of Class Action Lawsuit
2015-09-21,Aeterna Zentaris Announces Amendment To Series B Warrants
2015-09-03,Aeterna Zentaris To Present At Upcoming Rodman & Renshaw Annual Global Investment Conference In New York
2015-08-11,Aeterna Zentaris Announces Data And Safety Monitoring Board Scheduled To Complete Second Interim Analysis Of The ZoptEC Phase 3 Trial In Endometrial Cancer In Early October
2015-08-06,Aeterna Zentaris To Announce Second Quarter 2015 Financial And Operating Results On August 13, 2015
2015-08-04,Aeterna Zentaris To Present At Upcoming Canaccord Genuity 35th Annual Global Growth Conference In Boston
2015-07-29,Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development
2015-07-28,Aeterna Zentaris Grants Option To Develop And Commercialize Oral Allogenic Cancer Vaccine Technology
2015-07-27,Aeterna Zentaris Commences Promotional Activities For EMD Serono's Saizen® [Somatropin (rDNA Origin) For Injection]
2015-06-30,Aeterna Zentaris Completes Patient Recruitment For ZoptEC Phase 3 Study With Zoptarelin Doxorubicin In Advanced Endometrial Cancer
2015-06-25,Aeterna Zentaris Announces Selection Of Ergomed To Conduct Confirmatory Phase 3 Clinical Trial Of Macrilen™ In AGHD
2015-06-18,Aeterna Zentaris Announces Extension To Regain Compliance With NASDAQ's Minimum Bid Price Rule
2015-06-11,5 Stocks Under $10 Set to Soar
2015-05-26,Aeterna Zentaris' Confirmatory Phase 3 Study For Macrilen™ In AGHD Meets EMA's Study-Design Expectations
2015-05-07,Aeterna Zentaris And EMD Serono Finalize Promotional Services Agreement For Saizen® (Somatropin (rDNA Origin) For Injection) In The U.S.
2015-04-27,Aeterna Zentaris: Data Safety Monitoring Board Recommends Continuation Of Phase 3 Study Of Zoptarelin Doxorubicin In Advanced Endometrial Cancer
2015-04-23,Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) On Aeterna Zentaris Inc.
2015-04-16,Aeterna Zentaris Files Additional Patent Application To Strengthen IP Protection Of Zoptarelin Doxorubicin
2015-04-13,Aeterna Zentaris Announces Plans To Initiate Phase 3 Study Of Macrilen™ In AGHD Following Successful Meeting With FDA
2015-03-31,Aeterna Zentaris Signs Transfer Agreement Of Its Discovery Library With The Medical University Of South Carolina
2015-03-11,Aeterna Zentaris Announces Closing Of US$37 Million Public Offering Of Common Shares And Warrants
2015-03-10,Aeterna Zentaris To Announce Fourth Quarter And Full-Year 2014 Financial And Operating Results On March 17, 2015
2015-03-06,Aeterna Zentaris Announces Pricing Of US$37 Million Public Offering Of Common Shares And Warrants
2015-03-05,Aeterna Zentaris Announces Proposed Public Offering Of Common Shares And Warrants
2015-01-09,UPDATE - MONDAY DEADLINE: LEVI & KORSINSKY, LLP Notifies Investors Of Class Action Against Aeterna Zentaris Inc. And Its Board Of Directors And A Lead Plaintiff Deadline Of January 12, 2015 -- AEZS
2015-01-08,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors Of Class Action Against Aeterna Zentaris Inc. And Lead Plaintiff Deadline Of January 12, 2015
2015-01-06,EQUITY UPDATE: Rosen Law Firm Expands Class Period In Aeterna Zentaris, Inc. Investor Class Action To Include Purchasers Between April 2, 2012 And November 6, 2014 - AEZS
2015-01-06,Aeterna Zentaris To Present At Upcoming Biotech Showcase Conference In San Francisco
2015-01-05,SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors Of Class Action Against Aeterna Zentaris Inc. And Its Board Of Directors And A Lead Plaintiff Deadline Of January 12, 2015
2014-12-29,Aeterna Zentaris: Final Data For Phase 1 Portion Of Ongoing Phase 1/2 Trial With Zoptarelin Doxorubicin In Prostate Cancer Published In Clinical Cancer Research
2014-12-19,SHAREHOLDER ALERT: Pomerantz Law Firm Announces The Filing Of A Class Action Against Aeterna Zentaris, Inc. And Certain Officers - AEZS
2014-12-19,Aeterna Zentaris Receives Notification From NASDAQ Relating To Minimum Bid Price
2014-12-01,Aeterna Zentaris And Sinopharm A-Think Sign Master Collaboration Agreement For Zoptarelin Doxorubicin In China
2014-11-25,SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Aeterna Zentaris, Inc. To Contact Brower Piven Before The January 12, 2015 Lead Plaintiff Deadline In Class Action Lawsuit
2014-11-21,SHAREHOLDER ALERT: Class Action Lawsuit Against Aeterna Zentaris Inc. Filed By Glancy Binkow & Goldberg LLP
2014-11-20,Aeterna Zentaris Adds Hollings Cancer Center To Multi-National Phase 3 Trial In Endometrial Cancer
2014-11-14,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Aeterna Zentaris, Inc. - AEZS
2014-11-11,INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Aeterna Zentaris Inc. (AEZS) To Contact The Firm
2014-11-06,The Rosen Law Firm Announces Investigation Of Securities Claims Against Aeterna Zentaris, Inc.
2014-11-06,FDA Issues Complete Response Letter For Aeterna Zentaris' Macrilen™ NDA In Adult Growth Hormone Deficiency
2014-10-28,Aeterna Zentaris To Announce Third Quarter 2014 Financial And Operating Results On November 4, 2014
2014-10-27,Aeterna Zentaris Announces Formal Implementation Of Its Sales Force In Support Of Selling ASCEND's EstroGel®
2014-10-07,Aeterna Zentaris Appoints Phil Theodore As Chief Administrative Officer, General Counsel And Corporate Secretary
2014-09-02,Aeterna Zentaris To Present At Upcoming Rodman & Renshaw Annual Global Investment Conference In New York
2014-08-15,4 Stocks Under $10 to Trade Now
2014-08-06,Aeterna Zentaris To Present At Upcoming Canaccord Genuity 34th Annual Global Growth Conference In Boston
2014-08-05,Aeterna Zentaris And ASCEND Therapeutics Sign Co-Promotion Agreement For U.S. Market
2014-06-11,Aeterna Zentaris To Present At Upcoming Bloom Burton & Co. Healthcare Investor Conference In Toronto
2014-06-10,Aeterna Zentaris Implements Global Resources Optimization Program As Part Of Its Transition Into A Commercially Operating Specialty Biopharmaceutical Company
2014-06-02,Aeterna Zentaris: Poster Presented At ASCO Meeting On The Design Of The Current ZoptEC Phase 3 Trial In Endometrial Cancer
2014-05-09,Aeterna Zentaris Announces At The Market Issuance Program
2014-05-05,Aeterna Zentaris Selects Charleston, S.C. As New Location For Its North American Business And Global Commercial Operations
2014-04-30,Aeterna Zentaris To Announce First Quarter 2014 Financial And Operating Results On May 8, 2014 And Hold Annual Shareholders Meeting On May 9, 2014
2014-04-09,Aeterna Zentaris: Poster Presentation At AACR Meeting Provides Rationale For New Therapeutic Opportunities In Oncology With Erk Inhibitors
2014-03-28,Aeterna Zentaris Announces Effectiveness Of $50 Million Shelf Registration Statement For "At-the-Market" Common Share Issuance Programs
2014-03-12,Aeterna Zentaris To Announce Fourth Quarter And Full-Year 2013 Financial And Operating Results On March 20, 2014
2014-03-11,Speculative Money Propels Biotechs La Jolla Pharma, Aeterna Zentaris
2014-02-04,Aeterna Zentaris: Article On Phase 2 Results For Zoptarelin Doxorubicin In Endometrial Cancer Published In The International Journal Of Gynecological Cancer
2014-01-14,Aeterna Zentaris Announces Closing Of US$13.2 Million Public Offering Of Common Shares And Warrants
2014-01-09,Aeterna Zentaris Announces Pricing Of US$13.2 Million Public Offering Of Common Shares And Warrants
2014-01-08,Aeterna Zentaris Announces Proposed Public Offering Of Common Shares And Warrants
2014-01-06,Aeterna Zentaris NDA For Macimorelin Acetate In AGHD Accepted For Filing By The FDA
2014-01-03,Aeterna Zentaris Appoints Dr. Richard Sachse As Chief Scientific Officer
2013-12-23,Consider Buy Rated Stocks Under Five Bucks as Stocking Stuffers
2013-11-25,Aeterna Zentaris Announces Closing Of US$15.1 Million Public Offering Of Common Shares And Warrants
2013-11-20,Aeterna Zentaris Announces Pricing Of US$15.1 Million Public Offering Of Common Shares And Warrants
2013-11-19,Aeterna Zentaris Announces Proposed Public Offering Of Common Shares And Warrants
2013-11-05,Aeterna Zentaris Submits New Drug Application To FDA For Macimorelin Acetate (AEZS-130) For Evaluation Of AGHD
2013-11-01,Aeterna Zentaris Appoints Chief Commercial Officer, Reaffirming New Company Vision
2013-10-29,Aeterna Zentaris To Announce Third Quarter 2013 Financial And Operating Results On November 5, 2013
2013-10-01,Aeterna Zentaris Completes Successful Transfer Of Cetrotide® Manufacturing Rights To Merck KGaA
2013-08-29,Aeterna Zentaris To Present At Upcoming Rodman & Renshaw Annual Global Investment Conference In New York
2013-08-28,Aeterna Zentaris Announces Listing Transfer To NASDAQ Capital Market
2013-08-07,Aeterna Zentaris To Present At Upcoming Canaccord Genuity Global Growth Conference In Boston
2013-08-01,Aeterna Zentaris To Announce Second Quarter 2013 Financial And Operating Results On August 8, 2013
2013-07-31,Aeterna Zentaris: First Patient Dosed For Phase 3 Registration Trial In Endometrial Cancer With Zoptarelin Doxorubicin (AEZS-108)
2013-07-30,Aeterna Zentaris Completes $7.8 Million Registered Direct Offering
2013-07-25,Aeterna Zentaris To Raise US$7.8 Million In Registered Direct Offering
2013-06-06,Aeterna Zentaris Announces Dismissal Of Class Action Lawsuit
2013-06-03,Aeterna Zentaris: Encouraging Final Data For Phase 1 Portion Of Ongoing Phase 1/2 Trial With Zoptarelin Doxorubicin (AEZS-108) In Prostate Cancer Reported At ASCO
2013-05-21,Aeterna Zentaris Announces "At-the-Market" Issuance Program
2013-05-15,Aeterna Zentaris To Present At Upcoming Bloom Burton & Co. Healthcare Investor Conference In Toronto
2013-05-01,Aeterna Zentaris To Announce First Quarter 2013 Financial And Operating Results On May 7, 2013 And Hold Annual Shareholders Meeting On May 8, 2013
2013-04-23,Aeterna Zentaris Newly Appointed CEO, David A. Dodd, To Host Introductory Analyst And Investor Conference Call On Thursday, April 25, 2013
2013-04-17,Aeterna Zentaris Announces Transfer Of Manufacturing Rights Related To Cetrotide® To Merck KGaA
2013-04-15,David A. Dodd Appointed President & Chief Executive Officer Of Aeterna Zentaris Inc.
2013-04-10,Aeterna Zentaris Presents Encouraging Updated Data On Its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates At AACR Meeting
2013-04-10,Aeterna Zentaris And Ergomed Sign Co-Development And Profit Sharing Agreement For AEZS-108 In Endometrial Cancer
2013-03-13,Aeterna Zentaris To Present At Upcoming Roth 25th Annual OC Growth Stock Conference
2013-03-12,Aeterna Zentaris To Announce Fourth Quarter And Full Year 2012 Financial And Operating Results On March 21, 2013
2013-03-11,Aeterna Zentaris To Discontinue Phase 3 Trial In Multiple Myeloma With Perifosine Following Data Safety Monitoring Board Recommendation
2013-02-20,Aeterna Zentaris: First Patient Treated For Phase 2 Trial With AEZS-108 In Triple-Negative Breast Cancer
2013-02-07,5 Stocks Under $10 Ready to Soar Higher
2013-01-25,Biotech Stock Mailbag: Keryx, Sangamo, Threshold and Amarin
2012-12-28,Aeterna Zentaris Granted Special Protocol Assessment By The FDA For Phase 3 Registration Trial In Endometrial Cancer With AEZS-108
2012-12-11,Aeterna Zentaris: Final Phase 2 Data Demonstrate Perifosine And Sorafenib Combination Therapy Well Tolerated By Heavily Pretreated Lymphoma Patients
2012-12-04,Aeterna Zentaris To Present At Oppenheimer 23rd Annual Healthcare Conference In New York
2012-11-20,5 Biotech Stocks Rising on Unusual Volume
2012-11-19,Aeterna Zentaris: Data Demonstrate That Perifosine Combined With Temsirolimus Was Well Tolerated In Phase 1 Trial In Malignant Glioma
2012-11-12,Aeterna Zentaris Announces Initiation Of Phase 2 Portion Of Phase 1/2 Trial With AEZS-108 In Prostate Cancer
2012-11-08,Aeterna Zentaris Presents Proof-of-Concept For Disorazol Z Cytotoxic Conjugates, Such As AEZS-125, In Ovarian Cancer Mouse Model At ENA Symposium
2012-11-07,Aeterna Zentaris To Announce Third Quarter 2012 Financial And Operating Results On November 13, 2012
2012-10-22,Aeterna Zentaris Regains Compliance With NASDAQ $1.00 Minimum Bid Price Rule
2012-10-18,Aeterna Zentaris: Phase 3 Results For AEZS-130 In AGHD Presented At GRS And IGF Society Congress
2012-10-17,Aeterna Zentaris Announces Closing Of US$16.5 Million Public Offering Of Common Shares And Warrants
2012-10-12,Aeterna Zentaris Announces Pricing Of US$16.5 Million Public Offering Of Common Shares And Warrants
2012-10-11,Aeterna Zentaris Announces Proposed Public Offering Of Common Shares And Warrants
2017-03-15,Aeterna Zentaris Reports Fourth Quarter And Full-Year 2016 Financial And Operating Results
2017-03-07,Aeterna Zentaris Announces EMA Pediatric Committee Agreement On The Pediatric Investigation Plan For Macrilen™
2017-03-06,Aeterna Zentaris To Announce Fourth Quarter And Full-Year 2016 Financial And Operating Results On March 15, 2017
2017-03-02,Aeterna Zentaris Announces Presentation Regarding Macrilen™ At 99th Annual Meeting Of The Endocrine Society
2017-02-14,Aeterna Zentaris Announces Zoptrex™ Presentation In Prostate Cancer At 2017 Genitourinary Cancers Symposium
2017-02-13,Aeterna Zentaris Announces Plans To Pursue FDA Registration Of Macrilen™
2017-02-09,Aeterna Zentaris To Present At The 2nd Annual Disruptive Growth & Healthcare Conference
2017-02-07,Aeterna Zentaris To Present At The 2017 BIO CEO And Investor Conference
2017-01-30,Aeterna Zentaris Announces Completion Of Zoptrex™ Pivotal Phase 3 Clinical Trial In Advanced Endometrial Cancer; Expects To Report Top-Line Results In April 2017
2017-01-04,Aeterna Zentaris Announces Top-Line Results Of Confirmatory Phase 3 Trial Of Macrilen™
2016-11-08,Aeterna Zentaris Reports Third Quarter 2016 Financial And Operating Results
2016-11-01,Aeterna Zentaris Announces Closing Of US$7,560,000 Registered Direct Offering Of Common Shares And Warrants
2016-10-28,Aeterna Zentaris To Announce Third Quarter 2016 Financial And Operating Results On November 8, 2016
2016-10-27,Aeterna Zentaris Announces US$7,560,000 Registered Direct Offering Of Common Shares And Warrants
2016-10-26,Aeterna Zentaris Completes Patient Recruitment For Confirmatory Phase 3 Trial Of Macrilen™
2016-10-12,Aeterna Zentaris And Specialised Therapeutics Asia Sign Exclusive License Agreement For The Potential Marketing Of Zoptrex™ In Australia And New Zealand
2016-09-14,Aeterna Zentaris Announces Expiration Of Remaining Series B Warrants
2016-09-12,Aeterna Zentaris To Present At Upcoming Aegis Capital Corp. 2016 Growth Conference In Las Vegas, Nevada
2016-09-06,Aeterna Zentaris To Present At Upcoming Rodman & Renshaw Annual Global Investment Conference In New York
2016-08-09,Aeterna Zentaris Reports Second Quarter 2016 Financial And Operating Results
2016-08-08,Aeterna Zentaris Expands Promotion Of APIFINY® Into Florida
2016-08-01,Aeterna Zentaris And Rafa Laboratories Sign Exclusive License Agreement For Zoptrex™ In Israel
2016-07-27,Aeterna Zentaris To Announce Second Quarter 2016 Financial And Operating Results On August 9, 2016
2016-07-01,Aeterna Zentaris And Orient EuroPharma Co., Ltd. Sign Exclusive License Agreement For Zoptrex™ In Taiwan And Southeast Asia
2016-06-14,Aeterna Zentaris Announces IND Submission By Sinopharm A-Think
2016-06-06,Aeterna Zentaris Reconfirms Commitment To LHRH-receptor Targeting Zoptrex™ During 2016 ASCO Annual Meeting
2016-05-23,Aeterna Zentaris Elects Ms. Carolyn Egbert As Independent Chair Of The Board
2016-05-10,Aeterna Zentaris Announces Election Of Directors At 2016 Shareholders' Meeting
2016-05-09,Aeterna Zentaris Reports First Quarter 2016 Financial And Operating Results
2016-04-27,Aeterna Zentaris Acquires Exclusive U.S. Promotional Rights For APIFINY® Prostate Cancer Blood Test
2016-04-26,Aeterna Zentaris To Announce First Quarter 2016 Financial And Operating Results On May 9, 2016
2016-04-08,Aeterna Zentaris Mails Information Circular In Connection With Annual Meeting Of Shareholders
2016-04-01,Aeterna Zentaris Announces At The Market Issuance Program
2016-03-29,Aeterna Zentaris Reports Fourth Quarter And Full-Year 2015 Financial And Operating Results
2016-03-15,Aeterna Zentaris To Announce Fourth Quarter And Full-Year 2015 Financial And Operating Results On March 29, 2016
2016-03-01,Aeterna Zentaris Reports On Zoptrex™ Development Progress In China
2016-02-26,Company Profile For Aeterna Zentaris Inc.
2016-02-23,Aeterna Zentaris Commences Promotional Activities For APIFINY® Prostate Cancer Blood Test
2016-02-18,Aeterna Zentaris Appoints Geneviève Lemaire As Vice President, Finance And Chief Accounting Officer
2016-02-01,Aeterna Zentaris To Participate In 18th Annual BIO CEO & Investor Conference Seeking Partnering Opportunities
2016-01-29,Aeterna Zentaris Announces Appointments To Board Of Directors
2016-01-26,Aeterna Zentaris Files International Patent Application For Novel Method Of Manufacturing Zoptrex™
2016-01-25,Strong On High Volume: AEterna Zentaris (AEZS)
2016-01-25,Aeterna Zentaris Announces Additional Market Purchases Of Common Shares By Executive Management
2016-01-19,Aeterna Zentaris Concludes Successful Meeting Of Clinical Investigators For Confirmatory Phase 3 Trial Of Macrilen™
2016-01-13,Aeterna Zentaris Affirms Focus On Targeted Oncology During 2016 J.P. Morgan Healthcare Conference
2015-12-30,Aeterna Zentaris Announces Filing Of Preliminary Base Shelf Prospectus
2015-12-14,Aeterna Zentaris Announces Closing Of US$16.65 Million Public Offering Of Common Shares And Warrants
2015-12-09,Aeterna Zentaris Announces Pricing Of US$16.65 Million Public Offering Of Common Shares And Warrants
2015-12-08,Aeterna Zentaris Announces Proposed Public Offering Of Common Shares And Warrants
2015-12-08,Aeterna Zentaris Regains Compliance With NASDAQ $1.00 Minimum Bid Price Rule And Announces 2016 Corporate Objectives
2015-12-04,Today's Dead Cat Bounce Stock Is AEterna Zentaris (AEZS)
2015-12-01,Aeterna Zentaris And Armune BioScience Finalize Co-Marketing Agreement For APIFINY® Prostate Cancer Blood Test
2015-11-27,Trade-Ideas: AEterna Zentaris (AEZS) Is Today's "Perilous Reversal" Stock
2015-11-25,Aeterna Zentaris Affirms Fundamental Strength Of Business
2015-11-25,AEterna Zentaris (AEZS) Showing Signs Of A Dead Cat Bounce Today
2015-11-24,Aeterna Zentaris Confirms No Corporate Developments
2015-11-24,Aeterna Zentaris Announces Exercise Of Last Series B Warrants Covered By November 1, 2015 Agreement
2015-11-24,AEterna Zentaris (AEZS): Heavy Pre-Market Activity
2015-11-19,Aeterna Zentaris Announces First Patient Enrolled For Confirmatory Phase 3 Trial Of Macrilen™ For The Evaluation Of AGHD
2015-11-18,Aeterna Zentaris Announces Details And Implementation Of Share Consolidation To Regain NASDAQ Compliance
2015-11-16,Aeterna Zentaris Announces Shareholder Approval Of Share Consolidation
2015-11-12,Aeterna Zentaris Announces Exercise Of Series B Warrants
2015-11-11,Aeterna Zentaris Urges Shareholders To Vote In Favor Of The Share Consolidation And Highlights Support From ISS And Glass Lewis
2015-11-02,Aeterna Zentaris Announces Agreement To Exercise Substantially All Remaining Series B Warrants
2015-10-27,Leading Independent Advisory Firms ISS And Glass Lewis Recommend Shareholders Of Aeterna Zentaris Vote FOR Share Consolidation
2015-10-23,Aeterna Zentaris To Announce Third Quarter 2015 Financial And Operating Results On November 6, 2015
2015-10-16,Aeterna Zentaris Announces Special Meeting Of Shareholders And Mailing Of Management Information Circular
2015-10-13,Aeterna Zentaris: Data And Safety Monitoring Board Recommends Continuation Of ZoptEC Phase 3 Trial In Advanced Endometrial Cancer
2015-10-12,Aeterna Zentaris Announces Restructuring Of Finance & Accounting Operations And Closure Of Quebec City Office
2015-09-29,Today's Weak On High Volume Stock: AEterna Zentaris (AEZS)
2015-09-28,Aeterna Zentaris' Zoptarelin Doxorubicin Meets Phase 2 Primary Endpoint In Men With Heavily Pretreated Castration And Taxane Resistant Prostate Cancer
2015-09-25,Aeterna Zentaris Announces TSX Approval Of Series B Warrant Amendment
2015-09-24,Aeterna Zentaris Announces Dismissal Of Class Action Lawsuit
2015-09-21,Aeterna Zentaris Announces Amendment To Series B Warrants
2015-09-03,Aeterna Zentaris To Present At Upcoming Rodman & Renshaw Annual Global Investment Conference In New York
2015-08-11,Aeterna Zentaris Announces Data And Safety Monitoring Board Scheduled To Complete Second Interim Analysis Of The ZoptEC Phase 3 Trial In Endometrial Cancer In Early October
2015-08-06,Aeterna Zentaris To Announce Second Quarter 2015 Financial And Operating Results On August 13, 2015
2015-08-04,Aeterna Zentaris To Present At Upcoming Canaccord Genuity 35th Annual Global Growth Conference In Boston
2015-07-29,Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development
2015-07-28,Aeterna Zentaris Grants Option To Develop And Commercialize Oral Allogenic Cancer Vaccine Technology
2015-07-27,Aeterna Zentaris Commences Promotional Activities For EMD Serono's Saizen® [Somatropin (rDNA Origin) For Injection]
2015-06-30,Aeterna Zentaris Completes Patient Recruitment For ZoptEC Phase 3 Study With Zoptarelin Doxorubicin In Advanced Endometrial Cancer
2015-06-25,Aeterna Zentaris Announces Selection Of Ergomed To Conduct Confirmatory Phase 3 Clinical Trial Of Macrilen™ In AGHD
2015-06-18,Aeterna Zentaris Announces Extension To Regain Compliance With NASDAQ's Minimum Bid Price Rule
2015-06-11,5 Stocks Under $10 Set to Soar
2015-05-26,Aeterna Zentaris' Confirmatory Phase 3 Study For Macrilen™ In AGHD Meets EMA's Study-Design Expectations
2015-05-07,Aeterna Zentaris And EMD Serono Finalize Promotional Services Agreement For Saizen® (Somatropin (rDNA Origin) For Injection) In The U.S.
2015-04-27,Aeterna Zentaris: Data Safety Monitoring Board Recommends Continuation Of Phase 3 Study Of Zoptarelin Doxorubicin In Advanced Endometrial Cancer
2015-04-23,Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) On Aeterna Zentaris Inc.
2015-04-16,Aeterna Zentaris Files Additional Patent Application To Strengthen IP Protection Of Zoptarelin Doxorubicin
2015-04-13,Aeterna Zentaris Announces Plans To Initiate Phase 3 Study Of Macrilen™ In AGHD Following Successful Meeting With FDA
2015-03-31,Aeterna Zentaris Signs Transfer Agreement Of Its Discovery Library With The Medical University Of South Carolina
2015-03-11,Aeterna Zentaris Announces Closing Of US$37 Million Public Offering Of Common Shares And Warrants
2015-03-10,Aeterna Zentaris To Announce Fourth Quarter And Full-Year 2014 Financial And Operating Results On March 17, 2015
2015-03-06,Aeterna Zentaris Announces Pricing Of US$37 Million Public Offering Of Common Shares And Warrants
2015-03-05,Aeterna Zentaris Announces Proposed Public Offering Of Common Shares And Warrants
2015-01-09,UPDATE - MONDAY DEADLINE: LEVI & KORSINSKY, LLP Notifies Investors Of Class Action Against Aeterna Zentaris Inc. And Its Board Of Directors And A Lead Plaintiff Deadline Of January 12, 2015 -- AEZS
2015-01-08,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors Of Class Action Against Aeterna Zentaris Inc. And Lead Plaintiff Deadline Of January 12, 2015
2015-01-06,EQUITY UPDATE: Rosen Law Firm Expands Class Period In Aeterna Zentaris, Inc. Investor Class Action To Include Purchasers Between April 2, 2012 And November 6, 2014 - AEZS
2015-01-06,Aeterna Zentaris To Present At Upcoming Biotech Showcase Conference In San Francisco
2015-01-05,SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors Of Class Action Against Aeterna Zentaris Inc. And Its Board Of Directors And A Lead Plaintiff Deadline Of January 12, 2015
2014-12-29,Aeterna Zentaris: Final Data For Phase 1 Portion Of Ongoing Phase 1/2 Trial With Zoptarelin Doxorubicin In Prostate Cancer Published In Clinical Cancer Research
2014-12-19,SHAREHOLDER ALERT: Pomerantz Law Firm Announces The Filing Of A Class Action Against Aeterna Zentaris, Inc. And Certain Officers - AEZS
2014-12-19,Aeterna Zentaris Receives Notification From NASDAQ Relating To Minimum Bid Price
2014-12-01,Aeterna Zentaris And Sinopharm A-Think Sign Master Collaboration Agreement For Zoptarelin Doxorubicin In China
2014-11-25,SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Aeterna Zentaris, Inc. To Contact Brower Piven Before The January 12, 2015 Lead Plaintiff Deadline In Class Action Lawsuit
2014-11-21,SHAREHOLDER ALERT: Class Action Lawsuit Against Aeterna Zentaris Inc. Filed By Glancy Binkow & Goldberg LLP
2014-11-20,Aeterna Zentaris Adds Hollings Cancer Center To Multi-National Phase 3 Trial In Endometrial Cancer
2014-11-14,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Aeterna Zentaris, Inc. - AEZS
2014-11-11,INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Aeterna Zentaris Inc. (AEZS) To Contact The Firm
2014-11-06,The Rosen Law Firm Announces Investigation Of Securities Claims Against Aeterna Zentaris, Inc.
2014-11-06,FDA Issues Complete Response Letter For Aeterna Zentaris' Macrilen™ NDA In Adult Growth Hormone Deficiency
2014-10-28,Aeterna Zentaris To Announce Third Quarter 2014 Financial And Operating Results On November 4, 2014
2014-10-27,Aeterna Zentaris Announces Formal Implementation Of Its Sales Force In Support Of Selling ASCEND's EstroGel®
2014-10-07,Aeterna Zentaris Appoints Phil Theodore As Chief Administrative Officer, General Counsel And Corporate Secretary
2014-09-02,Aeterna Zentaris To Present At Upcoming Rodman & Renshaw Annual Global Investment Conference In New York
2014-08-15,4 Stocks Under $10 to Trade Now
2014-08-06,Aeterna Zentaris To Present At Upcoming Canaccord Genuity 34th Annual Global Growth Conference In Boston
2014-08-05,Aeterna Zentaris And ASCEND Therapeutics Sign Co-Promotion Agreement For U.S. Market
2014-06-11,Aeterna Zentaris To Present At Upcoming Bloom Burton & Co. Healthcare Investor Conference In Toronto
2014-06-10,Aeterna Zentaris Implements Global Resources Optimization Program As Part Of Its Transition Into A Commercially Operating Specialty Biopharmaceutical Company
2014-06-02,Aeterna Zentaris: Poster Presented At ASCO Meeting On The Design Of The Current ZoptEC Phase 3 Trial In Endometrial Cancer
2014-05-09,Aeterna Zentaris Announces At The Market Issuance Program
2014-05-05,Aeterna Zentaris Selects Charleston, S.C. As New Location For Its North American Business And Global Commercial Operations
2014-04-30,Aeterna Zentaris To Announce First Quarter 2014 Financial And Operating Results On May 8, 2014 And Hold Annual Shareholders Meeting On May 9, 2014
2014-04-09,Aeterna Zentaris: Poster Presentation At AACR Meeting Provides Rationale For New Therapeutic Opportunities In Oncology With Erk Inhibitors
2014-03-28,Aeterna Zentaris Announces Effectiveness Of $50 Million Shelf Registration Statement For "At-the-Market" Common Share Issuance Programs
2014-03-12,Aeterna Zentaris To Announce Fourth Quarter And Full-Year 2013 Financial And Operating Results On March 20, 2014
2014-03-11,Speculative Money Propels Biotechs La Jolla Pharma, Aeterna Zentaris
2014-02-04,Aeterna Zentaris: Article On Phase 2 Results For Zoptarelin Doxorubicin In Endometrial Cancer Published In The International Journal Of Gynecological Cancer
2014-01-14,Aeterna Zentaris Announces Closing Of US$13.2 Million Public Offering Of Common Shares And Warrants
2014-01-09,Aeterna Zentaris Announces Pricing Of US$13.2 Million Public Offering Of Common Shares And Warrants
2014-01-08,Aeterna Zentaris Announces Proposed Public Offering Of Common Shares And Warrants
2014-01-06,Aeterna Zentaris NDA For Macimorelin Acetate In AGHD Accepted For Filing By The FDA
2014-01-03,Aeterna Zentaris Appoints Dr. Richard Sachse As Chief Scientific Officer
2013-12-23,Consider Buy Rated Stocks Under Five Bucks as Stocking Stuffers
2013-11-25,Aeterna Zentaris Announces Closing Of US$15.1 Million Public Offering Of Common Shares And Warrants
2013-11-20,Aeterna Zentaris Announces Pricing Of US$15.1 Million Public Offering Of Common Shares And Warrants
2013-11-19,Aeterna Zentaris Announces Proposed Public Offering Of Common Shares And Warrants
2013-11-05,Aeterna Zentaris Submits New Drug Application To FDA For Macimorelin Acetate (AEZS-130) For Evaluation Of AGHD
2013-11-01,Aeterna Zentaris Appoints Chief Commercial Officer, Reaffirming New Company Vision
2013-10-29,Aeterna Zentaris To Announce Third Quarter 2013 Financial And Operating Results On November 5, 2013
2013-10-01,Aeterna Zentaris Completes Successful Transfer Of Cetrotide® Manufacturing Rights To Merck KGaA
2013-08-29,Aeterna Zentaris To Present At Upcoming Rodman & Renshaw Annual Global Investment Conference In New York
2013-08-28,Aeterna Zentaris Announces Listing Transfer To NASDAQ Capital Market
2013-08-07,Aeterna Zentaris To Present At Upcoming Canaccord Genuity Global Growth Conference In Boston
2013-08-01,Aeterna Zentaris To Announce Second Quarter 2013 Financial And Operating Results On August 8, 2013
2013-07-31,Aeterna Zentaris: First Patient Dosed For Phase 3 Registration Trial In Endometrial Cancer With Zoptarelin Doxorubicin (AEZS-108)
2013-07-30,Aeterna Zentaris Completes $7.8 Million Registered Direct Offering
2013-07-25,Aeterna Zentaris To Raise US$7.8 Million In Registered Direct Offering
2013-06-06,Aeterna Zentaris Announces Dismissal Of Class Action Lawsuit
2013-06-03,Aeterna Zentaris: Encouraging Final Data For Phase 1 Portion Of Ongoing Phase 1/2 Trial With Zoptarelin Doxorubicin (AEZS-108) In Prostate Cancer Reported At ASCO
2013-05-21,Aeterna Zentaris Announces "At-the-Market" Issuance Program
2013-05-15,Aeterna Zentaris To Present At Upcoming Bloom Burton & Co. Healthcare Investor Conference In Toronto
2013-05-01,Aeterna Zentaris To Announce First Quarter 2013 Financial And Operating Results On May 7, 2013 And Hold Annual Shareholders Meeting On May 8, 2013
2013-04-23,Aeterna Zentaris Newly Appointed CEO, David A. Dodd, To Host Introductory Analyst And Investor Conference Call On Thursday, April 25, 2013
2013-04-17,Aeterna Zentaris Announces Transfer Of Manufacturing Rights Related To Cetrotide® To Merck KGaA
2013-04-15,David A. Dodd Appointed President & Chief Executive Officer Of Aeterna Zentaris Inc.
2013-04-10,Aeterna Zentaris Presents Encouraging Updated Data On Its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates At AACR Meeting
2013-04-10,Aeterna Zentaris And Ergomed Sign Co-Development And Profit Sharing Agreement For AEZS-108 In Endometrial Cancer
2013-03-13,Aeterna Zentaris To Present At Upcoming Roth 25th Annual OC Growth Stock Conference
2013-03-12,Aeterna Zentaris To Announce Fourth Quarter And Full Year 2012 Financial And Operating Results On March 21, 2013
2013-03-11,Aeterna Zentaris To Discontinue Phase 3 Trial In Multiple Myeloma With Perifosine Following Data Safety Monitoring Board Recommendation
2013-02-20,Aeterna Zentaris: First Patient Treated For Phase 2 Trial With AEZS-108 In Triple-Negative Breast Cancer
2013-02-07,5 Stocks Under $10 Ready to Soar Higher
2013-01-25,Biotech Stock Mailbag: Keryx, Sangamo, Threshold and Amarin
2012-12-28,Aeterna Zentaris Granted Special Protocol Assessment By The FDA For Phase 3 Registration Trial In Endometrial Cancer With AEZS-108
2012-12-11,Aeterna Zentaris: Final Phase 2 Data Demonstrate Perifosine And Sorafenib Combination Therapy Well Tolerated By Heavily Pretreated Lymphoma Patients
2012-12-04,Aeterna Zentaris To Present At Oppenheimer 23rd Annual Healthcare Conference In New York
2012-11-20,5 Biotech Stocks Rising on Unusual Volume
2012-11-19,Aeterna Zentaris: Data Demonstrate That Perifosine Combined With Temsirolimus Was Well Tolerated In Phase 1 Trial In Malignant Glioma
2012-11-12,Aeterna Zentaris Announces Initiation Of Phase 2 Portion Of Phase 1/2 Trial With AEZS-108 In Prostate Cancer
2012-11-08,Aeterna Zentaris Presents Proof-of-Concept For Disorazol Z Cytotoxic Conjugates, Such As AEZS-125, In Ovarian Cancer Mouse Model At ENA Symposium
2012-11-07,Aeterna Zentaris To Announce Third Quarter 2012 Financial And Operating Results On November 13, 2012
2012-10-22,Aeterna Zentaris Regains Compliance With NASDAQ $1.00 Minimum Bid Price Rule
2012-10-18,Aeterna Zentaris: Phase 3 Results For AEZS-130 In AGHD Presented At GRS And IGF Society Congress
2012-10-17,Aeterna Zentaris Announces Closing Of US$16.5 Million Public Offering Of Common Shares And Warrants
2012-10-12,Aeterna Zentaris Announces Pricing Of US$16.5 Million Public Offering Of Common Shares And Warrants
2012-10-11,Aeterna Zentaris Announces Proposed Public Offering Of Common Shares And Warrants
2017-03-23,Affimed Announces Fourth Quarter And Year End 2016 Financial Results And Corporate Update Conference Call
2017-03-15,Affimed To Present At The Oppenheimer 27th Annual Healthcare Conference - New York
2017-03-14,Affimed To Present At The Oppenheimer 27th Annual Healthcare Conference - New York
2017-03-01,Affimed To Present Data On Immune Cell Engagers At The AACR Annual Meeting 2017
2017-02-28,Affimed To Present At The Cowen And Company 37th Annual Health Care Conference
2017-02-08,Affimed To Present At The Leerink Partners 6th Annual Global Healthcare Conference
2017-01-31,First Clinical Milestone Achieved In Collaboration Between AbCheck And Lilly
2017-01-25,Affimed Announces Closing Of Public Offering Of Common Stock
2017-01-20,Affimed Announces Pricing Of Public Offering Of Common Stock
2017-01-19,Affimed Announces Proposed Public Offering Of Common Stock
2017-01-19,Affimed Announces Proposed Public Offering Of Common Stock
2017-01-11,Affimed Provides Update On NK-Cell Immuno-Oncology Platform
2017-01-04,Affimed And MD Anderson Announce Clinical Immuno-Oncology Development Collaboration
2016-12-06,Affimed Presents New Preclinical Data On Bi- And Trispecific Immune Cell Engagers At ASH
2016-11-09,Affimed To Present At The Jefferies 2016 London Healthcare Conference
2016-11-08,Affimed To Present Preclinical Data On Bi- And Trispecific Immune Cell Engagers At ASH
2016-11-02,Affimed Reports Financial Results For Third Quarter 2016
2016-11-02,Affimed Reports Financial Results For Third Quarter 2016
2016-10-31,Affimed To Present At The Credit Suisse 25th Annual Healthcare Conference
2016-10-26,Affimed Announces Third Quarter 2016 Financial Results And Corporate Update Conference Call
2016-10-04,Affimed Presents Preclinical Data On Lead Candidate AFM13 At The Annual Meeting Of The Society For Natural Immunity
2016-09-22,Affimed To Present At The Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
2016-09-01,Affimed To Present At Upcoming Investor Conferences
2016-08-10,Affimed Reports Financial Results For Second Quarter 2016 And Provides Corporate Update
2016-08-03,Affimed Announces Second Quarter 2016 Financial Results And Corporate Update Conference Call
2016-06-03,These 7 Stocks Under $10 Are About to Break Out
2016-05-31,Affimed To Present At The Jefferies 2016 Healthcare Conference
2016-05-23,Affimed Announces Annual General Meeting Of Shareholders
2016-05-18,Affimed Reports Financial Results For First Quarter 2016
2016-05-17,Affimed To Present At The UBS Global Healthcare Conference -- New York
2016-05-11,Affimed Announces First Quarter 2016 Financial Results And Corporate Update Conference Call
2016-04-25,8 Breakout Stocks Under $10 to Trade for Big Profits
2016-04-21,Affimed Presents Data On AFM13-mediated Innate/Adaptive Immune Crosstalk At The AACR Annual Meeting 2016
2016-04-21,Affimed Presents Data On EGFRwt And EGFRvIII-targeting NK- And T-Cell TandAbs At The AACR Annual Meeting 2016
2016-04-20,Ratings Changes Today
2016-04-01,These 5 Biotech Stocks Under $10 Are About to Break Out
2016-03-30,Affimed Reports Financial Results For Fourth Quarter And Year End 2015
2016-03-23,Affimed Announces Fourth Quarter And Year End 2015 Financial Results And Corporate Update Conference Call
2016-03-17,Affimed To Present Data On NK- And T-Cell Engagers At The AACR Annual Meeting 2016
2016-02-29,Affimed To Present At The Cowen And Company 36th Annual Health Care Conference
2016-02-29,Affimed To Present At The Cowen And Company 36th Annual Health Care Conference
2016-02-25,5 Stocks Under $10 Set to Soar
2016-02-22,Affimed To Speak At Symposium On Emerging Approaches In Cancer Immunotherapy
2016-02-04,Affimed To Present At The Leerink Partners 5th Annual Global Healthcare Conference
2016-01-25,Here's Why Affimed (AFMD) Stock is Popping Today
2016-01-25,Affimed Enters Into Collaboration With Merck To Evaluate AFM13 In Combination With KEYTRUDA(R) (pembrolizumab) For Patients With Hodgkin Lymphoma
2016-01-21,Affimed Appoints Dr. Joerg Windisch As Chief Operating Officer And Adds Dr. Bernhard Ehmer To Supervisory Board
2016-01-20,Affimed To Host Hodgkin's Lymphoma Day With Key Opinion Leaders On January 26th In New York City
2016-01-14,Affimed Announces Addition Of Dr. Andrew Evens To Scientific Advisory Board
2016-01-12,Affimed To Present At Noble Financial Capital Markets' 12th Annual Investor Conference
2015-12-17,5 Stocks Under $10 Set to Soar
2015-12-14,Affimed Added To NASDAQ Biotech Index®
2015-12-06,Affimed Presents Data Comparing T-cell- And NK-cell-engaging TandAbs AFM11 And AFM12 At ASH
2015-12-06,Affimed Presents Additional Data On Combination Of AFM13 With Checkpoint Inhibitors At ASH
2015-12-02,Affimed Announces Appointment Of Andrew Curtis To Lead Corporate Strategy And Business Development, Expansion Of US Presence
2015-12-01,Affimed To Present At The Oppenheimer 26th Annual Healthcare Conference -- New York
2015-11-11,Affimed CEO To Present At The Jefferies 2015 Global Healthcare Conference -- London
2015-11-10,Affimed Reports Financial Results For Third Quarter 2015
2015-11-06,Affimed Presents Data On Potency Of NK- And T-cell EGFRvIII TandAbs At SITC
2015-11-05,Affimed To Present Data On NK- And T-Cell Engagers At ASH
2015-11-05,Affimed To Present Data On NK- And T-Cell Engagers At ASH
2015-11-03,Affimed Announces Third Quarter 2015 Financial Results And Corporate Update Conference Call
2015-10-30,4 Stocks Under $10 to Trade for Breakouts
2015-10-15,3 Biotech Stocks Under $10 to Buy for Breakout Gains
2015-10-14,Affimed Announces Significant Investment By An Existing Shareholder
2015-10-14,Affimed Announces Significant Investment By An Existing Shareholder
2015-10-06,Affimed To Present Data On Potency Of NK- And T-cell EGFRvIII TandAbs At SITC
2015-09-23,Affimed To Present At The Leerink Partners Inaugural Immuno-Oncology Roundtable Conference
2015-08-04,Affimed Reports Financial Results For Second Quarter 2015
2015-07-28,Affimed Announces Second Quarter 2015 Financial Results And Corporate Update Conference Call
2015-06-30,Affimed Added To Russell 2000(R) Index
2015-06-23,Affimed Announces Opening Of US Operations And Key US-based Hires
2015-06-17,AbCheck And Pierre Fabre Pharmaceuticals Enter Into Strategic Research Partnership
2015-06-17,AbCheck And Pierre Fabre Pharmaceuticals Enter Into Strategic Research Partnership
2015-06-03,Affimed Announces Newly Formed Scientific Advisory Board
2015-05-29,Affimed ASCO Data For The CD33/CD3-TandAb Program Demonstrate That CD33 And CD3 Binding Affinities Correlate With Potent T-cell Activation And Cytotoxicity
2015-05-29,Affimed ASCO Data Demonstrate Consistent Potency Of NK-Cell-Engaging Combination Therapy With Checkpoint Modulators
2015-05-27,Affimed To Present At The Jefferies 2015 Healthcare Conference -- New York
2015-05-21,Affimed Reports Financial Results For First Quarter 2015
2015-05-13,Affimed To Present Data At ASCO To Highlight Potency Of NK-Cell-Engaging Combination Therapy With Checkpoint Modulators
2015-05-13,Affimed Announces First Quarter 2015 Financial Results Conference Call
2015-05-13,Affimed Announces First Quarter 2015 Financial Results Conference Call
2015-05-12,Affimed N.V. Announces Closing Of Public Offering Of Common Stock And Exercise Of Underwriters' Option To Purchase Additional Shares
2015-05-12,Affimed N.V. Announces Shareholder Meeting
2015-05-12,Affimed To Present At The UBS Global Healthcare Conference - New York
2015-05-06,Affimed N.V. Announces Pricing Of Public Offering Of Common Stock
2015-05-04,Affimed N.V. Announces Proposed Public Offering Of Common Stock
2015-05-04,Affimed N.V. Announces Proposed Public Offering Of Common Stock
2015-03-25,Affimed Announces Financial Results For Fourth Quarter And Year End 2014
2015-03-24,Affimed Completes TandAb Development Candidate Activities Meeting Amphivena's And Janssen's Criteria And Achieves Milestone Ahead Of Schedule
2015-03-18,Affimed Announces Fourth Quarter And Year End 2014 Financial Results Conference Call
2015-03-03,Affimed To Present At The 27th Annual ROTH Conference
2015-02-03,Affimed To Present At The BIO CEO & Investor Conference And At The Leerink Partners Global Healthcare Conference
2015-01-20,Affimed Appoints Dr. Martin Treder As Chief Scientific Officer
2015-01-07,Affimed Receives EUR 2.4 Million ($3 Million) Research Grant From German Government To Fund Trispecific Abs
2014-12-08,Affimed Presents Final Data For AFM13 Phase 1 Trial At ASH
2014-11-18,Affimed Reports Financial Results For Third Quarter 2014
2014-11-12,Affimed To Present At The Jefferies Global Healthcare Conference - London
2014-11-11,Affimed Announces Third Quarter 2014 Financial Results Conference Call
2014-09-17,Affimed Announces Closing Of Initial Public Offering
2014-09-12,Affimed Announces Pricing Of Initial Public Offering
,
,
2017-03-16,Agile Therapeutics Announces A Poster Presentation Of Its SECURE Phase 3 Study At The Contraceptive Technology 2017 Conference
2017-03-08,Agile Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results
2017-03-03,UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders Of Agile Therapeutics, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of March 7, 2017
2017-03-02,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Agile Therapeutics, Inc. - AGRX
2017-03-01,Agile Therapeutics To Present At 29th Annual ROTH Conference
2017-02-27,DEADLINE ALERT: Brower Piven Reminds Investors Of The March 7, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess Of $100,000 From Investment In Agile Therapeutics, Inc. To Contact The Firm
2017-02-27,AGRX INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Agile Therapeutics, Inc. And A Lead Plaintiff Deadline Of March 7, 2017
2017-02-22,AGRX SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Agile Therapeutics, Inc. And A Lead Plaintiff Deadline Of March 7, 2017
2017-02-17,INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Agile Therapeutics, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of March 7, 2017 - AGRX
2017-02-14,Agile Therapeutics To Present At The RBC Capital Markets 2017 Global Healthcare Conference
2017-02-13,AGRX INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Agile Therapeutics, Inc. And A Lead Plaintiff Deadline Of March 7, 2017
2017-02-10,SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $50,000 Investing In Agile Therapeutics, Inc. To Contact The Firm Before Lead Plaintiff Deadline
2017-02-02,Agile Therapeutics To Present At The 2017 BIO CEO & Investor Conference
2017-01-27,RM LAW Announces Class Action Lawsuit Against Agile Therapeutics, Inc.
2017-01-27,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Agile Therapeutics, Inc. Of Class Action Lawsuit And Upcoming Deadline - AGRX
2017-01-20,INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Agile Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2017-01-19,Agile Therapeutics To Present At Noble Capital Markets' Thirteenth Annual Investor/Equity Conference
2017-01-18,AGILE THERAPEUTICS LOSS NOTICE: Rosen Law Firm Reminds Investors Of Important Class Action Deadline - AGRX
2017-01-18,Lifshitz & Miller Law Firm Announces Investigation Of Abeona Therapeutics Inc., Agile Therapeutics, Inc., Alere Inc., Floteck Industries, Inc., Insys Therapeutics Inc., MTS Systems Corporation, Ophthotech Corporation And Teekay Corporation
2017-01-10,IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces A Class Action Lawsuit Against Agile Therapeutics, Inc. And Advises Investors With Losses To Contact The Firm
2017-01-10,IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces A Class Action Lawsuit Against Agile Therapeutics, Inc. And Advises Investors With Losses To Contact The Firm
2017-01-10,AGILE (AGRX) ALERT: Johnson & Weaver, LLP Announces Filing Of Class Action Complaint Against Agile Therapeutics, Inc.; Encourages All Investors To Contact The Firm For Information
2017-01-09,Harwood Feffer LLP Announces Investigation Of Agile Therapeutics, Inc.
2017-01-09,AGILE NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $50,000 Investing In Agile Therapeutics, Inc. To Contact The Firm
2017-01-09,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Agile Therapeutics, Inc. - AGRX
2017-01-09,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against Agile Therapeutics, Inc. (AGRX) And Lead Plaintiff Deadline: March 7, 2017
2017-01-04,How a Birth Control Patch Hurt Agile Therapeutics' Stock
2017-01-04,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Agile Therapeutics, Inc. (AGRX)
2017-01-04,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Agile Therapeutics, Inc. - AGRX
2017-01-04,Here's Why General Motors Is One of Wednesday's Most Active Stocks
2017-01-04,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of Agile Therapeutics, Inc.
2017-01-03,Agile Therapeutics Announces Positive Top-line Phase 3 Results
2016-12-22,Agile Therapeutics To Present At Biotech Showcase 2017
2016-12-22,Agile Therapeutics To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-01,Agile Therapeutics Receives Approximately $3 Million In Non-Dilutive Funding From New Jersey's Technology Business Tax Certificate Transfer Program
2016-11-07,Agile Therapeutics Reports Third Quarter 2016 Financial Results And Announces Completion Of Subject Visits For Twirla® Phase 3 SECURE Clinical Trial
2016-08-08,Agile Therapeutics Reports Second Quarter 2016 Financial Results
2016-07-28,Agile Therapeutics Appoints Seth H. Z. Fischer To Its Board Of Directors
2016-07-12,Agile Therapeutics Announces Plans To Advance Contraceptive Pipeline
2016-07-06,Agile Therapeutics Strengthens Executive Leadership Team With New Chief Commercial Officer
2016-06-23,Agile Therapeutics To Present At The Cantor Fitzgerald's 2nd Annual Healthcare Conference
2016-06-16,Agile Therapeutics Announces Issuance Of Patent For Progestin Patch Designs
2016-06-07,Agile Therapeutics To Present At The William Blair & Company's 36th Annual Growth Stock Conference
2016-06-02,Agile Therapeutics To Present At The Jefferies 2016 Healthcare Conference
2016-05-09,Agile Therapeutics Reports First Quarter 2016 Financial Results
2016-04-15,Agile Therapeutics To Present At Women's Health 2016: The 24th Annual Congress
2016-03-30,Agile Therapeutics To Present At The 15th Annual Needham Healthcare Conference
2016-03-09,Agile Therapeutics Reports Fourth Quarter And Full Year 2015 Financial Results
2016-03-03,Agile Therapeutics To Present At The 28th Annual ROTH Conference
2016-02-24,Agile Therapeutics Appoints Ajit S. Shetty, Ph.D., To Its Board Of Directors
2016-02-16,Agile Therapeutics To Present At The 2016 RBC Capital Markets' Global Healthcare Conference
2016-02-04,Agile Therapeutics, Inc. Announces Full Exercise Of Option To Purchase Additional Shares By Underwriters
2016-01-22,Agile Therapeutics Becomes Oversold (AGRX)
2016-01-22,Agile Therapeutics Announces Pricing Of Its Public Offering Of Common Stock
2016-01-21,Agile Therapeutics Announces Proposed Offering Of Common Stock
2016-01-15,Agile Therapeutics To Present At Noble Financial Capital Markets' Twelfth Annual Equity Conference
2015-12-01,Agile Therapeutics Receives Approximately $6 Million In Non-Dilutive Funding From New Jersey's Technology Business Tax Certificate Transfer Program
2015-11-17,Agile Therapeutics Announces Participation At Upcoming Investor Conferences
2015-11-09,Agile Therapeutics Reports Third Quarter Financial Results
2015-10-19,Agile Therapeutics Announces Completion Of Patient Enrollment In Twirla(R) Phase 3 SECURE Clinical Trial
2015-09-03,Agile Therapeutics To Participate At FBR Second Annual Healthcare Conference
2015-08-31,Agile Therapeutics Announces Completion Of Patient Recruitment In Twirla(R) Phase 3 SECURE Clinical Trial
2015-08-27,Agile Therapeutics Announces Presentation At Upcoming Conferences
2015-08-14,5 Toxic Stocks to Stay Away From This Summer
2015-08-13,Agile Therapeutics Reports Second Quarter Financial Results
2015-07-23,Agile Therapeutics Announces Allowance of Several Patents on Novel Dosing Regimens for Its Pipeline of Follow-On Contraceptive Products
2015-07-09,4 Stocks Under $10 Making Big Moves
2015-07-06,Market News: Aetna, Versartis, Agile Therapeutics
2015-07-01,Agile Therapeutics To Present At The Cantor Fitzgerald Inaugural Healthcare Conference
2015-06-30,Agile Therapeutics Added To Membership Of Russell 2000(R), 3000(R) And Global Indexes
2015-06-15,Agile Therapeutics To Present At The JMP Securities Life Sciences Conference 2015
2015-06-12,Agile Therapeutics Announces Issuance Of Patent For Twirla(R) Patch Design
2015-05-28,Agile Therapeutics To Present At The William Blair 35th Annual Growth Stock Conference
2015-05-27,Oversold Conditions For Agile Therapeutics (AGRX)
2015-05-12,Agile Therapeutics Reports First Quarter Financial Results
2015-04-07,Agile Therapeutics To Present At The 14th Annual Needham Healthcare Conference
2015-03-26,Agile Therapeutics Reports Fourth Quarter And Full Year 2014 Financial Results
2015-03-02,Agile Therapeutics To Present At The 27th Annual ROTH Conference
2015-02-24,Agile Therapeutics Secures Debt Facility From Hercules Technology Growth Capital Of Up To $25.0 Million And Provides Update On Status Of Clinical Trial
2015-02-12,Agile Therapeutics To Present At The 2015 RBC Capital Markets' Global Healthcare Conference
2015-01-21,3 Stocks Under $10 Making Big Moves Higher: Arcos Dorados and More
2015-01-20,Agile Therapeutics Announces $20 Million Private Placement And Provides Clinical Trial Update
2015-01-06,Agile Therapeutics To Present At Noble Financial Capital Markets' Eleventh Annual Equity Conference
2014-12-22,Agile Therapeutics To Present At The 33rd Annual J.P. Morgan Healthcare Conference
2014-12-01,Agile Therapeutics Announces Publication Of Data On Low-Dose Investigational Contraceptive Patch
2014-11-18,Agile Therapeutics Appoints John Hubbard, Ph.D., FCP To Its Board Of Directors
2014-11-13,Agile Therapeutics Reports Third Quarter 2014 Financial Results
2014-10-01,Agile Therapeutics Appoints James P. Tursi, M.D. To Its Board Of Directors
2014-09-29,Agile Announces Dosing Of First Patients In Twirla(R) Phase 3 SECURE Study
2014-09-22,Agile To Present At The 21st Annual BioCentury NewsMakers Conference
2014-09-16,Agile Initiates Phase 3 SECURE Study For Twirla(TM)
2014-09-04,5 Breakout Stocks Under $10 Set to Soar
2014-09-02,Agile Therapeutics To Ring The NASDAQ Stock Market Closing Bell
2014-08-28,5 Breakout Stocks Under $10 Set to Soar
2014-08-14,Agile Therapeutics Reports Second Quarter 2014 Financial Results
2014-07-17,Agile Therapeutics Announces Allowance Of Additional Patent Claims For Skinfusion®
2014-06-23,Why Agile Therapeutics (AGRX) Stock Hit a One-Year High Today
,
,
2017-03-14,Achaogen Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update
2017-03-06,Achaogen To Host Conference Call And Webcast Of Fourth Quarter And Year 2016 Financial Results On March 14, 2017
2017-03-02,Achaogen To Present At The Cowen And Company 37th Annual Health Care Conference
2017-03-01,Achaogen Highlights Emerging Pipeline Of Antibacterials Including A New Orally-Administered Antibiotic Clinical Candidate At Company's R&D Day
2017-02-28,Achaogen Announces New Employment Inducement Grants
2017-02-27,Achaogen Adds Janet Dorling As Chief Commercial Officer
2017-02-23,Achaogen Announces Leadership Promotions
2017-02-22,Achaogen Announces Achievement Of A Key Milestone In Developing A Plazomicin Assay To Support Therapeutic Drug Management (TDM)
2017-02-15,Achaogen To Host R&D Day Focused On Advances And Opportunities In The Treatment Of Resistant Gram-Negative Infections
2017-02-09,Achaogen To Participate In The Leerink Partners 6th Annual Global Healthcare Conference
2017-01-31,Trading Action Has Improved, Here's What I Am Playing
2017-01-19,Jump on Harley Davidson, but Stay Away From Costamare: 'Mad Money' Lightning Round
2017-01-18,Earnings, Not Just the Trump Rally, Drive Stocks: Cramer's 'Mad Money' Recap (Wednesday 1/18/17)
2017-01-13,Surge From Bank Earnings Doesn't Last
2017-01-05,Achaogen Appoints Halley Gilbert To Its Board Of Directors
2017-01-05,Rev's Forum: The Fed Isn't Convinced the Trump Rally Is Justified
2017-01-04,Trying to Knock Out Some Individual Trades, but it Is not Easy
2016-12-19,Achaogen Announces Closing Of Public Offering Including Exercise Of Underwriters' Option To Purchase Additional Shares
2016-12-15,Markets Are Rising But Feel Confused
2016-12-14,Machines Are Pumping Up the Volume
2016-12-14,Achaogen Announces Pricing Of Public Offering Of Common Stock
2016-12-13,AKAO Crosses Above Average Analyst Target
2016-12-12,Achaogen Announces Proposed Public Offering Of Common Stock
2016-12-12,Achaogen Announces Positive Results In Phase 3 CUTI And CRE Clinical Trials Of Plazomicin
2016-12-11,Achaogen To Host Conference Call And Webcast To Review Plazomicin Phase 3 Clinical Results
2016-11-22,Achaogen Announces New Employment Inducement Grants
2016-11-15,Achaogen Adds Gary Loeb As General Counsel
2016-11-10,Achaogen To Present At The Stifel Healthcare Conference 2016
2016-11-07,Achaogen Reports Third Quarter 2016 Financial Results And Announces Acceleration Of Expected Timeline For Reporting Top-Line Results From Plazomicin Program
2016-11-01,Achaogen To Host Conference Call And Webcast Of Third Quarter 2016 Financial Results On November 7, 2016
2016-10-24,Achaogen To Present First Plazomicin CARE Trial Data In Patients With Carbapenem-Resistant Enterobacteriaceae (CRE) Infections At IDWeek 2016
2016-09-29,5 Stocks Under $10 Poised for Big Breakouts
2016-09-27,Achaogen Announces New Employment Inducement Grants
2016-09-01,Achaogen Completes Patient Enrollment In Phase 3 EPIC Clinical Trial Of Plazomicin
2016-08-22,Achaogen Announces New Employment Inducement Grants
2016-08-10,Achaogen To Present At The Wedbush PacGrow Healthcare Conference
2016-08-08,Achaogen Reports Second Quarter 2016 Financial Results And Provides Corporate Update
2016-07-15,Achaogen To Host Key Opinion Leader Meeting On Multi-Drug Resistant Infections On July 19, 2016 In New York
2016-07-06,Achaogen Announces New Employment Inducement Grants
2016-06-24,Achaogen Announces New Employment Inducement Grants
2016-06-20,Achaogen's Plazomicin Highlighted In Multiple Presentations At ASM Microbe 2016 Outlining Bactericidal Activity Against MDR Pathogens
2016-06-13,Achaogen (AKAO) Is Strong On High Volume Today
2016-06-09,Achaogen Announces Plazomicin Data Presentations At ASM Microbe 2016 Annual Meeting
2016-06-06,Achaogen (AKAO) Stock: Weak On High Volume Today
2016-06-03,Trade-Ideas: Achaogen (AKAO) Is Today's Strong On High Relative Volume Stock
2016-06-03,Achaogen Adds Tobin Schilke As Chief Financial Officer
2016-06-02,Achaogen Awarded $20 Million Contract Option By BARDA To Support Development Of Plazomicin For Multi-Drug Resistant Gram-Negative Infections
2016-06-02,Achaogen Raises $25 Million In Private Placement
2016-06-02,Achaogen Reaches 50 Percent Patient Enrollment In Phase 3 EPIC Registration Trial Of Plazomicin
2016-05-10,Achaogen And Crystal Bioscience Enter Into Collaboration And License Agreement To Identify And Develop Antibodies For Multiple Targets
2016-05-05,Achaogen Reports First Quarter 2016 Financial Results
2016-04-22,Achaogen Announces New Employment Inducement Grants
2016-04-21,Achaogen Awarded $2.4 Million Contract Option By NIAID To Support Development Of LpxC Inhibitors For The Treatment Of Serious Bacterial Infections
2016-04-15,7 Stocks Under $10 Making Big Moves
2016-04-06,Achaogen To Present At The 15th Annual Needham Health Care Conference
2016-04-05,Achaogen Announces Acceleration Of Expected Timeline For Reporting Top-Line Results From Phase 3 EPIC Registration Clinical Trial Of Plazomicin
2016-03-15,Achaogen Reports Fourth Quarter And Full Year 2015 Financial Results And Provides Corporate Update
2016-03-08,Achaogen To Host Conference Call And Webcast Of Fourth Quarter And Year 2015 Financial Results On March 15, 2016
2016-02-08,Achaogen And TRIANNI Sign Licensing Agreement For Use Of Trianni Transgenic Mouse Platform
2016-01-21,Achaogen Joins Leading International Healthcare Companies In Declaration To Further Mobilize Governments To Combat The Threat Of Antimicrobial Resistance
2016-01-11,Achaogen Announces Enrollment Of First Patient In EPIC, A Phase 3 Clinical Trial For The Treatment Of Complicated Urinary Tract Infections (cUTI) With Plazomicin
2015-12-17,Achaogen Announces Employment Inducement Grants
2015-11-05,Achaogen Announces Third Quarter 2015 Results
2015-11-04,Achaogen To Present At 2015 Credit Suisse Healthcare Conference
2015-10-06,Achaogen Announces Employment Inducement Grants
2015-09-15,Achaogen To Present Data On Plazomicin At 55th Annual ICAAC Meeting
2015-08-19,Achaogen Appoints Blake Wise As Chief Operating Officer
2015-08-17,5 Stocks Ready for Breakouts
2015-08-10,Achaogen Announces Second Quarter 2015 Results
2015-08-05,Achaogen To Present At The 2015 Wedbush PacGrow Healthcare Conference
2015-07-21,Achaogen Announces Employment Inducement Grants
2015-07-16,Achaogen Awarded $4.5 Million Contract With NIAID For Development Of Novel LpxC Inhibitors For The Treatment Of Bacterial Infections
2015-07-09,5 Stocks Under $10 Set to Soar
2015-07-01,Achaogen To Present At The Cantor Fitzgerald Inaugural Healthcare Conference
2015-06-18,4 Breakout Biotech Stocks Under $10 to Watch
2015-06-15,Achaogen To Participate In BIO And AIA Events Focused On Incentivizing Antibiotic Development
2015-06-11,Achaogen Announces Appointment Of Greg Stea To Board Of Directors And Results Of Annual Meeting Of Stockholders
2015-05-21,5 Stocks Under $10 Set to Soar
2015-05-19,Ratings Changes Today
2015-05-11,Achaogen Provides Clinical Update And First Quarter 2015 Results
2015-05-05,Achaogen To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference
2015-04-30,Achaogen To Receive $7.1 Million In Settlement Of Claim With Defense Threat Reduction Agency (DTRA)
2015-04-09,Achaogen To Present At 14th Annual Needham Healthcare Conference
2015-03-30,Achaogen Announces Webcast Providing Update On Development Plan For Plazomicin
2015-03-25,Achaogen Becomes Oversold (AKAO)
2015-03-16,Achaogen Announces Fourth Quarter And Full Year 2014 Results
2015-03-12,Achaogen To Present At The Jefferies 2015 Antibiotic Summit On March 18, 2015
2015-03-12,Achaogen Announces Appointment Of Kent Lieginger And Alan Colowick To Board Of Directors
2015-02-25,Achaogen To Present At The Cowen And Company 35th Annual Health Care Conference On March 3, 2015
2015-01-08,Achaogen Announces Plazomicin Granted QIDP Designation By FDA
2014-11-10,Achaogen Announces Third Quarter 2014 Results
2014-10-29,Achaogen To Present At 2014 Credit Suisse Healthcare Conference
2014-09-17,Isis Pharmaceuticals Earns $4 Million From Achaogen For The Initiation Of A Phase 3 Study Of Plazomicin
2014-09-17,Achaogen Announces First Patient Enrollment In A Phase 3 Clinical Trial Of Plazomicin To Treat Infections Caused By Carbapenem-Resistant Enterobacteriaceae (CRE)
2014-08-11,Achaogen Announces Second Quarter 2014 Results
2014-07-14,Achaogen Appoints Dr. Ian Friedland As Chief Medical Officer
2014-07-09,Is antibiotic-resistant bacteria a curse or a blessing for Big Pharma?
,
,
2017-03-06,Alder BioPharmaceuticals Announces Presentations At 69th Annual American Academy Of Neurology Meeting Supporting Development Of Eptinezumab For Migraine Prevention
2017-02-23,Alder BioPharmaceuticals Announces Fourth Quarter And Full Year 2016 Financial And Operating Results
2017-02-16,Alder BioPharmaceuticals To Host Conference Call To Discuss Fourth Quarter And Full Year 2016 Financial And Operating Results
2017-02-09,Alder BioPharmaceuticals To Present At The Leerink Partners 6th Annual Global Healthcare Conference
2017-01-25,Interesting ALDR Put And Call Options For March 17th
2017-01-06,Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View
2017-01-02,Alder BioPharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-11-28,Alder BioPharmaceuticals Initiates PROMISE 2 Pivotal Trial Of Eptinezumab For The Prevention Of Migraine
2016-11-01,Alder BioPharmaceuticals To Present At Two Upcoming November Conferences
2016-10-27,Alder BioPharmaceuticals Announces Third Quarter 2016 Financial And Operating Results
2016-10-20,Alder BioPharmaceuticals To Host Conference Call To Discuss Third Quarter 2016 Financial And Operating Results
2016-10-11,Alder BioPharmaceuticals Promotes Larry Benedict To Executive Vice President Of Finance And Principal Accounting Officer
2016-09-21,Allergan's Boldness may not be Limited to Tobira Deal
2016-09-21,Alder BioPharmaceuticals Appoints Nancy L. Boman, M.D., Ph.D., Senior Vice President Of Regulatory Affairs And Pharmacovigilance
2016-09-15,Alder Presents Positive ALD403 Clinical Data At European Headache And Migraine Trust International Congress
2016-09-08,Alder Announces Presentations At The European Headache And Migraine Trust International Congress Supporting Development Of ALD403 For Migraine Prevention
2016-09-06,Alder BioPharmaceuticals Appoints Elisabeth A. Sandoval As Chief Commercial Officer
2016-08-31,Alder BioPharmaceuticals To Present At Two Upcoming September Healthcare Conferences
2016-08-23,Under Armour, Starbucks, Alder Biopharmaceuticals, YY, And Google And More Offer Option-trading Opportunities That Offer Returns Of More Than 20%
2016-07-26,Alder BioPharmaceuticals Reports Second Quarter 2016 Financial And Operating Results
2016-07-25,Alder Reports Positive Top-Line 24-Week Data Demonstrating Persistent Migraine Prevention In Phase 2b Study Of ALD403 In Patients With Chronic Migraine
2016-07-19,Alder BioPharmaceuticals To Host Conference Call To Discuss Second Quarter 2016 Financial And Operating Results
2016-06-29,16 Biopharma Companies Besides Medivation That Are Attractive Targets
2016-06-29,Alder BioPharmaceuticals Appoints Timothy M. Whitaker, M.D., Chief Medical Officer
2016-06-09,Alder Presents Positive Clinical Data For ALD403 At The Annual Meeting Of The American Headache Society
2016-06-06,Alder BioPharmaceuticals Appoints Roger Cady, M.D., Vice President Of Neurology
2016-06-02,Alder Announces Presentations At Annual Meeting Of The American Headache Society Supporting Development Of ALD403 For Migraine Prevention
2016-05-26,Alder BioPharmaceuticals To Present At Two Upcoming June Events
2016-05-25,Alder BioPharmaceuticals Continues To Strengthen And Expand Leadership Team To Support Advancement Of ALD403 For Migraine Prevention
2016-05-23,Xenoport's Cost-Cutting Tactics Lead to Buyout With Hefty Premium
2016-05-06,Alder BioPharmaceuticals To Present At Bank Of America Merrill Lynch 2016 Health Care Conference
2016-05-06,Alder BioPharmaceuticals Licenses Clazakizumab Rights To Vitaeris
2016-04-28,Alder BioPharmaceuticals Reports First Quarter 2016 Financial And Operating Results
2016-04-21,Alder BioPharmaceuticals To Host Conference Call To Discuss First Quarter 2016 Financial And Operating Results
2016-04-12,Alder BioPharmaceuticals Announces Closing Of Public Offering Of Common Stock And Exercise In Full Of Option To Purchase Additional Shares
2016-04-08,Alder BioPharmaceuticals To Present At 15th Annual Needham Healthcare Conference
2016-04-06,Alder BioPharmaceuticals Prices Public Offering Of Common Stock
2016-04-06,Alder BioPharmaceuticals Announces Commencement Of Public Offering Of Common Stock
2016-04-03,Alder Presents Preclinical Data For ALD1613 At ENDO 2016
2016-03-28,Alder (ALDR) Stock Spikes on Successful Migraine Prevention Study
2016-03-28,Alder Reports Phase 2b Trial Of ALD403 Meets Primary And Secondary Endpoints Demonstrating Migraine Prevention In Patients With Chronic Migraine
2016-03-27,Alder BioPharmaceuticals To Hold Conference Call On Monday, March 28, At 8:30 Am ET
2016-03-23,First Week of ALDR May 20th Options Trading
2016-03-17,RSI Alert: Alder Biopharmaceuticals (ALDR) Now Oversold
2016-02-23,Relative Strength Alert For Alder Biopharmaceuticals
2016-02-23,Alder BioPharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial And Operating Results
2016-02-16,Alder BioPharmaceuticals To Host Conference Call To Discuss Fourth Quarter And Full Year 2015 Financial Results On February 23, 2016
2016-02-09,Alder BioPharmaceuticals Strengthens And Expands Leadership Team Supporting Advancement Of ALD403 Toward Future Commercialization
2016-02-04,Alder BioPharmaceuticals To Present At Leerink Partners 5th Annual Global Healthcare Conference
2016-01-15,Jim Cramer's Top Takeaways: Alder BioPharmaceuticals, Ensco
2016-01-14,Jim Cramer's 'Mad Money' Recap: Why We're Suddenly Feeling Good About Stocks Again
2016-01-05,Alder Biopharmaceuticals To Present At The 34th Annual J.P. Morgan Healthcare Conference
2015-11-05,Alder BioPharmaceuticals Reports Third Quarter 2015 Financial And Operating Results
2015-11-03,Alder BioPharmaceuticals To Present At The Credit Suisse 24th Annual Healthcare Conference
2015-10-29,Alder BioPharmaceuticals To Host Conference Call To Discuss Third Quarter Financial And Operating Results
2015-10-21,First Week Of December 18th Options Trading For Alder Biopharmaceuticals (ALDR)
2015-10-13,Alder BioPharmaceuticals Initiates Pivotal Clinical Trial Of ALD403 For Preventative Treatment Of Frequent Episodic Migraine
2015-10-08,Alder's Migraine Drug Trial Results Should Ease Shareholders' Pain, Says CEO
2015-10-08,Migraine Drug Results Will Cure Stock Headache Says Alder CEO
2015-09-30,Alder BioPharmaceuticals Appoints Paul R. Carter To Board Of Directors
2015-09-28,Relative Strength Alert For Alder Biopharmaceuticals
2015-09-22,Analysts Say Buy Select Biotech Stocks Ahead Of Clinton Drug Plan
2015-09-09,Alder BioPharmaceuticals To Present At Morgan Stanley Global Healthcare Conference
2015-09-02,Alder BioPharmaceuticals To Present At Wells Fargo 2015 Healthcare Conference
2015-08-28,Credit Suisse's 8 Pharmaceutical Stocks With 'Significant' Upside
2015-08-20,Alder BioPharmaceuticals Appoints Paul B. Cleveland To Board Of Directors
2015-08-13,Alder Biopharmaceuticals is Now Oversold (ALDR)
2015-08-05,Alder BioPharmaceuticals Reports Second Quarter 2015 Financial And Operating Results
2015-08-03,First Week Of August 21st Options Trading For Alder Biopharmaceuticals (ALDR)
2015-07-29,Alder BioPharmaceuticals To Host Conference Call To Discuss Second Quarter 2015 Financial And Operating Results
2015-07-08,What Will It Take to Boost Markets Back in the Green? Cramer Explains
2015-07-08,Jim Cramer: Expect Decline in Apple but Don't Trade It
2015-07-03,Blame the E.U.; Don't Ignore the Good News; ... But Stay Skeptical: Jim Cramer's Best Blogs
2015-07-01,Cramer Is Flying Southwest, Won't Recommend Sarepta Therapeutics
2015-07-01,Cramer Worried About Airline Overcapacity, Hints at Surprise McDonald's Piece
2015-06-30,Jim Cramer's 'Mad Money' Recap: Here Are the Stocks You Could've Picked Off Cheap
2015-06-30,Alder BioPharmaceuticals Announces Exercise In Full Of Option To Purchase Additional Shares
2015-06-30,Jim Cramer's Top Takeaways: Home Depot, Lowe's, Nike, G-III, Receptos
2015-06-29,Jim Cramer's 'Mad Money' Recap: What Were Those Delusional Bulls Thinking?
2015-06-26,Alder BioPharmaceuticals To Present At WBBA 2015 Life Science Innovation Northwest Conference
2015-06-26,Alder Biopharmaceuticals (ALDR) Stock Rises After Pricing Secondary Offering
2015-06-26,Jim Cramer -- Micron, Other PC-Tied Chip Stocks Continue to Struggle
2015-06-26,Cramer — Finish Line Turns the Tide and Has ‘Excellent Quarter’
2015-06-25,Alder BioPharmaceuticals Prices Public Offering Of Common Stock
2015-06-24,Alder BioPharmaceuticals Announces Commencement Of Public Offering Of Common Stock
2015-06-15,AXON, REGN, BURL, FIVE: Jim Cramer's Views
2015-06-05,Jim Cramer: Alder Biopharmaceuticals (ALDR) Is Meeting 'Gigantic Unmet Needs'
2015-06-05,Jim Cramer's Top Takeaways: Carnival, Alder Biopharmaceuticals, T-Mobile, Dish Network
2015-06-04,Jim Cramer's 'Mad Money' Recap: 3 Things Frightening the Market Right Now
2015-05-28,Alder BioPharmaceuticals To Present At Jefferies 2015 Global Healthcare Conference
2015-05-15,Alder Presents Positive Clinical Data For ALD403 At The 17th Congress Of The International Headache Society
2015-05-07,Alder BioPharmaceuticals Reports First Quarter 2015 Financial And Operating Results
2015-05-06,Commit To Purchase Alder Biopharmaceuticals At $22.50, Earn 20.4% Annualized Using Options
2015-05-06,Alder Announces Presentations At 17th Congress Of The International Headache Society On Data From ALD403 Clinical Trials
2015-05-05,Clazakizumab, An Anti-IL-6 Monoclonal Antibody For The Treatment Of Rheumatoid Arthritis, Meets Primary Endpoint In Follow-On Phase 2b Clinical Trial
2015-04-30,Alder BioPharmaceuticals To Host Conference Call To Discuss First Quarter 2015 Financial And Operating Results
2015-03-04,Alder BioPharmaceuticals Reports Fourth Quarter And Year-End 2014 Financial And Operating Results
2015-02-25,Alder BioPharmaceuticals To Host Conference Call To Discuss Fourth Quarter And Full Year 2014 Financial And Operating Results
2015-02-05,14 IPOs You Wish You Bought in 2014 (and Made a Killing On)
2015-02-05,Alder BioPharmaceuticals To Present At 2015 Leerink Global Healthcare Conference
2015-01-22,Alder BioPharmaceuticals Announces Exercise In Full Of Option To Purchase Additional Shares
2015-01-08,Alder BioPharmaceuticals Announces Pricing Of Follow-On Offering
2015-01-05,Alder BioPharmaceuticals Announces Commencement Of Follow-On Offering
2014-12-16,Alder BioPharmaceuticals Announces Addition To NASDAQ Biotechnology Index
2014-11-26,Alder BioPharmaceuticals To Present At 26th Annual Piper Jaffray Healthcare Conference
2014-11-15,Data From Phase 2b Clinical Trial Of Clazakizumab, An Anti-IL-6 Monoclonal Antibody For The Treatment Of Active Psoriatic Arthritis, To Be Presented At The American College Of Rheumatology Annual Meeting
2014-11-14,Assessing Third-Quarter Earnings Surprises
2014-11-04,Alder BioPharmaceuticals To Present At Credit Suisse 2014 Healthcare Conference
2014-11-03,Alder BioPharmaceuticals Reports Third Quarter 2014 Financial And Operating Results
2014-11-03,Alder BioPharmaceuticals Initiates Phase 2b Clinical Trial Of ALD403 For Preventative Treatment Of Chronic Migraine
2014-10-24,Alder BioPharmaceuticals To Host Conference Call To Discuss Third Quarter 2014 Financial And Operating Results
2014-10-06,Data From Alder BioPharmaceuticals' Proof-of-Concept Clinical Trial Of ALD403 Published In Lancet Neurology Demonstrates ALD403 Effective In The Preventive Treatment Of Migraine
2014-09-02,Alder BioPharmaceuticals Regains Worldwide Rights To Clazakizumab
2014-08-05,Alder BioPharmaceuticals Reports Second Quarter 2014 Financial And Operating Results
2014-07-29,Alder BioPharmaceuticals To Host Conference Call To Discuss Second Quarter 2014 Financial And Operating Results
2014-07-28,5 Stocks Ready for Breakouts
2014-06-30,4 Stocks Rising on Unusual Volume
2014-06-24,3 Big-Volume Stocks to Trade for Breakouts
,
,
2017-03-20,Alkermes To Present Data On Two-Month Dosing Option Of ARISTADA® At 16th International Congress On Schizophrenia Research
2017-03-16,Alkermes Initiates Phase 3 Gastrointestinal Tolerability Study Of ALKS 8700 For Treatment Of Multiple Sclerosis
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-08,Could These 9 Drugs Gain FDA Approval in the Age of Trump?
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-07,Alkermes' Corporate Presentation To Be Webcast At The Barclays Global Healthcare Conference
2017-02-28,Alkermes' Corporate Presentation To Be Webcast At The Cowen And Company 37th Annual Health Care Conference
2017-02-16,Ratings Changes Today
2017-02-15,Alkermes Plc Reports Financial Results For The Year Ended Dec. 31, 2016 And Provides Financial Expectations For 2017
2017-02-08,Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2016 Financial Results
2017-01-06,Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17)
2017-01-03,Alkermes' Corporate Presentation To Be Webcast At The 35th Annual J.P. Morgan Healthcare Conference
2016-11-28,Short Interest Makes 14% Move For ALKS
2016-11-15,Alkermes (ALKS) CEO Pops Says Biotech Stocks 'Recovered Quite a Bit' Post-Election
2016-11-09,Alkermes' Corporate Presentation To Be Webcast At The Jefferies 2016 London Healthcare Conference
2016-11-03,ALKERMES Inspiration Grants™ Awarded To Support People Affected By Mental Health And Substance Use Disorders
2016-11-02,Alkermes Plc Reports Third Quarter 2016 Financial Results
2016-11-01,Alkermes' Corporate Presentation To Be Webcast At The Credit Suisse 25th Annual Healthcare Conference
2016-10-27,Jim Cramer's Top Takeaways: Norfolk Southern, Apple, Snap-On
2016-10-26,Jim Cramer's 'Mad Money' Recap: Demand and Takeover Talk Lift Stocks
2016-10-26,Alkermes To Host Conference Call To Discuss Third Quarter 2016 Financial Results
2016-10-24,Bullish and Bearish Reversals for the Week
2016-10-21,A Democratic Sweep?; M&amp;A Just the Beginning: Jim Cramer's Best Blogs
2016-10-21,Jim Cramer's 'Mad Money' Recap: Takeover Talk Distracts From Earnings Focus
2016-10-21,Alkermes (ALKS) Stock Soars on Trial Results, Upgrades
2016-10-21,Cramer: M&amp;A Is Just the Beginning of Today's Story
2016-10-21,Analysts' Actions -- Alkermes, Chesapeake, Microsoft, Yahoo! and More
2016-10-20,Alkermes Depression Drug Finds Success on Third Study Attempt
2016-10-20,Alkermes Announces Positive Topline Results From FORWARD-5 Pivotal Phase 3 Study Of ALKS 5461 For Major Depressive Disorder
2016-10-03,Alkermes Announces Initiation Of Clinical Study Evaluating Metabolic Profile Of ALKS 3831 For Treatment Of Schizophrenia
2016-09-27,Jim Cramer -- Gilead Needs to Make an Acquisition
2016-09-19,Alkermes Announces Webcast Of Analyst And Investor Event On September 26, 2016
2016-09-12,ALKERMES™ Inspiration Grants Application
2016-09-06,Alkermes' Corporate Presentation To Be Webcast At The Morgan Stanley Global Healthcare Conference
2016-08-15,Want a Dash for Trash? Why Not Look at Alkermes
2016-08-08,Alkermes Submits Supplemental New Drug Application To FDA For Two-Month Dosing Option Of ARISTADA® For Treatment Of Schizophrenia
2016-07-29,Alkermes (ALKS) Is Today's Dead Cat Bounce Stock
2016-07-28,Water-Logged And Getting Wetter: Alkermes (ALKS)
2016-07-28,Alkermes Plc Reports Second Quarter 2016 Financial Results
2016-07-27,Jim Cramer's Top Takeaways: Acacia Communications, KeyCorp, Alkermes
2016-07-26,Jim Cramer's 'Mad Money' Recap: 'Good Enough' Is a Triumph
2016-07-21,Alkermes To Host Conference Call To Discuss Second Quarter 2016 Financial Results
2016-06-01,Alkermes' Corporate Presentation To Be Webcast At The Goldman Sachs 37th Annual Global Healthcare Conference
2016-05-26,Alkermes Appoints Nancy Snyderman, M.D., To Board Of Directors
2016-05-25,Alkermes Announces Initiation Of Phase 1 Clinical Study Of Immuno-Oncology Drug Candidate ALKS 4230
2016-05-24,Alkermes To Present Data On ALKS 5461 At Upcoming American Society Of Clinical Psychopharmacology Annual Meeting
2016-04-28,Alkermes Plc Reports First Quarter 2016 Financial Results
2016-04-28,Alkermes Announces Plan To Initiate Second Clinical Trial Of ALKS 7119 Based On Preliminary Phase 1 Results
2016-04-21,Alkermes To Host Conference Call To Discuss First Quarter 2016 Financial Results
2016-04-14,Stalking a Speculative Trade in Alkermes
2016-03-31,Buy Acadia, Alkermes, Starbucks and Verizon, Says Mott Capital Portfolio Manager
2016-03-31,Should Acadia, Alkermes Shares be at the Top of Your Buy List?
2016-03-31,Study On Extended-Release Naltrexone In Opioid-Dependent Patients Involved In Criminal Justice System Published In The New England Journal Of Medicine
2016-03-28,Alkermes To Present Data On Schizophrenia Portfolio At Upcoming Schizophrenia International Research Society Conference
2016-03-09,Alkermes' Corporate Presentation To Be Webcast At The Barclays Global Healthcare Conference
2016-03-09,Weak On High Volume: Alkermes (ALKS)
2016-03-07,Insider Trading Alert - HAFC, ALKS And PRGO Traded By Insiders
2016-03-04,Trade-Ideas: Alkermes (ALKS) Is Today's Post-Market Leader Stock
2016-03-01,Alkermes' Corporate Presentation To Be Webcast At The Cowen And Company 36th Annual Health Care Conference
2016-02-25,Feb. 25 Premarket Briefing: 10 Things You Should Know
2016-02-25,Alkermes Plc Reports Financial Results For The Year Ended Dec. 31, 2015 And Provides Financial Expectations For 2016
2016-02-25,Alkermes Announces Positive Topline Results From Clinical Study Of Two-Month Dosing Option Of ARISTADA® For Treatment Of Schizophrenia
2016-02-19,Alkermes (ALKS) Is Today's Dead Cat Bounce Stock
2016-02-18,Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2015 Financial Results
2016-02-12,5 Breakout Stocks to Trade for Big Gains
2016-02-11,Short Interest In Alkermes Drops 16%
2016-02-10,Alkermes Announces Initiation Of Second Phase 3 Study Of ALKS 3831 For Schizophrenia
2016-02-02,Alkermes' Corporate Presentation To Be Webcast At Two Upcoming Conferences
2016-01-25,Alkermes Announces Initiation Of Phase 1 Clinical Study Of New CNS Drug Candidate ALKS 7119
2016-01-24,8 Things That Could Lift Biotech Stocks Out of Bear Market
2016-01-21,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Violations Of Federal Securities Laws By The Board Of Alkermes Plc
2016-01-21,3 Drugs Stocks Dragging The Industry Down
2016-01-21,Jim Cramer -- Alkermes Is a Big Disappointment Today
2016-01-21,Analysts Split On Alkermes After Depression Trials Fail
2016-01-21,Alkermes (ALKS) Stock Plunges on Depression Treatment's Trial Results
2016-01-21,Alkermes Depression Drug Failure Crimps Future Growth Outlook
2016-01-21,Trade-Ideas: Alkermes (ALKS) Is Today's Pre-Market Mover With Heavy Volume Stock
2016-01-21,Alkermes Announces Topline Results Of FORWARD-3 And FORWARD-4, Two Phase 3 Studies Of ALKS 5461 In Major Depressive Disorder
2016-01-20,Weak On High Volume: Alkermes (ALKS)
2016-01-12,Alkermes (ALKS) Showing Signs Of Being Water-Logged And Getting Wetter
2016-01-05,Alkermes' Corporate Presentation To Be Webcast At The 34th Annual J.P. Morgan Healthcare Conference
2016-01-05,2016 Stock Picks From Mott Capital: Alkermes, Tesla, Disney, More
2016-01-05,Alkermes, Tesla & Disney Shares Set for Strong 2016 Performances
2016-01-04,Alkermes (ALKS) Is Today's Water-Logged And Getting Wetter Stock
2015-12-26,Sell These 6 Biotech Stocks Now Before It's Too Late
2015-12-16,Alkermes Announces Achievement Of Milestones For CNS Medicines In Proprietary Product And Pipeline Portfolio
2015-12-02,3 Stocks Raising The Health Care Sector Higher
2015-11-17,Jim Cramer's 'Mad Money' Recap: Why Good News Is Bad News in This Market
2015-11-17,Trade-Ideas: Alkermes (ALKS) Is Today's Post-Market Leader Stock
2015-11-16,No Snake Oil in These Four Pharmaceutical Stocks
2015-11-11,Alkermes' Corporate Presentation To Be Webcast At The Jefferies 2015 London Healthcare Conference
2015-11-05,Insider Trading Alert - ALKS, REIS And LAD Traded By Insiders
2015-11-04,Retrophin Sinks, Pharma Group Swings Back As Pricing Fight Escalates
2015-11-03,Alkermes' Corporate Presentation To Be Webcast At The Credit Suisse 24Th Annual Healthcare Conference
2015-10-29,Alkermes Plc Reports Third Quarter 2015 Financial Results
2015-10-29,Alkermes Announces Positive Clinical Trial Results And Streamlined Registration Pathway For ALKS 8700 For Treatment Of Multiple Sclerosis
2015-10-23,Alkermes (ALKS) Flagged As Strong On High Volume
2015-10-22,Alkermes To Host Conference Call To Discuss Third Quarter 2015 Financial Results
2015-10-08,Jim Cramer's Top Takeaways: Alkermes, Yum! Brands, Novocure
2015-10-07,Jim Cramer's 'Mad Money' Recap: Watching China Warily, Again
2015-10-07,Alkermes (ALKS) Stock Price Target Upped at Barclays
2015-10-07,Early Warning Signs Of Schizophrenia Are Not Acted On Soon Enough, According To New Survey Of Psychiatrists And Caregivers
2015-10-06,Insider Trading Alert - ALKS, ED And TRC Traded By Insiders
2015-10-05,ARISTADA™ Product Image. Please see Important Safety Information, including Boxed Warning, below and accompanying full Prescribing Information. (Photo: Business Wire)
2015-10-02,Morgan Stanley Says These 9 Health Care Stocks Are Best-Positioned, Despite Rising Drug Prices
2015-09-30,Alkermes (ALKS) Strong On High Relative Volume Today
2015-09-24,Alkermes (ALKS) Marked As Today's Roof Leaker Stock
2015-09-22,Analysts Say Buy Select Biotech Stocks Ahead Of Clinton Drug Plan
2015-09-10,Alkermes' Corporate Presentation To Be Webcast At The Morgan Stanley Global Healthcare Conference
2015-09-03,Insider Trading Alert - GMCR, ALKS And INUV Traded By Insiders
2015-09-01,Today's Dead Cat Bounce Stock Is Alkermes (ALKS)
2015-09-01,New Ratings on American Airlines, Delta and 8 Other Stocks -- Analysts' Actions
2015-08-28,Credit Suisse's 8 Pharmaceutical Stocks With 'Significant' Upside
2015-08-21,Alkermes Provides Update On FDA Review Of ARISTADA™ For The Treatment Of Schizophrenia
2015-07-30,Alkermes Plc Reports Second Quarter 2015 Financial Results
2015-07-23,Alkermes To Host Conference Call To Discuss Second Quarter 2015 Financial Results
2015-07-03,Insider Trading Alert - BXMT, ALKS And FRME Traded By Insiders
2015-06-18,Jim Cramer's Top Takeaways: Palo Alto Networks, Tesla, Ambarella, Allergan, Wingstop, Alkermes
2015-06-17,Jim Cramer's 'Mad Money' Recap: Thanks for Nothing, Janet Yellen
2015-06-16,Alkermes (ALKS) Stock Gains After Announcing Presentation at Annual ASCP Meeting
2015-06-16,Strong On High Relative Volume: Alkermes (ALKS)
2015-06-16,Alkermes To Present Data From Late-Stage CNS Portfolio At Upcoming American Society Of Clinical Psychopharmacology Annual Meeting
2015-06-09,Aripiprazole Lauroxil Phase 3 Schizophrenia Study Results Published In Journal Of Clinical Psychiatry
2015-06-02,Alkermes' Corporate Presentation To Be Webcast At The Goldman Sachs 36th Annual Global Healthcare Conference
2015-06-02,Insider Trading Alert - ALKS, CUBI And WLFC Traded By Insiders
2015-05-29,Alkermes To Present Clinical Data On ALKS 8700 At Annual Meeting Of The Consortium Of Multiple Sclerosis Centers
2015-05-26,Alkermes' Corporate Presentation To Be Webcast At The Jefferies 2015 Global Healthcare Conference
2015-05-11,Alkermes' Corporate Presentation To Be Webcast At The UBS Global Healthcare Conference
2015-04-30,Alkermes Plc Reports First Quarter 2015 Financial Results
2015-04-23,Alkermes To Host Conference Call To Discuss First Quarter 2015 Financial Results
2015-04-13,Alkermes To Present Preclinical Data On Novel Selective Effector Cell Activator (SECA™) Immuno-Oncology Candidate At Upcoming American Association For Cancer Research Annual Meeting
2015-04-06,Alkermes Announces Positive Topline Results From Complete Six-Month Phase 2 Clinical Trial Of ALKS 3831 In Schizophrenia
2015-03-23,Alkermes To Present Data On Aripiprazole Lauroxil And ALKS 3831 At 15th International Congress On Schizophrenia Research
2015-03-12,Analysts' Actions: Alkermes, GNC, Hewlett-Packard and More
2015-03-09,Alkermes Plc Announces Sale Of Gainesville, GA Manufacturing Facility To Recro Pharma, Inc.
2015-03-07,Value in Good Management; Biotechs Are Feeling Better: Jim Cramer's Best Blogs
2015-03-05,Trade-Ideas: Alkermes (ALKS) Is Today's Strong On High Relative Volume Stock
2015-03-04,Jim Cramer's 'Mad Money' Recap: The Market Is a Battlefield
2015-03-04,Alkermes Plc (ALKS) Downgraded From Hold to Sell
2015-03-03,Alkermes' Corporate Presentation To Be Webcast At The Barclays Global Healthcare Conference
2015-03-03,Ratings Changes Today
2015-03-02,Alkermes Announces New Drug Candidate, ALKS 7119, For Treatment Of Alzheimer's Agitation, Depression And Other CNS Diseases
2015-02-24,Alkermes' Corporate Presentation To Be Webcast At The Cowen And Company 35th Annual Health Care Conference
2015-02-24,Jim Cramer: Use Share Weakness to Buy Alkermes for Its Drug Pipeline
2015-02-24,Alkermes Plc Reports Financial Results For The Year Ended Dec. 31, 2014 And Provides Financial Expectations For 2015
2015-02-24,Alkermes Announces Results From Phase 1 Study Of ALKS 7106
2015-02-23,Alkermes Announces Webcast Of Analyst And Investor Event On March 2, 2015
2015-02-23,Alkermes Appoints Mark Namchuk, Ph.D., As Senior Vice President Of Research, Pharmaceutical And Nonclinical Development
2015-02-17,Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2014 Financial Results
2015-02-11,Jim Cramer's Top Stock Picks: GM HAS SAVE ALKS
2015-02-10,Jim Cramer's 'Mad Money' Recap: No Foreign News Is Great U.S. News
2015-02-09,Alkermes Announces Positive Topline Results From Phase 1 Study Of ALKS 8700 For Treatment Of Multiple Sclerosis
2015-02-03,Alkermes' Corporate Presentation To Be Webcast At Two Upcoming Conferences
2015-01-07,Jim Cramer Says Alkermes Shares Are Going 'Much Higher'
2015-01-07,Alkermes CEO: Our Proprietary Drug Pipeline Is 'Maturing Beautifully'
2015-01-07,Alkermes Announces Positive Results Of Phase 2 Clinical Trial Of ALKS 3831 In Schizophrenia
2015-01-06,Alkermes' Corporate Presentation To Be Webcast At The 33rd Annual J.P. Morgan Healthcare Conference
2015-01-06,Jim Cramer: Why Are You Shorting Innovative Biotech Stocks?
2015-01-06,Alkermes Announces Positive Results From Study Of ALKS 5461 For Treatment Of Major Depressive Disorder
2014-12-15,Alkermes Announces Initiation Of Clinical Study Of Extended Durations Of Aripiprazole Lauroxil For Treatment Of Schizophrenia
2014-11-25,Alkermes' Corporate Presentation To Be Webcast At The NASDAQ OMX 31st Investor Program
2014-11-19,Jim Cramer's Top Stock Picks: MMM UNH CELG AMZN HD ALKS PPG
2014-11-18,Jim Cramer's 'Mad Money' Recap: Why Running With the Bulls Is Profitable but Dangerous
2014-11-04,Alkermes' Corporate Presentation To Be Webcast At The Credit Suisse 2014 Healthcare Conference
2014-10-29,Alkermes Plc Reports Third Quarter 2014 Financial Results
2014-10-22,Alkermes To Host Conference Call To Discuss Third Quarter 2014 Financial Results
2014-10-22,Alkermes’ New Drug Application For Aripiprazole Lauroxil For Treatment Of Schizophrenia Accepted For Filing By U.S. FDA
2014-09-16,'Mad Money' Lightning Round: Buy, Buy, Buy St Jude Medical
2014-09-15,Jim Cramer's 'Mad Money' Recap: Time to Make Room for Alibaba
2014-09-03,Alkermes Announces Completion Of Patient Enrollment In Phase 2 Study Of ALKS 3831, A Novel, Broad-Spectrum Oral Antipsychotic
2014-09-02,Alkermes’ Corporate Presentation To Be Webcast At The Morgan Stanley Global Healthcare Conference
2014-08-26,Alkermes Announces Initiation Of Phase 1 Clinical Study Of ALKS 7106 For Treatment Of Pain
2014-08-25,Alkermes Submits New Drug Application To FDA For Aripiprazole Lauroxil For Treatment Of Schizophrenia
2014-07-31,Alkermes Plc Reports Second Quarter 2014 Financial Results
2014-07-30,Alkermes Announces Initiation Of FORWARD-5 Clinical Study Of ALKS 5461 For Treatment Of Major Depressive Disorder
2014-07-24,Alkermes To Host Conference Call To Discuss Second Quarter 2014 Financial Results
2014-07-17,Alkermes Announces Initiation Of Phase 1 Clinical Study Of ALKS 8700 For Treatment Of Multiple Sclerosis
2014-07-09,Alkermes Announces Notices Of Allowance For U.S. Patents For Four CNS Pipeline Candidates
2014-07-01,Alkermes Moves Up In Market Cap Rank, Passing Iron Mountain
2014-06-18,Alkermes Presents Phase 3 Data From Successful Pivotal Study Of Aripiprazole Lauroxil For Treatment Of Schizophrenia At ASCP Annual Meeting
2017-03-22,Regenxbio Leads Biotech Movers Ahead of Market's Open
2017-03-17,The Medicines Company And Alnylam Pharmaceuticals Report Positive Final Results From ORION-1 Phase II Study Of Inclisiran
2017-03-01,Alnylam Receives European Medicines Agency PRIME Designation For Accelerated Assessment Of Givosiran, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias
2017-02-28,Alnylam Acknowledges Rare Disease Day By Highlighting Services To Aid In Rare Disease Diagnosis
2017-02-27,Alnylam To Webcast Presentations At Upcoming March Investor Conferences
2017-02-10,This Healthy Snack Maker Is One of 5 Stocks Ready for a Major Breakout
2017-02-10,Alnylam Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2017-02-08,Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results And Highlights Recent Period Activity
2017-02-07,Alnylam To Webcast Presentation At Leerink Partners 6th Annual Global Healthcare Conference
2017-02-02,Alnylam Presents New Data On Fitusiran At EAHAD
2017-02-01,Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2016 Financial Results
2017-01-06,5 Stocks Setting Up for Big Breakouts
2017-01-03,Alnylam Announces Management Change And Key Promotion
2017-01-03,Alnylam To Webcast Presentation At 35th Annual J.P. Morgan Healthcare Conference
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2016-12-22,2016 Was a Terrible Year for Biotech but the Tweets Were on Point
2016-12-16,Alnylam Presents Initial 2017 Pipeline Goals At R&D Day With Focus On Alnylam 2020 Strategy
2016-12-08,Alnylam To Webcast R&D Day
2016-12-05,Alnylam Presents Updated Results From Phase 1/2 Study Of ALN-CC5 In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
2016-12-04,Alnylam Reports Positive Interim Clinical Results For Fitusiran From Ongoing Phase 2 Open Label Extension Study In Patients With Hemophilia A Or B Without Inhibitors
2016-12-03,Alnylam Reports Positive Interim Phase 1 Results For Fitusiran In Hemophilia A And B Patients With Inhibitors
2016-12-03,Alnylam Reports Positive Initial Clinical Activity Results For Givosiran (ALN-AS1), An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias
2016-11-15,The Medicines Company And Alnylam Pharmaceuticals Present Positive Results From ORION-1 Phase 2 Study Of Inclisiran (formerly PCSK9si)
2016-11-14,Alnylam Pharmaceuticals Announces Sanofi Genzyme Opt-in Decision For Co-Development And Co-Commercialization Of Fitusiran In Hemophilia And Rare Bleeding Disorders
2016-11-13,Http://www.themedicinescompany.com/
2016-11-03,Alnylam To Present New Clinical Results At 58th Annual Meeting Of The American Society Of Hematology (ASH)
2016-11-02,Alnylam Pharmaceuticals Reports Third Quarter 2016 Financial Results And Highlights Recent Period Activity
2016-10-31,Alnylam To Webcast Presentations At Upcoming November Investor Conferences
2016-10-28,Lifshitz & Miller Law Firm Announces Investigation Of Alnylam Pharmaceuticals, Inc., Chesapeake Energy Corporation, Cognizant Technology Solutions Corporation, Fenix Parts, Inc., Genworth Financial, Inc., Illumina Inc., ProNAi Therapeutics, Inc., And Supreme Industries Inc.
2016-10-26,Alnylam To Webcast Conference Call Discussing Third Quarter 2016 Financial Results
2016-10-10,Alnylam Pharmaceuticals (ALNY) Stock Gains on Late-Stage Trial Continuation
2016-10-10,Data Monitoring Committee Recommends Continuation Of APOLLO Phase 3 Clinical Trial Of Patisiran For Hereditary ATTR Amyloidosis With Polyneuropathy (hATTR-PN)
2016-10-07,Alnylam Pharmaceuticals (ALNY) Stock Lower as Drug Development Stopped, Downgrades
2016-10-07,Analysts' Actions -- Advanced Micro, Alnylam, Gap, Fifth Third and More
2016-10-06,Stocks Barely Budge as Wall Street Waits for Friday's Jobs Report
2016-10-06,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Alnylam Pharmaceuticals, Inc. (ALNY)
2016-10-06,Alnylam Pharmaceuticals Shares Plunge After Halting Drug Development
2016-10-06,Stocks Hold Mixed as Crude Settles Above $50, Wall Street Eyes Jobs Report
2016-10-06,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Securities Fraud Violations By Alnylam Pharmaceuticals, Inc. And Certain Officers And Directors
2016-10-06,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Alnylam Pharmaceuticals, Inc. - ALNY
2016-10-06,Stocks Extend Declines as Twitter Shares Sag
2016-10-06,Alnylam Pharma (ALNY) Stock Tumbles on Discontinued Drug, Downgraded
2016-10-06,Alnylam Gene-Silencing Drug Blows Up; Damage Could Spread Deep Into Biotech Sector
2016-10-06,Stock Futures Edge Lower as Jobless Claims Fall
2016-10-06,Analysts' Actions -- Alnylam, AutoNation, Tesla and More
2016-10-05,Alnylam Pharma (ALNY) Stock Plunges in After-Hours Trading, Stops Revusiran Development
2016-10-05,Alnylam Pharmaceuticals Discontinues Revusiran Development
2016-10-03,Alnylam Commemorates 10th Anniversary Of The Nobel Prize In Physiology Or Medicine Awarded For The Discovery Of RNAi
2016-09-28,Alnylam Presents Clinical And Non-Clinical Data Demonstrating Continued RNAi Platform Optimization And Leadership In The Development Of RNA-Based Therapeutics At 12th Annual Meeting Of The Oligonucleotide Therapeutics Society
2016-09-24,Alnylam Reports Positive Initial Results From Ongoing Phase 1/2 Study Of ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1
2016-09-21,Alnylam Pharmaceuticals, Inc. Reports Inducement Grant To New Chief Operating Officer
2016-09-19,Alnylam Expands And Strengthens Management Team As It Plans For Commercialization
2016-09-07,Alnylam Reports Positive Interim Results From Ongoing Phase 1 Study Of ALN-AS1, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias
2016-09-06,Alnylam To Webcast Presentations At Upcoming September Investor Conferences
2016-08-08,Alnylam Completes Enrollment In ENDEAVOUR Phase 3 Study With Revusiran, An Investigational RNAi Therapeutic For Patients With Hereditary ATTR Amyloidosis With Cardiomyopathy (hATTR-CM)
2016-08-04,Alnylam Pharmaceuticals Reports Second Quarter 2016 Financial Results And Highlights Recent Period Progress
2016-08-02,Alnylam To Webcast Presentation At Canaccord Genuity Growth Conference
2016-08-02,Perilous Reversal Stock: Alnylam Pharmaceuticals (ALNY)
2016-07-28,Alnylam To Webcast Conference Call Discussing Second Quarter 2016 Financial Results
2016-07-25,Alnylam Announces New Positive Interim Phase 1 Study Results For Fitusiran, A Once-Monthly, Subcutaneous, Investigational RNAi Therapeutic Targeting Antithrombin For The Treatment Of Hemophilia And Rare Bleeding Disorders
2016-07-25,Today's Weak On High Volume Stock: Alnylam Pharmaceuticals (ALNY)
2016-07-25,Alnylam To Report New Clinical Results With Fitusiran At The World Federation Of Hemophilia (WFH) 2016 World Congress
2016-07-15,5 Toxic Stocks to Sell as Anxiety Creeps Higher
2016-07-12,Alnylam To Host Third Annual "RNAi Roundtable" Webcast Series
2016-07-07,Alnylam Initiates Phase 1/2 Clinical Trial For ALN-HBV, An Investigational RNAi Therapeutic For The Treatment Of Chronic Hepatitis B Virus Infection
2016-07-01,Barbarian At The Gate: Alnylam Pharmaceuticals (ALNY)
2016-07-01,Alnylam Reports New Results From Investigational RNAi Therapeutic Programs For Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy (hATTR-PN) And Cardiomyopathy (hATTR-CM)
2016-06-29,Alnylam Pharmaceuticals (ALNY) Highlighted As Today's Perilous Reversal Stock
2016-06-27,Alnylam To Report New Patisiran And Revusiran Results At The XV International Symposium On Amyloidosis
2016-06-27,Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan
2016-06-25,'Mad Money' Lightning Round: Buy, Buy, Buy UnitedHealth Group
2016-06-11,Alnylam Reports Initial ALN-CC5 Results In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) From Ongoing Phase 1/2 Study
2016-06-09,Alnylam Initiates Phase 1 Clinical Trial For ALN-TTRsc02, An Investigational RNAi Therapeutic For The Treatment Of TTR-Mediated Amyloidosis
2016-06-06,Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Dead Cat Bounce" Stock
2016-06-03,Stock To Watch: Alnylam Pharmaceuticals (ALNY) In Perilous Reversal
2016-06-03,Alnylam To Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data
2016-05-31,Alnylam To Webcast Presentations At Upcoming June Investor Conferences
2016-05-27,Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Perilous Reversal" Stock
2016-05-26,Alnylam Rises After Ionis Partner Decides Not To Start Phase 3 Study
2016-05-16,Strong On High Volume: Alnylam Pharmaceuticals (ALNY)
2016-05-12,Insiders Now Seeing Red With ALNY At New 52-Week Low
2016-05-12,Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's Weak On High Relative Volume Stock
2016-05-03,Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Water-Logged And Getting Wetter" Stock
2016-05-02,Alnylam Pharmaceuticals Reports First Quarter 2016 Financial Results And Highlights Recent Period Progress
2016-04-28,Alnylam Manufacturing Facility To Be Built In Norton, Massachusetts. (Photo: Business Wire)
2016-04-26,Alnylam To Webcast Presentations At Upcoming May Investor Conferences
2016-04-25,Alnylam To Webcast Conference Call Discussing First Quarter 2016 Financial Results
2016-04-20,Alnylam Reports Complete 18-Month Data From Ongoing Phase 2 Open-Label Extension Study Of Patisiran, An Investigational RNAi Therapeutic Targeting Transthyretin For The Treatment Of Hereditary ATTR Amyloidosis With Polyneuropathy (hATTR-PN)
2016-04-07,Alnylam Pharmaceuticals (ALNY) Showing Signs Of Perilous Reversal Today
2016-04-06,Alnylam To Webcast Presentation At 15th Annual Needham Healthcare Conference
2016-04-03,Somber Sentiment Makes Me Wonder
2016-03-14,Alnylam Initiates Fitusiran (ALN-AT3) Dosing In Hemophilia A And B Patients With Inhibitors In Ongoing Phase 1 Study
2016-03-11,Analysts' Actions -- Blackstone, Chevron, Hertz, Kohl's and More
2016-03-10,3 Stocks Pulling The Drugs Industry Downward
2016-03-09,Alnylam Initiates Phase 1/2 Clinical Trial For ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)
2016-02-29,Alnylam To Webcast Presentations At Upcoming March Investor Conferences
2016-02-24,Alnylam Pharmaceuticals (ALNY) Is Weak On High Volume Today
2016-02-11,Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results And Highlights Recent Period Progress
2016-02-04,Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2015 Financial Results
2016-02-01,Alnylam To Webcast Presentations At Upcoming February Investor Conferences
2016-02-01,Alnylam Completes Enrollment In APOLLO Phase 3 Study With Patisiran, An Investigational RNAi Therapeutic For Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
2016-01-27,Weak On High Volume: Alnylam Pharmaceuticals (ALNY)
2016-01-14,Alnylam Pharmaceuticals (ALNY): Today's Weak On High Volume Stock
2016-01-11,Alnylam Outlines 2016 Goals For RNAi Therapeutics Pipeline
2016-01-04,Alnylam To Webcast Presentation At 34th Annual J.P. Morgan Healthcare Conference
2015-12-29,Alnylam To Webcast Presentation At Goldman Sachs "Healthcare CEOs Unscripted: A View From The Top" Conference
2015-12-26,Sell These 6 Biotech Stocks Now Before It's Too Late
2015-12-21,Alnylam Files Clinical Trial Application (CTA) For ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)
2015-12-18,Alnylam Announces Updates To Company's Board Of Directors Supportive Of Transition Towards Commercial Stage
2015-12-17,Alnylam Initiates Dosing In PNH Patients In Phase 1/2 Clinical Trial For ALN-CC5
2015-12-10,Alnylam Pharmaceuticals To Present Path To "Alnylam 2020" At R&D Day
2015-12-08,Today's Dead Cat Bounce Stock: Alnylam Pharmaceuticals (ALNY)
2015-12-07,Alnylam Reports Positive Phase 1 Study Results For Once-Monthly, Subcutaneous Fitusiran (ALN-AT3) In Patients With Hemophilia A And B
2015-12-06,Alnylam Reports That ALN-CC5 Achieves Up To 99 Percent Knockdown Of Serum C5 And Up To 98 Percent Inhibition Of Serum Hemolytic Activity With Durability Supportive Of Once Monthly And Possibly Once Quarterly Subcutaneous Dose Regimen
2015-12-03,3 Drugs Stocks Moving The Industry Upward
2015-12-02,Alnylam To Webcast R&D Day
2015-11-23,Alnylam To Webcast Presentations At Upcoming December Investor Conferences
2015-11-13,Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Dead Cat Bounce" Stock
2015-11-11,Alnylam Pharmaceuticals And The Medicines Company Announce That New ALN-PCSsc Results From Late-Breaking Presentation At American Heart Association Meeting Confirm Potential For Bi-Annual Hypercholesterolemia Dose Regimen
2015-11-09,Alnylam (ALNY) Stock Climbs Following Earnings Release
2015-11-09,3 Drugs Stocks Driving The Industry Higher
2015-11-09,Alnylam Pharmaceuticals Reports Third Quarter 2015 Financial Results And Highlights From Recent Period
2015-11-05,Alnylam To Present New Clinical Results With Investigational RNAi Therapeutics At 57th Annual Meeting Of The American Society Of Hematology (ASH)
2015-11-03,Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Barbarian At The Gate" Stock
2015-11-03,Alnylam Reports Positive Results From Ongoing Phase 2 Open-Label Extension (OLE) Studies For Patisiran And Revusiran, In Development For The Treatment Of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
2015-11-02,Alnylam To Webcast Presentations At Upcoming November Conferences
2015-11-02,Alnylam To Webcast Conference Call Discussing Third Quarter 2015 Financial Results
2015-10-29,Alnylam To Report New Clinical Results With Investigational RNAi Therapeutics For The Treatment Of Transthyretin-Mediated Amyloidosis At The First European Congress On Hereditary ATTR Amyloidosis
2015-10-14,Alnylam Demonstrates Continued Commitment To Transthyretin-Mediated Amyloidosis Patients With Advancement Of ALN-TTRsc02, An Investigational RNAi Therapeutic With Potential For Low Volume, Once Quarterly, Subcutaneous Dose Regimen
2015-10-13,Alnylam Advances New Innovations In RNAi Therapeutics
2015-10-08,Alnylam Initiates Phase 1 Open Label Extension (OLE) Study With ALN-AT3, An Investigational RNAi Therapeutic For The Treatment Of Hemophilia And Rare Bleeding Disorders
2015-10-07,Alnylam Pharmaceuticals (ALNY) Marked As A Dead Cat Bounce Stock
2015-10-01,Alnylam And Genzyme Announce That Genzyme Opts Into ALN-AT3 Hemophilia Program For Development And Commercialization Outside Of North America And Western Europe
2015-09-28,Alnylam Granted Summary Judgment By United States District Court For The District Of Massachusetts In Tuschl II Patent Inventorship Dispute
2015-09-28,Alnylam And Collaborators Report First-Ever Evidence That Patisiran Reduces Pathogenic, Misfolded Transthyretin (TTR) Monomers And Oligomers In TTR-Mediated Amyloidosis (ATTR Amyloidosis) Patients With Familial Amyloidotic Polyneuropathy (FAP)
2015-09-25,Alnylam Pharmaceuticals Becomes Oversold
2015-09-21,Today's Water-Logged And Getting Wetter Stock: Alnylam Pharmaceuticals (ALNY)
2015-09-15,Alnylam Reports Positive Initial Clinical Results For ALN-AS1, An Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) For The Treatment Of Acute Hepatic Porphyrias
2015-09-10,Alnylam To Webcast Presentations At Upcoming September Conferences
2015-09-09,Alnylam Pharmaceuticals (ALNY) Highlighted As Today's Perilous Reversal Stock
2015-09-08,Alnylam Accelerates Development Of ALN-GO1, A Subcutaneously Administered Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)
2015-08-31,3 High-Volume Stocks to Trade Now (or Not)
2015-08-31,Alnylam Pharmaceuticals (ALNY) Stock: Weak On High Volume Today
2015-08-30,(Graphic: Business Wire)
2015-08-21,Ratings Changes Today
2015-08-07,Water-Logged And Getting Wetter: Alnylam Pharmaceuticals (ALNY)
2015-08-07,Analysts' Actions -- Intel, Texas Instruments and Viacom
2015-08-06,Lagging In Post-Market Activity: Alnylam Pharmaceuticals (ALNY)
2015-08-06,Alnylam Pharmaceuticals Reports Second Quarter 2015 Financial Results And Highlights Recent Period Activities
2015-08-05,Alnylam To Webcast Presentation At Canaccord Genuity 35th Annual Growth Conference
2015-07-30,Alnylam To Webcast Conference Call Discussing Second Quarter 2015 Financial Results
2015-07-30,3 Stocks Pushing The Drugs Industry Downward
2015-07-27,Alnylam Initiates Phase 1/2 Clinical Trial For ALN-AAT, An Investigational RNAi Therapeutic For The Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)
2015-07-20,Alnylam Initiates Phase 3 Open Label Extension Study ("APOLLO-OLE") With Patisiran, An Investigational RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR Amyloidosis)
2015-07-17,Today's Stocks Driving Success For The Drugs Industry
2015-07-17,Faruqi & Faruqi, LLP Is Investigating Alnylam Pharmaceuticals, Inc. (ALNY) On Behalf Of Its Shareholders
2015-07-16,Alnylam To Reschedule First RNAi Roundtable Webcast
2015-07-06,Alnylam To Host Second Annual Summer "RNAi Roundtable" Webcast Series
2015-06-24,Alnylam Pharmaceuticals (ALNY) Is Weak On High Volume Today
2015-06-23,Alnylam Reports New Positive Clinical Data For ALN-AT3, A Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders
2015-06-12,Alnylam Pharmaceuticals (ALNY) Weak On High Volume Today
2015-06-12,Alnylam Reports Positive Initial Clinical Results For ALN-CC5, An Investigational RNAi Therapeutic Targeting Complement Component C5 For The Treatment Of Complement-Mediated Diseases
2015-06-10,Alnylam Files Trade Secret Misappropriation Suit Against Dicerna Pharmaceuticals
2015-06-08,Alnylam Appoints David-Alexandre Gros, M.D., Senior Vice President, Chief Business Officer
2015-06-05,Alnylam To Present New Data At International Society On Thrombosis And Haemostasis (ISTH) 2015 Congress With ALN-AT3, An Investigational RNAi Therapeutic For The Treatment Of Hemophilia And Rare Bleeding Disorders (RBD)
2015-05-28,Alnylam To Webcast Presentations At Upcoming June Investor Conferences
2015-05-26,Ratings Changes Today
2015-05-26,4 Big Biotech Companies to Sell Now
2015-05-26,Alnylam Initiates Phase 1 Clinical Trial For ALN-AS1, An Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) For The Treatment Of Acute Hepatic Porphyrias, Including Acute Intermittent Porphyria (AIP)
2015-05-20,Alnylam Receives Orphan Drug Designation From The United States Food & Drug Administration For Revusiran, An Investigational RNAi Therapeutic For The Treatment Of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
2015-05-17,Alnylam Files Clinical Trial Application (CTA) For ALN-AAT, An Investigational RNAi Therapeutic For The Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)
2015-05-15,3 Health Care Stocks Nudging The Sector Higher
2015-05-07,Alynlam Pharmaceuticals (ALNY) Stock Falls in After-Hours Despite Better Than Expected Earnings
2015-05-07,Alnylam Pharmaceuticals Reports First Quarter 2015 Financial Results And Highlights Recent Period Progress
2015-05-07,Fear of a 'Soliris Killer' Might Have Driven Alexion to Overpay for Synageva
2015-04-30,Alnylam To Webcast Conference Call Discussing First Quarter 2015 Financial Results
2015-04-29,Alnylam To Webcast Presentations At Upcoming May Investor Conferences
2015-04-21,Alnylam Reports 12-Month Clinical Data From Phase 2 Open Label Extension (OLE) Study Of Patisiran, An Investigational RNAi Therapeutic For Patients With Familial Amyloidotic Polyneuropathy (FAP)
2015-04-16,New Lifetime High For Alnylam Pharmaceuticals (ALNY)
2015-04-13,Alnylam And Collaborators Publish Pre-clinical Study Results In Nature Medicine On ALN-AT3, An Investigational RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders (RBD)
2017-03-22,Regenxbio Leads Biotech Movers Ahead of Market's Open
2017-03-17,The Medicines Company And Alnylam Pharmaceuticals Report Positive Final Results From ORION-1 Phase II Study Of Inclisiran
2017-03-01,Alnylam Receives European Medicines Agency PRIME Designation For Accelerated Assessment Of Givosiran, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias
2017-02-28,Alnylam Acknowledges Rare Disease Day By Highlighting Services To Aid In Rare Disease Diagnosis
2017-02-27,Alnylam To Webcast Presentations At Upcoming March Investor Conferences
2017-02-10,This Healthy Snack Maker Is One of 5 Stocks Ready for a Major Breakout
2017-02-10,Alnylam Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2017-02-08,Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results And Highlights Recent Period Activity
2017-02-07,Alnylam To Webcast Presentation At Leerink Partners 6th Annual Global Healthcare Conference
2017-02-02,Alnylam Presents New Data On Fitusiran At EAHAD
2017-02-01,Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2016 Financial Results
2017-01-06,5 Stocks Setting Up for Big Breakouts
2017-01-03,Alnylam Announces Management Change And Key Promotion
2017-01-03,Alnylam To Webcast Presentation At 35th Annual J.P. Morgan Healthcare Conference
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2016-12-22,2016 Was a Terrible Year for Biotech but the Tweets Were on Point
2016-12-16,Alnylam Presents Initial 2017 Pipeline Goals At R&D Day With Focus On Alnylam 2020 Strategy
2016-12-08,Alnylam To Webcast R&D Day
2016-12-05,Alnylam Presents Updated Results From Phase 1/2 Study Of ALN-CC5 In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
2016-12-04,Alnylam Reports Positive Interim Clinical Results For Fitusiran From Ongoing Phase 2 Open Label Extension Study In Patients With Hemophilia A Or B Without Inhibitors
2016-12-03,Alnylam Reports Positive Interim Phase 1 Results For Fitusiran In Hemophilia A And B Patients With Inhibitors
2016-12-03,Alnylam Reports Positive Initial Clinical Activity Results For Givosiran (ALN-AS1), An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias
2016-11-15,The Medicines Company And Alnylam Pharmaceuticals Present Positive Results From ORION-1 Phase 2 Study Of Inclisiran (formerly PCSK9si)
2016-11-14,Alnylam Pharmaceuticals Announces Sanofi Genzyme Opt-in Decision For Co-Development And Co-Commercialization Of Fitusiran In Hemophilia And Rare Bleeding Disorders
2016-11-13,Http://www.themedicinescompany.com/
2016-11-03,Alnylam To Present New Clinical Results At 58th Annual Meeting Of The American Society Of Hematology (ASH)
2016-11-02,Alnylam Pharmaceuticals Reports Third Quarter 2016 Financial Results And Highlights Recent Period Activity
2016-10-31,Alnylam To Webcast Presentations At Upcoming November Investor Conferences
2016-10-28,Lifshitz & Miller Law Firm Announces Investigation Of Alnylam Pharmaceuticals, Inc., Chesapeake Energy Corporation, Cognizant Technology Solutions Corporation, Fenix Parts, Inc., Genworth Financial, Inc., Illumina Inc., ProNAi Therapeutics, Inc., And Supreme Industries Inc.
2016-10-26,Alnylam To Webcast Conference Call Discussing Third Quarter 2016 Financial Results
2016-10-10,Alnylam Pharmaceuticals (ALNY) Stock Gains on Late-Stage Trial Continuation
2016-10-10,Data Monitoring Committee Recommends Continuation Of APOLLO Phase 3 Clinical Trial Of Patisiran For Hereditary ATTR Amyloidosis With Polyneuropathy (hATTR-PN)
2016-10-07,Alnylam Pharmaceuticals (ALNY) Stock Lower as Drug Development Stopped, Downgrades
2016-10-07,Analysts' Actions -- Advanced Micro, Alnylam, Gap, Fifth Third and More
2016-10-06,Stocks Barely Budge as Wall Street Waits for Friday's Jobs Report
2016-10-06,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Alnylam Pharmaceuticals, Inc. (ALNY)
2016-10-06,Alnylam Pharmaceuticals Shares Plunge After Halting Drug Development
2016-10-06,Stocks Hold Mixed as Crude Settles Above $50, Wall Street Eyes Jobs Report
2016-10-06,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Securities Fraud Violations By Alnylam Pharmaceuticals, Inc. And Certain Officers And Directors
2016-10-06,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Alnylam Pharmaceuticals, Inc. - ALNY
2016-10-06,Stocks Extend Declines as Twitter Shares Sag
2016-10-06,Alnylam Pharma (ALNY) Stock Tumbles on Discontinued Drug, Downgraded
2016-10-06,Alnylam Gene-Silencing Drug Blows Up; Damage Could Spread Deep Into Biotech Sector
2016-10-06,Stock Futures Edge Lower as Jobless Claims Fall
2016-10-06,Analysts' Actions -- Alnylam, AutoNation, Tesla and More
2016-10-05,Alnylam Pharma (ALNY) Stock Plunges in After-Hours Trading, Stops Revusiran Development
2016-10-05,Alnylam Pharmaceuticals Discontinues Revusiran Development
2016-10-03,Alnylam Commemorates 10th Anniversary Of The Nobel Prize In Physiology Or Medicine Awarded For The Discovery Of RNAi
2016-09-28,Alnylam Presents Clinical And Non-Clinical Data Demonstrating Continued RNAi Platform Optimization And Leadership In The Development Of RNA-Based Therapeutics At 12th Annual Meeting Of The Oligonucleotide Therapeutics Society
2016-09-24,Alnylam Reports Positive Initial Results From Ongoing Phase 1/2 Study Of ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1
2016-09-21,Alnylam Pharmaceuticals, Inc. Reports Inducement Grant To New Chief Operating Officer
2016-09-19,Alnylam Expands And Strengthens Management Team As It Plans For Commercialization
2016-09-07,Alnylam Reports Positive Interim Results From Ongoing Phase 1 Study Of ALN-AS1, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias
2016-09-06,Alnylam To Webcast Presentations At Upcoming September Investor Conferences
2016-08-08,Alnylam Completes Enrollment In ENDEAVOUR Phase 3 Study With Revusiran, An Investigational RNAi Therapeutic For Patients With Hereditary ATTR Amyloidosis With Cardiomyopathy (hATTR-CM)
2016-08-04,Alnylam Pharmaceuticals Reports Second Quarter 2016 Financial Results And Highlights Recent Period Progress
2016-08-02,Alnylam To Webcast Presentation At Canaccord Genuity Growth Conference
2016-08-02,Perilous Reversal Stock: Alnylam Pharmaceuticals (ALNY)
2016-07-28,Alnylam To Webcast Conference Call Discussing Second Quarter 2016 Financial Results
2016-07-25,Alnylam Announces New Positive Interim Phase 1 Study Results For Fitusiran, A Once-Monthly, Subcutaneous, Investigational RNAi Therapeutic Targeting Antithrombin For The Treatment Of Hemophilia And Rare Bleeding Disorders
2016-07-25,Today's Weak On High Volume Stock: Alnylam Pharmaceuticals (ALNY)
2016-07-25,Alnylam To Report New Clinical Results With Fitusiran At The World Federation Of Hemophilia (WFH) 2016 World Congress
2016-07-15,5 Toxic Stocks to Sell as Anxiety Creeps Higher
2016-07-12,Alnylam To Host Third Annual "RNAi Roundtable" Webcast Series
2016-07-07,Alnylam Initiates Phase 1/2 Clinical Trial For ALN-HBV, An Investigational RNAi Therapeutic For The Treatment Of Chronic Hepatitis B Virus Infection
2016-07-01,Barbarian At The Gate: Alnylam Pharmaceuticals (ALNY)
2016-07-01,Alnylam Reports New Results From Investigational RNAi Therapeutic Programs For Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy (hATTR-PN) And Cardiomyopathy (hATTR-CM)
2016-06-29,Alnylam Pharmaceuticals (ALNY) Highlighted As Today's Perilous Reversal Stock
2016-06-27,Alnylam To Report New Patisiran And Revusiran Results At The XV International Symposium On Amyloidosis
2016-06-27,Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan
2016-06-25,'Mad Money' Lightning Round: Buy, Buy, Buy UnitedHealth Group
2016-06-11,Alnylam Reports Initial ALN-CC5 Results In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) From Ongoing Phase 1/2 Study
2016-06-09,Alnylam Initiates Phase 1 Clinical Trial For ALN-TTRsc02, An Investigational RNAi Therapeutic For The Treatment Of TTR-Mediated Amyloidosis
2016-06-06,Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Dead Cat Bounce" Stock
2016-06-03,Stock To Watch: Alnylam Pharmaceuticals (ALNY) In Perilous Reversal
2016-06-03,Alnylam To Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data
2016-05-31,Alnylam To Webcast Presentations At Upcoming June Investor Conferences
2016-05-27,Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Perilous Reversal" Stock
2016-05-26,Alnylam Rises After Ionis Partner Decides Not To Start Phase 3 Study
2016-05-16,Strong On High Volume: Alnylam Pharmaceuticals (ALNY)
2016-05-12,Insiders Now Seeing Red With ALNY At New 52-Week Low
2016-05-12,Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's Weak On High Relative Volume Stock
2016-05-03,Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Water-Logged And Getting Wetter" Stock
2016-05-02,Alnylam Pharmaceuticals Reports First Quarter 2016 Financial Results And Highlights Recent Period Progress
2016-04-28,Alnylam Manufacturing Facility To Be Built In Norton, Massachusetts. (Photo: Business Wire)
2016-04-26,Alnylam To Webcast Presentations At Upcoming May Investor Conferences
2016-04-25,Alnylam To Webcast Conference Call Discussing First Quarter 2016 Financial Results
2016-04-20,Alnylam Reports Complete 18-Month Data From Ongoing Phase 2 Open-Label Extension Study Of Patisiran, An Investigational RNAi Therapeutic Targeting Transthyretin For The Treatment Of Hereditary ATTR Amyloidosis With Polyneuropathy (hATTR-PN)
2016-04-07,Alnylam Pharmaceuticals (ALNY) Showing Signs Of Perilous Reversal Today
2016-04-06,Alnylam To Webcast Presentation At 15th Annual Needham Healthcare Conference
2016-04-03,Somber Sentiment Makes Me Wonder
2016-03-14,Alnylam Initiates Fitusiran (ALN-AT3) Dosing In Hemophilia A And B Patients With Inhibitors In Ongoing Phase 1 Study
2016-03-11,Analysts' Actions -- Blackstone, Chevron, Hertz, Kohl's and More
2016-03-10,3 Stocks Pulling The Drugs Industry Downward
2016-03-09,Alnylam Initiates Phase 1/2 Clinical Trial For ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)
2016-02-29,Alnylam To Webcast Presentations At Upcoming March Investor Conferences
2016-02-24,Alnylam Pharmaceuticals (ALNY) Is Weak On High Volume Today
2016-02-11,Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results And Highlights Recent Period Progress
2016-02-04,Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2015 Financial Results
2016-02-01,Alnylam To Webcast Presentations At Upcoming February Investor Conferences
2016-02-01,Alnylam Completes Enrollment In APOLLO Phase 3 Study With Patisiran, An Investigational RNAi Therapeutic For Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
2016-01-27,Weak On High Volume: Alnylam Pharmaceuticals (ALNY)
2016-01-14,Alnylam Pharmaceuticals (ALNY): Today's Weak On High Volume Stock
2016-01-11,Alnylam Outlines 2016 Goals For RNAi Therapeutics Pipeline
2016-01-04,Alnylam To Webcast Presentation At 34th Annual J.P. Morgan Healthcare Conference
2015-12-29,Alnylam To Webcast Presentation At Goldman Sachs "Healthcare CEOs Unscripted: A View From The Top" Conference
2015-12-26,Sell These 6 Biotech Stocks Now Before It's Too Late
2015-12-21,Alnylam Files Clinical Trial Application (CTA) For ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)
2015-12-18,Alnylam Announces Updates To Company's Board Of Directors Supportive Of Transition Towards Commercial Stage
2015-12-17,Alnylam Initiates Dosing In PNH Patients In Phase 1/2 Clinical Trial For ALN-CC5
2015-12-10,Alnylam Pharmaceuticals To Present Path To "Alnylam 2020" At R&D Day
2015-12-08,Today's Dead Cat Bounce Stock: Alnylam Pharmaceuticals (ALNY)
2015-12-07,Alnylam Reports Positive Phase 1 Study Results For Once-Monthly, Subcutaneous Fitusiran (ALN-AT3) In Patients With Hemophilia A And B
2015-12-06,Alnylam Reports That ALN-CC5 Achieves Up To 99 Percent Knockdown Of Serum C5 And Up To 98 Percent Inhibition Of Serum Hemolytic Activity With Durability Supportive Of Once Monthly And Possibly Once Quarterly Subcutaneous Dose Regimen
2015-12-03,3 Drugs Stocks Moving The Industry Upward
2015-12-02,Alnylam To Webcast R&D Day
2015-11-23,Alnylam To Webcast Presentations At Upcoming December Investor Conferences
2015-11-13,Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Dead Cat Bounce" Stock
2015-11-11,Alnylam Pharmaceuticals And The Medicines Company Announce That New ALN-PCSsc Results From Late-Breaking Presentation At American Heart Association Meeting Confirm Potential For Bi-Annual Hypercholesterolemia Dose Regimen
2015-11-09,Alnylam (ALNY) Stock Climbs Following Earnings Release
2015-11-09,3 Drugs Stocks Driving The Industry Higher
2015-11-09,Alnylam Pharmaceuticals Reports Third Quarter 2015 Financial Results And Highlights From Recent Period
2015-11-05,Alnylam To Present New Clinical Results With Investigational RNAi Therapeutics At 57th Annual Meeting Of The American Society Of Hematology (ASH)
2015-11-03,Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Barbarian At The Gate" Stock
2015-11-03,Alnylam Reports Positive Results From Ongoing Phase 2 Open-Label Extension (OLE) Studies For Patisiran And Revusiran, In Development For The Treatment Of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
2015-11-02,Alnylam To Webcast Presentations At Upcoming November Conferences
2015-11-02,Alnylam To Webcast Conference Call Discussing Third Quarter 2015 Financial Results
2015-10-29,Alnylam To Report New Clinical Results With Investigational RNAi Therapeutics For The Treatment Of Transthyretin-Mediated Amyloidosis At The First European Congress On Hereditary ATTR Amyloidosis
2015-10-14,Alnylam Demonstrates Continued Commitment To Transthyretin-Mediated Amyloidosis Patients With Advancement Of ALN-TTRsc02, An Investigational RNAi Therapeutic With Potential For Low Volume, Once Quarterly, Subcutaneous Dose Regimen
2015-10-13,Alnylam Advances New Innovations In RNAi Therapeutics
2015-10-08,Alnylam Initiates Phase 1 Open Label Extension (OLE) Study With ALN-AT3, An Investigational RNAi Therapeutic For The Treatment Of Hemophilia And Rare Bleeding Disorders
2015-10-07,Alnylam Pharmaceuticals (ALNY) Marked As A Dead Cat Bounce Stock
2015-10-01,Alnylam And Genzyme Announce That Genzyme Opts Into ALN-AT3 Hemophilia Program For Development And Commercialization Outside Of North America And Western Europe
2015-09-28,Alnylam Granted Summary Judgment By United States District Court For The District Of Massachusetts In Tuschl II Patent Inventorship Dispute
2015-09-28,Alnylam And Collaborators Report First-Ever Evidence That Patisiran Reduces Pathogenic, Misfolded Transthyretin (TTR) Monomers And Oligomers In TTR-Mediated Amyloidosis (ATTR Amyloidosis) Patients With Familial Amyloidotic Polyneuropathy (FAP)
2015-09-25,Alnylam Pharmaceuticals Becomes Oversold
2015-09-21,Today's Water-Logged And Getting Wetter Stock: Alnylam Pharmaceuticals (ALNY)
2015-09-15,Alnylam Reports Positive Initial Clinical Results For ALN-AS1, An Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) For The Treatment Of Acute Hepatic Porphyrias
2015-09-10,Alnylam To Webcast Presentations At Upcoming September Conferences
2015-09-09,Alnylam Pharmaceuticals (ALNY) Highlighted As Today's Perilous Reversal Stock
2015-09-08,Alnylam Accelerates Development Of ALN-GO1, A Subcutaneously Administered Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)
2015-08-31,3 High-Volume Stocks to Trade Now (or Not)
2015-08-31,Alnylam Pharmaceuticals (ALNY) Stock: Weak On High Volume Today
2015-08-30,(Graphic: Business Wire)
2015-08-21,Ratings Changes Today
2015-08-07,Water-Logged And Getting Wetter: Alnylam Pharmaceuticals (ALNY)
2015-08-07,Analysts' Actions -- Intel, Texas Instruments and Viacom
2015-08-06,Lagging In Post-Market Activity: Alnylam Pharmaceuticals (ALNY)
2015-08-06,Alnylam Pharmaceuticals Reports Second Quarter 2015 Financial Results And Highlights Recent Period Activities
2015-08-05,Alnylam To Webcast Presentation At Canaccord Genuity 35th Annual Growth Conference
2015-07-30,Alnylam To Webcast Conference Call Discussing Second Quarter 2015 Financial Results
2015-07-30,3 Stocks Pushing The Drugs Industry Downward
2015-07-27,Alnylam Initiates Phase 1/2 Clinical Trial For ALN-AAT, An Investigational RNAi Therapeutic For The Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)
2015-07-20,Alnylam Initiates Phase 3 Open Label Extension Study ("APOLLO-OLE") With Patisiran, An Investigational RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR Amyloidosis)
2015-07-17,Today's Stocks Driving Success For The Drugs Industry
2015-07-17,Faruqi & Faruqi, LLP Is Investigating Alnylam Pharmaceuticals, Inc. (ALNY) On Behalf Of Its Shareholders
2015-07-16,Alnylam To Reschedule First RNAi Roundtable Webcast
2015-07-06,Alnylam To Host Second Annual Summer "RNAi Roundtable" Webcast Series
2015-06-24,Alnylam Pharmaceuticals (ALNY) Is Weak On High Volume Today
2015-06-23,Alnylam Reports New Positive Clinical Data For ALN-AT3, A Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders
2015-06-12,Alnylam Pharmaceuticals (ALNY) Weak On High Volume Today
2015-06-12,Alnylam Reports Positive Initial Clinical Results For ALN-CC5, An Investigational RNAi Therapeutic Targeting Complement Component C5 For The Treatment Of Complement-Mediated Diseases
2015-06-10,Alnylam Files Trade Secret Misappropriation Suit Against Dicerna Pharmaceuticals
2015-06-08,Alnylam Appoints David-Alexandre Gros, M.D., Senior Vice President, Chief Business Officer
2015-06-05,Alnylam To Present New Data At International Society On Thrombosis And Haemostasis (ISTH) 2015 Congress With ALN-AT3, An Investigational RNAi Therapeutic For The Treatment Of Hemophilia And Rare Bleeding Disorders (RBD)
2015-05-28,Alnylam To Webcast Presentations At Upcoming June Investor Conferences
2015-05-26,Ratings Changes Today
2015-05-26,4 Big Biotech Companies to Sell Now
2015-05-26,Alnylam Initiates Phase 1 Clinical Trial For ALN-AS1, An Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) For The Treatment Of Acute Hepatic Porphyrias, Including Acute Intermittent Porphyria (AIP)
2015-05-20,Alnylam Receives Orphan Drug Designation From The United States Food & Drug Administration For Revusiran, An Investigational RNAi Therapeutic For The Treatment Of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
2015-05-17,Alnylam Files Clinical Trial Application (CTA) For ALN-AAT, An Investigational RNAi Therapeutic For The Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)
2015-05-15,3 Health Care Stocks Nudging The Sector Higher
2015-05-07,Alynlam Pharmaceuticals (ALNY) Stock Falls in After-Hours Despite Better Than Expected Earnings
2015-05-07,Alnylam Pharmaceuticals Reports First Quarter 2015 Financial Results And Highlights Recent Period Progress
2015-05-07,Fear of a 'Soliris Killer' Might Have Driven Alexion to Overpay for Synageva
2015-04-30,Alnylam To Webcast Conference Call Discussing First Quarter 2015 Financial Results
2015-04-29,Alnylam To Webcast Presentations At Upcoming May Investor Conferences
2015-04-21,Alnylam Reports 12-Month Clinical Data From Phase 2 Open Label Extension (OLE) Study Of Patisiran, An Investigational RNAi Therapeutic For Patients With Familial Amyloidotic Polyneuropathy (FAP)
2015-04-16,New Lifetime High For Alnylam Pharmaceuticals (ALNY)
2015-04-13,Alnylam And Collaborators Publish Pre-clinical Study Results In Nature Medicine On ALN-AT3, An Investigational RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders (RBD)
2017-03-15,Amarin Announces Publication Of REDUCE-IT Cardiovascular Outcomes Study Rationale And Design In Clinical Cardiology
2017-02-28,Biotech Premarket Movers: Cempra, Novavax, Ionis
2017-02-28,Amarin Reports Record Fourth Quarter And Full Year 2016 Financial Results And Provides Update On Operations
2017-02-22,Interesting AMRN Call Options For May 19th
2017-02-22,Amarin To Report Fourth Quarter And Full Year 2016 Results And Host Conference Call On February 28th, 2017
2017-02-09,Amarin To Participate In The Leerink Partners 6th Annual Global Healthcare Conference
2017-01-20,Amarin Announces Debt Restructuring And Related Private Placement Of Exchangeable Senior Notes
2017-01-05,Amarin Provides Preliminary 2016 Results And 2017 Outlook
2016-12-16,Amarin Announces Contractual Reminder Of Optional Put To Holders Of $15.1 Million Principal Amount Of Outstanding 3.50% Exchangeable Senior Notes Due 2032
2016-11-14,Pure EPA Vascepa® (icosapent Ethyl) Showed Reductions In Potentially Atherogenic Lipid And Inflammatory Parameters In Statin-Treated Women With Persistent High Triglycerides
2016-11-11,Amarin To Present At The Jefferies 2016 London Healthcare Conference
2016-11-03,Amarin Reports Third Quarter 2016 Financial Results And Provides Update On Operations
2016-10-27,Amarin To Report Third Quarter 2016 Results And Host Conference Call On November 3, 2016
2016-10-25,Pure EPA Vascepa® Now Available In New, Smaller Half-Gram Capsule Size
2016-09-12,Amarin's REDUCE-IT Cardiovascular Outcomes Study Of Vascepa To Continue As Planned At Recommendation Of Independent Data Monitoring Committee
2016-09-07,Amarin To Present At The Rodman & Renshaw 18th Annual Global Investment Conference
2016-08-31,Amarin Randomizes Final Patient Into REDUCE-IT Cardiovascular Outcomes Study Of Vascepa
2016-08-26,Amarin Announces Mandatory Exchange Of Exchangeable Senior Notes Issued In May 2014 And November 2015
2016-08-15,Amarin Announces Underwriters' Exercise Of Option To Purchase Additional American Depositary Shares
2016-08-11,Amarin (AMRN) Stock Drops After Pricing Public Offering
2016-08-11,Amarin Prices Public Offering Of American Depositary Shares
2016-08-10,Amarin Announces Proposed Public Offering Of American Depositary Shares
2016-08-02,What Do You Know? Another Down Day!
2016-06-23,Interesting AMRN Put Options For August 5th
2016-01-22,Interesting AMRN Call Options For September 16th
2015-11-12,AMRN December 31st Options Begin Trading
2015-10-29,Interesting AMRN Call Options For December 11th
2015-09-14,Tetraphase Executive Profits Hours Before Stock Plummets
2015-08-27,First Week of November 20th Options Trading For Amarin (AMRN)
2015-07-10,5 Stocks Ready for Breakouts -- Must-See Charts
2015-07-09,AMRN August 28th Options Begin Trading
2015-07-02,Interesting AMRN Call Options For August 14th
2015-06-16,3 Stocks Under $10 Making Big Moves
2015-06-11,July 31st Options Now Available For Amarin (AMRN)
2015-06-04,AMRN July 24th Options Begin Trading
2015-05-28,Amarin Surges After Court Sides With Company On Vascepa Exclusivity
2015-05-07,Interesting AMRN Put And Call Options For June 26th
2015-04-21,First Week Of AMRN December 18th Options Trading
2015-04-09,May 29th Options Now Available For Amarin (AMRN)
2015-04-02,May 22nd Options Now Available For Amarin (AMRN)
2015-03-26,Interesting AMRN Put And Call Options For May 8th
2015-03-13,3 Biotech Stocks on Traders' Radars: Technical Charts
2015-03-13,Biotech Stock Mailbag: Neuralstem, Genfit, Intercept, Amarin
2015-03-12,AMRN May 1st Options Begin Trading
2015-02-10,4 Biotech Stocks Under $10 Triggering Breakouts: Amarin, Exelixis and More
2015-02-05,5 Stocks Under $10 Set to Soar: J.C. Penney, Amarin and More
2015-01-23,Interesting AMRN Put And Call Options For September 18th
2014-12-01,5 Under-$10 Stocks Setting Up to Trade Higher: Must-See Charts
2014-11-14,Biotech Stock Mailbag: Spectrum, Intercept, Orexigen, Amarin, MannKind
2014-09-12,Why Amarin (AMRN) Stock Is Plummeting Today
2014-09-12,Third Time Was No Charm, FDA Denies Amarin Vascepa SPA Appeal
2014-09-11,Interesting AMRN Call Options For October 31st
2014-09-09,Notice To Investors In Amarin Corp. Plc's (AMRN) July 10, 2013 Public Offering: Wolf Popper LLP Announces Anticipated Filing Of Amended Complaint Against Amarin Corp. Plc (NASDAQ: AMRN)
2014-09-08,Keryx Bear Case Bolstered by Less-Than-Zippy 'Zerenex' Label
2014-09-04,AMRN October 24th Options Begin Trading
2014-08-28,October 10th Options Now Available For Amarin (AMRN)
2014-08-26,Your September Biotech Back-to-School Calendar
2014-08-21,October 3rd Options Now Available For Amarin (AMRN)
2014-08-19,Top Swing Trade Ideas for Tuesday, August 19: Apple, Zynga, More
2014-07-31,Stock Market Today: Dow Turns Negative for the Year as Earnings Gloom Sets In
2014-07-31,Amarin Shocker: There's a Reason to be Bullish Right Now
2014-06-25,Rick Harrison Of Television's "Pawn Stars®" Discusses His Revelations On Seeking Treatment For His Very High Triglycerides In National Awareness Campaign
2014-05-19,Pfizer, Forget AstraZeneca -- Check Out These Biotechs: StockTwits
2014-05-15,Why Amarin (AMRN) Stock Is Plummeting Today
2014-05-15,Amarin Announces Private Exchange Transactions Regarding Outstanding Senior Exchangeable Notes
2014-05-09,Amarin Reports First Quarter 2014 Financial Results And Provides Update On Operations
2014-05-05,Amarin To Report First Quarter 2014 Results And Host Conference Call On May 9, 2014
2014-05-02,Amarin Announces Presentation Of New MARINE And ANCHOR Post-Hoc Analyses At National Lipid Association Annual Scientific Sessions Showing Vascepa(R) Significantly Reduced Apolipoprotein C-III Levels
2014-03-31,Amarin And Kowa Pharmaceuticals America, Inc. Announce U.S. Co-Promotion Agreement For Vascepa(R) (icosapent Ethyl) Capsules
2014-03-28,3 Biotech Stocks Under $10 to Trade for Breakouts
2014-03-21,Biotech Stock Mailbag: Amarin, Cytrx, Sangamo and 'Story Stocks'
2014-03-13,5 Stocks Under $10 Set to Soar
2014-03-12,3 Stocks Under $10 Triggering Breakouts
2014-02-27,Amarin Reports Fourth Quarter And Year-End 2013 Financial Results And Provides Update On Operations
2014-02-24,Amarin Loses Bid for Vascepa 5-Year Market Exclusivity
2014-02-24,Amarin To Report Fourth Quarter And Year-End 2013 Results And Host Conference Call On February 27, 2014
2014-02-21,Amarin Announces FDA Award Of Three-Year Exclusivity For Vascepa(R) (icosapent Ethyl) Capsules
2014-02-20,Biotech Stocks to Trade for Breakouts: Amarin
2014-02-06,Amarin To Present At The 2014 Leerink Global Healthcare Conference
2014-02-05,3 Biotech Stocks Under $10 Making Big Moves
2014-02-04,Amarin Announces Promotion Of Aaron Berg To Senior Vice President, Marketing And Sales
2014-02-03,Galena, Free Fentanyl Samples and the 'Zombie Apocalypse'
2014-01-21,Amarin Announces FDA Review Division Response To ANCHOR SPA Agreement Reinstatement Request
2014-01-16,February 14th Options Now Available For Amarin (AMRN)
2014-01-15,Amarin Announces FDA Review Division Response On ANCHOR SPA Agreement Reinstatement Request Will Be Delayed
2014-01-12,Amarin Out, Intercept Pharma In at JPMorgan Healthcare Confab
2014-01-07,The Twitterverse's Biotech Stock Picks for 2014
2014-01-03,5 Stocks Poised for Breakouts
2014-01-02,AMRN January 10th Options Begin Trading
2013-12-30,The Billion-Dollar Biotech Club: Speculation Trumped Risk
2013-12-24,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors Of Class Action Against Amarin Corp. Plc And Its Board Of Directors And Of A Lead Plaintiff Deadline Of January 3, 2014
2013-12-20,DEADLINE ALERT: Rigrodsky &amp; Long, P.A. Reminds Shareholders Of Amarin Corporation Plc Of Upcoming Deadline
2013-12-20,Amarin Receives FDA Notification That Action On ANCHOR SNDA Review Will Be Delayed
2013-12-19,Interesting AMRN Call Options For December 27th
2013-12-17,The Worst Biotech CEO of 2013 Is...
2013-12-16,Amarin Announces Leadership Changes
2013-12-12,Your Vote Counts: Who Is the Worst Biotech CEO of 2013?
2013-12-06,Biotech Stock Mailbag: Enteromedics, ARCA Biopharma, Keryx Pharma
2013-12-04,4 Biotech Stocks Under $10 to Watch
2013-12-03,Amarin in Deep Hole so Top Execs Get Cash Bonus Offer
2013-12-02,Amarin Announces Notification Of Patent Allowances For U.S. Applications 13/685,281, And 13/685,291 Related To Triglyceride Lowering With A Mixture Of Omega-3 Free Fatty Acid (Including EPA And/or DHA) In Both The MARINE And ANCHOR Patient Populations
2013-11-27,SHAREHOLDER ALERT: Pomerantz Law Firm Has Filed A Class Action Against Amarin Corporation, Plc And Certain Officers - AMRN
2013-11-27,Kantrowitz, Goldhamer &amp; Graifman, P.C. Files Class Action Suit Against Amarin Corporation Plc
2013-11-27,2014 FDA Drug Approval Decision Calendar
2013-11-22,Rigrodsky &amp; Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Amarin Corporation Plc
2013-11-19,SHAREHOLDER ALERT: Brower Piven Encourages Investors With More Than $150,000 In Losses From Investment In Amarin Corporation Plc To Contact Brower Piven Before The January 3, 2014 Lead Plaintiff Deadline
2013-11-19,First Week Of AMRN February 2014 Options Trading
2013-11-08,EQUITY ALERT: The Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit On Behalf Of Amarin Corporation Investors - AMRN
2013-11-08,Wolf Popper LLP Announces Continuing Investigation Into Class Action Allegations Against Amarin Corp. Plc - (AMRN)
2013-11-07,Biotech Stock Mailbag: Galectin, Keryx, Navidea, Cytori
2013-11-07,Amarin Reports Third Quarter 2013 Financial Results And Provides Update On Operations
2013-11-06,Attention Amarin Corporation Plc Investors: Amarin Corporation Plc Misled Investors According To A Newly Filed Class Action
2013-11-06,SHAREHOLDER ALERT: Brower Piven Encourages Investors With More Than $150,000 In Losses From Investment In Amarin Corporation Plc To Contact Brower Piven Before The January 3, 2014 Lead Plaintiff Deadline
2013-11-06,SHAREHOLDER ALERT: Investors With More Than $50,000 In Losses From Investments In Amarin Corporation Plc Are Encouraged To Contact Wolf Haldenstein Before The January 3, 2014 Lead Plaintiff Deadline
2013-11-04,Wolf Popper LLP Announces Filing Of Class Action Lawsuit Against Amarin Corp. Plc -(AMRN)
2013-11-01,Biotech Stock Mailbag: Chelsea's FDA Panel, Ariad's Future, Bio-Bubble Update
2013-10-31,Amarin To Report Third Quarter 2013 Results And Host Conference Call On November 7, 2013
2013-10-22,Amarin Announces Plans To Reduce Expenses By Decreasing Staff Following Recent FDA Advisory Committee Vote
2013-10-17,Amarin: Dead Stock Walking With Negative Vascepa Panel Vote
2013-10-16,AMARIN CORPORATION SHAREHOLDER ALERT: The Law Firm Of Levi &amp; Korsinsky, LLP Launches An Investigation Into Claims On Behalf Of Shareholders Of Amarin Corporation In Connection With FDA Release
2013-10-16,Amarin Announces FDA Advisory Committee Outcome For The Use Of Vascepa In The Treatment Of High Triglycerides With Mixed Dyslipidemia
2013-10-16,Amarin Vascepa FDA Panel Live Blog
2013-10-16,Amarin Corporation (NASDAQ: AMRN) Stock Trading Halted Today; FDA Advisory Committee To Review SNDA For Vascepa(R) ANCHOR Indication
2013-10-15,The Essential Investor Guide to Amarin's Vascepa FDA Panel
2013-10-14,AMARIN CORPORATION SHAREHOLDER ALERT: The Law Firm Of Levi &amp; Korsinsky, LLP Launches An Investigation Into Claims On Behalf Of Shareholders Of Amarin Corporation
2013-10-14,Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Amarin Corporation Plc
2013-10-13,AMRN SHAREHOLDER ALERT: The Law Firm Of Wohl &amp; Fruchter LLP Is Investigating Amarin Corporation Plc.
2013-10-09,Amarin To Host Conference Call On October 16, 2013 To Discuss Results Of FDA Advisory Committee Meeting On ANCHOR Supplemental New Drug Application (sNDA) For Vascepa(R)
2013-10-03,Amarin Informed By FDA That October 16th Advisory Committee Meeting Will Take Place As Scheduled
2013-09-25,Amarin Announces Enrollment Of The REDUCE-IT Cardiovascular Outcomes Study Surpasses 6,000 Patients
2013-09-24,U.S. Government Shutdown Could Postpone FDA Advisory Panels
2013-09-18,Amarin To Present At The 2013 Aegis Capital Healthcare Conference
2013-09-16,Grading the Twitterverse's 2013 Biotech Stock Picks
2013-09-13,Biotech Stock Mailbag: Ariad, NewLink, Zogenix, 5 Falling Stocks For Rest of '13
2013-09-09,Amarin Announces 30th Patent For Vascepa(R)
2013-09-04,This Biotech Stock Will Gain From Your Weight Loss
2013-08-29,Finally, Some Great News For Amarin (At Arena Pharma's Expense)
2013-08-26,Amarin Announces Submission Of Supplemental New Drug Application For Novasep As Fourth Vascepa(R) Active Pharmaceutical Ingredient Supplier
2013-08-23,'Mad Money' Lightning Round: Buy, Buy, Buy LinkedIn
2013-08-23,Biotech Stock Mailbag: MannKind, Osiris, BioCryst, Vical, Amarin
2013-08-22,Cramer's 'Mad Money' Recap: Nasdaq's Integrity Outage
2013-08-22,August 30th Options Now Available For Amarin Corp (AMRN)
2013-08-21,First Week Of AMRN November 16th Options Trading
2013-08-16,5 Stocks Poised for Breakouts
2013-08-16,Stocks Wake Up After Hard Selloff
2013-08-14,4 Biotech Stocks Under $10 Making Big Moves
2013-08-13,Amarin To Present At The Canaccord Genuity 33rd Annual Growth Conference
2013-08-08,Amarin Reports Second Quarter 2013 Financial Results And Provides Update On Operations
2013-08-02,Amarin To Report Second Quarter 2013 Results And Host Conference Call On August 8, 2013
2013-07-23,First Week Of March 2014 Options Trading For Amarin Corp (AMRN)
2013-07-12,Amarin Announces Completion Of Offering Of American Depositary Shares
2013-07-09,Amarin's Stock Sale Helps Shorts Cover Winning Trade
2013-07-08,Amarin Announces Public Offering Of American Depositary Shares
2013-06-24,Amarin Corp Becomes Oversold (AMRN)
2013-06-24,Isis Drug Shuts Down Gene Causing Higher Blood-Fat Levels
2013-06-21,Amarin Announces Positive Results Of Phase 1 Clinical Trial Measuring The Bioavailability Of A Fixed-Dose Combination Of Vascepa(R) And A Statin Compared To Concomitant Administration
2013-06-19,3 Drug Stocks Poised To Move As Bears Attack
2013-06-19,Amarin: FDA Panel Date, Misplaced Hype For Fixed-Dose Combo
2013-06-19,Amarin Informed By FDA Of October 16th Advisory Committee Date In Connection With Supplemental New Drug Application (sNDA) For Vascepa(R) In The Treatment Of Patients With High Triglycerides (>200 Mg/dL And 
2013-06-06,As If Amarin Needs Another Worry, Here Comes A Vascepa FDA Panel
2013-06-06,June 14th Options Now Available For Amarin Corp Plc (AMRN)
2013-05-30,Amarin To Present At The Jefferies 2013 Global Healthcare Conference
2013-05-30,June 7th Options Now Available For Amarin Corp Plc (AMRN)
2013-05-30,Amarin Announces Additional Effects Of Vascepa(R) On Lipoprotein Particle Concentration From The ANCHOR Study Presented At The National Lipid Association 2013 Annual Scientific Sessions
2013-05-29,Doc Claims SummerStreet's Amarin Report Is Inaccurate
2013-05-28,Big Pharma Wants Fish Oil After All, But At Half Amarin's Selling Price
2013-05-24,Biotech Stock Mailbag: Amarin, MannKind, Palatin
2013-05-22,Amarin Announces Notification Of Patent Allowance For U.S. Application 13/417,899 Related To Combination Product Of Vascepa(R) And Statin Therapy
2013-05-21,Why Keryx is Lagging But Acadia is Zooming (Hint: It's About NCE)
2013-05-21,2013 FDA Drug Approval Calendar
2013-05-10,Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin
2013-05-09,Photo Release -- Amarin Reports First Quarter 2013 Financial Results And Provides Update On Operations
2013-05-09,Amarin Trouble Grows As Does Evidence Against Fish Oil's Benefits
2013-05-03,Amarin To Report First Quarter 2013 Results And Host Conference Call On May 9, 2013
2013-04-30,Amarin Announces Approval Of Supplemental New Drug Application For BASF As Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier
2013-04-26,Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail!
2013-04-23,Futures Rise on Key Earnings
2013-04-23,Amarin Announces FDA Acceptance Of Supplemental New Drug Application (sNDA) For Vascepa(R) For The Treatment Of Patients With High Triglycerides (>200 Mg/dL And 
2013-04-22,Amarin's Fish Oil Pill Faces Even More Exclusivity Risks
2013-04-18,Amarin Announces Approval Of Supplemental New Drug Application For Chemport As Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier
2017-03-20,ANTH INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Anthera Pharmaceuticals, Inc. And A Lead Plaintiff Deadline Of April 17, 2017
2017-03-14,Anthera Pharmaceuticals Announces Pricing Of $15.0 Million Public Offering Of Common Stock And Warrants
2017-03-13,Anthera Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrants
2017-03-01,INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Anthera Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2017-02-27,Anthera Pharmaceuticals Provides Business Update And Reports 2016 Fourth Quarter And Fiscal Year Financial Results
2017-02-18,Johnson & Weaver, LLP Announces Investigations Of Clovis Oncology, Inc., USANA Health Sciences, Inc., Anthera Pharmaceuticals, Inc., And PixarBio Corporation
2017-02-13,Twitter, Coty, Micron Technology: Doug Kass' Views
2017-02-09,These 5 Stocks Under $10 Could Explode Up Soon
2017-02-03,Lifshitz & Miller LLP Announces Investigation Of Anthera Pharmaceuticals, Inc., Arctic Cat Inc., Banc Of California, Inc., Dollar General Corporation, MoneyGram International, Inc., QUALCOMM Incorporated, Stonegate Mortgage Corporation And Unilife Corporation
2017-01-17,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Anthera Pharmaceuticals, Inc. (ANTH)
2017-01-13,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of Anthera Pharmaceuticals, Inc.
2016-12-27,Anthera Announces The Phase 3 SOLUTION Study With Sollpura™ In Cystic Fibrosis Patients With Exocrine Pancreatic Insufficiency Demonstrates Encouraging Results - Additional Study Needed
2016-12-13,Anthera Pharmaceuticals Announces Continuation Of SIMPLICITY Study Of Sollpura™ Following Positive DMC Review
2016-12-08,These 5 Stocks Under $10 Could Make You a Lot of Money
2016-12-06,Anthera Announces Leadership Transition In Preparation Of Commercialization Of Sollpura And Future Development Of Blisibimod For IgA Nephropathy
2016-12-06,Anthera Reports Blisibimod BRIGHT-SC IgA Nephropathy Continues To Demonstrate Positive Trends In The Week 48 Analysis
2016-11-10,Anthera Announces That The Blisibimod CHABLIS-SC1 Phase 3 Study Did Not Achieve The Primary Endpoint In Patients With Active Systemic Lupus Erythematosus
2016-11-04,Anthera Pharmaceuticals Provides Business Update And Reports 2016 Third Quarter Financial Results
2016-11-02,Anthera Announces That Data From The Phase 2 BRIGHT-SC Study Has Been Accepted As A Late Breaking Abstract At The ASN Kidney Week 2016 Annual Meeting
2016-09-08,Anthera Pharmaceuticals Announces Initial $17.0 Million Closing Of A Potential $45.33 Million Registered Direct Offering To Biotechnology Value Fund And Rock Springs Capital
2016-08-16,Anthera Pharmaceuticals Announces Appointment Of Dr. William Shanahan Jr. As Chief Medical Officer
2016-08-16,Anthera Pharmaceuticals Announces Positive DSMB Review In Phase 3 SOLUTION Study Of Sollpura™
2016-08-09,Anthera Pharmaceuticals Provides Business Update And Reports 2016 Second Quarter Financial Results
2016-08-03,Anthera Pharmaceuticals Announces Completion Of Dosing In CHABLIS-SC1 Phase 3 Clinical Study With Blisibimod
2016-07-18,September 16th Options Now Available For Anthera Pharmaceuticals (ANTH)
2016-07-11,Anthera Pharmaceuticals (ANTH) Is Weak On High Volume Today
2016-06-28,Anthera Provides Clinical Program Updates For Blisibimod And Sollpura®
2016-06-21,First Week of August 19th Options Trading For Anthera Pharmaceuticals (ANTH)
2016-06-06,Ratings Changes Today
2016-05-09,Anthera Pharmaceuticals Provides Business Update And Reports 2016 First Quarter Financial Results
2016-04-27,Anthera Pharmaceuticals Appoints Brent Furse To Board Of Directors
2016-03-10,Anthera Pharmaceuticals Provides Business Update And Reports 2015 Fourth Quarter And Fiscal Year Financial Results
2016-03-07,Anthera Pharmaceuticals Announces Appointment Of Dr. James Pennington As Interim Chief Medical Officer
2016-03-03,Interesting ANTH Put And Call Options For October 21st
2016-01-05,Anthera Pharmaceuticals Announces Appointment Of Craig Thompson As President And Chief Operating Officer And Dr. Chuck Olson As Chief Technology Officer
2015-12-30,3 Biotech Stocks Under $10 Making Big Moves
2015-12-13,Short Interest Increases 15.8% For ANTH
2015-11-06,Anthera Pharmaceuticals Provides Business Update And Reports Third Quarter 2015 Financial Results
2015-10-28,Anthera Pharmaceuticals Announces Presentation At Healthcare Conferences, ACR Reception And Timing Of Third Quarter Financial Results
2015-10-02,Anthera Announces Initiation Of The SOLUTION Clinical Study Of Oral Sollpura(R) (liprotamase) Unit-Matched Therapy Of Non-Porcine Origin In People With Cystic Fibrosis
2015-09-28,First Week of ANTH November 20th Options Trading
2015-09-14,Anthera Announces Termination Of Blisibimod Partnership In Japan By Zenyaku
2015-08-28,First Week of April 2016 Options Trading For Anthera Pharmaceuticals (ANTH)
2015-08-10,Anthera Pharmaceuticals Reports 2015 Second Quarter And Operational Update
2015-07-30,Anthera Pharmaceuticals To Report 2015 Second Quarter And Operational Update On August 10
2015-07-23,4 Momentum Charts to Watch
2015-07-21,First Week Of September 18th Options Trading For Anthera Pharmaceuticals (ANTH)
2015-07-14,Anthera Pharmaceuticals Announces Completion Of Public Offering Of Common Stock And Exercise In Full Of Underwriters' Option To Purchase Additional Shares
2015-07-09,Anthera Pharmaceuticals (ANTH) Stock Dropping After Pricing Public Offering
2015-07-09,Anthera Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2015-07-08,Anthera Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2015-06-26,Anthera Pharmaceuticals Added To The Russell 2000(R) And Russell 3000(R) Indexes
2015-06-23,First Week Of ANTH August 21st Options Trading
2015-06-18,'Mad Money' Lightning Round: Buy, Buy, Buy Celgene; I'm a Believer
2015-06-17,Jim Cramer's 'Mad Money' Recap: Thanks for Nothing, Janet Yellen
2015-06-16,Anthera Pharmaceuticals Has Reached Enrollment Target In CHABLIS-SC1 Phase 3 Clinical Trial With Blisibimod
2015-06-04,Anthera Pharmaceuticals Announces Additional Data On Patient-Reported Outcomes From Phase 2b PEARL-SC Blisibimod Study
2015-05-28,5 Stocks Under $10 Triggering Breakout Trades
2015-05-27,Anthera Pharmaceuticals To Present At Annual Jefferies Healthcare Conference
2015-05-15,5 Stocks Ready for Breakouts: Must-See Charts
2015-05-11,Anthera Pharmaceuticals Reports 2015 First Quarter And Operational Update
2015-04-01,The Top-Performing Biotech Stock During a Sizzling First Quarter
2015-03-25,Interesting ANTH Call Options For May 15th
2015-03-23,Anthera Pharmaceuticals Announces Completion Of Public Offering Of Common Stock
2015-03-19,Anthera Announces $3 Million Research Award From Cystic Fibrosis Foundation Therapeutics For Development Of Sollpura - A Novel Enzyme Therapy
2015-03-18,Anthera Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2015-03-17,Anthera Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2015-03-16,Anthera Pharmaceuticals Announces Completion Of Interim Analysis From Phase 3 Trial With Blisibimod For IgA Nephropathy
2015-02-25,Interesting ANTH Call Options For October 16th
2015-02-19,Anthera Pharmaceuticals To Present At Cowen & Co. Healthcare Conference
2015-02-10,Anthera Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements
2015-02-10,Anthera Pharmaceuticals Announces Completion Of Interim Analysis From Phase 3 Trial With Blisibimod For Systemic Lupus Erythematosus
2015-01-07,Anthera Pharmaceuticals Announces Appointment Of Klara A. Dickinson As Senior Vice President, Chief Regulatory Officer
2014-12-30,Anthera Pharmaceuticals Announces Lupus Symposium During 2015 JP Morgan Healthcare Conference
2014-12-15,Anthera Pharmaceuticals Licenses Japan Rights For Blisibimod To Zenyaku Kogyo Co., Ltd.
2014-11-23,Anthera Pharmaceuticals To Present At Annual Piper Jaffray Healthcare Conference
2014-10-01,Anthera Pharmaceuticals Announces Update On Strategic Partnership Discussions For Blisibimod
2014-10-01,4 Stocks Under $10 to Trade for Breakouts
2014-07-14,Anthera Pharmaceuticals Announces Acquisition Of Sollpura® (liprotamase) For Exocrine Pancreatic Insufficiency From Eli Lilly And Company
2014-07-14,Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events
2014-06-23,Anthera Pharmaceuticals Appoints Brian R. Mueller To Board Of Directors
2014-06-13,Anthera Pharmaceuticals Appoints Dr. Philip Sager To Board Of Directors
2014-03-31,Anthera Pharmaceuticals Announces Personnel Changes
2014-01-30,Anthera Pharmaceuticals To Present At Leerink Swann, Cowen & Co., And BIO CEO Healthcare Conferences
2013-11-27,Anthera Pharmaceuticals To Present At Annual Piper Jaffray Healthcare Conference
2013-11-19,Two Drugs, Designed To Help Patients, Actually Hurt Them
2013-10-25,4 Stocks Under $10 Making Big Moves
2013-09-25,Anthera Pharmaceuticals Announces Emerging Data From Phase 2 Open-Label Extension Study To Be Presented At The ACR/ARHP 2013 Annual Scientific Meeting
2013-07-12,Anthera Pharmaceuticals Announces 1-for-8 Reverse Split Of Stock
2013-06-24,Anthera Announces Initiation Of BRIGHT-SC Phase 2 Clinical Study In IgA Nephropathy With Blisibimod
2013-06-21,Anthera Pharmaceuticals Announces Receipt Of Nasdaq Notice
2013-06-12,Anthera Pharmaceuticals Announces Personnel Changes
2013-05-31,Anthera Pharmaceuticals To Present At Annual Jefferies Healthcare Conference
2013-05-07,Anthera Pharmaceuticals Announces Additional Data From Phase 2b PEARL-SC Blisibimod Study
2013-05-03,Anthera Announces First Quarter 2013 Financial Report And Conference Call
2013-04-05,Anthera Refinances Existing Debt With New $20 Million Credit Facility And Secures $18.5 Million Committed Equity Financing Facility
2013-04-02,Ask SUT
2013-03-27,Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study In Lupus With Blisibimod
2013-03-22,Anthera Announces Data From The Phase 2b PEARL-SC Study Will Be Presented At The 10th International Congress On Systemic Lupus Erythematosus
2013-02-13,SHAREHOLDER ALERT: Levi &amp; Korsinsky, LLP Launches An Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Directors Of Anthera Pharmaceuticals, Inc. In Connection With Executive Compensation
2013-02-13,Faruqi & Faruqi, LLP Is Investigating Anthera Pharmaceuticals Incorporated On Behalf Of Its Shareholders - ANTH
2013-02-07,Anthera Pharmaceuticals To Present At The 2013 Leerink Global Healthcare Conference
2013-02-05,Anthera Pharmaceuticals Announces Departure Of Georgina Kilfoil
2013-01-30,5 Stocks Insiders Are Scooping Up
2013-01-30,Anthera Pharmaceuticals Announces Completion Of Public Offering Of Common Stock
2013-01-30,Top Insider Trades: NVR FIZZ COST ANTH
2013-01-25,Anthera Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2013-01-24,Anthera Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2013-01-23,The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Directors Of Anthera Pharmaceuticals, Inc. In Connection With Executive Compensation
2012-11-28,Anthera Announces Data From The Phase 2b PEARL-SC Study Presented At The 2012 Asian Lupus Summit
2012-11-20,Anthera Pharmaceuticals To Present At The Piper Jaffray Health Care Conference
2012-11-20,Biotech Stock Mailbag: Aveo, Anthera, Amarin, MAP Pharma
2012-11-13,Anthera Announces Additional Data From The Phase 2b PEARL-SC Presented At The ACR/ARHP 2012 Annual Scientific Meeting
2012-11-01,5 Stocks Under $10 Set to Trade Higher in November
2012-11-01,Anthera Announces The Phase 2b PEARL-SC Data Has Been Accepted As A Late Breaking Poster Presentation At The ACR/ARHP 2012 Annual Scientific Meeting
2012-10-18,Anthera Announces Third Quarter 2012 Financial Report And Conference Call
2012-09-17,Anthera Announces The Advancement Of Blisibimod Into Phase 3 Development For Patients With Systemic Lupus Erythematosus (SLE)
2012-08-01,Anthera To Report Second Quarter 2012 Financial Results
2012-07-24,Anthera Pharmaceuticals Announces Exercise In Full Of Over-Allotment Option And Completion Of Public Offering Of Common Stock
2012-07-19,Anthera Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2012-07-18,Anthera Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2012-07-09,Anthera Pharmaceuticals To Present At The 7th Annual JMP Securities Healthcare Conference
2012-06-21,5 Biotech Stocks Under $5 Making Bullish Moves
2012-06-07,7 Stocks Under $10 Streaking Higher
2012-05-10,8 Stocks Under $10 Soaring Higher
2012-04-25,Anthera Announces The Completion Of Patient Dosing In Phase 2b PEARL-SC Study
2012-04-19,8 Stocks Under $10 Moving Higher
2012-04-05,7 Stocks Under $10 Making Big Moves
2012-03-16,Stocks to Watch: ReneSola, UPS, AIG (Update 1)
2012-03-15,Anthera Provides Corporate Update On Recent Activities
2012-03-12,For Biotech, 'Fail' is Making a Big Comeback
2012-03-09,Anthera Halts VISTA-16 Clinical Study Due To Lack Of Efficacy Following Recommendation By The Independent Data Safety Monitoring Board
2012-03-05,Dr. Bogdan Dziurzynski Joins Anthera Pharmaceuticals Board Of Directors
2012-03-05,Anthera Pharmaceuticals Completes Interim Analysis Of PEARL-SC Clinical Trial With Blisibimod
2012-02-23,Anthera Pharmaceuticals To Present At The Citi Global Health Care Conference
2011-12-14,Anthera Announces Completion Of Safety Review By DSMB For VISTA-16
2011-12-05,Anthera Pharmaceuticals Promotes Dr. Debra Odink To Chief Technology Officer
2011-12-01,Anthera Pharmaceuticals Completes Interim B-Cell Analysis Of PEARL-SC Study
2011-10-25,Anthera Announces Last Patient Enrolled In PEARL-SC Study
2011-09-08,Anthera Pharmaceuticals Announces Notice Of Allowance Of U.S. Patent Application Covering A-002 Plus Statin Compositions
2011-06-08,Anthera Pharmaceuticals Announces Completion Of Public Offering Of Common Stock
2011-06-03,Anthera Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2011-06-02,Anthera Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2011-04-18,Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis Of VISTA-16 Study And Third Safety Review Of Varespladib Methyl
2011-02-08,Anthera Pharmaceuticals Names Lawrence Rosania As Vice President Of Global Regulatory Affairs And Compliance
2011-02-01,Dr. Peter Thompson Joins Anthera Pharmaceuticals Board Of Directors
2010-12-14,Anthera Pharmaceuticals Selects The Merck BioManufacturing Network As Manufacturing Supplier For A-623, Anthera's Investigational Novel Peptibody Agent
2010-12-07,Varespladib Receives 2010 European Society Pediatric Research Award
2010-11-24,Anthera Pharmaceuticals To Present At The 22nd Annual Piper Jaffray Health Care Conference
2010-10-25,FirstWind IPO -- Gone With the Wind?
2010-10-05,Oracle CEO Sells $54.5M Worth
2010-09-21,Anthera Pharmaceuticals Announces Pricing Of $31.5 Million PIPE Financing
2010-07-29,Anthera Initiates Expanded And Extended PEARL-SC Phase 2b Clinical Study In Lupus With A-623 - A Subcutaneous Dual Inhibitor Of Membrane And Soluble B-Cell Activating Factor (BAFF Or BLyS)
2010-06-23,Anthera Enrolls First Patients In Pivotal Varespladib Phase 3 Clinical Study
2010-06-10,Anthera Pharmaceuticals Updates Its Lupus Scientific Advisory Board
2010-06-03,Anthera Pharmaceuticals Promotes Colin Hislop, M.D., To Chief Medical Officer
2010-05-03,Anthera Pharmaceuticals Announces Additional Data From FRANCIS Study
2010-04-26,Anthera Pharmaceuticals To Present At Deutsche Bank Securities' 35th Annual Health Care Conference
2010-04-06,Anthera Pharmaceuticals Announces Closing Of Underwriters' Exercise Of Over-Allotment Option In Connection With Its Initial Public Offering
2010-03-23,Anthera Pharmaceuticals Welcomes Georgina Kilfoil As Senior Vice President Of Product Development And Clinical Operations
2010-03-05,Merriman Curhan Ford Acted As Co-Manager In Anthera's Public Offering Of Common Stock
2010-03-04,Anthera Pharmaceuticals Completes Initial Public Offering
2017-03-20,ANTH INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Anthera Pharmaceuticals, Inc. And A Lead Plaintiff Deadline Of April 17, 2017
2017-03-14,Anthera Pharmaceuticals Announces Pricing Of $15.0 Million Public Offering Of Common Stock And Warrants
2017-03-13,Anthera Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrants
2017-03-01,INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Anthera Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2017-02-27,Anthera Pharmaceuticals Provides Business Update And Reports 2016 Fourth Quarter And Fiscal Year Financial Results
2017-02-18,Johnson & Weaver, LLP Announces Investigations Of Clovis Oncology, Inc., USANA Health Sciences, Inc., Anthera Pharmaceuticals, Inc., And PixarBio Corporation
2017-02-13,Twitter, Coty, Micron Technology: Doug Kass' Views
2017-02-09,These 5 Stocks Under $10 Could Explode Up Soon
2017-02-03,Lifshitz & Miller LLP Announces Investigation Of Anthera Pharmaceuticals, Inc., Arctic Cat Inc., Banc Of California, Inc., Dollar General Corporation, MoneyGram International, Inc., QUALCOMM Incorporated, Stonegate Mortgage Corporation And Unilife Corporation
2017-01-17,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Anthera Pharmaceuticals, Inc. (ANTH)
2017-01-13,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of Anthera Pharmaceuticals, Inc.
2016-12-27,Anthera Announces The Phase 3 SOLUTION Study With Sollpura™ In Cystic Fibrosis Patients With Exocrine Pancreatic Insufficiency Demonstrates Encouraging Results - Additional Study Needed
2016-12-13,Anthera Pharmaceuticals Announces Continuation Of SIMPLICITY Study Of Sollpura™ Following Positive DMC Review
2016-12-08,These 5 Stocks Under $10 Could Make You a Lot of Money
2016-12-06,Anthera Announces Leadership Transition In Preparation Of Commercialization Of Sollpura And Future Development Of Blisibimod For IgA Nephropathy
2016-12-06,Anthera Reports Blisibimod BRIGHT-SC IgA Nephropathy Continues To Demonstrate Positive Trends In The Week 48 Analysis
2016-11-10,Anthera Announces That The Blisibimod CHABLIS-SC1 Phase 3 Study Did Not Achieve The Primary Endpoint In Patients With Active Systemic Lupus Erythematosus
2016-11-04,Anthera Pharmaceuticals Provides Business Update And Reports 2016 Third Quarter Financial Results
2016-11-02,Anthera Announces That Data From The Phase 2 BRIGHT-SC Study Has Been Accepted As A Late Breaking Abstract At The ASN Kidney Week 2016 Annual Meeting
2016-09-08,Anthera Pharmaceuticals Announces Initial $17.0 Million Closing Of A Potential $45.33 Million Registered Direct Offering To Biotechnology Value Fund And Rock Springs Capital
2016-08-16,Anthera Pharmaceuticals Announces Appointment Of Dr. William Shanahan Jr. As Chief Medical Officer
2016-08-16,Anthera Pharmaceuticals Announces Positive DSMB Review In Phase 3 SOLUTION Study Of Sollpura™
2016-08-09,Anthera Pharmaceuticals Provides Business Update And Reports 2016 Second Quarter Financial Results
2016-08-03,Anthera Pharmaceuticals Announces Completion Of Dosing In CHABLIS-SC1 Phase 3 Clinical Study With Blisibimod
2016-07-18,September 16th Options Now Available For Anthera Pharmaceuticals (ANTH)
2016-07-11,Anthera Pharmaceuticals (ANTH) Is Weak On High Volume Today
2016-06-28,Anthera Provides Clinical Program Updates For Blisibimod And Sollpura®
2016-06-21,First Week of August 19th Options Trading For Anthera Pharmaceuticals (ANTH)
2016-06-06,Ratings Changes Today
2016-05-09,Anthera Pharmaceuticals Provides Business Update And Reports 2016 First Quarter Financial Results
2016-04-27,Anthera Pharmaceuticals Appoints Brent Furse To Board Of Directors
2016-03-10,Anthera Pharmaceuticals Provides Business Update And Reports 2015 Fourth Quarter And Fiscal Year Financial Results
2016-03-07,Anthera Pharmaceuticals Announces Appointment Of Dr. James Pennington As Interim Chief Medical Officer
2016-03-03,Interesting ANTH Put And Call Options For October 21st
2016-01-05,Anthera Pharmaceuticals Announces Appointment Of Craig Thompson As President And Chief Operating Officer And Dr. Chuck Olson As Chief Technology Officer
2015-12-30,3 Biotech Stocks Under $10 Making Big Moves
2015-12-13,Short Interest Increases 15.8% For ANTH
2015-11-06,Anthera Pharmaceuticals Provides Business Update And Reports Third Quarter 2015 Financial Results
2015-10-28,Anthera Pharmaceuticals Announces Presentation At Healthcare Conferences, ACR Reception And Timing Of Third Quarter Financial Results
2015-10-02,Anthera Announces Initiation Of The SOLUTION Clinical Study Of Oral Sollpura(R) (liprotamase) Unit-Matched Therapy Of Non-Porcine Origin In People With Cystic Fibrosis
2015-09-28,First Week of ANTH November 20th Options Trading
2015-09-14,Anthera Announces Termination Of Blisibimod Partnership In Japan By Zenyaku
2015-08-28,First Week of April 2016 Options Trading For Anthera Pharmaceuticals (ANTH)
2015-08-10,Anthera Pharmaceuticals Reports 2015 Second Quarter And Operational Update
2015-07-30,Anthera Pharmaceuticals To Report 2015 Second Quarter And Operational Update On August 10
2015-07-23,4 Momentum Charts to Watch
2015-07-21,First Week Of September 18th Options Trading For Anthera Pharmaceuticals (ANTH)
2015-07-14,Anthera Pharmaceuticals Announces Completion Of Public Offering Of Common Stock And Exercise In Full Of Underwriters' Option To Purchase Additional Shares
2015-07-09,Anthera Pharmaceuticals (ANTH) Stock Dropping After Pricing Public Offering
2015-07-09,Anthera Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2015-07-08,Anthera Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2015-06-26,Anthera Pharmaceuticals Added To The Russell 2000(R) And Russell 3000(R) Indexes
2015-06-23,First Week Of ANTH August 21st Options Trading
2015-06-18,'Mad Money' Lightning Round: Buy, Buy, Buy Celgene; I'm a Believer
2015-06-17,Jim Cramer's 'Mad Money' Recap: Thanks for Nothing, Janet Yellen
2015-06-16,Anthera Pharmaceuticals Has Reached Enrollment Target In CHABLIS-SC1 Phase 3 Clinical Trial With Blisibimod
2015-06-04,Anthera Pharmaceuticals Announces Additional Data On Patient-Reported Outcomes From Phase 2b PEARL-SC Blisibimod Study
2015-05-28,5 Stocks Under $10 Triggering Breakout Trades
2015-05-27,Anthera Pharmaceuticals To Present At Annual Jefferies Healthcare Conference
2015-05-15,5 Stocks Ready for Breakouts: Must-See Charts
2015-05-11,Anthera Pharmaceuticals Reports 2015 First Quarter And Operational Update
2015-04-01,The Top-Performing Biotech Stock During a Sizzling First Quarter
2015-03-25,Interesting ANTH Call Options For May 15th
2015-03-23,Anthera Pharmaceuticals Announces Completion Of Public Offering Of Common Stock
2015-03-19,Anthera Announces $3 Million Research Award From Cystic Fibrosis Foundation Therapeutics For Development Of Sollpura - A Novel Enzyme Therapy
2015-03-18,Anthera Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2015-03-17,Anthera Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2015-03-16,Anthera Pharmaceuticals Announces Completion Of Interim Analysis From Phase 3 Trial With Blisibimod For IgA Nephropathy
2015-02-25,Interesting ANTH Call Options For October 16th
2015-02-19,Anthera Pharmaceuticals To Present At Cowen & Co. Healthcare Conference
2015-02-10,Anthera Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements
2015-02-10,Anthera Pharmaceuticals Announces Completion Of Interim Analysis From Phase 3 Trial With Blisibimod For Systemic Lupus Erythematosus
2015-01-07,Anthera Pharmaceuticals Announces Appointment Of Klara A. Dickinson As Senior Vice President, Chief Regulatory Officer
2014-12-30,Anthera Pharmaceuticals Announces Lupus Symposium During 2015 JP Morgan Healthcare Conference
2014-12-15,Anthera Pharmaceuticals Licenses Japan Rights For Blisibimod To Zenyaku Kogyo Co., Ltd.
2014-11-23,Anthera Pharmaceuticals To Present At Annual Piper Jaffray Healthcare Conference
2014-10-01,Anthera Pharmaceuticals Announces Update On Strategic Partnership Discussions For Blisibimod
2014-10-01,4 Stocks Under $10 to Trade for Breakouts
2014-07-14,Anthera Pharmaceuticals Announces Acquisition Of Sollpura® (liprotamase) For Exocrine Pancreatic Insufficiency From Eli Lilly And Company
2014-07-14,Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events
2014-06-23,Anthera Pharmaceuticals Appoints Brian R. Mueller To Board Of Directors
2014-06-13,Anthera Pharmaceuticals Appoints Dr. Philip Sager To Board Of Directors
2014-03-31,Anthera Pharmaceuticals Announces Personnel Changes
2014-01-30,Anthera Pharmaceuticals To Present At Leerink Swann, Cowen & Co., And BIO CEO Healthcare Conferences
2013-11-27,Anthera Pharmaceuticals To Present At Annual Piper Jaffray Healthcare Conference
2013-11-19,Two Drugs, Designed To Help Patients, Actually Hurt Them
2013-10-25,4 Stocks Under $10 Making Big Moves
2013-09-25,Anthera Pharmaceuticals Announces Emerging Data From Phase 2 Open-Label Extension Study To Be Presented At The ACR/ARHP 2013 Annual Scientific Meeting
2013-07-12,Anthera Pharmaceuticals Announces 1-for-8 Reverse Split Of Stock
2013-06-24,Anthera Announces Initiation Of BRIGHT-SC Phase 2 Clinical Study In IgA Nephropathy With Blisibimod
2013-06-21,Anthera Pharmaceuticals Announces Receipt Of Nasdaq Notice
2013-06-12,Anthera Pharmaceuticals Announces Personnel Changes
2013-05-31,Anthera Pharmaceuticals To Present At Annual Jefferies Healthcare Conference
2013-05-07,Anthera Pharmaceuticals Announces Additional Data From Phase 2b PEARL-SC Blisibimod Study
2013-05-03,Anthera Announces First Quarter 2013 Financial Report And Conference Call
2013-04-05,Anthera Refinances Existing Debt With New $20 Million Credit Facility And Secures $18.5 Million Committed Equity Financing Facility
2013-04-02,Ask SUT
2013-03-27,Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study In Lupus With Blisibimod
2013-03-22,Anthera Announces Data From The Phase 2b PEARL-SC Study Will Be Presented At The 10th International Congress On Systemic Lupus Erythematosus
2013-02-13,SHAREHOLDER ALERT: Levi &amp; Korsinsky, LLP Launches An Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Directors Of Anthera Pharmaceuticals, Inc. In Connection With Executive Compensation
2013-02-13,Faruqi & Faruqi, LLP Is Investigating Anthera Pharmaceuticals Incorporated On Behalf Of Its Shareholders - ANTH
2013-02-07,Anthera Pharmaceuticals To Present At The 2013 Leerink Global Healthcare Conference
2013-02-05,Anthera Pharmaceuticals Announces Departure Of Georgina Kilfoil
2013-01-30,5 Stocks Insiders Are Scooping Up
2013-01-30,Anthera Pharmaceuticals Announces Completion Of Public Offering Of Common Stock
2013-01-30,Top Insider Trades: NVR FIZZ COST ANTH
2013-01-25,Anthera Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2013-01-24,Anthera Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2013-01-23,The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Directors Of Anthera Pharmaceuticals, Inc. In Connection With Executive Compensation
2012-11-28,Anthera Announces Data From The Phase 2b PEARL-SC Study Presented At The 2012 Asian Lupus Summit
2012-11-20,Anthera Pharmaceuticals To Present At The Piper Jaffray Health Care Conference
2012-11-20,Biotech Stock Mailbag: Aveo, Anthera, Amarin, MAP Pharma
2012-11-13,Anthera Announces Additional Data From The Phase 2b PEARL-SC Presented At The ACR/ARHP 2012 Annual Scientific Meeting
2012-11-01,5 Stocks Under $10 Set to Trade Higher in November
2012-11-01,Anthera Announces The Phase 2b PEARL-SC Data Has Been Accepted As A Late Breaking Poster Presentation At The ACR/ARHP 2012 Annual Scientific Meeting
2012-10-18,Anthera Announces Third Quarter 2012 Financial Report And Conference Call
2012-09-17,Anthera Announces The Advancement Of Blisibimod Into Phase 3 Development For Patients With Systemic Lupus Erythematosus (SLE)
2012-08-01,Anthera To Report Second Quarter 2012 Financial Results
2012-07-24,Anthera Pharmaceuticals Announces Exercise In Full Of Over-Allotment Option And Completion Of Public Offering Of Common Stock
2012-07-19,Anthera Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2012-07-18,Anthera Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2012-07-09,Anthera Pharmaceuticals To Present At The 7th Annual JMP Securities Healthcare Conference
2012-06-21,5 Biotech Stocks Under $5 Making Bullish Moves
2012-06-07,7 Stocks Under $10 Streaking Higher
2012-05-10,8 Stocks Under $10 Soaring Higher
2012-04-25,Anthera Announces The Completion Of Patient Dosing In Phase 2b PEARL-SC Study
2012-04-19,8 Stocks Under $10 Moving Higher
2012-04-05,7 Stocks Under $10 Making Big Moves
2012-03-16,Stocks to Watch: ReneSola, UPS, AIG (Update 1)
2012-03-15,Anthera Provides Corporate Update On Recent Activities
2012-03-12,For Biotech, 'Fail' is Making a Big Comeback
2012-03-09,Anthera Halts VISTA-16 Clinical Study Due To Lack Of Efficacy Following Recommendation By The Independent Data Safety Monitoring Board
2012-03-05,Dr. Bogdan Dziurzynski Joins Anthera Pharmaceuticals Board Of Directors
2012-03-05,Anthera Pharmaceuticals Completes Interim Analysis Of PEARL-SC Clinical Trial With Blisibimod
2012-02-23,Anthera Pharmaceuticals To Present At The Citi Global Health Care Conference
2011-12-14,Anthera Announces Completion Of Safety Review By DSMB For VISTA-16
2011-12-05,Anthera Pharmaceuticals Promotes Dr. Debra Odink To Chief Technology Officer
2011-12-01,Anthera Pharmaceuticals Completes Interim B-Cell Analysis Of PEARL-SC Study
2011-10-25,Anthera Announces Last Patient Enrolled In PEARL-SC Study
2011-09-08,Anthera Pharmaceuticals Announces Notice Of Allowance Of U.S. Patent Application Covering A-002 Plus Statin Compositions
2011-06-08,Anthera Pharmaceuticals Announces Completion Of Public Offering Of Common Stock
2011-06-03,Anthera Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2011-06-02,Anthera Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2011-04-18,Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis Of VISTA-16 Study And Third Safety Review Of Varespladib Methyl
2011-02-08,Anthera Pharmaceuticals Names Lawrence Rosania As Vice President Of Global Regulatory Affairs And Compliance
2011-02-01,Dr. Peter Thompson Joins Anthera Pharmaceuticals Board Of Directors
2010-12-14,Anthera Pharmaceuticals Selects The Merck BioManufacturing Network As Manufacturing Supplier For A-623, Anthera's Investigational Novel Peptibody Agent
2010-12-07,Varespladib Receives 2010 European Society Pediatric Research Award
2010-11-24,Anthera Pharmaceuticals To Present At The 22nd Annual Piper Jaffray Health Care Conference
2010-10-25,FirstWind IPO -- Gone With the Wind?
2010-10-05,Oracle CEO Sells $54.5M Worth
2010-09-21,Anthera Pharmaceuticals Announces Pricing Of $31.5 Million PIPE Financing
2010-07-29,Anthera Initiates Expanded And Extended PEARL-SC Phase 2b Clinical Study In Lupus With A-623 - A Subcutaneous Dual Inhibitor Of Membrane And Soluble B-Cell Activating Factor (BAFF Or BLyS)
2010-06-23,Anthera Enrolls First Patients In Pivotal Varespladib Phase 3 Clinical Study
2010-06-10,Anthera Pharmaceuticals Updates Its Lupus Scientific Advisory Board
2010-06-03,Anthera Pharmaceuticals Promotes Colin Hislop, M.D., To Chief Medical Officer
2010-05-03,Anthera Pharmaceuticals Announces Additional Data From FRANCIS Study
2010-04-26,Anthera Pharmaceuticals To Present At Deutsche Bank Securities' 35th Annual Health Care Conference
2010-04-06,Anthera Pharmaceuticals Announces Closing Of Underwriters' Exercise Of Over-Allotment Option In Connection With Its Initial Public Offering
2010-03-23,Anthera Pharmaceuticals Welcomes Georgina Kilfoil As Senior Vice President Of Product Development And Clinical Operations
2010-03-05,Merriman Curhan Ford Acted As Co-Manager In Anthera's Public Offering Of Common Stock
2010-03-04,Anthera Pharmaceuticals Completes Initial Public Offering
2017-03-13,Apricus Biosciences Provides Corporate Update, Fourth Quarter And Full Year 2016 Financial Results
2017-03-09,Apricus Biosciences Announces Corporate Update, Fourth Quarter And Full Year 2016 Financial Results Conference Call
2017-03-08,Apricus Biosciences Announces Sale Of Ex-U.S. Vitaros Assets And Rights To Ferring Pharmaceuticals
2017-02-09,Apricus Biosciences Receives Positive Nasdaq Listing Determination
2017-02-08,Apricus Biosciences To Present At The 19th Annual BIO CEO & Investor Conference
2017-01-18,Apricus Biosciences Announces Approval Of Vitaros® For The Treatment Of Erectile Dysfunction In Mexico
2017-01-03,Apricus Biosciences Promotes Mary Naggs To Vice President, General Counsel
2016-12-27,Apricus Biosciences Announces The Launch Of Vitaros® For The Treatment Of Erectile Dysfunction In Lebanon By Elis Pharmaceuticals
2016-12-01,Apricus Biosciences Receives Nasdaq Compliance Notice
2016-11-29,Apricus Biosciences To Present At The 9th Annual LD Micro Main Event
2016-11-18,Apricus Biosciences Provides Update On Vitaros NDA Following Receipt Of FDA Feedback
2016-11-08,Apricus Biosciences Provides Corporate Update And Third Quarter Financial Results
2016-11-02,Apricus Biosciences Announces Corporate Update And Third Quarter 2016 Financial Results Conference Call
2016-11-01,Drug Makers Stocks Under Scanner -- Pernix Therapeutics, Novo Nordisk, Synergy Pharma, And Apricus Biosciences
2016-10-26,Apricus Biosciences Announces Approval Of Vitaros® For The Treatment Of Erectile Dysfunction In Greece
2016-10-20,Apricus Biosciences Announces 1-for-10 Reverse Stock Split
2016-10-12,Apricus Biosciences To Present At The 2016 BIO Investor Forum
2016-09-28,Apricus Biosciences Closes $3.7 Million Registered Direct Offering
2016-09-23,Apricus Biosciences Announces $4.6 Million Registered Direct Offering
2016-09-21,Apricus Biosciences Announces The Launch Of Vitaros® In The Czech Republic And Slovakia By Recordati
2016-09-20,Apricus Biosciences Announces Completion Of Transfer Of The Marketing Authorizations For Vitaros® In Finland And Denmark To Ferring Pharmaceuticals
2016-09-08,Apricus Biosciences Announces Approval Of Vitaros® For The Treatment Of Erectile Dysfunction In Argentina
2016-09-07,Apricus Biosciences To Present At The Rodman & Renshaw 18th Annual Global Investment Conference
2016-09-06,Apricus Biosciences Announces The Launch Of Its Novel Topical Treatment For Erectile Dysfunction In Portugal, Ireland And Poland By Recordati
2016-08-15,Apricus Biosciences Announces Completion Of Transfer Of The United Kingdom Marketing Authorization For Vitaros® To Ferring Pharmaceuticals
2016-08-10,Apricus Biosciences Announces Completion Of Transfer Of Vitaros® German Marketing Authorization To Ferring Pharmaceuticals
2016-08-04,Apricus Biosciences Provides Corporate Update And Second Quarter Financial Results
2016-08-03,Apricus Biosciences To Present At The Canaccord Genuity 36th Annual Growth Conference
2016-08-01,Apricus Biosciences Announces Corporate Update And Second Quarter 2016 Financial Results Conference Call
2016-07-27,Apricus Biosciences Announces Approval Of Vitaros(R) For The Treatment Of Erectile Dysfunction In Lebanon
2016-07-25,Apricus Biosciences Further Expands Existing Vitaros® Partnership With Ferring Pharmaceuticals In Europe And Asia
2016-07-06,Apricus Biosciences Enters Into Common Stock Purchase Agreement With Aspire Capital
2016-05-09,Apricus Biosciences Provides Corporate Update And First Quarter Financial Results
2016-05-03,CORRECTING And REPLACING -- Apricus Biosciences To Host Live Webcast KOL Event On May 9th Addressing Vitaros® And Erectile Dysfunction Population
2016-05-03,Apricus Biosciences To Host Live Webcast KOL Event On May 9th Addressing Vitaros® And Erectile Dysfunction Population
2016-05-03,Apricus Biosciences To Announce Corporate Update And First Quarter 2016 Financial Results
2016-04-06,Apricus Biosciences Updates Strategic Corporate Objectives
2016-03-28,Apricus Reports Top-Line Phase 2b Data For Fispemifene In Symptomatic Secondary Hypogonadism
2016-03-09,Apricus Biosciences Provides Corporate Update, Fourth Quarter And Full Year 2015 Financial Results
2016-03-08,Apricus Biosciences To Present At The 28th Annual ROTH Conference
2016-03-04,Apricus Biosciences Closes $10 Million Registered Direct Offering
2016-03-02,Apricus Biosciences Announces Corporate Update, Fourth Quarter And Full Year 2015 Financial Results Conference Call
2016-03-01,Apricus Biosciences To Present At The Cowen And Company 36th Annual Health Care Conference
2016-02-02,Apricus Biosciences To Present At The 18th Annual BIO CEO & Investor Conference
2016-01-13,Apricus Biosciences Announces $10 Million Registered Direct Offering
2016-01-06,Apricus Biosciences Announces Year-End 2015 Update And 2016 Growth Strategy
2015-12-01,Apricus Biosciences Confirms Clinical Strategy For Its Novel Treatment For Symptomatic Secondary Hypogonadism Fispemifene
2015-11-17,Apricus Biosciences Named To Deloitte's 2015 Technology Fast 500(TM) List Of Fastest Growing Companies In North America
2015-11-12,Apricus Biosciences To Present At The Stifel 2015 Healthcare Conference
2015-11-05,Apricus Biosciences Provides Corporate Update And Third Quarter 2015 Financial Results
2015-11-02,Apricus Biosciences Announces Corporate Update And Third Quarter 2015 Financial Results Conference Call
2015-10-28,Apricus Biosciences Completes Enrollment In Phase 2b Clinical Trial For Fispemifene In Men With Symptomatic Secondary Hypogonadism
2015-10-01,Apricus Biosciences And Ferring Pharmaceuticals Sign Exclusive Distribution Agreement To Market Topical Erectile Dysfunction Cream Vitaros(TM) In Latin American Countries
2015-09-17,Apricus Reports Top-Line Phase 2a Data For RayVa(TM), Its Topical Treatment For Raynaud's Phenomenon
2015-09-10,Apricus Biosciences (ARPI) Stock Climbs Following Allergan License Agreement
2015-09-10,Apricus Biosciences Enters Into License Agreement With Allergan For The U.S. Rights To Vitaros(TM)
2015-09-02,Apricus Biosciences To Present At The Rodman & Renshaw 17th Annual Global Investment Conference
2015-09-01,Apricus Biosciences Announces The Launch Of Its Novel Topical Treatment For Erectile Dysfunction In Italy By Bracco SpA
2015-08-19,Apricus Biosciences Announces It Is Seeking A Global Partner For Femprox, A Novel Treatment For Female Sexual Dysfunction
2015-08-10,Apricus Biosciences Announces Approval Of Vitaros(R) For The Treatment Of Erectile Dysfunction In Twelve Additional Countries
2015-08-05,Apricus Biosciences Provides Corporate Update And Second Quarter 2015 Financial Results
2015-08-05,Apricus Biosciences To Present At The Canaccord Genuity 35th Annual Growth Conference
2015-07-30,Apricus Biosciences Announces Corporate Update And Second Quarter 2015 Financial Results Conference Call
2015-06-15,Apricus Biosciences Announces Last Patient Enrolled In RayVa(TM) Phase 2a Clinical Trial For Raynaud's Phenomenon In Patients With Scleroderma
2015-06-01,Apricus Biosciences Enrolls First Patients In Phase 2b Clinical Trial For Fispemifene In Men With Symptomatic Secondary Hypogonadism
2015-05-28,Apricus Biosciences Announces The Launch Of Its Novel Topical Treatment For Erectile Dysfunction In France By Laboratoires Majorelle
2015-05-11,Apricus Biosciences Provides Corporate Update And First Quarter 2015 Financial Results
2015-05-06,Apricus Biosciences Announces The Launch Of Its Novel Topical Treatment For Erectile Dysfunction In Spain By Recordati
2015-05-04,Apricus Biosciences Announces Corporate Update And First Quarter 2015 Financial Results Conference Call
2015-04-28,Apricus Biosciences To Present At Two Investor Conferences In May
2015-03-16,Apricus Biosciences Provides Corporate Update And 2014 Year-End Financial Results
2015-03-09,Apricus Biosciences Announces Corporate Update And Fourth Quarter And Year-End 2014 Financial Results Conference Call
2015-03-04,Apricus Biosciences To Present At The 27th Annual Roth Conference
2015-02-11,Apricus Biosciences Announces $11 Million Registered Direct Offering With Sarissa Capital Management LP
2015-02-03,Apricus Biosciences Expands Exclusive License Agreement With An Existing Partner To Market Vitaros(R) In Select Asia-Pacific Countries
2015-02-03,Apricus Biosciences To Present At The 17th Annual BIO CEO & Investor Conference
2015-01-29,3 Biotech Stocks Under $10 in Breakout Territory: TrovaGene and More
2015-01-27,Apricus Biosciences Announces Issuance Of U.S. Patent For RayVa(TM)
2015-01-12,Apricus Biosciences Announces The Appointment Of Catherine Bovenizer As Vice President Of Finance, Chief Accounting Officer
2015-01-06,Apricus Biosciences To Present At Biotech Showcase 2015
2014-12-22,Apricus Biosciences Announces Year-End 2014 Update And 2015 Plans To Advance Its Clinical Pipeline And Further Commercialize Its Erectile Dysfunction Drug Vitaros(R)
2014-12-15,Apricus Biosciences Appoints Barbara Troupin, M.D. As Chief Medical Officer
2014-12-04,Apricus Biosciences Announces First Patient Enrolled In Phase 2a Clinical Trial For RayVa(TM) In Patients With Raynaud's Phenomenon
2014-12-02,Apricus Biosciences Appoints Brian T. Dorsey As Chief Development Officer
2014-11-10,Apricus Biosciences Announces Third Quarter 2014 Financial Results And Provides Corporate Update
2014-11-05,Apricus Biosciences To Present At Three Upcoming Investor Conferences In November And December Of 2014
2014-11-04,Apricus Biosciences Announces Corporate Update And Third Quarter 2014 Financial Results Conference Call
2014-11-03,Apricus Biosciences Announces The Launch Of Its Novel Topical Treatment For Erectile Dysfunction In Belgium By Sandoz
2014-10-20,Apricus Expands Development Pipeline With The In-Licensing Of U.S. Rights For Fispemifene, A Phase 2b Ready Asset, From Forendo Pharma Targeting Urological Conditions In Men
2014-10-13,Apricus Biosciences Announces Notice Of Allowance Of U.S. Patent Application For RayVa(TM)
2014-10-01,Apricus Biosciences To Present At The 13th Annual BIO Investor Forum
2014-09-03,Apricus Biosciences To Present At The Rodman & Renshaw 16th Annual Global Investment Conference
2014-08-18,Apricus Biosciences Announces The Launch Of Its Topical Treatment For Erectile Dysfunction Vitaros(R) In Germany By Hexal
2014-08-12,Apricus Biosciences Enters Into Common Stock Purchase Agreement With Aspire Capital
2014-08-12,Apricus Biosciences Provides Corporate Update And Second Quarter 2014 Financial Results
2014-08-11,Apricus Biosciences Announces Appointment Of Sandford D. Smith To Board Of Directors
2014-08-08,Apricus Biosciences Announces Multi-Year Partnership With The Scleroderma Research Foundation
2014-08-06,Apricus Biosciences To Present At The Canaccord Genuity 34th Annual Growth Conference
2014-08-04,Apricus Biosciences Announces Corporate Update And Second Quarter 2014 Financial Results Conference Call
2014-08-04,Apricus Biosciences Announces The Launch Of Its Topical Treatment For Erectile Dysfunction Vitaros(R) In Sweden By Sandoz
2014-06-16,Apricus Biosciences Announces The Launch Of Its Topical Treatment For Erectile Dysfunction Vitaros(R) In The United Kingdom
2014-05-12,Apricus Biosciences Receives FDA Clearance To Begin Clinical Trial Of RayVa(TM) For Secondary Raynaud's Phenomenon
2014-05-12,Apricus Biosciences Provides Corporate Update And First Quarter 2014 Financial Results
2014-04-28,Apricus Biosciences Announces Corporate Update And First Quarter 2014 Financial Results Conference Call
2014-04-24,Apricus Biosciences Announces National Phase Approval For Vitaros(R) In Spain
2014-04-16,Apricus Biosciences' Partner In The United Kingdom Accepts First Shipment Of Vitaros(R)
2014-04-07,Apricus Biosciences And Its European Partners To Sponsor Symposium On Vitaros(R) At The European Association Of Urology (EAU) Congress, Stockholm
2014-04-03,Apricus Biosciences Announces National Phase Approval For Vitaros(R) In Luxembourg
2014-03-20,Apricus Biosciences Expands Senior Management Team, Appointing Neil C. Morton As Vice President, Business Development
2014-03-17,Apricus Biosciences Provides Corporate Update And 2013 Year-End Financial Results
2014-03-10,Apricus Biosciences Announces Appointment Of Wendell Wierenga, Ph.D., To Board Of Directors
2014-03-10,Apricus Biosciences Announces Corporate Update And 2013 Year-End Financial Results Conference Call
2014-03-04,Apricus Biosciences To Present At The 26th Annual ROTH Conference
2014-02-10,Apricus And Recordati Sign Exclusive License Agreement To Market Topical Erectile Dysfunction Cream - Vitaros(R) In Spain, Russia, Turkey And Other Global Territories
2014-02-04,Apricus Biosciences To Present At The 16th Annual BIO CEO & Investor Conference
2014-01-23,Apricus Biosciences Announces National Phase Approval For Erectile Dysfunction Cream - Vitaros(R) In Belgium
2013-12-27,Interesting APRI Put And Call Options For August 2014
2013-12-19,Apricus Announces National Phase Approval For Erectile Dysfunction Cream - Vitaros(R) In France
2013-12-16,Apricus Expands Exclusive License Agreement With Its Partner In Germany To Market Vitaros(R) In Additional European Countries
2013-12-11,Apricus Elects Kleanthis G. Xanthopoulos, Ph.D. As New Chairman
2013-11-27,4 Stocks Under $10 in Breakout Territory
2013-11-25,Apricus Biosciences Announces National Phase Approval For Erectile Dysfunction Cream - Vitaros(R) In Italy
2013-11-13,Apricus Biosciences Provides Third Quarter 2013 Corporate Update
2013-11-13,Apricus And Laboratoires Majorelle Sign Exclusive License Agreement To Market Topical Erectile Dysfunction Cream Vitaros(R) In France, Monaco And Certain African Countries
2013-11-05,Apricus Biosciences Announces Third Quarter 2013 Corporate Update Conference Call
2013-10-07,Apricus Biosciences Announces National Phase Approval For Erectile Dysfunction Cream - Vitaros(R) In Germany
2013-09-09,Apricus Biosciences Updates Presentation Time At The 2013 Stifel Nicolaus Healthcare Conference
2013-09-04,Apricus Biosciences To Present At The 2013 Stifel Nicolaus Healthcare Conference
2013-08-29,Apricus Biosciences Provides Vitaros(R) Swissmedic Update
2013-08-15,Apricus Biosciences Receives National Phase Approvals For Vitaros(R) In Ireland And The Netherlands
2013-08-12,Apricus Biosciences Reports Corporate Update
2013-08-09,Apricus Biosciences Announces Corporate Update Conference Call
2013-07-05,Biotech Stock Mailbag: Apricus, Avanir
2013-06-21,Apricus Biosciences Presents Vitaros(R) Poster At The International Symposium On Prostate, Androgens And Men's Sexual Health
2013-06-10,Apricus Biosciences Receives European Approval For Vitaros(R) For The Treatment Of Erectile Dysfunction
2013-05-23,Apricus Biosciences Prices $17.1 Million Public Offering Of Common Stock And Warrants
2013-05-22,Apricus Biosciences Announces Proposed Public Offering Of Common Stock And Warrants
2013-05-10,Apricus Biosciences Provides First Quarter 2013 Corporate Update
2013-05-07,Apricus Biosciences Announces First Quarter 2013 Financial Results Conference Call
2013-05-07,Apricus Biosciences Announces Poster Presentation Of Vitaros(R) Data In Men Previously Unresponsive To PDE-5 Inhibitors At American Urological Association Annual Meeting
2013-04-18,Apricus Biosciences To Present At 2013 BIO International Convention
2013-04-01,Apricus Biosciences Announces Sale Of Non-Core Assets
2013-03-18,Apricus Biosciences Provides Corporate Update; Files Annual Report For Quarter And Year Ended December 31, 2012
2013-03-18,Apricus Biosciences Appoints Richard W. Pascoe As Chief Executive Officer
2013-03-14,Apricus Biosciences Announces 2012 Year End Financial Results Conference Call
2013-03-14,Apricus Biosciences Announces Ceasing Of Financing Of French Subsidiaries
2013-03-13,Apricus Biosciences To Present At The 25th Annual ROTH Conference
2013-03-07,Apricus Biosciences To Present At BIO-Europe Spring 2013
2013-02-06,Apricus Biosciences To Present At The 15th Annual BIO CEO & Investor Conference
2013-02-01,5 Stocks Poised for Breakouts
2013-01-03,Apricus Biosciences Announces Corporate Goals For 2013
2012-10-18,Apricus Biosciences Receives $2.5 Million Payment From Abbott Laboratories For Vitaros(R) In Canada
2012-10-01,Apricus Biosciences Announces Intent To File NDS For MycoVa(TM) In Canada
2012-09-25,Apricus Biosciences CEO To Present At Sachs Annual Biotech In Europe Investor Forum
2012-09-17,Apricus Biosciences Announces Publication In Journal Of Pharmaceutics And Drug Delivery Research
2012-09-13,Apricus Biosciences' Wholly-Owned Subsidiary NexMed (U.S.A.) And Takeda Pharmaceuticals International GmbH Sign Exclusive License Agreement To Market Vitaros(R) In The United Kingdom
2012-08-22,Apricus Biosciences' CEO To Present At The Stifel Nicolaus 2012 Healthcare Conference
2012-08-20,Apricus Biosciences Announces Podium Presentation Of Vitaros(R) Clinical Data At 2012 World Meeting On Sexual Medicine
2012-08-16,Apricus Biosciences Announces Podium Presentation Of Femprox(R) Phase III Clinical Data At 2012 World Meeting On Sexual Medicine
2012-08-11,Apricus Biosciences' CEO Discusses Q2 2012 Results - Earnings Call Transcript
2012-03-14,Apricus Biosciences, Inc. (APRI) Transforms From Development Company To Income Generating!
2012-02-09,Apricus Stock Gaps Down On Today's Open (APRI)
2012-01-02,Apricus Misses Promised Drug Launch Target
2011-12-09,The Worst Biotech CEO of 2011 Is ...
2011-09-23,Biotech Stock Mailbag: Medivation, Targacept
2011-09-16,Biotech Stock Mailbag: Vivus
2011-08-08,Apricus Biosciences To File For Market Authorization To Sell Vitaros® For Erectile Dysfunction In Latin America
2011-07-01,Biotech Stock Mailbag: Ranking Cheap Biotechs
2011-06-29,Biotech Data Mining Comes Up Empty
2011-03-24,Apricus Biosciences Adopts Shareholder Rights Plan
2011-03-22,Apricus Biosciences Announces Poster Presentations On Progress Of PrevOnco(TM) In Combination With NexACT(R) Technology At The American Association For Cancer Research 2011 Annual Meeting
2011-03-18,Biotech Stock Mailbag: Star Scientific
2011-03-15,Apricus Biosciences Announces Formation Of Clinical Advisory Board As Part Of Its Plans To Further The Clinical Development Of Femprox(R)
2011-03-11,Biotech Stock Mailbag: Cadence Pharma
2011-03-10,Apricus Biosciences To Present At The Bio-Europe Spring 2011 Conference
2011-03-09,Apricus Biosciences Announces 2010 Year End Financial Results Conference Call
2011-03-08,Apricus Biosciences Announces Removal Of Auditor's "Going Concern" Opinion From Its 2010 Form 10-K And Increased Cash Reserves
2011-03-01,Apricus Biosciences Announces Expanded European Patent Coverage For MycoVa(TM) For Nail Fungus
2011-02-17,Apricus Biosciences And FDA Initiate PrevOnco(TM) SPA Phase III Clinical Protocol Discussion
2011-02-14,Apricus Biosciences And Neopharm Group Sign Licensing Agreement For Vitaros(R) In Israel For Up To $4.35 Million, Plus Royalties
2017-02-09,Aradigm To Present At The Biotechnology Industry Organization (BIO) CEO & Investor Conference 2017 On February 13
2017-01-06,Aradigm To Present At 9th Annual Biotech Showcase Conference On January 9
2016-12-01,Dow Trades Above Record Close Despite Pull From Tech Selloff
2016-12-01,Bank Stocks Boost Dow, Crude Rallies for Day Two
2016-12-01,Aradigm Announces Top-Line Results From Two Phase 3 Studies Evaluating Pulmaquin For The Chronic Treatment Of Non-Cystic Fibrosis Bronchiectasis Patients With Lung Infections With Pseudomonas Aeruginosa
2016-11-10,Aradigm To Present At The Stifel 2016 Healthcare Conference On November 16
2016-11-09,Aradigm Announces Third Quarter 2016 Financial Results
2016-10-18,Multi-million Dollar DTRA Funding For Biodefense Research With Aradigm's Inhaled Ciprofloxacin
2016-10-07,Aradigm Announces Australian Research Council Funding To Develop Nanotechnologies Targeting Bacterial And Fungal Biofilms
2016-09-22,Aradigm Announces Last Patient Dosing Visit In ORBIT-3 And ORBIT-4 Phase 3 Studies Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis Patients
2016-09-21,Aradigm To Host Analyst Meeting And Webcast On September 26 In New York City
2016-09-20,Aradigm To Present At The Ladenburg Thalmann 2016 Healthcare Conference On September 27
2016-08-10,Aradigm Announces Second Quarter 2016 Financial Results
2016-05-11,Two Presentations On Aradigm's Inhaled Liposomal Ciprofloxacin Programs At The American Thoracic Society 2016 International Conference
2016-05-10,Aradigm Announces First Quarter 2016 Financial Results
2016-04-26,Aradigm Corporation Announces First Closing Of Private Placement Offering Of $23 Million Senior Convertible Notes Due 2021
2016-04-22,Aradigm Corporation Prices Private Placement Of Senior Notes
2016-03-17,Aradigm Announces Decision For Centralized Review Of Pulmaquin By The European Medicines Agency
2016-03-15,Aradigm Announces Fourth Quarter 2015 And Full Year Financial Results
2016-02-02,Aradigm To Present At The Biotechnology Industry Organization (BIO) CEO & Investor Conference 2016 On February 8
2016-01-05,Aradigm To Host Corporate Update Conference Call On January 6
2015-11-11,Aradigm Announces Third Quarter 2015 Financial Results
2015-10-13,Aradigm Corporation Completes Enrollment In The Second Phase III Study Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis (ORBIT-3)
2015-09-23,Aradigm To Present At The Ladenburg Thalmann 2015 Healthcare Conference On September 29
2015-09-22,Aradigm Corporation Completes Enrollment In Phase III Study Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis (ORBIT-4)
2015-09-10,Results From Pulmonary Non-Tuberculous Mycobacteria (PNTM) Study Using Aradigm's Liposomal Ciprofloxacin To Be Presented At ICAAC/ICC 2015
2015-08-20,3 Stocks Pushing The Drugs Industry Lower
2015-08-13,Aradigm Announces Second Quarter 2015 Financial Results
2015-08-12,3 Stocks Pushing The Drugs Industry Lower
2015-08-12,3 Stocks Pushing The Health Care Sector Lower
2015-08-06,3 Stocks Pushing The Health Care Sector Lower
2015-08-06,3 Stocks Pushing The Drugs Industry Lower
2015-06-08,Ratings Changes Today
2015-05-14,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Breaches Of Fiduciary Duty By The Board Of ARADIGM CORPORATION
2015-05-12,Results From Pulmonary Non-Tuberculous Mycobacteria (PNTM) Study Using Aradigm's Liposomal Ciprofloxacin To Be Presented At The American Thoracic Society 2015 International Conference
2015-05-11,Aradigm Announces First Quarter 2015 Financial Results
2015-04-21,Aradigm Announces Appointment Of Dr. Robert A. Reed As Vice President, Regulatory (Chemistry, Manufacturing And Controls) And Quality
2015-04-16,Aradigm To Host Key Opinion Leader Breakfast And Webcast On April 23 In New York City
2015-03-20,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Breaches Of Fiduciary Duty By The Board Of Aradigm Corporation -- ARDM
2015-03-17,Aradigm Announces Fourth Quarter 2014 And Full Year Financial Results
2015-02-04,Aradigm To Present At The Biotechnology Industry Organization (BIO) CEO & Investor Conference 2015 On February 10
2015-01-20,Aradigm (ARDM) Upgraded From Sell to Hold
2015-01-16,Ratings Changes Today
2015-01-14,Aradigm Granted Key Composition Of Matter Patents For Pulmaquin In Europe And Australia
2015-01-08,Aradigm To Present At Biotech Showcase 2015 On January 14
2014-11-12,Aradigm To Present At The Stifel Healthcare Conference 2014
2014-11-07,Aradigm Announces Third Quarter 2014 Financial Results
2014-10-31,Aradigm (ARDM) Downgraded From Hold to Sell
2014-10-30,Ratings Changes Today
2014-09-22,Aradigm (ARDM) Upgraded From Sell to Hold
2014-09-19,Ratings Changes Today
2014-09-04,FDA Grants Fast Track Designation To Aradigm’s Pulmaquin For Non-Cystic Fibrosis Bronchiectasis
2014-08-20,3 Drugs Stocks Pushing The Industry Higher
2014-08-14,3 Drugs Stocks Pushing The Industry Higher
2014-08-07,Aradigm Announces Second Quarter 2014 Financial Results
2014-08-06,Aradigm To Host Analyst Meeting And Webcast On August 12 In New York City
2014-06-25,Aradigm To Host Corporate Update Conference Call On June 26
2014-06-23,Aradigm Corporation Announces The Dosing Of The First Patient In Phase III Study Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis (ORBIT-4)
2014-06-03,Aradigm Receives $5 Million Milestone For Dosing Of The First Patient In Phase III Study Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis
2014-05-20,FDA Grants QIDP Designation To Aradigm&#8217;s Inhaled Antibiotic
2014-05-14,Aradigm Announces First Quarter 2014 Financial Results
2014-04-30,Aradigm Corporation Announces The Dosing Of The First Patient In Phase III Study Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis (ORBIT-3)
2014-04-15,Results From Non-Tuberculous Mycobacteria (NTM) Study Using Aradigm&#8217;s Liposomal Ciprofloxacin To Be Presented At The American Thoracic Society 2014 International Conference
2014-03-13,Aradigm Announces Fourth Quarter 2013 And Full Year Financial Results
2014-02-04,Aradigm To Present At The Biotechnology Industry Organization (BIO) CEO &amp; Investor Conference 2014 On February 11
2014-01-08,Aradigm To Present At Biotech Showcase 2014 On January 14
2013-11-19,Aradigm Announces Appointment Of Dr. Juergen Froehlich As Chief Medical Officer
2013-10-28,Aradigm Announces Third Quarter 2013 Financial Results
2013-09-18,Aradigm Announces Changes To Its Board Of Directors
2013-09-16,Sigma-Tau PharmaSource, Inc. And Aradigm Corporation Sign Manufacturing Agreement For The Clinical And Commercial Supply Of Pulmaquin
2013-09-09,Aradigm To Present At The Stifel Nicolaus 2013 Healthcare Conference
2013-08-28,Grifols And Aradigm Corporation Complete The Closing Of Worldwide Licensing Agreement To Develop And Commercialize Pulmaquin&#174;
2013-08-08,Aradigm Announces Second Quarter 2013 Financial Results
2013-08-07,Aradigm Awarded NIH Grant To Investigate New Methods Of Diagnoses Of Aspirations Of Gastrointestinal Contents Into The Respiratory Tract With Scientists At UC San Francisco
2013-08-01,Aradigm Awarded NIH Grant To Investigate The Treatment Of Pulmonary Non-Tuberculous Mycobacterial (PNTM) Infections With Pulmaquin And Lipoquin
2013-07-16,Aradigm Shareholders Approve Collaboration Transaction With Grifols, S.A. To Develop And Commercialize Pulmaquin
2013-03-26,Aradigm Announces Fourth Quarter 2012 And Full Year Financial Results
2013-02-06,Aradigm To Present At The Biotechnology Industry Organization (BIO) CEO &amp; Investor Conference 2013 On February 12
2013-01-03,Aradigm To Present At Biotech Showcase 2013 On January 9
2012-11-19,UK Scientists Report On Efficacy Of Aradigm&#8217;s Lipoquin&#8482; Against Pneumonic Plague
2012-11-08,Aradigm Announces Third Quarter 2012 Financial Results
2012-10-16,Virginia Commonwealth University Scientists Report Anti-Inflammatory Effect Of Aradigm&#8217;s Inhaled Liposomal Ciprofloxacin
2012-09-20,UK Scientists Report Successful Testing Of Aradigm&#8217;s Inhaled Liposomal Ciprofloxacin In Q Fever
2012-09-18,New U.S. Composition Of Matter Patent For Aradigm&#8217;s Pulmaquin&#8482; And Lipoquin&#8482; Provides Protection Until 2031
2012-09-05,Aradigm Patent Protection For Smoking Cessation Is Extended With Issuance Of A Method Of Treatment Patent
2012-08-30,Aradigm To Participate In FDA Workshop On Non-Cystic Fibrosis Bronchiectasis
2012-08-29,Aradigm To Present At The Stifel Nicolaus 2012 Healthcare Conference
2012-08-09,Aradigm Announces Second Quarter 2012 Financial Results
2012-03-27,Aradigm Announces Fourth Quarter 2011 And Full Year Financial Results
2012-03-12,Aradigm Receives U.S. FDA Clearance For Phase 3 Clinical Trial Of Pulmaquin&#8482; In Patients With Non-Cystic Fibrosis Bronchiectasis
2012-02-21,US Patent Protection For Pulmaquin&#8482; Is Extended With Issuance Of A Composition Of Matter Patent
2012-02-08,Aradigm To Present At The Biotechnology Industry Organization (BIO) CEO &amp; Investor Conference 2012 On February 13
2012-01-05,Aradigm To Present At Biotech Showcase 2012 On January 9
2011-12-07,Aradigm Selects Pulmaquin&#8482; For Phase 3 Development And Announces Issuance Of Its First U.S. Patent Covering Inhaled Ciprofloxacin Formulations
2011-11-10,Aradigm Announces Third Quarter 2011 Financial Results
2011-10-20,Aradigm To Present At The 10th Annual BIO Investor Forum On October 26
2011-09-21,Aradigm Presents Additional Analyses Of The Clinical Results From ORBIT-1 And ORBIT-2 Trials Of Inhaled Ciprofloxacin At The 2011 European Respiratory Society (ERS) Annual Congress
2011-09-07,Aradigm To Present At Rodman &amp; Renshaw Annual Global Investment Conference
2011-08-09,Aradigm Announces Second Quarter 2011 Financial Results
2011-07-06,Aradigm Announces Private Placement For $4.75 Million
2011-06-22,Aradigm Enters $8.5 Million Royalty Financing Agreement With PBS Capital Management LLC
2011-06-16,Aradigm Reports Successful ORBIT-1 Bronchiectasis Study With Inhaled Liposomal Ciprofloxacin
2011-06-06,Aradigm Receives FDA Orphan Drug Designation For Ciprofloxacin For Inhalation In Bronchiectasis
2011-05-12,Aradigm Announces First Quarter 2011 Financial Results
2011-05-03,Aradigm To Present Additional ORBIT-2 Clinical Trial Results At Respiratory Drug Delivery Europe 2011 Conference
2011-03-24,Aradigm Announces Fourth Quarter 2010 And Full Year Financial Results
2011-03-22,Aradigm Completes Enrollment In Phase 2b Study Of Inhaled Ciprofloxacin For The Management Of Respiratory Infections In Bronchiectasis
2011-03-10,Aradigm To Present At ROTH Capital Partners 23rd Annual OC Growth Stock Conference
2011-02-10,Aradigm To Present At The 13th Annual Biotechnology Industry Organization (BIO) CEO &amp; Investor Conference
2011-01-11,SUMAVEL DosePro Receives Marketing Approval In Germany And The United Kingdom
2011-01-06,Aradigm To Report Expanded Results From Successful Six-Month Phase 2b Bronchiectasis Study At Biotech Showcase 2011
2010-12-07,SUMAVEL DosePro Is Granted First European Approval
2010-11-11,Aradigm Announces Third Quarter 2010 Financial Results
2010-11-04,Aradigm Appoints Tamar Howson To Board Of Directors
2010-11-02,Aradigm Awarded Three Therapeutic Discovery Tax Credit Grants Totaling Over $733,000 For Inhaled Liposomal Ciprofloxacin Program
2010-10-20,Aradigm Reports Successful Phase 2b Bronchiectasis Study With Inhaled Liposomal Ciprofloxacin
2010-10-04,Aradigm To Present At The 9th Annual BIO Investor Forum On October 6
2010-09-30,Aradigm CEO Igor Gonda To Be Featured Guest Interview On StockGoodies.com Radio On September 30
2010-09-20,Aradigm Closes Equity For Debt Transaction With Novo Nordisk A/S
2010-09-17,Aradigm Presents Results Supporting Once-Daily Dosing With Its Inhaled Liposomal Ciprofloxacin Formulations At The 2010 European Respiratory Society (ERS) Annual Congress
2010-08-12,Aradigm Announces Second Quarter 2010 Financial Results
2010-08-02,Aradigm Announces Equity For Debt Transaction With Novo Nordisk
2010-06-21,Aradigm Announces Private Placement For $5 Million
2010-05-17,Aradigm Presents At The 2010 International Conference Of The American Thoracic Society
2010-05-13,Aradigm Announces First Quarter 2010 Financial Results
2010-05-05,Aradigm Receives FDA Clearance For Clinical Trial Of Inhaled Liposomal Ciprofloxacin In Pediatric Patients With Cystic Fibrosis
2010-03-25,Aradigm Completes Enrollment And Doses Last Patient In Long Term Phase 2 Study Of A Novel Inhaled Ciprofloxacin Formulation For The Management Of Respiratory Infections In Bronchiectasis
2010-02-23,Aradigm Doses First Patient In Its Second Phase 2b Clinical Trial Of Inhaled Liposomal Ciprofloxacin In Bronchiectasis Patients
2010-02-04,Aradigm Receives $4 Million Milestone Payment Upon First Commercial Sale Of SUMAVEL* DosePro*
2005-07-15,MannKind's Work Is Never Done
2005-06-10,Exubera-nce in the Insulin Market
2004-12-14,Pressure Builds in PIPEs
2004-09-29,Health Stocks in Motion
2001-07-17,Drug Delay Has Inhale Gasping and a Rival Catching Up
,
2017-02-27,Ardelyx Announces Presentation At Cowen And Company 37th Annual Healthcare Conference
2017-02-15,Biotech Premarket Movers: Ardelyx, Acorda Therapeutics, Medicines Co.
2017-02-15,Ardelyx Announces Successful Phase 3 Trial Of Tenapanor For Hyperphosphatemia In Patients With End-Stage Renal Disease
2017-01-03,Ardelyx Announces Initiation Of Two Clinical Trials For RDX7675 For Treatment Of Hyperkalemia
2017-01-03,Ardelyx Announces Presentation At J.P. Morgan 35th Annual Healthcare Conference
2016-10-31,Ardelyx To Announce Third Quarter 2016 Financial Results On November 7, 2016
2016-10-24,Ardelyx Strengthens Executive Leadership With The Appointment Of Reginald Seeto, MBBS, As Chief Operating Officer
2016-10-19,Ardelyx Announces The Presentation Of Positive Global Endpoint Findings From Phase 2b Trial Of Tenapanor In Patients With IBS-C At ACG Annual Meeting
2016-09-22,Ardelyx To Present At Ladenburg Thalmann 2016 Healthcare Conference
2016-08-15,Ardelyx To Present At Wedbush PacGrow Healthcare Conference
2016-08-01,Ardelyx To Report Second Quarter 2016 Financial Results On August 8th, 2016
2016-08-01,Ardelyx Receives Notice Of Allowance Of Composition Of Matter Patent Covering Its Novel Potassium Binder RDX227675
2016-07-21,Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal
2016-07-21,Investors Scour Big Pharma M&amp;A Scene for Next Big Takeover
2016-07-15,Robbins Arroyo LLP: Acquisition Of Ardelyx, Inc. (ARDX) By Multiple Acquirers (Private) May Not Be In Shareholders' Best Interests
2016-07-15,Ardelyx To Raise $110 Million In A Private Placement
2016-06-22,Ardelyx Reports Progress Of Development Programs
2016-06-07,Ardelyx Appoints Robert Bazemore To Its Board Of Directors
2016-06-03,Ardelyx Has Big Potential
2016-06-03,Ardelyx To Present At 2016 BIO International Convention
2016-05-12,Profiting on Small-Cap Biotech Earnings
2016-05-02,Ardelyx To Report First Quarter 2016 Financial Results On May 9, 2016
2016-04-13,Ardelyx Stock Sees Short Interest Move 20% Lower
2016-04-01,These 5 Biotech Stocks Under $10 Are About to Break Out
2016-03-30,7 Stocks Under $10 to Trade for Breakout Gains
2016-03-17,Oversold Conditions For Ardelyx (ARDX)
2016-02-25,Ardelyx To Report Fourth Quarter And Full Year 2015 Financial Results On March 4th, 2016
2016-02-22,Jim Cramer's 'Mad Money' Recap: This Week's Game Plan
2016-02-02,Ardelyx To Present At The 2016 Leerink Partners Global Healthcare Conference
2016-02-02,Ardelyx Becomes Oversold (ARDX)
2016-01-15,5 Stocks to Trade for Breakout Gains
2016-01-13,Ardelyx Announces Closing Of Public Offering Including Exercise Of Underwriters' Right To Purchase Additional Shares
2016-01-07,Ardelyx Announces Pricing Of Public Offering Of Common Stock
2016-01-07,Ardelyx is Now Oversold (ARDX)
2016-01-06,Ardelyx Announces Proposed Public Offering Of Common Stock
2016-01-05,Ardelyx Reports Positive Clinical Results Of RDX022 For The Treatment Of Hyperkalemia
2016-01-04,Ardelyx Strengthens Executive Leadership Team With The Appointment Of Paul Korner, MD, MBA, As Executive Vice President And Chief Medical Officer
2015-11-18,Ratings Changes Today
2015-10-29,Ardelyx To Report Third Quarter 2015 Financial Results On November 12, 2015
2015-10-26,Ardelyx Appoints William Bertrand, Jr. To Its Board Of Directors
2015-10-08,Ardelyx To Present Phase 2 Data For Tenapanor In IBS-C Patients At The 2015 American College Of Gastroenterology Annual Meeting
2015-09-04,Insider Trading Alert - ARDX, CARA And ALXN Traded By Insiders
2015-09-01,Ardelyx Regains NaP2b Program From Sanofi
2015-08-13,Ratings Changes Today
2015-08-05,Ardelyx To Report Second Quarter 2015 Financial Results On August 12, 2015
2015-08-05,Ardelyx To Present At The 2015 Wedbush PacGrow Healthcare Conference
2015-07-14,Ardelyx To Provide Updates On Research And Development Programs At Today's Inaugural R&D Day In New York City
2015-06-30,Ardelyx To Host Inaugural R&D Investor Day In New York City On July 14, 2015
2015-06-16,Ardelyx To Present At The 2015 JMP Securities Life Sciences Conference
2015-06-03,Market News: Ardelyx, Ocean Rig UDW, Vera Bradley
2015-06-03,Ardelyx To Raise $77.8 Million In A Private Placement And Announces New Product Candidate For The Treatment Of Hyperkalemia To Begin Clinical Development In Mid-2015
2015-06-03,Ardelyx Regains Worldwide Development And Commercialization Rights For Its Late-Stage Development Candidate, Tenapanor, And Related Portfolio Of NHE3 Compounds
2015-05-05,Ardelyx Reports Results From Phase 2a Clinical Trial Evaluating Tenapanor In Chronic Kidney Disease Patients With Type 2 Diabetes Mellitus And Albuminuria
2015-04-24,Oversold Conditions For Ardelyx (ARDX)
2015-04-20,Ardelyx Appoints Dr. Annalisa Jenkins To Its Board Of Directors
2015-04-02,Oversold Conditions For Ardelyx (ARDX)
2015-03-13,Ardelyx To Present At The 22nd Annual Future Leaders In The Biotech Industry Conference
2015-03-11,Ardelyx Becomes Oversold (ARDX)
2015-02-18,Ardelyx To Report Fourth Quarter And Full Year 2014 Financial Results On February 25th, 2015
2015-02-09,Ardelyx To Present At The 2015 Leerink Global Healthcare Conference
2015-02-03,Ardelyx Becomes Oversold (ARDX)
2015-02-02,Ardelyx Reports Results From Phase 2b Clinical Trial Evaluating Tenapanor In Treating Hyperphosphatemia In Chronic Kidney Disease Patients On Hemodialysis
2015-01-22,4 Stocks Breaking Out on Big Volume: eBay, Dollar Tree and More
2014-12-01,Ardelyx Appoints Jeremy S. Caldwell, Ph.D., As Executive Vice President And Chief Scientific Officer
2014-11-17,Ardelyx's Tenapanor Reduces Phosphorus Absorption And Protects Against Vascular Calcification In Preclinical In Vivo Model Of Chronic Kidney Disease
2014-10-30,Ardelyx To Report Third Quarter 2014 Financial Results On November 6, 2014
2014-10-23,Ardelyx's Tenapanor Selected For Oral And Poster Presentations At The American Society Of Nephrology's Kidney Week 2014
2014-10-01,Ardelyx Reports Positive Results From Its Phase 2b Clinical Trial Evaluating Tenapanor In IBS-C Patients
2014-09-05,Ardelyx Chief Scientific Officer, Dominique Charmot, Announces Retirement From The Company At Year-End
2014-08-05,Ardelyx To Present At The Wedbush 2014 Life Sciences Management Access Conference
,
,
,
2017-03-24,Lifshitz & Miller LLP Announces Investigation Of Argos Therapeutics, Inc., Avid Technology, Inc., HMS Holdings Corp., Invuity, Inc., SITO Mobile, Ltd., Trevena, Inc., USANA Health Sciences, Inc. And VAALCO Energy, Inc.
2017-02-27,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving The Board Of Argos Therapeutics, Inc. -- ARGS
2017-02-22,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving The Board Of Argos Therapeutics, Inc.
2017-02-22,S&P 500 Trades Lower as Fed Signals Move on Rates 'Fairly Soon'
2017-02-22,Dow Turns Positive in Wishy-Washy Trading Ahead of Fed Minutes
2017-02-22,Argos Therapeutics Tanks on Committee Suggestion to Stop Carcinoma Drug Study
2017-02-22,Stock Futures Waver as Wall Street Awaits Clarity From the Fed
2017-02-22,Argos Plummets 72%, Leads Biotech Movers
2017-02-22,Independent Data Monitoring Committee Recommends Discontinuation Of The ADAPT Phase 3 Clinical Trial Of Rocapuldencel-T In Metastatic Renal Cell Carcinoma For Futility Following Its Planned Interim Data Review
2017-02-13,Argos Therapeutics To Participate In 2017 Genitourinary Cancers Symposium
2017-02-10,Argos Therapeutics Stock Sees Short Interest Make 10.3% Move
2017-02-06,Argos Therapeutics To Participate In BIO CEO And Investor Conference
2017-02-02,Notable Thursday Option Activity: ARGS, CGI, MNKD
2017-01-19,Argos Therapeutics Completes Lease Agreement For Commercial Manufacturing Space On The Centennial Campus Of North Carolina State University
2016-12-14,Argos Therapeutics Enters Into Strategic Research Agreement With Personalis, Inc.
2016-12-13,Argos Therapeutics Appoints Dr. Ralph Snyderman And Irackly Mtibelishvily To The Company's Board Of Directors
2016-12-07,Argos Therapeutics Reports Highlights From Investor Day In New York City
2016-12-01,Argos Therapeutics Opens Registration For Upcoming Investor Day
2016-11-18,Cellthera Presents Preclinical Data At SITC Using Argos' Individualized Immunotherapy
2016-11-14,Argos Therapeutics Participating In Strategies For An HIV Cure 2016 Meeting
2016-11-14,Argos Therapeutics Reports Third Quarter 2016 Financial Results And Recent Operational Highlights
2016-11-11,Argos Therapeutics To Participate In Upcoming Investor Conferences
2016-11-10,Argos Therapeutics To Participate In SITC 2016 Annual Meeting
2016-11-07,Argos Therapeutics To Host Third Quarter 2016 Financial Results Conference Call On Monday, November 14, 2016
2016-11-03,Argos Therapeutics Announces Publication Of A Case Report On Long-term Survival Of Kidney Cancer Patients Treated With AGS-003 Individualized Immunotherapy Featured In The Kidney Cancer Journal
2016-11-02,Argos Therapeutics Participating In 4th International MRNA Health Conference
2016-10-26,Argos Therapeutics Announces CEO Jeff Abbey Elected To NCBIO Board Of Directors
2016-10-19,Argos Therapeutics To Host Investor Day On Wednesday, December 7, 2016
2016-10-14,Argos Therapeutics To Participate In 2016 BIO Investor Forum
2016-10-04,Is This Octoberfest? No, It's Chopfest
2016-10-03,Argos Therapeutics To Participate In 2016 Cell & Gene Meeting On The Mesa
2016-09-27,Short Interest In Argos Therapeutics Jumps 24.8%
2016-09-01,Argos Therapeutics To Participate In 23rd Annual NewsMakers In The Biotech Industry Conference
2016-08-16,Argos Therapeutics is Now Oversold (ARGS)
2016-08-10,Argos Therapeutics Reports Second Quarter 2016 Financial Results And Recent Operational Highlights
2016-08-04,Argos Therapeutics To Host Second Quarter 2016 Financial Results Conference Call On Wednesday, August 10, 2016
2016-07-28,Argos Therapeutics Announces Pricing Of $50 Million Public Offering Of Common Stock And Warrants
2016-07-27,Argos Therapeutics Announces Proposed Public Offering Of Common Stock And Warrants
2016-07-21,These 5 Stocks Under $10 Are Set to Soar Higher
2016-07-14,Argos Therapeutics Announces First Patient Dosed In Stage 2 Of Adult Eradication Trial Of AGS-004 In The Treatment Of HIV
2016-07-13,Short Interest In Argos Therapeutics Jumps 18.2%
2016-07-11,Dr. Richard D. Katz Joins Argos Therapeutics As Chief Financial Officer
2016-06-29,Argos Therapeutics Announces Closing Of $29.8 Million Second Tranche Of March 2016 Financing
2016-06-27,Argos Therapeutics Added To The Russell 2000® Index
2016-06-15,Argos Therapeutics Enters Into Strategic Research Agreement With Adaptive Biotechnologies
2016-06-13,Independent Data Monitoring Committee Recommends Continuation Of ADAPT Phase 3 Clinical Trial Of AGS-003 In Metastatic Renal Cell Carcinoma Following Interim Data Review
2016-06-08,Argos Therapeutics To Participate In Jefferies 2016 Healthcare Conference
2016-05-12,Argos Therapeutics Reports First Quarter 2016 Financial Results And Operational Highlights
2016-05-11,Argos Therapeutics To Participate In World Stem Cells And Regenerative Medicine Congress
2016-05-09,7 Stocks Under $10 Spiking Toward Big Gains
2016-05-05,Argos Therapeutics To Host First Quarter 2016 Financial Results Conference Call On Thursday, May 12, 2016
2016-04-07,Argos Therapeutics To Participate In 15th Annual Needham Healthcare Conference
2016-03-29,CORRECTION -- Argos Therapeutics Reports Fourth Quarter And Full-Year 2015 Financial Results And Operational Highlights
2016-03-29,Argos Therapeutics Reports Fourth Quarter And Full-Year 2015 Financial Results And Operational Highlights
2016-03-23,Argos Therapeutics Announces Initiation Of A Phase 2 Clinical Trial Of AGS-003 For The Treatment Of Non-small Cell Lung Cancer In Combination With Standard-of-Care Chemotherapy
2016-03-22,Argos Therapeutics To Host Fourth Quarter And Full-Year 2015 Financial Results Conference Call On Tuesday, March 29, 2016
2016-03-22,Argos Therapeutics To Participate In 6th Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference
2016-03-17,Argos Therapeutics To Participate In Alliance For Regenerative Medicine Cell And Gene Therapy Investor Day
2016-03-08,Biotech Rally Is Healing Small-Caps
2016-03-07,Argos Therapeutics Announces Financing Of Up To $60 Million
2016-03-06,We Need to Digest the Feast Before Rallying Again
2016-02-08,8 Stocks Under $10 Set to Soar
2016-01-22,5 Stocks Ready for Breakouts
2016-01-20,Dr. Lee F. Allen Joins Argos Therapeutics As Chief Medical Officer
2015-12-18,4 Biotech Stocks Under $10 Poised for Big Breakouts
2015-12-10,Independent Data Monitoring Committee Recommends Continuation Of ADAPT Phase 3 Clinical Trial Of AGS-003 For Metastatic Renal Cell Carcinoma Following Second Planned Interim Analysis
2015-12-09,Argos Therapeutics To Participate In The ROTH Immuno-Oncology Corporate Access Day
2015-11-16,Argos Therapeutics Reports Third Quarter 2015 Financial Results And Operational Highlights
2015-11-09,Argos Therapeutics To Host Third Quarter 2015 Financial Results Conference Call On Monday, November 16, 2015
2015-11-06,Argos Therapeutics To Participate In 3rd Annual EU Advanced Therapies Investor Day
2015-11-05,Argos Therapeutics To Participate In The 3rd International MRNA Health Conference
2015-10-05,Argos Therapeutics To Host Review Of The Current Clinical Research Landscape In Kidney Cancer Following The 40th Congress Of The European Society For Medical Oncology, With Insights From Dr. Charles Drake Of Johns Hopkins Sidney Kimmel Cancer Center
2015-10-02,Argos Therapeutics To Participate In 2015 Stem Cell Meeting On The Mesa
2015-09-23,Robert F. Carey Appointed To The Board Of Directors Of Argos Therapeutics
2015-09-08,Argos Therapeutics To Participate In FBR Second Annual Healthcare Conference
2015-09-01,Argos Therapeutics To Participate In Stem Cells And Regenerative Medicine Congress 2015
2015-08-24,Argos Therapeutics Awarded Patent For Its Experimental Individualized Immunotherapy For The Treatment Of HIV Infection
2015-08-12,Argos Therapeutics Reports Second Quarter 2015 Financial Results And Operational Highlights
2015-08-10,Argos Therapeutics Announces Pilot Clinical Trial Of AGS-003 As Neoadjuvant Immunotherapy For Localized Renal Cell Carcinoma
2015-08-05,Argos Therapeutics To Hold Second Quarter 2015 Financial Results Conference Call On Wednesday, August 12, 2015
2015-07-21,Argos Therapeutics Announces Formation Of Scientific Advisory Board
2015-07-17,Argos Therapeutics To Present At 8th IAS Conference On HIV Pathogenesis, Treatment And Prevention
2015-07-15,Argos Therapeutics Announces Completion Of Patient Enrollment In Pivotal Phase 3 ADAPT Clinical Trial Of AGS-003
2015-06-24,Argos Therapeutics Becomes Oversold (ARGS)
2015-06-16,Argos Therapeutics To Present At The 2015 JMP Securities Life Sciences Conference
2015-06-15,Argos Therapeutics Hires John D. Menditto As Vice President Of Corporate Communications And Investor Relations
2015-06-04,Independent Data Monitoring Committee Recommends Continuation Of Pivotal ADAPT Phase 3 Clinical Trial Of AGS-003 For Metastatic Renal Cell Carcinoma
2015-05-29,Argos Therapeutics To Present At The Annual Sachs Immuno-Oncology: BD&L And Investment Forum
2015-05-20,Argos Therapeutics To Present At The World Stem Cells Regenerative Medicine Congress 2015
2015-05-14,Argos Therapeutics Reports First Quarter 2015 Financial Results And Operational Highlights
2015-05-13,Argos Therapeutics Provides Update On Enrollment Progress For Ongoing Pivotal Phase 3 ADAPT Clinical Trial
2015-05-08,Argos Therapeutics To Present At 36th American Society For Apheresis Annual Meeting
2015-05-07,Argos Therapeutics To Hold First Quarter 2015 Financial Results Conference Call On Thursday, May 14, 2015
2015-04-23,Argos Therapeutics Recognized For Economic Development At The 17th Annual Triangle CREW Champion Awards
2015-04-21,Argos Therapeutics Announces Publication Of Data From Phase 2 Clinical Trial Of AGS-003 Fully Personalized Immunotherapy For Treatment Of Metastatic Renal Cell Carcinoma (mRCC)
2015-04-20,Argos Therapeutics To Present Update On Pivotal Phase 3 ADAPT Clinical Trial During 2015 ASCO Annual Meeting
2015-04-14,Argos Therapeutics Licenses Arcelis(R) Technology Platform To Lummy HK For Development Of Personalized Immunotherapies To Treat Cancer In China
2015-04-07,Argos Therapeutics To Present At The 14th Annual Needham Healthcare Conference
2015-04-02,Market News: CarMax, Motorola Solutions, Argos Therapeutics
2015-04-01,Ratings Changes Today
2015-04-01,NIH Funds Study Of Fully Personalized Immunotherapy AGS-004 Combined With A Latency Reversing Therapy For The Treatment Of HIV
2015-03-30,Argos Therapeutics Reports Fourth Quarter And Year-End 2014 Financial Results
2015-03-20,Argos Therapeutics Director Of Immunology To Present At HIV Vaccines Meeting
2015-03-16,Argos Therapeutics To Hold Fourth Quarter And Year-End 2014 Financial Results Conference Call On Monday, March 30, 2015
2015-03-04,Argos Therapeutics To Present At Three Upcoming Investor Conferences In March
2015-02-27,Argos Therapeutics Announces Update On Phase 3 ADAPT Trial To Be Presented During 2015 ASCO Genitourinary Cancers Symposium
2015-02-24,Joan C. Winterbottom Joins Argos Therapeutics As Chief Human Resources Officer
2015-02-02,Argos Therapeutics To Present At The 17th Annual BIO CEO & Investor Conference
2015-01-23,Argos Therapeutics Chief Operating Officer To Speak At Phacilitate Cell & Gene Therapy Forum 2015
2015-01-22,Argos Therapeutics Director Of Immunology To Speak At The GTCbio Novel Immunotherapeutics Summit 2015
2015-01-20,Argos Therapeutics Chief Scientific Officer To Speak At The Personalized Medicine World Conference 2015
2015-01-09,Oversold Conditions For Argos Therapeutics(ARGS)
2015-01-09,Argos Therapeutics Provides Update On Clinical Research For Investigational Fully Personalized Immunotherapy For The Treatment Of HIV
2015-01-06,Argos Therapeutics To Present At Biotech Showcase 2015
2015-01-06,Argos Therapeutics And Saint-Gobain Announce Agreement For Production Of Disposables Used In Automated Manufacturing Of Fully Personalized Immunotherapies
2014-11-25,Argos Therapeutics To Present At The 26th Annual Piper Jaffray Healthcare Conference
2014-11-24,Argos Therapeutics Receives 2014 Red Herring North America Top 100 Award
2014-11-13,Argos Therapeutics Reports Third Quarter 2014 Financial Results And Operational Highlights
2014-11-13,Philippe Van Holle Joins Argos Therapeutics Board Of Directors
2014-11-12,Argos Therapeutics To Present At The Stifel 2014 Healthcare Conference
2014-11-06,Argos Therapeutics To Hold Third Quarter 2014 Financial Results Conference Call On Thursday, November 13, 2014
2014-11-05,Invetech And Argos Therapeutics Announce Agreement To Support Global Production Of Fully Personalized Immunotherapies
2014-10-22,Argos Therapeutics Breaks Ground On State-of-the-Art Biomanufacturing Facility In Research Triangle Park Area
2014-10-03,Argos Therapeutics Announces Plans For New Manufacturing Facility In Research Triangle Park Area In Durham, North Carolina
2014-10-01,Argos Therapeutics To Present At The 13th Annual BIO Investor Forum
2014-09-30,Argos Therapeutics Enters Into $25 Million Venture Loan Facility Led By Horizon Technology Finance
2014-09-19,Argos Therapeutics To Present At The 21st Annual BioCentury NewsMakers Conference
2014-09-18,Enrollment In Argos Therapeutics' Pivotal Phase III ADAPT Trial Of AGS-003 For Metastatic Renal Cell Carcinoma Surpasses Fifty Percent
2014-09-08,Argos Announces Issuance Of Arcelis(R) Technology Platform Patent
2014-09-03,Argos Therapeutics To Present At The Rodman & Renshaw 16th Annual Global Investment Conference
2014-08-13,Argos Therapeutics Reports Second Quarter 2014 Financial Results And Operational Highlights
2014-08-06,Argos Therapeutics To Hold Second Quarter 2014 Financial Results Conference Call On Wednesday, August 13, 2014
2014-07-21,Argos Therapeutics Presents Data Showing The Impact Of HIV Antigen Sequence Divergence On Durable Viral Control Following Treatment With Autologous Immune Therapy
2014-06-11,Argos Therapeutics To Present At Two Upcoming Healthcare Conferences
2014-06-05,Argos Therapeutics To Host Post-American Society Of Clinical Oncology (ASCO) Conference Call And Webcast, Monday, June 9, 2014
2014-06-02,Treatment With AGS-003 And Sunitinib Associated With Doubling Of Expected Survival In Patients With Unfavorable Risk Metastatic Renal Cell Carcinoma (mRCC)
2014-05-28,Argos Therapeutics To Present At The Jefferies 2014 Global Healthcare Conference
2014-05-27,Argos Therapeutics Named As A Red Herring Top 100 North America Winner
2014-05-19,Argos Therapeutics CSO Dr. Charles Nicolette To Join Panel Discussion On Challenges In Clinical Trial Development At The Society Of Gene & Cell Therapy Annual Meeting
2014-05-15,Argos Therapeutics COO Fred Miesowicz To Join Panel Discussion On Manufacturing Challenges In Cell Therapy At The World Stem Cells And Regenerative Medicine Congress
2014-05-13,Argos Therapeutics Reports First Quarter 2014 Financial Results
2014-05-12,Argos Therapeutics To Present Data Related To Clinical Development Program For AGS-003 During 2014 ASCO Annual Meeting
2014-04-29,Argos Therapeutics To Hold First Quarter 2014 Financial Results Conference Call On Tuesday, May 13, 2014
2014-04-07,Argos Therapeutics Announces Filing Of Its Annual Report On Form 10-K
2014-04-01,Argos Therapeutics To Present At The 13th Annual Needham Healthcare Conference
2014-03-31,Argos Therapeutics Added To Russell 2000(R) And 3000(R) Indexes
2014-03-27,Argos Therapeutics Reports Fourth Quarter And Year-End 2013 Financial Results
2014-03-21,Argos Therapeutics To Present At 21st Annual Future Leaders In The Biotech Industry Conference
2014-03-19,Argos Therapeutics To Present At Regenerative Medicine And Cancer Immunotherapy Meetings
2014-03-17,Argos Therapeutics To Present At The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum
2014-03-14,Argos Therapeutics To Hold Fourth Quarter And Year End 2013 Financial Results Conference Call On Thursday, March 27, 2014
2014-03-04,Argos Therapeutics Presents New Data From Clinical Research For AGS-004 Patient-Specific Immunotherapy In Treatment Of HIV
2014-02-13,Top Insider Trades: EPB BYI ARGS BIOL
2014-02-07,Argos Therapeutics Prices Initial Public Offering
2017-03-15,After Soaring to $150, Can Incyte Stir Up More Upside?
2017-02-15,Biotech Buoyed by Deal Talk
2017-02-06,ARIAD Announces Submission Of Marketing Authorization Application For Brigatinib To The European Medicines Agency
2017-01-29,The Next Target in Biotech Land
2017-01-27,The Next Target in Biotech Land
2017-01-18,Ariad Pharmaceuticals, Inc. Acquisition May Not Be In The Best Interests Of ARIA Shareholders
2017-01-14,Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)
2017-01-13,ARIAD SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces The Investigation Of ARIAD Pharmaceuticals, Inc. (ARIA) Over The Proposed Sale Of The Company To Takeda Pharmaceutical Company Limited
2017-01-12,SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of ARIAD Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information
2017-01-10,4 Biotech Names That Could Be M&amp;A Targets
2017-01-09,The Merger Frenzy Is On: Here's What to Expect from the Rest of 2017
2017-01-09,These Stocks Are Too Hot, in a Bad Way : Jim Cramer's 'Mad Money' Recap
2017-01-09,Cramer: Stocks Need to Cool Down
2017-01-09,So the Nasdaq Is At a Historical High but the Dow Is Going Opposite Direction
2017-01-09,The Real Apple of the Dow's Eye -- ICYMI
2017-01-09,Harwood Feffer LLP Announces Investigation Of ARIAD Pharmaceuticals, Inc.
2017-01-09,Nasdaq Separates Itself From the Rest of the Market
2017-01-09,Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference
2017-01-09,Nasdaq Hits Records Even as Crude Selloff Sours Rest of Market
2017-01-09,Facebook Makes Powerful Move Higher -- How to Trade It, Along With 6 Other Active Stocks
2017-01-09,ARIAD PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
2017-01-09,Takeda Acquires Ariad Pharmaceuticals in $5.2 Billion Deal
2017-01-09,Midday Report: Ariad Pharmaceuticals Jumps on Deal; Dow Takes Pause on Road to 20,000
2017-01-09,Noteworthy Monday Option Activity: ARIA, DFRG, AYI
2017-01-09,Takeda Pays $5.2 Billion for Leukemia Drug Maker Ariad, Ending Months of Takeout Speculation
2017-01-09,Dow Steps Back From 20,000 as Crude Selloff Weighs on Energy Sector
2017-01-09,Stock Picks Are Hard to Find as Small-Caps Struggle
2017-01-09,Biotech Stocks Surge Monday Amid Flurry of Deal Activity
2017-01-09,Stock Futures Mostly Lower as Crude Oil Slides Below $53
2017-01-09,ARIAD Enters Into Definitive Agreement To Be Acquired By Takeda For $5.2 Billion
2017-01-09,Takeda To Acquire ARIAD Pharmaceuticals, Inc.
2017-01-05,What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017
2017-01-03,ARIAD To Present At The 35th Annual J.P. Morgan Healthcare Conference
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2016-12-22,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
2016-12-22,2016 Was a Terrible Year for Biotech but the Tweets Were on Point
2016-12-07,Dow Scores Another Record for Third Consecutive Day; S&amp;P 500 Also Hits New High
2016-12-07,Dow, S&amp;P 500 Trade at Session Highs in Broad Wall Street Rally
2016-12-07,S&amp;P 500 and Dow Reverse Losses to Post Intraday Records
2016-12-07,ARIAD's Investigational Medicine Brigatinib Demonstrated 15.6 Month Systemic Median Progression-Free Survival In ALTA Study
2016-12-06,ARIAD Announces Data Presentations At American Society Of Hematology Meeting
2016-12-05,ARIAD Presents Updated Brigatinib Data With 18.4 Months Median Intracranial Progression Free Survival (PFS) In ALK+ NSCLC Patients With CNS Metastases At The World Conference On Lung Cancer
2016-12-02,ARIAD To Host Webcast And Conference Call On Brigatinib Data Presentations At The World Conference On Lung Cancer
2016-11-29,ARIAD Announces FDA Full Approval And Label Update For Iclusig® (ponatinib) Based On Long-Term Efficacy And Safety Data From Phase 2 PACE Clinical Trial
2016-11-16,ARIAD Announces Data Presentations At The World Conference On Lung Cancer
2016-11-14,The Inaugural ALK+ Day Is November 15, During Lung Cancer Awareness Month. (Photo: Business Wire)
2016-11-12,'Mad Money' Lightning Round: 'Health Care Is All Over the Map'
2016-11-11,Jim Cramer's 'Mad Money' Recap: Markets Pivot From Shocked to Bullish
2016-11-09,ARIAD Announces Phase 1/2 Trial Data On Investigational Drug Brigatinib Published In The Lancet Oncology
2016-11-07,ARIAD Reports Third Quarter 2016 Financial Results
2016-11-02,Why Incyte's Shares Could Soon Hit $100
2016-11-02,ARIAD To Present At The Jefferies 2016 London Healthcare Conference
2016-11-01,ARIAD To Webcast Conference Call On Third Quarter 2016 Financial Results
2016-10-31,ARIAD Announces U.S. Food And Drug Administration Acceptance Of NDA Filing For Brigatinib
2016-10-28,SHAREHOLDER ALERT: Goldberg Law PC Announces An Investigation Of Ariad Pharmaceuticals Inc. And Advises Investors With Losses To Contact The Firm
2016-10-26,Pardon Me, but I Have a Few Things to Say... Vertex, Biogen, Ariad, Sarepta
2016-10-26,ARIAD Announces Publication Of The Preclinical Profile Of Brigatinib In The Journal Clinical Cancer Research
2016-10-25,Ariad Pharmaceuticals (ARIA) Stock Downgraded at JMP Securities
2016-10-25,Analysts' Actions -- Chesapeake, McCormick, Time Warner, VF Corp. and More
2016-10-24,Ariad Pharmaceuticals (ARIA) Stock Drops, JPMorgan Downgrades
2016-10-24,Analysts' Actions -- Kinder Morgan, AT&T, Verizon, 3M and More
2016-10-21,'Mad Money' Lightning Round: United and Southwest Better Than JetBlue?
2016-10-20,Jim Cramer's 'Mad Money' Recap: American Express Is Back on a Growth Track
2016-10-20,ARIAD Reaffirms Commitment To Discovering And Developing Treatments For Patients With Rare Cancers
2016-10-20,Why Ariad Pharmaceuticals (ARIA) Stock Is Sliding Today
2016-10-17,Pardon Me, but I Have a Few Things to Say... Trump, Bernie, Radius, Ariad
2016-10-17,Trader's Daily Notebook: You Might Consider Selling Facebook
2016-10-14,Why Ariad (ARIA) Stock Is Plunging Today
2016-10-14,'Mad Money' Lightning Round: I'm Faithful to Opko Health's CEO
2016-10-13,Jim Cramer's 'Mad Money' Recap: Don't Play the Short-Term Market Game
2016-10-07,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Ariad Pharmaceuticals, Inc. (ARIA)
2016-10-07,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Ariad Pharmaceuticals, Inc. - ARIA
2016-10-06,How Ariad Pharma Used a Safety Problem to Jack Up a Cancer Drug's Price
2016-09-30,Biotech Stock Mailbag: Dynavax, Puma, Ariad
2016-09-26,Ariad Pharmaceuticals (ARIA) Stock Climbs, Coverage Initiated at Leerink
2016-09-20,Ariad Pharma (ARIA) Stock Surged Today on Takeover Speculation
2016-09-19,Ariad Pharmaceuticals (ARIA) Stock Is Monday's 'Chart of the Day'
2016-09-19,Chart of the Day: Ariad
2016-08-30,ARIAD Completes Rolling Submission Of New Drug Application For Brigatinib To The U.S. Food And Drug Administration
2016-08-29,ARIAD To Present At The Morgan Stanley Global Healthcare Conference
2016-08-09,Why There Is Upside for Incyte Despite Recent Selloff
2016-08-01,PDL BioPharma Completes Second Tranche Payment Under Royalty Transaction With ARIAD Pharmaceuticals
2016-07-28,ARIAD (ARIA) Stock Pops After Q2 Beat
2016-07-28,ARIAD Reports Second Quarter And First Half 2016 Financial Results
2016-07-26,Insider Trading Alert - SKUL, EA And ARIA Traded By Insiders
2016-07-25,Bullish and Bearish Reversals for the Week
2016-07-21,These 5 Stocks Under $10 Are Set to Soar Higher
2016-07-20,Barbarian At The Gate: ARIAD Pharmaceuticals (ARIA)
2016-07-05,ARIAD To Webcast Conference Call On Second Quarter 2016 Financial Results
2016-06-24,ARIAD Announces Webcast Of Its Annual Stockholders Meeting
2016-06-20,ARIAD Pharmaceuticals (ARIA) Marked As A Dead Cat Bounce Stock
2016-06-17,ARIAD Completes Strategic Review And Announces Plans For Growth
2016-06-17,ARIAD Announces Distribution Agreements For Iclusig® In Latin America And The Middle East/North Africa
2016-06-17,ARIAD Initiates Submission Of New Drug Application For Brigatinib To The U.S. Food And Drug Administration Ahead Of Plan
2016-06-13,ARIAD Announces Long-Term Safety And Efficacy Data Of Ponatinib From Phase 2 Pace Clinical Trial
2016-06-08,ARIAD To Host Analyst & Investor Day In New York City
2016-06-07,Today's Weak On High Volume Stock: ARIAD Pharmaceuticals (ARIA)
2016-06-06,Cancer Drug Stocks: The Winners and Losers From ASCO 2016
2016-06-06,ARIAD's Investigational Medicine Brigatinib Demonstrates 54 Percent Confirmed Objective Response Rate And 12.9-Month Median Progression-Free Survival In ALTA Study
2016-06-04,ARIAD Presents Data From Mutational Profiling In Crizotinib-Resistant Patients Treated With Investigational Medicine Brigatinib Showing Similar Response Rates In Patients With And Without Secondary ALK Mutations
2016-06-04,ARIAD Presents Long-Term Phase 1/2 Trial Follow Up On Investigational Drug Brigatinib With Median Time On Treatment Of 17 Months In ALK+ NSCLC Patients
2016-06-02,Trade-Ideas: ARIAD Pharmaceuticals (ARIA) Is Today's Post-Market Leader Stock
2016-06-02,ARIAD Completes The Sale Of Its European Operations And Out-License Of European Rights To Iclusig®
2016-06-01,ARIAD To Present At The Jefferies 2016 Global Healthcare Conference
2016-05-31,Ariad Pharmaceuticals Is Nearly Done Building Base Pattern
2016-05-31,Trade-Ideas: ARIAD Pharmaceuticals (ARIA) Is Today's Strong On High Relative Volume Stock
2016-05-31,ARIAD Announces Initiation Of Phase 1/2 Clinical Trial Of AP32788, An Investigational Oral Inhibitor Of EGFR And HER2, In Patients With Non-Small Cell Lung Cancer
2016-05-26,Insider Trading Alert - DEPO, ARIA And ROG Traded By Insiders
2016-05-24,ARIAD Announces Appointment Of Jennifer L. Herron As Chief Commercial Officer
2016-05-19,ARIAD Announces Pricing And Reimbursement For Iclusig In France
2016-05-18,ARIAD Announces Data Presentations At The 2016 ASCO Annual Meeting
2016-05-10,Biotech Gets a Lifeline
2016-05-10,ARIAD Reports First Quarter 2016 Financial Results And Progress On Strategic Review
2016-05-09,Incyte Buys European Business Hub From Ariad Pharma
2016-04-27,Trade-Ideas: ARIAD Pharmaceuticals (ARIA) Is Today's Weak On High Relative Volume Stock
2016-04-26,Insider Trading Alert - DWRE, ARIA And PTC Traded By Insiders
2016-04-26,ARIAD To Webcast Conference Call On First Quarter 2016 Financial Results
2016-04-19,ARIAD Announces Results Of Preclinical Studies On AP32788 At The Annual Meeting Of The American Association For Cancer Research
2016-04-15,ARIAD Presents Updated Phase 1/2 Clinical Data On Brigatinib In Patients With ALK+ Non-Small Cell Lung Cancer
2016-04-11,ARIAD Announces Initiation Of Randomized, First-Line Phase 3 Trial Of Brigatinib In Treatment Of ALK-Positive Non-Small Cell Lung Cancer
2016-03-29,ARIAD Announces Reduction In Workforce As Part Of Ongoing Company-Wide Strategic Review
2016-03-22,ARIAD Reports Inducement Grant To New Chief Financial Officer
2016-03-11,Manmeet S. Soni (Photo: Business Wire)
2016-02-29,ARIAD To Present At Upcoming Investor Conferences
2016-02-24,First Week of April 15th Options Trading For ARIAD Pharmaceuticals (ARIA)
2016-02-23,ARIAD Reports 2015 Financial Results, Provides 2016 Product Revenue Guidance And Outlines Company Progress
2016-02-10,ARIAD To Present At The RBC Capital Markets Healthcare Conference
2016-02-04,Insider Trading Alert - AEP, JBSS And ARIA Traded By Insiders
2016-02-02,ARIAD To Webcast Conference Call On Fourth Quarter And Year-End 2015 Financial Results
2016-02-01,AP32788 (gray) Shown Binding To EGFR (Photo: Business Wire)
2016-01-19,ARIAD Pharmaceuticals (ARIA) Stock Gets ‘Underweight’ Rating at Barclays
2016-01-15,ARIAD Reports Inducement Grant To New Chief Executive Officer
2016-01-13,Perilous Reversal Watch: ARIAD Pharmaceuticals (ARIA)
2016-01-12,Trade-Ideas: ARIAD Pharmaceuticals (ARIA) Is Today's Strong On High Relative Volume Stock
2016-01-11,ARIAD Announces Termination Of Shareholder Rights Plan
2016-01-10,Alexander J. Denner, Ph.D (Photo: Business Wire)
2016-01-08,ARIAD And Otsuka Submit New Drug Application In Japan For Ponatinib
2016-01-07,Relative Strength Alert For ARIAD Pharmaceuticals
2015-12-18,Paris Panayiotopoulos, President And Chief Executive Officer Of ARIAD Pharmaceuticals, Inc., Effective January 1, 2016. (Photo: Business Wire).
2015-12-11,ARIAD Announces Pricing And Reimbursement Negotiations For Iclusig In France To Continue Into 2016
2015-12-07,ARIAD Announces Initiation Of OPTIC-2L Randomized Phase 3 Trial Of Ponatinib Vs. Nilotinib In Second-Line Patients With Chronic-Phase Chronic Myeloid Leukemia
2015-11-25,Interesting ARIA Put Options For January 2016
2015-11-05,ARIAD Announces Iclusig Data Presentations At Annual American Society Of Hematology Meeting
2015-11-03,ARIAD Reports Third Quarter 2015 Financial Results And Progress On Strategic Objectives
2015-10-27,ARIAD To Webcast Conference Call On Third Quarter 2015 Financial Results
2015-10-21,First Week of December 18th Options Trading For ARIAD Pharmaceuticals (ARIA)
2015-10-12,ARIA January 2018 Options Begin Trading
2015-09-30,ARIAD Pharmaceuticals (ARIA) Showing Signs Of A Dead Cat Bounce Today
2015-09-23,First Week of ARIA May 2016 Options Trading
2015-09-15,ARIAD Announces Full Enrollment In Phase 2 ALTA Trial Of Brigatinib
2015-09-14,Tetraphase Executive Profits Hours Before Stock Plummets
2015-09-04,Insider Trading Alert - SABR, DLTR And ARIA Traded By Insiders
2015-09-03,Interesting ARIA Put And Call Options For October 23rd
2015-09-03,Today's Dead Cat Bounce Stock Is ARIAD Pharmaceuticals (ARIA)
2015-09-02,Market News: Biogen, Vera Bradley, Ariad Pharmaceuticals
2015-08-31,3 High-Volume Stocks to Trade Now (or Not)
2015-08-31,Perilous Reversal Stock: ARIAD Pharmaceuticals (ARIA)
2015-08-28,Barbarian At The Gate: ARIAD Pharmaceuticals (ARIA)
2015-08-21,ARIAD Pharmaceuticals (ARIA) Marked As A Dead Cat Bounce Stock
2015-08-14,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Breaches Of Fiduciary Duty By The Board Of Ariad Pharmaceuticals Inc. -- ARIA
2015-08-10,ARIAD Announces First Patient Treated In Phase 2 Dose-Ranging Optic Trial Of Iclusig (Ponatinib)
2015-08-05,ARIAD Reports Second Quarter 2015 Financial Results And Progress On Strategic Objectives
2015-07-29,Perilous Reversal Watch: ARIAD Pharmaceuticals (ARIA)
2015-07-29,ARIAD To Receive Up To $200 Million Through Iclusig Non-Dilutive Synthetic-Royalty Financing With PDL BioPharma
2015-07-29,PDL BioPharma Completes Royalty Transaction With ARIAD Pharmaceuticals
2015-07-28,ARIAD Pharmaceuticals (ARIA) Flagged As Strong On High Volume
2015-07-22,ARIAD To Webcast Conference Call On Second Quarter 2015 Financial Results
2015-06-29,ARIAD Pharmaceuticals Is Now Oversold (ARIA)
2015-06-29,ARIA: Insiders Vs. Shorts
2015-06-23,First Week Of February 2016 Options Trading For ARIAD Pharmaceuticals (ARIA)
2015-06-12,ARIAD Announces Long-Term Safety And Efficacy Data Of Ponatinib From Phase 2 Pace Clinical Trial
2015-06-10,ARIAD And Paladin Announce Commercial Distribution Agreement For Iclusig (Ponatinib) In Canada
2015-06-08,ARIAD To Present At The Goldman Sachs Annual Global Healthcare Conference
2015-06-01,ARIAD Presents Updated Clinical Data On Brigatinib In Patients With ALK+ Non-Small Cell Lung Cancer At The 2015 ASCO Meeting
2015-05-31,ARIAD Announces Long-Term Safety And Efficacy Data Of Ponatinib In Chronic-Phase Chronic Myeloid Leukemia From Phase 1 Clinical Trial
2015-05-21,ARIAD To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-14,ARIAD Announces Data Presentations At The 2015 ASCO Annual Meeting
2015-05-07,ARIAD Reports First Quarter 2015 Financial Results And Progress On Strategic Objectives
2015-05-06,ARIAD Announces Commercial Distribution Agreement For Iclusig (ponatinib) In Turkey
2015-04-29,Strong On High Volume: ARIAD Pharmaceuticals (ARIA)
2017-03-20,Aralez CEO Purchases 500,000 Shares Of Company Common Stock On Open Market
2017-03-15,Biotech Premarket Movers: Arena, Immunomedics, Aralez
2017-03-13,Biotech Premarket Movers: Cempra, Blueprint Medicines, Aralez
2017-02-27,Aralez To Announce Fourth Quarter And Full-Year 2016 Results On March 13, 2017
2017-02-16,Aralez To Present At The RBC Capital Markets Global Healthcare Conference
2017-02-13,Aralez To Ring Closing Bell At Nasdaq On February 14, 2017
2017-01-27,Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen
2017-01-25,First Week of ARLZ February 17th Options Trading
2017-01-19,Aralez Pharmaceuticals is Now Oversold (ARLZ)
2017-01-11,Biotech Premarket Movers: IPXL, SGMO, ARLZ
2017-01-11,Aralez Announces Issuance Of Additional U.S. Patent For Yosprala
2017-01-09,Aralez Submits Marketing Authorization Application To The European Medicines Agency For PA10040
2017-01-09,Aralez Provides Update On PBM Formulary Status For Yosprala
2016-12-19,Aralez Added To The NASDAQ Biotechnology Index
2016-12-19,Aralez Announces Commercial Launch Of BLEXTEN™ In Canada
2016-12-15,Aralez Provides Update On PBM Formulary Status For Yosprala
2016-11-30,Aralez To Participate At Two Upcoming Healthcare Conferences
2016-11-02,Aralez To Present At The Jefferies London Healthcare Conference
2016-10-31,Aralez Completes Acquisition Of Toprol-XL® And Its Authorized Generic From AstraZeneca
2016-10-24,Aralez To Announce Third Quarter 2016 Results On November 7, 2016
2016-10-04,Aralez To Acquire From AstraZeneca U.S. Rights To Beta Blocker Toprol-XL®
2016-10-03,Aralez Announces U.S. Commercial Launch Of YOSPRALA For Secondary Prevention Of Cardiovascular And Cerebrovascular Events In Patients At Risk For Aspirin-Associated Gastric Ulcers
2016-09-30,Interesting ARLZ Put And Call Options For November 18th
2016-09-15,Aralez Pharmaceuticals (ARLZ) Stock Closed Higher on Yosprala FDA Approval
2016-09-15,Aralez Announces FDA Approval Of YOSPRALA For Secondary Prevention Of Cardiovascular And Cerebrovascular Events In Patients At Risk For Aspirin-Associated Gastric Ulcers
2016-09-07,Aralez Pharmaceuticals (ARLZ) Stock Advances, Buys Drug Rights from Merck
2016-09-07,Aralez Acquires United States And Canadian Rights To ZONTIVITY From Merck
2016-08-22,Interesting ARLZ Put And Call Options For October 21st
2016-07-26,Aralez To Announce Second Quarter 2016 Results On August 9, 2016
2016-07-06,Aralez To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference
2016-06-02,Aralez To Present At The Jefferies Healthcare Conference
2016-05-24,Insider Trading Alert - UDR, ARLZ And SMLP Traded By Insiders
2016-05-16,Aralez Distributes Meeting Materials For 2016 Annual General Meeting Of Shareholders
2016-04-28,Aralez To Present At The Deutsche Bank 41st Annual Healthcare Conference
2016-04-28,Aralez To Announce First Quarter 2016 Results On May 10, 2016
2016-04-25,Aralez To Present At The Bloom Burton & Co. Healthcare Investor Conference
2016-04-25,Aralez Receives Health Canada Approval For BLEXTEN™
2016-04-20,Aralez Announces Several Corporate Updates
2016-04-19,Aralez Appoints James L. Hall As General Manager Of Canadian Business
2016-04-19,First Week of ARLZ December 16th Options Trading
2016-04-08,Insider Trading Alert - VLGEA, ARLZ And GGP Traded By Insiders
2016-04-04,Aralez To Open Toronto Stock Exchange On April 5, 2016
2016-03-28,Aralez Announces FDA Acceptance Of New Drug Application For YOSPRALA™
2016-03-15,Relative Strength Alert For Aralez Pharmaceuticals
2016-03-15,Aralez Resubmits To FDA New Drug Application For YOSPRALA
2016-03-01,Aralez To Announce Fourth Quarter And Full-Year 2015 Results On March 15, 2016
2016-02-22,Aralez To Present At The Cowen And Company 36th Annual Healthcare Conference
2016-02-12,Aralez To Ring Closing Bell At Nasdaq On February 16, 2016
,
,
,
,
2017-03-20,Arena Pharmaceuticals Appoints Dr. Preston Klassen, M.D., M.H.S. As Executive Vice President, Research And Development And Chief Medical Officer
2017-03-15,How to Trade Wednesday's Most Active Stocks: Lloyds, Arena Pharma, MSCI and More
2017-03-15,Biotech Premarket Movers: Arena, Immunomedics, Aralez
2017-03-08,Arena Pharmaceuticals To Present At The 27th Annual Oppenheimer Healthcare Conference
2017-03-06,Arena Pharmaceuticals To Provide Corporate Update And Release Fourth Quarter And Full-Year 2016 Financial Results On Tuesday, March 14, 2017
2017-02-22,Interesting ARNA Call Options For October 20th
2017-02-14,Arena Pharmaceuticals Appoints Three New Members To Board Of Directors
2017-02-09,Arena Pharmaceuticals Announces Three Upcoming Presentations At The 12th Congress Of European Crohn's And Colitis Organisation - Inflammatory Bowel Diseases 2017
2017-01-28,You Can Also Get High on Marijuana Stocks -- Here's How
2017-01-04,Arena Pharmaceuticals And Eisai Amend Marketing And Supply Agreement For BELVIQ Globally
2016-12-19,Eisai And Arena Pharmaceuticals Announce Regulatory Approval Of BELVIQ® (lorcaserin HCl) In Brazil
2016-12-13,Arena Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-07,Arena Pharmaceuticals Completes Enrollment In Ralinepag Phase 2 Clinical Trial For Pulmonary Arterial Hypertension (PAH)
2016-11-30,Arena Pharmaceuticals Announces Four Upcoming Presentations At The 2016 Advances In Inflammatory Bowel Diseases: Crohn's & Colitis Foundation's Clinical And Research Conference
2016-11-21,July 2017 Options Now Available For Arena Pharmaceuticals (ARNA)
2016-11-09,Arena Pharmaceuticals To Present At The 28th Annual Piper Jaffray Healthcare Conference
2016-11-09,Arena Pharmaceuticals Announces Poster At The American Heart Association (AHA) Scientific Sessions 2016
2016-10-11,Arena Pharmaceuticals Announces Acceptance Of Late Breaking Etrasimod Abstract At The United European Gastroenterology Week (UEGW) Meeting
2016-09-01,Arena Pharmaceutics Announces Formation of Beacon Discovery
2016-08-22,ARNA April 2017 Options Begin Trading
2016-08-15,Arena Pharmaceuticals Announces Appointment Of Vincent Aurentz As Chief Business Officer
2016-08-08,How Will Arena Pharmaceuticals (ARNA) Stock React to Q2 Miss?
2016-08-01,Arena Pharmaceuticals To Release Second Quarter 2016 Financial Results And Provide Corporate Update On Monday, August 8, 2016
2016-07-19,Arena Pharmaceuticals (ARNA) Stock Gains as FDA Approves Weight-Loss Drug
2016-07-19,Trade-Ideas: Arena Pharmaceuticals (ARNA) Is Today's Strong On High Relative Volume Stock
2016-07-19,Eisai Inc. And Arena Pharmaceuticals Announce FDA Approval Of BELVIQ XR® (lorcaserin HCl) Extended-Release Tablets
2016-07-07,August 26th Options Now Available For Arena Pharmaceuticals (ARNA)
2016-06-23,Interesting ARNA Call Options For August 5th
2016-05-12,Interesting ARNA Put Options For July 1st
2016-05-09,Arena Pharmaceuticals Announces Appointment Of Amit D. Munshi As President And Chief Executive Officer
2016-05-02,Arena Pharmaceuticals To Host First Quarter 2016 Financial Results And Corporate Update Conference Call And Webcast On Monday, May 9
2016-04-12,Arena Pharma (ARNA) Stock Advancing on Favorable Trial Results
2016-04-12,Arena Pharmaceuticals Reports Favorable Results From Phase 1b Multiple-Ascending Dose Clinical Trial Of APD371
2016-03-30,Arena Pharmaceuticals (ARNA) Flagged As Strong On High Volume
2016-03-17,Weak On High Volume: Arena Pharmaceuticals (ARNA)
2016-02-29,Arena Pharmaceuticals (ARNA) Stock Edges Lower in After-Hours Trading on Q4 Results
2016-02-18,Weak On High Volume: Arena Pharmaceuticals (ARNA)
2016-01-12,Boehringer Ingelheim And Arena Pharmaceuticals Collaborate To Advance Research In Schizophrenia
2016-01-11,Arena Pharmaceuticals (ARNA): Today's Weak On High Volume Stock
2016-01-08,Commit To Purchase Arena Pharmaceuticals At $1, Earn 21% Using Options
2016-01-08,Strong On High Relative Volume: Arena Pharmaceuticals (ARNA)
2015-12-03,First Week of ARNA July 2016 Options Trading
2015-11-13,Short Interest Decreases By 11% For ARNA
2015-10-28,Arena Pharmaceuticals (ARNA) Stock: Weak On High Volume Today
2015-10-27,Arena Pharmaceuticals Announces New Strategic Focus And Cost Reduction Plan
2015-10-08,Arena Pharmaceuticals (ARNA) Is Weak On High Volume Today
2015-10-07,Harwood Feffer LLP Announces Investigation Of Arena Pharmaceuticals, Inc.
2015-10-07,Commit To Buy Arena Pharmaceuticals At $1.50, Earn 22% Using Options
2015-10-06,Market News: Arena Pharmaceuticals, Dupont, Illumina
2015-09-30,10 Worst NASDAQ Biotech Stocks in the Third Quarter
2015-09-29,Arena Pharmaceuticals (ARNA) Highlighted As Weak On High Volume
2015-09-25,Cannabis Companies Hunt for Financing, Growth
2015-09-15,Arena Pharmaceuticals Stock Sees Short Interest Decrease By 10.8%
2015-09-12,'Fast Money' Recap: Countdown to a Fed Rate Increase
2015-09-09,Biogen Takes on Celgene With New Autoimmune License Deal
2015-08-31,Arena Pharmaceuticals (ARNA) Is Today's Strong On High Volume Stock
2015-08-07,Biotech Stock Mailbag: Controversial Stocks Revisited
2015-07-16,Arena Pharmaceuticals (ARNA) Showing Signs Of Perilous Reversal Today
2015-07-15,3 Biotech Stocks to Trade Off the Receptos Buyout
2015-07-15,Analysts Break Down Impact Of $7.2B Receptos Buyout
2015-07-08,Commit To Purchase Arena Pharmaceuticals At $2.50, Earn 10.8% Using Options
2015-07-01,Arena Pharmaceuticals (ARNA): Today's Weak On High Volume Stock
2015-06-30,Arena Pharmaceuticals (ARNA) Flagged As Strong On High Volume
2015-06-17,Arena Pharmaceuticals (ARNA) Stock Declines on CFO Departure
2015-04-09,Commit To Purchase Arena Pharmaceuticals At $3, Earn 18.3% Using Options
2015-04-07,Arena Pharmaceuticals (ARNA) Stock Gains Today on New Patent Approval
2015-04-02,Trade-Ideas: Arena Pharmaceuticals (ARNA) Is Today's Strong On High Relative Volume Stock
2015-03-04,Arena Pharmaceuticals (ARNA) Marked As A Dead Cat Bounce Stock
2015-03-03,Orexigen Weight-Loss Pill Shows Surprise Heart-Safety Benefit
2015-03-03,Arena Pharmaceuticals (ARNA) Stock: Weak On High Volume Today
2015-02-20,Obesity Drugs: Orexigen Gains Market Share at Expense of Arena, Vivus
2015-01-23,Biotech Stock Mailbag: Arena Pharma, Agenus, EnteroMedics
2015-01-21,4 Big Stocks to Trade for Gains (or Not): Petrobras, AMD and More
2015-01-21,ARNA Makes Notable Cross Below Critical Moving Average
2015-01-15,Arena Pharmaceuticals (ARNA) Weak On High Volume Today
2015-01-14,Trade-Ideas: Arena Pharmaceuticals (ARNA) Is Today's Pre-Market Leader Stock
2015-01-12,Arena Pharmaceuticals (ARNA) Is Today's Strong On High Volume Stock
2015-01-09,Biotech Investors' Guide and Preview to J.P. Morgan Healthcare Conference: Part 2
2015-01-08,Today's Perilous Reversal Stock: Arena Pharmaceuticals (ARNA)
2015-01-07,Arena Pharmaceuticals (ARNA) Showing Signs Of A Dead Cat Bounce Today
2015-01-06,Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015
2014-12-26,First Week Of March 2015 Options Trading For Arena Pharmaceuticals
2014-12-26,Arena Pharmaceuticals (ARNA): Today's Weak On High Volume Stock
2014-12-19,Orexigen's 'Goldilocks' Weight-Loss Pill is Just Right for European Regulators
2014-12-12,Arena Pharmaceuticals (ARNA) Weak On High Volume Today
2014-11-25,Interesting ARNA Put And Call Options For July 2015
2014-11-03,Super Important Biotech and Drug Stock Events for November
2014-10-31,Biotech Stock Mailbag: Prosensa, Sarepta, Arena Pharma, Hemispherx
2014-10-30,ARNA December 12th Options Begin Trading
2014-10-29,Arena Skimps on Data Disclosure From Weight-Loss Combo Study
2014-10-27,ARNA December 5th Options Begin Trading
2014-10-17,Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents
2014-10-13,Interesting ARNA Put And Call Options For November 28th
2014-10-06,November 14th Options Now Available For Arena Pharmaceuticals (ARNA)
2014-09-19,Arena Pharmaceuticals (ARNA) Flagged As Strong On High Volume
2014-09-16,Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy
2014-09-11,How Will Orexigen Therapeutics (OREX) Stock Respond to FDA's Contrave Approval?
2014-09-11,Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised
2014-09-11,Interesting ARNA Put Options For October 31st
2014-09-04,Interesting ARNA Put Options For October 24th
2014-08-21,Interesting ARNA Put And Call Options For October 3rd
2014-08-19,First Week of ARNA April 2015 Options Trading
2014-08-07,Arena Pharmaceuticals is Now Oversold (ARNA)
2014-07-31,'Mad Money' Lightning Round: Stay With Thermo Fisher Scientific
2014-07-30,Jim Cramer's 'Mad Money' Recap: Thinking 5 Steps Ahead and Being Wrong
2014-07-15,Fed Chair Yellen Says Small Biotech Stocks Over-Valued
2014-07-14,Perilous Reversal Watch: Arena Pharmaceuticals (ARNA)
2014-07-10,August 29th Options Now Available For Arena Pharmaceuticals
2014-07-07,Why Arena Pharmaceuticals (ARNA) Stock Is Dropping Today
2014-07-07,4 Big Stocks Getting Big Attention
2014-07-07,Arena CEO Dumps Stock as Share Price, Investor Confidence Slide
2014-07-07,Insider Trading Alert - SFLY, ARNA And ENS Traded By Insiders
2014-06-12,EnteroMedics: A Preview of the Weight-Loss Zapper FDA Panel
2014-06-12,'Fast Money' Recap: Reacting to Today's Headlines
2014-06-11,FDA Delays Decision on Orexigen Obesity Pill by 3 Months
2014-06-09,Orexigen: 'Goldilocks' Obesity Pill Awaits FDA Approval Decision Wednesday
2014-06-06,Biotech Stock Hate Mailbag: The Hostile React-o-Meter Meltdown Edition
2014-06-05,The Expected Rise and Inevitable Fall of MannKind
2014-06-02,Two pharmaceutical stocks demonstrate portfolio pitfalls and rewards
2014-05-29,ARNA July 11th Options Begin Trading
2014-05-29,The Seven Deadly Sins of Biotech Investing
2014-05-20,The Stupid and Financially Reckless Argument for Eisai Buying Arena Pharma
2014-05-07,A View on Ariad Pharma's Bloated Valuation
2014-05-02,Arena Pharma Denied Request Added Market Exclusivity for Weight-Loss Drug
2014-04-16,'Mad Money' Lightning Round: Delta Is Flying to $40
2014-04-15,Jim Cramer's 'Mad Money' Recap: Fear and Loathing on Wall Street
2014-03-13,Interesting ARNA Put And Call Options For May 2nd
2014-03-06,ARNA April 25th Options Begin Trading
2014-02-27,First Week of ARNA October 18th Options Trading
2014-02-24,The 10 Most Heavily Shorted Bio-Pharma Stocks
2014-02-20,Interesting ARNA Put And Call Options For April 4th
2014-02-07,Biotech Stock Mailbag: Furiex, La Jolla Pharma, Sarepta
2014-02-06,Interesting ARNA Put And Call Options For March 14th
2014-02-03,Galena, Free Fentanyl Samples and the 'Zombie Apocalypse'
2014-01-31, Daily Patterns Have Gone Haywire
2014-01-29,Catalent leads parade of drugmakers headed to market
2014-01-23,Interesting ARNA Put And Call Options For February 28th
2014-01-21,Russell 2000 Remains January's Leader
2014-01-13,J.P. Morgan Healthcare Confab Live Blog: Day One
2014-01-06,Obesity Stocks Focus on Approvals As Arena Pharmaceuticals Goes Global
2014-01-02,February 7th Options Now Available For Arena Pharmaceuticals (ARNA)
2013-12-12,ARNA January 2014 Options Begin Trading
2013-11-27,ARNA January 2014 Options Begin Trading
2013-11-25,&#91;video&#93; A Chart You Should See: Investors Put Greater Weight Behind Orexigen Than Arena, Vivus
2013-11-25,&#91;video&#93; Orexigen Weight-Loss Pill Passes Safety Hurdle
2013-11-21,December 27th Options Now Available For Arena Pharmaceuticals (ARNA)
2013-11-19,Interesting ARNA Put And Call Options For July 2014
2013-11-14,ARNA December 13th Options Begin Trading
2013-11-12,Arena Expands Marketing Of Obesity Drug To Help Shrink Waistlines
2013-11-12,'Mad Money' Lightning Round: Pharmacyclics In, Arena Out
2013-11-11,Trade-Ideas: Arena Pharmaceuticals (ARNA) Is Today's "Barbarian At The Gate" Stock
2013-11-01,Uh Oh Arena Pharma! Q3 Belviq Sales Just $4.8M
2013-10-31,Interesting ARNA Put And Call Options For December 6th
2013-10-24,November 29th Options Now Available For Arena Pharmaceuticals (ARNA)
2013-10-10,November 8th Options Now Available For Arena Pharmaceuticals (ARNA)
2013-10-04,Biotech Stock Mailbag: Bubble Debate, Cel-Sci, Zogenix, Zalicus
2013-09-19,Ariad Pharma: Dismantling The Short Thesis
2013-09-18,'Mad Money' Lightning Round: Cisco Is Smokin'
2013-09-17,Jim Cramer's 'Mad Money' Recap: Don't Fear the Selloff
2013-09-16,Interesting ARNA Put And Call For January 2016
2013-09-16,Grading the Twitterverse's 2013 Biotech Stock Picks
2013-09-13,Biotech Stock Mailbag: Ariad, NewLink, Zogenix, 5 Falling Stocks For Rest of '13
2013-09-09,Another VIVUS CEO Could Be Good News For This Stock
2013-09-04,This Biotech Stock Will Gain From Your Weight Loss
2013-08-30,Trade-Ideas: Arena Pharmaceuticals (ARNA) Is Today's "Dead Cat Bounce" Stock
2013-08-30,'Mad Money' Lightning Round: I Don't Like U.S. Steel
2013-08-30,Biotech Stock Mailbag: Astex Pharma, My Essential Twitter Follows
2013-08-29,Cramer's 'Mad Money' Recap: Bull or Bear?
2013-08-29,Finally, Some Great News For Amarin (At Arena Pharma's Expense)
2013-08-21,Interesting ARNA Put And Call For April 2014
2013-08-01,Arena Pharmaceuticals Inc. (ARNA): Today's Featured Health Care Laggard
2013-08-01,Arena Pharma: Slow Belviq Launch but No Matter for Bel-Phen Data Coming
2013-07-30,Ask SUT
2013-07-30,Vivus Weight-Loss Pill Scripts Are Surging
2013-07-29,3 Things To Watch For With Arena Pharmaceuticals
2013-07-22,One Short Seller's Take On Arena's Slow Belviq Launch
2013-07-11,Playing Obesity Drugs the ETF Way
2013-07-10,Obesity Treatment Shift Could Aid Stocks
2013-07-08,The Best-Performing Obesity Drug Stock May Surprise You
2013-07-05,Arena Stock Hits New 52-Week Low (ARNA)
2017-03-07,ArQule Reports Fourth Quarter And Full Year 2016 Financial Results
2017-02-24,ArQule To Report Fourth Quarter And Year End 2016 Financial Results On March 7, 2017
2017-02-17,Daiichi Sankyo And ArQule Announce The Completion Of The METIV-HCC Phase 3 Study Of Tivantinib In Second-Line Treatment Of MET-Overexpressing Hepatocellular Carcinoma
2017-02-08,ArQule To Present At The Leerink Partners 6th Annual Global Healthcare Conference On February 15, 2017
2016-12-04,Data On Proprietary BTK Inhibitor, ARQ 531, Demonstrating Inhibition Of Wild Type And C481S Mutant BTK And Superiority To Ibrutinib In TCL1 Mouse Model Presented At The American Society Of Hematology Annual Meeting
2016-12-03,Preclinical Data On Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness In The Treatment Of Sickle Cell Disease Presented At The American Society Of Hematology Annual Meeting
2016-11-07,ArQule Reports Third Quarter 2016 Financial Results
2016-11-03,Advancements In ArQule's Proprietary Pipeline To Be Highlighted At The 2016 American Society Of Hematology Annual Meeting
2016-10-24,ArQule To Report Third Quarter 2016 Financial Results On November 7, 2016
2016-09-21,ArQule To Present At The Leerink Partners Rare Disease And Immuno-Oncology Roundtable On September 28, 2016
2016-09-15,ArQule Announces Publication Of Manuscript Highlighting Preclinical Activity Of FGFR Inhibitor, ARQ 087, In Peer Reviewed Journal
2016-08-03,ArQule Reports Second Quarter 2016 Financial Results
2016-07-20,ArQule To Report Second Quarter 2016 Financial Results On August 3, 2016
2016-07-18,ArQule Presents Preclinical Data For ARQ 531, A Proprietary Reversible Inhibitor Of Wild Type And Mutant BTK, At The 2016 Pan Pacific Lymphoma Conference
2016-07-05,ArQule To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference On July 12, 2016
2016-06-30,ArQule Presents Preliminary Clinical Data For ARQ 087 Demonstrating Evidence Of Anticancer Activity In Intrahepatic Cholangiocarcinoma At The ESMO 18th World Congress On Gastrointestinal Cancer
2016-06-23,ArQule To Present Preliminary Phase 1/2 Data For FGFR Inhibitor, ARQ 087, In Intrahepatic Cholangiocarcinoma At The ESMO 18th World Congress On Gastrointestinal Cancer
2016-05-04,ArQule Reports First Quarter 2016 Financial Results
2016-04-20,ArQule To Report First Quarter 2016 Financial Results On May 4, 2016
2016-04-05,ArQule To Present At The 15th Annual Needham Healthcare Conference On April 12, 2016
2016-03-22,Daiichi Sankyo And ArQule Announce Continuation Of METIV-HCC Phase 3 Study Of Tivantinib In Second-Line Hepatocellular Carcinoma
2016-02-29,ArQule Reports Fourth Quarter And Full Year 2015 Financial Results
2016-02-29,ArQule Announces $15.3 Million Registered Direct Offering Of Common Stock
2016-02-15,ArQule To Report Fourth Quarter And Full Year 2015 Financial Results On February 29, 2016
2016-02-04,ArQule To Present At Upcoming Investor Conferences
2016-01-28,ArQule Provides Proprietary Pipeline Update For AKT Inhibitors
2016-01-25,ArQule Presents Clinical Biomarker Data From Phase 2 Study And Ongoing Phase 3 METIV-HCC Study Of Tivantinib In Second-Line Hepatocellular Carcinoma At The 2016 Gastrointestinal Cancers Symposium
2015-12-21,Insider Trading Alert - SUMR, CVO And ARQL Traded By Insiders
2015-12-18,Insider Trading Alert - ARQL, MTSC And PFNX Traded By Insiders
2015-12-17,Insider Trading Alert - SAVE, ARQL And THST Traded By Insiders
2015-12-15,Insider Trading Alert - ORM, OLBK And ARQL Traded By Insiders
2015-12-15,ArQule Announces Orphan Drug Designation In Cholangiocarcinoma And Clinical Update For ARQ 087
2015-12-14,Insider Trading Alert - TIPT, RDNT And ARQL Traded By Insiders
2015-12-10,ArQule And Daiichi Sankyo Announce Completion Of Accrual In METIV-HCC Phase 3 Trial Of Tivantinib For Second-Line Hepatocellular Carcinoma
2015-11-17,ArQule And The National Human Genome Research Institute Of The National Institutes Of Health Announce Enrollment Of First Patient In The Phase 1 Proteus Syndrome Trial With ARQ 092
2015-11-09,UPDATE -- ArQule Presents Data On Tivantinib And Proprietary Pipeline At AACR-NCI-EORTC Conference
2015-11-09,ArQule Presents Data On Tivantinib And Propietary Pipeline At AACR-NCI-EORTC Conference
2015-11-04,ArQule Reports Third Quarter 2015 Financial Results
2015-10-27,ArQule To Present Data On Tivantinib, ARQ 087, ARQ 092, And ARQ 751 At AACR-NCI-EORTC Conference
2015-10-21,ArQule To Report Third Quarter 2015 Financial Results On November 4, 2015
2015-10-15,ArQule Announces Publication Of Manuscript Highlighting Activity Of AKT Inhibitor ARQ 092 And Next Generation AKT Inhibitor ARQ 751 In Oncology
2015-09-28,ArQule Presents Results From Phase 1b Expansion Study Of ARQ 092 At The 2015 European Cancer Conference
2015-09-25,ArQule To Present At Leerink Partners 4th Annual Rare Disease Roundtable On September 30, 2015
2015-09-08,ArQule Presents Additional Clinical Biomarker Data From Phase 2 Study Of Tivantinib In Hepatocellular Carcinoma At International Liver Cancer Association Conference
2015-08-05,ArQule Reports Second Quarter 2015 Financial Results
2015-07-29,ArQule To Report Second Quarter 2015 Financial Results On August 5, 2015
2015-07-06,ArQule Announces Interim Phase 2 Study Results For Tivantinib In Combination With Cetuximab In Patients With MET-High, KRAS Wild Type Colorectal Cancer Presented At ESMO World Congress On Gastrointestinal Cancer 2015
2015-06-01,ArQule Appoints Robert J. Weiskopf As Chief Financial Officer
2015-05-29,ArQule Announces Data Presentations With Tivantinib And ARQ 087 To Be Featured At ASCO 2015
2015-05-27,ArQule, Inc. To Present At Jefferies 2015 Global Healthcare Conference
2015-05-06,ArQule Reports First Quarter 2015 Financial Results
2015-05-05,ArQule And Beryllium Announce Collaborative Research And Development Agreement
2015-04-29,ArQule To Report First Quarter 2015 Financial Results On May 6, 2015
2015-04-21,ArQule Announces Data Presentations With ARQ 087, Inhibitor Of FGFR, At AACR
2015-04-07,ArQule, Inc. To Present At 14th Annual Needham Healthcare Conference
2015-03-25,Interesting ARQL Call Options For May 15th
2015-03-04,ArQule Reports Fiscal 2014 Year End And Fourth Quarter Results
2015-02-25,ArQule To Report Fiscal 2014 Financial Results On March 4, 2015
2015-02-17,ArQule, Inc. To Present At 2015 RBC Capital Markets' Global Healthcare Conference
2015-02-04,ArQule, Inc. To Present At Leerink Global Healthcare Conference
2014-11-21,Insider Trading Alert - ITG, CDXS And ARQL Traded By Insiders
2014-11-13,ArQule Announces Data Presentations With Pipeline Products To Be Featured At 26th EORTC-NCI-AACR Symposium
2014-11-11,ArQule Announces Collaboration With NIH For Clinical Development Of ARQ 092 In Proteus Syndrome
2014-11-10,ArQule Announces Positive Top-Line Results Of NIH-Sponsored Phase 2 Trial Of Tivantinib In Prostate Cancer
2014-11-10,ArQule Announces Third Quarter Fiscal 2014 Results
2014-11-03,ArQule To Report Third Quarter 2014 Financial Results On November 10, 2014
2014-08-05,ArQule Reports Second Quarter 2014 Financial Results
2014-07-29,ArQule To Report Second Quarter 2014 Financial Results On August 5, 2014
2014-06-20,4 Biotech Stocks Under $10 to Watch for Breakout Trades
2014-05-30,ArQule Announces Data Presentations With Tivantinib To Be Featured At ASCO 2014
2014-05-29,ArQule To Present At Jefferies Global Healthcare Conference
2014-05-27,First Week of ARQL January 2015 Options Trading
2014-05-22,5 Stocks Under $10 Set to Soar
2014-05-16,3 Stocks Under $10 Making Big Moves
2014-05-12,Short Interest In ArQule Increases 18.7%
2014-05-07,ArQule Reports First Quarter 2014 Financial Results
2014-04-30,ArQule To Report First Quarter 2014 Financial Results On May 7, 2014
2014-04-02,ArQule, Inc. To Present At Needham 13th Annual Healthcare Conference
2014-03-20,ARQL: Insiders vs. Shorts
2014-03-05,ArQule Reports Fiscal 2013 Year End And Fourth Quarter Results
2014-02-26,ArQule To Report Fiscal 2013 Financial Results On March 5, 2014
2014-02-18,ArQule, Inc. To Present At RBC Capital Markets Healthcare Conference
2014-02-05,ArQule, Inc. To Present At Leerink Swann Global Healthcare Conference
2014-02-04,First Week of March 22nd Options Trading For ArQule (ARQL)
2014-02-04,ArQule Announces Commencement Of Phase 3 Clinical Trial With Tivantinib In Hepatocellular Carcinoma By Partner Kyowa Hakko Kirin In Japan
2014-01-17,First Week of February 22nd Options Trading For ArQule (ARQL)
2014-01-16,ArQule Provides Updates On Clinical Trials In Hepatocellular Carcinoma And Non-Small Cell Lung Cancer With Tivantinib
2014-01-13,Short Interest Declines 16.5% For ARQL
2013-11-07,ArQule Announces Third Quarter Fiscal 2013 Results
2013-10-31,ArQule To Report Third Quarter 2013 Financial Results On November 7, 2013
2013-10-25,ArQule Stock Sees Short Interest Increase 18%
2013-09-30,Data Presented At European Cancer Congress Suggest Clinical Benefit Of Tivantinib In Patients With MET High Non-Squamous Non-Small Cell Lung Cancer
2013-08-12,ArQule Stock Sees Short Interest Decrease By 17%
2013-07-30,ArQule Reports Second Quarter 2013 Financial Results
2013-07-23,ArQule To Report Second Quarter 2013 Financial Results On July 30, 2013
2013-07-05,Commit To Purchase ArQule $2.50, Earn 29.6% Annualized
2013-07-03,ArQule, Inc. To Present At JMP Securities Annual Healthcare Conference
2013-05-15,10 ASCO '13 Abstracts You Can Read Right Now
2013-03-14,ArQule Reports Fiscal 2012 Year End And Fourth Quarter Results
2013-03-07,ArQule To Report Fiscal 2012 Financial Results On March 14, 2013
2013-02-27,ArQule, Inc. To Present At Cowen And Company 33rd Annual Health Care Conference
2013-02-19,ArQule, Inc. To Present At RBC Capital Markets Global Healthcare Conference
2013-02-07,ArQule, Inc. To Present At Leerink Swann Global Healthcare Conference
2013-01-31,Daiichi Sankyo And ArQule Enroll First Hepatocellular Carcinoma Patient Into Global Phase 3 Trial For Tivantinib
2013-01-11,Daiichi Sankyo And ArQule Announce Top-Line Results Of Phase 2 Trial With Tivantinib In Colorectal Cancer
2012-12-13,ArQule Enrolls First Patient In Phase 1 Trial With ARQ 087, An FGFR Inhibitor
2012-12-05,ArQule, Inc. To Present At Oppenheimer Healthcare Conference
2012-11-30,5 Under-$10 Stocks Setting Up to Trade Higher
2012-11-07,ArQule, Inc. To Present At Lazard Healthcare Conference
2012-11-01,ArQule Announces Third Quarter Fiscal 2012 Results
2012-10-26,5 Stocks Poised for Breakouts
2012-10-25,ArQule To Report Third Quarter 2012 Financial Results On November 1, 2012
2012-10-16,ArQule And Daiichi Sankyo Reach Agreement With FDA On Special Protocol Assessment For Phase 3 Trial Of Tivantinib In Hepatocellular Carcinoma
2012-10-02,Dow Closes Lower; Nasdaq, S&P 500 Edge Up
2012-10-02,Arqule Shutters Lung Cancer Study Early Due to Futility
2012-10-02,ArQule And Daiichi Sankyo Announce Discontinuation Of Phase 3 MARQUEE Clinical Trial In Non-Small Cell Lung Cancer
2012-09-12,ArQule, Inc. To Present At UBS Global Life Sciences Conference
2012-08-30,ArQule, Inc. To Present At Upcoming Investment Conferences
2012-08-29,Arqule Shares Slide on Lung Cancer Drug Safety Concern
2012-08-02,ArQule Reports Second Quarter 2012 Financial Results
2012-07-26,ArQule To Report Second Quarter 2012 Financial Results On August 2, 2012
2012-07-06,ArQule, Inc. To Present At JMP Securities Annual Healthcare Conference
2012-06-02,ASCO 2012 Live Blog -- Saturday
2012-06-02,Positive Phase 2 Study Results For Tivantinib In Previously Treated Hepatocellular Carcinoma To Be Presented At ASCO
2012-05-31,ArQule, Inc. To Present At Jefferies 2012 Global Healthcare Conferences
2012-05-22,22 Biopharma Stocks With Breakout Potential in 2012
2012-05-18,ArQule And Daiichi Sankyo Announce Completion Of Patient Recruitment In Phase 3 Clinical Trial Of Tivantinib In Non-Small Cell Lung Cancer
2012-05-17,Positive Phase 2 Clinical Data With Tivantinib In Hepatocellular Carcinoma To Be Highlighted In Oral Presentation At 2012 Annual Meeting Of American Society Of Clinical Oncology
2012-05-17,ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update)
2012-05-16,ASCO '12 Abstract Dump: Cancer Stocks in Focus
2012-05-03,ArQule Reports First Quarter 2012 Financial Results
2012-04-26,ArQule To Report First Quarter 2012 Financial Results On May 3, 2012
2012-04-16,ArQule Announces Completion Of Common Stock Offering With Full Exercise Of Option To Purchase Additional Shares
2012-04-11,ArQule Prices Public Offering Of Common Stock
2012-04-10,ArQule Announces Proposed Public Offering
2012-04-03,3 Stocks Under $10 Moving Higher
2012-03-29,ArQule Announces Presentations At AACR 102nd Annual Meeting
2012-03-28,ArQule, Inc. To Present At 11th Annual Needham Healthcare Conference
2012-03-14,7 Cancer Drug Stocks to Know Right Now
2012-03-02,ArQule, Inc. To Present At Cowen And Company 32nd Annual Healthcare Conference
2012-03-01,ArQule Reports Fiscal 2011 Year End And Fourth Quarter Results
2012-02-23,ArQule To Report Fiscal 2011 Financial Results On March 1, 2012
2012-02-21,ArQule, Inc. To Present At RBC Capital Markets And Citi Conferences
2012-02-09,ArQule, Inc. To Present At Leerink Swann 2012 Global Healthcare Conference
2011-12-06,ArQule, Inc. To Present At Oppenheimer 22nd Annual Healthcare Conference
2011-11-15,Arqule Inc. Stock Downgraded (ARQL)
2011-11-10,ArQule Announces Third Quarter Fiscal 2011 Results
2011-11-10,Daiichi Sankyo To License ARQ 092 From ArQule, The First New Compound Resulting From The Companies&#8217; Joint AKIP Research Collaboration
2011-11-08,ArQule, Inc. To Present At Lazard Capital Markets 8th Annual Healthcare Conference
2011-11-03,ArQule To Report Third Quarter 2011 Financial Results On November 10, 2011
2011-09-12,ArQule, Inc. To Present At UBS Global Life Sciences Conference
2011-09-01,ArQule, Inc. To Present At Stifel Nicolaus 2011 Global Healthcare Conference
2011-08-04,ArQule Reports Second Quarter 2011 Financial Results
2011-07-28,ArQule To Report Second Quarter 2011 Financial Results On August 4, 2011
2011-06-03,ArQule, Inc. To Present At Jefferies 2011 Global Healthcare Conference
2011-05-31,ArQule Comments On Presentations At ASCO 2011
2011-05-10,Arqule Inc. Stock Upgraded (ARQL)
2011-05-05,ArQule Reports First Quarter 2011 Financial Results
2011-04-28,ArQule To Report First Quarter 2011 Financial Results On May 5, 2011
2011-04-28,ArQule, Inc. Announces Appointment Of Dr. Susan Kelley To Board Of Directors
2011-04-11,ArQule, Inc. To Present At Future Leaders In The Biotech Industry Conference
2011-03-31,ArQule Announces Presentations At AACR 102nd Annual Meeting
2011-03-30,ArQule, Inc. To Present At Needham And Leerink Swann Conferences
2011-03-01,ArQule Reports Fiscal 2010 Year End And Fourth Quarter Results
2011-02-28,ArQule, Inc. Announces Departure Of Board Member
2011-02-23,ArQule, Inc. To Present At Citi And Cowen Investment Conferences
2011-02-22,ArQule To Report Fiscal 2010 Financial Results On March 1, 2011
2011-02-07,ArQule, Inc. To Present At 13th Annual BIO CEO And Investor Conference
2011-01-25,ArQule Announces Completion Of Common Stock Offering With Full Exercise Of Overallotment Option
2011-01-24,Phase 1 Results Of ARQ 197 C-MET Inhibitor In Colorectal Cancer Presented At ASCO 2011 Gastrointestinal Cancers Symposium
2011-01-20,ArQule Prices Public Offering Of Common Stock
2011-01-19,ArQule Announces Proposed Public Offering
2011-01-12,Daiichi Sankyo And ArQule Enroll First Non-Small Cell Lung Cancer Patient Into Global Phase 3 Trial For ARQ 197
2010-12-06,ArQule Enrolls First Patient In Phase 1 Trial Of ARQ 736, Its Pan-RAF Inhibitor
2010-11-10,ArQule, Inc. To Present At Lazard Capital Markets 7th Annual Healthcare Conference
2010-11-09,ArQule Announces Third Quarter Fiscal 2010 Results
2010-11-03,ArQule To Report Third Quarter 2010 Financial Results On November 9, 2010
2010-11-02,ArQule Awarded $978,000 In Grants Under The Patient Protection And Affordable Care Act
2010-10-26,ArQule, Inc. To Present At Oppenheimer 21st Annual Healthcare Conference
2010-10-12,ArQule And Daiichi Sankyo Expand Drug Discovery Collaboration In Oncology
2017-03-20,How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More
2017-03-20,Finding Bullish and Bearish Market Reversals
2017-03-20,Biotech Premarket Movers: CytomX, Aevi, Esperion
2017-03-19,Array BioPharma Provides NEMO Update
2017-02-28,PaylPal, CH Robinson Worldwide, Texas Instruments: 'Mad Money' Lightning Round
2017-02-28,Here's Why Buffett Is So Bullish About This Market: Cramer's 'Mad Money' Recap (Monday 2/27/17)
2017-02-03,Analysts' Actions -- Eaton, Ford, Altria, Ralph Lauren and More
2017-01-30,Analysts' Actions -- Air Products, Disney, Colgate-Palmolive, Noble and More
2017-01-21,Take-Two Interactive and Actvision Blizzard: 'Mad Money' Lightning Round
2017-01-21,Buy 'Trump Stocks' on Any Market-Induced Weakness: Cramer's 'Mad Money' Recap (Friday 1/20/17)
2016-12-19,Loxo Oncology Aims for Genetic Mutation Cancer Drug Approval in 2018
2016-12-14,'Mad Money' Lightning Round: Jim Cramer Focuses on Airline, Bank Stocks
2016-12-13,Jim Cramer's 'Mad Money' Recap: Don't Miss This Rotation Back Into the Nasdaq
2016-11-09,The Market Offers Some Opportunities but They're Disappearing Fast
2016-10-31,Take a Chill Pill: If Clinton Wins, Drug-Price Controls Aren't Guaranteed
2016-10-31,Research Reports On Biotech Equities -- Mast Therapeutics, Array BioPharma, Galena Biopharma, And Clovis Oncology
2016-09-30,Shark Bites: Market Responds With 'Deutsche Who?'
2016-09-27,Array BioPharma (ARRY) Stock Up, JPMorgan Raises Price Target on Drug Success
2016-09-26,Futures Swing Into Positive Territory During Debate, Asia Lower
2016-09-26,Noteworthy Monday Option Activity: ARRY, LLNW, LE
2016-09-26,5 Big-Volume Stocks You Should Stay Away From -- Plus 2 to Buy
2016-09-26,Shark Bites: Not Much Reason to Buy in This Environment
2016-09-26,Array BioPharma (ARRY) Stock Soars on Drug Success, Piper Jaffray Ups Price Target
2016-09-26,Putting 2 Biotechs Under the Microscope
2016-09-21,5 Stocks Insiders Love Right Now
2016-09-20,First Week of ARRY November 18th Options Trading
2016-08-29,Array BioPharma (ARRY) Stock Advances, Price Target Raised at Jefferies
2016-08-25,Short Interest Moves 13.5% Lower For ARRY
2016-08-22,Interesting ARRY Put And Call Options For October 21st
2016-08-10,Shareholder Alert: Purcell Julie & Lefkowitz LLP Is Investigating Array BioPharma Inc. For Potential Breaches Of Fiduciary Duty By Its Board Of Directors
2016-08-09,Array BioPharma (ARRY) Stock Drops on Failed Lung Cancer Drug Trial
2016-08-09,Array BioPharma (ARRY) Trading With Heavy Volume Before Market Open
2016-07-28,Array BioPharma Announces Appointment Of Jason Haddock As Chief Financial Officer
2016-06-28,5 Best-Positioned Biotech Stocks on Brexit Volatility
2016-06-08,Array BioPharma (ARRY) Stock: Weak On High Volume Today
2016-04-19,First Week of December 16th Options Trading For Array BioPharma (ARRY)
2016-04-17,Loxo Cancer Drug Targets Gene Mutation With Durable Responses in Early Study
2016-03-30,Array BioPharma (ARRY) Is Today's Strong On High Volume Stock
2016-02-10,Array BioPharma (ARRY) Is Strong On High Volume Today
2016-02-01,Dana-Farber Cancer Institute's Belfer Center Announces Immuno-Oncology Research Collaboration With Array BioPharma
2016-01-29,Array BioPharma (ARRY) Is Today's Strong On High Volume Stock
2016-01-15,Commit To Buy Array BioPharma At $2, Earn 25% Using Options
2016-01-14,Short Interest In Array BioPharma Moves 10.3% Lower
2016-01-13,5 Stocks Insiders Love Right Now
2016-01-11,QIAGEN Reaches Milestone With Portfolio Of Master Collaboration Agreements For Pharma Companion Diagnostics
2015-12-16,Array Biopharma (ARRY) Stock Spikes on Successful Drug Study
2015-12-16,Array BioPharma (ARRY) Moving On Heavy Pre-Market Trading
2015-11-30,Array BioPharma (ARRY): Today's Weak On High Volume Stock
2015-11-24,Array BioPharma (ARRY) Strong On High Relative Volume Today
2015-11-23,Trade-Ideas: Array BioPharma (ARRY) Is Today's Weak On High Relative Volume Stock
2015-11-17,Array BioPharma Enters Oversold Territory (ARRY)
2015-10-21,First Week of ARRY June 2016 Options Trading
2015-10-07,5 Stocks Insiders Love Right Now
2015-09-29,Array BioPharma Becomes Oversold (ARRY)
2015-09-25,Interesting ARRY Put And Call Options For November 20th
2015-09-25,Array BioPharma (ARRY) Flagged As Strong On High Volume
2015-09-08,Ratings Changes Today
2015-08-29,'Mad Money' Lightning Round: I'm No Fan of Groupon
2015-08-28,Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
2015-08-19,5 Stocks Insiders Love Right Now
2015-08-04,Jim Cramer's 'Mad Money' Recap: Nowhere to Run, Nowhere to Hide From China
2015-08-04,'Mad Money' Lightning Round: Marriott International Is a Buy
2015-08-03,Jim Cramer's 'Mad Money' Recap: Why the Oil and China News Isn't All Bad
2015-07-28,Today's Weak On High Volume Stock: Array BioPharma (ARRY)
2015-07-24,Oversold Conditions For Array BioPharma (ARRY)
2015-07-22,Array BioPharma (ARRY) Moving On Heavy Pre-Market Trading
2015-07-21,First Week Of ARRY March 2016 Options Trading
2015-06-01,Binimetinib And Encorafenib Combination Shows Promising Clinical Activity And Potential Differentiated Safety In BRAF-Mutant Melanoma
2015-05-19,First Week Of July 17th Options Trading For Array BioPharma (ARRY)
2015-05-06,Trade-Ideas: Array BioPharma (ARRY) Is Today's "Dead Cat Bounce" Stock
2015-05-05,Ratings Changes Today
2015-05-05,Perilous Reversal Stock: Array BioPharma (ARRY)
2015-05-04,Array Biopharma (ARRY) Stock Jumping After Earnings Beat
2015-04-27,Array BioPharma Enters Oversold Territory
2015-03-31,Array BioPharma CEO Sees Big Opportunities in the Future
2015-03-31,January 2017 Options Now Available For Array BioPharma (ARRY)
2015-03-25,First Week Of May 15th Options Trading For Array BioPharma (ARRY)
2015-02-26,Array BioPharma Stock Sees Short Interest Increase 19.5%
2015-02-05,Strong On High Volume: Array BioPharma (ARRY)
2015-01-30,'Mad Money' Lightning Round: Alliant Techsystems Is Fabulous
2015-01-29,Jim Cramer's 'Mad Money' Recap: The Bears Retreat and the Market Celebrates
2015-01-26,Today's Perilous Reversal Stock: Array BioPharma (ARRY)
2015-01-23,How to Trade the Market's Most-Active Stocks: UPS, Avon and More
2015-01-23,Array BioPharma (ARRY) Is Today's Strong On High Volume Stock
2014-12-26,First Week Of February 2015 Options Trading For Array BioPharma
2014-12-04,ARRY Crosses Above Key Moving Average Level
2014-12-03,Array Biopharma Regains Rights to Cancer Drug From Novartis
2014-11-25,First Week Of ARRY January 2015 Options Trading
2014-11-24,Array BioPharma (ARRY) Is Today's Strong On High Volume Stock
2014-11-04,Array BioPharma (ARRY) Strong On High Relative Volume Today
2014-09-24,First Week of ARRY November 22nd Options Trading
2014-09-12,Array BioPharma Appoints Victor Sandor, M.D., As Chief Medical Officer
2014-09-11,Array BioPharma Appoints Victor Sandor, M.D., As Chief Medical Officer
2014-09-10,June 2015 Options Now Available For Array BioPharma (ARRY)
2014-08-25,Five Billionaire-Owned Biotech Stocks You Could Acquire for 100%
2014-08-19,First Week of October 18th Options Trading For Array BioPharma (ARRY)
2014-07-22,Interesting ARRY Put And Call Options For March 2015
2014-06-14,'Mad Money' Lightning Round: Time Warner Cable Is a Buy, Buy, Buy
2014-06-13,Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
2014-06-02,Two Array-Invented MEK Inhibitors Showcased At ASCO
2014-05-28,Array BioPharma Announces Drug Discovery Collaboration Agreement With Biogen Idec
2014-05-20,First Week of July 19th Options Trading For Array BioPharma (ARRY)
2014-04-23,First Week of ARRY December 20th Options Trading
2014-03-26,First Week Of ARRY May 17th Options Trading
2014-03-18,ARRY Crosses Above Key Moving Average Level
2014-03-05,Price Movements, Clinical Trial Results, And Solid Financial Reports - Analyst Notes On Pfizer, Dendreon, DepoMed, Globus Medical, And Array
2014-02-26,Array CEO: Partnerships Smart While Cancer Drug Develops
2014-02-26,First Week of April 19th Options Trading For Array BioPharma (ARRY)
2014-01-23,First Week Of ARRY September 20th Options Trading
2013-12-04,Insider Trading Alert - MTOR, ARRY, SJM, RNR And AMZN Traded By Insiders
2013-12-04,4 Biotech Stocks Under $10 to Watch
2013-10-23,First Week Of June 2014 Options Trading For Array BioPharma (ARRY)
2013-10-01,Top Insider Trades: CPRT DOOR MCS ARRY
2013-09-28,Jim Cramer's Top Stock Picks: DNKN PCYC ARRY GME
2013-09-27,Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
2013-09-27,Interesting ARRY Put And Call For November 16th
2013-09-17,Top Insider Trades: HD PBF ARRY GBDC
2013-08-21,First Week Of October 19th Options Trading For Array BioPharma (ARRY)
2013-07-24,Interesting ARRY Put And Call For March 2014
2013-07-23,Array Seeks Asthma Drug Partner Following Mid-Stage Study Results
2013-07-02,TSRX, CYTK, ARRY: 3 Stocks on TV
2013-07-01,Cramer's 'Mad Money' Recap: Ignore the Headlines
2013-06-01,ASCO '13: Array Drug First to be Effective Against Melanoma of the Eye
2013-05-15,10 ASCO '13 Abstracts You Can Read Right Now
2013-04-29,Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2013 On May 6, 2013
2013-04-02,4 Health Care Stocks Under $10 to Watch
2013-01-10,10 Biotech Stocks With A History Of Beating Earning Expectations
2013-01-02,The Twitterverse's Biotech Stock Picks for 2013
2012-12-10,Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting
2012-11-27,4 Biotech Stocks Under $10 Moving Higher
2012-11-09,Stocks Finish Tough Week With Slight Gains
2012-11-09,Array BioPharma Announces Pricing Of Public Offering Of Common Stock
2012-09-25,4 Biotech Stocks Under $10 Soaring Higher
2012-09-25,Stocks Under $10: Blossoming Biotech Play
2012-09-20,3 Stocks Under $10 Moving Higher
2012-09-11,Array BioPharma To Present At The UBS Global Life Sciences Conference
2012-09-10,Array BioPharma's CEO Presents At Morgan Stanley Healthcare Conference - Transcript
2012-08-31,Array BioPharma Announces Changes To Board Of Directors
2012-08-29,Array BioPharma To Present At The Stifel Nicolaus Healthcare, NewsMakers In The Biotech Industry And Morgan Stanley Global Healthcare Conferences
2012-08-14,Array BioPharma's CEO Discusses F4Q2012 Results - Earnings Call Transcript
2012-08-13,Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2012
2012-08-06,Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2012 On August 13, 2012
2012-07-31,Array BioPharma&#8217;s ARRY-797 Meets Primary Endpoint In Clinical Proof Of Concept Trial In Osteoarthritis Patients Whose Pain Is Poorly Controlled By NSAIDs
2012-07-24,Andrew Robbins, Senior Vice President, Commercial Operations, Array BioPharma (Photo: Business Wire)
2012-07-19,8 Stocks Under $10 Skyrocketing Higher
2012-07-19,Array BioPharma Achieves $8.5 Million Clinical Milestone In&#160;Amgen Diabetes Collaboration
2012-07-16,Clovis Oncology And Array BioPharma Announce Agreement To Discover Novel Mutant KIT Inhibitor
2012-07-03,Array BioPharma To Present At The JMP Securities Healthcare Conference 2012
2012-06-25,Synta: Waiting, Waiting, Waiting for Lung Cancer Data
2012-06-04,Promising Data For KRAS Mutant Advanced NSCLC Patients Presented At ASCO
2012-06-04,MEK162 Shows Promising Clinical Activity In Ongoing Phase 2 Trial
2012-06-04,ASCO 2012 Live Blog -- Monday
2012-05-30,Array BioPharma To Present At The Jefferies 2012 Global Healthcare Conference
2012-05-25,Biotech Stock Mailbag: ASCO, Celldex, Obesity Drug Game-Changer
2012-05-25,The Next Big Thing in Biotech: ASCO Conference
2012-05-17,7 Stocks Under $10 Making Big Moves
2012-05-17,Biotech Stock Live Chat Recap: ASCO & Obesity
2012-05-17,ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update)
2012-05-16,ASCO '12 Abstract Dump: Cancer Stocks in Focus
2012-05-16,Hot Biotech Stocks Traded by Hedge Funds in First Quarter
2012-05-14,Array BioPharma And Genentech's Strategic Alliance Voted Breakthrough Alliance Of 2012
2012-04-30,Liam Ratcliffe, M.D., Ph.D., Independent Director, Array BioPharma Board Of Directors (Photo: Business Wire)
2012-04-23,Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2012 On April 30, 2012
2012-04-16,Array BioPharma Names Howard Holden, Ph.D., Vice President Of Regulatory Affairs And Quality Assurance
2012-04-05,7 Stocks Under $10 Making Big Moves
2012-04-04,Encouraging Selumetinib Results Announced For Phase 2 Trial In Ovarian Cancer
2012-03-14,7 Cancer Drug Stocks to Know Right Now
2012-02-27,Array BioPharma To Present At The Cowen And Company 32nd Annual Health Care Conference
2012-02-14,Array BioPharma Announces Closing Of Public Offering Of Common Stock And Exercise Of Overallotment Option
2012-02-09,Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
2012-02-09,Array BioPharma Announces Proposed Public Offering Of Common Stock
2012-02-09,Array BioPharma Stock Gaps Down On Today's Open (ARRY)
2012-02-08,Array BioPharma Announces Proposed Public Offering Of Common Stock
2012-01-31,8 Stocks Under $10 Soaring Higher
2012-01-30,Array BioPharma Names Gwen A. Fyfe, M.D. To Board Of Directors
2012-01-30,Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2012
2012-01-23,Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2012 On January 30, 2012
2012-01-16,Array BioPharma's Chief Executive Officer Robert E. Conway Resigns
2012-01-04,Array BioPharma To Present At The 30th Annual J.P. Morgan Healthcare Conference
2011-12-11,ARRY-614 Demonstrates Positive Single Agent Activity In Patients With Myelodysplastic Syndromes
2017-03-24,Stocks Under $10 Weekly Summary
2017-03-21,First Week of November 17th Options Trading For Antares Pharma (ATRS)
2017-03-17,Stocks Under $10 Weekly Summary
2017-03-14,Quarter Gives Antares Pharma a 'QuickShot'
2017-03-14,Antares Pharma Reports Fourth Quarter And Full Year 2016 Operating And Financial Results
2017-03-10,Stocks Under $10 Weekly Summary
2017-03-06,Antares Pharma To Report Fourth Quarter And Full Year 2016 Financial And Operating Results And Host Webcast And Conference Call
2017-03-03,Stocks Under $10 Weekly Summary
2017-02-28,Antares Pharma To Present At The Cowen And Company 37th Annual Healthcare Conference
2017-02-27,Antares Pharma Announces FDA Acceptance Of New Drug Application For Quickshot® Testosterone
2017-02-24,Stocks Under $10 Weekly Summary
2017-02-10,Stocks Under $10 Weekly Summary
2017-02-03,Stocks Under $10 Weekly Summary
2017-01-30,Injecting Some Testosterone Into the Portfolio
2017-01-11,2 Bargain Stocks Boasting Big Insider Buys
2016-12-21,Antares Pharma Announces Submission Of New Drug Application For Quickshot® Testosterone
2016-12-20,First Week of August 2017 Options Trading For Antares Pharma (ATRS)
2016-12-19,Antares Pharma Announces The Successful Completion Of Teva's Decentralized Procedure For Teriparatide Injection In Europe
2016-11-23,Antares Pharma To Present At The 28th Annual Piper Jaffray Healthcare Conference
2016-11-10,Antares Pharma To Present At The Jefferies 2016 Global Healthcare Conference
2016-11-09,Antares Pharma Reports Third Quarter 2016 Financial And Operating Results
2016-11-03,Antares Pharma To Report Third Quarter Financial And Operating Results And Host Webcast And Conference Call
2016-11-02,Antares Pharma Announces Presentations At The Sexual Medicine Society Scientific Annual Meeting
2016-10-31,Antares Pharma Appoints Fred M. Powell, Senior Vice President And Chief Financial Officer
2016-10-28,Antares Pharma Announces Multiple Presentations At The Sexual Medicine Society Scientific Annual Meeting
2016-09-22,Antares Pharma Announces Completion Of The QuickShot Testosterone Clinical Program
2016-09-20,Antares Pharma To Present At The Ladenburg Thalmann 2016 Healthcare Conference
2016-09-09,Teva Discusses EpiPen Comps as Host of Generics Unveiled
2016-08-09,Antares Pharma Reports Second Quarter 2016 Operating And Financial Results
2016-08-02,Antares Pharma To Report Second Quarter Financial And Operating Results And Host Webcast And Conference Call
2016-06-27,Teva And Antares Pharma Announce Launch Of Generic Imitrex® In The United States
2016-06-23,Antares Pharma Announces Settlement Of Patent Litigation For Key Alliance Business Product
2016-06-20,ATRS: Insiders vs. Shorts
2016-06-01,Antares Pharma To Present At The Jefferies 2016 Healthcare Conference
2016-06-01,Antares Pharma Announces Update To QuickShot Testosterone Clinical Program
2016-05-12,Short Interest Moves 16.5% Lower For ATRS
2016-05-09,Antares Pharma Reports First Quarter 2016 Operating And Financial Results
2016-05-02,Antares Pharma To Host First Quarter Operating And Financial Results Conference Call
2016-04-27,Antares Pharma To Present At The Deutsche Bank Securities, Inc. 41st Annual Health Care Conference
2016-04-25,OTREXUP.COM Website Awarded A Bronze Horizon Interactive Award
2016-03-29,Additional Dosage Strengths Of Otrexup™ (methotrexate) Injection Approved By FDA
2016-03-24,Insider Trading Alert - ATRS, CMT And CTIC Traded By Insiders
2016-03-22,Insider Trading Alert - FLML, WLFC And ATRS Traded By Insiders
2016-03-21,ATRS: Insiders vs. Shorts
2016-03-16,Antares Pharma Announces Completion Of The 52 Week QuickShot® Phase 3 Study In Testosterone Deficient Men
2016-03-08,Antares Pharma (ATRS) Stock Lower on Q4 Results
2016-03-08,Antares Pharma Reports Fourth Quarter And Full Year 2015 Operating And Financial Results
2016-03-02,Antares Pharma To Present At The Cowen And Company 36th Annual Healthcare Conference
2016-03-01,Antares Pharma To Host Fourth Quarter And Full Year 2015 Operating And Financial Results Conference Call
2016-01-26,Antares Pharma Announces CEO Transition
2016-01-07,Antares Pharma To Present At The 34th Annual J.P. Morgan Healthcare Conference
2015-12-14,Antares Pharma Announces FDA Approval Of Sumatriptan Injection USP
2015-12-06,5 Stocks Under $10 Set to Soar
2015-12-02,Antares Pharma To Present At The 26th Annual Oppenheimer Healthcare Conference
2015-11-20,Antares Pharma Announces Poster Presentation At The Sexual Medicine Society Scientific Annual Meeting
2015-11-09,Antares Pharma Announces Podium Presentation Of OTREXUP™ Dose Conversion Data At American College Of Rheumatology Annual Meeting
2015-11-05,Antares Pharma Reports Third Quarter 2015 Operating And Financial Results
2015-11-03,Antares Pharma Announces Enrollment Complete In Quickshot® Supplemental Safety Study QST-15-005
2015-10-30,Antares Pharma Announces Update To Quickshot Testosterone Clinical Program
2015-10-28,Antares Pharma To Host Third Quarter 2015 Operating And Financial Results Conference Call
2015-09-28,Antares Pharma Announces Publication Of QuickShot® Testosterone Data In Prestigious Health Journal
2015-09-24,Antares Pharma To Present At The Ladenburg Thalmann 2015 Healthcare Conference
2015-08-26,Insider Trading Alert - ATRS, SJW And N Traded By Insiders
2015-08-10,Antares Pharma Reports Second Quarter 2015 Operating And Financial Results
2015-08-04,Antares Pharma Announces First Patients Enrolled In QuickShot® Testosterone Supplemental Safety Study
2015-08-03,Antares Pharma To Host Second Quarter 2015 Operating And Financial Results Conference Call
2015-07-14,Antares Pharma Appoints Peter J. Graham, Esq., Senior Vice President, General Counsel, Human Resources, Chief Compliance Officer And Corporate Secretary
2015-06-29,Drawing Up a Potential Shopping List
2015-06-26,Short Interest Makes 11% Move For ATRS
2015-06-23,First Week Of February 2016 Options Trading For Antares Pharma (ATRS)
2015-06-16,Antares Pharma To Present At The JMP Securities Life Sciences Conference
2015-06-04,Sell These 7 Health Care Supplies Companies Now
2015-06-01,Antares Pharma Announces Additional Update To QuickShot Testosterone Program
2015-05-28,Antares Pharma To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-11,Antares Pharma Announces Closing Of Public Offering Of Common Stock
2015-05-11,Antares Pharma Reports First Quarter 2015 Operating And Financial Results
2015-05-06,Antares Pharma To Present At The Bank Of America Merrill Lynch 2015 Healthcare Conference
2015-05-06,Antares Pharma Announces Pricing Of Public Offering Of Common Stock
2015-05-05,Antares Pharma To Host First Quarter 2015 Operating And Financial Results Conference Call
2015-05-05,Antares Pharma Announces Proposed Public Offering Of Common Stock
2015-04-30,Antares Pharma To Present At The Deutsche Bank Securities, Inc. 40th Annual Health Care Conference
2015-04-27,Antares Pharma Regains U.S. Marketing Rights To OTREXUP For Psoriasis Indication - Announces Termination Of LEO Pharma Marketing Agreement
2015-04-21,First Week Of June 19th Options Trading For Antares Pharma (ATRS)
2015-04-16,Antares Pharma Announces Settlement Of Patent Infringement Lawsuits
2015-04-01,First Week Of November 20th Options Trading For Antares Pharma (ATRS)
2015-03-31,Antares Pharma Announces FDA Approval Of TEV-TROPIN(R) 10 Mg (Human Growth Hormone) Needle-Free Injector
2015-03-25,Insider Trading Alert - GMAN, ATRS And MMI Traded By Insiders
2015-03-12,Antares Pharma Reports Fourth Quarter And Full Year 2014 Operating And Financial Results
2015-03-05,Antares Pharma To Host Fourth Quarter 2014 Operating And Financial Results Conference Call
2015-02-25,Antares Pharma Announces Positive Top-Line Pharmacokinetic Results From The QuickShot® Phase 3 Study In Testosterone Deficient Men
2015-02-23,Antares Pharma To Present At The Cowen And Company 35Th Annual Healthcare Conference
2015-02-18,Antares Pharma To Present At The 2015 RBC Capital Markets' Global Healthcare Conference
2015-02-10,ATRS: Insiders Vs. Shorts
2015-02-09,First Week Of ATRS March 20th Options Trading
2015-01-26,Antares Pharma Provides Regulatory Update On Sumatriptan Injection USP
2015-01-13,Antares Pharma Announces Update To QuickShot® Testosterone Program
2015-01-08,Antares Pharma To Present At The 33rd Annual J.P. Morgan Healthcare Conference
2014-12-24,Interesting ATRS Put Options For August 2015
2014-12-11,Short Interest In Antares Pharma Decreases By 11%
2014-12-03,Antares Pharma To Present At The 25th Annual Oppenheimer Healthcare Conference
2014-11-25,Antares Pharma To Present At The 26th Annual Piper Jaffray Healthcare Conference
2014-11-18,Antares Pharma Appoints James E. Fickenscher, Senior Vice President, Chief Financial Officer
2014-11-06,Antares Pharma Reports Third Quarter 2014 Operating And Financial Results
2014-11-03,Antares Pharma Announces Last Patient Enrolled In Phase 3 QuickShot® Study Evaluating Testosterone-Deficient Adult Males
2014-10-30,Antares Pharma To Host Third Quarter 2014 Operating And Financial Results Conference Call
2014-09-24,Interesting ATRS Call Options For May 2015
2014-09-15,Antares Pharma Announces Promotion Of Robert F. Apple To Chief Operating Officer
2014-09-03,Antares Pharma To Participate At The Morgan Stanley Healthcare Conference
2014-08-28,5 Breakout Stocks Under $10 Set to Soar
2014-08-13,ATRS: Insiders vs. Shorts
2014-08-07,Antares Pharma Reports Second Quarter 2014 Operating And Financial Results
2014-07-31,Antares Pharma To Host Second Quarter 2014 Operating And Financial Results Conference Call
2014-07-22,Antares Pharma Announces First Patient Dosed In Phase 3 QuickShot Study Evaluating Testosterone-Deficient Adult Males
2014-06-25,Interesting ATRS Put Options For February 2015
2014-06-25,Rapid Restoration And Consistent Maintenance Of Steady Blood Levels Achieved With Once-Weekly Subcutaneous Administration Of Testosterone Delivered With A Novel Auto Injector
2014-06-24,Antares Pharma Announces Changes In Senior Leadership
2014-05-28,Antares Pharma To Present At The Jefferies 2014 Global Healthcare Conference
2014-05-22,Antares Pharma Appoints Jennifer Evans Stacey, Esq., Senior Vice President, General Counsel, Human Resources And Secretary
2014-05-20,Interesting ATRS Put Options For July 19th
2014-05-20,Antares Pharma Announces The Publication Of Three Abstracts At The 2014 European League Against Rheumatism Annual Congress
2014-05-13,Antares Pharma To Present At The UBS Global HealthCare Conference
2014-05-09,Antares Pharma Reports First Quarter 2014 Operating And Financial Results
2014-05-07,Antares Pharma To Present At The Bank Of America Merrill Lynch 2014 Healthcare Conference
2014-05-06,Antares Pharma Announces Update To QuickShot Testosterone Program
2014-05-02,Antares Pharma To Host First Quarter 2014 Operating And Financial Results Conference Call
2014-04-24,Antares Pharma To Present At The Deutsche Bank Securities, Inc. 39th Annual Health Care Conference
2014-04-17,Drug-Exposure Limitations Of Oral Methotrexate At Doses Greater Than Or Equal To 15 Mg May Be Overcome With Subcutaneous Administration
2014-04-16,Antares Pharma Announces Additional Patent Coverage For OTREXUP
2014-04-07,Antares Pharma Inc. Stock Downgraded (ATRS)
2014-04-04,Ratings Changes Today
2014-03-26,Interesting ATRS Put And Call Options For November 22nd
2014-03-13,Antares Pharma Reports Fourth Quarter And Full Year 2013 Operating And Financial Results
2014-03-12,Antares Pharma Receives Second Milestone Payment From LEO Pharma In OTREXUP Collaboration
2014-03-11,Medac Pharma, Inc. Announces The Issuance Of U.S. Patent For Treating Autoimmune Diseases With Concentrated Methotrexate Solutions Of More Than 30 Mg/ml
2014-03-10,Antares Pharma Announces LEO Pharma&#8217;s Launch Of OTREXUP (Methotrexate) Injection To Dermatologists For Adults With Psoriasis
2014-03-06,Antares Pharma To Host Fourth Quarter 2013 Operating And Financial Results Conference Call
2014-02-26,First Week Of ATRS April 19th Options Trading
2014-02-26,Antares Pharma To Present At The Cowen And Company 34th Annual Healthcare Conference
2014-02-20,Antares Pharma Announces Positive Results From The VIBEX QuickShot Pharmacokinetic Study In Testosterone Deficient Men
2014-02-19,Antares Pharma To Participate In The 2014 RBC Capital Markets&#8217; Global Healthcare Conference
2014-01-23,Interesting ATRS Call Options For March 22nd
2014-01-15,Antares Pharma Announces Availability Of OTREXUP (Methotrexate) Injection For Subcutaneous Use To Treat Rheumatoid Arthritis (RA) And Psoriasis In Adults, And Polyarticular Idiopathic Arthritis (pJIA) In Children
2014-01-09,Interesting ATRS Call Options For January 18th
2014-01-06,Antares Pharma To Present At The 32nd Annual J.P. Morgan Healthcare Conference
2013-12-27,Antares Pharma (ATRS) Shares Cross Below 200 DMA
2013-12-27,First Week of August 2014 Options Trading For Antares Pharma (ATRS)
2013-12-20,Antares Pharma&#174; Announces Notice Of Allowance For New Patent On Reconstitutable Lyophilized Injectables
2013-12-04,Antares Pharma To Present At The Oppenheimer 24th Annual Healthcare Conference
2013-11-26,Antares Pharma Announces Additional U.S. Patent Protection For OTREXUP&#8482;
2013-11-19,Antares Pharma Appoints David H. Bergstrom Ph.D. As Senior Vice President Pharmaceutical Development
2013-11-15,Antares Pharma To Present At The Jefferies 2013 Global Healthcare Conference
2013-11-14,Antares Pharma Enters Into An Exclusive U.S. Promotion And Marketing Agreement With LEO Pharma For OTREXUP&#8482; In Dermatology
2013-11-06,Antares Pharma Reports Third Quarter 2013 Operating And Financial Results
2013-11-04,Antares Pharma Appoints Dr. Bruce Freundlich As Senior Vice President
2013-10-31,Antares Pharma To Host Third Quarter 2013 Operating And Financial Results Conference Call
2013-10-25,Antares Pharma Announces The Issuance Of A New U.S. Patent On The VIBEX&#174; Device Platform
2013-10-23,First Week Of ATRS December 21st Options Trading
2013-10-16,Antares Announces Podium Presentation Of Pivotal OTREXUP&#8482; (methotrexate) Data At American College Of Rheumatology Annual Meeting
2013-10-14,Antares' Otrexup Approval Was Easy, Selling Drug Will be Hard
2013-10-14,OTREXUP&#8482; (methotrexate) Injection Approved By FDA A New Treatment For Adults With Rheumatoid Arthritis, Children With Polyarticular Idiopathic Arthritis, And Adults With Psoriasis
2013-10-02,Dividend Increases, Research Nominations, New Treatment Options, And Clinical Trials - Research Report On Covidien, Ironwood, ICON, Novadaq, And Antares
2013-10-02,4 Biotech Stocks Under $10 Making Moves
2013-09-26,First Week Of May 2014 Options Trading For Antares Pharma (ATRS)
2013-09-16,Antares Pharma Announces First Patients Dosed In VIBEX&#8482; QS T Study Evaluating Testosterone Deficient Males
2013-08-23,Ratings Changes Today
2013-08-07,3 Stocks Under $10 Moving Higher
2013-08-07,Antares Pharma Reports Second Quarter 2013 Operating And Financial Results
2013-07-31,Antares Pharma To Host Second Quarter 2013 Operating And Financial Results Conference Call
2013-07-30,Antares Pharma Welcomes Robert P. Roche Jr. To Board Of Directors
2013-07-24,First Week Of ATRS September 21st Options Trading
2013-06-28,Biotech Stock Mailbag: Antares Pharma, NewLink, Celgene
2013-06-27,Antares Pharma Announces The Issuance Of A New U. S. Patent For OTREXUP&#8482;
2013-06-13,Subcutaneous, Self-Administered Methotrexate For Rheumatoid Arthritis Demonstrated Significantly Greater Bioavailability Over Current Standard Of Care
2013-05-21,2013 FDA Drug Approval Calendar
2013-04-25,5 Stocks Under $10 Set to Soar
2013-03-13,Antares Pharma Reports Fourth Quarter And Full Year 2012 Operating And Financial Results
2013-03-06,Antares Pharma To Host Fourth Quarter 2012 Call
2013-02-27,Antares Pharma Announces FDA Acceptance Of New Drug Application For OTREXUP&#8482;
2013-02-26,Antares Pharma To Present At The Cowen And Company 33rd Annual Healthcare Conference
2013-02-20,Antares Pharma To Participate In The 2013 RBC Capital Markets&#8217; Healthcare Conference
2017-02-13,Aviragen Therapeutics Announces Top-Line Results From Phase 2b SPIRITUS Trial Of Vapendavir
2017-02-02,Aviragen Therapeutics Reports Second Quarter Fiscal Year 2017 Financial Results
2017-02-01,Aviragen Therapeutics Announces Top-Line Results From Phase 2a RSV Challenge Study Of BTA585
2017-01-26,Aviragen Therapeutics To Host Conference Call To Report Second Quarter Fiscal Year 2017 Financial Results On February 2, 2017
2016-11-09,Aviragen Therapeutics To Present At Stifel 2016 Healthcare Conference
2016-11-03,Aviragen Therapeutics Reports First Quarter Fiscal Year 2017 Financial Results
2016-10-27,Aviragen Therapeutics To Host Conference Call To Report First Quarter Fiscal Year 2017 Financial Results On November 3, 2016
2016-10-10,Aviragen Therapeutics To Host KOL Meeting On HRV Infections On October 13, 2016 In New York
2016-09-14,Aviragen Therapeutics Reports Fourth Quarter And Fiscal Year 2016 Financial Results
2016-09-13,Aviragen Therapeutics Announces Rescheduled Date And Time Of Fourth Quarter And Fiscal Year 2016 Financial Results On September 14, 2016
2016-09-07,Aviragen Therapeutics To Present At Upcoming Investor Conferences
2016-09-06,Aviragen Therapeutics Announces Inducement Grant For New Employees
2016-09-06,Aviragen Therapeutics Announces Schedule Change For Fourth Quarter And Fiscal Year End 2016 Financial Results Conference Call And Webcast
2016-09-01,Aviragen Therapeutics To Host Conference Call To Report Fourth Quarter And Fiscal Year 2016 Financial Results On September 8, 2016
2016-07-12,Aviragen Therapeutics Resumes Enrollment In Phase 2a RSV Challenge Trial
2016-07-05,Aviragen Therapeutics And Georgia State University Research Foundation Enter Exclusive License And Sponsored Research Agreement To Develop Novel Antiviral Therapies
2016-07-01,Aviragen Therapeutics Announces Inducement Grant For New Employee
2016-06-28,Aviragen Therapeutics Announces The Appointment Of Jonas Niaura As Vice President, Corporate Development And Strategy
2016-05-26,Aviragen Therapeutics Provides Update On Phase 2a Trial Of BTA585 For The Treatment Of RSV Infections
2016-05-05,Aviragen Therapeutics Reports Third Quarter Fiscal Year 2016 Financial Results
2016-04-28,Aviragen Therapeutics To Host Conference Call To Report Third Quarter Fiscal Year 2016 Financial Results On May 5, 2016
2016-04-25,Aviragen Therapeutics Completes Royalty Deal With HealthCare Royalty Partners For Proceeds Of $20 Million
2016-04-14,Aviragen Therapeutics To Participate In FBR & Co. Healthcare Series Focused On Infectious Diseases
2001-12-06,Who Wins, Who Loses in the MedImmune-Aviron Deal
2001-12-04,Biotech Bonus
2001-12-03,MedImmune Fattens Its Drug Pipeline by Buying Aviron
2001-12-03,MedImmune to Buy Aviron for $1.5 Billion
2001-09-04,Aviron Says Flu Drug Won't Be as Late as Feared
2001-08-15,Aviron Could Make a Healthy Comeback
2001-03-15,The Daily Interview: GenomicsFund.com's Steve Newby
,
,
,
,
,
2017-03-24,Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk
2017-03-21,Axovant Sciences To Present At Upcoming Scientific Meetings
2017-03-20,Axovant Sciences Announces Presentation Time Change At Oppenheimer Healthcare Conference
2017-03-14,Notable Tuesday Option Activity: AXON, GPRO, VHC
2017-02-27,Axovant Sciences To Present At Upcoming Investor Conferences
2017-02-13,Axovant Sciences Announces Preliminary Results From Interim Analysis Of Phase 2 Study Testing Investigational Drug Nelotanserin In Lewy Body Dementia Patients
2017-02-03,Axovant Sciences Announces $55.0 Million Venture Debt Financing From Hercules Capital
2017-01-25,Axovant Sciences To Present At Upcoming Investor Conferences
2017-01-09,Axovant Sciences Announces Pipeline Program Updates And Presentation At 35th Annual J.P. Morgan Conference
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2016-12-09,Axovant Unveils New Data Analysis Showing Addition Of Intepirdine To Standard Therapy May Help People With Alzheimer's Disease Maintain Independence Longer
2016-12-05,Axovant To Present Patient Function And Independence Data Analyses From Phase 2b Study Of Investigational Treatment Intepirdine In Alzheimer's Disease At CTAD 2016
2016-11-01,Axovant Sciences To Present At Upcoming Investor Conferences
2016-10-19,Patrick Machado Joins Board Of Directors Of Roivant Sciences
2016-09-26,Axovant Sciences Receives FDA Fast-Track Designation For Intepirdine As An Investigational Treatment For Dementia With Lewy Bodies
2016-09-22,Axovant Sciences (AXON) Stock Slumps, Baird: Weakness 'Unwarranted'
2016-09-22,Axovant Sinks on Rival's Alzheimer's Drug Setback
2016-09-21,Doctors Say Yearly Memory Evaluations Are Critical To Early Diagnosis, Effective Treatment Of Alzheimer's Disease
2016-09-06,Axovant Sciences To Present At The Morgan Stanley Global Healthcare Conference
2016-08-31,Axovant Sciences to Present at the Baird 2016 Global Healthcare Conference
2016-07-24,Alzheimer's Experts Call For End To Under-Treatment Of Disease
2016-07-18,Axovant Sciences Announces Presentations And Sponsored Symposium At The 2016 Alzheimer's Association International Conference
2016-07-13,Roivant Sciences Appoints Professor Andrew Lo, PhD As Independent Director
2016-06-15,Axovant Sciences To Present At The JMP Securities Life Sciences Conference
2016-05-23,Commit To Purchase Axovant Sciences At $10, Earn 29.6% Annualized Using Options
2016-05-13,Axovant Sciences Appoints Dr. Gary P. Pisano To Board Of Directors
2016-05-09,Axovant Sciences To Present At Upcoming Investor Conferences
2016-05-05,Acadia Drug Approval May Entice Biogen, Teva as Buyers
2016-04-19,Call To Action For Participation In Clinical Trials Is Topic Of Symposium At Alzheimer's Disease International Conference 2016
2016-04-04,Axovant Sciences To Present At The Goldman Sachs Alzheimer's Symposium
2016-02-23,Axovant Sciences To Present At Upcoming Investor Conference
2016-02-02,Axovant Sinks on Pfizer Alzheimer's Drug Blowup
2016-01-27,Axovant Sciences To Present At Upcoming Investor Conferences
2016-01-05,Editas' IPO Challenge: Edit Investor Expectations as Well as Diseased Genes
2016-01-01,Feuerstein's Heroes and Zeroes of Biotech Investing in 2015
2015-11-04,Axovant Sciences To Present At Upcoming Investor Conferences
2015-10-28,Axovant Sciences Announces RVT-101 Presentations At The Clinical Trials In Alzheimer's Disease (CTAD) Meeting
2015-10-26,Axovant Sciences To Announce Second Quarter 2015 Financial Results On November 2, 2015
2015-10-06,Axovant Sciences Announces Start Of Confirmatory Phase 3 MINDSET Study And Special Protocol Assessment (SPA) Agreement With FDA
2015-09-11,5 Stocks Ready for Breakouts
2015-09-02,Axovant Sciences To Present At Upcoming Investor Conferences
2015-08-14,'Mad Money' Lightning Round: Buy, Buy, Buy Stryker and Sell SeaDrill
2015-08-13,Jim Cramer's 'Mad Money' Recap: Cult Stocks Amazon, Netflix Gave Bulls a Boost
2015-07-22,Will Axovant Sciences (AXON) Stock be Helped by Alzheimer's Drug Results?
2015-07-15,Axovant Sciences (AXON) Stock Initiated with 'Market Outperform' Rating at JMP Securities
2015-07-06,NYSE Executive Expects Plethora of IPOs to Continue
2015-07-06,Biotech, Health Care Likely to Drive IPOs at NYSE in Second Half
2015-07-01,Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting
2015-06-29,Axovant Sciences To Present RVT-101 Alzheimer's Disease Clinical Data At AAIC 2015 Meeting
2015-06-12,The Dogfight Among Airlines; When to Sell Facebook and 3 Stocks With Potential: Jim Cramer's Best Blogs
2015-06-12,Jim Cramer: Take a Look at Axovant Sciences (AXON)
2015-06-12,Jim Cramer's Top Takeaways: Axovant Sciences, AmerisourceBergen, Isis Pharmaceuticals
2015-06-11,Jim Cramer's 'Mad Money' Recap: The Beginning of the Bottom?
,
,
,
,
2017-03-16,BioDelivery Sciences Announces Three Data Presentations On BELBUCA® At The American Academy Of Pain Medicine 33rd Annual Meeting
2017-03-09,BioDelivery Sciences To Host Conference Call And Webcast Reporting Fourth Quarter And Full-Year 2016 Financial Results On Friday, March 17
2017-02-10,Welcome to the Small-Cap Biotech Mailbag!
2017-01-26,BioDelivery Sciences To Hold Analyst And Investor Day To Discuss BELBUCA® Commercialization Plans On February 1st In New York City
2017-01-03,My Top 2017 Pick: Progenics Pharmaceuticals
2017-01-03,Top 2017 Pick: Progenics Pharmaceuticals
2016-12-30,Endo International Is Top 'Dog of the S&P 500'
2016-12-13,BioDelivery Sciences Announces Clonidine Topical Gel For Painful Diabetic Neuropathy Phase 2b Trial Fails To Meet Its Primary Efficacy Endpoint
2016-12-08,BioDelivery Sciences Reacquires License To BELBUCA™ From Endo Pharmaceuticals
2016-11-28,Some 'January Effect' Stock Picks
2016-11-08,BioDelivery Sciences To Present At The Stifel 2016 Healthcare Conference
2016-11-01,Small Biotechs on My Shopping List
2016-10-24,BioDelivery Sciences Announces Preferred Formulary Status For BUNAVAIL On Texas Medicaid
2016-10-05,BioDelivery Sciences Announces Additions To Its Board Of Directors
2016-09-30,BioDelivery Sciences Cites Impressive Number Of Physicians Granted Waiver To Increase Patient Limit For Opioid Dependence Treatment Following Recent HHS Rule
2016-09-29,3 Stocks for Growth in 2017
2016-09-23,BioDelivery Sciences (BDSI) Stock Jumps on Ratings Upgrade
2016-08-04,BioDelivery Sciences Announces Randomization Target Reached In Clinical Trial Of Clonidine Topical Gel For The Treatment Of Painful Diabetic Neuropathy
2016-06-21,First Week Of August 19th Options Trading For BioDelivery Sciences International (BDSI)
2016-06-08,BioDelivery Sciences To Present At The William Blair Annual Growth Stock Conference
2016-06-03,New Data Demonstrate Safety Of Long-Term, Around-The-Clock Treatment With BELBUCA™ (Buprenorphine) Buccal Film For Chronic Pain
2016-05-12,Profiting on Small-Cap Biotech Earnings
2016-05-11,BioDelivery Sciences And Collegium Pharmaceutical Announce The Signing Of A Licensing Agreement For ONSOLIS® In The U.S.
2016-04-20,These 7 Stocks Under $10 Are Breaking Out
2016-04-14,M&amp;A Could Ignite Next Leg Up for Biotech
2016-03-31,Revisiting 3 Promising Small Biotechs
2016-03-23,6 Biotech Stocks Under $10 to Trade for Big Breakouts
2016-03-22,Interesting BDSI Put And Call Options For May 20th
2016-03-18,BDSI: Insiders vs. Shorts
2016-03-18,Insider Trading Alert - IPGP, AMC And BDSI Traded By Insiders
2016-03-18,A Small Biotech Sells for Less Than Cash
2016-03-14,BioDelivery Sciences To Present Today At The 28th Annual ROTH Conference
2016-03-11,BioDelivery Sciences International (BDSI) Stock: Weak On High Volume Today
2016-03-10,BioDelivery Sciences Int&rsquo;l (BDSI) Stock Dips in After-Hours Trading on Q4 Miss
2016-03-08,Biotech Rally Is Healing Small-Caps
2016-03-03,5 Stocks Under $10 Set to Soar
2016-02-24,8 Stocks Under $10 Making Big Moves Higher
2016-02-22,Endo Announces Launch Of BELBUCA™ (Buprenorphine) Buccal Film For Chronic Pain Management
2016-01-25,BioDelivery Sciences To Host Analyst And Investor Day On February 25th In New York City
2015-12-24,4 Great Stock-ing Stuffers for 2016
2015-12-20,The Sky Is Falling, but It's Been Falling for a While
2015-12-18,BioDelivery Sciences Provides Pipeline Update
2015-11-30,Insider Trading Alert - TIPT, SPH And BDSI Traded By Insiders
2015-11-24,First Week of January 2016 Options Trading For BioDelivery Sciences International (BDSI)
2015-11-24,BioDelivery Sciences To Present At The 27th Annual Piper Jaffray Healthcare Conference
2015-11-20,BioDelivery Is About to Start Delivering
2015-11-05,5 Stocks Under $10 Set to Soar
2015-10-28,Today's Dead Cat Bounce Stock: BioDelivery Sciences International (BDSI)
2015-10-27,BioDelivery Sciences International (BDSI) Weak On High Volume Today
2015-10-26,BioDelivery Sciences International (BDSI): Heavy Pre-Market Activity
2015-10-26,FDA Approval Of BELBUCA™ (CIII) (Buprenorphine HCl) Buccal Film For Chronic Pain Triggers Milestone Payment Of $50 Million To BioDelivery Sciences From Partner Endo Pharmaceuticals
2015-10-26,U.S. FDA Approves BELBUCA™ (buprenorphine) Buccal Film For Chronic Pain Management
2015-10-22,Before The Move: Watch Endo Into FDA Action Date Tomorrow
2015-10-21,Interesting BDSI Put And Call Options For June 2016
2015-10-14,BioDelivery Sciences International (BDSI) Is Weak On High Volume Today
2015-09-30,Strong On High Volume: BioDelivery Sciences International (BDSI)
2015-09-29,Healthcare Sector Stocks Under Review - Celldex Therapeutics, Alexion Pharmaceuticals, Advaxis, BioDelivery Sciences And Cytori Therapeutics
2015-09-18,In A Move By The U.S. Department Of Health And Human Services - Patient Limit On Access To Opioid Dependence Treatments To Be Expanded
2015-09-15,Short Interest In BioDelivery Sciences International Jumps 13.3%
2015-09-09,Endo Pharmaceuticals And BioDelivery Sciences Present New Data On Investigational Product Buprenorphine HCl Buccal Film For Chronic Pain Management
2015-09-03,BioDelivery Sciences To Participate At The Wells Fargo Securities 2015 Healthcare Conference And The FBR Second Annual Healthcare Conference
2015-08-25,BDSI: Insiders vs. Shorts
2015-08-13,Today's Weak On High Volume Stock: BioDelivery Sciences International (BDSI)
2015-08-12,BioDelivery Sciences Strengthens Sales Force Leadership With Hiring Of Scott Plesha, Former Salix Head Of Sales
2015-07-31,BioDelivery Sciences International (BDSI) Is Strong On High Volume Today
2015-07-29,Weak On High Volume: BioDelivery Sciences International (BDSI)
2015-07-21,First Week Of March 2016 Options Trading For BioDelivery Sciences International (BDSI)
2015-07-16,BioDelivery Sciences International (BDSI) Flagged As Strong On High Volume
2015-07-14,BioDelivery Sciences Announces Hiring Of Enoch Bortey, Ph.D., As Vice President Of Clinical Biostatistics And Data Systems
2015-07-09,5 Stocks Under $10 Set to Soar
2015-06-30,Trade-Ideas: BioDelivery Sciences International (BDSI) Is Today's Strong On High Relative Volume Stock
2015-06-24,4 Stocks Rising on Unusual Volume to Trade for Breakouts
2015-06-15,BioDelivery Sciences International Stock Sees Short Interest Jump 18.4%
2015-06-08,BioDelivery Sciences Announces Hiring Of Stephana E. Patton As General Counsel
2015-06-04,3 Stocks Under $10 to Trade for Breakouts
2015-06-02,BioDelivery Sciences To Present At The Jefferies 2015 Healthcare Conference - Schedule Change
2015-06-01,BioDelivery Sciences Adds $20 Million In Debt Financing From MidCap Financial
2015-05-27,BioDelivery Sciences To Present At The Jefferies 2015 Healthcare Conference And The William Blair Growth Stock Conference
2015-05-26,BDSI: Insiders Vs. Shorts
2015-05-26,First Week Of BDSI July 17th Options Trading
2015-05-16,'Mad Money' Lightning Round: Buy, Buy, Buy Dunkin Brands
2015-05-15,Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
2015-05-14,Endo Pharmaceuticals And BioDelivery Sciences Present Pivotal Data From Two Phase 3 Trials Demonstrating Safety And Efficacy Of Buprenorphine HCl Buccal Film For The Management Of Chronic Pain
2015-05-14,5 Stocks Under $10 Set to Soar
2015-04-17,Perilous Reversal Watch: BioDelivery Sciences International (BDSI)
2015-04-14,BioDelivery Sciences International Stock Sees Short Interest Fall 11.5%
2015-03-30,BioDelivery Sciences International Becomes Oversold (BDSI)
2015-03-30,BioDelivery Sciences Announces Primary Endpoint In Phase 3 Study Of Clonidine Topical Gel For Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development
2015-03-26,First Week Of May 15th Options Trading For BioDelivery Sciences International (BDSI)
2015-03-17,Notable Two Hundred Day Moving Average Cross - BDSI
2015-03-16,5 Stocks Set to Soar on Bullish Earnings: Short-Squeeze Stocks
2015-03-03,BioDelivery Sciences To Present At The 27th Annual ROTH Conference
2015-02-27,Insiders Bullish On Certain Holdings Of XPH
2015-02-23,BioDelivery Sciences To Receive $10 Million Milestone Payment From Endo Pharmaceuticals Inc. In Conjunction With Acceptance Of NDA For BELBUCA™ (buprenorphine HCl) Buccal Film For Chronic Pain
2015-02-23,Endo Pharmaceuticals And BioDelivery Sciences Announce Acceptance Of NDA For BELBUCA™ (buprenorphine HCl) Buccal Film For The Management Of Chronic Pain
2015-02-18,BioDelivery Sciences To Present At The 2015 RBC Capital Markets Healthcare Conference
2015-02-03,BDSI Makes Bullish Cross Above Critical Moving Average
2015-01-30,BDSI April 17th Options Begin Trading
2015-01-27,BioDelivery Sciences Acquires North American Marketing Authorizations For ONSOLIS From Meda
2015-01-23,First Week Of September 18th Options Trading For BioDelivery Sciences International (BDSI)
2015-01-21,Insiders Bullish On Certain Holdings Of XPH
2015-01-13,BioDelivery Sciences International Breaks Above 200-Day Moving Average - Bullish For BDSI
2014-12-29,Commit To Purchase BioDelivery Sciences International At $10, Earn 24.4% Annualized Using Options
2014-12-26,BioDelivery Sciences International (BDSI) Is Today's Perilous Reversal Stock
2014-12-24,Strong On High Volume: BioDelivery Sciences International (BDSI)
2014-12-23,Endo Pharmaceuticals And BioDelivery Sciences Announce NDA Submission For Buprenorphine HCl Buccal Film For The Management Of Moderate To Severe Chronic Pain
2014-12-19,BioDelivery Sciences International (BDSI) Marked As A Dead Cat Bounce Stock
2014-12-17,Insider Trading Alert - BDSI, LDRH And LNKD Traded By Insiders
2014-12-16,BioDelivery Sciences International (BDSI) Strong On High Relative Volume Today
2014-12-15,Insider Trading Alert - HPJ, BDSI And MOH Traded By Insiders
2014-12-15,BioDelivery Sciences International Becomes Oversold (BDSI)
2014-12-15,BDSI Makes Notable Cross Below Critical Moving Average
2014-12-10,BioDelivery Sciences Launches InReach Support Program For Those Affected By Opioid Dependence
2014-12-08,BioDelivery Sciences Announces Completion Of Randomization In Phase 3 Trial Of Clonidine Topical Gel For The Treatment Of Painful Diabetic Neuropathy
2014-11-25,BioDelivery Sciences To Present At The 26th Annual Piper Jaffray Healthcare Conference
2014-11-17,BioDelivery Sciences International (BDSI) Marked As A Dead Cat Bounce Stock
2014-11-13,BioDelivery Sciences To Present At The Stifel 2014 Healthcare Conference And The Jefferies 2014 Global Healthcare Conference
2014-11-07,BioDelivery Sciences To Present At The Credit Suisse 2014 Healthcare Conference
2014-11-05,BioDelivery Sciences Provides Business Review And Update In Conjunction With Filing Of Third Quarter 2014 Financials
2014-11-03,BioDelivery Sciences Announces The Availability Of BUNAVAIL™ In The U.S.
2014-10-28,BioDelivery Sciences To Develop A Long-Acting Injectable Depot Formulation Of Buprenorphine With Evonik For Use In Opioid Dependence And Pain
2014-10-27,Surprising Stocks That Performed Best for Billionaires in 2014
2014-10-25,'Mad Money' Lightning Round: You're in Great Shape With Southern
2014-10-24,Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
2014-10-10,BioDelivery Sciences Announces The Hiring Of J. Chris Prue As Vice President Of Regulatory Affairs And Quality Assurance
2014-10-07,BioDelivery Sciences Surpasses +200% YTD Gain
2014-10-06,BioDelivery Sciences To Provide BUNAVAIL Launch Update
2014-09-12,This ETF Holds Stocks Insiders Want to Own
2014-09-11,3 Biotech Breakout Charts That Could See More Upside Next Week
2014-09-09,Trade-Ideas: BioDelivery Sciences International (BDSI) Is Today's New Lifetime High Stock
2014-09-08,Insider Trading Alert - MWIV, BDSI And VRTS Traded By Insiders
2014-09-08,BioDelivery Sciences To Present At The Morgan Stanley Global Healthcare Conference
2014-09-06,'Mad Money' Lightning Round: I Still Want to Own Freeport-McMoRan
2014-09-05,Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
2014-09-05,Today's Dead Cat Bounce Stock: BioDelivery Sciences International (BDSI)
2014-09-05,'Fast Money' Recap: The European Central Bank and Bonds
2014-09-04,BioDelivery Sciences International (BDSI) Highlighted As Weak On High Volume
2014-09-03,BioDelivery Sciences To Ring The NASDAQ Stock Market Opening Bell
2014-08-28,4 Breakout Stocks to Watch Going Into Labor Day
2014-08-27,BioDelivery Sciences To Host Investor And Analyst Event And Webcast Friday, September 5 On BUNAVAIL™ Launch And Pipeline
2014-08-26,BDSI: Insiders vs. Shorts
2014-08-26,Insiders Seeing Green With BDSI At New 52-Week High
2014-08-12,BioDelivery Sciences Announces BEMA Buprenorphine NDA Submission On Track Following Pre-NDA Meeting With FDA
2014-08-07,BioDelivery Sciences Provides Business Review And Update In Conjunction With Filing Of Second Quarter 2014 Financials
2014-08-07,Two Longs and Two Shorts to Watch in a Topsy-Turvy Market
2014-08-06,BioDelivery Sciences Provides Update On Ongoing Phase 3 Pivotal Trial For Clonidine Topical Gel For Painful Diabetic Neuropathy
2014-07-22,BioDelivery Sciences Appoints Charles J. Bramlage And Dr. Barry I. Feinberg To Its Board Of Directors
2014-07-15,4 Stocks With Some Interesting Patterns to Watch This Week
2014-07-11,Jim Cramer's Top Stock Picks: DF MNST BDSI
2014-07-10,Jim Cramer's 'Mad Money' Recap: Buy, Don't Sell, on European Weakness
2014-07-10,4 Stocks Rising on Big Volume
2014-07-08,Perilous Reversal Watch: BioDelivery Sciences International (BDSI)
2014-07-07,Why BioDelivery Sciences (BDSI) Stock Hit a One-Year High Today
2014-07-07,BioDelivery Sciences International (BDSI) Is Today's Pre-Market Mover With Heavy Volume Stock
2014-07-07,Endo And BioDelivery Sciences Announce Positive Top-line Results From The Phase III Clinical Trial Of BEMA® Buprenorphine In Opioid-experienced Patients With Chronic Pain
2014-06-26,BioDelivery Sciences Announces Completion Of Patient Enrollment In Its Initial Phase 3 Trial Of Clonidine Topical Gel For Painful Diabetic Neuropathy
2014-06-12,New Lifetime High Reached: BioDelivery Sciences International (BDSI)
2014-06-11,BioDelivery Sciences Featured On Bloomberg TV, TheStreet.com And Business News Network
2014-06-10,BioDelivery Sciences To Present At The William Blair And Wells Fargo Healthcare Conferences
2014-06-09,BioDelivery Sciences International (BDSI): Heavy Pre-Market Activity
2014-06-09,BioDelivery Sciences Receives FDA Approval For BUNAVAIL™ (buprenorphine And Naloxone) Buccal Film For The Maintenance Treatment Of Opioid Dependence
2014-06-06,BioDelivery Sciences Receives FDA Approval For BUNAVAIL™ (buprenorphine And Naloxone) Buccal Film For The Maintenance Treatment Of Opioid Dependence
2014-05-30,BioDelivery Sciences International Inc Stock Downgraded (BDSI)
2014-05-29,Ratings Changes Today
2014-05-13,BioDelivery Sciences International Inc Stock Upgraded (BDSI)
2014-05-12,Ratings Changes Today
2014-05-12,2014 FDA Drug Approval Calendar
2014-05-08,BioDelivery Sciences Provides Business Review And Update In Conjunction With Filing Of First Quarter 2014 Financials
2014-05-08,BioDelivery Sciences To Present At The Bank Of America Merrill Lynch 2014 Health Care Conference
2014-05-06,BioDelivery Sciences Announces Randomization Of Over 50% Of Subjects In Its Initial Phase 3 Study Of Clonidine Topical Gel For Painful Diabetic Neuropathy
2014-04-30,3 Stocks Under $10 Moving Higher
2014-04-14,Oversold Conditions For BioDelivery Sciences International (BDSI)
2014-04-07,BioDelivery Sciences Announces Four BUNAVAIL Abstracts To Be Presented At The 2014 American Society Of Addiction Medicine Annual Conference
2014-04-03,BioDelivery Sciences Announces Enrollment Of The First Patient In A Phase 3 Clinical Study Of Clonidine Topical Gel For Painful Diabetic Neuropathy
2014-03-27,BioDelivery Sciences Announces Commercialization Agreement With Quintiles To Support The Launch Of BUNAVAIL In The U.S.
2014-03-26,First Week Of May 17th Options Trading For BioDelivery Sciences International (BDSI)
2014-03-14,BioDelivery Sciences Provides Business Review And Update In Conjunction With Filing Of Its 2013 Annual Report
2014-03-05,BioDelivery Sciences To Present At The 26th Annual ROTH Conference
2014-02-28,Interesting BDSI Put And Call Options For April 19th
2014-02-28,BioDelivery Sciences To Present At The Cowen And Company 34th Annual Health Care Conference
2017-03-13,Bellerophon Reports Fourth Quarter 2016 Financial Results And Provides Business Update
2017-01-04,Bellerophon Therapeutics Announces FDA Acceptance Of Modifications To INOpulse Pulmonary Arterial Hypertension Phase 3 Program
2016-12-22,These 5 Stocks Under $10 Could Make You a Lot of Money
2016-11-23,Bellerophon Therapeutics, Inc. Announces $12 Million Public Offering
2016-11-08,Bellerophon Reports Third Quarter 2016 Financial Results And Provides Business Update
2016-11-01,INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Bellerophon Therapeutics, Inc. And Advises Investors With Losses To Contact The Firm
2016-11-01,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Bellerophon Therapeutics, Inc. (BLPH)
2016-10-26,Johnson & Weaver, LLP Initiates Investigations Of Bellerophon Therapeutics, Inc., KemPharm, Inc., Neos Therapeutics, Inc., CommVault Systems, Inc. And Resource Capital Corp.
2016-09-20,Bellerophon Therapeutics Announces Planned Management Transition By Year-End 2016
2016-09-06,Bellerophon To Present At The 18th Annual Rodman & Renshaw Global Investment Conference
2016-08-09,Bellerophon Reports Second Quarter 2016 Financial Results And Provides Business Update
2016-07-25,Bellerophon Receives Approval To Commence Phase 2 Trial In PH-COPD
2016-06-16,Bellerophon Therapeutics Announces Enrollment Of The First Patient In The INOvation-1 Phase 3 Clinical Trial For Pulmonary Arterial Hypertension (PAH)
2016-05-13,6 Stocks Under $10 Making Big Moves Higher
2016-05-10,Bellerophon Reports First Quarter 2016 Financial Results And Provides Business Update
2016-03-21,Bellerophon Reports 2015 Financial Results And Provides Business Update
2016-03-14,Bellerophon Therapeutics To Hold Full Year 2015 Financial Results Conference Call On Monday March 21, 2016
2016-03-04,Bellerophon Therapeutics To Present At The Cowen And Company 36th Annual Health Care Conference
2016-03-02,Bellerophon Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2016-02-23,Bellerophon Therapeutics Appoints Fabian Tenenbaum As Chief Financial Officer And Chief Business Officer
2016-02-16,Bellerophon Therapeutics Appoints Mary Ann Cloyd As An Independent Board Member
2016-02-09,Bellerophon Therapeutics Announces Positive Data From The Final Analysis Of The Phase 2 Long-Term Extension Study Of INOpulse For Treatment Of Pulmonary Arterial Hypertension
2016-02-03,Bellerophon To Participate In LEERINK Partners 5th Annual Global Healthcare Conference
2016-01-21,Bellerophon Therapeutics Announces Notice Of Intention To Grant A European Patent Supporting Its INOpulse Program
2016-01-19,Bellerophon Therapeutics Receives EC Certification For New INOpulse® Drug-Device Delivery System
2015-11-12,Bellerophon Reports 2015 Third Quarter Operational And Financial Results
2015-10-01,5 Stocks Under $10 Set to Soar
2015-09-30,Bellerophon Announces Functional Respiratory Imaging Data From Company Sponsored Clinical Trial Of INOpulse(R) In COPD Patients With Pulmonary Hypertension Presented Today At The European Respiratory Society (ERS) International Congress
2015-09-24,Bellerophon Therapeutics Announces Positive Data From Interim Analysis Of Phase 2 Long-Term Extension Study Of INOpulse(R) For Treatment Of Pulmonary Arterial Hypertension
2015-09-15,Bellerophon Therapeutics Announces Leadership Team Changes
2015-09-03,Bellerophon To Present In Upcoming Investor Conferences
2015-08-17,5 Stocks Ready for Breakouts
2015-08-13,Bellerophon Reports 2015 Second Quarter Operational And Financial Results
2015-07-29,Bellerophon Therapeutics Expands License Agreement With INO Therapeutics To Develop INOpulse(R) For Three Additional Cardiopulmonary Diseases
2015-07-27,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Of Bellerophon Therapeutics LLC And Its Board Of Directors In Connection With Possible Violations Of Federal Securities Laws
2015-07-27,Bellerophon Therapeutics Announces Top-Line Results From PRESERVATION I Clinical Trial For Bioabsorbable Cardiac Matrix (BCM)
2015-07-01,Bellerophon Therapeutics Announces Management And Board Additions
2015-05-27,Bellerophon Therapeutics Presents Late-Breaking Poster At The European Society Of Cardiology's Heart Failure 2015/2nd World Congress On Acute Heart Failure
2015-05-20,Bellerophon Therapeutics Adds To Experienced Drug And Device Development Management Team
2015-05-15,Bellerophon Reports 2015 First Quarter Financial And Operational Results
2015-05-13,Bellerophon Therapeutics Appoints Two New Independent Board Members
2015-05-07,Bellerophon Therapeutics Forms Scientific Advisory Board For INOpulse(R) Programs
2015-05-05,Bellerophon Therapeutics To Present Late-Breaking Poster At The European Society Of Cardiology's Heart Failure 2015/2nd World Congress On Acute Heart Failure
2015-03-31,Bellerophon Reports 2014 Full Year Financial And Operational Results
2015-03-25,Bellerophon Therapeutics Selects Flextronics To Manufacture The Mark2, Next-Generation INOpulse(R) Device
2015-03-16,Bellerophon Therapeutics To Ring The NASDAQ Stock Market Closing Bell
2015-02-13,Bellerophon Therapeutics Announces Pricing Of Its Initial Public Offering
,
,
,
,
2017-03-23,BioLineRx Announces Acquisition Of Agalimmune Ltd. To Accelerate Expansion Of Immuno-Oncology Pipeline
2017-03-20,BioLineRx Provides Update On Phase 2 Open-Label Study For BL-8040 As Novel Stem Cell Mobilization Treatment
2017-03-16,BioLineRx To Report Annual 2016 Results On March 23, 2017
2017-02-07,BioLineRx To Present At 2017 BIO CEO & Investor Conference In New York On February 14
2017-01-17,BioLineRx Announces Initiation Of Immuno-Oncology Phase 2 Study To Investigate Combination Of BL-8040 And KEYTRUDA® For Pancreatic Cancer
2017-01-04,BioLineRx To Present At Biotech Showcase 2017 Conference In San Francisco
2016-12-05,BioLineRx Presents Positive Phase 2a AML Study And Mechanism-of-Action Data For BL-8040 Oncology Platform At ASH 2016
2016-11-21,BioLineRx In-licenses Novel Anti-Inflammatory Treatment For Dry Eye Syndrome Under Strategic Collaboration With Major Global Pharmaceutical Company
2016-11-15,BioLineRx To Report Third Quarter Results On November 22, 2016
2016-11-03,BioLineRx Discloses Positive Correlative Data From Phase 2a AML Study And Mechanism-of-Action Data For BL-8040 Oncology Platform At ASH 2016
2016-10-05,BioLineRx Announces Acceptance Of BL-8040 Abstracts For Oral And Poster Presentations At 58th American Society Of Hematology (ASH) Annual Meeting
2016-09-23,BioLineRx (BLRX) Stock Soars on Liver Drug Licensing Agreement
2016-09-23,BioLineRx Announces In-licensing Of Novel Treatment For Liver Failure Conditions Under Strategic Collaboration
2016-09-22,BioLineRx Ltd. Presents Corporate Objectives At Investor Breakfast Meeting In NY
2016-09-20,BioLineRx Announces Initiation Of Phase 2a Trial Of BL-8040 In Combination With KEYTRUDA® (pembrolizumab) For Treatment Of Pancreatic Cancer
2016-09-09,BioLineRx Ltd. To Host Investor Breakfast Meeting September 22, 2016 In New York
2016-09-08,BioLineRx Presents Final Results From Phase 2a Trial For Relapsed/Refractory AML At SOHO Conference
2016-09-07,BioLineRx Announces Clinical Research Collaboration To Investigate Combination Of BL-8040 With Atezolizumab In Multiple Oncology Indications
2016-08-29,BioLineRx To Present At The 18th Annual Rodman & Renshaw Global Investment Conference In New York
2016-08-25,BioLineRx And I-Bridge Capital Establish A New Drug Development Joint Venture In China
2016-08-11,BioLineRx Names Philip A. Serlin As Chief Executive Officer
2016-08-08,BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement To Investigate Combination Of BL-8040 And KEYTRUDA® For Pancreatic Cancer
2016-08-04,BioLineRx To Report Second Quarter Results On August 11, 2016
2016-08-01,BioLineRx Announces In-licensing Of Liver Fibrosis Project Under Strategic Collaboration
2016-06-28,BioLineRx Announces Regulatory Submissions For Phase 2a Trial Of BL-8040 In Combination With KEYTRUDA® (pembrolizumab) For Treatment Of Pancreatic Cancer
2016-06-15,BioLineRx To Present At The JMP Securities Life Sciences Conference In New York
2016-05-19,BioLineRx's BL-8040 To Be Presented At Upcoming Scientific Conferences
2016-05-16,BioLineRx And MaRS Innovation Sign Framework Collaboration Agreement
2016-05-10,BioLineRx To Report First Quarter 2016 Results On May 17, 2016
2016-05-06,7 Stocks Under $10 to Trade for Big Profits
2016-04-19,BioLineRx Announces Presentation Of Detailed Mechanism Of Action Data For Lead Oncology Platform At AACR 2016
2016-04-15,7 Stocks Under $10 Making Big Moves
2016-04-04,BioLineRx's Novel Treatment For Non-Surgical Removal Of Skin Lesions Receives CE Mark Approval
2016-03-29,BioLineRx Reports Successful Top-Line Results In Phase 2 Trial For AML
2016-03-23,BioLineRx Announces Initiation Of Phase 2 Trial For BL-8040 As Novel Stem Cell Mobilization Treatment
2016-03-10,BioLineRx To Present At 2016 Annual Roth Conference In Southern California On March 14
2016-03-03,BioLineRx To Report Annual 2015 Results On March 10, 2016
2016-02-01,BioLineRx To Present At 2016 BIO CEO & Investor Conference In New York On February 8
2016-01-25,BioLineRx Receives Confirmation Of Medical Device Classification In Europe For Celiac Treatment
2016-01-12,BioLineRx Announces Collaboration With MSD To Investigate The Combination Of KEYTRUDA (pembrolizumab) And BL-8040 In Pancreatic Cancer
2016-01-04,BioLineRx To Present At Biotech Showcase 2016 Conference In San Francisco
2015-12-14,BioLineRx Announces Regulatory Submission For Phase 2 Trial Of BL-8040 As Novel Stem Cell Mobilization Treatment
2015-12-03,BioLineRx Establishes Oncology Scientific Advisory Board
2015-11-25,BioLineRx Ltd. To Host Investor Breakfast In New York On December 3, 2015
2015-11-24,BioLineRx To Present At The LD Micro Main Event
2015-11-16,BioLineRx Reports Third Quarter 2015 Financial Results
2015-11-09,BioLineRx To Report Third Quarter 2015 Results On November 16, 2015
2015-11-05,BioLineRx Announces Positive Clinical Results From First Part Of Phase 2 Trial In R/r AML
2015-09-09,BioLineRx's Novel Treatment For Non-Surgical Removal Of Skin Lesions Submitted For CE Mark Registration
2015-09-03,BioLineRx To Present At The 17th Annual Rodman & Renshaw Global Investment Conference In New York
2015-08-20,BioLineRx Reports Second Quarter 2015 Financial Results
2015-08-17,BioLineRx Announces Initiation Of Phase 2b Trial For Novel AML Consolidation Treatment
2015-08-13,BioLineRx To Report Second Quarter 2015 Results On August 20, 2015
2015-07-27,BioLineRx (BLRX) Stock Down on Negative Heart Disease Treatment Results
2015-07-27,BioLineRx Announces Top-Line Results From Bellerophon's PRESERVATION I Clinical Trial For Bioabsorbable Cardiac Matrix (BL-1040)
2015-06-22,Bioline RX (BLRX) Stock Gains on Positive Test Results, Coverage Initiation
2015-06-17,BioLineRx To Present Successful Results Of Phase 1/2 Study For Novel Celiac Treatment At International Celiac Disease Symposium
2015-06-16,BioLineRx To Present At The JMP Securities Life Sciences Conference In New York
2015-06-03,Research Underlying BioLineRx's Treatment Of Type 1 Diabetes Wins Hebrew University's Kaye Innovation Award
2015-06-01,BioLineRx Announces Peer-Reviewed Publication Of Phase 1/2 Trial Results For Novel Treatment For Non-Surgical Removal Of Skin Lesions
2015-05-27,BioLineRx To Present Positive Safety And Efficacy Clinical Data For Novel Stem Cell Mobilization Treatment At The European Hematology Annual Congress
2015-05-18,BioLineRx Reports First Quarter 2015 Financial Results
2015-05-11,BioLineRx To Report First Quarter 2015 Results On May 18, 2015
2015-05-04,BioLineRx Initiates Expansion Stage Of Phase 2 Clinical Trial For Novel Treatment For Acute Myeloid Leukemia
2015-04-07,4 Stocks Under $10 Making Big Moves
2015-03-25,BioLineRx Reports Successful Top-Line Safety And Efficacy Results For Novel Stem Cell Mobilization Treatment
2015-03-24,3 Stocks Under $10 Making Big Moves Higher
2015-03-23,BioLineRx Reports Year End 2014 Financial Results
2015-03-17,BioLineRx To Report Fourth Quarter And Year End 2014 Results On March 23, 2015
2015-03-11,BioLineRx Closes $28.75 Million Underwritten Public Offering Of Its American Depositary Shares
2015-03-11,BioLineRx's Treatment For Type 1 Diabetes Effective In Preclinical Trials
2015-03-06,BioLineRx To Present At The Annual Roth Conference In California
2015-03-06,BioLineRx Prices $25 Million Underwritten Public Offering Of Its American Depositary Shares
2015-03-05,BioLineRx Announces Underwritten Public Offering Of Its American Depositary Shares
2015-03-02,BioLineRx Announces Regulatory Submission For Phase 2b Trial For Novel AML Consolidation Treatment
2015-02-03,BioLineRx To Present At 2015 BIO CEO & Investor Conference In New York On February 10
2015-01-14,BioLineRx Announces Completion Of Enrollment In CE Mark Registration Trial Of BCM (BL-1040), A Novel Medical Device For Prevention Of Cardiac Remodeling Following Acute Myocardial Infarction
2015-01-06,BioLineRx Completes Dose Escalation Stage Of Phase 1 Trial For Novel Stem Cell Mobilization Treatment
2015-01-06,BioLineRx To Present At Biotech Showcase 2015 Conference In San Francisco
2014-12-23,BioLineRx Out-Licenses Novel Skin Lesion Treatment To Omega Pharma
2014-12-16,BioLineRx And Major Global Pharmaceutical Company Form Strategic Collaboration For Screening And Development Of Novel Drug Candidates
2014-12-12,BioLineRx Presents Multi-Year Clinical Development Plan For Its BL-8040 Hematological Cancer Therapeutic Platform
2014-12-08,BioLineRx Reports Positive Data From Ongoing Phase 2a Study For AML Treatment At ASH Conference
2014-11-10,BioLineRx Reports Third Quarter 2014 Financial Results
2014-11-05,BioLineRx Announces Successful Final Results Of Phase 1/2 Study For Novel Celiac Treatment
2014-11-03,BioLineRx To Report Third Quarter 2014 Results On November 10, 2014
2014-11-03,BioLineRx Files Protocol Amendment To Phase 2 Study For AML Treatment Based On Encouraging Efficacy And Strong Safety Profile
2014-10-31,BioLineRx Reports Publication In Peer Review Journal Of Results From Previous Phase 1/2 Trial For BCM (BL-1040), A Novel Medical Device For Prevention Of Cardiac Remodeling Following Acute Myocardial Infarction
2014-09-17,BioLineRx Presents Positive Preclinical Results In Treatment For AML Patients With FLT3 Mutations
2014-09-03,BioLineRx Doses First Patient For BL-8040’s Second Indication As Novel Stem Cell Mobilization Treatment
2014-09-02,BioLineRx To Present At The 16th Annual Rodman & Renshaw Global Investment Conference In New York
2014-08-21,BioLineRx Receives Notice Of Allowance For US Patent On BL-7010 Covering Use Of Novel Polymer In Prevention Of Gluten Toxicity
2014-08-06,BioLineRx Reports Second Quarter 2014 Financial Results
2014-07-30,BioLineRx To Report Second Quarter 2014 Results On August 6, 2014
2014-07-16,BioLineRx Announces Results From Phase 1/2 Study For Celiac Treatment
2014-06-23,BioLineRx In-Licenses Novel Compound For Treatment Of Neuropathic Pain
2014-06-16,BioLineRx Receives Approval To Commence Phase 1 Trial For Novel Stem Cell Mobilization Treatment
2014-06-11,BioLineRx Receives Notice Of Allowance For US Patent Covering Novel Treatment For Celiac Disease
2014-05-30,BioLineRx Enters Into Share Purchase Agreement With Lincoln Park Capital
2014-05-20,BioLineRx Reports First Quarter 2014 Financial Results
2014-05-15,BioLineRx To Report First Quarter 2014 Results On May 20, 2014
2014-04-10,BioLineRx Announces Investigator-Initiated Study For Novel Chronic Myeloid Leukemia Treatment
2014-03-17,BioLineRx Reports Year End 2013 Financial Results
2014-03-14,BioLineRx Announces Issuance Of United States Patent Covering Use Of BL-8040 In Immunotherapy
2014-03-11,BioLineRx To Report Fourth Quarter And Year End 2013 Results On March 17, 2014
2014-03-10,BioLineRx Completes Dose Escalation Stage Of Phase 1/2 Study For Novel Celiac Treatment
2014-03-07,BioLineRx Closes $24.1 Million Underwritten Public Offering Of Its American Depositary Shares
2014-03-05,BioLineRx To Present At The Annual ROTH Growth Stock Conference In California
2014-03-04,BioLineRx Prices $21.0 Million Underwritten Public Offering Of Its American Depositary Shares
2014-03-03,BioLineRx Announces Underwritten Public Offering Of Its American Depositary Shares
2014-02-24,BioLineRx Appoints Dr. Sandra Panem To Board Of Directors
2014-02-12,BioLineRx Announces Positive Preclinical Results For Novel Treatment For Chronic Myeloid Leukemia
2014-02-03,BioLineRx To Present At The 2014 BIO CEO & Investor Conference In New York On February 10
2014-01-23,BioLineRx Receives Orphan Drug Designation For Novel Stem Cell Mobilization Treatment
2014-01-21,BioLineRx Receives Approval To Commence Pivotal Trial For Novel Skin Lesion Treatment
2014-01-13,BioLineRx Announces Regulatory Submission For Novel Stem Cell Mobilization Treatment
2014-01-08,BioLineRx And JHL Biotech To Collaborate On Type 1 Diabetes Antibody Treatment
2014-01-07,BioLineRx To Present At Biotech Showcase Conference In San Francisco
2013-12-18,BioLineRx Enters Clinic With Novel Treatment For Celiac Disease
2013-12-16,BioLineRx Announces Promising Initial Phase 2 Results Of Acute Myeloid Leukemia Treatment
2013-12-10,BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
2013-11-26,BioLineRx Announces New Positive Results In Phase 2a Trial For Orally Available Inflammatory Bowel Disease Treatment
2013-11-19,BioLineRx Reports Publication In Peer Review Journal Of Positive Phase 1/2 Results In Stem Cell Mobilization For Multiple Myeloma
2013-11-06,BioLineRx To Report Third Quarter 2013 Results On November 13, 2013
2013-11-05,BioLineRx To Hold Analyst And Investor Day In New York On November 21, 2013
2013-11-04,BioLineRx Receives Regulatory Approval To Commence Phase 1/2 Trial For Novel Treatment Of Celiac Disease
2013-10-23,BioLineRx Announces In-Licensing Of BL-9020, For Treatment Of Type 1 Diabetes
2013-10-07,BioLineRx Announces Receipt Of Notice Of Allowance From USPTO For Patent Covering BL-5010, A Novel Treatment For Removal Of Skin Lesions
2013-09-24,BioLineRx Announces Regulatory Submission For Phase 1/2 Trial For Novel Treatment Of Celiac Disease
2013-09-17,BioLineRx Announces Receipt Of A Notice Of Allowance From USPTO For Patent On Use Of BL-8020, An Oral, Interferon-Free Treatment For Hepatitis C
2013-09-09,BioLineRx's BL-8040 Receives Orphan Drug Designation For Treatment Of AML
2013-09-03,BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
2013-09-03,BioLineRx Announces Issuance Of United States Patent Covering Use Of BL-8040 For Obtaining Stem Cells
2013-08-28,BioLineRx To Present At 15th International Celiac Disease Symposium
2013-08-27,BioLineRx To Present At 2013 Stifel Nicolaus Healthcare Conference In Boston
2013-08-19,BioLineRx Appoints B. J. Bormann To Board Of Directors
2013-08-05,BioLineRx Announces Publication Of Positive Pre-Clinical Results For BL-8040 In Treatment Of Thrombocytopenia
2013-07-30,BioLineRx To Report Second Quarter 2013 Results On August 6, 2013
2013-07-29,BioLineRx Announces CE-Mark Registration Trial Submission For Novel Treatment For Removal Of Skin Lesions
2013-07-02,BioLineRx To Present At 2013 Annual JMP Securities Healthcare Conference In New York
2013-04-18,5 Stocks Under $10 Set to Soar
2013-04-16,Oramed Pharmaceuticals Appoints New Chief Operating Officer And VP Of Business Development
2013-03-20,BioLineRx Shares Fall On Schizophrenia Drug Failure
2013-03-20,BioLineRx Announces Results From Interim Analysis Of Phase II/III CLARITY Trial Of BL-1020 For Schizophrenia
2013-03-13,BioLineRx Receives Approval From French Regulatory Authorities To Commence A Phase I/II Clinical Trial For BL-8020, An Oral, Interferon-Free Treatment For Hepatitis C
2013-03-12,BioLineRx Reports Year End 2012 Financial Results
2013-02-28,BioLineRx's EDP-14, For Treatment Of Severe And Persistent Asthma, To Enter The Company's Main Therapeutic Pipeline As BL-9010
2013-02-26,BioLineRx To Report Fourth Quarter And Year End 2012 Results On March 12, 2013
2013-02-22,4 Stocks Under $5 Making Big Moves
2013-02-13,BioLineRx Announces Closing Of $8 Million Offering Of American Depositary Shares
2013-02-06,BioLineRx Announces Offering Of American Depositary Shares
2013-02-04,BioLineRx Provides Clarification Regarding Interim Analysis Of CLARITY Trial For BL-1020
2013-01-31,BioLineRx To Present At The 2013 BIO CEO &amp; Investor Conference In New York On February 12th
2013-01-07,BioLineRx To Announce Interim Results Of Phase II/III Trial For Schizophrenia Drug During Week Of March 18, 2013
2012-11-30,BioLineRx To Present At The 2012 Fifth Annual LD MICRO Conference In Los Angeles On December 5th
2012-11-14,BioLineRx Reports Third Quarter 2012 Financial Results
2012-11-12,BioLineRx To Hold Analyst And Investor Day In New York On December 4, 2012
2012-11-07,BioLineRx Announces BL-8040, For The Treatment Of Leukemia And Other Types Of Hematological Cancer, To Be Presented At 2012 ASH Annual Meeting
2012-11-05,BioLineRx To Report Third Quarter 2012 Results On November 14, 2012
2012-10-24,BioLineRx To Conduct Interim Analysis Of Phase II/III CLARITY Clinical Trial Of BL-1020 For Treatment Of Schizophrenia
2012-10-16,BioLineRx Announces Successful Completion Of Pre-Clinical Development For BL-8020, An Oral, Interferon-Free Treatment For Hepatitis C
2012-10-09,BioLineRx Announces New Analysis Of EAGLE Phase IIb Study Showing A Significantly Greater Beneficial Effect Of BL-1020 On Cognitive Function In Schizophrenia Patients
2012-09-27,BioLineRx Enters Into Share Purchase Agreement With Lincoln Park Capital
2012-09-27,BioLineRx Announces Publication Of EAGLE Study Results Demonstrating BL-1020's Efficacy In Improving Cognitive Function In Schizophrenia Patients
2012-09-24,BioLineRx Receives Notice Of Allowance From USPTO For New Patent On BL-1020, Extending Patent Protection Until 2031
2012-09-10,BioLineRx Announces Pre-clinical Results Demonstrating The Safety Of BL-7010, An Oral Treatment For Celiac Disease And Gluten Sensitivity
2012-09-04,BioLineRx In-Licenses A Novel, Phase II Ready Drug For The Treatment Of Leukemia And Other Hematological Cancers
2012-08-15,BioLineRx Reports Second Quarter 2012 Results
2012-08-02,BioLineRx To Report Second Quarter 2012 Results On August 15, 2012
2012-07-09,BioLineRx Receives Notice Of Intention To Grant Additional European Patent Covering BL-1020, For The Treatment Of Schizophrenia
2012-06-28,BioLineRx To Present At The 2012 Annual JMP Securities Healthcare Conference In New York On July 13th
2012-06-13,Research Underlying BioLineRx's EDP 10, For Treatment Of Type 1 Diabetes, Wins Hebrew University's Kaye Award
2012-06-05,BioLineRx Announces Receipt Of Two Notices Of Allowance From USPTO For Patents Covering BL-1021, An Orally Available New Chemical Entity For Treatment Of Neuropathic Pain
2012-05-15,BioLineRx Reports First Quarter 2012 Results
2012-04-23,BioLineRx Launches Free Investor Relations App For IPhone
2012-03-28,BioLineRx To Present At The 2012 Annual Needham Healthcare Conference In New York On April 3rd
2012-03-22,High-level View Of Pipeline (Graphic: Business Wire)
2012-03-07,BioLineRx To Present At The 2012 Annual Roth Growth Conference In Orange County, California On March 14th
2012-03-07,BioLineRx Announces Grant Of European Patent Covering BL-1020, An Orally Available Treatment For Schizophrenia
2012-03-05,BioLineRx Receives Approval For Commencing Phase II Clinical Trial Of BL-7040, An Orally Available Treatment For Inflammatory Bowel Disease
2017-03-23,BioLineRx Announces Acquisition Of Agalimmune Ltd. To Accelerate Expansion Of Immuno-Oncology Pipeline
2017-03-20,BioLineRx Provides Update On Phase 2 Open-Label Study For BL-8040 As Novel Stem Cell Mobilization Treatment
2017-03-16,BioLineRx To Report Annual 2016 Results On March 23, 2017
2017-02-07,BioLineRx To Present At 2017 BIO CEO & Investor Conference In New York On February 14
2017-01-17,BioLineRx Announces Initiation Of Immuno-Oncology Phase 2 Study To Investigate Combination Of BL-8040 And KEYTRUDA® For Pancreatic Cancer
2017-01-04,BioLineRx To Present At Biotech Showcase 2017 Conference In San Francisco
2016-12-05,BioLineRx Presents Positive Phase 2a AML Study And Mechanism-of-Action Data For BL-8040 Oncology Platform At ASH 2016
2016-11-21,BioLineRx In-licenses Novel Anti-Inflammatory Treatment For Dry Eye Syndrome Under Strategic Collaboration With Major Global Pharmaceutical Company
2016-11-15,BioLineRx To Report Third Quarter Results On November 22, 2016
2016-11-03,BioLineRx Discloses Positive Correlative Data From Phase 2a AML Study And Mechanism-of-Action Data For BL-8040 Oncology Platform At ASH 2016
2016-10-05,BioLineRx Announces Acceptance Of BL-8040 Abstracts For Oral And Poster Presentations At 58th American Society Of Hematology (ASH) Annual Meeting
2016-09-23,BioLineRx (BLRX) Stock Soars on Liver Drug Licensing Agreement
2016-09-23,BioLineRx Announces In-licensing Of Novel Treatment For Liver Failure Conditions Under Strategic Collaboration
2016-09-22,BioLineRx Ltd. Presents Corporate Objectives At Investor Breakfast Meeting In NY
2016-09-20,BioLineRx Announces Initiation Of Phase 2a Trial Of BL-8040 In Combination With KEYTRUDA® (pembrolizumab) For Treatment Of Pancreatic Cancer
2016-09-09,BioLineRx Ltd. To Host Investor Breakfast Meeting September 22, 2016 In New York
2016-09-08,BioLineRx Presents Final Results From Phase 2a Trial For Relapsed/Refractory AML At SOHO Conference
2016-09-07,BioLineRx Announces Clinical Research Collaboration To Investigate Combination Of BL-8040 With Atezolizumab In Multiple Oncology Indications
2016-08-29,BioLineRx To Present At The 18th Annual Rodman & Renshaw Global Investment Conference In New York
2016-08-25,BioLineRx And I-Bridge Capital Establish A New Drug Development Joint Venture In China
2016-08-11,BioLineRx Names Philip A. Serlin As Chief Executive Officer
2016-08-08,BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement To Investigate Combination Of BL-8040 And KEYTRUDA® For Pancreatic Cancer
2016-08-04,BioLineRx To Report Second Quarter Results On August 11, 2016
2016-08-01,BioLineRx Announces In-licensing Of Liver Fibrosis Project Under Strategic Collaboration
2016-06-28,BioLineRx Announces Regulatory Submissions For Phase 2a Trial Of BL-8040 In Combination With KEYTRUDA® (pembrolizumab) For Treatment Of Pancreatic Cancer
2016-06-15,BioLineRx To Present At The JMP Securities Life Sciences Conference In New York
2016-05-19,BioLineRx's BL-8040 To Be Presented At Upcoming Scientific Conferences
2016-05-16,BioLineRx And MaRS Innovation Sign Framework Collaboration Agreement
2016-05-10,BioLineRx To Report First Quarter 2016 Results On May 17, 2016
2016-05-06,7 Stocks Under $10 to Trade for Big Profits
2016-04-19,BioLineRx Announces Presentation Of Detailed Mechanism Of Action Data For Lead Oncology Platform At AACR 2016
2016-04-15,7 Stocks Under $10 Making Big Moves
2016-04-04,BioLineRx's Novel Treatment For Non-Surgical Removal Of Skin Lesions Receives CE Mark Approval
2016-03-29,BioLineRx Reports Successful Top-Line Results In Phase 2 Trial For AML
2016-03-23,BioLineRx Announces Initiation Of Phase 2 Trial For BL-8040 As Novel Stem Cell Mobilization Treatment
2016-03-10,BioLineRx To Present At 2016 Annual Roth Conference In Southern California On March 14
2016-03-03,BioLineRx To Report Annual 2015 Results On March 10, 2016
2016-02-01,BioLineRx To Present At 2016 BIO CEO & Investor Conference In New York On February 8
2016-01-25,BioLineRx Receives Confirmation Of Medical Device Classification In Europe For Celiac Treatment
2016-01-12,BioLineRx Announces Collaboration With MSD To Investigate The Combination Of KEYTRUDA (pembrolizumab) And BL-8040 In Pancreatic Cancer
2016-01-04,BioLineRx To Present At Biotech Showcase 2016 Conference In San Francisco
2015-12-14,BioLineRx Announces Regulatory Submission For Phase 2 Trial Of BL-8040 As Novel Stem Cell Mobilization Treatment
2015-12-03,BioLineRx Establishes Oncology Scientific Advisory Board
2015-11-25,BioLineRx Ltd. To Host Investor Breakfast In New York On December 3, 2015
2015-11-24,BioLineRx To Present At The LD Micro Main Event
2015-11-16,BioLineRx Reports Third Quarter 2015 Financial Results
2015-11-09,BioLineRx To Report Third Quarter 2015 Results On November 16, 2015
2015-11-05,BioLineRx Announces Positive Clinical Results From First Part Of Phase 2 Trial In R/r AML
2015-09-09,BioLineRx's Novel Treatment For Non-Surgical Removal Of Skin Lesions Submitted For CE Mark Registration
2015-09-03,BioLineRx To Present At The 17th Annual Rodman & Renshaw Global Investment Conference In New York
2015-08-20,BioLineRx Reports Second Quarter 2015 Financial Results
2015-08-17,BioLineRx Announces Initiation Of Phase 2b Trial For Novel AML Consolidation Treatment
2015-08-13,BioLineRx To Report Second Quarter 2015 Results On August 20, 2015
2015-07-27,BioLineRx (BLRX) Stock Down on Negative Heart Disease Treatment Results
2015-07-27,BioLineRx Announces Top-Line Results From Bellerophon's PRESERVATION I Clinical Trial For Bioabsorbable Cardiac Matrix (BL-1040)
2015-06-22,Bioline RX (BLRX) Stock Gains on Positive Test Results, Coverage Initiation
2015-06-17,BioLineRx To Present Successful Results Of Phase 1/2 Study For Novel Celiac Treatment At International Celiac Disease Symposium
2015-06-16,BioLineRx To Present At The JMP Securities Life Sciences Conference In New York
2015-06-03,Research Underlying BioLineRx's Treatment Of Type 1 Diabetes Wins Hebrew University's Kaye Innovation Award
2015-06-01,BioLineRx Announces Peer-Reviewed Publication Of Phase 1/2 Trial Results For Novel Treatment For Non-Surgical Removal Of Skin Lesions
2015-05-27,BioLineRx To Present Positive Safety And Efficacy Clinical Data For Novel Stem Cell Mobilization Treatment At The European Hematology Annual Congress
2015-05-18,BioLineRx Reports First Quarter 2015 Financial Results
2015-05-11,BioLineRx To Report First Quarter 2015 Results On May 18, 2015
2015-05-04,BioLineRx Initiates Expansion Stage Of Phase 2 Clinical Trial For Novel Treatment For Acute Myeloid Leukemia
2015-04-07,4 Stocks Under $10 Making Big Moves
2015-03-25,BioLineRx Reports Successful Top-Line Safety And Efficacy Results For Novel Stem Cell Mobilization Treatment
2015-03-24,3 Stocks Under $10 Making Big Moves Higher
2015-03-23,BioLineRx Reports Year End 2014 Financial Results
2015-03-17,BioLineRx To Report Fourth Quarter And Year End 2014 Results On March 23, 2015
2015-03-11,BioLineRx Closes $28.75 Million Underwritten Public Offering Of Its American Depositary Shares
2015-03-11,BioLineRx's Treatment For Type 1 Diabetes Effective In Preclinical Trials
2015-03-06,BioLineRx To Present At The Annual Roth Conference In California
2015-03-06,BioLineRx Prices $25 Million Underwritten Public Offering Of Its American Depositary Shares
2015-03-05,BioLineRx Announces Underwritten Public Offering Of Its American Depositary Shares
2015-03-02,BioLineRx Announces Regulatory Submission For Phase 2b Trial For Novel AML Consolidation Treatment
2015-02-03,BioLineRx To Present At 2015 BIO CEO & Investor Conference In New York On February 10
2015-01-14,BioLineRx Announces Completion Of Enrollment In CE Mark Registration Trial Of BCM (BL-1040), A Novel Medical Device For Prevention Of Cardiac Remodeling Following Acute Myocardial Infarction
2015-01-06,BioLineRx Completes Dose Escalation Stage Of Phase 1 Trial For Novel Stem Cell Mobilization Treatment
2015-01-06,BioLineRx To Present At Biotech Showcase 2015 Conference In San Francisco
2014-12-23,BioLineRx Out-Licenses Novel Skin Lesion Treatment To Omega Pharma
2014-12-16,BioLineRx And Major Global Pharmaceutical Company Form Strategic Collaboration For Screening And Development Of Novel Drug Candidates
2014-12-12,BioLineRx Presents Multi-Year Clinical Development Plan For Its BL-8040 Hematological Cancer Therapeutic Platform
2014-12-08,BioLineRx Reports Positive Data From Ongoing Phase 2a Study For AML Treatment At ASH Conference
2014-11-10,BioLineRx Reports Third Quarter 2014 Financial Results
2014-11-05,BioLineRx Announces Successful Final Results Of Phase 1/2 Study For Novel Celiac Treatment
2014-11-03,BioLineRx To Report Third Quarter 2014 Results On November 10, 2014
2014-11-03,BioLineRx Files Protocol Amendment To Phase 2 Study For AML Treatment Based On Encouraging Efficacy And Strong Safety Profile
2014-10-31,BioLineRx Reports Publication In Peer Review Journal Of Results From Previous Phase 1/2 Trial For BCM (BL-1040), A Novel Medical Device For Prevention Of Cardiac Remodeling Following Acute Myocardial Infarction
2014-09-17,BioLineRx Presents Positive Preclinical Results In Treatment For AML Patients With FLT3 Mutations
2014-09-03,BioLineRx Doses First Patient For BL-8040’s Second Indication As Novel Stem Cell Mobilization Treatment
2014-09-02,BioLineRx To Present At The 16th Annual Rodman & Renshaw Global Investment Conference In New York
2014-08-21,BioLineRx Receives Notice Of Allowance For US Patent On BL-7010 Covering Use Of Novel Polymer In Prevention Of Gluten Toxicity
2014-08-06,BioLineRx Reports Second Quarter 2014 Financial Results
2014-07-30,BioLineRx To Report Second Quarter 2014 Results On August 6, 2014
2014-07-16,BioLineRx Announces Results From Phase 1/2 Study For Celiac Treatment
2014-06-23,BioLineRx In-Licenses Novel Compound For Treatment Of Neuropathic Pain
2014-06-16,BioLineRx Receives Approval To Commence Phase 1 Trial For Novel Stem Cell Mobilization Treatment
2014-06-11,BioLineRx Receives Notice Of Allowance For US Patent Covering Novel Treatment For Celiac Disease
2014-05-30,BioLineRx Enters Into Share Purchase Agreement With Lincoln Park Capital
2014-05-20,BioLineRx Reports First Quarter 2014 Financial Results
2014-05-15,BioLineRx To Report First Quarter 2014 Results On May 20, 2014
2014-04-10,BioLineRx Announces Investigator-Initiated Study For Novel Chronic Myeloid Leukemia Treatment
2014-03-17,BioLineRx Reports Year End 2013 Financial Results
2014-03-14,BioLineRx Announces Issuance Of United States Patent Covering Use Of BL-8040 In Immunotherapy
2014-03-11,BioLineRx To Report Fourth Quarter And Year End 2013 Results On March 17, 2014
2014-03-10,BioLineRx Completes Dose Escalation Stage Of Phase 1/2 Study For Novel Celiac Treatment
2014-03-07,BioLineRx Closes $24.1 Million Underwritten Public Offering Of Its American Depositary Shares
2014-03-05,BioLineRx To Present At The Annual ROTH Growth Stock Conference In California
2014-03-04,BioLineRx Prices $21.0 Million Underwritten Public Offering Of Its American Depositary Shares
2014-03-03,BioLineRx Announces Underwritten Public Offering Of Its American Depositary Shares
2014-02-24,BioLineRx Appoints Dr. Sandra Panem To Board Of Directors
2014-02-12,BioLineRx Announces Positive Preclinical Results For Novel Treatment For Chronic Myeloid Leukemia
2014-02-03,BioLineRx To Present At The 2014 BIO CEO & Investor Conference In New York On February 10
2014-01-23,BioLineRx Receives Orphan Drug Designation For Novel Stem Cell Mobilization Treatment
2014-01-21,BioLineRx Receives Approval To Commence Pivotal Trial For Novel Skin Lesion Treatment
2014-01-13,BioLineRx Announces Regulatory Submission For Novel Stem Cell Mobilization Treatment
2014-01-08,BioLineRx And JHL Biotech To Collaborate On Type 1 Diabetes Antibody Treatment
2014-01-07,BioLineRx To Present At Biotech Showcase Conference In San Francisco
2013-12-18,BioLineRx Enters Clinic With Novel Treatment For Celiac Disease
2013-12-16,BioLineRx Announces Promising Initial Phase 2 Results Of Acute Myeloid Leukemia Treatment
2013-12-10,BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
2013-11-26,BioLineRx Announces New Positive Results In Phase 2a Trial For Orally Available Inflammatory Bowel Disease Treatment
2013-11-19,BioLineRx Reports Publication In Peer Review Journal Of Positive Phase 1/2 Results In Stem Cell Mobilization For Multiple Myeloma
2013-11-06,BioLineRx To Report Third Quarter 2013 Results On November 13, 2013
2013-11-05,BioLineRx To Hold Analyst And Investor Day In New York On November 21, 2013
2013-11-04,BioLineRx Receives Regulatory Approval To Commence Phase 1/2 Trial For Novel Treatment Of Celiac Disease
2013-10-23,BioLineRx Announces In-Licensing Of BL-9020, For Treatment Of Type 1 Diabetes
2013-10-07,BioLineRx Announces Receipt Of Notice Of Allowance From USPTO For Patent Covering BL-5010, A Novel Treatment For Removal Of Skin Lesions
2013-09-24,BioLineRx Announces Regulatory Submission For Phase 1/2 Trial For Novel Treatment Of Celiac Disease
2013-09-17,BioLineRx Announces Receipt Of A Notice Of Allowance From USPTO For Patent On Use Of BL-8020, An Oral, Interferon-Free Treatment For Hepatitis C
2013-09-09,BioLineRx's BL-8040 Receives Orphan Drug Designation For Treatment Of AML
2013-09-03,BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
2013-09-03,BioLineRx Announces Issuance Of United States Patent Covering Use Of BL-8040 For Obtaining Stem Cells
2013-08-28,BioLineRx To Present At 15th International Celiac Disease Symposium
2013-08-27,BioLineRx To Present At 2013 Stifel Nicolaus Healthcare Conference In Boston
2013-08-19,BioLineRx Appoints B. J. Bormann To Board Of Directors
2013-08-05,BioLineRx Announces Publication Of Positive Pre-Clinical Results For BL-8040 In Treatment Of Thrombocytopenia
2013-07-30,BioLineRx To Report Second Quarter 2013 Results On August 6, 2013
2013-07-29,BioLineRx Announces CE-Mark Registration Trial Submission For Novel Treatment For Removal Of Skin Lesions
2013-07-02,BioLineRx To Present At 2013 Annual JMP Securities Healthcare Conference In New York
2013-04-18,5 Stocks Under $10 Set to Soar
2013-04-16,Oramed Pharmaceuticals Appoints New Chief Operating Officer And VP Of Business Development
2013-03-20,BioLineRx Shares Fall On Schizophrenia Drug Failure
2013-03-20,BioLineRx Announces Results From Interim Analysis Of Phase II/III CLARITY Trial Of BL-1020 For Schizophrenia
2013-03-13,BioLineRx Receives Approval From French Regulatory Authorities To Commence A Phase I/II Clinical Trial For BL-8020, An Oral, Interferon-Free Treatment For Hepatitis C
2013-03-12,BioLineRx Reports Year End 2012 Financial Results
2013-02-28,BioLineRx's EDP-14, For Treatment Of Severe And Persistent Asthma, To Enter The Company's Main Therapeutic Pipeline As BL-9010
2013-02-26,BioLineRx To Report Fourth Quarter And Year End 2012 Results On March 12, 2013
2013-02-22,4 Stocks Under $5 Making Big Moves
2013-02-13,BioLineRx Announces Closing Of $8 Million Offering Of American Depositary Shares
2013-02-06,BioLineRx Announces Offering Of American Depositary Shares
2013-02-04,BioLineRx Provides Clarification Regarding Interim Analysis Of CLARITY Trial For BL-1020
2013-01-31,BioLineRx To Present At The 2013 BIO CEO &amp; Investor Conference In New York On February 12th
2013-01-07,BioLineRx To Announce Interim Results Of Phase II/III Trial For Schizophrenia Drug During Week Of March 18, 2013
2012-11-30,BioLineRx To Present At The 2012 Fifth Annual LD MICRO Conference In Los Angeles On December 5th
2012-11-14,BioLineRx Reports Third Quarter 2012 Financial Results
2012-11-12,BioLineRx To Hold Analyst And Investor Day In New York On December 4, 2012
2012-11-07,BioLineRx Announces BL-8040, For The Treatment Of Leukemia And Other Types Of Hematological Cancer, To Be Presented At 2012 ASH Annual Meeting
2012-11-05,BioLineRx To Report Third Quarter 2012 Results On November 14, 2012
2012-10-24,BioLineRx To Conduct Interim Analysis Of Phase II/III CLARITY Clinical Trial Of BL-1020 For Treatment Of Schizophrenia
2012-10-16,BioLineRx Announces Successful Completion Of Pre-Clinical Development For BL-8020, An Oral, Interferon-Free Treatment For Hepatitis C
2012-10-09,BioLineRx Announces New Analysis Of EAGLE Phase IIb Study Showing A Significantly Greater Beneficial Effect Of BL-1020 On Cognitive Function In Schizophrenia Patients
2012-09-27,BioLineRx Enters Into Share Purchase Agreement With Lincoln Park Capital
2012-09-27,BioLineRx Announces Publication Of EAGLE Study Results Demonstrating BL-1020's Efficacy In Improving Cognitive Function In Schizophrenia Patients
2012-09-24,BioLineRx Receives Notice Of Allowance From USPTO For New Patent On BL-1020, Extending Patent Protection Until 2031
2012-09-10,BioLineRx Announces Pre-clinical Results Demonstrating The Safety Of BL-7010, An Oral Treatment For Celiac Disease And Gluten Sensitivity
2012-09-04,BioLineRx In-Licenses A Novel, Phase II Ready Drug For The Treatment Of Leukemia And Other Hematological Cancers
2012-08-15,BioLineRx Reports Second Quarter 2012 Results
2012-08-02,BioLineRx To Report Second Quarter 2012 Results On August 15, 2012
2012-07-09,BioLineRx Receives Notice Of Intention To Grant Additional European Patent Covering BL-1020, For The Treatment Of Schizophrenia
2012-06-28,BioLineRx To Present At The 2012 Annual JMP Securities Healthcare Conference In New York On July 13th
2012-06-13,Research Underlying BioLineRx's EDP 10, For Treatment Of Type 1 Diabetes, Wins Hebrew University's Kaye Award
2012-06-05,BioLineRx Announces Receipt Of Two Notices Of Allowance From USPTO For Patents Covering BL-1021, An Orally Available New Chemical Entity For Treatment Of Neuropathic Pain
2012-05-15,BioLineRx Reports First Quarter 2012 Results
2012-04-23,BioLineRx Launches Free Investor Relations App For IPhone
2012-03-28,BioLineRx To Present At The 2012 Annual Needham Healthcare Conference In New York On April 3rd
2012-03-22,High-level View Of Pipeline (Graphic: Business Wire)
2012-03-07,BioLineRx To Present At The 2012 Annual Roth Growth Conference In Orange County, California On March 14th
2012-03-07,BioLineRx Announces Grant Of European Patent Covering BL-1020, An Orally Available Treatment For Schizophrenia
2012-03-05,BioLineRx Receives Approval For Commencing Phase II Clinical Trial Of BL-7040, An Orally Available Treatment For Inflammatory Bowel Disease
2017-03-20,Bluebird Bio Appoints New Senior Manufacturing And Corporate Development Executives
2017-03-01,Bluebird Bio Announces Publication Of Case Study On First Patient With Severe Sickle Cell Disease Treated With Gene Therapy In The New England Journal Of Medicine
2017-02-28,Bluebird Bio To Present At Two Investor Conferences In March
2017-02-24,5 Stocks Set for Explosive Breakouts
2017-02-22,Bluebird Bio Reports Fourth Quarter And Full Year 2016 Financial Results And Recent Operational Progress
2017-02-15,Watching for More Movement in Bluebird BIO and 3 Others
2017-02-06,Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird
2017-02-03,Bluebird Bio Announces First Patient Treated With LentiGlobinTM Drug Product Under Amended Study Protocol In HGB-206 Phase 1 Study Of Patients With Severe Sickle Cell Disease
2017-01-31,Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence
2017-01-31,Bluebird Bio Looks Set to Soar Upward
2017-01-04,Bluebird Bio To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-28,Short Interest In Bluebird Bio Moves 11.2% Lower
2016-12-23,'Mad Money' Lightning Round: Southwestern Energy, UnitedHealth, Celgene and More
2016-12-22,Jim Cramer's 'Mad Money' Recap: Don't Worry About a Little Market Detour
2016-12-15,Bluebird Bio And Apceth Biopharma Establish Commercial Drug Product Manufacturing Agreement
2016-12-14,Bluebird Bio Announces First Patient Treated With LentiGlobinTM Drug Product In Northstar-2 (HGB-207) Phase 3 Trial Of Patients With Transfusion-Dependent ß-Thalassemia
2016-12-07,Biotech Only Sector in the Red as Trump Vows to Crackdown on Drug Pricing, Biggest Movers
2016-12-07,Dow Scores Another Record for Third Consecutive Day; S&amp;P 500 Also Hits New High
2016-12-07,Dow, S&amp;P 500 Trade at Session Highs in Broad Wall Street Rally
2016-12-07,S&amp;P 500 and Dow Reverse Losses to Post Intraday Records
2016-12-07,Trump's Drug Pricing Comment Sends Biotech Stocks Into Free-Fall
2016-12-06,Bluebird Bio Announces Pricing Of Public Offering Of Common Stock
2016-12-06,Bluebird Bio Announces Proposed Public Offering Of Common Stock
2016-12-05,Bluebird Bio Provides Updates On HSC Gene Therapy Programs
2016-12-05,Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting
2016-12-03,Bluebird Bio Presents New Data From HGB-205 Study Of LentiGlobinTM Drug Product In Patients With Transfusion-Dependent ß-Thalassemia (TDT) And Severe Sickle Cell Disease At American Society Of Hematology (ASH) Annual Meeting
2016-12-02,Bluebird Bio Announces Management Appointments
2016-12-01,Jim Cramer's 'Mad Money' Recap: This Rotation's Too Hard for the Bulls
2016-12-01,Oil Prices Keep Rising on OPEC Deal; Bluebird, Celgene T-Cell Therapy Sees Success
2016-11-30,Bluebird Bio Announces Interim Phase 1 Dose Escalation Data For Its Anti-BCMA CAR T Product Candidate In Patients With Relapsed/Refractory Multiple Myeloma
2016-11-30,Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects
2016-11-19,How Buying Blue Apron Ahead of any IPO Could Leave You Blue
2016-11-14,Bluebird Bio To Present New Data From Novel Anti-BCMA CAR T Cell Therapy Bb2121 At EORTC-NCI-AACR Molecular Targets And Cancer Therapies Symposium
2016-11-03,The Great 'ASH16' Abstract Drop Mostly Causes Drug Stocks to Do Same
2016-11-03,Bluebird Bio To Present New Data From Three LentiGlobinTM Clinical Studies At American Society Of Hematology (ASH) Annual Meeting
2016-11-02,Bluebird Bio Reports Third Quarter 2016 Financial Results And Recent Operational Progress
2016-11-01,Bluebird Bio To Present At Two Investor Conferences In November
2016-10-18,Why Celgene Is a Core Biotech Holding
2016-10-17,Trader's Daily Notebook: You Might Consider Selling Facebook
2016-10-14,Bluebird Bio Shares End Friday's Session Down 13%
2016-10-13,Bluebird Bio Provides Update On LentiGlobin™ Programs And Research And Development Strategy At Gene Therapy Day
2016-10-06,Bluebird Bio Announces Topics For Gene Therapy Day, October Investor Presentation
2016-09-30,Buy These 4 Stocks and Beat Biotech's Slump
2016-09-29,Bluebird Bio And Medigene Establish Strategic T Cell Receptor (TCR) Alliance In Cancer Immunotherapy
2016-09-28,Four Stellar Stocks to Beat the Biotech Slump
2016-09-26,OPEC, HP, Ulta Salon and Lululemon: Jim Cramer's Views
2016-09-24,'Mad Money' Lightning Round: Buy, Buy, Buy Advanced Micro Devices
2016-09-23,Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
2016-09-21,LentiGlobin™ Investigational Gene Therapy For Transfusion-Dependent Beta-Thalassemia Accepted Into European Medicines Agency's PRIME Program
2016-09-15,Bluebird Bio (BLUE) Stock Jumping, Goldman Adds to Conviction Buy List
2016-09-14,Here's a Reason Why Bluebird Bio (BLUE) Stock Is Jumping Today
2016-09-09,Bluebird Bio Announces Webcast Of Gene Therapy Day
2016-09-08,Bluebird Improves Its Gene Therapy, Removing an Investor Concern
2016-09-08,Bluebird Bio Opens Phase 3 Study Of LentiGlobin™ Drug Product In Patients With Transfusion-Dependent Beta-Thalassemia
2016-09-07,Oncorus®, Inc. Appoints Biotech Industry Veteran Cyrus D. Mozayeni, M.D., As President And Chief Business Officer
2016-08-30,Bluebird Bio To Present At Four Upcoming Conferences
2016-08-05,Trade-Ideas: Bluebird Bio (BLUE) Is Today's "Dead Cat Bounce" Stock
2016-08-04,Bluebird Bio (BLUE) In A Perilous Reversal
2016-08-04,Bluebird Bio To Present At Wedbush PacGrow Healthcare Conference
2016-08-03,Bluebird Bio Reports Second Quarter 2016 Financial Results And Recent Operational Progress
2016-08-01,Bluebird Bio (BLUE) Weak On High Volume
2016-07-28,4 Stocks to Play In Today's Market
2016-07-27,Bluebird Bio (BLUE) Marked As A Barbarian At The Gate
2016-07-22,Insider Trading Alert - AA, BLUE And VLGEA Traded By Insiders
2016-07-19,Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact
2016-07-18,Bluebird Bio Presents MegaTAL Genome Editing Data At American Society Of Hematology (ASH) Workshop On Genome Editing
2016-07-07,Juno Patient Deaths Crash Cancer-Killing CAR-T Party
2016-07-01,Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here
2016-06-27,A Biotech Stock Turnaround Requires an Alzheimer's Drug Miracle
2016-06-18,These 5 Stocks Could Be Toxic to Your Portfolio
2016-06-10,Global Blood Shows Extended, Safe Treatment Effect for Sickle Cell Disease Drug
2016-06-06,Bluebird Bio (BLUE) Is Today's Dead Cat Bounce Stock
2016-06-03,Stock To Watch: Bluebird Bio (BLUE) In Perilous Reversal
2016-05-23,Bluebird Bio To Present At Goldman Sachs 37th Annual Healthcare Conference
2016-05-13,Bluebird Bio (BLUE) Showing Signs Of A Dead Cat Bounce Today
2016-05-12,Mast Sickle Cell Drug Seeks to Defy Long Odds Like Leicester City
2016-05-10,Trade-Ideas: Bluebird Bio (BLUE) Is Today's "Perilous Reversal" Stock
2016-05-09,Bluebird Bio Presents Oncology And Gene Therapy Data At The ASGCT 19th Annual Meeting
2016-05-04,Bluebird Bio Reports First Quarter 2016 Financial Results And Recent Operational Progress
2016-04-27,Bluebird Bio To Present At Two Upcoming Investor Conferences
2016-04-20,Weak On High Volume: Bluebird Bio (BLUE)
2016-04-20,Bluebird Bio Reports Interim Clinical Data From Starbeam Study Of Lenti-D™ At AAN 2016 Annual Meeting
2016-04-20,Bluebird Bio Gene Therapy Shows Early Promise in Fatal Childhood Brain Disease
2016-04-18,Bluebird Bio To Present Immuno-Oncology And Gene Therapy Data At The ASGCT 19th Annual Meeting
2016-03-10,Bluebird Bio (BLUE) Is Today's Dead Cat Bounce Stock
2016-03-09,Today's Weak On High Volume Stock: Bluebird Bio (BLUE)
2016-03-03,Bluebird Bio To Present Clinical Data On Lenti-D In CALD In Plenary Session At AAN 2016 Annual Meeting
2016-03-02,Bluebird Bio To Present At Three Upcoming Investor Conferences
2016-02-26,Bluebird Bio (BLUE) Is Today's Dead Cat Bounce Stock
2016-02-25,Bluebird Bio Announces Transition Of Chief Financial Officer
2016-02-24,Bluebird Bio Reports Fourth Quarter And Full Year 2015 Financial Results And Recent Operational Progress
2016-02-17,Bluebird Bio Announces First Patient Treated With Bb2121 In CRB-401 Phase 1 Study In Patients With Relapsed/Refractory Multiple Myeloma
2016-02-02,Perilous Reversal Watch: Bluebird Bio (BLUE)
2016-01-29,Trade-Ideas: Bluebird Bio (BLUE) Is Today's "Dead Cat Bounce" Stock
2016-01-20,Commit To Buy bluebird bio At $22.50, Earn 20.4% Using Options
2016-01-13,bluebird bio (BLUE) Showing Signs of Perilous Reversal Today
2016-01-12,Bluebird Bio (BLUE) Is Today's Dead Cat Bounce Stock
2016-01-11,A Lack of News and Buzz at 'JPM16' Sinks Biotech Stocks
2016-01-11,Water-Logged And Getting Wetter Stock Of The Day: Bluebird Bio (BLUE)
2016-01-09,2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks
2016-01-05,Bluebird Bio To Present At The 34th Annual J.P. Morgan Healthcare Conference
2016-01-01,Feuerstein's Heroes and Zeroes of Biotech Investing in 2015
2015-12-08,2 'Rules of the Road' for Biotech Investing
2015-12-07,Stocks Slump as Oil Closes at Lowest Since 2009
2015-12-07,Bluebird Bio Crashes After ASH Meeting Followed By Downgrades
2015-12-07,Midday Report: Keurig Deal Boosts Peers; Energy Stocks Slump
2015-12-07,Stocks Plummet as Crude Oil Nears $38
2015-12-07,Bluebird Bio (BLUE) Stock Tanks Following Analyst Downgrade
2015-12-07,Stock Futures Turn Mixed as Keurig Jumps, Chipotle Slumps
2015-12-07,Analysts' Actions -- Big Lots, Bluebird Bio, Eli Lilly, Match Group and More
2015-12-07,Bluebird Bio (BLUE): Heavy Pre-Market Activity
2015-12-07,Investors Remain Skeptical about Bluebird Gene Therapy for Blood Disease
2015-12-06,Bluebird Bio Presents Pre-Clinical And Manufacturing Data From CAR T Oncology Programs At ASH Annual Meeting
2015-12-06,Bluebird Sickle Cell Gene Therapy Falls Short of High Expectations
2015-12-06,Bluebird Bio Reports New Beta-thalassemia Major And Severe Sickle Cell Disease Data From HGB-205 And HGB-206 Studies Of LentiGlobin® At ASH Annual Meeting
2015-12-05,Bluebird, Celgene See Promise in T Cell Therapy for Multiple Myeloma
2015-12-05,Bluebird Bio Reports New Beta-thalassemia Major Data From Northstar Study Of LentiGlobin® At ASH Annual Meeting
2015-12-03,Bluebird Bio And ViroMed Enter Into License Agreement For Novel Antibodies To Develop Chimeric Antigen Receptor T Cell Therapy
2015-12-02,Bluebird Bio (BLUE) Marked As A Dead Cat Bounce Stock
2015-12-01,Jim Cramer's 'Mad Money' Recap: Stocks Gain When Analysts Curb Negativity
2015-11-25,Bluebird Bio Announces Participation In 27th Annual Piper Jaffray Healthcare Conference
2015-11-22,Goldman Sachs Says These 12 Small-Cap Stocks Are Worth Buying
2015-11-21,Clovis Blowup Conjures Bad Biotech Memories of ImClone Darkness
2015-11-19,Perilous Reversal Stock: Bluebird Bio (BLUE)
2015-11-18,Goldman Sees Bluebird Shares Doubling On 'One-Shot' Gene Therapy
2015-11-18,Today's Pre-Market Trading Very Positive For Bluebird Bio (BLUE)
2015-11-13,Biotech Stock Mailbag: Relypsa, Sophiris, Bluebird, Zafgen, NW Bio
2015-11-06,Bluebird Bio (BLUE) Marked As A Dead Cat Bounce Stock
2015-11-05,Bluebird Bio (BLUE): Heavy Pre-Market Activity
2015-11-05,Bluebird Gene Therapy Narrative Shift: 'Cure' May Elude Some Patients
2015-11-05,Bluebird Bio To Present LentiGlobin® BB305 Clinical Data And Bb2121 Preclinical Data At Annual Meeting Of The American Society Of Hematology
2015-11-04,Bluebird Bio Reports Third Quarter 2015 Financial Results And Recent Operational Progress
2015-11-04,Bluebird Bio Announces Participation In 24th Annual Credit Suisse Healthcare Conference
2015-10-23,Trade-Ideas: Bluebird Bio (BLUE) Is Today's Strong On High Relative Volume Stock
2015-10-19,Bluebird Shares Plunge on Waning Effect of Old Gene Therapy
2015-10-19,Bluebird Bio (BLUE) Showing Signs Of Being Water-Logged And Getting Wetter
2015-10-19,Bluebird Bio Announces Presentation At Cooley's Anemia Foundation Symposium
2015-10-16,Trade-Ideas: Bluebird Bio (BLUE) Is Today's Strong On High Relative Volume Stock
2015-10-16,Biotech Stock Mailbag: New Sarepta Risk, Zafgen Patient Death, Bluebird Gene Therapy Update
2015-10-07,Jim Cramer -- Microsoft, General Mills, WhiteWave Are Buying Opportunities
2015-10-07,Jim Cramer Bullish on Microsoft, Likes General Mills and WhiteWave
2015-10-05,Spark Therapeutics Trial Success Seen As Positive For Gene Therapy Sector
2015-10-05,Trade-Ideas: Bluebird Bio (BLUE) Is Today's Pre-Market Leader Stock
2015-10-05,Analysts' Actions -- Twitter, AutoZone, Tyco, Viacom
2015-10-02,5 Stocks Poised for Breakouts
2015-09-29,Strong On High Volume: Bluebird Bio (BLUE)
2015-09-29,Alexandria Real Estate Equities, Inc. Announces 10-Year 253,000 RSF Full-Building Build-to-Suit Lease At 60 Binney Street For Bluebird Bio For Its New Office/Laboratory Headquarters In The Heart Of Kendall Square In Cambridge, MA
2015-09-25,bluebird bio is Now Oversold
2015-09-25,Biotech Stock Mailbag: Rebounding From Hillary's Drug Tweet; Global Blood Weighs on Bluebird
2015-09-24,Bluebird Bio Announces Participation In Leerink Partners Immuno-Oncology Roundtable
2015-09-21,Bluebird Bio (BLUE) Is Water-Logged And Getting Wetter Today
2015-09-11,Bluebird Bio Announces Participation At Morgan Stanley Global Healthcare Conference
2015-09-09,Perilous Reversal Watch: Bluebird Bio (BLUE)
2015-09-04,2 Issues Keeping Buyers on the Sidelines Today
2015-09-01,The Numbers Behind Biotech's Horrible, No Good, Awful August
2015-08-26,Biotech Selloff Has No Effect on Cellectis Advances: CEO
2015-08-26,Biotech Selloff Does Not Dim Immunotherapy Advances Says Cellectis CEO
2015-08-21,Biotech Stock Mailbag: Celldex, Bluebird, Kite, Inovio
2015-08-19,Biotech Stocks Get Burned This Summer, but Fall Might Bring Relief
2015-08-12,Bluebird, Pacira Pharmaceuticals Excite Life Science Investors
2015-08-12,Bluebird, Pacira Pharmaceuticals Gain Steam in Burgeoning Life Science Space
2015-08-10,BLUE, TEVA And AMGN, 3 Drugs Stocks Pushing The Industry Lower
2015-08-07,Water-Logged And Getting Wetter: Bluebird Bio (BLUE)
2015-08-06,Bluebird Bio Reports Second Quarter 2015 Financial Results And Recent Operational Progress
2015-08-05,Trade-Ideas: Bluebird Bio (BLUE) Is Today's Post-Market Leader Stock
2015-08-05,Bluebird Bio Announces Participation At The 2015 Wedbush PacGrow Healthcare Conference
2015-07-27,Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up
2015-07-02,Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point
2015-07-01,Today's Perilous Reversal Stock: Bluebird Bio (BLUE)
2015-06-30,Today's Top Performers In Health Care
2015-06-30,Celgene on My Shopping List for a Pullback
2015-06-29,Celgene is Desperate or Insane to Pay Ultra-High Premium for Juno Partnership
2015-06-29,Trade-Ideas: Bluebird Bio (BLUE) Is Today's Post-Market Leader Stock
2015-06-23,Bluebird Bio Announces Pricing Of Public Offering Of Common Stock
2015-06-23,Bluebird Bio Announces Proposed Public Offering Of Common Stock
2015-06-19,Biotech Stock Mailbag: Unstoppable Heron, Aerie Disclosure Fail, Gene Therapy, Hate Mail!
2015-06-19,'Mad Money' Lightning Round: Buy, Buy, Buy Citigroup
2015-06-18,Jim Cramer's 'Mad Money' Recap: Here's Why We Had a Rally Today
2015-06-16,Avalanche Fails Common-Sense Test, Kicked Out of Gene Therapy Credibility Club
2015-06-15,Philip Gregory, D. Phil., Joins Bluebird Bio As Chief Scientific Officer
2017-03-20,Bluebird Bio Appoints New Senior Manufacturing And Corporate Development Executives
2017-03-01,Bluebird Bio Announces Publication Of Case Study On First Patient With Severe Sickle Cell Disease Treated With Gene Therapy In The New England Journal Of Medicine
2017-02-28,Bluebird Bio To Present At Two Investor Conferences In March
2017-02-24,5 Stocks Set for Explosive Breakouts
2017-02-22,Bluebird Bio Reports Fourth Quarter And Full Year 2016 Financial Results And Recent Operational Progress
2017-02-15,Watching for More Movement in Bluebird BIO and 3 Others
2017-02-06,Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird
2017-02-03,Bluebird Bio Announces First Patient Treated With LentiGlobinTM Drug Product Under Amended Study Protocol In HGB-206 Phase 1 Study Of Patients With Severe Sickle Cell Disease
2017-01-31,Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence
2017-01-31,Bluebird Bio Looks Set to Soar Upward
2017-01-04,Bluebird Bio To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-28,Short Interest In Bluebird Bio Moves 11.2% Lower
2016-12-23,'Mad Money' Lightning Round: Southwestern Energy, UnitedHealth, Celgene and More
2016-12-22,Jim Cramer's 'Mad Money' Recap: Don't Worry About a Little Market Detour
2016-12-15,Bluebird Bio And Apceth Biopharma Establish Commercial Drug Product Manufacturing Agreement
2016-12-14,Bluebird Bio Announces First Patient Treated With LentiGlobinTM Drug Product In Northstar-2 (HGB-207) Phase 3 Trial Of Patients With Transfusion-Dependent ß-Thalassemia
2016-12-07,Biotech Only Sector in the Red as Trump Vows to Crackdown on Drug Pricing, Biggest Movers
2016-12-07,Dow Scores Another Record for Third Consecutive Day; S&amp;P 500 Also Hits New High
2016-12-07,Dow, S&amp;P 500 Trade at Session Highs in Broad Wall Street Rally
2016-12-07,S&amp;P 500 and Dow Reverse Losses to Post Intraday Records
2016-12-07,Trump's Drug Pricing Comment Sends Biotech Stocks Into Free-Fall
2016-12-06,Bluebird Bio Announces Pricing Of Public Offering Of Common Stock
2016-12-06,Bluebird Bio Announces Proposed Public Offering Of Common Stock
2016-12-05,Bluebird Bio Provides Updates On HSC Gene Therapy Programs
2016-12-05,Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting
2016-12-03,Bluebird Bio Presents New Data From HGB-205 Study Of LentiGlobinTM Drug Product In Patients With Transfusion-Dependent ß-Thalassemia (TDT) And Severe Sickle Cell Disease At American Society Of Hematology (ASH) Annual Meeting
2016-12-02,Bluebird Bio Announces Management Appointments
2016-12-01,Jim Cramer's 'Mad Money' Recap: This Rotation's Too Hard for the Bulls
2016-12-01,Oil Prices Keep Rising on OPEC Deal; Bluebird, Celgene T-Cell Therapy Sees Success
2016-11-30,Bluebird Bio Announces Interim Phase 1 Dose Escalation Data For Its Anti-BCMA CAR T Product Candidate In Patients With Relapsed/Refractory Multiple Myeloma
2016-11-30,Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects
2016-11-19,How Buying Blue Apron Ahead of any IPO Could Leave You Blue
2016-11-14,Bluebird Bio To Present New Data From Novel Anti-BCMA CAR T Cell Therapy Bb2121 At EORTC-NCI-AACR Molecular Targets And Cancer Therapies Symposium
2016-11-03,The Great 'ASH16' Abstract Drop Mostly Causes Drug Stocks to Do Same
2016-11-03,Bluebird Bio To Present New Data From Three LentiGlobinTM Clinical Studies At American Society Of Hematology (ASH) Annual Meeting
2016-11-02,Bluebird Bio Reports Third Quarter 2016 Financial Results And Recent Operational Progress
2016-11-01,Bluebird Bio To Present At Two Investor Conferences In November
2016-10-18,Why Celgene Is a Core Biotech Holding
2016-10-17,Trader's Daily Notebook: You Might Consider Selling Facebook
2016-10-14,Bluebird Bio Shares End Friday's Session Down 13%
2016-10-13,Bluebird Bio Provides Update On LentiGlobin™ Programs And Research And Development Strategy At Gene Therapy Day
2016-10-06,Bluebird Bio Announces Topics For Gene Therapy Day, October Investor Presentation
2016-09-30,Buy These 4 Stocks and Beat Biotech's Slump
2016-09-29,Bluebird Bio And Medigene Establish Strategic T Cell Receptor (TCR) Alliance In Cancer Immunotherapy
2016-09-28,Four Stellar Stocks to Beat the Biotech Slump
2016-09-26,OPEC, HP, Ulta Salon and Lululemon: Jim Cramer's Views
2016-09-24,'Mad Money' Lightning Round: Buy, Buy, Buy Advanced Micro Devices
2016-09-23,Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
2016-09-21,LentiGlobin™ Investigational Gene Therapy For Transfusion-Dependent Beta-Thalassemia Accepted Into European Medicines Agency's PRIME Program
2016-09-15,Bluebird Bio (BLUE) Stock Jumping, Goldman Adds to Conviction Buy List
2016-09-14,Here's a Reason Why Bluebird Bio (BLUE) Stock Is Jumping Today
2016-09-09,Bluebird Bio Announces Webcast Of Gene Therapy Day
2016-09-08,Bluebird Improves Its Gene Therapy, Removing an Investor Concern
2016-09-08,Bluebird Bio Opens Phase 3 Study Of LentiGlobin™ Drug Product In Patients With Transfusion-Dependent Beta-Thalassemia
2016-09-07,Oncorus®, Inc. Appoints Biotech Industry Veteran Cyrus D. Mozayeni, M.D., As President And Chief Business Officer
2016-08-30,Bluebird Bio To Present At Four Upcoming Conferences
2016-08-05,Trade-Ideas: Bluebird Bio (BLUE) Is Today's "Dead Cat Bounce" Stock
2016-08-04,Bluebird Bio (BLUE) In A Perilous Reversal
2016-08-04,Bluebird Bio To Present At Wedbush PacGrow Healthcare Conference
2016-08-03,Bluebird Bio Reports Second Quarter 2016 Financial Results And Recent Operational Progress
2016-08-01,Bluebird Bio (BLUE) Weak On High Volume
2016-07-28,4 Stocks to Play In Today's Market
2016-07-27,Bluebird Bio (BLUE) Marked As A Barbarian At The Gate
2016-07-22,Insider Trading Alert - AA, BLUE And VLGEA Traded By Insiders
2016-07-19,Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact
2016-07-18,Bluebird Bio Presents MegaTAL Genome Editing Data At American Society Of Hematology (ASH) Workshop On Genome Editing
2016-07-07,Juno Patient Deaths Crash Cancer-Killing CAR-T Party
2016-07-01,Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here
2016-06-27,A Biotech Stock Turnaround Requires an Alzheimer's Drug Miracle
2016-06-18,These 5 Stocks Could Be Toxic to Your Portfolio
2016-06-10,Global Blood Shows Extended, Safe Treatment Effect for Sickle Cell Disease Drug
2016-06-06,Bluebird Bio (BLUE) Is Today's Dead Cat Bounce Stock
2016-06-03,Stock To Watch: Bluebird Bio (BLUE) In Perilous Reversal
2016-05-23,Bluebird Bio To Present At Goldman Sachs 37th Annual Healthcare Conference
2016-05-13,Bluebird Bio (BLUE) Showing Signs Of A Dead Cat Bounce Today
2016-05-12,Mast Sickle Cell Drug Seeks to Defy Long Odds Like Leicester City
2016-05-10,Trade-Ideas: Bluebird Bio (BLUE) Is Today's "Perilous Reversal" Stock
2016-05-09,Bluebird Bio Presents Oncology And Gene Therapy Data At The ASGCT 19th Annual Meeting
2016-05-04,Bluebird Bio Reports First Quarter 2016 Financial Results And Recent Operational Progress
2016-04-27,Bluebird Bio To Present At Two Upcoming Investor Conferences
2016-04-20,Weak On High Volume: Bluebird Bio (BLUE)
2016-04-20,Bluebird Bio Reports Interim Clinical Data From Starbeam Study Of Lenti-D™ At AAN 2016 Annual Meeting
2016-04-20,Bluebird Bio Gene Therapy Shows Early Promise in Fatal Childhood Brain Disease
2016-04-18,Bluebird Bio To Present Immuno-Oncology And Gene Therapy Data At The ASGCT 19th Annual Meeting
2016-03-10,Bluebird Bio (BLUE) Is Today's Dead Cat Bounce Stock
2016-03-09,Today's Weak On High Volume Stock: Bluebird Bio (BLUE)
2016-03-03,Bluebird Bio To Present Clinical Data On Lenti-D In CALD In Plenary Session At AAN 2016 Annual Meeting
2016-03-02,Bluebird Bio To Present At Three Upcoming Investor Conferences
2016-02-26,Bluebird Bio (BLUE) Is Today's Dead Cat Bounce Stock
2016-02-25,Bluebird Bio Announces Transition Of Chief Financial Officer
2016-02-24,Bluebird Bio Reports Fourth Quarter And Full Year 2015 Financial Results And Recent Operational Progress
2016-02-17,Bluebird Bio Announces First Patient Treated With Bb2121 In CRB-401 Phase 1 Study In Patients With Relapsed/Refractory Multiple Myeloma
2016-02-02,Perilous Reversal Watch: Bluebird Bio (BLUE)
2016-01-29,Trade-Ideas: Bluebird Bio (BLUE) Is Today's "Dead Cat Bounce" Stock
2016-01-20,Commit To Buy bluebird bio At $22.50, Earn 20.4% Using Options
2016-01-13,bluebird bio (BLUE) Showing Signs of Perilous Reversal Today
2016-01-12,Bluebird Bio (BLUE) Is Today's Dead Cat Bounce Stock
2016-01-11,A Lack of News and Buzz at 'JPM16' Sinks Biotech Stocks
2016-01-11,Water-Logged And Getting Wetter Stock Of The Day: Bluebird Bio (BLUE)
2016-01-09,2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks
2016-01-05,Bluebird Bio To Present At The 34th Annual J.P. Morgan Healthcare Conference
2016-01-01,Feuerstein's Heroes and Zeroes of Biotech Investing in 2015
2015-12-08,2 'Rules of the Road' for Biotech Investing
2015-12-07,Stocks Slump as Oil Closes at Lowest Since 2009
2015-12-07,Bluebird Bio Crashes After ASH Meeting Followed By Downgrades
2015-12-07,Midday Report: Keurig Deal Boosts Peers; Energy Stocks Slump
2015-12-07,Stocks Plummet as Crude Oil Nears $38
2015-12-07,Bluebird Bio (BLUE) Stock Tanks Following Analyst Downgrade
2015-12-07,Stock Futures Turn Mixed as Keurig Jumps, Chipotle Slumps
2015-12-07,Analysts' Actions -- Big Lots, Bluebird Bio, Eli Lilly, Match Group and More
2015-12-07,Bluebird Bio (BLUE): Heavy Pre-Market Activity
2015-12-07,Investors Remain Skeptical about Bluebird Gene Therapy for Blood Disease
2015-12-06,Bluebird Bio Presents Pre-Clinical And Manufacturing Data From CAR T Oncology Programs At ASH Annual Meeting
2015-12-06,Bluebird Sickle Cell Gene Therapy Falls Short of High Expectations
2015-12-06,Bluebird Bio Reports New Beta-thalassemia Major And Severe Sickle Cell Disease Data From HGB-205 And HGB-206 Studies Of LentiGlobin® At ASH Annual Meeting
2015-12-05,Bluebird, Celgene See Promise in T Cell Therapy for Multiple Myeloma
2015-12-05,Bluebird Bio Reports New Beta-thalassemia Major Data From Northstar Study Of LentiGlobin® At ASH Annual Meeting
2015-12-03,Bluebird Bio And ViroMed Enter Into License Agreement For Novel Antibodies To Develop Chimeric Antigen Receptor T Cell Therapy
2015-12-02,Bluebird Bio (BLUE) Marked As A Dead Cat Bounce Stock
2015-12-01,Jim Cramer's 'Mad Money' Recap: Stocks Gain When Analysts Curb Negativity
2015-11-25,Bluebird Bio Announces Participation In 27th Annual Piper Jaffray Healthcare Conference
2015-11-22,Goldman Sachs Says These 12 Small-Cap Stocks Are Worth Buying
2015-11-21,Clovis Blowup Conjures Bad Biotech Memories of ImClone Darkness
2015-11-19,Perilous Reversal Stock: Bluebird Bio (BLUE)
2015-11-18,Goldman Sees Bluebird Shares Doubling On 'One-Shot' Gene Therapy
2015-11-18,Today's Pre-Market Trading Very Positive For Bluebird Bio (BLUE)
2015-11-13,Biotech Stock Mailbag: Relypsa, Sophiris, Bluebird, Zafgen, NW Bio
2015-11-06,Bluebird Bio (BLUE) Marked As A Dead Cat Bounce Stock
2015-11-05,Bluebird Bio (BLUE): Heavy Pre-Market Activity
2015-11-05,Bluebird Gene Therapy Narrative Shift: 'Cure' May Elude Some Patients
2015-11-05,Bluebird Bio To Present LentiGlobin® BB305 Clinical Data And Bb2121 Preclinical Data At Annual Meeting Of The American Society Of Hematology
2015-11-04,Bluebird Bio Reports Third Quarter 2015 Financial Results And Recent Operational Progress
2015-11-04,Bluebird Bio Announces Participation In 24th Annual Credit Suisse Healthcare Conference
2015-10-23,Trade-Ideas: Bluebird Bio (BLUE) Is Today's Strong On High Relative Volume Stock
2015-10-19,Bluebird Shares Plunge on Waning Effect of Old Gene Therapy
2015-10-19,Bluebird Bio (BLUE) Showing Signs Of Being Water-Logged And Getting Wetter
2015-10-19,Bluebird Bio Announces Presentation At Cooley's Anemia Foundation Symposium
2015-10-16,Trade-Ideas: Bluebird Bio (BLUE) Is Today's Strong On High Relative Volume Stock
2015-10-16,Biotech Stock Mailbag: New Sarepta Risk, Zafgen Patient Death, Bluebird Gene Therapy Update
2015-10-07,Jim Cramer -- Microsoft, General Mills, WhiteWave Are Buying Opportunities
2015-10-07,Jim Cramer Bullish on Microsoft, Likes General Mills and WhiteWave
2015-10-05,Spark Therapeutics Trial Success Seen As Positive For Gene Therapy Sector
2015-10-05,Trade-Ideas: Bluebird Bio (BLUE) Is Today's Pre-Market Leader Stock
2015-10-05,Analysts' Actions -- Twitter, AutoZone, Tyco, Viacom
2015-10-02,5 Stocks Poised for Breakouts
2015-09-29,Strong On High Volume: Bluebird Bio (BLUE)
2015-09-29,Alexandria Real Estate Equities, Inc. Announces 10-Year 253,000 RSF Full-Building Build-to-Suit Lease At 60 Binney Street For Bluebird Bio For Its New Office/Laboratory Headquarters In The Heart Of Kendall Square In Cambridge, MA
2015-09-25,bluebird bio is Now Oversold
2015-09-25,Biotech Stock Mailbag: Rebounding From Hillary's Drug Tweet; Global Blood Weighs on Bluebird
2015-09-24,Bluebird Bio Announces Participation In Leerink Partners Immuno-Oncology Roundtable
2015-09-21,Bluebird Bio (BLUE) Is Water-Logged And Getting Wetter Today
2015-09-11,Bluebird Bio Announces Participation At Morgan Stanley Global Healthcare Conference
2015-09-09,Perilous Reversal Watch: Bluebird Bio (BLUE)
2015-09-04,2 Issues Keeping Buyers on the Sidelines Today
2015-09-01,The Numbers Behind Biotech's Horrible, No Good, Awful August
2015-08-26,Biotech Selloff Has No Effect on Cellectis Advances: CEO
2015-08-26,Biotech Selloff Does Not Dim Immunotherapy Advances Says Cellectis CEO
2015-08-21,Biotech Stock Mailbag: Celldex, Bluebird, Kite, Inovio
2015-08-19,Biotech Stocks Get Burned This Summer, but Fall Might Bring Relief
2015-08-12,Bluebird, Pacira Pharmaceuticals Excite Life Science Investors
2015-08-12,Bluebird, Pacira Pharmaceuticals Gain Steam in Burgeoning Life Science Space
2015-08-10,BLUE, TEVA And AMGN, 3 Drugs Stocks Pushing The Industry Lower
2015-08-07,Water-Logged And Getting Wetter: Bluebird Bio (BLUE)
2015-08-06,Bluebird Bio Reports Second Quarter 2015 Financial Results And Recent Operational Progress
2015-08-05,Trade-Ideas: Bluebird Bio (BLUE) Is Today's Post-Market Leader Stock
2015-08-05,Bluebird Bio Announces Participation At The 2015 Wedbush PacGrow Healthcare Conference
2015-07-27,Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up
2015-07-02,Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point
2015-07-01,Today's Perilous Reversal Stock: Bluebird Bio (BLUE)
2015-06-30,Today's Top Performers In Health Care
2015-06-30,Celgene on My Shopping List for a Pullback
2015-06-29,Celgene is Desperate or Insane to Pay Ultra-High Premium for Juno Partnership
2015-06-29,Trade-Ideas: Bluebird Bio (BLUE) Is Today's Post-Market Leader Stock
2015-06-23,Bluebird Bio Announces Pricing Of Public Offering Of Common Stock
2015-06-23,Bluebird Bio Announces Proposed Public Offering Of Common Stock
2015-06-19,Biotech Stock Mailbag: Unstoppable Heron, Aerie Disclosure Fail, Gene Therapy, Hate Mail!
2015-06-19,'Mad Money' Lightning Round: Buy, Buy, Buy Citigroup
2015-06-18,Jim Cramer's 'Mad Money' Recap: Here's Why We Had a Rally Today
2015-06-16,Avalanche Fails Common-Sense Test, Kicked Out of Gene Therapy Credibility Club
2015-06-15,Philip Gregory, D. Phil., Joins Bluebird Bio As Chief Scientific Officer
2017-01-12,Short Interest Increases 10.3% For BMRN
2017-01-10,Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears
2017-01-09,Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference
2017-01-05,What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017
2017-01-03,Biotech Should Witness M&amp;A's Return in 2017
2016-12-15,Johnson & Johnson Looks for New Deal That's Just Right
2016-12-12,BioMarin Enrolls First Participant In Phase 3 Trial Of Vosoritide For Treatment Of Children With Achondroplasia
2016-11-29,BioMarin Surging Beneath the Surface
2016-11-13,Six Thoughts on President Trump and the Durability of the Biotech Stock Rally
2016-11-07,Analysts' Actions -- Biogen, GoPro, L Brands, Time Warner and More
2016-11-03,BioMarin To Attend Three Upcoming Investor Conferences
2016-10-27,BioMarin Announces Third Quarter 2016 Financial Results
2016-10-26,BioMarin Pharmaceutical Becomes #19 Most Shorted Nasdaq 100 Component, Replacing Dish Network
2016-10-19,BioMarin Presents Vosoritide Data In Achondroplasia At American Society Of Human Genetics (ASHG) 2016 Meeting
2016-10-17,PTC Therapeutics Getting Cold Shoulder From Regulators on Duchenne Drug Appeal
2016-10-13,UK Regulatory Agency Approves Continued Enrollment In BioMarin Phase 1/2 Study Of BMN 270 In Hemophilia A
2016-10-13,Pardon Me, but I Have a Few Things to Say... Seattle Genetics, Biomarin, Sarepta, TG Therapeutics
2016-10-11,BioMarin To Host Third Quarter 2016 Financial Results Conference Call And Webcast On Thursday, October 27 At 4:30pm ET
2016-09-22,New Setback for Sanofi's Lantus Increases Need for M&amp;A
2016-09-21,BioMarin Reviews Status Of Exon 51 Composition Of Matter And Method Of Use Patent Interference Cases Against Sarepta Therapeutics
2016-09-20,Biotech Stock Mailbag: Sarepta Therapeutics Approval Edition
2016-09-15,BioMarin Announces EMA Validation Of Brineura™ (Cerliponase Alfa) Marketing Authorization Application For Treatment Of CLN2 Disease, A Form Of Batten Disease
2016-09-14,These 5 Biotech Stocks Are Ready for a Volatility Break
2016-09-08,BioMarin Announces Two Oral And 16 Poster Presentations At Society For The Study Of Inborn Errors Of Metabolism 2016 Annual Meeting
2016-09-06,BioMarin Announces Update To Brineura™ (Cerliponase Alfa) Program For Treatment Of CLN2 Disease, A Form Of Batten Disease
2016-08-31,BioMarin To Attend Upcoming Investor Conferences
2016-08-24,Forbes Ranks BioMarin 10th Most Innovative Company In The World
2016-08-22,BioMarin (BMRN) Stock Surges on Takeover Speculation
2016-08-22,Facebook Stands Out and FormFactor Has a Good Start
2016-08-09,BioMarin Announces Pricing Of Public Offering Of Common Stock
2016-08-08,Cramer: Companies Are Issuing a Lot of Paper
2016-08-08,BioMarin (BMRN) Stock Tumbles in After-Hours Trading on Public Offering
2016-08-08,BioMarin Announces Public Offering Of Common Stock
2016-08-04,Trade-Ideas: Biomarin Pharmaceutical (BMRN) Is Today's Post-Market Leader Stock
2016-08-04,BioMarin Announces Second Quarter 2016 Financial Results
2016-08-01,Cramer: What Are You Thinking? It Should Be Long Term
2016-07-27,FDA Accepts BLA For BioMarin's Cerliponase Alfa For CLN2 Disease, Form Of Batten Disease
2016-07-27,Biomarin Hemophilia Gene Therapy Advances on Strong Study Results
2016-07-27,BioMarin Provides Positive Proof-of-Concept Data For BMN 270 Gene Therapy In Hemophilia A In Late Breaking Oral Presentation At The World Federation Of Hemophilia (WFH) 2016 World Congress
2016-07-21,BioMarin To Provide Updated Data For BMN 270 In Hemophilia A In Late Breaking Oral Presentation At The World Federation Of Hemophilia (WFH) 2016 World Congress July 27th
2016-07-21,Roche Beats First-Half Forecasts as Cancer Drug Sales Rise
2016-07-18,BioMarin Appoints Two BioPharmaceutical Veterans To Board Of Directors, Willard Dere, M.D. And Kathryn E. Falberg
2016-07-15,3 Stocks Driving The Drugs Industry Higher
2016-07-14,BioMarin To Host Second Quarter 2016 Financial Results Conference Call And Webcast On Thursday, August 4 At 4:30pm ET
2016-07-11,Cramer: 11 Reasons Why the Market Turned
2016-07-08,Biomarin Pharmaceutical (BMRN) Highlighted As Storm The Castle Stock
2016-07-07,Closing Bell: Humana Slumps on Deal Worries; U.S. Stocks Mixed
2016-07-07,BioMarin (BMRN) Stock Soars on Takeover Speculation
2016-07-07,Biomarin Pharmaceutical (BMRN) Trading With Heavy Volume Before Market Open
2016-07-07,Medivation Tries to Prove Its Worth
2016-07-06,Trade-Ideas: Biomarin Pharmaceutical (BMRN) Is Today's Post-Market Leader Stock
2016-07-01,Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here
2016-06-29,16 Biopharma Companies Besides Medivation That Are Attractive Targets
2016-06-24,RBC sees biopharma 'insulated' from Brexit, says buy Celgene for bounceback
2016-06-20,BioMarin Announces Acceptance Of Late Breaking Abstract For BMN 270 At The World Federation Of Hemophilia (WFH) 2016 World Congress July 27 In Orlando, FL
2016-06-17,BioMarin Pharmaceuticals Jumps on Takeover Talk
2016-06-17,BioMarin Takeout Rumors Swirl, Industry Insiders Aren't Convinced
2016-06-16,Why BioMarin (BMRN) Stock Is Lower Today
2016-06-15,3 Drugs Stocks Driving The Industry Higher
2016-06-15,Biomarin Pharmaceutical (BMRN) Is Today's Strong On High Volume Stock
2016-06-08,3 Stocks Dragging In The Health Care Sector
2016-05-31,BioMarin Announces Withdrawal Of Market Authorization Application For Kyndrisa™ (drisapersen) In Europe
2016-05-31,3 Health Care Stocks Pushing Sector Growth
2016-05-26,Insider Trading Alert - SUM, KLXI And BMRN Traded By Insiders
2016-05-25,The New #24 Most Shorted Nasdaq 100 Component: BioMarin Pharmaceutical
2016-05-25,A 'What's Next?' Scenario for the Delayed Sarepta Duchenne Drug Review
2016-05-16,AbSci Appoints Daniel Gold, Ph.D. To Board Of Directors
2016-05-05,3 Stocks Pulling The Drugs Industry Downward
2016-05-04,BioMarin To Attend Upcoming Investor Conferences
2016-05-03,Biogen's Hemophilia Franchise IPO Is Disappointing
2016-05-03,BioMarin Pharmaceutical Becomes #35 Most Shorted Nasdaq 100 Component, Replacing Monster Beverage
2016-05-03,BioMarin Announces EMA Grants Accelerated Assessment For Cerliponase Alfa, Experimental Treatment For A Form Of Batten Disease
2016-04-29,Sanofi First Quarter Shows Why It Wants but Doesn't Need Medivation
2016-04-28,Biomarin Pharmaceutical (BMRN) Lags In Post-Market Trading
2016-04-28,BioMarin Announces First Quarter 2016 Financial Results
2016-04-28,Sanofi Presses Medivation to Hold Talks After $9.3B Offer
2016-04-22,Biotech Stock Mailbag: Is There a Future for Sarepta Therapeutics?
2016-04-21,BioMarin Enrolls First Patient In Phase 1/2 Trial Of NAGLU Fusion Protein BMN 250 For Treatment Of MPS IIIB (Sanfilippo B Syndrome)
2016-04-21,Jim Cramer's Top Takeaways: Intel, BioMarin Pharmaceuticals
2016-04-20,Jim Cramer's 'Mad Money' Recap: This Market Is Rising No Matter What You Think
2016-04-20,BioMarin Provides Program Update On Vosoritide In Achondroplasia
2016-04-20,BioMarin Provides Encouraging Preliminary Data On First 8 Patients In Hemophilia A Gene Therapy Program
2016-04-18,BioMarin To Highlight Breadth Of Innovative Development Pipeline At R&D Day On April 20th In New York
2016-04-12,BioMarin To Host First Quarter 2016 Financial Results Conference Call And Webcast On Thursday, April 28 At 4:30pm ET
2016-04-12,Anavex Plays the Orphan Drug Stock Promotion Game
2016-04-07,BioMarin (BMRN) Stock is the 'Chart of the Day'
2016-04-07,BioMarin Has Juice Left in the Tank
2016-04-07,Chart of the Day: BioMarin Pharmaceutical
2016-04-01,Sell These 5 Toxic Stocks Now, Before It's Too Late
2016-03-31,Biomarin Pharmaceutical (BMRN) Strong On High Relative Volume Today
2016-03-29,3 Stocks Pushing The Drugs Industry Downward
2016-03-28,A Rolling-Nowhere Market Gathers More Bears
2016-03-24,BioMarin Receives European Orphan Drug Designation For BMN 270, First Investigational AAV-Factor VIII Gene Therapy For Patients With Hemophilia A
2016-03-22,Biomarin Pharmaceutical (BMRN) Strong On High Relative Volume Today
2016-03-21,BioMarin PKU Drug Shows Mixed Results in Pivotal Study
2016-03-21,BioMarin Phase 3 Study Of Pegvaliase For Phenylketonuria (PKU) Meets Primary Endpoint Of Blood Phenylalanine (Phe) Reduction (p
2016-03-17,Insider Trading Alert - BRT, BMRN And CSGS Traded By Insiders
2016-03-12,Biotech Stock Mailbag: Biomarin PKU Preview, Celldex Post-Mortem
2016-03-09,BMRN, INCY And ALXN, Pushing Drugs Industry Downward
2016-03-08,Jim Cramer Says BioMarin Is the Last Bear Market
2016-03-08,Jim Cramer: Bear Markets in Many Sectors Have Ended
2016-03-06,JPMorgan's 7 Best Stock Picks With Near-Term Catalysts
2016-03-03,Biomarin Drug Provides 'Substantial Benefit' to Kids with Rare, Fatal Brain Disease
2016-03-03,BioMarin To Attend Three Upcoming Investor Conferences In March
2016-03-02,BioMarin Announces Positive Data From Cerliponase Alfa Program For Treatment Of CLN2 Disease, A Form Of Batten Disease, At 12th Annual WORLDSymposium(TM) 2016
2016-03-01,BioMarin Receives Orphan Drug Designation From FDA For First AAV-Factor VIII Gene Therapy, BMN 270, For Patients With Hemophilia A
2016-02-29,BioMarin Faces a Key Test of Rare Disease Pipeline
2016-02-29,BioMarin Announces BioMarin RareConnections(TM) Rebranding And Consolidating BioMarin's Comprehensive Support And Services For Eligible Rare Disease Patients
2016-02-29,BioMarin Announces 21 Presentations At 12th Annual WORLDSymposium™ 2016 February 29-March 4 In San Diego, California: 6 Oral And 15 Poster
2016-02-25,Biomarin Pharmaceutical (BMRN) Down In After-Hours Trading
2016-02-25,BioMarin Announces Fourth Quarter And Full Year 2015 Financial Results
2016-02-17,Rally Generates Mixed Emotions So Far
2016-02-08,Trade-Ideas: Biomarin Pharmaceutical (BMRN) Is Today's Post-Market Leader Stock
2016-01-28,Today's Weak On High Volume Stock: Biomarin Pharmaceutical (BMRN)
2016-01-28,BioMarin To Host Fourth Quarter And Full Year 2015 Financial Results Conference Call And Webcast On Thursday, February 25 At 4:30pm ET
2016-01-24,Biotech Stock Mailbag: Snow Stops Sarepta's FDA Show, so What's Next?
2016-01-15,Sarepta Plunges on Harsh FDA Eteplirsen Review Ahead of Next Week's Advisory Panel Meeting
2016-01-14,Today's Dead Cat Bounce Stock Is Biomarin Pharmaceutical (BMRN)
2016-01-14,FDA Issues Complete Response Letter For KyndrisaTM For Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping
2016-01-12,Water-Logged and Getting Wetter Stock of the Day: Biomarin Pharmaceutical (BMRN)
2016-01-11,BioMarin Announces Interim Analysis Of INSPIRE Clinical Trial In Pompe Disease At 34th Annual J.P. Morgan Annual Healthcare Conference
2016-01-09,2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks
2016-01-05,BioMarin To Present At 34th Annual J.P. Morgan Healthcare Conference In San Francisco
2016-01-04,BioMarin Announces Addition Of David Pyott, Former Allergan Chairman And CEO, To Company's Board Of Directors
2015-12-26,Sell These 6 Biotech Stocks Now Before It's Too Late
2015-12-19,The Naughty List: Finalists for Worst Biopharma CEO of 2015
2015-12-18,3 Drugs Stocks Pushing Industry Growth
2015-12-18,BioMarin Announces That FDA Has Advised It Will Not Take Action On The Kyndrisa™ (drisapersen) New Drug Application By The PDUFA Date
2015-12-17,3 Convertible Bonds That Belong in Your Portfolio
2015-12-17,Teva, Biomarin Offer Convertible Opportunities Says MainStay Manager
2015-12-02,Biotech Stock Mailbag: Anavex, Northwest Bio, Threshold Therapeutics
2015-11-25,Biomarin Pharmaceutical (BMRN) Down In Early Morning Trading
2015-11-25,BioMarin's Duchenne Drug Is Done, Sarepta Survives but Faces Challenge
2015-11-24,FDA Advisory Committee Discusses Clinical Data Package For BioMarin's Kyndrisa(TM) (drisapersen) For The Treatment Of Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping
2015-11-24,BioMarin Posts Presentation From FDA Advisory Committee Meeting For Kyndrisa(TM) (drisapersen) For The Treatment Of Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping
2015-11-24,BioMarin FDA Panel Live Blog
2015-11-24,BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Announced Today The Stock Is Halted
2015-11-23,NICE Recommends BioMarin's Vimizim® (elosulfase Alfa) For The Treatment Of Morquio A Syndrome In England
2015-11-20,3 Stocks to Buy on Big Volume
2015-11-20,Jim Cramer -- Market Powers Higher Despite the Woes of BioMarin, Mentor Graphics
2015-11-20,BioMarin Duchenne Drug Receives Harsh Review From FDA
2015-11-20,BioMarin Announces Data Analysis Demonstrating Consistent Efficacy Of Kyndrisa™ (drisapersen) In Comparable Patients Across Three Randomized Studies
2015-11-20,FDA Posts Briefing Documents For Advisory Committee Meeting To Review Kyndrisa™ (drisapersen) For The Potential Treatment Of Duchenne Muscular Dystrophy Amendable To Exon 51 Skipping
2015-11-20,Before the Move: Watch BioMarin Into FDA Advisory Committee
2015-11-19,These Biotech Stocks Could Move on BioMarin's Duchenne Drug FDA Panel
2015-11-18,Goldman Sees Bluebird Shares Doubling On 'One-Shot' Gene Therapy
2015-11-18,How to Prepare for BioMarin's (and Biotech's) Biggest Event of 2015
2015-11-16,Ernst & Young Names BioMarin CEO Jean-Jacques Bienaime EY Entrepreneur Of The Year® 2015 National Award Winner In Life Sciences
2015-11-04,Retrophin Sinks, Pharma Group Swings Back As Pricing Fight Escalates
2015-11-02,FDA Letter Raises Questions About Biomarin Handling of Muscular Dystrophy Drug
2015-10-29,BioMarin Announces Third Quarter 2015 Financial Results And Company Update
2015-10-27,BioMarin To Attend Upcoming Investor Conference In November
2015-10-23,Ratings Changes Today
2015-10-16,Investing Moves for a No-Growth World; ETF Distortion: Jim Cramer's Best Blogs
2015-10-16,Biotech Stock Mailbag: New Sarepta Risk, Zafgen Patient Death, Bluebird Gene Therapy Update
2015-10-15,Jim Cramer's 'Mad Money' Recap: Buy Growth Where You Can
2015-10-15,BioMarin To Host Third Quarter 2015 Financial Results Conference Call And Webcast On Thursday, October 29 At 4:30pm ET
2015-10-15,BioMarin Announces FDA Advisory Committee To Review Drisapersen For Treatment Of Patients With Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping
2015-10-14,BioMarin Secures FDA Panel Date for Duchenne Drug but Where is Sarepta? (Update)
2015-10-13,Jim Cramer's Top Takeaways: Helen of Troy, BioMarin, Energy Transfer Partners
2015-10-12,BioMarin's Initial 6-Month Data From Phase 2 Study Of Vosoritide (BMN 111) In Children With Achondroplasia Presented At The American Society For Bone And Mineral Research Annual 2015 Meeting
2015-10-05,Spark Therapeutics Trial Success Seen As Positive For Gene Therapy Sector
2015-10-01,BioMarin Buys Kuvan Drug Rights From Merck
2015-10-01,Sarepta Unveils New Data to Make Stronger Case for Duchenne Drug Approval
2015-10-01,BioMarin To Acquire Rights To Phenylketonuria (PKU) Franchise From Merck Serono
2015-09-30,BioMarin To Present Research Results On Duchenne Muscular Dystrophy And Pompe Disease Programs At The 20th International Congress Of The World Muscle Society
2015-09-30,BioMarin Pharmaceutical (BMRN) Stock Climbs on Patent Win
2015-09-30,Cramer -- BioMarin's Patent Win Could Spark a Biotech Bounce
2015-09-29,BioMarin Receives Favorable Ruling In The Use Of Exon 51 Antisense Oligonucleotides Patent Interference
2015-09-28,BioMarin Enrolls First Patient In Phase 1/2 Trial Of Gene Therapy Drug Candidate BMN 270 For The Treatment Of Hemophilia A
2015-09-25,RSI Alert: BioMarin Pharmaceutical Now Oversold
2015-09-25,Biotech Stock Mailbag: Rebounding From Hillary's Drug Tweet; Global Blood Weighs on Bluebird
2015-09-22,Biomarin Pharmaceutical (BMRN) Is Today's Roof Leaker Stock
2015-09-22,Analysts Say Buy Select Biotech Stocks Ahead Of Clinton Drug Plan
2015-09-18,BioMarin Announces Kuvan(R) (sapropterin Dihydrochloride) Patent Challenge Settlement
2015-09-10,Is FDA Having Trouble Setting Date for Biomarin, Sarepta Advisory Panels?
2015-09-03,Biotech Stock Mailbag: Sarepta, Biomarin, Spark, Raptor
2015-09-02,BioMarin To Attend Upcoming Investor Conferences In September
2015-09-01,BioMarin Launches KNOWyourDuchenne, Comprehensive Program For Patients With Duchenne Muscular Dystrophy To Understand Their Genetic Mutation
2015-08-31,BioMarin Announces Two Oral And 19 Poster Presentations At The Society For The Study Of Inborn Errors Of Metabolism 2015 Annual Meeting
2017-01-12,Short Interest Increases 10.3% For BMRN
2017-01-10,Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears
2017-01-09,Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference
2017-01-05,What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017
2017-01-03,Biotech Should Witness M&amp;A's Return in 2017
2016-12-15,Johnson & Johnson Looks for New Deal That's Just Right
2016-12-12,BioMarin Enrolls First Participant In Phase 3 Trial Of Vosoritide For Treatment Of Children With Achondroplasia
2016-11-29,BioMarin Surging Beneath the Surface
2016-11-13,Six Thoughts on President Trump and the Durability of the Biotech Stock Rally
2016-11-07,Analysts' Actions -- Biogen, GoPro, L Brands, Time Warner and More
2016-11-03,BioMarin To Attend Three Upcoming Investor Conferences
2016-10-27,BioMarin Announces Third Quarter 2016 Financial Results
2016-10-26,BioMarin Pharmaceutical Becomes #19 Most Shorted Nasdaq 100 Component, Replacing Dish Network
2016-10-19,BioMarin Presents Vosoritide Data In Achondroplasia At American Society Of Human Genetics (ASHG) 2016 Meeting
2016-10-17,PTC Therapeutics Getting Cold Shoulder From Regulators on Duchenne Drug Appeal
2016-10-13,UK Regulatory Agency Approves Continued Enrollment In BioMarin Phase 1/2 Study Of BMN 270 In Hemophilia A
2016-10-13,Pardon Me, but I Have a Few Things to Say... Seattle Genetics, Biomarin, Sarepta, TG Therapeutics
2016-10-11,BioMarin To Host Third Quarter 2016 Financial Results Conference Call And Webcast On Thursday, October 27 At 4:30pm ET
2016-09-22,New Setback for Sanofi's Lantus Increases Need for M&amp;A
2016-09-21,BioMarin Reviews Status Of Exon 51 Composition Of Matter And Method Of Use Patent Interference Cases Against Sarepta Therapeutics
2016-09-20,Biotech Stock Mailbag: Sarepta Therapeutics Approval Edition
2016-09-15,BioMarin Announces EMA Validation Of Brineura™ (Cerliponase Alfa) Marketing Authorization Application For Treatment Of CLN2 Disease, A Form Of Batten Disease
2016-09-14,These 5 Biotech Stocks Are Ready for a Volatility Break
2016-09-08,BioMarin Announces Two Oral And 16 Poster Presentations At Society For The Study Of Inborn Errors Of Metabolism 2016 Annual Meeting
2016-09-06,BioMarin Announces Update To Brineura™ (Cerliponase Alfa) Program For Treatment Of CLN2 Disease, A Form Of Batten Disease
2016-08-31,BioMarin To Attend Upcoming Investor Conferences
2016-08-24,Forbes Ranks BioMarin 10th Most Innovative Company In The World
2016-08-22,BioMarin (BMRN) Stock Surges on Takeover Speculation
2016-08-22,Facebook Stands Out and FormFactor Has a Good Start
2016-08-09,BioMarin Announces Pricing Of Public Offering Of Common Stock
2016-08-08,Cramer: Companies Are Issuing a Lot of Paper
2016-08-08,BioMarin (BMRN) Stock Tumbles in After-Hours Trading on Public Offering
2016-08-08,BioMarin Announces Public Offering Of Common Stock
2016-08-04,Trade-Ideas: Biomarin Pharmaceutical (BMRN) Is Today's Post-Market Leader Stock
2016-08-04,BioMarin Announces Second Quarter 2016 Financial Results
2016-08-01,Cramer: What Are You Thinking? It Should Be Long Term
2016-07-27,FDA Accepts BLA For BioMarin's Cerliponase Alfa For CLN2 Disease, Form Of Batten Disease
2016-07-27,Biomarin Hemophilia Gene Therapy Advances on Strong Study Results
2016-07-27,BioMarin Provides Positive Proof-of-Concept Data For BMN 270 Gene Therapy In Hemophilia A In Late Breaking Oral Presentation At The World Federation Of Hemophilia (WFH) 2016 World Congress
2016-07-21,BioMarin To Provide Updated Data For BMN 270 In Hemophilia A In Late Breaking Oral Presentation At The World Federation Of Hemophilia (WFH) 2016 World Congress July 27th
2016-07-21,Roche Beats First-Half Forecasts as Cancer Drug Sales Rise
2016-07-18,BioMarin Appoints Two BioPharmaceutical Veterans To Board Of Directors, Willard Dere, M.D. And Kathryn E. Falberg
2016-07-15,3 Stocks Driving The Drugs Industry Higher
2016-07-14,BioMarin To Host Second Quarter 2016 Financial Results Conference Call And Webcast On Thursday, August 4 At 4:30pm ET
2016-07-11,Cramer: 11 Reasons Why the Market Turned
2016-07-08,Biomarin Pharmaceutical (BMRN) Highlighted As Storm The Castle Stock
2016-07-07,Closing Bell: Humana Slumps on Deal Worries; U.S. Stocks Mixed
2016-07-07,BioMarin (BMRN) Stock Soars on Takeover Speculation
2016-07-07,Biomarin Pharmaceutical (BMRN) Trading With Heavy Volume Before Market Open
2016-07-07,Medivation Tries to Prove Its Worth
2016-07-06,Trade-Ideas: Biomarin Pharmaceutical (BMRN) Is Today's Post-Market Leader Stock
2016-07-01,Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here
2016-06-29,16 Biopharma Companies Besides Medivation That Are Attractive Targets
2016-06-24,RBC sees biopharma 'insulated' from Brexit, says buy Celgene for bounceback
2016-06-20,BioMarin Announces Acceptance Of Late Breaking Abstract For BMN 270 At The World Federation Of Hemophilia (WFH) 2016 World Congress July 27 In Orlando, FL
2016-06-17,BioMarin Pharmaceuticals Jumps on Takeover Talk
2016-06-17,BioMarin Takeout Rumors Swirl, Industry Insiders Aren't Convinced
2016-06-16,Why BioMarin (BMRN) Stock Is Lower Today
2016-06-15,3 Drugs Stocks Driving The Industry Higher
2016-06-15,Biomarin Pharmaceutical (BMRN) Is Today's Strong On High Volume Stock
2016-06-08,3 Stocks Dragging In The Health Care Sector
2016-05-31,BioMarin Announces Withdrawal Of Market Authorization Application For Kyndrisa™ (drisapersen) In Europe
2016-05-31,3 Health Care Stocks Pushing Sector Growth
2016-05-26,Insider Trading Alert - SUM, KLXI And BMRN Traded By Insiders
2016-05-25,The New #24 Most Shorted Nasdaq 100 Component: BioMarin Pharmaceutical
2016-05-25,A 'What's Next?' Scenario for the Delayed Sarepta Duchenne Drug Review
2016-05-16,AbSci Appoints Daniel Gold, Ph.D. To Board Of Directors
2016-05-05,3 Stocks Pulling The Drugs Industry Downward
2016-05-04,BioMarin To Attend Upcoming Investor Conferences
2016-05-03,Biogen's Hemophilia Franchise IPO Is Disappointing
2016-05-03,BioMarin Pharmaceutical Becomes #35 Most Shorted Nasdaq 100 Component, Replacing Monster Beverage
2016-05-03,BioMarin Announces EMA Grants Accelerated Assessment For Cerliponase Alfa, Experimental Treatment For A Form Of Batten Disease
2016-04-29,Sanofi First Quarter Shows Why It Wants but Doesn't Need Medivation
2016-04-28,Biomarin Pharmaceutical (BMRN) Lags In Post-Market Trading
2016-04-28,BioMarin Announces First Quarter 2016 Financial Results
2016-04-28,Sanofi Presses Medivation to Hold Talks After $9.3B Offer
2016-04-22,Biotech Stock Mailbag: Is There a Future for Sarepta Therapeutics?
2016-04-21,BioMarin Enrolls First Patient In Phase 1/2 Trial Of NAGLU Fusion Protein BMN 250 For Treatment Of MPS IIIB (Sanfilippo B Syndrome)
2016-04-21,Jim Cramer's Top Takeaways: Intel, BioMarin Pharmaceuticals
2016-04-20,Jim Cramer's 'Mad Money' Recap: This Market Is Rising No Matter What You Think
2016-04-20,BioMarin Provides Program Update On Vosoritide In Achondroplasia
2016-04-20,BioMarin Provides Encouraging Preliminary Data On First 8 Patients In Hemophilia A Gene Therapy Program
2016-04-18,BioMarin To Highlight Breadth Of Innovative Development Pipeline At R&D Day On April 20th In New York
2016-04-12,BioMarin To Host First Quarter 2016 Financial Results Conference Call And Webcast On Thursday, April 28 At 4:30pm ET
2016-04-12,Anavex Plays the Orphan Drug Stock Promotion Game
2016-04-07,BioMarin (BMRN) Stock is the 'Chart of the Day'
2016-04-07,BioMarin Has Juice Left in the Tank
2016-04-07,Chart of the Day: BioMarin Pharmaceutical
2016-04-01,Sell These 5 Toxic Stocks Now, Before It's Too Late
2016-03-31,Biomarin Pharmaceutical (BMRN) Strong On High Relative Volume Today
2016-03-29,3 Stocks Pushing The Drugs Industry Downward
2016-03-28,A Rolling-Nowhere Market Gathers More Bears
2016-03-24,BioMarin Receives European Orphan Drug Designation For BMN 270, First Investigational AAV-Factor VIII Gene Therapy For Patients With Hemophilia A
2016-03-22,Biomarin Pharmaceutical (BMRN) Strong On High Relative Volume Today
2016-03-21,BioMarin PKU Drug Shows Mixed Results in Pivotal Study
2016-03-21,BioMarin Phase 3 Study Of Pegvaliase For Phenylketonuria (PKU) Meets Primary Endpoint Of Blood Phenylalanine (Phe) Reduction (p
2016-03-17,Insider Trading Alert - BRT, BMRN And CSGS Traded By Insiders
2016-03-12,Biotech Stock Mailbag: Biomarin PKU Preview, Celldex Post-Mortem
2016-03-09,BMRN, INCY And ALXN, Pushing Drugs Industry Downward
2016-03-08,Jim Cramer Says BioMarin Is the Last Bear Market
2016-03-08,Jim Cramer: Bear Markets in Many Sectors Have Ended
2016-03-06,JPMorgan's 7 Best Stock Picks With Near-Term Catalysts
2016-03-03,Biomarin Drug Provides 'Substantial Benefit' to Kids with Rare, Fatal Brain Disease
2016-03-03,BioMarin To Attend Three Upcoming Investor Conferences In March
2016-03-02,BioMarin Announces Positive Data From Cerliponase Alfa Program For Treatment Of CLN2 Disease, A Form Of Batten Disease, At 12th Annual WORLDSymposium(TM) 2016
2016-03-01,BioMarin Receives Orphan Drug Designation From FDA For First AAV-Factor VIII Gene Therapy, BMN 270, For Patients With Hemophilia A
2016-02-29,BioMarin Faces a Key Test of Rare Disease Pipeline
2016-02-29,BioMarin Announces BioMarin RareConnections(TM) Rebranding And Consolidating BioMarin's Comprehensive Support And Services For Eligible Rare Disease Patients
2016-02-29,BioMarin Announces 21 Presentations At 12th Annual WORLDSymposium™ 2016 February 29-March 4 In San Diego, California: 6 Oral And 15 Poster
2016-02-25,Biomarin Pharmaceutical (BMRN) Down In After-Hours Trading
2016-02-25,BioMarin Announces Fourth Quarter And Full Year 2015 Financial Results
2016-02-17,Rally Generates Mixed Emotions So Far
2016-02-08,Trade-Ideas: Biomarin Pharmaceutical (BMRN) Is Today's Post-Market Leader Stock
2016-01-28,Today's Weak On High Volume Stock: Biomarin Pharmaceutical (BMRN)
2016-01-28,BioMarin To Host Fourth Quarter And Full Year 2015 Financial Results Conference Call And Webcast On Thursday, February 25 At 4:30pm ET
2016-01-24,Biotech Stock Mailbag: Snow Stops Sarepta's FDA Show, so What's Next?
2016-01-15,Sarepta Plunges on Harsh FDA Eteplirsen Review Ahead of Next Week's Advisory Panel Meeting
2016-01-14,Today's Dead Cat Bounce Stock Is Biomarin Pharmaceutical (BMRN)
2016-01-14,FDA Issues Complete Response Letter For KyndrisaTM For Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping
2016-01-12,Water-Logged and Getting Wetter Stock of the Day: Biomarin Pharmaceutical (BMRN)
2016-01-11,BioMarin Announces Interim Analysis Of INSPIRE Clinical Trial In Pompe Disease At 34th Annual J.P. Morgan Annual Healthcare Conference
2016-01-09,2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks
2016-01-05,BioMarin To Present At 34th Annual J.P. Morgan Healthcare Conference In San Francisco
2016-01-04,BioMarin Announces Addition Of David Pyott, Former Allergan Chairman And CEO, To Company's Board Of Directors
2015-12-26,Sell These 6 Biotech Stocks Now Before It's Too Late
2015-12-19,The Naughty List: Finalists for Worst Biopharma CEO of 2015
2015-12-18,3 Drugs Stocks Pushing Industry Growth
2015-12-18,BioMarin Announces That FDA Has Advised It Will Not Take Action On The Kyndrisa™ (drisapersen) New Drug Application By The PDUFA Date
2015-12-17,3 Convertible Bonds That Belong in Your Portfolio
2015-12-17,Teva, Biomarin Offer Convertible Opportunities Says MainStay Manager
2015-12-02,Biotech Stock Mailbag: Anavex, Northwest Bio, Threshold Therapeutics
2015-11-25,Biomarin Pharmaceutical (BMRN) Down In Early Morning Trading
2015-11-25,BioMarin's Duchenne Drug Is Done, Sarepta Survives but Faces Challenge
2015-11-24,FDA Advisory Committee Discusses Clinical Data Package For BioMarin's Kyndrisa(TM) (drisapersen) For The Treatment Of Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping
2015-11-24,BioMarin Posts Presentation From FDA Advisory Committee Meeting For Kyndrisa(TM) (drisapersen) For The Treatment Of Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping
2015-11-24,BioMarin FDA Panel Live Blog
2015-11-24,BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Announced Today The Stock Is Halted
2015-11-23,NICE Recommends BioMarin's Vimizim® (elosulfase Alfa) For The Treatment Of Morquio A Syndrome In England
2015-11-20,3 Stocks to Buy on Big Volume
2015-11-20,Jim Cramer -- Market Powers Higher Despite the Woes of BioMarin, Mentor Graphics
2015-11-20,BioMarin Duchenne Drug Receives Harsh Review From FDA
2015-11-20,BioMarin Announces Data Analysis Demonstrating Consistent Efficacy Of Kyndrisa™ (drisapersen) In Comparable Patients Across Three Randomized Studies
2015-11-20,FDA Posts Briefing Documents For Advisory Committee Meeting To Review Kyndrisa™ (drisapersen) For The Potential Treatment Of Duchenne Muscular Dystrophy Amendable To Exon 51 Skipping
2015-11-20,Before the Move: Watch BioMarin Into FDA Advisory Committee
2015-11-19,These Biotech Stocks Could Move on BioMarin's Duchenne Drug FDA Panel
2015-11-18,Goldman Sees Bluebird Shares Doubling On 'One-Shot' Gene Therapy
2015-11-18,How to Prepare for BioMarin's (and Biotech's) Biggest Event of 2015
2015-11-16,Ernst & Young Names BioMarin CEO Jean-Jacques Bienaime EY Entrepreneur Of The Year® 2015 National Award Winner In Life Sciences
2015-11-04,Retrophin Sinks, Pharma Group Swings Back As Pricing Fight Escalates
2015-11-02,FDA Letter Raises Questions About Biomarin Handling of Muscular Dystrophy Drug
2015-10-29,BioMarin Announces Third Quarter 2015 Financial Results And Company Update
2015-10-27,BioMarin To Attend Upcoming Investor Conference In November
2015-10-23,Ratings Changes Today
2015-10-16,Investing Moves for a No-Growth World; ETF Distortion: Jim Cramer's Best Blogs
2015-10-16,Biotech Stock Mailbag: New Sarepta Risk, Zafgen Patient Death, Bluebird Gene Therapy Update
2015-10-15,Jim Cramer's 'Mad Money' Recap: Buy Growth Where You Can
2015-10-15,BioMarin To Host Third Quarter 2015 Financial Results Conference Call And Webcast On Thursday, October 29 At 4:30pm ET
2015-10-15,BioMarin Announces FDA Advisory Committee To Review Drisapersen For Treatment Of Patients With Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping
2015-10-14,BioMarin Secures FDA Panel Date for Duchenne Drug but Where is Sarepta? (Update)
2015-10-13,Jim Cramer's Top Takeaways: Helen of Troy, BioMarin, Energy Transfer Partners
2015-10-12,BioMarin's Initial 6-Month Data From Phase 2 Study Of Vosoritide (BMN 111) In Children With Achondroplasia Presented At The American Society For Bone And Mineral Research Annual 2015 Meeting
2015-10-05,Spark Therapeutics Trial Success Seen As Positive For Gene Therapy Sector
2015-10-01,BioMarin Buys Kuvan Drug Rights From Merck
2015-10-01,Sarepta Unveils New Data to Make Stronger Case for Duchenne Drug Approval
2015-10-01,BioMarin To Acquire Rights To Phenylketonuria (PKU) Franchise From Merck Serono
2015-09-30,BioMarin To Present Research Results On Duchenne Muscular Dystrophy And Pompe Disease Programs At The 20th International Congress Of The World Muscle Society
2015-09-30,BioMarin Pharmaceutical (BMRN) Stock Climbs on Patent Win
2015-09-30,Cramer -- BioMarin's Patent Win Could Spark a Biotech Bounce
2015-09-29,BioMarin Receives Favorable Ruling In The Use Of Exon 51 Antisense Oligonucleotides Patent Interference
2015-09-28,BioMarin Enrolls First Patient In Phase 1/2 Trial Of Gene Therapy Drug Candidate BMN 270 For The Treatment Of Hemophilia A
2015-09-25,RSI Alert: BioMarin Pharmaceutical Now Oversold
2015-09-25,Biotech Stock Mailbag: Rebounding From Hillary's Drug Tweet; Global Blood Weighs on Bluebird
2015-09-22,Biomarin Pharmaceutical (BMRN) Is Today's Roof Leaker Stock
2015-09-22,Analysts Say Buy Select Biotech Stocks Ahead Of Clinton Drug Plan
2015-09-18,BioMarin Announces Kuvan(R) (sapropterin Dihydrochloride) Patent Challenge Settlement
2015-09-10,Is FDA Having Trouble Setting Date for Biomarin, Sarepta Advisory Panels?
2015-09-03,Biotech Stock Mailbag: Sarepta, Biomarin, Spark, Raptor
2015-09-02,BioMarin To Attend Upcoming Investor Conferences In September
2015-09-01,BioMarin Launches KNOWyourDuchenne, Comprehensive Program For Patients With Duchenne Muscular Dystrophy To Understand Their Genetic Mutation
2015-08-31,BioMarin Announces Two Oral And 19 Poster Presentations At The Society For The Study Of Inborn Errors Of Metabolism 2015 Annual Meeting
2017-03-20,BioTime To Present At Oppenheimer 27th Annual Healthcare Conference
2017-03-16,BioTime, Inc. Reports Fourth Quarter And Fiscal Year 2016 Financial Results And Recent Corporate Accomplishments
2017-03-15,Data From BioTime's OpRegen® Trial In Dry-AMD To Be Presented At ARVO On May 8
2017-03-13,BioTime Expands OpRegen® Clinical Trial In Dry-AMD With Opening Of First US Sites
2017-02-23,BioTime, Inc. To Announce Fourth Quarter And Fiscal 2016 Results On March 16, 2017
2017-02-21,BioTime Reports Pro Forma Gain On Deconsolidation Of OncoCyte Subsidiary
2017-02-15,BioTime, Inc. Announces Closing Of Public Offering Of Common Stock
2017-02-13,BioTime To Present At Two Upcoming Investor Conferences
2017-02-10,BioTime, Inc. Announces Pricing Of Public Offering Of Common Stock
2017-02-09,BioTime, Inc. Announces Proposed Public Offering Of Common Stock
2017-02-09,Acorda, Amgen and Regeneron Lead Premarket Biotech Movers
2017-02-07,BioTime Appoints Industry Veteran, Stephana Patton, Ph.D., J.D., As General Counsel
2017-02-06,BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement For Next-Generation Retinal Disease Therapy From University Of Pittsburgh Medical Center
2017-01-26,BioTime To Present At Noble Capital Markets' Thirteenth Annual Investor Conference
2017-01-19,Additional Data From BioTime's OpRegen® Clinical Trial In Dry-AMD To Be Presented At ARVO 2017
2017-01-03,BioTime And Subsidiary Cell Cure Neurosciences Establish Innovative Cell Therapy Manufacturing Center In Jerusalem, Israel
2016-12-28,Ascendance Biotechnology Licenses The Right To Manufacture, Market And Sell Cytiva Cardiomyocytes
2016-12-14,BioTime Achieves Patient Recruitment Milestone In Renevia Pivotal Trial
2016-12-12,BioTime To Present At Global Bioproduction Summit
2016-12-08,BioTime Co-CEO Dr. Michael D. West To Deliver Plenary Presentation On The Field Of Induced Tissue Regeneration At World Stem Cell Summit
2016-11-18,Positive Early Data From BioTime's Renevia Pivotal Trial Presented At IFATS Meeting
2016-11-10,BioTime Co-CEO Dr. Michael D. West To Chair Cell Therapy Track At World Precision Medicine Congress USA 2016
2016-11-07,Ratings Changes Today
2016-11-03,BioTime, Inc. Reports Third Quarter Results And Recent Clinical Progress
2016-11-01,Data From BioTime's Renevia Pivotal Trial In HIV-Associated Facial Liopatrophy To Be Presented At The 14th Annual IFATS Meeting On November 17
2016-10-31,BioTime Appoints Industry Veteran Jim Knight As Senior Vice President, Head Of Corporate Development
2016-10-24,BioTime, Inc. To Announce Third Quarter Results On November 3, 2016
2016-10-20,First Patient Cohort Data From BioTime's OpRegen® Clinical Trial In Dry-AMD To Be Presented At ISOPT Clinical Symposium On December 2, 2016
2016-10-18,LifeMap Solutions Joins Medidata AppConnect Partner Program To Drive MHealth Innovation
2016-10-13,BioTime To Present At The BIO Investor Forum
2016-09-23,BioTime To Webcast Presentation At The Ladenburg Thalmann 2016 Healthcare Conference
2016-09-15,BioTime Affiliate, Asterias Biotherapeutics, Announced Positive Interim Efficacy Data From Trial In Patients With Complete Cervical Spinal Cord Injuries
2016-09-06,BioTime To Present At Two Upcoming Investor Conferences
2016-08-15,BioTime Announces Issuance Of 31 New Patents To Strengthen Its Patent Portfolio In Regenerative Medicine
2016-08-09,BioTime, Inc. Reports Second Quarter Results And Recent Corporate Accomplishments
2016-07-27,BioTime, Inc. To Report Second Quarter Results On August 9, 2016
2016-07-05,BioTime, Inc. Announces Full Exercise And Closing Of Underwriters' Over-Allotment Option
2016-06-29,BioTime Presents Online Resource For Applying Artificial Intelligence To Stem Cell Biology At Mensa 2016 Annual Gathering
2016-06-21,BioTime, Inc. Announces Closing Of Public Offering Of Common Stock
2016-06-16,BioTime, Inc. Announces Pricing Of Public Offering Of Common Stock
2016-06-15,BioTime, Inc. Announces Proposed Public Offering Of Common Stock
2016-06-13,BioTime's Subsidiary Cell Cure Neurosciences Receives DSMB Approval To Start Second Patient Cohort In Clinical Trial For Dry-AMD
2016-06-10,BioTime Announces $2.2 Million Grant For Further Development Of Dry-AMD Program
2016-06-09,BioTime To Present At The Jefferies 2016 Global Healthcare Conference
2016-05-20,BioTime To Present At Two Upcoming Investor Conferences
2016-05-10,BioTime, Inc. Reports First Quarter Results And Recent Corporate Accomplishments
2016-04-26,BioTime Co-CEO Dr. Michael West Presents At Biomedical Innovation For Healthy Longevity, International Conference
2016-04-25,LifeMap Solutions Launches Full-Service Mobile Health App Design & Development To Meet The Needs Of Medical, Research, And Commercial Partners
2016-04-05,BioTime Co-CEO Dr. Michael West To Present At Stem Cells In Drug Discovery 2016 In Cambridge, UK
2016-03-29,5 Hated Stocks Poised to Turn Around on Earnings
2016-03-21,BioTime, Inc. To Host Conference Call To Update Investors On Recent Accomplishments And Corporate Objectives For 2016
2016-02-29,Asterias Biotherapeutics Appoints Stephen L. Cartt President And Chief Executive Officer
2016-02-24,BioTime Subsidiary Asterias Biotherapeutics Reports The Successful End-of-Phase II FDA Meeting For Immunotherapy In Acute Myeloid Leukemia
2016-02-16,BioTime And Asterias Sign Share Transfer Agreement And Cross-License Agreement For Pluripotent Stem Cell Related Patents
2016-02-01,BioTime, Inc. To Present At Three Investor Conferences In February
2016-01-12,Adjustments Affecting BioTime, Inc. Common Share Purchase Warrants Expiring October 1, 2018
2015-12-31,BioTime Completes Distribution Of Approximately 4.75 Million Shares Of OncoCyte Corporation Common Stock
2015-12-30,BioTime Announces "When-Issued" Trading Of Subsidiary OncoCyte Corporation In Connection With Planned Distribution
2015-12-23,OncoCyte Appoints Dr. Andrew J. Last To Its Board Of Directors
2015-12-11,BioTime Co-Chief Executive Officer Michael D. West, PhD To Deliver Keynote Speech At The 2015 World Stem Cell Summit
2015-12-11,BioTime, Inc. Announces Record Date, Distribution Ratio, And Distribution Date For Distribution Of Shares Of Subsidiary OncoCyte Corporation
2015-12-04,BioTime, Inc. To Present At Oppenheimer Annual Healthcare Conference
2015-12-03,LifeMap Solutions Launches COPD Navigator App For Consumers And Commercial Partners
2015-11-18,BioTime, Inc. Announces The Appointment Of Life Sciences Industry Veteran Russell Skibsted As Chief Financial Officer
2015-11-13,Short Interest Jumps 11.8% For BTX
2015-11-11,Insider Trading Alert - TIPT, BTX And WASH Traded By Insiders
2015-11-09,BioTime, Inc. Reports Third Quarter 2015 Results And Recent Corporate Accomplishments
2015-11-06,BioTime, Inc. And Hepregen Corporation Form Ascendance Biotechnology, Inc. To Address The In Vitro Cell Biology Market
2015-10-19,Adi Mohanty Joins Michael D. West, PhD, As Co-CEO Of BioTime, Inc.
2015-10-07,BioTime's Subsidiary OncoCyte Corporation Files Form 10 Registration Statement For Planned Distribution
2015-10-02,BioTime, Inc. Agrees To Sell $5.1 Million Of Equity
2015-10-01,BioTime Announces The Closing Of A $20 Million Direct Registered Offering; Demand Exceeds NIS 80 Million Offered
2015-09-30,Heraeus Medical GmbH And BioTime Subsidiary OrthoCyte Corporation Enter Into Exclusive Worldwide Development And Licensing Agreements
2015-09-29,Mount Sinai And LifeMap Solutions Announce Initial Results For Asthma Health App And New Features To Enhance Clinical Impact
2015-09-28,BioTime's Subsidiary Cell Cure Neurosciences Ltd. Receives FDA Fast-Track Designation For OpRegen® for The Treatment Of The Dry Form Of Age-Related Macular Degeneration
2015-09-25,BioTime, Inc. Agrees To Sell Up To $20.7 Million Of Common Shares
2015-09-14,BioTime Subsidiary OncoCyte Corporation Appoints Cavan Redmond To Its Board Of Directors
2015-09-14,BioTime, Inc. Agrees To Sell $8.58 Million Of Common Shares
2015-09-04,BioTime Announces Dual Listing On The Tel Aviv Stock Exchange
2015-09-01,BioTime Chief Executive Officer Dr. Michael D. West To Be Keynote Speaker At Stem Cells & Regenerative Medicine Congress 2015
2015-08-31,BioTime Subsidiary Asterias Therapeutics Concludes Recruitment Of Initial Safety Cohort Of The SCiStar Phase 1/2a Dose-Escalation Clinical Trial Of AST-OPC1 For Complete Cervical Spinal Cord Injury
2015-08-28,BioTime Management To Present At Rodman & Renshaw 17th Annual Global Investment Conference
2015-08-27,Insider Trading Alert - ASYS, BTX And STAG Traded By Insiders
2015-08-18,The Wistar Institute And BioTime Subsidiary OncoCyte Corporation Expand Agreement To Develop Molecular Diagnostic Test For The Detection Of Lung Cancer
2015-08-10,BioTime, Inc. Reports Second Quarter 2015 Results And Recent Developments
2015-08-10,BioTime Announces The Issuance Of 27 New Patents Protecting Stem Cell-Based Product Development
2015-07-15,OncoCyte Announces Appointment Of Andy Arno To Board Of Directors
2015-06-17,First Week Of July 17th Options Trading For BioTime (BTX)
2015-06-16,William Annett Named Chief Executive Officer Of OncoCyte Corporation
2015-05-20,BioTime To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-19,OncoCyte's Collaborators At The Wistar Institute Present Positive Clinical Interim Results Of Blood-Based Diagnostic Test For Non-Invasive Detection Of Lung Cancer
2015-05-14,OncoCyte Corporation Completes Equity Financing Round
2015-05-13,BioTime's Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.6 Million Grant From Israel's Office Of The Chief Scientist
2015-05-11,BioTime, Inc. Reports First Quarter 2015 Results And Recent Corporate Accomplishments
2015-05-04,Cell Cure Neurosciences Announces Preclinical Efficacy Data Demonstrating OpRegen® Preserves Vision
2015-04-27,BioTime's Clinical Grade Stem Cells From Subsidiary ES Cell International To Be Used In Planned CIRM-Funded Preclinical Studies Of Huntington's Disease
2015-04-22,BioTime Licenses Beckman Research Institute Of City Of Hope To Manufacture Clinical Grade Stem Cells
2015-04-20,OncoCyte Announces Initial Data From Ongoing Clinical Study Of Collagen Type X As A Marker And Potential Diagnostic For Breast Cancer And Other Types Of Human Cancers
2015-04-20,Positive Clinical Results Of OncoCyte's PanC-Dx™ Diagnostic Test Demonstrate High Level Of Sensitivity And Specificity In Non-Invasive Detection Of Bladder Cancer
2015-03-31,Www.lifemap-solutions.com
2015-03-20,OncoCyte Announces Availability Of Abstracts With New Clinical Data From Studies Of PanC-Dx™ Cancer Diagnostic In Bladder And Breast Cancer
2015-03-11,BioTime, Inc. Reports Fourth Quarter And Fiscal Year End 2014 Financial Results And Recent Corporate Accomplishments
2015-03-09,Icahn School Of Medicine At Mount Sinai And LifeMap Solutions Launch Asthma Study For IPhone
2015-02-24,BioTime Announces First Patient Treated In Pivotal Clinical Trial Of Renevia™ For HIV-Associated Lipoatrophy
2015-02-17,Cell Cure Neurosciences Ltd. Provides Update On Its Product Development And Partnering Activities
2015-02-10,Asterias Biotherapeutics Completes Public Offering And Private Placement Of Common Stock
2015-02-06,OncoCyte To Present Cancer Diagnostic Clinical Study Data At AACR Annual Meeting
2015-02-05,Asterias Biotherapeutics Prices Public Offering Of Common Stock
2015-02-04,Asterias Biotherapeutics Announces Public Offering Of Common Stock
2015-01-26,BioTime Announces Issuance Of 14 New Patents In The Fields Of Regenerative Medicine, Stem Cell Technology, And Cancer Therapy
2015-01-12,BioTime Subsidiary OncoCyte Corporation Appoints William Annett To Its Board Of Directors
2014-12-29,BioTime Appoints Adi Mohanty Chief Operating Officer
2014-12-15,BioTime Subsidiary ES Cell International And GE Healthcare Cross-License Patents In The Field Of Cell Assays For Drug Testing
2014-12-15,BioTime, Inc. Subsidiary OncoCyte Corporation Completes Initial Enrollment Of Clinical Study Of Urine-Based Bladder Cancer Diagnostic
2014-12-15,BioTime Appoints Angus C. Russell To Board Of Directors
2014-12-12,BioTime To Host Investor And Analyst Day On December 15, 2014
2014-12-09,Commit To Purchase BioTime At $2.50, Earn 14.5% Annualized Using Options
2014-12-03,BioTime To Present At The LD Micro VII Conference
2014-11-10,BioTime Reports Third Quarter Results And Recent Progress
2014-11-04,BioTime Receives Authorization To Begin Pivotal Human Clinical Trial Of Renevia™ In Europe
2014-11-03,BioTime's Subsidiary Cell Cure Neurosciences Receives FDA Authorization To Initiate Phase I/IIa Trial Of Embryonic Stem Cell-Derived OpRegen® For The Treatment Of The Dry Form Of Age-Related Macular Degeneration
2014-10-31,Asterias Biotherapeutics To Report Third Quarter Results On November 10, 2014
2014-10-20,Asterias Biotherapeutics Announces Notice Of Grant Award With CIRM For Phase 1/2a Clinical Trial Of AST-OPC1 In Complete Cervical Spinal Cord Injury
2014-10-09,BioTime, Inc. Closes $31 Million Financing
2014-10-06,Asterias Biotherapeutics To List Its Series A Common Stock On NYSE MKT
2014-10-06,Michael H. Mulroy And Stephen L. Cartt Joining BioTime Board Of Directors
2014-10-06,BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Files An IND With The FDA For OpRegen® Designed To Treat Patients With Dry-AMD
2014-10-06,BioTime, Inc. And Subsidiaries To Raise $31 Million Through Sales Of Common Shares
2014-10-03,BioTime’s Subsidiary OncoCyte Corporation Announces Completion Of Multi-Site Clinical Study Of Lung Cancer Diagnostic By Collaborators At The Wistar Institute
2014-10-01,LifeMap Solutions Adds Chief Technology Officer To Leadership Team
2014-09-29,Asterias Biotherapeutics Announces Distribution Date Of BioTime Warrants And Conversion Date Of Series B Common Stock Into Series A Common Stock
2014-09-19,BioTime, Inc.’s Subsidiary OncoCyte Corporation’s CEO Dr. Joseph Wagner To Present At BTIG’s Inaugural “Emerging Technologies In Healthcare Diagnostics” Symposium
2014-09-17,BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Demonstrates The Safety And Efficacy Of OpRegen® In Preclinical Animal Studies
2014-09-15,BioTime, Inc.’s Subsidiary OncoCyte Corporation And Abcodia To Collaborate On Breast Cancer Diagnostic Development
2014-09-11,BioTime Subsidiary, Asterias Biotherapeutics, And Cancer Research UK And Cancer Research Technology Partner For Clinical Trial Of Immunotherapy Vaccine For Lung Cancer
2014-09-11,Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer
2014-09-09,BioTime CEO Dr. Michael D. West To Present At Rodman & Renshaw 16th Annual Healthcare Conference
2014-09-04,Asterias Biotherapeutics Announces Record Date For Distribution Of BioTime Warrants To Holders Of Asterias Series A Common Stock
2014-08-28,BioTime To Collaborate With The University Of Wisconsin And Louvain University In Test Of HyStem®-Based Hydrogel For Vocal Fold Scarring
2014-08-27,BioTime Subsidiary Asterias Biotherapeutics Receives U.S. FDA Clearance To Initiate Phase 1/2a Clinical Trial Of AST-OPC1 In Patients With Cervical Complete Spinal Cord Injury
2014-08-27,Asterias Biotherapeutics Receives U.S. FDA Clearance To Initiate Phase 1/2a Clinical Trial Of AST-OPC1 In Patients With Cervical Complete Spinal Cord Injury
2014-08-25,Asterias Biotherapeutics Announces Investor Briefing Conference Call And Webcast
2014-08-21,Asterias Biotherapeutics Appoints Two Independent Directors And Announces Completion Of Series A Common Stock Distribution
2014-08-12,BioTime Receives FDA Premarket Notification Clearance For Premvia™ 510(k)
2014-08-12,BioTime Announces Second Quarter 2014 Results And Recent Developments
2014-07-31,BioTime, Inc. Subsidiary OncoCyte Corporation Expands Clinical Development Of Bladder Cancer Diagnostic By Initiating A Large Multi-Site Clinical Trial
2014-07-24,Asterias Biotherapeutics Announces Live Investor Webcast
2014-07-14,BioTime Announces Issuance Of 14 Patents In The Fields Of Regenerative Medicine, And Cancer Diagnosis And Therapy
2014-06-17,BioTime Subsidiary Asterias Biotherapeutics Raises $13.0 Million In Equity Financing
2014-06-17,BioTime Subsidiary Asterias Biotherapeutics Announces Investment By CEO
2014-06-12,BioTime Subsidiary Asterias Biotherapeutics Appoints Former Pfizer Senior Executive Pedro Lichtinger As President And Chief Executive Officer
2014-06-02,BioTime To Present At The Jefferies 2014 Global Healthcare Conference
2014-05-30,BioTime's Subsidiary Asterias Biotherapeutics, Inc. Announces A $14.3 Million Strategic Partnership Award From The California Institute For Regenerative Medicine
2014-05-28,BioTime&#8217;s Subsidiary Asterias Biotherapeutics, Inc. Settles Patent Interference Proceedings
2014-05-28,BioTime Receives ISO 13485 Certification For Medical Devices
2014-05-27,BioTime&#8217;s Subsidiary OncoCyte Corporation And Cornell University Enter License Agreement To Accelerate Lung Cancer Diagnostic Product Development
2014-05-21,Asterias Biotherapeutics, Inc. Launches New Website: Asteriasbiotherapeutics.com
2014-05-13,Asterias Biotherapeutics, Inc. To Present Phase I Clinical Data At The 17th Annual Meeting Of The American Society Of Gene &amp; Cell Therapy
2014-05-12,BioTime Announces First Quarter 2014 Results And Recent Developments
2014-05-07,LifeMap Solutions, Inc. To Develop Mobile Health Products With Mount Sinai&#8217;s Icahn School Of Medicine
2014-05-05,BioTime Raises $6.4 Million In Equity Financing
2014-04-24,BioTime To Present At GTC Stem Cell Summit 2014
2014-04-14,BioTime, Inc. Announces Board Membership Changes And Management And Board Changes At Its Subsidiary Asterias Biotherapeutics, Inc.
2014-04-07,BioTime To Present At 13th Annual Needham Healthcare Conference
2014-03-25,BioTime To Present At Regen Med Investor Day March 26 In New York
2014-03-17,BioTime Announces Fourth Quarter And Fiscal Year End 2013 Financial Results And Recent Corporate Accomplishments
2014-03-05,5 Stocks With Big Insider Buying
2014-03-05,BioTime Raises $3.5 Million Through Preferred Stock Offering
2014-03-03,BioTime Provides Financing And Product Development Update
2014-02-28,Top Insider Trades: TWI CYTK CLFD BTX
2014-02-18,BioTime CEO Dr. Michael West To Present At 9th Annual Stem Cell Summit
2014-01-27,BioTime, Inc. Subsidiary OncoCyte Corporation Initiates Clinical Development Of Bladder Cancer Diagnostics In The United States And China
2014-01-17,BioTime&#8217;s Subsidiary LifeMap Sciences Announces Release Of LifeMap Discovery&#8482; Version 1.5 With GeneAnalytics&#8482;, A Powerful Gene Expression Analysis Tool
2014-01-13,BioTime Reports Results Of Clinical Safety Trial Of Renevia&#8482;
2014-01-02,Asterias Biotherapeutics, Inc., A Subsidiary Of BioTime, Inc., Leases Facilities For Expanded Product Development And Manufacturing
2013-12-31,5 Stocks Insiders Love Right Now
2013-12-31,Top Insider Trades: BTX TTGT OFG ACCL
2013-12-23,BioTime&#8217;s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.7 Million Grant From Israel&#8217;s Office Of The Chief Scientist
2013-12-20,BioTime Reports Isolation Of Novel Brain-Associated Cells From Human Embryonic Stem Cells
2013-12-06,LifeMap Sciences, A Subsidiary Of BioTime, Announces Release Of GeneCards&#174; Version 3.11
2017-03-07,Capricor Therapeutics To Hold Fourth Quarter And Full Year 2016 Financial Results And Corporate Update Conference Call On Wednesday, March 15
2017-02-23,Capricor Therapeutics To Present At Two Investor Conferences In March
2017-02-16,Capricor Therapeutics Provides Update On Natriuretic Peptide Program
2017-02-07,Capricor Therapeutics To Present At The 2017 BIO CEO And Investor Conference
2016-11-21,Capricor Therapeutics To Present At The 28th Annual Piper Jaffray Healthcare Conference
2016-11-10,Capricor Therapeutics Announces Plans To Expand Clinical Development Program In Duchenne Muscular Dystrophy To Evaluate Peripheral And Respiratory Muscle Function
2016-11-03,Capricor Therapeutics To Hold Third Quarter 2016 Business Update And Financial Results Conference Call And Webcast On Thursday, November 10 At 5:00 P.m. ET
2016-10-20,Capricor Therapeutics Awarded Up To $4.2 Million From National Institutes Of Health To Evaluate Exosomes For Hypoplastic Left Heart Syndrome
2016-10-05,Capricor Therapeutics Completes Enrollment In Phase II ALLSTAR Clinical Trial
2016-09-29,Capricor Therapeutics To Present At Upcoming Investor Conferences
2016-09-26,Capricor Therapeutics Awarded $2.4 Million From U.S. Department Of Defense To Support Manufacturing Process Development For Therapeutic Exosomes
2016-09-21,Capricor Therapeutics Announces Closing Of Public Offerings Raising Approximately $10.0 Million In Net Proceeds
2016-09-16,Capricor Therapeutics Announces Pricing Of Offerings Of Common Stock
2016-09-15,Capricor Therapeutics Announces Proposed Public Offering Of Common Stock
2016-09-07,Capricor Therapeutics Completes Enrollment in Randomized HOPE Clinical Trial in Duchenne Muscular Dystrophy
2016-09-01,Capricor Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2016-08-12,Capricor Therapeutics To Hold Second Quarter 2016 Business Update And Financial Results Conference Call And Webcast On Monday, August 15 At 4:30 P.m. ET
2016-06-23,Capricor Therapeutics Provides Enrollment Update On HOPE Clinical Trial In Duchenne Muscular Dystrophy
2016-06-22,Capricor Therapeutics To Present At JMP Life Sciences Conference
2016-05-31,Capricor Therapeutics To Present At 2016 BIO International Convention
2016-05-05,Capricor Therapeutics To Hold First Quarter 2016 Business Update And Financial Results Conference Call On May 12, 2016 At 4:30 P.m. EDT
2016-05-05,Capricor Therapeutics To Hold First Quarter 2016 Business Update And Financial Results Conference Call On May 12, 2016 At 4:30 P.m. EDT
2016-04-04,Capricor Therapeutics Announces DSMB Recommends Continuation Of HOPE-Duchenne Clinical Trial
2016-03-17,Capricor Awarded $3.4 Million Grant From California Institute For Regenerative Medicine
2016-03-15,Capricor Therapeutics Announces $4 Million Registered Direct Offering
2016-03-10,Capricor Therapeutics To Hold Fourth Quarter 2015 Financial Results And Business Update Conference Call On March 17, 2016 At 4:30 P.m. EDT
2016-03-08,Capricor Therapeutics To Present At Upcoming Investor Conferences
2016-02-23,Capricor Therapeutics Appoints Leland J. Gershell, M.D., Ph.D. As Chief Financial Officer
2016-02-22,Capricor Therapeutics Announces The First Patient With Duchenne Muscular Dystrophy-Related Cardiomyopathy Treated With CAP-1002 In The HOPE-Duchenne Phase I/II Clinical Trial
2016-02-02,Capricor Therapeutics To Present At 18th Annual BIO CEO & Investor Conference
2016-01-05,Capricor Therapeutics To Present At Biotech Showcase 2016
2015-12-10,Capricor Therapeutics To Present At The 2015 JMP Securities DMD Forum
2015-11-24,Capricor Therapeutics To Present At The 2015 Piper Jaffray Healthcare Conference
2015-11-23,BioLife Solutions Customer Capricor Therapeutics Provides Update On Heart Failure Cell Therapy Safety Data At American Heart Association Scientific Sessions
2015-11-06,Capricor Therapeutics To Present Data From The DYNAMIC Clinical Trial At American Heart Association Scientific Sessions 2015
2015-11-04,Capricor Therapeutics To Hold Third Quarter 2015 Business Update And Financial Results Conference Call On November 12, 2015 At 4:30 P.m. EST
2015-10-29,Capricor Therapeutics And CureDuchenne To Host Webinar On November 3, 2015 At 3:00 P.m. ET
2015-09-30,Capricor Therapeutics To Present At 2015 Stem Cell Meeting On The Mesa
2015-08-13,Capricor Therapeutics Reports Second Quarter 2015 Business & Financial Highlights
2015-08-06,Capricor Therapeutics To Hold Second Quarter 2015 Business Update And Financial Results Conference Call On August 13, 2015 At 4:30 P.m. EDT
2015-08-04,Capricor Therapeutics Appoints Deborah Ascheim, M.D. As Chief Medical Officer
2015-07-30,Four Stem-Cell Stocks With Promise
2015-07-30,Pluristem, Capricor Lead Regenerative Space Says Raymond James Analyst
2015-06-17,Capricor Therapeutics Appoints Houman Hemmati M.D., Ph.D. To Vice President Of Medical And Clinical Development For New Therapies
2015-06-15,Capricor Therapeutics And CureDuchenne To Host Webinar On June 19, 2015 At 3:00 P.m. ET
2015-06-08,Capricor Announces Receipt Of FDA Clearance For The Phase I/II Study Of CAP-1002 For The Treatment Of Duchenne Muscular Dystrophy Related Cardiomyopathy
2015-05-26,Capricor Therapeutics To Participate In Two Upcoming Investor Conferences In June
2015-05-22,Ratings Changes Today
2015-05-12,Capricor Therapeutics Reports First Quarter 2015 Financial & Business Highlights
2015-05-05,Capricor Therapeutics To Hold First Quarter 2015 Business Update And Financial Results Conference Call On May 12, 2015 At 4:30 P.m. EDT
2015-04-22,Capricor Granted FDA Orphan Drug Designation For Allogeneic Cardiosphere-Derived Cells For The Treatment Of Duchenne Muscular Dystrophy
2015-04-08,Capricor Completes Enrollment Of Initial Phase Of DYNAMIC Clinical Trial Of Cardiosphere-Derived Cell Therapy For Treatment Of Advanced Heart Failure
2015-03-31,Capricor Therapeutics Completes Enrollment Of Phase II Clinical Trial For Cenderitide To Treat Heart Failure
2015-03-23,Capricor Therapeutics To Present At 3rd Annual Regen Med Investor Day On March 25, 2015 In New York
2015-03-18,Capricor Therapeutics Reports Fourth Quarter And Full Year 2014 Financial & Business Highlights
2015-03-12,Capricor Therapeutics To Hold Fourth Quarter 2014 Business Update Conference Call On March 18, 2015 At 4:30 P.m. EDT
2015-03-10,Capricor Therapeutics To Present At The 27th Annual ROTH Conference
2015-03-05,Capricor Announces Enrollment Of Its Phase II Clinical Trial For Cenderitide To Treat Heart Failure
2015-03-05,Capricor Therapeutics Announces Uplisting To NASDAQ Capital Market
2015-02-27,Capricor Therapeutics Appoints Thomas Copmann, Ph.D. As Vice President Of Regulatory Affairs And Drug Development
2015-02-04,Capricor Therapeutics Announces $7 Million Private Placement Of Common Stock
2015-01-21,Capricor Therapeutics And CureDuchenne To Host Webinar On January 21, 2015 At 3:00 P.m. ET
2015-01-12,Capricor Therapeutics Initiates The DYNAMIC Clinical Trial For The Treatment Of Advanced Heart Failure
2015-01-12,Capricor Therapeutics Announces $10 Million Private Placement Of Common Stock
2014-12-02,Capricor Therapeutics Announces Linda Marban, Ph.D. Will Present A Company Overview And Serve As An Expert Panelist At Piper Jaffray's 26th Annual Healthcare Conference
2014-11-18,Capricor Therapeutics Announces Favorable ALLSTAR Phase I Safety Results
2014-11-18,Capricor Therapeutics Announces Positive Pre-Clinical Data For Cardiosphere-Derived Cells (CDCs) On Duchenne Muscular Dystrophy Cardiomyopathy
2014-11-12,Capricor Therapeutics Reports Third Quarter 2014 Financial & Business Highlights
2014-11-07,Capricor Therapeutics To Hold Duchenne Muscular Dystrophy Data Presentation Call On November 18, 2014 At 9:30 A.m. ET
2014-10-31,Capricor Therapeutics To Hold Third Quarter 2014 Business Update Conference Call On November 12, 2014 At 4:30 P.m. ET
2014-10-14,Capricor Therapeutics Announces Acquisition Of Intellectual Property Rights To Family Of Natriuretic Peptides From Medtronic, Inc.
2014-10-09,Capricor Therapeutics Announces Plans To Pursue A Cenderitide Clinical Program And Enters Into Research Support Agreement With Insulet Corporation
2014-10-06,Capricor Announces Plans To Pursue Clinical Program For The Treatment Of Duchenne Muscular Dystrophy With Cardiosphere-Derived Cells (CDCs)
2014-09-18,Capricor Presents Safety And Preliminary Efficacy Results From ALLSTAR Phase I Clinical Trial At TCT 2014
2014-08-13,Capricor Therapeutics Reports Second Quarter 2014 Financial & Business Highlights
2014-08-04,Capricor Therapeutics To Hold Second Quarter 2014 Business Update Conference Call On August 13, 2014 At 4:30 P.m. Eastern Time
2014-07-16,Capricor Announces Encouraging Results From Phase I ALLSTAR Trial; Phase II Trial Underway
2002-04-01,Three to Eye: Hasbro, Gateway, Isle of Capri
,
,
,
2017-03-07,Capricor Therapeutics To Hold Fourth Quarter And Full Year 2016 Financial Results And Corporate Update Conference Call On Wednesday, March 15
2017-02-23,Capricor Therapeutics To Present At Two Investor Conferences In March
2017-02-16,Capricor Therapeutics Provides Update On Natriuretic Peptide Program
2017-02-07,Capricor Therapeutics To Present At The 2017 BIO CEO And Investor Conference
2016-11-21,Capricor Therapeutics To Present At The 28th Annual Piper Jaffray Healthcare Conference
2016-11-10,Capricor Therapeutics Announces Plans To Expand Clinical Development Program In Duchenne Muscular Dystrophy To Evaluate Peripheral And Respiratory Muscle Function
2016-11-03,Capricor Therapeutics To Hold Third Quarter 2016 Business Update And Financial Results Conference Call And Webcast On Thursday, November 10 At 5:00 P.m. ET
2016-10-20,Capricor Therapeutics Awarded Up To $4.2 Million From National Institutes Of Health To Evaluate Exosomes For Hypoplastic Left Heart Syndrome
2016-10-05,Capricor Therapeutics Completes Enrollment In Phase II ALLSTAR Clinical Trial
2016-09-29,Capricor Therapeutics To Present At Upcoming Investor Conferences
2016-09-26,Capricor Therapeutics Awarded $2.4 Million From U.S. Department Of Defense To Support Manufacturing Process Development For Therapeutic Exosomes
2016-09-21,Capricor Therapeutics Announces Closing Of Public Offerings Raising Approximately $10.0 Million In Net Proceeds
2016-09-16,Capricor Therapeutics Announces Pricing Of Offerings Of Common Stock
2016-09-15,Capricor Therapeutics Announces Proposed Public Offering Of Common Stock
2016-09-07,Capricor Therapeutics Completes Enrollment in Randomized HOPE Clinical Trial in Duchenne Muscular Dystrophy
2016-09-01,Capricor Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2016-08-12,Capricor Therapeutics To Hold Second Quarter 2016 Business Update And Financial Results Conference Call And Webcast On Monday, August 15 At 4:30 P.m. ET
2016-06-23,Capricor Therapeutics Provides Enrollment Update On HOPE Clinical Trial In Duchenne Muscular Dystrophy
2016-06-22,Capricor Therapeutics To Present At JMP Life Sciences Conference
2016-05-31,Capricor Therapeutics To Present At 2016 BIO International Convention
2016-05-05,Capricor Therapeutics To Hold First Quarter 2016 Business Update And Financial Results Conference Call On May 12, 2016 At 4:30 P.m. EDT
2016-05-05,Capricor Therapeutics To Hold First Quarter 2016 Business Update And Financial Results Conference Call On May 12, 2016 At 4:30 P.m. EDT
2016-04-04,Capricor Therapeutics Announces DSMB Recommends Continuation Of HOPE-Duchenne Clinical Trial
2016-03-17,Capricor Awarded $3.4 Million Grant From California Institute For Regenerative Medicine
2016-03-15,Capricor Therapeutics Announces $4 Million Registered Direct Offering
2016-03-10,Capricor Therapeutics To Hold Fourth Quarter 2015 Financial Results And Business Update Conference Call On March 17, 2016 At 4:30 P.m. EDT
2016-03-08,Capricor Therapeutics To Present At Upcoming Investor Conferences
2016-02-23,Capricor Therapeutics Appoints Leland J. Gershell, M.D., Ph.D. As Chief Financial Officer
2016-02-22,Capricor Therapeutics Announces The First Patient With Duchenne Muscular Dystrophy-Related Cardiomyopathy Treated With CAP-1002 In The HOPE-Duchenne Phase I/II Clinical Trial
2016-02-02,Capricor Therapeutics To Present At 18th Annual BIO CEO & Investor Conference
2016-01-05,Capricor Therapeutics To Present At Biotech Showcase 2016
2015-12-10,Capricor Therapeutics To Present At The 2015 JMP Securities DMD Forum
2015-11-24,Capricor Therapeutics To Present At The 2015 Piper Jaffray Healthcare Conference
2015-11-23,BioLife Solutions Customer Capricor Therapeutics Provides Update On Heart Failure Cell Therapy Safety Data At American Heart Association Scientific Sessions
2015-11-06,Capricor Therapeutics To Present Data From The DYNAMIC Clinical Trial At American Heart Association Scientific Sessions 2015
2015-11-04,Capricor Therapeutics To Hold Third Quarter 2015 Business Update And Financial Results Conference Call On November 12, 2015 At 4:30 P.m. EST
2015-10-29,Capricor Therapeutics And CureDuchenne To Host Webinar On November 3, 2015 At 3:00 P.m. ET
2015-09-30,Capricor Therapeutics To Present At 2015 Stem Cell Meeting On The Mesa
2015-08-13,Capricor Therapeutics Reports Second Quarter 2015 Business & Financial Highlights
2015-08-06,Capricor Therapeutics To Hold Second Quarter 2015 Business Update And Financial Results Conference Call On August 13, 2015 At 4:30 P.m. EDT
2015-08-04,Capricor Therapeutics Appoints Deborah Ascheim, M.D. As Chief Medical Officer
2015-07-30,Four Stem-Cell Stocks With Promise
2015-07-30,Pluristem, Capricor Lead Regenerative Space Says Raymond James Analyst
2015-06-17,Capricor Therapeutics Appoints Houman Hemmati M.D., Ph.D. To Vice President Of Medical And Clinical Development For New Therapies
2015-06-15,Capricor Therapeutics And CureDuchenne To Host Webinar On June 19, 2015 At 3:00 P.m. ET
2015-06-08,Capricor Announces Receipt Of FDA Clearance For The Phase I/II Study Of CAP-1002 For The Treatment Of Duchenne Muscular Dystrophy Related Cardiomyopathy
2015-05-26,Capricor Therapeutics To Participate In Two Upcoming Investor Conferences In June
2015-05-22,Ratings Changes Today
2015-05-12,Capricor Therapeutics Reports First Quarter 2015 Financial & Business Highlights
2015-05-05,Capricor Therapeutics To Hold First Quarter 2015 Business Update And Financial Results Conference Call On May 12, 2015 At 4:30 P.m. EDT
2015-04-22,Capricor Granted FDA Orphan Drug Designation For Allogeneic Cardiosphere-Derived Cells For The Treatment Of Duchenne Muscular Dystrophy
2015-04-08,Capricor Completes Enrollment Of Initial Phase Of DYNAMIC Clinical Trial Of Cardiosphere-Derived Cell Therapy For Treatment Of Advanced Heart Failure
2015-03-31,Capricor Therapeutics Completes Enrollment Of Phase II Clinical Trial For Cenderitide To Treat Heart Failure
2015-03-23,Capricor Therapeutics To Present At 3rd Annual Regen Med Investor Day On March 25, 2015 In New York
2015-03-18,Capricor Therapeutics Reports Fourth Quarter And Full Year 2014 Financial & Business Highlights
2015-03-12,Capricor Therapeutics To Hold Fourth Quarter 2014 Business Update Conference Call On March 18, 2015 At 4:30 P.m. EDT
2015-03-10,Capricor Therapeutics To Present At The 27th Annual ROTH Conference
2015-03-05,Capricor Announces Enrollment Of Its Phase II Clinical Trial For Cenderitide To Treat Heart Failure
2015-03-05,Capricor Therapeutics Announces Uplisting To NASDAQ Capital Market
2015-02-27,Capricor Therapeutics Appoints Thomas Copmann, Ph.D. As Vice President Of Regulatory Affairs And Drug Development
2015-02-04,Capricor Therapeutics Announces $7 Million Private Placement Of Common Stock
2015-01-21,Capricor Therapeutics And CureDuchenne To Host Webinar On January 21, 2015 At 3:00 P.m. ET
2015-01-12,Capricor Therapeutics Initiates The DYNAMIC Clinical Trial For The Treatment Of Advanced Heart Failure
2015-01-12,Capricor Therapeutics Announces $10 Million Private Placement Of Common Stock
2014-12-02,Capricor Therapeutics Announces Linda Marban, Ph.D. Will Present A Company Overview And Serve As An Expert Panelist At Piper Jaffray's 26th Annual Healthcare Conference
2014-11-18,Capricor Therapeutics Announces Favorable ALLSTAR Phase I Safety Results
2014-11-18,Capricor Therapeutics Announces Positive Pre-Clinical Data For Cardiosphere-Derived Cells (CDCs) On Duchenne Muscular Dystrophy Cardiomyopathy
2014-11-12,Capricor Therapeutics Reports Third Quarter 2014 Financial & Business Highlights
2014-11-07,Capricor Therapeutics To Hold Duchenne Muscular Dystrophy Data Presentation Call On November 18, 2014 At 9:30 A.m. ET
2014-10-31,Capricor Therapeutics To Hold Third Quarter 2014 Business Update Conference Call On November 12, 2014 At 4:30 P.m. ET
2014-10-14,Capricor Therapeutics Announces Acquisition Of Intellectual Property Rights To Family Of Natriuretic Peptides From Medtronic, Inc.
2014-10-09,Capricor Therapeutics Announces Plans To Pursue A Cenderitide Clinical Program And Enters Into Research Support Agreement With Insulet Corporation
2014-10-06,Capricor Announces Plans To Pursue Clinical Program For The Treatment Of Duchenne Muscular Dystrophy With Cardiosphere-Derived Cells (CDCs)
2014-09-18,Capricor Presents Safety And Preliminary Efficacy Results From ALLSTAR Phase I Clinical Trial At TCT 2014
2014-08-13,Capricor Therapeutics Reports Second Quarter 2014 Financial & Business Highlights
2014-08-04,Capricor Therapeutics To Hold Second Quarter 2014 Business Update Conference Call On August 13, 2014 At 4:30 P.m. Eastern Time
2014-07-16,Capricor Announces Encouraging Results From Phase I ALLSTAR Trial; Phase II Trial Underway
2002-04-01,Three to Eye: Hasbro, Gateway, Isle of Capri
,
,
,
2017-03-13,Cascadian Therapeutics Announces Changes To Board Of Directors
2017-03-09,Cascadian Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results
2017-02-27,Cascadian Therapeutics To Present At Cowen And Company 37th Annual Health Care Conference
2017-01-24,Cascadian Therapeutics Prices $82.5 Million Concurrent Offerings Of Common Stock And Preferred Stock
2017-01-23,Cascadian Therapeutics Announces Proposed Concurrent Public Offerings Of Common Stock And Preferred Stock
2017-01-05,Cascadian Therapeutics Announces 2017 Outlook And Recent Drug Portfolio Progress
2017-01-04,Cascadian Therapeutics Appoints Dr. Marc L. Lesnick As Senior Vice President, Regulatory Affairs And Quality
2016-12-07,Cascadian Therapeutics Enlarges Breast Cancer Pill Study to Meet FDA Registration Standards
2016-12-07,Cascadian Therapeutics Amends HER2CLIMB Phase 2 Trial Of Tucatinib In Metastatic HER2-Positive Breast Cancer To Support Registration
2016-11-28,Cascadian Therapeutics Strengthens Management Team With Key Hires, Monique M. Greer And Marc C. Chamberlain, M.D.
2016-11-23,Cascadian Therapeutics Announces Stockholders And Board Of Directors Approve Reverse Stock Split
2016-11-07,Cascadian Therapeutics Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-10-10,Cascadian Therapeutics Announces Presentation Of Tucatinib In Combination Therapy In Patients With Cutaneous HER2+ Metastatic Breast Cancer
2016-10-04,Cascadian Therapeutics Announces Proposal For Reverse Stock Split
2016-09-28,Cascadian Therapeutics Announces Poster Presentations On Tucatinib At The European Society Of Medical Oncology (ESMO) 2016 Congress
2016-09-20,Cascadian Therapeutics To Present At The Ladenburg Thalmann 2016 Healthcare Conference
2016-09-15,7 Stocks Under $10 Making Big Moves Higher
2016-09-06,Cascadian Therapeutics To Present At The Rodman & Renshaw 18th Annual Global Investment Conference
2016-08-24,6 Stocks that Seth Klarman Loves
2016-08-08,Cascadian Therapeutics Reports Second Quarter 2016 Financial Results And Provides Corporate Update
2016-06-29,Cascadian Therapeutics Receives ONT-380 Fast Track Designation From FDA For The Treatment Of Advanced HER2+ Metastatic Breast Cancer
2016-06-28,Cascadian Therapeutics Announces Exercise Of Underwriters' Over-Allotment Option And Closing Of $46.0 Million Concurrent Offerings Of Common Stock And Series D Convertible Preferred Stock
2016-06-23,Cascadian Therapeutics Prices $41.8 Million Concurrent Offerings Of Common Stock And Series D Convertible Preferred Stock
2016-06-22,Cascadian Therapeutics Announces Proposed Public Offering
2016-06-20,Biotech Stock Mailbag: Cascadian Therapeutics, Global Blood Therapeutics, Bad Favus
2016-06-14,Cascadian Therapeutics Reports Topline ONT-380 "Triplet" Data And Outlines Key Development Strategies
2013-03-28,Toyota Industries Corporation Completes Acquisition Of Cascade Corporation
2013-03-28,Toyota Industries Corporation Announces Successful Completion Of Cash Tender Offer For Shares Of Cascade Corporation
2013-03-25,Cascade Corporation Announces Financial Results For The Fourth Quarter And Year Ended January 31, 2013
2013-03-06,Toyota Industries Corporation Announces Extension Of Cash Tender Offer For Shares Of Cascade Corporation
2013-02-28,Toyota Industries Corporation Announces Certification Of Substantial Compliance And Extension Of Cash Tender Offer For Shares Of Cascade Corporation
2013-01-24,Toyota Industries Corporation Announces Extension Of Cash Tender Offer For Shares Of Cascade Corporation
2012-12-20,Toyota Industries Corporation Announces Extension Of Cash Tender Offer For Shares Of Cascade Corporation
2012-12-03,Toyota Industries Corporation Announces Extension Of Cash Tender Offer For Shares Of Cascade Corporation
2012-11-28,Cascade Corporation Announces Financial Results For The Third Quarter Ended October 31, 2012
2012-11-05,Cascade Corporation Directors Approve Dividend
2012-11-02,Finkelstein Thompson LLP Announces Investigation Of Cascade Corporation
2012-11-02,Toyota Industries Corporation Commences Tender Offer To Acquire Cascade Corporation
2012-10-26,Law Office Of Brodsky &amp; Smith, LLC Announces Investigation Of Cascade Corporation
2012-10-24,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Class Action Against Ubiquiti Networks, Inc. (UBNT) And Questcor Pharmaceuticals, Inc. (QCOR) And Investigation Of Cascade Corporation (CASC) And Cymer Inc. (CYMI)
2012-10-23,SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Announces Investigation Of Cascade Corporation (CASC), Cymer Inc. (CYMI) And Versant Corp. (VSNT) And Class Action Against Peregrine Pharmaceuticals, Inc. (PPHM)
2012-10-23,Law Office Of Brodsky & Smith, LLC Announces Investigation Of Cascade Corporation
2012-10-23,Ryan &amp; Maniskas, LLP Announces Investigation Of Cascade Corp.
2012-10-22,SHAREHOLDER ALERT: Levi &amp; Korsinsky, LLP Announces Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Cascade Corporation In Connection With The Sale Of The Company To Toyota Industries Corporation
2012-10-22,Faruqi &amp; Faruqi, LLP Is Seeking More Cash For The Shareholders Of Cascade Corporation (CASC)
2012-10-22,Stocks Race to Positive Finish
2012-10-22,Kendall Law Group Investigates Cascade Corp.
2012-10-22,Cascade Corporation Investor Alert: Proposed Sale Investigated By Securities Attorneys At The Briscoe Law Firm And Powers Taylor, LLP
2012-10-22,Harwood Feffer LLP Announces Investigation Of Cascade Corporation
2012-10-22,SHAREHOLDER ALERT: Levi &amp; Korsinsky, LLP Announces Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Cascade Corporation In Connection With The Sale Of The Company To Toyota Industries Corporation
2012-10-22,Rigrodsky & Long, P.A. Announces Investigations Of Ancestry.com, Inc. And Cascade Corporation Buyouts
2012-10-22,Toyota Industries Corporation To Acquire Cascade Corporation
2012-08-30,Cascade Corporation Announces Financial Results For The Second Quarter Ended July 31, 2012
2012-08-23,Cascade Corporation Announces Second Quarter Fiscal 2013 Earnings Call
2012-06-07,Cascade Corporation Announces Financial Results For The First Quarter Ended April 30, 2012
2012-05-31,Cascade Corporation Announces First Quarter Fiscal 2013 Earnings Call
2012-03-29,Cascade Corporation Announces Financial Results For The Fourth Quarter And Year Ended January 31, 2012
2012-03-22,Cascade Corporation Announces Fourth Quarter And Year Ended January 31, 2012 Earnings Call
2012-02-02,Cascade Reaches New 52-Week High (CASC)
2012-01-25,Cascade Stock Hits New 52-Week High (CASC)
2011-12-01,Cascade Corporation Announces Financial Results For The Third Quarter Ended October 31, 2011
2011-11-28,Getting a Jump on a 10% Dividend Yield
2011-11-25,Cascade Corporation Announces Third Quarter Fiscal 2012 Earnings Call
2011-09-01,Cascade Corporation Announces Financial Results For The Second Quarter Ended July 31, 2011
2011-08-25,Cascade Corporation Announces Second Quarter Fiscal 2012 Earnings Call
2011-07-21,Cascade Reaches New 52-Week High (CASC)
2011-07-07,Cascade Stock Hits New 52-Week High (CASC)
2011-06-20,Cascade Corporation Stock Upgraded (CASC)
2011-06-03,Cascade Stock Gaps Up On Today's Open (CASC)
2011-06-02,Cascade Corporation Announces Financial Results For The First Quarter Ended April 30, 2011
2011-05-26,Cascade Corporation Announces Financial Results For The First Quarter Ended April 30, 2011
2011-04-05,Cascade Stock Hits New 52-Week High (CASC)
2011-03-31,Cascade Corporation Announces Financial Results For The Fourth Quarter And Year Ended January 31, 2011
2011-03-24,Cascade Corporation Announces Financial Results For The Fourth Quarter And Year Ended January 31, 2011
2011-02-14,Cascade Corporation Releases Information Regarding Operations In Australia
2010-12-03,NYSE Stocks Posting Largest Percentage Increases
2010-12-02,Cascade Corporation Announces Financial Results For The Third Quarter Ended October 31, 2010
2010-11-29,NYSE Stocks Posting Largest Percentage Decreases
2010-11-24,Cascade Corporation Announces Third Quarter Fiscal 2011 Earnings Call
2010-09-02,Cascade Corporation Announces Financial Results For The Second Quarter Ended July 31, 2010
2010-08-26,Cascade Corporation Announces Second Quarter Fiscal 2011 Earnings Call
2010-06-07,Cascade Corporation Announces Financial Results For The First Quarter Ended April 30, 2010
2010-06-01,Cascade Corporation Announces First Quarter Fiscal 2011 Earnings Call
2010-03-25,Cascade Corporation Announces Fourth Quarter Fiscal 2010 Earnings Call
2009-12-03,Cascade Shares Spike After 3Q Results Top Views
,
,
,
2017-03-16,Catabasis Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results And Recent Corporate Highlights
2017-03-15,Catabasis Pharmaceuticals To Present At Oppenheimer's 27th Annual Healthcare Conference
2017-03-13,Catabasis Pharmaceuticals To Present At The 2017 Muscular Dystrophy Association Scientific Conference
2017-03-02,Catabasis Pharmaceuticals To Report Fourth Quarter And Full Year 2016 Financial Results And Recent Corporate Developments On Thursday, March 16
2017-03-01,Catabasis Pharmaceuticals To Present At Cowen And Company 37th Annual Health Care Conference
2017-02-17,Catabasis Pharmaceuticals Announces Promotion Of Ted Hibben To Chief Business Officer
2017-02-02,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Catabasis Pharmaceuticals, Inc.
2017-01-31,Catabasis Pharmaceuticals Announces Top-Line Results For Part B Of The MoveDMD® Trial For Edasalonexent (CAT-1004) In Duchenne Muscular Dystrophy
2017-01-19,Catabasis Pharmaceuticals Phase 1 Data On Edasalonexent (CAT-1004), A Potential Disease-Modifying Therapy Being Developed For Duchenne Muscular Dystrophy, Published In The Journal Of Clinical Pharmacology
2017-01-05,Catabasis Pharmaceuticals Research On CAT-5571, A Novel Activator Of Autophagy And Potential Oral Treatment For Cystic Fibrosis, Published In Journal Of Medicinal Chemistry
2017-01-04,Positive Preclinical Research On The Edasalonexent (CAT-1004) Program, A Potential Disease-Modifying Therapy For Duchenne Muscular Dystrophy, Published In JCI Insight
2016-11-17,Catabasis Pharmaceuticals Provides Edasalonexent And Rare Disease Pipeline Updates At Investor Day
2016-11-10,Catabasis Pharmaceuticals Reports Third Quarter 2016 Financial Results And Recent Corporate Highlights
2016-11-03,Catabasis Pharmaceuticals To Host Investor Day In New York City On November 17
2016-10-27,Catabasis Pharmaceuticals Presents Positive Data For CAT-5571, A Novel Activator Of Autophagy, As A Potential Oral Treatment For Cystic Fibrosis At The 30th Annual North American Cystic Fibrosis Conference
2016-10-26,Catabasis Pharmaceuticals To Report Third Quarter 2016 Financial Results And Recent Corporate Developments On Thursday, November 10
2016-10-20,Catabasis Pharmaceuticals To Present CAT-5571, A Novel Activator Of Autophagy, As A Potential Treatment For Cystic Fibrosis At The 30th Annual North American Cystic Fibrosis Conference
2016-10-11,Catabasis Pharmaceuticals To Present The MoveDMD® Trial Of Edasalonexent (CAT-1004), A Potential Disease-Modifying Therapy For DMD, At The American Neurological Association's 2016 Annual Meeting
2016-10-06,Catabasis Pharmaceuticals Presents Positive Data From Part A Of The MoveDMD® Trial Of Edasalonexent (CAT-1004), A Potential Disease-Modifying Therapy For DMD, At The World Muscle Society Congress
2016-10-05,Catabasis Pharmaceuticals Announces Promotion Of Andrew Nichols, Ph.D. To Chief Scientific Officer And Angelika Fretzen To Senior Vice President Of Product Development
2016-10-04,Catabasis Pharmaceuticals Completes Target Enrollment For Part B Of The MoveDMD® Trial, A Phase 2 Trial Of Edasalonexent (CAT-1004) For The Potential Treatment Of Duchenne Muscular Dystrophy
2016-09-29,Catabasis Pharmaceuticals And Sarepta Therapeutics Announce A Joint Research Collaboration In Duchenne Muscular Dystrophy
2016-09-28,Catabasis Pharmaceuticals Announces Closing Of $11.5 Million Offering Of Common Stock, Including Full Exercise Of Underwriter's Option To Purchase Additional Shares
2016-09-23,Catabasis Pharmaceuticals Announces Pricing Of $10 Million Offering Of Common Stock
2016-08-11,Catabasis Pharmaceuticals Reports Second Quarter 2016 Financial Results And Recent Corporate Highlights
2016-08-09,Catabasis Pharmaceuticals To Present At 2016 Wedbush PacGrow Healthcare Conference
2016-07-28,These 5 Stocks Under $10 Are Set to Soar Higher
2016-07-28,Catabasis Pharmaceuticals To Report Second Quarter 2016 Financial Results And Recent Corporate Developments On Thursday, August 11
2016-07-12,Catabasis Pharmaceuticals Names Joseph Johnston VP, Regulatory Affairs
2016-07-07,Catabasis Pharmaceuticals Announces The Initiation Of An Open-Label Extension For The MoveDMD® Trial Studying Edasalonexent (CAT-1004) In Duchenne Muscular Dystrophy
2016-06-26,7 Stocks Under $10 to Trade for Big Post-Brexit Gains
2016-06-20,Catabasis Pharmaceuticals To Present Edasalonexent (CAT-1004), An Oral Agent Targeting NF-kB: MoveDMDSM Trial In Duchenne Muscular Dystrophy (DMD) At The 2016 PPMD Annual Connect Conference
2016-06-08,Catabasis Pharmaceuticals And Parent Project Muscular Dystrophy To Host A Webinar On MoveDMDSM: A Clinical Trial Of Edasalonexent (CAT-1004) In Boys With Duchenne Muscular Dystrophy
2016-06-07,Catabasis Pharmaceuticals Announces Top-Line Phase 2a Results For CAT-2054
2016-05-21,Catabasis Pharmaceuticals Presents Positive Pre-Clinical Data At Digestive Disease Week 2016; Data Support CAT-2054, A Phase 2 Asset, As A Potential Treatment For Nonalcoholic Steatohepatitis (NASH)
2016-05-16,Catabasis Pharmaceuticals To Present Pre-Clinical Data Supporting CAT-2054 As A Potential Treatment For Nonalcoholic Steatohepatitis (NASH) At Digestive Disease Week 2016
2016-05-16,Catabasis Pharmaceuticals To Present CAT-2054, A Potential Treatment For Nonalcoholic Steatohepatitis (NASH) And Hypercholesterolemia, At The National Lipid Association 2016 Scientific Sessions
2016-05-12,Catabasis Pharmaceuticals Reports First Quarter 2016 Financial Results And Recent Corporate Highlights
2016-04-28,Catabasis Pharmaceuticals To Report First Quarter 2016 Financial Results And Recent Corporate Developments On Thursday, May 12
2016-04-12,Catabasis Pharmaceuticals Initiates Part B Of The MoveDMDSM Trial Of CAT-1004 For The Treatment Of Duchenne Muscular Dystrophy
2016-04-07,Catabasis Pharmaceuticals To Present At Needham And Company's 15th Annual Healthcare Conference
2016-04-06,Catabasis Pharmaceuticals Announces Additions To Board Of Directors And The Formation Of A Science And Technology Committee
2016-04-01,Catabasis Pharmaceuticals Announces Resignation Of Chief Financial Officer
2016-03-21,Catabasis Pharmaceuticals Presents Positive CAT-1004 Data From Part A Of The MoveDMDSM Trial At The 2016 Muscular Dystrophy Association Clinical Conference
2016-03-18,Catabasis Pharmaceuticals To Present CAT-1004 Data From Part A Of The MoveDMDSM Trial At The 2016 Muscular Dystrophy Association Clinical Conference
2016-03-04,5 Stocks Poised for Big Breakouts
2016-03-02,Catabasis Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results And Recent Corporate Developments
2016-03-02,Catabasis Pharmaceuticals To Present At Cowen And Company's 36th Annual Health Care Conference
2016-02-17,Catabasis Pharmaceuticals To Report Fourth Quarter And Full Year 2015 Financial Results And Recent Corporate Developments On Wednesday, March 2
2016-02-10,Catabasis Pharmaceuticals Will Present CAT-1004, A Potential Disease-Modifying Agent In Development For The Treatment Of Duchenne Muscular Dystrophy, At The XIV International Conference On Duchenne And Becker Muscular Dystrophy
2016-02-05,Muscular Dystrophy Association To Collaborate With Catabasis Pharmaceuticals On Development Of CAT-1004, A Potential Novel Oral Disease-Modifying Treatment For Duchenne Muscular Dystrophy
2016-01-25,Catabasis Pharmaceuticals Announces Positive Top-Line Results From Part A Of The MoveDMD¿ Trial, A Phase 1 / 2 Trial Of CAT-1004 For The Treatment Of Duchenne Muscular Dystrophy
2016-01-19,FARA Announces Catabasis Pharmaceuticals As The Recipient Of The Kyle Bryant Translational Research Award To Evaluate CAT-4001 As A Potential Therapy For Friedreich's Ataxia
2015-12-18,Catabasis Pharmaceuticals Completes Enrollment For Part A Of The MoveDMDSM Trial, A Phase 1/2 Trial Of CAT-1004 For The Treatment Of Duchenne Muscular Dystrophy
2015-12-17,Catabasis Names Deirdre Cunnane SVP, General Counsel
2015-12-09,Catabasis Pharmaceuticals Announces First Patient Dosed In Phase 2a Trial Of CAT-2054 For The Treatment Of Hypercholesterolemia
2015-12-02,Catabasis Pharmaceuticals To Present At The Oppenheimer 26th Annual Healthcare Conference
2015-11-19,Catabasis And ActiGraph Collaborate On An Observational Trial To Explore The Benefits Of Daily Physiological Activity Monitoring In Patients With Duchenne Muscular Dystrophy
2015-11-12,Catabasis Pharmaceuticals Reports Third Quarter 2015 Financial Results And Recent Corporate Highlights
2015-10-27,Catabasis Pharmaceuticals Will Present CAT-1004, A Potential Disease-Modifying Agent In Development For The Treatment Of Duchenne Muscular Dystrophy, At The Action Duchenne International Conference
2015-10-26,Catabasis Pharmaceuticals To Report Third Quarter 2015 Financial Results And Recent Corporate Developments On Thursday, November 12
2015-10-26,European Commission Grants Orphan Medicinal Product Designation For CAT-1004, Catabasis Pharmaceuticals' Investigational Therapy For The Treatment Of Duchenne Muscular Dystrophy
2015-09-25,Catabasis Pharmaceuticals Will Present CAT-1004, A Potential Disease-Modifying Agent In Development For The Treatment Of Duchenne Muscular Dystrophy, At The World Muscle Society Congress
2015-09-14,Catabasis Pharmaceuticals Receives Rare Pediatric Disease Designation From FDA For CAT-1004 For The Potential Treatment Of Duchenne Muscular Dystrophy
2015-09-02,Catabasis Pharmaceuticals To Participate In The Citi 10th Annual Biotech Conference And Present At The NewsMakers In The Biotech Industry Conference
2015-08-13,Catabasis Pharmaceuticals Reports Second Quarter 2015 Financial Results And Recent Corporate Highlights
2015-08-13,Catabasis Pharmaceuticals Announces Positive Top-line Phase 1 Data For Hypercholesterolemia Product Candidate CAT-2054
2015-08-11,Catabasis Pharmaceuticals To Present At The American Chemical Society National Conference
2015-08-04,Catabasis Pharmaceuticals To Present At The Wedbush PacGrow Healthcare Conference
2015-07-28,Catabasis Pharmaceuticals Will Present The CAT-2000 Program Of SREBP Modulators For Hyperlipidemias At The Kern Lipid Conference
2015-07-27,Catabasis Pharmaceuticals And UT Southwestern Medical Center Enter Into A Sponsored Research Agreement For CAT-2000 Series In Serious Lipid Disorders
2015-07-06,Catabasis Pharmaceuticals Receives FDA Fast Track Designation For CAT-1004 For The Treatment Of Duchenne Muscular Dystrophy
2015-06-30,Catabasis Pharmaceuticals Announces Closing Of Initial Public Offering
2015-06-25,Catabasis Pharmaceuticals Announces Pricing Of Initial Public Offering
,
,
,
2017-03-22,ChemoCentryx Receives FDA Orphan Drug Designation For Avacopan In The Treatment Of Debilitating Kidney Disease C3 Glomerulopathy (C3G)
2017-03-14,ChemoCentryx Reports Fourth Quarter And Full Year 2016 Financial Results
2017-03-10,Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix
2017-03-01,ChemoCentryx To Hold Fourth Quarter 2016 Financial Results Conference Call On Tuesday, March 14, 2017
2017-02-28,ChemoCentryx To Present At The Cowen And Company 37th Annual Health Care Conference
2017-02-14,Vifor Pharma And ChemoCentryx Announce Expansion Of Avacopan Agreement For Rare Renal Diseases
2017-01-20,ChemoCentryx Announces Presentation Of Data From Ongoing Phase Ib Clinical Trial Of CCR2 Inhibitor CCX872 In Patients With Advanced Non-Resectable Pancreatic Cancer
2017-01-09,ChemoCentryx Provides Corporate Update Including Development Strategy For Lead Programs In Rare Renal Diseases
2017-01-04,ChemoCentryx To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-22,Vifor Pharma And ChemoCentryx Announce Expansion Of Kidney Health Alliance To Include CCX140 To Treat Renal Diseases
2016-11-07,ChemoCentryx Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-11-07,ChemoCentryx Announces Presentations Of Positive Results From Phase II ANCA-Associated Vasculitis Trials ('CLEAR' And 'CLASSIC') Of Orally Administered Complement 5a Receptor Inhibitor CCX168 ('Avacopan')
2016-10-28,ChemoCentryx To Hold Third Quarter 2016 Financial Results Conference Call On Monday, November 7, 2016
2016-10-20,ChemoCentryx Appoints Henry A. McKinnell, Jr. To Board Of Directors
2016-10-18,ChemoCentryx's CCR2 Inhibitor CCX872 Shown To Reduce Liver Fibrosis In NASH Models
2016-10-17,ChemoCentryx Announces Presentation Of Positive Data From Ongoing Pilot Phase II Trial Of CCX168 (Avacopan) In Atypical Hemolytic Uremic Syndrome (aHUS) At ASN Kidney Week 2016
2016-09-01,ChemoCentryx Reports Initial Results From Ongoing Phase Ib Clinical Trial Of CCX872 In Patients With Advanced Pancreatic Cancer
2016-08-25,ChemoCentryx To Present At The Baird 2016 Global Healthcare Conference
2016-08-08,ChemoCentryx Reports Second Quarter 2016 Financial Results And Provides Corporate Update
2016-08-01,ChemoCentryx To Hold Second Quarter 2016 Financial Results Conference Call On Monday, August 8, 2016
2016-06-29,ChemoCentryx To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference
2016-06-22,First Week of CCXI February 2017 Options Trading
2016-06-16,ChemoCentryx Announces Positive Top-Line Results For CCX168 From The Phase II ANCA-Associated Vasculitis CLASSIC Study And Advances Plans To Initiate Phase III Development
2016-06-01,ChemoCentryx Receives European Medicines Agency PRIority MEdicines (PRIME) Designation For Accelerated Assessment Of Complement 5a Receptor Inhibitor CCX168 For Treatment Of Patients With ANCA-Associated Vasculitis
2016-05-25,ChemoCentryx To Present At The Jefferies 2016 Healthcare Conference
2016-05-23,ChemoCentryx Announces Presentation Of Positive Results From Phase II ANCA-Associated Vasculitis CLEAR Trial Of Orally Administered Complement 5a Receptor Inhibitor CCX168 At The 53rd ERA-EDTA Congress
2016-05-12,5 Breakout Stocks Under $10 Set to Soar
2016-05-12,ChemoCentryx Announces Data Presentation Of Novel CCR6 Inhibitors At The 2016 Society For Investigative Dermatology (SID) Annual Meeting
2016-05-11,ChemoCentryx To Host R&D Day On May 18, 2016
2016-05-10,ChemoCentryx Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-05-10,Vifor Pharma Licenses Rights To Commercialize ChemoCentryx's Orally-Administered Complement 5aR Inhibitor CCX168 For Orphan And Rare Renal Diseases In Europe And Certain Other Major Markets
2016-05-05,ChemoCentryx To Hold First Quarter 2016 Financial Results Conference Call On Tuesday, May 10, 2016
2016-04-28,ChemoCentryx Receives FDA Orphan Products Development Grant For Orally Administered Complement 5a Receptor Inhibitor CCX168 For Treatment Of ANCA-Associated Vasculitis
2016-04-18,ChemoCentryx Announces Immuno-Oncology Data Presentation At The American Association For Cancer Research (AACR) Annual Meeting
2016-04-01,5 Stocks Poised for Big Breakouts
2016-03-14,ChemoCentryx Reports Fourth Quarter 2015 Financial Results And Provides Corporate Update
2016-02-29,ChemoCentryx To Hold Fourth Quarter 2015 Financial Results Conference Call On Monday, March 14, 2016
2016-02-25,ChemoCentryx To Present At The Cowen And Company 36th Annual Healthcare Conference
2016-01-07,ChemoCentryx To Present At The 34th Annual J.P. Morgan Healthcare Conference
2016-01-06,ChemoCentryx is Now Oversold (CCXI)
2016-01-06,ChemoCentryx Announces Positive Results In Phase II ANCA-Associated Vasculitis CLEAR Trial Of Orally Administered Complement 5a Receptor Inhibitor CCX168
2015-11-12,ChemoCentryx To Present At Two Upcoming Investor Conferences
2015-11-09,ChemoCentryx Reports Third Quarter 2015 Financial Results And Provides Corporate Update
2015-11-05,ChemoCentryx Highlights Results In Diabetic Nephropathy And Atypical Hemolytic Uremic Syndrome At The American Society Of Nephrology Annual Meeting
2015-11-04,ChemoCentryx Announces Immuno-Oncology Data Presentations At The AACR-NCI-EORTC Molecular Targets And Cancer Therapeutics Meeting
2015-10-29,ChemoCentryx To Hold Third Quarter 2015 Financial Results Conference Call On Monday, November 9, 2015
2015-09-02,ChemoCentryx To Present At The Rodman & Renshaw 17th Annual Global Investment Conference
2015-08-06,ChemoCentryx Reports Second Quarter 2015 Financial Results And Provides Corporate Update
2015-08-06,Oversold Conditions For ChemoCentryx (CCXI)
2015-07-30,ChemoCentryx Announces Changes To Its Board Of Directors
2015-07-29,ChemoCentryx To Hold Second Quarter 2015 Financial Results Conference Call On Thursday, August 6, 2015
2015-05-29,Positive Results From ChemoCentryx Phase II Diabetic Nephropathy Trial With Chemokine Receptor CCR2 Inhibitor CCX140 Highlighted At The 52nd ERA-EDTA Congress
2015-05-26,Positive Clinical Data From ChemoCentryx Phase II Trial In Diabetic Nephropathy To Be Presented At The 52nd Annual ERA-EDTA Congress
2015-05-12,ChemoCentryx To Present At Two Upcoming Investor Conferences
2015-05-06,ChemoCentryx Reports First Quarter 2015 Financial Results And Provides Corporate Update
2015-04-29,Relative Strength Alert For ChemoCentryx
2015-04-22,ChemoCentryx To Hold First Quarter 2015 Financial Results Conference Call On Wednesday, May 6, 2015
2015-04-20,ChemoCentryx Initiates Clinical Trial Of CCX872, Its Next-Generation, Orally Administered CCR2 Inhibitor, In Pancreatic Cancer
2015-03-12,ChemoCentryx Reports Fourth Quarter 2014 Financial Results And Provides Corporate Update
2015-02-26,ChemoCentryx To Hold Fourth Quarter 2014 Financial Results Conference Call On Thursday, March 12, 2015
2015-02-17,ChemoCentryx To Present At The Cowen And Company 35th Annual Health Care Conference
2015-01-26,First Week Of CCXI August 21st Options Trading
2015-01-16,Commit To Buy ChemoCentryx At $5, Earn 26.9% Annualized Using Options
2015-01-06,ChemoCentryx To Present At The 33rd Annual J.P. Morgan Healthcare Conference
2014-12-12,ChemoCentryx Announces Positive Results In Phase II Diabetic Nephropathy Trial With CCR2 Inhibitor CCX140
2014-12-11,ChemoCentryx To Host Conference Call On Friday, December 12, 2014 To Discuss Top-Line Phase II Results In Patients With Diabetic Nephropathy With CCX140, An Orally Administered CCR2 Inhibitor
2014-12-04,Relative Strength Alert For ChemoCentryx
2014-12-04,ChemoCentryx Granted EU Orphan Drug Designation For CCX168, An Orally Administered Complement C5a Receptor Inhibitor, For The Treatment Of Microscopic Polyangiitis And Granulomatosis With Polyangiitis, Two Forms Of ANCA-Associated Vasculitis
2014-11-20,ChemoCentryx's CCX168, An Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation In Atypical Hemolytic Uremic Syndrome Treatment By The FDA
2014-11-17,ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit In Non-Renal ANCA Vasculitis Disease Activity, In Addition To Previously Shown Kidney Disease Improvements
2014-11-06,ChemoCentryx To Present At Two Upcoming Investor Conferences
2014-11-05,ChemoCentryx Reports Third Quarter 2014 Financial Results And Provides Corporate Update
2014-10-22,ChemoCentryx To Hold Third Quarter 2014 Financial Results Conference Call On Wednesday, November 5, 2014
2014-10-21,ChemoCentryx's Orally Administered CCR9 Inhibitor, CCX507, Shown To Be Well Tolerated And Effective In CCR9 Blockade In Phase I Study
2014-10-20,ChemoCentryx Releases Phase III SHIELD 4 Clinical Results In Patients With Crohn's Disease
2014-10-02,ChemoCentryx Becomes Oversold (CCXI)
2014-09-22,ChemoCentryx Appoints Israel F. Charo, M.D., Ph.D., Senior Vice President Of Research
2014-08-05,ChemoCentryx Announces Financial Results For The Second Quarter Ended June 30, 2014
2014-07-23,ChemoCentryx To Hold Second Quarter 2014 Financial Results Conference Call On Tuesday, August 5, 2014
2014-06-03,ChemoCentryx's CCX168, An Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation In ANCA-Associated Diseases By The FDA
2014-06-02,ChemoCentryx's Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit In ANCA-Associated Vasculitis Based On Birmingham Vasculitis Activity Score And Renal Disease Measurements
2014-05-08,ChemoCentryx Announces Financial Results For The First Quarter Ended March 31, 2014
2014-05-02,3 Stocks Under $10 Moving Higher
2014-04-29,ChemoCentryx To Hold First Quarter 2014 Financial Results Conference Call On Thursday, May 8, 2014
2014-04-15,ChemoCentryx is Now Oversold (CCXI)
2014-03-27,ChemoCentryx Appoints Anne-Marie S. Duliege, M.D., M.S. To Chief Strategic Development Role And Head Of Immuno-Oncology
2014-03-13,ChemoCentryx Announces Financial Results For The Quarter And Year Ended December 31, 2013
2014-03-03,ChemoCentryx To Hold Fourth Quarter And Year-End 2013 Financial Results Conference Call On Thursday, March 13, 2014
2014-02-27,Short Interest In ChemoCentryx Makes 16% Move
2014-02-25,ChemoCentryx To Present At The Cowen And Company 34th Annual Health Care Conference
2014-02-21,5 Stocks Poised for Breakouts
2014-01-13,ChemoCentryx Stock Sees Short Interest Move 38.4% Lower
2014-01-10,5 Under-$10 Biotech Stocks to Watch
2014-01-08,ChemoCentryx To Present At The 32nd Annual J.P. Morgan Healthcare Conference
2014-01-02,Interesting CCXI Put And Call Options For August 16th
2013-12-03,ChemoCentryx Announces Positive Top-Line CCX168 Phase II Data In ANCA-Associated Renal Vasculitis
2013-11-25,5 Stocks Poised for Breakouts
2013-11-15,4 Stocks Under $10 to Trade for Breakouts
2013-11-12,Oversold Conditions For ChemoCentryx (CCXI)
2013-11-07,ChemoCentryx Announces Financial Results For The Quarter Ended September 30, 2013
2013-11-07,Top Insider Trades: PBYI USAK RT CCXI
2013-11-06,ChemoCentryx To Present At The 2013 Credit Suisse Annual Health Care Conference
2013-11-04,Top Insider Trades: ACHN, CCXI, ACCL, WLT
2013-10-31,ChemoCentryx, Inc. To Hold Third Quarter 2013 Financial Results Conference Call On Thursday, November 7, 2013
2013-10-18,ChemoCentryx Becomes Oversold (CCXI)
2013-10-16,5 Stocks With Big Insider Buying
2013-10-11,Short Interest In ChemoCentryx Moves 91.5% Higher
2013-10-11,Top Insider Trades: CCXI HA USCR ACW
2013-10-09,5 Stocks Insiders Are Scooping Up
2013-10-08,Top Insider Trades: CCXI AYR FATE CFIS
2013-09-23,ChemoCentryx To Present At BioCentury's NewsMakers In The Biotech Industry Conference
2013-09-18,ChemoCentryx To Regain Global Rights For Vercirnon From GlaxoSmithKline
2013-09-18,4 Biotech Stocks Under $10 to Watch
2013-09-17,Ratings Changes Today
2013-09-16,Top Insider Trades: CCXI, GBDC, MVC, FUND
2013-09-10,ChemoCentryx Falls on Weak Diabetic Nephropathy Drug Data
2013-09-10,ChemoCentryx Announces Top-Line Interim Results For CCX140, An Orally Administered CCR2 Inhibitor, In An Ongoing 52 Week Phase II Trial In Patients With Diabetic Nephropathy
2013-09-04,ChemoCentryx To Present At Two Upcoming Investor Conferences
2013-08-23,ChemoCentryx Announces GlaxoSmithKline's Release Of Top-Line Results From The SHIELD-1 Phase III Study Of Vercirnon
2013-08-12,ChemoCentryx Announces Financial Results For The Quarter Ended June 30, 2013
2013-08-09,ChemoCentryx Is Now Oversold (CCXI)
2013-08-01,ChemoCentryx, Inc. To Hold Second Quarter 2013 Financial Results Conference Call On Monday, August 12, 2013
2013-07-25,ChemoCentryx Stock Sees Short Interest Make 124.7% Move
2013-06-26,Commit To Buy ChemoCentryx At $12.50, Earn 24.8% Annualized
2013-06-19,ChemoCentryx Announces Completion Of Target Enrollment Of CCX140 Phase II Clinical Trial In Diabetic Nephropathy
2013-06-07,Biotech Stock Mailbag: 2013 Clinical Trials Calendar
2013-06-05,ChemoCentryx To Present At Two Upcoming Healthcare Conferences And Ring Opening Bell At The NASDAQ Stock Market
2013-05-28,ChemoCentryx Announces Appointment Of Health Care Insurance Executive Ira Klein, MD, To Company's Board Of Directors
2013-05-21,ChemoCentryx Announces Phase I Data With CCX507, Company's New Generation Orally Administered CCR9 Inhibitor
2013-05-15,ChemoCentryx To Host Analyst Day
2013-05-13,ChemoCentryx Announces Financial Results For The Quarter Ended March 31, 2013
2013-05-10,Short Interest In ChemoCentryx Plummets 66%
2013-05-02,ChemoCentryx, Inc. To Hold First Quarter 2013 Financial Results Conference Call On Monday, May 13, 2013
2013-05-02,ChemoCentryx To Present At Bank Of America Merrill Lynch Healthcare Conference
2013-04-22,ChemoCentryx Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Over-Allotment Option
2013-04-16,ChemoCentryx Announces Pricing Of Follow-On Offering
2013-04-15,ChemoCentryx Announces Proposed Public Offering Of Common Stock
2013-03-13,ChemoCentryx Announces 2012 Fourth Quarter And Year-End Financial Results
2013-02-28,ChemoCentryx, Inc. To Hold Fourth Quarter And Year-End 2012 Financial Results Conference Call On Wednesday, March 13, 2013
2013-02-20,ChemoCentryx To Present At Upcoming Investor Conferences
2013-02-06,ChemoCentryx To Present At 15th Annual BIO CEO & Investor Conference
2013-01-07,ChemoCentryx Advances A New Generation CCR9 Inhibitor, CCX507, Into Clinical Development
2013-01-03,ChemoCentryx To Present At The 31st Annual J.P. Morgan Healthcare Conference
2012-10-24,ChemoCentryx To Report Data For CCX140, An Orally Administered CCR2 Inhibitor, At The American Society Of Nephrology's Kidney Week 2012
2012-10-02,ChemoCentryx Reports Data For CCX872, The Company's Orally Bioavailable, Next-Generation CCR2 Inhibitor, In A Preclinical Model Of Diabetic Nephropathy
2012-08-30,ChemoCentryx To Present At The BioCentury NewsMakers In The Biotech Industry Conference
2012-08-10,ChemoCentryx Announces Financial Results For The Quarter Ended June 30, 2012
2012-04-12,ChemoCentryx To Present At The 19th Annual Future Leaders In The Biotech Industry Conference
,
2017-03-22,ChemoCentryx Receives FDA Orphan Drug Designation For Avacopan In The Treatment Of Debilitating Kidney Disease C3 Glomerulopathy (C3G)
2017-03-14,ChemoCentryx Reports Fourth Quarter And Full Year 2016 Financial Results
2017-03-10,Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix
2017-03-01,ChemoCentryx To Hold Fourth Quarter 2016 Financial Results Conference Call On Tuesday, March 14, 2017
2017-02-28,ChemoCentryx To Present At The Cowen And Company 37th Annual Health Care Conference
2017-02-14,Vifor Pharma And ChemoCentryx Announce Expansion Of Avacopan Agreement For Rare Renal Diseases
2017-01-20,ChemoCentryx Announces Presentation Of Data From Ongoing Phase Ib Clinical Trial Of CCR2 Inhibitor CCX872 In Patients With Advanced Non-Resectable Pancreatic Cancer
2017-01-09,ChemoCentryx Provides Corporate Update Including Development Strategy For Lead Programs In Rare Renal Diseases
2017-01-04,ChemoCentryx To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-22,Vifor Pharma And ChemoCentryx Announce Expansion Of Kidney Health Alliance To Include CCX140 To Treat Renal Diseases
2016-11-07,ChemoCentryx Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-11-07,ChemoCentryx Announces Presentations Of Positive Results From Phase II ANCA-Associated Vasculitis Trials ('CLEAR' And 'CLASSIC') Of Orally Administered Complement 5a Receptor Inhibitor CCX168 ('Avacopan')
2016-10-28,ChemoCentryx To Hold Third Quarter 2016 Financial Results Conference Call On Monday, November 7, 2016
2016-10-20,ChemoCentryx Appoints Henry A. McKinnell, Jr. To Board Of Directors
2016-10-18,ChemoCentryx's CCR2 Inhibitor CCX872 Shown To Reduce Liver Fibrosis In NASH Models
2016-10-17,ChemoCentryx Announces Presentation Of Positive Data From Ongoing Pilot Phase II Trial Of CCX168 (Avacopan) In Atypical Hemolytic Uremic Syndrome (aHUS) At ASN Kidney Week 2016
2016-09-01,ChemoCentryx Reports Initial Results From Ongoing Phase Ib Clinical Trial Of CCX872 In Patients With Advanced Pancreatic Cancer
2016-08-25,ChemoCentryx To Present At The Baird 2016 Global Healthcare Conference
2016-08-08,ChemoCentryx Reports Second Quarter 2016 Financial Results And Provides Corporate Update
2016-08-01,ChemoCentryx To Hold Second Quarter 2016 Financial Results Conference Call On Monday, August 8, 2016
2016-06-29,ChemoCentryx To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference
2016-06-22,First Week of CCXI February 2017 Options Trading
2016-06-16,ChemoCentryx Announces Positive Top-Line Results For CCX168 From The Phase II ANCA-Associated Vasculitis CLASSIC Study And Advances Plans To Initiate Phase III Development
2016-06-01,ChemoCentryx Receives European Medicines Agency PRIority MEdicines (PRIME) Designation For Accelerated Assessment Of Complement 5a Receptor Inhibitor CCX168 For Treatment Of Patients With ANCA-Associated Vasculitis
2016-05-25,ChemoCentryx To Present At The Jefferies 2016 Healthcare Conference
2016-05-23,ChemoCentryx Announces Presentation Of Positive Results From Phase II ANCA-Associated Vasculitis CLEAR Trial Of Orally Administered Complement 5a Receptor Inhibitor CCX168 At The 53rd ERA-EDTA Congress
2016-05-12,5 Breakout Stocks Under $10 Set to Soar
2016-05-12,ChemoCentryx Announces Data Presentation Of Novel CCR6 Inhibitors At The 2016 Society For Investigative Dermatology (SID) Annual Meeting
2016-05-11,ChemoCentryx To Host R&D Day On May 18, 2016
2016-05-10,ChemoCentryx Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-05-10,Vifor Pharma Licenses Rights To Commercialize ChemoCentryx's Orally-Administered Complement 5aR Inhibitor CCX168 For Orphan And Rare Renal Diseases In Europe And Certain Other Major Markets
2016-05-05,ChemoCentryx To Hold First Quarter 2016 Financial Results Conference Call On Tuesday, May 10, 2016
2016-04-28,ChemoCentryx Receives FDA Orphan Products Development Grant For Orally Administered Complement 5a Receptor Inhibitor CCX168 For Treatment Of ANCA-Associated Vasculitis
2016-04-18,ChemoCentryx Announces Immuno-Oncology Data Presentation At The American Association For Cancer Research (AACR) Annual Meeting
2016-04-01,5 Stocks Poised for Big Breakouts
2016-03-14,ChemoCentryx Reports Fourth Quarter 2015 Financial Results And Provides Corporate Update
2016-02-29,ChemoCentryx To Hold Fourth Quarter 2015 Financial Results Conference Call On Monday, March 14, 2016
2016-02-25,ChemoCentryx To Present At The Cowen And Company 36th Annual Healthcare Conference
2016-01-07,ChemoCentryx To Present At The 34th Annual J.P. Morgan Healthcare Conference
2016-01-06,ChemoCentryx is Now Oversold (CCXI)
2016-01-06,ChemoCentryx Announces Positive Results In Phase II ANCA-Associated Vasculitis CLEAR Trial Of Orally Administered Complement 5a Receptor Inhibitor CCX168
2015-11-12,ChemoCentryx To Present At Two Upcoming Investor Conferences
2015-11-09,ChemoCentryx Reports Third Quarter 2015 Financial Results And Provides Corporate Update
2015-11-05,ChemoCentryx Highlights Results In Diabetic Nephropathy And Atypical Hemolytic Uremic Syndrome At The American Society Of Nephrology Annual Meeting
2015-11-04,ChemoCentryx Announces Immuno-Oncology Data Presentations At The AACR-NCI-EORTC Molecular Targets And Cancer Therapeutics Meeting
2015-10-29,ChemoCentryx To Hold Third Quarter 2015 Financial Results Conference Call On Monday, November 9, 2015
2015-09-02,ChemoCentryx To Present At The Rodman & Renshaw 17th Annual Global Investment Conference
2015-08-06,ChemoCentryx Reports Second Quarter 2015 Financial Results And Provides Corporate Update
2015-08-06,Oversold Conditions For ChemoCentryx (CCXI)
2015-07-30,ChemoCentryx Announces Changes To Its Board Of Directors
2015-07-29,ChemoCentryx To Hold Second Quarter 2015 Financial Results Conference Call On Thursday, August 6, 2015
2015-05-29,Positive Results From ChemoCentryx Phase II Diabetic Nephropathy Trial With Chemokine Receptor CCR2 Inhibitor CCX140 Highlighted At The 52nd ERA-EDTA Congress
2015-05-26,Positive Clinical Data From ChemoCentryx Phase II Trial In Diabetic Nephropathy To Be Presented At The 52nd Annual ERA-EDTA Congress
2015-05-12,ChemoCentryx To Present At Two Upcoming Investor Conferences
2015-05-06,ChemoCentryx Reports First Quarter 2015 Financial Results And Provides Corporate Update
2015-04-29,Relative Strength Alert For ChemoCentryx
2015-04-22,ChemoCentryx To Hold First Quarter 2015 Financial Results Conference Call On Wednesday, May 6, 2015
2015-04-20,ChemoCentryx Initiates Clinical Trial Of CCX872, Its Next-Generation, Orally Administered CCR2 Inhibitor, In Pancreatic Cancer
2015-03-12,ChemoCentryx Reports Fourth Quarter 2014 Financial Results And Provides Corporate Update
2015-02-26,ChemoCentryx To Hold Fourth Quarter 2014 Financial Results Conference Call On Thursday, March 12, 2015
2015-02-17,ChemoCentryx To Present At The Cowen And Company 35th Annual Health Care Conference
2015-01-26,First Week Of CCXI August 21st Options Trading
2015-01-16,Commit To Buy ChemoCentryx At $5, Earn 26.9% Annualized Using Options
2015-01-06,ChemoCentryx To Present At The 33rd Annual J.P. Morgan Healthcare Conference
2014-12-12,ChemoCentryx Announces Positive Results In Phase II Diabetic Nephropathy Trial With CCR2 Inhibitor CCX140
2014-12-11,ChemoCentryx To Host Conference Call On Friday, December 12, 2014 To Discuss Top-Line Phase II Results In Patients With Diabetic Nephropathy With CCX140, An Orally Administered CCR2 Inhibitor
2014-12-04,Relative Strength Alert For ChemoCentryx
2014-12-04,ChemoCentryx Granted EU Orphan Drug Designation For CCX168, An Orally Administered Complement C5a Receptor Inhibitor, For The Treatment Of Microscopic Polyangiitis And Granulomatosis With Polyangiitis, Two Forms Of ANCA-Associated Vasculitis
2014-11-20,ChemoCentryx's CCX168, An Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation In Atypical Hemolytic Uremic Syndrome Treatment By The FDA
2014-11-17,ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit In Non-Renal ANCA Vasculitis Disease Activity, In Addition To Previously Shown Kidney Disease Improvements
2014-11-06,ChemoCentryx To Present At Two Upcoming Investor Conferences
2014-11-05,ChemoCentryx Reports Third Quarter 2014 Financial Results And Provides Corporate Update
2014-10-22,ChemoCentryx To Hold Third Quarter 2014 Financial Results Conference Call On Wednesday, November 5, 2014
2014-10-21,ChemoCentryx's Orally Administered CCR9 Inhibitor, CCX507, Shown To Be Well Tolerated And Effective In CCR9 Blockade In Phase I Study
2014-10-20,ChemoCentryx Releases Phase III SHIELD 4 Clinical Results In Patients With Crohn's Disease
2014-10-02,ChemoCentryx Becomes Oversold (CCXI)
2014-09-22,ChemoCentryx Appoints Israel F. Charo, M.D., Ph.D., Senior Vice President Of Research
2014-08-05,ChemoCentryx Announces Financial Results For The Second Quarter Ended June 30, 2014
2014-07-23,ChemoCentryx To Hold Second Quarter 2014 Financial Results Conference Call On Tuesday, August 5, 2014
2014-06-03,ChemoCentryx's CCX168, An Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation In ANCA-Associated Diseases By The FDA
2014-06-02,ChemoCentryx's Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit In ANCA-Associated Vasculitis Based On Birmingham Vasculitis Activity Score And Renal Disease Measurements
2014-05-08,ChemoCentryx Announces Financial Results For The First Quarter Ended March 31, 2014
2014-05-02,3 Stocks Under $10 Moving Higher
2014-04-29,ChemoCentryx To Hold First Quarter 2014 Financial Results Conference Call On Thursday, May 8, 2014
2014-04-15,ChemoCentryx is Now Oversold (CCXI)
2014-03-27,ChemoCentryx Appoints Anne-Marie S. Duliege, M.D., M.S. To Chief Strategic Development Role And Head Of Immuno-Oncology
2014-03-13,ChemoCentryx Announces Financial Results For The Quarter And Year Ended December 31, 2013
2014-03-03,ChemoCentryx To Hold Fourth Quarter And Year-End 2013 Financial Results Conference Call On Thursday, March 13, 2014
2014-02-27,Short Interest In ChemoCentryx Makes 16% Move
2014-02-25,ChemoCentryx To Present At The Cowen And Company 34th Annual Health Care Conference
2014-02-21,5 Stocks Poised for Breakouts
2014-01-13,ChemoCentryx Stock Sees Short Interest Move 38.4% Lower
2014-01-10,5 Under-$10 Biotech Stocks to Watch
2014-01-08,ChemoCentryx To Present At The 32nd Annual J.P. Morgan Healthcare Conference
2014-01-02,Interesting CCXI Put And Call Options For August 16th
2013-12-03,ChemoCentryx Announces Positive Top-Line CCX168 Phase II Data In ANCA-Associated Renal Vasculitis
2013-11-25,5 Stocks Poised for Breakouts
2013-11-15,4 Stocks Under $10 to Trade for Breakouts
2013-11-12,Oversold Conditions For ChemoCentryx (CCXI)
2013-11-07,ChemoCentryx Announces Financial Results For The Quarter Ended September 30, 2013
2013-11-07,Top Insider Trades: PBYI USAK RT CCXI
2013-11-06,ChemoCentryx To Present At The 2013 Credit Suisse Annual Health Care Conference
2013-11-04,Top Insider Trades: ACHN, CCXI, ACCL, WLT
2013-10-31,ChemoCentryx, Inc. To Hold Third Quarter 2013 Financial Results Conference Call On Thursday, November 7, 2013
2013-10-18,ChemoCentryx Becomes Oversold (CCXI)
2013-10-16,5 Stocks With Big Insider Buying
2013-10-11,Short Interest In ChemoCentryx Moves 91.5% Higher
2013-10-11,Top Insider Trades: CCXI HA USCR ACW
2013-10-09,5 Stocks Insiders Are Scooping Up
2013-10-08,Top Insider Trades: CCXI AYR FATE CFIS
2013-09-23,ChemoCentryx To Present At BioCentury's NewsMakers In The Biotech Industry Conference
2013-09-18,ChemoCentryx To Regain Global Rights For Vercirnon From GlaxoSmithKline
2013-09-18,4 Biotech Stocks Under $10 to Watch
2013-09-17,Ratings Changes Today
2013-09-16,Top Insider Trades: CCXI, GBDC, MVC, FUND
2013-09-10,ChemoCentryx Falls on Weak Diabetic Nephropathy Drug Data
2013-09-10,ChemoCentryx Announces Top-Line Interim Results For CCX140, An Orally Administered CCR2 Inhibitor, In An Ongoing 52 Week Phase II Trial In Patients With Diabetic Nephropathy
2013-09-04,ChemoCentryx To Present At Two Upcoming Investor Conferences
2013-08-23,ChemoCentryx Announces GlaxoSmithKline's Release Of Top-Line Results From The SHIELD-1 Phase III Study Of Vercirnon
2013-08-12,ChemoCentryx Announces Financial Results For The Quarter Ended June 30, 2013
2013-08-09,ChemoCentryx Is Now Oversold (CCXI)
2013-08-01,ChemoCentryx, Inc. To Hold Second Quarter 2013 Financial Results Conference Call On Monday, August 12, 2013
2013-07-25,ChemoCentryx Stock Sees Short Interest Make 124.7% Move
2013-06-26,Commit To Buy ChemoCentryx At $12.50, Earn 24.8% Annualized
2013-06-19,ChemoCentryx Announces Completion Of Target Enrollment Of CCX140 Phase II Clinical Trial In Diabetic Nephropathy
2013-06-07,Biotech Stock Mailbag: 2013 Clinical Trials Calendar
2013-06-05,ChemoCentryx To Present At Two Upcoming Healthcare Conferences And Ring Opening Bell At The NASDAQ Stock Market
2013-05-28,ChemoCentryx Announces Appointment Of Health Care Insurance Executive Ira Klein, MD, To Company's Board Of Directors
2013-05-21,ChemoCentryx Announces Phase I Data With CCX507, Company's New Generation Orally Administered CCR9 Inhibitor
2013-05-15,ChemoCentryx To Host Analyst Day
2013-05-13,ChemoCentryx Announces Financial Results For The Quarter Ended March 31, 2013
2013-05-10,Short Interest In ChemoCentryx Plummets 66%
2013-05-02,ChemoCentryx, Inc. To Hold First Quarter 2013 Financial Results Conference Call On Monday, May 13, 2013
2013-05-02,ChemoCentryx To Present At Bank Of America Merrill Lynch Healthcare Conference
2013-04-22,ChemoCentryx Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Over-Allotment Option
2013-04-16,ChemoCentryx Announces Pricing Of Follow-On Offering
2013-04-15,ChemoCentryx Announces Proposed Public Offering Of Common Stock
2013-03-13,ChemoCentryx Announces 2012 Fourth Quarter And Year-End Financial Results
2013-02-28,ChemoCentryx, Inc. To Hold Fourth Quarter And Year-End 2012 Financial Results Conference Call On Wednesday, March 13, 2013
2013-02-20,ChemoCentryx To Present At Upcoming Investor Conferences
2013-02-06,ChemoCentryx To Present At 15th Annual BIO CEO & Investor Conference
2013-01-07,ChemoCentryx Advances A New Generation CCR9 Inhibitor, CCX507, Into Clinical Development
2013-01-03,ChemoCentryx To Present At The 31st Annual J.P. Morgan Healthcare Conference
2012-10-24,ChemoCentryx To Report Data For CCX140, An Orally Administered CCR2 Inhibitor, At The American Society Of Nephrology's Kidney Week 2012
2012-10-02,ChemoCentryx Reports Data For CCX872, The Company's Orally Bioavailable, Next-Generation CCR2 Inhibitor, In A Preclinical Model Of Diabetic Nephropathy
2012-08-30,ChemoCentryx To Present At The BioCentury NewsMakers In The Biotech Industry Conference
2012-08-10,ChemoCentryx Announces Financial Results For The Quarter Ended June 30, 2012
2012-04-12,ChemoCentryx To Present At The 19th Annual Future Leaders In The Biotech Industry Conference
,
2017-03-13,Biotech Premarket Movers: Cempra, Blueprint Medicines, Aralez
2017-03-13,Cempra Retains Morgan Stanley To Lead Review Of Strategic Business Options
2017-03-03,Cempra To Present At 29th Annual ROTH Conference
2017-02-28,Biotech Premarket Movers: Cempra, Novavax, Ionis
2017-02-28,Cempra Provides Corporate Update And Reports Fourth Quarter And Full Year 2016 Financial Results
2017-02-27,Biotech Premarket Movers: BioCryst, Sangamo, Cempra
2017-02-24,4 Biotech Stocks on the Move
2017-02-24,Biotech Movers: Cempra Flys High On Phase Three Results
2017-02-24,Cempra's Fusidic Acid Achieves Primary Endpoint In Phase 3 Study Of ABSSSI
2017-02-14,Cempra To Report Fourth Quarter And Full Year 2016 Financial Results
2017-02-09,Acorda, Amgen and Regeneron Lead Premarket Biotech Movers
2017-02-08,CORRECTING And REPLACING -- Cempra To Present At Upcoming Investor Conferences
2017-02-08,Cempra To Present At Upcoming Investor Conferences
2017-01-04,Cempra To Present At J.P. Morgan Healthcare Conference
2017-01-03,INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Cempra, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 3, 2017
2016-12-30,GPM Reminds Investors Of The January 3 Deadline In The Class Action Lawsuit Against Cempra, Inc.
2016-12-29,Wall Street Falls Again as Financial Stocks Lead the Decline
2016-12-29,Wall Street Slumps As Financial Stocks Lead the Decline
2016-12-29,Midday Report: Volatile Stocks Turn Negative; Cempra Plummets, Sears Soars
2016-12-29,Stocks Volatile After Trade Deficit Data; Oil Inventories Rise
2016-12-29,Cempra Receives Complete Response Letter From FDA For Solithromycin NDAs
2016-12-27,CEMP SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Shareholders Of Commencement Of A Class Action Involving Cempra, Inc. And A Lead Plaintiff Deadline Of January 3, 2017
2016-12-23,CEMP INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Shareholders Of Commencement Of A Class Action Involving Cempra, Inc. And A Lead Plaintiff Deadline Of January 3, 2017
2016-12-20,Interesting CEMP Put And Call Options For February 2017
2016-12-16,CEMP SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Shareholders Of A Class Action Involving Cempra, Inc. And A Lead Plaintiff Deadline Of January 3, 2017
2016-12-15,CEMP LOSS NOTICE: Rosen Law Firm Reminds Cempra, Inc. Investors Of Important Deadline In Class Action - CEMP
2016-12-14,CEMPRA INC. INVESTOR REMINDER: Hagens Berman Reminds Cempra Investors Of Lead Plaintiff Deadline
2016-12-12,Cempra Appoints Dr. David Zaccardelli As Acting Chief Executive Officer, Promotes Chief Commercial Officer David Moore To President
2016-12-07,DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Cempra, Inc. To Contact The Firm
2016-12-05,Toyama Chemical (a Subsidiary Of FUJIFILM Holdings Corporation) Begins Phase 3 Studies In Japan With Cempra's Solithromycin
2016-12-01,Lifshitz & Miller Law Firm Announces Investigation Of Adeptus Health Inc., Avid Technology, Inc., Cempra, Inc., Clovis Oncology, Inc., Impax Laboratories, Inc., Ligand Pharmaceuticals Incorporated, Pattern Energy Group Inc. And Kandi Technologies Group, Inc.
2016-11-30,Rosen Law Firm Reminds Cempra, Inc. Investors Of Important Deadline In Class Action - CEMP
2016-11-28,SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Cempra, Inc. To Contact The Firm Before Lead Plaintiff Deadline
2016-11-28,Short Interest Decreases By 21.6% For CEMP
2016-11-23,'Mad Money' Lightning Round: Jim Cramer Sees Steel Companies Shining
2016-11-22,Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Cempra, Inc.
2016-11-22,Jim Cramer's 'Mad Money' Recap: Expect More Earnings Surprises
2016-11-22,First Week of CEMP July 2017 Options Trading
2016-11-16,CEMPRA (CEMP) SHAREHOLDER ALERT: Johnson & Weaver, LLP Announces Filing Of Class Action Complaint Against Cempra, Inc.; Encourages All Investors To Contact The Firm For Information
2016-11-14,SHAREHOLDER ALERT: Securities Class Action Lawsuit Against Cempra Announced By Holzer & Holzer; Firm Investigating Expanded Class Period
2016-11-11,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Cempra, Inc. Of Class Action Lawsuit And Upcoming Deadline - CEMP
2016-11-11,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Cempra, Inc.
2016-11-09,Cempra To Present At Two Upcoming Investor Conferences
2016-11-08,IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Cempra, Inc. And Encourages Investors With Losses In Excess Of $250,000 To Contact The Firm
2016-11-08,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against Cempra Inc. (CEMP) And Lead Plaintiff Deadline - January 3, 2017
2016-11-08,IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Cempra, Inc. And Encourages Investors With Losses To Contact The Firm
2016-11-07,IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Cempra, Inc. And Encourages Investors With Losses In Excess Of $250,000 To Contact The Firm
2016-11-07,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Cempra, Inc. - CEMP
2016-11-07,Cempra Antibiotic Approval Still in Doubt Even With Positive FDA Panel Vote
2016-11-04,FDA Advisory Committee Votes That Efficacy Results Of Cempra's Solithromycin Outweigh Risks For Community-Acquired Bacterial Pneumonia
2016-11-04,Cempra Stock Trading Halted Today; FDA Advisory Committee To Discuss Solithromycin
2016-11-03,Cempra (CEMP) Stock Downgraded at JPMorgan on FDA Pneumonia Drug Review
2016-11-03,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Cempra, Inc. - CEMP
2016-11-03,IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Cempra, Inc. And Advises Investors With Losses To Contact The Firm
2016-11-03,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Cempra Inc. (CEMP)
2016-11-03,'Mad Money' Lightning Round: J.C. Penney Is 'A Lot Better,' Jim Cramer Says
2016-11-02,Jim Cramer's 'Mad Money' Recap: It's Chicago Versus Cleveland -- Stocks, That Is
2016-11-02,INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Cempra, Inc. And Advises Investors With Losses In Excess Of $200,000 To Contact The Firm
2016-11-02,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By Certain Officers And Directors Of Cempra, Inc.
2016-11-02,IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces An Investigation Of Cempra, Inc. And Encourages Investors With Losses To Contact The Firm
2016-11-02,SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into Cempra Inc. And Encourages Investors To Contact The Firm For Additional Information
2016-11-01,Cempra Receives $10 Million Milestone Payment From Toyama Chemical (a Subsidiary Of FUJIFILM Holdings Corporation) As Solithromycin Progresses To Phase 3 Studies In Japan
2016-10-31,Bullish and Bearish Reversals for the Week
2016-10-27,Cempra Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-10-25,Cempra To Report Third Quarter 2016 Financial Results
2016-10-04,Cempra Presents Analysis Showing Rates Of Failure For Existing CABP Antibiotics From Claims Database At Academy Of Managed Care Pharmacy Meeting
2016-09-29,Cempra Announces Anti-NASH Effects Of Solithromycin: Interim Results From Phase 2 Study
2016-09-16,Cempra Is Ready to Run
2016-09-14,These 5 Biotech Stocks Are Ready for a Volatility Break
2016-09-01,Cempra To Present At Three Upcoming Investor Conferences
2016-08-30,Cempra To Present Solithromycin At FDA Antimicrobial Drugs Advisory Committee Meeting On November 4, 2016
2016-08-25,Cempra's Pivotal Phase 3 SOLITAIRE-IV Study Of IV To Oral Solithromycin Published In Clinical Infectious Diseases
2016-08-23,Cempra Announces European Medicines Agency Validates MAA For Solithromycin For Treatment Of CABP
2016-08-11,Cempra Appoints Dr. David Zaccardelli To Board Of Directors
2016-08-08,Perilous Reversal Watch: Cempra (CEMP)
2016-08-01,Cempra Reports Second Quarter 2016 Financial Results And Provides Corporate Update
2016-08-01,Cempra (CEMP) Is Today's Strong On High Volume Stock
2016-08-01,Cempra Appoints John Bluth Executive Vice President, Investor Relations And Corporate Communications
2016-07-25,Cempra To Report Second Quarter 2016 Financial Results
2016-07-14,Antibiotic for Treatment of Superbugs Could Send Cempra Shares Soaring
2016-07-12,Cempra (CEMP) Is Today's Strong On High Volume Stock
2016-07-05,Cempra Announces FDA Acceptance Of Solithera™ New Drug Applications In The Treatment Of Community-Acquired Bacterial Pneumonia
2016-06-28,Cempra Submits Marketing Authorization Application To EMA For Solithromycin In The Treatment Of Community-Acquired Bacterial Pneumonia
2016-06-21,Commit To Purchase Cempra At $15, Earn 36.5% Annualized Using Options
2016-06-16,Cempra To Host Analyst And Investor Day On June 23, 2016
2016-06-13,Strong On High Volume: Cempra (CEMP)
2016-06-10,Cempra Announces Solithromycin Presentations At ASM Microbe 2016 Conference
2016-06-06,Today's Dead Cat Bounce Stock: Cempra (CEMP)
2016-06-03,Cempra (CEMP) Stock: Weak On High Volume Today
2016-06-02,Cempra To Present At The Jefferies 2016 Healthcare Conference
2016-05-25,Cempra Announces Successful Results In The Phase 2 Community Acquired Bacterial Pneumonia (CABP) Trial Conducted By Japanese Partner, Toyama Chemical (a Subsidiary Of FUJIFILM Holdings Corporation)
2016-05-12,Cempra To Present Solithromycin IV Data At ATS 2016
2016-05-10,Cempra (CEMP): Today's Weak On High Volume Stock
2016-05-02,Cempra (CEMP) Strong On High Relative Volume Today
2016-05-01,Cempra Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-05-01,Cempra Completes NDA Submissions For Solithromycin In The Treatment Of Community-Acquired Bacterial Pneumonia
2016-04-25,Cempra To Report First Quarter 2016 Financial Results
2016-04-11,Facebook, Ford and General Motors: Doug Kass' Views
2016-04-06,Cempra To Present At The Needham And Company 15th Annual Healthcare Conference
2016-04-04,Cempra To Present Data On Solithromycin At ECCMID
2016-03-23,First Week of May 20th Options Trading For Cempra (CEMP)
2016-03-16,Insiders Now Seeing Red With CEMP At New 52-Week Low
2016-03-08,Cempra To Participate In Nature's Webcast On Combating Antibiotic Resistance On March 9
2016-03-07,Cempra Authorized To Receive Funds From BARDA For A Phase 2/3 Clinical Trial Of Solithromycin In Pediatric Patients
2016-03-07,Tesla, Amazon and Netflix: Doug Kass' Views
2016-03-01,CEMP: Insiders vs. Shorts
2016-03-01,Weak On High Volume: Cempra (CEMP)
2016-02-29,Cempra To Present At The Cowen And Company 36th Annual Healthcare Conference
2016-02-25,Interesting CEMP Put And Call Options For October 21st
2016-02-24,Cempra Reports Fourth Quarter And Full Year 2015 Financial Results And Provides Corporate Update
2016-02-19,What Carl Icahn Is Doing; Biotech Breakout: Best of Kass
2016-02-17,Cempra To Report Fourth Quarter And Full Year 2015 Financial Results
2016-02-15,JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views
2016-02-05,The Lancet Infectious Diseases Publishes Positive Phase 3 Study Results For Cempra's Oral Solithromycin In Community-Acquired Bacterial Pneumonia
2016-02-03,Oversold Conditions For Cempra (CEMP)
2016-02-03,Cempra To Present At The Leerink Partners 5th Annual Global Healthcare Conference
2016-02-01,Cempra And Macrolide Pharmaceuticals Enter Synthetic Manufacturing Process Development Agreement For Solithromycin
2016-02-01,Biotech String: Assessing the January Damage, Gilead's Bottoming P/E, Sarepta Panel Date?
2016-01-29,Short Interest Moves 11.4% Lower For CEMP
2016-01-28,Spreading Zika Virus Is a Cause for Alarm, Says Cempra CEO
2016-01-28,Spreading Zika Virus Is a Cause for Alarm, Says Cempra CEO
2016-01-26,Cempra To Ring NASDAQ Closing Bell To Mark 10th Anniversary
2016-01-22,Interesting CEMP Put And Call Options For March 18th
2016-01-12,Cempra Completes Public Offering Of Common Stock
2016-01-07,Oversold Conditions For Cempra (CEMP)
2016-01-07,Heavy Trading On Cempra (CEMP) Before Market Open
2016-01-06,Cempra Prices Public Offering Of Common Stock
2016-01-06,Cempra To Present At J.P. Morgan Healthcare Conference
2016-01-05,Cempra Announces Proposed Public Offering Of $175 Million Of Common Stock
2016-01-05,Trade-Ideas: Cempra (CEMP) Is Today's "Dead Cat Bounce" Stock
2016-01-05,Cempra Doses Initial Patient In Phase 2 Clinical Trial Of Solithromycin In NASH
2015-12-29,2 Speculative Biotech Stocks for 2016
2015-12-22,Cempra Enters Into A CRADA With The NIAID And Expands The Phase 3 Solithromycin Clinical Trial In Urogenital Gonorrhea To Include Additional Female Patients And Adolescents
2015-12-09,Perilous Reversal Watch: Cempra (CEMP)
2015-12-08,Cempra Doses First Patient In Phase 3 Clinical Trial Of Taksta(TM) In Acute Bacterial Skin And Skin Structure Infections
2015-12-01,CEMP: Insiders vs. Shorts
2015-11-24,First Week of July 2016 Options Trading For Cempra (CEMP)
2015-11-24,Cempra (CEMP) Is Today's Perilous Reversal Stock
2015-11-11,Cempra To Present Anti-NASH Data For Solithromycin At The Liver Meeting(R) 2015
2015-11-10,Cempra To Present At Two Upcoming Investor Conferences
2015-11-02,Cempra (CEMP) Is Today's Dead Cat Bounce Stock
2015-10-30,Cempra’s New Drug Holds Potential, but Risk for Investors
2015-10-26,Cempra (CEMP) In A Perilous Reversal
2015-10-23,Cempra To Present Solithromycin Oral Data At CHEST 2015
2015-10-22,Cempra (CEMP): Today's Weak On High Volume Stock
2015-10-22,Cempra Reports Third Quarter 2015 Financial Results And Provides Corporate Update
2015-10-19,Cempra To Report Third Quarter 2015 Financial Results
2015-10-16,4 Big Stocks on Traders' Radars -- and What You Should Do With Them Now
2015-10-16,Heavy Trading On Cempra (CEMP) Before Market Open
2015-10-16,Cempra Announces Positive Topline Phase 3 Clinical Results For Intravenous Solithromycin In The Treatment Of Community-Acquired Bacterial Pneumonia
2015-10-14,Today's Dead Cat Bounce Stock: Cempra (CEMP)
2015-10-05,Cempra To Present Solithromycin Data At ID Week 2015
2015-09-24,Cempra To Present Solithromycin Data In COPD Patient Subgroup At European Respiratory Society International Congress
2015-09-22,Analysts Say Buy Select Biotech Stocks Ahead Of Clinton Drug Plan
2015-09-18,Strong On High Volume: Cempra (CEMP)
2015-09-18,FDA Grants Qualified Infectious Disease Product Designation To Taksta(TM) Cempra's Fusidic Acid Antibiotic
2015-09-16,CEMP Makes Notable Cross Below Critical Moving Average
2015-09-10,Cempra To Present Data From Antibiotic Drug Development Programs At ICAAC/ICC 2015 Meeting
2015-09-09,Trade-Ideas: Cempra (CEMP) Is Today's Weak On High Relative Volume Stock
2015-09-08,Cempra (CEMP) Flagged As Strong On High Volume
2015-09-03,Cempra To Present At Three Upcoming Investor Conferences
2015-08-20,Cempra (CEMP) In A Perilous Reversal
2015-08-19,FDA Grants Fast Track Designation To Cempra For Solithromycin In The Treatment Of Community Acquired Bacterial Pneumonia
2015-08-07,Today's Weak On High Volume Stock: Cempra (CEMP)
2015-08-04,Cempra To Present At The Wedbush PacGrow 2015 Healthcare Conference
2015-07-31,Cempra (CEMP) Is Today's Dead Cat Bounce Stock
2015-07-29,Cempra Reports Second Quarter 2015 Financial Results And Provides Corporate Update
2015-07-22,Cempra To Report Second Quarter 2015 Financial Results
2015-07-21,First Week Of CEMP September 18th Options Trading
2015-07-21,Stock To Watch: Cempra (CEMP) In Perilous Reversal
2015-07-17,New Lifetime High Reached: Cempra (CEMP)
2015-07-07,Cempra Completes Patient Enrollment Of Solitaire-IV Phase 3 Clinical Trial
2015-07-01,Cempra (CEMP) Is Today's Perilous Reversal Stock
2015-06-30,Cempra (CEMP) Showing Signs Of A Dead Cat Bounce Today
2015-06-24,Stock To Watch: Cempra (CEMP) In Perilous Reversal
2015-05-26,Cempra To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-19,First Week Of January 2016 Options Trading For Cempra (CEMP)
2015-05-19,Cempra Presenting Additional Data From The Phase 3 Oral Solithromycin Study In Community Acquired Bacterial Pneumonia At The American Thoracic Society Conference
2015-05-12,Cempra To Present Solithromycin Data At Two Upcoming Medical Conferences
2015-05-01,Trade-Ideas: Cempra (CEMP) Is Today's Strong On High Relative Volume Stock
2017-03-13,Biotech Premarket Movers: Cempra, Blueprint Medicines, Aralez
2017-03-13,Cempra Retains Morgan Stanley To Lead Review Of Strategic Business Options
2017-03-03,Cempra To Present At 29th Annual ROTH Conference
2017-02-28,Biotech Premarket Movers: Cempra, Novavax, Ionis
2017-02-28,Cempra Provides Corporate Update And Reports Fourth Quarter And Full Year 2016 Financial Results
2017-02-27,Biotech Premarket Movers: BioCryst, Sangamo, Cempra
2017-02-24,4 Biotech Stocks on the Move
2017-02-24,Biotech Movers: Cempra Flys High On Phase Three Results
2017-02-24,Cempra's Fusidic Acid Achieves Primary Endpoint In Phase 3 Study Of ABSSSI
2017-02-14,Cempra To Report Fourth Quarter And Full Year 2016 Financial Results
2017-02-09,Acorda, Amgen and Regeneron Lead Premarket Biotech Movers
2017-02-08,CORRECTING And REPLACING -- Cempra To Present At Upcoming Investor Conferences
2017-02-08,Cempra To Present At Upcoming Investor Conferences
2017-01-04,Cempra To Present At J.P. Morgan Healthcare Conference
2017-01-03,INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Cempra, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 3, 2017
2016-12-30,GPM Reminds Investors Of The January 3 Deadline In The Class Action Lawsuit Against Cempra, Inc.
2016-12-29,Wall Street Falls Again as Financial Stocks Lead the Decline
2016-12-29,Wall Street Slumps As Financial Stocks Lead the Decline
2016-12-29,Midday Report: Volatile Stocks Turn Negative; Cempra Plummets, Sears Soars
2016-12-29,Stocks Volatile After Trade Deficit Data; Oil Inventories Rise
2016-12-29,Cempra Receives Complete Response Letter From FDA For Solithromycin NDAs
2016-12-27,CEMP SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Shareholders Of Commencement Of A Class Action Involving Cempra, Inc. And A Lead Plaintiff Deadline Of January 3, 2017
2016-12-23,CEMP INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Shareholders Of Commencement Of A Class Action Involving Cempra, Inc. And A Lead Plaintiff Deadline Of January 3, 2017
2016-12-20,Interesting CEMP Put And Call Options For February 2017
2016-12-16,CEMP SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Shareholders Of A Class Action Involving Cempra, Inc. And A Lead Plaintiff Deadline Of January 3, 2017
2016-12-15,CEMP LOSS NOTICE: Rosen Law Firm Reminds Cempra, Inc. Investors Of Important Deadline In Class Action - CEMP
2016-12-14,CEMPRA INC. INVESTOR REMINDER: Hagens Berman Reminds Cempra Investors Of Lead Plaintiff Deadline
2016-12-12,Cempra Appoints Dr. David Zaccardelli As Acting Chief Executive Officer, Promotes Chief Commercial Officer David Moore To President
2016-12-07,DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Cempra, Inc. To Contact The Firm
2016-12-05,Toyama Chemical (a Subsidiary Of FUJIFILM Holdings Corporation) Begins Phase 3 Studies In Japan With Cempra's Solithromycin
2016-12-01,Lifshitz & Miller Law Firm Announces Investigation Of Adeptus Health Inc., Avid Technology, Inc., Cempra, Inc., Clovis Oncology, Inc., Impax Laboratories, Inc., Ligand Pharmaceuticals Incorporated, Pattern Energy Group Inc. And Kandi Technologies Group, Inc.
2016-11-30,Rosen Law Firm Reminds Cempra, Inc. Investors Of Important Deadline In Class Action - CEMP
2016-11-28,SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Cempra, Inc. To Contact The Firm Before Lead Plaintiff Deadline
2016-11-28,Short Interest Decreases By 21.6% For CEMP
2016-11-23,'Mad Money' Lightning Round: Jim Cramer Sees Steel Companies Shining
2016-11-22,Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Cempra, Inc.
2016-11-22,Jim Cramer's 'Mad Money' Recap: Expect More Earnings Surprises
2016-11-22,First Week of CEMP July 2017 Options Trading
2016-11-16,CEMPRA (CEMP) SHAREHOLDER ALERT: Johnson & Weaver, LLP Announces Filing Of Class Action Complaint Against Cempra, Inc.; Encourages All Investors To Contact The Firm For Information
2016-11-14,SHAREHOLDER ALERT: Securities Class Action Lawsuit Against Cempra Announced By Holzer & Holzer; Firm Investigating Expanded Class Period
2016-11-11,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Cempra, Inc. Of Class Action Lawsuit And Upcoming Deadline - CEMP
2016-11-11,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Cempra, Inc.
2016-11-09,Cempra To Present At Two Upcoming Investor Conferences
2016-11-08,IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Cempra, Inc. And Encourages Investors With Losses In Excess Of $250,000 To Contact The Firm
2016-11-08,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against Cempra Inc. (CEMP) And Lead Plaintiff Deadline - January 3, 2017
2016-11-08,IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Cempra, Inc. And Encourages Investors With Losses To Contact The Firm
2016-11-07,IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Cempra, Inc. And Encourages Investors With Losses In Excess Of $250,000 To Contact The Firm
2016-11-07,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Cempra, Inc. - CEMP
2016-11-07,Cempra Antibiotic Approval Still in Doubt Even With Positive FDA Panel Vote
2016-11-04,FDA Advisory Committee Votes That Efficacy Results Of Cempra's Solithromycin Outweigh Risks For Community-Acquired Bacterial Pneumonia
2016-11-04,Cempra Stock Trading Halted Today; FDA Advisory Committee To Discuss Solithromycin
2016-11-03,Cempra (CEMP) Stock Downgraded at JPMorgan on FDA Pneumonia Drug Review
2016-11-03,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Cempra, Inc. - CEMP
2016-11-03,IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Cempra, Inc. And Advises Investors With Losses To Contact The Firm
2016-11-03,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Cempra Inc. (CEMP)
2016-11-03,'Mad Money' Lightning Round: J.C. Penney Is 'A Lot Better,' Jim Cramer Says
2016-11-02,Jim Cramer's 'Mad Money' Recap: It's Chicago Versus Cleveland -- Stocks, That Is
2016-11-02,INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Cempra, Inc. And Advises Investors With Losses In Excess Of $200,000 To Contact The Firm
2016-11-02,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By Certain Officers And Directors Of Cempra, Inc.
2016-11-02,IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces An Investigation Of Cempra, Inc. And Encourages Investors With Losses To Contact The Firm
2016-11-02,SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into Cempra Inc. And Encourages Investors To Contact The Firm For Additional Information
2016-11-01,Cempra Receives $10 Million Milestone Payment From Toyama Chemical (a Subsidiary Of FUJIFILM Holdings Corporation) As Solithromycin Progresses To Phase 3 Studies In Japan
2016-10-31,Bullish and Bearish Reversals for the Week
2016-10-27,Cempra Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-10-25,Cempra To Report Third Quarter 2016 Financial Results
2016-10-04,Cempra Presents Analysis Showing Rates Of Failure For Existing CABP Antibiotics From Claims Database At Academy Of Managed Care Pharmacy Meeting
2016-09-29,Cempra Announces Anti-NASH Effects Of Solithromycin: Interim Results From Phase 2 Study
2016-09-16,Cempra Is Ready to Run
2016-09-14,These 5 Biotech Stocks Are Ready for a Volatility Break
2016-09-01,Cempra To Present At Three Upcoming Investor Conferences
2016-08-30,Cempra To Present Solithromycin At FDA Antimicrobial Drugs Advisory Committee Meeting On November 4, 2016
2016-08-25,Cempra's Pivotal Phase 3 SOLITAIRE-IV Study Of IV To Oral Solithromycin Published In Clinical Infectious Diseases
2016-08-23,Cempra Announces European Medicines Agency Validates MAA For Solithromycin For Treatment Of CABP
2016-08-11,Cempra Appoints Dr. David Zaccardelli To Board Of Directors
2016-08-08,Perilous Reversal Watch: Cempra (CEMP)
2016-08-01,Cempra Reports Second Quarter 2016 Financial Results And Provides Corporate Update
2016-08-01,Cempra (CEMP) Is Today's Strong On High Volume Stock
2016-08-01,Cempra Appoints John Bluth Executive Vice President, Investor Relations And Corporate Communications
2016-07-25,Cempra To Report Second Quarter 2016 Financial Results
2016-07-14,Antibiotic for Treatment of Superbugs Could Send Cempra Shares Soaring
2016-07-12,Cempra (CEMP) Is Today's Strong On High Volume Stock
2016-07-05,Cempra Announces FDA Acceptance Of Solithera™ New Drug Applications In The Treatment Of Community-Acquired Bacterial Pneumonia
2016-06-28,Cempra Submits Marketing Authorization Application To EMA For Solithromycin In The Treatment Of Community-Acquired Bacterial Pneumonia
2016-06-21,Commit To Purchase Cempra At $15, Earn 36.5% Annualized Using Options
2016-06-16,Cempra To Host Analyst And Investor Day On June 23, 2016
2016-06-13,Strong On High Volume: Cempra (CEMP)
2016-06-10,Cempra Announces Solithromycin Presentations At ASM Microbe 2016 Conference
2016-06-06,Today's Dead Cat Bounce Stock: Cempra (CEMP)
2016-06-03,Cempra (CEMP) Stock: Weak On High Volume Today
2016-06-02,Cempra To Present At The Jefferies 2016 Healthcare Conference
2016-05-25,Cempra Announces Successful Results In The Phase 2 Community Acquired Bacterial Pneumonia (CABP) Trial Conducted By Japanese Partner, Toyama Chemical (a Subsidiary Of FUJIFILM Holdings Corporation)
2016-05-12,Cempra To Present Solithromycin IV Data At ATS 2016
2016-05-10,Cempra (CEMP): Today's Weak On High Volume Stock
2016-05-02,Cempra (CEMP) Strong On High Relative Volume Today
2016-05-01,Cempra Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-05-01,Cempra Completes NDA Submissions For Solithromycin In The Treatment Of Community-Acquired Bacterial Pneumonia
2016-04-25,Cempra To Report First Quarter 2016 Financial Results
2016-04-11,Facebook, Ford and General Motors: Doug Kass' Views
2016-04-06,Cempra To Present At The Needham And Company 15th Annual Healthcare Conference
2016-04-04,Cempra To Present Data On Solithromycin At ECCMID
2016-03-23,First Week of May 20th Options Trading For Cempra (CEMP)
2016-03-16,Insiders Now Seeing Red With CEMP At New 52-Week Low
2016-03-08,Cempra To Participate In Nature's Webcast On Combating Antibiotic Resistance On March 9
2016-03-07,Cempra Authorized To Receive Funds From BARDA For A Phase 2/3 Clinical Trial Of Solithromycin In Pediatric Patients
2016-03-07,Tesla, Amazon and Netflix: Doug Kass' Views
2016-03-01,CEMP: Insiders vs. Shorts
2016-03-01,Weak On High Volume: Cempra (CEMP)
2016-02-29,Cempra To Present At The Cowen And Company 36th Annual Healthcare Conference
2016-02-25,Interesting CEMP Put And Call Options For October 21st
2016-02-24,Cempra Reports Fourth Quarter And Full Year 2015 Financial Results And Provides Corporate Update
2016-02-19,What Carl Icahn Is Doing; Biotech Breakout: Best of Kass
2016-02-17,Cempra To Report Fourth Quarter And Full Year 2015 Financial Results
2016-02-15,JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views
2016-02-05,The Lancet Infectious Diseases Publishes Positive Phase 3 Study Results For Cempra's Oral Solithromycin In Community-Acquired Bacterial Pneumonia
2016-02-03,Oversold Conditions For Cempra (CEMP)
2016-02-03,Cempra To Present At The Leerink Partners 5th Annual Global Healthcare Conference
2016-02-01,Cempra And Macrolide Pharmaceuticals Enter Synthetic Manufacturing Process Development Agreement For Solithromycin
2016-02-01,Biotech String: Assessing the January Damage, Gilead's Bottoming P/E, Sarepta Panel Date?
2016-01-29,Short Interest Moves 11.4% Lower For CEMP
2016-01-28,Spreading Zika Virus Is a Cause for Alarm, Says Cempra CEO
2016-01-28,Spreading Zika Virus Is a Cause for Alarm, Says Cempra CEO
2016-01-26,Cempra To Ring NASDAQ Closing Bell To Mark 10th Anniversary
2016-01-22,Interesting CEMP Put And Call Options For March 18th
2016-01-12,Cempra Completes Public Offering Of Common Stock
2016-01-07,Oversold Conditions For Cempra (CEMP)
2016-01-07,Heavy Trading On Cempra (CEMP) Before Market Open
2016-01-06,Cempra Prices Public Offering Of Common Stock
2016-01-06,Cempra To Present At J.P. Morgan Healthcare Conference
2016-01-05,Cempra Announces Proposed Public Offering Of $175 Million Of Common Stock
2016-01-05,Trade-Ideas: Cempra (CEMP) Is Today's "Dead Cat Bounce" Stock
2016-01-05,Cempra Doses Initial Patient In Phase 2 Clinical Trial Of Solithromycin In NASH
2015-12-29,2 Speculative Biotech Stocks for 2016
2015-12-22,Cempra Enters Into A CRADA With The NIAID And Expands The Phase 3 Solithromycin Clinical Trial In Urogenital Gonorrhea To Include Additional Female Patients And Adolescents
2015-12-09,Perilous Reversal Watch: Cempra (CEMP)
2015-12-08,Cempra Doses First Patient In Phase 3 Clinical Trial Of Taksta(TM) In Acute Bacterial Skin And Skin Structure Infections
2015-12-01,CEMP: Insiders vs. Shorts
2015-11-24,First Week of July 2016 Options Trading For Cempra (CEMP)
2015-11-24,Cempra (CEMP) Is Today's Perilous Reversal Stock
2015-11-11,Cempra To Present Anti-NASH Data For Solithromycin At The Liver Meeting(R) 2015
2015-11-10,Cempra To Present At Two Upcoming Investor Conferences
2015-11-02,Cempra (CEMP) Is Today's Dead Cat Bounce Stock
2015-10-30,Cempra’s New Drug Holds Potential, but Risk for Investors
2015-10-26,Cempra (CEMP) In A Perilous Reversal
2015-10-23,Cempra To Present Solithromycin Oral Data At CHEST 2015
2015-10-22,Cempra (CEMP): Today's Weak On High Volume Stock
2015-10-22,Cempra Reports Third Quarter 2015 Financial Results And Provides Corporate Update
2015-10-19,Cempra To Report Third Quarter 2015 Financial Results
2015-10-16,4 Big Stocks on Traders' Radars -- and What You Should Do With Them Now
2015-10-16,Heavy Trading On Cempra (CEMP) Before Market Open
2015-10-16,Cempra Announces Positive Topline Phase 3 Clinical Results For Intravenous Solithromycin In The Treatment Of Community-Acquired Bacterial Pneumonia
2015-10-14,Today's Dead Cat Bounce Stock: Cempra (CEMP)
2015-10-05,Cempra To Present Solithromycin Data At ID Week 2015
2015-09-24,Cempra To Present Solithromycin Data In COPD Patient Subgroup At European Respiratory Society International Congress
2015-09-22,Analysts Say Buy Select Biotech Stocks Ahead Of Clinton Drug Plan
2015-09-18,Strong On High Volume: Cempra (CEMP)
2015-09-18,FDA Grants Qualified Infectious Disease Product Designation To Taksta(TM) Cempra's Fusidic Acid Antibiotic
2015-09-16,CEMP Makes Notable Cross Below Critical Moving Average
2015-09-10,Cempra To Present Data From Antibiotic Drug Development Programs At ICAAC/ICC 2015 Meeting
2015-09-09,Trade-Ideas: Cempra (CEMP) Is Today's Weak On High Relative Volume Stock
2015-09-08,Cempra (CEMP) Flagged As Strong On High Volume
2015-09-03,Cempra To Present At Three Upcoming Investor Conferences
2015-08-20,Cempra (CEMP) In A Perilous Reversal
2015-08-19,FDA Grants Fast Track Designation To Cempra For Solithromycin In The Treatment Of Community Acquired Bacterial Pneumonia
2015-08-07,Today's Weak On High Volume Stock: Cempra (CEMP)
2015-08-04,Cempra To Present At The Wedbush PacGrow 2015 Healthcare Conference
2015-07-31,Cempra (CEMP) Is Today's Dead Cat Bounce Stock
2015-07-29,Cempra Reports Second Quarter 2015 Financial Results And Provides Corporate Update
2015-07-22,Cempra To Report Second Quarter 2015 Financial Results
2015-07-21,First Week Of CEMP September 18th Options Trading
2015-07-21,Stock To Watch: Cempra (CEMP) In Perilous Reversal
2015-07-17,New Lifetime High Reached: Cempra (CEMP)
2015-07-07,Cempra Completes Patient Enrollment Of Solitaire-IV Phase 3 Clinical Trial
2015-07-01,Cempra (CEMP) Is Today's Perilous Reversal Stock
2015-06-30,Cempra (CEMP) Showing Signs Of A Dead Cat Bounce Today
2015-06-24,Stock To Watch: Cempra (CEMP) In Perilous Reversal
2015-05-26,Cempra To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-19,First Week Of January 2016 Options Trading For Cempra (CEMP)
2015-05-19,Cempra Presenting Additional Data From The Phase 3 Oral Solithromycin Study In Community Acquired Bacterial Pneumonia At The American Thoracic Society Conference
2015-05-12,Cempra To Present Solithromycin Data At Two Upcoming Medical Conferences
2015-05-01,Trade-Ideas: Cempra (CEMP) Is Today's Strong On High Relative Volume Stock
2017-03-13,Biotech Premarket Movers: Cempra, Blueprint Medicines, Aralez
2017-03-13,Cempra Retains Morgan Stanley To Lead Review Of Strategic Business Options
2017-03-03,Cempra To Present At 29th Annual ROTH Conference
2017-02-28,Biotech Premarket Movers: Cempra, Novavax, Ionis
2017-02-28,Cempra Provides Corporate Update And Reports Fourth Quarter And Full Year 2016 Financial Results
2017-02-27,Biotech Premarket Movers: BioCryst, Sangamo, Cempra
2017-02-24,4 Biotech Stocks on the Move
2017-02-24,Biotech Movers: Cempra Flys High On Phase Three Results
2017-02-24,Cempra's Fusidic Acid Achieves Primary Endpoint In Phase 3 Study Of ABSSSI
2017-02-14,Cempra To Report Fourth Quarter And Full Year 2016 Financial Results
2017-02-09,Acorda, Amgen and Regeneron Lead Premarket Biotech Movers
2017-02-08,CORRECTING And REPLACING -- Cempra To Present At Upcoming Investor Conferences
2017-02-08,Cempra To Present At Upcoming Investor Conferences
2017-01-04,Cempra To Present At J.P. Morgan Healthcare Conference
2017-01-03,INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Cempra, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 3, 2017
2016-12-30,GPM Reminds Investors Of The January 3 Deadline In The Class Action Lawsuit Against Cempra, Inc.
2016-12-29,Wall Street Falls Again as Financial Stocks Lead the Decline
2016-12-29,Wall Street Slumps As Financial Stocks Lead the Decline
2016-12-29,Midday Report: Volatile Stocks Turn Negative; Cempra Plummets, Sears Soars
2016-12-29,Stocks Volatile After Trade Deficit Data; Oil Inventories Rise
2016-12-29,Cempra Receives Complete Response Letter From FDA For Solithromycin NDAs
2016-12-27,CEMP SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Shareholders Of Commencement Of A Class Action Involving Cempra, Inc. And A Lead Plaintiff Deadline Of January 3, 2017
2016-12-23,CEMP INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Shareholders Of Commencement Of A Class Action Involving Cempra, Inc. And A Lead Plaintiff Deadline Of January 3, 2017
2016-12-20,Interesting CEMP Put And Call Options For February 2017
2016-12-16,CEMP SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Shareholders Of A Class Action Involving Cempra, Inc. And A Lead Plaintiff Deadline Of January 3, 2017
2016-12-15,CEMP LOSS NOTICE: Rosen Law Firm Reminds Cempra, Inc. Investors Of Important Deadline In Class Action - CEMP
2016-12-14,CEMPRA INC. INVESTOR REMINDER: Hagens Berman Reminds Cempra Investors Of Lead Plaintiff Deadline
2016-12-12,Cempra Appoints Dr. David Zaccardelli As Acting Chief Executive Officer, Promotes Chief Commercial Officer David Moore To President
2016-12-07,DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Cempra, Inc. To Contact The Firm
2016-12-05,Toyama Chemical (a Subsidiary Of FUJIFILM Holdings Corporation) Begins Phase 3 Studies In Japan With Cempra's Solithromycin
2016-12-01,Lifshitz & Miller Law Firm Announces Investigation Of Adeptus Health Inc., Avid Technology, Inc., Cempra, Inc., Clovis Oncology, Inc., Impax Laboratories, Inc., Ligand Pharmaceuticals Incorporated, Pattern Energy Group Inc. And Kandi Technologies Group, Inc.
2016-11-30,Rosen Law Firm Reminds Cempra, Inc. Investors Of Important Deadline In Class Action - CEMP
2016-11-28,SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Cempra, Inc. To Contact The Firm Before Lead Plaintiff Deadline
2016-11-28,Short Interest Decreases By 21.6% For CEMP
2016-11-23,'Mad Money' Lightning Round: Jim Cramer Sees Steel Companies Shining
2016-11-22,Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Cempra, Inc.
2016-11-22,Jim Cramer's 'Mad Money' Recap: Expect More Earnings Surprises
2016-11-22,First Week of CEMP July 2017 Options Trading
2016-11-16,CEMPRA (CEMP) SHAREHOLDER ALERT: Johnson & Weaver, LLP Announces Filing Of Class Action Complaint Against Cempra, Inc.; Encourages All Investors To Contact The Firm For Information
2016-11-14,SHAREHOLDER ALERT: Securities Class Action Lawsuit Against Cempra Announced By Holzer & Holzer; Firm Investigating Expanded Class Period
2016-11-11,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Cempra, Inc. Of Class Action Lawsuit And Upcoming Deadline - CEMP
2016-11-11,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Cempra, Inc.
2016-11-09,Cempra To Present At Two Upcoming Investor Conferences
2016-11-08,IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Cempra, Inc. And Encourages Investors With Losses In Excess Of $250,000 To Contact The Firm
2016-11-08,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against Cempra Inc. (CEMP) And Lead Plaintiff Deadline - January 3, 2017
2016-11-08,IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Cempra, Inc. And Encourages Investors With Losses To Contact The Firm
2016-11-07,IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Cempra, Inc. And Encourages Investors With Losses In Excess Of $250,000 To Contact The Firm
2016-11-07,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Cempra, Inc. - CEMP
2016-11-07,Cempra Antibiotic Approval Still in Doubt Even With Positive FDA Panel Vote
2016-11-04,FDA Advisory Committee Votes That Efficacy Results Of Cempra's Solithromycin Outweigh Risks For Community-Acquired Bacterial Pneumonia
2016-11-04,Cempra Stock Trading Halted Today; FDA Advisory Committee To Discuss Solithromycin
2016-11-03,Cempra (CEMP) Stock Downgraded at JPMorgan on FDA Pneumonia Drug Review
2016-11-03,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Cempra, Inc. - CEMP
2016-11-03,IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Cempra, Inc. And Advises Investors With Losses To Contact The Firm
2016-11-03,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Cempra Inc. (CEMP)
2016-11-03,'Mad Money' Lightning Round: J.C. Penney Is 'A Lot Better,' Jim Cramer Says
2016-11-02,Jim Cramer's 'Mad Money' Recap: It's Chicago Versus Cleveland -- Stocks, That Is
2016-11-02,INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Cempra, Inc. And Advises Investors With Losses In Excess Of $200,000 To Contact The Firm
2016-11-02,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By Certain Officers And Directors Of Cempra, Inc.
2016-11-02,IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces An Investigation Of Cempra, Inc. And Encourages Investors With Losses To Contact The Firm
2016-11-02,SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into Cempra Inc. And Encourages Investors To Contact The Firm For Additional Information
2016-11-01,Cempra Receives $10 Million Milestone Payment From Toyama Chemical (a Subsidiary Of FUJIFILM Holdings Corporation) As Solithromycin Progresses To Phase 3 Studies In Japan
2016-10-31,Bullish and Bearish Reversals for the Week
2016-10-27,Cempra Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-10-25,Cempra To Report Third Quarter 2016 Financial Results
2016-10-04,Cempra Presents Analysis Showing Rates Of Failure For Existing CABP Antibiotics From Claims Database At Academy Of Managed Care Pharmacy Meeting
2016-09-29,Cempra Announces Anti-NASH Effects Of Solithromycin: Interim Results From Phase 2 Study
2016-09-16,Cempra Is Ready to Run
2016-09-14,These 5 Biotech Stocks Are Ready for a Volatility Break
2016-09-01,Cempra To Present At Three Upcoming Investor Conferences
2016-08-30,Cempra To Present Solithromycin At FDA Antimicrobial Drugs Advisory Committee Meeting On November 4, 2016
2016-08-25,Cempra's Pivotal Phase 3 SOLITAIRE-IV Study Of IV To Oral Solithromycin Published In Clinical Infectious Diseases
2016-08-23,Cempra Announces European Medicines Agency Validates MAA For Solithromycin For Treatment Of CABP
2016-08-11,Cempra Appoints Dr. David Zaccardelli To Board Of Directors
2016-08-08,Perilous Reversal Watch: Cempra (CEMP)
2016-08-01,Cempra Reports Second Quarter 2016 Financial Results And Provides Corporate Update
2016-08-01,Cempra (CEMP) Is Today's Strong On High Volume Stock
2016-08-01,Cempra Appoints John Bluth Executive Vice President, Investor Relations And Corporate Communications
2016-07-25,Cempra To Report Second Quarter 2016 Financial Results
2016-07-14,Antibiotic for Treatment of Superbugs Could Send Cempra Shares Soaring
2016-07-12,Cempra (CEMP) Is Today's Strong On High Volume Stock
2016-07-05,Cempra Announces FDA Acceptance Of Solithera™ New Drug Applications In The Treatment Of Community-Acquired Bacterial Pneumonia
2016-06-28,Cempra Submits Marketing Authorization Application To EMA For Solithromycin In The Treatment Of Community-Acquired Bacterial Pneumonia
2016-06-21,Commit To Purchase Cempra At $15, Earn 36.5% Annualized Using Options
2016-06-16,Cempra To Host Analyst And Investor Day On June 23, 2016
2016-06-13,Strong On High Volume: Cempra (CEMP)
2016-06-10,Cempra Announces Solithromycin Presentations At ASM Microbe 2016 Conference
2016-06-06,Today's Dead Cat Bounce Stock: Cempra (CEMP)
2016-06-03,Cempra (CEMP) Stock: Weak On High Volume Today
2016-06-02,Cempra To Present At The Jefferies 2016 Healthcare Conference
2016-05-25,Cempra Announces Successful Results In The Phase 2 Community Acquired Bacterial Pneumonia (CABP) Trial Conducted By Japanese Partner, Toyama Chemical (a Subsidiary Of FUJIFILM Holdings Corporation)
2016-05-12,Cempra To Present Solithromycin IV Data At ATS 2016
2016-05-10,Cempra (CEMP): Today's Weak On High Volume Stock
2016-05-02,Cempra (CEMP) Strong On High Relative Volume Today
2016-05-01,Cempra Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-05-01,Cempra Completes NDA Submissions For Solithromycin In The Treatment Of Community-Acquired Bacterial Pneumonia
2016-04-25,Cempra To Report First Quarter 2016 Financial Results
2016-04-11,Facebook, Ford and General Motors: Doug Kass' Views
2016-04-06,Cempra To Present At The Needham And Company 15th Annual Healthcare Conference
2016-04-04,Cempra To Present Data On Solithromycin At ECCMID
2016-03-23,First Week of May 20th Options Trading For Cempra (CEMP)
2016-03-16,Insiders Now Seeing Red With CEMP At New 52-Week Low
2016-03-08,Cempra To Participate In Nature's Webcast On Combating Antibiotic Resistance On March 9
2016-03-07,Cempra Authorized To Receive Funds From BARDA For A Phase 2/3 Clinical Trial Of Solithromycin In Pediatric Patients
2016-03-07,Tesla, Amazon and Netflix: Doug Kass' Views
2016-03-01,CEMP: Insiders vs. Shorts
2016-03-01,Weak On High Volume: Cempra (CEMP)
2016-02-29,Cempra To Present At The Cowen And Company 36th Annual Healthcare Conference
2016-02-25,Interesting CEMP Put And Call Options For October 21st
2016-02-24,Cempra Reports Fourth Quarter And Full Year 2015 Financial Results And Provides Corporate Update
2016-02-19,What Carl Icahn Is Doing; Biotech Breakout: Best of Kass
2016-02-17,Cempra To Report Fourth Quarter And Full Year 2015 Financial Results
2016-02-15,JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views
2016-02-05,The Lancet Infectious Diseases Publishes Positive Phase 3 Study Results For Cempra's Oral Solithromycin In Community-Acquired Bacterial Pneumonia
2016-02-03,Oversold Conditions For Cempra (CEMP)
2016-02-03,Cempra To Present At The Leerink Partners 5th Annual Global Healthcare Conference
2016-02-01,Cempra And Macrolide Pharmaceuticals Enter Synthetic Manufacturing Process Development Agreement For Solithromycin
2016-02-01,Biotech String: Assessing the January Damage, Gilead's Bottoming P/E, Sarepta Panel Date?
2016-01-29,Short Interest Moves 11.4% Lower For CEMP
2016-01-28,Spreading Zika Virus Is a Cause for Alarm, Says Cempra CEO
2016-01-28,Spreading Zika Virus Is a Cause for Alarm, Says Cempra CEO
2016-01-26,Cempra To Ring NASDAQ Closing Bell To Mark 10th Anniversary
2016-01-22,Interesting CEMP Put And Call Options For March 18th
2016-01-12,Cempra Completes Public Offering Of Common Stock
2016-01-07,Oversold Conditions For Cempra (CEMP)
2016-01-07,Heavy Trading On Cempra (CEMP) Before Market Open
2016-01-06,Cempra Prices Public Offering Of Common Stock
2016-01-06,Cempra To Present At J.P. Morgan Healthcare Conference
2016-01-05,Cempra Announces Proposed Public Offering Of $175 Million Of Common Stock
2016-01-05,Trade-Ideas: Cempra (CEMP) Is Today's "Dead Cat Bounce" Stock
2016-01-05,Cempra Doses Initial Patient In Phase 2 Clinical Trial Of Solithromycin In NASH
2015-12-29,2 Speculative Biotech Stocks for 2016
2015-12-22,Cempra Enters Into A CRADA With The NIAID And Expands The Phase 3 Solithromycin Clinical Trial In Urogenital Gonorrhea To Include Additional Female Patients And Adolescents
2015-12-09,Perilous Reversal Watch: Cempra (CEMP)
2015-12-08,Cempra Doses First Patient In Phase 3 Clinical Trial Of Taksta(TM) In Acute Bacterial Skin And Skin Structure Infections
2015-12-01,CEMP: Insiders vs. Shorts
2015-11-24,First Week of July 2016 Options Trading For Cempra (CEMP)
2015-11-24,Cempra (CEMP) Is Today's Perilous Reversal Stock
2015-11-11,Cempra To Present Anti-NASH Data For Solithromycin At The Liver Meeting(R) 2015
2015-11-10,Cempra To Present At Two Upcoming Investor Conferences
2015-11-02,Cempra (CEMP) Is Today's Dead Cat Bounce Stock
2015-10-30,Cempra’s New Drug Holds Potential, but Risk for Investors
2015-10-26,Cempra (CEMP) In A Perilous Reversal
2015-10-23,Cempra To Present Solithromycin Oral Data At CHEST 2015
2015-10-22,Cempra (CEMP): Today's Weak On High Volume Stock
2015-10-22,Cempra Reports Third Quarter 2015 Financial Results And Provides Corporate Update
2015-10-19,Cempra To Report Third Quarter 2015 Financial Results
2015-10-16,4 Big Stocks on Traders' Radars -- and What You Should Do With Them Now
2015-10-16,Heavy Trading On Cempra (CEMP) Before Market Open
2015-10-16,Cempra Announces Positive Topline Phase 3 Clinical Results For Intravenous Solithromycin In The Treatment Of Community-Acquired Bacterial Pneumonia
2015-10-14,Today's Dead Cat Bounce Stock: Cempra (CEMP)
2015-10-05,Cempra To Present Solithromycin Data At ID Week 2015
2015-09-24,Cempra To Present Solithromycin Data In COPD Patient Subgroup At European Respiratory Society International Congress
2015-09-22,Analysts Say Buy Select Biotech Stocks Ahead Of Clinton Drug Plan
2015-09-18,Strong On High Volume: Cempra (CEMP)
2015-09-18,FDA Grants Qualified Infectious Disease Product Designation To Taksta(TM) Cempra's Fusidic Acid Antibiotic
2015-09-16,CEMP Makes Notable Cross Below Critical Moving Average
2015-09-10,Cempra To Present Data From Antibiotic Drug Development Programs At ICAAC/ICC 2015 Meeting
2015-09-09,Trade-Ideas: Cempra (CEMP) Is Today's Weak On High Relative Volume Stock
2015-09-08,Cempra (CEMP) Flagged As Strong On High Volume
2015-09-03,Cempra To Present At Three Upcoming Investor Conferences
2015-08-20,Cempra (CEMP) In A Perilous Reversal
2015-08-19,FDA Grants Fast Track Designation To Cempra For Solithromycin In The Treatment Of Community Acquired Bacterial Pneumonia
2015-08-07,Today's Weak On High Volume Stock: Cempra (CEMP)
2015-08-04,Cempra To Present At The Wedbush PacGrow 2015 Healthcare Conference
2015-07-31,Cempra (CEMP) Is Today's Dead Cat Bounce Stock
2015-07-29,Cempra Reports Second Quarter 2015 Financial Results And Provides Corporate Update
2015-07-22,Cempra To Report Second Quarter 2015 Financial Results
2015-07-21,First Week Of CEMP September 18th Options Trading
2015-07-21,Stock To Watch: Cempra (CEMP) In Perilous Reversal
2015-07-17,New Lifetime High Reached: Cempra (CEMP)
2015-07-07,Cempra Completes Patient Enrollment Of Solitaire-IV Phase 3 Clinical Trial
2015-07-01,Cempra (CEMP) Is Today's Perilous Reversal Stock
2015-06-30,Cempra (CEMP) Showing Signs Of A Dead Cat Bounce Today
2015-06-24,Stock To Watch: Cempra (CEMP) In Perilous Reversal
2015-05-26,Cempra To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-19,First Week Of January 2016 Options Trading For Cempra (CEMP)
2015-05-19,Cempra Presenting Additional Data From The Phase 3 Oral Solithromycin Study In Community Acquired Bacterial Pneumonia At The American Thoracic Society Conference
2015-05-12,Cempra To Present Solithromycin Data At Two Upcoming Medical Conferences
2015-05-01,Trade-Ideas: Cempra (CEMP) Is Today's Strong On High Relative Volume Stock
2017-02-16,Take a Look at These Stocks Poised to Trade Higher
2017-02-16,These 5 Stocks Under $10 Could Explode Higher
2016-10-10,Cerecor To Present At The 15th Annual BIO Investor Forum In San Francisco On October 18th, 2016
2016-09-26,Cerecor Announces Acquisition Of TARP-¿8-AMPA Receptor Antagonist (CERC-611) From Lilly
2016-09-21,Cerecor Announces Completion Of Enrollment In Phase 2 Clinical Trial With CERC-301 As An Oral, Adjunctive Treatment Of Major Depressive Disorder
2016-09-12,Cerecor Enters Into A $15 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC
2016-09-06,Cerecor Announces Last Patient Enrolled In Phase 2 Clinical Trial With CERC-501 For Smoking Cessation
2016-09-01,Cerecor To Present At 23rd Annual NewsMakers In The Biotech Industry Conference In New York City, September 9, 2016
2016-08-29,Cerecor Inc. Announces Initiation Of Second CERC-501 Phase 2 Clinical Trial In Smokers
2016-08-22,Cerecor To Present At The 18th Annual Rodman & Renshaw Global Investment Conference In New York City September 11-13th, 2016
2016-08-15,Cerecor Inc. Reports Second Quarter 2016 Financial Results
2016-07-29,These 5 Stocks Are Poised for Breakouts
2016-07-25,Cerecor Announces Research Grant From The Department Of Defense To Study CERC-501 In Animal Models For Co-Morbid Post-Traumatic Stress Disorder And Alcohol Use Disorder
2016-07-20,Cerecor Announces $1.0 Million Research & Development Grant From The National Institute On Alcohol Abuse And Alcoholism At The National Institutes Of Health
2016-05-16,Cerecor Inc. Reports First Quarter 2016 Financial Results
2016-04-11,Cerecor Announces $1.0 Million Research & Development Grant From The National Institute On Drug Abuse (NIDA) At The National Institutes Of Health
2016-03-23,Cerecor Inc. Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2015
2016-03-08,Cerecor Inc. To Present At The Roth Conference On March 16th
2016-02-22,Cerecor To Host R&D Day In New York City On March 1, 2016
2016-02-02,Cerecor Announces Initiation Of Phase 2 Clinical Trial With CERC-501 For Smoking Cessation
2016-02-01,Cerecor Inc. To Present At The BIO CEO & Investor Conference In New York City
2016-01-19,Cerecor Announces Publication Describing Antidepressant Activity Of CERC-301 In Preclinical Model
2016-01-12,Cerecor Inc. Appoints Thomas Aasen To Board Of Directors
2016-01-04,Cerecor Inc. To Present At Biotech Showcase 2016 In San Francisco
2015-12-21,Cerecor Inc. Names Uli Hacksell, Chairman Of Cerecor And Former CEO Of ACADIA, As President And CEO
2015-12-11,Publication Reports Human Brain Penetration And Target Engagement Of Cerecor's Oral Kappa Opioid Receptor Antagonist, CERC-501
,
,
,
,
,
2017-03-20,Cerulean And Daré To Host Conference Call On Proposed Transaction On March 23
2017-03-20,Cerulean Pharma And Daré Bioscience Enter Into Stock Purchase Agreement
2017-03-15,Stick to Small, Fast Trades Until the Fed's out of the Way
2017-02-01,Cerulean Announces Review Of Strategic Alternatives
2016-12-04,5 Stocks Poised for Major Breakouts--Gold, Pharma and Tech
2016-11-03,Cerulean Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-10-27,Cerulean To Host Third Quarter 2016 Conference Call On November 3
2016-10-26,Cerulean Announces Promotion Of Scott Eliasof, PhD To Senior Vice President And Chief Scientific Officer
2016-10-25,First Week of June 2017 Options Trading For Cerulean Pharma (CERU)
2016-10-19,Cerulean Announces Technology Platform Collaboration
2016-10-19,Cerulean Announces $20 Million Firm Commitment At-The-Market Stock Purchase Agreement With Aspire Capital Fund, LLC
2016-10-06,Cerulean Announces Data Presentations At The 2016 European Society For Medical Oncology Annual Meeting
2016-08-18,Cerulean Announces Reduction In Force
2016-08-18,Cerulean Pharma (CERU) Stock Tumbles on Lead Kidney Cancer Drug Failure
2016-08-17,Cerulean Announces Results From Phase 2 Clinical Trial Of CRLX101 And Avastin® Combination In Relapsed Renal Cell Carcinoma
2016-08-04,Cerulean Reports Second Quarter 2016 Corporate Highlights And Financial Results
2016-07-28,Cerulean To Host Second Quarter 2016 Conference Call On August 4
2016-07-19,Cerulean Receives FDA Fast Track Designation For CRLX101 For The Treatment Of Platinum-Resistant Ovarian Cancer
2016-06-23,Cerulean Announces First Patient Dosed In Phase 2a Expansion Stage Evaluating CRLX301 In Patients With Advanced Solid Tumors
2016-06-22,Cerulean Announces Publication In Cancer Research
2016-06-14,Cerulean To Present At JMP Securities Life Sciences Conference
2016-06-09,Cerulean Announces Manuscript Published In Annals Of Oncology
2016-05-19,Cerulean Announces Oral Presentation Of CRLX101 Clinical Data At Gynecologic Oncology 2016 Conference
2016-05-18,Cerulean To Present At The 2016 ASCO Annual Meeting
2016-05-10,Cerulean Announces First Patient Dosed In Phase 1/2 Trial Evaluating CRLX101 In Combination With LYNPARZA™
2016-05-02,Cerulean Reports First Quarter 2016 Corporate Highlights And Financial Results
2016-04-25,Cerulean Announces Oral Presentation Of CRLX101 Clinical Data At Gynecologic Oncology 2016 Conference
2016-04-25,Cerulean To Host First Quarter 2016 Conference Call On May 2
2016-04-19,Cerulean Announces Presentation At 2016 American Association For Cancer Research Annual Meeting Of Stage 1 Data From Phase 2 Trial In Platinum-Resistant Ovarian Cancer
2016-04-05,Cerulean To Present At 15th Annual Needham Healthcare Conference
2016-03-23,Here's Why Cerulean Pharma (CERU) Stock is Spiking Today
2016-03-23,Cerulean Announces Publication Showing CRLX101 Localizes Selectively In Human Tumors, Sparing Adjacent Healthy Tissue
2016-03-21,Cerulean Presents CRLX301 Phase 1 Data At The 14th International Congress On Targeted Anticancer Therapies
2016-03-16,Cerulean Announces Data Presentations At The 2016 American Association For Cancer Research Annual Meeting
2016-03-10,Cerulean Reports Fourth Quarter 2015 Corporate Highlights And Financial Results
2016-03-07,Cerulean To Present At Two Upcoming March Conferences
2016-03-03,Cerulean To Host Fourth Quarter 2015 Conference Call On March 10
2016-02-01,Cerulean To Present At Two Upcoming Conferences
2015-12-21,Cerulean Announces Relocation To New Office And Laboratory Space In Waltham, Massachusetts
2015-11-17,Cerulean Announces Clinical Collaboration With AstraZeneca And The National Cancer Institute To Evaluate The Combination Of LYNPARZA™ And CRLX101
2015-11-16,Cerulean Reports Third Quarter 2015 Corporate Highlights And Financial Results
2015-11-09,Cerulean Announces Data At The 2015 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
2015-11-05,Cerulean To Host Third Quarter 2015 Conference Call On November 16
2015-10-27,Cerulean Announces Poster Presentations At The 2015 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
2015-10-19,Cerulean Announces First Patient Dosed In Clinical Trial To Evaluate Weekly Dosing Schedule With CRLX101
2015-10-15,Cerulean Announces Completion Of Enrollment Of Randomized Phase 2 Trial Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma
2015-09-30,Cerulean Announces CRLX101 Advances To Second Stage Of Phase 2 Clinical Trial Of CRLX101 In Combination With Avastin® In Relapsed Ovarian Cancer
2015-09-24,Cerulean Appoints David R. Walt, Ph.D. To Board Of Directors
2015-09-08,Cerulean Appoints Adrian Senderowicz, M.D., As Chief Medical Officer
2015-09-03,Cerulean To Present At Two Upcoming Conferences
2015-08-06,Cerulean Reports Second Quarter 2015 Corporate Highlights And Financial Results
2015-08-05,Cerulean To Present At Two Upcoming Conferences
2015-07-30,Cerulean To Host Second Quarter 2015 Conference Call On August 6
2015-07-21,Cerulean Announces First Patient Dosed In Phase 1b Trial Of CRLX101 In Combination With Weekly Paclitaxel In Relapsed Ovarian Cancer
2015-06-29,Cerulean Pharma Is Now Oversold (CERU)
2015-06-29,Cerulean Pharma Appoints Stuart A. Arbuckle To Board Of Directors
2015-06-16,Cerulean To Present At The JMP Securities Life Sciences Conference
2015-06-02,Oversold Conditions For Cerulean Pharma (CERU)
2015-06-01,Cerulean Announces Presentation Of Full Data From Phase 1b/2 Trial Of CRLX101 In Combination With Avastin® In Metastatic Renal Cell Carcinoma At The Annual Meeting Of The American Society For Clinical Oncology
2015-05-27,Cerulean Appoints Interim Chief Financial Officer
2015-05-26,Cerulean's CRLX101 Receives Orphan Drug Designation From The FDA For The Treatment Of Ovarian Cancer
2015-05-12,Cerulean To Present At The UBS Global Healthcare Conference
2015-05-06,Cerulean Reports First Quarter 2015 Corporate Highlights And Financial Results
2015-04-30,Cerulean To Present At The Deutsche Bank 40th Annual Health Care Conference
2015-04-29,Cerulean To Host First-Quarter 2015 Conference Call On May 6
2015-04-28,Cerulean Announces Fast Track Designation Granted For CRLX101 In Metastatic Renal Cell Carcinoma
2015-04-16,Cerulean Announces Three Posters To Be Presented With Preclinical CRLX101 Data At The American Association For Cancer Research Annual Meeting
2015-04-15,Cerulean To Present At 14th Annual Needham Healthcare Conference
2015-04-13,Cerulean Announces Publication Showing CRLX101 Targets Breast Cancer Stem Cells And Impedes Resistance To Anti-angiogenic Therapy In Preclinical Models
2015-04-10,Cerulean Closes Public Offering Of Common Stock
2015-04-08,Cerulean To Present At 14th Annual Needham Healthcare Conference
2015-04-07,Cerulean Announces Pricing Of Public Offering Of Common Stock
2015-03-30,Cerulean Announces Proposed Public Offering Of Common Stock
2015-03-20,Cerulean Appoints Chris Guiffre President & Chief Executive Officer
2015-03-19,Cerulean Reports Fourth Quarter 2014 Corporate Highlights And Financial Results
2015-03-19,Cerulean Announces Phase 1b/2 Trial Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma Meets Primary Endpoint
2015-03-12,Cerulean To Host Fourth-Quarter And Year-End 2014 Conference Call On March 19
2015-03-03,Cerulean Establishes Clinical Collaboration With The GOG Foundation To Study CRLX101 In Combination With Weekly Paclitaxel In Relapsed Ovarian Cancer
2015-03-02,Cerulean To Present At Two Upcoming Conferences
2015-02-19,CRLX101 Selected For Oral Presentation At 17th Annual Symposium On Anti-Angiogenesis And Immune Therapies For Cancer
2015-02-03,Cerulean To Present At Two Upcoming Conferences
2015-01-29,Cerulean Appoints Vice President, Clinical Operations
2015-01-19,CRLX101 Rectal Cancer Data Presented At ASCO 2015 Gastrointestinal Cancers Symposium
2015-01-08,Cerulean Secures Debt Facility From Hercules Technology Growth Capital Of Up To $26.0 Million
2015-01-06,Cerulean Announces Publication Describing Synergistic Anti-Tumor Activity Of CRLX101 With Avastin In Advanced Metastatic Ovarian Tumor Models
2014-12-17,Cerulean Announces First Patient Dosed With CRLX301 In Phase 1/2a Trial In Advanced Solid Tumors
2014-12-15,Cerulean Announces Completion Of Enrollment Of A Phase 1b/2 Study Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma
2014-11-13,Cerulean Reports Third-Quarter 2014 Corporate Highlights And Financial Results
2014-10-30,Cerulean To Host Third-Quarter 2014 Conference Call On November 13
2014-10-27,Cerulean Pharma Appoints David Parkinson, M.D., To Board Of Directors
2014-10-27,Cerulean Announces Management Changes
2014-10-08,Cerulean Appoints Susan L. Kelley, M.D., To Its Board Of Directors
2014-10-06,Cerulean Appoints Vice President, Regulatory Affairs
2014-09-29,Cerulean Appoints General Counsel
2014-09-18,Cerulean To Present At BioCentury's Newsmakers In Biotechnology Conference
2014-08-12,Cerulean Reports Second Quarter 2014 Corporate Highlights And Financial Results
2014-08-06,Cerulean To Present At Upcoming Conferences
2014-08-05,Cerulean To Report Second Quarter 2014 Corporate Highlights And Financial Results On August 12, 2014
,
,
2017-03-20,Cerulean And Daré To Host Conference Call On Proposed Transaction On March 23
2017-03-20,Cerulean Pharma And Daré Bioscience Enter Into Stock Purchase Agreement
2017-03-15,Stick to Small, Fast Trades Until the Fed's out of the Way
2017-02-01,Cerulean Announces Review Of Strategic Alternatives
2016-12-04,5 Stocks Poised for Major Breakouts--Gold, Pharma and Tech
2016-11-03,Cerulean Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-10-27,Cerulean To Host Third Quarter 2016 Conference Call On November 3
2016-10-26,Cerulean Announces Promotion Of Scott Eliasof, PhD To Senior Vice President And Chief Scientific Officer
2016-10-25,First Week of June 2017 Options Trading For Cerulean Pharma (CERU)
2016-10-19,Cerulean Announces Technology Platform Collaboration
2016-10-19,Cerulean Announces $20 Million Firm Commitment At-The-Market Stock Purchase Agreement With Aspire Capital Fund, LLC
2016-10-06,Cerulean Announces Data Presentations At The 2016 European Society For Medical Oncology Annual Meeting
2016-08-18,Cerulean Announces Reduction In Force
2016-08-18,Cerulean Pharma (CERU) Stock Tumbles on Lead Kidney Cancer Drug Failure
2016-08-17,Cerulean Announces Results From Phase 2 Clinical Trial Of CRLX101 And Avastin® Combination In Relapsed Renal Cell Carcinoma
2016-08-04,Cerulean Reports Second Quarter 2016 Corporate Highlights And Financial Results
2016-07-28,Cerulean To Host Second Quarter 2016 Conference Call On August 4
2016-07-19,Cerulean Receives FDA Fast Track Designation For CRLX101 For The Treatment Of Platinum-Resistant Ovarian Cancer
2016-06-23,Cerulean Announces First Patient Dosed In Phase 2a Expansion Stage Evaluating CRLX301 In Patients With Advanced Solid Tumors
2016-06-22,Cerulean Announces Publication In Cancer Research
2016-06-14,Cerulean To Present At JMP Securities Life Sciences Conference
2016-06-09,Cerulean Announces Manuscript Published In Annals Of Oncology
2016-05-19,Cerulean Announces Oral Presentation Of CRLX101 Clinical Data At Gynecologic Oncology 2016 Conference
2016-05-18,Cerulean To Present At The 2016 ASCO Annual Meeting
2016-05-10,Cerulean Announces First Patient Dosed In Phase 1/2 Trial Evaluating CRLX101 In Combination With LYNPARZA™
2016-05-02,Cerulean Reports First Quarter 2016 Corporate Highlights And Financial Results
2016-04-25,Cerulean Announces Oral Presentation Of CRLX101 Clinical Data At Gynecologic Oncology 2016 Conference
2016-04-25,Cerulean To Host First Quarter 2016 Conference Call On May 2
2016-04-19,Cerulean Announces Presentation At 2016 American Association For Cancer Research Annual Meeting Of Stage 1 Data From Phase 2 Trial In Platinum-Resistant Ovarian Cancer
2016-04-05,Cerulean To Present At 15th Annual Needham Healthcare Conference
2016-03-23,Here's Why Cerulean Pharma (CERU) Stock is Spiking Today
2016-03-23,Cerulean Announces Publication Showing CRLX101 Localizes Selectively In Human Tumors, Sparing Adjacent Healthy Tissue
2016-03-21,Cerulean Presents CRLX301 Phase 1 Data At The 14th International Congress On Targeted Anticancer Therapies
2016-03-16,Cerulean Announces Data Presentations At The 2016 American Association For Cancer Research Annual Meeting
2016-03-10,Cerulean Reports Fourth Quarter 2015 Corporate Highlights And Financial Results
2016-03-07,Cerulean To Present At Two Upcoming March Conferences
2016-03-03,Cerulean To Host Fourth Quarter 2015 Conference Call On March 10
2016-02-01,Cerulean To Present At Two Upcoming Conferences
2015-12-21,Cerulean Announces Relocation To New Office And Laboratory Space In Waltham, Massachusetts
2015-11-17,Cerulean Announces Clinical Collaboration With AstraZeneca And The National Cancer Institute To Evaluate The Combination Of LYNPARZA™ And CRLX101
2015-11-16,Cerulean Reports Third Quarter 2015 Corporate Highlights And Financial Results
2015-11-09,Cerulean Announces Data At The 2015 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
2015-11-05,Cerulean To Host Third Quarter 2015 Conference Call On November 16
2015-10-27,Cerulean Announces Poster Presentations At The 2015 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
2015-10-19,Cerulean Announces First Patient Dosed In Clinical Trial To Evaluate Weekly Dosing Schedule With CRLX101
2015-10-15,Cerulean Announces Completion Of Enrollment Of Randomized Phase 2 Trial Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma
2015-09-30,Cerulean Announces CRLX101 Advances To Second Stage Of Phase 2 Clinical Trial Of CRLX101 In Combination With Avastin® In Relapsed Ovarian Cancer
2015-09-24,Cerulean Appoints David R. Walt, Ph.D. To Board Of Directors
2015-09-08,Cerulean Appoints Adrian Senderowicz, M.D., As Chief Medical Officer
2015-09-03,Cerulean To Present At Two Upcoming Conferences
2015-08-06,Cerulean Reports Second Quarter 2015 Corporate Highlights And Financial Results
2015-08-05,Cerulean To Present At Two Upcoming Conferences
2015-07-30,Cerulean To Host Second Quarter 2015 Conference Call On August 6
2015-07-21,Cerulean Announces First Patient Dosed In Phase 1b Trial Of CRLX101 In Combination With Weekly Paclitaxel In Relapsed Ovarian Cancer
2015-06-29,Cerulean Pharma Is Now Oversold (CERU)
2015-06-29,Cerulean Pharma Appoints Stuart A. Arbuckle To Board Of Directors
2015-06-16,Cerulean To Present At The JMP Securities Life Sciences Conference
2015-06-02,Oversold Conditions For Cerulean Pharma (CERU)
2015-06-01,Cerulean Announces Presentation Of Full Data From Phase 1b/2 Trial Of CRLX101 In Combination With Avastin® In Metastatic Renal Cell Carcinoma At The Annual Meeting Of The American Society For Clinical Oncology
2015-05-27,Cerulean Appoints Interim Chief Financial Officer
2015-05-26,Cerulean's CRLX101 Receives Orphan Drug Designation From The FDA For The Treatment Of Ovarian Cancer
2015-05-12,Cerulean To Present At The UBS Global Healthcare Conference
2015-05-06,Cerulean Reports First Quarter 2015 Corporate Highlights And Financial Results
2015-04-30,Cerulean To Present At The Deutsche Bank 40th Annual Health Care Conference
2015-04-29,Cerulean To Host First-Quarter 2015 Conference Call On May 6
2015-04-28,Cerulean Announces Fast Track Designation Granted For CRLX101 In Metastatic Renal Cell Carcinoma
2015-04-16,Cerulean Announces Three Posters To Be Presented With Preclinical CRLX101 Data At The American Association For Cancer Research Annual Meeting
2015-04-15,Cerulean To Present At 14th Annual Needham Healthcare Conference
2015-04-13,Cerulean Announces Publication Showing CRLX101 Targets Breast Cancer Stem Cells And Impedes Resistance To Anti-angiogenic Therapy In Preclinical Models
2015-04-10,Cerulean Closes Public Offering Of Common Stock
2015-04-08,Cerulean To Present At 14th Annual Needham Healthcare Conference
2015-04-07,Cerulean Announces Pricing Of Public Offering Of Common Stock
2015-03-30,Cerulean Announces Proposed Public Offering Of Common Stock
2015-03-20,Cerulean Appoints Chris Guiffre President & Chief Executive Officer
2015-03-19,Cerulean Reports Fourth Quarter 2014 Corporate Highlights And Financial Results
2015-03-19,Cerulean Announces Phase 1b/2 Trial Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma Meets Primary Endpoint
2015-03-12,Cerulean To Host Fourth-Quarter And Year-End 2014 Conference Call On March 19
2015-03-03,Cerulean Establishes Clinical Collaboration With The GOG Foundation To Study CRLX101 In Combination With Weekly Paclitaxel In Relapsed Ovarian Cancer
2015-03-02,Cerulean To Present At Two Upcoming Conferences
2015-02-19,CRLX101 Selected For Oral Presentation At 17th Annual Symposium On Anti-Angiogenesis And Immune Therapies For Cancer
2015-02-03,Cerulean To Present At Two Upcoming Conferences
2015-01-29,Cerulean Appoints Vice President, Clinical Operations
2015-01-19,CRLX101 Rectal Cancer Data Presented At ASCO 2015 Gastrointestinal Cancers Symposium
2015-01-08,Cerulean Secures Debt Facility From Hercules Technology Growth Capital Of Up To $26.0 Million
2015-01-06,Cerulean Announces Publication Describing Synergistic Anti-Tumor Activity Of CRLX101 With Avastin In Advanced Metastatic Ovarian Tumor Models
2014-12-17,Cerulean Announces First Patient Dosed With CRLX301 In Phase 1/2a Trial In Advanced Solid Tumors
2014-12-15,Cerulean Announces Completion Of Enrollment Of A Phase 1b/2 Study Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma
2014-11-13,Cerulean Reports Third-Quarter 2014 Corporate Highlights And Financial Results
2014-10-30,Cerulean To Host Third-Quarter 2014 Conference Call On November 13
2014-10-27,Cerulean Pharma Appoints David Parkinson, M.D., To Board Of Directors
2014-10-27,Cerulean Announces Management Changes
2014-10-08,Cerulean Appoints Susan L. Kelley, M.D., To Its Board Of Directors
2014-10-06,Cerulean Appoints Vice President, Regulatory Affairs
2014-09-29,Cerulean Appoints General Counsel
2014-09-18,Cerulean To Present At BioCentury's Newsmakers In Biotechnology Conference
2014-08-12,Cerulean Reports Second Quarter 2014 Corporate Highlights And Financial Results
2014-08-06,Cerulean To Present At Upcoming Conferences
2014-08-05,Cerulean To Report Second Quarter 2014 Corporate Highlights And Financial Results On August 12, 2014
,
,
2017-03-13,Coherus BioSciences Reports Fourth Quarter And Full Year 2016 Corporate Highlights And Financial Results
2017-03-06,Coherus Addresses Trade Secret Action Filed By Amgen
2017-03-02,Statement By Coherus CEO Regarding Biosimilars User Fees
2017-03-02,Coherus Announces CHS-1420 Pharmacokinetic Clinical Bioequivalence Study Meets Primary Endpoint
2017-03-01,Coherus BioSciences Management To Present At Two Investor Healthcare Conferences In March
2017-02-21,Coherus BioSciences To Report Fourth Quarter And Full Year 2016 Financial Results On March 13th
2017-02-17,Coherus BioSciences Announces New Employment Inducement Grants
2017-02-16,Here's What Blackstone Bought and Sold in the Fourth Quarter
2017-02-16,Here's What Blackstone and KKR Are Buying
2017-02-08,Coherus Prices Public Offering Of Common Stock
2017-02-07,Coherus Announces Proposed Public Offering Of Common Stock
2017-01-31,Coherus BioSciences Files Four Petitions For Inter Partes Review Against AbbVie's HUMIRA® Formulation Patent 9,085,619
2017-01-10,Coherus BioSciences Announces Positive Topline 24-Week Treatment Phase Three Results For CHS-1420 (HUMIRA® Biosimilar Candidate) In Patients With Psoriasis
2017-01-04,Coherus BioSciences Management To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-07,Coherus BioSciences To Present At BMO - Prescriptions For Success Healthcare Conference On December 14th
2016-11-29,Coherus' Marketing Authorization Application To European Medicines Agency For CHS-1701 (Pegfilgrastim Biosimilar Candidate) Accepted
2016-11-17,Coherus BioSciences Announces New Employment Inducement Grants
2016-11-09,Coherus BioSciences Reports Third Quarter 2016 Operating And Financial Results
2016-11-07,Notable Monday Option Activity: CHRS, FMI, OLED
2016-11-07,AbbVie Notches Legal Win Over Coherus
2016-11-07,AbbVie Stock Higher on Humira Patent Win
2016-11-07,Coherus BioSciences Receives Decision Denying Institution Of The '166 IPR Related To AbbVie's HUMIRA® Formulation
2016-11-04,Coherus BioSciences Announces New Employment Inducement Grants
2016-11-01,Coherus BioSciences To Report Third Quarter 2016 Financial Results On November 9th
2016-11-01,Coherus BioSciences Management To Present At Two Investor Healthcare Conferences In November 
2016-10-21,Coherus BioSciences Announces New Employment Inducement Grants
2016-10-06,Coherus BioSciences Announces FDA Acceptance Of 351(k) Biologics License Application To U.S. Food And Drug Administration For CHS-1701 (Pegfilgrastim Biosimilar Candidate)
2016-10-06,Coherus BioSciences Completes Two Pharmacokinetic Bioequivalence Studies Of CHS-0214
2016-10-05,Momenta, Coherus BioSciences Are Both Good Options in the Biosimilar Space
2016-09-27,Coherus BioSciences Regains Development And Commercial Rights To CHS-0214 From Shire
2016-09-16,Coherus BioSciences Announces New Employment Inducement Grants
2016-09-14,AbbVie's Battle Royale
2016-09-01,Coherus BioSciences Management To Present At Two Investor Healthcare Conferences In September 
2016-08-31,Coherus BioSciences Announces New Employment Inducement Grants
2016-08-09,Coherus BioSciences Reports Second Quarter 2016 Financial And Operating Results
2016-08-09,Coherus BioSciences Submits 351(k) Biologics License Application To U.S. Food And Drug Administration For CHS-1701 (Pegfilgrastim Biosimilar Candidate)
2016-08-08,Coherus BioSciences Announces Positive Topline Phase Three Results For CHS-1420 (Humira® Biosimilar Candidate) In Patients With Psoriasis
2016-07-25,Coherus BioSciences To Report Second Quarter 2016 Financial Results On August 9th
2016-07-11,Coherus Announces Positive Topline Results For CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic And Pharmacodynamic Biosimilarity Study
2016-06-29,16 Biopharma Companies Besides Medivation That Are Attractive Targets
2016-06-28,Coherus Announces Positive Phase 2b Efficacy Data On Novel Oral Therapy In Relapsing Remitting Multiple Sclerosis
2016-06-13,Coherus BioSciences Provides Update On IPRs
2016-06-10,Coherus Presents Study Results Demonstrating Equivalence Of Its CHS-0214 Biosimilar To Etanercept
2016-06-03,Coherus BioSciences To Present At Jefferies 2016 Healthcare Conference On June 8
2016-05-26,Coherus BioSciences Advances Differentiated IP Strategy For Humira Market Access
2016-05-23,Coherus Prices Public Offering Of Common Stock
2016-05-23,Coherus Announces Proposed Public Offering Of Common Stock
2016-05-20,2 Big -- and Mispriced -- Biotech Stocks
2016-05-17,Coherus BioSciences Provides Update On '135 IPR
2016-05-16,Coherus BioSciences Appoints Patrick O'Brien As Senior Vice President, Investor Relations
2016-05-13,Coherus BioSciences is Now Oversold (CHRS)
2016-05-10,Coherus BioSciences (CHRS) Is Weak On High Volume Today
2016-05-09,Coherus BioSciences Reports First Quarter 2016 Financial And Operating Results
2016-05-06,Commit To Buy Coherus BioSciences At $17.50, Earn 35.8% Annualized Using Options
2016-05-04,Coherus BioSciences To Present At Bank Of America Merrill Lynch Health Care Conference On May 11
2016-05-02,Coherus BioSciences To Report First Quarter 2016 Financial Results On May 9
2016-03-29,Coherus BioSciences To Present At Barclays Generic Pharmaceuticals Symposium On April 6
2016-03-07,Coherus BioSciences To Present At Barclays Global Healthcare Conference On March 16
2016-02-29,Coherus BioSciences Reports Fourth Quarter And Year End 2015 Financial And Operating Results
2016-02-29,Coherus BioSciences Announces Private Placement Of $100 Million Senior Convertible Notes
2016-02-26,Coherus BioSciences To Present At Cowen And Company Healthcare Conference On March 8
2016-02-15,Coherus BioSciences To Report Fourth Quarter And Year End 2015 Financial Results On February 29
2016-02-05,Commit To Purchase Coherus BioSciences At $12.50, Earn 37.6% Annualized Using Options
2016-02-05,Coherus BioSciences To Present At Bloomberg Intelligence Healthcare Event On February 12th
2016-02-01,Coherus Announces The Appointment Of Jim Daly, Executive Chairman, Commercial Advisory Committee
2016-02-01,Coherus Announces CHS-1701 (Neulasta® Biosimilar) Met Both Primary Endpoints In Registration-Enabling Immunogenicity Study
2016-01-11,Coherus And Baxalta Announce CHS-0214 (Investigational Etanercept Biosimilar) Met Primary Efficacy Endpoint In Phase 3 Rheumatoid Arthritis Clinical Study (RaPsODY)
2016-01-07,Coherus BioSciences Enters Oversold Territory (CHRS)
2016-01-04,Coherus BioSciences To Present At J.P. Morgan Healthcare Conference On January 11
2015-12-21,Coherus BioSciences Signs Strategic Manufacturing Agreement With KBI Biopharma For Commercial Supply Of CHS-1701
2015-12-09,Coherus BioSciences (CHRS) Highlighted As Weak On High Volume
2015-12-08,Coherus BioSciences Reports Update To CHS-1701 Program
2015-12-08,Ratings Changes Today
2015-11-10,Coherus BioSciences To Present At Jefferies Autumn 2015 Global Healthcare Conference On November 18
2015-11-09,Coherus BioSciences Reports Third Quarter 2015 Financial And Operating Results And Corporate Events
2015-11-09,Coherus And Baxalta Announce CHS-0214 (Investigational Etanercept Biosimilar) Met Primary Efficacy Endpoints In Phase 3 Psoriasis Clinical Study (RaPsODY)
2015-10-28,Coherus BioSciences To Present At Credit Suisse Healthcare Conference On November 10
2015-10-27,Coherus BioSciences To Present At Bloomberg Biosimilars Conference On November 2
2015-10-26,Coherus BioSciences To Report Third Quarter 2015 Financial Results On November 9
2015-10-01,Coherus Announces Topline Results Of CHS-1701 Pharmacokinetic And Pharmacodynamic Biosimilarity Study
2015-09-25,Oversold Conditions For Coherus BioSciences
2015-09-09,Coherus Appoints Juliana M. Reed, Vice President, Government Affairs
2015-09-04,Coherus BioSciences To Present At Morgan Stanley Global Healthcare Conference On September 17
2015-09-03,Coherus Provides Updates On Clinical Studies
2015-08-25,Put Impax, Akorn and Sagent on Your Watch List of Generics Targets
2015-08-10,Coherus BioSciences Reports Second Quarter 2015 Financial And Operating Results
2015-07-28,Short Interest In Coherus BioSciences Jumps 41.2%
2015-07-28,Coherus BioSciences To Report Second Quarter 2015 Financial Results On August 10
2015-05-27,Coherus BioSciences To Present At Jefferies Healthcare Conference On June 3
2015-05-11,Coherus BioSciences Reports First Quarter 2015 Financial And Operating Results
2015-05-04,Coherus BioSciences To Report First Quarter 2015 Financial Results On May 11
2015-04-30,Coherus BioSciences To Present At Deutsche Bank Health Care Conference On May 7
2015-04-15,Coherus BioSciences And Baxter Announce Amendment To Etanercept Biosimilar Collaboration Agreement
2015-03-31,Coherus Prices Upsized Public Offering Of $120.0 Million Of Common Stock
2015-03-31,How Novartis Drug Approval Makes Biosimilar Makers Ripe for Acquisition
2015-03-30,Coherus Announces Proposed Public Offering Of Common Stock
2015-03-23,Coherus BioSciences Reports Fourth Quarter and Year End 2014 Financial and Operating Results
2015-03-17,Coherus Finalizes CHS-1701 BLA Enabling Clinical Program And Initiates Pivotal Pharmacokinetic And Pharmacodynamic Study
2015-03-16,Coherus BioSciences To Report Fourth Quarter And Year End 2014 Financial Results On March 23
2015-02-23,Coherus BioSciences To Present At Cowen And Company Health Care Conference On March 2
2015-02-04,Coherus BioSciences To Present At Leerink Healthcare Conference On February 11
2015-01-09,How to Invest in the New Industry of 'Biosimilar' or 'Generic' Biological Drugs
2014-12-15,Coherus BioSciences Reports Third Quarter 2014 Financial And Operating Results
2014-12-08,Coherus BioSciences To Present At The J.P. Morgan Healthcare Conference On January 12
2014-12-04,Coherus BioSciences To Host Earnings Conference Call On December 15
2014-11-12,Coherus BioSciences Announces Closing Of Initial Public Offering And Exercise Of Underwriters' Option To Purchase Additional Shares
2014-11-06,Coherus BioSciences Prices Initial Public Offering Of $85 Million Of Common Stock
2013-10-08,Dan Loeb's Doomed Sotheby's Campaign
2013-06-20,The Deal: Men's Wearhouse Fires Founder in Course of Review
2012-07-27,Charming Shoppes, Inc. Announces Results Of Its Offer To Purchase Its Outstanding 1.125% Senior Convertible Notes Due 2014
2012-06-28,Charming Shoppes, Inc. Announces Offer To Purchase Any Or All Of Its Outstanding 1.125% Senior Convertible Notes Due 2014 Through A Tender Offer
2012-06-15,Business Highlights
2012-06-13,Charming Shoppes Stock Hits New 52-Week High (CHRS)
2012-06-13,Ascena Retail Group, Inc. Successfully Completes Tender Offer For Shares Of Charming Shoppes, Inc.
2012-06-07,Cramer's 'Mad Money' Recap: America Between Rock, Hard Place
2012-05-29,Stocks to Watch: Facebook, RIM (Update 1)
2012-05-21,Faruqi &amp; Faruqi, LLP Announces Investigation Regarding The Acquisition Of Charming Shoppes Inc.
2012-05-15,Charming Shoppes, Inc. Announces Fundamental Change And Right To Convert 1.125% Senior Convertible Notes
2012-05-10,Law Office Of Brodsky &amp; Smith, LLC Announces Investigation Of Charming Shoppes, Inc.
2012-05-10,Charming Shoppes Reaches New 52-Week High (CHRS)
2012-05-09,The Law Firm Of Levi & Korsinsky, LLP Announces Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Charming Shoppes, Inc. In Connection With The Sale Of The Company To Ascena Retail Group, Inc.
2012-05-07,Faruqi &amp; Faruqi, LLP Announces Investigation Of Charming Shoppers Inc.
2012-05-02,The Law Firm Of Levi &amp; Korsinsky, LLP Announces Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Charming Shoppes, Inc. In Connection With The Sale Of The Company To Ascena Retail Group, Inc.
2012-05-02,The Lin Law Firm Announces Investigation Regarding The Acquisition Of Charming Shoppes, Inc.
2012-05-02,Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Charming Shoppes, Inc.
2012-05-02,The Law Firm Of Levi &amp; Korsinsky, LLP Announces Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Charming Shoppes, Inc. In Connection With The Sale Of The Company To Ascena Retail Group, Inc.
2012-05-02,Charming Shoppes Investor Alert: The Briscoe Law Firm And Powers Taylor, LLP Investigate Charming Shoppes, Inc. Sale To Ascena Retail Group, Inc.
2012-05-02,Rigrodsky &amp; Long, P.A. Announces Investigation Of Charming Shoppes, Inc. Over Its Agreement To Be Acquired By Ascena Retail Group, Inc.
2012-05-02,Barnes & Noble Adds NFC to Nook: Hot Trends
2012-05-02,Charming Shoppes Rises On Unusually High Volume (CHRS)
2012-05-02,Barnes & Noble Adds NFC to Nook: Hot Trends
2012-05-02,5 Things You Should Know Before the Stock Market Opens
2012-04-03,Charming Shoppes Reaches New 52-Week High (CHRS)
2012-03-30,Insiders Trading ET, CPWM, CHRS and RNR
2012-03-29,3 Stocks Under $10 Moving Higher
2012-03-28,Charming Shoppes, Inc. To Participate In Telsey Advisory Group's 4th Annual Spring Consumer Conference
2012-03-26,Charming Shoppes Announces Jeffrey H. Liss Promoted To Senior Vice President - General Manager - Charming Direct
2012-03-16,Charming Shoppes, Inc. Hosts Fourth Quarter And Fiscal Year 2011 Sales And Earnings Conference Call On Tuesday, March 27, 2012
2012-02-24,5 Stocks Insiders Love Right Now
2012-02-24,Cacique Makes Comfort Sexy
2012-02-24,Charming Shoppes Stock Hits New 52-Week High (CHRS)
2012-02-13,Charming Shoppes Stock Hits New 52-Week High (CHRS)
2012-02-03,Charming Shoppes Reaches New 52-Week High (CHRS)
2012-01-30,Leading Plus Size Retailer Sonsi.com Adds Exciting New Apparel And Accessories Brands To Its Online Shopping Experience
2012-01-19,Charming Shoppes Stock Hits New 52-Week High (CHRS)
2012-01-04,Charming Shoppes, Inc. To Participate In The 14th Annual ICR XChange Conference 2012
2011-12-19,TheStreet Ratings Top 10 Rating Changes
2011-12-16,6 Stocks Hitting New Highs
2011-12-14,Charming Shoppes Inc Stock Upgraded (CHRS)
2011-11-22,Charming Shoppes, Inc. Hosts Third Quarter Fiscal 2011 Sales And Earnings Conference Call On Thursday, December 1, 2011
2011-10-18,Charming Shoppes Goes Global Online
2011-10-13,Shopping Hub Sonsi Partners With Plus Size Supermodel And Advocate, Emme
2011-10-10,Charming Shoppes Inc (CHRS): Today's Featured Retail Loser
2011-09-12,Charming Shoppes, Inc. To Participate In CL King's 9th Annual Best Ideas Conference
2011-09-09,Charming Shoppes Stock Hits New 52-Week Low (CHRS)
2011-09-05,Charming Shoppes Inc Stock Downgraded (CHRS)
2011-08-30,5 Short-Squeeze Possibilities on Earnings
2011-08-26,Charming Shoppes, Inc. Hosts Second Quarter Fiscal 2011 Sales And Earnings Conference Call On Thursday, September 1, 2011
2011-08-18,Charming Shoppes Stock Hits New 52-Week Low (CHRS)
2011-08-09,Charming Shoppes Stock Hits New 52-Week Low (CHRS)
2011-07-11,Charming Shoppes Inc. Stock Upgraded (CHRS)
2011-06-15,Charming Shoppes, Inc. To Participate In The Jefferies 2011 Global Consumer Conference
2011-06-13,Plus-Size Retailer Sonsi.com Celebrates First Anniversary With Relaunch, Unveils New Style Your Way™ Outfitting Tool
2011-06-02,Goldman Sachs, Orbitz, Yahoo Are Big Movers
2011-05-24,Applied Materials: After-Hours Trading
2011-05-24,Retail Winners & Losers: DSW, Office Depot
2011-05-23,Charming Shoppes Spikes on Possible Fashion Bug Sale
2011-05-16,Charming Shoppes, Inc. Hosts First Quarter Fiscal 2011 Sales And Earnings Conference Call On Thursday, June 2, 2011
2011-05-10,Plus Size Retailer Sonsi® Celebrates First Anniversary With Fashionista Fans At NYC's Full Figured Fashion Week™
2011-04-15,Retail Stock Winners: American Apparel, Finish Line
2011-03-29,Charming Shoppes, Inc. To Participate In The Telsey Advisory Group's 3rd Annual Spring Consumer Conference
2011-03-25,Retail Stock Winners: Wet Seal, Charming Shoppes
2011-03-24,Drugstore.com, Talbots: Small-Cap Winners
2011-03-24,Women's Apparel Stocks In Fashion: Retail Winners
2011-03-24,Charming Shoppes, Inc. Announces The Appointment Of Paula A. Price To Its Board Of Directors
2011-03-24,Charming Shoppes, Inc. Appoints Anthony M. Romano As President And Chief Executive Officer And Brian Woolf As Group President - Lane Bryant
2011-03-09,Charming Shoppes, Inc. Hosts Fourth Quarter Fiscal 2010 Sales And Earnings Conference Call On Thursday, March 24, 2011
2011-03-09,Charming Shoppes, Inc. Hosts Fourth Quarter Fiscal 2010 Sales And Earnings Conference Call On Thursday, March 24, 2011
2011-01-28,5 Stocks That Could Rebound in 2011
2010-12-20,10 Retail Stock Losers of 2010: Which Will Recover in 2011?
2017-03-17,Caladrius Biosciences Announces 2016 Fourth Quarter And Full Year Financial Results
2017-03-16,Hitachi Chemical Signs Agreement To Purchase From Caladrius Biosciences The Remaining 80.1% Interest In PCT For $75 Million
2017-03-13,Caladrius Biosciences To Host 2016 Fourth Quarter And Full Year Financial Results Conference Call On March 17, 2017 At 8:30 Am Eastern Time
2017-03-02,Caladrius Biosciences To Present At Upcoming March Conferences
2017-02-23,Caladrius Biosciences Awarded $12.2 Million Grant From CIRM In Support Of Phase 2 Clinical Trial Of CLBS03 To Treat Type 1 Diabetes
2017-02-01,Caladrius Biosciences To Present At Upcoming February Conferences
2017-01-25,Caladrius Biosciences Announces Addition Of Three Clinical Sites, Including University Of California, San Francisco, For The Ongoing Phase 2 Study Of CLBS03 In T1D
2017-01-06,Caladrius Biosciences Updates Status Of Receipt Of Funds For A Portion Of Previously Announced Private Placement
2017-01-03,Caladrius Biosciences To Present At Upcoming January Conferences
2016-12-05,Caladrius Biosciences To Present At Upcoming December Conferences
2016-11-22,Caladrius Biosciences Subsidiary, PCT, Earns FACT Re-Accreditation For Its Cell Therapy Development And Manufacturing Facilities
2016-11-07,Caladrius Biosciences Reports 2016 Third Quarter Financial Results
2016-11-02,Caladrius Biosciences To Host 2016 Third Quarter Financial Results Conference Call On November 7 At 5:00 Pm Eastern Time
2016-10-31,Caladrius Biosciences Begins Enrollment Of Second Cohort Of Phase 2 Trial Of CLBS03 As A Treatment For Type 1 Diabetes Following Favorable Safety Data From First Cohort
2016-10-27,Caladrius Biosciences To Present At Upcoming November Conferences
2016-10-12,Caladrius Biosciences Appoints Gregory R. Brown, MD, To Its Board Of Directors
2016-10-04,Caladrius Biosciences To Present At Upcoming October Conferences
2016-09-19,Caladrius Subsidiary, PCT, Announces Five-Year Strategic Manufacturing Services Agreement With Adaptimmune
2016-09-15,Caladrius Biosciences, Inc. Enters Into Agreements To Raise $25 Million In Common Equity Priced At Market Without Warrants
2016-09-08,Caladrius Biosciences To Present At Upcoming September Conferences
2016-09-06,Caladrius Biosciences Completes Enrollment Of First Patient Cohort In Phase 2 Trial Of CLBS03 To Treat Type 1 Diabetes
2016-08-09,Caladrius Biosciences Reports 2016 Second Quarter Financial Results
2016-08-02,Caladrius Biosciences To Host 2016 Second Quarter Financial Results Conference Call On August 9 At 5:00 Pm Eastern Time
2016-07-28,Caladrius Biosciences Receives FDA Fast Track Designation For CLBS03 To Treat Recent Onset Type 1 Diabetes
2016-07-27,Caladrius Biosciences Announces 1-for-10 Reverse Split
2016-07-07,Caladrius Biosciences To Present At Upcoming July Conferences
2016-06-27,Caladrius Biosciences SVP And President Of PCT, Robert Preti, PhD, Named Chairman Of The Alliance For Regenerative Medicine
2016-06-21,Caladrius Subsidiary, PCT, To Manufacture Phase 3 Cell Therapy Product For Kiadis Pharma
2016-06-01,Caladrius Biosciences To Present At Upcoming June Conferences
2016-05-26,Caladrius Biosciences Licenses Cell Therapy Technology For Ovarian Cancer And Subleases Irvine Facility To AiVita Biomedical
2016-05-12,Caladrius Biosciences Receives Orphan Drug Designation For CLBS03 To Treat Type 1 Diabetes
2016-05-09,Caladrius Biosciences To Present At Multiple Upcoming May Conferences
2016-05-05,Caladrius Biosciences Reports 2016 First Quarter Financial Results
2016-05-05,5 Breakout Stocks Under $10 Set to Soar
2016-04-28,Caladrius Biosciences To Host 2016 First Quarter Financial Results Conference Call On May 5 At 5:00 Pm Eastern Time
2016-04-20,Caladrius Biosciences To Present At Multiple Upcoming April Conferences
2016-04-18,Caladrius Reaches Agreement With Japanese Regulators On Development Plan For CD34 Cell Therapy For Critical Limb Ischemia
2016-03-29,Caladrius Biosciences Announces First Subject Treated In CLBS03 Type 1 Diabetes Phase 2 Trial
2016-03-17,Caladrius Biosciences To Present At Multiple Upcoming March Conferences
2016-03-15,Caladrius Biosciences Announces 2015 Fourth Quarter And Full Year Financial Results
2016-03-14,Caladrius Biosciences Subsidiary PCT, LLC Enters Into Global Collaboration And License Agreement With Hitachi Chemical
2016-03-11,7 Stocks Under $10 Making Big Moves Higher
2016-03-08,Caladrius Biosciences To Host 2015 Fourth Quarter And Full Year Financial Results Conference Call On March 15 At 5:00 Pm Eastern Time
2016-02-17,Caladrius Biosciences Licenses Dermatology Cell Technology To AiVita Biomedical
2016-02-08,8 Stocks Under $10 Set to Soar
2016-01-28,Caladrius Biosciences Announces Presentations At Upcoming Investor Conferences In February
2016-01-22,8 Stocks Under $10 Making Big Moves Higher
2016-01-13,Caladrius Biosciences Announces Presentations At Multiple Upcoming Conferences In January
2016-01-11,Caladrius Biosciences Out-Licenses CD34 Technology To SPS Cardio, LLC For Chronic Heart Failure And Acute Myocardial Infarction
2016-01-06,Caladrius Tightens Strategic Focus And Provides 2016 Revenue Guidance
2015-12-23,UPDATE -- Caladrius Announces Changes To Its Board Of Directors
2015-12-23,Caladrius Announces Changes To Its Board Of Directors
2015-12-01,Caladrius Announces Publication Of Two-Year Results From Phase 1 Trial Of Type 1 Diabetes Product Candidate In Science Translational Medicine
2015-11-09,Caladrius Biosciences Presents Additional Data Supporting Lead Product Candidate For Metastatic Melanoma At SITC 2015
2015-11-05,Caladrius Biosciences Announces Third Quarter 2015 Financial Results And Provides Corporate Update
2015-11-02,Caladrius Biosciences To Present At Multiple Upcoming November Conferences
2015-10-29,Caladrius Biosciences To Host Third Quarter 2015 Financial Results Conference Call On November 5 At 5:00 Pm
2015-10-08,Caladrius Biosciences Announces Management And Board Changes
2015-10-01,Caladrius Biosciences To Present At Multiple Upcoming October Conferences
2015-09-30,Caladrius To Present Data Elucidating CLBS20 Mechanism Of Action
2015-09-24,Caladrius Biosciences Receives Award From The National Cancer Institute
2015-09-22,Caladrius Biosciences And Sanford Research Establish Strategic Collaboration With Goal Of Developing Major Advance In Treatment Of Type 1 Diabetes
2015-09-10,Caladrius To Present At Multiple Upcoming Conferences
2015-09-08,PCT, LLC, A Caladrius Company, To Manufacture EU-Compliant Cell Therapy Product For IRX Therapeutics, Inc. From Its New Jersey Facility
2015-09-01,4 Biotech Stocks Under $10 to Trade for Breakouts
2015-08-13,5 Stocks Under $10 Set to Soar
2015-08-06,Caladrius Biosciences, Inc. Announces Second Quarter 2015 Financial Results And Provides Corporate Update
2015-08-06,Correction: Caladrius Biosciences Announces Second Quarter 2015 Financial Results Conference Call
2015-07-30,Caladrius Biosciences Announces Second Quarter 2015 Financial Results Conference Call
2015-07-23,Caladrius Biosciences Announces NIH Grant To Fund Retinal Disease Research
2015-06-29,Caladrius Biosciences Establishes Cardiovascular Scientific Advisory Board To Support Ongoing Development Efforts Using CD34 Cells
2015-06-23,Caladrius Biosciences Announces First Patient Dosed In Phase 3 Immunotherapy Trial For Melanoma
2015-06-18,Caladrius Announces Research Collaboration With The University Of Southern California And California Institute Of Technology
2015-06-15,PCT, A Caladrius Company, Expands Relationship With ImmunoCellular Therapeutics To Provide Manufacturing For Their Phase 3 Trial
,
,
,
2017-03-01,Lilly Completes Acquisition Of CoLucid Pharmaceuticals
2017-02-02,INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Whether The Sale Of CoLucid Pharmaceuticals, Inc. To Eli Lilly & Co. For $46.50 Per Share Is Fair To Shareholders
2017-01-31,Bragar Eagel & Squire, P.C. Is Investigating The Board Of Directors Of CoLucid Pharmaceuticals, Inc. (CLCD) On Behalf Of Stockholders And Encourages Investors To Contact The Firm
2017-01-31,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Into Whether The Sale Of CoLucid Pharmaceuticals, Inc. To Eli Lilly & Co. For $46.50 Per Share Is Fair To Shareholders -- CLCD
2017-01-30,INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional Information
2017-01-27,INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Whether The Sale Of CoLucid Pharmaceuticals, Inc. To Eli Lilly & Co. For $46.50 Per Share Is Fair To Shareholders -- CLCD
2017-01-23,SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information
2017-01-20,SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces An Investigation Of The Board Of Directors Of CoLucid Pharmaceuticals, Inc. -CLCD
2017-01-20,COLUCID SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces The Investigation Of CoLucid Pharmaceuticals, Inc. (CLCD) Over The Proposed Sale Of The Company To Eli Lilly And Company
2017-01-19,Robbins Arroyo LLP: Acquisition Of CoLucid Pharmaceuticals, Inc. (CLCD) By Eli Lilly And Company (LLY) May Not Be In Shareholders' Best Interests
2017-01-19,CoLucid Pharmaceuticals Reaches Analyst Target Price
2017-01-18,Harwood Feffer LLP Announces Investigation Of CoLucid Pharmaceuticals, Inc.
2017-01-18,Stocks Hold Mixed as Fed's Yellen Forecasts Series of Rate Hikes
2017-01-18,Must-Know Tricks On Trading Goldman Sachs, Ford and Other Very Active Stocks
2017-01-18,COLUCID PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Believes The Acquisition By Eli Lilly And Company May Be Unfair To Shareholders
2017-01-18,COLUCID PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
2017-01-18,Stocks Struggle for Direction as Economic Improvements May Push Fed Moves
2017-01-18,Stock Futures Inch Higher as Citigroup, Goldman Sachs Get Trading Boost
2017-01-18,Jazz Pharma, CoLucid Spike Premarket, Plus Other Biotech Movers
2017-01-18,CoLucid (CLCD) Alert: Johnson & Weaver, LLP Launches An Investigation Into The Fairness Of Price And Process In Proposed Sale Of CoLucid Pharmaceuticals, Inc.; Is $46.50 A Fair Price?
2017-01-18,Eli Lilly Acquires CoLucid Pharma, Adds Migraine Drug to Pipeline
2017-01-18,Lilly And CoLucid Pharmaceuticals Announce Agreement For Lilly To Acquire CoLucid
2016-11-28,CoLucid Pharmaceuticals To Present At The 28th Annual Piper Jaffray Healthcare Conference
2016-11-15,Airline Stocks Get Airborne
2016-11-14,CoLucid Pharmaceuticals Provides SPARTAN Enrollment Update
2016-11-09,CoLucid Pharmaceuticals Announces 2016 Third Quarter Results And Corporate Highlights
2016-11-08,CoLucid Pharmaceuticals To Present At The Stifel 2016 Healthcare Conference
2016-10-20,Why These 4 Little-Known Stocks Have Outgunned the DJIA This Year
2016-10-05,CoLucid Pharmaceuticals Announces Additional Analyses Of Lasmiditan's Onset Of Action Data From SAMURAI And Supporting Non-Clinical Data
2016-09-29,4 Stocks with Strong Technicals to Buy Now
2016-09-26,CoLucid Pharmaceuticals To Present At The Ladenburg Thalmann 2016 Healthcare Conference
2016-09-19,CORRECTING And REPLACING - CoLucid Pharmaceuticals Provides Interim Update On GLADIATOR
2016-09-19,CoLucid Pharmaceuticals Provides Interim Update On GLADIATOR
2016-09-17,CoLucid Pharmaceuticals Announces Achievement Of Secondary Endpoints In SAMURAI
2016-09-09,Here's a Reason Why CoLucid Pharmaceuticals (CLCD) Stock Is Higher Today
2016-09-09,CoLucid Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2016-09-08,CoLucid Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2016-09-07,CoLucid Pharmaceuticals Reaches Analyst Target Price
2016-09-06,CoLucid Pharmaceuticals (CLCD) Stock Skyrockets on Migraine Drug Trial Success
2016-09-06,CoLucid Pharmaceuticals Announces Achievement Of Both Primary And Key Secondary Endpoints In The SAMURAI Phase 3 Pivotal Trial Of Lasmiditan In Migraine
2016-08-26,These 5 Stocks Are Breaking Out
2016-08-18,King Fish Media Announces Website Launch For CoLucid Pharmaceuticals
2016-08-10,CoLucid Pharmaceuticals Announces 2016 Second Quarter Results And Corporate Highlights
2016-06-22,CoLucid Pharmaceuticals Hosting Key Opinion Leader Meeting In New York City
2016-06-07,CoLucid Pharmaceuticals Announces Last Patient Randomized In SAMURAI Phase 3 Pivotal Trial Of Lasmiditan In Migraine
2016-06-02,CoLucid Pharmaceuticals To Participate At The Jefferies 2016 Healthcare Conference
2016-05-19,CoLucid Pharmaceuticals Announces Initiation Of Second Phase 3 Pivotal Trial Of Lasmiditan In Migraine
2016-05-11,CoLucid Pharmaceuticals Announces 2016 First Quarter Results And Corporate Highlights
2016-03-15,CoLucid Pharmaceuticals Announces Election Of Alison Lawton To Board Of Directors
2016-03-03,CoLucid Pharmaceuticals To Present Corporate Overview At The Cowen & Company 36th Annual Health Care Conference
2016-03-02,CoLucid Pharmaceuticals Announces 2015 Fourth Quarter And Year-End Results And Corporate Highlights
2016-03-01,CoLucid Pharmaceuticals Announces Special Protocol Agreement For SPARTAN
2016-02-23,CoLucid Pharmaceuticals Announces Confirmatory Support For Non-vasoconstrictive Mechanism Of Action For Lasmiditan
2016-02-02,CoLucid Pharmaceuticals To Present Corporate Overview At The BIO CEO & Investor Conference
2016-01-05,CoLucid Pharmaceuticals And IMS Health Publish White Paper To Address Migraine Market Misperceptions
2015-12-08,CoLucid Pharmaceuticals Announces Appointment Of Dr. Raymond Skwierczynski As Head, Pharmaceutical Operations
2015-11-30,CoLucid Pharmaceuticals Provides SAMURAI Enrollment Update
2015-11-12,CoLucid Pharmaceuticals To Present Corporate Overview At The Stifel 2015 Healthcare Conference
2015-11-10,CoLucid Pharmaceuticals Announces Third Quarter 2015 Results And Corporate Highlights
2015-10-27,CoLucid Pharmaceuticals Announces Election Of Mark Corrigan, M.D., To Board Of Directors
2015-10-08,CoLucid Pharmaceuticals Announces Initiation Of Phase 3 Long-Term, Open-Label Trial Of Lasmiditan In Migraine
2015-09-03,CoLucid Pharmaceuticals To Present At Two Investor Conferences In September
2015-08-12,CoLucid Pharmaceuticals Announces Second Quarter 2015 Results And Corporate Highlights
2015-07-13,CoLucid Pharmaceuticals Announces Appointment Of Marvin L. White To Board Of Directors
2015-05-06,CoLucid Pharmaceuticals Announces Pricing Of Initial Public Offering
,
,
,
2017-03-21,First Week Of November 17th Options Trading For Celldex Therapeutics (CLDX)
2017-03-14,Celldex Provides Corporate Update And Reports Full Year 2016 Results
2017-03-01,Celldex Therapeutics Announces Appointment To Board Of Directors
2017-02-27,First Week of CLDX March 17th Options Trading
2017-02-13,Celldex Therapeutics Announces Upcoming Investor Presentations And 2016 Year-End Call
2017-01-12,Are People Finally Noticing?
2016-12-22,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
2016-12-22,2016 Was a Terrible Year for Biotech but the Tweets Were on Point
2016-12-14,Celldex Therapeutics Announces Appointment To Board Of Directors
2016-12-05,Theresa LaVallee, Ph.D., Joins Celldex Therapeutics' Senior Management Team
2016-12-05,Celldex Presents Data On CDX-1140, A Novel CD40 Agonist Antibody For Hematologic And Solid Malignancies, At The American Society Of Hematology (ASH) Annual Meeting
2016-11-29,Celldex Therapeutics Completes Acquisition Of Kolltan Pharmaceuticals
2016-11-28,Commit To Buy Celldex Therapeutics At $3, Earn 23.3% Using Options
2016-11-15,Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive
2016-11-14,Celldex Presents Data On New Product Candidate, CDX-1140, A Novel CD40 Agonist Antibody
2016-11-07,Celldex Reports Third Quarter 2016 Results
2016-11-01,Celldex Expands Antibody And Immuno-Oncology Portfolio With The Acquisition Of Kolltan Pharmaceuticals
2016-10-09,Phase 2 Study Of Single-agent Glembatumumab Vedotin In Patients With Checkpoint-Refractory Metastatic Melanoma Meets Primary Overall Response Endpoint And Demonstrates Clinically Meaningful Duration Of Response
2016-09-23,Celldex Therapeutics To Present At The Leerink Partners Rare Disease & Immuno-Oncology Roundtable
2016-08-11,Celldex Appoints Elizabeth Crowley As Chief Product Development Officer
2016-08-09,Celldex Therapeutics (CLDX) Stock Up on Q2 Results
2016-08-09,Celldex Therapeutics (CLDX) Is Strong On High Volume Today
2016-08-08,Celldex Reports Second Quarter 2016 Results
2016-08-02,Celldex To Report Second Quarter 2016 Financial Results And Host Corporate 2016 Objectives Update Call
2016-07-11,Celldex Therapeutics Initiates Phase 1/2 Clinical Trial Of New Product Candidate CDX-014 In Advanced Renal Cell Carcinoma
2016-07-07,Celldex Therapeutics To Participate In The Cantor Fitzgerald 2nd Annual Healthcare Conference
2016-06-07,Celldex Therapeutics (CLDX) In A Perilous Reversal
2016-06-06,Celldex Therapeutics (CLDX) Marked As A Dead Cat Bounce Stock
2016-06-04,Celldex Therapeutics' CDX-1401, CDX-301 Combination Generates Potent NY-ESO-1 Immune Responses In Patients With Melanoma
2016-06-03,Immunomedics Kicked Out of Prestigious ASCO Cancer Conference
2016-06-03,Celldex Therapeutics (CLDX): Today's Weak On High Volume Stock
2016-06-01,Great Breadth Fails to Counter Boring Market
2016-05-31,6 Breakout Stocks Under $10 Set to Soar
2016-05-26,Commit To Buy Celldex Therapeutics At $3, Earn 30% Using Options
2016-05-23,Celldex Therapeutics (CLDX) Is Today's Strong On High Volume Stock
2016-05-10,Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Perilous Reversal" Stock
2016-05-05,Celldex Therapeutics (CLDX) Weak On High Volume
2016-05-05,Celldex Reports First Quarter 2016 Results
2016-04-27,Celldex Therapeutics Initiates Phase 1/2 Study Of Glembatumumab Vedotin In Squamous Cell Lung Cancer
2016-04-20,Celldex Therapeutics Presents Data Supporting The Clinical Development Of Glembatumumab Vedotin And The Preclinical CD40 Program At The AACR Annual Meeting 2016
2016-04-18,Celldex Therapeutics Presents Favorable Safety Profile And Immune Response Data From Phase 1/2 Study Of Varlilumab And Nivolumab At The AACR Annual Meeting 2016
2016-04-13,Short Interest In Celldex Therapeutics Increases 12%
2016-04-12,Anavex Plays the Orphan Drug Stock Promotion Game
2016-04-07,Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Perilous Reversal" Stock
2016-04-04,Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's Strong On High Relative Volume Stock
2016-03-30,7 Stocks Under $10 to Trade for Breakout Gains
2016-03-23,Celldex Therapeutics (CLDX) Highlighted As Today's Perilous Reversal Stock
2016-03-23,6 Biotech Stocks Under $10 to Trade for Big Breakouts
2016-03-17,Celldex Therapeutics To Present New Clinical And Preclinical Data At The AACR Annual Meeting 2016
2016-03-12,Biotech Stock Mailbag: Biomarin PKU Preview, Celldex Post-Mortem
2016-03-09,Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's Weak On High Relative Volume Stock
2016-03-08,Today's Dead Cat Bounce Stock Is Celldex Therapeutics (CLDX)
2016-03-08,Celldex Therapeutics (CLDX) Stock Downgraded at Jefferies
2016-03-07,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Of Celldex Therapeutics, Inc. And Its Board Of Directors In Connection With Possible Violations Of Federal Securities Laws
2016-03-07,3 Stocks Pushing The Health Care Sector Lower
2016-03-07,Here's Why Celldex (CLDX) Stock is Plunging Today
2016-03-07,Heavy Trading On Celldex Therapeutics (CLDX) Before Market Open
2016-03-07,Celldex Brain Tumor Vaccine Fails Pivotal Clinical Trial
2016-03-07,Data Safety And Monitoring Board Recommends Celldex's Phase 3 Study Of RINTEGA® (rindopepimut) In Newly Diagnosed Glioblastoma Be Discontinued As It Is Unlikely To Meet Primary Overall Survival Endpoint In Patients With Minimal Residual Disease
2016-03-03,Celldex Therapeutics To Present At The Cowen And Company 36th Annual Health Care Conference
2016-03-01,Celldex Therapeutics (CLDX) Marked As A Dead Cat Bounce Stock
2016-02-29,Celldex Therapeutics (CLDX) Showing Signs Of Perilous Reversal Today
2016-02-26,Celldex Therapeutics (CLDX) Stock Price Target Lowered at Cantor Fitzgerald
2016-02-25,Celldex Therapeutics (CLDX) Stock Gaining on Q4 Results
2016-02-25,Celldex Reports Fourth Quarter And Year-End 2015 Results
2016-02-24,First Week of April 15th Options Trading For Celldex Therapeutics (CLDX)
2016-02-24,Today's Weak On High Volume Stock: Celldex Therapeutics (CLDX)
2016-02-20,Celldex Presents Preliminary Cohort Data From Pilot Study Of CDX-301 In Allogeneic Hematopoietic Stem Cell Harvest At The 2016 BMT Tandem Meeting
2016-02-19,'Mad Money' Lightning Round: I'm Not Going Against Amgen
2016-02-18,Jim Cramer's 'Mad Money' Recap: Time to Start Buying Cheap Stocks
2016-02-18,Celldex To Report Fourth Quarter And Year-End 2015 Business/Financial Results And Host 2016 Corporate Strategy Conference Call
2016-02-18,Celldex Therapeutics is Now Oversold
2016-02-17,Celldex Therapeutics (CLDX) In A Perilous Reversal
2016-02-11,Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Dead Cat Bounce" Stock
2016-02-04,Celldex Therapeutics To Present At The Leerink Partners 5th Annual Global Healthcare Conference
2016-02-03,Weak On High Volume: Celldex Therapeutics (CLDX)
2016-01-28,Celldex Nears Pivotal Decision Point for Brain Tumor Therapy
2016-01-27,Oversold Conditions For Celldex Therapeutics (CLDX)
2016-01-27,Celldex Therapeutics (CLDX) Highlighted As Weak On High Volume
2016-01-24,8 Things That Could Lift Biotech Stocks Out of Bear Market
2016-01-14,New 52-Week Low Could Prompt More Insider Buying At CLDX
2016-01-13,'Mad Money' Lightning Round: Buy, Buy, Buy Cedar Fair for the Yield
2016-01-12,Jim Cramer's 'Mad Money' Recap: Oil Is What's Fueling This Market
2016-01-11,Celldex Therapeutics (CLDX) Highlighted As Weak On High Volume
2016-01-08,Today's Dead Cat Bounce Stock: Celldex Therapeutics (CLDX)
2015-12-14,Cancer Immunotherapy ETF Offers High Growth Investing Potential
2015-12-08,Celldex Therapeutics Initiates Phase 1/2 Study Of Varlilumab In Combination With Atezolizumab In Renal Cell Carcinoma
2015-12-04,Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Dead Cat Bounce" Stock
2015-11-30,Celldex Therapeutics (CLDX) Strong On High Relative Volume Today
2015-11-24,Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Perilous Reversal" Stock
2015-11-24,4 Big-Volume Stocks to Trade for Big Gains
2015-11-23,Celldex Therapeutics (CLDX) Strong On High Relative Volume Today
2015-11-20,Barbarian At The Gate: Celldex Therapeutics (CLDX)
2015-11-20,Long-term Survival Benefit Demonstrated In Phase 2 ReACT Study Of RINTEGA(R) In Recurrent Bevacizumab-naive Glioblastoma
2015-11-13,Today's Dead Cat Bounce Stock: Celldex Therapeutics (CLDX)
2015-11-10,Celldex Therapeutics (CLDX) Showing Signs Of Perilous Reversal Today
2015-11-09,Celldex Therapeutics (CLDX) Is Strong On High Volume Today
2015-11-06,Watch Out: Barbarians At The Gate For Celldex Therapeutics (CLDX)
2015-11-06,Celldex Presents Varlilumab Mechanism Data At SITC Annual Meeting 2015
2015-11-05,Celldex Reports Third Quarter 2015 Results
2015-10-21,First Week of CLDX December 18th Options Trading
2015-10-16,Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's Strong On High Relative Volume Stock
2015-10-12,CLDX January 2018 Options Begin Trading
2015-10-09,Celldex Therapeutics (CLDX) Strong On High Relative Volume Today
2015-10-09,5 Stocks Ready for Breakouts
2015-09-30,10 Worst NASDAQ Biotech Stocks in the Third Quarter
2015-09-30,Celldex Therapeutics to Present at the Leerink Partners Immuno-Oncology Roundtable
2015-09-29,Interesting CLDX Put And Call Options For October 16th
2015-09-29,Healthcare Sector Stocks Under Review - Celldex Therapeutics, Alexion Pharmaceuticals, Advaxis, BioDelivery Sciences And Cytori Therapeutics
2015-09-23,Relative Strength Alert For Celldex Therapeutics
2015-09-04,Today's Dead Cat Bounce Stock: Celldex Therapeutics (CLDX)
2015-09-01,The Numbers Behind Biotech's Horrible, No Good, Awful August
2015-08-27,Insider Trading Alert - SWI, CLDX And CLGX Traded By Insiders
2015-08-26,Perilous Reversal Stock: Celldex Therapeutics (CLDX)
2015-08-24,Northwest Bio Forced to Temporarily Halt Enrollment of Brain Tumor Vaccine Study (Update)
2015-08-21,Celldex Therapeutics (CLDX) Is Today's Dead Cat Bounce Stock
2015-08-21,Biotech Stock Mailbag: Celldex, Bluebird, Kite, Inovio
2015-08-14,CLDX: Insiders vs. Shorts
2015-08-10,Celldex Reports Second Quarter 2015 Results
2015-08-04,Celldex To Report Second Quarter 2015 Financial Results And Host Corporate 2015 Objectives Update Call
2015-07-21,Weak On High Volume: Celldex Therapeutics (CLDX)
2015-07-15,Strong On High Relative Volume: Celldex Therapeutics (CLDX)
2015-07-02,Celldex Therapeutics To Present At The Cantor Fitzgerald Inaugural Healthcare Conference
2015-07-01,Celldex Therapeutics Appoints Richard Wright As Chief Commercial Officer
2015-06-30,Celldex Therapeutics (CLDX) Is Today's Dead Cat Bounce Stock
2015-06-29,Independent Data Safety And Monitoring Board Recommends Continuation Of Celldex's Phase 3 Study Of RINTEGA(R) (rindopepimut) In Newly Diagnosed Glioblastoma
2015-06-05,Biotech Stock Mailbag: More Duchenne Drama, CAR-T Trouble, ASCO '15 Rewind
2015-06-01,Heavy Early Morning Activity On Celldex Therapeutics (CLDX)
2015-06-01,ASCO '15 Report Card: Grading Biotech and Drug Stocks at Cancer Drug Confab
2015-05-31,ASCO '15: Celldex Immunotherapy Maintains Survival Benefit for Recurrent Brain Tumor Patients
2015-05-31,Randomized Phase 2 ReACT Study Of RINTEGA(R) In Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Overall Survival And Emergence Of Long-term Survival Benefit; Primary Endpoint Of PFS6 Met
2015-05-28,Celldex Therapeutics Initiates Phase 1/2 Study Of Varlilumab In Combination With Sunitinib In Metastatic Clear Cell Renal Cell Carcinoma
2015-05-27,Celldex Therapeutics To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-22,Biotech Stock Mailbag: ASCO Preview, CAR-T stocks, MannKind, Hate Mail!
2015-05-13,Celldex Therapeutics To Present Data From The ReACT Study At 2015 ASCO Annual Meeting
2015-05-13,Jumpstart ASCO '15 With This Quick List of Hot Research Abstracts
2015-05-01,Biotech Stock Mailbag: Biotech Bull So Insanely Good It Will Make You Forget Week's Pain
2015-04-29,Celldex Reports First Quarter 2015 Results
2015-04-28,Today's Dead Cat Bounce Stock Is Celldex Therapeutics (CLDX)
2015-04-27,Nasdaq Backs Off Record High as Biotech Drags Markets Lower
2015-04-27,Biotech Drags on Stocks; Crude Oil Drops Below $57
2015-04-27,Celldex Therapeutics (CLDX) Showing Signs Of Being Water-Logged And Getting Wetter
2015-04-20,Celldex's Varlilumab Demonstrates Synergistic Anti-Tumor Activity With PD-1 Signaling Blockade In Preclinical Studies
2015-04-07,Stock Index Tracking Red-Hot Cancer Immunotherapy Field Launched
2015-04-06,Celldex Therapeutics' Phase 2 EMERGE Study Of Glembatumumab Vedotin In Metastatic Breast Cancer Published In Journal Of Clinical Oncology
2015-04-06,Celldex Therapeutics Announces Initiation Of Phase 1/2 Study Of Varlilumab In Combination With Ipilimumab And CDX-1401 In Metastatic Melanoma
2015-03-17,Celldex Therapeutics Announces Clinical Trial Collaboration With Roche To Evaluate The Combination Of Varlilumab And MPDL3280A
2015-03-03,Stock To Watch: Celldex Therapeutics (CLDX) In Perilous Reversal
2015-03-03,Celldex Therapeutics Announces Upcoming Presentation At The Cowen And Company 35th Annual Health Care Conference
2015-02-27,Celldex Announces Exercise Of Underwriters' Option To Purchase Additional Shares
2015-02-27,Biotech Stock Mailbag: Receptos, Celldex Therapeutics, Exact Sciences
2015-02-25,Celldex Therapeutics Prices Public Offering Of Common Stock
2015-02-24,Celldex Therapeutics Announces Proposed Public Offering Of Common Stock
2015-02-24,Celldex Therapeutics (CLDX) Stock Rises Today on Rintega FDA Designation, Fourth-Quarter Earnings
2015-02-24,Celldex Reports Fourth Quarter And Year-End 2014 Results
2015-02-23,Celldex's Rindopepimut (Rintega(R)) Receives FDA Breakthrough Therapy Designation For The Treatment Of Adult Patients With EGFRvIII-positive Glioblastoma
2015-02-19,Celldex To Report Fourth Quarter And Fiscal 2014 Business/Financial Results And Host 2015 Corporate Strategy Conference Call
2015-02-09,Celldex Therapeutics Announces Upcoming Presentation At The 2015 Leerink Global Healthcare Conference
2015-01-29,Celldex Therapeutics (CLDX) Weak On High Volume Today
2015-01-29,Celldex Therapeutics And Bristol Myers-Squibb Announce Initiation Of Phase 1/2 Combination Study Of Varlilumab And Opdivo(R) In Advanced Refractory Solid Tumors
2015-01-21,Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Barbarian At The Gate" Stock
2015-01-06,Traders Are Placing Long-Term Bets on Celldex Therapeutics
2014-12-18,Six Biotech and Technology Stocks With Strong Technical Set-Ups
2014-12-18,Celldex Therapeutics Announces Appointment To Board Of Directors
2014-12-15,Celldex Announces Completion Of Enrollment In Phase 3 Study Of Rindopepimut In Frontline Glioblastoma
2014-12-05,Today's Dead Cat Bounce Stock: Celldex Therapeutics (CLDX)
2014-12-04,An Unproductive Day in the Markets
2014-12-04,Celldex Therapeutics Initiates A Phase 2 Study Of Glembatumumab Vedotin In Patients With Advanced Melanoma
2014-11-21,Biotech Stock Mailbag: Northwest Bio, Celldex, Puma, MannKind
2014-11-20,Celldex Therapeutics (CLDX) Stock Rises Today on High Volume
2014-11-18,Celldex Therapeutics (CLDX) Stock Sells Off Today Following Monday's Gains
2014-11-18,Perilous Reversal Stock: Celldex Therapeutics (CLDX)
2014-11-17,Celldex Therapeutics (CLDX) Stock Surges Following Brain Tumor Immunotherapy Results
2014-11-17,Heavy Early Morning Activity On Celldex Therapeutics (CLDX)
2014-11-14,Celldex Immunotherapy Prolongs Survival for Recurrent Brain Tumor Patients
2014-11-14,Interim Update From Randomized Phase 2 ReACT Study Of Rindopepimut In Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Survival Benefit
2014-11-07,Celldex Presents Varlilumab Proof Of Concept Data At SITC Annual Meeting 2014
2014-11-05,Celldex Therapeutics (CLDX) Stock Drops on Change in Phase 3 Enrollment Criteria
2014-11-05,Celldex Therapeutics Shares Fall on Breast Cancer Study Changes
2014-11-04,Celldex Reports Third Quarter 2014 Results
2017-03-20,Look for Clovis Oncology to Resume Its Advance
2017-03-15,Notable Wednesday Option Activity: CLVS, KMG, NYLD
2017-03-15,Goldman Sachs Raises Clovis Oncology Price Target to $75
2017-03-15,6 Stocks Trending Up With Major Volume
2017-03-14,AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results
2017-03-12,Clovis Oncology Presents New Data From Phase 2 Studies Of Rucaparib In Advanced Ovarian Cancer At 2017 SGO Annual Meeting On Women's Cancer
2017-02-22,Clovis Oncology Announces 2016 Operating Results
2017-02-18,Johnson & Weaver, LLP Announces Investigations Of Clovis Oncology, Inc., USANA Health Sciences, Inc., Anthera Pharmaceuticals, Inc., And PixarBio Corporation
2017-02-17,Clovis, Tesaro Soar on Astrazeneca Phase Three News
2017-02-13,Morgan Stanley, Twitter, Tesaro: Doug Kass' Views
2017-02-10,Clovis Oncology Inc Reaches Analyst Target Price
2017-02-09,Clovis Oncology To Announce Fourth Quarter/Year-End 2016 Financial Results And Host Webcast Conference Call On February 22
2017-02-08,Biotech Tesaro Climbs on Takeout Reports
2017-02-01,Clovis Oncology And Strata Oncology Announce Collaboration To Accelerate Enrollment In Rucaparib Prostate Cancer Development Program
2017-01-10,4 Biotech Names That Could Be M&amp;A Targets
2017-01-09,Clovis Oncology To Present At The 35th Annual J.P. Morgan Healthcare Conference
2017-01-04,Clovis Oncology Announces Exercise In Full Of Underwriters' Option To Purchase Additional Shares Of Common Stock
2017-01-03,Clovis Oncology Announces Upsizing And Pricing Of Public Offering Of Common Stock
2017-01-03,Clovis Oncology Announces Proposed Offering Of Common Stock
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2016-12-19,Noteworthy Monday Option Activity: CLVS, GTY, BEAT
2016-12-19,Big-Cap Tech Names, Biotechs, Oils Lifting Market
2016-12-19,Clovis Oncology Announces FDA Accelerated Approval Of RUBRACA™ (rucaparib) For The Monotherapy Treatment Of Advanced Ovarian Cancer In Women With Deleterious Germline Or Somatic BRCA Mutations Treated With Two Or More Chemotherapies
2016-12-19,Clovis Oncology Gets FDA Approval for New Ovarian Cancer Drug
2016-12-19,Clovis Oncology Secures FDA Approval for New Ovarian Cancer Drug
2016-12-01,Lifshitz & Miller Law Firm Announces Investigation Of Adeptus Health Inc., Avid Technology, Inc., Cempra, Inc., Clovis Oncology, Inc., Impax Laboratories, Inc., Ligand Pharmaceuticals Incorporated, Pattern Energy Group Inc. And Kandi Technologies Group, Inc.
2016-11-30,Newman Ferrara LLP Announces Corporate Governance Investigation Of Clovis Oncology Inc.
2016-11-22,First Week of July 2017 Options Trading For Clovis Oncology (CLVS)
2016-11-17,Robbins Arroyo LLP: Clovis Oncology, Inc. (CLVS) Misled Shareholders According To A Recently Filed Lawsuit
2016-11-14,CLVS Crosses Above Average Analyst Target
2016-11-03,Clovis Oncology Announces Q3 2016 Operating Results And Corporate Update
2016-11-01,'Mad Money' Lightning Round: No Sunshine for Solar Plays
2016-10-31,Jim Cramer's 'Mad Money' Recap: Earnings, Politics and Uncertainty Stir the Pot
2016-10-31,Research Reports On Biotech Equities -- Mast Therapeutics, Array BioPharma, Galena Biopharma, And Clovis Oncology
2016-10-31,Clovis Oncology To Present At The 2016 Credit Suisse Healthcare Conference
2016-10-27,Clovis Oncology To Announce Third Quarter 2016 Financial Results And Host Webcast Conference Call On November 3
2016-10-25,After FDA Approval, Merck Posts Better-Than-Expected Earnings
2016-10-19,'Mad Money' Lightning Round: People Keep Underrating Cable Stocks
2016-10-18,Jim Cramer's 'Mad Money' Recap: These Companies Have Changed How We Live
2016-10-08,How to Anticipate When a Positive Stock Trend Is About to Reverse
2016-10-08,Tesaro Drug Delays Recurrence of Ovarian Cancer, New Clinical Trial Shows
2016-10-07,Clovis Oncology (CLVS) Stock Tumbles on Trial Update, SunTrust Bullish
2016-10-07,Clovis Falls on Fears Ovarian Cancer Drug Inferior to Competition
2016-10-07,Clovis Oncology Presents Efficacy And Safety Data From New Drug Application (NDA) Population For Rucaparib In The Treatment Of Advanced Mutant BRCA Ovarian Cancer At 2016 ESMO Congress
2016-10-04,Investor's Guide to This Week's Clovis, Tesaro Ovarian Cancer Drug Updates
2016-09-29,Jim Cramer's 'Mad Money' Recap: Blame the Banks for Today's Market Drop
2016-09-28,Clovis Oncology Announces Rucaparib Data Presentations At ESMO 2016 Congress
2016-09-23,Takeover Chatter Around Clovis May Be Overdone
2016-09-22,'Mad Money' Lightning Round: Broadcom Is Going to $200
2016-09-21,Jim Cramer's 'Mad Money' Recap: Just Buy What's Working
2016-09-21,Here's Why Shares of Clovis Oncology Are Higher Wednesday
2016-09-21,Clovis Oncology Charts Suggest Aggressive Buying
2016-09-21,Clovis Oncology (CLVS) Stock Advances, Credit Suisse Upgrades
2016-09-21,Morning Movers: MYL, XOM, MSFT, GIS, CLVS
2016-09-21,Analysts' Actions -- Clovis, Altria, Sketchers, Wells Fargo and More
2016-09-08,Here's A Reason Why Clovis Oncology (CLVS) Stock Is Surging Today
2016-08-31,Here's a Reason Why Clovis Oncology (CLVS) Stock Is Gaining Today
2016-08-26,'Mad Money' Lightning Round: I Can't Recommend Gilead
2016-08-25,Jim Cramer's 'Mad Money' Recap: Markets Make This Economy, Not the Fed
2016-08-24,7 Stocks Trading on Big Volume -- and What to Do With Them Now
2016-08-24,CLVS Crosses Above Average Analyst Target
2016-08-23,Here's a Reason Why Clovis Oncology (CLVS) Stock Climbed Today
2016-08-23,FDA Accepts Clovis Oncology's New Drug Application For Rucaparib For Priority Review For The Treatment Of Advanced Mutant BRCA Ovarian Cancer
2016-08-08,Clovis Oncology Announces Q2 2016 Operating Results And Corporate Update
2016-07-26,Clovis Oncology To Announce Second Quarter 2016 Financial Results And Host Webcast Conference Call On August 8
2016-06-29,16 Biopharma Companies Besides Medivation That Are Attractive Targets
2016-06-06,Clovis Oncology Presents Data From Phase 2 Studies Of Rucaparib In Advanced Ovarian Cancer And Pancreatic Cancer At 2016 ASCO Annual Meeting
2016-05-19,Clovis Oncology Announces Data Presentations At 2016 ASCO Annual Meeting
2016-05-12,Clovis Oncology Becomes Oversold (CLVS)
2016-05-11,The Shuman Law Firm Investigates Clovis Oncology, Inc.
2016-05-05,Clovis Oncology Announces Q1 2016 Operating Results And Corporate Update
2016-04-26,Clovis Oncology To Announce First Quarter 2016 Financial Results And Host Webcast Conference Call On May 5
2016-04-13,Why Clovis Oncology (CLVS) Stock is Tumbling Today
2016-04-12,Clovis Oncology Provides Update On FDA Oncologic Drugs Advisory Committee Meeting To Review Rociletinib For Treatment Of Advanced T790M-Positive Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer
2016-04-12,Clovis Lung Cancer Drug Trashed at FDA Panel, CEO Exit Next?
2016-04-12,Trading Of Clovis Oncology, Inc. Common Stock Halted
2016-04-11,Why Clovis Oncology (CLVS) Stock is Dropping Today
2016-04-08,Clovis Smart Move is to Drop Damaged Lung Cancer Drug Altogether
2016-04-08,FDA Posts Briefing Documents For Advisory Committee Meeting To Review Clovis Oncology's Rociletinib For Treatment Of Advanced T790M-Positive Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer
2016-03-22,First Week of May 20th Options Trading For Clovis Oncology (CLVS)
2016-02-25,Clovis Oncology Announces 2015 Operating Results
2016-02-16,Clovis Oncology To Announce Fourth Quarter/Year-End 2015 Financial Results And Host Webcast Conference Call On February 25
2016-02-12,Clovis Oncology Announces Rociletinib New Drug Application Scheduled For Presentation At Upcoming FDA Oncologic Drugs Advisory Committee Meeting
2016-01-27,Clovis Oncology Initiates Immunotherapy Combination Trial
2016-01-26,Clovis Oncology Becomes Oversold (CLVS)
2016-01-25,Clovis Oncology Appoints Dale Hooks As Chief Commercial Officer
2016-01-18,UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders Of Clovis Oncology, Inc. Of Filing Of Class Action Lawsuit And Lead Plaintiff Deadline Of January 18, 2016 - CLVS
2016-01-15,SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Clovis Oncology, Inc. - CLVS
2016-01-12,UPCOMING DEADLINE ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Clovis Oncology, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2016-01-12,INVESTOR ALERT: The Law Offices Of Vincent Wong Remind Investors Of Class Action Involving Clovis Oncology, Inc. And A Lead Plaintiff Deadline Of January 19, 2016
2016-01-08,Lifshitz & Miller Law Firm Announces Investigation Of Chipotle Mexican Grill, Inc., Clovis Oncology, Inc., Consolidated Tomoka Land Co., Marchex, Inc., Multi-Color Corp., SunEdison, Inc., And Vital Therapies, Inc.
2016-01-08,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Clovis Oncology, Inc. Of Filing Of Class Action Lawsuit And Lead Plaintiff Deadline Of January 18, 2016 - CLVS
2016-01-08,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Clovis Oncology, Inc. Of Class Action Lawsuit And Upcoming Deadline - CLVS
2016-01-07,Levi & Korsinsky, LLP Notifies Shareholders Of Clovis Oncology, Inc. Of Filing Of Class Action Lawsuit And Lead Plaintiff Deadline Of January 18, 2016
2016-01-06,Clovis Oncology To Present At The 34th Annual J.P. Morgan Healthcare Conference
2015-12-19,The Naughty List: Finalists for Worst Biopharma CEO of 2015
2015-12-16,CLVS Investors: GPM Reminds Investors Of The Deadline In The Securities Class Action On Behalf Of Clovis Oncology, Inc. Investors
2015-12-15,Clovis Oncology Receives Notification Of PDUFA Extension For Rociletinib
2015-12-11,Investor Deadline Alert: Law Offices Of Howard G. Smith Reminds Clovis Oncology, Inc. Investors Of Upcoming Lead Plaintiff Deadline
2015-12-10,Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Clovis Oncology, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2015-12-08,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Clovis Oncology, Inc. - CLVS
2015-12-08,IMPORTANT SHAREHOLDER NOTICE: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against Clovis Oncology, Inc. And Encourages Investors To Contact The Firm Before The Deadline
2015-12-04,CLVS INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Clovis Oncology, Inc.
2015-12-02,Clovis Oncology, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors
2015-12-02,STOCK ALERT: Rosen Law Firm Reminds Clovis Oncology, Inc. Investors Of Important Deadline In Class Action Filed By Firm
2015-12-02,Shareholder Class Action Filed Against Clovis Oncology, Inc. - CLVS
2015-12-02,Clovis Oncology, Inc. Stock Alert: Schubert Firm Investigates Potential Breaches Of Fiduciary Duty
2015-11-30,Wolf Popper LLP Announces Investigation On Behalf Of Investors In Clovis Oncology, Inc.
2015-11-23,Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Clovis Oncology, Inc.
2015-11-23,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors Of Class Action Against Clovis Oncology, Inc. And Lead Plaintiff Deadline
2015-11-21,Clovis Blowup Conjures Bad Biotech Memories of ImClone Darkness
2015-11-20,Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Clovis Oncology, Inc.
2015-11-20,EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Clovis Oncology, Inc.
2015-11-19,INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Securities Fraud By Clovis Oncology, Inc. And Certain Officers And Directors
2015-11-17,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Securities Fraud By Clovis Oncology, Inc. And Certain Officers And Directors -- CLVS
2015-11-17,SHAREHOLDER NOTICE: Goldberg Law PC Announces An Ongoing Investigation Of Claims Against Clovis Oncology, Inc. And Encourages Shareholders To Contact The Firm
2015-11-16,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Clovis Oncology, Inc.
2015-11-16,Market News: Range Resources, Steadymed, Clovis Oncology
2015-11-16,Stocks Rally to Close Higher After Choppy Start
2015-11-16,EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Clovis Oncology, Inc. - CLVS
2015-11-16,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud By Clovis Oncology, Inc. And Certain Officers And Directors
2015-11-16,Stocks Are Trading Near Session Highs
2015-11-16,Clovis Oncology (CLVS) Stock Plunging On Anticipated Delay in FDA Drug Approval
2015-11-16,Clovis Craters on Lung Cancer Drug-Review Delay
2015-11-16,Clovis Oncology Announces Regulatory Update For Rociletinib NDA Filing
2015-11-05,Clovis Oncology Announces Third Quarter 2015 Operating Results
2015-11-03,Clovis Oncology To Present At The 2015 Credit Suisse Healthcare Conference
2015-10-22,Clovis Oncology To Announce Third Quarter 2015 Financial Results And Host Webcast Conference Call On November 5
2015-09-29,Clovis Oncology Announces U.S. And E.U. Regulatory Milestones For Rociletinib In The Treatment Of Advanced EGFR-Mutant T790M+ Non-Small Cell Lung Cancer
2015-09-23,Clovis Oncology Announces Data Presentations At 2015 European Cancer Congress
2015-09-10,Clovis Oncology To Present At The Morgan Stanley Global Healthcare Conference 2015
2015-09-04,Clovis Oncology Announces Data Presentations At 16th World Conference On Lung Cancer
2015-08-11,Clovis Oncology Enters Into Clinical Trial Collaboration
2015-08-06,Clovis Oncology Announces Second Quarter 2015 Operating Results
2015-08-03,Clovis Oncology Completes U.S. And E.U. Regulatory Submissions For Rociletinib For The Treatment Of Advanced EGFR-Mutant T790M+ Non-small Cell Lung Cancer
2015-07-23,Clovis Oncology To Announce Second Quarter 2015 Financial Results And Host Webcast Conference Call On August 6
2015-07-10,Clovis Oncology Announces Exercise In Full Of Underwriters' Option To Purchase Additional Shares Of Common Stock
2015-07-08,Clovis Oncology Announces Pricing Of Public Offering Of Common Stock
2015-07-07,Clovis Oncology Announces Proposed Offering Of Common Stock
2015-07-02,Fly Watch: Biotech Sector Events To Watch For This Summer
2015-07-01,Clovis Oncology Initiates Rolling NDA Submission To The FDA For Rociletinib In The Treatment Of Advanced EGFR-Mutant Non-small Cell Lung Cancer
2015-06-22,Clovis Oncology Appoints Dr. Lindsey Rolfe As Chief Medical Officer
2015-06-01,ASCO '15 Report Card: Grading Biotech and Drug Stocks at Cancer Drug Confab
2015-06-01,Clovis Wins One ASCO '15 Battle, Loses Another, Against Rival AstraZeneca
2015-05-31,Clovis Oncology's Rociletinib (CO-1686) Phase 2 Study Results Demonstrate Consistent And Promising Clinical Activity And Disease Control In Very Advanced Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
2015-05-30,Clovis Oncology's Phase 2 Studies Of Rucaparib In Ovarian Cancer Demonstrate Highly Compelling Clinical Activity, In Both BRCA-mutant And BRCA-like Patients, Together Comprising Approximately 60 Percent Of Patients
2015-05-29,Fly Watch: Several Names That May Move Following ASCO Meeting
2015-05-22,Biotech Stock Mailbag: ASCO Preview, CAR-T stocks, MannKind, Hate Mail!
2015-05-13,Clovis Oncology Announces Data Presentations At 2015 ASCO Annual Meeting
2015-05-13,Jumpstart ASCO '15 With This Quick List of Hot Research Abstracts
2015-05-06,Clovis Oncology Announces First Quarter 2015 Operating Results
2015-04-23,Clovis Oncology To Announce First Quarter 2015 Financial Results And Host Webcast Conference Call On May 6
2015-04-13,Clovis Oncology (CLVS) Stock Spikes Today on Analyst Upgrade
2015-04-06,Clovis Oncology (CLVS) Stock Gains in After-Hours Trading After 'Breakthrough Therapy' Designation
2015-04-06,Clovis Oncology Receives Breakthrough Therapy Designation For Rucaparib For Monotherapy Treatment Of Advanced Ovarian Cancer In Patients With BRCA-mutated Tumors (Inclusive Of Both Germline And Somatic BRCA Mutations)
2015-03-21,'Fast Money' Recap: How to Buy Into Biotech Without Going Crazy
2015-02-25,Clovis Oncology Announces 2014 Operating Results
2015-02-17,Clovis Oncology To Announce Fourth Quarter/Year-End 2014 Financial Results And Host Webcast Conference Call On February 25
2015-02-04,Clovis Oncology To Present At The 2015 Leerink Global Healthcare Conference
2015-01-13,International Tower Hill Mines Gets A John Paulson Lift?
2015-01-05,Clovis Oncology To Present At The 33rd Annual J.P. Morgan Healthcare Conference
2014-11-19,Initial Data From Ongoing Phase 2 ARIEL2 Study Of Rucaparib In Ovarian Cancer Demonstrate Encouraging Clinical Activity And Safety In Both BRCA Mutant And BRCAness Patients
2014-11-19,Clovis Lung Cancer Update Swings Momentum to Rival, Slightly
2014-11-18,Interim Data From Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling And Durable Clinical Activity And Progression-free Survival (PFS) In Patients With EGFR-Mutant Non-small Cell Lung Cancer (NSCLC)
2014-11-17,Clovis Oncology Enters Into Oncology Clinical Trial Collaboration With GlaxoSmithKline
2014-11-12,Clovis Oncology Announces First Patient Enrolled In TIGER-1 Study
2014-11-06,Clovis Oncology Announces Third Quarter 2014 Operating Results
2014-11-04,Clovis Oncology To Present At The 2014 Credit Suisse Healthcare Conference
2014-11-03,Super Important Biotech and Drug Stock Events for November
2014-10-27,Short Interest In Clovis Oncology Jumps 21.4%
2014-10-24,First Week of December 20th Options Trading For Clovis Oncology (CLVS)
2014-10-23,Clovis Oncology Announces First Patient Enrolled In Lucitanib Phase 2 Study In Squamous Non-small Cell Lung Cancer
2014-10-22,Clovis Oncology To Announce Third Quarter 2014 Financial Results And Host Webcast Conference Call On November 6
2014-10-02,Three Speculative Biotech Plays
2014-09-30,3 Unusual-Volume Stocks Triggering Breakout Trades
2014-09-29,Clovis Shares Higher on Improved Outlook for Lung Cancer Drug
2014-09-28,Data From Ongoing Phase 2 Studies Of Rucaparib In Ovarian Cancer Demonstrate Safety And Clinical Activity, Validate Differentiated Strategy
2014-09-10,Clovis Oncology Announces First Patient Enrolled In Lucitanib Phase 2 Study In FGF-aberrant Advanced Breast Cancer
2014-09-09,Clovis Oncology Announces Exercise In Full By Initial Purchasers Of Their Option To Purchase An Additional $37.5 Million Aggregate Principal Amount Of The Company’s 2.50% Convertible Senior Notes Due 2021
2014-09-08,Clovis Oncology To Present At The 2014 Morgan Stanley Global Healthcare Conference
import os

filenames = os.listdir('.')
with open('ALLNEWS.txt', 'w') as outfile:
    for fname in filenames:
        with open(fname) as infile:
            outfile.write(infile.read())
2017-03-22,Corium To Participate In BioPharma Dealmakers Webcast On New Innovations In Drug Delivery Technology
2017-03-20,Corium Reports Positive Progress In Pilot Bioequivalence Study Of Once-Weekly Corplex™ Donepezil Patch
2017-02-13,Corium Reports First Quarter Fiscal 2017 Financial Results
2017-02-07,Corium To Present At Upcoming Investor Conferences
2017-02-06,Corium To Report First Quarter Fiscal Year 2017 Financial Results On Monday, February 13, 2017
2017-02-02,Corium Prices Follow-On Offering Of Common Stock
2017-02-01,Corium Announces Proposed Public Offering Of Common Stock
2016-11-21,Corium Reports Fourth Quarter And Fiscal Year 2016 Financial Results And Recent Corporate Highlights
2016-11-15,Corium To Report Fourth Quarter And Year-end Fiscal Year 2016 Financial Results On Monday, November 21, 2016
2016-10-13,Corium To Present At Dawson James Securities Growth Stock Conference
2016-08-24,Corium Announces Streamlined Bioequivalence Development Path For Transdermal Corplex™ Memantine
2016-08-04,Corium Reports Third Quarter Fiscal 2016 Financial Results And Recent Corporate Highlights
2016-07-28,Corium To Report Third Quarter Fiscal Year 2016 Financial Results On Thursday, August 4, 2016
2016-07-27,Corium Presents Full Clinical Results From Phase 1 Pharmacokinetic Study Of Once-weekly Corplex™ Donepezil Transdermal System
2016-07-20,Corium To Present Clinical Data From A Phase 1 Pharmacokinetic Study Of Once-Weekly Corplex™ Donepezil Transdermal System
2016-07-05,Corium To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference
2016-05-25,Corium To Present At The Jefferies 2016 Healthcare Conference
2016-05-23,CORI: Insiders vs. Shorts
2016-05-10,Corium Reports Second Quarter Fiscal 2016 Financial Results And Recent Corporate Highlights
2016-05-03,Corium To Report Second Quarter Fiscal Year 2016 Financial Results On Tuesday, May 10, 2016
2016-05-02,Corium Announces Streamlined Bioequivalence Development Path For Transdermal Corplex™ Donepezil Following Positive Pre-IND Communication From FDA
2016-05-02,7 Stocks Under $10 Making Big Moves Toward Big Profits
2016-03-31,Corium To Present At 15th Annual Needham Healthcare Conference
2016-03-29,Corium Announces Positive Preclinical Results With Long-acting Potent GLP-1 Analog Delivered In MicroCor® Transdermal Patch
2016-02-22,Corium Announces Positive Topline Results From Phase 1 Clinical Study Of Transdermal Corplex™ Memantine As A Potential Treatment Of Alzheimer's Disease
2016-02-08,Corium Reports First Quarter Fiscal 2016 Financial Results
2016-02-03,Corium Announces Positive Topline Results From Phase 1 PK Clinical Study Of Once-Weekly Transdermal Corplex™ Donepezil As A Potential Treatment Of Alzheimer's Disease
2016-02-01,Corium To Report First Quarter Fiscal Year 2016 Financial Results On Monday, February 8, 2016
2016-01-26,Corium To Present At LEERINK Partners 5th Annual Global Healthcare Conference
2015-11-12,Corium Reports Fourth Quarter And Fiscal Year 2015 Financial Results And Year-End Highlights
2015-11-05,Corium To Report Fourth Quarter And Year-End Fiscal Year 2015 Financial Results On Thursday, November 12, 2015
2015-10-26,Oversold Conditions For Corium International (CORI)
2015-09-28,Corium International Enters Oversold Territory (CORI)
2015-08-26,Corium Announces Issuance Of U.S. Patent For MicroCor(R) Transdermal System For A Broad Range Of Therapeutics And Vaccines
2015-08-25,Corium Initiates Phase 1 Clinical Trial Of Corplex(TM) Donepezil Transdermal System For The Treatment Of Alzheimer's Disease
2015-08-05,Corium Prices Follow-On Offering Of Common Stock
2015-08-03,Corium Announces Proposed Public Offering Of Common Stock
2015-07-29,Corium Reports Third Quarter Fiscal 2015 Financial Results
2015-07-28,Corium Announces Positive Topline Results From Phase 2a Study Of Transdermal MicroCor(R) PTH In Post-Menopausal Women
2015-07-27,Corium Co-Founder Dr. Gary W. Cleary Honored With Controlled Release Society Founders Award
2015-05-20,Corium To Present At Jefferies 2015 Global Healthcare Conference
2015-05-18,Corium Announces Publication Of Promising Data For Needle-Free Transdermal Influenza Vaccine
2015-05-11,Ratings Changes Today
2015-05-07,Corium Reports Second Quarter Fiscal 2015 Financial Results
2015-04-30,Corium To Report Second Quarter Fiscal 2015 Financial Results On Thursday, May 7, 2015
2015-04-28,Aequus And Corium Enter Into Product Development Collaboration Focused On CNS
2015-04-28,Joseph J. Sarret, M.D., J.D. Joins Corium As Chief Business Officer
2015-04-02,Corium To Present At The 14th Annual Needham Healthcare Conference
2015-04-01,Corium Announces Appointment Of Eric H. Bjerkholt To Board Of Directors
2015-02-10,Corium Reports First Quarter Fiscal 2015 Financial Results
2015-02-03,Corium To Report First Quarter Fiscal 2015 Financial Results On Tuesday, February 10, 2015
2015-01-30,Corium To Present At The 2015 Leerink Global Healthcare Conference
2015-01-21,Robbins Arroyo LLP Is Investigating The Officers And Directors Of Corium International, Inc. (CORI) On Behalf Of Shareholders
2014-12-08,Corium Announces Appointment Of Ivan Gergel, M.D. To Board Of Directors
2014-12-04,Corium Announces Closing Of Expanded Term Loan Facility With CRG
2014-11-17,Corium Reports Fiscal Year-End 2014 Financial Results And Recent Corporate Developments
2014-11-11,Corium To Report Fiscal Year-end 2014 Financial Results On Monday, November 17, 2014
2014-10-21,Leon Cooperman Picks Ocwen, Altisource Tumble
2014-09-17,Corium Announces Appointment Of Paul Goddard, Ph.D. To Board Of Directors
2014-08-12,Corium Reports Third Fiscal Quarter 2014 Financial Results
2014-08-05,Corium To Report Third Quarter Fiscal Year 2014 Financial Results On Tuesday, August 12, 2014
2007-02-21,Earnings on Tap
2007-02-14,Wednesday's Small-Cap Winners & Losers
2007-02-14,Wednesday's Tech Winners & Losers
2007-02-14,CheckFree to Buy Corillian
2007-02-09,Friday's Early Winners & Losers
2005-04-01,More Early Stocks in Motion
2004-11-17,Slim Pickings for Bears
2004-07-12,Don't Pin Hopes on the Unknowable
2004-06-22,Emotions Are Enemies of Trading
2004-03-16,Putting Your Plan in Motion
2004-02-03,Don't Overlook the Positive Stories
2003-11-18,My Top Five Single-Digit Stocks for 2004
2002-01-03,Corillan Sees Wider-Than-Expected Fourth-Quarter Loss
2000-10-16,Sector Spotlight: Some 'Enabler' E-Finance Stocks Still Blooming
,
,
,
2017-03-20,Biotechs Remain the Best Place For Stock Picking
2017-02-22,Interesting CRBP Put And Call Options For October 20th
2017-02-17,A Few Names on my Radar on This Softness
2017-01-24,First Week of March 17th Options Trading For Corbus Pharmaceuticals Holdings (CRBP)
2016-12-28,Corbus Pharmaceuticals Looks to Be a Winner, While Pershing Gold Requires Patience
2016-12-28,Here Are 4 Somewhat Risky Stocks That May Deliver Explosive Gains
2016-12-22,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
2016-12-20,First Week of CRBP February 2017 Options Trading
2016-11-23,Jim Cramer's Top Takeaways: Home Depot, Corbus Pharmaceuticals
2016-11-22,Jim Cramer's 'Mad Money' Recap: Expect More Earnings Surprises
2016-11-22,Interesting CRBP Put And Call Options For July 2017
2016-11-15,Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive
2016-11-14,Jim Cramer -- Corbus Pharma Shows the Upside of Biotech Risk
2016-10-29,'Mad Money' Lightning Round: Smith and Wesson Represents Value, Cramer Says
2016-10-28,Jim Cramer's 'Mad Money' Recap: How Powerful Are GE, Royal Dutch Shell and Occidental?
2016-10-25,Interesting CRBP Put And Call Options For December 16th
2016-10-25,Bear Thesis on Corbus Pharma Could Cause a Crash Landing for High-Flying Biotech Stock
2016-10-19,Jim Cramer's 'Mad Money' Recap: Politics and Your Portfolio
2016-10-06,These 5 Stocks Under $10 Could Make You a Lot of Money
2016-10-05,Corbus Pharmaceuticals (CRBP) Stock Closed Sharply Higher, Cantor Fitzgerald Initiates Coverage
2016-09-23,Corbus CEO on Resunab and the Pharma's Unstoppable Stock
2016-09-23,Resunab Results Keeping Corbus on Fast Track Says CEO
2016-09-20,First Week of November 18th Options Trading For Corbus Pharmaceuticals Holdings (CRBP)
2016-09-15,Corbus Pharmaceuticals Holdings Reaches Analyst Target Price
2016-09-02,Ratings Changes Today
2016-08-11,5 Stocks Under $10 Set to Soar
2015-11-13,8 Stocks Under $10 Making Big Moves Higher
2015-08-20,5 Stocks Under $10 Set to Soar
2015-08-19,Corbus Pharmaceuticals (CRBP) Stock Spikes on FDA Fast Track Status Designation
2015-07-31,5 Stocks Ready for Breakouts
2015-07-16,OTC Markets Group Announces Second Quarter 2015 Index Performance And Rebalancing
2015-06-03,Corbus Focused on Research and in No Hurry for Partnerships, Says CEO
2015-06-03,Corbus Ready to Take Cystic Fibrosis Drug the Distance Says CEO
2014-12-01,Corbus Pharmaceuticals to Present at VirtualInvestorConferences.com Online Event on December 4, 2014
,
,
,
,
2017-03-20,Biotechs Remain the Best Place For Stock Picking
2017-02-22,Interesting CRBP Put And Call Options For October 20th
2017-02-17,A Few Names on my Radar on This Softness
2017-01-24,First Week of March 17th Options Trading For Corbus Pharmaceuticals Holdings (CRBP)
2016-12-28,Corbus Pharmaceuticals Looks to Be a Winner, While Pershing Gold Requires Patience
2016-12-28,Here Are 4 Somewhat Risky Stocks That May Deliver Explosive Gains
2016-12-22,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
2016-12-20,First Week of CRBP February 2017 Options Trading
2016-11-23,Jim Cramer's Top Takeaways: Home Depot, Corbus Pharmaceuticals
2016-11-22,Jim Cramer's 'Mad Money' Recap: Expect More Earnings Surprises
2016-11-22,Interesting CRBP Put And Call Options For July 2017
2016-11-15,Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive
2016-11-14,Jim Cramer -- Corbus Pharma Shows the Upside of Biotech Risk
2016-10-29,'Mad Money' Lightning Round: Smith and Wesson Represents Value, Cramer Says
2016-10-28,Jim Cramer's 'Mad Money' Recap: How Powerful Are GE, Royal Dutch Shell and Occidental?
2016-10-25,Interesting CRBP Put And Call Options For December 16th
2016-10-25,Bear Thesis on Corbus Pharma Could Cause a Crash Landing for High-Flying Biotech Stock
2016-10-19,Jim Cramer's 'Mad Money' Recap: Politics and Your Portfolio
2016-10-06,These 5 Stocks Under $10 Could Make You a Lot of Money
2016-10-05,Corbus Pharmaceuticals (CRBP) Stock Closed Sharply Higher, Cantor Fitzgerald Initiates Coverage
2016-09-23,Corbus CEO on Resunab and the Pharma's Unstoppable Stock
2016-09-23,Resunab Results Keeping Corbus on Fast Track Says CEO
2016-09-20,First Week of November 18th Options Trading For Corbus Pharmaceuticals Holdings (CRBP)
2016-09-15,Corbus Pharmaceuticals Holdings Reaches Analyst Target Price
2016-09-02,Ratings Changes Today
2016-08-11,5 Stocks Under $10 Set to Soar
2015-11-13,8 Stocks Under $10 Making Big Moves Higher
2015-08-20,5 Stocks Under $10 Set to Soar
2015-08-19,Corbus Pharmaceuticals (CRBP) Stock Spikes on FDA Fast Track Status Designation
2015-07-31,5 Stocks Ready for Breakouts
2015-07-16,OTC Markets Group Announces Second Quarter 2015 Index Performance And Rebalancing
2015-06-03,Corbus Focused on Research and in No Hurry for Partnerships, Says CEO
2015-06-03,Corbus Ready to Take Cystic Fibrosis Drug the Distance Says CEO
2014-12-01,Corbus Pharmaceuticals to Present at VirtualInvestorConferences.com Online Event on December 4, 2014
,
,
,
,
2016-07-18,CorMedix Inc. Presentation Now Available For On-Demand Viewing
2016-07-11,CorMedix Inc. To Webcast, Live, At VirtualInvestorConferences.com July 14
2016-04-12,CorMedix Inc. To Present Post-Market Clinical Utility Data From Neutrolin® Usage Monitoring Program On May 23, 2016
2016-01-21,CorMedix To Present At National Kidney Foundation® 2016 Spring Clinical Meetings
2016-01-06,CorMedix To Present At Biotech Showcase™ 2016
2015-12-14,CorMedix Announces Enrollment And Dosing Of First Patient In Phase 3 Neutrolin® Trial In Hemodialysis
2015-10-07,Pacific Premier Bancorp, Inc. Announces The Appointment Of New Director
2015-09-17,4 Stocks Under $10 to Trade for Big Breakouts
2015-09-02,Law Offices Of Howard G. Smith Reminds Investors: Two Days Left To File Lead Plaintiff Motion In The Class Action Lawsuit Against CorMedix, Inc.
2015-09-01,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of CorMedix, Inc. Of Pendency Of Class Action Lawsuit And A Lead Plaintiff Deadline Of September 4, 2015
2015-08-31,IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against CorMedix, Inc. And Encourages Investors To Contact The Firm
2015-08-31,GPM Reminds Investors Of The September 4, 2015 Deadline In The Class Action Lawsuit On Behalf Of CorMedix, Inc. Investors
2015-08-20,GPM Announces The Filing Of A Securities Class Action On Behalf Of CorMedix, Inc. Investors
2015-08-17,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of CorMedix, Inc. Of Pendency Of Class Action Lawsuit And A Lead Plaintiff Deadline Of September 4, 2015
2015-08-13,SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In CorMedix, Inc. To Contact The Firm
2015-07-31,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of CorMedix, Inc. Of Pendency Of Class Action Lawsuit And A Lead Plaintiff Deadline Of September 4, 2015 - CRMD
2015-07-30,3 Stocks Under $10 Making Big Moves
2015-07-28,CorMedix Stock Sees Short Interest Expand By 40%
2015-07-24,Ryan & Maniskas, LLP Announces Class Action Lawsuit Against CorMedix, Inc.
2015-07-21,Interesting CRMD Put And Call Options For March 2016
2015-07-17,TRADING ALERT: The Rosen Law Firm Reminds CorMedix, Inc. Investors Of The Important Deadline In The Class Action
2015-07-13,Robbins Arroyo LLP: CorMedix, Inc. (CRMD) Misled Shareholders According To A Recently Filed Class Action
2015-07-08,SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against CorMedix Inc.
2015-07-07,EQUITY ALERT: The Rosen Law Firm Announces The Filing Of A Securities Class Action Lawsuit Against CorMedix, Inc. To Recover Investor Losses
2015-06-30,CRMD INVESTOR ALERT: Investigation Of CorMedix, Inc., Announced By Glancy Prongay & Murray LLP
2015-06-30,Cormedix (CRMD): Today's Weak On High Volume Stock
2015-06-30,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of CorMedix, Inc.
2015-06-29,EQUITY ALERT: The Rosen Law Firm Announces Investigation Of Securities Claims Against CorMedix, Inc. - CRMD
2015-06-22,CorMedix Inc. To Join Russell Global And Russell 3000 Indexes
2015-06-19,Biotech Stock Mailbag: Unstoppable Heron, Aerie Disclosure Fail, Gene Therapy, Hate Mail!
2015-06-17,CorMedix (CRMD) Stock Gains After Receiving Positive FDA Feedback for Neutrolin
2015-06-17,CorMedix Inc. Receives Positive Feedback From FDA For Neutrolin® Clinical Trial Protocol For Oncology Patients
2015-06-12,Cormedix (CRMD): Today's Weak On High Volume Stock
2015-06-11,Oversold Conditions For CorMedix (CRMD)
2015-06-05,Trade-Ideas: Cormedix (CRMD) Is Today's Weak On High Relative Volume Stock
2015-06-01,CorMedix Presents Neutrolin® Post Marketing Surveillance Data At European Renal Association - European Dialysis And Transplant Association (ERA-EDTA) Conference
2015-05-26,Strong On High Relative Volume: Cormedix (CRMD)
2015-05-21,January 2017 Options Now Available For CorMedix (CRMD)
2015-05-18,Trade-Ideas: Cormedix (CRMD) Is Today's Weak On High Relative Volume Stock
2015-05-12,Ratings Changes Today
2015-05-05,CorMedix, Inc. To Report First Quarter Financial Results On May 8, 2015
2015-04-23,CorMedix Presents Data From Neutrolin® Post Marketing Surveillance Study At Two Medical Conferences
2015-04-16,4 Stocks Under $10 Making Big Moves
2015-04-09,CorMedix Institutes Program To Reduce Neutrolin® Cost Of Goods; Reports On Strategic Review Process Managed By Evercore
2015-04-01,The Top-Performing Biotech Stock During a Sizzling First Quarter
2015-03-25,Interesting CRMD Call Options For May 15th
2015-03-20,CorMedix Announces Effectiveness Of Registration Statements For Shares Underlying Publicly Traded Warrants
2015-03-09,CorMedix Clarifies Extension Of Expiration Date For Publicly Traded Warrants
2015-03-04,CorMedix Inc. Provides Multiple Strategic Business Updates
2015-01-29,FDA Grants QIDP Designation To Neutrolin®, CorMedix Inc.'s Lead Product Candidate In The U.S.
2015-01-28,3 Stocks Raising The Drugs Industry Higher
2015-01-15,CorMedix Inc. Receives Fast Track Designation For Neutrolin®
2014-12-23,CorMedix Inc. Finalizes First Middle East Neutrolin® Sales/Distribution Agreement In The Kingdom Of Saudi Arabia
2014-12-04,CorMedix Inc. Files Request With FDA For QIDP Designation For Neutrolin®
2014-12-03,Neutrolin Label Expansion Approved In Germany
2014-11-06,CorMedix, Inc. To Announce Third Quarter 2014 Results On November 13, 2014; Conference Call Hosted At 9 Am On Friday, November 14, 2014
2014-09-25,CorMedix Announces FDA IND Filing For Neutrolin® In United States
2014-09-22,Neutrolin Label Expansion Approved For The European Union
2014-09-16,CorMedix Amends And Restates Outstanding Securities To Remove Provisions Causing Derivative Liability Classification
2014-08-14,FDA Accepts CorMedix, Inc. Pivotal Phase 3 Study Protocol
2014-08-01,4 Biotech Stocks Under $10 to Trade for Breakouts
2014-07-24,CorMedix, Inc. Granted Extension Of NYSE-MKT Listing
2014-06-23,CorMedix, Inc. Finalizes Pivotal Phase 3 Study Protocol For FDA
2014-05-23,CorMedix Notified Of NYSE MKT Listing Deficiency
2014-05-13,CorMedix Inc. To Announce First Quarter 2014 Results On May 15, 2014
2014-04-07,CorMedix Inc. Welcomes Additional Board Members
2014-03-27,CorMedix Inc. To Report 2013 Year End Results On March 31, 2014, And Host Conference Call At 9 Am On April 1, 2014
2014-03-26,3 Biotech Stocks Under $10 to Trade
2014-03-10,CorMedix Inc. Announces Close Of Registered Direct Offering
2014-03-04,CorMedix Inc. Announces Registered Direct Offering
2014-01-21,It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013
2014-01-13,CorMedix Expands NeutrolinA® Sales With Middle East Distribution Agreements
2014-01-10,CorMedix Awarded European Patent For Neutrolin
2014-01-08,CorMedix Inc. To Raise $2,000,000 In Follow On Offering
2013-12-23,CorMedix Receives Minutes From Neutrolin Pre-IND Meeting With FDA
2013-12-12,CorMedix Announces First Sales Of NeutrolinA® In The European Union
2013-11-15,CorMedix To Report Third Quarter Financial Results On November 19, 2013
2013-10-23,CorMedix Inc. Closes $3,000,000 Preferred Stock Offerings
2013-10-18,CorMedix Inc. To Raise $3,000,000 In Concurrent Offerings
2013-09-05,CorMedix Reports Receipt Of European Patent Office Decision To Allow Prosl Patent To Proceed In European Union
2013-07-15,CorMedix Granted Extension Of NYSE MKT Listing
2013-07-05,CorMedix Receives CE Mark For Neutrolin&#174; Catheter Lock Solution
2013-03-27,CorMedix Reports Year End 2012 Financial Results
2013-02-07,CorMedix Granted Extension Of NYSE MKT Listing
2013-01-15,CorMedix Signs Sales And Marketing Agreement With MKM Co-Pharma, Bolsters Commercial Management Team To Ready Neutrolin&#174; Catheter Lock Solution For European Market
2012-11-14,CorMedix: Final Closing Of 2012 Financing
2012-10-11,CorMedix Successfully Completes And Passes ISO 13485 Certification Audit
2012-09-25,CorMedix: Initial Close On Financing And Extension Granted To Regain Compliance With NYSE Amex Listing Standards
2012-07-02,CorMedix: Granted Extension Of NYSE Amex Listing
2012-06-14,CorMedix Provides An Update On CE Marking Process For Neutrolin&#174; In The EU
2012-04-24,CorMedix Receives NYSE Amex Notice Of Delisting For Non-Compliance
2012-03-19,CorMedix Reports Year End 2011 Financial Results
2011-12-30,CorMedix Provides Year End 2011 Update
2011-11-28,CorMedix Appoints Pharmaceutical Veteran, Matthew Duffy To Board Of Directors
2011-11-10,CorMedix Reports Third Quarter 2011 Results
2011-10-07,CorMedix To Host Conference Call On Recent Developments
2011-09-30,CorMedix Announces Strategic Changes
2011-09-29,CorMedix Announces FDA Designation For Neutrolin (CRMD003)
2011-09-07,CorMedix To Present At The Rodman &amp; Renshaw Annual Global Investment Conference
2011-09-06,CorMedix Announces Amended Agreement For CRMD001 (A Proprietary Formulation Of Deferiprone)
2011-08-12,CorMedix Announces Appointment Of Steven W. Lefkowitz To Board Of Directors
2011-08-09,CorMedix Reports Second Quarter 2011 Results
2011-07-07,CorMedix Submits Design Dossier For Neutrolin&#174; (CRMD003) To Start European Approval Process
2011-06-23,CorMedix Provides Regulatory Update For CRMD003 (Neutrolin&#174;)
2011-06-21,CorMedix Announces SPA Agreement With FDA For Phase 3 Trial In The Prevention Of Contrast-Induced Acute Kidney Injury Study With CRMD001 (A Proprietary Formulation Of Deferiprone)
2011-06-14,CorMedix Announces Successful Completion Of Patient Recruitment In Phase II Contrast-Induced Acute Kidney Injury Study With CRMD001 (A Proprietary Formulation Of Deferiprone)
2011-05-10,CorMedix Reports First Quarter 2011 Financial Results
2011-03-31,CorMedix Announces Interim Analysis &amp; Clinical Update For Phase II Study Of CRMD001 (A Proprietary Formulation Of Deferiprone)
2011-03-11,CorMedix Reports Year End 2010 Financial Results
2011-03-02,CorMedix Appoints Mark A. Klausner, M.D. As Chief Medical Officer
2011-02-08,CorMedix To Present At 13th Annual BIO CEO And Investor Conference
2011-01-12,CorMedix Statement On Today&#8217;s Market Activity
2011-01-04,CorMedix Provides Year End Summary Of 2010 Achievements
2010-11-15,CorMedix To Present At The Maxim Group Growth Conference
2010-11-09,CorMedix Reports Third Quarter 2010 Results And Provides Business Update
2010-11-03,CorMedix Awarded Grants From Federal Qualifying Therapeutic Discovery Project Program
2010-10-26,LifeSci Advisors Announces Investment Opinion On CorMedix Inc.
2010-09-28,CorMedix To Present At BIO Investor Forum Conference
2010-09-03,CorMedix To Present At The Rodman &amp; Renshaw Annual Global Investment Conference
2010-08-12,CorMedix Reports Second Quarter 2010 Results
2010-08-10,CorMedix Announces Appointment Of Key Positions
2010-08-03,CorMedix Statement On Today&#8217;s Market Activity
2010-06-29,CorMedix Added To Russell Microcap&#174; Index
2010-06-25,CorMedix Doses First Patient In Phase II Clinical Trial Of CRMD-001
,
2017-03-14,ContraVir Pharmaceuticals To Present At BIO-Europe Spring 2017
2017-02-14,ContraVir To Highlight Clinical Data From Ongoing Phase 2a Study Of Tenofovir Exalidex (TXL™) For Treating Hepatitis B
2017-02-07,ContraVir Pharmaceuticals To Present At BIO CEO & Investor Conference
2017-01-03,ContraVir Awarded Grant From Canada's National Research Council To Advance CRV431 For The Treatment Of Hepatitis B
2016-12-19,ContraVir Expands Phase 2a Trial Of Tenofovir Exalidex (Formerly CMX157) To Include Doses Above 100 Mg
2016-12-15,ContraVir Appoints Business Development Executive Tamar Howson To Its Board Of Directors
2016-12-08,Biotechs Bolstered on 21st Century Cures Passage
2016-12-08,ContraVir's Cyclophilin Inhibitor CRV431 Potently Inhibits Essential Pathway In Hepatitis B
2016-11-18,These 5 Stocks Are Ready to Break Out
2016-10-17,CMX157 Advances Head-to-Head Phase 2a Clinical Study In Hepatitis B Patients With Favorable Recommendation From DSMB
2016-10-13,CMX157 Demonstrates 99% Viral Load Reduction In Ongoing Head-to-Head Phase 2a Clinical Study Vs. Viread® In Hepatitis B Patients
2016-09-29,ContraVir To Receive $1.8 Million Through New Jersey Technology Business Tax Certificate Transfer (NOL) Program
2016-09-21,ContraVir Pharmaceuticals Appoints Thomas H. Adams, Ph.D., To Board Of Directors
2016-09-15,These 5 Stocks Under $10 Could Make You a Lot of Money
2016-09-12,ContraVir Reports New CRV431 Data Highlighting Synergistic Activity With CMX157 Against Hepatitis B
2016-09-06,ContraVir to Present at Upcoming Investor and Industry Conferences
2016-08-02,ContraVir Reports Positive Data From Phase 1b Study Of CMX157
2016-07-18,ContraVir Expands Scientific Advisory Board To Focus On Seeking Curative Therapy For Hepatitis B
2016-06-29,Center Point Clinical Services Signs Partnership Agreement With ContraVir Pharmaceuticals
2016-06-21,ContraVir Doses First Patients In Head-to-Head Study Of CMX157 Vs. Viread® For Treating Hepatitis B
2016-06-16,ContraVir Pharmaceuticals Expands Patient Enrollment Criteria For Ongoing Phase 3 Clinical Study Of FV-100 For Treating Shingles
2016-06-13,ContraVir Completes Merger With Ciclofilin Pharmaceuticals
2016-06-01,ContraVir Initiates Head-to-Head Phase 2a Clinical Study Of CMX157 Vs. Viread® For Treating Hepatitis B
2016-05-31,ContraVir To Expand Hepatitis B Portfolio Through Strategic Merger Agreement With Ciclofilin Pharmaceuticals
2016-05-25,ContraVir To Showcase CMX157 Data In Poster At The 3rd ANRS HBV Cure Workshop
2016-04-19,ContraVir Doses First Subject In Phase 1b Clinical Study Of CMX157 For Treating Chronic Hepatitis B Infection
2016-04-05,ContraVir Pharmaceuticals To Webcast Live At VirtualInvestorConferences.com April 7
2016-04-04,ContraVir Pharmaceuticals, Inc. Announces Closing Of Public Offering Of Common Stock And Warrants
2016-03-31,ContraVir Pharmaceuticals Appoints John Cavan As Chief Financial Officer
2016-03-30,ContraVir Pharmaceuticals, Inc. Pricing Underwritten Public Offering Of Common Stock And Warrants To Purchase Common Stock
2016-03-29,ContraVir Pharmaceuticals, Inc. Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock
2016-03-29,Here's Why ContraVir Pharma (CTRV) Stock is Soaring Today
2016-03-29,ContraVir's CMX157 Outperforms Gilead's Tenofovir AF (TAF) Against Hepatitis B Virus In Independent Head-to-Head In-Vitro Study
2016-03-21,ContraVir Initiates Phase 1/2a Clinical Study Of CMX157 For Treating Chronic Hepatitis B Infection
2016-03-17,ContraVir Pharmaceuticals To Ring The NASDAQ Stock Market Closing Bell March 21, 2016
2016-03-03,ContraVir Pharmaceuticals Reports Positive Results Confirming The Safety Of Its Shingles Candidate FV-100 In A Drug-Drug Interaction Study
2016-01-29,5 Stocks Ready for Breakouts
2015-12-08,ContraVir Reports Key CMX157 Data At HEP DART 2015 Demonstrating Enhanced In Vitro Safety Profile Compared To Viread®
2015-12-03,ContraVir Strengthens Board Of Directors With Addition Of Industry Veteran Arnold Lippa, Ph.D.
2015-12-01,ContraVir To Present New CMX157 Data At HEP DART 2015
2015-10-13,ContraVir Pharmaceuticals, Inc. Announces Closing Of Public Offering Of Common Stock And Warrants
2015-10-07,ContraVir Pharmaceuticals (CTRV) Stock Drops After Pricing Secondary Offering
2015-10-07,ContraVir Pharmaceuticals, Inc. Pricing Underwritten Public Offering Of Common Stock
2015-10-06,ContraVir Pharmaceuticals, Inc. Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock
2015-10-05,ContraVir Reports New Data Demonstrating CMX157 To Be 60-Fold More Potent Against Hepatitis B Virus Than Gilead's Viread®
2015-08-12,ContraVir Presentation Now Available For On-Demand Viewing
2015-08-04,ContraVir To Webcast Investor Presentation On August 6: VirtualInvestorConferences.com
2015-08-03,ContraVir Pharmaceuticals Enrolls First Patient In Pivotal Phase 3 Study Of FV-100 For Treatment Of Shingles And Shingles-Associated Pain
2015-06-03,ContraVir Engages The Baruch S. Blumberg Institute To Further Research And Develop CMX157
2015-03-09,ContraVir Pharmaceuticals To Initiate Pivotal Phase 3 Study Of FV-100 For Prevention Of Shingles-Associated PHN
2015-02-25,ContraVir Pharmaceuticals Announces Uplisting To The NASDAQ Capital Market
2015-02-20,ContraVir Pharmaceuticals Provides Clinical Update On FV-100
2015-02-04,ContraVir Pharmaceuticals' HBV Compound CMX157 Receives Extended Patent Life
2015-01-20,ContraVir Pharmaceuticals Adds Carol L. Brosgart, M.D., To Scientific Advisory Board
2015-01-13,ContraVir Pharmaceuticals Appoints John Sullivan-Bolyai, M.D., MPH, As Chief Medical Officer
2015-01-08,ContraVir Pharmaceuticals Adds Renu Gupta, M.D., To Scientific Advisory Board
2015-01-07,ContraVir Pharmaceuticals Granted FDA Meeting To Discuss Proposal For Phase 3 Trial Of FV-100
2014-12-18,Chimerix And ContraVir Pharmaceuticals Establish Strategic Collaboration For Antiviral Drug Candidate CMX157
2014-12-16,ContraVir Pharmaceuticals Appoints Nathaniel Katz, M.D., Chairman Of New Scientific Advisory Board
2014-12-11,ContraVir Pharmaceuticals' CEO Issues Letter To Shareholders Highlighting Significant Progress
2014-12-09,ContraVir Pharmaceuticals Initiates Pharmacokinetic Study Of Lead Antiviral FV-100 For Treating Shingles
2014-11-05,ContraVir Pharmaceuticals Selected To Present At Cavendish Global Health Impact Forum
2014-10-16,ContraVir Pharmaceuticals Selects Pharmaceutical Product Development To Manage Phase 2b Study Of Lead Antiviral FV-100 For Treating Shingles
2014-10-15,ContraVir Pharmaceuticals Closes $9.0 Million Financing To Advance Lead Shingles Candidate
2014-07-08,ContraVir Appoints Industry Veteran William Hornung As Its Chief Financial Officer
,
,
,
2017-03-21,Cyclacel Pharmaceuticals To Release Fourth Quarter And Full Year 2016 Financial Results
2017-03-07,Cyclacel's CDK Inhibitor CYC065 Causes Anaphase Catastrophe, A Novel Cancer-Specific Mechanism Of Action, In Research Published In JNCI
2017-02-23,Biotech Movers: Shire Rises on Encouraging Angioedema Results
2017-02-23,Cyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study In Elderly Patients With Acute Myeloid Leukemia
2017-02-07,Cyclacel Pharmaceuticals' Preferred Stock Shares Cross 9% Yield Mark
2017-02-06,Cyclacel Pharmaceuticals To Present At The 19th Annual BIO CEO & Investor Conference
2016-12-01,Cyclacel's Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential In Esophageal Cancer And Acute Leukemia
2016-11-18,Moleculin Biotech gets good verbal Ok from FDA which should cut time to Phase 1/2 trial down
2016-11-14,Cyclacel Pharmaceuticals Reports 3rd Quarter 2016 Financial Results
2016-11-08,Cyclacel Pharmaceuticals's Preferred Stock Shares Cross 9% Yield Mark
2016-11-07,Cyclacel Pharmaceuticals To Release Third Quarter 2016 Financial Results
2016-09-06,Cyclacel's CYC065 Demonstrates Promising Activity In MYCN-Addicted Neuroblastoma In Preclinical Data Presented At Childhood Cancer 2016
2016-08-22,Cyclacel Stock Runs on Momentum Rocket Fueled by 'Dumb &amp; Dumber' Optimism
2016-08-22,Here's Why Cyclacel Pharmaceuticals (CYCC) Stock Is Surging Today
2016-08-12,Cyclacel Pharmaceuticals (CYCC) Stock Pops, H.C. Wainwright Bullish
2016-08-10,Cyclacel Pharmaceuticals Reports 2nd Quarter 2016 Financial Results
2016-08-03,Cyclacel Pharmaceuticals To Release Second Quarter 2016 Financial Results
2016-08-02,Cyclacel's CYC065 Demonstrates Promising Activity In Uterine Serous Carcinoma In Preclinical Data Published By Independent Academic Researchers
2016-06-16,Cyclacel Regains Compliance With Nasdaq Continued Listing Requirements
2016-06-06,Cyclacel Reports Updated Data From Its DNA Damage Response Program On Seliciclib And Sapacitabine Combination In Patients With Solid Tumors At ASCO
2016-05-27,Cyclacel Announces Reverse Stock Split
2016-05-19,Cyclacel's Seliciclib-Sapacitabine Abstract Selected For Oral Presentation At The 2016 American Society Of Clinical Oncology (ASCO) Annual Meeting
2016-05-11,Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results
2016-05-04,Cyclacel Pharmaceuticals To Release First Quarter 2016 Financial Results
2016-04-18,Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Is An Effective Inducer Of Cell Death In B-cell Lymphoma And Synergizes With Bcl-2 Or BET Inhibitors
2016-04-11,Cyclacel Announces Receipt Of Nasdaq Extension
2016-03-24,Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results
2016-03-17,Cyclacel Pharmaceuticals To Release Fourth Quarter And Full Year 2015 Financial Results
2016-03-01,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Breaches Of Fiduciary Duty By The Board Of Cyclacel Pharmaceuticals, Inc.
2016-02-05,Cyclacel Announces Receipt Of Nasdaq Staff Determination; Company To Request Hearing
2016-02-02,Cyclacel Pharmaceuticals To Present At The 18th Annual BIO CEO & Investor Conference
2016-01-11,Cyclacel Reviews 2015 Achievements And Announces Key Business Objectives For 2016
2015-12-14,Molecular Basis For Development Of Cyclacel's CYC065 CDK2/9 Inhibitor In Triple-Negative Breast Cancer Presented At San Antonio Breast Cancer Symposium
2015-11-23,CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival In MYCN-Addicted Neuroblastoma Models
2015-11-12,Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results
2015-11-09,Mechanistic Rationale For CYC065, Cyclacel's CDK2/9 Inhibitor, In Targeted Solid Tumors And Hematological Malignancies Presented At AACR-NCI-EORTC International Conference
2015-11-05,Cyclacel Pharmaceuticals To Release Third Quarter 2015 Financial Results
2015-10-26,Data To Be Presented On CYC065, Cyclacel's CDK2/9 Inhibitor, At AACR-NCI-EORTC International Conference
2015-10-22,Cyclacel Doses First Patient In Phase 1 Trial Of Its Novel CDK2/9 Inhibitor, CYC065, For The Treatment Of Advanced Solid Tumors
2015-09-17,Cyclacel Presents Molecular Rationale For Clinical Development Of CYC065 CDK Inhibitor In Leukemias And Lymphomas
2015-09-03,Cyclacel Pharmaceuticals To Present At Rodman & Renshaw 17th Annual Global Investment Conference
2015-08-11,Cyclacel Pharmaceuticals Reports Second Quarter 2015 Financial Results
2015-08-05,Cyclacel Pharmaceuticals To Release Second Quarter 2015 Financial Results
2015-07-02,First Patient Dosed In IST Of CDK Inhibitor Seliciclib In Cushing's Disease, A Serious Endocrine Disorder
2015-06-29,Cyclacel & ManRos Therapeutics Announce Licensing & Supply Agreement Regarding Development Of Seliciclib In Cystic Fibrosis
2015-06-19,5 Stocks Ready for Breakouts
2015-06-17,Cyclacel Pharmaceuticals To Present At 10th Annual JMP Securities Healthcare Conference
2015-05-12,Cyclacel Pharmaceuticals Reports First Quarter 2015 Financial Results
2015-05-05,Cyclacel Pharmaceuticals To Release First Quarter 2015 Financial Results
2015-04-20,Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential And Synergy With Other Anti-Cancer Compounds
2015-04-14,3 Stocks Under $10 to Trade for Breakouts
2015-03-24,Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
2015-03-20,Cyclacel's CYC065 Featured In Presentations At The American Association For Cancer Research Annual Meeting 2015
2015-03-17,Cyclacel Pharmaceuticals To Release Fourth Quarter And Full Year 2014 Financial Results
2015-03-12,Constellium Climbs Despite Q4 Loss
2015-03-04,Autohome Surges On 2014 Results Numbers
2015-03-04,Cyclacel Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2015-03-03,Orexigen Surges - Even If Regulators Aren't Happy About It
2015-03-03,Cyclacel Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2015-03-02,Leon Cooperman Gets A Boost Off Of NXP Semiconductors Surge
2015-03-02,Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels
2015-02-26,Penn Virginia Takes George Soros' Advice, Surges
2015-02-04,Staples Dips Down After Yesterday's Surge
2015-02-03,Cyclacel Pharmaceuticals To Present At The 17th Annual BIO CEO & Investor Conference
2015-01-06,Cyclacel Pharmaceuticals To Present At The Biotech Showcase(TM) 2015 Conference
2015-01-03,Billionaires Got Burned by These Six Struggling Stocks in 2014
2014-12-16,Cyclacel Announces Enrollment Of 486 Patients, DSMB Recommendations And That The Seamless Phase 3 Trial Of Sapacitabine In AML Will Continue To Final Analysis
2014-11-11,Cyclacel Pharmaceuticals Reports Third Quarter 2014 Financial Results
2014-11-04,Cyclacel Pharmaceuticals To Release 2014 Third Quarter Financial Results
2014-10-09,Cyclacel Announces Data Safety Monitoring Board Recommendation To Continue The Seamless Phase 3 Trial Of Sapacitabine In AML
2014-09-19,Cyclacel To Present At BioCentury's Newsmakers In The Biotech Industry Conference
2014-09-18,Cyclacel's CYC065 CDK Inhibitor Demonstrates Therapeutic Potential In Acute Leukemias With Mixed Lineage Leukemia (MLL) Rearrangements
2014-09-11,Cyclacel Pharmaceuticals Appoints Samuel L. Barker, Ph.D., To Board Of Directors
2014-09-10,Cyclacel Announces Abstract Selected For Presentation At Society Of Hematologic Oncology Annual Meeting
2014-09-02,Cyclacel Pharmaceuticals To Present At 16th Rodman & Renshaw Annual Global Investment Conference
2014-08-12,Cyclacel Pharmaceuticals Reports Second Quarter 2014 Financial Results
2014-08-06,Cyclacel Pharmaceuticals To Release 2014 Second Quarter Financial Results
2014-06-17,Cyclacel Pharmaceuticals To Present At 9th Annual JMP Securities Healthcare Conference
2014-05-31,Cyclacel Pharmaceuticals Provides Update On Its Clinical Development Plan Of Sapacitabine For Myelodysplastic Syndromes (MDS)
2014-05-28,Cyclacel Pharmaceuticals To Webcast Institutional Investor And Analyst Presentation On Clinical Development Plan Of Sapacitabine For MDS
2014-05-13,Cyclacel Pharmaceuticals Reports First Quarter 2014 Financial Results
2014-05-06,Cyclacel Pharmaceuticals To Release 2014 First Quarter Financial Results
2014-05-05,New Japanese Patents Issued Covering Sapacitabine Pharmaceutical Formulations And Combination Treatments
2014-04-10,Independent Investigators Present Non-Clinical Data Providing Rationale For Sapacitabine Combination Treatment With Bcr-Abl Inhibitors In CML
2014-04-09,Cyclacel Pharmaceuticals, Inc. Announces Closing Of $10 Million Underwritten Offering
2014-04-04,Cyclacel Pharmaceuticals Announces $10 Million Underwritten Offering
2014-04-03,Cyclacel Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2014-03-25,Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2013 Financial Results
2014-03-13,Cyclacel Pharmaceuticals To Release Fourth Quarter And Full Year 2013 Financial Results
2014-02-03,Cyclacel Pharmaceuticals To Present At The 16th Annual BIO CEO & Investor Conference
2014-01-13,Cyclacel Reviews 2013 Achievements And Announces Key Business Objectives For 2014
2014-01-06,Cyclacel Pharmaceuticals To Present At Biotech Showcase(TM) 2014 Conference
2013-12-31,Cyclacel Pharmaceuticals's 6% Preferred Stock Yield Pushes Past 6.5%
2013-12-09,Cyclacel Reports New Phase 2 Data Of Sapacitabine For MDS At ASH
2013-11-25,Cyclacel Announces Data Safety Monitoring Board Recommendation To Continue The SEAMLESS Phase 3 Trial Of Sapacitabine In AML
2013-11-19,First Week Of July 2014 Options Trading For Cyclacel Pharmaceuticals (CYCC)
2013-11-12,Cyclacel Reports Third Quarter 2013 Financial Results
2013-11-07,Researchers To Present New Phase 2 Data On Sapacitabine As A Treatment For Patients With MDS At ASH Annual Meeting
2013-11-06,Cyclacel Pharmaceuticals To Release Third Quarter 2013 Financial Results
2013-11-05,New US Patents Issued Covering Sapacitabine Use With Hypomethylating Agents And Sapacitabine Dosing Regimens
2013-10-31,Cyclacel Pharmaceuticals To Present At The 2013 Therapeutic Area Partnerships Conference
2013-10-15,Cyclacel Pharmaceuticals Convertible Exchangeable Preferred Stock Ex-Dividend Reminder - 10/17/13
2013-09-27,First Week Of November 16th Options Trading For Cyclacel Pharmaceuticals (CYCC)
2013-09-19,Cyclacel's Sapacitabine Reported To Have Anti-Tumor Activity Against Ovarian Cancer
2013-08-14,Cyclacel Reports Second Quarter 2013 Financial Results
2013-08-12,Cyclacel's Seliciclib To Be Evaluated In Investigator-Initiated Clinical Study To Treat Rheumatoid Arthritis
2013-08-08,Cyclacel Pharmaceuticals To Announce Release Of Second Quarter 2013 Financial Results
2013-07-05,Cyclacel Pharmaceuticals To Present At The JMP Securities Healthcare Conference 2013
2013-05-29,5 Stocks Insiders Love Right Now
2013-05-23,Top Insider Trades: RH, AMBI, LULU, CYCC
2013-05-21,Cyclacel Pharmaceuticals Announces Closing Of Underwritten Offering
2013-05-16,Cyclacel Pharmaceuticals Announces $20 Million Underwritten Offering
2013-05-15,Cyclacel Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2013-05-13,Cyclacel Reports First Quarter 2013 Financial Results
2013-05-10,Cyclacel Pharmaceuticals To Announce Release Of First Quarter 2013 Financial Results
2013-04-30,Cyclacel Reports Updated Phase 2 Survival Data Of Sapacitabine For MDS
2013-04-23,Cyclacel Pharmaceuticals To Present At The 12th Annual Needham Healthcare Conference
2013-04-16,Reminder: Cyclacel Pharmaceuticals' 6% Preferred Stock Goes Ex-Dividend Soon
2013-04-09,Combination Potential Of Cyclacel's Sapacitabine And Seliciclib Reported At AACR
2013-04-08,AACR Press Conference Highlights Combination Potential Of Two Cyclacel Drugs
2013-04-04,Cyclacel Announces Sale Of Four Cyclacel Romidepsin-Related Patents To Celgene And Dismissal Of All Claims In Their Patent Litigation
2013-04-03,Cyclacel Announces Multiple Abstracts Selected For Presentation At American Association For Cancer Research Annual Meeting
2013-03-27,Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2012 Financial Results
2013-03-25,5 Stocks Set to Soar on Bullish Earnings
2013-03-22,Cyclacel To Announce Year-End And Fourth Quarter 2012 Financial Results
2013-02-12,Cyclacel Announces Grants Of New U.S. & European Patents Covering Sapacitabine Used In Combination With HDAC Inhibitors
2013-02-04,Cyclacel Pharmaceuticals To Present At The 15th Annual BIO CEO & Investor Conference
2013-01-25,4 Stocks Under $10 Moving Higher
2013-01-07,Cyclacel Reviews 2012 Achievements And Announces Key Business Objectives For 2013
2012-12-17,Cyclacel Enters Into A $20 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC
2012-12-10,Cyclacel Presents Updated Survival Data From The Pilot Study And Lead-In Phase Of Seamless Phase 3 Study At The 2012 ASH Annual Meeting
2012-10-25,4 Biotech Stocks Under $10 Moving Higher
2012-10-19,5 Stocks Ready to Break Out
2012-10-17,How to Prep for the Inevitable Bursting of the Biotech Stock Bubble
2012-10-15,Cyclacel's Sapacitabine Nearly Doubles Expected Survival Of Elderly Patients With MDS After Front-Line Therapy Failure
2012-10-12,Updated Phase 2 Survival Data Of Cyclacel's Sapacitabine For MDS Presented At The Eighth Annual Hematologic Malignancies 2012 Conference
2012-10-02,Cyclacel To Present At BIO Investor Forum
2012-09-21,Biotech Stock Mailbag: Pending Sarepta Results, Cyclacel
2012-09-19,Biotech Stock Live Chat: Fall Preview
2012-09-13,Cyclacel Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement
2012-09-11,4 Biotech Stocks Under $10 Making Big Moves
2012-08-29,Cyclacel To Present At Stifel Nicolaus 2012 Healthcare Conference
2012-08-24,Cyclacel Announces Reverse Stock Split
2012-08-14,Cyclacel Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript
2012-08-14,Cyclacel Reports Second Quarter 2012 Financial Results
2012-08-10,Cyclacel Pharmaceuticals To Announce Release Of Second Quarter 2012 Financial Results
2012-03-02,Friday's Top 10 Articles, Videos on TheStreet
2012-03-02,Biotech Stock Mailbag: Cyclacel Fallout, the Skinny on Vivus, Celldex's Crash
2012-02-13,BIO CEO Conference Live Blog
2011-12-09,The Worst Biotech CEO of 2011 Is ...
2011-11-16,The Biotech Stock 13F Review: What Hedge Funds Were Buying and Selling
2011-10-07,Biotech Stock Mailbag: Somaxon, Transcept
2011-09-30,Biotech Stock Mailbag: Research Backs Shorting Micro-Cap Cancer Drug Stocks
2011-08-12,Biotech Stock Mailbag: Cyclacel Pharma
2011-08-08,Cyclacel Stock Gaps Down On Today's Open (CYCC)
2011-07-01,Biotech Stock Mailbag: Ranking Cheap Biotechs
2011-06-28,10 Cheap Biotech Stocks That Could Soar
2011-05-19,ASCO: Traders Love Speculative Cancer Stocks
2011-03-29,Cyclacel Announces Abstracts Selected For Presentation At American Association For Cancer Research Annual Meeting
2011-03-25,Biotech Stock Mailbag: Bio-Hazards
2011-03-23,Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2010 Financial Results
2011-03-07,Cyclacel Pharmaceuticals To Announce Year End & Fourth Quarter 2010 Financial Results And Presentation At Upcoming Conference
2011-02-17,Data Published In The Proceedings Of The National Academy Of Sciences Highlight The Potential Of Cyclacel's Targeted CDK Inhibitors In Breast Cancer
2011-02-01,Cyclacel Pharmaceuticals To Present At The 13th Annual BIO CEO & Investor Conference
2011-01-11,Cyclacel Begins Pivotal Phase 3 "SEAMLESS" Trial Of Sapacitabine As Front-Line Treatment For AML Under A Special Protocol Assessment
2011-01-06,Cyclacel Reviews 2010 Achievements And Key Clinical Development Objectives For 2011
2010-12-21,Cyclacel Announces Topline Results From The Appraise Phase 2b Study Of Seliciclib In Heavily-Pretreated Patients With Non-Small Cell Lung Cancer
2010-12-05,Cyclacel's Second Generation Cyclin-Dependent Inhibitor CYC065 Demonstrates Activity In Multiple Myeloma
2010-12-04,Cyclacel Reports Phase 2 Survival Data With Sapacitabine In Myelodysplastic Syndromes At 2010 ASH Annual Meeting
2010-11-19,Cyclacel Pharmaceuticals To Present Sapacitabine Phase 2 MDS Data At The Upcoming American Society Of Hematology Meeting
2010-11-12,Cyclacel To Present At Upcoming Conferences
2010-11-11,Cyclacel Pharmaceuticals Reports Third Quarter 2010 Financial Results
2010-11-10,Publications Highlight Novel Combinations Of Sapacitabine With Targeted Agents For The Treatment Of Cancer
2010-11-04,Cyclacel Pharmaceuticals To Announce Release Of Third Quarter 2010 Financial Results
2010-10-08,Biotech Stock Mailbag: Cyclacel Pharma
2010-10-07,Cyclacel Completes Previously Announced Private Placement
2010-10-06,Cyclacel Announces Adjournment Of Special Preferred Stockholders Meeting
2010-10-05,Cyclacel Announces Private Placement Financing For Up To $22.1 Million
2010-09-29,Cyclacel To Present At BIO Investor Forum
2010-09-13,Ariad, Cyclacel To Start Key Drug Trials
2016-10-18,Cynapsus Therapeutics Obtains Final Court Order And HSR Waiting Period Expires For Plan Of Arrangement With Sunovion Pharmaceuticals
2016-10-13,Cynapsus Therapeutics Securityholders Approve The Plan Of Arrangement With Sunovion Pharmaceuticals
2016-09-28,ISS Recommends Cynapsus Therapeutics Securityholders Vote For The Plan Of Arrangement
2016-09-08,Cynapsus Therapeutics Inc. Acquisition May Not Be In The Best Interests Of CYNA Shareholders
2016-09-06,CYNAPSUS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces The Investigation Of Cynapsus Therapeutics Inc. (CYNA) Over The Proposed Sale Of The Company To Sunovion Pharmaceuticals Inc.
2016-09-01,Stocks Get Off to Shaky September Start in Wait for Jobs Report
2016-09-01,Why Cynapsus Therapeutics (CYNA) Stock Is Soaring Today
2016-08-29,Cynapsus Receives FDA Fast Track Designation For APL-130277 For The Treatment Of OFF Episodes In Patients With Parkinson's Disease
2016-08-15,Cynapsus Announces Positive Opinion From Data And Safety Monitoring Board On Phase 3 Parkinson's Disease Clinical Study Allowing For At-Home Titration
2016-08-12,Cynapsus Announces Publication In The Journal Movement Disorders Of Data For The Treatment Of OFF Episodes In Patients With Parkinson's Disease
2016-08-10,Cynapsus Therapeutics Reports Second Quarter 2016 Financial Results And Recent Developments
2016-07-18,Cynapsus Therapeutics Announces Positive Phase 3 Dose Titration Phase Results With APL-130277 For The Treatment Of OFF Episodes In Patients With Parkinson's Disease
2016-07-18,Cynapsus Therapeutics Provides European Clinical Update For APL-130277 For The Treatment Of OFF Episodes In Patients With Parkinson's Disease
2016-07-06,Cynapsus Therapeutics Announces 2016 Analyst And Investor Day
2016-06-30,Cynapsus Therapeutics Enrolls Last Patient In Pivotal Phase 3 Efficacy Trial Of APL-130277 To Treat OFF Episodes In Patients With Parkinson's Disease
2016-06-21,Cynapsus Therapeutics Announces Data Presentations At The International Congress Of Parkinson's Disease And Movement Disorders
2016-05-30,Cynapsus Therapeutics Announces Data Presentations At The European Academy Of Neurology Annual Meeting
2016-05-20,Cynapsus Therapeutics Appoints Frederick Driscoll To Its Board Of Directors
2016-05-11,Cynapsus Therapeutics Reports First Quarter 2016 Financial Results And Recent Developments
2016-05-11,Cynapsus Therapeutics Announces Results Of AGM
2016-04-28,Cynapsus Therapeutics To Present At Several Upcoming Investor Conferences
2016-04-15,Cynapsus Therapeutics Announces Data Presentations At The American Academy Of Neurology Annual Meeting
2016-04-04,Cynapsus Therapeutics And MonoSol Rx Announce Global IP Licensing Agreement
2016-03-17,Cynapsus Therapeutics is Now Oversold (CYNA)
2016-03-09,Cynapsus Therapeutics Reports Financial Results For The Fourth Quarter And Year Ended 2015
2016-03-07,Cynapsus Therapeutics Provides Company Update At Cowen & Co. 36th Annual Health Care Conference
2016-03-01,Cynapsus Therapeutics To Present At Cowen & Co. 36th Annual Health Care Conference
2016-02-09,Relative Strength Alert For Cynapsus Therapeutics
2016-01-13,Cynapsus Therapeutics To Present At Noble Financial Capital Markets Twelfth Annual Investor Conference
2016-01-07,Cynapsus And Michael J. Fox Foundation Collaborate On Pilot Use Of Wearable Device And Data Science Approaches In Phase 3 Parkinson's Clinical Study
2016-01-07,Cynapsus And Michael J. Fox Foundation Collaborate On Pilot Use Of Wearable Device And Data Science Approaches In Phase 3 Parkinson's Clinical Study
2016-01-04,Cynapsus Therapeutics Completes Short-Form Amalgamation With Wholly-Owned Subsidiary
2015-12-14,Relative Strength Alert For Cynapsus Therapeutics
2015-12-10,Cynapsus Therapeutics Announces Successful Completion Of Bioavailability And Pharmacokinetic Study And Provides Update On European Clinical Plans
2015-12-08,Cynapsus Therapeutics Announces Positive Data Presentations At World Congress On Parkinson's Disease And Related Disorders Meeting
2015-11-19,Cynapsus Therapeutics Expands Senior Leadership Team
2015-11-13,Cynapsus Therapeutics To Present At Stifel 2015 Healthcare Conference
2015-11-12,Cynapsus Therapeutics Reports Third Quarter 2015 Financial Results And Recent Developments
2015-09-03,Cynapsus Therapeutics To Present At Two Upcoming Healthcare Conferences
2015-09-02,Cynapsus Therapeutics Enrolls First Patient In Pivotal Phase 3 Safety Study Of APL-130277 For The Treatment Of OFF Episodes In Patients With Parkinson's Disease
2015-08-11,Cynapsus Therapeutics Enters Oversold Territory (CYNA)
2015-07-30,Cynapsus CEO Says IPO Funds Will Help Parkinson’s Patients Get Unstuck
2015-07-30,Parkinson’s Drug Delivery System on Track Says Cynapsus CEO
2015-07-16,OTC Markets Group Announces Second Quarter 2015 Index Performance And Rebalancing
,
,
,
,
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-08,Could These 9 Drugs Gain FDA Approval in the Age of Trump?
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-07,CytRx To Present At The 29th Annual ROTH Conference
2017-02-06,CytRx To Present At The 19th Annual BIO CEO & Investor Conference
2017-01-25,First Week of CYTR September 15th Options Trading
2017-01-04,CytRx Granted Type B Pre-NDA Meeting With U.S. FDA For Registration Pathway With Aldoxorubicin As A Treatment For Patients With Relapsed Soft Tissue Sarcomas
2016-12-22,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
2016-12-19,CytRx Appoints Chief Medical Officer Dr. Daniel Levitt As Chief Operating Officer
2016-12-13,CytRx Corporation Announces $8.1 Million Registered Direct Offering Of Common Stock
2016-12-02,Leading Sarcoma Expert Dr. Earl W. Brien Joins CytRx Board Of Directors
2016-11-29,CytRx CEO Pockets Millions of Dollars as Failed Sarcoma Drug Moves to FDA
2016-11-15,Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive
2016-11-11,CytRx Presents Positive Interim Results From On-going Phase 1b/2 Aldoxorubicin Combination Clinical Trial At The 2016 CTOS Annual Meeting
2016-10-10,CytRx Presents Interim Results From On-going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial At ESMO 2016 Congress
2016-09-22,24-Hour Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of The Upcoming September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation
2016-09-22,DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016 - CYTR
2016-09-20,SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In CytRx Corporation To Contact The Firm Before Imminent Lead Plaintiff Deadline
2016-09-19,GPM Reminds Investors Of The September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation And Encourages Investors To Contact The Firm
2016-09-12,CytRx To Present Data At The European Society For Medical Oncology 2016 Congress From Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial
2016-09-09,INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016 - CYTR
2016-09-07,INVESTOR ALERT: Rosen Law Firm Reminds CytRx Corporation Investors Of Important September 23 Deadline In Class Action - CYTR
2016-09-07,CytRx Announces the Completion of Enrollment in Its Global Phase 2b Clinical Trial of Aldoxorubicin in Patients with Second-Line Small Cell Lung Cancer
2016-09-06,CYTR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving CytRx Corporation And A Lead Plaintiff Deadline Of September 23, 2016
2016-09-06,CytRx to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
2016-08-31,CYTR INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving CytRx Corporation and a Lead Plaintiff Deadline of September 23, 2016
2016-08-26,Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of CytRx Corporation Investors And Encourages Investors To Contact The Firm
2016-08-26,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016
2016-08-25,Brower Piven Alerts Shareholders Of Upcoming Deadline In Class Action Lawsuit And Encourages Those With Losses From Investment In CytRx Corporation To Contact The Firm
2016-08-22,CYTR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving CytRx Corporation And A Lead Plaintiff Deadline Of September 23, 2016
2016-08-15,Federman & Sherwood Reminds Investors Of Imminent Lead Plaintiff Deadline In Securities Class Action Lawsuit Against CytRx Corporation
2016-08-12,STOCK NOTICE: Rosen Law Firm Reminds CytRx Corporation Investors Of Important Deadline In Class Action
2016-08-11,Robbins Arroyo LLP: CytRx Corporation (CYTR) Misled Shareholders According To A Recently Filed Class Action
2016-08-05,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In CytRx Corporation Of Class Action Lawsuit And Upcoming Deadline - CYTR
2016-08-05,Lifshitz & Miller Law Firm Announces Investigation Of American Renal Associates Holdings, Inc., CytRx Corporation, El Pollo Loco Holdings, Inc., EndoChoice Holdings, Inc., Full Circle Capital Corporation And ZIOPHARM Oncology, Inc.
2016-08-03,INVESTOR ALERT: Brower Piven Notifies Shareholders Of Securities Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In CytRx Corporation To Contact Brower Piven Before The Lead Plaintiff Deadline
2016-08-03,CytRx Corporation Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors
2016-08-02,SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against CytRx Corporation (CYTR) And Lead Plaintiff Deadline: September 23, 2016
2016-07-29,CytRx (CYTR) Strong On High Relative Volume Today
2016-07-29,These 5 Stocks Are Poised for Breakouts
2016-07-27,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against CytRx Corporation - CYTR
2016-07-25,Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of CytRx Corporation Investors And Encourages Investors To Contact The Firm
2016-07-20,SHAREHOLDER ALERT: Goldberg Law PC Announces An Investigation Of Claims Against CytRx Corporation And Advises Investors With Losses To Contact The Firm
2016-07-18,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of CytRx Corporation
2016-07-18,Interesting CYTR Put And Call Options For March 2017
2016-07-15,CytRx Corporation Announces Pricing Of $20 Million Public Offering Of Common Stock And Warrants
2016-07-14,SHAREHOLDER NOTICE: Khang & Khang LLP Announces An Investigation Of CytRx Corporation And Reminds Investors With Losses To Contact The Firm
2016-07-14,CytRx Corporation Announces Proposed Public Offering Of Common Stock And Warrants
2016-07-14,INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of CytRx Corporation - CYTR
2016-07-13,Trade-Ideas: CytRx (CYTR) Is Today's Weak On High Relative Volume Stock
2016-07-12,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of CytRx Corporation (CYTR)
2016-07-12,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of CytRx Corporation
2016-07-11,CytRx Sarcoma Drug Flops in Late-Stage Clinical Trial
2016-07-11,CytRx Announces Initial Results Of Phase 3 Trial Of Aldoxorubicin In Patients With Second-Line Soft Tissue Sarcoma; Subsequent Analysis To Be Announced Fourth Quarter 2016
2016-06-06,CytRx Presents Updated Aldoxorubicin Clinical Trial Results At The 2016 American Society Of Clinical Oncology Annual Meeting
2016-05-31,CytRx To Present At Jefferies 2016 Global Healthcare Conference
2016-05-13,Biotech Stock Mailbag: Why Intrexon CEO R.J. Kirk Should Not Be Trusted
2016-05-10,CytRx Bear Thesis Explained: Why Sarcoma Drug Trial Will Fail
2016-04-28,CytRx To Present At Joseph Gunnar And Co.'s PIONEERS 2016 Investor Conference
2016-04-25,CytRx (CYTR) Flagged As Strong On High Volume
2016-04-25,CytRx And PRA Health Sciences Receive Gold Awards For Excellence In Clinical Research As The Strategic Partnership Team Of The Year
2016-04-20,CytRx To Present Updated Aldoxorubicin Clinical Trial Data At The American Society Of Clinical Oncology Annual Meeting In June 2016
2016-04-18,CYTR December 16th Options Begin Trading
2016-04-18,CytRx (CYTR) Strong On High Relative Volume Today
2016-04-11,CytRx (CYTR) Stock: Weak On High Volume Today
2016-04-04,CytRx Global Pivotal Phase 3 Clinical Trial With Aldoxorubicin Achieves 191 Target Events Triggering Statistical Data Analysis
2016-03-22,First Week of May 20th Options Trading For CytRx (CYTR)
2016-03-22,CytRx To Present New Data Using Its Proprietary LADR™ Technology At The 2016 American Association For Cancer Research Annual Meeting
2016-02-29,Interesting CYTR Put And Call Options For April 15th
2016-02-29,CytRx To Present At The Cowen & Company's 36th Annual Health Care Conference
2016-02-12,First Week of September 16th Options Trading For CytRx (CYTR)
2016-02-08,CytRx Secures $40 Million Long-Term Loan Facility
2016-02-01,CytRx To Present At The 18th Annual BIO CEO & Investor Conference
2016-01-11,CytRx Corporation Appoints Olivia Ware As Chief Commercial Officer
2016-01-05,CytRx Announces Settlement Of California Stockholder Derivative Lawsuit
2015-12-10,CytRx Announces Settlement Of The Consolidated Securities Class Action Lawsuit
2015-12-07,CytRx Nominates Next Clinical Drug Candidate DK049
2015-12-03,CytRx Announces Participation At The 26th Annual Oppenheimer Healthcare Conference
2015-12-01,CytRx Announces The Completion Of Enrollment In Pivotal Global Phase 3 Trial Ahead Of Schedule
2015-11-23,Aldoxorubicin Continues To Demonstrate Positive Clinical Activity In Phase 2 Glioblastoma Trial
2015-10-28,CytRx To Present Additional Data From Its Phase 1b/2 Clinical Trial Combining Aldoxorubicin With Ifosfamide/Mesna At The CTOS 2015 Annual Meeting
2015-10-20,First Week of June 2016 Options Trading For CytRx (CYTR)
2015-09-21,CytRx Announces The Publication Of Its Positive Global Phase 2b Clinical Trial Results For Soft Tissue Sarcoma In The Peer-Reviewed JAMA Oncology
2015-09-03,CytRx Announces The Presentation Of Its Phase 2b Clinical Trial Design In Small Cell Lung Cancer At The World Conference On Lung Cancer In Denver, Colorado
2015-09-01,CytRx Announces Participation At FBR & Co. Second Annual Health Conference And Rodman & Renshaw 17th Annual Global Investment Conference
2015-08-13,Short Interest In CytRx Decreases By 10.4%
2015-07-24,CytRx Announces Closing Of Public Offering Of Common Stock, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-07-21,CytRx Announces Pricing Of Public Offering Of 9.1 Million Shares Of Common Stock
2015-07-20,CytRx Announces Proposed Public Offering Of Common Stock
2015-06-30,CytRx Unveils Novel LADR™ (Linker Activated Drug Release) Technology Platform
2015-06-29,CytRx Announces Presentation Of Interim Phase 2 Data For Aldoxorubicin For HIV-Related Kaposi's Sarcoma
2015-06-24,Cheryl Cohen, Former Medivation Chief Commercial Officer, Joins CytRx Board Of Directors
2015-06-02,CytRx Announces Settlement Of Stockholder Derivative Lawsuit In Delaware
2015-05-29,Fly Watch: Several Names That May Move Following ASCO Meeting
2015-05-27,CytRx To Present Aldoxorubicin Clinical Data At The 2015 ASCO Annual Meeting
2015-05-26,CytRx To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-21,CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results In Glioblastoma Multiforme (Brain Cancer)
2015-05-19,First Week Of July 17th Options Trading For CytRx (CYTR)
2015-05-05,CytRx (CYTR) Is Weak On High Volume Today
2015-05-04,CytRx (CYTR) Is Strong On High Volume Today
2015-05-04,CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage And Improved Quality Of Life In Chemotherapy Resistant Cancers
2015-04-29,CytRx Announces Publication Of Glioblastoma Clinical Case Study In Journal Of Nuclear Medicine & Radiation Therapy
2015-04-21,Interesting CYTR Put And Call Options For December 18th
2015-04-17,CytRx (CYTR) Stock Rises Today Following Oppenheimer Coverage Initiation
2015-04-17,Strong On High Relative Volume: CytRx (CYTR)
2015-03-11,Dr. Anita J. Chawla Joins CytRx Board Of Directors To Add Additional Drug Commercialization Expertise In Oncology
2015-02-25,CytRx To Present At The Cowen & Company 35th Annual Health Care Conference
2015-02-02,CytRx To Present At The 17th Annual BIO CEO & Investor Conference On February 9, 2015 In New York City
2015-01-23,First Week Of September 18th Options Trading For CYTR
2015-01-22,CytRx Announces Overall Survival Results From Its Global Phase 2b Clinical Trial Of Aldoxorubicin In Soft Tissue Sarcoma
2015-01-20,CytRx Announces FDA's Removal Of Partial Clinical Hold For Aldoxorubicin Clinical Trials Permitting Immediate Enrollment Of New Patients
2015-01-08,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results As A Treatment For HIV-Related Kaposi's Sarcoma (KS)
2015-01-06,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results In Glioblastoma Multiforme (Brain Cancer)
2014-12-15,Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...
2014-12-03,CytRx Receives Written FDA Communication Regarding Partial Clinical Hold For Aldoxorubicin Clinical Trials
2014-12-02,Five Biotech Firms Whose Stock-Promoting Efforts Didn't Pay Off
2014-12-02,CytRx To Present At The Oppenheimer 25th Annual Healthcare Conference
2014-11-18,CytRx Announces Partial Clinical Hold Affecting Aldoxorubicin Clinical Trials
2014-10-30,CytRx Announces Oral Presentation At 2014 Chemotherapy Foundation Symposium
2014-10-29,CytRx Announces Publication Of Preclinical Glioblastoma Data In Neoplasia
2014-10-20,CytRx Announces Publication Of Phase 1b/2 Aldoxorubicin Clinical Data In Soft Tissue Sarcoma In Cancer, The Peer-Reviewed Journal Of The American Cancer Society
2014-10-17,CytRx To Present Data From Global Phase 2b Clinical Trial Of Aldoxorubicin In First-Line Soft Tissue Sarcoma At 2014 CTOS Annual Meeting
2014-10-16,CytRx Appoints Steven A. Kriegsman As Chairman Of The Board
2014-10-13,CytRx Launches Discovery Laboratory To Develop Albumin-Binding Anti-Cancer Drug Platform
2014-10-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Gemcitabine In Patients With Metastatic Solid Tumors
2014-10-07,CytRx Announces Unexpected Passing Of Chairman Max Link, PhD
2014-09-30,CytRx Initiates Global Phase 2b Clinical Trial Of Aldoxorubicin For The Treatment Of Relapsed/Refractory Small Cell Lung Cancer
2014-09-29,CytRx Receives Multiple FDA Orphan Drug Designations For Aldoxorubicin For The Treatment Of Glioblastoma, Small Cell Lung Cancer And Ovarian Cancer
2014-09-26,CytRx Updates Presentation Time At BioCentury's 2014 NewsMakers In The Biotech Industry Conference
2014-09-22,CytRx Announces Presentation Of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas And Global Phase 2b Small Cell Lung Cancer Trial Designs At ESMO 2014 Congress
2014-09-19,CytRx To Present At BioCentury's 2014 NewsMakers In The Biotech Industry Conference
2014-09-16,Federman & Sherwood Investigates CytRx Corporation For Possible Violations Of Federal Securities Laws
2014-09-15,Former Louisiana Attorney General And KSF Announce Appointment As Lead Counsel In CytRx Securities Fraud Lawsuit: Secondary Offering Shareholders (January 31, 2014) Should Inquire For More Information
2014-09-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Ifosfamide/Mesna As First-Line Treatment In Patients With Advanced Sarcomas
2014-09-05,CytRx Updates Presentation Time At Aegis 2014 Healthcare & Technology Conference
2014-09-02,CytRx To Present At Upcoming Investor Conferences In New York City And Las Vegas
2014-08-28,5 Breakout Stocks Under $10 Set to Soar
2014-08-27,4 Under-$10 Biotech Stocks in Breakout Territory
2014-08-22,Biotech Stock Mailbag: Threshold, Galena, CytRx
2014-08-11,SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into CytRx Corporation Regarding Possible Breaches Of Fiduciary Duty
2014-08-07,Oral Presentation Of CytRx’s Aldoxorubicin Phase 2b Clinical Trial In Soft Tissue Sarcoma Highlighted In The Lancet Oncology
2014-08-06,CytRx Reports 2014 Second Quarter Financial Results
2014-07-09,SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into CytRx Corporation Regarding Possible Breaches Of Fiduciary Duty
2014-06-30,CytRx Added To Russell 3000&#174; And Russell 2000&#174; Indexes
2014-06-13,5 Stocks Poised for Breakouts
2014-06-06,5 Stocks Poised to Break Out
2014-06-04,3 Stocks Under $10 Moving Higher
2014-05-29,5 Stocks Under $10 Set to Soar
2014-05-29,CytRx To Present At The Jefferies 2014 Global Healthcare Conference
2014-05-28,CytRx Highlights Aldoxorubicin Data From Its Global Phase 2b Clinical Trial In First-Line Soft Tissue Sarcoma
2014-05-22,5 Stocks Under $10 Set to Soar
2014-05-14,3 Biotech Stocks Under $10 to Watch
2014-05-09,SHAREHOLDER ALERT: Pomerantz Law Firm Announces The Filing Of A Class Action Against CytRx Corporation And Certain Officers - CYTR
2014-05-06,Hagens Berman: 7 Days Remain Until May 13, 2014 Lead Plaintiff Deadline In CytRx Securities Fraud Class Action
2014-05-05,CytRx Reports Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma
2014-05-02,Pre-Market Review On Top Gainers -- Research On SouFun Holdings, CytRx, Iridium Communications, And Qihoo 360 Technology
2014-05-01,CytRx Reports 2014 First Quarter Financial Results
2014-04-28,CytRx To Present Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma At Upcoming Research And Development Day
2014-04-24,CytRx Announces Global Phase 2b Trial Of Aldoxorubicin In Soft Tissue Sarcomas Selected For Oral Presentation At The 2014 ASCO Annual Meeting
2014-04-23,Hagens Berman: 21 Days Remain Until May 13, 2014 Lead Plaintiff Deadline In CytRx Securities Fraud Class Action
2014-04-23,Lieff Cabraser Reminds CytRx Corporation Investors Of Upcoming Deadline In Class Action Litigation &#8211; CYTR
2014-04-22,Interesting CYTR Put And Call Options For December 20th
2014-04-15,SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In CytRx Corporation To Contact Brower Piven Before The May 13, 2014 Lead Plaintiff Deadline
2014-04-11,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors Of Class Action Against CYTRX CORPORATION And Its Board Of Directors And A Lead Plaintiff Deadline Of May 13, 2014 -- CYTR
2014-04-10,CytRx Announces Research And Development Day And Webcast
2014-04-09,Hagens Berman Reminds CytRx Investors Of May 13, 2014 Lead Plaintiff Deadline And Inclusion Of Those Who Purchased Stock From Feb. 5, 2014 Offering
2014-04-04,Technical Update On Active Stocks -- Research On CytRx, FireEye, Yandex, And Hewlett-Packard
2014-04-03,Why CytRx (CYTR) Stock Is Surging Today
2014-04-03,CytRx To Present Updated Aldoxorubicin Preclinical Glioblastoma Study Results At The 2014 AACR Annual Meeting
2014-04-01,Speculative Biotech Stock Offers Opportunity Amid Controversy
2014-03-31,CORRECTING and REPLACING Hagens Berman Reminds CytRx Investors of May 13, 2014 Lead Plaintiff Deadline and Continued Securities Fraud Investigation
2014-03-31,CytRx Receives Orphan Medicinal Product Designation From The European Commission For Aldoxorubicin In Soft Tissue Sarcoma
2014-03-28,Cohen Milstein Sellers &amp; Toll PLLC Announces The Investigation Of CytRx Corporation
2014-03-27,Today's Dead Cat Bounce Stock: CytRx Corporation (CYTR)
2014-03-27,CytRx Issues Statement Regarding Recent Lawsuits
2014-03-26,Interesting CYTR Put And Call Options For May 17th
2014-03-25,These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
2014-03-24,In This Trader's Market, a Week or More Is Now Long Term
2014-03-24,CytRx Initiates Pivotal Global Phase 3 Clinical Trial With Aldoxorubicin For Second-Line Treatment Of Soft Tissue Sarcoma
2014-03-21,/C O R R E C T I O N -- Robbins Arroyo LLP/
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-08,Could These 9 Drugs Gain FDA Approval in the Age of Trump?
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-07,CytRx To Present At The 29th Annual ROTH Conference
2017-02-06,CytRx To Present At The 19th Annual BIO CEO & Investor Conference
2017-01-25,First Week of CYTR September 15th Options Trading
2017-01-04,CytRx Granted Type B Pre-NDA Meeting With U.S. FDA For Registration Pathway With Aldoxorubicin As A Treatment For Patients With Relapsed Soft Tissue Sarcomas
2016-12-22,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
2016-12-19,CytRx Appoints Chief Medical Officer Dr. Daniel Levitt As Chief Operating Officer
2016-12-13,CytRx Corporation Announces $8.1 Million Registered Direct Offering Of Common Stock
2016-12-02,Leading Sarcoma Expert Dr. Earl W. Brien Joins CytRx Board Of Directors
2016-11-29,CytRx CEO Pockets Millions of Dollars as Failed Sarcoma Drug Moves to FDA
2016-11-15,Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive
2016-11-11,CytRx Presents Positive Interim Results From On-going Phase 1b/2 Aldoxorubicin Combination Clinical Trial At The 2016 CTOS Annual Meeting
2016-10-10,CytRx Presents Interim Results From On-going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial At ESMO 2016 Congress
2016-09-22,24-Hour Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of The Upcoming September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation
2016-09-22,DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016 - CYTR
2016-09-20,SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In CytRx Corporation To Contact The Firm Before Imminent Lead Plaintiff Deadline
2016-09-19,GPM Reminds Investors Of The September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation And Encourages Investors To Contact The Firm
2016-09-12,CytRx To Present Data At The European Society For Medical Oncology 2016 Congress From Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial
2016-09-09,INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016 - CYTR
2016-09-07,INVESTOR ALERT: Rosen Law Firm Reminds CytRx Corporation Investors Of Important September 23 Deadline In Class Action - CYTR
2016-09-07,CytRx Announces the Completion of Enrollment in Its Global Phase 2b Clinical Trial of Aldoxorubicin in Patients with Second-Line Small Cell Lung Cancer
2016-09-06,CYTR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving CytRx Corporation And A Lead Plaintiff Deadline Of September 23, 2016
2016-09-06,CytRx to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
2016-08-31,CYTR INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving CytRx Corporation and a Lead Plaintiff Deadline of September 23, 2016
2016-08-26,Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of CytRx Corporation Investors And Encourages Investors To Contact The Firm
2016-08-26,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016
2016-08-25,Brower Piven Alerts Shareholders Of Upcoming Deadline In Class Action Lawsuit And Encourages Those With Losses From Investment In CytRx Corporation To Contact The Firm
2016-08-22,CYTR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving CytRx Corporation And A Lead Plaintiff Deadline Of September 23, 2016
2016-08-15,Federman & Sherwood Reminds Investors Of Imminent Lead Plaintiff Deadline In Securities Class Action Lawsuit Against CytRx Corporation
2016-08-12,STOCK NOTICE: Rosen Law Firm Reminds CytRx Corporation Investors Of Important Deadline In Class Action
2016-08-11,Robbins Arroyo LLP: CytRx Corporation (CYTR) Misled Shareholders According To A Recently Filed Class Action
2016-08-05,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In CytRx Corporation Of Class Action Lawsuit And Upcoming Deadline - CYTR
2016-08-05,Lifshitz & Miller Law Firm Announces Investigation Of American Renal Associates Holdings, Inc., CytRx Corporation, El Pollo Loco Holdings, Inc., EndoChoice Holdings, Inc., Full Circle Capital Corporation And ZIOPHARM Oncology, Inc.
2016-08-03,INVESTOR ALERT: Brower Piven Notifies Shareholders Of Securities Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In CytRx Corporation To Contact Brower Piven Before The Lead Plaintiff Deadline
2016-08-03,CytRx Corporation Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors
2016-08-02,SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against CytRx Corporation (CYTR) And Lead Plaintiff Deadline: September 23, 2016
2016-07-29,CytRx (CYTR) Strong On High Relative Volume Today
2016-07-29,These 5 Stocks Are Poised for Breakouts
2016-07-27,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against CytRx Corporation - CYTR
2016-07-25,Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of CytRx Corporation Investors And Encourages Investors To Contact The Firm
2016-07-20,SHAREHOLDER ALERT: Goldberg Law PC Announces An Investigation Of Claims Against CytRx Corporation And Advises Investors With Losses To Contact The Firm
2016-07-18,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of CytRx Corporation
2016-07-18,Interesting CYTR Put And Call Options For March 2017
2016-07-15,CytRx Corporation Announces Pricing Of $20 Million Public Offering Of Common Stock And Warrants
2016-07-14,SHAREHOLDER NOTICE: Khang & Khang LLP Announces An Investigation Of CytRx Corporation And Reminds Investors With Losses To Contact The Firm
2016-07-14,CytRx Corporation Announces Proposed Public Offering Of Common Stock And Warrants
2016-07-14,INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of CytRx Corporation - CYTR
2016-07-13,Trade-Ideas: CytRx (CYTR) Is Today's Weak On High Relative Volume Stock
2016-07-12,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of CytRx Corporation (CYTR)
2016-07-12,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of CytRx Corporation
2016-07-11,CytRx Sarcoma Drug Flops in Late-Stage Clinical Trial
2016-07-11,CytRx Announces Initial Results Of Phase 3 Trial Of Aldoxorubicin In Patients With Second-Line Soft Tissue Sarcoma; Subsequent Analysis To Be Announced Fourth Quarter 2016
2016-06-06,CytRx Presents Updated Aldoxorubicin Clinical Trial Results At The 2016 American Society Of Clinical Oncology Annual Meeting
2016-05-31,CytRx To Present At Jefferies 2016 Global Healthcare Conference
2016-05-13,Biotech Stock Mailbag: Why Intrexon CEO R.J. Kirk Should Not Be Trusted
2016-05-10,CytRx Bear Thesis Explained: Why Sarcoma Drug Trial Will Fail
2016-04-28,CytRx To Present At Joseph Gunnar And Co.'s PIONEERS 2016 Investor Conference
2016-04-25,CytRx (CYTR) Flagged As Strong On High Volume
2016-04-25,CytRx And PRA Health Sciences Receive Gold Awards For Excellence In Clinical Research As The Strategic Partnership Team Of The Year
2016-04-20,CytRx To Present Updated Aldoxorubicin Clinical Trial Data At The American Society Of Clinical Oncology Annual Meeting In June 2016
2016-04-18,CYTR December 16th Options Begin Trading
2016-04-18,CytRx (CYTR) Strong On High Relative Volume Today
2016-04-11,CytRx (CYTR) Stock: Weak On High Volume Today
2016-04-04,CytRx Global Pivotal Phase 3 Clinical Trial With Aldoxorubicin Achieves 191 Target Events Triggering Statistical Data Analysis
2016-03-22,First Week of May 20th Options Trading For CytRx (CYTR)
2016-03-22,CytRx To Present New Data Using Its Proprietary LADR™ Technology At The 2016 American Association For Cancer Research Annual Meeting
2016-02-29,Interesting CYTR Put And Call Options For April 15th
2016-02-29,CytRx To Present At The Cowen & Company's 36th Annual Health Care Conference
2016-02-12,First Week of September 16th Options Trading For CytRx (CYTR)
2016-02-08,CytRx Secures $40 Million Long-Term Loan Facility
2016-02-01,CytRx To Present At The 18th Annual BIO CEO & Investor Conference
2016-01-11,CytRx Corporation Appoints Olivia Ware As Chief Commercial Officer
2016-01-05,CytRx Announces Settlement Of California Stockholder Derivative Lawsuit
2015-12-10,CytRx Announces Settlement Of The Consolidated Securities Class Action Lawsuit
2015-12-07,CytRx Nominates Next Clinical Drug Candidate DK049
2015-12-03,CytRx Announces Participation At The 26th Annual Oppenheimer Healthcare Conference
2015-12-01,CytRx Announces The Completion Of Enrollment In Pivotal Global Phase 3 Trial Ahead Of Schedule
2015-11-23,Aldoxorubicin Continues To Demonstrate Positive Clinical Activity In Phase 2 Glioblastoma Trial
2015-10-28,CytRx To Present Additional Data From Its Phase 1b/2 Clinical Trial Combining Aldoxorubicin With Ifosfamide/Mesna At The CTOS 2015 Annual Meeting
2015-10-20,First Week of June 2016 Options Trading For CytRx (CYTR)
2015-09-21,CytRx Announces The Publication Of Its Positive Global Phase 2b Clinical Trial Results For Soft Tissue Sarcoma In The Peer-Reviewed JAMA Oncology
2015-09-03,CytRx Announces The Presentation Of Its Phase 2b Clinical Trial Design In Small Cell Lung Cancer At The World Conference On Lung Cancer In Denver, Colorado
2015-09-01,CytRx Announces Participation At FBR & Co. Second Annual Health Conference And Rodman & Renshaw 17th Annual Global Investment Conference
2015-08-13,Short Interest In CytRx Decreases By 10.4%
2015-07-24,CytRx Announces Closing Of Public Offering Of Common Stock, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-07-21,CytRx Announces Pricing Of Public Offering Of 9.1 Million Shares Of Common Stock
2015-07-20,CytRx Announces Proposed Public Offering Of Common Stock
2015-06-30,CytRx Unveils Novel LADR™ (Linker Activated Drug Release) Technology Platform
2015-06-29,CytRx Announces Presentation Of Interim Phase 2 Data For Aldoxorubicin For HIV-Related Kaposi's Sarcoma
2015-06-24,Cheryl Cohen, Former Medivation Chief Commercial Officer, Joins CytRx Board Of Directors
2015-06-02,CytRx Announces Settlement Of Stockholder Derivative Lawsuit In Delaware
2015-05-29,Fly Watch: Several Names That May Move Following ASCO Meeting
2015-05-27,CytRx To Present Aldoxorubicin Clinical Data At The 2015 ASCO Annual Meeting
2015-05-26,CytRx To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-21,CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results In Glioblastoma Multiforme (Brain Cancer)
2015-05-19,First Week Of July 17th Options Trading For CytRx (CYTR)
2015-05-05,CytRx (CYTR) Is Weak On High Volume Today
2015-05-04,CytRx (CYTR) Is Strong On High Volume Today
2015-05-04,CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage And Improved Quality Of Life In Chemotherapy Resistant Cancers
2015-04-29,CytRx Announces Publication Of Glioblastoma Clinical Case Study In Journal Of Nuclear Medicine & Radiation Therapy
2015-04-21,Interesting CYTR Put And Call Options For December 18th
2015-04-17,CytRx (CYTR) Stock Rises Today Following Oppenheimer Coverage Initiation
2015-04-17,Strong On High Relative Volume: CytRx (CYTR)
2015-03-11,Dr. Anita J. Chawla Joins CytRx Board Of Directors To Add Additional Drug Commercialization Expertise In Oncology
2015-02-25,CytRx To Present At The Cowen & Company 35th Annual Health Care Conference
2015-02-02,CytRx To Present At The 17th Annual BIO CEO & Investor Conference On February 9, 2015 In New York City
2015-01-23,First Week Of September 18th Options Trading For CYTR
2015-01-22,CytRx Announces Overall Survival Results From Its Global Phase 2b Clinical Trial Of Aldoxorubicin In Soft Tissue Sarcoma
2015-01-20,CytRx Announces FDA's Removal Of Partial Clinical Hold For Aldoxorubicin Clinical Trials Permitting Immediate Enrollment Of New Patients
2015-01-08,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results As A Treatment For HIV-Related Kaposi's Sarcoma (KS)
2015-01-06,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results In Glioblastoma Multiforme (Brain Cancer)
2014-12-15,Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...
2014-12-03,CytRx Receives Written FDA Communication Regarding Partial Clinical Hold For Aldoxorubicin Clinical Trials
2014-12-02,Five Biotech Firms Whose Stock-Promoting Efforts Didn't Pay Off
2014-12-02,CytRx To Present At The Oppenheimer 25th Annual Healthcare Conference
2014-11-18,CytRx Announces Partial Clinical Hold Affecting Aldoxorubicin Clinical Trials
2014-10-30,CytRx Announces Oral Presentation At 2014 Chemotherapy Foundation Symposium
2014-10-29,CytRx Announces Publication Of Preclinical Glioblastoma Data In Neoplasia
2014-10-20,CytRx Announces Publication Of Phase 1b/2 Aldoxorubicin Clinical Data In Soft Tissue Sarcoma In Cancer, The Peer-Reviewed Journal Of The American Cancer Society
2014-10-17,CytRx To Present Data From Global Phase 2b Clinical Trial Of Aldoxorubicin In First-Line Soft Tissue Sarcoma At 2014 CTOS Annual Meeting
2014-10-16,CytRx Appoints Steven A. Kriegsman As Chairman Of The Board
2014-10-13,CytRx Launches Discovery Laboratory To Develop Albumin-Binding Anti-Cancer Drug Platform
2014-10-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Gemcitabine In Patients With Metastatic Solid Tumors
2014-10-07,CytRx Announces Unexpected Passing Of Chairman Max Link, PhD
2014-09-30,CytRx Initiates Global Phase 2b Clinical Trial Of Aldoxorubicin For The Treatment Of Relapsed/Refractory Small Cell Lung Cancer
2014-09-29,CytRx Receives Multiple FDA Orphan Drug Designations For Aldoxorubicin For The Treatment Of Glioblastoma, Small Cell Lung Cancer And Ovarian Cancer
2014-09-26,CytRx Updates Presentation Time At BioCentury's 2014 NewsMakers In The Biotech Industry Conference
2014-09-22,CytRx Announces Presentation Of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas And Global Phase 2b Small Cell Lung Cancer Trial Designs At ESMO 2014 Congress
2014-09-19,CytRx To Present At BioCentury's 2014 NewsMakers In The Biotech Industry Conference
2014-09-16,Federman & Sherwood Investigates CytRx Corporation For Possible Violations Of Federal Securities Laws
2014-09-15,Former Louisiana Attorney General And KSF Announce Appointment As Lead Counsel In CytRx Securities Fraud Lawsuit: Secondary Offering Shareholders (January 31, 2014) Should Inquire For More Information
2014-09-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Ifosfamide/Mesna As First-Line Treatment In Patients With Advanced Sarcomas
2014-09-05,CytRx Updates Presentation Time At Aegis 2014 Healthcare & Technology Conference
2014-09-02,CytRx To Present At Upcoming Investor Conferences In New York City And Las Vegas
2014-08-28,5 Breakout Stocks Under $10 Set to Soar
2014-08-27,4 Under-$10 Biotech Stocks in Breakout Territory
2014-08-22,Biotech Stock Mailbag: Threshold, Galena, CytRx
2014-08-11,SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into CytRx Corporation Regarding Possible Breaches Of Fiduciary Duty
2014-08-07,Oral Presentation Of CytRx’s Aldoxorubicin Phase 2b Clinical Trial In Soft Tissue Sarcoma Highlighted In The Lancet Oncology
2014-08-06,CytRx Reports 2014 Second Quarter Financial Results
2014-07-09,SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into CytRx Corporation Regarding Possible Breaches Of Fiduciary Duty
2014-06-30,CytRx Added To Russell 3000&#174; And Russell 2000&#174; Indexes
2014-06-13,5 Stocks Poised for Breakouts
2014-06-06,5 Stocks Poised to Break Out
2014-06-04,3 Stocks Under $10 Moving Higher
2014-05-29,5 Stocks Under $10 Set to Soar
2014-05-29,CytRx To Present At The Jefferies 2014 Global Healthcare Conference
2014-05-28,CytRx Highlights Aldoxorubicin Data From Its Global Phase 2b Clinical Trial In First-Line Soft Tissue Sarcoma
2014-05-22,5 Stocks Under $10 Set to Soar
2014-05-14,3 Biotech Stocks Under $10 to Watch
2014-05-09,SHAREHOLDER ALERT: Pomerantz Law Firm Announces The Filing Of A Class Action Against CytRx Corporation And Certain Officers - CYTR
2014-05-06,Hagens Berman: 7 Days Remain Until May 13, 2014 Lead Plaintiff Deadline In CytRx Securities Fraud Class Action
2014-05-05,CytRx Reports Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma
2014-05-02,Pre-Market Review On Top Gainers -- Research On SouFun Holdings, CytRx, Iridium Communications, And Qihoo 360 Technology
2014-05-01,CytRx Reports 2014 First Quarter Financial Results
2014-04-28,CytRx To Present Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma At Upcoming Research And Development Day
2014-04-24,CytRx Announces Global Phase 2b Trial Of Aldoxorubicin In Soft Tissue Sarcomas Selected For Oral Presentation At The 2014 ASCO Annual Meeting
2014-04-23,Hagens Berman: 21 Days Remain Until May 13, 2014 Lead Plaintiff Deadline In CytRx Securities Fraud Class Action
2014-04-23,Lieff Cabraser Reminds CytRx Corporation Investors Of Upcoming Deadline In Class Action Litigation &#8211; CYTR
2014-04-22,Interesting CYTR Put And Call Options For December 20th
2014-04-15,SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In CytRx Corporation To Contact Brower Piven Before The May 13, 2014 Lead Plaintiff Deadline
2014-04-11,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors Of Class Action Against CYTRX CORPORATION And Its Board Of Directors And A Lead Plaintiff Deadline Of May 13, 2014 -- CYTR
2014-04-10,CytRx Announces Research And Development Day And Webcast
2014-04-09,Hagens Berman Reminds CytRx Investors Of May 13, 2014 Lead Plaintiff Deadline And Inclusion Of Those Who Purchased Stock From Feb. 5, 2014 Offering
2014-04-04,Technical Update On Active Stocks -- Research On CytRx, FireEye, Yandex, And Hewlett-Packard
2014-04-03,Why CytRx (CYTR) Stock Is Surging Today
2014-04-03,CytRx To Present Updated Aldoxorubicin Preclinical Glioblastoma Study Results At The 2014 AACR Annual Meeting
2014-04-01,Speculative Biotech Stock Offers Opportunity Amid Controversy
2014-03-31,CORRECTING and REPLACING Hagens Berman Reminds CytRx Investors of May 13, 2014 Lead Plaintiff Deadline and Continued Securities Fraud Investigation
2014-03-31,CytRx Receives Orphan Medicinal Product Designation From The European Commission For Aldoxorubicin In Soft Tissue Sarcoma
2014-03-28,Cohen Milstein Sellers &amp; Toll PLLC Announces The Investigation Of CytRx Corporation
2014-03-27,Today's Dead Cat Bounce Stock: CytRx Corporation (CYTR)
2014-03-27,CytRx Issues Statement Regarding Recent Lawsuits
2014-03-26,Interesting CYTR Put And Call Options For May 17th
2014-03-25,These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
2014-03-24,In This Trader's Market, a Week or More Is Now Long Term
2014-03-24,CytRx Initiates Pivotal Global Phase 3 Clinical Trial With Aldoxorubicin For Second-Line Treatment Of Soft Tissue Sarcoma
2014-03-21,/C O R R E C T I O N -- Robbins Arroyo LLP/
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-08,Could These 9 Drugs Gain FDA Approval in the Age of Trump?
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-07,CytRx To Present At The 29th Annual ROTH Conference
2017-02-06,CytRx To Present At The 19th Annual BIO CEO & Investor Conference
2017-01-25,First Week of CYTR September 15th Options Trading
2017-01-04,CytRx Granted Type B Pre-NDA Meeting With U.S. FDA For Registration Pathway With Aldoxorubicin As A Treatment For Patients With Relapsed Soft Tissue Sarcomas
2016-12-22,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
2016-12-19,CytRx Appoints Chief Medical Officer Dr. Daniel Levitt As Chief Operating Officer
2016-12-13,CytRx Corporation Announces $8.1 Million Registered Direct Offering Of Common Stock
2016-12-02,Leading Sarcoma Expert Dr. Earl W. Brien Joins CytRx Board Of Directors
2016-11-29,CytRx CEO Pockets Millions of Dollars as Failed Sarcoma Drug Moves to FDA
2016-11-15,Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive
2016-11-11,CytRx Presents Positive Interim Results From On-going Phase 1b/2 Aldoxorubicin Combination Clinical Trial At The 2016 CTOS Annual Meeting
2016-10-10,CytRx Presents Interim Results From On-going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial At ESMO 2016 Congress
2016-09-22,24-Hour Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of The Upcoming September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation
2016-09-22,DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016 - CYTR
2016-09-20,SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In CytRx Corporation To Contact The Firm Before Imminent Lead Plaintiff Deadline
2016-09-19,GPM Reminds Investors Of The September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation And Encourages Investors To Contact The Firm
2016-09-12,CytRx To Present Data At The European Society For Medical Oncology 2016 Congress From Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial
2016-09-09,INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016 - CYTR
2016-09-07,INVESTOR ALERT: Rosen Law Firm Reminds CytRx Corporation Investors Of Important September 23 Deadline In Class Action - CYTR
2016-09-07,CytRx Announces the Completion of Enrollment in Its Global Phase 2b Clinical Trial of Aldoxorubicin in Patients with Second-Line Small Cell Lung Cancer
2016-09-06,CYTR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving CytRx Corporation And A Lead Plaintiff Deadline Of September 23, 2016
2016-09-06,CytRx to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
2016-08-31,CYTR INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving CytRx Corporation and a Lead Plaintiff Deadline of September 23, 2016
2016-08-26,Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of CytRx Corporation Investors And Encourages Investors To Contact The Firm
2016-08-26,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016
2016-08-25,Brower Piven Alerts Shareholders Of Upcoming Deadline In Class Action Lawsuit And Encourages Those With Losses From Investment In CytRx Corporation To Contact The Firm
2016-08-22,CYTR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving CytRx Corporation And A Lead Plaintiff Deadline Of September 23, 2016
2016-08-15,Federman & Sherwood Reminds Investors Of Imminent Lead Plaintiff Deadline In Securities Class Action Lawsuit Against CytRx Corporation
2016-08-12,STOCK NOTICE: Rosen Law Firm Reminds CytRx Corporation Investors Of Important Deadline In Class Action
2016-08-11,Robbins Arroyo LLP: CytRx Corporation (CYTR) Misled Shareholders According To A Recently Filed Class Action
2016-08-05,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In CytRx Corporation Of Class Action Lawsuit And Upcoming Deadline - CYTR
2016-08-05,Lifshitz & Miller Law Firm Announces Investigation Of American Renal Associates Holdings, Inc., CytRx Corporation, El Pollo Loco Holdings, Inc., EndoChoice Holdings, Inc., Full Circle Capital Corporation And ZIOPHARM Oncology, Inc.
2016-08-03,INVESTOR ALERT: Brower Piven Notifies Shareholders Of Securities Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In CytRx Corporation To Contact Brower Piven Before The Lead Plaintiff Deadline
2016-08-03,CytRx Corporation Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors
2016-08-02,SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against CytRx Corporation (CYTR) And Lead Plaintiff Deadline: September 23, 2016
2016-07-29,CytRx (CYTR) Strong On High Relative Volume Today
2016-07-29,These 5 Stocks Are Poised for Breakouts
2016-07-27,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against CytRx Corporation - CYTR
2016-07-25,Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of CytRx Corporation Investors And Encourages Investors To Contact The Firm
2016-07-20,SHAREHOLDER ALERT: Goldberg Law PC Announces An Investigation Of Claims Against CytRx Corporation And Advises Investors With Losses To Contact The Firm
2016-07-18,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of CytRx Corporation
2016-07-18,Interesting CYTR Put And Call Options For March 2017
2016-07-15,CytRx Corporation Announces Pricing Of $20 Million Public Offering Of Common Stock And Warrants
2016-07-14,SHAREHOLDER NOTICE: Khang & Khang LLP Announces An Investigation Of CytRx Corporation And Reminds Investors With Losses To Contact The Firm
2016-07-14,CytRx Corporation Announces Proposed Public Offering Of Common Stock And Warrants
2016-07-14,INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of CytRx Corporation - CYTR
2016-07-13,Trade-Ideas: CytRx (CYTR) Is Today's Weak On High Relative Volume Stock
2016-07-12,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of CytRx Corporation (CYTR)
2016-07-12,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of CytRx Corporation
2016-07-11,CytRx Sarcoma Drug Flops in Late-Stage Clinical Trial
2016-07-11,CytRx Announces Initial Results Of Phase 3 Trial Of Aldoxorubicin In Patients With Second-Line Soft Tissue Sarcoma; Subsequent Analysis To Be Announced Fourth Quarter 2016
2016-06-06,CytRx Presents Updated Aldoxorubicin Clinical Trial Results At The 2016 American Society Of Clinical Oncology Annual Meeting
2016-05-31,CytRx To Present At Jefferies 2016 Global Healthcare Conference
2016-05-13,Biotech Stock Mailbag: Why Intrexon CEO R.J. Kirk Should Not Be Trusted
2016-05-10,CytRx Bear Thesis Explained: Why Sarcoma Drug Trial Will Fail
2016-04-28,CytRx To Present At Joseph Gunnar And Co.'s PIONEERS 2016 Investor Conference
2016-04-25,CytRx (CYTR) Flagged As Strong On High Volume
2016-04-25,CytRx And PRA Health Sciences Receive Gold Awards For Excellence In Clinical Research As The Strategic Partnership Team Of The Year
2016-04-20,CytRx To Present Updated Aldoxorubicin Clinical Trial Data At The American Society Of Clinical Oncology Annual Meeting In June 2016
2016-04-18,CYTR December 16th Options Begin Trading
2016-04-18,CytRx (CYTR) Strong On High Relative Volume Today
2016-04-11,CytRx (CYTR) Stock: Weak On High Volume Today
2016-04-04,CytRx Global Pivotal Phase 3 Clinical Trial With Aldoxorubicin Achieves 191 Target Events Triggering Statistical Data Analysis
2016-03-22,First Week of May 20th Options Trading For CytRx (CYTR)
2016-03-22,CytRx To Present New Data Using Its Proprietary LADR™ Technology At The 2016 American Association For Cancer Research Annual Meeting
2016-02-29,Interesting CYTR Put And Call Options For April 15th
2016-02-29,CytRx To Present At The Cowen & Company's 36th Annual Health Care Conference
2016-02-12,First Week of September 16th Options Trading For CytRx (CYTR)
2016-02-08,CytRx Secures $40 Million Long-Term Loan Facility
2016-02-01,CytRx To Present At The 18th Annual BIO CEO & Investor Conference
2016-01-11,CytRx Corporation Appoints Olivia Ware As Chief Commercial Officer
2016-01-05,CytRx Announces Settlement Of California Stockholder Derivative Lawsuit
2015-12-10,CytRx Announces Settlement Of The Consolidated Securities Class Action Lawsuit
2015-12-07,CytRx Nominates Next Clinical Drug Candidate DK049
2015-12-03,CytRx Announces Participation At The 26th Annual Oppenheimer Healthcare Conference
2015-12-01,CytRx Announces The Completion Of Enrollment In Pivotal Global Phase 3 Trial Ahead Of Schedule
2015-11-23,Aldoxorubicin Continues To Demonstrate Positive Clinical Activity In Phase 2 Glioblastoma Trial
2015-10-28,CytRx To Present Additional Data From Its Phase 1b/2 Clinical Trial Combining Aldoxorubicin With Ifosfamide/Mesna At The CTOS 2015 Annual Meeting
2015-10-20,First Week of June 2016 Options Trading For CytRx (CYTR)
2015-09-21,CytRx Announces The Publication Of Its Positive Global Phase 2b Clinical Trial Results For Soft Tissue Sarcoma In The Peer-Reviewed JAMA Oncology
2015-09-03,CytRx Announces The Presentation Of Its Phase 2b Clinical Trial Design In Small Cell Lung Cancer At The World Conference On Lung Cancer In Denver, Colorado
2015-09-01,CytRx Announces Participation At FBR & Co. Second Annual Health Conference And Rodman & Renshaw 17th Annual Global Investment Conference
2015-08-13,Short Interest In CytRx Decreases By 10.4%
2015-07-24,CytRx Announces Closing Of Public Offering Of Common Stock, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-07-21,CytRx Announces Pricing Of Public Offering Of 9.1 Million Shares Of Common Stock
2015-07-20,CytRx Announces Proposed Public Offering Of Common Stock
2015-06-30,CytRx Unveils Novel LADR™ (Linker Activated Drug Release) Technology Platform
2015-06-29,CytRx Announces Presentation Of Interim Phase 2 Data For Aldoxorubicin For HIV-Related Kaposi's Sarcoma
2015-06-24,Cheryl Cohen, Former Medivation Chief Commercial Officer, Joins CytRx Board Of Directors
2015-06-02,CytRx Announces Settlement Of Stockholder Derivative Lawsuit In Delaware
2015-05-29,Fly Watch: Several Names That May Move Following ASCO Meeting
2015-05-27,CytRx To Present Aldoxorubicin Clinical Data At The 2015 ASCO Annual Meeting
2015-05-26,CytRx To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-21,CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results In Glioblastoma Multiforme (Brain Cancer)
2015-05-19,First Week Of July 17th Options Trading For CytRx (CYTR)
2015-05-05,CytRx (CYTR) Is Weak On High Volume Today
2015-05-04,CytRx (CYTR) Is Strong On High Volume Today
2015-05-04,CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage And Improved Quality Of Life In Chemotherapy Resistant Cancers
2015-04-29,CytRx Announces Publication Of Glioblastoma Clinical Case Study In Journal Of Nuclear Medicine & Radiation Therapy
2015-04-21,Interesting CYTR Put And Call Options For December 18th
2015-04-17,CytRx (CYTR) Stock Rises Today Following Oppenheimer Coverage Initiation
2015-04-17,Strong On High Relative Volume: CytRx (CYTR)
2015-03-11,Dr. Anita J. Chawla Joins CytRx Board Of Directors To Add Additional Drug Commercialization Expertise In Oncology
2015-02-25,CytRx To Present At The Cowen & Company 35th Annual Health Care Conference
2015-02-02,CytRx To Present At The 17th Annual BIO CEO & Investor Conference On February 9, 2015 In New York City
2015-01-23,First Week Of September 18th Options Trading For CYTR
2015-01-22,CytRx Announces Overall Survival Results From Its Global Phase 2b Clinical Trial Of Aldoxorubicin In Soft Tissue Sarcoma
2015-01-20,CytRx Announces FDA's Removal Of Partial Clinical Hold For Aldoxorubicin Clinical Trials Permitting Immediate Enrollment Of New Patients
2015-01-08,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results As A Treatment For HIV-Related Kaposi's Sarcoma (KS)
2015-01-06,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results In Glioblastoma Multiforme (Brain Cancer)
2014-12-15,Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...
2014-12-03,CytRx Receives Written FDA Communication Regarding Partial Clinical Hold For Aldoxorubicin Clinical Trials
2014-12-02,Five Biotech Firms Whose Stock-Promoting Efforts Didn't Pay Off
2014-12-02,CytRx To Present At The Oppenheimer 25th Annual Healthcare Conference
2014-11-18,CytRx Announces Partial Clinical Hold Affecting Aldoxorubicin Clinical Trials
2014-10-30,CytRx Announces Oral Presentation At 2014 Chemotherapy Foundation Symposium
2014-10-29,CytRx Announces Publication Of Preclinical Glioblastoma Data In Neoplasia
2014-10-20,CytRx Announces Publication Of Phase 1b/2 Aldoxorubicin Clinical Data In Soft Tissue Sarcoma In Cancer, The Peer-Reviewed Journal Of The American Cancer Society
2014-10-17,CytRx To Present Data From Global Phase 2b Clinical Trial Of Aldoxorubicin In First-Line Soft Tissue Sarcoma At 2014 CTOS Annual Meeting
2014-10-16,CytRx Appoints Steven A. Kriegsman As Chairman Of The Board
2014-10-13,CytRx Launches Discovery Laboratory To Develop Albumin-Binding Anti-Cancer Drug Platform
2014-10-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Gemcitabine In Patients With Metastatic Solid Tumors
2014-10-07,CytRx Announces Unexpected Passing Of Chairman Max Link, PhD
2014-09-30,CytRx Initiates Global Phase 2b Clinical Trial Of Aldoxorubicin For The Treatment Of Relapsed/Refractory Small Cell Lung Cancer
2014-09-29,CytRx Receives Multiple FDA Orphan Drug Designations For Aldoxorubicin For The Treatment Of Glioblastoma, Small Cell Lung Cancer And Ovarian Cancer
2014-09-26,CytRx Updates Presentation Time At BioCentury's 2014 NewsMakers In The Biotech Industry Conference
2014-09-22,CytRx Announces Presentation Of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas And Global Phase 2b Small Cell Lung Cancer Trial Designs At ESMO 2014 Congress
2014-09-19,CytRx To Present At BioCentury's 2014 NewsMakers In The Biotech Industry Conference
2014-09-16,Federman & Sherwood Investigates CytRx Corporation For Possible Violations Of Federal Securities Laws
2014-09-15,Former Louisiana Attorney General And KSF Announce Appointment As Lead Counsel In CytRx Securities Fraud Lawsuit: Secondary Offering Shareholders (January 31, 2014) Should Inquire For More Information
2014-09-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Ifosfamide/Mesna As First-Line Treatment In Patients With Advanced Sarcomas
2014-09-05,CytRx Updates Presentation Time At Aegis 2014 Healthcare & Technology Conference
2014-09-02,CytRx To Present At Upcoming Investor Conferences In New York City And Las Vegas
2014-08-28,5 Breakout Stocks Under $10 Set to Soar
2014-08-27,4 Under-$10 Biotech Stocks in Breakout Territory
2014-08-22,Biotech Stock Mailbag: Threshold, Galena, CytRx
2014-08-11,SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into CytRx Corporation Regarding Possible Breaches Of Fiduciary Duty
2014-08-07,Oral Presentation Of CytRx’s Aldoxorubicin Phase 2b Clinical Trial In Soft Tissue Sarcoma Highlighted In The Lancet Oncology
2014-08-06,CytRx Reports 2014 Second Quarter Financial Results
2014-07-09,SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into CytRx Corporation Regarding Possible Breaches Of Fiduciary Duty
2014-06-30,CytRx Added To Russell 3000&#174; And Russell 2000&#174; Indexes
2014-06-13,5 Stocks Poised for Breakouts
2014-06-06,5 Stocks Poised to Break Out
2014-06-04,3 Stocks Under $10 Moving Higher
2014-05-29,5 Stocks Under $10 Set to Soar
2014-05-29,CytRx To Present At The Jefferies 2014 Global Healthcare Conference
2014-05-28,CytRx Highlights Aldoxorubicin Data From Its Global Phase 2b Clinical Trial In First-Line Soft Tissue Sarcoma
2014-05-22,5 Stocks Under $10 Set to Soar
2014-05-14,3 Biotech Stocks Under $10 to Watch
2014-05-09,SHAREHOLDER ALERT: Pomerantz Law Firm Announces The Filing Of A Class Action Against CytRx Corporation And Certain Officers - CYTR
2014-05-06,Hagens Berman: 7 Days Remain Until May 13, 2014 Lead Plaintiff Deadline In CytRx Securities Fraud Class Action
2014-05-05,CytRx Reports Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma
2014-05-02,Pre-Market Review On Top Gainers -- Research On SouFun Holdings, CytRx, Iridium Communications, And Qihoo 360 Technology
2014-05-01,CytRx Reports 2014 First Quarter Financial Results
2014-04-28,CytRx To Present Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma At Upcoming Research And Development Day
2014-04-24,CytRx Announces Global Phase 2b Trial Of Aldoxorubicin In Soft Tissue Sarcomas Selected For Oral Presentation At The 2014 ASCO Annual Meeting
2014-04-23,Hagens Berman: 21 Days Remain Until May 13, 2014 Lead Plaintiff Deadline In CytRx Securities Fraud Class Action
2014-04-23,Lieff Cabraser Reminds CytRx Corporation Investors Of Upcoming Deadline In Class Action Litigation &#8211; CYTR
2014-04-22,Interesting CYTR Put And Call Options For December 20th
2014-04-15,SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In CytRx Corporation To Contact Brower Piven Before The May 13, 2014 Lead Plaintiff Deadline
2014-04-11,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors Of Class Action Against CYTRX CORPORATION And Its Board Of Directors And A Lead Plaintiff Deadline Of May 13, 2014 -- CYTR
2014-04-10,CytRx Announces Research And Development Day And Webcast
2014-04-09,Hagens Berman Reminds CytRx Investors Of May 13, 2014 Lead Plaintiff Deadline And Inclusion Of Those Who Purchased Stock From Feb. 5, 2014 Offering
2014-04-04,Technical Update On Active Stocks -- Research On CytRx, FireEye, Yandex, And Hewlett-Packard
2014-04-03,Why CytRx (CYTR) Stock Is Surging Today
2014-04-03,CytRx To Present Updated Aldoxorubicin Preclinical Glioblastoma Study Results At The 2014 AACR Annual Meeting
2014-04-01,Speculative Biotech Stock Offers Opportunity Amid Controversy
2014-03-31,CORRECTING and REPLACING Hagens Berman Reminds CytRx Investors of May 13, 2014 Lead Plaintiff Deadline and Continued Securities Fraud Investigation
2014-03-31,CytRx Receives Orphan Medicinal Product Designation From The European Commission For Aldoxorubicin In Soft Tissue Sarcoma
2014-03-28,Cohen Milstein Sellers &amp; Toll PLLC Announces The Investigation Of CytRx Corporation
2014-03-27,Today's Dead Cat Bounce Stock: CytRx Corporation (CYTR)
2014-03-27,CytRx Issues Statement Regarding Recent Lawsuits
2014-03-26,Interesting CYTR Put And Call Options For May 17th
2014-03-25,These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
2014-03-24,In This Trader's Market, a Week or More Is Now Long Term
2014-03-24,CytRx Initiates Pivotal Global Phase 3 Clinical Trial With Aldoxorubicin For Second-Line Treatment Of Soft Tissue Sarcoma
2014-03-21,/C O R R E C T I O N -- Robbins Arroyo LLP/
2017-03-23,Cytori Reports Fourth Quarter And Full Year 2016 Business And Financial Results
2017-03-17,Cytori To Webcast Fourth Quarter Financial Results On March 23rd
2017-02-15,Cytori Completes Acquisition Of Azaya Therapeutics Assets, Initiates Nanomedicine Program
2017-02-14,Cytori Provides Latest Corporate Update At The 2nd Annual Disruptive Growth & Healthcare Conference
2017-02-06,Cytori Receives U.S. Small Business Designation - Substantially Reduces 2017 FDA Filing Fees
2017-01-19,GNC Plummets, Mallinckrodt Regains Ground Ahead of Market's Open
2017-01-19,Cytori To Acquire Proprietary Nanoparticle Development Platform To Enhance Regenerative Medicine Leadership Position
2017-01-10,Cytori To Expand Scleroderma Focus To Broader Hand Therapy Franchise Under The Habeo™ Cell Therapy Brand
2017-01-06,Cytori Therapeutics To Provide Corporate Update At 2017 Biotech Showcase™
2016-12-29,Cytori Announces Common Stock Purchase Agreement With Institutional Investor, Lincoln Park Capital Fund, LLC
2016-12-28,Ronald Martell To Join Cytori Therapeutics' Board Of Directors
2016-12-14,Cytori Pivotal ADRESU Incontinence Trial Hits 50% Enrollment Milestone
2016-12-05,Cytori To Present At The 9th Annual LD Micro Main Event Conference On December 6th, 2016
2016-12-05,Sustained Clinical Benefit After 3 Year Follow Up In Scleroderma Trial
2016-11-29,Cytori Announces Two Year Follow-Up Published On EU Scleroderma Trial
2016-11-16,Cytori Strengthens Global Intellectual Property Portfolio With Key Patents
2016-11-14,Cytori Granted FDA Orphan Drug Designation For ECCS-50 In Scleroderma
2016-11-09,Cytori Reports Third Quarter 2016 Business And Financial Results
2016-11-04,Cytori To Present Data In Two Distinct Models Of Impaired Wound Healing
2016-10-26,Cytori To Webcast Third Quarter Financial Results On November 9
2016-10-26,Cytori Presents Scleroderma Clinical Trial Data At The 2016 American College Of Rheumatology Annual Meeting
2016-10-24,Cytori Publication On Cytori Cell Therapy For Combined Radiation And Thermal Injury
2016-09-19,BARDA Increases Contract Option With Cytori To Advance Countermeasure Clinical Trial
2016-09-01,Cytori To Present In Investor Events In September 2016
2016-08-22,Cytori Therapeutics Receives Frost & Sullivan 2016 Technology Innovation Award
2016-08-05,Cytori Therapeutics Announced Inducement Grant For New Employee
2016-08-04,Cytori Reports Second Quarter 2016 Business And Financial Results
2016-07-22,Cytori To Webcast Second Quarter Financial Results On August 4
2016-07-19,Cytori Cell Therapy™ Phase I Trial Reports Maxillofacial Bone Regeneration
2016-06-28,Cytori ATHENA Trial For Chronic Ischemic Cardiovascular Disease
2016-06-27,Cytori Cell Therapy Receives Limited Approval For Osteoarthritis In Japan
2016-06-15,Cytori Closes Rights Offering For Gross Proceeds Of $17.1 Million
2016-06-13,Cytori Announces Expiration Of Rights Offering And Estimated Gross Proceeds Of $17.1 Million
2016-06-10,Cytori Cell Therapy™ Leads To Improved Function And Reduced Scar Tissue In A Urinary Injury Model
2016-06-08,Presentation Of Twelve Month Pilot Trial Data Of Cytori® Cell Therapy™ For ACL Reconstruction
2016-06-07,Cytori Announces Enrollment Completion In U.S. Phase III Scleroderma Trial
2016-06-06,Cytori Extends Rights Offering Subscription Period To Friday, June 10, And Adjusts Unit Pricing
2016-05-31,Cytori Announces Commencement Of Subscription Period For Previously Announced Rights Offering
2016-05-25,Cytori Fully Enrolls Pivotal U.S. Phase III Scleroderma Trial
2016-05-17,Cytori Informs Stockholders Of Key Dates Related To Announced Rights Offering
2016-05-17,European Scleroderma Trial Investigating Cytori Cell Therapy To Be Presented In Japan
2016-05-10,Cytori Reports First Quarter 2016 Business And Financial Results
2016-05-10,Cytori Granted Broad European Orphan Drug Designation
2016-05-06,Cytori ATHENA Trial Results Support Symptomatic Benefit From Cytori Cell Therapy
2016-05-05,Cytori Reports Preliminary Preclinical Data Supporting Use Of Cytori Cell Therapy™ For Both The Prevention And Treatment Of Hypertrophic Scars
2016-04-29,Cytori To Webcast First Quarter Financial Results On May 10
2016-04-27,Cytori Announces Timing For Full Enrollment In U.S. Phase III Scleroderma Trial
2016-04-18,Cytori Strengthens Global Patent Portfolio
2016-04-14,Cytori Therapeutics To Present Preliminary Safety And Efficacy Preclinical Data At The 2016 American Burn Association Meeting
2016-03-24,Cytori Update On Its U.S. Phase III Scleroderma Trial
2016-03-23,Cytori Granted SME Status By European Medicines Agency
2016-03-03,Cytori Reports Fourth Quarter And Full Year 2015 Business And Financial Results
2016-02-22,Data Reports Sustained Benefit At Two Years With Single Administration Cytori Cell Therapy For Scleroderma
2016-02-19,Cytori Management To Discuss Scleroderma Clinical Trial Findings
2016-02-10,Scleroderma Two Year Data To Be Presented At The 4th Systemic Sclerosis World Congress
2016-02-08,Cytori Reports Interim Data On U.S. Phase II Osteoarthritis Trial
2016-02-04,Cytori Provides Latest Corporate Update At Source Capital Conference
2016-02-03,Cytori Cell Therapy Safe And Potentially Effective In EU Phase I Erectile Dysfunction Trial
2016-01-25,Cytori Update On Its U.S. Phase III Scleroderma Trial
2016-01-21,Cytori Partner Kerastem Expands US Phase II Trial For Early Stage Hair Loss
2016-01-19,Enrollment Begun On Phase II Clinical Trial In Crohn's Disease
2016-01-12,Cytori Enters Agreement With Idis To Launch Managed Access Program In EMEA
2016-01-05,Cytori Therapeutics To Provide Corporate Update At 2016 Biotech Showcase™
2015-12-18,Cytori Amends Corporate Warrant Agreements Simplifying Capital Structure And Updates On 2015 Operating Cash Burn Guidance
2015-12-11,Cytori To Address Nasdaq Listing Via Nasdaq Hearing Panel
2015-12-02,Top Line Data Demonstrates Sustained Two-Year Benefit Of Cytori Cell Therapy In Treatment Of Scleroderma
2015-12-01,Cytori And Worthington Enter Celase® GMP Distribution Agreement To Facilitate Translational Research
2015-11-30,Topical Administration Of Cytori Cell Therapy Effective In Thermal Burn Approach
2015-11-05,Cytori Reports Third Quarter 2015 Business And Financial Results
2015-10-22,Phase I Trial Of Cytori Cell Therapy For Inflammatory Bowel Disease Published
2015-10-22,Cytori Third Quarter Financial Results Update
2015-10-19,Enrollment Initiated In Cytori European Scleroderma Trial
2015-09-29,Healthcare Sector Stocks Under Review - Celldex Therapeutics, Alexion Pharmaceuticals, Advaxis, BioDelivery Sciences And Cytori Therapeutics
2015-09-15,Cytori Presentation With Scleroderma Twelve Month Follow Up Data Available For Investor Download
2015-09-10,Scleroderma Therapy Benefit Sustained At One Year Follow Up
2015-09-08,Cytori Appoints VP And General Manager Of Cell Therapy
2015-09-04,Insider Trading Alert - SUNE, NRIM And CYTX Traded By Insiders
2015-09-03,Cytori Therapeutics To Provide Corporate Update And Investor Presentation Live, At VirtualInvestorConferences.com September 10
2015-09-03,Enrollment Begins In Cytori Phase III/Pivotal ADRESU Urinary Incontinence Trial
2015-08-06,Cytori Reports Second Quarter 2015 Business And Financial Results
2015-08-06,Enrollment Begins In Cytori U.S. Phase III/Pivotal Scleroderma Trial
2015-07-30,Japanese Approval Trial For Stress Urinary Incontinence Using Cytori Cell Therapy Announced
2015-07-29,Cytori Appoints VP Of Business Development And General Counsel
2015-07-28,Cytori Licensee Kerastem Receives Conditional Approval From FDA For Alopecia Trial
2015-07-27,Cytori Second Quarter Financial Results Update
2015-06-15,Cytori Completes Enrollment In US Phase IIb Osteoarthritis Trial
2015-06-10,Cytori Therapeutics' Preclinical Data For The Treatment Of Thermal Injury Published In The Journal Burns
2015-06-01,Cytori Restructures Its Debt To A $17.7 Million Term Loan
2015-05-28,5 Stocks Under $10 Triggering Breakout Trades
2015-05-11,Cytori Reports First Quarter 2015 Business And Financial Results
2015-05-05,Short Interest In Cytori Therapeutics Drops 18.2%
2015-05-05,Cytori Prices Registered Direct Offering Providing For Up To $25 Million In Equity Financing
2015-04-30,Cytori First Quarter Financial Results Update
2015-04-23,Cytori Reports Preclinical And Mechanistic Data Supporting Use Of Cytori Cell Therapy In Wounds Combining Thermal Burn And Radiation Exposure
2015-04-21,Insider Trading Alert - CYTX, KIRK And BXMT Traded By Insiders
2015-04-13,Cytori Provides Twelve Month Data Update On Scleradec-I Trial
2015-04-08,Cytori CEO Tries His Best to Spin Stem-Cell Company's Setbacks
2015-04-07,Cytori Granted Orphan Drug Status For Cellular Therapeutic In European Union
2015-04-06,Cytori Therapeutics (CYTX) Stock Spikes Today on Chinese Approval of Regenerative Cell Technology
2015-04-06,Cytori And Lorem Vascular Receive Regulatory Clearance In China
2015-03-25,Cytori Launches Celase® GMP Product
2015-03-23,Cytori Presents Thermal Burn Data At The 2015 American Burn Association Meeting
2015-03-13,Cytori Therapeutics (CYTX) Stock: Weak On High Volume Today
2015-03-12,Cytori Reports Fourth Quarter And Full Year 2014 Business And Financial Results
2015-03-06,Cytori To Provide Corporate Update At The 27th Annual ROTH Conference In Laguna Niguel, California
2015-03-04,Cytori Provides Business Update Along With Top-line Unaudited 2014 Financial Results At The Cowen And Company 35th Annual Health Care Conference In Boston
2015-03-03,Cytori To Provide Corporate Update At Cowen And Company 35th Annual Health Care Conference
2015-02-26,FDA Approves Expansion Of Pivotal Scleroderma STAR Trial To 20 Clinical Sites
2015-02-24,Cytori Receives Positive European Opinion On Orphan Drug Status
2015-02-17,Cytori Begins Enrollment In ACT-OA: US Phase II Trial For Knee Osteoarthritis
2015-02-10,Enrollment Begins European Knee Meniscus Injury Pilot Trial To Evaluate Cytori Cell Therapy
2015-01-20,Cytori And Leading Expert Discuss Importance Of 'STAR' Trial And Treatment For Scleroderma Patients
2015-01-12,FDA Approves Cytori U.S. Pivotal Scleroderma Trial
2014-12-26,Cytori Therapeutics Risk Play
2014-12-19,Cytori And BARDA Amend Contract Option To Accelerate The Advancement Of A Thermal Burn Injury Countermeasure
2014-12-18,Cytori To Host An Informational Session On Its Planned U.S. STAR Pivotal Trial With Principal Investigator, Dr. Dinesh Khanna
2014-12-17,Cytori To Provide Corporate Update At 2015 Biotech Showcase™ In San Francisco
2014-12-05,Cytori Therapeutics' Investor Presentation Now Available For On-Demand Viewing
2014-12-04,Cytori Expects New Japan Laws To Boost Adoption Of Cytori Cell Therapy
2014-11-21,Cytori Announces Promising Results In A Feasibility Trial Of Cytori Cell Therapy In Conjunction With Anterior Cruciate Ligament Repair
2014-11-20,Cytori Therapeutics To Provide Corporate Update And Investor Presentation On December 4 Through A Live, Interactive Webcast
2014-11-18,Safety And Feasibility Of Cytori Cell Therapy In Acute Myocardial Infarction Presented At 2014 American Heart Association Meeting
2014-11-06,Cytori Reports Third Quarter 2014 Business And Financial Results
2014-10-24,Cytori To Webcast Third Quarter Financial Results On November 6
2014-10-22,Cytori Therapeutics Receives FDA Approval To Resume ATHENA Trial Enrollment
2014-10-20,Cytori Therapeutics, Inc. Announces Resignation Of Lloyd H. Dean Effective November 1, 2014
2014-10-10,Cytori Therapeutics, Inc. Announces Closing Of Financing
2014-10-09,Cytori Therapeutics Invited To Participate In Trade Mission To Asia With U.S. Secretary Of Commerce
2014-10-08,Cytori Therapeutics, Inc. To Raise $13.5 Million In Registered Direct Offering
2014-09-22,Cytori Consolidates And Restructures Its Operations, Provides Business Update
2014-09-02,Cytori Consolidates European Operations To Newly Opened Welsh Manufacturing Facility
2014-08-19,BARDA Executes Contract Option With Cytori For Continued Development Of Thermal Burn Injury Counter Measure
2014-08-18,Cytori Appoints A New Vice President Of Finance And Chief Financial Officer
2014-08-12,Cytori Cell Therapy Reduces Hand Disability And Pain In Scleroderma Patients
2014-08-11,Cytori Reports Second Quarter 2014 Business And Financial Results
2014-08-05,Cytori Provides Update On ATHENA Trial Status
2014-08-04,Cytori To Webcast Second Quarter Financial Results On August 11
2014-07-22,Cytori Technology Selected For NHLBI Funded Trial In LVAD Patients
2014-07-07,Cytori Receives Notice Of Intent To Exercise First Contract Option From BARDA
2014-06-12,Cytori Appoints Ruud J.P. Jona And Nominates Gail K. Naughton To Board Of Directors
2014-06-06,Cytori Therapeutics Closes Previously Announced $10 Million Offering
2014-06-03,Cytori To Present At The Jefferies 2014 Global Healthcare Conference On June 4
2014-05-30,Cytori Therapeutics To Raise $10 Million In Registered Direct Offering
2014-05-12,Cytori Reports First Quarter 2014 Business And Financial Results
2014-05-01,Cytori To Webcast First Quarter Financial Results On May 12
2014-04-14,Long-Term Outcomes From Cytori Cell Therapy Trial For Heart Failure Published In American Heart Journal
2014-04-02,Cytori Announces Senior Management Changes
2014-03-24,Independent Sports Medicine Study Using Cytori Cell Therapy To Treat ACL Injury Underway In Spain
2014-03-20,Cytori Therapeutics To Present At Regen Med Investor Day March 26 In New York
2014-03-11,Cytori Reports Fourth Quarter And Full Year 2013 Business And Financial Results
2014-03-06,Cytori Therapeutics To Present At The 26th Annual Roth Conference On March 12
2014-03-04,Cytori To Webcast Fourth Quarter And Year End Financial Results On March 11
2014-02-20,5 Stocks Under $10 Ready to Explode
2014-02-14,4 Stocks Under $10 Triggering Breakouts
2014-01-13,Cytori To Initiate U.S. Clinical Trial Of Adipose-Derived Regenerative Cells In Hamstring Injuries
2014-01-07,Cytori Announces Presentation At Biotech Showcase&#8482; On January 13
2013-12-03,Cytori Therapeutics To Present At The LD Micro Conference On December 5
2013-11-21,Cytori Comments On New Legislation For Regenerative Medicine In Japan
2013-11-20,First Week Of January 2014 Options Trading For Cytori Therapeutics (CYTX)
2013-11-07,Biotech Stock Mailbag: Galectin, Keryx, Navidea, Cytori
2013-11-07,Cytori Reports Nine Month And Third Quarter 2013 Business And Financial Results
2013-11-07,Cytori Receives $12 Million For The First Installment From The Lorem Vascular Partnership Equity Agreement
2013-11-06,What Cytori Therapeutics Isn't Telling Investors About Its Asian Partner
2013-11-04,Cytori Licenses Asia-Pacific Cardiovascular, Renal &amp; Diabetes Markets To Lorem Vascular For Up To $531 Million
2013-11-01,Cytori To Webcast Third Quarter Financial Results On November 7
2013-10-10,Cytori Patents Adipose-Derived Cell Therapy For Cardiovascular Disease In Australia
2013-10-09,Gary A. Lyons To Join Cytori Therapeutics&#8217; Board Of Directors
2013-10-08,Cytori Therapeutics Announces Participation At The 2013 Stem Cell Meeting On The Mesa&#8217;s 3rd Annual Regen Med Partnering Forum On October 14th And 15th
2013-10-07,Cytori Obtains Celution&#174; System Approval In Singapore
2013-10-03,First Week Of November 16th Options Trading For Cytori Therapeutics (CYTX)
2013-09-16,CYTX: Insiders Vs. Shorts
2013-08-08,Cytori Reports First Half And 2nd Quarter 2013 Business And Financial Results
2013-08-07,Cytori&#8217;s Celution&#174; System Approved In Australia For Processing And Delivering Adipose-Derived Regenerative Cells
2013-08-01,Cytori To Webcast Second Quarter Financial Results On August 8
2013-07-31,Cytori Divests Puregraft&#174; Products, Licenses Celution&#174; For Alopecia And Options Broader Aesthetic Market Rights
2013-07-09,Cytori Appoints David M. Rickey As Chairman Of The Board Of Directors
2013-07-03,Cytori To Webcast At The JMP Securities Healthcare Conference On July 10, 2013
2013-07-01,Cytori Enters $27 Million Term Loan With Oxford Finance Corporation And Silicon Valley Bank
2013-04-16,4 Health Care Stocks Under $10 to Watch
2013-03-28,Cytori Patents Method Of Treating Renal Diseases Using Adipose-Derived Regenerative Cells
2017-03-21,Dermira Presents New Data Highlighting Patient Outcomes In Axillary Hyperhidrosis At Maui Derm Meeting
2017-03-17,Dermira To Highlight Data For Three Clinical Programs At Annual Maui Derm Meeting
2017-03-07,Dermira Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
2017-03-04,New CIMZIA® (certolizumab Pegol) Data In Moderate-to-severe Plaque Psoriasis And Psoriatic Arthritis Presented At American Academy Of Dermatology 2017 Annual Meeting
2017-03-03,Dermira Presents New Data In Primary Axillary Hyperhidrosis And Acne At American Academy Of Dermatology 2017 Annual Meeting
2017-03-02,Dermira To Present At Cowen And Company 37th Annual Health Care Conference
2017-03-01,Dermira Prices $168.5 Million Public Offering Of Common Stock
2017-02-28,Dermira Announces Proposed Public Offering Of Common Stock
2017-02-28,Dermira Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update
2017-02-27,Dermira Data From DRM04 And Olumacostat Glasaretil Clinical Programs To Be Presented At American Academy Of Dermatology Annual Meeting
2017-02-22,Dermira To Report Fourth Quarter And Full Year 2016 Financial Results
2017-02-15,5&nbsp;Ways Allergan Can Keep Up Momentum
2017-02-08,Dermira To Present At Leerink Partners 6th Annual Global Healthcare Conference
2017-01-19,Final CIMZIA® (certolizumab Pegol) Phase 3 Trial Meets Primary Efficacy Endpoint In Patients With Moderate-to-Severe Chronic Plaque Psoriasis
2017-01-06,Dermira Provides Corporate Update
2017-01-05,Lori Lyons-Williams Joins Dermira As Chief Commercial Officer
2017-01-04,Dermira Elects Emmanuel Caeymaex To Board Of Directors
2017-01-03,Dermira Initiates Phase 3 Clinical Program In Acne
2016-12-15,Notable Thursday Option Activity: DERM, HCI, TAHO
2016-12-15,Notable Thursday Option Activity: DERM, HCI, TAHO
2016-12-08,Second CIMZIA® (certolizumab Pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints In Patients With Moderate-to-Severe Chronic Plaque Psoriasis
2016-11-10,Ratings Changes Today
2016-11-09,Dermira To Present At Stifel 2016 Healthcare Conference
2016-11-07,Dermira Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-10-21,Dermira Presents Data From DRM01 Phase 2b Clinical Program At Annual Meeting For Dermatologists
2016-10-13,Short Interest In Dermira Falls 13.6%
2016-10-13,Dermira To Present Data From DRM01 And DRM04 Clinical Programs At Fall Clinical Dermatology Conference
2016-10-03,CIMZIA® (certolizumab Pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints In Patients With Moderate-to-Severe Chronic Plaque Psoriasis
2016-10-01,Dermira Presents Data From DRM04 Phase 3 Clinical Program In Late-Breaking News Session At European Academy Of Dermatology And Venereology Congress
2016-09-28,Dermira To Present Data From DRM04 Phase 3 Clinical Trials At Late-Breaking News Session At European Academy Of Dermatology And Venereology Congress
2016-09-20,Dermira Licenses DRM04 To Maruho For Hyperhidrosis In Japan
2016-09-12,Dermira Acquires Option To License Exclusive Rights For Up To Three Early-Stage Programs From Takeda
2016-08-08,Dermira Reports Second Quarter 2016 Financial Results And Provides Corporate Update
2016-07-19,These 4 Stocks Are Poised for Breakout Profits
2016-07-15,These 5 Stocks Are Primed for Breakouts
2016-07-13,Short Interest Expands By 37% For DERM
2016-06-13,Dermira Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
2016-06-10,Short Interest In Dermira Expands By 32.4%
2016-06-08,Dermira Prices $126 Million Public Offering Of Common Stock
2016-06-07,Dermira Announces Proposed Public Offering Of Common Stock
2016-06-02,Dermira (DERM) Stock Slumps Despite Favorable Trial Results
2016-06-01,Dermira Announces Positive Topline Results From Two Pivotal Phase 3 Clinical Trials For DRM04 In Patients With Primary Axillary Hyperhidrosis
2016-05-11,Dermira To Present Preclinical Data From DRM01 Acne Program At The Society For Investigative Dermatology 75th Annual Meeting
2016-05-10,Dermira Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-05-10,Dermira Announces Positive Topline Phase 2b Clinical Trial Results For DRM01 In Patients With Facial Acne Vulgaris
2016-05-03,Commit To Buy Dermira At $20, Earn 24.1% Annualized Using Options
2016-04-10,Allergan Could Buy These Drug Companies Now That the Pfizer Merger Is Scuttled
2016-04-06,Biotech M&amp;A Will Flow From the Ashes of Scuttled Pfizer-Allergan Merger
2016-04-05,Dermira To Present At 15th Annual Needham Healthcare Conference
2016-03-22,7 Stocks Spiking on Unusual Volume
2016-03-16,Dermira Enters Oversold Territory (DERM)
2016-03-14,Dermira's Co-founder And Chief Medical Officer, Eugene A. Bauer, M.D., Receives Presidential Citation From The American Academy Of Dermatology
2016-03-03,Dermira Reports Fourth Quarter And Full Year 2015 Financial Results And Provides Corporate Update
2016-03-01,Dermira To Report Fourth Quarter And Full Year 2015 Financial Results
2016-03-01,Dermira To Present At Cowen And Company 36th Annual Health Care Conference
2016-02-29,Dermira Completes Patient Enrollment For DRM04 Phase 3 Pivotal Trials In Primary Axillary Hyperhidrosis
2016-02-08,Oversold Conditions For Dermira (DERM)
2016-02-04,Dermira To Present At The Leerink Partners 5th Annual Global Healthcare Conference
2016-02-02,Commit To Buy Dermira At $22.50, Earn 17.5% Annualized Using Options
2016-01-08,Dermira Completes Patient Enrollment For Third CIMZIA® (certolizumab Pegol) Phase 3 Clinical Trial In Psoriasis Program And Updates Guidance For Release Of Topline Data
2016-01-07,Dermira Provides DRM01 And DRM04 Development Program Updates
2015-12-15,8 Stocks Spiking on Unusually High Volume
2015-12-15,Dermira Added To NASDAQ Biotechnology Index
2015-11-20,Commit To Purchase Dermira At $25, Earn 11.8% Annualized Using Options
2015-11-19,Dermira Completes Patient Enrollment For Second CIMZIA(R) (certolizumab Pegol) Phase 3 Clinical Trial In Psoriasis Program
2015-11-10,Dermira Reports Third Quarter 2015 Financial Results And Provides Corporate Update
2015-10-12,Dermira Completes Patient Enrollment For First CIMZIA(R) (Certolizumab Pegol) Phase 3 Clinical Trial In Psoriasis Program
2015-10-07,Dermira Presents Data From DRM01 Phase 2a Trial At European Academy Of Dermatology And Venereology
2015-09-30,Dermira Elects Kathleen Sebelius To Board Of Directors
2015-09-29,Dermira To Present Data For DRM01 Acne Program At EADV Congress 2015
2015-09-10,Skin Disposition Study Results For Dermira's DRM01 Program In Acne Presented At International Dermatology Meeting
2015-09-03,Dermira To Present Data For DRM01 Acne Program At 45th Annual ESDR Meeting
2015-08-13,Dermira Reports Second Quarter 2015 Financial Results And Provides Corporate Update
2015-08-11,Dermira Announces Closing Of Follow-on Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-08-05,Dermira Prices Follow-On Public Offering Of Common Stock
2015-08-04,Dermira Commences Follow-on Public Offering Of Common Stock
2015-08-03,Dermira Doses First Patients In DRM04 Phase 3 Program In Axillary Hyperhidrosis
2015-06-09,Dermira's Phase 2a DRM01 Acne Trial Data Presented At The World Congress Of Dermatology Meeting
2015-06-02,Dermira Announces Poster Presentation On DRM01 In Acne At World Congress Of Dermatology
2015-05-28,Dermira To Present At Jefferies 2015 Global Healthcare Conference
2015-05-12,Dermira Reports First Quarter 2015 Financial Results And Provides Corporate Update
2015-04-09,Dermira Doses First Patient In DRM01 Phase 2b Acne Trial
2015-04-08,Dermira To Present At The 14th Annual Needham Healthcare Conference
2015-03-25,Dermira Reports Fourth Quarter And Full Year 2014 Financial Results And Provides Corporate Update
2015-03-23,Clinical Data For Dermira's DRM01 Acne Program Presented At Dermatology Meeting
2015-03-18,Dermira To Report Fourth Quarter And Full Year 2014 Financial Results
2015-03-12,Dermira Announces Late-Breaking Oral Presentation On DRM01 In Acne At 2015 AAD Annual Meeting
2015-02-05,Dermira Announces Positive Phase 2b Results For DRM04 In Patients With Hyperhidrosis
2015-01-29,Dermira To Present At The 2015 Leerink Global Healthcare Conference
2015-01-08,Dermira And UCB Announce Start Of Phase 3 Program For CIMZIA(R) (certolizumab Pegol) In Psoriasis
2014-12-22,Dermira Added To Russell 2000(R) Index
2014-11-12,Dermira Reports Third Quarter 2014 Financial Results And Provides Corporate Update
,
,
2017-03-09,Dimension Therapeutics Announces Full Year 2016 Financial Results And Recent Updates Across Rare And Metabolic Disease Portfolio And In HeLa Manufacturing
2017-03-07,Dimension Therapeutics To Hold Full Year 2016 Financial Results And Recent Program Updates Conference Call
2017-02-17,Lifshitz & Miller LLP Announces Investigation Of BT Group Plc, Celadon Group, Inc., Community Health Systems, Inc., Dimension Therapeutics, Inc., Home Capital Group Inc., Lifevantage Corporation, OvaScience, Inc. And Under Armour, Inc.
2017-02-14,Newman Ferrara LLP Announces Corporate Governance Investigation Of Dimension Therapeutics Inc.
2017-02-07,Dimension Therapeutics Elects Dr. John A. Hohneker To Its Board Of Directors
2017-02-02,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Dimension Therapeutics, Inc.
2017-01-31,Dimension Announces Interim Topline Results From Ongoing Phase 1/2 Clinical Program For DTX101, Dimension's Lead AAV Product Candidate In Development For Adult Patients With Moderate/Severe To Severe Hemophilia B
2016-12-13,Dimension Therapeutics Announces FDA Acceptance Of Investigational New Drug Application For DTX301 To Treat OTC Deficiency
2016-12-05,Dimension Therapeutics Announces Presentation At The 58th American Society Of Hematology (ASH) Annual Meeting
2016-11-29,Dimension Therapeutics Receives Positive Opinion For European Orphan Drug Designation Of DTX401 For The Treatment Of Glycogen Storage Disease Type Ia (GSDIa)
2016-11-23,Ratings Changes Today
2016-11-10,Dimension Therapeutics Reports Recent Corporate Progress And Third Quarter 2016 Financial Results
2016-11-03,Dimension Therapeutics Announces Presentation At The Upcoming 58th American Society Of Hematology (ASH) Annual Meeting
2016-10-18,Dimension Therapeutics Announces Presentations Highlighting Advances In AAV Manufacturing At The European Society Of Gene And Cell Therapy (ESGCT) Congress
2016-10-11,Dimension Therapeutics Announces Presentations At The Upcoming European Society Of Gene And Cell Therapy (ESGCT) Congress
2016-10-04,Dimension Therapeutics Announces Orphan Drug Designation Of DTX401 For The Treatment Of Glycogen Storage Disease Type Ia (GSDIa)
2016-08-24,Dimension Therapeutics Announces Participation In Two Upcoming Investor Conferences
2016-08-11,Dimension Therapeutics Reports Recent Corporate Progress And Second Quarter 2016 Financial Results
2016-08-02,Dimension Therapeutics To Present At The Canaccord Genuity 36th Annual Growth Conference
2016-07-08,These 5 Stocks Are Breaking Out
2016-07-07,Aptuit LLC And Dimension Therapeutics Enter Strategic Partnership To Advance Select Dimension Programs Toward IND Filing
2016-06-29,Dimension Therapeutics To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference
2016-06-27,Dimension Therapeutics Becomes Oversold (DMTX)
2016-06-22,Dimension Therapeutics Announces Recombinant DNA Advisory Committee's Unanimous Approval Of Phase 1/2 Study Protocol For DTX301, Lead Inherited Metabolic Disease (IMD) Product Candidate To Treat OTC Deficiency
2016-06-21,Dimension Therapeutics Opens New Facility In Woburn And Expands Management Team
2016-05-31,Dimension Therapeutics To Present At Two Upcoming Investor Conferences
2016-05-27,Dimension Therapeutics Announces Presentations At The 8th European Conference On Rare Diseases & Orphan Products (ECRD)
2016-05-20,7 Stocks Under $10 Making Big Moves Higher
2016-05-19,Dimension Therapeutics Announces Presentations At The Upcoming 21st Congress Of The European Hematology Association (EHA)
2016-05-12,Dimension Therapeutics Reports Recent Corporate Progress And First Quarter 2016 Financial Results
2016-05-07,Dimension Therapeutics Announces Preclinical Data From Bayer-Partnered Hemophilia A Program At American Society For Gene And Cell Therapy (ASGCT) Annual Meeting
2016-05-05,Dimension Therapeutics Announces Gene Therapy Research Collaboration With The University Of Pennsylvania And Expansion Of Inherited Metabolic Disease Portfolio
2016-05-05,Dimension Therapeutics Announces Preclinical Data Supporting Ongoing DTX101 Phase 1/2 Clinical Trial At American Society For Gene And Cell Therapy (ASGCT) Annual Meeting
2016-04-28,Dimension Therapeutics Announces Participation In Two Upcoming Conferences
2016-04-18,Dimension Therapeutics Announces Presentations At The Upcoming American Society For Gene And Cell Therapy (ASGCT) Annual Meeting
2016-04-06,Dimension Therapeutics To Present At The British Society For Gene And Cell Therapy (BSGCT) Annual Conference
2016-03-24,Dimension Therapeutics Reports Recent Corporate Progress And Full Year 2015 Financial Results
2016-03-17,Dimension Therapeutics Receives Positive Opinion For European Orphan Drug Designation For DTX301 For The Treatment Of Ornithine Transcarbamylase (OTC) Deficiency
2016-03-01,Dimension Therapeutics To Present At Two Upcoming Investor Conferences
2016-01-27,Dimension Therapeutics To Participate In Canaccord Genuity 2016 Rare Disease Biopharma Day And SunTrust Robinson Humphrey 2016 Orphan Drug Day
2016-01-07,Dimension Therapeutics Announces Initiation Of Phase 1/2 Study For DTX101 For The Treatment Of Hemophilia B
2016-01-06,Dimension Therapeutics Announces Orphan Drug Designation Of DTX301 For The Treatment Of Ornithine Transcarbamylase (OTC) Deficiency
2015-12-04,Dimension Therapeutics Reports Recent Corporate Progress And Third Quarter 2015 Financial Results
2015-11-03,Dimension Therapeutics Announces Expansion Of Internal Research And Process Development Capabilities
,
,
,
,
2017-01-25,SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Dipexium Pharma - DPRX
2016-12-22,Dipexium And PLx Pharma Announce Merger Agreement
2016-10-25,Dipexium Announces Top-line Data From OneStep Phase 3 Trials With Locilex® In Mild Diabetic Foot Infection Did Not Meet Primary Clinical Endpoint Of Superiority Versus Vehicle Plus Standardized Wound Care
2016-10-20,Dipexium Provides Update On Availability Of Results From Pivotal Phase 3 Clinical Trials With Locilex®
2016-10-04,Dipexium Receives European Medicines Agency Designation As A Small And Medium Enterprise
2016-09-07,Dipexium Pharmaceuticals Announces Issuance of Locilex® Patent by European Union
2016-08-24,Dipexium Pharmaceuticals Announces Participation In September Investor Conferences
2016-07-28,Dipexium Pharmaceuticals To Hold Second Quarter 2016 Financial Results Conference Call On Thursday, August 4, 2016, At 8:30 A.m. ET
2016-06-20,Dipexium Pharmaceuticals' Locilex® Microbiology Data Presented At ASM Microbe 2016 Conference
2016-05-16,Dipexium Announces Completion Of Enrollment Objective In OneStep-1 Pivotal Phase 3 Clinical Trial
2016-05-09,Dipexium Pharmaceuticals To Hold First Quarter 2016 Financial Results Conference Call On Thursday, May 12, 2016, At 8:30 A.m. ET
2016-03-28,Dipexium Pharmaceuticals Announces Issuance Of Locilex® Patent In Japan
2016-03-14,Dipexium Pharmaceuticals to Hold Year End 2015 Financial Results Conference Call on Wednesday, March 23, 2016, 8:30 a.m. ET
2016-03-02,Dipexium Pharmaceuticals Announces Presentation At Raymond James 37th Annual Institutional Investors Conference
2016-02-24,8 Stocks Under $10 Making Big Moves Higher
2016-02-04,Dipexium Pharmaceuticals Reaches 75% Enrollment Milestone In Pivotal Phase 3 Clinical Trials
2016-02-01,Dipexium Pharmaceuticals Announces Issuance Of Locilex® Patents In Australia And New Zealand
2016-01-29,Dipexium Pharmaceuticals Announces Presentation At 18th Annual BIO CEO & Investor Conference
2015-12-01,Dipexium Pharmaceuticals Announces Presentation At Oppenheimer 26th Annual Healthcare Conference
2015-11-09,Dipexium Pharmaceuticals To Hold Third Quarter 2015 Financial Results Conference Call On Monday, November 16, 2015, At 8:30 A.m. ET
2015-10-01,Dipexium Pharmaceuticals Reaches 50% Enrollment In Second Pivotal Phase 3 Clinical Trial
2015-09-21,Dipexium Pharmaceuticals Presents Locilex® Microbiology Data At ICAAC/ICC 2015 Conference
2015-08-31,Dipexium Pharmaceuticals Announces Participation In Four Investor Conferences In September
2015-08-20,Dipexium Pharmaceuticals Surpasses Treatment Of 50% Of Subjects In Pivotal Phase 3 Clinical Trial
2015-08-06,Dipexium Pharmaceuticals To Hold Second Quarter 2015 Financial Results Conference Call On Thursday, August 13, 2015, At 8:30 A.m. ET
2015-07-28,Dipexium Pharmaceuticals' Pexiganan Demonstrates Microbiological Activity Against Pathogens Resistant To Other Topical Antibiotics
2015-06-30,Dipexium Announces Closing Of Public Offering Of Common Stock
2015-06-25,Dipexium Announces Pricing Of Public Offering Of Common Stock
2015-06-24,Dipexium Announces Proposed Public Offering Of Common Stock
2015-06-02,Dipexium Receives European Medicines Agency Scientific Advice On Clinical And Regulatory Pathway For Locilex® Marketing Approval In European Union
2015-05-21,Dipexium Announces Presentation At 7th International Symposium On The Diabetic Foot
2015-05-07,Dipexium Pharmaceuticals To Hold First Quarter 2015 Financial Results Conference Call On Thursday, May 14, 2015, At 8:30 A.m. ET
2015-03-18,Dipexium Pharmaceuticals To Hold Year End 2014 Financial Results Conference Call On Tuesday, March 24, 2015, 8:30 A.m. ET
2015-03-12,Dipexium Pharmaceuticals To Present At Jefferies 2015 Antibiotic Summit
2015-02-25,Dipexium Pharmaceuticals Passes 25% Enrollment In Locilex® Pivotal Phase 3 Clinical Trials
2015-02-17,Dipexium Pharmaceuticals Announces Successful Completion And Initial Results Of Phase 1 Skin Sensitization Trial Of Locilex®
2015-02-02,Dipexium Pharmaceuticals Announces Presentation At 17th Annual BIO CEO & Investor Conference
2014-11-17,Dipexium Pharmaceuticals Announces Presentation At Oppenheimer 25th Annual Healthcare Conference
2014-09-10,3 Under-$10 Stocks Triggering Breakout Trades
2014-09-08,Dipexium Pharmaceuticals Presents Updated Locilex® Microbiology Data At 54th ICAAC Conference
2014-09-02,Dipexium Pharmaceuticals Announces Presentation At Rodman & Renshaw 16th Annual Global Investment Conference
2014-07-21,Dipexium Pharmaceuticals Initiates Second Of Two Pivotal Phase 3 Clinical Trials Of Locilex® In Patients With Mild Infections Of Diabetic Foot Ulcers
2014-07-17,Dipexium Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial Of Locilex® In Patients With Mild Infections Of Diabetic Foot Ulcers
2014-07-17,Dipexium Pharmaceuticals Announces Successful Completion Of Phase 1 Skin Irritation Trial Of Locilex®
,
,
,
,
2017-03-23,Dicerna To Report Fourth Quarter And Full Year 2016 Financial Results And Host Conference Call On March 30, 2017
2017-03-01,Dicerna To Present At Cowen And Company 37th Annual Health Care Conference
2017-02-08,Dicerna To Participate In Fireside Chat At The Leerink Partners Global Healthcare Conference
2017-02-02,Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2016-11-09,Dicerna To Present At The Stifel 2016 Healthcare Conference
2016-11-07,Dicerna Reports Third Quarter 2016 Financial And Operational Results
2016-10-31,Dicerna To Report Third Quarter 2016 Financial Results And Host Conference Call On November 7, 2016
2016-09-26,Dicerna Prioritizes Resources To Advance GalXC™ Product Candidates
2016-09-06,Dicerna To Present At September Investor Conferences
2016-08-04,Dicerna Reports Second Quarter 2016 Financial And Operational Results
2016-07-28,Dicerna To Report Second Quarter 2016 Financial Results And Host Conference Call On August 4, 2016
2016-06-29,New Preclinical Data Show Potential Of Dicerna GalXC™ Subcutaneous Delivery Platform As RNAi Drug Discovery Engine
2016-06-29,7 Stocks Under $10 Making Big Moves
2016-06-15,Dicerna Appoints Martin Freed, M.D., To Board Of Directors
2016-06-02,Dicerna To Present At The Jefferies 2016 Healthcare Conference
2016-05-13,Dicerna Announces Dosing Of First Patient In Phase 1 Clinical Trial Of DCR-PH1 In Patients With Primary Hyperoxaluria Type 1 (PH1)
2016-05-11,Dicerna Reports Potent Preclinical Activity With GalNAc-DsiRNA-EX Conjugates
2016-05-09,Dicerna Reports First Quarter 2016 Financial And Operational Results
2016-05-02,Dicerna To Report First Quarter 2016 Financial Results And Host Conference Call On May 9, 2016
2016-04-18,John B. "Jack" Green, Chief Financial Officer At Dicerna (Photo: Business Wire)
2016-03-20,8 Biotech Stocks Under $10 Making Big Moves Higher
2016-03-10,Dicerna Announces Fourth Quarter And Full Year 2015 Financial And Operational Results
2016-03-04,Dicerna To Announce Fourth Quarter And Full Year 2015 Financial Results And Host Conference Call On March 10, 2016
2016-03-03,5 Stocks Under $10 Set to Soar
2016-03-02,Dicerna To Present At Two March Conferences
2016-02-25,Dicerna Reports Progress With GalNAc-DsiRNA-EX-Conjugates
2016-02-04,Dicerna To Present At The 2016 Leerink Partners Global Healthcare Conference
2016-01-11,Dicerna Pharmaceuticals Becomes Oversold (DRNA)
2015-12-31,Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2015-12-21,Dicerna Begins Dosing In First Clinical Trial Of Therapy For Primary Hyperoxaluria Type 1 (PH1) In Healthy Volunteers
2015-12-21,Dicerna Updates Progress on the Development of DCR-MYC for the Treatment of Solid Tumors
2015-12-16,Dicerna Announces Addition To NASDAQ Biotechnology Index
2015-12-15,Dicerna Pharmaceuticals Appoints John "Jack" Green Interim Chief Financial Officer
2015-11-13,Dicerna To Present At Two November Conferences
2015-11-10,Dicerna Announces Third Quarter 2015 Financial And Operational Results
2015-11-03,Dicerna To Announce Third Quarter 2015 Financial Results And Host Conference Call On November 10, 2015
2015-09-30,Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2015-09-30,Dicerna To Present Advances In Conjugate Delivery Technology At Leerink Partners Rare Disease Roundtable
2015-09-24,Dicerna To Present At The Leerink Partners Rare Disease Roundtable
2015-09-18,5 Stocks Ready for Breakouts
2015-08-06,Dicerna Announces Second Quarter 2015 Financial And Operational Results
2015-08-06,EMA Grants Orphan Drug Designation To DCR-PH1, Dicerna's Investigational Therapy For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)
2015-07-29,Dicerna To Announce Second Quarter 2015 Financial Results And Host Conference Call On August 6, 2015
2015-07-01,Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2015-06-19,Dicerna To Present At The JMP Securities Life Sciences Conference 2015
2015-06-11,Dicerna Responds To Alnylam Complaint
2015-06-05,Dicerna Pharmaceuticals Enters Oversold Territory (DRNA)
2015-06-01,Dicerna Presents Preliminary Safety And Efficacy Data From DCR-MYC Phase 1 Study In Patients With Advanced Solid Tumors At The 2015 ASCO Annual Meeting
2015-05-29,Dicerna To Present At The Jefferies 2015 Healthcare Conference
2015-05-20,Dicerna Announces Pricing Of Follow-On Offering Of Common Stock
2015-05-18,Dicerna Announces Follow-On Public Offering Of Common Stock
2015-05-14,Dicerna Announces Expansion Of Ongoing DCR-MYC Phase 1 Study To Evaluate Safety And Efficacy In Patients With Advanced Pancreatic Neuroendocrine Tumors (PNETs)
2015-05-13,Dicerna To Present Interim Clinical Data From First DCR-MYC Phase 1 Study In Patients With Advanced Solid Tumors At The 2015 ASCO Annual Meeting
2015-05-11,Dicerna Announces First Quarter 2015 Financial And Operational Results
2015-05-06,Dicerna Announces Potent, Durable Knockdown Of Gene Expression In Non-human Primates With DsiRNA-EX Conjugates Being Investigated For Treatment Of Primary Hyperoxaluria Type 1 (PH1)
2015-05-04,Dicerna To Present At The 17th Annual TIDES: Oligonucleotide And Peptide® Therapeutics From Research Through Commercialization Conference
2015-04-29,Dicerna To Present At The Deutsche Bank 40th Annual Health Care Conference
2015-04-29,Dicerna To Announce First Quarter 2015 Financial Results And Host Conference Call On May 11, 2015
2015-04-23,FDA Grants Orphan Drug Designation For DCR-PH1, Dicerna's Investigational Therapy For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)
2015-04-10,Dicerna Presents New ß-catenin Data From Multiple Tumor Models At The 2015 RNA & Oligonucleotide Therapeutics Meeting At Cold Spring Harbor Laboratory
2015-04-06,Relative Strength Alert For Dicerna Pharmaceuticals
2015-03-31,Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2015-03-19,'Mad Money' Lightning Round: I'm Staying Away From Five Below
2015-03-18,Jim Cramer's 'Mad Money' Recap: The Fed Does the Right Thing
2015-03-12,Dicerna Announces Fourth Quarter And Full Year 2014 Financial And Operational Results
2015-03-10,5 Hated Earnings Stocks You Should Love
2015-03-09,Dicerna To Announce Fourth Quarter And Full Year 2014 Financial Results And Host Conference Call On March 12, 2015
2015-02-26,Dicerna Pharmaceuticals Announces Move To Larger Office And Lab Space In Cambridge, Massachusetts
2015-02-04,Dicerna To Present At The 2015 Leerink Global Healthcare Conference
2015-02-02,Dicerna Pharmaceuticals Announces First Patient Dosed In Phase 1b/2 Clinical Trial Of DCR-MYC, An Investigational RNAi Therapeutic Targeting The MYC Oncogene, In Patients With Advanced Hepatocellular Carcinoma
2015-01-12,Dicerna Announces Issuance Of US Patent Providing Broad Coverage Of DsiRNA-EX RNAi Payloads
2015-01-12,Dicerna Pharmaceuticals Presents Positive Preclinical Data On Its DsiRNA Therapeutics Targeting MYC And ß-Catenin At AACR MYC: From Biology To Therapy Meeting
2014-12-17,Dicerna Announces The Appointment Of Theodore T. Ashburn, M.D., Ph.D. To Senior Vice President, Product Strategy And Operations, And Inducement Grant Of Stock Options Under NASDAQ Listing Rule 5635 (c)(4)
2014-12-15,Dicerna R&D Update Webcast Reminder
2014-11-25,Dicerna To Present At The 2014 Deutsche Bank BioFEST
2014-11-17,Dicerna Reports On Progress Of Development Programs
2014-11-17,Dicerna Announces License Agreement With Tekmira To Advance Dicerna's PH1 Development Program
2014-11-14,Dicerna To Present At Two Upcoming Investor Conferences
2014-11-06,Dicerna Announces Third Quarter 2014 Financial And Operational Results
2014-11-04,Oversold Conditions For Dicerna Pharmaceuticals (DRNA)
2014-10-24,Dicerna To Announce Third-Quarter 2014 Financial Results And Host Conference Call On November 6, 2014
2014-10-14,Dicerna Presents Preclinical Data For Investigational RNAi Therapeutic DCR-PH1 In Primary Hyperoxaluria Type 1 (PH1) At The 10th Annual Meeting Of The Oligonucleotide Therapeutics Society
2014-10-14,Oversold Conditions For Dicerna Pharmaceuticals (DRNA)
2014-09-29,Dicerna To Present At Three Upcoming Investor Conferences
2014-09-15,Dicerna Announces Appointment Of Biotech Industry Leader Bruce Peacock To Its Board Of Directors And Audit Committee
2014-09-02,Dicerna To Present At The Baird 2014 Health Care Conference
2014-08-21,Dicerna Announces The Issuance Of Multiple Patents Covering Claims For Dicer Substrate SiRNAs
2014-08-19,Dicerna Pharmaceuticals Becomes Oversold (DRNA)
2014-08-07,Dicerna Provides Operational Update And Reports Second Quarter 2014 Financial Results
2014-07-28,3 Stocks Spiking on Big Volume
2014-07-25,Dicerna To Announce Second-Quarter 2014 Financial Results And Host Conference Call On August 7, 2014
2014-07-11,Dicerna To Ring The NASDAQ Stock Market Closing Bell July 15th
2014-07-01,3 Stocks Spiking on Big Volume
2014-02-06,Top Insider Trades: DRNA RGLS RARE CARA
,
,
2017-03-20,How These Drug Makers Stocks Are Faring? -- Orexigen Therapeutics, United Therapeutics, DURECT, And SciClone Pharma
2017-02-24,DURECT Corporation Invites You To Join Its Fourth Quarter 2016 Earnings Conference Call
2017-01-30,DURECT Corporation Announces Update On DUR-928 Development Program
2017-01-12,Durect Stock Sees Short Interest Fall 19.6%
2016-11-10,Short Interest In Durect Moves 21.5% Higher
2016-10-31,DURECT Corporation Announces Update On DUR-928 Development Program
2016-10-21,DURECT Corporation Invites You To Join Its Third Quarter 2016 Earnings Conference Call
2016-10-05,5 Stocks Insiders Love Right Now
2016-09-26,Durect Corp. (DRRX) Stock Tumbles on FDA Opioid Analgesic Drug Rejection
2016-09-26,5 Big-Volume Stocks You Should Stay Away From -- Plus 2 to Buy
2016-09-26,DURECT's Licensee Pain Therapeutics Receives Complete Response Letter From FDA For REMOXY® ER (oxycodone) Extended-Release Capsules CII
2016-09-06,DURECT to Present at the Rodman & Renshaw Global Investment Conference
2016-08-22,Interesting DRRX Call Options For April 2017
2016-07-25,DURECT Corporation Invites You To Join Its Second Quarter 2016 Earnings Conference Call
2016-07-01,DURECT Provides REMOXY® Update
2016-06-28,DURECT To Present At The Cantor Fitzgerald Healthcare Conference
2016-05-31,DURECT To Present At The Jefferies Healthcare Conference
2016-05-19,DURECT Announces FDA Advisory Committee Meeting For REMOXY®
2016-05-11,DURECT Announces New REMOXY® Data Being Presented At American Pain Society Meeting
2016-04-29,DURECT Announces Closing Of Public Offering Of Common Stock
2016-04-28,DURECT Corporation Invites You To Join Its First Quarter 2016 Earnings Conference Call
2016-04-28,Insider Trading Alert - SMLP, DRRX And MDSO Traded By Insiders
2016-04-26,DURECT Announces Pricing Of Public Offering Of Common Stock
2016-04-25,DURECT Announces Proposed Public Offering Of Common Stock
2016-04-12,DURECT Announces FDA Acceptance Of REMOXY® NDA, PDUFA Date Of September 25, 2016
2016-04-07,DURECT Announces POSIMIR® Program Update
2016-03-29,DURECT Announces Resubmission Of REMOXY® New Drug Application To The U.S. Food And Drug Administration
2016-02-18,DURECT Corporation Invites You To Join Its Fourth Quarter 2015 Earnings Conference Call
2016-01-28,DURECT To Present At The BIO CEO & Investor Conference
2016-01-13,Insider Trading Alert - DRRX, EA and KAI Traded By Insiders
2016-01-11,DURECT Announces Initiation Of DUR-928 Dosing In Patients
2016-01-06,DURECT Announces Positive Phase 1 Data For DUR-928
2015-11-30,DURECT To Present At The Oppenheimer Healthcare Conference
2015-11-05,DURECT To Present At The Stifel Nicolaus Healthcare Conference
2015-10-26,DURECT Corporation Invites You To Join Its Third Quarter 2015 Earnings Conference Call
2015-10-15,DURECT To Present At The BIO Investor Forum
2015-08-27,DURECT To Participate In Upcoming Healthcare Conferences
2015-07-29,Durect Stock Sees Short Interest Make 130.4% Move
2015-07-24,DURECT Corporation Invites You To Join Its Second Quarter 2015 Earnings Conference Call
2015-07-23,Cancer Prevention Pharmaceuticals, Inc. Announces Appointment Of Jon S. Saxe To Its Board Of Directors
2015-06-29,DURECT To Present At The Cantor Fitzgerald Healthcare Conference
2015-06-23,First Week Of DRRX August 21st Options Trading
2015-06-23,DURECT Announces Plans For A New POSIDUR™ (SABER®-Bupivacaine) Clinical Trial
2015-06-19,Durect (DRRX) Is Strong On High Volume Today
2015-06-18,Durect (DRRX) Weak On High Volume
2015-06-05,Durect (DRRX) Highlighted As Weak On High Volume
2015-05-26,3 Biotech Stocks Under $10 to Trade for Breakouts
2015-05-19,First Week Of January 2016 Options Trading For Durect (DRRX)
2015-05-18,DURECT Announces Positive Results From DUR-928 Multi-Dose Phase 1 Study
2015-04-27,Trade-Ideas: Durect (DRRX) Is Today's Strong On High Relative Volume Stock
2015-04-22,DURECT Corporation Invites You To Join Its First Quarter 2015 Earnings Conference Call
2015-03-30,DURECT Announces Initiation Of DUR-928 Multi-Dose Phase 1 Study
2015-03-25,5 Stocks Insiders Love Right Now
2015-03-02,DURECT Announces Epigenomic Regulator Program Including A New NAFLD/NASH And Acute Organ Injury Product Candidate In Development
2015-02-23,DURECT Corporation Invites You To Join Its Fourth Quarter 2014 Earnings Conference Call
2015-01-29,DURECT To Present At The BIO CEO & Investor Conference
2014-12-16,DURECT Enters Into License Agreement Granting Santen The Worldwide Rights To A Sustained Release SABER® Ophthalmology Product
2014-12-01,DURECT To Present At The Oppenheimer Healthcare Conference
2014-11-11,DURECT Provides Update On POSIDUR™ Program
2014-10-27,DURECT Provides Update On REMOXY® And POSIDUR™ Programs
2014-10-24,DURECT Corporation Invites You To Join Its Third Quarter 2014 Earnings Conference Call
2014-10-10,DURECT Announces POSIDUR™ (SABER®-Bupivacaine) Data Presentation At The American Society Of Anesthesiologists Annual Meeting
2014-08-25,DURECT To Present At The Rodman & Renshaw Investment Conference
2014-07-30,DURECT Corporation Invites You To Join Its Second Quarter 2014 Earnings Conference Call
2014-06-27,Why Durect Corp. (DRRX) Stock Is Jumping Today
2014-06-26,DURECT Secures $20 Million Debt Financing
2014-06-20,3 Stocks Under $10 to Trade for Breakouts
2014-06-13,3 Stocks Under $10 in Breakout Territory
2014-06-09,DURECT To Present At The Wall Street Analyst Forum Institutional Investor Conference
2014-05-30,4 Under-$10 Stocks to Trade for Breakouts
2014-05-16,DURECT Announces POSIDUR&#8482; (SABERA®-Bupivacaine) Data Presentation At The International Anesthesia Research Society (IARS) Annual Meeting
2014-05-07,DURECT Announces Participation In Bay Area Prescription Drug Abuse Summit Meeting
2014-04-23,DURECT Corporation Invites You To Join Its First Quarter 2014 Earnings Conference Call
2014-04-01,DURECT Announces POSIDUR&#8482; (SABERA®-Bupivacaine) Data Presentations At The 39th Annual American Society Of Regional Anesthetic And Pain Medicine Meeting
2014-03-18,Lifshitz & Miller Law Firm Announces Investigation Of CytRx Corporation, DURECT Corporation, Hastings Entertainment, Inc., Immunomedics, Inc. And NII Holdings, Inc.
2014-03-07,Harwood Feffer LLP Announces Investigation Of DURECT Corporation
2014-03-07,Harwood Feffer LLP Announces Investigation Of DURECT Corporation
2014-03-06,Robbins Arroyo LLP Is Investigating The Officers And Directors Of DURECT Corporation On Behalf Of Shareholders
2014-02-26,First Week of DRRX October 18th Options Trading
2014-02-20,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of DURECT Corporation
2014-02-18,DURECT Corporation Invites You To Join Its Fourth Quarter 2013 Earnings Conference Call And Upcoming Investor Conference
2014-02-14,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of DURECT Corporation - DRRX
2014-02-12,DURECT Receives Complete Response Letter From FDA For POSIDUR&#8482; (SABERA®-Bupivacaine)
2014-01-23,Interesting DRRX Call Options For March 22nd
2014-01-07,First Week of February 22nd Options Trading For Durect (DRRX)
2014-01-07,Impax And DURECT Sign A $63 Million Agreement To Develop And Commercialize DURECT&#8217;s ELADUR&#174; Pain Patch
2013-11-25,First Week Of DRRX July 2014 Options Trading
2013-11-13,DURECT Announces Closing Of Public Offering Of Common Stock
2013-11-13,5 Stocks With Big Insider Buying
2013-11-08,DURECT Announces Pricing Of Public Offering Of Common Stock
2013-11-07,DURECT Announces Proposed Public Offering Of Common Stock
2013-10-28,DURECT Corporation Invites You To Join Its Third Quarter 2013 Earnings Conference Call
2013-10-22,Pfizer Proceeding With REMOXY® Development
2013-09-27,DURECT Announces Changes To Its Board Of Directors
2013-09-11,6 Under-$10 Stocks Moving Higher
2013-09-03,DURECT To Participate In Upcoming Healthcare Conferences
2013-08-21,First Week Of April 2014 Options Trading For Durect (DRRX)
2013-08-01,DURECT Announces Selection With Orient PHARMA Of Lead Formulation For ORADUR®-Methylphenidate
2013-07-26,DURECT Corporation Invites You To Join Its Second Quarter 2013 Earnings Conference Call
2013-07-25,5 Stocks Under $10 Set to Soar
2013-07-17,4 Biotech Stocks Under $10 Making Big Moves
2013-06-25,4 Stocks Under $10 Making Big Moves
2013-06-20,DURECT Announces FDA Acceptance Of New Drug Application (NDA) Submission For POSIDUR® (SABER®-Bupivacaine)
2013-05-17,Ratings Changes Coming on 5/7/2013
2013-05-10,DURECT Announces Update On Remoxy®
2013-05-07,Durect Corporation Stock Downgraded (DRRX)
2013-04-24,DURECT Corporation Invites You To Join Its First Quarter 2013 Earnings Conference Call
2013-04-16,DURECT Announces Submission Of New Drug Application For POSIDUR™ (SABER®-Bupivacaine)
2013-03-19,4 Stocks Under $5 Moving Higher
2013-02-26,4 Stocks Under $5 Making Big Moves
2013-02-22,DURECT Corporation Invites You To Join Its Fourth Quarter 2012 Earnings Conference Call
2013-02-05,DURECT To Participate In Upcoming Healthcare Conferences
2013-01-25,5 Stocks Setting Up to Break Out
2013-01-03,DURECT Announces Positive Results From Relday™ Phase 1 Clinical Trial
2012-12-06,DURECT Announces Pricing Of Public Offering Of Common Stock
2012-11-13,DURECT To Participate In Upcoming Healthcare Conferences
2012-10-30,DURECT Corporation Invites You To Join Its Third Quarter 2012 Earnings Conference Call
2012-08-30,8 Stocks Under $10 Making Big Moves
2012-08-21,DURECT To Participate In Upcoming Healthcare Conferences
2012-08-06,DURECT Announces Intent To Submit NDA For POSIDUR™ For Post-Operative Analgesia
2012-07-26,DURECT Corporation Invites You To Join Its Second Quarter 2012 Earnings Conference Call
2012-07-24,Durect Corporation Stock Upgraded (DRRX)
2012-06-18,Alkermes Needs to Build on Drug Delivery Success
2012-03-29,DURECT Receives Back U.S. And Canadian Product Rights To POSIDUR™
2012-02-24,DURECT Corporation Invites You To Join Its Fourth Quarter 2011 Earnings Conference Call
2012-02-23,DURECT To Participate In Upcoming Healthcare Conferences
2012-02-07,DURECT To Present At The BIO CEO & Investor Conference
2012-01-30,DURECT Receives Back European Product Rights To POSIDUR™
2012-01-05,DURECT Announces Top-line Data From BESST (POSIDUR® U.S. Pivotal Phase III Trial)
2011-11-07,DURECT Corporation To Participate In Upcoming Healthcare Conferences
2011-10-26,DURECT Corporation Invites You To Join Its Third Quarter 2011 Earnings Conference Call
2011-09-06,DURECT Completes Enrollment In Pivotal U.S. Phase III Trial For POSIDUR® (BESST)
2011-08-31,DURECT Corporation To Participate In Upcoming Healthcare Conferences
2011-07-28,DURECT Corporation Invites You To Join Its Second Quarter 2011 Earnings Conference Call
2011-06-24,Business Highlights
2011-06-24,Durect Stock Gaps Down On Today's Open (DRRX)
2011-06-24,Pfizer, Pain Therapeutics Drug Rejected by FDA
2011-06-24,Pfizer Receives Complete Response Letter From FDA For REMOXY®
2011-06-03,DURECT To Present At The Jefferies Healthcare Conference
2011-06-02,DURECT Announces Resignation Of Chief Medical Officer
2011-05-12,DURECT To Present At The UBS Global Specialty Pharmaceuticals Conference
2011-04-28,DURECT Corporation Invites You To Join Its First Quarter 2011 Earnings Conference Call
2011-04-12,10 Stocks to Watch: Alcoa, BP
2011-04-11,DURECT Announces ELADUR® (TRANSDUR®-Bupivacaine) Phase II Study Results In Chronic Low Back Pain
2011-03-01,DURECT To Present At Cowen And Company Health Care Conference
2011-02-24,DURECT Corporation Invites You To Join Its Fourth Quarter 2010 Earnings Conference Call
2011-02-22,Biotech Calendar: 2011 FDA Drug Approvals
2011-02-09,DURECT Reports Data From European Phase IIb Shoulder Study Of POSIDUR™ (SABER™-Bupivacaine) And Amendment Of The Nycomed Agreement
2011-02-08,DURECT Announces Launch Of First FDA Approved SABER™-Injectable Peptide Product
2011-02-07,DURECT To Present At The BIO CEO & Investor Conference
2011-01-27,REMOXY® New Drug Application Accepted By The FDA With PDUFA Goal Date Of June 23, 2011
2010-12-27,REMOXY® New Drug Application Resubmitted
2010-11-22,DURECT To Present At The Piper Jaffray 2010 Health Care Conference
2010-11-08,DURECT To Present At The Credit Suisse 2010 Healthcare Conference
2010-11-02,DURECT Awarded $733,438 In Grants Under The Patient Protection And Affordable Care Program
2010-10-27,DURECT Corporation Invites You To Join Its Third Quarter 2010 Earnings Conference Call
2010-09-07,DURECT Corporation To Participate In Upcoming Healthcare Conferences
2010-07-29,DURECT Corporation Invites You To Join Its Second Quarter 2010 Earnings Conference Call
2010-07-28,DURECT To Present At The BMO Capital Markets Focus On Healthcare Conference
2010-07-01,DURECT Corporation Secures $50 Million Committed Equity Financing Facility
2010-06-16,DURECT Reports Data From European Phase IIb Hysterectomy Study Of POSIDUR(TM) (SABER(TM)-Bupivacaine)
2010-06-07,DURECT Corporation Invites You To Join A Conference Call Today Regarding Its POSIDUR(TM) Collaboration With Hospira
2010-06-07,Hospira And DURECT Sign Agreement To Develop And Commercialize POSIDUR(TM) (SABER(TM)-Bupivacaine) In The U.S. And Canada
2010-06-01,DURECT To Present At The Jefferies Global Life Sciences Conference
2010-05-13,DURECT To Present At The Rodman & Renshaw Global Healthcare Conference
2010-05-11,DURECT Corporation Q1 2010 Earnings Call Transcript
2010-05-04,DURECT Corporation Invites You To Join Its First Quarter 2010 Earnings Conference Call
2010-04-07,DURECT Corporation Announces Commencement Of Phase IIb ELADUR(TM) (TRANSDUR(TM)-Bupivacaine) Clinical Trial By King Pharmaceuticals
2010-03-17,DURECT To Present At The Barclays Capital Global Healthcare Conference
2010-03-01,DURECT To Present At The Cowen And Company Healthcare Conference
2010-02-24,DURECT Corporation Announces Fourth Quarter And Year End 2009 Financial Results
2010-02-22,DURECT And Nycomed Amend POSIDUR(TM) License Agreement To Separate Funding And Control Of U.S. And E.U. Clinical Programs And To Expand Territory
2010-02-18,DURECT Corporation Invites You To Join Its Fourth Quarter 2009 Earnings Conference Call
2010-02-17,DURECT Corporation Invites You To Join Its Fourth Quarter 2009 Earnings Conference Call
2010-01-19,DURECT Initiates U.S. Pivotal Phase III POSIDUR(TM) Clinical Trial
2009-12-17,DURECT Reports Positive Phase IIb Data From POSIDUR(TM) Clinical Program
2009-11-23,DURECT To Present At The 21st Annual Piper Jaffray Health Care Conference
2009-03-16,Durect Says Pain Patch Met Goals In Clinical Study
2008-05-08,Thursday's Winners & Losers: Durect
2008-05-08,Health Winners & Losers: Barr
2017-03-20,How These Drug Makers Stocks Are Faring? -- Orexigen Therapeutics, United Therapeutics, DURECT, And SciClone Pharma
2017-02-24,DURECT Corporation Invites You To Join Its Fourth Quarter 2016 Earnings Conference Call
2017-01-30,DURECT Corporation Announces Update On DUR-928 Development Program
2017-01-12,Durect Stock Sees Short Interest Fall 19.6%
2016-11-10,Short Interest In Durect Moves 21.5% Higher
2016-10-31,DURECT Corporation Announces Update On DUR-928 Development Program
2016-10-21,DURECT Corporation Invites You To Join Its Third Quarter 2016 Earnings Conference Call
2016-10-05,5 Stocks Insiders Love Right Now
2016-09-26,Durect Corp. (DRRX) Stock Tumbles on FDA Opioid Analgesic Drug Rejection
2016-09-26,5 Big-Volume Stocks You Should Stay Away From -- Plus 2 to Buy
2016-09-26,DURECT's Licensee Pain Therapeutics Receives Complete Response Letter From FDA For REMOXY® ER (oxycodone) Extended-Release Capsules CII
2016-09-06,DURECT to Present at the Rodman & Renshaw Global Investment Conference
2016-08-22,Interesting DRRX Call Options For April 2017
2016-07-25,DURECT Corporation Invites You To Join Its Second Quarter 2016 Earnings Conference Call
2016-07-01,DURECT Provides REMOXY® Update
2016-06-28,DURECT To Present At The Cantor Fitzgerald Healthcare Conference
2016-05-31,DURECT To Present At The Jefferies Healthcare Conference
2016-05-19,DURECT Announces FDA Advisory Committee Meeting For REMOXY®
2016-05-11,DURECT Announces New REMOXY® Data Being Presented At American Pain Society Meeting
2016-04-29,DURECT Announces Closing Of Public Offering Of Common Stock
2016-04-28,DURECT Corporation Invites You To Join Its First Quarter 2016 Earnings Conference Call
2016-04-28,Insider Trading Alert - SMLP, DRRX And MDSO Traded By Insiders
2016-04-26,DURECT Announces Pricing Of Public Offering Of Common Stock
2016-04-25,DURECT Announces Proposed Public Offering Of Common Stock
2016-04-12,DURECT Announces FDA Acceptance Of REMOXY® NDA, PDUFA Date Of September 25, 2016
2016-04-07,DURECT Announces POSIMIR® Program Update
2016-03-29,DURECT Announces Resubmission Of REMOXY® New Drug Application To The U.S. Food And Drug Administration
2016-02-18,DURECT Corporation Invites You To Join Its Fourth Quarter 2015 Earnings Conference Call
2016-01-28,DURECT To Present At The BIO CEO & Investor Conference
2016-01-13,Insider Trading Alert - DRRX, EA and KAI Traded By Insiders
2016-01-11,DURECT Announces Initiation Of DUR-928 Dosing In Patients
2016-01-06,DURECT Announces Positive Phase 1 Data For DUR-928
2015-11-30,DURECT To Present At The Oppenheimer Healthcare Conference
2015-11-05,DURECT To Present At The Stifel Nicolaus Healthcare Conference
2015-10-26,DURECT Corporation Invites You To Join Its Third Quarter 2015 Earnings Conference Call
2015-10-15,DURECT To Present At The BIO Investor Forum
2015-08-27,DURECT To Participate In Upcoming Healthcare Conferences
2015-07-29,Durect Stock Sees Short Interest Make 130.4% Move
2015-07-24,DURECT Corporation Invites You To Join Its Second Quarter 2015 Earnings Conference Call
2015-07-23,Cancer Prevention Pharmaceuticals, Inc. Announces Appointment Of Jon S. Saxe To Its Board Of Directors
2015-06-29,DURECT To Present At The Cantor Fitzgerald Healthcare Conference
2015-06-23,First Week Of DRRX August 21st Options Trading
2015-06-23,DURECT Announces Plans For A New POSIDUR™ (SABER®-Bupivacaine) Clinical Trial
2015-06-19,Durect (DRRX) Is Strong On High Volume Today
2015-06-18,Durect (DRRX) Weak On High Volume
2015-06-05,Durect (DRRX) Highlighted As Weak On High Volume
2015-05-26,3 Biotech Stocks Under $10 to Trade for Breakouts
2015-05-19,First Week Of January 2016 Options Trading For Durect (DRRX)
2015-05-18,DURECT Announces Positive Results From DUR-928 Multi-Dose Phase 1 Study
2015-04-27,Trade-Ideas: Durect (DRRX) Is Today's Strong On High Relative Volume Stock
2015-04-22,DURECT Corporation Invites You To Join Its First Quarter 2015 Earnings Conference Call
2015-03-30,DURECT Announces Initiation Of DUR-928 Multi-Dose Phase 1 Study
2015-03-25,5 Stocks Insiders Love Right Now
2015-03-02,DURECT Announces Epigenomic Regulator Program Including A New NAFLD/NASH And Acute Organ Injury Product Candidate In Development
2015-02-23,DURECT Corporation Invites You To Join Its Fourth Quarter 2014 Earnings Conference Call
2015-01-29,DURECT To Present At The BIO CEO & Investor Conference
2014-12-16,DURECT Enters Into License Agreement Granting Santen The Worldwide Rights To A Sustained Release SABER® Ophthalmology Product
2014-12-01,DURECT To Present At The Oppenheimer Healthcare Conference
2014-11-11,DURECT Provides Update On POSIDUR™ Program
2014-10-27,DURECT Provides Update On REMOXY® And POSIDUR™ Programs
2014-10-24,DURECT Corporation Invites You To Join Its Third Quarter 2014 Earnings Conference Call
2014-10-10,DURECT Announces POSIDUR™ (SABER®-Bupivacaine) Data Presentation At The American Society Of Anesthesiologists Annual Meeting
2014-08-25,DURECT To Present At The Rodman & Renshaw Investment Conference
2014-07-30,DURECT Corporation Invites You To Join Its Second Quarter 2014 Earnings Conference Call
2014-06-27,Why Durect Corp. (DRRX) Stock Is Jumping Today
2014-06-26,DURECT Secures $20 Million Debt Financing
2014-06-20,3 Stocks Under $10 to Trade for Breakouts
2014-06-13,3 Stocks Under $10 in Breakout Territory
2014-06-09,DURECT To Present At The Wall Street Analyst Forum Institutional Investor Conference
2014-05-30,4 Under-$10 Stocks to Trade for Breakouts
2014-05-16,DURECT Announces POSIDUR&#8482; (SABERA®-Bupivacaine) Data Presentation At The International Anesthesia Research Society (IARS) Annual Meeting
2014-05-07,DURECT Announces Participation In Bay Area Prescription Drug Abuse Summit Meeting
2014-04-23,DURECT Corporation Invites You To Join Its First Quarter 2014 Earnings Conference Call
2014-04-01,DURECT Announces POSIDUR&#8482; (SABERA®-Bupivacaine) Data Presentations At The 39th Annual American Society Of Regional Anesthetic And Pain Medicine Meeting
2014-03-18,Lifshitz & Miller Law Firm Announces Investigation Of CytRx Corporation, DURECT Corporation, Hastings Entertainment, Inc., Immunomedics, Inc. And NII Holdings, Inc.
2014-03-07,Harwood Feffer LLP Announces Investigation Of DURECT Corporation
2014-03-07,Harwood Feffer LLP Announces Investigation Of DURECT Corporation
2014-03-06,Robbins Arroyo LLP Is Investigating The Officers And Directors Of DURECT Corporation On Behalf Of Shareholders
2014-02-26,First Week of DRRX October 18th Options Trading
2014-02-20,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of DURECT Corporation
2014-02-18,DURECT Corporation Invites You To Join Its Fourth Quarter 2013 Earnings Conference Call And Upcoming Investor Conference
2014-02-14,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of DURECT Corporation - DRRX
2014-02-12,DURECT Receives Complete Response Letter From FDA For POSIDUR&#8482; (SABERA®-Bupivacaine)
2014-01-23,Interesting DRRX Call Options For March 22nd
2014-01-07,First Week of February 22nd Options Trading For Durect (DRRX)
2014-01-07,Impax And DURECT Sign A $63 Million Agreement To Develop And Commercialize DURECT&#8217;s ELADUR&#174; Pain Patch
2013-11-25,First Week Of DRRX July 2014 Options Trading
2013-11-13,DURECT Announces Closing Of Public Offering Of Common Stock
2013-11-13,5 Stocks With Big Insider Buying
2013-11-08,DURECT Announces Pricing Of Public Offering Of Common Stock
2013-11-07,DURECT Announces Proposed Public Offering Of Common Stock
2013-10-28,DURECT Corporation Invites You To Join Its Third Quarter 2013 Earnings Conference Call
2013-10-22,Pfizer Proceeding With REMOXY® Development
2013-09-27,DURECT Announces Changes To Its Board Of Directors
2013-09-11,6 Under-$10 Stocks Moving Higher
2013-09-03,DURECT To Participate In Upcoming Healthcare Conferences
2013-08-21,First Week Of April 2014 Options Trading For Durect (DRRX)
2013-08-01,DURECT Announces Selection With Orient PHARMA Of Lead Formulation For ORADUR®-Methylphenidate
2013-07-26,DURECT Corporation Invites You To Join Its Second Quarter 2013 Earnings Conference Call
2013-07-25,5 Stocks Under $10 Set to Soar
2013-07-17,4 Biotech Stocks Under $10 Making Big Moves
2013-06-25,4 Stocks Under $10 Making Big Moves
2013-06-20,DURECT Announces FDA Acceptance Of New Drug Application (NDA) Submission For POSIDUR® (SABER®-Bupivacaine)
2013-05-17,Ratings Changes Coming on 5/7/2013
2013-05-10,DURECT Announces Update On Remoxy®
2013-05-07,Durect Corporation Stock Downgraded (DRRX)
2013-04-24,DURECT Corporation Invites You To Join Its First Quarter 2013 Earnings Conference Call
2013-04-16,DURECT Announces Submission Of New Drug Application For POSIDUR™ (SABER®-Bupivacaine)
2013-03-19,4 Stocks Under $5 Moving Higher
2013-02-26,4 Stocks Under $5 Making Big Moves
2013-02-22,DURECT Corporation Invites You To Join Its Fourth Quarter 2012 Earnings Conference Call
2013-02-05,DURECT To Participate In Upcoming Healthcare Conferences
2013-01-25,5 Stocks Setting Up to Break Out
2013-01-03,DURECT Announces Positive Results From Relday™ Phase 1 Clinical Trial
2012-12-06,DURECT Announces Pricing Of Public Offering Of Common Stock
2012-11-13,DURECT To Participate In Upcoming Healthcare Conferences
2012-10-30,DURECT Corporation Invites You To Join Its Third Quarter 2012 Earnings Conference Call
2012-08-30,8 Stocks Under $10 Making Big Moves
2012-08-21,DURECT To Participate In Upcoming Healthcare Conferences
2012-08-06,DURECT Announces Intent To Submit NDA For POSIDUR™ For Post-Operative Analgesia
2012-07-26,DURECT Corporation Invites You To Join Its Second Quarter 2012 Earnings Conference Call
2012-07-24,Durect Corporation Stock Upgraded (DRRX)
2012-06-18,Alkermes Needs to Build on Drug Delivery Success
2012-03-29,DURECT Receives Back U.S. And Canadian Product Rights To POSIDUR™
2012-02-24,DURECT Corporation Invites You To Join Its Fourth Quarter 2011 Earnings Conference Call
2012-02-23,DURECT To Participate In Upcoming Healthcare Conferences
2012-02-07,DURECT To Present At The BIO CEO & Investor Conference
2012-01-30,DURECT Receives Back European Product Rights To POSIDUR™
2012-01-05,DURECT Announces Top-line Data From BESST (POSIDUR® U.S. Pivotal Phase III Trial)
2011-11-07,DURECT Corporation To Participate In Upcoming Healthcare Conferences
2011-10-26,DURECT Corporation Invites You To Join Its Third Quarter 2011 Earnings Conference Call
2011-09-06,DURECT Completes Enrollment In Pivotal U.S. Phase III Trial For POSIDUR® (BESST)
2011-08-31,DURECT Corporation To Participate In Upcoming Healthcare Conferences
2011-07-28,DURECT Corporation Invites You To Join Its Second Quarter 2011 Earnings Conference Call
2011-06-24,Business Highlights
2011-06-24,Durect Stock Gaps Down On Today's Open (DRRX)
2011-06-24,Pfizer, Pain Therapeutics Drug Rejected by FDA
2011-06-24,Pfizer Receives Complete Response Letter From FDA For REMOXY®
2011-06-03,DURECT To Present At The Jefferies Healthcare Conference
2011-06-02,DURECT Announces Resignation Of Chief Medical Officer
2011-05-12,DURECT To Present At The UBS Global Specialty Pharmaceuticals Conference
2011-04-28,DURECT Corporation Invites You To Join Its First Quarter 2011 Earnings Conference Call
2011-04-12,10 Stocks to Watch: Alcoa, BP
2011-04-11,DURECT Announces ELADUR® (TRANSDUR®-Bupivacaine) Phase II Study Results In Chronic Low Back Pain
2011-03-01,DURECT To Present At Cowen And Company Health Care Conference
2011-02-24,DURECT Corporation Invites You To Join Its Fourth Quarter 2010 Earnings Conference Call
2011-02-22,Biotech Calendar: 2011 FDA Drug Approvals
2011-02-09,DURECT Reports Data From European Phase IIb Shoulder Study Of POSIDUR™ (SABER™-Bupivacaine) And Amendment Of The Nycomed Agreement
2011-02-08,DURECT Announces Launch Of First FDA Approved SABER™-Injectable Peptide Product
2011-02-07,DURECT To Present At The BIO CEO & Investor Conference
2011-01-27,REMOXY® New Drug Application Accepted By The FDA With PDUFA Goal Date Of June 23, 2011
2010-12-27,REMOXY® New Drug Application Resubmitted
2010-11-22,DURECT To Present At The Piper Jaffray 2010 Health Care Conference
2010-11-08,DURECT To Present At The Credit Suisse 2010 Healthcare Conference
2010-11-02,DURECT Awarded $733,438 In Grants Under The Patient Protection And Affordable Care Program
2010-10-27,DURECT Corporation Invites You To Join Its Third Quarter 2010 Earnings Conference Call
2010-09-07,DURECT Corporation To Participate In Upcoming Healthcare Conferences
2010-07-29,DURECT Corporation Invites You To Join Its Second Quarter 2010 Earnings Conference Call
2010-07-28,DURECT To Present At The BMO Capital Markets Focus On Healthcare Conference
2010-07-01,DURECT Corporation Secures $50 Million Committed Equity Financing Facility
2010-06-16,DURECT Reports Data From European Phase IIb Hysterectomy Study Of POSIDUR(TM) (SABER(TM)-Bupivacaine)
2010-06-07,DURECT Corporation Invites You To Join A Conference Call Today Regarding Its POSIDUR(TM) Collaboration With Hospira
2010-06-07,Hospira And DURECT Sign Agreement To Develop And Commercialize POSIDUR(TM) (SABER(TM)-Bupivacaine) In The U.S. And Canada
2010-06-01,DURECT To Present At The Jefferies Global Life Sciences Conference
2010-05-13,DURECT To Present At The Rodman & Renshaw Global Healthcare Conference
2010-05-11,DURECT Corporation Q1 2010 Earnings Call Transcript
2010-05-04,DURECT Corporation Invites You To Join Its First Quarter 2010 Earnings Conference Call
2010-04-07,DURECT Corporation Announces Commencement Of Phase IIb ELADUR(TM) (TRANSDUR(TM)-Bupivacaine) Clinical Trial By King Pharmaceuticals
2010-03-17,DURECT To Present At The Barclays Capital Global Healthcare Conference
2010-03-01,DURECT To Present At The Cowen And Company Healthcare Conference
2010-02-24,DURECT Corporation Announces Fourth Quarter And Year End 2009 Financial Results
2010-02-22,DURECT And Nycomed Amend POSIDUR(TM) License Agreement To Separate Funding And Control Of U.S. And E.U. Clinical Programs And To Expand Territory
2010-02-18,DURECT Corporation Invites You To Join Its Fourth Quarter 2009 Earnings Conference Call
2010-02-17,DURECT Corporation Invites You To Join Its Fourth Quarter 2009 Earnings Conference Call
2010-01-19,DURECT Initiates U.S. Pivotal Phase III POSIDUR(TM) Clinical Trial
2009-12-17,DURECT Reports Positive Phase IIb Data From POSIDUR(TM) Clinical Program
2009-11-23,DURECT To Present At The 21st Annual Piper Jaffray Health Care Conference
2009-03-16,Durect Says Pain Patch Met Goals In Clinical Study
2008-05-08,Thursday's Winners & Losers: Durect
2008-05-08,Health Winners & Losers: Barr
2017-03-17,2 Questions From the Biotech Mailbag
2017-03-10,Short Interest Decreases By 14.2% For DVAX
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-08,Could These 9 Drugs Gain FDA Approval in the Age of Trump?
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-01,4 Smaller Biotech Names Worth Researching
2017-01-13,UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders Of Dynavax Technologies Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017 - DVAX
2017-01-09,DVAX SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Dynavax Technologies Corporation And A Lead Plaintiff Deadline Of January 17, 2017
2017-01-07,DEADLINE ALERT: Brower Piven Reminds Investors Of The January 17, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess Of $100,000 From Investment In Dynavax Technologies Corporation To Contact The Firm
2017-01-03,My Top 2017 Pick: Progenics Pharmaceuticals
2017-01-03,DVAX INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Dynavax Technologies Corporation And A Lead Plaintiff Deadline Of January 17, 2017
2017-01-03,Top 2017 Pick: Progenics Pharmaceuticals
2016-12-28,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Dynavax Technologies Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017
2016-12-22,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
2016-12-21,DVAX SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Dynavax Technologies Corporation And A Lead Plaintiff Deadline Of January 17, 2017
2016-12-19,The Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Dynavax Technologies Corporation Investors And Encourages Investors To Contact The Firm
2016-12-14,The Worst Biopharma CEOs of 2016 Are ...
2016-12-04,5 Stocks Poised for Major Breakouts--Gold, Pharma and Tech
2016-12-01,Lifshitz & Miller Law Firm Announces Investigation Of Cempra, Inc., Commvault Systems, Inc., Dakota Plains Holdings, Inc., Diplomat Pharmacy, Inc., Dynavax Technologies Corporation, Endologix, Inc., OneMain Holdings, Inc. And StoneMor Partners L.P.
2016-11-28,Oversold Conditions For Dynavax Technologies (DVAX)
2016-11-25,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Dynavax Technologies Corporation Of Class Action Lawsuit And Upcoming Deadline - DVAX
2016-11-21,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against Dynavax Technologies Corporation (DVAX) & Lead Plaintiff Deadline: January 17, 2017
2016-11-18,INVESTOR ALERT: Goldberg Law PC Announces The Filing Of A Securities Class Action Lawsuit Against Dynavax Technologies Corporation And Encourages Investors With Losses To Contact The Firm
2016-11-18,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Dynavax Technologies Corporation
2016-11-14,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Dynavax Technologies Corporation (DVAX)
2016-11-14,Dow Scores Slim New Record While Nasdaq, S&P 500 Fall
2016-11-14,Stocks Waver as Wall Street's Trump Rally Fades
2016-11-14,Dynavax Shares Plunge on Rejected Application
2016-11-14,How to Trade Monday's Most Active Stocks - Facebook, Dynavax, Barrick Gold, More
2016-11-14,Midday Report: Dynavax Slumps on FDA Rejection; U.S. Stocks Fluctuate
2016-11-14,Noteworthy Monday Option Activity: DVAX, GLPI, HRTX
2016-11-14,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By Certain Officers And Directors Of Dynavax Technologies Corporation
2016-11-14,Stocks Fluctuate as Wall Street Picks Apart Trump's Policies
2016-11-14,Dynavax Shares Fall on FDA Rejection of Hepatitis B Vaccine
2016-11-10,Dynavax Technologies Stock Sees Short Interest Increase 10.3%
2016-10-05,Notable Wednesday Option Activity: DVAX, GTY, ENH
2016-10-04,FDA Precedent Suggests Dynavax Hep B Vaccine Faces High Rejection Risk
2016-09-30,New 52-Week Low Could Prompt More Insider Buying At DVAX
2016-09-30,Biotech Stock Mailbag: Dynavax, Puma, Ariad
2016-09-16,5 Stocks to Trade for Big Breakout Gains
2016-09-10,'Mad Money' Lightning Round: I Don't Care for Cabela's
2016-09-09,Jim Cramer's 'Mad Money' Recap: Here's What I'm Watching Next Week
2016-09-09,4 Biotechs Set to Provide a Shot in the Arm
2016-09-09,4 Biotechs Set to Provide a Shot in the Arm
2016-09-06,Here's a Reason Why Dynavax Technologies (DVAX) Stock Is Soaring Today
2016-09-06,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Dynavax Technologies Corporation (DVAX)
2016-09-06,How to Play It When the FDA Slams Your Stock
2016-09-02,EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Dynavax Technologies Corporation - DVAX
2016-09-02,Dynavax Technologies Corp is Now Oversold
2016-09-02,Dynavax Technologies (DVAX) Stock Plummets on Cancelled FDA Meeting
2016-08-24,DVAX: Insiders vs. Shorts
2016-08-22,DVAX April 2017 Options Begin Trading
2016-08-05,5 Breakout Stocks to Buy for Big Gains
2016-07-31,5 Small-Cap Biotechs With Big Potential
2016-07-29,5 Small-Cap Biotechs With Big Potential
2016-07-14,A Mid-Year Look at 4 Best Ideas Picks
2016-06-27,Will Insiders Be Tempted To Buy More DVAX At The New 52-Week Low?
2016-06-21,Commit To Purchase Dynavax Technologies Corp At $12, Earn 35.7% Annualized Using Options
2016-05-25,DVAX: Insiders Vs. Shorts
2016-05-10,Perilous Reversal Stock: Dynavax Technologies (DVAX)
2016-05-04,Dynavax Technologies Enters Oversold Territory (DVAX)
2016-05-02,4 Possible Biotech M&amp;A Targets
2016-04-27,Today's Pre-Market Mover With Heavy Volume: Dynavax Technologies (DVAX)
2016-04-19,Strong On High Volume: Dynavax Technologies (DVAX)
2016-04-14,M&amp;A Could Ignite Next Leg Up for Biotech
2016-04-05,'Mad Money' Lightning Round: Take Lockheed Martin Over Boeing
2016-04-04,Jim Cramer's 'Mad Money' Recap: Be Brave, Keep Investing in Stocks
2016-03-31,Here's Why Dynavax Technologies (DVAX) Stock is Climbing Today
2016-03-31,Revisiting 3 Promising Small Biotechs
2016-03-22,Interesting DVAX Put And Call Options For May 20th
2016-03-18,A Small Biotech Sells for Less Than Cash
2016-03-15,Biotech Stocks Are Beginning to Stir
2016-03-08,Dynavax Technologies (DVAX) Weak On High Volume
2016-02-24,Dynavax Technologies Becomes Oversold (DVAX)
2016-02-19,Cashing In on the Biotech Bear Market
2016-01-22,Storm The Castle Stock Of The Day: Dynavax Technologies (DVAX)
2016-01-15,3 Scorned Biotechs Destined to Rebound
2016-01-08,Stock To Watch: Dynavax Technologies (DVAX) In Perilous Reversal
2016-01-07,Dynavax Technologies (DVAX) Shares Cross Above 200 DMA
2016-01-07,Today's Pre-Market Mover With Heavy Volume: Dynavax Technologies (DVAX)
2016-01-06,Dynavax Technologies Becomes Oversold (DVAX)
2015-11-21,JPMorgan Likes These 5 Biotech Stocks
2015-11-03,Buy These Biotechs Before They Bounce
2015-10-21,First Week of December 18th Options Trading For Dynavax Technologies (DVAX)
2015-10-13,Dynavax Technologies Stock Sees Short Interest Decline 10%
2015-10-08,How to Build a Good Foundation in Biotechs
2015-10-02,Today's Weak On High Volume Stock: Dynavax Technologies (DVAX)
2015-09-28,First Week of DVAX November 20th Options Trading
2015-09-12,My Wall Street Fantasy Football League
2015-09-03,Today's Perilous Reversal Stock: Dynavax Technologies (DVAX)
2015-08-10,Dynavax Technologies (DVAX) Marked As A Barbarian At The Gate
2015-08-07,'Mad Money' Lightning Round: Monster Beverage Is the One to Buy
2015-08-06,Jim Cramer's 'Mad Money' Recap: This Stock Market Is No Bargain
2015-07-23,Trade-Ideas: Dynavax Technologies (DVAX) Is Today's "Perilous Reversal" Stock
2015-07-22,Dynavax Technologies (DVAX) Trading With Heavy Volume Before Market Open
2015-07-10,Dynavax: Revisiting A 'Best Idea'
2015-07-07,Dynavax Technologies (DVAX) Highlighted As Today's Perilous Reversal Stock
2015-07-07,4 Big-Volume Stocks to Trade for Breakouts
2015-07-06,Strong On High Relative Volume: Dynavax Technologies (DVAX)
2015-06-26,Commit To Purchase Dynavax Technologies Corp At $15, Earn 18.6% Annualized Using Options
2015-06-15,Short Interest Drops 18.5% For DVAX
2015-04-17,Check in to Diamondrock Hospitality
2015-04-16,Strong On High Volume: Dynavax Technologies (DVAX)
2015-03-27,'Mad Money' Lightning Round: If You Want Hotels, You Want Marriott
2015-03-26,Jim Cramer's 'Mad Money' Recap: A So-So Victory for the Bulls
2015-03-24,How I Play the Biotechs
2015-03-03,Dynavax Technologies: A New 'Best Idea'
2015-01-12,Strong On High Relative Volume: Dynavax Technologies (DVAX)
2014-12-30,Three Small Caps for 2015
2014-12-05,Agenus: A Promising Biotech Play
2014-11-28,A Biotech With Enormous Potential
2014-10-31,Invest in a Healthy Liver
2014-10-24,3 Stocks Under $10 Triggering Breakout Trades
2014-08-19,Interesting DVAX Put And Call Options For April 2015
2014-05-20,First Week of January 2015 Options Trading For Dynavax Technologies (DVAX)
2014-03-28,First Week of May 17th Options Trading For Dynavax Technologies (DVAX)
2014-02-26,First Week of DVAX October 18th Options Trading
2013-12-31,Interesting DVAX Call Options For February 2014
2013-11-20,4 Stocks Under $10 Moving Higher
2013-11-19,Interesting DVAX Put And Call Options For July 2014
2013-10-17,5 Stocks Under $10 Set to Soar
2013-08-12,SHAREHOLDER ALERT: Brower Piven Informs Shareholders Who Have Substantial Losses From Investment In Dynavax Technologies Corporation That Less Than One Week Remains To Move For Appointment As Lead Plaintiff In Securities Class Action Lawsuit
2013-08-06,SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors With Losses On Their Investment In Dynavax Technologies Corporation Of Class Action Lawsuit And Deadline Of August 19, 2013 To Seek Lead Plaintiff Position
2013-07-29,SHAREHOLDER ALERT: Levi &amp; Korsinsky Notifies Investors With Losses On Their Investment In Dynavax Technologies Corporation Of Class Action Lawsuit And Deadline Of August 19, 2013, To Seek Lead Plaintiff Position
2013-07-22,SHAREHOLDER ALERT: Levi &amp; Korsinsky Notifies Investors With Losses On Their Investment In Dynavax Technologies Corporation Of Class Action Lawsuit And Deadline Of August 19, 2013 To Seek Lead Plaintiff Position
2013-06-25,Lifshitz Law Firm Announces Investigation Of Dynavax Technologies Corporation, Keynote Systems, Inc., STec, Inc. And Vanguard Health Systems Inc.
2013-06-21,Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Dynavax Technologies Corporation To Contact The Firm
2013-06-21,Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Dynavax Technologies Corporation
2013-06-21,Dynavax Shareholder Alert: Briscoe Law And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors
2013-06-20,Dynavax Technologies Corp. Sued By Investor
2013-06-18,SHAREHOLDER ALERT: Brower Piven Announces An Investigation Of Dynavax Technologies Corporation For Potential Violations Of The Federal Securities Laws
2013-06-12,Law Firm Finkelstein Thompson LLP Announces Investigation Of Dynavax Technologies Corp.
2013-06-11,Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Dynavax Technologies Corporation
2013-06-10,DVAX, RDY, ONXX, ALXN And VRX, 5 Health Care Stocks Pushing The Sector Lower
2013-03-13,5 Stocks Under $5 to Watch
2013-02-25,Stocks Tumble, VIX Pops as Eurozone Anxieties Intensify
2013-02-25,Stock Futures Point to Higher Open
2013-02-25,Dynavax May Seek Quick Re-File of HepB Vax Following FDA Rejection
2013-02-13,Run-Up Trade Into Dynavax's FDA Approval Decision
2013-02-12,Dynavax Options Trade for Heplisav FDA Approval Decision
2013-02-08,Biotech Stock Mailbag: Dynavax, ImmunoCellular, Celldex and Medgenics
2013-02-07,5 Stocks Under $10 Ready to Soar Higher
2013-02-07,'Mad Money' Lightning Round: I'm Avoiding Controversial Coinstar
2013-02-06,Cramer's 'Mad Money' Recap: Pay Attention
2013-01-30,5 Biotech Stocks Under $10 Moving Higher
2012-11-28,Investing Ideas For Flu Season
2012-11-28,'Mad Money' Lightning Round: Wendy's Leaves a Bad Taste
2012-11-27,Cramer's 'Mad Money' Recap: The Looming Cliff
2012-11-20,5 Biotech Stocks Rising on Unusual Volume
2012-11-20,Dynavax: Speculative Upside Options Trade
2012-11-19,First 90 Days of 2013 Are Live or Die For These Biotech Stocks
2012-11-19,Cramer's Top Stock Picks: DFRG, KMX, DVAX, AAPL
2012-11-16,Cramer's 'Mad Money' Recap: Staying Cautious for Coming Week's Earnings
2012-11-16,Stocks Finish Week on Positive Note
2012-11-16,5 Stocks Pushing The Drugs Industry Lower
2012-11-13,Cramer's 'Mad Money' Recap: Good Reasons to Stay in the Market
2012-11-09,The Next Big Thing in Biotech: Dynavax
2012-11-05,21 Most Volatile Biopharma Stocks Closing Out 2012
2012-10-18,Insiders Trading THC RMTR DVAX ASCMA
2012-10-17,'Mad Money' Lightning Round: Put the Brakes on Ford
2012-10-16,Cramer's 'Mad Money' Recap: Time to Change Your Mind (Correct)
2012-10-03,Jim Cramer's 8-Point Plan for Higher Stock Prices
2012-09-14,Cramer's 'Mad Money' Recap: Next Week's Game Plan
2012-09-11,Dynavax: The BioRunUp Trade Into An FDA Panel
2012-05-09,Dynavax Stock Gaps Down On Today's Open (DVAX)
2012-03-16,10 Stocks Boosting Little Funds to Big Returns (Update2)
2012-02-02,8 Stocks Under $10 Moving Higher
2012-01-20,10 Stocks of Top-Performing Funds in 2012
2011-10-03,Biotech Calendar: Key Dates for October
2011-08-31,Biotech Calendar: Key Dates for September
2011-07-20,Dynavax Stock Gaps Down On Today's Open (DVAX)
2011-06-16,10 Pharma Stocks Under $3
2011-04-13,4 Biotech Penny Stocks to Buy: Navellier
2010-04-27,Dynavax, Frontier Financial: Early Volume Plays
2010-04-15,Dynavax, Santarus: Early Volume Plays
2010-03-23,Sirius XM, Conolog: Early Volume Plays
2010-02-09,Dynavax, CFS Bancorp: Early Volume Plays
2010-01-26,Dynavax, Matrixx: Early Volume Plays
2009-10-23,Midday Movers: Pump Up the Volume
2009-09-10,Dynavax Says FDA Allows New Testing Of Heplisav
2017-03-14,Auris Medical Provides Business Update And Reports Full Year 2016 Financial Results
2017-03-08,Auris Medical To Present At The 29th Annual Roth Conference On March 14
2017-03-07,Auris Medical To Announce Full Year 2016 Financial Results And Host Conference Call On March 14
2017-02-24,Auris Medical Stock Suring on AM-111 Fast Track Designation
2017-02-24,Auris Medical Receives FDA Fast Track Designation For AM-111 In Acute Sensorineural Hearing Loss
2017-02-22,Auris Medical And King's College London Extend Tinnitus Collaboration
2017-02-21,Auris Medical Announces Closing Of $10 Million Public Offering
2017-02-15,Auris Medical Announces Pricing Of $10 Million Public Offering
2017-02-14,Auris Medical Announces Proposed Public Offering Of Common Shares And Warrants
2017-02-03,Auris Medical Expands Clinical Development Pipeline With Intranasal Betahistine For The Treatment Of Meniere's Disease And Vestibular Vertigo
2017-02-02,Auris Medical To Announce Business Update And Host Conference Call And Webcast Tomorrow, February 3, 2017
2017-01-26,Auris Medical Resumes Enrollment In TACTT3 Phase 3 Trial Of Keyzilen In Acute And Post-Acute Tinnitus
2016-12-06,Auris Medical On Track To Resume Enrollment Of Keyzilen Tinnitus Program Following Regulatory Feedback
2016-12-06,Auris Medical On Track To Resume Enrollment Of Keyzilen™ Tinnitus Program Following Regulatory Feedback
2016-11-10,Auris Medical Provides Business Update And Reports Third Quarter 2016 Financial Results
2016-11-03,Auris Medical To Announce Third Quarter 2016 Financial Results And Host Conference Call On Thursday, November 10, 2016
2016-10-11,Auris Medical Provides Update On Development Of Keyzilen For The Treatment Of Acute Inner Ear Tinnitus
2016-10-10,Auris Medical To Announce Keyzilen Program Update And Host Conference Call And Webcast Tomorrow, October 11, 2016
2016-09-13,Auris Medical Announces AAO-HNSF Annual Meeting Activities
2016-09-09,Auris Medical Achieves Midpoint For Enrollment In Phase 3 Trial Of AM-111 In Sudden Deafness
2016-08-18,5 Breakout Stocks Under $10 Set to Soar
2016-08-18,Auris Medical (EARS) Stock Plummets on Clinical Trial Miss, Q2 Loss
2016-08-18,Auris Medical Provides Business Update And Reports Second Quarter 2016 Financial Results
2016-08-18,Auris Medical Reports Top-Line Results From TACTT2 Trial With Keyzilen In Acute Inner Ear Tinnitus
2016-08-16,Auris Medical To Announce Second Quarter 2016 Financial Results And Host Conference Call And Webcast On Thursday, August 18, 2016
2016-07-19,Auris Medical Secures Loan Facility Of Up To $20 Million
2016-07-18,FDA Grants Auris Medical Fast Track Designation For Keyzilen In Acute Peripheral Tinnitus
2016-07-08,Auris Medical To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference On Tuesday, July 12
2016-06-28,Auris Medical Completes Enrollment Of Phase 3 TACTT3 Trial With Keyzilen In Acute And Post-Acute Inner Ear Tinnitus
2016-06-17,Auris Medical Initiates ASSENT Phase 3 Trial Of AM-111 For Treatment Of Sudden Deafness
2016-06-16,Auris Medical To Present At The JMP Securities Life Sciences Conference On Wednesday, June 22
2016-06-14,Auris Medical Hosts Key Opinion Leader Event Focused On Phase 3 Program For Acute Inner Ear Tinnitus
2016-06-07,Auris Medical To Host Key Opinion Leader Event Focused On Acute Inner Ear Tinnitus And AM-101's Phase 3 Program On June 14 In New York City
2016-06-02,Auris Medical To Present At The Jefferies 2016 Healthcare Conference On Thursday, June 9
2016-05-11,Auris Medical Provides Business Update And Reports First Quarter 2016 Financial Results
2016-05-04,Auris Medical To Announce First Quarter 2016 Financial Results And Host Conference Call On Wednesday, May 11, 2016
2016-04-05,Auris Medical To Present At The 15th Annual Needham Healthcare Conference On Tuesday, April 12
2016-03-30,Auris Medical Completes Enrollment Of TACTT2 Phase 3 Trial Of AM-101 In Acute Inner Ear Tinnitus
2016-03-14,Auris Medical Provides Business Update And Reports Fourth Quarter And Full Year 2015 Financial Results
2016-03-02,Auris Medical To Announce Fourth Quarter And Full Year 2015 Financial Results And Host Conference Call On Monday, March 14, 2016
2016-02-18,Auris Medical To Host Key Opinion Leader Meeting And Webcast Focused On Acute Sensorineural Hearing Loss On February 26 In New York City
2016-02-05,Auris Medical To Present At The 2016 Leerink Global Healthcare Conference On Thursday, February 11
2016-01-07,5 Stocks Under $10 Set to Soar
2015-11-13,Auris Medical Announces Enrollment Of First Patient In HEALOS Study Of AM-111 In Treatment Of Idiopathic Sudden Sensorineural Hearing Loss
2015-11-12,Auris Medical AG : Auris Medical Holding AG Reports Third Quarter 2015 Financial Results And Provides Business Update
2015-11-05,Auris Medical To Announce Third Quarter 2015 Financial Results And Host Conference Call On Thursday, November 12, 2015
2015-10-23,Auris Medical And King's College London Collaborate In Drug Discovery For Second Generation Tinnitus Treatment
2015-09-25,Auris Medical To Host Corporate Symposium On Rational Pharmacotherapy For Acute Hearing Loss On September 28, 2015
2015-09-23,Auris Medical To Present At The Leerink Partners 4th Annual Rare Disease Roundtable On Wednesday, September 30, 2015
2015-08-19,Auris Medical Holding AG Reports Second Quarter 2015 Financial Results And Provides Business Update
2015-08-12,Auris Medical To Announce Second Quarter 2015 Financial Results And Host Conference Call On Wednesday, August 19, 2015
2015-08-03,Auris Medical Promotes Anne Sabine Zoller To General Counsel
2015-07-02,Auris Medical Holding AG Provides Update On U.S. Intellectual Property Portfolio
2015-06-25,Auris Medical And Cochlear To Collaborate On Clinical Trial With AM-111 For Otoprotection During Cochlear Implant Surgery
2015-06-17,Auris Medical To Present At The JMP Securities Life Sciences Conference 2015 On Wednesday, June 24
2015-06-02,Auris Medical Holding Becomes Oversold (EARS)
2015-06-02,Auris Medical To Present At The Jefferies 2015 Global Healthcare Conference On Tuesday, June 2
2015-05-28,Auris Medical Holding AG Reports First Quarter 2015 Financial Results And Provides Business Update
2015-05-22,Auris Medical To Announce First Quarter 2015 Financial Results And Host Conference Call On Thursday, May 28, 2015
2015-05-20,Auris Medical Holding AG Announces Closing Of Public Offering Of Common Shares
2015-05-18,Auris Medical Holding AG Announces Notice Of Allowance From USPTO Related To Treating Middle Ear Diseases With Poloxamer-Based Fluoroquinolone Compositions
2015-05-15,Auris Medical Holding AG Announces Pricing Of Public Offering Of Common Shares
2015-05-04,Auris Medical Holding AG Announces Proposed Public Offering Of Common Shares
2015-05-04,Auris Medical Holding AG Provides Update On Clinical Development Plan For AM-111
2015-04-20,Auris Medical Announces Publications Related To AM-101 In Peer-Reviewed Scientific And Medical Journals
2015-03-30,Auris Medical To Propose Election Of Two New Board Members At Forthcoming Annual General Meeting
2015-03-19,Auris Medical Holding AG Reports Fourth Quarter And Full Year 2014 Financial Results And Provides Business Update
2015-03-16,Auris Medical To Announce Fourth Quarter And Full Year 2014 Financial Results And Host Conference Call On Thursday, March 19, 2015
2015-03-13,Auris Medical Announces Recently Granted Patent In India For The Treatment Of Tinnitus
2015-03-11,Auris Medical To Host Key Opinion Leader Meeting On Tinnitus Treatments On March 13 In New York City
2015-03-10,Auris Medical Announces Completion Of Interim Analysis In Post-Acute Tinnitus Stratum Of TACTT3 Trial With AM-101
2015-02-11,Auris Medical Announces Recently Granted Patent In China For The Treatment Of Tinnitus
2015-02-04,Auris Medical To Present At The Leerink Global Healthcare Conference
2015-02-02,3 Stocks Boosting The Drugs Industry Higher
2015-01-26,3 Drugs Stocks Nudging The Industry Higher
2015-01-21,3 Stocks Pushing The Drugs Industry Lower
2015-01-20,3 Drugs Stocks Pushing The Industry Higher
2015-01-14,Auris Medical Holding AG Achieves 50% Enrolment Milestone In Post-Acute Tinnitus Stratum Of TACTT3 Clinical Trial
2015-01-08,3 Drugs Stocks Driving The Industry Higher
2015-01-06,3 Stocks Pushing The Drugs Industry Lower
2015-01-06,3 Stocks Pushing The Health Care Sector Lower
2015-01-05,3 Stocks Pushing The Drugs Industry Lower
2014-12-03,Auris Medical Q3 2014 Earnings Release
2014-12-01,Auris Medical To Announce Third Quarter 2014 Financial Results And Host Conference Call On Wednesday, December 3, 2014
2014-09-15,Auris Medical Holding AG Reports Second Quarter 2014 Financial Results And Provides Business Update
2014-09-08,Auris Medical To Announce Second Quarter 2014 Financial Results And Host Conference Call On Monday, September 15, 2014
2014-08-19,Auris Medical Holding AG Announces Exercise Of IPO Over-Allotment Option
2014-08-11,Auris Medical Holding AG Announces Closing Of Initial Public Offering
2014-08-05,Auris Medical Holding AG Announces Pricing Of Initial Public Offering
,
,
,
2017-03-24,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Egalet Corporation - EGLT
2017-03-24,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed A Complaint To Recover Losses Suffered By Investors In Egalet Corporation
2017-03-23,Egalet Announces Issuance Of New U.S. And International Patents For Guardian™ Technology
2017-03-17,2 Questions From the Biotech Mailbag
2017-03-13,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed A Complaint To Recover Losses Suffered By Investors In Egalet Corporation
2017-03-10,Egalet Makes Friday's Biotech Mailbag
2017-03-08,EGLT SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Egalet Corporation And A Lead Plaintiff Deadline Of March 28, 2017
2017-03-07,Egalet To Present At Several Upcoming Scientific Conferences
2017-03-03,EGLT INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving Egalet Corporation And A Lead Plaintiff Deadline Of March 28, 2017
2017-03-03,DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Egalet Corporation To Contact The Firm
2017-02-27,INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed A Complaint To Recover Losses Suffered By Investors In Egalet Corporation
2017-02-24,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Egalet Corporation Of Class Action Lawsuit And Upcoming Deadline - EGLT
2017-02-23,Egalet To Host Conference Call And Webcast To Discuss Fourth Quarter And Year-End 2016 Financial Results On March 9, 2017
2017-02-22,EGLT SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Egalet Corporation And A Lead Plaintiff Deadline Of March 28, 2017
2017-02-08,EGLT LOSS NOTICE: Rosen Law Firm Reminds Egalet Corporation Investors Of Important Deadline In Class Action - EGLT
2017-02-08,INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Egalet Corporation To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2017-02-02,Lifshitz & Miller Law Firm Announces Investigation Of Alcobra Ltd., Egalet Corporation, Sanderson Farms, Inc., Surgical Care Affiliates, Inc., State Street Corporation, Tenet Healthcare Corp., Vista Outdoor Inc. And Zagg Inc.
2017-02-01,IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Egalet Corporation And Encourages Investors With Losses To Contact The Firm
2017-01-31,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Egalet Corporation - EGLT
2017-01-30,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against Egalet Corporation (EGLT) & Lead Plaintiff Deadline: March 28, 2017
2017-01-24,First Week of March 17th Options Trading For Egalet (EGLT)
2017-01-18,Egalet Closes Second Tranche Of $80 Million Secured Debt Financing
2017-01-12,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of Egalet Corporation
2017-01-12,EGALET NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Egalet Corporation To Contact The Firm
2016-12-20,A Biotech Trio to Like Going Into 2017
2016-12-16,Egalet Announces Positive Top-Line Results From An Intranasal Human Abuse Potential Study Of Egalet-002
2016-12-08,Egalet Corporation Appoints Robert Roche To Board Of Directors
2016-12-06,Egalet Announces Issuance Of New Patent For Egalet-002 And Guardian™ Technology
2016-12-01,Egalet Announces Filing Of Supplemental New Drug Application For OXAYDO® To FDA
2016-11-25,Biotech Hits an Inflection Point
2016-11-17,Egalet Announces OXAYDO® Receives Pharmaceutical Composition Patent Protection Through 2024
2016-10-28,Oversold Conditions For Egalet (EGLT)
2016-10-28,Egalet To Present At Abuse-Deterrent Formulations And Investor Conferences This Fall
2016-10-20,Egalet To Host Conference Call And Webcast To Discuss Third Quarter 2016 Financial Results On November 4, 2016
2016-10-13,Egalet Notified that FDA Will Not Meet PDUFA Goal Date for ARYMO ER
2016-09-27,Editorial Discussing Approaches To Category 1 Testing Of Abuse-Deterrent Formulations Of Opioids Published In Pain Practice
2016-09-22,Egalet Announces Publications In Pain Medicine From ARYMO™ ER Oral And Intranasal Human Abuse Potential Studies
2016-09-19,Egalet Appoints Patrick Shea As Chief Commercial Officer
2016-09-15,Bought Aerie Earlier? Congratulations
2016-09-13,Egalet Stock Sees Short Interest Jump 30%
2016-09-12,Egalet Announces OXAYDO® Demonstrates Bioequivalence At 15 Mg Dose
2016-09-08,Egalet Announces Category 1 Abuse-Deterrent Data Demonstrating OXAYDO® Resists Syringeability
2016-08-31,Egalet Completes $40 Million Secured Debt Financing
2016-08-25,Egalet Announces Scientific Presentations At PAINWeek 2016 Meeting
2016-07-21,4 Small-Cap Biotechs With Big Stories to Tell
2016-07-21,Egalet To Host Conference Call And Webcast On August 4, 2016 To Discuss Second Quarter 2016 Financial Results
2016-07-19,Egalet Announces Issuance Of Two New U.S. Patents For Guardian™ Technology
2016-07-07,Insider Trading Alert - EGLT, FMI And ICLD Traded By Insiders
2016-07-07,Egalet To Present At Cantor Fitzgerald Healthcare Conference
2016-06-28,Egalet Announces FDA Advisory Committee Meeting Will Take Place August 4, 2016 For Lead Abuse-Deterrent Candidate ARYMO™ ER (Morphine Sulfate) Extended-Release Tablets
2016-06-17,Egalet Enters Oversold Territory (EGLT)
2016-06-10,Egalet President And CEO Bob Radie Named EY Entrepreneur Of The Year®
2016-05-23,Egalet Settles Patent Litigations With Purdue Pharma
2016-05-06,Relative Strength Alert For Egalet
2016-05-05,Egalet Announces Scientific Presentations At American Pain Society Meeting
2016-05-04,Egalet To Present At Upcoming Investor Conferences This Spring
2016-04-27,Egalet To Host Conference Call And Webcast To Discuss First Quarter 2016 Financial Results On May 10, 2016
2016-04-21,Egalet Announces Upcoming Opportunities For Community To Dispose Of Prescription Medications
2016-04-07,Insider Trading Alert - CTSH, EGLT And CMC Traded By Insiders
2016-04-06,Insider Trading Alert - PNY, EGLT And MA Traded By Insiders
2016-04-05,Insider Trading Alert - ATOS, EGLT And VRNS Traded By Insiders
2016-03-24,Egalet Announces ALERRT(SM) Study Demonstrated Egalet-002 Required Significantly More Effort To Manipulate Than OxyContin®
2016-03-08,Capella Bioscience Completes Series A Financing Of £11 Million ($15.5 Million) To Progress Antibody Pipeline
2016-02-29,Egalet Announces FDA Acceptance Of New Drug Application For ARYMO™ ER (Morphine Sulfate) Extended-Release Tablets
2016-02-23,Egalet To Host Conference Call And Webcast To Discuss Fourth Quarter 2016 Financial Results On March 8, 2016
2016-02-09,Egalet To Present At BIO CEO & Investor Conference
2016-02-08,Egalet Signs Agreement With Septodont, Inc. To Promote SPRIX® (ketorolac Tromethamine) Nasal Spray To Dentists In United States
2016-02-02,Medicxi Ventures, Formerly Index Ventures Life Sciences, Launches As An Independent Venture Capital Firm And Announces Closing Of A €210m Fund Including GSK And Johnson & Johnson Innovation
2016-01-15,Oversold Conditions For Egalet (EGLT)
2016-01-08,Insider Trading Alert - ADSK, EGLT And CPE Traded By Insiders
2016-01-06,Insider Trading Alert - PLOW, DST And EGLT Traded By Insiders
2015-12-17,Egalet Added To NASDAQ Biotechnology Index
2015-12-15,Egalet Submits New Drug Application To U.S. Food And Drug Administration For ARYMO™ ER (Morphine Sulfate) Extended-Release Tablets
2015-12-14,Egalet Signs Agreement With Teva Pharmaceutical Industries To Commercialize SPRIX® (ketorolac Tromethamine) Nasal Spray In Select Geographies Outside The United States
2015-12-09,Egalet Appoints Leading Experts To Scientific Advisory Board
2015-12-03,Egalet Announces Termination Of Shionogi Collaboration
2015-11-16,Egalet Hires Paul Varki As Senior Vice President And General Counsel
2015-11-12,Egalet Announces Issuance Of U.S. Patent Covering Guardian™ Technology And Its Abuse-Deterrent Product Candidates
2015-10-28,Egalet To Participate In Abuse-Deterrent Formulation And Investor Conferences And Will Co-Host A Category 1 Focus Group Meeting In November
2015-10-22,Egalet is Now Oversold (EGLT)
2015-10-21,Egalet To Host Conference Call And Webcast To Discuss Third Quarter 2015 Financial Results On November 4, 2015
2015-10-05,Insider Trading Alert - LOCK, CYBX And EGLT Traded By Insiders
2015-10-05,Egalet Appoints Mark Strobeck, Ph.D. To Executive Vice President And Chief Operating Officer
2015-09-29,Egalet Provides Commercial Update On SPRIX® Nasal Spray And OXAYDO™ Along With Pipeline Review At Investor Day
2015-09-15,Egalet Announces Investor Day
2015-09-10,Egalet Announces Scientific Data At PAINWeek 2015 Meeting Supports Analgesic Efficacy Of SPRIX® Nasal Spray Versus Commonly Prescribed Oral Combination Opioids In Treatment Of Moderate To Severe Short-Term Pain
2015-09-09,Egalet Announces Commercial Launch Of OXAYDO™, The First And Only Immediate-Release Oxycodone Designed To Discourage Intranasal Abuse, And Launch Of IMPACT-Rx, A Patient Access Initiative
2015-09-01,Egalet Announces Scientific Presentations At PainWeek 2015 Meeting
2015-07-31,Egalet Announces Closing Of Public Offering Of Common Stock And Exercise In Full Of Underwriters' Option To Purchase Additional Shares
2015-07-28,Egalet Announces Pricing Of Public Offering Of Common Stock
2015-07-27,Egalet Announces Proposed Public Offering Of Common Stock
2015-07-23,Egalet To Host Conference Call And Webcast To Discuss Second Quarter 2015 Financial Results On August 6, 2015
2015-07-10,Insider Trading Alert - EGLT, STFC And CVGW Traded By Insiders
2015-07-03,Insider Trading Alert - SFBS, WIFI And EGLT Traded By Insiders
2015-07-01,Egalet To Present At Upcoming Conferences This Summer
2015-06-30,Egalet Announces Top-Line Results From Oral Human Abuse Liability Study Of Egalet-002
2015-06-29,Egalet Announces Positive Top-Line Results From Intranasal Human Abuse Liability Study Of Abuse-Deterrent Morphine, Egalet-001
2015-06-25,Egalet's Abuse-Deterrent, Extended-Release Morphine Demonstrates Bioequivalence At 60 Mg Dose
2015-06-23,Egalet Announces Launch Of Specialty Pharmaceutical Sales Force
2015-05-28,Egalet Category 1 Abuse-Deterrent Studies Demonstrated Strong Abuse-Deterrent Properties Of Egalet-002 Compared To Reformulated OxyContin®
2015-05-26,Egalet To Present At Upcoming Conferences In June
2015-05-19,Egalet Announces Issuance Of U.S. Patents Covering Guardian™ Technology And Product Candidates
2015-05-12,Egalet President And Chief Executive Officer Bob Radie Appointed To Pennsylvania Bio Board Of Directors
2015-05-08,Ratings Changes Today
2015-04-23,Egalet To Host Conference Call And Webcast To Discuss First Quarter 2015 Financial Results On May 7, 2015
2015-04-16,Oversold Conditions For Egalet (EGLT)
2015-04-13,Egalet Appoints Nicholas Nicolaides, Ph.D. And John Osborn To Board Of Directors
2015-04-07,Egalet Announces Closing Of $60 Million Offering Of Convertible Senior Notes Due 2020
2015-04-01,Egalet Announces Proposed $60 Million Offering Of Convertible Senior Notes Due 2020
2015-03-24,Rigontec GmbH Raises €4.8m In A Second Closing Of Its Series A Financing
2015-03-17,Egalet Earns $10 Million Milestone Payment Triggered By Advancement Of Shionogi's Abuse-Deterrent, Extended-Release Hydrocodone, S-718632, Using Egalet's Guardian™ Technology
2015-03-09,Egalet To Release 2014 Fourth Quarter And Year-End Financial Results On March 16, 2015 And To Host Conference Call And Webcast To Discuss Commercial Launch On March 25, 2015
2015-02-02,Egalet To Present At Upcoming Conferences In February
2015-01-26,Egalet (EGLT) Stock Gains Today on Price Target Increase
2015-01-22,Egalet Announces Positive Top-Line Results From Oral Human Abuse Liability Study Of Abuse-Deterrent Morphine, Egalet-001
2015-01-12,ORYZON Appoints Greg Weaver As Global Chief Financial Officer
2015-01-09,Egalet Appoints Deanne F. Melloy As Chief Commercial Officer
2015-01-08,Egalet Acquires/Licenses Two Innovative Approved Pain Products
2014-11-05,Egalet To Present At The Stifel 2014 Healthcare Conference On November 18
2014-10-29,Egalet To Host Conference Call And Webcast To Discuss Third Quarter Financial Results On November 12, 2014
2014-10-17,2 Oversold Stocks Under $10 Ready to Bounce Higher
2014-09-23,Egalet Announces Update On Clinical Development Plan For Abuse-Deterrent Morphine Egalet-001
2014-09-11,Egalet Announces Issuance Of U.S. Patents Covering Guardian(TM) Technology And Product Candidates
2014-09-04,Egalet To Present Data From Abuse-Deterrence Studies At PAINWeek 2014 In Las Vegas
2014-08-18,Egalet Announces Successful End-of-Phase 2 Meeting With The FDA For Egalet-002
2014-08-11,Oversold Conditions For Egalet (EGLT)
2014-08-06,Egalet Announces Topline Results From Bioequivalence Studies Of Abuse-Deterrent Morphine, Egalet-001
2014-07-30,Egalet To Present At The Canaccord Genuity Growth Conference On August 13
2014-07-29,Egalet To Host Conference Call And Webcast To Discuss Second Quarter Financial Results On August 12, 2014
2014-07-28,Egalet Appoints Jeffrey M. Dayno, M.D. As Chief Medical Officer
2014-07-15,Egalet Reports Positive Top-Line Results From Category 1 Abuse Deterrence Studies Demonstrating Egalet-001 Resists Physical And Chemical Manipulation
2006-09-06,Wednesday's Small-Cap Winners & Losers
,
2017-03-06,Eiger BioPharmaceuticals To Present At The ROTH And Oppenheimer Investor Conferences In March 2017
2017-01-30,Eiger BioPharmaceuticals To Present At BIO CEO & Investor Conference February 13th And Participate In SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th
2017-01-04,Eiger Completes $25 Million Debt Financing With Oxford Finance
2017-01-03,Eiger Announces First Patient Dosed In Open-Label Extension Of Phase 2 LIBERTY Study Of Ubenimex In Pulmonary Arterial Hypertension (PAH)
2016-12-12,Eiger Announces Multiple Advances In Exendin 9-39 Program For The Treatment Of Post-Bariatric Hypoglycemia (PBH)
2016-11-29,Eiger Updates Progress In Clinical Development Program For Exendin 9-39 To Treat Post-Bariatric Hypoglycemia (PBH)
2016-11-21,Eiger BioPharmaceuticals To Participate In Two Investor Conferences In November 2016
2016-11-14,Eiger Announces Additional LOWR HDV Program Data, Clinical And Regulatory Plans At The American Association For The Study Of Liver Diseases (AASLD) Meeting
2016-11-14,Eiger Announces Positive Phase 2 Data At The American Association For The Study Of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified With Lonafarnib Therapy In LOWR HDV Program
2016-10-24,Eiger BioPharmaceuticals Launches Nationwide Hepatitis Delta Virus (HDV) Campaign To Expand Awareness And Testing For HDV Infection
2016-10-19,Eiger Announces First Patient Dosed In Phase 2 Study Of Pegylated Interferon Lambda In Hepatitis D Virus (HDV) Infection
2016-10-17,Eiger Announces Orphan Designation Of Exendin 9-39 For Treatment Of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) From European Medicines Agency (EMA)
2016-10-13,Eiger Announces Abstracts And Presentations Of LOWR HDV Program At The American Association For The Study Of Liver Diseases (AASLD) Meeting
2016-09-07,Eiger Announces Completion of Dosing in Phase 2 LOWR HDV - 4 Study at Hannover Medical School
2016-09-06,Eiger BioPharmaceuticals to Present at the BioCentury NewsMakers in the Biotech Industry Conference on September 9th
2016-09-01,Eiger BioPharmaceuticals To Present At The 5th Annual Liolios Gateway Conference On September 7, 2016
2016-08-18,Eiger BioPharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2016-08-17,Eiger BioPharmaceuticals Announces Proposed Public Offering Of Common Stock
2016-08-08,Eiger BioPharmaceuticals To Present At The 2016 Wedbush PacGrow Healthcare Conference On August 17th
2016-07-25,Eiger BioPharmaceuticals Announces First Patient Dosed In Phase 2 ULTRA Study Of Ubenimex In Secondary Lymphedema
2016-07-18,Eiger BioPharmaceuticals Announces First Patient Dosed In Phase 2 LIBERTY Study Of Ubenimex In Pulmonary Arterial Hypertension
2016-06-13,Eiger Announces Positive Clinical Results Of Single Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Post-Bariatric Hypoglycemia
2016-05-10,Eiger Announces First Patient Dosed In Phase 2 Multiple Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Hypoglycemia Post-Gastric Bypass Surgery
2016-05-03,Eiger Bio Strengthens Senior Management Team With Announcement Of Debra Odink, PhD As Senior Vice President Of Technical Operations
2016-04-20,Eiger BioPharmaceuticals Announces License Of Worldwide Rights To Pegylated Interferon Lambda-1a From Bristol-Myers Squibb
2016-04-04,Eiger BioPharmaceuticals Strengthens Board Of Directors With Addition Of Industry Veteran Charles J. "Chuck" Bramlage
2016-03-30,Eiger BioPharmaceuticals Announces Abstracts And Presentations Of Lonafarnib Data In Hepatitis Delta At The European Association For The Study Of The Liver (EASL) Meeting
2016-03-28,Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation For Ubenimex In Pulmonary Arterial Hypertension By European Medicines Agency
,
,
,
,
,
2017-03-06,Eiger BioPharmaceuticals To Present At The ROTH And Oppenheimer Investor Conferences In March 2017
2017-01-30,Eiger BioPharmaceuticals To Present At BIO CEO & Investor Conference February 13th And Participate In SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th
2017-01-04,Eiger Completes $25 Million Debt Financing With Oxford Finance
2017-01-03,Eiger Announces First Patient Dosed In Open-Label Extension Of Phase 2 LIBERTY Study Of Ubenimex In Pulmonary Arterial Hypertension (PAH)
2016-12-12,Eiger Announces Multiple Advances In Exendin 9-39 Program For The Treatment Of Post-Bariatric Hypoglycemia (PBH)
2016-11-29,Eiger Updates Progress In Clinical Development Program For Exendin 9-39 To Treat Post-Bariatric Hypoglycemia (PBH)
2016-11-21,Eiger BioPharmaceuticals To Participate In Two Investor Conferences In November 2016
2016-11-14,Eiger Announces Additional LOWR HDV Program Data, Clinical And Regulatory Plans At The American Association For The Study Of Liver Diseases (AASLD) Meeting
2016-11-14,Eiger Announces Positive Phase 2 Data At The American Association For The Study Of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified With Lonafarnib Therapy In LOWR HDV Program
2016-10-24,Eiger BioPharmaceuticals Launches Nationwide Hepatitis Delta Virus (HDV) Campaign To Expand Awareness And Testing For HDV Infection
2016-10-19,Eiger Announces First Patient Dosed In Phase 2 Study Of Pegylated Interferon Lambda In Hepatitis D Virus (HDV) Infection
2016-10-17,Eiger Announces Orphan Designation Of Exendin 9-39 For Treatment Of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) From European Medicines Agency (EMA)
2016-10-13,Eiger Announces Abstracts And Presentations Of LOWR HDV Program At The American Association For The Study Of Liver Diseases (AASLD) Meeting
2016-09-07,Eiger Announces Completion of Dosing in Phase 2 LOWR HDV - 4 Study at Hannover Medical School
2016-09-06,Eiger BioPharmaceuticals to Present at the BioCentury NewsMakers in the Biotech Industry Conference on September 9th
2016-09-01,Eiger BioPharmaceuticals To Present At The 5th Annual Liolios Gateway Conference On September 7, 2016
2016-08-18,Eiger BioPharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2016-08-17,Eiger BioPharmaceuticals Announces Proposed Public Offering Of Common Stock
2016-08-08,Eiger BioPharmaceuticals To Present At The 2016 Wedbush PacGrow Healthcare Conference On August 17th
2016-07-25,Eiger BioPharmaceuticals Announces First Patient Dosed In Phase 2 ULTRA Study Of Ubenimex In Secondary Lymphedema
2016-07-18,Eiger BioPharmaceuticals Announces First Patient Dosed In Phase 2 LIBERTY Study Of Ubenimex In Pulmonary Arterial Hypertension
2016-06-13,Eiger Announces Positive Clinical Results Of Single Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Post-Bariatric Hypoglycemia
2016-05-10,Eiger Announces First Patient Dosed In Phase 2 Multiple Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Hypoglycemia Post-Gastric Bypass Surgery
2016-05-03,Eiger Bio Strengthens Senior Management Team With Announcement Of Debra Odink, PhD As Senior Vice President Of Technical Operations
2016-04-20,Eiger BioPharmaceuticals Announces License Of Worldwide Rights To Pegylated Interferon Lambda-1a From Bristol-Myers Squibb
2016-04-04,Eiger BioPharmaceuticals Strengthens Board Of Directors With Addition Of Industry Veteran Charles J. "Chuck" Bramlage
2016-03-30,Eiger BioPharmaceuticals Announces Abstracts And Presentations Of Lonafarnib Data In Hepatitis Delta At The European Association For The Study Of The Liver (EASL) Meeting
2016-03-28,Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation For Ubenimex In Pulmonary Arterial Hypertension By European Medicines Agency
,
,
,
,
,
2017-03-06,Eiger BioPharmaceuticals To Present At The ROTH And Oppenheimer Investor Conferences In March 2017
2017-01-30,Eiger BioPharmaceuticals To Present At BIO CEO & Investor Conference February 13th And Participate In SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th
2017-01-04,Eiger Completes $25 Million Debt Financing With Oxford Finance
2017-01-03,Eiger Announces First Patient Dosed In Open-Label Extension Of Phase 2 LIBERTY Study Of Ubenimex In Pulmonary Arterial Hypertension (PAH)
2016-12-12,Eiger Announces Multiple Advances In Exendin 9-39 Program For The Treatment Of Post-Bariatric Hypoglycemia (PBH)
2016-11-29,Eiger Updates Progress In Clinical Development Program For Exendin 9-39 To Treat Post-Bariatric Hypoglycemia (PBH)
2016-11-21,Eiger BioPharmaceuticals To Participate In Two Investor Conferences In November 2016
2016-11-14,Eiger Announces Additional LOWR HDV Program Data, Clinical And Regulatory Plans At The American Association For The Study Of Liver Diseases (AASLD) Meeting
2016-11-14,Eiger Announces Positive Phase 2 Data At The American Association For The Study Of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified With Lonafarnib Therapy In LOWR HDV Program
2016-10-24,Eiger BioPharmaceuticals Launches Nationwide Hepatitis Delta Virus (HDV) Campaign To Expand Awareness And Testing For HDV Infection
2016-10-19,Eiger Announces First Patient Dosed In Phase 2 Study Of Pegylated Interferon Lambda In Hepatitis D Virus (HDV) Infection
2016-10-17,Eiger Announces Orphan Designation Of Exendin 9-39 For Treatment Of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) From European Medicines Agency (EMA)
2016-10-13,Eiger Announces Abstracts And Presentations Of LOWR HDV Program At The American Association For The Study Of Liver Diseases (AASLD) Meeting
2016-09-07,Eiger Announces Completion of Dosing in Phase 2 LOWR HDV - 4 Study at Hannover Medical School
2016-09-06,Eiger BioPharmaceuticals to Present at the BioCentury NewsMakers in the Biotech Industry Conference on September 9th
2016-09-01,Eiger BioPharmaceuticals To Present At The 5th Annual Liolios Gateway Conference On September 7, 2016
2016-08-18,Eiger BioPharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2016-08-17,Eiger BioPharmaceuticals Announces Proposed Public Offering Of Common Stock
2016-08-08,Eiger BioPharmaceuticals To Present At The 2016 Wedbush PacGrow Healthcare Conference On August 17th
2016-07-25,Eiger BioPharmaceuticals Announces First Patient Dosed In Phase 2 ULTRA Study Of Ubenimex In Secondary Lymphedema
2016-07-18,Eiger BioPharmaceuticals Announces First Patient Dosed In Phase 2 LIBERTY Study Of Ubenimex In Pulmonary Arterial Hypertension
2016-06-13,Eiger Announces Positive Clinical Results Of Single Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Post-Bariatric Hypoglycemia
2016-05-10,Eiger Announces First Patient Dosed In Phase 2 Multiple Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Hypoglycemia Post-Gastric Bypass Surgery
2016-05-03,Eiger Bio Strengthens Senior Management Team With Announcement Of Debra Odink, PhD As Senior Vice President Of Technical Operations
2016-04-20,Eiger BioPharmaceuticals Announces License Of Worldwide Rights To Pegylated Interferon Lambda-1a From Bristol-Myers Squibb
2016-04-04,Eiger BioPharmaceuticals Strengthens Board Of Directors With Addition Of Industry Veteran Charles J. "Chuck" Bramlage
2016-03-30,Eiger BioPharmaceuticals Announces Abstracts And Presentations Of Lonafarnib Data In Hepatitis Delta At The European Association For The Study Of The Liver (EASL) Meeting
2016-03-28,Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation For Ubenimex In Pulmonary Arterial Hypertension By European Medicines Agency
,
,
,
,
,
2017-03-06,Eiger BioPharmaceuticals To Present At The ROTH And Oppenheimer Investor Conferences In March 2017
2017-01-30,Eiger BioPharmaceuticals To Present At BIO CEO & Investor Conference February 13th And Participate In SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th
2017-01-04,Eiger Completes $25 Million Debt Financing With Oxford Finance
2017-01-03,Eiger Announces First Patient Dosed In Open-Label Extension Of Phase 2 LIBERTY Study Of Ubenimex In Pulmonary Arterial Hypertension (PAH)
2016-12-12,Eiger Announces Multiple Advances In Exendin 9-39 Program For The Treatment Of Post-Bariatric Hypoglycemia (PBH)
2016-11-29,Eiger Updates Progress In Clinical Development Program For Exendin 9-39 To Treat Post-Bariatric Hypoglycemia (PBH)
2016-11-21,Eiger BioPharmaceuticals To Participate In Two Investor Conferences In November 2016
2016-11-14,Eiger Announces Additional LOWR HDV Program Data, Clinical And Regulatory Plans At The American Association For The Study Of Liver Diseases (AASLD) Meeting
2016-11-14,Eiger Announces Positive Phase 2 Data At The American Association For The Study Of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified With Lonafarnib Therapy In LOWR HDV Program
2016-10-24,Eiger BioPharmaceuticals Launches Nationwide Hepatitis Delta Virus (HDV) Campaign To Expand Awareness And Testing For HDV Infection
2016-10-19,Eiger Announces First Patient Dosed In Phase 2 Study Of Pegylated Interferon Lambda In Hepatitis D Virus (HDV) Infection
2016-10-17,Eiger Announces Orphan Designation Of Exendin 9-39 For Treatment Of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) From European Medicines Agency (EMA)
2016-10-13,Eiger Announces Abstracts And Presentations Of LOWR HDV Program At The American Association For The Study Of Liver Diseases (AASLD) Meeting
2016-09-07,Eiger Announces Completion of Dosing in Phase 2 LOWR HDV - 4 Study at Hannover Medical School
2016-09-06,Eiger BioPharmaceuticals to Present at the BioCentury NewsMakers in the Biotech Industry Conference on September 9th
2016-09-01,Eiger BioPharmaceuticals To Present At The 5th Annual Liolios Gateway Conference On September 7, 2016
2016-08-18,Eiger BioPharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2016-08-17,Eiger BioPharmaceuticals Announces Proposed Public Offering Of Common Stock
2016-08-08,Eiger BioPharmaceuticals To Present At The 2016 Wedbush PacGrow Healthcare Conference On August 17th
2016-07-25,Eiger BioPharmaceuticals Announces First Patient Dosed In Phase 2 ULTRA Study Of Ubenimex In Secondary Lymphedema
2016-07-18,Eiger BioPharmaceuticals Announces First Patient Dosed In Phase 2 LIBERTY Study Of Ubenimex In Pulmonary Arterial Hypertension
2016-06-13,Eiger Announces Positive Clinical Results Of Single Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Post-Bariatric Hypoglycemia
2016-05-10,Eiger Announces First Patient Dosed In Phase 2 Multiple Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Hypoglycemia Post-Gastric Bypass Surgery
2016-05-03,Eiger Bio Strengthens Senior Management Team With Announcement Of Debra Odink, PhD As Senior Vice President Of Technical Operations
2016-04-20,Eiger BioPharmaceuticals Announces License Of Worldwide Rights To Pegylated Interferon Lambda-1a From Bristol-Myers Squibb
2016-04-04,Eiger BioPharmaceuticals Strengthens Board Of Directors With Addition Of Industry Veteran Charles J. "Chuck" Bramlage
2016-03-30,Eiger BioPharmaceuticals Announces Abstracts And Presentations Of Lonafarnib Data In Hepatitis Delta At The European Association For The Study Of The Liver (EASL) Meeting
2016-03-28,Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation For Ubenimex In Pulmonary Arterial Hypertension By European Medicines Agency
,
,
,
,
,
2017-03-21,Biotech Premarket Movers: Esperion, Minerva and BioCryst
2017-03-20,How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More
2017-03-20,Biotechs Remain the Best Place For Stock Picking
2017-03-20,Biotech Premarket Movers: CytomX, Aevi, Esperion
2017-03-20,Esperion Announces FDA Confirmation Regarding Regulatory Pathway To Approval For An LDL-C Lowering Indication For Bempedoic Acid
2017-03-17,AveXis, Esperion and Amgen Among Biotech Movers
2017-03-07,Esperion Announces Initiation Of Phase 2 Triplet Oral Therapy Study Of Bempedoic Acid/Ezetimibe/Atorvastatin
2017-03-06,Esperion Announces Oral Presentation On Genetic Validation Of ATP Citrate Lyase Inhibition At The American College Of Cardiology 66th Annual Scientific Session
2017-02-28,PaylPal, CH Robinson Worldwide, Texas Instruments: 'Mad Money' Lightning Round
2017-02-28,Here's Why Buffett Is So Bullish About This Market: Cramer's 'Mad Money' Recap (Monday 2/27/17)
2017-02-22,First Week of April 21st Options Trading For Esperion Therapeutics
2017-02-22,Esperion Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter And Full Year 2016 Financial Results
2017-02-15,Esperion To Participate In Fireside Chat At RBC Capital Markets Global Healthcare Conference
2017-02-07,Esperion Therapeutics Reaches Analyst Target Price
2017-02-03,Premarket Biotech Movers: Portola, Esperion, Medicines
2017-01-25,Esperion Completes Enrollment Of Pivotal Phase 3 Long-Term Safety And Tolerability Study Of Bempedoic Acid In Patients With Hypercholesterolemia
2017-01-11,Notable Two Hundred Day Moving Average Cross - ESPR
2017-01-09,Esperion Announces Initiation Of Global Cardiovascular Outcomes Trial For Bempedoic Acid
2017-01-08,Esperion Announces Initiation Of Three Pivotal Phase 3 Studies For Bempedoic Acid
2017-01-06,Commit To Buy Esperion Therapeutics At $11, Earn 24.7% Annualized Using Options
2017-01-04,Esperion To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-19,Bullish Two Hundred Day Moving Average Cross - ESPR
2016-11-29,ESPR: Insiders vs. Shorts
2016-11-28,Esperion Therapeutics Announces Publication Of Definitive Paper On Bempedoic Acid Mechanism Of Action In Nature Communications
2016-11-09,Esperion Therapeutics To Present At The Stifel 2016 Healthcare Conference
2016-11-03,Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Third Quarter 2016 Financial Results
2016-11-01,Esperion Therapeutics To Present At The Credit Suisse 25th Annual Healthcare Conference
2016-10-13,Bempedoic Acid Global Phase 3 Clinical Program To Include Patients On Any Statin At Any Dose
2016-09-23,7 Unusual-Volume Stocks That Are About to Break Out
2016-08-31,ESPR: Insiders vs. Shorts
2016-08-04,Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Second Quarter 2016 Financial Results
2016-07-15,It's Time to Bring the Heat
2016-07-08,These 5 Stocks Are Breaking Out
2016-07-07,Commit To Purchase Esperion Therapeutics At $8, Earn 28.2% Annualized Using Options
2016-06-28,Esperion Falls on Regulatory Setback for Cholesterol-Lowering Pill
2016-06-28,Esperion Therapeutics Provides Clinical Development And Regulatory Update For Bempedoic Acid
2016-06-01,ESPR: Insiders vs. Shorts
2016-05-04,Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2016 Financial Results
2016-04-08,Commit To Buy Esperion Therapeutics At $13, Earn 23.5% Annualized Using Options
2016-03-11,INVESTOR DEADLINE: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Esperion Therapeutics, Inc.
2016-03-08,Esperion Therapeutics To Present At The Barclays Global Healthcare Conference
2016-03-08,Scott + Scott, LLP Notifies Investors That Monday, March 14, 2016 Is Last Day To File Lead Plaintiff Papers In Esperion Therapeutics (ESPR) Securities Case
2016-03-08,INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Esperion Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of March 14, 2016 - ESPR
2016-03-07,Scott + Scott, LLP Notifies Investors Of Monday, March 14, 2016 Deadline In Esperion Therapeutics (ESPR) Securities Case
2016-03-04,SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Esperion Therapeutics, Inc.
2016-03-03,Scott + Scott, LLP Notifies Investors Of Monday, March 14, 2016 Deadline In Esperion Therapeutics (ESPR) Securities Case
2016-03-02,ESPR: Insiders vs. Shorts
2016-03-02,Scott + Scott, LLP Reminds Investors Of Monday, March 14, 2016 Deadline To File Lead Plaintiff Papers In Esperion Therapeutics (ESPR) Securities Case
2016-02-26,The Former Attorney General Of Louisiana & Kahn Swick & Foti, LLC Remind Large Investors Of Lead Plaintiff Deadline In Class Action Lawsuit Against Esperion Therapeutics, Inc. - ESPR
2016-02-26,INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Esperion Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of March 14, 2016
2016-02-25,Esperion Therapeutics Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter And Full Year 2015 Financial Results
2016-02-23,ESPERION INVESTORS NOTICE: Lieff Cabraser Reminds Investors Of Deadline In Class Action Against Esperion Therapeutics, Inc.
2016-02-23,SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notify Investors Of Class Action Lawsuit Involving Esperion Therapeutics, Inc. And A Lead Plaintiff Deadline Of March 14, 2016
2016-02-22,SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Esperion Therapeutics, Inc. - ESPR
2016-02-19,INVESTOR ALERT: The Law Offices Of Vincent Wong Notify Investors Of Class Action Lawsuit Involving Esperion Therapeutics, Inc. And A Lead Plaintiff Deadline Of March 14, 2016 - ESPR
2016-02-16,Esperion Therapeutics To Present At The 2016 RBC Capital Markets Global Healthcare Conference
2016-02-16,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Esperion Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of March 14, 2016
2016-02-14,UPCOMING DEADLINE ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Esperion Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2016-02-10,SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notify Investors Of Class Action Involving Esperion Therapeutics, Inc. And A Lead Plaintiff Deadline Of March 14, 2016
2016-02-09,ESPERION INVESTORS ALERT: Lieff Cabraser Reminds Investors Of Deadline In Class Action Against Esperion Therapeutics, Inc.
2016-02-09,SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Esperion Therapeutics, Inc. To Contact The Firm Before Upcoming Lead Plaintiff Deadline
2016-02-05,5 Stocks Ready for Breakouts
2016-02-02,Investor Alert: Peiffer Rosca Wolf Law Firm Announces Filing Of A Shareholder Class Action Against Esperion Therapeutics, Inc. ("Esperion" Or "Company") (NASDAQ: ESPR) In The U.S. District Court For The Eastern District Of Michigan.
2016-02-01,Investor Alert: Peiffer Rosca Wolf Law Firm Announces Filing Of A Shareholder Class Action Against Esperion Therapeutics, Inc. ("Esperion" Or "Company") (NASDAQ: ESPR) In The U.S. District Court For The Eastern District Of Michigan
2016-02-01,ESPR INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Esperion Therapeutics, Inc.
2016-01-25,INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Esperion Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2016-01-22,Investor Alert: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against Esperion Therapeutics, Inc. And Encourages Investors To Contact The Firm Before The Deadline
2016-01-22,STOCK ALERT: Rosen Law Firm Reminds Esperion Therapeutics, Inc. Investors Of Important Deadline In Class Action
2016-01-19,Esperion Therapeutics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors
2016-01-16,IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Esperion Therapeutics, Inc. And Encourages Investors With Losses To Contact The Firm
2016-01-15,The Former Attorney General Of Louisiana & Kahn Swick & Foti, LLC Remind Large Investors Of Lead Plaintiff Deadline In Class Action Lawsuit Against Esperion Therapeutics, Inc.
2016-01-14,Shareholder Class Action Filed Against Esperion Therapeutics, Inc. - ESPR
2016-01-14,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Esperion Therapeutics, Inc. - ESPR
2016-01-14,Law Offices Of Marc S. Henzel Announces Investigation Of Companies For Violations Of The Federal Securities Laws
2016-01-13,Lifshitz & Miller Law Firm Announces Investigation Of Anavex Life Sciences Corp., Esperion Therapeutics, Inc., Fitbit Inc., KLX, Inc., Natural Health Trends Corp., Nimble Storage, Inc., And Straight Path Communications Inc.
2016-01-13,Kirby McInerney LLP Advises Esperion Therapeutics, Inc. Investors Of Potential Claims
2016-01-13,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against Esperion Therapeutics, Inc. (ESPR) And Lead Plaintiff Deadline March 14, 2016
2016-01-13,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Esperion Therapeutics, Inc. - ESPR
2016-01-13,Esperion Therapeutics Announces Initiation Of Phase 3 Clinical Program With Long-Term Safety And Tolerability Study
2016-01-12,Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Esperion Therapeutics, Inc.
2016-01-12,Esperion Therapeutics Announces Initiation Of Phase 2 Clinical Study Of Bempedoic Acid In Patients Treated With High-Dose Statin Therapy
2016-01-08,Commit To Purchase Esperion Therapeutics At $12, Earn 21.7% Annualized Using Options
2016-01-06,Esperion Therapeutics is Now Oversold (ESPR)
2016-01-06,Esperion Therapeutics To Present At 34th Annual J.P. Morgan Healthcare Conference
2016-01-06,Investor Alert: Investigation Of Esperion Therapeutics Announced By Holzer & Holzer, LLC
2015-11-13,'Mad Money' Lightning Round: Forget Revance, I Want Allergan
2015-11-12,Jim Cramer's 'Mad Money' Recap: There's Negative, and There's Too Negative
2015-10-12,Why Esperion Therapeutics (ESPR) Stock is Climbing Today
2015-10-12,Lilly Sinks as Cholesterol-Lowering Pill Trial Shut Down
2015-10-05,Relative Strength Alert For Esperion Therapeutics
2015-10-02,Amicus, Other Biotech CEOs Should Listen More, Talk Less About FDA Matters
2015-09-28,Interesting ESPR Put And Call Options For November 20th
2015-09-16,Amgen Adds Cholesterol-Lowering Pill to Pipeline With New Acquisition
2015-08-14,Commit To Buy Esperion Therapeutics At $55, Earn 35.3% Annualized Using Options
2015-08-14,Esperion Therapeutics Stock Sees Short Interest Move 19.6% Lower
2015-08-10,Scott Braunstein Joins Aisling Capital As Operating Partner
2015-07-30,This Market Lift Should Linger
2015-06-10,Jim Cramer -- Investors Should Be Patient on Regeneron Cholesterol Drug
2015-06-03,Where the Money Was Made the Last 5 Years
2015-04-01,The Top-Performing Biotech Stock During a Sizzling First Quarter
2015-03-20,Jim Cramer's Top Takeaways: Esperion Therapeutics, Platform Specialty Products
2015-03-19,Jim Cramer's 'Mad Money' Recap: The Markets Are Getting It All Wrong
2015-03-19,Esperion (ESPR) Stock Hits Another 52-Week High Today
2015-03-19,Jim Cramer's Top Takeaways: Starbucks, Magellan Mainstream, Regeneron
2015-03-18,Jim Cramer's 'Mad Money' Recap: The Fed Does the Right Thing
2015-03-18,Esperion (ESPR) Stock Hits 52-Week High on Analyst Upgrade - Jim Cramer Asks Where Profit-Takers Are
2015-03-17,Jim Cramer's 'Mad Money' Recap: This Maddening Market Can't Make Up Its Mind
2015-03-17,Cramer: Buy Bank of America, Citigroup if There's a Bounce in Stocks
2015-03-17,Esperion CEO Twitter Trolls His Larger, Cholesterol-Lowering Rivals
2015-03-10,'Mad Money' Lightning Round: Buy, Buy, Buy Spirit Airlines
2015-03-09,Jim Cramer's 'Mad Money' Recap: 6 Years of Market Gains, 10 Years of 'Mad Money'
2015-03-06,4 Big-Volume Stocks to Trade for Breakouts: Big Lots, Fresh Market and More
2015-02-03,Esperion Seen As Target After FDA Removes Hold On Cholesterol Drug Trial
2015-01-20,Eyes on the ECB
2015-01-16,Interesting ESPR Put And Call Options For February 20th
2015-01-15,Jim Cramer's Top Stock Picks: MNST ESPR CRL
2015-01-14,Jim Cramer's 'Mad Money' Recap: Will You Still Hate the Markets Tomorrow?
2015-01-06,Jim Cramer's 'Mad Money' Recap: Knowing Where to Look for Bargains
2015-01-05,Esperion Therapeutics To Present At 33rd Annual J.P. Morgan Healthcare Conference
2014-11-25,Commit To Buy Esperion Therapeutics At $25, Earn 26% Annualized Using Options
2014-11-12,Esperion Therapeutics To Present At Stifel 2014 Healthcare Conference
2014-11-11,Esperion Therapeutics To Host And Webcast Live Investor Event
2014-11-10,Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Third Quarter 2014 Financial Results
2014-11-05,Esperion Therapeutics To Present At Credit Suisse Healthcare Conference
2014-11-03,Esperion Therapeutics To Provide Third Quarter 2014 Results
2014-10-21,Esperion Therapeutics Announces Closing Of Follow-On Public Offering And Exercise In Full Of Underwriters’ Option To Purchase Additional Shares Of Common Stock
2014-10-15,Esperion Therapeutics Prices Public Offering Of Common Stock
2014-10-14,Esperion Therapeutics Announces Proposed Public Offering Of Common Stock
2014-10-07,It's True, Small-Cap Biotech Stocks Are Acting Badly These Days
2014-10-01,Why Esperion Therapeutics (ESPR) Stock Is Soaring in After-Hours Trading Today
2014-10-01,Esperion Therapeutics Announces Positive Top-Line Phase 2b Results For ETC-1002, An Investigational Therapy For Patients With Hypercholesterolemia
2014-09-22,Esperion Therapeutics To Present At BioCentury’s NewsMakers In The Biotech Industry Conference
2014-08-12,Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Second Quarter 2014 Financial Results
2014-08-05,Esperion Therapeutics To Provide Second Quarter 2014 Results
2014-08-04,4 Stocks Rising on Unusual Volume
2014-07-31,3 Biotech Stocks Breaking Out on Big Volume
2014-07-24,Esperion Therapeutics Announces Initiation Of A Phase 2 Clinical Study Of ETC-1002 In Patients With Hypercholesterolemia And Hypertension
2014-07-16,Esperion Therapeutics To Host Inaugural Analyst And Investor Day
2014-06-26,Esperion Therapeutics Announces The Appointment Of Gilbert S. Omenn, M.D., Ph.D. To Board Of Directors
2014-06-17,Esperion Therapeutics To Present At JMP Securities Healthcare Conference
2014-05-29,Esperion Therapeutics To Present At Jefferies 2014 Global Healthcare Conference
2014-05-12,Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports First Quarter 2014 Financial Results
2014-05-06,Esperion Therapeutics To Present At Bank Of America Merrill Lynch Healthcare Conference
2014-05-05,Esperion Therapeutics To Provide First Quarter 2014 Financial Results
2014-05-01,Esperion Therapeutics To Deliver Three Scientific Poster Presentations At The 2014 Annual Scientific Sessions Of The National Lipid Association
2014-03-24,Esperion Therapeutics To Present At BioCentury Future Leaders In The Biotech Industry Conference
2014-03-05,Esperion Therapeutics Provides ETC-1002 Program Update; Reports Fourth Quarter And Full Year 2013 Financial Results
2014-02-26,Esperion Therapeutics To Provide ETC-1002 Program Update; Fourth Quarter And Full Year 2013 Financial Results
2014-02-13,Esperion Therapeutics Names Mark E. McGovern, M.D., FACC, FACP, Director
2014-01-13,Esperion Therapeutics Announces The Appointment Of Antonio M. Gotto Jr., M.D., DPhil, As Director
2013-12-23,Esperion Therapeutics Added To The NASDAQ Biotechnology Index
2013-12-04,Relative Strength Alert For Esperion Therapeutics
2013-11-18,Esperion Therapeutics Presents Full Results Of Phase 2 Clinical Study Demonstrating That ETC-1002 Lowered LDL-C By An Average Of 32 Percent And Was Well Tolerated In Patients With Hypercholesterolemia And History Of Statin Intolerance
2013-11-11,Esperion Therapeutics Announces Oral Presentation On ETC-1002 At 2013 Scientific Sessions Of The American Heart Association
2013-11-06,Esperion Therapeutics Reports Third Quarter 2013 Financial Results And Provides Development Program Updates
2013-11-05,Esperion Therapeutics To Present At Credit Suisse Healthcare Conference
2013-10-30,Esperion Therapeutics Announces Initiation Of Phase 2b Clinical Study Of ETC-1002 In Patients With Or Without Statin Intolerance And Hypercholesterolemia
2013-09-24,Esperion Therapeutics To Present At BioCentury Newsmakers In The Biotech Industry Conference
2013-09-10,Esperion Therapeutics To Present At Stifel Nicolaus 2013 Healthcare Conference
2013-09-03,Esperion Therapeutics Announces Positive Top-Line Results From Phase 2 Clinical Study Of ETC-1002 As An Add-On To Statin Therapy In Patients With Hypercholesterolemia
2013-08-30,Esperion Therapeutics To Host Conference Call On September 3, 2013 To Announce Top-line Results From A Phase 2 Clinical Study Of ETC-1002 As An Add-On To Statin Therapy In Patients With Hypercholesterolemia
2013-08-12,Esperion Therapeutics Reports Second Quarter Financial Results And Provides Corporate Update
2013-07-11,Esperion Therapeutics, Inc. Announces Exercise Of Underwriters&#8217; Over-Allotment Option For Initial Public Offering
2013-06-26,NanoString Best BioTech IPO
2004-08-11,Fund Manager Sacane Sued by Short Over Wacky Stock Trades
2004-01-08,Another Company Settles With Sacane's Durus
2003-12-28,Weekend Reading: Not Your Typical Review
2003-12-23,Biotechs Benefit From Big Pharma's Buying Mood
2003-12-22,Terror Warning, Tremors Can't Derail the Dow
2003-12-22,Durus: How to Succeed in Stocks Without Really Trying
2003-12-22,Esperion Buyout Could Be Windfall for Sacane's Durus
2003-11-05,Stocks Close Mostly Lower
2003-11-04,Early Data Peek Puts Esperion Shares in a Jam
2003-11-04,Early Data Peek Puts Esperion Shares in a Jam
2003-10-27,Durus to Settle With Allos
2003-10-07,Now Novoste Sues Durus
2003-10-01,Durus Bails Out of Various Medical Holdings
2003-09-30,Appearance Is Everything at Quarter's End
2003-09-09,Screw Turning on Sacane at Durus Capital
2003-08-25,Another Company Sues Sacane, Durus
2017-03-06,Exelixis' Cabozantinib Granted Orphan Drug Designation For The Treatment Of Hepatocellular Carcinoma
2017-03-01,Exelixis Announces Webcasts Of Investor Conference Presentations In March
2017-02-28,Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2017-02-27,Exelixis Announces Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update
2017-02-27,Exelixis Announces Clinical Trial Collaboration With Roche To Evaluate Cabozantinib And Atezolizumab In Locally Advanced Or Metastatic Solid Tumors
2017-02-27,Exelixis And Bristol-Myers Squibb Enter Clinical Collaboration For Late-Stage Combination Trial In First-Line Renal Cell Carcinoma
2017-02-23,Incyte, Skyworks Solutions, Western Digital, Constellation Brands: 'Mad Money' Lightning Round
2017-02-23,What You Should Do if This Market Is Overvalued: Cramer's 'Mad Money' Recap (Wednesday 2/22/17)
2017-02-17,Exelixis Announces Phase 1 Trial Results For Cabozantinib In Combination With Nivolumab With Or Without Ipilimumab In Refractory Metastatic Urothelial Carcinoma And Other Genitourinary Tumors
2017-02-13,Morgan Stanley, Twitter, Tesaro: Doug Kass' Views
2017-02-07,Exelixis To Present At The Leerink Partners Global Healthcare Conference On February 15
2017-02-07,Banks, Oil, Deregulation and Your Investments: Cramer's 'Mad Money' Recap (Monday 2/6/17)
2017-02-06,Box, Nucor, Exelixis, American Airlines and more: 'Mad Money' Lightning Round
2017-02-03,Hopes for Tax Reform, Less Regulation Lift Indices
2017-02-02,Exelixis To Release Fourth Quarter And Full Year 2016 Financial Results On Monday, February 27, 2017
2017-01-31,Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2017-01-30,Exelixis And Takeda Enter Into Exclusive Licensing Agreement To Commercialize And Develop Novel Cancer Therapy Cabozantinib In Japan
2017-01-29,The Next Target in Biotech Land
2017-01-27,The Next Target in Biotech Land
2017-01-18,Home Depot, Marathon Petroleum, Huntsman: 'Mad Money' Lightning Round
2017-01-18,Investors Need a Strong Stomach as Trump Tweets: Cramer's 'Mad Money' Recap (Tuesday 1/17/17)
2017-01-10,4 Biotech Names That Could Be M&amp;A Targets
2017-01-09,Update On Dispute Between Exelixis And Genentech, A Member Of The Roche Group
2017-01-03,Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2016-12-21,Exelixis And Ipsen Amend Exclusive Licensing Agreement For The Commercialization And Development Of Cabozantinib To Include Canada
2016-12-19,The Best Biopharma CEOs of 2016 Are...
2016-12-07,Exelixis Announces Leadership Hires In Public Affairs And Business Development To Support Growth Of Company And Pipeline
2016-12-02,Look at Silver Miners and Some Names That Have Pulled Back
2016-11-30,Exelixis To Present At The BMO Prescription For Success Healthcare Conference On December 14
2016-11-29,Shark Bites: Eager Buyers Pounce on Pullback
2016-11-23,Biotech School: How to Use Kaplan-Meier Survival Curves to Become a Smarter Investor
2016-11-22,How to Be a Smarter Biotech Investor
2016-11-21,Exelixis To Present At The Piper Jaffray 28th Annual Healthcare Conference On November 29
2016-11-07,Exelixis To Present At The Stifel 2016 Healthcare Conference On November 15
2016-11-07,Exelixis Announces Presentation Of Cobimetinib Combination Therapy Data At The Society For Melanoma Research 2016 Congress That Support Genentech's Planned Phase 3 Pivotal Trials
2016-11-04,Exelixis (EXEL) Stock Gains on Q3 Results
2016-11-03,Exelixis Announces Third Quarter And Year To Date 2016 Financial Results And Provides Corporate Update
2016-10-20,Exelixis To Release Third Quarter 2016 Financial Results On Thursday, November 3, 2016
2016-10-10,Exelixis Announces Positive Results From Phase 2 CABOSUN Trial Of Cabozantinib Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma Presented At ESMO 2016
2016-10-07,Exelixis Announces Genentech Presentation Of Preliminary Phase 1b Results For The Combination Of Cobimetinib, Vemurafenib And Atezolizumab At ESMO 2016 Congress
2016-10-07,Exelixis Announces Phase 1 Trial Results For Cabozantinib In Combination With Nivolumab In Advanced Genitourinary Tumors
2016-10-03,Exelixis And Ipsen To Host Investor And Media Briefing To Discuss Data Presented At The ESMO 2016 Congress
2016-09-28,Exelixis (EXEL) Stock Plummets on Cancer Drug Trial Results, Leerink: Selloff Overdone
2016-09-26,Exelixis Elects Julie Anne Smith To Its Board Of Directors
2016-09-26,Exelixis Announces Collaborator Daiichi Sankyo's Initiation Of Phase 3 Clinical Development For CS-3150, A Selective Mineralocorticoid Receptor Antagonist
2016-09-23,'Mad Money' Lightning Round: Don't Sell Scripps
2016-09-22,Jim Cramer's 'Mad Money' Recap: Tune Out the Fed, Focus on What Matters
2016-09-20,Exelixis Provides Update On Timing Of Key Cabozantinib Clinical Data Presentation At The ESMO 2016 Congress
2016-09-20,2 Bullish Stock Picks and 2 Stocks to Sell Short
2016-09-14,Exelixis (EXEL) Stock Advances, EC Approves Kidney Cancer Drug
2016-09-14,European Commission Approves CABOMETYX™ (cabozantinib) Tablets For The Treatment Of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy
2016-09-06,Exelixis Announces Outcome From First Planned Interim Analysis Of The Phase 3 CELESTIAL Trial Of Cabozantinib In Patients With Advanced Hepatocellular Carcinoma
2016-08-31,Exelixis To Present At The Morgan Stanley Global Healthcare Conference On September 13
2016-08-31,Exelixis-discovered Compounds To Be Featured In 15 Presentations At The ESMO 2016 Congress
2016-08-25,Exelixis Stock Sees Short Interest Decrease By 29.7%
2016-08-24,Exelixis Announces Redemption Of All Remaining 4.25% Convertible Senior Subordinated Notes Due 2019
2016-08-23,4 Biotech Stock Charts You Must See
2016-08-11,3 Biotech-Investing Mistakes to Avoid
2016-08-05,Trade-Ideas: Exelixis (EXEL) Is Today's "Perilous Reversal" Stock
2016-08-04,Why Exelixis (EXEL) Stock Is Soaring Today
2016-08-04,Don't Roll the Dice on Central Bank News
2016-08-03,Exelixis Announces Second Quarter And Year To Date 2016 Financial Results And Provides Corporate Update
2016-07-28,4 Tech and Biotech Stocks With Momentum to Watch
2016-07-12,Exelixis To Release Second Quarter 2016 Financial Results On Wednesday, August 3, 2016
2016-07-08,Biotech Stock Mailbag: Heron, Exelixis
2016-06-15,'Mad Money' Lightning Round: I'm Sticking With Wells Fargo
2016-06-14,Jim Cramer's 'Mad Money' Recap: We've Seen This 'Brexit' Movie Before
2016-06-09,Trade-Ideas: Exelixis (EXEL) Is Today's Strong On High Relative Volume Stock
2016-06-07,Today's Perilous Reversal Stock: Exelixis (EXEL)
2016-06-06,Exelixis (EXEL) Stock Gains on Positive Trial Results for Kidney Cancer Treatment
2016-06-06,Exelixis And Its Partner Ipsen Announce Positive Overall Survival Results From Subgroup Analyses Of Phase 3 Trial Of CABOMETYX™ (cabozantinib) Tablets In Advanced Renal Cell Carcinoma At 2016 ASCO Annual Meeting
2016-06-06,Exelixis And Its Partner Ipsen Announce Positive Overall Survival Results From Subgroup Analyses Of Phase 3 Trial Of CABOMETYX™ (cabozantinib) Tablets In Advanced Renal Cell Carcinoma At 2016 ASCO Annual Meeting
2016-06-05,Exelixis And Its Partner Ipsen Announce Phase 3 Trial Results Of CABOMETYX™ (Cabozantinib) Tablets Demonstrating Significant Overall Survival Benefit For Previously Treated Patients With Advanced Renal Cell Carcinoma Presented At ASCO
2016-06-05,Exelixis Announces Genentech Presentation Of Preliminary Phase 1B Trial Results For The Combination Of Cobimetinib And Atezolizumab At ASCO 2016 Annual Meeting
2016-05-23,Strong On High Volume: Exelixis (EXEL)
2016-05-23,Exelixis Announces Results From Randomized Phase 2 Trial CABOSUN Demonstrate Cabozantinib Significantly Improved Progression-Free Survival Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma
2016-05-16,Exelixis (EXEL) Showing Signs Of Perilous Reversal Today
2016-05-05,Exelixis To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference On May 10
2016-05-04,Exelixis Announces First Quarter 2016 Financial Results And Provides Corporate Update
2016-04-26,Exelixis To Release First Quarter 2016 Financial Results On Wednesday, May 4, 2016
2016-04-25,CABOMETYX™ 60 Mg Tablets
2016-04-20,Exelixis-Discovered Compounds To Be Featured In 18 Presentations At 2016 ASCO Annual Meeting
2016-04-04,Exelixis (EXEL) Stock Climbs, Stifel Upgrades
2016-03-03,Exelixis To Present At Two Investor Conferences In March
2016-03-01,Exelixis (EXEL) Stock Climbs on Q4 Results
2016-02-29,Exelixis Announces Fourth Quarter And Full Year 2015 Financial Results And Provides Corporate Update
2016-02-29,Exelixis And Ipsen Enter Into Exclusive Licensing Agreement To Commercialize And Develop Novel Cancer Therapy Cabozantinib In Regions Outside The United States, Canada And Japan
2016-02-15,Exelixis To Release Fourth Quarter And Full Year 2015 Financial Results On Monday, February 29, 2016
2016-02-04,Exelixis To Present At The Leerink Partners 5th Annual Global Healthcare Conference On February 10
2016-02-01,Exelixis Kidney Cancer Survival Benefit Doesn't Address Competitive Question
2016-02-01,Exelixis Announces Positive Overall Survival Results From METEOR, The Phase 3 Pivotal Trial Of Cabozantinib In Advanced Renal Cell Carcinoma
2016-01-28,Exelixis Announces European Medicines Agency Acceptance Of Marketing Authorization Application For Cabozantinib As A Treatment For Advanced Renal Cell Carcinoma
2016-01-28,Exelixis Announces U.S. FDA Deems New Drug Application Sufficiently Complete And Grants Priority Review For Cabozantinib As A Treatment For Advanced Renal Cell Carcinoma
2016-01-20,'Mad Money' Lightning Round: Move on From Broadcom
2016-01-19,Jim Cramer's 'Mad Money' Recap: Wait for Weakness, Then Pounce
2016-01-11,Exelixis Submits Marketing Authorization Application In The European Union For Cabozantinib As A Treatment For Advanced Renal Cell Carcinoma
2016-01-04,Exelixis Announces Positive Results From Subgroup Analyses Of The METEOR Phase 3 Pivotal Trial Of Cabozantinib In Advanced Renal Cell Carcinoma To Be Presented At ASCO 2016 Genitourinary Cancers Symposium
2015-12-23,Exelixis (EXEL) Stock Spikes, Submits New Drug Application
2015-12-23,Exelixis Completes Submission Of New Drug Application For Cabozantinib For The Treatment Of Advanced Renal Cell Carcinoma
2015-11-25,Exelixis Announces European Commission Approval Of COTELLIC™ (Cobimetinib) For Use In Combination With Vemurafenib In Advanced BRAF V600 Mutation-Positive Melanoma
2015-11-21,Exelixis Announces Presentation Of Positive Overall Survival Results For COTELLIC™ In Combination With Vemurafenib In Advanced BRAF V600 Mutation-Positive Melanoma At Society For Melanoma Research 2015 International Congress
2015-11-12,Exelixis To Present At The Stifel 2015 Healthcare Conference On Tuesday, November 17
2015-11-11,Exelixis (EXEL) Stock Dropped Following Earnings Release
2015-11-10,Exelixis (EXEL) Stock Declines in After-Hours Trading on Quarterly Loss
2015-11-10,Exelixis Announces Third Quarter 2015 Financial Results And Provides Corporate Update
2015-11-10,FDA Approves COTELLIC™ (Cobimetinib) For Use In Combination With Vemurafenib To Treat Advanced Melanoma
2015-10-22,Exelixis Initiates Rolling Submission Of U.S. New Drug Application For Cabozantinib For The Treatment Of Advanced Kidney Cancer
2015-10-20,Exelixis To Release Third Quarter 2015 Financial Results On Tuesday, November 10, 2015
2015-10-06,Exelixis Announces Positive Overall Survival Results From Phase 3 Pivotal Trial Of Cobimetinib In Combination With Vemurafenib In Patients With BRAF V600 Mutation-Positive Advanced Melanoma
2015-09-30,10 Best Nasdaq Biotech Stocks in the Third Quarter
2015-09-29,4 Stocks Under $10 Making Big Moves Higher
2015-09-25,Exelixis Announces Positive Results From METEOR Phase 3 Pivotal Trial Of Cabozantinib In Advanced Renal Cell Carcinoma Presented At European Cancer Congress 2015
2015-09-25,Bristol, Exelixis Drugs Demonstrate Treatment Benefit in Kidney Cancer
2015-09-25,European CHMP Adopts Positive Opinion For Cobimetinib In Combination With Vemurafenib For The Treatment Of Advanced Melanoma
2015-09-24,Exelixis Announces Key Senior Leadership Hires In Medical Affairs, Sales, And Marketing To Support Commercialization Of Cabozantinib And Cobimetinib
2015-09-22,Exelixis To Host Investor/Analyst Webcast During European Cancer Congress 2015
2015-09-18,Biotech Stock Mailbag: Bristol, Exelixis, Lion Bio, GW Pharma
2015-09-16,'Mad Money' Lightning Round: Buy, Buy, Buy Bristol-Myers Squibb
2015-09-15,Jim Cramer's 'Mad Money' Recap: 6 Ways Markets Will Be Hit by a Rate Hike
2015-08-31,Interesting EXEL Put And Call Options For October 16th
2015-08-27,Exelixis (EXEL) Stock Climbs as Melanoma Treatment Gets Swiss Regulatory Approval
2015-08-27,Use Options For a Chance To Buy EXEL at a 58% Discount
2015-08-27,Exelixis Announces First Regulatory Approval Of Cobimetinib In Switzerland
2015-08-24,Data From METEOR Pivotal Trial Of Cabozantinib In Advanced Renal Cell Carcinoma Accepted As Late-Breaker Presentation In Presidential Session At European Cancer Congress 2015
2015-08-24,FDA Grants Breakthrough Therapy Designation To Exelixis' Cabozantinib For The Treatment Of Renal Cell Carcinoma In Patients Who Received One Prior Therapy
2015-08-21,'Mad Money' Lightning Round: I'm Staying Away From Alibaba
2015-08-20,Jim Cramer's 'Mad Money' Recap: Market Slaughters Disney, With More to Come
2015-08-11,Exelixis Announces Second Quarter 2015 Financial Results And Provides Corporate Update
2015-08-04,'Mad Money' Lightning Round: Marriott International Is a Buy
2015-08-03,Jim Cramer's 'Mad Money' Recap: Why the Oil and China News Isn't All Bad
2015-07-28,Exelixis To Release Second Quarter 2015 Financial Results On Tuesday, August 11, 2015
2015-07-27,Exelixis (EXEL) Stock Falls on Upsized Secondary Offering
2015-07-24,How to Trade 4 of the Market's Most Active Stocks
2015-07-23,Exelixis Prices Public Offering Of Common Stock
2015-07-22,Exelixis (EXEL) Stock Declines on Secondary Public Offering
2015-07-21,Exelixis Launches Proposed Public Offering Of Common Stock
2015-07-20,Exelixis Scores Much-Needed Kidney Cancer Study Win to Boost Drug Sales
2015-07-20,Exelixis Announces Positive Top-Line Results From METEOR, The Phase 3 Pivotal Trial Of Cabozantinib Versus Everolimus In Patients With Metastatic Renal Cell Carcinoma
2015-07-15,Exelixis Appoints Chris Senner As Executive Vice President And Chief Financial Officer
2015-07-13,Exelixis Announces Start Of Phase 1 Trial Of Cabozantinib In Combination With Nivolumab Or Nivolumab Plus Ipilimumab In Patients With Advanced/Metastatic Urothelial Carcinoma And Other Genitourinary Tumors
2015-07-01,10 Best Biotech Stocks in the NASDAQ
2015-07-01,Exelixis Provides Update On Genentech's Pending New Drug Application For Cobimetinib, An Exelixis-Discovered Compound
2015-06-26,First Week Of EXEL February 2016 Options Trading
2015-06-26,Biotech Stock Mailbag: Exelixis, Puma Bio
2015-06-03,Where the Money Was Made the Last 5 Years
2015-05-31,Exelixis Announces Positive Results From Phase 2 Investigator-Sponsored Trial Of Cabozantinib In RET-Rearranged Non-Small Cell Lung Cancers
2015-05-31,Exelixis Announces Positive Results From Phase 2 Trial Of Cabozantinib In Patients With EGFR Wild-Type Non-Small Cell Lung Cancer
2015-05-30,Updated Positive Results From Two Trials Of Cobimetinib In Combination With Vemurafenib For The Treatment Of Patients With Advanced Melanoma Presented At 2015 ASCO Annual Meeting
2015-05-23,'Mad Money' Lightning Round: Buy Disney, Be Careful With Exelixis
2015-05-22,Jim Cramer's 'Mad Money' Recap: Here's My Game Plan for Next Week
2015-05-19,First Week Of EXEL July 17th Options Trading
2015-05-08,Exelixis (EXEL) Stock Spikes on First Quarter Earnings Report
2015-05-04,Exelixis To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference On May 12
2015-04-30,Cabozantinib And Cobimetinib To Be Featured In Fourteen Presentations At 2015 ASCO Annual Meeting
2015-04-30,Exelixis Announces First Quarter 2015 Financial Results And Provides Corporate Update
2015-04-16,Exelexis (EXEL) Is The 'Chart of the Day'
2015-04-09,Exelixis To Release First Quarter 2015 Financial Results On Thursday, April 30, 2015
2015-04-09,Exelixis (EXEL) Stock Rises Today Following FDA Fast Track Designation
2015-04-09,Exelixis' Cabozantinib Granted Fast Track Designation By FDA For Advanced Renal Cell Carcinoma
2015-03-12,Exelixis (EXEL) Highlighted As Weak On High Volume
2015-03-03,Exelixis (EXEL) In A Perilous Reversal
2015-02-26,Exelixis To Present At The Cowen And Company 35th Annual Health Care Conference On Tuesday, March 3
2015-02-24,Exelixis Announces Fourth Quarter And Full Year 2014 Financial Results And Provides Corporate Update
2015-02-19,Exelixis Announces Acceptance Of New Drug Application For Cobimetinib In Combination With Vemurafenib For Treatment Of Patients With BRAF V600 Mutation-Positive Advanced Melanoma
2015-02-11,Exelixis (EXEL) Is Today's Strong On High Volume Stock
2015-02-10,4 Biotech Stocks Under $10 Triggering Breakouts: Amarin, Exelixis and More
2015-02-02,Exelixis To Release Fourth Quarter And Full Year 2014 Financial Results On Tuesday, February 24, 2015
2015-01-29,Exelixis To Present At The Leerink Global Healthcare Conference On Wednesday, February 11
2015-01-28,Exelixis (EXEL) Flagged As Strong On High Volume
2015-01-08,Exelixis (EXEL) Is Today's Strong On High Volume Stock
2015-01-07,Exelixis And Swedish Orphan Biovitrum AB (Sobi) Extend And Restructure Distribution Agreement For COMETRIQ® For Medullary Thyroid Cancer
2014-12-15,Exelixis' Collaborator Genentech Files New Drug Application For The Combination Of Cobimetinib And Vemurafenib For The Treatment Of Patients With BRAF V600 Mutation-Positive Advanced Melanoma
2014-12-01,Future of Exelixis Cancer Drug Dims Further With Second Failed Prostate Cancer Study
2014-12-01,Exelixis Announces Results From The COMET-2 Pivotal Phase 3 Trial Of Cabozantinib In Men With Metastatic Castration-Resistant Prostate Cancer
2014-11-25,Exelixis To Present At The Piper Jaffray 26th Annual Healthcare Conference On Tuesday, December 2
2014-11-16,Exelixis Announces Positive Preliminary Data From An Investigator-Sponsored Phase 1 Trial Of XL888 And Vemurafenib
2014-11-11,Exelixis To Present At The Stifel 2014 Healthcare Conference On Tuesday, November 18
2014-11-06,Exelixis Completes Enrollment Of The METEOR Phase 3 Pivotal Trial Of Cabozantinib In Metastatic Renal Cell Carcinoma
2014-11-04,Exelixis Announces Positive Top-Line Results From A Phase 2 Trial Of Cabozantinib And Erlotinib In Patients With EGFR Wild-Type Non-Small Cell Lung Cancer
2014-11-04,Exelixis Announces Third Quarter 2014 Financial Results And Provides Corporate Update
2017-03-13,EyeGate Pharma Strengthens Scientific Advisory Board With Appointments Of Daniel S. Durrie, M.D. And Randall J. Olson, M.D.
2017-02-23,EyeGate Pharmaceuticals Reports Full-year 2016 Financial Results And Provides Business Update
2017-02-21,Valeant Acquires Eyegate Licensing Rights
2017-02-21,Stocks Trade Above Records as Crude Rally Boosts Energy
2017-02-21,Dow Higher for Eighth Straight Session as Retailers Rise
2017-02-21,Stock Futures Rise After Walmart, Home Depot Top Earnings Estimates
2017-02-06,EyeGate Pharmaceuticals Announces Executive Promotions
2017-01-30,EyeGate Pharma Announces Positive Top-line Data From First-in-Human Pilot Trial Of Ocular Bandage Gel In Corneal Epithelial Defects
2017-01-24,EyeGate Pharmaceuticals To Present At The Noble Financial Capital Markets' 13th Annual Investor Conference
2017-01-23,EyeGate Pharma Awarded Canadian Patent For Proprietary Iontophoretic Formulation And Use Of The Formulation For Ocular Delivery Of Dexamethasone Phosphate
2017-01-09,EyeGate Receives Additional Milestone Payment From Valeant Pharmaceuticals For EGP-437
2016-12-05,EyeGate Reports Positive Data From Third Stage Of Phase 1b/2a Clinical Trial Of EGP-437 In Cataract Surgery Patients
2016-11-17,FDA Confirms A 510(k) De Novo Path For EyeGate's Device, The Ocular Bandage Gel, Following Pre-Submission Meeting
2016-11-02,EyeGate Pharmaceuticals Reports Third Quarter 2016 Financial Results And Provides Business Update
2016-09-21,EyeGate Pharmaceuticals To Present At The 2016 Aegis Capital Conference
2016-09-13,EyeGate Awarded $448,185 For Second Year Of Funding Of Phase II SBIR Grant From U.S. Department Of Defense
2016-09-12,EyeGate Receives Additional Milestone Payment From Valeant Pharmaceuticals For EGP-437
2016-09-06,EyeGate Pharmaceuticals To Present At The 18th Annual Rodman And Renshaw Global Investment Conference
2016-08-10,EyeGate Pharmaceuticals Reports Second Quarter 2016 Financial Results And Provides Business Update
2016-08-01,EyeGate Announces Positive Top-line Data From Phase 1b/2a Clinical Trial Of EGP-437 For Treatment Of Post-Operative Inflammation And Pain In Cataract Surgery Patients
2016-06-30,EyeGate Announces Completion Of $3.77 Million Registered Direct Offering
2016-06-27,EyeGate Announces $3.77 Million Registered Direct Offering
2016-06-01,EyeGate Announces Encouraging Interim Data From Phase 1b/2a Clinical Trial Of EGP-437 For Treatment Of Ocular Inflammation And Pain Post Cataract Surgery
2016-05-24,EyeGate Pharma Announces At The Market Issuance Program
2016-05-13,Eyegate Pharmaceuticals Reports First Quarter 2016 Financial Results And Provides Business Update
2016-05-06,EyeGate Pharma Appoints Dr. Brenda K. Mann As Vice President, Research And Development
2016-04-27,EyeGate Pharma Appoints Ryan R. Brenneman As Chief Financial Officer
2016-04-26,EyeGate Pharma To Present Four Posters At ARVO 2016 Annual Meeting Supporting Development Of CMHA-S
2016-03-29,EyeGate Reports Full-year 2015 Financial Results And Provides Business Update
2016-03-07,EyeGate Pharma Acquires Jade Therapeutics
2016-03-02,EyeGate Receives Additional Milestone Payment From Valeant Pharmaceuticals For EGP-437
2016-01-19,EyeGate Pharma Enrolls First Patient In Confirmatory Phase 3 Clinical Trial EGP-437-006 For Non-Infectious Anterior Uveitis
2016-01-14,Eyegate Pharmaceuticals To Present At The Noble Financial Capital Markets' 12th Annual Investor Conference
2015-11-12,EyeGate Reports Third Quarter 2015 Financial Results And Provides Business Update
2015-11-05,EyeGate Announces Interim Data From Phase 1b / 2a Clinical Trial Of Iontophoretic EGP-437 Ophthalmic Solution In Macular Edema Patients
2015-10-15,EyeGate Pharma Receives USPTO Notice Of Allowance For Next Generation Of Proprietary Iontophoretic Delivery System
2015-09-01,Eyegate Pharmaceuticals To Present At The 17th Rodman And Renshaw 2015 Annual Global Investment Conference
2015-08-05,Eyegate Pharmaceuticals Announces Closing Of Public Offering Of Common Stock And Warrants
2015-07-30,EyeGate Pharmaceuticals Announces Pricing Of $10,000,000 Public Offering Of Common Stock And Warrants
2015-07-24,EyeGate Pharma Receives USPTO Notice Of Allowance For Proprietary Dexamethasone Phosphate Formulation
2015-07-14,EyeGate Pharma Treats First Patient In Phase 1b / 2a Trial Of EGP-437 In Macular Edema
2015-07-10,EyeGate Signs Licensing Agreement With Valeant Pharmaceuticals For EGP-437 Combination Product In Uveitis
2015-05-04,EyeGate Pharma Receives Positive Guidance From FDA On NDA Filing Requirements Of EGP-437 For The Treatment Of Anterior Uveitis
2015-03-31,EyeGate Pharmaceuticals Reports Full Year 2014 Financial Results
2015-03-02,Eyegate Pharmaceuticals Names Michael B. Raizman, MD, Consulting Chief Medical Officer
,
,
,
,
2017-03-01,FibroGen Reports Fiscal 2016 Financial Results
2017-02-22,FibroGen To Report Fiscal 2016 Financial Results on March 1, 2017
2017-02-03,FibroGen Announces Publication Of Pamrevlumab (FG-3019) Clinical Data In Pancreatic Cancer Showing Safety And Improved Survival Outcomes In Combination With Chemotherapy
2017-01-30,7 Things to Watch in Biotech Now
2017-01-30,Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen
2017-01-30,FibroGen's Roxadustat (FG-4592) Meets Primary Endpoints In Two Phase 3 Anemia Studies In China
2017-01-24,Interesting FGEN Put And Call Options For September 15th
2017-01-20,Pamrevlumab Pancreatic Cancer Clinical Data Presented At ASCO 2017 Gastrointestinal Cancers Symposium
2017-01-12,First Week of February 17th Options Trading For FibroGen (FGEN)
2016-12-20,Akebia Funds Late-Stage Studies of Anemia Pill With Partnership for U.S. Commercial Rights
2016-12-12,Facebook, Apple, Starbucks: Doug Kass' Views
2016-12-05,Apple, Starbucks, Cisco: Doug Kass' Views
2016-11-25,Apple Continues to Underperform; the Market Is Resistant: Best of Kass
2016-11-08,FibroGen Reports Financial Results For The Third Quarter Of 2016 And Provides Corporate Update
2016-11-01,FibroGen To Report Third Quarter 2016 Financial Results On November 8, 2016
2016-10-31,FibroGen Completes Enrollment In Roxadustat Phase 3 Studies In China
2016-08-08,FibroGen Reports Financial Results For The Second Quarter Of 2016
2016-08-02,FibroGen To Report Second Quarter 2016 Financial Results On August 8, 2016
2016-07-25,Astellas And FibroGen Announce First Patient Treated In Phase 3 Studies And Positive Phase 2 Results Of Roxadustat In Patients With Chronic Kidney Disease In Japan
2016-07-08,FibroGen Announces Receipt Of $62 Million License Payment From AstraZeneca
2016-06-21,First Week of August 19th Options Trading For FibroGen (FGEN)
2016-06-15,Trade-Ideas: FibroGen (FGEN) Is Today's Weak On High Relative Volume Stock
2016-06-09,FibroGen Announces Initiation By Astellas Of Phase 3 Clinical Study In Japan Of Roxadustat/ASP1517 For The Treatment Of Anemia Of Chronic Kidney Disease Triggering $10.0 Million Milestone Payment
2016-06-06,FibroGen To Present At The Goldman Sachs 37th Annual Global Healthcare Conference
2016-05-09,FibroGen Reports Financial Results For The First Quarter Of 2016
2016-05-02,FibroGen To Report First Quarter 2016 Financial Results On May 9, 2016
2016-04-20,Promising Phase 2 Data Show Roxadustat Corrected Anemia In Chronic Kidney Disease Patients Before Intervention With Dialysis
2016-04-07,Weak On High Volume: FibroGen (FGEN)
2016-03-21,FibroGen (FGEN) Flagged As Strong On High Volume
2016-03-11,FibroGen Announces Publication Of Phase 2 Study Results Supporting The Potential Of FG-3019 To Treat Patients With Idiopathic Pulmonary Fibrosis
2016-02-29,FibroGen Announces Fiscal 2015 Financial Results
2016-02-19,FibroGen To Report Fourth Quarter And Full Year 2015 Financial Results On February 29, 2016
2016-02-16,FibroGen Publishes Encouraging Phase 2 Anemia Data Demonstrating Roxadustat's Ability To Maintain Hemoglobin Levels In Patients With Chronic Kidney Disease
2016-02-04,FibroGen (FGEN) Stock: Weak On High Volume Today
2016-01-28,FibroGen (FGEN) Is Weak On High Volume Today
2016-01-27,FibroGen Announces Early Phase 2 Data From A Clinical Study Of FG-3019 In Combination With Chemotherapy As Neoadjuvant In Locally Advanced, Unresectable Pancreatic Cancer
2016-01-06,FibroGen Enrolls First Patients In Phase 2 Clinical Study Of Anti-Fibrotic Drug Candidate FG-3019 For The Treatment Of Duchenne Muscular Dystrophy
2015-12-18,Insider Trading Alert - FGEN, RSPP And CNBKA Traded By Insiders
2015-12-15,Ratings Changes Today
2015-12-14,Akebia Secures Asian Partner and Funding for Anemia Pill
2015-11-12,FibroGen Announces Third Quarter 2015 Financial Results
2015-11-05,FibroGen To Report Third Quarter 2015 Financial Results On November 12, 2015
2015-11-03,FibroGen To Present Roxadustat Clinical Data In Four Presentations At American Society Of Nephrology - Kidney Week 2015
2015-10-29,FibroGen Appoints Jeffrey Edwards To Board Of Directors
2015-10-22,Phase 2 Data For Investigational Orally Active HIF-PHI Roxadustat (FG-4592) Show Anemia Correction In Incident Dialysis Chronic Kidney Disease Patients Regardless Of Iron Repletion Status, Iron Supplementation Regimen, Or Dialysis Modality
2015-10-02,Biotech Stock Mailbag: Akebia, Neuralstem, Arrowhead
2015-08-13,FibroGen Announces Second Quarter 2015 Financial Results
2015-08-12,Nephrology Dialysis Transplantation Reports Phase 2 Data Of Investigational Orally Active HIF-PHI Roxadustat (FG-4592) Shows Improved Hemoglobin Levels In Non-Dialysis CKD Subjects With Anemia
2015-08-10,FibroGen To Report Second Quarter 2015 Financial Results On August 13, 2015
2015-08-06,FibroGen Appoints Jeffrey W. Henderson To Board Of Directors
2015-07-27,FibroGen Receives FDA Clearance To Proceed With Clinical Study Of FG-3019 In Duchenne Muscular Dystrophy
2015-07-20,Analysts' Actions -- Amazon, Hertz and Kraft Heinz
2015-06-29,FibroGen Announces Receipt Of $120 Million License Payment From AstraZeneca
2015-06-12,5 Stocks Ready for Breakouts
2015-06-08,3 Stocks Rising on Unusual Volume
2015-06-01,FibroGen To Webcast Presentation At The Goldman Sachs Global Healthcare Conference
2015-05-12,FibroGen Announces First Quarter 2015 Financial Results
2015-05-07,FibroGen Announces Receipt Of Milestone Payment From AstraZeneca For Successful Completion Of Long-Term Pre-Clinical Safety Studies Of Roxadustat
2015-04-22,Oversold Conditions For FibroGen (FGEN)
2015-03-26,FibroGen Announces 2014 Financial Results And Provides Corporate Update
2015-03-19,FibroGen To Report Fourth Quarter And Full Year 2014 Financial Results On March 26, 2015
2015-03-06,5 Stocks Poised for Breakouts: Trevena, Inventergy and More
2014-11-17,FibroGen, Inc. Announces Full Exercise Of Greenshoe Option
,
,
,
2017-03-26,How I'd Play Biotech Buyout Rumors
2017-03-24,How I'd Play Biotech Buyout Rumors
2017-03-23,Stocks Fall as House Leaders Delay Health Care Vote
2017-03-23,Noteworthy Thursday Option Activity: FLXN, Z, SWC
2017-03-23,Health Care Vote Impacts Trump's Deal Maker Image
2017-03-23,Sanofi Said to Be Near $1 Billion Deal for Flexion
2017-03-09,Flexion Reports Year-End 2016 Financial Results
2017-03-03,Flexion Therapeutics To Present At Upcoming Investor Conferences
2017-03-02,Flexion Therapeutics To Report Year-End 2016 Financial Results On March 9, 2017
2017-02-23,Flexion Therapeutics Initiates Clinical Trial To Evaluate The Safety Of Repeat Administration Of Zilretta™ (FX006) In Patients With Osteoarthritis Of The Knee
2017-02-15,Flexion Therapeutics To Present At The RBC Capital Markets Global Healthcare Conference
2017-02-07,Flexion Therapeutics Announces New Drug Application For Zilretta™ (FX006) Accepted By U.S. Food And Drug Administration
2016-12-12,Flexion Therapeutics Stock Sees Short Interest Decline 20%
2016-12-12,Flexion Therapeutics Submits New Drug Application For Zilretta™ To Treat Knee Osteoarthritis Pain
2016-12-09,Flexion Therapeutics To Present At The BMO Capital Markets Prescriptions For Success Healthcare Conference
2016-11-28,Commit To Buy Flexion Therapeutics At $10, Earn 17% Annualized Using Options
2016-11-16,Flexion Therapeutics Announces Pricing Of Public Offering Of Common Stock
2016-11-15,Flexion Therapeutics Announces Proposed Public Offering Of Common Stock
2016-11-11,Flexion Therapeutics Announces Presentation Of Phase 3 Data Demonstrating That Extended-Release Zilretta™ Achieves Clinically Significant Improvement Of Pain, Stiffness And Function In Patients With Osteoarthritis Of The Knee
2016-11-10,Insiders Seeing Green With FLXN At New 52-Week High
2016-11-07,Flexion Therapeutics Reports Third Quarter 2016 Financial Results
2016-11-03,Flexion Therapeutics Announces That Analysis From Phase 3 Clinical Trial Of Zilretta™ For Osteoarthritis Of The Knee To Be Presented At AAHKS
2016-11-01,Flexion Therapeutics Reports Primary Endpoint Met In Clinical Trial Evaluating Investigational Drug Candidate Zilretta™ In Type 2 Diabetes Patients With Knee Osteoarthritis
2016-10-28,Flexion Therapeutics To Report Third-Quarter 2016 Financial Results On November 7, 2016
2016-09-29,Flexion Therapeutics Announces Appointment Of John Magee as Vice President Of Sales
2016-09-14,Flexion Therapeutics Announces Appointment Of Mark Stejbach To Its Board Of Directors
2016-09-12,Flexion Therapeutics Announces Two Key Corporate Appointments
2016-08-31,Flexion Therapeutics To Present At 2016 Wells Fargo Healthcare Conference
2016-08-04,Seeing Some Good Action in Individual Stocks
2016-08-03,Flexion Therapeutics Reports Second-Quarter 2016 Financial Results
2016-07-25,Flexion Therapeutics To Report Second-Quarter 2016 Financial Results On August 3, 2016
2016-07-06,Flexion Therapeutics Adds Three New Executives In Key Roles To Support The Planned Commercial Launch Of Zilretta™
2016-06-08,Flexion (FLXN) Stock Plunged Today After Announcing Stock Offering
2016-06-08,Market Digging Metal and Mining Stocks
2016-06-08,Flexion Therapeutics Announces Pricing Of Public Offering Of Common Stock
2016-06-07,Flexion Therapeutics Announces Proposed Public Offering Of Common Stock
2016-05-26,Commit To Buy Flexion Therapeutics At $10, Earn 22.8% Annualized Using Options
2016-05-26,Flexion Therapeutics Receives Positive Guidance From FDA On New Drug Application (NDA) Submission For Zilretta™ For Osteoarthritis Of The Knee
2016-05-12,Flexion Therapeutics Reports First-Quarter 2016 Financial Results
2016-05-05,Flexion Therapeutics To Report First-Quarter 2016 Financial Results On May 12, 2016
2016-04-28,Flexion Therapeutics Enrolls First Patient In Phase 2 Trial Of Zilretta™ Among Type 2 Diabetes Patients With Knee Osteoarthritis
2016-04-07,Flexion Therapeutics To Present At 15th Annual Needham Healthcare Conference
2016-04-04,Flexion Therapeutics Announces Presentation Of Results From Pivotal Phase 2b And Phase 3 Clinical Trials For Zilretta™ At Osteoarthritis Research Society International (OARSI) 2016 World Congress
2016-04-01,Flexion To Present Pivotal Phase 2b And Phase 3 Results For Zilretta™ At Osteoarthritis Research Society International (OARSI) 2016 World Congress
2016-03-30,7 Stocks Under $10 to Trade for Breakout Gains
2016-03-10,Flexion Reports Year-End 2015 Financial Results
2016-03-07,Flexion Therapeutics To Present At Cowen And Company's 36th Annual Health Care Conference
2016-03-03,Flexion Therapeutics To Report Year-End 2015 Earnings Results On March 10, 2016
2016-02-29,Flexion Therapeutics Enters Oversold Territory (FLXN)
2016-02-25,Interesting FLXN Put And Call Options For April 15th
2016-02-18,Flexion Therapeutics To Present At RBC Capital Markets 2016 Global Healthcare Conference
2016-02-17,Flexion (FLXN) Stock Climbs on Phase 3 Trial Results for Osteoarthritis Treatment
2016-02-16,Flexion Therapeutics Reports Primary Endpoint Met In Pivotal Phase 3 Trial Of Zilretta™ In Knee Osteoarthritis
2016-01-20,Flexion Therapeutics Becomes Oversold (FLXN)
2015-12-04,Flexion Therapeutics To Present At Oppenheimer 26th Annual Healthcare Conference
2015-12-01,Flexion Therapeutics Enrolls First Patient In Pharmacokinetic Study Of Zilretta™ For Osteoarthritis Of The Knee
2015-11-16,Flexion Therapeutics To Present At Stifel 2015 Healthcare Conference
2015-11-09,Flexion Therapeutics Reports Third-Quarter 2015 Financial Results
2015-11-02,Flexion Therapeutics To Report Third-Quarter 2015 Financial Results On November 9, 2015
2015-09-28,First Week of May 2016 Options Trading For Flexion Therapeutics (FLXN)
2015-09-08,Tuesday's Clinical Trial Scorecard: Akebia Wins, Tetraphase, Flexion, Theravance Lose
2015-09-08,Flexion Therapeutics Reports Top-Line Data From Pivotal Phase 2b Clinical Trial For FX006
2015-09-01,Flexion Therapeutics Granted Fast Track Status By The FDA For FX006 For Treatment Of Osteoarthritis Of The Knee
2015-08-06,Flexion Therapeutics Reports Second-Quarter 2015 Financial Results
2015-08-04,Flexion Therapeutics Secures $30 Million In Debt Financing
2015-08-04,Flexion Therapeutics Expands Supply Capacity For FX006 By Entering Into Agreement With Patheon
2015-07-30,Flexion Therapeutics To Report Second-Quarter 2015 Financial Results On August 6, 2015
2015-07-29,Flexion Therapeutics Completes Enrollment In Phase 3 Clinical Trial With Lead Compound FX006 In Patients With Osteoarthritis Of The Knee
2015-07-14,Commit To Buy Flexion Therapeutics At $22.50, Earn 40.2% Annualized Using Options
2015-06-03,Flexion Therapeutics' Final FX006 Data From Completed Phase 2b Dose-Ranging Trial Published In Journal Of Bone And Joint Surgery
2015-05-07,Flexion Therapeutics Reports First-Quarter 2015 Financial Results
2015-04-30,Flexion Therapeutics To Report First-Quarter 2015 Financial Results On May 7, 2015
2015-04-29,Flexion Therapeutics Awarded Approximately $2 Million From U.S. Department Of Defense To Conduct Clinical Trial Of FX006 In Military Personnel With Osteoarthritis Of The Knee
2015-04-08,Flexion Therapeutics To Present At 14th Annual Needham Healthcare Conference
2015-03-23,Flexion Reports Year-End 2014 Financial Results
2015-03-16,Flexion Therapeutics To Report Year-End 2014 Earnings Results On March 23, 2015
2015-03-06,Flexion Therapeutics Announces Changes To Board Of Directors
2015-02-24,Flexion Therapeutics Completes Enrollment In Pivotal Phase 2b Confirmatory Clinical Trial With Lead Compound FX006
2015-02-17,Flexion Therapeutics To Present At RBC Capital Markets Healthcare Conference
2015-02-13,3 Stocks Spiking on Big Volume: Baidu, LogMeIn and Flexion
2015-02-02,Flexion Therapeutics Initiates Phase 3 Clinical Trial Of FX006 In Patients With Osteoarthritis Of The Knee
2014-12-17,Flexion Therapeutics Announces Exercise Of Underwriters' Over-Allotment Option And Closing Of Public Offering Of Common Stock
2014-12-12,Flexion Therapeutics Announces Pricing Of Public Offering Of Common Stock
2014-12-08,Flexion Therapeutics Announces Public Offering Of Common Stock
2014-12-01,Flexion Therapeutics Announces That FDA Has Removed Clinical Hold On FX006
2014-11-17,Flexion Therapeutics To Present At Stifel Healthcare Conference 2014
2014-11-13,Flexion Therapeutics Reports Third-Quarter 2014 Financial Results
2014-11-06,Flexion Therapeutics To Report Third-Quarter 2014 Financial Results
2014-09-17,Why Flexion Therapeutics (FLXN) Stock Is Plummeting in After-Hours Trading Today
2014-09-17,Flexion Therapeutics Announces Clinical Hold Of FX006 Phase 2b Clinical Trial In Osteoarthritis Of The Knee
2014-09-12,Flexion Therapeutics Keeps Climbing
2014-09-10,Fraud Allegations Cause 21Vianet Group to Plunge
2014-09-09,Flexion Therapeutics Announces Issuance Of U.S. Composition Of Matter Patent For Lead Candidate FX006
2014-09-04,Kamada Plunges Following Missed Marks in Trial
2014-09-03,Flexion Therapeutics To Start FX006 Phase 3 Pivotal Trial In 2014; Following FDA Meeting, Development Plan Advanced By One Year
2014-08-07,Flexion Therapeutics Reports Second-Quarter 2014 Financial Results
2014-07-31,Flexion Therapeutics To Report Second Quarter 2014 Financial Results On August 7, 2014
2014-07-28,Flexion Therapeutics And Southwest Research Institute(R) (SwRI(R)) Sign Worldwide Exclusive License For Proprietary Microsphere Manufacturing Technologies
2014-07-24,Flexion Therapeutics Announces Board Changes
,
,
2017-03-08,Amicus Therapeutics Launches Galafold™ (Migalastat) For Treatment Of Fabry Disease In Italy
2017-03-02,Amicus Therapeutics To Present At Upcoming Investor Conferences
2017-03-01,Amicus CEO John Crowley, Not His Daughter Megan, Might Compel Trump to Make Big Changes at FDA
2017-03-01,Amicus Therapeutics Announces Full-Year 2016 Financial Results And Corporate Updates
2017-02-27,Amicus Therapeutics Launches Galafold™ (Migalastat) For Treatment Of Fabry Disease In The United Kingdom
2017-02-22,Amicus Therapeutics To Announce Full-Year 2016 Financial Results And Corporate Updates On March 1, 2017
2017-02-15,Amicus Therapeutics Presents Additional Positive Preliminary Phase 1/2 Data At WORLDSymposium™ 2017
2017-02-15,Amicus Therapeutics Presents Important New Scientific Findings And Preclinical Data For Pompe Program At WORLDSymposium™ 2017
2017-02-14,Amicus Therapeutics Highlights New Fabry Program Data At WORLDSymposium™ 2017
2017-02-10,Short Interest In Amicus Therapeutics Jumps 14%
2017-02-06,Interesting FOLD Call Options For February 17th
2017-02-06,Amicus Therapeutics To Present At The Leerink Partners 6th Annual Global Healthcare Conference
2017-01-30,7 Things to Watch in Biotech Now
2017-01-24,Biotech Premarket Movers: Amicus Therapeutics, Nantkwest and Organovo
2017-01-24,Amicus Therapeutics Announces Presentations And Posters At 13th Annual WORLDSymposium™ 2017
2017-01-17,October 20th Options Now Available For Amicus Therapeutics (FOLD)
2017-01-09,Amicus Therapeutics Provides Full-Year 2017 Strategic Outlook And Financial Guidance
2017-01-04,National Institute For Health And Care Excellence (NICE) Issues Final Positive Recommendation For Galafold™ (migalastat) For Fabry Disease In England
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2017-01-01,5 Stocks Insiders Love Right Now
2016-12-29,3 Small Biotechs With Insider Buying
2016-12-23,Amicus Therapeutics To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-21,Amicus Therapeutics Announces Closing Of Offering Of Senior Convertible Notes And Exercise In Full Of Option To Purchase Additional Notes
2016-12-20,A Biotech Trio to Like Going Into 2017
2016-12-15,Amicus Therapeutics Announces Pricing Of Offering Of Convertible Senior Notes
2016-12-14,Amicus Therapeutics Announces Proposed Offering Of Convertible Senior Notes
2016-12-08,Amicus Therapeutics Announces Positive Preliminary Data From Phase 1/2 Study Of Novel Treatment Paradigm For Pompe Disease
2016-12-01,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Amicus Therapeutics, Inc. - FOLD
2016-11-29,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Amicus Therapeutics, Inc. (FOLD)
2016-11-29,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By Certain Officers And Directors Of Amicus Therapeutics, Inc.
2016-11-29,FOLD Makes Notable Cross Below Critical Moving Average
2016-11-28,Futures Flat as Investors Take Profits; Asia Mixed
2016-11-28,Amicus Tumbles on Lengthy Delay to U.S. Fabry Drug FDA Filing Plan
2016-11-28,Amicus Therapeutics Announces U.S. Regulatory Pathway For Migalastat For Fabry Disease
2016-11-22,4 Promising Small Biotechs to Watch in 2017
2016-11-22,First Week of FOLD July 2017 Options Trading
2016-11-11,Journal Of Medical Genetics Publishes Pivotal Phase 3 ATTRACT Study Of Migalastat For Patients With Fabry Disease
2016-11-07,Amicus Therapeutics Announces Third Quarter 2016 Financial Results And Corporate Updates
2016-11-03,Amicus Therapeutics Becomes Oversold (FOLD)
2016-11-01,Amicus Therapeutics To Announce Third Quarter 2016 Financial Results On November 7, 2016
2016-10-25,First Week of December 16th Options Trading For Amicus Therapeutics (FOLD)
2016-10-14,Amicus Therapeutics (FOLD) Shares Cross Below 200 DMA
2016-09-22,Amicus Therapeutics To Present At LEERINK Roundtable Series: Rare Disease & Immuno-Oncology
2016-09-13,UPDATE -- Amicus Therapeutics To Present At Bank Of America Merrill Lynch Global Healthcare Conference 2016
2016-09-12,Amicus Therapeutics To Present At Bank Of America Merrill Lynch Global Healthcare Conference 2016
2016-09-01,Amicus Therapeutics To Present At Robert W. Baird & Co. 2016 Healthcare Conference
2016-08-31,Amicus Therapeutics To Highlight Fabry Disease Program At Society For The Study Of Inborn Errors Of Metabolism (SSIEM) Annual Symposium
2016-08-12,TG Therapeutics Looks Like a Healthy Play
2016-08-11,3 Biotech-Investing Mistakes to Avoid
2016-08-11,Amicus (FOLD) CEO Crowley to CNBC: 'Our Job is to Stay Focused and Keep Making Great Medicines'
2016-08-10,UPDATE -- New England Journal Of Medicine Publishes Pivotal Phase 3 FACETS Study Of Migalastat For Patients With Fabry Disease
2016-08-10,New England Journal Of Medicine Publishes Pivotal Phase 3 FACETS Study Of Migalastat For Patients With Fabry Disease
2016-08-09,Amicus Therapeutics (FOLD) Stock Slumps on Q2 Loss
2016-08-09,Amicus Therapeutics Announces Second Quarter 2016 Financial Results And Corporate Updates
2016-08-03,Amicus Therapeutics To Submit Japanese New Drug Application For Migalastat For Fabry Disease In 1H17
2016-08-01,Amicus Therapeutics To Announce Second Quarter 2016 Financial Results On August 9, 2016
2016-07-31,5 Small-Cap Biotechs With Big Potential
2016-07-29,5 Small-Cap Biotechs With Big Potential
2016-07-12,Amicus Therapeutics Appoints Former FDA Division Deputy Director Andrew Mulberg As Vice President, Regulatory Strategy
2016-07-06,Amicus Therapeutics Expands Biologics Pipeline With New Preclinical Program For Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency
2016-06-30,2 Small Biotech Stocks With Big Milestones
2016-06-20,Commit To Buy Amicus Therapeutics At $3, Earn 18.3% Using Options
2016-06-10,Relative Strength Alert For Amicus Therapeutics
2016-06-10,Amicus Therapeutics Appoints Craig A. Wheeler To Board Of Directors
2016-06-02,5 Breakout Stocks Under $10 Set to Soar
2016-06-01,Amicus Therapeutics To Present At The Goldman Sachs 37th Annual Global Healthcare Conference
2016-05-31,Amicus Therapeutics Announces European Commission Approval For Galafold™ (Migalastat) In Patients With Fabry Disease In European Union
2016-05-12,Oversold Conditions For Amicus Therapeutics (FOLD)
2016-05-05,Amicus Therapeutics To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference
2016-05-03,Amicus Therapeutics Announces First Quarter 2016 Financial Results And Corporate Updates
2016-04-26,Amicus Therapeutics To Announce First Quarter 2016 Financial Results On May 3, 2016
2016-04-12,Amicus Shares Barely Budge on Prediction of $3 Billion Buyout
2016-04-01,Amicus (FOLD) Stock Soars After EU Regulator Recommended Drug
2016-04-01,Amicus Therapeutics Receives Positive CHMP Opinion For Approval Of Migalastat In Patients With Fabry Disease In European Union
2016-04-01,Amicus Fabry Drug Takes Big Step Toward European Approval
2016-03-23,6 Biotech Stocks Under $10 to Trade for Big Breakouts
2016-03-22,First Week of FOLD May 20th Options Trading
2016-03-22,Amicus Therapeutics Announces Expanded Access Program For Migalastat
2016-03-14,7 Breakout Stocks Spiking on Big Volume
2016-03-08,'Mad Money' Lightning Round: Buy, Buy, Buy Bristol-Myers Squibb
2016-03-07,Jim Cramer's 'Mad Money' Recap: Commodities Are Healing, so Are Markets
2016-03-02,Amicus Therapeutics To Present At The Cowen And Company 36th Annual Health Care Conference
2016-03-01,Amicus Therapeutics Highlights New Phase 3 Fabry Data And Preclinical Pompe Data At WORLDSymposium™ 2016
2016-02-26,First Week of October 21st Options Trading For Amicus Therapeutics (FOLD)
2016-02-26,Amicus Therapeutics Announces Full-Year 2015 Financial Results And Corporate Updates
2016-02-22,Amicus Fabry Drug Set for Crucial European Approval Vote
2016-02-18,Amicus Therapeutics To Announce Full-Year 2015 Financial Results And Corporate Updates On February 26, 2016
2016-02-10,Amicus Therapeutics Announces Presentations And Posters At 12th Annual WORLDSymposium™ 2016  
2016-02-09,Amicus Therapeutics Strengthens Executive Leadership Team
2016-02-08,Amicus Therapeutics Enters Oversold Territory (FOLD)
2016-02-03,Amicus Therapeutics To Present At The Leerink Partners 5th Annual Global Healthcare Conference
2016-01-15,3 Biotech Stocks Under $10 to Trade for Big Gains
2016-01-11,Amicus Therapeutics is Now Oversold (FOLD)
2016-01-11,Amicus Therapeutics Provides Full-Year 2016 Strategic Outlook And Financial Guidance
2016-01-04,Amicus Therapeutics To Present At The 34th Annual J.P. Morgan Healthcare Conference And 3rd Annual Dermatology Summit
2015-12-22,Amicus Therapeutics Commences Phase 1/2 Study Of Novel ERT For Treatment Of Pompe Disease
2015-12-03,UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders Of Amicus Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of December 7, 2015
2015-12-01,Jim Cramer -- Demand More From IBM Than Buffett Does; Be Choosy With Biotech
2015-12-01,Warren Buffett Is Satisfied With IBM, but Jim Cramer Wants More
2015-12-01,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors Of Class Action Against Amicus Therapeutics, Inc. And Lead Plaintiff Deadline December 7, 2015
2015-11-26,DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Amicus Therapeutics, Inc. And Encourages Investors With Losses To Contact The Firm
2015-11-21,JPMorgan Likes These 5 Biotech Stocks
2015-11-21,Clovis Blowup Conjures Bad Biotech Memories of ImClone Darkness
2015-11-17,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Amicus Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of December 7, 2015
2015-11-12,Amicus Therapeutics To Present At Goldman Sachs US Emerging / SMID Cap Growth Conference
2015-11-11,Wolf Popper LLP Updates Investigation And Reminds Shareholders Of Amicus Therapeutics, Inc. Of Class Action Lawsuit And Upcoming Lead Plaintiff Deadline
2015-11-10,DEADLINE ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Amicus Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2015-11-03,Amicus Therapeutics Announces Third Quarter 2015 Financial Results And Corporate Updates
2015-11-02,Law Offices Of Marc S. Henzel Commences Investigations Of Fifth Street Finance Corp., Amicus Therapeutics, Inc., 6D Global Technologies, Inc., BofI Holdings, Inc., Zafgen, Inc., And Valeant Pharmaceuticals, Inc.
2015-10-30,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Amicus Therapeutics, Inc. Of Pendency Of Class Action Lawsuit And A Lead Plaintiff Deadline Of December 7, 2015 - FOLD
2015-10-28,5 Biotech Stocks Under $10 Triggering Breakout Trades
2015-10-27,Amicus Therapeutics To Announce Third Quarter 2015 Financial Results On November 3, 2015
2015-10-26,The Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Amicus Therapeutics, Inc. Investors
2015-10-22,IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Amicus Therapeutics, Inc. And Encourages Shareholders To Contact The Firm
2015-10-21,SHAREHOLDER ALERT: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against Amicus Therapeutics, Inc. And Encourages Investors To Contact The Firm
2015-10-21,TRADING ALERT: Rosen Law Firm Reminds Amicus Therapeutics, Inc. Investors Of Important Deadline In Class Action - FOLD
2015-10-16,INVESTOR ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Amicus Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2015-10-16,Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Amicus Therapeutics, Inc.
2015-10-15,3 Biotech Stocks Under $10 to Buy for Breakout Gains
2015-10-14,Amicus Therapeutics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors
2015-10-13,SHAREHOLDER ALERT: Pomerantz Law Firm Announces The Filing Of A Class Action Against Amicus Therapeutics, Inc. And Certain Officers - FOLD
2015-10-12,Robbins Arroyo LLP: Amicus Therapeutics, Inc. (FOLD) Misled Shareholders According To A Recently Filed Class Action
2015-10-12,IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Amicus Therapeutics, Inc. And Encourages Shareholders To Contact The Firm
2015-10-09,Harwood Feffer LLP Announces Investigation Of Amicus Therapeutics, Inc.
2015-10-09,Kirby McInerney LLP Advises Amicus Therapeutics, Inc. Investors Of Potential Claims
2015-10-08,Amicus Therapeutics, Inc. Sued For Securities Fraud In An Expanded Class Period
2015-10-08,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Amicus Therapeutics, Inc.
2015-10-07,Amicus Therapeutics, Inc. Sued For Securities Fraud After Revealing Its NDA Will Not Be Filed This Year
2015-10-02,Market News: Amicus Therapeutics, Edge Therapeutics, Wynn Resorts
2015-10-02,Block & Leviton LLP Investigates Amicus Therapeutics After Announcement That It Will Not File A New Drug Application This Year As Originally Announced
2015-10-02,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Amicus Therapeutics, Inc.
2015-10-02,Amicus Therapeutics Enters Oversold Territory (FOLD)
2015-10-02,Amicus Therapeutics (FOLD) Stock Drops as FDA Requests More Data on Drug Candidate
2015-10-02,Amicus, Other Biotech CEOs Should Listen More, Talk Less About FDA Matters
2015-10-02,Amicus Therapeutics To Host FDA Update Conference Call Today
2015-10-02,Amicus Therapeutics Provides U.S. Regulatory Update For Migalastat Monotherapy
2015-09-30,Amicus Therapeutics Completes Acquisition Of Scioderm, Inc.
2015-09-22,Amicus Therapeutics To Present At LEERINK Partners Rare Disease Roundtable
2015-09-15,Amicus Therapeutics Plans To Submit New Drug Application (NDA) For Migalastat For Fabry Disease Following Positive Pre-NDA Meeting With FDA
2015-09-14,FOLD January 2018 Options Begin Trading
2015-08-31,Stocks Close August With Worst Monthly Losses Since 2012
2015-08-31,Stocks Lower but Crude Oil Wipes Out August Losses
2015-08-31,Interesting FOLD Put And Call Options For April 2016
2015-08-31,Stocks Extend Losses as Investors Still Have No Clue on Rate Hike Timeline
2015-08-31,Aug. 31 Premarket Briefing: 10 Things You Should Know
2015-08-31,Amicus Acquires Scioderm, Adds Drug for Rare Skin Disorder to Pipeline
2015-08-31,Amicus Therapeutics To Acquire Rare Disease Company Scioderm, Inc.
2015-08-20,'Mad Money' Lightning Round: Forget El Pollo Loco, Buy Chipotle
2015-08-19,Jim Cramer's 'Mad Money' Recap: What to Buy When the Fed Raises Rates
2015-08-05,Amicus Therapeutics Announces Second Quarter 2015 Financial Results And Corporate Updates
2015-07-29,Amicus Therapeutics Stock Sees Short Interest Expand By 48.6%
2015-07-29,Amicus Therapeutics To Announce Second Quarter 2015 Financial Results On August 5, 2015
2015-06-29,Amicus Therapeutics Joins Russell 3000(R) And Russell 2000(R) Indexes
2015-06-25,Amicus Therapeutics Announces Galafold(TM) Marketing Authorization Application (MAA) Validated By European Medicines Agency (EMA)
2015-06-17,Amicus Therapeutics Announces Closing Of Underwritten Offering Of Common Stock And Full Exercise Of Over-Allotment Option
2015-06-12,Amicus Therapeutics (FOLD) Stock Gains Following Pricing of Secondary Offering
2015-06-11,Amicus Therapeutics Prices Underwritten Offering Of Common Stock
2015-06-10,Amicus Therapeutics Announces Public Offering Of Common Stock
2015-06-08,Amicus Therapeutics Strengthens Executive Leadership Team
2015-06-03,Amicus Therapeutics Submits Marketing Authorization Application (MAA) For Full Approval Of Fabry Monotherapy Galafold(TM) (Migalastat) In European Union
2015-06-02,5 Big Trades Under $15 That Could Deliver Big Gains
2015-05-26,Amicus Therapeutics' Fabry Monotherapy Granted Accelerated Assessment By European Regulators
2015-05-06,Amicus Therapeutics (FOLD) Strong On High Relative Volume Today
2015-05-05,Amicus Therapeutics Announces First Quarter 2015 Financial Results And Corporate Updates
2015-05-05,First Week Of FOLD May 15th Options Trading
2015-05-01,Amicus Therapeutics To Announce First Quarter 2015 Financial Results On May 5, 2015
2015-04-28,Amicus Therapeutics (FOLD) Marked As A Dead Cat Bounce Stock
2015-04-27,Amicus Therapeutics Appoints David Allsop As Senior Vice President, International
2015-04-13,Trade-Ideas: Amicus Therapeutics (FOLD) Is Today's "Perilous Reversal" Stock
2015-04-09,Amicus Therapeutics Honors Fabry Disease Awareness Month And International Pompe Day
2015-03-20,Amicus Therapeutics (FOLD) Highlighted As Today's Perilous Reversal Stock
2015-03-19,Amicus Therapeutics (FOLD) Stock Spikes Today Following Accelerated Approval Filing Plan
2015-03-19,Amicus Therapeutics (FOLD) Trading With Heavy Volume Before Market Open
2015-03-19,Amicus Accelerates Approval Filing Plans for Rare Disease Drug
2015-03-19,Amicus Therapeutics Provides Positive Global Regulatory Updates From EMA And FDA Meetings For Fabry Monotherapy
2015-03-16,Insiders Were Right: FOLD Makes New 52-Week High
2015-03-03,Amicus Therapeutics Announces Full-Year 2014 Financial Results And Corporate Updates
2015-02-26,Amicus Therapeutics To Present At Cowen And Company 35th Annual Health Care Conference
2015-02-25,First Week Of FOLD October 16th Options Trading
2015-02-25,Amicus Therapeutics To Announce Full-Year 2014 Financial Results On March 3, 2015
2017-03-08,Amicus Therapeutics Launches Galafold™ (Migalastat) For Treatment Of Fabry Disease In Italy
2017-03-02,Amicus Therapeutics To Present At Upcoming Investor Conferences
2017-03-01,Amicus CEO John Crowley, Not His Daughter Megan, Might Compel Trump to Make Big Changes at FDA
2017-03-01,Amicus Therapeutics Announces Full-Year 2016 Financial Results And Corporate Updates
2017-02-27,Amicus Therapeutics Launches Galafold™ (Migalastat) For Treatment Of Fabry Disease In The United Kingdom
2017-02-22,Amicus Therapeutics To Announce Full-Year 2016 Financial Results And Corporate Updates On March 1, 2017
2017-02-15,Amicus Therapeutics Presents Additional Positive Preliminary Phase 1/2 Data At WORLDSymposium™ 2017
2017-02-15,Amicus Therapeutics Presents Important New Scientific Findings And Preclinical Data For Pompe Program At WORLDSymposium™ 2017
2017-02-14,Amicus Therapeutics Highlights New Fabry Program Data At WORLDSymposium™ 2017
2017-02-10,Short Interest In Amicus Therapeutics Jumps 14%
2017-02-06,Interesting FOLD Call Options For February 17th
2017-02-06,Amicus Therapeutics To Present At The Leerink Partners 6th Annual Global Healthcare Conference
2017-01-30,7 Things to Watch in Biotech Now
2017-01-24,Biotech Premarket Movers: Amicus Therapeutics, Nantkwest and Organovo
2017-01-24,Amicus Therapeutics Announces Presentations And Posters At 13th Annual WORLDSymposium™ 2017
2017-01-17,October 20th Options Now Available For Amicus Therapeutics (FOLD)
2017-01-09,Amicus Therapeutics Provides Full-Year 2017 Strategic Outlook And Financial Guidance
2017-01-04,National Institute For Health And Care Excellence (NICE) Issues Final Positive Recommendation For Galafold™ (migalastat) For Fabry Disease In England
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2017-01-01,5 Stocks Insiders Love Right Now
2016-12-29,3 Small Biotechs With Insider Buying
2016-12-23,Amicus Therapeutics To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-21,Amicus Therapeutics Announces Closing Of Offering Of Senior Convertible Notes And Exercise In Full Of Option To Purchase Additional Notes
2016-12-20,A Biotech Trio to Like Going Into 2017
2016-12-15,Amicus Therapeutics Announces Pricing Of Offering Of Convertible Senior Notes
2016-12-14,Amicus Therapeutics Announces Proposed Offering Of Convertible Senior Notes
2016-12-08,Amicus Therapeutics Announces Positive Preliminary Data From Phase 1/2 Study Of Novel Treatment Paradigm For Pompe Disease
2016-12-01,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Amicus Therapeutics, Inc. - FOLD
2016-11-29,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Amicus Therapeutics, Inc. (FOLD)
2016-11-29,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By Certain Officers And Directors Of Amicus Therapeutics, Inc.
2016-11-29,FOLD Makes Notable Cross Below Critical Moving Average
2016-11-28,Futures Flat as Investors Take Profits; Asia Mixed
2016-11-28,Amicus Tumbles on Lengthy Delay to U.S. Fabry Drug FDA Filing Plan
2016-11-28,Amicus Therapeutics Announces U.S. Regulatory Pathway For Migalastat For Fabry Disease
2016-11-22,4 Promising Small Biotechs to Watch in 2017
2016-11-22,First Week of FOLD July 2017 Options Trading
2016-11-11,Journal Of Medical Genetics Publishes Pivotal Phase 3 ATTRACT Study Of Migalastat For Patients With Fabry Disease
2016-11-07,Amicus Therapeutics Announces Third Quarter 2016 Financial Results And Corporate Updates
2016-11-03,Amicus Therapeutics Becomes Oversold (FOLD)
2016-11-01,Amicus Therapeutics To Announce Third Quarter 2016 Financial Results On November 7, 2016
2016-10-25,First Week of December 16th Options Trading For Amicus Therapeutics (FOLD)
2016-10-14,Amicus Therapeutics (FOLD) Shares Cross Below 200 DMA
2016-09-22,Amicus Therapeutics To Present At LEERINK Roundtable Series: Rare Disease & Immuno-Oncology
2016-09-13,UPDATE -- Amicus Therapeutics To Present At Bank Of America Merrill Lynch Global Healthcare Conference 2016
2016-09-12,Amicus Therapeutics To Present At Bank Of America Merrill Lynch Global Healthcare Conference 2016
2016-09-01,Amicus Therapeutics To Present At Robert W. Baird & Co. 2016 Healthcare Conference
2016-08-31,Amicus Therapeutics To Highlight Fabry Disease Program At Society For The Study Of Inborn Errors Of Metabolism (SSIEM) Annual Symposium
2016-08-12,TG Therapeutics Looks Like a Healthy Play
2016-08-11,3 Biotech-Investing Mistakes to Avoid
2016-08-11,Amicus (FOLD) CEO Crowley to CNBC: 'Our Job is to Stay Focused and Keep Making Great Medicines'
2016-08-10,UPDATE -- New England Journal Of Medicine Publishes Pivotal Phase 3 FACETS Study Of Migalastat For Patients With Fabry Disease
2016-08-10,New England Journal Of Medicine Publishes Pivotal Phase 3 FACETS Study Of Migalastat For Patients With Fabry Disease
2016-08-09,Amicus Therapeutics (FOLD) Stock Slumps on Q2 Loss
2016-08-09,Amicus Therapeutics Announces Second Quarter 2016 Financial Results And Corporate Updates
2016-08-03,Amicus Therapeutics To Submit Japanese New Drug Application For Migalastat For Fabry Disease In 1H17
2016-08-01,Amicus Therapeutics To Announce Second Quarter 2016 Financial Results On August 9, 2016
2016-07-31,5 Small-Cap Biotechs With Big Potential
2016-07-29,5 Small-Cap Biotechs With Big Potential
2016-07-12,Amicus Therapeutics Appoints Former FDA Division Deputy Director Andrew Mulberg As Vice President, Regulatory Strategy
2016-07-06,Amicus Therapeutics Expands Biologics Pipeline With New Preclinical Program For Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency
2016-06-30,2 Small Biotech Stocks With Big Milestones
2016-06-20,Commit To Buy Amicus Therapeutics At $3, Earn 18.3% Using Options
2016-06-10,Relative Strength Alert For Amicus Therapeutics
2016-06-10,Amicus Therapeutics Appoints Craig A. Wheeler To Board Of Directors
2016-06-02,5 Breakout Stocks Under $10 Set to Soar
2016-06-01,Amicus Therapeutics To Present At The Goldman Sachs 37th Annual Global Healthcare Conference
2016-05-31,Amicus Therapeutics Announces European Commission Approval For Galafold™ (Migalastat) In Patients With Fabry Disease In European Union
2016-05-12,Oversold Conditions For Amicus Therapeutics (FOLD)
2016-05-05,Amicus Therapeutics To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference
2016-05-03,Amicus Therapeutics Announces First Quarter 2016 Financial Results And Corporate Updates
2016-04-26,Amicus Therapeutics To Announce First Quarter 2016 Financial Results On May 3, 2016
2016-04-12,Amicus Shares Barely Budge on Prediction of $3 Billion Buyout
2016-04-01,Amicus (FOLD) Stock Soars After EU Regulator Recommended Drug
2016-04-01,Amicus Therapeutics Receives Positive CHMP Opinion For Approval Of Migalastat In Patients With Fabry Disease In European Union
2016-04-01,Amicus Fabry Drug Takes Big Step Toward European Approval
2016-03-23,6 Biotech Stocks Under $10 to Trade for Big Breakouts
2016-03-22,First Week of FOLD May 20th Options Trading
2016-03-22,Amicus Therapeutics Announces Expanded Access Program For Migalastat
2016-03-14,7 Breakout Stocks Spiking on Big Volume
2016-03-08,'Mad Money' Lightning Round: Buy, Buy, Buy Bristol-Myers Squibb
2016-03-07,Jim Cramer's 'Mad Money' Recap: Commodities Are Healing, so Are Markets
2016-03-02,Amicus Therapeutics To Present At The Cowen And Company 36th Annual Health Care Conference
2016-03-01,Amicus Therapeutics Highlights New Phase 3 Fabry Data And Preclinical Pompe Data At WORLDSymposium™ 2016
2016-02-26,First Week of October 21st Options Trading For Amicus Therapeutics (FOLD)
2016-02-26,Amicus Therapeutics Announces Full-Year 2015 Financial Results And Corporate Updates
2016-02-22,Amicus Fabry Drug Set for Crucial European Approval Vote
2016-02-18,Amicus Therapeutics To Announce Full-Year 2015 Financial Results And Corporate Updates On February 26, 2016
2016-02-10,Amicus Therapeutics Announces Presentations And Posters At 12th Annual WORLDSymposium™ 2016  
2016-02-09,Amicus Therapeutics Strengthens Executive Leadership Team
2016-02-08,Amicus Therapeutics Enters Oversold Territory (FOLD)
2016-02-03,Amicus Therapeutics To Present At The Leerink Partners 5th Annual Global Healthcare Conference
2016-01-15,3 Biotech Stocks Under $10 to Trade for Big Gains
2016-01-11,Amicus Therapeutics is Now Oversold (FOLD)
2016-01-11,Amicus Therapeutics Provides Full-Year 2016 Strategic Outlook And Financial Guidance
2016-01-04,Amicus Therapeutics To Present At The 34th Annual J.P. Morgan Healthcare Conference And 3rd Annual Dermatology Summit
2015-12-22,Amicus Therapeutics Commences Phase 1/2 Study Of Novel ERT For Treatment Of Pompe Disease
2015-12-03,UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders Of Amicus Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of December 7, 2015
2015-12-01,Jim Cramer -- Demand More From IBM Than Buffett Does; Be Choosy With Biotech
2015-12-01,Warren Buffett Is Satisfied With IBM, but Jim Cramer Wants More
2015-12-01,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors Of Class Action Against Amicus Therapeutics, Inc. And Lead Plaintiff Deadline December 7, 2015
2015-11-26,DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Amicus Therapeutics, Inc. And Encourages Investors With Losses To Contact The Firm
2015-11-21,JPMorgan Likes These 5 Biotech Stocks
2015-11-21,Clovis Blowup Conjures Bad Biotech Memories of ImClone Darkness
2015-11-17,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Amicus Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of December 7, 2015
2015-11-12,Amicus Therapeutics To Present At Goldman Sachs US Emerging / SMID Cap Growth Conference
2015-11-11,Wolf Popper LLP Updates Investigation And Reminds Shareholders Of Amicus Therapeutics, Inc. Of Class Action Lawsuit And Upcoming Lead Plaintiff Deadline
2015-11-10,DEADLINE ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Amicus Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2015-11-03,Amicus Therapeutics Announces Third Quarter 2015 Financial Results And Corporate Updates
2015-11-02,Law Offices Of Marc S. Henzel Commences Investigations Of Fifth Street Finance Corp., Amicus Therapeutics, Inc., 6D Global Technologies, Inc., BofI Holdings, Inc., Zafgen, Inc., And Valeant Pharmaceuticals, Inc.
2015-10-30,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Amicus Therapeutics, Inc. Of Pendency Of Class Action Lawsuit And A Lead Plaintiff Deadline Of December 7, 2015 - FOLD
2015-10-28,5 Biotech Stocks Under $10 Triggering Breakout Trades
2015-10-27,Amicus Therapeutics To Announce Third Quarter 2015 Financial Results On November 3, 2015
2015-10-26,The Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Amicus Therapeutics, Inc. Investors
2015-10-22,IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Amicus Therapeutics, Inc. And Encourages Shareholders To Contact The Firm
2015-10-21,SHAREHOLDER ALERT: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against Amicus Therapeutics, Inc. And Encourages Investors To Contact The Firm
2015-10-21,TRADING ALERT: Rosen Law Firm Reminds Amicus Therapeutics, Inc. Investors Of Important Deadline In Class Action - FOLD
2015-10-16,INVESTOR ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Amicus Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2015-10-16,Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Amicus Therapeutics, Inc.
2015-10-15,3 Biotech Stocks Under $10 to Buy for Breakout Gains
2015-10-14,Amicus Therapeutics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors
2015-10-13,SHAREHOLDER ALERT: Pomerantz Law Firm Announces The Filing Of A Class Action Against Amicus Therapeutics, Inc. And Certain Officers - FOLD
2015-10-12,Robbins Arroyo LLP: Amicus Therapeutics, Inc. (FOLD) Misled Shareholders According To A Recently Filed Class Action
2015-10-12,IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Amicus Therapeutics, Inc. And Encourages Shareholders To Contact The Firm
2015-10-09,Harwood Feffer LLP Announces Investigation Of Amicus Therapeutics, Inc.
2015-10-09,Kirby McInerney LLP Advises Amicus Therapeutics, Inc. Investors Of Potential Claims
2015-10-08,Amicus Therapeutics, Inc. Sued For Securities Fraud In An Expanded Class Period
2015-10-08,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Amicus Therapeutics, Inc.
2015-10-07,Amicus Therapeutics, Inc. Sued For Securities Fraud After Revealing Its NDA Will Not Be Filed This Year
2015-10-02,Market News: Amicus Therapeutics, Edge Therapeutics, Wynn Resorts
2015-10-02,Block & Leviton LLP Investigates Amicus Therapeutics After Announcement That It Will Not File A New Drug Application This Year As Originally Announced
2015-10-02,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Amicus Therapeutics, Inc.
2015-10-02,Amicus Therapeutics Enters Oversold Territory (FOLD)
2015-10-02,Amicus Therapeutics (FOLD) Stock Drops as FDA Requests More Data on Drug Candidate
2015-10-02,Amicus, Other Biotech CEOs Should Listen More, Talk Less About FDA Matters
2015-10-02,Amicus Therapeutics To Host FDA Update Conference Call Today
2015-10-02,Amicus Therapeutics Provides U.S. Regulatory Update For Migalastat Monotherapy
2015-09-30,Amicus Therapeutics Completes Acquisition Of Scioderm, Inc.
2015-09-22,Amicus Therapeutics To Present At LEERINK Partners Rare Disease Roundtable
2015-09-15,Amicus Therapeutics Plans To Submit New Drug Application (NDA) For Migalastat For Fabry Disease Following Positive Pre-NDA Meeting With FDA
2015-09-14,FOLD January 2018 Options Begin Trading
2015-08-31,Stocks Close August With Worst Monthly Losses Since 2012
2015-08-31,Stocks Lower but Crude Oil Wipes Out August Losses
2015-08-31,Interesting FOLD Put And Call Options For April 2016
2015-08-31,Stocks Extend Losses as Investors Still Have No Clue on Rate Hike Timeline
2015-08-31,Aug. 31 Premarket Briefing: 10 Things You Should Know
2015-08-31,Amicus Acquires Scioderm, Adds Drug for Rare Skin Disorder to Pipeline
2015-08-31,Amicus Therapeutics To Acquire Rare Disease Company Scioderm, Inc.
2015-08-20,'Mad Money' Lightning Round: Forget El Pollo Loco, Buy Chipotle
2015-08-19,Jim Cramer's 'Mad Money' Recap: What to Buy When the Fed Raises Rates
2015-08-05,Amicus Therapeutics Announces Second Quarter 2015 Financial Results And Corporate Updates
2015-07-29,Amicus Therapeutics Stock Sees Short Interest Expand By 48.6%
2015-07-29,Amicus Therapeutics To Announce Second Quarter 2015 Financial Results On August 5, 2015
2015-06-29,Amicus Therapeutics Joins Russell 3000(R) And Russell 2000(R) Indexes
2015-06-25,Amicus Therapeutics Announces Galafold(TM) Marketing Authorization Application (MAA) Validated By European Medicines Agency (EMA)
2015-06-17,Amicus Therapeutics Announces Closing Of Underwritten Offering Of Common Stock And Full Exercise Of Over-Allotment Option
2015-06-12,Amicus Therapeutics (FOLD) Stock Gains Following Pricing of Secondary Offering
2015-06-11,Amicus Therapeutics Prices Underwritten Offering Of Common Stock
2015-06-10,Amicus Therapeutics Announces Public Offering Of Common Stock
2015-06-08,Amicus Therapeutics Strengthens Executive Leadership Team
2015-06-03,Amicus Therapeutics Submits Marketing Authorization Application (MAA) For Full Approval Of Fabry Monotherapy Galafold(TM) (Migalastat) In European Union
2015-06-02,5 Big Trades Under $15 That Could Deliver Big Gains
2015-05-26,Amicus Therapeutics' Fabry Monotherapy Granted Accelerated Assessment By European Regulators
2015-05-06,Amicus Therapeutics (FOLD) Strong On High Relative Volume Today
2015-05-05,Amicus Therapeutics Announces First Quarter 2015 Financial Results And Corporate Updates
2015-05-05,First Week Of FOLD May 15th Options Trading
2015-05-01,Amicus Therapeutics To Announce First Quarter 2015 Financial Results On May 5, 2015
2015-04-28,Amicus Therapeutics (FOLD) Marked As A Dead Cat Bounce Stock
2015-04-27,Amicus Therapeutics Appoints David Allsop As Senior Vice President, International
2015-04-13,Trade-Ideas: Amicus Therapeutics (FOLD) Is Today's "Perilous Reversal" Stock
2015-04-09,Amicus Therapeutics Honors Fabry Disease Awareness Month And International Pompe Day
2015-03-20,Amicus Therapeutics (FOLD) Highlighted As Today's Perilous Reversal Stock
2015-03-19,Amicus Therapeutics (FOLD) Stock Spikes Today Following Accelerated Approval Filing Plan
2015-03-19,Amicus Therapeutics (FOLD) Trading With Heavy Volume Before Market Open
2015-03-19,Amicus Accelerates Approval Filing Plans for Rare Disease Drug
2015-03-19,Amicus Therapeutics Provides Positive Global Regulatory Updates From EMA And FDA Meetings For Fabry Monotherapy
2015-03-16,Insiders Were Right: FOLD Makes New 52-Week High
2015-03-03,Amicus Therapeutics Announces Full-Year 2014 Financial Results And Corporate Updates
2015-02-26,Amicus Therapeutics To Present At Cowen And Company 35th Annual Health Care Conference
2015-02-25,First Week Of FOLD October 16th Options Trading
2015-02-25,Amicus Therapeutics To Announce Full-Year 2014 Financial Results On March 3, 2015
2017-03-08,Amicus Therapeutics Launches Galafold™ (Migalastat) For Treatment Of Fabry Disease In Italy
2017-03-02,Amicus Therapeutics To Present At Upcoming Investor Conferences
2017-03-01,Amicus CEO John Crowley, Not His Daughter Megan, Might Compel Trump to Make Big Changes at FDA
2017-03-01,Amicus Therapeutics Announces Full-Year 2016 Financial Results And Corporate Updates
2017-02-27,Amicus Therapeutics Launches Galafold™ (Migalastat) For Treatment Of Fabry Disease In The United Kingdom
2017-02-22,Amicus Therapeutics To Announce Full-Year 2016 Financial Results And Corporate Updates On March 1, 2017
2017-02-15,Amicus Therapeutics Presents Additional Positive Preliminary Phase 1/2 Data At WORLDSymposium™ 2017
2017-02-15,Amicus Therapeutics Presents Important New Scientific Findings And Preclinical Data For Pompe Program At WORLDSymposium™ 2017
2017-02-14,Amicus Therapeutics Highlights New Fabry Program Data At WORLDSymposium™ 2017
2017-02-10,Short Interest In Amicus Therapeutics Jumps 14%
2017-02-06,Interesting FOLD Call Options For February 17th
2017-02-06,Amicus Therapeutics To Present At The Leerink Partners 6th Annual Global Healthcare Conference
2017-01-30,7 Things to Watch in Biotech Now
2017-01-24,Biotech Premarket Movers: Amicus Therapeutics, Nantkwest and Organovo
2017-01-24,Amicus Therapeutics Announces Presentations And Posters At 13th Annual WORLDSymposium™ 2017
2017-01-17,October 20th Options Now Available For Amicus Therapeutics (FOLD)
2017-01-09,Amicus Therapeutics Provides Full-Year 2017 Strategic Outlook And Financial Guidance
2017-01-04,National Institute For Health And Care Excellence (NICE) Issues Final Positive Recommendation For Galafold™ (migalastat) For Fabry Disease In England
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2017-01-01,5 Stocks Insiders Love Right Now
2016-12-29,3 Small Biotechs With Insider Buying
2016-12-23,Amicus Therapeutics To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-21,Amicus Therapeutics Announces Closing Of Offering Of Senior Convertible Notes And Exercise In Full Of Option To Purchase Additional Notes
2016-12-20,A Biotech Trio to Like Going Into 2017
2016-12-15,Amicus Therapeutics Announces Pricing Of Offering Of Convertible Senior Notes
2016-12-14,Amicus Therapeutics Announces Proposed Offering Of Convertible Senior Notes
2016-12-08,Amicus Therapeutics Announces Positive Preliminary Data From Phase 1/2 Study Of Novel Treatment Paradigm For Pompe Disease
2016-12-01,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Amicus Therapeutics, Inc. - FOLD
2016-11-29,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Amicus Therapeutics, Inc. (FOLD)
2016-11-29,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By Certain Officers And Directors Of Amicus Therapeutics, Inc.
2016-11-29,FOLD Makes Notable Cross Below Critical Moving Average
2016-11-28,Futures Flat as Investors Take Profits; Asia Mixed
2016-11-28,Amicus Tumbles on Lengthy Delay to U.S. Fabry Drug FDA Filing Plan
2016-11-28,Amicus Therapeutics Announces U.S. Regulatory Pathway For Migalastat For Fabry Disease
2016-11-22,4 Promising Small Biotechs to Watch in 2017
2016-11-22,First Week of FOLD July 2017 Options Trading
2016-11-11,Journal Of Medical Genetics Publishes Pivotal Phase 3 ATTRACT Study Of Migalastat For Patients With Fabry Disease
2016-11-07,Amicus Therapeutics Announces Third Quarter 2016 Financial Results And Corporate Updates
2016-11-03,Amicus Therapeutics Becomes Oversold (FOLD)
2016-11-01,Amicus Therapeutics To Announce Third Quarter 2016 Financial Results On November 7, 2016
2016-10-25,First Week of December 16th Options Trading For Amicus Therapeutics (FOLD)
2016-10-14,Amicus Therapeutics (FOLD) Shares Cross Below 200 DMA
2016-09-22,Amicus Therapeutics To Present At LEERINK Roundtable Series: Rare Disease & Immuno-Oncology
2016-09-13,UPDATE -- Amicus Therapeutics To Present At Bank Of America Merrill Lynch Global Healthcare Conference 2016
2016-09-12,Amicus Therapeutics To Present At Bank Of America Merrill Lynch Global Healthcare Conference 2016
2016-09-01,Amicus Therapeutics To Present At Robert W. Baird & Co. 2016 Healthcare Conference
2016-08-31,Amicus Therapeutics To Highlight Fabry Disease Program At Society For The Study Of Inborn Errors Of Metabolism (SSIEM) Annual Symposium
2016-08-12,TG Therapeutics Looks Like a Healthy Play
2016-08-11,3 Biotech-Investing Mistakes to Avoid
2016-08-11,Amicus (FOLD) CEO Crowley to CNBC: 'Our Job is to Stay Focused and Keep Making Great Medicines'
2016-08-10,UPDATE -- New England Journal Of Medicine Publishes Pivotal Phase 3 FACETS Study Of Migalastat For Patients With Fabry Disease
2016-08-10,New England Journal Of Medicine Publishes Pivotal Phase 3 FACETS Study Of Migalastat For Patients With Fabry Disease
2016-08-09,Amicus Therapeutics (FOLD) Stock Slumps on Q2 Loss
2016-08-09,Amicus Therapeutics Announces Second Quarter 2016 Financial Results And Corporate Updates
2016-08-03,Amicus Therapeutics To Submit Japanese New Drug Application For Migalastat For Fabry Disease In 1H17
2016-08-01,Amicus Therapeutics To Announce Second Quarter 2016 Financial Results On August 9, 2016
2016-07-31,5 Small-Cap Biotechs With Big Potential
2016-07-29,5 Small-Cap Biotechs With Big Potential
2016-07-12,Amicus Therapeutics Appoints Former FDA Division Deputy Director Andrew Mulberg As Vice President, Regulatory Strategy
2016-07-06,Amicus Therapeutics Expands Biologics Pipeline With New Preclinical Program For Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency
2016-06-30,2 Small Biotech Stocks With Big Milestones
2016-06-20,Commit To Buy Amicus Therapeutics At $3, Earn 18.3% Using Options
2016-06-10,Relative Strength Alert For Amicus Therapeutics
2016-06-10,Amicus Therapeutics Appoints Craig A. Wheeler To Board Of Directors
2016-06-02,5 Breakout Stocks Under $10 Set to Soar
2016-06-01,Amicus Therapeutics To Present At The Goldman Sachs 37th Annual Global Healthcare Conference
2016-05-31,Amicus Therapeutics Announces European Commission Approval For Galafold™ (Migalastat) In Patients With Fabry Disease In European Union
2016-05-12,Oversold Conditions For Amicus Therapeutics (FOLD)
2016-05-05,Amicus Therapeutics To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference
2016-05-03,Amicus Therapeutics Announces First Quarter 2016 Financial Results And Corporate Updates
2016-04-26,Amicus Therapeutics To Announce First Quarter 2016 Financial Results On May 3, 2016
2016-04-12,Amicus Shares Barely Budge on Prediction of $3 Billion Buyout
2016-04-01,Amicus (FOLD) Stock Soars After EU Regulator Recommended Drug
2016-04-01,Amicus Therapeutics Receives Positive CHMP Opinion For Approval Of Migalastat In Patients With Fabry Disease In European Union
2016-04-01,Amicus Fabry Drug Takes Big Step Toward European Approval
2016-03-23,6 Biotech Stocks Under $10 to Trade for Big Breakouts
2016-03-22,First Week of FOLD May 20th Options Trading
2016-03-22,Amicus Therapeutics Announces Expanded Access Program For Migalastat
2016-03-14,7 Breakout Stocks Spiking on Big Volume
2016-03-08,'Mad Money' Lightning Round: Buy, Buy, Buy Bristol-Myers Squibb
2016-03-07,Jim Cramer's 'Mad Money' Recap: Commodities Are Healing, so Are Markets
2016-03-02,Amicus Therapeutics To Present At The Cowen And Company 36th Annual Health Care Conference
2016-03-01,Amicus Therapeutics Highlights New Phase 3 Fabry Data And Preclinical Pompe Data At WORLDSymposium™ 2016
2016-02-26,First Week of October 21st Options Trading For Amicus Therapeutics (FOLD)
2016-02-26,Amicus Therapeutics Announces Full-Year 2015 Financial Results And Corporate Updates
2016-02-22,Amicus Fabry Drug Set for Crucial European Approval Vote
2016-02-18,Amicus Therapeutics To Announce Full-Year 2015 Financial Results And Corporate Updates On February 26, 2016
2016-02-10,Amicus Therapeutics Announces Presentations And Posters At 12th Annual WORLDSymposium™ 2016  
2016-02-09,Amicus Therapeutics Strengthens Executive Leadership Team
2016-02-08,Amicus Therapeutics Enters Oversold Territory (FOLD)
2016-02-03,Amicus Therapeutics To Present At The Leerink Partners 5th Annual Global Healthcare Conference
2016-01-15,3 Biotech Stocks Under $10 to Trade for Big Gains
2016-01-11,Amicus Therapeutics is Now Oversold (FOLD)
2016-01-11,Amicus Therapeutics Provides Full-Year 2016 Strategic Outlook And Financial Guidance
2016-01-04,Amicus Therapeutics To Present At The 34th Annual J.P. Morgan Healthcare Conference And 3rd Annual Dermatology Summit
2015-12-22,Amicus Therapeutics Commences Phase 1/2 Study Of Novel ERT For Treatment Of Pompe Disease
2015-12-03,UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders Of Amicus Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of December 7, 2015
2015-12-01,Jim Cramer -- Demand More From IBM Than Buffett Does; Be Choosy With Biotech
2015-12-01,Warren Buffett Is Satisfied With IBM, but Jim Cramer Wants More
2015-12-01,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors Of Class Action Against Amicus Therapeutics, Inc. And Lead Plaintiff Deadline December 7, 2015
2015-11-26,DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Amicus Therapeutics, Inc. And Encourages Investors With Losses To Contact The Firm
2015-11-21,JPMorgan Likes These 5 Biotech Stocks
2015-11-21,Clovis Blowup Conjures Bad Biotech Memories of ImClone Darkness
2015-11-17,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Amicus Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of December 7, 2015
2015-11-12,Amicus Therapeutics To Present At Goldman Sachs US Emerging / SMID Cap Growth Conference
2015-11-11,Wolf Popper LLP Updates Investigation And Reminds Shareholders Of Amicus Therapeutics, Inc. Of Class Action Lawsuit And Upcoming Lead Plaintiff Deadline
2015-11-10,DEADLINE ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Amicus Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2015-11-03,Amicus Therapeutics Announces Third Quarter 2015 Financial Results And Corporate Updates
2015-11-02,Law Offices Of Marc S. Henzel Commences Investigations Of Fifth Street Finance Corp., Amicus Therapeutics, Inc., 6D Global Technologies, Inc., BofI Holdings, Inc., Zafgen, Inc., And Valeant Pharmaceuticals, Inc.
2015-10-30,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Amicus Therapeutics, Inc. Of Pendency Of Class Action Lawsuit And A Lead Plaintiff Deadline Of December 7, 2015 - FOLD
2015-10-28,5 Biotech Stocks Under $10 Triggering Breakout Trades
2015-10-27,Amicus Therapeutics To Announce Third Quarter 2015 Financial Results On November 3, 2015
2015-10-26,The Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Amicus Therapeutics, Inc. Investors
2015-10-22,IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Amicus Therapeutics, Inc. And Encourages Shareholders To Contact The Firm
2015-10-21,SHAREHOLDER ALERT: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against Amicus Therapeutics, Inc. And Encourages Investors To Contact The Firm
2015-10-21,TRADING ALERT: Rosen Law Firm Reminds Amicus Therapeutics, Inc. Investors Of Important Deadline In Class Action - FOLD
2015-10-16,INVESTOR ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Amicus Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2015-10-16,Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Amicus Therapeutics, Inc.
2015-10-15,3 Biotech Stocks Under $10 to Buy for Breakout Gains
2015-10-14,Amicus Therapeutics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors
2015-10-13,SHAREHOLDER ALERT: Pomerantz Law Firm Announces The Filing Of A Class Action Against Amicus Therapeutics, Inc. And Certain Officers - FOLD
2015-10-12,Robbins Arroyo LLP: Amicus Therapeutics, Inc. (FOLD) Misled Shareholders According To A Recently Filed Class Action
2015-10-12,IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Amicus Therapeutics, Inc. And Encourages Shareholders To Contact The Firm
2015-10-09,Harwood Feffer LLP Announces Investigation Of Amicus Therapeutics, Inc.
2015-10-09,Kirby McInerney LLP Advises Amicus Therapeutics, Inc. Investors Of Potential Claims
2015-10-08,Amicus Therapeutics, Inc. Sued For Securities Fraud In An Expanded Class Period
2015-10-08,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Amicus Therapeutics, Inc.
2015-10-07,Amicus Therapeutics, Inc. Sued For Securities Fraud After Revealing Its NDA Will Not Be Filed This Year
2015-10-02,Market News: Amicus Therapeutics, Edge Therapeutics, Wynn Resorts
2015-10-02,Block & Leviton LLP Investigates Amicus Therapeutics After Announcement That It Will Not File A New Drug Application This Year As Originally Announced
2015-10-02,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Amicus Therapeutics, Inc.
2015-10-02,Amicus Therapeutics Enters Oversold Territory (FOLD)
2015-10-02,Amicus Therapeutics (FOLD) Stock Drops as FDA Requests More Data on Drug Candidate
2015-10-02,Amicus, Other Biotech CEOs Should Listen More, Talk Less About FDA Matters
2015-10-02,Amicus Therapeutics To Host FDA Update Conference Call Today
2015-10-02,Amicus Therapeutics Provides U.S. Regulatory Update For Migalastat Monotherapy
2015-09-30,Amicus Therapeutics Completes Acquisition Of Scioderm, Inc.
2015-09-22,Amicus Therapeutics To Present At LEERINK Partners Rare Disease Roundtable
2015-09-15,Amicus Therapeutics Plans To Submit New Drug Application (NDA) For Migalastat For Fabry Disease Following Positive Pre-NDA Meeting With FDA
2015-09-14,FOLD January 2018 Options Begin Trading
2015-08-31,Stocks Close August With Worst Monthly Losses Since 2012
2015-08-31,Stocks Lower but Crude Oil Wipes Out August Losses
2015-08-31,Interesting FOLD Put And Call Options For April 2016
2015-08-31,Stocks Extend Losses as Investors Still Have No Clue on Rate Hike Timeline
2015-08-31,Aug. 31 Premarket Briefing: 10 Things You Should Know
2015-08-31,Amicus Acquires Scioderm, Adds Drug for Rare Skin Disorder to Pipeline
2015-08-31,Amicus Therapeutics To Acquire Rare Disease Company Scioderm, Inc.
2015-08-20,'Mad Money' Lightning Round: Forget El Pollo Loco, Buy Chipotle
2015-08-19,Jim Cramer's 'Mad Money' Recap: What to Buy When the Fed Raises Rates
2015-08-05,Amicus Therapeutics Announces Second Quarter 2015 Financial Results And Corporate Updates
2015-07-29,Amicus Therapeutics Stock Sees Short Interest Expand By 48.6%
2015-07-29,Amicus Therapeutics To Announce Second Quarter 2015 Financial Results On August 5, 2015
2015-06-29,Amicus Therapeutics Joins Russell 3000(R) And Russell 2000(R) Indexes
2015-06-25,Amicus Therapeutics Announces Galafold(TM) Marketing Authorization Application (MAA) Validated By European Medicines Agency (EMA)
2015-06-17,Amicus Therapeutics Announces Closing Of Underwritten Offering Of Common Stock And Full Exercise Of Over-Allotment Option
2015-06-12,Amicus Therapeutics (FOLD) Stock Gains Following Pricing of Secondary Offering
2015-06-11,Amicus Therapeutics Prices Underwritten Offering Of Common Stock
2015-06-10,Amicus Therapeutics Announces Public Offering Of Common Stock
2015-06-08,Amicus Therapeutics Strengthens Executive Leadership Team
2015-06-03,Amicus Therapeutics Submits Marketing Authorization Application (MAA) For Full Approval Of Fabry Monotherapy Galafold(TM) (Migalastat) In European Union
2015-06-02,5 Big Trades Under $15 That Could Deliver Big Gains
2015-05-26,Amicus Therapeutics' Fabry Monotherapy Granted Accelerated Assessment By European Regulators
2015-05-06,Amicus Therapeutics (FOLD) Strong On High Relative Volume Today
2015-05-05,Amicus Therapeutics Announces First Quarter 2015 Financial Results And Corporate Updates
2015-05-05,First Week Of FOLD May 15th Options Trading
2015-05-01,Amicus Therapeutics To Announce First Quarter 2015 Financial Results On May 5, 2015
2015-04-28,Amicus Therapeutics (FOLD) Marked As A Dead Cat Bounce Stock
2015-04-27,Amicus Therapeutics Appoints David Allsop As Senior Vice President, International
2015-04-13,Trade-Ideas: Amicus Therapeutics (FOLD) Is Today's "Perilous Reversal" Stock
2015-04-09,Amicus Therapeutics Honors Fabry Disease Awareness Month And International Pompe Day
2015-03-20,Amicus Therapeutics (FOLD) Highlighted As Today's Perilous Reversal Stock
2015-03-19,Amicus Therapeutics (FOLD) Stock Spikes Today Following Accelerated Approval Filing Plan
2015-03-19,Amicus Therapeutics (FOLD) Trading With Heavy Volume Before Market Open
2015-03-19,Amicus Accelerates Approval Filing Plans for Rare Disease Drug
2015-03-19,Amicus Therapeutics Provides Positive Global Regulatory Updates From EMA And FDA Meetings For Fabry Monotherapy
2015-03-16,Insiders Were Right: FOLD Makes New 52-Week High
2015-03-03,Amicus Therapeutics Announces Full-Year 2014 Financial Results And Corporate Updates
2015-02-26,Amicus Therapeutics To Present At Cowen And Company 35th Annual Health Care Conference
2015-02-25,First Week Of FOLD October 16th Options Trading
2015-02-25,Amicus Therapeutics To Announce Full-Year 2014 Financial Results On March 3, 2015
2017-02-23,RSI Alert: Foamix Pharmaceuticals Now Oversold
2016-11-28,Foamix To Host Key Opinion Leader Luncheon For Investors Focused On Dermatology, With A Focus On Acne And Rosacea
2016-11-28,Foamix Announces Completion Of Patient Enrollment In Phase 3 Acne Trials For Minocycline Foam FMX101
2016-11-04,Ratings Changes Today
2016-11-03,Foamix Pharmaceuticals To Present At The 25th Annual Credit Suisse Healthcare Conference On November 7
2016-09-28,Foamix Pharmaceuticals Ltd. Announces Pricing Of Its $57 Million Follow-on Offering Of Ordinary Shares
2016-09-27,Foamix Pharmaceuticals Ltd. Announces Proposed Follow-on Offering Of Ordinary Shares
2016-09-06,Foamix To Present Corporate Overview At The Rodman & Renshaw 18th Annual Global Investment Conference
2016-08-10,Foamix Reports Second Quarter 2016 Financial Results And Provides Business Update
2016-08-03,Ratings Changes Today
2016-07-25,Foamix Pharmaceuticals Second Quarter Financial Results Conference Call & Webcast Scheduled For Wednesday, August 10
2016-06-01,Foamix To Present At The BIO International Convention
2016-05-31,Foamix Pharmaceuticals Announces Publication Of Abstract On FDX-104 In The Treatment Of EGFRI Induced Rash For The 2016 ASCO Meeting
2016-05-26,Foamix To Present Corporate Overview At The Jefferies 2016 Healthcare Conference
2016-05-16,Foamix Names Dr. Stanley Hirsch As Chairman, And Dr. Dalia Megiddo As A Member Of The Board Of Foamix Pharmaceuticals
2016-05-10,Foamix Reports First Quarter 2016 Financial Results And Provides Business Update
2016-05-09,Foamix Announces Dosing Of First Patient In Phase 3 Acne Studies For Minocycline Foam FMX101
2016-05-03,Foamix Announces Completion Of Enrollment In Phase 2 Clinical Trial Of Minocycline Foam (FMX103) For Treatment Of Papulopustular Rosacea
2016-04-28,Foamix Pharmaceuticals First Quarter Financial Results Conference Call & Webcast Scheduled For Tuesday, May 10
2016-03-09,Foamix To Present Corporate Overview At The Barclays Global Healthcare Conference
2016-03-07,Foamix To Present Corporate Overview At The 28th Annual ROTH Conference
2016-03-03,Foamix Reports Fiscal Year 2015 Financial Results And Provides Business Update
2016-02-29,Foamix To Present Corporate Overview At The 36th Annual Cowen & Company Healthcare Conference
2016-02-18,Foamix Pharmaceuticals Fourth Quarter And Fiscal Year 2015 Financial Results Conference Call & Webcast Scheduled For Thursday, March 3
2016-01-28,Foamix Pharmaceuticals Enters Oversold Territory (FOMX)
2016-01-07,Foamix Announces Positive Results From Phase 1 Study To Characterize Minocycline Bioavailability Of FMX-101 Compared To Solodyn® (Minocycline HCl) Extended-Release Tablets
2016-01-04,Foamix To Present Corporate Overview At The 3rd Annual Dermatology Summit Meeting
2015-12-31,5 Stocks Under $10 Set to Soar
2015-12-03,Foamix Announces Positive Top-Line Results From Phase II Study For FDX104 (Doxycycline Foam) In The Prevention Of Acneiform Rash Associated With Targeted Antibody Treatments For Colon And Head And Neck Cancers
2015-12-02,Foamix To Host Conference Call & Webcast To Discuss Topline Results From Phase 2 Study Of FDX-104 In Acneiform Rash Associated With Targeted Antibody Treatments For Colon And Head And Neck Cancers
2015-12-01,Foamix To Present Corporate Overview At The Oppenheimer 26th Annual Healthcare Conference
2015-11-12,Ratings Changes Today
2015-11-11,Foamix To Present Corporate Overview At Jefferies Autumn 2015 Global Healthcare Conference In London
2015-11-11,Foamix Reports Third Quarter 2015 Financial Results And Provides Business Update
2015-10-27,Foamix Pharmaceuticals Third Quarter 2015 Conference Call And Webcast Scheduled For Wednesday, November 11
2015-10-20,Foamix Announces Enrollment Of First Patient In Phase 2 Clinical Trial Of FMX103 In Papulopustular Rosacea
2015-08-19,Foamix Reports Second Quarter 2015 Financial Results And Provides Business Update
2015-08-13,Foamix Pharmaceuticals Second Quarter 2015 Conference Call & Webcast Scheduled For Thursday, August 20
2015-07-31,Finacea(R) (azelaic Acid) Foam 15%, Approved By U.S. FDA For Topical Treatment Of The Inflammatory Papules And Pustules Of Mild To Moderate Rosacea
2015-06-16,MERZ North America Makes Milestone Payment To Foamix
2015-06-16,Foamix Receives Milestone Payment From Merz North America
2015-06-01,Foamix To Present Corporate Overview At The Jefferies 2015 Global Healthcare Conference
2015-05-12,Foamix Reports First Quarter Financial Results
2015-05-07,Foamix Announces Appointment Of Dr. Aaron Schwartz To Board Of Directors
2015-04-29,Foamix Pharmaceuticals First Quarter 2015 Conference Call & Webcast Scheduled For Wednesday, May 13
2015-04-20,Foamix Pharmaceuticals Ltd. Announces Closing Of Its $69 Million Public Offering Of Ordinary Shares
2015-04-15,Foamix Pharmaceuticals (FOMX) Stock Spiked Following Pricing of Upsized Offering
2015-04-15,Foamix Pharmaceuticals Ltd. Announces Upsizing And Pricing Of Its $60 Million Public Offering Of Ordinary Shares
2015-04-01,Foamix Pharmaceuticals Ltd. Files Registration Statement For Proposed Follow-On Offering
2015-03-18,Foamix Reports Financial Results For The Year Ended December 31, 2014
2015-03-10,Foamix Pharmaceuticals Fourth Quarter 2014 Conference Call & Webcast Scheduled For Wednesday, March 18
2015-03-04,Foamix To Present Corporate Overview At The 27th Annual ROTH Conference
2015-03-03,Foamix To Present Corporate Overview At The Barclays Global Healthcare Conference
2015-02-26,Foamix To Present Corporate Overview At The Cowen & Company 35th Annual Health Care Conference
2014-12-16,Foamix Earns US$ 2.5 Million Milestone Payment From Bayer HealthCare
2014-12-05,Foamix To Present Corporate Overview At The Oppenheimer & Co. 25th Annual Healthcare Conference
2014-11-14,Foamix Reports Financial Results For Third Quarter And Nine Months Ended September 30, 2014
2014-11-13,Foamix Announces Two New U.S. Patents Relating To Topical Tetracycline Compositions
2014-11-10,Foamix Pharmaceuticals Third Quarter 2014 Conference Call & Webcast Scheduled For Monday, November 17, 2014
2014-10-29,Foamix Pharmaceuticals To Host Key Opinion Leader Meeting And Webcast On November 4th In New York City
2014-10-24,5 Stocks Under $10 Set to Soar
2014-10-06,Foamix Pharmaceuticals Ltd. Announces Initiation Of Phase II Trial With FDX104 In Chemotherapy Induced Rash
2014-09-23,Foamix Pharmaceuticals Ltd. Announces Closing Of Initial Public Offering
2014-09-18,Foamix Pharmaceuticals (FOMX) Stock Pops After IPO Pricing
2014-09-18,Foamix Pharmaceuticals Ltd. Prices Initial Public Offering
,
,
,
2017-03-24,Lifshitz & Miller LLP Announces Investigation Of Air Methods Corporation, Fortress Investment Group LLC, Galena Biopharma, Inc., Ionis Pharmaceuticals, Inc., LMI Aerospace, Inc., Lumos Networks Corp., Silver Bay Realty Trust Corp. And TerraForm Global, Inc.
2017-03-17,Galena Biopharma Presents Positive Final GALE-301 (E39) Phase 1/2a Clinical Trial Data
2017-03-15,Galena Biopharma Reports Fourth Quarter And Year End 2016 Financial Results And Provides A Corporate Update
2017-03-09,Galena Biopharma Engages Canaccord Genuity To Advise On Strategic Alternatives
2017-02-26,INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Galena Biopharma, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2017-02-23,How to Dig Deep for Value in These Exuberant Markets
2017-02-23,Value Investors Have to Go Deeper
2017-02-22,Investor Alert: Kaplan Fox Announces Investigation Of Galena Biopharma Inc.
2017-02-21,Galena Biopharma Board Of Directors Appoints Stephen F. Ghiglieri As Interim Chief Executive Officer
2017-02-20,GALE FRAUD NOTICE: Rosen Law Firm Reminds Galena Biopharma, Inc. Investors Of Important Deadline In Class Action - GALE
2017-02-15,Glancy Prongay & Murray LLP Files Securities Class Action Lawsuit Against Galena BioPharma, Inc.
2017-02-13,Galena Biopharma Announces Closing Of Public Offering Of Common Stock And Warrants
2017-02-13,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against Galena Biopharma, Inc. (GALE) & Lead Plaintiff Deadline: April 14, 2017
2017-02-13,EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Galena Biopharma, Inc.
2017-02-10,IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces An Investigation Of Galena Biopharma Inc. And Encourages Investors To Contact The Firm
2017-02-10,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Galena Biopharma, Inc. - GALE
2017-02-10,IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces An Investigation Of Galena Biopharma Inc. And Encourages Investors To Contact The Firm
2017-02-10,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Galena Biopharma, Inc. (GALE)
2017-02-10,EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Galena Biopharma, Inc. - GALE
2017-02-08,Gilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments
2017-02-08,Galena Biopharma Announces Pricing Of Public Offering Of Common Stock And Warrants
2017-02-07,Galena Biopharma Announces Proposed Public Offering Of Common Stock And Warrants
2017-02-06,How to Expertly Trade Monday's Most Active Stocks -- AMD, Newell Brands, Hasbro and More
2017-02-06,Galena Biopharma Reports Positive Outcome From The Data Safety Monitoring Board On The Two NeuVax™ (nelipepimut-S) Clinical Trials In Combination With Trastuzumab
2017-01-31,Galena Sacks CEO Amid Escalating Criminal Probe Into Fentanyl Drug Marketing
2017-01-31,Galena Biopharma Announces The Resignation Of Its President And Chief Executive Officer And The Evaluation Of Strategic Alternatives
2017-01-05,Galena Biopharma To Provide Corporate And Clinical Update And 2017 Outlook During Presentation At Biotech Showcase 2017
2016-12-28,Post-Trump Rally Stalls as Dow Jones Slips Further From 20,000 Mark
2016-12-28,Stocks Slump Continues With All S&P 500 Sectors in Negative Territory
2016-12-28,Midday Report: Stocks Snatch Earlier Gains as Dow Moves Away From 20,000 Mark
2016-12-28,Stocks Turn Negative, Prolonging Dow's Trek Toward 20,000
2016-12-28,Galena Biopharma Confirms Regulatory Pathway For GALE-401 (Anagrelide Controlled Release)
2016-12-22,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
2016-12-14,Galena Biopharma Announces The Phase 2 Clinical Trial Of NeuVax™ (nelipepimut-S) In Ductal Carcinoma In Situ (DCIS) Is Open For Enrollment And Screening Patients
2016-12-12,Galena Biopharma Presented Two Posters At The San Antonio Breast Cancer Symposium
2016-12-05,Galena Biopharma Inc. Presentation Now Available For On-Demand Viewing
2016-11-30,Galena Biopharma To Present Two Posters At The San Antonio Breast Cancer Symposium
2016-11-22,Galena Biopharma Inc. To Webcast, Live, At VirtualInvestorConferences.com December 1
2016-11-14,Galena Biopharma Presents GALE-301/GALE-302 Phase 1b Data At The Society For Immunotherapy Of Cancer Conference 2016
2016-11-09,Galena Biopharma Reports Third Quarter 2016 Financial Results And Provides A Corporate Update
2016-11-03,Galena Biopharma Appoints Stephen F. Ghiglieri As Executive Vice President And Chief Financial Officer
2016-10-31,Galena Biopharma Announces Reverse Stock Split
2016-10-31,Research Reports On Biotech Equities -- Mast Therapeutics, Array BioPharma, Galena Biopharma, And Clovis Oncology
2016-10-26,Galena Biopharma To Report Third Quarter 2016 Financial Results And Provide A Corporate Update On Wednesday, November 9, 2016
2016-10-20,Galena Biopharma Presents GALE-301/GALE-302 Phase 1b Data At The American College Of Surgeons Clinical Congress 2016
2016-10-10,Galena Biopharma To Present NeuVax™ (nelipepimut-S) Plus Trastuzumab Interim Safety Data At The European Society For Medical Oncology (ESMO) 2016 Congress
2016-09-29,Galena Biopharma To Present NeuVax™ (nelipepimut-S) Interim Safety Data At The European Society For Medical Oncology (ESMO) 2016 Congress
2016-09-27,Galena Biopharma Presents GALE-301 Folate Binding Protein Expression Data At The CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
2016-09-20,Galena Biopharma To Present At The Sachs Associates 16th Annual Biotech In Europe Forum
2016-09-15,Notable Thursday Option Activity: GALE, ETSY, TKAI
2016-09-14,Galena Biopharma To Present At The 2016 Aegis Growth Conference
2016-09-13,Galena Biopharma Presents Preclinical NeuVax™ (nelipepimut-S) Data In Ovarian And Pancreatic Cancer At The Progress In Vaccination Against Cancer (PIVAC) Conference
2016-09-12,Galena Biopharma Expands GALE-401 Intellectual Property Protection With Patent Issuance In Japan
2016-09-09,Galena Biopharma To Present At The Rodman & Renshaw 18th Annual Global Investment Conference
2016-08-09,Galena Biopharma Reports Second Quarter 2016 Financial Results And Provides A Corporate Update
2016-07-26,Galena Biopharma To Report Second Quarter 2016 Financial Results And Provide A Corporate Update On Tuesday, August 9, 2016
2016-07-13,Galena Biopharma Announces Closing Of Registered Direct Offering
2016-07-08,Galena Biopharma To Host Webcast And Conference Call Today
2016-07-08,Galena Biopharma Announces Pricing Of Registered Direct Offering
2016-06-29,2 Big-Volume Stocks to Add to Your Buy List -- Plus 5 Risky Ones to Avoid
2016-06-29,Galena Craters on Breast Cancer Vaccine Study Failure
2016-06-29,Galena Biopharma Discontinues NeuVax™ (nelipepimut-S) Phase 3, PRESENT Interim Analysis Based On Independent Data Monitoring Committee Recommendation
2016-06-21,First Week of GALE August 19th Options Trading
2016-06-13,Galena Biopharma Presents GALE-401 Combined Safety Data At The European Hematology Association 21st Congress
2016-06-10,Galena Biopharma Receives Two Orphan Drug Designations For GALE-301 And GALE-301/GALE-302
2016-06-07,SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Galena Biopharma, Inc. For Potential Breaches Of Fiduciary Duty By Its Board Of Directors
2016-06-06,Galena Biopharma Presents GALE-301 Phase 1/2a Primary Analysis At The American Society Of Clinical Oncology Annual Meeting 2016
2016-06-01,Galena (GALE) Stock Soared Today, Breast Cancer Treatment Received 'Fast Track' Designation
2016-06-01,7 Big-Volume Stocks to Trade for Big Gains
2016-06-01,Why Galena Biopharma (GALE) Stock Is Spiking Today
2016-06-01,Galena Biopharma Receives Fast Track Designation For NeuVax™ (nelipepimut-S) PRESENT Clinical Trial
2016-05-24,Noteworthy Tuesday Option Activity: GALE, ANF, VEEV
2016-05-24,Galena Biopharma To Present At The Sachs Associates 2nd Annual Immuno-Oncology BD&L And Investment Forum
2016-05-19,Galena Biopharma To Present GALE-401 Combined Safety Data At The European Hematology Association 21st Congress
2016-05-18,Galena Biopharma To Present The GALE-301 Phase 1/2a Primary Analysis At The American Society Of Clinical Oncology Annual Meeting 2016
2016-05-10,Galena Biopharma Reports First Quarter 2016 Financial Results And Provides A Corporate Update
2016-04-27,Galena Biopharma To Report First Quarter 2016 Financial Results And Provide A Corporate Update On Tuesday, May 10, 2016
2016-04-26,Galena Biopharma Appoints Mary Ann Gray, Ph.D., To Its Board Of Directors
2016-04-19,Galena Biopharma Presents GALE-301/GALE-302 Clinical Booster Data At The American Association For Cancer Research (AACR) Annual Meeting
2016-04-05,Commit To Purchase Galena Biopharma At $1, Earn 36.1% Annualized Using Options
2016-04-03,Biotech Stock Mailbag: Intercept, Acadia, Keryx, Galena
2016-03-29,Here&rsquo;s Why Galena Biopharma (GALE) Stock is Spiking Today
2016-03-29,Galena Biopharma Phase 3 PRESENT Clinical Trial With NeuVax™ (nelipepimut-S) Achieves 70th Qualifying Disease Free Survival Event
2016-03-22,Notable Tuesday Option Activity: GALE, BPI, GMED
2016-03-11,Galena Not Named Target of Federal Criminal Probe Into Painkiller Use
2016-03-11,Galena Biopharma Corrects Error In Form 10-K
2016-03-10,Galena Biopharma Reports Fourth Quarter And Year End 2015 Financial Results And Provides A Corporate Update
2016-03-07,Galena Biopharma To Present At The 28th Annual ROTH Conference
2016-02-26,Galena Biopharma To Report Fourth Quarter And Year End 2015 Financial Results And Provide A Corporate Update On Thursday, March 10, 2016
2016-02-17,Notable Wednesday Option Activity: GALE, WSTC, SEAS
2016-02-16,Galena Biopharma Announces Proposed Settlement Of Derivative Litigation
2016-02-08,Galena Biopharma Announces Notice Of Allowance Of U.S. Patent For NeuVax™ (nelipepimut-S)
2016-02-02,Galena Biopharma To Present At The BIO CEO & Investor Conference
2016-01-21,Galena Biopharma Presents Observational Study Data In Gastric Cancer Patients At The ASCO 2016 Gastrointestinal Cancers Symposium
2016-01-13,Galena Biopharma Provides 2016 Outlook
2016-01-11,Galena Biopharma To Present At NobleCon12 - Noble Financial Capital Markets' Twelfth Annual Investor Conference
2016-01-09,2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks
2016-01-07,Galena Biopharma Announces Pricing Of Public Offering Of Common Stock And Warrants
2016-01-06,Galena Biopharma Announces Proposed Public Offering Of Common Stock And Warrants
2015-12-24,Galena Biopharma Announces A Change To Its Board Of Directors
2015-12-18,Galena Biopharma To Sell Zuplenz® (ondansetron) Oral Soluble Film, Completing Divestiture Of Commercial Operations
2015-12-11,Galena Biopharma Announces Departure Of Chief Financial Officer
2015-12-08,Galena Biopharma Presents Final GALE-401 Phase 2 Clinical Data At The 57th American Society Of Hematology (ASH) Annual Meeting And Exposition
2015-12-04,Galena Biopharma Announces Settlement Of Securities Class Action And Shareholder Derivative Lawsuits
2015-11-30,Galena Biopharma To Present At The Oppenheimer 26th Annual Healthcare Conference
2015-11-20,Galena Biopharma Completes Divestiture Of Abstral(R) (fentanyl) Sublingual Tablets As Part Of Strategic Focus On Its Immunotherapy Pipeline
2015-11-12,Galena Biopharma (GALE) Stock Rating Upgraded at Oppenheimer
2015-11-10,Galena Biopharma (GALE) Stock Declines on Earnings Miss
2015-11-09,Galena Biopharma Reports Third Quarter 2015 Financial Results And Announces Exclusive Focus On Its Clinical Development Programs With Planned Divestiture Of The Commercial Business
2015-11-09,Galena Biopharma Presents GALE-302 Preliminary Immunologic Data Optimizing GALE-301 At The Society For Immunotherapy Of Cancer (SITC) 30th Anniversary Annual Meeting
2015-11-06,Galena Biopharma To Present Final GALE-401 Phase 2 Clinical Data At The 57th American Society Of Hematology (ASH) Annual Meeting And Exposition
2015-10-30,Galena Biopharma Appoints Bijan Nejadnik, M.D., As Executive Vice President And Chief Medical Officer
2015-10-26,Galena Biopharma To Report Third Quarter Financial Results And Provide Business Update On Monday, November 9, 2015
2015-10-22,Galena Biopharma To Present GALE-302 Preliminary Immunological Data Optimizing GALE-301, And The Phase 2 NeuVax(TM) Data Impact On Cancer Survivorship At Two Upcoming Medical Conferences
2015-09-30,Galena Biopharma Collaborates With The National Cancer Institute On A Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) In Ductal Carcinoma In Situ Patients
2015-09-28,Galena Biopharma Presents Positive GALE-301 Phase 2a Clinical Trial Data At The European Cancer Congress 2015
2015-09-14,Galena Biopharma To Present GALE-301 Phase 2a Clinical Trial Data At The European Society For Medical Oncology (ESMO) European Cancer Congress 2015
2015-09-01,Galena Biopharma To Present At Two Upcoming Healthcare Investment Conferences
2015-08-31,Galena Biopharma, Inc. Stock Alert: Schubert Firm Investigates Potential Breaches Of Fiduciary Duty
2015-08-24,Galena Biopharma Announces Independent Data Safety Monitoring Committee Recommends Reduction Of Cardiac Toxicity Monitoring For NeuVax(TM) PRESENT Trial
2015-08-06,Galena Biopharma Reports Second Quarter 2015 Financial Results
2015-08-06,August 6 Premarket Briefing: 10 Things You Should Know
2015-07-29,Galena Biopharma Launches Zuplenz(R) (ondansetron) Oral Soluble Film
2015-07-28,Galena Biopharma To Report Second Quarter Financial Results On Thursday, August 6, 2015
2015-07-21,First Week Of GALE September 18th Options Trading
2015-06-23,Interesting GALE Call Options For August 21st
2015-06-15,Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Phase 2 Data At The European Hematology Association 20th Congress
2015-06-10,Galena Biopharma (GALE) Is Today's Dead Cat Bounce Stock
2015-06-08,3 Big Stocks on Traders' Radars -- and What to Do With Them
2015-06-08,Galena Biopharma (GALE) Highlighted As Weak On High Volume
2015-06-04,Strong On High Volume: Galena Biopharma (GALE)
2015-05-28,Galena Biopharma To Present At The Sachs Immuno-Oncology BD&L And Investment Forum
2015-05-27,Galena Biopharma (GALE) Stock Spikes on Promising Cancer Vaccine Study Results
2015-05-27,Galena Biopharma Announces Publication Of Two Abstracts At The 2015 American Society Of Clinical Oncology Annual Meeting
2015-05-26,3 Biotech Stocks Under $10 to Trade for Breakouts
2015-05-22,Galena Biopharma To Present GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial Data At The European Hematology Association 20th Congress
2015-05-07,Galena Biopharma Reports First Quarter 2015 Financial Results
2015-05-07,May 7 Premarket Briefing: 10 Things You Should Know
2015-04-24,5 Stocks Ready for Breakouts
2015-04-23,Galena Biopharma To Report First Quarter Financial Results On Thursday, May 7, 2015
2015-04-14,Galena Biopharma Completes Over-Enrollment Of NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT Clinical Trial
2015-04-10,Galena Biopharma Announces Closing Of Over-Allotment Option, Increasing Total Gross Proceeds To $43.7 Million
2015-03-31,Galena Biopharma To Present At The 14th Annual Needham Healthcare Conference
2015-03-26,Galena Biopharma Expands Patient Population In NeuVax(TM) (nelipepimut-S) And Trastuzumab Phase 2b Combination Clinical Trial In HER2 1+/2+ Patients
2015-03-18,Galena Biopharma Announces Closing Of Public Offering Of Common Stock And Warrants
2015-03-13,3 Biotech Stocks on Traders' Radars: Technical Charts
2015-03-13,Galena Biopharma Announces Pricing Of Public Offering Of Common Stock And Warrants
2015-03-12,Galena Biopharma Announces Proposed Public Offering Of Common Stock And Warrants
2015-03-05,Galena Biopharma Reports Fourth Quarter And Year End 2014 Financial Results
2015-03-03,Galena Biopharma To Present At The 27th Annual ROTH Conference
2015-02-19,Galena Biopharma To Report Fourth Quarter And Year End 2014 Financial Results On Thursday, March 5, 2015
2015-02-09,Galena Biopharma Enrolls 700th Patient In NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT Clinical Trial
2015-02-05,GALE March 27th Options Begin Trading
2015-02-05,Galena Biopharma Announces Orexo's Filing Of A Patent Infringement Lawsuit Against Actavis Concerning Abstral(R) (fentanyl) Sublingual Tablets In The U.S.
2015-01-28,Galena Biopharma To Present At The 17th Annual BIO CEO & Investor Conference
2015-01-20,Galena Biopharma Hires Joseph Lasaga As Vice President, Business Development And Alliance Management
2015-01-15,Galena Biopharma To Present At The Noble Financial Capital Markets 11th Annual Investor Conference
2015-01-14,Galena Biopharma (GALE) Is Weak On High Volume Today
2015-01-08,GALE February 27th Options Begin Trading
2015-01-08,Galena Biopharma Provides 2015 Outlook
2014-12-29,Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens
2014-12-19,Adam Feuerstein's 2014 Biotech Stock Report Card (No Grading on a Curve)
2014-12-15,Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...
2014-12-11,Galena Biopharma Presents HER2 Screening Data Including Preliminary Leica Bond Oracle(TM) Results From The Phase 3 NeuVax(TM) (nelipepimut-S) Clinical Trial At The 2014 San Antonio Breast Cancer Symposium (SABCS)
2014-12-08,Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Clinical Trial Data At The 56th American Society Of Hematology (ASH) Annual Meeting & Exposition
2014-12-05,Galena Biopharma To Present HER2 Screening Data From The Phase 3 NeuVax(TM) (nelipepimut-S) Clinical Trial At The 2014 San Antonio Breast Cancer Symposium (SABCS)
2014-12-02,Galena Biopharma Receives Notice Of Allowance Of U.S. Patent Application For GALE-401 (Anagrelide Controlled Release) Composition Of Matter
2014-12-01,Galena Biopharma To Present GALE-401 (Anagrelide Controlled Release) Phase 1 Clinical Trial Data At The 56th American Society Of Hematology (ASH) Annual Meeting & Exposition
2014-11-25,Galena Biopharma To Present At The Oppenheimer 25th Annual Healthcare Conference
2014-11-24,Galena, Shunned by Wall Street, Forced to Seek Pricey Vulture Financing
2014-11-20,Galena Biopharma Announces Purchase Agreement For Up To $55.0 Million With Lincoln Park Capital Fund, LLC
2014-11-18,Galena Biopharma Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial
2014-11-13,Galena Biopharma To Present At The Stifel 2014 Healthcare Conference
2014-11-11,Galena Biopharma Doses First Patient In Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) In Combination With Herceptin(R) (trastuzumab) To Treat High-Risk HER2 3+ Or HER2 Gene-Amplified Breast Cancer Patients
2014-11-07,Galena Biopharma Presents GALE-301 (Folate Binding Protein Immunotherapy) Phase 2a Clinical Trial Data At The Society For Immunotherapy Of Cancer (SITC) 29th Annual Meeting
2014-11-04,Galena Biopharma To Present GALE-301 (Folate Binding Protein) Phase 2a Clinical Trial Data At The Society For The Immunotherapy Of Cancer (SITC) 29th Annual Meeting On Friday, November 7, 2014
2014-11-03,Galena Biopharma Reports Third Quarter 2014 Results
2014-10-27,Galena Biopharma To Report Third Quarter 2014 Financial Results On Monday, November 3, 2014
2014-10-24,Interesting GALE Put Options For December 20th
2014-10-14,Galena Biopharma Receives Notice Of Allowance Of Improvement Patent For NeuVax(TM) (nelipepimut-S) In Japan
2016-06-21,Trade-Ideas: GlobeImmune (GBIM) Is Today's Strong On High Relative Volume Stock
2016-06-20,GlobeImmune (GBIM) Weak On High Volume Today
2016-05-19,5 Stocks Under $10 Set to Soar
2016-04-25,8 Breakout Stocks Under $10 to Trade for Big Profits
2015-09-03,4 Stocks Under $10 Triggering Breakout Trades
2015-08-04,Ratings Changes Today
2014-07-08,GlobeImmune Announces Closing Of Initial Public Offering And Full Exercise Of Underwriter's Overallotment Option
2014-07-01,GlobeImmune Announces Pricing Of Initial Public Offering
2012-09-19,New Edge IPOs: Trulia, GlobeImmune, Smith Electric Vehicles
,
,
,
,
,
2016-06-21,Trade-Ideas: GlobeImmune (GBIM) Is Today's Strong On High Relative Volume Stock
2016-06-20,GlobeImmune (GBIM) Weak On High Volume Today
2016-05-19,5 Stocks Under $10 Set to Soar
2016-04-25,8 Breakout Stocks Under $10 to Trade for Big Profits
2015-09-03,4 Stocks Under $10 Triggering Breakout Trades
2015-08-04,Ratings Changes Today
2014-07-08,GlobeImmune Announces Closing Of Initial Public Offering And Full Exercise Of Underwriter's Overallotment Option
2014-07-01,GlobeImmune Announces Pricing Of Initial Public Offering
2012-09-19,New Edge IPOs: Trulia, GlobeImmune, Smith Electric Vehicles
,
,
,
,
,
2017-03-06,Howard Mayer, M.D., Of Shire, Joins Genocea Biosciences' Board Of Directors
2017-03-01,Genocea To Present At The Cowen And Company 37th Annual Health Care Conference
2017-02-16,Genocea Reports Fourth Quarter And Year-End 2016 Financial Results
2017-02-09,Genocea To Host Fourth Quarter And Year End 2016 Financial Results Conference Call & Webcast On February 16, 2017
2017-01-05,Genocea Announces Positive 6-Month Results From GEN-003 Phase 2b Clinical Trial
2016-12-14,Genocea R&D Day Highlighted Lead Program, GEN-003, For The Treatment Of Genital Herpes And Introduced Immuno-Oncology Programs & Strategy
2016-12-14,Genocea Announces Research Collaboration With Checkmate Pharmaceuticals In Advanced Melanoma
2016-12-08,Genocea To Host Virtual R&D Day On December 14th, 2016
2016-11-11,Genocea's Proprietary ATLAS™ Technology Identifies Unique Candidate Antigens For Potential Personalized Cancer Vaccines
2016-11-09,Genocea To Present At Two Upcoming November Conferences
2016-11-03,Genocea Reports Third Quarter 2016 Financial Results
2016-10-28,Genocea Presents New 12 Month Data On Genital Herpes Immunotherapy GEN-003 At IDWeek 2016
2016-10-27,Genocea To Host Third Quarter 2016 Financial Results Conference Call & Webcast On November 3, 2016
2016-10-06,RSI Alert: Genocea Biosciences (GNCA) Now Oversold
2016-09-29,Genocea's Genital Herpes Immunotherapy GEN-003 Demonstrates Significant Reduction Of Viral Shedding In Phase 2b Clinical Trial
2016-08-09,Genocea Congratulates Jessica Baker Flechtner, Ph.D. For Recognition On 2016's 40 Women To Watch Over 40 List
2016-08-04,Genocea Reports Second Quarter 2016 Financial Results
2016-07-28,Genocea To Host Second Quarter 2016 Financial Results Conference Call & Webcast On August 4, 2016
2016-07-06,Genocea To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference
2016-06-29,Genocea Biosciences (GNCA) Highlighted As Weak On High Volume
2016-06-29,7 Stocks Under $10 Making Big Moves
2016-06-09,Genocea Appoints Ron Cooper To Board Of Directors
2016-06-09,Genocea Showcases Potential Of Genital Herpes Immunotherapy GEN-003 At ASM Microbe 2016
2016-05-31,6 Breakout Stocks Under $10 Set to Soar
2016-05-23,Genocea Appoints Dr. John E. Bishop As Senior Vice President Of Pharmaceutical Sciences
2016-05-17,Genocea To Present At The 2016 UBS Global Healthcare Conference
2016-05-05,Genocea Reports First Quarter 2016 Financial Results
2016-04-28,Genocea To Host First Quarter 2016 Financial Results Conference Call & Webcast On May 5, 2016
2016-04-20,Genocea Congratulates Dr. George Siber, 2016 Albert B. Sabin Gold Medal Award Recipient
2016-04-12,Today's Dead Cat Bounce Stock: Genocea Biosciences (GNCA)
2016-04-11,Genocea Biosciences (GNCA) Highlighted As Weak On High Volume
2016-04-06,Genocea To Present At The 15th Annual Needham Healthcare Conference
2016-04-05,Strong On High Relative Volume: Genocea Biosciences (GNCA)
2016-04-04,Trade-Ideas: Genocea Biosciences (GNCA) Is Today's "Dead Cat Bounce" Stock
2016-04-01,Genocea Biosciences (GNCA) In A Perilous Reversal
2016-03-31,Genocea Biosciences (GNCA) Stock Soars on Positive Trial Results
2016-03-31,Genital Herpes Immunotherapy GEN-003 Shows Sustained Reduction Of Viral Shedding Rate, Durable Impact On Clinical Disease 12 Months Post-Dosing
2016-03-10,5 Stocks Under $10 Set to Soar Higher
2016-02-29,Genocea To Present At The Cowen And Company 36th Annual Health Care Conference
2016-02-26,Short Interest In Genocea Biosciences Moves 31.7% Higher
2016-02-12,5 Breakout Stocks to Trade for Big Gains
2016-02-11,Genocea Reports Fourth Quarter And Year-End 2015 Financial Results
2016-02-04,Genocea To Host Fourth Quarter And Year End 2015 Financial Results Conference Call & Webcast On February 11, 2016
2016-02-01,Genocea To Present At 2016 BIO CEO & Investor Conference
2016-01-29,Genocea Commences Dosing In Phase 2b Study For Genital Herpes Treatment, GEN-003
2016-01-22,8 Stocks Under $10 Making Big Moves Higher
2016-01-06,Genocea Biosciences Becomes Oversold (GNCA)
2015-12-17,Insider Trading Alert - GNCA, DXCM And SCOR Traded By Insiders
2015-11-24,Genocea To Present At The Piper Jaffray 27th Annual Healthcare Conference
2015-11-11,Genocea To Present At The Stifel 2015 Healthcare Conference
2015-11-05,Genocea Reports Third Quarter 2015 Financial Results
2015-11-05,Genocea Announces Immuno-Oncology Research Collaboration With Memorial Sloan Kettering Cancer Center
2015-11-04,Genocea Presents Positive Findings From ATLASTM Immuno-Oncology Research Collaboration At 2015 SITC Annual Meeting
2015-10-29,5 Stocks Under $10 Set to Soar Higher
2015-10-29,Genocea To Host Third Quarter 2015 Financial Results Conference Call & Webcast On November 5, 2015
2015-10-27,Genocea Announces Publications Highlighting ATLAS™ T Cell Antigen Discovery Efforts In Chlamydia And Malaria
2015-10-19,Relative Strength Alert For Genocea Biosciences
2015-10-19,Genocea Announces Top-Line Results From Phase 2a Trial For Universal Pneumococcal Vaccine Candidate GEN-004
2015-10-14,Genocea Biosciences (GNCA): Today's Weak On High Volume Stock
2015-10-13,Genocea Biosciences (GNCA) Flagged As Strong On High Volume
2015-10-07,Genocea Announces Positive Durability Data From 6-Month Analysis Of Phase 2 Clinical Trial Of Genital Herpes Immunotherapy GEN-003
2015-08-06,Genocea Reports Second Quarter 2015 Financial Results
2015-08-04,Genocea Biosciences, Inc. Announces Closing Of $50 Million Public Offering Of Common Stock
2015-07-30,Genocea To Host Second Quarter 2015 Financial Results Conference Call & Webcast On August 6, 2015
2015-07-30,Genocea Biosciences, Inc. Announces Pricing Of $50 Million Public Offering
2015-07-29,Genocea Biosciences, Inc. Commences Public Offering Of Common Stock
2015-05-20,Genocea Announces Positive Top-Line Phase 2 Data For Genital Herpes Immunotherapy GEN-003
2015-05-13,Genocea To Present At The UBS Global Healthcare Conference
2015-05-07,Genocea Biosciences is Now Oversold (GNCA)
2015-05-07,Genocea Reports First Quarter 2015 Financial Results
2015-04-30,Genocea To Host First Quarter 2015 Financial Results Conference Call & Webcast On May 7, 2015
2015-04-22,Genocea Completes Enrollment In Phase 2a Human Challenge Study Of GEN-004 For The Prevention Of Infection By Pneumococcus
2015-04-08,Genocea To Present At The 14th Annual Needham & Co. Healthcare Conference
2015-03-17,Genocea Biosciences, Inc. Announces Closing Of $51.7 Million Public Offering Of Common Stock And Exercise In Full Of Underwriters' Option To Purchase Additional Shares
2015-03-12,3 Health Care Stocks Under $10 to Trade for Breakouts
2015-03-12,Genocea Biosciences, Inc. Announces Pricing Of $45 Million Public Offering
2015-03-11,Genocea Biosciences, Inc. Commences Public Offering Of Common Stock
2015-03-06,Ratings Changes Today
2015-02-27,Genocea Appoints Michael Higgins To Its Board Of Directors
2015-02-25,Genocea To Present At The Cowen And Company 35th Annual Health Care Conference
2015-02-12,Genocea Reports Fourth Quarter And Year-End 2014 Financial Results
2015-02-05,Genocea To Host Fourth Quarter And Year End 2014 Financial Results Conference Call & Webcast On February 12, 2015
2015-02-02,Genocea To Present At The 2015 BIO CEO & Investor Conference
2015-01-29,5 Under-$10 Health Care Stocks Setting Up to Trade Higher
2015-01-21,RSI Alert: Genocea Biosciences (GNCA) Now Oversold
2015-01-07,Genocea Completes Enrollment Early In Phase 2 Dose Optimization Trial Of GEN-003 For Treatment Of Genital Herpes
2014-12-15,Genocea Appoints Eric S. Hoffman As Chief Business Officer
2014-11-25,Genocea To Present At Upcoming Investor Conferences
2014-11-21,Genocea Secures Debt Facility From Hercules Technology Growth Capital Of Up To $27 Million
2014-11-13,Genocea Named In Top Places To Work List By The Boston Globe
2014-11-12,Genocea To Present At The Stifel Nicolaus 2014 Healthcare Conference
2014-11-06,Genocea Reports Third Quarter 2014 Financial Results
2014-11-05,Genocea Profiles T Cell Responses To Identify Antigens Associated With Malaria Episodes
2014-10-30,Genocea To Announce Third Quarter 2014 Financial Results On November 6, 2014
2014-10-08,Genocea Presents Complete Phase 1/2a Data For HSV-2 Immunotherapy At IDWeek
2014-09-23,Genocea Announces $1.2 Million Grant For Malaria Vaccine Discovery
2014-09-22,Genocea Biosciences Becomes Oversold (GNCA)
2014-09-19,Genocea To Present At The 21st Annual NewsMakers In The Biotech Industry Conference
2014-09-16,Virology Publishes Genocea HSV-2 Antigen Discovery Paper
2014-09-11,Genocea Commences Phase 2a Trial For GEN-004, Universal Pneumococcal Vaccine Candidate
2014-09-11,Genocea Appoints Kenneth Bate To Its Board Of Directors
2014-09-06,Genocea Presents Phase 1 Immunology Data For Novel Pneumoccocus Vaccine At ICAAC
2014-08-06,Genocea Reports Second Quarter 2014 Financial Results
2014-07-30,Genocea To Announce Second Quarter 2014 Financial Results On August 6, 2014
2014-07-22,Genocea HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses In Vaccinated Subjects
2014-07-21,Genocea Commences Phase 2 Dose Optimization Trial For GEN-003 HSV-2 Immunotherapy
2014-07-16,Genocea Biosciences, Inc. Elects Not To Pursue Public Offering
2014-07-14,Genocea Biosciences, Inc. Commences Public Offering Of Common Stock
2014-06-23,4 Stocks Breaking Out on Big Volume
2014-04-01,3 Biotech Stocks Rising on Unusual Volume
2014-02-12,Top Insider Trades: EPZM IDTI GAIN GNCA
,
,
2017-03-15,GTx Provides Corporate Update And Reports Fourth Quarter And Year-End 2016 Financial Results
2017-03-07,GTx, Inc. To Report Fourth Quarter And Full Year 2016 Financial Results On March 15, 2017
2016-12-08,GTx Reports Results From Ongoing Enobosarm Phase 2 Clinical Trial In ER+/AR+ Breast Cancer
2016-12-05,GTx, Inc. Announces 1-for-10 Reverse Stock Split
2016-11-28,Enobosarm Meets Pre-Specified Primary Efficacy Endpoint In Ongoing Phase 2 Clinical Trial In ER+/AR+ Breast Cancer
2016-11-23,GTx Announces Webcast Of Corporate Presentation At The 28th Annual Piper Jaffray Healthcare Conference
2016-11-16,GTx Achieves Second Stage 1 Milestone In Phase 2 Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer
2016-11-11,GTx Announces Webcast Of Corporate Presentation At The Stifel 2016 Healthcare Conference
2016-11-03,GTx Provides Corporate Update And Reports Third Quarter 2016 Financial Results
2016-10-12,GTx Announces $14.0 Million Registered Direct Common Stock Offering
2016-09-08,GTx Achieves Stage 1 Milestone In Phase 2 Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer
2016-09-02,GTx Announces Webcast Of Corporate Presentation At Baird's 2016 Healthcare Conference
2016-09-01,GTx Appoints Dr. Garry Neil To Board Of Directors
2016-08-09,GTx Provides Corporate Update And Reports Second Quarter 2016 Financial Results
2016-07-05,XBiotech Cancer Drug Survival Claim Falls Apart Under Scrutiny
2016-06-02,GTx Announces Webcast Of Corporate Presentation At Jefferies 2016 Global Healthcare Conference
2016-05-16,GTx Announces Webcast Of Corporate Presentation At The UBS Global Healthcare Conference 2016
2016-05-10,GTx Provides Corporate Update And Reports First Quarter 2016 Financial Results
2016-05-09,GTx Announces Presentation Of Preclinical Data Demonstrating The Ability Of SARDs To Degrade And Inhibit The Androgen Receptor At The American Urological Association Annual Meeting
2016-04-27,GTx, Inc. To Report First Quarter 2016 Financial Results On May 10, 2016
2016-03-03,GTx Provides Corporate Update And Reports Fourth Quarter And Year-End 2015 Financial Results
2016-02-24,GTx Announces Presentation Of Preclinical Data Demonstrating The Effect Of GTx SARMs On Pelvic Floor Muscle Loss At The Society Of Urodynamics, Female Pelvic Medicine And Urogenital Reconstruction (SUFU) Meeting
2016-02-18,GTx, Inc. To Host Fourth Quarter And Full Year 2015 Financial Results Conference Call And Webcast
2016-01-13,GTx Announces Initiation Of Phase 2 Clinical Trial Of Enobosarm In Stress Urinary Incontinence
2015-10-29,GTx Provides Corporate Update And Reports Third Quarter 2015 Financial Results
2015-10-15,GTx, Inc. To Host Third Quarter 2015 Financial Results Conference Call And Webcast
2015-10-13,GTx Receives FDA Clearance To Initiate Clinical Trial In Stress Urinary Incontinence
2015-10-06,GTx Announces Enrollment Of First Patient In Phase 2 Clinical Trial Of Enobosarm In Triple Negative Breast Cancer
2015-09-29,GTx Announces Enrollment Of First Patient In Phase 2 Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer
2015-08-06,GTx Provides Corporate Update And Reports Second Quarter 2015 Financial Results
2015-07-23,GTx, Inc. To Host Second Quarter 2015 Financial Results Conference Call And Webcast
2015-07-08,GTx Appoints Diane Young, M.D. As Vice President, Chief Medical Officer
2015-06-02,GTx Regains Compliance With NASDAQ Bid Price Requirement
2015-05-26,GTx Announces Webcast Of Corporate Presentation At Jefferies 2015 Global Healthcare Conference
2015-05-12,GTx Announces Webcast Of Corporate Presentation At The UBS Global Healthcare Conference 2015
2015-05-08,GTx Provides Corporate Update And Reports First Quarter 2015 Financial Results
2015-04-30,3 Stocks Under $10 to Trade for Big Breakouts
2015-04-23,GTx And The University Of Tennessee Research Foundation Enter Into Exclusive License Agreement To Develop UTRF's SARD Drug Technology
2015-04-02,GTx Provides Corporate Update Regarding NASDAQ Stock Listing
2015-03-04,GTx Provides Corporate Update And Reports Fourth Quarter And Year-End 2014 Financial Results
2015-02-19,GTx, Inc. To Host Fourth Quarter And Full Year 2014 Financial Results Conference Call And Webcast
2015-02-17,GTx Appoints Robert J. Wills, Ph.D. To Board Of Directors
2014-12-08,GTx To Present Results On Enobosarm 9mg In Women With Metastatic Breast Cancer At 2014 San Antonio Breast Cancer Symposium
2014-11-17,GTx Announces Closing Of $43.4 Private Placement
2014-11-12,GTx Announces Webcast Of Corporate Presentation At The Stifel 2014 Healthcare Conference
2014-11-10,GTx Provides Corporate Update And Reports Third Quarter 2014 Financial Results
2014-11-10,GTx Announces $43.4 Million Private Placement
2014-11-03,GTx, Inc. To Host Third Quarter 2014 Financial Results Conference Call And Webcast
2014-08-07,GTx Announces Webcast Of Corporate Presentation At The 2014 Wedbush Pacgrow Life Sciences Management Access Conference
2014-08-05,GTx Provides Corporate Update And Reports Second Quarter 2014 Financial Results
2014-07-22,GTx, Inc. To Report Second Quarter 2014 Financial Results On August 5, 2014
2014-07-02,4 Biotech Stocks Under $10 to Watch for Breakout Trades
2014-06-02,GTx Reports Positive Clinical Data From Open Label Phase 2 Study Of Enobosarm In Patients With Androgen And Estrogen Receptor Positive Metastatic Breast Cancer
2014-05-22,GTx Announces Webcast Of Corporate Presentation At Jefferies 2014 Global Healthcare Conference
2014-05-19,GTx To Present Clinical Data On Enobosarm In Breast Cancer And NSCLC At ASCO 2014 Annual Meeting
2014-05-08,GTx Provides Corporate Update And Reports First Quarter 2014 Financial Results
2014-04-24,GTx, Inc. To Report First Quarter 2014 Financial Results On May 8, 2014
2014-04-04,GTx Announces Departure Of CEO
2014-03-06,GTx, Inc. Announces Closing Of Private Placement
2014-03-05,GTx Announces Webcast Of Corporate Presentation At 26TH Annual ROTH Conference
2014-03-04,GTx Provides Corporate Update And Reports 2013 Financial Results
2014-03-04,GTx, Inc. Announces Pricing Of Private Placement
2014-02-26,GTx Announces Webcast Of Corporate Presentation At Cowen And Company 34th Annual Health Care Conference
2014-02-18,GTx, Inc. To Host Fourth Quarter And Full Year 2013 Financial Results Conference Call And Webcast
2014-02-04,First Week of March 22nd Options Trading For GTXI
2014-02-04,GTx Announces Webcast Of Corporate Presentation At Bio CEO &amp; Investor Conference
2014-01-29,Preliminary Findings From The Phase 2 Clinical Trial Of GTx-758 In Men With Castration Resistant Prostate Cancer To Be Presented At ASCO Genitourinary Cancer Symposium
2013-12-19,5 Stocks Under $10 Set to Soar
2013-12-12,GTx Presents On Enobosarm As Targeted Therapy For The Treatment Of Androgen Receptor-Positive Breast Cancer At The San Antonio Breast Cancer Symposium
2013-11-12,GTx Provides Corporate Update And Reports Third Quarter 2013 Financial Results
2013-10-29,GTx, Inc. To Host Third Quarter 2013 Financial Results Conference Call And Webcast
2013-10-24,GTx Presents Results From Enobosarm POWER Trials For The Prevention And Treatment Of Muscle Wasting In Patients With Non-Small Cell Lung Cancer At 15th World Conference On Lung Cancer
2013-09-24,GTx Announces Late Breaker Presentation On Results From The Two Phase 3 POWER Trials Of Enobosarm, A Selective Androgen Receptor Modulator (SARM), For The Prevention And Treatment Of Muscle Wasting In NSCLC Patients During 2013 European Cancer Congress
2013-09-16,5 Stocks Ready for Breakouts
2013-09-11,6 Under-$10 Stocks Moving Higher
2013-09-06,GTx Announces Webcast Of Corporate Presentation At Stifel Nicolaus 2013 Healthcare Conference
2013-08-29,GTx, Inc. Sued By Investor
2013-08-27,Short Interest In GTx Inc Increases 32%
2013-08-23,Top Insider Trades: GLP ACW GTXI AHH
2013-08-23,The 5 Dumbest Things on Wall Street This Week: Aug. 23
2013-08-23,5 Dumbest Things on Wall Street
2013-08-19,Shareholder Rights Law Firm Johnson &amp; Weaver, LLP Announces Investigation Of GTx Inc.
2013-08-19,GTXI SHAREHOLDER ALERT: The Law Firm Of Wohl &amp; Fruchter LLP Announces Investigation Of GTX Inc.
2013-08-19,GTx: Survival Spin Job Follows Enobosarm Study Flop
2013-08-19,GTx Reports Results For Enobosarm POWER Trials For The Prevention And Treatment Of Muscle Wasting In Patients With Non-Small Cell Lung Cancer
2013-08-12,Short Interest Moves 47.3% Higher For GTXI
2013-08-04,MannKind, Vical, GTx: Investors Predict Pivotal Clinical Trial Results
2013-08-02,GTx Inc Is Now Oversold (GTXI)
2013-07-19,GTx Provides Corporate Update And Second Quarter 2013 Financial Results
2013-07-12,Biotech Stock Mailbag: GTx, Vanda, Pharmacyclics
2013-07-11,October 19th Options Now Available For GTx
2013-07-10,The GTx Cancer Muscle-Wasting Drug Studies Will Fail. Here's Why
2013-06-28,GTx Presents On Enobosarm For The Prevention And Treatment Of Muscle Wasting In Cancer Patients At The 2013 MASCC/ISOO International Symposium On Supportive Care In Cancer
2013-06-24,GTx Announces Symposium And Presentation Of Scientific Poster Presentations On Enobosarm At The 2013 MASCC/ISOO International Symposium On Supportive Care In Cancer
2013-06-07,Biotech Stock Mailbag: 2013 Clinical Trials Calendar
2013-05-23,Commit To Buy GTx At $4, Earn 69% Annualized
2013-04-18,5 Health Care Stocks Under $10 Ready to Rip Higher
2013-03-19,GTx-758 Poster Presentation Of Phase II Trial Data In Advanced Prostate Cancer Selected As One Of The Best Posters At The 28th Annual European Association Of Urology Congress
2013-03-14,Enobosarm Phase 2 Trial For Muscle Wasting And Physical Function In Patients With Cancer Published In The Lancet Oncology
2013-02-27,GTx Announces Webcast Of Corporate Presentation At Cowen And Company 33rd Annual Health Care Conference
2013-02-21,GTx Provides Corporate Update And Reports 2012 Financial Results
2013-02-19,GTx Announces Webcast Of Corporate Presentation At 2013 Citi Global Healthcare Conference
2013-02-14,GTx To Present Preclinical Data On A New Therapeutic Target In Prostate Cancer
2013-02-13,Novel Findings From Clinical Studies Examining The Effects Of Capesaris&#174; (GTx-758) For The Treatment Of Advanced Prostate Cancer To Be Presented At 2013 American Society Of Clinical Oncology Genitourinary Cancer Symposium
2013-02-12,GTx Announces Webcast For Capesaris&#174;(GTx-758) Analyst Day
2013-02-07,GTx, Inc. To Host Fourth Quarter And Full Year 2012 Financial Results Conference Call And Webcast
2013-02-05,GTx Announces Webcast Of Corporate Presentation At Bio CEO &amp; Investor Conference
2013-01-08,GTx Announces FDA&#8217;s Grant Of Fast Track Designation To Enobosarm For The Prevention And Treatment Of Muscle Wasting In Patients With Non-Small Cell Lung Cancer
2012-12-17,GTx Attains Enrollment Goal For Its Enobosarm POWER 1 And POWER 2 Phase III Clinical Studies
2012-12-11,4 Stocks Soaring on Unusual Volume
2012-11-08,GTx Announces Webcast Of Corporate Presentation At Jefferies 2012 Global Healthcare Conference
2012-11-08,GTx Provides Corporate Update And Reports Third Quarter 2012 Financial Results
2012-11-06,GTx Announces Webcast Of Corporate Presentation At Lazard Capital Markets 9th Annual Healthcare Conference
2012-10-29,GTx's Phase III Clinical Development Of Enobosarm (GTx-024) For Muscle Wasting In Lung Cancer Patients On Course Following Planned Safety Review
2012-10-25,GTx, Inc. To Host Third Quarter 2012 Financial Results Conference Call And Webcast
2012-10-08,GTx To Present Scientific Poster Presentations On Enobosarm To Prevent And Treat Muscle Wasting In Cancer Patients
2012-10-01,GTx Announces Sale Of Fareston&#174;
2012-09-19,GTx Announces Presentation On The Ability Of Capesaris&#174; To Reduce Free Testosterone And Suppress PSA In Men With Castration Resistant Prostate Cancer
2012-09-17,GTx Announces Symposium And Presentation Of Data On Muscle Wasting In Non-Small Cell Lung Cancer Patients
2012-08-28,GTx Announces Webcast Of Corporate Presentation At NewsMakers In The Biotech Industry Conference
2012-08-27,GTx Announces Webcast Of Corporate Presentation At Stifel Nicolaus 2012 Healthcare Conference
2012-08-14,5 Biotech Stocks Under $10 Blasting Higher
2012-08-08,GTx's CEO Discusses Q2 2012 Results - Earnings Call Transcript
2012-08-08,GTx Provides Corporate Update And Reports Second Quarter 2012 Financial Results
2012-08-06,GTx Announces Webcast Of Corporate Presentation At Wedbush 2012 Life Sciences: Management Access Conference
2012-07-26,GTx, Inc. To Host Second Quarter 2012 Financial Results Conference Call And Webcast
2012-06-26,GTx Announces Presentations On The Effect Of Enobosarm On Improving Physical Function In Cancer Patients
2012-06-25,GTx Announces Presentation On Enobosarm&#8217;s Improvement In Physical Function In Cancer Patients With Both Low And Normal Testosterone Levels
2012-06-22,GTx Announces Panel Presentation On Muscle Wasting In Non-Small Cell Lung Cancer Patients
2012-06-13,GTx Announces Poster Presentation On The Prevalence And Impact Of Hypogonadism In Cancer Patients With Muscle Wasting From Its Phase IIb Enobosarm Clinical Trial At The Endocrine Society&#8217;s 2012 Annual Meeting
2012-05-29,GTx Announces Webcast Of Corporate Presentation At Jefferies 2012 Global Healthcare Conference
2012-05-08,7 Stocks Soaring in a Weak Market
2012-05-08,GTx Announces Removal Of Full Clinical Hold By FDA For Capesaris&#174; In Advanced Prostate Cancer
2012-04-25,GTx, Inc. To Host First Quarter 2012 Financial Results Conference Call And Webcast
2012-04-04,GTx Submits Clinical Hold Complete Response Letter To FDA For Its Planned Phase II Clinical Study Of Capesaris&#174; For Secondary Hormonal Therapy Of Advanced Prostate Cancer
2012-03-15,5 Stocks Insiders Love Right Now
2012-03-02,GTx Announces Webcast Of Corporate Presentation At The Cowen And Co. Annual Health Care Conference
2012-02-24,GTx Announces Webcast Of Corporate Presentation At The Citi 2012 Global Health Care Conference
2012-02-21,GTx Stock Gaps Down On Today's Open (GTXI)
2012-02-21,GTx Provides Corporate Update And Reports 2011 Financial Results
2012-02-21,GTx Announces Clinical Hold On Clinical Trials Evaluating Capesaris&#174; For First And Second Line Treatments Of Advanced Prostate Cancer
2012-02-13,GTx, Inc. To Host Fourth Quarter And Full Year 2011 Financial Results Conference Call And Webcast
2011-11-10,GTx Announces Webcast Of Corporate Presentation At The Lazard Capital Markets Annual Healthcare Conference
2011-11-04,GTx, Inc. Provides Corporate Update And Reports Third Quarter 2011 Financial Results
2011-10-21,GTx, Inc. To Host Third Quarter 2011 Financial Results Conference Call And Webcast
2011-08-31,GTx Announces Panel Discussion At Citi&#8217;s 6th Annual Biotech Day
2011-08-11,GTx Announces Webcast Of Corporate Presentation At The 2011 Wedbush Life Sciences Conference
2011-08-09,GTx, Inc. Provides Corporate Update And Reports Second Quarter 2011 Financial Results
2011-07-28,GTx, Inc. To Host Second Quarter 2011 Financial Results Conference Call And Webcast
2011-07-01,5 Stocks With Big Insider Buying
2011-06-30,GTx Announces Upcoming Presentations Of Effects Of Ostarine&#8482; In Non-Small Cell Lung Cancer Patients At World Conference On Lung Cancer
2011-06-29,Insiders Trading KIOR, NWN, GTXI
2011-06-28,10 Cheap Biotech Stocks That Could Soar
2011-06-23,GTx Announces Pricing Of Public Offering Of Common Stock
2011-06-22,GTx Announces Proposed Public Offering Of Common Stock
2011-06-20,GTx Initiates Phase IIb Clinical Trial Evaluating&#160;Oral&#160;Capesaris&#8482;&#160;Tablets Versus Lupron&#160;Depot&#174;&#160;for First Line Treatment Of Advanced Prostate Cancer
2011-06-13,GTx Set To Join Russell 3000 Index
2011-06-06,GTx Announces Agreement With FDA On Phase III Clinical Development Plan Evaluating Ostarine&#8482; (GTx-024) For The Prevention And Treatment Of Muscle Wasting In Patients With Non-Small Cell Lung Cancer
2011-05-18,GTx Announces ASCO Presentations Highlighting Effects Of Ostarine&#8482; On Physical Function And Survival In Patients With Non-Small Cell Lung Cancer
2011-05-17,GTx Presents Preclinical Study Results Demonstrating That Capesaris&#8482; (GTx-758) Chronic Treatment Does Not Cause Gynecomastia In Male Primates
2011-05-11,GTx Inc. Stock Downgraded (GTXI)
2011-05-09,GTx Inc. Stock Upgraded (GTXI)
2011-05-09,GTx Provides Corporate Update And Reports First Quarter 2011 Financial Results
2011-05-02,GTx, Inc. To Host First Quarter 2011 Financial Results Conference Call And Webcast
2011-03-02,GTx And Ipsen Terminate Their Toremifene Collaboration
2011-03-01,GTx Announces Webcast Of Corporate Presentation At The Cowen And Company Annual Health Care Conference
2011-02-24,GTx Provides Corporate Update And Reports 2010 Financial Results
2011-02-23,GTx Announces Webcast Of Corporate Presentation At The Citi 2011 Global Health Care Conference
2011-02-17,GTx Announces Presentation At The ASCO Genitourinary Cancers Symposium Of Additional Study Results From The Phase III Clinical Trial Evaluating Toremifene 80 Mg For The Reduction Of Fractures In Men With Prostate Cancer On ADT
2011-02-15,GTx, Inc. To Host Fourth Quarter And Year End 2010 Financial Results Conference Call And Webcast
2011-01-04,GTx Announces Webcast Of Corporate Presentation At The JP Morgan Healthcare Conference
2010-12-13,GTx Presents Results Of The Capesaris&#8482; (GTx-758) Phase II Proof Of Concept Pharmacokinetic-Pharmacodynamic Clinical Trial
2010-11-15,GTx Presents Preclinical Studies Of GTx-758, A Selective Estrogen Receptor Alpha Agonist For First Line Treatment Of Advanced Prostate Cancer, And GTx-230, An Orally Available Tubulin Antagonist For Cancer Refractory To Taxane And Vinca Alkaloid Therapy
2010-11-11,GTx Announces Corporate Presentation At The Lazard Capital Markets Annual Healthcare Conference
2010-11-09,GTx, Inc. Reports Third Quarter 2010 Corporate Results
2010-11-08,GTx Appoints Dr. Barry Furr To The Board Of Directors
2010-11-03,GTx Awarded $1.2 Million In Grants For Qualifying Therapeutic Discovery Projects
2010-11-02,GTx, Inc. Announces Third Quarter 2010 Financial Results Conference Call And Webcast
2010-10-27,GTx Announces Pricing Of Public Offering Of Common Stock
2010-10-26,GTx Announces Proposed Public Offering Of Common Stock
2017-03-15,GTx Provides Corporate Update And Reports Fourth Quarter And Year-End 2016 Financial Results
2017-03-07,GTx, Inc. To Report Fourth Quarter And Full Year 2016 Financial Results On March 15, 2017
2016-12-08,GTx Reports Results From Ongoing Enobosarm Phase 2 Clinical Trial In ER+/AR+ Breast Cancer
2016-12-05,GTx, Inc. Announces 1-for-10 Reverse Stock Split
2016-11-28,Enobosarm Meets Pre-Specified Primary Efficacy Endpoint In Ongoing Phase 2 Clinical Trial In ER+/AR+ Breast Cancer
2016-11-23,GTx Announces Webcast Of Corporate Presentation At The 28th Annual Piper Jaffray Healthcare Conference
2016-11-16,GTx Achieves Second Stage 1 Milestone In Phase 2 Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer
2016-11-11,GTx Announces Webcast Of Corporate Presentation At The Stifel 2016 Healthcare Conference
2016-11-03,GTx Provides Corporate Update And Reports Third Quarter 2016 Financial Results
2016-10-12,GTx Announces $14.0 Million Registered Direct Common Stock Offering
2016-09-08,GTx Achieves Stage 1 Milestone In Phase 2 Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer
2016-09-02,GTx Announces Webcast Of Corporate Presentation At Baird's 2016 Healthcare Conference
2016-09-01,GTx Appoints Dr. Garry Neil To Board Of Directors
2016-08-09,GTx Provides Corporate Update And Reports Second Quarter 2016 Financial Results
2016-07-05,XBiotech Cancer Drug Survival Claim Falls Apart Under Scrutiny
2016-06-02,GTx Announces Webcast Of Corporate Presentation At Jefferies 2016 Global Healthcare Conference
2016-05-16,GTx Announces Webcast Of Corporate Presentation At The UBS Global Healthcare Conference 2016
2016-05-10,GTx Provides Corporate Update And Reports First Quarter 2016 Financial Results
2016-05-09,GTx Announces Presentation Of Preclinical Data Demonstrating The Ability Of SARDs To Degrade And Inhibit The Androgen Receptor At The American Urological Association Annual Meeting
2016-04-27,GTx, Inc. To Report First Quarter 2016 Financial Results On May 10, 2016
2016-03-03,GTx Provides Corporate Update And Reports Fourth Quarter And Year-End 2015 Financial Results
2016-02-24,GTx Announces Presentation Of Preclinical Data Demonstrating The Effect Of GTx SARMs On Pelvic Floor Muscle Loss At The Society Of Urodynamics, Female Pelvic Medicine And Urogenital Reconstruction (SUFU) Meeting
2016-02-18,GTx, Inc. To Host Fourth Quarter And Full Year 2015 Financial Results Conference Call And Webcast
2016-01-13,GTx Announces Initiation Of Phase 2 Clinical Trial Of Enobosarm In Stress Urinary Incontinence
2015-10-29,GTx Provides Corporate Update And Reports Third Quarter 2015 Financial Results
2015-10-15,GTx, Inc. To Host Third Quarter 2015 Financial Results Conference Call And Webcast
2015-10-13,GTx Receives FDA Clearance To Initiate Clinical Trial In Stress Urinary Incontinence
2015-10-06,GTx Announces Enrollment Of First Patient In Phase 2 Clinical Trial Of Enobosarm In Triple Negative Breast Cancer
2015-09-29,GTx Announces Enrollment Of First Patient In Phase 2 Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer
2015-08-06,GTx Provides Corporate Update And Reports Second Quarter 2015 Financial Results
2015-07-23,GTx, Inc. To Host Second Quarter 2015 Financial Results Conference Call And Webcast
2015-07-08,GTx Appoints Diane Young, M.D. As Vice President, Chief Medical Officer
2015-06-02,GTx Regains Compliance With NASDAQ Bid Price Requirement
2015-05-26,GTx Announces Webcast Of Corporate Presentation At Jefferies 2015 Global Healthcare Conference
2015-05-12,GTx Announces Webcast Of Corporate Presentation At The UBS Global Healthcare Conference 2015
2015-05-08,GTx Provides Corporate Update And Reports First Quarter 2015 Financial Results
2015-04-30,3 Stocks Under $10 to Trade for Big Breakouts
2015-04-23,GTx And The University Of Tennessee Research Foundation Enter Into Exclusive License Agreement To Develop UTRF's SARD Drug Technology
2015-04-02,GTx Provides Corporate Update Regarding NASDAQ Stock Listing
2015-03-04,GTx Provides Corporate Update And Reports Fourth Quarter And Year-End 2014 Financial Results
2015-02-19,GTx, Inc. To Host Fourth Quarter And Full Year 2014 Financial Results Conference Call And Webcast
2015-02-17,GTx Appoints Robert J. Wills, Ph.D. To Board Of Directors
2014-12-08,GTx To Present Results On Enobosarm 9mg In Women With Metastatic Breast Cancer At 2014 San Antonio Breast Cancer Symposium
2014-11-17,GTx Announces Closing Of $43.4 Private Placement
2014-11-12,GTx Announces Webcast Of Corporate Presentation At The Stifel 2014 Healthcare Conference
2014-11-10,GTx Provides Corporate Update And Reports Third Quarter 2014 Financial Results
2014-11-10,GTx Announces $43.4 Million Private Placement
2014-11-03,GTx, Inc. To Host Third Quarter 2014 Financial Results Conference Call And Webcast
2014-08-07,GTx Announces Webcast Of Corporate Presentation At The 2014 Wedbush Pacgrow Life Sciences Management Access Conference
2014-08-05,GTx Provides Corporate Update And Reports Second Quarter 2014 Financial Results
2014-07-22,GTx, Inc. To Report Second Quarter 2014 Financial Results On August 5, 2014
2014-07-02,4 Biotech Stocks Under $10 to Watch for Breakout Trades
2014-06-02,GTx Reports Positive Clinical Data From Open Label Phase 2 Study Of Enobosarm In Patients With Androgen And Estrogen Receptor Positive Metastatic Breast Cancer
2014-05-22,GTx Announces Webcast Of Corporate Presentation At Jefferies 2014 Global Healthcare Conference
2014-05-19,GTx To Present Clinical Data On Enobosarm In Breast Cancer And NSCLC At ASCO 2014 Annual Meeting
2014-05-08,GTx Provides Corporate Update And Reports First Quarter 2014 Financial Results
2014-04-24,GTx, Inc. To Report First Quarter 2014 Financial Results On May 8, 2014
2014-04-04,GTx Announces Departure Of CEO
2014-03-06,GTx, Inc. Announces Closing Of Private Placement
2014-03-05,GTx Announces Webcast Of Corporate Presentation At 26TH Annual ROTH Conference
2014-03-04,GTx Provides Corporate Update And Reports 2013 Financial Results
2014-03-04,GTx, Inc. Announces Pricing Of Private Placement
2014-02-26,GTx Announces Webcast Of Corporate Presentation At Cowen And Company 34th Annual Health Care Conference
2014-02-18,GTx, Inc. To Host Fourth Quarter And Full Year 2013 Financial Results Conference Call And Webcast
2014-02-04,First Week of March 22nd Options Trading For GTXI
2014-02-04,GTx Announces Webcast Of Corporate Presentation At Bio CEO &amp; Investor Conference
2014-01-29,Preliminary Findings From The Phase 2 Clinical Trial Of GTx-758 In Men With Castration Resistant Prostate Cancer To Be Presented At ASCO Genitourinary Cancer Symposium
2013-12-19,5 Stocks Under $10 Set to Soar
2013-12-12,GTx Presents On Enobosarm As Targeted Therapy For The Treatment Of Androgen Receptor-Positive Breast Cancer At The San Antonio Breast Cancer Symposium
2013-11-12,GTx Provides Corporate Update And Reports Third Quarter 2013 Financial Results
2013-10-29,GTx, Inc. To Host Third Quarter 2013 Financial Results Conference Call And Webcast
2013-10-24,GTx Presents Results From Enobosarm POWER Trials For The Prevention And Treatment Of Muscle Wasting In Patients With Non-Small Cell Lung Cancer At 15th World Conference On Lung Cancer
2013-09-24,GTx Announces Late Breaker Presentation On Results From The Two Phase 3 POWER Trials Of Enobosarm, A Selective Androgen Receptor Modulator (SARM), For The Prevention And Treatment Of Muscle Wasting In NSCLC Patients During 2013 European Cancer Congress
2013-09-16,5 Stocks Ready for Breakouts
2013-09-11,6 Under-$10 Stocks Moving Higher
2013-09-06,GTx Announces Webcast Of Corporate Presentation At Stifel Nicolaus 2013 Healthcare Conference
2013-08-29,GTx, Inc. Sued By Investor
2013-08-27,Short Interest In GTx Inc Increases 32%
2013-08-23,Top Insider Trades: GLP ACW GTXI AHH
2013-08-23,The 5 Dumbest Things on Wall Street This Week: Aug. 23
2013-08-23,5 Dumbest Things on Wall Street
2013-08-19,Shareholder Rights Law Firm Johnson &amp; Weaver, LLP Announces Investigation Of GTx Inc.
2013-08-19,GTXI SHAREHOLDER ALERT: The Law Firm Of Wohl &amp; Fruchter LLP Announces Investigation Of GTX Inc.
2013-08-19,GTx: Survival Spin Job Follows Enobosarm Study Flop
2013-08-19,GTx Reports Results For Enobosarm POWER Trials For The Prevention And Treatment Of Muscle Wasting In Patients With Non-Small Cell Lung Cancer
2013-08-12,Short Interest Moves 47.3% Higher For GTXI
2013-08-04,MannKind, Vical, GTx: Investors Predict Pivotal Clinical Trial Results
2013-08-02,GTx Inc Is Now Oversold (GTXI)
2013-07-19,GTx Provides Corporate Update And Second Quarter 2013 Financial Results
2013-07-12,Biotech Stock Mailbag: GTx, Vanda, Pharmacyclics
2013-07-11,October 19th Options Now Available For GTx
2013-07-10,The GTx Cancer Muscle-Wasting Drug Studies Will Fail. Here's Why
2013-06-28,GTx Presents On Enobosarm For The Prevention And Treatment Of Muscle Wasting In Cancer Patients At The 2013 MASCC/ISOO International Symposium On Supportive Care In Cancer
2013-06-24,GTx Announces Symposium And Presentation Of Scientific Poster Presentations On Enobosarm At The 2013 MASCC/ISOO International Symposium On Supportive Care In Cancer
2013-06-07,Biotech Stock Mailbag: 2013 Clinical Trials Calendar
2013-05-23,Commit To Buy GTx At $4, Earn 69% Annualized
2013-04-18,5 Health Care Stocks Under $10 Ready to Rip Higher
2013-03-19,GTx-758 Poster Presentation Of Phase II Trial Data In Advanced Prostate Cancer Selected As One Of The Best Posters At The 28th Annual European Association Of Urology Congress
2013-03-14,Enobosarm Phase 2 Trial For Muscle Wasting And Physical Function In Patients With Cancer Published In The Lancet Oncology
2013-02-27,GTx Announces Webcast Of Corporate Presentation At Cowen And Company 33rd Annual Health Care Conference
2013-02-21,GTx Provides Corporate Update And Reports 2012 Financial Results
2013-02-19,GTx Announces Webcast Of Corporate Presentation At 2013 Citi Global Healthcare Conference
2013-02-14,GTx To Present Preclinical Data On A New Therapeutic Target In Prostate Cancer
2013-02-13,Novel Findings From Clinical Studies Examining The Effects Of Capesaris&#174; (GTx-758) For The Treatment Of Advanced Prostate Cancer To Be Presented At 2013 American Society Of Clinical Oncology Genitourinary Cancer Symposium
2013-02-12,GTx Announces Webcast For Capesaris&#174;(GTx-758) Analyst Day
2013-02-07,GTx, Inc. To Host Fourth Quarter And Full Year 2012 Financial Results Conference Call And Webcast
2013-02-05,GTx Announces Webcast Of Corporate Presentation At Bio CEO &amp; Investor Conference
2013-01-08,GTx Announces FDA&#8217;s Grant Of Fast Track Designation To Enobosarm For The Prevention And Treatment Of Muscle Wasting In Patients With Non-Small Cell Lung Cancer
2012-12-17,GTx Attains Enrollment Goal For Its Enobosarm POWER 1 And POWER 2 Phase III Clinical Studies
2012-12-11,4 Stocks Soaring on Unusual Volume
2012-11-08,GTx Announces Webcast Of Corporate Presentation At Jefferies 2012 Global Healthcare Conference
2012-11-08,GTx Provides Corporate Update And Reports Third Quarter 2012 Financial Results
2012-11-06,GTx Announces Webcast Of Corporate Presentation At Lazard Capital Markets 9th Annual Healthcare Conference
2012-10-29,GTx's Phase III Clinical Development Of Enobosarm (GTx-024) For Muscle Wasting In Lung Cancer Patients On Course Following Planned Safety Review
2012-10-25,GTx, Inc. To Host Third Quarter 2012 Financial Results Conference Call And Webcast
2012-10-08,GTx To Present Scientific Poster Presentations On Enobosarm To Prevent And Treat Muscle Wasting In Cancer Patients
2012-10-01,GTx Announces Sale Of Fareston&#174;
2012-09-19,GTx Announces Presentation On The Ability Of Capesaris&#174; To Reduce Free Testosterone And Suppress PSA In Men With Castration Resistant Prostate Cancer
2012-09-17,GTx Announces Symposium And Presentation Of Data On Muscle Wasting In Non-Small Cell Lung Cancer Patients
2012-08-28,GTx Announces Webcast Of Corporate Presentation At NewsMakers In The Biotech Industry Conference
2012-08-27,GTx Announces Webcast Of Corporate Presentation At Stifel Nicolaus 2012 Healthcare Conference
2012-08-14,5 Biotech Stocks Under $10 Blasting Higher
2012-08-08,GTx's CEO Discusses Q2 2012 Results - Earnings Call Transcript
2012-08-08,GTx Provides Corporate Update And Reports Second Quarter 2012 Financial Results
2012-08-06,GTx Announces Webcast Of Corporate Presentation At Wedbush 2012 Life Sciences: Management Access Conference
2012-07-26,GTx, Inc. To Host Second Quarter 2012 Financial Results Conference Call And Webcast
2012-06-26,GTx Announces Presentations On The Effect Of Enobosarm On Improving Physical Function In Cancer Patients
2012-06-25,GTx Announces Presentation On Enobosarm&#8217;s Improvement In Physical Function In Cancer Patients With Both Low And Normal Testosterone Levels
2012-06-22,GTx Announces Panel Presentation On Muscle Wasting In Non-Small Cell Lung Cancer Patients
2012-06-13,GTx Announces Poster Presentation On The Prevalence And Impact Of Hypogonadism In Cancer Patients With Muscle Wasting From Its Phase IIb Enobosarm Clinical Trial At The Endocrine Society&#8217;s 2012 Annual Meeting
2012-05-29,GTx Announces Webcast Of Corporate Presentation At Jefferies 2012 Global Healthcare Conference
2012-05-08,7 Stocks Soaring in a Weak Market
2012-05-08,GTx Announces Removal Of Full Clinical Hold By FDA For Capesaris&#174; In Advanced Prostate Cancer
2012-04-25,GTx, Inc. To Host First Quarter 2012 Financial Results Conference Call And Webcast
2012-04-04,GTx Submits Clinical Hold Complete Response Letter To FDA For Its Planned Phase II Clinical Study Of Capesaris&#174; For Secondary Hormonal Therapy Of Advanced Prostate Cancer
2012-03-15,5 Stocks Insiders Love Right Now
2012-03-02,GTx Announces Webcast Of Corporate Presentation At The Cowen And Co. Annual Health Care Conference
2012-02-24,GTx Announces Webcast Of Corporate Presentation At The Citi 2012 Global Health Care Conference
2012-02-21,GTx Stock Gaps Down On Today's Open (GTXI)
2012-02-21,GTx Provides Corporate Update And Reports 2011 Financial Results
2012-02-21,GTx Announces Clinical Hold On Clinical Trials Evaluating Capesaris&#174; For First And Second Line Treatments Of Advanced Prostate Cancer
2012-02-13,GTx, Inc. To Host Fourth Quarter And Full Year 2011 Financial Results Conference Call And Webcast
2011-11-10,GTx Announces Webcast Of Corporate Presentation At The Lazard Capital Markets Annual Healthcare Conference
2011-11-04,GTx, Inc. Provides Corporate Update And Reports Third Quarter 2011 Financial Results
2011-10-21,GTx, Inc. To Host Third Quarter 2011 Financial Results Conference Call And Webcast
2011-08-31,GTx Announces Panel Discussion At Citi&#8217;s 6th Annual Biotech Day
2011-08-11,GTx Announces Webcast Of Corporate Presentation At The 2011 Wedbush Life Sciences Conference
2011-08-09,GTx, Inc. Provides Corporate Update And Reports Second Quarter 2011 Financial Results
2011-07-28,GTx, Inc. To Host Second Quarter 2011 Financial Results Conference Call And Webcast
2011-07-01,5 Stocks With Big Insider Buying
2011-06-30,GTx Announces Upcoming Presentations Of Effects Of Ostarine&#8482; In Non-Small Cell Lung Cancer Patients At World Conference On Lung Cancer
2011-06-29,Insiders Trading KIOR, NWN, GTXI
2011-06-28,10 Cheap Biotech Stocks That Could Soar
2011-06-23,GTx Announces Pricing Of Public Offering Of Common Stock
2011-06-22,GTx Announces Proposed Public Offering Of Common Stock
2011-06-20,GTx Initiates Phase IIb Clinical Trial Evaluating&#160;Oral&#160;Capesaris&#8482;&#160;Tablets Versus Lupron&#160;Depot&#174;&#160;for First Line Treatment Of Advanced Prostate Cancer
2011-06-13,GTx Set To Join Russell 3000 Index
2011-06-06,GTx Announces Agreement With FDA On Phase III Clinical Development Plan Evaluating Ostarine&#8482; (GTx-024) For The Prevention And Treatment Of Muscle Wasting In Patients With Non-Small Cell Lung Cancer
2011-05-18,GTx Announces ASCO Presentations Highlighting Effects Of Ostarine&#8482; On Physical Function And Survival In Patients With Non-Small Cell Lung Cancer
2011-05-17,GTx Presents Preclinical Study Results Demonstrating That Capesaris&#8482; (GTx-758) Chronic Treatment Does Not Cause Gynecomastia In Male Primates
2011-05-11,GTx Inc. Stock Downgraded (GTXI)
2011-05-09,GTx Inc. Stock Upgraded (GTXI)
2011-05-09,GTx Provides Corporate Update And Reports First Quarter 2011 Financial Results
2011-05-02,GTx, Inc. To Host First Quarter 2011 Financial Results Conference Call And Webcast
2011-03-02,GTx And Ipsen Terminate Their Toremifene Collaboration
2011-03-01,GTx Announces Webcast Of Corporate Presentation At The Cowen And Company Annual Health Care Conference
2011-02-24,GTx Provides Corporate Update And Reports 2010 Financial Results
2011-02-23,GTx Announces Webcast Of Corporate Presentation At The Citi 2011 Global Health Care Conference
2011-02-17,GTx Announces Presentation At The ASCO Genitourinary Cancers Symposium Of Additional Study Results From The Phase III Clinical Trial Evaluating Toremifene 80 Mg For The Reduction Of Fractures In Men With Prostate Cancer On ADT
2011-02-15,GTx, Inc. To Host Fourth Quarter And Year End 2010 Financial Results Conference Call And Webcast
2011-01-04,GTx Announces Webcast Of Corporate Presentation At The JP Morgan Healthcare Conference
2010-12-13,GTx Presents Results Of The Capesaris&#8482; (GTx-758) Phase II Proof Of Concept Pharmacokinetic-Pharmacodynamic Clinical Trial
2010-11-15,GTx Presents Preclinical Studies Of GTx-758, A Selective Estrogen Receptor Alpha Agonist For First Line Treatment Of Advanced Prostate Cancer, And GTx-230, An Orally Available Tubulin Antagonist For Cancer Refractory To Taxane And Vinca Alkaloid Therapy
2010-11-11,GTx Announces Corporate Presentation At The Lazard Capital Markets Annual Healthcare Conference
2010-11-09,GTx, Inc. Reports Third Quarter 2010 Corporate Results
2010-11-08,GTx Appoints Dr. Barry Furr To The Board Of Directors
2010-11-03,GTx Awarded $1.2 Million In Grants For Qualifying Therapeutic Discovery Projects
2010-11-02,GTx, Inc. Announces Third Quarter 2010 Financial Results Conference Call And Webcast
2010-10-27,GTx Announces Pricing Of Public Offering Of Common Stock
2010-10-26,GTx Announces Proposed Public Offering Of Common Stock
2017-03-22,Cannabis, Coats, and Social Media: The Good, Bad, and Ugly of 2017's IPOs
2017-03-15,Ratings Changes Today
2017-03-11,Bring On The Rate Hike!: Cramer's 'Mad Money' Recap (Friday 3/10/17)
2017-03-10,Burlington Stores, Ross Stores, TJX Companies: 'Mad Money' Lightning Round
2017-03-07,GW Pharmaceuticals Announces The Appointment Of Scott Giacobello As Chief Financial Officer And Adam George As Managing Director - UK
2017-03-02,Ignore the 'Sessions Effect' and Shun These 2 Over-Hyped Pot Stocks
2017-03-02,GW Pharmaceuticals To Present At The Cowen And Company 37th Annual Healthcare Conference On Wednesday, 8 March, 2017
2017-03-02,Trump's Anti-Pot Stance Won't Hurt This 'Canna-Business' Stock
2017-03-01,3 Reasons Why Marijuana's Momentum Is Stronger than Ever
2017-02-09,GW Pharmaceuticals Is Set to Benefit as Cannabis Takes on Cancer
2017-02-08,GW Pharmaceuticals To Present At The Leerink Partners 6th Annual Global Healthcare Conference On 15 February
2017-02-07,GW Pharmaceuticals Achieves Positive Results In Phase 2 Proof Of Concept Study In Glioma
2017-02-07,GW Pharmaceuticals Plc Reports First Quarter 2017 Financial Results And Operational Progress
2017-01-30,GW Pharmaceuticals To Report Q1 Financial Results And Host Conference Call On 7 February, 2017
2017-01-28,You Can Also Get High on Marijuana Stocks -- Here's How
2017-01-25,Cannabis Stocks Do Not Trade on Earnings, Instead on Pipeline of Drugs
2017-01-12,Fund Manager High On Marijuana, Zinc as Shelters in Pullback
2017-01-10,'Mad Money Lightning Round: Schlumberger Is the Best of Breed
2017-01-09,These Stocks Are Too Hot, in a Bad Way : Jim Cramer's 'Mad Money' Recap
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2016-12-07,Canadian Marijuana Market More Mature, Outperforms U.S. Market
2016-12-07,4 Stocks You Can Buy to Profit From the Rising Use of Medical Marijuana
2016-12-06,Stocks Back to the Ol' Chop and Grind
2016-12-05,Dow Marches to Another Record Close as S&P 500, Nasdaq Also Rise
2016-12-05,Financials and Tech Shares Lift Wall Street; Dow Hits Record High
2016-12-05,Dow Sets Record High as Oil Maintains Momentum
2016-12-05,Stock Futures Rise as Wall Street Shrugs Off Italy Referendum Defeat; Oil Gains
2016-12-05,GW Pharmaceuticals Plc Reports Fourth Quarter And Year-End 2016 Financial Results And Operational Progress
2016-12-05,GW Announces New Epidiolex® (CBD) Positive Phase 3 Data In Dravet Syndrome And Lennox-Gastaut Syndrome
2016-12-04,Week Ahead: It Gets Quieter as Wall Street Looks Down Road for Fed Meeting
2016-12-01,GW Pharmaceuticals Plc Announces Epidiolex® (cannabidiol) Data Presentations And Educational Programs At The American Society Of Epilepsy Annual Meeting
2016-11-30,GW Pharmaceuticals To Report Q4 And Year-End Financial Results And Host Conference Call On 5 December, 2016
2016-11-22,GW Pharmaceuticals Stock Poised to Hit New Heights After Marijuana's Election Day Boost
2016-11-22,GW Pharmaceuticals To Present At The 28th Annual Piper Jaffray Healthcare Conference On 29 November
2016-11-15,Even in a Trump Presidency, Marijuana Is a Good Investment
2016-11-12,Don't Let Post-Election Market Volatility Scare You Into Ruining Your Retirement
2016-11-09,Nasdaq Cannabis Stocks Rally After Recreational and Medical Use Passes
2016-11-07,Nasdaq Cannabis Stocks Spike in Volume Ahead of Election for Recreational and Medical Use
2016-11-03,'Mad Money' Lightning Round: J.C. Penney Is 'A Lot Better,' Jim Cramer Says
2016-11-02,Jim Cramer's 'Mad Money' Recap: It's Chicago Versus Cleveland -- Stocks, That Is
2016-10-31,Stocks Ready to Benefit From Rising Marijuana Legalization, Usage
2016-10-27,Pot Is on the Ballot in Election 2016, but Investors Should Proceed With Caution
2016-10-26,Here's Why These 3 Cheap Marijuana Stocks May Quadruple in Price
2016-10-26,GW Pharmaceuticals Stock Can Make Even More Gains -- Here's Why
2016-10-14,New Colombia Resources Forming Joint Venture To Apply For An Orphan Drug Designation With The Food And Drug Administration (FDA) For A Medical Cannabis Pharmaceutical Product
2016-10-03,Rev's Forum: Stock Pickers Have Some Opportunities
2016-09-28,GW Pharmaceuticals Is Taking Off as the Cannabis Industry Grows
2016-09-27,Jim Cramer -- Gilead Needs to Make an Acquisition
2016-09-27,Cramer: How Do You Play This Answer to the Opiate Epidemic?
2016-09-27,Jim Cramer's Top Takeaways: GW Pharmaceuticals, Apple, Align Technology
2016-09-26,Jim Cramer's 'Mad Money' Recap: Why Tonight's Debate Doesn't Really Matter
2016-09-26,Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies
2016-09-26,GW Pharmaceuticals (GWPH) Stock Soars on Positive Trial Results, Piper Jaffray Bullish
2016-09-26,GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial For Epidiolex® (cannabidiol) In The Treatment Of Lennox-Gastaut Syndrome
2016-09-18,Stephen King's Maximum Oversold (by Midweek)
2016-09-13,'Mad Money' Lightning Round: Abbvie Is a Great Long-Term Position
2016-09-12,Jim Cramer's 'Mad Money' Recap: Why You Shouldn't Be Jumping In and Out of Stocks
2016-09-09,4 Companies Likely to Benefit From Widening Legalization of Marijuana
2016-09-07,GW Pharmaceuticals (GWPH) Closed Higher on Takeover Speculation
2016-09-07,GW Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
2016-08-09,GW Pharmaceuticals Plc Reports Third Quarter 2016 Financial Results And Operational Progress
2016-08-02,GW Pharmaceuticals To Report Q3 Financial Results And Host Conference Call On 9 August, 2016
2016-07-29,'Mad Money' Lightning Round: Weight Watchers Is Not for Me
2016-07-28,Jim Cramer's 'Mad Money' Recap: I Can't Figure Out the Consumer
2016-07-18,GW Pharmaceuticals Plc Announces The Closing Of U.S. Public Offering Of American Depositary Shares (ADSs) Raising $289.8 Million On The NASDAQ Global Market And Full Exercise Of Underwriter's Option To Purchase Additional ADSs
2016-07-15,Why Nasdaq-Traded Marijuana Stocks Remain Undervalued
2016-07-12,GW Pharmaceuticals Plc Announces Pricing Of U.S. Public Offering Of ADSs Raising $252.0 Million On NASDAQ Global Market
2016-07-12,GW Pharmaceuticals Announces Proposed Public Offering Of ADSs
2016-06-27,Consumer Staples And Utilities Sectors Avoided Volatility in Brexit Aftermath
2016-06-27,Janney Says Sell GW Pharma Despite Marijuana-Derived Drug Success In Seizures
2016-06-27,GW Pharmaceuticals (GWPH) Moving On Heavy Volume In The Pre-Market Hours
2016-06-27,GW Pharma Marijuana Drug Confirms Seizure Benefit in Second Pivotal Trial
2016-06-27,GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results For Epidiolex® (cannabidiol) In The Treatment Of Lennox-Gastaut Syndrome
2016-06-23,Brexit Vote Leaves Investors Cautious
2016-06-22,Here&rsquo;s How You Should Invest If Gary Johnson Makes It to the White House
2016-06-21,GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol Or CBD) Development Program In Infantile Spasms (IS)
2016-06-20,Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan
2016-06-18,'Mad Money' Lightning Round: Buy, Buy, Buy Edward Lifesciences
2016-06-15,Economics of Pot: The Problems With Investing in Marijuana
2016-05-31,GW Pharmaceuticals To Present At The Goldman Sachs 37th Annual Global Healthcare Conference And The Jefferies 2016 Healthcare Conference
2016-05-27,'Mad Money' Lightning Round: Buy, Buy, Buy Intuit
2016-05-26,Jim Cramer's 'Mad Money' Recap: Stay Disciplined in This Market
2016-05-18,4 Top Stocks in the Growing Medical Marijuana Industry
2016-05-16,GW Pharmaceuticals To Present At The 2016 UBS Global Healthcare Conference On 24 May
2016-05-05,GW Pharmaceuticals Plc Reports Second Quarter And Half-Year 2016 Financial Results And Operational Progress
2016-05-04,The Cannabis Market Reaches New Heights
2016-05-04,GW Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2016 Healthcare Conference On 10 May
2016-05-03,5 Stocks Set to Soar on Bullish Earnings
2016-04-28,GW Pharmaceuticals To Report Q2, Half-Year Financial Results And Host Conference Call On 5 May, 2016
2016-04-21,Making the Right Budding Investment: Medical Versus Recreational Cannabis Companies
2016-04-21,GW Pharmaceuticals Receives Orphan Drug Designation From FDA For Cannabidiol For The Treatment Of Tuberous Sclerosis Complex
2016-04-20,How to Invest in Nasdaq-Traded Marijuana Stocks and Private Pot Companies
2016-04-20,Expansion Of Legalized Cannabis Continues At A Torrid Pace In The U.S. And Globally For Leading Markets Worldwide; Company Receives Purchase Order For Medical Marijuana Products
2016-04-15,These 3 Marijuana-Related Stocks Are Poised for Strong Growth
2016-04-11,GW Pharmaceuticals Initiates Phase 3 Pivotal Study In Tuberous Sclerosis Complex
2016-03-17,'Mad Money' Lightning Round: Step Into Skechers Long Term
2016-03-16,Jim Cramer's 'Mad Money' Recap: We've Won the War Against the Dollar
2016-03-15,INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of GW Pharmaceuticals Plc Of Class Action And A Lead Plaintiff Deadline Of March 21, 2016
2016-03-15,Why Pot Stock GW Pharmaceuticals Could Go Even Higher in 2016
2016-03-15,GWPH Momentum Passed Around to Other Pot Stocks
2016-03-14,GW Pharma (GWPH) Stock Spiked on Promising Cannabis-Derived Drug, Jim Cramer's Take
2016-03-14,Jim Cramer -- GW Pharma's Cannabinoid Treatment Could Be the Start
2016-03-14,Here's Why GW Pharma (GWPH) Stock Is Skyrocketing Today
2016-03-14,GW Pharma Marijuana Drug Cuts Seizure Rate in Pivotal Study
2016-03-14,GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results For Epidiolex® (cannabidiol)
2016-03-12,SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of GW Pharmaceuticals Plc
2016-03-11,SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notify Investors Of Class Action Lawsuit Involving GW Pharmaceuticals Plc And A Lead Plaintiff Deadline Of March 21, 2016
2016-03-10,SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of GW Pharmaceuticals Plc - GWPH
2016-03-09,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against GW Pharmaceuticals PLC (GWPH) And Lead Plaintiff Deadline: March 21, 2016
2016-03-08,'Mad Money' Lightning Round: Buy, Buy, Buy Bristol-Myers Squibb
2016-03-07,Jim Cramer's 'Mad Money' Recap: Commodities Are Healing, so Are Markets
2016-03-07,SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notify Investors Of Class Action Lawsuit Involving GW Pharmaceuticals Plc And A Lead Plaintiff Deadline Of March 21, 2016 - GWPH
2016-03-01,Oversold Conditions For GW Pharmaceuticals (GWPH)
2016-02-26,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of GW Pharmaceuticals Plc Of Class Action And A Lead Plaintiff Deadline Of March 21, 2016
2016-02-23,IMPORTANT SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In GW Pharmaceuticals PLC To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2016-02-22,INVESTOR ALERT: The Law Offices Of Vincent Wong Notify Investors Of Class Action Involving GW Pharmaceuticals Plc And A Lead Plaintiff Deadline Of March 21, 2016
2016-02-22,Jim Cramer's 'Mad Money' Recap: This Week's Game Plan
2016-02-20,'Mad Money' Lightning Round: Cramer Likes FedEx and UPS
2016-02-19,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In GW Pharmaceuticals Plc Of Class Action Lawsuit And Upcoming Deadline - GWPH
2016-02-10,STOCK ALERT: Rosen Law Firm Reminds GW Pharmaceuticals Plc Investors Of Important Deadline In Class Action - GWPH
2016-02-10,GW Pharmaceuticals Plc Reports First Quarter 2016 Financial Results And Operational Progress
2016-02-09,SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In GW Pharmaceuticals Plc To Contact The Firm Before Lead Plaintiff Deadline
2016-02-04,GW Pharmaceuticals To Present At The Leerink Partners 5th Annual Global Healthcare Conference
2016-02-02,GW Pharmaceuticals To Report Q1 Financial Results And Host Conference Call On 10 February, 2016
2016-01-26,Mood Swing Tape Continues
2016-01-25,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against GW Pharmaceuticals Plc - GWPH
2016-01-24,8 Things That Could Lift Biotech Stocks Out of Bear Market
2016-01-22,Bernstein Liebhard LLP Announces That A Suit Has Been Filed Against GW Pharmaceuticals Plc
2016-01-13,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of GW Pharmaceuticals PLC (GWPH)
2016-01-13,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of GW Pharmaceuticals Plc - GWPH
2016-01-11,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Securities Fraud By GW Pharmaceuticals Plc And Certain Officers And Directors
2016-01-11,GW Pharmaceuticals Plc Investigated For Potential Securities Law Violations By Block & Leviton LLP
2016-01-05,Jim Cramer Says Own Salesforce.com, Regeneron, First Solar
2015-12-24,The Lancet Neurology Publishes Data From The Epidiolex® Expanded Access Program In Children And Young Adults With Treatment-Resistant Epilepsy
2015-12-23,This Is the Only Stock to Buy Right Now to Profit From Legalized Weed
2015-12-22,'Mad Money' Lightning Round: It's OK to Buy Pandora Media Now
2015-12-21,Jim Cramer's 'Mad Money' Recap: Winners, Losers and the Chasm Between Them
2015-12-09,'Mad Money' Lightning Round: Take Mattel Over Hasbro
2015-12-08,Jim Cramer's 'Mad Money' Recap: Play the Hand You're Dealt
2015-12-07,GW Pharmaceuticals Plc Reports Fourth Quarter And Year-End 2015 Financial Results And Operational Progress
2015-12-07,GW Pharmaceuticals Announces New Physician Reports Of Epidiolex(R) Treatment Effect In Children And Young Adults With Treatment-Resistant Epilepsy
2015-12-02,Jim Cramer Answers 8 Questions From Viewers Including CEO Henry Blodget
2015-12-02,Jim Cramer Fields Questions From Viewers Including Henry Blodget
2015-11-30,GW Pharmaceuticals Announces Date And Time Change For Q4 And Year-End 2015 Financial Results And Conference Call
2015-11-25,New Epidiolex(R) (CBD) Data Accepted For Presentation At The 69th Annual Meeting Of The American Epilepsy Society
2015-11-24,GW Pharmaceuticals To Present At The Piper Jaffray 27th Annual Healthcare Conference
2015-11-24,GW Pharmaceuticals To Report Q4 And Year-End 2015 Financial Results And Host Conference Call On 3 December, 2015
2015-11-11,'Mad Money' Lightning Round: Northrop Grumman, Lockheed Martin Both Terrific
2015-11-10,Jim Cramer's 'Mad Money' Recap: Winners Remain When Rates Rise
2015-10-27,GW Pharmaceuticals And The Government Of New South Wales Announce A Strategic Agreement To Study Epidiolex(R) And CBDV In A Clinical Trial And Research Program For Children With Epilepsy
2015-10-27,GW Pharmaceuticals And Otsuka Announce Results From Two Remaining Sativex(R) Phase 3 Cancer Pain Trials
2015-10-10,'Mad Money' Lightning Round: Buy AT&T, Verizon, Walgreens Boots Alliance
2015-10-09,Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
2015-09-26,'Mad Money' Lightning Round: Buy, Buy, Buy Blackstone and KKR
2015-09-25,Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
2015-09-18,Biotech Stock Mailbag: Bristol, Exelixis, Lion Bio, GW Pharma
2015-09-15,Cramer: I'm Impressed by GW Pharma's Cannabis Data, Wait to Buy Kimberly-Clark
2015-09-15,GW Pharmaceuticals Announces Positive Proof Of Concept Data In Schizophrenia
2015-09-10,GW Pharmaceuticals To Present At Two Upcoming Investor Conferences
2015-08-13,Jim Cramer: Rite Aid and GW Pharmaceuticals Are Ripe for a Rally
2015-08-06,GW Pharmaceuticals Plc Reports Third Quarter 2015 Financial Results And Operational Progress
2015-08-06,GW Pharmaceuticals Receives FDA Fast Track And EMA Orphan Designations For Intravenous Cannabidiol In The Treatment Of Neonatal Hypoxic-Ischemic Encephalopathy (NHIE)
2015-08-05,'Mad Money' Lightning Round: Sell, Sell, Sell LinkedIn
2015-08-04,Jim Cramer's 'Mad Money' Recap: Nowhere to Run, Nowhere to Hide From China
2015-07-23,GW Pharmaceuticals To Report Q3 2015 Financial Results And Host Conference Call On 6 August, 2015
2015-07-21,GW Pharmaceuticals Announces Appointment Of Julian Gangolli To Board Of Directors
2015-06-26,Jim Cramer's Top Takeaways: Domino's, GW Pharmaceuticals, Bed Bath & Beyond
2015-06-25,Jim Cramer's 'Mad Money' Recap: Supreme Court Almost Makes Market Forget Greece
2015-06-23,Marijuana Stocks and the Risks of a '420 Friendly' Portfolio
2015-06-11,GW Pharmaceuticals Initiates Second Phase 3 Pivotal Study Of Epidiolex(R) (CBD) In Lennox-Gastaut Syndrome
2015-06-08,Jim Cramer Explains What Markets Will Do When the Fed Raises Rates
2015-06-08,Cramer: Markets to Dip for a Few Weeks When the Fed Raises Rates
2015-05-19,GW Appoints Senior Industry Executive To President, North America And Relocates CEO To The U.S.
2015-05-11,GW Pharmaceuticals To Present At Bank Of America Merrill Lynch 2015 Healthcare Conference
2015-05-11,GW Pharmaceuticals Initiates Phase 3 Pivotal Study Of Epidiolex(R) (CBD) In Lennox-Gastaut Syndrome
2015-05-11,GW Pharmaceuticals Plc Reports Second Quarter 2015 Financial Results And Operational Progress
2015-05-06,GW Pharmaceuticals To Report Q2 2015 Financial Results And Host Conference Call On 11 May, 2015
2015-05-06,GW Pharmaceuticals Initiates Phase 2 Clinical Study Of Cannabidivarin (CBDV) In Epilepsy
2015-05-05,GW Pharmaceuticals Plc Announces The Closing Of U.S. Public Offering Of American Depositary Shares (ADSs) Raising Approximately $179.2 Million On The NASDAQ Global Market
2015-04-28,GW Pharmaceuticals Plc Announces Pricing Of U.S. Public Offering Of ADSs Raising $179.2 Million On NASDAQ Global Market
2017-03-22,Cannabis, Coats, and Social Media: The Good, Bad, and Ugly of 2017's IPOs
2017-03-15,Ratings Changes Today
2017-03-11,Bring On The Rate Hike!: Cramer's 'Mad Money' Recap (Friday 3/10/17)
2017-03-10,Burlington Stores, Ross Stores, TJX Companies: 'Mad Money' Lightning Round
2017-03-07,GW Pharmaceuticals Announces The Appointment Of Scott Giacobello As Chief Financial Officer And Adam George As Managing Director - UK
2017-03-02,Ignore the 'Sessions Effect' and Shun These 2 Over-Hyped Pot Stocks
2017-03-02,GW Pharmaceuticals To Present At The Cowen And Company 37th Annual Healthcare Conference On Wednesday, 8 March, 2017
2017-03-02,Trump's Anti-Pot Stance Won't Hurt This 'Canna-Business' Stock
2017-03-01,3 Reasons Why Marijuana's Momentum Is Stronger than Ever
2017-02-09,GW Pharmaceuticals Is Set to Benefit as Cannabis Takes on Cancer
2017-02-08,GW Pharmaceuticals To Present At The Leerink Partners 6th Annual Global Healthcare Conference On 15 February
2017-02-07,GW Pharmaceuticals Plc Reports First Quarter 2017 Financial Results And Operational Progress
2017-02-07,GW Pharmaceuticals Achieves Positive Results In Phase 2 Proof Of Concept Study In Glioma
2017-01-30,GW Pharmaceuticals To Report Q1 Financial Results And Host Conference Call On 7 February, 2017
2017-01-28,You Can Also Get High on Marijuana Stocks -- Here's How
2017-01-25,Cannabis Stocks Do Not Trade on Earnings, Instead on Pipeline of Drugs
2017-01-12,Fund Manager High On Marijuana, Zinc as Shelters in Pullback
2017-01-10,'Mad Money Lightning Round: Schlumberger Is the Best of Breed
2017-01-09,These Stocks Are Too Hot, in a Bad Way : Jim Cramer's 'Mad Money' Recap
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2016-12-07,Canadian Marijuana Market More Mature, Outperforms U.S. Market
2016-12-07,4 Stocks You Can Buy to Profit From the Rising Use of Medical Marijuana
2016-12-06,Stocks Back to the Ol' Chop and Grind
2016-12-05,Dow Marches to Another Record Close as S&P 500, Nasdaq Also Rise
2016-12-05,Financials and Tech Shares Lift Wall Street; Dow Hits Record High
2016-12-05,Dow Sets Record High as Oil Maintains Momentum
2016-12-05,Stock Futures Rise as Wall Street Shrugs Off Italy Referendum Defeat; Oil Gains
2016-12-05,GW Pharmaceuticals Plc Reports Fourth Quarter And Year-End 2016 Financial Results And Operational Progress
2016-12-05,GW Announces New Epidiolex® (CBD) Positive Phase 3 Data In Dravet Syndrome And Lennox-Gastaut Syndrome
2016-12-04,Week Ahead: It Gets Quieter as Wall Street Looks Down Road for Fed Meeting
2016-12-01,GW Pharmaceuticals Plc Announces Epidiolex® (cannabidiol) Data Presentations And Educational Programs At The American Society Of Epilepsy Annual Meeting
2016-11-30,GW Pharmaceuticals To Report Q4 And Year-End Financial Results And Host Conference Call On 5 December, 2016
2016-11-22,GW Pharmaceuticals Stock Poised to Hit New Heights After Marijuana's Election Day Boost
2016-11-22,GW Pharmaceuticals To Present At The 28th Annual Piper Jaffray Healthcare Conference On 29 November
2016-11-15,Even in a Trump Presidency, Marijuana Is a Good Investment
2016-11-12,Don't Let Post-Election Market Volatility Scare You Into Ruining Your Retirement
2016-11-09,Nasdaq Cannabis Stocks Rally After Recreational and Medical Use Passes
2016-11-07,Nasdaq Cannabis Stocks Spike in Volume Ahead of Election for Recreational and Medical Use
2016-11-03,'Mad Money' Lightning Round: J.C. Penney Is 'A Lot Better,' Jim Cramer Says
2016-11-02,Jim Cramer's 'Mad Money' Recap: It's Chicago Versus Cleveland -- Stocks, That Is
2016-10-31,Stocks Ready to Benefit From Rising Marijuana Legalization, Usage
2016-10-27,Pot Is on the Ballot in Election 2016, but Investors Should Proceed With Caution
2016-10-26,Here's Why These 3 Cheap Marijuana Stocks May Quadruple in Price
2016-10-26,GW Pharmaceuticals Stock Can Make Even More Gains -- Here's Why
2016-10-14,New Colombia Resources Forming Joint Venture To Apply For An Orphan Drug Designation With The Food And Drug Administration (FDA) For A Medical Cannabis Pharmaceutical Product
2016-10-03,Rev's Forum: Stock Pickers Have Some Opportunities
2016-09-28,GW Pharmaceuticals Is Taking Off as the Cannabis Industry Grows
2016-09-27,Jim Cramer -- Gilead Needs to Make an Acquisition
2016-09-27,Cramer: How Do You Play This Answer to the Opiate Epidemic?
2016-09-27,Jim Cramer's Top Takeaways: GW Pharmaceuticals, Apple, Align Technology
2016-09-26,Jim Cramer's 'Mad Money' Recap: Why Tonight's Debate Doesn't Really Matter
2016-09-26,Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies
2016-09-26,GW Pharmaceuticals (GWPH) Stock Soars on Positive Trial Results, Piper Jaffray Bullish
2016-09-26,GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial For Epidiolex® (cannabidiol) In The Treatment Of Lennox-Gastaut Syndrome
2016-09-18,Stephen King's Maximum Oversold (by Midweek)
2016-09-13,'Mad Money' Lightning Round: Abbvie Is a Great Long-Term Position
2016-09-12,Jim Cramer's 'Mad Money' Recap: Why You Shouldn't Be Jumping In and Out of Stocks
2016-09-09,4 Companies Likely to Benefit From Widening Legalization of Marijuana
2016-09-07,GW Pharmaceuticals (GWPH) Closed Higher on Takeover Speculation
2016-09-07,GW Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
2016-08-09,GW Pharmaceuticals Plc Reports Third Quarter 2016 Financial Results And Operational Progress
2016-08-02,GW Pharmaceuticals To Report Q3 Financial Results And Host Conference Call On 9 August, 2016
2016-07-29,'Mad Money' Lightning Round: Weight Watchers Is Not for Me
2016-07-28,Jim Cramer's 'Mad Money' Recap: I Can't Figure Out the Consumer
2016-07-18,GW Pharmaceuticals Plc Announces The Closing Of U.S. Public Offering Of American Depositary Shares (ADSs) Raising $289.8 Million On The NASDAQ Global Market And Full Exercise Of Underwriter's Option To Purchase Additional ADSs
2016-07-15,Why Nasdaq-Traded Marijuana Stocks Remain Undervalued
2016-07-12,GW Pharmaceuticals Plc Announces Pricing Of U.S. Public Offering Of ADSs Raising $252.0 Million On NASDAQ Global Market
2016-07-12,GW Pharmaceuticals Announces Proposed Public Offering Of ADSs
2016-06-27,Consumer Staples And Utilities Sectors Avoided Volatility in Brexit Aftermath
2016-06-27,Janney Says Sell GW Pharma Despite Marijuana-Derived Drug Success In Seizures
2016-06-27,GW Pharmaceuticals (GWPH) Moving On Heavy Volume In The Pre-Market Hours
2016-06-27,GW Pharma Marijuana Drug Confirms Seizure Benefit in Second Pivotal Trial
2016-06-27,GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results For Epidiolex® (cannabidiol) In The Treatment Of Lennox-Gastaut Syndrome
2016-06-23,Brexit Vote Leaves Investors Cautious
2016-06-22,Here&rsquo;s How You Should Invest If Gary Johnson Makes It to the White House
2016-06-21,GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol Or CBD) Development Program In Infantile Spasms (IS)
2016-06-20,Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan
2016-06-18,'Mad Money' Lightning Round: Buy, Buy, Buy Edward Lifesciences
2016-06-15,Economics of Pot: The Problems With Investing in Marijuana
2016-05-31,GW Pharmaceuticals To Present At The Goldman Sachs 37th Annual Global Healthcare Conference And The Jefferies 2016 Healthcare Conference
2016-05-27,'Mad Money' Lightning Round: Buy, Buy, Buy Intuit
2016-05-26,Jim Cramer's 'Mad Money' Recap: Stay Disciplined in This Market
2016-05-18,4 Top Stocks in the Growing Medical Marijuana Industry
2016-05-16,GW Pharmaceuticals To Present At The 2016 UBS Global Healthcare Conference On 24 May
2016-05-05,GW Pharmaceuticals Plc Reports Second Quarter And Half-Year 2016 Financial Results And Operational Progress
2016-05-04,The Cannabis Market Reaches New Heights
2016-05-04,GW Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2016 Healthcare Conference On 10 May
2016-05-03,5 Stocks Set to Soar on Bullish Earnings
2016-04-28,GW Pharmaceuticals To Report Q2, Half-Year Financial Results And Host Conference Call On 5 May, 2016
2016-04-21,Making the Right Budding Investment: Medical Versus Recreational Cannabis Companies
2016-04-21,GW Pharmaceuticals Receives Orphan Drug Designation From FDA For Cannabidiol For The Treatment Of Tuberous Sclerosis Complex
2016-04-20,How to Invest in Nasdaq-Traded Marijuana Stocks and Private Pot Companies
2016-04-20,Expansion Of Legalized Cannabis Continues At A Torrid Pace In The U.S. And Globally For Leading Markets Worldwide; Company Receives Purchase Order For Medical Marijuana Products
2016-04-15,These 3 Marijuana-Related Stocks Are Poised for Strong Growth
2016-04-11,GW Pharmaceuticals Initiates Phase 3 Pivotal Study In Tuberous Sclerosis Complex
2016-03-17,'Mad Money' Lightning Round: Step Into Skechers Long Term
2016-03-16,Jim Cramer's 'Mad Money' Recap: We've Won the War Against the Dollar
2016-03-15,INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of GW Pharmaceuticals Plc Of Class Action And A Lead Plaintiff Deadline Of March 21, 2016
2016-03-15,Why Pot Stock GW Pharmaceuticals Could Go Even Higher in 2016
2016-03-15,GWPH Momentum Passed Around to Other Pot Stocks
2016-03-14,GW Pharma (GWPH) Stock Spiked on Promising Cannabis-Derived Drug, Jim Cramer's Take
2016-03-14,Jim Cramer -- GW Pharma's Cannabinoid Treatment Could Be the Start
2016-03-14,Here's Why GW Pharma (GWPH) Stock Is Skyrocketing Today
2016-03-14,GW Pharma Marijuana Drug Cuts Seizure Rate in Pivotal Study
2016-03-14,GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results For Epidiolex® (cannabidiol)
2016-03-12,SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of GW Pharmaceuticals Plc
2016-03-11,SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notify Investors Of Class Action Lawsuit Involving GW Pharmaceuticals Plc And A Lead Plaintiff Deadline Of March 21, 2016
2016-03-10,SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of GW Pharmaceuticals Plc - GWPH
2016-03-09,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against GW Pharmaceuticals PLC (GWPH) And Lead Plaintiff Deadline: March 21, 2016
2016-03-08,'Mad Money' Lightning Round: Buy, Buy, Buy Bristol-Myers Squibb
2016-03-07,Jim Cramer's 'Mad Money' Recap: Commodities Are Healing, so Are Markets
2016-03-07,SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notify Investors Of Class Action Lawsuit Involving GW Pharmaceuticals Plc And A Lead Plaintiff Deadline Of March 21, 2016 - GWPH
2016-03-01,Oversold Conditions For GW Pharmaceuticals (GWPH)
2016-02-26,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of GW Pharmaceuticals Plc Of Class Action And A Lead Plaintiff Deadline Of March 21, 2016
2016-02-23,IMPORTANT SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In GW Pharmaceuticals PLC To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2016-02-22,INVESTOR ALERT: The Law Offices Of Vincent Wong Notify Investors Of Class Action Involving GW Pharmaceuticals Plc And A Lead Plaintiff Deadline Of March 21, 2016
2016-02-22,Jim Cramer's 'Mad Money' Recap: This Week's Game Plan
2016-02-20,'Mad Money' Lightning Round: Cramer Likes FedEx and UPS
2016-02-19,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In GW Pharmaceuticals Plc Of Class Action Lawsuit And Upcoming Deadline - GWPH
2016-02-10,STOCK ALERT: Rosen Law Firm Reminds GW Pharmaceuticals Plc Investors Of Important Deadline In Class Action - GWPH
2016-02-10,GW Pharmaceuticals Plc Reports First Quarter 2016 Financial Results And Operational Progress
2016-02-09,SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In GW Pharmaceuticals Plc To Contact The Firm Before Lead Plaintiff Deadline
2016-02-04,GW Pharmaceuticals To Present At The Leerink Partners 5th Annual Global Healthcare Conference
2016-02-02,GW Pharmaceuticals To Report Q1 Financial Results And Host Conference Call On 10 February, 2016
2016-01-26,Mood Swing Tape Continues
2016-01-25,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against GW Pharmaceuticals Plc - GWPH
2016-01-24,8 Things That Could Lift Biotech Stocks Out of Bear Market
2016-01-22,Bernstein Liebhard LLP Announces That A Suit Has Been Filed Against GW Pharmaceuticals Plc
2016-01-13,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of GW Pharmaceuticals PLC (GWPH)
2016-01-13,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of GW Pharmaceuticals Plc - GWPH
2016-01-11,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Securities Fraud By GW Pharmaceuticals Plc And Certain Officers And Directors
2016-01-11,GW Pharmaceuticals Plc Investigated For Potential Securities Law Violations By Block & Leviton LLP
2016-01-05,Jim Cramer Says Own Salesforce.com, Regeneron, First Solar
2015-12-24,The Lancet Neurology Publishes Data From The Epidiolex® Expanded Access Program In Children And Young Adults With Treatment-Resistant Epilepsy
2015-12-23,This Is the Only Stock to Buy Right Now to Profit From Legalized Weed
2015-12-22,'Mad Money' Lightning Round: It's OK to Buy Pandora Media Now
2015-12-21,Jim Cramer's 'Mad Money' Recap: Winners, Losers and the Chasm Between Them
2015-12-09,'Mad Money' Lightning Round: Take Mattel Over Hasbro
2015-12-08,Jim Cramer's 'Mad Money' Recap: Play the Hand You're Dealt
2015-12-07,GW Pharmaceuticals Plc Reports Fourth Quarter And Year-End 2015 Financial Results And Operational Progress
2015-12-07,GW Pharmaceuticals Announces New Physician Reports Of Epidiolex(R) Treatment Effect In Children And Young Adults With Treatment-Resistant Epilepsy
2015-12-02,Jim Cramer Answers 8 Questions From Viewers Including CEO Henry Blodget
2015-12-02,Jim Cramer Fields Questions From Viewers Including Henry Blodget
2015-11-30,GW Pharmaceuticals Announces Date And Time Change For Q4 And Year-End 2015 Financial Results And Conference Call
2015-11-25,New Epidiolex(R) (CBD) Data Accepted For Presentation At The 69th Annual Meeting Of The American Epilepsy Society
2015-11-24,GW Pharmaceuticals To Present At The Piper Jaffray 27th Annual Healthcare Conference
2015-11-24,GW Pharmaceuticals To Report Q4 And Year-End 2015 Financial Results And Host Conference Call On 3 December, 2015
2015-11-11,'Mad Money' Lightning Round: Northrop Grumman, Lockheed Martin Both Terrific
2015-11-10,Jim Cramer's 'Mad Money' Recap: Winners Remain When Rates Rise
2015-10-27,GW Pharmaceuticals And The Government Of New South Wales Announce A Strategic Agreement To Study Epidiolex(R) And CBDV In A Clinical Trial And Research Program For Children With Epilepsy
2015-10-27,GW Pharmaceuticals And Otsuka Announce Results From Two Remaining Sativex(R) Phase 3 Cancer Pain Trials
2015-10-10,'Mad Money' Lightning Round: Buy AT&T, Verizon, Walgreens Boots Alliance
2015-10-09,Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
2015-09-26,'Mad Money' Lightning Round: Buy, Buy, Buy Blackstone and KKR
2015-09-25,Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
2015-09-18,Biotech Stock Mailbag: Bristol, Exelixis, Lion Bio, GW Pharma
2015-09-15,Cramer: I'm Impressed by GW Pharma's Cannabis Data, Wait to Buy Kimberly-Clark
2015-09-15,GW Pharmaceuticals Announces Positive Proof Of Concept Data In Schizophrenia
2015-09-10,GW Pharmaceuticals To Present At Two Upcoming Investor Conferences
2015-08-13,Jim Cramer: Rite Aid and GW Pharmaceuticals Are Ripe for a Rally
2015-08-06,GW Pharmaceuticals Plc Reports Third Quarter 2015 Financial Results And Operational Progress
2015-08-06,GW Pharmaceuticals Receives FDA Fast Track And EMA Orphan Designations For Intravenous Cannabidiol In The Treatment Of Neonatal Hypoxic-Ischemic Encephalopathy (NHIE)
2015-08-05,'Mad Money' Lightning Round: Sell, Sell, Sell LinkedIn
2015-08-04,Jim Cramer's 'Mad Money' Recap: Nowhere to Run, Nowhere to Hide From China
2015-07-23,GW Pharmaceuticals To Report Q3 2015 Financial Results And Host Conference Call On 6 August, 2015
2015-07-21,GW Pharmaceuticals Announces Appointment Of Julian Gangolli To Board Of Directors
2015-06-26,Jim Cramer's Top Takeaways: Domino's, GW Pharmaceuticals, Bed Bath & Beyond
2015-06-25,Jim Cramer's 'Mad Money' Recap: Supreme Court Almost Makes Market Forget Greece
2015-06-23,Marijuana Stocks and the Risks of a '420 Friendly' Portfolio
2015-06-11,GW Pharmaceuticals Initiates Second Phase 3 Pivotal Study Of Epidiolex(R) (CBD) In Lennox-Gastaut Syndrome
2015-06-08,Jim Cramer Explains What Markets Will Do When the Fed Raises Rates
2015-06-08,Cramer: Markets to Dip for a Few Weeks When the Fed Raises Rates
2015-05-19,GW Appoints Senior Industry Executive To President, North America And Relocates CEO To The U.S.
2015-05-11,GW Pharmaceuticals To Present At Bank Of America Merrill Lynch 2015 Healthcare Conference
2015-05-11,GW Pharmaceuticals Initiates Phase 3 Pivotal Study Of Epidiolex(R) (CBD) In Lennox-Gastaut Syndrome
2015-05-11,GW Pharmaceuticals Plc Reports Second Quarter 2015 Financial Results And Operational Progress
2015-05-06,GW Pharmaceuticals To Report Q2 2015 Financial Results And Host Conference Call On 11 May, 2015
2015-05-06,GW Pharmaceuticals Initiates Phase 2 Clinical Study Of Cannabidivarin (CBDV) In Epilepsy
2015-05-05,GW Pharmaceuticals Plc Announces The Closing Of U.S. Public Offering Of American Depositary Shares (ADSs) Raising Approximately $179.2 Million On The NASDAQ Global Market
2015-04-28,GW Pharmaceuticals Plc Announces Pricing Of U.S. Public Offering Of ADSs Raising $179.2 Million On NASDAQ Global Market
2017-03-22,Cannabis, Coats, and Social Media: The Good, Bad, and Ugly of 2017's IPOs
2017-03-15,Ratings Changes Today
2017-03-11,Bring On The Rate Hike!: Cramer's 'Mad Money' Recap (Friday 3/10/17)
2017-03-10,Burlington Stores, Ross Stores, TJX Companies: 'Mad Money' Lightning Round
2017-03-07,GW Pharmaceuticals Announces The Appointment Of Scott Giacobello As Chief Financial Officer And Adam George As Managing Director - UK
2017-03-02,Ignore the 'Sessions Effect' and Shun These 2 Over-Hyped Pot Stocks
2017-03-02,GW Pharmaceuticals To Present At The Cowen And Company 37th Annual Healthcare Conference On Wednesday, 8 March, 2017
2017-03-02,Trump's Anti-Pot Stance Won't Hurt This 'Canna-Business' Stock
2017-03-01,3 Reasons Why Marijuana's Momentum Is Stronger than Ever
2017-02-09,GW Pharmaceuticals Is Set to Benefit as Cannabis Takes on Cancer
2017-02-08,GW Pharmaceuticals To Present At The Leerink Partners 6th Annual Global Healthcare Conference On 15 February
2017-02-07,GW Pharmaceuticals Plc Reports First Quarter 2017 Financial Results And Operational Progress
2017-02-07,GW Pharmaceuticals Achieves Positive Results In Phase 2 Proof Of Concept Study In Glioma
2017-01-30,GW Pharmaceuticals To Report Q1 Financial Results And Host Conference Call On 7 February, 2017
2017-01-28,You Can Also Get High on Marijuana Stocks -- Here's How
2017-01-25,Cannabis Stocks Do Not Trade on Earnings, Instead on Pipeline of Drugs
2017-01-12,Fund Manager High On Marijuana, Zinc as Shelters in Pullback
2017-01-10,'Mad Money Lightning Round: Schlumberger Is the Best of Breed
2017-01-09,These Stocks Are Too Hot, in a Bad Way : Jim Cramer's 'Mad Money' Recap
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2016-12-07,Canadian Marijuana Market More Mature, Outperforms U.S. Market
2016-12-07,4 Stocks You Can Buy to Profit From the Rising Use of Medical Marijuana
2016-12-06,Stocks Back to the Ol' Chop and Grind
2016-12-05,Dow Marches to Another Record Close as S&P 500, Nasdaq Also Rise
2016-12-05,Financials and Tech Shares Lift Wall Street; Dow Hits Record High
2016-12-05,Dow Sets Record High as Oil Maintains Momentum
2016-12-05,Stock Futures Rise as Wall Street Shrugs Off Italy Referendum Defeat; Oil Gains
2016-12-05,GW Pharmaceuticals Plc Reports Fourth Quarter And Year-End 2016 Financial Results And Operational Progress
2016-12-05,GW Announces New Epidiolex® (CBD) Positive Phase 3 Data In Dravet Syndrome And Lennox-Gastaut Syndrome
2016-12-04,Week Ahead: It Gets Quieter as Wall Street Looks Down Road for Fed Meeting
2016-12-01,GW Pharmaceuticals Plc Announces Epidiolex® (cannabidiol) Data Presentations And Educational Programs At The American Society Of Epilepsy Annual Meeting
2016-11-30,GW Pharmaceuticals To Report Q4 And Year-End Financial Results And Host Conference Call On 5 December, 2016
2016-11-22,GW Pharmaceuticals Stock Poised to Hit New Heights After Marijuana's Election Day Boost
2016-11-22,GW Pharmaceuticals To Present At The 28th Annual Piper Jaffray Healthcare Conference On 29 November
2016-11-15,Even in a Trump Presidency, Marijuana Is a Good Investment
2016-11-12,Don't Let Post-Election Market Volatility Scare You Into Ruining Your Retirement
2016-11-09,Nasdaq Cannabis Stocks Rally After Recreational and Medical Use Passes
2016-11-07,Nasdaq Cannabis Stocks Spike in Volume Ahead of Election for Recreational and Medical Use
2016-11-03,'Mad Money' Lightning Round: J.C. Penney Is 'A Lot Better,' Jim Cramer Says
2016-11-02,Jim Cramer's 'Mad Money' Recap: It's Chicago Versus Cleveland -- Stocks, That Is
2016-10-31,Stocks Ready to Benefit From Rising Marijuana Legalization, Usage
2016-10-27,Pot Is on the Ballot in Election 2016, but Investors Should Proceed With Caution
2016-10-26,Here's Why These 3 Cheap Marijuana Stocks May Quadruple in Price
2016-10-26,GW Pharmaceuticals Stock Can Make Even More Gains -- Here's Why
2016-10-14,New Colombia Resources Forming Joint Venture To Apply For An Orphan Drug Designation With The Food And Drug Administration (FDA) For A Medical Cannabis Pharmaceutical Product
2016-10-03,Rev's Forum: Stock Pickers Have Some Opportunities
2016-09-28,GW Pharmaceuticals Is Taking Off as the Cannabis Industry Grows
2016-09-27,Jim Cramer -- Gilead Needs to Make an Acquisition
2016-09-27,Cramer: How Do You Play This Answer to the Opiate Epidemic?
2016-09-27,Jim Cramer's Top Takeaways: GW Pharmaceuticals, Apple, Align Technology
2016-09-26,Jim Cramer's 'Mad Money' Recap: Why Tonight's Debate Doesn't Really Matter
2016-09-26,Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies
2016-09-26,GW Pharmaceuticals (GWPH) Stock Soars on Positive Trial Results, Piper Jaffray Bullish
2016-09-26,GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial For Epidiolex® (cannabidiol) In The Treatment Of Lennox-Gastaut Syndrome
2016-09-18,Stephen King's Maximum Oversold (by Midweek)
2016-09-13,'Mad Money' Lightning Round: Abbvie Is a Great Long-Term Position
2016-09-12,Jim Cramer's 'Mad Money' Recap: Why You Shouldn't Be Jumping In and Out of Stocks
2016-09-09,4 Companies Likely to Benefit From Widening Legalization of Marijuana
2016-09-07,GW Pharmaceuticals (GWPH) Closed Higher on Takeover Speculation
2016-09-07,GW Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
2016-08-09,GW Pharmaceuticals Plc Reports Third Quarter 2016 Financial Results And Operational Progress
2016-08-02,GW Pharmaceuticals To Report Q3 Financial Results And Host Conference Call On 9 August, 2016
2016-07-29,'Mad Money' Lightning Round: Weight Watchers Is Not for Me
2016-07-28,Jim Cramer's 'Mad Money' Recap: I Can't Figure Out the Consumer
2016-07-18,GW Pharmaceuticals Plc Announces The Closing Of U.S. Public Offering Of American Depositary Shares (ADSs) Raising $289.8 Million On The NASDAQ Global Market And Full Exercise Of Underwriter's Option To Purchase Additional ADSs
2016-07-15,Why Nasdaq-Traded Marijuana Stocks Remain Undervalued
2016-07-12,GW Pharmaceuticals Plc Announces Pricing Of U.S. Public Offering Of ADSs Raising $252.0 Million On NASDAQ Global Market
2016-07-12,GW Pharmaceuticals Announces Proposed Public Offering Of ADSs
2016-06-27,Consumer Staples And Utilities Sectors Avoided Volatility in Brexit Aftermath
2016-06-27,Janney Says Sell GW Pharma Despite Marijuana-Derived Drug Success In Seizures
2016-06-27,GW Pharmaceuticals (GWPH) Moving On Heavy Volume In The Pre-Market Hours
2016-06-27,GW Pharma Marijuana Drug Confirms Seizure Benefit in Second Pivotal Trial
2016-06-27,GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results For Epidiolex® (cannabidiol) In The Treatment Of Lennox-Gastaut Syndrome
2016-06-23,Brexit Vote Leaves Investors Cautious
2016-06-22,Here&rsquo;s How You Should Invest If Gary Johnson Makes It to the White House
2016-06-21,GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol Or CBD) Development Program In Infantile Spasms (IS)
2016-06-20,Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan
2016-06-18,'Mad Money' Lightning Round: Buy, Buy, Buy Edward Lifesciences
2016-06-15,Economics of Pot: The Problems With Investing in Marijuana
2016-05-31,GW Pharmaceuticals To Present At The Goldman Sachs 37th Annual Global Healthcare Conference And The Jefferies 2016 Healthcare Conference
2016-05-27,'Mad Money' Lightning Round: Buy, Buy, Buy Intuit
2016-05-26,Jim Cramer's 'Mad Money' Recap: Stay Disciplined in This Market
2016-05-18,4 Top Stocks in the Growing Medical Marijuana Industry
2016-05-16,GW Pharmaceuticals To Present At The 2016 UBS Global Healthcare Conference On 24 May
2016-05-05,GW Pharmaceuticals Plc Reports Second Quarter And Half-Year 2016 Financial Results And Operational Progress
2016-05-04,The Cannabis Market Reaches New Heights
2016-05-04,GW Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2016 Healthcare Conference On 10 May
2016-05-03,5 Stocks Set to Soar on Bullish Earnings
2016-04-28,GW Pharmaceuticals To Report Q2, Half-Year Financial Results And Host Conference Call On 5 May, 2016
2016-04-21,Making the Right Budding Investment: Medical Versus Recreational Cannabis Companies
2016-04-21,GW Pharmaceuticals Receives Orphan Drug Designation From FDA For Cannabidiol For The Treatment Of Tuberous Sclerosis Complex
2016-04-20,How to Invest in Nasdaq-Traded Marijuana Stocks and Private Pot Companies
2016-04-20,Expansion Of Legalized Cannabis Continues At A Torrid Pace In The U.S. And Globally For Leading Markets Worldwide; Company Receives Purchase Order For Medical Marijuana Products
2016-04-15,These 3 Marijuana-Related Stocks Are Poised for Strong Growth
2016-04-11,GW Pharmaceuticals Initiates Phase 3 Pivotal Study In Tuberous Sclerosis Complex
2016-03-17,'Mad Money' Lightning Round: Step Into Skechers Long Term
2016-03-16,Jim Cramer's 'Mad Money' Recap: We've Won the War Against the Dollar
2016-03-15,INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of GW Pharmaceuticals Plc Of Class Action And A Lead Plaintiff Deadline Of March 21, 2016
2016-03-15,Why Pot Stock GW Pharmaceuticals Could Go Even Higher in 2016
2016-03-15,GWPH Momentum Passed Around to Other Pot Stocks
2016-03-14,GW Pharma (GWPH) Stock Spiked on Promising Cannabis-Derived Drug, Jim Cramer's Take
2016-03-14,Jim Cramer -- GW Pharma's Cannabinoid Treatment Could Be the Start
2016-03-14,Here's Why GW Pharma (GWPH) Stock Is Skyrocketing Today
2016-03-14,GW Pharma Marijuana Drug Cuts Seizure Rate in Pivotal Study
2016-03-14,GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results For Epidiolex® (cannabidiol)
2016-03-12,SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of GW Pharmaceuticals Plc
2016-03-11,SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notify Investors Of Class Action Lawsuit Involving GW Pharmaceuticals Plc And A Lead Plaintiff Deadline Of March 21, 2016
2016-03-10,SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of GW Pharmaceuticals Plc - GWPH
2016-03-09,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against GW Pharmaceuticals PLC (GWPH) And Lead Plaintiff Deadline: March 21, 2016
2016-03-08,'Mad Money' Lightning Round: Buy, Buy, Buy Bristol-Myers Squibb
2016-03-07,Jim Cramer's 'Mad Money' Recap: Commodities Are Healing, so Are Markets
2016-03-07,SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notify Investors Of Class Action Lawsuit Involving GW Pharmaceuticals Plc And A Lead Plaintiff Deadline Of March 21, 2016 - GWPH
2016-03-01,Oversold Conditions For GW Pharmaceuticals (GWPH)
2016-02-26,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of GW Pharmaceuticals Plc Of Class Action And A Lead Plaintiff Deadline Of March 21, 2016
2016-02-23,IMPORTANT SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In GW Pharmaceuticals PLC To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2016-02-22,INVESTOR ALERT: The Law Offices Of Vincent Wong Notify Investors Of Class Action Involving GW Pharmaceuticals Plc And A Lead Plaintiff Deadline Of March 21, 2016
2016-02-22,Jim Cramer's 'Mad Money' Recap: This Week's Game Plan
2016-02-20,'Mad Money' Lightning Round: Cramer Likes FedEx and UPS
2016-02-19,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In GW Pharmaceuticals Plc Of Class Action Lawsuit And Upcoming Deadline - GWPH
2016-02-10,STOCK ALERT: Rosen Law Firm Reminds GW Pharmaceuticals Plc Investors Of Important Deadline In Class Action - GWPH
2016-02-10,GW Pharmaceuticals Plc Reports First Quarter 2016 Financial Results And Operational Progress
2016-02-09,SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In GW Pharmaceuticals Plc To Contact The Firm Before Lead Plaintiff Deadline
2016-02-04,GW Pharmaceuticals To Present At The Leerink Partners 5th Annual Global Healthcare Conference
2016-02-02,GW Pharmaceuticals To Report Q1 Financial Results And Host Conference Call On 10 February, 2016
2016-01-26,Mood Swing Tape Continues
2016-01-25,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against GW Pharmaceuticals Plc - GWPH
2016-01-24,8 Things That Could Lift Biotech Stocks Out of Bear Market
2016-01-22,Bernstein Liebhard LLP Announces That A Suit Has Been Filed Against GW Pharmaceuticals Plc
2016-01-13,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of GW Pharmaceuticals PLC (GWPH)
2016-01-13,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of GW Pharmaceuticals Plc - GWPH
2016-01-11,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Securities Fraud By GW Pharmaceuticals Plc And Certain Officers And Directors
2016-01-11,GW Pharmaceuticals Plc Investigated For Potential Securities Law Violations By Block & Leviton LLP
2016-01-05,Jim Cramer Says Own Salesforce.com, Regeneron, First Solar
2015-12-24,The Lancet Neurology Publishes Data From The Epidiolex® Expanded Access Program In Children And Young Adults With Treatment-Resistant Epilepsy
2015-12-23,This Is the Only Stock to Buy Right Now to Profit From Legalized Weed
2015-12-22,'Mad Money' Lightning Round: It's OK to Buy Pandora Media Now
2015-12-21,Jim Cramer's 'Mad Money' Recap: Winners, Losers and the Chasm Between Them
2015-12-09,'Mad Money' Lightning Round: Take Mattel Over Hasbro
2015-12-08,Jim Cramer's 'Mad Money' Recap: Play the Hand You're Dealt
2015-12-07,GW Pharmaceuticals Plc Reports Fourth Quarter And Year-End 2015 Financial Results And Operational Progress
2015-12-07,GW Pharmaceuticals Announces New Physician Reports Of Epidiolex(R) Treatment Effect In Children And Young Adults With Treatment-Resistant Epilepsy
2015-12-02,Jim Cramer Answers 8 Questions From Viewers Including CEO Henry Blodget
2015-12-02,Jim Cramer Fields Questions From Viewers Including Henry Blodget
2015-11-30,GW Pharmaceuticals Announces Date And Time Change For Q4 And Year-End 2015 Financial Results And Conference Call
2015-11-25,New Epidiolex(R) (CBD) Data Accepted For Presentation At The 69th Annual Meeting Of The American Epilepsy Society
2015-11-24,GW Pharmaceuticals To Present At The Piper Jaffray 27th Annual Healthcare Conference
2015-11-24,GW Pharmaceuticals To Report Q4 And Year-End 2015 Financial Results And Host Conference Call On 3 December, 2015
2015-11-11,'Mad Money' Lightning Round: Northrop Grumman, Lockheed Martin Both Terrific
2015-11-10,Jim Cramer's 'Mad Money' Recap: Winners Remain When Rates Rise
2015-10-27,GW Pharmaceuticals And The Government Of New South Wales Announce A Strategic Agreement To Study Epidiolex(R) And CBDV In A Clinical Trial And Research Program For Children With Epilepsy
2015-10-27,GW Pharmaceuticals And Otsuka Announce Results From Two Remaining Sativex(R) Phase 3 Cancer Pain Trials
2015-10-10,'Mad Money' Lightning Round: Buy AT&T, Verizon, Walgreens Boots Alliance
2015-10-09,Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
2015-09-26,'Mad Money' Lightning Round: Buy, Buy, Buy Blackstone and KKR
2015-09-25,Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
2015-09-18,Biotech Stock Mailbag: Bristol, Exelixis, Lion Bio, GW Pharma
2015-09-15,Cramer: I'm Impressed by GW Pharma's Cannabis Data, Wait to Buy Kimberly-Clark
2015-09-15,GW Pharmaceuticals Announces Positive Proof Of Concept Data In Schizophrenia
2015-09-10,GW Pharmaceuticals To Present At Two Upcoming Investor Conferences
2015-08-13,Jim Cramer: Rite Aid and GW Pharmaceuticals Are Ripe for a Rally
2015-08-06,GW Pharmaceuticals Plc Reports Third Quarter 2015 Financial Results And Operational Progress
2015-08-06,GW Pharmaceuticals Receives FDA Fast Track And EMA Orphan Designations For Intravenous Cannabidiol In The Treatment Of Neonatal Hypoxic-Ischemic Encephalopathy (NHIE)
2015-08-05,'Mad Money' Lightning Round: Sell, Sell, Sell LinkedIn
2015-08-04,Jim Cramer's 'Mad Money' Recap: Nowhere to Run, Nowhere to Hide From China
2015-07-23,GW Pharmaceuticals To Report Q3 2015 Financial Results And Host Conference Call On 6 August, 2015
2015-07-21,GW Pharmaceuticals Announces Appointment Of Julian Gangolli To Board Of Directors
2015-06-26,Jim Cramer's Top Takeaways: Domino's, GW Pharmaceuticals, Bed Bath & Beyond
2015-06-25,Jim Cramer's 'Mad Money' Recap: Supreme Court Almost Makes Market Forget Greece
2015-06-23,Marijuana Stocks and the Risks of a '420 Friendly' Portfolio
2015-06-11,GW Pharmaceuticals Initiates Second Phase 3 Pivotal Study Of Epidiolex(R) (CBD) In Lennox-Gastaut Syndrome
2015-06-08,Jim Cramer Explains What Markets Will Do When the Fed Raises Rates
2015-06-08,Cramer: Markets to Dip for a Few Weeks When the Fed Raises Rates
2015-05-19,GW Appoints Senior Industry Executive To President, North America And Relocates CEO To The U.S.
2015-05-11,GW Pharmaceuticals To Present At Bank Of America Merrill Lynch 2015 Healthcare Conference
2015-05-11,GW Pharmaceuticals Initiates Phase 3 Pivotal Study Of Epidiolex(R) (CBD) In Lennox-Gastaut Syndrome
2015-05-11,GW Pharmaceuticals Plc Reports Second Quarter 2015 Financial Results And Operational Progress
2015-05-06,GW Pharmaceuticals To Report Q2 2015 Financial Results And Host Conference Call On 11 May, 2015
2015-05-06,GW Pharmaceuticals Initiates Phase 2 Clinical Study Of Cannabidivarin (CBDV) In Epilepsy
2015-05-05,GW Pharmaceuticals Plc Announces The Closing Of U.S. Public Offering Of American Depositary Shares (ADSs) Raising Approximately $179.2 Million On The NASDAQ Global Market
2015-04-28,GW Pharmaceuticals Plc Announces Pricing Of U.S. Public Offering Of ADSs Raising $179.2 Million On NASDAQ Global Market
2017-03-16,Slowly but Surely, Post-Fed Euphoria Dissipates
2017-03-09,There Should Be More Selling
2017-02-23,Halozyme Therapeutics To Present At Upcoming Healthcare Conferences
2017-02-13,MabVax Therapeutics Studies Lead Investigational Drug MVT-5873 With Halozyme PEGPH20
2017-02-01,Halozyme To Host Fourth Quarter 2016 Financial Results Conference Call
2017-01-09,Halozyme Provides Program Updates, 2017 Financial Guidance At 35th Annual JP Morgan Healthcare Conference
2017-01-06,Constellation Brands, Halozyme Therapeutics: Jim Cramer's Top Takeaways
2017-01-05,Retail, Politics and Bonds Signal Trend Changes: Cramer's 'Mad Money' Recap (Thursday 1/5/17)
2017-01-05,Halozyme Announces Phase 2 Study In Advanced Pancreas Cancer Meets Key Endpoints
2016-12-22,Halozyme Therapeutics To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-20,First Week Of HALO February 2017 Options Trading
2016-11-21,Halozyme Provides Update On AbbVie Collaboration
2016-11-15,Halozyme Therapeutics Reaches Analyst Target Price
2016-11-10,Halozyme Announces Broad Clinical Collaboration Agreement To Evaluate PEGPH20 And Tecentriq In Up To Eight Tumor Types
2016-11-03,FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
2016-10-13,Halozyme To Host Third Quarter 2016 Financial Results Conference Call
2016-10-04,PEGPH20 Selected For Inclusion In Groundbreaking Clinical Trial Initiative Designed To Transform Outcomes For Pancreatic Cancer Patients
2016-09-28,Are Your Stocks Just Running in Place?
2016-09-19,Bullish &amp; Bearish Reversals for the Week
2016-09-19,Netflix Can Break out Soon
2016-09-16,One Reason Why Halozyme Therapeutics (HALO) Stock Is Climbing Today
2016-09-08,Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2016 Global Health Care Conference
2016-09-01,Halozyme Names Mark J. Gergen As Chief Operating Officer
2016-08-31,Halozyme Therapeutics To Present At Upcoming Healthcare Conferences
2016-07-26,Eisai And Halozyme Initiate Phase 1b/2 Clinical Trial With First Patient Dosing Of Eribulin In Combination With PEGPH20
2016-07-25,Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Trial With KEYTRUDA
2016-07-11,Halozyme To Host Second Quarter 2016 Financial Results Conference Call
2016-07-07,These 5 Stocks Under $10 Are Set to Soar
2016-07-06,Halozyme Therapeutics (HALO) Is Today's Dead Cat Bounce Stock
2016-06-20,Today's Dead Cat Bounce Stock: Halozyme Therapeutics (HALO)
2016-06-08,Halozyme Announces Agreement To Refinance Debt, Increases 2016 Guidance For Year-End Cash Balance
2016-06-07,Today's Weak On High Volume Stock: Halozyme Therapeutics (HALO)
2016-06-04,Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20
2016-05-23,July 15th Options Now Available For Halozyme Therapeutics (HALO)
2016-05-17,Halozyme Therapeutics To Present At The UBS 2016 Global Health Care Conference
2016-05-13,Strong On High Volume: Halozyme Therapeutics (HALO)
2016-05-11,Today's Weak On High Volume Stock: Halozyme Therapeutics (HALO)
2016-04-24,I'm Not Sure I Trust a Market That Uranium Heats
2016-04-20,Halozyme To Host First Quarter 2016 Financial Results Conference Call
2016-04-18,Halozyme Expands Oncology Pipeline With Two Compounds Designed For Activity In The Tumor Microenvironment
2016-04-14,Halozyme Therapeutics (HALO) Is Today's Strong On High Volume Stock
2016-03-30,Trade-Ideas: Halozyme Therapeutics (HALO) Is Today's Strong On High Relative Volume Stock
2016-03-17,Halozyme To Present Data From Five Preclinical Studies At American Association Of Cancer Research Annual Conference
2016-03-16,Halozyme Doses First Patient In Phase 3 Clinical Trial Of PEGPH20 In Combination With ABRAXANE® And Gemcitabine
2016-03-09,Trade-Ideas: Halozyme Therapeutics (HALO) Is Today's Weak On High Relative Volume Stock
2016-03-07,Halozyme Appoints Jim Daly To Board Of Directors
2016-03-02,Halozyme Therapeutics To Present At Upcoming Healthcare Conferences
2016-02-25,First Week of HALO April 15th Options Trading
2016-02-12,8 Biotech Stocks Under $10 Poised for Breakouts
2016-02-01,Halozyme To Host Fourth Quarter And 2015 Year-End Financial Results Conference Call
2016-01-26,Halozyme Announces Closing Of $150 Million Royalty-Backed Debt Financing
2016-01-21,5 Stocks Under $10 Set to Soar
2016-01-21,Halozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE™ Technology
2016-01-14,Halozyme Therapeutics (HALO) Highlighted As Weak On High Volume
2016-01-12,Halozyme Therapeutics (HALO) Is Strong On High Volume Today
2016-01-05,Halozyme Therapeutics To Present At The 34th Annual J.P. Morgan Healthcare Conference
2016-01-04,Halozyme Enters Into Agreement For $150 Million Non-Dilutive Royalty-Backed Debt Financing
2015-12-21,Halozyme Enters Into Global Collaboration And Licensing Agreement With Lilly
2015-11-24,Halozyme Therapeutics To Present At Upcoming Healthcare Conferences
2015-11-18,'Mad Money' Lightning Round: Procter & Gamble Is Done Going Down
2015-11-17,Jim Cramer's 'Mad Money' Recap: Why Good News Is Bad News in This Market
2015-11-17,Halozyme To Expand With A Satellite Office In San Francisco
2015-11-05,First Patient Dosed In Clinical Trial Of Halozyme Investigational Drug PEGPH20 In Combination With Merck Immuno-oncology Drug KEYTRUDA
2015-11-05,'Mad Money' Lightning Round: Buy 'Unknown' Sinclair Broadcasting
2015-11-04,Jim Cramer's 'Mad Money' Recap: Today's Market Punished the Innocent
2015-11-04,Halozyme Announces First Clinical Dosing Of Janssen's Daratumumab Using ENHANZE™ Technology
2015-11-03,Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
2015-11-03,Today's Perilous Reversal Stock: Halozyme Therapeutics (HALO)
2015-10-29,Halozyme Announces First Clinical Dosing Of Pfizer's Rivipansel Using Enhanze™ Technology
2015-10-19,/C O R R E C T I O N -- Halozyme Therapeutics, Inc./
2015-10-14,Today's Dead Cat Bounce Stock: Halozyme Therapeutics (HALO)
2015-08-24,Halozyme Appoints Michael J. Labarre As Chief Scientific Officer
2015-08-18,Biotech: Partnerships Spell Success
2015-08-17,Today's Dead Cat Bounce Stock Is Halozyme Therapeutics (HALO)
2015-08-11,Halozyme (HALO) Stock Spikes Following Earnings Release
2015-08-11,Strong On High Relative Volume: Halozyme Therapeutics (HALO)
2015-08-10,Halozyme Therapeutics (HALO) Showing Signs Of A Dead Cat Bounce Today
2015-08-06,UCSF To Study Halozyme PEGPH20 In Pancreatic Cancer Patients Who Are Candidates For Potentially Curative Surgery
2015-08-05,Halozyme Appoints Jeffrey W. Henderson To Board
2015-08-03,Halozyme To Host Second Quarter 2015 Financial Results Conference Call
2015-07-16,'Mad Money' Lightning Round: I Like Clean Energy Fuels, Not Its Stock
2015-07-15,Jim Cramer's 'Mad Money' Recap: Take Notice of the Best Investors in the World
2015-07-01,Jim Cramer's 'Mad Money' Recap: We're Not Out of the Woods Yet
2015-07-01,10 Best Biotech Stocks in the NASDAQ
2015-06-30,New Lifetime High Today: Halozyme Therapeutics (HALO)
2015-06-26,'Mad Money' Lightning Round: Stay Away From Las Vegas Sands
2015-06-25,Jim Cramer's 'Mad Money' Recap: Supreme Court Almost Makes Market Forget Greece
2015-06-25,Trade-Ideas: Halozyme Therapeutics (HALO) Is Today's "Dead Cat Bounce" Stock
2015-06-19,Halozyme Therapeutics To Present At The JMP Securities 2015 Life Sciences Conference
2015-06-19,Halozyme Therapeutics (HALO) Hits New Lifetime High
2015-06-09,Playing Biotechs with the House's Money
2015-06-03,New Lifetime High Reached: Halozyme Therapeutics (HALO)
2015-06-03,Halozyme Enters Into Global Collaboration And Licensing Agreement With AbbVie
2015-05-31,Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients
2015-05-27,New Lifetime High Reached: Halozyme Therapeutics (HALO)
2015-05-13,Jumpstart ASCO '15 With This Quick List of Hot Research Abstracts
2015-05-12,Halozyme Therapeutics To Present At The UBS 2015 Global Health Care Conference
2015-05-07,Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference
2015-05-04,Halozyme To Host First Quarter 2015 Financial Results Conference Call
2015-04-24,Partnerships Lift Small Caps
2015-04-22,First Week Of December 18th Options Trading For Halozyme Therapeutics
2015-04-20,Halozyme Presents New Preclinical Data At The American Association For Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO
2015-04-13,Halozyme Therapeutics Appoints Harry J. Leonhardt, Esq. As Senior Vice President, General Counsel And Chief Compliance Officer
2015-04-08,Halozyme Provides Update Following Type B FDA Meeting
2015-04-02,First Week Of HALO May 15th Options Trading
2015-03-24,How I Play the Biotechs
2015-03-23,Halozyme Therapeutics Appoints James Mazzola To Lead Corporate Communications, Investor Relations
2015-03-20,Take Aim at Threshold Pharmaceuticals
2015-03-17,HALO: Insiders Vs. Shorts
2015-03-10,Insider Trading Alert - GCAP, HALO And ALIM Traded By Insiders
2015-03-10,Halozyme Therapeutics Reports Selection Of First Product Candidate Under Janssen Collaboration
2015-03-06,Insiders Pile Into Holdings Of XBI ETF
2015-03-06,Small-Cap Focus: Navidea
2015-03-03,Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference
2015-03-02,Nasdaq 5K: There's No Comparison
2015-02-23,Halozyme To Host Fourth Quarter And 2014 Year-End Financial Results Conference Call
2015-02-20,Small-Cap Friday's Little Gem
2015-02-17,Halozyme Announces Preclinical Study Results Of PEGPH20 Published In Molecular Cancer Therapeutics
2015-02-13,Two Small-Cap Biotechs To Consider
2015-01-29,This ETF Holds Stocks Insiders Want To Own
2015-01-21,Halozyme Appoints Jean-Pierre Bizzari, M.D. To Board Of Directors
2015-01-14,Jim Cramer's Top Stock Picks: AAPL FLEX DIS CELG HALO
2015-01-13,Jim Cramer's 'Mad Money' Recap: How to Maneuver in a Trader's Market
2015-01-12,Halozyme Therapeutics Provides An Update On Anticipated Milestones For 2015 At The 33rd Annual J. P. Morgan Healthcare Conference
2015-01-10,'Mad Money' Lightning Round: Be Careful Investing in Google
2015-01-09,Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
2015-01-09,Today's Perilous Reversal Stock: Halozyme Therapeutics (HALO)
2015-01-08,Barbarian At The Gate: Halozyme Therapeutics (HALO)
2015-01-07,Halozyme Provides Agenda Highlights For Analyst And Investor Meeting
2015-01-06,Halozyme Therapeutics To Present At The 33rd Annual J.P. Morgan Healthcare Conference
2015-01-06,Why I'm Sticking With Biotech
2015-01-05,Halozyme Therapeutics Appoints Athena Countouriotis, M.D. As Chief Medical Officer
2014-12-30,First Week Of February 2015 Options Trading For Halozyme Therapeutics
2014-12-30,Halozyme Therapeutics To Host Analyst And Investor Meeting
2014-12-19,Halozyme Receives European Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer
2014-12-18,Get Off the Energy Roller Coaster
2014-12-17,Halozyme Therapeutics Enters A Global Collaboration With Janssen To Develop And Commercialize Subcutaneous Products Using ENHANZE™ Technology
2014-12-15,Relative Strength Alert For Halozyme Therapeutics
2014-12-12,Halozyme Announces Presentations Of Preclinical Data At The San Antonio Breast Cancer Symposium Annual Meeting
2014-12-03,Halozyme Therapeutics To Present At The 25th Annual Oppenheimer Healthcare Conference
2014-11-25,Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference
2014-11-17,Interesting HALO Call Options For January 2017
2014-11-11,Halozyme Therapeutics (HALO) Stock Is Slipping Today on Weak Third Quarter Earnings
2014-11-05,Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
2014-11-03,Halozyme To Host Third Quarter 2014 Financial Results Conference Call
2014-10-20,Baxter Launches HYQVIA In The United States For Adult Patients With Primary Immunodeficiency
2014-10-20,Halozyme Receives FDA Approval For Additional Manufacturing Facilities For Hylenex® Recombinant
2014-10-09,Halozyme Announces Podium Presentation On PEGPH20 At The New York Academy Of Sciences
2014-10-07,Halozyme Announces Issuance Of U.S. Patent For Companion Diagnostic For PEGPH20
2014-10-03,Halozyme Receives Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer
2014-09-18,SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer
2014-09-17,HALO: Insiders vs. Shorts
2014-09-17,5 Stocks With Big Insider Buying
2014-09-12,FDA Approves Baxter’s HYQVIA For Treatment Of Adults With Primary Immunodeficiency
2014-09-03,Halozyme's PEGPH20 Program In Metastatic Pancreatic Cancer Receives Fast Track Designation
2014-08-04,Halozyme To Host Second Quarter 2014 Financial Results Conference Call
2014-08-01,Trade-Ideas: Halozyme Therapeutics (HALO) Is Today's "Perilous Reversal" Stock
2014-07-31,FDA Advisory Committee Panel Provides Favorable Recommendation On Baxter&#8217;s HyQvia For Primary Immunodeficiency
2014-07-30,3 Biotech Stocks Under $10 in Breakout Territory
2014-07-22,Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer
2014-07-21,Trade-Ideas: Halozyme Therapeutics (HALO) Is Today's "Perilous Reversal" Stock
2014-06-25,Roche's Commercial Launch Of MabThera SC Triggers Milestone Payment To Halozyme
2014-06-17,Halozyme Therapeutics To Present At The JMP Securities 2014 Healthcare Conference
2014-06-15,Halozyme Announces Presentation Of Clinical Data At The American Diabetes Association 74th Scientific Sessions
2014-06-13,Swing Trade Ideas for Friday June 13: First Majestic Silver, Clovis, More
2014-06-13,Halozyme Therapeutics (HALO) In A Perilous Reversal
2014-06-12,Analysts' Actions: Halozyme, Hewlett-Packard, Immunogen, Sprouts
2014-06-12,Why Halozyme Therapeutics Was Upgraded To 'Buy' This Morning
2014-06-11,3 Stocks Under $10 to Trade for Breakouts
2014-06-06,Today's Perilous Reversal Stock: Halozyme Therapeutics (HALO)
2014-06-05,Why Halozyme Therapeutics (HALO) Stock Is Spiking Today
2014-06-05,Halozyme Therapeutics (HALO) Moving On Heavy Pre-Market Trading
2014-06-04,Why Halozyme Therapeutics Is Soaring in After-Hours Trading Today
2014-06-04,Halozyme To Resume PEGPH20 Clinical Program In Pancreatic Cancer
2014-05-29,Halozyme Therapeutics To Present At The Jefferies 2014 Global Health Care Conference
2014-05-21,Halozyme Therapeutics Becomes Oversold (HALO)
2014-05-20,Interesting HALO Put And Call Options For July 19th
2014-05-14,Halozyme Therapeutics To Present At The UBS 2014 Global Health Care Conference
2014-05-13,Why Halozyme Therapeutics (HALO) Stock Is Surging Today
2014-05-13,Halozyme Therapeutics (HALO) Is Today's Pre-Market Mover With Heavy Volume Stock
2017-03-13,Heron Therapeutics To Present At The Oppenheimer 27th Annual Healthcare Conference
2017-02-28,Heron Therapeutics To Present At The 37th Annual Cowen And Company Healthcare Conference
2017-02-24,Heron Therapeutics Announces Inclusion Of SUSTOL® (Granisetron) Extended-Release Injection In NCCN® Antiemesis Guidelines
2017-02-23,Heron Therapeutics Announces Fourth Quarter And Full Year 2016 Financial Results And Recent Corporate Progress
2017-02-08,Heron Therapeutics To Present At The Leerink Partners 6th Annual Global Healthcare Conference
2017-01-31,Heron Therapeutics Announces Underwriters' Exercise In Full Of Option To Purchase Additional Shares
2017-01-25,First Week of HRTX September 15th Options Trading
2017-01-19,Heron Therapeutics Announces Pricing Of Underwritten Public Offering Of Common Stock
2017-01-18,Heron Therapeutics Announces Proposed Public Offering Of Common Stock
2017-01-12,Heron Announces Submission Of CINVANTI™ NDA For The Prevention Of Chemotherapy-Induced Nausea And Vomiting (CINV)
2017-01-05,Heron Therapeutics To Present At The 35th Annual J.P. Morgan Healthcare Conference
2017-01-04,Heron Therapeutics Establishes Synergy Of Bupivacaine And Meloxicam With HTX-011 For Prevention Of Post-Operative Pain In Phase 2 Clinical Studies
2017-01-04,Heron Therapeutics Announces Positive Topline Results From Phase 2 Clinical Trial Of HTX-011 In Abdominoplasty
2016-12-20,First Week Of HRTX February 2017 Options Trading
2016-11-29,Susan G. Komen® Joins Forces With Heron Therapeutics To Raise Awareness Of The Supportive Care Needs Of Patients With Breast Cancer
2016-11-08,Heron Therapeutics Reports Financial Results For The Three And Nine Months Ended September 30, 2016 And Recent Corporate Progress
2016-10-31,Heron Therapeutics is Now Oversold (HRTX)
2016-10-17,Commit To Buy Heron Therapeutics At $7.50, Earn 12.7% Using Options
2016-10-13,Short Interest Moves 18.5% Higher For HRTX
2016-09-09,Noteworthy Friday Option Activity: HRTX, AERI, UBNT
2016-09-08,Heron Therapeutics Announces Presentations Of Results From Phase 2 Clinical Trial Of HTX-011 In Hernia Repair At PAINWeek® 2016
2016-09-06,Here's Why Investors Should Steer Clear of Opioids
2016-08-29,Heron Therapeutics Announces Poster Presentations Of Data From Phase 2 Clinical Program For HTX-011 At PAINWeek® 2016
2016-08-12,Biotech Stock Mailbag: Heron, Acadia, Exact Sciences, Sarepta
2016-08-10,Bullish Two Hundred Day Moving Average Cross - HRTX
2016-08-10,Heron Therapeutics Announces U.S. FDA Approval Of SUSTOL® (granisetron) Extended-Release Injection For The Prevention Of Chemotherapy-Induced Nausea And Vomiting
2016-08-08,Heron Therapeutics Reports Second Quarter 2016 Financial Results And Recent Corporate Progress
2016-08-02,Heron Therapeutics Enters Into Loan Agreement For Up To $100 Million
2016-08-01,Notable Monday Option Activity: HRTX, SGMS, BSFT
2016-08-01,Heron Therapeutics Reports Positive Top-Line Results From Phase 2 Studies Of HTX-011 For Management Of Post-Operative Pain
2016-07-19,Noteworthy Tuesday Option Activity: HRTX, OMF, SCLN
2016-07-18,HRTX March 2017 Options Begin Trading
2016-07-08,Biotech Stock Mailbag: Heron, Exelixis
2016-06-27,First Week of August 19th Options Trading For Heron Therapeutics (HRTX)
2016-06-22,Heron Therapeutics Announces Appointment Of Christian Waage To Board Of Directors
2016-06-15,Heron Therapeutics To Present At The JMP Securities Life Sciences Conference
2016-05-18,Heron and the Never-Ending FDA Drug Review
2016-05-05,Heron Therapeutics Announces First Quarter 2016 Financial Results And Recent Corporate Progress
2016-04-18,Heron Therapeutics Provides Update On FDA Review Of SUSTOL® NDA
2016-04-11,Noteworthy Monday Option Activity: HRTX, Z, CLD
2016-03-23,First Week of HRTX May 20th Options Trading
2016-03-17,Heron Therapeutics Appoints David L. Szekeres, SVP Business Development, General Counsel And Corporate Secretary
2016-03-03,Heron Therapeutics Provides Update On SUSTOL® NDA
2016-02-29,Heron Therapeutics Provides Update On SUSTOL® NDA
2016-02-19,Heron Therapeutics Announces Fourth Quarter And Full Year 2015 Financial Results And Recent Corporate Progress
2016-02-04,Heron Therapeutics To Present At The Leerink Partners 5th Annual Global Healthcare Conference
2016-01-28,Heron Therapeutics Appoints Kimberly J. Manhard As Executive Vice President Of Drug Development
2016-01-20,Oversold Conditions For Heron Therapeutics (HRTX)
2016-01-15,Heron Therapeutics Notified By FDA That It Will Not Take Action On SUSTOL® New Drug Application By The PDUFA Date
2016-01-05,Commit To Purchase Heron Therapeutics At $15, Earn 27.3% Using Options
2015-12-23,HERON THERAPEUTICS (HRTX) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Heron Therapeutics, Inc. For Potential Securities Violations And Breach Of Fiduciary Duty
2015-11-10,Heron Therapeutics To Participate In Investor Conferences In November 2015
2015-11-06,Heron Therapeutics Announces Third Quarter 2015 Financial Results And Recent Corporate Progress
2015-10-12,Heron Therapeutics Appoints Neil J. Clendeninn, M.D., Ph.D. As Senior Vice President And Chief Medical Officer
2015-09-28,Heron Therapeutics Announces Oral Presentation Of Data From Completed Phase 3 MAGIC Study For SUSTOL® At The ASCO Breast Cancer Symposium
2015-09-22,Heron Therapeutics Reports Positive Top-Line Results From Phase 2 Study Of HTX-011 In The Management Of Post-Operative Pain
2015-09-22,Heron Therapeutics To Present Data From Completed Phase 3 MAGIC Study Of SUSTOL® At ASCO Breast Cancer Symposium
2015-09-18,Heron Therapeutics Announces FDA Acceptance Of New Drug Application For SUSTOL®
2015-08-07,Heron Therapeutics Announces Second Quarter 2015 Financial Results And Recent Corporate Progress
2015-07-20,Heron Therapeutics Resubmits SUSTOL® New Drug Application To FDA
2015-06-19,Biotech Stock Mailbag: Unstoppable Heron, Aerie Disclosure Fail, Gene Therapy, Hate Mail!
2015-06-16,Heron Therapeutics Initiates Phase 2 Clinical Trial Of HTX-011 For The Treatment Of Post-Operative Pain
2015-06-10,Heron Therapeutics (HRTX) Stock Spikes After Pricing Secondary Offering
2015-06-03,Where the Money Was Made the Last 5 Years
2015-06-01,New Cancer Therapy Study Results - MAGIC Trial
2015-05-28,Heron Therapeutics Announces Positive Results From Phase 3 MAGIC Study Of SUSTOL®
2015-05-26,Heron Therapeutics To Present At Investor Conferences In June 2015
2015-05-19,First Week Of HRTX July 17th Options Trading
2015-05-14,Heron Therapeutics Announces Positive Outcome From Meeting With FDA For HTX-019
2015-05-08,Heron Therapeutics Announces First Quarter 2015 Financial Results And Corporate Progress
2015-04-27,Heron Therapeutics To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference
2015-04-02,Heron Therapeutics Reaches Target Patient Enrollment In MAGIC Phase 3 Study Of SUSTOL®
2015-03-19,Heron Therapeutics Reports Positive Results From Phase 1 Study Of HTX-011
2015-03-13,Heron Therapeutics Announces Fourth Quarter And Full Year 2014 Financial Results And Corporate Progress
2015-02-23,Heron Therapeutics To Present At Upcoming Healthcare Conferences
2015-02-11,Heron Therapeutics Initiates Phase 1 Clinical Study Of HTX-011 For The Treatment Of Post-Operative Pain
2015-02-03,Heron Therapeutics To Present At The Leerink Partners 2015 Global Healthcare Conference
2015-01-21,Relative Strength Alert For Heron Therapeutics
2014-12-11,5 Stocks Under $10 Setting Up to Trade Higher: Covisint and More
2014-12-02,Heron Therapeutics To Present At The Oppenheimer 25th Annual Healthcare Conference
2014-11-06,Heron Therapeutics Discloses New Proprietary Intravenous Formulation Of NK-1 Receptor Antagonist For Prevention Of CINV
2014-11-06,Heron Therapeutics Announces Third Quarter And Year-to-Date 2014 Financial Results And Corporate Highlights
2014-10-08,Heron Therapeutics is Now Oversold (HRTX)
2014-08-25,Heron Therapeutics Appoints Esmé C. Smith As Vice President, General Counsel And Secretary
2014-08-04,Heron Therapeutics Announces Second Quarter And Year-to-Date 2014 Financial Results
2014-07-30,4 Stocks Under $10 Making Big Moves
2014-07-16,Heron Therapeutics Enters Oversold Territory (HRTX)
,
,
,
2017-03-23,Heat Biologics Prices Offering Of 5,000,000 Shares Of Common Stock
2017-03-22,Heat Biologics Announces Proposed Public Offering Of Common Stock
2017-03-21,Heat Biologics Reports Positive Interim Phase 2 Lung Cancer Results In Patients Treated With HS-110 In Combination With A Checkpoint Inhibitor
2017-03-16,Florida Department Of Health Awards Three-Year Grant To Develop Gp96-based Zika Vaccine
2017-03-13,Heat Biologics Meets Efficacy Endpoint In Its Phase 1b Lung Cancer Trial To Progress To Phase 2
2017-03-09,Heat Biologics To Present At 29th Annual ROTH Conference
2017-03-08,Heat Biologics Announces Agreement To Acquire Pelican Therapeutics
2017-03-02,Heat Biologics To Present At The American Association For Cancer Research (AACR) Annual Meeting
2017-02-17,Heat Biologics Presents Immune Data On Its HS-410 Phase 2 Bladder Cancer Trial At The Genitourinary Cancers Symposium
2017-02-14,Heat Biologics To Present At The Genitourinary Cancers Symposium
2017-01-27,These 5 Stocks Under $10 Could Get Hot Soon
2017-01-24,Heat Biologics To Present At NobleCon13
2017-01-05,Heat Biologics To Present At Biotech Showcase 2017 Conference In San Francisco
2017-01-04,Heat Biologics Appoints Jeff Hutchins, Ph.D., As Chief Scientific Officer
2016-12-06,Heat Biologics Presents Topline HS-110/Nivolumab Combination Lung Cancer Results
2016-12-01,Rosen Law Firm Closes Investigation And Concludes There Is No Basis For Securities Claims Against HTBX
2016-12-01,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Heat Biologics, Inc. (HTBX)
2016-12-01,INVESTOR LOSS ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Heat Biologics, Inc. - HTBX
2016-11-30,Heat Biologics Presents Topline HS-410 Phase 2 Bladder Cancer Results At The Society Of Urological Oncology Annual Meeting
2016-11-17,Heat Biologics To Present Topline HS-110/Nivolumab Combination Phase Ib Lung Cancer Results At The International Society For The Study Of Lung Cancer Annual Meeting
2016-11-16,Heat Biologics To Present Topline HS-410 Phase II Bladder Cancer Results At The Society Of Urological Oncology Annual Meeting
2016-11-14,Heat Biologics Presents ComPACT Preclinical Data At The Society For Immunotherapy Of Cancer Annual Meeting
2016-11-10,Heat Biologics Provides Corporate Update And Reports Third Quarter 2016 Financial Results
2016-11-07,Heat Biologics To Present At The Society For Immunotherapy Of Cancer (SITC) Annual Meeting
2016-10-25,Heat Biologics And University Of Miami Announce Zika Vaccine Collaboration
2016-10-17,Heat Biologics To Present At Two Upcoming Investor Conferences And Panel Discussion
2016-10-13,Heat Biologics Remains On Track To Achieve  Multiple Topline Data Readouts This Quarter
2016-10-11,Heat Biologics Selects Adaptive Biotechnologies To Discover Potential Clinical Biomarkers To Advance Novel Immunotherapies
2016-10-07,Heat Biologics Substantially Reduces Debt And Reports Proceeds Of Approximately $2.8 Million Year-to-Date From The Exercise Of Warrants
2016-09-13,Heat Biologics To Present At Two Upcoming Investor Conferences
2016-08-15,Heat Biologics Provides Corporate Update And Reports Second Quarter 2016 Financial Results
2016-07-22,Heat Biologics Announces Suspension Of Proposed Public Offering Of Common Stock
2016-07-21,Heat Biologics Announces Proposed Public Offering Of Common Stock
2016-06-06,Heat Biologics Presents A Poster On Its HS-110/Nivolumab Combination Phase 1b Non-Small Cell Lung Cancer Trial At ASCO Annual Meeting
2016-05-27,7 Stocks Under $10 to Trade for Big Profits
2016-05-11,Heat Biologics Reports First Quarter 2016 Financial Results
2016-04-26,Heat Biologics To Present At PIONEERS 2016, Presented By Joseph Gunnar & Co.
2016-04-25,8 Breakout Stocks Under $10 to Trade for Big Profits
2016-04-25,Heat Biologics Appoints Dr. John Prendergast To Board Of Directors
2016-04-18,Heat Biologics And OncoSec Present Data At The American Conference For Cancer Research (AACR) Annual Meeting
2016-04-18,OncoSec And Heat Biologics Present Data At The American Conference For Cancer Research (AACR) Annual Meeting
2016-04-12,Heat Biologics To Present At The American Association For Cancer Research (AACR) Annual Meeting
2016-04-07,Heat Biologics Announces Cost-Saving Measures And Focused Corporate Strategy To Achieve Important Clinical Milestones
2016-03-30,Heat Biologics To Participate In The 6th Annual Cancer Immunotherapy: A Long-Awaited Reality Conference
2016-03-23,Heat Biologics Announces Closing Of Public Offering
2016-03-18,Heat Biologics Announces Public Offering Of Common Stock And Warrants
2016-03-09,Heat Biologics' CSO To Participate In The 27th Annual Cancer Progress Conference By Defined Health
2016-03-07,Heat Biologics Presents Positive ComPACT Preclinical Data At The Keystone Symposia
2016-03-04,Heat Biologics To Present At The 28th Annual ROTH Conference
2016-02-25,Heat Biologics Provides Update On Its HS-410 Phase 2 Monotherapy Bladder Cancer Trial Arm
2016-02-18,Heat Biologics Reports Fiscal Year 2015 Financial Results
2016-02-10,FDA Lifts Heat Biologics Partial Clinical Hold
2016-02-03,Heat Biologics Reports Update On Its HS-410 Phase 2 Bladder Cancer Trial
2016-01-26,Heat Biologics CSO To Present Interim Results From The Monotherapy Arm In Its Ongoing HS-410 Phase 2 Bladder Cancer Trial At The Phacilitate Immunotherapy World Conference
2016-01-07,Heat Biologics To Present At Biotech Showcase 2016
2015-12-01,Heat Biologics Appoints Timothy Creech As Chief Financial Officer
2015-11-18,Heat Biologics Selected As One Of Informa's 2015 Top 10 Immuno-Oncology Companies To Watch
2015-11-06,Heat Biologics Reports HS-410 Phase 1 Bladder Cancer Trial Results At The Society For Immunotherapy Of Cancer (SITC) Annual Meeting
2015-11-03,Results Of Heat Biologics' HS-410 Phase 1 Safety Trial In Non-Muscle Invasive Bladder Cancer To Be Presented At SITC Annual Meeting
2015-10-30,Heat Biologics Releases Third Quarter 2015 Financial Results
2015-10-14,Heat Biologics Expands Scientific And Clinical Advisory Board With Appointments Of Drs. Holbrook Kohrt And Kapil Dhingra
2015-10-08,Heat Biologics Completes Patient Enrollment For Randomized Arms Of Its Phase 2 HS-410 Bladder Cancer Trial
2015-10-07,Heat Biologics To Participate In The Annual Prostate Cancer Foundation Scientific Retreat
2015-09-16,Heat Biologics To Present New Data On Its ComPACT Platform At The CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference
2015-09-02,Heat Biologics, Inc. To Present At The 17th Annual Global Investment Conference
2015-09-01,Heat Biologics Announces Clinical Trial Combining HS-110 And PD-1 Checkpoint Inhibitor In NSCLC
2015-08-13,Heat Biologics Announces Financial Results For The Second Quarter Ended June 30, 2015
2015-07-28,4 Breakout Stocks Under $10 Making Big Moves
2015-07-27,Heat Biologics, Inc. Announces Promotions Of Taylor Schreiber, M.D., Ph.D., To Chief Scientific Officer, And Melissa Price, Ph.D., To Vice President Of Product Development
2015-07-01,Heat Biologics, Inc. To Present At The Cantor Fitzgerald Healthcare Conference
2015-06-15,Heat Biologics Announces Development Of ComPACT, A Next Generation Combination Immunotherapy Platform
2015-05-29,Heat Biologics, Inc. To Present Interim Immune Response Data From Ongoing Phase II Trial With HS-110 In Advanced NSCLC At ASCO
2015-05-21,Heat Biologics, Inc. To Present At The Marcum Microcap Conference
2015-05-14,Heat Biologics Announces Financial Results For The First Quarter Ended March 31, 2015
2015-05-11,CORRECTING And REPLACING -- Heat Biologics Announces Initiation Of Phase 1b Trial Of Viagenpumatucel-L (HS-110) In Non-Small Cell Lung Cancer (NSCLC)
2015-05-11,Heat Biologics Announces Initiation Of Phase 1b Trial Of Viagenpumatucel-L (HS-110) In Non-Small Cell Lung Cancer (NSCLC)
2015-04-22,Heat Biologics, Inc. To Present At The 2015 American Association For Cancer Research Annual Meeting
2015-04-15,Heat Biologics, Inc. To Present At The 2015 American Association For Cancer Research Annual Meeting
2015-03-27,Heat Biologics Announces Financial Results For The Year Ended December 31, 2014
2015-03-16,Heat Biologics, Inc. Announces Closing Of Public Offering Of Common Stock And Full Exercise Of The Underwriters' Over-Allotment Option
2015-03-10,Heat Biologics, Inc. Announces Pricing Of Public Offering Of $10,660,000 Of Common Stock
2015-03-10,Heat Biologics, Inc. Announces Proposed Public Offering Of Common Stock
2015-03-09,Heat Biologics, Inc. Receives US FDA Fast Track Designation For HS-410 (Vesigenurtacel L) In Combination With BCG For The Treatment Of Non-Muscle Invasive Bladder Cancer
2015-02-26,Heat Biologics Provides Update At Key Opinion Leader Event
2015-02-23,Heat Biologics, Inc. To Host Key Opinion Leader Meeting On February 26 In New York City
2015-02-18,Heat Biologics, Inc. And OncoSec Medical Inc. Announce Collaboration To Evaluate Combination Of Immunotherapy Platforms
2015-02-18,OncoSec Medical Inc. And Heat Biologics, Inc. Announce Collaboration To Evaluate Combination Of Immunotherapy Platforms
2015-02-11,Heat Biologics Presents Positive Preclinical Data On A Novel Approach To Combination Immunotherapy At The Keystone Symposia On Tumor Immunology
2015-02-02,Heat Biologics, Inc. To Present At The BIO CEO & Investor Conference
2015-02-02,Heat Biologics, Inc. Outlines 2015 Corporate Objectives
2015-01-26,Heat Biologics, Inc. Presents Positive Immunological Data On HS-410 In Non-Muscle Invasive Bladder Cancer At The 7th Annual Phacilitate Immunotherapy Forum 2015
2015-01-23,Heat Biologics, Inc. To Present At The 7th Annual Phacilitate Immunotherapy Forum 2015
2015-01-15,Heat Biologics, Inc. To Present At The Noble Financial Capital Markets Equity Conference
2014-12-02,Heat Biologics, Inc. Expands Product Development Team To Support Development Of Lead Product Candidates In Oncology
2014-12-01,Heat Biologics, Inc. To Present At The Piper Jaffray 26th Annual Healthcare Conference On December 2 In New York
2014-11-14,Heat Biologics, Inc. Reports 2014 Third Quarter Financial Results
2014-10-27,Heat Biologics, Inc. Commences Patient Dosing Of Phase 2 Clinical Study Of Vesigenurtacel-L For The Treatment Of Bladder Cancer
2014-10-02,Heat Biologics, Inc. Completes Enrollment Of Phase 1 Clinical Trial Of Vesigenurtacel-L For The Treatment Of Bladder Cancer Required To Advance To Phase 2
2014-09-30,Heat Biologics, Inc. To Present At The 13th Annual BIO Investor Forum In San Francisco On Tuesday, October 7, 2014
2014-09-18,Heat Biologics Commences Patient Dosing In Phase 2 Study Of Viagenpumatucel-L For The Treatment Of Non-Small Cell Lung Cancer
2014-09-04,Heat Biologics, Inc. To Present And Webcast At Two Investor Conferences In September
2014-08-25,Heat Biologics, Inc. Closes On Up To $7.5 Million Secured Term Loan Facility
2014-08-14,Heat Biologics, Inc. Reports 2014 Second Quarter Financial Results
2014-08-13,3 Stocks Advancing The Drugs Industry
2014-08-07,3 Stocks Boosting The Drugs Industry Higher
2014-08-04,Heat Biologics Amends Bladder Cancer Protocol For Early Advancement Into Phase 2 Clinical Studies
2014-07-29,3 Drugs Stocks Pushing The Industry Higher
2014-07-28,3 Stocks Pushing The Drugs Industry Lower
2014-05-29,3 Drugs Stocks Driving The Industry Higher
2014-03-21,3 Stocks Under $10 Making Big Moves
2013-08-24,A Time to Test Biotechs' Strength
,
,
2017-03-23,Heat Biologics Prices Offering Of 5,000,000 Shares Of Common Stock
2017-03-22,Heat Biologics Announces Proposed Public Offering Of Common Stock
2017-03-21,Heat Biologics Reports Positive Interim Phase 2 Lung Cancer Results In Patients Treated With HS-110 In Combination With A Checkpoint Inhibitor
2017-03-16,Florida Department Of Health Awards Three-Year Grant To Develop Gp96-based Zika Vaccine
2017-03-13,Heat Biologics Meets Efficacy Endpoint In Its Phase 1b Lung Cancer Trial To Progress To Phase 2
2017-03-09,Heat Biologics To Present At 29th Annual ROTH Conference
2017-03-08,Heat Biologics Announces Agreement To Acquire Pelican Therapeutics
2017-03-02,Heat Biologics To Present At The American Association For Cancer Research (AACR) Annual Meeting
2017-02-17,Heat Biologics Presents Immune Data On Its HS-410 Phase 2 Bladder Cancer Trial At The Genitourinary Cancers Symposium
2017-02-14,Heat Biologics To Present At The Genitourinary Cancers Symposium
2017-01-27,These 5 Stocks Under $10 Could Get Hot Soon
2017-01-24,Heat Biologics To Present At NobleCon13
2017-01-05,Heat Biologics To Present At Biotech Showcase 2017 Conference In San Francisco
2017-01-04,Heat Biologics Appoints Jeff Hutchins, Ph.D., As Chief Scientific Officer
2016-12-06,Heat Biologics Presents Topline HS-110/Nivolumab Combination Lung Cancer Results
2016-12-01,Rosen Law Firm Closes Investigation And Concludes There Is No Basis For Securities Claims Against HTBX
2016-12-01,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Heat Biologics, Inc. (HTBX)
2016-12-01,INVESTOR LOSS ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Heat Biologics, Inc. - HTBX
2016-11-30,Heat Biologics Presents Topline HS-410 Phase 2 Bladder Cancer Results At The Society Of Urological Oncology Annual Meeting
2016-11-17,Heat Biologics To Present Topline HS-110/Nivolumab Combination Phase Ib Lung Cancer Results At The International Society For The Study Of Lung Cancer Annual Meeting
2016-11-16,Heat Biologics To Present Topline HS-410 Phase II Bladder Cancer Results At The Society Of Urological Oncology Annual Meeting
2016-11-14,Heat Biologics Presents ComPACT Preclinical Data At The Society For Immunotherapy Of Cancer Annual Meeting
2016-11-10,Heat Biologics Provides Corporate Update And Reports Third Quarter 2016 Financial Results
2016-11-07,Heat Biologics To Present At The Society For Immunotherapy Of Cancer (SITC) Annual Meeting
2016-10-25,Heat Biologics And University Of Miami Announce Zika Vaccine Collaboration
2016-10-17,Heat Biologics To Present At Two Upcoming Investor Conferences And Panel Discussion
2016-10-13,Heat Biologics Remains On Track To Achieve  Multiple Topline Data Readouts This Quarter
2016-10-11,Heat Biologics Selects Adaptive Biotechnologies To Discover Potential Clinical Biomarkers To Advance Novel Immunotherapies
2016-10-07,Heat Biologics Substantially Reduces Debt And Reports Proceeds Of Approximately $2.8 Million Year-to-Date From The Exercise Of Warrants
2016-09-13,Heat Biologics To Present At Two Upcoming Investor Conferences
2016-08-15,Heat Biologics Provides Corporate Update And Reports Second Quarter 2016 Financial Results
2016-07-22,Heat Biologics Announces Suspension Of Proposed Public Offering Of Common Stock
2016-07-21,Heat Biologics Announces Proposed Public Offering Of Common Stock
2016-06-06,Heat Biologics Presents A Poster On Its HS-110/Nivolumab Combination Phase 1b Non-Small Cell Lung Cancer Trial At ASCO Annual Meeting
2016-05-27,7 Stocks Under $10 to Trade for Big Profits
2016-05-11,Heat Biologics Reports First Quarter 2016 Financial Results
2016-04-26,Heat Biologics To Present At PIONEERS 2016, Presented By Joseph Gunnar & Co.
2016-04-25,8 Breakout Stocks Under $10 to Trade for Big Profits
2016-04-25,Heat Biologics Appoints Dr. John Prendergast To Board Of Directors
2016-04-18,Heat Biologics And OncoSec Present Data At The American Conference For Cancer Research (AACR) Annual Meeting
2016-04-18,OncoSec And Heat Biologics Present Data At The American Conference For Cancer Research (AACR) Annual Meeting
2016-04-12,Heat Biologics To Present At The American Association For Cancer Research (AACR) Annual Meeting
2016-04-07,Heat Biologics Announces Cost-Saving Measures And Focused Corporate Strategy To Achieve Important Clinical Milestones
2016-03-30,Heat Biologics To Participate In The 6th Annual Cancer Immunotherapy: A Long-Awaited Reality Conference
2016-03-23,Heat Biologics Announces Closing Of Public Offering
2016-03-18,Heat Biologics Announces Public Offering Of Common Stock And Warrants
2016-03-09,Heat Biologics' CSO To Participate In The 27th Annual Cancer Progress Conference By Defined Health
2016-03-07,Heat Biologics Presents Positive ComPACT Preclinical Data At The Keystone Symposia
2016-03-04,Heat Biologics To Present At The 28th Annual ROTH Conference
2016-02-25,Heat Biologics Provides Update On Its HS-410 Phase 2 Monotherapy Bladder Cancer Trial Arm
2016-02-18,Heat Biologics Reports Fiscal Year 2015 Financial Results
2016-02-10,FDA Lifts Heat Biologics Partial Clinical Hold
2016-02-03,Heat Biologics Reports Update On Its HS-410 Phase 2 Bladder Cancer Trial
2016-01-26,Heat Biologics CSO To Present Interim Results From The Monotherapy Arm In Its Ongoing HS-410 Phase 2 Bladder Cancer Trial At The Phacilitate Immunotherapy World Conference
2016-01-07,Heat Biologics To Present At Biotech Showcase 2016
2015-12-01,Heat Biologics Appoints Timothy Creech As Chief Financial Officer
2015-11-18,Heat Biologics Selected As One Of Informa's 2015 Top 10 Immuno-Oncology Companies To Watch
2015-11-06,Heat Biologics Reports HS-410 Phase 1 Bladder Cancer Trial Results At The Society For Immunotherapy Of Cancer (SITC) Annual Meeting
2015-11-03,Results Of Heat Biologics' HS-410 Phase 1 Safety Trial In Non-Muscle Invasive Bladder Cancer To Be Presented At SITC Annual Meeting
2015-10-30,Heat Biologics Releases Third Quarter 2015 Financial Results
2015-10-14,Heat Biologics Expands Scientific And Clinical Advisory Board With Appointments Of Drs. Holbrook Kohrt And Kapil Dhingra
2015-10-08,Heat Biologics Completes Patient Enrollment For Randomized Arms Of Its Phase 2 HS-410 Bladder Cancer Trial
2015-10-07,Heat Biologics To Participate In The Annual Prostate Cancer Foundation Scientific Retreat
2015-09-16,Heat Biologics To Present New Data On Its ComPACT Platform At The CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference
2015-09-02,Heat Biologics, Inc. To Present At The 17th Annual Global Investment Conference
2015-09-01,Heat Biologics Announces Clinical Trial Combining HS-110 And PD-1 Checkpoint Inhibitor In NSCLC
2015-08-13,Heat Biologics Announces Financial Results For The Second Quarter Ended June 30, 2015
2015-07-28,4 Breakout Stocks Under $10 Making Big Moves
2015-07-27,Heat Biologics, Inc. Announces Promotions Of Taylor Schreiber, M.D., Ph.D., To Chief Scientific Officer, And Melissa Price, Ph.D., To Vice President Of Product Development
2015-07-01,Heat Biologics, Inc. To Present At The Cantor Fitzgerald Healthcare Conference
2015-06-15,Heat Biologics Announces Development Of ComPACT, A Next Generation Combination Immunotherapy Platform
2015-05-29,Heat Biologics, Inc. To Present Interim Immune Response Data From Ongoing Phase II Trial With HS-110 In Advanced NSCLC At ASCO
2015-05-21,Heat Biologics, Inc. To Present At The Marcum Microcap Conference
2015-05-14,Heat Biologics Announces Financial Results For The First Quarter Ended March 31, 2015
2015-05-11,CORRECTING And REPLACING -- Heat Biologics Announces Initiation Of Phase 1b Trial Of Viagenpumatucel-L (HS-110) In Non-Small Cell Lung Cancer (NSCLC)
2015-05-11,Heat Biologics Announces Initiation Of Phase 1b Trial Of Viagenpumatucel-L (HS-110) In Non-Small Cell Lung Cancer (NSCLC)
2015-04-22,Heat Biologics, Inc. To Present At The 2015 American Association For Cancer Research Annual Meeting
2015-04-15,Heat Biologics, Inc. To Present At The 2015 American Association For Cancer Research Annual Meeting
2015-03-27,Heat Biologics Announces Financial Results For The Year Ended December 31, 2014
2015-03-16,Heat Biologics, Inc. Announces Closing Of Public Offering Of Common Stock And Full Exercise Of The Underwriters' Over-Allotment Option
2015-03-10,Heat Biologics, Inc. Announces Pricing Of Public Offering Of $10,660,000 Of Common Stock
2015-03-10,Heat Biologics, Inc. Announces Proposed Public Offering Of Common Stock
2015-03-09,Heat Biologics, Inc. Receives US FDA Fast Track Designation For HS-410 (Vesigenurtacel L) In Combination With BCG For The Treatment Of Non-Muscle Invasive Bladder Cancer
2015-02-26,Heat Biologics Provides Update At Key Opinion Leader Event
2015-02-23,Heat Biologics, Inc. To Host Key Opinion Leader Meeting On February 26 In New York City
2015-02-18,Heat Biologics, Inc. And OncoSec Medical Inc. Announce Collaboration To Evaluate Combination Of Immunotherapy Platforms
2015-02-18,OncoSec Medical Inc. And Heat Biologics, Inc. Announce Collaboration To Evaluate Combination Of Immunotherapy Platforms
2015-02-11,Heat Biologics Presents Positive Preclinical Data On A Novel Approach To Combination Immunotherapy At The Keystone Symposia On Tumor Immunology
2015-02-02,Heat Biologics, Inc. To Present At The BIO CEO & Investor Conference
2015-02-02,Heat Biologics, Inc. Outlines 2015 Corporate Objectives
2015-01-26,Heat Biologics, Inc. Presents Positive Immunological Data On HS-410 In Non-Muscle Invasive Bladder Cancer At The 7th Annual Phacilitate Immunotherapy Forum 2015
2015-01-23,Heat Biologics, Inc. To Present At The 7th Annual Phacilitate Immunotherapy Forum 2015
2015-01-15,Heat Biologics, Inc. To Present At The Noble Financial Capital Markets Equity Conference
2014-12-02,Heat Biologics, Inc. Expands Product Development Team To Support Development Of Lead Product Candidates In Oncology
2014-12-01,Heat Biologics, Inc. To Present At The Piper Jaffray 26th Annual Healthcare Conference On December 2 In New York
2014-11-14,Heat Biologics, Inc. Reports 2014 Third Quarter Financial Results
2014-10-27,Heat Biologics, Inc. Commences Patient Dosing Of Phase 2 Clinical Study Of Vesigenurtacel-L For The Treatment Of Bladder Cancer
2014-10-02,Heat Biologics, Inc. Completes Enrollment Of Phase 1 Clinical Trial Of Vesigenurtacel-L For The Treatment Of Bladder Cancer Required To Advance To Phase 2
2014-09-30,Heat Biologics, Inc. To Present At The 13th Annual BIO Investor Forum In San Francisco On Tuesday, October 7, 2014
2014-09-18,Heat Biologics Commences Patient Dosing In Phase 2 Study Of Viagenpumatucel-L For The Treatment Of Non-Small Cell Lung Cancer
2014-09-04,Heat Biologics, Inc. To Present And Webcast At Two Investor Conferences In September
2014-08-25,Heat Biologics, Inc. Closes On Up To $7.5 Million Secured Term Loan Facility
2014-08-14,Heat Biologics, Inc. Reports 2014 Second Quarter Financial Results
2014-08-13,3 Stocks Advancing The Drugs Industry
2014-08-07,3 Stocks Boosting The Drugs Industry Higher
2014-08-04,Heat Biologics Amends Bladder Cancer Protocol For Early Advancement Into Phase 2 Clinical Studies
2014-07-29,3 Drugs Stocks Pushing The Industry Higher
2014-07-28,3 Stocks Pushing The Drugs Industry Lower
2014-05-29,3 Drugs Stocks Driving The Industry Higher
2014-03-21,3 Stocks Under $10 Making Big Moves
2013-08-24,A Time to Test Biotechs' Strength
,
,
2017-03-22,Horizon Pharma Plc To Present Data On RAVICTI® (glycerol Phenylbutyrate) Oral Liquid For Urea Cycle Disorder Patients Aged Two Months To Two Years
2017-03-16,Horizon Pharma Plc Announces "UCD In Common" For The Urea Cycle Disorder (UCD) Community
2017-03-04,Boeing, Chicago Bridge and Iron, Mobileye, Horizon Pharmaceuticals: 'Mad Money' Lightning Round
2017-03-03,Jobs Data, Earnings Back in the Spotlight for Next Week: Cramer's 'Mad Money' Recap (Friday 3/3/17)
2017-03-02,Horizon Pharma Plc Announces Urea Cycle Disorders Medical Foods And Supplements Financial Assistance Program
2017-02-28,Horizon Pharma Plc Launches RAREis™ Campaign Elevating Faces Of The Rare Disease Community
2017-02-27,Horizon Pharma Plc Announces Fourth-Quarter And Full-Year 2016 Financial Results And Provides Full-Year 2017 Net Sales And Adjusted EBITDA Guidance
2017-02-14,Horizon Pharma Plc To Participate In Cowen And Company 37th Annual Health Care Conference
2017-01-27,Horizon Pharma Plc To Host Fourth-Quarter 2016 Conference Call And Webcast On February 27, 2017
2017-01-17,Global Genes® And Horizon Pharma Plc Partner To Offer Nephropathic Cystinosis Scholarships
2017-01-12,Short Interest In Horizon Pharma Jumps 19.7%
2017-01-07,These 9 Allergan Drugs May Now Cost as Much as 9.5% More in 2017
2016-12-22,Horizon Pharma Plc Announces The U.S. Patent And Trademark Office Issuance Of An Additional Notice Of Allowance With Claims Covering RAVICTI® (glycerol Phenylbutyrate) Oral Liquid
2016-12-22,Horizon Pharma Plc To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-22,Horizon Pharma Plc Announces Availability Of QUINSAIR™ (levofloxacin Inhalation Solution) In Canada For The Treatment Of Specific Lung Infections In Adults With Cystic Fibrosis
2016-12-16,Notable Friday Option Activity: HZNP, GPRO, TRUE
2016-12-08,Horizon Pharma Plc To Participate In Investor Conference In December
2016-12-08,Horizon Pharma Tanks on Failed Late-Stage Study
2016-12-08,Horizon Fails Late-Stage Freidreich's Ataxia Trial
2016-12-08,Horizon Pharma Plc Announces Topline Results From Phase 3 Study Of  ACTIMMUNE® (interferon Gamma-1b) In Friedreich's Ataxia
2016-12-07,'Mad Money Lightning Round: Buy, Buy, Buy Western Digital
2016-12-06,Jim Cramer's 'Mad Money' Recap: The Trump Rally Is Showing Cracks
2016-11-28,Notable Monday Option Activity: HZNP, STAR, ELS
2016-11-19,Mad Money Lightning Round: Cramer Doesn't Want Health-Care Headaches
2016-11-18,Jim Cramer's Mad Money: Keep One Eye on Earnings, the Other on Politics Next Week
2016-11-11,Horizon Pharma Plc Selected As One Of Chicago Tribune's 2016 Top Workplaces
2016-11-08,Jim Cramer's 'Mad Money' Recap: Get Your Shopping List Ready for Next Week
2016-11-08,Depomed Reports Dip in Earnings, Reduces Revenue Guidance
2016-11-07,How Do the Charts Look for Jim Cramer's Weekly Shopping List?
2016-11-07,Horizon Pharma Plc Announces Third-Quarter 2016 Financial Results
2016-11-04,Horizon Pharma Plc To Participate In Investor Conferences In November
2016-11-03,Noteworthy Thursday Option Activity: HZNP, AIRM, CVT
2016-11-03,Horizon Pharma Plc Announces Availability Of RAVICTI® (glycerol Phenylbutyrate) Oral Liquid In Canada
2016-10-25,Horizon Pharma Plc Completes Acquisition Of Raptor Pharmaceutical Corp.
2016-10-20,Horizon Pharma Plc Announces Pricing Of Private Offering Of Senior Notes
2016-10-13,Horizon Pharma Plc Announces Proposed Private Offering Of Senior Notes And Intention To Borrow Incremental Term Loans Under Its Existing Senior Secured Credit Facility
2016-10-13,Horizon Pharma Plc Named One Of The Country's Best Medium Workplaces By Fortune Magazine
2016-10-11,Horizon Pharma Plc To Host Third-Quarter 2016 Conference Call And Webcast On November 7, 2016
2016-10-04,Drug Win for Depomed Could Be Hurdle for Starboard
2016-09-29,Horizon Pharma Plc Provides Update On PBM Formulary Status For Primary Care Medicines
2016-09-26,Biotech ETFs May Be a Prescription for Investment Success, Especially if Trump Becomes President
2016-09-19,Arbor and Purdue Seen as Likely Bidders for DepoMed
2016-09-13,More Rare Disease Dealmaking to Follow Horizon's Raptor Deal
2016-09-13,Horizon Pharma (HZNP) Stock Price Target Increased at Brean Capital
2016-09-12,Fed Dove Brainard Pushes Stocks Into Rally Mode
2016-09-12,Closing Bell: Fed's Brainard Cautions 'Prudence'; U.S. Stocks Soar
2016-09-12,7 Stocks Trading on Big Volume -- and What to Do With Them Now
2016-09-12,Stocks Extend Gains as Fed's Brainard Urges 'Prudence' With Rates; Oil Gains
2016-09-12,Stocks Rise but Come Off Highs Amid Rate Hike Worries
2016-09-12,Stock Futures Pare Losses After Fed's Lockhart Stays Coy on Interest Rates
2016-09-12,Horizon Pharma Swoops In on Raptor With $800 Million Bid
2016-09-12,Horizon Pharma Plc To Acquire Raptor Pharmaceutical Corp. As Further Step In Building Leading Rare Disease Business
2016-09-06,Horizon Pharma Plc To Participate In Morgan Stanley Global Healthcare Conference
2016-09-02,Horizon Pharma (HZNP) Stock Stumbles, Could Be at Risk from Clinton Drug Plan
2016-09-01,Nuvo Pharmaceuticals™ Inc. Appoints New Chief Financial Officer
2016-08-26,'Mad Money' Lightning Round: I Can't Recommend Gilead
2016-08-25,Jim Cramer's 'Mad Money' Recap: Markets Make This Economy, Not the Fed
2016-08-18,Horizon Pharma Plc Announces The U.S. Patent And Trademark Office Issuance Of An Additional Notice Of Allowance With Claims Covering RAYOS® (prednisone) Delayed-Release Tablets
2016-08-08,Horizon Pharma (HZNP) Stock Pops on Q2 Beat
2016-08-08,Horizon Pharma Plc Announces Second-Quarter 2016 Financial Results
2016-08-01,Horizon Pharma (HZNP) Falls Further As It's Water-Logged And Getting Wetter
2016-07-11,Horizon Pharma (HZNP) Stock Rises, Morgan Stanley Upgrades
2016-07-11,Analysts' Actions -- Baker Hughes, ConocoPhillips, GameStop, Toll Brothers and More
2016-07-07,Horizon Pharma Plc To Host Second-Quarter 2016 Conference Call And Webcast On August 8, 2016
2016-06-30,Horizon Pharma (HZNP) Earnings Report: Q1 2016 Conference Call Transcript
2016-06-29,Horizon Pharma (HZNP) Stock Closed Up as BMO Initiates Coverage
2016-06-28,Today's Dead Cat Bounce Stock Is Horizon Pharma (HZNP)
2016-06-28,June 28 Premarket Briefing: 10 Things You Should Know
2016-06-10,Tweets on the Street: Pimco's Eurozone Concerns, Shkreli on Horizon Pharma
2016-06-07,Perilous Reversal Watch: Horizon Pharma (HZNP)
2016-06-03,Sell Alert: These 5 Stocks Look Toxic Right Now
2016-05-12,A Move Lower Is on the Horizon (Pharma)
2016-05-11,Ratings Changes Today
2016-05-10,Trade-Ideas: Horizon Pharma (HZNP) Is Today's "Perilous Reversal" Stock
2016-05-09,Teva Reports Better-Than-Expected Q1 As Revenue from Branded Biz Beats Estimates
2016-05-09,Horizon Pharma Needs a Health Check
2016-05-09,Depomed Jumps After Mizuho Says Buy Amid Rising Takeover Chances
2016-05-09,Today's Dead Cat Bounce Stock: Horizon Pharma (HZNP)
2016-05-09,Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan
2016-05-09,AAPL, AMZN, SQ: Jim Cramer's Views
2016-05-06,Cramer: Collateral Damage Is Giving These Stocks a Bad Name
2016-05-06,UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders Of Horizon Pharma Plc Of Class Action Lawsuit And A Lead Plaintiff Deadline Of May 9, 2016 - HZNP
2016-05-05,Horizon Pharma (HZNP) Falling In After-Hours Activity
2016-05-04,Jeffrey Smith Says It's Time to Buy Depomed and WestRock: Sohn 2016
2016-04-25,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Horizon Pharma Plc Of Class Action Lawsuit And A Lead Plaintiff Deadline Of May 9, 2016
2016-04-22,HZNP INVESTORS ALERT: Lieff Cabraser Reminds Investors Of Deadline In Class Action Against Horizon Pharma PLC
2016-04-15,INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of Class Action Involving Horizon Pharma Plc And A Lead Plaintiff Deadline Of May 9, 2016
2016-04-14,SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Horizon Pharma Plc To Contact The Firm Before Lead Plaintiff Deadline
2016-04-14,SHAREHOLDER ALERT- Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against Horizon Pharma, Plc. (HZNP) And Lead Plaintiff Deadline: May 9, 2016
2016-04-13,Today's Dead Cat Bounce Stock Is Horizon Pharma (HZNP)
2016-04-12,Here's Why Horizon Pharma (HZNP) Stock Is Tanking Today
2016-04-12,Heavy Trading On Horizon Pharma (HZNP) Before Market Open
2016-04-12,'Mad Money' Lightning Round: UnitedHealth May Be the Dow's Best Stock
2016-04-11,Jim Cramer's 'Mad Money' Recap: These Stocks Are New-High Winners
2016-04-11,HORIZON PHARMA Plc SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Horizon Pharma Plc To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2016-04-11,SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of Class Action Involving Horizon Pharma Plc And A Lead Plaintiff Deadline Of May 9, 2016 - HZNP
2016-04-06,INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of Class Action Involving Horizon Pharma Plc And A Lead Plaintiff Deadline Of May 9, 2016
2016-04-06,INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Horizon Pharma Plc Of Class Action Lawsuit And A Lead Plaintiff Deadline Of May 9, 2016 - HZNP
2016-04-04,The Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Horizon Pharma Plc Investors And Encourages Investors To Contact The Firm
2016-03-31,Law Offices Of Marc S. Henzel Commences Investigation Of Companies For Violations Of The Federal Securities Laws
2016-03-28,HZNP INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Horizon Pharma PLC
2016-03-28,INVESTOR ALERT: The Law Offices Of Vincent Wong Remind Investors Of Class Action Involving Horizon Pharma Plc And A Lead Plaintiff Deadline Of May 9, 2016
2016-03-24,STOCK ALERT: Rosen Law Firm Reminds Horizon Pharma Plc Investors Of Important Deadline In Class Action - HZNP
2016-03-23,Horizon Pharma (HZNP) Is Today's Strong On High Volume Stock
2016-03-17,INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Horizon Pharma Plc To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2016-03-17,Glancy, Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of Horizon Pharma Plc Investors And Encourages Investors To Contact The Firm
2016-03-17,Horizon Pharma (HZNP) Highlighted As Weak On High Volume
2016-03-16,Strong On High Relative Volume: Horizon Pharma (HZNP)
2016-03-15,IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Horizon Pharma Plc And Encourages Investors With Losses To Contact The Firm
2016-03-11,Ratings Changes Today
2016-03-11,INVESTOR ALERT: Khang & Khang LLP Announces An Investigation Of Claims Against Horizon Pharma Plc And Strongly Encourages Investors To Contact The Firm
2016-03-10,IMPORTANT SHAREHOLDER NOTICE: Khang & Khang LLP Announces An Investigation Of Claims Against Horizon Pharma Plc And Strongly Encourages Investors To Contact The Firm
2016-03-10,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Horizon Pharma Plc - HZNP
2016-03-02,Trade-Ideas: Horizon Pharma (HZNP) Is Today's Strong On High Relative Volume Stock
2016-03-01,Jim Cramer Recommends Ford Over General Motors Among Autos
2016-03-01,Insider Trading Alert - BRT, TNAV And HZNP Traded By Insiders
2016-03-01,Silly Season Continues for Biotech
2016-03-01,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Horizon Pharma, Plc. (HZNP)
2016-02-29,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Horizon Pharma Plc - HZNP
2016-02-29,3 Stocks Trading on Big Volume -- and What to Do With Them Now
2016-02-29,Will Horizon Pharma (HZNP) Stock Be Helped By Earnings Beat?
2016-02-10,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By Horizon Pharma Plc And Certain Officers And Directors
2016-02-04,Horizon Pharma (HZNP) In A Perilous Reversal
2016-01-21,With Martin Shkreli Long Gone, Retrophin is an 'Interesting Opportunity'
2016-01-21,Despite Shkreli Drama, Retrophin Looks Interesting Now
2016-01-19,Today's Weak On High Volume Stock: Horizon Pharma (HZNP)
2016-01-15,Stock To Watch: Horizon Pharma (HZNP) In Perilous Reversal
2016-01-12,Horizon Pharma (HZNP) Stock Gains on Raised Guidance
2016-01-12,Jim Cramer's Top Takeaways: Alcoa and Horizon Pharmaceuticals
2016-01-11,Jim Cramer's 'Mad Money' Recap: Here's My Checklist for Markets to Make Money
2016-01-05,These 5 Health Care Stocks Are Ready for Breakout Moves: Must-See Charts
2016-01-04,Jim Cramer -- Think Twice During This Selloff; Watch Out for Auto Stocks
2016-01-04,Jim Cramer Says Don't Rush in to Buy Stocks in Monday Selloff
2015-12-14,Horizon Pharma (HZNP) Is Today's Dead Cat Bounce Stock
2015-12-11,Horizon Pharma (HZNP) Stock Down on Crealta Holdings Acquisition
2015-12-09,Horizon Pharma (HZNP) Highlighted As Today's Perilous Reversal Stock
2015-11-24,Horizon Pharma (HZNP) Highlighted As Today's Perilous Reversal Stock
2015-11-23,Horizon Pharma (HZNP) Stock Reinstated With 'Buy' Rating at Jefferies
2015-11-20,Horizon Pharma (HZNP) Stock Climbs, Withdraws Depomed Offer
2015-11-19,Depomed Comments On Horizon Withdrawal Of Offer To Acquire Company
2015-11-16,Diplomat Seen As Compelling Amid Specialty Pharmacy Fallout
2015-11-12,Today's Dead Cat Bounce Stock Is Horizon Pharma (HZNP)
2015-11-11,EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Horizon Pharma Plc
2015-11-11,INVESTOR ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By Horizon Pharma Plc And Certain Officers And Directors-- HZNP
2015-11-11,Jim Cramer Says Amazon Rules This Holiday Season, Bah Humbug Macy's
2015-11-11,Horizon Pharma (HZNP) Stock Plummets as Express Scripts Severs Ties
2015-11-11,3 Stocks Dragging The Drugs Industry Downward
2015-11-11,Bah Humbug Macy's, Jim Cramer Says the Holiday Season Belongs to Amazon
2015-11-11,Specialty Pharmacy Ties Claim Next Victim In Horizon Pharma
2015-11-10,Horizon Pharma (HZNP) Highlighted As Today's Perilous Reversal Stock
2015-11-10,Jim Cramer's Top Takeaways: Blackhawk, Horizon Pharmaceuticals, CyberArk
2015-11-09,Jim Cramer's 'Mad Money' Recap: Opportunities as Rates Rise
2015-11-09,4 Stocks on Traders' Radars: Must-See Charts
2015-11-09,Why Horizon Pharma (HZNP) Stock Is Up Today
2015-11-06,Today's Unusual Social Activity Stock: Horizon Pharma (HZNP)
2015-11-06,Horizon Pharma (HZNP) Stock Popping on Earnings Beat
2015-11-05,Trade-Ideas: Horizon Pharma (HZNP) Is Today's Post-Market Leader Stock
2015-11-03,ISS And Glass Lewis Recommend Horizon Pharma Shareholders Vote AGAINST The Issuance Of Horizon Shares In Connection With Horizon's Attempted Takeover Of Depomed
2015-11-03,Stock To Watch: Horizon Pharma (HZNP) In Perilous Reversal
2015-11-02,Trade-Ideas: Horizon Pharma (HZNP) Is Today's "Dead Cat Bounce" Stock
2015-11-02,Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan
2015-10-31,'Mad Money' Lightning Round: Buy, Buy, Buy RR Donnelley
2015-10-28,Athenahealth and Horizon Pharma Shares Can Still Move Higher -- Here's Why
2015-10-26,Why Biotech Has Bottomed
2015-10-26,Perilous Reversal Watch: Horizon Pharma (HZNP)
2015-10-23,Horizon Pharma (HZNP) Is Today's Strong On High Volume Stock
2015-10-22,INVESTOR NOTICE: Khang & Khang LLP Announces An Investigation Of Claims Against Horizon Pharma Plc And Advises Shareholders To Contact The Firm
2015-10-22,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Horizon Pharma Plc
2015-10-22,Before The Move: Watch Endo Into FDA Action Date Tomorrow
2015-10-22,Depomed Comments On Recent Reports Regarding Horizon Pharma's Business Model
2015-10-21,IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Claims Against Horizon Pharma Plc And Encourages Investors To Contact The Firm
2015-10-21,Horizon Pharmaceutical (HZNP) Stock Tumbles on Use of Specialty Pharmacies
2015-10-21,INVESTIGATION ALERT: Rigrodsky & Long, P.A. Announces Commencement Of An Investigation Of Horizon Pharma Plc For Possible Violations Of Federal Securities Laws
2015-10-21,Valeant Plunges After Citron Claims To Have 'Smoking Gun'
2015-10-21,Horizon Pharma (HZNP) Is Today's Dead Cat Bounce Stock
2015-10-20,HZNP SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By Horizon Pharma Plc And Certain Officers And Directors
2015-10-20,Jim Cramer -- Microsoft, IBM Should Have Their Eyes on the Buys
2015-10-20,Jim Cramer Says Tech Giants Microsoft, IBM Should Make Acquisitions
2015-10-12,Horizon Pharma (HZNP) In A Perilous Reversal
2015-10-09,A Small Pharma Stock With Big Potential
2017-03-22,Commit To Buy Idera Pharmaceuticals At $2, Earn 62.9% Annualized Using Options
2017-03-15,Idera Pharmaceuticals Reports Fourth Quarter And Year End 2016 Financial Results And Provides Corporate Update
2017-03-02,Idera To Present At The 37th Annual Cowen And Company Health Care Conference
2017-02-24,Idera Pharmaceuticals Presents Update From Ongoing Phase 1 Dose Escalation Clinical Trial Of Intratumoral IMO-2125 In Combination With Ipilimumab In Metastatic Melanoma Patients Refractory To Anti-PD-1 Treatment At The 2017 ASCO-SITC Clinical Immuno-Oncology Symposium
2017-02-06,Idera Announces Appointment Of Jonathan Yingling, Ph.D. As Senior Vice President Of Early Development
2017-01-26,Short Interest Decreases By 23% For IDRA
2017-01-04,Idera To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-11-28,Idera Pharmaceuticals And Vivelix Pharmaceuticals, Ltd. Enter Into Exclusive License Agreement For The Worldwide Rights To IMO-9200
2016-11-11,Idera Pharmaceuticals Reports Translational Data Supporting The Mechanism Of Action Of Intratumoral IMO-2125 From Ongoing Phase 1 Dose Escalation In Clinical Trial In Combination With Ipilimumab In Metastatic Melanoma Patients Refractory To Anti-PD-1 Treatment
2016-11-10,Idera To Present At The Stifel 2016 Healthcare Conference
2016-11-09,Idera Pharmaceuticals To Provide Multiple Presentations On Intratumoral IMO-2125 At The 2016 Society For Immunotherapy Of Cancer (SITC) Annual Meeting
2016-10-31,Tax-Loss Selling Offers Stock-Picking Opportunities
2016-10-28,Idera Pharmaceuticals Reports Third Quarter 2016 Financial Results
2016-10-14,5 Stocks Insiders Love Right Now
2016-10-07,Idera Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2016-10-05,Idera Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2016-09-27,Idera Pharmaceuticals Presents New Third Generation Antisense (3GA) Data At The 12th Annual Meeting Of The Oligonucleotide Therapeutics Society
2016-09-26,Idera Pharmaceuticals Reports Promising Data From Ongoing Phase 1 Dose Escalation In Clinical Trial Of Intra-tumoral IMO-2125 In Combination With Ipilimumab In Patients With PD-1 Refractory Metastatic Melanoma
2016-08-24,Idera Pharmaceuticals Presents The Novel Mechanism Of Action Of Its Third Generation Antisense Technology
2016-08-12,Idera To Present At The 2016 Wedbush PacGrow Healthcare Conference
2016-08-08,Commit To Buy Idera Pharmaceuticals At $1, Earn 18.9% Annualized Using Options
2016-08-02,Idera Pharmaceuticals Reports Second Quarter 2016 Financial Results And Provides Corporate Update
2016-06-07,Idera To Present At Two June Investor Healthcare Conferences
2016-05-09,Idera Pharmaceuticals Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-05-05,Idera To Release 2016 First Quarter Results On May 9, 2016
2016-04-19,Idera Presents Preclinical Data Demonstrating Enhanced Systemic Anti-Tumor Activity From Combination Treatment With Intra-tumoral IMO-2125 And IDO-1 Inhibitor At AACR Annual Meeting 2016
2016-04-11,Idera To Present At The 15th Annual Needham Healthcare Conference
2016-03-20,8 Biotech Stocks Under $10 Making Big Moves Higher
2016-03-10,Idera Pharmaceuticals Reports Fourth Quarter And Year End 2015 Financial Results And Provides Corporate Update
2016-03-03,Idera To Present At Two March Investor Healthcare Conferences
2016-01-29,5 Stocks Ready for Breakouts
2016-01-22,First Week of March 18th Options Trading For Idera Pharmaceuticals (IDRA)
2016-01-19,Trade-Ideas: Idera Pharmaceuticals (IDRA) Is Today's Weak On High Relative Volume Stock
2016-01-06,Idera Pharmaceuticals Announces Appointment Of Dr. Maxine Gowen To Its Board Of Directors
2016-01-05,Idera To Present At The 34th Annual J.P. Morgan Healthcare Conference
2015-12-14,Idera Pharmaceuticals Announces Initiation Of Phase 1/2 Clinical Trial Of Intra-tumoral IMO-2125 In Combination With Ipilimumab In Patients With Metastatic Melanoma
2015-12-09,Idera Pharmaceuticals (IDRA): Today's Weak On High Volume Stock
2015-12-08,5 Outperforming Stocks to Watch
2015-12-05,Idera Pharmaceuticals Reports Positive Data From Ongoing Phase 1/2 Clinical Trial Of IMO-8400 In Patients With Waldenstrom's Macroglobulinemia
2015-12-01,Today's Weak On High Volume Stock: Idera Pharmaceuticals (IDRA)
2015-11-30,Idera Pharmaceuticals Announces Several Key Leadership Additions
2015-11-24,Interesting IDRA Put And Call Options For January 2016
2015-11-23,Idera (IDRA) Stock Soars on GlaxoSmithKline Partnership
2015-11-23,Idera To Collaborate With GSK To Identify 3rd Generation Antisense Molecules For Treatment Of Renal Disease
2015-11-21,JPMorgan Likes These 5 Biotech Stocks
2015-11-18,Strong On High Relative Volume: Idera Pharmaceuticals (IDRA)
2015-11-18,Idera Announces Appointment Of Joanna Horobin As Chief Medical Officer
2015-11-09,Idera Pharmaceuticals Announces Initiation Of Phase 2 Clinical Trial Of IMO-8400 In Patients With Dermatomyositis
2015-11-06,Idera Pharmaceuticals Reports Third Quarter 2015 Financial Results And Provides Corporate Update
2015-11-05,Idera Pharmaceuticals Presents Preclinical Data Demonstrating Potent Anti-Tumor Response From Combination Treatment With Intra-Tumoral IMO-2125 And Anti-PD-1 Monoclonal Antibody At AACR-NCI-EORTC International Conference
2015-11-05,Idera Pharmaceuticals To Present Phase 1/2 IMO-8400 Clinical Data In Waldenstrom's Macroglobulinemia At The 2015 American Society Of Hematology Annual Meeting
2015-10-13,Short Interest Falls 32.2% For IDRA
2015-09-28,Have We Failed at a Retest?
2015-09-21,Idera Pharmaceuticals (IDRA) Weak On High Volume
2015-09-16,Idera Pharmaceuticals Presents New Intratumoral IMO-2125 Preclinical Data At CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference
2015-09-04,Idera To Present At The 22nd Annual NewsMakers In The Biotech Industry Conference
2015-08-31,Idera Pharmaceuticals (IDRA) Is Today's Strong On High Volume Stock
2015-08-07,Idera To Present At The 2015 Wedbush PacGrow Healthcare Conference
2015-08-06,Idera Pharmaceuticals Reports Second Quarter 2015 Financial Results And Provides Corporate Update
2015-07-23,6 Stocks Under $10 Triggering Breakout Trades
2015-07-23,Idera Pharmaceuticals (IDRA) Flagged As Strong On High Volume
2015-07-21,First Week Of September 18th Options Trading For Idera Pharmaceuticals (IDRA)
2015-07-06,Was This a Good Test of the Market Low?
2015-06-29,Idera Pharmaceuticals Announces Appointment Of Mark J. Casey As General Counsel And Secretary Of The Board Of Directors
2015-06-26,Short Interest In Idera Pharmaceuticals Increases 16%
2015-06-23,First Week Of February 2016 Options Trading For Idera Pharmaceuticals (IDRA)
2015-06-18,4 Breakout Biotech Stocks Under $10 to Watch
2015-06-15,Idera Phamaceuticals (IDRA) Stock Jumping Following New Coverage
2015-06-15,Analysts' Actions -- EMC, Lowe's, Micron and More
2015-06-11,I Still Don't Hear a Whoosh
2015-06-11,3 Stocks Under $10 Triggering Breakout Trades
2015-06-08,Idera Pharmaceuticals Enters Into A Strategic Clinical Research Alliance With MD Anderson Cancer Center To Advance Clinical Development Of Intratumoral TLR9 Agonist In Combination With Checkpoint Inhibitors
2015-06-01,Idera Pharmaceuticals (IDRA) Weak On High Volume Today
2015-05-28,What Is the TRIN Telling Us?
2015-05-27,Idera To Present At Two June Investor Healthcare Conferences
2015-05-19,First Week Of July 17th Options Trading For Idera Pharmaceuticals (IDRA)
2015-05-18,Strong On High Volume: Idera Pharmaceuticals (IDRA)
2015-05-18,Idera Pharmaceuticals Provides Development Update On IMO-9200, An Antagonist Of Toll-like Receptors
2015-05-11,Idera Pharmaceuticals (IDRA) Is Strong On High Volume Today
2015-05-11,Idera Pharmaceuticals Reports First Quarter 2015 Financial Results And Provides Corporate Update
2015-04-27,First Week Of IDRA June 19th Options Trading
2015-04-13,Idera To Present At The 14th Annual Needham Healthcare Conference
2015-04-01,Idera Pharmaceuticals (IDRA): Today's Weak On High Volume Stock
2015-04-01,Idera Announces FDA Orphan Drug Designation For IMO-8400 For The Treatment Of Diffuse Large B-Cell Lymphoma
2015-03-25,Interesting IDRA Put And Call Options For November 20th
2015-03-23,Idera Pharmaceuticals (IDRA) Weak On High Volume
2015-03-12,Idera Pharmaceuticals Reports Fourth Quarter And Year End 2014 Financial Results And Provides Corporate Update
2015-02-27,Idera Pharmaceuticals (IDRA) In A Perilous Reversal
2015-02-24,Interesting IDRA Call Options For April 17th
2015-02-23,Idera To Present At Two Upcoming Investor Healthcare Conferences
2015-02-19,Idera Pharmaceuticals Announces Closing Of Public Offering Of Common Stock
2015-02-17,One Reason Idera Pharmaceuticals (IDRA) Stock is Up Today
2015-02-13,Idera Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2015-02-09,Idera Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2015-01-26,Idera Announces Leadership Appointments
2015-01-09,Idera To Present At The 33rd Annual J.P. Morgan Healthcare Conference
2014-12-30,Idera Pharmaceuticals (IDRA) Is Strong On High Volume Today
2014-12-30,Idera Provides Key Updates On Clinical Development Of IMO-8400 For Treatment Of Waldenstrom's Macroglobulinemia
2014-12-29,Idera Pharmaceuticals (IDRA) Stock Surges After FDA Grants Orphan Designation for Cancer Treatment
2014-12-16,Idera Pharmaceuticals (IDRA) Marked As A Dead Cat Bounce Stock
2014-12-15,Idera Announces Several Key Additions To Management Team
2014-12-10,Idera Pharmaceuticals (IDRA) Is Weak On High Volume Today
2014-12-08,Idera Pharmaceuticals Presents Data Supporting IMO-8400 As Novel Therapy For Genetically Defined Forms Of B-Cell Lymphoma At Annual ASH Meeting
2014-12-04,First Week Of January 2015 Options Trading For Idera Pharmaceuticals (IDRA)
2014-12-02,Idera Pharmaceuticals Announces Cancer Immunotherapy Regimen With Intratumoral IMO-2055 Demonstrated Potent And Systemic Anti-Tumor Activity In Preclinical Models
2014-12-02,Idera Announces Appointment Of Robert A. Doody Jr. As Vice President Of Investor Relations And Corporate Communications
2014-12-02,Idera Pharmaceuticals To Present At The Piper Jaffray Healthcare Conference
2014-12-01,Idera Pharmaceuticals Names Vincent J. Milano Chief Executive Officer
2014-11-28,Idera Pharmaceuticals (IDRA) Is Today's Strong On High Volume Stock
2014-11-13,Idera Pharmaceuticals To Present At The Stifel 2014 Healthcare Conference
2014-11-07,Idera Pharmaceuticals Reports Third Quarter Financial Results And Announces Expansion Of Rare Disease Development Portfolio
2014-11-07,Idera Pharmaceuticals And Parent Project Muscular Dystrophy Announce Collaboration To Advance New Treatment Approach For Duchenne Muscular Dystrophy
2014-11-06,Idera Pharmaceuticals Announces Upcoming Presentations Of Data From Oncology Programs At Key Scientific Meetings
2014-10-29,Idera Pharmaceuticals To Announce Third Quarter 2014 Financial Results And Corporate Update On November 7, 2014
2014-10-14,Idera Pharmaceuticals Expands Pipeline By Initiating Clinical Development Of Proprietary TLR Antagonist Candidate IMO-9200
2014-08-22,4 Stocks Under $10 to Trade for Breakouts
2014-08-12,Idera Pharmaceuticals Reports Second Quarter 2014 Financial Results And Provides Corporate Update
2014-08-07,Idera Pharmaceuticals And The Myositis Association Join Forces To Advance The Clinical Development Of A Novel TLR Antagonist, IMO-8400, For The Treatment Of Myositis
2014-08-06,4 Under-$10 Stocks to Trade for Breakouts
2014-08-06,Idera Pharmaceuticals And Collaborators Publish Promising Preclinical Data Targeting MicroRNA With Gene Silencing Oligonucleotide Technology
2014-08-05,Idera Pharmaceuticals To Host Conference Call And Webcast To Report Second Quarter 2014 Financial Results
2014-07-28,Interesting IDRA Put And Call Options For September 20th
2014-06-27,Idera Pharmaceuticals To Be Added To The Russell 3000&#174; And Russell 2000&#174; Indexes
2014-06-25,First Week Of February 2015 Options Trading For Idera Pharmaceuticals (IDRA)
2014-06-23,5 Stocks Setting Up to Break Out
2014-06-17,Idera Pharmaceuticals To Participate In A Panel Discussion At The Piper Jaffray GenomeRx Symposium
2014-06-13,Idera Pharmaceuticals To Present At The Nucleic Acid Summit 2014
2014-05-28,Idera Pharmaceuticals To Present At The Jefferies 2014 Global Healthcare Conference
2014-05-21,First Week of July 19th Options Trading For Idera Pharmaceuticals (IDRA)
2014-05-13,Idera Pharmaceuticals Reports First Quarter 2014 Financial Results And Provides Update On Key Programs And Business Strategy
2014-05-08,Insider buying on the rise at these 5 stocks with earnings next week
2014-05-08,Idera Announces Agreement With Abbott To Develop A Companion Diagnostic For IMO-8400 In Genetically Defined Forms Of B-cell Lymphoma
2014-05-06,Idera Pharmaceuticals To Host Conference Call And Webcast To Report First Quarter 2014 Financial Results And Provide A Detailed Pipeline Review
2014-05-05,Idera Expands Management Team With Three Key Hires
2014-04-22,Will Idera Pharmaceuticals (IDRA) Stock Sustain Today's Rally?
2014-04-22,Interesting IDRA Put And Call Options For June 21st
2014-04-11,Today's Dead Cat Bounce Stock Is Idera Pharmaceuticals (IDRA)
2014-04-07,Idera Presents Preclinical Data At AACR Showing IMO-8400 Inhibits Tumor Growth And Survival Signaling In B-cell Lymphoma Cells With Oncogenic MYD88 L265P Mutation
2014-04-01,Idera Pharmaceuticals (IDRA) Marked As A Dead Cat Bounce Stock
2014-03-31,Today's Perilous Reversal Stock: Idera Pharmaceuticals (IDRA)
2014-03-28,Idera Pharmaceuticals Inc. Stock Downgraded (IDRA)
2014-03-28,Idera Pharmaceuticals (IDRA) Is Today's Pre-Market Mover With Heavy Volume Stock
2014-03-28,Idera Pharmaceuticals Announces Positive Top-line Data In Phase 2 Trial Of IMO-8400
2014-03-27,Ratings Changes Today
2014-03-26,First Week of November 22nd Options Trading For Idera Pharmaceuticals (IDRA)
2014-03-25,Today's Dead Cat Bounce Stock Is Idera Pharmaceuticals (IDRA)
2014-03-20,Insider buying is on the rise in these 4 rallying stocks
2014-03-13,Idera Pharmaceuticals Reports Fourth Quarter And Year End 2013 Financial Results And Provides Corporate Update
2014-03-13,Idera Pharmaceuticals Announces Expansion Of Pipeline Into Two Orphan Autoimmune Diseases
2014-03-12,Idera Pharmaceuticals Announces Appointment Of Julian Baker And Dr. Kelvin Neu To Its Board Of Directors
2014-03-06,Idera To Host Conference Call And Webcast To Report Fourth Quarter And Full Year 2013 Financial Results On Thursday, March 13, 2014
2014-02-26,Interesting IDRA Put And Call Options For April 19th
2014-02-26,Idera To Present At The Cowen &amp; Co. 34th Annual Health Care Conference
2014-02-24,Idera Pharmaceuticals (IDRA) Showing Signs Of Perilous Reversal Today
2014-02-18,Idera To Present At The 2014 RBC Capital Markets&#8217; Global Healthcare Conference
2014-02-10,Idera Pharmaceuticals Announces Closing Of Public Offering Of Common Stock And Pre-Funded Warrants
2014-02-07,2 Biotech Stocks Under $10 in Breakout Territory
2014-02-06,Idera To Present At 16th Annual BIO CEO &amp; Investor Conference
2014-02-05,Idera Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock And Pre-Funded Warrants
2014-02-04,Idera Pharmaceuticals Announces Public Offering Of Common Stock And Pre-Funded Warrants
2014-01-23,First Week Of IDRA March 22nd Options Trading
2014-01-23,Perilous Reversal Watch: Idera Pharmaceuticals (IDRA)
2014-01-22,Idera Announces Publication Of New Data Demonstrating Impact Of Inhibiting TLRs 7, 8, And 9 In A Preclinical Model Of Autoimmune Disease
2014-01-09,Today's Dead Cat Bounce Stock Is Idera Pharmaceuticals (IDRA)
2014-01-09,Idera Expands Leadership Team And Strengthens Clinical Development Expertise In Oncology And Orphan Diseases
2014-01-08,Perilous Reversal Watch: Idera Pharmaceuticals (IDRA)
2013-12-20,Ratings Changes Today
2013-12-12,5 Stocks Under $10 Set to Soar
2013-12-11,4 Health Care Stocks Under $10 to Watch
2013-12-04,Idera Pharmaceuticals Opens Enrollment For Phase 1/2 Clinical Trial Of IMO-8400 In Waldenstr&#246;m&#8217;s Macroglobulinemia
2013-11-25,Idera Pharmaceuticals To Present At The 25th Annual Piper Jaffray Healthcare Conference
2013-11-14,Idera Pharmaceuticals Reports Third Quarter 2013 Financial Results And Provides Corporate Update
2013-11-07,Idera Pharmaceuticals To Host Conference Call To Report Third Quarter 2013 Financial Results On Thursday, November 14, 2013
2013-09-30,Idera Pharmaceuticals Announces Closing Of Public Offering Of Common Stock And Pre-Funded Warrants
2013-09-25,Idera Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock And Pre-Funded Warrants
2013-09-24,Idera Pharmaceuticals Announces Public Offering Of Common Stock And Pre-Funded Warrants
2013-09-12,Idera To Provide Update On Programs At Stifel Nicolaus Healthcare Conference
2013-09-10,Idera To Present At The Stifel Nicolaus 2013 Healthcare Conference
2013-08-29,Idera Pharmaceuticals Enters Into Agreement With NCI To Evaluate Use Of TLR Antagonists For The Treatment Of Genetically Defined Lymphomas
2013-08-21,5 Stocks With Big Insider Buying
2017-03-12,ImmunoGen Presents Phase 1 Biopsy Expansion Cohort Data At The Society Of Gynecologic Oncology Annual Meeting
2017-03-01,ImmunoGen Announces Presentations At AACR Annual Meeting
2017-02-17,ImmunoGen Reports Recent Progress And Operating Results For Six-Month Period And Quarter Ended December 31, 2016
2017-02-10,Short Interest Jumps 11.2% For IMGN
2017-02-02,ImmunoGen Announces Webcasts Of Presentations At Upcoming Investor Conferences
2017-01-26,ImmunoGen Announces First Patient Dosed In FORWARD I Phase 3 Study Of Mirvetuximab Soravtansine In Platinum-Resistant Ovarian Cancer
2017-01-25,ImmunoGen Announces Conference Call To Discuss Its Results For Six-Month Period And Quarter Ended December 31
2017-01-23,ImmunoGen Announces Departure Of Sandra Poole
2017-01-12,Short Interest Declines 10.4% For IMGN
2016-12-28,ImmunoGen Announces Mirvetuximab Soravtansine Phase 1 Expansion Cohort Results In Platinum-Resistant Ovarian Cancer Published In The Journal Of Clinical Oncology
2016-12-28,ImmunoGen Announces Webcast Of Presentation And Q&A At The 35th Annual J. P. Morgan Healthcare Conference
2016-12-05,Preclinical Data On IMGN632, A Novel CD123-Targeting ADC, Presented At ASH Annual Meeting
2016-11-11,ImmunoGen To Present Preclinical Data Highlighting Potential Of Combining Mirvetuximab Soravtansine With An Immune Checkpoint Inhibitor At SITC 2016 Annual Meeting
2016-11-03,ImmunoGen Announces Preclinical Data Presentations For Two ADCs With Novel IGN Payloads At Upcoming 58th ASH Annual Meeting
2016-10-28,ImmunoGen Reports Financial Results For Quarter Ended September 30 And Reviews Business Highlights
2016-10-14,ImmunoGen, Inc. Announces Conference Call To Discuss Its Financial Results For Quarter Ended September 30
2016-09-29,ImmunoGen Completes Strategic Review To Strengthen The Organization And Drive Long-Term Growth
2016-08-22,IMGN April 2017 Options Begin Trading
2016-08-12,7 Stocks Under $10 Making Big Up Moves
2016-08-09,ImmunoGen Announces Departure Of Chief Development Officer
2016-08-05,Strong On High Relative Volume: Immunogen (IMGN)
2016-08-05,ImmunoGen, Inc. Announces Webcasts Of Presentations At Upcoming Investor Conferences
2016-08-04,ImmunoGen Reports Fourth Quarter And Fiscal Year 2016 Financial Results And Provides Quarterly Business Update
2016-08-02,5 Hated Earnings Stocks You Should Love
2016-07-28,These 5 Stocks Under $10 Are Set to Soar Higher
2016-07-21,ImmunoGen, Inc. Announces Conference Call To Discuss Its Fourth Quarter And Fiscal Year 2016 Financial Results
2016-06-21,First Week of August 19th Options Trading For ImmunoGen (IMGN)
2016-06-15,ImmunoGen Announces Pricing Of $100 Million Offering Of 4.50% Convertible Senior Notes Due 2021
2016-06-13,ImmunoGen Announces Proposed $100 Million Offering Of Convertible Senior Notes Due 2021
2016-06-07,ImmunoGen Becomes Oversold (IMGN)
2016-06-06,Immunogen (IMGN) Weak On High Volume
2016-06-02,5 Breakout Stocks Under $10 Set to Soar
2016-05-18,ImmunoGen Reports Efficacy And Safety Data From A 46-Patient Cohort Of Mirvetuximab Soravtansine In FRa-Positive Ovarian Cancer
2016-05-11,ImmunoGen, Inc. Announces Webcasts Of Presentations At Upcoming Investor Conferences
2016-05-03,Relative Strength Alert For ImmunoGen
2016-05-03,Immunogen (IMGN): Today's Weak On High Volume Stock
2016-04-29,ImmunoGen Reports Third Quarter Fiscal Year 2016 Financial Results And Provides Corporate Update
2016-04-26,ImmunoGen Appoints Mark J. Enyedy As President And Chief Executive Officer
2016-04-18,ImmunoGen Announces Initiation Of Clinical Testing Of First-in-Class IMGN779 For Acute Myeloid Leukemia
2016-04-11,ImmunoGen, Inc. Announces Conference Call To Discuss Its Third Quarter Fiscal Year 2016 Financial Results
2016-04-05,Daniel Junius To Retire As President And CEO Of ImmunoGen, Inc.
2016-03-29,ImmunoGen, Inc. Announces Presentations At Upcoming AACR Annual Meeting
2016-03-22,Interesting IMGN Put And Call Options For May 20th
2016-03-20,8 Biotech Stocks Under $10 Making Big Moves Higher
2016-03-09,Today's Weak On High Volume Stock: Immunogen (IMGN)
2016-02-04,ImmunoGen And Merck Establish Collaboration For Clinical Evaluation Of Mirvetuximab Soravtansine In Combination With Keytruda® (pembrolizumab) For The Treatment Of Ovarian Cancer
2016-02-03,ImmunoGen, Inc. Announces Webcasts Of Presentations At Upcoming Investor Conferences
2016-02-01,Commit To Buy ImmunoGen At $6, Earn 14.8% Annualized Using Options
2016-01-29,RSI Alert: ImmunoGen (IMGN) Now Oversold
2016-01-29,ImmunoGen Reports Second Quarter Fiscal Year 2016 Financial Results And Provides Corporate Update
2016-01-26,ImmunoGen Earns Milestone With Bayer's Initiation Of A Phase 2 Clinical Study Designed To Support Anetumab Ravtansine Registration
2016-01-20,ImmunoGen, Inc. Announces Conference Call To Discuss Its Second Quarter Fiscal Year 2016 Financial Results
2016-01-12,Strong On High Volume: Immunogen (IMGN)
2016-01-10,ImmunoGen Announces Recent Product Program Advancements And Anticipated 2016 Events In Advance Of J.P. Morgan Healthcare Conference
2016-01-07,Relative Strength Alert For ImmunoGen
2016-01-04,ImmunoGen, Inc. Announces Webcast Of Presentation And Q&A At The 34th Annual J. P. Morgan Healthcare Conference
2015-12-15,Immunogen (IMGN) Is Strong On High Volume Today
2015-12-02,ImmunoGen, Inc. Announces Oppenheimer 26th Annual Healthcare Conference Webcast
2015-12-01,ImmunoGen, Inc. Announces Data Presentations At Upcoming 57th ASH Annual Meeting And Exposition
2015-11-17,Immunogen (IMGN) Is Today's Dead Cat Bounce Stock
2015-11-16,Notable Two Hundred Day Moving Average Cross - IMGN
2015-11-13,ImmunoGen Named One Of The Boston Globe's Top Places To Work For Third Consecutive Year
2015-11-08,ImmunoGen Refines Drug Targeting for Ovarian Cancer Patients
2015-11-08,Treatment Response To ImmunoGen's Mirvetuximab Soravtansine Found To Be Substantially Greater In Ovarian Cancer With High Expression Of Folate Receptor Alpha
2015-10-27,ImmunoGen Reports First Quarter Fiscal Year 2016 Financial Results And Provides Corporate Update
2015-10-23,IMGN Crosses Above Key Moving Average Level
2015-10-14,Trade-Ideas: Immunogen (IMGN) Is Today's "Dead Cat Bounce" Stock
2015-10-13,ImmunoGen, Inc. Announces Conference Call To Discuss Its First Quarter Fiscal Year 2016 Financial Results
2015-09-21,Immunogen (IMGN) Stock: Weak On High Volume Today
2015-09-18,Immunogen (IMGN) In A Perilous Reversal
2015-09-17,Webcast Of The ImmunoGen, Inc. Analyst & Investor Event On September 18, 2015
2015-09-10,ImmunoGen, Inc. Announces Morgan Stanley Global Healthcare Conference Webcast
2015-08-20,ImmunoGen, Inc. Announces Webcast Of Its Analyst And Investor Event On September 18, 2015
2015-08-18,Perilous Reversal Watch: Immunogen (IMGN)
2015-08-10,ImmunoGen, Inc. Announces Canaccord Genuity Growth Conference Webcast
2015-08-03,Analysts' Actions -- Bunge, Coach, Realogy and More
2015-07-31,ImmunoGen, Inc. Reports Fourth Quarter And Fiscal Year 2015 Financial Results
2015-07-15,ImmunoGen, Inc. Announces Conference Call To Discuss Its Fourth Quarter And Fiscal Year 2015 Financial Results
2015-07-01,10 Best Biotech Stocks in the NASDAQ
2015-06-17,ImmunoGen's IMGN529 For B-Cell Malignancies Demonstrates Synergistic Activity With Rituximab In Preclinical Models Of Non-Hodgkin Lymphoma
2015-06-04,Top-Performing Biotech and Drug Stocks During ASCO '15
2015-06-03,Where the Money Was Made the Last 5 Years
2015-06-02,Perilous Reversal Stock: Immunogen (IMGN)
2015-06-01,Market News: ImmunoGen, SINA Corp, Renewable Energy Group
2015-06-01,ImmunoGen (IMGN) Stock Spikes on Positive Ovarian Cancer Treatment Presentation
2015-06-01,Immunogen (IMGN) Trading With Heavy Volume Before Market Open
2015-06-01,June 1 Premarket Briefing: 10 Things You Should Know
2015-06-01,ASCO '15 Report Card: Grading Biotech and Drug Stocks at Cancer Drug Confab
2015-06-01,ASCO '15: ImmunoGen Finds Redemption in Strong Ovarian Cancer Drug Results
2015-05-30,ImmunoGen's Mirvetuximab Soravtansine (IMGN853) Demonstrates Notable Single Agent Activity For Patients With Platinum-Resistant Ovarian Cancer
2015-05-26,ImmunoGen (IMGN) Shares Cross Above 200 DMA
2015-05-14,Immunogen (IMGN) Showing Signs Of Perilous Reversal Today
2015-05-13,ImmunoGen, Inc. Announces Clinical Data Presentations At Upcoming ASCO Annual Meeting
2015-05-04,ImmunoGen, Inc. Announces Webcast Of Presentations At Upcoming Investor Conferences
2015-05-04,First Week Of IMGN May 15th Options Trading
2015-04-24,ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2015 Financial Results
2015-04-10,'Mad Money' Lightning Round: Buy, Buy, Buy Starbucks, AT&T
2015-04-09,Jim Cramer's 'Mad Money' Recap: Ignore the Chatter, Stick With Best-of-Breed Stocks
2015-04-09,ImmunoGen, Inc. Announces Conference Call To Discuss Its Third Quarter Fiscal Year 2015 Financial Results
2015-04-01,Stock To Watch: Immunogen (IMGN) In Perilous Reversal
2015-04-01,ImmunoGen, Inc. Appoints Anna Berkenblit, MD, MMSc Vice President And Chief Medical Officer
2015-03-31,Immunogen (IMGN) Stock Gains Today After Selling Kadcyla Royalty Rights for $200 Million
2015-03-31,Immunogen (IMGN) Strong On High Relative Volume Today
2015-03-30,ImmunoGen, Inc. Announces $200 Million Non-Dilutive Royalty Transaction
2015-03-24,Perilous Reversal Stock: Immunogen (IMGN)
2015-03-23,ImmunoGen (IMGN) Stock Gains Today on Japanese Licensing Agreement
2015-03-23,Immunogen (IMGN): Heavy Pre-Market Activity
2015-03-23,Takeda Licenses Rights To Use ImmunoGen, Inc.'s Novel Antibody-Drug Conjugate Technology
2015-03-20,Immunogen (IMGN) Strong On High Relative Volume Today
2015-03-19,ImmunoGen, Inc. Announces Presentations At Upcoming AACR Annual Meeting 2015
2015-03-09,First Week Of IMGN March 20th Options Trading
2015-02-24,ImmunoGen, Inc. Announces Webcast Of Presentation At Upcoming Investor Conference
2015-02-19,4 Health Care Stocks Under $10 to Watch: ImmunoGen, Bacterin and More
2015-02-04,ImmunoGen, Inc. Announces Webcast Of Presentations At Upcoming Investor Conferences
2015-02-02,Stock To Watch: Immunogen (IMGN) In Perilous Reversal
2015-01-30,ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2015 Financial Results
2015-01-21,ImmunoGen, Inc. Announces Conference Call To Discuss Its Second Quarter Fiscal Year 2015 Financial Results
2015-01-11,ImmunoGen, Inc. Announces 2015 Outlook For Product Pipeline
2014-12-30,Perilous Reversal Stock: Immunogen (IMGN)
2014-12-22,Immunogen (IMGN) Showing Signs Of A Dead Cat Bounce Today
2014-12-22,ImmunoGen, Inc. Appoints Richard J. Gregory, Ph.D. As EVP, Chief Scientific Officer; John M. Lambert, Ph.D. Named EVP, Distinguished Research Fellow
2014-12-19,Stocks at Session Highs as Energy Sector Picks Up Steam
2014-12-19,ImmunoGen Enters Oversold Territory (IMGN)
2014-12-19,Cramer: ‘Downside’ to Biotech as ImmunoGen Stock Cut in Half
2014-12-19,ImmunoGen (IMGN) Stock Plummets to One-Year Low on Disappointing Breast Cancer Drug Results
2014-12-19,ImmunoGen Reports Roche Has Provided An Update On The MARIANNE Trial
2014-12-15,ImmunoGen, Inc. Announces Webcast Of Presentation At The 33rd Annual J.P. Morgan Healthcare Conference
2014-12-06,ImmunoGen, Inc. Announces Encouraging IMGN529 Clinical Data Presented At 56th ASH Annual Meeting And Exposition
2014-12-03,Insider Trading Alert - UNT, IMGN And PSXP Traded By Insiders
2014-12-03,'Mad Money' Lightning Round: You're on Your Own With Tesla
2014-12-02,Jim Cramer's 'Mad Money' Recap: Forget Bargain Losers, Look for the 52-Week Winners
2014-11-24,ImmunoGen, Inc. Announces Clinical And Preclinical Data Presentations At Upcoming 56th ASH Annual Meeting And Exposition
2014-11-13,ImmunoGen, Inc. Again Named One Of The Boston Globe's Top Places To Work
2014-10-24,ImmunoGen, Inc. Reports First Quarter Fiscal Year 2015 Financial Results
2014-10-21,Immunogen (IMGN) Highlighted As Today's Perilous Reversal Stock
2014-10-20,Trade-Ideas: Immunogen (IMGN) Is Today's Strong On High Relative Volume Stock
2014-10-17,Today's Weak On High Volume Stock: Immunogen (IMGN)
2014-10-10,ImmunoGen, Inc. Announces Conference Call To Discuss Its First Quarter Fiscal Year 2015 Financial Results
2014-10-08,Oversold Conditions For ImmunoGen (IMGN)
2014-09-16,SEC Slaps Biotech Hedge Fund for Short-Selling Violations
2014-09-15,ImmunoGen, Inc. Hires Sandra E. Poole As Senior Vice President Of Technical Operations
2014-09-11,First Week of September 20th Options Trading For ImmunoGen (IMGN)
2014-09-09,'Mad Money' Lightning Round: Stick With Wendy's
2014-09-08,Jim Cramer's 'Mad Money' Recap: 5 Reasons Why More Americans Are Bearish
2014-09-02,ImmunoGen, Inc. Announces Morgan Stanley Global Healthcare Conference Webcast
2014-08-28,Trade-Ideas: Immunogen (IMGN) Is Today's Strong On High Relative Volume Stock
2014-08-14,A Trio of Healthcare Plays
2014-08-04,ImmunoGen, Inc. Announces Webcast Of Presentations At Upcoming Investor Conferences
2014-08-01,ImmunoGen, Inc. Reports Fourth Quarter And Fiscal Year 2014 Financial Results
2014-07-21,Stock To Watch: Immunogen (IMGN) In Perilous Reversal
2014-07-21,3 Biotech Stocks Breaking Out on Big Volume
2014-07-18,ImmunoGen, Inc. Announces Conference Call To Discuss Its Fourth Quarter And Fiscal Year 2014 Financial Results
2014-07-17,4 Stocks Spiking on Big Volume
2014-06-16,CORRECTING and REPLACING ImmunoGen, Inc. Announces Preclinical Findings for IMGN779, a Potential Treatment for Acute Myeloid Leukemia
2014-06-12,Will This Analyst Upgrade Help Immunogen (IMGN) Stock Today?
2014-06-12,Analysts' Actions: Halozyme, Hewlett-Packard, Immunogen, Sprouts
2014-06-01,ImmunoGen, Inc. Announces Favorable STARLYTE Phase II Clinical Data With Sanofi&#8217;s SAR3419 In Diffuse Large B-Cell Lymphoma
2014-05-22,Commit To Buy ImmunoGen At $9, Earn 13.5% Annualized Using Options
2014-05-14,ImmunoGen, Inc. Announces Clinical Data Presentations At Upcoming 50th Annual Meeting Of ASCO
2014-05-08,Relative Strength Alert For ImmunoGen
2014-05-06,ImmunoGen, Inc. Announces Webcast Of Presentations At Upcoming Investor Conferences
2014-04-25,Why ImmunoGen (IMGN) Stock Is Down Today
2014-04-25,ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2014 Financial Results And Provides Corporate Update &#8722;Quarterly Conference Call Today At 8:00 Am ET&#8722;
2014-04-17,ImmunoGen, Inc. Announces Conference Call To Discuss Its Third Quarter Fiscal Year 2014 Financial Results
2014-03-17,ImmunoGen, Inc. Announces Presentations By Company Scientists At Upcoming AACR Annual Meeting
2014-03-11,IDEXX Laboratories Elects Daniel Junius To Board Of Directors
2014-02-27,ImmunoGen, Inc. Announces Webcast Of Presentations At Upcoming Investor Conferences
2014-02-20,Commit To Purchase ImmunoGen At $14, Earn 14% Annualized Using Options
2014-02-20,ImmunoGen, Inc. Appoints Ellie Harrison As Chief Human Resources Officer
2014-02-14,Bullish Two Hundred Day Moving Average Cross - IMGN
2014-02-06,ImmunoGen, Inc. Announces Webcast Of Presentations At Upcoming Investor Conferences
2014-01-31,ImmunoGen, Inc. Appoints Eric Guempel As Vice President Of Product Strategy And Program Management
2014-01-31,ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2014 Financial Results And Provides Corporate Update
2014-01-24,ImmunoGen, Inc. Announces Conference Call To Discuss Its Second Quarter Fiscal Year 2014 Financial Results
2014-01-14,Weaving an Overnight Basket
2014-01-09,CytomX Therapeutics And ImmunoGen, Inc. Announce Strategic Collaboration To Develop Probody-Drug Conjugates Against Cancer Targets
2014-01-06,ImmunoGen, Inc. Announces Webcast Of Presentation At The 32nd Annual J.P. Morgan Healthcare Conference
2013-12-30,ImmunoGen, Inc. Appoints David Johnston As Chief Financial Officer
2013-12-09,ImmunoGen, Inc. Announces Activity Reported With SAR3419 Plus Rituxan In Difficult-to-Treat Patient Population
2013-12-09,ImmunoGen, Inc. Announces Favorable Initial Safety And Response Findings For CD38-Targeting Anticancer Compound, SAR650984
2017-03-19,Here's a Look at the 64 Best Performing Stocks Over the Last 4 Months
2017-03-15,After Soaring to $150, Can Incyte Stir Up More Upside?
2017-03-13,Incyte Corporation Stock Rises on Price Target Increase
2017-03-10,Incyte Pops on Continued Gilead Takeout Speculation
2017-03-10,Incyte Likely to Incite Further Gains
2017-03-10,Don't Give the Fed Credit for This Bull: Cramer's 'Mad Money' Recap (Thursday 3/9/17)
2017-03-09,Cramer: Don't Give the Fed Credit
2017-03-02,Incyte's Targeted Therapy And Immuno-oncology Portfolio To Be Featured In 20 Abstracts At The AACR Annual Meeting 2017
2017-02-28,Voices Of MPN Heroes Video
2017-02-27,Cramer: Money's Being Thrown at Almost Everything in the Market
2017-02-27,Cramer: Money's Being Thrown at Almost Everything in the Market
2017-02-24,4 Biotech Stocks on the Move
2017-02-24,Biotech Movers: Cempra Flys High On Phase Three Results
2017-02-23,Incyte Announces Oncology Research Alliance With The Abramson Cancer Center At The University Of Pennsylvania
2017-02-23,Incyte, Skyworks Solutions, Western Digital, Constellation Brands: 'Mad Money' Lightning Round
2017-02-23,What You Should Do if This Market Is Overvalued: Cramer's 'Mad Money' Recap (Wednesday 2/22/17)
2017-02-21,Incyte To Present At Upcoming Investor Conferences
2017-02-15,Additional Results From Pivotal RA-BEAM Study Published In New England Journal Of Medicine Show Baricitinib-treated Patients Demonstrated Sustained Improvement In Rheumatoid Arthritis Compared To Adalimumab And Placebo
2017-02-15,Softness in Incyte Should Be Short-Lived, if Our Quants Are Right
2017-02-15,Ratings Changes Today
2017-02-14,Http://www.agenusbio.com
2017-02-14,Incyte Reports 2016 Fourth-Quarter And Year-End Financial Results, Provides 2017 Financial Guidance And Updates On Key Clinical Programs
2017-02-14,5 Things You Must Know Before the Market Opens Tuesday
2017-02-12,Week Ahead: Federal Reserve Officials, Major Economic Data to Drive Market Movement
2017-01-30,Incyte And Calithera Biosciences Announce Global Collaboration To Develop And Commercialize CB-1158, A First-in-class, Small Molecule Arginase Inhibitor
2017-01-24,Incyte To Report Fourth Quarter And Year-End Financial Results
2017-01-10,4 Biotech Names That Could Be M&amp;A Targets
2017-01-09,Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference
2017-01-09,Merck Cancer Drug Test Sends Incyte Shares Higher
2017-01-09,Biotech Stocks Surge Monday Amid Flurry of Deal Activity
2017-01-09,Incyte And Merck To Advance Clinical Development Program Investigating The Combination Of Epacadostat With KEYTRUDA® (pembrolizumab)
2017-01-05,What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017
2017-01-03,Biotech Should Witness M&amp;A's Return in 2017
2016-12-30,Incyte Announces First Patient Treated In Pivotal Clinical Trial Program For Ruxolitinib (Jakafi®) In Graft-versus-Host Disease
2016-12-21,Incyte And Merus Announce Global Strategic Research Collaboration To Discover And Develop Bispecific Antibodies
2016-12-13,Incyte To Present At Upcoming Investor Conference
2016-12-04,Pooled Analysis Of Five-Year Data From Two Phase 3 Studies Further Supports Overall Survival Advantage Observed In Patients With Myelofibrosis Treated With Jakafi® (ruxolitinib)
2016-11-18,2 Small-Cap Biotech Buyout Targets
2016-11-17,Get Excited About Incyte
2016-11-17,Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!
2016-11-14,Baricitinib Demonstrates Early Response Compared To Placebo And Significant Improvement Compared To Adalimumab In Patient-Reported Outcomes
2016-11-13,Six Thoughts on President Trump and the Durability of the Biotech Stock Rally
2016-11-10,Incyte Becomes #40 Most Shorted Nasdaq 100 Component, Replacing Stericycle
2016-11-08,Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance
2016-11-03,More Than 20 Abstracts Highlighting Data From Incyte's Portfolio Accepted For Presentation At The 58th Annual ASH Meeting
2016-11-02,Why Incyte's Shares Could Soon Hit $100
2016-11-02,Incyte To Present At Upcoming Investor Conference
2016-11-01,Incyte Reports 2016 Third-Quarter Financial Results And Updates Key Clinical Programs
2016-11-01,There's Still Time to Buy These 5 Breakout Trades
2016-10-14,Incyte To Report Third Quarter Financial Results
2016-10-07,Additional Phase 1 Data From ECHO-202 Reinforce Durability Of Response In Patients With Treatment-naive Advanced Or Metastatic Melanoma Treated With Epacadostat In Combination With Keytruda® (pembrolizumab)
2016-09-28,Updated Phase 1 Data Reinforce The Clinical Profile Of Epacadostat In Combination With Keytruda® (Pembrolizumab)
2016-09-27,The New #42 Most Shorted Nasdaq 100 Component: Incyte
2016-09-27,NCCN Guidelines® Recommend Jakafi® (ruxolitinib) For The Treatment Of Myelofibrosis
2016-09-22,New Setback for Sanofi's Lantus Increases Need for M&amp;A
2016-09-08,Incyte Supports Those Affected By Rare Blood Cancers On MPN Awareness Day And Throughout Blood Cancer Awareness Month
2016-09-01,'Mad Money' Lightning Round: I'm Staying With Potash
2016-08-31,Jim Cramer's 'Mad Money' Recap: Oil Regains Control of the Stock Market
2016-08-30,Incyte To Present At Upcoming Investor Conferences
2016-08-25,Forbes Magazine Names Incyte To Its List Of World's Most Innovative Companies For Second Consecutive Year
2016-08-22,Incyte (INCY) Stock Rises on Takeover Speculation After $14 Billion Pfizer, Medivation Deal
2016-08-10,How Will Incyte (INCY) Stock React to Price Target Raise at Barclays?
2016-08-09,Why There Is Upside for Incyte Despite Recent Selloff
2016-08-09,Today's Roof Leaker Stock Is Incyte (INCY)
2016-08-09,Incyte Reports 2016 Second-Quarter Financial Results And Updates Key Clinical Programs
2016-08-03,Insider Trading Alert - CFFI, KERX And INCY Traded By Insiders
2016-08-01,Could a Spin-off of its Hepatitis C Division be in Gilead's Future?
2016-07-27,The New #38 Most Shorted Nasdaq 100 Component: Incyte
2016-07-22,3 Stocks Dragging In The Drugs Industry
2016-07-19,Updated Data For Epacadostat, Incyte's Selective IDO1 Inhibitor, Accepted For Presentation At The ESMO Annual Congress 2016
2016-07-14,Incyte To Report Second Quarter Financial Results
2016-07-13,3 Stocks Pushing The Health Care Sector Lower
2016-07-01,Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here
2016-06-29,16 Biopharma Companies Besides Medivation That Are Attractive Targets
2016-06-23,FDA Grants Breakthrough Therapy Designation For Incyte's Ruxolitinib (Jakafi®) In Acute Graft-Versus-Host Disease (GVHD)
2016-06-22,Incyte Announces First Patient Treated In ECHO-301 Phase 3 Study
2016-06-10,New Phase 3 Data Show Jakafi® (ruxolitinib) Is Superior To Best Available Therapy In Patients With Polycythemia Vera (PV)
2016-06-06,Five-year Results From Phase 3 Study Of Jakafi® (ruxolitinib) Show Sustained Overall Survival Benefit In Patients With Myelofibrosis (MF)
2016-06-01,Incyte And Moffitt Cancer Center Establish Multi-Year Oncology Research Alliance
2016-05-31,Incyte Announces The Launch Of The Incyte Charitable Giving Foundation
2016-05-31,3 Health Care Stocks Pushing Sector Growth
2016-05-26,Investors Eager for Gilead to Make Big Moves
2016-05-25,Gilead (GILD) Shares Spike After Executive Board Appointment
2016-05-19,Incyte Highlights Jakafi® (ruxolitinib) And Capmatinib Abstracts To Be Presented At The 2016 ASCO And EHA Annual Meetings
2016-05-18,Incyte To Present At Upcoming Investor Conferences
2016-05-09,Incyte Buys European Business Hub From Ariad Pharma
2016-05-09,Incyte First Quarter Financial Results Conference Call And Webcast
2016-05-09,Incyte Reports 2016 First-Quarter Financial Results And Updates Shareholders On Key Clinical Programs
2016-05-03,The New #44 Most Shorted Nasdaq 100 Component: Incyte
2016-04-28,Incyte To Present At Upcoming Investor Conferences
2016-04-18,Incyte (INCY) Weak On High Volume
2016-04-15,Incyte Investor Event At AACR 2016 To Highlight Innovative And Diversified Research And Development Portfolio
2016-04-14,Incyte To Report First Quarter Financial Results
2016-04-06,Incyte Acquires Rights From Lilly To Develop And Commercialize Ruxolitinib (Jakafi®) For The Treatment Of Patients With Graft-Versus-Host Disease (GVHD)
2016-03-31,Jim Cramer's 'Mad Money' Recap: Good Riddance to a Roller-Coaster Quarter
2016-03-31,Strong On High Relative Volume: Incyte (INCY)
2016-03-31,Phase 3 Study Findings Demonstrate Treatment With Baricitinib Results In Significant Improvements For Patients With Rheumatoid Arthritis Who Had Inadequate Response To Biologics
2016-03-26,5 Stocks Insiders Love Right Now
2016-03-16,Incyte's Immuno-oncology And Targeted Therapy Portfolio To Be Featured At The AACR Annual Meeting 2016
2016-03-09,BMRN, INCY And ALXN, Pushing Drugs Industry Downward
2016-03-02,5 Stocks Insiders Have Been Scooping Up Lately
2016-02-29,Voices Of MPN Rare Disease Day Video
2016-02-20,Jim Jubak&rsquo;s Four Favorite Stocks for Turbulent Markets
2016-02-20,Jim Jubak’s Four Favorite Stocks for Volatile Times
2016-02-17,Ratings Changes Today
2016-02-16,Incyte To Present At Upcoming Investor Conferences
2016-02-12,Incyte (INCY) Stock Price Target Lowered at Jefferies
2016-02-11,Here's Why Incyte (INCY) Stock is Tanking Today
2016-02-11,Unusual Social Activity Today Around Incyte (INCY)
2016-02-11,Incyte Falls on Jakafi Solid-Tumor Setback
2016-02-11,Incyte Reports 2015 Fourth-Quarter And Year-End Financial Results, Provides 2016 Financial Guidance And Updates Shareholders On Key Clinical Programs
2016-02-11,Incyte Announces Decision To Discontinue JANUS Studies Of Ruxolitinib Plus Capecitabine In Patients With Advanced Or Metastatic Pancreatic Cancer
2016-02-05,Incyte (INCY): Today's Weak On High Volume Stock
2016-01-27,Post-Market Activity Shows Incyte (INCY) Down
2016-01-27,Incyte Announces Decision To Stop Phase 2 Sub-study Of Ruxolitinib Plus Regorafenib In Patients With Metastatic Colorectal Cancer And High CRP
2016-01-25,Strong On High Relative Volume: Incyte (INCY)
2016-01-21,Incyte To Report Fourth Quarter/Year-End Financial Results
2016-01-19,Lilly And Incyte Announce Submission Of New Drug Application To FDA For Oral Once-Daily Baricitinib For Treatment Of Moderate-to-Severe Rheumatoid Arthritis
2016-01-12,Incyte (INCY) Shows Signs Of Being Water-Logged And Getting Wetter
2016-01-12,3 Stocks Pulling The Drugs Industry Downward
2016-01-11,Incyte Presents Significant Progress In Its Development Portfolio
2016-01-11,Incyte And AstraZeneca Announce New Lung Cancer Clinical Trial Collaboration
2016-01-07,Trade-Ideas: Incyte (INCY) Is Today's Weak On High Relative Volume Stock
2016-01-07,Jim Cramer's Top Takeaways: Starbucks, Alphabet, Ulta Salon, Micron, Viacom
2016-01-06,Jim Cramer's 'Mad Money' Recap: Good Things to Remember Amid the Fallout
2016-01-01,Feuerstein's Heroes and Zeroes of Biotech Investing in 2015
2015-12-26,Sell These 6 Biotech Stocks Now Before It's Too Late
2015-12-24,4 Great Stock-ing Stuffers for 2016
2015-12-22,NVO, INCY And ILMN, Pushing Drugs Industry Downward
2015-12-14,Incyte To Present At The 34th Annual J. P. Morgan Healthcare Conference
2015-12-05,Two Phase 3 Studies Reinforce Sustained Benefits Of Treatment With Jakafi® (ruxolitinib) In Patients With Myeloproliferative Neoplasms (MPNs)
2015-12-05,Phase 3 RESPONSE-2 Study Of Jakafi® (ruxolitinib) Meets Primary Endpoint
2015-12-01,3 Stocks Dragging The Drugs Industry Downward
2015-11-30,Incyte's Jakafi® (ruxolitinib) To Be Featured In Over 60 Abstracts At ASH Annual Meeting
2015-11-18,Goldman Sees Bluebird Shares Doubling On 'One-Shot' Gene Therapy
2015-11-13,Bearish Bets: Personal Bear Market Continues for Energy Stocks
2015-11-09,3 Drugs Stocks Driving The Industry Higher
2015-11-09,Incyte (INCY) Showing Signs Of A Dead Cat Bounce Today
2015-11-07,Detailed Results Demonstrate Baricitinib Superiority To Adalimumab In Improving Signs And Symptoms Of Rheumatoid Arthritis
2015-11-06,Incyte (INCY) Is Today's Roof Leaker Stock
2015-11-06,Ratings Changes Today
2015-11-04,Retrophin Sinks, Pharma Group Swings Back As Pricing Fight Escalates
2015-11-03,Weak On High Volume: Incyte (INCY)
2015-11-03,Epacadostat In Combination With Pembrolizumab Demonstrates Promising Clinical Activity In Multiple Advanced Cancers
2015-11-03,Incyte Reports 2015 Third-Quarter Financial Results And Updates Shareholders On Key Clinical Programs
2015-10-22,Northwest Bio Bothers British Bestie for Bounteous Bucks
2015-10-16,3 Stocks Dragging The Health Care Sector Downward
2015-10-16,Trade-Ideas: Incyte (INCY) Is Today's "Perilous Reversal" Stock
2015-10-13,Incyte To Report Third Quarter Financial Results
2015-10-13,Incyte And Merck Expand Clinical Collaboration To Include Phase 3 Study Investigating The Combination Of Epacadostat With Keytruda® (pembrolizumab) As First-line Treatment For Advanced Melanoma
2015-10-05,Incyte (INCY) Highlighted As Today's Perilous Reversal Stock
2015-10-02,Data At SITC Annual Meeting To Highlight Progress Of Incyte's Immuno-oncology Portfolio
2015-09-30,10 Best Nasdaq Biotech Stocks in the Third Quarter
2015-09-30,Strong On High Relative Volume: Incyte (INCY)
2015-09-29,Market News: Under Armour, OvaScience, Incyte Corporation
2015-09-29,Incyte (INCY) Stock Climbs on Positive Arthritis Test Results
2015-09-29,Eli Lilly (LLY) Stock Climbs on Positive Arthritis Drug Test Results
2015-09-29,Incyte (INCY) Weak On High Volume
2015-09-28,Trade-Ideas: Incyte (INCY) Is Today's "Roof Leaker" Stock
2015-09-16,Insider Trading Alert - RP, LAYN And INCY Traded By Insiders
2015-09-15,Incyte To Present At The Leerink Partners Inaugural Immuno-Oncology Roundtable Conference
2015-09-14,Incyte (INCY) In A Perilous Reversal
2015-09-03,Incyte (INCY) In A Perilous Reversal
2015-09-02,Incyte Announces Global License Agreement With Jiangsu Hengrui Medicine For SHR-1210, An Investigational Anti-PD-1 Monoclonal Antibody
2015-09-01,Incyte To Present At Upcoming Investor Conferences
2015-08-21,Incyte Named 7th Most Innovative Company In The World By Forbes Magazine
2015-08-14,3 Stocks Dragging The Drugs Industry Downward
2015-08-04,Incyte Reports 2015 Second-Quarter Financial Results And Updates Shareholders On Key Clinical Programs
2015-07-15,Analysts Break Down Impact Of $7.2B Receptos Buyout
2015-07-14,Incyte To Report Second Quarter Financial Results On August 4
2015-07-07,Incyte And Vanderbilt University Medical Center Establish Multi-Year Oncology Research Alliance
2015-07-06,3 Stocks Boosting The Health Care Sector Higher
2015-06-23,Agenus Gets Billion-Dollar Valuation From Analyst Based on Cancer Drug That Doesn't Exist
2015-06-19,Incyte Announces Organizational And Management Changes To Drive Future Global Expansion
2015-06-05,'Mad Money' Lightning Round: Buy Taser, Have Patience With Baxter
2015-06-04,Jim Cramer's 'Mad Money' Recap: 3 Things Frightening the Market Right Now
2015-06-01,Advaxis Announces FDA Clearance Of Investigational New Drug Application For Phase 2 Study Of ADXS-HPV And Incyte's Epacadostat For The Treatment Of HPV-Associated Early Stage Cervical Cancer
2015-05-30,ASCO '15: CTI Biopharma Takes on Myelofibrosis Drug Rival
2015-05-29,3 Health Care Stocks On The Rise
2015-05-28,Put Health Care Stocks on Your Shopping List
2017-03-19,Here's a Look at the 64 Best Performing Stocks Over the Last 4 Months
2017-03-15,After Soaring to $150, Can Incyte Stir Up More Upside?
2017-03-13,Incyte Corporation Stock Rises on Price Target Increase
2017-03-10,Incyte Pops on Continued Gilead Takeout Speculation
2017-03-10,Incyte Likely to Incite Further Gains
2017-03-10,Don't Give the Fed Credit for This Bull: Cramer's 'Mad Money' Recap (Thursday 3/9/17)
2017-03-09,Cramer: Don't Give the Fed Credit
2017-03-02,Incyte's Targeted Therapy And Immuno-oncology Portfolio To Be Featured In 20 Abstracts At The AACR Annual Meeting 2017
2017-02-28,Voices Of MPN Heroes Video
2017-02-27,Cramer: Money's Being Thrown at Almost Everything in the Market
2017-02-27,Cramer: Money's Being Thrown at Almost Everything in the Market
2017-02-24,4 Biotech Stocks on the Move
2017-02-24,Biotech Movers: Cempra Flys High On Phase Three Results
2017-02-23,Incyte Announces Oncology Research Alliance With The Abramson Cancer Center At The University Of Pennsylvania
2017-02-23,Incyte, Skyworks Solutions, Western Digital, Constellation Brands: 'Mad Money' Lightning Round
2017-02-23,What You Should Do if This Market Is Overvalued: Cramer's 'Mad Money' Recap (Wednesday 2/22/17)
2017-02-21,Incyte To Present At Upcoming Investor Conferences
2017-02-15,Additional Results From Pivotal RA-BEAM Study Published In New England Journal Of Medicine Show Baricitinib-treated Patients Demonstrated Sustained Improvement In Rheumatoid Arthritis Compared To Adalimumab And Placebo
2017-02-15,Softness in Incyte Should Be Short-Lived, if Our Quants Are Right
2017-02-15,Ratings Changes Today
2017-02-14,Http://www.agenusbio.com
2017-02-14,Incyte Reports 2016 Fourth-Quarter And Year-End Financial Results, Provides 2017 Financial Guidance And Updates On Key Clinical Programs
2017-02-14,5 Things You Must Know Before the Market Opens Tuesday
2017-02-12,Week Ahead: Federal Reserve Officials, Major Economic Data to Drive Market Movement
2017-01-30,Incyte And Calithera Biosciences Announce Global Collaboration To Develop And Commercialize CB-1158, A First-in-class, Small Molecule Arginase Inhibitor
2017-01-24,Incyte To Report Fourth Quarter And Year-End Financial Results
2017-01-10,4 Biotech Names That Could Be M&amp;A Targets
2017-01-09,Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference
2017-01-09,Merck Cancer Drug Test Sends Incyte Shares Higher
2017-01-09,Biotech Stocks Surge Monday Amid Flurry of Deal Activity
2017-01-09,Incyte And Merck To Advance Clinical Development Program Investigating The Combination Of Epacadostat With KEYTRUDA® (pembrolizumab)
2017-01-05,What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017
2017-01-03,Biotech Should Witness M&amp;A's Return in 2017
2016-12-30,Incyte Announces First Patient Treated In Pivotal Clinical Trial Program For Ruxolitinib (Jakafi®) In Graft-versus-Host Disease
2016-12-21,Incyte And Merus Announce Global Strategic Research Collaboration To Discover And Develop Bispecific Antibodies
2016-12-13,Incyte To Present At Upcoming Investor Conference
2016-12-04,Pooled Analysis Of Five-Year Data From Two Phase 3 Studies Further Supports Overall Survival Advantage Observed In Patients With Myelofibrosis Treated With Jakafi® (ruxolitinib)
2016-11-18,2 Small-Cap Biotech Buyout Targets
2016-11-17,Get Excited About Incyte
2016-11-17,Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!
2016-11-14,Baricitinib Demonstrates Early Response Compared To Placebo And Significant Improvement Compared To Adalimumab In Patient-Reported Outcomes
2016-11-13,Six Thoughts on President Trump and the Durability of the Biotech Stock Rally
2016-11-10,Incyte Becomes #40 Most Shorted Nasdaq 100 Component, Replacing Stericycle
2016-11-08,Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance
2016-11-03,More Than 20 Abstracts Highlighting Data From Incyte's Portfolio Accepted For Presentation At The 58th Annual ASH Meeting
2016-11-02,Why Incyte's Shares Could Soon Hit $100
2016-11-02,Incyte To Present At Upcoming Investor Conference
2016-11-01,Incyte Reports 2016 Third-Quarter Financial Results And Updates Key Clinical Programs
2016-11-01,There's Still Time to Buy These 5 Breakout Trades
2016-10-14,Incyte To Report Third Quarter Financial Results
2016-10-07,Additional Phase 1 Data From ECHO-202 Reinforce Durability Of Response In Patients With Treatment-naive Advanced Or Metastatic Melanoma Treated With Epacadostat In Combination With Keytruda® (pembrolizumab)
2016-09-28,Updated Phase 1 Data Reinforce The Clinical Profile Of Epacadostat In Combination With Keytruda® (Pembrolizumab)
2016-09-27,The New #42 Most Shorted Nasdaq 100 Component: Incyte
2016-09-27,NCCN Guidelines® Recommend Jakafi® (ruxolitinib) For The Treatment Of Myelofibrosis
2016-09-22,New Setback for Sanofi's Lantus Increases Need for M&amp;A
2016-09-08,Incyte Supports Those Affected By Rare Blood Cancers On MPN Awareness Day And Throughout Blood Cancer Awareness Month
2016-09-01,'Mad Money' Lightning Round: I'm Staying With Potash
2016-08-31,Jim Cramer's 'Mad Money' Recap: Oil Regains Control of the Stock Market
2016-08-30,Incyte To Present At Upcoming Investor Conferences
2016-08-25,Forbes Magazine Names Incyte To Its List Of World's Most Innovative Companies For Second Consecutive Year
2016-08-22,Incyte (INCY) Stock Rises on Takeover Speculation After $14 Billion Pfizer, Medivation Deal
2016-08-10,How Will Incyte (INCY) Stock React to Price Target Raise at Barclays?
2016-08-09,Why There Is Upside for Incyte Despite Recent Selloff
2016-08-09,Today's Roof Leaker Stock Is Incyte (INCY)
2016-08-09,Incyte Reports 2016 Second-Quarter Financial Results And Updates Key Clinical Programs
2016-08-03,Insider Trading Alert - CFFI, KERX And INCY Traded By Insiders
2016-08-01,Could a Spin-off of its Hepatitis C Division be in Gilead's Future?
2016-07-27,The New #38 Most Shorted Nasdaq 100 Component: Incyte
2016-07-22,3 Stocks Dragging In The Drugs Industry
2016-07-19,Updated Data For Epacadostat, Incyte's Selective IDO1 Inhibitor, Accepted For Presentation At The ESMO Annual Congress 2016
2016-07-14,Incyte To Report Second Quarter Financial Results
2016-07-13,3 Stocks Pushing The Health Care Sector Lower
2016-07-01,Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here
2016-06-29,16 Biopharma Companies Besides Medivation That Are Attractive Targets
2016-06-23,FDA Grants Breakthrough Therapy Designation For Incyte's Ruxolitinib (Jakafi®) In Acute Graft-Versus-Host Disease (GVHD)
2016-06-22,Incyte Announces First Patient Treated In ECHO-301 Phase 3 Study
2016-06-10,New Phase 3 Data Show Jakafi® (ruxolitinib) Is Superior To Best Available Therapy In Patients With Polycythemia Vera (PV)
2016-06-06,Five-year Results From Phase 3 Study Of Jakafi® (ruxolitinib) Show Sustained Overall Survival Benefit In Patients With Myelofibrosis (MF)
2016-06-01,Incyte And Moffitt Cancer Center Establish Multi-Year Oncology Research Alliance
2016-05-31,Incyte Announces The Launch Of The Incyte Charitable Giving Foundation
2016-05-31,3 Health Care Stocks Pushing Sector Growth
2016-05-26,Investors Eager for Gilead to Make Big Moves
2016-05-25,Gilead (GILD) Shares Spike After Executive Board Appointment
2016-05-19,Incyte Highlights Jakafi® (ruxolitinib) And Capmatinib Abstracts To Be Presented At The 2016 ASCO And EHA Annual Meetings
2016-05-18,Incyte To Present At Upcoming Investor Conferences
2016-05-09,Incyte Buys European Business Hub From Ariad Pharma
2016-05-09,Incyte First Quarter Financial Results Conference Call And Webcast
2016-05-09,Incyte Reports 2016 First-Quarter Financial Results And Updates Shareholders On Key Clinical Programs
2016-05-03,The New #44 Most Shorted Nasdaq 100 Component: Incyte
2016-04-28,Incyte To Present At Upcoming Investor Conferences
2016-04-18,Incyte (INCY) Weak On High Volume
2016-04-15,Incyte Investor Event At AACR 2016 To Highlight Innovative And Diversified Research And Development Portfolio
2016-04-14,Incyte To Report First Quarter Financial Results
2016-04-06,Incyte Acquires Rights From Lilly To Develop And Commercialize Ruxolitinib (Jakafi®) For The Treatment Of Patients With Graft-Versus-Host Disease (GVHD)
2016-03-31,Jim Cramer's 'Mad Money' Recap: Good Riddance to a Roller-Coaster Quarter
2016-03-31,Strong On High Relative Volume: Incyte (INCY)
2016-03-31,Phase 3 Study Findings Demonstrate Treatment With Baricitinib Results In Significant Improvements For Patients With Rheumatoid Arthritis Who Had Inadequate Response To Biologics
2016-03-26,5 Stocks Insiders Love Right Now
2016-03-16,Incyte's Immuno-oncology And Targeted Therapy Portfolio To Be Featured At The AACR Annual Meeting 2016
2016-03-09,BMRN, INCY And ALXN, Pushing Drugs Industry Downward
2016-03-02,5 Stocks Insiders Have Been Scooping Up Lately
2016-02-29,Voices Of MPN Rare Disease Day Video
2016-02-20,Jim Jubak&rsquo;s Four Favorite Stocks for Turbulent Markets
2016-02-20,Jim Jubak’s Four Favorite Stocks for Volatile Times
2016-02-17,Ratings Changes Today
2016-02-16,Incyte To Present At Upcoming Investor Conferences
2016-02-12,Incyte (INCY) Stock Price Target Lowered at Jefferies
2016-02-11,Here's Why Incyte (INCY) Stock is Tanking Today
2016-02-11,Unusual Social Activity Today Around Incyte (INCY)
2016-02-11,Incyte Falls on Jakafi Solid-Tumor Setback
2016-02-11,Incyte Reports 2015 Fourth-Quarter And Year-End Financial Results, Provides 2016 Financial Guidance And Updates Shareholders On Key Clinical Programs
2016-02-11,Incyte Announces Decision To Discontinue JANUS Studies Of Ruxolitinib Plus Capecitabine In Patients With Advanced Or Metastatic Pancreatic Cancer
2016-02-05,Incyte (INCY): Today's Weak On High Volume Stock
2016-01-27,Post-Market Activity Shows Incyte (INCY) Down
2016-01-27,Incyte Announces Decision To Stop Phase 2 Sub-study Of Ruxolitinib Plus Regorafenib In Patients With Metastatic Colorectal Cancer And High CRP
2016-01-25,Strong On High Relative Volume: Incyte (INCY)
2016-01-21,Incyte To Report Fourth Quarter/Year-End Financial Results
2016-01-19,Lilly And Incyte Announce Submission Of New Drug Application To FDA For Oral Once-Daily Baricitinib For Treatment Of Moderate-to-Severe Rheumatoid Arthritis
2016-01-12,Incyte (INCY) Shows Signs Of Being Water-Logged And Getting Wetter
2016-01-12,3 Stocks Pulling The Drugs Industry Downward
2016-01-11,Incyte Presents Significant Progress In Its Development Portfolio
2016-01-11,Incyte And AstraZeneca Announce New Lung Cancer Clinical Trial Collaboration
2016-01-07,Trade-Ideas: Incyte (INCY) Is Today's Weak On High Relative Volume Stock
2016-01-07,Jim Cramer's Top Takeaways: Starbucks, Alphabet, Ulta Salon, Micron, Viacom
2016-01-06,Jim Cramer's 'Mad Money' Recap: Good Things to Remember Amid the Fallout
2016-01-01,Feuerstein's Heroes and Zeroes of Biotech Investing in 2015
2015-12-26,Sell These 6 Biotech Stocks Now Before It's Too Late
2015-12-24,4 Great Stock-ing Stuffers for 2016
2015-12-22,NVO, INCY And ILMN, Pushing Drugs Industry Downward
2015-12-14,Incyte To Present At The 34th Annual J. P. Morgan Healthcare Conference
2015-12-05,Two Phase 3 Studies Reinforce Sustained Benefits Of Treatment With Jakafi® (ruxolitinib) In Patients With Myeloproliferative Neoplasms (MPNs)
2015-12-05,Phase 3 RESPONSE-2 Study Of Jakafi® (ruxolitinib) Meets Primary Endpoint
2015-12-01,3 Stocks Dragging The Drugs Industry Downward
2015-11-30,Incyte's Jakafi® (ruxolitinib) To Be Featured In Over 60 Abstracts At ASH Annual Meeting
2015-11-18,Goldman Sees Bluebird Shares Doubling On 'One-Shot' Gene Therapy
2015-11-13,Bearish Bets: Personal Bear Market Continues for Energy Stocks
2015-11-09,3 Drugs Stocks Driving The Industry Higher
2015-11-09,Incyte (INCY) Showing Signs Of A Dead Cat Bounce Today
2015-11-07,Detailed Results Demonstrate Baricitinib Superiority To Adalimumab In Improving Signs And Symptoms Of Rheumatoid Arthritis
2015-11-06,Incyte (INCY) Is Today's Roof Leaker Stock
2015-11-06,Ratings Changes Today
2015-11-04,Retrophin Sinks, Pharma Group Swings Back As Pricing Fight Escalates
2015-11-03,Weak On High Volume: Incyte (INCY)
2015-11-03,Epacadostat In Combination With Pembrolizumab Demonstrates Promising Clinical Activity In Multiple Advanced Cancers
2015-11-03,Incyte Reports 2015 Third-Quarter Financial Results And Updates Shareholders On Key Clinical Programs
2015-10-22,Northwest Bio Bothers British Bestie for Bounteous Bucks
2015-10-16,3 Stocks Dragging The Health Care Sector Downward
2015-10-16,Trade-Ideas: Incyte (INCY) Is Today's "Perilous Reversal" Stock
2015-10-13,Incyte To Report Third Quarter Financial Results
2015-10-13,Incyte And Merck Expand Clinical Collaboration To Include Phase 3 Study Investigating The Combination Of Epacadostat With Keytruda® (pembrolizumab) As First-line Treatment For Advanced Melanoma
2015-10-05,Incyte (INCY) Highlighted As Today's Perilous Reversal Stock
2015-10-02,Data At SITC Annual Meeting To Highlight Progress Of Incyte's Immuno-oncology Portfolio
2015-09-30,10 Best Nasdaq Biotech Stocks in the Third Quarter
2015-09-30,Strong On High Relative Volume: Incyte (INCY)
2015-09-29,Market News: Under Armour, OvaScience, Incyte Corporation
2015-09-29,Incyte (INCY) Stock Climbs on Positive Arthritis Test Results
2015-09-29,Eli Lilly (LLY) Stock Climbs on Positive Arthritis Drug Test Results
2015-09-29,Incyte (INCY) Weak On High Volume
2015-09-28,Trade-Ideas: Incyte (INCY) Is Today's "Roof Leaker" Stock
2015-09-16,Insider Trading Alert - RP, LAYN And INCY Traded By Insiders
2015-09-15,Incyte To Present At The Leerink Partners Inaugural Immuno-Oncology Roundtable Conference
2015-09-14,Incyte (INCY) In A Perilous Reversal
2015-09-03,Incyte (INCY) In A Perilous Reversal
2015-09-02,Incyte Announces Global License Agreement With Jiangsu Hengrui Medicine For SHR-1210, An Investigational Anti-PD-1 Monoclonal Antibody
2015-09-01,Incyte To Present At Upcoming Investor Conferences
2015-08-21,Incyte Named 7th Most Innovative Company In The World By Forbes Magazine
2015-08-14,3 Stocks Dragging The Drugs Industry Downward
2015-08-04,Incyte Reports 2015 Second-Quarter Financial Results And Updates Shareholders On Key Clinical Programs
2015-07-15,Analysts Break Down Impact Of $7.2B Receptos Buyout
2015-07-14,Incyte To Report Second Quarter Financial Results On August 4
2015-07-07,Incyte And Vanderbilt University Medical Center Establish Multi-Year Oncology Research Alliance
2015-07-06,3 Stocks Boosting The Health Care Sector Higher
2015-06-23,Agenus Gets Billion-Dollar Valuation From Analyst Based on Cancer Drug That Doesn't Exist
2015-06-19,Incyte Announces Organizational And Management Changes To Drive Future Global Expansion
2015-06-05,'Mad Money' Lightning Round: Buy Taser, Have Patience With Baxter
2015-06-04,Jim Cramer's 'Mad Money' Recap: 3 Things Frightening the Market Right Now
2015-06-01,Advaxis Announces FDA Clearance Of Investigational New Drug Application For Phase 2 Study Of ADXS-HPV And Incyte's Epacadostat For The Treatment Of HPV-Associated Early Stage Cervical Cancer
2015-05-30,ASCO '15: CTI Biopharma Takes on Myelofibrosis Drug Rival
2015-05-29,3 Health Care Stocks On The Rise
2015-05-28,Put Health Care Stocks on Your Shopping List
2017-03-06,IPI-549 Featured At 15th International Congress On Targeted Anticancer Therapies
2017-03-02,Infinity Announces Presentation On IPI-549 At AACR Annual Meeting
2017-02-28,Infinity Announces The Date Of Its Full-Year 2016 Financial Results Conference Call And Webcast
2017-02-27,Infinity To Present At 37th Annual Cowen And Company Healthcare Conference
2017-02-13,Infinity Announces Promotion Of Jeffery Kutok, M.D., Ph.D. To Chief Scientific Officer
2017-02-06,Infinity To Present At The 2017 BIO CEO & Investor Conference
2017-01-20,Infinity Presents Preclinical Data And Phase 1 Clinical Data On IPI-549 At PI3K Keystone Symposia Conference
2017-01-11,Dow Needs to Hit 20K to Shake Things Up
2017-01-09,Infinity Provides 2017 Goals And Financial Guidance
2017-01-08,Don't Tell Anyone: Insiders Are Buying These Stocks Like Crazy
2017-01-05,Infinity To Present At 35th Annual J.P. Morgan Annual Healthcare Conference
2017-01-04,Infinity Announces Organizational Changes
2016-12-21,5 Stocks Insiders Love Right Now
2016-11-11,Notable Friday Option Activity: INFI, RSO, P
2016-11-09,Infinity Announces Second Publication On PI3K-Gamma In Nature
2016-11-09,Bristol-Myers Squibb And Infinity Pharmaceuticals Announce Clinical Collaboration To Evaluate Opdivo (Nivolumab) In Combination With IPI-549 In Advanced Solid Tumors
2016-11-09,Bristol-Myers Squibb And Infinity Pharmaceuticals Announce Clinical Collaboration To Evaluate Opdivo (nivolumab) In Combination With IPI-549 In Advanced Solid Tumors
2016-11-04,Infinity Moves The Date Of Its Third Quarter 2016 Financial Results Conference Call And Webcast
2016-11-02,Verastem Licenses Duvelisib From Infinity Pharmaceuticals
2016-11-02,Verastem Licenses Duvelisib From Infinity Pharmaceuticals
2016-10-31,Infinity Announces The Date Of Its Third Quarter 2016 Financial Results Conference Call And Webcast
2016-10-26,Short Interest Jumps 24.6% For INFI
2016-09-27,Infinity Pharmaceuticals (INFI) Stock Rises on 'Favorable' Cancer Drug Trial Results
2016-09-26,Infinity Presents Initial Clinical And New Preclinical Data On IPI-549 At Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
2016-09-19,Infinity Announces Publication On PI3K-Gamma In Nature
2016-09-06,Infinity Announces Presentations On IPI-549 At Upcoming Immuno-Oncology Meeting
2016-08-02,Infinity Announces The Date Of Its Second Quarter 2016 Financial Results Conference Call And Webcast
2016-06-28,Infinity Regains Worldwide Rights To Duvelisib Following Mutual Agreement With AbbVie To End Collaboration
2016-06-26,7 Stocks Under $10 to Trade for Big Post-Brexit Gains
2016-06-17,Lifshitz & Miller Law Firm Announces Investigation Of CBL & Associates Properties, Inc., Eagle Pharmaceuticals, Inc., HCP, Inc., Immunomedics, Inc., Infinity Pharmaceuticals Inc., Neovasc, Inc., And Unilife Corporation
2016-06-16,Infinity Pharmaceuticals (INFI) Highlighted As Weak On High Volume
2016-06-15,Infinity Pharmaceuticals Faces Downgrades as Drug Results Disappoint
2016-06-15,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Infinity Pharmaceuticals Inc. (INFI)
2016-06-15,Infinity Pharmaceuticals Cannot Cure Downgrades After Drug Study
2016-06-15,Strong On High Volume: Infinity Pharmaceuticals (INFI)
2016-06-14,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Into Possible Securities Fraud Violations By Certain Officers And Directors Of Infinity Pharmaceuticals, Inc.
2016-06-14,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Infinity Pharmaceuticals Inc. - INFI
2016-06-14,Why Infinity Pharmaceuticals (INFI) Stock Is Tanking Today
2016-06-14,Morning Movers: BIDU, WGP, NERV, INFI
2016-06-14,Infinity Reports Topline Results From DYNAMO™, A Phase 2 Monotherapy Study Of Investigational Molecule Duvelisib In Refractory Indolent Non-Hodgkin Lymphoma
2016-06-01,Infinity Announces Launch Of Disease Awareness Campaign For Hematologic Malignancies
2016-05-31,Infinity To Participate In Three June Investor Conferences
2016-05-19,Infinity Announces Presentations On Investigational Development Candidates, Duvelisib And IPI-549, At Upcoming EHA And ASCO Meetings
2016-05-05,Infinity Pharmaceuticals is Now Oversold (INFI)
2016-04-27,Infinity To Participate In Three May Investor Conferences
2016-04-20,Infinity Announces The Date Of Its First Quarter 2016 Financial Results Conference Call And Webcast
2016-04-18,IPI-549 Alters The Immune-Suppressive Microenvironment And Enhances The Activity Of Checkpoint Inhibitors In Preclinical Models
2016-04-17,8 Stocks Under $10 to Trade for Big Gains
2016-04-13,Short Interest Falls 21.2% For INFI
2016-04-06,Trade-Ideas: Infinity Pharmaceuticals (INFI) Is Today's Strong On High Relative Volume Stock
2016-03-14,Strong On High Volume: Infinity Pharmaceuticals (INFI)
2016-02-17,Infinity To Participate In Two Upcoming Investor Conferences
2016-02-09,Infinity Announces The Date Of Its Full-Year 2015 Financial Results Conference Call And Webcast
2016-02-08,Infinity Pharmaceuticals Enters Oversold Territory (INFI)
2016-01-14,Infinity Pharmaceuticals Stock Sees Short Interest Fall 27.8%
2016-01-11,Infinity Pharmaceuticals Is Now Oversold (INFI)
2016-01-11,Infinity Provides Key 2016 Goals And Financial Guidance
2016-01-06,Infinity To Present At J.P. Morgan Annual Healthcare Conference
2016-01-05,Infinity Pharmaceuticals (INFI) Is Today's Strong On High Volume Stock
2015-11-24,First Week of July 2016 Options Trading For Infinity Pharmaceuticals (INFI)
2015-11-17,Trade-Ideas: Infinity Pharmaceuticals (INFI) Is Today's Strong On High Relative Volume Stock
2015-11-17,Infinity Announces Completion Of Target Enrollment In DUO™, A Phase 3 Study Evaluating Duvelisib In Chronic Lymphocytic Leukemia
2015-11-12,Infinity Pharmaceuticals (INFI) Weak On High Volume
2015-10-28,Infinity Announces The Date Of Its Third Quarter 2015 Financial Results Conference Call And Webcast
2015-10-21,First Week of INFI December 18th Options Trading
2015-10-06,Infinity Pharmaceuticals (INFI) Weak On High Volume Today
2015-10-06,Infinity To Provide Update On Duvelisib And Immuno-Oncology Development Candidate IPI-549 During 2015 Research And Development Day
2015-09-30,Infinity Announces Enrollment Of 120th Patient In Phase 2 DYNAMO™ Study Evaluating Duvelisib In Indolent Non-Hodgkin Lymphoma
2015-09-29,Infinity Pharmaceuticals (INFI) Flagged As Strong On High Volume
2015-09-24,Interesting INFI Put And Call Options For November 20th
2015-09-23,Commit To Buy Infinity Pharmaceuticals At $9, Earn 26.7% Annualized Using Options
2015-09-22,Infinity To Host 2015 Research & Development Day
2015-09-21,4 Stocks Rising on Unusual Volume
2015-09-21,Trade-Ideas: Infinity Pharmaceuticals (INFI) Is Today's Strong On High Relative Volume Stock
2015-09-18,Infinity Expands Pipeline With Addition Of IPI-549, An Immuno-Oncology Development Candidate For The Treatment Of Solid Tumors
2015-09-18,5 Stocks Ready for Breakouts
2015-09-02,Infinity To Participate In Three Conferences In September
2015-08-21,Trade-Ideas: Infinity Pharmaceuticals (INFI) Is Today's Strong On High Relative Volume Stock
2015-08-06,Infinity Provides Company Update And Reports Second Quarter 2015 Financial Results
2015-07-30,Infinity Announces The Date Of Its Second Quarter 2015 Financial Results Conference Call And Webcast
2015-07-21,Infinity Pharmaceuticals Enters Oversold Territory (INFI)
2015-07-21,Infinity To Participate In Two Upcoming Conferences
2015-07-01,10 Worst Biotech Stocks in the NASDAQ
2015-06-25,Commit To Purchase Infinity Pharmaceuticals At $9, Earn 14.9% Annualized Using Options
2015-06-09,RSI Alert: Infinity Pharmaceuticals (INFI) Now Oversold
2015-05-31,Infinity Reports Phase 1 Data Showing Clinical Activity Of Duvelisib In Treatment-Naïve Patients With Chronic Lymphocytic Leukemia
2015-05-27,Infinity To Participate In Three Investor Conferences In June
2015-05-26,Infinity Reports Preclinical Data For Duvelisib Demonstrating Synergy With Standard-of-Care Therapies And Emerging Agents In Development For The Treatment Of Hematologic Malignancies
2015-05-18,Strong On High Volume: Infinity Pharmaceuticals (INFI)
2015-05-14,Today's Weak On High Volume Stock: Infinity Pharmaceuticals (INFI)
2015-05-13,Infinity Announces New Data For Duvelisib To Be Presented At The 2015 American Society Of Clinical Oncology Annual Meeting
2015-05-06,Oversold Conditions For Infinity Pharmaceuticals (INFI)
2015-05-06,Infinity Reports First Quarter 2015 Financial Results And Recent Corporate Developments
2015-04-30,Infinity To Participate In Three Conferences In May
2015-04-22,Infinity Announces The Date Of Its First Quarter 2015 Financial Results Conference Call And Webcast
2015-04-20,Infinity Reports Preclinical Data For Duvelisib In Combination With Venetoclax At The 2015 American Association For Cancer Research Annual Meeting
2015-04-14,Sujay Kango, Executive Vice President, Chief Commercial Officer (Photo: Business Wire)
2015-04-01,Notable Two Hundred Day Moving Average Cross - INFI
2015-03-31,Infinity Exercises Option To Buy Out All Future Royalty Obligations To Takeda For Duvelisib Sales In Oncology
2015-03-25,Commit To Purchase Infinity Pharmaceuticals At $10, Earn 7.4% Annualized Using Options
2015-03-02,Infinity Pharmaceuticals (INFI) Downgraded From Hold to Sell
2015-02-27,Ratings Changes Today
2015-02-24,Infinity Provides Company Update And Reports Full-Year 2014 Financial Results
2015-02-18,Infinity To Present At The RBC Capital Markets 2015 Healthcare Conference
2015-02-10,Infinity Announces The Date Of Its Full-Year 2014 Financial Results Conference Call And Webcast
2015-01-12,Infinity Provides Key 2015 Goals And Financial Guidance
2015-01-08,Infinity Reports Topline Results From Phase 2 Study Of Duvelisib In Rheumatoid Arthritis
2015-01-05,Infinity To Present At J.P. Morgan 33rd Annual Healthcare Conference
2014-12-24,Commit To Buy Infinity Pharmaceuticals At $10, Earn 10% Using Options
2014-12-09,Infinity Reports New Results From Phase 1 Study Of Investigational Oncology Compound Duvelisib At The American Society Of Hematology Annual Meeting
2014-12-08,Infinity Reports New Translational Research And Updated Phase 1 Data Of Investigational Oncology Compound Duvelisib At American Society Of Hematology Annual Meeting
2014-11-26,Infinity Pharmaceuticals Stock Sees Short Interest Fall 18%
2014-11-26,Infinity Pharmaceuticals (INFI) Is Today's Strong On High Volume Stock
2014-11-24,Infinity To Present At The Deutsche Bank Securities 2014 BioFEST Conference
2014-11-14,Infinity Pharmaceuticals (INFI) Is Strong On High Volume Today
2014-11-14,Infinity Pharmaceuticals (INFI) Upgraded From Sell to Hold
2014-11-13,Ratings Changes Today
2014-11-06,Infinity Reports Third Quarter 2014 Financial Results And Provides Company Update
2014-11-06,Infinity Announces Clinical And Preclincal Data For Duvelisib To Be Presented At ASH 2014 Annual Meeting
2014-10-30,Infinity To Participate In Four Conferences In November
2014-10-23,Infinity Announces The Date Of Its Third Quarter 2014 Financial Results Conference Call And Webcast
2014-10-16,Infinity Reports Topline Data From Phase 2a Exploratory Study Of Duvelisib In Patients With Mild, Allergic Asthma
2014-09-24,First Week Of INFI November 22nd Options Trading
2014-09-03,Why Infinity Pharmaceuticals (INFI) Stock Is Soaring Today
2014-09-03,Infinity Pharma Snags Abbvie for Blood Cancer Drug Partnership
2014-09-03,Infinity And AbbVie Announce Global Strategic Collaboration To Develop And Commercialize Duvelisib (IPI-145) In Oncology
2014-09-03,Infinity And AbbVie Announce Global Strategic Collaboration To Develop And Commercialize Duvelisib (IPI-145) In Oncology
2014-09-03,Infinity Enters Into Master Clinical Supply Agreement And Material Transfer Agreement With Roche
2014-08-27,Infinity Pharmaceuticals Stock Sees Short Interest Move 13% Lower
2014-08-27,Infinity To Participate In Two Conferences In September
2014-08-12,Infinity Pharmaceuticals Stock Sees Short Interest Decrease By 11.6%
2014-08-11,3 Stocks Breaking Out With Unusual Volume
2014-08-06,3 Stocks Under $10 Making Big Moves
2014-08-05,Infinity Reports Second Quarter 2014 Financial Results And Provides Company Update
2014-08-04,Infinity Amends PI3K-Delta, Gamma Agreement With Millennium
2014-08-04,Interesting INFI Put And Call Options For August 16th
2014-07-31,Relative Strength Alert For Infinity Pharmaceuticals
2014-07-24,Infinity Announces The Date Of Its Second Quarter 2014 Financial Results Conference Call And Webcast
2014-07-22,Infinity To Participate In The BMO Capital Markets 3RD Annual Biotech Corporate Access Day
2014-06-03,Infinity To Present At The Goldman Sachs 35th Annual Global Healthcare Conference
2014-05-30,'Fast Money' Recap: What's On? How About Netflix Stock?
2014-05-27,Infinity To Participate In Four Conferences In June
2014-05-06,Infinity Reports First Quarter 2014 Financial Results And Provides Company Update
2014-04-30,Infinity To Participate In 3 Upcoming Conferences
2014-04-25,RSI Alert: Infinity Pharmaceuticals (INFI) Now Oversold
2014-04-24,Infinity Announces The Date Of Its First Quarter 2014 Financial Results Conference Call And Webcast
2014-04-03,Infinity Pharmaceuticals Enters Oversold Territory (INFI)
2014-03-10,Infinity Appoints Two Experienced Life Science Leaders to Its Board of Directors
2014-03-03,Infinity To Present At The Upcoming Bernstein Emerging Biotech Conference
2014-02-25,Infinity Provides Company Update And Reports Full-Year 2013 Financial Results
2014-02-19,Infinity To Participate In 3 Upcoming Conferences
2014-02-11,Infinity Announces The Date Of Its Full-Year 2013 Financial Results Conference Call And Webcast
2014-02-04,Infinity Announces Promotion Of David A. Roth To Chief Medical Officer
2014-01-23,Infinity Reports Phase 1 Data Of IPI-145 At Sixth Annual T-Cell Lymphoma Forum
2014-01-13,Infinity Provides Key 2014 Goals And Financial Guidance
2014-01-06,Infinity To Present At J.P. Morgan Annual Healthcare Conference
2013-12-30,The Billion-Dollar Biotech Club: Speculation Trumped Risk
2013-12-18,Why Investors Are Writing Off Infinity Pharma
2013-12-17,Commit To Purchase Infinity Pharmaceuticals At $8, Earn 13.8% Using Options
2013-12-08,Infinity Reports Updated Phase 1 Data Showing Encouraging Clinical Activity Of IPI-145 In Chronic Lymphocytic Leukemia And T-Cell Lymphoma At ASH Annual Meeting
2013-12-07,Infinity Reports Updated Phase 1 Data Of IPI-145 In Indolent Non-Hodgkin Lymphoma At ASH Annual Meeting
2013-12-07,Infinity Reports Preclinical Data At ASH Annual Meeting In Diffuse Large B-Cell Lymphoma And T-Cell Acute Lymphoblastic Leukemia Suggesting Broad Potential Of IPI-145 In Blood Cancers
2013-12-06,Infinity To Present At The Oppenheimer 24th Annual Healthcare Conference
2013-11-15,5 Stocks Poised for Breakouts
2013-11-11,Infinity Announces New Date And Time For Credit Suisse 2013 Healthcare Conference Presentation And Webcast
2013-11-07,Infinity Reports Third Quarter 2013 Financial Results And Provides Company Update
2013-11-07,Infinity Announces Clinical And Preclincial Data To Be Presented At ASH 2013 Annual Meeting
2013-11-06,Infinity To Participate In Three Upcoming Conferences
2013-10-30,RSI Alert: Infinity Pharmaceuticals (INFI) Now Oversold
2013-10-24,Infinity Announces The Date Of Its Third Quarter 2013 Financial Results Conference Call And Webcast
2013-10-16,Bulls Bet Infinity Pharma Will Rebound
2013-10-08,RSI Alert For Infinity Pharmaceuticals (INFI)
2013-09-25,Infinity Reports Topline Data From Phase 2 Study Of Retaspimycin Hydrochloride, Its Hsp90 Inhibitor, In Patients With Non-Small Cell Lung Cancer
2013-09-16,Julian Adams, Ph.D., Of Infinity Pharmaceuticals Named Corporate Chair For The Leukemia &amp; Lymphoma Society&#8217;s Light The Night Walk
2013-09-04,Infinity Expands Executive Leadership Team, Appointing David A. Roth As Senior Vice President, Clinical Development And Medical Affairs
2013-09-03,Infinity Supports Blood Cancer Awareness Month With Launch Of Sparks Of Inspiration, A Campaign To Honor People Affected By Blood Cancer
2013-08-27,Infinity To Participate In Three Conferences In September
2013-08-08,Infinity Reports Second Quarter 2013 Financial Results And Provides Company Update
2013-08-06,5 Stocks Poised to Pop on Bullish Earnings
2013-08-01,Infinity Announces The Date Of Its Second Quarter 2013 Financial Results Conference Call And Webcast
2017-03-24,Lifshitz & Miller LLP Announces Investigation Of Aratana Therapeutics, Inc., FXCM Inc., Innocoll Holdings Plc, Momenta Pharmaceuticals, Inc., Omnicom Group Inc., Perrigo Company Plc, Santander Consumer USA Holdings Inc. And The Interpublic Group Of Companies, Inc.
2017-03-16,Innocoll Holdings Plc Announces Fourth Quarter And Full-Year 2016 Financial And Operating Results And Provides Corporate Update
2017-03-16,Innocoll Holdings Announces Statement Re: Possible Offer
2017-03-13,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Innocoll Holdings Plc - INNL
2017-03-13,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors Of Innocoll Holdings Plc Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of March 27, 2017 - INNL
2017-03-09,INNL INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving Innocoll Holdings Plc And A Lead Plaintiff Deadline Of March 27, 2017
2017-03-03,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Innocoll Holdings Public Limited Company Of Class Action Lawsuit And Upcoming Deadline - INNL
2017-03-03,INNL SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving Innocoll Holdings Plc And A Lead Plaintiff Deadline Of March 27, 2017
2017-02-27,INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors Of Innocoll Holdings Plc Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of March 27, 2017
2017-02-26,DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Innocoll Holdings Plc To Contact The Firm
2017-02-22,INNL EXPANDED CLASS PERIOD: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Innocoll Holdings Plc And A Lead Plaintiff Deadline Of March 27, 2017
2017-02-03,INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Innocoll Holdings Plc To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2017-01-31,INNL LOSS ALERT: Rosen Law Firm Reminds Innocoll Holdings Plc Investors Of Important Deadline In First-Filed Case By Firm
2017-01-25,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against Innocoll Holdings, Plc (INNL) And Lead Plaintiff Deadline: March 27, 2017
2017-01-24,EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Innocoll Holdings Plc - INNL
2017-01-01,Dow, S&P 500 and Nasdaq Close Out 2016 With Strong Gains
2016-12-30,Dow, S&P 500 and Nasdaq Fall as Technology Sector Pulls Markets Down
2016-12-30,IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Innocoll Holdings Plc And Advises Investors With Losses To Contact The Firm
2016-12-30,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Innocoll Holdings Plc - INNL
2016-12-30,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Innocoll Holdings, Plc (INNL)
2016-12-30,EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Innocoll Holdings Plc - INNL
2016-12-30,Stocks Hold Lower; Cabela's, Innocoll Shares Drop Heading Into 2017
2016-12-30,Stocks Mostly Lower on Last Trading Day of 2016
2016-12-29,Innocoll Receives Refusal to File Letter from U.S. FDA for XARACOLL® (bupivacaine HCl collagen-matrix implants) New Drug Application
2016-11-23,Innocoll Holdings Plc To Present At The Piper Jaffray Annual Healthcare Conference
2016-11-22,Innocoll Holdings Plc Announces Third Quarter 2016 Financial And Operating Results And Provides Corporate Update
2016-11-15,Innocoll To Report Third Quarter 2016 Financial Results And Host Webcast And Conference Call On November 22, 2016
2016-11-14,Innocoll Holdings Plc To Present At The Stifel 2016 Healthcare Conference
2016-11-03,Innocoll Announces Top-Line Data From Phase 3 Trials With COGENZIA And NDA Submission For XARACOLL
2016-10-27,RSI Alert: Innocoll Holdings (INNL) Now Oversold
2016-09-07,Innocoll Holdings Plc To Present At The Morgan Stanley Global Healthcare Conference
2016-08-17,Innocoll Holdings Plc Announces Second Quarter 2016 Financial And Operating Results And Provides Corporate Update
2016-08-11,Innocoll To Report Second Quarter 2016 Financial Results And Host Webcast And Conference Call On August 17, 2016
2016-07-07,These 5 Stocks Under $10 Are Set to Soar
2016-07-06,Innocoll Holdings Plc To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference
2016-06-23,Innocoll Holdings Plc Announces The Completion Of Enrollment In Two Pivotal Phase 3 Clinical Trials Of COGENZIA For The Treatment Of Diabetic Foot Infections
2016-06-22,Innocoll Holdings Plc Announces Closing Of Public Offering
2016-06-17,Innocoll Holdings Enters Oversold Territory (INNL)
2016-06-16,Innocoll Holdings Plc Announces Pricing Of Public Offering Of Ordinary Shares
2016-06-16,Innocoll Holdings Plc To Present At The JMP Securities Life Sciences Conference
2016-06-13,Innocoll Holdings Plc Announces Proposed Public Offering Of Ordinary Shares
2016-05-31,Innocoll Holdings Plc Announces First Quarter 2016 Financial and Operating Results And Provides Corporate Update
2016-05-25,Innocoll Announces XARACOLL® (bupivacaine-collagen Bioresorbable Implant) Meets Primary Endpoint In Both Pivotal Phase 3 Trials In Postoperative Pain Relief
2016-05-24,Innocoll To Host Live Webcast On Top-Line Results From Two Pivotal Phase 3 Trials Of XARACOLL® (bupivacaine-collagen Bioresorbable Implant) In Postoperative Pain Relief
2016-05-18,Innocoll To Report First Quarter 2016 Financial Results And Host Webcast And Conference Call On May 31, 2016
2016-04-20,Innocoll Holdings Plc Appoints Lesley Russell, MBChB, MRCP, As Chief Medical Officer
2016-03-17,Innocoll Holdings Plc Announces Fourth Quarter And Full-Year 2015 Financial And Operating Results And Provides Corporate Update
2016-03-11,Innocoll To Report Fourth Quarter 2015 Financial Results And Host Webcast And Conference Call On March 17, 2016
2015-12-17,Innocoll AG Appoints Charles Katzer As Head Of Manufacturing And Technical Operations
2015-12-16,Innocoll is Now Oversold (INNL)
2015-12-09,Innocoll AG Announces Plan To Move Corporate Domicile To Ireland
2015-11-12,Innocoll is Now Oversold (INNL)
2015-11-11,Innocoll AG Announces Third Quarter 2015 Financial And Operating Results And Corporate Update
2015-11-04,Innocoll To Report Third Quarter 2015 Financial Results And Host Webcast And Conference Call On November 11, 2015
2015-09-16,Innocoll AG Announces First Patient Dosed In The XaraColl MATRIX-2 Phase 3 Study For The Treatment Of Postoperative Pain
2015-09-14,Innocoll AG Announces Departure Of Chief Medical Officer
2015-09-02,Innocoll AG Announces First Patient Dosed In The XaraColl MATRIX-1 Phase 3 Study For The Treatment Of Postoperative Pain
2015-08-26,Ratings Changes Today
2015-08-19,3 Stocks Driving The Drugs Industry Higher
2015-08-14,Innocoll AG Announces Second Quarter 2015 Financial And Operating Results And Updates Late-Stage Product Portfolio Progress
2015-08-13,Innocoll AG Appoints Rich Fante As Chief Commercial Officer And Head Of Business Development
2015-08-11,3 Stocks Pushing The Drugs Industry Lower
2015-08-07,Innocoll To Report Second Quarter 2015 Financial Results And Host Webcast And Conference Call On August 14, 2015
2015-07-01,Innocoll AG Appoints Jose Carmona As Chief Financial Officer
2015-06-30,Innocoll AG Announces Qualified Infectious Disease Product (QIDP) Designation For Cogenzia For The Adjunctive Treatment Of Moderate And Severe Diabetic Foot Infection
2015-06-17,Innocoll AG To Present At JMP Securities Healthcare Conference
2015-06-15,Innocoll AG Announces First Patient Dosed In The Cogenzia COACT-2 Phase 3 Study For The Treatment Of Diabetic Foot Infection
2015-05-15,Innocoll AG Announces First Patient Dosed In The Cogenzia COACT-1 Phase 3 Study For The Treatment Of Diabetic Foot Infection
2015-05-14,Innocoll AG Announces First Quarter Financial And Operating Results
2015-05-07,Innocoll To Report First Quarter 2015 Financial Results And Host Webcast And Conference Call On May 14, 2015
2015-04-24,Innocoll AG Announces Pricing Of Follow-On Offering
2015-04-01,Pivotal Pharmacokinetic Study Of Innocoll's XaraColl(R) Supports Use Of 300 Mg Dose For Phase 3 Clinical Studies In Post-Operative Pain
2015-03-30,Innocoll AG Secures EUR 25 Million Loan Commitment From European Investment Bank (EIB)
2015-03-19,Innocoll AG Announces Fourth Quarter And Full Year 2014 Financial And Operating Results
2015-03-18,Innocoll AG Appoints James Tursi, M.D., As Chief Medical Officer
2015-03-13,Innocoll To Report Fourth Quarter And Full Year 2014 Financial Results And Host Webcast And Conference Call On March 19, 2015
2015-03-09,3 Stocks Pushing The Drugs Industry Lower
2014-12-08,Innocoll AG Appoints Tony Zook As Chief Executive Officer As Company Progresses Toward Becoming A Fully-Integrated Commercial Company
2014-11-13,Innocoll AG Announces Third Quarter 2014 Financial And Operating Results
2014-11-06,Innocoll To Report Third Quarter 2014 Financial Results And Host Webcast And Conference Call On November 13, 2014
2014-10-22,Innocoll AG Proposes Changes To Supervisory Board And Stock Option Plan
2014-07-30,Innocoll AG Announces Closing Of Initial Public Offering
2014-07-25,Innocoll AG Announces Pricing Of Initial Public Offering
,
,
,
2017-03-24,Lifshitz & Miller LLP Announces Investigation Of Aratana Therapeutics, Inc., FXCM Inc., Innocoll Holdings Plc, Momenta Pharmaceuticals, Inc., Omnicom Group Inc., Perrigo Company Plc, Santander Consumer USA Holdings Inc. And The Interpublic Group Of Companies, Inc.
2017-03-16,Innocoll Holdings Plc Announces Fourth Quarter And Full-Year 2016 Financial And Operating Results And Provides Corporate Update
2017-03-16,Innocoll Holdings Announces Statement Re: Possible Offer
2017-03-13,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Innocoll Holdings Plc - INNL
2017-03-13,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors Of Innocoll Holdings Plc Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of March 27, 2017 - INNL
2017-03-09,INNL INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving Innocoll Holdings Plc And A Lead Plaintiff Deadline Of March 27, 2017
2017-03-03,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Innocoll Holdings Public Limited Company Of Class Action Lawsuit And Upcoming Deadline - INNL
2017-03-03,INNL SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving Innocoll Holdings Plc And A Lead Plaintiff Deadline Of March 27, 2017
2017-02-27,INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors Of Innocoll Holdings Plc Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of March 27, 2017
2017-02-26,DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Innocoll Holdings Plc To Contact The Firm
2017-02-22,INNL EXPANDED CLASS PERIOD: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Innocoll Holdings Plc And A Lead Plaintiff Deadline Of March 27, 2017
2017-02-03,INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Innocoll Holdings Plc To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2017-01-31,INNL LOSS ALERT: Rosen Law Firm Reminds Innocoll Holdings Plc Investors Of Important Deadline In First-Filed Case By Firm
2017-01-25,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against Innocoll Holdings, Plc (INNL) And Lead Plaintiff Deadline: March 27, 2017
2017-01-24,EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Innocoll Holdings Plc - INNL
2017-01-01,Dow, S&P 500 and Nasdaq Close Out 2016 With Strong Gains
2016-12-30,Dow, S&P 500 and Nasdaq Fall as Technology Sector Pulls Markets Down
2016-12-30,IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Innocoll Holdings Plc And Advises Investors With Losses To Contact The Firm
2016-12-30,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Innocoll Holdings Plc - INNL
2016-12-30,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Innocoll Holdings, Plc (INNL)
2016-12-30,EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Innocoll Holdings Plc - INNL
2016-12-30,Stocks Hold Lower; Cabela's, Innocoll Shares Drop Heading Into 2017
2016-12-30,Stocks Mostly Lower on Last Trading Day of 2016
2016-12-29,Innocoll Receives Refusal to File Letter from U.S. FDA for XARACOLL® (bupivacaine HCl collagen-matrix implants) New Drug Application
2016-11-23,Innocoll Holdings Plc To Present At The Piper Jaffray Annual Healthcare Conference
2016-11-22,Innocoll Holdings Plc Announces Third Quarter 2016 Financial And Operating Results And Provides Corporate Update
2016-11-15,Innocoll To Report Third Quarter 2016 Financial Results And Host Webcast And Conference Call On November 22, 2016
2016-11-14,Innocoll Holdings Plc To Present At The Stifel 2016 Healthcare Conference
2016-11-03,Innocoll Announces Top-Line Data From Phase 3 Trials With COGENZIA And NDA Submission For XARACOLL
2016-10-27,RSI Alert: Innocoll Holdings (INNL) Now Oversold
2016-09-07,Innocoll Holdings Plc To Present At The Morgan Stanley Global Healthcare Conference
2016-08-17,Innocoll Holdings Plc Announces Second Quarter 2016 Financial And Operating Results And Provides Corporate Update
2016-08-11,Innocoll To Report Second Quarter 2016 Financial Results And Host Webcast And Conference Call On August 17, 2016
2016-07-07,These 5 Stocks Under $10 Are Set to Soar
2016-07-06,Innocoll Holdings Plc To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference
2016-06-23,Innocoll Holdings Plc Announces The Completion Of Enrollment In Two Pivotal Phase 3 Clinical Trials Of COGENZIA For The Treatment Of Diabetic Foot Infections
2016-06-22,Innocoll Holdings Plc Announces Closing Of Public Offering
2016-06-17,Innocoll Holdings Enters Oversold Territory (INNL)
2016-06-16,Innocoll Holdings Plc Announces Pricing Of Public Offering Of Ordinary Shares
2016-06-16,Innocoll Holdings Plc To Present At The JMP Securities Life Sciences Conference
2016-06-13,Innocoll Holdings Plc Announces Proposed Public Offering Of Ordinary Shares
2016-05-31,Innocoll Holdings Plc Announces First Quarter 2016 Financial and Operating Results And Provides Corporate Update
2016-05-25,Innocoll Announces XARACOLL® (bupivacaine-collagen Bioresorbable Implant) Meets Primary Endpoint In Both Pivotal Phase 3 Trials In Postoperative Pain Relief
2016-05-24,Innocoll To Host Live Webcast On Top-Line Results From Two Pivotal Phase 3 Trials Of XARACOLL® (bupivacaine-collagen Bioresorbable Implant) In Postoperative Pain Relief
2016-05-18,Innocoll To Report First Quarter 2016 Financial Results And Host Webcast And Conference Call On May 31, 2016
2016-04-20,Innocoll Holdings Plc Appoints Lesley Russell, MBChB, MRCP, As Chief Medical Officer
2016-03-17,Innocoll Holdings Plc Announces Fourth Quarter And Full-Year 2015 Financial And Operating Results And Provides Corporate Update
2016-03-11,Innocoll To Report Fourth Quarter 2015 Financial Results And Host Webcast And Conference Call On March 17, 2016
2015-12-17,Innocoll AG Appoints Charles Katzer As Head Of Manufacturing And Technical Operations
2015-12-16,Innocoll is Now Oversold (INNL)
2015-12-09,Innocoll AG Announces Plan To Move Corporate Domicile To Ireland
2015-11-12,Innocoll is Now Oversold (INNL)
2015-11-11,Innocoll AG Announces Third Quarter 2015 Financial And Operating Results And Corporate Update
2015-11-04,Innocoll To Report Third Quarter 2015 Financial Results And Host Webcast And Conference Call On November 11, 2015
2015-09-16,Innocoll AG Announces First Patient Dosed In The XaraColl MATRIX-2 Phase 3 Study For The Treatment Of Postoperative Pain
2015-09-14,Innocoll AG Announces Departure Of Chief Medical Officer
2015-09-02,Innocoll AG Announces First Patient Dosed In The XaraColl MATRIX-1 Phase 3 Study For The Treatment Of Postoperative Pain
2015-08-26,Ratings Changes Today
2015-08-19,3 Stocks Driving The Drugs Industry Higher
2015-08-14,Innocoll AG Announces Second Quarter 2015 Financial And Operating Results And Updates Late-Stage Product Portfolio Progress
2015-08-13,Innocoll AG Appoints Rich Fante As Chief Commercial Officer And Head Of Business Development
2015-08-11,3 Stocks Pushing The Drugs Industry Lower
2015-08-07,Innocoll To Report Second Quarter 2015 Financial Results And Host Webcast And Conference Call On August 14, 2015
2015-07-01,Innocoll AG Appoints Jose Carmona As Chief Financial Officer
2015-06-30,Innocoll AG Announces Qualified Infectious Disease Product (QIDP) Designation For Cogenzia For The Adjunctive Treatment Of Moderate And Severe Diabetic Foot Infection
2015-06-17,Innocoll AG To Present At JMP Securities Healthcare Conference
2015-06-15,Innocoll AG Announces First Patient Dosed In The Cogenzia COACT-2 Phase 3 Study For The Treatment Of Diabetic Foot Infection
2015-05-15,Innocoll AG Announces First Patient Dosed In The Cogenzia COACT-1 Phase 3 Study For The Treatment Of Diabetic Foot Infection
2015-05-14,Innocoll AG Announces First Quarter Financial And Operating Results
2015-05-07,Innocoll To Report First Quarter 2015 Financial Results And Host Webcast And Conference Call On May 14, 2015
2015-04-24,Innocoll AG Announces Pricing Of Follow-On Offering
2015-04-01,Pivotal Pharmacokinetic Study Of Innocoll's XaraColl(R) Supports Use Of 300 Mg Dose For Phase 3 Clinical Studies In Post-Operative Pain
2015-03-30,Innocoll AG Secures EUR 25 Million Loan Commitment From European Investment Bank (EIB)
2015-03-19,Innocoll AG Announces Fourth Quarter And Full Year 2014 Financial And Operating Results
2015-03-18,Innocoll AG Appoints James Tursi, M.D., As Chief Medical Officer
2015-03-13,Innocoll To Report Fourth Quarter And Full Year 2014 Financial Results And Host Webcast And Conference Call On March 19, 2015
2015-03-09,3 Stocks Pushing The Drugs Industry Lower
2014-12-08,Innocoll AG Appoints Tony Zook As Chief Executive Officer As Company Progresses Toward Becoming A Fully-Integrated Commercial Company
2014-11-13,Innocoll AG Announces Third Quarter 2014 Financial And Operating Results
2014-11-06,Innocoll To Report Third Quarter 2014 Financial Results And Host Webcast And Conference Call On November 13, 2014
2014-10-22,Innocoll AG Proposes Changes To Supervisory Board And Stock Option Plan
2014-07-30,Innocoll AG Announces Closing Of Initial Public Offering
2014-07-25,Innocoll AG Announces Pricing Of Initial Public Offering
,
,
,
2017-03-24,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In INSYS Therapeutics, Inc. Of Class Action Lawsuit And Upcoming Deadline - INSY
2017-03-24,INSY NOTICE: Rosen Law Firm Reminds Insys Therapeutics, Inc. Investors Of Important Deadline Class Action
2017-03-23,Biotech Premarket Movers: Insys, Ultragenyx, Alexion
2017-03-23,DEA Schedules Insys Therapeutics' Syndros (dronabinol Oral Solution) As Schedule II Drug
2017-03-21,First Week of INSY November 17th Options Trading
2017-03-17,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Insys Therapeutics, Inc. - INSY
2017-03-17,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against INSYS Therapeutics, Inc. (INSY) & Lead Plaintiff Deadline: May 16, 2017
2017-03-16,EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Insys Therapeutics, Inc. - INSY
2017-03-16,IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Insys Therapeutics, And Advises Investors With Losses To Contact The Firm
2017-03-16,Insys Falls on Earnings Delay
2017-03-16,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of INSYS Therapeutics, Inc. (INSY)
2017-03-16,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By Certain Officers And Directors Of INSYS Therapeutics, Inc.
2017-03-16,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of INSYS Therapeutics, Inc - INSY
2017-03-15,Insys Therapeutics Announces Delay In The Release Of Its Fourth Quarter And Full Year 2016 Results
2017-03-14,5 Earnings Short-Squeeze Plays: Tiffany, Athene and More
2017-03-10,Short Interest Drops 14.7% For INSY
2017-03-02,Insys Therapeutics To Report Fourth Quarter And Full Year 2016 Results
2017-02-22,Insys Therapeutics Shares Cross Above 200 DMA
2017-02-15,Insys Therapeutics Announces Use Of Cannabidiol Oral Solution For Compassionate Use Studies In Patients Completing Long-Term Safety Study
2017-02-14,Insys Therapeutics, Inc. To Present At 2017 RBC Capital Markets Global Healthcare Conference
2017-01-31,Galena Sacks CEO Amid Escalating Criminal Probe Into Fentanyl Drug Marketing
2017-01-26,Research Reports Coverage On Biotech Stocks -- OncoGenex Pharma, INSYS Therapeutics, Threshold Pharma, And AmpliPhi Biosciences
2017-01-25,Cannabis Stocks Do Not Trade on Earnings, Instead on Pipeline of Drugs
2017-01-24,Interesting INSY Put And Call Options For March 17th
2017-01-18,Lifshitz & Miller Law Firm Announces Investigation Of Abeona Therapeutics Inc., Agile Therapeutics, Inc., Alere Inc., Floteck Industries, Inc., Insys Therapeutics Inc., MTS Systems Corporation, Ophthotech Corporation And Teekay Corporation
2017-01-09,Insys Therapeutics Announces Retirement Of Dr. John N. Kapoor As CEO And Chairman; Appoints Dr. Santosh Vetticaden As Interim CEO And Steven Meyer As Chairman Of The Board
2017-01-07,These 9 Allergan Drugs May Now Cost as Much as 9.5% More in 2017
2017-01-04,Insys Therapeutics, Inc. To Present At J.P. Morgan 35th Annual Healthcare Conference
2016-12-30,Insys Therapeutics Enters Oversold Territory (INSY)
2016-12-14,The Worst Biopharma CEOs of 2016 Are ...
2016-12-13,INVESTOR ALERT: Investigation Of Insys Therapeutics Announced By Holzer & Holzer
2016-12-08,Insys Therapeutics, Inc. Issues Statement Regarding Department Of Justice Press Release
2016-12-07,Canadian Marijuana Market More Mature, Outperforms U.S. Market
2016-12-07,4 Stocks You Can Buy to Profit From the Rising Use of Medical Marijuana
2016-11-30,'Mad Money' Lightning Round: American Electric Power, Amgen, Dow Chemical
2016-11-29,Jim Cramer's 'Mad Money' Recap: We've Been Afraid of Higher Rates for Years
2016-11-28,Commit To Buy Insys Therapeutics At $9, Earn 22.4% Annualized Using Options
2016-11-23,Three Pot Stocks to Watch for 2017
2016-11-22,Medtronic, Patterson Among Day's Biggest Losers, Trump Continues to Pressure Healthcare Sector
2016-11-18,Insys Therapeutics, Inc. To Present At Piper Jaffray 28th Annual Healthcare Conference
2016-11-15,Even in a Trump Presidency, Marijuana Is a Good Investment
2016-11-09,Nasdaq Cannabis Stocks Rally After Recreational and Medical Use Passes
2016-11-07,Nasdaq Cannabis Stocks Spike in Volume Ahead of Election for Recreational and Medical Use
2016-11-03,Insys Therapeutics Reports Third Quarter 2016 Results
2016-10-27,Insys Therapeutics To Report Third Quarter 2016 Results
2016-10-26,'Mad Money' Lightning Round: Yum! Brands Split is a 'Great Idea'
2016-10-25,Jim Cramer's 'Mad Money' Recap: Don't Surrender to the Index Funds
2016-10-14,New Colombia Resources Forming Joint Venture To Apply For An Orphan Drug Designation With The Food And Drug Administration (FDA) For A Medical Cannabis Pharmaceutical Product
2016-10-13,Insys Therapeutics Reports Preliminary Estimated Revenues From Subsys For The Third Quarter 2016
2016-09-28,Relative Strength Alert For Insys Therapeutics
2016-09-21,Insys Therapeutics Announces CEO Succession Plan
2016-09-01,Insys Therapeutics, Inc. To Present At Morgan Stanley Global Healthcare Conference
2016-08-30,Purcell Julie & Lefkowitz LLP Is Investigating Insys Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
2016-08-24,Insys Therapeutics Reports Phase 3 Trial Of Sublingual Buprenorphine Spray Met Primary Endpoint In Patients With Moderate-to-Severe Postoperative Pain After Bunionectomy
2016-08-18,Insys Therapeutics Announces First Patient Enrolled In Phase II Trial For The Treatment Of Cocaine Dependence Using Pharmaceutical Cannabidiol
2016-08-03,Insys Therapeutics Reports Second Quarter 2016 Results
2016-08-01,These 5 Stocks Are Set to Soar on Bullish Earnings
2016-07-20,Insys Therapeutics To Report Second Quarter 2016 Results
2016-07-15,Why Nasdaq-Traded Marijuana Stocks Remain Undervalued
2016-07-05,Insys Therapeutics (INSY) Stock Soars on FDA Approval
2016-07-05,Pre-Market Activity Shows Heavy Volume And Movement For Insys Therapeutics (INSY)
2016-07-05,Insys Therapeutics Announces FDA Approval Of Syndros™
2016-06-06,Trade-Ideas: Insys Therapeutics (INSY) Is Today's "Dead Cat Bounce" Stock
2016-05-26,Insys Therapeutics, Inc. To Present At Two Upcoming Conferences In June
2016-05-26,Commit To Purchase Insys Therapeutics At $11, Earn 16% Annualized Using Options
2016-05-24,Insys Therapeutics Successfully Completes Safety And Pharmacokinetic (PK) Study Of Cannabidiol Oral Solution In Pediatric Epilepsy Patients
2016-05-18,4 Top Stocks in the Growing Medical Marijuana Industry
2016-05-06,Insys Therapeutics Enters Oversold Territory (INSY)
2016-05-03,Marijuana Companies Evolving and Scaling to List on Nasdaq, Attract Investors
2016-04-28,Insys Therapeutics Reports First Quarter 2016 Results
2016-04-26,Insys Therapeutics, Inc. To Present At Deutsche Bank 41st Annual Health Care Conference
2016-04-25,5 Earnings Stocks Everyone Hates but You Should Love
2016-04-21,Making the Right Budding Investment: Medical Versus Recreational Cannabis Companies
2016-04-20,How to Invest in Nasdaq-Traded Marijuana Stocks and Private Pot Companies
2016-04-15,These 3 Marijuana-Related Stocks Are Poised for Strong Growth
2016-04-14,Insys Therapeutics To Report First Quarter 2016 Results
2016-04-14,'Mad Money' Lightning Round: I Believe in Cypress Semiconductor
2016-04-13,Jim Cramer's 'Mad Money' Recap: These Winning Stocks Fit the Buying Pattern
2016-04-12,Notable Tuesday Option Activity: INSY, SWN, SNAK
2016-04-11,Insys Therapeutics (INSY) Stock Tanks on Preliminary Subsys Revenues
2016-04-11,Endo International Tumbles as Insys Expects Weak Painkiller Sales
2016-04-11,Trade-Ideas: Insys Therapeutics (INSY) Is Today's Weak On High Relative Volume Stock
2016-04-11,Insys Therapeutics Reports Preliminary Estimated Revenues From Subsys For The First Quarter 2016
2016-03-30,April 4 Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of The Upcoming Lead Plaintiff Deadline In The Class Action Lawsuit Against Insys Therapeutics, Inc. And Encourages Investors To Contact The Firm
2016-03-30,Important Lead Plaintiff Deadline Reminder For Insys Therapeutics Shareholders
2016-03-28,INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of INSYS Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of April 4, 2016
2016-03-26,SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Insys Therapeutics, Inc - INSY
2016-03-23,Today's Perilous Reversal Stock: Insys Therapeutics (INSY)
2016-03-22,Insys Therapeutics, Inc. Announces 3-Month Extension Of PDUFA Date For Syndros
2016-03-21,SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notify Investors Of Class Action Involving INSYS Therapeutics, Inc. And A Lead Plaintiff Deadline Of April 4, 2016
2016-03-18,The Former Attorney General Of Louisiana & Kahn Swick & Foti, LLC Remind Large Investors Of Lead Plaintiff Deadline In Class Action Lawsuit Against Insys Therapeutics, Inc. - INSY
2016-03-18,SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Insys Therapeutics, Inc. To Contact The Firm Before Lead Plaintiff Deadline
2016-03-18,INSY INVESTOR REMINDER: Class Action Deadline Reminder From Lieff Cabraser For Investors In Insys Therapeutics, Inc.
2016-03-16,INVESTOR ALERT: The Law Offices Of Vincent Wong Notify Investors Of Class Action Involving INSYS Therapeutics, Inc. And A Lead Plaintiff Deadline Of April 4, 2016 - INSY
2016-03-15,Insys Therapeutics (INSY) In A Perilous Reversal
2016-03-11,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of INSYS Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of April 4, 2016
2016-03-11,Galena Not Named Target of Federal Criminal Probe Into Painkiller Use
2016-03-10,USPTO Declines To Institute All Inter Partes Review Petitions Filed By CFAD Of Insys U.S. Patents Directed To SUBSYS (fentanyl Sublingual Spray)
2016-03-09,GPM Announces The Filing Of A Securities Class Action On Behalf Of Insys Therapeutics, Inc. Investors
2016-03-09,Insys Therapeutics (INSY) Highlighted As Weak On High Volume
2016-03-08,Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In INSYS Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2016-03-08,INSY INVESTORS NOTICE: Lieff Cabraser Reminds Investors Of Deadline In Class Action Against Insys Therapeutics, Inc.
2016-03-07,Scott + Scott, LLP Reminds Investors Of April 4, 2016 Deadline To File Lead Plaintiff Papers In Insys Therapeutics (INSY) Securities Case
2016-03-07,SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notify Investors Of Class Action Involving INSYS Therapeutics, Inc. And A Lead Plaintiff Deadline Of April 4, 2016
2016-03-07,Insys Therapeutics Shareholder Alert: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders Of Important April 4, 2016 Deadline - INSY
2016-03-04,The Former Attorney General Of Louisiana & Kahn Swick & Foti, LLC Remind Large Investors Of Lead Plaintiff Deadline In Class Action Lawsuit Against Insys Therapeutics, Inc.
2016-03-03,Scott + Scott, LLP Reminds Investors Of April 4, 2016 Deadline To File Lead Plaintiff Papers In Insys Therapeutics, Inc. (INSY) Securities Case
2016-03-02,GPM Announces The Filing Of A Securities Class Action On Behalf Of Insys Therapeutics, Inc. Investors
2016-02-29,Insys Therapeutics (INSY) Highlighted As Today's Perilous Reversal Stock
2016-02-25,First Week of April 15th Options Trading For Insys Therapeutics (INSY)
2016-02-23,Lifshitz & Miller Law Firm Announces Investigation Of Aerojet Rocketdyne Holdings, Inc., Brixmor Property Group, Inc., Cardiovascular Systems, Inc., DeVry Education Group Inc., Freeport-McMoRan Inc., Imprivata, Inc., And Insys Therapeutics Inc.
2016-02-23,INSY INVESTORS ALERT: Lieff Cabraser Reminds Investors Of Deadline In Class Action Against Insys Therapeutics, Inc.
2016-02-23,Ratings Changes Today
2016-02-23,Insys Therapeutics Reports Fourth Quarter And Year End 2015 Results
2016-02-22,STOCK NOTICE: Rosen Law Firm Reminds INSYS Therapeutics, Inc. Investors Of Important Deadline In Class Action - INSY
2016-02-18,Insys Therapeutics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors
2016-02-16,INSYS INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Insys Therapeutics, Inc.
2016-02-10,Insys Therapeutics, Inc. To Present At RBC Capital Markets 2016 Global Healthcare Conference
2016-02-09,Insys Therapeutics Enrolls First Patient In Phase II Study For The Treatment Of Infantile Spasms Using Pharmaceutical CBD
2016-02-08,IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against INSYS Therapeutics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm
2016-02-08,Law Offices Of Marc S. Henzel Announces Investigation Of Companies For Violations Of The Federal Securities Laws
2016-02-05,Bragar Eagel & Squire, P.C. Is Investigating The Officers And Directors Of Insys Therapeutics Incorporated (INSY) On Behalf Of Stockholders And Encourages Investors To Contact The Firm
2016-02-04,Bernstein Liebhard LLP Announces That A Suit Has Been Filed Against Insys Therapeutics Inc.
2016-02-04,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against INSYS Therapeutics, Inc. (INSYS) And Lead Plaintiff Deadline: April 4, 2016
2016-02-03,Insys Therapeutics To Report Fourth Quarter And Full Year 2015 Results
2016-02-03,Harwood Feffer LLP Announces Investigation Of Insys Therapeutics, Inc.
2016-02-03,/C O R R E C T I O N -- Kessler Topaz Meltzer & Check, LLP/
2016-01-26,Insys Therapeutics (INSY) Highlighted As Weak On High Volume
2016-01-25,Insys Therapeutics Releases Statement On Its Patient Services Center
2016-01-25,Insys Therapeutics Investigated For Securities Fraud By Block & Leviton LLP After Publication Of Reports Accusing The Company Of Insurance Fraud
2015-12-30,Insys Therapeutics, Inc. To Present At J.P. Morgan 34th Annual Healthcare Conference
2015-12-19,The Naughty List: Finalists for Worst Biopharma CEO of 2015
2015-12-11,3 Stocks the Market Hates But Analysts Love
2015-12-09,Stock To Watch: Insys Therapeutics (INSY) In Perilous Reversal
2015-12-04,Insys Therapeutics (INSY) Is Today's Dead Cat Bounce Stock
2015-12-04,Insys Therapeutics Responds To False And Misleading Report
2015-12-02,Insys Therapeutics, Inc. Announces Speakers For December 3, 2015 Investor Day
2015-11-24,Insys Therapeutics, Inc. To Host Investor Day On December 3, 2015
2015-11-23,Insys Therapeutics, Inc. To Present At Piper Jaffray 27th Annual Healthcare Conference
2015-11-23,Insys Therapeutics, Inc. Issues Statement
2015-11-16,Diplomat Seen As Compelling Amid Specialty Pharmacy Fallout
2015-11-12,Insys Therapeutics, Inc. To Present At Jefferies Autumn 2015 Global Healthcare Conference
2015-11-05,Insys Therapeutics (INSY) Is Today's Dead Cat Bounce Stock
2015-11-05,Insys Therapeutics Announces Stock Repurchase Program
2015-11-05,Insys Therapeutics Announces Senior Management Changes And Appointments
2015-11-05,Insys Therapeutics Reports Record Third Quarter 2015 Results
2015-11-03,5 Hated Stocks You Should Love
2015-10-27,Insys Therapeutics (INSY) Is Today's Strong On High Volume Stock
2015-10-22,RBC Capital Markets Says Buy These 5 Pharmaceutical Stocks, Despite 'Irrational' Sell Off
2015-10-02,Insys Therapeutics (INSY) Is Today's Dead Cat Bounce Stock
2015-07-27,Weak On High Volume: Insys Therapeutics (INSY)
2015-07-21,Jim Cramer's 'Mad Money' Recap: Seeing a Double Standard in Market Valuations
2015-07-17,Biotech Stock Mailbag: Alzheimer's Conference Preview, Why Stock Prices Sometimes Lie
2015-07-15,Trade-Ideas: Insys Therapeutics (INSY) Is Today's Strong On High Relative Volume Stock
2015-06-25,Water-Logged And Getting Wetter: Insys Therapeutics (INSY)
2015-06-23,Marijuana Stocks and the Risks of a '420 Friendly' Portfolio
2015-06-19,'Mad Money' Lightning Round: Buy, Buy, Buy Citigroup
2015-06-18,Jim Cramer's 'Mad Money' Recap: Here's Why We Had a Rally Today
2015-06-18,Strong On High Relative Volume: Insys Therapeutics (INSY)
2015-05-28,Insider Trading Alert - INSY, HF And NEWT Traded By Insiders
2015-05-19,Insider Trading Alert - REXI, MNTX And INSY Traded By Insiders
2015-05-05,5 Hated Earnings Stocks You Should Love
2015-04-02,'Mad Money' Lightning Round: Kinder Morgan, HCA Are Winners
2015-04-01,Jim Cramer's 'Mad Money' Recap: Get Ready for a Rough Ride
2015-03-13,Insider Trading Alert - INSY, SYNT And ASGN Traded By Insiders
2015-03-11,Russell Flexes Its Muscles
2015-03-09,Commit To Purchase Insys Therapeutics At $50, Earn 22.6% Annualized Using Options
2014-11-21,Insider Trading Alert - INSY, LNKD And IMPV Traded By Insiders
2014-11-17,INSY: Insiders Vs. Shorts
2014-11-13,Insys Therapeutics (INSY) Upgraded From Hold to Buy
2014-11-12,Ratings Changes Today
2014-11-12,Insys Therapeutics (INSY) Is Weak On High Volume Today
2014-11-11,Insys Therapeutics (INSY) Stock Soars Today on Third Quarter Earnings Beat
2014-11-04,Insys Therapeutics (INSY) Marked As A Dead Cat Bounce Stock
2014-10-07,Insys Therapeutics (INSY) Marked As A Dead Cat Bounce Stock
2014-10-01,Weak On High Volume: Insys Therapeutics (INSY)
2014-09-26,Strong On High Relative Volume: Insys Therapeutics (INSY)
2014-08-19,Perilous Reversal Stock: Insys Therapeutics (INSY)
2014-08-19,5 Stocks Jumping on Unusual Volume
2014-08-11,5 Stocks Set to Soar on Bullish Earnings
2017-03-24,Lifshitz & Miller LLP Announces Investigation Of Air Methods Corporation, Fortress Investment Group LLC, Galena Biopharma, Inc., Ionis Pharmaceuticals, Inc., LMI Aerospace, Inc., Lumos Networks Corp., Silver Bay Realty Trust Corp. And TerraForm Global, Inc.
2017-03-24,Ford Motor, Constellation Brands, Cypress Semiconductor: 'Mad Money' Lightning Round
2017-03-20,Finding Bullish and Bearish Market Reversals
2017-03-14,AbbVie, Abbott Laboratories, Amplify Snacks, Skyworks Solutions: 'Mad Money' Lightning Round
2017-03-14,This Bull Could Feel the Chill: Cramer's 'Mad Money' Monday Recap
2017-03-10,Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix
2017-03-10,Analysts' Actions -- Kimberly-Clark, IberiaBank, Ionis Pharma, Actuant and More
2017-03-06,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Of Ionis Pharmaceuticals, Inc.
2017-03-06,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Ionis Pharmaceuticals, Inc. (IONS)
2017-03-06,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Ionis Pharmaceuticals, Inc. - IONS
2017-03-06,Akcea And Ionis Announce Positive Results From Pivotal Study Of Volanesorsen In Patients With Familial Chylomicronemia Syndrome (FCS)
2017-02-28,Biotech Premarket Movers: Cempra, Novavax, Ionis
2017-02-16,Ionis And Akcea Close On Strategic Collaboration With Global Pharmaceutical Company To Develop And Commercialize AKCEA-APO(a)-LRx And AKCEA-APOCIII-LRx
2017-02-15,Ionis Pharmaceuticals To Hold 2016 Financial Results Conference Call
2017-02-14,Ionis Earns $75 Million From Bayer For Advancing IONIS-FXI Rx And IONIS-FXI-L Rx
2017-02-10,Short Interest Increases 10.4% For IONS
2017-02-02,Ionis Earns $5 Million Milestone Payment From Biogen For Advancing A New Program Under Its Broad Neurology Strategic Collaboration
2017-02-01,Ionis Pharmaceuticals To Present At Upcoming Investor Conferences
2017-01-26,Biogen Rallies Despite Mixed Revenue Guidance
2017-01-13,New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk Of Death Or Permanent Ventilation In Infantile-Onset Spinal Muscular Atrophy
2017-01-11,Biotech Investors 'Spooked' After Trump's Comments, JMP's King Says
2017-01-10,'Mad Money Lightning Round: Schlumberger Is the Best of Breed
2017-01-09,These Stocks Are Too Hot, in a Bad Way : Jim Cramer's 'Mad Money' Recap
2017-01-06,Ionis Pharmaceuticals Significantly Improves Upon 2016 Financial Guidance
2017-01-06,Ionis, Novartis Ink Collaboration Worth Up to $1.6B Plus Royalties
2017-01-06,Ionis And Akcea Enter Into Strategic Collaboration With Global Pharmaceutical Company To Develop And Commercialize AKCEA-APO(a)-L Rx And AKCEA-APOCIII-L Rx
2017-01-05,Warning: Sell-Side Analyst Call on Failed Ionis-Biogen Drug Causes Projectile Vomiting
2017-01-04,Ionis Pharmaceuticals Reports Positive Data From Phase 2 Study Of IONIS-GCGR Rx In Patients With Type 2 Diabetes
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2016-12-27,Dow Jones Loses Momentum on March to 20,000 While Nasdaq Hits Record
2016-12-27,Dow Retreats from 20,000 Milestone; Stocks Steady as Oil Closes Higher
2016-12-27,Biogen's Spinal Muscular Atrophy Drug Wins FDA Approval
2016-12-27,Dow Moves Toward 20,000; Stocks Higher as Consumer Confidence Rises
2016-12-27,Biogen Scores FDA Approval for First Spinal Muscular Atrophy Drug
2016-12-23,SPINRAZA™ (nusinersen) Approved In U.S. To Treat Broad Range Of Patients With Spinal Muscular Atrophy
2016-12-22,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
2016-12-22,Ionis Pharmaceuticals Earns Milestone Payment From Janssen For Advancing A New Program Under GI Collaboration
2016-12-20,Jim Cramer's Top Takeaways: Nordstrom, Ionis, Cimarex Energy
2016-12-19,Jim Cramer's 'Mad Money' Recap: Here's a Powerful Incentive to Keep Buying, Stay Long
2016-12-19,Ionis And AstraZeneca Advance First Generation 2.5 LICA Drug Into Preclinical Development To Treat Cardiovascular Disease
2016-12-19,Akcea And Ionis Announce Positive Results From Compass Phase 3 Study Of Volanesorsen
2016-12-16,Ionis Earns $28 Million From AstraZeneca For A New Drug To Treat Cancer
2016-12-15,Ionis Pharmaceuticals To Host A Pipeline Update Webcast
2016-12-13,Ionis Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-07,Dow Scores Another Record for Third Consecutive Day; S&amp;P 500 Also Hits New High
2016-12-07,Dow, S&amp;P 500 Trade at Session Highs in Broad Wall Street Rally
2016-12-07,S&amp;P 500 and Dow Reverse Losses to Post Intraday Records
2016-12-07,Ionis Pharmaceuticals To Present At The BMO Capital Markets Prescriptions For Success Healthcare Conference
2016-11-15,Ionis Pharmaceuticals Reports Positive Clinical Data From IONIS-ANGPTL3-L Rx
2016-11-14,Bullish and Bearish Chart Reversals
2016-11-07,Shares of Biogen, Ionis Gain on Positive Spinraza Trial
2016-11-07,Biogen And Ionis Pharmaceuticals Announce SPINRAZA (nusinersen) Meets Primary Endpoint At Interim Analysis Of Phase 3 CHERISH Study In Later-Onset Spinal Muscular Atrophy
2016-11-02,Ionis Pharmaceuticals To Present At Upcoming Investor Conferences
2016-11-01,Ionis Pharmaceuticals Reports Positive Phase 2 Data For IONIS-FXI Rx In Patients With End-Stage Renal Disease On Hemodialysis
2016-10-26,Webcast Alert: Ionis Pharmaceuticals' Third Quarter 2016 Financial Results Conference Call
2016-10-08,New Data Presented At World Muscle Society Congress Support Potential Benefit Of Investigational Treatment Nusinersen In Spinal Muscular Atrophy
2016-10-06,Here's a Reason Why Ionis Pharmaceuticals (IONS) Stock Is Slumping Today
2016-10-06,Analysts' Actions -- Alnylam, AutoNation, Tesla and More
2016-09-28,Ionis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives Lifetime Achievement Award From The Oligonucleotide Therapeutics Society
2016-09-26,Biogen Completes Rolling Submission Of New Drug Application To FDA For Nusinersen As A Treatment For Spinal Muscular Atrophy
2016-09-22,Akcea Announces Publication In The Lancet Of Clinical Results With Lp(a)-Lowering Drugs Designed To Treat Cardiovascular Disease
2016-09-15,Akcea Therapeutics Announces Presentations Of New Data Underscoring Burden Of Disease In Familial Chylomicronemia Syndrome
2016-09-06,Is Biogen's Rough Ride Over?
2016-08-31,Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
2016-08-22,Ionis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives E. B. Hershberg Award From The American Chemical Society
2016-08-09,Will Ionis Pharmaceuticals (IONS) Stock Be Helped By Q2 Revenue Beat, Guidance?
2016-08-09,5 Things You Must Know Before the Market Opens Tuesday
2016-08-08,CMCSA, IDXX, ZTS: Jim Cramer's Views
2016-08-05,Biotech Stock Mailbag: Ionis, Trust Issues and 'Oops! Don't Look at That Slide Deck'
2016-08-03,Jim Cramer's 'Mad Money' Recap: Four Winning Themes, Four to Avoid
2016-08-03,Cramer: Here's What to Embrace and What to Shun
2016-08-02,Stock To Watch: Ionis Pharmaceuticals (IONS) In Perilous Reversal
2016-08-02,Jim Cramer's Top Takeaways: Deluxe, Kimco Realty, Ionis Pharmaceuticals
2016-08-01,Jim Cramer's 'Mad Money' Recap: Why You Need a Long-Term View Past August
2016-08-01,Biogen and Ionis See Boost From Clinical Drug Trial
2016-08-01,S&amp;P 500, Dow Drop as Crude Closes at April Low
2016-08-01,S&amp;P 500, Dow Remain Lower as Crude Closes Just Above $40
2016-08-01,These 7 Stocks Are Seeing Big Volume Today -- Here's How to Trade Them Now
2016-08-01,Trending Tickers: MUR, DO, BIIB, VZ
2016-08-01,Ionis Childhood Spine Disorder Drug Notches Pivotal Study Win, Triggers Biogen Option
2016-08-01,Bullish and Bearish Reversals for the Week
2016-08-01,Cramer: What Are You Thinking? It Should Be Long Term
2016-08-01,Midday Report: Biogen Lifts Biotech; U.S. Stocks Break Higher
2016-08-01,Stocks Turn Higher as Biotech Gains Outweigh Energy Losses
2016-08-01,Jim Cramer -- Celgene Igniting a Rally in Biotech
2016-08-01,Jim Cramer -- Ionis Has a Childhood Spine Treatment Winner
2016-08-01,Today's Pre-Market Mover With Heavy Volume: Ionis Pharmaceuticals (IONS)
2016-08-01,Biogen And Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint At Interim Analysis Of Phase 3 ENDEAR Study In Infantile-Onset Spinal Muscular Atrophy
2016-07-28,Akcea Therapeutics Receives Orphan Designation In Europe For Volanesorsen For The Treatment Of Familial Partial Lipodystrophy (FPL)
2016-07-26,Webcast Alert: Ionis Pharmaceuticals' Second Quarter 2016 Financial Results Conference Call
2016-07-19,Ionis Pharmaceuticals Licenses First Oral Antisense Drug Acting Locally In The GI Tract To Janssen
2016-07-15,Ionis Pharmaceuticals (IONS) Marked As A Barbarian At The Gate
2016-07-12,Ionis Pharmaceuticals Announces Publication In Nature Biotechnology Of A Novel Mechanism Of Action For Antisense Drugs That Significantly Expands Therapeutic Opportunities
2016-07-07,Ionis Pharmaceuticals Reports Positive Clinical Data On IONIS-TTR Rx At The XV International Symposium On Amyloidosis
2016-06-29,Akcea Therapeutics Announces Launch Of IN-FOCUS, A Research Study To Assess Impact Of Familial Chylomicronemia Syndrome
2016-06-27,Akcea Announces Publication Of Positive Volanesorsen Clinical Data Showing Reduced Triglycerides And Improved Insulin Sensitivity In Patients With High Triglycerides And Type 2 Diabetes
2016-06-22,Ionis Pharmaceuticals To Host R&D Day
2016-06-08,Ionis Pharmaceuticals (IONS): Today's Weak On High Volume Stock
2016-06-03,Today's Perilous Reversal Stock: Ionis Pharmaceuticals (IONS)
2016-05-30,AAPL, TWX, NFLX: Jim Cramer's Views
2016-05-27,Ionis Pharmaceuticals (IONS) Showing Signs Of A Dead Cat Bounce Today
2016-05-27,Ionis Pharmaceuticals (IONS) Stock Falls, BMO Downgrades on GlaxoSmithKline Trial Delay
2016-05-27,Analysts' Actions -- Deckers, Palo Alto Networks, Signet Jewelers, Workday and More
2016-05-26,Jim Cramer's 'Mad Money' Recap: Stay Disciplined in This Market
2016-05-26,Cramer: Avoid Sloppiness by Watching Your Stock Table Manners
2016-05-26,3 Stocks Underperforming Today In The Drugs Industry
2016-05-26,Why Ionis Pharmaceuticals (IONS) Stock Is Tanking Today
2016-05-26,Alnylam Rises After Ionis Partner Decides Not To Start Phase 3 Study
2016-05-26,Heavy Trading On Ionis Pharmaceuticals (IONS) Before Market Open
2016-05-26,Ionis Pharmaceuticals Provides Update On IONIS-TTR Rx Program
2016-05-23,Ionis Pharmaceuticals And MD Anderson Form Strategic Alliance To Advance Novel Cancer Therapeutics
2016-05-16,Akcea Therapeutics Announces Completion Of Enrollment In Phase 3 COMPASS Trial Of Volanesorsen
2016-05-13,Today's Dead Cat Bounce Stock: Ionis Pharmaceuticals (IONS)
2016-05-05,Ionis Pharmaceuticals (IONS) Is Weak On High Volume Today
2016-05-05,Ionis Pharmaceuticals Provides Corporate Update At 2016 Annual Meeting Of Stockholders
2016-05-04,Ionis Pharmaceuticals (IONS) Showing Signs Of Being Water-Logged And Getting Wetter
2016-05-03,Ionis Pharmaceuticals And Kastle Therapeutics Announce Acquisition Of KYNAMRO®
2016-04-22,Webcast Alert: Ionis Pharmaceuticals' First Quarter 2016 Financial Results Conference Call
2016-04-20,Ionis Pharmaceuticals Reports Data Update From Nusinersen Phase 2 Study In Infants With Spinal Muscular Atrophy And Reviews Neurological Disease Franchise
2016-04-19,'Mad Money' Lightning Round: Ciena Is Dead
2016-04-18,Jim Cramer's 'Mad Money' Recap: Here Are Today's Top 10 Winning Stocks
2016-04-15,Ionis Pharmaceuticals Highlights Antisense Drugs To Treat Neurological Diseases At The AAN Meeting
2016-04-07,Here's Why Ionis Pharma (IONS) Stock is Sinking Today
2016-04-07,Perilous Reversal Watch: Ionis Pharmaceuticals (IONS)
2016-04-07,Ionis Pharmaceuticals Provides Update On IONIS-TTRRX Program
2016-04-06,Akcea Therapeutics To Present At 15th Annual Needham Healthcare Conference
2016-04-01,Ionis Pharmaceuticals To Present At Upcoming Investor Conferences
2016-03-31,Ionis Pharmaceuticals Advances Nusinersen In The Ongoing SHINE Study In Patients With SMA
2016-03-31,Akcea Therapeutics Supports World Lipodystrophy Day
2016-03-25,Gilead, Biogen Troubles Remind Investors Why Strong Drug Patents Are Vital
2016-03-25,'Mad Money' Lightning Round: I Don't Want AstraZeneca
2016-03-23,Trade-Ideas: Ionis Pharmaceuticals (IONS) Is Today's Pre-Market Mover With Heavy Volume Stock
2016-03-22,Trade-Ideas: Ionis Pharmaceuticals (IONS) Is Today's Post-Market Leader Stock
2016-03-22,Ionis Pharmaceuticals And Merck Receive Positive Verdict On Gilead HCV Drug Patent Case
2016-03-04,Bearish Bets: Tech, Pharma and Consumer Stocks That Look Good Short
2016-03-04,Akcea Therapeutics To Present At Cowen And Company 36th Annual Health Care Conference
2016-02-29,Ionis Pharmaceuticals Supports Rare Disease Day
2016-02-26,Ratings Changes Today
2016-02-16,Trade-Ideas: Ionis Pharmaceuticals (IONS) Is Today's Strong On High Relative Volume Stock
2016-02-12,'Mad Money' Lightning Round: Sell Marathon Petroleum and Tiffany
2016-02-11,Jim Cramer's 'Mad Money' Recap: Don't Panic, Start Buying
2016-02-11,Ionis Pharmaceuticals To Hold 2015 Financial Results Conference Call
2016-02-09,Ionis Pharmaceuticals (IONS) Flagged As Strong On High Volume
2016-02-08,Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan
2016-02-06,'Mad Money' Lightning Round: Expect More Pain From Regeneron Pharmaceuticals
2016-02-04,Ionis Pharmaceuticals To Present At Upcoming Investor Conferences
2016-01-19,Akcea Therapeutics Appoints Louis St. L. O'Dea As Chief Medical Officer
2016-01-13,Ionis Pharmaceuticals Announces That GSK Has Initiated A Phase 1 Study Of IONIS-HBV-L Rx
2016-01-12,Ionis Pharmaceuticals Completes Target Enrollment For Nusinersen Phase 3 Study, CHERISH, In Children With Spinal Muscular Atrophy
2016-01-11,Ionis Pharmaceuticals Revises 2015 Financial Guidance And Provides Pipeline Update In Conjunction With J.P. Morgan Conference
2016-01-11,Trade-Ideas: Ionis Pharmaceuticals (IONS) Is Today's "Water-Logged And Getting Wetter" Stock
2016-01-09,2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks
2016-01-07,Ionis Pharmaceuticals (IONS): Today's Weak On High Volume Stock
2016-01-05,Ionis Pharmaceuticals Receives Orphan Drug Designation From The US FDA For IONIS-HTT Rx For The Treatment Of Patients With Huntington's Disease
2016-01-04,Have a CIGAR, You'll Go Far in 2016
2016-01-04,Ionis Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference
2017-03-24,Lifshitz & Miller LLP Announces Investigation Of Air Methods Corporation, Fortress Investment Group LLC, Galena Biopharma, Inc., Ionis Pharmaceuticals, Inc., LMI Aerospace, Inc., Lumos Networks Corp., Silver Bay Realty Trust Corp. And TerraForm Global, Inc.
2017-03-24,Ford Motor, Constellation Brands, Cypress Semiconductor: 'Mad Money' Lightning Round
2017-03-20,Finding Bullish and Bearish Market Reversals
2017-03-14,AbbVie, Abbott Laboratories, Amplify Snacks, Skyworks Solutions: 'Mad Money' Lightning Round
2017-03-14,This Bull Could Feel the Chill: Cramer's 'Mad Money' Monday Recap
2017-03-10,Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix
2017-03-10,Analysts' Actions -- Kimberly-Clark, IberiaBank, Ionis Pharma, Actuant and More
2017-03-06,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Of Ionis Pharmaceuticals, Inc.
2017-03-06,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Ionis Pharmaceuticals, Inc. (IONS)
2017-03-06,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Ionis Pharmaceuticals, Inc. - IONS
2017-03-06,Akcea And Ionis Announce Positive Results From Pivotal Study Of Volanesorsen In Patients With Familial Chylomicronemia Syndrome (FCS)
2017-02-28,Biotech Premarket Movers: Cempra, Novavax, Ionis
2017-02-16,Ionis And Akcea Close On Strategic Collaboration With Global Pharmaceutical Company To Develop And Commercialize AKCEA-APO(a)-LRx And AKCEA-APOCIII-LRx
2017-02-15,Ionis Pharmaceuticals To Hold 2016 Financial Results Conference Call
2017-02-14,Ionis Earns $75 Million From Bayer For Advancing IONIS-FXI Rx And IONIS-FXI-L Rx
2017-02-10,Short Interest Increases 10.4% For IONS
2017-02-02,Ionis Earns $5 Million Milestone Payment From Biogen For Advancing A New Program Under Its Broad Neurology Strategic Collaboration
2017-02-01,Ionis Pharmaceuticals To Present At Upcoming Investor Conferences
2017-01-26,Biogen Rallies Despite Mixed Revenue Guidance
2017-01-13,New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk Of Death Or Permanent Ventilation In Infantile-Onset Spinal Muscular Atrophy
2017-01-11,Biotech Investors 'Spooked' After Trump's Comments, JMP's King Says
2017-01-10,'Mad Money Lightning Round: Schlumberger Is the Best of Breed
2017-01-09,These Stocks Are Too Hot, in a Bad Way : Jim Cramer's 'Mad Money' Recap
2017-01-06,Ionis Pharmaceuticals Significantly Improves Upon 2016 Financial Guidance
2017-01-06,Ionis, Novartis Ink Collaboration Worth Up to $1.6B Plus Royalties
2017-01-06,Ionis And Akcea Enter Into Strategic Collaboration With Global Pharmaceutical Company To Develop And Commercialize AKCEA-APO(a)-L Rx And AKCEA-APOCIII-L Rx
2017-01-05,Warning: Sell-Side Analyst Call on Failed Ionis-Biogen Drug Causes Projectile Vomiting
2017-01-04,Ionis Pharmaceuticals Reports Positive Data From Phase 2 Study Of IONIS-GCGR Rx In Patients With Type 2 Diabetes
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2016-12-27,Dow Jones Loses Momentum on March to 20,000 While Nasdaq Hits Record
2016-12-27,Dow Retreats from 20,000 Milestone; Stocks Steady as Oil Closes Higher
2016-12-27,Biogen's Spinal Muscular Atrophy Drug Wins FDA Approval
2016-12-27,Dow Moves Toward 20,000; Stocks Higher as Consumer Confidence Rises
2016-12-27,Biogen Scores FDA Approval for First Spinal Muscular Atrophy Drug
2016-12-23,SPINRAZA™ (nusinersen) Approved In U.S. To Treat Broad Range Of Patients With Spinal Muscular Atrophy
2016-12-22,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
2016-12-22,Ionis Pharmaceuticals Earns Milestone Payment From Janssen For Advancing A New Program Under GI Collaboration
2016-12-20,Jim Cramer's Top Takeaways: Nordstrom, Ionis, Cimarex Energy
2016-12-19,Jim Cramer's 'Mad Money' Recap: Here's a Powerful Incentive to Keep Buying, Stay Long
2016-12-19,Ionis And AstraZeneca Advance First Generation 2.5 LICA Drug Into Preclinical Development To Treat Cardiovascular Disease
2016-12-19,Akcea And Ionis Announce Positive Results From Compass Phase 3 Study Of Volanesorsen
2016-12-16,Ionis Earns $28 Million From AstraZeneca For A New Drug To Treat Cancer
2016-12-15,Ionis Pharmaceuticals To Host A Pipeline Update Webcast
2016-12-13,Ionis Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-07,Dow Scores Another Record for Third Consecutive Day; S&amp;P 500 Also Hits New High
2016-12-07,Dow, S&amp;P 500 Trade at Session Highs in Broad Wall Street Rally
2016-12-07,S&amp;P 500 and Dow Reverse Losses to Post Intraday Records
2016-12-07,Ionis Pharmaceuticals To Present At The BMO Capital Markets Prescriptions For Success Healthcare Conference
2016-11-15,Ionis Pharmaceuticals Reports Positive Clinical Data From IONIS-ANGPTL3-L Rx
2016-11-14,Bullish and Bearish Chart Reversals
2016-11-07,Shares of Biogen, Ionis Gain on Positive Spinraza Trial
2016-11-07,Biogen And Ionis Pharmaceuticals Announce SPINRAZA (nusinersen) Meets Primary Endpoint At Interim Analysis Of Phase 3 CHERISH Study In Later-Onset Spinal Muscular Atrophy
2016-11-02,Ionis Pharmaceuticals To Present At Upcoming Investor Conferences
2016-11-01,Ionis Pharmaceuticals Reports Positive Phase 2 Data For IONIS-FXI Rx In Patients With End-Stage Renal Disease On Hemodialysis
2016-10-26,Webcast Alert: Ionis Pharmaceuticals' Third Quarter 2016 Financial Results Conference Call
2016-10-08,New Data Presented At World Muscle Society Congress Support Potential Benefit Of Investigational Treatment Nusinersen In Spinal Muscular Atrophy
2016-10-06,Here's a Reason Why Ionis Pharmaceuticals (IONS) Stock Is Slumping Today
2016-10-06,Analysts' Actions -- Alnylam, AutoNation, Tesla and More
2016-09-28,Ionis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives Lifetime Achievement Award From The Oligonucleotide Therapeutics Society
2016-09-26,Biogen Completes Rolling Submission Of New Drug Application To FDA For Nusinersen As A Treatment For Spinal Muscular Atrophy
2016-09-22,Akcea Announces Publication In The Lancet Of Clinical Results With Lp(a)-Lowering Drugs Designed To Treat Cardiovascular Disease
2016-09-15,Akcea Therapeutics Announces Presentations Of New Data Underscoring Burden Of Disease In Familial Chylomicronemia Syndrome
2016-09-06,Is Biogen's Rough Ride Over?
2016-08-31,Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
2016-08-22,Ionis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives E. B. Hershberg Award From The American Chemical Society
2016-08-09,Will Ionis Pharmaceuticals (IONS) Stock Be Helped By Q2 Revenue Beat, Guidance?
2016-08-09,5 Things You Must Know Before the Market Opens Tuesday
2016-08-08,CMCSA, IDXX, ZTS: Jim Cramer's Views
2016-08-05,Biotech Stock Mailbag: Ionis, Trust Issues and 'Oops! Don't Look at That Slide Deck'
2016-08-03,Jim Cramer's 'Mad Money' Recap: Four Winning Themes, Four to Avoid
2016-08-03,Cramer: Here's What to Embrace and What to Shun
2016-08-02,Stock To Watch: Ionis Pharmaceuticals (IONS) In Perilous Reversal
2016-08-02,Jim Cramer's Top Takeaways: Deluxe, Kimco Realty, Ionis Pharmaceuticals
2016-08-01,Jim Cramer's 'Mad Money' Recap: Why You Need a Long-Term View Past August
2016-08-01,Biogen and Ionis See Boost From Clinical Drug Trial
2016-08-01,S&amp;P 500, Dow Drop as Crude Closes at April Low
2016-08-01,S&amp;P 500, Dow Remain Lower as Crude Closes Just Above $40
2016-08-01,These 7 Stocks Are Seeing Big Volume Today -- Here's How to Trade Them Now
2016-08-01,Trending Tickers: MUR, DO, BIIB, VZ
2016-08-01,Ionis Childhood Spine Disorder Drug Notches Pivotal Study Win, Triggers Biogen Option
2016-08-01,Bullish and Bearish Reversals for the Week
2016-08-01,Cramer: What Are You Thinking? It Should Be Long Term
2016-08-01,Midday Report: Biogen Lifts Biotech; U.S. Stocks Break Higher
2016-08-01,Stocks Turn Higher as Biotech Gains Outweigh Energy Losses
2016-08-01,Jim Cramer -- Celgene Igniting a Rally in Biotech
2016-08-01,Jim Cramer -- Ionis Has a Childhood Spine Treatment Winner
2016-08-01,Today's Pre-Market Mover With Heavy Volume: Ionis Pharmaceuticals (IONS)
2016-08-01,Biogen And Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint At Interim Analysis Of Phase 3 ENDEAR Study In Infantile-Onset Spinal Muscular Atrophy
2016-07-28,Akcea Therapeutics Receives Orphan Designation In Europe For Volanesorsen For The Treatment Of Familial Partial Lipodystrophy (FPL)
2016-07-26,Webcast Alert: Ionis Pharmaceuticals' Second Quarter 2016 Financial Results Conference Call
2016-07-19,Ionis Pharmaceuticals Licenses First Oral Antisense Drug Acting Locally In The GI Tract To Janssen
2016-07-15,Ionis Pharmaceuticals (IONS) Marked As A Barbarian At The Gate
2016-07-12,Ionis Pharmaceuticals Announces Publication In Nature Biotechnology Of A Novel Mechanism Of Action For Antisense Drugs That Significantly Expands Therapeutic Opportunities
2016-07-07,Ionis Pharmaceuticals Reports Positive Clinical Data On IONIS-TTR Rx At The XV International Symposium On Amyloidosis
2016-06-29,Akcea Therapeutics Announces Launch Of IN-FOCUS, A Research Study To Assess Impact Of Familial Chylomicronemia Syndrome
2016-06-27,Akcea Announces Publication Of Positive Volanesorsen Clinical Data Showing Reduced Triglycerides And Improved Insulin Sensitivity In Patients With High Triglycerides And Type 2 Diabetes
2016-06-22,Ionis Pharmaceuticals To Host R&D Day
2016-06-08,Ionis Pharmaceuticals (IONS): Today's Weak On High Volume Stock
2016-06-03,Today's Perilous Reversal Stock: Ionis Pharmaceuticals (IONS)
2016-05-30,AAPL, TWX, NFLX: Jim Cramer's Views
2016-05-27,Ionis Pharmaceuticals (IONS) Showing Signs Of A Dead Cat Bounce Today
2016-05-27,Ionis Pharmaceuticals (IONS) Stock Falls, BMO Downgrades on GlaxoSmithKline Trial Delay
2016-05-27,Analysts' Actions -- Deckers, Palo Alto Networks, Signet Jewelers, Workday and More
2016-05-26,Jim Cramer's 'Mad Money' Recap: Stay Disciplined in This Market
2016-05-26,Cramer: Avoid Sloppiness by Watching Your Stock Table Manners
2016-05-26,3 Stocks Underperforming Today In The Drugs Industry
2016-05-26,Why Ionis Pharmaceuticals (IONS) Stock Is Tanking Today
2016-05-26,Alnylam Rises After Ionis Partner Decides Not To Start Phase 3 Study
2016-05-26,Heavy Trading On Ionis Pharmaceuticals (IONS) Before Market Open
2016-05-26,Ionis Pharmaceuticals Provides Update On IONIS-TTR Rx Program
2016-05-23,Ionis Pharmaceuticals And MD Anderson Form Strategic Alliance To Advance Novel Cancer Therapeutics
2016-05-16,Akcea Therapeutics Announces Completion Of Enrollment In Phase 3 COMPASS Trial Of Volanesorsen
2016-05-13,Today's Dead Cat Bounce Stock: Ionis Pharmaceuticals (IONS)
2016-05-05,Ionis Pharmaceuticals (IONS) Is Weak On High Volume Today
2016-05-05,Ionis Pharmaceuticals Provides Corporate Update At 2016 Annual Meeting Of Stockholders
2016-05-04,Ionis Pharmaceuticals (IONS) Showing Signs Of Being Water-Logged And Getting Wetter
2016-05-03,Ionis Pharmaceuticals And Kastle Therapeutics Announce Acquisition Of KYNAMRO®
2016-04-22,Webcast Alert: Ionis Pharmaceuticals' First Quarter 2016 Financial Results Conference Call
2016-04-20,Ionis Pharmaceuticals Reports Data Update From Nusinersen Phase 2 Study In Infants With Spinal Muscular Atrophy And Reviews Neurological Disease Franchise
2016-04-19,'Mad Money' Lightning Round: Ciena Is Dead
2016-04-18,Jim Cramer's 'Mad Money' Recap: Here Are Today's Top 10 Winning Stocks
2016-04-15,Ionis Pharmaceuticals Highlights Antisense Drugs To Treat Neurological Diseases At The AAN Meeting
2016-04-07,Here's Why Ionis Pharma (IONS) Stock is Sinking Today
2016-04-07,Perilous Reversal Watch: Ionis Pharmaceuticals (IONS)
2016-04-07,Ionis Pharmaceuticals Provides Update On IONIS-TTRRX Program
2016-04-06,Akcea Therapeutics To Present At 15th Annual Needham Healthcare Conference
2016-04-01,Ionis Pharmaceuticals To Present At Upcoming Investor Conferences
2016-03-31,Ionis Pharmaceuticals Advances Nusinersen In The Ongoing SHINE Study In Patients With SMA
2016-03-31,Akcea Therapeutics Supports World Lipodystrophy Day
2016-03-25,Gilead, Biogen Troubles Remind Investors Why Strong Drug Patents Are Vital
2016-03-25,'Mad Money' Lightning Round: I Don't Want AstraZeneca
2016-03-23,Trade-Ideas: Ionis Pharmaceuticals (IONS) Is Today's Pre-Market Mover With Heavy Volume Stock
2016-03-22,Trade-Ideas: Ionis Pharmaceuticals (IONS) Is Today's Post-Market Leader Stock
2016-03-22,Ionis Pharmaceuticals And Merck Receive Positive Verdict On Gilead HCV Drug Patent Case
2016-03-04,Bearish Bets: Tech, Pharma and Consumer Stocks That Look Good Short
2016-03-04,Akcea Therapeutics To Present At Cowen And Company 36th Annual Health Care Conference
2016-02-29,Ionis Pharmaceuticals Supports Rare Disease Day
2016-02-26,Ratings Changes Today
2016-02-16,Trade-Ideas: Ionis Pharmaceuticals (IONS) Is Today's Strong On High Relative Volume Stock
2016-02-12,'Mad Money' Lightning Round: Sell Marathon Petroleum and Tiffany
2016-02-11,Jim Cramer's 'Mad Money' Recap: Don't Panic, Start Buying
2016-02-11,Ionis Pharmaceuticals To Hold 2015 Financial Results Conference Call
2016-02-09,Ionis Pharmaceuticals (IONS) Flagged As Strong On High Volume
2016-02-08,Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan
2016-02-06,'Mad Money' Lightning Round: Expect More Pain From Regeneron Pharmaceuticals
2016-02-04,Ionis Pharmaceuticals To Present At Upcoming Investor Conferences
2016-01-19,Akcea Therapeutics Appoints Louis St. L. O'Dea As Chief Medical Officer
2016-01-13,Ionis Pharmaceuticals Announces That GSK Has Initiated A Phase 1 Study Of IONIS-HBV-L Rx
2016-01-12,Ionis Pharmaceuticals Completes Target Enrollment For Nusinersen Phase 3 Study, CHERISH, In Children With Spinal Muscular Atrophy
2016-01-11,Ionis Pharmaceuticals Revises 2015 Financial Guidance And Provides Pipeline Update In Conjunction With J.P. Morgan Conference
2016-01-11,Trade-Ideas: Ionis Pharmaceuticals (IONS) Is Today's "Water-Logged And Getting Wetter" Stock
2016-01-09,2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks
2016-01-07,Ionis Pharmaceuticals (IONS): Today's Weak On High Volume Stock
2016-01-05,Ionis Pharmaceuticals Receives Orphan Drug Designation From The US FDA For IONIS-HTT Rx For The Treatment Of Patients With Huntington's Disease
2016-01-04,Have a CIGAR, You'll Go Far in 2016
2016-01-04,Ionis Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference
2017-03-10,Ironwood Pharmaceuticals To Present At Barclays Global Healthcare Conference
2017-03-09,Ironwood Pharmaceuticals Showcases Progress Delivering Innovative Medicines To Patients And Building A Top-Performing Commercial Biotech At R&D Day 2017
2017-02-28,Ironwood Pharmaceuticals To Present At Cowen And Company 37th Annual Health Care Conference
2017-02-23,Ironwood Pharmaceuticals To Host R&D Day On March 9, 2017
2017-02-21,Ironwood Pharmaceuticals Provides Fourth Quarter And Full Year 2016 Investor Update
2017-02-15,5&nbsp;Ways Allergan Can Keep Up Momentum
2017-02-10,Ironwood Pharmaceuticals Reaches Analyst Target Price
2017-02-07,Ironwood Pharmaceuticals To Host Fourth Quarter And Full-Year 2016 Investor Update Call
2017-01-30,Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen
2017-01-29,Astellas And Ironwood Report Positive Top-Line Results From Phase III Linaclotide Trial For Patients With Chronic Constipation Conducted In Japan
2017-01-20,Synergy Pharmaceuticals Secures Approval for Linzess Competitor
2017-01-08,Ironwood Pharmaceuticals Demonstrates Strong Execution On Strategy To Build Top-Performing Commercial Biotech
2017-01-04,Ironwood Pharmaceuticals Appoints Amy Schulman To Board Of Directors
2017-01-04,Ironwood Announces New Drug Application For DUZALLO™ (Fixed-Dose Combination Of Lesinurad And Allopurinol) Has Been Accepted For FDA Review
2017-01-03,Ironwood Pharmaceuticals To Present At J.P. Morgan Healthcare Conference
2016-12-22,Ironwood And Allergan Report Topline Phase IIb Data Supporting Advancement Of Linaclotide Colonic Release-1 (CR1) In IBS-C
2016-12-22,Ironwood And Allergan Report Topline Phase IIb Data Supporting Further Investigation Of Linaclotide Colonic Release-2 (CR2) For Abdominal Pain In Non-Constipation Subtypes Of IBS
2016-12-19,Ironwood Pharmaceuticals Announces Approval Of LINZESS® (linaclotide) In Japan For The Treatment Of Adults With IBS-C
2016-11-13,Ironwood Highlights ZURAMPIC® (lesinurad) Phase III Extension Study Data At The American College Of Rheumatology 2016 Annual Meeting
2016-11-10,Ironwood Pharmaceuticals To Present At Stifel 2016 Healthcare Conference
2016-11-03,Ironwood Pharmaceuticals Provides Third Quarter 2016 Investor Update
2016-11-01,Ironwood Pharmaceuticals To Present At Credit Suisse 25th Annual Healthcare Conference
2016-10-25,Ironwood Highlights Breadth Of Gout Research With Presentations At The American College Of Rheumatology 2016 Annual Meeting
2016-10-20,Ironwood Pharmaceuticals To Host Third Quarter 2016 Investor Update Call
2016-10-03,Nine In Ten Physicians Agree Target Goal For Gout Is Imperative, Yet Half Of Patients Fail To Reach It, New Survey Shows
2016-10-03,ZURAMPIC® (lesinurad) Is Now Available In Pharmacies Throughout The United States. (Photo: Business Wire)
2016-09-26,Ironwood Closes $150 Million Debt Refinancing
2016-09-07,Ironwood Pharmaceuticals To Present At Morgan Stanley Global Healthcare Conference
2016-09-01,Ironwood Pharmaceuticals To Present At Wells Fargo 2016 Healthcare Conference
2016-08-05,Ironwood Pharmaceuticals (IRWD): Today's Weak On High Volume Stock
2016-08-04,Ironwood Pharmaceuticals Provides Second Quarter 2016 Investor Update
2016-07-22,Synergy Pharma Offers Lots of Synergies
2016-07-21,Ironwood Pharmaceuticals To Host Second Quarter 2016 Investor Update Call
2016-07-15,3 Stocks Pushing The Health Services Industry Higher
2016-07-15,Strong On High Relative Volume: Ironwood Pharmaceuticals (IRWD)
2016-06-07,Insider Trading Alert - WTS, IRWD And SALM Traded By Insiders
2016-06-06,Ironwood Pharmaceuticals To Present At Jefferies 2016 Healthcare Conference
2016-06-03,Ironwood Pharmaceuticals Closes U.S. Transaction With AstraZeneca For Lesinurad
2016-06-01,Ironwood Pharmaceuticals To Present At Goldman Sachs 37th Annual Global Healthcare Conference
2016-05-23,IRWD July 15th Options Begin Trading
2016-05-18,Ironwood Pharmaceuticals To Present At 2016 UBS Global Healthcare Conference
2016-05-17,Ironwood Pharmaceuticals To Present Linaclotide Data At Digestive Disease Week® 2016
2016-05-09,Ironwood Pharmaceuticals Provides First Quarter 2016 Investor Update
2016-05-03,Ironwood Pharmaceuticals To Present At Bank Of America Merrill Lynch 2016 Health Care Conference
2016-04-28,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Ironwood Pharmaceuticals, Inc. (IRWD)
2016-04-28,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Ironwood Pharmaceuticals, Inc. - IRWD
2016-04-27,Today's Dead Cat Bounce Stock: Ironwood Pharmaceuticals (IRWD)
2016-04-26,Ironwood Pharmaceuticals Investigated For Potential Violations Of Federal Securities Laws By Block & Leviton LLP
2016-04-26,Ironwood Pharmaceuticals Enters Into U.S. Licensing Agreement With AstraZeneca For Lesinurad
2016-04-25,Ironwood Pharmaceuticals To Host First Quarter 2016 Investor Update Call
2016-04-19,Synergy Pharmaceuticals Soars After FDA Filing Accepted
2016-04-07,Ironwood Pharmaceuticals Appoints Andrew Dreyfus To Board Of Directors
2016-04-05,Ironwood Pharmaceuticals Reports Top-Line Data From Exploratory Phase IIa Study Of IW-9179 In Diabetic Gastroparesis
2016-03-30,Ironwood Pharmaceuticals (IRWD) Is Today's Strong On High Volume Stock
2016-03-30,Ironwood Pharmaceuticals To Present Clinical And Preclinical Data On SGC Stimulators At Upcoming Scientific Conferences
2016-03-23,Ironwood Pharmaceuticals Initiates Phase IIb Clinical Trial Of IW-3718 In Refractory Gastroesophageal Reflux Disease
2016-03-09,Ironwood Pharmaceuticals To Present At Barclays Global Healthcare Conference
2016-03-01,Ironwood Pharmaceuticals To Present At Cowen And Company 36th Annual Health Care Conference
2016-02-29,Updated 2016 Direct-to-Consumer Awareness Campaign For LINZESS® (linaclotide)
2016-02-24,Ironwood Pharmaceuticals Announces Filing By Astellas Of New Drug Application In Japan With Linaclotide For The Treatment Of Adults With IBS-C
2016-02-19,Ironwood Pharmaceuticals (IRWD) Stock Gaining on Q4 Results
2016-02-18,Ironwood Pharmaceuticals Provides Fourth Quarter And Full Year 2015 Investor Update
2016-02-18,Ironwood Pharmaceuticals Progresses Vascular And Fibrotic Disease Platform With Positive Top-Line Phase Ia Data On Soluble Guanylate Cyclase Stimulator IW-1701
2016-02-17,Ironwood Pharmaceuticals To Present At 2016 RBC Capital Markets Global Healthcare Conference
2016-02-04,Ironwood Pharmaceuticals To Host Fourth Quarter And Full-Year 2015 Investor Update Call
2016-01-11,(Graphic: Business Wire)
2016-01-08,Trade-Ideas: Ironwood Pharmaceuticals (IRWD) Is Today's Strong On High Relative Volume Stock
2016-01-04,Ironwood Pharmaceuticals To Present At J.P. Morgan Healthcare Conference
2015-12-09,Insider Trading Alert - ANCX, IRWD And MPLX Traded By Insiders
2015-11-30,Astellas And Ironwood Report Positive Top-Line Data From Phase III IBS-C Trial Conducted In Japan
2015-11-30,Ironwood Reports Positive Top-Line Data From Phase II Trial Of Linaclotide In Adult Patients With Opioid-Induced Constipation
2015-11-24,First Week of January 2016 Options Trading For Ironwood Pharmaceuticals (IRWD)
2015-11-03,Ironwood Pharmaceuticals Provides Third Quarter 2015 Investor Update
2015-11-03,Ironwood Pharmaceuticals Initiates Clinical Studies Of Soluble Guanylate Cyclase Stimulators IW-1973 And IW-1701
2015-11-02,Ironwood And Allergan Initiate Phase IIb Clinical Trial Of Linaclotide Colonic Release In Adults With Irritable Bowel Syndrome With Constipation
2015-10-30,'Mad Money' Lightning Round: I'm Not Tempted by Vonage, I Want Verizon
2015-10-29,Jim Cramer's 'Mad Money' Recap: Using What Went Wrong to Find Buying Opportunities
2015-10-27,Allergan Acquires Rights To Ironwood's CONSTELLA® (Linaclotide) From Almirall In More Than 40 Countries
2015-10-21,First Week of December 18th Options Trading For Ironwood Pharmaceuticals (IRWD)
2015-10-19,Ironwood Highlights Refractory GERD And Constipation Research At The American College Of Gastroenterology 2015 Annual Scientific Meeting
2015-10-14,Ironwood Pharmaceuticals To Host Third Quarter 2015 Investor Update Call
2015-10-13,Ironwood Reports Positive Top-Line Results From Phase III Trial Of 72 Mcg Linaclotide In Adults With Chronic Idiopathic Constipation
2015-09-29,Ironwood Pharmaceuticals (IRWD) Flagged As Strong On High Volume
2015-09-10,Ironwood Pharmaceuticals To Present At Morgan Stanley Global Healthcare Conference
2015-08-28,First Week of IRWD October 16th Options Trading
2015-08-05,Ironwood Pharmaceuticals Provides Second Quarter 2015 Investor Update
2015-08-05,Ironwood And Allergan Enter Agreement To Co-Promote VIBERZI For Irritable Bowel Syndrome With Diarrhea (IBS-D) In The U.S.
2015-07-22,Ironwood Progresses SGC Stimulator Platform With Positive Top-Line Phase I Data On IW-1973
2015-07-15,Ironwood Pharmaceuticals To Host Second Quarter 2015 Investor Update Call
2015-07-08,AstraZeneca And Ironwood Report Positive Top-Line Data From Phase III IBS-C Trial Designed To Support Linaclotide Approval In China
2015-06-23,First Week Of IRWD February 2016 Options Trading
2015-06-17,Synergy Rises on Positive Results from Constipation Drug Study
2015-06-17,Synergy A Potential Takeover Target After Constipation Drug Data
2015-06-17,Ironwood Pharmaceuticals (IRWD): Heavy Pre-Market Activity
2015-06-10,Trade-Ideas: Ironwood Pharmaceuticals (IRWD) Is Today's Pre-Market Mover With Heavy Volume Stock
2015-06-10,Ironwood Pharmaceuticals Prices $300 Million Of Convertible Senior Notes
2015-06-08,Ironwood Pharmaceuticals Announces Proposed Offering Of $300 Million Of Convertible Senior Notes
2015-06-04,Ironwood Pharmaceuticals To Present At Goldman Sachs 36th Annual Global Healthcare Conference
2015-05-20,Today's Weak On High Volume Stock: Ironwood Pharmaceuticals (IRWD)
2015-05-19,First Week Of July 17th Options Trading For Ironwood Pharmaceuticals (IRWD)
2015-05-13,Ironwood Presents Gastrointestinal Disease Research At Digestive Disease Week® 2015
2015-05-08,IBS In America: American Gastroenterological Association Initiates Comprehensive Survey Of Patients And Physicians
2015-05-07,Ironwood Pharmaceuticals To Present At Bank Of America Merrill Lynch 2015 Health Care Conference
2015-05-05,Ironwood Pharmaceuticals Provides First Quarter 2015 Investor Update
2015-04-16,Ironwood Pharmaceuticals Appoints Lawrence Olanoff, M.D., Ph.D., To Board Of Directors
2015-04-15,Ironwood Pharmaceuticals To Host First Quarter 2015 Investor Update Call
2015-03-23,Insider Trading Alert - LCUT, IRWD And NLY Traded By Insiders
2015-03-09,Exact Sciences And Ironwood Pharmaceuticals Enter Co-Promotion Agreement For Cologuard®
2015-03-05,Ironwood Pharmaceuticals Initiates Phase I Clinical Study Of Sgc Stimulator IW-1973
2015-03-04,Ironwood Pharmaceuticals To Present At Barclays Global Healthcare Conference
2015-02-23,Ironwood Pharmaceuticals To Present At Cowen And Company 35th Annual Health Care Conference
2015-02-13,Weak On High Volume: Ironwood Pharmaceuticals (IRWD)
2015-02-12,Ironwood Pharmaceuticals Provides Fourth Quarter 2014 Investor Update
2015-02-04,Ironwood Reports Positive Top-Line Data From Exploratory Phase IIa Trial Of IW-3718 In Refractory Gastroesophageal Reflux Disease
2015-01-29,Ironwood Pharmaceuticals To Host Fourth Quarter 2014 Investor Update Call
2015-01-23,Trade-Ideas: Ironwood Pharmaceuticals (IRWD) Is Today's Strong On High Relative Volume Stock
2015-01-21,'Sell the News' ECB Reaction Would Be Best
2015-01-08,Interesting IRWD Put And Call Options For August 21st
2015-01-05,Ironwood Pharmaceuticals To Present At J.P. Morgan Healthcare Conference
2014-12-12,Updating a Small Speculative Play
2014-12-09,Ironwood Pharmaceuticals Initiates Phase IIa Clinical Study Of IW-9179 In Diabetic Gastroparesis
2014-11-20,Ironwood Earns $15 Million Milestone From Astellas Upon Initiation Of Enrollment In Linaclotide Phase III IBS-C Clinical Trial In Japan
2014-11-06,Ironwood Pharmaceuticals (IRWD) Stock Downgraded Today at Cantor Fitzgerald
2014-11-06,Analysts' Actions: American Electric, Cornerstone OnDemand, CST Brands
2014-11-05,Ironwood Pharmaceuticals To Present At Credit Suisse 2014 Healthcare Conference
2014-11-04,Ironwood Pharmaceuticals Initiates Phase III Trial Of 72 Mcg Linaclotide In Adult Patients With Chronic Idiopathic Constipation
2014-11-04,Ironwood Pharmaceuticals Provides Third Quarter 2014 Investor Update
2014-10-20,Ironwood Presents IW-9179 Phase IIa Data At American College Of Gastroenterology 2014 Annual Scientific Meeting
2014-10-16,Ironwood Pharmaceuticals Announces Initiation Of Phase II Trial Of Linaclotide In Adult Patients With Opioid-Induced Constipation
2014-10-14,Ironwood Pharmaceuticals To Host Third Quarter 2014 Investor Update Call
2014-10-09,Ironwood And Actavis To Present Linaclotide Data At The American College Of Gastroenterology 2014 Annual Scientific Meeting
2014-09-25,Bullish Two Hundred Day Moving Average Cross - IRWD
2014-09-04,Ironwood Pharmaceuticals (IRWD) Is Weak On High Volume Today
2014-09-03,Ironwood Pharmaceuticals To Present At Morgan Stanley Global Healthcare Conference
2014-09-02,Ironwood Appoints Two New Senior Executives To Support Continued Growth As A Leader In Gastroenterology
2014-08-06,Trade-Ideas: Ironwood Pharmaceuticals (IRWD) Is Today's "Dead Cat Bounce" Stock
2014-08-05,Why Ironwood Pharmaceuticals (IRWD) Stock Is Falling Today
2014-08-04,Ironwood Pharmaceuticals Provides Second Quarter 2014 Investor Update
2014-07-11,Short Interest In Ironwood Pharmaceuticals Declines 11.2%
2014-07-07,Ironwood Pharmaceuticals To Host Second Quarter 2014 Investor Update Call
2014-06-13,Use Options For a Chance To Buy IRWD at a 23% Discount
2014-06-05,Ironwood Pharmaceuticals To Present At Goldman Sachs Global Healthcare Conference
2014-06-04,Ironwood Pharmaceuticals Appoints Douglas Williams, Ph.D., To Board Of Directors
2014-06-02,Insider Trading Alert - TIF, CRM And IRWD Traded By Insiders
2014-05-20,First Week of July 19th Options Trading For Ironwood Pharmaceuticals (IRWD)
2014-05-15,Use Options For a Chance To Buy IRWD at a 15% Discount
2014-05-07,Ironwood Pharmaceuticals To Present At Bank Of America Merrill Lynch 2014 Healthcare Conference
2014-05-01,Ironwood And Forest To Present Linaclotide Data At Digestive Disease Week&#174; 2014
2014-04-29,Why Ironwood Pharmaceuticals (IRWD) Stock Is Soaring Today
2014-04-29,Ironwood Pharmaceuticals Provides First Quarter 2014 Investor Update
2014-04-10,CIC Fact Sheet
2014-04-08,Ironwood Pharmaceuticals To Host First Quarter 2014 Investor Update Call
2014-03-27,First Week of IRWD November 22nd Options Trading
2014-03-25,Notable Two Hundred Day Moving Average Cross - IRWD
2014-03-19,Use Options For a Chance To Buy IRWD at a 31% Discount
2014-03-18,Ironwood Pharmaceuticals Initiates Phase II Clinical Study Of IW-3718 In Refractory Gastroesophageal Reflux Disease
2014-02-24,Ironwood Pharmaceuticals To Present At Cowen And Company 34th Annual Health Care Conference
2014-02-14,Use Options For a Chance To Buy IRWD at a 16% Discount
2014-02-13,Ironwood Pharmaceuticals Announces Exercise Of Underwriters&#8217; Option In Public Offering Of Common Stock
2014-02-13,4 Stocks Breaking Out on Big Volume
2014-02-12,Ironwood Pharmaceuticals Appoints Julie McHugh To Board Of Directors
2014-02-11,Ironwood Pharmaceuticals Prices Public Offering Of Common Stock
2014-02-10,Ironwood Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2014-02-10,Ironwood Receives Notice Of Allowance For Methods Of Use Formulation Patent Expected To Extend LINZESS&#174; Patent Protection Through 2031
2014-02-07,Ironwood Pharmaceuticals To Present At Leerink Global Healthcare Conference
2014-02-07,Biotech Stock Mailbag: Furiex, La Jolla Pharma, Sarepta
2014-02-04,Furiex Pharma Diarrhea Drug Produces Solid Results in Pivotal Studies
2014-01-23,First Week of March 22nd Options Trading For Ironwood Pharmaceuticals (IRWD)
2014-01-21,Ironwood Pharmaceuticals Provides Fourth Quarter 2013 Investor Update
2014-01-17,Insider Trading Alert - IRWD, GMED, DST, RRC And GTN Traded By Insiders
2014-01-14,Insider Trading Alert - MU, APA, IRWD, IBKR And DDR Traded By Insiders
2014-01-14,Top Insider Trades: DDR IRWD DSCI ROYE
2014-01-13,4 Unusual-Volume Stocks in Breakout Territory
2014-01-08,Ironwood Pharmaceuticals Announces Alignment Of Workforce With Priority Growth Platforms
2014-01-07,Ironwood Pharmaceuticals To Host Fourth Quarter 2013 Investor Update Call
2014-01-06,Ironwood Pharmaceuticals To Present At J.P. Morgan Healthcare Conference
2013-12-12,Ironwood Pharmaceuticals Details Strategy To Establish Leading Gastrointestinal Therapeutics Company
2013-11-21,Ironwood Pharmaceuticals To Host Investor Day On December 12, 2013
2013-11-19,Interesting IRWD Put And Call Options For January 2014
2013-11-06,Ironwood Pharmaceuticals To Present At Credit Suisse 2013 Healthcare Conference
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-08,Could These 9 Drugs Gain FDA Approval in the Age of Trump?
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-02,7 Stocks Trending With Monster Volume
2017-03-01,Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2016 Financial Results And Provides Corporate Update
2017-02-28,5 Earnings Short-Squeeze Trade Ideas
2017-02-28,Intra-Cellular Therapies To Present At The Cowen And Company 37th Annual Health Care Conference
2017-02-22,Intra-Cellular Therapies Enters Oversold Territory
2017-02-22,Intra-Cellular Therapies To Host Fourth Quarter And Full Year 2016 Financial Results Conference Call And Webcast
2017-01-24,Relative Strength Alert For Intra-Cellular Therapies
2017-01-12,Short Interest In Intra-Cellular Therapies Makes 10.6% Move
2017-01-06,Noteworthy Friday Option Activity: ITCI, ACOR, SC
2017-01-04,Intra-Cellular Therapies To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-29,Commit To Purchase Intra-Cellular Therapies At $12.50, Earn 21.6% Annualized Using Options
2016-12-01,Intra-Cellular Therapies To Present At The 55th Annual Meeting Of The American College Of Neuropsychopharmacology
2016-11-23,Intra-Cellular Therapies To Participate At Upcoming Investor Conferences
2016-11-18,These 5 Stocks Are Ready to Break Out
2016-11-09,Intra-Cellular Therapies Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-11-02,Intra-Cellular Therapies To Host Third Quarter 2016 Financial Results Conference Call And Webcast
2016-10-31,Intra-Cellular Therapies Presents the ITI-007 Clinical Development Program In Schizophrenia At The CNS Summit 2016 Annual Conference
2016-09-29,Intra-Cellular Therapies (ITCI) Stock Tanks on Drug Failure, JMP Securities Downgrades
2016-09-29,Shares of Intra-Cellular Plummet in Thursday's Trading Session
2016-09-29,Intra-Cellular Therapies (ITCI) Alert: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation Of Intra-Cellular Therapies, Inc.; Investors Encouraged To Contact Firm
2016-09-29,Intra-Cellular Therapies (ITCI) Stock Plunges on Schizophrenia Drug Failure, Downgrade
2016-09-29,Analysts' Actions -- eBay, Fitbit, Texas Roadhouse and More
2016-09-29,Intra-Cellular Therapies Future Uncertain Following Schizophrenia Drug Study Failure
2016-09-28,Intra-Cellular Therapies Announces Top-Line Results From The Second Phase 3 Trial Of ITI-007 In Patients With Schizophrenia (Study '302)
2016-09-20,First Week of ITCI May 2017 Options Trading
2016-08-04,Intra-Cellular Therapies Reports Second Quarter 2016 Financial Results And Provides Corporate Update
2016-07-25,Intra-Cellular Therapies To Host Second Quarter 2016 Financial Results Conference Call And Webcast
2016-07-22,Rev's Forum: Beating the Bushes for Some Good Trade Ideas
2016-07-06,Intra-Cellular Therapies To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference
2016-06-30,Intra-Cellular Therapies Reports Completion Of Enrollment Of ITI-007-302 Phase 3 Clinical Trial For The Treatment Of Schizophrenia
2016-06-28,Intra-Cellular Therapies Announces Initiation Of ITI-007-201 Phase 3 Clinical Trial For The Treatment Of Agitation In Patients With Dementia, Including Alzheimer's Disease
2016-06-21,Interesting ITCI Put And Call Options For February 2017
2016-06-17,Intra-Cellular Therapies (ITCI): Today's Weak On High Volume Stock
2016-06-15,Intra-Cellular Therapies To Present At The JMP Securities Life Sciences Conference
2016-05-31,Intra-Cellular Therapies To Present At The Jefferies 2016 Healthcare Conference
2016-05-26,Intra-Cellular Therapies To Present At The American Society Of Clinical Psychopharmacology 2016 Annual Meeting
2016-05-18,Intra-Cellular Therapies Presents At The Annual Meetings Of The Society Of Biological Psychiatry And The American Psychiatric Association
2016-05-10,Intra-Cellular Therapies To Present At The American Psychiatric Association 169th Annual Meeting And The Society Of Biological Psychiatry 71st Annual Meeting
2016-05-05,Acadia Drug Approval May Entice Biogen, Teva as Buyers
2016-05-04,Intra-Cellular Therapies To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference
2016-05-03,'Mad Money' Lightning Round: I'm Buy, Buy, Buying Xerox
2016-05-02,Jim Cramer's 'Mad Money' Recap: Why Warren Buffett's Approach Beats Carl Icahn's
2016-04-28,Intra-Cellular Therapies Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-04-21,Intra-Cellular Therapies To Host First Quarter 2016 Financial Results Conference Call And Webcast
2016-04-06,Intra-Cellular Therapies Presents Additional ITI-007 Data At The 5th Biennial Schizophrenia International Research Society (SIRS) Conference
2016-04-04,Intra-Cellular Therapies To Present At The 15th Annual Needham Healthcare Conference
2016-03-30,Intra-Cellular Therapies Announces Upcoming Presentations At The 5th Biennial Schizophrenia International Research Society Conference
2016-03-18,Intra-Cellular Therapies (ITCI) Marked As A Dead Cat Bounce Stock
2016-03-04,Ratings Changes Today
2016-02-29,Intra-Cellular Therapies To Present At The Cowen And Company 36th Annual Health Care Conference
2016-02-26,Today's Dead Cat Bounce Stock Is Intra-Cellular Therapies (ITCI)
2016-02-25,Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2015 Financial Results And Provides Corporate Update
2016-02-18,Intra-Cellular Therapies To Host Fourth Quarter And Full-Year 2015 Financial Results Conference Call And Webcast
2016-02-16,Intra-Cellular Therapies To Present At The 2016 RBC Capital Markets' Healthcare Conference
2016-02-01,Intra-Cellular Therapies To Present At The Leerink Partners' 5th Annual Global Healthcare Conference
2015-12-23,Intra-Cellular Therapies Reports Initiation Of Patient Enrollment For ITI-007 Phase 3 Clinical Trials In Bipolar Depression
2015-12-21,Intra-Cellular Therapies To Present At The 34th Annual J.P. Morgan Healthcare Conference
2015-12-12,3 Rising Biotechs That Should Continue Their Upward Trends
2015-12-09,Intra-Cellular Therapies Presents Additional Efficacy And Safety Data From The Positive Phase 3 Clinical Trial Of ITI-007 For The Treatment Of Schizophrenia And From The Positron Emission Tomography Study
2015-12-08,Intra-Cellular Therapies (ITCI) Marked As A Dead Cat Bounce Stock
2015-12-07,Today's Perilous Reversal Stock: Intra-Cellular Therapies (ITCI)
2015-12-07,Intra-Cellular Therapies To Present At The 54th Annual Meeting Of The American College Of Neuropsychopharmacology
2015-12-01,Trade-Ideas: Intra-Cellular Therapies (ITCI) Is Today's "Dead Cat Bounce" Stock
2015-11-23,Intra-Cellular Therapies To Participate At Upcoming Investor Conferences
2015-11-11,Intra-Cellular Therapies (ITCI) In A Perilous Reversal
2015-11-11,Intra-Cellular Therapies To Present At Jefferies Autumn 2015 Global Healthcare Conference In London
2015-11-06,Intra-Cellular Therapies To Present At The CTAD 2015 Conference
2015-11-05,Intra-Cellular Therapies Reports Third Quarter 2015 Financial Results And Provides Corporate Update
2015-11-02,Today's Dead Cat Bounce Stock: Intra-Cellular Therapies (ITCI)
2015-10-29,Intra-Cellular Therapies To Host Third Quarter 2015 Financial Results Conference Call And Webcast
2015-10-09,Intra-Cellular Therapies To Present At The CNS Summit 2015 Conference
2015-10-07,Today's Dead Cat Bounce Stock: Intra-Cellular Therapies (ITCI)
2015-10-05,Stock To Watch: Intra-Cellular Therapies (ITCI) In Perilous Reversal
2015-09-28,Intra-Cellular Therapies Announces Closing Of $345 Million Public Offering Including Exercise Of Underwriters' Option To Purchase Additional Shares
2015-09-24,Intra-Cellular Therapies To Present At The Ladenburg Thalmann 2015 Healthcare Conference
2015-09-23,Intra-Cellular Therapies (ITCI) Stock Climbs After Pricing 6.9 Million Share Offering
2015-09-23,Intra-Cellular Therapies (ITCI) Showing Signs Of A Dead Cat Bounce Today
2015-09-22,Intra-Cellular Therapies Prices $300 Million Public Offering Of Common Stock
2015-09-21,Intra-Cellular Therapies Announces Completion Of Phase 1 Studies For ITI-214, A Phosphodiesterase Type 1 Inhibitor, And Assumes IND Sponsorship For ITI-214
2015-09-21,Intra-Cellular Therapies Announces Proposed Public Offering Of Common Stock
2015-09-21,Intra-Cellular Therapies (ITCI) Is Weak On High Volume Today
2015-09-18,Stock Strategy: Finding the Right Entry Point
2015-09-18,Intra-Cellular Therapies (ITCI) Highlighted As Today's Perilous Reversal Stock
2015-09-17,New Lifetime High Reached By Intra-Cellular Therapies (ITCI)
2015-09-16,Intra-Cellular Therapies (ITCI) Stock Spikes on Positive Schizophrenia Trial Data
2015-09-16,Intra-Cellular Surges on Optimistic Outlook for Schizophrenia Drug
2015-09-16,Heavy Early Morning Activity On Intra-Cellular Therapies (ITCI)
2015-09-16,Intra-Cellular Therapies Announces Positive Top-Line Results From The First Phase 3 Trial Of ITI-007 In Patients With Schizophrenia And Confirms The Unique Pharmacology Of ITI-007 In A Separate Positron Emission Tomography Study
2015-09-02,Intra-Cellular Therapies (ITCI) Weak On High Volume Today
2015-09-01,Intra-Cellular Therapies Announces Publication Of Positive Phase 2 Schizophrenia Study In The Journal Biological Psychiatry
2015-08-05,Intra-Cellular Therapies Reports Second Quarter 2015 Financial Results And Provides Corporate Update
2015-08-03,Intra-Cellular Therapies Expands Leadership Team
2015-07-31,Trade-Ideas: Intra-Cellular Therapies (ITCI) Is Today's Strong On High Relative Volume Stock
2015-07-31,Intra-Cellular Keeps Investors in Dark About Schizophrenia Drug Study
2015-07-30,Intra-Cellular Therapies To Host Second Quarter 2015 Financial Results Conference Call And Webcast
2015-07-23,Intra-Cellular Therapies (ITCI) Is Today's Perilous Reversal Stock
2015-07-23,First Week Of September 18th Options Trading For Intra-Cellular Therapies (ITCI)
2015-07-22,Intra-Cellular Therapies Announces Phase 3 Clinical Development Program For The Treatment Of Depressive Episodes Associated With Bipolar Disorder (Bipolar Depression)
2015-06-23,Intra-Cellular Therapies (ITCI) Is Strong On High Volume Today
2015-06-23,Intra-Cellular Therapies Reports Initiation Of Randomization For ITI-007-302 Phase 3 Trial In Schizophrenia
2015-06-22,New Lifetime High Reached: Intra-Cellular Therapies (ITCI)
2015-06-17,Intra-Cellular Therapies To Present At The JMP Securities Life Sciences Conference 2015
2015-06-15,Intra-Cellular Therapies Reports Completion Of Enrollment With 450 Patients Randomized In The ITI-007-301 Phase 3 Clinical Trial For The Treatment Of Schizophrenia
2015-05-29,Short Interest In Intra-Cellular Therapies Moves 20% Higher
2015-05-26,Intra-Cellular Therapies To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-18,Intra-Cellular Therapies Announces Further Analyses Of The Phase 2 Clinical Trial Of ITI-007 In Schizophrenia At The 168th Annual Meeting Of The American Psychiatric Association
2015-05-11,Intra-Cellular Therapies To Present At The 2015 UBS Global Healthcare Conference
2015-05-07,Intra-Cellular Therapies To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference
2015-05-06,Short Interest In Intra-Cellular Therapies Jumps 44.4%
2015-04-30,Intra-Cellular Therapies Reports First Quarter 2015 Financial Results And Provides Corporate Update
2015-04-24,Intra-Cellular Therapies To Host First Quarter 2015 Financial Results Conference Call And Webcast
2015-04-14,Commit To Purchase Intra-Cellular Therapies At $20, Earn 46.5% Annualized Using Options
2015-03-31,Intra-Cellular Therapies Presents The ITI-007 Clinical Development Program At The 15th International Congress On Schizophrenia Research
2015-03-25,Intra-Cellular Therapies To Present At The 15th International Congress On Schizophrenia Research
2015-03-13,Ratings Changes Today
2015-03-12,Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2014 Financial Results And Provides Corporate Update
2015-03-11,Intra-Cellular Therapies Announces Closing Of $130 Million Public Offering Including Exercise Of Underwriters' Option To Purchase Additional Shares
2015-03-05,Intra-Cellular Therapies Prices $114 Million Public Offering Of Common Stock
2015-03-04,Intra-Cellular Therapies Announces Proposed Public Offering Of Common Stock
2015-02-23,Intra-Cellular Therapies To Present At The Cowen And Company 35th Annual Healthcare Conference
2015-02-17,Intra-Cellular Therapies To Present At The 2015 RBC Capital Markets' Healthcare Conference
2015-02-02,Intra-Cellular Therapies To Present At The Leerink Global Healthcare Conference
2015-01-12,Intra-Cellular Therapies To Present At The 33rd Annual J.P. Morgan Healthcare Conference
2014-11-25,Intra-Cellular Therapies Announces Enrollment Of First Patient In Phase 3 Trial Of ITI-007 For The Treatment Of Schizophrenia
2014-11-21,Intra-Cellular Therapies Announces Additional Results From Phase I/II Clinical Trial For ITI-007 In Healthy Geriatric Subjects And Patients With Dementia
2014-11-03,Intra-Cellular Therapies Reports Third Quarter 2014 Financial Results And Provides Corporate Update
2014-11-03,Intra-Cellular Therapies And Takeda Announce Mutual Termination Of Collaboration To Develop Phosphodiesterase (PDE1) Inhibitors For CNS Disorders
2014-10-27,Intra-Cellular Therapies To Host Conference Call On Monday, November 3, At 8:30 Am Eastern Time, On Third Quarter 2014 Financial Results
2014-10-13,Intra-Cellular Therapies Announces Topline Safety Results From Phase I/II Clinical Trial For ITI-007 In Healthy Geriatric Subjects And Patients With Dementia
2014-10-06,Intra-Cellular Therapies To Present Results From Phase I/II Clinical Trial For ITI-007 In Healthy Geriatric Subjects And Patients With Dementia At The American Neurological Association 139th Annual Meeting
2014-08-25,Standard & Poor's Raises Alexandria's Credit Outlook To Positive
2014-08-12,Intra-Cellular Therapies Reports Financial Results For Second Quarter Ended June 30, 2014
2014-08-05,Intra-Cellular Therapies To Host Conference Call On Tuesday, August 12, At 8:30 Am Eastern Time, On Second Quarter 2014 Financial Results
2014-07-31,Intra-Cellular Therapies Announces The Appointment Of Michael Halstead As Senior Vice President And General Counsel
,
2017-03-16,Inotek Pharmaceuticals Corporation Reports Fiscal Year 2016 Financial Results And Operational Highlights
2017-03-06,INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed A Class Action Lawsuit Against Inotek Pharmaceuticals Corporation And A Lead Plaintiff Deadline Of March 7, 2017 - ITEK
2017-02-27,Inotek Pharmaceuticals Announces Participation At Upcoming Investor Conferences
2017-02-24,URGENT: Monteverde & Associates PC Invites Inotek Pharmaceuticals Corporation Shareholders With Losses To Contact The Firm Immediately - ITEK
2017-02-24,Inotek Pharmaceuticals Announces Poster Presentations On Trabodenoson At The American Glaucoma Society 2017 Annual Meeting
2017-02-22,INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed A Class Action Lawsuit Against Inotek Pharmaceuticals Corporation And A Lead Plaintiff Deadline Of March 7, 2017
2017-02-17,ITEK SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Inotek Pharmaceuticals Corporation And A Lead Plaintiff Deadline Of March 7, 2017
2017-02-14,Bragar Eagel & Squire, P.C. Reminds Investors That A Class Action Lawsuit Has Been Filed Against Inotek Pharmaceuticals Corporation (ITEK) And Encourages Investors With Losses To Contact The Firm
2017-02-13,ITEK INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Inotek Pharmaceuticals Corporation And A Lead Plaintiff Deadline Of March 7, 2017
2017-02-10,Inotek Pharmaceuticals To Present At The BIO CEO And Investor Conference
2017-02-06,Bragar Eagel & Squire, P.C. Announces That A Class Action Lawsuit Has Been Filed Against Inotek Pharmaceuticals Corporation (ITEK) And Encourages Investors To Contact The Firm
2017-02-06,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed A Class Action Lawsuit Against Inotek Pharmaceuticals Corporation And A Lead Plaintiff Deadline Of March 7, 2017
2017-02-02,ITEK SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving Inotek Pharmaceuticals Corporation And A Lead Plaintiff Deadline Of March 7, 2017
2017-02-02,SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Inotek Pharmaceuticals Corporation To Contact The Firm Before Lead Plaintiff Deadline
2017-01-20,Johnson & Weaver, LLP Initiates Investigations Of Rent-A-Center, Inc., KalVista Pharmaceuticals, Inc., NovoCure Limited And Inotek Pharmaceuticals Corp.
2017-01-18,Lifshitz & Miller Law Firm Announces Investigation Of DaVita Inc., First NBC Bank Holdings Company, Fresenius Medical Care AG & Co. KGAA, Inotek Pharmaceuticals Corporation, Natural Health Trends Corp., NeoPhotonics Corporation, NewLink Genetics Corporation And PayPal Holdings, Inc.
2017-01-12,These 5 Stocks Under $10 Could Explode Higher Soon
2017-01-10,INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Inotek Pharmaceuticals Corporation And Encourages Investors With Losses To Contact The Firm
2017-01-10,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against Inotek Pharmaceuticals Corporation (ITEK) & Lead Plaintiff Deadline: March 7, 2017
2017-01-09,IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Inotek Pharmaceuticals Corporation And Encourages Investors With Losses To Contact The Firm
2017-01-04,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of Inotek Pharmaceuticals Corporation
2017-01-03,Inotek Pharma Shares Plummet Following Negative Glaucoma Trial Results
2017-01-03,Inotek Pharma Glaucoma Drug Suffers Study Setback at Start of New Year
2017-01-03,Inotek Announces Top-line Results For MATrX-1, First Phase 3 Trial Of Trabodenoson For Glaucoma
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2016-11-28,Inotek Pharmaceuticals Stock Sees Short Interest Fall 22%
2016-11-22,Oversold Conditions For Inotek Pharmaceuticals (ITEK)
2016-11-10,Inotek Pharmaceuticals Announces Participation At Upcoming Investor Conferences
2016-11-09,Inotek Pharmaceuticals Corporation Reports Third Quarter 2016 Financial Results And Operational Highlights
2016-10-13,Inotek Pharmaceuticals Stock Sees Short Interest Move 20% Higher
2016-10-07,Inotek Pharmaceuticals To Present At The 2016 Ophthalmology Innovation Summit
2016-09-30,Commit To Buy Inotek Pharmaceuticals Corp At $7.50, Earn 41.3% Annualized Using Options
2016-09-29,Inotek Pharmaceuticals Appoints Timothy Barberich To Board Of Directors
2016-09-27,Inotek Pharmaceuticals Stock Sees Short Interest Move 13% Lower
2016-09-15,7 Stocks Under $10 Making Big Moves Higher
2016-09-13,Inotek Pharmaceuticals Stock Sees Short Interest Jump 17.2%
2016-09-09,Inotek Pharmaceuticals Becomes Oversold (ITEK)
2016-09-06,Inotek Pharmaceuticals Announces Participation At Upcoming Investor Conferences
2016-08-24,Inotek Pharmaceuticals Announces The Completion Of The Recruitment Phase Of MATrX-1, The First Phase 3 Clinical Trial Of Trabodenoson For Glaucoma
2016-08-18,Inotek Pharmaceuticals Appoints Patrick Machado, JD, To Board Of Directors
2016-08-10,Inotek Pharmaceuticals Corporation Reports Second Quarter 2016 Financial Results And Operational Highlights
2016-08-02,Notable Tuesday Option Activity: ITEK, WEB, FIT
2016-08-02,Inotek Pharmaceuticals Announces Pricing Of $50.0 Million Of 5.75% Convertible Senior Notes Due 2021
2016-08-01,Inotek Pharmaceuticals Announces Proposed Public Offering Of $50 Million Of Convertible Senior Notes Due 2021
2016-07-22,Inotek Pharmaceuticals Expands Intellectual Property Portfolio With Combination Patent
2016-07-12,Inotek Pharmaceuticals Initiates Phase 2 Dose-ranging Trial Of A Fixed-Dose Combination Of Trabodenoson, A Novel Treatment For Glaucoma, And Latanoprost
2016-07-08,Inotek Pharmaceuticals To Present At Upcoming Investor Conferences
2016-06-16,Inotek Pharmaceuticals Announces Participation In Fireside Chat At JMP Securities 2016 Life Sciences Conference
2016-06-15,Beleaguered Valeant Appoints Lead Independent Director
2016-06-13,RSI Alert: Inotek Pharmaceuticals (ITEK) Now Oversold
2016-05-26,InVentiv Health Elects David Southwell To Company's Board Of Directors
2016-05-11,Inotek Pharmaceuticals Corporation Reports First Quarter 2016 Financial Results And Operational Highlights
2016-04-29,Government Probes for Valeant; New Board Members Put Forth
2016-04-26,Inotek Pharmaceuticals Announces Poster Presentations On Trabodenoson At The ARVO 2016 Annual Meeting
2016-04-21,Inotek Pharmaceuticals Corporation Announces Publication Of Phase 1 Data For Trabodenoson In Healthy Adult Volunteers In The Journal Of Ocular Pharmacology And Therapeutics
2016-04-11,Inotek Pharmaceuticals Announces The Journal Of Ocular Pharmacology And Therapeutics Has Published Its Phase 2 Data For Trabodenoson In Patients With Glaucoma And Ocular Hypertension
2016-04-04,Inotek Pharmaceuticals Announces Changes To Board Of Directors
2016-03-23,Inotek Pharmaceuticals Corporation Reports Fiscal Year 2015 Financial Results And Operational Highlights
2016-03-20,8 Biotech Stocks Under $10 Making Big Moves Higher
2016-03-14,Inotek Pharmaceuticals To Present At GTCbio's 8th Ocular Diseases And Drug Discovery Conference
2016-03-09,Inotek Pharmaceuticals Strengthens Patent Estate For Lead Product Candidate Trabodenoson
2016-02-29,Inotek Pharmaceuticals To Present At Cowen And Company's 36th Annual Health Care Conference
2016-02-24,Inotek Pharmaceuticals Announces Poster Presentation At The American Glaucoma Society's 2016 Annual Meeting
2016-02-05,Inotek Pharmaceuticals is Now Oversold (ITEK)
2016-02-01,Inotek Pharmaceuticals Announces Participation In Ophthalmology Panel At 18th Annual BIO CEO & Investor Conference On February 8th
2016-01-28,Inotek Pharmaceuticals To Present At Glaucoma 360 New Horizons Forum
2016-01-12,Inotek Pharmaceuticals Appoints Carsten Boess To Board Of Directors
2015-12-16,Inotek To Webcast First Research And Development Day
2015-12-11,Buy These 5 Stocks Now to Catch the Breakouts
2015-11-25,Inotek To Host First Research And Development Day In New York City On December 17th, 2015
2015-11-24,Inotek Pharmaceuticals To Present At The Piper Jaffray 27th Annual Healthcare Conference
2015-11-12,Inotek Pharmaceuticals Corporation Reports Third Quarter 2015 Financial Results And Operational Highlights
2015-11-05,Inotek Pharmaceuticals To Present At The 2015 Ophthalmology Innovation Summit
2015-10-30,5 Stocks Ready to Break Out Higher
2015-10-16,Inotek Pharmaceuticals Initiates Dosing Of MATRx-1, The First Pivotal Phase 3 Clinical Trial Of Trabodenoson, A Novel Treatment For Glaucoma
2015-10-13,Inotek Pharmaceuticals Appoints Gary M. Phillips, MD, MBA, To Board Of Directors
2015-08-18,Inotek Pharmaceuticals Corporation Announces Closing Of $79.2 Million Public Offering Including Exercise In Full Of Underwriters' Option To Purchase Additional Shares
2015-08-12,Inotek Pharmaceuticals Corporation Announces Pricing Of $68.9 Million Public Offering
2015-08-06,Inotek Pharmaceuticals Corporation Reports Second Quarter 2015 Financial Results And Operational Highlights
2015-07-30,Inotek Pharmaceuticals Announces Conversion Of $21 Million Principal Amount Of 5.0% Convertible Senior Notes Due 2020
2015-07-27,4 Stocks Spiking on Unusual Volume
2015-07-24,Cramer: Biogen's Horseman May Have Fallen Off, But These 3 Are Better
2015-07-24,Cramer: Biogen's Horseman May Have Fallen Off, I Like Others More
2015-07-23,Market News: 3M, Caterpillar, Inotek Pharmaceuticals
2015-07-23,Inotek Pharmaceuticals Announces Positive End-of-Phase 2 Meeting With FDA And Phase 3 Development Strategy For Trabodenoson, A Novel Treatment For Glaucoma
2015-07-22,Inotek Pharmaceuticals Appoints Dr. Cadmus Collins Rich As Vice President, Medical Affairs And Clinical Development
2015-07-21,Inotek Pharmaceuticals Appoints Richard N. Spivey PharmD, Ph.D. To Board Of Directors
2015-07-20,Inotek Pharmaceuticals Corporation Appoints Claudine Prowse, Ph.D. As Vice President, Strategy And Investor Relations Officer
2015-05-15,Inotek Pharmaceuticals Corporation Reports First Quarter 2015 Operational And Financial Results
2015-04-01,Inotek Pharmaceuticals Corporation Reports 2014 Financial Results
2015-02-18,Inotek Pharmaceuticals Corporation Announces Pricing Of Initial Public Offering Of 6,667,000 Shares Of Common Stock And 5.0% Convertible Senior Notes Due 2020
,
,
2017-03-21,Commit To Purchase Keryx Biopharmaceuticals At $3, Earn 20% Using Options
2017-03-20,Keryx Announces The Largest Medicare Part D Plan Sponsor Added Auryxia® To Its Medicare Part D Plan Formularies
2017-03-08,Keryx Biopharmaceuticals Announces U.S. FDA Filing Acceptance Of Supplemental New Drug Application For Auryxia® (ferric Citrate) Tablets
2017-03-07,SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Keryx Biopharmaceuticals, Inc. For Potential Breaches Of Fiduciary Duty By Its Board Of Directors
2017-03-01,Keryx Biopharmaceuticals Announces Fourth Quarter And Full Year 2016 Financial Results
2017-02-23,Keryx Biopharmaceuticals To Webcast Its Presentations At Two Investor Conferences In March 2017
2017-02-16,Keryx Biopharmaceuticals To Host Conference Call Of Fourth Quarter And Full Year 2016 Financial Results On Wednesday, March 1, 2017
2017-02-08,Keryx Biopharmaceuticals To Webcast Its Presentation At RBC Capital Markets' 2017 Global Healthcare Conference On February 22, 2017
2017-02-06,Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird
2017-01-24,Keryx Biopharmaceuticals is Now Oversold (KERX)
2017-01-12,Keryx Biopharmaceuticals Announces Publication Of Auryxia® (ferric Citrate) Phase 3 Trial Results For Iron Deficiency Anemia (IDA) In Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) In Journal Of The American Society Of Nephrology
2017-01-08,Keryx Biopharmaceuticals Announces Recent Business Progress And Reviews Corporate Strategy At 35th Annual J.P. Morgan Healthcare Conference
2016-12-22,Keryx Biopharmaceuticals To Webcast Its Presentation At J.P. Morgan's 35th Annual Healthcare Conference On January 11, 2017
2016-12-20,First Week Of KERX February 2017 Options Trading
2016-11-18,Keryx Biopharmaceuticals Announces Case Study Data Of Auryxia® Presented At ASN's Kidney Week
2016-11-17,Keryx Biopharmaceuticals Announces Multiple Scientific Presentations Of Phase 3 Trial Results Of Ferric Citrate For Iron Deficiency Anemia (IDA) In Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)
2016-11-14,January 2019 Options Now Available For Keryx Biopharmaceuticals (KERX)
2016-11-09,Keryx Biopharmaceuticals Announces U.S. FDA Approval Of Second Contract Manufacturer For Auryxia® (ferric Citrate)
2016-11-09,Keryx Biopharmaceuticals Announces Third Quarter 2016 Financial Results And Provides Corporate Update
2016-11-03,Keryx Biopharmaceuticals To Webcast Its Presentation At Stifel's 2016 Healthcare Conference On November 15
2016-11-01,Keryx Biopharmaceuticals To Host Conference Call Of Third Quarter 2016 Financial Results On Wednesday, November 9, 2016
2016-10-14,Keryx Biopharmaceuticals Announces Presentations Of Data At The American Society Of Nephrology Kidney Week 2016 Annual Meeting
2016-10-12,Humana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday
2016-09-30,KERYX 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General And Kahn Swick & Foti, LLC Remind Investors Of Deadline In Class Action Lawsuit Against Keryx Biopharmaceuticals Inc. - KERX
2016-09-30,UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders Of Keryx Biopharmaceuticals, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of October 3, 2016 - KERX
2016-09-27,October 3rd Deadline Alert: GPM Reminds Investors Of The Upcoming Deadline In The Class Action Lawsuit Against Keryx Pharmaceuticals, Inc. And Announces Expanded Class Period
2016-09-22,KERX Crosses Above Key Moving Average Level
2016-09-21,Keryx Biopharmaceuticals To Webcast Its Presentation At Ladenburg Thalmann's 2016 Healthcare Conference
2016-09-19,INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Keryx Biopharmaceuticals, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of October 3, 2016
2016-09-16,DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Keryx Biopharmaceuticals, Inc. Of Upcoming Deadline
2016-09-15,KERX SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Keryx Biopharmaceuticals, Inc. And A Lead Plaintiff Deadline Of October 3, 2016
2016-09-09,KERX INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Keryx Biopharmaceuticals, Inc. And A Lead Plaintiff Deadline Of October 3, 2016
2016-09-08,INVESTOR ALERT: Rosen Law Firm Reminds Keryx Biopharmaceuticals Inc. Investors Of Important October 3 Deadline In Class Action - KERX
2016-09-07,Robbins Geller Rudman & Dowd LLP Updates Investors Regarding Securities Class Action Suit Against Keryx Biopharmaceuticals, Inc. And Lead Plaintiff Opportunity
2016-09-06,Brower Piven Alerts Shareholders Of Upcoming Deadline In Class Action Lawsuit And Encourages Those With Losses From Investment In Keryx Pharmaceuticals, Inc. To Contact The Firm
2016-09-06,Lifshitz & Miller Law Firm Announces Investigation of BBX Capital Corporation, Concordia International Corp., Corrections Corporation of America, Epiq Systems, Inc., Goldcorp Inc., Keryx Biopharmaceuticals, Inc., Northern Oil and Gas, Inc., and Post Properties, Inc.
2016-09-06,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Keryx Biopharmaceuticals, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of October 3, 2016
2016-09-01,Keryx Biopharmaceuticals To Present At Two Upcoming Investor Healthcare Conferences
2016-08-31,KERX SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Keryx Biopharmaceuticals, Inc. And A Lead Plaintiff Deadline Of October 3, 2016
2016-08-30,Keryx Biopharmaceuticals Becomes Oversold (KERX)
2016-08-26,KERYX SHAREHOLDER ALERT By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Keryx Biopharmaceuticals Inc. - KERX
2016-08-26,Keryx Biopharmaceuticals, Inc. Sued By Block & Leviton For Violations Of The Federal Securities Laws
2016-08-18,5 Breakout Stocks Under $10 Set to Soar
2016-08-12,KERYX SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Keryx Biopharmaceuticals Inc. - KERX
2016-08-12,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Keryx Biopharmaceuticals, Inc. Of Class Action Lawsuit And Upcoming Deadline - KERX
2016-08-12,SHAREHOLDER ALERT: Rosen Law Firm Reminds Keryx Biopharmaceuticals Inc. Investors Of Important Deadline In Class Action - KERX
2016-08-11,Cohen Milstein Sellers & Toll PLLC Announces The Investigation Of Keryx Biopharmaceuticals, Inc.
2016-08-11,INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Keryx Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2016-08-11,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against Keryx Biopharmaceuticals Inc. (KERX) And Lead Plaintiff Deadline: October 3, 2016
2016-08-10,Bragar Eagel & Squire, P.C. Announces That A Class Action Lawsuit Has Been Filed Against Keryx Biopharmaceuticals, Inc. (KERX) And Encourages Investors To Contact The Firm
2016-08-09,Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Keryx Biopharmaceuticals Inc.
2016-08-09,Block & Leviton LLP Announces The Filing Of A Class Action Lawsuit Against Keryx Biopharmaceuticals Inc. For Violations Of The Federal Securities Laws
2016-08-08,Today's Perilous Reversal Stock: Keryx Biopharmaceuticals (KERX)
2016-08-04,Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Keryx Biopharmaceuticals, Inc.
2016-08-03,IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Keryx Biopharmaceuticals Inc. And Encourages Investors With Losses To Contact The Firm
2016-08-03,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Keryx Biopharmaceuticals Inc.
2016-08-03,Insider Trading Alert - CFFI, KERX And INCY Traded By Insiders
2016-08-03,Keryx Biopharmaceuticals (KERX) Marked As A Dead Cat Bounce Stock
2016-08-02,SHAREHOLDER NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit Against Keryx Biopharmaceuticals Inc. And Encourages Investors With Losses To Contact The Firm
2016-08-02,Keryx Biopharmaceuticals (KERX) Stock Continues to Fall on Disrupted Production
2016-08-02,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Keryx Biopharmaceuticals Inc. - KERX
2016-08-02,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Keryx Biopharmaceuticals Inc. (KERX)
2016-08-02,EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Keryx Biopharmaceuticals Inc.
2016-08-02,IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces An Investigation Of Keryx Biopharmaceuticals Inc. And Advises Investors With Losses To Contact The Firm
2016-08-02,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of Keryx Biopharmaceuticals, Inc.
2016-08-02,Keryx Biopharmaceuticals Inc. Investigated For Securities Fraud By Block & Leviton After Keryx Halts The Distribution Of Auryxia And Withdraws Its Full-Year Financial Forecast
2016-08-02,Wolf Popper LLP Announces Investigation Of Fraud Claims On Behalf Of Investors In Keryx Biopharmaceuticals, Inc.
2016-08-01,Noteworthy Monday Option Activity: KERX, DATA, GDDY
2016-08-01,Oversold Conditions For Keryx Biopharmaceuticals (KERX)
2016-08-01,3 Stocks Underperforming Today In The Drugs Industry
2016-08-01,Bullish and Bearish Reversals for the Week
2016-08-01,Why Keryx Biopharmaceuticals (KERX) Stock Is Plummeting Today
2016-08-01,Keryx Biopharmaceuticals Announces Interruption In Supply Of Auryxia® (ferric Citrate) And Second Quarter 2016 Financial Results
2016-07-29,Keryx Biopharmaceuticals To Host Conference Call Of Second Quarter 2016 Financial Results On Monday, August 1, 2016
2016-07-14,Kamich's 10 Stocks Under $10
2016-07-13,Short Interest In Keryx Biopharmaceuticals Falls 12.4%
2016-06-30,5 Hot Stocks to Watch Right Now
2016-06-30,Keryx Biopharmaceuticals (KERX) Is Weak On High Volume Today
2016-06-28,'Mad Money' Lightning Round: You're in Good Shape With Charter Communications
2016-06-27,Jim Cramer's 'Mad Money' Recap: 'Brexit' Is the Dumbest Financial Mistake Ever
2016-06-27,Douglas Jermasek To Join Keryx Biopharmaceuticals As Vice President, Marketing And Strategy
2016-06-21,Keryx Biopharmaceuticals Appoints Two New Board Members
2016-06-20,Keryx Biopharmaceuticals (KERX) Flagged As Strong On High Volume
2016-06-14,Keryx Biopharmaceuticals To Present At JMP's Life Science Conference On Tuesday, June 21
2016-06-03,First Week of KERX December 16th Options Trading
2016-06-02,Here's a Reason Why Keryx (KERX) Stock Is Spiking Today
2016-06-02,Keryx Biopharmaceuticals (KERX) Is Strong On High Volume Today
2016-04-28,Keryx Biopharmaceuticals Announces First Quarter 2016 Financial Results
2016-04-14,Keryx Biopharmaceuticals To Host Conference Call Of First Quarter 2016 Financial Results On Thursday, April 28, 2016
2016-04-03,Biotech Stock Mailbag: Intercept, Acadia, Keryx, Galena
2016-04-01,Keryx Biopharmaceuticals Announces New Appointments And Changes To Its Board Of Directors
2016-03-30,Keryx Biopharmaceuticals (KERX) In A Perilous Reversal
2016-03-29,Keryx Biopharmaceuticals (KERX) Stock Shoots Up on Positive Anemia Drug Results
2016-03-29,Keryx Biopharmaceuticals (KERX) Trading With Heavy Volume Before Market Open
2016-03-29,Keryx Biopharmaceuticals Announces Positive Top-line Results From Pivotal  Phase 3 Study Of Ferric Citrate For The Treatment Of Iron Deficiency Anemia  in Adults With Non-Dialysis Dependent Chronic Kidney Disease
2016-03-22,Interesting KERX Put And Call Options For May 20th
2016-03-01,Keryx Biopharmaceuticals To Present At Cowen And Company's 36th Annual Health Care Conference On Monday, March 7
2016-03-01,Rockwell Medical's 'Exceptional Year' of Nonexistent Dialysis Drug Sales
2016-02-25,Keryx Biopharmaceuticals Announces Fourth Quarter And Year-End 2015 Financial Results
2016-02-18,Keryx Biopharmaceuticals (KERX) Weak On High Volume Today
2016-02-11,Keryx Biopharmaceuticals To Host Conference Call On Fourth Quarter And Year End 2015 Financial Results On Thursday, February 25, 2016
2016-02-03,KERX: Insiders vs. Shorts
2016-01-20,Will Insiders Be Tempted To Buy More KERX At The New 52-Week Low?
2016-01-14,Short Interest Drops 12% For KERX
2016-01-12,Keryx Biopharmaceuticals (KERX) Is Strong On High Volume Today
2016-01-09,2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks
2016-01-07,Insider Trading Alert - KERX, QTWO And ENSG Traded By Insiders
2016-01-05,Commit To Buy Keryx Biopharmaceuticals At $3, Earn 30% Using Options
2016-01-01,Feuerstein's Heroes and Zeroes of Biotech Investing in 2015
2015-12-31,Today's Dead Cat Bounce Stock: Keryx Biopharmaceuticals (KERX)
2015-12-22,Keryx Biopharmaceuticals To Present At The 34th Annual J.P. Morgan Healthcare Conference On Monday, January 11
2015-12-21,Trade-Ideas: Keryx Biopharmaceuticals (KERX) Is Today's "Perilous Reversal" Stock
2015-12-18,Keryx Biopharmaceuticals (KERX) Is Strong On High Volume Today
2015-12-10,Keryx Announces Appointment Of John P. Butler To Its Board Of Directors
2015-12-01,Keryx Biopharmaceuticals Announces Webcast Of Presentation At Oppenheimer's 26th Annual Healthcare Conference
2015-11-27,Trade-Ideas: Keryx Biopharmaceuticals (KERX) Is Today's Strong On High Relative Volume Stock
2015-11-13,Insider Trading Alert - ENOC, QTS And KERX Traded By Insiders
2015-11-06,Insider Trading Alert - JASN, HFWA And KERX Traded By Insiders
2015-11-03,Keryx Biopharmaceuticals Announces Participation At Two Upcoming Investor Conferences
2015-10-30,Perilous Reversal Watch: Keryx Biopharmaceuticals (KERX)
2015-10-29,Keryx Biopharmaceuticals Announces Third Quarter 2015 Financial Results
2015-10-21,Keryx Biopharmaceuticals (KERX) Is Today's Dead Cat Bounce Stock
2015-10-21,Keryx Biopharmaceuticals To Host Conference Call Of Third Quarter 2015 Financial Results On Thursday, October 29, 2015
2015-10-20,Trade-Ideas: Keryx Biopharmaceuticals (KERX) Is Today's "Perilous Reversal" Stock
2015-10-15,Keryx Biopharmaceuticals Announces $125 Million Private Placement Of Convertible Senior Notes With The Baupost Group, L.L.C.
2015-10-12,Keryx Biopharmaceuticals (KERX) Is Today's Perilous Reversal Stock
2015-10-06,Trade-Ideas: Keryx Biopharmaceuticals (KERX) Is Today's Strong On High Relative Volume Stock
2015-10-02,Trade-Ideas: Keryx Biopharmaceuticals (KERX) Is Today's "Dead Cat Bounce" Stock
2015-09-24,Keryx Biopharmaceuticals (KERX) Stock Jumps on European Regulatory Approval
2015-09-24,Keryx Receives European Approval For Fexeric(R) (ferric Citrate Coordination Complex) For The Treatment Of Hyperphosphatemia In Adults With Chronic Kidney Disease
2015-09-18,Biotech Stock Mailbag: Bristol, Exelixis, Lion Bio, GW Pharma
2015-09-09,Keryx Biopharmaceuticals Announces Participation At Upcoming Investor Conferences
2015-09-04,Battleground: Will This $5 Biotech Stock Go To $22 Or $1.50?
2015-08-28,5 Breakout Stocks to Trade for Big Gains
2015-08-25,Insider Trading Alert - WPX, MBI And KERX Traded By Insiders
2015-08-17,Insider Trading Alert - MBI, KERX And EGAS Traded By Insiders
2015-08-13,Insider Trading Alert - TAP, KERX And HUN Traded By Insiders
2015-08-10,Keryx Biopharmaceuticals (KERX) Highlighted As Weak On High Volume
2015-08-07,Biotech Stock Mailbag: Controversial Stocks Revisited
2015-08-06,KERX: Insiders vs. Shorts
2015-08-05,Keryx Biopharmaceuticals Announces Second Quarter 2015 Financial Results
2015-07-28,Keryx Biopharmaceuticals To Host Conference Call Of Second Quarter 2015 Financial Results On Wednesday, August 5, 2015
2015-07-27,Keryx Biopharmaceuticals Appoints Scott A. Holmes As Chief Financial Officer
2015-07-24,RSI Alert: Keryx Biopharmaceuticals (KERX) Now Oversold
2015-07-24,Keryx Receives CHMP Positive Opinion For Fexeric(R) (Ferric Citrate Coordination Complex) For The Treatment Of Hyperphosphatemia In Adults With Chronic Kidney Disease
2015-07-21,Interesting KERX Put And Call Options For March 2016
2015-07-16,Faruqi & Faruqi, LLP Is Investigating Keryx Biopharmaceuticals, Inc. (KERX) On Behalf Of Its Shareholders
2015-07-09,Insider Trading Alert - STFC, HRTG And KERX Traded By Insiders
2015-07-07,Blame Keryx Executives, Not Short Sellers, for Dismal Drug Launch, Sinking Stock
2015-07-02,Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point
2015-07-01,Keryx Biopharmaceuticals (KERX) Highlighted As Today's Perilous Reversal Stock
2015-06-24,Keryx Announces Two National Insurance Providers Added Auryxia(TM) To Their Medicare Part D Formularies
2015-06-23,First Week Of August 21st Options Trading For Keryx Biopharmaceuticals (KERX)
2015-06-16,Keryx Biopharmaceuticals To Present At The JMP Securities Life Sciences Conference 2015
2015-05-27,MKM Partners' 4 Health Care Stocks to Sell Before June
2015-05-12,CORRECTING And REPLACING -- Keryx Biopharmaceuticals To Present At Bank Of America Merrill Lynch 2015 Health Care Conference
2015-05-12,Keryx Biopharmaceuticals (KERX) Highlighted As Today's Perilous Reversal Stock
2015-05-11,Barbarian At The Gate: Keryx Biopharmaceuticals (KERX)
2015-05-07,KERX: Insiders Vs. Shorts
2015-05-05,Keryx Biopharmaceuticals To Present At Bank Of America Merrill Lynch 2015 Health Care Conference
2015-05-04,Keryx Biopharmaceuticals Announces First Quarter 2015 Financial Results
2015-04-30,Keryx Biopharmaceuticals Completes Transition Of CEO Role To Greg Madison
2015-04-27,Keryx Biopharmaceuticals, Inc. To Host Conference Call On First Quarter 2015 Financial Results
2015-04-23,Keryx Biopharmaceuticals Appoints John F. Neylan, MD, As Chief Medical Officer
2015-04-09,Insider Trading Alert - KCG, ALJ And KERX Traded By Insiders
2015-03-27,'Mad Money' Lightning Round: If You Want Hotels, You Want Marriott
2015-03-26,Jim Cramer's 'Mad Money' Recap: A So-So Victory for the Bulls
2015-03-18,Dyadic International Announces The Appointment Of Jack Kaye To Its Board Of Directors
2015-03-10,Keryx Biopharmaceuticals Announces Appointment Of Greg Madison To Its Board Of Directors
2015-03-04,Keryx Biopharmaceuticals Announces Publication Of Auryxia(TM) (ferric Citrate) Analysis In Journal Of The American Society Of Nephrology
2015-02-27,Keryx Announces Fourth Quarter And Year-End 2014 Financial Results
2015-02-25,Keryx Biopharmaceuticals Announces Participation At Upcoming Investor Conferences
2015-02-25,First Week Of April 17th Options Trading For Keryx Biopharmaceuticals (KERX)
2015-02-18,Keryx Biopharmaceuticals, Inc. To Host Conference Call On Fourth Quarter And Year End 2014 Financial Results
2015-02-13,Keryx Biopharmaceuticals (KERX) Is Today's Perilous Reversal Stock
2015-02-09,Keryx Biopharmaceuticals Is Now Oversold (KERX)
2015-02-09,Well-Fed Analysts Stay Mum on Keryx Biopharma's Slow Drug Launch
2015-01-23,First Week Of KERX September 18th Options Trading
2015-01-22,Heavy Volume And Pre-Market Movement For Keryx Biopharmaceuticals (KERX)
2015-01-21,Keryx Biopharmaceuticals, Inc. Announces Pricing Of $110 Million Public Offering Of Common Stock
2017-03-22,Regenxbio Leads Biotech Movers Ahead of Market's Open
2017-03-16,Kite Announces Appointment Of Renowned Cancer Researcher, Owen N. Witte, M.D., To Its Board Of Directors
2017-03-14,Kite Pharma Highlights Publication From The National Cancer Institute Demonstrating Durable Complete Remissions In Patients With Relapsed/Refractory Non-Hodgkin Lymphoma Following Low Dose Conditioning Chemotherapy And Anti-CD19 CAR T-Cell Therapy
2017-03-14,Rev's Forum: Don't Underestimate the Power of a Plodding Market
2017-03-13,Market Takes 'National Napping Day' Seriously
2017-03-13,Biotech Leads the Way Again Today
2017-03-13,Rev's Forum: Bulls Still Believe, but Negative Catalysts are Building
2017-03-10,Late Market Rally but No Bounce for Bulls
2017-03-09,Shark Bites: Market Needs a Bounce in Its Step
2017-03-09,Market Set Up for Oversold Bounce
2017-03-08,Watching Financials and Biotech in This Tepid Market
2017-03-08,Kite Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
2017-03-07,Inside the Head of a Trader: Tuesday Morning With James 'Rev Shark' Deporre
2017-03-07,Woe to Those Who Are Trapped When the Daily Pattern Is Broken
2017-03-06,Still Watching Price Action, but Playing Strong Defense
2017-03-06,Kite To Present At March 2017 Investor Conferences
2017-03-05,Richard L. Wang Named Chief Executive Officer Of Fosun Kite Biotechnology Co., Ltd., A Joint Venture To Lead Development Of Axicabtagene Ciloleucel And Other Engineered T-Cell Therapies For Treatment Of Cancers In China
2017-03-02,With Big Hopes for Cancer Drug, Kite Raising $350M
2017-03-02,Market Taking a Break, but Probably Not for Long
2017-03-02,Biotech Premarket Movers: Aurinia, Puma, PTC, Juno
2017-03-02,Kite Announces Pricing Of Public Offering Of Common Stock
2017-03-02,7 Stocks Trending With Monster Volume
2017-03-02,Kite Announces Commencement Of Public Offering Of Common Stock
2017-02-28,It Wasn't a Good Change, but at Least It Was a Change
2017-02-28,Kite Pharma CAR-T Therapy Shows Results in Lymphoma Patients
2017-02-28,Kite Pharma CAR-T Cancer Therapy Shows Strong, Durable Effect in Lymphoma Patients
2017-02-28,Kite Reports Fourth Quarter And Full Year 2016 Financial Results
2017-02-28,Kite Announces Positive Topline Primary Results Of Axicabtagene Ciloleucel From First Pivotal CAR-T Trial In Patients With Aggressive Non-Hodgkin Lymphoma
2017-02-27,Kite To Report Fourth Quarter And Full Year 2016 Financial Results On February 28, 2017
2017-02-07,Cellectis Gains FDA Nod to Test New Gene-Edited Cancer Treatment
2017-01-10,Biotech Premarket Movers: ILMN, NSTG, KITE
2017-01-10,Kite Pharma And Fosun Pharma Establish Joint Venture In China To Develop And Commercialize Autologous T-Cell Therapies To Treat Cancer
2017-01-09,Kite Pharma Establishes A Strategic Partnership With Daiichi Sankyo To Develop And Commercialize Axicabtagene Ciloleucel (KTE-C19) In Japan
2017-01-05,Kite Pharma Enhances Commercial Expertise With The Appointment Of Ian T. Clark To Its Board Of Directors
2017-01-05,What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017
2017-01-04,Kite Pharma To Present At The 35th Annual J.P. Morgan Healthcare Conference
2017-01-03,Kite Pharma Submits Investigational New Drug (IND) Application For KITE-718, An Investigational Next Generation T-Cell Receptor (TCR) Therapy Targeting Cancer Antigens MAGE A3 And MAGE A6
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2016-12-19,Kite Pharma Announces Successful Defense Of Roberts Patent And Intent To Appeal U.S. Patent And Trademark Office Decision On A Narrow Patent Focused On Select CD28 CAR-T Products
2016-12-14,The Worst Biopharma CEOs of 2016 Are ...
2016-12-13,Kite Pharma And Vitruvian Networks Enter Strategic Partnership To Develop Best-In-Class Logistics And Data Analytics Software For Engineered T-cell Therapies At Commercial Scale
2016-12-12,Kite Pharma Announces Publication Of T-Cell Therapy Targeting Mutant KRAS In Cancer By The National Cancer Institute (NCI) In New England Journal Of Medicine
2016-12-06,Kite Pharma Presents Results Of Multi-Center Pivotal ZUMA-1 Trial Of Axicabtagene Ciloleucel (KTE-C19) In Aggressive Non-Hodgkin Lymphoma As Late-Breaking Abstract At Annual Meeting Of American Society Of Hematology
2016-12-05,Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting
2016-12-05,Patient Deaths, Safety Concerns Cause Juno's CAR-T Pipeline to Skid Out
2016-12-04,Kite Pharma Reports 82 Percent Of Patients Achieved Complete Remission In Preliminary Analysis From Phase 1 ZUMA-3 And ZUMA-4 Trials Of KTE-C19 In Adult And Pediatric Patients With High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia
2016-12-01,Kite Pharma Appoints Jian Irish, PhD As Senior Vice President Of Supply Chain
2016-11-30,Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects
2016-11-28,Four Stocks Ready for Breakouts -- Check These Charts
2016-11-21,Kite Pharma To Present Interim Results From The ZUMA-1 Pivotal Trial Of KTE-C19 In A Late-Breaking Session At The 2016 American Society Of Hematology Annual Meeting
2016-11-17,Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!
2016-11-09,Kite Pharma Reports Third Quarter 2016 Financial Results
2016-11-09,'Mad Money' Lightning Round: Ollie's Bargain Outlet, Walmart Are Winners
2016-11-08,Jim Cramer's 'Mad Money' Recap: If This Election Hits Stocks, Here's What You Should Do
2016-11-03,Kite Pharma To Present KTE-C19 Data From Interim Analysis Of The ZUMA-1 Pivotal Trial In Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) And Transformed Follicular Lymphoma (TFL) At The 2016 American Society Hematology Annual Meeting
2016-11-02,Kite Pharma To Report Third Quarter 2016 Financial Results On November 9, 2016
2016-10-28,Kite Pharma To Present At November 2016 Investor Conferences
2016-10-19,Kite Pharma Details KTE-C19 Launch Preparedness And Near-Term, Next Generation CAR/TCR Product Candidates At Investor Day
2016-10-17,Trader's Daily Notebook: You Might Consider Selling Facebook
2016-10-13,Chris Nowers, Head Of Europe, Kite Pharma (Photo: Business Wire)
2016-10-11,Kite Pharma To Host Investor Day On October 18, 2016 Spotlighting An Industry-Leading CAR/TCR Pipeline, Next Generation Research And Development, And KTE-C19 Launch Readiness
2016-10-07,Kite Pharma Presents 12-Month Follow-Up Data From ZUMA-1 Phase 1 At The European Society For Medical Oncology (ESMO) Annual Congress
2016-10-06,Kite Pharma Initiates Phase 1b/2 Combination Study For KTE-C19 And Atezolizumab In Patients With Refractory Diffuse Large B-cell Lymphoma (DLBCL)
2016-09-29,Christine Cassiano, SVP, Corporate Communications & Investor Relations, Kite Pharma (Photo: Business Wire)
2016-09-27,Kite Pharma (KITE) Stock Surges on Lymphoma Trial, Cowen: Drug's Efficacy 'Impressive'
2016-09-26,Kite Pharma Claims CAR-T Trial Victory, FDA Filing Next
2016-09-26,Kite Pharma Announces Positive Topline KTE-C19 Data From ZUMA-1 Pivotal Trial In Patients With Aggressive Non-Hodgkin Lymphoma (NHL)
2016-09-21,Kite Pharma Isn't Airborne Yet
2016-09-20,Kite Pharma Announces Exclusive License With The National Institutes Of Health For Multiple Neoantigen Directed T-Cell Receptor (TCR) Product Candidates To Treat Solid Tumors Expressing Mutated KRAS
2016-09-12,5 Questions and Answers Take a Measure of Biotech Investor Sentiment
2016-08-31,Kite Pharma To Participate In September 2016 Investor Conferences
2016-08-19,Kite Pharma Advisors And Scientific Pioneers In Cancer Immunotherapy Receive Prestigious Cellular Immune Therapy Award
2016-08-18,Ratings Changes Today
2016-08-08,Kite Pharma Reports Second Quarter 2016 Financial Results
2016-08-03,Kite Pharma To Present At The Canaccord Genuity 36th Annual Growth Conference
2016-08-01,Kite Pharma To Report Second Quarter 2016 Financial Results On August 8, 2016
2016-07-29,Bullish Two Hundred Day Moving Average Cross - KITE
2016-07-27,Kite Pharma Announces Exclusive License With The National Institutes Of Health For Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) Product Candidate To Treat B-Cell Malignancies
2016-07-25,Kite Pharma Licenses Enabling Technology For The Development Of Off-the-Shelf Allogeneic T-Cell Therapies
2016-07-08,Notable Friday Option Activity: KITE, VSI, QUAD
2016-07-08,Assessing the Impact of Juno's Cancer CAR-T Stumble on Biotech Stocks
2016-07-07,Kite Pharma Completes Enrollment Of All Patients With Diffuse Large B-Cell Lymphoma (DLBCL) In Pivotal Multi-Center Phase 2 Study Of KTE-C19 (ZUMA-1)
2016-07-07,Juno Patient Deaths Crash Cancer-Killing CAR-T Party
2016-06-27,A Biotech Stock Turnaround Requires an Alzheimer's Drug Miracle
2016-06-23,Blame for Northwest Bio Collapse Lies With CEO, Not With Mythical 'Wolfpack'
2016-06-20,Kite Pharma Opens State-of-the-Art T-Cell Therapy Manufacturing Facility
2016-06-20,Kite Pharma Expands Development Of T-Cell Receptor (TCR) Therapies Targeting HPV-Associated Cancers In Partnership With The National Cancer Institute (NCI)
2016-06-08,Kite Pharma To Highlight Key Data From CAR T-Cell Therapy Pipeline In Oral Presentations At The 2016 European Hematology Association (EHA) Annual Congress
2016-06-06,Kite/NCI Anti-CD19 CAR T-Cell Therapy Demonstrates Durable Complete Remissions In Advanced Non-Hodgkin Lymphoma
2016-06-06,Kite Pharma Announces The First Meta-Analysis Of Outcomes In Chemorefractory Diffuse Large B-Cell Lymphoma (SCHOLAR-1)
2016-06-06,Kite Pharma Presents Ongoing Complete Responses At 9 Months In Phase 1 Of ZUMA-1 In Patients With Chemorefractory Non-Hodgkin Lymphoma
2016-06-02,Kite Pharma And Cell Design Labs Announce Exclusive Research Collaboration Using Molecular 'On/Off Switches' For CAR T-Cell Immunotherapies
2016-06-01,Kite Pharma Granted Access To Priority Medicines (PRIME) Regulatory Support For KTE-C19 In The Treatment Of Chemorefractory Diffuse Large B-Cell Lymphoma (DLBCL)
2016-05-31,Kite Pharma To Highlight Key Data From Engineered CAR T Cell Therapy Pipeline At The 2016 American Society Of Clinical Oncology Annual Meeting
2016-05-27,Kite Pharma To Present At June 2016 Investor Conferences
2016-05-20,Ziopharm Subpar Cancer Therapies Can't Support Lofty Market Valuation
2016-05-16,Kite Pharma Expands Leadership Team, Appoints Paul L. Jenkinson As Chief Financial Officer
2016-05-13,Biotech Stock Mailbag: Why Intrexon CEO R.J. Kirk Should Not Be Trusted
2016-05-09,Kite Pharma Reports First Quarter 2016 Financial Results
2016-05-03,Kite Pharma To Report First Quarter 2016 Financial Results On May 9, 2016
2016-05-02,Kite Pharma Announces FDA Orphan Drug Designations For KTE-C19 In Five Additional Indications
2016-04-28,Kite Pharma Announces Presentations At The Annual Meeting Of The American Society Of Gene & Cell Therapy (ASGCT)
2016-04-19,Kite Pharma Presents Updated Phase 1 Results From ZUMA-1 At The American Association Of Cancer Research (AACR) Annual Meeting
2016-04-18,Kite Pharma Commends Scientific Advisory Board Members On Awards Received From The American Association Of Cancer Research (AACR)
2016-04-16,Kite Pharma Announces Review Of National Cancer Institute's Manufacturing Facilities
2016-04-15,Kite Pharma Announces Key Presentations On KTE-C19 And Engineered Cell Therapy Pipeline Programs At The Annual Meeting Of The American Association For Cancer Research (AACR)
2016-03-17,Kite Pharma Announces Clinical Collaboration To Evaluate Two Novel Immunotherapies For Patients With Non-Hodgkin Lymphoma
2016-03-16,Kite Pharma Announces Clinical And Manufacturing Updates On KTE-C19 And MAGE-A3 Product Candidates At The Annual Meeting Of The American Association For Cancer Research (AACR)
2016-03-16,Kite Pharma Deepens Cell Manufacturing And Operations Expertise With Appointment Of Tim Moore
2016-03-03,Kite Pharma To Present At March 2016 Investor Conferences
2016-02-29,Kite Pharma Reports Fourth Quarter And Full-Year 2015 Financial Results
2016-02-24,Kite Pharma Augments Commercial Leadership Team
2016-02-24,Kite Pharma To Report Fourth Quarter And Full Year 2015 Financial Results On February 29, 2016
2016-02-24,'Mad Money' Lightning Round: Buy Lockheed Martin at These Prices
2016-02-23,Jim Cramer's 'Mad Money' Recap: Industrials Are Looking Good Again
2016-02-16,Kite Pharma To Participate In The 2016 RBC Capital Markets Global Healthcare Conference
2016-01-26,Juno, Kite Valuations at Risk From Simpler T-Cell Cancer Therapy
2016-01-13,Kite Pharma And Leiden University Medical Center Sign Research And License Agreement For T Cell Receptors Targeting HPV-Associated Cancers
2016-01-09,2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks
2016-01-07,Kite Pharma Expands Its Clinical And Research Partnership With The National Cancer Institute (NCI) For Next-Generation CAR Programs To Treat B-Cell Malignancies
2016-01-06,Kite Pharma To Present At The 34th Annual J.P. Morgan Healthcare Conference
2016-01-05,Editas' IPO Challenge: Edit Investor Expectations as Well as Diseased Genes
2016-01-01,Feuerstein's Heroes and Zeroes of Biotech Investing in 2015
2015-12-21,Kite Pharma Appoints Industry Leader Shawn Cline Tomasello As Chief Commercial Officer
2015-12-14,Cancer Immunotherapy ETF Offers High Growth Investing Potential
2015-12-14,Cancer Immunotherapy ETF Offers High Growth Investing Option
2015-12-11,Kite Pharma Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-12-10,Kite Pharma Announces Pricing Of Public Offering Of Common Stock
2015-12-08,Kite Pharma Announces Proposed Public Offering Of Common Stock
2015-12-07,Kite Pharma Announces Clinical Biomarker Results Of Anti-CD19 CAR T Cell Therapy At The 57th American Society Of Hematology Annual Meeting (ASH)
2015-12-07,Kite Pharma Presents Phase 1 Results From ZUMA-1 At The 57th American Society Of Hematology (ASH) Annual Meeting
2015-12-07,Kite Pharma Receives FDA Breakthrough Therapy Designation For KTE-C19 For The Treatment Of Refractory, Aggressive Non Hodgkin Lymphoma (NHL)
2015-12-07,Kite Pharma Initiates The ZUMA-4 Study To Support Registration Of KTE-C19 For Relapsed Or Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) In Children And Young Adults
2015-12-03,Kite Pharma And GE Global Research Announce Strategic Collaboration To Automate Manufacturing Of Engineered T Cell Therapies
2015-12-02,Kite Pharma Initiates The ZUMA-3 Study To Support Registration Of KTE-C19 For Relapsed Or Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) In Adult Subjects
2015-11-22,Goldman Sachs Says These 12 Small-Cap Stocks Are Worth Buying
2015-11-18,Goldman Sees Bluebird Shares Doubling On 'One-Shot' Gene Therapy
2015-11-12,Kite Pharma Reports Third Quarter 2015 Financial Results And Provides Business Update
2015-11-09,Kite Pharma To Host Third Quarter 2015 Financial Results Conference Call And Webcast
2015-11-09,Kite Pharma Initiates Phase 2 Clinical Study Of KTE-C19 (ZUMA-2) In Patients With Relapsed Or Refractory Mantle Cell Lymphoma (r/r MCL) To Support Registration For A Second Indication
2015-11-05,Juno, Kite, Novartis Yelp 'Oh Merde!' at Cellectis Off-the-Shelf CAR-T Data
2015-11-05,Kite Pharma To Present Four Abstracts, Including Safety And Efficacy Data From The KTE-C19 Phase 1 Study In Patients With Refractory, Aggressive NHL (ZUMA-1), At The 57th American Society Of Hematology Annual Meeting (ASH)
2015-11-04,Kite Pharma To Present At Upcoming Investor Conferences In November 2015
2015-11-02,Before the Move: Watch Cellectis Into UCART19 Data
2015-11-02,Kite Pharma Initiates ZUMA-1 Phase 2 In Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma (NHL) To Support Registration Of KTE-C19
2015-10-27,Kite Pharma And Alpine Immune Sciences Announce Research Collaboration And License Agreement To Enhance Immune Response In The Tumor Microenvironment
2015-10-22,Northwest Bio Bothers British Bestie for Bounteous Bucks
2015-10-20,Kite Pharma Announces Exclusive License With The National Institutes Of Health For T Cell Receptor (TCR)-Based Products To Treat Tumors Expressing MAGE
2015-10-15,Kite Pharma Receives Positive Opinions For Orphan Drug Designation In The European Union (EU) For KTE-C19 In Three Additional Hematological Indications
2015-10-07,Kite Pharma Commends Steven A. Rosenberg, M.D., Ph.D., On The Prestigious Medal Of Honor Award From The American Cancer Society
2015-10-01,Kite Pharma Announces Peer-Reviewed Publication Of T Cell Receptor Based Product Candidate To Treat HPV-Associated Cancers
2015-09-24,Kite Pharma To Present At IBC Life Sciences' IMMUNO-ONCOLOGY: Advancing The Next Generation Of Cancer Immunotherapies Conference
2015-09-15,Franz B. Humer, Former Chairman And CEO Of Roche Group, Appointed To Kite Pharma's Board Of Directors
2015-09-14,Kite Pharma Expands Collaboration With Netherlands Cancer Institute (NKI)
2015-09-11,Kite Pharma Receives Positive Opinion For Orphan Drug Designation In The European Union For KTE-C19, Kite's Lead Cancer T-Cell Immunotherapy
2015-09-03,Kite Pharma Commends Honors Conferred To Scientific Advisory Board Members For Their Significant Contributions To Medicine
2015-09-03,Kite Pharma To Participate In Upcoming Investor Conferences In September 2015
2015-09-01,The Numbers Behind Biotech's Horrible, No Good, Awful August
2015-08-26,Biotech Selloff Has No Effect on Cellectis Advances: CEO
2015-08-26,Biotech Selloff Does Not Dim Immunotherapy Advances Says Cellectis CEO
2015-08-21,Biotech Stock Mailbag: Celldex, Bluebird, Kite, Inovio
2015-08-19,Biotech Stocks Get Burned This Summer, but Fall Might Bring Relief
2015-08-17,Kite Pharma (KITE) Stock Rises, Patient Death Not Related to Treatment Candidate
2015-08-17,Kite Pharma Provides Update On KTE-C19 Clinical Trial
2015-08-14,Kite Pharma To Hold Conference Call To Provide A Corporate Update On Monday, August 17, 2015
2015-08-10,Kite Pharma Reports Second Quarter 2015 Financial Results
2015-08-06,Kite Pharma To Host Second Quarter 2015 Financial Results Conference Call And Webcast
2015-08-05,Kite Pharma To Present At The Canaccord Genuity 35th Annual Growth Conference
2015-08-03,Kite Pharma (KITE) Stock Is the 'Chart of the Day'
2015-08-03,Kite Pharma May Soon Be Flying High
2015-08-03,Chart of the Day: KITE
2015-07-15,'Fast Money' Recap: Netflix, Google, Other Tech Earnings to Watch
2015-07-10,5 Stocks Ready for Breakouts -- Must-See Charts
2015-07-01,Kite Pharma And The Leukemia & Lymphoma Society(R) Enter Into Collaboration To Enhance The Development Of KTE-C19 In Refractory Aggressive Non-Hodgkin Lymphoma And Launch CAR T-Cell Therapy Educational Programs
2015-07-01,'Fast Money' Recap: Greece's Uncertain Future Extends to U.S. Stocks
2015-06-29,Celgene is Desperate or Insane to Pay Ultra-High Premium for Juno Partnership
2015-06-22,Kite Pharma And Bluebird Bio Announce Strategic Collaboration To Advance Second Generation TCR Cell Therapy Products To Treat HPV-Associated Cancers
2015-06-19,'Mad Money' Lightning Round: Buy, Buy, Buy Citigroup
2015-06-18,Jim Cramer's 'Mad Money' Recap: Here's Why We Had a Rally Today
2015-06-16,Kite Pharma To Host Investor Day On June 23, 2015
2017-03-16,Karyopharm Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Selinexor Clinical Update
2017-03-10,Karyopharm Announces Partial Clinical Hold To Pause Enrollment In Selinexor Trials
2017-03-09,Karyopharm To Report Fourth Quarter And Year End 2016 Financial Results On March 16, 2017
2017-03-03,Biotech Premarket Movers: Karyopharm, Lexicon, Prothena
2017-03-02,Karyopharm Announces Results From Interim Analysis Of Phase 2 SOPRA Study Evaluating Selinexor In Relapsed/Refractory Acute Myeloid Leukemia
2017-03-01,Karyopharm Announces The Presentation Of New Data At The 2017 American Association For Cancer Research Annual Meeting
2017-01-31,Karyopharm To Participate In Upcoming Investor Conferences
2017-01-19,Commit To Buy Karyopharm Therapeutics At $7.50, Earn 19.6% Annualized Using Options
2017-01-12,Short Interest Jumps 19.7% For KPTI
2017-01-03,Karyopharm To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-15,Karyopharm And Collaborators Awarded Grant For ALS Research
2016-12-05,Karyopharm Presents Updated Phase 1b STOMP Data At The American Society Of Hematology 2016 Annual Meeting
2016-12-04,Karyopharm Presents Updated Phase 2b STORM Data At The American Society Of Hematology 2016 Annual Meeting
2016-12-04,Karyopharm Presents Updated Phase 2 SAIL Relapsed/Refractory AML Clinical Data At The American Society Of Hematology 2016 Annual Meeting
2016-11-30,Karyopharm And The Multiple Myeloma Research Foundation Announce Panel Discussion Featuring Leading Multiple Myeloma Thought Leaders
2016-11-10,Karyopharm To Present At The Jefferies 2016 London Healthcare Conference
2016-11-07,Karyopharm Reports Third Quarter 2016 Financial Results And Highlights Recent Progress
2016-11-03,Karyopharm To Present Updated Phase 2b STORM And Phase 1b STOMP Clinical Data At The American Society Of Hematology 2016 Annual Meeting
2016-11-02,Karyopharm To Ring The Nasdaq Stock Market Closing Bell
2016-10-31,Karyopharm To Report Third Quarter 2016 Financial Results On November 7, 2016
2016-10-28,Karyopharm Therapeutics is Now Oversold (KPTI)
2016-10-20,Commit To Purchase Karyopharm Therapeutics At $7.50, Earn 32.4% Annualized Using Options
2016-10-11,Karyopharm To Present At The 15th Annual BIO Investor Forum
2016-10-05,Karyopharm To Present Updated SIGN Phase 2 Clinical Data At European Society Of Medical Oncology 2016 Annual Meeting
2016-09-29,Karyopharm Publishes Preclinical Data In Nature Demonstrating Selinexor's Potential In KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
2016-09-28,Karyopharm Publishes Preclinical And Phase 1 Clinical Data For Selinexor In Ovarian Cancer In Clinical Cancer Research Publication
2016-09-12,Karyopharm Appoints Humphrey A.R. Gardner MD, FCAP As Senior Vice President, Clinical Development
2016-09-06,Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug
2016-09-06,Karyopharm Reports Positive Top-Line Phase 2b STORM Results And Reviews The Planned Development Path For Selinexor In Multiple Myeloma
2016-08-30,Markets Very Sluggish as August Nears an End
2016-08-30,Karyopharm To Host Conference Call With Update On Multiple Myeloma Plans
2016-08-22,Noteworthy Monday Option Activity: KPTI, SHLD, MXWL
2016-08-19,These 7 Stocks Under $10 Could Make You a Lot of Money
2016-08-04,Karyopharm Reports Second Quarter 2016 Financial Results And Highlights Recent Progress
2016-08-03,Karyopharm To Present At Upcoming Investor Conferences
2016-07-28,Karyopharm To Report Second Quarter 2016 Financial Results On August 4, 2016
2016-07-27,Karyopharm To Present Updated Phase 2 Clinical Data From SIGN Study At European Society Of Medical Oncology 2016 Annual Meeting
2016-07-27,Karyopharm Announces Phase 1b Selinexor Sarcoma Data Published In Journal Of Clinical Oncology
2016-07-19,Commit To Purchase Karyopharm Therapeutics At $5, Earn 20.6% Annualized Using Options
2016-07-06,Karyopharm To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference
2016-06-22,Karyopharm Initiates Phase 1 Clinical Trial With KPT-9274
2016-06-16,Oversold Conditions For Karyopharm Therapeutics (KPTI)
2016-06-16,Karyopharm Outlines Key Selinexor Clinical Development Achievements
2016-06-15,Karyopharm To Present At The 2016 JMP Securities Life Science Conference
2016-06-10,Karyopharm Presents Preliminary STOMP Phase 1b Clinical Data At 2016 European Hematology Association Annual Meeting
2016-06-07,Insider Trading Alert - TRUP, KPTI And FCBC Traded By Insiders
2016-06-01,Karyopharm To Present At The Jefferies 2016 Healthcare Conference
2016-05-31,Insider Trading Alert - KPTI, CPIX And LB Traded By Insiders
2016-05-24,Insider Trading Alert - W, KPTI And GVP Traded By Insiders
2016-05-19,Karyopharm To Present Preliminary STOMP Phase 1B Clinical Data At 2016 European Hematology Association Annual Meeting
2016-05-18,Karyopharm To Present Selinexor Clinical Data At The American Society Of Clinical Oncology Annual Meeting
2016-05-09,Karyopharm Reports First Quarter 2016 Financial Results And Highlights Recent Progress
2016-05-02,Karyopharm To Report First Quarter 2016 Financial Results On May 9, 2016
2016-04-20,Karyopharm Presents Data Demonstrating The Potential Of Nuclear Export Protein Exportin 1 (XPO1) Inhibition In The Treatment Of Traumatic Brain Injury
2016-04-06,Karyopharm Taps TransPerfect As ETMF And Functional TMF Provider
2016-04-05,Karyopharm To Present At The 15th Annual Needham Healthcare Conference
2016-03-31,Karyopharm Receives NIAID Grant To Advance Development Of KPT-350 For The Treatment Of Lupus
2016-03-22,Karyopharm Therapeutics (KPTI) Strong On High Relative Volume Today
2016-03-16,Karyopharm To Present Data On Oncology Pipeline At The 2016 American Association For Cancer Research Annual Meeting
2016-03-14,Karyopharm Reports Fourth Quarter And Full Year 2015 Financial Results And Highlights Recent Progress
2016-03-07,Karyopharm To Report Fourth Quarter And Full Year 2015 Financial Results On March 14, 2016
2016-03-04,Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published In Journal Of Clinical Oncology
2016-03-02,7 Stocks Under $10 Making Big Breakout Moves
2016-02-03,Karyopharm To Present At The Leerink Partners 5th Annual Global Healthcare Conference
2016-01-21,5 Stocks Under $10 Set to Soar
2016-01-19,Karyopharm Initiates Second Generation SINE™ Compound Clinical Trial In Multiple Myeloma
2016-01-14,Karyopharm Initiates Clinical Trial Of Oral Selinexor In Advanced Liposarcoma
2016-01-06,Karyopharm Therapeutics is Now Oversold (KPTI)
2016-01-06,Karyopharm Therapeutics (KPTI) Highlighted As Weak On High Volume
2016-01-04,Karyopharm To Present At The 34th Annual J.P. Morgan Healthcare Conference
2015-12-07,Karyopharm Therapeutics Presents Positive Clinical Data On The Activity Of Selinexor In Combination With Other Anticancer Agents Across Multiple Hematologic Malignancies At The 2015 American Society Of Hematology (ASH) Annual Meeting
2015-11-30,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Hematologic Malignancies
2015-11-13,Karyopharm Therapeutics Stock Sees Short Interest Drop 13.5%
2015-11-09,Karyopharm Reports Third Quarter 2015 Financial Results And Highlights Recent Progress
2015-11-05,Karyopharm To Present Data On Oncology Pipeline At American Society Of Hematology 2015 Annual Meeting
2015-11-02,Karyopharm To Report Third Quarter 2015 Financial Results On November 9, 2015
2015-10-30,5 Stocks Ready to Break Out Higher
2015-10-19,Karyopharm Initiates STOMP Clinical Trial Of Oral Selinexor In Multiple Myeloma
2015-10-13,Short Interest Falls 11% For KPTI
2015-09-30,10 Worst NASDAQ Biotech Stocks in the Third Quarter
2015-09-29,Karyopharm Therapeutics is Now Oversold (KPTI)
2015-09-03,Karyopharm Advancing Neuroprotective SINE(TM) Compounds In Amyotrophic Lateral Sclerosis (ALS)
2015-08-28,5 Breakout Stocks to Trade for Big Gains
2015-08-25,Strong On High Relative Volume: Karyopharm Therapeutics (KPTI)
2015-08-18,Karyopharm Therapeutics is Now Oversold (KPTI)
2015-08-18,Perilous Reversal Watch: Karyopharm Therapeutics (KPTI)
2015-08-17,Karyopharm Therapeutics (KPTI) Showing Signs Of A Dead Cat Bounce Today
2015-08-14,Weak On High Volume: Karyopharm Therapeutics (KPTI)
2015-08-11,Karyopharm Therapeutics (KPTI) Is Strong On High Volume Today
2015-08-10,Karyopharm Reports Second Quarter 2015 Financial Results And Highlights Recent Progress
2015-08-06,Commit To Purchase Karyopharm Therapeutics At $20, Earn 31% Annualized Using Options
2015-08-04,Jim Cramer's 'Mad Money' Recap: Nowhere to Run, Nowhere to Hide From China
2015-08-03,Karyopharm To Report Second Quarter 2015 Financial Results On August 10, 2015
2015-07-24,Oversold Conditions For Karyopharm Therapeutics (KPTI)
2015-07-07,KPTI: Insiders Vs. Shorts
2015-06-26,Short Interest Increases 11.6% For KPTI
2015-06-22,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At International Conference On Malignant Lymphoma
2015-06-15,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
2015-06-05,5 Biotech Stocks Poised for Breakouts
2015-06-04,'Mad Money' Lightning Round: Buy, Buy, Buy Juno Therapeutics
2015-06-03,Jim Cramer's 'Mad Money' Recap: Individual Stocks Beat Baskets Any Day
2015-06-01,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Recurrent Glioblastoma And Advanced Sarcomas At 2015 ASCO Annual Meeting
2015-05-30,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Heavily Pretreated Gynecological Cancers And Asian Patients With Advanced Malignancies At 2015 ASCO Annual Meeting
2015-05-29,Fly Watch: Several Names That May Move Following ASCO Meeting
2015-05-28,Karyopharm Initiates STORM Clinical Trial Of Oral Selinexor (KPT-330) In Multiple Myeloma
2015-05-27,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Solid Tumors
2015-05-21,Karyopharm To Present Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
2015-05-14,Karyopharm Therapeutics (KPTI) Stock: Weak On High Volume Today
2015-05-13,Karyopharm To Present Solid Tumor Data On Lead Drug Candidate Selinexor At 2015 American Society Of Clinical Oncology Annual Meeting
2015-05-13,Jumpstart ASCO '15 With This Quick List of Hot Research Abstracts
2015-05-11,Karyopharm Reports First Quarter 2015 Financial Results And Highlights Recent Progress
2015-05-07,Karyopharm To Present At Bank Of America Merrill Lynch 2015 Healthcare Conference
2015-05-06,Commit To Purchase Karyopharm Therapeutics At $20, Earn 12.9% Annualized Using Options
2015-05-05,Karyopharm To Report First Quarter 2015 Financial Results On May 11, 2015
2015-04-17,Karyopharm To Present Late-Breaking Data At American Association For Cancer Research Annual Meeting
2015-04-14,Ratings Changes Today
2015-04-13,Karyopharm Granted U.S. Composition-of-Matter Patent For Selinexor (KPT-330)
2015-04-07,KPTI: Insiders Vs. Shorts
2015-04-02,'Mad Money' Lightning Round: Kinder Morgan, HCA Are Winners
2015-04-01,Jim Cramer's 'Mad Money' Recap: Get Ready for a Rough Ride
2015-04-01,Karyopharm Appoints Mikael Dolsten, MD, PhD To Its Board Of Directors
2015-03-18,Karyopharm To Present Data On Its Novel Oral PAK4 Allosteric Modulator (PAM) At The American Association For Cancer Research Annual Meeting
2015-03-18,Karyopharm To Present Data On Oncology Pipeline At American Association For Cancer Research Annual Meeting
2015-03-16,Karyopharm Reports Fourth Quarter And Full Year 2014 Financial Results And Highlights Recent Progress
2015-03-09,Karyopharm To Report Fourth Quarter And Full Year 2014 Financial Results On March 16, 2015
2015-02-23,Nature Neuroscience Publishes Data Demonstrating Potential Therapeutic Benefits Of Karyopharm's SINE(TM) Compounds In The Treatment Of Multiple Sclerosis
2015-02-05,Karyopharm To Present At Leerink Partners Global Healthcare Conference
2015-01-26,Commit To Purchase Karyopharm Therapeutics At $22.50, Earn 19.6% Annualized Using Options
2015-01-16,Karyopharm Therapeutics Is Now Oversold (KPTI)
2015-01-08,Karyopharm Announces Orphan Designation Granted By FDA For Selinexor (KPT-330) In Multiple Myeloma
2015-01-07,Karyopharm To Present At J.P. Morgan 33rd Annual Healthcare Conference
2015-01-06,Karyopharm Therapeutics Announces Pricing Of Public Offering Of Common Stock
2015-01-05,Karyopharm Therapeutics Announces Proposed Public Offering Of Common Stock
2014-12-15,Karyopharm Announces Addition To The NASDAQ Biotechnology Index
2014-12-11,Karyopharm Initiates Third Registration-Directed Clinical Trial Of Oral Selinexor (KPT-330)
2014-12-08,Jim Cramer's 'Mad Money' Recap: Why You Should Buy Disney, Starbucks, Nike Now
2014-12-08,Karyopharm Presents Positive Clinical Data For Selinexor (KPT-330) In NHL Patients At ASH 2014 Annual Meeting
2014-12-08,Karyopharm Presents Positive Combination Data For Selinexor (KPT-330) In Multiple Myeloma Patients At ASH 2014 Annual Meeting
2014-12-04,Karyopharm To Present At Oppenheimer 25th Annual Healthcare Conference
2014-12-01,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Oncology
2014-12-01,Karyopharm Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission
2014-11-24,Karyopharm Presents Data On Oncology Pipeline At EORTC-NCI-AACR Annual Meeting
2014-11-10,Karyopharm Reports Third Quarter 2014 Financial Results And Highlights Recent Progress
2014-11-10,Karyopharm Initiates Registration-Directed Clinical Study Of Selinexor (KPT-330) In Patients With Richter's Transformation
2014-11-06,Karyopharm Announces Data Presentations At American Society Of Hematology Annual Meeting
2014-11-05,Karyopharm To Present At Credit Suisse 2014 Healthcare Conference
2014-11-04,Karyopharm Appoints J. Scott Garland To Its Board Of Directors
2014-10-30,Karyopharm To Report Third Quarter 2014 Financial Results On November 10, 2014
2014-10-27,Karyopharm Expands Global Presence With European Subsidiary
2014-09-29,Karyopharm Announces Clinical Data For Selinexor (KPT-330) In Advanced Solid Tumors
2014-09-29,3 Unusual-Volume Biotech Stocks in Breakout Territory
2014-09-25,Karyopharm To Host Conference Call To Discuss Selinexor (KPT-330) Data Presented At ESMO 2014
2014-09-09,Karyopharm Announces Three Clinical Data Presentations At ESMO 2014
2014-08-08,Karyopharm Appoints Justin Renz Executive Vice President And Chief Financial Officer
2014-08-07,Karyopharm To Present At The Wedbush 2014 Life Sciences Management Access Conference
2014-08-07,Karyopharm Therapeutics Reports Second Quarter Financial Results For 2014
2014-08-01,Karyopharm To Host Second Quarter 2014 Earnings Call On August 7, 2014
2014-06-17,A Beaten-Down Biotech Stock Poised for an Epic Short Squeeze
2014-06-03,3 Big-Volume Stocks in Breakout Territory
2014-05-30,ASCO '14: What's on Tap for Saturday
2014-05-28,5 Stocks Insiders Love Right Now
2017-03-16,Karyopharm Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Selinexor Clinical Update
2017-03-10,Karyopharm Announces Partial Clinical Hold To Pause Enrollment In Selinexor Trials
2017-03-09,Karyopharm To Report Fourth Quarter And Year End 2016 Financial Results On March 16, 2017
2017-03-03,Biotech Premarket Movers: Karyopharm, Lexicon, Prothena
2017-03-02,Karyopharm Announces Results From Interim Analysis Of Phase 2 SOPRA Study Evaluating Selinexor In Relapsed/Refractory Acute Myeloid Leukemia
2017-03-01,Karyopharm Announces The Presentation Of New Data At The 2017 American Association For Cancer Research Annual Meeting
2017-01-31,Karyopharm To Participate In Upcoming Investor Conferences
2017-01-19,Commit To Buy Karyopharm Therapeutics At $7.50, Earn 19.6% Annualized Using Options
2017-01-12,Short Interest Jumps 19.7% For KPTI
2017-01-03,Karyopharm To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-15,Karyopharm And Collaborators Awarded Grant For ALS Research
2016-12-05,Karyopharm Presents Updated Phase 1b STOMP Data At The American Society Of Hematology 2016 Annual Meeting
2016-12-04,Karyopharm Presents Updated Phase 2b STORM Data At The American Society Of Hematology 2016 Annual Meeting
2016-12-04,Karyopharm Presents Updated Phase 2 SAIL Relapsed/Refractory AML Clinical Data At The American Society Of Hematology 2016 Annual Meeting
2016-11-30,Karyopharm And The Multiple Myeloma Research Foundation Announce Panel Discussion Featuring Leading Multiple Myeloma Thought Leaders
2016-11-10,Karyopharm To Present At The Jefferies 2016 London Healthcare Conference
2016-11-07,Karyopharm Reports Third Quarter 2016 Financial Results And Highlights Recent Progress
2016-11-03,Karyopharm To Present Updated Phase 2b STORM And Phase 1b STOMP Clinical Data At The American Society Of Hematology 2016 Annual Meeting
2016-11-02,Karyopharm To Ring The Nasdaq Stock Market Closing Bell
2016-10-31,Karyopharm To Report Third Quarter 2016 Financial Results On November 7, 2016
2016-10-28,Karyopharm Therapeutics is Now Oversold (KPTI)
2016-10-20,Commit To Purchase Karyopharm Therapeutics At $7.50, Earn 32.4% Annualized Using Options
2016-10-11,Karyopharm To Present At The 15th Annual BIO Investor Forum
2016-10-05,Karyopharm To Present Updated SIGN Phase 2 Clinical Data At European Society Of Medical Oncology 2016 Annual Meeting
2016-09-29,Karyopharm Publishes Preclinical Data In Nature Demonstrating Selinexor's Potential In KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
2016-09-28,Karyopharm Publishes Preclinical And Phase 1 Clinical Data For Selinexor In Ovarian Cancer In Clinical Cancer Research Publication
2016-09-12,Karyopharm Appoints Humphrey A.R. Gardner MD, FCAP As Senior Vice President, Clinical Development
2016-09-06,Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug
2016-09-06,Karyopharm Reports Positive Top-Line Phase 2b STORM Results And Reviews The Planned Development Path For Selinexor In Multiple Myeloma
2016-08-30,Markets Very Sluggish as August Nears an End
2016-08-30,Karyopharm To Host Conference Call With Update On Multiple Myeloma Plans
2016-08-22,Noteworthy Monday Option Activity: KPTI, SHLD, MXWL
2016-08-19,These 7 Stocks Under $10 Could Make You a Lot of Money
2016-08-04,Karyopharm Reports Second Quarter 2016 Financial Results And Highlights Recent Progress
2016-08-03,Karyopharm To Present At Upcoming Investor Conferences
2016-07-28,Karyopharm To Report Second Quarter 2016 Financial Results On August 4, 2016
2016-07-27,Karyopharm To Present Updated Phase 2 Clinical Data From SIGN Study At European Society Of Medical Oncology 2016 Annual Meeting
2016-07-27,Karyopharm Announces Phase 1b Selinexor Sarcoma Data Published In Journal Of Clinical Oncology
2016-07-19,Commit To Purchase Karyopharm Therapeutics At $5, Earn 20.6% Annualized Using Options
2016-07-06,Karyopharm To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference
2016-06-22,Karyopharm Initiates Phase 1 Clinical Trial With KPT-9274
2016-06-16,Oversold Conditions For Karyopharm Therapeutics (KPTI)
2016-06-16,Karyopharm Outlines Key Selinexor Clinical Development Achievements
2016-06-15,Karyopharm To Present At The 2016 JMP Securities Life Science Conference
2016-06-10,Karyopharm Presents Preliminary STOMP Phase 1b Clinical Data At 2016 European Hematology Association Annual Meeting
2016-06-07,Insider Trading Alert - TRUP, KPTI And FCBC Traded By Insiders
2016-06-01,Karyopharm To Present At The Jefferies 2016 Healthcare Conference
2016-05-31,Insider Trading Alert - KPTI, CPIX And LB Traded By Insiders
2016-05-24,Insider Trading Alert - W, KPTI And GVP Traded By Insiders
2016-05-19,Karyopharm To Present Preliminary STOMP Phase 1B Clinical Data At 2016 European Hematology Association Annual Meeting
2016-05-18,Karyopharm To Present Selinexor Clinical Data At The American Society Of Clinical Oncology Annual Meeting
2016-05-09,Karyopharm Reports First Quarter 2016 Financial Results And Highlights Recent Progress
2016-05-02,Karyopharm To Report First Quarter 2016 Financial Results On May 9, 2016
2016-04-20,Karyopharm Presents Data Demonstrating The Potential Of Nuclear Export Protein Exportin 1 (XPO1) Inhibition In The Treatment Of Traumatic Brain Injury
2016-04-06,Karyopharm Taps TransPerfect As ETMF And Functional TMF Provider
2016-04-05,Karyopharm To Present At The 15th Annual Needham Healthcare Conference
2016-03-31,Karyopharm Receives NIAID Grant To Advance Development Of KPT-350 For The Treatment Of Lupus
2016-03-22,Karyopharm Therapeutics (KPTI) Strong On High Relative Volume Today
2016-03-16,Karyopharm To Present Data On Oncology Pipeline At The 2016 American Association For Cancer Research Annual Meeting
2016-03-14,Karyopharm Reports Fourth Quarter And Full Year 2015 Financial Results And Highlights Recent Progress
2016-03-07,Karyopharm To Report Fourth Quarter And Full Year 2015 Financial Results On March 14, 2016
2016-03-04,Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published In Journal Of Clinical Oncology
2016-03-02,7 Stocks Under $10 Making Big Breakout Moves
2016-02-03,Karyopharm To Present At The Leerink Partners 5th Annual Global Healthcare Conference
2016-01-21,5 Stocks Under $10 Set to Soar
2016-01-19,Karyopharm Initiates Second Generation SINE™ Compound Clinical Trial In Multiple Myeloma
2016-01-14,Karyopharm Initiates Clinical Trial Of Oral Selinexor In Advanced Liposarcoma
2016-01-06,Karyopharm Therapeutics is Now Oversold (KPTI)
2016-01-06,Karyopharm Therapeutics (KPTI) Highlighted As Weak On High Volume
2016-01-04,Karyopharm To Present At The 34th Annual J.P. Morgan Healthcare Conference
2015-12-07,Karyopharm Therapeutics Presents Positive Clinical Data On The Activity Of Selinexor In Combination With Other Anticancer Agents Across Multiple Hematologic Malignancies At The 2015 American Society Of Hematology (ASH) Annual Meeting
2015-11-30,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Hematologic Malignancies
2015-11-13,Karyopharm Therapeutics Stock Sees Short Interest Drop 13.5%
2015-11-09,Karyopharm Reports Third Quarter 2015 Financial Results And Highlights Recent Progress
2015-11-05,Karyopharm To Present Data On Oncology Pipeline At American Society Of Hematology 2015 Annual Meeting
2015-11-02,Karyopharm To Report Third Quarter 2015 Financial Results On November 9, 2015
2015-10-30,5 Stocks Ready to Break Out Higher
2015-10-19,Karyopharm Initiates STOMP Clinical Trial Of Oral Selinexor In Multiple Myeloma
2015-10-13,Short Interest Falls 11% For KPTI
2015-09-30,10 Worst NASDAQ Biotech Stocks in the Third Quarter
2015-09-29,Karyopharm Therapeutics is Now Oversold (KPTI)
2015-09-03,Karyopharm Advancing Neuroprotective SINE(TM) Compounds In Amyotrophic Lateral Sclerosis (ALS)
2015-08-28,5 Breakout Stocks to Trade for Big Gains
2015-08-25,Strong On High Relative Volume: Karyopharm Therapeutics (KPTI)
2015-08-18,Karyopharm Therapeutics is Now Oversold (KPTI)
2015-08-18,Perilous Reversal Watch: Karyopharm Therapeutics (KPTI)
2015-08-17,Karyopharm Therapeutics (KPTI) Showing Signs Of A Dead Cat Bounce Today
2015-08-14,Weak On High Volume: Karyopharm Therapeutics (KPTI)
2015-08-11,Karyopharm Therapeutics (KPTI) Is Strong On High Volume Today
2015-08-10,Karyopharm Reports Second Quarter 2015 Financial Results And Highlights Recent Progress
2015-08-06,Commit To Purchase Karyopharm Therapeutics At $20, Earn 31% Annualized Using Options
2015-08-04,Jim Cramer's 'Mad Money' Recap: Nowhere to Run, Nowhere to Hide From China
2015-08-03,Karyopharm To Report Second Quarter 2015 Financial Results On August 10, 2015
2015-07-24,Oversold Conditions For Karyopharm Therapeutics (KPTI)
2015-07-07,KPTI: Insiders Vs. Shorts
2015-06-26,Short Interest Increases 11.6% For KPTI
2015-06-22,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At International Conference On Malignant Lymphoma
2015-06-15,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
2015-06-05,5 Biotech Stocks Poised for Breakouts
2015-06-04,'Mad Money' Lightning Round: Buy, Buy, Buy Juno Therapeutics
2015-06-03,Jim Cramer's 'Mad Money' Recap: Individual Stocks Beat Baskets Any Day
2015-06-01,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Recurrent Glioblastoma And Advanced Sarcomas At 2015 ASCO Annual Meeting
2015-05-30,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Heavily Pretreated Gynecological Cancers And Asian Patients With Advanced Malignancies At 2015 ASCO Annual Meeting
2015-05-29,Fly Watch: Several Names That May Move Following ASCO Meeting
2015-05-28,Karyopharm Initiates STORM Clinical Trial Of Oral Selinexor (KPT-330) In Multiple Myeloma
2015-05-27,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Solid Tumors
2015-05-21,Karyopharm To Present Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
2015-05-14,Karyopharm Therapeutics (KPTI) Stock: Weak On High Volume Today
2015-05-13,Karyopharm To Present Solid Tumor Data On Lead Drug Candidate Selinexor At 2015 American Society Of Clinical Oncology Annual Meeting
2015-05-13,Jumpstart ASCO '15 With This Quick List of Hot Research Abstracts
2015-05-11,Karyopharm Reports First Quarter 2015 Financial Results And Highlights Recent Progress
2015-05-07,Karyopharm To Present At Bank Of America Merrill Lynch 2015 Healthcare Conference
2015-05-06,Commit To Purchase Karyopharm Therapeutics At $20, Earn 12.9% Annualized Using Options
2015-05-05,Karyopharm To Report First Quarter 2015 Financial Results On May 11, 2015
2015-04-17,Karyopharm To Present Late-Breaking Data At American Association For Cancer Research Annual Meeting
2015-04-14,Ratings Changes Today
2015-04-13,Karyopharm Granted U.S. Composition-of-Matter Patent For Selinexor (KPT-330)
2015-04-07,KPTI: Insiders Vs. Shorts
2015-04-02,'Mad Money' Lightning Round: Kinder Morgan, HCA Are Winners
2015-04-01,Jim Cramer's 'Mad Money' Recap: Get Ready for a Rough Ride
2015-04-01,Karyopharm Appoints Mikael Dolsten, MD, PhD To Its Board Of Directors
2015-03-18,Karyopharm To Present Data On Its Novel Oral PAK4 Allosteric Modulator (PAM) At The American Association For Cancer Research Annual Meeting
2015-03-18,Karyopharm To Present Data On Oncology Pipeline At American Association For Cancer Research Annual Meeting
2015-03-16,Karyopharm Reports Fourth Quarter And Full Year 2014 Financial Results And Highlights Recent Progress
2015-03-09,Karyopharm To Report Fourth Quarter And Full Year 2014 Financial Results On March 16, 2015
2015-02-23,Nature Neuroscience Publishes Data Demonstrating Potential Therapeutic Benefits Of Karyopharm's SINE(TM) Compounds In The Treatment Of Multiple Sclerosis
2015-02-05,Karyopharm To Present At Leerink Partners Global Healthcare Conference
2015-01-26,Commit To Purchase Karyopharm Therapeutics At $22.50, Earn 19.6% Annualized Using Options
2015-01-16,Karyopharm Therapeutics Is Now Oversold (KPTI)
2015-01-08,Karyopharm Announces Orphan Designation Granted By FDA For Selinexor (KPT-330) In Multiple Myeloma
2015-01-07,Karyopharm To Present At J.P. Morgan 33rd Annual Healthcare Conference
2015-01-06,Karyopharm Therapeutics Announces Pricing Of Public Offering Of Common Stock
2015-01-05,Karyopharm Therapeutics Announces Proposed Public Offering Of Common Stock
2014-12-15,Karyopharm Announces Addition To The NASDAQ Biotechnology Index
2014-12-11,Karyopharm Initiates Third Registration-Directed Clinical Trial Of Oral Selinexor (KPT-330)
2014-12-08,Jim Cramer's 'Mad Money' Recap: Why You Should Buy Disney, Starbucks, Nike Now
2014-12-08,Karyopharm Presents Positive Clinical Data For Selinexor (KPT-330) In NHL Patients At ASH 2014 Annual Meeting
2014-12-08,Karyopharm Presents Positive Combination Data For Selinexor (KPT-330) In Multiple Myeloma Patients At ASH 2014 Annual Meeting
2014-12-04,Karyopharm To Present At Oppenheimer 25th Annual Healthcare Conference
2014-12-01,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Oncology
2014-12-01,Karyopharm Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission
2014-11-24,Karyopharm Presents Data On Oncology Pipeline At EORTC-NCI-AACR Annual Meeting
2014-11-10,Karyopharm Reports Third Quarter 2014 Financial Results And Highlights Recent Progress
2014-11-10,Karyopharm Initiates Registration-Directed Clinical Study Of Selinexor (KPT-330) In Patients With Richter's Transformation
2014-11-06,Karyopharm Announces Data Presentations At American Society Of Hematology Annual Meeting
2014-11-05,Karyopharm To Present At Credit Suisse 2014 Healthcare Conference
2014-11-04,Karyopharm Appoints J. Scott Garland To Its Board Of Directors
2014-10-30,Karyopharm To Report Third Quarter 2014 Financial Results On November 10, 2014
2014-10-27,Karyopharm Expands Global Presence With European Subsidiary
2014-09-29,Karyopharm Announces Clinical Data For Selinexor (KPT-330) In Advanced Solid Tumors
2014-09-29,3 Unusual-Volume Biotech Stocks in Breakout Territory
2014-09-25,Karyopharm To Host Conference Call To Discuss Selinexor (KPT-330) Data Presented At ESMO 2014
2014-09-09,Karyopharm Announces Three Clinical Data Presentations At ESMO 2014
2014-08-08,Karyopharm Appoints Justin Renz Executive Vice President And Chief Financial Officer
2014-08-07,Karyopharm To Present At The Wedbush 2014 Life Sciences Management Access Conference
2014-08-07,Karyopharm Therapeutics Reports Second Quarter Financial Results For 2014
2014-08-01,Karyopharm To Host Second Quarter 2014 Earnings Call On August 7, 2014
2014-06-17,A Beaten-Down Biotech Stock Poised for an Epic Short Squeeze
2014-06-03,3 Big-Volume Stocks in Breakout Territory
2014-05-30,ASCO '14: What's on Tap for Saturday
2014-05-28,5 Stocks Insiders Love Right Now
2017-03-16,Karyopharm Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Selinexor Clinical Update
2017-03-10,Karyopharm Announces Partial Clinical Hold To Pause Enrollment In Selinexor Trials
2017-03-09,Karyopharm To Report Fourth Quarter And Year End 2016 Financial Results On March 16, 2017
2017-03-03,Biotech Premarket Movers: Karyopharm, Lexicon, Prothena
2017-03-02,Karyopharm Announces Results From Interim Analysis Of Phase 2 SOPRA Study Evaluating Selinexor In Relapsed/Refractory Acute Myeloid Leukemia
2017-03-01,Karyopharm Announces The Presentation Of New Data At The 2017 American Association For Cancer Research Annual Meeting
2017-01-31,Karyopharm To Participate In Upcoming Investor Conferences
2017-01-19,Commit To Buy Karyopharm Therapeutics At $7.50, Earn 19.6% Annualized Using Options
2017-01-12,Short Interest Jumps 19.7% For KPTI
2017-01-03,Karyopharm To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-15,Karyopharm And Collaborators Awarded Grant For ALS Research
2016-12-05,Karyopharm Presents Updated Phase 1b STOMP Data At The American Society Of Hematology 2016 Annual Meeting
2016-12-04,Karyopharm Presents Updated Phase 2b STORM Data At The American Society Of Hematology 2016 Annual Meeting
2016-12-04,Karyopharm Presents Updated Phase 2 SAIL Relapsed/Refractory AML Clinical Data At The American Society Of Hematology 2016 Annual Meeting
2016-11-30,Karyopharm And The Multiple Myeloma Research Foundation Announce Panel Discussion Featuring Leading Multiple Myeloma Thought Leaders
2016-11-10,Karyopharm To Present At The Jefferies 2016 London Healthcare Conference
2016-11-07,Karyopharm Reports Third Quarter 2016 Financial Results And Highlights Recent Progress
2016-11-03,Karyopharm To Present Updated Phase 2b STORM And Phase 1b STOMP Clinical Data At The American Society Of Hematology 2016 Annual Meeting
2016-11-02,Karyopharm To Ring The Nasdaq Stock Market Closing Bell
2016-10-31,Karyopharm To Report Third Quarter 2016 Financial Results On November 7, 2016
2016-10-28,Karyopharm Therapeutics is Now Oversold (KPTI)
2016-10-20,Commit To Purchase Karyopharm Therapeutics At $7.50, Earn 32.4% Annualized Using Options
2016-10-11,Karyopharm To Present At The 15th Annual BIO Investor Forum
2016-10-05,Karyopharm To Present Updated SIGN Phase 2 Clinical Data At European Society Of Medical Oncology 2016 Annual Meeting
2016-09-29,Karyopharm Publishes Preclinical Data In Nature Demonstrating Selinexor's Potential In KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
2016-09-28,Karyopharm Publishes Preclinical And Phase 1 Clinical Data For Selinexor In Ovarian Cancer In Clinical Cancer Research Publication
2016-09-12,Karyopharm Appoints Humphrey A.R. Gardner MD, FCAP As Senior Vice President, Clinical Development
2016-09-06,Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug
2016-09-06,Karyopharm Reports Positive Top-Line Phase 2b STORM Results And Reviews The Planned Development Path For Selinexor In Multiple Myeloma
2016-08-30,Markets Very Sluggish as August Nears an End
2016-08-30,Karyopharm To Host Conference Call With Update On Multiple Myeloma Plans
2016-08-22,Noteworthy Monday Option Activity: KPTI, SHLD, MXWL
2016-08-19,These 7 Stocks Under $10 Could Make You a Lot of Money
2016-08-04,Karyopharm Reports Second Quarter 2016 Financial Results And Highlights Recent Progress
2016-08-03,Karyopharm To Present At Upcoming Investor Conferences
2016-07-28,Karyopharm To Report Second Quarter 2016 Financial Results On August 4, 2016
2016-07-27,Karyopharm To Present Updated Phase 2 Clinical Data From SIGN Study At European Society Of Medical Oncology 2016 Annual Meeting
2016-07-27,Karyopharm Announces Phase 1b Selinexor Sarcoma Data Published In Journal Of Clinical Oncology
2016-07-19,Commit To Purchase Karyopharm Therapeutics At $5, Earn 20.6% Annualized Using Options
2016-07-06,Karyopharm To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference
2016-06-22,Karyopharm Initiates Phase 1 Clinical Trial With KPT-9274
2016-06-16,Oversold Conditions For Karyopharm Therapeutics (KPTI)
2016-06-16,Karyopharm Outlines Key Selinexor Clinical Development Achievements
2016-06-15,Karyopharm To Present At The 2016 JMP Securities Life Science Conference
2016-06-10,Karyopharm Presents Preliminary STOMP Phase 1b Clinical Data At 2016 European Hematology Association Annual Meeting
2016-06-07,Insider Trading Alert - TRUP, KPTI And FCBC Traded By Insiders
2016-06-01,Karyopharm To Present At The Jefferies 2016 Healthcare Conference
2016-05-31,Insider Trading Alert - KPTI, CPIX And LB Traded By Insiders
2016-05-24,Insider Trading Alert - W, KPTI And GVP Traded By Insiders
2016-05-19,Karyopharm To Present Preliminary STOMP Phase 1B Clinical Data At 2016 European Hematology Association Annual Meeting
2016-05-18,Karyopharm To Present Selinexor Clinical Data At The American Society Of Clinical Oncology Annual Meeting
2016-05-09,Karyopharm Reports First Quarter 2016 Financial Results And Highlights Recent Progress
2016-05-02,Karyopharm To Report First Quarter 2016 Financial Results On May 9, 2016
2016-04-20,Karyopharm Presents Data Demonstrating The Potential Of Nuclear Export Protein Exportin 1 (XPO1) Inhibition In The Treatment Of Traumatic Brain Injury
2016-04-06,Karyopharm Taps TransPerfect As ETMF And Functional TMF Provider
2016-04-05,Karyopharm To Present At The 15th Annual Needham Healthcare Conference
2016-03-31,Karyopharm Receives NIAID Grant To Advance Development Of KPT-350 For The Treatment Of Lupus
2016-03-22,Karyopharm Therapeutics (KPTI) Strong On High Relative Volume Today
2016-03-16,Karyopharm To Present Data On Oncology Pipeline At The 2016 American Association For Cancer Research Annual Meeting
2016-03-14,Karyopharm Reports Fourth Quarter And Full Year 2015 Financial Results And Highlights Recent Progress
2016-03-07,Karyopharm To Report Fourth Quarter And Full Year 2015 Financial Results On March 14, 2016
2016-03-04,Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published In Journal Of Clinical Oncology
2016-03-02,7 Stocks Under $10 Making Big Breakout Moves
2016-02-03,Karyopharm To Present At The Leerink Partners 5th Annual Global Healthcare Conference
2016-01-21,5 Stocks Under $10 Set to Soar
2016-01-19,Karyopharm Initiates Second Generation SINE™ Compound Clinical Trial In Multiple Myeloma
2016-01-14,Karyopharm Initiates Clinical Trial Of Oral Selinexor In Advanced Liposarcoma
2016-01-06,Karyopharm Therapeutics is Now Oversold (KPTI)
2016-01-06,Karyopharm Therapeutics (KPTI) Highlighted As Weak On High Volume
2016-01-04,Karyopharm To Present At The 34th Annual J.P. Morgan Healthcare Conference
2015-12-07,Karyopharm Therapeutics Presents Positive Clinical Data On The Activity Of Selinexor In Combination With Other Anticancer Agents Across Multiple Hematologic Malignancies At The 2015 American Society Of Hematology (ASH) Annual Meeting
2015-11-30,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Hematologic Malignancies
2015-11-13,Karyopharm Therapeutics Stock Sees Short Interest Drop 13.5%
2015-11-09,Karyopharm Reports Third Quarter 2015 Financial Results And Highlights Recent Progress
2015-11-05,Karyopharm To Present Data On Oncology Pipeline At American Society Of Hematology 2015 Annual Meeting
2015-11-02,Karyopharm To Report Third Quarter 2015 Financial Results On November 9, 2015
2015-10-30,5 Stocks Ready to Break Out Higher
2015-10-19,Karyopharm Initiates STOMP Clinical Trial Of Oral Selinexor In Multiple Myeloma
2015-10-13,Short Interest Falls 11% For KPTI
2015-09-30,10 Worst NASDAQ Biotech Stocks in the Third Quarter
2015-09-29,Karyopharm Therapeutics is Now Oversold (KPTI)
2015-09-03,Karyopharm Advancing Neuroprotective SINE(TM) Compounds In Amyotrophic Lateral Sclerosis (ALS)
2015-08-28,5 Breakout Stocks to Trade for Big Gains
2015-08-25,Strong On High Relative Volume: Karyopharm Therapeutics (KPTI)
2015-08-18,Karyopharm Therapeutics is Now Oversold (KPTI)
2015-08-18,Perilous Reversal Watch: Karyopharm Therapeutics (KPTI)
2015-08-17,Karyopharm Therapeutics (KPTI) Showing Signs Of A Dead Cat Bounce Today
2015-08-14,Weak On High Volume: Karyopharm Therapeutics (KPTI)
2015-08-11,Karyopharm Therapeutics (KPTI) Is Strong On High Volume Today
2015-08-10,Karyopharm Reports Second Quarter 2015 Financial Results And Highlights Recent Progress
2015-08-06,Commit To Purchase Karyopharm Therapeutics At $20, Earn 31% Annualized Using Options
2015-08-04,Jim Cramer's 'Mad Money' Recap: Nowhere to Run, Nowhere to Hide From China
2015-08-03,Karyopharm To Report Second Quarter 2015 Financial Results On August 10, 2015
2015-07-24,Oversold Conditions For Karyopharm Therapeutics (KPTI)
2015-07-07,KPTI: Insiders Vs. Shorts
2015-06-26,Short Interest Increases 11.6% For KPTI
2015-06-22,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At International Conference On Malignant Lymphoma
2015-06-15,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
2015-06-05,5 Biotech Stocks Poised for Breakouts
2015-06-04,'Mad Money' Lightning Round: Buy, Buy, Buy Juno Therapeutics
2015-06-03,Jim Cramer's 'Mad Money' Recap: Individual Stocks Beat Baskets Any Day
2015-06-01,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Recurrent Glioblastoma And Advanced Sarcomas At 2015 ASCO Annual Meeting
2015-05-30,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Heavily Pretreated Gynecological Cancers And Asian Patients With Advanced Malignancies At 2015 ASCO Annual Meeting
2015-05-29,Fly Watch: Several Names That May Move Following ASCO Meeting
2015-05-28,Karyopharm Initiates STORM Clinical Trial Of Oral Selinexor (KPT-330) In Multiple Myeloma
2015-05-27,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Solid Tumors
2015-05-21,Karyopharm To Present Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
2015-05-14,Karyopharm Therapeutics (KPTI) Stock: Weak On High Volume Today
2015-05-13,Karyopharm To Present Solid Tumor Data On Lead Drug Candidate Selinexor At 2015 American Society Of Clinical Oncology Annual Meeting
2015-05-13,Jumpstart ASCO '15 With This Quick List of Hot Research Abstracts
2015-05-11,Karyopharm Reports First Quarter 2015 Financial Results And Highlights Recent Progress
2015-05-07,Karyopharm To Present At Bank Of America Merrill Lynch 2015 Healthcare Conference
2015-05-06,Commit To Purchase Karyopharm Therapeutics At $20, Earn 12.9% Annualized Using Options
2015-05-05,Karyopharm To Report First Quarter 2015 Financial Results On May 11, 2015
2015-04-17,Karyopharm To Present Late-Breaking Data At American Association For Cancer Research Annual Meeting
2015-04-14,Ratings Changes Today
2015-04-13,Karyopharm Granted U.S. Composition-of-Matter Patent For Selinexor (KPT-330)
2015-04-07,KPTI: Insiders Vs. Shorts
2015-04-02,'Mad Money' Lightning Round: Kinder Morgan, HCA Are Winners
2015-04-01,Jim Cramer's 'Mad Money' Recap: Get Ready for a Rough Ride
2015-04-01,Karyopharm Appoints Mikael Dolsten, MD, PhD To Its Board Of Directors
2015-03-18,Karyopharm To Present Data On Its Novel Oral PAK4 Allosteric Modulator (PAM) At The American Association For Cancer Research Annual Meeting
2015-03-18,Karyopharm To Present Data On Oncology Pipeline At American Association For Cancer Research Annual Meeting
2015-03-16,Karyopharm Reports Fourth Quarter And Full Year 2014 Financial Results And Highlights Recent Progress
2015-03-09,Karyopharm To Report Fourth Quarter And Full Year 2014 Financial Results On March 16, 2015
2015-02-23,Nature Neuroscience Publishes Data Demonstrating Potential Therapeutic Benefits Of Karyopharm's SINE(TM) Compounds In The Treatment Of Multiple Sclerosis
2015-02-05,Karyopharm To Present At Leerink Partners Global Healthcare Conference
2015-01-26,Commit To Purchase Karyopharm Therapeutics At $22.50, Earn 19.6% Annualized Using Options
2015-01-16,Karyopharm Therapeutics Is Now Oversold (KPTI)
2015-01-08,Karyopharm Announces Orphan Designation Granted By FDA For Selinexor (KPT-330) In Multiple Myeloma
2015-01-07,Karyopharm To Present At J.P. Morgan 33rd Annual Healthcare Conference
2015-01-06,Karyopharm Therapeutics Announces Pricing Of Public Offering Of Common Stock
2015-01-05,Karyopharm Therapeutics Announces Proposed Public Offering Of Common Stock
2014-12-15,Karyopharm Announces Addition To The NASDAQ Biotechnology Index
2014-12-11,Karyopharm Initiates Third Registration-Directed Clinical Trial Of Oral Selinexor (KPT-330)
2014-12-08,Jim Cramer's 'Mad Money' Recap: Why You Should Buy Disney, Starbucks, Nike Now
2014-12-08,Karyopharm Presents Positive Clinical Data For Selinexor (KPT-330) In NHL Patients At ASH 2014 Annual Meeting
2014-12-08,Karyopharm Presents Positive Combination Data For Selinexor (KPT-330) In Multiple Myeloma Patients At ASH 2014 Annual Meeting
2014-12-04,Karyopharm To Present At Oppenheimer 25th Annual Healthcare Conference
2014-12-01,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Oncology
2014-12-01,Karyopharm Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission
2014-11-24,Karyopharm Presents Data On Oncology Pipeline At EORTC-NCI-AACR Annual Meeting
2014-11-10,Karyopharm Reports Third Quarter 2014 Financial Results And Highlights Recent Progress
2014-11-10,Karyopharm Initiates Registration-Directed Clinical Study Of Selinexor (KPT-330) In Patients With Richter's Transformation
2014-11-06,Karyopharm Announces Data Presentations At American Society Of Hematology Annual Meeting
2014-11-05,Karyopharm To Present At Credit Suisse 2014 Healthcare Conference
2014-11-04,Karyopharm Appoints J. Scott Garland To Its Board Of Directors
2014-10-30,Karyopharm To Report Third Quarter 2014 Financial Results On November 10, 2014
2014-10-27,Karyopharm Expands Global Presence With European Subsidiary
2014-09-29,Karyopharm Announces Clinical Data For Selinexor (KPT-330) In Advanced Solid Tumors
2014-09-29,3 Unusual-Volume Biotech Stocks in Breakout Territory
2014-09-25,Karyopharm To Host Conference Call To Discuss Selinexor (KPT-330) Data Presented At ESMO 2014
2014-09-09,Karyopharm Announces Three Clinical Data Presentations At ESMO 2014
2014-08-08,Karyopharm Appoints Justin Renz Executive Vice President And Chief Financial Officer
2014-08-07,Karyopharm To Present At The Wedbush 2014 Life Sciences Management Access Conference
2014-08-07,Karyopharm Therapeutics Reports Second Quarter Financial Results For 2014
2014-08-01,Karyopharm To Host Second Quarter 2014 Earnings Call On August 7, 2014
2014-06-17,A Beaten-Down Biotech Stock Poised for an Epic Short Squeeze
2014-06-03,3 Big-Volume Stocks in Breakout Territory
2014-05-30,ASCO '14: What's on Tap for Saturday
2014-05-28,5 Stocks Insiders Love Right Now
2017-03-16,Karyopharm Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Selinexor Clinical Update
2017-03-10,Karyopharm Announces Partial Clinical Hold To Pause Enrollment In Selinexor Trials
2017-03-09,Karyopharm To Report Fourth Quarter And Year End 2016 Financial Results On March 16, 2017
2017-03-03,Biotech Premarket Movers: Karyopharm, Lexicon, Prothena
2017-03-02,Karyopharm Announces Results From Interim Analysis Of Phase 2 SOPRA Study Evaluating Selinexor In Relapsed/Refractory Acute Myeloid Leukemia
2017-03-01,Karyopharm Announces The Presentation Of New Data At The 2017 American Association For Cancer Research Annual Meeting
2017-01-31,Karyopharm To Participate In Upcoming Investor Conferences
2017-01-19,Commit To Buy Karyopharm Therapeutics At $7.50, Earn 19.6% Annualized Using Options
2017-01-12,Short Interest Jumps 19.7% For KPTI
2017-01-03,Karyopharm To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-15,Karyopharm And Collaborators Awarded Grant For ALS Research
2016-12-05,Karyopharm Presents Updated Phase 1b STOMP Data At The American Society Of Hematology 2016 Annual Meeting
2016-12-04,Karyopharm Presents Updated Phase 2b STORM Data At The American Society Of Hematology 2016 Annual Meeting
2016-12-04,Karyopharm Presents Updated Phase 2 SAIL Relapsed/Refractory AML Clinical Data At The American Society Of Hematology 2016 Annual Meeting
2016-11-30,Karyopharm And The Multiple Myeloma Research Foundation Announce Panel Discussion Featuring Leading Multiple Myeloma Thought Leaders
2016-11-10,Karyopharm To Present At The Jefferies 2016 London Healthcare Conference
2016-11-07,Karyopharm Reports Third Quarter 2016 Financial Results And Highlights Recent Progress
2016-11-03,Karyopharm To Present Updated Phase 2b STORM And Phase 1b STOMP Clinical Data At The American Society Of Hematology 2016 Annual Meeting
2016-11-02,Karyopharm To Ring The Nasdaq Stock Market Closing Bell
2016-10-31,Karyopharm To Report Third Quarter 2016 Financial Results On November 7, 2016
2016-10-28,Karyopharm Therapeutics is Now Oversold (KPTI)
2016-10-20,Commit To Purchase Karyopharm Therapeutics At $7.50, Earn 32.4% Annualized Using Options
2016-10-11,Karyopharm To Present At The 15th Annual BIO Investor Forum
2016-10-05,Karyopharm To Present Updated SIGN Phase 2 Clinical Data At European Society Of Medical Oncology 2016 Annual Meeting
2016-09-29,Karyopharm Publishes Preclinical Data In Nature Demonstrating Selinexor's Potential In KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
2016-09-28,Karyopharm Publishes Preclinical And Phase 1 Clinical Data For Selinexor In Ovarian Cancer In Clinical Cancer Research Publication
2016-09-12,Karyopharm Appoints Humphrey A.R. Gardner MD, FCAP As Senior Vice President, Clinical Development
2016-09-06,Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug
2016-09-06,Karyopharm Reports Positive Top-Line Phase 2b STORM Results And Reviews The Planned Development Path For Selinexor In Multiple Myeloma
2016-08-30,Markets Very Sluggish as August Nears an End
2016-08-30,Karyopharm To Host Conference Call With Update On Multiple Myeloma Plans
2016-08-22,Noteworthy Monday Option Activity: KPTI, SHLD, MXWL
2016-08-19,These 7 Stocks Under $10 Could Make You a Lot of Money
2016-08-04,Karyopharm Reports Second Quarter 2016 Financial Results And Highlights Recent Progress
2016-08-03,Karyopharm To Present At Upcoming Investor Conferences
2016-07-28,Karyopharm To Report Second Quarter 2016 Financial Results On August 4, 2016
2016-07-27,Karyopharm To Present Updated Phase 2 Clinical Data From SIGN Study At European Society Of Medical Oncology 2016 Annual Meeting
2016-07-27,Karyopharm Announces Phase 1b Selinexor Sarcoma Data Published In Journal Of Clinical Oncology
2016-07-19,Commit To Purchase Karyopharm Therapeutics At $5, Earn 20.6% Annualized Using Options
2016-07-06,Karyopharm To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference
2016-06-22,Karyopharm Initiates Phase 1 Clinical Trial With KPT-9274
2016-06-16,Oversold Conditions For Karyopharm Therapeutics (KPTI)
2016-06-16,Karyopharm Outlines Key Selinexor Clinical Development Achievements
2016-06-15,Karyopharm To Present At The 2016 JMP Securities Life Science Conference
2016-06-10,Karyopharm Presents Preliminary STOMP Phase 1b Clinical Data At 2016 European Hematology Association Annual Meeting
2016-06-07,Insider Trading Alert - TRUP, KPTI And FCBC Traded By Insiders
2016-06-01,Karyopharm To Present At The Jefferies 2016 Healthcare Conference
2016-05-31,Insider Trading Alert - KPTI, CPIX And LB Traded By Insiders
2016-05-24,Insider Trading Alert - W, KPTI And GVP Traded By Insiders
2016-05-19,Karyopharm To Present Preliminary STOMP Phase 1B Clinical Data At 2016 European Hematology Association Annual Meeting
2016-05-18,Karyopharm To Present Selinexor Clinical Data At The American Society Of Clinical Oncology Annual Meeting
2016-05-09,Karyopharm Reports First Quarter 2016 Financial Results And Highlights Recent Progress
2016-05-02,Karyopharm To Report First Quarter 2016 Financial Results On May 9, 2016
2016-04-20,Karyopharm Presents Data Demonstrating The Potential Of Nuclear Export Protein Exportin 1 (XPO1) Inhibition In The Treatment Of Traumatic Brain Injury
2016-04-06,Karyopharm Taps TransPerfect As ETMF And Functional TMF Provider
2016-04-05,Karyopharm To Present At The 15th Annual Needham Healthcare Conference
2016-03-31,Karyopharm Receives NIAID Grant To Advance Development Of KPT-350 For The Treatment Of Lupus
2016-03-22,Karyopharm Therapeutics (KPTI) Strong On High Relative Volume Today
2016-03-16,Karyopharm To Present Data On Oncology Pipeline At The 2016 American Association For Cancer Research Annual Meeting
2016-03-14,Karyopharm Reports Fourth Quarter And Full Year 2015 Financial Results And Highlights Recent Progress
2016-03-07,Karyopharm To Report Fourth Quarter And Full Year 2015 Financial Results On March 14, 2016
2016-03-04,Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published In Journal Of Clinical Oncology
2016-03-02,7 Stocks Under $10 Making Big Breakout Moves
2016-02-03,Karyopharm To Present At The Leerink Partners 5th Annual Global Healthcare Conference
2016-01-21,5 Stocks Under $10 Set to Soar
2016-01-19,Karyopharm Initiates Second Generation SINE™ Compound Clinical Trial In Multiple Myeloma
2016-01-14,Karyopharm Initiates Clinical Trial Of Oral Selinexor In Advanced Liposarcoma
2016-01-06,Karyopharm Therapeutics is Now Oversold (KPTI)
2016-01-06,Karyopharm Therapeutics (KPTI) Highlighted As Weak On High Volume
2016-01-04,Karyopharm To Present At The 34th Annual J.P. Morgan Healthcare Conference
2015-12-07,Karyopharm Therapeutics Presents Positive Clinical Data On The Activity Of Selinexor In Combination With Other Anticancer Agents Across Multiple Hematologic Malignancies At The 2015 American Society Of Hematology (ASH) Annual Meeting
2015-11-30,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Hematologic Malignancies
2015-11-13,Karyopharm Therapeutics Stock Sees Short Interest Drop 13.5%
2015-11-09,Karyopharm Reports Third Quarter 2015 Financial Results And Highlights Recent Progress
2015-11-05,Karyopharm To Present Data On Oncology Pipeline At American Society Of Hematology 2015 Annual Meeting
2015-11-02,Karyopharm To Report Third Quarter 2015 Financial Results On November 9, 2015
2015-10-30,5 Stocks Ready to Break Out Higher
2015-10-19,Karyopharm Initiates STOMP Clinical Trial Of Oral Selinexor In Multiple Myeloma
2015-10-13,Short Interest Falls 11% For KPTI
2015-09-30,10 Worst NASDAQ Biotech Stocks in the Third Quarter
2015-09-29,Karyopharm Therapeutics is Now Oversold (KPTI)
2015-09-03,Karyopharm Advancing Neuroprotective SINE(TM) Compounds In Amyotrophic Lateral Sclerosis (ALS)
2015-08-28,5 Breakout Stocks to Trade for Big Gains
2015-08-25,Strong On High Relative Volume: Karyopharm Therapeutics (KPTI)
2015-08-18,Karyopharm Therapeutics is Now Oversold (KPTI)
2015-08-18,Perilous Reversal Watch: Karyopharm Therapeutics (KPTI)
2015-08-17,Karyopharm Therapeutics (KPTI) Showing Signs Of A Dead Cat Bounce Today
2015-08-14,Weak On High Volume: Karyopharm Therapeutics (KPTI)
2015-08-11,Karyopharm Therapeutics (KPTI) Is Strong On High Volume Today
2015-08-10,Karyopharm Reports Second Quarter 2015 Financial Results And Highlights Recent Progress
2015-08-06,Commit To Purchase Karyopharm Therapeutics At $20, Earn 31% Annualized Using Options
2015-08-04,Jim Cramer's 'Mad Money' Recap: Nowhere to Run, Nowhere to Hide From China
2015-08-03,Karyopharm To Report Second Quarter 2015 Financial Results On August 10, 2015
2015-07-24,Oversold Conditions For Karyopharm Therapeutics (KPTI)
2015-07-07,KPTI: Insiders Vs. Shorts
2015-06-26,Short Interest Increases 11.6% For KPTI
2015-06-22,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At International Conference On Malignant Lymphoma
2015-06-15,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
2015-06-05,5 Biotech Stocks Poised for Breakouts
2015-06-04,'Mad Money' Lightning Round: Buy, Buy, Buy Juno Therapeutics
2015-06-03,Jim Cramer's 'Mad Money' Recap: Individual Stocks Beat Baskets Any Day
2015-06-01,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Recurrent Glioblastoma And Advanced Sarcomas At 2015 ASCO Annual Meeting
2015-05-30,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Heavily Pretreated Gynecological Cancers And Asian Patients With Advanced Malignancies At 2015 ASCO Annual Meeting
2015-05-29,Fly Watch: Several Names That May Move Following ASCO Meeting
2015-05-28,Karyopharm Initiates STORM Clinical Trial Of Oral Selinexor (KPT-330) In Multiple Myeloma
2015-05-27,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Solid Tumors
2015-05-21,Karyopharm To Present Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
2015-05-14,Karyopharm Therapeutics (KPTI) Stock: Weak On High Volume Today
2015-05-13,Karyopharm To Present Solid Tumor Data On Lead Drug Candidate Selinexor At 2015 American Society Of Clinical Oncology Annual Meeting
2015-05-13,Jumpstart ASCO '15 With This Quick List of Hot Research Abstracts
2015-05-11,Karyopharm Reports First Quarter 2015 Financial Results And Highlights Recent Progress
2015-05-07,Karyopharm To Present At Bank Of America Merrill Lynch 2015 Healthcare Conference
2015-05-06,Commit To Purchase Karyopharm Therapeutics At $20, Earn 12.9% Annualized Using Options
2015-05-05,Karyopharm To Report First Quarter 2015 Financial Results On May 11, 2015
2015-04-17,Karyopharm To Present Late-Breaking Data At American Association For Cancer Research Annual Meeting
2015-04-14,Ratings Changes Today
2015-04-13,Karyopharm Granted U.S. Composition-of-Matter Patent For Selinexor (KPT-330)
2015-04-07,KPTI: Insiders Vs. Shorts
2015-04-02,'Mad Money' Lightning Round: Kinder Morgan, HCA Are Winners
2015-04-01,Jim Cramer's 'Mad Money' Recap: Get Ready for a Rough Ride
2015-04-01,Karyopharm Appoints Mikael Dolsten, MD, PhD To Its Board Of Directors
2015-03-18,Karyopharm To Present Data On Its Novel Oral PAK4 Allosteric Modulator (PAM) At The American Association For Cancer Research Annual Meeting
2015-03-18,Karyopharm To Present Data On Oncology Pipeline At American Association For Cancer Research Annual Meeting
2015-03-16,Karyopharm Reports Fourth Quarter And Full Year 2014 Financial Results And Highlights Recent Progress
2015-03-09,Karyopharm To Report Fourth Quarter And Full Year 2014 Financial Results On March 16, 2015
2015-02-23,Nature Neuroscience Publishes Data Demonstrating Potential Therapeutic Benefits Of Karyopharm's SINE(TM) Compounds In The Treatment Of Multiple Sclerosis
2015-02-05,Karyopharm To Present At Leerink Partners Global Healthcare Conference
2015-01-26,Commit To Purchase Karyopharm Therapeutics At $22.50, Earn 19.6% Annualized Using Options
2015-01-16,Karyopharm Therapeutics Is Now Oversold (KPTI)
2015-01-08,Karyopharm Announces Orphan Designation Granted By FDA For Selinexor (KPT-330) In Multiple Myeloma
2015-01-07,Karyopharm To Present At J.P. Morgan 33rd Annual Healthcare Conference
2015-01-06,Karyopharm Therapeutics Announces Pricing Of Public Offering Of Common Stock
2015-01-05,Karyopharm Therapeutics Announces Proposed Public Offering Of Common Stock
2014-12-15,Karyopharm Announces Addition To The NASDAQ Biotechnology Index
2014-12-11,Karyopharm Initiates Third Registration-Directed Clinical Trial Of Oral Selinexor (KPT-330)
2014-12-08,Jim Cramer's 'Mad Money' Recap: Why You Should Buy Disney, Starbucks, Nike Now
2014-12-08,Karyopharm Presents Positive Clinical Data For Selinexor (KPT-330) In NHL Patients At ASH 2014 Annual Meeting
2014-12-08,Karyopharm Presents Positive Combination Data For Selinexor (KPT-330) In Multiple Myeloma Patients At ASH 2014 Annual Meeting
2014-12-04,Karyopharm To Present At Oppenheimer 25th Annual Healthcare Conference
2014-12-01,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Oncology
2014-12-01,Karyopharm Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission
2014-11-24,Karyopharm Presents Data On Oncology Pipeline At EORTC-NCI-AACR Annual Meeting
2014-11-10,Karyopharm Reports Third Quarter 2014 Financial Results And Highlights Recent Progress
2014-11-10,Karyopharm Initiates Registration-Directed Clinical Study Of Selinexor (KPT-330) In Patients With Richter's Transformation
2014-11-06,Karyopharm Announces Data Presentations At American Society Of Hematology Annual Meeting
2014-11-05,Karyopharm To Present At Credit Suisse 2014 Healthcare Conference
2014-11-04,Karyopharm Appoints J. Scott Garland To Its Board Of Directors
2014-10-30,Karyopharm To Report Third Quarter 2014 Financial Results On November 10, 2014
2014-10-27,Karyopharm Expands Global Presence With European Subsidiary
2014-09-29,Karyopharm Announces Clinical Data For Selinexor (KPT-330) In Advanced Solid Tumors
2014-09-29,3 Unusual-Volume Biotech Stocks in Breakout Territory
2014-09-25,Karyopharm To Host Conference Call To Discuss Selinexor (KPT-330) Data Presented At ESMO 2014
2014-09-09,Karyopharm Announces Three Clinical Data Presentations At ESMO 2014
2014-08-08,Karyopharm Appoints Justin Renz Executive Vice President And Chief Financial Officer
2014-08-07,Karyopharm To Present At The Wedbush 2014 Life Sciences Management Access Conference
2014-08-07,Karyopharm Therapeutics Reports Second Quarter Financial Results For 2014
2014-08-01,Karyopharm To Host Second Quarter 2014 Earnings Call On August 7, 2014
2014-06-17,A Beaten-Down Biotech Stock Poised for an Epic Short Squeeze
2014-06-03,3 Big-Volume Stocks in Breakout Territory
2014-05-30,ASCO '14: What's on Tap for Saturday
2014-05-28,5 Stocks Insiders Love Right Now
2017-03-24,Lifshitz & Miller LLP Announces Investigation Of Cemtrex, Inc., Kitov Pharmaceuticals Holdings LTD, NantHealth, Inc., Omega Protein Corporation, Pearson Plc, Trecora Resources, Trivago N.V. And WPP Plc
2017-03-14,DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Kitov Pharmaceuticals Holdings Ltd. To Contact The Firm
2017-03-10,Cohen Milstein Sellers & Toll PLLC Announces Investigation Of Kitov Pharmaceuticals Holdings Ltd.
2017-03-08,Kitov Announces License Agreement For KIT-302 In South Korea
2017-02-21,INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Kitov Pharmaceuticals Holdings Ltd. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2017-02-13,KTOV STOCK DROP NOTICE: Rosen Law Firm Reminds Kitov Pharmaceutical Holdings Ltd. Investors Of Important Deadline In Class Action - KTOV
2017-02-10,Kitov Announces Settlement Agreement With Minority Shareholder Of Recently Acquired TyrNovo
2017-02-09,Kitov Provides Further Update On Formal Investigation By Israeli Securities Authority
2017-02-08,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against Kitov Pharmaceutical Holdings LTD (KTOV) & Lead Plaintiff Deadline: April 10, 2017
2017-02-08,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Kitov Pharmaceutical Holdings Ltd. - KTOV
2017-02-07,Kitov Announces Initiation Of Formal Investigation By Israeli Securities Authority
2017-02-07,KTOV NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Kitov Pharmaceutical Holdings Ltd. To Contact The Firm
2017-02-07,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Kitov Pharmaceutical Holdings LTD (KTOV)
2017-02-06,EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Kitov Pharmaceutical Holdings Ltd.
2017-02-06,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Kitov Pharmaceutical Holdings Ltd. - KTOV
2017-02-01,Kitov Granted Notice Of Allowance From U.S. Patent & Trademark Office For KIT-302
2017-01-17,Kitov To Host Business Update Call On Monday, January 23, 2017
2017-01-12,Kitov Enters Immuno-Oncology Field Through Acquisition Of TyrNovo
2016-12-07,Kitov Successfully Completes All KIT-302 Testing Required For New Drug Application To U.S. FDA
2016-09-27,Kitov Reports Successful Results For Additional KIT-302 Pharmacokinetic Bioequivalence Study
2016-09-06,Kitov Pharmaceuticals To Present Data From A U.S. Market Assessment For KIT-302
2016-08-17,Kitov Pharmaceuticals Issues First Half 2016 Financial Reports
2016-08-10,Kitov Announces Issuance Of U.S. Patent Securing Long-Term Exclusivity For KIT-302 Ahead Of New Drug Application To The FDA
2016-07-05,Kitov Pharmaceuticals Announces Closing Of A $12 Million Follow-On Public Offering In The U.S.A.
2016-06-29,Kitov Pharmaceuticals Announces Pricing Of $12 Million Follow-On Public Offering In The U.S.A.
2016-06-28,Kitov's Lead Drug KIT-302 Achieves Manufacturing Milestone Ahead Of Planned NDA Filing With U.S. FDA
2016-06-24,Kitov Reports New Data Demonstrating KIT-302 Has Beneficial Effects On Kidney Function
2016-05-27,Kitov Announces Completion Of Manufacturing Pivotal Batches Of KIT-302 Required For Registration In The U.S.
2016-05-12,Kitov Granted Notice Of Allowance From U.S. Patent Office For KIT-302
2016-05-12,Kitov Receives Pre-NDA Meeting Response From FDA For KIT-302, Supporting Its NDA Submission
2016-05-10,Kitov Reports KIT-302 Study Successfully Meets U.S. Food & Drug Administration Bioequivalence Standards
2016-05-04,Kitov Pharmaceuticals To Present At Pioneers 2016, Presented By Joseph Gunnar, In NYC On May 5, 2016
2016-01-11,Kitov Pharmaceuticals To Present At Biotech Showcase In San Francisco On January 11, 2016
2016-01-08,Kitov Pharmaceuticals Appoints Dr. Gil Ben-Menachem As V.P. Of Business Development
2015-12-17,Kitov Pharmaceuticals Reports Additional Data From Its Phase III Trial On The Beneficial Blood Pressure Effects Of KIT-302
2015-12-15,Kitov Pharmaceuticals (KTOV) Stock Soars on Hypertension Drug Trial Results
2015-12-15,Kitov Pharmaceuticals' Pivotal Phase III Trial Successfully Meets Primary Efficacy Endpoint
2015-12-10,Kitov Pharmaceuticals To Announce Interim Results Of The Pivotal Phase III Trial On December 15, 2015 At 7:00am ET
2015-11-25,Kitov Pharmaceuticals Holdings Announces Closing Of U.S. Initial Public Offering
2015-11-20,Kitov Pharmaceuticals Holdings Announces Pricing Of U.S. Initial Public Offering And NASDAQ Listing
,
,
,
,
2017-03-14,Kura Oncology Reports Fourth Quarter And Full Year 2016 Operational And Financial Results
2017-03-07,Kura Oncology To Report Fourth Quarter And Full Year 2016 Financial Results
2017-03-06,Kura Oncology Reports Updated Clinical Activity Data In Ongoing Phase 2 Trial For Tipifarnib
2017-02-27,Kura Oncology Announces Presentation Of Preliminary Clinical Data For Tipifarnib In HRAS Mutant Squamous Cell Carcinomas Of The Head And Neck At TAT 2017
2017-02-09,Kura Oncology To Participate In Three Upcoming Investor Conferences
2017-01-17,Kura Oncology Doses First Patient In Phase 2 Study Of Tipifarnib In Chronic Myelomonocytic Leukemia
2017-01-04,Kura Oncology Receives FDA Clearance To Proceed With Clinical Trial For ERK Inhibitor KO-947 And Nominates KO-539 As Development Candidate For Menin-MLL Inhibitor Program
2017-01-03,Kura Oncology Appoints Steven Stein, M.D. To Board Of Directors
2016-12-01,Kura Oncology Presents Preclinical Data On KO-947 And Menin-MLL Inhibitor Program At The EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics
2016-11-18,Moleculin Biotech gets good verbal Ok from FDA which should cut time to Phase 1/2 trial down
2016-11-15,Kura Oncology To Present Preclinical Data On Pipeline Programs At EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics
2016-11-07,Kura Oncology Reports Third Quarter 2016 Financial Results
2016-11-04,Kura Oncology Presents Update On Pipeline Programs Targeting RAS-ERK Pathway At European Scientific Oncology Conference
2016-11-01,Kura Oncology To Participate In Two Upcoming Investor Conferences
2016-10-31,Kura Oncology To Report Third Quarter 2016 Financial Results
2016-10-31,Kura Oncology To Participate In The 9th European Scientific Oncology Conference
2016-09-14,Kura Oncology To Participate In The 2016 Aegis Growth Conference
2016-09-02,Kura Oncology To Participate In The 5th Annual Gateway Conference
2016-08-24,7 Stocks Under $10 Making Big Up Moves
2016-08-11,Here's Why Kura Oncology (KURA) Stock Is Soaring Today
2016-08-10,Kura Oncology Reports Second Quarter 2016 Financial Results
2016-08-03,Kura Oncology To Report Second Quarter 2016 Financial Results
2016-06-16,Kura Oncology Doses First Patient In Phase 2 Study Of Tipifarnib In Lower Risk Myelodysplastic Syndromes
2016-06-14,Kura Oncology To Participate In The 2016 JMP Life Sciences Conference
2016-06-03,Kura Oncology To Participate In The Jefferies 2016 Healthcare Conference
2016-05-11,Kura Oncology Reports First Quarter 2016 Financial Results
2016-03-17,Kura Oncology Reports Fourth Quarter And Full Year 2015 Operational And Financial Results
2016-03-11,Kura Oncology To Report Fourth Quarter And Full Year 2015 Financial Results
2016-02-04,Kura Oncology To Participate In The Leerink Global Healthcare Conference
2016-01-08,Reverse Mergers Losing Out to Lower-Cost Offerings
2015-12-03,Kura Oncology Announces Data Presentation On Lead Product Candidate Tipifarnib At The Upcoming ASH Meeting
2015-12-01,Kura Oncology To Present At The Oppenheimer 2015 Healthcare Conference
2015-11-30,Kura Oncology To Present At Upcoming Investor Conference
2015-11-30,Kura Oncology Announces First Patient Dosed In An Investigator-Sponsored Phase 2 Trial Of Tipifarnib In Patients With HRAS Mutant Urothelial Cancer
2015-11-11,Kura Oncology To Present At The Jefferies 2015 Global Healthcare Conference
,
,
,
,
2017-03-15,ATyr Pharma Announces Issuance Of US Patent That Extends Patent Protection Of Physiocrines Derived From 20 Out Of 20 Human TRNA Synthetases
2017-03-03,ATyr Pharma Receives EMA Orphan Drug Designation For The Treatment Of Limb Girdle Muscular Dystrophy With Resolaris™
2017-03-01,ATyr Pharma To Present At Cowen And Company 37th Annual Health Care Conference
2017-02-28,ATyr Pharma Receives U.S. FDA Orphan Drug Designation For The Treatment Of Limb Girdle Muscular Dystrophy With Resolaris™
2016-12-13,ATyr Pharma Reports Promising Signals Of Clinical Activity In Multiple Rare Genetically Distinct Myopathies With Resolaris™ In Exploratory Trials
2016-12-09,ATyr Pharma To Present At The BMO Prescriptions For Success Healthcare Conference
2016-11-21,ATyr Pharma Enters Into $20 Million Credit Facility
2016-10-24,ATyr Pharma Receives FDA Fast Track Designation For Resolaris™ To Treat Facioscapulohumeral Muscular Dystrophy (FSHD)
2016-10-06,ATyr Pharma Presents Additional Data For Resolaris™ Phase 1b/2 Trial In Adult Patients With Facioscapulohumeral Muscular Dystrophy At The 21st International Annual Congress Of The World Muscle Society
2016-09-29,ATyr Pharma Announces Presentation At The 21st International Annual Congress Of The World Muscle Society
2016-09-21,ATyr Pharma Appoints Industry Veteran In Novel Biology Biologics, David J. King, PhD, As Senior Vice President, Research
2016-09-15,7 Stocks Under $10 Making Big Moves Higher
2016-08-12,These 5 Stocks Are Breaking Out
2016-06-03,ATyr Pharma To Present At Jefferies 2016 Healthcare Conference
2016-05-05,ATyr Pharma Appoints Grove Matsuoka As Senior Vice President, Product Programs And Planning
2016-04-29,ATyr Pharma To Present At Upcoming May Investor Conferences
2016-04-13,5 Stocks With Big Insider Buying
2016-04-12,Here&rsquo;s A Reason aTyr Pharma (LIFE) Stock is Rising Today
2016-04-08,5 Stocks Poised for Breakouts
2016-04-07,ATyr Pharma (LIFE) Alert: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation Of ATyr Pharma, Inc.; Encourages Investors To Contact The Firm For Additional Information
2016-03-30,ATyr Pharma Appoints Sanjay Shukla, MD, MS, As Chief Medical Officer
2016-03-21,LifeWatch Discloses Supplemental Information On Highmark Arbitration Case
2016-03-03,LifeWatch™ Appoints Andrew Moore As Chief Financial Officer
2016-02-09,LifeWatch™ Receives FDA Clearance For Its Continuous Vital Signs Monitoring Service
2016-01-18,LifeWatch Receives FDA Clearance For Its Mobile Cardiac Telemetry 1-Lead Patch
2016-01-12,AliveCor Partners With LifeWatch To Expand Into Remote Patient Monitoring
2016-01-11,ATyr Provides Corporate Update And Outlook For 2016
2016-01-07,ATyr Pharma To Present At 34th Annual J.P. Morgan Healthcare Conference
2016-01-06,ATyr Pharma Appoints Sanuj Ravindran, M.D., As Chief Business Officer
2015-12-16,ATyr Pharma Added To NASDAQ Biotechnology Index
2015-11-19,Oversold Conditions For aTyr Pharma (LIFE)
2015-11-11,ATyr Pharma Selects Second IND Candidate, The First Engineered Physiocrine For GMP Process Development And For Potential Treatment Of Severe Lung Diseases
2015-11-10,ATyr Pharma To Host Breakout Session At The 6th Annual World Orphan Drug Congress
2015-11-09,ATyr Pharma Initiates Phase 1b/2 Clinical Trial In Patients With Early Onset FSHD
2015-11-04,Publication In Nature Demonstrates Physiocrine Genetic Mutation Disrupts A Key Signaling Pathway In Neuronal Biology
2015-11-03,ATyr Pharma To Present At 24th Annual Credit Suisse Healthcare Conference
2015-10-13,ATyr Pharma Initiates Phase 1b/2 Clinical Trial For Patients With Limb Girdle Muscular Dystrophy 2B
2015-09-24,ATyr Pharma Announces Presentations At The World Muscle Congress And 10th International Symposium On Aminoacyl-tRNA Synthetases (AARS2015)
2015-09-10,ATyr Pharma Doses First Patient In Long-Term Safety Extension Study Of Resolaris™ For Treatment Of Adult Patients With FSHD
2015-07-20,ATyr Pharma Announces Transitions In Clinical Development & Operations
2015-06-29,ATyr Pharma Added To Russell 2000®, 3000® And Global Indexes
2015-06-03,ATyr Pharma To Present At 35th Annual William Blair Growth Stock Conference
2015-05-12,ATyr Pharma, Inc. Announces Closing Of Initial Public Offering
2015-05-06,ATyr Pharma, Inc. Announces Pricing Of Initial Public Offering
2015-01-31,Prudential A Franchise Pick As Jefferies Initiates Coverage On 12 Life Insurers
2014-01-31,Three Plays on the Table
2014-01-24,Agree To Buy Life Technologies Corp At $75, Earn 0.8% Annualized Using Options
2014-01-21,Life Technologies Introduces First USDA-Licensed Real-Time PCR Test For The Detection Of Tritrichomonas Foetus DNA In Bulls
2014-01-16,Trade-Ideas: Life Technologies (LIFE) Is Today's New Lifetime High Stock
2014-01-09,Life Technologies To Provide Ion Torrent Sequencing Platform To Quest Diagnostics For Development Of New Molecular Tests
2014-01-06,Thanks to GE, Thermo Fisher Will Buy Life Technologies
2014-01-06,The Deal: GE Picks Up $1B in Thermo Fisher Assets
2013-12-20,Life Technologies' Ion AmpliSeq&#8482; Exome Certified Service Provider Program Adds 12 New Members In US, Europe And Asia Pacific
2013-12-11,Life Technologies Receives 2013 Presidential Green Chemistry Challenge Award By Environmental Protection Agency
2013-12-09,Life Technologies Collaborates With Canadian Centre For DNA Barcoding On Species Biodiversity Study
2013-12-08,Every Saudi's Choice To Have Genetic Code Mapped To Transform The Kingdom's Healthcare
2013-12-03,Plant Breeding Academy Opens In Nairobi That Will Boost Africa's Food Supply With Improved Indigenous Crops
2013-11-27,Do Lower CEO Pay Ratios Lead To High ROI For These 5 Stocks?
2013-11-12,Cincinnati Children's Joins Boston Children's To Establish The Claritas Pediatric Genomic Network
2013-10-24,Life Technologies Awards Digital PCR Innovation Grants To Five Research Labs
2013-10-22,Life Technologies' Ion Torrent Breakthrough Award Honors Discoveries And Genomic Research Fueled By Next-Generation Sequencing
2013-10-22,Ion Torrent Reduces Systematic Sequencing Error By 90 Percent, Cuts Template Preparation Time By More Than Five-Fold With Breakthrough Technologies
2013-10-21,Claritas Genomics To Sequence Exomes For VA Million Veteran Program With Ion Torrent Next-Generation Sequencers
2013-10-21,BGI Partners With Life Technologies To Offer Faster, More Affordable Sequencing Applications On Ion Torrent™
2013-10-15,Life Technologies Extends Partnership With DNAVEC, Launches Next Generation Stem Cell Reprogramming Solution
2013-10-11,Life Technologies Corp Stock Downgraded (LIFE)
2013-10-10,Ratings Changes Today
2013-10-09,Trade-Ideas: Life Technologies (LIFE) Is Today's "Water-Logged And Getting Wetter" Stock
2013-10-09,Life Technologies' GlobalFiler™ Express Kit Receives Approval For Use By The National DNA Index System
2013-10-09,Ion World 2013 Showcases Breakthrough Discoveries That Will Shape The Future Of Health Care
2013-10-08,Life Technologies' Ion AmpliSeq™ Exome Certified Service Provider Program Adds Eleven New Members
2013-09-30,Life Technologies And Advanced Cell Diagnostics Sign Global Distribution Agreement
2013-09-24,IGenomics To Purchase 32 Ion Proton™ Next-Generation Sequencers
2013-09-18,TriCore Reference Laboratories Named First Next-Generation Sequencing Center Of Excellence By Life Technologies
2013-09-18,Life Technologies Tops Life Sciences Sector Of Dow Jones 2013 Sustainability Index
2013-09-10,Exome Sequencing Now Fast And Affordable With Life Technologies' New Ion AmpliSeq™ Exome Certified Service Provider Program
2013-08-27,Life Technologies Launches Industry's First End-to-End Sequencing Solution For Human Exome Copy Number Variation Analysis
2013-08-26,Life Technologies Expands Food Testing Portfolio To Global Brewing And Beverage Industry
2013-08-21,Life Technologies Stockholders Approve Acquisition By Thermo Fisher
2013-08-16,Stock Futures Rise on Positive Consumer Data as Pandora Jumps
2013-08-05,Life Technologies And RainTree Oncology Services Announce Collaboration To Bring Molecular Tumor Testing To Community Oncologists
2013-08-01,Life Technologies Opens State-of-the-Art DNA Forensics Laboratory In India
2013-07-31,Life Technologies Enters Into An Exclusive License And Supply Agreement For Dynabeads
2013-07-30,Life Technologies Signs Five-Year Agreement With The FDA
2013-07-25,Life Technologies Expands CEERAM Food Safety Range To Global Market
2013-07-24,Life Technologies Expands Line Of High-Performance QPCR Instruments
2013-07-22,Life Technologies Announces Filing Of Definitive Proxy Statement
2013-07-16,Life Technologies To Collaborate With Merck Serono For Companion Diagnostics Development And Commercialization
2013-07-15,Life Technologies Makes Automated Cell Imaging Accessible To All Labs
2013-07-10,Life Reaches New 52-Week High (LIFE)
2013-07-10,Life Technologies Corp Stock Buy Recommendation Reiterated (LIFE)
2013-07-03,Insider Trading Alert - Life Technologies And 4 Others Traded By Insiders
2013-07-03,Insider Trading Alert - Life Technologies And 4 Others Traded By Insiders
2013-07-02,Life Technologies Ion AmpliSeq™ Exome Kit Delivers Industry's Best Performance And Simplest, Fastest Workflow*
2013-07-01,Life Technologies Corp Stock Buy Recommendation Reiterated (LIFE)
2013-06-26,Life Technologies Supports Global Effort To Help Accelerate Emergency Screening Of Novel Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
2013-06-19,Life Technologies Signs Licensing Agreement With Suzhou Ribo Life Sciences For Development Of SiRNA Therapeutics In China
2013-06-17,Life Technologies Expands Range Of Stem Cell Reprogramming Solutions
2013-06-13,Life Technologies Corp Stock Buy Recommendation Reiterated (LIFE)
2013-06-13,Life Technologies Acquires LSK, Leading Instruments Distributor In Korea
2013-06-12,Life Technologies Launches Industry's First Stem Cell Characterization Panel
2013-06-10,Life Technologies Begins Shipping QuantStudio™ 3D Digital PCR System
2013-06-10,Life Technologies Launches Compendia Oncomine® NGS Power Tools For Cancer Researchers, Discovers Novel Gene Fusions
2013-05-31,4 M&A Deal Stocks to Watch in June
2013-05-30,Life Stock Hits New 52-Week High (LIFE)
2013-05-22,Life Reaches New 52-Week High (LIFE)
2013-05-21,Life Technologies Corp Stock Buy Recommendation Reiterated (LIFE)
2013-05-14,New Ion PGM™ Solution Outperforms Competitor On Major Performance Metrics For Benchtop Sequencing
2013-05-13,Patent Protection For TAL Effector Technology Enables Licensing Path For Life Technologies Customers
2013-05-08,The Deal: Thermo Fisher's Purchase of Life Technologies Runs Through China
2013-05-03,Life Technologies Corp Stock Buy Recommendation Reiterated (LIFE)
2013-04-30,'Mad Money' Lightning Round: Staying Away From Sandstorm Gold
2013-04-29,Cramer's 'Mad Money' Recap: Dazed and Confused Markets
2013-04-26,Life Technologies Supports Global Effort To Help Accelerate Emergency Screening Of Avian Influenza (H7N9) Virus
2013-04-24,Life Stock Hits New 52-Week High (LIFE)
2013-04-23,Life Technologies' Ion Proton™ To Power Stratified Medicine Scotland Innovation Centre
2013-04-22,Lifshitz Law Firm Announces Investigation Of Anaren, Inc., Archon Corporation, Life Technologies Corporation And National Financial Partners Corp.
2013-04-22,Life Technologies Corp Stock Buy Recommendation Reiterated (LIFE)
2013-04-18,Life Technologies Partners With Ridom And Releases SeqSphere+ Software To Speed And Simplify Bacterial Typing
2013-04-17,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Life Technologies Corporation In Connection With The Sale Of The Company To Thermo Fisher Scientific, Inc.
2013-04-16,Law Office Of Brodsky & Smith, LLC Announces Investigation Of Life Technologies Corporation
2013-04-15,S&P Drops Most in 5 Months as Boston Explosion Heightens Market Concerns
2013-04-15,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Life Technologies Corporation - LIFE
2013-04-15,Block & Leviton LLP Investigates Life Technologies Corporation For Possible Breaches Of Fiduciary Duty In Connection With Its Acquisition By Thermo Fisher Scientific Inc.
2013-04-15,Citi Beats, Thermo Fisher's $13.6B Deal
2013-04-15,Thermo Fisher Jumps on $13.6B Life Tech Deal
2013-04-15,Life Technologies Corporation Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Thermo Fisher Scientific
2013-04-15,Life Rises On Unusually High Volume (LIFE)
2013-04-15,Dish Offers to Buy Sprint for $25.5 Billion: Ahead of the Ticker
2013-04-15,Stock Futures Signal Declines as China Grows Less Than Forecast
2013-04-15,Morning Briefing: 10 Things You Should Know
2013-04-15,Stocks to Watch: Citigroup, Charles Schwab
2013-04-14,Thermo Fisher Near Deal for Life Tech: Reports
2013-04-12,Life Reaches New 52-Week High (LIFE)
2013-04-12,Life Technologies Acquires KDR Biotech Co., LTD., Leading Reagents Distributor
2013-04-11,Life Technologies Launches New Bioinformatics Software Platform Enabling Bio-Design And Gene Synthesis From Next Generation Sequencing Data
2013-04-10,Law Office Of Brodsky & Smith, LLC Announces Investigation Of Life Technologies Corporation
2013-04-10,Stocks to Watch: Yahoo!, Apple, Health Management
2013-04-04,Life Technologies Launches Oncomine® Bioinformatics Solutions For Cancer Researchers
2013-04-02,Life Reaches New 52-Week High (LIFE)
2013-04-02,Life Technologies Launches Two Ion AmpliSeq™ Community Panel Designs: Ion AmpliSeq™ BRCA1 And BRCA2 Panel And The Ion AmpliSeq™ Colon & Lung Cancer Panel
2013-04-01,Higher Than Normal Risk Ahead
2013-03-28,Life Technologies To Invest $18 Million In Facility Expansion And Current Good Manufacturing Practice Compliance Plan
2013-03-27,Life Technologies Announces SFDA Clearance For Its 3500xL Dx Genetic Analyzer In China And The Launch Of 10 Assays From Its Joint Venture With Daan Gene
2013-03-20,BioMed Realty To Lease 204,900 Square Feet To Life Technologies At The Science Center At Oyster Point In South San Francisco
2013-03-18,Quidel And Life Technologies Receive FDA Clearance For Clostridium Difficile Assay And QuantStudio™ Dx And 7500 Fast Dx Real-Time PCR Instruments
2013-03-12,S&P Ends Seven-Day Winning Streak as Markets Exhale
2013-03-12,Life Technologies Corp (LIFE): Today's Featured Health Care Winner
2013-03-12,Stock Futures Dip After Recent Big Run-Up
2013-03-12,Morning Briefing: 10 Things You Should Know
2013-03-12,Stocks to Watch: Costco, Yum! Brands
2013-03-06,5 Stocks Pushing The Health Care Sector Lower
2013-03-04,Life Technologies Signs License And Collaborative Stem Cell Research Agreement With Harvard University
2013-03-01,Life Technologies Corp (LIFE): Today's Featured Health Care Winner
2013-02-22,Ion Semiconductor Sequencing Data Presentations At AGBT Demonstrate More Than >1,000-fold Throughput Scaling In First Two Years On The Market
2013-02-21,4 Biotech Stock Stars Losing Their Luster
2013-02-21,Roswell Park Cancer Institute Purchases Six Ion Torrent Sequencers
2013-02-21,Life Technologies To Present At Barclays Global Healthcare Conference
2013-02-20,Life Technologies Bolsters Its 60 Percent Market Share Lead In Benchtop Sequencers With 12 New Ion Torrent™ Products
2013-02-13,Life Technologies Corp (LIFE): Today's Featured Health Care Winner
2013-02-13,5 Stocks Pushing The Health Services Industry Higher
2013-02-11,Life Technologies Receives FDA 510(k) Clearance For Diagnostic Use Of Sanger Sequencing Platform And HLA Typing Kits
2013-02-06,'Mad Money' Lightning Round: There's Safety in KeyCorp
2013-02-05,Cramer's 'Mad Money' Recap: Follow the Big Money
2013-02-04,Life Technologies Corp (LIFE): Today's Featured Health Care Laggard
2013-01-30,5 Stocks Pushing The Health Care Sector Higher
2013-01-30,Life Technologies To Help Identify Up To 20,000 Human Remains Found In Libya's Mass Graves
2013-01-29,Life Technologies Establishes International Influenza Network
2013-01-28,Analysts' Actions: AKS BBBY IMGN RIG LIFE
2013-01-25,Life Reaches New 52-Week High (LIFE)
2013-01-25,Life Technologies To Present At Leerink Swann Global Healthcare Conference
2013-01-23,Life Technologies Named #33 Among Global 100 Most Sustainable Corporations
2013-01-22,Life Technologies Acquires BAC BV, Expands Capabilities In Bioprocessing
2013-01-18,Life Rises On Unusually High Volume (LIFE)
2013-01-17,Life Reaches New 52-Week High (LIFE)
2013-01-17,Life Technologies To Report Fourth Quarter And Fiscal Year 2012 On Feb. 4
2013-01-08,Life Stock Hits New 52-Week High (LIFE)
2012-12-19,Stocks Under $5: Stealth Health Care Play
2012-12-19,Life Technologies 400 Base-pair Sequencing Kit For Ion PGM™ Sequencer Delivers Reads 60 Percent Longer Than Comparable High-throughput Benchtop Sequencers
2012-12-18,Life Technologies To Present At JP Morgan 2013 Healthcare Conference
2017-03-23,La Jolla Pharmaceutical Company Announces Pricing Of Public Offering Of Common Stock
2017-03-20,La Jolla Pharmaceutical Company Announces Proposed Underwritten Public Offering Of Common Stock
2017-03-20,Insider Bets Paying Off At LJPC As New 52-Week High Reached
2017-03-20,Biotechs Remain the Best Place For Stock Picking
2017-02-28,6 Stocks with Unusual Volume Activity
2017-02-28,6 Stocks on the Move With Unusual Volume
2017-02-27,Stocks Inch Higher in Cautious Trading Ahead of Trump's Budget, Tax Plans
2017-02-27,How to Trade 7 Most-Active Stocks: AMD, La Jolla Pharma, Tesla and More
2017-02-27,Stocks Trade Flat as Trump Pledges $54B Bump in Defense Spending
2017-02-27,What You Need to Know About La Jolla's Shock-Treatment Drug
2017-02-27,Stock Futures Retreat as Wall Street Awaits Details of Trump's Tax Plan
2017-02-27,La Jolla Pharma Drug Raises Blood Pressure in Late-Stage Study of Shock Patients
2017-02-27,La Jolla Pharmaceutical Stock Spikes on Positive Trial Results
2017-02-27,La Jolla Pharmaceutical Company Announces Positive Top-Line Results From ATHOS-3 Phase 3 Study Of LJPC-501
2017-02-23,La Jolla Pharmaceutical Company Announces Fourth Quarter And Full Year 2016 Financial Results And Corporate Progress
2017-02-13,Notable Monday Option Activity: LJPC, ILG, PF
2017-01-13,Notable Friday Option Activity: LJPC, AIG, AVXL
2016-11-03,La Jolla Pharmaceutical Company Announces Financial Results For The Three And Nine Months Ended September 30, 2016 And Recent Corporate Progress
2016-10-24,La Jolla Pharmaceutical Company Receives Positive Opinion From European Orphan Committee For LJPC-401
2016-10-13,Short Interest Expands By 32% For LJPC
2016-10-04,Commit To Buy La Jolla Pharmaceutical Co. At $15, Earn 24.5% Annualized Using Options
2016-09-09,These 7 Stocks Are Spiking on Big Volume
2016-09-08,Shark Bites: Aratana Therapeutics Makes Its Move
2016-09-07,La Jolla Pharmaceutical Company Announces Agreement With European Medicines Agency On Pivotal Study Of LJPC-401
2016-09-07,La Jolla Pharmaceutical Company Reports Positive Results From Phase 1 Study Of LJPC-401
2016-08-22,LJPC: Insiders vs. Shorts
2016-08-08,La Jolla Pharmaceutical Company Announces Financial Results For The Three And Six Months Ended June 30, 2016
2016-06-06,La Jolla Pharmaceutical Company To Provide Corporate Overview At The Jefferies 2016 Global Healthcare Conference
2016-06-03,5 Stocks Triggering Breakout Trades
2016-05-23,Jim Cramer's 'Mad Money' Recap: These 5 Are Falling for Holding Too Much Cash
2016-05-10,Relative Strength Alert For La Jolla Pharmaceutical
2016-05-06,La Jolla Pharmaceutical Company Announces First Quarter 2016 Financial Results And Recent Corporate Progress
2016-04-05,Commit To Buy La Jolla Pharmaceutical At $17.50, Earn 28% Annualized Using Options
2016-03-03,La Jolla Pharmaceutical Company To Provide Corporate Overview At The Cowen And Company 36th Annual Health Care Conference
2016-02-25,La Jolla Pharmaceutical Company Announces Fourth Quarter And Full Year 2015 Financial Results And Highlights Corporate Progress
2016-02-08,La Jolla Pharmaceutical Becomes Oversold (LJPC)
2016-01-29,La Jolla Pharmaceutical Company To Provide Corporate Overview At The 2016 BIO CEO & Investor Conference
2016-01-14,Short Interest Jumps 24% For LJPC
2016-01-08,La Jolla Pharmaceutical Enters Oversold Territory (LJPC)
2016-01-04,Commit To Purchase La Jolla Pharmaceutical At $17.50, Earn 25.9% Annualized Using Options
2015-11-30,La Jolla Pharmaceutical Company Announces Notice Of Allowance For U.S. Patent Covering LJPC-501
2015-11-20,La Jolla Pharmaceutical (LJPC) Weak On High Volume Today
2015-11-06,La Jolla Pharmaceutical Company Announces Third Quarter 2015 Financial Results And Recent Corporate Progress
2015-10-19,La Jolla Pharmaceutical Company Doses First Patient In Phase 1 Clinical Trial Of LJPC-401 In Patients At Risk Of Iron Overload
2015-09-29,'Mad Money' Lightning Round: Take PPG Over Sherwin-Williams
2015-09-28,Jim Cramer's 'Mad Money' Recap: 5 Groups You Once Loved but Now Hate
2015-09-28,First Week of November 20th Options Trading For La Jolla Pharmaceutical (LJPC)
2015-09-15,La Jolla Pharmaceutical Company Closes Offering Of Common Stock
2015-09-11,La Jolla Pharmaceutical Company Receives Positive Opinion From European Orphan Committee For LJPC-401
2015-09-10,La Jolla Pharmaceutical Company Announces Pricing Of Underwritten Offering Of Common Stock
2015-09-09,La Jolla Pharmaceutical Company Announces Proposed Underwritten Offering Of Common Stock
2015-08-18,La Jolla Pharmaceutical Company Receives Orphan Drug Designation For Two Novel Compounds For Fibrodysplasia Ossificans Progressiva
2015-08-18,La Jolla Pharmaceutical Company And Vanderbilt University Enter Exclusive Research And License Agreement Covering Novel BMP Type-I Receptor Inhibitors
2015-08-11,La Jolla Pharmaceutical Company Announces FDA Acceptance Of IND For LJPC-401
2015-08-07,La Jolla Pharmaceutical Company Announces Second Quarter 2015 Financial Results And Recent Corporate Progress
2015-08-05,La Jolla Pharmaceutical Company Announces Exclusive Worldwide License Agreements Covering LJPC-30Sa And LJPC-30Sb
2015-08-04,Jim Cramer's 'Mad Money' Recap: Nowhere to Run, Nowhere to Hide From China
2015-07-06,Commit To Purchase La Jolla Pharmaceutical At $20, Earn 22.7% Annualized Using Options
2015-07-01,Lakhmir S. Chawla, M.D. Receives The International Vicenza Award
2015-06-17,La Jolla Pharmaceutical Company To Provide Corporate Overview At The JMP Securities Life Science Conference 2015
2015-05-27,La Jolla Pharmaceutical Company To Provide Corporate Overview At The Jefferies 2015 Global Healthcare Conference
2015-05-07,La Jolla Pharmaceutical Company Acquires Rights To Next-Generation Gentamicin Derivatives
2015-05-07,La Jolla Pharmaceutical Company Announces Portfolio Reprioritization
2015-04-29,La Jolla Pharmaceutical Company Announces First Quarter 2015 Financial Results And Corporate Highlights
2015-04-27,La Jolla Pharmaceutical Company Appoints Lakhmir S. Chawla, M.D., As Chief Medical Officer
2015-04-22,La Jolla Pharmaceutical Company Announces Additions To LJPC-401 Advisory Board
2015-04-17,5 Stocks Ready for Breakouts
2015-04-06,La Jolla Pharmaceutical Company Appoints Dennis Mulroy As Chief Financial Officer
2015-03-24,La Jolla Pharmaceutical Company Announces Initiation Of Phase 3 Clinical Trial Of LJPC-501 In Catecholamine-Resistant Hypotension
2015-03-18,La Jolla Pharmaceutical Company Announces Initiation Of Phase 2b Clinical Trial Of GCS-100 In Advanced Chronic Kidney Disease
2015-03-16,La Jolla Pharmaceutical Company Announces Fourth Quarter And Full Year 2014 Financial Results And Corporate Highlights
2015-03-02,4 Big-Volume Stocks to Trade for Breakouts: La Jolla Pharma and More
2015-02-09,La Jolla Pharmaceutical Company Announces Special Protocol Assessment For Planned Phase 3 Trial Of LJPC-501 In Catecholamine-Resistant Hypotension
2015-02-04,La Jolla Pharmaceutical Company To Provide Corporate Overview At 17th Annual BIO CEO & Investor Conference
2014-12-09,La Jolla Pharmaceutical Company And The George Washington University Announce Exclusive Worldwide License Agreement
2014-11-12,Results From Phase 2 Study Of GCS-100 In Chronic Kidney Disease Being Presented At American Society Of Nephrology Kidney Week
2014-11-12,La Jolla Pharmaceutical Company Announces Third Quarter And Year-to-Date 2014 Financial Results And Corporate Highlights
2014-10-27,5 Stocks Spiking on Unusual Volume
2014-10-23,La Jolla Pharmaceutical Company Announces Data Presentation At The American Society Of Nephrology Kidney Week
2014-10-10,La Jolla Pharmaceutical Becomes Oversold (LJPC)
2014-09-08,La Jolla Pharmaceutical Company To Provide Corporate Overview At The Rodman & Renshaw 16th Annual Global Investment Conference
2014-08-25,La Jolla Pharmaceutical Company Announces First Patient Enrolled In Clinical Trial Of LJPC-501 In Hepatorenal Syndrome
2014-08-14,La Jolla Pharmaceutical Company Announces Second Quarter And Year-to-Date 2014 Financial Results
2014-08-14,La Jolla Pharmaceutical Company Receives Notice Of Allowance For Additional Patent Claims Covering Modified Pectin For The Treatment Of Chronic Inflammation
2014-08-11,La Jolla Pharmaceutical Company To Provide Corporate Overview At The 2014 Wedbush Securities Life Sciences Conference
2014-07-29,Galectin Drug is a Fatty Liver Flop
2014-07-28,La Jolla Pharmaceutical Company Closes Offering Of Common Stock
2014-07-24,4 Biotech Stocks Breaking Out on Big Volume
2014-07-23,La Jolla Pharmaceutical Company Announces Pricing Of Underwritten Offering Of Common Stock
2014-07-22,La Jolla Pharmaceutical Company Announces Proposed Underwritten Offering Of Common Stock
2014-07-15,La Jolla Pharmaceutical Announces Positive Pre-Clinical Data For Oral Galectin-3 Inhibitor In Nonalcoholic Steatohepatitis (NASH)
2014-07-14,5 Stocks Breaking Out With Big Volume
2014-07-08,La Jolla Pharmaceutical Company Announces Planned Initiation Of Phase 3 Registration Program For LJPC-501 In Resistant Hypotension
2014-07-07,La Jolla Pharmaceutical Company Strengthens Board Of Directors With Appointment Of Robert H. Rosen
2014-06-30,La Jolla Pharmaceutical Company Added To The Russell Microcap Index
2014-06-19,La Jolla Pharmaceutical Company To Provide Corporate Overview At The 2014 BIO International Convention
2014-06-18,La Jolla Pharmaceutical Company To Provide Corporate Overview At The 9th Annual JMP Securities Healthcare Conference
2014-06-16,La Jolla Pharmaceutical Company Enters Into Agreement With Stanford University For New Drug Delivery Technology
2014-06-04,La Jolla Pharmaceutical Company Announces Completion Of Enrollment Of Phase 2 Extension Study Of GCS-100 In Chronic Kidney Disease
2014-05-28,La Jolla Pharmaceutical Company To Provide Corporate Overview At The Jefferies 2014 Global Healthcare Conference
2014-04-30,La Jolla Pharmaceutical Company Announces First-Quarter 2014 Financial Results
2014-03-31,La Jolla Pharmaceutical Company Announces Fourth-Quarter And Full-Year 2013 Financial Results And Highlights Recent Corporate Progress
2014-03-31,La Jolla Pharmaceutical Company Receives Patent Allowance Covering Broad Range Of Modified Pectin
2014-03-14,5 Stocks Poised for Breakouts
2014-03-12,Small-Cap Biotech on the Verge of a Breakout: ABIO
2014-03-11,Speculative Money Propels Biotechs La Jolla Pharma, Aeterna Zentaris
2014-03-11,Why La Jolla (LJPC) Is Surging Today
2014-03-11,La Jolla's Kidney Drug Is Statistical Noise but Stock Soars
2014-03-11,Morning Es Trading
2014-03-10,La Jolla Pharmaceutical Company Reports Positive, Top-Line Results From Phase 2 Clinical Trial Of GCS-100 In Chronic Kidney Disease
2014-03-07,5 Stocks Ready for Breakouts
2014-03-05,La Jolla Pharmaceutical Company To Present At 26th Annual ROTH Growth Stock Conference
2014-02-27,La Jolla Pharmaceutical Company And The George Washington University Enter Into Agreement For Technology Related To LJPC-501
2014-02-21,La Jolla Pharmaceutical Company Announces Final Dosing In Phase 2 Clinical Trial Of GCS-100 In Chronic Kidney Disease
2014-02-20,La Jolla Pharmaceutical Company Receives Notice Of Allowance For Patent Claims Covering Modified Pectin For Treatment Of Chronic Inflammation
2014-02-07,Biotech Stock Mailbag: Furiex, La Jolla Pharma, Sarepta
2012-07-20,La Jolla Pharmaceutical Company Investor Presentation Now Available For On-Demand Viewing At RetailInvestorConferences.com
2012-01-20,La Jolla Pharmaceutical Company Acquires GCS-100, A First-in-Class Galectin-3 Antagonist
2011-04-13,La Jolla Pharmaceutical Company Announces Reverse Stock Split
2011-04-05,La Jolla Pharmaceutical Company To Focus On Regenerative Medicine With The Acquisition Of Novel Class Of Compounds
2010-12-07,La Jolla Pharmaceutical Company Announces Appointment Of Dr. Bertrand C. Liang To Board Of Directors
2010-09-07,La Jolla Pharmaceutical Company Provides Update On Search For Clinical Products To In-License Or Acquire
2010-05-25,LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES FINANCING OF UP TO $16.3 MILLION
2010-03-05,La Jolla Pharmaceutical Announces Termination Of Merger Agreement With Adamis Pharmaceuticals
2010-03-03,La Jolla Pharmaceutical Announces Delisting From Nasdaq And Failure To Get Stockholder Vote For Merger
2010-03-01,La Jolla Pharmaceutical Company Announces The Adjournment Of Special Meeting Of Stockholders
2010-02-24,La Jolla Pharmaceutical Company Provides Voting Update - More Votes Needed Or La Jolla Will Likely Close
2009-10-19,Midday Movers: Pump Up the Volume
2009-07-15,Odds, Analysts Against Human Genome's Lupus Drug
2009-03-11,Genentech Lupus Data Fall Short
2009-03-11,Human Genome's Plan B: Lupus Drug
2009-01-06,BioMarin Buys Rights to Long-Delayed La Jolla Drug
2008-05-03,Feuerstein's Biotech-Stock Mailbag
2007-06-13,Wednesday's Health Winners & Losers
2007-05-24,Reversal of Fortune
2007-05-24,Positive Drug Data Lift La Jolla Pharma
2007-03-17,Feuerstein's Biotech Mailbag
2007-03-08,Thursday's Small-Cap Winners & Losers
2005-10-07,The Health Stocks in Motion
2005-07-12,'Mad Money' Mailbag: Cheap Stocks Will Cost You
2005-03-30,La Jolla Pharma Slashing Jobs
2004-10-18,La Jolla on High Road as Tough Journey Awaits
2004-10-15,Health Stocks in Motion
2003-11-26,Vision of Kinder, Gentler FDA to Be Challenged
2003-05-05,La Jolla Pharmaceutical Shoots Up on Drug Application
2003-02-18,La Jolla Shares Crash After Drug Disappointment
,
2017-03-09,Lexicon To Present At The Barclays Global Healthcare Conference
2017-03-06,Lexicon To Present At The Cowen And Company 37th Annual Healthcare Conference
2017-03-03,Biotech Premarket Movers: Karyopharm, Lexicon, Prothena
2017-03-01,Lexicon To Report Fourth Quarter And Year End 2016 Financial Results On March 3, 2017
2017-03-01,4 Smaller Biotech Names Worth Researching
2017-02-28,FDA Approves Lexicon Drug XERMELO™ (telotristat Ethyl) 250 Mg As First And Only Oral Treatment For Carcinoid Syndrome Diarrhea In Cancer Patients With Metastatic Neuroendocrine Tumors
2017-02-13,Lexicon To Present At The Leerink Partners 6th Annual Global Healthcare Conference
2017-01-30,7 Things to Watch in Biotech Now
2017-01-12,These 3 Biotech Stocks Are Already Moving Wildly on Thursday
2017-01-09,Lexicon Begins Phase 1 Clinical Trial Of Locally-acting SGLT1 Inhibitor, LX2761, For Potential Treatment Of Diabetes
2017-01-05,Lexicon To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-22,First Week of LXRX February 2017 Options Trading
2016-12-21,Lexicon Reports Positive Top-line Results In Second Pivotal Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes
2016-12-16,Notable Friday Option Activity: LXRX, WTW, XBIT
2016-12-05,Lexicon Reports Top-Line Results From Phase 2 Clinical Trial Conducted In Collaboration With JDRF
2016-11-21,Lexicon Announces The Establishment Of The Commercial Leadership Team For Telotristat Ethyl
2016-11-14,Lexicon To Present At The Stifel 2016 Healthcare Conference And The Jefferies 2016 Global Healthcare Conference
2016-11-07,Lexicon Pharmaceuticals Acquires Exclusive Rights To Development Candidate For Neuropathic Pain From Its Alliance With Bristol-Myers Squibb
2016-11-02,Ratings Changes Today
2016-10-31,Lexicon Announces Publication Of TELESTAR Study Results For Telotristat Ethyl In The Journal Of Clinical Oncology
2016-10-25,Lexicon Reports Positive Top-Line Results In Phase 2 Dose-Ranging Study For Sotagliflozin In Patients With Type 1 Diabetes
2016-10-25,Lexicon To Report Third Quarter 2016 Financial Results On November 1, 2016
2016-10-13,Short Interest In Lexicon Pharmaceuticals Moves 16% Higher
2016-10-05,Lexicon Pharmaceuticals Announces Agreement To Buy Out Remaining Obligations To Symphony Icon
2016-10-03,Telecast Data Presented At The 2016 North American Neuroendocrine Tumor Society Annual Symposium
2016-09-14,FDA Extends PDUFA Date For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome
2016-09-09,Lexicon Reports Positive Top-Line Results In Pivotal Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes
2016-09-07,Lexicon To Present At The Bank Of America Merrill Lynch Global Health Care Conference
2016-08-12,Lexicon To Present At The 2016 Wedbush PacGrow Healthcare Conference
2016-08-01,Lexicon To Report Second Quarter 2016 Financial Results On August 4, 2016
2016-07-18,Lexicon Announces The Validation By The European Medicine Agency Of The Marketing Authorization Application For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome
2016-07-07,Lexicon To Present At The Cantor Fitzgerald Healthcare Conference
2016-07-07,First Week Of LXRX August 19th Options Trading
2016-06-06,Lexicon To Present At The Jefferies 2016 Healthcare Conference
2016-06-02,Lexicon Announces The Launch Of Aboutcarcinoid.com To Provide Carcinoid Syndrome Disease Education To Patients, Caregivers And Physicians
2016-05-31,Lexicon Announces FDA Priority Review Of New Drug Application For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome
2016-05-24,7 Stocks Spiking on Big Volume
2016-05-10,Praveen Tyle, Ph.D. Joins Lexicon As Executive Vice President Of Research And Development
2016-05-05,Lexicon To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference
2016-04-29,Lexicon To Report First Quarter 2016 Financial Results On May 3, 2016
2016-04-07,Lexicon To Present At The 15th Annual Needham Healthcare Conference
2016-03-30,Lexicon Submits New Drug Application To FDA For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome
2016-03-09,Lexicon Pharmaceuticals (LXRX) Weak On High Volume Today
2016-03-08,Lexicon Announces Telotristat Etiprate Data To Be Presented At European Neuroendocrine Tumor Society Conference
2016-03-03,Lexicon To Present At The 36th Annual Cowen Healthcare Conference
2016-03-02,Ratings Changes Today
2016-03-01,Strong On High Volume: Lexicon Pharmaceuticals (LXRX)
2016-02-25,Lexicon To Report Fourth Quarter And Year End 2015 Financial Results On March 1, 2016
2016-02-05,Lexicon Pharmaceuticals Enters Oversold Territory (LXRX)
2016-02-04,Blueprint Medicines Appoints Lonnel Coats To Board Of Directors
2016-01-14,Short Interest Falls 10.8% For LXRX
2016-01-07,Lexicon To Present At The 34th Annual J.P. Morgan Healthcare Conference
2015-12-07,Lexicon To Present At The Oppenheimer 26th Annual Healthcare Conference
2015-12-01,Telotristat Etiprate Achieves Positive Top-Line Results In Second Phase 3 Clinical Trial
2015-11-12,Lexicon To Present At The Stifel 2015 Healthcare Conference And The Jefferies 2015 Global Healthcare Conference
2015-11-10,Stock To Watch: Lexicon Pharmaceuticals (LXRX) In Perilous Reversal
2015-11-06,Sanofi And Lexicon Pharmaceuticals To Collaborate On Sotagliflozin, An Investigational New Oral Medicine For People With Diabetes
2015-11-06,Sanofi And Lexicon Pharmaceuticals To Collaborate On Sotagliflozin, An Investigational New Oral Medicine For People With Diabetes
2015-11-05,Lexicon To Report Third Quarter 2015 Financial Results On November 6, 2015
2015-10-28,Today's Weak On High Volume Stock: Lexicon Pharmaceuticals (LXRX)
2015-10-19,Cancer Patients Treated With Lexicon's Telotristat Etiprate Report Improved Function And Well-Being
2015-10-09,Lexicon Announces Telotristat Etiprate Data To Be Presented At North American Neuroendocrine Tumor Society Annual Symposium
2015-09-30,10 Best Nasdaq Biotech Stocks in the Third Quarter
2015-09-29,Lexicon's Telotristat Etiprate Shows Clinical Benefit In Treating Carcinoid Syndrome In Cancer Patients When Added To Standard Of Care
2015-09-28,Media Alert: Lexicon To Discuss Complete Results Of Pivotal Phase 3 TELESTAR Study
2015-09-08,Lexicon Announces Sotagliflozin Data To Be Presented At European Association For The Study Of Diabetes
2015-09-04,2 Issues Keeping Buyers on the Sidelines Today
2015-09-03,Today's Perilous Reversal Stock: Lexicon Pharmaceuticals (LXRX)
2015-08-26,Lexicon Announces Telotristat Etiprate Data To Be Presented At European Cancer Congress
2015-08-20,Lexicon Pharmaceuticals (LXRX) Is Today's Strong On High Volume Stock
2015-08-18,Trade-Ideas: Lexicon Pharmaceuticals (LXRX) Is Today's "Perilous Reversal" Stock
2015-08-10,Lexicon To Present At The 2015 Wedbush PacGrow Healthcare Conference
2015-08-05,Lexicon To Report Second Quarter 2015 Financial Results On August 7, 2015
2015-08-04,Lexicon Shares Soar After Success in Late-Stage Cancer Drug Trial
2015-08-04,Lexicon CEO: Carcinoid Drug Offers Biggest Advance in Over a Decade
2015-08-04,Stock To Watch: Lexicon Pharmaceuticals (LXRX) In Perilous Reversal
2015-08-03,Today's Pre-Market Mover With Heavy Volume: Lexicon Pharmaceuticals (LXRX)
2015-08-03,Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome
2015-07-27,Weak On High Volume: Lexicon Pharmaceuticals (LXRX)
2015-07-20,Lexicon Pharmaceuticals (LXRX) Strong On High Relative Volume Today
2015-06-19,Lexicon Pharmaceuticals (LXRX) Weak On High Volume Today
2015-06-06,Lexicon Announces Presentation Of Manuscript At The American Diabetes Association Diabetes Care Symposium
2015-05-28,Lexicon To Present At The Jefferies 2015 Healthcare Conference
2015-05-27,Today's Weak On High Volume Stock: Lexicon Pharmaceuticals (LXRX)
2015-05-21,Lexicon Pharmaceuticals Larger Than S&P 500 Component Tenet Healthcare
2015-05-12,Lexicon Announces Selection Of Manuscript To Be Presented At The American Diabetes Association Diabetes Care Symposium
2015-05-07,Lexicon To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference
2015-04-29,Lexicon Announces One For Seven Reverse Stock Split Effective May 20, 2015
2015-04-27,Lexicon To Report First Quarter 2015 Financial Results On April 29, 2015
2015-04-15,Lexicon Pharmaceuticals And Bristol-Myers Squibb Select Development Candidate For Neuropathic Pain In Neuroscience Drug Discovery And Development Alliance
2015-04-09,Lexicon To Present At Needham & Company's 14th Annual Healthcare Conference
2015-03-25,Lexicon Pharmaceuticals Announces First Patient Screened In Pivotal Phase 3 Clinical Trial Of Sotagliflozin
2015-03-18,Lexicon And Ipsen Expand Their Licensing And Commercialization Agreement For Telotristat Etiprate To Include Canada
2015-03-09,Lexicon Pharmaceuticals Completes Enrollment In Pivotal Phase 3 Clinical Trial Of Telotristat Etiprate
2015-03-03,4 Stocks Under $10 Triggering Breakout Trades
2015-03-02,Lexicon To Report Fourth Quarter And Year End 2014 Financial Results On March 4, 2015
2015-02-26,Lexicon To Present At The Cowen 35th Annual Health Care Conference
2015-02-23,Lexicon Announces Management Change
2015-02-06,Lexicon To Present At The BIO CEO & Investor Conference
2015-01-07,Lexicon To Present At The 33rd Annual J.P. Morgan Healthcare Conference
2014-12-08,Lexicon To Present At The Oppenheimer 25th Annual Healthcare Conference
2014-11-21,Lexicon Announces Pricing Of Common Stock Offering
2014-11-19,Lexicon Announces Proposed Common Stock Offering
2014-11-19,Lexicon Announces Proposed Convertible Senior Notes Offering
2014-11-04,Lexicon Strengthens Clincial Operations And Commercial Readiness
2014-11-03,Lexicon To Report Third Quarter 2014 Financial Results On November 4, 2014
2014-10-22,Lexicon And Ipsen Enter Into Ex-North America/Japan Licensing And Commercialization Agreement For Telotristat Etiprate
2014-10-22,Lexicon And Ipsen Enter Into Ex-North America/Japan Licensing And Commercialization Agreement For Telotristat Etiprate
2014-09-11,Lexicon Announces A Publication In The American Diabetes Association's Journal, Diabetes Care
2014-09-04,Lexicon To Present At The Morgan Stanley 2014 Global Healthcare Conference
2014-08-08,Lexicon To Present At The 2014 Wedbush Life Sciences Management Access Conference
2014-08-05,Lexicon To Report Second Quarter 2014 Financial Results On August 7, 2014
2014-07-09,Lexicon And JDRF Collaborate For Phase 2 Clinical Trial Of LX4211 In Type 1 Diabetes
2014-07-07,Lexicon Announces Appointment Of Lonnel Coats As President And Chief Executive Officer
2014-06-14,Lexicon Presents LX4211 Data At American Diabetes Association Meeting
2014-05-30,Lexicon To Present At The Jefferies 2014 Global Healthcare Conference
2014-05-09,Lexicon To Present At The 2014 Bank Of America Merrill Lynch Healthcare Conference
2014-05-05,Lexicon To Report First Quarter 2014 Financial Results On May 8, 2014
2014-04-14,LX4211 Achieves Positive Results In Type 1 Diabetes Clinical Trial
2014-04-03,Lexicon To Present At The 2014 Needham Healthcare Conference
2014-02-20,Lexicon To Report Fourth Quarter And Year End 2013 Financial Results On February 28, 2014
2014-02-03,Lexicon To Present At The BIO CEO And Investor Conference
2014-01-30,5 Stocks Under $10 Set to Soar
2014-01-13,Lexicon Announces Focus On Late-Stage Development Programs And Preparation For Commercialization
2014-01-08,Lexicon To Present At The J.P. Morgan Healthcare Conference
2013-12-30,The Billion-Dollar Biotech Club: Speculation Trumped Risk
2013-12-03,Lexicon Completes Phase 2 Study Of LX1033 In IBS-d
2013-12-02,Lexicon Pharmaceuticals To Host 2013 Research And Development Day
2013-11-15,Lexicon To Present At The Jefferies Global Healthcare Conference
2013-11-07,Lexicon To Present At The Credit Suisse Healthcare Conference
2013-11-06,Lexicon To Report Third Quarter Financial Results On November 12, 2013
2013-10-09,Lexicon Completes Pilot Study Of Telotristat Etiprate In Ulcerative Colitis
2013-10-01,LX4211 Achieves Positive Results In Type 2 Diabetes Patients With Renal Impairment
2013-09-06,Lexicon To Present At The Stifel Nicolaus Healthcare Conference
2013-09-05,Lexicon To Present At The Morgan Stanley Global Healthcare Conference
2013-08-07,Lexicon To Present At The Wedbush PacGrow Life Sciences Management Access Conference
2013-08-01,Lexicon Pharma's Never-Ending Diabetes Drug Partner Talks
2013-07-23,Lexicon To Report Second Quarter Financial Results On July 30, 2013
2013-06-24,Lexicon Presents Preclinical Data On LX2761, A New Clinical Candidate For Diabetes Designed To Reduce Glucose Absorption From Gastrointestinal Tract
2013-06-24,Lexicon Presents Data At The American Diabetes Association Meeting On Blood Pressure Reduction And Weight Loss In Clinical Trial Of LX4211
2013-06-18,John Northcott Joins Lexicon As Vice President Of Marketing, Commercial Strategy And Operations
2013-06-07,Lexicon To Present At The Goldman Sachs Global Healthcare Conference
2013-05-31,Lexicon To Present At The Jefferies Global Healthcare Conference
2013-05-28,Lexicon To Present At The Deutsche Bank DbAccess Healthcare Conference
2013-05-13,Lexicon To Present At The Bank Of America Merrill Lynch Healthcare Conference
2013-05-10,Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
2013-05-03,Lexicon To Report First Quarter Financial Results On May 10, 2013
2013-04-29,Lexicon Pharma Falls on Concerns Raised by Merck-Pfizer Diabetes Partnership
2013-04-25,Lexicon To Present At The Needham Healthcare Conference
2013-04-02,8 Stocks Under $5 Seeing Institutional And Insider Buying
2013-03-20,7 Biotechnology Stocks With Insider Buying Activity
2013-03-11,10 Stocks Insiders And Hedge Funds Think Will Go Higher
2013-03-01,Lexicon To Present At The Cowen Healthcare Conference
2013-02-25,Lexicon To Present At The RBC Capital Markets Healthcare Conference
2013-02-18,Lexicon To Report Fourth Quarter And Year End 2012 Financial Results On February 21, 2013
2013-02-06,Lexicon To Present At The BIO CEO & Investor Conference
2013-01-03,Lexicon To Present At The J.P. Morgan Healthcare Conference
2012-12-17,Lexicon's Drug Candidate For Irritable Bowel Syndrome Receives Fast Track Status From The FDA
2012-11-20,Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
2012-11-12,Lexicon Pharmaceuticals To Present At The Jefferies 2012 Global Healthcare Conference
2012-11-07,Still Bullish on BioMarin, Lexicon Pharma
2012-11-06,LX4211 Phase 2b Results Presented At American Heart Association Annual Conference
2012-10-31,5 Stocks Insiders Love Right Now
2012-10-31,Lexicon To Provide Third Quarter 2012 Financial Results
2012-10-18,Lexicon Announces Pricing Of Common Stock Offering
2012-10-17,Lexicon Announces Proposed Common Stock Offering
2012-10-16,Lexicon Pharma: Blockbuster Potential From A Diabetes Drug
2012-10-12,Lexicon Initiates Phase 3 Clinical Trial Of Telotristat Etiprate In Patients With Carcinoid Syndrome
2012-10-12,Second Phase 2 Trial Of Telotristat Etiprate Shows Positive Results In Carcinoid Syndrome
2012-09-11,Lexicon Pharmaceuticals' CEO Presents At Morgan Stanley Healthcare Conference (Transcript)
2012-09-07,Lexicon Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
2012-08-31,Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
2012-08-16,Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
2012-08-14,Lexicon's CEO Presents At Wedbush PacGrow 2012 Life Sciences Management Access Conference (Transcript)
2012-08-10,Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
2012-07-31,Lexicon Pharmaceutical's CEO Discusses Q2 2012 Results - Earnings Call Transcript
2012-07-24,Lexicon To Provide Second Quarter 2012 Financial Results
2012-07-12,5 Stocks Under $10 Set to Soar
2012-06-29,Lexicon Announces Publication Of Results Of Two Studies Of LX4211 In Patients With Type 2 Diabetes In The Journal Clinical Pharmacology & Therapeutics
2012-06-26,Lexicon Pharmaceuticals' CEO Discusses LX4211 Top-line Data From Phase 2b Trial (Transcript)
2017-03-15,Mateon Therapeutics Announces Initial Data From Third Cohort Of Phase 1b Study Of OXi4503 In Relapsed/Refractory AML
2017-03-08,Mateon Therapeutics To Present At 29th Annual ROTH Conference
2017-02-13,Mateon Therapeutics Announces Initial Pre-clinical Data On Combination Of CA4P With Checkpoint Inhibitors
2017-02-07,Mateon Therapeutics To Present At BIO CEO & Investor Conference On February 13, 2017
2017-01-20,Mateon Therapeutics To Present Data On Study OX4218 In Neuroendocrine Tumors At ASCO Gastrointestinal Cancers Symposium
2016-12-08,OTC Markets Group Welcomes Mateon Therapeutics To OTCQX
2016-12-07,Mateon Common Stock To Trade On OTCQX Beginning On December 8, 2016
2016-12-06,Mateon Announces Presentation Of OXi4503 AML Study Data At 58th Annual Meeting Of American Society Of Hematology
2016-11-14,Mateon Provides Corporate Update And Reports Third Quarter 2016 Financial Results
2016-11-11,Mateon Announces Adjournment Of Special Meeting Of Stockholders
2016-10-31,Mateon Announces Presentation Of CA4P Posters At Meeting Of The International Gynecologic Cancer Society
2016-10-27,Mateon Expands Board Of Directors With The Appointments Of Donald R. Reynolds And Bobby W. Sandage, Jr., Ph.D.
2016-10-10,Mateon Announces Issuance Of US Patent For Cathepsin Inhibition
2016-09-26,Mateon Announces Collaboration With US Oncology Research To Participate In Phase 2/3 FOCUS Study
2016-09-20,Mateon Therapeutics To Present At The Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016
2016-09-07,Mateon Therapeutics To Present At The 18th Annual Rodman And Renshaw Global Investment Conference In New York On September 12, 2016
2016-08-03,Mateon Provides Corporate Update And Reports Second Quarter 2016 Financial Results
2016-07-21,Mateon Announces Enrollment Of First Patient In Phase 2 Portion Of PAZOFOS Study In Recurrent Ovarian Cancer
2016-06-23,Mateon Announces Initiation Of FOCUS Study In Platinum-Resistant Ovarian Cancer
,
,
,
,
,
2017-03-15,Mateon Therapeutics Announces Initial Data From Third Cohort Of Phase 1b Study Of OXi4503 In Relapsed/Refractory AML
2017-03-08,Mateon Therapeutics To Present At 29th Annual ROTH Conference
2017-02-13,Mateon Therapeutics Announces Initial Pre-clinical Data On Combination Of CA4P With Checkpoint Inhibitors
2017-02-07,Mateon Therapeutics To Present At BIO CEO & Investor Conference On February 13, 2017
2017-01-20,Mateon Therapeutics To Present Data On Study OX4218 In Neuroendocrine Tumors At ASCO Gastrointestinal Cancers Symposium
2016-12-08,OTC Markets Group Welcomes Mateon Therapeutics To OTCQX
2016-12-07,Mateon Common Stock To Trade On OTCQX Beginning On December 8, 2016
2016-12-06,Mateon Announces Presentation Of OXi4503 AML Study Data At 58th Annual Meeting Of American Society Of Hematology
2016-11-14,Mateon Provides Corporate Update And Reports Third Quarter 2016 Financial Results
2016-11-11,Mateon Announces Adjournment Of Special Meeting Of Stockholders
2016-10-31,Mateon Announces Presentation Of CA4P Posters At Meeting Of The International Gynecologic Cancer Society
2016-10-27,Mateon Expands Board Of Directors With The Appointments Of Donald R. Reynolds And Bobby W. Sandage, Jr., Ph.D.
2016-10-10,Mateon Announces Issuance Of US Patent For Cathepsin Inhibition
2016-09-26,Mateon Announces Collaboration With US Oncology Research To Participate In Phase 2/3 FOCUS Study
2016-09-20,Mateon Therapeutics To Present At The Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016
2016-09-07,Mateon Therapeutics To Present At The 18th Annual Rodman And Renshaw Global Investment Conference In New York On September 12, 2016
2016-08-03,Mateon Provides Corporate Update And Reports Second Quarter 2016 Financial Results
2016-07-21,Mateon Announces Enrollment Of First Patient In Phase 2 Portion Of PAZOFOS Study In Recurrent Ovarian Cancer
2016-06-23,Mateon Announces Initiation Of FOCUS Study In Platinum-Resistant Ovarian Cancer
,
,
,
,
,
2017-03-17,How to Trade the Week's Most Active Stocks--Rite Aid, Amgen, MuleSoft and More
2017-03-17,The Medicines Company And Alnylam Pharmaceuticals Report Positive Final Results From ORION-1 Phase II Study Of Inclisiran
2017-03-17,AveXis, Esperion and Amgen Among Biotech Movers
2017-03-14,The Medicines Company To Webcast Presentation Of ORION-1 Phase II Study Of Inclisiran At ACC.17
2017-03-06,The Medicines Company To Host Conference Call And Webcast At Upcoming American College Of Cardiology's 66th Annual Scientific Sessions
2017-02-28,The Medicines Company Reports Fourth-Quarter And Full-Year 2016 Financial Results
2017-02-21,The Medicines Company Announces FDA Filing Acceptance Of New Drug Application For Intravenous Antibiotic Carbavance® (meropenem-vaborbactam)
2017-02-17,The Medicines Company To Announce Fourth-Quarter And Full-Year 2016 Financial Results On February 28, 2017
2017-02-15,Biotech Premarket Movers: Ardelyx, Acorda Therapeutics, Medicines Co.
2017-02-03,Insiders Seeing Green With MDCO At New 52-Week High
2017-02-03,Premarket Biotech Movers: Portola, Esperion, Medicines
2017-01-25,The Medicines Company To Present Results From ORION-1 Phase 2 Study Of Inclisiran At The American College Of Cardiology's 66th Annual Scientific Session
2017-01-08,The Medicines Company Announces Positive Top-Line Results From Day 180 Interim Analysis In Ongoing ORION-1 Phase 2 Study Of Inclisiran (formerly, PCSK9si)
2017-01-06,Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View
2017-01-04,The Medicines Company To Present At J. P. Morgan Healthcare Conference
2016-12-15,5 Stocks Insiders Love Right Now
2016-11-15,The Medicines Company And Alnylam Pharmaceuticals Present Positive Results From ORION-1 Phase 2 Study Of Inclisiran (formerly PCSK9si)
2016-11-13,Http://www.themedicinescompany.com/
2016-11-10,The Medicines Company To Host Conference Call And Webcast To Review Data From Ongoing ORION-1 Phase 2 Study Of PCSK9si
2016-11-07,The Medicines Company Discontinues Development Of MDCO-216, Its Investigational Cholesterol Efflux Promoter
2016-10-26,The Medicines Company Reports Third-Quarter 2016 Financial Results
2016-10-18,The Medicines Company Announces Positive Top-Line Results From Day 90 Interim Analysis In Ongoing ORION-1 Phase 2 Study Of PCSK9si
2016-10-17,The Medicines Company To Announce Third Quarter Financial Results On October 26, 2016
2016-10-17,The Medicines Company's Infectious Disease Portfolio Featured In 16 Presentations At IDWeek 2016
2016-10-13,The Medicines Company To Present Data From Its Investigational Anesthetic MDCO-700 At The ANESTHESIOLOGY® 2016 Annual Meeting And The ISAP 25th Annual Meeting
2016-10-06,Why Medicines Co. (MDCO) Stock is Falling Today
2016-10-05,The Medicines Company Provides Progress Update On Ongoing ORION-1 Study Of PCSK9si
2016-10-05,Notable Wednesday Option Activity: MDCO, PEIX, BEAT
2016-09-21,The Medicines Company Awarded Up To $132 Million To Develop Portfolio Of New Antibiotics Targeting Drug-Resistant Infections Under Strategic Partnership With BARDA
2016-08-30,The Medicines Company Provides Update On Dyslipidemia Programs
2016-07-27,The Medicines Company Reports Second-Quarter 2016 Business And Financial Results
2016-07-18,The Medicines Company To Announce Second Quarter Financial Results On July 27, 2016
2016-07-12,Federal Circuit Rules For The Medicines Company In Angiomax® (bivalirudin) Patent Litigation
2016-07-11,Barbarian At The Gate: Medicines (MDCO)
2016-06-27,Medicines (MDCO) Flagged As Strong On High Volume
2016-06-27,The Medicines Company Announces Positive Top- Line Results For Phase 3 TANGO 1 Clinical Trial Of CARBAVANCE®
2016-06-21,The Medicines Company Completes Divestiture Of Its Non-Core Cardiovascular Assets To Chiesi
2016-06-15,Insiders Are Scooping Up Shares of These 5 Stocks
2016-06-14,The Medicines Company Announces Initiation Of Phase II Study For Its Investigational Anesthetic, ABP-700
2016-06-13,The Medicines Company Announces Participation At ASM MICROBE 2016 To Be Held June 16 - 20 In Boston
2016-06-09,MDCO: Insiders vs. Shorts
2016-06-07,Medicines (MDCO) Moving On Heavy Pre-Market Trading
2016-06-06,The Medicines Company Prices $350 Million Of Convertible Notes
2016-06-06,Barbarian At The Gate: Medicines (MDCO)
2016-06-06,The Medicines Company Announces Intention To Offer $350 Million Of Convertible Notes
2016-06-02,The Medicines Company Completes Patient Enrollment For ORION-1 Study Of PCSK9si
2016-05-26,The Medicines Company Announces Completion Of Patient Enrollment In Phase 3 TANGO 1 Study Of CARBAVANCE® (meropenem-vaborbactam) For Treatment Of Complicated Urinary Tract Infections (cUTI)
2016-05-25,The Medicines Company To Present At Two Upcoming Investor Conferences
2016-05-18,5 Stocks Insiders Are Scooping Up Right Now
2016-05-16,The Medicines Company Appoints Tony Kingsley As President And Chief Operating Officer
2016-05-09,The Medicines Company Reports First-Quarter 2016 Business And Financial Results
2016-05-09,The Medicines Company Agrees To Divest Non-Core Cardiovascular Assets To Chiesi Farmaceutici S.p.A.
2016-05-02,The Medicines Company To Present At Bank Of America Merrill Lynch 2016 Health Care Conference
2016-04-26,The Medicines Company To Announce First Quarter Financial Results On May 9, 2016
2016-04-11,FDA Grants Fast Track Status For Investigational Antibiotic CARBAVANCE® (meropenem-vaborbactam)
2016-04-04,The Medicines Company Announces Participation At 2016 European Congress Of Clinical Microbiology And Infectious Diseases (ECCMID) To Be Held April 9-12 In Amsterdam
2016-03-28,The Medicines Company Announces Participation At 2016 American College Of Cardiology (ACC) Scientific Sessions In Chicago
2016-03-09,Insider Trading Alert - MDCO, DXCM And WMGI Traded By Insiders
2016-03-02,The Medicines Company To Present At Cowen And Company 36th Annual Health Care Conference
2016-02-19,The Medicines Company To Participate In 2016 RBC Capital Markets Global Healthcare Conference
2016-02-18,Medicines (MDCO) Stock Price Target Lowered at Jefferies
2016-02-17,Medicines Co. (MDCO) Stock Jumping on Q4 Results
2016-02-17,The Medicines Company Reports Fourth-Quarter And Full-Year 2015 Business And Financial Results
2016-02-05,Clive Meanwell, MD, PhD Receives Dr. Sol J. Barer Award At BioNJ Gala Event
2016-02-04,The Medicines Company To Announce Fourth Quarter And Full Year 2015 Financial Results On Wednesday, February 17, 2016
2016-02-03,The Medicines Company Appoints Alexander J. Denner, Ph.D. To Its Board Of Directors
2016-02-02,The Medicines Company To Participate In Leerink Partners 5th Annual Global Healthcare Conference
2016-02-01,The Medicines Company Completes Divestiture Of Its Hemostasis Portfolio To Mallinckrodt Plc
2016-01-21,Medicines (MDCO) Highlighted As Today's Perilous Reversal Stock
2016-01-20,Why Medicines (MDCO) Stock is Advancing Today
2016-01-20,Strong On High Volume: Medicines (MDCO)
2016-01-11,The Medicines Company Advances Clinical Development Of Investigational First-in-Class PCSK9 Synthesis Inhibitor For Atherosclerotic Cardiovascular Disease (ASCVD)
2016-01-04,Medicines (MDCO) Stock: Weak On High Volume Today
2016-01-04,The Medicines Company To Participate In J.P. Morgan 34th Annual Healthcare Conference
2015-12-22,Today's Dead Cat Bounce Stock Is Medicines (MDCO)
2015-12-18,Mallinckrodt Diversifies Hospital Growth Portfolio, Acquiring Three Commercial-Stage, Global Specialty Hemostasis Brands From The Medicines Company
2015-12-18,The Medicines Company Agrees To Divest Its Hemostasis Portfolio To Mallinckrodt Plc
2015-12-14,The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published In European Heart Journal- Cardiovascular Pharmacotherapy
2015-12-09,Glenn Sblendorio To Retire As President And Chief Financial Officer From The Medicines Company
2015-12-04,The Medicines Company To Participate In Oppenheimer 26th Annual Healthcare Conference
2015-11-20,The Medicines Company Receives European Commission Approval For IONSYS® 40 Micrograms Per Dose Transdermal System (fentanyl) To Treat Post-Operative Pain In Adult Hospitalized Patients
2015-11-13,Federal Circuit Overturns District Court Decision On Angiomax Patents; Grants The Medicines Company's Request For Rehearing Of Appeal
2015-11-13,Medicines Company (MDCO) Marked As A Barbarian At The Gate
2015-11-11,Alnylam Pharmaceuticals And The Medicines Company Announce That New ALN-PCSsc Results From Late-Breaking Presentation At American Heart Association Meeting Confirm Potential For Bi-Annual Hypercholesterolemia Dose Regimen
2015-11-04,The Medicines Company To Present New Data On Cardiovascular Portfolio At American Heart Association (AHA) Scientific Sessions
2015-11-03,Medicines Company (MDCO) Flagged As Strong On High Volume
2015-11-03,The Medicines Company Reports Third-Quarter And First Nine Months 2015 Business And Financial Results
2015-10-26,Results Of First-in-Man Study With Investigational Anesthetic ABP-700 Presented At ANESTHESIOLOGY® 2015 And International Society Of Anesthetic Pharmacology Annual Meetings
2015-10-22,The Medicines Company To Present Data On Potentially Innovative Surgical Anesthetic At American Society Of Anesthesiologists 2015 Meeting
2015-10-16,The Medicines Company To Announce Third Quarter 2015 Financial Results On Tuesday, November 3, 2015
2015-10-06,The Medicines Company And SymBio Pharmaceuticals Establish Strategic Partnership For IONSYS® (fentanyl Iontophoretic Transdermal System) In Japan
2015-10-01,The Medicines Company Announces Participation At IDWeek 2015 Meeting
2015-10-01,The Medicines Company Announces BARDA Exercises Next Option On Contract For Support Of The Development Of CARBAVANCE® (meropenem/RPX7009) For Drug-Resistant Gram-Negative Pathogens
2015-09-30,10 Best Nasdaq Biotech Stocks in the Third Quarter
2015-09-28,Short Interest Makes 17.2% Move For MDCO
2015-09-25,First Week Of November 20th Options Trading For Medicines
2015-09-25,The Medicines Company Receives CHMP Positive Opinion For IONSYS® To Treat Post-operative Pain In Adult Patients
2015-09-18,Trade-Ideas: Medicines Company (MDCO) Is Today's Post-Market Leader Stock
2015-09-18,The Medicines Company Reports Discovery Of New Series Of Beta-Lactamase Inhibitors At ICAAC/ICC 2015
2015-09-18,New Treatment Options For Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Needed, According To Study By The Medicines Company
2015-09-15,The Medicines Company Announces Participation At ICAAC/ICC 2015 Meeting
2015-09-09,Medicines Company (MDCO) Hits New Lifetime High Today
2015-09-09,EUSA Pharma Appoints William W Crouse To Its Board Of Directors
2015-09-01,MATRIX Trial Results Presented At Hot Line Session Of ESC Congress 2015 And Simultaneously Published In The New England Journal Of Medicine
2015-09-01,Medicines Company (MDCO) Reaches New Lifetime High Today
2015-09-01,Analysis From CHAMPION PHOENIX Trial Highlight The Efficacy Of Cangrelor Among Patients Undergoing PCI Via The Radial Approach
2015-08-31,Market News: The Medicine Company, Netflix, Twitter
2015-08-31,3 High-Volume Stocks to Trade Now (or Not)
2015-08-31,3 Health Care Stocks Nudging The Sector Higher
2015-08-31,Medicines (MDCO) Stock Skyrockets Following Promising Cholesterol Drug Results
2015-08-31,Medicines Company (MDCO) Moving On Heavy Volume In The Pre-Market Hours
2015-08-31,The Medicines Company Appoints Dr. Fred Eshelman As Non-Executive Chairman Of The Board
2015-08-30,(Graphic: Business Wire)
2015-08-28,Analysts' Actions -- Akamai, Borg Warner, Urban Outfitters, United States Steel and More
2015-08-24,The Medicines Company Announces Participation At 2015 European Society Of Cardiology (ESC) Congress In London
2015-08-19,The Medicines Co. (MDCO) Stock Price Target Raised at Leerink
2015-07-29,Today's Weak On High Volume Stock: Medicines Company (MDCO)
2015-07-29,The Medicines Company Reports Second-Quarter And First-Half 2015 Financial Results
2015-07-13,The Medicines Company To Announce Second Quarter Financial Results On Wednesday July 29, 2015
2015-07-09,The Medicines Company Authorizes Generic Launch Of ANGIOMAX® (bivalirudin)
2015-07-07,4 Stocks Rising on Unusual Volume
2015-07-06,Strong On High Relative Volume: Medicines Company (MDCO)
2015-07-02,Will Medicines & Co. (MDCO) Stock be Hurt by Court Patent Ruling?
2015-07-02,Federal Circuit Rules Against The Medicines Company In Angiomax® (bivalirudin) Patent Litigation
2015-06-25,Medicines Company (MDCO) Marked As A Barbarian At The Gate
2015-06-22,KENGREAL(TM)(cangrelor)(Photo: Business Wire)
2015-06-11,Insider Trading Alert - CLCT, MDCO And LQ Traded By Insiders
2015-06-01,The Medicines Company To Hold Conference Call On Tuesday, June 2 To Discuss Clinical Trial Results Of ABP-700 And MDCO-216
2015-06-01,Bios/Backgrounders
2015-05-26,The Medicines Company Presents New Data Showing Remodeling Effect Of MDCO-216 On HDL Particles In Coronary Artery Disease Patients
2015-05-22,The Medicines Company To Participate In The Jefferies 2015 Healthcare Conference
2015-05-19,First Week Of January 2016 Options Trading For Medicines (MDCO)
2015-05-07,The Medicines Company To Participate In Bank Of America Merrill Lynch 2015 Health Care Conference
2015-05-05,The Medicines Company Reports First Quarter 2015 Financial Results And Operational Developments
2015-04-30,The Medicines Company Announces FDA Approval Of RAPLIXA™ (Fibrin Sealant), The First And Only Powdered Fibrin Sealant Ready-to-Use For Mild To Moderate Surgical Bleeding
2015-04-30,The Medicines Company Announces FDA Approval Of IONSYS® (fentanyl Iontophoretic Transdermal System) For The Management Of Acute Post-Operative Pain For Adult Patients In The Hospital
2015-04-21,Insider Trading Alert - AMP, MDCO And MEMP Traded By Insiders
2015-04-21,The Medicines Company To Announce First Quarter Financial Results On Tuesday, May 5, 2015
2015-04-20,Medicines Company (MDCO) Weak On High Volume
2015-04-20,FDA Approves New Formulation Of MINOCIN® (minocycline) For Injection
2015-04-15,FDA Advisory Committee Recommends Approval Of The Medicines Company's Antiplatelet Therapy Cangrelor
2015-04-15,The Medicines Company Stock Trading Halted Today
2015-04-13,Medicines Company (MDCO) Strong On High Relative Volume Today
2015-04-10,Medicines Company (MDCO) Moving On Heavy Volume In The Pre-Market Hours
2015-04-09,EQUITY ALERT: The Rosen Law Firm Announces Investigation Of Securities Claims Against The Medicines Company - MDCO
2015-04-09,The Medicines Company Announces Preliminary Worldwide Net Revenue For The First Quarter Of 2015
2015-04-01,The Medicines Company Settles Angiomax® (Bivalirudin) Patent Litigation With Sun
2015-03-30,The Medicines Company Receives European Commission Approval For Three Hospital Acute Care Products: KENGREXAL™ (cangrelor), ORBACTIV® (oritavancin) And RAPLIXA™ (sealant Powder)
2015-03-19,Insider Trading Alert - MDCO, NMIH And LNG Traded By Insiders
2015-03-16,Independent Research Confirms Reduction In Mortality And Bleeding Associated With Bivalirudin In High-Risk Acute Coronary Syndrome Patients Undergoing PCI
2015-03-11,The Medicines Company Announces Participation At 2015 American College Of Cardiology (ACC) Scientific Sessions In San Diego
2015-02-27,The Medicines Company To Participate In Cowen 35th Annual Health Care Conference
2015-02-20,The Medicines Company To Participate In 2015 RBC Capital Markets' Global Healthcare Conference
2015-02-18,The Medicines Company Reports Fourth Quarter And Full Year 2014 Financial Results
2015-02-12,Interesting MDCO Put And Call Options For March 20th
2015-02-12,Short Interest In Medicines Expands By 16.5%
2015-02-05,The Medicines Company To Participate In Leerink Global Healthcare Conference
2015-02-04,The Medicines Company Acquires Annovation Biopharma, Inc.
2015-02-04,The Medicines Company To Announce Fourth Quarter And Full Year 2014 Financial Results On Wednesday, February 18, 2015
2015-01-23,The Medicines Company Receives CHMP Positive Opinions For Three Hospital Acute Care Products: KENGREXAL™ (cangrelor), ORBACTIV™ (oritavancin) And RAPLIXA™ (sealant Powder)
2015-01-21,Eyes On Medicines Company (MDCO): Highlighted Storm The Castle Stock
2015-01-07,The Medicines Company Prices $350 Million Of Convertible Notes
2015-01-06,The Medicines Company Announces Intention To Offer $300 Million Of Convertible Notes
2015-01-05,The Medicines Company To Participate In 33rd Annual J.P. Morgan Healthcare Conference
2014-12-31,Weak On High Volume: Medicines Company (MDCO)
2014-12-24,Commit To Purchase Medicines At $21, Earn 11.9% Annualized Using Options
2014-12-18,The Medicines Company And SciClone Pharmaceuticals Establish Strategic Partnership For Two Cardiovascular Products In China
2014-12-11,Http://www.themedicinescompany.com/
2014-12-08,The Medicines Company To Participate In Oppenheimer 25th Annual Healthcare Conference
2014-11-16,The Medicines Company Presents New Phase 1 Data Showing Investigational Agent MDCO-216 Modified Key Lipid Parameters And Was Well-Tolerated In Healthy And Coronary Artery Disease (CAD) Patients
2014-11-14,The Medicines Company To Present New Data On Investigational Lipid-Modifying Agent MDCO-216 And Investigational Antiplatelet Agent Cangrelor At 2014 American Heart Association (AHA) Annual Scientific Sessions In Chicago
2014-11-11,The Medicines Company To Participate In Credit Suisse Healthcare Conference
2014-11-07,Health Economic Data On The Medicines Company's Infectious Disease And Cardiology Portfolios To Be Presented At The 17th Annual European Congress Of The International Society For Pharmacoeconomics And Outcomes Research (ISPOR)
2014-11-05,The Medicines Company Announces First Patient Enrollment In Phase 3 Studies Of CARBAVANCE™ In Development For The Treatment Of Serious Bacterial Infections Due To Gram-Negative Bacteria
2014-11-04,Update To The Medicines Company Investor & Analyst Day On November 5
2014-10-30,The Medicines Company To Webcast Investor & Analyst Day On November 5
2014-10-28,Twitter Takes A Tumble As Ability To Innovate Comes Into Question
2014-10-28,The Medicines Company Announces Presentation Of Investigational Hemostatic Agent RAPLIXA™ (fibrin Sealant) Phase III FINISH-3 Trial Results At The 2014 Clinical Conference Of The American College Of Surgeons
2014-10-28,Alnylam And The Medicines Company Announce Filing Of A Clinical Trial Application To Initiate A Phase 1 Study For ALN-PCSsc, An Investigational, Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 For The Treatment Of Hypercholesterolemia
2014-10-27,The Medicines Company Wins Favorable Judgment In Angiomax® (Bivalirudin) Patent Litigation
2017-03-17,How to Trade the Week's Most Active Stocks--Rite Aid, Amgen, MuleSoft and More
2017-03-17,The Medicines Company And Alnylam Pharmaceuticals Report Positive Final Results From ORION-1 Phase II Study Of Inclisiran
2017-03-17,AveXis, Esperion and Amgen Among Biotech Movers
2017-03-14,The Medicines Company To Webcast Presentation Of ORION-1 Phase II Study Of Inclisiran At ACC.17
2017-03-06,The Medicines Company To Host Conference Call And Webcast At Upcoming American College Of Cardiology's 66th Annual Scientific Sessions
2017-02-28,The Medicines Company Reports Fourth-Quarter And Full-Year 2016 Financial Results
2017-02-21,The Medicines Company Announces FDA Filing Acceptance Of New Drug Application For Intravenous Antibiotic Carbavance® (meropenem-vaborbactam)
2017-02-17,The Medicines Company To Announce Fourth-Quarter And Full-Year 2016 Financial Results On February 28, 2017
2017-02-15,Biotech Premarket Movers: Ardelyx, Acorda Therapeutics, Medicines Co.
2017-02-03,Insiders Seeing Green With MDCO At New 52-Week High
2017-02-03,Premarket Biotech Movers: Portola, Esperion, Medicines
2017-01-25,The Medicines Company To Present Results From ORION-1 Phase 2 Study Of Inclisiran At The American College Of Cardiology's 66th Annual Scientific Session
2017-01-08,The Medicines Company Announces Positive Top-Line Results From Day 180 Interim Analysis In Ongoing ORION-1 Phase 2 Study Of Inclisiran (formerly, PCSK9si)
2017-01-06,Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View
2017-01-04,The Medicines Company To Present At J. P. Morgan Healthcare Conference
2016-12-15,5 Stocks Insiders Love Right Now
2016-11-15,The Medicines Company And Alnylam Pharmaceuticals Present Positive Results From ORION-1 Phase 2 Study Of Inclisiran (formerly PCSK9si)
2016-11-13,Http://www.themedicinescompany.com/
2016-11-10,The Medicines Company To Host Conference Call And Webcast To Review Data From Ongoing ORION-1 Phase 2 Study Of PCSK9si
2016-11-07,The Medicines Company Discontinues Development Of MDCO-216, Its Investigational Cholesterol Efflux Promoter
2016-10-26,The Medicines Company Reports Third-Quarter 2016 Financial Results
2016-10-18,The Medicines Company Announces Positive Top-Line Results From Day 90 Interim Analysis In Ongoing ORION-1 Phase 2 Study Of PCSK9si
2016-10-17,The Medicines Company To Announce Third Quarter Financial Results On October 26, 2016
2016-10-17,The Medicines Company's Infectious Disease Portfolio Featured In 16 Presentations At IDWeek 2016
2016-10-13,The Medicines Company To Present Data From Its Investigational Anesthetic MDCO-700 At The ANESTHESIOLOGY® 2016 Annual Meeting And The ISAP 25th Annual Meeting
2016-10-06,Why Medicines Co. (MDCO) Stock is Falling Today
2016-10-05,The Medicines Company Provides Progress Update On Ongoing ORION-1 Study Of PCSK9si
2016-10-05,Notable Wednesday Option Activity: MDCO, PEIX, BEAT
2016-09-21,The Medicines Company Awarded Up To $132 Million To Develop Portfolio Of New Antibiotics Targeting Drug-Resistant Infections Under Strategic Partnership With BARDA
2016-08-30,The Medicines Company Provides Update On Dyslipidemia Programs
2016-07-27,The Medicines Company Reports Second-Quarter 2016 Business And Financial Results
2016-07-18,The Medicines Company To Announce Second Quarter Financial Results On July 27, 2016
2016-07-12,Federal Circuit Rules For The Medicines Company In Angiomax® (bivalirudin) Patent Litigation
2016-07-11,Barbarian At The Gate: Medicines (MDCO)
2016-06-27,Medicines (MDCO) Flagged As Strong On High Volume
2016-06-27,The Medicines Company Announces Positive Top- Line Results For Phase 3 TANGO 1 Clinical Trial Of CARBAVANCE®
2016-06-21,The Medicines Company Completes Divestiture Of Its Non-Core Cardiovascular Assets To Chiesi
2016-06-15,Insiders Are Scooping Up Shares of These 5 Stocks
2016-06-14,The Medicines Company Announces Initiation Of Phase II Study For Its Investigational Anesthetic, ABP-700
2016-06-13,The Medicines Company Announces Participation At ASM MICROBE 2016 To Be Held June 16 - 20 In Boston
2016-06-09,MDCO: Insiders vs. Shorts
2016-06-07,Medicines (MDCO) Moving On Heavy Pre-Market Trading
2016-06-06,The Medicines Company Prices $350 Million Of Convertible Notes
2016-06-06,Barbarian At The Gate: Medicines (MDCO)
2016-06-06,The Medicines Company Announces Intention To Offer $350 Million Of Convertible Notes
2016-06-02,The Medicines Company Completes Patient Enrollment For ORION-1 Study Of PCSK9si
2016-05-26,The Medicines Company Announces Completion Of Patient Enrollment In Phase 3 TANGO 1 Study Of CARBAVANCE® (meropenem-vaborbactam) For Treatment Of Complicated Urinary Tract Infections (cUTI)
2016-05-25,The Medicines Company To Present At Two Upcoming Investor Conferences
2016-05-18,5 Stocks Insiders Are Scooping Up Right Now
2016-05-16,The Medicines Company Appoints Tony Kingsley As President And Chief Operating Officer
2016-05-09,The Medicines Company Reports First-Quarter 2016 Business And Financial Results
2016-05-09,The Medicines Company Agrees To Divest Non-Core Cardiovascular Assets To Chiesi Farmaceutici S.p.A.
2016-05-02,The Medicines Company To Present At Bank Of America Merrill Lynch 2016 Health Care Conference
2016-04-26,The Medicines Company To Announce First Quarter Financial Results On May 9, 2016
2016-04-11,FDA Grants Fast Track Status For Investigational Antibiotic CARBAVANCE® (meropenem-vaborbactam)
2016-04-04,The Medicines Company Announces Participation At 2016 European Congress Of Clinical Microbiology And Infectious Diseases (ECCMID) To Be Held April 9-12 In Amsterdam
2016-03-28,The Medicines Company Announces Participation At 2016 American College Of Cardiology (ACC) Scientific Sessions In Chicago
2016-03-09,Insider Trading Alert - MDCO, DXCM And WMGI Traded By Insiders
2016-03-02,The Medicines Company To Present At Cowen And Company 36th Annual Health Care Conference
2016-02-19,The Medicines Company To Participate In 2016 RBC Capital Markets Global Healthcare Conference
2016-02-18,Medicines (MDCO) Stock Price Target Lowered at Jefferies
2016-02-17,Medicines Co. (MDCO) Stock Jumping on Q4 Results
2016-02-17,The Medicines Company Reports Fourth-Quarter And Full-Year 2015 Business And Financial Results
2016-02-05,Clive Meanwell, MD, PhD Receives Dr. Sol J. Barer Award At BioNJ Gala Event
2016-02-04,The Medicines Company To Announce Fourth Quarter And Full Year 2015 Financial Results On Wednesday, February 17, 2016
2016-02-03,The Medicines Company Appoints Alexander J. Denner, Ph.D. To Its Board Of Directors
2016-02-02,The Medicines Company To Participate In Leerink Partners 5th Annual Global Healthcare Conference
2016-02-01,The Medicines Company Completes Divestiture Of Its Hemostasis Portfolio To Mallinckrodt Plc
2016-01-21,Medicines (MDCO) Highlighted As Today's Perilous Reversal Stock
2016-01-20,Why Medicines (MDCO) Stock is Advancing Today
2016-01-20,Strong On High Volume: Medicines (MDCO)
2016-01-11,The Medicines Company Advances Clinical Development Of Investigational First-in-Class PCSK9 Synthesis Inhibitor For Atherosclerotic Cardiovascular Disease (ASCVD)
2016-01-04,Medicines (MDCO) Stock: Weak On High Volume Today
2016-01-04,The Medicines Company To Participate In J.P. Morgan 34th Annual Healthcare Conference
2015-12-22,Today's Dead Cat Bounce Stock Is Medicines (MDCO)
2015-12-18,Mallinckrodt Diversifies Hospital Growth Portfolio, Acquiring Three Commercial-Stage, Global Specialty Hemostasis Brands From The Medicines Company
2015-12-18,The Medicines Company Agrees To Divest Its Hemostasis Portfolio To Mallinckrodt Plc
2015-12-14,The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published In European Heart Journal- Cardiovascular Pharmacotherapy
2015-12-09,Glenn Sblendorio To Retire As President And Chief Financial Officer From The Medicines Company
2015-12-04,The Medicines Company To Participate In Oppenheimer 26th Annual Healthcare Conference
2015-11-20,The Medicines Company Receives European Commission Approval For IONSYS® 40 Micrograms Per Dose Transdermal System (fentanyl) To Treat Post-Operative Pain In Adult Hospitalized Patients
2015-11-13,Federal Circuit Overturns District Court Decision On Angiomax Patents; Grants The Medicines Company's Request For Rehearing Of Appeal
2015-11-13,Medicines Company (MDCO) Marked As A Barbarian At The Gate
2015-11-11,Alnylam Pharmaceuticals And The Medicines Company Announce That New ALN-PCSsc Results From Late-Breaking Presentation At American Heart Association Meeting Confirm Potential For Bi-Annual Hypercholesterolemia Dose Regimen
2015-11-04,The Medicines Company To Present New Data On Cardiovascular Portfolio At American Heart Association (AHA) Scientific Sessions
2015-11-03,Medicines Company (MDCO) Flagged As Strong On High Volume
2015-11-03,The Medicines Company Reports Third-Quarter And First Nine Months 2015 Business And Financial Results
2015-10-26,Results Of First-in-Man Study With Investigational Anesthetic ABP-700 Presented At ANESTHESIOLOGY® 2015 And International Society Of Anesthetic Pharmacology Annual Meetings
2015-10-22,The Medicines Company To Present Data On Potentially Innovative Surgical Anesthetic At American Society Of Anesthesiologists 2015 Meeting
2015-10-16,The Medicines Company To Announce Third Quarter 2015 Financial Results On Tuesday, November 3, 2015
2015-10-06,The Medicines Company And SymBio Pharmaceuticals Establish Strategic Partnership For IONSYS® (fentanyl Iontophoretic Transdermal System) In Japan
2015-10-01,The Medicines Company Announces Participation At IDWeek 2015 Meeting
2015-10-01,The Medicines Company Announces BARDA Exercises Next Option On Contract For Support Of The Development Of CARBAVANCE® (meropenem/RPX7009) For Drug-Resistant Gram-Negative Pathogens
2015-09-30,10 Best Nasdaq Biotech Stocks in the Third Quarter
2015-09-28,Short Interest Makes 17.2% Move For MDCO
2015-09-25,First Week Of November 20th Options Trading For Medicines
2015-09-25,The Medicines Company Receives CHMP Positive Opinion For IONSYS® To Treat Post-operative Pain In Adult Patients
2015-09-18,Trade-Ideas: Medicines Company (MDCO) Is Today's Post-Market Leader Stock
2015-09-18,The Medicines Company Reports Discovery Of New Series Of Beta-Lactamase Inhibitors At ICAAC/ICC 2015
2015-09-18,New Treatment Options For Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Needed, According To Study By The Medicines Company
2015-09-15,The Medicines Company Announces Participation At ICAAC/ICC 2015 Meeting
2015-09-09,Medicines Company (MDCO) Hits New Lifetime High Today
2015-09-09,EUSA Pharma Appoints William W Crouse To Its Board Of Directors
2015-09-01,MATRIX Trial Results Presented At Hot Line Session Of ESC Congress 2015 And Simultaneously Published In The New England Journal Of Medicine
2015-09-01,Medicines Company (MDCO) Reaches New Lifetime High Today
2015-09-01,Analysis From CHAMPION PHOENIX Trial Highlight The Efficacy Of Cangrelor Among Patients Undergoing PCI Via The Radial Approach
2015-08-31,Market News: The Medicine Company, Netflix, Twitter
2015-08-31,3 High-Volume Stocks to Trade Now (or Not)
2015-08-31,3 Health Care Stocks Nudging The Sector Higher
2015-08-31,Medicines (MDCO) Stock Skyrockets Following Promising Cholesterol Drug Results
2015-08-31,Medicines Company (MDCO) Moving On Heavy Volume In The Pre-Market Hours
2015-08-31,The Medicines Company Appoints Dr. Fred Eshelman As Non-Executive Chairman Of The Board
2015-08-30,(Graphic: Business Wire)
2015-08-28,Analysts' Actions -- Akamai, Borg Warner, Urban Outfitters, United States Steel and More
2015-08-24,The Medicines Company Announces Participation At 2015 European Society Of Cardiology (ESC) Congress In London
2015-08-19,The Medicines Co. (MDCO) Stock Price Target Raised at Leerink
2015-07-29,Today's Weak On High Volume Stock: Medicines Company (MDCO)
2015-07-29,The Medicines Company Reports Second-Quarter And First-Half 2015 Financial Results
2015-07-13,The Medicines Company To Announce Second Quarter Financial Results On Wednesday July 29, 2015
2015-07-09,The Medicines Company Authorizes Generic Launch Of ANGIOMAX® (bivalirudin)
2015-07-07,4 Stocks Rising on Unusual Volume
2015-07-06,Strong On High Relative Volume: Medicines Company (MDCO)
2015-07-02,Will Medicines & Co. (MDCO) Stock be Hurt by Court Patent Ruling?
2015-07-02,Federal Circuit Rules Against The Medicines Company In Angiomax® (bivalirudin) Patent Litigation
2015-06-25,Medicines Company (MDCO) Marked As A Barbarian At The Gate
2015-06-22,KENGREAL(TM)(cangrelor)(Photo: Business Wire)
2015-06-11,Insider Trading Alert - CLCT, MDCO And LQ Traded By Insiders
2015-06-01,The Medicines Company To Hold Conference Call On Tuesday, June 2 To Discuss Clinical Trial Results Of ABP-700 And MDCO-216
2015-06-01,Bios/Backgrounders
2015-05-26,The Medicines Company Presents New Data Showing Remodeling Effect Of MDCO-216 On HDL Particles In Coronary Artery Disease Patients
2015-05-22,The Medicines Company To Participate In The Jefferies 2015 Healthcare Conference
2015-05-19,First Week Of January 2016 Options Trading For Medicines (MDCO)
2015-05-07,The Medicines Company To Participate In Bank Of America Merrill Lynch 2015 Health Care Conference
2015-05-05,The Medicines Company Reports First Quarter 2015 Financial Results And Operational Developments
2015-04-30,The Medicines Company Announces FDA Approval Of RAPLIXA™ (Fibrin Sealant), The First And Only Powdered Fibrin Sealant Ready-to-Use For Mild To Moderate Surgical Bleeding
2015-04-30,The Medicines Company Announces FDA Approval Of IONSYS® (fentanyl Iontophoretic Transdermal System) For The Management Of Acute Post-Operative Pain For Adult Patients In The Hospital
2015-04-21,Insider Trading Alert - AMP, MDCO And MEMP Traded By Insiders
2015-04-21,The Medicines Company To Announce First Quarter Financial Results On Tuesday, May 5, 2015
2015-04-20,Medicines Company (MDCO) Weak On High Volume
2015-04-20,FDA Approves New Formulation Of MINOCIN® (minocycline) For Injection
2015-04-15,FDA Advisory Committee Recommends Approval Of The Medicines Company's Antiplatelet Therapy Cangrelor
2015-04-15,The Medicines Company Stock Trading Halted Today
2015-04-13,Medicines Company (MDCO) Strong On High Relative Volume Today
2015-04-10,Medicines Company (MDCO) Moving On Heavy Volume In The Pre-Market Hours
2015-04-09,EQUITY ALERT: The Rosen Law Firm Announces Investigation Of Securities Claims Against The Medicines Company - MDCO
2015-04-09,The Medicines Company Announces Preliminary Worldwide Net Revenue For The First Quarter Of 2015
2015-04-01,The Medicines Company Settles Angiomax® (Bivalirudin) Patent Litigation With Sun
2015-03-30,The Medicines Company Receives European Commission Approval For Three Hospital Acute Care Products: KENGREXAL™ (cangrelor), ORBACTIV® (oritavancin) And RAPLIXA™ (sealant Powder)
2015-03-19,Insider Trading Alert - MDCO, NMIH And LNG Traded By Insiders
2015-03-16,Independent Research Confirms Reduction In Mortality And Bleeding Associated With Bivalirudin In High-Risk Acute Coronary Syndrome Patients Undergoing PCI
2015-03-11,The Medicines Company Announces Participation At 2015 American College Of Cardiology (ACC) Scientific Sessions In San Diego
2015-02-27,The Medicines Company To Participate In Cowen 35th Annual Health Care Conference
2015-02-20,The Medicines Company To Participate In 2015 RBC Capital Markets' Global Healthcare Conference
2015-02-18,The Medicines Company Reports Fourth Quarter And Full Year 2014 Financial Results
2015-02-12,Interesting MDCO Put And Call Options For March 20th
2015-02-12,Short Interest In Medicines Expands By 16.5%
2015-02-05,The Medicines Company To Participate In Leerink Global Healthcare Conference
2015-02-04,The Medicines Company Acquires Annovation Biopharma, Inc.
2015-02-04,The Medicines Company To Announce Fourth Quarter And Full Year 2014 Financial Results On Wednesday, February 18, 2015
2015-01-23,The Medicines Company Receives CHMP Positive Opinions For Three Hospital Acute Care Products: KENGREXAL™ (cangrelor), ORBACTIV™ (oritavancin) And RAPLIXA™ (sealant Powder)
2015-01-21,Eyes On Medicines Company (MDCO): Highlighted Storm The Castle Stock
2015-01-07,The Medicines Company Prices $350 Million Of Convertible Notes
2015-01-06,The Medicines Company Announces Intention To Offer $300 Million Of Convertible Notes
2015-01-05,The Medicines Company To Participate In 33rd Annual J.P. Morgan Healthcare Conference
2014-12-31,Weak On High Volume: Medicines Company (MDCO)
2014-12-24,Commit To Purchase Medicines At $21, Earn 11.9% Annualized Using Options
2014-12-18,The Medicines Company And SciClone Pharmaceuticals Establish Strategic Partnership For Two Cardiovascular Products In China
2014-12-11,Http://www.themedicinescompany.com/
2014-12-08,The Medicines Company To Participate In Oppenheimer 25th Annual Healthcare Conference
2014-11-16,The Medicines Company Presents New Phase 1 Data Showing Investigational Agent MDCO-216 Modified Key Lipid Parameters And Was Well-Tolerated In Healthy And Coronary Artery Disease (CAD) Patients
2014-11-14,The Medicines Company To Present New Data On Investigational Lipid-Modifying Agent MDCO-216 And Investigational Antiplatelet Agent Cangrelor At 2014 American Heart Association (AHA) Annual Scientific Sessions In Chicago
2014-11-11,The Medicines Company To Participate In Credit Suisse Healthcare Conference
2014-11-07,Health Economic Data On The Medicines Company's Infectious Disease And Cardiology Portfolios To Be Presented At The 17th Annual European Congress Of The International Society For Pharmacoeconomics And Outcomes Research (ISPOR)
2014-11-05,The Medicines Company Announces First Patient Enrollment In Phase 3 Studies Of CARBAVANCE™ In Development For The Treatment Of Serious Bacterial Infections Due To Gram-Negative Bacteria
2014-11-04,Update To The Medicines Company Investor & Analyst Day On November 5
2014-10-30,The Medicines Company To Webcast Investor & Analyst Day On November 5
2014-10-28,Twitter Takes A Tumble As Ability To Innovate Comes Into Question
2014-10-28,The Medicines Company Announces Presentation Of Investigational Hemostatic Agent RAPLIXA™ (fibrin Sealant) Phase III FINISH-3 Trial Results At The 2014 Clinical Conference Of The American College Of Surgeons
2014-10-28,Alnylam And The Medicines Company Announce Filing Of A Clinical Trial Application To Initiate A Phase 1 Study For ALN-PCSsc, An Investigational, Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 For The Treatment Of Hypercholesterolemia
2014-10-27,The Medicines Company Wins Favorable Judgment In Angiomax® (Bivalirudin) Patent Litigation
2017-03-17,How to Trade the Week's Most Active Stocks--Rite Aid, Amgen, MuleSoft and More
2017-03-17,The Medicines Company And Alnylam Pharmaceuticals Report Positive Final Results From ORION-1 Phase II Study Of Inclisiran
2017-03-17,AveXis, Esperion and Amgen Among Biotech Movers
2017-03-14,The Medicines Company To Webcast Presentation Of ORION-1 Phase II Study Of Inclisiran At ACC.17
2017-03-06,The Medicines Company To Host Conference Call And Webcast At Upcoming American College Of Cardiology's 66th Annual Scientific Sessions
2017-02-28,The Medicines Company Reports Fourth-Quarter And Full-Year 2016 Financial Results
2017-02-21,The Medicines Company Announces FDA Filing Acceptance Of New Drug Application For Intravenous Antibiotic Carbavance® (meropenem-vaborbactam)
2017-02-17,The Medicines Company To Announce Fourth-Quarter And Full-Year 2016 Financial Results On February 28, 2017
2017-02-15,Biotech Premarket Movers: Ardelyx, Acorda Therapeutics, Medicines Co.
2017-02-03,Insiders Seeing Green With MDCO At New 52-Week High
2017-02-03,Premarket Biotech Movers: Portola, Esperion, Medicines
2017-01-25,The Medicines Company To Present Results From ORION-1 Phase 2 Study Of Inclisiran At The American College Of Cardiology's 66th Annual Scientific Session
2017-01-08,The Medicines Company Announces Positive Top-Line Results From Day 180 Interim Analysis In Ongoing ORION-1 Phase 2 Study Of Inclisiran (formerly, PCSK9si)
2017-01-06,Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View
2017-01-04,The Medicines Company To Present At J. P. Morgan Healthcare Conference
2016-12-15,5 Stocks Insiders Love Right Now
2016-11-15,The Medicines Company And Alnylam Pharmaceuticals Present Positive Results From ORION-1 Phase 2 Study Of Inclisiran (formerly PCSK9si)
2016-11-13,Http://www.themedicinescompany.com/
2016-11-10,The Medicines Company To Host Conference Call And Webcast To Review Data From Ongoing ORION-1 Phase 2 Study Of PCSK9si
2016-11-07,The Medicines Company Discontinues Development Of MDCO-216, Its Investigational Cholesterol Efflux Promoter
2016-10-26,The Medicines Company Reports Third-Quarter 2016 Financial Results
2016-10-18,The Medicines Company Announces Positive Top-Line Results From Day 90 Interim Analysis In Ongoing ORION-1 Phase 2 Study Of PCSK9si
2016-10-17,The Medicines Company To Announce Third Quarter Financial Results On October 26, 2016
2016-10-17,The Medicines Company's Infectious Disease Portfolio Featured In 16 Presentations At IDWeek 2016
2016-10-13,The Medicines Company To Present Data From Its Investigational Anesthetic MDCO-700 At The ANESTHESIOLOGY® 2016 Annual Meeting And The ISAP 25th Annual Meeting
2016-10-06,Why Medicines Co. (MDCO) Stock is Falling Today
2016-10-05,The Medicines Company Provides Progress Update On Ongoing ORION-1 Study Of PCSK9si
2016-10-05,Notable Wednesday Option Activity: MDCO, PEIX, BEAT
2016-09-21,The Medicines Company Awarded Up To $132 Million To Develop Portfolio Of New Antibiotics Targeting Drug-Resistant Infections Under Strategic Partnership With BARDA
2016-08-30,The Medicines Company Provides Update On Dyslipidemia Programs
2016-07-27,The Medicines Company Reports Second-Quarter 2016 Business And Financial Results
2016-07-18,The Medicines Company To Announce Second Quarter Financial Results On July 27, 2016
2016-07-12,Federal Circuit Rules For The Medicines Company In Angiomax® (bivalirudin) Patent Litigation
2016-07-11,Barbarian At The Gate: Medicines (MDCO)
2016-06-27,Medicines (MDCO) Flagged As Strong On High Volume
2016-06-27,The Medicines Company Announces Positive Top- Line Results For Phase 3 TANGO 1 Clinical Trial Of CARBAVANCE®
2016-06-21,The Medicines Company Completes Divestiture Of Its Non-Core Cardiovascular Assets To Chiesi
2016-06-15,Insiders Are Scooping Up Shares of These 5 Stocks
2016-06-14,The Medicines Company Announces Initiation Of Phase II Study For Its Investigational Anesthetic, ABP-700
2016-06-13,The Medicines Company Announces Participation At ASM MICROBE 2016 To Be Held June 16 - 20 In Boston
2016-06-09,MDCO: Insiders vs. Shorts
2016-06-07,Medicines (MDCO) Moving On Heavy Pre-Market Trading
2016-06-06,The Medicines Company Prices $350 Million Of Convertible Notes
2016-06-06,Barbarian At The Gate: Medicines (MDCO)
2016-06-06,The Medicines Company Announces Intention To Offer $350 Million Of Convertible Notes
2016-06-02,The Medicines Company Completes Patient Enrollment For ORION-1 Study Of PCSK9si
2016-05-26,The Medicines Company Announces Completion Of Patient Enrollment In Phase 3 TANGO 1 Study Of CARBAVANCE® (meropenem-vaborbactam) For Treatment Of Complicated Urinary Tract Infections (cUTI)
2016-05-25,The Medicines Company To Present At Two Upcoming Investor Conferences
2016-05-18,5 Stocks Insiders Are Scooping Up Right Now
2016-05-16,The Medicines Company Appoints Tony Kingsley As President And Chief Operating Officer
2016-05-09,The Medicines Company Reports First-Quarter 2016 Business And Financial Results
2016-05-09,The Medicines Company Agrees To Divest Non-Core Cardiovascular Assets To Chiesi Farmaceutici S.p.A.
2016-05-02,The Medicines Company To Present At Bank Of America Merrill Lynch 2016 Health Care Conference
2016-04-26,The Medicines Company To Announce First Quarter Financial Results On May 9, 2016
2016-04-11,FDA Grants Fast Track Status For Investigational Antibiotic CARBAVANCE® (meropenem-vaborbactam)
2016-04-04,The Medicines Company Announces Participation At 2016 European Congress Of Clinical Microbiology And Infectious Diseases (ECCMID) To Be Held April 9-12 In Amsterdam
2016-03-28,The Medicines Company Announces Participation At 2016 American College Of Cardiology (ACC) Scientific Sessions In Chicago
2016-03-09,Insider Trading Alert - MDCO, DXCM And WMGI Traded By Insiders
2016-03-02,The Medicines Company To Present At Cowen And Company 36th Annual Health Care Conference
2016-02-19,The Medicines Company To Participate In 2016 RBC Capital Markets Global Healthcare Conference
2016-02-18,Medicines (MDCO) Stock Price Target Lowered at Jefferies
2016-02-17,Medicines Co. (MDCO) Stock Jumping on Q4 Results
2016-02-17,The Medicines Company Reports Fourth-Quarter And Full-Year 2015 Business And Financial Results
2016-02-05,Clive Meanwell, MD, PhD Receives Dr. Sol J. Barer Award At BioNJ Gala Event
2016-02-04,The Medicines Company To Announce Fourth Quarter And Full Year 2015 Financial Results On Wednesday, February 17, 2016
2016-02-03,The Medicines Company Appoints Alexander J. Denner, Ph.D. To Its Board Of Directors
2016-02-02,The Medicines Company To Participate In Leerink Partners 5th Annual Global Healthcare Conference
2016-02-01,The Medicines Company Completes Divestiture Of Its Hemostasis Portfolio To Mallinckrodt Plc
2016-01-21,Medicines (MDCO) Highlighted As Today's Perilous Reversal Stock
2016-01-20,Why Medicines (MDCO) Stock is Advancing Today
2016-01-20,Strong On High Volume: Medicines (MDCO)
2016-01-11,The Medicines Company Advances Clinical Development Of Investigational First-in-Class PCSK9 Synthesis Inhibitor For Atherosclerotic Cardiovascular Disease (ASCVD)
2016-01-04,Medicines (MDCO) Stock: Weak On High Volume Today
2016-01-04,The Medicines Company To Participate In J.P. Morgan 34th Annual Healthcare Conference
2015-12-22,Today's Dead Cat Bounce Stock Is Medicines (MDCO)
2015-12-18,Mallinckrodt Diversifies Hospital Growth Portfolio, Acquiring Three Commercial-Stage, Global Specialty Hemostasis Brands From The Medicines Company
2015-12-18,The Medicines Company Agrees To Divest Its Hemostasis Portfolio To Mallinckrodt Plc
2015-12-14,The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published In European Heart Journal- Cardiovascular Pharmacotherapy
2015-12-09,Glenn Sblendorio To Retire As President And Chief Financial Officer From The Medicines Company
2015-12-04,The Medicines Company To Participate In Oppenheimer 26th Annual Healthcare Conference
2015-11-20,The Medicines Company Receives European Commission Approval For IONSYS® 40 Micrograms Per Dose Transdermal System (fentanyl) To Treat Post-Operative Pain In Adult Hospitalized Patients
2015-11-13,Federal Circuit Overturns District Court Decision On Angiomax Patents; Grants The Medicines Company's Request For Rehearing Of Appeal
2015-11-13,Medicines Company (MDCO) Marked As A Barbarian At The Gate
2015-11-11,Alnylam Pharmaceuticals And The Medicines Company Announce That New ALN-PCSsc Results From Late-Breaking Presentation At American Heart Association Meeting Confirm Potential For Bi-Annual Hypercholesterolemia Dose Regimen
2015-11-04,The Medicines Company To Present New Data On Cardiovascular Portfolio At American Heart Association (AHA) Scientific Sessions
2015-11-03,Medicines Company (MDCO) Flagged As Strong On High Volume
2015-11-03,The Medicines Company Reports Third-Quarter And First Nine Months 2015 Business And Financial Results
2015-10-26,Results Of First-in-Man Study With Investigational Anesthetic ABP-700 Presented At ANESTHESIOLOGY® 2015 And International Society Of Anesthetic Pharmacology Annual Meetings
2015-10-22,The Medicines Company To Present Data On Potentially Innovative Surgical Anesthetic At American Society Of Anesthesiologists 2015 Meeting
2015-10-16,The Medicines Company To Announce Third Quarter 2015 Financial Results On Tuesday, November 3, 2015
2015-10-06,The Medicines Company And SymBio Pharmaceuticals Establish Strategic Partnership For IONSYS® (fentanyl Iontophoretic Transdermal System) In Japan
2015-10-01,The Medicines Company Announces Participation At IDWeek 2015 Meeting
2015-10-01,The Medicines Company Announces BARDA Exercises Next Option On Contract For Support Of The Development Of CARBAVANCE® (meropenem/RPX7009) For Drug-Resistant Gram-Negative Pathogens
2015-09-30,10 Best Nasdaq Biotech Stocks in the Third Quarter
2015-09-28,Short Interest Makes 17.2% Move For MDCO
2015-09-25,First Week Of November 20th Options Trading For Medicines
2015-09-25,The Medicines Company Receives CHMP Positive Opinion For IONSYS® To Treat Post-operative Pain In Adult Patients
2015-09-18,Trade-Ideas: Medicines Company (MDCO) Is Today's Post-Market Leader Stock
2015-09-18,The Medicines Company Reports Discovery Of New Series Of Beta-Lactamase Inhibitors At ICAAC/ICC 2015
2015-09-18,New Treatment Options For Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Needed, According To Study By The Medicines Company
2015-09-15,The Medicines Company Announces Participation At ICAAC/ICC 2015 Meeting
2015-09-09,Medicines Company (MDCO) Hits New Lifetime High Today
2015-09-09,EUSA Pharma Appoints William W Crouse To Its Board Of Directors
2015-09-01,MATRIX Trial Results Presented At Hot Line Session Of ESC Congress 2015 And Simultaneously Published In The New England Journal Of Medicine
2015-09-01,Medicines Company (MDCO) Reaches New Lifetime High Today
2015-09-01,Analysis From CHAMPION PHOENIX Trial Highlight The Efficacy Of Cangrelor Among Patients Undergoing PCI Via The Radial Approach
2015-08-31,Market News: The Medicine Company, Netflix, Twitter
2015-08-31,3 High-Volume Stocks to Trade Now (or Not)
2015-08-31,3 Health Care Stocks Nudging The Sector Higher
2015-08-31,Medicines (MDCO) Stock Skyrockets Following Promising Cholesterol Drug Results
2015-08-31,Medicines Company (MDCO) Moving On Heavy Volume In The Pre-Market Hours
2015-08-31,The Medicines Company Appoints Dr. Fred Eshelman As Non-Executive Chairman Of The Board
2015-08-30,(Graphic: Business Wire)
2015-08-28,Analysts' Actions -- Akamai, Borg Warner, Urban Outfitters, United States Steel and More
2015-08-24,The Medicines Company Announces Participation At 2015 European Society Of Cardiology (ESC) Congress In London
2015-08-19,The Medicines Co. (MDCO) Stock Price Target Raised at Leerink
2015-07-29,Today's Weak On High Volume Stock: Medicines Company (MDCO)
2015-07-29,The Medicines Company Reports Second-Quarter And First-Half 2015 Financial Results
2015-07-13,The Medicines Company To Announce Second Quarter Financial Results On Wednesday July 29, 2015
2015-07-09,The Medicines Company Authorizes Generic Launch Of ANGIOMAX® (bivalirudin)
2015-07-07,4 Stocks Rising on Unusual Volume
2015-07-06,Strong On High Relative Volume: Medicines Company (MDCO)
2015-07-02,Will Medicines & Co. (MDCO) Stock be Hurt by Court Patent Ruling?
2015-07-02,Federal Circuit Rules Against The Medicines Company In Angiomax® (bivalirudin) Patent Litigation
2015-06-25,Medicines Company (MDCO) Marked As A Barbarian At The Gate
2015-06-22,KENGREAL(TM)(cangrelor)(Photo: Business Wire)
2015-06-11,Insider Trading Alert - CLCT, MDCO And LQ Traded By Insiders
2015-06-01,The Medicines Company To Hold Conference Call On Tuesday, June 2 To Discuss Clinical Trial Results Of ABP-700 And MDCO-216
2015-06-01,Bios/Backgrounders
2015-05-26,The Medicines Company Presents New Data Showing Remodeling Effect Of MDCO-216 On HDL Particles In Coronary Artery Disease Patients
2015-05-22,The Medicines Company To Participate In The Jefferies 2015 Healthcare Conference
2015-05-19,First Week Of January 2016 Options Trading For Medicines (MDCO)
2015-05-07,The Medicines Company To Participate In Bank Of America Merrill Lynch 2015 Health Care Conference
2015-05-05,The Medicines Company Reports First Quarter 2015 Financial Results And Operational Developments
2015-04-30,The Medicines Company Announces FDA Approval Of RAPLIXA™ (Fibrin Sealant), The First And Only Powdered Fibrin Sealant Ready-to-Use For Mild To Moderate Surgical Bleeding
2015-04-30,The Medicines Company Announces FDA Approval Of IONSYS® (fentanyl Iontophoretic Transdermal System) For The Management Of Acute Post-Operative Pain For Adult Patients In The Hospital
2015-04-21,Insider Trading Alert - AMP, MDCO And MEMP Traded By Insiders
2015-04-21,The Medicines Company To Announce First Quarter Financial Results On Tuesday, May 5, 2015
2015-04-20,Medicines Company (MDCO) Weak On High Volume
2015-04-20,FDA Approves New Formulation Of MINOCIN® (minocycline) For Injection
2015-04-15,FDA Advisory Committee Recommends Approval Of The Medicines Company's Antiplatelet Therapy Cangrelor
2015-04-15,The Medicines Company Stock Trading Halted Today
2015-04-13,Medicines Company (MDCO) Strong On High Relative Volume Today
2015-04-10,Medicines Company (MDCO) Moving On Heavy Volume In The Pre-Market Hours
2015-04-09,EQUITY ALERT: The Rosen Law Firm Announces Investigation Of Securities Claims Against The Medicines Company - MDCO
2015-04-09,The Medicines Company Announces Preliminary Worldwide Net Revenue For The First Quarter Of 2015
2015-04-01,The Medicines Company Settles Angiomax® (Bivalirudin) Patent Litigation With Sun
2015-03-30,The Medicines Company Receives European Commission Approval For Three Hospital Acute Care Products: KENGREXAL™ (cangrelor), ORBACTIV® (oritavancin) And RAPLIXA™ (sealant Powder)
2015-03-19,Insider Trading Alert - MDCO, NMIH And LNG Traded By Insiders
2015-03-16,Independent Research Confirms Reduction In Mortality And Bleeding Associated With Bivalirudin In High-Risk Acute Coronary Syndrome Patients Undergoing PCI
2015-03-11,The Medicines Company Announces Participation At 2015 American College Of Cardiology (ACC) Scientific Sessions In San Diego
2015-02-27,The Medicines Company To Participate In Cowen 35th Annual Health Care Conference
2015-02-20,The Medicines Company To Participate In 2015 RBC Capital Markets' Global Healthcare Conference
2015-02-18,The Medicines Company Reports Fourth Quarter And Full Year 2014 Financial Results
2015-02-12,Interesting MDCO Put And Call Options For March 20th
2015-02-12,Short Interest In Medicines Expands By 16.5%
2015-02-05,The Medicines Company To Participate In Leerink Global Healthcare Conference
2015-02-04,The Medicines Company Acquires Annovation Biopharma, Inc.
2015-02-04,The Medicines Company To Announce Fourth Quarter And Full Year 2014 Financial Results On Wednesday, February 18, 2015
2015-01-23,The Medicines Company Receives CHMP Positive Opinions For Three Hospital Acute Care Products: KENGREXAL™ (cangrelor), ORBACTIV™ (oritavancin) And RAPLIXA™ (sealant Powder)
2015-01-21,Eyes On Medicines Company (MDCO): Highlighted Storm The Castle Stock
2015-01-07,The Medicines Company Prices $350 Million Of Convertible Notes
2015-01-06,The Medicines Company Announces Intention To Offer $300 Million Of Convertible Notes
2015-01-05,The Medicines Company To Participate In 33rd Annual J.P. Morgan Healthcare Conference
2014-12-31,Weak On High Volume: Medicines Company (MDCO)
2014-12-24,Commit To Purchase Medicines At $21, Earn 11.9% Annualized Using Options
2014-12-18,The Medicines Company And SciClone Pharmaceuticals Establish Strategic Partnership For Two Cardiovascular Products In China
2014-12-11,Http://www.themedicinescompany.com/
2014-12-08,The Medicines Company To Participate In Oppenheimer 25th Annual Healthcare Conference
2014-11-16,The Medicines Company Presents New Phase 1 Data Showing Investigational Agent MDCO-216 Modified Key Lipid Parameters And Was Well-Tolerated In Healthy And Coronary Artery Disease (CAD) Patients
2014-11-14,The Medicines Company To Present New Data On Investigational Lipid-Modifying Agent MDCO-216 And Investigational Antiplatelet Agent Cangrelor At 2014 American Heart Association (AHA) Annual Scientific Sessions In Chicago
2014-11-11,The Medicines Company To Participate In Credit Suisse Healthcare Conference
2014-11-07,Health Economic Data On The Medicines Company's Infectious Disease And Cardiology Portfolios To Be Presented At The 17th Annual European Congress Of The International Society For Pharmacoeconomics And Outcomes Research (ISPOR)
2014-11-05,The Medicines Company Announces First Patient Enrollment In Phase 3 Studies Of CARBAVANCE™ In Development For The Treatment Of Serious Bacterial Infections Due To Gram-Negative Bacteria
2014-11-04,Update To The Medicines Company Investor & Analyst Day On November 5
2014-10-30,The Medicines Company To Webcast Investor & Analyst Day On November 5
2014-10-28,Twitter Takes A Tumble As Ability To Innovate Comes Into Question
2014-10-28,The Medicines Company Announces Presentation Of Investigational Hemostatic Agent RAPLIXA™ (fibrin Sealant) Phase III FINISH-3 Trial Results At The 2014 Clinical Conference Of The American College Of Surgeons
2014-10-28,Alnylam And The Medicines Company Announce Filing Of A Clinical Trial Application To Initiate A Phase 1 Study For ALN-PCSsc, An Investigational, Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 For The Treatment Of Hypercholesterolemia
2014-10-27,The Medicines Company Wins Favorable Judgment In Angiomax® (Bivalirudin) Patent Litigation
2016-12-15,Medgenics, Inc. Announces Name Change To Aevi Genomic Medicine, Inc.
2016-11-04,Oversold Conditions For Medgenics (MDGN)
2016-10-29,Medgenics Presents New Data Showing Prevalence Of Genetic Mutations In Pediatric Populations With Attention Deficit Hyperactivity Disorder
2016-10-26,Short Interest In Medgenics Moves 100% Lower
2016-09-09,Medgenics Enters Oversold Territory (MDGN)
2016-08-16,Commit To Buy Medgenics At $5, Earn 15.4% Annualized Using Options
2016-03-20,8 Biotech Stocks Under $10 Making Big Moves Higher
2016-01-26,Medgenics To Participate In The 2016 Canaccord Genuity Rare Disease, BioPharma One-On-One Day
2016-01-07,RSI Alert: Medgenics (MDGN) Now Oversold
2016-01-07,MDGN: Insiders vs. Shorts
2016-01-06,Medgenics Licenses Novel GeneRide Gene Therapy Technology From Stanford University
2015-12-22,Medgenics Announces Annual Renewal Of Rare And Orphan Disease Research Collaboration With The Children's Hospital Of Philadelphia
2015-12-16,Medgenics Announces Beta Thalassemia Research Program
2015-11-25,Medgenics To Present At 27th Annual Piper Jaffray Healthcare Conference
2015-10-22,Medgenics Reports Third Quarter 2015 Financial Results
2015-10-15,Medgenics To Host Conference Call To Announce Third Quarter 2015 Results On October 22, 2015
2015-10-14,5 Stocks Insiders Love Right Now
2015-10-13,Medgenics Announces Key Appointments
2015-10-12,Medgenics Announces Completion Of Public Offering Of Common Stock And Exercise In Full Of Option To Purchase Additional Shares Of Common Stock
2015-10-09,MDGN: Insiders vs. Shorts
2015-10-05,Spark Therapeutics Trial Success Seen As Positive For Gene Therapy Sector
2015-10-01,Medgenics Prices Public Offering Of Common Stock
2015-09-30,Medgenics Announces Public Offering Of Common Stock
2015-09-09,Medgenics Acquires Phase 2-Ready CNS Program: NFC-1
2015-09-03,Medgenics To Present At 22nd Annual NewsMakers In The Biotech Industry Conference
2015-08-27,Short Interest Increases 15% For MDGN
2015-08-10,Medgenics Reports Second Quarter 2015 Financial Results
2015-07-28,Short Interest Expands By 61.4% For MDGN
2015-07-15,Medgenics Announces First Patient Enrolled In U.S.-Based Phase 2 Clinical Trial Of TARGT-EPO For Treatment Of Anemia In ESRD Patients Undergoing Peritoneal Dialysis
2015-06-29,Medgenics Added To RUSSELL 3000(R) And Global Indexes
2015-06-22,Medgenics Becomes Oversold (MDGN)
2015-06-17,Medgenics To Present At JMP Securities Life Sciences Conference 2015
2015-06-11,Medgenics Awarded $3.4 Million Grant From The Israeli Office Of The Chief Scientist
2015-06-10,Medgenics Announces Appointment Of Barbara Duncan To Board Of Directors
2015-06-04,Medgenics To Present Clinical Data At The 20th Congress Of The European Hematology Association
2015-05-07,Medgenics Announces Participation In Upcoming Conferences
2015-04-17,Medgenics Reports First Quarter 2015 Financial Results
2015-04-02,Medgenics To Host Conference Call To Announce First Quarter 2015 Results On April 17, 2015
2015-03-02,Medgenics To Present At Upcoming Investor Conferences
2015-02-25,5 Stocks Insiders Love Right Now: GE, Mondelez and More
2015-02-13,Medgenics Reports Fourth Quarter And Full Year 2014 Financial Results
2015-01-30,Medgenics To Host Conference Call To Announce Fourth Quarter And Full Year 2014 Results On February 13, 2015
2015-01-08,Medgenics To Present At Biotech Showcase 2015 Conference
2014-11-25,Medgenics To Present At 26th Annual Piper Jaffray Healthcare Conference
2014-11-25,Medgenics Prices Public Offering Of Common Stock
2014-11-24,Medgenics Announces Public Offering Of Common Stock
2014-11-12,Medgenics Announces Rare & Orphan Disease Research Collaboration With The Children's Hospital Of Philadelphia
2014-10-15,Medgenics Reports Positive Initial Clinical Data And Third Quarter Financial Results
2014-10-08,Medgenics To Host Conference Call To Announce Third Quarter 2014 Results And Provide Initial Clinical Data On MDGN-201 On October 15, 2014
2014-10-07,Medgenics To Present Initial Clinical Data From MDGN-201 Study At European Society Of Gene And Cell Therapy Congress
2014-09-24,Medgenics To Announce Third Quarter 2014 Results And Provide Initial Clinical Data On MDGN-201 (EPODURE(TM)) Trial On October 15, 2014
2014-09-10,Medgenics Announces The Appointment Of Scott Applebaum As Chief Legal Officer
2014-08-28,Medgenics Enters Oversold Territory (MDGN)
2014-07-17,Medgenics Becomes Oversold (MDGN)
2014-07-16,Medgenics Reports Second Quarter Financial Results
2014-06-18,Medgenics Announces Global Head, Research And Development, Garry Neil, M.D. Receives FDA Commissioner's Special Citation Award
2014-06-16,Medgenics To Present At Two Upcoming Healthcare Investor Conferences
2014-06-05,Medgenics Announces First Patient Implanted In Phase 1/2 Clinical Trial Of MDGN-201 (EPODURE)
2014-05-08,Medgenics Reports First Quarter Financial Results
2014-04-30,Medgenics Becomes Oversold (MDGN)
2014-04-15,Medgenics Awarded $2.2 Million Grant From The Israeli Office Of The Chief Scientist
2014-04-09,Medgenics Announces Results Of 2014 Annual Meeting Of Stockholders
2014-04-03,Medgenics Becomes Oversold (MDGN)
2014-03-14,Faruqi & Faruqi, LLP Launches An Investigation Against Medgenics, Inc. (MDGN) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
2014-03-05,Medgenics, Inc. To Present At The 26th Annual ROTH Capital Growth Conference
2014-02-20,Medgenics Reports 2013 Financial Results
2014-01-07,Medgenics Issues Stock Options And Restricted Shares To Non-Executive Directors
2013-12-24,Medgenics Announces Director Enters Into Stock Trading Plan And Change Of Adviser
2013-12-18,Medgenics Reports Open Market Purchase Of Common Stock By Director
2013-12-16,Medgenics Reports Open Market Purchase Of Common Stock By Chairman Of The Board
2013-12-13,Medgenics Becomes Oversold (MDGN)
2013-12-04,Medgenics To Present At The Oppenheimer 24th Annual Healthcare Conference
2013-12-04,Top Insider Trades: CYTR TROX KTOS MDGN
2013-12-04,Medgenics Reports Sale Of Common Stock By Director
2013-12-04,3 Stocks Under $10 in Breakout Territory
2013-12-03,Medgenics Reports Open Market Purchase Of Common Stock By Chairman Of The Board
2013-11-07,Medgenics Reports Third Quarter Financial Results
2013-11-04,Medgenics To Host Business Update Conference Call On Friday, November 8th At 8:30 A.m. Eastern Time
2013-10-27,Medgenics Reports Positive Data With Second-Generation Viral Vectors At European Society Of Gene And Cell Therapy Congress
2013-10-23,Medgenics To Present Poster At European Society Of Gene And Cell Therapy Congress To Highlight Results From Second-Generation Viral Vector
2013-10-17,Medgenics Appoints Biopharmaceutical Industry Veteran Bill Gantz To Its Board Of Directors
2013-09-20,Top Insider Trades: PCI BTH HALL MDGN
2013-09-16,Medgenics Announces New Executive Leadership Team
2013-08-06,Medgenics Reports Second Quarter Financial Results
2013-07-09,Medgenics Awarded $1.9 Million Grant From The Israeli Office Of The Chief Scientist
2013-07-08,Medgenics To Present At The 8th Annual JMP Securities Healthcare Conference
2013-03-26,Medgenics Announces Exercise By Underwriters Of Over-Allotment Option
2013-03-15,Medgenics To Present At The 25th Annual Roth Conference
2013-03-14,Medgenics Reports 2012 Financial Results
2013-03-12,Medgenics Appoints Former Chairman And CEO Of UBS Financial Services Joseph J. Grano, Jr. To Board Of Directors
2013-02-21,5 Stocks Under $10 Triggering Breakouts
2013-02-14,Medgenics Announces Closing Of Public Offering Of Common Stock And Warrants
2013-02-11,Fisking Ray Dirks on Medgenics and Shaming Seeking Alpha
2013-02-08,Biotech Stock Mailbag: Dynavax, ImmunoCellular, Celldex and Medgenics
2013-02-08,Medgenics Prices Public Offering Of Common Stock And Warrants
2013-01-30,Medgenics Launches First Clinical Trial In Hepatitis To Use INFRADURE Tissue Treatment
2013-01-04,Medgenics, Inc. (the &#8220;Company&#8221;) Issue Of Options And Restricted Shares To Directors And Officers
2012-12-06,Medgenics Key Patent Claims Allowed In Japan Protecting Core Technology To Be Used In Hepatitis Treatment
2012-11-28,Renowned Experts Affirm Potential Of Medgenics&#8217; INFRADURE Technology For The Treatment Of Hepatitis B And D
2012-11-21,Medgenics Granted U.S. Patent For Core Technology Used In Sustained Delivery Of Erythropoietin, Aimed At Multi-Billion Dollar Anemia Market
2012-11-14,Medgenics Reports Third Quarter 2012 Financial Results
2012-11-02,Medgenics Presents Preliminary Data From Phase IIa Study With EPODURE To Treat Anemia In Dialysis Patients At Kidney Week 2012
2012-10-25,5 Stocks Under $10 Set to Soar
2012-10-23,Medgenics Announces EPODURE To Be Presented In Poster Session At The American Society Of Nephrology&#8217;s Kidney Week 2012
2012-10-16,Medgenics Announces Filing Of Shelf Registration
2012-08-29,Medgenics&#8217; Novel Tissue Implant Approved For Two Hepatitis C Clinical Trials In Israel
2012-08-28,Medgenics Mourns The Loss Of Board Member Gary Brukardt
2012-08-14,Medgenics Appoints Dr. Marvin Garovoy As Chief Medical Officer
2012-08-13,Medgenics Announces Second Quarter 2012 Financial Results
2012-07-23,Medgenics Announces Registration Of Shares To Be Issued Upon Exercises Of Warrants Listed On NYSE MKT
2012-07-17,First Subjects Enrolled In Phase IIa Clinical Trial Of EPODURE Biopumps To Treat Anemia In Patients With End-Stage Renal Disease On Dialysis
2012-07-02,Medgenics Appoints Former Celgene CEO Dr. Sol Barer As Chairman Of The Board
2012-06-20,Medgenics Receives Orphan Drug Designation From FDA For INFRADURE Biopump To Treat Hepatitis D
2012-06-19,Medgenics, Inc. Raises $9.5 Million In Private Placement
2012-06-07,Medgenics Initiates U.S. Biopump Processing Site
2012-05-18,Medgenics To Present At The 11th Annual ILSI BIOMED 2012
2012-05-17,Medgenics Receives FDA Clearance To Commence Phase IIb Trial Of EPODURE For Sustained Anemia Treatment In Dialysis Patients
2012-04-26,Medgenics Comments On Market Trading Activity
2012-04-17,Medgenics Files IND Application For EPODURE Biopump Phase IIb Anemia Study In Dialysis Patients
2012-04-05,Medgenics Announces Results Of 2012 Annual Meeting Of Stockholders
2012-03-26,Medgenics Reports Positive Meeting With NIH Recombinant DNA Advisory Committee
2012-03-23,Medgenics Cleared To Initiate Phase IIa Anemia Study Of EPODURE Biopump In Dialysis Patients In Israel
2012-03-21,Medgenics To Present At The Maxim Group Growth Conference
2012-03-13,Medgenics Announces Participation In Roth Conference And Other Matters
2012-03-06,Medgenics Announces 2011 Financial Results
2012-02-15,Medgenics To Present At LHA Life Sciences &amp; Medical Technologies Virtual Conference
2012-01-25,Medgenics Sets Record Date For 2012 Annual Meeting Of Stockholders
2012-01-24,Medgenics Adds Two Key Opinion Leaders To Strategic Advisory Board
2012-01-20,Medgenics' Receives Allowance For Key European Patent
2012-01-09,Medgenics, Inc. Announces Issue Of Options And Restricted Shares To Directors And Officers
2011-11-28,Medgenics To Present At The Piper Jaffray 23rd Annual Healthcare Conference
2011-11-15,Medgenics Presents Expanded Results Of Phase I/II Study Of EPODURE Biopump For The Treatment Of Anemia At&#160;the American Society Of Nephrology&#8217;s Kidney Week 2011
2011-11-10,Medgenics Reports Third Quarter Financial Results
2011-11-09,Medgenics Provides Clinical And Regulatory Update
2011-10-14,Update On Development Of Factor VIII Biopump
2011-09-09,Medgenics To Present At Rodman &amp; Renshaw 13th Annual Global Investment Conference
2011-09-09,Medgenics Announces Actions Taken At Annual Meeting Of Stockholders
2011-08-30,Medgenics Announces Annual Meeting Of Stockholders
2011-08-12,Medgenics Reports Second Quarter Financial Results
2011-08-10,Medgenics Awarded Grant From The Israeli Office Of The Chief Scientist
2011-07-06,Medgenics Extends Collaboration With Baxter On Development Of Factor VIII Biopump
2011-07-05,Medgenics Names Clarence &#8220;Butch&#8221; Dellio As Chief Operating Officer
2011-06-08,Leading Biotechnology Entrepreneur And Investor Isaac Blech Joins Medgenics Board Of Directors
2011-05-19,Medgenics To Present At The 10th Annual ILSI Biomed 2011 Conference
2011-05-12,Medgenics Announces First Quarter Financial Results
,
2017-03-26,How I'd Play Biotech Buyout Rumors
2017-03-24,How I'd Play Biotech Buyout Rumors
2017-02-17,Clovis, Tesaro Soar on Astrazeneca Phase Three News
2017-02-15,Biotech Buoyed by Deal Talk
2017-02-08,Biotech Tesaro Climbs on Takeout Reports
2016-12-22,2016 Was a Terrible Year for Biotech but the Tweets Were on Point
2016-11-11,Pfizer Finds Breaking Up Is Hard to Do
2016-10-28,Sanofi Gains Boost from MS Treatments as Diabetes Drug Lantus Flounders
2016-10-25,After FDA Approval, Merck Posts Better-Than-Expected Earnings
2016-10-24,What to Watch in Sanofi's Third-Quarter Results
2016-10-04,Investor's Guide to This Week's Clovis, Tesaro Ovarian Cancer Drug Updates
2016-10-03,Vigorous M&amp;A Activity Signals Economic Health
2016-09-28,Pfizer Completes Acquisition Of Medivation
2016-09-26,Read Scraps Pfizer Break-Up as Megadeals Escape Its Grasp
2016-09-23,Takeover Chatter Around Clovis May Be Overdone
2016-09-23,Pfizer Announces Expiration Of HSR Waiting Period For Proposed Acquisition Of Medivation
2016-09-22,New Setback for Sanofi's Lantus Increases Need for M&amp;A
2016-09-09,Faruqi & Faruqi, LLP Announces Filing of a Class Action Lawsuit Against Medivation, Inc.
2016-09-06,MEDIVATION SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces The Investigation Of Medivation, Inc. (MDVN) Over The Proposed Sale Of The Company To Pfizer Inc.
2016-09-02,SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces An Investigation Of The Board Of Directors Of Medivation, Inc.
2016-08-31,Medivation Proxy Shows Pfizer Battled Four Bidders to Seal a Deal
2016-08-30,Jim Cramer's 'Mad Money' Recap: The Urge to Merge Rules Wall Street
2016-08-25,INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation, Inc. And Encourages Shareholders To Contact The Firm For Additional Information
2016-08-25,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Regarding Whether The Sale Of Medivation, Inc. For $81.50 Per Share Is Fair To Shareholders
2016-08-24,Portfolio Manager: Is Pfizer Acquiring Too Quickly?
2016-08-24,Pfizer Is Buying a Portion of AstraZeneca's Antibiotics Business
2016-08-24,Why Pfizer's Latest Deal Could Send Its Shares Soaring
2016-08-24,5 Things You Must Know Before the Market Opens Wednesday
2016-08-23,SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces An Investigation Of The Board Of Directors Of Medivation, Inc. -MDVN
2016-08-23,INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Regarding Whether The Sale Of Medivation, Inc. To Pfizer Inc. Is Fair To Shareholders
2016-08-23,Medivation (MDVN) Stock Downgraded After Pfizer Deal
2016-08-22,Jim Cramer's 'Mad Money' Recap: I'm Watching Best Buy, PVH, Yellen This Week
2016-08-22,SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation, Inc. And Encourages Investors To Contact The Firm For Additional Information
2016-08-22,Market Keeps Chasing Its Own Tail
2016-08-22,Stocks Waver as Investors Wait for Fed Clarity
2016-08-22,Stocks Struggle for Direction as Jackson Hole Conference Looms
2016-08-22,Medivation, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Merger With Pfizer Inc.
2016-08-22,Medivation Scores Premium in Sale to Pfizer
2016-08-22,Cramer: A Bunch of Semis Are Ripe for the Picking
2016-08-22,Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back
2016-08-22,Crude Selloff, Health Care Rally Split Wall Street
2016-08-22,MEDIVATION, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
2016-08-22,Pfizer to Pick Up Medivation in All-Cash Deal
2016-08-22,Facebook Stands Out and FormFactor Has a Good Start
2016-08-22,More Squawk from Jim Cramer: Pfizer Buys Medivation (MDVN) for $14 Billion
2016-08-22,Pfizer Is Buying Medivation for $14 Billion
2016-08-22,Stock Futures Slide as Crude's Winning Streak Is Snapped
2016-08-22,Morning Movers: PFE, VRX, VIAB, FL, UA
2016-08-22,Pfizer Buys Medivation, the Crown Jewel in Cancer Therapy
2016-08-22,5 Things You Must Know Before the Market Opens Monday
2016-08-22,Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation
2016-08-22,Pfizer To Acquire Medivation
2016-08-15,What CVS and Express Scripts' Drug Exclusion Lists Means for Your Portfolio
2016-08-11,Ratings Changes Today
2016-08-10,Analysts' Actions -- Coach, SunPower, Wayfair, Yelp and More
2016-08-09,Medivation (MDVN) Stock Sliding in After-Hours Trading on Q2 Revenue Miss
2016-08-02,Biotech Pop-Up Party in Full Swing
2016-08-02,It's 'All Systems Go' for Biotech
2016-08-01,Could a Spin-off of its Hepatitis C Division be in Gilead's Future?
2016-07-29,Barbarian At The Gate: Medivation (MDVN)
2016-07-29,Sanofi Quarterly Earnings, Sales Slide, but It Reiterates Discipline on Medivation
2016-07-21,Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal
2016-07-21,Investors Scour Big Pharma M&amp;A Scene for Next Big Takeover
2016-07-14,Shire Could Divest ADHD Treatment, Other Assets, for More Upside Post-Baxalta
2016-07-11,Cramer: 11 Reasons Why the Market Turned
2016-07-11,Cramer: 5 Market Themes for the Rest of 2016
2016-07-07,Medivation Tries to Prove Its Worth
2016-07-06,Wall Street Closes Higher as Fed Doves Make Case for Waiting on Rates
2016-07-06,Stocks Add to Gains as Fed Stresses Prudence in Policy-Making
2016-07-06,Crude Turns Lower Again as Brexit Worries Weigh on Markets
2016-07-06,Medivation (MDVN) Stock Up on Potential Sanofi Deal
2016-07-06,Stock Futures Set Up for Another Decline as Crude Tumbles, Trade Gap Widens
2016-07-06,Medivation Shares Spike as Company Opens Door to Full-Fledged Auction
2016-07-06,Stocks Feeling the Pressure of 'Brexit', Italian Banks Weakness
2016-07-06,SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Medivation, Inc. For Potential Breaches Of Fiduciary Duty By Its Board Of Directors
2016-07-06,REMINDER: Medivation To Host Conference Call And Webcast Providing Detailed Review Of Talazoparib On July 6, 2016
2016-07-06,July 6 Premarket Briefing: 10 Things You Should Know
2016-07-05,An Auction Process Could Be on Medivation's Horizon
2016-07-05,Medivation Enters Into Confidentiality Agreements, Including With Sanofi
2016-07-05,Trade-Ideas: Medivation (MDVN) Is Today's "Barbarian At The Gate" Stock
2016-07-01,'Mad Money' Lightning Round: You Should Be Buying Visa
2016-06-30,Jim Cramer's 'Mad Money' Recap: Thank the Short-Sellers for This Continued Rally
2016-06-30,5 Hot Stocks to Watch Right Now
2016-06-29,What Tesaro's Cancer Drug Success Means for Medivation
2016-06-29,16 Biopharma Companies Besides Medivation That Are Attractive Targets
2016-06-27,Sanofi to Exit Animal Care in $25 Billion Asset Swap With Boehringer
2016-06-24,Glass Lewis Recommends Medivation's Stockholders Support The Company's Current Board
2016-06-23,Medivation's Letter To Stockholders
2016-06-23,Sanofi's Likely Sweetener for Medivation Panned
2016-06-17,BioMarin Takeout Rumors Swirl, Industry Insiders Aren't Convinced
2016-06-14,MEDIVATION INVESTIGATION ALERT - Andrews & Springer LLC Is Investigating Medivation, Inc. For Potential Breaches Of Fiduciary Duty - MDVN
2016-06-13,Medivation Urges Shareholders to Reject Sanofi Proposal
2016-06-13,(Graphic: Business Wire)
2016-06-13,MEDIVATION (MDVN) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Medivation, Inc. For Potential Breach Of Fiduciary Duty
2016-06-10,The Ingenious Moneymaking Method of the World's Super Investors: Buffett, Lynch, Icahn
2016-06-07,Valeant's Share Price Tumbles, Even as Papa Reiterates Plans for Divestitures
2016-06-07,Insider Trading Alert - MYL, PKD And MDVN Traded By Insiders
2016-06-02,Medivation Pulls Up Shareholder Drawbridge as Sanofi Battle Looms
2016-06-02,Astellas And Medivation Initiate Phase III Trial Of Enzalutamide In Patients With Triple-Negative Breast Cancer
2016-06-01,Medivation Sets Record Date For Sanofi's Proposed Consent Solicitation
2016-05-31,Biotech M&amp;A Waking Up After Long Nap
2016-05-27,Medivation Fires Back Following Sanofi's Board Proposal
2016-05-27,Medivation Files Preliminary Consent Revocation Statement
2016-05-25,European Markets End in Positive Territory; Rally for Second Day
2016-05-25,Pfizer Wants to Be Seen as an Oncology Powerhouse
2016-05-25,Sanofi Moves to Oust Medivation Board
2016-05-25,Medivation Urges Stockholders To Reject Sanofi's Attempt To Replace Medivation Board Of Directors
2016-05-25,'Mad Money' Lightning Round: I'm Flying With Delta
2016-05-24,Jim Cramer's 'Mad Money' Recap: These Catalysts Pushed the Market Up Today
2016-05-23,2 Promising Biopharmas Reach Key Junctures
2016-05-17,Biotech Is Showing Some Bargains
2016-05-16,Pfizer Beats Allergan to Eczema Drugmaker Anacor for $5.2B
2016-05-13,Medivation Shares Stand Pat Amid Further Bid Speculation
2016-05-11,It's Macy's Fault Sales Are Down, Not Shoppers'
2016-05-11,Global Pharma Players Likely to Flock to Medivation
2016-05-09,Medivation (MDVN) Stock Surges, Will Explore Sale
2016-05-09,Analysts' Actions -- Fidelity, Medivation, Occidental, Paccar and More
2016-05-06,TV Lives; Growth, Growth, Who's Got the Growth?: Jim Cramer&rsquo;s Best Blogs
2016-05-06,2 Longs and 2 Shorts to Watch in the Stock Market
2016-05-05,Medivation Reiterates Rejection Of Sanofi's Substantially Inadequate Proposal
2016-05-05,Sanofi Threatens to go Hostile in Medivation Battle
2016-05-04,Interest Rises in Medivation Oncology Prospects
2016-05-04,Cramer: Where'd All the Growth Go?
2016-05-04,Will a Third Medivation Suitor Present Itself?
2016-05-04,Today's Stocks Driving Success For The Health Care Sector
2016-05-04,Medivation (MDVN) Stock Climbs on Potential Pfizer Deal
2016-05-04,Medivation (MDVN) Highlighted As Momo Momentum Stock
2016-05-04,Pfizer Reportedly Approaches Drugmaker Medivation About a Buyout
2016-05-04,May 4 Premarket Briefing: 10 Things You Should Know
2016-04-29,Week in Review: Apple Becomes a Drag on Wall Street
2016-04-29,Sanofi First Quarter Shows Why It Wants but Doesn't Need Medivation
2016-04-29,European Stocks Fall; British Airways Owner Crashes on Brussels Impact
2016-04-28,Jim Cramer's 'Mad Money' Recap: Ignore Icahn, Think for Yourself
2016-04-28,Stocks Slip as Slower U.S. Growth Overshadows Facebook Earnings
2016-04-28,$40 Billion Takeover Has Big Pharma Giddy
2016-04-28,Nasdaq Leads Stocks Higher After Facebook Earnings Win
2016-04-28,Medivation (MDVN) Stock Surges on Sanofi Bid
2016-04-28,Stock Futures Hold Losses as U.S. Growth Slows
2016-04-28,Medivation (MDVN) Off To A Strong Start In Pre-Market Activity
2016-04-28,Sanofi Presses Medivation to Hold Talks After $9.3B Offer
2016-04-28,April 28 Premarket Briefing: 10 Things You Should Know
2016-04-28,European Markets Fall After Bank of Japan Rate Disappointment
2016-04-22,4 Biotech Stocks You Should Be Watching Right Now
2016-04-20,Analysts' Actions -- Boeing, Hershey, Spirit, Regeneron and More
2016-04-19,Ratings Changes Today
2016-04-19,Analysts' Actions -- CarMax, Illumina, Pulte, Panera and More
2016-04-18,Medivation (MDVN) Stock Surges on Takeover Speculation
2016-04-18,European Stocks Fall as Oil Plunges on Doha deadlock &nbsp;
2016-04-16,3 Biotech Stocks With Charts to Watch -- And One Bonus Stock!
2016-04-15,Strong On High Relative Volume: Medivation (MDVN)
2016-04-14,M&amp;A Could Ignite Next Leg Up for Biotech
2016-04-13,Here's Why Medivation (MDVN) Stock is Spiking Today
2016-04-12,Trade-Ideas: Medivation (MDVN) Is Today's Post-Market Leader Stock
2016-04-12,Medivation (MDVN) Stock Receives &lsquo;Market Perform&rsquo; Rating at BMO Capital
2016-04-07,CHMP Issues Positive Opinion To Include New Data In European Label For XTANDI® (enzalutamide)
2016-04-06,Just a Routine Market Pullback
2016-03-31,Jim Cramer's 'Mad Money' Recap: Good Riddance to a Roller-Coaster Quarter
2016-03-31,Medivation (MDVN) Stock Soars on Takeover Interest
2016-03-31,Medivation Jumps After Reportedly Hiring Bankers To Fight Takeover
2016-03-31,Medivation Surges on Takeover Chatter; Wall Street Scouts for Big Pharma M&A
2016-03-31,March 31 Premarket Briefing: 10 Things You Should Know
2016-03-30,Medivation (MDVN) Showing Signs Of A Dead Cat Bounce Today
2016-03-29,One Reason Medivation (MDVN) Stock is Plunging Today
2016-03-29,Today's Weak On High Volume Stock: Medivation (MDVN)
2016-03-28,Medivation (MDVN) In A Perilous Reversal
2016-03-24,Pivotal Phase III Trial Of Enzalutamide Initiated In Metastatic Hormone Sensitive Prostate Cancer
2016-03-22,Medivation (MDVN) Is Today's Strong On High Volume Stock
2016-03-08,Insider Trading Alert - MDVN, CRM And MOBL Traded By Insiders
2016-03-02,2 Stocks That Could Be the Next Netflix-Like Growth Stock
2016-02-25,Trade-Ideas: Medivation (MDVN) Is Today's Post-Market Leader Stock
2016-02-22,FDA Accepts For Review Supplemental New Drug Application For XTANDI® (enzalutamide) Capsules In Metastatic Castration-resistant Prostate Cancer With Data From Head-to-Head Studies Of Enzalutamide Versus Bicalutamide
2016-02-09,Strong On High Volume: Medivation (MDVN)
2016-02-06,Credit Suisse Picks 7 Health Care Stocks to Own for the Next 6 Months
2016-02-02,Weak On High Volume: Medivation (MDVN)
2016-02-01,Biotech String: Assessing the January Damage, Gilead's Bottoming P/E, Sarepta Panel Date?
2016-01-27,Analysts' Actions -- Best Buy, Fitbit, McDonald's, Sprint and More
2016-01-26,Post-Market Laggard: Medivation (MDVN)
2016-01-26,Journal Of Clinical Oncology Publishes Results From The STRIVE Trial Of Enzalutamide Compared To Bicalutamide In Castration-resistant Prostate Cancer
2016-01-21,Medivation (MDVN) Stock Gets ‘Outperform’ Rating at Credit Suisse
2016-01-13,Lancet Oncology Publishes Results From The Phase 2 TERRAIN Trial Of Enzalutamide Compared To Bicalutamide In Metastatic Castration-Resistant Prostate Cancer
2017-03-26,How I'd Play Biotech Buyout Rumors
2017-03-24,How I'd Play Biotech Buyout Rumors
2017-02-17,Clovis, Tesaro Soar on Astrazeneca Phase Three News
2017-02-15,Biotech Buoyed by Deal Talk
2017-02-08,Biotech Tesaro Climbs on Takeout Reports
2016-12-22,2016 Was a Terrible Year for Biotech but the Tweets Were on Point
2016-11-11,Pfizer Finds Breaking Up Is Hard to Do
2016-10-28,Sanofi Gains Boost from MS Treatments as Diabetes Drug Lantus Flounders
2016-10-25,After FDA Approval, Merck Posts Better-Than-Expected Earnings
2016-10-24,What to Watch in Sanofi's Third-Quarter Results
2016-10-04,Investor's Guide to This Week's Clovis, Tesaro Ovarian Cancer Drug Updates
2016-10-03,Vigorous M&amp;A Activity Signals Economic Health
2016-09-28,Pfizer Completes Acquisition Of Medivation
2016-09-26,Read Scraps Pfizer Break-Up as Megadeals Escape Its Grasp
2016-09-23,Takeover Chatter Around Clovis May Be Overdone
2016-09-23,Pfizer Announces Expiration Of HSR Waiting Period For Proposed Acquisition Of Medivation
2016-09-22,New Setback for Sanofi's Lantus Increases Need for M&amp;A
2016-09-09,Faruqi & Faruqi, LLP Announces Filing of a Class Action Lawsuit Against Medivation, Inc.
2016-09-06,MEDIVATION SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces The Investigation Of Medivation, Inc. (MDVN) Over The Proposed Sale Of The Company To Pfizer Inc.
2016-09-02,SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces An Investigation Of The Board Of Directors Of Medivation, Inc.
2016-08-31,Medivation Proxy Shows Pfizer Battled Four Bidders to Seal a Deal
2016-08-30,Jim Cramer's 'Mad Money' Recap: The Urge to Merge Rules Wall Street
2016-08-25,INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation, Inc. And Encourages Shareholders To Contact The Firm For Additional Information
2016-08-25,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Regarding Whether The Sale Of Medivation, Inc. For $81.50 Per Share Is Fair To Shareholders
2016-08-24,Portfolio Manager: Is Pfizer Acquiring Too Quickly?
2016-08-24,Pfizer Is Buying a Portion of AstraZeneca's Antibiotics Business
2016-08-24,Why Pfizer's Latest Deal Could Send Its Shares Soaring
2016-08-24,5 Things You Must Know Before the Market Opens Wednesday
2016-08-23,SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces An Investigation Of The Board Of Directors Of Medivation, Inc. -MDVN
2016-08-23,INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Regarding Whether The Sale Of Medivation, Inc. To Pfizer Inc. Is Fair To Shareholders
2016-08-23,Medivation (MDVN) Stock Downgraded After Pfizer Deal
2016-08-22,Jim Cramer's 'Mad Money' Recap: I'm Watching Best Buy, PVH, Yellen This Week
2016-08-22,SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation, Inc. And Encourages Investors To Contact The Firm For Additional Information
2016-08-22,Market Keeps Chasing Its Own Tail
2016-08-22,Stocks Waver as Investors Wait for Fed Clarity
2016-08-22,Stocks Struggle for Direction as Jackson Hole Conference Looms
2016-08-22,Medivation, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Merger With Pfizer Inc.
2016-08-22,Medivation Scores Premium in Sale to Pfizer
2016-08-22,Cramer: A Bunch of Semis Are Ripe for the Picking
2016-08-22,Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back
2016-08-22,Crude Selloff, Health Care Rally Split Wall Street
2016-08-22,MEDIVATION, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
2016-08-22,Pfizer to Pick Up Medivation in All-Cash Deal
2016-08-22,Facebook Stands Out and FormFactor Has a Good Start
2016-08-22,More Squawk from Jim Cramer: Pfizer Buys Medivation (MDVN) for $14 Billion
2016-08-22,Pfizer Is Buying Medivation for $14 Billion
2016-08-22,Stock Futures Slide as Crude's Winning Streak Is Snapped
2016-08-22,Morning Movers: PFE, VRX, VIAB, FL, UA
2016-08-22,Pfizer Buys Medivation, the Crown Jewel in Cancer Therapy
2016-08-22,5 Things You Must Know Before the Market Opens Monday
2016-08-22,Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation
2016-08-22,Pfizer To Acquire Medivation
2016-08-15,What CVS and Express Scripts' Drug Exclusion Lists Means for Your Portfolio
2016-08-11,Ratings Changes Today
2016-08-10,Analysts' Actions -- Coach, SunPower, Wayfair, Yelp and More
2016-08-09,Medivation (MDVN) Stock Sliding in After-Hours Trading on Q2 Revenue Miss
2016-08-02,Biotech Pop-Up Party in Full Swing
2016-08-02,It's 'All Systems Go' for Biotech
2016-08-01,Could a Spin-off of its Hepatitis C Division be in Gilead's Future?
2016-07-29,Barbarian At The Gate: Medivation (MDVN)
2016-07-29,Sanofi Quarterly Earnings, Sales Slide, but It Reiterates Discipline on Medivation
2016-07-21,Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal
2016-07-21,Investors Scour Big Pharma M&amp;A Scene for Next Big Takeover
2016-07-14,Shire Could Divest ADHD Treatment, Other Assets, for More Upside Post-Baxalta
2016-07-11,Cramer: 11 Reasons Why the Market Turned
2016-07-11,Cramer: 5 Market Themes for the Rest of 2016
2016-07-07,Medivation Tries to Prove Its Worth
2016-07-06,Wall Street Closes Higher as Fed Doves Make Case for Waiting on Rates
2016-07-06,Stocks Add to Gains as Fed Stresses Prudence in Policy-Making
2016-07-06,Crude Turns Lower Again as Brexit Worries Weigh on Markets
2016-07-06,Medivation (MDVN) Stock Up on Potential Sanofi Deal
2016-07-06,Stock Futures Set Up for Another Decline as Crude Tumbles, Trade Gap Widens
2016-07-06,Medivation Shares Spike as Company Opens Door to Full-Fledged Auction
2016-07-06,Stocks Feeling the Pressure of 'Brexit', Italian Banks Weakness
2016-07-06,SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Medivation, Inc. For Potential Breaches Of Fiduciary Duty By Its Board Of Directors
2016-07-06,REMINDER: Medivation To Host Conference Call And Webcast Providing Detailed Review Of Talazoparib On July 6, 2016
2016-07-06,July 6 Premarket Briefing: 10 Things You Should Know
2016-07-05,An Auction Process Could Be on Medivation's Horizon
2016-07-05,Medivation Enters Into Confidentiality Agreements, Including With Sanofi
2016-07-05,Trade-Ideas: Medivation (MDVN) Is Today's "Barbarian At The Gate" Stock
2016-07-01,'Mad Money' Lightning Round: You Should Be Buying Visa
2016-06-30,Jim Cramer's 'Mad Money' Recap: Thank the Short-Sellers for This Continued Rally
2016-06-30,5 Hot Stocks to Watch Right Now
2016-06-29,What Tesaro's Cancer Drug Success Means for Medivation
2016-06-29,16 Biopharma Companies Besides Medivation That Are Attractive Targets
2016-06-27,Sanofi to Exit Animal Care in $25 Billion Asset Swap With Boehringer
2016-06-24,Glass Lewis Recommends Medivation's Stockholders Support The Company's Current Board
2016-06-23,Medivation's Letter To Stockholders
2016-06-23,Sanofi's Likely Sweetener for Medivation Panned
2016-06-17,BioMarin Takeout Rumors Swirl, Industry Insiders Aren't Convinced
2016-06-14,MEDIVATION INVESTIGATION ALERT - Andrews & Springer LLC Is Investigating Medivation, Inc. For Potential Breaches Of Fiduciary Duty - MDVN
2016-06-13,Medivation Urges Shareholders to Reject Sanofi Proposal
2016-06-13,(Graphic: Business Wire)
2016-06-13,MEDIVATION (MDVN) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Medivation, Inc. For Potential Breach Of Fiduciary Duty
2016-06-10,The Ingenious Moneymaking Method of the World's Super Investors: Buffett, Lynch, Icahn
2016-06-07,Valeant's Share Price Tumbles, Even as Papa Reiterates Plans for Divestitures
2016-06-07,Insider Trading Alert - MYL, PKD And MDVN Traded By Insiders
2016-06-02,Medivation Pulls Up Shareholder Drawbridge as Sanofi Battle Looms
2016-06-02,Astellas And Medivation Initiate Phase III Trial Of Enzalutamide In Patients With Triple-Negative Breast Cancer
2016-06-01,Medivation Sets Record Date For Sanofi's Proposed Consent Solicitation
2016-05-31,Biotech M&amp;A Waking Up After Long Nap
2016-05-27,Medivation Fires Back Following Sanofi's Board Proposal
2016-05-27,Medivation Files Preliminary Consent Revocation Statement
2016-05-25,European Markets End in Positive Territory; Rally for Second Day
2016-05-25,Pfizer Wants to Be Seen as an Oncology Powerhouse
2016-05-25,Sanofi Moves to Oust Medivation Board
2016-05-25,Medivation Urges Stockholders To Reject Sanofi's Attempt To Replace Medivation Board Of Directors
2016-05-25,'Mad Money' Lightning Round: I'm Flying With Delta
2016-05-24,Jim Cramer's 'Mad Money' Recap: These Catalysts Pushed the Market Up Today
2016-05-23,2 Promising Biopharmas Reach Key Junctures
2016-05-17,Biotech Is Showing Some Bargains
2016-05-16,Pfizer Beats Allergan to Eczema Drugmaker Anacor for $5.2B
2016-05-13,Medivation Shares Stand Pat Amid Further Bid Speculation
2016-05-11,It's Macy's Fault Sales Are Down, Not Shoppers'
2016-05-11,Global Pharma Players Likely to Flock to Medivation
2016-05-09,Medivation (MDVN) Stock Surges, Will Explore Sale
2016-05-09,Analysts' Actions -- Fidelity, Medivation, Occidental, Paccar and More
2016-05-06,TV Lives; Growth, Growth, Who's Got the Growth?: Jim Cramer&rsquo;s Best Blogs
2016-05-06,2 Longs and 2 Shorts to Watch in the Stock Market
2016-05-05,Medivation Reiterates Rejection Of Sanofi's Substantially Inadequate Proposal
2016-05-05,Sanofi Threatens to go Hostile in Medivation Battle
2016-05-04,Interest Rises in Medivation Oncology Prospects
2016-05-04,Cramer: Where'd All the Growth Go?
2016-05-04,Will a Third Medivation Suitor Present Itself?
2016-05-04,Today's Stocks Driving Success For The Health Care Sector
2016-05-04,Medivation (MDVN) Stock Climbs on Potential Pfizer Deal
2016-05-04,Medivation (MDVN) Highlighted As Momo Momentum Stock
2016-05-04,Pfizer Reportedly Approaches Drugmaker Medivation About a Buyout
2016-05-04,May 4 Premarket Briefing: 10 Things You Should Know
2016-04-29,Week in Review: Apple Becomes a Drag on Wall Street
2016-04-29,Sanofi First Quarter Shows Why It Wants but Doesn't Need Medivation
2016-04-29,European Stocks Fall; British Airways Owner Crashes on Brussels Impact
2016-04-28,Jim Cramer's 'Mad Money' Recap: Ignore Icahn, Think for Yourself
2016-04-28,Stocks Slip as Slower U.S. Growth Overshadows Facebook Earnings
2016-04-28,$40 Billion Takeover Has Big Pharma Giddy
2016-04-28,Nasdaq Leads Stocks Higher After Facebook Earnings Win
2016-04-28,Medivation (MDVN) Stock Surges on Sanofi Bid
2016-04-28,Stock Futures Hold Losses as U.S. Growth Slows
2016-04-28,Medivation (MDVN) Off To A Strong Start In Pre-Market Activity
2016-04-28,Sanofi Presses Medivation to Hold Talks After $9.3B Offer
2016-04-28,April 28 Premarket Briefing: 10 Things You Should Know
2016-04-28,European Markets Fall After Bank of Japan Rate Disappointment
2016-04-22,4 Biotech Stocks You Should Be Watching Right Now
2016-04-20,Analysts' Actions -- Boeing, Hershey, Spirit, Regeneron and More
2016-04-19,Ratings Changes Today
2016-04-19,Analysts' Actions -- CarMax, Illumina, Pulte, Panera and More
2016-04-18,Medivation (MDVN) Stock Surges on Takeover Speculation
2016-04-18,European Stocks Fall as Oil Plunges on Doha deadlock &nbsp;
2016-04-16,3 Biotech Stocks With Charts to Watch -- And One Bonus Stock!
2016-04-15,Strong On High Relative Volume: Medivation (MDVN)
2016-04-14,M&amp;A Could Ignite Next Leg Up for Biotech
2016-04-13,Here's Why Medivation (MDVN) Stock is Spiking Today
2016-04-12,Trade-Ideas: Medivation (MDVN) Is Today's Post-Market Leader Stock
2016-04-12,Medivation (MDVN) Stock Receives &lsquo;Market Perform&rsquo; Rating at BMO Capital
2016-04-07,CHMP Issues Positive Opinion To Include New Data In European Label For XTANDI® (enzalutamide)
2016-04-06,Just a Routine Market Pullback
2016-03-31,Jim Cramer's 'Mad Money' Recap: Good Riddance to a Roller-Coaster Quarter
2016-03-31,Medivation (MDVN) Stock Soars on Takeover Interest
2016-03-31,Medivation Jumps After Reportedly Hiring Bankers To Fight Takeover
2016-03-31,Medivation Surges on Takeover Chatter; Wall Street Scouts for Big Pharma M&A
2016-03-31,March 31 Premarket Briefing: 10 Things You Should Know
2016-03-30,Medivation (MDVN) Showing Signs Of A Dead Cat Bounce Today
2016-03-29,One Reason Medivation (MDVN) Stock is Plunging Today
2016-03-29,Today's Weak On High Volume Stock: Medivation (MDVN)
2016-03-28,Medivation (MDVN) In A Perilous Reversal
2016-03-24,Pivotal Phase III Trial Of Enzalutamide Initiated In Metastatic Hormone Sensitive Prostate Cancer
2016-03-22,Medivation (MDVN) Is Today's Strong On High Volume Stock
2016-03-08,Insider Trading Alert - MDVN, CRM And MOBL Traded By Insiders
2016-03-02,2 Stocks That Could Be the Next Netflix-Like Growth Stock
2016-02-25,Trade-Ideas: Medivation (MDVN) Is Today's Post-Market Leader Stock
2016-02-22,FDA Accepts For Review Supplemental New Drug Application For XTANDI® (enzalutamide) Capsules In Metastatic Castration-resistant Prostate Cancer With Data From Head-to-Head Studies Of Enzalutamide Versus Bicalutamide
2016-02-09,Strong On High Volume: Medivation (MDVN)
2016-02-06,Credit Suisse Picks 7 Health Care Stocks to Own for the Next 6 Months
2016-02-02,Weak On High Volume: Medivation (MDVN)
2016-02-01,Biotech String: Assessing the January Damage, Gilead's Bottoming P/E, Sarepta Panel Date?
2016-01-27,Analysts' Actions -- Best Buy, Fitbit, McDonald's, Sprint and More
2016-01-26,Post-Market Laggard: Medivation (MDVN)
2016-01-26,Journal Of Clinical Oncology Publishes Results From The STRIVE Trial Of Enzalutamide Compared To Bicalutamide In Castration-resistant Prostate Cancer
2016-01-21,Medivation (MDVN) Stock Gets ‘Outperform’ Rating at Credit Suisse
2016-01-13,Lancet Oncology Publishes Results From The Phase 2 TERRAIN Trial Of Enzalutamide Compared To Bicalutamide In Metastatic Castration-Resistant Prostate Cancer
2017-03-15,Durable Three-Year Outcomes In Degenerative Disc Disease After a Single Injection Of Mesoblast's Cell Therapy
2017-03-07,FDA Grants Fast Track Designation For Mesoblast's Cell Therapy In Children With Acute Graft Versus Host Disease
2017-02-26,Mesoblast Presents Corporate Update And Financial Results For The Half Year Period Ended December 31, 2016
2017-02-24,Mesoblast To Host Second Quarter And First Half Financial Results Conference Call And Webcast
2017-02-15,Durable Responses And Sustained Low Disease Activity Over Nine Months After A Single Dose Of Mesoblast Cell Therapy In Rheumatoid Arthritis Patients Resistant To Anti-TNF Agents
2017-02-13,Published Study Results Show That Mesoblast Cells Administered Intravenously Significantly Ameliorate Joint Disease In Model Of Early Rheumatoid Arthritis
2017-01-31,Mesoblast Director Recognized By Peers For Cardiovascular Leadership
2017-01-11,Mesoblast To Present At 35th Annual J.P. Morgan Healthcare Conference
2017-01-09,Mesoblast Receives A$29.6 Million Following Share Issue To Mallinckrodt
2016-12-22,Mesoblast And Mallinckrodt Enter Into Equity Purchase Agreement To Exclusively Negotiate Development And Commercialization Of Mesoblast's Cell Therapy Products For Chronic Low Back Pain And Acute Graft Versus Host Disease
2016-12-09,United States Congress Legislates New Accelerated Approval Pathway For Regenerative Advanced Therapies
2016-12-06,MD Anderson Cancer Center And National Institutes Of Health To Fund Clinical Trial Combining Two Proprietary Mesoblast Technologies For Rapid Engraftment Of Stem Cell Transplants In Cancer Patients
2016-11-14,Mesoblast Provides Corporate Update And Financial Results For The First Quarter Ended September 30, 2016
2016-11-14,Mesoblast Announces Successful Interim Futility Analysis In Phase 3 Trial For Acute Graft Versus Host Disease
2016-11-09,Mesoblast To Host First Quarter Financial Results Conference Call And Webcast
2016-10-18,Mesoblast Named 2016 Cell Therapy Company Of The Year At Frost & Sullivan Asia Pacific Best Practices Awards
2016-10-12,Mesoblast Japan Strategy Highlighted At Australia-Japan Business Council Annual Meeting
2016-10-06,Phase 2 Trial Results Of Mesoblast's Cell Therapy In Diabetic Kidney Disease Published
2016-09-29,Mesoblast Enters Oversold Territory (MESO)
2016-09-01,Mesoblast Appoints Bill Burns, Former Chief Executive Of Roche Pharmaceuticals, As Vice Chairman
2016-08-24,Mesoblast Reports Financial Results And Operational Highlights For The Three Months And For The Year Ended 30 June 2016
2016-08-19,Mesoblast To Host Fourth Quarter And Full Year Financial Results Conference Call And Webcast
2016-08-17,Mesoblast Strengthens Key United States Patent Portfolio For The Treatment Of Rheumatic Diseases
2016-08-08,Phase 2 Trial Results Of Mesoblast's Cell Therapy Show Dose-Related Improvements In Biologic Refractory Rheumatoid Arthritis
2016-08-01,Mesoblast's Full 24-Month Trial Results For Chronic Low Back Pain Presented At Spine Intervention Society Annual Meeting, Receive Award For Best Basic Science
2016-07-01,Mesoblast Provides Update On Heart Failure Trial And Funding Of Clinical Operations
2016-06-13,Mesoblast Provides Update On Global Heart Failure Program
2016-05-31,Ratings Changes Today
2016-05-09,Mesoblast Reports Financial Results For Period Ended 31 March 2016 And Provides Corporate Update
2016-05-06,Mesoblast To Host Third Quarter And Nine Months Financial Results Conference Call And Webcast
2016-05-05,Mesoblast is Now Oversold (MESO)
2016-04-01,Mesoblast Cell Therapy Shows Disease Modifying Effects On Knee Osteoarthritis
2016-03-24,Key United States Patent Granted For Cell-Based Treatment Of Rheumatoid Arthritis And Other Rheumatic Conditions
2016-03-17,New Mesoblast Cell Targeting Technology Shows Potential To Induce Durable Reversal Of Type 1 Diabetes
2016-02-24,First Allogeneic Cell Therapy Product Launched In Japan By Mesoblast Licensee
2016-02-22,Mesoblast's Cell Therapy Increases Survival In Children With Acute Graft Versus Host Disease
2016-02-16,Mesoblast Reports On First Half And Second Quarter Financial Results
2016-02-16,Mesoblast Cell Therapy Shows Clinical Benefit In First Cohort Of Patients With Biologic Refractory Rheumatoid Arthritis
2016-02-11,Mesoblast To Host Second Quarter And First Half Financial Results Conference Call And Webcast
2016-01-11,Phase 3 Heart Failure Trial Size To Be Substantially Reduced Following FDA Discussions
2016-01-07,Mesoblast To Present At The 34th Annual J. P. Morgan Healthcare Conference
2015-12-16,Mesoblast Provides Strategic Update And Reports On First Quarter Financial Results
2015-12-15,Mesoblast To Host First Quarter Financial Results Conference Call And Webcast On 16 December 2015
2015-11-27,Mesoblast's Japan Licensee Receives Pricing For TEMCELL® HS Inj. For Treatment Of Acute Graft Versus Host Disease
2015-11-23,Mesoblast Investor Update
,
,
,
,
2017-02-27,MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected For Presentation At The 5th Quadrennial Meeting Of The World Federation Of Neuro-Oncology Societies In Zurich, Switzerland
2017-02-07,MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted For Presentation At The American Academy Of Neurology (AAN) 69th Annual Meeting In Boston
2017-02-06,MediciNova Announces Positive Findings From Completed Trial Of MN-166 (ibudilast) In Methamphetamine Dependence Presented At The 50th Winter Conference On Brain Research
2017-02-01,MediciNova To Attend Mizuho Healthcare Conference In New York
2017-01-30,Medicinova is Now Oversold (MNOV)
2017-01-23,MediciNova Announces Publication Of Positive Findings On MN-166 (ibudilast) In Alcohol Dependence
2016-12-29,Oversold Conditions For Medicinova (MNOV)
2016-12-20,MediciNova Announces European Commission Grants Orphan Medicinal Product Designation For MN-166 (ibudilast) For Amyotrophic Lateral Sclerosis
2016-12-19,MediciNova Announces Phase 2b Trial Of MN-166 (ibudilast) In Progressive MS Will Continue As Planned Following DSMB Review Of Interim Efficacy Analysis
2016-12-14,MediciNova Added To NASDAQ Biotechnology Index
2016-12-09,MediciNova Announces Exploratory Interim Clinical Outcomes Data From Clinical Trial Of MN-166 (ibudilast) In ALS Presented At The 27th International Symposium On ALS/MND In Dublin, Ireland
2016-11-15,Noteworthy Tuesday Option Activity: MNOV, ESPR, PAY
2016-11-14,MediciNova To Present At The Piper Jaffray Healthcare Conference In New York
2016-11-10,MediciNova Announces European Medicines Agency Recommends Orphan Medicinal Product Designation For MN-166 (ibudilast) For Amyotrophic Lateral Sclerosis
2016-11-07,MediciNova To Attend Global Mizuho Investor Conference In New York
2016-10-30,MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted For Presentation At The 27th International Symposium On ALS/MND In Dublin, Ireland
2016-10-11,MediciNova Announces FDA Granted Orphan Drug Designation To MN-166 (ibudilast) For Amyotrophic Lateral Sclerosis
2016-09-25,Options On MediciNova Common Stock Listed On CBOE
2016-08-31,Medicinova Enters Oversold Territory (MNOV)
2016-07-24,MediciNova Receives Notice Of Allowance For New Patent Covering MN-001 And MN-002 For The Treatment Of Fibrosis
2016-07-13,MediciNova Announces Initiation Of Interim Efficacy Analysis In Phase 2b Trial Of MN-166 (ibudilast) In Progressive MS
2016-06-29,MediciNova Announces Results From Clinical Trial Of MN-166 (ibudilast) In Alcohol Dependence Presented At The 39th Annual Scientific Meeting Of The Research Society On Alcoholism In New Orleans, Louisiana
2016-06-26,MediciNova Added To Russell 3000® Index And Russell Global Index
2016-05-25,MediciNova Announces Additional Results From The Completed Trial Of MN-166 (ibudilast) In Alcohol Dependence To Be Presented At The 39th Annual Scientific Meeting Of The Research Society On Alcoholism In New Orleans, Louisiana
2016-04-20,MediciNova Announces Interim Data From Clinical Trial Of MN-166 (ibudilast) In ALS Presented At The American Academy Of Neurology (AAN) 68th Annual Meeting In Vancouver, Canada
2016-03-30,MediciNova Announces Publication Of Positive Findings From Completed Phase 1b Clinical Trial Of MN-166 (ibudilast) In Methamphetamine Dependence
2016-03-27,MediciNova Receives Notice Of Allowance For New Patent Covering MN-001 In China
2016-03-23,MediciNova Receives Notice Of Allowance For New Patent Covering MN-001 And MN-002 For The Treatment Of Hypertriglyceridemia, Hypercholesterolemia, And Hyperlipoproteinemia
2016-03-22,FDA Grants Fast Track Designation For MediciNova's MN-166 (ibudilast) For Progressive Multiple Sclerosis
2016-03-07,MediciNova Receives Notice Of Allowance For New Patent Covering MN-166 (ibudilast) For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)
2016-03-06,MediciNova Announces Positive Findings From A Completed Phase 2 Trial Of MN-166 (ibudilast) In Opioid Dependence At The Behavior, Biology And Chemistry: Translational Research In Addiction Meeting In San Antonio, Texas
2016-02-22,MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted For Dual Presentation At The American Academy Of Neurology (AAN) 68th Annual Meeting In Vancouver, Canada
2016-02-11,MediciNova Announces Presentation Regarding MN-166 (ibudilast) And Methamphetamine Dependence At The Behavior, Biology And Chemistry Annual Meeting And Symposium In San Antonio, Texas
2016-02-07,MediciNova Announces Presentation Of Data From The Completed Phase 2 Trial Of MN-166 (ibudilast) In Opioid Dependence At The Behavior, Biology And Chemistry Annual Meeting And Symposium In San Antonio, Texas
2016-01-27,MediciNova Receives Notice Of Allowance For New Patent Covering MN-001 And MN-002 For The Treatment Of Advanced NASH With Fibrosis
2016-01-18,FDA Grants Rare Pediatric Disease Designation To MediciNova's MN-166 (ibudilast) For The Treatment Of Krabbe Disease
2016-01-13,MediciNova Receives Notice Of Allowance For New Patent Covering MN-029 (denibulin) Di-hydrochloride In Europe
2015-12-16,FDA Grants Fast Track Designation For MediciNova's MN-166 (ibudilast) For The Treatment Of Amyotrophic Lateral Sclerosis
2015-12-14,MediciNova Receives Notice Of Allowance For New Patent Covering MN-029 (denibulin) Di-hydrochloride In China
2015-12-13,MediciNova Announces Positive Interim Safety And Clinical Outcomes Data From Clinical Trial Of MN-166 (ibudilast) In ALS Presented At The 26th International Symposium On ALS/MND In Orlando, FL
2015-12-09,MediciNova Announces Positive Findings From A Clinical Trial Of MN-166 (ibudilast) In Alcohol Use Disorder (AUD) Reported At The American College Of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting
2015-12-06,MediciNova Announces Presentation Regarding Clinical Trial Of MN-166 (ibudilast) In ALS At The 6th Annual California ALS Pac10 And Research Network Meeting At UCSD, La Jolla, California 
2015-11-19,MediciNova To Initiate Clinical Trial Evaluating MN-001 In NASH Patients With Hypertriglyceridemia 
2015-11-10,MediciNova Receives Notice Of Allowance For New Patent Covering MN-221 (bedoradrine) For The Treatment Of Irritable Bowel Syndrome In Japan
2015-11-09,FDA Approves A New Clinical Protocol To Evaluate The Effects Of MN-166 (ibudilast) On A Biomarker Of ALS; MediciNova Plans To Initiate A Clinical Trial With MGH (Massachusetts General Hospital)  
2015-11-04,MediciNova Announces Interim Data From Clinical Trial Of MN-166 (ibudilast) In ALS To Be Presented At The 14th Annual NEALS (Northeast Amyotrophic Lateral Sclerosis) Meeting In Clearwater Beach, Florida
2015-10-13,MediciNova To Present Preclinical Data On MN-166 (ibudilast) At The 26th International Symposium On ALS/MND In Orlando, FL
2015-10-09,MediciNova To Initiate Clinical Trial Of MN-001 (tipelukast) In IPF
2015-09-24,MediciNova To Present At The Ladenburg Thalmann 2015 Healthcare Conference
2015-09-10,FDA Grants Fast Track Designation For MediciNova's MN-001 (tipelukast) For The Treatment Of Idiopathic Pulmonary Fibrosis
2015-09-02,MediciNova Announces First Advanced ALS Patient Using Non-Invasive Ventilation Support Enrolled In Phase 2 Clinical Trial Of MN-166 (ibudilast)
2015-08-24,MediciNova Announces Closing Of Underwritten Public Offering Of Common Stock
2015-08-18,MediciNova Announces Pricing Of Underwritten Public Offering Of Common Stock
2015-08-18,MediciNova Announces Proposed Underwritten Public Offering Of Common Stock
2015-07-28,MN-166 (ibudilast) ALS Abstract Accepted For Presentation At The 26th International Symposium On ALS/MND In Orlando, FL: Interim Safety And Clinical Outcomes To Be Presented
2015-07-27,MediciNova Announces FDA Approval Of The Second Phase 2 Protocol For MN-001 In NASH Which Targets NASH Patients With Hypertriglyceridemia
2015-07-21,MediciNova Announces Update On Development Plans For MN-001 In IPF
2015-06-30,MediciNova Announces The Completion Of Enrollment In Clinical Trial Of MN-166 (ibudilast) In Alcohol Dependence
2015-06-24,MediciNova Announces Presentation Of Interim Data From Clinical Trial Of MN-166 (ibudilast) In Alcohol Dependence At The 38th Annual RSA (Research Society On Alcoholism) Scientific Meeting
2015-06-16,MediciNova Announces New Article Published On MN-166 (ibudilast) In Addiction Biology
2015-06-12,MediciNova Announces Randomization Of 255 Subjects Completed In Phase 2b Trial Of MN-166 (ibudilast) In Progressive MS
2015-06-03,MediciNova Announces FDA Granted Orphan Drug Designation To MN-166 (ibudilast) For Krabbe Disease
2015-05-07,MediciNova Announces Full Enrollment In Phase 2b Trial Of MN-166 (ibudilast) In Progressive MS
2015-04-23,Baseline Characteristics Of 228 Subjects Enrolled In MediciNova's Phase 2b Trial Of MN-166 (ibudilast) In Progressive MS Presented At The American Academy Of Neurology (AAN) 67th Annual Meeting
2015-04-21,MediciNova Announces Positive Interim Safety Data From Clinical Trial Of MN-166 (ibudilast) In ALS
2015-04-16,MedicNova (MNOV) Stock is Gaining Today After Drug Receives Fast Track Designation
2015-04-16,Tokyo Stock Exchange Announces New Rule Affecting Trading Of MediciNova Stock In Japan
2015-04-16,FDA Grants Fast Track Designation For MediciNova's MN-001 (tipelukast) For The Treatment Of NASH With Fibrosis
2015-03-02,MN-166 (Ibudilast) Effects In Opioid Dependence Selected For Presentation At The 77th Annual Meeting Of The College On Problems Of Drug Dependence In Phoenix, Arizona
2015-02-25,MediciNova's MN-001 (tipelukast) NASH With Advanced Fibrosis Abstract Accepted For Presentation At The AASLD And Industry Colloquium: Novel Targets And Therapies In Liver Disease In Durham, North Carolina
2015-02-16,MediciNova Provides Update On Clinical Trial Of MN-166 (Ibudilast) In ALS
2015-02-10,MediciNova Announces FDA Approval Of Protocol For Phase 2 Trial Of MN-001 In IPF
2015-02-03,MediciNova Receives Notice Of Allowance For New Patent Covering MN-001 And MN-002 For The Treatment Of NASH
2015-02-02,MN-166 (ibudilast) ALS Abstract Accepted For Dual Presentation At The American Academy Of Neurology (AAN) 67th Annual Meeting In Washington, DC
2015-02-01,MN-166 (ibudilast) Progressive MS Abstract Accepted For Presentation At The American Academy Of Neurology (AAN) 67th Annual Meeting In Washington, DC
2015-01-29,MediciNova Receives New Patent Covering MN-029 (denibulin) Di-hydrochloride In Japan
2015-01-28,MediciNova Announces An Open Investigational New Drug (IND) Application For MN-001 In NASH
2014-12-09,MediciNova Receives Notice Of Allowance For New Patent Covering MN-001 And MN-002 For The Treatment Of Liver Disorders
2014-12-02,Five Biotech Firms Whose Stock-Promoting Efforts Didn't Pay Off
2014-10-23,U.S. Centers For Disease Control And Prevention (CDC) Supports Recruitment For MediciNova's Clinical Trial Of MN-166 (Ibudilast) In ALS
2014-10-22,MediciNova Announces FDA Granted Orphan Drug Designation To MN-001 (tipelukast) For Idiopathic Pulmonary Fibrosis (IPF)
2014-10-08,MediciNova Receives Feedback From FDA Regarding Study Protocol For Phase 2 Trial Of MN-001 (tipelukast) In NASH
2014-10-07,It's True, Small-Cap Biotech Stocks Are Acting Badly These Days
2014-10-06,MediciNova's MN-001 (tipelukast) NASH Abstract Selected For Late-Breaking Session At The 65th Annual AASLD Meeting In Boston
2014-09-29,Overview Of MediciNova's Clinical Trial Of MN-166 (ibudilast) In ALS To Be Presented At The 13th Annual NEALS Meeting
2014-09-23,MediciNova Provides Update On Phase 2b Trial Of MN-166 (ibudilast) In Progressive MS
2014-09-07,MediciNova Announces New NIDA Grant For MN-166 (ibudilast) In Opioid Dependence
2014-09-02,3 Stocks Raising The Drugs Industry Higher
2014-09-01,MediciNova To Present Data On MN-001 (tipelukast) For The Treatment Of Idiopathic Pulmonary Fibrosis (IPF) During The 18th International Colloquium On Lung And Airway Fibrosis (ICLAF)
2014-08-26,3 Stocks Pushing The Drugs Industry Higher
2014-08-25,MediciNova To Initiate Clinical Trial Of MN-166 (ibudilast) In ALS
2014-08-18,MediciNova Announces Positive Interim Results Of Phase 2a Study Of MN-166 (ibudilast) In Opioid Dependence
2014-08-11,MediciNova Receives Notice Of Allowance For New Patent Covering MN-001 And MN-002 For The Treatment Of Nonalcoholic Fatty Liver Disease
2014-08-05,3 Stocks Pushing The Drugs Industry Lower
2014-08-05,MediciNova Announces Positive Results Of MN-001 In Advanced NASH Mouse Model; MediciNova Requests A Meeting With FDA
2014-07-30,3 Drugs Stocks Pushing The Industry Higher
2014-07-07,MediciNova To Present Data On MN-001 For The Treatment Of NASH (Nonalcoholic Steatohepatitis) During The JDDW 2014 (Japan Digestive Disease Week 2014)
2014-06-11,MediciNova Announces Positive Results In Study Of MN-001 In Mouse Model Of Pulmonary Fibrosis
2014-04-08,MediciNova Appoints Yoshio Ishizaka To Its Board Of Directors
2014-04-08,MediciNova Announces Management Appointment
2014-01-17,Five Worst, Pandering Drug Stocks of J.P. Morgan Healthcare Confab Week
2014-01-14,MediciNova Announces Positive Results In NASH Mouse Model With MN-001 And Prepares To Initiate Phase 2 Trial In The U.S.
2013-11-11,MediciNova Receives New Patent Covering MN-221 In Irritable Bowel Syndrome
2013-11-07,MediciNova Reports Third Quarter 2013 Results
2013-10-16,MediciNova Appoints Yutaka Kobayashi To Its Board Of Directors
2013-10-16,MediciNova Appoints Geoffrey O'Brien As Vice President
2013-10-06,MediciNova Receives Notice Of Allowance For New Patent Covering MN-029 (denibulin) Di-hydrochloride
2013-08-25,National Institute On Alcohol Abuse And Alcoholism Funds New UCLA Clinical Trial Of MediciNova's MN-166 In Treating Alcoholism
2013-08-08,MediciNova Reports Second Quarter 2013 Results
2013-07-18,MediciNova Announces Initiation Of A Cooperative Phase 2b Trial Of MN-166 In Progressive Multiple Sclerosis
2013-06-18,UCLA Presents Data On MediciNova's MN-166 In Methamphetamine Addiction At The 75th Annual Meeting Of The College On Problems Of Drug Dependence
2013-05-08,MediciNova Reports First Quarter 2013 Results
2013-03-28,MediciNova Reports Fourth Quarter And Full Year 2012 Results
2013-03-20,MediciNova Announces MN-166 (ibudilast) Opioid Withdrawal And Analgesia Data Presentation At The American Academy Of Neurology Annual Meeting
2013-02-25,FDA Grants Fast Track Designation For MediciNova's MN-166 (ibudilast) For The Treatment Of Methamphetamine Dependence
2013-01-03,MediciNova Provides Development Update
2012-10-22,MediciNova Meets With FDA For End-of-Phase 2 Meeting For MN-221 For The Treatment Of Acute Exacerbations Of Asthma
2012-09-04,NIH Funds UCLA Phase 2 Study Of MediciNova's MN-166 In Treating Drug Addiction
2012-08-28,MediciNova To Present At The Rodman & Renshaw Annual Global Investment Conference On September 11, 2012
2012-08-23,MediciNova Announces Positive Preliminary Results From A Multi-Day, Repeat-Dose Clinical Trial With MN-221 In Chronic Obstructive Pulmonary Disease Patients
2012-08-20,MediciNova Enters Into A $20 Million Common Stock Purchase Agreement With Aspire Capital Fund
2012-08-09,MediciNova Reports Second Quarter 2012 Results
2012-05-04,5 Stocks Under $10 Set to Soar
2011-03-23,MediciNova Prices $8.25 Million Public Offering Of Common Stock And Warrants
2011-03-23,MediciNova Announces Proposed Public Offering Of Common Stock And Warrants
2011-03-21,5 Health Care Stocks With Upside
2011-03-09,MediciNova Receives A Notice Of Allowance For A Method Of Treating Drug Addiction Or Dependence
2011-03-03,Joint Venture Announced
2011-02-03,10 Pharma Stocks With 100% Buy Ratings
2010-12-13,Columbia University/New York State Psychiatric Institute And MediciNova Report Preliminary Safety And Efficacy Of Ibudilast In Heroin-dependent Volunteers
2010-11-15,MediciNova Reports Third Quarter 2010 Results
2010-10-28,MedicNova Announces Poster Presentations At Annual Meeting Of The American College Of Chest Physicians
2010-10-19,MediciNova's MN-166 Program Recognized As One Of Windhover's Top 10 Neuroscience Projects To Watch
2010-09-27,UCLA Initiates A NIDA-Supported Phase 1b Study With Ibudilast In Methamphetamine-Dependent Volunteers
2010-09-02,MediciNova To Present At The Rodman And Renshaw Annual Global Investment Conference
2010-08-16,MediciNova Reports Second Quarter 2010 Results
2010-08-02,$5 Stocks That Analysts Expect to Double
2010-07-12,MediciNova Announces Estimated Timing Of Payments To Former Avigen Stockholders
2010-07-07,Insight On MediciNova's MN-166 Mechanism Of Action Reported In Proceedings Of The National Academy Of Sciences
2010-07-06,MediciNova Nets $9.5 Million From Settlement Of Auction Rate Securities Held By UBS
2010-06-14,MediciNova Appoints Michael Coffee As Chief Business Officer
2010-05-11,MediciNova Secures $15 Million Debt Facility From Oxford Finance Corporation
2010-04-23,MediciNova Releases Notice Of Pendency And Settlement Of Class Action
2009-01-09,Latest News in Activist Investing
,
2017-03-15,Marinus Pharmaceuticals To Present At Oppenheimer Healthcare Conference
2017-03-13,Marinus Pharmaceuticals Provides Business Update And 2016 Financial Results
2017-02-14,Ganaxolone Reduces Seizures And Improves Behaviors In Angelman Syndrome Preclinical Model
2017-02-01,Marinus Appoints Michael R. Dougherty To Its Board Of Directors
2017-01-23,Marinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder
2017-01-05,Marinus Provides Business Outlook For 2017
2017-01-03,Marinus Pharmaceuticals Receives FDA Orphan Drug Designation For Ganaxolone To Treat Fragile X Syndrome
2016-11-15,Ganaxolone And Diazepam Administered Intravenously Synergistically Block Seizures In Animal Model Of Status Epilepticus
2016-11-03,Marinus Pharmaceuticals Provides Business Update And Reports Third Quarter 2016 Financial Results
2016-10-19,Ganaxolone Phase 1 Data Supports Progressing To Phase 2 In Patients With Status Epilepticus
2016-09-29,5 Stocks Under $10 Poised for Big Breakouts
2016-09-29,Ganaxolone Reduces Seizures In Females With PCDH19 Pediatric Epilepsy
2016-09-07,Marinus Appoints Seth H.Z. Fischer To Its Board Of Directors
2016-08-09,Marinus Pharmaceuticals Provides Business Update And Reports Second Quarter 2016 Financial Results
2016-07-13,Cheap Stocks: These Aren't Necessarily a Lucky 7
2016-07-13,7 Stocks Under $10 That Could Make You a Lot of Money
2016-07-07,These 5 Stocks Under $10 Are Set to Soar
2016-06-28,Results From Phase 2 Exploratory Clinical Study Support Continued Development Of Ganaxolone In Fragile X Syndrome
2016-06-27,Marinus Pharmaceuticals To Host Conference Call On Tuesday, June 28
2016-06-22,Marinus Pharmaceuticals Doses First Subject In Phase 1 Clinical Trial For Ganaxolone IV
2016-06-13,Closing Bell: Apple Opens Siri to Third Parties; U.S. Stocks Slide
2016-06-13,Stocks Hold Lower Ahead of Tuesday's Fed Meeting
2016-06-13,Stocks Seesaw as 'Brexit' Fears, Fed Feed Nerves
2016-06-13,Stock Futures Slide; Microsoft to Buy LinkedIn
2016-06-13,Marinus Pharmaceuticals Announces Top-Line Results From Phase 3 Trial In Adult Focal Onset Seizures
2016-05-03,Marinus Pharmaceuticals To Participate In Bank Of America Merrill Lynch Healthcare Conference
2016-05-02,Marinus Pharmaceuticals Provides Business Update And Reports First Quarter 2016 Financial Results
2016-04-19,Marinus Pharmaceuticals' Ganaxolone IV Demonstrates Robust Efficacy In Benzodiazepine-Resistant Model Of Status Epilepticus
2016-04-17,8 Stocks Under $10 to Trade for Big Gains
2016-04-15,Marinus Pharmaceuticals Receives FDA Orphan Drug Designation For Ganaxolone IV To Treat Status Epilepticus
2016-04-12,Marinus Pharmaceuticals To Present Ganaxolone IV Data At American Academy Of Neurology Annual Meeting
2016-03-24,These 5 Under-$10 Stocks Are Set to Soar Higher
2016-03-07,Marinus Pharmaceuticals Provides Business Update And 2015 Financial Results
2016-03-04,8 Stocks Under $10 to Trade for Big Gains
2016-03-01,Marinus Pharmaceuticals To Present At The Cowen & Company Annual Healthcare Conference
2016-01-27,Marinus Pharmaceuticals To Participate In Canaccord Genuity Rare Disease Biopharma Day
2016-01-22,Marinus Pharmaceuticals: Set to Climb Back
2015-12-18,4 Biotech Stocks Under $10 Poised for Big Breakouts
2015-12-16,Marinus Pharmaceuticals Completes Patient Recruitment In Phase 3 Clinical Trial Of Ganaxolone In Focal Onset Seizures
2015-12-07,Marinus Presents Additional Responder Analysis Data For Ganaxolone In Focal Onset Seizures At The American Epilepsy Society Annual Meeting
2015-12-03,Marinus Pharmaceuticals Bolsters Clinical And Regulatory Expertise
2015-11-19,Marinus's Ganaxolone To Be Featured In Two Poster Presentations At The 69th Annual Meeting Of The American Epilepsy Society
2015-11-12,Marinus Pharmaceuticals To Present At Stifel Healthcare Conference
2015-11-10,Marinus Pharmaceuticals To Present At Credit Suisse Healthcare Conference
2015-11-06,Marinus Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2015-11-05,Marinus Pharmaceuticals Announces Public Offering Of Common Stock
2015-10-29,Marinus Pharmaceuticals Enters Oversold Territory (MRNS)
2015-10-29,Marinus Pharmaceuticals Provides Business Update And Reports Third Quarter 2015 Financial Results
2015-10-29,Marinus Announces Clinical Development Plans For Ganaxolone Intravenous Formulation
2015-10-26,Marinus Announces Key Initial Observations From Study In PCDH19 Female Pediatric Epilepsy
2015-09-09,Marinus Pharmaceuticals Announces Positive End-of-Phase 2 Meeting With FDA For Ganaxolone In Focal Onset Seizures
2015-08-04,Marinus Pharmaceuticals Provides Business Update And Reports Second Quarter 2015 Financial Results
2015-07-06,Published Data Support Scientific Basis For Ganaxolone Use In PCDH19 Female Epilepsy
2015-06-16,Marinus Pharmaceuticals To Present At JMP Securities Life Sciences Conference
2015-06-09,Market News: AudioCodes. Lululemon Athletica, Marinus Pharmaceuticals
2015-05-18,Marinus Pharmaceuticals Presents Clinical Data Of Ganaxolone In Pediatric Epilepsies At Antiepileptic Drug And Device Trials XIII Conference
2015-05-11,Marinus Pharmaceuticals Provides Business Update And Reports First Quarter 2015 Financial Results
2015-05-05,Marinus Pharmaceuticals Becomes Oversold (MRNS)
2015-05-01,5 Stocks Ready for Breakouts
2015-04-16,3 Stocks Under $10 to Trade for Breakouts
2015-03-25,Marinus Pharmaceuticals' Ganaxolone Receives FDA Orphan Drug Designation In PCDH19 Female Epilepsy
2015-03-16,Marinus Pharmaceuticals To Participate In Future Leaders In The Biotech Industry Conference
2015-03-12,Marinus Pharmaceuticals Provides Business Update And Reports Year End 2014 Financial Results
2015-02-24,Marinus Pharmaceuticals To Participate In Cowen & Company Annual Healthcare Conference
2015-02-09,Marinus Pharmaceuticals To Participate In Leerink Global Healthcare Conference
2015-02-03,U.S. Congressman Patrick Meehan To Present Keynote Address At 22nd Annual Groundhog Investment Forum
2015-02-03,Marinus Pharmaceuticals Initiates Clinical Trial With Ganaxolone In PCDH19 Female Pediatric Epilepsy
2015-02-02,Marinus Pharmaceuticals To Present At BIO CEO & Investor Conference
2015-01-29,Investment Industry To Gather In Philadelphia At 22nd Annual Groundhog Day Investment Forum
2015-01-27,Marinus Pharmaceuticals To Participate In Canaccord Genuity Rare Disease Biopharma Day
2015-01-07,Marinus Pharmaceuticals Hires Dr. Albena Patroneva As Chief Medical Officer
2014-12-03,Marinus Pharmaceuticals To Present At The Oppenheimer Healthcare Conference
2014-11-13,Marinus Pharmaceuticals Provides Business Update And Reports Third Quarter 2014 Financial Results
2014-11-11,Marinus Pharmaceuticals To Present At The Stifel Healthcare Conference
2014-09-25,Marinus Pharmaceuticals, Inc. To Present At The 21st Annual BioCentury Newsmakers Conference On Friday, September 26, 2014
2014-09-02,Marinus Pharmaceuticals, Inc. Announces Exercise Of Over-Allotment Option In Public Offering Of Common Stock
2014-08-25,Marinus Pharmaceuticals, Inc. To Ring The Opening Bell Of The NASDAQ Stock Market
2014-08-12,Marinus Pharmaceuticals, Inc. Enters Into Use Agreement With CyDex Pharmaceuticals, Inc. For Use Of Captisol(R) For Ganaxolone IV
,
,
,
2017-03-16,Merus Named BioCapital Europe 2017 Company Of The Year
2017-02-27,Merus To Present At The Cowen & Co. 37th Annual Health Care Conference
2017-02-09,Merus To Present At The Leerink Partners 6th Annual Global Healthcare Conference
2017-01-23,Merus Announces Closing Of Global Strategic Research Collaboration With Incyte To Discover And Develop Bispecific Antibodies
2017-01-05,Merus And The Institute For Research In Biomedicine (IRB) Barcelona Form Research Collaboration To Develop Bispecific Antibodies Targeting The Tumor Microenvironment
2016-12-21,Incyte And Merus Announce Global Strategic Research Collaboration To Discover And Develop Bispecific Antibodies
2016-11-15,Merus Announces Favorable Decisions In Europe And Japan For Patents Covering Genetically-Modified Mice For Common Light Chain Human Monoclonal Antibodies
2016-11-10,Merus To Present At The Jefferies London Healthcare Conference
2016-11-09,Merus N.V. Receives €1.5 Million EUREKA Eurostars Grant With Aquila BioMedical Ltd To Jointly Develop Immunological Assays For Identification Of Novel Immunomodulatory Bispecific Antibodies
2016-11-07,Merus Announces Third Quarter 2016 Financial Results And Corporate Developments
2016-11-03,Merus Strengthens Executive Management Team With The Appointment Of John Crowley As Chief Financial Officer
2016-10-26,Merus Expands Executive Management Team With The Appointment Of L. Andres Sirulnik, MD, PhD, As Chief Medical Officer
2016-10-19,Merus Receives Milestone Payment From Ono Pharmaceutical For Selection Of Bispecific Antibody Candidate For Clinical Development And Extends Partnership With CMC Service Agreement
2016-08-31,Merus To Participate In Upcoming Investor Conferences
2016-08-10,Merus To Present At The 2016 Wedbush PacGrow Healthcare Conference
2016-08-08,Merus Announces Second Quarter 2016 Financial Results And Reviews Recent Clinical Progress And Corporate Developments
2016-07-12,Merus Announces First Quarter 2016 Financial Results And Highlights Recent Clinical Progress And Corporate Developments
2016-06-03,What You Need to Know About Biotech IPOs This Year
2016-06-01,Merus N.V. Signs Commercial Multi-Product License For ProBioGen's GlymaxX® ADCC Enhancement Technology
2016-05-31,Merus N.V. Announces Closing Of Partial Exercise Of Underwriters' Over-Allotment Option
2016-05-24,Merus N.V. Announces Closing Of Initial Public Offering
,
,
,
,
,
2017-03-16,Merus Named BioCapital Europe 2017 Company Of The Year
2017-02-27,Merus To Present At The Cowen & Co. 37th Annual Health Care Conference
2017-02-09,Merus To Present At The Leerink Partners 6th Annual Global Healthcare Conference
2017-01-23,Merus Announces Closing Of Global Strategic Research Collaboration With Incyte To Discover And Develop Bispecific Antibodies
2017-01-05,Merus And The Institute For Research In Biomedicine (IRB) Barcelona Form Research Collaboration To Develop Bispecific Antibodies Targeting The Tumor Microenvironment
2016-12-21,Incyte And Merus Announce Global Strategic Research Collaboration To Discover And Develop Bispecific Antibodies
2016-11-15,Merus Announces Favorable Decisions In Europe And Japan For Patents Covering Genetically-Modified Mice For Common Light Chain Human Monoclonal Antibodies
2016-11-10,Merus To Present At The Jefferies London Healthcare Conference
2016-11-09,Merus N.V. Receives €1.5 Million EUREKA Eurostars Grant With Aquila BioMedical Ltd To Jointly Develop Immunological Assays For Identification Of Novel Immunomodulatory Bispecific Antibodies
2016-11-07,Merus Announces Third Quarter 2016 Financial Results And Corporate Developments
2016-11-03,Merus Strengthens Executive Management Team With The Appointment Of John Crowley As Chief Financial Officer
2016-10-26,Merus Expands Executive Management Team With The Appointment Of L. Andres Sirulnik, MD, PhD, As Chief Medical Officer
2016-10-19,Merus Receives Milestone Payment From Ono Pharmaceutical For Selection Of Bispecific Antibody Candidate For Clinical Development And Extends Partnership With CMC Service Agreement
2016-08-31,Merus To Participate In Upcoming Investor Conferences
2016-08-10,Merus To Present At The 2016 Wedbush PacGrow Healthcare Conference
2016-08-08,Merus Announces Second Quarter 2016 Financial Results And Reviews Recent Clinical Progress And Corporate Developments
2016-07-12,Merus Announces First Quarter 2016 Financial Results And Highlights Recent Clinical Progress And Corporate Developments
2016-06-03,What You Need to Know About Biotech IPOs This Year
2016-06-01,Merus N.V. Signs Commercial Multi-Product License For ProBioGen's GlymaxX® ADCC Enhancement Technology
2016-05-31,Merus N.V. Announces Closing Of Partial Exercise Of Underwriters' Over-Allotment Option
2016-05-24,Merus N.V. Announces Closing Of Initial Public Offering
,
,
,
,
,
2017-03-16,Mast Therapeutics Sets Date For Special Meeting Of Stockholders To Vote On Proposed Merger With Savara
2017-03-06,Mast Therapeutics Announces Clinical Study Of AIR001 For The Treatment Of Chronic Infection In Cystic Fibrosis Patients
2017-01-07,Mast Therapeutics And Savara Sign Merger Agreement
2016-12-22,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
2016-12-06,Mast Therapeutics Announces Initiation Of Patient Enrollment In Additional Phase 2 Study Of AIR001 For The Treatment Of Heart Failure With Preserved Ejection Fraction
2016-11-21,How to Trade These Most Active Stocks -- LifeLock, Tyson Foods and More
2016-11-21,Mast Therapeutics Provides Update On Strategic Direction
2016-11-03,Positive Interim Results From Phase 2 Study Of AIR001 In Patients With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction (PH-HFpEF) Published In Journal Of Clinical Investigation
2016-11-01,Mast Therapeutics To Host Third Quarter 2016 Financial Results And Business Update Conference Call
2016-10-31,Research Reports On Biotech Equities -- Mast Therapeutics, Array BioPharma, Galena Biopharma, And Clovis Oncology
2016-10-17,Mast Therapeutics Announces Agreement With Philips For Supply Of Adaptive Aerosol Delivery System For AIR001
2016-10-13,Mast Therapeutics To Present At 2016 BIO Investor Forum On October 19th
2016-09-26,Mast Therapeutics Provides Business Update
2016-09-21,5 Big-Volume Stocks to Add to Your Buy List -- Plus 2 to Avoid
2016-09-20,Mast Therapeutics Reports Top-Line Results From Phase 3 Study In Sickle Cell Disease
2016-09-06,Mast Therapeutics Joins New Sickle Cell Disease Coalition, Supports Campaign To Improve Treatment And Care
2016-09-01,Mast Therapeutics To Present At 18th Annual Rodman & Renshaw Global Investment Conference On September 13th
2016-08-22,MSTX April 2017 Options Begin Trading
2016-08-08,Mast Therapeutics Awarded Small Business Innovation Research Grant From The National Institutes Of Health
2016-08-03,Mast Therapeutics Announces Issuance Of Composition Of Matter Patent Covering Vepoloxamer
2016-08-02,Mast Therapeutics To Present At 36th Annual Canaccord Genuity Growth Conference On August 10
2016-08-01,Mast Therapeutics Announces Initiation Of Phase 2 Study Of AIR001 Conducted By The Heart Failure Clinical Research Network
2016-06-08,Mast Therapeutics Receives Notice Of Allowance Of Composition Of Matter Patent Application Covering Vepoloxamer
2016-05-23,Results Of Vepoloxamer Nonclinical Studies In Advanced Heart Failure Presented At European Society Of Cardiology 3rd World Congress On Acute Heart Failure
2016-05-16,Positive Interim Results From Second Phase 2a Study Of AIR001 In Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) Presented At American Thoracic Society International Conference
2016-05-12,Mast Sickle Cell Drug Seeks to Defy Long Odds Like Leicester City
2016-04-13,Mast Therapeutics Announces Agreement For Phase 2 Study Of AIR001 To Be Conducted By The Heart Failure Clinical Research Network
2016-04-04,Results Of Vepoloxamer Nonclinical Studies In Advanced Heart Failure Presented At American College Of Cardiology 65th Annual Scientific Sessions & Expo
2016-03-01,Mast Therapeutics To Present At Cowen And Company 36th Annual Health Care Conference On March 7th
2016-02-29,Mast Announces Amendment To Loan And Security Agreement With Hercules Capital
2016-02-22,Mast Therapeutics Completes Patient Enrollment In Pivotal Phase 3 "EPIC" Study For The Treatment Of Sickle Cell Crisis
2016-02-16,Mast Therapeutics Closes $8 Million Public Offering
2016-02-10,Mast Therapeutics Announces Pricing Of Underwritten Public Offering
2016-02-09,Mast Therapeutics Announces Proposed Public Offering Of Common Stock And Warrants
2016-02-02,Mast Therapeutics To Present At 2016 BIO CEO & Investor Conference On February 8th
2016-02-01,Mast Therapeutics' AIR001 Selected By The Heart Failure Clinical Research Network For Evaluation In A 100-Patient Multicenter Phase 2 Study
2016-02-01,Mast Therapeutics Announces Positive Top-Line Results From Phase 2a Study Of AIR001 In Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) Conducted At Mayo Clinic
2016-01-07,Mast Therapeutics Provides Business Update
2015-11-24,Mast Therapeutics To Present At The Piper Jaffray 27th Annual Healthcare Conference
2015-11-16,Vepoloxamer Data Selected For Presentation At 57th Annual American Society Of Hematology (ASH) Meeting
2015-11-09,Vepoloxamer Nonclinical Study Results In Advanced Heart Failure To Be Presented At 2015 American Heart Association Scientific Sessions
2015-11-09,Mast Therapeutics Announces Appointment Of Peter Greenleaf To Board Of Directors
2015-11-02,Mast Therapeutics Announces Appointment Of Matthew Pauls To Board Of Directors
2015-10-29,Mast Therapeutics To Host Third Quarter 2015 Financial Results And Corporate Update Conference Call
2015-10-26,Mast Therapeutics Initiates Phase 2 Study Of Vepoloxamer For The Treatment Of Chronic Heart Failure
2015-10-13,BASF to Develop a High Purity Poloxamer for Mast Therapeutics
2015-09-30,Mast Announces Amendment To Loan And Security Agreement With Hercules Technology Growth Capital
2015-09-29,3 Stocks Under $10 to Trade for Big Breakouts
2015-09-28,Mast Announces Presentation Of Results Of Nonclinical Study Of Vepoloxamer In Chronic Heart Failure At The HFSA's Annual Scientific Meeting
2015-09-23,Mast Therapeutics To Host Analyst & Investor Day On October 7, 2015
2015-08-06,Mast Therapeutics To Host Second Quarter 2015 Financial Results And Corporate Update Conference Call
2015-05-28,Mast Therapeutics Announces Change In Board Of Directors
2015-05-26,Mast Therapeutics Announces Initiation Of EPIC-E Study
2015-04-21,Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark
2015-04-09,Mast To Present New Data Supporting Vepoloxamer (MST-188) In Sickle Cell Disease At 9th Annual Sickle Cell Disease Research And Education Symposium And 38th National Sickle Cell Disease Scientific Meeting
2015-03-23,Mast To Develop Vepoloxamer (MST-188) In Chronic Heart Failure
2015-03-02,Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure
2015-02-24,Mast Therapeutics To Present At Cowen And Company's 35th Annual Healthcare Conference On March 2nd
2015-02-13,Biotech Stock Mailbag: MannKind, Mast Therapeutics, Bluebird
2015-02-11,Mast Therapeutics Announces New Data Supporting Vepoloxamer In Embolic Stroke
2015-02-04,Mast Therapeutics Announces Initiation Of Phase 2a Studies Of AIR001 In Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
2015-02-03,Mast Therapeutics To Present At 17th Annual BIO CEO & Investor Conference On February 9th
2015-01-24,Mast Therapeutics Announces Management Change
2015-01-07,Mast Therapeutics To Present At 2015 Biotech Showcase Conference On January 12th
2015-01-05,Mast Therapeutics Provides Update On Epic Study Enrollment And 2015 Milestones
2014-12-30,Mast Therapeutics To Host Corporate Conference Call
2014-12-09,Mast Announces Plans For Development Of Vepoloxamer (MST-188) In Heart Failure
2014-11-26,Mast Therapeutics To Present At The 26th Annual Piper Jaffray Healthcare Conference On December 3rd
2014-11-20,Two Small-Cap Biotechnology Gems
2014-11-19,New Data From Nonclinical Heart Failure Study To Be Presented At American Heart Association Conference
2014-11-17,Mast Therapeutics To Present MST-188 Data At 2014 American Society Of Hematology Conference
2014-11-13,Mast Therapeutics Announces Closing Of Underwritten Public Offering
2014-11-06,Mast Therapeutics Announces Pricing Of Underwritten Public Offering
2014-11-05,Mast Therapeutics Announces Underwritten Public Offering
2014-10-02,Mast Therapeutics Announces Appointment Of Chief Medical Officer
2014-09-08,Mast Therapeutics Announces Positive Top Line Results From Phase 2 Study Of AIR001 For Pulmonary Arterial Hypertension And AIR001 Clinical Development Plan
2014-09-02,Mast Therapeutics To Present At The Rodman And Renshaw 16th Annual Global Investment Conference On September 9th
2014-08-29,Mast Therapeutics Announces Management Change
2014-08-07,Mast Therapeutics To Present At The Canaccord Genuity 34th Annual Growth Conference On August 14th
2014-06-20,4 Biotech Stocks Under $10 to Watch for Breakout Trades
2014-06-19,Mast Announces Appointment Of Howard C. Dittrich M.D. To Board Of Directors
2014-06-16,Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial
2014-05-29,5 Stocks Under $10 Set to Soar
2014-05-19,Interesting MSTX Put And Call Options For January 2015
2014-04-14,Mast Therapeutics Announces New Data Supporting MST-188 In Sickle Cell Disease
2014-03-26,A Small-Cap Biotech Stock With Promise: MSTX
2014-03-26,Mast Therapeutics Initiates Phase 2 Study Of MST-188 In Patients With Acute Limb Ischemia
2014-03-11,Purified Poloxamer Granted Unique Nonproprietary Name (Vepoloxamer) By U.S. Adopted Names Council
2014-03-06,5 Stocks Under $10 Set to Soar
2014-02-27,Mast Therapeutics Completes Acquisition Of Aires Pharmaceuticals, Inc.
2014-02-25,Interesting MSTX Call Options For October 18th
2014-02-25,Mast Therapeutics To Present At The Cowen & Co. 34th Annual Healthcare Conference On March 3rd
2014-02-24,Mast Therapeutics Announces International Expansion Of Phase 3 "EPIC" Study Of MST-188
2014-02-18,Mast Therapeutics Provides Additional Results From Nonclinical Heart Failure Study
2014-02-10,Mast Therapeutics Signs Definitive Agreement To Acquire Aires Pharmaceuticals, Inc.
2014-01-23,Interesting MSTX Call Options For March 22nd
2014-01-08,Mast Therapeutics Provides Enrollment Update On Phase 3 "EPIC" Study Of MST-188
2014-01-07,Mast Therapeutics To Present At The OneMedForum Emerging Company Finance Conference On January 14
2014-01-06,Mast Therapeutics Announces Positive Data In Model Of Heart Failure
2013-11-26,Mast Therapeutics To Present At The 25th Annual Piper Jaffray Healthcare Conference On December 3
2013-11-13,FDA Designates MST-188 As An Orphan Drug For Treatment Of Acute Limb Ischemia
2013-10-30,5 Stocks Under $10 on the Verge of Breakouts
2013-10-01,Mast Therapeutics To Present At The 12th Annual BIO Investor Forum On October 8
2013-09-30,Mast Therapeutics To Present At The Leerink Swann Rare Disease Roundtable On October 2
2013-09-06,Mast Therapeutics Hosting 2nd Annual Sickle Cell Disease Therapeutics Conference On September 19, 2013
2013-09-03,Mast Therapeutics To Present At The Rodman & Renshaw 15th Annual Healthcare Conference On September 10
2013-07-23,Mast Therapeutics Reports Results From Clinical QT Study Of MST-188
2013-07-19,2 Biotech Stocks Under $10 to Watch
2013-07-03,Mast Therapeutics To Present At The JMP Securities Healthcare Conference On July 9
2013-06-14,Mast Therapeutics Prices Public Offering Of Units
2013-04-17,Mast Therapeutics Presents MST-188 Data At 7Th Annual Sickle Cell Disease Research And Educational Symposium
2013-03-28,Mast Therapeutics Engages ESC Advisors To Identify Partnering Opportunities For MST-188
2013-03-25,European Commission Designates MST-188 As An Orphan Medicinal Product
,
,
2017-03-21,Neurocrine Announces American Journal Of Psychiatry Publication Of Positive Results From Kinect 3 Phase III Study Of INGREZZA TM (valbenazine) For The Treatment Of Tardive Dyskinesia
2017-02-09,Neurocrine And BIAL Announce Exclusive North American Licensing Agreement For Opicapone
2017-02-07,Neurocrine Biosciences Announces Conference Call And Webcast To Report Fourth Quarter And Year-End 2016 Results
2017-01-27,Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen
2017-01-27,Analysts' Actions -- Ford, Intel, Whirlpool, Wynn and More
2017-01-17,Neurocrine Drug Fails to Reduce Tic Severity in Tourette Syndrome Patients
2017-01-17,Neurocrine Announces Completion Of Phase II Clinical Study Of VMAT2 Inhibitor INGREZZA™ (valbenazine) In Adults With Tourette Syndrome
2017-01-06,Neurocrine Biosciences Announces The Appointment Of David-Alexandre Gros M.D. President And Chief Operating Officer
2017-01-05,Neurocrine Provides Update On FDA Advisory Committee For INGREZZA™ (valbenazine) For The Treatment Of Tardive Dyskinesia
2017-01-03,Neurocrine Biosciences To Present At The 35th Annual J.P. Morgan Healthcare Conference
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2016-12-21,Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin To Step Down
2016-12-07,Neurocrine Biosciences To Present At The 2016 BMO Capital Markets Prescription For Success Healthcare Conference
2016-12-05,Neurocrine Biosciences Announces INGREZZA™ (valbenazine) Long-Term Data To Be Presented At The 55th Annual Meeting Of The American College Of Neuropsychopharmacology
2016-11-29,Neurocrine Announces FDA Advisory Committee Meeting To Review INGREZZA™ (valbenazine) New Drug Application For The Treatment Of Tardive Dyskinesia
2016-11-21,Neurocrine Biosciences To Present At The 28th Annual Piper Jaffray Healthcare Conference
2016-11-10,Neurocrine Biosciences To Present At The Jefferies 2016 London Healthcare Conference
2016-10-31,Neurocrine Biosciences To Present At The Credit Suisse 25th Annual Healthcare Conference
2016-10-31,Research Reports Coverage On Generic Drugs Stocks -- Evoke Pharma, Catalyst Pharma, Neurocrine Biosciences, And Galectin Therapeutics
2016-10-26,Neurocrine Biosciences Announces Conference Call And Webcast To Report Third Quarter 2016 Results
2016-10-19,AbbVie Announces Positive Pivotal Phase 3 Data Demonstrating Investigational Medicine Elagolix Reduces Menstrual And Non-Menstrual Pelvic Pain Associated With Endometriosis At The American Society For Reproductive Medicine Scientific Congress
2016-10-11,Neurocrine Announces INGREZZA™ (valbenazine) New Drug Application For The Treatment Of Tardive Dyskinesia Has Been Accepted For Priority Review By U.S. FDA
2016-09-14,These 5 Biotech Stocks Are Ready for a Volatility Break
2016-09-07,Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
2016-09-01,Neurocrine Biosciences to Present at the Baird 2016 Healthcare Conference
2016-08-31,Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA™ for VMAT2 Inhibitor Valbenazine
2016-08-29,Neurocrine Submits New Drug Application for Valbenazine for Treatment of Tardive Dyskinesia
2016-07-28,Neurocrine Announces Initiation Of A Long-Term Phase II Clinical Study Of VMAT2 Inhibitor Valbenazine In Tourette Syndrome
2016-07-27,Short Interest In Neurocrine Biosciences Jumps 14%
2016-07-27,Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2016 Results
2016-07-22,Bearish Bets: Biotech, Energy and Other Stocks that Look Good to Short
2016-07-22,Biogen Should Either a Buyer or a Seller Be
2016-07-15,Ratings Changes Today
2016-07-13,Short Interest In Neurocrine Biosciences Decreases By 30%
2016-06-02,Neurocrine Biosciences To Present At The Jefferies 2016 Healthcare Conference
2016-05-31,Neurocrine Biosciences (NBIX) Strong On High Relative Volume Today
2016-05-27,Insider Trading Alert - NBIX, FRGI And LBAI Traded By Insiders
2016-05-23,Xenoport's Cost-Cutting Tactics Lead to Buyout With Hefty Premium
2016-05-20,Neurocrine Biosciences Announces The Retirement Of W. Thomas Mitchell From The Board Of Directors
2016-05-18,Strong On High Volume: Neurocrine Biosciences (NBIX)
2016-05-12,Short Interest Moves 11% Higher For NBIX
2016-05-06,Neurocrine Biosciences To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference
2016-05-06,Neurocrine Biosciences Announces Additional Valbenazine (NBI-98854) Data To Be Presented At The American Psychiatric Association's 2016 Annual Meeting In Atlanta
2016-04-29,Neurocrine Biosciences Announces Conference Call And Webcast To Report First Quarter 2016 Results
2016-04-27,Neurocrine Biosciences To Present At The Deutsche Bank 41st Annual Health Care Conference
2016-04-08,'Mad Money' Lightning Round: I'm Taking Starbucks Over Bojangles
2016-04-07,Jim Cramer's 'Mad Money' Recap: Uncle Sam, Back Off Business!
2016-04-07,Neurocrine Biosciences (NBIX) Stock Gets &lsquo;Outperform&rsquo; Rating at BMO Capital
2016-03-09,Neurocrine Biosciences To Present At The Barclays Global Healthcare Conference
2016-03-02,Neurocrine Biosciences To Present At The Cowen And Company 36th Annual Health Care Conference
2016-03-02,Neurocrine Biosciences Announces The Acceptance Of Three Scientific Abstracts For Valbenazine (NBI-98854) At The 68th Annual Meeting Of The American Academy Of Neurology In Vancouver April 2016
2016-02-08,Neurocrine Biosciences Announces Conference Call And Webcast To Report Fourth Quarter And Year-End 2015 Results
2016-02-03,Neurocrine Biosciences To Present At The Leerink Partners 5th Annual Global Healthcare Conference
2016-02-02,Neurocrine Announces Initiation Of Phase II Clinical Study Of VMAT2 Inhibitor Valbenazine In Children And Adolescents With Tourette Syndrome
2016-01-28,AbbVie Initiates Enrollment In Phase 3 Clinical Program For Elagolix In Patients With Uterine Fibroids
2016-01-04,Neurocrine Biosciences To Present At The 34th Annual J.P. Morgan Healthcare Conference
2015-12-16,Neurocrine Announces Successful Completion Of Phase Ib T-Force Study Of VMAT2 Inhibitor NBI-98854 In Adolescents And Children With Tourette Syndrome
2015-12-08,J.P. Morgan's 53 Top Stock Picks for 2016
2015-11-25,Neurocrine Biosciences To Present At The 27th Annual Piper Jaffray Healthcare Conference
2015-11-21,JPMorgan Likes These 5 Biotech Stocks
2015-11-11,Neurocrine Biosciences To Present At The Jefferies Autumn 2015 Global Healthcare Conference
2015-11-04,Neurocrine Biosciences To Present At Credit Suisse's 24th Annual Healthcare Conference
2015-11-04,Neurocrine Biosciences Announces Expansion Of Its Clinical Pipeline
2015-10-22,Neurocrine Biosciences Announces Conference Call And Webcast To Report Third Quarter 2015 Results
2015-10-20,Insider Trading Alert - NBIX, HELE And FB Traded By Insiders
2015-10-20,Neurocrine Announces Initiation Of Phase II Clinical Study Of VMAT2 Inhibitor NBI-98854 In Adults With Tourette Syndrome
2015-10-09,Perilous Reversal Stock: Neurocrine Biosciences (NBIX)
2015-10-08,Neurocrine Biosciences (NBIX) Stock Spikes on Positive Phase 3 Results
2015-10-08,Pre-Market Activity Shows Heavy Volume And Movement For Neurocrine Biosciences (NBIX)
2015-10-01,Neurocrine Biosciences (NBIX) Showing Signs Of Perilous Reversal Today
2015-09-30,Neurocrine Biosciences Announces The Appointment Of George J. Morrow To Its Board Of Directors
2015-09-30,Strong On High Volume: Neurocrine Biosciences (NBIX)
2015-09-22,Insider Trading Alert - NBIX, TPLM And HURC Traded By Insiders
2015-09-21,Neurocrine Biosciences (NBIX) Showing Signs Of Being Water-Logged And Getting Wetter
2015-09-16,AbbVie Announces Plans To Proceed To Phase 3 Evaluation Of Elagolix In Patients With Uterine Fibroids
2015-09-10,Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
2015-09-10,Trade-Ideas: Neurocrine Biosciences (NBIX) Is Today's Strong On High Relative Volume Stock
2015-09-03,Neurocrine Biosciences Announces The Appointment Of Dr. Alfred W. Sandrock To Its Board Of Directors
2015-09-02,Neurocrine Biosciences To Present At The Baird 2015 Healthcare Conference
2015-08-13,Neurocrine Announces Completion Of Enrollment Into Kinect 3 Tardive Dyskinesia Study
2015-07-27,Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up
2015-07-22,Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2015 Results
2015-07-20,Water-Logged And Getting Wetter Stock Of The Day: Neurocrine Biosciences (NBIX)
2015-06-08,Neurocrine Biosciences Provides Update On NBI-77860 Program For Congenital Adrenal Hyperplasia
2015-06-02,Neurocrine Biosciences, Inc. Announces Appointment Of Eric Benevich As Chief Commercial Officer
2015-05-27,Neurocrine Biosciences To Present At The Jefferies 2015 Healthcare Conference
2015-05-18,Ratings Changes Today
2015-05-14,Neurocrine Biosciences (NBIX) Highlighted As Today's Perilous Reversal Stock
2015-05-12,Neurocrine Biosciences To Host Analyst And Investor Day In New York City On May 21, 2015
2015-05-08,Neurocrine Biosciences To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference
2015-05-04,Neurocrine Biosciences, Inc. Announces Appointment Of Dr. Bill Aurora As Vice President, Medical Affairs
2015-04-30,Neurocrine Biosciences To Present At The Deutsche Bank 40th Annual Health Care Conference
2015-04-23,Neurocrine Biosciences Announces Conference Call And Webcast To Report First Quarter 2015 Results
2015-04-23,First Week Of NBIX June 19th Options Trading
2015-03-31,Neurocrine Biosciences And Mitsubishi Tanabe Pharma Announce Agreement To Develop And Commercialize VMAT2 Inhibitor NBI-98854 For Movement Disorders In Japan And Other Select Asian Markets
2015-03-31,'Mad Money' Lightning Round: Alcoa Is Doing Everything Right
2015-03-30,Jim Cramer's 'Mad Money' Recap: Good Headlines Make All the Difference
2015-03-11,Short Interest In Neurocrine Biosciences Drops 20.6%
2015-03-03,Neurocrine Biosciences To Present At The Barclays Global Healthcare Conference Live Audio Webcast Will Be On March 10, 2015
2015-02-24,Neurocrine Biosciences To Present At Cowen And Company's 35th Annual Health Care Conference
2015-02-20,Neurocrine Biosciences, Inc. Announces Exercise In Full Of Underwriters' Option To Purchase Additional Shares
2015-02-19,Neurocrine Biosciences, Inc. Prices Public Offering Of Common Stock
2015-02-17,Neurocrine Biosciences, Inc. Announces Proposed Public Offering Of $225 Million Of Common Stock
2015-02-04,Neurocrine Biosciences To Present At The 2015 Leerink Global Healthcare Conference
2015-02-02,Neurocrine Biosciences Announces Conference Call And Webcast To Report Fourth Quarter And Year-End 2014 Results
2015-01-20,Neurocrine Biosciences Announces Oral Presentation Of NBI-77860 Clinical Trial Data In Classic Congenital Adrenal Hyperplasia At ENDO 2015
2015-01-16,Neurocrine Biosciences Announces Granting Of Orphan Drug Status For NBI-77860 In Congenital Adrenal Hyperplasia
2015-01-09,Biotech Investors' Guide and Preview to J.P. Morgan Healthcare Conference: Part 2
2015-01-08,Neurocrine Biosciences To Present At The 33rd Annual J.P. Morgan Healthcare Conference
2015-01-08,AbbVie Announces Positive Top-Line Results From Phase 3 Study Of Investigational Medicine Elagolix In Patients With Endometriosis
2014-12-24,Commit To Buy Neurocrine Biosciences At $17, Earn 30.2% Annualized Using Options
2014-12-17,2015 Biotech Drug/Stock Outlook: Here's What You Need to Know
2014-12-16,Auspex Drug Reduces Uncontrolled Movements in Huntington's Patients
2014-12-10,Neurocrine Biosciences Announces Expansion Of Its Clinical Pipeline
2014-12-04,Neurocrine Biosciences To Present At The 25th Annual Oppenheimer Healthcare Conference
2014-11-25,Neurocrine To Present At The 2014 Deutsche Bank BioFEST And The 26th Annual Piper Jaffray Healthcare Conference
2014-11-12,Neurocrine Biosciences to Present at the Jefferies 2014 Global Healthcare Conference
2014-11-04,Neurocrine Biosciences, Inc. Announces Appointment Of Darin Lippoldt As Chief Legal Officer
2014-11-03,Neurocrine Biosciences To Present At The Nomura Biotechnology Conference
2014-10-30,Neurocrine Biosciences Receives Breakthrough Therapy Designation For NBI-98854 In Tardive Dyskinesia
2014-10-27,Neurocrine Biosciences Announces Conference Call And Webcast To Report Third Quarter 2014 Financial Results
2014-10-20,Neurocrine Announces Initiation Of Phase III Study For VMAT2 Inhibitor NBI-98854
2014-10-02,Neurocrine Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study
2014-10-01,Neurocrine Biosciences, Inc. Announces Appointment Of Malcolm Lloyd-Smith As Chief Regulatory Officer
2014-09-25,2 Big-Volume Biotech Stocks to Trade for Breakouts
2014-09-03,Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
2014-08-26,The Best Hedge Fund You've Never Heard Of and Its Top 5 Stock Picks
2014-08-06,NBIX Crosses Above Key Moving Average Level
2014-07-29,Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results
2014-07-08,Commit To Purchase Neurocrine Biosciences At $12, Earn 27.6% Annualized Using Options
2014-06-11,Neurocrine Biosciences Presenting NBI-98854 Scientific Abstracts And Posters At The International Parkinson And Movement Disorder Society's 18th Annual Congress
2014-05-29,Neurocrine Biosciences To Present At The Jefferies 2014 Global Healthcare Conference
2014-05-08,Neurocrine Biosciences To Present At The Bank Of America Merrill Lynch 2014 Health Care Conference
2014-05-08,Bullish Two Hundred Day Moving Average Cross - NBIX
2014-05-01,Neurocrine Biosciences To Present At Deutsche Bank's 39th Annual Health Care Conference
2014-04-25,Neurocrine Biosciences Announces Conference Call And Webcast To Report First Quarter 2014 Financial Results
2014-04-16,Neurocrine Biosciences Inc. Stock Downgraded (NBIX)
2014-04-15,Ratings Changes Today
2014-04-11,Neurocrine Biosciences is Now Oversold (NBIX)
2014-04-07,Commit To Purchase Neurocrine Biosciences At $11, Earn 23.9% Annualized Using Options
2014-03-04,Neurocrine Biosciences To Present At The 26th Annual Roth Conference
2014-02-27,Neurocrine Biosciences To Present At The Cowen And Company 34th Annual Health Care Conference
2014-02-27,Heavy Trading On Neurocrine Biosciences (NBIX) Before Market Open
2014-02-26,Neurocrine Biosciences, Inc. Prices Public Offering Of Common Stock
2014-02-25,Neurocrine Biosciences, Inc. Announces Proposed Public Offering Of Common Stock
2014-02-25,Neurocrine Biosciences Announces NBI-98854 Scientific Presentations At The International Parkinson And Movement Disorder Society's 18th Annual Congress
2014-02-24,Multiple Sectors Punch Market to New Highs
2014-02-07,Neurocrine Biosciences To Present At The Leerink Global Healthcare Conference
2014-02-04,Neurocrine Biosciences Announces Conference Call And Webcast To Report Fourth Quarter And Year-End 2013 Financial Results
2014-01-21,It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013
2014-01-14,Insider Trading Alert - NDSN, FNSR, NUVA, DECK And NBIX Traded By Insiders
2014-01-14,Insider Trading Alert - NDSN, FNSR, NUVA, DECK And NBIX Traded By Insiders
2014-01-09,Neurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854
2014-01-09,Biotech Trading 2014 Starts Hot, But Surprise, Last Year Was Even Better
2014-01-09,Insider Trading Alert - SWI, ADBE, GLUU, NBIX And AXE Traded By Insiders
2014-01-09,Insider Trading Alert - SWI, ADBE, GLUU, NBIX And AXE Traded By Insiders
2014-01-08,Trade-Ideas: Neurocrine Biosciences (NBIX) Is Today's "Perilous Reversal" Stock
2014-01-07,Why Neurocrine Biosciences (NBIX) Is Spiking Today
2014-01-07,Heavy Trading On Neurocrine Biosciences (NBIX) Before Market Open
2014-01-02,First Week Of August 16th Options Trading For Neurocrine Biosciences (NBIX)
2013-12-04,Neurocrine Biosciences To Present At Oppenheimer's 24th Annual Healthcare Conference
2013-11-26,Neurocrine Biosciences To Present At Deutsche Bank 2013 Biofest And The 25th Annual Piper Jaffray Healthcare Conference
2013-10-31,December 2014 Options Now Available For Neurocrine Biosciences (NBIX)
2013-10-28,Interesting NBIX Put And Call Options For December 21st
2013-10-22,Neurocrine Biosciences Announces Conference Call And Webcast To Present Third Quarter 2013 Financial Results
2013-10-07,January 2015 Options Now Available For Neurocrine Biosciences (NBIX)
2013-10-04,5 Stocks Poised for Breakouts
2013-09-26,First Week Of NBIX May 2014 Options Trading
2013-09-13,Neurocrine Biosciences Becomes Oversold (NBIX)
2013-09-10,4 Stocks Dragging In The Drugs Industry
2013-09-03,Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
2013-08-29,Neurocrine Biosciences Announces The Start Of Second Phase III Study Of Elagolix In Endometriosis
2013-08-22,5 Stocks Spiking on Unusual Volume
2013-07-18,Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2013 Financial Results
2013-07-03,Interesting NBIX Put And Call For September 21st
2013-07-01,Neurocrine Announces Completion Of Enrollment Into Kinect Study For Treatment Of Tardive Dyskinesia
2013-05-30,'Mad Money' Lightning Round: Hold on to Sprint
2013-05-29,Cramer's 'Mad Money' Recap: Stop Being Complacent
2013-05-29,Neurocrine Biosciences To Present At The Jefferies 2013 Global Healthcare Conference
2013-05-24,Commit To Buy Neurocrine Biosciences At $9, Earn 28.8% Annualized
2017-03-21,NeuroDerm To Host Fourth Quarter And 2016 Fiscal Year Financial Results Conference Call On March 30, 2017
2017-03-02,First Week of NDRM August 18th Options Trading
2017-03-01,NeuroDerm Achieves Primary Endpoint In ND0612H Phase II Trial For Advanced Parkinson's Disease; Seeks Broader EU Label Based On INDiGO Trial Following EMA Meeting
2017-02-27,NeuroDerm CEO To Present At Upcoming Investor Conferences
2017-01-26,NeuroDerm Announces Extraordinary General Meeting Of Shareholders
2017-01-03,NeuroDerm CEO To Present At The 35th Annual J.P. Morgan Healthcare Conference On January 12, 2017
2016-12-23,Neuroderm Has a Promising Pipeline
2016-12-22,NeuroDerm Announces Closing Of Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares
2016-12-22,NeuroDerm Announces Completion Of Patient Enrollment And Treatment In A Phase II Trial Of ND0612H For Advanced Parkinson's Disease
2016-12-12,NeuroDerm Announces Closing Of A Follow-On Offering Of Ordinary Shares
2016-12-07,NeuroDerm Announces Pricing Of A Follow-On Offering Of Ordinary Shares
2016-12-06,NeuroDerm Announces Launch Of A Follow-On Offering Of Ordinary Shares
2016-12-05,NeuroDerm To Replace Two Phase 3 Clinical Trials With Small Pharmacokinetic Trials Following FDA Meeting On ND0612 Regulatory Development
2016-12-02,NeuroDerm Announces Top-Line Results Of Pilot PK Trial Comparing ND0701 With Commercial Apomorphine
2016-11-10,NeuroDerm Announces Third Quarter 2016 Financial Results
2016-11-03,NeuroDerm CEO To Present At Upcoming Investor Conferences
2016-11-01,NeuroDerm To Host Third Quarter 2016 Financial Results Conference Call On November 10, 2016
2016-09-29,NeuroDerm Provides Updates On ND0612 Long-Term Safety Trial And Submission Of Marketing Applications
2016-09-22,NeuroDerm's ND0612 Mini-Pump Delivery System Successfully Used By Parkinson's Disease Patients In Home Setting
2016-09-19,NeuroDerm To Present ND0612 Data At 4th World Parkinson Congress Demonstrating Ease Of Use Of Mini-Pump Delivery System
2016-08-25,NeuroDerm Announces Second Quarter 2016 Financial Results And Provides Corporate Update
2016-08-25,NeuroDerm Initiates Patient Enrollment In A Phase III Trial Of ND0612L For The Treatment Of Parkinson's Disease
2016-08-11,NeuroDerm To Host Second Quarter 2016 Financial Results Conference Call On August 25, 2016
2016-07-27,NeuroDerm Announces Issuance Of A New U.S. Patent For Aqueous Apomorphine Covering Concentrated Subcutaneously Delivered Pharmaceutical Compositions
2016-07-26,NeuroDerm Announces Start Of Bioequivalence Trial In Healthy Volunteers Of ND0701, A New Continuous Subcutaneously Delivered Apomorphine Product Candidate For The Treatment Of Advanced Parkinson's Disease
2016-07-06,NeuroDerm Announces Additions To Management Team
2016-07-05,NeuroDerm To Present At The Cantor Fitzgerald Healthcare Conference On July 13
2016-06-30,NeuroDerm Announces Start Of U.S. Patient Enrollment In Trial 006, A Phase II Trial Of ND0612H For Advanced Parkinson's Disease
2016-06-28,NeuroDerm Announces ND0612H Achieves Comparable Pharmacokinetics To DUODOPA® In Head-To-Head Pilot PK Comparison Trial
2016-06-24,NeuroDerm Added To Russell Global Index
2016-06-23,NeuroDerm Presents Three Posters At The 20th International Congress Of Parkinson's Disease And Movement Disorders
2016-06-16,NeuroDerm To Present Design Of The First Clinical Efficacy Study Of ND0612H And Other Clinical Data At The 20th International Congress Of Parkinson's Disease And Movement Disorders
2016-05-31,NeuroDerm CEO To Present At Jefferies 2016 Healthcare Conference On June 7
2016-05-26,NeuroDerm Announces First Quarter 2016 Financial Results
2016-05-17,NeuroDerm To Host First Quarter 2016 Financial Results Conference Call On May 26, 2016
2016-05-09,NeuroDerm Announces Patient Enrollment In Long-Term Safety Trial Of ND0612 For Parkinson's Disease
2016-05-05,NeuroDerm Announces 2016 Annual General Meeting Of Shareholders
2016-04-22,NeuroDerm Announces Removal Of FDA Import Alert Of Infusion Pumps Used In ND0612 Clinical Trials
2016-04-05,NeuroDerm Parkinson's Disease Clinical Data Selected For Two Oral Presentations At The American Academy Of Neurology 68th Annual Meeting
2016-03-31,NeuroDerm Announces Fourth Quarter And Full Year 2015 Financial Results And Provides A Corporate Update
2016-03-22,NeuroDerm To Host Fourth Quarter And 2015 Fiscal Year Financial Results Conference Call On March 31, 2016
2016-03-02,NeuroDerm To Present At Upcoming Investor Conferences
2016-02-08,NeuroDerm Enters Oversold Territory (NDRM)
2016-01-11,NeuroDerm is Now Oversold (NDRM)
2016-01-04,NeuroDerm CEO To Present At The 34th Annual J.P. Morgan  Healthcare Conference On January 14, 2016
2015-12-30,NeuroDerm Announces Start Of Patient Enrollment In Phase II Trial Of ND0612H For Advanced Parkinson's Disease
2015-12-18,NeuroDerm Added To The Nasdaq Biotechnology Index
2015-11-12,NeuroDerm CEO To Present At Upcoming Investor Conferences
2015-11-11,NeuroDerm Announces Third Quarter 2015 Financial Results
2015-11-11,NeuroDerm Announces Streamlined U.S. Development Plan Following FDA Feedback On ND0612H And ND0612L For The Treatment Of Parkinson's Disease
2015-11-04,NeuroDerm To Host Third Quarter 2015 Financial Results Conference Call On November 11, 2015
2015-09-24,NeuroDerm Announces 2015 Annual General Meeting Of Shareholders
2015-08-06,NeuroDerm Announces Second Quarter 2015 Financial Results And Provides Corporate Update
2015-07-30,NeuroDerm To Host Second Quarter 2015 Financial Results Conference Call On August 6, 2015
2015-07-21,NeuroDerm Ltd. Announces Closing Of Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-07-15,NeuroDerm Ltd. Announces Pricing Of Public Offering
2015-07-02,NeuroDerm Ltd. Files Registration Statement For Proposed Follow-On Offering
2015-06-18,NeuroDerm Poster Selected For Blue Ribbon Highlights Session During 19th International Congress Of Parkinson's Disease And Movement Disorders Annual Meeting
2015-06-11,NeuroDerm Announces Start Of A Pharmacokinetic, Head-To-Head Comparison Study Of ND0612H And Duodopa(R)
2015-06-09,NeuroDerm's Latest Clinical Data Accepted As Late Breaking News To The International Parkinson And Movement Disorder Society's 19th International Congress On June 14-18, 2015 In San Diego
2015-06-02,NeuroDerm To Ring The Nasdaq Stock Market Opening Bell On June 3, 2015
2015-05-27,NeuroDerm Announces First Quarter 2015 Financial Results And Provides Corporate Update
2015-05-26,NeuroDerm CEO To Present At Jefferies 2015 Healthcare Conference On June 1, 2015
2015-05-20,NeuroDerm To Host First Quarter 2015 Financial Results Conference Call On May 27, 2015
2015-05-08,NeuroDerm Announces Lifting Of FDA Clinical Hold On ND0612, A Subcutaneously Delivered Levodopa/Carbidopa For The Treatment Of Parkinson's Disease
2015-04-29,NeuroDerm Files Annual Report On Form 20-F For The Year Ended December 31, 2014
2015-04-02,NeuroDerm Announces Fourth Quarter And 2014 Fiscal Year Financial Results And Provides A Corporate Update
2015-04-01,NeuroDerm To Announce Updated Topline Results Of Phase II Study Of Continuous, Subcutaneously-Delivered Levodopa/Carbidopa For The Treatment Of Parkinson's Disease At The 67th Annual Meeting Of The American Academy Of Neurology
2015-02-24,NeuroDerm CEO To Present At Upcoming Investor Conferences
2015-01-19,NeuroDerm Announces Extraordinary General Meeting Of Shareholders For Ratification Of Election Of External Directors And Adoption Of Compensation Policy
2014-12-31,Market News: Civeo Corp, Eagle Rock Energy Partners, Neuderm Ltd
2014-12-31,NeuroDerm (NDRM) Stock Plunges Today Following Tuesday's Gains
2014-12-30,Stocks Fall in Light Trading as Oil and Greece Weigh on Markets
2014-12-30,Market News: Neuroderm Ltd, Civeo Corp, Expedia Inc
2014-12-30,NeuroDerm (NDRM) Stock Skyrockets to One-Year High After Encouraging Parkinson's Treatment Results
2014-12-30,NeuroDerm Announces Topline Results Of Phase IIa Pharmacokinetic Study Of ND0612H And ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa For The Treatment Of Parkinson's Disease
2014-12-18,NeuroDerm Announces Third Quarter 2014 Financial Results And Provides A Corporate Update
2014-12-05,NeuroDerm CEO To Present At Oppenheimer Healthcare Conference On December 10, 2014
,
,
,
2017-03-21,Traders Are Aggressively Fading the Open
2017-03-21,Rev's Forum: Don't Just Sit There, Do Something!
2017-03-20,How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More
2017-03-20,Biotechs Remain the Best Place For Stock Picking
2017-03-20,Biotech Premarket Movers: CytomX, Aevi, Esperion
2017-03-20,Nektar Addiction-Resistant Opioid Reduces Chronic Pain in Late-Stage Study
2017-03-20,NKTR-181 Meets Primary And Secondary Endpoints In Phase 3 SUMMIT-07 Study In Chronic Pain
2017-03-06,Bullish and Bearish Reversals in the Market
2017-03-02,Nektar To Webcast Presentation At Cowen And Company's 37th Annual Health Care Conference In Boston
2017-03-01,Nektar Therapeutics Announces Upcoming Presentations At The American Association For Cancer Research Annual Meeting
2017-02-22,Nektar To Announce Financial Results For The Fourth Quarter And Year-Ended 2016 On Wednesday, March 1, 2017, After Close Of U.S.-Based Financial Markets
2017-02-18,Clinical Data From Phase 1 Dose-Escalation Study Of Single-Agent NKTR-214 In Patients With Renal Cell Carcinoma Presented At The ASCO 2017 Genitourinary Cancers Symposium
2017-01-24,Interesting NKTR Put And Call Options For March 17th
2017-01-07,These 9 Allergan Drugs May Now Cost as Much as 9.5% More in 2017
2017-01-05,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 35th Annual J.P. Morgan Healthcare Conference In San Francisco, CA
2016-12-27,Shire Announces FDA Approval Of Adynovate® [Antihemophilic Factor (Recombinant), Pegylated] For Use In Children And Surgical Settings
2016-12-21,First Week of NKTR August 2017 Options Trading
2016-11-14,Nektar Therapeutics To Present At Jefferies 2016 Global Healthcare Conference In London
2016-11-09,Nektar Therapeutics Presents New Clinical Data From Ongoing Phase 1 Dose-Escalation Study Of NKTR-214 At The Society For Immunotherapy Of Cancer (SITC) 2016 Annual Meeting
2016-10-28,Nektar To Hold Investor & Analyst Event At 2016 Society For Immunotherapy Of Cancer Annual Meeting
2016-10-28,Nektar Therapeutics Announces Upcoming Presentations At The 2016 Society For Immunotherapy Of Cancer Annual Meeting
2016-10-27,Nektar To Announce Financial Results For The Third Quarter 2016 On Thursday, November 3, 2016, After Close Of U.S.-Based Financial Markets
2016-10-26,Short Interest Jumps 12.5% For NKTR
2016-10-24,Schlumberger, Amazon, Apple: Doug Kass' Views
2016-10-19,Nektar Therapeutics (NKTR) Stock Falls on Public Offering Pricing
2016-10-19,Nektar Therapeutics Prices Public Offering Of Shares Of Common Stock
2016-10-17,Nektar Therapeutics Announces Public Offering Of Shares Of Common Stock
2016-09-27,Nektar Therapeutics To Host Investor & Analyst Conference Call To Discuss New Clinical Collaboration With Bristol-Myers Squibb
2016-09-27,Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy
2016-09-27,Bristol-Myers Squibb And Nektar Therapeutics Announce Oncology Clinical Collaboration To Evaluate The Combination Of Opdivo (nivolumab) And NKTR-214
2016-09-06,Here's Why Investors Should Steer Clear of Opioids
2016-08-23,4 Biotech Stock Charts You Must See
2016-08-08,Rev's Forum: Let's See If Bulls Can Sustain Friday's Momentum
2016-08-04,Don't Roll the Dice on Central Bank News
2016-07-29,Using My Metal Detector Amid Gold and Silver Strength
2016-07-27,Nektar To Announce Financial Results For The Second Quarter 2016 On Wednesday, August 3, 2016, After Close Of U.S.-Based Financial Markets
2016-07-21,Nektar Therapeutics (NKTR) Flagged As Strong On High Volume
2016-06-06,Preclinical Data Presented At ASCO 2016 Annual Meeting Demonstrate That Single-Agent NKTR-214 Produces A Large Increase In Tumor-Infiltrating Lymphocytes To Provide Durable Anti-Tumor Activity
2016-06-02,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The Jefferies 2016 Global Healthcare Conference In New York City
2016-06-02,Nektar Therapeutics Announces Executive Management Promotions
2016-06-01,Nektar Therapeutics And Daiichi Sankyo Europe GmbH Sign European Licensing Agreement For ONZEALD™ (etirinotecan Pegol), An Investigational Drug Candidate Being Developed To Treat Patients With Advanced Breast Cancer And Brain Metastases
2016-05-04,Nektar Therapeutics (NKTR) Weak On High Volume Today
2016-04-28,Nektar To Announce Financial Results For The First Quarter 2016 On Tuesday, May 3, 2016, After Close Of U.S.-Based Financial Markets
2016-04-18,Preclinical Data Presented At AACR Demonstrate That Combining NKTR-214 With Checkpoint Blockade Is Superior To Dual Checkpoint Inhibition In Increasing Clonality Of The T Cell Receptor (TCR) Repertoire And T Cell Tumor Infiltration
2016-04-11,Facebook, Ford and General Motors: Doug Kass' Views
2016-03-08,Novice Trade: Nektar Therapeutics
2016-03-03,Nektar Therapeutics To Present At Cowen And Company's 36th Annual Health Care Conference In Boston, MA
2016-03-02,Nektar Therapeutics (NKTR) Stock Slumps Despite Q4 Beat
2016-02-26,Nektar To Announce Financial Results For The Fourth Quarter And Year-Ended 2015 On Tuesday, March 1, 2016, After Close Of U.S.-Based Financial Markets
2016-02-25,Baxalta Announces Submission Of Supplemental BLAs To Expand Use Of ADYNOVATE To Pediatric Patients And Surgical Settings
2016-02-19,What Carl Icahn Is Doing; Biotech Breakout: Best of Kass
2016-02-15,JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views
2016-02-15,General Motors, MetLife and Tesla: Doug Kass' Views
2016-02-01,Nektar Publishes Pre-clinical Results For NKTR-214, An Investigational CD122-Biased Immune-Stimulatory Cytokine For The Treatment Of Cancer In Clinical Cancer Research
2016-01-06,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 34th Annual J.P. Morgan Healthcare Conference In San Francisco, CA
2015-12-21,Baxalta's ADYNOVATE Meets Endpoints In Phase 3 Study Of Hemophilia A Patients Under 12 Years Of Age
2015-12-21,Baxalta's ADYNOVATE Meets Endpoints In Phase 3 Study Of Hemophilia A Patients Under 12 Years Of Age
2015-12-08,Nektar Therapeutics To Present At Oppenheimer 26th Annual Healthcare Conference In New York
2015-12-08,Nektar Announces First Patient Dosed In Phase 1/2 Clinical Study Of NKTR-214, A CD122-Biased Immuno-Stimulatory Cytokine
2015-12-07,Baxalta Presents Additional Data On Newly-Approved ADYNOVATE And Plans For New Indications During 57th American Society Of Hematology (ASH) Annual Meeting
2015-11-30,Baxalta Announces U.S. Availability Of ADYNOVATE, A New Treatment For Adult Patients With Hemophilia A With A Simple, Twice-Weekly Dosing Schedule
2015-11-17,Get Ready for Nektar Therapeutics (NKTR) Stock to Break Out
2015-11-17,Nektar Therapeutics To Present At Jefferies Autumn 2015 Global Healthcare Conference In London
2015-11-16,Baxalta To Advance Care For Hemophilia A Patients With FDA Approval Of ADYNOVATE, A Simple, Twice-weekly Treatment To Reduce Bleeds
2015-10-29,Nektar To Announce Financial Results For The Third Quarter 2015 On Thursday, November 5, 2015, After Close Of U.S.-Based Financial Markets
2015-10-20,First Week of December 18th Options Trading For Nektar Therapeutics (NKTR)
2015-10-08,Nektar Reports On Advancements With Pain And Oncology Clinical Pipeline At Investor And Analyst R&D Day
2015-10-07,Nektar Therapeutics (NKTR) Marked As A Dead Cat Bounce Stock
2015-10-07,Nektar Submits Investigational New Drug Application (IND) For NKTR-214 To Treat Solid Tumor Malignancies
2015-10-06,Nektar Closes Direct Private Placement With TPG Special Situations Partners Of $250 Million Of Senior Secured Notes Due In 2020
2015-10-01,Nektar To Host Research & Development Day For Analysts And Investors On October 8th
2015-09-21,Nektar Presents Data Demonstrating That NKTR-214, A CD122-Biased Immunostimulatory Cytokine, Induces Durable And Specific Anti-Tumor Immunity As A Single-Agent And When Combined With Checkpoint Inhibitors In Preclinical Models
2015-09-15,NKTR Makes Bullish Cross Above Critical Moving Average
2015-09-01,Nektar Announces Receipt Of $40 Million Milestone Payment Resulting From First Commercial Sale Of MOVENTIG® (naloxegol) Tablets In Major European Market
2015-08-25,Ratings Changes Today
2015-07-29,Nektar To Announce Financial Results For The Second Quarter 2015 On Wednesday, August 5, 2015, After Close Of U.S.-Based Financial Markets
2015-07-16,Baxalta's BAX 855 Pivotal Data Published In Blood Shows Potential To Provide Strong Bleed Prevention With Twice Weekly Dosing For Patients With Hemophilia A
2015-06-26,Nektar Therapeutics (NKTR) Stock: Weak On High Volume Today
2015-06-23,First Week Of February 2016 Options Trading For Nektar Therapeutics (NKTR)
2015-06-15,Today's Weak On High Volume Stock: Nektar Therapeutics (NKTR)
2015-06-02,Nektar And MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration For NKTR-214, A CD122-Biased Immuno-Stimulatory Cytokine
2015-05-28,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The Jefferies 2015 Global Healthcare Conference In New York City
2015-05-01,Ratings Changes Today
2015-05-01,Nektar Therapeutics (NKTR) Is Today's Dead Cat Bounce Stock
2015-04-23,Nektar To Announce Financial Results For The First Quarter 2015 On Thursday, April 30, 2015, After Close Of U.S.-Based Financial Markets
2015-04-21,First Week Of NKTR June 19th Options Trading
2015-04-16,Baxter Submits Application To Japan's MHLW For Approval Of BAX 855, Extended Half-Life Recombinant FVIII Based On ADVATE For Hemophilia A
2015-04-13,Nektar Therapeutics To Present At The 14th Annual Needham Healthcare Conference
2015-04-02,Nektar Announces Receipt Of $100 Million Milestone Payment From AstraZeneca
2015-03-25,Interesting NKTR Put And Call Options For November 20th
2015-03-19,Trade-Ideas: Nektar Therapeutics (NKTR) Is Today's Weak On High Relative Volume Stock
2015-03-18,Bernstein Liebhard LLP Investigates Claims On Behalf Of Those Who Invested In Nektar Therapeutics
2015-03-18,Nektar Therapeutics (NKTR) Stock Tanks Today on Failed Phase III Breast Cancer Treatment Results
2015-03-18,Nektar Therapeutics (NKTR): Heavy Pre-Market Activity
2015-03-17,Etirinotecan Pegol (NKTR-102) Prolonged Median Overall Survival By 2.1 Months Versus Active Control In Patients With Advanced Breast Cancer In Phase 3 Study; Trial Did Not Achieve Statistical Significance (p=0.08)
2015-03-13,Fly Watch: Nektar Therapeutics Breast Cancer Data Expected Soon
2015-02-25,Nektar Announces Start Of Phase 3 SUMMIT-07 Study Of NKTR-181 In Patients With Chronic Low Back Pain
2015-02-17,Nektar To Announce Financial Results For The Fourth Quarter And Year-Ended 2014 On Tuesday, February 24, 2015, After Close Of U.S.-Based Financial Markets
2015-02-11,Baxter Presents Additional Data From Pivotal Study Of BAX 855, Extended Half-life Investigational Recombinant FVIII Based On ADVATE For Hemophilia A
2015-01-22,First Week Of March 20th Options Trading For Nektar Therapeutics (NKTR)
2015-01-06,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 33rd Annual J.P. Morgan Healthcare Conference In San Francisco, CA
2014-12-24,Interesting NKTR Put And Call Options For August 2015
2014-12-11,Nektar Presents Data On Target-Specific Biomarkers From Circulating Tumor Cell Sub-Study Of Phase 3 BEACON Study Of Etirinotecan Pegol (NKTR-102) In Patients With Advanced Breast Cancer
2014-12-01,Baxter Submits Application For US FDA Approval Of BAX 855, Extended Half-Life Recombinant FVIII Based On ADVATE For Hemophilia A
2014-11-24,FDA Grants QIDP Designation To Bayer's Amikacin Inhale And Ciprofloxacin Dry Powder For Inhalation
2014-11-20,Nektar Presents Preclinical Study Findings For Etirinotecan Pegol (NKTR-102) In Combination With A PARP Inhibitor In BRCA1-deficient Cancer Model
2014-10-30,Nektar To Announce Financial Results For The Third Quarter 2014 On Thursday, November 6, 2014, After Close Of U.S.-Based Financial Markets
2014-10-17,Nektar Therapeutics (NKTR) Weak On High Volume Today
2014-09-26,Nektar Therapeutics Announces MOVENTIG® (naloxegol) Receives Positive CHMP Opinion In EU For Treatment Of Adults With Opioid-Induced Constipation
2014-09-19,Nektar Presents Positive Preclinical Data On Oral, Peripherally-Acting Kappa Agonist Molecules At 2014 American Academy Of Pain Management Meeting
2014-09-16,How Will AstraZeneca (AZN) Stock React to FDA's Movantik Approval?
2014-09-16,FDA Approves MOVANTIK™ (naloxegol) Tablets For The Treatment Of Opioid-Induced Constipation In Adult Patients With Chronic Non-Cancer Pain
2014-08-21,Baxter Announces Positive Top-Line Results From Its Phase 3 Study Of BAX 855, Extended Half-Life Recombinant FVIII For Hemophilia A Patients
2014-07-22,Nektar To Announce Financial Results For The Second Quarter 2014 On Thursday, July 31, 2014, After Close Of U.S.-Based Financial Markets
2014-07-08,Notable Two Hundred Day Moving Average Cross - NKTR
2014-06-24,First Week of February 2015 Options Trading For Nektar Therapeutics (NKTR)
2014-06-13,3 Stocks Driving The Drugs Industry Higher
2014-06-12,US FDA ADVISORY COMMITTEE RECOMMENDS NO CARDIOVASCULAR OUTCOMES TRIAL FOR PERIPHERALLY-ACTING MU-OPIOID RECEPTOR ANTAGONIST (PAMORA) CLASS INCLUDING MOVANTIK
2014-06-11,Nektar Therapeutics Stock Trading Halted Today; FDA Advisory Committee To Discuss Peripherally-Acting Opioid Receptor Antagonists
2014-05-31,Positive Data From Phase 2 Trial Of NKTR-102 In Patients With AvastinA®-Refractory High-Grade Glioma Presented At 50th ASCO Meeting
2014-05-20,First Week of July 19th Options Trading For Nektar Therapeutics (NKTR)
2014-05-16,Nektar Therapeutics To Present At The UBS 2014 Global Healthcare Conference In New York City
2014-05-01,Nektar To Announce Financial Results For The First Quarter 2014 On Wednesday, May 7, 2014, After Close Of U.S.-Based Financial Markets
2014-04-22,Why Nektar Therapeutics (NKTR) Stock Is Up Today
2014-04-10,MannKind Rival, Also Developing Inhaled Insulin Device, Files $75M IPO
2014-02-25,First Week of April 19th Options Trading For Nektar Therapeutics (NKTR)
2014-02-24,Use Options For A Chance To Buy NKTR At A 42% Discount
2014-01-23,Nektar Therapeutics (NKTR) Is Today's Pre-Market Mover With Heavy Volume Stock
2014-01-22,Nektar Therapeutics Prices Public Offering Of Common Stock
2014-01-22,Interesting NKTR Put And Call Options For March 22nd
2014-01-21,Nektar Therapeutics Announces Public Offering Of 8,500,000 Shares Of Common Stock
2014-01-08,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 32nd Annual J.P. Morgan Healthcare Conference In San Francisco, CA
2013-12-24,First Week of NKTR August 2014 Options Trading
2013-11-13,Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A
2013-10-11,Short Interest In Nektar Therapeutics Falls 12.5%
2013-10-09,Oversold Conditions For Nektar Therapeutics (NKTR)
2013-10-02,Nektar To Host Investor And Analyst R&D Day In New York City
2013-09-30,Trade-Ideas: Nektar Therapeutics (NKTR) Is Today's "Dead Cat Bounce" Stock
2013-09-30,Nektar Reports That Partner AstraZeneca Announced European Medicines Agency Acceptance Of Marketing Authorisation Application For Naloxegol
2013-09-27,Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
2013-09-26,Nektar Announces Preliminary Topline Results From Phase 2 Efficacy Study For NKTR-181 In Chronic Pain Patients With Osteoarthritis Of The Knee
2013-08-21,First Week Of October 19th Options Trading For Nektar Therapeutics (NKTR)
2013-08-12,2 Health Care Stocks to Trade for Breakouts
2013-08-02,Bulls Pile Into Nektar Therapeutics
2013-08-01,Nektar To Announce Financial Results For The Second Quarter Of 2013 On Thursday, August 8, 2013, After Close Of U.S.-Based Financial Markets
2013-07-23,First Week Of NKTR September 21st Options Trading
2013-06-20,3 Health Care Stocks Spiking on Big Volume
2013-06-13,Short Interest Drops 20.3% For NKTR
2013-05-30,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The Jefferies 2013 Global Healthcare Conference In New York City
2013-05-22,NKTR Crosses Below Key Moving Average Level
2013-05-16,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 2013 UBS Global Healthcare Conference In New York City
2013-05-10,Nektar Therapeutics Enters Oversold Territory (NKTR)
2013-04-29,Chaotic Phases Require Patience 
2013-04-16,Bayer Initiates Phase III Trial Of Investigational Inhaled Amikacin Solution (BAY41-6551T) In Mechanically Ventilated Patients With Gram-negative Pneumonia
2013-03-01,Nektar Therapeutics To Present At The 33rd Annual Cowen And Company Healthcare Conference In Boston
2013-02-26,AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation
2013-02-22,4 Stocks Under $10 Spiking Higher
2013-02-01,5 Stocks Poised for Breakouts
2013-01-09,J.P. Morgan Healthcare Confab Live Blog Day Three
2013-01-04,Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab
2013-01-04,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 31st Annual J.P. Morgan Healthcare Conference In San Francisco, CA
2013-01-02,A Buysider's Preview of Biotech's Biggest Conference
2012-11-13,AstraZeneca, Nektar Opioid Constipation Drug May Have Failed Phase III Study
2012-11-12,FDA Places New Heart-Safety Hurdle in Path of Opioid Constipation Drugs
2012-11-06,Nektar To Announce Financial Results For The Third Quarter Of 2012 On Tuesday, November 13, 2012, After Close Of U.S.-Based Financial Markets
2012-11-05,21 Most Volatile Biopharma Stocks Closing Out 2012
2012-09-28,5 Biotech Stocks Poised for Breakouts
2012-09-13,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The UBS 2012 Global Life Sciences Conference In New York City
2012-09-12,Nektar Therapeutics Is a Short
2012-08-31,5 Stocks Poised for Big Breakouts
2012-08-09,Nektar Therapeutics' CEO Discusses Q2 2012 Results - Earnings Transcript
2012-08-02,Nektar To Announce Financial Results For The Second Quarter Of 2012 On Thursday, August 9, 2012, After Close Of U.S.-Based Financial Markets
2012-07-10,Nektar Therapeutics Announces Private Placement Of $125 Million Of Senior Secured Notes Due In 2017
2012-05-22,22 Biopharma Stocks With Breakout Potential in 2012
2012-04-10,Nektar To Host Investor And Analyst R&D Day In New York City
2012-04-02,Nektar Doses First Subjects In Phase 1 Clinical Study Evaluating NKTR-192, A New Short-Acting Opioid Molecule For The Treatment Of Acute Pain
2012-03-26,Signs Point to MAP Pharma Drug Rejection
2012-03-20,Nektar Consolidates Research At Its State-of-the-Art R&D Center Located In San Francisco At Mission Bay
2012-03-08,Time to Go Short
2012-03-02,Nektar Therapeutics Announces Webcast Of Presentation At The 32nd Annual Cowen And Company Healthcare Conference In Boston
2017-03-21,Traders Are Aggressively Fading the Open
2017-03-21,Rev's Forum: Don't Just Sit There, Do Something!
2017-03-20,How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More
2017-03-20,Biotechs Remain the Best Place For Stock Picking
2017-03-20,Biotech Premarket Movers: CytomX, Aevi, Esperion
2017-03-20,Nektar Addiction-Resistant Opioid Reduces Chronic Pain in Late-Stage Study
2017-03-20,NKTR-181 Meets Primary And Secondary Endpoints In Phase 3 SUMMIT-07 Study In Chronic Pain
2017-03-06,Bullish and Bearish Reversals in the Market
2017-03-02,Nektar To Webcast Presentation At Cowen And Company's 37th Annual Health Care Conference In Boston
2017-03-01,Nektar Therapeutics Announces Upcoming Presentations At The American Association For Cancer Research Annual Meeting
2017-02-22,Nektar To Announce Financial Results For The Fourth Quarter And Year-Ended 2016 On Wednesday, March 1, 2017, After Close Of U.S.-Based Financial Markets
2017-02-18,Clinical Data From Phase 1 Dose-Escalation Study Of Single-Agent NKTR-214 In Patients With Renal Cell Carcinoma Presented At The ASCO 2017 Genitourinary Cancers Symposium
2017-01-24,Interesting NKTR Put And Call Options For March 17th
2017-01-07,These 9 Allergan Drugs May Now Cost as Much as 9.5% More in 2017
2017-01-05,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 35th Annual J.P. Morgan Healthcare Conference In San Francisco, CA
2016-12-27,Shire Announces FDA Approval Of Adynovate® [Antihemophilic Factor (Recombinant), Pegylated] For Use In Children And Surgical Settings
2016-12-21,First Week of NKTR August 2017 Options Trading
2016-11-14,Nektar Therapeutics To Present At Jefferies 2016 Global Healthcare Conference In London
2016-11-09,Nektar Therapeutics Presents New Clinical Data From Ongoing Phase 1 Dose-Escalation Study Of NKTR-214 At The Society For Immunotherapy Of Cancer (SITC) 2016 Annual Meeting
2016-10-28,Nektar To Hold Investor & Analyst Event At 2016 Society For Immunotherapy Of Cancer Annual Meeting
2016-10-28,Nektar Therapeutics Announces Upcoming Presentations At The 2016 Society For Immunotherapy Of Cancer Annual Meeting
2016-10-27,Nektar To Announce Financial Results For The Third Quarter 2016 On Thursday, November 3, 2016, After Close Of U.S.-Based Financial Markets
2016-10-26,Short Interest Jumps 12.5% For NKTR
2016-10-24,Schlumberger, Amazon, Apple: Doug Kass' Views
2016-10-19,Nektar Therapeutics (NKTR) Stock Falls on Public Offering Pricing
2016-10-19,Nektar Therapeutics Prices Public Offering Of Shares Of Common Stock
2016-10-17,Nektar Therapeutics Announces Public Offering Of Shares Of Common Stock
2016-09-27,Nektar Therapeutics To Host Investor & Analyst Conference Call To Discuss New Clinical Collaboration With Bristol-Myers Squibb
2016-09-27,Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy
2016-09-27,Bristol-Myers Squibb And Nektar Therapeutics Announce Oncology Clinical Collaboration To Evaluate The Combination Of Opdivo (nivolumab) And NKTR-214
2016-09-06,Here's Why Investors Should Steer Clear of Opioids
2016-08-23,4 Biotech Stock Charts You Must See
2016-08-08,Rev's Forum: Let's See If Bulls Can Sustain Friday's Momentum
2016-08-04,Don't Roll the Dice on Central Bank News
2016-07-29,Using My Metal Detector Amid Gold and Silver Strength
2016-07-27,Nektar To Announce Financial Results For The Second Quarter 2016 On Wednesday, August 3, 2016, After Close Of U.S.-Based Financial Markets
2016-07-21,Nektar Therapeutics (NKTR) Flagged As Strong On High Volume
2016-06-06,Preclinical Data Presented At ASCO 2016 Annual Meeting Demonstrate That Single-Agent NKTR-214 Produces A Large Increase In Tumor-Infiltrating Lymphocytes To Provide Durable Anti-Tumor Activity
2016-06-02,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The Jefferies 2016 Global Healthcare Conference In New York City
2016-06-02,Nektar Therapeutics Announces Executive Management Promotions
2016-06-01,Nektar Therapeutics And Daiichi Sankyo Europe GmbH Sign European Licensing Agreement For ONZEALD™ (etirinotecan Pegol), An Investigational Drug Candidate Being Developed To Treat Patients With Advanced Breast Cancer And Brain Metastases
2016-05-04,Nektar Therapeutics (NKTR) Weak On High Volume Today
2016-04-28,Nektar To Announce Financial Results For The First Quarter 2016 On Tuesday, May 3, 2016, After Close Of U.S.-Based Financial Markets
2016-04-18,Preclinical Data Presented At AACR Demonstrate That Combining NKTR-214 With Checkpoint Blockade Is Superior To Dual Checkpoint Inhibition In Increasing Clonality Of The T Cell Receptor (TCR) Repertoire And T Cell Tumor Infiltration
2016-04-11,Facebook, Ford and General Motors: Doug Kass' Views
2016-03-08,Novice Trade: Nektar Therapeutics
2016-03-03,Nektar Therapeutics To Present At Cowen And Company's 36th Annual Health Care Conference In Boston, MA
2016-03-02,Nektar Therapeutics (NKTR) Stock Slumps Despite Q4 Beat
2016-02-26,Nektar To Announce Financial Results For The Fourth Quarter And Year-Ended 2015 On Tuesday, March 1, 2016, After Close Of U.S.-Based Financial Markets
2016-02-25,Baxalta Announces Submission Of Supplemental BLAs To Expand Use Of ADYNOVATE To Pediatric Patients And Surgical Settings
2016-02-19,What Carl Icahn Is Doing; Biotech Breakout: Best of Kass
2016-02-15,JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views
2016-02-15,General Motors, MetLife and Tesla: Doug Kass' Views
2016-02-01,Nektar Publishes Pre-clinical Results For NKTR-214, An Investigational CD122-Biased Immune-Stimulatory Cytokine For The Treatment Of Cancer In Clinical Cancer Research
2016-01-06,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 34th Annual J.P. Morgan Healthcare Conference In San Francisco, CA
2015-12-21,Baxalta's ADYNOVATE Meets Endpoints In Phase 3 Study Of Hemophilia A Patients Under 12 Years Of Age
2015-12-21,Baxalta's ADYNOVATE Meets Endpoints In Phase 3 Study Of Hemophilia A Patients Under 12 Years Of Age
2015-12-08,Nektar Therapeutics To Present At Oppenheimer 26th Annual Healthcare Conference In New York
2015-12-08,Nektar Announces First Patient Dosed In Phase 1/2 Clinical Study Of NKTR-214, A CD122-Biased Immuno-Stimulatory Cytokine
2015-12-07,Baxalta Presents Additional Data On Newly-Approved ADYNOVATE And Plans For New Indications During 57th American Society Of Hematology (ASH) Annual Meeting
2015-11-30,Baxalta Announces U.S. Availability Of ADYNOVATE, A New Treatment For Adult Patients With Hemophilia A With A Simple, Twice-Weekly Dosing Schedule
2015-11-17,Get Ready for Nektar Therapeutics (NKTR) Stock to Break Out
2015-11-17,Nektar Therapeutics To Present At Jefferies Autumn 2015 Global Healthcare Conference In London
2015-11-16,Baxalta To Advance Care For Hemophilia A Patients With FDA Approval Of ADYNOVATE, A Simple, Twice-weekly Treatment To Reduce Bleeds
2015-10-29,Nektar To Announce Financial Results For The Third Quarter 2015 On Thursday, November 5, 2015, After Close Of U.S.-Based Financial Markets
2015-10-20,First Week of December 18th Options Trading For Nektar Therapeutics (NKTR)
2015-10-08,Nektar Reports On Advancements With Pain And Oncology Clinical Pipeline At Investor And Analyst R&D Day
2015-10-07,Nektar Therapeutics (NKTR) Marked As A Dead Cat Bounce Stock
2015-10-07,Nektar Submits Investigational New Drug Application (IND) For NKTR-214 To Treat Solid Tumor Malignancies
2015-10-06,Nektar Closes Direct Private Placement With TPG Special Situations Partners Of $250 Million Of Senior Secured Notes Due In 2020
2015-10-01,Nektar To Host Research & Development Day For Analysts And Investors On October 8th
2015-09-21,Nektar Presents Data Demonstrating That NKTR-214, A CD122-Biased Immunostimulatory Cytokine, Induces Durable And Specific Anti-Tumor Immunity As A Single-Agent And When Combined With Checkpoint Inhibitors In Preclinical Models
2015-09-15,NKTR Makes Bullish Cross Above Critical Moving Average
2015-09-01,Nektar Announces Receipt Of $40 Million Milestone Payment Resulting From First Commercial Sale Of MOVENTIG® (naloxegol) Tablets In Major European Market
2015-08-25,Ratings Changes Today
2015-07-29,Nektar To Announce Financial Results For The Second Quarter 2015 On Wednesday, August 5, 2015, After Close Of U.S.-Based Financial Markets
2015-07-16,Baxalta's BAX 855 Pivotal Data Published In Blood Shows Potential To Provide Strong Bleed Prevention With Twice Weekly Dosing For Patients With Hemophilia A
2015-06-26,Nektar Therapeutics (NKTR) Stock: Weak On High Volume Today
2015-06-23,First Week Of February 2016 Options Trading For Nektar Therapeutics (NKTR)
2015-06-15,Today's Weak On High Volume Stock: Nektar Therapeutics (NKTR)
2015-06-02,Nektar And MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration For NKTR-214, A CD122-Biased Immuno-Stimulatory Cytokine
2015-05-28,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The Jefferies 2015 Global Healthcare Conference In New York City
2015-05-01,Ratings Changes Today
2015-05-01,Nektar Therapeutics (NKTR) Is Today's Dead Cat Bounce Stock
2015-04-23,Nektar To Announce Financial Results For The First Quarter 2015 On Thursday, April 30, 2015, After Close Of U.S.-Based Financial Markets
2015-04-21,First Week Of NKTR June 19th Options Trading
2015-04-16,Baxter Submits Application To Japan's MHLW For Approval Of BAX 855, Extended Half-Life Recombinant FVIII Based On ADVATE For Hemophilia A
2015-04-13,Nektar Therapeutics To Present At The 14th Annual Needham Healthcare Conference
2015-04-02,Nektar Announces Receipt Of $100 Million Milestone Payment From AstraZeneca
2015-03-25,Interesting NKTR Put And Call Options For November 20th
2015-03-19,Trade-Ideas: Nektar Therapeutics (NKTR) Is Today's Weak On High Relative Volume Stock
2015-03-18,Bernstein Liebhard LLP Investigates Claims On Behalf Of Those Who Invested In Nektar Therapeutics
2015-03-18,Nektar Therapeutics (NKTR) Stock Tanks Today on Failed Phase III Breast Cancer Treatment Results
2015-03-18,Nektar Therapeutics (NKTR): Heavy Pre-Market Activity
2015-03-17,Etirinotecan Pegol (NKTR-102) Prolonged Median Overall Survival By 2.1 Months Versus Active Control In Patients With Advanced Breast Cancer In Phase 3 Study; Trial Did Not Achieve Statistical Significance (p=0.08)
2015-03-13,Fly Watch: Nektar Therapeutics Breast Cancer Data Expected Soon
2015-02-25,Nektar Announces Start Of Phase 3 SUMMIT-07 Study Of NKTR-181 In Patients With Chronic Low Back Pain
2015-02-17,Nektar To Announce Financial Results For The Fourth Quarter And Year-Ended 2014 On Tuesday, February 24, 2015, After Close Of U.S.-Based Financial Markets
2015-02-11,Baxter Presents Additional Data From Pivotal Study Of BAX 855, Extended Half-life Investigational Recombinant FVIII Based On ADVATE For Hemophilia A
2015-01-22,First Week Of March 20th Options Trading For Nektar Therapeutics (NKTR)
2015-01-06,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 33rd Annual J.P. Morgan Healthcare Conference In San Francisco, CA
2014-12-24,Interesting NKTR Put And Call Options For August 2015
2014-12-11,Nektar Presents Data On Target-Specific Biomarkers From Circulating Tumor Cell Sub-Study Of Phase 3 BEACON Study Of Etirinotecan Pegol (NKTR-102) In Patients With Advanced Breast Cancer
2014-12-01,Baxter Submits Application For US FDA Approval Of BAX 855, Extended Half-Life Recombinant FVIII Based On ADVATE For Hemophilia A
2014-11-24,FDA Grants QIDP Designation To Bayer's Amikacin Inhale And Ciprofloxacin Dry Powder For Inhalation
2014-11-20,Nektar Presents Preclinical Study Findings For Etirinotecan Pegol (NKTR-102) In Combination With A PARP Inhibitor In BRCA1-deficient Cancer Model
2014-10-30,Nektar To Announce Financial Results For The Third Quarter 2014 On Thursday, November 6, 2014, After Close Of U.S.-Based Financial Markets
2014-10-17,Nektar Therapeutics (NKTR) Weak On High Volume Today
2014-09-26,Nektar Therapeutics Announces MOVENTIG® (naloxegol) Receives Positive CHMP Opinion In EU For Treatment Of Adults With Opioid-Induced Constipation
2014-09-19,Nektar Presents Positive Preclinical Data On Oral, Peripherally-Acting Kappa Agonist Molecules At 2014 American Academy Of Pain Management Meeting
2014-09-16,How Will AstraZeneca (AZN) Stock React to FDA's Movantik Approval?
2014-09-16,FDA Approves MOVANTIK™ (naloxegol) Tablets For The Treatment Of Opioid-Induced Constipation In Adult Patients With Chronic Non-Cancer Pain
2014-08-21,Baxter Announces Positive Top-Line Results From Its Phase 3 Study Of BAX 855, Extended Half-Life Recombinant FVIII For Hemophilia A Patients
2014-07-22,Nektar To Announce Financial Results For The Second Quarter 2014 On Thursday, July 31, 2014, After Close Of U.S.-Based Financial Markets
2014-07-08,Notable Two Hundred Day Moving Average Cross - NKTR
2014-06-24,First Week of February 2015 Options Trading For Nektar Therapeutics (NKTR)
2014-06-13,3 Stocks Driving The Drugs Industry Higher
2014-06-12,US FDA ADVISORY COMMITTEE RECOMMENDS NO CARDIOVASCULAR OUTCOMES TRIAL FOR PERIPHERALLY-ACTING MU-OPIOID RECEPTOR ANTAGONIST (PAMORA) CLASS INCLUDING MOVANTIK
2014-06-11,Nektar Therapeutics Stock Trading Halted Today; FDA Advisory Committee To Discuss Peripherally-Acting Opioid Receptor Antagonists
2014-05-31,Positive Data From Phase 2 Trial Of NKTR-102 In Patients With AvastinA®-Refractory High-Grade Glioma Presented At 50th ASCO Meeting
2014-05-20,First Week of July 19th Options Trading For Nektar Therapeutics (NKTR)
2014-05-16,Nektar Therapeutics To Present At The UBS 2014 Global Healthcare Conference In New York City
2014-05-01,Nektar To Announce Financial Results For The First Quarter 2014 On Wednesday, May 7, 2014, After Close Of U.S.-Based Financial Markets
2014-04-22,Why Nektar Therapeutics (NKTR) Stock Is Up Today
2014-04-10,MannKind Rival, Also Developing Inhaled Insulin Device, Files $75M IPO
2014-02-25,First Week of April 19th Options Trading For Nektar Therapeutics (NKTR)
2014-02-24,Use Options For A Chance To Buy NKTR At A 42% Discount
2014-01-23,Nektar Therapeutics (NKTR) Is Today's Pre-Market Mover With Heavy Volume Stock
2014-01-22,Nektar Therapeutics Prices Public Offering Of Common Stock
2014-01-22,Interesting NKTR Put And Call Options For March 22nd
2014-01-21,Nektar Therapeutics Announces Public Offering Of 8,500,000 Shares Of Common Stock
2014-01-08,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 32nd Annual J.P. Morgan Healthcare Conference In San Francisco, CA
2013-12-24,First Week of NKTR August 2014 Options Trading
2013-11-13,Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A
2013-10-11,Short Interest In Nektar Therapeutics Falls 12.5%
2013-10-09,Oversold Conditions For Nektar Therapeutics (NKTR)
2013-10-02,Nektar To Host Investor And Analyst R&D Day In New York City
2013-09-30,Trade-Ideas: Nektar Therapeutics (NKTR) Is Today's "Dead Cat Bounce" Stock
2013-09-30,Nektar Reports That Partner AstraZeneca Announced European Medicines Agency Acceptance Of Marketing Authorisation Application For Naloxegol
2013-09-27,Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
2013-09-26,Nektar Announces Preliminary Topline Results From Phase 2 Efficacy Study For NKTR-181 In Chronic Pain Patients With Osteoarthritis Of The Knee
2013-08-21,First Week Of October 19th Options Trading For Nektar Therapeutics (NKTR)
2013-08-12,2 Health Care Stocks to Trade for Breakouts
2013-08-02,Bulls Pile Into Nektar Therapeutics
2013-08-01,Nektar To Announce Financial Results For The Second Quarter Of 2013 On Thursday, August 8, 2013, After Close Of U.S.-Based Financial Markets
2013-07-23,First Week Of NKTR September 21st Options Trading
2013-06-20,3 Health Care Stocks Spiking on Big Volume
2013-06-13,Short Interest Drops 20.3% For NKTR
2013-05-30,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The Jefferies 2013 Global Healthcare Conference In New York City
2013-05-22,NKTR Crosses Below Key Moving Average Level
2013-05-16,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 2013 UBS Global Healthcare Conference In New York City
2013-05-10,Nektar Therapeutics Enters Oversold Territory (NKTR)
2013-04-29,Chaotic Phases Require Patience 
2013-04-16,Bayer Initiates Phase III Trial Of Investigational Inhaled Amikacin Solution (BAY41-6551T) In Mechanically Ventilated Patients With Gram-negative Pneumonia
2013-03-01,Nektar Therapeutics To Present At The 33rd Annual Cowen And Company Healthcare Conference In Boston
2013-02-26,AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation
2013-02-22,4 Stocks Under $10 Spiking Higher
2013-02-01,5 Stocks Poised for Breakouts
2013-01-09,J.P. Morgan Healthcare Confab Live Blog Day Three
2013-01-04,Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab
2013-01-04,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 31st Annual J.P. Morgan Healthcare Conference In San Francisco, CA
2013-01-02,A Buysider's Preview of Biotech's Biggest Conference
2012-11-13,AstraZeneca, Nektar Opioid Constipation Drug May Have Failed Phase III Study
2012-11-12,FDA Places New Heart-Safety Hurdle in Path of Opioid Constipation Drugs
2012-11-06,Nektar To Announce Financial Results For The Third Quarter Of 2012 On Tuesday, November 13, 2012, After Close Of U.S.-Based Financial Markets
2012-11-05,21 Most Volatile Biopharma Stocks Closing Out 2012
2012-09-28,5 Biotech Stocks Poised for Breakouts
2012-09-13,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The UBS 2012 Global Life Sciences Conference In New York City
2012-09-12,Nektar Therapeutics Is a Short
2012-08-31,5 Stocks Poised for Big Breakouts
2012-08-09,Nektar Therapeutics' CEO Discusses Q2 2012 Results - Earnings Transcript
2012-08-02,Nektar To Announce Financial Results For The Second Quarter Of 2012 On Thursday, August 9, 2012, After Close Of U.S.-Based Financial Markets
2012-07-10,Nektar Therapeutics Announces Private Placement Of $125 Million Of Senior Secured Notes Due In 2017
2012-05-22,22 Biopharma Stocks With Breakout Potential in 2012
2012-04-10,Nektar To Host Investor And Analyst R&D Day In New York City
2012-04-02,Nektar Doses First Subjects In Phase 1 Clinical Study Evaluating NKTR-192, A New Short-Acting Opioid Molecule For The Treatment Of Acute Pain
2012-03-26,Signs Point to MAP Pharma Drug Rejection
2012-03-20,Nektar Consolidates Research At Its State-of-the-Art R&D Center Located In San Francisco At Mission Bay
2012-03-08,Time to Go Short
2012-03-02,Nektar Therapeutics Announces Webcast Of Presentation At The 32nd Annual Cowen And Company Healthcare Conference In Boston
2017-03-21,Traders Are Aggressively Fading the Open
2017-03-21,Rev's Forum: Don't Just Sit There, Do Something!
2017-03-20,How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More
2017-03-20,Biotechs Remain the Best Place For Stock Picking
2017-03-20,Biotech Premarket Movers: CytomX, Aevi, Esperion
2017-03-20,Nektar Addiction-Resistant Opioid Reduces Chronic Pain in Late-Stage Study
2017-03-20,NKTR-181 Meets Primary And Secondary Endpoints In Phase 3 SUMMIT-07 Study In Chronic Pain
2017-03-06,Bullish and Bearish Reversals in the Market
2017-03-02,Nektar To Webcast Presentation At Cowen And Company's 37th Annual Health Care Conference In Boston
2017-03-01,Nektar Therapeutics Announces Upcoming Presentations At The American Association For Cancer Research Annual Meeting
2017-02-22,Nektar To Announce Financial Results For The Fourth Quarter And Year-Ended 2016 On Wednesday, March 1, 2017, After Close Of U.S.-Based Financial Markets
2017-02-18,Clinical Data From Phase 1 Dose-Escalation Study Of Single-Agent NKTR-214 In Patients With Renal Cell Carcinoma Presented At The ASCO 2017 Genitourinary Cancers Symposium
2017-01-24,Interesting NKTR Put And Call Options For March 17th
2017-01-07,These 9 Allergan Drugs May Now Cost as Much as 9.5% More in 2017
2017-01-05,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 35th Annual J.P. Morgan Healthcare Conference In San Francisco, CA
2016-12-27,Shire Announces FDA Approval Of Adynovate® [Antihemophilic Factor (Recombinant), Pegylated] For Use In Children And Surgical Settings
2016-12-21,First Week of NKTR August 2017 Options Trading
2016-11-14,Nektar Therapeutics To Present At Jefferies 2016 Global Healthcare Conference In London
2016-11-09,Nektar Therapeutics Presents New Clinical Data From Ongoing Phase 1 Dose-Escalation Study Of NKTR-214 At The Society For Immunotherapy Of Cancer (SITC) 2016 Annual Meeting
2016-10-28,Nektar To Hold Investor & Analyst Event At 2016 Society For Immunotherapy Of Cancer Annual Meeting
2016-10-28,Nektar Therapeutics Announces Upcoming Presentations At The 2016 Society For Immunotherapy Of Cancer Annual Meeting
2016-10-27,Nektar To Announce Financial Results For The Third Quarter 2016 On Thursday, November 3, 2016, After Close Of U.S.-Based Financial Markets
2016-10-26,Short Interest Jumps 12.5% For NKTR
2016-10-24,Schlumberger, Amazon, Apple: Doug Kass' Views
2016-10-19,Nektar Therapeutics (NKTR) Stock Falls on Public Offering Pricing
2016-10-19,Nektar Therapeutics Prices Public Offering Of Shares Of Common Stock
2016-10-17,Nektar Therapeutics Announces Public Offering Of Shares Of Common Stock
2016-09-27,Nektar Therapeutics To Host Investor & Analyst Conference Call To Discuss New Clinical Collaboration With Bristol-Myers Squibb
2016-09-27,Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy
2016-09-27,Bristol-Myers Squibb And Nektar Therapeutics Announce Oncology Clinical Collaboration To Evaluate The Combination Of Opdivo (nivolumab) And NKTR-214
2016-09-06,Here's Why Investors Should Steer Clear of Opioids
2016-08-23,4 Biotech Stock Charts You Must See
2016-08-08,Rev's Forum: Let's See If Bulls Can Sustain Friday's Momentum
2016-08-04,Don't Roll the Dice on Central Bank News
2016-07-29,Using My Metal Detector Amid Gold and Silver Strength
2016-07-27,Nektar To Announce Financial Results For The Second Quarter 2016 On Wednesday, August 3, 2016, After Close Of U.S.-Based Financial Markets
2016-07-21,Nektar Therapeutics (NKTR) Flagged As Strong On High Volume
2016-06-06,Preclinical Data Presented At ASCO 2016 Annual Meeting Demonstrate That Single-Agent NKTR-214 Produces A Large Increase In Tumor-Infiltrating Lymphocytes To Provide Durable Anti-Tumor Activity
2016-06-02,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The Jefferies 2016 Global Healthcare Conference In New York City
2016-06-02,Nektar Therapeutics Announces Executive Management Promotions
2016-06-01,Nektar Therapeutics And Daiichi Sankyo Europe GmbH Sign European Licensing Agreement For ONZEALD™ (etirinotecan Pegol), An Investigational Drug Candidate Being Developed To Treat Patients With Advanced Breast Cancer And Brain Metastases
2016-05-04,Nektar Therapeutics (NKTR) Weak On High Volume Today
2016-04-28,Nektar To Announce Financial Results For The First Quarter 2016 On Tuesday, May 3, 2016, After Close Of U.S.-Based Financial Markets
2016-04-18,Preclinical Data Presented At AACR Demonstrate That Combining NKTR-214 With Checkpoint Blockade Is Superior To Dual Checkpoint Inhibition In Increasing Clonality Of The T Cell Receptor (TCR) Repertoire And T Cell Tumor Infiltration
2016-04-11,Facebook, Ford and General Motors: Doug Kass' Views
2016-03-08,Novice Trade: Nektar Therapeutics
2016-03-03,Nektar Therapeutics To Present At Cowen And Company's 36th Annual Health Care Conference In Boston, MA
2016-03-02,Nektar Therapeutics (NKTR) Stock Slumps Despite Q4 Beat
2016-02-26,Nektar To Announce Financial Results For The Fourth Quarter And Year-Ended 2015 On Tuesday, March 1, 2016, After Close Of U.S.-Based Financial Markets
2016-02-25,Baxalta Announces Submission Of Supplemental BLAs To Expand Use Of ADYNOVATE To Pediatric Patients And Surgical Settings
2016-02-19,What Carl Icahn Is Doing; Biotech Breakout: Best of Kass
2016-02-15,JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views
2016-02-15,General Motors, MetLife and Tesla: Doug Kass' Views
2016-02-01,Nektar Publishes Pre-clinical Results For NKTR-214, An Investigational CD122-Biased Immune-Stimulatory Cytokine For The Treatment Of Cancer In Clinical Cancer Research
2016-01-06,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 34th Annual J.P. Morgan Healthcare Conference In San Francisco, CA
2015-12-21,Baxalta's ADYNOVATE Meets Endpoints In Phase 3 Study Of Hemophilia A Patients Under 12 Years Of Age
2015-12-21,Baxalta's ADYNOVATE Meets Endpoints In Phase 3 Study Of Hemophilia A Patients Under 12 Years Of Age
2015-12-08,Nektar Therapeutics To Present At Oppenheimer 26th Annual Healthcare Conference In New York
2015-12-08,Nektar Announces First Patient Dosed In Phase 1/2 Clinical Study Of NKTR-214, A CD122-Biased Immuno-Stimulatory Cytokine
2015-12-07,Baxalta Presents Additional Data On Newly-Approved ADYNOVATE And Plans For New Indications During 57th American Society Of Hematology (ASH) Annual Meeting
2015-11-30,Baxalta Announces U.S. Availability Of ADYNOVATE, A New Treatment For Adult Patients With Hemophilia A With A Simple, Twice-Weekly Dosing Schedule
2015-11-17,Get Ready for Nektar Therapeutics (NKTR) Stock to Break Out
2015-11-17,Nektar Therapeutics To Present At Jefferies Autumn 2015 Global Healthcare Conference In London
2015-11-16,Baxalta To Advance Care For Hemophilia A Patients With FDA Approval Of ADYNOVATE, A Simple, Twice-weekly Treatment To Reduce Bleeds
2015-10-29,Nektar To Announce Financial Results For The Third Quarter 2015 On Thursday, November 5, 2015, After Close Of U.S.-Based Financial Markets
2015-10-20,First Week of December 18th Options Trading For Nektar Therapeutics (NKTR)
2015-10-08,Nektar Reports On Advancements With Pain And Oncology Clinical Pipeline At Investor And Analyst R&D Day
2015-10-07,Nektar Therapeutics (NKTR) Marked As A Dead Cat Bounce Stock
2015-10-07,Nektar Submits Investigational New Drug Application (IND) For NKTR-214 To Treat Solid Tumor Malignancies
2015-10-06,Nektar Closes Direct Private Placement With TPG Special Situations Partners Of $250 Million Of Senior Secured Notes Due In 2020
2015-10-01,Nektar To Host Research & Development Day For Analysts And Investors On October 8th
2015-09-21,Nektar Presents Data Demonstrating That NKTR-214, A CD122-Biased Immunostimulatory Cytokine, Induces Durable And Specific Anti-Tumor Immunity As A Single-Agent And When Combined With Checkpoint Inhibitors In Preclinical Models
2015-09-15,NKTR Makes Bullish Cross Above Critical Moving Average
2015-09-01,Nektar Announces Receipt Of $40 Million Milestone Payment Resulting From First Commercial Sale Of MOVENTIG® (naloxegol) Tablets In Major European Market
2015-08-25,Ratings Changes Today
2015-07-29,Nektar To Announce Financial Results For The Second Quarter 2015 On Wednesday, August 5, 2015, After Close Of U.S.-Based Financial Markets
2015-07-16,Baxalta's BAX 855 Pivotal Data Published In Blood Shows Potential To Provide Strong Bleed Prevention With Twice Weekly Dosing For Patients With Hemophilia A
2015-06-26,Nektar Therapeutics (NKTR) Stock: Weak On High Volume Today
2015-06-23,First Week Of February 2016 Options Trading For Nektar Therapeutics (NKTR)
2015-06-15,Today's Weak On High Volume Stock: Nektar Therapeutics (NKTR)
2015-06-02,Nektar And MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration For NKTR-214, A CD122-Biased Immuno-Stimulatory Cytokine
2015-05-28,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The Jefferies 2015 Global Healthcare Conference In New York City
2015-05-01,Ratings Changes Today
2015-05-01,Nektar Therapeutics (NKTR) Is Today's Dead Cat Bounce Stock
2015-04-23,Nektar To Announce Financial Results For The First Quarter 2015 On Thursday, April 30, 2015, After Close Of U.S.-Based Financial Markets
2015-04-21,First Week Of NKTR June 19th Options Trading
2015-04-16,Baxter Submits Application To Japan's MHLW For Approval Of BAX 855, Extended Half-Life Recombinant FVIII Based On ADVATE For Hemophilia A
2015-04-13,Nektar Therapeutics To Present At The 14th Annual Needham Healthcare Conference
2015-04-02,Nektar Announces Receipt Of $100 Million Milestone Payment From AstraZeneca
2015-03-25,Interesting NKTR Put And Call Options For November 20th
2015-03-19,Trade-Ideas: Nektar Therapeutics (NKTR) Is Today's Weak On High Relative Volume Stock
2015-03-18,Bernstein Liebhard LLP Investigates Claims On Behalf Of Those Who Invested In Nektar Therapeutics
2015-03-18,Nektar Therapeutics (NKTR) Stock Tanks Today on Failed Phase III Breast Cancer Treatment Results
2015-03-18,Nektar Therapeutics (NKTR): Heavy Pre-Market Activity
2015-03-17,Etirinotecan Pegol (NKTR-102) Prolonged Median Overall Survival By 2.1 Months Versus Active Control In Patients With Advanced Breast Cancer In Phase 3 Study; Trial Did Not Achieve Statistical Significance (p=0.08)
2015-03-13,Fly Watch: Nektar Therapeutics Breast Cancer Data Expected Soon
2015-02-25,Nektar Announces Start Of Phase 3 SUMMIT-07 Study Of NKTR-181 In Patients With Chronic Low Back Pain
2015-02-17,Nektar To Announce Financial Results For The Fourth Quarter And Year-Ended 2014 On Tuesday, February 24, 2015, After Close Of U.S.-Based Financial Markets
2015-02-11,Baxter Presents Additional Data From Pivotal Study Of BAX 855, Extended Half-life Investigational Recombinant FVIII Based On ADVATE For Hemophilia A
2015-01-22,First Week Of March 20th Options Trading For Nektar Therapeutics (NKTR)
2015-01-06,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 33rd Annual J.P. Morgan Healthcare Conference In San Francisco, CA
2014-12-24,Interesting NKTR Put And Call Options For August 2015
2014-12-11,Nektar Presents Data On Target-Specific Biomarkers From Circulating Tumor Cell Sub-Study Of Phase 3 BEACON Study Of Etirinotecan Pegol (NKTR-102) In Patients With Advanced Breast Cancer
2014-12-01,Baxter Submits Application For US FDA Approval Of BAX 855, Extended Half-Life Recombinant FVIII Based On ADVATE For Hemophilia A
2014-11-24,FDA Grants QIDP Designation To Bayer's Amikacin Inhale And Ciprofloxacin Dry Powder For Inhalation
2014-11-20,Nektar Presents Preclinical Study Findings For Etirinotecan Pegol (NKTR-102) In Combination With A PARP Inhibitor In BRCA1-deficient Cancer Model
2014-10-30,Nektar To Announce Financial Results For The Third Quarter 2014 On Thursday, November 6, 2014, After Close Of U.S.-Based Financial Markets
2014-10-17,Nektar Therapeutics (NKTR) Weak On High Volume Today
2014-09-26,Nektar Therapeutics Announces MOVENTIG® (naloxegol) Receives Positive CHMP Opinion In EU For Treatment Of Adults With Opioid-Induced Constipation
2014-09-19,Nektar Presents Positive Preclinical Data On Oral, Peripherally-Acting Kappa Agonist Molecules At 2014 American Academy Of Pain Management Meeting
2014-09-16,How Will AstraZeneca (AZN) Stock React to FDA's Movantik Approval?
2014-09-16,FDA Approves MOVANTIK™ (naloxegol) Tablets For The Treatment Of Opioid-Induced Constipation In Adult Patients With Chronic Non-Cancer Pain
2014-08-21,Baxter Announces Positive Top-Line Results From Its Phase 3 Study Of BAX 855, Extended Half-Life Recombinant FVIII For Hemophilia A Patients
2014-07-22,Nektar To Announce Financial Results For The Second Quarter 2014 On Thursday, July 31, 2014, After Close Of U.S.-Based Financial Markets
2014-07-08,Notable Two Hundred Day Moving Average Cross - NKTR
2014-06-24,First Week of February 2015 Options Trading For Nektar Therapeutics (NKTR)
2014-06-13,3 Stocks Driving The Drugs Industry Higher
2014-06-12,US FDA ADVISORY COMMITTEE RECOMMENDS NO CARDIOVASCULAR OUTCOMES TRIAL FOR PERIPHERALLY-ACTING MU-OPIOID RECEPTOR ANTAGONIST (PAMORA) CLASS INCLUDING MOVANTIK
2014-06-11,Nektar Therapeutics Stock Trading Halted Today; FDA Advisory Committee To Discuss Peripherally-Acting Opioid Receptor Antagonists
2014-05-31,Positive Data From Phase 2 Trial Of NKTR-102 In Patients With AvastinA®-Refractory High-Grade Glioma Presented At 50th ASCO Meeting
2014-05-20,First Week of July 19th Options Trading For Nektar Therapeutics (NKTR)
2014-05-16,Nektar Therapeutics To Present At The UBS 2014 Global Healthcare Conference In New York City
2014-05-01,Nektar To Announce Financial Results For The First Quarter 2014 On Wednesday, May 7, 2014, After Close Of U.S.-Based Financial Markets
2014-04-22,Why Nektar Therapeutics (NKTR) Stock Is Up Today
2014-04-10,MannKind Rival, Also Developing Inhaled Insulin Device, Files $75M IPO
2014-02-25,First Week of April 19th Options Trading For Nektar Therapeutics (NKTR)
2014-02-24,Use Options For A Chance To Buy NKTR At A 42% Discount
2014-01-23,Nektar Therapeutics (NKTR) Is Today's Pre-Market Mover With Heavy Volume Stock
2014-01-22,Nektar Therapeutics Prices Public Offering Of Common Stock
2014-01-22,Interesting NKTR Put And Call Options For March 22nd
2014-01-21,Nektar Therapeutics Announces Public Offering Of 8,500,000 Shares Of Common Stock
2014-01-08,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 32nd Annual J.P. Morgan Healthcare Conference In San Francisco, CA
2013-12-24,First Week of NKTR August 2014 Options Trading
2013-11-13,Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A
2013-10-11,Short Interest In Nektar Therapeutics Falls 12.5%
2013-10-09,Oversold Conditions For Nektar Therapeutics (NKTR)
2013-10-02,Nektar To Host Investor And Analyst R&D Day In New York City
2013-09-30,Trade-Ideas: Nektar Therapeutics (NKTR) Is Today's "Dead Cat Bounce" Stock
2013-09-30,Nektar Reports That Partner AstraZeneca Announced European Medicines Agency Acceptance Of Marketing Authorisation Application For Naloxegol
2013-09-27,Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
2013-09-26,Nektar Announces Preliminary Topline Results From Phase 2 Efficacy Study For NKTR-181 In Chronic Pain Patients With Osteoarthritis Of The Knee
2013-08-21,First Week Of October 19th Options Trading For Nektar Therapeutics (NKTR)
2013-08-12,2 Health Care Stocks to Trade for Breakouts
2013-08-02,Bulls Pile Into Nektar Therapeutics
2013-08-01,Nektar To Announce Financial Results For The Second Quarter Of 2013 On Thursday, August 8, 2013, After Close Of U.S.-Based Financial Markets
2013-07-23,First Week Of NKTR September 21st Options Trading
2013-06-20,3 Health Care Stocks Spiking on Big Volume
2013-06-13,Short Interest Drops 20.3% For NKTR
2013-05-30,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The Jefferies 2013 Global Healthcare Conference In New York City
2013-05-22,NKTR Crosses Below Key Moving Average Level
2013-05-16,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 2013 UBS Global Healthcare Conference In New York City
2013-05-10,Nektar Therapeutics Enters Oversold Territory (NKTR)
2013-04-29,Chaotic Phases Require Patience 
2013-04-16,Bayer Initiates Phase III Trial Of Investigational Inhaled Amikacin Solution (BAY41-6551T) In Mechanically Ventilated Patients With Gram-negative Pneumonia
2013-03-01,Nektar Therapeutics To Present At The 33rd Annual Cowen And Company Healthcare Conference In Boston
2013-02-26,AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation
2013-02-22,4 Stocks Under $10 Spiking Higher
2013-02-01,5 Stocks Poised for Breakouts
2013-01-09,J.P. Morgan Healthcare Confab Live Blog Day Three
2013-01-04,Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab
2013-01-04,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 31st Annual J.P. Morgan Healthcare Conference In San Francisco, CA
2013-01-02,A Buysider's Preview of Biotech's Biggest Conference
2012-11-13,AstraZeneca, Nektar Opioid Constipation Drug May Have Failed Phase III Study
2012-11-12,FDA Places New Heart-Safety Hurdle in Path of Opioid Constipation Drugs
2012-11-06,Nektar To Announce Financial Results For The Third Quarter Of 2012 On Tuesday, November 13, 2012, After Close Of U.S.-Based Financial Markets
2012-11-05,21 Most Volatile Biopharma Stocks Closing Out 2012
2012-09-28,5 Biotech Stocks Poised for Breakouts
2012-09-13,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The UBS 2012 Global Life Sciences Conference In New York City
2012-09-12,Nektar Therapeutics Is a Short
2012-08-31,5 Stocks Poised for Big Breakouts
2012-08-09,Nektar Therapeutics' CEO Discusses Q2 2012 Results - Earnings Transcript
2012-08-02,Nektar To Announce Financial Results For The Second Quarter Of 2012 On Thursday, August 9, 2012, After Close Of U.S.-Based Financial Markets
2012-07-10,Nektar Therapeutics Announces Private Placement Of $125 Million Of Senior Secured Notes Due In 2017
2012-05-22,22 Biopharma Stocks With Breakout Potential in 2012
2012-04-10,Nektar To Host Investor And Analyst R&D Day In New York City
2012-04-02,Nektar Doses First Subjects In Phase 1 Clinical Study Evaluating NKTR-192, A New Short-Acting Opioid Molecule For The Treatment Of Acute Pain
2012-03-26,Signs Point to MAP Pharma Drug Rejection
2012-03-20,Nektar Consolidates Research At Its State-of-the-Art R&D Center Located In San Francisco At Mission Bay
2012-03-08,Time to Go Short
2012-03-02,Nektar Therapeutics Announces Webcast Of Presentation At The 32nd Annual Cowen And Company Healthcare Conference In Boston
2017-03-21,Traders Are Aggressively Fading the Open
2017-03-21,Rev's Forum: Don't Just Sit There, Do Something!
2017-03-20,How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More
2017-03-20,Biotechs Remain the Best Place For Stock Picking
2017-03-20,Biotech Premarket Movers: CytomX, Aevi, Esperion
2017-03-20,Nektar Addiction-Resistant Opioid Reduces Chronic Pain in Late-Stage Study
2017-03-20,NKTR-181 Meets Primary And Secondary Endpoints In Phase 3 SUMMIT-07 Study In Chronic Pain
2017-03-06,Bullish and Bearish Reversals in the Market
2017-03-02,Nektar To Webcast Presentation At Cowen And Company's 37th Annual Health Care Conference In Boston
2017-03-01,Nektar Therapeutics Announces Upcoming Presentations At The American Association For Cancer Research Annual Meeting
2017-02-22,Nektar To Announce Financial Results For The Fourth Quarter And Year-Ended 2016 On Wednesday, March 1, 2017, After Close Of U.S.-Based Financial Markets
2017-02-18,Clinical Data From Phase 1 Dose-Escalation Study Of Single-Agent NKTR-214 In Patients With Renal Cell Carcinoma Presented At The ASCO 2017 Genitourinary Cancers Symposium
2017-01-24,Interesting NKTR Put And Call Options For March 17th
2017-01-07,These 9 Allergan Drugs May Now Cost as Much as 9.5% More in 2017
2017-01-05,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 35th Annual J.P. Morgan Healthcare Conference In San Francisco, CA
2016-12-27,Shire Announces FDA Approval Of Adynovate® [Antihemophilic Factor (Recombinant), Pegylated] For Use In Children And Surgical Settings
2016-12-21,First Week of NKTR August 2017 Options Trading
2016-11-14,Nektar Therapeutics To Present At Jefferies 2016 Global Healthcare Conference In London
2016-11-09,Nektar Therapeutics Presents New Clinical Data From Ongoing Phase 1 Dose-Escalation Study Of NKTR-214 At The Society For Immunotherapy Of Cancer (SITC) 2016 Annual Meeting
2016-10-28,Nektar To Hold Investor & Analyst Event At 2016 Society For Immunotherapy Of Cancer Annual Meeting
2016-10-28,Nektar Therapeutics Announces Upcoming Presentations At The 2016 Society For Immunotherapy Of Cancer Annual Meeting
2016-10-27,Nektar To Announce Financial Results For The Third Quarter 2016 On Thursday, November 3, 2016, After Close Of U.S.-Based Financial Markets
2016-10-26,Short Interest Jumps 12.5% For NKTR
2016-10-24,Schlumberger, Amazon, Apple: Doug Kass' Views
2016-10-19,Nektar Therapeutics (NKTR) Stock Falls on Public Offering Pricing
2016-10-19,Nektar Therapeutics Prices Public Offering Of Shares Of Common Stock
2016-10-17,Nektar Therapeutics Announces Public Offering Of Shares Of Common Stock
2016-09-27,Nektar Therapeutics To Host Investor & Analyst Conference Call To Discuss New Clinical Collaboration With Bristol-Myers Squibb
2016-09-27,Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy
2016-09-27,Bristol-Myers Squibb And Nektar Therapeutics Announce Oncology Clinical Collaboration To Evaluate The Combination Of Opdivo (nivolumab) And NKTR-214
2016-09-06,Here's Why Investors Should Steer Clear of Opioids
2016-08-23,4 Biotech Stock Charts You Must See
2016-08-08,Rev's Forum: Let's See If Bulls Can Sustain Friday's Momentum
2016-08-04,Don't Roll the Dice on Central Bank News
2016-07-29,Using My Metal Detector Amid Gold and Silver Strength
2016-07-27,Nektar To Announce Financial Results For The Second Quarter 2016 On Wednesday, August 3, 2016, After Close Of U.S.-Based Financial Markets
2016-07-21,Nektar Therapeutics (NKTR) Flagged As Strong On High Volume
2016-06-06,Preclinical Data Presented At ASCO 2016 Annual Meeting Demonstrate That Single-Agent NKTR-214 Produces A Large Increase In Tumor-Infiltrating Lymphocytes To Provide Durable Anti-Tumor Activity
2016-06-02,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The Jefferies 2016 Global Healthcare Conference In New York City
2016-06-02,Nektar Therapeutics Announces Executive Management Promotions
2016-06-01,Nektar Therapeutics And Daiichi Sankyo Europe GmbH Sign European Licensing Agreement For ONZEALD™ (etirinotecan Pegol), An Investigational Drug Candidate Being Developed To Treat Patients With Advanced Breast Cancer And Brain Metastases
2016-05-04,Nektar Therapeutics (NKTR) Weak On High Volume Today
2016-04-28,Nektar To Announce Financial Results For The First Quarter 2016 On Tuesday, May 3, 2016, After Close Of U.S.-Based Financial Markets
2016-04-18,Preclinical Data Presented At AACR Demonstrate That Combining NKTR-214 With Checkpoint Blockade Is Superior To Dual Checkpoint Inhibition In Increasing Clonality Of The T Cell Receptor (TCR) Repertoire And T Cell Tumor Infiltration
2016-04-11,Facebook, Ford and General Motors: Doug Kass' Views
2016-03-08,Novice Trade: Nektar Therapeutics
2016-03-03,Nektar Therapeutics To Present At Cowen And Company's 36th Annual Health Care Conference In Boston, MA
2016-03-02,Nektar Therapeutics (NKTR) Stock Slumps Despite Q4 Beat
2016-02-26,Nektar To Announce Financial Results For The Fourth Quarter And Year-Ended 2015 On Tuesday, March 1, 2016, After Close Of U.S.-Based Financial Markets
2016-02-25,Baxalta Announces Submission Of Supplemental BLAs To Expand Use Of ADYNOVATE To Pediatric Patients And Surgical Settings
2016-02-19,What Carl Icahn Is Doing; Biotech Breakout: Best of Kass
2016-02-15,JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views
2016-02-15,General Motors, MetLife and Tesla: Doug Kass' Views
2016-02-01,Nektar Publishes Pre-clinical Results For NKTR-214, An Investigational CD122-Biased Immune-Stimulatory Cytokine For The Treatment Of Cancer In Clinical Cancer Research
2016-01-06,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 34th Annual J.P. Morgan Healthcare Conference In San Francisco, CA
2015-12-21,Baxalta's ADYNOVATE Meets Endpoints In Phase 3 Study Of Hemophilia A Patients Under 12 Years Of Age
2015-12-21,Baxalta's ADYNOVATE Meets Endpoints In Phase 3 Study Of Hemophilia A Patients Under 12 Years Of Age
2015-12-08,Nektar Therapeutics To Present At Oppenheimer 26th Annual Healthcare Conference In New York
2015-12-08,Nektar Announces First Patient Dosed In Phase 1/2 Clinical Study Of NKTR-214, A CD122-Biased Immuno-Stimulatory Cytokine
2015-12-07,Baxalta Presents Additional Data On Newly-Approved ADYNOVATE And Plans For New Indications During 57th American Society Of Hematology (ASH) Annual Meeting
2015-11-30,Baxalta Announces U.S. Availability Of ADYNOVATE, A New Treatment For Adult Patients With Hemophilia A With A Simple, Twice-Weekly Dosing Schedule
2015-11-17,Get Ready for Nektar Therapeutics (NKTR) Stock to Break Out
2015-11-17,Nektar Therapeutics To Present At Jefferies Autumn 2015 Global Healthcare Conference In London
2015-11-16,Baxalta To Advance Care For Hemophilia A Patients With FDA Approval Of ADYNOVATE, A Simple, Twice-weekly Treatment To Reduce Bleeds
2015-10-29,Nektar To Announce Financial Results For The Third Quarter 2015 On Thursday, November 5, 2015, After Close Of U.S.-Based Financial Markets
2015-10-20,First Week of December 18th Options Trading For Nektar Therapeutics (NKTR)
2015-10-08,Nektar Reports On Advancements With Pain And Oncology Clinical Pipeline At Investor And Analyst R&D Day
2015-10-07,Nektar Therapeutics (NKTR) Marked As A Dead Cat Bounce Stock
2015-10-07,Nektar Submits Investigational New Drug Application (IND) For NKTR-214 To Treat Solid Tumor Malignancies
2015-10-06,Nektar Closes Direct Private Placement With TPG Special Situations Partners Of $250 Million Of Senior Secured Notes Due In 2020
2015-10-01,Nektar To Host Research & Development Day For Analysts And Investors On October 8th
2015-09-21,Nektar Presents Data Demonstrating That NKTR-214, A CD122-Biased Immunostimulatory Cytokine, Induces Durable And Specific Anti-Tumor Immunity As A Single-Agent And When Combined With Checkpoint Inhibitors In Preclinical Models
2015-09-15,NKTR Makes Bullish Cross Above Critical Moving Average
2015-09-01,Nektar Announces Receipt Of $40 Million Milestone Payment Resulting From First Commercial Sale Of MOVENTIG® (naloxegol) Tablets In Major European Market
2015-08-25,Ratings Changes Today
2015-07-29,Nektar To Announce Financial Results For The Second Quarter 2015 On Wednesday, August 5, 2015, After Close Of U.S.-Based Financial Markets
2015-07-16,Baxalta's BAX 855 Pivotal Data Published In Blood Shows Potential To Provide Strong Bleed Prevention With Twice Weekly Dosing For Patients With Hemophilia A
2015-06-26,Nektar Therapeutics (NKTR) Stock: Weak On High Volume Today
2015-06-23,First Week Of February 2016 Options Trading For Nektar Therapeutics (NKTR)
2015-06-15,Today's Weak On High Volume Stock: Nektar Therapeutics (NKTR)
2015-06-02,Nektar And MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration For NKTR-214, A CD122-Biased Immuno-Stimulatory Cytokine
2015-05-28,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The Jefferies 2015 Global Healthcare Conference In New York City
2015-05-01,Ratings Changes Today
2015-05-01,Nektar Therapeutics (NKTR) Is Today's Dead Cat Bounce Stock
2015-04-23,Nektar To Announce Financial Results For The First Quarter 2015 On Thursday, April 30, 2015, After Close Of U.S.-Based Financial Markets
2015-04-21,First Week Of NKTR June 19th Options Trading
2015-04-16,Baxter Submits Application To Japan's MHLW For Approval Of BAX 855, Extended Half-Life Recombinant FVIII Based On ADVATE For Hemophilia A
2015-04-13,Nektar Therapeutics To Present At The 14th Annual Needham Healthcare Conference
2015-04-02,Nektar Announces Receipt Of $100 Million Milestone Payment From AstraZeneca
2015-03-25,Interesting NKTR Put And Call Options For November 20th
2015-03-19,Trade-Ideas: Nektar Therapeutics (NKTR) Is Today's Weak On High Relative Volume Stock
2015-03-18,Bernstein Liebhard LLP Investigates Claims On Behalf Of Those Who Invested In Nektar Therapeutics
2015-03-18,Nektar Therapeutics (NKTR) Stock Tanks Today on Failed Phase III Breast Cancer Treatment Results
2015-03-18,Nektar Therapeutics (NKTR): Heavy Pre-Market Activity
2015-03-17,Etirinotecan Pegol (NKTR-102) Prolonged Median Overall Survival By 2.1 Months Versus Active Control In Patients With Advanced Breast Cancer In Phase 3 Study; Trial Did Not Achieve Statistical Significance (p=0.08)
2015-03-13,Fly Watch: Nektar Therapeutics Breast Cancer Data Expected Soon
2015-02-25,Nektar Announces Start Of Phase 3 SUMMIT-07 Study Of NKTR-181 In Patients With Chronic Low Back Pain
2015-02-17,Nektar To Announce Financial Results For The Fourth Quarter And Year-Ended 2014 On Tuesday, February 24, 2015, After Close Of U.S.-Based Financial Markets
2015-02-11,Baxter Presents Additional Data From Pivotal Study Of BAX 855, Extended Half-life Investigational Recombinant FVIII Based On ADVATE For Hemophilia A
2015-01-22,First Week Of March 20th Options Trading For Nektar Therapeutics (NKTR)
2015-01-06,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 33rd Annual J.P. Morgan Healthcare Conference In San Francisco, CA
2014-12-24,Interesting NKTR Put And Call Options For August 2015
2014-12-11,Nektar Presents Data On Target-Specific Biomarkers From Circulating Tumor Cell Sub-Study Of Phase 3 BEACON Study Of Etirinotecan Pegol (NKTR-102) In Patients With Advanced Breast Cancer
2014-12-01,Baxter Submits Application For US FDA Approval Of BAX 855, Extended Half-Life Recombinant FVIII Based On ADVATE For Hemophilia A
2014-11-24,FDA Grants QIDP Designation To Bayer's Amikacin Inhale And Ciprofloxacin Dry Powder For Inhalation
2014-11-20,Nektar Presents Preclinical Study Findings For Etirinotecan Pegol (NKTR-102) In Combination With A PARP Inhibitor In BRCA1-deficient Cancer Model
2014-10-30,Nektar To Announce Financial Results For The Third Quarter 2014 On Thursday, November 6, 2014, After Close Of U.S.-Based Financial Markets
2014-10-17,Nektar Therapeutics (NKTR) Weak On High Volume Today
2014-09-26,Nektar Therapeutics Announces MOVENTIG® (naloxegol) Receives Positive CHMP Opinion In EU For Treatment Of Adults With Opioid-Induced Constipation
2014-09-19,Nektar Presents Positive Preclinical Data On Oral, Peripherally-Acting Kappa Agonist Molecules At 2014 American Academy Of Pain Management Meeting
2014-09-16,How Will AstraZeneca (AZN) Stock React to FDA's Movantik Approval?
2014-09-16,FDA Approves MOVANTIK™ (naloxegol) Tablets For The Treatment Of Opioid-Induced Constipation In Adult Patients With Chronic Non-Cancer Pain
2014-08-21,Baxter Announces Positive Top-Line Results From Its Phase 3 Study Of BAX 855, Extended Half-Life Recombinant FVIII For Hemophilia A Patients
2014-07-22,Nektar To Announce Financial Results For The Second Quarter 2014 On Thursday, July 31, 2014, After Close Of U.S.-Based Financial Markets
2014-07-08,Notable Two Hundred Day Moving Average Cross - NKTR
2014-06-24,First Week of February 2015 Options Trading For Nektar Therapeutics (NKTR)
2014-06-13,3 Stocks Driving The Drugs Industry Higher
2014-06-12,US FDA ADVISORY COMMITTEE RECOMMENDS NO CARDIOVASCULAR OUTCOMES TRIAL FOR PERIPHERALLY-ACTING MU-OPIOID RECEPTOR ANTAGONIST (PAMORA) CLASS INCLUDING MOVANTIK
2014-06-11,Nektar Therapeutics Stock Trading Halted Today; FDA Advisory Committee To Discuss Peripherally-Acting Opioid Receptor Antagonists
2014-05-31,Positive Data From Phase 2 Trial Of NKTR-102 In Patients With AvastinA®-Refractory High-Grade Glioma Presented At 50th ASCO Meeting
2014-05-20,First Week of July 19th Options Trading For Nektar Therapeutics (NKTR)
2014-05-16,Nektar Therapeutics To Present At The UBS 2014 Global Healthcare Conference In New York City
2014-05-01,Nektar To Announce Financial Results For The First Quarter 2014 On Wednesday, May 7, 2014, After Close Of U.S.-Based Financial Markets
2014-04-22,Why Nektar Therapeutics (NKTR) Stock Is Up Today
2014-04-10,MannKind Rival, Also Developing Inhaled Insulin Device, Files $75M IPO
2014-02-25,First Week of April 19th Options Trading For Nektar Therapeutics (NKTR)
2014-02-24,Use Options For A Chance To Buy NKTR At A 42% Discount
2014-01-23,Nektar Therapeutics (NKTR) Is Today's Pre-Market Mover With Heavy Volume Stock
2014-01-22,Nektar Therapeutics Prices Public Offering Of Common Stock
2014-01-22,Interesting NKTR Put And Call Options For March 22nd
2014-01-21,Nektar Therapeutics Announces Public Offering Of 8,500,000 Shares Of Common Stock
2014-01-08,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 32nd Annual J.P. Morgan Healthcare Conference In San Francisco, CA
2013-12-24,First Week of NKTR August 2014 Options Trading
2013-11-13,Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A
2013-10-11,Short Interest In Nektar Therapeutics Falls 12.5%
2013-10-09,Oversold Conditions For Nektar Therapeutics (NKTR)
2013-10-02,Nektar To Host Investor And Analyst R&D Day In New York City
2013-09-30,Trade-Ideas: Nektar Therapeutics (NKTR) Is Today's "Dead Cat Bounce" Stock
2013-09-30,Nektar Reports That Partner AstraZeneca Announced European Medicines Agency Acceptance Of Marketing Authorisation Application For Naloxegol
2013-09-27,Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
2013-09-26,Nektar Announces Preliminary Topline Results From Phase 2 Efficacy Study For NKTR-181 In Chronic Pain Patients With Osteoarthritis Of The Knee
2013-08-21,First Week Of October 19th Options Trading For Nektar Therapeutics (NKTR)
2013-08-12,2 Health Care Stocks to Trade for Breakouts
2013-08-02,Bulls Pile Into Nektar Therapeutics
2013-08-01,Nektar To Announce Financial Results For The Second Quarter Of 2013 On Thursday, August 8, 2013, After Close Of U.S.-Based Financial Markets
2013-07-23,First Week Of NKTR September 21st Options Trading
2013-06-20,3 Health Care Stocks Spiking on Big Volume
2013-06-13,Short Interest Drops 20.3% For NKTR
2013-05-30,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The Jefferies 2013 Global Healthcare Conference In New York City
2013-05-22,NKTR Crosses Below Key Moving Average Level
2013-05-16,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 2013 UBS Global Healthcare Conference In New York City
2013-05-10,Nektar Therapeutics Enters Oversold Territory (NKTR)
2013-04-29,Chaotic Phases Require Patience 
2013-04-16,Bayer Initiates Phase III Trial Of Investigational Inhaled Amikacin Solution (BAY41-6551T) In Mechanically Ventilated Patients With Gram-negative Pneumonia
2013-03-01,Nektar Therapeutics To Present At The 33rd Annual Cowen And Company Healthcare Conference In Boston
2013-02-26,AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation
2013-02-22,4 Stocks Under $10 Spiking Higher
2013-02-01,5 Stocks Poised for Breakouts
2013-01-09,J.P. Morgan Healthcare Confab Live Blog Day Three
2013-01-04,Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab
2013-01-04,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 31st Annual J.P. Morgan Healthcare Conference In San Francisco, CA
2013-01-02,A Buysider's Preview of Biotech's Biggest Conference
2012-11-13,AstraZeneca, Nektar Opioid Constipation Drug May Have Failed Phase III Study
2012-11-12,FDA Places New Heart-Safety Hurdle in Path of Opioid Constipation Drugs
2012-11-06,Nektar To Announce Financial Results For The Third Quarter Of 2012 On Tuesday, November 13, 2012, After Close Of U.S.-Based Financial Markets
2012-11-05,21 Most Volatile Biopharma Stocks Closing Out 2012
2012-09-28,5 Biotech Stocks Poised for Breakouts
2012-09-13,Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The UBS 2012 Global Life Sciences Conference In New York City
2012-09-12,Nektar Therapeutics Is a Short
2012-08-31,5 Stocks Poised for Big Breakouts
2012-08-09,Nektar Therapeutics' CEO Discusses Q2 2012 Results - Earnings Transcript
2012-08-02,Nektar To Announce Financial Results For The Second Quarter Of 2012 On Thursday, August 9, 2012, After Close Of U.S.-Based Financial Markets
2012-07-10,Nektar Therapeutics Announces Private Placement Of $125 Million Of Senior Secured Notes Due In 2017
2012-05-22,22 Biopharma Stocks With Breakout Potential in 2012
2012-04-10,Nektar To Host Investor And Analyst R&D Day In New York City
2012-04-02,Nektar Doses First Subjects In Phase 1 Clinical Study Evaluating NKTR-192, A New Short-Acting Opioid Molecule For The Treatment Of Acute Pain
2012-03-26,Signs Point to MAP Pharma Drug Rejection
2012-03-20,Nektar Consolidates Research At Its State-of-the-Art R&D Center Located In San Francisco At Mission Bay
2012-03-08,Time to Go Short
2012-03-02,Nektar Therapeutics Announces Webcast Of Presentation At The 32nd Annual Cowen And Company Healthcare Conference In Boston
2017-03-09,These 5 Stocks Under $10 Could Ignite Soon
2017-02-28,Biotech Premarket Movers: Cempra, Novavax, Ionis
2017-02-27,Novavax Reports Fourth Quarter And Year-End 2016 Financial Results
2017-02-20,Novavax To Host Conference Call To Discuss Fourth Quarter And Year-End 2016 Financial Results On February 27, 2017
2017-02-17,Sage Therapeutics Leads Biotech Movers on False Takeout Rumors
2017-01-24,Biotech Premarket Movers: Amicus Therapeutics, Nantkwest and Organovo
2017-01-19,Novavax Initiates Phase 2 Safety And Immunogenicity Trial Of The RSV F Vaccine In Older Adults
2017-01-06,5 Stocks Setting Up for Big Breakouts
2017-01-05,Novavax To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-22,Commit To Purchase Novavax At $1, Earn 25% Using Options
2016-12-06,Novavax To Participate In The 4th Annual Guggenheim Boston Healthcare Conference
2016-11-30,Novavax To Participate In The Citi 2016 Global Healthcare Conference
2016-11-22,Novavax To Present At The 28th Annual Piper Jaffray Healthcare Conference
2016-11-09,Novavax Reports Third Quarter 2016 Financial Results
2016-11-02,UPDATE -- Novavax To Host Conference Call To Discuss Third Quarter Financial Results On November 9, 2016
2016-11-02,Novavax To Host Conference Call To Discuss Third Quarter Financial Results On November 9, 2016
2016-10-07,Novavax Reschedules 4th Annual Investor And Analyst Meeting
2016-10-04,Novavax To Host 4th Annual Investor And Analyst Meeting
2016-09-22,5 Stocks Under $10 That Could Make You a Lot of Money
2016-09-19,These 7 Stocks Are Trading on Big Volume -- Here's What to Do With Them Now
2016-09-19,5 Big-Volume Stocks to Add to Your Buy List -- Plus 2 to Avoid
2016-09-19,Twitter, Intel, Starbucks: Doug Kass' Views
2016-09-16,Underlying Risks in Speculative Biotechs; Trump Speaks, Bonds Slide : Best of Kass
2016-09-16,Novavax's Chart Looked Good, Until It Didn't
2016-09-16,Look to Costamare for Value in Shipping
2016-09-16,Novavax's Steep Decline Underlines Small-Cap Biotech Risk
2016-09-16,Novavax (NVAX) Stock Tumbles on Vaccine Trial Failure, Ratings Downgrades
2016-09-16,Analysts' Actions -- Citigroup, Comerica, Novavax, PepsiCo and More
2016-09-15,Novavax (NVAX) Stock Tanking in After-Hours Trading on Vaccine Trial Failure
2016-09-15,Novavax Announces Topline RSV F Vaccine Data From Two Clinical Trials In Older Adults
2016-09-15,Bought Aerie Earlier? Congratulations
2016-09-09,4 Biotechs Set to Provide a Shot in the Arm
2016-09-09,4 Biotechs Set to Provide a Shot in the Arm
2016-09-07,Novavax To Host 4th Annual Investor And Analyst Meeting
2016-08-31,'Mad Money' Lightning Round: Lockheed Martin Can Fly to $210
2016-08-30,Jim Cramer's 'Mad Money' Recap: The Urge to Merge Rules Wall Street
2016-08-11,3 Biotech-Investing Mistakes to Avoid
2016-08-10,Novavax (NVAX) Stock Dropping as Q2 Results Miss Expectations
2016-08-09,How Will Novavax (NVAX) Stock React After Q2 Miss?
2016-08-09,Novavax Reports Second Quarter 2016 Financial Results
2016-08-02,Novavax To Host Conference Call To Discuss Second Quarter Financial Results On August 9, 2016
2016-07-21,4 Small-Cap Biotechs With Big Stories to Tell
2016-06-30,5 Hot Stocks to Watch Right Now
2016-06-28,Novavax (NVAX) Showing Signs Of A Dead Cat Bounce Today
2016-06-17,Novavax Recognized By Washington Post As Top Workplace
2016-06-09,Novavax (NVAX) Is Today's Strong On High Volume Stock
2016-06-06,Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan
2016-06-04,'Mad Money' Lightning Round: Take General Mills Over Kellogg
2016-06-02,Novavax Announces New Seasonal Combination Respiratory Vaccine Program
2016-05-26,Today's Weak On High Volume Stock: Novavax (NVAX)
2016-05-25,U.S. FDA Grants Fast Track Designation To Novavax' RSV F Vaccine For Older Adults
2016-05-12,Novavax Receives The Tech Council Of Maryland's Chairman's Award
2016-05-11,Novavax To Participate In The 2016 Citi Midwest Healthcare Access Day
2016-05-10,Novavax (NVAX) Is Weak On High Volume Today
2016-05-04,Novavax Reports First Quarter 2016 Financial Results
2016-04-27,Novavax To Host Conference Call To Discuss First Quarter Financial Results On May 4, 2016
2016-04-22,Novavax (NVAX) Showing Signs Of Perilous Reversal Today
2016-04-13,Novavax To Participate In The FBR New Prescriptions Conference
2016-04-06,Novavax To Present At The 15th Annual Needham Healthcare Conference
2016-04-05,Correction's Just Getting Started
2016-04-05,One Reason Novavax (NVAX) Stock is Advancing Today
2016-04-04,Novavax Announces Management Promotion
2016-04-04,Novavax (NVAX) Is Today's Perilous Reversal Stock
2016-03-30,Trade-Ideas: Novavax (NVAX) Is Today's Strong On High Relative Volume Stock
2016-03-23,Novavax (NVAX) Is Today's Perilous Reversal Stock
2016-03-17,Novavax Announces Management Promotions
2016-03-17,Novavax Appoints Bob Darius Senior Vice President, Quality Operations
2016-03-15,Novavax (NVAX) Is Today's Perilous Reversal Stock
2016-03-15,'Mad Money' Lightning Round: I'm Not Giving Up on VeriFone
2016-03-14,Jim Cramer's 'Mad Money' Recap: Buy These 6 Sectors on Any Fed-Induced Weakness
2016-03-01,Novavax (NVAX) Showing Signs Of A Dead Cat Bounce Today
2016-02-29,Novavax (NVAX) Stock Plunges on Disappointing Q4 Results
2016-02-29,Novavax (NVAX) Is Weak On High Volume Today
2016-02-29,Novavax Reports Fourth Quarter And Year-End 2015 Financial Results
2016-02-22,Novavax To Host Conference Call To Discuss Fourth Quarter And Full Year 2015 Financial Results On February 29, 2016
2016-02-15,JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views
2016-02-05,Novavax Announces Exercise Of Over-Allotment Option To Purchase Additional Shares
2016-02-02,Insider Trading Alert - PII, NVAX And NOG Traded By Insiders
2016-01-29,Novavax Announces Closing Of $300 Million Offering Of Convertible Senior Notes Due 2023
2016-01-29,Trade-Ideas: Novavax (NVAX) Is Today's "Dead Cat Bounce" Stock
2016-01-29,'Mad Money' Lightning Round: I'm Buy, Buy, Buying T-Mobile US
2016-01-28,Jim Cramer's 'Mad Money' Recap: Market 'Trash' Will Make You Money
2016-01-25,Novavax Prices $300 Million Of Convertible Senior Notes Due 2023
2016-01-25,Trade-Ideas: Novavax (NVAX) Is Today's "Perilous Reversal" Stock
2016-01-25,Novavax Announces Proposed Offering Of $200 Million Of Convertible Senior Notes Due 2023
2016-01-15,Jim Cramer Still Likes Home Depot, Kroger, But Tough to Buy Them Now
2016-01-15,Stock To Watch: Novavax (NVAX) In Perilous Reversal
2016-01-14,Will Insiders Be Tempted To Buy More NVAX At The New 52-Week Low?
2016-01-13,Jim Cramer's Top Takeaways: Dow Chemical, Novavax, Fitbit, Alcoa
2016-01-12,Jim Cramer's 'Mad Money' Recap: Oil Is What's Fueling This Market
2016-01-08,Novavax (NVAX) Marked As A Dead Cat Bounce Stock
2016-01-08,Novavax Appoints Jeffrey Stoddard, M.D., Vice President, Medical Affairs
2016-01-07,Novavax (NVAX) Stock: Weak On High Volume Today
2016-01-06,Novavax To Present At The 34th Annual J.P. Morgan Healthcare Conference
2015-12-21,Novavax Appoints Mark Twyman Vice President Marketing
2015-12-21,Insider Trading Alert - HIL, NVAX And TPC Traded By Insiders
2015-12-14,Novavax Completes Enrollment Of Pivotal Phase 3 Trial Of The RSV F Vaccine In Older Adults
2015-12-08,Novavax To Participate In The Guggenheim Securities 3rd Annual Boston Healthcare Conference
2015-12-04,Novavax (NVAX) Showing Signs Of A Dead Cat Bounce Today
2015-12-03,Novavax Initiates Global Pivotal Phase 3 Trial Of The RSV F Vaccine To Protect Infants Via Maternal Immunization
2015-12-01,Today's Perilous Reversal Stock: Novavax (NVAX)
2015-11-24,Novavax To Present At The 27th Annual Piper Jaffray Healthcare Conference
2015-11-16,Novavax To Make Multiple Presentations At RSV Vaccines For The World
2015-11-13,Short Interest In Novavax Expands By 34%
2015-11-10,Novavax To Present At The Stifel 2015 Healthcare Conference
2015-11-09,Novavax (NVAX) Stock Down on Earnings Miss
2015-11-09,Novavax Reports Third Quarter 2015 Financial Results
2015-11-09,Novavax Initiates Pivotal Phase 3 Trial Of The RSV F Vaccine In Older Adults
2015-11-03,Novavax (NVAX) Showing Signs Of Perilous Reversal Today
2015-11-02,Novavax To Host Conference Call To Discuss Third Quarter Financial Results On November 9, 2015
2015-10-30,'Mad Money' Lightning Round: I'm Not Tempted by Vonage, I Want Verizon
2015-10-29,Jim Cramer's 'Mad Money' Recap: Using What Went Wrong to Find Buying Opportunities
2015-10-26,Trade-Ideas: Novavax (NVAX) Is Today's "Perilous Reversal" Stock
2015-10-22,Novavax Initiates Phase 2 Safety And Immunogenicity Trial To Evaluate Annual Re-Dosing Of The RSV F Vaccine In Older Adults
2015-10-08,Trade-Ideas: Novavax (NVAX) Is Today's "Perilous Reversal" Stock
2015-10-07,It's Just Like 2011 -- Except It's Not
2015-10-01,Novavax Announces Management Promotion
2015-09-30,Today's Dead Cat Bounce Stock Is Novavax (NVAX)
2015-09-29,Jim Cramer's 'Mad Money' Recap: Here's the Silver Lining Behind the Dark Market Cloud
2015-09-29,Novavax Announces Positive Top-Line Data From RSV F Vaccine Phase 1 Clinical Trial In Pediatrics
2015-09-29,Heavy Trading On Novavax (NVAX) Before Market Open
2015-09-29,Novavax To Host 3rd Annual Analyst And Investor Meeting
2015-09-29,Novavax Announces Grant Of Up To $89 Million To Support Development Of RSV F Vaccine To Protect Infants Via Maternal Immunization
2015-09-25,Oversold Conditions For Novavax
2015-09-22,Novavax To Host 3rd Annual Analyst And Investor Meeting
2015-09-21,Novavax To Present At The Ladenburg Thalmann 2015 Healthcare Conference
2015-09-15,Trade-Ideas: Novavax (NVAX) Is Today's Post-Market Leader Stock
2015-09-15,Novavax RSV F Vaccine Is Highly Immunogenic With Robust Transplacental Antibody Transfer In Preclinical Maternal Immunization Model
2015-09-14,January 2018 Options Now Available For Novavax
2015-09-10,Novavax RSV F Vaccine Clinical Trial Data In Women Of Child Bearing Age Published In The Journal Of Infectious Disease
2015-09-02,Novavax To Participate In Multiple Investor Conferences In September
2015-08-26,Novavax To Host 3rd Annual Analyst And Investor Meeting
2015-08-13,Jim Cramer's Top Takeaways: Novavax, Cisco, Freshpet, Macy's
2015-08-12,Jim Cramer's 'Mad Money' Recap: How the Market Got Its Groove Back
2015-08-12,Novavax (NVAX) In A Perilous Reversal
2015-08-11,Today's Stocks Driving Success For The Health Care Sector
2015-08-10,Novavax Reports Second Quarter 2015 Financial Results
2015-08-05,Novavax To Present At The Wedbush PacGrow Healthcare Conference
2015-08-03,Novavax To Host Conference Call To Discuss Second Quarter Financial Results On August 10, 2015
2015-07-30,Novavax Announces Positive Data From Phase 2 Trial Of Quadrivalent Seasonal Influenza VLP
2015-07-21,Novavax Announces Positive Top-Line Data From Phase 1 Ebola Vaccine Trial On WHO Teleconference
2015-07-15,Novavax (NVAX) Flagged As Strong On High Volume
2015-07-10,'Mad Money' Lightning Round: Sell, Sell, Sell Dillard's, It's Overdone
2015-07-09,Jim Cramer's 'Mad Money' Recap: Timing Is Everything in Buying Stocks
2015-06-23,Insider Trading Alert - GEVO, LNG And NVAX Traded By Insiders
2015-06-22,Insiders Seeing Green With NVAX At New 52-Week High
2015-06-22,Novavax (NVAX) Marked As A Barbarian At The Gate
2015-06-19,Novavax Recognized By Washington Post As Top Workplace
2015-06-18,Novavax (NVAX) Strong On High Relative Volume Today
2015-06-18,Novavax Appoints Gail Boudreaux To Board
2015-06-15,Novavax Announces Management Promotion
2015-06-05,Novavax (NVAX) Weak On High Volume Today
2015-05-07,Novavax Reports First Quarter 2015 Financial Results
2015-04-30,Novavax To Host Conference Call To Discuss First Quarter Financial Results On May 7, 2015
2015-04-08,Novavax To Present At The 14th Annual Needham Healthcare Conference
2015-03-31,Novavax Announces Closing Of Public Offering
2015-03-28,Novavax Presents New Data From Non-Human Primate Ebola Challenge At The 7th International Symposium On Filoviruses
2015-03-27,Novavax (NVAX) Marked As A Dead Cat Bounce Stock
2015-03-26,Novavax Prices Public Offering Of Common Stock
2015-03-25,Novavax (NVAX) Stock Declines Today After Announcing $175 Million Public Stock Offering
2015-03-24,Novavax Announces Proposed Public Offering Of Common Stock
2015-03-13,'Mad Money' Lightning Round: Buy, Buy, Buy MasterCard
2015-03-12,Jim Cramer's 'Mad Money' Recap: Be Positive, Don't Be Complacent
2015-03-10,Novavax Appoints Brian Rosen As Vice President, Government Affairs
2015-02-26,Novavax Reports Fourth Quarter And Year-End 2014 Financial Results
2015-02-26,4 Big Stocks on Traders' Radars: Hewlett-Packard and More
2015-02-19,Novavax To Host Conference Call To Discuss Fourth Quarter And Full Year 2014 Financial Results On February 26, 2015
2015-02-18,No Market Surge After Fed Minutes
2015-02-14,Jim Cramer's Top Stock Picks: ACT PCLN CLX HAIN WWAV NVAX
2015-02-13,Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
2015-02-12,Novavax Announces Initiation Of Ebola Vaccine Phase 1 Clinical Trial Supported By Non-Human Primate Challenge Data And Documented Rapid Manufacturing Capabilities
2015-02-04,Insider Trading Alert - TIPT, VNTV And NVAX Traded By Insiders
2015-01-21,Trade-Ideas: Novavax (NVAX) Is Today's Strong On High Relative Volume Stock
2015-01-16,Jim Cramer's Top Stock Picks: NVAX TGT BMRN RCPT
2015-01-15,Jim Cramer's 'Mad Money' Recap: 5 Reasons Why You Must Buy American Stocks
2015-01-15,Novavax (NVAX) Is Today's Dead Cat Bounce Stock
2015-01-08,Novavax Announces Management Promotion
2015-01-07,Novavax To Present At The 33rd Annual J.P. Morgan Healthcare Conference
2014-12-24,Twelve Posts of Christmas, Part 4
2014-11-26,Novavax To Present At The 26th Annual Piper Jaffray Healthcare Conference
2017-03-09,These 5 Stocks Under $10 Could Ignite Soon
2017-02-28,Biotech Premarket Movers: Cempra, Novavax, Ionis
2017-02-27,Novavax Reports Fourth Quarter And Year-End 2016 Financial Results
2017-02-20,Novavax To Host Conference Call To Discuss Fourth Quarter And Year-End 2016 Financial Results On February 27, 2017
2017-02-17,Sage Therapeutics Leads Biotech Movers on False Takeout Rumors
2017-01-24,Biotech Premarket Movers: Amicus Therapeutics, Nantkwest and Organovo
2017-01-19,Novavax Initiates Phase 2 Safety And Immunogenicity Trial Of The RSV F Vaccine In Older Adults
2017-01-06,5 Stocks Setting Up for Big Breakouts
2017-01-05,Novavax To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-22,Commit To Purchase Novavax At $1, Earn 25% Using Options
2016-12-06,Novavax To Participate In The 4th Annual Guggenheim Boston Healthcare Conference
2016-11-30,Novavax To Participate In The Citi 2016 Global Healthcare Conference
2016-11-22,Novavax To Present At The 28th Annual Piper Jaffray Healthcare Conference
2016-11-09,Novavax Reports Third Quarter 2016 Financial Results
2016-11-02,UPDATE -- Novavax To Host Conference Call To Discuss Third Quarter Financial Results On November 9, 2016
2016-11-02,Novavax To Host Conference Call To Discuss Third Quarter Financial Results On November 9, 2016
2016-10-07,Novavax Reschedules 4th Annual Investor And Analyst Meeting
2016-10-04,Novavax To Host 4th Annual Investor And Analyst Meeting
2016-09-22,5 Stocks Under $10 That Could Make You a Lot of Money
2016-09-19,These 7 Stocks Are Trading on Big Volume -- Here's What to Do With Them Now
2016-09-19,5 Big-Volume Stocks to Add to Your Buy List -- Plus 2 to Avoid
2016-09-19,Twitter, Intel, Starbucks: Doug Kass' Views
2016-09-16,Underlying Risks in Speculative Biotechs; Trump Speaks, Bonds Slide : Best of Kass
2016-09-16,Novavax's Chart Looked Good, Until It Didn't
2016-09-16,Look to Costamare for Value in Shipping
2016-09-16,Novavax's Steep Decline Underlines Small-Cap Biotech Risk
2016-09-16,Novavax (NVAX) Stock Tumbles on Vaccine Trial Failure, Ratings Downgrades
2016-09-16,Analysts' Actions -- Citigroup, Comerica, Novavax, PepsiCo and More
2016-09-15,Novavax (NVAX) Stock Tanking in After-Hours Trading on Vaccine Trial Failure
2016-09-15,Novavax Announces Topline RSV F Vaccine Data From Two Clinical Trials In Older Adults
2016-09-15,Bought Aerie Earlier? Congratulations
2016-09-09,4 Biotechs Set to Provide a Shot in the Arm
2016-09-09,4 Biotechs Set to Provide a Shot in the Arm
2016-09-07,Novavax To Host 4th Annual Investor And Analyst Meeting
2016-08-31,'Mad Money' Lightning Round: Lockheed Martin Can Fly to $210
2016-08-30,Jim Cramer's 'Mad Money' Recap: The Urge to Merge Rules Wall Street
2016-08-11,3 Biotech-Investing Mistakes to Avoid
2016-08-10,Novavax (NVAX) Stock Dropping as Q2 Results Miss Expectations
2016-08-09,How Will Novavax (NVAX) Stock React After Q2 Miss?
2016-08-09,Novavax Reports Second Quarter 2016 Financial Results
2016-08-02,Novavax To Host Conference Call To Discuss Second Quarter Financial Results On August 9, 2016
2016-07-21,4 Small-Cap Biotechs With Big Stories to Tell
2016-06-30,5 Hot Stocks to Watch Right Now
2016-06-28,Novavax (NVAX) Showing Signs Of A Dead Cat Bounce Today
2016-06-17,Novavax Recognized By Washington Post As Top Workplace
2016-06-09,Novavax (NVAX) Is Today's Strong On High Volume Stock
2016-06-06,Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan
2016-06-04,'Mad Money' Lightning Round: Take General Mills Over Kellogg
2016-06-02,Novavax Announces New Seasonal Combination Respiratory Vaccine Program
2016-05-26,Today's Weak On High Volume Stock: Novavax (NVAX)
2016-05-25,U.S. FDA Grants Fast Track Designation To Novavax' RSV F Vaccine For Older Adults
2016-05-12,Novavax Receives The Tech Council Of Maryland's Chairman's Award
2016-05-11,Novavax To Participate In The 2016 Citi Midwest Healthcare Access Day
2016-05-10,Novavax (NVAX) Is Weak On High Volume Today
2016-05-04,Novavax Reports First Quarter 2016 Financial Results
2016-04-27,Novavax To Host Conference Call To Discuss First Quarter Financial Results On May 4, 2016
2016-04-22,Novavax (NVAX) Showing Signs Of Perilous Reversal Today
2016-04-13,Novavax To Participate In The FBR New Prescriptions Conference
2016-04-06,Novavax To Present At The 15th Annual Needham Healthcare Conference
2016-04-05,Correction's Just Getting Started
2016-04-05,One Reason Novavax (NVAX) Stock is Advancing Today
2016-04-04,Novavax Announces Management Promotion
2016-04-04,Novavax (NVAX) Is Today's Perilous Reversal Stock
2016-03-30,Trade-Ideas: Novavax (NVAX) Is Today's Strong On High Relative Volume Stock
2016-03-23,Novavax (NVAX) Is Today's Perilous Reversal Stock
2016-03-17,Novavax Announces Management Promotions
2016-03-17,Novavax Appoints Bob Darius Senior Vice President, Quality Operations
2016-03-15,Novavax (NVAX) Is Today's Perilous Reversal Stock
2016-03-15,'Mad Money' Lightning Round: I'm Not Giving Up on VeriFone
2016-03-14,Jim Cramer's 'Mad Money' Recap: Buy These 6 Sectors on Any Fed-Induced Weakness
2016-03-01,Novavax (NVAX) Showing Signs Of A Dead Cat Bounce Today
2016-02-29,Novavax (NVAX) Stock Plunges on Disappointing Q4 Results
2016-02-29,Novavax (NVAX) Is Weak On High Volume Today
2016-02-29,Novavax Reports Fourth Quarter And Year-End 2015 Financial Results
2016-02-22,Novavax To Host Conference Call To Discuss Fourth Quarter And Full Year 2015 Financial Results On February 29, 2016
2016-02-15,JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views
2016-02-05,Novavax Announces Exercise Of Over-Allotment Option To Purchase Additional Shares
2016-02-02,Insider Trading Alert - PII, NVAX And NOG Traded By Insiders
2016-01-29,Novavax Announces Closing Of $300 Million Offering Of Convertible Senior Notes Due 2023
2016-01-29,Trade-Ideas: Novavax (NVAX) Is Today's "Dead Cat Bounce" Stock
2016-01-29,'Mad Money' Lightning Round: I'm Buy, Buy, Buying T-Mobile US
2016-01-28,Jim Cramer's 'Mad Money' Recap: Market 'Trash' Will Make You Money
2016-01-25,Novavax Prices $300 Million Of Convertible Senior Notes Due 2023
2016-01-25,Trade-Ideas: Novavax (NVAX) Is Today's "Perilous Reversal" Stock
2016-01-25,Novavax Announces Proposed Offering Of $200 Million Of Convertible Senior Notes Due 2023
2016-01-15,Jim Cramer Still Likes Home Depot, Kroger, But Tough to Buy Them Now
2016-01-15,Stock To Watch: Novavax (NVAX) In Perilous Reversal
2016-01-14,Will Insiders Be Tempted To Buy More NVAX At The New 52-Week Low?
2016-01-13,Jim Cramer's Top Takeaways: Dow Chemical, Novavax, Fitbit, Alcoa
2016-01-12,Jim Cramer's 'Mad Money' Recap: Oil Is What's Fueling This Market
2016-01-08,Novavax (NVAX) Marked As A Dead Cat Bounce Stock
2016-01-08,Novavax Appoints Jeffrey Stoddard, M.D., Vice President, Medical Affairs
2016-01-07,Novavax (NVAX) Stock: Weak On High Volume Today
2016-01-06,Novavax To Present At The 34th Annual J.P. Morgan Healthcare Conference
2015-12-21,Novavax Appoints Mark Twyman Vice President Marketing
2015-12-21,Insider Trading Alert - HIL, NVAX And TPC Traded By Insiders
2015-12-14,Novavax Completes Enrollment Of Pivotal Phase 3 Trial Of The RSV F Vaccine In Older Adults
2015-12-08,Novavax To Participate In The Guggenheim Securities 3rd Annual Boston Healthcare Conference
2015-12-04,Novavax (NVAX) Showing Signs Of A Dead Cat Bounce Today
2015-12-03,Novavax Initiates Global Pivotal Phase 3 Trial Of The RSV F Vaccine To Protect Infants Via Maternal Immunization
2015-12-01,Today's Perilous Reversal Stock: Novavax (NVAX)
2015-11-24,Novavax To Present At The 27th Annual Piper Jaffray Healthcare Conference
2015-11-16,Novavax To Make Multiple Presentations At RSV Vaccines For The World
2015-11-13,Short Interest In Novavax Expands By 34%
2015-11-10,Novavax To Present At The Stifel 2015 Healthcare Conference
2015-11-09,Novavax (NVAX) Stock Down on Earnings Miss
2015-11-09,Novavax Reports Third Quarter 2015 Financial Results
2015-11-09,Novavax Initiates Pivotal Phase 3 Trial Of The RSV F Vaccine In Older Adults
2015-11-03,Novavax (NVAX) Showing Signs Of Perilous Reversal Today
2015-11-02,Novavax To Host Conference Call To Discuss Third Quarter Financial Results On November 9, 2015
2015-10-30,'Mad Money' Lightning Round: I'm Not Tempted by Vonage, I Want Verizon
2015-10-29,Jim Cramer's 'Mad Money' Recap: Using What Went Wrong to Find Buying Opportunities
2015-10-26,Trade-Ideas: Novavax (NVAX) Is Today's "Perilous Reversal" Stock
2015-10-22,Novavax Initiates Phase 2 Safety And Immunogenicity Trial To Evaluate Annual Re-Dosing Of The RSV F Vaccine In Older Adults
2015-10-08,Trade-Ideas: Novavax (NVAX) Is Today's "Perilous Reversal" Stock
2015-10-07,It's Just Like 2011 -- Except It's Not
2015-10-01,Novavax Announces Management Promotion
2015-09-30,Today's Dead Cat Bounce Stock Is Novavax (NVAX)
2015-09-29,Jim Cramer's 'Mad Money' Recap: Here's the Silver Lining Behind the Dark Market Cloud
2015-09-29,Novavax Announces Positive Top-Line Data From RSV F Vaccine Phase 1 Clinical Trial In Pediatrics
2015-09-29,Heavy Trading On Novavax (NVAX) Before Market Open
2015-09-29,Novavax To Host 3rd Annual Analyst And Investor Meeting
2015-09-29,Novavax Announces Grant Of Up To $89 Million To Support Development Of RSV F Vaccine To Protect Infants Via Maternal Immunization
2015-09-25,Oversold Conditions For Novavax
2015-09-22,Novavax To Host 3rd Annual Analyst And Investor Meeting
2015-09-21,Novavax To Present At The Ladenburg Thalmann 2015 Healthcare Conference
2015-09-15,Trade-Ideas: Novavax (NVAX) Is Today's Post-Market Leader Stock
2015-09-15,Novavax RSV F Vaccine Is Highly Immunogenic With Robust Transplacental Antibody Transfer In Preclinical Maternal Immunization Model
2015-09-14,January 2018 Options Now Available For Novavax
2015-09-10,Novavax RSV F Vaccine Clinical Trial Data In Women Of Child Bearing Age Published In The Journal Of Infectious Disease
2015-09-02,Novavax To Participate In Multiple Investor Conferences In September
2015-08-26,Novavax To Host 3rd Annual Analyst And Investor Meeting
2015-08-13,Jim Cramer's Top Takeaways: Novavax, Cisco, Freshpet, Macy's
2015-08-12,Jim Cramer's 'Mad Money' Recap: How the Market Got Its Groove Back
2015-08-12,Novavax (NVAX) In A Perilous Reversal
2015-08-11,Today's Stocks Driving Success For The Health Care Sector
2015-08-10,Novavax Reports Second Quarter 2015 Financial Results
2015-08-05,Novavax To Present At The Wedbush PacGrow Healthcare Conference
2015-08-03,Novavax To Host Conference Call To Discuss Second Quarter Financial Results On August 10, 2015
2015-07-30,Novavax Announces Positive Data From Phase 2 Trial Of Quadrivalent Seasonal Influenza VLP
2015-07-21,Novavax Announces Positive Top-Line Data From Phase 1 Ebola Vaccine Trial On WHO Teleconference
2015-07-15,Novavax (NVAX) Flagged As Strong On High Volume
2015-07-10,'Mad Money' Lightning Round: Sell, Sell, Sell Dillard's, It's Overdone
2015-07-09,Jim Cramer's 'Mad Money' Recap: Timing Is Everything in Buying Stocks
2015-06-23,Insider Trading Alert - GEVO, LNG And NVAX Traded By Insiders
2015-06-22,Insiders Seeing Green With NVAX At New 52-Week High
2015-06-22,Novavax (NVAX) Marked As A Barbarian At The Gate
2015-06-19,Novavax Recognized By Washington Post As Top Workplace
2015-06-18,Novavax (NVAX) Strong On High Relative Volume Today
2015-06-18,Novavax Appoints Gail Boudreaux To Board
2015-06-15,Novavax Announces Management Promotion
2015-06-05,Novavax (NVAX) Weak On High Volume Today
2015-05-07,Novavax Reports First Quarter 2015 Financial Results
2015-04-30,Novavax To Host Conference Call To Discuss First Quarter Financial Results On May 7, 2015
2015-04-08,Novavax To Present At The 14th Annual Needham Healthcare Conference
2015-03-31,Novavax Announces Closing Of Public Offering
2015-03-28,Novavax Presents New Data From Non-Human Primate Ebola Challenge At The 7th International Symposium On Filoviruses
2015-03-27,Novavax (NVAX) Marked As A Dead Cat Bounce Stock
2015-03-26,Novavax Prices Public Offering Of Common Stock
2015-03-25,Novavax (NVAX) Stock Declines Today After Announcing $175 Million Public Stock Offering
2015-03-24,Novavax Announces Proposed Public Offering Of Common Stock
2015-03-13,'Mad Money' Lightning Round: Buy, Buy, Buy MasterCard
2015-03-12,Jim Cramer's 'Mad Money' Recap: Be Positive, Don't Be Complacent
2015-03-10,Novavax Appoints Brian Rosen As Vice President, Government Affairs
2015-02-26,Novavax Reports Fourth Quarter And Year-End 2014 Financial Results
2015-02-26,4 Big Stocks on Traders' Radars: Hewlett-Packard and More
2015-02-19,Novavax To Host Conference Call To Discuss Fourth Quarter And Full Year 2014 Financial Results On February 26, 2015
2015-02-18,No Market Surge After Fed Minutes
2015-02-14,Jim Cramer's Top Stock Picks: ACT PCLN CLX HAIN WWAV NVAX
2015-02-13,Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
2015-02-12,Novavax Announces Initiation Of Ebola Vaccine Phase 1 Clinical Trial Supported By Non-Human Primate Challenge Data And Documented Rapid Manufacturing Capabilities
2015-02-04,Insider Trading Alert - TIPT, VNTV And NVAX Traded By Insiders
2015-01-21,Trade-Ideas: Novavax (NVAX) Is Today's Strong On High Relative Volume Stock
2015-01-16,Jim Cramer's Top Stock Picks: NVAX TGT BMRN RCPT
2015-01-15,Jim Cramer's 'Mad Money' Recap: 5 Reasons Why You Must Buy American Stocks
2015-01-15,Novavax (NVAX) Is Today's Dead Cat Bounce Stock
2015-01-08,Novavax Announces Management Promotion
2015-01-07,Novavax To Present At The 33rd Annual J.P. Morgan Healthcare Conference
2014-12-24,Twelve Posts of Christmas, Part 4
2014-11-26,Novavax To Present At The 26th Annual Piper Jaffray Healthcare Conference
2017-03-20,Novocure Receives MHLW Approval For Second Generation Optune® In Japan
2017-03-01,Novocure Announces Data Presentations At The American Association For Cancer Research Annual Meeting 2017
2017-02-23,Biotech Movers: Shire Rises on Encouraging Angioedema Results
2017-02-23,Novocure Announces Departure Of Chief Commercial Officer
2017-02-23,Novocure Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Company Update
2017-02-15,First Patient Enrolled In Novocure's Phase 3 Pivotal LUNAR Trial Testing Tumor Treating Fields For The Treatment Of Advanced Non-Small Cell Lung Cancer After Failing Platinum-Based Therapy
2017-02-07,Novocure To Participate In The BIO 2017 CEO & Investor Conference
2017-01-24,Novocure To Participate In Noble Capital Markets' 13th Annual Investor Conference
2017-01-20,Johnson & Weaver, LLP Initiates Investigations Of Rent-A-Center, Inc., KalVista Pharmaceuticals, Inc., NovoCure Limited And Inotek Pharmaceuticals Corp.
2017-01-19,GNC Plummets, Mallinckrodt Regains Ground Ahead of Market's Open
2017-01-19,Novocure's Optune® Now Available At 500 Cancer Treatment Centers In The U.S.
2017-01-18,RSI Alert: NovoCure (NVCR) Now Oversold
2017-01-12,First Week of February 17th Options Trading For NovoCure (NVCR)
2017-01-10,Novocure Announces Preliminary Fourth Quarter And Full Year 2016 Operating Statistics
2017-01-10,Novocure To Report Fourth Quarter And Full Year 2016 Financial Results
2016-12-22,INVESTOR ALERT: Law Offices Of Howard G. Smith Commences Investigation On Behalf Of NovoCure Limited Investors
2016-12-21,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of NovoCure Limited (NVCR)
2016-12-19,Novocure's Optune® (NovoTTF-100A) Approved In Japan For The Treatment Of Newly Diagnosed Glioblastoma
2016-12-15,Novocure To Participate In 35th Annual J.P. Morgan Healthcare Conference
2016-12-12,Novocure Presents Second Cohort Of Phase 2 Pilot PANOVA Trial Results Suggesting Tumor Treating Fields Plus Nab-Paclitaxel And Gemcitabine May Be Safe As First-Line Treatment And May Improve One-Year Survival Rate Of Patients With Advanced Pancreatic Cancer
2016-12-12,Novocure Presents Phase 2 Pilot INNOVATE Trial Results Suggesting Tumor Treating Fields Plus Paclitaxel May Be Safe As First-Line Treatment And May Improve Survival Of Patients With Recurrent Ovarian Cancer
2016-12-08,Novocure Announces Agenda For Research And Development Day On Dec. 12, 2016
2016-11-22,First Week of January 2017 Options Trading For NovoCure (NVCR)
2016-11-18,Noteworthy Friday Option Activity: NVCR, VHC, TERP
2016-11-18,Long-Term Analysis Of All 695 Patients Enrolled In Novocure's Phase 3 Pivotal Trial In Newly Diagnosed Glioblastoma Confirms Successful Interim Analysis Results And Demonstrates Superior Two- And Four-Year Survival Rates
2016-11-17,Novocure Presents Interim STELLAR Results At IASLC Suggesting Treatment With Tumor Treating Fields Plus Chemotherapy May Extend Survival Of Patients With Mesothelioma
2016-11-14,Novocure Has Sponsored Pulitzer Prize-winning Author Dr. Siddhartha Mukherjee As The Keynote Speaker Of 21st Annual Scientific Meeting Of The Society For Neuro-Oncology On Nov. 19, 2016, In Scottsdale, Arizona. (Photo: Business Wire)
2016-11-11,Ratings Changes Today
2016-11-07,Novocure Announces 38 Presentations On Tumor Treating Fields At 21st Annual Scientific Meeting Of The Society Of Neuro-Oncology
2016-11-03,Noteworthy Thursday Option Activity: NVCR, TWLO, DHT
2016-11-03,United Healthcare Issues Positive Coverage Decision For Optune
2016-11-02,Novocure Reports Third Quarter 2016 Financial Results And Provides Company Update
2016-11-01,Novocure Recognizes National Family Caregivers Month By Supporting GBM Heroes Event
2016-10-12,Novocure Enrolls First Patient In Phase 3 Pivotal Brain Metastases Trial
2016-09-30,CORRECTING And REPLACING - Novocure To Report Third Quarter 2016 Financial Results
2016-09-30,Novocure To Report Third Quarter 2016 Financial Results
2016-09-19,CNS Oncology Publishes Tumor Treating Fields Treatment Planning And Patient Follow-up Guidelines In Glioblastoma
2016-09-15,Commit To Buy NovoCure At $7.50, Earn 31.9% Annualized Using Options
2016-09-15,Novocure's Executive Chairman William Doyle To Present On Tumor Treating Fields At New York Academy Of Sciences' Symposium On Bioelectronic Medicine
2016-09-14,Two Institutions Publish Independent Data On Novocure's Tumor Treating Fields
2016-09-12,Martin Romero Sanchez Of Houston, Texas, Is An Optune Patient.
2016-09-01,International Journal Of Cancer Publishes Data Showing Tumor Treating Fields In Combination With Paclitaxel Is Therapeutically Effective Against Ovarian Cancer Cells In Vitro And In Vivo
2016-09-01,'Mad Money' Lightning Round: I'm Staying With Potash
2016-08-31,Jim Cramer's 'Mad Money' Recap: Oil Regains Control of the Stock Market
2016-08-29,NovoCure is Now Oversold (NVCR)
2016-08-16,(Photo: Business Wire)
2016-08-10,Short Interest In NovoCure Moves 11.5% Lower
2016-08-08,Novocure To Present At Upcoming Investor Conferences
2016-07-28,NovoCure Enters Oversold Territory (NVCR)
2016-07-28,Novocure Reports Second Quarter 2016 Financial Results And Provides Company Update
2016-07-28,Novocure To Host Research And Development Day On Dec. 12, 2016
2016-07-26,NCCN Guidelines Recommend Optune As A Standard Treatment Option For Newly Diagnosed Glioblastoma
2016-07-13,Novocure's New System Aims To Make Optune Therapy Even Easier For Glioblastoma Patients. Actor Portrayal. (Photo: Business Wire)
2016-06-30,Novocure Announces $75 Million Drawdown Under Its Term Loan Agreement Through Pharmakon Advisors
2016-06-30,Novocure To Report Second Quarter 2016 Financial Results
2016-06-20,Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan
2016-06-18,'Mad Money' Lightning Round: Buy, Buy, Buy Edward Lifesciences
2016-06-08,Novocure To Present At JMP Securities 2016 Life Sciences Conference
2016-05-31,Novocure Receives IDE Approval To Initiate METIS Trial
2016-05-23,Novocure Enrolls Last Patient In PANOVA Trial Of Tumor Treating Fields Plus Chemotherapy In Advanced Pancreatic Cancer
2016-05-19,Novocure Enrolls Last Patient In INNOVATE Trial Testing Tumor Treating Fields Plus Paclitaxel In Recurrent Ovarian Cancer
2016-05-18,Novocure Announces Presentation Of Subgroup Analysis Of PANOVA Data Showing Overall Survival Benefit Of Tumor Treating Fields Plus Gemcitabine In Advanced Pancreatic Cancer Patients
2016-05-13,Novocure To Present New Preclinical Data Showing Additive Efficacy Of Tumor Treating Fields And PD-1 Inhibitors At The American Association Of Immunologists' Annual Meeting 2016
2016-05-12,Bill Doyle's Pershing Exit Adds to Disastrous Quarter for Bill Ackman
2016-05-11,Novocure Enters Into Employment Agreement With William Doyle
2016-05-09,Novocure Reports First Quarter 2016 Financial Results And Provides Company Update
2016-05-06,Novocure Kicks Off Brain Tumor Awareness Month With New Activities To Support And Inspire Those Affected By Glioblastoma
2016-05-05,Novocure Delivers New Informational Resource For Glioblastoma Brain Cancer
2016-05-04,Blue Cross Blue Shield Of Michigan Issues Positive Coverage Decision For Optune
2016-04-26,Novocure's Optune Now Available At More Than 360 Cancer Treatment Centers In The U.S.
2016-04-25,FDA Approves Investigational Device Exemption For RTOG Trial Of Novocure's Optune Together With Bevacizumab For Patients With Bevacizumab-Refractory Recurrent Glioblastoma
2016-04-07,Jim Cramer's 'Mad Money' Recap: Uncle Sam, Back Off Business!
2016-04-07,Novocure To Present New Preclinical Data On Tumor Treating Fields At American Association For Cancer Research Annual Meeting 2016
2016-04-05,Novocure To Report First Quarter 2016 Financial Results
2016-03-09,Red Journal Publishes Data Supporting Personalized Treatment Planning To Increase TTFields Efficacy For Patients With Glioblastoma
2016-03-03,Humana Issues Positive Coverage Decision For Optune
2016-02-29,Novocure Reports 2015 Operating Statistics And Financial Results
2016-02-23,Novocure To Present At Cowen And Company 36th Annual Health Care Conference
2016-02-22,Jim Cramer's 'Mad Money' Recap: This Week's Game Plan
2016-02-12,Anthem Inc. Issues Positive Coverage Decision For Optune In Newly Diagnosed Glioblastoma
2016-02-08,Novocure's Phase 3 Pivotal Trial Results In Newly Diagnosed Glioblastoma Selected For ASCO's Clinical Cancer Advances 2016 Report
2016-02-01,Novocure To Report Fourth Quarter, Year-End Financial Results
2016-01-19,Novocure Presents Phase 2 PANOVA Results At ASCO GI Suggesting Tumor Treating Fields Therapy Plus Chemotherapy May Be Safe As First-Line Treatment And Improve Survival Of Patients With Advanced Pancreatic Cancer
2016-01-11,Novocure Announces Preliminary 2015 Operating Statistics
2016-01-07,Novocure Submits PMA Partial Amendment Application To Japanese Pharmaceuticals And Medical Devices Agency For Treatment Of Newly Diagnosed Glioblastoma Patients
2016-01-07,Oversold Conditions For NovoCure (NVCR)
2016-01-06,Novocure Files Premarket Approval Supplement Application With FDA For Second Generation Optune System
2016-01-04,Novocure To Participate In 34th Annual J.P. Morgan Healthcare Conference
2015-12-18,5 Stocks Ready for Breakouts
2015-12-15,Novocure To Hold Webcast To Discuss JAMA Publication Of EF-14 Phase 3 Clinical Trial Data
2015-12-15,Journal Of The American Medical Association (JAMA) Publishes Pivotal Phase 3 Data For Optune Plus Temozolomide To Treat Newly Diagnosed Glioblastoma
2015-12-14,New Data On Tumor Treating Fields' Anti-Mitotic Mechanism Of Action Published In Scientific Reports
2015-12-08,5 Outperforming Stocks to Watch
2015-12-07,Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan
2015-12-05,Jim Cramer's Top Takeaways: Zoe's, Novocure, Ulta Salon, PVH
2015-12-03,Retrospective Analysis Shows Optune Safe In Glioblastoma Patients With Implanted Non-Programmable Shunts
2015-12-02,Preliminary Phase 2 Data Demonstrate Tumor Treating Fields Is Safe In Patients With Brain Metastases Originating From Non-Small Cell Lung Cancer
2015-11-20,New Phase 3 Data Show Optune In Combination With Second Line Chemotherapy Is Superior To Second Line Chemotherapy Alone In Glioblastoma Patients At First Recurrence
2015-11-17,Novocure Announces Webcast To Discuss New EF-14 Clinical Trial Analyses And Tumor Treating Fields Presentations From SNO 2015
2015-11-17,Novocure Announces 18 Presentations On Tumor Treating Fields At SNO 2015 Including New Analyses Of The EF-14 Newly Diagnosed Glioblastoma Clinical Trial Data
2015-10-26,Novocure Reports Third Quarter 2015 Operating And Financial Results
2015-10-23,'Mad Money' Lightning Round: I See Waste Management Rising to $60
2015-10-22,Jim Cramer's 'Mad Money' Recap: Surprises Turn Market on Its Head
2015-10-19,NovoCure Limited Announces Closing Of Partial Exercise Of IPO Over-Allotment Option
2015-10-16,Novocure To Offer On Demand Optune Certification Training For The Radiation Oncology Community At ASTRO 2015
2015-10-16,Novocure To Report Third Quarter 2015 Financial Results On Monday, October 26
2015-10-08,Jim Cramer's Top Takeaways: Alkermes, Yum! Brands, Novocure
2015-10-07,Jim Cramer's 'Mad Money' Recap: Watching China Warily, Again
2015-10-07,NovoCure Limited Announces Closing Of Initial Public Offering
2015-10-05,Optune Device (Photo: Business Wire)
2015-10-02,NovoCure Debuts on Nasdaq, Despite Weakness in IPO Market
2015-10-02,September Job Growth a Big Disappointment, U.S. Stocks Open Lower
2015-10-01,NovoCure Limited Announces Launch Of Initial Public Offering
,
,
2017-03-10,Ocera Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update
2017-03-08,Ocera To Announce Additional Encouraging Results From Its Phase 2b STOP-HE Study Of IV OCR-002 In Patients With Hepatic Encephalopathy
2017-02-28,Ocera To Present At The Cowen And Company 37th Annual Healthcare Conference
2017-02-17,Lifshitz & Miller LLP Announces Investigation Of Centrue Financial Corporation, Motorola Solutions, Inc., Natus Medical Incorporated, Northern Dynasty Minerals Ltd., Ocera Therapeutics, Inc., Psychemedics Corporation, RH And Stemline Therapeutics, Inc.
2017-02-02,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Ocera Therapeutics, Inc.
2017-01-30,Ocera Announces Top-line Results For Phase 2b Study In Hepatic Encephalopathy
2017-01-05,Ocera Announces Successful Phase 1 Clinical Study Of Orally-Administered OCR-002 In Patients With Cirrhosis
2016-12-07,Ocera Completes Enrollment Of STOP-HE, A Phase 2b Study Of OCR-002 In Hospitalized Patients With Hepatic Encephalopathy
2016-11-09,Ocera To Present At The Stifel 2016 Healthcare Conference
2016-11-02,Ocera Therapeutics Reports Third Quarter 2016 Financial Results And Company Update
2016-10-28,Ocera Therapeutics Appoints Biopharmaceutical Veteran Willard Dere, M.D. To Board Of Directors
2016-10-24,Ocera Therapeutics Announces Late-Breaker Abstract Accepted For Presentation At The AASLD Liver Meeting 2016
2016-10-10,Ocera To Present At The 2016 BIO Investor Forum
2016-09-21,Ocera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study Of OCR-002 In The Treatment Of Patients With Acute Liver Failure
2016-09-20,Ocera To Present At The Ladenburg Thalmann 2nd Annual Healthcare Conference
2016-09-19,Ocera Initiates Phase 1 Clinical Study Of Orally Available OCR-002 In Patients With Cirrhosis For The Prevention Of Hepatic Encephalopathy
2016-09-15,Ocera Announces Management Transition
2016-08-03,Ocera Therapeutics Reports Second Quarter 2016 Financial Results And Company Update
2016-06-13,Ocera To Present At The JMP Securities Life Sciences Conference
2016-05-31,Ocera To Present At The Jefferies 2016 Healthcare Conference
2016-05-26,Ocera To Present At The 2016 BIO International Convention
2016-04-29,Ocera Therapeutics Reports First Quarter 2016 Financial Results And Pipeline Progress
2016-04-15,Ocera Therapeutics Announces Presentation Of Two Preclinical Studies Further Supporting Its Ammonia Scavenger OCR-002 At The International Liver Congress™ 2016 Of The European Association For The Study Of The Liver (EASL)
2016-04-11,Ocera Therapeutics Announces Publication Of Promising Preclinical Data In Support Of Its Ammonia Scavenger OCR-002 In The Journal Of Hepatology
2016-04-05,Ocera To Present At The 15th Annual Needham Healthcare Conference
2016-03-03,Ocera Therapeutics Reports Fourth Quarter And Full Year 2015 Financial Results And Provides Corporate Update
2016-02-29,Ocera To Present At The Cowen And Company 36th Annual Health Care Conference
2016-02-02,Ocera To Present At The 18th Annual BIO CEO & Investor Conference
2016-01-08,Ocera Announces Complete Plasma Data From Pilot Phase 1 Study For Orally-Available OCR-002 In Development For The Prevention Of Chronic Hepatic Encephalopathy
2016-01-07,Ocera Appoints Dr. Stan Bukofzer As Chief Medical Officer
2015-11-17,Ocera (OCRX) Stock Rises on Positive Drug Trial Results
2015-11-16,Ocera Announces Positive Phase 1 Results For Oral OCR-002 In Development For The Prevention Of Chronic Hepatic Encephalopathy
2015-11-09,Ocera To Present At Stifel 2015 Healthcare Conference
2015-11-04,Ocera Therapeutics Reports Third Quarter 2015 Financial Results
2015-10-13,Ocera To Present At BIO Investor Forum 2015
2015-10-05,Ocera Therapeutics Highlights OCR-002 Data To Be Presented At The Annual Meeting Of The American Association For The Study Of Liver Diseases (AASLD)
2015-09-24,5 Stocks Under $10 Set to Soar
2015-09-16,Ocera Initiates Phase 1 Clinical Trial Of Oral Drug Candidate OCR-002 For Prevention Of Hepatic Encephalopathy
2015-09-01,Ocera To Present At The Rodman & Renshaw 17th Annual Global Investment Conference
2015-08-03,Ocera Therapeutics Reports Second Quarter 2015 Financial Results
2015-07-30,Ocera Therapeutics Secures $20 Million Debt Facility From Oxford Finance And Silicon Valley Bank
2015-06-25,Insider Trading Alert - SWHC, MTSI And OCRX Traded By Insiders
2015-06-16,Ocera Therapeutics To Present At The JMP Securities Life Sciences Conference
2015-05-29,Ocera Therapeutics To Present At The Jefferies 2015 Healthcare Conference
2015-05-07,Insider Trading Alert - DXCM, FDP And OCRX Traded By Insiders
2015-05-04,Ocera CEO To Be Honored At The 17th Annual American Liver Foundation's Salute To Excellence Awards Gala In San Francisco
2015-05-04,Ocera Therapeutics Announces Change In Executive Team
2015-04-30,Ocera Reports Pipeline Progress And First Quarter 2015 Financial Results
2015-04-22,Ocera Therapeutics To Report Pipeline Progress And First Quarter 2015 Financial Results
2015-04-01,Ocera Completes Interim Analysis Of OCR-002 In Phase 2b STOP-HE Study For The Treatment Of Acute Hepatic Encephalopathy
2015-03-11,Ocera Reports Fourth Quarter And Full Year 2014 Financial Results
2015-03-02,Ocera Therapeutics To Announce Fourth Quarter And Full Year 2014 Financial Results
2015-02-23,Ocera Therapeutics To Present At 35th Annual Cowen And Company Health Care Conference
2015-02-18,Ocera Announces Preliminary Topline Results From Phase 2a Investigator-Sponsored Study Of OCR-002
2014-12-03,Ratings Changes Today
2014-12-03,Ratings Changes Today
2014-12-03,Ocera Therapeutics Promotes Michael Byrnes To Chief Financial Officer
2014-11-13,Ocera Reports Third Quarter 2014 Financial Results
2014-11-10,Ocera Therapeutics To Present At Stifel 2014 Healthcare Conference
2014-11-04,Ocera Therapeutics To Announce Third Quarter 2014 Financial Results
2014-09-29,Ocera Therapeutics To Present At 13th Annual BIO Investor Forum
2014-09-18,Ocera Therapeutics Announces Appointment Of Steven P. James To Board
2014-08-11,Ocera Announces Appointment Of Rajiv Patni, M.D. As Chief Development Officer
2014-08-11,Ocera Reports Second Quarter 2014 Financial Results
2014-07-31,Ocera Therapeutics To Announce Second Quarter Financial Results
2014-07-10,Why Ocera Therapeutics (OCRX) Stock Is Plunging Today
2014-07-10,Ocera Therapeutics Raises $25.2 Million In Public Offering
2014-07-09,Ocera Therapeutics Announces Proposed Public Offering Of Common Stock
2014-06-17,Ocera Therapeutics To Present At The JMP Securities Healthcare Conference 2014
2014-05-21,Ocera Therapeutics To Present At The Jefferies 2014 Global Healthcare Conference
2014-05-08,Ocera Reports First Quarter Financial Results
2014-05-08,Ocera Therapeutics Becomes Oversold (OCRX)
2014-05-02,Ocera Therapeutics Announces Appointment Of Gaurav Aggarwal, M.D., As Chief Business Officer
2014-04-29,Ocera Therapeutics To Announce First Quarter Financial Results
2014-03-31,Oversold Conditions For Ocera Therapeutics (OCRX)
2014-03-13,Ocera Reports Fourth Quarter And Year-End 2013 Financial Results
2014-03-06,3 Stocks Rising on Big Volume
2014-03-04,Ocera Therapeutics To Announce Fourth Quarter And Year End Financial Results
2014-02-26,Ocera Therapeutics To Present At The Cowen And Company 34th Annual Health Care Conference
2014-02-19,5 Stocks Poised to Skyrocket Higher
2014-01-08,Ocera Therapeutics Announces Enrollment Of The First Patient In A Phase IIb Study For Treatment Of Acute Hepatic Encephalopathy
2013-12-24,Ocera Therapeutics Announces Election Of Wendell Wierenga To Board
2013-12-17,Ocera Therapeutics And The Roche Group Enter Into Technology Transfer And License Agreement
2013-12-11,Ocera Therapeutics Announces Staffing Transition
2013-11-26,Ocera Therapeutics To Present At Piper Jaffrey Healthcare Conference
2013-11-13,Ocera Reports Third Quarter Business Update And Financial Results
2013-11-06,Ocera Therapeutics Announces $28 Million Private Placement
2013-09-25,Ocera Therapeutics To Present At BIO Investor On October 8, 2013
2013-09-17,Ocera Announces Post-Merger Closure Of Quebec Research Site
2013-09-03,Jeryl L. Hilleman Joins Ocera Therapeutics As Chief Financial Officer
2013-08-13,Ocera Therapeutics Announces Second Quarter 2013 Financial Results
2013-07-26,Ocera Therapeutics To Report Second Quarter 2013 Financial Results
,
,
2017-03-15,New Publication Describes Positive Patient Experience In Study Of Ocular Therapeutix' DEXTENZA™ Following Cataract Surgery
2017-03-10,Ocular Therapeutix™ Reports Fourth Quarter And Full Year 2016 Financial Results
2017-03-08,Ocular Therapeutix™ To Report Fourth Quarter And Full Year 2016 Financial Results
2017-02-22,Ocular Therapeutix™ Announces FDA Acceptance Of NDA Resubmission For DEXTENZA™ For The Treatment Of Ocular Pain Occurring After Ophthalmic Surgery
2017-02-09,Ocular TherapeutixTM To Present At Three Upcoming Investor Conferences
2017-01-24,Relative Strength Alert For Ocular Therapeutix
2017-01-24,Ocular Therapeutix, Inc. Announces Pricing Of Public Offering Of Common Stock
2017-01-23,Ocular Therapeutix, Inc. Announces Public Offering Of Common Stock
2017-01-23,Ocular Therapeutix™ Resubmits NDA For DEXTENZA™ For The Treatment Of Ocular Pain Occurring After Ophthalmic Surgery
2017-01-04,Ocular Therapeutix™ Announces Additional Successful Results For Phase 3 Clinical Trial Of DEXTENZA™
2016-12-29,3 Small Biotechs With Insider Buying
2016-12-28,Ocular Therapeutix Stock Sees Short Interest Increase 16%
2016-11-14,Ocular Therapeutix™ Announces Successful Topline Results For Both Inflammation And Pain Primary Efficacy Endpoints From Phase 3 Clinical Trial Of DEXTENZA™
2016-11-10,Short Interest In Ocular Therapeutix Jumps 10.5%
2016-11-09,Ocular Therapeutix™ To Present At Two Upcoming Investor Conferences
2016-11-09,Ocular Therapeutix™ Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-11-02,Ocular Therapeutix™ To Hold Third Quarter 2016 Financial Results Conference Call On Wednesday, November 9, 2016
2016-10-20,Ocular Therapeutix™ Strengthens Management Team With The Appointment Of Andy Hurley As Chief Commercial Officer
2016-10-13,Ocular Therapeutix (OCUL) Stock Soars on Regeneron Deal
2016-10-13,Ocular Therapeutix™ Outlines Development Strategy For Its Sustained Release Intravitreal Depots To Address Serious Retinal Diseases
2016-10-13,Ocular Therapeutix™ And Regeneron Enter Into Strategic Collaboration To Develop Sustained Release Formulation Of Aflibercept For The Treatment Of Wet AMD And Other Serious Retinal Diseases
2016-10-04,Ocular Therapeutix™ Begins Enrollment In First Phase 3 Clinical Trial With OTX-TP (Sustained Release Travoprost) For The Treatment Of Glaucoma And Ocular Hypertension
2016-09-13,Lifshitz & Miller Law Firm Announces Investigation Of AECOM, American Farmland Company, Centene Corp., Cepheid, Cray Inc., Echo Global Logistics, Inc., Ocular Therapeutix, Inc., And Pure Storage, Inc.
2016-09-13,Short Interest Increases 16.4% For OCUL
2016-08-31,Ocular Therapeutix™ To Participate In The Morgan Stanley Global Healthcare Conference
2016-08-09,Today's Weak On High Volume Stock: Ocular Therapeutix (OCUL)
2016-08-09,Ocular Therapeutix™ Reports Second Quarter 2016 Financial Results And Provides Corporate Update
2016-08-05,These 7 Stocks Under $10 Are Making Big Moves Higher
2016-08-05,Ocular Therapeutix™ Announces Presentation At The Ophthalmology Innovation Summit (OIS) At The American Society Of Retina Specialists (ASRS)
2016-08-04,Ocular Therapeutix (OCL) Stock Soars, FDA: Corrective Actions Address Concerns
2016-08-03,Ocular Therapeutix™ Provides Update On NDA For DEXTENZA™ For The Treatment Of Post-Surgical Ocular Pain
2016-08-02,Ocular Therapeutix™ To Report Second Quarter 2016 Financial Results
2016-08-01,IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Ocular Therapeutix, Inc. And Advises Investors With Losses To Contact The Firm
2016-07-27,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Regarding Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of Ocular Therapeutix Inc.
2016-07-25,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Ocular Therapeutix, Inc. (OCUL)
2016-07-25,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Ocular Therapeutix, Inc. - OCUL
2016-07-25,Ocular Therapeutix™ Receives Complete Response Letter From FDA For Its NDA For DEXTENZA™ For The Treatment Of Post-Surgical Ocular Pain
2016-07-13,Ocular Therapeutix Enters Oversold Territory (OCUL)
2016-07-12,Ocular Therapeutix (OCUL) Stock: Weak On High Volume Today
2016-07-06,Ocular Therapeutix™ To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference
2016-06-27,Ocular Therapeutix Stock Sees Short Interest Fall 17.3%
2016-06-06,Noteworthy Monday Option Activity: OCUL, MED, MGM
2016-06-06,Stocks at Session Highs as Crude Closes Near $50
2016-06-06,Why Ocular Therapeutix (OCUL) Stock Is Tanking Today
2016-06-06,Ocular Therapeutix is Now Oversold (OCUL)
2016-06-06,Stocks Hover Near Session Highs Ahead of Yellen Speech
2016-06-06,Stock Futures Inch Higher as Wall Street Awaits Yellen
2016-06-06,Ocular Therapeutix™ Announces Topline Results Of Second Phase 3 Clinical Trial Of DEXTENZA™ For The Treatment Of Allergic Conjunctivitis
2016-06-02,Ocular Therapeutix™ To Present At Two Upcoming Investor Conferences
2016-05-10,Ocular Therapeutix™ Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-05-03,Ocular Therapeutix™ To Report First Quarter 2016 Financial Results
2016-04-27,Ocular TherapeutixTM Completes End-of-Phase 2 Review With FDA For OTX-TP (Sustained Release Travoprost) For Glaucoma And Ocular Hypertension
2016-04-22,4 Biotech Stocks You Should Be Watching Right Now
2016-04-21,Commit To Purchase Ocular Therapeutix At $12.50, Earn 41.5% Annualized Using Options
2016-04-16,3 Biotech Stocks With Charts to Watch -- And One Bonus Stock!
2016-03-30,7 Stocks Under $10 to Trade for Breakout Gains
2016-03-28,Ocular TherapeutixTM To Host Investor Day On April 6, 2016
2016-03-18,These 7 Stocks Under $10 Are Set to Soar Higher
2016-03-10,Ocular TherapeutixTM Reports Fourth Quarter And Full Year 2015 Financial Results
2016-03-02,Ocular Therapeutix™ To Report Fourth Quarter And Full Year 2015 Financial Results
2016-02-18,Trade-Ideas: Ocular Therapeutix (OCUL) Is Today's Weak On High Relative Volume Stock
2016-02-18,Ocular TherapeutixTM To Present At Two Upcoming Investor Conferences
2016-02-17,One Reason Why Ocular (OCUL) Stock is Advancing Today
2016-02-16,Ocular Therapeutix™ Announces Phase 3 Clinical Development Plan For OTX-TP, An Innovative Therapy For Glaucoma And Ocular Hypertension
2016-02-12,Ocular Therapeutix is Now Oversold (OCUL)
2016-01-11,Ocular TherapeutixTM Strengthens Executive Management Team With The Appointment Of Highly Regarded Ophthalmologist Jonathan H. Talamo, M.D., As Chief Medical Officer
2015-12-18,4 Biotech Stocks Under $10 Poised for Big Breakouts
2015-12-14,Ocular Therapeutix™ Announces Encouraging Top-Line Results From Exploratory Phase 2 Trial For DEXTENZA™ In Patients With Inflammatory Dry Eye Disease
2015-12-09,Ocular Therapeutix™ Announces FDA Acceptance Of NDA Filing For DEXTENZA™ For The Treatment Of Post-Surgical Ocular Pain
2015-11-24,Ocular Therapeutix™ To Present At The Piper Jaffray 27th Annual Healthcare Conference
2015-11-24,Ocular Therapeutix™ Begins Enrollment In Its Second Phase 3 Clinical Trial For DEXTENZA™ For The Treatment Of Allergic Conjunctivitis
2015-11-10,Ocular Therapeutix™ Reports Third Quarter 2015 Financial Results
2015-11-09,Ocular Therapeutix™ Expands Its Board Of Directors With The Election Of Industry Leader W. James O'Shea
2015-11-03,Ocular Therapeutix™ To Report Third Quarter 2015 Financial Results
2015-10-28,Ocular Therapeutix™ To Participate In Three Conferences In November 2015
2015-10-28,5 Biotech Stocks Under $10 Triggering Breakout Trades
2015-10-23,Ocular Therapeutix is Now Oversold (OCUL)
2015-10-22,Ocular TherapeutixTM Reports On Topline Results Of Phase 2b Glaucoma Clinical Trial
2015-10-22,Ocular Therapeutix™ Announces Topline Results Of Phase 3 Clinical Trial For DEXTENZA™ For The Treatment Of Allergic Conjunctivitis
2015-10-14,Ocular Therapeutix™ Begins Enrollment In Third Phase 3 Clinical Trial For DEXTENZA™ for The Treatment Of Post-Surgical Ocular Inflammation And Pain
2015-09-28,Ocular Therapeutix™ Submits New Drug Application To U.S. Food And Drug Administration For DEXTENZA® For The Treatment Of Post-Surgical Ocular Pain
2015-09-23,5 Stocks Insiders Love Right Now
2015-09-14,Ocular Therapeutix Expands Its Board Of Directors With The Appointment Of Renowned Retinal Specialist Jeffrey S. Heier, M.D.
2015-09-03,Ocular Therapeutix™ To Participate In Two Investor Conferences In September 2015
2015-08-26,Ratings Changes Today
2015-08-20,Commit To Purchase Ocular Therapeutix At $15, Earn 33.5% Annualized Using Options
2015-08-11,Oversold Conditions For Ocular Therapeutix (OCUL)
2015-08-10,Ocular Therapeutix™ Reports Second Quarter 2015 Financial Results
2015-08-03,Ocular Therapeutix™ To Report Second Quarter 2015 Financial Results
2015-07-14,Market News: Micron Technology, SeaSpine Holdings, Ocular Therapeutix
2015-07-02,RSI Alert: Ocular Therapeutix (OCUL) Now Oversold
2015-06-30,Ocular Therapeutix™ To Participate At The Cantor Fitzgerald Inaugural Healthcare Conference
2015-06-26,5 Stocks Ready for Breakouts
2015-06-16,Ocular Therapeutix™ Begins Enrollment In Phase 3 Clinical Trial For DEXTENZA™ For The Treatment Of Allergic Conjunctivitis
2015-06-04,Ocular Therapeutix, Inc. Announces Pricing Of Public Offering Of Common Stock
2015-06-02,Ocular Therapeutix, Inc. Announces Proposed Public Offering Of Common Stock
2015-05-15,Ocular TherapeutixTM Announces Plans To Proceed With An NDA Submission For OTX-DP For Treatment Of Post-Surgical Ocular Pain Indication; Reports First Quarter 2015 Financial Results
2015-05-06,Ocular Therapeutix™ To Report First Quarter 2015 Financial Results
2015-05-01,Ocular Therapeutix To Present Eight Posters Highlighting Its Sustained Release Hydrogel Platform Technology At The Association For Research In Vision And Ophthalmology Annual Meeting
2015-04-07,Ocular Therapeutix Enters Oversold Territory (OCUL)
2015-04-06,Ocular Therapeutix Eye-Pain Plug Flops Confirmatory Pivotal Trial
2015-04-06,Ocular Therapeutix™ Reports Topline Clinical Data For Its Second Phase 3 Clinical Trial Evaluating OTX-DP For The Treatment Of Post-Surgical Ocular Inflammation And Pain
2015-03-10,Ocular Therapeutix Eye-Pain Plug Benefits Still Unclear
2015-03-10,Ocular Therapeutix™ Reports Fourth Quarter And Full Year 2014 Financial Results
2015-03-10,Ocular Therapeutix™ Reports Positive Topline Clinical Data For The First Of Two Phase 3 Clinical Trials Evaluating OTX-DP For The Treatment Of Post-Surgical Ocular Inflammation And Pain
2015-03-03,Ocular Therapeutix™ To Report Fourth Quarter And Full Year 2014 Financial Results
2015-02-19,Ocular Therapeutix™ To Participate In Two Upcoming Investor Conferences
2015-02-05,14 IPOs You Wish You Bought in 2014 (and Made a Killing On)
2015-02-04,Ocular Therapeutix™ To Present At The 17th Annual BIO CEO & Investor Conference
2015-01-21,Ocular Therapeutix™ Enrolls First Patient In Phase 2 Clinical Trial For Sustained Release Dexamethasone For The Treatment Of Dry Eye Disease
2014-12-02,Ocular Therapeutix™ To Present At Oppenheimer 25th Annual Healthcare Conference
2014-11-12,Ocular Therapeutix™ Reports Third Quarter 2014 Financial Results
2014-11-12,Ocular Therapeutix™ Enrolls First Patients In Phase 2b Clinical Trial For Sustained Release Travoprost For The Treatment Of Glaucoma And Ocular Hypertension
2014-11-12,Ocular Therapeutix™ Announces Top-Line Results From Phase 2 Sustained Release Dexamethasone Trial For Allergic Conjunctivitis
2014-11-05,Ocular Therapeutix™ To Report Third Quarter 2014 Financial Results And Provide Business Updates On Wednesday, November 12, 2014
2014-10-31,Ocular Therapeutix™ To Participate In Two Investor Conferences In November 2014
2014-10-14,Ocular Therapeutix™ To Attend American Academy Of Ophthalmology Annual Meeting In Chicago, Illinois
2014-10-08,Ocular Therapeutix™ Completes Enrollment In Phase 3 Sustained Release Dexamethasone Trials For Post-Operative Inflammation And Pain
2014-09-16,Ocular Therapeutix To Present At The 21st Annual NewsMakers In The Biotech Industry Investment Conference On Friday, September 26
2014-09-03,Ocular Therapeutix To Present At Morgan Stanley 2014 Global Healthcare Conference
2014-08-28,Ocular Therapeutix Announces Second Quarter 2014 Financial Results
2014-08-19,Ocular Therapeutix Announces Exercise Of Over-Allotment Option
2014-07-30,Ocular Therapeutix Announces Closing Of Initial Public Offering
,
2017-03-08,Achieve Life Sciences And OncoGenex Pharmaceuticals Announce Cytisine Symposium At The Annual Society For Research In Nicotine And Tobacco Conference ("SRNT")
2017-03-01,Achieve Life Science And OncoGenex Pharmaceuticals Announce Strategic Collaboration With The National Institutes Of Health To Advance The Development Of Cytisine For Smoking Cessation
2017-02-21,OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data For Two Clinical Trials Presented At The American Society Of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium
2017-02-16,OncoGenex To Report Year End 2016 Financial Results On Feb. 23, 2017
2017-01-26,Research Reports Coverage On Biotech Stocks -- OncoGenex Pharma, INSYS Therapeutics, Threshold Pharma, And AmpliPhi Biosciences
2017-01-05,OncoGenex Pharmaceuticals, Inc. And Achieve Life Science, Inc. Announce Definitive Merger Agreement
2016-11-15,Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive
2016-11-03,OncoGenex To Report Third Quarter 2016 Financial Results On Nov. 10, 2016
2016-10-25,OncoGenex Announces Positive Survival Results From Apatorsen Phase 2 Borealis-2™ Trial In Metastatic Bladder Cancer
2016-10-13,OncoGenex Announces Results From The Phase 3 ENSPIRIT Trial Of Custirsen In Non-Small Cell Lung Cancer
2016-08-16,OncoGenex Announces Results From The Phase 3 AFFINITY Trial Of Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
2016-07-21,OncoGenex To Report Second Quarter 2016 Financial Results On August 4, 2016
2016-04-28,OncoGenex To Report First Quarter 2016 Financial Results On May 12, 2016
2016-04-25,8 Breakout Stocks Under $10 to Trade for Big Profits
2016-04-05,OncoGenex Pharmaceuticals To Present At The 15th Annual Needham Healthcare Conference
2016-02-24,OncoGenex To Report Fourth Quarter And Year End 2015 Financial Results On March 9, 2016
2016-02-04,OncoGenex Announces Reduction In Force To Extend Cash Runway And Align Operations With Clinical Development Priorities
2016-01-20,OncoGenex Announces Update On Phase 2 Spruce Trial In Previously Untreated Metastatic Non-Small Cell Lung Cancer
2016-01-06,4 Stocks Under $10 to Trade for Big Breakouts
2015-12-09,OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion Of Futility Analysis
2015-12-01,OncoGenex Announces Phase 3 AFFINITY Trial With Custirsen Continues Following Interim Analyses
2015-11-05,OncoGenex Pharmaceuticals To Present At The Stifel 2015 Healthcare Conference
2015-10-29,OncoGenex To Report Third Quarter 2015 Financial Results On November 12, 2015
2015-10-08,OncoGenex Announces EMA Support For Phase 3 AFFINITY Trial Protocol Amendment
2015-09-30,OncoGenex Announces Completion Of Patient Enrollment In Borealis-2™ Clinical Trial Evaluating Apatorsen In Relapsed Or Refractory Metastatic Bladder Cancer
2015-09-28,OncoGenex Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels In Metastatic Prostate Cancer Patients; Low Levels Correlate With Improved Survival In Those At Increased Risk For Poor Outcomes
2015-09-23,OncoGenex Announces Phase 2 Rainier Results In Previously Untreated Metastatic Pancreatic Cancer
2015-08-31,OncoGenex Pharmaceuticals (OGXI) Is Today's Strong On High Volume Stock
2015-07-30,OncoGenex To Report Second Quarter 2015 Financial Results On August 13, 2015
2015-07-29,OncoGenex Pharmaceuticals (OGXI) Weak On High Volume Today
2015-07-13,OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Continues Following Completion Of Final Futility Survival Analysis
2015-06-12,Revisiting 2 Little Biotech Gems
2015-06-10,FDA Agrees With OncoGenex' Phase 3 AFFINITY Protocol Amendment
2015-06-01,OncoGenex Announces Data From Borealis-1™ Trial Showing Clinical Benefit With Apatorsen In Metastatic Bladder Cancer
2015-05-30,OncoGenex Announces Data From The Phase 3 SYNERGY Trial Showing A Survival Benefit With Custirsen In Patients With Poor Prognosis
2015-05-20,OncoGenex Announces Data To Be Presented At ASCO 2015 Annual Meeting
2015-05-04,OncoGenex To Report First Quarter 2015 Financial Results On May 14, 2015
2015-04-30,OncoGenex Announces Share Purchase Agreement With Lincoln Park Capital Fund, LLC
2015-04-30,OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Update
2015-04-27,OncoGenex Regains Rights To Custirsen From Teva
2015-04-09,OncoGenex Pharmaceuticals To Present At The 14th Annual Needham Healthcare Conference
2015-03-23,OncoGenex To Report Financial Results For Fourth Quarter And Year End 2014 On March 26, 2015
2015-02-24,OncoGenex And Sarah Cannon Announce Completion Of Patient Enrollment In The Spruce™ Clinical Trial Evaluating Apatorsen In Combination With Carboplatin And Pemetrexed In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
2015-02-20,Small-Cap Friday's Little Gem
2015-02-12,OncoGenex Announces Relocation Of Corporate Headquarters, Expected To Yield Savings Of At Least $4 Million Over Next Three Years
2015-01-16,OncoGenex Announces Update On Phase 3 AFFINITY Trial Evaluating Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
2014-12-30,OncoGenex To Regain Rights To Custirsen From Teva
2014-12-19,OncoGenex Announces Results From The Phase 2 Borealis-1™ Trial Of Apatorsen In The Treatment Of Metastatic Bladder Cancer
2014-12-16,OncoGenex Announces Completion Of Patient Enrollment In The Rainier™ Clinical Trial Evaluating Apatorsen In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer
2014-12-12,5 Stocks Poised for Breakouts: Trulia and More
2014-11-17,OncoGenex Pharmaceuticals To Present At The Stifel 2014 Healthcare Conference
2014-10-29,Some Of Soros' Stocks Surged Today, While Others Soured
2014-10-16,OncoGenex To Report Financial Results For Third Quarter 2014 On October 30, 2014
2014-09-18,5 Stocks Under $10 to Trade for Breakouts
2014-09-16,OncoGenex Announces Completion Of Patient Enrollment In The Phase 3 AFFINITY Trial Of Custirsen In Combination With Cabazitaxel/Prednisone As Second-line Chemotherapy In Men With Metastatic Castrate-Resistant Prostate Cancer
2014-08-27,4 Under-$10 Biotech Stocks in Breakout Territory
2014-08-21,OncoGenex Announces Update On Phase 3 ENSPIRIT Trial Evaluating Custirsen In Advanced Non-Small Cell Lung Cancer
2014-08-08,4 Stocks Under $10 Making Big Moves
2014-08-07,OncoGenex Pharmaceuticals Announces Appointment Of John A. Bencich As Vice President And Chief Financial Officer
2014-07-24,OncoGenex To Report Financial Results For Second Quarter 2014 On August 7, 2014
2014-07-01,OncoGenex Announces Cedar™ Clinical Trial Evaluating Apatorsen In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer Is Now Open For Enrollment
2014-06-26,OncoGenex Pharmaceuticals Announces Pricing Of $24 Million Underwritten Registered Direct Offering
2014-05-06,The Feuerstein-Ratain Rule Update: Still Perfect Predicting Small-Cap Cancer Drug Failure
2014-05-01,5 Stocks Under $10 Set to Soar
2014-04-28,Why OncoGenex (OXGI) Stock Hit a One-Year Low Today
2014-04-28,OncoGenex To Report Financial Results For First Quarter 2014 On April 30, 2014
2014-04-28,OncoGenex Announces Top-Line Survival Results Of Phase 3 SYNERGY Trial Evaluating Custirsen For Metastatic Castrate-Resistant Prostate Cancer
2014-04-28,Teva And OncoGenex Announce Top-Line Survival Results Of Phase III SYNERGY Trial Evaluating Custirsen In Combination With First-line Docetaxel And Prednisone For Metastatic Castrate-Resistant Prostate Cancer
2014-04-23,OncoGenex Announces Fast Track Designation Granted For Custirsen In Combination With Cabazitaxel/Prednisone As Second-line Chemotherapy In Phase 3 AFFINITY Trial Of Men With Metastatic Castrate-Resistant Prostate Cancer
2014-03-06,3 Big-Volume Stocks in Breakout Territory
2014-02-25,OncoGenex To Report Financial Results For Fourth Quarter And Year-Ended 2013 On March 11, 2014
2014-02-21,Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!
2014-02-11,OncoGenex Announces Target Number Of Events Reached In Phase 3 SYNERGY Trial Of Custirsen In Metastatic Castrate-Resistant Prostate Cancer
2014-02-06,OncoGenex To Present At Leerink Global Healthcare Investor Conference
2013-11-19,OncoGenex Announces Update On Phase 3 SYNERGY Trial Evaluating Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
2013-11-05,OncoGenex To Present At Credit Suisse Healthcare Investor Conference
2013-10-30,OncoGenex To Report Financial Results For Third Quarter 2013 And Address Key Questions From Investors On November 7, 2013
2013-10-25,Biotech Stock Mailbag: Vanda, Onconova, Catalyst Pharma, Sarepta
2013-10-21,Oversold Conditions For OncoGenex Pharmaceuticals (OGXI)
2013-08-29,OncoGenex Announces That The Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer Is Now Open For Enrollment
2013-08-27,OncoGenex Announces That The Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer Is Now Open For Enrollment
2013-08-15,OncoGenex Pharmaceuticals Getting Very Oversold (OGXI)
2013-08-07,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2013-08-01,OncoGenex Announces That The Spruce™ Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Non-Squamous Non-Small Cell Lung Cancer Is Now Open For Enrollment
2013-07-30,OncoGenex To Webcast Discussion Of Clinical Development Program And Second Quarter 2013 Financial Results On August 8, 2013
2013-07-16,OncoGenex Announces Completion Of Patient Enrollment In The Borealis-1™ Trial Of OGX-427 In Metastatic Bladder Cancer
2013-06-20,Commit To Purchase OncoGenex Pharmaceuticals At $7.50, Earn 14.9% Annualized
2013-05-28,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2013-05-23,OncoGenex Announces Plans For The Initiation Of The Cedar™ Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer
2013-05-22,OncoGenex Announces Multiple 'Trials In Progress' Presentations At The 2013 ASCO Annual Meeting
2013-05-01,OncoGenex Pharmaceuticals Becomes Oversold (OGXI)
2013-05-01,OncoGenex Announces Plans For The Initiation Of The Rainier™ Clinical Trial Evaluating OGX-427 In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer
2013-04-30,OncoGenex Announces That The Borealis-2™ Clinical Trial Of OGX-427 In Previously Treated Metastatic Bladder Cancer Is Now Open For Enrollment
2013-04-25,OncoGenex To Webcast Discussion Of Clinical Development Program And First Quarter 2013 Financial Results On May 2, 2013
2013-04-23,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2013-04-11,OncoGenex Announces Plans For The Initiation Of The Spruce™ Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Non-Squamous Non-Small Cell Lung Cancer
2013-03-28,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2013-02-28,OncoGenex To Webcast Update On Clinical Development Program And Discussion Of Fourth Quarter And Full Year 2012 Financial Results On Thursday, March 7, 2013
2013-02-12,OncoGenex Announces Plans For The Initiation Of The Borealis-2 Clinical Trial Evaluating OGX-427 In Combination With Second-Line Therapy For Bladder Cancer
2013-02-05,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conferences
2012-12-19,OncoGenex Announces Initiation Of Randomized Phase 2 "PACIFIC" Study Of OGX-427 In Combination With Zytiga® In Men With Metastatic Castrate-Resistant Prostate Cancer
2012-11-09,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2012-11-06,OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
2012-10-30,OncoGenex To Webcast Discussion Of Third Quarter 2012 Financial Results On Thursday, November 8, 2012
2012-09-27,OncoGenex Announces Initiation Of A Phase 3 Trial For Custirsen In Advanced Non-Small Cell Lung Cancer
2012-08-28,OncoGenex Pharmaceuticals To Present At Two Upcoming Investor Conferences
2012-08-07,OncoGenex Announces Initiation Of The Phase 3 "AFFINITY" Trial For Patients With Advanced Prostate Cancer
2012-07-25,OncoGenex To Webcast Discussion Of Second Quarter 2012 Financial Results On Thursday, August 2, 2012
2012-07-10,OncoGenex Announces Clinical Development Plans For Custirsen In Non-Small Cell Lung Cancer
2012-06-04,Data From A Phase 2 Study Presented At The 2012 ASCO Annual Meeting Continues To Show Early Activity Of OGX-427 In Patients With Prostate Cancer
2012-03-27,OncoGenex Pharmaceuticals To Present At Two Upcoming Investor Conferences
2012-03-23,OncoGenex Pharmaceuticals, Inc. Announces Full Exercise Of Overallotment Option By Underwriters
2012-03-16,OncoGenex Stock Gaps Down On Today's Open (OGXI)
2012-03-16,OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
2012-03-15,OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering Of Common Stock
2012-03-08,Teva And OncoGenex Announce Updates To Custirsen Development Program In Advanced Prostate Cancer
2012-02-28,OncoGenex To Webcast Discussion Of Fourth Quarter 2011 Financial Results On Thursday, March 8, 2012
2012-02-27,OncoGenex Announces Data Highlighting OGX-427 At 27th Annual European Association Of Urology Congress
2012-02-07,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conferences
2012-02-02,Clinical Data On OGX-427 Presented At The ASCO 2012 Genitourinary Cancers Symposium Provide Ongoing Evidence Of Hsp27 As A Potential Therapeutic Target In Advanced Prostate Cancer
2012-02-02,Phase 1 Study Of OGX-427 Presented At The ASCO 2012 Genitourinary Cancers Symposium Shows Early Evidence Of Activity In Bladder Cancer
2012-01-04,OncoGenex Announces Publication Of Phase I/II Custirsen (OGX-011/TV-1011) Data In Journal Of Thoracic Oncology
2011-11-07,Edison Expands Oncology Sector Presence With Launch Of Research Coverage On OncoGenex Pharmaceuticals
2011-10-26,OncoGenex Announces Publication Of OGX-427 Pre-Clinical Data In Pancreatic Cancer
2011-10-20,OncoGenex Pharmaceuticals Initiates An International, Randomized, Phase II Clinical Trial Evaluating OGX-427 In Advanced Bladder Cancer
2011-10-18,OncoGenex To Webcast Discussion Of Third Quarter Financial Results On Thursday, November 3, 2011
2011-09-19,OncoGenex Announces Completion Of A Special Protocol Assessment (SPA) Amendment With The FDA Increasing Patient Eligibility For The Custirsen Phase III Prostate Cancer SATURN Clinical Trial
2011-09-15,OncoGenex Pharmaceuticals To Present At UBS Global Life Sciences Conference
2011-09-06,OncoGenex Announces Publication Of Custirsen Phase II Clinical And Pre-Clinical Data In Leading Cancer Journals
2011-09-01,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conferences
2011-08-10,OncoGenex To Present At The 2011 Wedbush Securities Life Sciences Management Access Conference
2011-07-28,OncoGenex To Webcast Discussion Of Second Quarter Financial Results On Thursday, August 4, 2011
2011-06-28,OncoGenex Pharmaceuticals Added To Russell Indexes
2011-06-07,10 Health-Care Stocks Outperforming the Index
2011-06-06,Data From Pre-Clinical Studies Presented At The 2011 ASCO Annual Meeting Show Potential Combinability Of Custirsen With MDV3100 And Hsp90 Inhibitors To Enhance Anti-Tumor Activity In Prostate Cancer
2011-05-19,Teva And OncoGenex To Present Data On Custirsen In Prostate Cancer At The 2011 ASCO Annual Meeting
2011-05-17,OncoGenex To Present At The UBS Global Specialty Pharmaceuticals Conference
2011-05-05,9 Health Care Stocks With 100% Buy Ratings
2011-05-02,OncoGenex To Webcast Discussion Of First Quarter Financial Results On Monday, May 9, 2011
2011-04-14,OncoGenex Pharmaceuticals Announces Issuance Of Key European Patent For OGX-427
2011-04-06,Teva And OncoGenex Present Preclinical Data On The Activity Of Its Antisense Compound Custirsen (OGX-011/TV-1011) At The American Association Of Cancer Research (AACR) Annual Meeting 2011
2011-04-04,OncoGenex Announces Data Highlighting OGX-427 At American Association Of Cancer Research (AACR) 102nd Annual Meeting 2011
2011-03-29,OncoGenex To Present At The Needham & Company 10th Annual Healthcare Conference
2011-03-07,OncoGenex To Webcast Discussion Of Fourth Quarter And Full Year 2010 Financial Results On Thursday, March 10, 2011
2011-02-28,OncoGenex Pharmaceuticals To Participate In Panel Discussion On Novel Cancer Treatments At RBC Capital Markets Healthcare Conference
2011-02-25,Biotech Stock Mailbag: Exact Sciences
2011-02-14,BIO CEO Conference Live Blog
2010-10-19,10 Biotech Stocks Expected to at Least Double
2010-10-11,10 Stocks Expected to Double Amid QE2
2010-05-10,OncoGenex Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript
2010-01-11,Looking for a Down Day
2009-12-21,OncoGenex Slammed on Teva Partnership: BioBuzz
2009-12-21,Teva, OncoGenex Sign Drug Development Deal
2009-12-21,Isis Pharmaceuticals To Receive $10 Million From OncoGenex' License Of OGX-011 To Teva
2009-10-20,Galleon's Biotech Stock Holdings: BioBuzz
2009-10-06,OncoGenex Prostate Cancer Drug Gets Special Review
2009-09-21,Movers Roundup: LivePerson, Tenneco
2009-09-21,OncoGenex Shares Rise On RBC Analyst Outlook
2009-08-25,Movers Roundup: FreightCar America, OncoGenex
2009-08-25,OncoGenex Hits Year High On 'Overweight' Rating
2009-07-10,J&J Finishes Cougar Biotech Deal
2009-05-30,OncoGenex Prostate Drug Extends Survival
2009-05-28,Small-Cap Biotechs Pop Before Conference
2009-05-22,J&J Just Made Medivation's Day
2009-05-22,Biotech Stock Mailbag: Gilead Still Got It?
2009-05-20,Tiny Biotechs Dancing in the Bull Pen
2017-03-08,Achieve Life Sciences And OncoGenex Pharmaceuticals Announce Cytisine Symposium At The Annual Society For Research In Nicotine And Tobacco Conference ("SRNT")
2017-03-01,Achieve Life Science And OncoGenex Pharmaceuticals Announce Strategic Collaboration With The National Institutes Of Health To Advance The Development Of Cytisine For Smoking Cessation
2017-02-21,OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data For Two Clinical Trials Presented At The American Society Of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium
2017-02-16,OncoGenex To Report Year End 2016 Financial Results On Feb. 23, 2017
2017-01-26,Research Reports Coverage On Biotech Stocks -- OncoGenex Pharma, INSYS Therapeutics, Threshold Pharma, And AmpliPhi Biosciences
2017-01-05,OncoGenex Pharmaceuticals, Inc. And Achieve Life Science, Inc. Announce Definitive Merger Agreement
2016-11-15,Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive
2016-11-03,OncoGenex To Report Third Quarter 2016 Financial Results On Nov. 10, 2016
2016-10-25,OncoGenex Announces Positive Survival Results From Apatorsen Phase 2 Borealis-2™ Trial In Metastatic Bladder Cancer
2016-10-13,OncoGenex Announces Results From The Phase 3 ENSPIRIT Trial Of Custirsen In Non-Small Cell Lung Cancer
2016-08-16,OncoGenex Announces Results From The Phase 3 AFFINITY Trial Of Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
2016-07-21,OncoGenex To Report Second Quarter 2016 Financial Results On August 4, 2016
2016-04-28,OncoGenex To Report First Quarter 2016 Financial Results On May 12, 2016
2016-04-25,8 Breakout Stocks Under $10 to Trade for Big Profits
2016-04-05,OncoGenex Pharmaceuticals To Present At The 15th Annual Needham Healthcare Conference
2016-02-24,OncoGenex To Report Fourth Quarter And Year End 2015 Financial Results On March 9, 2016
2016-02-04,OncoGenex Announces Reduction In Force To Extend Cash Runway And Align Operations With Clinical Development Priorities
2016-01-20,OncoGenex Announces Update On Phase 2 Spruce Trial In Previously Untreated Metastatic Non-Small Cell Lung Cancer
2016-01-06,4 Stocks Under $10 to Trade for Big Breakouts
2015-12-09,OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion Of Futility Analysis
2015-12-01,OncoGenex Announces Phase 3 AFFINITY Trial With Custirsen Continues Following Interim Analyses
2015-11-05,OncoGenex Pharmaceuticals To Present At The Stifel 2015 Healthcare Conference
2015-10-29,OncoGenex To Report Third Quarter 2015 Financial Results On November 12, 2015
2015-10-08,OncoGenex Announces EMA Support For Phase 3 AFFINITY Trial Protocol Amendment
2015-09-30,OncoGenex Announces Completion Of Patient Enrollment In Borealis-2™ Clinical Trial Evaluating Apatorsen In Relapsed Or Refractory Metastatic Bladder Cancer
2015-09-28,OncoGenex Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels In Metastatic Prostate Cancer Patients; Low Levels Correlate With Improved Survival In Those At Increased Risk For Poor Outcomes
2015-09-23,OncoGenex Announces Phase 2 Rainier Results In Previously Untreated Metastatic Pancreatic Cancer
2015-08-31,OncoGenex Pharmaceuticals (OGXI) Is Today's Strong On High Volume Stock
2015-07-30,OncoGenex To Report Second Quarter 2015 Financial Results On August 13, 2015
2015-07-29,OncoGenex Pharmaceuticals (OGXI) Weak On High Volume Today
2015-07-13,OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Continues Following Completion Of Final Futility Survival Analysis
2015-06-12,Revisiting 2 Little Biotech Gems
2015-06-10,FDA Agrees With OncoGenex' Phase 3 AFFINITY Protocol Amendment
2015-06-01,OncoGenex Announces Data From Borealis-1™ Trial Showing Clinical Benefit With Apatorsen In Metastatic Bladder Cancer
2015-05-30,OncoGenex Announces Data From The Phase 3 SYNERGY Trial Showing A Survival Benefit With Custirsen In Patients With Poor Prognosis
2015-05-20,OncoGenex Announces Data To Be Presented At ASCO 2015 Annual Meeting
2015-05-04,OncoGenex To Report First Quarter 2015 Financial Results On May 14, 2015
2015-04-30,OncoGenex Announces Share Purchase Agreement With Lincoln Park Capital Fund, LLC
2015-04-30,OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Update
2015-04-27,OncoGenex Regains Rights To Custirsen From Teva
2015-04-09,OncoGenex Pharmaceuticals To Present At The 14th Annual Needham Healthcare Conference
2015-03-23,OncoGenex To Report Financial Results For Fourth Quarter And Year End 2014 On March 26, 2015
2015-02-24,OncoGenex And Sarah Cannon Announce Completion Of Patient Enrollment In The Spruce™ Clinical Trial Evaluating Apatorsen In Combination With Carboplatin And Pemetrexed In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
2015-02-20,Small-Cap Friday's Little Gem
2015-02-12,OncoGenex Announces Relocation Of Corporate Headquarters, Expected To Yield Savings Of At Least $4 Million Over Next Three Years
2015-01-16,OncoGenex Announces Update On Phase 3 AFFINITY Trial Evaluating Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
2014-12-30,OncoGenex To Regain Rights To Custirsen From Teva
2014-12-19,OncoGenex Announces Results From The Phase 2 Borealis-1™ Trial Of Apatorsen In The Treatment Of Metastatic Bladder Cancer
2014-12-16,OncoGenex Announces Completion Of Patient Enrollment In The Rainier™ Clinical Trial Evaluating Apatorsen In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer
2014-12-12,5 Stocks Poised for Breakouts: Trulia and More
2014-11-17,OncoGenex Pharmaceuticals To Present At The Stifel 2014 Healthcare Conference
2014-10-29,Some Of Soros' Stocks Surged Today, While Others Soured
2014-10-16,OncoGenex To Report Financial Results For Third Quarter 2014 On October 30, 2014
2014-09-18,5 Stocks Under $10 to Trade for Breakouts
2014-09-16,OncoGenex Announces Completion Of Patient Enrollment In The Phase 3 AFFINITY Trial Of Custirsen In Combination With Cabazitaxel/Prednisone As Second-line Chemotherapy In Men With Metastatic Castrate-Resistant Prostate Cancer
2014-08-27,4 Under-$10 Biotech Stocks in Breakout Territory
2014-08-21,OncoGenex Announces Update On Phase 3 ENSPIRIT Trial Evaluating Custirsen In Advanced Non-Small Cell Lung Cancer
2014-08-08,4 Stocks Under $10 Making Big Moves
2014-08-07,OncoGenex Pharmaceuticals Announces Appointment Of John A. Bencich As Vice President And Chief Financial Officer
2014-07-24,OncoGenex To Report Financial Results For Second Quarter 2014 On August 7, 2014
2014-07-01,OncoGenex Announces Cedar™ Clinical Trial Evaluating Apatorsen In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer Is Now Open For Enrollment
2014-06-26,OncoGenex Pharmaceuticals Announces Pricing Of $24 Million Underwritten Registered Direct Offering
2014-05-06,The Feuerstein-Ratain Rule Update: Still Perfect Predicting Small-Cap Cancer Drug Failure
2014-05-01,5 Stocks Under $10 Set to Soar
2014-04-28,Why OncoGenex (OXGI) Stock Hit a One-Year Low Today
2014-04-28,OncoGenex To Report Financial Results For First Quarter 2014 On April 30, 2014
2014-04-28,OncoGenex Announces Top-Line Survival Results Of Phase 3 SYNERGY Trial Evaluating Custirsen For Metastatic Castrate-Resistant Prostate Cancer
2014-04-28,Teva And OncoGenex Announce Top-Line Survival Results Of Phase III SYNERGY Trial Evaluating Custirsen In Combination With First-line Docetaxel And Prednisone For Metastatic Castrate-Resistant Prostate Cancer
2014-04-23,OncoGenex Announces Fast Track Designation Granted For Custirsen In Combination With Cabazitaxel/Prednisone As Second-line Chemotherapy In Phase 3 AFFINITY Trial Of Men With Metastatic Castrate-Resistant Prostate Cancer
2014-03-06,3 Big-Volume Stocks in Breakout Territory
2014-02-25,OncoGenex To Report Financial Results For Fourth Quarter And Year-Ended 2013 On March 11, 2014
2014-02-21,Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!
2014-02-11,OncoGenex Announces Target Number Of Events Reached In Phase 3 SYNERGY Trial Of Custirsen In Metastatic Castrate-Resistant Prostate Cancer
2014-02-06,OncoGenex To Present At Leerink Global Healthcare Investor Conference
2013-11-19,OncoGenex Announces Update On Phase 3 SYNERGY Trial Evaluating Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
2013-11-05,OncoGenex To Present At Credit Suisse Healthcare Investor Conference
2013-10-30,OncoGenex To Report Financial Results For Third Quarter 2013 And Address Key Questions From Investors On November 7, 2013
2013-10-25,Biotech Stock Mailbag: Vanda, Onconova, Catalyst Pharma, Sarepta
2013-10-21,Oversold Conditions For OncoGenex Pharmaceuticals (OGXI)
2013-08-29,OncoGenex Announces That The Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer Is Now Open For Enrollment
2013-08-27,OncoGenex Announces That The Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer Is Now Open For Enrollment
2013-08-15,OncoGenex Pharmaceuticals Getting Very Oversold (OGXI)
2013-08-07,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2013-08-01,OncoGenex Announces That The Spruce™ Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Non-Squamous Non-Small Cell Lung Cancer Is Now Open For Enrollment
2013-07-30,OncoGenex To Webcast Discussion Of Clinical Development Program And Second Quarter 2013 Financial Results On August 8, 2013
2013-07-16,OncoGenex Announces Completion Of Patient Enrollment In The Borealis-1™ Trial Of OGX-427 In Metastatic Bladder Cancer
2013-06-20,Commit To Purchase OncoGenex Pharmaceuticals At $7.50, Earn 14.9% Annualized
2013-05-28,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2013-05-23,OncoGenex Announces Plans For The Initiation Of The Cedar™ Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer
2013-05-22,OncoGenex Announces Multiple 'Trials In Progress' Presentations At The 2013 ASCO Annual Meeting
2013-05-01,OncoGenex Pharmaceuticals Becomes Oversold (OGXI)
2013-05-01,OncoGenex Announces Plans For The Initiation Of The Rainier™ Clinical Trial Evaluating OGX-427 In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer
2013-04-30,OncoGenex Announces That The Borealis-2™ Clinical Trial Of OGX-427 In Previously Treated Metastatic Bladder Cancer Is Now Open For Enrollment
2013-04-25,OncoGenex To Webcast Discussion Of Clinical Development Program And First Quarter 2013 Financial Results On May 2, 2013
2013-04-23,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2013-04-11,OncoGenex Announces Plans For The Initiation Of The Spruce™ Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Non-Squamous Non-Small Cell Lung Cancer
2013-03-28,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2013-02-28,OncoGenex To Webcast Update On Clinical Development Program And Discussion Of Fourth Quarter And Full Year 2012 Financial Results On Thursday, March 7, 2013
2013-02-12,OncoGenex Announces Plans For The Initiation Of The Borealis-2 Clinical Trial Evaluating OGX-427 In Combination With Second-Line Therapy For Bladder Cancer
2013-02-05,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conferences
2012-12-19,OncoGenex Announces Initiation Of Randomized Phase 2 "PACIFIC" Study Of OGX-427 In Combination With Zytiga® In Men With Metastatic Castrate-Resistant Prostate Cancer
2012-11-09,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2012-11-06,OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
2012-10-30,OncoGenex To Webcast Discussion Of Third Quarter 2012 Financial Results On Thursday, November 8, 2012
2012-09-27,OncoGenex Announces Initiation Of A Phase 3 Trial For Custirsen In Advanced Non-Small Cell Lung Cancer
2012-08-28,OncoGenex Pharmaceuticals To Present At Two Upcoming Investor Conferences
2012-08-07,OncoGenex Announces Initiation Of The Phase 3 "AFFINITY" Trial For Patients With Advanced Prostate Cancer
2012-07-25,OncoGenex To Webcast Discussion Of Second Quarter 2012 Financial Results On Thursday, August 2, 2012
2012-07-10,OncoGenex Announces Clinical Development Plans For Custirsen In Non-Small Cell Lung Cancer
2012-06-04,Data From A Phase 2 Study Presented At The 2012 ASCO Annual Meeting Continues To Show Early Activity Of OGX-427 In Patients With Prostate Cancer
2012-03-27,OncoGenex Pharmaceuticals To Present At Two Upcoming Investor Conferences
2012-03-23,OncoGenex Pharmaceuticals, Inc. Announces Full Exercise Of Overallotment Option By Underwriters
2012-03-16,OncoGenex Stock Gaps Down On Today's Open (OGXI)
2012-03-16,OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
2012-03-15,OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering Of Common Stock
2012-03-08,Teva And OncoGenex Announce Updates To Custirsen Development Program In Advanced Prostate Cancer
2012-02-28,OncoGenex To Webcast Discussion Of Fourth Quarter 2011 Financial Results On Thursday, March 8, 2012
2012-02-27,OncoGenex Announces Data Highlighting OGX-427 At 27th Annual European Association Of Urology Congress
2012-02-07,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conferences
2012-02-02,Clinical Data On OGX-427 Presented At The ASCO 2012 Genitourinary Cancers Symposium Provide Ongoing Evidence Of Hsp27 As A Potential Therapeutic Target In Advanced Prostate Cancer
2012-02-02,Phase 1 Study Of OGX-427 Presented At The ASCO 2012 Genitourinary Cancers Symposium Shows Early Evidence Of Activity In Bladder Cancer
2012-01-04,OncoGenex Announces Publication Of Phase I/II Custirsen (OGX-011/TV-1011) Data In Journal Of Thoracic Oncology
2011-11-07,Edison Expands Oncology Sector Presence With Launch Of Research Coverage On OncoGenex Pharmaceuticals
2011-10-26,OncoGenex Announces Publication Of OGX-427 Pre-Clinical Data In Pancreatic Cancer
2011-10-20,OncoGenex Pharmaceuticals Initiates An International, Randomized, Phase II Clinical Trial Evaluating OGX-427 In Advanced Bladder Cancer
2011-10-18,OncoGenex To Webcast Discussion Of Third Quarter Financial Results On Thursday, November 3, 2011
2011-09-19,OncoGenex Announces Completion Of A Special Protocol Assessment (SPA) Amendment With The FDA Increasing Patient Eligibility For The Custirsen Phase III Prostate Cancer SATURN Clinical Trial
2011-09-15,OncoGenex Pharmaceuticals To Present At UBS Global Life Sciences Conference
2011-09-06,OncoGenex Announces Publication Of Custirsen Phase II Clinical And Pre-Clinical Data In Leading Cancer Journals
2011-09-01,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conferences
2011-08-10,OncoGenex To Present At The 2011 Wedbush Securities Life Sciences Management Access Conference
2011-07-28,OncoGenex To Webcast Discussion Of Second Quarter Financial Results On Thursday, August 4, 2011
2011-06-28,OncoGenex Pharmaceuticals Added To Russell Indexes
2011-06-07,10 Health-Care Stocks Outperforming the Index
2011-06-06,Data From Pre-Clinical Studies Presented At The 2011 ASCO Annual Meeting Show Potential Combinability Of Custirsen With MDV3100 And Hsp90 Inhibitors To Enhance Anti-Tumor Activity In Prostate Cancer
2011-05-19,Teva And OncoGenex To Present Data On Custirsen In Prostate Cancer At The 2011 ASCO Annual Meeting
2011-05-17,OncoGenex To Present At The UBS Global Specialty Pharmaceuticals Conference
2011-05-05,9 Health Care Stocks With 100% Buy Ratings
2011-05-02,OncoGenex To Webcast Discussion Of First Quarter Financial Results On Monday, May 9, 2011
2011-04-14,OncoGenex Pharmaceuticals Announces Issuance Of Key European Patent For OGX-427
2011-04-06,Teva And OncoGenex Present Preclinical Data On The Activity Of Its Antisense Compound Custirsen (OGX-011/TV-1011) At The American Association Of Cancer Research (AACR) Annual Meeting 2011
2011-04-04,OncoGenex Announces Data Highlighting OGX-427 At American Association Of Cancer Research (AACR) 102nd Annual Meeting 2011
2011-03-29,OncoGenex To Present At The Needham & Company 10th Annual Healthcare Conference
2011-03-07,OncoGenex To Webcast Discussion Of Fourth Quarter And Full Year 2010 Financial Results On Thursday, March 10, 2011
2011-02-28,OncoGenex Pharmaceuticals To Participate In Panel Discussion On Novel Cancer Treatments At RBC Capital Markets Healthcare Conference
2011-02-25,Biotech Stock Mailbag: Exact Sciences
2011-02-14,BIO CEO Conference Live Blog
2010-10-19,10 Biotech Stocks Expected to at Least Double
2010-10-11,10 Stocks Expected to Double Amid QE2
2010-05-10,OncoGenex Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript
2010-01-11,Looking for a Down Day
2009-12-21,OncoGenex Slammed on Teva Partnership: BioBuzz
2009-12-21,Teva, OncoGenex Sign Drug Development Deal
2009-12-21,Isis Pharmaceuticals To Receive $10 Million From OncoGenex' License Of OGX-011 To Teva
2009-10-20,Galleon's Biotech Stock Holdings: BioBuzz
2009-10-06,OncoGenex Prostate Cancer Drug Gets Special Review
2009-09-21,Movers Roundup: LivePerson, Tenneco
2009-09-21,OncoGenex Shares Rise On RBC Analyst Outlook
2009-08-25,Movers Roundup: FreightCar America, OncoGenex
2009-08-25,OncoGenex Hits Year High On 'Overweight' Rating
2009-07-10,J&J Finishes Cougar Biotech Deal
2009-05-30,OncoGenex Prostate Drug Extends Survival
2009-05-28,Small-Cap Biotechs Pop Before Conference
2009-05-22,J&J Just Made Medivation's Day
2009-05-22,Biotech Stock Mailbag: Gilead Still Got It?
2009-05-20,Tiny Biotechs Dancing in the Bull Pen
2017-03-08,Achieve Life Sciences And OncoGenex Pharmaceuticals Announce Cytisine Symposium At The Annual Society For Research In Nicotine And Tobacco Conference ("SRNT")
2017-03-01,Achieve Life Science And OncoGenex Pharmaceuticals Announce Strategic Collaboration With The National Institutes Of Health To Advance The Development Of Cytisine For Smoking Cessation
2017-02-21,OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data For Two Clinical Trials Presented At The American Society Of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium
2017-02-16,OncoGenex To Report Year End 2016 Financial Results On Feb. 23, 2017
2017-01-26,Research Reports Coverage On Biotech Stocks -- OncoGenex Pharma, INSYS Therapeutics, Threshold Pharma, And AmpliPhi Biosciences
2017-01-05,OncoGenex Pharmaceuticals, Inc. And Achieve Life Science, Inc. Announce Definitive Merger Agreement
2016-11-15,Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive
2016-11-03,OncoGenex To Report Third Quarter 2016 Financial Results On Nov. 10, 2016
2016-10-25,OncoGenex Announces Positive Survival Results From Apatorsen Phase 2 Borealis-2™ Trial In Metastatic Bladder Cancer
2016-10-13,OncoGenex Announces Results From The Phase 3 ENSPIRIT Trial Of Custirsen In Non-Small Cell Lung Cancer
2016-08-16,OncoGenex Announces Results From The Phase 3 AFFINITY Trial Of Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
2016-07-21,OncoGenex To Report Second Quarter 2016 Financial Results On August 4, 2016
2016-04-28,OncoGenex To Report First Quarter 2016 Financial Results On May 12, 2016
2016-04-25,8 Breakout Stocks Under $10 to Trade for Big Profits
2016-04-05,OncoGenex Pharmaceuticals To Present At The 15th Annual Needham Healthcare Conference
2016-02-24,OncoGenex To Report Fourth Quarter And Year End 2015 Financial Results On March 9, 2016
2016-02-04,OncoGenex Announces Reduction In Force To Extend Cash Runway And Align Operations With Clinical Development Priorities
2016-01-20,OncoGenex Announces Update On Phase 2 Spruce Trial In Previously Untreated Metastatic Non-Small Cell Lung Cancer
2016-01-06,4 Stocks Under $10 to Trade for Big Breakouts
2015-12-09,OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion Of Futility Analysis
2015-12-01,OncoGenex Announces Phase 3 AFFINITY Trial With Custirsen Continues Following Interim Analyses
2015-11-05,OncoGenex Pharmaceuticals To Present At The Stifel 2015 Healthcare Conference
2015-10-29,OncoGenex To Report Third Quarter 2015 Financial Results On November 12, 2015
2015-10-08,OncoGenex Announces EMA Support For Phase 3 AFFINITY Trial Protocol Amendment
2015-09-30,OncoGenex Announces Completion Of Patient Enrollment In Borealis-2™ Clinical Trial Evaluating Apatorsen In Relapsed Or Refractory Metastatic Bladder Cancer
2015-09-28,OncoGenex Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels In Metastatic Prostate Cancer Patients; Low Levels Correlate With Improved Survival In Those At Increased Risk For Poor Outcomes
2015-09-23,OncoGenex Announces Phase 2 Rainier Results In Previously Untreated Metastatic Pancreatic Cancer
2015-08-31,OncoGenex Pharmaceuticals (OGXI) Is Today's Strong On High Volume Stock
2015-07-30,OncoGenex To Report Second Quarter 2015 Financial Results On August 13, 2015
2015-07-29,OncoGenex Pharmaceuticals (OGXI) Weak On High Volume Today
2015-07-13,OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Continues Following Completion Of Final Futility Survival Analysis
2015-06-12,Revisiting 2 Little Biotech Gems
2015-06-10,FDA Agrees With OncoGenex' Phase 3 AFFINITY Protocol Amendment
2015-06-01,OncoGenex Announces Data From Borealis-1™ Trial Showing Clinical Benefit With Apatorsen In Metastatic Bladder Cancer
2015-05-30,OncoGenex Announces Data From The Phase 3 SYNERGY Trial Showing A Survival Benefit With Custirsen In Patients With Poor Prognosis
2015-05-20,OncoGenex Announces Data To Be Presented At ASCO 2015 Annual Meeting
2015-05-04,OncoGenex To Report First Quarter 2015 Financial Results On May 14, 2015
2015-04-30,OncoGenex Announces Share Purchase Agreement With Lincoln Park Capital Fund, LLC
2015-04-30,OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Update
2015-04-27,OncoGenex Regains Rights To Custirsen From Teva
2015-04-09,OncoGenex Pharmaceuticals To Present At The 14th Annual Needham Healthcare Conference
2015-03-23,OncoGenex To Report Financial Results For Fourth Quarter And Year End 2014 On March 26, 2015
2015-02-24,OncoGenex And Sarah Cannon Announce Completion Of Patient Enrollment In The Spruce™ Clinical Trial Evaluating Apatorsen In Combination With Carboplatin And Pemetrexed In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
2015-02-20,Small-Cap Friday's Little Gem
2015-02-12,OncoGenex Announces Relocation Of Corporate Headquarters, Expected To Yield Savings Of At Least $4 Million Over Next Three Years
2015-01-16,OncoGenex Announces Update On Phase 3 AFFINITY Trial Evaluating Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
2014-12-30,OncoGenex To Regain Rights To Custirsen From Teva
2014-12-19,OncoGenex Announces Results From The Phase 2 Borealis-1™ Trial Of Apatorsen In The Treatment Of Metastatic Bladder Cancer
2014-12-16,OncoGenex Announces Completion Of Patient Enrollment In The Rainier™ Clinical Trial Evaluating Apatorsen In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer
2014-12-12,5 Stocks Poised for Breakouts: Trulia and More
2014-11-17,OncoGenex Pharmaceuticals To Present At The Stifel 2014 Healthcare Conference
2014-10-29,Some Of Soros' Stocks Surged Today, While Others Soured
2014-10-16,OncoGenex To Report Financial Results For Third Quarter 2014 On October 30, 2014
2014-09-18,5 Stocks Under $10 to Trade for Breakouts
2014-09-16,OncoGenex Announces Completion Of Patient Enrollment In The Phase 3 AFFINITY Trial Of Custirsen In Combination With Cabazitaxel/Prednisone As Second-line Chemotherapy In Men With Metastatic Castrate-Resistant Prostate Cancer
2014-08-27,4 Under-$10 Biotech Stocks in Breakout Territory
2014-08-21,OncoGenex Announces Update On Phase 3 ENSPIRIT Trial Evaluating Custirsen In Advanced Non-Small Cell Lung Cancer
2014-08-08,4 Stocks Under $10 Making Big Moves
2014-08-07,OncoGenex Pharmaceuticals Announces Appointment Of John A. Bencich As Vice President And Chief Financial Officer
2014-07-24,OncoGenex To Report Financial Results For Second Quarter 2014 On August 7, 2014
2014-07-01,OncoGenex Announces Cedar™ Clinical Trial Evaluating Apatorsen In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer Is Now Open For Enrollment
2014-06-26,OncoGenex Pharmaceuticals Announces Pricing Of $24 Million Underwritten Registered Direct Offering
2014-05-06,The Feuerstein-Ratain Rule Update: Still Perfect Predicting Small-Cap Cancer Drug Failure
2014-05-01,5 Stocks Under $10 Set to Soar
2014-04-28,Why OncoGenex (OXGI) Stock Hit a One-Year Low Today
2014-04-28,OncoGenex To Report Financial Results For First Quarter 2014 On April 30, 2014
2014-04-28,OncoGenex Announces Top-Line Survival Results Of Phase 3 SYNERGY Trial Evaluating Custirsen For Metastatic Castrate-Resistant Prostate Cancer
2014-04-28,Teva And OncoGenex Announce Top-Line Survival Results Of Phase III SYNERGY Trial Evaluating Custirsen In Combination With First-line Docetaxel And Prednisone For Metastatic Castrate-Resistant Prostate Cancer
2014-04-23,OncoGenex Announces Fast Track Designation Granted For Custirsen In Combination With Cabazitaxel/Prednisone As Second-line Chemotherapy In Phase 3 AFFINITY Trial Of Men With Metastatic Castrate-Resistant Prostate Cancer
2014-03-06,3 Big-Volume Stocks in Breakout Territory
2014-02-25,OncoGenex To Report Financial Results For Fourth Quarter And Year-Ended 2013 On March 11, 2014
2014-02-21,Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!
2014-02-11,OncoGenex Announces Target Number Of Events Reached In Phase 3 SYNERGY Trial Of Custirsen In Metastatic Castrate-Resistant Prostate Cancer
2014-02-06,OncoGenex To Present At Leerink Global Healthcare Investor Conference
2013-11-19,OncoGenex Announces Update On Phase 3 SYNERGY Trial Evaluating Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
2013-11-05,OncoGenex To Present At Credit Suisse Healthcare Investor Conference
2013-10-30,OncoGenex To Report Financial Results For Third Quarter 2013 And Address Key Questions From Investors On November 7, 2013
2013-10-25,Biotech Stock Mailbag: Vanda, Onconova, Catalyst Pharma, Sarepta
2013-10-21,Oversold Conditions For OncoGenex Pharmaceuticals (OGXI)
2013-08-29,OncoGenex Announces That The Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer Is Now Open For Enrollment
2013-08-27,OncoGenex Announces That The Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer Is Now Open For Enrollment
2013-08-15,OncoGenex Pharmaceuticals Getting Very Oversold (OGXI)
2013-08-07,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2013-08-01,OncoGenex Announces That The Spruce™ Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Non-Squamous Non-Small Cell Lung Cancer Is Now Open For Enrollment
2013-07-30,OncoGenex To Webcast Discussion Of Clinical Development Program And Second Quarter 2013 Financial Results On August 8, 2013
2013-07-16,OncoGenex Announces Completion Of Patient Enrollment In The Borealis-1™ Trial Of OGX-427 In Metastatic Bladder Cancer
2013-06-20,Commit To Purchase OncoGenex Pharmaceuticals At $7.50, Earn 14.9% Annualized
2013-05-28,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2013-05-23,OncoGenex Announces Plans For The Initiation Of The Cedar™ Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer
2013-05-22,OncoGenex Announces Multiple 'Trials In Progress' Presentations At The 2013 ASCO Annual Meeting
2013-05-01,OncoGenex Pharmaceuticals Becomes Oversold (OGXI)
2013-05-01,OncoGenex Announces Plans For The Initiation Of The Rainier™ Clinical Trial Evaluating OGX-427 In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer
2013-04-30,OncoGenex Announces That The Borealis-2™ Clinical Trial Of OGX-427 In Previously Treated Metastatic Bladder Cancer Is Now Open For Enrollment
2013-04-25,OncoGenex To Webcast Discussion Of Clinical Development Program And First Quarter 2013 Financial Results On May 2, 2013
2013-04-23,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2013-04-11,OncoGenex Announces Plans For The Initiation Of The Spruce™ Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Non-Squamous Non-Small Cell Lung Cancer
2013-03-28,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2013-02-28,OncoGenex To Webcast Update On Clinical Development Program And Discussion Of Fourth Quarter And Full Year 2012 Financial Results On Thursday, March 7, 2013
2013-02-12,OncoGenex Announces Plans For The Initiation Of The Borealis-2 Clinical Trial Evaluating OGX-427 In Combination With Second-Line Therapy For Bladder Cancer
2013-02-05,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conferences
2012-12-19,OncoGenex Announces Initiation Of Randomized Phase 2 "PACIFIC" Study Of OGX-427 In Combination With Zytiga® In Men With Metastatic Castrate-Resistant Prostate Cancer
2012-11-09,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2012-11-06,OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
2012-10-30,OncoGenex To Webcast Discussion Of Third Quarter 2012 Financial Results On Thursday, November 8, 2012
2012-09-27,OncoGenex Announces Initiation Of A Phase 3 Trial For Custirsen In Advanced Non-Small Cell Lung Cancer
2012-08-28,OncoGenex Pharmaceuticals To Present At Two Upcoming Investor Conferences
2012-08-07,OncoGenex Announces Initiation Of The Phase 3 "AFFINITY" Trial For Patients With Advanced Prostate Cancer
2012-07-25,OncoGenex To Webcast Discussion Of Second Quarter 2012 Financial Results On Thursday, August 2, 2012
2012-07-10,OncoGenex Announces Clinical Development Plans For Custirsen In Non-Small Cell Lung Cancer
2012-06-04,Data From A Phase 2 Study Presented At The 2012 ASCO Annual Meeting Continues To Show Early Activity Of OGX-427 In Patients With Prostate Cancer
2012-03-27,OncoGenex Pharmaceuticals To Present At Two Upcoming Investor Conferences
2012-03-23,OncoGenex Pharmaceuticals, Inc. Announces Full Exercise Of Overallotment Option By Underwriters
2012-03-16,OncoGenex Stock Gaps Down On Today's Open (OGXI)
2012-03-16,OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
2012-03-15,OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering Of Common Stock
2012-03-08,Teva And OncoGenex Announce Updates To Custirsen Development Program In Advanced Prostate Cancer
2012-02-28,OncoGenex To Webcast Discussion Of Fourth Quarter 2011 Financial Results On Thursday, March 8, 2012
2012-02-27,OncoGenex Announces Data Highlighting OGX-427 At 27th Annual European Association Of Urology Congress
2012-02-07,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conferences
2012-02-02,Clinical Data On OGX-427 Presented At The ASCO 2012 Genitourinary Cancers Symposium Provide Ongoing Evidence Of Hsp27 As A Potential Therapeutic Target In Advanced Prostate Cancer
2012-02-02,Phase 1 Study Of OGX-427 Presented At The ASCO 2012 Genitourinary Cancers Symposium Shows Early Evidence Of Activity In Bladder Cancer
2012-01-04,OncoGenex Announces Publication Of Phase I/II Custirsen (OGX-011/TV-1011) Data In Journal Of Thoracic Oncology
2011-11-07,Edison Expands Oncology Sector Presence With Launch Of Research Coverage On OncoGenex Pharmaceuticals
2011-10-26,OncoGenex Announces Publication Of OGX-427 Pre-Clinical Data In Pancreatic Cancer
2011-10-20,OncoGenex Pharmaceuticals Initiates An International, Randomized, Phase II Clinical Trial Evaluating OGX-427 In Advanced Bladder Cancer
2011-10-18,OncoGenex To Webcast Discussion Of Third Quarter Financial Results On Thursday, November 3, 2011
2011-09-19,OncoGenex Announces Completion Of A Special Protocol Assessment (SPA) Amendment With The FDA Increasing Patient Eligibility For The Custirsen Phase III Prostate Cancer SATURN Clinical Trial
2011-09-15,OncoGenex Pharmaceuticals To Present At UBS Global Life Sciences Conference
2011-09-06,OncoGenex Announces Publication Of Custirsen Phase II Clinical And Pre-Clinical Data In Leading Cancer Journals
2011-09-01,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conferences
2011-08-10,OncoGenex To Present At The 2011 Wedbush Securities Life Sciences Management Access Conference
2011-07-28,OncoGenex To Webcast Discussion Of Second Quarter Financial Results On Thursday, August 4, 2011
2011-06-28,OncoGenex Pharmaceuticals Added To Russell Indexes
2011-06-07,10 Health-Care Stocks Outperforming the Index
2011-06-06,Data From Pre-Clinical Studies Presented At The 2011 ASCO Annual Meeting Show Potential Combinability Of Custirsen With MDV3100 And Hsp90 Inhibitors To Enhance Anti-Tumor Activity In Prostate Cancer
2011-05-19,Teva And OncoGenex To Present Data On Custirsen In Prostate Cancer At The 2011 ASCO Annual Meeting
2011-05-17,OncoGenex To Present At The UBS Global Specialty Pharmaceuticals Conference
2011-05-05,9 Health Care Stocks With 100% Buy Ratings
2011-05-02,OncoGenex To Webcast Discussion Of First Quarter Financial Results On Monday, May 9, 2011
2011-04-14,OncoGenex Pharmaceuticals Announces Issuance Of Key European Patent For OGX-427
2011-04-06,Teva And OncoGenex Present Preclinical Data On The Activity Of Its Antisense Compound Custirsen (OGX-011/TV-1011) At The American Association Of Cancer Research (AACR) Annual Meeting 2011
2011-04-04,OncoGenex Announces Data Highlighting OGX-427 At American Association Of Cancer Research (AACR) 102nd Annual Meeting 2011
2011-03-29,OncoGenex To Present At The Needham & Company 10th Annual Healthcare Conference
2011-03-07,OncoGenex To Webcast Discussion Of Fourth Quarter And Full Year 2010 Financial Results On Thursday, March 10, 2011
2011-02-28,OncoGenex Pharmaceuticals To Participate In Panel Discussion On Novel Cancer Treatments At RBC Capital Markets Healthcare Conference
2011-02-25,Biotech Stock Mailbag: Exact Sciences
2011-02-14,BIO CEO Conference Live Blog
2010-10-19,10 Biotech Stocks Expected to at Least Double
2010-10-11,10 Stocks Expected to Double Amid QE2
2010-05-10,OncoGenex Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript
2010-01-11,Looking for a Down Day
2009-12-21,OncoGenex Slammed on Teva Partnership: BioBuzz
2009-12-21,Teva, OncoGenex Sign Drug Development Deal
2009-12-21,Isis Pharmaceuticals To Receive $10 Million From OncoGenex' License Of OGX-011 To Teva
2009-10-20,Galleon's Biotech Stock Holdings: BioBuzz
2009-10-06,OncoGenex Prostate Cancer Drug Gets Special Review
2009-09-21,Movers Roundup: LivePerson, Tenneco
2009-09-21,OncoGenex Shares Rise On RBC Analyst Outlook
2009-08-25,Movers Roundup: FreightCar America, OncoGenex
2009-08-25,OncoGenex Hits Year High On 'Overweight' Rating
2009-07-10,J&J Finishes Cougar Biotech Deal
2009-05-30,OncoGenex Prostate Drug Extends Survival
2009-05-28,Small-Cap Biotechs Pop Before Conference
2009-05-22,J&J Just Made Medivation's Day
2009-05-22,Biotech Stock Mailbag: Gilead Still Got It?
2009-05-20,Tiny Biotechs Dancing in the Bull Pen
2017-03-08,OncoMed Pharmaceuticals Announces Fourth Quarter And Full Year 2016 Financial Results
2017-03-02,OncoMed Announces Multiple Abstracts Related To Anti-TIGIT Program Accepted For Presentation At The American Association For Cancer Research Annual Meeting 2017
2017-03-01,OncoMed Pharmaceuticals To Report Fourth Quarter And Year End Financial Results On March 8, 2017
2017-02-13,OncoMed Enrolls First Patient In Phase 1b Clinical Trial Of Its Anti-DLL4/VEGF Bispecific Antibody In Patients With Platinum-Resistant Ovarian Cancer
2017-02-08,OncoMed Pharmaceuticals To Present At The BIO CEO And Investor And Leerink Global Healthcare Conferences
2017-02-08,Noteworthy Wednesday Option Activity: OMED, ZEN, FMI
2017-01-27,5 Stocks Under $10 That Could Rocket Higher Soon
2017-01-27,These 5 Stocks Under $10 Could Get Hot Soon
2017-01-20,OncoMed Initiates Enrollment Of Phase 1b Clinical Trial Of Brontictuzumab For The Treatment Of Metastatic Colorectal Cancer Patients
2017-01-05,OncoMed Announces Year-End Cash Balance And 2017 Outlook
2017-01-04,OncoMed Initiates Enrollment Of Phase 1b Clinical Trial Of Anti-DLL4/VEGF Bispecific Antibody As Second-line Treatment For Metastatic Colorectal Cancer Patients
2016-12-19,Noteworthy Monday Option Activity: OMED, NKTR, MNKD
2016-12-05,OncoMed Announces Departure Of Chief Medical Officer
2016-12-01,RSI Alert: OncoMed Pharmaceuticals (OMED) Now Oversold
2016-11-29,OncoMed Presents Initial First-in-Human Data For Anti-DLL4/VEGF Bispecific And Anti-RSPO3 At The 28th EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium
2016-11-22,OncoMed Pharmaceuticals To Present At The 28th Annual Piper Jaffray Healthcare Conference
2016-11-15,OncoMed To Present Clinical Data For Anti-RSPO3 And Anti-DLL4/VEGF Bispecific Antibody At The 28th EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium
2016-11-01,OncoMed Pharmaceuticals Reports Third Quarter 2016 Financial Results
2016-10-26,OncoMed Pharmaceuticals To Report Financial Results For The Third Quarter On Tuesday, November 1, 2016
2016-10-10,OncoMed Presents Interim Phase 1b Data For Ipafricept And Vantictumab In Pancreatic Cancer At The ESMO 2016 Congress
2016-09-30,Noteworthy Friday Option Activity: OMED, HLF, CIA
2016-09-29,OncoMed To Present Clinical Data For Wnt Inhibitors At The ESMO 2016 Congress
2016-09-01,OncoMed Pharmaceuticals Completes Enrollment Of Phase 2 YOSEMITE Clinical Trial Of Demcizumab In Pancreatic Cancer
2016-08-31,OncoMed Management To Present At Two Upcoming Investment Conferences
2016-08-30,OncoMed Pharmaceuticals Completes Enrollment Of Phase 2 PINNACLE Clinical Trial Of Tarextumab In Small Cell Lung Cancer
2016-08-23,OncoMed Pharmaceuticals Announces Closing Of Public Offering Including Exercise Of Underwriters' Right To Purchase Additional Shares
2016-08-18,Oversold Conditions For OncoMed Pharmaceuticals (OMED)
2016-08-18,OncoMed Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2016-08-17,OncoMed Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2016-08-15,Noteworthy Monday Option Activity: OMED, ISRG, STAA
2016-08-10,Short Interest In OncoMed Pharmaceuticals Moves 18% Higher
2016-08-09,OncoMed Pharmaceuticals Reports Second Quarter 2016 Financial Results
2016-08-03,OncoMed Pharmaceuticals To Report Financial Results For The Second Quarter 2016 On Tuesday, August 9, 2016
2016-07-27,Commit To Purchase OncoMed Pharmaceuticals At $10, Earn 29.6% Annualized Using Options
2016-07-07,OncoMed Management To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference
2016-06-28,5 Best-Positioned Biotech Stocks on Brexit Volatility
2016-06-06,OncoMed Management To Present At Two Upcoming Investment Conferences
2016-06-05,OncoMed Presents Phase 1b Data For First-in-Class Treatments In Ovarian, Breast And Lung Cancer At The 2016 ASCO Annual Meeting
2016-05-05,OncoMed Pharmaceuticals Announces First Quarter 2016 Financial Results
2016-04-29,OncoMed Pharmaceuticals To Report Financial Results For The First Quarter 2016 On Thursday, May 5, 2016
2016-04-28,Commit To Purchase OncoMed Pharmaceuticals At $12.50, Earn 23% Annualized Using Options
2016-04-21,OncoMed Announces Clinical Data To Be Presented At The 2016 ASCO Annual Meeting
2016-04-20,OncoMed Presents Biomarker Research For Two Clinical Programs And Demcizumab Mechanism Data At The AACR Annual Meeting 2016
2016-04-19,OncoMed Presents GITRL-Fc Research At The AACR Annual Meeting 2016
2016-03-17,OncoMed Initiates Phase 1b Immuno-Oncology Combination Clinical Trial For Demcizumab And Pembrolizumab (anti-PD1)
2016-03-16,OncoMed To Present Data At The American Association Of Cancer Research Annual Meeting 2016
2016-03-10,OncoMed Pharmaceuticals Announces Full Year And Fourth Quarter 2015 Financial Results And 2016 Guidance
2016-03-04,OncoMed Pharmaceuticals To Report Fourth Quarter And Year-End 2015 Financial Results On Thursday, March 10, 2016
2016-03-02,7 Stocks Under $10 Making Big Breakout Moves
2016-02-22,OncoMed Presents Updated Phase 1b Data For Tarextumab In Small Cell Lung Cancer
2016-02-18,5 Stocks Under $10 Set to Soar
2016-02-08,OncoMed Provides Update On Tarextumab Phase 2 Programs
2016-02-04,OncoMed Pharmaceuticals To Present At Upcoming Investor Conferences
2016-01-25,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Violations Of Federal Securities Laws By The Board Of OncoMed Pharmaceuticals, Inc.
2016-01-25,Noteworthy Monday Option Activity: OMED, ROCK, STAR
2016-01-25,OncoMed (OMED) Stock Plummets on Pancreatic Cancer Drug Trial Results
2016-01-25,OncoMed Provides Update On Tarextumab Phase 2 Pancreatic Cancer ALPINE Trial
2016-01-22,OncoMed Presents Updated Phase 1b Data For Demcizumab In First-Line Pancreatic Cancer At The Gastrointestinal Cancers Symposium
2016-01-15,Oversold Conditions For OncoMed Pharmaceuticals (OMED)
2016-01-11,Insider Trading Alert - MENT, TINY And OMED Traded By Insiders
2016-01-11,OncoMed Enrolls First Patient In Phase 1b Anti-RSPO3 Trial
2016-01-08,OncoMed Announces Publication Of Anti-RSPO Antibody Research In Cancer Research
2016-01-06,OncoMed Pharmaceuticals Appoints Perry Karsen To Board Of Directors
2016-01-05,OncoMed Achieves $72.5 Million In Milestone Payments From Celgene; Announces Year-End Cash Balance
2016-01-04,OncoMed Pharmaceuticals CEO To Present At The 34th Annual JPMorgan Healthcare Conference
2015-12-11,OncoMed Presents Vantictumab Biomarker Data At The San Antonio Breast Cancer Symposium (SABCS)
2015-11-12,OncoMed Pharmaceuticals To Present At Upcoming Investor Conferences
2015-11-09,Commit To Buy OncoMed Pharmaceuticals At $20, Earn 28.1% Annualized Using Options
2015-11-09,OncoMed Presents Data From Brontictuzumab, Vantictumab And Anti-DLL4/VEGF Bispecific Programs At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
2015-11-07,OncoMed Presents Immuno-Oncology Data For Combined Blockade Of DLL4, VEGF And PD1 At The Society For Immunotherapy Of Cancer Annual Meeting
2015-11-05,OncoMed Pharmaceuticals Reports Third Quarter 2015 Financial Results
2015-11-04,OncoMed To Present Preclinical Data For The Combination Of Anti-DLL4/VEGF Bispecific Plus Anti-PD1 At The Society Of Immunotherapy For Cancer Meeting
2015-10-29,OncoMed Pharmaceuticals To Report Third Quarter 2015 Financial Results On Thursday, November 5, 2015
2015-10-28,Insider Trading Alert - LRCX, OMED And POOL Traded By Insiders
2015-10-27,OncoMed Announces Multiple Abstracts Accepted For Presentation At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
2015-09-29,OncoMed To Present At The Leerink Partners Inaugural Immuno-Oncology Roundtable Conference
2015-09-22,OncoMed Pharmaceuticals Becomes Oversold (OMED)
2015-09-16,OncoMed Presents Immuno-Oncology Data For GITRL-Fc Candidate At The Inaugural International Cancer Immunotherapy Conference
2015-09-09,OncoMed Pharmaceuticals Announces Presentation Of Tarextumab Small Cell Lung Cancer Data At The 16th World Conference On Lung Cancer
2015-08-31,OncoMed Pharmaceuticals Completes Enrollment Of Phase 2 ALPINE Clinical Trial Of Tarextumab In Pancreatic Cancer
2015-08-27,Notch3 Biomarker Results And Updated Data From OncoMed's Phase 1b/2 PINNACLE Clinical Trial Accepted For Presentation At The 16th World Conference On Lung Cancer
2015-08-10,OncoMed Pharmaceuticals Announces Second Quarter 2015 Financial Results And Updates Demcizumab Phase 1b Non-Small Cell Lung Cancer Survival Data
2015-08-07,Commit To Purchase OncoMed Pharmaceuticals At $17.50, Earn 13.5% Annualized Using Options
2015-08-05,OncoMed Pharmaceuticals To Report Second Quarter 2015 Financial Results On Monday, August 10, 2015
2015-07-31,5 Stocks Ready for Breakouts
2015-07-28,OncoMed Initiates Phase 1 Clinical Trial For Anti-RSPO3 Antibody
2015-07-08,OncoMed Pharmaceuticals Enters Oversold Territory (OMED)
2015-07-06,OncoMed To Present At The Cantor Fitzgerald Inaugural Healthcare Conference
2015-06-29,OncoMed Pharmaceuticals Appoints Rick Winningham To Board Of Directors
2015-06-01,OncoMed Presents Phase 1b Clinical Trial Data For Tarextumab In Small Cell Lung Cancer At The 2015 ASCO Annual Meeting
2015-06-01,OncoMed Presents Data From Phase 1b Trial Of Demcizumab In Pancreatic Cancer At The 2015 ASCO Annual Meeting
2015-06-01,OncoMed Presents Updated Demcizumab Data In Non-Small Cell Lung Cancer At The 2015 ASCO Annual Meeting
2015-05-28,OncoMed Pharmaceuticals To Review Key ASCO Data For Demcizumab And Tarextumab During Conference Call On Tuesday, June 2, 2015
2015-05-28,OncoMed To Present At Upcoming Investment Conferences
2015-05-22,Bearish Bets: Northwest Natural Gas Deflates
2015-05-21,Insider Trading Alert - OMED, ALQA And SNBC Traded By Insiders
2015-05-14,OncoMed To Present At UBS Global Healthcare Conference
2015-05-14,Ratings Changes Today
2015-05-07,OncoMed Pharmaceuticals Announces First Quarter 2015 Financial Results
2015-05-07,Commit To Buy OncoMed Pharmaceuticals At $17.50, Earn 15.8% Annualized Using Options
2015-05-04,OncoMed Pharmaceuticals To Report First Quarter 2015 Financial Results On Thursday, May 7, 2015
2015-05-04,OncoMed To Present At The Credit Suisse Antibody Day
2015-05-01,OncoMed Publishes Data On Tarextumab's Anti-Cancer Stem Cell Activity In Clinical Cancer Research
2015-04-29,OncoMed Highlights Immuno-Oncology Discoveries During 2015 Research & Development Day
2015-04-23,OncoMed Pharmaceuticals To Webcast 2015 Research And Development Day On April 29, 2015
2015-04-22,OncoMed Initiates Dosing In Randomized Phase 2 Clinical Trial Of Demcizumab In Pancreatic Cancer Patients
2015-04-21,OncoMed Presents Data On Clinical And Preclinical Anti-Cancer Stem Cell Programs At American Association For Cancer Research Annual Meeting
2015-04-21,OncoMed Announces Abstracts Accepted For Presentation At The 2015 ASCO Annual Meeting
2015-04-16,OncoMed Presents Demcizumab Data From Phase 1b Clinical Trial In Non-Small Cell Lung Cancer Patients At The European Lung Cancer Conference
2015-04-09,OncoMed To Present At The Needham Healthcare Conference
2015-04-09,OncoMed To Present Clinical Data For Demcizumab At The European Lung Cancer Conference
2015-04-02,OncoMed And Lilly Enter Clinical Supply Agreement To Evaluate The Combination Of Demcizumab And Alimta(R) (pemetrexed For Injection) In Lung Cancer
2015-03-23,Ratings Changes Today
2015-03-20,Insider Trading Alert - CCNE, OMED And ALSN Traded By Insiders
2015-03-19,OncoMed To Present Data On Multiple Anti-Cancer Stem Cell Candidates At The American Association Of Cancer Research Meeting
2015-03-12,OncoMed Pharmaceuticals Reports Full Year And Fourth Quarter 2014 Financial Results And Recent Highlights
2015-03-03,OncoMed Pharmaceuticals To Report Full Year And Fourth Quarter 2014 Financial Results On Thursday, March 12, 2015
2015-02-05,Commit To Buy OncoMed Pharmaceuticals At $20, Earn 23.9% Annualized Using Options
2015-02-04,OncoMed Initiates Dosing In Phase 2 Clinical Trial Of Demcizumab For The Treatment Of Non-Small Cell Lung Cancer
2015-01-29,FDA Grants Orphan Drug Designations To OncoMed's Tarextumab For The Treatment Of Pancreatic And Small Cell Lung Cancer
2015-01-28,OncoMed Pharmaceuticals To Present At The BIO CEO And Investor And Leerink Global Healthcare Conferences In February
2015-01-22,Insider Trading Alert - ATSG, OMED And IMPV Traded By Insiders
2015-01-16,OncoMed Presents Final Phase 1b Safety, Efficacy And Biomarker Data For Tarextumab In Pancreatic Cancer At The 2015 Gastrointestinal Cancer Symposium
2015-01-15,OncoMed Enrolls First Biomarker-Selected Patient In Expansion Stage Of Anti-Notch1 Phase 1a Trial In Solid Tumors
2015-01-13,OncoMed To Present Clinical Data And Biomarker Analysis For Tarextumab At The 2015 Gastrointestinal Cancer Symposium
2015-01-12,OncoMed Pre-Announces 2014 Year-End Cash Balance And Provides 2015 Guidance
2015-01-08,Jim Cramer's 'Mad Money' Recap: You'll Make More Money Buying Into Panic
2015-01-08,OncoMed Pharmaceuticals (OMED) Stock: Weak On High Volume Today
2015-01-07,OncoMed Pharmaceuticals To Present At The 33rd Annual J.P. Morgan Healthcare Conference
2015-01-05,OncoMed Doses First Patient In Phase 1 Clinical Trial Of Novel Anti-DLL4/VEGF Bispecific Antibody
2014-12-15,OncoMed Pharmaceuticals Becomes Oversold (OMED)
2014-12-01,OncoMed Begins Patient Dosing In Phase 2 Clinical Trial Of Tarextumab (Anti-Notch 2/3, OMP-59R5) In Small Cell Lung Cancer
2014-11-21,OncoMed Presents New Clinical And Biomarker Data From Its Tarextumab And Demcizumab Clinical Trials At The EORTC-NCI-AACR Symposium
2014-11-20,OncoMed Pharmaceuticals To Present At Piper Jaffray Healthcare Conference
2014-11-19,OncoMed Presents Biomarker-Focused Clinical Data From Phase 1a Trial Of Anti-Notch1 (OMP-52M51) In Oral Plenary Session At The 26th EORTC-NCI-AACR Symposium
2014-11-07,Commit To Purchase OncoMed Pharmaceuticals At $15, Earn 17.9% Annualized Using Options
2014-11-04,OncoMed Pharmaceuticals Announces Third Quarter 2014 Financial And Operating Results
2014-11-03,OncoMed Pharmaceuticals Granted Anti-DLL4/Anti-VEGF Bispecific Antibody Patent In The U.S.
2014-10-30,OncoMed To Present Clinical And Preclinical Data At The 26th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics Meeting
2014-10-29,OncoMed To Announce Financial Results For The Third Quarter 2014 On Tuesday, November 4, 2014, After Close Of U.S.-Based Financial Markets
2014-10-10,Short Interest Expands By 13.4% For OMED
2014-10-07,OncoMed Pharmaceuticals To Present At The 13th Annual BIO Investor Forum
2014-09-30,OncoMed Pharmaceuticals Announces Selection Of First Small Molecule Product Candidate Targeting The Wnt Pathway Under Collaboration With Bayer Pharma AG
2014-09-29,OncoMed Presents Encouraging Data From Clinical Trials Of Tarextumab (Anti-Notch2/3) In Pancreatic Cancer And Small Cell Lung Cancer At The ESMO 2014 Congress
2014-09-28,OncoMed's Demcizumab Phase 1b Clinical Trials Show Encouraging Safety And Anti-Tumor Activity At ESMO
2014-09-23,4 Health Care Stocks Triggering Breakout Trades on Unusual Volume
2014-09-17,OncoMed To Present New And Emerging Data From Demcizumab (anti-DLL4, OMP-21M18) And Tarextumab (anti-Notch2/3, OMP-59R5) Clinical Studies At The European Society For Medical Oncology 2014 Congress
2014-09-04,FDA Removes Partial Clinical Hold On OncoMed's Ipafricept
2014-09-02,OncoMed Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
2014-08-28,OncoMed Pharmaceuticals Announces Removal Of Partial Clinical Hold By The FDA For Vantictumab
2014-08-27,5 Stocks With Big Insider Buying
2014-08-22,OMED: Insiders vs. Shorts
2014-08-19,Ratings Changes Today
2014-08-11,Earnings Report Card for Small-Caps
2014-08-07,OncoMed Pharmaceuticals Announces Second Quarter 2014 Financial Results
2014-07-24,4 Biotech Stocks Breaking Out on Big Volume
2014-07-16,OncoMed Pharmaceuticals Initiates Randomized Phase 2 "ALPINE" Clinical Trial Of Tarextumab (Anti-Notch 2/3, OMP-59R5) For Pancreatic Cancer
2014-07-02,OncoMed Pharmaceuticals Granted Broad FZD-Fc Composition-of-Matter And Use Patent In U.S.
2014-06-19,OncoMed Pharmaceuticals To Present At The 9th Annual JMP Securities Healthcare Conference
2014-06-18,OncoMed Provides Update On FZD8-Fc (OMP-54F28) Phase I Clinical Trials
2014-06-14,OncoMed Presents Data For Notch1 Diagnostic Assay At The 19th European Hematology Association Congress
2014-06-13,Vantictumab Placed On Partial Clinical Hold By FDA Following Voluntary Halt By OncoMed
2014-06-13,OncoMed Voluntarily Halts Enrollment And Dosing In Phase 1 Vantictumab And Fzd8-Fc Trials
2014-06-04,OncoMed To Present Data For Notch1 Program At The 19th European Hematology Association Congress
2014-05-28,OncoMed Pharmaceuticals To Present At The Jefferies 2014 Global Healthcare Conference
2014-05-14,OncoMed To Present Data From Three Clinical Studies At The 2014 ASCO Annual Meeting
2014-05-08,OncoMed Pharmaceuticals Announces First Quarter 2014 Financial Results
2014-05-02,OncoMed Receives Orphan Drug Designation From The FDA For Demcizumab In Pancreatic Cancer
2014-04-23,OncoMed Announces Abstracts Accepted At The 2014 ASCO Annual Meeting
2014-04-08,OncoMed Presents Data On Multiple Anti-Cancer Stem Cell Programs At American Association For Cancer Research Annual Meeting
2014-03-18,OncoMed Pharmaceuticals Announces Full Year And Fourth Quarter 2013 Financial Results
2014-03-06,OncoMed To Present Data On Anti-Cancer Stem Cell Candidates At The American Association Of Cancer Research Meeting
2014-02-28,OncoMed Pharmaceuticals To Present At The Cowen And Company 34th Annual Health Care Conference
2014-02-20,OncoMed Pharmaceuticals Commences Third Phase 1b Clinical Trial For OMP-54F28 (Fzd8-Fc) With Carboplatin And Paclitaxel In Ovarian Cancer
2014-02-18,OncoMed Pharmaceuticals Initiates Second Phase 1b Clinical Trial For OMP-54F28 (Fzd8-Fc) With Sorafenib (Nexavar(R)) In Hepatocellular Cancer
2014-02-03,OncoMed Pharmaceuticals Granted Fourth RSPO-LGR Pathway Patent In U.S.
2014-01-27,OncoMed Pharmaceuticals To Present At Two Investor Conferences In February
2014-01-17,OncoMed Pharmaceuticals Presents Data From The Phase 1b Portion Of The ALPINE Clinical Study Of OMP-59R5 In Pancreatic Cancer At The 2014 Gastrointestinal Cancers Symposium
2014-01-17,OncoMed Pharmaceuticals Presents Data From Demcizumab Phase 1b Clinical Study In Pancreatic Cancer At The 2014 Gastrointestinal Cancers Symposium
2014-01-13,OncoMed Pharmaceuticals Initiates First Phase 1b Clinical Trial Of OMP-54F28 (Fzd8-Fc) With Nab-Paclitaxel (Abraxane(R)) And Gemcitabine In Pancreatic Cancer
2017-03-02,Spark Therapeutics To Participate In Multiple Conferences In March
2017-03-01,Spark Therapeutics And Pfizer Announce That SPK-9001, An Investigational Hemophilia B Medicine, Has Been Granted Access To The PRIority MEdicines (PRIME) Program By The European Medicines Agency
2017-02-22,Spark Therapeutics Reports 2016 Financial Results And Business Highlights
2017-02-21,We May Be Back to Maximum Overbought by Thursday
2017-02-15,Spark Therapeutics To Host Conference Call On Wednesday, Feb. 22 At 8:30 A.m. To Discuss 2016 Results
2017-02-03,Spark Therapeutics Reaches Analyst Target Price
2017-01-26,Spark Therapeutics To Participate In Multiple February Conferences
2017-01-09,Spark Therapeutics Announces U.S. Orphan Drug Designation Amendment And Study Updates For Lead Investigational Gene Therapy
2017-01-04,Spark Therapeutics Announces $15 Million Milestone Payment From Pfizer For Progress In Hemophilia B Gene Therapy Program
2017-01-03, Spark Therapeutics To Participate In J.P. Morgan Healthcare Conference
2016-12-05,Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting
2016-12-05,Spark Therapeutics Adds Chief Operating Officer To Management Team
2016-12-05,Spark Therapeutics Enters Into Licensing Agreement With Selecta Biosciences
2016-12-03,Spark's Hemophilia Gene Therapy Remains Effective Despite Immune Reactions
2016-12-03,Spark Therapeutics And Pfizer Present Updated Preliminary Data From Hemophilia B Phase 1/2 Trial Suggesting Consistent And Sustained Levels Of Factor IX Activity At Annual ASH Meeting
2016-11-30,Spark Therapeutics Announces Multiple Presentations On Updated Hemophilia B Phase 1/2 Data At American Society Of Hematology Annual Meeting
2016-11-03,The Great 'ASH16' Abstract Drop Mostly Causes Drug Stocks to Do Same
2016-11-03,Spark Therapeutics And Pfizer Announce Updated Data From Hemophilia B Phase 1/2 Trial Suggesting Sustained Therapeutic Levels Of Factor IX Activity
2016-11-03,Spark Therapeutics Reports Third Quarter 2016 Financial Results And Recent Business Highlights
2016-10-31,Spark Therapeutics To Participate In Multiple Upcoming Conferences
2016-10-27,Spark Therapeutics To Host Conference Call On Thursday, Nov. 3 At 8:30 A.m. To Discuss Third Quarter 2016 Results
2016-10-20,Spark Therapeutics Announces Collaboration With Leading Gene Therapy Center At University Of Massachusetts Medical School
2016-10-14,Data Presented Today At The American Academy Of Ophthalmology 2016 Annual Meeting Reinforce Efficacy And Durability Of Voretigene Neparvovec In RPE65-Mediated Inherited Retinal Disease
2016-10-13,Spark Therapeutics Launches Initiative To Improve Access To Genetic Testing For Inherited Retinal Diseases
2016-10-10, Spark Therapeutics To Participate In AAO Annual Meeting
2016-09-21,Spark Therapeutics To Participate In Multiple Upcoming Conferences
2016-09-09,Jim Cramer's Top Takeaways: Spark Therapeutics, General Mills, Kellogg, ConAgra, Campbell
2016-09-08,Jim Cramer's 'Mad Money' Recap: This Market Has a One-Track Mind
2016-08-31,Spark Therapeutics To Participate In Multiple September Conferences
2016-08-10,Spark Therapeutics Reports Second Quarter 2016 Financial Results And Recent Business Highlights
2016-08-10,Spark Therapeutics Announces New Positive Data From Continuation Of Phase 3 Trial Of Voretigene Neparvovec
2016-08-02,Spark Therapeutics, Inc. To Host Conference Call On August 10th At 8:30a.m. To Discuss Second Quarter 2016 Results
2016-07-25,Spark Therapeutics And Pfizer Announce Updated Data From First Cohort In Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels Of Factor IX Activity
2016-07-21,13 Companies to Watch From MIT's Smart 50 List, Including 4 Buys
2016-07-21,Spark Therapeutics And Pfizer Announce Receipt Of FDA Breakthrough Therapy Designation For SPK-9001 For The Treatment Of Hemophilia B
2016-07-12,Strong On High Relative Volume: Spark Therapeutics (ONCE)
2016-07-08,Spark Therapeutics Announces Participation In Conferences In July
2016-07-01,Spark Therapeutics Announces Publication Of Positive Follow-Up Data From Phase 1 Trial Of Voretigene Neparvovec In The Lancet
2016-06-30,'Mad Money' Lightning Round: You Should Own General Electric
2016-06-29,Jim Cramer's 'Mad Money' Recap: What a Relief! This Rally Has Legs
2016-06-20,Spark Therapeutics Announces Closing Of Public Offering
2016-06-16,Spark Therapeutics (ONCE) Stock: Weak On High Volume Today
2016-06-15,Spark Therapeutics (ONCE) Trading With Heavy Volume Before Market Open
2016-06-14,Spark Therapeutics Announces Pricing Of Public Offering
2016-06-13,Spark Therapeutics Announces Launch Of Public Offering
2016-06-13,Spark Therapeutics Announces Updated Data From First Cohort In Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels Of Factor IX Activity
2016-06-09,Spark Therapeutics, Inc. To Host Conference Call On Monday June 13th At 8:30 A.m. To Discuss SPK-9001 Phase 1/2 Data For The Treatment Of Hemophilia B Presented At EHA
2016-06-06,Spark Therapeutics Announces Participation And Attendance For Conferences In June
2016-05-24,Spark Therapeutics (ONCE) Highlighted As Today's Perilous Reversal Stock
2016-05-19,Strong On High Relative Volume: Spark Therapeutics (ONCE)
2016-05-19,Spark Therapeutics And Pfizer Announce Data From Initial Subjects In Hemophilia B Trial Demonstrating Consistent Therapeutic Levels Of Factor IX Expression
2016-05-04,Spark Therapeutics Reports First Quarter 2016 Financial Results And Recent Business Highlights
2016-05-03,Spark Therapeutics Announces Multiple Presentations At Upcoming Investor Meetings
2016-04-28,Spark Therapeutics Announces Multiple Presentations At Upcoming Scientific Meetings
2016-04-27,Spark Therapeutics, Inc. To Host Conference Call On May 4th At 8:30a.m. To Discuss First Quarter 2016 Results
2016-03-11,Analysts' Actions -- Blackstone, Chevron, Hertz, Kohl's and More
2016-03-10,Ratings Changes Today
2016-03-09,Spark Therapeutics Reports 2015 Financial Results And Business Highlights
2016-03-07,Spark Therapeutics Announces Acquisition Of Genable Technologies
2016-03-02,Spark Therapeutics Announces Cowen Healthcare Conference Participation
2016-03-02,Spark Therapeutics, Inc. To Host Conference Call On March 9th At 8:30 A.m. To Discuss 2015 Results
2016-02-29,Spark Therapeutics Announces Launch Of ASharedVision, A New Online Resource To Unite And Inform Those Affected By Inherited Retinal Diseases
2016-02-11,Commit To Buy Spark Therapeutics At $20, Earn 29.3% Annualized Using Options
2016-02-08,Relative Strength Alert For Spark Therapeutics
2016-02-01,Emerald Investment Conference Shadows Groundhog Day - Investment Professionals Gathering In Philadelphia On February 3rd
2016-01-21,WHAT'S AHEAD FOR 2016: Investment Trends And Themes To Be Highlighted At The Emerald Groundhog Day Investment Forum
2016-01-11,Spark Unveils Vision Of Having 10 Clinical-Stage Gene Therapy Programs By 2018, Including One Commercial And Two In Pivotal Trials
2016-01-06,Spark Therapeutics Announces Addition Of Lota Zoth To Its Board Of Directors
2016-01-05,Spark Therapeutics Announces J.P. Morgan Healthcare Conference Participation
2016-01-01,Feuerstein's Heroes and Zeroes of Biotech Investing in 2015
2015-12-15,Spark Therapeutics Announces Pricing Of Public Offering
2015-12-14,Spark Therapeutics Announces Launch Of Public Offering
2015-12-14,Spark Therapeutics Announces Addition To NASDAQ Biotechnology Index
2015-12-09,Spark Therapeutics Announces $15 Million Milestone Payment From Pfizer For Progress In Hemophilia B Gene Therapy Program
2015-11-30,Spark Therapeutics Announces December Conference Participation
2015-11-25,Spark Therapeutics Announces Filing Of Registration Statement For Proposed Public Offering
2015-11-14,Spark Therapeutics Announces Presentation Of Additional Phase 3 Data On SPK-RPE65 At The American Academy Of Ophthalmology 2015 Annual Meeting
2015-11-11,Spark Therapeutics Announces SPK-TPP1, Its First Program Targeting Neurodegenerative Disease
2015-11-04,Spark Therapeutics Reports Third Quarter 2015 Financial Results And Recent Business Highlights
2015-10-28,Spark Therapeutics, Inc. To Host Conference Call On November 4th At 8:30a.m. To Discuss Third Quarter 2015 Results
2015-10-23,Spark Therapeutics To Participate In Four Conferences In October And November
2015-10-14,5 Stocks Insiders Love Right Now
2015-10-10,Spark Therapeutics Announces Presentation Of Additional Phase 3 And Durability Data On SPK-RPE65 At The Retina Society 48th Annual Scientific Meeting
2015-10-05,Apple Sits Out Tech Rally; S&P 500 Enjoys Record 2015 Winning Streak
2015-10-05,Spark Therapeutics Trial Success Seen As Positive For Gene Therapy Sector
2015-10-05,Spark Therapeutics Announces Positive Top-line Results From Pivotal Phase 3 Trial Of SPK-RPE65 For Genetic Blinding Conditions
2015-09-29,'Mad Money' Lightning Round: Take PPG Over Sherwin-Williams
2015-09-28,Jim Cramer's 'Mad Money' Recap: 5 Groups You Once Loved but Now Hate
2015-09-25,Biotech Stock Mailbag: Rebounding From Hillary's Drug Tweet; Global Blood Weighs on Bluebird
2015-09-18,5 Stocks Ready for Breakouts
2015-09-10,Spark Tries to Quell Investor Fears About Gene Therapy Test
2015-09-09,Spark Therapeutics Announces Database Lock For SPK-RPE65 Phase 3 Clinical Trial And Expected Release Of Top-Line Data In October
2015-09-03,Biotech Stock Mailbag: Sarepta, Biomarin, Spark, Raptor
2015-09-01,The Numbers Behind Biotech's Horrible, No Good, Awful August
2015-08-19,Biotech Stocks Get Burned This Summer, but Fall Might Bring Relief
2015-08-05,Spark Therapeutics Reports Second Quarter 2015 Results
2015-07-29,Spark Therapeutics, Inc. To Host Conference Call On August 5th At 8:30a.m. To Discuss Second Quarter 2015 Results
2015-07-23,Jim Cramer: Spark Therapeutics (ONCE) Is Capable of Doing Amazing Things
2015-07-23,Jim Cramer's Top Takeaways: Live Nation, Spark Therapeutics, Ambarella
2015-07-22,Jim Cramer's 'Mad Money' Recap: Road to China Is Lined With Bears and Bulls
2015-06-26,Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
2015-06-18,Spark Therapeutics To Present With Pfizer Inc. Preclinical Data On Their Lead SPK-FIX Product Candidate For Hemophilia B At The 2015 International Society Of Thrombosis And Haemostasis Congress In June
2015-06-18,'Mad Money' Lightning Round: Buy, Buy, Buy Celgene; I'm a Believer
2015-06-17,Jim Cramer's 'Mad Money' Recap: Thanks for Nothing, Janet Yellen
2015-06-17,Spark Therapeutics To Participate In Two International Conferences In London In June
2015-06-13,Bluebird Sickle Cell Gene Therapy Results Keep Getting Better
2015-05-21,Bluebird Bio First Look at Gene Therapy for Sickle Cell Disease
2015-05-06,Spark Therapeutics Reports First Quarter 2015 Results
2015-05-04,Spark Therapeutics Drops After Rival Blindness Therapy Effectiveness Declines
2015-05-01,Spark Therapeutics To Have Multiple Presentations At 2015 ARVO Meeting
2015-04-30,Spark Therapeutics, Inc. To Host Conference Call On May 6th At 8:30a.m. To Discuss First Quarter 2015 Results
2015-04-28,Spark Therapeutics And Clearside Biomedical Announce Exclusive Option To License Technology For Potentially Differentiated Delivery Of Gene Therapy To The Eye
2015-04-26,Gene Therapy Stocks on Watch Following Failure of Celladon's Heart Failure Trial
2015-04-17,IPO Market 'Has Been a Lonely Place' but Pace Is Picking Up
2015-04-16,The Top 5 Best IPO Performers in the Last Year
2015-04-06,Biotech Stocks Still Feeling Healthy Despite Bubble Talk
2015-03-25,Celladon Heart-Failure Study Looms Large as Next Big Test for Gene Therapy
2015-03-18,Spark Therapeutics Reports Full Year 2014 Financial Results
2015-03-17,'Mad Money' Lightning Round: I LIke H&R Block, RR Donnelley
2015-03-16,Jim Cramer's 'Mad Money' Recap: This Is One Stupid Market
2015-02-26,Spark Therapeutics To Participate In The 35th Annual Cowen And Company Health Care Conference
2015-02-04,Spark Therapeutics Announces Closing Of Its Initial Public Offering
2015-01-30,IPO Roundup: Shake Shack Shares More Than Double Out of Gate
2015-01-30,Spark Therapeutics Announces Pricing Of Its Initial Public Offering
,
2017-03-02,Spark Therapeutics To Participate In Multiple Conferences In March
2017-03-01,Spark Therapeutics And Pfizer Announce That SPK-9001, An Investigational Hemophilia B Medicine, Has Been Granted Access To The PRIority MEdicines (PRIME) Program By The European Medicines Agency
2017-02-22,Spark Therapeutics Reports 2016 Financial Results And Business Highlights
2017-02-21,We May Be Back to Maximum Overbought by Thursday
2017-02-15,Spark Therapeutics To Host Conference Call On Wednesday, Feb. 22 At 8:30 A.m. To Discuss 2016 Results
2017-02-03,Spark Therapeutics Reaches Analyst Target Price
2017-01-26,Spark Therapeutics To Participate In Multiple February Conferences
2017-01-09,Spark Therapeutics Announces U.S. Orphan Drug Designation Amendment And Study Updates For Lead Investigational Gene Therapy
2017-01-04,Spark Therapeutics Announces $15 Million Milestone Payment From Pfizer For Progress In Hemophilia B Gene Therapy Program
2017-01-03, Spark Therapeutics To Participate In J.P. Morgan Healthcare Conference
2016-12-05,Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting
2016-12-05,Spark Therapeutics Adds Chief Operating Officer To Management Team
2016-12-05,Spark Therapeutics Enters Into Licensing Agreement With Selecta Biosciences
2016-12-03,Spark's Hemophilia Gene Therapy Remains Effective Despite Immune Reactions
2016-12-03,Spark Therapeutics And Pfizer Present Updated Preliminary Data From Hemophilia B Phase 1/2 Trial Suggesting Consistent And Sustained Levels Of Factor IX Activity At Annual ASH Meeting
2016-11-30,Spark Therapeutics Announces Multiple Presentations On Updated Hemophilia B Phase 1/2 Data At American Society Of Hematology Annual Meeting
2016-11-03,The Great 'ASH16' Abstract Drop Mostly Causes Drug Stocks to Do Same
2016-11-03,Spark Therapeutics And Pfizer Announce Updated Data From Hemophilia B Phase 1/2 Trial Suggesting Sustained Therapeutic Levels Of Factor IX Activity
2016-11-03,Spark Therapeutics Reports Third Quarter 2016 Financial Results And Recent Business Highlights
2016-10-31,Spark Therapeutics To Participate In Multiple Upcoming Conferences
2016-10-27,Spark Therapeutics To Host Conference Call On Thursday, Nov. 3 At 8:30 A.m. To Discuss Third Quarter 2016 Results
2016-10-20,Spark Therapeutics Announces Collaboration With Leading Gene Therapy Center At University Of Massachusetts Medical School
2016-10-14,Data Presented Today At The American Academy Of Ophthalmology 2016 Annual Meeting Reinforce Efficacy And Durability Of Voretigene Neparvovec In RPE65-Mediated Inherited Retinal Disease
2016-10-13,Spark Therapeutics Launches Initiative To Improve Access To Genetic Testing For Inherited Retinal Diseases
2016-10-10, Spark Therapeutics To Participate In AAO Annual Meeting
2016-09-21,Spark Therapeutics To Participate In Multiple Upcoming Conferences
2016-09-09,Jim Cramer's Top Takeaways: Spark Therapeutics, General Mills, Kellogg, ConAgra, Campbell
2016-09-08,Jim Cramer's 'Mad Money' Recap: This Market Has a One-Track Mind
2016-08-31,Spark Therapeutics To Participate In Multiple September Conferences
2016-08-10,Spark Therapeutics Reports Second Quarter 2016 Financial Results And Recent Business Highlights
2016-08-10,Spark Therapeutics Announces New Positive Data From Continuation Of Phase 3 Trial Of Voretigene Neparvovec
2016-08-02,Spark Therapeutics, Inc. To Host Conference Call On August 10th At 8:30a.m. To Discuss Second Quarter 2016 Results
2016-07-25,Spark Therapeutics And Pfizer Announce Updated Data From First Cohort In Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels Of Factor IX Activity
2016-07-21,13 Companies to Watch From MIT's Smart 50 List, Including 4 Buys
2016-07-21,Spark Therapeutics And Pfizer Announce Receipt Of FDA Breakthrough Therapy Designation For SPK-9001 For The Treatment Of Hemophilia B
2016-07-12,Strong On High Relative Volume: Spark Therapeutics (ONCE)
2016-07-08,Spark Therapeutics Announces Participation In Conferences In July
2016-07-01,Spark Therapeutics Announces Publication Of Positive Follow-Up Data From Phase 1 Trial Of Voretigene Neparvovec In The Lancet
2016-06-30,'Mad Money' Lightning Round: You Should Own General Electric
2016-06-29,Jim Cramer's 'Mad Money' Recap: What a Relief! This Rally Has Legs
2016-06-20,Spark Therapeutics Announces Closing Of Public Offering
2016-06-16,Spark Therapeutics (ONCE) Stock: Weak On High Volume Today
2016-06-15,Spark Therapeutics (ONCE) Trading With Heavy Volume Before Market Open
2016-06-14,Spark Therapeutics Announces Pricing Of Public Offering
2016-06-13,Spark Therapeutics Announces Launch Of Public Offering
2016-06-13,Spark Therapeutics Announces Updated Data From First Cohort In Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels Of Factor IX Activity
2016-06-09,Spark Therapeutics, Inc. To Host Conference Call On Monday June 13th At 8:30 A.m. To Discuss SPK-9001 Phase 1/2 Data For The Treatment Of Hemophilia B Presented At EHA
2016-06-06,Spark Therapeutics Announces Participation And Attendance For Conferences In June
2016-05-24,Spark Therapeutics (ONCE) Highlighted As Today's Perilous Reversal Stock
2016-05-19,Strong On High Relative Volume: Spark Therapeutics (ONCE)
2016-05-19,Spark Therapeutics And Pfizer Announce Data From Initial Subjects In Hemophilia B Trial Demonstrating Consistent Therapeutic Levels Of Factor IX Expression
2016-05-04,Spark Therapeutics Reports First Quarter 2016 Financial Results And Recent Business Highlights
2016-05-03,Spark Therapeutics Announces Multiple Presentations At Upcoming Investor Meetings
2016-04-28,Spark Therapeutics Announces Multiple Presentations At Upcoming Scientific Meetings
2016-04-27,Spark Therapeutics, Inc. To Host Conference Call On May 4th At 8:30a.m. To Discuss First Quarter 2016 Results
2016-03-11,Analysts' Actions -- Blackstone, Chevron, Hertz, Kohl's and More
2016-03-10,Ratings Changes Today
2016-03-09,Spark Therapeutics Reports 2015 Financial Results And Business Highlights
2016-03-07,Spark Therapeutics Announces Acquisition Of Genable Technologies
2016-03-02,Spark Therapeutics Announces Cowen Healthcare Conference Participation
2016-03-02,Spark Therapeutics, Inc. To Host Conference Call On March 9th At 8:30 A.m. To Discuss 2015 Results
2016-02-29,Spark Therapeutics Announces Launch Of ASharedVision, A New Online Resource To Unite And Inform Those Affected By Inherited Retinal Diseases
2016-02-11,Commit To Buy Spark Therapeutics At $20, Earn 29.3% Annualized Using Options
2016-02-08,Relative Strength Alert For Spark Therapeutics
2016-02-01,Emerald Investment Conference Shadows Groundhog Day - Investment Professionals Gathering In Philadelphia On February 3rd
2016-01-21,WHAT'S AHEAD FOR 2016: Investment Trends And Themes To Be Highlighted At The Emerald Groundhog Day Investment Forum
2016-01-11,Spark Unveils Vision Of Having 10 Clinical-Stage Gene Therapy Programs By 2018, Including One Commercial And Two In Pivotal Trials
2016-01-06,Spark Therapeutics Announces Addition Of Lota Zoth To Its Board Of Directors
2016-01-05,Spark Therapeutics Announces J.P. Morgan Healthcare Conference Participation
2016-01-01,Feuerstein's Heroes and Zeroes of Biotech Investing in 2015
2015-12-15,Spark Therapeutics Announces Pricing Of Public Offering
2015-12-14,Spark Therapeutics Announces Launch Of Public Offering
2015-12-14,Spark Therapeutics Announces Addition To NASDAQ Biotechnology Index
2015-12-09,Spark Therapeutics Announces $15 Million Milestone Payment From Pfizer For Progress In Hemophilia B Gene Therapy Program
2015-11-30,Spark Therapeutics Announces December Conference Participation
2015-11-25,Spark Therapeutics Announces Filing Of Registration Statement For Proposed Public Offering
2015-11-14,Spark Therapeutics Announces Presentation Of Additional Phase 3 Data On SPK-RPE65 At The American Academy Of Ophthalmology 2015 Annual Meeting
2015-11-11,Spark Therapeutics Announces SPK-TPP1, Its First Program Targeting Neurodegenerative Disease
2015-11-04,Spark Therapeutics Reports Third Quarter 2015 Financial Results And Recent Business Highlights
2015-10-28,Spark Therapeutics, Inc. To Host Conference Call On November 4th At 8:30a.m. To Discuss Third Quarter 2015 Results
2015-10-23,Spark Therapeutics To Participate In Four Conferences In October And November
2015-10-14,5 Stocks Insiders Love Right Now
2015-10-10,Spark Therapeutics Announces Presentation Of Additional Phase 3 And Durability Data On SPK-RPE65 At The Retina Society 48th Annual Scientific Meeting
2015-10-05,Apple Sits Out Tech Rally; S&P 500 Enjoys Record 2015 Winning Streak
2015-10-05,Spark Therapeutics Trial Success Seen As Positive For Gene Therapy Sector
2015-10-05,Spark Therapeutics Announces Positive Top-line Results From Pivotal Phase 3 Trial Of SPK-RPE65 For Genetic Blinding Conditions
2015-09-29,'Mad Money' Lightning Round: Take PPG Over Sherwin-Williams
2015-09-28,Jim Cramer's 'Mad Money' Recap: 5 Groups You Once Loved but Now Hate
2015-09-25,Biotech Stock Mailbag: Rebounding From Hillary's Drug Tweet; Global Blood Weighs on Bluebird
2015-09-18,5 Stocks Ready for Breakouts
2015-09-10,Spark Tries to Quell Investor Fears About Gene Therapy Test
2015-09-09,Spark Therapeutics Announces Database Lock For SPK-RPE65 Phase 3 Clinical Trial And Expected Release Of Top-Line Data In October
2015-09-03,Biotech Stock Mailbag: Sarepta, Biomarin, Spark, Raptor
2015-09-01,The Numbers Behind Biotech's Horrible, No Good, Awful August
2015-08-19,Biotech Stocks Get Burned This Summer, but Fall Might Bring Relief
2015-08-05,Spark Therapeutics Reports Second Quarter 2015 Results
2015-07-29,Spark Therapeutics, Inc. To Host Conference Call On August 5th At 8:30a.m. To Discuss Second Quarter 2015 Results
2015-07-23,Jim Cramer: Spark Therapeutics (ONCE) Is Capable of Doing Amazing Things
2015-07-23,Jim Cramer's Top Takeaways: Live Nation, Spark Therapeutics, Ambarella
2015-07-22,Jim Cramer's 'Mad Money' Recap: Road to China Is Lined With Bears and Bulls
2015-06-26,Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
2015-06-18,Spark Therapeutics To Present With Pfizer Inc. Preclinical Data On Their Lead SPK-FIX Product Candidate For Hemophilia B At The 2015 International Society Of Thrombosis And Haemostasis Congress In June
2015-06-18,'Mad Money' Lightning Round: Buy, Buy, Buy Celgene; I'm a Believer
2015-06-17,Jim Cramer's 'Mad Money' Recap: Thanks for Nothing, Janet Yellen
2015-06-17,Spark Therapeutics To Participate In Two International Conferences In London In June
2015-06-13,Bluebird Sickle Cell Gene Therapy Results Keep Getting Better
2015-05-21,Bluebird Bio First Look at Gene Therapy for Sickle Cell Disease
2015-05-06,Spark Therapeutics Reports First Quarter 2015 Results
2015-05-04,Spark Therapeutics Drops After Rival Blindness Therapy Effectiveness Declines
2015-05-01,Spark Therapeutics To Have Multiple Presentations At 2015 ARVO Meeting
2015-04-30,Spark Therapeutics, Inc. To Host Conference Call On May 6th At 8:30a.m. To Discuss First Quarter 2015 Results
2015-04-28,Spark Therapeutics And Clearside Biomedical Announce Exclusive Option To License Technology For Potentially Differentiated Delivery Of Gene Therapy To The Eye
2015-04-26,Gene Therapy Stocks on Watch Following Failure of Celladon's Heart Failure Trial
2015-04-17,IPO Market 'Has Been a Lonely Place' but Pace Is Picking Up
2015-04-16,The Top 5 Best IPO Performers in the Last Year
2015-04-06,Biotech Stocks Still Feeling Healthy Despite Bubble Talk
2015-03-25,Celladon Heart-Failure Study Looms Large as Next Big Test for Gene Therapy
2015-03-18,Spark Therapeutics Reports Full Year 2014 Financial Results
2015-03-17,'Mad Money' Lightning Round: I LIke H&R Block, RR Donnelley
2015-03-16,Jim Cramer's 'Mad Money' Recap: This Is One Stupid Market
2015-02-26,Spark Therapeutics To Participate In The 35th Annual Cowen And Company Health Care Conference
2015-02-04,Spark Therapeutics Announces Closing Of Its Initial Public Offering
2015-01-30,IPO Roundup: Shake Shack Shares More Than Double Out of Gate
2015-01-30,Spark Therapeutics Announces Pricing Of Its Initial Public Offering
,
2017-03-10,OPHTHOTECH 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General And Kahn Swick & Foti, LLC Remind Investors Of Deadline In Class Action Lawsuit Against Ophthotech Corporation - (OPHT)
2017-03-03,SHAREHOLDER COMPLAINT: Levi & Korsinsky, LLP Reminds Investors Of Ophthotech Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of March 13, 2017
2017-02-28,Ophthotech Corporation Selected Financial Data (unaudited) (in Thousands, Except Per Share Data)
2017-02-27,OPHT SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Ophthotech Corporation And A Lead Plaintiff Deadline Of March 13, 2017
2017-02-22,SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Ophthotech Corporation To Contact The Firm Before Lead Plaintiff Deadline
2017-02-22,OPHT INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Ophthotech Corporation And A Lead Plaintiff Deadline Of March 13, 2017
2017-02-22,Ophthotech Corporation To Report Fourth Quarter And Full Year 2016 Financial Results And Host Conference Call On Tuesday, February 28, 2017
2017-02-17,OPHTHOTECH SHAREHOLDER ALERT By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ophthotech Corporation - (OPHT)
2017-02-17,INVESTOR COMPLAINT: Levi & Korsinsky, LLP Reminds Investors Of Ophthotech Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of March 13, 2017
2017-02-13,OPHT SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Ophthotech Corporation And A Lead Plaintiff Deadline Of March 13, 2017
2017-02-08,DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Ophthotech Corporation To Contact The Firm
2017-02-03,OPHTHOTECH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ophthotech Corporation - (OPHT)
2017-02-01,Ophthotech Announces Strategic Review Plan
2017-01-30,Robbins Arroyo LLP: Ophthotech Corporation (OPHT) Misled Shareholders According To A Recently Filed Class Action
2017-01-30,Bragar Eagel & Squire, P.C. Announces That A Class Action Lawsuit Has Been Filed Against Ophthotech Corporation (OPHT) And Encourages Investors To Contact The Firm
2017-01-18,Lifshitz & Miller Law Firm Announces Investigation Of Abeona Therapeutics Inc., Agile Therapeutics, Inc., Alere Inc., Floteck Industries, Inc., Insys Therapeutics Inc., MTS Systems Corporation, Ophthotech Corporation And Teekay Corporation
2017-01-17,SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against Ophthotech Corporation (OPHT) & Lead Plaintiff Deadline - March 13, 2017
2017-01-05,These 5 Stocks Under $10 Could Make You a Lot of Money
2016-12-17,Learn to Shift Gears in Your Trading
2016-12-12,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Ophthotech Corporation (OPHT)
2016-12-12,Dow Posts Another Record Close but Nasdaq Slips Amid Tech Declines
2016-12-12,Dow Sets Record as Oil Settles Higher but Nasdaq Slips Amid Tech Declines
2016-12-12,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of An Investigation Involving Possible Securities Fraud Violations By Ophthotech Corporation And Certain Officers And Directors
2016-12-12,How to Trade Monday's Most Active Stocks - AMD, CBS, Ophthotech and More
2016-12-12,Oversold Conditions For Ophthotech (OPHT)
2016-12-12,Dow Hits Record, Gets Lift From Energy Sector as Oil Prices Surge
2016-12-12,Ophthotech Plunges on Eye-Drug-Study Failure
2016-12-12,Jim Cramer -- Ophthotech's Loss a Cautionary Win for Regeneron
2016-12-12,Ophthtech Shares Plunge as Drug Fails in Late Stage Trial
2016-12-12,Ophthotech Announces Results From Pivotal Phase 3 Trials Of Fovista® In Wet Age-Related Macular Degeneration
2016-11-14,January 2019 Options Now Available For Ophthotech (OPHT)
2016-11-08,Ophthotech Reports Third Quarter 2016 Financial And Operating Results
2016-10-31,Ophthotech Announces The Publication Of Fovista® In Combination With Lucentis® Phase 2b Study Results In Ophthalmology®, The Journal Of The American Academy Of Ophthalmology
2016-10-24,Ophthotech Corporation To Report Third Quarter 2016 Financial Results And Host Conference Call On Tuesday, November 8, 2016
2016-10-21,'Mad Money' Lightning Round: United and Southwest Better Than JetBlue?
2016-10-20,Jim Cramer's 'Mad Money' Recap: American Express Is Back on a Growth Track
2016-09-06,Ophthotech Corporation To Present At The Morgan Stanley Global Healthcare Conference
2016-08-03,Insider Trading Alert - OPHT, MXIM And JBLU Traded By Insiders
2016-08-03,Ophthotech Reports Second Quarter 2016 Financial And Operating Results
2016-08-02,Ophthotech Announces Election Of Ian F. Smith, Vertex Executive Vice President And Chief Financial Officer, To Its Board Of Directors
2016-07-27,Short Interest Moves 17% Higher For OPHT
2016-07-25,Ophthotech Corporation To Report Second Quarter 2016 Financial Results And Host Conference Call On Wednesday, August 3, 2016
2016-07-19,These 4 Stocks Are Poised for Breakout Profits
2016-06-20,Ophthotech Completes Patient Recruitment In Phase 3 Trial Of Fovista® Anti-PDGF Therapy In Combination With Eylea® Or Avastin® In Wet Age-Related Macular Degeneration
2016-06-08,Insider Trading Alert - OPHT, MMS And MLNX Traded By Insiders
2016-06-03,Stock To Watch: Ophthotech (OPHT) In Perilous Reversal
2016-06-02,Analysts' Actions -- Box, Bristol-Myers, Newmont Mining, Exxon Mobil and More
2016-05-31,Ophthotech Corporation To Present At The Goldman Sachs 37th Annual Global Healthcare Conference
2016-05-04,Ophthotech Reports First Quarter 2016 Financial And Operating Results
2016-04-28,Carmen A. Puliafito, MD, MBA, Former Dean Of Keck School Of Medicine Of The University Of Southern California, Joins Ophthotech As Chief Of Strategic Development
2016-04-26,Ophthotech Corporation To Report First Quarter 2016 Financial Results And Host Conference Call On Wednesday, May 4, 2016
2016-04-22,Trade-Ideas: Ophthotech (OPHT) Is Today's "Perilous Reversal" Stock
2016-04-11,Ophthotech (OPHT) Highlighted As Weak On High Volume
2016-03-31,Ophthotech (OPHT) Is Today's Dead Cat Bounce Stock
2016-03-30,Perilous Reversal Stock: Ophthotech (OPHT)
2016-03-08,Ophthotech Corporation To Present At Barclays Global Healthcare Conference 2016
2016-03-04,Ophthotech (OPHT) Showing Signs Of A Dead Cat Bounce Today
2016-02-24,Ophthotech Reports Fourth Quarter And Full Year 2015 Financial And Operating Results
2016-02-19,Ophthotech (OPHT) Is Today's Dead Cat Bounce Stock
2016-02-18,Ophthotech Corporation To Present At RBC Capital Markets Healthcare Conference
2016-02-17,Ophthotech Corporation To Report Fourth Quarter 2015 Financial Results And Host Conference Call On Wednesday, February 24, 2016
2016-02-03,Insider Trading Alert - TLMR, TWC And OPHT Traded By Insiders
2016-02-03,Ophthotech Corporation To Present At The LEERINK Partners 5th Annual Global Healthcare Conference
2016-01-27,Ophthotech Announces First Patient Dosed In Zimura® Phase 2/3 Study To Evaluate Treatment In Patients With Geographic Atrophy, An Advanced Form Of Dry Age-Related Macular Degeneration
2016-01-22,Ophthotech (OPHT) Is Today's Dead Cat Bounce Stock
2016-01-06,Ophthotech Announces Appointment Of David E. Redlick To Its Board Of Directors
2016-01-05,Glenn P. Sblendorio To Join Ophthotech As Executive Vice President, Chief Operating Officer And Chief Financial Officer
2016-01-04,Ophthotech Corporation To Present At The 34th Annual J.P. Morgan Healthcare Conference
2015-12-18,Today Ophthotech (OPHT) Hits New Lifetime High
2015-12-17,Ophthotech (OPHT) Stock: Weak On High Volume Today
2015-12-10,Ophthotech (OPHT) Is Today's Dead Cat Bounce Stock
2015-12-07,Ophthotech (OPHT) Strong On High Relative Volume Today
2015-12-02,Ophthotech Corporation To Present At The Oppenheimer 26th Annual Healthcare Conference
2015-12-01,Ophthotech Corporation To Host R&D Investor Day On December 3, 2015
2015-11-17,Ophthotech Announces That Genentech, A Roche Wholly-Owned Subsidiary, Elects To Exercise Its Right To Opt-in To The Novartis Portion Of The Ophthotech / Novartis Ex-US Agreement For Fovista® To Treat Wet Age-Related Macular Degeneration
2015-11-13,Today's Dead Cat Bounce Stock Is Ophthotech (OPHT)
2015-11-12,Ophthotech Corporation To Present At The 2015 Stifel Healthcare Conference
2015-11-10,Ratings Changes Today
2015-11-05,Ophthotech Reports Third Quarter 2015 Financial And Operating Results
2015-11-02,Ophthotech Corporation To Report Third Quarter 2015 Financial Results And Host Conference Call On Thursday, November 5, 2015
2015-10-26,Ophthotech Completes Patient Recruitment Of The Second Phase 3 Pivotal Trial Of Fovista® Anti-PDGF Therapy In Combination With Lucentis® In Wet Age-Related Macular Degeneration
2015-09-25,Interesting OPHT Put And Call Options For November 20th
2015-09-15,Short Interest Jumps 14.2% For OPHT
2015-09-09,Ophthotech Corporation To Present At The Morgan Stanley Global Healthcare Conference
2015-09-04,Battleground: Will This $5 Biotech Stock Go To $22 Or $1.50?
2015-09-03,First Week of OPHT October 16th Options Trading
2015-09-02,Ophthotech Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2015-08-21,Ophthotech Becomes Oversold (OPHT)
2015-08-07,Analysts' Actions -- Intel, Texas Instruments and Viacom
2015-08-05,Ophthotech Reports Second Quarter 2015 Financial And Operating Results
2015-07-29,Ophthotech Corporation To Report Second Quarter 2015 Financial Results And Host Conference Call On Wednesday, August 5, 2015
2015-07-21,Ophthotech Announces New Senior Leadership Appointments
2015-06-03,Ophthotech Corporation To Present At The Goldman Sachs 36th Annual Global Healthcare Conference
2015-05-13,Ophthotech Corporation To Present At The UBS Global Healthcare Conference
2015-05-11,Ophthotech Reports First Quarter 2015 Financial And Operating Results
2015-05-11,Ophthotech Completes Patient Recruitment Of The First Phase 3 Pivotal Trial Of Fovista® Anti-PDGF Therapy In Combination With Lucentis® In Wet Age-Related Macular Degeneration Program
2015-05-06,Ophthotech Corporation To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference
2015-05-05,Ophthotech Corporation To Announce First Quarter 2015 Financial Results And Host Conference Call On Monday, May 11, 2015
2015-05-04,Ophthotech Corporation To Present At The Deutsche Bank 40th Annual Health Care Conference
2015-03-10,Ophthotech Corporation Achieves Second $50 Million Enrollment Milestone Under Ex-US Licensing And Commercial Agreement With Novartis For Fovista®
2015-03-03,Ophthotech Corporation To Present At The Barclays Global Healthcare Conference
2015-02-23,Ophthotech Reports Fourth Quarter And Full Year 2014 Financial And Operating Results
2015-02-18,Ophthotech Corporation To Announce Fourth Quarter And Full Year 2014 Financial Results And Host Conference Call On Monday, February 23, 2015
2015-02-05,Ophthotech Corporation To Present At The Leerink Global Healthcare Conference
2015-01-05,Ophthotech Corporation To Present At The 33rd Annual J.P. Morgan Healthcare Conference
2014-12-15,Ophthotech Added To NASDAQ Biotechnology Index
2014-12-02,Ophthotech Corporation To Present At The Oppenheimer 25th Annual Healthcare Conference
2014-11-14,Shotgun Investing in Biotech
2014-11-13,Ophthotech Corporation To Present At The Stifel 2014 Healthcare Conference
2014-11-11,Ophthotech Provides Business Update And Reports Third Quarter 2014 Financial Results
2014-11-04,Ophthotech Corporation To Present At The Credit Suisse 2014 Healthcare Conference
2014-11-03,Ophthotech Corporation To Announce Third Quarter 2014 Financial Results And Host Conference Call On Tuesday, November 11, 2014
2014-10-03,Ophthotech Corporation Names Todd N. Smith As Chief Commercial Officer
2014-09-23,Ophthotech Corporation Names Michael G. Atieh As Executive Vice President And Chief Financial And Business Officer
2014-09-16,Ophthotech Announces Fovista® Phase 2b Independent Analysis Shows That Fovista® Anti-PDGF Therapy, Combined With Anti-VEGF Therapy, Is Associated With A Reduction Of Sub-retinal Fibrosis In Wet AMD Patients
2014-09-08,Ophthotech Corporation Achieves $50 Million Milestone Under Ex-US Licensing And Commercial Agreement With Novartis For Fovista®
2014-09-02,Ophthotech Corporation To Present At The 2014 Morgan Stanley Global Healthcare Conference
2014-08-06,Ophthotech Reports Second Quarter 2014 Financial Results And Provides Business Update
2014-08-05,Ophthotech Initiates First Of Several Expansion Studies To Further Evaluate Fovista® (Anti-PDGF) Therapy In Patients With Wet Age-Related Macular Degeneration
2014-07-29,Ophthotech Corporation To Announce Second Quarter 2014 Financial Results And Host Conference Call On Wednesday, August 6, 2014
2014-06-06,4 Swing Trades for Friday, June 6 and Beyond: InterMune, Sanmina, More
2014-06-05,3 Stocks Spiking on Unusual Volume
2014-05-20,Stocks Stumble on Weak Retail Results; GM Slides on Recall Charges
2014-05-20,Why Ophthotech (OPHT) Stock Is Surging Today
2014-02-13,4 Stocks Rising on Unusual Volume
2013-10-03,Top Insider Trades: ACHN PARR OPHT OGEN
2013-09-24,Pharma IPOs: Evoke, Ophthotech
,
2017-03-24,Ford Motor, Constellation Brands, Cypress Semiconductor: 'Mad Money' Lightning Round
2017-03-24,Legislative Circus Is Stalling Stocks: Cramer's 'Mad Money' Recap (Thursday 3/23/17)
2017-03-22,OPKO Receives FDA Orphan Drug Status For Its New Oligonucleotide To Treat Genetic Neurological Disorder
2017-03-16,4 Stocks Under $10 Setting Up to Break Out
2017-03-14,OPKO Health's GeneDx To Have Significant Presence At ACMG 2017
2017-03-14,OPKO Health To Participate In The Barclays Global Healthcare Conference
2017-03-08,OPKO Receives EU Orphan Drug Status For Its New Oligonucleotide To Treat Genetic Neurological Disorder 
2017-03-07,OPKO Subsidiary GenPath Women's Health Announces The Availability Of ClariTest™
2017-03-03,OPKO Health Appoints Dr. Akhtar Ashfaq As Renal Division Senior Vice President, Clinical Research And Development
2017-03-02,Is This The Best Biotech Play for 2017?
2017-03-02,Opko Health, FireEye, KBR: 'Mad Money' Lightning Round
2017-03-02,Don't Be Cowed in the Face of This Bull: Cramer's 'Mad Money' Recap (Wednesday March 1)
2017-03-01,OPKO Health Reports 2016 Financial And Operating Results
2017-02-28,These 5 Stocks Under $10 Are Breaking Out
2017-02-28,OPKO Health's GeneDx Announces Participation In Illumina's IHope Program On International Rare Disease Day
2017-02-27,OPKO Health To Announce 2016 Fourth Quarter Financial Results On March 1, 2017
2017-02-21,OPKO Health To Participate At Upcoming Healthcare Investment Conferences
2017-02-10,Bearish Bets:  A PBM, a Regional Airline and Other Stocks That Look Good Short
2017-02-08,OPKO Spain To Start Trial Of Once-A-Year Intra-Articular Injectable For Osteoarthritis
2017-02-07,OPKO Health Promotes Thomas Nusbickel To Renal Division Chief Commercial Officer
2017-02-02,Ratings Changes Today
2017-02-01,5 Stocks Insiders Love Right Now
2017-02-01,OPKO'S GeneDx Announces Research Collaboration With The Wellcome Trust Sanger Institute
2017-01-10,OPKO Investee Zebra Biologics Announces Collaboration With AbbVie To Discover New Antibody Therapeutics
2017-01-09,OPKO Announces Initiation Of Claros® 1 Clinical Trial For Total PSA
2017-01-04,OPKO Health To Present At The J.P. Morgan 35th Annual Healthcare Conference
2017-01-01,Dow, S&P 500 and Nasdaq Close Out 2016 With Strong Gains
2016-12-30,Closing Bell: Stocks Fall for the Day, but Gain in 2016; Apple, Opko Health Shares Drop
2016-12-30,Dow, S&P 500 and Nasdaq Fall as Technology Sector Pulls Markets Down
2016-12-30,Stocks Mostly Lower on Last Trading Day of 2016
2016-12-30,OPKO Health Provides Update On HGH-CTP Clinical Programs
2016-12-21,RXi Pharmaceuticals Announces Closing Of $11.5 Million Underwritten Public Offering And Full Exercise Of Over-allotment Option
2016-12-20,Analysts' Actions -- Ciena, Salesforce, Square, Western Digital and More
2016-12-19,Ratings Changes Today
2016-12-19,OPKO Health To Be Added To The NASDAQ Biotechnology Index
2016-12-15,'Mad Money' Lightning Round: Kohlberg Kravis Roberts, Opko Health Are Worth It
2016-12-14,Jim Cramer's 'Mad Money' Recap: Mild Pullback Means We Are Getting Back to Normal
2016-11-30,OPKO Health To Participate At Three Investment Conferences In December
2016-11-23,OPKO Announces U.S. Launch Of RAYALDEE™
2016-11-17,Opko Health Has 3 Very Attractive Charts
2016-11-17,OPKO Presents Data On RAYALDEE® At ASN Kidney Week 2016
2016-11-10,Ratings Changes Today
2016-11-07,OPKO Health Reports Third Quarter Financial And Operating Results
2016-11-04,Opko Healthcare's Phillip Frost Is a Major Microcap Investor
2016-11-03,OPKO To Announce Third Quarter Operating And Financial Results On November 7, 2016
2016-10-27,OPKO Health Enters Companion Animal Health Market
2016-10-14,'Mad Money' Lightning Round: I'm Faithful to Opko Health's CEO
2016-10-13,Jim Cramer's 'Mad Money' Recap: Don't Play the Short-Term Market Game
2016-09-27,OPKO Health Appoints Dr. Benjamin Solomon As Managing Director Of GeneDx
2016-09-19,OPKO Health To Present At The Ladenburg Thalmann 2016 Healthcare Conference
2016-09-14,Look for Test of Key Index Again
2016-09-13,OPKO Health Appoints Jane Pine Wood As Chief Legal And Compliance Officer Of BioReference Laboratories
2016-09-06,OPKO To Present Long-acting Human Growth Hormone (hGH-CTP) Phase 2 Pediatric Growth Hormone Deficiency Data At The 55th Annual Meeting Of The European Society For Paediatric Endocrinology
2016-09-01,OPKO Health To Participate In Upcoming September Conferences
2016-08-31,OPKO Health Completes Acquisition Of Transition Therapeutics
2016-08-30,'Mad Money' Lightning Round: I Am Committed to Opko Health
2016-08-29,Jim Cramer's 'Mad Money' Recap: These Are the Sectors to Buy Now
2016-08-26,Transition Therapeutics Shareholders Approve Acquisition By OPKO Health
2016-08-23,OPKO Health Responds To Law Firm Notice Of Investigation
2016-08-23,SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating OPKO Health, Inc. For Potential Breaches Of Fiduciary Duty By Its Board Of Directors
2016-08-22,MabVax Therapeutics Announces The Closing Of Its Public Offering
2016-08-09,Opko Health (OPK) Stock Higher After Q2 Earnings Beat
2016-08-08,OPKO Health Reports Improved Financial And Operating Results
2016-08-04,'Mad Money' Lightning Round: I'm Still With Opko Health
2016-08-03,Jim Cramer's 'Mad Money' Recap: Four Winning Themes, Four to Avoid
2016-08-03,OPKO To Announce Second Quarter Operating And Financial Results On August 8, 2016
2016-06-30,Opko Is a Buying Opportunity After FDA's Approval of Kidney Drug
2016-06-30,OPKO Health To Acquire Transition Therapeutics
2016-06-22,Weak On High Volume: Opko Health (OPK)
2016-06-21,Opko (OPK) Stock Gains as FDA Approves Rayaldee
2016-06-21,Morning Movers: BAC, MRO, NKE, OPK
2016-06-21,'Mad Money' Lightning Round: Buy, Buy, Buy Medtronic
2016-06-21,FDA Approves New Drug Application For RAYALDEE® To Treat Secondary Hyperparathyroidism Associated With Vitamin D Insufficiency In Stage 3-4 Chronic Kidney Disease
2016-06-20,Jim Cramer's 'Mad Money' Recap: Today's Rally Was Good but We Need More
2016-06-14,OPKO Health To Host Analyst & Investor Day In New York City On June 15
2016-06-13,Opko Health (OPK) Is Today's Strong On High Volume Stock
2016-06-13,OPKO Health Announces Move To NASDAQ Stock Market
2016-06-07,OPKO To Discuss Draft Coverage Determinations For 4Kscore® Test At 2016 Jefferies Healthcare Conference
2016-06-02,OPKO Health To Present At The 2016 Jefferies Healthcare Conference
2016-05-27,OPKO Health Receives Proposed/Draft Medicare Local Coverage Determination For 4Kscore® Test
2016-05-11,OPKO Announces Appointment Of Douglass Laidlaw As Vice President Of Medical Affairs
2016-05-10,Biotech Gets a Lifeline
2016-05-10,OPKO Announces Appointment Of Thomas Nusbickel As Senior Vice President Of Pharmaceutical Marketing And Market Access
2016-05-09,OPKO Health Reports First Quarter Financial And Operating Results
2016-05-09,Vifor Fresenius Medical Care Renal Pharma And OPKO Health Enter Into Agreement For OPKO's RAYALDEE®
2016-04-28,OPKO To Announce First Quarter Operating And Financial Results On May 9, 2016
2016-04-28,OPKO Presents Additional Data On RAYALDEE® At National Kidney Foundation Spring Clinical Meetings 2016
2016-04-27,Insiders Are Scooping Up These 5 Stocks
2016-04-27,FDA Accepts Resubmission Of New Drug Application For RAYALDEE®
2016-04-25,OPKO Announces Appointment Of James DeMarco As Senior Vice President Of Pharmaceutical Sales
2016-04-06,5 Stocks Insiders Love Right Now
2016-04-01,OPKO Presents Additional Data On RAYALDEE® At ENDO 2016
2016-03-31,OPKO Presents Additional Data On RAYALDEE® To Treat Secondary Hyperparathyroidism In Chronic Kidney Disease
2016-03-30,4 Big-Volume Stocks to Trade for Big Gains
2016-03-30,Opko Health Plunges, but Still Optimistic After New Drug Fails to Get FDA OK
2016-03-30,Here's Why Opko (OPK) Stock is Plunging Today
2016-03-30,OPKO Receives Complete Response Letter From FDA For RAYALDEE® New Drug Application
2016-03-28,One Reason Opko Health (OPK) Stock is Gaining Today
2016-03-28,OPKO Health Announces Executive Appointment
2016-03-24,OPKO To Present 18-24 Month Clinical Data On Its Long-acting Human Growth Hormone (hGH-CTP) From Open Label Extension (OLE) Phase 2 Pediatric Growth Hormone Deficiency Clinical Study In Oral Presentation At ENDO 2016
2016-03-23,Opko Health Rallies on Expected FDA Approval
2016-03-23,'Mad Money' Lightning Round: Take Coach Over Kors
2016-03-22,Jim Cramer's 'Mad Money' Recap: Markets Keep Moving Despite Terrorism
2016-03-21,Ratings Changes Today
2016-03-16,OPKO Health Announces Dosing Of First Subject In Phase 1 Clinical Study Of A Long-Acting Oxyntomodulin For The Treatment Of Obesity And Type II Diabetes
2016-03-15,OPKO 4Kscore® Recommended In 2016 European Association Of Urology Prostate Cancer Guidelines
2016-03-15,OPKO Health Names Dr. Gregory Henderson President Of Bio-Reference Laboratories
2016-03-07,OPKO Health To Present At The 2016 Barclays Global Healthcare Conference
2016-03-02,OPKO's GeneDx Presenting On A Number Of Topics At The 2016 ACMG Annual Clinical Genetics Meeting
2016-03-01,Opko Health (OPK) Stock Down Following Q4 Results
2016-03-01,Ratings Changes Today
2016-02-29,OPKO Announces Financial And Operating Results
2016-02-29,OPKO's GeneDx Recognizes International Rare Disease Day With Donation Of Free Exome Tests To Syndromes Without A Name
2016-02-24,OPKO's GeneDx Participating In The Molecular Medicine Tri-Conference 2016 In San Francisco
2016-02-23,OPKO Health Announces Dosing Of First Patient In Phase 2a Clinical Study Of A Long-Acting Factor VIIa For The Treatment Of Hemophilia
2016-02-23,OPKO To Announce 2015 Fourth Quarter And Full Year Financial Results On February 29, 2016
2016-02-18,OPKO Health To Present At The RBC Capital Markets Global Healthcare Conference
2016-02-17,Opko Health (OPK) Marked As A Barbarian At The Gate
2016-02-09,Study Demonstrates OPKO's 4Kscore Test Reduces Unnecessary Prostate Biopsies While Improving Risk Prediction For Aggressive Prostate Cancer
2016-01-29,'Mad Money' Lightning Round: I'm Buy, Buy, Buying T-Mobile US
2016-01-28,Jim Cramer's 'Mad Money' Recap: Market 'Trash' Will Make You Money
2016-01-22,OPKO's GeneDx To Present At Personalized Medicine World Conference
2016-01-14,Will Insiders Be Tempted To Buy More OPK At The New 52-Week Low?
2016-01-06,OPKO Health To Present At The J.P. Morgan 34th Annual Healthcare Conference
2016-01-05,Conversion Right Extended On OPKO 3.0% Convertible Senior Notes
2015-12-23,Jim Cramer's 'Mad Money' Recap: The Sellers Have Left the Building
2015-12-21,OPKO's GeneDx Study Of More Than 10,000 Individuals Tested With Multigene NGS Hereditary Cancer Panel Reveals New Risks
2015-12-14,OPKO's GeneDx Subsidiary And North Shore-LIJ Health System Form Strategic Alliance For Genetic Testing
2015-12-10,'Mad Money' Lightning Round: Take a Longer View on Skechers
2015-12-09,Jim Cramer's 'Mad Money' Recap: Don't Leave the Market's Table Now
2015-12-09,OPKO's GeneDx Study Demonstrates Whole Exome Sequencing Usefulness In Diagnosing Rare Disorders
2015-12-02,OPKO Health To Present At The Oppenheimer 26th Annual Healthcare Conference
2015-11-17,OPKO Health To Present At The Jefferies Autumn 2015 Global Healthcare Conference
2015-11-16,OPKO Licensee TESARO Announces The Launch Of VARUBI(TM) (Rolapitant) In The United States
2015-11-13,Ratings Changes Today
2015-11-12,OPKO 4Kscore Test Receives Category I CPT Code Approval
2015-11-11,Opko Health (OPK) Strong On High Relative Volume Today
2015-11-10,Opko Health (OPK) Stock Soaring on Earnings Beat
2015-11-09,OPKO Announces Third Quarter Financial And Operating Results
2015-11-09,Opko Health (OPK) Stock Declines Ahead of Earnings
2015-11-06,OPKO Health Refinances Bio-Reference Laboratories Credit Facility
2015-11-05,OPKO To Announce Third Quarter Operating And Financial Results On November 9, 2015
2015-11-05,Additional Phase 3 Data Supporting OPKO's Rayaldee As A Treatment For Secondary Hyperparathyroidism In Chronic Kidney Disease To Be Presented At Kidney Week 2015
2015-10-22,OPKO Health Expands Portfolio Of Tests For Inherited Forms Of Cancer
2015-10-20,Opko Health (OPK) In A Perilous Reversal
2015-10-15,5 Stocks Under $10 to Buy on Weakness
2015-10-15,'Mad Money' Lightning Round: I'm Not Abandoning Rite Aid
2015-10-14,Jim Cramer's 'Mad Money' Recap: Be Patient, Then Start Buying
2015-10-14,Opko Health (OPK) Is Strong On High Volume Today
2015-10-13,Vanderbilt University School Of Medicine And OPKO Health Collaborate On Genomics
2015-10-08,OPKO To Host Symposium To Present Clinical Data On Its Long-acting Human Growth Hormone At The 49th Annual Meeting Of The Japanese Society For Pediatric Endocrinology
2015-10-07,OPKO Presents Clinical Data On Its Long-acting Human Growth Hormone (hGH-CTP) In Two Oral Presentations At The 54th Annual Meeting Of The European Society For Pediatric Endocrinology (ESPE)
2015-10-01,Conversion Right Extended On OPKO 3.0% Convertible Senior Notes
2015-10-01,Interesting OPK Put And Call Options For November 13th
2015-09-25,Water-Logged And Getting Wetter: Opko Health (OPK)
2015-09-25,Jim Cramer's Top Takeaways: Eli Lilly, Caterpillar, Opko Health
2015-09-24,Jim Cramer's 'Mad Money' Recap: Don't Take It Personal but Your Stocks Are Going Down
2015-09-24,Strong On High Volume: Opko Health (OPK)
2015-09-22,OPKO Health To Present At The Ladenburg Thalmann 2015 Healthcare Conference
2015-09-16,Insider Trading Alert - RNST, OPK And IVR Traded By Insiders
2015-09-16,5 Stocks Insiders Love Right Now
2015-09-11,3 Drugs Stocks Dragging The Industry Down
2015-09-09,OPKO Health Announces Global License Agreement For The Discovery Of Novel Antimicrobials
2015-09-03,Interesting OPK Put And Call Options For October 23rd
2015-09-02,OPKO Licensee TESARO Receives FDA Approval For VARUBI™ (rolapitant)
2015-09-01,The Numbers Behind Biotech's Horrible, No Good, Awful August
2015-08-31,Ratings Changes Today
2015-08-27,Perilous Reversal Watch: Opko Health (OPK)
2015-08-26,Strong On High Volume: Opko Health (OPK)
2015-08-26,OPKO Letter To Shareholders
2015-08-25,OPKO Health To Be Present At The Barrington Research Fall Investment Conference
2015-08-24,Today's Weak On High Volume Stock: Opko Health (OPK)
2015-08-21,'Mad Money' Lightning Round: I'm Staying Away From Alibaba
2015-08-20,Jim Cramer's 'Mad Money' Recap: Market Slaughters Disney, With More to Come
2015-08-20,OPKO Completes Acquisition Of Bio-Reference Laboratories
2015-08-19,OPKO Lab Signs Contracts With Leading Preferred Provider Networks For Laboratory Testing Services Including The 4Kscore® Test
2015-08-06,3 Stocks Pushing The Health Services Industry Lower
2015-08-05,OPKO Announces Second Quarter Operating And Financial Results
2015-08-05,Two Reports On HGH-CTP Pediatric Phase 2 Clinical Data Accepted For Oral Presentation At The 54th Annual Meeting Of The European Society For Paediatric Endocrinology (ESPE Conference)
2015-07-30,OPKO To Announce Second Quarter Operating And Financial Results On August 5, 2015
2017-03-24,Ford Motor, Constellation Brands, Cypress Semiconductor: 'Mad Money' Lightning Round
2017-03-24,Legislative Circus Is Stalling Stocks: Cramer's 'Mad Money' Recap (Thursday 3/23/17)
2017-03-22,OPKO Receives FDA Orphan Drug Status For Its New Oligonucleotide To Treat Genetic Neurological Disorder
2017-03-16,4 Stocks Under $10 Setting Up to Break Out
2017-03-14,OPKO Health's GeneDx To Have Significant Presence At ACMG 2017
2017-03-14,OPKO Health To Participate In The Barclays Global Healthcare Conference
2017-03-08,OPKO Receives EU Orphan Drug Status For Its New Oligonucleotide To Treat Genetic Neurological Disorder 
2017-03-07,OPKO Subsidiary GenPath Women's Health Announces The Availability Of ClariTest™
2017-03-03,OPKO Health Appoints Dr. Akhtar Ashfaq As Renal Division Senior Vice President, Clinical Research And Development
2017-03-02,Is This The Best Biotech Play for 2017?
2017-03-02,Opko Health, FireEye, KBR: 'Mad Money' Lightning Round
2017-03-02,Don't Be Cowed in the Face of This Bull: Cramer's 'Mad Money' Recap (Wednesday March 1)
2017-03-01,OPKO Health Reports 2016 Financial And Operating Results
2017-02-28,These 5 Stocks Under $10 Are Breaking Out
2017-02-28,OPKO Health's GeneDx Announces Participation In Illumina's IHope Program On International Rare Disease Day
2017-02-27,OPKO Health To Announce 2016 Fourth Quarter Financial Results On March 1, 2017
2017-02-21,OPKO Health To Participate At Upcoming Healthcare Investment Conferences
2017-02-10,Bearish Bets:  A PBM, a Regional Airline and Other Stocks That Look Good Short
2017-02-08,OPKO Spain To Start Trial Of Once-A-Year Intra-Articular Injectable For Osteoarthritis
2017-02-07,OPKO Health Promotes Thomas Nusbickel To Renal Division Chief Commercial Officer
2017-02-02,Ratings Changes Today
2017-02-01,5 Stocks Insiders Love Right Now
2017-02-01,OPKO'S GeneDx Announces Research Collaboration With The Wellcome Trust Sanger Institute
2017-01-10,OPKO Investee Zebra Biologics Announces Collaboration With AbbVie To Discover New Antibody Therapeutics
2017-01-09,OPKO Announces Initiation Of Claros® 1 Clinical Trial For Total PSA
2017-01-04,OPKO Health To Present At The J.P. Morgan 35th Annual Healthcare Conference
2017-01-01,Dow, S&P 500 and Nasdaq Close Out 2016 With Strong Gains
2016-12-30,Closing Bell: Stocks Fall for the Day, but Gain in 2016; Apple, Opko Health Shares Drop
2016-12-30,Dow, S&P 500 and Nasdaq Fall as Technology Sector Pulls Markets Down
2016-12-30,Stocks Mostly Lower on Last Trading Day of 2016
2016-12-30,OPKO Health Provides Update On HGH-CTP Clinical Programs
2016-12-21,RXi Pharmaceuticals Announces Closing Of $11.5 Million Underwritten Public Offering And Full Exercise Of Over-allotment Option
2016-12-20,Analysts' Actions -- Ciena, Salesforce, Square, Western Digital and More
2016-12-19,Ratings Changes Today
2016-12-19,OPKO Health To Be Added To The NASDAQ Biotechnology Index
2016-12-15,'Mad Money' Lightning Round: Kohlberg Kravis Roberts, Opko Health Are Worth It
2016-12-14,Jim Cramer's 'Mad Money' Recap: Mild Pullback Means We Are Getting Back to Normal
2016-11-30,OPKO Health To Participate At Three Investment Conferences In December
2016-11-23,OPKO Announces U.S. Launch Of RAYALDEE™
2016-11-17,Opko Health Has 3 Very Attractive Charts
2016-11-17,OPKO Presents Data On RAYALDEE® At ASN Kidney Week 2016
2016-11-10,Ratings Changes Today
2016-11-07,OPKO Health Reports Third Quarter Financial And Operating Results
2016-11-04,Opko Healthcare's Phillip Frost Is a Major Microcap Investor
2016-11-03,OPKO To Announce Third Quarter Operating And Financial Results On November 7, 2016
2016-10-27,OPKO Health Enters Companion Animal Health Market
2016-10-14,'Mad Money' Lightning Round: I'm Faithful to Opko Health's CEO
2016-10-13,Jim Cramer's 'Mad Money' Recap: Don't Play the Short-Term Market Game
2016-09-27,OPKO Health Appoints Dr. Benjamin Solomon As Managing Director Of GeneDx
2016-09-19,OPKO Health To Present At The Ladenburg Thalmann 2016 Healthcare Conference
2016-09-14,Look for Test of Key Index Again
2016-09-13,OPKO Health Appoints Jane Pine Wood As Chief Legal And Compliance Officer Of BioReference Laboratories
2016-09-06,OPKO To Present Long-acting Human Growth Hormone (hGH-CTP) Phase 2 Pediatric Growth Hormone Deficiency Data At The 55th Annual Meeting Of The European Society For Paediatric Endocrinology
2016-09-01,OPKO Health To Participate In Upcoming September Conferences
2016-08-31,OPKO Health Completes Acquisition Of Transition Therapeutics
2016-08-30,'Mad Money' Lightning Round: I Am Committed to Opko Health
2016-08-29,Jim Cramer's 'Mad Money' Recap: These Are the Sectors to Buy Now
2016-08-26,Transition Therapeutics Shareholders Approve Acquisition By OPKO Health
2016-08-23,OPKO Health Responds To Law Firm Notice Of Investigation
2016-08-23,SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating OPKO Health, Inc. For Potential Breaches Of Fiduciary Duty By Its Board Of Directors
2016-08-22,MabVax Therapeutics Announces The Closing Of Its Public Offering
2016-08-09,Opko Health (OPK) Stock Higher After Q2 Earnings Beat
2016-08-08,OPKO Health Reports Improved Financial And Operating Results
2016-08-04,'Mad Money' Lightning Round: I'm Still With Opko Health
2016-08-03,Jim Cramer's 'Mad Money' Recap: Four Winning Themes, Four to Avoid
2016-08-03,OPKO To Announce Second Quarter Operating And Financial Results On August 8, 2016
2016-06-30,Opko Is a Buying Opportunity After FDA's Approval of Kidney Drug
2016-06-30,OPKO Health To Acquire Transition Therapeutics
2016-06-22,Weak On High Volume: Opko Health (OPK)
2016-06-21,Opko (OPK) Stock Gains as FDA Approves Rayaldee
2016-06-21,Morning Movers: BAC, MRO, NKE, OPK
2016-06-21,'Mad Money' Lightning Round: Buy, Buy, Buy Medtronic
2016-06-21,FDA Approves New Drug Application For RAYALDEE® To Treat Secondary Hyperparathyroidism Associated With Vitamin D Insufficiency In Stage 3-4 Chronic Kidney Disease
2016-06-20,Jim Cramer's 'Mad Money' Recap: Today's Rally Was Good but We Need More
2016-06-14,OPKO Health To Host Analyst & Investor Day In New York City On June 15
2016-06-13,Opko Health (OPK) Is Today's Strong On High Volume Stock
2016-06-13,OPKO Health Announces Move To NASDAQ Stock Market
2016-06-07,OPKO To Discuss Draft Coverage Determinations For 4Kscore® Test At 2016 Jefferies Healthcare Conference
2016-06-02,OPKO Health To Present At The 2016 Jefferies Healthcare Conference
2016-05-27,OPKO Health Receives Proposed/Draft Medicare Local Coverage Determination For 4Kscore® Test
2016-05-11,OPKO Announces Appointment Of Douglass Laidlaw As Vice President Of Medical Affairs
2016-05-10,Biotech Gets a Lifeline
2016-05-10,OPKO Announces Appointment Of Thomas Nusbickel As Senior Vice President Of Pharmaceutical Marketing And Market Access
2016-05-09,OPKO Health Reports First Quarter Financial And Operating Results
2016-05-09,Vifor Fresenius Medical Care Renal Pharma And OPKO Health Enter Into Agreement For OPKO's RAYALDEE®
2016-04-28,OPKO To Announce First Quarter Operating And Financial Results On May 9, 2016
2016-04-28,OPKO Presents Additional Data On RAYALDEE® At National Kidney Foundation Spring Clinical Meetings 2016
2016-04-27,Insiders Are Scooping Up These 5 Stocks
2016-04-27,FDA Accepts Resubmission Of New Drug Application For RAYALDEE®
2016-04-25,OPKO Announces Appointment Of James DeMarco As Senior Vice President Of Pharmaceutical Sales
2016-04-06,5 Stocks Insiders Love Right Now
2016-04-01,OPKO Presents Additional Data On RAYALDEE® At ENDO 2016
2016-03-31,OPKO Presents Additional Data On RAYALDEE® To Treat Secondary Hyperparathyroidism In Chronic Kidney Disease
2016-03-30,4 Big-Volume Stocks to Trade for Big Gains
2016-03-30,Opko Health Plunges, but Still Optimistic After New Drug Fails to Get FDA OK
2016-03-30,Here's Why Opko (OPK) Stock is Plunging Today
2016-03-30,OPKO Receives Complete Response Letter From FDA For RAYALDEE® New Drug Application
2016-03-28,One Reason Opko Health (OPK) Stock is Gaining Today
2016-03-28,OPKO Health Announces Executive Appointment
2016-03-24,OPKO To Present 18-24 Month Clinical Data On Its Long-acting Human Growth Hormone (hGH-CTP) From Open Label Extension (OLE) Phase 2 Pediatric Growth Hormone Deficiency Clinical Study In Oral Presentation At ENDO 2016
2016-03-23,Opko Health Rallies on Expected FDA Approval
2016-03-23,'Mad Money' Lightning Round: Take Coach Over Kors
2016-03-22,Jim Cramer's 'Mad Money' Recap: Markets Keep Moving Despite Terrorism
2016-03-21,Ratings Changes Today
2016-03-16,OPKO Health Announces Dosing Of First Subject In Phase 1 Clinical Study Of A Long-Acting Oxyntomodulin For The Treatment Of Obesity And Type II Diabetes
2016-03-15,OPKO 4Kscore® Recommended In 2016 European Association Of Urology Prostate Cancer Guidelines
2016-03-15,OPKO Health Names Dr. Gregory Henderson President Of Bio-Reference Laboratories
2016-03-07,OPKO Health To Present At The 2016 Barclays Global Healthcare Conference
2016-03-02,OPKO's GeneDx Presenting On A Number Of Topics At The 2016 ACMG Annual Clinical Genetics Meeting
2016-03-01,Opko Health (OPK) Stock Down Following Q4 Results
2016-03-01,Ratings Changes Today
2016-02-29,OPKO Announces Financial And Operating Results
2016-02-29,OPKO's GeneDx Recognizes International Rare Disease Day With Donation Of Free Exome Tests To Syndromes Without A Name
2016-02-24,OPKO's GeneDx Participating In The Molecular Medicine Tri-Conference 2016 In San Francisco
2016-02-23,OPKO Health Announces Dosing Of First Patient In Phase 2a Clinical Study Of A Long-Acting Factor VIIa For The Treatment Of Hemophilia
2016-02-23,OPKO To Announce 2015 Fourth Quarter And Full Year Financial Results On February 29, 2016
2016-02-18,OPKO Health To Present At The RBC Capital Markets Global Healthcare Conference
2016-02-17,Opko Health (OPK) Marked As A Barbarian At The Gate
2016-02-09,Study Demonstrates OPKO's 4Kscore Test Reduces Unnecessary Prostate Biopsies While Improving Risk Prediction For Aggressive Prostate Cancer
2016-01-29,'Mad Money' Lightning Round: I'm Buy, Buy, Buying T-Mobile US
2016-01-28,Jim Cramer's 'Mad Money' Recap: Market 'Trash' Will Make You Money
2016-01-22,OPKO's GeneDx To Present At Personalized Medicine World Conference
2016-01-14,Will Insiders Be Tempted To Buy More OPK At The New 52-Week Low?
2016-01-06,OPKO Health To Present At The J.P. Morgan 34th Annual Healthcare Conference
2016-01-05,Conversion Right Extended On OPKO 3.0% Convertible Senior Notes
2015-12-23,Jim Cramer's 'Mad Money' Recap: The Sellers Have Left the Building
2015-12-21,OPKO's GeneDx Study Of More Than 10,000 Individuals Tested With Multigene NGS Hereditary Cancer Panel Reveals New Risks
2015-12-14,OPKO's GeneDx Subsidiary And North Shore-LIJ Health System Form Strategic Alliance For Genetic Testing
2015-12-10,'Mad Money' Lightning Round: Take a Longer View on Skechers
2015-12-09,Jim Cramer's 'Mad Money' Recap: Don't Leave the Market's Table Now
2015-12-09,OPKO's GeneDx Study Demonstrates Whole Exome Sequencing Usefulness In Diagnosing Rare Disorders
2015-12-02,OPKO Health To Present At The Oppenheimer 26th Annual Healthcare Conference
2015-11-17,OPKO Health To Present At The Jefferies Autumn 2015 Global Healthcare Conference
2015-11-16,OPKO Licensee TESARO Announces The Launch Of VARUBI(TM) (Rolapitant) In The United States
2015-11-13,Ratings Changes Today
2015-11-12,OPKO 4Kscore Test Receives Category I CPT Code Approval
2015-11-11,Opko Health (OPK) Strong On High Relative Volume Today
2015-11-10,Opko Health (OPK) Stock Soaring on Earnings Beat
2015-11-09,OPKO Announces Third Quarter Financial And Operating Results
2015-11-09,Opko Health (OPK) Stock Declines Ahead of Earnings
2015-11-06,OPKO Health Refinances Bio-Reference Laboratories Credit Facility
2015-11-05,OPKO To Announce Third Quarter Operating And Financial Results On November 9, 2015
2015-11-05,Additional Phase 3 Data Supporting OPKO's Rayaldee As A Treatment For Secondary Hyperparathyroidism In Chronic Kidney Disease To Be Presented At Kidney Week 2015
2015-10-22,OPKO Health Expands Portfolio Of Tests For Inherited Forms Of Cancer
2015-10-20,Opko Health (OPK) In A Perilous Reversal
2015-10-15,5 Stocks Under $10 to Buy on Weakness
2015-10-15,'Mad Money' Lightning Round: I'm Not Abandoning Rite Aid
2015-10-14,Jim Cramer's 'Mad Money' Recap: Be Patient, Then Start Buying
2015-10-14,Opko Health (OPK) Is Strong On High Volume Today
2015-10-13,Vanderbilt University School Of Medicine And OPKO Health Collaborate On Genomics
2015-10-08,OPKO To Host Symposium To Present Clinical Data On Its Long-acting Human Growth Hormone At The 49th Annual Meeting Of The Japanese Society For Pediatric Endocrinology
2015-10-07,OPKO Presents Clinical Data On Its Long-acting Human Growth Hormone (hGH-CTP) In Two Oral Presentations At The 54th Annual Meeting Of The European Society For Pediatric Endocrinology (ESPE)
2015-10-01,Conversion Right Extended On OPKO 3.0% Convertible Senior Notes
2015-10-01,Interesting OPK Put And Call Options For November 13th
2015-09-25,Water-Logged And Getting Wetter: Opko Health (OPK)
2015-09-25,Jim Cramer's Top Takeaways: Eli Lilly, Caterpillar, Opko Health
2015-09-24,Jim Cramer's 'Mad Money' Recap: Don't Take It Personal but Your Stocks Are Going Down
2015-09-24,Strong On High Volume: Opko Health (OPK)
2015-09-22,OPKO Health To Present At The Ladenburg Thalmann 2015 Healthcare Conference
2015-09-16,Insider Trading Alert - RNST, OPK And IVR Traded By Insiders
2015-09-16,5 Stocks Insiders Love Right Now
2015-09-11,3 Drugs Stocks Dragging The Industry Down
2015-09-09,OPKO Health Announces Global License Agreement For The Discovery Of Novel Antimicrobials
2015-09-03,Interesting OPK Put And Call Options For October 23rd
2015-09-02,OPKO Licensee TESARO Receives FDA Approval For VARUBI™ (rolapitant)
2015-09-01,The Numbers Behind Biotech's Horrible, No Good, Awful August
2015-08-31,Ratings Changes Today
2015-08-27,Perilous Reversal Watch: Opko Health (OPK)
2015-08-26,Strong On High Volume: Opko Health (OPK)
2015-08-26,OPKO Letter To Shareholders
2015-08-25,OPKO Health To Be Present At The Barrington Research Fall Investment Conference
2015-08-24,Today's Weak On High Volume Stock: Opko Health (OPK)
2015-08-21,'Mad Money' Lightning Round: I'm Staying Away From Alibaba
2015-08-20,Jim Cramer's 'Mad Money' Recap: Market Slaughters Disney, With More to Come
2015-08-20,OPKO Completes Acquisition Of Bio-Reference Laboratories
2015-08-19,OPKO Lab Signs Contracts With Leading Preferred Provider Networks For Laboratory Testing Services Including The 4Kscore® Test
2015-08-06,3 Stocks Pushing The Health Services Industry Lower
2015-08-05,OPKO Announces Second Quarter Operating And Financial Results
2015-08-05,Two Reports On HGH-CTP Pediatric Phase 2 Clinical Data Accepted For Oral Presentation At The 54th Annual Meeting Of The European Society For Paediatric Endocrinology (ESPE Conference)
2015-07-30,OPKO To Announce Second Quarter Operating And Financial Results On August 5, 2015
2017-01-12,These 5 Stocks Under $10 Could Explode Higher Soon
2016-05-26,These 5 Stocks Under $10 Are About to Soar Higher
2015-11-17,Opexa Therapeutics Chosen As One Of The Top Autoimmune Therapy Projects To Watch
2015-11-10,Opexa Therapeutics Announces Supportive Preclinical Study Results For Its Neuromyelitis Optica (NMO) Program
2015-11-10,Opexa Therapeutics Reports Third Quarter 2015 Financial Results And Provides Corporate Update
2015-11-06,Opexa Therapeutics Announces News Release Schedule For Third Quarter 2015 Financial Results
2015-10-19,Opexa Therapeutics To Host Analyst And Investor Event On November 10 In New York
2015-10-15,Opexa Therapeutics Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement
2015-10-13,Opexa Therapeutics To Present At BIO Investor Forum
2015-10-06,Opexa Announces Granting Of New T-cell Patents Covering Tcelna®; Patent Estate Increases To 160 Issued Patents
2015-10-01,5 Stocks Under $10 Set to Soar
2015-09-28,Opexa Announces Reverse Stock Split
2015-09-01,Opexa Secures Private Funding For Its NMO Orphan Development Program, Including Planned Phase I/II Clinical Study
2015-08-28,Opexa Therapeutics To Present At September Conferences
2015-08-12,Opexa Therapeutics Reports Second Quarter 2015 Financial Results And Provides Corporate Update
2015-08-03,Opexa Therapeutics Announces News Release And Conference Call Schedule To Discuss Second Quarter 2015 Financial Results
2015-06-11,Opexa Therapeutics CEO To Present At BIO 2015 International Convention
2015-06-09,Opexa Hires Experienced Pharmaceutical Executive As Vice President Of Business Development
2015-06-08,Trade-Ideas: Opexa Therapeutics (OPXA) Is Today's Weak On High Relative Volume Stock
2015-05-29,Today's Weak On High Volume Stock: Opexa Therapeutics (OPXA)
2015-05-21,Opexa Therapeutics To Present At The 2015 Marcum Microcap Conference
2015-05-13,Opexa Therapeutics CEO Invited To Participate In Multiple May Conferences
2015-05-12,Opexa Therapeutics Reports First Quarter 2015 Financial Results And Provides Corporate Update
2015-05-11,Opexa Therapeutics Announces News Release And Conference Call Schedule To Discuss First Quarter 2015 Financial Results
2015-04-20,Opexa Therapeutics Invited To Present Biomarker Data From NMO Patients At The American Academy Of Neurology (AAN) 2015 Annual Meeting
2015-04-09,Opexa Therapeutics, Inc. Announces Completion Of Rights Offering
2015-04-06,Opexa Therapeutics Reminds Shareholders That Rights Offering Expires On April 8, 2015 At 5:00 PM ET
2015-03-10,Opexa Therapeutics Reminds Shareholders That Rights Offering Ownership Date And Time Is Tuesday, March 10, 2015 At 4:00 PM ET
2015-03-09,Opexa Amends Agreement With Merck Serono And Receives Additional $3 Million Payment To Support Ongoing Development Of Tcelna® For Multiple Sclerosis
2015-02-25,Opexa Therapeutics, Inc. Announces Record Date And Subscription Price For Rights Offering
2015-02-23,Opexa Therapeutics Reports Year End 2014 Financial Results And Provides Corporate Update
2015-01-28,Opexa Therapeutics, Inc. Files Registration Statement For Rights Offering
2014-11-18,Opexa Therapeutics Selected As One Of The "Top 10 Advanced Therapy Projects To Watch"
2014-11-11,Opexa Therapeutics CEO Invited To Join Personalized Medicine Panel At New York CEO Conference
2014-11-06,Opexa Therapeutics Reports Third Quarter 2014 Financial Results And Provides Corporate Update
2014-11-05,Opexa Therapeutics Announces News Release And Conference Call Schedule To Discuss Third Quarter 2014 Financial Results
2014-10-22,Opexa Therapeutics Supports National Multiple Sclerosis Society And Walk MS
2014-10-20,Opexa Therapeutics To Present At Cleveland Clinic’s 12th Annual Medical Innovation Summit
2014-10-02,Opexa Therapeutics Announces Analyst And Investor Event
2014-09-29,Opexa Strengthens Patent Portfolio With Expansion Into B-cell Diseases And Announces Allowance Of 98th T-cell Patent
2014-09-16,Opexa Therapeutics, Inc. Announces Termination Of Public Offering Of Common Stock
2014-09-15,Opexa Therapeutics, Inc. Announces Proposed Public Offering Of Common Stock
2014-09-08,Opexa Therapeutics To Target Rare Disease Neuromyelitis Optica (NMO) As Next Development Program
2014-09-02,Opexa Therapeutics To Present At September Conferences
2014-08-14,Opexa Therapeutics Reports Second Quarter 2014 Financial Results And Provides Corporate Update
2014-08-11,Opexa Therapeutics Announces News Release And Conference Call Schedule To Discuss Second Quarter 2014 Financial Results
2014-07-07,Ratings Changes Today
2014-06-30,Opexa Therapeutics Joins Russell Microcap Index
2014-05-14,Opexa Therapeutics Reports First Quarter 2014 Financial Results And Provides Corporate Update
2014-05-13,Opexa Reaches Enrollment Target In Phase IIb Trial Of Personalized Immunotherapy For Secondary Progressive Multiple Sclerosis
2014-05-12,Opexa Therapeutics Announces News Release And Conference Call To Discuss First Quarter 2014 Financial Results
2014-04-22,Opexa Therapeutics To Attend The American Academy Of Neurology Annual Meeting
2014-03-21,Lawsuits, Clinical Studies, Financial Results, And Stock Movements - Analyst Notes On Idenix, BG Medicine, Progenics, Omeros, And Opexa
2014-03-20,Opexa Therapeutics Appoints Prof. Hans-Peter Hartung And Timothy Barabe To The Board Of Directors
2014-02-27,Opexa Therapeutics Reports Year End 2013 Financial Results And Provides Corporate Update
2014-02-26,Opexa Therapeutics Announces News Release And Conference Call Schedule To Discuss Year End 2013 Financial Results
2014-02-11,Opexa Therapeutics CEO To Present At The 2014 Leerink Global Healthcare Conference
2014-01-29,Opexa Therapeutics To Present At The 16th Annual BIO CEO &amp; Investor Conference
2014-01-23,Opexa Therapeutics Chief Scientific Officer Invited As Guest Speaker At The Phacilitate Cell &amp; Gene Therapy Forum
2013-12-23,Opexa Therapeutics, Inc. Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters&#8217;&#160;Option&#160;to Purchase Additional Shares
2013-12-17,Opexa Therapeutics, Inc. Announces Pricing Of Public Offering Of&#160;Common&#160;Stock
2013-12-17,Opexa Therapeutics, Inc. Announces Proposed Public Offering Of Common Stock
2013-12-16,Opexa Therapeutics Provides MS Trial Enrollment Update; 70% Of Patients Enrolled
2013-11-12,Opexa Therapeutics Selected As A &#8220;Top 10 Advanced Therapy Projects To Watch&#8221;
2013-11-08,Opexa CEO Invited To Join Personalized Medicine Panel At New York CEO Conference
2013-11-07,Opexa Therapeutics Reports Third Quarter 2013 Financial Results And Provides Corporate Update
2013-11-06,Opexa Therapeutics Announces News Release And Conference Call Schedule To Discuss Third Quarter 2013 Financial Results
2013-11-06,3 Health Care Stocks Under $10 Making Big Moves
2013-10-23,Opexa Therapeutics Supports National Multiple Sclerosis Society As A Corporate Sponsor Of Walk MS
2013-10-21,Opexa Therapeutics Immune Monitoring Program Featured In Neurology Reviews
2013-10-08,Faruqi &amp; Faruqi, LLP Launches An Investigation Against Opexa Therapeutics, Inc. (OPXA) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
2013-10-07,Opexa Therapeutics&#8217; CEO Featured In Leading Life Science Publication
2013-10-02,Opexa Therapeutics&#8217; Therapy For Multiple Sclerosis Featured In FOX Television News Story
2013-09-30,Opexa CEO Invited Panelist At 9th Annual Burrill Personalized Medicine Meeting
2013-09-27,Opexa To Present At The Aegis Capital Corp. 2013 Healthcare Conference
2013-09-25,Opexa Announces Conversion Of All Convertible Secured Promissory Notes Into&#160;Common&#160;Stock
2013-09-05,Opexa To Present At The Rodman &amp; Renshaw 15th Annual Global Investment Conference
2013-09-04,Opexa Therapeutics, Inc. Announces Closing Of Partial Exercise Of Underwriters&#8217; Option To Purchase Additional Shares Of Common Stock
2013-08-27,Opexa Announces Issuance Of 50th Patent For T-cell Immunotherapy Platform
2013-08-14,Opexa Therapeutics Reports Second Quarter 2013 Financial Results And Provides Corporate Update
2013-08-13,Opexa Therapeutics Announces News Release And Conference Call Schedule To Discuss Second Quarter 2013 Financial Results
2013-08-13,Opexa Therapeutics, Inc. Announces Closing Of Public Offering Of Common Stock
2013-08-07,Opexa Therapeutics, Inc. Announces Pricing Of Public Offering Of&#160;Common&#160;Stock
2013-06-07,5 Stocks Poised for Breakouts
2013-05-31,4 Health Care Stocks Under $10 to Watch
2013-03-15,4 Biotech Stocks Under $5 to Watch
2013-03-04,Opexa Therapeutics To Present At The 6th Annual European Life Science CEO Forum
2013-02-07,Opexa Therapeutics, Inc. Announces Pricing Of Common Stock And Warrant Offering
2013-02-07,Opexa Therapeutics To Present At The 15th Annual BIO CEO &amp; Investor Conference
2013-02-05,Stocks Rebound Sharply; S&P 500, Nasdaq Rise Over 1%
2013-02-05,Investors Overreact to Opexa Finding Scant Interest for Failed Multiple Sclerosis Drug
2013-02-05,Merck Serono And Opexa Therapeutics Enter Into Option And License Agreement For Development Of Tcelna&#8482; (imilecleucel-T) For Treatment Of Multiple Sclerosis
2013-01-23,Opexa Therapeutics Closes Private Note Offering
2013-01-15,Opexa Therapeutics Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement
2012-12-14,Opexa Therapeutics Announces Reverse Stock Split
2012-11-14,Opexa Therapeutics Reports Third Quarter 2012 Financial Results And Provides Corporate Update
2012-11-13,Opexa Receives Clinical Trial Approval From Health Canada For Novel T-Cell Therapy
2012-11-12,Opexa Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
2012-11-05,Opexa Announces Agreements For Up To $16.5 Million In Equity Commitments
2012-10-12,5 Stocks Poised for Breakouts
2012-10-02,Lessons From Biotech's Best Third Quarter Stocks
2012-09-17,Opexa To Participate At UBS Global Life Sciences Conference
2012-09-12,Opexa Initiates Late Stage Clinical Study Of Tcelna In Patients With Secondary Progressive Multiple Sclerosis (SPMS)
2012-09-10,Opexa To Participate At Upcoming Industry Conferences
2012-08-13,Opexa Therapeutics Reports Second Quarter 2012 Financial Results And Provides Corporate Update
2012-07-26,Opexa Therapeutics Closes Secured Note Financing
2012-05-21,Opexa Therapeutics Announces TcelnaTM As New Brand Name For MS Therapy
2012-05-11,Opexa Therapeutics Reports First Quarter 2012 Financial Results And Provides Corporate Update
2012-02-29,Opexa Therapeutics Executes Strategic Service Agreement With Pharmaceutical Research Associates To Manage Clinical Trial
2012-02-27,Opexa Therapeutics Reports Year End 2011 Financial Results And Provides Corporate Update
2012-02-08,Opexa Therapeutics To Present At The 14th Annual BIO CEO &amp; Investor Conference
2012-01-17,Opexa Therapeutics To Present At The BOCEMb; Noble Financial Capital Markets&#8217; Eighth Annual Equity Conference
2011-12-09,Opexa Therapeutics To Present At The Oppenheimer 22nd Annual Healthcare Conference
2011-11-14,Opexa Announces Publication In Multiple Sclerosis Journal Of Tovaxin&#174; Phase IIb Clinical Trial Results
2011-11-11,Opexa Therapeutics To Present At The Lazard Capital Markets 8th Annual Healthcare Conference
2011-11-08,Opexa&#8217;s Tovaxin&#174; For The Treatment Of Multiple Sclerosis Granted Fast Track Designation By FDA
2011-11-04,Opexa Therapeutics Reports Third Quarter 2011 Financial Results And Provides Corporate Update
2011-11-02,Opexa Elects Gail Maderis To Board Of Directors
2011-09-19,Opexa&#8217;s CEO Invited To Present At Two Cell Therapy Forums In Asia During September, 2011
2011-09-12,Dr. Mark Freedman To Join Opexa&#8217;s Scientific Advisory Board
2011-09-07,Opexa To Present At The Rodman &amp; Renshaw Annual Global Investment Conference - Healthcare On September 13, 2011
2011-08-11,Opexa Therapeutics Reports Second Quarter 2011 Financial Results And Provides Corporate Update
2011-06-28,Opexa Executes Service Agreement With Blood Group Alliance, Inc.
2011-06-02,Opexa Initiates Discussions With Health Canada In Pre-CTA Meeting
2011-05-17,Opexa Executes Strategic Service Agreement With The American Red Cross
2011-05-06,Opexa Therapeutics Reports First Quarter 2011 Financial Results
2011-04-20,Vista Partners Updates Coverage On Opexa Therapeutics, Inc.; Maintains Target Price Of $6.50
2011-04-15,Opexa Presents Tovaxin&#174; Data At American Academy Of Neurology 2011 Annual Meeting
2011-03-23,Opexa To Present Tovaxin&#174; Data At 2011 American Academy Of Neurology Annual Meeting
2011-03-08,Opexa Therapeutics Reports Year End 2010 Financial Results And Provides Corporate Update
2011-02-22,Opexa CEO Invited As Keynote Speaker At Cell Therapy Conference In Beijing, China
2011-02-09,Opexa To Present At The 13th Annual BIO CEO &amp; Investor Conference On February 14, 2011
2011-02-08,Opexa Therapeutics, Inc. Announces Pricing Of Public Offering Of&#160;Common&#160;Stock And Warrants
2011-02-07,Opexa Therapeutics, Inc. Announces Proposed Public Offering Of Common Stock And Warrants
2011-01-07,Biotech Stock Mailbag: Best Stocks to Watch in '11
2011-01-05,Opexa Completes Successful Meetings With FDA To Pursue Phase 3 Clinical Study For Tovaxin&#174; In Multiple Sclerosis
2010-11-09,Opexa Therapeutics Reports Third Quarter 2010 Financial Results
2010-09-13,Otix Global, Entropic: Volume Movers
2010-09-08,Opexa To Present At The Rodman &amp; Renshaw 12th Annual Healthcare Conference On September 14, 2010
2010-08-06,Opexa Therapeutics Reports Second Quarter 2010 Financial Results
2010-08-05,Opexa Reconstitutes Scientific Advisory Board With Industry Leaders
2010-06-03,Opexa To Prepay Convertible Notes Issued In 2009
2010-05-13,Opexa Therapeutics Reports First Quarter 2010 Financial Results
2010-05-11,Opexa Strengthens Tovaxin&#174; Patent Estate Through Issuance Of Key Patents
2010-04-27,Opexa Strengthens Management Team With Hire Of Cell Therapy Expert
2010-04-14,Opexa Presents Tovaxin&#174; Data At The American Academy Of Neurology 2010 Annual Meeting
2010-04-09,Biotech Stock Mailbag: Vertex Pharma
2010-04-06,Opexa To Present Tovaxin&#174; Data At The American Academy Of Neurology 2010 Annual Meeting
2010-04-01,Opexa To Participate In Panel Discussion On Personalized Medicine For Multiple Sclerosis
2010-03-30,Versar, Opexa Therapeutics: Midday Volume Plays
2010-02-03,Opexa To Present At The 12th Annual BIO CEO &amp; Investor Conference On February 8, 2010
2009-09-23,YRC Worldwide: Pump Up the Volume
2009-09-11,Biotech Stock Mailbag: Genta Takes Another Stab
2009-09-09,Big Weight Loss for Vivus Drug: BioBuzz
2009-09-08,Biocryst Flu Drug Missing From CDC Guidelines: BioBuzz
2006-09-19,Tuesday's Health Winners & Losers
2017-03-14,Otonomy Becomes Oversold (OTIC)
2017-03-02,Otonomy Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update
2017-02-28,Otonomy To Present At Cowen And Company Health Care Conference
2017-02-24,Otonomy To Report Fourth Quarter And Full Year 2016 Financial Results And Provide Corporate Update
2017-01-26,Otonomy Enters Oversold Territory (OTIC)
2017-01-19,Otonomy Initiates Patient Enrollment In Phase 2 Clinical Trial Of OTO-104 As Protectant Against Cisplatin-Induced Hearing Loss
2017-01-09,Otonomy Provides Corporate And Product Pipeline Update
2017-01-06,First Week of OTIC February 17th Options Trading
2017-01-05,Otonomy Announces Positive Top-Line Results From Phase 3 Clinical Trial Of OTIPRIO® In Patients With Acute Otitis Externa
2017-01-03,Otonomy To Present At The J.P. Morgan Healthcare Conference
2016-11-30,Otonomy Appoints Kathie M. Bishop, Ph.D., As Chief Scientific Officer
2016-11-22,Otonomy To Present At Piper Jaffray Healthcare Conference
2016-11-03,Otonomy Enters Oversold Territory (OTIC)
2016-11-03,Otonomy Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-11-02,Otonomy Announces Assignment Of J Code For OTIPRIO®
2016-10-27,Otonomy To Report Third Quarter 2016 Financial Results And Provide Corporate Update
2016-10-07,Otonomy Holds Investor And Analyst Day And Provides Corporate Update
2016-10-04,Otonomy Successfully Completes Phase 2 Clinical Trial Of OTIPRIO® In Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes
2016-09-29,Otonomy To Host Investor And Analyst Day On October 7, 2016
2016-09-15,Late Recovery Wave Lifts Market
2016-09-15,Otonomy Successfully Completes Open-Label Clinical Trial For OTIPRIO® in Patients With History Of Otitis Media Requiring Tympanostomy Tubes
2016-09-13,Otonomy Announces OTIPRIO® Data Presentation And Symposium At American Academy Of Otolaryngology - Head And Neck Surgery Foundation Annual Meeting
2016-09-01,Otonomy To Present At Baird Global Healthcare Conference
2016-08-04,Otonomy Reports Second Quarter 2016 Financial Results And Provides Corporate Update
2016-08-01,Otonomy Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial For OTO-104 In Meniere's Disease Patients
2016-07-28,Otonomy To Report Second Quarter 2016 Financial Results And Provide Corporate Update
2016-06-09,Otonomy Initiates Patient Enrollment In Single Phase 3 Clinical Trial Of OTIPRIO™ In Patients With Acute Otitis Externa
2016-05-20,Otonomy Announces Assignment Of C Code And Pass-Through Payment Status For OTIPRIO™
2016-05-16,Otonomy Announces OTIPRIO™ Data Presentation And Symposium At Combined Otolaryngology Spring Meetings
2016-05-13,Commit To Buy Otonomy At $10, Earn 27.5% Annualized Using Options
2016-05-09,Otonomy Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-05-05,Oversold Conditions For Otonomy (OTIC)
2016-05-05,Otonomy To Present At The Bank Of America Merrill Lynch Healthcare Conference
2016-04-18,Otonomy Announces Phase 3 Clinical Trial Plan For OTIPRIO™ In Otitis Externa Patients Based On Successful End-of-Phase 2 Review By FDA
2016-03-23,Otonomy Initiates Patient Enrollment In Second Phase 3 Clinical Trial Of OTO-104 In Meniere's Disease
2016-03-18,Otonomy Announces Publication Of OTIPRIO™ Phase 3 Clinical Trial Results In JAMA Otolaryngology
2016-03-07,Otonomy Reports Fourth Quarter And Full Year 2015 Financial Results And Provides Corporate Update
2016-03-03,Otonomy Initiates Phase 2 Clinical Trial Of OTIPRIO™ In Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes
2016-03-02,Otonomy Announces Commercial Availability Of OTIPRIO™
2016-02-29,Otonomy To Present At Cowen And Company Health Care Conference
2016-02-26,Otonomy To Report Fourth Quarter And Full Year 2015 Financial Results And Provide Corporate Update
2016-02-18,Otonomy Enters Oversold Territory
2016-02-15,JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views
2016-02-15,General Motors, MetLife and Tesla: Doug Kass' Views
2016-02-11,Commit To Buy Otonomy At $10, Earn 11.7% Annualized Using Options
2016-01-26,Otonomy Announces Publication Supporting Development Of OTO-104 As Protectant Against Cisplatin-Induced Hearing Loss
2016-01-12,Otonomy Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
2016-01-08,Otonomy To Present At J.P. Morgan Healthcare Conference
2016-01-06,Otonomy Announces Pricing Of Public Offering Of Common Stock
2016-01-06,Otonomy is Now Oversold (OTIC)
2016-01-05,Otonomy Announces Proposed Public Offering Of Common Stock
2015-12-15,Otonomy Added To NASDAQ Biotechnology Index
2015-12-11,Otonomy Announces FDA Approval Of OTIPRIO(TM) For The Treatment Of Pediatric Patients Undergoing Tympanostomy Tube Placement Surgery
2015-12-01,Otonomy Completes Enrollment In OTIPRIO(TM) Phase 2 Trial And Demonstrates Clinical Feasibility In Patients With Acute Otitis Externa
2015-11-24,Otonomy To Present At Piper Jaffray Healthcare Conference
2015-11-18,Otonomy Initiates Patient Enrollment In U.S. Phase 3 Clinical Trial Of OTO-104 In Meniere's Disease
2015-11-16,Otonomy Initiates Phase 1 Clinical Trial For Tinnitus Product Candidate, OTO-311
2015-11-10,Otonomy Reports Third Quarter 2015 Financial Results And Provides Corporate Update
2015-11-03,Otonomy Initiates Open-Label Clinical Trial For OTIPRIO(TM) In Pediatric Patients With History Of Otitis Media Requiring Tympanostomy Tubes
2015-10-27,Commit To Purchase Otonomy At $20, Earn 21.1% Annualized Using Options
2015-10-07,Otonomy Holds Investor And Analyst Day And Provides Corporate Update
2015-10-05,Otonomy Receives FDA Clearance Of Investigational New Drug Application For Tinnitus Product Candidate, OTO-311
2015-09-30,Otonomy To Host Investor And Analyst Day On October 7, 2015
2015-09-24,Otonomy To Present Results For AuriPro(TM) Phase 3 And OTO-104 Phase 2b Clinical Trials At 2015 AAO-HNSF Annual Meeting
2015-09-09,Otonomy Announces Successful End-of-Phase 2 Meeting With The FDA For OTO-104 In Meniere's Disease
2015-09-01,Otonomy Appoints Ted Schroeder To Board Of Directors
2015-08-12,Otonomy Reports Second Quarter 2015 Financial Results And Provides Corporate Update
2015-07-28,Commit To Purchase Otonomy At $25, Earn 15.6% Annualized Using Options
2015-07-28,Otonomy Initiates Phase 2 Clinical Trial For AuriPro(TM) In Second Label Expansion Indication
2015-07-17,5 Health Care Stocks Ready for Breakouts
2015-06-25,Relative Strength Alert For Otonomy
2015-06-02,Otonomy Enters Oversold Territory (OTIC)
2015-05-21,Otonomy Reports Phase 2b Topline Data For OTO-104 In Meniere's Disease
2015-05-18,Otonomy Appoints Eric Loumeau As General Counsel And Chief Compliance Officer
2015-05-12,Otonomy Reports First Quarter 2015 Financial Results And Provides Corporate Update
2015-05-07,Otonomy Completes Enrollment In Phase 2 Clinical Trial For AuriPro(TM) In Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes
2015-05-06,Otonomy To Present At Two Upcoming Investor Conferences
2015-04-30,Otonomy Appoints George Morrow To Board Of Directors
2015-04-28,Otonomy Announces FDA Acceptance Of AuriPro(TM) New Drug Application
2015-04-27,Otonomy Presents AuriPro(TM) Phase 3 Results At American Society Of Pediatric Otolaryngology Conference
2015-04-21,Otonomy To Present AuriPro(TM) Phase 3 Results At American Society Of Pediatric Otolaryngology Conference
2015-04-20,Otonomy Completes Enrollment Of OTO-104 Multiple-Dose Safety Study In Meniere's Disease Patients
2015-04-01,Otonomy Appoints Dean Hakanson, M.D., As Chief Medical Officer
2015-03-26,Otonomy Initiates Phase 2 Clinical Trial For AuriPro(TM) In Label Expansion Indication
2015-03-18,Otonomy Reports Fourth Quarter And Full Year 2014 Financial Results And Provides Corporate Update
2015-03-12,Otonomy To Report Fourth Quarter And Full Year 2014 Financial Results And Provide Corporate Update
2015-02-26,Otonomy Submits New Drug Application To The FDA For AuriPro(TM)
2015-02-24,Otonomy To Present At Two Upcoming Investor Conferences
2015-01-28,Otonomy Announces Closing Of Follow-on Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-01-22,Otonomy Announces Pricing Of Follow-on Public Offering
2015-01-21,Otonomy Announces Launch Of Follow-on Public Offering
2015-01-08,Otonomy Files Registration Statement For Proposed Follow-on Public Offering
2015-01-08,Otonomy Provides Corporate And Product Pipeline Update
2015-01-06,Otonomy To Present At The J.P. Morgan Healthcare Conference
2014-12-01,Otonomy Achieves Patient Enrollment Target In Phase 2b Clinical Trial Of OTO-104 In Meniere's Disease
2014-11-20,Otonomy To Present At The Piper Jaffray Healthcare Conference
2014-11-12,Otonomy Reports Third Quarter 2014 Financial Results And Provides Corporate Update
2014-11-06,Otonomy Obtains Rights To Gacyclidine Data From Ipsen To Support Development Of OTO-311 As A Treatment For Tinnitus
2014-10-21,Otonomy Appoints Anthony J. Yost Chief Commercial Officer
2014-10-09,Otonomy Enrolls First Meniere's Disease Patients In OTO-104 Multiple-Dose Safety Study
2014-10-01,Otonomy Added To Russell 2000(R) Index
2014-09-03,Otonomy Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares
2014-08-13,RiverVest Venture Partners’ Otonomy Completes $100 Million Initial Public Offering
2014-08-13,Otonomy Announces Pricing Of Initial Public Offering
,
,
2016-04-21,5 Stocks Under $10 Set to Soar Higher
2015-10-28,3 Stocks Under $10 Making Big Up Moves
2015-09-29,4 Stocks Under $10 Making Big Moves Higher
2015-07-28,4 Breakout Stocks Under $10 Making Big Moves
2015-07-07,Prima Biomed (PBMD) Stock Spikes on European Regulatory Feedback for Breast Cancer Drug
2015-05-20,Prima Biomed (PBMD) Stock Nearly Quardruples in Value on Positive Clinical Study Results
2014-08-19,CVac™ CAN-003 Abstract Accepted For Poster Presentation At The Society For Immunotherapy Of Cancer Annual Meeting
2014-01-10,5 Under-$10 Biotech Stocks to Watch
,
,
,
,
,
2017-03-20,Finding Bullish and Bearish Market Reversals
2017-03-12,Biotechs Among 5 Stocks Setting Up for Major Breakouts
2017-03-10,Biotech Stock Mailbag: Puma's Rebound Explained, TG Therapeutics Approval Debate, Aurinia Next Steps
2017-03-09,These Stocks Are Trending Up With Monster Volume
2017-03-09,7 Stocks Trending Up With Monster Volume
2017-03-02,Puma Biotechnology To Present At Cowen's Health Care Conference
2017-03-02,Dow Declines, Caterpillar Weighs on Index as Feds Swarm Offices
2017-03-02,Stocks Slide as Rally Runs Out of Steam; Snap Makes Trading Debut
2017-03-02,Biotech Premarket Movers: Aurinia, Puma, PTC, Juno
2017-03-02,What You Need to Know About Roche AG's Breast Cancer Drug Perjeta
2017-03-02,Roche Shares Soar, Puma Bio Sinks on Perjeta Breast Cancer Study Win
2017-03-01,Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2017
2017-03-01,Puma Biotechnology Provides Update On Review Of Marketing Authorisation Application For PB272
2017-03-01,Puma Biotechnology Reports Fourth Quarter And Full Year 2016 Financial Results
2017-02-14,Puma Biotechnology To Present At RBC Capital Markets Healthcare Conference
2017-02-08,Puma Biotechnology To Present At LEERINK Partners Global Healthcare Conference
2017-02-03,Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?
2017-01-09,Newman Ferrara LLP Announces Corporate Governance Investigation Of Puma Biotechnology, Inc. - PBYI
2017-01-06,Puma Biotechnology Expands Cohort In Phase II SUMMIT Trial Of PB272 In HER2 Mutation-Positive Cancer Patients
2017-01-03,Puma Biotechnology To Present At J.P. Morgan Healthcare Conference
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2016-12-22,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
2016-12-20,First Week of PBYI February 2017 Options Trading
2016-12-19,Puma Biotechnology To Move Stock Exchange Listing To Nasdaq
2016-12-08,Figure 1: Treatment Emergent Diarrhea By Month In ExteNET Versus CONTROL (Graphic: Business Wire)
2016-12-07,Puma Biotechnology Presents Results Of Biomarker Analysis Of Phase II Trial Of PB272 In Neoadjuvant Treatment Of HER2-Positive Locally Advanced Breast Cancer At The 2016 San Antonio Breast Cancer Symposium
2016-12-07,Puma Biotechnology Presents Interim Results Of Phase II Trial Of PB272 For ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer At The 2016 San Antonio Breast Cancer Symposium
2016-12-07,Cascadian Therapeutics Enlarges Breast Cancer Pill Study to Meet FDA Registration Standards
2016-12-06,Puma Biotechnology Initiates A Managed Access Program For PB272 (Neratinib) Outside The United States
2016-11-15,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Puma Biotechnology, Inc. (PBYI)
2016-11-15,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Puma Biotechnology, Inc. - PBYI
2016-11-14,Puma Biotechnology Announces Presentations Of Investigational Data At The San Antonio Breast Cancer Symposium (SABCS)
2016-11-14,Puma Bio Falls on Escalating Concerns About Diarrhea Risk With Breast Cancer Drug
2016-11-11,Puma Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Puma Biotechnology, Inc. - PBYI
2016-11-09,Puma Biotechnology Reports Third Quarter 2016 Financial Results
2016-10-31,Puma Biotechnology To Present At Credit Suisse Healthcare Conference
2016-10-31,Lifshitz & Miller Law Firm Announces Investigation Of Electronics For Imaging, Inc., Ferrellgas Partners LP, Fusion Pharm, Inc., Humana Inc., KemPharm, Inc., National Beverage Corp., Puma Biotechnology, Inc., And TG Therapeutics, Inc.
2016-10-28,PUMA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Puma Biotechnology, Inc. - PBYI
2016-10-25,Puma Biotechnology Closes $172 Million Public Offering Of Common Stock
2016-10-24,June 2017 Options Now Available For Puma Biotechnology (PBYI)
2016-10-21,Puma Biotechnology Announces Underwriters' Full Exercise Of Option To Purchase Additional Shares
2016-10-20,Puma Bio's Desperate Money Grab Signals Breast Cancer Drug Trouble
2016-10-19,Puma Biotechnology Prices Public Offering Of Common Stock
2016-10-18,Puma Biotechnology (PBYI) Stock Down in After-Hours Trading on Public Offering
2016-10-18,Puma Biotechnology Announces Proposed Public Offering Of Common Stock
2016-10-14,PUMA INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Puma Biotechnology, Inc. - PBYI
2016-10-12,Robbins Arroyo LLP: Puma Biotechnology, Inc. (PBYI) Investors Survive Defendants' Motion To Dismiss In Securities Class Action
2016-10-11,Puma Biotechnology, Inc. Shareholder Alert: Schubert Firm Investigates Company's Top Executives
2016-10-10,Johnson & Weaver, LLP Initiates Investigations Of Puma Biotechnology, Inc., Virtus Investment Partners, Inc., AAC Holdings, Inc. And Spectrum Pharmaceuticals, Inc.; Encourages Long-Term Investors To Contact The Firm Regarding Their Legal Rights
2016-09-30,Biotech Stock Mailbag: Dynavax, Puma, Ariad
2016-09-22,Puma Biotechnology Shares Leap Forward
2016-09-20,Why Puma Biotechnology (PBYI) Stock Is Surging Today
2016-09-20,Puma Biotechnology Announces U.S. FDA Acceptance Of New Drug Application For PB272 (Neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer
2016-09-02,Jim Cramer's Top Takeaways: Salesforce.com, GCP Applied Technologies, Puma Biotechnology
2016-09-01,Jim Cramer's 'Mad Money' Recap: What Is Going on With This Market?
2016-08-24,Noteworthy Wednesday Option Activity: PBYI, MOV, BOFI
2016-08-23,4 Biotech Stock Charts You Must See
2016-08-22,Puma Biotechnology Announces European Medicines Agency Validation Of Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe
2016-08-09,Puma Biotechnology Reports Second Quarter 2016 Financial Results
2016-07-29,Biotech Stock Mailbag: Puma Roars, Relypsa Soars, XBiotech Bombs
2016-07-22,Morning Movers: GE, AMD, P, PBYI
2016-07-21,Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data From Phase III Trial Of PB272 (Neratinib) In Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)
2016-07-21,Puma Biotechnology Submits New Drug Application For PB272 (Neratinib) To U.S. FDA For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer
2016-07-07,Puma Biotechnology Announces I-SPY 2 Phase II Study Of Neratinib Published In The New England Journal Of Medicine
2016-06-29,16 Biopharma Companies Besides Medivation That Are Attractive Targets
2016-06-29,'Mad Money' Lightning Round: I Like Sirius XM Radio
2016-06-28,Jim Cramer's 'Mad Money' Recap: Add These 2 Stocks to FANG
2016-06-27,Puma Biotechnology Submits Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe
2016-06-20,August 19th Options Now Available For Puma Biotechnology (PBYI)
2016-06-10,Short Interest Increases 11.8% For PBYI
2016-06-05,Puma Biotechnology Presents Positive Phase II Data At The 2016 ASCO Annual Meeting
2016-05-18,Puma Biotechnology Announces Publication Of Neratinib Abstract For The 2016 ASCO Annual Meeting
2016-05-17,Puma Biotechnology To Present At UBS Global Healthcare Conference
2016-05-12,July 1st Options Now Available For Puma Biotechnology (PBYI)
2016-05-10,Puma Biotechnology Reports First Quarter 2016 Financial Results
2016-05-04,Puma Biotechnology To Present At Bank Of America Merrill Lynch Health Care Conference
2016-04-20,Puma Biotechnology's Neratinib Featured In Poster Presentations At The AACR Annual Meeting 2016
2016-04-14,Puma Biotechnology's NEfERT-T Phase II Study Published Online In JAMA Oncology
2016-03-29,Puma Biotechnology (PBYI) Stock Plunges on Delayed Marketing Application
2016-03-28,Puma Biotechnology Updates Timeline For Filing New Drug Application
2016-03-18,Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2016
2016-03-02,Puma Biotechnology To Present At Cowen's Health Care Conference
2016-02-29,Puma Biotechnology Reports Fourth Quarter And Full Year 2015 Financial Results
2016-02-17,Puma Biotechnology To Participate In Fireside Chat At RBC Capital Markets Global Healthcare Conference
2016-02-16,Puma Biotechnology Announces The Conclusion And Final Results Of Eshelman's Consent Solicitation
2016-02-11,Puma Biotechnology's ExteNET Phase III Study Published Online In The Lancet Oncology
2016-02-03,Puma Biotechnology To Participate In Fireside Chat At Leerink Partners Global Healthcare Conference
2016-01-22,Interesting PBYI Put And Call Options For September 16th
2016-01-14,Puma Biotechnology Stock Sees Short Interest Make 46% Move
2016-01-09,2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks
2016-01-08,Puma Biotechnology Shareholders Overwhelmingly Reject Eshelman's Consent Solicitation
2016-01-04,Puma Biotechnology To Present At J.P. Morgan Healthcare Conference
2016-01-01,Feuerstein's Heroes and Zeroes of Biotech Investing in 2015
2015-12-30,Third Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation By REVOKING CONSENT On Puma's BLUE Consent Revocation Card
2015-12-29,Second Leading Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation By REVOKING CONSENT On Puma's BLUE Consent Revocation Card
2015-12-23,ISS Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation By REVOKING CONSENT On Puma's BLUE Consent Revocation Card
2015-12-18,Puma Biotechnology Expands Third Cohort In Phase II Trial Of PB272 In HER2 Mutation Positive Cancer Patients
2015-12-16,Puma Biotechnology To Host Conference Call To Discuss Loperamide Prophylaxis To Reduce Neratinib-Related Diarrhea
2015-12-15,8 Stocks Spiking on Unusually High Volume
2015-12-11,Puma Biotechnology Presents 3-Year Disease Free Survival Data From Phase III Trial Of PB272 In Extended Adjuvant Breast Cancer (ExteNET Trial) At The 2015 San Antonio Breast Cancer Symposium
2015-12-10,Puma Biotechnology Presents Interim Results Of Phase II Trial Of PB272 For ERBB2 Mutant, HER2 Non-Amplified, Metastatic Breast Cancer At The 2015 San Antonio Breast Cancer Symposium
2015-12-10,Puma Biotechnology Announces Results Of Phase II Trial Of PB272 In Neoadjuvant Treatment Of HER2-Positive Locally Advanced Breast Cancer
2015-11-30,Puma Biotechnology Provides Update From Meeting With European Medicines Agency
2015-11-13,Puma Biotechnology To Present Data At The San Antonio Breast Cancer Symposium (SABCS)
2015-11-09,Puma Biotechnology Reports Third Quarter 2015 Financial Results
2015-11-03,Puma Biotechnology To Present At Credit Suisse Healthcare Conference
2015-09-26,Puma Biotechnology Announces Presentation Of Phase III Trial Of PB272 In Extended Adjuvant Breast Cancer (ExteNET Trial) In Centrally Confirmed HER2-Positive Early Stage Breast Cancer Patients
2015-09-10,Puma Biotechnology Announces Publication Of PB272 In HER2 Non-Amplified Metastatic Breast Cancer With A HER2 Mutation
2015-09-04,Battleground: Will This $5 Biotech Stock Go To $22 Or $1.50?
2015-09-03,Jim Cramer's Top Takeaways: Puma Biotechnology and H&R Block
2015-09-02,Jim Cramer's 'Mad Money' Recap: A Rally or Calm Before the Storm?
2015-08-10,Puma Biotechnology Reports Second Quarter 2015 Financial Results
2015-08-10,August 10 Premarket Briefing: 10 Things You Should Know
2015-07-31,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Puma Biotechnology, Inc. Of Pendency Of Class Action Lawsuit And A Lead Plaintiff Deadline Of August 3, 2015 - PBYI
2015-07-24,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Puma Biotechnology, Inc. Of Pendency Of Class Action Lawsuit And A Lead Plaintiff Deadline Of August 3, 2015 - PBYI
2015-07-20,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors Of Class Action Against Puma Biotechnology, Inc. And Lead Plaintiff Deadline Of August 3, 2015
2015-07-11,'Mad Money' Lightning Round: Stay Away From Barracuda Networks
2015-07-10,Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
2015-07-03,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Puma Biotechnology, Inc. Of Class Action Lawsuit And Upcoming Deadline - PBYI
2015-07-02,Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point
2015-06-26,IMPORTANT INVESTOR DEADLINE: Goldberg Law PC Reminds Investors With Losses Greater Than $100,000 In Puma Biotechnology, Inc. Of The August 3, 2015 Deadline
2015-06-26,Biotech Stock Mailbag: Exelixis, Puma Bio
2015-06-23,Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Puma Biotechnology, Inc.
2015-06-22,Harwood Feffer LLP Announces Securities Class Action Lawsuit Against Puma Biotechnology, Inc. And Advises Shareholders To Contact Harwood Feffer LLP Prior To The Lead Plaintiff Deadline
2015-06-05,Biotech Stock Mailbag: More Duchenne Drama, CAR-T Trouble, ASCO '15 Rewind
2015-06-04,Puma Biotechnology To Present At Goldman Sachs Healthcare Conference
2015-06-04,Top-Performing Biotech and Drug Stocks During ASCO '15
2015-06-01,Puma Bio Breast Cancer Drug Given Rough Treatment at ASCO '15
2015-06-01,Puma Biotechnology Investors Encouraged To Contact Securities Law Firm About Investigation Into Allegations Of Corporate Wrongdoing
2015-06-01,Puma Biotechnology Announces Phase III Trial Of PB272 In Extended Adjuvant Breast Cancer (ExteNET Trial) Demonstrates Statistically Significant Improvement In Disease Free Survival
2015-06-01,Puma Biotech Hoping for a Bounce at Annual Meeting of Cancer Society
2015-06-01,ASCO '15 Report Card: Grading Biotech and Drug Stocks at Cancer Drug Confab
2015-06-01,Cancer Breakthroughs Expected at Annual Meeting of Cancer Society
2015-06-01,Oncothyreon Breast Cancer Drug Exits ASCO '15 With Good Buzz
2015-05-29,Fly Watch: Several Names That May Move Following ASCO Meeting
2015-05-28,Puma Bio Restricting Access to Breast Cancer Event at ASCO Chicago
2015-05-27,Puma Biotechnology To Present At Jefferies 2015 Healthcare Conference
2015-05-22,Biotech Stock Mailbag: ASCO Preview, CAR-T stocks, MannKind, Hate Mail!
2015-05-15,6 Stocks Spiking on Big Volume
2015-05-14,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Puma Biotechnology, Inc.
2015-05-14,Walmart Stores Is Working on a Rival to Amazon's Prime Service
2015-05-13,Puma Biotechnology Announces Publication Of Abstracts For The 2015 American Society Of Clinical Oncology (ASCO) Annual Meeting
2015-05-13,Jumpstart ASCO '15 With This Quick List of Hot Research Abstracts
2015-05-12,Puma Biotechnology To Participate In Fireside Chat At UBS Global Healthcare Conference
2015-05-11,Puma Biotechnology Reports First Quarter 2015 Financial Results
2015-05-06,Puma Biotechnology To Present At Bank Of America Merrill Lynch Health Care Conference
2015-04-30,Puma Biotechnology To Present At Deutsche Bank Health Care Conference
2015-04-27,Puma Biotechnology Larger Than S&P 500 Component Mallinckrodt
2015-04-14,Puma Biotechnology Expands Cohort In Phase II Trial Of PB272 In HER2 Mutation Positive Cancer Patients
2015-03-10,Puma Biotechnology Initiates Phase II Trial Of PB272 In Early Stage HER2-Positive Breast Cancer
2015-03-06,Biotech Stock Mailbag: Next Biotech Takeout Targets, NewLink Genetics
2015-03-05,Market News: Mallinckrodt, Kroger, Puma Biotechnology
2015-03-02,Puma Biotechnology Reports Fourth Quarter And Full Year 2014 Financial Results
2015-02-24,Puma Biotechnology To Present At Cowen Health Care Conference
2015-02-18,Puma Biotechnology To Participate In Fireside Chat At RBC Capital Markets' Global Healthcare Conference
2015-02-10,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Puma Biotechnology, Inc.
2015-02-09,INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Puma Biotechnology, Inc. (PBYI) To Contact The Firm
2015-02-05,Puma Biotechnology To Present At Leerink Global Healthcare Conference
2015-01-27,Puma Biotechnology Closes $218 Million Public Offering Of Common Stock
2015-01-22,Puma Biotechnology Announces Underwriters' Full Exercise Of Option To Purchase Additional Shares
2015-01-22,4 Stocks Spiking on Unusual Volume: Puma Biotech, Nexstar and More
2015-01-21,Puma Biotechnology Prices Public Offering Of Common Stock
2015-01-20,Puma Biotechnology Announces Proposed Public Offering
2015-01-08,The Best And Worst Analyst Recommendations Of 2014
2015-01-06,Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015
2015-01-05,Puma Biotechnology To Present At J.P. Morgan Healthcare Conference
2014-12-12,Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data At 2014 CTRC-AACR San Antonio Breast Cancer Symposium
2014-12-10,SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Possible Violations Of Federal Securities Laws By The Board Of Directors Of Puma Biotechnology, Inc.
2014-12-04,Lifshitz & Miller Law Firm Announces Investigation Of Avanir Pharmaceuticals, Inc., Carbonite, Inc., Casey's General Stores, Inc., Nymox Pharmaceutical Corporation, Puma Biotechnology Inc., RealD Inc., And Spansion, Inc.
2014-12-03,Stocks Close Higher, Helped by Continued Strength in Economy
2014-12-03,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Puma Biotechnology, Inc.
2014-12-03,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Puma Biotechnology, Inc. - PBYI
2014-12-03,Stocks Trade Higher as Services Sector Grows More Than Expected
2014-12-02,Puma Forced to Delay Breast Cancer FDA Submission Due to New Safety Data Requirement
2014-12-02,Puma Biotechnology Updates Timeline For Filing New Drug Application
2014-11-25,One Solution to the Growth vs. Value Debate: Combine Them
2014-11-21,Biotech Stock Mailbag: Northwest Bio, Celldex, Puma, MannKind
2014-11-13,Puma Biotechnology Announces Positive Top Line Results From PB272 Phase II Trial In HER2 Positive Metastatic Breast Cancer (NEfERTT Trial)
2014-11-12,Puma Biotechnology To Present At Stifel 2014 Healthcare Conference
2014-11-10,Puma Biotechnology Reports Third Quarter 2014 Financial Results
2017-03-20,Finding Bullish and Bearish Market Reversals
2017-03-12,Biotechs Among 5 Stocks Setting Up for Major Breakouts
2017-03-10,Biotech Stock Mailbag: Puma's Rebound Explained, TG Therapeutics Approval Debate, Aurinia Next Steps
2017-03-09,These Stocks Are Trending Up With Monster Volume
2017-03-09,7 Stocks Trending Up With Monster Volume
2017-03-02,Puma Biotechnology To Present At Cowen's Health Care Conference
2017-03-02,Dow Declines, Caterpillar Weighs on Index as Feds Swarm Offices
2017-03-02,Stocks Slide as Rally Runs Out of Steam; Snap Makes Trading Debut
2017-03-02,Biotech Premarket Movers: Aurinia, Puma, PTC, Juno
2017-03-02,What You Need to Know About Roche AG's Breast Cancer Drug Perjeta
2017-03-02,Roche Shares Soar, Puma Bio Sinks on Perjeta Breast Cancer Study Win
2017-03-01,Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2017
2017-03-01,Puma Biotechnology Provides Update On Review Of Marketing Authorisation Application For PB272
2017-03-01,Puma Biotechnology Reports Fourth Quarter And Full Year 2016 Financial Results
2017-02-14,Puma Biotechnology To Present At RBC Capital Markets Healthcare Conference
2017-02-08,Puma Biotechnology To Present At LEERINK Partners Global Healthcare Conference
2017-02-03,Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?
2017-01-09,Newman Ferrara LLP Announces Corporate Governance Investigation Of Puma Biotechnology, Inc. - PBYI
2017-01-06,Puma Biotechnology Expands Cohort In Phase II SUMMIT Trial Of PB272 In HER2 Mutation-Positive Cancer Patients
2017-01-03,Puma Biotechnology To Present At J.P. Morgan Healthcare Conference
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2016-12-22,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
2016-12-20,First Week of PBYI February 2017 Options Trading
2016-12-19,Puma Biotechnology To Move Stock Exchange Listing To Nasdaq
2016-12-08,Figure 1: Treatment Emergent Diarrhea By Month In ExteNET Versus CONTROL (Graphic: Business Wire)
2016-12-07,Puma Biotechnology Presents Results Of Biomarker Analysis Of Phase II Trial Of PB272 In Neoadjuvant Treatment Of HER2-Positive Locally Advanced Breast Cancer At The 2016 San Antonio Breast Cancer Symposium
2016-12-07,Puma Biotechnology Presents Interim Results Of Phase II Trial Of PB272 For ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer At The 2016 San Antonio Breast Cancer Symposium
2016-12-07,Cascadian Therapeutics Enlarges Breast Cancer Pill Study to Meet FDA Registration Standards
2016-12-06,Puma Biotechnology Initiates A Managed Access Program For PB272 (Neratinib) Outside The United States
2016-11-15,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Puma Biotechnology, Inc. (PBYI)
2016-11-15,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Puma Biotechnology, Inc. - PBYI
2016-11-14,Puma Biotechnology Announces Presentations Of Investigational Data At The San Antonio Breast Cancer Symposium (SABCS)
2016-11-14,Puma Bio Falls on Escalating Concerns About Diarrhea Risk With Breast Cancer Drug
2016-11-11,Puma Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Puma Biotechnology, Inc. - PBYI
2016-11-09,Puma Biotechnology Reports Third Quarter 2016 Financial Results
2016-10-31,Puma Biotechnology To Present At Credit Suisse Healthcare Conference
2016-10-31,Lifshitz & Miller Law Firm Announces Investigation Of Electronics For Imaging, Inc., Ferrellgas Partners LP, Fusion Pharm, Inc., Humana Inc., KemPharm, Inc., National Beverage Corp., Puma Biotechnology, Inc., And TG Therapeutics, Inc.
2016-10-28,PUMA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Puma Biotechnology, Inc. - PBYI
2016-10-25,Puma Biotechnology Closes $172 Million Public Offering Of Common Stock
2016-10-24,June 2017 Options Now Available For Puma Biotechnology (PBYI)
2016-10-21,Puma Biotechnology Announces Underwriters' Full Exercise Of Option To Purchase Additional Shares
2016-10-20,Puma Bio's Desperate Money Grab Signals Breast Cancer Drug Trouble
2016-10-19,Puma Biotechnology Prices Public Offering Of Common Stock
2016-10-18,Puma Biotechnology (PBYI) Stock Down in After-Hours Trading on Public Offering
2016-10-18,Puma Biotechnology Announces Proposed Public Offering Of Common Stock
2016-10-14,PUMA INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Puma Biotechnology, Inc. - PBYI
2016-10-12,Robbins Arroyo LLP: Puma Biotechnology, Inc. (PBYI) Investors Survive Defendants' Motion To Dismiss In Securities Class Action
2016-10-11,Puma Biotechnology, Inc. Shareholder Alert: Schubert Firm Investigates Company's Top Executives
2016-10-10,Johnson & Weaver, LLP Initiates Investigations Of Puma Biotechnology, Inc., Virtus Investment Partners, Inc., AAC Holdings, Inc. And Spectrum Pharmaceuticals, Inc.; Encourages Long-Term Investors To Contact The Firm Regarding Their Legal Rights
2016-09-30,Biotech Stock Mailbag: Dynavax, Puma, Ariad
2016-09-22,Puma Biotechnology Shares Leap Forward
2016-09-20,Why Puma Biotechnology (PBYI) Stock Is Surging Today
2016-09-20,Puma Biotechnology Announces U.S. FDA Acceptance Of New Drug Application For PB272 (Neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer
2016-09-02,Jim Cramer's Top Takeaways: Salesforce.com, GCP Applied Technologies, Puma Biotechnology
2016-09-01,Jim Cramer's 'Mad Money' Recap: What Is Going on With This Market?
2016-08-24,Noteworthy Wednesday Option Activity: PBYI, MOV, BOFI
2016-08-23,4 Biotech Stock Charts You Must See
2016-08-22,Puma Biotechnology Announces European Medicines Agency Validation Of Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe
2016-08-09,Puma Biotechnology Reports Second Quarter 2016 Financial Results
2016-07-29,Biotech Stock Mailbag: Puma Roars, Relypsa Soars, XBiotech Bombs
2016-07-22,Morning Movers: GE, AMD, P, PBYI
2016-07-21,Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data From Phase III Trial Of PB272 (Neratinib) In Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)
2016-07-21,Puma Biotechnology Submits New Drug Application For PB272 (Neratinib) To U.S. FDA For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer
2016-07-07,Puma Biotechnology Announces I-SPY 2 Phase II Study Of Neratinib Published In The New England Journal Of Medicine
2016-06-29,16 Biopharma Companies Besides Medivation That Are Attractive Targets
2016-06-29,'Mad Money' Lightning Round: I Like Sirius XM Radio
2016-06-28,Jim Cramer's 'Mad Money' Recap: Add These 2 Stocks to FANG
2016-06-27,Puma Biotechnology Submits Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe
2016-06-20,August 19th Options Now Available For Puma Biotechnology (PBYI)
2016-06-10,Short Interest Increases 11.8% For PBYI
2016-06-05,Puma Biotechnology Presents Positive Phase II Data At The 2016 ASCO Annual Meeting
2016-05-18,Puma Biotechnology Announces Publication Of Neratinib Abstract For The 2016 ASCO Annual Meeting
2016-05-17,Puma Biotechnology To Present At UBS Global Healthcare Conference
2016-05-12,July 1st Options Now Available For Puma Biotechnology (PBYI)
2016-05-10,Puma Biotechnology Reports First Quarter 2016 Financial Results
2016-05-04,Puma Biotechnology To Present At Bank Of America Merrill Lynch Health Care Conference
2016-04-20,Puma Biotechnology's Neratinib Featured In Poster Presentations At The AACR Annual Meeting 2016
2016-04-14,Puma Biotechnology's NEfERT-T Phase II Study Published Online In JAMA Oncology
2016-03-29,Puma Biotechnology (PBYI) Stock Plunges on Delayed Marketing Application
2016-03-28,Puma Biotechnology Updates Timeline For Filing New Drug Application
2016-03-18,Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2016
2016-03-02,Puma Biotechnology To Present At Cowen's Health Care Conference
2016-02-29,Puma Biotechnology Reports Fourth Quarter And Full Year 2015 Financial Results
2016-02-17,Puma Biotechnology To Participate In Fireside Chat At RBC Capital Markets Global Healthcare Conference
2016-02-16,Puma Biotechnology Announces The Conclusion And Final Results Of Eshelman's Consent Solicitation
2016-02-11,Puma Biotechnology's ExteNET Phase III Study Published Online In The Lancet Oncology
2016-02-03,Puma Biotechnology To Participate In Fireside Chat At Leerink Partners Global Healthcare Conference
2016-01-22,Interesting PBYI Put And Call Options For September 16th
2016-01-14,Puma Biotechnology Stock Sees Short Interest Make 46% Move
2016-01-09,2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks
2016-01-08,Puma Biotechnology Shareholders Overwhelmingly Reject Eshelman's Consent Solicitation
2016-01-04,Puma Biotechnology To Present At J.P. Morgan Healthcare Conference
2016-01-01,Feuerstein's Heroes and Zeroes of Biotech Investing in 2015
2015-12-30,Third Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation By REVOKING CONSENT On Puma's BLUE Consent Revocation Card
2015-12-29,Second Leading Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation By REVOKING CONSENT On Puma's BLUE Consent Revocation Card
2015-12-23,ISS Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation By REVOKING CONSENT On Puma's BLUE Consent Revocation Card
2015-12-18,Puma Biotechnology Expands Third Cohort In Phase II Trial Of PB272 In HER2 Mutation Positive Cancer Patients
2015-12-16,Puma Biotechnology To Host Conference Call To Discuss Loperamide Prophylaxis To Reduce Neratinib-Related Diarrhea
2015-12-15,8 Stocks Spiking on Unusually High Volume
2015-12-11,Puma Biotechnology Presents 3-Year Disease Free Survival Data From Phase III Trial Of PB272 In Extended Adjuvant Breast Cancer (ExteNET Trial) At The 2015 San Antonio Breast Cancer Symposium
2015-12-10,Puma Biotechnology Presents Interim Results Of Phase II Trial Of PB272 For ERBB2 Mutant, HER2 Non-Amplified, Metastatic Breast Cancer At The 2015 San Antonio Breast Cancer Symposium
2015-12-10,Puma Biotechnology Announces Results Of Phase II Trial Of PB272 In Neoadjuvant Treatment Of HER2-Positive Locally Advanced Breast Cancer
2015-11-30,Puma Biotechnology Provides Update From Meeting With European Medicines Agency
2015-11-13,Puma Biotechnology To Present Data At The San Antonio Breast Cancer Symposium (SABCS)
2015-11-09,Puma Biotechnology Reports Third Quarter 2015 Financial Results
2015-11-03,Puma Biotechnology To Present At Credit Suisse Healthcare Conference
2015-09-26,Puma Biotechnology Announces Presentation Of Phase III Trial Of PB272 In Extended Adjuvant Breast Cancer (ExteNET Trial) In Centrally Confirmed HER2-Positive Early Stage Breast Cancer Patients
2015-09-10,Puma Biotechnology Announces Publication Of PB272 In HER2 Non-Amplified Metastatic Breast Cancer With A HER2 Mutation
2015-09-04,Battleground: Will This $5 Biotech Stock Go To $22 Or $1.50?
2015-09-03,Jim Cramer's Top Takeaways: Puma Biotechnology and H&R Block
2015-09-02,Jim Cramer's 'Mad Money' Recap: A Rally or Calm Before the Storm?
2015-08-10,Puma Biotechnology Reports Second Quarter 2015 Financial Results
2015-08-10,August 10 Premarket Briefing: 10 Things You Should Know
2015-07-31,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Puma Biotechnology, Inc. Of Pendency Of Class Action Lawsuit And A Lead Plaintiff Deadline Of August 3, 2015 - PBYI
2015-07-24,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Puma Biotechnology, Inc. Of Pendency Of Class Action Lawsuit And A Lead Plaintiff Deadline Of August 3, 2015 - PBYI
2015-07-20,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors Of Class Action Against Puma Biotechnology, Inc. And Lead Plaintiff Deadline Of August 3, 2015
2015-07-11,'Mad Money' Lightning Round: Stay Away From Barracuda Networks
2015-07-10,Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
2015-07-03,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Puma Biotechnology, Inc. Of Class Action Lawsuit And Upcoming Deadline - PBYI
2015-07-02,Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point
2015-06-26,IMPORTANT INVESTOR DEADLINE: Goldberg Law PC Reminds Investors With Losses Greater Than $100,000 In Puma Biotechnology, Inc. Of The August 3, 2015 Deadline
2015-06-26,Biotech Stock Mailbag: Exelixis, Puma Bio
2015-06-23,Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Puma Biotechnology, Inc.
2015-06-22,Harwood Feffer LLP Announces Securities Class Action Lawsuit Against Puma Biotechnology, Inc. And Advises Shareholders To Contact Harwood Feffer LLP Prior To The Lead Plaintiff Deadline
2015-06-05,Biotech Stock Mailbag: More Duchenne Drama, CAR-T Trouble, ASCO '15 Rewind
2015-06-04,Puma Biotechnology To Present At Goldman Sachs Healthcare Conference
2015-06-04,Top-Performing Biotech and Drug Stocks During ASCO '15
2015-06-01,Puma Bio Breast Cancer Drug Given Rough Treatment at ASCO '15
2015-06-01,Puma Biotechnology Investors Encouraged To Contact Securities Law Firm About Investigation Into Allegations Of Corporate Wrongdoing
2015-06-01,Puma Biotechnology Announces Phase III Trial Of PB272 In Extended Adjuvant Breast Cancer (ExteNET Trial) Demonstrates Statistically Significant Improvement In Disease Free Survival
2015-06-01,Puma Biotech Hoping for a Bounce at Annual Meeting of Cancer Society
2015-06-01,ASCO '15 Report Card: Grading Biotech and Drug Stocks at Cancer Drug Confab
2015-06-01,Cancer Breakthroughs Expected at Annual Meeting of Cancer Society
2015-06-01,Oncothyreon Breast Cancer Drug Exits ASCO '15 With Good Buzz
2015-05-29,Fly Watch: Several Names That May Move Following ASCO Meeting
2015-05-28,Puma Bio Restricting Access to Breast Cancer Event at ASCO Chicago
2015-05-27,Puma Biotechnology To Present At Jefferies 2015 Healthcare Conference
2015-05-22,Biotech Stock Mailbag: ASCO Preview, CAR-T stocks, MannKind, Hate Mail!
2015-05-15,6 Stocks Spiking on Big Volume
2015-05-14,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Puma Biotechnology, Inc.
2015-05-14,Walmart Stores Is Working on a Rival to Amazon's Prime Service
2015-05-13,Puma Biotechnology Announces Publication Of Abstracts For The 2015 American Society Of Clinical Oncology (ASCO) Annual Meeting
2015-05-13,Jumpstart ASCO '15 With This Quick List of Hot Research Abstracts
2015-05-12,Puma Biotechnology To Participate In Fireside Chat At UBS Global Healthcare Conference
2015-05-11,Puma Biotechnology Reports First Quarter 2015 Financial Results
2015-05-06,Puma Biotechnology To Present At Bank Of America Merrill Lynch Health Care Conference
2015-04-30,Puma Biotechnology To Present At Deutsche Bank Health Care Conference
2015-04-27,Puma Biotechnology Larger Than S&P 500 Component Mallinckrodt
2015-04-14,Puma Biotechnology Expands Cohort In Phase II Trial Of PB272 In HER2 Mutation Positive Cancer Patients
2015-03-10,Puma Biotechnology Initiates Phase II Trial Of PB272 In Early Stage HER2-Positive Breast Cancer
2015-03-06,Biotech Stock Mailbag: Next Biotech Takeout Targets, NewLink Genetics
2015-03-05,Market News: Mallinckrodt, Kroger, Puma Biotechnology
2015-03-02,Puma Biotechnology Reports Fourth Quarter And Full Year 2014 Financial Results
2015-02-24,Puma Biotechnology To Present At Cowen Health Care Conference
2015-02-18,Puma Biotechnology To Participate In Fireside Chat At RBC Capital Markets' Global Healthcare Conference
2015-02-10,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Puma Biotechnology, Inc.
2015-02-09,INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Puma Biotechnology, Inc. (PBYI) To Contact The Firm
2015-02-05,Puma Biotechnology To Present At Leerink Global Healthcare Conference
2015-01-27,Puma Biotechnology Closes $218 Million Public Offering Of Common Stock
2015-01-22,Puma Biotechnology Announces Underwriters' Full Exercise Of Option To Purchase Additional Shares
2015-01-22,4 Stocks Spiking on Unusual Volume: Puma Biotech, Nexstar and More
2015-01-21,Puma Biotechnology Prices Public Offering Of Common Stock
2015-01-20,Puma Biotechnology Announces Proposed Public Offering
2015-01-08,The Best And Worst Analyst Recommendations Of 2014
2015-01-06,Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015
2015-01-05,Puma Biotechnology To Present At J.P. Morgan Healthcare Conference
2014-12-12,Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data At 2014 CTRC-AACR San Antonio Breast Cancer Symposium
2014-12-10,SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Possible Violations Of Federal Securities Laws By The Board Of Directors Of Puma Biotechnology, Inc.
2014-12-04,Lifshitz & Miller Law Firm Announces Investigation Of Avanir Pharmaceuticals, Inc., Carbonite, Inc., Casey's General Stores, Inc., Nymox Pharmaceutical Corporation, Puma Biotechnology Inc., RealD Inc., And Spansion, Inc.
2014-12-03,Stocks Close Higher, Helped by Continued Strength in Economy
2014-12-03,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Puma Biotechnology, Inc.
2014-12-03,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Puma Biotechnology, Inc. - PBYI
2014-12-03,Stocks Trade Higher as Services Sector Grows More Than Expected
2014-12-02,Puma Forced to Delay Breast Cancer FDA Submission Due to New Safety Data Requirement
2014-12-02,Puma Biotechnology Updates Timeline For Filing New Drug Application
2014-11-25,One Solution to the Growth vs. Value Debate: Combine Them
2014-11-21,Biotech Stock Mailbag: Northwest Bio, Celldex, Puma, MannKind
2014-11-13,Puma Biotechnology Announces Positive Top Line Results From PB272 Phase II Trial In HER2 Positive Metastatic Breast Cancer (NEfERTT Trial)
2014-11-12,Puma Biotechnology To Present At Stifel 2014 Healthcare Conference
2014-11-10,Puma Biotechnology Reports Third Quarter 2014 Financial Results
2017-03-20,Finding Bullish and Bearish Market Reversals
2017-03-12,Biotechs Among 5 Stocks Setting Up for Major Breakouts
2017-03-10,Biotech Stock Mailbag: Puma's Rebound Explained, TG Therapeutics Approval Debate, Aurinia Next Steps
2017-03-09,These Stocks Are Trending Up With Monster Volume
2017-03-09,7 Stocks Trending Up With Monster Volume
2017-03-02,Puma Biotechnology To Present At Cowen's Health Care Conference
2017-03-02,Dow Declines, Caterpillar Weighs on Index as Feds Swarm Offices
2017-03-02,Stocks Slide as Rally Runs Out of Steam; Snap Makes Trading Debut
2017-03-02,Biotech Premarket Movers: Aurinia, Puma, PTC, Juno
2017-03-02,What You Need to Know About Roche AG's Breast Cancer Drug Perjeta
2017-03-02,Roche Shares Soar, Puma Bio Sinks on Perjeta Breast Cancer Study Win
2017-03-01,Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2017
2017-03-01,Puma Biotechnology Provides Update On Review Of Marketing Authorisation Application For PB272
2017-03-01,Puma Biotechnology Reports Fourth Quarter And Full Year 2016 Financial Results
2017-02-14,Puma Biotechnology To Present At RBC Capital Markets Healthcare Conference
2017-02-08,Puma Biotechnology To Present At LEERINK Partners Global Healthcare Conference
2017-02-03,Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?
2017-01-09,Newman Ferrara LLP Announces Corporate Governance Investigation Of Puma Biotechnology, Inc. - PBYI
2017-01-06,Puma Biotechnology Expands Cohort In Phase II SUMMIT Trial Of PB272 In HER2 Mutation-Positive Cancer Patients
2017-01-03,Puma Biotechnology To Present At J.P. Morgan Healthcare Conference
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2016-12-22,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
2016-12-20,First Week of PBYI February 2017 Options Trading
2016-12-19,Puma Biotechnology To Move Stock Exchange Listing To Nasdaq
2016-12-08,Figure 1: Treatment Emergent Diarrhea By Month In ExteNET Versus CONTROL (Graphic: Business Wire)
2016-12-07,Puma Biotechnology Presents Results Of Biomarker Analysis Of Phase II Trial Of PB272 In Neoadjuvant Treatment Of HER2-Positive Locally Advanced Breast Cancer At The 2016 San Antonio Breast Cancer Symposium
2016-12-07,Puma Biotechnology Presents Interim Results Of Phase II Trial Of PB272 For ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer At The 2016 San Antonio Breast Cancer Symposium
2016-12-07,Cascadian Therapeutics Enlarges Breast Cancer Pill Study to Meet FDA Registration Standards
2016-12-06,Puma Biotechnology Initiates A Managed Access Program For PB272 (Neratinib) Outside The United States
2016-11-15,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Puma Biotechnology, Inc. (PBYI)
2016-11-15,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Puma Biotechnology, Inc. - PBYI
2016-11-14,Puma Biotechnology Announces Presentations Of Investigational Data At The San Antonio Breast Cancer Symposium (SABCS)
2016-11-14,Puma Bio Falls on Escalating Concerns About Diarrhea Risk With Breast Cancer Drug
2016-11-11,Puma Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Puma Biotechnology, Inc. - PBYI
2016-11-09,Puma Biotechnology Reports Third Quarter 2016 Financial Results
2016-10-31,Puma Biotechnology To Present At Credit Suisse Healthcare Conference
2016-10-31,Lifshitz & Miller Law Firm Announces Investigation Of Electronics For Imaging, Inc., Ferrellgas Partners LP, Fusion Pharm, Inc., Humana Inc., KemPharm, Inc., National Beverage Corp., Puma Biotechnology, Inc., And TG Therapeutics, Inc.
2016-10-28,PUMA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Puma Biotechnology, Inc. - PBYI
2016-10-25,Puma Biotechnology Closes $172 Million Public Offering Of Common Stock
2016-10-24,June 2017 Options Now Available For Puma Biotechnology (PBYI)
2016-10-21,Puma Biotechnology Announces Underwriters' Full Exercise Of Option To Purchase Additional Shares
2016-10-20,Puma Bio's Desperate Money Grab Signals Breast Cancer Drug Trouble
2016-10-19,Puma Biotechnology Prices Public Offering Of Common Stock
2016-10-18,Puma Biotechnology (PBYI) Stock Down in After-Hours Trading on Public Offering
2016-10-18,Puma Biotechnology Announces Proposed Public Offering Of Common Stock
2016-10-14,PUMA INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Puma Biotechnology, Inc. - PBYI
2016-10-12,Robbins Arroyo LLP: Puma Biotechnology, Inc. (PBYI) Investors Survive Defendants' Motion To Dismiss In Securities Class Action
2016-10-11,Puma Biotechnology, Inc. Shareholder Alert: Schubert Firm Investigates Company's Top Executives
2016-10-10,Johnson & Weaver, LLP Initiates Investigations Of Puma Biotechnology, Inc., Virtus Investment Partners, Inc., AAC Holdings, Inc. And Spectrum Pharmaceuticals, Inc.; Encourages Long-Term Investors To Contact The Firm Regarding Their Legal Rights
2016-09-30,Biotech Stock Mailbag: Dynavax, Puma, Ariad
2016-09-22,Puma Biotechnology Shares Leap Forward
2016-09-20,Why Puma Biotechnology (PBYI) Stock Is Surging Today
2016-09-20,Puma Biotechnology Announces U.S. FDA Acceptance Of New Drug Application For PB272 (Neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer
2016-09-02,Jim Cramer's Top Takeaways: Salesforce.com, GCP Applied Technologies, Puma Biotechnology
2016-09-01,Jim Cramer's 'Mad Money' Recap: What Is Going on With This Market?
2016-08-24,Noteworthy Wednesday Option Activity: PBYI, MOV, BOFI
2016-08-23,4 Biotech Stock Charts You Must See
2016-08-22,Puma Biotechnology Announces European Medicines Agency Validation Of Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe
2016-08-09,Puma Biotechnology Reports Second Quarter 2016 Financial Results
2016-07-29,Biotech Stock Mailbag: Puma Roars, Relypsa Soars, XBiotech Bombs
2016-07-22,Morning Movers: GE, AMD, P, PBYI
2016-07-21,Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data From Phase III Trial Of PB272 (Neratinib) In Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)
2016-07-21,Puma Biotechnology Submits New Drug Application For PB272 (Neratinib) To U.S. FDA For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer
2016-07-07,Puma Biotechnology Announces I-SPY 2 Phase II Study Of Neratinib Published In The New England Journal Of Medicine
2016-06-29,16 Biopharma Companies Besides Medivation That Are Attractive Targets
2016-06-29,'Mad Money' Lightning Round: I Like Sirius XM Radio
2016-06-28,Jim Cramer's 'Mad Money' Recap: Add These 2 Stocks to FANG
2016-06-27,Puma Biotechnology Submits Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe
2016-06-20,August 19th Options Now Available For Puma Biotechnology (PBYI)
2016-06-10,Short Interest Increases 11.8% For PBYI
2016-06-05,Puma Biotechnology Presents Positive Phase II Data At The 2016 ASCO Annual Meeting
2016-05-18,Puma Biotechnology Announces Publication Of Neratinib Abstract For The 2016 ASCO Annual Meeting
2016-05-17,Puma Biotechnology To Present At UBS Global Healthcare Conference
2016-05-12,July 1st Options Now Available For Puma Biotechnology (PBYI)
2016-05-10,Puma Biotechnology Reports First Quarter 2016 Financial Results
2016-05-04,Puma Biotechnology To Present At Bank Of America Merrill Lynch Health Care Conference
2016-04-20,Puma Biotechnology's Neratinib Featured In Poster Presentations At The AACR Annual Meeting 2016
2016-04-14,Puma Biotechnology's NEfERT-T Phase II Study Published Online In JAMA Oncology
2016-03-29,Puma Biotechnology (PBYI) Stock Plunges on Delayed Marketing Application
2016-03-28,Puma Biotechnology Updates Timeline For Filing New Drug Application
2016-03-18,Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2016
2016-03-02,Puma Biotechnology To Present At Cowen's Health Care Conference
2016-02-29,Puma Biotechnology Reports Fourth Quarter And Full Year 2015 Financial Results
2016-02-17,Puma Biotechnology To Participate In Fireside Chat At RBC Capital Markets Global Healthcare Conference
2016-02-16,Puma Biotechnology Announces The Conclusion And Final Results Of Eshelman's Consent Solicitation
2016-02-11,Puma Biotechnology's ExteNET Phase III Study Published Online In The Lancet Oncology
2016-02-03,Puma Biotechnology To Participate In Fireside Chat At Leerink Partners Global Healthcare Conference
2016-01-22,Interesting PBYI Put And Call Options For September 16th
2016-01-14,Puma Biotechnology Stock Sees Short Interest Make 46% Move
2016-01-09,2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks
2016-01-08,Puma Biotechnology Shareholders Overwhelmingly Reject Eshelman's Consent Solicitation
2016-01-04,Puma Biotechnology To Present At J.P. Morgan Healthcare Conference
2016-01-01,Feuerstein's Heroes and Zeroes of Biotech Investing in 2015
2015-12-30,Third Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation By REVOKING CONSENT On Puma's BLUE Consent Revocation Card
2015-12-29,Second Leading Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation By REVOKING CONSENT On Puma's BLUE Consent Revocation Card
2015-12-23,ISS Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation By REVOKING CONSENT On Puma's BLUE Consent Revocation Card
2015-12-18,Puma Biotechnology Expands Third Cohort In Phase II Trial Of PB272 In HER2 Mutation Positive Cancer Patients
2015-12-16,Puma Biotechnology To Host Conference Call To Discuss Loperamide Prophylaxis To Reduce Neratinib-Related Diarrhea
2015-12-15,8 Stocks Spiking on Unusually High Volume
2015-12-11,Puma Biotechnology Presents 3-Year Disease Free Survival Data From Phase III Trial Of PB272 In Extended Adjuvant Breast Cancer (ExteNET Trial) At The 2015 San Antonio Breast Cancer Symposium
2015-12-10,Puma Biotechnology Presents Interim Results Of Phase II Trial Of PB272 For ERBB2 Mutant, HER2 Non-Amplified, Metastatic Breast Cancer At The 2015 San Antonio Breast Cancer Symposium
2015-12-10,Puma Biotechnology Announces Results Of Phase II Trial Of PB272 In Neoadjuvant Treatment Of HER2-Positive Locally Advanced Breast Cancer
2015-11-30,Puma Biotechnology Provides Update From Meeting With European Medicines Agency
2015-11-13,Puma Biotechnology To Present Data At The San Antonio Breast Cancer Symposium (SABCS)
2015-11-09,Puma Biotechnology Reports Third Quarter 2015 Financial Results
2015-11-03,Puma Biotechnology To Present At Credit Suisse Healthcare Conference
2015-09-26,Puma Biotechnology Announces Presentation Of Phase III Trial Of PB272 In Extended Adjuvant Breast Cancer (ExteNET Trial) In Centrally Confirmed HER2-Positive Early Stage Breast Cancer Patients
2015-09-10,Puma Biotechnology Announces Publication Of PB272 In HER2 Non-Amplified Metastatic Breast Cancer With A HER2 Mutation
2015-09-04,Battleground: Will This $5 Biotech Stock Go To $22 Or $1.50?
2015-09-03,Jim Cramer's Top Takeaways: Puma Biotechnology and H&R Block
2015-09-02,Jim Cramer's 'Mad Money' Recap: A Rally or Calm Before the Storm?
2015-08-10,Puma Biotechnology Reports Second Quarter 2015 Financial Results
2015-08-10,August 10 Premarket Briefing: 10 Things You Should Know
2015-07-31,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Puma Biotechnology, Inc. Of Pendency Of Class Action Lawsuit And A Lead Plaintiff Deadline Of August 3, 2015 - PBYI
2015-07-24,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Puma Biotechnology, Inc. Of Pendency Of Class Action Lawsuit And A Lead Plaintiff Deadline Of August 3, 2015 - PBYI
2015-07-20,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors Of Class Action Against Puma Biotechnology, Inc. And Lead Plaintiff Deadline Of August 3, 2015
2015-07-11,'Mad Money' Lightning Round: Stay Away From Barracuda Networks
2015-07-10,Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
2015-07-03,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Puma Biotechnology, Inc. Of Class Action Lawsuit And Upcoming Deadline - PBYI
2015-07-02,Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point
2015-06-26,IMPORTANT INVESTOR DEADLINE: Goldberg Law PC Reminds Investors With Losses Greater Than $100,000 In Puma Biotechnology, Inc. Of The August 3, 2015 Deadline
2015-06-26,Biotech Stock Mailbag: Exelixis, Puma Bio
2015-06-23,Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Puma Biotechnology, Inc.
2015-06-22,Harwood Feffer LLP Announces Securities Class Action Lawsuit Against Puma Biotechnology, Inc. And Advises Shareholders To Contact Harwood Feffer LLP Prior To The Lead Plaintiff Deadline
2015-06-05,Biotech Stock Mailbag: More Duchenne Drama, CAR-T Trouble, ASCO '15 Rewind
2015-06-04,Puma Biotechnology To Present At Goldman Sachs Healthcare Conference
2015-06-04,Top-Performing Biotech and Drug Stocks During ASCO '15
2015-06-01,Puma Bio Breast Cancer Drug Given Rough Treatment at ASCO '15
2015-06-01,Puma Biotechnology Investors Encouraged To Contact Securities Law Firm About Investigation Into Allegations Of Corporate Wrongdoing
2015-06-01,Puma Biotechnology Announces Phase III Trial Of PB272 In Extended Adjuvant Breast Cancer (ExteNET Trial) Demonstrates Statistically Significant Improvement In Disease Free Survival
2015-06-01,Puma Biotech Hoping for a Bounce at Annual Meeting of Cancer Society
2015-06-01,ASCO '15 Report Card: Grading Biotech and Drug Stocks at Cancer Drug Confab
2015-06-01,Cancer Breakthroughs Expected at Annual Meeting of Cancer Society
2015-06-01,Oncothyreon Breast Cancer Drug Exits ASCO '15 With Good Buzz
2015-05-29,Fly Watch: Several Names That May Move Following ASCO Meeting
2015-05-28,Puma Bio Restricting Access to Breast Cancer Event at ASCO Chicago
2015-05-27,Puma Biotechnology To Present At Jefferies 2015 Healthcare Conference
2015-05-22,Biotech Stock Mailbag: ASCO Preview, CAR-T stocks, MannKind, Hate Mail!
2015-05-15,6 Stocks Spiking on Big Volume
2015-05-14,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Puma Biotechnology, Inc.
2015-05-14,Walmart Stores Is Working on a Rival to Amazon's Prime Service
2015-05-13,Puma Biotechnology Announces Publication Of Abstracts For The 2015 American Society Of Clinical Oncology (ASCO) Annual Meeting
2015-05-13,Jumpstart ASCO '15 With This Quick List of Hot Research Abstracts
2015-05-12,Puma Biotechnology To Participate In Fireside Chat At UBS Global Healthcare Conference
2015-05-11,Puma Biotechnology Reports First Quarter 2015 Financial Results
2015-05-06,Puma Biotechnology To Present At Bank Of America Merrill Lynch Health Care Conference
2015-04-30,Puma Biotechnology To Present At Deutsche Bank Health Care Conference
2015-04-27,Puma Biotechnology Larger Than S&P 500 Component Mallinckrodt
2015-04-14,Puma Biotechnology Expands Cohort In Phase II Trial Of PB272 In HER2 Mutation Positive Cancer Patients
2015-03-10,Puma Biotechnology Initiates Phase II Trial Of PB272 In Early Stage HER2-Positive Breast Cancer
2015-03-06,Biotech Stock Mailbag: Next Biotech Takeout Targets, NewLink Genetics
2015-03-05,Market News: Mallinckrodt, Kroger, Puma Biotechnology
2015-03-02,Puma Biotechnology Reports Fourth Quarter And Full Year 2014 Financial Results
2015-02-24,Puma Biotechnology To Present At Cowen Health Care Conference
2015-02-18,Puma Biotechnology To Participate In Fireside Chat At RBC Capital Markets' Global Healthcare Conference
2015-02-10,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Puma Biotechnology, Inc.
2015-02-09,INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Puma Biotechnology, Inc. (PBYI) To Contact The Firm
2015-02-05,Puma Biotechnology To Present At Leerink Global Healthcare Conference
2015-01-27,Puma Biotechnology Closes $218 Million Public Offering Of Common Stock
2015-01-22,Puma Biotechnology Announces Underwriters' Full Exercise Of Option To Purchase Additional Shares
2015-01-22,4 Stocks Spiking on Unusual Volume: Puma Biotech, Nexstar and More
2015-01-21,Puma Biotechnology Prices Public Offering Of Common Stock
2015-01-20,Puma Biotechnology Announces Proposed Public Offering
2015-01-08,The Best And Worst Analyst Recommendations Of 2014
2015-01-06,Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015
2015-01-05,Puma Biotechnology To Present At J.P. Morgan Healthcare Conference
2014-12-12,Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data At 2014 CTRC-AACR San Antonio Breast Cancer Symposium
2014-12-10,SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Possible Violations Of Federal Securities Laws By The Board Of Directors Of Puma Biotechnology, Inc.
2014-12-04,Lifshitz & Miller Law Firm Announces Investigation Of Avanir Pharmaceuticals, Inc., Carbonite, Inc., Casey's General Stores, Inc., Nymox Pharmaceutical Corporation, Puma Biotechnology Inc., RealD Inc., And Spansion, Inc.
2014-12-03,Stocks Close Higher, Helped by Continued Strength in Economy
2014-12-03,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Puma Biotechnology, Inc.
2014-12-03,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Puma Biotechnology, Inc. - PBYI
2014-12-03,Stocks Trade Higher as Services Sector Grows More Than Expected
2014-12-02,Puma Forced to Delay Breast Cancer FDA Submission Due to New Safety Data Requirement
2014-12-02,Puma Biotechnology Updates Timeline For Filing New Drug Application
2014-11-25,One Solution to the Growth vs. Value Debate: Combine Them
2014-11-21,Biotech Stock Mailbag: Northwest Bio, Celldex, Puma, MannKind
2014-11-13,Puma Biotechnology Announces Positive Top Line Results From PB272 Phase II Trial In HER2 Positive Metastatic Breast Cancer (NEfERTT Trial)
2014-11-12,Puma Biotechnology To Present At Stifel 2014 Healthcare Conference
2014-11-10,Puma Biotechnology Reports Third Quarter 2014 Financial Results
2017-03-24,Data From Phase 2 Study Of Progenics' PSMA-Targeted Imaging Agent 1404 Published In Journal Of Nuclear Medicine
2017-03-21,First Week Of November 17th Options Trading For Progenics Pharmaceuticals (PGNX)
2017-03-09,Progenics Pharmaceuticals Announces Fourth Quarter And Full-Year 2016 Financial Results And Business Update
2017-03-05,4 Small-Cap Biotech Stars
2017-03-03,4 Small-Cap Biotech Stars
2017-02-23,Progenics Pharmaceuticals Sets Fourth Quarter And Year-End 2016 Financial Results Call For March 9
2017-02-16,Biotech Premarket Movers: Progenics, Alexion, BioCryst
2017-02-14,Progenics Pharmaceuticals Announces Initiation Of A Phase 1 Clinical Trial Of Its PSMA-Targeted Therapeutic Candidate 1095 For The Treatment Of Metastatic Prostate Cancer
2017-02-08,Progenics Pharmaceuticals, Inc. To Participate In February Investor Conferences
2017-02-01,First Week of March 17th Options Trading For Progenics Pharmaceuticals (PGNX)
2017-01-20,Commit To Buy Progenics Pharmaceuticals At $7, Earn 12.9% Using Options
2017-01-03,My Top 2017 Pick: Progenics Pharmaceuticals
2017-01-03,Top 2017 Pick: Progenics Pharmaceuticals
2016-12-22,Progenics Pharmaceuticals Announces Independent Committee's Positive Recommendation For Continuation Of Phase 3 Clinical Trial Of SPECT/CT Imaging Agent 1404
2016-12-07,Progenics Pharmaceuticals Announces First Patient Dosed In Phase 2/3 Clinical Trial Of PSMA-Targeted PET/CT Imaging Agent PyL™
2016-12-01,'Yuge' Sector Rotation Will Continue
2016-11-25,Biotech Hits an Inflection Point
2016-11-08,Ratings Changes Today
2016-11-08,Progenics Pharmaceuticals To Present At Upcoming Investor Conferences
2016-11-07,Progenics Pharmaceuticals Announces Third Quarter 2016 Financial Results And Business Update
2016-11-07,Progenics Announces $50 Million RELISTOR® Royalty-Backed Financing
2016-11-01,Small Biotechs on My Shopping List
2016-10-26,Oversold Conditions For Progenics Pharmaceuticals (PGNX)
2016-10-24,Progenics Pharmaceuticals Sets Third Quarter 2016 Financial Results Call For November 7
2016-10-21,Progenics Pharmaceuticals To Present At The 23rd Annual Prostate Cancer Foundation Scientific Retreat
2016-10-20,Commit To Buy Progenics Pharmaceuticals At $3, Earn 13.3% Using Options
2016-10-20,Biotech Bargain Bin Bursts With Bounty
2016-09-29,3 Stocks for Growth in 2017
2016-09-07,Progenics Pharmaceuticals Announces Appointment Of Bryce V. Tenbarge As Vice President Of Commercial
2016-09-06,Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets
2016-09-02,Progenics Pharmaceuticals To Present At The 23rd Annual NewsMakers In The Biotech Industry Conference
2016-08-25,Short Interest Increases 10% For PGNX
2016-08-23,4 Biotech Stock Charts You Must See
2016-08-04,Progenics Pharmaceuticals Announces Second Quarter 2016 Financial And Business Results
2016-07-31,5 Small-Cap Biotechs With Big Potential
2016-07-29,5 Small-Cap Biotechs With Big Potential
2016-07-26,Progenics Receives $50 Million Milestone Payment Following FDA Approval Of RELISTOR® Tablets For The Treatment Of Opioid-Induced Constipation In Adults With Chronic Non-cancer Pain
2016-07-22,Progenics Pharmaceuticals Sets Second Quarter 2016 Financial Results Call For August 4
2016-07-21,Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal
2016-07-21,Investors Scour Big Pharma M&amp;A Scene for Next Big Takeover
2016-07-21,Progenics Pharmaceuticals (PGNX) Is Today's Perilous Reversal Stock
2016-07-21,4 Small-Cap Biotechs With Big Stories to Tell
2016-07-20,Dow Closes at Record High for 7th Straight Session as Microsoft Surges
2016-07-20,These 3 Stocks Are Rising on Big Volume -- Is It Time to Buy?
2016-07-20,S&amp;P 500, Dow on Track to Break Records as Microsoft Surges
2016-07-20,Midday Report: Valeant Jumps on FDA Approval; Dow at Records
2016-07-20,Progenics (PGNX) Stock Soars as Relistor Receives FDA Approval
2016-07-20,Stocks Move Higher as Crude Pares Losses
2016-07-20,Dow on Track for Another Record Open as Microsoft Surges
2016-07-20,Heavy Early Morning Activity On Progenics Pharmaceuticals (PGNX)
2016-07-19,Futures Point Downward for U.S. Markets as Asia Opens Lower
2016-07-19,Valeant And Progenics Announce FDA Approves RELISTOR® Tablets For The Treatment Of Opioid-Induced Constipation In Adults With Chronic Non-cancer Pain
2016-07-19,Progenics Pharmaceuticals (PGNX) Stock: Weak On High Volume Today
2016-07-18,Interesting PGNX Put And Call Options For September 16th
2016-07-08,Progenics Pharmaceuticals To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference
2016-07-07,5 Stocks I Like for 2016's Second Half
2016-07-05,Trade-Ideas: Progenics Pharmaceuticals (PGNX) Is Today's Strong On High Relative Volume Stock
2016-06-28,3 Stocks on my Brexit Shopping List
2016-06-27,Noteworthy Monday Option Activity: PGNX, SIG, AMTG
2016-06-21,First Week of February 2017 Options Trading For Progenics Pharmaceuticals (PGNX)
2016-06-13,Progenics Pharmaceuticals Announces Presentations On Its Prostate Cancer Imaging Programs At SNMMI 2016
2016-06-12,Put Agenus, Progenics on Your Small-Cap List
2016-06-10,Put Agenus, Progenics on Your Small-Cap List
2016-06-09,Bradley Campbell, President And COO Of Amicus Therapeutics, Elected To Progenics Board Of Directors
2016-06-02,Progenics Pharmaceuticals To Present At The Jefferies 2016 Healthcare Conference
2016-05-05,Progenics Pharmaceuticals Announces First Quarter 2016 Financial And Business Results
2016-05-02,Progenics Licenses PSMA Antibody Technology To Bayer For Development Of Alpha-Radiolabeled Therapeutic Antibodies
2016-04-25,Progenics Pharmaceuticals (PGNX) Is Today's Strong On High Volume Stock
2016-04-21,Progenics Pharmaceuticals Sets First Quarter 2016 Financial Results Call For May 5
2016-04-18,All Eyes on Allergan and Potential Targets
2016-04-15,2 Small Biopharma Stocks on the Move
2016-04-07,Progenics Pharmaceuticals (PGNX) Is Strong On High Volume Today
2016-04-06,Progenics Pharmaceuticals To Present At The 15th Annual Needham Healthcare Conference
2016-04-04,Valeant And Progenics Announce PDUFA Date Extension For Oral RELISTOR
2016-03-30,Strong On High Relative Volume: Progenics Pharmaceuticals (PGNX)
2016-03-22,First Week of PGNX November 18th Options Trading
2016-03-18,A Small Biotech Sells for Less Than Cash
2016-03-15,Biotech Stocks Are Beginning to Stir
2016-03-11,Progenics Pharmaceuticals Announces Fourth Quarter And Full-Year 2015 Financial And Business Results
2016-03-09,Progenics Pharmaceuticals To Present At 28th Annual ROTH Conference
2016-03-09,Progenics Pharmaceuticals (PGNX) Highlighted As Weak On High Volume
2016-03-01,Progenics Pharmaceuticals Sets Fourth Quarter And Full-Year 2015 Financial Results Call For March 11
2016-02-25,First Week of PGNX April 15th Options Trading
2016-02-01,Progenics Pharmaceuticals To Present At Upcoming Investor Conferences
2016-01-25,First Week of PGNX March 18th Options Trading
2016-01-14,Short Interest Drops 21.4% For PGNX
2016-01-08,Progenics Pharmaceuticals Becomes Oversold (PGNX)
2016-01-07,Progenics Pharmaceuticals Commences Pivotal Phase 3 Study Of PSMA Targeted Imaging Agent 1404 For Prostate Cancer
2015-12-10,Progenics Pharmaceuticals Enters Oversold Territory (PGNX)
2015-12-03,Progenics Pharmaceuticals Achieves Target Enrollment In Its Phase 2b Pivotal Trial Of Azedra™
2015-11-23,Ratings Changes Today
2015-11-19,Gilead Leads a Biotech Rally
2015-11-19,Gilead Leads a Biotech Rally
2015-11-16,Progenics Pharmaceuticals Announces The Appointment Of Patrick Fabbio As Chief Financial Officer
2015-11-10,Progenics Pharmaceuticals To Present At The Stifel Healthcare Conference
2015-11-09,Progenics Pharmaceuticals Announces Third Quarter 2015 Financial Results
2015-11-03,Strong On High Relative Volume: Progenics Pharmaceuticals (PGNX)
2015-11-02,Progenics Pharmaceuticals Sets Third Quarter Financial Results Call For November 9
2015-10-14,Strong On High Relative Volume: Progenics Pharmaceuticals (PGNX)
2015-10-13,Progenics Announces Offer To Acquire EXINI
2015-10-12,Data From Phase 2 Study Of Progenics' 1404 Imaging Agent Presented At EANM Congress 2015
2015-10-12,Phase 2 Dosimetry Data For Progenics' AZEDRA Presented At EANM Congress 2015
2015-09-28,Progenics Pharmaceuticals is Now Oversold (PGNX)
2015-09-24,Progenics Pharmaceuticals To Host Research And Development Day On October 1, 2015
2015-09-17,Don't Miss These 3 Biotech Stocks
2015-08-06,Progenics Pharmaceuticals Announces Second Quarter 2015 Financial Results
2015-08-04,Jim Cramer's 'Mad Money' Recap: Nowhere to Run, Nowhere to Hide From China
2015-08-04,Progenics Pharmaceuticals Announces Exclusive Worldwide Licensing Agreement With Johns Hopkins University For Agent To Image Prostate Cancer Using PET Scan
2015-07-31,These 2 Small Caps Enjoy Strong Growth
2015-07-30,Today's Dead Cat Bounce Stock Is Progenics Pharmaceuticals (PGNX)
2015-07-28,Progenics Announces Breakthrough Therapy Designation For Azedra In Pheochromocytoma And Paraganglioma
2015-07-27,Stock To Watch: Progenics Pharmaceuticals (PGNX) In Perilous Reversal
2015-07-21,Interesting PGNX Put And Call Options For September 18th
2015-07-21,Progenics Pharmaceuticals Sets Second Quarter Financial Results Call For August 6
2015-07-07,Progenics Pharmaceuticals Announces Plans To Move Forward With 1404 Phase 3 Trial
2015-07-01,Progenics Pharmaceuticals (PGNX) Highlighted As Today's Perilous Reversal Stock
2015-06-24,Progenics Pharmaceuticals To Present At Cantor Fitzgerald's Inaugural Healthcare Conference
2015-06-23,First Week Of PGNX February 2016 Options Trading
2015-06-23,Perilous Reversal Stock: Progenics Pharmaceuticals (PGNX)
2015-06-12,Revisiting 2 Little Biotech Gems
2015-06-03,RELISTOR(R) Receives European Approval For Expanded Indication To Treat All Opioid-Induced Constipation
2015-05-27,Progenics Pharmaceuticals To Present At Jefferies 2015 Healthcare Conference
2015-05-07,Ratings Changes Today
2015-05-06,Progenics Pharmaceuticals (PGNX) Flagged As Strong On High Volume
2015-05-06,Progenics Pharmaceuticals Announces First Quarter 2015 Financial Results
2015-04-30,Progenics Pharmaceuticals Enters Oversold Territory (PGNX)
2015-04-29,Progenics Pharmaceuticals Sets First Quarter 2015 Financial Results Call For May 6
2015-04-24,Partnerships Lift Small Caps
2015-04-10,A Small, but Promising Biotech Stock
2015-04-08,Progenics Pharmaceuticals To Present At 14th Annual Needham Healthcare Conference
2015-04-07,Progenics Announces The Initiation Of Fuji's Phase 2 Trial For 1404 In Japan
2015-03-25,First Week Of November 20th Options Trading For Progenics Pharmaceuticals (PGNX)
2015-03-21,Betting the Underdog Can Be Profitable
2015-03-17,Ratings Changes Today
2015-03-16,On Deck Capital Up Nearly 25% In Five-Day Run
2015-03-16,Progenics Pharmaceuticals Announces Fourth Quarter And Year-End 2014 Financial Results
2015-03-09,Progenics Pharmaceuticals (PGNX) Is Weak On High Volume Today
2015-03-09,Progenics Pharmaceuticals Sets Fourth Quarter And Year End 2014 Financial Results Call For March 16
2015-03-02,Progenics Pharmaceuticals Announces Presentation At ENDO 2015
2015-02-26,Progenics Pharmaceuticals Presents Positive Phase 2 Data For PSMA ADC In Metastatic Castration-Resistant Prostate Cancer
2015-02-25,Interesting PGNX Put And Call Options For April 17th
2015-02-23,Progenics Pharmaceuticals To Present Full Phase 2 Data For PSMA ADC At The 2015 ASCO GU Symposium
2015-02-17,Progenics Pharmaceuticals To Present At The 2015 RBC Capital Markets' Healthcare Conference
2015-02-03,Progenics Pharmaceuticals To Present At The 17th Annual BIO CEO & Investor Conference
2015-01-23,Progenics Pharmaceuticals Relaunches Pivotal Trial Of AZEDRA(TM) In Pheochromocytoma
2014-12-12,First Week Of January 2015 Options Trading For Progenics Pharmaceuticals (PGNX)
2014-12-02,Progenics Pharmaceuticals Announces Presentation At RSNA Annual Meeting
2014-11-20,Two Small-Cap Biotechnology Gems
2014-11-14,Assessing Third-Quarter Earnings Surprises
2014-11-11,Progenics Pharmaceuticals To Participate In Upcoming Conferences
2014-11-11,Progenics Pharmaceutical (PGNX) Upgraded From Sell to Hold
2014-11-10,Ratings Changes Today
2014-11-07,Progenics Pharmaceuticals Announces Third Quarter 2014 Financial Results
2014-10-28,Volatile Market Presents Mixed Bag
2014-10-27,Interesting PGNX Put And Call Options For December 20th
2014-10-27,Progenics Pharmaceuticals Sets Third Quarter Financial Results Call For November 7
2014-10-20,Phase 2 Data For Progenics' 1404 Imaging Agent Presented At EANM Congress
2014-10-06,Progenics Receives $40 Million Milestone Following FDA Approval Of RELISTOR For OIC Patients With Chronic Non-Cancer Pain
2014-09-29,FDA Approves RELISTOR® Subcutaneous Injection For The Treatment Of Opioid-Induced Constipation In Patients With Chronic Non-cancer Pain
2014-09-24,First Week Of May 2015 Options Trading For Progenics Pharmaceuticals (PGNX)
2014-09-22,Progenics Pharmaceuticals Presents Long Term Follow-Up Of Pivotal Phase 2 Trial Of Azedra In Malignant Pheochromocytoma
2014-08-22,First Week of October 18th Options Trading For Progenics Pharmaceuticals (PGNX)
2014-08-12,Short Interest In Progenics Pharmaceuticals Increases 14.8%
2014-08-11,FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date For RELISTOR® Subcutaneous Injection SNDA For The Treatment Of Opioid-induced Constipation In Patients With Chronic Non-cancer Pain
2014-08-08,Progenics Pharmaceuticals Announces Second Quarter 2014 Financial Results
2014-07-31,Progenics Pharmaceuticals Sets Second Quarter Financial Results Call For August 8
2014-07-14,Progenics Holds Conference Call This Morning On FDA Appeal Response Regarding Relistor(R) SNDA For Patients With Chronic Non-Cancer Pain
2014-07-14,FDA Office Of Drug Evaluation III Approves Salix&#8217;s Request That The FDA Approve The RELISTOR&#174; Subcutaneous Injection SNDA For The Treatment Of Opioid-induced Constipation In Patients With Chronic Non-cancer Pain
2014-06-25,First Week of February 2015 Options Trading For Progenics Pharmaceuticals (PGNX)
2014-06-12,Progenics Schedules Investor Conference Call Following FDA Advisory Committee
2014-06-11,Progenics Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee To Consider And Provide Recommendations Regarding Peripherally-Acting Opioid Receptor Antagonists
2014-06-02,Progenics Pharmaceuticals CEO Mark Baker To Present At Jefferies Global Healthcare Conference
2014-05-30,Progenics Pharmaceuticals' PSMA ADC Data Selected For Poster Highlight Presentation At ASCO 2014
2014-05-09,Progenics Pharmaceuticals Announces First Quarter 2014 Financial Results
2014-05-01,Progenics Pharmaceuticals Sets First Quarter 2014 Financial Results Call For May 9
2014-04-24,Progenics Pharmaceuticals Announces The Completion Of Enrollment Of Chemotherapy Naive Cohort In Phase II Trial Of PSMA ADC
2014-04-22,Salix Pharmaceuticals And Progenics Pharmaceuticals Announce The Acceptance Of Submission To Expand The Use Of RELISTOR In Chronic Non-Cancer Pain By The European Medicines Agency
2014-04-07,Progenics Pharmaceuticals CEO, Mark R. Baker, To Present At 13th Annual Needham Healthcare Conference
2014-04-01,Progenics Pharmaceuticals And Centre For Probe Development And Commercialization Announce Agreement To Manufacture Targeted Radiotherapeutic Candidate For Ultra-Orphan Indications
2014-03-26,First Week Of PGNX November 22nd Options Trading
2017-03-24,Data From Phase 2 Study Of Progenics' PSMA-Targeted Imaging Agent 1404 Published In Journal Of Nuclear Medicine
2017-03-21,First Week Of November 17th Options Trading For Progenics Pharmaceuticals (PGNX)
2017-03-09,Progenics Pharmaceuticals Announces Fourth Quarter And Full-Year 2016 Financial Results And Business Update
2017-03-05,4 Small-Cap Biotech Stars
2017-03-03,4 Small-Cap Biotech Stars
2017-02-23,Progenics Pharmaceuticals Sets Fourth Quarter And Year-End 2016 Financial Results Call For March 9
2017-02-16,Biotech Premarket Movers: Progenics, Alexion, BioCryst
2017-02-14,Progenics Pharmaceuticals Announces Initiation Of A Phase 1 Clinical Trial Of Its PSMA-Targeted Therapeutic Candidate 1095 For The Treatment Of Metastatic Prostate Cancer
2017-02-08,Progenics Pharmaceuticals, Inc. To Participate In February Investor Conferences
2017-02-01,First Week of March 17th Options Trading For Progenics Pharmaceuticals (PGNX)
2017-01-20,Commit To Buy Progenics Pharmaceuticals At $7, Earn 12.9% Using Options
2017-01-03,My Top 2017 Pick: Progenics Pharmaceuticals
2017-01-03,Top 2017 Pick: Progenics Pharmaceuticals
2016-12-22,Progenics Pharmaceuticals Announces Independent Committee's Positive Recommendation For Continuation Of Phase 3 Clinical Trial Of SPECT/CT Imaging Agent 1404
2016-12-07,Progenics Pharmaceuticals Announces First Patient Dosed In Phase 2/3 Clinical Trial Of PSMA-Targeted PET/CT Imaging Agent PyL™
2016-12-01,'Yuge' Sector Rotation Will Continue
2016-11-25,Biotech Hits an Inflection Point
2016-11-08,Ratings Changes Today
2016-11-08,Progenics Pharmaceuticals To Present At Upcoming Investor Conferences
2016-11-07,Progenics Pharmaceuticals Announces Third Quarter 2016 Financial Results And Business Update
2016-11-07,Progenics Announces $50 Million RELISTOR® Royalty-Backed Financing
2016-11-01,Small Biotechs on My Shopping List
2016-10-26,Oversold Conditions For Progenics Pharmaceuticals (PGNX)
2016-10-24,Progenics Pharmaceuticals Sets Third Quarter 2016 Financial Results Call For November 7
2016-10-21,Progenics Pharmaceuticals To Present At The 23rd Annual Prostate Cancer Foundation Scientific Retreat
2016-10-20,Commit To Buy Progenics Pharmaceuticals At $3, Earn 13.3% Using Options
2016-10-20,Biotech Bargain Bin Bursts With Bounty
2016-09-29,3 Stocks for Growth in 2017
2016-09-07,Progenics Pharmaceuticals Announces Appointment Of Bryce V. Tenbarge As Vice President Of Commercial
2016-09-06,Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets
2016-09-02,Progenics Pharmaceuticals To Present At The 23rd Annual NewsMakers In The Biotech Industry Conference
2016-08-25,Short Interest Increases 10% For PGNX
2016-08-23,4 Biotech Stock Charts You Must See
2016-08-04,Progenics Pharmaceuticals Announces Second Quarter 2016 Financial And Business Results
2016-07-31,5 Small-Cap Biotechs With Big Potential
2016-07-29,5 Small-Cap Biotechs With Big Potential
2016-07-26,Progenics Receives $50 Million Milestone Payment Following FDA Approval Of RELISTOR® Tablets For The Treatment Of Opioid-Induced Constipation In Adults With Chronic Non-cancer Pain
2016-07-22,Progenics Pharmaceuticals Sets Second Quarter 2016 Financial Results Call For August 4
2016-07-21,Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal
2016-07-21,Investors Scour Big Pharma M&amp;A Scene for Next Big Takeover
2016-07-21,Progenics Pharmaceuticals (PGNX) Is Today's Perilous Reversal Stock
2016-07-21,4 Small-Cap Biotechs With Big Stories to Tell
2016-07-20,Dow Closes at Record High for 7th Straight Session as Microsoft Surges
2016-07-20,These 3 Stocks Are Rising on Big Volume -- Is It Time to Buy?
2016-07-20,S&amp;P 500, Dow on Track to Break Records as Microsoft Surges
2016-07-20,Midday Report: Valeant Jumps on FDA Approval; Dow at Records
2016-07-20,Progenics (PGNX) Stock Soars as Relistor Receives FDA Approval
2016-07-20,Stocks Move Higher as Crude Pares Losses
2016-07-20,Dow on Track for Another Record Open as Microsoft Surges
2016-07-20,Heavy Early Morning Activity On Progenics Pharmaceuticals (PGNX)
2016-07-19,Futures Point Downward for U.S. Markets as Asia Opens Lower
2016-07-19,Valeant And Progenics Announce FDA Approves RELISTOR® Tablets For The Treatment Of Opioid-Induced Constipation In Adults With Chronic Non-cancer Pain
2016-07-19,Progenics Pharmaceuticals (PGNX) Stock: Weak On High Volume Today
2016-07-18,Interesting PGNX Put And Call Options For September 16th
2016-07-08,Progenics Pharmaceuticals To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference
2016-07-07,5 Stocks I Like for 2016's Second Half
2016-07-05,Trade-Ideas: Progenics Pharmaceuticals (PGNX) Is Today's Strong On High Relative Volume Stock
2016-06-28,3 Stocks on my Brexit Shopping List
2016-06-27,Noteworthy Monday Option Activity: PGNX, SIG, AMTG
2016-06-21,First Week of February 2017 Options Trading For Progenics Pharmaceuticals (PGNX)
2016-06-13,Progenics Pharmaceuticals Announces Presentations On Its Prostate Cancer Imaging Programs At SNMMI 2016
2016-06-12,Put Agenus, Progenics on Your Small-Cap List
2016-06-10,Put Agenus, Progenics on Your Small-Cap List
2016-06-09,Bradley Campbell, President And COO Of Amicus Therapeutics, Elected To Progenics Board Of Directors
2016-06-02,Progenics Pharmaceuticals To Present At The Jefferies 2016 Healthcare Conference
2016-05-05,Progenics Pharmaceuticals Announces First Quarter 2016 Financial And Business Results
2016-05-02,Progenics Licenses PSMA Antibody Technology To Bayer For Development Of Alpha-Radiolabeled Therapeutic Antibodies
2016-04-25,Progenics Pharmaceuticals (PGNX) Is Today's Strong On High Volume Stock
2016-04-21,Progenics Pharmaceuticals Sets First Quarter 2016 Financial Results Call For May 5
2016-04-18,All Eyes on Allergan and Potential Targets
2016-04-15,2 Small Biopharma Stocks on the Move
2016-04-07,Progenics Pharmaceuticals (PGNX) Is Strong On High Volume Today
2016-04-06,Progenics Pharmaceuticals To Present At The 15th Annual Needham Healthcare Conference
2016-04-04,Valeant And Progenics Announce PDUFA Date Extension For Oral RELISTOR
2016-03-30,Strong On High Relative Volume: Progenics Pharmaceuticals (PGNX)
2016-03-22,First Week of PGNX November 18th Options Trading
2016-03-18,A Small Biotech Sells for Less Than Cash
2016-03-15,Biotech Stocks Are Beginning to Stir
2016-03-11,Progenics Pharmaceuticals Announces Fourth Quarter And Full-Year 2015 Financial And Business Results
2016-03-09,Progenics Pharmaceuticals To Present At 28th Annual ROTH Conference
2016-03-09,Progenics Pharmaceuticals (PGNX) Highlighted As Weak On High Volume
2016-03-01,Progenics Pharmaceuticals Sets Fourth Quarter And Full-Year 2015 Financial Results Call For March 11
2016-02-25,First Week of PGNX April 15th Options Trading
2016-02-01,Progenics Pharmaceuticals To Present At Upcoming Investor Conferences
2016-01-25,First Week of PGNX March 18th Options Trading
2016-01-14,Short Interest Drops 21.4% For PGNX
2016-01-08,Progenics Pharmaceuticals Becomes Oversold (PGNX)
2016-01-07,Progenics Pharmaceuticals Commences Pivotal Phase 3 Study Of PSMA Targeted Imaging Agent 1404 For Prostate Cancer
2015-12-10,Progenics Pharmaceuticals Enters Oversold Territory (PGNX)
2015-12-03,Progenics Pharmaceuticals Achieves Target Enrollment In Its Phase 2b Pivotal Trial Of Azedra™
2015-11-23,Ratings Changes Today
2015-11-19,Gilead Leads a Biotech Rally
2015-11-19,Gilead Leads a Biotech Rally
2015-11-16,Progenics Pharmaceuticals Announces The Appointment Of Patrick Fabbio As Chief Financial Officer
2015-11-10,Progenics Pharmaceuticals To Present At The Stifel Healthcare Conference
2015-11-09,Progenics Pharmaceuticals Announces Third Quarter 2015 Financial Results
2015-11-03,Strong On High Relative Volume: Progenics Pharmaceuticals (PGNX)
2015-11-02,Progenics Pharmaceuticals Sets Third Quarter Financial Results Call For November 9
2015-10-14,Strong On High Relative Volume: Progenics Pharmaceuticals (PGNX)
2015-10-13,Progenics Announces Offer To Acquire EXINI
2015-10-12,Data From Phase 2 Study Of Progenics' 1404 Imaging Agent Presented At EANM Congress 2015
2015-10-12,Phase 2 Dosimetry Data For Progenics' AZEDRA Presented At EANM Congress 2015
2015-09-28,Progenics Pharmaceuticals is Now Oversold (PGNX)
2015-09-24,Progenics Pharmaceuticals To Host Research And Development Day On October 1, 2015
2015-09-17,Don't Miss These 3 Biotech Stocks
2015-08-06,Progenics Pharmaceuticals Announces Second Quarter 2015 Financial Results
2015-08-04,Jim Cramer's 'Mad Money' Recap: Nowhere to Run, Nowhere to Hide From China
2015-08-04,Progenics Pharmaceuticals Announces Exclusive Worldwide Licensing Agreement With Johns Hopkins University For Agent To Image Prostate Cancer Using PET Scan
2015-07-31,These 2 Small Caps Enjoy Strong Growth
2015-07-30,Today's Dead Cat Bounce Stock Is Progenics Pharmaceuticals (PGNX)
2015-07-28,Progenics Announces Breakthrough Therapy Designation For Azedra In Pheochromocytoma And Paraganglioma
2015-07-27,Stock To Watch: Progenics Pharmaceuticals (PGNX) In Perilous Reversal
2015-07-21,Interesting PGNX Put And Call Options For September 18th
2015-07-21,Progenics Pharmaceuticals Sets Second Quarter Financial Results Call For August 6
2015-07-07,Progenics Pharmaceuticals Announces Plans To Move Forward With 1404 Phase 3 Trial
2015-07-01,Progenics Pharmaceuticals (PGNX) Highlighted As Today's Perilous Reversal Stock
2015-06-24,Progenics Pharmaceuticals To Present At Cantor Fitzgerald's Inaugural Healthcare Conference
2015-06-23,First Week Of PGNX February 2016 Options Trading
2015-06-23,Perilous Reversal Stock: Progenics Pharmaceuticals (PGNX)
2015-06-12,Revisiting 2 Little Biotech Gems
2015-06-03,RELISTOR(R) Receives European Approval For Expanded Indication To Treat All Opioid-Induced Constipation
2015-05-27,Progenics Pharmaceuticals To Present At Jefferies 2015 Healthcare Conference
2015-05-07,Ratings Changes Today
2015-05-06,Progenics Pharmaceuticals (PGNX) Flagged As Strong On High Volume
2015-05-06,Progenics Pharmaceuticals Announces First Quarter 2015 Financial Results
2015-04-30,Progenics Pharmaceuticals Enters Oversold Territory (PGNX)
2015-04-29,Progenics Pharmaceuticals Sets First Quarter 2015 Financial Results Call For May 6
2015-04-24,Partnerships Lift Small Caps
2015-04-10,A Small, but Promising Biotech Stock
2015-04-08,Progenics Pharmaceuticals To Present At 14th Annual Needham Healthcare Conference
2015-04-07,Progenics Announces The Initiation Of Fuji's Phase 2 Trial For 1404 In Japan
2015-03-25,First Week Of November 20th Options Trading For Progenics Pharmaceuticals (PGNX)
2015-03-21,Betting the Underdog Can Be Profitable
2015-03-17,Ratings Changes Today
2015-03-16,On Deck Capital Up Nearly 25% In Five-Day Run
2015-03-16,Progenics Pharmaceuticals Announces Fourth Quarter And Year-End 2014 Financial Results
2015-03-09,Progenics Pharmaceuticals (PGNX) Is Weak On High Volume Today
2015-03-09,Progenics Pharmaceuticals Sets Fourth Quarter And Year End 2014 Financial Results Call For March 16
2015-03-02,Progenics Pharmaceuticals Announces Presentation At ENDO 2015
2015-02-26,Progenics Pharmaceuticals Presents Positive Phase 2 Data For PSMA ADC In Metastatic Castration-Resistant Prostate Cancer
2015-02-25,Interesting PGNX Put And Call Options For April 17th
2015-02-23,Progenics Pharmaceuticals To Present Full Phase 2 Data For PSMA ADC At The 2015 ASCO GU Symposium
2015-02-17,Progenics Pharmaceuticals To Present At The 2015 RBC Capital Markets' Healthcare Conference
2015-02-03,Progenics Pharmaceuticals To Present At The 17th Annual BIO CEO & Investor Conference
2015-01-23,Progenics Pharmaceuticals Relaunches Pivotal Trial Of AZEDRA(TM) In Pheochromocytoma
2014-12-12,First Week Of January 2015 Options Trading For Progenics Pharmaceuticals (PGNX)
2014-12-02,Progenics Pharmaceuticals Announces Presentation At RSNA Annual Meeting
2014-11-20,Two Small-Cap Biotechnology Gems
2014-11-14,Assessing Third-Quarter Earnings Surprises
2014-11-11,Progenics Pharmaceuticals To Participate In Upcoming Conferences
2014-11-11,Progenics Pharmaceutical (PGNX) Upgraded From Sell to Hold
2014-11-10,Ratings Changes Today
2014-11-07,Progenics Pharmaceuticals Announces Third Quarter 2014 Financial Results
2014-10-28,Volatile Market Presents Mixed Bag
2014-10-27,Interesting PGNX Put And Call Options For December 20th
2014-10-27,Progenics Pharmaceuticals Sets Third Quarter Financial Results Call For November 7
2014-10-20,Phase 2 Data For Progenics' 1404 Imaging Agent Presented At EANM Congress
2014-10-06,Progenics Receives $40 Million Milestone Following FDA Approval Of RELISTOR For OIC Patients With Chronic Non-Cancer Pain
2014-09-29,FDA Approves RELISTOR® Subcutaneous Injection For The Treatment Of Opioid-Induced Constipation In Patients With Chronic Non-cancer Pain
2014-09-24,First Week Of May 2015 Options Trading For Progenics Pharmaceuticals (PGNX)
2014-09-22,Progenics Pharmaceuticals Presents Long Term Follow-Up Of Pivotal Phase 2 Trial Of Azedra In Malignant Pheochromocytoma
2014-08-22,First Week of October 18th Options Trading For Progenics Pharmaceuticals (PGNX)
2014-08-12,Short Interest In Progenics Pharmaceuticals Increases 14.8%
2014-08-11,FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date For RELISTOR® Subcutaneous Injection SNDA For The Treatment Of Opioid-induced Constipation In Patients With Chronic Non-cancer Pain
2014-08-08,Progenics Pharmaceuticals Announces Second Quarter 2014 Financial Results
2014-07-31,Progenics Pharmaceuticals Sets Second Quarter Financial Results Call For August 8
2014-07-14,Progenics Holds Conference Call This Morning On FDA Appeal Response Regarding Relistor(R) SNDA For Patients With Chronic Non-Cancer Pain
2014-07-14,FDA Office Of Drug Evaluation III Approves Salix&#8217;s Request That The FDA Approve The RELISTOR&#174; Subcutaneous Injection SNDA For The Treatment Of Opioid-induced Constipation In Patients With Chronic Non-cancer Pain
2014-06-25,First Week of February 2015 Options Trading For Progenics Pharmaceuticals (PGNX)
2014-06-12,Progenics Schedules Investor Conference Call Following FDA Advisory Committee
2014-06-11,Progenics Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee To Consider And Provide Recommendations Regarding Peripherally-Acting Opioid Receptor Antagonists
2014-06-02,Progenics Pharmaceuticals CEO Mark Baker To Present At Jefferies Global Healthcare Conference
2014-05-30,Progenics Pharmaceuticals' PSMA ADC Data Selected For Poster Highlight Presentation At ASCO 2014
2014-05-09,Progenics Pharmaceuticals Announces First Quarter 2014 Financial Results
2014-05-01,Progenics Pharmaceuticals Sets First Quarter 2014 Financial Results Call For May 9
2014-04-24,Progenics Pharmaceuticals Announces The Completion Of Enrollment Of Chemotherapy Naive Cohort In Phase II Trial Of PSMA ADC
2014-04-22,Salix Pharmaceuticals And Progenics Pharmaceuticals Announce The Acceptance Of Submission To Expand The Use Of RELISTOR In Chronic Non-Cancer Pain By The European Medicines Agency
2014-04-07,Progenics Pharmaceuticals CEO, Mark R. Baker, To Present At 13th Annual Needham Healthcare Conference
2014-04-01,Progenics Pharmaceuticals And Centre For Probe Development And Commercialization Announce Agreement To Manufacture Targeted Radiotherapeutic Candidate For Ultra-Orphan Indications
2014-03-26,First Week Of PGNX November 22nd Options Trading
2017-03-16,Protalix BioTherapeutics Reports 2016 Full Year Results And Provides Corporate Update
2017-03-09,Protalix BioTherapeutics To Hold Full-Year 2016 Financial Results And Corporate Update Conference Call On March 16, 2017
2017-02-17,Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta
2017-02-14,Protalix BioTherapeutics Announces Record Date For The 2017 Annual Meeting Of Stockholders
2017-02-13,Protalix BioTherapeutics To Participate In The 13th Annual WORLDSymposium™ 2017
2017-01-09,Protalix BioTherapeutics Provides Review Of 2016 And Strategic Outlook For 2017
2017-01-03,Protalix BioTherapeutics Announces Positive Interim Results From Phase II Clinical Trial Of Alidornase Alfa (AIR DNase™) For The Treatment Of Cystic Fibrosis
2016-12-27,Protalix BioTherapeutics Receives Confirmation Of Order For Over $24 Million Of Alfataliglicerase To Treat Gaucher Patients In Brazil
2016-12-22,Protalix BioTherapeutics Announces Last Patient Enrolled In The AIR DNase™ Phase II Clinical Trial For Cystic Fibrosis
2016-12-14,Protalix BioTherapeutics Receives Letter Detailing Intended Purchases Of Approximately $24 Million Of Alfataliglicerase To Treat Gaucher Patients In Brazil
2016-12-01,Protalix BioTherapeutics Announces Investor Call
2016-12-01,Protalix BioTherapeutics Announces Private Note Exchanges And Private Placement Of Secured Convertible Notes Due 2021
2016-11-30,Protalix BioTherapeutics Enrolls First Patient In Phase II Clinical Trial Of OPRX-106 For The Treatment Of Ulcerative Colitis
2016-11-22,Alfataliglicerase Approved For Pediatric Indications In Brazil For The Treatment Of Gaucher Disease In Children Four Years And Older
2016-11-09,Protalix BioTherapeutics Provides Update And Reports 2016 Third Quarter Results
2016-10-25,Protalix BioTherapeutics Doses First Patient In Global Phase III Clinical Trial Of PRX-102 For The Treatment Of Fabry Disease
2016-09-07,Protalix BioTherapeutics Announces Presentation Of Results From The Phase I/II Clinical Trial Of PRX-102 For The Treatment Of Fabry Disease At The Society For The Study Of Inborn Errors Of Metabolism
2016-08-10,Protalix BioTherapeutics Announces Additional Positive Data From Its Phase I/II Clinical Trial For PRX-102 For The Treatment Of Fabry Disease
2016-08-08,Protalix BioTherapeutics Reports Second Quarter 2016 Financial Results
2016-07-07,Protalix BioTherapeutics Announces First Patient Dosed In The AIR DNase™ Phase II Clinical Trial For Cystic Fibrosis
2016-07-04,IIROC Trading Resumption - PLX
2016-06-06,Protalix BioTherapeutics Initiates PRX-102 Global Phase III Clinical Trial Of Fabry Disease To Support United States And European Filings
2016-06-02,Protalix BioTherapeutics To Present At The Jefferies 2016 Global Healthcare Conference
2016-05-09,Protalix BioTherapeutics Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-03-08,Protalix BioTherapeutics Reports Fiscal Year 2015 Financial Results And Provides Corporate Update
2016-03-03,Protalix BioTherapeutics Presents Positive Six And Twelve Month Interim Clinical Data On PRX-102 For The Treatment Of Fabry Disease At The 12th Annual WORLDSymposium™ 2016
2016-02-22,Protalix BioTherapeutics To Participate In The SunTrust Robinson Humphrey Orphan Drug Day And The 12th Annual WORLDSymposium™ 2016
2015-11-16,Protalix BioTherapeutics To Conduct Phase III Clinical Trial For PRX-102 For The Treatment Of Fabry Disease Following A Successful End-of-Phase II Meeting With FDA
2015-11-09,Protalix BioTherapeutics Reports Third Quarter 2015 Financial Results
2015-10-22,5 Stocks Under $10 Set to Soar
2015-10-21,5 Stocks Insiders Love Right Now
2015-10-19,Protalix BioTherapeutics Reports Positive Long Term Data On PRX-102 For Fabry Disease
2015-10-13,Protalix BioTherapeutics Sells Its Share In Collaboration Agreement For ELELYSO And A 6% Equity Stake In Protalix To Pfizer For A Total Of $46 Million
2015-10-05,Protalix BioTherapeutics To Explore Non Alcoholic Steato Hepatitis (NASH) As An Indication For Its PRX 106 Oral Anti TNF
2015-09-09,Protalix BioTherapeutics Reports Positive Phase I/II Interim Clinical Data On The 1mg/kg Cohort Of PRX-102 For Fabry Disease
2015-08-10,Protalix BioTherapeutics Reports Second Quarter 2015 Financial Results
2015-08-03,Protalix BioTherapeutics Reports Positive Phase I Clinical Study Results For PRX-106 Oral Anti-TNF
2015-07-28,CollPlant Names Shomrat Shurtz Senior Director Of Business Development
2015-06-12,Protalix BioTherapeutics Announces AIR DNase(TM) Data Presented At The 38th European Cystic Fibrosis Conference
2015-05-14,Protalix BioTherapeutics To Present At Two Upcoming Healthcare Conferences
2015-05-07,Protalix BioTherapeutics Reports First Quarter 2015 Financial Results
2015-03-12,Protalix BioTherapeutics Reports Full Year 2014 Financial Results And Provides Corporate Update
2015-02-12,Protalix BioTherapeutics Presents Additional Positive Phase I/II Interim Clinical Data On PRX-102 For Fabry Disease At The WORLD Symposium
2015-02-02,Protalix BioTherapeutics Completes Enrollment In Phase I/II Clinical Trial Of PRX-102 For Fabry Disease
2015-01-08,Protalix BioTherapeutics Reports Positive Interim Data From Phase I/II Clinical Trial Of PRX-102 For The Treatment Of Fabry Disease
2015-01-05,Protalix BioTherapeutics To Present At The 2015 J.P. Morgan Healthcare Conference
2015-01-05,Protalix BioTherapeutics Announces New Strategy For Accelerated Growth
2014-10-20,5 Stocks Ready to Break Out and Soar Higher
2014-10-14,Interesting PLX Put And Call Options For May 2015
2014-09-29,Protalix BioTherapeutics Appoints Moshe Manor As President And Chief Executive Officer
2014-09-04,Protalix BioTherapeutics To Present At The Rodman & Renshaw 16th Annual Global Investment Conference
2014-08-28,Protalix Announces Conference Call To Discuss ELELYSO Pediatric Approval And Provide Updates On Additional Programs
2014-08-28,Why Protalix BioTherapeutics (PLX) Stock Is Surging Today
2014-08-28,Pfizer And Protalix BioTherapeutics Announce FDA Approval Of Pediatric Indication For ELELYSO™ (taliglucerase Alfa) For Injection, For Intravenous Use For The Treatment Of Type 1 Gaucher Disease
2014-07-24,Protalix BioTherapeutics Names Shlomo Yanai As Chairman Of The Board Of Directors
2014-06-27,Protalix Announces New Data On ELELYSO(TM) (taliglucerase Alfa) Presented At The European Working Group On Gaucher Disease 2014 11th Meeting
2014-06-23,Protalix BioTherapeutics Announces New Data On ELELYSO(TM) (taliglucerase Alfa) And Oral GCD To Be Presented At The European Working Group On Gaucher Disease 2014 11th Meeting
2014-06-18,Protalix BioTherapeutics Initiates Phase II Study With PRX-112, An Orally-Administered Enzyme Replacement Therapy For The Treatment Of Gaucher Disease
2014-06-13,Protalix BioTherapeutics' President And Chief Executive Officer, David Aviezer, Ph.D., Will Retire This Year
2014-05-30,Protalix Announces ELELYSO(TM) (taliglucerase Alfa) Approved In Canada For The Treatment Of Gaucher Disease In Both Adult And Pediatric Patients
2014-05-28,Protalix BioTherapeutics To Present At Two Upcoming Healthcare Conferences
2014-05-22,Protalix Announces ELELYSO(TM) (taliglucerase Alfa) Approved In Australia For The Treatment Of Gaucher Disease In Both Adult And Pediatric Patients
2014-05-07,Protalix BioTherapeutics To Present At The Oppenheimer 15th Annual Israeli Conference And The MIXiii Israel Innovation Conference, Biomed
2014-04-25,Relative Strength Alert For Protalix BioTherapeutics
2014-04-23,Protalix Announces Data On Oral AntiTNF To Be Presented At Digestive Disease Week 2014 Meeting
2014-02-12,Protalix BioTherapeutics Announces Oral GCD Data To Be Presented At WORLD Symposium 2014
2014-02-06,Protalix BioTherapeutics' Technology Transfer Agreement For UPLYSO(TM) (alfataliglicerase) With Brazil's Ministry Of Health Approved By The Brazilian National Institute Of Industrial Property
2014-01-23,Protalix Announces Successful Manufacturing Facility Evaluation By Health Canada
2014-01-17,2 Biotech Stocks Under $10 to Watch
2014-01-13,Protalix BioTherapeutics Provides Full-Year 2014 Strategic Outlook
2014-01-07,Protalix BioTherapeutics To Present At The 32nd Annual J.P. Morgan Healthcare Conference
2013-12-03,Protalix BioTherapeutics To Present At Oppenheimer's 24th Annual Healthcare Conference
2013-10-31,Protalix BioTherapeutics To Present At Upcoming Scientific And Medical Meetings
2013-10-14,Protalix BioTherapeutics Announces Positive Phase I Clinical Trial Results For Oral GCD In Gaucher Disease Patients
2013-09-23,Protalix BioTherapeutics Becomes Oversold (PLX)
2013-09-18,Protalix BioTherapeutics Announces Closing Of $69 Million Offering Of Convertible Notes
2013-09-12,Protalix BioTherapeutics Announces Pricing Of $60 Million Offering Of Convertible Notes
2013-09-11,Protalix BioTherapeutics Announces Proposed $60 Million Offering Of Convertible Notes
2013-06-20,Protalix BioTherapeutics Discloses Three New Compounds In Development
2013-06-19,Protalix BioTherapeutics And Brazil's Ministry Of Health Enter Into Supply And Technology Transfer Agreement For UPLYSO(TM) (alfataliglicerase) In Brazil
2013-06-12,Protalix BioTherapeutics To Host Analyst Event In New York City
2013-05-31,Oversold Conditions For Protalix BioTherapeutics (PLX)
2013-05-29,Protalix BioTherapeutics To Present At Three Upcoming Healthcare Conferences
2013-05-20,PLX July Options Begin Trading
2013-05-08,Protalix BioTherapeutics To Present At The Oppenheimer 14th Annual Israeli Conference
2013-04-29,UPLYSO(TM) (alfataliglicerase) Approved In Mexico And Chile For The Treatment Of Gaucher Disease
2013-04-04,5 Stocks Under $10 Set to Soar
2013-04-02,Protalix BioTherapeutics Treats First Gaucher Patient In Phase I Study With PRX-112, An Orally-Administered Enzyme Treatment Of Gaucher Disease
2013-03-18,UPLYSO(TM) (alfataliglicerase) Approved In Brazil By ANVISA For The Treatment Of Gaucher Disease
2013-03-07,Protalix BioTherapeutics Receives Approval To Initiate Phase I Study In Gaucher Patients With PRX-112, An Orally-Administered Candidate For The Treatment Of Gaucher Disease
2013-02-13,Protalix Announces New Clinical Data On ELELYSO(TM) To Be Presented At The WORLD Symposium 2013
2013-02-05,Protalix BioTherapeutics Reviewing Partnering And Other Alternatives
2013-02-05,Protalix BioTherapeutics To Present At The 15th Annual BIO CEO & Investor Conference
2013-01-31,Protalix BioTherapeutics Announces New Clinical Data On Taliglucerase Alfa To Be Presented At The WORLD Lysosomal Disease Network Symposium
2012-12-10,Protalix BioTherapeutics Announces First Patient Treated In Phase I/II Study Of Fabry Patients With PRX-102
2012-11-13,4 Plays Under $10 on the Rise
2012-09-27,Protalix BioTherapeutics Receives Marketing Authorization For Elelyso(TM) For The Treatment Of Gaucher Disease From The Israeli Ministry Of Health
2012-09-12,Protalix BioTherapeutics To Present At The UBS Global Life Sciences Conference
2012-08-13,Protalix BioTherapeutics Receives FDA IND Clearance To Initiate A Phase I/II Study Of Fabry Disease Patients With PRX-102, A Modified Enzyme Replacement Therapy
2012-08-09,Protalix BioTherapeutics To Present At The Canaccord Genuity 32nd Annual Growth Conference
2012-07-24,4 Biotech Stocks Under $10 With Relative Strength
2012-06-22,Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX)
2012-06-21,5 Stocks Under $10 Set to Soar
2012-05-04,Friday's Top 10 Articles, Videos on TheStreet
2012-05-04,Biotech Stock Mailbag: Exelixis, Protalix, Arena
2012-05-01,Pfizer And Protalix BioTherapeutics Announce FDA Approval Of ELELYSO&#8482; (taliglucerase Alfa) For The Treatment Of Gaucher Disease
2012-05-01,Protalix BioTherapeutics Stock Falls On Unusually High Volume (PLX)
2012-04-19,8 Stocks Under $10 Moving Higher
2012-02-16,Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX)
2011-12-06,Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX)
2011-12-06,FDA Extends Taliglucerase Alfa PDUFA Date To May 1, 2012
2011-12-01,Protalix Announces Successful European GMP Audit
2011-11-10,Protalix's Acetylcholinesterase Demonstrates Potential Role In The Treatment Of Parkinson's Disease
2011-10-26,Protalix BioTherapeutics To Present At Four Upcoming Conferences
2011-09-21,Protalix BioTherapeutics To Present At The Jefferies 2011 Global Healthcare Conference
2011-09-13,Protalix BioTherapeutics To Present At The UBS Global Life Sciences Conference
2011-09-12,Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX)
2011-09-08,Protalix BioTherapeutics' Taliglucerase Alfa Phase III Results Published In Blood, The Journal Of The American Society Of Hematology
2011-08-31,Protalix BioTherapeutics Inc. Stock Downgraded (PLX)
2011-08-18,Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX)
2011-08-17,Protalix BioTherapeutics Announces FDA Accepts For Review Complete Response Resubmission For Taliglucerase Alfa And Assigns PDUFA Date
2011-08-01,Protalix Submits Reply To FDA Complete Response Letter For Taliglucerase Alfa And Reports Top-Line Results From The Company's Switchover Trial
2011-07-15,Protalix BioTherapeutics Inc. Stock Upgraded (PLX)
2011-06-15,10 Stocks to Watch: DST, SunPower
2011-06-15,Protalix Announces Successful GMP Manufacturing Audit By Brazil's National Health Surveillance Agency
2011-04-07,Protalix BioTherapeutics To Present At The Tel Aviv Stock Exchange 100 Investment Conference
2011-02-25,Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX)
2011-02-24,Protalix BioTherapeutics Stock Falls On Unusually High Volume (PLX)
2011-02-11,Biotech Stock Mailbag: Protalix BioTherapeutics
2011-01-31,Biotech Calendar: Key Dates for February
2010-11-29,Pfizer And Protalix BioTherapeutics Announce Submission Of Taliglucerase Alfa For European Marketing Authorization For The Treatment Of Gaucher Disease
2010-09-13,Protalix BioTherapeutics To Present At The UBS Global Life Sciences Conference
2010-05-17,14 Biotech Stocks Facing FDA Approval
2010-03-03,Protalix Announces Successful GMP Manufacturing Audit By Israel's Ministry Of Health
2009-12-01,Business Highlights
2009-12-01,Movers Roundup: Bed Bath & Beyond
2009-12-01,Smartphone Stocks, Under $10s and a Poland ETF
2009-12-01,Protalix Shares Fall Following Pfizer Deal
2009-12-01,Pfizer Inks Deal For New Drugmaking Technology
2009-12-01,Protalix-Pfizer Tag Team Against Genzyme: BioBuzz
2009-12-01,Pfizer Signs Development Deal With Protalix
2009-11-17,Genzyme's Termeer: Worst Biotech CEO of '09
2009-10-15,Protalix Says Gaucher Drug Met Goals In Trial
2009-09-08,Protalix's PrGCD Gets Orphan Drug Status From FDA
2009-08-31,Cell Therapeutics' Pixantrone: Priority Review or Not?
2009-08-25,Protalix Drug Will Get Faster Review From FDA
2009-08-17,Ahead Of The Bell: Gaucher Disease Treatments
2009-08-17,Protalix's Gaucher Drug Gets Early Approval
2009-08-03,Shire to Take on Genzyme With Gaucher Drug
2007-12-05,Wednesday's Health Winners & Losers
2007-10-25,Thursday's Health Winners & Losers
2007-07-27,Inverse Funds Clean Up in Market Rout
2007-06-20,Wednesday's Health Winners & Losers
2004-03-02,Plains Resources' Pipeline Sparks a Bidding War
2004-02-26,Readers React Regarding Drugs and Gas
2017-03-16,Protalix BioTherapeutics Reports 2016 Full Year Results And Provides Corporate Update
2017-03-09,Protalix BioTherapeutics To Hold Full-Year 2016 Financial Results And Corporate Update Conference Call On March 16, 2017
2017-02-17,Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta
2017-02-14,Protalix BioTherapeutics Announces Record Date For The 2017 Annual Meeting Of Stockholders
2017-02-13,Protalix BioTherapeutics To Participate In The 13th Annual WORLDSymposium™ 2017
2017-01-09,Protalix BioTherapeutics Provides Review Of 2016 And Strategic Outlook For 2017
2017-01-03,Protalix BioTherapeutics Announces Positive Interim Results From Phase II Clinical Trial Of Alidornase Alfa (AIR DNase™) For The Treatment Of Cystic Fibrosis
2016-12-27,Protalix BioTherapeutics Receives Confirmation Of Order For Over $24 Million Of Alfataliglicerase To Treat Gaucher Patients In Brazil
2016-12-22,Protalix BioTherapeutics Announces Last Patient Enrolled In The AIR DNase™ Phase II Clinical Trial For Cystic Fibrosis
2016-12-14,Protalix BioTherapeutics Receives Letter Detailing Intended Purchases Of Approximately $24 Million Of Alfataliglicerase To Treat Gaucher Patients In Brazil
2016-12-01,Protalix BioTherapeutics Announces Investor Call
2016-12-01,Protalix BioTherapeutics Announces Private Note Exchanges And Private Placement Of Secured Convertible Notes Due 2021
2016-11-30,Protalix BioTherapeutics Enrolls First Patient In Phase II Clinical Trial Of OPRX-106 For The Treatment Of Ulcerative Colitis
2016-11-22,Alfataliglicerase Approved For Pediatric Indications In Brazil For The Treatment Of Gaucher Disease In Children Four Years And Older
2016-11-09,Protalix BioTherapeutics Provides Update And Reports 2016 Third Quarter Results
2016-10-25,Protalix BioTherapeutics Doses First Patient In Global Phase III Clinical Trial Of PRX-102 For The Treatment Of Fabry Disease
2016-09-07,Protalix BioTherapeutics Announces Presentation Of Results From The Phase I/II Clinical Trial Of PRX-102 For The Treatment Of Fabry Disease At The Society For The Study Of Inborn Errors Of Metabolism
2016-08-10,Protalix BioTherapeutics Announces Additional Positive Data From Its Phase I/II Clinical Trial For PRX-102 For The Treatment Of Fabry Disease
2016-08-08,Protalix BioTherapeutics Reports Second Quarter 2016 Financial Results
2016-07-07,Protalix BioTherapeutics Announces First Patient Dosed In The AIR DNase™ Phase II Clinical Trial For Cystic Fibrosis
2016-07-04,IIROC Trading Resumption - PLX
2016-06-06,Protalix BioTherapeutics Initiates PRX-102 Global Phase III Clinical Trial Of Fabry Disease To Support United States And European Filings
2016-06-02,Protalix BioTherapeutics To Present At The Jefferies 2016 Global Healthcare Conference
2016-05-09,Protalix BioTherapeutics Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-03-08,Protalix BioTherapeutics Reports Fiscal Year 2015 Financial Results And Provides Corporate Update
2016-03-03,Protalix BioTherapeutics Presents Positive Six And Twelve Month Interim Clinical Data On PRX-102 For The Treatment Of Fabry Disease At The 12th Annual WORLDSymposium™ 2016
2016-02-22,Protalix BioTherapeutics To Participate In The SunTrust Robinson Humphrey Orphan Drug Day And The 12th Annual WORLDSymposium™ 2016
2015-11-16,Protalix BioTherapeutics To Conduct Phase III Clinical Trial For PRX-102 For The Treatment Of Fabry Disease Following A Successful End-of-Phase II Meeting With FDA
2015-11-09,Protalix BioTherapeutics Reports Third Quarter 2015 Financial Results
2015-10-22,5 Stocks Under $10 Set to Soar
2015-10-21,5 Stocks Insiders Love Right Now
2015-10-19,Protalix BioTherapeutics Reports Positive Long Term Data On PRX-102 For Fabry Disease
2015-10-13,Protalix BioTherapeutics Sells Its Share In Collaboration Agreement For ELELYSO And A 6% Equity Stake In Protalix To Pfizer For A Total Of $46 Million
2015-10-05,Protalix BioTherapeutics To Explore Non Alcoholic Steato Hepatitis (NASH) As An Indication For Its PRX 106 Oral Anti TNF
2015-09-09,Protalix BioTherapeutics Reports Positive Phase I/II Interim Clinical Data On The 1mg/kg Cohort Of PRX-102 For Fabry Disease
2015-08-10,Protalix BioTherapeutics Reports Second Quarter 2015 Financial Results
2015-08-03,Protalix BioTherapeutics Reports Positive Phase I Clinical Study Results For PRX-106 Oral Anti-TNF
2015-07-28,CollPlant Names Shomrat Shurtz Senior Director Of Business Development
2015-06-12,Protalix BioTherapeutics Announces AIR DNase(TM) Data Presented At The 38th European Cystic Fibrosis Conference
2015-05-14,Protalix BioTherapeutics To Present At Two Upcoming Healthcare Conferences
2015-05-07,Protalix BioTherapeutics Reports First Quarter 2015 Financial Results
2015-03-12,Protalix BioTherapeutics Reports Full Year 2014 Financial Results And Provides Corporate Update
2015-02-12,Protalix BioTherapeutics Presents Additional Positive Phase I/II Interim Clinical Data On PRX-102 For Fabry Disease At The WORLD Symposium
2015-02-02,Protalix BioTherapeutics Completes Enrollment In Phase I/II Clinical Trial Of PRX-102 For Fabry Disease
2015-01-08,Protalix BioTherapeutics Reports Positive Interim Data From Phase I/II Clinical Trial Of PRX-102 For The Treatment Of Fabry Disease
2015-01-05,Protalix BioTherapeutics To Present At The 2015 J.P. Morgan Healthcare Conference
2015-01-05,Protalix BioTherapeutics Announces New Strategy For Accelerated Growth
2014-10-20,5 Stocks Ready to Break Out and Soar Higher
2014-10-14,Interesting PLX Put And Call Options For May 2015
2014-09-29,Protalix BioTherapeutics Appoints Moshe Manor As President And Chief Executive Officer
2014-09-04,Protalix BioTherapeutics To Present At The Rodman & Renshaw 16th Annual Global Investment Conference
2014-08-28,Protalix Announces Conference Call To Discuss ELELYSO Pediatric Approval And Provide Updates On Additional Programs
2014-08-28,Why Protalix BioTherapeutics (PLX) Stock Is Surging Today
2014-08-28,Pfizer And Protalix BioTherapeutics Announce FDA Approval Of Pediatric Indication For ELELYSO™ (taliglucerase Alfa) For Injection, For Intravenous Use For The Treatment Of Type 1 Gaucher Disease
2014-07-24,Protalix BioTherapeutics Names Shlomo Yanai As Chairman Of The Board Of Directors
2014-06-27,Protalix Announces New Data On ELELYSO(TM) (taliglucerase Alfa) Presented At The European Working Group On Gaucher Disease 2014 11th Meeting
2014-06-23,Protalix BioTherapeutics Announces New Data On ELELYSO(TM) (taliglucerase Alfa) And Oral GCD To Be Presented At The European Working Group On Gaucher Disease 2014 11th Meeting
2014-06-18,Protalix BioTherapeutics Initiates Phase II Study With PRX-112, An Orally-Administered Enzyme Replacement Therapy For The Treatment Of Gaucher Disease
2014-06-13,Protalix BioTherapeutics' President And Chief Executive Officer, David Aviezer, Ph.D., Will Retire This Year
2014-05-30,Protalix Announces ELELYSO(TM) (taliglucerase Alfa) Approved In Canada For The Treatment Of Gaucher Disease In Both Adult And Pediatric Patients
2014-05-28,Protalix BioTherapeutics To Present At Two Upcoming Healthcare Conferences
2014-05-22,Protalix Announces ELELYSO(TM) (taliglucerase Alfa) Approved In Australia For The Treatment Of Gaucher Disease In Both Adult And Pediatric Patients
2014-05-07,Protalix BioTherapeutics To Present At The Oppenheimer 15th Annual Israeli Conference And The MIXiii Israel Innovation Conference, Biomed
2014-04-25,Relative Strength Alert For Protalix BioTherapeutics
2014-04-23,Protalix Announces Data On Oral AntiTNF To Be Presented At Digestive Disease Week 2014 Meeting
2014-02-12,Protalix BioTherapeutics Announces Oral GCD Data To Be Presented At WORLD Symposium 2014
2014-02-06,Protalix BioTherapeutics' Technology Transfer Agreement For UPLYSO(TM) (alfataliglicerase) With Brazil's Ministry Of Health Approved By The Brazilian National Institute Of Industrial Property
2014-01-23,Protalix Announces Successful Manufacturing Facility Evaluation By Health Canada
2014-01-17,2 Biotech Stocks Under $10 to Watch
2014-01-13,Protalix BioTherapeutics Provides Full-Year 2014 Strategic Outlook
2014-01-07,Protalix BioTherapeutics To Present At The 32nd Annual J.P. Morgan Healthcare Conference
2013-12-03,Protalix BioTherapeutics To Present At Oppenheimer's 24th Annual Healthcare Conference
2013-10-31,Protalix BioTherapeutics To Present At Upcoming Scientific And Medical Meetings
2013-10-14,Protalix BioTherapeutics Announces Positive Phase I Clinical Trial Results For Oral GCD In Gaucher Disease Patients
2013-09-23,Protalix BioTherapeutics Becomes Oversold (PLX)
2013-09-18,Protalix BioTherapeutics Announces Closing Of $69 Million Offering Of Convertible Notes
2013-09-12,Protalix BioTherapeutics Announces Pricing Of $60 Million Offering Of Convertible Notes
2013-09-11,Protalix BioTherapeutics Announces Proposed $60 Million Offering Of Convertible Notes
2013-06-20,Protalix BioTherapeutics Discloses Three New Compounds In Development
2013-06-19,Protalix BioTherapeutics And Brazil's Ministry Of Health Enter Into Supply And Technology Transfer Agreement For UPLYSO(TM) (alfataliglicerase) In Brazil
2013-06-12,Protalix BioTherapeutics To Host Analyst Event In New York City
2013-05-31,Oversold Conditions For Protalix BioTherapeutics (PLX)
2013-05-29,Protalix BioTherapeutics To Present At Three Upcoming Healthcare Conferences
2013-05-20,PLX July Options Begin Trading
2013-05-08,Protalix BioTherapeutics To Present At The Oppenheimer 14th Annual Israeli Conference
2013-04-29,UPLYSO(TM) (alfataliglicerase) Approved In Mexico And Chile For The Treatment Of Gaucher Disease
2013-04-04,5 Stocks Under $10 Set to Soar
2013-04-02,Protalix BioTherapeutics Treats First Gaucher Patient In Phase I Study With PRX-112, An Orally-Administered Enzyme Treatment Of Gaucher Disease
2013-03-18,UPLYSO(TM) (alfataliglicerase) Approved In Brazil By ANVISA For The Treatment Of Gaucher Disease
2013-03-07,Protalix BioTherapeutics Receives Approval To Initiate Phase I Study In Gaucher Patients With PRX-112, An Orally-Administered Candidate For The Treatment Of Gaucher Disease
2013-02-13,Protalix Announces New Clinical Data On ELELYSO(TM) To Be Presented At The WORLD Symposium 2013
2013-02-05,Protalix BioTherapeutics Reviewing Partnering And Other Alternatives
2013-02-05,Protalix BioTherapeutics To Present At The 15th Annual BIO CEO & Investor Conference
2013-01-31,Protalix BioTherapeutics Announces New Clinical Data On Taliglucerase Alfa To Be Presented At The WORLD Lysosomal Disease Network Symposium
2012-12-10,Protalix BioTherapeutics Announces First Patient Treated In Phase I/II Study Of Fabry Patients With PRX-102
2012-11-13,4 Plays Under $10 on the Rise
2012-09-27,Protalix BioTherapeutics Receives Marketing Authorization For Elelyso(TM) For The Treatment Of Gaucher Disease From The Israeli Ministry Of Health
2012-09-12,Protalix BioTherapeutics To Present At The UBS Global Life Sciences Conference
2012-08-13,Protalix BioTherapeutics Receives FDA IND Clearance To Initiate A Phase I/II Study Of Fabry Disease Patients With PRX-102, A Modified Enzyme Replacement Therapy
2012-08-09,Protalix BioTherapeutics To Present At The Canaccord Genuity 32nd Annual Growth Conference
2012-07-24,4 Biotech Stocks Under $10 With Relative Strength
2012-06-22,Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX)
2012-06-21,5 Stocks Under $10 Set to Soar
2012-05-04,Friday's Top 10 Articles, Videos on TheStreet
2012-05-04,Biotech Stock Mailbag: Exelixis, Protalix, Arena
2012-05-01,Pfizer And Protalix BioTherapeutics Announce FDA Approval Of ELELYSO&#8482; (taliglucerase Alfa) For The Treatment Of Gaucher Disease
2012-05-01,Protalix BioTherapeutics Stock Falls On Unusually High Volume (PLX)
2012-04-19,8 Stocks Under $10 Moving Higher
2012-02-16,Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX)
2011-12-06,Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX)
2011-12-06,FDA Extends Taliglucerase Alfa PDUFA Date To May 1, 2012
2011-12-01,Protalix Announces Successful European GMP Audit
2011-11-10,Protalix's Acetylcholinesterase Demonstrates Potential Role In The Treatment Of Parkinson's Disease
2011-10-26,Protalix BioTherapeutics To Present At Four Upcoming Conferences
2011-09-21,Protalix BioTherapeutics To Present At The Jefferies 2011 Global Healthcare Conference
2011-09-13,Protalix BioTherapeutics To Present At The UBS Global Life Sciences Conference
2011-09-12,Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX)
2011-09-08,Protalix BioTherapeutics' Taliglucerase Alfa Phase III Results Published In Blood, The Journal Of The American Society Of Hematology
2011-08-31,Protalix BioTherapeutics Inc. Stock Downgraded (PLX)
2011-08-18,Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX)
2011-08-17,Protalix BioTherapeutics Announces FDA Accepts For Review Complete Response Resubmission For Taliglucerase Alfa And Assigns PDUFA Date
2011-08-01,Protalix Submits Reply To FDA Complete Response Letter For Taliglucerase Alfa And Reports Top-Line Results From The Company's Switchover Trial
2011-07-15,Protalix BioTherapeutics Inc. Stock Upgraded (PLX)
2011-06-15,10 Stocks to Watch: DST, SunPower
2011-06-15,Protalix Announces Successful GMP Manufacturing Audit By Brazil's National Health Surveillance Agency
2011-04-07,Protalix BioTherapeutics To Present At The Tel Aviv Stock Exchange 100 Investment Conference
2011-02-25,Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX)
2011-02-24,Protalix BioTherapeutics Stock Falls On Unusually High Volume (PLX)
2011-02-11,Biotech Stock Mailbag: Protalix BioTherapeutics
2011-01-31,Biotech Calendar: Key Dates for February
2010-11-29,Pfizer And Protalix BioTherapeutics Announce Submission Of Taliglucerase Alfa For European Marketing Authorization For The Treatment Of Gaucher Disease
2010-09-13,Protalix BioTherapeutics To Present At The UBS Global Life Sciences Conference
2010-05-17,14 Biotech Stocks Facing FDA Approval
2010-03-03,Protalix Announces Successful GMP Manufacturing Audit By Israel's Ministry Of Health
2009-12-01,Business Highlights
2009-12-01,Movers Roundup: Bed Bath & Beyond
2009-12-01,Smartphone Stocks, Under $10s and a Poland ETF
2009-12-01,Protalix Shares Fall Following Pfizer Deal
2009-12-01,Pfizer Inks Deal For New Drugmaking Technology
2009-12-01,Protalix-Pfizer Tag Team Against Genzyme: BioBuzz
2009-12-01,Pfizer Signs Development Deal With Protalix
2009-11-17,Genzyme's Termeer: Worst Biotech CEO of '09
2009-10-15,Protalix Says Gaucher Drug Met Goals In Trial
2009-09-08,Protalix's PrGCD Gets Orphan Drug Status From FDA
2009-08-31,Cell Therapeutics' Pixantrone: Priority Review or Not?
2009-08-25,Protalix Drug Will Get Faster Review From FDA
2009-08-17,Ahead Of The Bell: Gaucher Disease Treatments
2009-08-17,Protalix's Gaucher Drug Gets Early Approval
2009-08-03,Shire to Take on Genzyme With Gaucher Drug
2007-12-05,Wednesday's Health Winners & Losers
2007-10-25,Thursday's Health Winners & Losers
2007-07-27,Inverse Funds Clean Up in Market Rout
2007-06-20,Wednesday's Health Winners & Losers
2004-03-02,Plains Resources' Pipeline Sparks a Bidding War
2004-02-26,Readers React Regarding Drugs and Gas
2017-03-01,ProQR To Present At Two Upcoming Investor Conferences In March
2017-02-28,ProQR Announces Results For The Fourth Quarter And Full Year 2016 And Provides A Business Update
2017-02-27,On A Shared Quest To Find Treatments For Rare Diseases, ProQR Supports Rare Disease Day
2017-02-09,These 5 Stocks Under $10 Could Explode Up Soon
2017-02-07,ProQR To Present At The LEERINK Partners Global Healthcare Conference
2016-11-14,ProQR Announces Results For The Third Quarter Of 2016
2016-11-02,ProQR Therapeutics Enters Oversold Territory (PRQR)
2016-10-27,ProQR Cystic Fibrosis Drug Passes First, Early Efficacy Test
2016-10-27,ProQR Announces That QR-010 Meets The Primary Endpoint In A Proof Of Concept Study Of Homozygous F508del Cystic Fibrosis Patients
2016-09-27,ProQR Announces Clinical Data Presentations And Investor & Analyst Event At NACFC
2016-09-06,ProQR To Present At Scientific And Investor Conferences In September
2016-08-17,ProQR Announces Results For The Second Quarter Of 2016
2016-07-19,ProQR Receives Fast Track Designation From FDA For QR-010 For Cystic Fibrosis
2016-06-21,ProQR To Release Topline Data From Proof Of Concept Study Of QR-010 In Cystic Fibrosis Patients At NACFC
2016-06-01,ProQR's Drug Candidate QR-110 For Leber's Congenital Amaurosis Type 10 Receives EMA And FDA Orphan Drug Designation
2016-06-01,ProQR Announces Presentations At The European CF Conference And The JMP Life Science Conference
2016-05-18,ProQR Announces Results For The First Quarter Of 2016
2016-04-25,ProQR Announces An Investor And Analyst Event And Pre-Clinical Data Presentations For QR-110 For LCA10 At The 2016 ARVO Annual Meeting
2016-04-07,ProQR Announces Annual Meeting Of Shareholders
2016-03-11,Ratings Changes Today
2016-03-01,ProQR To Highlight A Growing Pipeline During A Research & Development Day And Present At The Barclays Global Healthcare Conference
2016-02-17,ProQR Announces Results For The Fourth Quarter And Full Year 2015
2016-02-03,ProQR To Present At The Leerink Partners Global Healthcare Conference
2015-12-31,5 Stocks Under $10 Set to Soar
2015-12-17,Oversold Conditions For ProQR Therapeutics (PRQR)
2015-11-30,ProQR Announces R&D Day And Provides Update On Innovation Portfolio
2015-11-23,ProQR Therapeutics Becomes Oversold (PRQR)
2015-11-23,ProQR Announces Results For The Third Quarter Of 2015 And Provides Update On Clinical Trials
2015-10-08,Vertex to Test New Cystic Fibrosis Drugs, Seeking Broader, More Effective Treatments
2015-10-01,ProQR Announces An Investor And Analyst Event And Pre-Clinical Data Presentations For QR-010 For Cystic Fibrosis At Two Upcoming Scientific Conferences
2015-09-23,ProQR To Present At The Leerink Partners 4th Annual Rare Disease Roundtable
2015-09-14,ProQR Announces A Proof-of-Concept Nasal Potential Difference Study Of QR-010 Is Open For Enrollment
2015-08-19,ProQR Announces Results For The Second Quarter Of 2015
2015-07-08,ProQR Therapeutics Becomes Oversold (PRQR)
2015-06-26,ProQR Announces Enrollment Has Started In Global Phase 1b Study Of QR-010 In Cystic Fibrosis Patients
2015-06-16,ProQR To Present At The JMP Securities Life Science Conference
2015-05-21,ProQR Therapeutics Announces Results For The First Quarter Of 2015
2015-04-29,ProQR To Present At Two Upcoming Investor Conferences In May
2015-04-29,ProQR Therapeutics Announces Annual Shareholder Meeting
2015-02-26,ProQR Therapeutics Announces Results For The Fourth Quarter And Full Year 2014
2015-02-04,ProQR To Present At The 2015 Leerink Global Healthcare Conference
2014-11-24,ProQR Therapeutics Announces Results For The Third Quarter Of 2014
2014-09-26,Biotech Stock Mailbag: ProQR, Vertex Pharma, Tekmira, Agios
2014-09-23,ProQR Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares
2014-09-18,ProQR Announces Pricing Of Initial Public Offering
,
,
,
,
2017-03-23,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By Certain Officers And Directors Of Proteon Therapeutics, Inc.
2017-03-17,Proteon Therapeutics To Present At The Oppenheimer 27th Annual Healthcare Conference March 22nd
2017-03-16,Proteon Therapeutics Announces Full-Year 2016 Financial Results And Changes To The Ongoing Phase 3 PATENCY-2 Clinical Trial
2017-02-06,Proteon Therapeutics Announces Two Presentations At The American Society Of Diagnostic And Interventional Nephrology Meeting  
2017-01-05,These 5 Stocks Under $10 Could Make You a Lot of Money
2016-12-13,Proteon Therapeutics Announces Top-Line Data From Phase 3 PATENCY-1 Clinical Trial Of Investigational Vonapanitase In Patients With CKD
2016-11-10,Proteon Therapeutics Announces First Patient Dosed In Phase 1 Study Evaluating Vonapanitase For The Treatment Of Peripheral Artery Disease Below The Knee
2016-11-09,Proteon Therapeutics To Participate In Two Upcoming Investor Conferences
2016-11-07,Proteon Therapeutics Announces Third Quarter 2016 Financial Results
2016-10-25,Proteon Therapeutics Announces Overview Of Phase 1 Clinical Program Of Investigational Vonapanitase In Peripheral Artery Disease To Be Presented At The 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference
2016-10-20,Proteon Therapeutics Appoints Paul Hastings Chairman Of Its Board Of Directors
2016-09-01,Proteon Therapeutics To Present At Two Upcoming Investor Conferences
2016-08-08,Proteon Therapeutics Announces Second Quarter 2016 Financial Results
2016-06-26,7 Stocks Under $10 to Trade for Big Post-Brexit Gains
2016-06-15,Proteon Therapeutics To Present At The JMP Securities Life Sciences Conference June 22nd
2016-05-09,Proteon Therapeutics Announces First Quarter 2016 Financial Results
2016-04-28,Proteon Therapeutics Announces Survey Findings Demonstrating Impact Of Vascular Access Failure On Hemodialysis Patients
2016-04-13,Proteon Therapeutics Announces Publication In The Journal Of Cardiovascular Pharmacology Of Promising Nonclinical Results For Vonapanitase In Peripheral Artery Disease
2016-03-14,Proteon Therapeutics Announces Fourth Quarter And Full-Year 2015 Financial Results
2016-03-02,Proteon Therapeutics To Present At The Cowen And Company 36th Annual Health Care Conference On March 8th
2016-02-02,Proteon Therapeutics To Present At The 2016 BIO CEO & Investor Conference February 8th
2016-01-12,RSI Alert: Proteon Therapeutics (PRTO) Now Oversold
2015-12-02,Proteon Therapeutics To Present At The Oppenheimer 26th Annual Healthcare Conference December 9th
2015-11-13,Proteon Therapeutics To Present At The Stifel 2015 Healthcare Conference On November 17th
2015-11-12,Proteon Therapeutics Announces Third Quarter 2015 Financial Results
2015-11-09,Proteon Therapeutics To Host Research And Development Day On November 20, 2015
2015-11-02,Proteon Therapeutics Completes Enrollment In PATENCY-1, First Phase 3 Clinical Study Of Investigational Vonapanitase
2015-10-28,Proteon Therapeutics To Present At The BIO-Europe 2015 Conference November 3
2015-10-19,Proteon Therapeutics Appoints Tony Kingsley To Its Board Of Directors
2015-10-12,Proteon Therapeutics Announces Results From Phase 1 Study Of Investigational Drug Vonapanitase In Patients With Symptomatic Peripheral Artery Disease Presented At TCT 2015
2015-09-02,Proteon Therapeutics To Present At Two Upcoming Investor Conferences
2015-09-01,Proteon Therapeutics Appoints Jennifer Panagoulias As Vice President Of Regulatory Affairs
2015-08-14,Proteon Therapeutics Becomes Oversold (PRTO)
2015-08-13,Proteon Therapeutics Announces Second Quarter 2015 Financial Results
2015-08-13,Proteon Therapeutics Announces Top-Line Results From Phase 1 Study Of Investigational Drug Vonapanitase In Patients With Symptomatic Peripheral Artery Disease
2015-08-12,Proteon Therapeutics Initiates Second Phase 3 Clinical Study Of Investigational Drug Vonapanitase
2015-07-22,Proteon Therapeutics Appoints Scott Canute To Its Board Of Directors
2015-06-29,Proteon Therapeutics Announces Addition To Russell 2000 Index
2015-06-17,Proteon Therapeutics To Present At The JMP Securities Life Science Conference June 24th
2015-06-02,Proteon Therapeutics Appoints Scott Toner As Senior Vice President Of Marketing
2015-05-22,Proteon Therapeutics To Present At Upcoming ERA-EDTA Annual Congress
2015-05-13,Proteon Therapeutics Announces First Quarter 2015 Financial Results
2015-04-13,Proteon Therapeutics To Present At Two International Vascular Access Conferences
2015-03-26,Proteon Therapeutics Announces Positive Long-Term Results From Phase 2 Study Of Investigational New Drug Vonapanitase In Chronic Kidney Disease Patients Undergoing Surgical Creation Of An Arteriovenous Fistula For Hemodialysis
2015-03-20,Proteon Therapeutics Announces Fourth Quarter And Full-Year 2014 Financial Results
2015-02-26,Proteon Therapeutics To Present At The Cowen And Company 35th Annual Healthcare Conference On March 4th
2015-02-06,Proteon Therapeutics To Ring The Nasdaq Stock Market Opening Bell On February 9th
2015-02-05,Proteon Therapeutics To Present At The 17th Annual BIO CEO & Investor Conference February 9th
2015-01-08,Journal Of Cardiovascular Pharmacology Publishes Positive Nonclinical Results Of Proteon Therapeutics' PRT-201 In Peripheral Artery Disease
2014-12-08,Proteon Therapeutics To Present At The Oppenheimer 25th Annual Healthcare Conference December 11th
2014-11-25,Proteon Therapeutics Announces Third Quarter 2014 Financial Results
2014-11-24,Proteon Therapeutics Announces The Closing Of Initial Public Offering And The Underwriters' Option To Purchase Additional Shares
2014-11-17,Proteon Therapeutics To Present At The Stifel Nicolaus 2014 Healthcare Conference November 18th
,
,
,
,
2017-03-23,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By Certain Officers And Directors Of Proteon Therapeutics, Inc.
2017-03-17,Proteon Therapeutics To Present At The Oppenheimer 27th Annual Healthcare Conference March 22nd
2017-03-16,Proteon Therapeutics Announces Full-Year 2016 Financial Results And Changes To The Ongoing Phase 3 PATENCY-2 Clinical Trial
2017-02-06,Proteon Therapeutics Announces Two Presentations At The American Society Of Diagnostic And Interventional Nephrology Meeting  
2017-01-05,These 5 Stocks Under $10 Could Make You a Lot of Money
2016-12-13,Proteon Therapeutics Announces Top-Line Data From Phase 3 PATENCY-1 Clinical Trial Of Investigational Vonapanitase In Patients With CKD
2016-11-10,Proteon Therapeutics Announces First Patient Dosed In Phase 1 Study Evaluating Vonapanitase For The Treatment Of Peripheral Artery Disease Below The Knee
2016-11-09,Proteon Therapeutics To Participate In Two Upcoming Investor Conferences
2016-11-07,Proteon Therapeutics Announces Third Quarter 2016 Financial Results
2016-10-25,Proteon Therapeutics Announces Overview Of Phase 1 Clinical Program Of Investigational Vonapanitase In Peripheral Artery Disease To Be Presented At The 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference
2016-10-20,Proteon Therapeutics Appoints Paul Hastings Chairman Of Its Board Of Directors
2016-09-01,Proteon Therapeutics To Present At Two Upcoming Investor Conferences
2016-08-08,Proteon Therapeutics Announces Second Quarter 2016 Financial Results
2016-06-26,7 Stocks Under $10 to Trade for Big Post-Brexit Gains
2016-06-15,Proteon Therapeutics To Present At The JMP Securities Life Sciences Conference June 22nd
2016-05-09,Proteon Therapeutics Announces First Quarter 2016 Financial Results
2016-04-28,Proteon Therapeutics Announces Survey Findings Demonstrating Impact Of Vascular Access Failure On Hemodialysis Patients
2016-04-13,Proteon Therapeutics Announces Publication In The Journal Of Cardiovascular Pharmacology Of Promising Nonclinical Results For Vonapanitase In Peripheral Artery Disease
2016-03-14,Proteon Therapeutics Announces Fourth Quarter And Full-Year 2015 Financial Results
2016-03-02,Proteon Therapeutics To Present At The Cowen And Company 36th Annual Health Care Conference On March 8th
2016-02-02,Proteon Therapeutics To Present At The 2016 BIO CEO & Investor Conference February 8th
2016-01-12,RSI Alert: Proteon Therapeutics (PRTO) Now Oversold
2015-12-02,Proteon Therapeutics To Present At The Oppenheimer 26th Annual Healthcare Conference December 9th
2015-11-13,Proteon Therapeutics To Present At The Stifel 2015 Healthcare Conference On November 17th
2015-11-12,Proteon Therapeutics Announces Third Quarter 2015 Financial Results
2015-11-09,Proteon Therapeutics To Host Research And Development Day On November 20, 2015
2015-11-02,Proteon Therapeutics Completes Enrollment In PATENCY-1, First Phase 3 Clinical Study Of Investigational Vonapanitase
2015-10-28,Proteon Therapeutics To Present At The BIO-Europe 2015 Conference November 3
2015-10-19,Proteon Therapeutics Appoints Tony Kingsley To Its Board Of Directors
2015-10-12,Proteon Therapeutics Announces Results From Phase 1 Study Of Investigational Drug Vonapanitase In Patients With Symptomatic Peripheral Artery Disease Presented At TCT 2015
2015-09-02,Proteon Therapeutics To Present At Two Upcoming Investor Conferences
2015-09-01,Proteon Therapeutics Appoints Jennifer Panagoulias As Vice President Of Regulatory Affairs
2015-08-14,Proteon Therapeutics Becomes Oversold (PRTO)
2015-08-13,Proteon Therapeutics Announces Second Quarter 2015 Financial Results
2015-08-13,Proteon Therapeutics Announces Top-Line Results From Phase 1 Study Of Investigational Drug Vonapanitase In Patients With Symptomatic Peripheral Artery Disease
2015-08-12,Proteon Therapeutics Initiates Second Phase 3 Clinical Study Of Investigational Drug Vonapanitase
2015-07-22,Proteon Therapeutics Appoints Scott Canute To Its Board Of Directors
2015-06-29,Proteon Therapeutics Announces Addition To Russell 2000 Index
2015-06-17,Proteon Therapeutics To Present At The JMP Securities Life Science Conference June 24th
2015-06-02,Proteon Therapeutics Appoints Scott Toner As Senior Vice President Of Marketing
2015-05-22,Proteon Therapeutics To Present At Upcoming ERA-EDTA Annual Congress
2015-05-13,Proteon Therapeutics Announces First Quarter 2015 Financial Results
2015-04-13,Proteon Therapeutics To Present At Two International Vascular Access Conferences
2015-03-26,Proteon Therapeutics Announces Positive Long-Term Results From Phase 2 Study Of Investigational New Drug Vonapanitase In Chronic Kidney Disease Patients Undergoing Surgical Creation Of An Arteriovenous Fistula For Hemodialysis
2015-03-20,Proteon Therapeutics Announces Fourth Quarter And Full-Year 2014 Financial Results
2015-02-26,Proteon Therapeutics To Present At The Cowen And Company 35th Annual Healthcare Conference On March 4th
2015-02-06,Proteon Therapeutics To Ring The Nasdaq Stock Market Opening Bell On February 9th
2015-02-05,Proteon Therapeutics To Present At The 17th Annual BIO CEO & Investor Conference February 9th
2015-01-08,Journal Of Cardiovascular Pharmacology Publishes Positive Nonclinical Results Of Proteon Therapeutics' PRT-201 In Peripheral Artery Disease
2014-12-08,Proteon Therapeutics To Present At The Oppenheimer 25th Annual Healthcare Conference December 11th
2014-11-25,Proteon Therapeutics Announces Third Quarter 2014 Financial Results
2014-11-24,Proteon Therapeutics Announces The Closing Of Initial Public Offering And The Underwriters' Option To Purchase Additional Shares
2014-11-17,Proteon Therapeutics To Present At The Stifel Nicolaus 2014 Healthcare Conference November 18th
,
,
,
,
2017-03-16,Biotech Premarket Movers: Seres, PTC, Inovio
2017-03-16,PTC Therapeutics Announces Agreement To Acquire Emflaza™ For The Treatment Of Duchenne Muscular Dystrophy In U.S.
2017-03-13,PTC Therapeutics Announces Timing Change For Fourth Quarter And Year End 2016 Financial Results
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-08,Could These 9 Drugs Gain FDA Approval in the Age of Trump?
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-06,Biotech Premarket Movers: PTC, Teligent, Minerva
2017-03-06,PTC Therapeutics Announces FDA Acknowledgment Of New Drug Application Filing For Translarna™ For The Treatment Of Nonsense Mutation Duchenne Muscular Dystrophy
2017-03-02,Relative Strength Alert For PTC Therapeutics
2017-03-02,Biotech Premarket Movers: Aurinia, Puma, PTC, Juno
2017-03-02,PTC Therapeutics Suffers Cystic Fibrosis Setback, Dimming Hopes for Any U.S. Approvals
2017-03-02,PTC Therapeutics Announces Results From Pivotal Phase 3 Clinical Trial Of Ataluren In Patients Living With Nonsense Mutation Cystic Fibrosis
2017-02-21,PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2017-02-10,Noteworthy Friday Option Activity: PTCT, UVV, SREV
2017-02-08,PTC Therapeutics Announces Third Annual STRIVE Grant Award Program For Duchenne Muscular Dystrophy
2017-01-10,Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears
2017-01-10,PTCT Crosses Above Average Analyst Target
2017-01-09,European Commission Ratifies Positive CHMP Opinion For The Renewal Of Translarna™ Marketing Authorization For The Treatment Of Nonsense Mutation Duchenne Muscular Dystrophy
2017-01-09,PTC Therapeutics Provides Corporate Update And Outlines 2017 Strategic Priorities To Maximize The Global Value Of Translarna™ And Advance Its Innovative Pipeline
2017-01-06,RG7916 Granted Orphan Drug Designation In The U.S. For The Treatment Of Spinal Muscular Atrophy
2017-01-05,PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2017-01-05,Notable Thursday Option Activity: PTCT, HAIN, MRTX
2017-01-05,PTC Therapeutics Announces Initiation Of FIREFISH Study In Infant (Type I) SMA Patients
2016-12-22,Commit To Purchase PTC Therapeutics At $8, Earn 23.8% Using Options
2016-12-16,PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2016-12-08,PTC Therapeutics Receives France's 2016 Prix Galien For Translarna™
2016-11-18,PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2016-11-11,PTC Therapeutics Duchenne Drug Wins Extended European Approval
2016-11-11,CHMP Recommends Renewal Of Translarna's™ Marketing Authorization For Nonsense Mutation Duchenne Muscular Dystrophy Based On Continued Positive Benefit-Risk Assessment
2016-10-24,Bullish and Bearish Reversals for the Week
2016-10-20,Spinal Muscular Atrophy Program Advances Into Phase 2 Clinical Studies In SMA Patients With RG7916
2016-10-19,RSI Alert: PTC Therapeutics (PTCT) Now Oversold
2016-10-17,PTC Therapeutics Getting Cold Shoulder From Regulators on Duchenne Drug Appeal
2016-10-17,PTC Therapeutics Provides Regulatory Update On Translarna™ (ataluren) For Nonsense Mutation Duchenne Muscular Dystrophy
2016-10-06,PTC Therapeutics Announces New Analyses That Support The Potential Benefit Of Ataluren In Preserving Lung Function In Non-Ambulatory Nonsense Mutation Duchenne Muscular Dystrophy Patients
2016-10-04,New Research Validates Translarna's™ (ataluren) Mechanism Of Action To Promote Readthrough Of Nonsense Mutations And Produce Full-length Functional Protein
2016-09-20,Commit To Purchase PTC Therapeutics At $5, Earn 22% Using Options
2016-09-12,PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2016-09-07,PTC Therapeutics Recognizes World Duchenne Awareness Day by Announcing Winners of Global Duchenne Muscular Dystrophy Patient Group Awards and Expanding Disease State Awareness Website
2016-08-16,10 Best-Performing Stocks This Earnings Season
2016-08-08,Today's Perilous Reversal Stock: PTC Therapeutics (PTCT)
2016-08-05,Strong On High Volume: PTC Therapeutics (PTCT)
2016-07-25,PTC Therapeutics Duchenne Drug Stuck on Conditional Approval Status in Europe
2016-07-25,PTC Therapeutics Provides Regulatory Update On Translarna™ (ataluren)
2016-07-20,Strong On High Relative Volume: PTC Therapeutics (PTCT)
2016-07-07,NHS England Enables Access To Translarna™ ¿ (ataluren) For Patients With Nonsense Mutation Duchenne Muscular Dystrophy
2016-06-21,Commit To Purchase PTC Therapeutics At $5, Earn 30% Using Options
2016-06-13,PTC Therapeutics Appoints Dawn Svoronos To Board Of Directors
2016-06-10,New Analyses From Phase 3 Study 009 Of Translarna™ (ataluren) In Patients With Cystic Fibrosis Presented At 39th European Cystic Fibrosis Conference
2016-06-10,Biotech Stock Mailbag: Sarepta! Always More Sarepta. And Gilead, Too
2016-06-06,PTC Therapeutics (PTCT) Marked As A Dead Cat Bounce Stock
2016-05-25,PTC Therapeutics (PTCT) Weak On High Volume
2016-05-02,PTC Therapeutics (PTCT) Marked As A Dead Cat Bounce Stock
2016-05-02,DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders Of PTC Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of May 2, 2016 - PTCT
2016-04-29,GPM Reminds Investors Of The May 2 Deadline In The Class Action Lawsuit Against PTC Therapeutics, Inc. And Encourages Investors To Contact The Firm
2016-04-26,PTC Therapeutics Appoints Dr. Tuyen Ong As Chief Medical Officer
2016-04-22,PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2016-04-22,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of PTC Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of May 2, 2016 - PTCT
2016-04-20,EXPANDED CLASS PERIOD: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against PTC Therapeutics, Inc. And Encourages Investors With Losses To Contact The Firm
2016-04-19,INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of Class Action Involving PTC Therapeutics, Inc. And A Lead Plaintiff Deadline Of May 2, 2016 - PTCT
2016-04-19,Today's Dead Cat Bounce Stock Is PTC Therapeutics (PTCT)
2016-04-18,Perilous Reversal Stock: PTC Therapeutics (PTCT)
2016-04-15,The Former Attorney General Of Louisiana & Kahn Swick & Foti, LLC Remind Large Investors Of Lead Plaintiff Deadline In Class Action Lawsuit Against PTC Therapeutics, Inc. - PTCT
2016-04-15,SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Class Action Involving PTC Therapeutics, Inc. And A Lead Plaintiff Deadline Of May 2, 2016 - PTCT
2016-04-15,Why PTC Therapeutics (PTCT) Stock Is Spiking Today
2016-04-15,NICE Recommends Translarna™ (ataluren) For The Treatment Of Patients With Nonsense Mutation Duchenne Muscular Dystrophy In England
2016-04-14,SHAREHOLDER ALERT- Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against PTC Therapeutics Inc. (PTCT) And Lead Plaintiff Deadline: May 2, 2016
2016-04-12,INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of PTC Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of May 2, 2016
2016-04-11,Wolf Popper LLP Reminds Shareholders Of The Class Action Lawsuit Against PTC Therapeutics, Inc.
2016-04-08,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In PTC Therapeutics, Inc. Of Class Action Lawsuit And Upcoming Deadline - PTCT
2016-04-08,INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Class Action Involving PTC Therapeutics, Inc. And A Lead Plaintiff Deadline Of May 2, 2016 - PTCT
2016-04-02,Looking for Sunshine in Biotech's Gloomy First-Quarter Performance
2016-04-01,The Former Attorney General Of Louisiana & Kahn Swick & Foti, LLC Remind Large Investors Of Lead Plaintiff Deadline In Class Action Lawsuit Against PTC Therapeutics, Inc.
2016-03-24,STOCK NOTICE: Rosen Law Firm Reminds PTC Therapeutics, Inc. Investors Of Important Deadline In Class Action
2016-03-24,SHAREHOLDER ALERT: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against PTC Therapeutics, Inc. And Encourages Investors With Losses To Contact The Firm
2016-03-23,PTC Therapeutics Announces Workforce Reduction As Part Of Operating Expense Management Plan
2016-03-22,First Week Of May 20th Options Trading For PTC Therapeutics (PTCT)
2016-03-21,Shareholder Class Action Filed Against PTC Therapeutics, Inc. - PTCT
2016-03-17,5 Stocks Under $10 Set to Soar
2016-03-14,PTC Therapeutics (PTCT) In A Perilous Reversal
2016-03-14,PTC Therapeutics Provides Update On Health Canada Review Of Translarna™ (ataluren) For The Treatment Of Duchenne Muscular Dystrophy
2016-03-14,PTC Therapeutics Announces Presentation Of Results From Phase 3 ACT DMD Clinical Trial Of Translarna™ (ataluren) In Patients With Duchenne Muscular Dystrophy At 5th International Congress Of Myology
2016-03-14,7 Breakout Stocks Spiking on Big Volume
2016-03-11,Law Offices Of Marc S. Henzel Commences Investigation Of Companies For Violations Of The Federal Securities Laws
2016-03-09,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against PTC Therapeutics, Inc.
2016-03-02,Today's Dead Cat Bounce Stock Is PTC Therapeutics (PTCT)
2016-03-02,PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2016-03-01,IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Investigation Of PTC Therapeutics, Inc. And Urges Investors With Losses To Contact The Firm
2016-03-01,PTC Therapeutics (PTCT) Stock Price Cut at Credit Suisse
2016-02-26,Germany Slaps PTC Therapeutics With Big Drug Price Cut
2016-02-26,PTC Therapeutics Provides Update On German Pricing And Reimbursement Process For Translarna™ (ataluren)
2016-02-26,Perilous Reversal Watch: PTC Therapeutics (PTCT)
2016-02-25,PTC Therapeutics (PTCT) Stock Price Target Cut at Oppenheimer
2016-02-24,Here&rsquo;s Why PTC Therapeutics (PTCT) Stock is Down Today
2016-02-24,PTC Therapeutics (PTCT) Is Today's Dead Cat Bounce Stock
2016-02-24,PTC Therapeutics (PTCT) Stock Upgraded at Jefferies
2016-02-24,Investigation Of PTC Therapeutics By Block & Leviton For Possible Violations Of Federal Securities Laws
2016-02-23,PTC INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates PTC Therapeutics, Inc. For Possible Securities Fraud
2016-02-23,EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against PTC Therapeutics, Inc. - PTCT
2016-02-23,Noteworthy Tuesday Option Activity: PTCT, HSNI, CRAI
2016-02-23,GPM Announces Investigation On Behalf Of PTC Therapeutics, Inc. Investors
2016-02-23,SHAREHOLDER ALERT: Scott + Scott, LLP Investigating PTC Therapeutics (PTCT) For Possible Securities Fraud
2016-02-23,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Securities Fraud Violations By The Board Of PTC Therapeutics, Inc.
2016-02-23,Relative Strength Alert For PTC Therapeutics
2016-02-23,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of PTC Therapeutics Inc. (PTCT)
2016-02-23,PTC Therapeutics (PTCT) Stock Plunges After Receiving FDA 'Refuse to File' Letter
2016-02-23,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of PTC Therapeutics, Inc. - PTCT
2016-02-23,PTC Therapeutics (PTCT) Trading With Heavy Volume Before Market Open
2016-02-23,PTC Receives Refuse To File Letter From FDA For Translarna™ (ataluren)
2016-02-12,PTC Therapeutics Announces Second Annual STRIVE Grant Award Program For Duchenne Muscular Dystrophy
2016-02-11,Short Interest In PTC Therapeutics Increases 19%
2016-01-19,PTC Therapeutics (PTCT) Strong On High Relative Volume Today
2016-01-15,PTC Therapeutics (PTCT) Showing Signs Of Perilous Reversal Today
2016-01-11,PTC Therapeutics Enters Oversold Territory (PTCT)
2016-01-11,PTC Therapeutics Outlines Business Priorities For The Development And Commercialization Of Translarna™ And Progress Of The Company Pipeline
2016-01-08,PTC Completes Rolling NDA Submission To FDA And Submits Phase 3 ACT DMD Clinical Trial Results To EMA For Translarna™ (ataluren) For Treatment Of Nonsense Mutation Duchenne Muscular Dystrophy
2016-01-07,Spinal Muscular Atrophy Program Advances With Additional Product Candidate Entering Clinical Development
2016-01-06,PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2016-01-05,These 5 Health Care Stocks Are Ready for Breakout Moves: Must-See Charts
2015-12-16,Notable Wednesday Option Activity: PTCT, FMI, ENPH
2015-12-16,PTC Therapeutics (PTCT) Marked As A Barbarian At The Gate
2015-12-09,PTC Therapeutics And Massachusetts General Hospital Collaborate On Rare Disease Research
2015-12-04,PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2015-11-24,PTC Therapeutics (PTCT) Is Today's Perilous Reversal Stock
2015-11-20,PTC Therapeutics (PTCT) Showing Signs Of A Dead Cat Bounce Today
2015-11-20,Before the Move: Watch BioMarin Into FDA Advisory Committee
2015-11-19,These Biotech Stocks Could Move on BioMarin's Duchenne Drug FDA Panel
2015-11-19,PTC Completes Enrollment Of Phase 3 Clinical Trial Of Translarna™ For Patients With Cystic Fibrosis
2015-11-18,Strong On High Volume: PTC Therapeutics (PTCT)
2015-11-03,PTC Therapeutics (PTCT) Stock: Weak On High Volume Today
2015-10-29,PTC Therapeutics Announces Launch Of STRIVE Grant Award Program For Cystic Fibrosis
2015-10-27,PTC Therapeutics To Host Conference Call To Discuss Third Quarter 2015 Financial Results
2015-10-27,Today's Dead Cat Bounce Stock Is PTC Therapeutics (PTCT)
2015-10-21,First Week Of June 2016 Options Trading For PTC Therapeutics (PTCT)
2015-10-19,Perilous Reversal Stock: PTC Therapeutics (PTCT)
2015-10-16,Today's Pre-Market Mover With Heavy Volume: PTC Therapeutics (PTCT)
2015-10-15,PTC Announces Results From Phase 3 ACT DMD Clinical Trial Of Translarna™ (ataluren) In Patients With Duchenne Muscular Dystrophy
2015-10-05,Perilous Reversal Stock: PTC Therapeutics (PTCT)
2015-10-04,Phase 2 Data From Spinal Muscular Atrophy Program To Be Presented At The 20th International Annual Congress Of The World Muscle Society
2015-10-02,PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2015-09-30,PTC Therapeutics Submits European Application For Translarna™ For Cystic Fibrosis
2015-09-29,Oversold Conditions For PTC Therapeutics (PTCT)
2015-09-28,Short Interest In PTC Therapeutics Jumps 10.6%
2015-09-25,Biotech Stock Mailbag: Rebounding From Hillary's Drug Tweet; Global Blood Weighs on Bluebird
2015-09-23,PTC Therapeutics (PTCT) Is Weak On High Volume Today
2015-09-21,Perilous Reversal Stock: PTC Therapeutics (PTCT)
2015-09-18,'Mad Money' Lightning Round: Eaton Is a Buy, Buy, Buy
2015-09-17,Jim Cramer's 'Mad Money' Recap: The Fed Is Making All the Right Moves
2015-09-17,PTC Therapeutics (PTCT) Marked As A Dead Cat Bounce Stock
2015-08-28,First Week of October 16th Options Trading For PTC Therapeutics (PTCT)
2015-08-27,Predicting the Outcome of the BioMarin and Sarepta FDA Drug Reviews
2015-08-25,PTC Therapeutics (PTCT) Is Strong On High Volume Today
2015-08-21,PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2015-08-19,‘Female Viagra’ approval seen as positive for Sarepta, BioMarin
2015-08-18,Perilous Reversal Stock: PTC Therapeutics (PTCT)
2015-08-14,PTC Therapeutics Announces Closing Of $150 Million Of Convertible Senior Notes
2015-08-11,Today's Pre-Market Mover With Heavy Volume: PTC Therapeutics (PTCT)
2015-08-11,PTC Therapeutics Announces Pricing Of $125 Million Of Convertible Senior Notes
2015-08-10,PTC Therapeutics Announces Intention To Offer Convertible Senior Notes
2015-07-22,Today's Dead Cat Bounce Stock: PTC Therapeutics (PTCT)
2015-07-22,Interesting PTCT Put And Call Options For March 2016
2015-07-16,PTC Therapeutics To Host Conference Call To Discuss Second Quarter 2015 Financial Results
2015-07-15,Strong On High Relative Volume: PTC Therapeutics (PTCT)
2015-07-15,Analysts' Actions -- CSX, LinkedIn, Micron and More
2015-06-23,PTC Therapeutics' CEO Stuart W. Peltz, Ph.D. Recipient Of The 2015 NJBiz Innovation Hero Award
2015-06-22,Insider Trading Alert - PTCT, HES And HTGC Traded By Insiders
2015-06-17,Trade-Ideas: PTC Therapeutics (PTCT) Is Today's "Dead Cat Bounce" Stock
2015-05-27,November 20th Options Now Available For PTC Therapeutics (PTCT)
2015-05-21,German Federal Joint Committee Issues Positive Medical Benefit Rating For Translarna™ In Patients With Nonsense Mutation Duchenne Muscular Dystrophy
2015-05-19,First Week Of July 17th Options Trading For PTC Therapeutics (PTCT)
2015-05-15,PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2015-05-11,PTC Therapeutics Launches STRIVE Grant Award Program
2015-05-06,PTC Therapeutics (PTCT) Marked As A Dead Cat Bounce Stock
2015-04-28,PTC Therapeutics' Cancer Stem Cell Program Targeting BMI1 Enters Phase 1
2015-04-23,Santhera -- A Duchenne Drug With Positive Study Results That Few Know About
2015-04-20,PTC Therapeutics To Host Conference Call To Discuss First Quarter 2015 Financial Results
2015-04-20,Phase 1 Data From Spinal Muscular Atrophy Program To Be Presented At The 2015 American Academy Of Neurology Annual Meeting
2015-04-10,PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2015-04-09,Deutsche Compares PTC Therapeutics To Vertex, Boosts Target By $40
2015-04-08,PTC Therapeutics Names Eric Pauwels SVP & General Manager Commercial Operations, Americas
2017-03-20,Pain Therapeutics Announces Positive Regulatory Guidance For REMOXY™ ER
2017-02-17,Pain Therapeutics Reports 2016 Financial Results
2016-12-20,Pain Therapeutics To Discuss REMOXY® ER With FDA
2016-10-20,Pain Therapeutics Reports Q3 2016 Financial Results
2016-09-26,5 Big-Volume Stocks You Should Stay Away From -- Plus 2 to Buy
2016-09-26,For Pain Therapeutics CEO, 3 FDA Rejections Are Worth $23 Million
2016-09-26,Putting 2 Biotechs Under the Microscope
2016-09-26,DURECT's Licensee Pain Therapeutics Receives Complete Response Letter From FDA For REMOXY® ER (oxycodone) Extended-Release Capsules CII
2016-09-26,Complete Response Letter For REMOXY®
2016-07-19,Pain Therapeutics Reports Q2 2016 Financial Results
2016-07-01,DURECT Provides REMOXY® Update
2016-07-01,Pain Therapeutics Announces Advisory Committee Meeting For REMOXY® Is Not Needed
2016-05-19,DURECT Announces FDA Advisory Committee Meeting For REMOXY®
2016-05-19,Pain Therapeutics Announces FDA Advisory Committee Meeting For REMOXY®
2016-05-11,Pain Therapeutics To Present New REMOXY Data At American Pain Society Meeting
2016-05-11,DURECT Announces New REMOXY® Data Being Presented At American Pain Society Meeting
2016-05-05,Pain Therapeutics Reports Q1 2016 Financial Results
2016-04-12,DURECT Announces FDA Acceptance Of REMOXY® NDA, PDUFA Date Of September 25, 2016
2016-04-12,FDA Accepts REMOXY NDA For Review, Sets PDUFA Date Of September 25, 2016
2016-03-29,DURECT Announces Resubmission Of REMOXY® New Drug Application To The U.S. Food And Drug Administration
2016-03-29,Pain Therapeutics Resubmits REMOXY New Drug Application To The U.S. Food And Drug Administration
2016-03-01,Pain Therapeutics Reports 2015 Financial Results And Corporate Update
2015-11-09,Pain Therapeutics Reports Q3 2015 Financial Results And Update On REMOXY
2015-09-21,NIH Awards $1.7 Million Innovation Grant To Pain Therapeutics
2015-06-15,Short Interest In Pain Therapeutics Makes 27.2% Move
2015-05-12,Pain Therapeutics Announces Positive Top-Line Results From Human Abuse Potential Study With REMOXY
2015-05-11,Pain Therapeutics Announces Update On Drug Portfolio
2015-05-07,Pain Therapeutics Reports Q1 2015 Financial Results
2015-04-23,Pain Therapeutics Announces Appointment Of Senior Vice President, Regulatory Affairs
2015-04-21,Pain Therapeutics Resumes Responsibility For REMOXY
2015-02-17,Pain Therapeutics Reports FY 2014 Financial Results
2014-11-12,Short Interest Decreases By 20% For PTIE
2014-10-30,Pain Therapeutics Reports Q3 2014 Financial Results
2014-10-27,Pfizer (PFE) Stock Falls After Dropping Pain Drug
2014-10-27,DURECT Provides Update On REMOXY® And POSIDUR™ Programs
2014-10-27,Pain Therapeutics To Regain Full Rights To REMOXY(R)
2014-10-23,Pain Therapeutics To Host Conference Call To Discuss Q3 2014 Financial Results
2014-09-26,Pain Therapeutics Expands Pipeline With FENROCK(TM), An Abuse-Deterrent Pain Patch
2014-09-17,Pain Therapeutics To Present At The BioCentury NewsMakers Conference On Friday, September 26th
2014-08-05,Pain Therapeutics Reports Q2 2014 Financial Results
2014-08-01,Relative Strength Alert For Pain Therapeutics
2014-07-30,Pain Therapeutics To Host Conference Call To Discuss Q2 2014 Financial Results
2014-05-27,Pain Therapeutics To Present At The Jefferies 2014 Global Healthcare Conference
2014-05-15,Oversold Conditions For Pain Therapeutics (PTIE)
2014-05-08,Pain Therapeutics To Present At The Bank Of America Merrill Lynch 2014 Health Care Conference
2014-05-06,Pain Therapeutics Reports Q1 2014 Financial Results
2014-04-30,Pain Therapeutics To Host Conference Call To Discuss Q1 2014 Financial Results
2014-03-14,Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
2014-03-06,Pain Therapeutics Invited To Present At 26th Annual ROTH Conference
2014-02-25,Pain Therapeutics Invited To Present At Cowen Health Care Conference In Boston
2014-02-05,Ratings Changes Today
2014-02-04,Pain Therapeutics Reports 2013 Financial Results And Provides Guidance For 2014
2014-01-29,Pain Therapeutics To Host Year-End Conference Call On February 4, 2014
2013-11-26,Pain Therapeutics To Present At The Piper Jaffray Healthcare Conference
2013-10-31,Pain Therapeutics Reports Q3 2013 Financial Results
2013-10-24,5 Stocks Under $10 Set to Soar
2013-10-22,Pfizer Proceeding With REMOXY® Development
2013-10-22,Pain Therapeutics Reports Pfizer Elects To Continue Development Of REMOXY(R)
2013-10-11,5 Stocks Ready to Break Out
2013-10-02,4 Biotech Stocks Under $10 Making Moves
2013-09-13,6 Stocks Moving on Unusual Volume
2013-08-01,Pain Therapeutics Reports Q2 2013 Financial Results
2013-05-30,Pain Therapeutics To Present At The Jeffries 2013 Global Healthcare Conference
2013-05-13,Pain Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
2013-05-10,Pain Therapeutics Files Form 8-K Regarding Correspondence From Pfizer, Inc.
2013-05-03,5 Stocks Poised for Breakouts
2013-04-24,Pain Therapeutics Reports Q1 2013 Financial Results
2013-02-12,Pain Therapeutics Announces New Board Member
2013-02-06,Pain Therapeutics Reports 2012 Financial Results
2013-01-10,5 Under-$10 Stocks Primed to Rise in January
2012-11-12,Pain Therapeutics Inc. Stock Downgraded (PTIE)
2012-10-16,9 Stocks On Winning Streaks With Significant Hedge Fund Buying
2012-10-11,Pain Therapeutics Inc. Stock Upgraded (PTIE)
2012-09-11,4 Biotech Stocks Under $10 Making Big Moves
2012-08-06,Pain Therapeutics Inc. Stock Downgraded (PTIE)
2012-07-09,Pain Therapeutics Inc. Stock Upgraded (PTIE)
2012-06-27,Faruqi & Faruqi, LLP Is Investigating Pain Therapeutics Inc. On Behalf Of Its Shareholders (PTIE)
2012-06-07,7 Stocks Under $10 Streaking Higher
2012-01-06,Harwood Feffer LLP Announces Investigation Of Pain Therapeutics, Inc.
2012-01-05,The Law Firm Of Levi &amp; Korsinsky Notifies Investors With Losses On Their Investment In Pain Therapeutics, Inc. Of Class Action Lawsuit And The Deadline Of January 31, 2012 To Seek A Lead Plaintiff Position
2011-12-05,Faruqi &amp; Faruqi, LLP Announces Investigation Of Pain Therapeutics, Inc.
2011-08-26,Bronstein, Gewirtz &amp; Grossman, LLC Investigates Miller Energy Resources, Inc.
2011-07-04,Pain Therapeutics Inc. Stock Downgraded (PTIE)
2011-06-28,Pain Rises On Unusually High Volume (PTIE)
2011-06-24,Business Highlights
2011-06-24,Pain Stock Falls On Unusually High Volume (PTIE)
2011-06-24,Futures Flatten on Tepid U.S. Data
2011-06-24,10 Stocks to Watch: PTIE, PFE, SUG
2011-06-24,Pfizer, Pain Therapeutics Drug Rejected by FDA
2011-06-24,Pfizer Receives Complete Response Letter From FDA For REMOXY®
2011-06-24,FDA Complete Response Letter Received For REMOXY
2011-06-20,Pfizer, Acura Painkiller Approved by FDA
2011-06-20,A Busy Week for Six Biotech Stocks
2011-06-02,Pain Stock Hits New 52-Week High (PTIE)
2011-05-31,Pain Rises On Unusually High Volume (PTIE)
2011-05-02,Pain Therapeutics Inc. Stock Upgraded (PTIE)
2011-03-30,Pain Therapeutics To Present At Needham Health Care Conference
2011-03-01,Pain Therapeutics To Present At Cowen And Company Health Care Conference
2011-02-23,Pain Therapeutics To Present At RBC Capital Markets Healthcare Conference
2011-02-03,Pain Therapeutics Announces 2010 Financial Results And Outlines Business Goals For 2011
2011-01-28,Pain Therapeutics Receives $5,000,000 Payment
2011-01-27,REMOXY® New Drug Application Accepted By The FDA With PDUFA Goal Date Of June 23, 2011
2011-01-27,REMOXY New Drug Application Accepted By FDA
2010-12-27,King Pharmaceuticals And Pain Therapeutics Announce Resubmission Of New Drug Application For REMOXY(R)
2010-12-27,REMOXY® New Drug Application Resubmitted
2010-12-13,Pain Therapeutics Completes Special Distribution To Shareholders
2010-11-02,Pain Therapeutics Awarded $2,000,000 Research Grant
2010-10-28,Pain Therapeutics Reports Third Quarter 2010 Financial Results
2010-10-27,Pain Therapeutics Declares Special One-Time Cash Distribution To Shareholders
2010-10-12,Biotech Winners: King Pharmaceuticals, Pain Therapeutics
2010-10-12,Pfizer Adds New Partners Through King Buy
2010-10-12,King Pharmaceuticals, Oil Rigs: Hot Trends
2010-08-05,Pain Therapeutics To Present At Bank Of America Merrill Lynch Pharmaceuticals Conference
2010-07-28,Pain Therapeutics Reports Second Quarter 2010 Financial Results
2010-06-28,Pain Therapeutics Modifies Strategic Alliance For REMOXY(R) In Europe
2010-06-04,Pain Therapeutics To Present At Needham Healthcare Conference
2010-06-03,Pain Therapeutics To Present At Jefferies Healthcare Conference
2009-09-21,King Pharma Says It Launched Pain Drug Embeda
2009-08-14,Ahead Of The Bell: King Pharmaceuticals
2009-07-10,Director Buys $6.9M Worth of Jazz Pharma
2009-07-07,A Pair of Product Updates
2009-06-16,Deborah Marriott Harrison Sells $3M Worth
2009-06-11,Funds Sell $4M Worth of Pain Therapeutics
2009-04-07,Two Funds Sells $6.3M of Pain Therapeutics
2008-11-12,Health Winners & Losers: Vivus
2008-08-12,Health Winners & Losers: Altus
2008-03-28,Friday's Health Winners & Losers
2007-12-08,Feuerstein's Biotech-Stock Mailbag
2007-12-06,Study Results Boost Pain Therapeutics
2007-07-09,Stockpickr Lists: Chicago Board of Trade Hits High
2007-05-02,Wednesday's Small-Cap Winners & Losers
2007-03-29,Thursday's Buybacks: Pain Therapeutics for $20 Million
2007-03-09,Stockpickr: Check Out These Two Biotechs
2006-12-28,Patterns Lack Bullishness
2006-03-07,Selling Pressure Continues
2006-03-01,'RealMoney' Radio Recap: The Mercurial Market
2006-02-10,Today's Health Winners and Losers
2006-02-09,Cramer's 'Mad Money' Recap: A Pain-Free Stock Play
2005-12-12,Health Stocks in Motion
2005-11-22,Health Stocks in Motion
2005-11-15,Cramer's 'Mad Money' Recap: Chile Con Economy
2005-11-10,Health Stocks in Motion
2005-11-10,King Induces Sharp Increase in Pain
2005-09-09,Health Stocks in Motion
2005-08-29,Health Stocks in Motion
2005-04-25,Decoding Support and Resistance
2005-03-24,Pain Therapeutics Sees Gain
2005-03-24,Health Stocks in Motion
2004-09-22,Health Stocks in Motion
2004-06-30,Fuzzy Math at Pain Therapeutics
2004-06-29,Pain Therapeutics: Abuse-Proof Narcotic?
2000-12-28,Sunrise or Sunset?
2000-12-20,Lockup Expirations Due. Yawn.
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-08,Could These 9 Drugs Gain FDA Approval in the Age of Trump?
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-07,Portola Pharmaceuticals Announces Betrixaban And AndexXa™ (andexanet Alfa) Presentations At ACC.17
2017-03-05,4 Small-Cap Biotech Stars
2017-03-03,4 Small-Cap Biotech Stars
2017-03-01,Portola Pharmaceuticals To Present At Two Upcoming Investor Conferences
2017-02-28,Portola Pharmaceuticals Reports Fourth Quarter And Year-End 2016 Financial Results And Provides Corporate Update
2017-02-24,Analysts' Actions -- Danaher, Goldman Sachs, Goodyear, Wendy's and More
2017-02-21,Portola Pharmaceuticals To Announce Fourth Quarter And Year-End 2016 Financial Results And Host Conference Call On Tuesday, February 28
2017-02-08,FDA Informs Portola Pharmaceuticals At Mid-Cycle Review For Betrixaban That It Has Not Identified Issues That Require An Advisory Committee Meeting
2017-02-03,Synergy, Portola Still in My Sights
2017-02-03,Premarket Biotech Movers: Portola, Esperion, Medicines
2017-02-03,Portola Pharmaceuticals Signs $150 Million Royalty Agreement With HealthCare Royalty Partners For Development And Commercialization Of Andexanet Alfa
2017-01-24,First Week of September 15th Options Trading For Portola Pharmaceuticals (PTLA)
2017-01-13,Biotech Premarket Movers: SGMO, IPXL, PTLA
2017-01-03,Portola Pharmaceuticals To Webcast Corporate Update On January 10, 2017
2016-12-27,Biotech Poised for Rebound
2016-12-27,Biotech Poised for Rebound
2016-12-23,Portola Pharmaceuticals Announces FDA Accepts New Drug Application For Priority Review And EMA Validates Marketing Authorization Application For Oral, Factor Xa Inhibitor Anticoagulant Betrixaban
2016-12-20,A Biotech Trio to Like Going Into 2017
2016-12-20,First Week of PTLA February 2017 Options Trading
2016-12-19,Portola Pharmaceuticals Enters Into $50 Million Loan Agreement With Bristol-Myers Squibb And Pfizer For Continued Development Of AndexXa™ (andexanet Alfa)
2016-12-12,Portola Pharmaceuticals Stock Sees Short Interest Jump 13.4%
2016-12-05,Apple, Starbucks, Cisco: Doug Kass' Views
2016-11-28,Portola Pharmaceuticals Announces AndexXa™ (andexanet Alfa), Betrixaban And Cerdulatinib Data To Be Presented At 2016 American Society Of Hematology Annual Meeting And Exposition
2016-11-22,First Week of January 2017 Options Trading For Portola Pharmaceuticals (PTLA)
2016-11-17,Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios
2016-11-14,Portola Pharmaceuticals Announces Three Phase 3 APEX Substudy Results Showing Further Benefits Of Treating Acute Medically Ill Patients With Extended-Duration Betrixaban
2016-11-07,Portola Pharmaceuticals Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-11-07,Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data To Be Presented At American Heart Association Scientific Sessions 2016
2016-11-07,Cisco, Allergan, Facebook: Doug Kass' Views
2016-11-02,Portola Pharmaceuticals To Present At The Credit Suisse 25th Annual Healthcare Conference
2016-11-01,Portola Pharmaceuticals Expands Clinical Collaboration Agreement With Daiichi Sankyo Worth Up To $25 Million To Develop AndexXa™ (andexanet Alfa) In Germany
2016-10-31,Portola Pharmaceuticals To Announce Third Quarter 2016 Financial Results And Host Conference Call On Monday, November 7
2016-10-25,First Week Of PTLA June 2017 Options Trading
2016-10-25,Portola Pharmaceuticals Submits New Drug Application To U.S. FDA For Betrixaban For Extended Duration Prophylaxis Of Venous Thromboembolism In Acute Medically Ill Patients
2016-10-24,Schlumberger, Amazon, Apple: Doug Kass' Views
2016-09-20,First Week of November 18th Options Trading For Portola Pharmaceuticals (PTLA)
2016-09-16,Underlying Risks in Speculative Biotechs; Trump Speaks, Bonds Slide : Best of Kass
2016-09-13,Portola Pharmaceuticals Announces Upcoming Data Presentations On AndexXa™ (andexanet Alfa) At Neurocritical Care Society 2016 Annual Meeting
2016-09-06,How to Play It When the FDA Slams Your Stock
2016-08-30,Portola Pharmaceuticals Announces Interim Results From Ongoing Phase 3b/4 ANNEXXA-4™ Study Of Factor Xa Inhibitor Antidote AndexXa™ (andexanet Alfa) In Patients With Acute Major Bleeding
2016-08-26,Portola Pharmaceuticals Announces Presentation Of Interim Results From Phase 3b/4 ANNEXA™-4 Study Of AndexXa™ (andexanet Alfa) At European Society Of Cardiology 2016 Congress
2016-08-22,October 21st Options Now Available For Portola Pharmaceuticals (PTLA)
2016-08-19,Portola Pharmaceuticals (PTLA) Stock Falls, Citi Downgrades
2016-08-19,Portola Pharmaceuticals Announces Validation Of Marketing Authorization Application (MAA) By European Medicines Agency (EMA) For IndexXa™ (andexanet Alfa), A Factor Xa Inhibitor Antidote
2016-08-18,Portola Pharmaceuticals (PTLA) Stock Slumps on FDA Complete Response Letter
2016-08-17,Portola Pharmaceuticals Receives Complete Response Letter From FDA For Biologics License Application For AndexXa™ (andexanet Alfa)
2016-08-09,Portola Pharmaceuticals Reports Second Quarter 2016 Financial Results And Provides Corporate Update
2016-08-04,Strong On High Volume: Portola Pharmaceuticals (PTLA)
2016-08-02,Portola Pharmaceuticals To Announce Second Quarter 2016 Financial Results And Host Conference Call On Tuesday, August 9
2016-07-31,5 Small-Cap Biotechs With Big Potential
2016-07-29,5 Small-Cap Biotechs With Big Potential
2016-06-02,4 Possible Acquisition Targets in Biotech
2016-06-01,Portola Pharmaceuticals Announces Dosing Of First Patient In Phase 2a Study Of Cerdulatinib For Treatment Of Hematologic Cancer And Upcoming Presentations Of New Phase 1 Clinical Data At ASCO And EHA Annual Meetings
2016-05-31,Portola Pharmaceuticals To Present At Goldman Sachs 37th Annual Global Healthcare Conference
2016-05-27,Portola Pharmaceuticals Announces Full Results Of Phase 3 APEX Study Of Betrixaban Presented At International Society On Thrombosis And Haemostasis (ISTH) Meeting
2016-05-23,Portola Pharmaceuticals Announces Upcoming Data Presentations On Betrixaban And AndexXa™ (andexanet Alfa) At International Society On Thrombosis And Haemostasis (ISTH) 2016 Scientific And Standardization Committee Meeting
2016-05-17,Portola Pharmaceuticals (PTLA) Is Today's Perilous Reversal Stock
2016-05-16,Monsanto, Amazon and Apple: Doug Kass' Views
2016-05-06,Portola Pharmaceuticals Becomes Oversold (PTLA)
2016-05-05,Portola Pharmaceuticals Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-04-28,Portola Pharmaceuticals To Announce First Quarter 2016 Financial Results And Host Conference Call On Thursday, May 5
2016-04-14,Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation At American Association For Cancer Research (AACR) Annual Meeting 2016
2016-04-11,Facebook, Ford and General Motors: Doug Kass' Views
2016-04-07,Perilous Reversal Stock: Portola Pharmaceuticals (PTLA)
2016-04-06,Portola Pharmaceuticals Announces Presentation Of Phase 3 APEX Study Results At International Society On Thrombosis And Haemostasis (ISTH) SSC Meeting 2016 On May 27, 2016
2016-04-04,Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Daiichi Sankyo To Develop Andexanet Alfa With Edoxaban In Japan
2016-03-31,Jim Cramer's 'Mad Money' Recap: Good Riddance to a Roller-Coaster Quarter
2016-03-29,Portola Pharmaceuticals (PTLA) Is Today's Dead Cat Bounce Stock
2016-03-28,Here&rsquo;s Why Portola Pharmaceuticals (PTLA) Stock is Falling Today
2016-03-28,Portola Pharmaceuticals (PTLA) Weak On High Volume Today
2016-03-24,Why Portola Pharmaceuticals (PTLA) Stock is Plunging Today
2016-03-24,Portola Pharmaceuticals (PTLA) Stock Falls on Blood Clot Trial Results
2016-03-24,Heavy Trading On Portola Pharmaceuticals (PTLA) Before Market Open
2016-03-24,Portola Pharmaceuticals Announces Topline Results From Phase 3 APEX Trial Of Betrixaban For Prevention Of Blood Clots In Acute Medically Ill Patients
2016-03-24,Portola Pharmaceuticals To Hold Conference Call On Thursday, March 24, At 8:30 Am ET
2016-03-07,Tesla, Amazon and Netflix: Doug Kass' Views
2016-03-01,Portola Pharmaceuticals To Present At Cowen And Company 36th Annual Health Care Conference
2016-02-26,Portola Pharmaceuticals Reports Fourth Quarter And Year-End 2015 Financial Results And Provides Corporate Update
2016-02-19,Portola Pharmaceuticals To Announce Fourth Quarter And Year-End 2015 Financial Results And Host Conference Call On Friday, February 26
2016-02-17,Portola Pharmaceuticals Announces Biologics License Application For Andexanet Alfa Accepted For Review By FDA
2016-02-15,JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views
2016-02-01,Portola Pharmaceuticals Enters Into Licensing Agreements For Investigational Agent Andexanet Alfa In Japan Worth Up To $120 Million
2016-01-08,Portola Pharmaceuticals To Webcast Corporate Update On January 12, 2016
2015-12-18,Portola Pharmaceuticals Completes BLA Submission To U.S. Food And Drug Administration For Andexanet Alfa
2015-12-05,Portola Pharmaceuticals Announces Andexanet Alfa And Cerdulatinib Data Presentations At The 2015 American Society Of Hematology Annual Meeting And Exposition
2015-12-04,Portola Announces Pricing Of Public Offering Of Common Stock
2015-12-03,Portola Pharmaceuticals Announces Proposed Offering Of Common Stock
2015-11-13,5 Stocks Ready for Breakouts
2015-11-12,Portola Pharmaceuticals To Host Analyst And Investor Day On November 19
2015-11-11,The New England Journal Of Medicine Publishes Results Of Portola Pharmaceuticals' Phase 3 ANNEXA Studies Of Andexanet Alfa
2015-11-09,Portola Pharmaceuticals Reports Third Quarter 2015 Financial Results And Provides Corporate Update
2015-11-06,Portola Pharmaceuticals Announces Phase 3 ANNEXA™-R Part 2 Study Results To Be Presented At American Heart Association Scientific Sessions 2015
2015-11-04,Portola Pharmaceuticals To Present At Credit Suisse 24th Annual Healthcare Conference
2015-11-02,Portola Pharmaceuticals To Announce Third Quarter 2015 Financial Results And Host Conference Call On Monday, November 9
2015-10-30,Portola Pharmaceuticals Completes Enrollment In Pivotal Phase 3 APEX Study Of Betrixaban For Prevention Of Blood Clots In Acute Medically Ill Patients
2015-10-13,Portola Pharmaceuticals Announces FDA Grants Fast Track Designation To Betrixaban For Prevention Of Blood Clots In Acute Medically Ill Patients
2015-09-24,Portola Pharmaceuticals Appoints Dr. David C. Stump To Board Of Directors
2015-09-21,Portola Pharmaceuticals (PTLA) In A Perilous Reversal
2015-09-18,New Lifetime High For Portola Pharmaceuticals (PTLA)
2015-09-15,Portola Pharmaceuticals Announces Second Part Of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa And Rivaroxaban Meets Primary And Secondary Endpoints
2015-09-10,Portola Pharmaceuticals To Present At Morgan Stanley Global Healthcare Conference
2015-08-28,Credit Suisse's 8 Pharmaceutical Stocks With 'Significant' Upside
2015-08-27,Portola Pharmaceuticals To Present Preclinical Data With Andexanet Alfa And Factor Xa Inhibitor Edoxaban At European Society Of Cardiology Congress 2015
2015-08-11,Portola Pharmaceuticals (PTLA) Hits New Lifetime High Today
2015-08-05,3 Stocks Pushing The Drugs Industry Lower
2015-08-04,Portola Pharmaceuticals Reports Second Quarter 2015 Financial Results And Provides Corporate Update
2015-07-28,Portola Pharmaceuticals To Announce Second Quarter 2015 Financial Results And Host Conference Call On Tuesday, August 4
2015-07-15,New Lifetime High For Portola Pharmaceuticals (PTLA)
2015-07-14,Short Interest Falls 11.2% For PTLA
2015-06-29,Short Interest In Portola Pharmaceuticals Expands By 16%
2015-06-24,Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding And Reversed Anticoagulation Activity Of Rivaroxaban While Four-Factor Prothrombin Complex Concentrate Did Not
2015-06-22,New Lifetime High Today: Portola Pharmaceuticals (PTLA)
2015-06-22,Portola, Bristol-Myers Squibb And Pfizer Announce Full Results Of Second Part Of Phase 3 ANNEXA-A(TM) Study Demonstrating That Investigational Andexanet Alfa Sustained Reversal Of Anticoagulant Effect Of Factor Xa Inhibitor Eliquis (apixaban)
2015-06-15,Portola Pharmaceuticals Appoints Industry Leader Tao Fu As Executive Vice President, Chief Commercial And Business Officer
2015-06-12,Portola Pharmaceuticals (PTLA) Hits New Lifetime High
2015-06-09,Portola Pharmaceuticals Announces Upcoming Data Presentations On Andexanet Alfa At International Society On Thrombosis And Haemostasis (ISTH) 2015 Congress
2015-06-03,Portola Pharmaceuticals To Present At Goldman Sachs 36th Annual Global Healthcare Conference
2015-05-29,Portola Pharmaceuticals Presents Updated Data From Ongoing Phase 1/2a Study Of Dual Kinase Inhibitor Cerdulatinib
2015-05-18,Portola Pharmaceuticals Announces Upcoming Data Presentation On Dual Kinase Inhibitor Cerdulatinib At American Society Of Clinical Oncology (ASCO) Annual Meeting
2015-05-06,Portola Pharmaceuticals Reports First Quarter 2015 Financial Results And Provides Corporate Update
2015-05-05,Portola Pharmaceuticals Announces Collaboration With Ora, Inc. For Syk-selective Inhibitor (PRT2761) In Ophthalmic Diseases
2015-05-05,Portola Pharmaceuticals To Present At Bank Of America Merrill Lynch 2015 Health Care Conference
2015-04-29,Portola Pharmaceuticals To Announce First Quarter 2015 Financial Results And Host Conference Call On Wednesday, May 6
2015-04-08,Portola Pharmaceuticals Announces New Topline Data From Phase 3 ANNEXA-A(TM) Trial Part 2: Breakthrough Designated Andexanet Alfa Successfully Meets Primary Endpoint For Prolonged Reversal Of Factor Xa Inhibitor Eliquis (apixaban)
2015-04-01,Portola Pharmaceuticals (PTLA) Weak On High Volume Today
2015-03-25,First Week Of PTLA May 15th Options Trading
2015-03-10,Portola Announces Pricing Of Public Offering Of Common Stock
2015-03-09,Portola Pharmaceuticals Announces Proposed Offering Of Common Stock
2015-03-02,Strong On High Relative Volume: Portola Pharmaceuticals (PTLA)
2015-03-02,Portola Announces Full Results From Positive Phase 3 ANNEXA(TM)-R Study Demonstrating That Andexanet Alfa Rapidly And Significantly Reversed Anticoagulant Effect Of Factor Xa Inhibitor XARELTO(R)
2015-03-02,Portola Pharmaceuticals Reports Fourth Quarter And Year-End 2014 Financial Results And Provides Corporate Update
2015-02-26,Portola Pharmaceuticals Receives FDA Orphan Drug Designation For Andexanet Alfa, Its Breakthrough-Designated Factor Xa Inhibitor Antidote
2015-02-25,Portola Pharmaceuticals To Present At The Cowen And Company 35th Annual Health Care Conference
2015-02-24,Portola Pharmaceuticals To Announce Fourth Quarter And Year End 2014 Financial Results And Host Conference Call On Monday, March 2
2015-02-09,Portola Pharmaceuticals Appoints Two Biotechnology Industry Veterans, Laura Brege And Dr. Dennis Fenton, To Board Of Directors
2015-02-05,Portola's Factor Xa Inhibitor Betrixaban Successfully Passes Futility Analysis In Phase 3 APEX Study; Trial Continues As Planned And Remains On Track For Enrollment Completion By Year-End
2015-01-26,Portola Pharmaceuticals Announces Dr. Robert Califf Retires From The Board Of Directors To Accept Position As Deputy Commissioner For Medical Products And Tobacco At The Food And Drug Administration (FDA)
2015-01-12,Portola Pharmaceuticals Initiates Phase 4 Study To Support Accelerated Approval Of Andexanet Alfa -- Its Breakthrough-Designated Factor Xa Inhibitor Antidote
2015-01-09,Portola Announces Phase 3 ANNEXA-R Study Of Andexanet Alfa And Factor Xa Inhibitor XARELTO(R) (rivaroxaban) Met Primary Endpoint With High Statistical Significance
2015-01-06,Portola Pharmaceuticals Announces Webcast Of Corporate Presentation On January 12, 2015
2014-11-26,Insider Trading Alert - NEWT, PTLA And RLGY Traded By Insiders
2014-11-17,Portola, Bristol-Myers Squibb And Pfizer Announce Statistically Significant Results From The First Part Of The Phase 3 ANNEXA(TM)-A Studies Of Investigational Andexanet Alfa With Eliquis (apixaban)
2014-11-10,Portola Pharmaceuticals Reports Third Quarter Financial Results And Provides Corporate Update
2014-11-06,Portola Pharmaceuticals Announces Upcoming Presentations At The American Society Of Hematology 2014 Annual Meeting
2014-11-06,Portola Pharmaceuticals To Present At The Credit Suisse 2014 Healthcare Conference
2014-11-03,5 Breakout Stocks to Trade Now: Westport Innovations, MakeMyTrip, EXCO Resources and More
2014-11-03,Portola Pharmaceuticals To Announce Third Quarter 2014 Financial Results And Host Conference Call On Monday, November 10, 2014
2014-10-16,Portola Pharmaceuticals Announces Commercial Supply Agreement For Andexanet Alfa With Lonza
2014-10-06,3 Big-Volume Biotech Stocks to Trade for Breakouts
2014-10-03,Portola Pharmaceuticals (PTLA): Heavy Pre-Market Activity
2014-10-02,Portola Announces Pricing Of Public Offering Of Common Stock
2014-10-02,Portola Pharmaceuticals (PTLA) Is Today's Perilous Reversal Stock
2014-10-01,Market News: Angie's List, Masimo Corporation, Portola Pharmaceuticals
2014-10-01,Portola Pharmaceuticals Announces Proposed Offering Of Common Stock
2014-10-01,Portola Pharmaceuticals (PTLA) Is Today's Strong On High Volume Stock
2014-10-01,Portola Pharmaceuticals Announces Phase 3 ANNEXA(TM)-A Study Of Andexanet Alfa And Eliquis (Apixaban) Met Primary And Secondary Endpoints With High Statistical Significance
2014-09-02,Portola Pharmaceuticals To Present At The 2014 Morgan Stanley Global Healthcare Conference
2014-08-26,Insider Trading Alert - PTLA, TAL And EAT Traded By Insiders
2014-08-14,Commit To Buy Portola Pharmaceuticals At $22.50, Earn 18.6% Annualized Using Options
2014-08-13,Ratings Changes Today
2014-08-06,Portola Pharmaceuticals Reports Second Quarter Financial Results And Provides Corporate Update
2014-07-30,Portola Pharmaceuticals To Announce Second Quarter 2014 Financial Results And Host Conference Call On Wednesday, August 6, 2014
2014-07-07,Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Daiichi Sankyo For Phase 3 Studies Of Factor Xa Inhibitor Antidote, Andexanet Alfa, And Edoxaban
2014-06-12,Portola Pharmaceuticals To Present At The 2014 Wells Fargo Securities Healthcare Conference
2014-06-11,Portola Pharmaceuticals Announces Positive Phase 2 Data With FDA-Designated Breakthrough Therapy Andexanet Alfa And Enoxaparin
2014-05-16,Portola Pharmaceuticals Enters Oversold Territory (PTLA)
2014-05-14,Portola Pharmaceuticals Announces Two Presentations Of Data On Cerdulatinib, An Oral Dual Syk/JAK Inhibitor, At 2014 ASCO Annual Meeting
2014-05-12,Portola Pharmaceuticals Reports First Quarter Financial Results And Provides Corporate Update
2014-05-12,Portola Pharmaceuticals Begins Enrollment In Phase 3 Study Of FDA-Designated Breakthrough Therapy Andexanet Alfa And Factor Xa Inhibitor XARELTO(R)
2014-05-12,Portola Pharmaceuticals To Present At Bank Of America Merrill Lynch 2014 Health Care Conference
2014-05-09,Commit To Purchase Portola Pharmaceuticals At $20, Earn 15.4% Annualized Using Options
2014-05-05,Portola Pharmaceuticals To Announce First Quarter 2014 Financial Results And Host Conference Call On Monday, May 12, 2014
2014-04-14,Portola Pharmaceuticals Announces Publication Of Phase 3 APEX Study Design And Rationale In American Heart Journal
2014-04-11,RSI Alert: Portola Pharmaceuticals (PTLA) Now Oversold
2014-03-27,Portola Pharmaceuticals Initiates Phase 2 Study Of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, And Factor Xa Inhibitor Edoxaban
2014-03-19,Portola Pharmaceuticals Initiates Phase 3 Study Of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, Under Accelerated Approval Pathway
2014-03-18,Portola Pharmaceuticals Appoints John H. Johnson To Board Of Directors
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-08,Could These 9 Drugs Gain FDA Approval in the Age of Trump?
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-07,Portola Pharmaceuticals Announces Betrixaban And AndexXa™ (andexanet Alfa) Presentations At ACC.17
2017-03-05,4 Small-Cap Biotech Stars
2017-03-03,4 Small-Cap Biotech Stars
2017-03-01,Portola Pharmaceuticals To Present At Two Upcoming Investor Conferences
2017-02-28,Portola Pharmaceuticals Reports Fourth Quarter And Year-End 2016 Financial Results And Provides Corporate Update
2017-02-24,Analysts' Actions -- Danaher, Goldman Sachs, Goodyear, Wendy's and More
2017-02-21,Portola Pharmaceuticals To Announce Fourth Quarter And Year-End 2016 Financial Results And Host Conference Call On Tuesday, February 28
2017-02-08,FDA Informs Portola Pharmaceuticals At Mid-Cycle Review For Betrixaban That It Has Not Identified Issues That Require An Advisory Committee Meeting
2017-02-03,Synergy, Portola Still in My Sights
2017-02-03,Premarket Biotech Movers: Portola, Esperion, Medicines
2017-02-03,Portola Pharmaceuticals Signs $150 Million Royalty Agreement With HealthCare Royalty Partners For Development And Commercialization Of Andexanet Alfa
2017-01-24,First Week of September 15th Options Trading For Portola Pharmaceuticals (PTLA)
2017-01-13,Biotech Premarket Movers: SGMO, IPXL, PTLA
2017-01-03,Portola Pharmaceuticals To Webcast Corporate Update On January 10, 2017
2016-12-27,Biotech Poised for Rebound
2016-12-27,Biotech Poised for Rebound
2016-12-23,Portola Pharmaceuticals Announces FDA Accepts New Drug Application For Priority Review And EMA Validates Marketing Authorization Application For Oral, Factor Xa Inhibitor Anticoagulant Betrixaban
2016-12-20,A Biotech Trio to Like Going Into 2017
2016-12-20,First Week of PTLA February 2017 Options Trading
2016-12-19,Portola Pharmaceuticals Enters Into $50 Million Loan Agreement With Bristol-Myers Squibb And Pfizer For Continued Development Of AndexXa™ (andexanet Alfa)
2016-12-12,Portola Pharmaceuticals Stock Sees Short Interest Jump 13.4%
2016-12-05,Apple, Starbucks, Cisco: Doug Kass' Views
2016-11-28,Portola Pharmaceuticals Announces AndexXa™ (andexanet Alfa), Betrixaban And Cerdulatinib Data To Be Presented At 2016 American Society Of Hematology Annual Meeting And Exposition
2016-11-22,First Week of January 2017 Options Trading For Portola Pharmaceuticals (PTLA)
2016-11-17,Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios
2016-11-14,Portola Pharmaceuticals Announces Three Phase 3 APEX Substudy Results Showing Further Benefits Of Treating Acute Medically Ill Patients With Extended-Duration Betrixaban
2016-11-07,Portola Pharmaceuticals Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-11-07,Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data To Be Presented At American Heart Association Scientific Sessions 2016
2016-11-07,Cisco, Allergan, Facebook: Doug Kass' Views
2016-11-02,Portola Pharmaceuticals To Present At The Credit Suisse 25th Annual Healthcare Conference
2016-11-01,Portola Pharmaceuticals Expands Clinical Collaboration Agreement With Daiichi Sankyo Worth Up To $25 Million To Develop AndexXa™ (andexanet Alfa) In Germany
2016-10-31,Portola Pharmaceuticals To Announce Third Quarter 2016 Financial Results And Host Conference Call On Monday, November 7
2016-10-25,First Week Of PTLA June 2017 Options Trading
2016-10-25,Portola Pharmaceuticals Submits New Drug Application To U.S. FDA For Betrixaban For Extended Duration Prophylaxis Of Venous Thromboembolism In Acute Medically Ill Patients
2016-10-24,Schlumberger, Amazon, Apple: Doug Kass' Views
2016-09-20,First Week of November 18th Options Trading For Portola Pharmaceuticals (PTLA)
2016-09-16,Underlying Risks in Speculative Biotechs; Trump Speaks, Bonds Slide : Best of Kass
2016-09-13,Portola Pharmaceuticals Announces Upcoming Data Presentations On AndexXa™ (andexanet Alfa) At Neurocritical Care Society 2016 Annual Meeting
2016-09-06,How to Play It When the FDA Slams Your Stock
2016-08-30,Portola Pharmaceuticals Announces Interim Results From Ongoing Phase 3b/4 ANNEXXA-4™ Study Of Factor Xa Inhibitor Antidote AndexXa™ (andexanet Alfa) In Patients With Acute Major Bleeding
2016-08-26,Portola Pharmaceuticals Announces Presentation Of Interim Results From Phase 3b/4 ANNEXA™-4 Study Of AndexXa™ (andexanet Alfa) At European Society Of Cardiology 2016 Congress
2016-08-22,October 21st Options Now Available For Portola Pharmaceuticals (PTLA)
2016-08-19,Portola Pharmaceuticals (PTLA) Stock Falls, Citi Downgrades
2016-08-19,Portola Pharmaceuticals Announces Validation Of Marketing Authorization Application (MAA) By European Medicines Agency (EMA) For IndexXa™ (andexanet Alfa), A Factor Xa Inhibitor Antidote
2016-08-18,Portola Pharmaceuticals (PTLA) Stock Slumps on FDA Complete Response Letter
2016-08-17,Portola Pharmaceuticals Receives Complete Response Letter From FDA For Biologics License Application For AndexXa™ (andexanet Alfa)
2016-08-09,Portola Pharmaceuticals Reports Second Quarter 2016 Financial Results And Provides Corporate Update
2016-08-04,Strong On High Volume: Portola Pharmaceuticals (PTLA)
2016-08-02,Portola Pharmaceuticals To Announce Second Quarter 2016 Financial Results And Host Conference Call On Tuesday, August 9
2016-07-31,5 Small-Cap Biotechs With Big Potential
2016-07-29,5 Small-Cap Biotechs With Big Potential
2016-06-02,4 Possible Acquisition Targets in Biotech
2016-06-01,Portola Pharmaceuticals Announces Dosing Of First Patient In Phase 2a Study Of Cerdulatinib For Treatment Of Hematologic Cancer And Upcoming Presentations Of New Phase 1 Clinical Data At ASCO And EHA Annual Meetings
2016-05-31,Portola Pharmaceuticals To Present At Goldman Sachs 37th Annual Global Healthcare Conference
2016-05-27,Portola Pharmaceuticals Announces Full Results Of Phase 3 APEX Study Of Betrixaban Presented At International Society On Thrombosis And Haemostasis (ISTH) Meeting
2016-05-23,Portola Pharmaceuticals Announces Upcoming Data Presentations On Betrixaban And AndexXa™ (andexanet Alfa) At International Society On Thrombosis And Haemostasis (ISTH) 2016 Scientific And Standardization Committee Meeting
2016-05-17,Portola Pharmaceuticals (PTLA) Is Today's Perilous Reversal Stock
2016-05-16,Monsanto, Amazon and Apple: Doug Kass' Views
2016-05-06,Portola Pharmaceuticals Becomes Oversold (PTLA)
2016-05-05,Portola Pharmaceuticals Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-04-28,Portola Pharmaceuticals To Announce First Quarter 2016 Financial Results And Host Conference Call On Thursday, May 5
2016-04-14,Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation At American Association For Cancer Research (AACR) Annual Meeting 2016
2016-04-11,Facebook, Ford and General Motors: Doug Kass' Views
2016-04-07,Perilous Reversal Stock: Portola Pharmaceuticals (PTLA)
2016-04-06,Portola Pharmaceuticals Announces Presentation Of Phase 3 APEX Study Results At International Society On Thrombosis And Haemostasis (ISTH) SSC Meeting 2016 On May 27, 2016
2016-04-04,Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Daiichi Sankyo To Develop Andexanet Alfa With Edoxaban In Japan
2016-03-31,Jim Cramer's 'Mad Money' Recap: Good Riddance to a Roller-Coaster Quarter
2016-03-29,Portola Pharmaceuticals (PTLA) Is Today's Dead Cat Bounce Stock
2016-03-28,Here&rsquo;s Why Portola Pharmaceuticals (PTLA) Stock is Falling Today
2016-03-28,Portola Pharmaceuticals (PTLA) Weak On High Volume Today
2016-03-24,Why Portola Pharmaceuticals (PTLA) Stock is Plunging Today
2016-03-24,Portola Pharmaceuticals (PTLA) Stock Falls on Blood Clot Trial Results
2016-03-24,Heavy Trading On Portola Pharmaceuticals (PTLA) Before Market Open
2016-03-24,Portola Pharmaceuticals Announces Topline Results From Phase 3 APEX Trial Of Betrixaban For Prevention Of Blood Clots In Acute Medically Ill Patients
2016-03-24,Portola Pharmaceuticals To Hold Conference Call On Thursday, March 24, At 8:30 Am ET
2016-03-07,Tesla, Amazon and Netflix: Doug Kass' Views
2016-03-01,Portola Pharmaceuticals To Present At Cowen And Company 36th Annual Health Care Conference
2016-02-26,Portola Pharmaceuticals Reports Fourth Quarter And Year-End 2015 Financial Results And Provides Corporate Update
2016-02-19,Portola Pharmaceuticals To Announce Fourth Quarter And Year-End 2015 Financial Results And Host Conference Call On Friday, February 26
2016-02-17,Portola Pharmaceuticals Announces Biologics License Application For Andexanet Alfa Accepted For Review By FDA
2016-02-15,JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views
2016-02-01,Portola Pharmaceuticals Enters Into Licensing Agreements For Investigational Agent Andexanet Alfa In Japan Worth Up To $120 Million
2016-01-08,Portola Pharmaceuticals To Webcast Corporate Update On January 12, 2016
2015-12-18,Portola Pharmaceuticals Completes BLA Submission To U.S. Food And Drug Administration For Andexanet Alfa
2015-12-05,Portola Pharmaceuticals Announces Andexanet Alfa And Cerdulatinib Data Presentations At The 2015 American Society Of Hematology Annual Meeting And Exposition
2015-12-04,Portola Announces Pricing Of Public Offering Of Common Stock
2015-12-03,Portola Pharmaceuticals Announces Proposed Offering Of Common Stock
2015-11-13,5 Stocks Ready for Breakouts
2015-11-12,Portola Pharmaceuticals To Host Analyst And Investor Day On November 19
2015-11-11,The New England Journal Of Medicine Publishes Results Of Portola Pharmaceuticals' Phase 3 ANNEXA Studies Of Andexanet Alfa
2015-11-09,Portola Pharmaceuticals Reports Third Quarter 2015 Financial Results And Provides Corporate Update
2015-11-06,Portola Pharmaceuticals Announces Phase 3 ANNEXA™-R Part 2 Study Results To Be Presented At American Heart Association Scientific Sessions 2015
2015-11-04,Portola Pharmaceuticals To Present At Credit Suisse 24th Annual Healthcare Conference
2015-11-02,Portola Pharmaceuticals To Announce Third Quarter 2015 Financial Results And Host Conference Call On Monday, November 9
2015-10-30,Portola Pharmaceuticals Completes Enrollment In Pivotal Phase 3 APEX Study Of Betrixaban For Prevention Of Blood Clots In Acute Medically Ill Patients
2015-10-13,Portola Pharmaceuticals Announces FDA Grants Fast Track Designation To Betrixaban For Prevention Of Blood Clots In Acute Medically Ill Patients
2015-09-24,Portola Pharmaceuticals Appoints Dr. David C. Stump To Board Of Directors
2015-09-21,Portola Pharmaceuticals (PTLA) In A Perilous Reversal
2015-09-18,New Lifetime High For Portola Pharmaceuticals (PTLA)
2015-09-15,Portola Pharmaceuticals Announces Second Part Of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa And Rivaroxaban Meets Primary And Secondary Endpoints
2015-09-10,Portola Pharmaceuticals To Present At Morgan Stanley Global Healthcare Conference
2015-08-28,Credit Suisse's 8 Pharmaceutical Stocks With 'Significant' Upside
2015-08-27,Portola Pharmaceuticals To Present Preclinical Data With Andexanet Alfa And Factor Xa Inhibitor Edoxaban At European Society Of Cardiology Congress 2015
2015-08-11,Portola Pharmaceuticals (PTLA) Hits New Lifetime High Today
2015-08-05,3 Stocks Pushing The Drugs Industry Lower
2015-08-04,Portola Pharmaceuticals Reports Second Quarter 2015 Financial Results And Provides Corporate Update
2015-07-28,Portola Pharmaceuticals To Announce Second Quarter 2015 Financial Results And Host Conference Call On Tuesday, August 4
2015-07-15,New Lifetime High For Portola Pharmaceuticals (PTLA)
2015-07-14,Short Interest Falls 11.2% For PTLA
2015-06-29,Short Interest In Portola Pharmaceuticals Expands By 16%
2015-06-24,Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding And Reversed Anticoagulation Activity Of Rivaroxaban While Four-Factor Prothrombin Complex Concentrate Did Not
2015-06-22,New Lifetime High Today: Portola Pharmaceuticals (PTLA)
2015-06-22,Portola, Bristol-Myers Squibb And Pfizer Announce Full Results Of Second Part Of Phase 3 ANNEXA-A(TM) Study Demonstrating That Investigational Andexanet Alfa Sustained Reversal Of Anticoagulant Effect Of Factor Xa Inhibitor Eliquis (apixaban)
2015-06-15,Portola Pharmaceuticals Appoints Industry Leader Tao Fu As Executive Vice President, Chief Commercial And Business Officer
2015-06-12,Portola Pharmaceuticals (PTLA) Hits New Lifetime High
2015-06-09,Portola Pharmaceuticals Announces Upcoming Data Presentations On Andexanet Alfa At International Society On Thrombosis And Haemostasis (ISTH) 2015 Congress
2015-06-03,Portola Pharmaceuticals To Present At Goldman Sachs 36th Annual Global Healthcare Conference
2015-05-29,Portola Pharmaceuticals Presents Updated Data From Ongoing Phase 1/2a Study Of Dual Kinase Inhibitor Cerdulatinib
2015-05-18,Portola Pharmaceuticals Announces Upcoming Data Presentation On Dual Kinase Inhibitor Cerdulatinib At American Society Of Clinical Oncology (ASCO) Annual Meeting
2015-05-06,Portola Pharmaceuticals Reports First Quarter 2015 Financial Results And Provides Corporate Update
2015-05-05,Portola Pharmaceuticals Announces Collaboration With Ora, Inc. For Syk-selective Inhibitor (PRT2761) In Ophthalmic Diseases
2015-05-05,Portola Pharmaceuticals To Present At Bank Of America Merrill Lynch 2015 Health Care Conference
2015-04-29,Portola Pharmaceuticals To Announce First Quarter 2015 Financial Results And Host Conference Call On Wednesday, May 6
2015-04-08,Portola Pharmaceuticals Announces New Topline Data From Phase 3 ANNEXA-A(TM) Trial Part 2: Breakthrough Designated Andexanet Alfa Successfully Meets Primary Endpoint For Prolonged Reversal Of Factor Xa Inhibitor Eliquis (apixaban)
2015-04-01,Portola Pharmaceuticals (PTLA) Weak On High Volume Today
2015-03-25,First Week Of PTLA May 15th Options Trading
2015-03-10,Portola Announces Pricing Of Public Offering Of Common Stock
2015-03-09,Portola Pharmaceuticals Announces Proposed Offering Of Common Stock
2015-03-02,Strong On High Relative Volume: Portola Pharmaceuticals (PTLA)
2015-03-02,Portola Announces Full Results From Positive Phase 3 ANNEXA(TM)-R Study Demonstrating That Andexanet Alfa Rapidly And Significantly Reversed Anticoagulant Effect Of Factor Xa Inhibitor XARELTO(R)
2015-03-02,Portola Pharmaceuticals Reports Fourth Quarter And Year-End 2014 Financial Results And Provides Corporate Update
2015-02-26,Portola Pharmaceuticals Receives FDA Orphan Drug Designation For Andexanet Alfa, Its Breakthrough-Designated Factor Xa Inhibitor Antidote
2015-02-25,Portola Pharmaceuticals To Present At The Cowen And Company 35th Annual Health Care Conference
2015-02-24,Portola Pharmaceuticals To Announce Fourth Quarter And Year End 2014 Financial Results And Host Conference Call On Monday, March 2
2015-02-09,Portola Pharmaceuticals Appoints Two Biotechnology Industry Veterans, Laura Brege And Dr. Dennis Fenton, To Board Of Directors
2015-02-05,Portola's Factor Xa Inhibitor Betrixaban Successfully Passes Futility Analysis In Phase 3 APEX Study; Trial Continues As Planned And Remains On Track For Enrollment Completion By Year-End
2015-01-26,Portola Pharmaceuticals Announces Dr. Robert Califf Retires From The Board Of Directors To Accept Position As Deputy Commissioner For Medical Products And Tobacco At The Food And Drug Administration (FDA)
2015-01-12,Portola Pharmaceuticals Initiates Phase 4 Study To Support Accelerated Approval Of Andexanet Alfa -- Its Breakthrough-Designated Factor Xa Inhibitor Antidote
2015-01-09,Portola Announces Phase 3 ANNEXA-R Study Of Andexanet Alfa And Factor Xa Inhibitor XARELTO(R) (rivaroxaban) Met Primary Endpoint With High Statistical Significance
2015-01-06,Portola Pharmaceuticals Announces Webcast Of Corporate Presentation On January 12, 2015
2014-11-26,Insider Trading Alert - NEWT, PTLA And RLGY Traded By Insiders
2014-11-17,Portola, Bristol-Myers Squibb And Pfizer Announce Statistically Significant Results From The First Part Of The Phase 3 ANNEXA(TM)-A Studies Of Investigational Andexanet Alfa With Eliquis (apixaban)
2014-11-10,Portola Pharmaceuticals Reports Third Quarter Financial Results And Provides Corporate Update
2014-11-06,Portola Pharmaceuticals Announces Upcoming Presentations At The American Society Of Hematology 2014 Annual Meeting
2014-11-06,Portola Pharmaceuticals To Present At The Credit Suisse 2014 Healthcare Conference
2014-11-03,5 Breakout Stocks to Trade Now: Westport Innovations, MakeMyTrip, EXCO Resources and More
2014-11-03,Portola Pharmaceuticals To Announce Third Quarter 2014 Financial Results And Host Conference Call On Monday, November 10, 2014
2014-10-16,Portola Pharmaceuticals Announces Commercial Supply Agreement For Andexanet Alfa With Lonza
2014-10-06,3 Big-Volume Biotech Stocks to Trade for Breakouts
2014-10-03,Portola Pharmaceuticals (PTLA): Heavy Pre-Market Activity
2014-10-02,Portola Announces Pricing Of Public Offering Of Common Stock
2014-10-02,Portola Pharmaceuticals (PTLA) Is Today's Perilous Reversal Stock
2014-10-01,Market News: Angie's List, Masimo Corporation, Portola Pharmaceuticals
2014-10-01,Portola Pharmaceuticals Announces Proposed Offering Of Common Stock
2014-10-01,Portola Pharmaceuticals (PTLA) Is Today's Strong On High Volume Stock
2014-10-01,Portola Pharmaceuticals Announces Phase 3 ANNEXA(TM)-A Study Of Andexanet Alfa And Eliquis (Apixaban) Met Primary And Secondary Endpoints With High Statistical Significance
2014-09-02,Portola Pharmaceuticals To Present At The 2014 Morgan Stanley Global Healthcare Conference
2014-08-26,Insider Trading Alert - PTLA, TAL And EAT Traded By Insiders
2014-08-14,Commit To Buy Portola Pharmaceuticals At $22.50, Earn 18.6% Annualized Using Options
2014-08-13,Ratings Changes Today
2014-08-06,Portola Pharmaceuticals Reports Second Quarter Financial Results And Provides Corporate Update
2014-07-30,Portola Pharmaceuticals To Announce Second Quarter 2014 Financial Results And Host Conference Call On Wednesday, August 6, 2014
2014-07-07,Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Daiichi Sankyo For Phase 3 Studies Of Factor Xa Inhibitor Antidote, Andexanet Alfa, And Edoxaban
2014-06-12,Portola Pharmaceuticals To Present At The 2014 Wells Fargo Securities Healthcare Conference
2014-06-11,Portola Pharmaceuticals Announces Positive Phase 2 Data With FDA-Designated Breakthrough Therapy Andexanet Alfa And Enoxaparin
2014-05-16,Portola Pharmaceuticals Enters Oversold Territory (PTLA)
2014-05-14,Portola Pharmaceuticals Announces Two Presentations Of Data On Cerdulatinib, An Oral Dual Syk/JAK Inhibitor, At 2014 ASCO Annual Meeting
2014-05-12,Portola Pharmaceuticals Reports First Quarter Financial Results And Provides Corporate Update
2014-05-12,Portola Pharmaceuticals Begins Enrollment In Phase 3 Study Of FDA-Designated Breakthrough Therapy Andexanet Alfa And Factor Xa Inhibitor XARELTO(R)
2014-05-12,Portola Pharmaceuticals To Present At Bank Of America Merrill Lynch 2014 Health Care Conference
2014-05-09,Commit To Purchase Portola Pharmaceuticals At $20, Earn 15.4% Annualized Using Options
2014-05-05,Portola Pharmaceuticals To Announce First Quarter 2014 Financial Results And Host Conference Call On Monday, May 12, 2014
2014-04-14,Portola Pharmaceuticals Announces Publication Of Phase 3 APEX Study Design And Rationale In American Heart Journal
2014-04-11,RSI Alert: Portola Pharmaceuticals (PTLA) Now Oversold
2014-03-27,Portola Pharmaceuticals Initiates Phase 2 Study Of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, And Factor Xa Inhibitor Edoxaban
2014-03-19,Portola Pharmaceuticals Initiates Phase 3 Study Of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, Under Accelerated Approval Pathway
2014-03-18,Portola Pharmaceuticals Appoints John H. Johnson To Board Of Directors
2017-03-20,Palatin Technologies Receives Notice Of Allowance On Bremelanotide Methods Of Use Patent For Treatment Of Hypoactive Sexual Desire Disorder In Premenopausal Women
2017-03-09,Palatin Technologies To Present At The 29th Annual ROTH Conference
2017-02-03,Palatin Technologies Announces Closing Of License Agreement With AMAG Pharmaceuticals For North American Rights To Rekynda™
2017-01-10,Palatin Technologies To Hold Call Following Closing Of Licensing Agreement For North American Rights To Rekynda™
2016-12-07,Palatin Technologies Closes On $16.5 Million Financing
2016-12-01,Palatin Technologies Announces Pricing Of Public Offering Of Common Stock And Warrants
2016-11-30,Palatin Technologies Announces Proposed Public Offering Of Common Stock And Warrants
2016-11-02,How to Trade Today's Most Active Stocks -- Ford, Palatin, More
2016-11-02,Palatin Female Libido-Boosting Shot Fails Crucial Sex Frequency Test
2016-11-01,Bremelanotide Meets Co-Primary Endpoints In Palatin's Phase 3 Trials For Hypoactive Sexual Desire Disorder
2016-09-23,Palatin Technologies Receives Audit Opinion With Going Concern Explanation
2016-09-23,Palatin Technologies Presents Bremelanotide Neurobiology And Treatment Efficacy Review At World Meeting On Sexual Medicine
2016-08-08,Palatin Technologies To Present At The 36th Annual Canaccord Genuity Growth Conference
2016-08-04,Palatin Technologies Announces Closing Of $9.2 Million Financing
2016-08-04,Palatin Technologies Announces Completion Of All Patient Visits In Phase 3 Clinical Trials Of Bremelanotide For Hypoactive Sexual Desire Disorder
2016-08-01,Palatin Technologies Announces $9.25 Million Financing
2016-06-06,Palatin Technologies Receives Patent Strengthening Its Melanocortin Peptide Intellectual Property
2016-05-26,Palatin Technologies Receives Patent Strengthening Its Melanocortin Peptide Intellectual Property
2016-02-26,Palatin Technologies Presents Bremelanotide Alcohol Interaction Study At International Society For The Study Of Women's Sexual Health Annual Meeting
2016-02-08,Palatin Technologies Strengthens Intellectual Property Surrounding Use Of Bremelanotide For Female Sexual Dysfunction
2016-02-04,Palatin Technologies To Present At The BIO CEO & Investor Conference
2015-12-10,Palatin Technologies Achieves Target Patient Enrollment In Pivotal Phase 3 Studies For Bremelanotide For Female Sexual Dysfunction
2015-10-06,Insider Trading Alert - AEL, PTN And BSX Traded By Insiders
2015-09-28,Preclinical Data On PL-3994 For Heart Failure And Resistant Hypertension Presented At 2015 Heart Failure Society Of America Annual Meeting
2015-09-21,Palatin Technologies And Richter Terminate License Agreement For Bremelanotide For Female Sexual Dysfunction
2015-08-20,Palatin Technologies (PTN) Stock Up After FDA Approval of 'Female Viagra'
2015-08-19,Palatin Technologies (PTN) Stock Climbing on FDA Approval of 'Female Viagra'
2015-08-18,Palatin Technologies Supports FDA's Approval Of The First-Ever Treatment For Female Sexual Dysfunction
2015-07-06,Palatin Technologies Completes $30 Million Financing
2015-06-08,Palatin Technologies (PTN) Strong On High Relative Volume Today
2015-06-05,Palatin Technologies (PTN) Stock Spikes Following FDA Approval of 'Female Viagra' Treatment
2015-06-04,Palatin Supports FDA Advisory Committee's Recommendation To Approve The First-Ever Treatment For Hypoactive Sexual Desire Disorder
2015-04-21,3 Stocks Under $10 to Trade for Breakouts
2015-03-06,Palatin Technologies To Present At The 27th Annual ROTH Conference
2015-02-20,Palatin Launches Reconnectstudy.com In Support Of Bremelanotide Phase 3 Program For Female Sexual Dysfunction
2015-02-06,Palatin Technologies To Present At The BIO CEO & Investor Conference
2014-12-29,Palatin Announces Start Of Bremelanotide Phase 3 Program For Female Sexual Dysfunction
2014-12-24,Palatin Completes $20 Million Equity And $10 Million Debt Financings
2014-10-08,Palatin Technologies To Present At The 13th Annual BIO Investor Forum
2014-09-03,Palatin Technologies Licenses Bremelanotide In Europe And Other Selected Countries To Richter
2014-08-27,3 Stocks Pushing The Drugs Industry Lower
2014-07-09,Palatin Technologies Announces Notification Of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
2014-06-27,Palatin Technologies To Join Russell Microcap Index
2014-06-10,Palatin Technologies Announces Notification Of Patent Allowance On Next Generation Melanocortin Receptor-Specific Peptides
2014-05-06,Palatin Technologies Presents At The American Psychiatric Association (APA)
2014-05-01,Palatin Technologies Announces Option Exercise By Specialty Pharmaceutical Company To License Bremelanotide In Europe
2014-04-29,Palatin Technologies Presents At The Annual Clinical Meeting Of The American College Of Obstetricians And Gynecologists (ACOG)
2014-03-31,Palatin Technologies Announces Option Extension For License To Bremelanotide In Europe
2014-03-06,Palatin Technologies To Present At The 26Th Annual ROTH Conference
2014-02-24,Palatin Technologies Presents Positive New Data Analyses Demonstrating Efficacy Of Bremelanotide In Female Hypoactive Sexual Desire Disorder
2014-01-30,Palatin Technologies To Present At The 16th Congress Of The European Society For Sexual Medicine
2014-01-23,Palatin Technologies, Inc. Receives $1.85 Million From Sale Of New Jersey State Tax Credits
2014-01-16,Palatin Technologies To Present At "TEN", Noble Financial Capital Markets' Tenth Annual Equity Conference
2014-01-13,Palatin Technologies Responds To Unusual Market Activity
2013-12-02,Palatin Technologies To Participate In The 25th Annual Piper Jaffray Healthcare Conference
2013-11-25,Palatin Technologies, Inc. And PHT Corporation To Present On Best Practices In Female Sexual Dysfunction (FSD) Clinical Study Design At Managing ECOA Data Summit
2013-11-13,Palatin Technologies Announces Option For License To Bremelanotide In Europe
2013-11-12,Palatin Technologies Announces Issuance Of Two Natriuretic Peptide Receptor-Specific Mimetic Patents
2013-10-28,Palatin Technologies Reports Successful Completion Of Device Bioequivalence Trial
2013-10-04,Palatin Technologies To Present At The 12th Annual BIO Investor Forum
2013-05-24,Biotech Stock Mailbag: Amarin, MannKind, Palatin
2013-05-02,Palatin Technologies Announces Notification Of Patent Allowance On Melanocortin Receptor-Specific Peptides For Sexual Dysfunction
2013-03-19,Palatin Technologies Announces Notification Of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
2013-03-15,Palatin Technologies To Present At The 25th Annual ROTH Conference
2013-03-04,Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
2013-02-07,Palatin Technologies, Inc. To Present At 15th Annual BIO CEO & Investor Conference
2013-01-03,Palatin Technologies Receives $1.75 Million From Sale Of New Jersey State Tax Credits
2012-11-20,Palatin Technologies, Inc. To Present At The 24th Annual Piper Jaffray Healthcare Conference
2012-11-12,Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
2012-11-08,Palatin Technologies Reports Positive Results For Phase 2B Bremelanotide Female Sexual Dysfunction Trial
2012-10-26,5 Stocks Poised for Breakouts
2012-09-11,Palatin Technologies' CEO Discusses F4Q12 Results - Earnings Call Transcript
2012-09-10,Palatin Technologies Announces Last Patient Completed Treatment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
2012-09-07,Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration With AstraZeneca
2012-07-02,Palatin Technologies, Inc. Announces Pricing Of $35 Million Private Placement Of Common Stock And Warrants
2012-06-19,Palatin Technologies Announces Halting Of Phase I Clinical Trial Of Obesity Compound In AstraZeneca Research Collaboration
2012-05-14,Palatin Technologies' CEO Discusses F3Q2012 Results - Earnings Call Transcript
2012-03-08,Palatin Technologies Completes Enrollment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
2012-03-07,Palatin Technologies, Inc. To Present At The 24th Annual ROTH OC Growth Stock Conference
2012-02-15,Palatin Technologies' CEO Discusses F2Q2012 Results - Earnings Call Transcript
2012-02-09,Palatin Technologies To Present At 14th Annual BIO CEO & Investor Conference
2012-01-17,Palatin Technologies Receives $1.1 Million From Sale Of New Jersey State Tax Credits
2012-01-16,Palatin Technologies To Present At BOCEMb, Noble Financial Capital Markets' Eighth Annual Equity Conference
2011-11-30,Palatin Technologies To Present At Windhover's Therapeutic Area Partnerships Conference
2011-11-15,Palatin Technologies CEO Discusses F1Q12 Results - Earnings Call Transcript
2011-10-21,Palatin Technologies To Present At 10th Annual BIO Investor Forum
2011-09-22,Palatin Technologies CEO Discusses F4Q2011 Results - Earnings Call Transcript
2011-09-09,Palatin Technologies, Inc. To Present At The Rodman & Renshaw Annual Global Investment Conference
2011-08-04,Palatin Announces Commencement Of A Phase 1 Trial For Obesity Compound In Collaboration With AstraZeneca
2011-06-28,Palatin Technologies, Inc. Initiates Enrollment In Phase 2b Trial With Bremelanotide In Women With Female Sexual Dysfunction
2011-06-23,Alan Dunton, M.D., Joins Board Of Directors Of Palatin Technologies, Inc.
2011-06-21,Palatin Technologies, Inc. Issued U.S. Patent For Key Component In PL-3994 Drug Candidate
2011-06-15,Palatin Technologies, Inc. Announces Presentation And Publication On Validation Of Scale For Subjective Male Sexual Arousal
2011-05-16,Palatin Technologies CEO Discusses F3Q2011 Results - Earnings Call Transcript
2011-05-11,Palatin Technologies, Inc. Announces Results Of Annual Stockholders' Meeting
2011-03-09,Palatin Technologies, Inc. To Present At The ROTH 23rd Annual OC Growth Stock Conference
2011-03-03,FDA Clears Palatin Technologies' IND Filing To Commence Clinical Studies For Asthma
2011-03-01,Palatin Technologies, Inc. Closes $23 Million Public Offering
2011-02-24,Palatin Technologies CEO Discusses Q4 2010 Results - Earnings Call Transcript
2011-02-24,Palatin Technologies, Inc. Announces Pricing Of Public Offering Of Common Stock And Warrants
2011-02-23,Palatin Technologies, Inc. Announces Proposed Public Offering Of Common Stock And Warrants
2011-02-04,Palatin Technologies Listing Compliance Plan Accepted By NYSE Amex
2010-12-02,Palatin Technologies Receives Non-Compliance Letter From NYSE Amex
2010-11-16,Palatin Technologies CEO Discusses F1Q2011 Results - Earnings Call Transcript
2010-11-16,Palatin Technologies Appoints Jeffrey D. Edelson, M.D., Chief Medical Officer
2010-11-02,Palatin Technologies, Inc. Receives $978,000 In Grants Under The Patient Protection And Affordable Care Program
2010-10-01,Palatin Technologies To Present At 9th Annual BIO Investor Forum
2010-09-30,Globecomm Systems - Upgrades & Downgrades
2010-09-27,Palatin CEO Discusses F4Q2010 Results - Earnings Call Transcript
2010-09-24,Palatin Announces Strategic Realignment Of Operations
2010-09-10,Palatin Technologies To Present At Rodman & Renshaw Annual Global Investment Conference
2010-08-17,Palatin Technologies, Inc. Announces Positive Safety Results In Subcutaneous Bremelanotide Trial In Men
2010-06-25,Palatin Technologies, Inc. To Raise $2.0 Million Dollars In Registered Direct Offering
2010-06-24,Palatin Technologies, Inc. Announces Last Patient Dosed And Database Lock In Subcutaneous Bremelanotide Trial In Men
2010-05-24,Bill Gross Buys Into Pimco Funds
2010-05-13,Palatin Technologies, Inc. F3Q10 (Qtr End 03/31/10) Earnings Call Transcript
2010-05-04,Palatin Technologies, Inc. Issued U.S. Patent And Receives Patent Allowance On Seven Additional Patents
2010-03-23,Palatin Technologies, Inc. Receives $2.5 Million From AstraZeneca
2010-02-25,Palatin Technologies, Inc. To Raise $2.6 Million Dollars In Registered Direct Offering
2010-02-16,Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference And Webcast To Be Held On February 16, 2010
2010-02-09,Palatin Technologies, Inc. Announces Dosing Of Subcutaneous Bremelanotide Trial In Men
2009-12-01,Palatin Technologies, Inc. Issued U.S. Patent For Heart Failure Drug Candidate
2007-11-09,Friday's Health Winners & Losers
2007-09-14,Friday's Small-Cap Winners & Losers
2007-08-30,Thursday's Small-Cap Winners & Losers
2007-08-30,Thursday's Health Winners & Losers
2007-01-31,Wednesday's Small-Cap Winners & Losers
2006-01-13,Four Stocks Ready to Get Off the Canvas
2005-04-12,King Pharmaceuticals' Sales Guidance Is Light
2004-04-13,Time Remains to Right the Boat
,
2017-03-15,UniQure Announces 2016 Financial Results And Provides Update On Company Progress
2017-03-03,UniQure Receives 2017 Frost & Sullivan Manufacturing Leadership Award
2017-03-01,UniQure Announces Presentations At Upcoming March Conferences
2017-02-06,UniQure Announces Presentations At Upcoming February Conferences
2017-01-30,UniQure Announces FDA Breakthrough Therapy Designation For AMT-060 In Hemophilia B
2017-01-25,UniQure Appoints Alexander Kuta As Senior Vice President Of Regulatory Affairs
2017-01-09,UniQure Outlines Key Initiatives For 2017 And Vision For 2018
2017-01-06,5 Stocks Setting Up for Big Breakouts
2016-12-19,UniQure Appoints Matthew Kapusta As Chief Executive Officer
2016-12-05,Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting
2016-12-03,UniQure Announces First Clinical Data From Second Dose Cohort Of AMT-060 In Ongoing Phase I/II Trial In Patients With Severe Hemophilia B
2016-12-03,Spark's Hemophilia Gene Therapy Remains Effective Despite Immune Reactions
2016-12-02,UniQure To Present At The Genetic Rx Boston Biotech Conference At Harvard Medical School
2016-11-22,UniQure Announces Financial Results For Third Quarter 2016 And Provides Update On Company Progress
2016-11-22,UniQure Announces Financial Results For Third Quarter 2016 And Provides Update On Company Progress
2016-11-15,UniQure Completes Strategic Review To Refocus Its Pipeline, Reduce Operating Costs And Deliver Long-Term Shareholder Value
2016-09-26,UniQure To Present At The Jefferies Gene Editing And Gene Therapy Summit In New York City
2016-09-22,UniQure Announces Management And Board Changes
2016-09-16,UniQure Receives NASDAQ Deficiency Letter Related To Board Composition
2016-08-25,UniQure Announces Financial Results For Second Quarter 2016 And Update On Company Progress
2016-08-25,UniQure Announces Financial Results For Second Quarter 2016 And Update On Company Progress
2016-08-17,UniQure To Present At Upcoming Investor Conferences In September
2016-07-29,8 Stocks Under $10 to Trade for Huge Profits
2016-07-27,UniQure Presents Updated Clinical Data In Patients With Severe Hemophilia B Demonstrating Up To 9 Months Of Sustained Levels Of Factor IX Activity And Therapeutic Effect
2016-07-11,UniQure Announces Oral Presentation Of Updated Results For AMT-060 At The World Federation Of Hemophilia (WFH) 2016 World Congress
2016-07-07,UniQure Appoints Jonathan Garen As Chief Business Officer
2016-07-01,These 5 Stocks Are Ready for Breakouts
2016-06-27,UniQure Appoints Maria E. Cantor As Senior Vice President, Investor Relations & Communications
2016-06-14,Trade-Ideas: UniQure (QURE) Is Today's Weak On High Relative Volume Stock
2016-06-11,UniQure Presents Clinical Data From Ongoing Phase I/II Study In Hemophilia B Demonstrating 6 Months Of Sustained Increases In Factor IX Activity
2016-05-31,UniQure Announces Results For First Quarter 2016
2016-05-19,UniQure Announces Oral Presentation Of Clinical Data From Ongoing Phase I/II Study Of AMT-060 In Hemophilia B At The 21st Congress Of The European Hematology Association
2016-05-12,UniQure To Present At Upcoming Investor Conferences In New York City
2016-05-09,UniQure Announces The Nomination Of Jack Kaye To Its Board Of Directors And Proposed Corporate Governance Changes
2016-05-09,UniQure Announces The Nomination Of Jack Kaye To Its Board Of Directors And Proposed Corporate Governance Changes
2016-05-09,UniQure Presents Preclinical Data On AAV Re-Administration, Regulated Gene Expression And Total Brain Transduction At ASGCT
2016-05-03,UniQure Appoints Paul Firuta As Chief Commercial Officer
2016-04-19,UniQure To Present Data On Gene Therapy Technology Advances At Annual Meeting Of The American Society Of Gene And Cell Therapy
2016-04-19,UniQure To Present Data On Gene Therapy Technology Advances At Annual Meeting Of The American Society Of Gene And Cell Therapy
2016-04-04,CORRECTING And REPLACING -- UniQure Announces Results For Fourth Quarter And Financial Year 2015
2016-04-04,UniQure Announces Results For Fourth Quarter And Financial Year 2015
2016-03-24,Interesting QURE Put And Call Options For May 20th
2016-03-22,UniQure Announces Preclinical Proof Of Concept For Gene Therapy Approach In Huntington's Disease
2016-03-14,UniQure Announces Dosing Of First Patient In High-Dose Cohort In Phase I/II Hemophilia B Clinical Trial
2016-03-02,UniQure To Present At The 36th Cowen & Company Health Care Conference
2016-02-15,UniQure To Present At The RBC Capital Markets 2016 Global Healthcare Conference
2016-01-28,'Mad Money' Lightning Round: Take the Money and Run From Sprint
2016-01-27,Jim Cramer's 'Mad Money' Recap: More Pain Ahead, Thanks to the Fed
2016-01-11,UniQure (QURE) Weak On High Volume Today
2016-01-08,Buy These 5 Breakout Stocks Now for Big Gains
2016-01-07,UniQure Announces Preliminary Topline Results From Low-Dose Cohort In Hemophilia B Phase I/II Gene Therapy Clinical Trial
2016-01-06,UniQure Announces Conference Call And Webcast To Discuss Topline Results From Low-Dose Cohort In Hemophilia B Phase I/II Gene Therapy Clinical Trial
2015-12-18,UniQure Appoints Dan Soland As Chief Executive Officer
2015-12-14,UniQure Added To NASDAQ Biotechnology Index
2015-11-30,UniQure (QURE) Weak On High Volume Today
2015-11-30,UniQure Announces Financial Results For Third Quarter 2015 And Provides Update On Product Pipeline And Company Developments
2015-11-23,UniQure Announces Conference Call And Webcast To Discuss Third Quarter Financial Results And Corporate Update
2015-11-12,UniQure To Present At The Jefferies 2015 Global Healthcare Conference - London
2015-11-06,Interesting QURE Put And Call Options For November 20th
2015-10-07,UniQure To Host Investor Day In New York City On October 15, 2015
2015-10-05,Spark Therapeutics Trial Success Seen As Positive For Gene Therapy Sector
2015-09-30,UniQure (QURE) Marked As A Dead Cat Bounce Stock
2015-09-22,Today's Dead Cat Bounce Stock: UniQure (QURE)
2015-09-21,UniQure (QURE) Trading With Heavy Volume Before Market Open
2015-09-19,Positive Topline Results Announced From Phase I/II Trial In Sanfilippo B Syndrome Patients Using UniQure's Novel AAV5-Based Gene Therapy
2015-09-18,UniQure (QURE) Is Today's Strong On High Volume Stock
2015-09-03,Biotech Stock Mailbag: Sarepta, Biomarin, Spark, Raptor
2015-09-01,UniQure To Present At NewsMakers In The Biotech Industry Conference - NYC
2015-08-27,UniQure Announces Financial Results For Second Quarter 2015
2015-08-10,UniQure Announces Receipt Of $53 Million From Bristol-Myers Squibb For Target Selection Payment And Additional Equity Investment
2015-08-04,Jim Cramer's 'Mad Money' Recap: Nowhere to Run, Nowhere to Hide From China
2015-07-16,Dr. Charles W. Richard Joins UniQure As Senior Vice President To Lead Development Of CNS-focused Gene Therapy Pipeline
2015-06-13,Bluebird Sickle Cell Gene Therapy Results Keep Getting Better
2015-06-11,UniQure Announces Financial Results For First Quarter 2015
2015-05-27,UniQure To Present At The Jefferies 2015 Healthcare Conference
2015-05-26,UniQure Announces Closing Of Strategic Collaboration With Bristol-Myers Squibb To Develop Gene Therapies For Cardiovascular Disease
2015-05-21,Bluebird Bio First Look at Gene Therapy for Sickle Cell Disease
2015-05-12,Ratings Changes Today
2015-04-26,Gene Therapy Stocks on Watch Following Failure of Celladon's Heart Failure Trial
2015-04-15,UniQure Announces Closing Of Follow-on Public Offering
2015-04-09,UniQure Announces Pricing Of Follow-on Public Offering
2015-04-07,UniQure Announces Launch Of Follow-on Public Offering
2015-04-06,Market News: Tesla Motors Inc, Uniqure NV, Transocean LTD
2015-04-06,Stocks Spike on Fed Rate Hike Speculation; Microsoft Leads Dow
2015-04-06,Stocks Drive Higher as Energy Rally Overshadows Weak Jobs Report
2015-04-06,UniQure NV (QURE) Stock Soars to 52-Week High on Bristol-Myers Squibb Investment
2015-04-06,UniQure Announces Webcast To Discuss Bristol-Myers Squibb Collaboration
2015-04-06,UniQure Announces Results For Fourth Quarter And Financial Year 2014
2015-04-06,Bristol-Myers Squibb And UniQure Enter Into Exclusive Strategic Collaboration To Develop Gene Therapies For Cardiovascular Diseases
2015-02-23,UniQure To Present At The At The Cowen And Company 35th Annual Health Care Conference
2015-02-06,UniQure To Present At The At The Leerink Partners Global Healthcare Conference
2015-01-15,Gold Surge Spells Good Things For Soros, Dalio
2015-01-14,Treeway Announces License And Collaboration Agreement With UniQure To Develop A Gene Therapy For Amyotrophic Lateral Sclerosis (ALS)
2015-01-09,UniQure Appoints Matthew Kapusta As Chief Financial Officer
2015-01-05,Ackman Short Keeps Looking Better As Herbalife Takes A Dive
2014-12-05,UniQure To Present At The Oppenheimer 25th Healthcare Conference - NYC
2014-12-01,UniQure Announces Results For The Third Quarter Of 2014
2014-11-21,UniQure To Host Investor Day In New York City
2014-11-10,UniQure To Present At Jefferies Global Healthcare Conference - London
2014-10-27,AIPGENE Consortium Presents 1 Year Follow-Up Clinical Data From Acute Intermittent Porphyria Phase I Clinical Trial Using AAV5-PBGD Gene Therapy Candidate
2014-09-25,UniQure To Present At The Leerink Partners Rare Disease Roundtable Conference
2014-09-02,UniQure Announces Results For The Second Quarter And First Half Of 2014 And Provides Update On Gene Therapy Programs
2014-08-11,UniQure Acquires Cardiology Gene Therapy Company InoCard
2014-08-04,Chiesi And UniQure Provide Update On Glybera(r) Launch
2014-04-28,3 Stocks Rising on Big Volume
,
,
2017-03-15,UniQure Announces 2016 Financial Results And Provides Update On Company Progress
2017-03-03,UniQure Receives 2017 Frost & Sullivan Manufacturing Leadership Award
2017-03-01,UniQure Announces Presentations At Upcoming March Conferences
2017-02-06,UniQure Announces Presentations At Upcoming February Conferences
2017-01-30,UniQure Announces FDA Breakthrough Therapy Designation For AMT-060 In Hemophilia B
2017-01-25,UniQure Appoints Alexander Kuta As Senior Vice President Of Regulatory Affairs
2017-01-09,UniQure Outlines Key Initiatives For 2017 And Vision For 2018
2017-01-06,5 Stocks Setting Up for Big Breakouts
2016-12-19,UniQure Appoints Matthew Kapusta As Chief Executive Officer
2016-12-05,Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting
2016-12-03,UniQure Announces First Clinical Data From Second Dose Cohort Of AMT-060 In Ongoing Phase I/II Trial In Patients With Severe Hemophilia B
2016-12-03,Spark's Hemophilia Gene Therapy Remains Effective Despite Immune Reactions
2016-12-02,UniQure To Present At The Genetic Rx Boston Biotech Conference At Harvard Medical School
2016-11-22,UniQure Announces Financial Results For Third Quarter 2016 And Provides Update On Company Progress
2016-11-22,UniQure Announces Financial Results For Third Quarter 2016 And Provides Update On Company Progress
2016-11-15,UniQure Completes Strategic Review To Refocus Its Pipeline, Reduce Operating Costs And Deliver Long-Term Shareholder Value
2016-09-26,UniQure To Present At The Jefferies Gene Editing And Gene Therapy Summit In New York City
2016-09-22,UniQure Announces Management And Board Changes
2016-09-16,UniQure Receives NASDAQ Deficiency Letter Related To Board Composition
2016-08-25,UniQure Announces Financial Results For Second Quarter 2016 And Update On Company Progress
2016-08-25,UniQure Announces Financial Results For Second Quarter 2016 And Update On Company Progress
2016-08-17,UniQure To Present At Upcoming Investor Conferences In September
2016-07-29,8 Stocks Under $10 to Trade for Huge Profits
2016-07-27,UniQure Presents Updated Clinical Data In Patients With Severe Hemophilia B Demonstrating Up To 9 Months Of Sustained Levels Of Factor IX Activity And Therapeutic Effect
2016-07-11,UniQure Announces Oral Presentation Of Updated Results For AMT-060 At The World Federation Of Hemophilia (WFH) 2016 World Congress
2016-07-07,UniQure Appoints Jonathan Garen As Chief Business Officer
2016-07-01,These 5 Stocks Are Ready for Breakouts
2016-06-27,UniQure Appoints Maria E. Cantor As Senior Vice President, Investor Relations & Communications
2016-06-14,Trade-Ideas: UniQure (QURE) Is Today's Weak On High Relative Volume Stock
2016-06-11,UniQure Presents Clinical Data From Ongoing Phase I/II Study In Hemophilia B Demonstrating 6 Months Of Sustained Increases In Factor IX Activity
2016-05-31,UniQure Announces Results For First Quarter 2016
2016-05-19,UniQure Announces Oral Presentation Of Clinical Data From Ongoing Phase I/II Study Of AMT-060 In Hemophilia B At The 21st Congress Of The European Hematology Association
2016-05-12,UniQure To Present At Upcoming Investor Conferences In New York City
2016-05-09,UniQure Announces The Nomination Of Jack Kaye To Its Board Of Directors And Proposed Corporate Governance Changes
2016-05-09,UniQure Announces The Nomination Of Jack Kaye To Its Board Of Directors And Proposed Corporate Governance Changes
2016-05-09,UniQure Presents Preclinical Data On AAV Re-Administration, Regulated Gene Expression And Total Brain Transduction At ASGCT
2016-05-03,UniQure Appoints Paul Firuta As Chief Commercial Officer
2016-04-19,UniQure To Present Data On Gene Therapy Technology Advances At Annual Meeting Of The American Society Of Gene And Cell Therapy
2016-04-19,UniQure To Present Data On Gene Therapy Technology Advances At Annual Meeting Of The American Society Of Gene And Cell Therapy
2016-04-04,CORRECTING And REPLACING -- UniQure Announces Results For Fourth Quarter And Financial Year 2015
2016-04-04,UniQure Announces Results For Fourth Quarter And Financial Year 2015
2016-03-24,Interesting QURE Put And Call Options For May 20th
2016-03-22,UniQure Announces Preclinical Proof Of Concept For Gene Therapy Approach In Huntington's Disease
2016-03-14,UniQure Announces Dosing Of First Patient In High-Dose Cohort In Phase I/II Hemophilia B Clinical Trial
2016-03-02,UniQure To Present At The 36th Cowen & Company Health Care Conference
2016-02-15,UniQure To Present At The RBC Capital Markets 2016 Global Healthcare Conference
2016-01-28,'Mad Money' Lightning Round: Take the Money and Run From Sprint
2016-01-27,Jim Cramer's 'Mad Money' Recap: More Pain Ahead, Thanks to the Fed
2016-01-11,UniQure (QURE) Weak On High Volume Today
2016-01-08,Buy These 5 Breakout Stocks Now for Big Gains
2016-01-07,UniQure Announces Preliminary Topline Results From Low-Dose Cohort In Hemophilia B Phase I/II Gene Therapy Clinical Trial
2016-01-06,UniQure Announces Conference Call And Webcast To Discuss Topline Results From Low-Dose Cohort In Hemophilia B Phase I/II Gene Therapy Clinical Trial
2015-12-18,UniQure Appoints Dan Soland As Chief Executive Officer
2015-12-14,UniQure Added To NASDAQ Biotechnology Index
2015-11-30,UniQure (QURE) Weak On High Volume Today
2015-11-30,UniQure Announces Financial Results For Third Quarter 2015 And Provides Update On Product Pipeline And Company Developments
2015-11-23,UniQure Announces Conference Call And Webcast To Discuss Third Quarter Financial Results And Corporate Update
2015-11-12,UniQure To Present At The Jefferies 2015 Global Healthcare Conference - London
2015-11-06,Interesting QURE Put And Call Options For November 20th
2015-10-07,UniQure To Host Investor Day In New York City On October 15, 2015
2015-10-05,Spark Therapeutics Trial Success Seen As Positive For Gene Therapy Sector
2015-09-30,UniQure (QURE) Marked As A Dead Cat Bounce Stock
2015-09-22,Today's Dead Cat Bounce Stock: UniQure (QURE)
2015-09-21,UniQure (QURE) Trading With Heavy Volume Before Market Open
2015-09-19,Positive Topline Results Announced From Phase I/II Trial In Sanfilippo B Syndrome Patients Using UniQure's Novel AAV5-Based Gene Therapy
2015-09-18,UniQure (QURE) Is Today's Strong On High Volume Stock
2015-09-03,Biotech Stock Mailbag: Sarepta, Biomarin, Spark, Raptor
2015-09-01,UniQure To Present At NewsMakers In The Biotech Industry Conference - NYC
2015-08-27,UniQure Announces Financial Results For Second Quarter 2015
2015-08-10,UniQure Announces Receipt Of $53 Million From Bristol-Myers Squibb For Target Selection Payment And Additional Equity Investment
2015-08-04,Jim Cramer's 'Mad Money' Recap: Nowhere to Run, Nowhere to Hide From China
2015-07-16,Dr. Charles W. Richard Joins UniQure As Senior Vice President To Lead Development Of CNS-focused Gene Therapy Pipeline
2015-06-13,Bluebird Sickle Cell Gene Therapy Results Keep Getting Better
2015-06-11,UniQure Announces Financial Results For First Quarter 2015
2015-05-27,UniQure To Present At The Jefferies 2015 Healthcare Conference
2015-05-26,UniQure Announces Closing Of Strategic Collaboration With Bristol-Myers Squibb To Develop Gene Therapies For Cardiovascular Disease
2015-05-21,Bluebird Bio First Look at Gene Therapy for Sickle Cell Disease
2015-05-12,Ratings Changes Today
2015-04-26,Gene Therapy Stocks on Watch Following Failure of Celladon's Heart Failure Trial
2015-04-15,UniQure Announces Closing Of Follow-on Public Offering
2015-04-09,UniQure Announces Pricing Of Follow-on Public Offering
2015-04-07,UniQure Announces Launch Of Follow-on Public Offering
2015-04-06,Market News: Tesla Motors Inc, Uniqure NV, Transocean LTD
2015-04-06,Stocks Spike on Fed Rate Hike Speculation; Microsoft Leads Dow
2015-04-06,Stocks Drive Higher as Energy Rally Overshadows Weak Jobs Report
2015-04-06,UniQure NV (QURE) Stock Soars to 52-Week High on Bristol-Myers Squibb Investment
2015-04-06,UniQure Announces Webcast To Discuss Bristol-Myers Squibb Collaboration
2015-04-06,UniQure Announces Results For Fourth Quarter And Financial Year 2014
2015-04-06,Bristol-Myers Squibb And UniQure Enter Into Exclusive Strategic Collaboration To Develop Gene Therapies For Cardiovascular Diseases
2015-02-23,UniQure To Present At The At The Cowen And Company 35th Annual Health Care Conference
2015-02-06,UniQure To Present At The At The Leerink Partners Global Healthcare Conference
2015-01-15,Gold Surge Spells Good Things For Soros, Dalio
2015-01-14,Treeway Announces License And Collaboration Agreement With UniQure To Develop A Gene Therapy For Amyotrophic Lateral Sclerosis (ALS)
2015-01-09,UniQure Appoints Matthew Kapusta As Chief Financial Officer
2015-01-05,Ackman Short Keeps Looking Better As Herbalife Takes A Dive
2014-12-05,UniQure To Present At The Oppenheimer 25th Healthcare Conference - NYC
2014-12-01,UniQure Announces Results For The Third Quarter Of 2014
2014-11-21,UniQure To Host Investor Day In New York City
2014-11-10,UniQure To Present At Jefferies Global Healthcare Conference - London
2014-10-27,AIPGENE Consortium Presents 1 Year Follow-Up Clinical Data From Acute Intermittent Porphyria Phase I Clinical Trial Using AAV5-PBGD Gene Therapy Candidate
2014-09-25,UniQure To Present At The Leerink Partners Rare Disease Roundtable Conference
2014-09-02,UniQure Announces Results For The Second Quarter And First Half Of 2014 And Provides Update On Gene Therapy Programs
2014-08-11,UniQure Acquires Cardiology Gene Therapy Company InoCard
2014-08-04,Chiesi And UniQure Provide Update On Glybera(r) Launch
2014-04-28,3 Stocks Rising on Big Volume
,
,
2017-03-15,UniQure Announces 2016 Financial Results And Provides Update On Company Progress
2017-03-03,UniQure Receives 2017 Frost & Sullivan Manufacturing Leadership Award
2017-03-01,UniQure Announces Presentations At Upcoming March Conferences
2017-02-06,UniQure Announces Presentations At Upcoming February Conferences
2017-01-30,UniQure Announces FDA Breakthrough Therapy Designation For AMT-060 In Hemophilia B
2017-01-25,UniQure Appoints Alexander Kuta As Senior Vice President Of Regulatory Affairs
2017-01-09,UniQure Outlines Key Initiatives For 2017 And Vision For 2018
2017-01-06,5 Stocks Setting Up for Big Breakouts
2016-12-19,UniQure Appoints Matthew Kapusta As Chief Executive Officer
2016-12-05,Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting
2016-12-03,UniQure Announces First Clinical Data From Second Dose Cohort Of AMT-060 In Ongoing Phase I/II Trial In Patients With Severe Hemophilia B
2016-12-03,Spark's Hemophilia Gene Therapy Remains Effective Despite Immune Reactions
2016-12-02,UniQure To Present At The Genetic Rx Boston Biotech Conference At Harvard Medical School
2016-11-22,UniQure Announces Financial Results For Third Quarter 2016 And Provides Update On Company Progress
2016-11-22,UniQure Announces Financial Results For Third Quarter 2016 And Provides Update On Company Progress
2016-11-15,UniQure Completes Strategic Review To Refocus Its Pipeline, Reduce Operating Costs And Deliver Long-Term Shareholder Value
2016-09-26,UniQure To Present At The Jefferies Gene Editing And Gene Therapy Summit In New York City
2016-09-22,UniQure Announces Management And Board Changes
2016-09-16,UniQure Receives NASDAQ Deficiency Letter Related To Board Composition
2016-08-25,UniQure Announces Financial Results For Second Quarter 2016 And Update On Company Progress
2016-08-25,UniQure Announces Financial Results For Second Quarter 2016 And Update On Company Progress
2016-08-17,UniQure To Present At Upcoming Investor Conferences In September
2016-07-29,8 Stocks Under $10 to Trade for Huge Profits
2016-07-27,UniQure Presents Updated Clinical Data In Patients With Severe Hemophilia B Demonstrating Up To 9 Months Of Sustained Levels Of Factor IX Activity And Therapeutic Effect
2016-07-11,UniQure Announces Oral Presentation Of Updated Results For AMT-060 At The World Federation Of Hemophilia (WFH) 2016 World Congress
2016-07-07,UniQure Appoints Jonathan Garen As Chief Business Officer
2016-07-01,These 5 Stocks Are Ready for Breakouts
2016-06-27,UniQure Appoints Maria E. Cantor As Senior Vice President, Investor Relations & Communications
2016-06-14,Trade-Ideas: UniQure (QURE) Is Today's Weak On High Relative Volume Stock
2016-06-11,UniQure Presents Clinical Data From Ongoing Phase I/II Study In Hemophilia B Demonstrating 6 Months Of Sustained Increases In Factor IX Activity
2016-05-31,UniQure Announces Results For First Quarter 2016
2016-05-19,UniQure Announces Oral Presentation Of Clinical Data From Ongoing Phase I/II Study Of AMT-060 In Hemophilia B At The 21st Congress Of The European Hematology Association
2016-05-12,UniQure To Present At Upcoming Investor Conferences In New York City
2016-05-09,UniQure Announces The Nomination Of Jack Kaye To Its Board Of Directors And Proposed Corporate Governance Changes
2016-05-09,UniQure Announces The Nomination Of Jack Kaye To Its Board Of Directors And Proposed Corporate Governance Changes
2016-05-09,UniQure Presents Preclinical Data On AAV Re-Administration, Regulated Gene Expression And Total Brain Transduction At ASGCT
2016-05-03,UniQure Appoints Paul Firuta As Chief Commercial Officer
2016-04-19,UniQure To Present Data On Gene Therapy Technology Advances At Annual Meeting Of The American Society Of Gene And Cell Therapy
2016-04-19,UniQure To Present Data On Gene Therapy Technology Advances At Annual Meeting Of The American Society Of Gene And Cell Therapy
2016-04-04,CORRECTING And REPLACING -- UniQure Announces Results For Fourth Quarter And Financial Year 2015
2016-04-04,UniQure Announces Results For Fourth Quarter And Financial Year 2015
2016-03-24,Interesting QURE Put And Call Options For May 20th
2016-03-22,UniQure Announces Preclinical Proof Of Concept For Gene Therapy Approach In Huntington's Disease
2016-03-14,UniQure Announces Dosing Of First Patient In High-Dose Cohort In Phase I/II Hemophilia B Clinical Trial
2016-03-02,UniQure To Present At The 36th Cowen & Company Health Care Conference
2016-02-15,UniQure To Present At The RBC Capital Markets 2016 Global Healthcare Conference
2016-01-28,'Mad Money' Lightning Round: Take the Money and Run From Sprint
2016-01-27,Jim Cramer's 'Mad Money' Recap: More Pain Ahead, Thanks to the Fed
2016-01-11,UniQure (QURE) Weak On High Volume Today
2016-01-08,Buy These 5 Breakout Stocks Now for Big Gains
2016-01-07,UniQure Announces Preliminary Topline Results From Low-Dose Cohort In Hemophilia B Phase I/II Gene Therapy Clinical Trial
2016-01-06,UniQure Announces Conference Call And Webcast To Discuss Topline Results From Low-Dose Cohort In Hemophilia B Phase I/II Gene Therapy Clinical Trial
2015-12-18,UniQure Appoints Dan Soland As Chief Executive Officer
2015-12-14,UniQure Added To NASDAQ Biotechnology Index
2015-11-30,UniQure (QURE) Weak On High Volume Today
2015-11-30,UniQure Announces Financial Results For Third Quarter 2015 And Provides Update On Product Pipeline And Company Developments
2015-11-23,UniQure Announces Conference Call And Webcast To Discuss Third Quarter Financial Results And Corporate Update
2015-11-12,UniQure To Present At The Jefferies 2015 Global Healthcare Conference - London
2015-11-06,Interesting QURE Put And Call Options For November 20th
2015-10-07,UniQure To Host Investor Day In New York City On October 15, 2015
2015-10-05,Spark Therapeutics Trial Success Seen As Positive For Gene Therapy Sector
2015-09-30,UniQure (QURE) Marked As A Dead Cat Bounce Stock
2015-09-22,Today's Dead Cat Bounce Stock: UniQure (QURE)
2015-09-21,UniQure (QURE) Trading With Heavy Volume Before Market Open
2015-09-19,Positive Topline Results Announced From Phase I/II Trial In Sanfilippo B Syndrome Patients Using UniQure's Novel AAV5-Based Gene Therapy
2015-09-18,UniQure (QURE) Is Today's Strong On High Volume Stock
2015-09-03,Biotech Stock Mailbag: Sarepta, Biomarin, Spark, Raptor
2015-09-01,UniQure To Present At NewsMakers In The Biotech Industry Conference - NYC
2015-08-27,UniQure Announces Financial Results For Second Quarter 2015
2015-08-10,UniQure Announces Receipt Of $53 Million From Bristol-Myers Squibb For Target Selection Payment And Additional Equity Investment
2015-08-04,Jim Cramer's 'Mad Money' Recap: Nowhere to Run, Nowhere to Hide From China
2015-07-16,Dr. Charles W. Richard Joins UniQure As Senior Vice President To Lead Development Of CNS-focused Gene Therapy Pipeline
2015-06-13,Bluebird Sickle Cell Gene Therapy Results Keep Getting Better
2015-06-11,UniQure Announces Financial Results For First Quarter 2015
2015-05-27,UniQure To Present At The Jefferies 2015 Healthcare Conference
2015-05-26,UniQure Announces Closing Of Strategic Collaboration With Bristol-Myers Squibb To Develop Gene Therapies For Cardiovascular Disease
2015-05-21,Bluebird Bio First Look at Gene Therapy for Sickle Cell Disease
2015-05-12,Ratings Changes Today
2015-04-26,Gene Therapy Stocks on Watch Following Failure of Celladon's Heart Failure Trial
2015-04-15,UniQure Announces Closing Of Follow-on Public Offering
2015-04-09,UniQure Announces Pricing Of Follow-on Public Offering
2015-04-07,UniQure Announces Launch Of Follow-on Public Offering
2015-04-06,Market News: Tesla Motors Inc, Uniqure NV, Transocean LTD
2015-04-06,Stocks Spike on Fed Rate Hike Speculation; Microsoft Leads Dow
2015-04-06,Stocks Drive Higher as Energy Rally Overshadows Weak Jobs Report
2015-04-06,UniQure NV (QURE) Stock Soars to 52-Week High on Bristol-Myers Squibb Investment
2015-04-06,UniQure Announces Webcast To Discuss Bristol-Myers Squibb Collaboration
2015-04-06,UniQure Announces Results For Fourth Quarter And Financial Year 2014
2015-04-06,Bristol-Myers Squibb And UniQure Enter Into Exclusive Strategic Collaboration To Develop Gene Therapies For Cardiovascular Diseases
2015-02-23,UniQure To Present At The At The Cowen And Company 35th Annual Health Care Conference
2015-02-06,UniQure To Present At The At The Leerink Partners Global Healthcare Conference
2015-01-15,Gold Surge Spells Good Things For Soros, Dalio
2015-01-14,Treeway Announces License And Collaboration Agreement With UniQure To Develop A Gene Therapy For Amyotrophic Lateral Sclerosis (ALS)
2015-01-09,UniQure Appoints Matthew Kapusta As Chief Financial Officer
2015-01-05,Ackman Short Keeps Looking Better As Herbalife Takes A Dive
2014-12-05,UniQure To Present At The Oppenheimer 25th Healthcare Conference - NYC
2014-12-01,UniQure Announces Results For The Third Quarter Of 2014
2014-11-21,UniQure To Host Investor Day In New York City
2014-11-10,UniQure To Present At Jefferies Global Healthcare Conference - London
2014-10-27,AIPGENE Consortium Presents 1 Year Follow-Up Clinical Data From Acute Intermittent Porphyria Phase I Clinical Trial Using AAV5-PBGD Gene Therapy Candidate
2014-09-25,UniQure To Present At The Leerink Partners Rare Disease Roundtable Conference
2014-09-02,UniQure Announces Results For The Second Quarter And First Half Of 2014 And Provides Update On Gene Therapy Programs
2014-08-11,UniQure Acquires Cardiology Gene Therapy Company InoCard
2014-08-04,Chiesi And UniQure Provide Update On Glybera(r) Launch
2014-04-28,3 Stocks Rising on Big Volume
,
,
2017-03-23,Biotech Premarket Movers: Insys, Ultragenyx, Alexion
2017-03-22,Ultragenyx Announces Topline Data From Phase 2 UX007 Glucose Transporter Type-1 Deficiency Syndrome Seizure Study
2017-03-02,Ultragenyx To Present At Upcoming Investor Conferences
2017-02-16,Ultragenyx Reports Fourth Quarter And Full Year 2016 Financial Results And Corporate Update
2017-02-10,Ultragenyx To Present At Leerink Partners Global Healthcare Conference
2017-02-09,Ultragenyx To Host Conference Call For Fourth Quarter And Full Year 2016 Financial Results And Corporate Update
2017-01-05,Ultragenyx And Kyowa Kirin International Announce Marketing Authorization Application For KRN23 Filed And Accepted For Review By European Medicines Agency
2017-01-04,Ultragenyx To Present At J.P. Morgan Healthcare Conference
2016-11-30,Ultragenyx Announces Positive Data From Phase 2 Study Of UX007 In Long-Chain Fatty Acid Oxidation Disorder Patients
2016-11-17,Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios
2016-11-11,Ultragenyx Announces Withdrawal Of Marketing Authorization Application For Aceneuramic Acid Prolonged Release (Ace-ER) In The European Union
2016-11-08,Ultragenyx To Present At Upcoming Investor Conferences
2016-11-07,Ultragenyx Reports Third Quarter 2016 Financial Results And Corporate Update
2016-10-31,Ultragenyx To Host Conference Call For Third Quarter 2016 Financial Results And Corporate Update
2016-10-26,Ultragenyx Announces First Patient Enrolled In Global Phase 3 Study Of KRN23 In Pediatric Patients With X-Linked Hypophosphatemia (XLH)
2016-09-27,Ultragenyx To Present At Leerink Partners Roundtable Series
2016-09-19,Ultragenyx Reports Positive Interim Data From Pediatric And Adult Phase 2 Studies Of KRN23 In X-Linked Hypophosphatemia
2016-09-18,Ultragenyx Reports Positive Interim Data From Phase 2 Study Of KRN23 For The Treatment Of Tumor-Induced Osteomalacia
2016-09-16,Ultragenyx To Host Conference Call To Discuss KRN23 Data Presented At ASBMR 2016 Annual Meeting
2016-09-01,Ultragenyx To Present At Baird 2016 Global Healthcare Conference
2016-08-23,Ultragenyx Announces KRN23 Data Presentations At ASBMR 2016 Annual Meeting
2016-08-09,Ultragenyx To Present At Upcoming Investor Conferences
2016-08-08,Ultragenyx Reports Second Quarter 2016 Financial Results And Corporate Update
2016-08-01,Ultragenyx To Host Conference Call For Second Quarter 2016 Financial Results And Corporate Update
2016-07-28,Ultragenyx Announces Completion Of Enrollment In Phase 3 Study Of KRN23 In Adults With X-Linked Hypophosphatemia (XLH)
2016-07-27,Ultragenyx Announces Completion Of Enrollment In Phase 3 Study Of Aceneuramic Acid Extended Release (Ace-ER) In GNE Myopathy
2016-07-26,These 5 Stocks Are Breaking Out This Summer
2016-07-14,Ultragenyx Announces Positive Topline Data From Phase 3 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7
2016-07-13,Ultragenyx To Present Phase 3 Data For Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7 (MPS 7) At 14th International Symposium On MPS And Related Diseases
2016-06-29,16 Biopharma Companies Besides Medivation That Are Attractive Targets
2016-06-28,Ultragenyx Receives Breakthrough Therapy Designation For KRN23 In Pediatric Patients With X-Linked Hypophosphatemia
2016-06-20,Ultragenyx Appoints Karah Parschauer As Executive Vice President, General Counsel
2016-06-07,Ultragenyx And Takeda Enter Into A Collaboration To Develop And Commercialize Therapies For Rare Genetic Diseases
2016-06-01,Ultragenyx To Present At Upcoming Investor Conferences
2016-05-09,Ultragenyx Reports First Quarter 2016 Financial Results And Corporate Update
2016-05-06,Ultragenyx To Present At Bank Of America Merrill Lynch Healthcare Conference
2016-04-29,Ultragenyx To Host Conference Call For First Quarter 2016 Financial Results And Corporate Update
2016-04-21,Ultragenyx Reports Positive Interim Data From Phase 2 Study Of KRN23 For The Treatment Of Tumor-Induced Osteomalacia
2016-03-23,Ultragenyx And Saint Louis University's Center For World Health And Medicine Announce Research Collaboration To Advance Muscular Dystrophy Treatment
2016-03-21,Ultragenyx Appoints Lars Ekman, M.D., Ph.D., To Board Of Directors
2016-03-02,Ultragenyx To Present At The Cowen And Company 36th Annual Health Care Conference
2016-03-01,Ultragenyx Announces Data Presentations Of RhGUS And RhPPCA At 12th Annual WORLD Symposium™
2016-02-25,Ultragenyx Reports Fourth Quarter 2015 And Full-Year 2015 Financial Results And Corporate Update
2016-02-19,Ultragenyx Pharmaceutical (RARE) Stock Gets 'Outperform' Rating at Leerink
2016-02-18,Ultragenyx To Host Conference Call For Fourth Quarter And Full-Year 2015 Financial Results And Corporate Update
2016-02-09,Ultragenyx To Present At The Leerink Partners Annual Healthcare Conference
2016-01-05,Ultragenyx To Present At The J.P. Morgan Healthcare Conference
2015-12-03,Ultragenyx Announces First Patient Enrolled In Global Phase 3 Study Of KRN23 In Adults With X-Linked Hypophosphatemia (XLH)
2015-12-02,Ultragenyx To Present At The Oppenheimer Annual Healthcare Conference
2015-12-02,Ultragenyx Reports Positive Interim 40-Week Data From Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
2015-11-11,Ultragenyx To Present At Upcoming Investor Conferences
2015-11-09,Ultragenyx Reports Third Quarter 2015 Financial Results And Corporate Update
2015-11-06,Ultragenyx Announces Update To UX007 Development Program In Glucose Transporter Type-1 Deficiency Syndrome
2015-11-03,Ultragenyx To Present At The Credit Suisse Annual Healthcare Conference
2015-11-03,Ultragenyx To Host Conference Call For Third Quarter 2015 Financial Results And Corporate Update
2015-10-29,Ultragenyx Pharmaceutical And Arcturus Therapeutics Announce A Research Collaboration And License Agreement To Develop RNA Therapeutics For Rare Diseases
2015-10-29,Ultragenyx Pharmaceutical And Arcturus Therapeutics Announce A Research Collaboration And License Agreement To Develop RNA Therapeutics For Rare Diseases
2015-10-13,Short Interest In Ultragenyx Pharmaceutical Falls 16.8%
2015-10-13,Ultragenyx Announces Positive Interim Data From Phase 2 Study Of UX007 In Long-Chain Fatty Acid Oxidation Disorder Patients
2015-10-02,Ultragenyx Announces Aceneuramic Acid Prolonged Release Marketing Authorization Application Filed And Accepted For Review By European Medicines Agency
2015-09-04,Battleground: Will This $5 Biotech Stock Go To $22 Or $1.50?
2015-09-02,Ultragenyx To Present At The Baird Health Care Conference
2015-09-01,Ultragenyx Announces Presentation Of Data From Long-Chain Fatty Acid Oxidation Disorder Patients With Cardiomyopathy Treated With Triheptanoin
2015-08-13,Ultragenyx Reports Second Quarter 2015 Financial Results And Corporate Update
2015-08-13,Ultragenyx Pharmaceutical Stock Sees Short Interest Decline 25.7%
2015-08-06,Ultragenyx To Host Conference Call For Second Quarter 2015 Financial Results And Corporate Update
2015-08-05,Ultragenyx Announces Initiation Of Phase 2 Study Of Recombinant Human Beta-Glucuronidase In Patients Under Five Years Old With Mucopolysaccharidosis 7
2015-08-04,Ultragenyx To Present At Upcoming Investor Conferences
2015-07-29,Short Interest Jumps 28.6% For RARE
2015-07-27,Analysts' Actions -- Cigna, Monster Beverage, Qualcomm and More
2015-07-21,Ultragenyx Announces Closing Of Public Offering Of Common Stock And Exercise Of Underwriters' Option To Purchase Additional Shares
2015-07-20,Ultragenyx Appoints John Pinion As Chief Quality Operations Officer And Senior Vice President, Analytical Sciences And Research
2015-07-15,Ultragenyx Announces Pricing Of Public Offering Of Common Stock
2015-07-14,Ultragenyx Announces Proposed Public Offering Of Common Stock
2015-07-09,Ultragenyx Releases Positive Interim 40-Week Bone Treatment Data From Ongoing Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
2015-07-01,10 Best Biotech Stocks in the NASDAQ
2015-06-25,Ultragenyx Names Daniel G. Welch As Chairman Of The Board
2015-06-22,Ultragenyx Appoints Jayson Dallas, M.D., As Chief Commercial Officer And Senior Vice President
2015-06-17,Ultragenyx Pharmaceutical Larger Than S&P 500 Component QEP Resources
2015-06-17,Ultragenyx To Present At The JMP Securities Healthcare Conference
2015-06-08,Ultragenyx Announces Completion Of Enrollment In Phase 3 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7
2015-06-04,Ultragenyx Appoints Dennis Huang As Chief Technical Operations Officer And Senior Vice President
2015-06-03,Where the Money Was Made the Last 5 Years
2015-06-02,Ultragenyx Releases Positive 16-Week Interim Data From Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
2015-05-28,Ultragenyx Announces First Patient Enrolled In Global Phase 3 Study Of Aceneuramic Acid (Sialic Acid) Extended Release In GNE Myopathy
2015-05-26,Ultragenyx To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-11,Ultragenyx Reports First Quarter 2015 Financial Results And Corporate Update
2015-05-05,Ultragenyx To Host Conference Call For First Quarter 2015 Financial Results And Corporate Update
2015-04-23,Ultragenyx Granted Additional Orphan Drug Designations For Triheptanoin
2015-04-22,Ultragenyx Announces Positive Data From Investigator-Sponsored Trial Of Triheptanoin In Glucose Transporter Type-1 Deficiency Syndrome
2015-04-13,Ultragenyx Appoints Daniel G. Welch To Board Of Directors
2015-03-25,Ultragenyx Reports Fourth Quarter And Full-Year 2014 Financial Results And Corporate Update
2015-03-20,Ultragenyx To Host Conference Call For Fourth Quarter And Full-Year 2014 Financial Results And Corporate Update
2015-03-09,Ultragenyx Announces Presentation Of Disease Burden Data In Adult Patients With X-Linked Hypophosphatemia
2015-03-05,Use Options For A Chance To Buy RARE At A 31% Discount
2015-03-04,Ultragenyx To Present At The Barclays Global Healthcare Conference
2015-02-25,Ultragenyx To Present At The Cowen And Company 35th Annual Health Care Conference In Boston
2015-02-24,Ultragenyx Appoints Michael Narachi To Board Of Directors
2015-02-17,Ultragenyx Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-02-10,Ultragenyx Announces Positive 36-Week Data From Phase 1/2 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis 7
2015-02-04,Ultragenyx Announces Pricing Of Public Offering Of Common Stock
2015-02-03,Ultragenyx Announces Proposed Public Offering Of Common Stock
2015-01-12,Ultragenyx Announces Intent To File For Conditional Approval In Europe For Sialic Acid Extended-Release Tablets In Hereditary Inclusion Body Myopathy
2015-01-07,Ultragenyx Announces License Of Intellectual Property Related To The Treatment Of Huntington's Disease With Triheptanoin
2015-01-06,Ultragenyx Initiates New Development Program Studying KRN23 For The Treatment Of Tumor-Induced Osteomalacia
2015-01-05,Ultragenyx To Present At The J.P. Morgan Healthcare Conference
2014-12-15,Ultragenyx Announces Initiation Of Phase 3 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7
2014-12-03,Ultragenyx To Present At The Oppenheimer Healthcare Conference
2014-11-10,Ultragenyx Reports Third Quarter 2014 Financial Results And Corporate Update
2014-11-04,Ultragenyx To Present At The Credit Suisse Annual Healthcare Conference
2014-10-30,Ultragenyx Granted EU Orphan Drug Designation For KRN23 For The Treatment Of X-Linked Hypophosphatemia
2014-10-27,Ultragenyx Granted Orphan Drug Designation For Triheptanoin For The Treatment Of Glucose Transporter Type-1 Deficiency Syndrome
2014-10-20,Use Options For a Chance To Buy RARE at a 31% Discount
2014-10-13,Ultragenyx Announces Interim Data From Phase 2 Extension Study Of Sialic Acid Extended-Release At International Congress Of The World Muscle Society
2014-09-24,Ultragenyx To Present At The Leerink Partners Rare Disease Roundtable
2014-09-15,Ultragenyx Announces Positive Results From A Long-Term Phase 1/2 Study Of KRN23 In Adult Patients With X-Linked Hypophosphatemia
2014-09-04,Ultragenyx To Present At The Morgan Stanley Global Healthcare Conference
2014-09-03,Ultragenyx Announces Positive Interim Data From Phase 1/2 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis 7
2014-08-27,Ultragenyx To Present At The Baird Health Care Conference
2014-08-26,3 Big-Volume Biotech Stocks to Trade for Breakouts
2014-08-12,Ultragenyx Pharmaceutical Stock Sees Short Interest Expand By 33.2%
2014-08-11,Ultragenyx Reports Second Quarter 2014 Financial Results And Corporate Update
2014-08-07,3 Big-Volume Biotech Stocks to Trade for Breakouts
2014-08-06,Ultragenyx To Present At Upcoming Investor Conferences
2014-08-05,Ultragenyx Announces License Of Intellectual Property For The Treatment Of Epilepsy And Other Seizure-Related Disorders With Triheptanoin
2014-07-31,3 Biotech Stocks Breaking Out on Big Volume
2014-07-25,Short Interest In Ultragenyx Pharmaceutical Decreases By 17%
2014-07-23,Ultragenyx Appoints Sunil Agarwal, M.D. As Chief Medical Officer And Senior Vice President
2014-07-21,3 Biotech Stocks Breaking Out on Big Volume
2014-07-14,Ultragenyx Announces Closing Of Public Offering Of Common Stock And Exercise Of Underwriters' Option To Purchase Additional Shares
2014-07-09,Ultragenyx Announces Pricing Of Public Offering Of Common Stock
2014-07-07,Ultragenyx Announces Proposed Public Offering Of Common Stock
2014-06-27,'Fast Money' Recap: Rangebound Treasury Yields
2014-06-21,'Mad Money' Lightning Round: Globalstar Is a Real Winner
2014-06-20,Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
2014-04-09,'Fast Money' Recap: S&P Snapback
2014-02-06,Top Insider Trades: DRNA RGLS RARE CARA
2007-09-18,Darden Earnings Jump
2007-08-21,Stockpickr Lists: Buffett Eyeing Countrywide?
2007-08-17,Friday's Winners & Losers: Rare Hospitality
2007-08-16,Darden Buying Rare
2007-07-13,Stock Upgrades, Downgrades from TheStreet.com Ratings
2007-04-27,Restaurants Reeking
2007-03-14,Rare Hospitality's Prospects Juicy
2007-02-16,Friday's Analysts' Upgrades and Downgrades
2007-01-18,Thursday's Analysts' Upgrades and Downgrades
2005-10-20,Stocks in Motion: MoneyGram
2004-02-05,A Rare Find Among Restaurants
2004-01-22,A New Year, a New Barrel
2004-01-16,Restaurant Stocks Survive Mad Cow
2004-01-12,Nasdaq Hits a New 30-Month High
2003-10-08,Restaurant Earnings a Smorgasbord
2003-09-03,Bottom of the Barrel: Old-Timers Take the Field
2003-08-21,Bottom of the Barrel: The Art of the Sale
2003-04-07,Wendy's Same-Store Sales Dip
2003-04-04,Rare Hospitality Sees Earnings Rising
2003-03-19,Bottom of the Barrel: Small-Caps for Uncertain Times
2003-01-09,Bottom of the Barrel: Cleaning Out the Portfolio
2002-07-31,Bottom of the Barrel: Tropical Treat With Hawaiian Electric
2002-07-24,Bottom of the Barrel: What to Do When Everything Sinks
2002-04-10,Bottom of the Barrel: Heads and Tails of the First Quarter
2002-03-13,Bottom of the Barrel: The Portfolio Gets a Spring Cleaning
2002-02-20,Bottom of the Barrel: A Rare Chance in the Restaurant Business
2017-03-23,Biotech Premarket Movers: Insys, Ultragenyx, Alexion
2017-03-22,Ultragenyx Announces Topline Data From Phase 2 UX007 Glucose Transporter Type-1 Deficiency Syndrome Seizure Study
2017-03-02,Ultragenyx To Present At Upcoming Investor Conferences
2017-02-16,Ultragenyx Reports Fourth Quarter And Full Year 2016 Financial Results And Corporate Update
2017-02-10,Ultragenyx To Present At Leerink Partners Global Healthcare Conference
2017-02-09,Ultragenyx To Host Conference Call For Fourth Quarter And Full Year 2016 Financial Results And Corporate Update
2017-01-05,Ultragenyx And Kyowa Kirin International Announce Marketing Authorization Application For KRN23 Filed And Accepted For Review By European Medicines Agency
2017-01-04,Ultragenyx To Present At J.P. Morgan Healthcare Conference
2016-11-30,Ultragenyx Announces Positive Data From Phase 2 Study Of UX007 In Long-Chain Fatty Acid Oxidation Disorder Patients
2016-11-17,Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios
2016-11-11,Ultragenyx Announces Withdrawal Of Marketing Authorization Application For Aceneuramic Acid Prolonged Release (Ace-ER) In The European Union
2016-11-08,Ultragenyx To Present At Upcoming Investor Conferences
2016-11-07,Ultragenyx Reports Third Quarter 2016 Financial Results And Corporate Update
2016-10-31,Ultragenyx To Host Conference Call For Third Quarter 2016 Financial Results And Corporate Update
2016-10-26,Ultragenyx Announces First Patient Enrolled In Global Phase 3 Study Of KRN23 In Pediatric Patients With X-Linked Hypophosphatemia (XLH)
2016-09-27,Ultragenyx To Present At Leerink Partners Roundtable Series
2016-09-19,Ultragenyx Reports Positive Interim Data From Pediatric And Adult Phase 2 Studies Of KRN23 In X-Linked Hypophosphatemia
2016-09-18,Ultragenyx Reports Positive Interim Data From Phase 2 Study Of KRN23 For The Treatment Of Tumor-Induced Osteomalacia
2016-09-16,Ultragenyx To Host Conference Call To Discuss KRN23 Data Presented At ASBMR 2016 Annual Meeting
2016-09-01,Ultragenyx To Present At Baird 2016 Global Healthcare Conference
2016-08-23,Ultragenyx Announces KRN23 Data Presentations At ASBMR 2016 Annual Meeting
2016-08-09,Ultragenyx To Present At Upcoming Investor Conferences
2016-08-08,Ultragenyx Reports Second Quarter 2016 Financial Results And Corporate Update
2016-08-01,Ultragenyx To Host Conference Call For Second Quarter 2016 Financial Results And Corporate Update
2016-07-28,Ultragenyx Announces Completion Of Enrollment In Phase 3 Study Of KRN23 In Adults With X-Linked Hypophosphatemia (XLH)
2016-07-27,Ultragenyx Announces Completion Of Enrollment In Phase 3 Study Of Aceneuramic Acid Extended Release (Ace-ER) In GNE Myopathy
2016-07-26,These 5 Stocks Are Breaking Out This Summer
2016-07-14,Ultragenyx Announces Positive Topline Data From Phase 3 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7
2016-07-13,Ultragenyx To Present Phase 3 Data For Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7 (MPS 7) At 14th International Symposium On MPS And Related Diseases
2016-06-29,16 Biopharma Companies Besides Medivation That Are Attractive Targets
2016-06-28,Ultragenyx Receives Breakthrough Therapy Designation For KRN23 In Pediatric Patients With X-Linked Hypophosphatemia
2016-06-20,Ultragenyx Appoints Karah Parschauer As Executive Vice President, General Counsel
2016-06-07,Ultragenyx And Takeda Enter Into A Collaboration To Develop And Commercialize Therapies For Rare Genetic Diseases
2016-06-01,Ultragenyx To Present At Upcoming Investor Conferences
2016-05-09,Ultragenyx Reports First Quarter 2016 Financial Results And Corporate Update
2016-05-06,Ultragenyx To Present At Bank Of America Merrill Lynch Healthcare Conference
2016-04-29,Ultragenyx To Host Conference Call For First Quarter 2016 Financial Results And Corporate Update
2016-04-21,Ultragenyx Reports Positive Interim Data From Phase 2 Study Of KRN23 For The Treatment Of Tumor-Induced Osteomalacia
2016-03-23,Ultragenyx And Saint Louis University's Center For World Health And Medicine Announce Research Collaboration To Advance Muscular Dystrophy Treatment
2016-03-21,Ultragenyx Appoints Lars Ekman, M.D., Ph.D., To Board Of Directors
2016-03-02,Ultragenyx To Present At The Cowen And Company 36th Annual Health Care Conference
2016-03-01,Ultragenyx Announces Data Presentations Of RhGUS And RhPPCA At 12th Annual WORLD Symposium™
2016-02-25,Ultragenyx Reports Fourth Quarter 2015 And Full-Year 2015 Financial Results And Corporate Update
2016-02-19,Ultragenyx Pharmaceutical (RARE) Stock Gets 'Outperform' Rating at Leerink
2016-02-18,Ultragenyx To Host Conference Call For Fourth Quarter And Full-Year 2015 Financial Results And Corporate Update
2016-02-09,Ultragenyx To Present At The Leerink Partners Annual Healthcare Conference
2016-01-05,Ultragenyx To Present At The J.P. Morgan Healthcare Conference
2015-12-03,Ultragenyx Announces First Patient Enrolled In Global Phase 3 Study Of KRN23 In Adults With X-Linked Hypophosphatemia (XLH)
2015-12-02,Ultragenyx To Present At The Oppenheimer Annual Healthcare Conference
2015-12-02,Ultragenyx Reports Positive Interim 40-Week Data From Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
2015-11-11,Ultragenyx To Present At Upcoming Investor Conferences
2015-11-09,Ultragenyx Reports Third Quarter 2015 Financial Results And Corporate Update
2015-11-06,Ultragenyx Announces Update To UX007 Development Program In Glucose Transporter Type-1 Deficiency Syndrome
2015-11-03,Ultragenyx To Present At The Credit Suisse Annual Healthcare Conference
2015-11-03,Ultragenyx To Host Conference Call For Third Quarter 2015 Financial Results And Corporate Update
2015-10-29,Ultragenyx Pharmaceutical And Arcturus Therapeutics Announce A Research Collaboration And License Agreement To Develop RNA Therapeutics For Rare Diseases
2015-10-29,Ultragenyx Pharmaceutical And Arcturus Therapeutics Announce A Research Collaboration And License Agreement To Develop RNA Therapeutics For Rare Diseases
2015-10-13,Short Interest In Ultragenyx Pharmaceutical Falls 16.8%
2015-10-13,Ultragenyx Announces Positive Interim Data From Phase 2 Study Of UX007 In Long-Chain Fatty Acid Oxidation Disorder Patients
2015-10-02,Ultragenyx Announces Aceneuramic Acid Prolonged Release Marketing Authorization Application Filed And Accepted For Review By European Medicines Agency
2015-09-04,Battleground: Will This $5 Biotech Stock Go To $22 Or $1.50?
2015-09-02,Ultragenyx To Present At The Baird Health Care Conference
2015-09-01,Ultragenyx Announces Presentation Of Data From Long-Chain Fatty Acid Oxidation Disorder Patients With Cardiomyopathy Treated With Triheptanoin
2015-08-13,Ultragenyx Reports Second Quarter 2015 Financial Results And Corporate Update
2015-08-13,Ultragenyx Pharmaceutical Stock Sees Short Interest Decline 25.7%
2015-08-06,Ultragenyx To Host Conference Call For Second Quarter 2015 Financial Results And Corporate Update
2015-08-05,Ultragenyx Announces Initiation Of Phase 2 Study Of Recombinant Human Beta-Glucuronidase In Patients Under Five Years Old With Mucopolysaccharidosis 7
2015-08-04,Ultragenyx To Present At Upcoming Investor Conferences
2015-07-29,Short Interest Jumps 28.6% For RARE
2015-07-27,Analysts' Actions -- Cigna, Monster Beverage, Qualcomm and More
2015-07-21,Ultragenyx Announces Closing Of Public Offering Of Common Stock And Exercise Of Underwriters' Option To Purchase Additional Shares
2015-07-20,Ultragenyx Appoints John Pinion As Chief Quality Operations Officer And Senior Vice President, Analytical Sciences And Research
2015-07-15,Ultragenyx Announces Pricing Of Public Offering Of Common Stock
2015-07-14,Ultragenyx Announces Proposed Public Offering Of Common Stock
2015-07-09,Ultragenyx Releases Positive Interim 40-Week Bone Treatment Data From Ongoing Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
2015-07-01,10 Best Biotech Stocks in the NASDAQ
2015-06-25,Ultragenyx Names Daniel G. Welch As Chairman Of The Board
2015-06-22,Ultragenyx Appoints Jayson Dallas, M.D., As Chief Commercial Officer And Senior Vice President
2015-06-17,Ultragenyx Pharmaceutical Larger Than S&P 500 Component QEP Resources
2015-06-17,Ultragenyx To Present At The JMP Securities Healthcare Conference
2015-06-08,Ultragenyx Announces Completion Of Enrollment In Phase 3 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7
2015-06-04,Ultragenyx Appoints Dennis Huang As Chief Technical Operations Officer And Senior Vice President
2015-06-03,Where the Money Was Made the Last 5 Years
2015-06-02,Ultragenyx Releases Positive 16-Week Interim Data From Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
2015-05-28,Ultragenyx Announces First Patient Enrolled In Global Phase 3 Study Of Aceneuramic Acid (Sialic Acid) Extended Release In GNE Myopathy
2015-05-26,Ultragenyx To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-11,Ultragenyx Reports First Quarter 2015 Financial Results And Corporate Update
2015-05-05,Ultragenyx To Host Conference Call For First Quarter 2015 Financial Results And Corporate Update
2015-04-23,Ultragenyx Granted Additional Orphan Drug Designations For Triheptanoin
2015-04-22,Ultragenyx Announces Positive Data From Investigator-Sponsored Trial Of Triheptanoin In Glucose Transporter Type-1 Deficiency Syndrome
2015-04-13,Ultragenyx Appoints Daniel G. Welch To Board Of Directors
2015-03-25,Ultragenyx Reports Fourth Quarter And Full-Year 2014 Financial Results And Corporate Update
2015-03-20,Ultragenyx To Host Conference Call For Fourth Quarter And Full-Year 2014 Financial Results And Corporate Update
2015-03-09,Ultragenyx Announces Presentation Of Disease Burden Data In Adult Patients With X-Linked Hypophosphatemia
2015-03-05,Use Options For A Chance To Buy RARE At A 31% Discount
2015-03-04,Ultragenyx To Present At The Barclays Global Healthcare Conference
2015-02-25,Ultragenyx To Present At The Cowen And Company 35th Annual Health Care Conference In Boston
2015-02-24,Ultragenyx Appoints Michael Narachi To Board Of Directors
2015-02-17,Ultragenyx Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-02-10,Ultragenyx Announces Positive 36-Week Data From Phase 1/2 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis 7
2015-02-04,Ultragenyx Announces Pricing Of Public Offering Of Common Stock
2015-02-03,Ultragenyx Announces Proposed Public Offering Of Common Stock
2015-01-12,Ultragenyx Announces Intent To File For Conditional Approval In Europe For Sialic Acid Extended-Release Tablets In Hereditary Inclusion Body Myopathy
2015-01-07,Ultragenyx Announces License Of Intellectual Property Related To The Treatment Of Huntington's Disease With Triheptanoin
2015-01-06,Ultragenyx Initiates New Development Program Studying KRN23 For The Treatment Of Tumor-Induced Osteomalacia
2015-01-05,Ultragenyx To Present At The J.P. Morgan Healthcare Conference
2014-12-15,Ultragenyx Announces Initiation Of Phase 3 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7
2014-12-03,Ultragenyx To Present At The Oppenheimer Healthcare Conference
2014-11-10,Ultragenyx Reports Third Quarter 2014 Financial Results And Corporate Update
2014-11-04,Ultragenyx To Present At The Credit Suisse Annual Healthcare Conference
2014-10-30,Ultragenyx Granted EU Orphan Drug Designation For KRN23 For The Treatment Of X-Linked Hypophosphatemia
2014-10-27,Ultragenyx Granted Orphan Drug Designation For Triheptanoin For The Treatment Of Glucose Transporter Type-1 Deficiency Syndrome
2014-10-20,Use Options For a Chance To Buy RARE at a 31% Discount
2014-10-13,Ultragenyx Announces Interim Data From Phase 2 Extension Study Of Sialic Acid Extended-Release At International Congress Of The World Muscle Society
2014-09-24,Ultragenyx To Present At The Leerink Partners Rare Disease Roundtable
2014-09-15,Ultragenyx Announces Positive Results From A Long-Term Phase 1/2 Study Of KRN23 In Adult Patients With X-Linked Hypophosphatemia
2014-09-04,Ultragenyx To Present At The Morgan Stanley Global Healthcare Conference
2014-09-03,Ultragenyx Announces Positive Interim Data From Phase 1/2 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis 7
2014-08-27,Ultragenyx To Present At The Baird Health Care Conference
2014-08-26,3 Big-Volume Biotech Stocks to Trade for Breakouts
2014-08-12,Ultragenyx Pharmaceutical Stock Sees Short Interest Expand By 33.2%
2014-08-11,Ultragenyx Reports Second Quarter 2014 Financial Results And Corporate Update
2014-08-07,3 Big-Volume Biotech Stocks to Trade for Breakouts
2014-08-06,Ultragenyx To Present At Upcoming Investor Conferences
2014-08-05,Ultragenyx Announces License Of Intellectual Property For The Treatment Of Epilepsy And Other Seizure-Related Disorders With Triheptanoin
2014-07-31,3 Biotech Stocks Breaking Out on Big Volume
2014-07-25,Short Interest In Ultragenyx Pharmaceutical Decreases By 17%
2014-07-23,Ultragenyx Appoints Sunil Agarwal, M.D. As Chief Medical Officer And Senior Vice President
2014-07-21,3 Biotech Stocks Breaking Out on Big Volume
2014-07-14,Ultragenyx Announces Closing Of Public Offering Of Common Stock And Exercise Of Underwriters' Option To Purchase Additional Shares
2014-07-09,Ultragenyx Announces Pricing Of Public Offering Of Common Stock
2014-07-07,Ultragenyx Announces Proposed Public Offering Of Common Stock
2014-06-27,'Fast Money' Recap: Rangebound Treasury Yields
2014-06-21,'Mad Money' Lightning Round: Globalstar Is a Real Winner
2014-06-20,Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
2014-04-09,'Fast Money' Recap: S&P Snapback
2014-02-06,Top Insider Trades: DRNA RGLS RARE CARA
2007-09-18,Darden Earnings Jump
2007-08-21,Stockpickr Lists: Buffett Eyeing Countrywide?
2007-08-17,Friday's Winners & Losers: Rare Hospitality
2007-08-16,Darden Buying Rare
2007-07-13,Stock Upgrades, Downgrades from TheStreet.com Ratings
2007-04-27,Restaurants Reeking
2007-03-14,Rare Hospitality's Prospects Juicy
2007-02-16,Friday's Analysts' Upgrades and Downgrades
2007-01-18,Thursday's Analysts' Upgrades and Downgrades
2005-10-20,Stocks in Motion: MoneyGram
2004-02-05,A Rare Find Among Restaurants
2004-01-22,A New Year, a New Barrel
2004-01-16,Restaurant Stocks Survive Mad Cow
2004-01-12,Nasdaq Hits a New 30-Month High
2003-10-08,Restaurant Earnings a Smorgasbord
2003-09-03,Bottom of the Barrel: Old-Timers Take the Field
2003-08-21,Bottom of the Barrel: The Art of the Sale
2003-04-07,Wendy's Same-Store Sales Dip
2003-04-04,Rare Hospitality Sees Earnings Rising
2003-03-19,Bottom of the Barrel: Small-Caps for Uncertain Times
2003-01-09,Bottom of the Barrel: Cleaning Out the Portfolio
2002-07-31,Bottom of the Barrel: Tropical Treat With Hawaiian Electric
2002-07-24,Bottom of the Barrel: What to Do When Everything Sinks
2002-04-10,Bottom of the Barrel: Heads and Tails of the First Quarter
2002-03-13,Bottom of the Barrel: The Portfolio Gets a Spring Cleaning
2002-02-20,Bottom of the Barrel: A Rare Chance in the Restaurant Business
2017-03-23,Biotech Premarket Movers: Insys, Ultragenyx, Alexion
2017-03-22,Ultragenyx Announces Topline Data From Phase 2 UX007 Glucose Transporter Type-1 Deficiency Syndrome Seizure Study
2017-03-02,Ultragenyx To Present At Upcoming Investor Conferences
2017-02-16,Ultragenyx Reports Fourth Quarter And Full Year 2016 Financial Results And Corporate Update
2017-02-10,Ultragenyx To Present At Leerink Partners Global Healthcare Conference
2017-02-09,Ultragenyx To Host Conference Call For Fourth Quarter And Full Year 2016 Financial Results And Corporate Update
2017-01-05,Ultragenyx And Kyowa Kirin International Announce Marketing Authorization Application For KRN23 Filed And Accepted For Review By European Medicines Agency
2017-01-04,Ultragenyx To Present At J.P. Morgan Healthcare Conference
2016-11-30,Ultragenyx Announces Positive Data From Phase 2 Study Of UX007 In Long-Chain Fatty Acid Oxidation Disorder Patients
2016-11-17,Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios
2016-11-11,Ultragenyx Announces Withdrawal Of Marketing Authorization Application For Aceneuramic Acid Prolonged Release (Ace-ER) In The European Union
2016-11-08,Ultragenyx To Present At Upcoming Investor Conferences
2016-11-07,Ultragenyx Reports Third Quarter 2016 Financial Results And Corporate Update
2016-10-31,Ultragenyx To Host Conference Call For Third Quarter 2016 Financial Results And Corporate Update
2016-10-26,Ultragenyx Announces First Patient Enrolled In Global Phase 3 Study Of KRN23 In Pediatric Patients With X-Linked Hypophosphatemia (XLH)
2016-09-27,Ultragenyx To Present At Leerink Partners Roundtable Series
2016-09-19,Ultragenyx Reports Positive Interim Data From Pediatric And Adult Phase 2 Studies Of KRN23 In X-Linked Hypophosphatemia
2016-09-18,Ultragenyx Reports Positive Interim Data From Phase 2 Study Of KRN23 For The Treatment Of Tumor-Induced Osteomalacia
2016-09-16,Ultragenyx To Host Conference Call To Discuss KRN23 Data Presented At ASBMR 2016 Annual Meeting
2016-09-01,Ultragenyx To Present At Baird 2016 Global Healthcare Conference
2016-08-23,Ultragenyx Announces KRN23 Data Presentations At ASBMR 2016 Annual Meeting
2016-08-09,Ultragenyx To Present At Upcoming Investor Conferences
2016-08-08,Ultragenyx Reports Second Quarter 2016 Financial Results And Corporate Update
2016-08-01,Ultragenyx To Host Conference Call For Second Quarter 2016 Financial Results And Corporate Update
2016-07-28,Ultragenyx Announces Completion Of Enrollment In Phase 3 Study Of KRN23 In Adults With X-Linked Hypophosphatemia (XLH)
2016-07-27,Ultragenyx Announces Completion Of Enrollment In Phase 3 Study Of Aceneuramic Acid Extended Release (Ace-ER) In GNE Myopathy
2016-07-26,These 5 Stocks Are Breaking Out This Summer
2016-07-14,Ultragenyx Announces Positive Topline Data From Phase 3 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7
2016-07-13,Ultragenyx To Present Phase 3 Data For Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7 (MPS 7) At 14th International Symposium On MPS And Related Diseases
2016-06-29,16 Biopharma Companies Besides Medivation That Are Attractive Targets
2016-06-28,Ultragenyx Receives Breakthrough Therapy Designation For KRN23 In Pediatric Patients With X-Linked Hypophosphatemia
2016-06-20,Ultragenyx Appoints Karah Parschauer As Executive Vice President, General Counsel
2016-06-07,Ultragenyx And Takeda Enter Into A Collaboration To Develop And Commercialize Therapies For Rare Genetic Diseases
2016-06-01,Ultragenyx To Present At Upcoming Investor Conferences
2016-05-09,Ultragenyx Reports First Quarter 2016 Financial Results And Corporate Update
2016-05-06,Ultragenyx To Present At Bank Of America Merrill Lynch Healthcare Conference
2016-04-29,Ultragenyx To Host Conference Call For First Quarter 2016 Financial Results And Corporate Update
2016-04-21,Ultragenyx Reports Positive Interim Data From Phase 2 Study Of KRN23 For The Treatment Of Tumor-Induced Osteomalacia
2016-03-23,Ultragenyx And Saint Louis University's Center For World Health And Medicine Announce Research Collaboration To Advance Muscular Dystrophy Treatment
2016-03-21,Ultragenyx Appoints Lars Ekman, M.D., Ph.D., To Board Of Directors
2016-03-02,Ultragenyx To Present At The Cowen And Company 36th Annual Health Care Conference
2016-03-01,Ultragenyx Announces Data Presentations Of RhGUS And RhPPCA At 12th Annual WORLD Symposium™
2016-02-25,Ultragenyx Reports Fourth Quarter 2015 And Full-Year 2015 Financial Results And Corporate Update
2016-02-19,Ultragenyx Pharmaceutical (RARE) Stock Gets 'Outperform' Rating at Leerink
2016-02-18,Ultragenyx To Host Conference Call For Fourth Quarter And Full-Year 2015 Financial Results And Corporate Update
2016-02-09,Ultragenyx To Present At The Leerink Partners Annual Healthcare Conference
2016-01-05,Ultragenyx To Present At The J.P. Morgan Healthcare Conference
2015-12-03,Ultragenyx Announces First Patient Enrolled In Global Phase 3 Study Of KRN23 In Adults With X-Linked Hypophosphatemia (XLH)
2015-12-02,Ultragenyx To Present At The Oppenheimer Annual Healthcare Conference
2015-12-02,Ultragenyx Reports Positive Interim 40-Week Data From Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
2015-11-11,Ultragenyx To Present At Upcoming Investor Conferences
2015-11-09,Ultragenyx Reports Third Quarter 2015 Financial Results And Corporate Update
2015-11-06,Ultragenyx Announces Update To UX007 Development Program In Glucose Transporter Type-1 Deficiency Syndrome
2015-11-03,Ultragenyx To Present At The Credit Suisse Annual Healthcare Conference
2015-11-03,Ultragenyx To Host Conference Call For Third Quarter 2015 Financial Results And Corporate Update
2015-10-29,Ultragenyx Pharmaceutical And Arcturus Therapeutics Announce A Research Collaboration And License Agreement To Develop RNA Therapeutics For Rare Diseases
2015-10-29,Ultragenyx Pharmaceutical And Arcturus Therapeutics Announce A Research Collaboration And License Agreement To Develop RNA Therapeutics For Rare Diseases
2015-10-13,Short Interest In Ultragenyx Pharmaceutical Falls 16.8%
2015-10-13,Ultragenyx Announces Positive Interim Data From Phase 2 Study Of UX007 In Long-Chain Fatty Acid Oxidation Disorder Patients
2015-10-02,Ultragenyx Announces Aceneuramic Acid Prolonged Release Marketing Authorization Application Filed And Accepted For Review By European Medicines Agency
2015-09-04,Battleground: Will This $5 Biotech Stock Go To $22 Or $1.50?
2015-09-02,Ultragenyx To Present At The Baird Health Care Conference
2015-09-01,Ultragenyx Announces Presentation Of Data From Long-Chain Fatty Acid Oxidation Disorder Patients With Cardiomyopathy Treated With Triheptanoin
2015-08-13,Ultragenyx Reports Second Quarter 2015 Financial Results And Corporate Update
2015-08-13,Ultragenyx Pharmaceutical Stock Sees Short Interest Decline 25.7%
2015-08-06,Ultragenyx To Host Conference Call For Second Quarter 2015 Financial Results And Corporate Update
2015-08-05,Ultragenyx Announces Initiation Of Phase 2 Study Of Recombinant Human Beta-Glucuronidase In Patients Under Five Years Old With Mucopolysaccharidosis 7
2015-08-04,Ultragenyx To Present At Upcoming Investor Conferences
2015-07-29,Short Interest Jumps 28.6% For RARE
2015-07-27,Analysts' Actions -- Cigna, Monster Beverage, Qualcomm and More
2015-07-21,Ultragenyx Announces Closing Of Public Offering Of Common Stock And Exercise Of Underwriters' Option To Purchase Additional Shares
2015-07-20,Ultragenyx Appoints John Pinion As Chief Quality Operations Officer And Senior Vice President, Analytical Sciences And Research
2015-07-15,Ultragenyx Announces Pricing Of Public Offering Of Common Stock
2015-07-14,Ultragenyx Announces Proposed Public Offering Of Common Stock
2015-07-09,Ultragenyx Releases Positive Interim 40-Week Bone Treatment Data From Ongoing Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
2015-07-01,10 Best Biotech Stocks in the NASDAQ
2015-06-25,Ultragenyx Names Daniel G. Welch As Chairman Of The Board
2015-06-22,Ultragenyx Appoints Jayson Dallas, M.D., As Chief Commercial Officer And Senior Vice President
2015-06-17,Ultragenyx Pharmaceutical Larger Than S&P 500 Component QEP Resources
2015-06-17,Ultragenyx To Present At The JMP Securities Healthcare Conference
2015-06-08,Ultragenyx Announces Completion Of Enrollment In Phase 3 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7
2015-06-04,Ultragenyx Appoints Dennis Huang As Chief Technical Operations Officer And Senior Vice President
2015-06-03,Where the Money Was Made the Last 5 Years
2015-06-02,Ultragenyx Releases Positive 16-Week Interim Data From Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
2015-05-28,Ultragenyx Announces First Patient Enrolled In Global Phase 3 Study Of Aceneuramic Acid (Sialic Acid) Extended Release In GNE Myopathy
2015-05-26,Ultragenyx To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-11,Ultragenyx Reports First Quarter 2015 Financial Results And Corporate Update
2015-05-05,Ultragenyx To Host Conference Call For First Quarter 2015 Financial Results And Corporate Update
2015-04-23,Ultragenyx Granted Additional Orphan Drug Designations For Triheptanoin
2015-04-22,Ultragenyx Announces Positive Data From Investigator-Sponsored Trial Of Triheptanoin In Glucose Transporter Type-1 Deficiency Syndrome
2015-04-13,Ultragenyx Appoints Daniel G. Welch To Board Of Directors
2015-03-25,Ultragenyx Reports Fourth Quarter And Full-Year 2014 Financial Results And Corporate Update
2015-03-20,Ultragenyx To Host Conference Call For Fourth Quarter And Full-Year 2014 Financial Results And Corporate Update
2015-03-09,Ultragenyx Announces Presentation Of Disease Burden Data In Adult Patients With X-Linked Hypophosphatemia
2015-03-05,Use Options For A Chance To Buy RARE At A 31% Discount
2015-03-04,Ultragenyx To Present At The Barclays Global Healthcare Conference
2015-02-25,Ultragenyx To Present At The Cowen And Company 35th Annual Health Care Conference In Boston
2015-02-24,Ultragenyx Appoints Michael Narachi To Board Of Directors
2015-02-17,Ultragenyx Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-02-10,Ultragenyx Announces Positive 36-Week Data From Phase 1/2 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis 7
2015-02-04,Ultragenyx Announces Pricing Of Public Offering Of Common Stock
2015-02-03,Ultragenyx Announces Proposed Public Offering Of Common Stock
2015-01-12,Ultragenyx Announces Intent To File For Conditional Approval In Europe For Sialic Acid Extended-Release Tablets In Hereditary Inclusion Body Myopathy
2015-01-07,Ultragenyx Announces License Of Intellectual Property Related To The Treatment Of Huntington's Disease With Triheptanoin
2015-01-06,Ultragenyx Initiates New Development Program Studying KRN23 For The Treatment Of Tumor-Induced Osteomalacia
2015-01-05,Ultragenyx To Present At The J.P. Morgan Healthcare Conference
2014-12-15,Ultragenyx Announces Initiation Of Phase 3 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7
2014-12-03,Ultragenyx To Present At The Oppenheimer Healthcare Conference
2014-11-10,Ultragenyx Reports Third Quarter 2014 Financial Results And Corporate Update
2014-11-04,Ultragenyx To Present At The Credit Suisse Annual Healthcare Conference
2014-10-30,Ultragenyx Granted EU Orphan Drug Designation For KRN23 For The Treatment Of X-Linked Hypophosphatemia
2014-10-27,Ultragenyx Granted Orphan Drug Designation For Triheptanoin For The Treatment Of Glucose Transporter Type-1 Deficiency Syndrome
2014-10-20,Use Options For a Chance To Buy RARE at a 31% Discount
2014-10-13,Ultragenyx Announces Interim Data From Phase 2 Extension Study Of Sialic Acid Extended-Release At International Congress Of The World Muscle Society
2014-09-24,Ultragenyx To Present At The Leerink Partners Rare Disease Roundtable
2014-09-15,Ultragenyx Announces Positive Results From A Long-Term Phase 1/2 Study Of KRN23 In Adult Patients With X-Linked Hypophosphatemia
2014-09-04,Ultragenyx To Present At The Morgan Stanley Global Healthcare Conference
2014-09-03,Ultragenyx Announces Positive Interim Data From Phase 1/2 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis 7
2014-08-27,Ultragenyx To Present At The Baird Health Care Conference
2014-08-26,3 Big-Volume Biotech Stocks to Trade for Breakouts
2014-08-12,Ultragenyx Pharmaceutical Stock Sees Short Interest Expand By 33.2%
2014-08-11,Ultragenyx Reports Second Quarter 2014 Financial Results And Corporate Update
2014-08-07,3 Big-Volume Biotech Stocks to Trade for Breakouts
2014-08-06,Ultragenyx To Present At Upcoming Investor Conferences
2014-08-05,Ultragenyx Announces License Of Intellectual Property For The Treatment Of Epilepsy And Other Seizure-Related Disorders With Triheptanoin
2014-07-31,3 Biotech Stocks Breaking Out on Big Volume
2014-07-25,Short Interest In Ultragenyx Pharmaceutical Decreases By 17%
2014-07-23,Ultragenyx Appoints Sunil Agarwal, M.D. As Chief Medical Officer And Senior Vice President
2014-07-21,3 Biotech Stocks Breaking Out on Big Volume
2014-07-14,Ultragenyx Announces Closing Of Public Offering Of Common Stock And Exercise Of Underwriters' Option To Purchase Additional Shares
2014-07-09,Ultragenyx Announces Pricing Of Public Offering Of Common Stock
2014-07-07,Ultragenyx Announces Proposed Public Offering Of Common Stock
2014-06-27,'Fast Money' Recap: Rangebound Treasury Yields
2014-06-21,'Mad Money' Lightning Round: Globalstar Is a Real Winner
2014-06-20,Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
2014-04-09,'Fast Money' Recap: S&P Snapback
2014-02-06,Top Insider Trades: DRNA RGLS RARE CARA
2007-09-18,Darden Earnings Jump
2007-08-21,Stockpickr Lists: Buffett Eyeing Countrywide?
2007-08-17,Friday's Winners & Losers: Rare Hospitality
2007-08-16,Darden Buying Rare
2007-07-13,Stock Upgrades, Downgrades from TheStreet.com Ratings
2007-04-27,Restaurants Reeking
2007-03-14,Rare Hospitality's Prospects Juicy
2007-02-16,Friday's Analysts' Upgrades and Downgrades
2007-01-18,Thursday's Analysts' Upgrades and Downgrades
2005-10-20,Stocks in Motion: MoneyGram
2004-02-05,A Rare Find Among Restaurants
2004-01-22,A New Year, a New Barrel
2004-01-16,Restaurant Stocks Survive Mad Cow
2004-01-12,Nasdaq Hits a New 30-Month High
2003-10-08,Restaurant Earnings a Smorgasbord
2003-09-03,Bottom of the Barrel: Old-Timers Take the Field
2003-08-21,Bottom of the Barrel: The Art of the Sale
2003-04-07,Wendy's Same-Store Sales Dip
2003-04-04,Rare Hospitality Sees Earnings Rising
2003-03-19,Bottom of the Barrel: Small-Caps for Uncertain Times
2003-01-09,Bottom of the Barrel: Cleaning Out the Portfolio
2002-07-31,Bottom of the Barrel: Tropical Treat With Hawaiian Electric
2002-07-24,Bottom of the Barrel: What to Do When Everything Sinks
2002-04-10,Bottom of the Barrel: Heads and Tails of the First Quarter
2002-03-13,Bottom of the Barrel: The Portfolio Gets a Spring Cleaning
2002-02-20,Bottom of the Barrel: A Rare Chance in the Restaurant Business
2017-03-22,RedHill Biopharma To Present At The 2017 MAP Conference
2017-03-21,RedHill Biopharma Announces First Patient Dosed In The Open-Label Extension Study To The Phase III Study With RHB-104 For Crohn's Disease
2017-03-13,RedHill Biopharma To Present At The BIO-Europe Spring 2017 Conference
2017-03-07,RedHill Biopharma's Co-Promotion Partner Concordia Announces U.S. District Court Grants Treble Damages Relating To Donnatal®
2017-03-06,3 Small Biotechs That Still Have Upside
2017-02-23,RedHill Biopharma Announces Availability Of Its Annual Report On Form 20-F Through Its Website
2017-02-23,RedHill Biopharma Reports 2016 Fourth Quarter And Full-Year Financial Results
2017-02-21,RedHill Biopharma Completes Treatment Of Last Patient In BEKINDA® Phase III Study For Acute Gastroenteritis
2017-02-16,RedHill Biopharma To Host Fourth Quarter And Full-Year 2016 Financial Results Conference Call On February 23, 2017
2017-02-13,RedHill Biopharma Announces Enrollment Of Last Patient In BEKINDA® Phase III Study For Acute Gastroenteritis
2017-02-06,RedHill Biopharma To Present At The BIO CEO & Investor Conference
2017-01-12,RedHill Biopharma Provides 2017 Semi-Annual Business Update
2017-01-11,RedHill Biopharma Announces QIDP Fast-Track Designation Granted By FDA To RHB-104 For Nontuberculous Mycobacteria Infections
2017-01-10,RedHill Biopharma Announces First Dosing In RHB-105 Supportive PK Studies Ahead Of Confirmatory Phase III Study For H. Pylori Infection
2017-01-09,RedHill Biopharma's RHB-105 Positive Phase III Study Results For H. Pylori Infection Presented At The Innovations In Gastroenterology 2017 Symposium
2017-01-09,RedHill Biopharma Announces Exercise Of Stock Options By Directors And Senior Management
2017-01-06,RedHill Biopharma Announces YELIVA® (ABC294640) Abstract Presentation At The 2017 Cholangiocarcinoma Foundation Annual Conference
2017-01-05,RedHill Biopharma Announces New Research Collaboration With Aarhus University For Oncology Drug MESUPRON
2017-01-04,RedHill Biopharma To Present The Positive Results Of The First Phase III Study With RHB-105 For H. Pylori Infection At The Innovations In Gastroenterology 2017 Symposium
2017-01-03,RedHill Biopharma Announces Exercise Of Underwriters' Option
2017-01-03,RedHill Biopharma Announces Exclusive U.S. Co-Promotion Agreement With Concordia For GI Drug Donnatal®
2016-12-28,RedHill Biopharma To Present At The Biotech Showcase 2017
2016-12-27,RedHill Biopharma Announces Closing Of Concurrent Public Offering And Registered Direct Offering Of Its American Depositary Shares And Warrants And Partial Exercise Of The Option Of Underwriters
2016-12-21,RedHill Biopharma Prices Concurrent Public Offering And Registered Direct Offering Of Its American Depositary Shares And Warrants 
2016-12-20,RedHill Biopharma Announces Proposed Concurrent Public Offering And Registered Direct Offering Of Its American Depositary Shares And Warrants
2016-12-19,RedHill Biopharma Announces First Patient Dosed In Phase Ib/II Study With YELIVA® For Multiple Myeloma
2016-12-14,RedHill Biopharma And IntelGenx Announce Definitive Agreement For Commercialization Of RIZAPORT® For Migraines With Pharmatronic Co. In South Korea
2016-12-13,RedHill Biopharma Announces Positive And Unanimous DSMB Recommendation For Continuation Of Phase III Study With RHB-104 For Crohn's Disease
2016-12-12,RedHill Biopharma Announces Phase IIa 48-Week Final Results Further Supporting Potential Of RHB-104 In Multiple Sclerosis
2016-12-05,RedHill Biopharma To Present At The Jefferies Microbiome Summit
2016-11-21,RedHill Biopharma Announces YELIVA™ (ABC294640) Poster Presentation At The 2016 EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium
2016-11-16,RedHill Biopharma To Present At The German Equity Forum 2016
2016-11-14,RedHill Biopharma Reports 2016 Third Quarter Financial Results
2016-11-10,RedHill Biopharma Reports Positive FDA Type B Meeting On RHB-105 For H. Pylori Infection Ahead Of Confirmatory Phase III Study
2016-11-07,RedHill Biopharma To Host Third Quarter 2016 Financial Results Conference Call On November 14, 2016
2016-11-07,RedHill Biopharma To Present At The Jefferies 2016 London Healthcare Conference
2016-11-03,RedHill Biopharma Provides Update On Ongoing Phase III And Phase II Studies With BEKINDA® And Expected Timing Of Top-Line Results
2016-11-02,RedHill Biopharma Announces Withdrawal Of Public Offering Of Its American Depositary Shares
2016-11-01,RedHill Biopharma To Host Investor Conference Call Today At 18:00 EDT Following Announcement Of Proposed Public Offering Of Its American Depository Shares
2016-11-01,RedHill Biopharma Announces Proposed Public Offering Of Its American Depository Shares
2016-10-31,RedHill Biopharma To Present At The BIO-Europe 2016 Conference
2016-10-18,RedHill Biopharma Announces Allowance Of A Patent In Japan Supporting RHB-104 For Multiple Sclerosis
2016-10-13,RedHill Biopharma To Present At The BIO Investor Forum 2016
2016-10-06,RedHill Biopharma To Host Webcast Today At 8:30 Am EDT Following Announcement Of Progress Update On RHB-104 Phase III Crohn's Disease Program Including The Introduction Of An Option For Early Stop For Success In Q2/2017
2016-10-06,RedHill Biopharma Provides Progress Update On RHB-104 Phase III Crohn's Disease Program And Introduces Option For Early Stop For Success In Q2/2017
2016-10-05,RedHill Biopharma Announces Initiation Of Phase II Study With YELIVA™ In Hepatocellular Carcinoma At The Medical University Of South Carolina
2016-09-27,RedHill Biopharma To Present At The BioNetwork West 2016 Partnering Summit
2016-09-21,RedHill Biopharma And IntelGenx Announce RIZAPORT® Commercialization Term Sheet With Pharmatronic Co. For Korea
2016-09-12,RedHill Biopharma Announces Research Collaboration With Stanford University For YELIVA™
2016-09-08,RedHill Biopharma Announces Phase Ib/II Study With YELIVA™ Initiated For Multiple Myeloma At A Leading U.S. Academic Medical Center
2016-09-01,RedHill Biopharma To Present At The 9th Annual BioPharm America International Partnering Conference
2016-08-31,RedHill Biopharma To Present At The Rodman & Renshaw 18th Annual Global Investment Conference
2016-08-29,RedHill Biopharma Announces Approval Of A European Patent Supporting RHB-104 For Multiple Sclerosis
2016-08-19,One Small Pharma Stock Has Big Potential
2016-08-11,RedHill Biopharma Provides 2016 Semi-Annual R&D Update
2016-08-01,RedHill Biopharma Announces Last Patient Visit In Phase IIa Study With RHB-104 For Multiple Sclerosis
2016-07-31,5 Small-Cap Biotechs With Big Potential
2016-07-29,5 Small-Cap Biotechs With Big Potential
2016-07-26,RedHill Biopharma Reports 2016 Second Quarter Financial Results
2016-07-21,RedHill Biopharma Receives Additional U.S. Patent Covering RHB-105 Ahead Of Confirmatory Phase III Study For H. Pylori Infection
2016-07-19,RedHill Biopharma To Host Second Quarter 2016 Financial Results Conference Call On July 26, 2016
2016-07-13,RedHill Biopharma Announces Research Collaboration With NIH For Potential Ebola Treatment
2016-07-05,RedHill Biopharma And IntelGenx Announce Definitive Agreement For Commercialization Of RIZAPORT™ For Migraines With Grupo JUSTE In Spain And Additional Potential Territories
2016-06-22,RedHill Biopharma Announces Publication Demonstrating Potential Efficacy Of RHB-104 For Crohn's Disease Associated With MAP Infection
2016-06-21,RedHill Biopharma Announces Positive Final Results With Primary And Secondary Endpoints Met In Phase 1 Study With YELIVA™ In Advanced Solid Tumors
2016-06-21,RedHill Biopharma Announces Positive Final Results With Primary And Secondary Endpoints Met In Phase 1 Study With YELIVA™ In Advanced Solid Tumors
2016-06-20,RedHill Biopharma Announces First Patients Dosed In Phase II Study With BEKINDA™ For IBS-D
2016-06-15,RedHill Biopharma To Present At JMP Securities Life Sciences Conference
2016-05-31,RedHill Biopharma To Present At The 2016 BIO International Convention
2016-05-30,RedHill Biopharma To Present At Jefferies 2016 Healthcare Conference
2016-05-04,RedHill Biopharma Announces National Cancer Institute Grant Supporting YELIVA™ Phase II Hepatocellular Carcinoma Study
2016-04-25,RedHill Biopharma To Present At BioNetwork East 2016 Partnering Summit
2016-04-20,RedHill Biopharma Reports 2016 First Quarter Financial Results
2016-04-19,RedHill Biopharma To Participate In The FBR & Co. Healthcare Series Focused On Infectious Diseases
2016-04-18,RedHill Biopharma Announces Positive FDA Meeting On RHB-105 Path To Approval And Planned Confirmatory Phase III Study For H. Pylori Infection
2016-04-13,RedHill Biopharma To Host First Quarter 2016 Financial Results Conference Call On April 20, 2016
2016-04-11,RedHill Biopharma Initiates Phase II Study Of BEKINDA™ For Irritable Bowel Syndrome
2016-03-31,RedHill Biopharma Announces Interim Results From Phase IIa Proof-of-Concept Study Supporting Therapeutic Potential Of RHB-104 In Multiple Sclerosis
2016-03-29,RedHill Biopharma And IntelGenx Announce RIZAPORT™ Commercialization Term Sheet With Grupo JUSTE For Spain And Additional Potential Territories
2016-03-28,RedHill Biopharma To Present At Bio-Europe Spring 2016 Conference
2016-03-10,RedHill Biopharma Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential Of YELIVA™ In Cholangiocarcinoma Cancer
2016-03-09,RedHill Biopharma To Present At The 28th Annual ROTH Conference
2016-03-08,RedHill Biopharma Reports Successful Final Results Of Phase III Study With RHB-105 For H. Pylori Infection
2016-03-01,RedHill Biopharma Provides 2016 R&D Update
2016-02-25,RedHill Biopharma Announces Availability Of Its Annual Report On Form 20-F Through Its Website
2016-02-25,RedHill Biopharma Reports 2015 Fourth Quarter And Full-Year Financial Results
2016-02-18,RedHill Biopharma Announces Notice Of Allowance For U.S. Patent Covering RIZAPORT™ For Migraines
2016-02-18,RedHill Biopharma To Host 2015 Fourth Quarter And Year-End Financial Results Conference Call On February 25, 2016
2016-02-17,RedHill Biopharma Appoints Dr. June S. Almenoff And Ms. Theresa M. Stevens To Advisory Board
2016-02-11,RedHill Biopharma Announces Successful PK Study With BEKINDA™ 12 Mg And Submission To FDA Of IBS-D Phase II Study Protocol
2016-02-10,RedHill Biopharma Receives Notice Of Allowance Of Fifth U.S. Patent Covering RHB-104 Phase III Crohn's Disease Program
2016-02-09,RedHill Biopharma Issues Letter To Shareholders
2016-02-08,RedHill Biopharma Announces Collaboration With Germany's Fraunhofer Institute For Oncology Drug RP101
2016-02-02,RedHill Biopharma To Present At The 18th Annual BIO CEO & Investor Conference
2016-01-05,RedHill Biopharma To Present At Biotech Showcase 2016
2015-12-30,RedHill Biopharma Announces Appointment Of Micha Ben Chorin As Chief Financial Officer
2015-12-15,RedHill Biopharma Announces Appointment Of Rick D. Scruggs To Board Of Directors
2015-11-30,RedHill Biopharma Announces Completion Of Dosing In Phase IIa Study Of RHB-104 For Multiple Sclerosis
2015-11-30,RedHill Biopharma Announces Passing Of Board Member Alicia Rotbard
2015-11-12,RedHill Biopharma To Present At The Jefferies Autumn 2015 Global Healthcare Conference
2015-11-09,RedHill Biopharma Reports Results For The Third Quarter Of 2015
2015-11-09,RedHill Biopharma And IntelGenx Announce First European Marketing Approval Of RIZAPORT(TM) (RHB-103) For Migraines
2015-10-29,RedHill Biopharma To Host Third Quarter 2015 Financial Results Conference Call On November 9, 2015
2015-10-28,RedHill Biopharma To Present At The BIO-Europe 2015 Conference
2015-10-26,RedHill Biopharma Announces Positive Top-line Results From YELIVA(TM) (ABC294640) Phase I Study In Advanced Solid Tumors
2015-10-26,RedHill Biopharma Announces Positive Top-line Results From YELIVA(TM) (ABC294640) Phase I Study In Advanced Solid Tumors
2015-10-22,RedHill Biopharma To Present At Gelbart-Kahana Biomed Conference On October 25, 2015
2015-10-22,RedHill Biopharma Announces Planned Management Changes
2015-10-22,RedHill Biopharma Announces National Cancer Institute Grant Awarded To Apogee Biotechnology Corp. For YELIVA(TM) (ABC294640) Prostate Cancer Research
2015-10-19,RedHill Biopharma To Present At The BioNetwork West Partnering Summit
2015-10-14,RedHill Biopharma Provides Update On BEKINDA(TM) Ongoing Phase III Study For Gastroenteritis And Announces Planned Phase II Study For IBS-D
2015-09-10,RedHill Biopharma And IntelGenx Announce RIZAPORT(TM) (RHB-103) Marketing Authorization Application Is Approvable Under The European Decentralized Procedure
2015-09-09,RedHill Biopharma Announces $2 Million National Cancer Institute Grant for YELIVA(TM) (ABC294640) Phase II Study for Multiple Myeloma
2015-09-08,RedHill Biopharma Announces Standard-of-Care Eradication Data From the RHB-105 Phase III Study Further Supporting the Study's Positive Results
2015-09-02,RedHill Biopharma To Present At The Rodman & Renshaw 17th Annual Global Investment Conference
2015-09-01,RedHill Biopharma Announces Last Patient Visit In The Phase I Study With YELIVA(TM) (ABC294640) For Advanced Solid Tumors
2015-08-27,RedHill Biopharma Receives Notice Of Allowance For New Israeli Patent Covering RHB-104 For The Treatment Of Crohn's Disease
2015-08-24,Ratings Changes Today
2015-08-24,RedHill Biopharma Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential Of ABC294640 (YELIVA(TM)) In Prostate Cancer
2015-08-12,RedHill Biopharma To Present RHB-104 Phase III Crohn's Program At The International Research Symposium On Crohn's Disease
2015-07-29,RedHill Biopharma Reports Results For The Second Quarter Of 2015
2015-07-27,RedHill Biopharma Provides Update On RHB-106 Program Partnered With Salix Pharmaceuticals
2015-07-23,RedHill Biopharma To Host Second Quarter 2015 Financial Results Conference Call On July 29, 2015
2015-07-22,RedHill Biopharma Announces Closing Of Public Offering Of Its American Depository Shares
2015-07-16,RedHill Biopharma Prices Public Offering Of Its American Depository Shares
2015-07-15,RedHill Biopharma Announces Size Of Proposed Public Offering Of Its American Depository Shares
2015-07-15,RedHill Biopharma Extends Option Agreement For Phase II-Stage Pancreatic Cancer Drug RP101
2015-07-14,RedHill Biopharma Announces Proposed Public Offering Of Its American Depository Shares
2015-07-06,RedHill Biopharma Receives Authorization In Australia And New Zealand For Ongoing Phase III Crohn's Disease Study With RHB-104
2015-07-01,RedHill Biopharma Receives Notice Of Allowance For Two Additional U.S. Patents Covering RHB-104 Ongoing Phase III Crohn's Disease Program
2015-06-29,RedHill Biopharma Initiates Phase I/II Study Of ABC294640 For Refractory Lymphoma
2015-06-19,Redhill Biopharma (RDHL) Is Weak On High Volume Today
2015-06-16,RedHill Biopharma Announces Acceptance Of Phase III Trial Application In Europe With RHB-104 For Crohn's Disease
2015-06-16,RedHill Biopharma To Present At The 2015 BIO International Convention
2015-06-15,RedHill Biopharma To Host Conference Call Today To Review Positive Phase III Top-Line Results With RHB-105 For H. Pylori Infection
2015-06-15,RedHill Biopharma Successfully Meets Primary Endpoint In Phase III Study Of RHB-105 For H. Pylori Infection
2015-06-09,RedHill Biopharma Announces Completion Of Patient Enrollment In The Phase IIa Study Of RHB-104 For Multiple Sclerosis
2015-06-08,RedHill Biopharma Completes Treatment Of Last Patient With RHB-105 In Phase III Study
2015-06-03,RedHill Biopharma Provides Update On Development Pipeline And Expected Timing For RHB-105 Phase III Top-Line Results
2015-05-27,RedHill Biopharma To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-18,RedHill Biopharma's Investor Webcast Forum Provides Update On The RHB-105 Phase III Program And Potential H. Pylori Eradication Market
2015-05-08,RedHill Biopharma To Present At The BioTrinity 2015 Partnering Conference
2015-05-07,RedHill Biopharma To Host Investor Webcast Forum Following Completion Of RHB-105 Dosing In Phase III Study
2015-05-04,Ratings Changes Today
2015-05-04,RedHill Biopharma To Present At The Oppenheimer 16th Annual Israeli Conference
2015-04-30,RedHill Biopharma Reports Results For The First Quarter Of 2015
2015-04-28,RedHill Biopharma To Present At The BioNetwork East 2015 Partnering Conference
2015-04-27,RedHill Biopharma Announces Completion Of Patient Enrollment In A Phase III Study Of RHB-105 For H. Pylori Infection
2015-04-21,RedHill Biopharma To Host First Quarter 2015 Financial Results Conference Call On April 30, 2015
2015-04-16,RedHill Biopharma Receives Notice Of Allowance For Additional U.S. Patent For RHB-105 H. Pylori Bacterial Infection Treatment
2015-03-31,RedHill Biopharma Acquires Phase II First-in-Class Oral Small Molecule SK2 Inhibitor From Apogee Biotech
2015-03-23,RedHill Biopharma To Present At The 3rd Annual Autoimmune & Inflammation Leaders' Forum 2015
2015-03-03,RedHill Biopharma To Present At VirtualInvestorConferences.com Online Event On March 5, 2015
2015-03-03,RedHill Biopharma To Present At Bio-Europe Spring 2015 International Partnering Conference
2015-03-03,RedHill Biopharma To Present At The 27th Annual ROTH Conference
2015-03-02,Positive Bioavailability Studies Of RedHill's BEKINDA(TM) To Be Presented At The 2015 American Society For Clinical Pharmacology And Therapeutics (ASCPT) Meeting
2015-02-26,RedHill Biopharma Reports 2014 Fourth Quarter And Year-End Financial Results
2015-02-19,RedHill Biopharma To Host 2014 Fourth Quarter And Year-End Financial Results Conference Call On February 26, 2015
2015-02-18,RedHill Biopharma Announces Full Exercise Of Underwriters' Over-Allotment Option
2015-02-13,RedHill Biopharma Announces Closing Of Public Offering Of Its American Depository Shares
2015-02-12,RedHill Biopharma To Present At The Life Sciences Israel(TM) 2015 3rd Annual International Partnering Conference
2015-02-10,RedHill Biopharma Prices Public Offering Of Its American Depository Shares
2015-02-09,RedHill Biopharma Announces Proposed Public Offering Of Its American Depository Shares
2015-01-29,RedHill Biopharma Provides Update On Progress With RHB-104 Ongoing Phase III Program For Crohn's Disease Following FDA Meeting
2015-01-28,RedHill Biopharma To Present At The 17th Annual BIO CEO & Investor Conference
2015-01-09,RedHill Biopharma To Present At Biotech Showcase(TM) 2015 Conference In San Francisco
2015-01-05,RedHill Biopharma Business Outlook And Anticipated Key Milestones For 2015
2014-12-31,RedHill Biopharma Announces Acceptance For Review Of BEKINDA(TM) European Marketing Application For Oncology Support
2014-12-18,RedHill Biopharma Acquires Technology From University Of Minnesota As Part Of Ongoing RHB-104 Phase III Crohn's Program
2014-12-17,RedHill Biopharma Announces First Patients Enrolled In The Phase III Study Of RHB-102 (BEKINDA(TM)) For Gastroenteritis And Gastritis
2014-12-09,RedHill Biopharma Submits BEKINDA(TM) (RHB-102) European Marketing Authorization Application For Oncology Support
2014-12-02,RedHill Biopharma To Sponsor And Exhibit Its Ongoing Phase III Crohn's Program At The Israeli IBD Society Meeting
2014-12-01,RedHill Biopharma And IntelGenx Announce Acceptance For Review Of European Marketing Application For RIZAPORT(TM) For Migraines
2014-11-10,FDA Grants QIDP Fast-Track Designation To RedHill Biopharma's Phase III H. Pylori Drug RHB-105
2014-11-10,RedHill Biopharma Reports Results For The Third Quarter Of 2014
2014-10-28,RedHill Biopharma To Host Third Quarter 2014 Financial Results Conference Call On November 10, 2014
2014-10-22,RedHill Biopharma To Present At The 20th Annual BIO-Europe International Partnering Conference
2014-10-08,Redhill Biopharma Ramat Gan is Now Oversold (RDHL)
2014-10-01,RedHill Biopharma And IntelGenx Submit European Marketing Authorization Application For Migraine Drug RIZAPORT(R) (formerly RHB-103)
2014-09-16,RedHill Biopharma To Present At The 14th Annual Biotech In Europe Forum For Global Partnering & Investment
2017-03-22,RedHill Biopharma To Present At The 2017 MAP Conference
2017-03-21,RedHill Biopharma Announces First Patient Dosed In The Open-Label Extension Study To The Phase III Study With RHB-104 For Crohn's Disease
2017-03-13,RedHill Biopharma To Present At The BIO-Europe Spring 2017 Conference
2017-03-07,RedHill Biopharma's Co-Promotion Partner Concordia Announces U.S. District Court Grants Treble Damages Relating To Donnatal®
2017-03-06,3 Small Biotechs That Still Have Upside
2017-02-23,RedHill Biopharma Announces Availability Of Its Annual Report On Form 20-F Through Its Website
2017-02-23,RedHill Biopharma Reports 2016 Fourth Quarter And Full-Year Financial Results
2017-02-21,RedHill Biopharma Completes Treatment Of Last Patient In BEKINDA® Phase III Study For Acute Gastroenteritis
2017-02-16,RedHill Biopharma To Host Fourth Quarter And Full-Year 2016 Financial Results Conference Call On February 23, 2017
2017-02-13,RedHill Biopharma Announces Enrollment Of Last Patient In BEKINDA® Phase III Study For Acute Gastroenteritis
2017-02-06,RedHill Biopharma To Present At The BIO CEO & Investor Conference
2017-01-12,RedHill Biopharma Provides 2017 Semi-Annual Business Update
2017-01-11,RedHill Biopharma Announces QIDP Fast-Track Designation Granted By FDA To RHB-104 For Nontuberculous Mycobacteria Infections
2017-01-10,RedHill Biopharma Announces First Dosing In RHB-105 Supportive PK Studies Ahead Of Confirmatory Phase III Study For H. Pylori Infection
2017-01-09,RedHill Biopharma's RHB-105 Positive Phase III Study Results For H. Pylori Infection Presented At The Innovations In Gastroenterology 2017 Symposium
2017-01-09,RedHill Biopharma Announces Exercise Of Stock Options By Directors And Senior Management
2017-01-06,RedHill Biopharma Announces YELIVA® (ABC294640) Abstract Presentation At The 2017 Cholangiocarcinoma Foundation Annual Conference
2017-01-05,RedHill Biopharma Announces New Research Collaboration With Aarhus University For Oncology Drug MESUPRON
2017-01-04,RedHill Biopharma To Present The Positive Results Of The First Phase III Study With RHB-105 For H. Pylori Infection At The Innovations In Gastroenterology 2017 Symposium
2017-01-03,RedHill Biopharma Announces Exercise Of Underwriters' Option
2017-01-03,RedHill Biopharma Announces Exclusive U.S. Co-Promotion Agreement With Concordia For GI Drug Donnatal®
2016-12-28,RedHill Biopharma To Present At The Biotech Showcase 2017
2016-12-27,RedHill Biopharma Announces Closing Of Concurrent Public Offering And Registered Direct Offering Of Its American Depositary Shares And Warrants And Partial Exercise Of The Option Of Underwriters
2016-12-21,RedHill Biopharma Prices Concurrent Public Offering And Registered Direct Offering Of Its American Depositary Shares And Warrants 
2016-12-20,RedHill Biopharma Announces Proposed Concurrent Public Offering And Registered Direct Offering Of Its American Depositary Shares And Warrants
2016-12-19,RedHill Biopharma Announces First Patient Dosed In Phase Ib/II Study With YELIVA® For Multiple Myeloma
2016-12-14,RedHill Biopharma And IntelGenx Announce Definitive Agreement For Commercialization Of RIZAPORT® For Migraines With Pharmatronic Co. In South Korea
2016-12-13,RedHill Biopharma Announces Positive And Unanimous DSMB Recommendation For Continuation Of Phase III Study With RHB-104 For Crohn's Disease
2016-12-12,RedHill Biopharma Announces Phase IIa 48-Week Final Results Further Supporting Potential Of RHB-104 In Multiple Sclerosis
2016-12-05,RedHill Biopharma To Present At The Jefferies Microbiome Summit
2016-11-21,RedHill Biopharma Announces YELIVA™ (ABC294640) Poster Presentation At The 2016 EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium
2016-11-16,RedHill Biopharma To Present At The German Equity Forum 2016
2016-11-14,RedHill Biopharma Reports 2016 Third Quarter Financial Results
2016-11-10,RedHill Biopharma Reports Positive FDA Type B Meeting On RHB-105 For H. Pylori Infection Ahead Of Confirmatory Phase III Study
2016-11-07,RedHill Biopharma To Host Third Quarter 2016 Financial Results Conference Call On November 14, 2016
2016-11-07,RedHill Biopharma To Present At The Jefferies 2016 London Healthcare Conference
2016-11-03,RedHill Biopharma Provides Update On Ongoing Phase III And Phase II Studies With BEKINDA® And Expected Timing Of Top-Line Results
2016-11-02,RedHill Biopharma Announces Withdrawal Of Public Offering Of Its American Depositary Shares
2016-11-01,RedHill Biopharma To Host Investor Conference Call Today At 18:00 EDT Following Announcement Of Proposed Public Offering Of Its American Depository Shares
2016-11-01,RedHill Biopharma Announces Proposed Public Offering Of Its American Depository Shares
2016-10-31,RedHill Biopharma To Present At The BIO-Europe 2016 Conference
2016-10-18,RedHill Biopharma Announces Allowance Of A Patent In Japan Supporting RHB-104 For Multiple Sclerosis
2016-10-13,RedHill Biopharma To Present At The BIO Investor Forum 2016
2016-10-06,RedHill Biopharma To Host Webcast Today At 8:30 Am EDT Following Announcement Of Progress Update On RHB-104 Phase III Crohn's Disease Program Including The Introduction Of An Option For Early Stop For Success In Q2/2017
2016-10-06,RedHill Biopharma Provides Progress Update On RHB-104 Phase III Crohn's Disease Program And Introduces Option For Early Stop For Success In Q2/2017
2016-10-05,RedHill Biopharma Announces Initiation Of Phase II Study With YELIVA™ In Hepatocellular Carcinoma At The Medical University Of South Carolina
2016-09-27,RedHill Biopharma To Present At The BioNetwork West 2016 Partnering Summit
2016-09-21,RedHill Biopharma And IntelGenx Announce RIZAPORT® Commercialization Term Sheet With Pharmatronic Co. For Korea
2016-09-12,RedHill Biopharma Announces Research Collaboration With Stanford University For YELIVA™
2016-09-08,RedHill Biopharma Announces Phase Ib/II Study With YELIVA™ Initiated For Multiple Myeloma At A Leading U.S. Academic Medical Center
2016-09-01,RedHill Biopharma To Present At The 9th Annual BioPharm America International Partnering Conference
2016-08-31,RedHill Biopharma To Present At The Rodman & Renshaw 18th Annual Global Investment Conference
2016-08-29,RedHill Biopharma Announces Approval Of A European Patent Supporting RHB-104 For Multiple Sclerosis
2016-08-19,One Small Pharma Stock Has Big Potential
2016-08-11,RedHill Biopharma Provides 2016 Semi-Annual R&D Update
2016-08-01,RedHill Biopharma Announces Last Patient Visit In Phase IIa Study With RHB-104 For Multiple Sclerosis
2016-07-31,5 Small-Cap Biotechs With Big Potential
2016-07-29,5 Small-Cap Biotechs With Big Potential
2016-07-26,RedHill Biopharma Reports 2016 Second Quarter Financial Results
2016-07-21,RedHill Biopharma Receives Additional U.S. Patent Covering RHB-105 Ahead Of Confirmatory Phase III Study For H. Pylori Infection
2016-07-19,RedHill Biopharma To Host Second Quarter 2016 Financial Results Conference Call On July 26, 2016
2016-07-13,RedHill Biopharma Announces Research Collaboration With NIH For Potential Ebola Treatment
2016-07-05,RedHill Biopharma And IntelGenx Announce Definitive Agreement For Commercialization Of RIZAPORT™ For Migraines With Grupo JUSTE In Spain And Additional Potential Territories
2016-06-22,RedHill Biopharma Announces Publication Demonstrating Potential Efficacy Of RHB-104 For Crohn's Disease Associated With MAP Infection
2016-06-21,RedHill Biopharma Announces Positive Final Results With Primary And Secondary Endpoints Met In Phase 1 Study With YELIVA™ In Advanced Solid Tumors
2016-06-21,RedHill Biopharma Announces Positive Final Results With Primary And Secondary Endpoints Met In Phase 1 Study With YELIVA™ In Advanced Solid Tumors
2016-06-20,RedHill Biopharma Announces First Patients Dosed In Phase II Study With BEKINDA™ For IBS-D
2016-06-15,RedHill Biopharma To Present At JMP Securities Life Sciences Conference
2016-05-31,RedHill Biopharma To Present At The 2016 BIO International Convention
2016-05-30,RedHill Biopharma To Present At Jefferies 2016 Healthcare Conference
2016-05-04,RedHill Biopharma Announces National Cancer Institute Grant Supporting YELIVA™ Phase II Hepatocellular Carcinoma Study
2016-04-25,RedHill Biopharma To Present At BioNetwork East 2016 Partnering Summit
2016-04-20,RedHill Biopharma Reports 2016 First Quarter Financial Results
2016-04-19,RedHill Biopharma To Participate In The FBR & Co. Healthcare Series Focused On Infectious Diseases
2016-04-18,RedHill Biopharma Announces Positive FDA Meeting On RHB-105 Path To Approval And Planned Confirmatory Phase III Study For H. Pylori Infection
2016-04-13,RedHill Biopharma To Host First Quarter 2016 Financial Results Conference Call On April 20, 2016
2016-04-11,RedHill Biopharma Initiates Phase II Study Of BEKINDA™ For Irritable Bowel Syndrome
2016-03-31,RedHill Biopharma Announces Interim Results From Phase IIa Proof-of-Concept Study Supporting Therapeutic Potential Of RHB-104 In Multiple Sclerosis
2016-03-29,RedHill Biopharma And IntelGenx Announce RIZAPORT™ Commercialization Term Sheet With Grupo JUSTE For Spain And Additional Potential Territories
2016-03-28,RedHill Biopharma To Present At Bio-Europe Spring 2016 Conference
2016-03-10,RedHill Biopharma Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential Of YELIVA™ In Cholangiocarcinoma Cancer
2016-03-09,RedHill Biopharma To Present At The 28th Annual ROTH Conference
2016-03-08,RedHill Biopharma Reports Successful Final Results Of Phase III Study With RHB-105 For H. Pylori Infection
2016-03-01,RedHill Biopharma Provides 2016 R&D Update
2016-02-25,RedHill Biopharma Announces Availability Of Its Annual Report On Form 20-F Through Its Website
2016-02-25,RedHill Biopharma Reports 2015 Fourth Quarter And Full-Year Financial Results
2016-02-18,RedHill Biopharma Announces Notice Of Allowance For U.S. Patent Covering RIZAPORT™ For Migraines
2016-02-18,RedHill Biopharma To Host 2015 Fourth Quarter And Year-End Financial Results Conference Call On February 25, 2016
2016-02-17,RedHill Biopharma Appoints Dr. June S. Almenoff And Ms. Theresa M. Stevens To Advisory Board
2016-02-11,RedHill Biopharma Announces Successful PK Study With BEKINDA™ 12 Mg And Submission To FDA Of IBS-D Phase II Study Protocol
2016-02-10,RedHill Biopharma Receives Notice Of Allowance Of Fifth U.S. Patent Covering RHB-104 Phase III Crohn's Disease Program
2016-02-09,RedHill Biopharma Issues Letter To Shareholders
2016-02-08,RedHill Biopharma Announces Collaboration With Germany's Fraunhofer Institute For Oncology Drug RP101
2016-02-02,RedHill Biopharma To Present At The 18th Annual BIO CEO & Investor Conference
2016-01-05,RedHill Biopharma To Present At Biotech Showcase 2016
2015-12-30,RedHill Biopharma Announces Appointment Of Micha Ben Chorin As Chief Financial Officer
2015-12-15,RedHill Biopharma Announces Appointment Of Rick D. Scruggs To Board Of Directors
2015-11-30,RedHill Biopharma Announces Completion Of Dosing In Phase IIa Study Of RHB-104 For Multiple Sclerosis
2015-11-30,RedHill Biopharma Announces Passing Of Board Member Alicia Rotbard
2015-11-12,RedHill Biopharma To Present At The Jefferies Autumn 2015 Global Healthcare Conference
2015-11-09,RedHill Biopharma Reports Results For The Third Quarter Of 2015
2015-11-09,RedHill Biopharma And IntelGenx Announce First European Marketing Approval Of RIZAPORT(TM) (RHB-103) For Migraines
2015-10-29,RedHill Biopharma To Host Third Quarter 2015 Financial Results Conference Call On November 9, 2015
2015-10-28,RedHill Biopharma To Present At The BIO-Europe 2015 Conference
2015-10-26,RedHill Biopharma Announces Positive Top-line Results From YELIVA(TM) (ABC294640) Phase I Study In Advanced Solid Tumors
2015-10-26,RedHill Biopharma Announces Positive Top-line Results From YELIVA(TM) (ABC294640) Phase I Study In Advanced Solid Tumors
2015-10-22,RedHill Biopharma To Present At Gelbart-Kahana Biomed Conference On October 25, 2015
2015-10-22,RedHill Biopharma Announces Planned Management Changes
2015-10-22,RedHill Biopharma Announces National Cancer Institute Grant Awarded To Apogee Biotechnology Corp. For YELIVA(TM) (ABC294640) Prostate Cancer Research
2015-10-19,RedHill Biopharma To Present At The BioNetwork West Partnering Summit
2015-10-14,RedHill Biopharma Provides Update On BEKINDA(TM) Ongoing Phase III Study For Gastroenteritis And Announces Planned Phase II Study For IBS-D
2015-09-10,RedHill Biopharma And IntelGenx Announce RIZAPORT(TM) (RHB-103) Marketing Authorization Application Is Approvable Under The European Decentralized Procedure
2015-09-09,RedHill Biopharma Announces $2 Million National Cancer Institute Grant for YELIVA(TM) (ABC294640) Phase II Study for Multiple Myeloma
2015-09-08,RedHill Biopharma Announces Standard-of-Care Eradication Data From the RHB-105 Phase III Study Further Supporting the Study's Positive Results
2015-09-02,RedHill Biopharma To Present At The Rodman & Renshaw 17th Annual Global Investment Conference
2015-09-01,RedHill Biopharma Announces Last Patient Visit In The Phase I Study With YELIVA(TM) (ABC294640) For Advanced Solid Tumors
2015-08-27,RedHill Biopharma Receives Notice Of Allowance For New Israeli Patent Covering RHB-104 For The Treatment Of Crohn's Disease
2015-08-24,Ratings Changes Today
2015-08-24,RedHill Biopharma Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential Of ABC294640 (YELIVA(TM)) In Prostate Cancer
2015-08-12,RedHill Biopharma To Present RHB-104 Phase III Crohn's Program At The International Research Symposium On Crohn's Disease
2015-07-29,RedHill Biopharma Reports Results For The Second Quarter Of 2015
2015-07-27,RedHill Biopharma Provides Update On RHB-106 Program Partnered With Salix Pharmaceuticals
2015-07-23,RedHill Biopharma To Host Second Quarter 2015 Financial Results Conference Call On July 29, 2015
2015-07-22,RedHill Biopharma Announces Closing Of Public Offering Of Its American Depository Shares
2015-07-16,RedHill Biopharma Prices Public Offering Of Its American Depository Shares
2015-07-15,RedHill Biopharma Announces Size Of Proposed Public Offering Of Its American Depository Shares
2015-07-15,RedHill Biopharma Extends Option Agreement For Phase II-Stage Pancreatic Cancer Drug RP101
2015-07-14,RedHill Biopharma Announces Proposed Public Offering Of Its American Depository Shares
2015-07-06,RedHill Biopharma Receives Authorization In Australia And New Zealand For Ongoing Phase III Crohn's Disease Study With RHB-104
2015-07-01,RedHill Biopharma Receives Notice Of Allowance For Two Additional U.S. Patents Covering RHB-104 Ongoing Phase III Crohn's Disease Program
2015-06-29,RedHill Biopharma Initiates Phase I/II Study Of ABC294640 For Refractory Lymphoma
2015-06-19,Redhill Biopharma (RDHL) Is Weak On High Volume Today
2015-06-16,RedHill Biopharma Announces Acceptance Of Phase III Trial Application In Europe With RHB-104 For Crohn's Disease
2015-06-16,RedHill Biopharma To Present At The 2015 BIO International Convention
2015-06-15,RedHill Biopharma To Host Conference Call Today To Review Positive Phase III Top-Line Results With RHB-105 For H. Pylori Infection
2015-06-15,RedHill Biopharma Successfully Meets Primary Endpoint In Phase III Study Of RHB-105 For H. Pylori Infection
2015-06-09,RedHill Biopharma Announces Completion Of Patient Enrollment In The Phase IIa Study Of RHB-104 For Multiple Sclerosis
2015-06-08,RedHill Biopharma Completes Treatment Of Last Patient With RHB-105 In Phase III Study
2015-06-03,RedHill Biopharma Provides Update On Development Pipeline And Expected Timing For RHB-105 Phase III Top-Line Results
2015-05-27,RedHill Biopharma To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-18,RedHill Biopharma's Investor Webcast Forum Provides Update On The RHB-105 Phase III Program And Potential H. Pylori Eradication Market
2015-05-08,RedHill Biopharma To Present At The BioTrinity 2015 Partnering Conference
2015-05-07,RedHill Biopharma To Host Investor Webcast Forum Following Completion Of RHB-105 Dosing In Phase III Study
2015-05-04,Ratings Changes Today
2015-05-04,RedHill Biopharma To Present At The Oppenheimer 16th Annual Israeli Conference
2015-04-30,RedHill Biopharma Reports Results For The First Quarter Of 2015
2015-04-28,RedHill Biopharma To Present At The BioNetwork East 2015 Partnering Conference
2015-04-27,RedHill Biopharma Announces Completion Of Patient Enrollment In A Phase III Study Of RHB-105 For H. Pylori Infection
2015-04-21,RedHill Biopharma To Host First Quarter 2015 Financial Results Conference Call On April 30, 2015
2015-04-16,RedHill Biopharma Receives Notice Of Allowance For Additional U.S. Patent For RHB-105 H. Pylori Bacterial Infection Treatment
2015-03-31,RedHill Biopharma Acquires Phase II First-in-Class Oral Small Molecule SK2 Inhibitor From Apogee Biotech
2015-03-23,RedHill Biopharma To Present At The 3rd Annual Autoimmune & Inflammation Leaders' Forum 2015
2015-03-03,RedHill Biopharma To Present At VirtualInvestorConferences.com Online Event On March 5, 2015
2015-03-03,RedHill Biopharma To Present At Bio-Europe Spring 2015 International Partnering Conference
2015-03-03,RedHill Biopharma To Present At The 27th Annual ROTH Conference
2015-03-02,Positive Bioavailability Studies Of RedHill's BEKINDA(TM) To Be Presented At The 2015 American Society For Clinical Pharmacology And Therapeutics (ASCPT) Meeting
2015-02-26,RedHill Biopharma Reports 2014 Fourth Quarter And Year-End Financial Results
2015-02-19,RedHill Biopharma To Host 2014 Fourth Quarter And Year-End Financial Results Conference Call On February 26, 2015
2015-02-18,RedHill Biopharma Announces Full Exercise Of Underwriters' Over-Allotment Option
2015-02-13,RedHill Biopharma Announces Closing Of Public Offering Of Its American Depository Shares
2015-02-12,RedHill Biopharma To Present At The Life Sciences Israel(TM) 2015 3rd Annual International Partnering Conference
2015-02-10,RedHill Biopharma Prices Public Offering Of Its American Depository Shares
2015-02-09,RedHill Biopharma Announces Proposed Public Offering Of Its American Depository Shares
2015-01-29,RedHill Biopharma Provides Update On Progress With RHB-104 Ongoing Phase III Program For Crohn's Disease Following FDA Meeting
2015-01-28,RedHill Biopharma To Present At The 17th Annual BIO CEO & Investor Conference
2015-01-09,RedHill Biopharma To Present At Biotech Showcase(TM) 2015 Conference In San Francisco
2015-01-05,RedHill Biopharma Business Outlook And Anticipated Key Milestones For 2015
2014-12-31,RedHill Biopharma Announces Acceptance For Review Of BEKINDA(TM) European Marketing Application For Oncology Support
2014-12-18,RedHill Biopharma Acquires Technology From University Of Minnesota As Part Of Ongoing RHB-104 Phase III Crohn's Program
2014-12-17,RedHill Biopharma Announces First Patients Enrolled In The Phase III Study Of RHB-102 (BEKINDA(TM)) For Gastroenteritis And Gastritis
2014-12-09,RedHill Biopharma Submits BEKINDA(TM) (RHB-102) European Marketing Authorization Application For Oncology Support
2014-12-02,RedHill Biopharma To Sponsor And Exhibit Its Ongoing Phase III Crohn's Program At The Israeli IBD Society Meeting
2014-12-01,RedHill Biopharma And IntelGenx Announce Acceptance For Review Of European Marketing Application For RIZAPORT(TM) For Migraines
2014-11-10,FDA Grants QIDP Fast-Track Designation To RedHill Biopharma's Phase III H. Pylori Drug RHB-105
2014-11-10,RedHill Biopharma Reports Results For The Third Quarter Of 2014
2014-10-28,RedHill Biopharma To Host Third Quarter 2014 Financial Results Conference Call On November 10, 2014
2014-10-22,RedHill Biopharma To Present At The 20th Annual BIO-Europe International Partnering Conference
2014-10-08,Redhill Biopharma Ramat Gan is Now Oversold (RDHL)
2014-10-01,RedHill Biopharma And IntelGenx Submit European Marketing Authorization Application For Migraine Drug RIZAPORT(R) (formerly RHB-103)
2014-09-16,RedHill Biopharma To Present At The 14th Annual Biotech In Europe Forum For Global Partnering & Investment
2017-03-22,RedHill Biopharma To Present At The 2017 MAP Conference
2017-03-21,RedHill Biopharma Announces First Patient Dosed In The Open-Label Extension Study To The Phase III Study With RHB-104 For Crohn's Disease
2017-03-13,RedHill Biopharma To Present At The BIO-Europe Spring 2017 Conference
2017-03-07,RedHill Biopharma's Co-Promotion Partner Concordia Announces U.S. District Court Grants Treble Damages Relating To Donnatal®
2017-03-06,3 Small Biotechs That Still Have Upside
2017-02-23,RedHill Biopharma Announces Availability Of Its Annual Report On Form 20-F Through Its Website
2017-02-23,RedHill Biopharma Reports 2016 Fourth Quarter And Full-Year Financial Results
2017-02-21,RedHill Biopharma Completes Treatment Of Last Patient In BEKINDA® Phase III Study For Acute Gastroenteritis
2017-02-16,RedHill Biopharma To Host Fourth Quarter And Full-Year 2016 Financial Results Conference Call On February 23, 2017
2017-02-13,RedHill Biopharma Announces Enrollment Of Last Patient In BEKINDA® Phase III Study For Acute Gastroenteritis
2017-02-06,RedHill Biopharma To Present At The BIO CEO & Investor Conference
2017-01-12,RedHill Biopharma Provides 2017 Semi-Annual Business Update
2017-01-11,RedHill Biopharma Announces QIDP Fast-Track Designation Granted By FDA To RHB-104 For Nontuberculous Mycobacteria Infections
2017-01-10,RedHill Biopharma Announces First Dosing In RHB-105 Supportive PK Studies Ahead Of Confirmatory Phase III Study For H. Pylori Infection
2017-01-09,RedHill Biopharma's RHB-105 Positive Phase III Study Results For H. Pylori Infection Presented At The Innovations In Gastroenterology 2017 Symposium
2017-01-09,RedHill Biopharma Announces Exercise Of Stock Options By Directors And Senior Management
2017-01-06,RedHill Biopharma Announces YELIVA® (ABC294640) Abstract Presentation At The 2017 Cholangiocarcinoma Foundation Annual Conference
2017-01-05,RedHill Biopharma Announces New Research Collaboration With Aarhus University For Oncology Drug MESUPRON
2017-01-04,RedHill Biopharma To Present The Positive Results Of The First Phase III Study With RHB-105 For H. Pylori Infection At The Innovations In Gastroenterology 2017 Symposium
2017-01-03,RedHill Biopharma Announces Exercise Of Underwriters' Option
2017-01-03,RedHill Biopharma Announces Exclusive U.S. Co-Promotion Agreement With Concordia For GI Drug Donnatal®
2016-12-28,RedHill Biopharma To Present At The Biotech Showcase 2017
2016-12-27,RedHill Biopharma Announces Closing Of Concurrent Public Offering And Registered Direct Offering Of Its American Depositary Shares And Warrants And Partial Exercise Of The Option Of Underwriters
2016-12-21,RedHill Biopharma Prices Concurrent Public Offering And Registered Direct Offering Of Its American Depositary Shares And Warrants 
2016-12-20,RedHill Biopharma Announces Proposed Concurrent Public Offering And Registered Direct Offering Of Its American Depositary Shares And Warrants
2016-12-19,RedHill Biopharma Announces First Patient Dosed In Phase Ib/II Study With YELIVA® For Multiple Myeloma
2016-12-14,RedHill Biopharma And IntelGenx Announce Definitive Agreement For Commercialization Of RIZAPORT® For Migraines With Pharmatronic Co. In South Korea
2016-12-13,RedHill Biopharma Announces Positive And Unanimous DSMB Recommendation For Continuation Of Phase III Study With RHB-104 For Crohn's Disease
2016-12-12,RedHill Biopharma Announces Phase IIa 48-Week Final Results Further Supporting Potential Of RHB-104 In Multiple Sclerosis
2016-12-05,RedHill Biopharma To Present At The Jefferies Microbiome Summit
2016-11-21,RedHill Biopharma Announces YELIVA™ (ABC294640) Poster Presentation At The 2016 EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium
2016-11-16,RedHill Biopharma To Present At The German Equity Forum 2016
2016-11-14,RedHill Biopharma Reports 2016 Third Quarter Financial Results
2016-11-10,RedHill Biopharma Reports Positive FDA Type B Meeting On RHB-105 For H. Pylori Infection Ahead Of Confirmatory Phase III Study
2016-11-07,RedHill Biopharma To Host Third Quarter 2016 Financial Results Conference Call On November 14, 2016
2016-11-07,RedHill Biopharma To Present At The Jefferies 2016 London Healthcare Conference
2016-11-03,RedHill Biopharma Provides Update On Ongoing Phase III And Phase II Studies With BEKINDA® And Expected Timing Of Top-Line Results
2016-11-02,RedHill Biopharma Announces Withdrawal Of Public Offering Of Its American Depositary Shares
2016-11-01,RedHill Biopharma To Host Investor Conference Call Today At 18:00 EDT Following Announcement Of Proposed Public Offering Of Its American Depository Shares
2016-11-01,RedHill Biopharma Announces Proposed Public Offering Of Its American Depository Shares
2016-10-31,RedHill Biopharma To Present At The BIO-Europe 2016 Conference
2016-10-18,RedHill Biopharma Announces Allowance Of A Patent In Japan Supporting RHB-104 For Multiple Sclerosis
2016-10-13,RedHill Biopharma To Present At The BIO Investor Forum 2016
2016-10-06,RedHill Biopharma To Host Webcast Today At 8:30 Am EDT Following Announcement Of Progress Update On RHB-104 Phase III Crohn's Disease Program Including The Introduction Of An Option For Early Stop For Success In Q2/2017
2016-10-06,RedHill Biopharma Provides Progress Update On RHB-104 Phase III Crohn's Disease Program And Introduces Option For Early Stop For Success In Q2/2017
2016-10-05,RedHill Biopharma Announces Initiation Of Phase II Study With YELIVA™ In Hepatocellular Carcinoma At The Medical University Of South Carolina
2016-09-27,RedHill Biopharma To Present At The BioNetwork West 2016 Partnering Summit
2016-09-21,RedHill Biopharma And IntelGenx Announce RIZAPORT® Commercialization Term Sheet With Pharmatronic Co. For Korea
2016-09-12,RedHill Biopharma Announces Research Collaboration With Stanford University For YELIVA™
2016-09-08,RedHill Biopharma Announces Phase Ib/II Study With YELIVA™ Initiated For Multiple Myeloma At A Leading U.S. Academic Medical Center
2016-09-01,RedHill Biopharma To Present At The 9th Annual BioPharm America International Partnering Conference
2016-08-31,RedHill Biopharma To Present At The Rodman & Renshaw 18th Annual Global Investment Conference
2016-08-29,RedHill Biopharma Announces Approval Of A European Patent Supporting RHB-104 For Multiple Sclerosis
2016-08-19,One Small Pharma Stock Has Big Potential
2016-08-11,RedHill Biopharma Provides 2016 Semi-Annual R&D Update
2016-08-01,RedHill Biopharma Announces Last Patient Visit In Phase IIa Study With RHB-104 For Multiple Sclerosis
2016-07-31,5 Small-Cap Biotechs With Big Potential
2016-07-29,5 Small-Cap Biotechs With Big Potential
2016-07-26,RedHill Biopharma Reports 2016 Second Quarter Financial Results
2016-07-21,RedHill Biopharma Receives Additional U.S. Patent Covering RHB-105 Ahead Of Confirmatory Phase III Study For H. Pylori Infection
2016-07-19,RedHill Biopharma To Host Second Quarter 2016 Financial Results Conference Call On July 26, 2016
2016-07-13,RedHill Biopharma Announces Research Collaboration With NIH For Potential Ebola Treatment
2016-07-05,RedHill Biopharma And IntelGenx Announce Definitive Agreement For Commercialization Of RIZAPORT™ For Migraines With Grupo JUSTE In Spain And Additional Potential Territories
2016-06-22,RedHill Biopharma Announces Publication Demonstrating Potential Efficacy Of RHB-104 For Crohn's Disease Associated With MAP Infection
2016-06-21,RedHill Biopharma Announces Positive Final Results With Primary And Secondary Endpoints Met In Phase 1 Study With YELIVA™ In Advanced Solid Tumors
2016-06-21,RedHill Biopharma Announces Positive Final Results With Primary And Secondary Endpoints Met In Phase 1 Study With YELIVA™ In Advanced Solid Tumors
2016-06-20,RedHill Biopharma Announces First Patients Dosed In Phase II Study With BEKINDA™ For IBS-D
2016-06-15,RedHill Biopharma To Present At JMP Securities Life Sciences Conference
2016-05-31,RedHill Biopharma To Present At The 2016 BIO International Convention
2016-05-30,RedHill Biopharma To Present At Jefferies 2016 Healthcare Conference
2016-05-04,RedHill Biopharma Announces National Cancer Institute Grant Supporting YELIVA™ Phase II Hepatocellular Carcinoma Study
2016-04-25,RedHill Biopharma To Present At BioNetwork East 2016 Partnering Summit
2016-04-20,RedHill Biopharma Reports 2016 First Quarter Financial Results
2016-04-19,RedHill Biopharma To Participate In The FBR & Co. Healthcare Series Focused On Infectious Diseases
2016-04-18,RedHill Biopharma Announces Positive FDA Meeting On RHB-105 Path To Approval And Planned Confirmatory Phase III Study For H. Pylori Infection
2016-04-13,RedHill Biopharma To Host First Quarter 2016 Financial Results Conference Call On April 20, 2016
2016-04-11,RedHill Biopharma Initiates Phase II Study Of BEKINDA™ For Irritable Bowel Syndrome
2016-03-31,RedHill Biopharma Announces Interim Results From Phase IIa Proof-of-Concept Study Supporting Therapeutic Potential Of RHB-104 In Multiple Sclerosis
2016-03-29,RedHill Biopharma And IntelGenx Announce RIZAPORT™ Commercialization Term Sheet With Grupo JUSTE For Spain And Additional Potential Territories
2016-03-28,RedHill Biopharma To Present At Bio-Europe Spring 2016 Conference
2016-03-10,RedHill Biopharma Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential Of YELIVA™ In Cholangiocarcinoma Cancer
2016-03-09,RedHill Biopharma To Present At The 28th Annual ROTH Conference
2016-03-08,RedHill Biopharma Reports Successful Final Results Of Phase III Study With RHB-105 For H. Pylori Infection
2016-03-01,RedHill Biopharma Provides 2016 R&D Update
2016-02-25,RedHill Biopharma Announces Availability Of Its Annual Report On Form 20-F Through Its Website
2016-02-25,RedHill Biopharma Reports 2015 Fourth Quarter And Full-Year Financial Results
2016-02-18,RedHill Biopharma Announces Notice Of Allowance For U.S. Patent Covering RIZAPORT™ For Migraines
2016-02-18,RedHill Biopharma To Host 2015 Fourth Quarter And Year-End Financial Results Conference Call On February 25, 2016
2016-02-17,RedHill Biopharma Appoints Dr. June S. Almenoff And Ms. Theresa M. Stevens To Advisory Board
2016-02-11,RedHill Biopharma Announces Successful PK Study With BEKINDA™ 12 Mg And Submission To FDA Of IBS-D Phase II Study Protocol
2016-02-10,RedHill Biopharma Receives Notice Of Allowance Of Fifth U.S. Patent Covering RHB-104 Phase III Crohn's Disease Program
2016-02-09,RedHill Biopharma Issues Letter To Shareholders
2016-02-08,RedHill Biopharma Announces Collaboration With Germany's Fraunhofer Institute For Oncology Drug RP101
2016-02-02,RedHill Biopharma To Present At The 18th Annual BIO CEO & Investor Conference
2016-01-05,RedHill Biopharma To Present At Biotech Showcase 2016
2015-12-30,RedHill Biopharma Announces Appointment Of Micha Ben Chorin As Chief Financial Officer
2015-12-15,RedHill Biopharma Announces Appointment Of Rick D. Scruggs To Board Of Directors
2015-11-30,RedHill Biopharma Announces Completion Of Dosing In Phase IIa Study Of RHB-104 For Multiple Sclerosis
2015-11-30,RedHill Biopharma Announces Passing Of Board Member Alicia Rotbard
2015-11-12,RedHill Biopharma To Present At The Jefferies Autumn 2015 Global Healthcare Conference
2015-11-09,RedHill Biopharma Reports Results For The Third Quarter Of 2015
2015-11-09,RedHill Biopharma And IntelGenx Announce First European Marketing Approval Of RIZAPORT(TM) (RHB-103) For Migraines
2015-10-29,RedHill Biopharma To Host Third Quarter 2015 Financial Results Conference Call On November 9, 2015
2015-10-28,RedHill Biopharma To Present At The BIO-Europe 2015 Conference
2015-10-26,RedHill Biopharma Announces Positive Top-line Results From YELIVA(TM) (ABC294640) Phase I Study In Advanced Solid Tumors
2015-10-26,RedHill Biopharma Announces Positive Top-line Results From YELIVA(TM) (ABC294640) Phase I Study In Advanced Solid Tumors
2015-10-22,RedHill Biopharma To Present At Gelbart-Kahana Biomed Conference On October 25, 2015
2015-10-22,RedHill Biopharma Announces Planned Management Changes
2015-10-22,RedHill Biopharma Announces National Cancer Institute Grant Awarded To Apogee Biotechnology Corp. For YELIVA(TM) (ABC294640) Prostate Cancer Research
2015-10-19,RedHill Biopharma To Present At The BioNetwork West Partnering Summit
2015-10-14,RedHill Biopharma Provides Update On BEKINDA(TM) Ongoing Phase III Study For Gastroenteritis And Announces Planned Phase II Study For IBS-D
2015-09-10,RedHill Biopharma And IntelGenx Announce RIZAPORT(TM) (RHB-103) Marketing Authorization Application Is Approvable Under The European Decentralized Procedure
2015-09-09,RedHill Biopharma Announces $2 Million National Cancer Institute Grant for YELIVA(TM) (ABC294640) Phase II Study for Multiple Myeloma
2015-09-08,RedHill Biopharma Announces Standard-of-Care Eradication Data From the RHB-105 Phase III Study Further Supporting the Study's Positive Results
2015-09-02,RedHill Biopharma To Present At The Rodman & Renshaw 17th Annual Global Investment Conference
2015-09-01,RedHill Biopharma Announces Last Patient Visit In The Phase I Study With YELIVA(TM) (ABC294640) For Advanced Solid Tumors
2015-08-27,RedHill Biopharma Receives Notice Of Allowance For New Israeli Patent Covering RHB-104 For The Treatment Of Crohn's Disease
2015-08-24,Ratings Changes Today
2015-08-24,RedHill Biopharma Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential Of ABC294640 (YELIVA(TM)) In Prostate Cancer
2015-08-12,RedHill Biopharma To Present RHB-104 Phase III Crohn's Program At The International Research Symposium On Crohn's Disease
2015-07-29,RedHill Biopharma Reports Results For The Second Quarter Of 2015
2015-07-27,RedHill Biopharma Provides Update On RHB-106 Program Partnered With Salix Pharmaceuticals
2015-07-23,RedHill Biopharma To Host Second Quarter 2015 Financial Results Conference Call On July 29, 2015
2015-07-22,RedHill Biopharma Announces Closing Of Public Offering Of Its American Depository Shares
2015-07-16,RedHill Biopharma Prices Public Offering Of Its American Depository Shares
2015-07-15,RedHill Biopharma Announces Size Of Proposed Public Offering Of Its American Depository Shares
2015-07-15,RedHill Biopharma Extends Option Agreement For Phase II-Stage Pancreatic Cancer Drug RP101
2015-07-14,RedHill Biopharma Announces Proposed Public Offering Of Its American Depository Shares
2015-07-06,RedHill Biopharma Receives Authorization In Australia And New Zealand For Ongoing Phase III Crohn's Disease Study With RHB-104
2015-07-01,RedHill Biopharma Receives Notice Of Allowance For Two Additional U.S. Patents Covering RHB-104 Ongoing Phase III Crohn's Disease Program
2015-06-29,RedHill Biopharma Initiates Phase I/II Study Of ABC294640 For Refractory Lymphoma
2015-06-19,Redhill Biopharma (RDHL) Is Weak On High Volume Today
2015-06-16,RedHill Biopharma Announces Acceptance Of Phase III Trial Application In Europe With RHB-104 For Crohn's Disease
2015-06-16,RedHill Biopharma To Present At The 2015 BIO International Convention
2015-06-15,RedHill Biopharma To Host Conference Call Today To Review Positive Phase III Top-Line Results With RHB-105 For H. Pylori Infection
2015-06-15,RedHill Biopharma Successfully Meets Primary Endpoint In Phase III Study Of RHB-105 For H. Pylori Infection
2015-06-09,RedHill Biopharma Announces Completion Of Patient Enrollment In The Phase IIa Study Of RHB-104 For Multiple Sclerosis
2015-06-08,RedHill Biopharma Completes Treatment Of Last Patient With RHB-105 In Phase III Study
2015-06-03,RedHill Biopharma Provides Update On Development Pipeline And Expected Timing For RHB-105 Phase III Top-Line Results
2015-05-27,RedHill Biopharma To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-18,RedHill Biopharma's Investor Webcast Forum Provides Update On The RHB-105 Phase III Program And Potential H. Pylori Eradication Market
2015-05-08,RedHill Biopharma To Present At The BioTrinity 2015 Partnering Conference
2015-05-07,RedHill Biopharma To Host Investor Webcast Forum Following Completion Of RHB-105 Dosing In Phase III Study
2015-05-04,Ratings Changes Today
2015-05-04,RedHill Biopharma To Present At The Oppenheimer 16th Annual Israeli Conference
2015-04-30,RedHill Biopharma Reports Results For The First Quarter Of 2015
2015-04-28,RedHill Biopharma To Present At The BioNetwork East 2015 Partnering Conference
2015-04-27,RedHill Biopharma Announces Completion Of Patient Enrollment In A Phase III Study Of RHB-105 For H. Pylori Infection
2015-04-21,RedHill Biopharma To Host First Quarter 2015 Financial Results Conference Call On April 30, 2015
2015-04-16,RedHill Biopharma Receives Notice Of Allowance For Additional U.S. Patent For RHB-105 H. Pylori Bacterial Infection Treatment
2015-03-31,RedHill Biopharma Acquires Phase II First-in-Class Oral Small Molecule SK2 Inhibitor From Apogee Biotech
2015-03-23,RedHill Biopharma To Present At The 3rd Annual Autoimmune & Inflammation Leaders' Forum 2015
2015-03-03,RedHill Biopharma To Present At VirtualInvestorConferences.com Online Event On March 5, 2015
2015-03-03,RedHill Biopharma To Present At Bio-Europe Spring 2015 International Partnering Conference
2015-03-03,RedHill Biopharma To Present At The 27th Annual ROTH Conference
2015-03-02,Positive Bioavailability Studies Of RedHill's BEKINDA(TM) To Be Presented At The 2015 American Society For Clinical Pharmacology And Therapeutics (ASCPT) Meeting
2015-02-26,RedHill Biopharma Reports 2014 Fourth Quarter And Year-End Financial Results
2015-02-19,RedHill Biopharma To Host 2014 Fourth Quarter And Year-End Financial Results Conference Call On February 26, 2015
2015-02-18,RedHill Biopharma Announces Full Exercise Of Underwriters' Over-Allotment Option
2015-02-13,RedHill Biopharma Announces Closing Of Public Offering Of Its American Depository Shares
2015-02-12,RedHill Biopharma To Present At The Life Sciences Israel(TM) 2015 3rd Annual International Partnering Conference
2015-02-10,RedHill Biopharma Prices Public Offering Of Its American Depository Shares
2015-02-09,RedHill Biopharma Announces Proposed Public Offering Of Its American Depository Shares
2015-01-29,RedHill Biopharma Provides Update On Progress With RHB-104 Ongoing Phase III Program For Crohn's Disease Following FDA Meeting
2015-01-28,RedHill Biopharma To Present At The 17th Annual BIO CEO & Investor Conference
2015-01-09,RedHill Biopharma To Present At Biotech Showcase(TM) 2015 Conference In San Francisco
2015-01-05,RedHill Biopharma Business Outlook And Anticipated Key Milestones For 2015
2014-12-31,RedHill Biopharma Announces Acceptance For Review Of BEKINDA(TM) European Marketing Application For Oncology Support
2014-12-18,RedHill Biopharma Acquires Technology From University Of Minnesota As Part Of Ongoing RHB-104 Phase III Crohn's Program
2014-12-17,RedHill Biopharma Announces First Patients Enrolled In The Phase III Study Of RHB-102 (BEKINDA(TM)) For Gastroenteritis And Gastritis
2014-12-09,RedHill Biopharma Submits BEKINDA(TM) (RHB-102) European Marketing Authorization Application For Oncology Support
2014-12-02,RedHill Biopharma To Sponsor And Exhibit Its Ongoing Phase III Crohn's Program At The Israeli IBD Society Meeting
2014-12-01,RedHill Biopharma And IntelGenx Announce Acceptance For Review Of European Marketing Application For RIZAPORT(TM) For Migraines
2014-11-10,FDA Grants QIDP Fast-Track Designation To RedHill Biopharma's Phase III H. Pylori Drug RHB-105
2014-11-10,RedHill Biopharma Reports Results For The Third Quarter Of 2014
2014-10-28,RedHill Biopharma To Host Third Quarter 2014 Financial Results Conference Call On November 10, 2014
2014-10-22,RedHill Biopharma To Present At The 20th Annual BIO-Europe International Partnering Conference
2014-10-08,Redhill Biopharma Ramat Gan is Now Oversold (RDHL)
2014-10-01,RedHill Biopharma And IntelGenx Submit European Marketing Authorization Application For Migraine Drug RIZAPORT(R) (formerly RHB-103)
2014-09-16,RedHill Biopharma To Present At The 14th Annual Biotech In Europe Forum For Global Partnering & Investment
2017-03-21,First Week Of May 19th Options Trading For Radius Health (RDUS)
2017-03-15,5 Stocks Insiders Love Right Now
2017-03-10,Radius Health Receives Notification Of PDUFA Extension For Abaloparatide-SC
2017-02-28,Radius Health To Present At Cowen And Company 37th Annual Health Care Conference
2017-02-23,Radius Health Reports Fourth Quarter And Full Year 2016 Financial And Operating Results
2017-02-01,Mayo Clinic Proceedings Publishes Positive Results From The ACTIVExtend Clinical Trial Of Abaloparatide-SC In Postmenopausal Women With Osteoporosis
2017-01-31,Radius Health To Announce Fourth Quarter And Full Year 2016 Financial Results, Host Conference Call And Live Webcast On February 23, 2017
2017-01-25,Interesting RDUS Put And Call Options For March 17th
2017-01-06,Radius Health To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-08,Radius Presents Positive Phase I Data For Investigational Drug RAD1901 At The San Antonio Breast Cancer Symposium (SABCS) 2016
2016-11-03,Radius Health Reports Third Quarter 2016 Financial And Operating Results
2016-11-01,Radius Health To Present At The Credit Suisse 25th Annual Healthcare Conference
2016-10-18,'Mad Money' Lightning Round: Take Citi Over CIT Group
2016-10-17,Jim Cramer's 'Mad Money' Recap: Here's What's Ailing This Market
2016-10-17,Pardon Me, but I Have a Few Things to Say... Trump, Bernie, Radius, Ariad
2016-10-14,'Mad Money' Lightning Round: I'm Faithful to Opko Health's CEO
2016-10-13,Jim Cramer's 'Mad Money' Recap: Don't Play the Short-Term Market Game
2016-10-12,Radius Health To Announce Third Quarter 2016 Financial Results, Host Conference Call And Live Webcast On November 3, 2016
2016-09-29,Jim Cramer's Top Takeaways: Nike, Newell Brands, Paychex, Radius Health
2016-09-28,Jim Cramer's 'Mad Money' Recap: Don't Touch These 'Third Rail' Stocks
2016-09-19,Radius Presents Abaloparatide Transdermal Patch Development Program At American Society For Bone And Mineral Research (ASBMR) 2016 Annual Meeting
2016-09-18,Radius Announces Publication Of Additional Positive Results From The Phase 3 ACTIVE Trial Of Abaloparatide-SC In JBMR
2016-09-13,Short Interest Increases 11.4% For RDUS
2016-09-02,These 5 Stocks Are Poised for Big Breakouts
2016-08-30,Radius Health Announces Three Presentations On RAD1901 At The San Antonio Breast Cancer Symposium (SABCS) December 6-10, 2016
2016-08-16,JAMA Publishes Positive Phase 3 Data For Abaloparatide In Postmenopausal Women With Osteoporosis
2016-08-12,Overboarded Directors at Valeant, Yahoo! and Elsewhere Struggle With Activists, M&A
2016-08-10,Radius Health, Subject of Takeover Talk, Rises Again
2016-08-04,Radius Health Reports Second Quarter 2016 Financial And Operating Results
2016-08-02,Radius Health To Present At The 36th Annual Canaccord Genuity Growth Conference
2016-07-20,Radius Health Announces Multiple Presentations At The American Society For Bone And Mineral Research 2016 Annual Meeting September 16-19, 2016
2016-07-15,Radius Health To Announce Second Quarter 2016 Financial Results, Host Conference Call And Live Webcast On August 4, 2016
2016-07-14,'Mad Money' Lightning Round: I'm Not Turning My Back on Blackstone
2016-07-13,Jim Cramer's 'Mad Money' Recap: Is the Bull Resting or Out the Gate?
2016-07-05,Radius Health To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference
2016-06-28,5 Best-Positioned Biotech Stocks on Brexit Volatility
2016-06-01,Radius Health To Present At The Goldman Sachs Thirty-Seventh Annual 2016 Healthcare Conference
2016-05-31,Radius Announces FDA Acceptance For Filing Of New Drug Application For Abaloparatide-SC For The Treatment Of Postmenopausal Women With Osteoporosis
2016-05-13,Radius Health Announces New Employment Inducement Grants
2016-05-05,Radius Health Reports First Quarter 2016 Financial And Operating Results
2016-05-02,Radius Health To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference
2016-04-21,Radius Health To Present At The Deutsche Bank 41st Annual Health Care Conference
2016-04-15,Radius Announces Three Oral Presentations For Abaloparatide-SC At World Congress On Osteoporosis, Osteoarthritis And Musculoskeletal Disease
2016-04-12,Radius Health To Announce First Quarter 2016 Financial Results, Host Conference Call And Live Webcast On May 5, 2016
2016-04-01,Radius Health Announces New Employment Inducement Grants
2016-04-01,Radius Presents Analysis Results On Fracture Risk Reduction In Phase 3 ACTIVE Trial For Investigational Drug Abaloparatide-SC At The ENDO 2016 Annual Meeting
2016-04-01,Jim Cramer's Top Takeaways: Radius Health, Seres Therapeutics
2016-03-31,Jim Cramer's 'Mad Money' Recap: Good Riddance to a Roller-Coaster Quarter
2016-03-30,Radius Health Submits New Drug Application To The U.S. Food And Drug Administration For Abaloparatide-SC For The Treatment Of Postmenopausal Women With Osteoporosis
2016-03-22,'Mad Money' Lightning Round: I'm a Palo Alto Networks Guy
2016-03-21,Jim Cramer's 'Mad Money' Recap: Buy These Winners When the Smoke Clears
2016-03-11,Radius Health Announces New Employment Inducement Grants
2016-02-29,Radius Health To Present At The Cowen And Company 36th Annual Health Care Conference
2016-02-29,Radius Health (RDUS) Stock Price Target Cut at Cantor Fitzgerald
2016-02-25,Radius Health Reports Fourth Quarter And Full Year 2015 Financial And Operating Results
2016-02-24,Radius Health (RDUS) Stock Falls as Jefferies Cuts to 'Hold'
2016-02-24,Analysts' Actions -- Ford, Macy's, AT&amp;T, Walmart and More
2016-02-22,Here's Why Radius Health (RDUS) Stock Skyrocketed Today
2016-02-22,Amgen Osteoporosis Drug Lowers Spine Fracture Risk in Key Study
2016-02-02,Radius Health To Announce Fourth Quarter And Full Year 2015 Financial Results, Host Conference Call And Live Webcast On February 25, 2016
2016-01-28,Radius Health Announces Conference Call And Webcast To Provide An Update On Its Progress On Corporate Milestones, Including Its Clinical Collaboration For Investigational Drug RAD1901
2016-01-27,Radius Health Announces Clinical Collaboration With A Leading Pharmaceutical Company To Evaluate RAD1901 Combination Regimens In Advanced Breast Cancer
2016-01-25,Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan
2016-01-23,'Mad Money' Lightning Round: Hold Altria for the Long Term
2016-01-08,'Mad Money' Lightning Round: Take a Long-Term View on Radius Health
2016-01-07,Jim Cramer's 'Mad Money' Recap: New Rules for a Tanking Market
2015-12-23,Jim Cramer's 'Mad Money' Recap: The Sellers Have Left the Building
2015-12-22,Radius Health To Present At The 34th Annual J.P. Morgan Healthcare Conference
2015-12-11,'Mad Money' Lightning Round: Avoid Staples and Transocean
2015-12-10,Jim Cramer's 'Mad Money' Recap: Brace Yourself for the Fed
2015-12-07,Radius Health Appoints Former GlaxoSmithKline CEO Jean-Pierre Garnier To Board Of Directors
2015-12-07,Radius Health Announces Conference Call And Webcast On New Data For Investigational Drug RAD1901 To Be Presented At San Antonio Breast Cancer Symposium 2015
2015-12-04,Radius Announces European Medicines Agency Validates Marketing Authorization Application For Abaloparatide-SC For The Treatment Of Osteoporosis In Postmenopausal Women
2015-11-18,'Mad Money' Lightning Round: Procter & Gamble Is Done Going Down
2015-11-18,Jim Cramer's Top Takeaways: Radius, TJX, Home Depot, Walmart
2015-11-17,Jim Cramer's 'Mad Money' Recap: Why Good News Is Bad News in This Market
2015-11-17,Radius Health Has Submitted A Marketing Authorization Application For The Investigational Drug Abaloparatide-SC For The Treatment Of Postmenopausal Osteoporosis In Europe
2015-11-12,Radius Health To Host 2015 Investor Day On November 17th In New York City
2015-11-11,Radius Health To Present At The Goldman Sachs U.S. Emerging/SMID Cap Growth Conference
2015-11-05,Radius Health Reports Third Quarter 2015 Financial And Operating Results
2015-11-02,Radius Health To Present Promising Single-Agent Data For Investigational Oral Drug RAD1901 At 2015 American Association For Cancer Research - National Cancer Institute - European Organisation For Research And Treatment Of Cancer (AACR-NCI-EORTC) International Conference
2015-10-29,Jim Cramer -- Allergan May Get a Higher Bid from Pfizer; Biotech to Buy
2015-10-29,Jim Cramer Says Hold Allergan, as it May Not Take First Bid From Pfizer
2015-10-28,Radius Health To Announce Third Quarter 2015 Financial Results, Host Conference Call And Live Webcast On November 5, 2015
2015-10-20,Jim Cramer -- Microsoft, IBM Should Have Their Eyes on the Buys
2015-10-20,Jim Cramer Says Tech Giants Microsoft, IBM Should Make Acquisitions
2015-10-12,Investigational Drug Abaloparatide Reduces The Incidence Of Fractures In Postmenopausal Women With Osteoporosis
2015-10-10,Radius Health Presents Positive Phase 3 Top-Line Data For Investigational Osteoporosis Therapy Abaloparatide At The American Society For Bone And Mineral Research 2015 Annual Meeting
2015-10-10,'Mad Money' Lightning Round: Buy AT&T, Verizon, Walgreens Boots Alliance
2015-10-09,Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
2015-10-02,Strong Bounces Fill the Gaps
2015-09-25,'Mad Money' Lightning Round: IBM Is Getting Attractive
2015-09-24,Jim Cramer's 'Mad Money' Recap: Don't Take It Personal but Your Stocks Are Going Down
2015-09-22,Radius Health, Inc. Announces Webcast On Investigational Drug RAD1901, Upcoming Presentations And Investor Day In New York City On November 17th, 2015
2015-09-09,Radius Health Appoints Global Pharmaceutical Leader David P. Snow As Chief Commercial Officer
2015-08-26,5 Stocks Insiders Love Right Now
2015-08-18,Radius Health Announced That It Has Appointed Catherine Friedman To The Board Of Directors
2015-08-11,Jim Cramer's Top Takeaways: Radius Health, Inovio Pharmaceuticals
2015-08-11,'Mad Money' Lightning Round: Buy, Buy, Buy MGM Resorts
2015-08-10,Jim Cramer's 'Mad Money' Recap: 10 Things That Created Today's Market Rally
2015-08-06,Radius Health Reports Second Quarter 2015 Financial And Operating Results
2015-08-05,Radius Health To Present At The 35th Annual Canaccord Genuity Growth Conference
2015-07-30,Radius Health To Announce Second Quarter 2015 Financial Results, Host Conference Call And Live Webcast On August 6, 2015
2015-07-29,5 Stocks Insiders Love Right Now
2015-07-28,Radius Health, Inc. Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-07-27,Radius Health Announces That It Has Hired Dr. Lorraine Fitzpatrick, Former GlaxoSmithKline Development Leader For Denosumab, As Chief Medical Officer
2015-07-22,Radius Health, Inc. Announces Pricing Of Public Offering
2015-07-21,Radius Health, Inc. Announces Proposed Public Offering
2015-07-20,Radius Health Announced That It Has Appointed Debasish Roychowdhury, MD, To Its Board Of Directors And The Formation Of The Radius Oncology Clinical Advisory Board (OCAB)
2015-07-15,Radius Health Today Announced Preclinical Data For Its Investigational Drug RAD1901 In Combination With CDK And MTOR Inhibitors
2015-07-14,Radius Health Announces Multiple Presentations At The American Society For Bone And Mineral Research 2015 Annual Meeting
2015-07-08,What Will It Take to Boost Markets Back in the Green? Cramer Explains
2015-07-08,Jim Cramer: Expect Decline in Apple but Don't Trade It
2015-07-03,Blame the E.U.; Don't Ignore the Good News; ... But Stay Skeptical: Jim Cramer's Best Blogs
2015-07-01,Cramer Is Flying Southwest, Won't Recommend Sarepta Therapeutics
2015-07-01,Cramer Worried About Airline Overcapacity, Hints at Surprise McDonald's Piece
2015-06-30,Jim Cramer's 'Mad Money' Recap: Here Are the Stocks You Could've Picked Off Cheap
2015-06-30,Jim Cramer's Top Takeaways: Home Depot, Lowe's, Nike, G-III, Receptos
2015-06-29,Jim Cramer's 'Mad Money' Recap: What Were Those Delusional Bulls Thinking?
2015-06-23,Jim Cramer's Top Takeaways: UnitedHealth, Ambarella, Radius Health
2015-06-22,Jim Cramer's 'Mad Money' Recap: Let the Good Stocks Shine
2015-06-19,Jim Cramer's Top Takeaways: BioMarin, Radius Health, Allergan, Diageo, Wayfair
2015-06-18,Jim Cramer's 'Mad Money' Recap: Here's Why We Had a Rally Today
2015-06-18,Martha Stewart Surges on Deal Reports; Nasdaq Seals Record Close
2015-06-18,Jim Cramer -- BioMarin and Radius Health Deserve Today's Big Rally
2015-06-18,Radius Health (RDUS) Stock Spikes on Positive Top-Line Trial Data
2015-06-17,Radius Announces Positive Top-Line Data From ACTIVExtend Trial Including Combined 25 Month Results
2015-06-15,AXON, REGN, BURL, FIVE: Jim Cramer's Views
2015-06-03,Radius Health To Present At The Goldman Sachs Thirty-Sixth Annual 2015 Healthcare Conference
2015-06-01,Radius Health Announces Engagement With Myrtle Potter & Company For Development Of Abaloparatide Commercialization Strategy
2015-05-28,'Mad Money' Lightning Round: Buy, Buy, Buy Yahoo!, Not Alibaba
2015-05-27,Jim Cramer's 'Mad Money' Recap: 'Hit and Run' Investors Are the Worst
2015-05-27,Radius Health To Present At The Jefferies 2015 Health Care Conference
2015-05-13,Cramer: I Like Receptos and Radius, as Well as the Four Horsemen
2015-05-08,Radius Health To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference
2015-05-06,Radius Health Reports First Quarter 2015 Financial And Operating Results
2015-04-30,Radius Health To Present At The Deutsche Bank 40th Annual Health Care Conference
2015-04-28,Radius Health To Announce First Quarter 2015 Financial Results, Host Conference Call And Live Webcast On May 6, 2015
2015-04-16,The Top 5 Best IPO Performers in the Last Year
2015-04-10,Radius Health Today Announced That It Has Appointed Brent Hatzis-Schoch As Senior Vice President And General Counsel
2015-04-09,Radius Health Announces Upcoming Oral Presentation "Treatment With Abaloparatide Significantly Reduces Wrist Fractures Compared To Teriparatide" In The HOT TOPICS Session At The ECTS-IBMS 2015 Congress On April 28, 2015
2015-03-13,Radius Health To Present At The Bank Of America Merrill Lynch Smid Cap Conference
2015-03-11,5 Stocks Insiders Love Right Now
2015-03-10,Radius Health Reports Fourth Quarter And Full Year 2014 Financial And Operating Results
2015-03-09,Radius Health Announced Today That It Has Acquired The License To Develop And Market RAD1901 In Japan, And Has Hired Dinesh Purandare, Former Sanofi Oncology Executive To The Position Of Senior Vice President (SVP) And Head Of Global Oncology At Radius
2015-03-02,Radius Health Appoints Former Novartis Executive Tony Rosenberg To Board Of Directors
2015-02-26,Short Interest In Radius Health Jumps 30.8%
2015-02-24,Radius Health To Present At The BIO-Europe Spring 2015 Paris Expo March 9-11, 2015
2015-02-24,Radius Health To Present At The Cowen And Company 35th Annual Health Care Conference
2015-02-19,Radius Health To Announce Fourth Quarter And Full Year 2014 Financial Results, Host Conference Call And Live Webcast On March 10, 2015
2015-02-16,Radius Health To Present At The 2015 RBC Capital Markets Global Healthcare Conference
2015-02-06,Biotechs and Drugmakers Expected to Seek More Mergers in 2015
2015-02-05,14 IPOs You Wish You Bought in 2014 (and Made a Killing On)
2015-02-03,Radius Health To Present At 2015 BIO CEO Investor Conference To Be Held February 9th & 10th In New York City
2015-01-30,Jim Cramer's Top Stock Picks: BA MCD FB CLB RDUS
2015-01-29,Jim Cramer's 'Mad Money' Recap: The Bears Retreat and the Market Celebrates
2015-01-29,Radius Health Announces Oral Presentation Of The ACTIVE Phase 3 Clinical Trial Of Abaloparatide-SC For Postmenopausal Women With Osteoporosis At The International Society Of Endocrinology And The Endocrine Society (ICE/ENDO 2015)
2015-01-28,Radius Health, Inc. Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-01-27,Microsoft Dips As Long-Term Shift Spurs Short-Term Stumble
2015-01-22,Radius Health, Inc. Announces Pricing Of Public Offering
2015-01-20,Radius Health, Inc. Announces Proposed Public Offering
2015-01-12,Radius Announces Follow-Up On The Positive Phase 3 Top-Line Results For Its Investigational Drug Abaloparatide-SC In Postmenopausal Women With Severe Osteoporosis
2015-01-08,Here's the Best Way for Investors to Play the IPO Market
2014-12-21,Radius Announces Positive Phase 3 Top-Line Results For Its Investigational Drug Abaloparatide-SC In Postmenopausal Women With Severe Osteoporosis
2014-12-19,FDA Accepts IND Application For Radius Health's Investigational Drug RAD1901 Being Developed For Potential Use In Metastatic Breast Cancer
2014-12-18,Six Biotech and Technology Stocks With Strong Technical Set-Ups
2014-12-15,The NASDAQ OMX Group, Inc. Today Announced That Radius Health Will Be Added To Its Biotechnology Index Effective Before Market Open On Monday, December 22, 2014
2014-12-11,Radius Health Presents RAD1901 Data At 2014 San Antonio Breast Cancer Symposium
2014-11-24,The Journal Of Clinical Endocrinology & Metabolism Publishes Radius Health's Phase II Study Of The Investigational Drug Abaloparatide In Postmenopausal Women With Osteoporosis
2014-11-17,Radius Health's Investigational Drug RAD1901 Selected As One Of Informa And Kantar Health's 2014 Top 10 Most Interesting Oncology Projects To Watch
2014-11-17,Radius Health To Present At The Jefferies 2014 Global London Healthcare Conference
2014-11-13,King Digital Entertainment Gains On Game Launch
2014-11-11,Rackspace Bounces, Making Dan Loeb $34 Million In The Process
2014-11-10,Radius Health Reports Third Quarter 2014 Financial And Operating Results
2014-11-03,Radius Health Appoints Industry Veteran Dr. Willard Dere To Board Of Directors
2014-10-28,Radius Health To Present At The 2014 BIO-Europe International Partnering Conference
2014-10-23,Radius Health Sponsors The Cancer Support Community "Elevating The Patient Voice" Symposium In Recognition Of National Breast Cancer Awareness Month
2014-10-21,Radius Health To Announce Third Quarter 2014 Financial Results, Host Conference Call And Live Webcast On Nov 11, 2014
2014-10-09,3 Stocks Spiking on Big Volume
2014-10-07,Radius Health, Inc. Announces Closing Of Public Offering Of Common Stock And Partial Exercise Of Underwriters' Option To Purchase Additional Shares
2017-03-16,Recro Pharma To Present At The Oppenheimer 27th Annual Healthcare Conference
2017-03-06,Recro Pharma Reports Year End 2016 Financial Results
2017-03-06,Recro Pharma Appoints Bryan Reasons To Its Board Of Directors
2017-03-02,Recro Pharma To Present At Upcoming Investor Conferences
2017-02-27,Recro Pharma Completes Enrollment In Phase III Safety Study Of IV Meloxicam
2016-12-16,Recro Pharma Announces Closing Of $40 Million Public Offering Of Common Stock
2016-12-15,5 Stocks Insiders Love Right Now
2016-12-13,Recro Pharma Announces Pricing Of Public Offering Of Common Stock
2016-12-08,Recro Pharma Announces Proposed Public Offering Of Common Stock
2016-11-28,Recro Pharma Reports Positive Top-Line Results From Pivotal Phase III Clinical Trial Of IV Meloxicam
2016-11-10,Recro Pharma Reports Third Quarter 2016 Financial Results
2016-11-09,Recro Pharma To Present At Upcoming Investor Conferences
2016-09-07,Recro Pharma Presents Clinical Data At PAINWeek 2016
2016-09-06,Recro Pharma To Present At The Rodman & Renshaw 18th Annual Global Investment Conference
2016-08-30,Ratings Changes Today
2016-08-19,Recro Pharma Announces Closing Of Public Offering Of Common Stock
2016-08-16,Recro Pharma Announces Pricing Of Public Offering Of Common Stock
2016-08-15,Recro Pharma Announces Proposed Public Offering Of Common Stock
2016-08-11,Recro Pharma Reports Second Quarter 2016 Financial Results
2016-07-26,Recro Pharma Reports Positive Top-Line Results From Pivotal Phase III Clinical Trial Of IV Meloxicam
2016-07-05,Recro Pharma Appoints Michael Celano As Chief Financial Officer
2016-06-02,Recro Pharma To Present At The Jefferies 2016 Global Healthcare Conference
2016-05-12,Recro Pharma Reports First Quarter 2016 Financial Results
2016-05-12,Recro Pharma Presents Clinical Data At American Pain Society 35th Annual Scientific Meeting
2016-03-24,Recro Pharma Reports Year End 2015 Financial Results
2016-03-07,Recro Pharma To Present At The 28th Annual ROTH Conference
2016-02-16,Recro Pharma Appoints Fred Graff As Chief Commercial Officer
2016-02-01,Recro Pharma Initiates Second Pivotal Phase III Clinical Trial Of IV Meloxicam For Acute Postoperative Pain
2016-01-27,Recro Pharma Initiates Pivotal Phase III Clinical Trial Of IV Meloxicam For Acute Postoperative Pain
2016-01-14,Recro Pharma To Present At NobleCon12 Investor Conference
2016-01-06,Recro Pharma Reports Positive Top-Line Results For Phase II Clinical Trial Of IV Meloxicam
2015-12-02,Recro Pharma Appoints Stewart McCallum, MD, As Chief Medical Officer
2015-11-24,Recro Pharma To Present At The 2015 Piper Jaffray Healthcare Conference
2015-11-13,Recro Pharma Reports Third Quarter 2015 Financial Results
2015-11-12,Recro Pharma To Participate In Upcoming Investor Conferences
2015-10-26,Recro Pharma Provides Pipeline Update
2015-09-10,Recro Pharma Appoints Karen A. Flynn To Its Board Of Directors
2015-09-10,Recro Pharma Announces Presentations At PAINWeek 2015
2015-08-14,Recro Pharma Reports Second Quarter 2015 Financial Results
2015-07-24,Recro Pharma Announces Additional Information For Phase II Clinical Trial Of Dex-IN
2015-07-20,Recro Pharma Appoints Scott Rizzo As General Manager
2015-07-17,Recro Pharma Announces Positive Top-Line Results For Phase II Clinical Trial Of Dex-IN
2015-07-07,Recro Pharma Completes $16 Million Private Financing
2015-07-01,Recro Pharma Announces $16 Million Financing
2015-06-08,3 Unusual-Volume Stocks to Trade for Breakouts
2015-05-28,Recro Pharma To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-12,Recro Pharma Reports First Quarter 2015 Financial Results
2015-04-13,Recro Pharma Completes Acquisition Of IV/IM Meloxicam And CGMP Manufacturing Facility And Business Unit From Alkermes
2015-04-09,Recro Pharma Announces Update On On-Going Phase II Clinical Trial Of Dex-IN For Treatment Of Acute Pain On Day 1 Following Surgery
2015-03-25,Recro Pharma Reports Fourth Quarter And Full Year 2014 Financial Results
2015-03-09,3 Stocks Improving Performance Of The Drugs Industry
2015-03-09,3 Stocks Driving The Health Care Sector Higher
2015-03-09,Recro Pharma To Acquire IV/IM Meloxicam And Gainesville, GA GMP Manufacturing Facility And Business Unit From Alkermes
2015-02-06,13 IPOs You Wish You Didn't Buy in 2014 (And Killed Your Portfolio)
2015-02-03,Recro Pharma Enters Into Common Stock Purchase Agreement With Aspire Capital
2015-02-02,Recro Pharma To Present At The 17th Annual BIO CEO & Investor Conference
2014-11-10,Recro Pharma Reports Third Quarter 2014 Financial Results
2014-10-29,Recro Pharma Announces Dosing Of First Patient In Phase II REC-14-013 Clinical Trial Of Dex-IN For Treatment Of Acute Pain On Day 1 Following Surgery
2014-09-10,3 Stocks Under $10 Moving Higher
2014-09-08,Recro Pharma To Present At The 2014 Aegis Healthcare & Technology Conference
2014-09-04,Recro Pharma Provides Clinical Strategy Update Following Interim Analysis For Phase IIb Clinical Trial Of Dex-IN
2014-08-12,Recro Pharma Reports Second Quarter 2014 Financial Results
,
,
,
2017-03-24,Immunomedics, Mylan Lead Biotech Movers
2017-03-22,Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 18% Using Options
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-08,Could These 9 Drugs Gain FDA Approval in the Age of Trump?
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-02-28,Rigel Announces Conference Call And Webcast To Report Fourth Quarter And Year End 2016 Financial Results
2017-02-03,Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares
2017-01-31,Rigel Announces Pricing Of Public Offering Of Common Stock
2017-01-30,Rigel Announces Proposed Public Offering Of Common Stock
2017-01-30,Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen
2017-01-16,Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2017-01-05,Rigel Provides Business Updates And Preliminary Data In IgA Nephropathy
2016-12-20,First Week Of RIGL February 2017 Options Trading
2016-11-22,First Week of January 2017 Options Trading For Rigel Pharmaceuticals (RIGL)
2016-11-10,Rigel To Present At Jefferies 2016 London Healthcare Conference
2016-10-28,Rigel Announces Conference Call And Webcast To Report Third Quarter 2016 Financial Results
2016-10-10,Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2016-10-07,Rigel Expands Leadership Team In Research And Business Development
2016-09-27,Short Interest Moves 115.3% Higher For RIGL
2016-09-20,Interesting RIGL Put And Call Options For November 18th
2016-09-15,Rigel Restructures To Focus On Fostamatinib Commercialization
2016-08-30,Rigel Pharma (RIGL) Stock Jumps on Study Results, Piper Jaffray Ups Price Target
2016-08-30,Markets Very Sluggish as August Nears an End
2016-08-30,Rigel Pharma Claims Late-Stage Study Win for Blood Platelet Drug
2016-08-30,Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP
2016-08-29,Rigel Announces Press Release and Conference Call Schedule on Tuesday, August 30, 2016
2016-08-08,Rigel Pharmaceuticals (RIGL) Weak On High Volume Today
2016-07-26,Rigel Announces Conference Call And Webcast To Report Second Quarter 2016 Financial Results
2016-06-02,Rigel To Present At Jefferies 2016 Healthcare Conference
2016-05-05,Rigel To Present At Upcoming American Association Of Immunologists (AAI) Annual Meeting
2016-04-26,Rigel Announces Conference Call And Webcast To Report First Quarter 2016 Financial Results
2016-04-12,Rigel Announces Presentations At Upcoming American Association Of Cancer Research (AACR) Conference
2016-04-01,Rigel Completes Enrollment Of FIT Phase 3 Program For Fostamatinib In ITP
2016-03-08,Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer
2016-03-01,Rigel Announces Conference Call And Webcast To Report Fourth Quarter And Year End 2015 Financial Results
2016-02-29,Rigel To Present At Cowen And Company 36th Annual Health Care Conference
2016-02-25,Rigel Initiates Phase 2 Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia
2016-01-28,Rigel Completes Enrollment Of First Phase 3 Study Of Fostamatinib In ITP (FIT)
2016-01-07,Rigel Reviews Recent Progress And Announces Presentation At The 34th Annual J.P. Morgan Healthcare Conference In San Francisco
2015-10-27,Rigel Announces Conference Call And Webcast To Report Third Quarter 2015 Financial Results
2015-09-09,Rigel And Aclaris Therapeutics International Sign License Agreement For JAK Inhibitors To Treat Skin Disorders
2015-09-08,Rigel Granted Orphan Drug Designation For Fostamatinib In ITP
2015-07-28,Rigel Announces Conference Call And Webcast To Report Second Quarter 2015 Financial Results
2015-06-30,Rigel Welcomes Keith A. Katkin To Board Of Directors
2015-06-26,Short Interest In Rigel Pharmaceuticals Makes 14.2% Move
2015-05-28,Rigel To Present At Jefferies 2015 Global Healthcare Conference
2015-05-14,Rigel Pharmaceuticals (RIGL) Strong On High Relative Volume Today
2015-04-30,Rigel Announces Conference Call And Webcast To Report First Quarter 2015 Financial Results And Pipeline Update
2015-03-09,Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 11.3% Annualized Using Options
2015-02-23,Bristol-Myers Commits Up to $1.25 Billion to Add Flexus Cancer Therapies
2015-02-23,Rigel And Bristol-Myers Squibb Announce Research And Development Collaboration For TGF Beta Receptor Kinase Inhibitors For Use In Immuno-Oncology Related Indications
2015-01-13,Short Interest Moves 40.6% Lower For RIGL
2015-01-08,Rigel To Present At The 33rd Annual J.P. Morgan Healthcare Conference
2014-11-24,Rigel Announces Executive Management Changes
2014-08-13,Why Rigel Pharmaceuticals (RIGL) Stock Is Declining Today
2014-08-13,R348 Did Not Meet Endpoints In Phase 2 Dry Eye Study
2014-08-06,First Week of RIGL March 2015 Options Trading
2014-07-16,Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
2014-05-29,Rigel To Present At Jefferies 2014 Global Healthcare Conference
2014-05-21,First Week of July 19th Options Trading For Rigel Pharmaceuticals (RIGL)
2014-04-30,Rigel Announces Webcast Of Investor Day On May 6, 2014
2014-03-06,Rigel Announces Publication Of R118 AMPK Activator Research
2014-02-27,Rigel Announces Participation At Two Investor Conferences
2014-02-26,First Week of April 19th Options Trading For Rigel Pharmaceuticals (RIGL)
2014-02-06,Rigel Announces Participation At Two Investor Conferences
2014-01-23,First Week Of September 20th Options Trading For Rigel Pharmaceuticals (RIGL)
2014-01-10,Rigel Will Present Clinical Product Portfolio Update At J.P. Morgan Healthcare Conference
2013-12-27,First Week of February 2014 Options Trading For Rigel Pharmaceuticals (RIGL)
2013-12-05,Rigel To Present At Oppenheimer Healthcare Conference
2013-10-24,Rigel Provides Pipeline Update
2013-09-27,First Week Of November 16th Options Trading For Rigel Pharmaceuticals (RIGL)
2013-09-06,Rigel To Present At Stifel Healthcare Conference
2013-09-05,Rigel To Focus On ITP, DLE And Dry Eye
2013-08-26,Rigel's R343 Did Not Meet Primary Endpoint In Asthma Study
2013-08-07,3 Stocks Under $10 Moving Higher
2013-06-11,Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 11.3% Annualized
2013-05-22,Rigel's R348 To Initiate Phase 2 Clinical Trial In Dry Eye
2013-05-03,Rigel Pharmaceuticals Becomes Oversold (RIGL)
2013-04-18,5 Health Care Stocks Under $10 Ready to Rip Higher
2013-04-12,5 Stocks Poised for Breakouts
2013-04-05,Frail Jobs Gains Give Markets Jitters
2013-04-05,Astra, Rigel Arthritis Pill Posts Mixed Trial Results
2013-03-15,3 Stocks Under $10 Making Big Moves
2013-02-28,Rigel Announces Participation At Two Investor Conferences
2013-02-07,Rigel To Present At BIO CEO & Investor Conference
2013-01-03,Rigel To Focus On Extensive Clinical Pipeline At Upcoming J.P. Morgan Presentation
2012-12-13,AstraZeneca Announces Top-Line Results Of OSKIRA-4 Phase IIb Study Of Fostamatinib As A Monotherapy For Rheumatoid Arthritis
2012-11-08,Rigel To Present At Jefferies 2012 Global Healthcare Conference In London
2012-10-03,Rigel Announces Pricing Of Public Offering Of Common Stock
2012-10-02,Rigel Announces Proposed Public Offering Of Common Stock
2012-09-25,Stocks Under $10: Blossoming Biotech Play
2012-09-17,Rigel To Present At UBS Global Life Sciences Conference
2012-09-05,Rigel Initiates Phase 2 Clinical Studies With R343 For Asthma And R333 For Discoid Lupus
2012-06-19,AstraZeneca And Rigel Sign Worldwide License Agreement For A Potential New Treatment For Chronic Asthma
2012-05-31,Rigel Announces Participation At Two Investor Conferences
2012-05-16,Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim At Acute And Chronic Lung Disease
2012-05-04,The Next Big Thing in Biotech: Pfizer
2012-02-23,Rigel Announces Participation At Two Investor Conferences
2012-01-05,Rigel Announces Initiation Of Clinical Trials In Two Immunology Programs
2011-12-07,Rigel To Present At Oppenheimer Annual Healthcare Conference
2011-11-03,Rigel To Participate At Two Upcoming Investor Conferences
2011-10-06,Rigel To Webcast Investor Day On October 13, 2011
2011-10-03,Biotech Calendar: Key Dates for October
2011-09-06,Vertex Arthritis Pill Shines in Mid-Stage Study
2011-06-16,Rigel To Present At Wells Fargo Securities Healthcare Conference
2011-06-03,Rigel To Present At Jefferies Global Healthcare Conference
2011-05-26,Rigel Stock Falls On Unusually High Volume (RIGL)
2011-05-26,Rigel Announces Pricing Of Public Offering Of Common Stock
2011-05-25,Rigel Announces Proposed Public Offering Of Common Stock
2011-05-06,Rigel Assumes Development Responsibility For Inhaled Asthma Therapy
2011-05-05,Rigel To Present At Bank Of America Merrill Lynch Health Care Conference
2011-03-07,Rigel Pharmaceuticals Inc. Stock Downgraded (RIGL)
2010-02-16,Brocade, Rigel, ARM: Early Volume Plays
2010-02-16,Rigel May Get $1.245B in Drug License Pact
2010-01-05,Analysts Name Top Biotech Stocks for 2010: BioBuzz
2009-11-23,Rigel Shares Rise On RBC Analyst Upgrade
2009-11-10,Bristol Licenses Arthritis Drug: BioBuzz
2009-11-03,Rigel 3Q Loss Narrows On Lower Costs
2009-10-20,Galleon's Biotech Stock Holdings: BioBuzz
2009-09-17,Psst... These Drug Firms Are Getting Bought: BioBuzz
2009-07-09,Rigel's R788 Drug Improves RA Symptoms
2009-06-15,New RA Data Could Be Magic Pill for Rigel
2009-06-10,Biotech Calendar: Key Clinical Trial Dates
2009-06-09,Movers Roundup: Rigel Pharma, Mueller Water
2009-06-09,Analyst: Rigel Arthritis Drug Poised To Compete
2009-02-03,Rigel Falls on Drug-Deal Delays, Layoffs
2008-12-08,Single Drugmakers Seek Rich Partners
2008-10-28,Health Winners & Losers: Genzyme
2008-10-28,Rigel Shares Tank on Arthritis Data (Update)
2008-10-27,Incyte's Rheumatoid Arthritis Pill Promising
2008-08-27,Health Winners & Losers: Cell Genesys
2008-08-15,Biotech-Stock Mailbag: Genentech
2008-03-17,Feuerstein's Biotech-Stock Mailbag: Navigating the Sector Swoon
2008-01-31,Focus on Jobs Report
2007-12-14,Friday's Health Winners & Losers
2007-12-13,Thursday's Health Winners & Losers
2007-12-13,Fed Fallout Keeps Bull Contained
2007-12-13,Rigel Pharma Surges on Drug Data
2007-12-06,Thursday's Health Winners & Losers
2007-05-03,Stock Sale Hits Rigel
2007-04-30,Monday's Health Winners and Losers
2006-12-12,Tuesday's Health Winners & Losers
2006-05-17,Today's Health Winners and Losers
2005-12-01,Health Stocks in Motion
2005-12-01,Rigel Shares Get Crushed
2005-12-01,Stocks in Motion: World Wrestling
2005-07-15,Health Stocks in Motion
2004-11-05,Health Stocks in Motion
2004-08-08,Weekend Reading: Jobs Data Surprise Becomes Fed Fear
2004-08-02,Health Stocks in Motion
2001-05-23,Don't Lose Sleep Over Specialty Laboratories
2001-05-16,Rigel Expiration Could Signal a Yard Sale
2017-03-24,Immunomedics, Mylan Lead Biotech Movers
2017-03-22,Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 18% Using Options
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-08,Could These 9 Drugs Gain FDA Approval in the Age of Trump?
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-02-28,Rigel Announces Conference Call And Webcast To Report Fourth Quarter And Year End 2016 Financial Results
2017-02-03,Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares
2017-01-31,Rigel Announces Pricing Of Public Offering Of Common Stock
2017-01-30,Rigel Announces Proposed Public Offering Of Common Stock
2017-01-30,Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen
2017-01-16,Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2017-01-05,Rigel Provides Business Updates And Preliminary Data In IgA Nephropathy
2016-12-20,First Week Of RIGL February 2017 Options Trading
2016-11-22,First Week of January 2017 Options Trading For Rigel Pharmaceuticals (RIGL)
2016-11-10,Rigel To Present At Jefferies 2016 London Healthcare Conference
2016-10-28,Rigel Announces Conference Call And Webcast To Report Third Quarter 2016 Financial Results
2016-10-10,Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2016-10-07,Rigel Expands Leadership Team In Research And Business Development
2016-09-27,Short Interest Moves 115.3% Higher For RIGL
2016-09-20,Interesting RIGL Put And Call Options For November 18th
2016-09-15,Rigel Restructures To Focus On Fostamatinib Commercialization
2016-08-30,Rigel Pharma (RIGL) Stock Jumps on Study Results, Piper Jaffray Ups Price Target
2016-08-30,Markets Very Sluggish as August Nears an End
2016-08-30,Rigel Pharma Claims Late-Stage Study Win for Blood Platelet Drug
2016-08-30,Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP
2016-08-29,Rigel Announces Press Release and Conference Call Schedule on Tuesday, August 30, 2016
2016-08-08,Rigel Pharmaceuticals (RIGL) Weak On High Volume Today
2016-07-26,Rigel Announces Conference Call And Webcast To Report Second Quarter 2016 Financial Results
2016-06-02,Rigel To Present At Jefferies 2016 Healthcare Conference
2016-05-05,Rigel To Present At Upcoming American Association Of Immunologists (AAI) Annual Meeting
2016-04-26,Rigel Announces Conference Call And Webcast To Report First Quarter 2016 Financial Results
2016-04-12,Rigel Announces Presentations At Upcoming American Association Of Cancer Research (AACR) Conference
2016-04-01,Rigel Completes Enrollment Of FIT Phase 3 Program For Fostamatinib In ITP
2016-03-08,Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer
2016-03-01,Rigel Announces Conference Call And Webcast To Report Fourth Quarter And Year End 2015 Financial Results
2016-02-29,Rigel To Present At Cowen And Company 36th Annual Health Care Conference
2016-02-25,Rigel Initiates Phase 2 Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia
2016-01-28,Rigel Completes Enrollment Of First Phase 3 Study Of Fostamatinib In ITP (FIT)
2016-01-07,Rigel Reviews Recent Progress And Announces Presentation At The 34th Annual J.P. Morgan Healthcare Conference In San Francisco
2015-10-27,Rigel Announces Conference Call And Webcast To Report Third Quarter 2015 Financial Results
2015-09-09,Rigel And Aclaris Therapeutics International Sign License Agreement For JAK Inhibitors To Treat Skin Disorders
2015-09-08,Rigel Granted Orphan Drug Designation For Fostamatinib In ITP
2015-07-28,Rigel Announces Conference Call And Webcast To Report Second Quarter 2015 Financial Results
2015-06-30,Rigel Welcomes Keith A. Katkin To Board Of Directors
2015-06-26,Short Interest In Rigel Pharmaceuticals Makes 14.2% Move
2015-05-28,Rigel To Present At Jefferies 2015 Global Healthcare Conference
2015-05-14,Rigel Pharmaceuticals (RIGL) Strong On High Relative Volume Today
2015-04-30,Rigel Announces Conference Call And Webcast To Report First Quarter 2015 Financial Results And Pipeline Update
2015-03-09,Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 11.3% Annualized Using Options
2015-02-23,Bristol-Myers Commits Up to $1.25 Billion to Add Flexus Cancer Therapies
2015-02-23,Rigel And Bristol-Myers Squibb Announce Research And Development Collaboration For TGF Beta Receptor Kinase Inhibitors For Use In Immuno-Oncology Related Indications
2015-01-13,Short Interest Moves 40.6% Lower For RIGL
2015-01-08,Rigel To Present At The 33rd Annual J.P. Morgan Healthcare Conference
2014-11-24,Rigel Announces Executive Management Changes
2014-08-13,Why Rigel Pharmaceuticals (RIGL) Stock Is Declining Today
2014-08-13,R348 Did Not Meet Endpoints In Phase 2 Dry Eye Study
2014-08-06,First Week of RIGL March 2015 Options Trading
2014-07-16,Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
2014-05-29,Rigel To Present At Jefferies 2014 Global Healthcare Conference
2014-05-21,First Week of July 19th Options Trading For Rigel Pharmaceuticals (RIGL)
2014-04-30,Rigel Announces Webcast Of Investor Day On May 6, 2014
2014-03-06,Rigel Announces Publication Of R118 AMPK Activator Research
2014-02-27,Rigel Announces Participation At Two Investor Conferences
2014-02-26,First Week of April 19th Options Trading For Rigel Pharmaceuticals (RIGL)
2014-02-06,Rigel Announces Participation At Two Investor Conferences
2014-01-23,First Week Of September 20th Options Trading For Rigel Pharmaceuticals (RIGL)
2014-01-10,Rigel Will Present Clinical Product Portfolio Update At J.P. Morgan Healthcare Conference
2013-12-27,First Week of February 2014 Options Trading For Rigel Pharmaceuticals (RIGL)
2013-12-05,Rigel To Present At Oppenheimer Healthcare Conference
2013-10-24,Rigel Provides Pipeline Update
2013-09-27,First Week Of November 16th Options Trading For Rigel Pharmaceuticals (RIGL)
2013-09-06,Rigel To Present At Stifel Healthcare Conference
2013-09-05,Rigel To Focus On ITP, DLE And Dry Eye
2013-08-26,Rigel's R343 Did Not Meet Primary Endpoint In Asthma Study
2013-08-07,3 Stocks Under $10 Moving Higher
2013-06-11,Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 11.3% Annualized
2013-05-22,Rigel's R348 To Initiate Phase 2 Clinical Trial In Dry Eye
2013-05-03,Rigel Pharmaceuticals Becomes Oversold (RIGL)
2013-04-18,5 Health Care Stocks Under $10 Ready to Rip Higher
2013-04-12,5 Stocks Poised for Breakouts
2013-04-05,Frail Jobs Gains Give Markets Jitters
2013-04-05,Astra, Rigel Arthritis Pill Posts Mixed Trial Results
2013-03-15,3 Stocks Under $10 Making Big Moves
2013-02-28,Rigel Announces Participation At Two Investor Conferences
2013-02-07,Rigel To Present At BIO CEO & Investor Conference
2013-01-03,Rigel To Focus On Extensive Clinical Pipeline At Upcoming J.P. Morgan Presentation
2012-12-13,AstraZeneca Announces Top-Line Results Of OSKIRA-4 Phase IIb Study Of Fostamatinib As A Monotherapy For Rheumatoid Arthritis
2012-11-08,Rigel To Present At Jefferies 2012 Global Healthcare Conference In London
2012-10-03,Rigel Announces Pricing Of Public Offering Of Common Stock
2012-10-02,Rigel Announces Proposed Public Offering Of Common Stock
2012-09-25,Stocks Under $10: Blossoming Biotech Play
2012-09-17,Rigel To Present At UBS Global Life Sciences Conference
2012-09-05,Rigel Initiates Phase 2 Clinical Studies With R343 For Asthma And R333 For Discoid Lupus
2012-06-19,AstraZeneca And Rigel Sign Worldwide License Agreement For A Potential New Treatment For Chronic Asthma
2012-05-31,Rigel Announces Participation At Two Investor Conferences
2012-05-16,Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim At Acute And Chronic Lung Disease
2012-05-04,The Next Big Thing in Biotech: Pfizer
2012-02-23,Rigel Announces Participation At Two Investor Conferences
2012-01-05,Rigel Announces Initiation Of Clinical Trials In Two Immunology Programs
2011-12-07,Rigel To Present At Oppenheimer Annual Healthcare Conference
2011-11-03,Rigel To Participate At Two Upcoming Investor Conferences
2011-10-06,Rigel To Webcast Investor Day On October 13, 2011
2011-10-03,Biotech Calendar: Key Dates for October
2011-09-06,Vertex Arthritis Pill Shines in Mid-Stage Study
2011-06-16,Rigel To Present At Wells Fargo Securities Healthcare Conference
2011-06-03,Rigel To Present At Jefferies Global Healthcare Conference
2011-05-26,Rigel Stock Falls On Unusually High Volume (RIGL)
2011-05-26,Rigel Announces Pricing Of Public Offering Of Common Stock
2011-05-25,Rigel Announces Proposed Public Offering Of Common Stock
2011-05-06,Rigel Assumes Development Responsibility For Inhaled Asthma Therapy
2011-05-05,Rigel To Present At Bank Of America Merrill Lynch Health Care Conference
2011-03-07,Rigel Pharmaceuticals Inc. Stock Downgraded (RIGL)
2010-02-16,Brocade, Rigel, ARM: Early Volume Plays
2010-02-16,Rigel May Get $1.245B in Drug License Pact
2010-01-05,Analysts Name Top Biotech Stocks for 2010: BioBuzz
2009-11-23,Rigel Shares Rise On RBC Analyst Upgrade
2009-11-10,Bristol Licenses Arthritis Drug: BioBuzz
2009-11-03,Rigel 3Q Loss Narrows On Lower Costs
2009-10-20,Galleon's Biotech Stock Holdings: BioBuzz
2009-09-17,Psst... These Drug Firms Are Getting Bought: BioBuzz
2009-07-09,Rigel's R788 Drug Improves RA Symptoms
2009-06-15,New RA Data Could Be Magic Pill for Rigel
2009-06-10,Biotech Calendar: Key Clinical Trial Dates
2009-06-09,Movers Roundup: Rigel Pharma, Mueller Water
2009-06-09,Analyst: Rigel Arthritis Drug Poised To Compete
2009-02-03,Rigel Falls on Drug-Deal Delays, Layoffs
2008-12-08,Single Drugmakers Seek Rich Partners
2008-10-28,Health Winners & Losers: Genzyme
2008-10-28,Rigel Shares Tank on Arthritis Data (Update)
2008-10-27,Incyte's Rheumatoid Arthritis Pill Promising
2008-08-27,Health Winners & Losers: Cell Genesys
2008-08-15,Biotech-Stock Mailbag: Genentech
2008-03-17,Feuerstein's Biotech-Stock Mailbag: Navigating the Sector Swoon
2008-01-31,Focus on Jobs Report
2007-12-14,Friday's Health Winners & Losers
2007-12-13,Thursday's Health Winners & Losers
2007-12-13,Fed Fallout Keeps Bull Contained
2007-12-13,Rigel Pharma Surges on Drug Data
2007-12-06,Thursday's Health Winners & Losers
2007-05-03,Stock Sale Hits Rigel
2007-04-30,Monday's Health Winners and Losers
2006-12-12,Tuesday's Health Winners & Losers
2006-05-17,Today's Health Winners and Losers
2005-12-01,Health Stocks in Motion
2005-12-01,Rigel Shares Get Crushed
2005-12-01,Stocks in Motion: World Wrestling
2005-07-15,Health Stocks in Motion
2004-11-05,Health Stocks in Motion
2004-08-08,Weekend Reading: Jobs Data Surprise Becomes Fed Fear
2004-08-02,Health Stocks in Motion
2001-05-23,Don't Lose Sleep Over Specialty Laboratories
2001-05-16,Rigel Expiration Could Signal a Yard Sale
2017-03-24,Immunomedics, Mylan Lead Biotech Movers
2017-03-22,Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 18% Using Options
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-08,Could These 9 Drugs Gain FDA Approval in the Age of Trump?
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-02-28,Rigel Announces Conference Call And Webcast To Report Fourth Quarter And Year End 2016 Financial Results
2017-02-03,Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares
2017-01-31,Rigel Announces Pricing Of Public Offering Of Common Stock
2017-01-30,Rigel Announces Proposed Public Offering Of Common Stock
2017-01-30,Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen
2017-01-16,Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2017-01-05,Rigel Provides Business Updates And Preliminary Data In IgA Nephropathy
2016-12-20,First Week Of RIGL February 2017 Options Trading
2016-11-22,First Week of January 2017 Options Trading For Rigel Pharmaceuticals (RIGL)
2016-11-10,Rigel To Present At Jefferies 2016 London Healthcare Conference
2016-10-28,Rigel Announces Conference Call And Webcast To Report Third Quarter 2016 Financial Results
2016-10-10,Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2016-10-07,Rigel Expands Leadership Team In Research And Business Development
2016-09-27,Short Interest Moves 115.3% Higher For RIGL
2016-09-20,Interesting RIGL Put And Call Options For November 18th
2016-09-15,Rigel Restructures To Focus On Fostamatinib Commercialization
2016-08-30,Rigel Pharma (RIGL) Stock Jumps on Study Results, Piper Jaffray Ups Price Target
2016-08-30,Markets Very Sluggish as August Nears an End
2016-08-30,Rigel Pharma Claims Late-Stage Study Win for Blood Platelet Drug
2016-08-30,Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP
2016-08-29,Rigel Announces Press Release and Conference Call Schedule on Tuesday, August 30, 2016
2016-08-08,Rigel Pharmaceuticals (RIGL) Weak On High Volume Today
2016-07-26,Rigel Announces Conference Call And Webcast To Report Second Quarter 2016 Financial Results
2016-06-02,Rigel To Present At Jefferies 2016 Healthcare Conference
2016-05-05,Rigel To Present At Upcoming American Association Of Immunologists (AAI) Annual Meeting
2016-04-26,Rigel Announces Conference Call And Webcast To Report First Quarter 2016 Financial Results
2016-04-12,Rigel Announces Presentations At Upcoming American Association Of Cancer Research (AACR) Conference
2016-04-01,Rigel Completes Enrollment Of FIT Phase 3 Program For Fostamatinib In ITP
2016-03-08,Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer
2016-03-01,Rigel Announces Conference Call And Webcast To Report Fourth Quarter And Year End 2015 Financial Results
2016-02-29,Rigel To Present At Cowen And Company 36th Annual Health Care Conference
2016-02-25,Rigel Initiates Phase 2 Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia
2016-01-28,Rigel Completes Enrollment Of First Phase 3 Study Of Fostamatinib In ITP (FIT)
2016-01-07,Rigel Reviews Recent Progress And Announces Presentation At The 34th Annual J.P. Morgan Healthcare Conference In San Francisco
2015-10-27,Rigel Announces Conference Call And Webcast To Report Third Quarter 2015 Financial Results
2015-09-09,Rigel And Aclaris Therapeutics International Sign License Agreement For JAK Inhibitors To Treat Skin Disorders
2015-09-08,Rigel Granted Orphan Drug Designation For Fostamatinib In ITP
2015-07-28,Rigel Announces Conference Call And Webcast To Report Second Quarter 2015 Financial Results
2015-06-30,Rigel Welcomes Keith A. Katkin To Board Of Directors
2015-06-26,Short Interest In Rigel Pharmaceuticals Makes 14.2% Move
2015-05-28,Rigel To Present At Jefferies 2015 Global Healthcare Conference
2015-05-14,Rigel Pharmaceuticals (RIGL) Strong On High Relative Volume Today
2015-04-30,Rigel Announces Conference Call And Webcast To Report First Quarter 2015 Financial Results And Pipeline Update
2015-03-09,Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 11.3% Annualized Using Options
2015-02-23,Bristol-Myers Commits Up to $1.25 Billion to Add Flexus Cancer Therapies
2015-02-23,Rigel And Bristol-Myers Squibb Announce Research And Development Collaboration For TGF Beta Receptor Kinase Inhibitors For Use In Immuno-Oncology Related Indications
2015-01-13,Short Interest Moves 40.6% Lower For RIGL
2015-01-08,Rigel To Present At The 33rd Annual J.P. Morgan Healthcare Conference
2014-11-24,Rigel Announces Executive Management Changes
2014-08-13,Why Rigel Pharmaceuticals (RIGL) Stock Is Declining Today
2014-08-13,R348 Did Not Meet Endpoints In Phase 2 Dry Eye Study
2014-08-06,First Week of RIGL March 2015 Options Trading
2014-07-16,Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
2014-05-29,Rigel To Present At Jefferies 2014 Global Healthcare Conference
2014-05-21,First Week of July 19th Options Trading For Rigel Pharmaceuticals (RIGL)
2014-04-30,Rigel Announces Webcast Of Investor Day On May 6, 2014
2014-03-06,Rigel Announces Publication Of R118 AMPK Activator Research
2014-02-27,Rigel Announces Participation At Two Investor Conferences
2014-02-26,First Week of April 19th Options Trading For Rigel Pharmaceuticals (RIGL)
2014-02-06,Rigel Announces Participation At Two Investor Conferences
2014-01-23,First Week Of September 20th Options Trading For Rigel Pharmaceuticals (RIGL)
2014-01-10,Rigel Will Present Clinical Product Portfolio Update At J.P. Morgan Healthcare Conference
2013-12-27,First Week of February 2014 Options Trading For Rigel Pharmaceuticals (RIGL)
2013-12-05,Rigel To Present At Oppenheimer Healthcare Conference
2013-10-24,Rigel Provides Pipeline Update
2013-09-27,First Week Of November 16th Options Trading For Rigel Pharmaceuticals (RIGL)
2013-09-06,Rigel To Present At Stifel Healthcare Conference
2013-09-05,Rigel To Focus On ITP, DLE And Dry Eye
2013-08-26,Rigel's R343 Did Not Meet Primary Endpoint In Asthma Study
2013-08-07,3 Stocks Under $10 Moving Higher
2013-06-11,Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 11.3% Annualized
2013-05-22,Rigel's R348 To Initiate Phase 2 Clinical Trial In Dry Eye
2013-05-03,Rigel Pharmaceuticals Becomes Oversold (RIGL)
2013-04-18,5 Health Care Stocks Under $10 Ready to Rip Higher
2013-04-12,5 Stocks Poised for Breakouts
2013-04-05,Frail Jobs Gains Give Markets Jitters
2013-04-05,Astra, Rigel Arthritis Pill Posts Mixed Trial Results
2013-03-15,3 Stocks Under $10 Making Big Moves
2013-02-28,Rigel Announces Participation At Two Investor Conferences
2013-02-07,Rigel To Present At BIO CEO & Investor Conference
2013-01-03,Rigel To Focus On Extensive Clinical Pipeline At Upcoming J.P. Morgan Presentation
2012-12-13,AstraZeneca Announces Top-Line Results Of OSKIRA-4 Phase IIb Study Of Fostamatinib As A Monotherapy For Rheumatoid Arthritis
2012-11-08,Rigel To Present At Jefferies 2012 Global Healthcare Conference In London
2012-10-03,Rigel Announces Pricing Of Public Offering Of Common Stock
2012-10-02,Rigel Announces Proposed Public Offering Of Common Stock
2012-09-25,Stocks Under $10: Blossoming Biotech Play
2012-09-17,Rigel To Present At UBS Global Life Sciences Conference
2012-09-05,Rigel Initiates Phase 2 Clinical Studies With R343 For Asthma And R333 For Discoid Lupus
2012-06-19,AstraZeneca And Rigel Sign Worldwide License Agreement For A Potential New Treatment For Chronic Asthma
2012-05-31,Rigel Announces Participation At Two Investor Conferences
2012-05-16,Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim At Acute And Chronic Lung Disease
2012-05-04,The Next Big Thing in Biotech: Pfizer
2012-02-23,Rigel Announces Participation At Two Investor Conferences
2012-01-05,Rigel Announces Initiation Of Clinical Trials In Two Immunology Programs
2011-12-07,Rigel To Present At Oppenheimer Annual Healthcare Conference
2011-11-03,Rigel To Participate At Two Upcoming Investor Conferences
2011-10-06,Rigel To Webcast Investor Day On October 13, 2011
2011-10-03,Biotech Calendar: Key Dates for October
2011-09-06,Vertex Arthritis Pill Shines in Mid-Stage Study
2011-06-16,Rigel To Present At Wells Fargo Securities Healthcare Conference
2011-06-03,Rigel To Present At Jefferies Global Healthcare Conference
2011-05-26,Rigel Stock Falls On Unusually High Volume (RIGL)
2011-05-26,Rigel Announces Pricing Of Public Offering Of Common Stock
2011-05-25,Rigel Announces Proposed Public Offering Of Common Stock
2011-05-06,Rigel Assumes Development Responsibility For Inhaled Asthma Therapy
2011-05-05,Rigel To Present At Bank Of America Merrill Lynch Health Care Conference
2011-03-07,Rigel Pharmaceuticals Inc. Stock Downgraded (RIGL)
2010-02-16,Brocade, Rigel, ARM: Early Volume Plays
2010-02-16,Rigel May Get $1.245B in Drug License Pact
2010-01-05,Analysts Name Top Biotech Stocks for 2010: BioBuzz
2009-11-23,Rigel Shares Rise On RBC Analyst Upgrade
2009-11-10,Bristol Licenses Arthritis Drug: BioBuzz
2009-11-03,Rigel 3Q Loss Narrows On Lower Costs
2009-10-20,Galleon's Biotech Stock Holdings: BioBuzz
2009-09-17,Psst... These Drug Firms Are Getting Bought: BioBuzz
2009-07-09,Rigel's R788 Drug Improves RA Symptoms
2009-06-15,New RA Data Could Be Magic Pill for Rigel
2009-06-10,Biotech Calendar: Key Clinical Trial Dates
2009-06-09,Movers Roundup: Rigel Pharma, Mueller Water
2009-06-09,Analyst: Rigel Arthritis Drug Poised To Compete
2009-02-03,Rigel Falls on Drug-Deal Delays, Layoffs
2008-12-08,Single Drugmakers Seek Rich Partners
2008-10-28,Health Winners & Losers: Genzyme
2008-10-28,Rigel Shares Tank on Arthritis Data (Update)
2008-10-27,Incyte's Rheumatoid Arthritis Pill Promising
2008-08-27,Health Winners & Losers: Cell Genesys
2008-08-15,Biotech-Stock Mailbag: Genentech
2008-03-17,Feuerstein's Biotech-Stock Mailbag: Navigating the Sector Swoon
2008-01-31,Focus on Jobs Report
2007-12-14,Friday's Health Winners & Losers
2007-12-13,Thursday's Health Winners & Losers
2007-12-13,Fed Fallout Keeps Bull Contained
2007-12-13,Rigel Pharma Surges on Drug Data
2007-12-06,Thursday's Health Winners & Losers
2007-05-03,Stock Sale Hits Rigel
2007-04-30,Monday's Health Winners and Losers
2006-12-12,Tuesday's Health Winners & Losers
2006-05-17,Today's Health Winners and Losers
2005-12-01,Health Stocks in Motion
2005-12-01,Rigel Shares Get Crushed
2005-12-01,Stocks in Motion: World Wrestling
2005-07-15,Health Stocks in Motion
2004-11-05,Health Stocks in Motion
2004-08-08,Weekend Reading: Jobs Data Surprise Becomes Fed Fear
2004-08-02,Health Stocks in Motion
2001-05-23,Don't Lose Sleep Over Specialty Laboratories
2001-05-16,Rigel Expiration Could Signal a Yard Sale
2017-02-27,Rexahn Pharmaceuticals Reports Full Year 2016 Financial Results And Provides Corporate Update
2017-02-23,Rexahn Pharmaceuticals Doses First Patient In A Phase IIa Trial Of Supinoxin™ In Patients With Metastatic Triple Negative Breast Cancer
2017-01-20,Rexahn Pharmaceuticals Presents An Update Of The Ongoing Phase IIa Clinical Trial Of RX-3117 In Metastatic Pancreatic Cancer At The American Society Of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium
2017-01-03,Rexahn Pharmaceuticals To Present At Biotech Showcase™ 2017
2016-11-07,Rexahn Pharmaceuticals Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-10-31,Rexahn Pharmaceuticals Receives A Notice Of Allowance From The U.S. Patent And Trademark Office For A Patent Covering The Manufacturing Of RX-3117 - A Cancer Cell Specific Anticancer Agent
2016-10-26,Rexahn Pharmaceuticals Receives U.S. Patent For RX-21101: A Novel Nano-Polymer Conjugate Of Docetaxel For The Targeted Treatment Of Solid Tumors
2016-10-10,Rexahn Pharmaceuticals Presents Preliminary Efficacy Data From Phase Ib/IIa Trial Of RX-3117 In Metastatic Pancreatic Cancer And Supinoxin™ Phase I Trial At 2016 European Society For Medical Oncology (ESMO) Congress
2016-10-04,Rexahn Pharmaceuticals Presents Preliminary Efficacy Data From Phase Ib/IIa Trial Of RX-3117 In Metastatic Pancreatic Cancer And Supinoxin™ Phase I Trial At 2016 European Society For Medical Oncology (ESMO) Congress
2016-09-14,Rexahn Announces $6 Million Registered Direct Offering
2016-09-12,Rexahn Pharmaceuticals Initiates Stage 2 Of Phase Ib/IIa Clinical Trial Of RX-3117 In Relapsed Or Refractory Metastatic Pancreatic Cancer
2016-09-07,Rexahn Pharmaceuticals To Present At 18th Annual Rodman & Renshaw  Global Investment Conference On September 12, 2016
2016-08-08,Rexahn Pharmaceuticals Reports Second Quarter 2016 Financial And Operational Results
2016-07-11,Rexahn Pharmaceuticals Strengthens Leadership Team
2016-06-06,Rexahn Pharmaceuticals Presents Clinical Data For Three Novel Targeted Oncology Programs At The 2016 American Society Of Clinical Oncology Annual Meeting
2016-05-23,Rexahn Pharmaceuticals To Present At The American Society Of Clinical Oncology (ASCO) 2016 Annual Meeting
2016-05-09,Rexahn Pharmaceuticals Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-04-20,Rexahn Pharmaceuticals Presents Clinical Trial Results For Archexin® At The 2016 American Association For Cancer Research Annual Meeting
2016-04-13,Rexahn Pharmaceuticals To Present At The 2016 American Association For Cancer Research Annual Meeting
2016-03-29,Rexahn Pharmaceuticals Announces Initiation Of Phase Ib/IIa Clinical Trial Of Its Novel Oral Anti-Cancer Therapeutic RX-3117 In The Treatment Of Pancreatic And Bladder Cancer
2016-03-24,Rexahn Pharmaceuticals Presents Additional Data For Supinoxin For The Treatment Of Triple Negative Breast Cancer At The 2016 Targeted Anticancer Therapeutics Congress
2016-03-14,Rexahn Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results
2016-02-26,Rexahn Announces $5 Million Registered Direct Offering
2016-02-12,8 Biotech Stocks Under $10 Poised for Breakouts
2016-02-08,Rexahn Pharmaceuticals Completes Stage 1 And Begins Enrollment In Stage 2 Of Archexin® Phase IIa Clinical Trial In Metastatic Renal Cell Carcinoma
2016-02-01,Rexahn Pharmaceuticals To Present At The 18th Annual BIO CEO & Investor Conference On Monday, February 8, 2016
2016-01-25,Rexahn Pharmaceuticals Announces Supinoxin™ Poster Presentations At The 2016 Gastrointestinal Cancers Symposium
2016-01-12,New Preclinical Data For Supinoxin™ Show Oral Administration Produces Clinically Meaningful Tumor Growth Inhibition
2016-01-11,Rexahn Pharmaceuticals' Archexin® Shows Dose-Dependent Tumor Reduction In A Phase IIa Clinical Study
2016-01-05,Rexahn Pharmaceuticals To Present At Biotech Showcase™ 2016
2015-12-14,Rexahn Pharmaceuticals Announces New Data For Supinoxin™ Showing Potent Tumor Growth Inhibition
2015-11-11,Rexahn Pharmaceuticals To Present At The Stifel 2015 Healthcare Conference On November 18, 2015
2015-11-06,Rexahn Announces $7.0 Million Registered Direct Offering
2015-11-05,Rexahn Pharmaceuticals Reports Interim Clinical Data For Archexin® At The 14th International Kidney Cancer Symposium
2015-11-04,4 Stocks Under $10 Making Big Up Moves on Big Volume
2015-11-03,Rexahn Pharmaceuticals Reports Third Quarter 2015 Financial Results And Provides Corporate Update
2015-10-26,Rexahn Pharmaceuticals Receives U.S. Patent for RX-3117 Anti-Cancer Program
2015-10-14,Rexahn Pharmaceuticals To Present At The 14th Annual BIO Investor Forum
2015-09-28,Rexahn Pharmaceuticals Presents Preliminary Clinical Data For Supinoxin(TM) And RX-3117 Oncology Programs At The European Cancer Congress 2015
2015-09-25,Rexahn Pharmaceuticals To Present Preliminary Clinical Data At The European Cancer Congress 2015
2015-09-23,Rexahn Pharmaceuticals To Present At The 15th Annual Biotech In Europe Investor Forum
2015-09-08,Rexahn Pharmaceuticals To Present At The Biopharm America(TM) 2015 Conference In Boston
2015-08-31,Rexahn Pharmaceuticals To Present At The 17th Annual Rodman And Renshaw Global Investment Conference On September 10, 2015
2015-08-10,Rexahn Pharmaceuticals Reports Second Quarter 2015 Financial Results And Provides Corporate Update
2015-07-14,Rexahn Pharmaceuticals Awarded Patent In Japan For Novel Targeted Cancer Drug Delivery Platform
2015-06-22,Rexahn Announces The Appointment Of Peter Brandt As Chairman Of The Board
2015-06-09,Data On Rexahn's RX-3117 In Non-Small Cell Lung Cancer Presented At 16th International Symposium Of The Purine And Pyrimidine Society
2015-06-08,National Cancer Institute Accepts Rexahn's RX-21101 For Its Nanotechnology Characterization Laboratory's Preclinical Characterization Program
2015-05-29,5 Stocks Under $10 Ready to Spike Higher
2015-05-13,Rexahn Announces Poster Presentations At The 2015 American Society Of Clinical Oncology (ASCO) Annual Meeting
2015-05-11,Rexahn Pharmaceuticals Reports First Quarter 2015 Financial Results And Pipeline Update
2015-04-21,New Data Show Rexahn's Supinoxin(TM) Decreases The Migration Of Human Triple Negative Breast Cancer Cells In A Metastatic Cancer Model
2015-04-20,Rexahn Identifies RX-3117 Biomarker & Presents Data At The 2015 American Association For Cancer Research Annual Meeting
2015-04-13,Rexahn Pharmaceuticals To Present Data On RX-3117 And Supinoxin(TM) At The 2015 American Association For Cancer Research Annual Meeting
2015-03-18,Rexahn Pharmaceuticals To Present At The 12th Annual BIO Asia International Conference In Tokyo, Japan
2015-03-17,Rexahn Pharmaceuticals Reports Fourth Quarter And Full-Year 2014 Financial Results And Pipeline Update
2015-03-04,Rexahn Pharmaceuticals To Present At The BIO-Europe Spring(R) 2015 Conference In Paris, France
2015-03-02,Rexahn Pharmaceuticals To Present At The ROTH Capital Partners 27th Annual Growth Stock Conference
2015-02-18,Rexahn Pharmaceuticals To Present At The 3rd Annual Sachs Cancer Bio Partnering & Investment Forum In New York
2015-02-09,Rexahn Pharmaceuticals Announces The Publication Of Preclinical Data For Supinoxin(TM) (RX-5902) Demonstrating Mechanism Of Action
2015-02-04,Rexahn Pharmaceuticals Announces The Appointment Of Ely Benaim, M.D., As Chief Medical Officer
2015-02-02,Rexahn Pharmaceuticals To Present At The 17th Annual BIO CEO & Investor Conference
2015-01-07,Rexahn Pharmaceuticals To Present At Biotech Showcase(TM) 2015
2015-01-06,Rexahn Pharmaceuticals Announces Publication Of Preclinical Data For RX-3117 Demonstrating Effectiveness Against Gemcitabine Resistant Human Cancer Cells
2014-12-04,Rexahn Pharmaceuticals To Present At The Oppenheimer Healthcare Conference On December 10, 2014
2014-12-03,Rexahn Pharmaceuticals Appoints Richard Rodgers To Its Board Of Directors
2014-11-17,Rexahn Pharmaceuticals To Participate In Brean Capital 2014 Life Sciences Summit
2014-11-13,Rexahn Pharmaceuticals Reports Third Quarter 2014 Financial Results And Pipeline Update
2014-11-11,Rexahn Pharmaceuticals To Present At The Stifel 2014 Healthcare Conference On November 18, 2014
2014-10-28,Rexahn Pharmaceuticals To Present At The BIO-Europe(R) Conference In Frankfurt, Germany
2014-09-30,Rexahn Pharmaceuticals To Present At 13th Annual BIO Investor Forum
2014-09-24,Rexahn Receives FDA Orphan Drug Designation For RX-3117 In Treatment Of Pancreatic Cancer
2014-09-23,Rexahn Pharmaceuticals To Present At The 14th Annual Biotech In Europe Investor Forum For Global Partnering And Investment In Basel, Switzerland
2014-09-16,Rexahn Pharmaceuticals To Present At The BioPharm America™ 2014 In Boston, Massachusetts, USA
2014-09-04,Rexahn Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference On September 9, 2014
2014-09-03,Rexahn Receives A Notice Of Allowance From The U.S. Patent And Trademark Office For A Novel Targeted Cancer Drug Delivery Platform
2014-08-14,Rexahn Pharmaceuticals Reports Second Quarter 2014 Financial Results And Pipeline Update
2014-07-18,Rexahn Pharmaceuticals Provides Update On Phase I Supinoxin Trial In Cancer Patients With Solid Tumors
2014-05-15,Rexahn Pharmaceuticals Reports First Quarter 2014 Financial Results And Pipeline Update
2014-05-08,RX-3117 Showed Greater Efficacy (tumor Growth Inhibition) As Compared To Gemcitabine In Four Different Xenograft Animal Models With Gemcitabine Resistant Human Cancer Cell Lines: Colorectal Cancer (Colo205), Small Cell Lung Cancer (H69), Cervical Cancer (CaSki) And Pancreatic Cancer (CTG-0298).
2014-04-21,Rexahn Presents Data From Preclinical Studies Of RX-21101
2014-04-02,Rexahn Pharmaceuticals To Present Data On RX-3117 And RX-21101 At The 2014 American Association For Clinical Research Annual Meeting
2014-03-24,Rexahn Pharmaceuticals Reports Fourth Quarter And Full-Year 2013 Financial Results And Recent Highlights
2014-03-19,3 Stocks Under $10 Making Big Moves
2014-03-17,Rexahn Pharmaceuticals To Present At The 2nd Annual Sachs Cancer Bio Partnering &amp; Investment Forum In New York
2014-03-11,Rexahn Announces Initial Results From Phase I Trial Of SupinoxinTM (RX-5902) For Solid Cancer Tumors
2014-03-07,Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine
2014-03-04,Rexahn Pharmaceuticals To Present At The 26th Annual ROTH Conference
2014-03-03,Rexahn Pharmaceuticals Appoints Mark Carthy To Board Of Directors
2014-03-01,Biotech Sector Performance February 2014: Red Hot But...
2014-02-26,4 Biotech Stocks Under $10 Moving Higher
2014-02-06,5 Stocks Under $10 Set to Soar
2014-02-04,Rexahn Pharmaceuticals To Present At The 16th Annual BIO CEO &amp; Investor Conference
2014-01-31,4 Health Care Stocks Under $10 to Watch
2014-01-21,It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013
2014-01-15,Rexahn Announces $20 Million Registered Direct Offering
2014-01-14,Rexahn Initiates Phase IIa Clinical Trial Of Archexin&#174; In Patients With Metastatic Renal Cell Carcinoma
2014-01-10,Why Rexahn Pharmaceuticals (RNN) Is Up Today
2014-01-08,Rexahn Initiates Phase Ib Clinical Trial Of RX-3117 For Treatment Of Solid Tumors
2014-01-07,Rexahn Pharmaceuticals To Present At The Biotech Showcase 2014
2013-12-11,Rexahn Receives Method Patent For Treatment Of Solid Tumor Cancers For Supinoxin TM&#160;(RX-5902)
2013-11-19,Rexahn Pharmaceuticals To Participate In Brean Capital 2013 Life Sciences Summit
2013-11-14,Rexahn Pharmaceuticals Reports Third Quarter Financial Results And Pipeline Update
2013-10-11,Rexahn Announces $5.3 Million At Market Registered Direct Offering
2013-10-10,Rexahn Pharmaceuticals In-Licenses Novel Oligonucleotide Targeted Drug Delivery Platform From Ohio State University
2013-10-03,5 Stocks Under $10 Set to Soar
2013-09-30,Rexahn Pharmaceuticals Announces Publication Of Preclinical Data For Novel Anti-Cancer Compound RX-3117
2013-09-12,Rexahn Awarded Patent In Europe For Cancer Drug Archexin&#174;
2013-09-05,Rexahn Pharmaceuticals To Present At The 15th Annual Rodman &amp; Renshaw Global Investment Conference On September 9, 2013
2013-09-04,Rexahn Pharmaceuticals Provides A Clinical Development And Financial Update
2013-08-28,Rexahn Pharmaceuticals Announces Teva Will Not Exercise Its Option To License RX-3117
2013-08-07,Rexahn Pharmaceuticals Initiates Dosing In Phase I Trial Of SupinoxinTM (RX-5902) A Candidate For Treating Solid Cancer Tumors
2013-07-24,Rexahn Pharmaceuticals Announces $5.7 Million Registered Direct Offering
2013-07-17,Rexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery Platform
2013-07-15,Rexahn Pharmaceuticals Announce IND Submission For RX-3117
2013-07-09,Rexahn Pharmaceuticals Awarded Patent In Japan For Novel Anti-cancer Isoquinolinamine Compounds&#160;&#160;
2013-06-17,Rexahn Awarded U.S. Patent For Novel Anti-Cancer Compounds
2013-05-20,Rexahn Pharmaceuticals To Present At The Second Annual Marcum LLP MicroCap Conference
2013-03-11,Rexahn Pharmaceuticals To Present At The 25th Annual ROTH Conference
2013-02-19,Rexahn Pharmaceuticals Provides Key Goals For 2013
2013-01-22,Rexahn Pharmaceuticals Appoints Peter D. Suzdak As Chief Executive Officer
2012-12-17,Rexahn Pharmaceuticals Expands Its Intellectual Property Around Class Of Potent Anti-cancer Isoquinolinamine Compounds
2012-12-04,Rexahn Pharmaceuticals Closes Public Offering For $6,600,000 In Gross Proceeds
2012-11-29,Rexahn Pharmaceuticals Prices Public Offering Of Stock
2012-11-28,Rexahn Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrant
2012-11-28,Teva Pharmaceutical To Increase Ownership In Rexahn
2012-11-21,Rexahn Pharmaceuticals Issued US Patent For Quinoxalinyl-piperazine Compounds
2012-09-26,Rexahn Pharmaceuticals Granted European Patent For Novel Anti-cancer Isoquinolinamine Compounds
2012-09-06,Rexahn Pharmaceuticals To Present At The Rodman &amp; Renshaw 14th Annual Healthcare Conference
2012-09-04,Rexahn Pharmaceuticals Provides Update On 2012 Strategic Goals
2012-08-31,Biotech Stock Mailbag: Rexahn, Vertex, Peregrine, Sarepta
2012-08-30,Rexahn Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
2012-08-28,Rexahn Pharmaceuticals Announces Positive Top-line Phase IIa Data For Archexin In Patients With Metastatic Pancreatic Cancer
2012-08-06,Rexahn Pharmaceuticals Completes Exploratory Phase I Clinical Study Of RX-3117
2012-07-02,Rexahn Submits An Investigational New Drug Application To The FDA For First-in-Class P68 Helicase Inhibitor, RX-5902
2012-05-30,Rexahn Pharmaceuticals Announces Publication Of New Preclinical Research Data For Novel Anti-Cancer Compound RX-3117
2012-05-08,Rexahn Pharmaceuticals Submits Archexin Phase II Protocol For Ovarian Cancer To FDA
2012-03-27,Rexahn Pharmaceuticals To Present Data On Novel Anti-Cancer Small Molecule RX-3117 At AACR 103rd Annual Meeting
2012-03-13,Rexahn Pharmaceuticals Enrolls First Subject In Exploratory Phase I Clinical Study Of RX-3117
2012-01-25,Rexahn Pharmaceuticals Publishes New Preclinical Data For Quinoxalinyl-Piperazine Compounds
2012-01-18,Rexahn Pharmaceuticals Secures Approval In Europe To Conduct A First-in-Human Trial Of RX-3117 In Solid Tumors
2012-01-17,Rexahn Pharmaceuticals Provides Key Goals For 2012
2011-11-04,Rexahn Pharmaceuticals Announces Phase II Results For Serdaxin&#174; As Treatment For Major Depressive Disorder
2011-10-12,Rexahn Pharmaceuticals Granted US Patent For Novel Anti-cancer Isoquinolinamine Compounds
2011-10-03,Rexahn Pharmaceuticals Announces Publication Of Study Validating Mechanism Of Action Of Serdaxin&#174;
2011-09-28,Rexahn Pharmaceuticals Completes Patient Enrollment For Archexin Phase II Clinical Trial In Metastatic Pancreatic Cancer
2011-09-08,Rexahn Pharmaceuticals To Present At The Rodman &amp; Renshaw 13th Annual Healthcare Conference
2011-09-06,Rexahn Pharmaceuticals Announces US Patent Issued For CNS-based Treatment Of Sexual Dysfunction
2011-08-08,European Patent Granted For Neurotherapeutic Compositions
2011-06-22,Rexahn Pharmaceuticals Completes Patient Enrollment In Serdaxin Phase IIb Clinical Trial For Major Depressive Disorder
2011-05-23,Insiders Trading FURX, MELI, FRP
2011-05-05,Rexahn Pharmaceuticals Reports Enrollment Progress On Phase IIb Clinical Trial Of Serdaxin For Depression
2011-04-12,6 Stocks With Big Insider Buying
2011-04-06,Insiders Trading RNN, LULU, KYN, GES
2011-04-04,Rexahn Pharmaceuticals To Present At Needham &amp; Company&#8217;s 10th Annual Healthcare Conference
2011-03-31,Rexahn Closes $10 Million In Registered Direct Offering
2011-03-30,Rexahn Pharmaceuticals To Present Data On Novel Anti-Cancer Small Molecule RX-5902 At AACR 102nd Annual Meeting
2011-03-28,Rexahn To Raise $10 Million In Registered Direct Offering
2011-03-23,Rexahn Pharmaceuticals Enrolls 100 Patients In Serdaxin&#174; Phase IIb Clinical Trial For Depression
2011-03-14,Rexahn Pharmaceuticals To Present At The Roth Capital Partners 23rd Annual OC Growth Stock Conference
2011-03-07,Rexahn Announces CEO Transition To CSO And Search For New CEO
2011-02-28,Rexahn Pharmaceuticals Granted European Patent For New Quinoxalinyl-piperazine Compounds
2011-02-18,Biotech Mailbag: BIO CEO Wrap
2011-02-11,Biotech Stock Mailbag: Protalix BioTherapeutics
2011-02-08,Rexahn Higher on Deja Vu Stock Promotion
2011-02-01,6 Penny Stocks for the Biotech Boom
2011-01-25,Rexahn Pharmaceuticals Enrolls First Patient In Serdaxin&#174; Phase IIb Clinical Trial
2011-01-24,Genoptix, Clinical Data: Small-Cap Winners
2011-01-20,Wendy's/Arby's, BioLase: Small-Cap Winners
2011-01-20,Teva Pharmaceutical Increases Its Investment In Rexahn For The Continued Research And Development Of The Pre-Clinical Anti-Cancer Compound, RX-3117
2010-12-20,Rexahn Awarded Patent In Japan For RX-0047
2010-12-08,Rexahn Pharmaceuticals Presents Serdaxin Phase IIa Clinical Data At The American College Of Neuropsychopharmacologists Annual Meeting
2010-12-06,U.S. Patent Issued For New Method For Treating Cognitive Disorders
2010-11-22,Additional U.S. Patent Issued For Rexahn&#8217;s CNS Treatment Portfolio
2010-11-08,Rexahn Pharmaceuticals Announces Publication Of New Preclinical Research Data For Novel Anticancer Compounds
2010-11-04,Rexahn Awarded Qualifying Therapeutic Discovery Project Grants To Further Develop Anti-Cancer, Depression, And Erectile Dysfunction Treatments
2010-10-26,Rexahn To Use MedAvante Centralized Ratings In MDD Phase 2b Study
2010-10-20,Rexahn Pharmaceuticals To Attend BioNetwork West
2010-10-19,Rexahn Pharmaceuticals Publishes New Data On Anti-Cancer Isoquinolinamine Derivatives
2010-09-21,Rexahn Pharmaceuticals Announces Publication Of Study On Neuroprotective Effects Of Clavulanic Acid
2017-02-27,Rexahn Pharmaceuticals Reports Full Year 2016 Financial Results And Provides Corporate Update
2017-02-23,Rexahn Pharmaceuticals Doses First Patient In A Phase IIa Trial Of Supinoxin™ In Patients With Metastatic Triple Negative Breast Cancer
2017-01-20,Rexahn Pharmaceuticals Presents An Update Of The Ongoing Phase IIa Clinical Trial Of RX-3117 In Metastatic Pancreatic Cancer At The American Society Of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium
2017-01-03,Rexahn Pharmaceuticals To Present At Biotech Showcase™ 2017
2016-11-07,Rexahn Pharmaceuticals Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-10-31,Rexahn Pharmaceuticals Receives A Notice Of Allowance From The U.S. Patent And Trademark Office For A Patent Covering The Manufacturing Of RX-3117 - A Cancer Cell Specific Anticancer Agent
2016-10-26,Rexahn Pharmaceuticals Receives U.S. Patent For RX-21101: A Novel Nano-Polymer Conjugate Of Docetaxel For The Targeted Treatment Of Solid Tumors
2016-10-10,Rexahn Pharmaceuticals Presents Preliminary Efficacy Data From Phase Ib/IIa Trial Of RX-3117 In Metastatic Pancreatic Cancer And Supinoxin™ Phase I Trial At 2016 European Society For Medical Oncology (ESMO) Congress
2016-10-04,Rexahn Pharmaceuticals Presents Preliminary Efficacy Data From Phase Ib/IIa Trial Of RX-3117 In Metastatic Pancreatic Cancer And Supinoxin™ Phase I Trial At 2016 European Society For Medical Oncology (ESMO) Congress
2016-09-14,Rexahn Announces $6 Million Registered Direct Offering
2016-09-12,Rexahn Pharmaceuticals Initiates Stage 2 Of Phase Ib/IIa Clinical Trial Of RX-3117 In Relapsed Or Refractory Metastatic Pancreatic Cancer
2016-09-07,Rexahn Pharmaceuticals To Present At 18th Annual Rodman & Renshaw  Global Investment Conference On September 12, 2016
2016-08-08,Rexahn Pharmaceuticals Reports Second Quarter 2016 Financial And Operational Results
2016-07-11,Rexahn Pharmaceuticals Strengthens Leadership Team
2016-06-06,Rexahn Pharmaceuticals Presents Clinical Data For Three Novel Targeted Oncology Programs At The 2016 American Society Of Clinical Oncology Annual Meeting
2016-05-23,Rexahn Pharmaceuticals To Present At The American Society Of Clinical Oncology (ASCO) 2016 Annual Meeting
2016-05-09,Rexahn Pharmaceuticals Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-04-20,Rexahn Pharmaceuticals Presents Clinical Trial Results For Archexin® At The 2016 American Association For Cancer Research Annual Meeting
2016-04-13,Rexahn Pharmaceuticals To Present At The 2016 American Association For Cancer Research Annual Meeting
2016-03-29,Rexahn Pharmaceuticals Announces Initiation Of Phase Ib/IIa Clinical Trial Of Its Novel Oral Anti-Cancer Therapeutic RX-3117 In The Treatment Of Pancreatic And Bladder Cancer
2016-03-24,Rexahn Pharmaceuticals Presents Additional Data For Supinoxin For The Treatment Of Triple Negative Breast Cancer At The 2016 Targeted Anticancer Therapeutics Congress
2016-03-14,Rexahn Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results
2016-02-26,Rexahn Announces $5 Million Registered Direct Offering
2016-02-12,8 Biotech Stocks Under $10 Poised for Breakouts
2016-02-08,Rexahn Pharmaceuticals Completes Stage 1 And Begins Enrollment In Stage 2 Of Archexin® Phase IIa Clinical Trial In Metastatic Renal Cell Carcinoma
2016-02-01,Rexahn Pharmaceuticals To Present At The 18th Annual BIO CEO & Investor Conference On Monday, February 8, 2016
2016-01-25,Rexahn Pharmaceuticals Announces Supinoxin™ Poster Presentations At The 2016 Gastrointestinal Cancers Symposium
2016-01-12,New Preclinical Data For Supinoxin™ Show Oral Administration Produces Clinically Meaningful Tumor Growth Inhibition
2016-01-11,Rexahn Pharmaceuticals' Archexin® Shows Dose-Dependent Tumor Reduction In A Phase IIa Clinical Study
2016-01-05,Rexahn Pharmaceuticals To Present At Biotech Showcase™ 2016
2015-12-14,Rexahn Pharmaceuticals Announces New Data For Supinoxin™ Showing Potent Tumor Growth Inhibition
2015-11-11,Rexahn Pharmaceuticals To Present At The Stifel 2015 Healthcare Conference On November 18, 2015
2015-11-06,Rexahn Announces $7.0 Million Registered Direct Offering
2015-11-05,Rexahn Pharmaceuticals Reports Interim Clinical Data For Archexin® At The 14th International Kidney Cancer Symposium
2015-11-04,4 Stocks Under $10 Making Big Up Moves on Big Volume
2015-11-03,Rexahn Pharmaceuticals Reports Third Quarter 2015 Financial Results And Provides Corporate Update
2015-10-26,Rexahn Pharmaceuticals Receives U.S. Patent for RX-3117 Anti-Cancer Program
2015-10-14,Rexahn Pharmaceuticals To Present At The 14th Annual BIO Investor Forum
2015-09-28,Rexahn Pharmaceuticals Presents Preliminary Clinical Data For Supinoxin(TM) And RX-3117 Oncology Programs At The European Cancer Congress 2015
2015-09-25,Rexahn Pharmaceuticals To Present Preliminary Clinical Data At The European Cancer Congress 2015
2015-09-23,Rexahn Pharmaceuticals To Present At The 15th Annual Biotech In Europe Investor Forum
2015-09-08,Rexahn Pharmaceuticals To Present At The Biopharm America(TM) 2015 Conference In Boston
2015-08-31,Rexahn Pharmaceuticals To Present At The 17th Annual Rodman And Renshaw Global Investment Conference On September 10, 2015
2015-08-10,Rexahn Pharmaceuticals Reports Second Quarter 2015 Financial Results And Provides Corporate Update
2015-07-14,Rexahn Pharmaceuticals Awarded Patent In Japan For Novel Targeted Cancer Drug Delivery Platform
2015-06-22,Rexahn Announces The Appointment Of Peter Brandt As Chairman Of The Board
2015-06-09,Data On Rexahn's RX-3117 In Non-Small Cell Lung Cancer Presented At 16th International Symposium Of The Purine And Pyrimidine Society
2015-06-08,National Cancer Institute Accepts Rexahn's RX-21101 For Its Nanotechnology Characterization Laboratory's Preclinical Characterization Program
2015-05-29,5 Stocks Under $10 Ready to Spike Higher
2015-05-13,Rexahn Announces Poster Presentations At The 2015 American Society Of Clinical Oncology (ASCO) Annual Meeting
2015-05-11,Rexahn Pharmaceuticals Reports First Quarter 2015 Financial Results And Pipeline Update
2015-04-21,New Data Show Rexahn's Supinoxin(TM) Decreases The Migration Of Human Triple Negative Breast Cancer Cells In A Metastatic Cancer Model
2015-04-20,Rexahn Identifies RX-3117 Biomarker & Presents Data At The 2015 American Association For Cancer Research Annual Meeting
2015-04-13,Rexahn Pharmaceuticals To Present Data On RX-3117 And Supinoxin(TM) At The 2015 American Association For Cancer Research Annual Meeting
2015-03-18,Rexahn Pharmaceuticals To Present At The 12th Annual BIO Asia International Conference In Tokyo, Japan
2015-03-17,Rexahn Pharmaceuticals Reports Fourth Quarter And Full-Year 2014 Financial Results And Pipeline Update
2015-03-04,Rexahn Pharmaceuticals To Present At The BIO-Europe Spring(R) 2015 Conference In Paris, France
2015-03-02,Rexahn Pharmaceuticals To Present At The ROTH Capital Partners 27th Annual Growth Stock Conference
2015-02-18,Rexahn Pharmaceuticals To Present At The 3rd Annual Sachs Cancer Bio Partnering & Investment Forum In New York
2015-02-09,Rexahn Pharmaceuticals Announces The Publication Of Preclinical Data For Supinoxin(TM) (RX-5902) Demonstrating Mechanism Of Action
2015-02-04,Rexahn Pharmaceuticals Announces The Appointment Of Ely Benaim, M.D., As Chief Medical Officer
2015-02-02,Rexahn Pharmaceuticals To Present At The 17th Annual BIO CEO & Investor Conference
2015-01-07,Rexahn Pharmaceuticals To Present At Biotech Showcase(TM) 2015
2015-01-06,Rexahn Pharmaceuticals Announces Publication Of Preclinical Data For RX-3117 Demonstrating Effectiveness Against Gemcitabine Resistant Human Cancer Cells
2014-12-04,Rexahn Pharmaceuticals To Present At The Oppenheimer Healthcare Conference On December 10, 2014
2014-12-03,Rexahn Pharmaceuticals Appoints Richard Rodgers To Its Board Of Directors
2014-11-17,Rexahn Pharmaceuticals To Participate In Brean Capital 2014 Life Sciences Summit
2014-11-13,Rexahn Pharmaceuticals Reports Third Quarter 2014 Financial Results And Pipeline Update
2014-11-11,Rexahn Pharmaceuticals To Present At The Stifel 2014 Healthcare Conference On November 18, 2014
2014-10-28,Rexahn Pharmaceuticals To Present At The BIO-Europe(R) Conference In Frankfurt, Germany
2014-09-30,Rexahn Pharmaceuticals To Present At 13th Annual BIO Investor Forum
2014-09-24,Rexahn Receives FDA Orphan Drug Designation For RX-3117 In Treatment Of Pancreatic Cancer
2014-09-23,Rexahn Pharmaceuticals To Present At The 14th Annual Biotech In Europe Investor Forum For Global Partnering And Investment In Basel, Switzerland
2014-09-16,Rexahn Pharmaceuticals To Present At The BioPharm America™ 2014 In Boston, Massachusetts, USA
2014-09-04,Rexahn Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference On September 9, 2014
2014-09-03,Rexahn Receives A Notice Of Allowance From The U.S. Patent And Trademark Office For A Novel Targeted Cancer Drug Delivery Platform
2014-08-14,Rexahn Pharmaceuticals Reports Second Quarter 2014 Financial Results And Pipeline Update
2014-07-18,Rexahn Pharmaceuticals Provides Update On Phase I Supinoxin Trial In Cancer Patients With Solid Tumors
2014-05-15,Rexahn Pharmaceuticals Reports First Quarter 2014 Financial Results And Pipeline Update
2014-05-08,RX-3117 Showed Greater Efficacy (tumor Growth Inhibition) As Compared To Gemcitabine In Four Different Xenograft Animal Models With Gemcitabine Resistant Human Cancer Cell Lines: Colorectal Cancer (Colo205), Small Cell Lung Cancer (H69), Cervical Cancer (CaSki) And Pancreatic Cancer (CTG-0298).
2014-04-21,Rexahn Presents Data From Preclinical Studies Of RX-21101
2014-04-02,Rexahn Pharmaceuticals To Present Data On RX-3117 And RX-21101 At The 2014 American Association For Clinical Research Annual Meeting
2014-03-24,Rexahn Pharmaceuticals Reports Fourth Quarter And Full-Year 2013 Financial Results And Recent Highlights
2014-03-19,3 Stocks Under $10 Making Big Moves
2014-03-17,Rexahn Pharmaceuticals To Present At The 2nd Annual Sachs Cancer Bio Partnering &amp; Investment Forum In New York
2014-03-11,Rexahn Announces Initial Results From Phase I Trial Of SupinoxinTM (RX-5902) For Solid Cancer Tumors
2014-03-07,Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine
2014-03-04,Rexahn Pharmaceuticals To Present At The 26th Annual ROTH Conference
2014-03-03,Rexahn Pharmaceuticals Appoints Mark Carthy To Board Of Directors
2014-03-01,Biotech Sector Performance February 2014: Red Hot But...
2014-02-26,4 Biotech Stocks Under $10 Moving Higher
2014-02-06,5 Stocks Under $10 Set to Soar
2014-02-04,Rexahn Pharmaceuticals To Present At The 16th Annual BIO CEO &amp; Investor Conference
2014-01-31,4 Health Care Stocks Under $10 to Watch
2014-01-21,It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013
2014-01-15,Rexahn Announces $20 Million Registered Direct Offering
2014-01-14,Rexahn Initiates Phase IIa Clinical Trial Of Archexin&#174; In Patients With Metastatic Renal Cell Carcinoma
2014-01-10,Why Rexahn Pharmaceuticals (RNN) Is Up Today
2014-01-08,Rexahn Initiates Phase Ib Clinical Trial Of RX-3117 For Treatment Of Solid Tumors
2014-01-07,Rexahn Pharmaceuticals To Present At The Biotech Showcase 2014
2013-12-11,Rexahn Receives Method Patent For Treatment Of Solid Tumor Cancers For Supinoxin TM&#160;(RX-5902)
2013-11-19,Rexahn Pharmaceuticals To Participate In Brean Capital 2013 Life Sciences Summit
2013-11-14,Rexahn Pharmaceuticals Reports Third Quarter Financial Results And Pipeline Update
2013-10-11,Rexahn Announces $5.3 Million At Market Registered Direct Offering
2013-10-10,Rexahn Pharmaceuticals In-Licenses Novel Oligonucleotide Targeted Drug Delivery Platform From Ohio State University
2013-10-03,5 Stocks Under $10 Set to Soar
2013-09-30,Rexahn Pharmaceuticals Announces Publication Of Preclinical Data For Novel Anti-Cancer Compound RX-3117
2013-09-12,Rexahn Awarded Patent In Europe For Cancer Drug Archexin&#174;
2013-09-05,Rexahn Pharmaceuticals To Present At The 15th Annual Rodman &amp; Renshaw Global Investment Conference On September 9, 2013
2013-09-04,Rexahn Pharmaceuticals Provides A Clinical Development And Financial Update
2013-08-28,Rexahn Pharmaceuticals Announces Teva Will Not Exercise Its Option To License RX-3117
2013-08-07,Rexahn Pharmaceuticals Initiates Dosing In Phase I Trial Of SupinoxinTM (RX-5902) A Candidate For Treating Solid Cancer Tumors
2013-07-24,Rexahn Pharmaceuticals Announces $5.7 Million Registered Direct Offering
2013-07-17,Rexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery Platform
2013-07-15,Rexahn Pharmaceuticals Announce IND Submission For RX-3117
2013-07-09,Rexahn Pharmaceuticals Awarded Patent In Japan For Novel Anti-cancer Isoquinolinamine Compounds&#160;&#160;
2013-06-17,Rexahn Awarded U.S. Patent For Novel Anti-Cancer Compounds
2013-05-20,Rexahn Pharmaceuticals To Present At The Second Annual Marcum LLP MicroCap Conference
2013-03-11,Rexahn Pharmaceuticals To Present At The 25th Annual ROTH Conference
2013-02-19,Rexahn Pharmaceuticals Provides Key Goals For 2013
2013-01-22,Rexahn Pharmaceuticals Appoints Peter D. Suzdak As Chief Executive Officer
2012-12-17,Rexahn Pharmaceuticals Expands Its Intellectual Property Around Class Of Potent Anti-cancer Isoquinolinamine Compounds
2012-12-04,Rexahn Pharmaceuticals Closes Public Offering For $6,600,000 In Gross Proceeds
2012-11-29,Rexahn Pharmaceuticals Prices Public Offering Of Stock
2012-11-28,Rexahn Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrant
2012-11-28,Teva Pharmaceutical To Increase Ownership In Rexahn
2012-11-21,Rexahn Pharmaceuticals Issued US Patent For Quinoxalinyl-piperazine Compounds
2012-09-26,Rexahn Pharmaceuticals Granted European Patent For Novel Anti-cancer Isoquinolinamine Compounds
2012-09-06,Rexahn Pharmaceuticals To Present At The Rodman &amp; Renshaw 14th Annual Healthcare Conference
2012-09-04,Rexahn Pharmaceuticals Provides Update On 2012 Strategic Goals
2012-08-31,Biotech Stock Mailbag: Rexahn, Vertex, Peregrine, Sarepta
2012-08-30,Rexahn Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
2012-08-28,Rexahn Pharmaceuticals Announces Positive Top-line Phase IIa Data For Archexin In Patients With Metastatic Pancreatic Cancer
2012-08-06,Rexahn Pharmaceuticals Completes Exploratory Phase I Clinical Study Of RX-3117
2012-07-02,Rexahn Submits An Investigational New Drug Application To The FDA For First-in-Class P68 Helicase Inhibitor, RX-5902
2012-05-30,Rexahn Pharmaceuticals Announces Publication Of New Preclinical Research Data For Novel Anti-Cancer Compound RX-3117
2012-05-08,Rexahn Pharmaceuticals Submits Archexin Phase II Protocol For Ovarian Cancer To FDA
2012-03-27,Rexahn Pharmaceuticals To Present Data On Novel Anti-Cancer Small Molecule RX-3117 At AACR 103rd Annual Meeting
2012-03-13,Rexahn Pharmaceuticals Enrolls First Subject In Exploratory Phase I Clinical Study Of RX-3117
2012-01-25,Rexahn Pharmaceuticals Publishes New Preclinical Data For Quinoxalinyl-Piperazine Compounds
2012-01-18,Rexahn Pharmaceuticals Secures Approval In Europe To Conduct A First-in-Human Trial Of RX-3117 In Solid Tumors
2012-01-17,Rexahn Pharmaceuticals Provides Key Goals For 2012
2011-11-04,Rexahn Pharmaceuticals Announces Phase II Results For Serdaxin&#174; As Treatment For Major Depressive Disorder
2011-10-12,Rexahn Pharmaceuticals Granted US Patent For Novel Anti-cancer Isoquinolinamine Compounds
2011-10-03,Rexahn Pharmaceuticals Announces Publication Of Study Validating Mechanism Of Action Of Serdaxin&#174;
2011-09-28,Rexahn Pharmaceuticals Completes Patient Enrollment For Archexin Phase II Clinical Trial In Metastatic Pancreatic Cancer
2011-09-08,Rexahn Pharmaceuticals To Present At The Rodman &amp; Renshaw 13th Annual Healthcare Conference
2011-09-06,Rexahn Pharmaceuticals Announces US Patent Issued For CNS-based Treatment Of Sexual Dysfunction
2011-08-08,European Patent Granted For Neurotherapeutic Compositions
2011-06-22,Rexahn Pharmaceuticals Completes Patient Enrollment In Serdaxin Phase IIb Clinical Trial For Major Depressive Disorder
2011-05-23,Insiders Trading FURX, MELI, FRP
2011-05-05,Rexahn Pharmaceuticals Reports Enrollment Progress On Phase IIb Clinical Trial Of Serdaxin For Depression
2011-04-12,6 Stocks With Big Insider Buying
2011-04-06,Insiders Trading RNN, LULU, KYN, GES
2011-04-04,Rexahn Pharmaceuticals To Present At Needham &amp; Company&#8217;s 10th Annual Healthcare Conference
2011-03-31,Rexahn Closes $10 Million In Registered Direct Offering
2011-03-30,Rexahn Pharmaceuticals To Present Data On Novel Anti-Cancer Small Molecule RX-5902 At AACR 102nd Annual Meeting
2011-03-28,Rexahn To Raise $10 Million In Registered Direct Offering
2011-03-23,Rexahn Pharmaceuticals Enrolls 100 Patients In Serdaxin&#174; Phase IIb Clinical Trial For Depression
2011-03-14,Rexahn Pharmaceuticals To Present At The Roth Capital Partners 23rd Annual OC Growth Stock Conference
2011-03-07,Rexahn Announces CEO Transition To CSO And Search For New CEO
2011-02-28,Rexahn Pharmaceuticals Granted European Patent For New Quinoxalinyl-piperazine Compounds
2011-02-18,Biotech Mailbag: BIO CEO Wrap
2011-02-11,Biotech Stock Mailbag: Protalix BioTherapeutics
2011-02-08,Rexahn Higher on Deja Vu Stock Promotion
2011-02-01,6 Penny Stocks for the Biotech Boom
2011-01-25,Rexahn Pharmaceuticals Enrolls First Patient In Serdaxin&#174; Phase IIb Clinical Trial
2011-01-24,Genoptix, Clinical Data: Small-Cap Winners
2011-01-20,Wendy's/Arby's, BioLase: Small-Cap Winners
2011-01-20,Teva Pharmaceutical Increases Its Investment In Rexahn For The Continued Research And Development Of The Pre-Clinical Anti-Cancer Compound, RX-3117
2010-12-20,Rexahn Awarded Patent In Japan For RX-0047
2010-12-08,Rexahn Pharmaceuticals Presents Serdaxin Phase IIa Clinical Data At The American College Of Neuropsychopharmacologists Annual Meeting
2010-12-06,U.S. Patent Issued For New Method For Treating Cognitive Disorders
2010-11-22,Additional U.S. Patent Issued For Rexahn&#8217;s CNS Treatment Portfolio
2010-11-08,Rexahn Pharmaceuticals Announces Publication Of New Preclinical Research Data For Novel Anticancer Compounds
2010-11-04,Rexahn Awarded Qualifying Therapeutic Discovery Project Grants To Further Develop Anti-Cancer, Depression, And Erectile Dysfunction Treatments
2010-10-26,Rexahn To Use MedAvante Centralized Ratings In MDD Phase 2b Study
2010-10-20,Rexahn Pharmaceuticals To Attend BioNetwork West
2010-10-19,Rexahn Pharmaceuticals Publishes New Data On Anti-Cancer Isoquinolinamine Derivatives
2010-09-21,Rexahn Pharmaceuticals Announces Publication Of Study On Neuroprotective Effects Of Clavulanic Acid
2017-02-03,Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?
2017-02-02,Repros Announces New CEO
2017-01-30,FDA Grants End Of Phase 2 Meeting To Discuss Phase 3 Requirements For Oral Proellex® In The Treatment Of Uterine Fibroids
2016-12-19,Repros Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex® In The Treatment Of Endometriosis
2016-12-12,Repros Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex® In The Treatment Of Symptomatic Uterine Fibroids
2016-12-06,FDA Advisory Committee Discusses Clinical Trial Designs For Obesity-Related Hypogonadism
2016-11-14,Repros Reports Topline Positive Clinical Data After Two 18 Week Courses Of Proellex® Delivered Orally And Vaginally For The Treatment Of Uterine Fibroids
2016-11-08,Repros Therapeutics Inc.® Reports Third Quarter 2016 Financial Results
2016-10-05,Repros Announces Acceptance Of Dossier For Enclomiphene For Secondary Hypogonadism By European Authorities
2016-09-26,FDA Schedules Advisory Committee Meeting To Discuss Secondary Hypogonadism
2016-09-12,Repros Announces Submission Of MAA To The European Medicines Agency For Enclomiphene In The Treatment Of Secondary Hypogonadism
2016-09-07,Repros Provides Phase 2 Results Showing Positive Outcomes For Oral Proellex® In Women With Moderate To Severe Endometriosis
2016-08-15,Repros Provides Six Month Interim Results For Enclomiphene Study In Obese Secondary Hypogonadal Men
2016-08-09,Repros Therapeutics Inc.® Reports Second Quarter 2016 Financial Results
2016-07-29,8 Stocks Under $10 to Trade for Huge Profits
2016-06-01,Repros Provides Update On EU Submission Of Enclomiphene For The Treatment Of Secondary Hypogonadism And 3 Month Interim Results For Enclomiphene Study In Obese Secondary Hypogonadal Men
2016-05-18,Repros Reports Positive Clinical Data For Oral Proellex® In Women With Severe Menstrual Bleeding Due To Uterine Fibroids
2016-05-16,Repros Announces The Appointment Of Mr. Patrick Fourteau As Chairman Of The Board
2016-05-10,Repros Therapeutics Inc.® Reports First Quarter 2016 Financial Results
2016-04-14,5 Stocks Under $10 Set to Soar
2016-04-12,Repros Reports Positive Clinical Data For Vaginal Proellex® In Women With Severe Menstrual Bleeding Due To Uterine Fibroids
2016-03-15,Repros Announces Initiation Of Formal Approval Process By The European Medicines Agency
2016-03-14,Repros Therapeutics Inc.® Reports Fourth Quarter And Year End 2015 Financial Results
2016-02-16,Repros Completes Randomization Of Enclomiphene Phase 2 Proof Of Concept Study In Obese Secondary Hypogonadal Men
2016-02-08,Repros Holds Meeting With FDA To Discuss Complete Response Letter For Enclomiphene In The Treatment Of Secondary Hypogonadism
2016-01-11,Repros Announces Court Of Appeals' Affirmation Of Summary Judgment In Favor Of The Company
2016-01-04,Repros Updates Enclomiphene Program
2015-12-21,Repros Updates Proellex® Program
2015-12-01,Repros (RPRX) Stock Plummets After FDA Rejects Hypogonadism Drug Trial Results
2015-12-01,Repros Therapeutics Receives Complete Response Letter From FDA For Enclomiphene
2015-11-29,4 Stocks Under $10 to Trade for Big Breakouts
2015-11-12,Repros Therapeutics Completes Randomization Of Phase 2b Study Of Vaginal Proellex(R) In Women With Symptomatic Uterine Fibroid Bleeding
2015-11-09,Repros Therapeutics Inc.(R) Reports Third Quarter 2015 Financial Results
2015-10-29,Repros Therapeutics Announces Cancellation Of FDA Advisory Committee Meeting To Review Enclomiphene For The Treatment Of Secondary Hypogonadism
2015-10-22,Oversold Conditions For Repros Therapeutics (RPRX)
2015-10-01,Oversold Rally, but Not Where We Wanted
2015-08-10,Repros Therapeutics Inc.(R) Reports Second Quarter 2015 Financial Results
2015-07-09,3 Stocks Under $10 Triggering Breakout Trades
2015-06-26,Short Interest Makes 16.6% Move For RPRX
2015-06-18,3 Biotech Stocks Under $10 to Trade for Breakouts
2015-06-08,Repros Announces Date Of FDA Advisory Committee Review Of NDA
2015-05-28,Repros Therapeutics Is Now Oversold (RPRX)
2015-05-07,Repros Therapeutics Inc.(R) Reports First Quarter 2015 Financial Results
2015-04-30,Repros Therapeutics Enters Oversold Territory (RPRX)
2015-04-15,Repros Announces November 30, 2015 PDUFA Goal Date For New Drug Application
2015-04-06,Repros Receives Confirmation Of Eligibility For Submission Of A Centralized Marketing Authorization Application To The European Medicines Agency As A New Active Substance
2015-04-02,Voltari Corp. Dips After Icahn-Driven Surge
2015-04-01,Repros Announces Acceptance For Filing Of NDA
2015-03-16,Repros Therapeutics Inc.(R) Reports Fourth Quarter And Year End 2014 Financial Results
2015-03-05,5 Stocks Under $10 Set to Soar: Breakout Stocks
2015-02-26,5 Stocks Under $10 to Trade for Breakouts: SouFun, Repros and More
2015-02-02,Repros Submits New Drug Application To FDA For Androxal (R)
2015-01-13,Short Interest In Repros Therapeutics Moves 15.2% Lower
2014-12-29,Energy Spinoffs Transocean Partners, Seventy Seven Energy Tumble
2014-12-29,Repros Updates Androxal(R) Global Regulatory Status
2014-12-29,Repros Initiates Two Phase 2B Uterine Fibroid Studies
2014-12-29,Court Rules Inventors Correctly Named On Androxal(R) Patents
2014-12-19,5 Stocks Poised for Breakouts: RetailMeNot, Repros and More
2014-12-15,Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...
2014-12-12,RPRX: Insiders Vs. Shorts
2014-11-10,Repros Therapeutics Inc.(R) Reports Third Quarter 2014 Financial Results
2014-11-07,Sears Soars Nearly +40% As REIT News Boosts Confidence
2014-11-07,Repros Therapeutics (RPRX) Stock Skyrockets After Meeting with FDA About Androxal
2014-11-06,Repros Holds Constructive Meeting With FDA Regarding Androxal(R) NDA Filing
2014-10-27,Repros To Webcast Investor And Analyst Day On October 31st
2014-10-27,Short Interest Makes 14.2% Move For RPRX
2014-10-21,Results From Long-Term Study Of Androxal(R) Exhibit Positive Safety Profile
2014-10-20,SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Possible Violations Of Federal Securities Laws By The Board Of Directors Of Repros Therapeutics Inc. - RPRX
2014-10-20,INVESTOR ALERT: Investigation Of Repros Therapeutics Inc. Announced By Glancy Binkow & Goldberg LLP
2014-10-20,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Repros Therapeutics Inc.
2014-10-17,INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Repros Therapeutics Inc. (RPRX) To Contact The Firm
2014-10-17,EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Repros Therapeutics Inc. - RPRX
2014-10-17,Troubles Continue for Repros Therapeutics
2014-10-17,Repros Therapeutics Enters Oversold Territory (RPRX)
2014-10-17,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Repros Therapeutics, Inc. - RPRX
2014-10-16,Upcoming FDA Meeting To Be Type C Meeting
2014-09-29,Interesting RPRX Put Options For December 20th
2014-09-26,5 Breakout Stocks Under $10 Set to Soar
2014-09-26,FDA Schedules Type B Pre-NDA Meeting With Repros
2014-09-25,Androxal(R) Second Pivotal Study Achieves Superiority In Top Line Analysis For Both Co-Primary Endpoints Versus Marketed Topical Gel In The Treatment Of Secondary Hypogonadism
2014-09-24,Interesting RPRX Put And Call Options For May 2015
2014-09-22,Repros Gives Update On Androxal(R) With Respect To Recent FDA Advisory Panel Outcome And Announces Upcoming Presentation At Biocentury
2014-09-18,Rite Aid Plunges as Full-Year Outlook Dims
2014-09-18,Why Repros Therapeutics (RPRX) Stock Plummeted to a One-Year Low Today
2014-09-18,Repros Therapeutics Enters Oversold Territory (RPRX)
2014-09-17,With No Buyers In Sight, Rackspace Dives
2014-09-05,Infoblox Inc. (BLOX) Climbs on Earnings
2014-09-04,Bad News for the Bull Market
2014-09-03,Arrowhead Research Climbs +8.54% Midday, Is Up Over +50% YTD
2014-08-28,Williams-Sonoma Stumbles After Yesterday's Surge
2014-08-28,Why Repros Therapeutics (RPRX) Stock Is Surging Today
2014-08-27,Androxal(R) Achieves Superiority In Top Line Analysis For Both Co-Primary Endpoints And Various Secondary Endpoints Versus Marketed Topical Gel In First Of Two Identical Studies In The Treatment Of Secondary Hypogonadism
2014-08-25,Five Billionaire-Owned Biotech Stocks You Could Acquire for 100%
2014-08-25,5 Stocks Spiking on Big Volume
2014-08-11,Repros Therapeutics Inc.(R) Reports Second Quarter 2014 Financial Results
2014-07-28,Oversold Conditions For Repros Therapeutics (RPRX)
2014-07-16,FDA Confirms Sperm And Testosterone Endpoints As Key Parameters For Assessment Of Androxal(R) Versus Approved Topical Gel And Placebo
2014-05-13,Repros Fully Enrolls Second Previously Announced Head To Head Study Of Androxal(R) Versus The Leading Topical Testosterone Gel
2014-05-12,Repros Therapeutics Inc.(R) Reports First Quarter 2014 Financial Results
2014-05-05,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Repros Therapeutics, Inc. - RPRX
2014-05-02,First Week of November 22nd Options Trading For Repros Therapeutics (RPRX)
2014-04-30,FDA Recommends Sperm Endpoints As Key Parameters For Assessment Of Androxal(R) Versus Approved Topical Gel
2014-04-14,Repros Fully Enrolls First Of Two Previously Announced Head To Head Studies Of Androxal(R) Versus The Leading Topical Testosterone Gel
2014-04-11,Oversold Conditions For Repros Therapeutics (RPRX)
2014-03-20,RPRX Crosses Above Key Moving Average Level
2014-03-17,Repros Allowed To Conduct Phase 1 And 2 Clinical Studies Of Low Dose Oral Proellex(R) In The Treatment Of Uterine Fibroids And Endometriosis
2014-03-13,Repros Therapeutics Inc.(R) Reports Fourth Quarter And Year End 2013 Financial Results
2014-02-10,Repros Reports Findings From The Six Month Study Of Androxal(R) In Men With Secondary Hypogonadism
2014-02-06,Repros Meets With FDA To Discuss Data Requirements For Androxal(R) In The Treatment Of Secondary Hypogonadism
2014-02-04,Repros Therapeutics Enters Oversold Territory (RPRX)
2014-01-27,Notable Two Hundred Day Moving Average Cross - RPRX
2014-01-15,Pre-Market Pulse: Dendreon, Novartis AG, Stryker, And Repros Therapeutics
2014-01-08,Repros Initiates Two Head To Head Studies Of Androxal(R) Versus The Leading Topical Testosterone Gel
2013-12-19,Repros Adds Marketing And Commercialization Expertise To Board Of Directors
2013-12-19,RPRX Makes Bullish Cross Above Critical Moving Average
2013-12-04,Attention Repros Therapeutics, Inc. Investors: Law Firm Investigates On Behalf Of Shareholders
2013-11-25,Repros To Present Data On The Benefits Of Testosterone Restoration With Androxal(R) Compared To T Replacement With Gels At 9th Men's Health World Congress
2013-11-25,FDA Schedules Face To Face Meeting With Repros To Discuss Androxal(R) Efficacy
2013-11-07,Repros Therapeutics Inc.(R) Reports Third Quarter 2013 Financial Results
2013-11-04,Repros Receives FDA Guidance For Proellex(R) Low Dose Oral Uterine Fibroid Clinical Program
2013-10-28,Top Insider Trades: HLX, RT, STI, RPRX
2013-10-25,5 Dumbest Things on Wall Street
2013-10-24,Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Investors Of Repros Therapeutics Inc.
2013-10-24,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Repros Therapeutics, Inc. - RPRX
2013-10-23,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Repros Therapeutics, Inc.
2013-10-23,FDA Questions Credibility of Repros Testosterone Pill Data
2013-10-22,Repros Receives FDA Guidance For Androxal(R) Clinical Program
2013-10-07,Repros Announces Three Studies Accepted For Presentation At The Annual Meeting Of The Sexual Medicine Society Of North America
2013-09-23,Repros To Present At Biocentury's NewsMakers In The Biotech Industry Conference
2013-09-19,4 Biotech Stocks Triggering Breakout Trades
2013-09-18,Repros Provides Additional Information Confirming Success For Study ZA-302
2013-09-17,Why Repros Is Still Risky Despite Stock's Ascent
2013-09-16,Repros Reports Preliminary Findings: Second Pivotal Study And 6-Month Safety Study Support Androxal(R) Approvability
2013-09-04,3 Biotech Stocks Triggering Breakouts on Big Volume
2013-08-20,Repros Reports 6 Month Bone Mineral Density Data From Ongoing Study ZA-303
2013-08-07,Repros Therapeutics Inc.(R) Reports Second Quarter 2013 Financial Results
2013-08-05,Repros Worried About Validity of its Androxal Patent
2013-08-05,Repros Seeks To Affirm Its Intellectual Property Rights In Androxal(R)
2013-07-11,5 Stocks Setting Up to Break Out
2013-07-09,Repros Announces Formation Of Androxal(R) Clinical And Commercial Advisory Board
2013-07-03,RPRX September 21st Options Begin Trading
2013-06-25,Repros Therapeutics Inc.(R) Announces The Closing Of Public Offering Of Common Stock
2013-06-19,Repros Therapeutics Inc.(R) Announces Pricing Of Public Offering Of Common Stock
2013-06-17,Repros Therapeutics Inc.(R) Announces Proposed Public Offering Of Common Stock
2013-06-03,Repros To Webcast Investor And Analyst Day On June 6th
2013-05-31,The 5 Dumbest Things on Wall Street This Week: May 31
2013-05-22,FDA Recommends Running Phase 2b Trial Of Proellex(R)-V In The Treatment Of Severe Menstrual Bleeding Associated With Uterine Fibroids
2013-05-10,Repros Therapeutics Inc.(R) Reports First Quarter 2013 Financial Results
2013-05-10,Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin
2013-05-09,Repros Patent Problems Began When Harry Met Joe
2013-05-02,Repros Reports Second Pivotal Androxal(R) Study Fully Enrolled Ahead Of Schedule
2013-04-29,Repros' Proellex(R) In Breast Cancer Phase 2 Study In Collaboration With Northwestern University
2013-04-29,Repros To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
2013-04-10,Repros Reports Issuance Of Two Additional U.S. Androxal(R) Patents
2013-04-05,5 Dumbest Things on Wall Street This Week: April 5
2013-04-05,The Five Dumbest Things on Wall Street: April 5
2013-03-28,Repros CEO: My Testosterone Drug Helped Gay Cubans Have Lots of Sex
2013-03-27,Repros Reports Both Primary Endpoints Successfully Met In First Pivotal Study Of Androxal(R)
2013-03-25,American Urological Association (AUA) Accepts Androxal(R) Versus Topical Gel Comparative Study For Podium Presentation At Annual Meeting
2013-03-18,Repros Therapeutics Inc.(R) Reports Fourth Quarter And Year End 2012 Financial Results
2013-02-28,FDA Grants Repros An End Of Phase 2 Meeting In Late May To Discuss Proellex(R)-V Phase 3 Study Design
2013-02-21,Repros Reports FDA Recommends Pivotal Study ZA-301 Of Androxal(R) To Be Completed As Originally Planned
2013-02-11,Repros Therapeutics Corporate Update
2013-01-28,Repros Updates Guidance For Top Line Results From First Pivotal Androxal(R) Study To Q3 2013
2013-01-07,Repros Reports Core 1-Year DEXA Study Fully Enrolled Ahead Of Schedule And Provides Update For Androxal(R) Clinical Program
2013-01-03,Repros' Proellex(R)-V Topline Analysis Suggests 12 Mg Dose Effective And Well Tolerated In Phase 2 For Uterine Fibroids
2012-12-18,11 Stocks With Significant Institutional And Insider Buying
2012-12-17,4 Stocks Rising on Unusual Volume
2012-12-04,10 Stocks With Bullish Institutional And Insider Buying Activities
2012-11-13,5 Heavily-Shorted Stocks About to Report
2012-10-08,FDA Reclassifies Proellex(R) Clinical Hold Status: Repros To Proceed With Phase 2 Study Of Low Dose Oral Proellex(R) In The Treatment Of Endometriosis
2012-09-12,Repros Provides Clinical Update For Androxal(R) Phase 3 Program
2012-09-04,Repros Announces The Offering Of Unregistered Shares Of Common Stock In The Amount Of $23.6 Million
2012-08-27,FDA Provides Recommendations For Phase 2 Protocol For Low Dose Oral Proellex(R) In The Treatment Of Endometriosis
2012-08-20,4 Big-Volume Stocks Surging Higher
2012-08-13,Repros Therapeutics Inc.(R) Reports Second Quarter 2012 Financial Results
2012-05-16,5 Stocks That Insiders Love Right Now
2012-05-14,Insiders Trading GHDX, PDH, RPRX
2012-05-10,8 Stocks Under $10 Soaring Higher
2011-03-30,16 Small-Cap Stocks in Danger of Delisting
2017-02-03,Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?
2017-02-02,Repros Announces New CEO
2017-01-30,FDA Grants End Of Phase 2 Meeting To Discuss Phase 3 Requirements For Oral Proellex® In The Treatment Of Uterine Fibroids
2016-12-19,Repros Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex® In The Treatment Of Endometriosis
2016-12-12,Repros Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex® In The Treatment Of Symptomatic Uterine Fibroids
2016-12-06,FDA Advisory Committee Discusses Clinical Trial Designs For Obesity-Related Hypogonadism
2016-11-14,Repros Reports Topline Positive Clinical Data After Two 18 Week Courses Of Proellex® Delivered Orally And Vaginally For The Treatment Of Uterine Fibroids
2016-11-08,Repros Therapeutics Inc.® Reports Third Quarter 2016 Financial Results
2016-10-05,Repros Announces Acceptance Of Dossier For Enclomiphene For Secondary Hypogonadism By European Authorities
2016-09-26,FDA Schedules Advisory Committee Meeting To Discuss Secondary Hypogonadism
2016-09-12,Repros Announces Submission Of MAA To The European Medicines Agency For Enclomiphene In The Treatment Of Secondary Hypogonadism
2016-09-07,Repros Provides Phase 2 Results Showing Positive Outcomes For Oral Proellex® In Women With Moderate To Severe Endometriosis
2016-08-15,Repros Provides Six Month Interim Results For Enclomiphene Study In Obese Secondary Hypogonadal Men
2016-08-09,Repros Therapeutics Inc.® Reports Second Quarter 2016 Financial Results
2016-07-29,8 Stocks Under $10 to Trade for Huge Profits
2016-06-01,Repros Provides Update On EU Submission Of Enclomiphene For The Treatment Of Secondary Hypogonadism And 3 Month Interim Results For Enclomiphene Study In Obese Secondary Hypogonadal Men
2016-05-18,Repros Reports Positive Clinical Data For Oral Proellex® In Women With Severe Menstrual Bleeding Due To Uterine Fibroids
2016-05-16,Repros Announces The Appointment Of Mr. Patrick Fourteau As Chairman Of The Board
2016-05-10,Repros Therapeutics Inc.® Reports First Quarter 2016 Financial Results
2016-04-14,5 Stocks Under $10 Set to Soar
2016-04-12,Repros Reports Positive Clinical Data For Vaginal Proellex® In Women With Severe Menstrual Bleeding Due To Uterine Fibroids
2016-03-15,Repros Announces Initiation Of Formal Approval Process By The European Medicines Agency
2016-03-14,Repros Therapeutics Inc.® Reports Fourth Quarter And Year End 2015 Financial Results
2016-02-16,Repros Completes Randomization Of Enclomiphene Phase 2 Proof Of Concept Study In Obese Secondary Hypogonadal Men
2016-02-08,Repros Holds Meeting With FDA To Discuss Complete Response Letter For Enclomiphene In The Treatment Of Secondary Hypogonadism
2016-01-11,Repros Announces Court Of Appeals' Affirmation Of Summary Judgment In Favor Of The Company
2016-01-04,Repros Updates Enclomiphene Program
2015-12-21,Repros Updates Proellex® Program
2015-12-01,Repros (RPRX) Stock Plummets After FDA Rejects Hypogonadism Drug Trial Results
2015-12-01,Repros Therapeutics Receives Complete Response Letter From FDA For Enclomiphene
2015-11-29,4 Stocks Under $10 to Trade for Big Breakouts
2015-11-12,Repros Therapeutics Completes Randomization Of Phase 2b Study Of Vaginal Proellex(R) In Women With Symptomatic Uterine Fibroid Bleeding
2015-11-09,Repros Therapeutics Inc.(R) Reports Third Quarter 2015 Financial Results
2015-10-29,Repros Therapeutics Announces Cancellation Of FDA Advisory Committee Meeting To Review Enclomiphene For The Treatment Of Secondary Hypogonadism
2015-10-22,Oversold Conditions For Repros Therapeutics (RPRX)
2015-10-01,Oversold Rally, but Not Where We Wanted
2015-08-10,Repros Therapeutics Inc.(R) Reports Second Quarter 2015 Financial Results
2015-07-09,3 Stocks Under $10 Triggering Breakout Trades
2015-06-26,Short Interest Makes 16.6% Move For RPRX
2015-06-18,3 Biotech Stocks Under $10 to Trade for Breakouts
2015-06-08,Repros Announces Date Of FDA Advisory Committee Review Of NDA
2015-05-28,Repros Therapeutics Is Now Oversold (RPRX)
2015-05-07,Repros Therapeutics Inc.(R) Reports First Quarter 2015 Financial Results
2015-04-30,Repros Therapeutics Enters Oversold Territory (RPRX)
2015-04-15,Repros Announces November 30, 2015 PDUFA Goal Date For New Drug Application
2015-04-06,Repros Receives Confirmation Of Eligibility For Submission Of A Centralized Marketing Authorization Application To The European Medicines Agency As A New Active Substance
2015-04-02,Voltari Corp. Dips After Icahn-Driven Surge
2015-04-01,Repros Announces Acceptance For Filing Of NDA
2015-03-16,Repros Therapeutics Inc.(R) Reports Fourth Quarter And Year End 2014 Financial Results
2015-03-05,5 Stocks Under $10 Set to Soar: Breakout Stocks
2015-02-26,5 Stocks Under $10 to Trade for Breakouts: SouFun, Repros and More
2015-02-02,Repros Submits New Drug Application To FDA For Androxal (R)
2015-01-13,Short Interest In Repros Therapeutics Moves 15.2% Lower
2014-12-29,Energy Spinoffs Transocean Partners, Seventy Seven Energy Tumble
2014-12-29,Repros Updates Androxal(R) Global Regulatory Status
2014-12-29,Repros Initiates Two Phase 2B Uterine Fibroid Studies
2014-12-29,Court Rules Inventors Correctly Named On Androxal(R) Patents
2014-12-19,5 Stocks Poised for Breakouts: RetailMeNot, Repros and More
2014-12-15,Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...
2014-12-12,RPRX: Insiders Vs. Shorts
2014-11-10,Repros Therapeutics Inc.(R) Reports Third Quarter 2014 Financial Results
2014-11-07,Sears Soars Nearly +40% As REIT News Boosts Confidence
2014-11-07,Repros Therapeutics (RPRX) Stock Skyrockets After Meeting with FDA About Androxal
2014-11-06,Repros Holds Constructive Meeting With FDA Regarding Androxal(R) NDA Filing
2014-10-27,Repros To Webcast Investor And Analyst Day On October 31st
2014-10-27,Short Interest Makes 14.2% Move For RPRX
2014-10-21,Results From Long-Term Study Of Androxal(R) Exhibit Positive Safety Profile
2014-10-20,SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Possible Violations Of Federal Securities Laws By The Board Of Directors Of Repros Therapeutics Inc. - RPRX
2014-10-20,INVESTOR ALERT: Investigation Of Repros Therapeutics Inc. Announced By Glancy Binkow & Goldberg LLP
2014-10-20,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Repros Therapeutics Inc.
2014-10-17,INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Repros Therapeutics Inc. (RPRX) To Contact The Firm
2014-10-17,EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Repros Therapeutics Inc. - RPRX
2014-10-17,Troubles Continue for Repros Therapeutics
2014-10-17,Repros Therapeutics Enters Oversold Territory (RPRX)
2014-10-17,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Repros Therapeutics, Inc. - RPRX
2014-10-16,Upcoming FDA Meeting To Be Type C Meeting
2014-09-29,Interesting RPRX Put Options For December 20th
2014-09-26,5 Breakout Stocks Under $10 Set to Soar
2014-09-26,FDA Schedules Type B Pre-NDA Meeting With Repros
2014-09-25,Androxal(R) Second Pivotal Study Achieves Superiority In Top Line Analysis For Both Co-Primary Endpoints Versus Marketed Topical Gel In The Treatment Of Secondary Hypogonadism
2014-09-24,Interesting RPRX Put And Call Options For May 2015
2014-09-22,Repros Gives Update On Androxal(R) With Respect To Recent FDA Advisory Panel Outcome And Announces Upcoming Presentation At Biocentury
2014-09-18,Rite Aid Plunges as Full-Year Outlook Dims
2014-09-18,Why Repros Therapeutics (RPRX) Stock Plummeted to a One-Year Low Today
2014-09-18,Repros Therapeutics Enters Oversold Territory (RPRX)
2014-09-17,With No Buyers In Sight, Rackspace Dives
2014-09-05,Infoblox Inc. (BLOX) Climbs on Earnings
2014-09-04,Bad News for the Bull Market
2014-09-03,Arrowhead Research Climbs +8.54% Midday, Is Up Over +50% YTD
2014-08-28,Williams-Sonoma Stumbles After Yesterday's Surge
2014-08-28,Why Repros Therapeutics (RPRX) Stock Is Surging Today
2014-08-27,Androxal(R) Achieves Superiority In Top Line Analysis For Both Co-Primary Endpoints And Various Secondary Endpoints Versus Marketed Topical Gel In First Of Two Identical Studies In The Treatment Of Secondary Hypogonadism
2014-08-25,Five Billionaire-Owned Biotech Stocks You Could Acquire for 100%
2014-08-25,5 Stocks Spiking on Big Volume
2014-08-11,Repros Therapeutics Inc.(R) Reports Second Quarter 2014 Financial Results
2014-07-28,Oversold Conditions For Repros Therapeutics (RPRX)
2014-07-16,FDA Confirms Sperm And Testosterone Endpoints As Key Parameters For Assessment Of Androxal(R) Versus Approved Topical Gel And Placebo
2014-05-13,Repros Fully Enrolls Second Previously Announced Head To Head Study Of Androxal(R) Versus The Leading Topical Testosterone Gel
2014-05-12,Repros Therapeutics Inc.(R) Reports First Quarter 2014 Financial Results
2014-05-05,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Repros Therapeutics, Inc. - RPRX
2014-05-02,First Week of November 22nd Options Trading For Repros Therapeutics (RPRX)
2014-04-30,FDA Recommends Sperm Endpoints As Key Parameters For Assessment Of Androxal(R) Versus Approved Topical Gel
2014-04-14,Repros Fully Enrolls First Of Two Previously Announced Head To Head Studies Of Androxal(R) Versus The Leading Topical Testosterone Gel
2014-04-11,Oversold Conditions For Repros Therapeutics (RPRX)
2014-03-20,RPRX Crosses Above Key Moving Average Level
2014-03-17,Repros Allowed To Conduct Phase 1 And 2 Clinical Studies Of Low Dose Oral Proellex(R) In The Treatment Of Uterine Fibroids And Endometriosis
2014-03-13,Repros Therapeutics Inc.(R) Reports Fourth Quarter And Year End 2013 Financial Results
2014-02-10,Repros Reports Findings From The Six Month Study Of Androxal(R) In Men With Secondary Hypogonadism
2014-02-06,Repros Meets With FDA To Discuss Data Requirements For Androxal(R) In The Treatment Of Secondary Hypogonadism
2014-02-04,Repros Therapeutics Enters Oversold Territory (RPRX)
2014-01-27,Notable Two Hundred Day Moving Average Cross - RPRX
2014-01-15,Pre-Market Pulse: Dendreon, Novartis AG, Stryker, And Repros Therapeutics
2014-01-08,Repros Initiates Two Head To Head Studies Of Androxal(R) Versus The Leading Topical Testosterone Gel
2013-12-19,Repros Adds Marketing And Commercialization Expertise To Board Of Directors
2013-12-19,RPRX Makes Bullish Cross Above Critical Moving Average
2013-12-04,Attention Repros Therapeutics, Inc. Investors: Law Firm Investigates On Behalf Of Shareholders
2013-11-25,Repros To Present Data On The Benefits Of Testosterone Restoration With Androxal(R) Compared To T Replacement With Gels At 9th Men's Health World Congress
2013-11-25,FDA Schedules Face To Face Meeting With Repros To Discuss Androxal(R) Efficacy
2013-11-07,Repros Therapeutics Inc.(R) Reports Third Quarter 2013 Financial Results
2013-11-04,Repros Receives FDA Guidance For Proellex(R) Low Dose Oral Uterine Fibroid Clinical Program
2013-10-28,Top Insider Trades: HLX, RT, STI, RPRX
2013-10-25,5 Dumbest Things on Wall Street
2013-10-24,Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Investors Of Repros Therapeutics Inc.
2013-10-24,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Repros Therapeutics, Inc. - RPRX
2013-10-23,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Repros Therapeutics, Inc.
2013-10-23,FDA Questions Credibility of Repros Testosterone Pill Data
2013-10-22,Repros Receives FDA Guidance For Androxal(R) Clinical Program
2013-10-07,Repros Announces Three Studies Accepted For Presentation At The Annual Meeting Of The Sexual Medicine Society Of North America
2013-09-23,Repros To Present At Biocentury's NewsMakers In The Biotech Industry Conference
2013-09-19,4 Biotech Stocks Triggering Breakout Trades
2013-09-18,Repros Provides Additional Information Confirming Success For Study ZA-302
2013-09-17,Why Repros Is Still Risky Despite Stock's Ascent
2013-09-16,Repros Reports Preliminary Findings: Second Pivotal Study And 6-Month Safety Study Support Androxal(R) Approvability
2013-09-04,3 Biotech Stocks Triggering Breakouts on Big Volume
2013-08-20,Repros Reports 6 Month Bone Mineral Density Data From Ongoing Study ZA-303
2013-08-07,Repros Therapeutics Inc.(R) Reports Second Quarter 2013 Financial Results
2013-08-05,Repros Worried About Validity of its Androxal Patent
2013-08-05,Repros Seeks To Affirm Its Intellectual Property Rights In Androxal(R)
2013-07-11,5 Stocks Setting Up to Break Out
2013-07-09,Repros Announces Formation Of Androxal(R) Clinical And Commercial Advisory Board
2013-07-03,RPRX September 21st Options Begin Trading
2013-06-25,Repros Therapeutics Inc.(R) Announces The Closing Of Public Offering Of Common Stock
2013-06-19,Repros Therapeutics Inc.(R) Announces Pricing Of Public Offering Of Common Stock
2013-06-17,Repros Therapeutics Inc.(R) Announces Proposed Public Offering Of Common Stock
2013-06-03,Repros To Webcast Investor And Analyst Day On June 6th
2013-05-31,The 5 Dumbest Things on Wall Street This Week: May 31
2013-05-22,FDA Recommends Running Phase 2b Trial Of Proellex(R)-V In The Treatment Of Severe Menstrual Bleeding Associated With Uterine Fibroids
2013-05-10,Repros Therapeutics Inc.(R) Reports First Quarter 2013 Financial Results
2013-05-10,Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin
2013-05-09,Repros Patent Problems Began When Harry Met Joe
2013-05-02,Repros Reports Second Pivotal Androxal(R) Study Fully Enrolled Ahead Of Schedule
2013-04-29,Repros' Proellex(R) In Breast Cancer Phase 2 Study In Collaboration With Northwestern University
2013-04-29,Repros To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
2013-04-10,Repros Reports Issuance Of Two Additional U.S. Androxal(R) Patents
2013-04-05,5 Dumbest Things on Wall Street This Week: April 5
2013-04-05,The Five Dumbest Things on Wall Street: April 5
2013-03-28,Repros CEO: My Testosterone Drug Helped Gay Cubans Have Lots of Sex
2013-03-27,Repros Reports Both Primary Endpoints Successfully Met In First Pivotal Study Of Androxal(R)
2013-03-25,American Urological Association (AUA) Accepts Androxal(R) Versus Topical Gel Comparative Study For Podium Presentation At Annual Meeting
2013-03-18,Repros Therapeutics Inc.(R) Reports Fourth Quarter And Year End 2012 Financial Results
2013-02-28,FDA Grants Repros An End Of Phase 2 Meeting In Late May To Discuss Proellex(R)-V Phase 3 Study Design
2013-02-21,Repros Reports FDA Recommends Pivotal Study ZA-301 Of Androxal(R) To Be Completed As Originally Planned
2013-02-11,Repros Therapeutics Corporate Update
2013-01-28,Repros Updates Guidance For Top Line Results From First Pivotal Androxal(R) Study To Q3 2013
2013-01-07,Repros Reports Core 1-Year DEXA Study Fully Enrolled Ahead Of Schedule And Provides Update For Androxal(R) Clinical Program
2013-01-03,Repros' Proellex(R)-V Topline Analysis Suggests 12 Mg Dose Effective And Well Tolerated In Phase 2 For Uterine Fibroids
2012-12-18,11 Stocks With Significant Institutional And Insider Buying
2012-12-17,4 Stocks Rising on Unusual Volume
2012-12-04,10 Stocks With Bullish Institutional And Insider Buying Activities
2012-11-13,5 Heavily-Shorted Stocks About to Report
2012-10-08,FDA Reclassifies Proellex(R) Clinical Hold Status: Repros To Proceed With Phase 2 Study Of Low Dose Oral Proellex(R) In The Treatment Of Endometriosis
2012-09-12,Repros Provides Clinical Update For Androxal(R) Phase 3 Program
2012-09-04,Repros Announces The Offering Of Unregistered Shares Of Common Stock In The Amount Of $23.6 Million
2012-08-27,FDA Provides Recommendations For Phase 2 Protocol For Low Dose Oral Proellex(R) In The Treatment Of Endometriosis
2012-08-20,4 Big-Volume Stocks Surging Higher
2012-08-13,Repros Therapeutics Inc.(R) Reports Second Quarter 2012 Financial Results
2012-05-16,5 Stocks That Insiders Love Right Now
2012-05-14,Insiders Trading GHDX, PDH, RPRX
2012-05-10,8 Stocks Under $10 Soaring Higher
2011-03-30,16 Small-Cap Stocks in Danger of Delisting
2017-02-03,Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?
2017-02-02,Repros Announces New CEO
2017-01-30,FDA Grants End Of Phase 2 Meeting To Discuss Phase 3 Requirements For Oral Proellex® In The Treatment Of Uterine Fibroids
2016-12-19,Repros Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex® In The Treatment Of Endometriosis
2016-12-12,Repros Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex® In The Treatment Of Symptomatic Uterine Fibroids
2016-12-06,FDA Advisory Committee Discusses Clinical Trial Designs For Obesity-Related Hypogonadism
2016-11-14,Repros Reports Topline Positive Clinical Data After Two 18 Week Courses Of Proellex® Delivered Orally And Vaginally For The Treatment Of Uterine Fibroids
2016-11-08,Repros Therapeutics Inc.® Reports Third Quarter 2016 Financial Results
2016-10-05,Repros Announces Acceptance Of Dossier For Enclomiphene For Secondary Hypogonadism By European Authorities
2016-09-26,FDA Schedules Advisory Committee Meeting To Discuss Secondary Hypogonadism
2016-09-12,Repros Announces Submission Of MAA To The European Medicines Agency For Enclomiphene In The Treatment Of Secondary Hypogonadism
2016-09-07,Repros Provides Phase 2 Results Showing Positive Outcomes For Oral Proellex® In Women With Moderate To Severe Endometriosis
2016-08-15,Repros Provides Six Month Interim Results For Enclomiphene Study In Obese Secondary Hypogonadal Men
2016-08-09,Repros Therapeutics Inc.® Reports Second Quarter 2016 Financial Results
2016-07-29,8 Stocks Under $10 to Trade for Huge Profits
2016-06-01,Repros Provides Update On EU Submission Of Enclomiphene For The Treatment Of Secondary Hypogonadism And 3 Month Interim Results For Enclomiphene Study In Obese Secondary Hypogonadal Men
2016-05-18,Repros Reports Positive Clinical Data For Oral Proellex® In Women With Severe Menstrual Bleeding Due To Uterine Fibroids
2016-05-16,Repros Announces The Appointment Of Mr. Patrick Fourteau As Chairman Of The Board
2016-05-10,Repros Therapeutics Inc.® Reports First Quarter 2016 Financial Results
2016-04-14,5 Stocks Under $10 Set to Soar
2016-04-12,Repros Reports Positive Clinical Data For Vaginal Proellex® In Women With Severe Menstrual Bleeding Due To Uterine Fibroids
2016-03-15,Repros Announces Initiation Of Formal Approval Process By The European Medicines Agency
2016-03-14,Repros Therapeutics Inc.® Reports Fourth Quarter And Year End 2015 Financial Results
2016-02-16,Repros Completes Randomization Of Enclomiphene Phase 2 Proof Of Concept Study In Obese Secondary Hypogonadal Men
2016-02-08,Repros Holds Meeting With FDA To Discuss Complete Response Letter For Enclomiphene In The Treatment Of Secondary Hypogonadism
2016-01-11,Repros Announces Court Of Appeals' Affirmation Of Summary Judgment In Favor Of The Company
2016-01-04,Repros Updates Enclomiphene Program
2015-12-21,Repros Updates Proellex® Program
2015-12-01,Repros (RPRX) Stock Plummets After FDA Rejects Hypogonadism Drug Trial Results
2015-12-01,Repros Therapeutics Receives Complete Response Letter From FDA For Enclomiphene
2015-11-29,4 Stocks Under $10 to Trade for Big Breakouts
2015-11-12,Repros Therapeutics Completes Randomization Of Phase 2b Study Of Vaginal Proellex(R) In Women With Symptomatic Uterine Fibroid Bleeding
2015-11-09,Repros Therapeutics Inc.(R) Reports Third Quarter 2015 Financial Results
2015-10-29,Repros Therapeutics Announces Cancellation Of FDA Advisory Committee Meeting To Review Enclomiphene For The Treatment Of Secondary Hypogonadism
2015-10-22,Oversold Conditions For Repros Therapeutics (RPRX)
2015-10-01,Oversold Rally, but Not Where We Wanted
2015-08-10,Repros Therapeutics Inc.(R) Reports Second Quarter 2015 Financial Results
2015-07-09,3 Stocks Under $10 Triggering Breakout Trades
2015-06-26,Short Interest Makes 16.6% Move For RPRX
2015-06-18,3 Biotech Stocks Under $10 to Trade for Breakouts
2015-06-08,Repros Announces Date Of FDA Advisory Committee Review Of NDA
2015-05-28,Repros Therapeutics Is Now Oversold (RPRX)
2015-05-07,Repros Therapeutics Inc.(R) Reports First Quarter 2015 Financial Results
2015-04-30,Repros Therapeutics Enters Oversold Territory (RPRX)
2015-04-15,Repros Announces November 30, 2015 PDUFA Goal Date For New Drug Application
2015-04-06,Repros Receives Confirmation Of Eligibility For Submission Of A Centralized Marketing Authorization Application To The European Medicines Agency As A New Active Substance
2015-04-02,Voltari Corp. Dips After Icahn-Driven Surge
2015-04-01,Repros Announces Acceptance For Filing Of NDA
2015-03-16,Repros Therapeutics Inc.(R) Reports Fourth Quarter And Year End 2014 Financial Results
2015-03-05,5 Stocks Under $10 Set to Soar: Breakout Stocks
2015-02-26,5 Stocks Under $10 to Trade for Breakouts: SouFun, Repros and More
2015-02-02,Repros Submits New Drug Application To FDA For Androxal (R)
2015-01-13,Short Interest In Repros Therapeutics Moves 15.2% Lower
2014-12-29,Energy Spinoffs Transocean Partners, Seventy Seven Energy Tumble
2014-12-29,Repros Updates Androxal(R) Global Regulatory Status
2014-12-29,Repros Initiates Two Phase 2B Uterine Fibroid Studies
2014-12-29,Court Rules Inventors Correctly Named On Androxal(R) Patents
2014-12-19,5 Stocks Poised for Breakouts: RetailMeNot, Repros and More
2014-12-15,Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...
2014-12-12,RPRX: Insiders Vs. Shorts
2014-11-10,Repros Therapeutics Inc.(R) Reports Third Quarter 2014 Financial Results
2014-11-07,Sears Soars Nearly +40% As REIT News Boosts Confidence
2014-11-07,Repros Therapeutics (RPRX) Stock Skyrockets After Meeting with FDA About Androxal
2014-11-06,Repros Holds Constructive Meeting With FDA Regarding Androxal(R) NDA Filing
2014-10-27,Repros To Webcast Investor And Analyst Day On October 31st
2014-10-27,Short Interest Makes 14.2% Move For RPRX
2014-10-21,Results From Long-Term Study Of Androxal(R) Exhibit Positive Safety Profile
2014-10-20,SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Possible Violations Of Federal Securities Laws By The Board Of Directors Of Repros Therapeutics Inc. - RPRX
2014-10-20,INVESTOR ALERT: Investigation Of Repros Therapeutics Inc. Announced By Glancy Binkow & Goldberg LLP
2014-10-20,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Repros Therapeutics Inc.
2014-10-17,INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Repros Therapeutics Inc. (RPRX) To Contact The Firm
2014-10-17,EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Repros Therapeutics Inc. - RPRX
2014-10-17,Troubles Continue for Repros Therapeutics
2014-10-17,Repros Therapeutics Enters Oversold Territory (RPRX)
2014-10-17,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Repros Therapeutics, Inc. - RPRX
2014-10-16,Upcoming FDA Meeting To Be Type C Meeting
2014-09-29,Interesting RPRX Put Options For December 20th
2014-09-26,5 Breakout Stocks Under $10 Set to Soar
2014-09-26,FDA Schedules Type B Pre-NDA Meeting With Repros
2014-09-25,Androxal(R) Second Pivotal Study Achieves Superiority In Top Line Analysis For Both Co-Primary Endpoints Versus Marketed Topical Gel In The Treatment Of Secondary Hypogonadism
2014-09-24,Interesting RPRX Put And Call Options For May 2015
2014-09-22,Repros Gives Update On Androxal(R) With Respect To Recent FDA Advisory Panel Outcome And Announces Upcoming Presentation At Biocentury
2014-09-18,Rite Aid Plunges as Full-Year Outlook Dims
2014-09-18,Why Repros Therapeutics (RPRX) Stock Plummeted to a One-Year Low Today
2014-09-18,Repros Therapeutics Enters Oversold Territory (RPRX)
2014-09-17,With No Buyers In Sight, Rackspace Dives
2014-09-05,Infoblox Inc. (BLOX) Climbs on Earnings
2014-09-04,Bad News for the Bull Market
2014-09-03,Arrowhead Research Climbs +8.54% Midday, Is Up Over +50% YTD
2014-08-28,Williams-Sonoma Stumbles After Yesterday's Surge
2014-08-28,Why Repros Therapeutics (RPRX) Stock Is Surging Today
2014-08-27,Androxal(R) Achieves Superiority In Top Line Analysis For Both Co-Primary Endpoints And Various Secondary Endpoints Versus Marketed Topical Gel In First Of Two Identical Studies In The Treatment Of Secondary Hypogonadism
2014-08-25,Five Billionaire-Owned Biotech Stocks You Could Acquire for 100%
2014-08-25,5 Stocks Spiking on Big Volume
2014-08-11,Repros Therapeutics Inc.(R) Reports Second Quarter 2014 Financial Results
2014-07-28,Oversold Conditions For Repros Therapeutics (RPRX)
2014-07-16,FDA Confirms Sperm And Testosterone Endpoints As Key Parameters For Assessment Of Androxal(R) Versus Approved Topical Gel And Placebo
2014-05-13,Repros Fully Enrolls Second Previously Announced Head To Head Study Of Androxal(R) Versus The Leading Topical Testosterone Gel
2014-05-12,Repros Therapeutics Inc.(R) Reports First Quarter 2014 Financial Results
2014-05-05,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Repros Therapeutics, Inc. - RPRX
2014-05-02,First Week of November 22nd Options Trading For Repros Therapeutics (RPRX)
2014-04-30,FDA Recommends Sperm Endpoints As Key Parameters For Assessment Of Androxal(R) Versus Approved Topical Gel
2014-04-14,Repros Fully Enrolls First Of Two Previously Announced Head To Head Studies Of Androxal(R) Versus The Leading Topical Testosterone Gel
2014-04-11,Oversold Conditions For Repros Therapeutics (RPRX)
2014-03-20,RPRX Crosses Above Key Moving Average Level
2014-03-17,Repros Allowed To Conduct Phase 1 And 2 Clinical Studies Of Low Dose Oral Proellex(R) In The Treatment Of Uterine Fibroids And Endometriosis
2014-03-13,Repros Therapeutics Inc.(R) Reports Fourth Quarter And Year End 2013 Financial Results
2014-02-10,Repros Reports Findings From The Six Month Study Of Androxal(R) In Men With Secondary Hypogonadism
2014-02-06,Repros Meets With FDA To Discuss Data Requirements For Androxal(R) In The Treatment Of Secondary Hypogonadism
2014-02-04,Repros Therapeutics Enters Oversold Territory (RPRX)
2014-01-27,Notable Two Hundred Day Moving Average Cross - RPRX
2014-01-15,Pre-Market Pulse: Dendreon, Novartis AG, Stryker, And Repros Therapeutics
2014-01-08,Repros Initiates Two Head To Head Studies Of Androxal(R) Versus The Leading Topical Testosterone Gel
2013-12-19,Repros Adds Marketing And Commercialization Expertise To Board Of Directors
2013-12-19,RPRX Makes Bullish Cross Above Critical Moving Average
2013-12-04,Attention Repros Therapeutics, Inc. Investors: Law Firm Investigates On Behalf Of Shareholders
2013-11-25,Repros To Present Data On The Benefits Of Testosterone Restoration With Androxal(R) Compared To T Replacement With Gels At 9th Men's Health World Congress
2013-11-25,FDA Schedules Face To Face Meeting With Repros To Discuss Androxal(R) Efficacy
2013-11-07,Repros Therapeutics Inc.(R) Reports Third Quarter 2013 Financial Results
2013-11-04,Repros Receives FDA Guidance For Proellex(R) Low Dose Oral Uterine Fibroid Clinical Program
2013-10-28,Top Insider Trades: HLX, RT, STI, RPRX
2013-10-25,5 Dumbest Things on Wall Street
2013-10-24,Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Investors Of Repros Therapeutics Inc.
2013-10-24,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Repros Therapeutics, Inc. - RPRX
2013-10-23,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Repros Therapeutics, Inc.
2013-10-23,FDA Questions Credibility of Repros Testosterone Pill Data
2013-10-22,Repros Receives FDA Guidance For Androxal(R) Clinical Program
2013-10-07,Repros Announces Three Studies Accepted For Presentation At The Annual Meeting Of The Sexual Medicine Society Of North America
2013-09-23,Repros To Present At Biocentury's NewsMakers In The Biotech Industry Conference
2013-09-19,4 Biotech Stocks Triggering Breakout Trades
2013-09-18,Repros Provides Additional Information Confirming Success For Study ZA-302
2013-09-17,Why Repros Is Still Risky Despite Stock's Ascent
2013-09-16,Repros Reports Preliminary Findings: Second Pivotal Study And 6-Month Safety Study Support Androxal(R) Approvability
2013-09-04,3 Biotech Stocks Triggering Breakouts on Big Volume
2013-08-20,Repros Reports 6 Month Bone Mineral Density Data From Ongoing Study ZA-303
2013-08-07,Repros Therapeutics Inc.(R) Reports Second Quarter 2013 Financial Results
2013-08-05,Repros Worried About Validity of its Androxal Patent
2013-08-05,Repros Seeks To Affirm Its Intellectual Property Rights In Androxal(R)
2013-07-11,5 Stocks Setting Up to Break Out
2013-07-09,Repros Announces Formation Of Androxal(R) Clinical And Commercial Advisory Board
2013-07-03,RPRX September 21st Options Begin Trading
2013-06-25,Repros Therapeutics Inc.(R) Announces The Closing Of Public Offering Of Common Stock
2013-06-19,Repros Therapeutics Inc.(R) Announces Pricing Of Public Offering Of Common Stock
2013-06-17,Repros Therapeutics Inc.(R) Announces Proposed Public Offering Of Common Stock
2013-06-03,Repros To Webcast Investor And Analyst Day On June 6th
2013-05-31,The 5 Dumbest Things on Wall Street This Week: May 31
2013-05-22,FDA Recommends Running Phase 2b Trial Of Proellex(R)-V In The Treatment Of Severe Menstrual Bleeding Associated With Uterine Fibroids
2013-05-10,Repros Therapeutics Inc.(R) Reports First Quarter 2013 Financial Results
2013-05-10,Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin
2013-05-09,Repros Patent Problems Began When Harry Met Joe
2013-05-02,Repros Reports Second Pivotal Androxal(R) Study Fully Enrolled Ahead Of Schedule
2013-04-29,Repros' Proellex(R) In Breast Cancer Phase 2 Study In Collaboration With Northwestern University
2013-04-29,Repros To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
2013-04-10,Repros Reports Issuance Of Two Additional U.S. Androxal(R) Patents
2013-04-05,5 Dumbest Things on Wall Street This Week: April 5
2013-04-05,The Five Dumbest Things on Wall Street: April 5
2013-03-28,Repros CEO: My Testosterone Drug Helped Gay Cubans Have Lots of Sex
2013-03-27,Repros Reports Both Primary Endpoints Successfully Met In First Pivotal Study Of Androxal(R)
2013-03-25,American Urological Association (AUA) Accepts Androxal(R) Versus Topical Gel Comparative Study For Podium Presentation At Annual Meeting
2013-03-18,Repros Therapeutics Inc.(R) Reports Fourth Quarter And Year End 2012 Financial Results
2013-02-28,FDA Grants Repros An End Of Phase 2 Meeting In Late May To Discuss Proellex(R)-V Phase 3 Study Design
2013-02-21,Repros Reports FDA Recommends Pivotal Study ZA-301 Of Androxal(R) To Be Completed As Originally Planned
2013-02-11,Repros Therapeutics Corporate Update
2013-01-28,Repros Updates Guidance For Top Line Results From First Pivotal Androxal(R) Study To Q3 2013
2013-01-07,Repros Reports Core 1-Year DEXA Study Fully Enrolled Ahead Of Schedule And Provides Update For Androxal(R) Clinical Program
2013-01-03,Repros' Proellex(R)-V Topline Analysis Suggests 12 Mg Dose Effective And Well Tolerated In Phase 2 For Uterine Fibroids
2012-12-18,11 Stocks With Significant Institutional And Insider Buying
2012-12-17,4 Stocks Rising on Unusual Volume
2012-12-04,10 Stocks With Bullish Institutional And Insider Buying Activities
2012-11-13,5 Heavily-Shorted Stocks About to Report
2012-10-08,FDA Reclassifies Proellex(R) Clinical Hold Status: Repros To Proceed With Phase 2 Study Of Low Dose Oral Proellex(R) In The Treatment Of Endometriosis
2012-09-12,Repros Provides Clinical Update For Androxal(R) Phase 3 Program
2012-09-04,Repros Announces The Offering Of Unregistered Shares Of Common Stock In The Amount Of $23.6 Million
2012-08-27,FDA Provides Recommendations For Phase 2 Protocol For Low Dose Oral Proellex(R) In The Treatment Of Endometriosis
2012-08-20,4 Big-Volume Stocks Surging Higher
2012-08-13,Repros Therapeutics Inc.(R) Reports Second Quarter 2012 Financial Results
2012-05-16,5 Stocks That Insiders Love Right Now
2012-05-14,Insiders Trading GHDX, PDH, RPRX
2012-05-10,8 Stocks Under $10 Soaring Higher
2011-03-30,16 Small-Cap Stocks in Danger of Delisting
2017-03-23,John A. Orwin Joins Retrophin Board Of Directors
2017-03-21,RSI Alert: Retrophin (RTRX) Now Oversold
2017-03-07,Retrophin To Present At The Barclays Global Healthcare Conference
2017-03-01,Retrophin Provides Sparsentan Regulatory Update; Reports Fourth Quarter And Full Year 2016 Financial Results
2017-02-15,Retrophin To Report Fourth Quarter And Full Year 2016 Financial Results
2017-02-13,Retrophin Appoints William Rote Senior Vice President, Research And Development
2017-01-09,First Week of RTRX February 17th Options Trading
2017-01-09,Retrophin Provides Corporate Update And 2017 Preview
2017-01-04,Retrophin Appoints Elizabeth Reed General Counsel
2016-12-29,Retrophin To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-11-30,Retrophin To Present At The BMO Capital Markets Healthcare Conference
2016-11-19,Retrophin Reports Additional Positive Data From Phase 2 DUET Study Of Sparsentan In Focal Segmental Glomerulosclerosis At ASN Kidney Week 2016
2016-11-14,RTRX January 2019 Options Begin Trading
2016-11-10,Retrophin Reaches Agreement With FDA Under Special Protocol Assessment For Pivotal Trial Evaluating RE-024 In PKAN
2016-11-08,Retrophin Becomes Oversold (RTRX)
2016-11-07,Ratings Changes Today
2016-11-03,Retrophin Reports Third Quarter 2016 Financial Results
2016-10-21,Retrophin To Present Additional Data From Phase 2 DUET Study Of Sparsentan In Late-Breaking Oral Session At ASN Kidney Week 2016
2016-10-20,Retrophin To Report Third Quarter 2016 Financial Results
2016-10-06,Dr. Alvin Shih Departing Retrophin To Lead Biotechnology Start-Up
2016-09-30,Retrophin Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2016-09-22,Health Care Stocks Bound for Declines After 2016 Election
2016-09-14,Retrophin To Present At The Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series
2016-09-07,Retrophin Announces Positive Results for Kidney Disease Drug
2016-09-07,Retrophin (RTRX) Stock Price Target Upped at Leerink on Kidney Drug Trial
2016-09-07,Retrophin (With Help From Martin Shkreli) Advances Drug for Rare Kidney Disease
2016-09-07,Retrophin Announces Positive Top-Line Results From Phase 2 DUET Study Of Sparsentan In Patients With Focal Segmental Glomerulosclerosis
2016-08-30,Big Pharma's Punishment in Court of Public Opinion
2016-08-15,Retrophin Appoints Neil McFarlane Chief Operating Officer
2016-08-04,Retrophin Reports Second Quarter 2016 Financial Results
2016-07-21,Retrophin To Report Second Quarter 2016 Financial Results
2016-07-19,Retrophin Appoints Roy D. Baynes, M.D., Ph.D., To Board Of Directors
2016-07-18,Retrophin (RTRX) Weak On High Volume Today
2016-06-23,Retrophin Announces New Data From Physician-Initiated Treatment With RE-024 At The 20th International Congress Of Parkinson's Disease And Movement Disorders
2016-06-22,First Week of August 19th Options Trading For Retrophin (RTRX)
2016-06-22,Retrophin (RTRX) Is Today's Strong On High Volume Stock
2016-06-20,Retrophin Acquires Liquid Formulation Of Ursodeoxycholic Acid
2016-06-20,Notable Monday Option Activity: RTRX, TPX, ENOC
2016-06-20,Commit To Purchase Retrophin At $10, Earn 14% Using Options
2016-05-26,Retrophin To Present At Upcoming Investor Conferences
2016-05-05,Today's Weak On High Volume Stock: Retrophin (RTRX)
2016-05-04,Notable Wednesday Option Activity: RTRX, CONN, RMTI
2016-05-04,Retrophin (RTRX) Flagged As Strong On High Volume
2016-05-03,Retrophin Reports First Quarter 2016 Financial Results
2016-04-21,Retrophin To Present At The Deutsche Bank 41st Annual Health Care Conference
2016-04-19,Retrophin To Report First Quarter 2016 Financial Results
2016-04-04,Retrophin Names Gary A. Lyons Chairman Of The Board Of Directors
2016-03-30,Retrophin Completes Enrollment Of Phase 2 DUET Study Of Sparsentan In Focal Segmental Glomerulosclerosis
2016-03-24,Retrophin Announces Acceptance Of Four RE-024 Abstracts For Presentation At The 20th International Congress Of Parkinson's Disease And Movement Disorders
2016-03-22,First Week Of RTRX May 20th Options Trading
2016-03-09,Retrophin Announces New Data Supporting Further Clinical Development Of RE-024 For PKAN At The 2016 American College Of Medical Genetics And Genomics Annual Clinical Genetics Meeting
2016-03-08,Insider Trading Alert - RTRX, SWK And CVGI Traded By Insiders
2016-03-03,Retrophin To Present At The Barclays Global Healthcare Conference
2016-02-29,Ratings Changes Today
2016-02-25,Retrophin Reports Fourth Quarter And Full Year 2015 Financial Results
2016-02-25,Feb. 25 Premarket Briefing: 10 Things You Should Know
2016-02-24,Retrophin Receives European Orphan Drug Designation For RE-024 For The Treatment Of Pantothenate Kinase-Associated Neurodegeneration
2016-02-23,Retrophin To Present At The Cowen And Company 36th Annual Health Care Conference
2016-02-11,Retrophin To Report Fourth Quarter And Full Year 2015 Financial Results
2016-02-10,Statement On Imprimis Pharmaceuticals' Announcement Regarding Thiola®
2016-02-08,Retrophin is Now Oversold (RTRX)
2016-02-02,Retrophin (RTRX) Weak On High Volume
2016-01-29,KaloBios Distances Itself From Ex-CEO Martin Shkreli, Wants to Pay Employee Bonuses
2016-01-27,Retrophin To Present At The Leerink Partners 5th Annual Global Healthcare Conference
2016-01-25,First Week of September 16th Options Trading For Retrophin (RTRX)
2016-01-21,With Martin Shkreli Long Gone, Retrophin is an 'Interesting Opportunity'
2016-01-21,Despite Shkreli Drama, Retrophin Looks Interesting Now
2016-01-11,Commit To Buy Retrophin At $12.50, Earn 16% Using Options
2016-01-11,Retrophin Announces Preliminary Full-Year 2015 Revenue Of Approximately $99.9 Million
2015-12-30,Dec. 30 Premarket Briefing: 10 Things You Should Know
2015-12-20,Shkreli 'Was Running Turing Like a Hedge Fund'
2015-12-18,Notable Friday Option Activity: RTRX, BBW, MESG
2015-12-17,Retrophin Statement On Indictment Of Martin Shkreli
2015-12-17,Shkreli Arrest Won't Stop Drug Price Debate but Could Kill KaloBios
2015-11-18,Portfolio adjustments in a turbulent market
2015-11-16,Retrophin Receives European Orphan Drug Designation For Sparsentan For The Treatment Of Focal Segmental Glomerulosclerosis
2015-11-05,Retrophin (RTRX) Is Today's Dead Cat Bounce Stock
2015-11-05,Retrophin Announces Research Collaboration With The Grace Wilsey Foundation And The Warren Family Research Center For Drug Discovery And Development At The University Of Notre Dame
2015-11-04,Today's Weak On High Volume Stock: Retrophin (RTRX)
2015-11-04,Retrophin Sinks, Pharma Group Swings Back As Pricing Fight Escalates
2015-11-03,Retrophin Reports Third Quarter 2015 Financial Results
2015-11-03,Retrophin (RTRX) Showing Signs Of Perilous Reversal Today
2015-11-02,Strong On High Relative Volume: Retrophin (RTRX)
2015-10-20,Retrophin To Report Third Quarter 2015 Financial Results
2015-10-09,Insider Trading Alert - JASN, RTRX And RST Traded By Insiders
2015-09-24,Retrophin (RTRX) In A Perilous Reversal
2015-09-23,Retrophin (RTRX) Marked As A Dead Cat Bounce Stock
2015-09-22,Relative Strength Alert For Retrophin
2015-09-16,Retrophin To Present At The Leerink Partners 4th Annual Rare Disease Roundtable
2015-09-16,Retrophin (RTRX) Weak On High Volume
2015-09-04,Today's Dead Cat Bounce Stock Is Retrophin (RTRX)
2015-09-03,Stock To Watch: Retrophin (RTRX) In Perilous Reversal
2015-08-28,First Week of October 16th Options Trading For Retrophin (RTRX)
2015-08-06,Retrophin (RTRX) Highlighted As Today's Perilous Reversal Stock
2015-08-04,Retrophin Reports Second Quarter 2015 Financial Results
2015-08-03,Retrophin (RTRX) Strong On High Relative Volume Today
2015-07-21,Retrophin To Report Second Quarter 2015 Financial Results
2015-07-06,Retrophin Closes Sale Of Priority Review Voucher
2015-07-01,10 Best Biotech Stocks in the NASDAQ
2015-07-01,Insider Trading Alert - RTRX, SCOR And SMLP Traded By Insiders
2015-06-19,New Lifetime High For Retrophin (RTRX)
2015-06-09,Retrophin's Record Asset Sales Enhance Outlook
2015-06-03,Where the Money Was Made the Last 5 Years
2015-06-01,Today Retrophin (RTRX) Hits New Lifetime High
2015-05-28,Weak On High Volume: Retrophin (RTRX)
2015-05-27,Heavy Trading On Retrophin (RTRX) Before Market Open
2015-05-27,Retrophin Agrees To Sell Priority Review Voucher To Sanofi
2015-05-21,RTRX: Insiders Vs. Shorts
2015-05-20,Retrophin To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-18,Strong And Under The Radar: Retrophin (RTRX)
2015-05-15,Ratings Changes Today
2015-05-11,Retrophin Reports First Quarter 2015 Financial Results
2015-05-05,Retrophin Receives FDA Orphan Drug Designation For RE-024 For The Treatment Of Pantothenate Kinase-Associated Neurodegeneration
2015-04-30,Retrophin Announces FDA Review Of IND For RE-024 And Clearance To Proceed With Phase 1 Clinical Study In Healthy Adult Volunteers
2015-04-27,Retrophin To Report First Quarter 2015 Financial Results
2015-04-23,Technicals Flash Mixed Messages
2015-04-17,Why I'm Bullish On Biotech Firm Retrophin
2015-04-14,Retrophin Stock Sees Short Interest Decrease By 14.5%
2015-04-01,Retrophin's Board Of Directors Appoints John W. Kozarich, Ph.D. As Independent Director And Names Jeffrey A. Meckler As Chairman
2015-03-24,Retrophin Closes Public Offering Of 7,866,000 Shares Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-03-24,Insiders Were Right: RTRX Makes New 52-Week High
2015-03-19,Retrophin (RTRX) Stock Rises Today After Pricing Public Offering of Common Stock
2015-03-19,Retrophin Prices Public Offering Of 6,840,000 Shares Of Common Stock
2015-03-18,U.S. Food And Drug Administration Approves Cholbam For The Treatment Of Rare Bile Acid Synthesis Disorders And Grants Rare Pediatric Disease Priority Review Voucher
2015-03-16,Retrophin Announces Proposed Public Offering Of 5,100,000 Shares Of Common Stock
2015-03-05,Retrophin Reports Fourth Quarter And Full Year 2014 Financial Results
2015-03-04,Tim Coughlin Joins Retrophin's Board Of Directors
2015-02-24,Launch Of Turing Pharmaceuticals Announced - New Drug Company To Focus On Treating Unmet Medical Needs Across Broad Therapeutic Areas
2015-02-19,Retrophin To Report Fourth Quarter And Full Year 2014 Financial Results
2015-02-19,RTRX: Insiders Vs. Shorts
2015-02-05,Retrophin To Present At The 2015 Leerink Global Healthcare Conference
2015-02-03,Retrophin Announces Voting Results Of Special Meeting Of Stockholders
2015-01-13,Short Interest In Retrophin Falls 15.4%
2015-01-12,Retrophin Announces Acquisition Of Exclusive Right To Purchase Cholic Acid From Asklepion Pharmaceuticals
2015-01-09,Ryan & Maniskas, LLP Announces Investigation Of Retrophin, Inc.
2015-01-09,Ligand Partner Retrophin Receives Orphan Drug Designation For Sparsentan
2015-01-09,Retrophin Provides Corporate Update
2015-01-08,Updated: Harwood Feffer LLP Announces Investigation Of Retrophin, Inc.
2015-01-06,Retrophin Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2014-12-18,The Winners for Best and Worst Biotech CEOs of 2014 Are...
2014-12-16,Retrophin Announces Addition To The NASDAQ Biotechnology Index
2014-12-15,Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...
2014-12-12,INVESTOR ALERT: Class Action Lawsuit Against Retrophin, Inc. Announced By Law Offices Of Howard G. Smith
2014-12-12,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors Of Class Action Against Retrophin, Inc. And Lead Plaintiff Deadline Of December 19, 2014
2014-12-11,SHAREHOLDER ALERT: Investigation On Behalf Of Retrophin, Inc. Investors Announced By Law Offices Of Howard G. Smith
2014-12-01,SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Retrophin, Inc. To Contact Brower Piven Before The December 19, 2014 Lead Plaintiff Deadline In Class Action Lawsuit
2014-12-01,UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Reminds Investors Of Class Action Against Retrophin, Inc. And Its Board Of Directors And A Lead Plaintiff Deadline Of December 19, 2014 -- RTRX
2014-11-25,Ousted Retrophin CEO Sold Stock While Urging Investors to Buy
2014-11-24,UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Reminds Investors Of Class Action Against Retrophin, Inc. And Its Board Of Directors And A Lead Plaintiff Deadline Of December 19, 2014
2014-11-20,RTRX: Insiders Vs. Shorts
2014-11-19,Retrophin Names Margaret Valeur-Jensen, Ph.D. As General Counsel
2014-11-18,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors Of Class Action Against Retrophin, Inc. And Its Board Of Directors And A Lead Plaintiff Deadline Of December 19, 2014 -- RTRX
2014-11-17,Retrophin Names Laura M. Clague As Chief Financial Officer
2014-11-13,Retrophin Reports Third Quarter 2014 Financial Results
2014-11-10,Retrophin Announces Appointment Of Stephen Aselage As Chief Executive Officer
2014-11-07,Retrophin Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors
2014-11-05,Lifshitz & Miller Law Firm Announces Investigation Of AmREIT, Inc., Digital River, Inc., Greater Sacramento Bancorp., Hampden Bancorp, Inc., Integrity Bancshares, Inc., Retrophin, Inc. And Sapient Corp.
2014-11-03,Super Important Biotech and Drug Stock Events for November
2014-10-31,SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Retrophin, Inc. To Contact Brower Piven Before The December 19, 2014 Lead Plaintiff Deadline In Class Action Lawsuit
2014-10-30,Retrophin To Report Third Quarter 2014 Financial Results
2014-10-22,Harwood Feffer LLP Announces Investigation Of Retrophin, Inc.
2014-10-21,INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Retrophin, Inc. (RTRX) To Contact The Firm
2014-10-14,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Retrophin, Inc.
2014-10-14,Retrophin Announces Divestment Of Non-Core Assets To Turing Pharmaceuticals
2014-10-10,Retrophin Announces Appointment Of Jeffrey A. Meckler To Board Of Directors
2014-10-09,Retrophin Announces Appointment Of Gary Lyons To Board Of Directors
2014-10-03,Retrophin Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2014-09-30,Shkreli's Inability to Focus, Immaturity Cost Him Retrophin CEO Job
2014-09-30,Retrophin Announces Leadership Reorganization
2014-09-30,RSI Alert: Retrophin (RTRX) Now Oversold
2014-09-30,Catalyst Pharma Closer to Unconscionable Price Hike for Rare-Disease Drug
2014-09-24,5 Stocks Insiders Love Right Now
2014-09-17,Harwood Feffer LLP Announces Investigation Of Retrophin, Inc.
2014-09-17,INVESTOR ALERT: Investigation On Behalf Of Retrophin, Inc. Shareholders Announced By Glancy Binkow & Goldberg LLP
2014-09-17,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Retrophin, Inc.
2014-09-17,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Retrophin, Inc. - RTRX
2014-09-16,Retrophin Announces Changes To Board Of Directors And Management Team
2014-09-10,Retrophin Assailed for 'Exorbitant' Price Hike
2014-08-12,Retrophin Reports Second Quarter 2014 Financial Results
2014-08-11,Retrophin CEO Under Fire for Twitter Faux Pas
2016-09-22,5 Stocks Under $10 That Could Make You a Lot of Money
2016-03-10,Ritter Pharmaceuticals To Present At The 28th Annual ROTH Conference
2016-02-11,5 Stocks Under $10 Set to Soar
2016-01-08,3 Biotech Stocks Under $10 to Trade for Big Breakouts
2015-11-17,Ritter Pharmaceuticals Provides Third Quarter 2015 Financial Results And Business Update
2015-10-22,5 Stocks Under $10 Set to Soar
2015-10-06,Ritter Pharmaceuticals Appoints AnnKatrin Petersen-Jappelli, M.D., M.SC. As Chief Medical Officer
2015-10-01,Ritter Pharmaceuticals To Present At The 2015 Aegis Growth Conference
2015-09-08,Ritter Pharmaceuticals To Present At The 3rd Microbiome R&D Business Collaboration Forum
2015-09-04,3 Breakout Stocks Under $10 to Trade Now
2015-06-29,Ritter Pharmaceuticals, Inc. Announces Closing Of $20,000,000 Initial Public Offering
2015-06-24,Ritter Pharmaceuticals, Inc. Announces Pricing Of Initial Public Offering
,
,
,
,
,
2017-03-07,Revance Completes Enrollment In Phase 3 Pivotal Trials Of RT002 Injectable For The Treatment Of Glabellar (Frown) Lines
2017-03-03,Revance Announces BELMONT Phase 2 Clinical Data To Be Presented At The 2017 American Academy Of Dermatology (AAD) Annual Meeting
2017-02-27,Revance Releases Fourth Quarter And Full Year 2016 Results
2017-02-22,Revance To Participate In Upcoming Investor Conferences
2017-02-16,Revance Therapeutics To Release Fourth Quarter 2016 Financial Results Monday, February 27, 2017
2017-01-26,BELMONT Phase 2 Clinical Data To Be Presented At IMCAS World Congress 2017
2017-01-18,Revance Presents Clinical Data For RT002 Injectable At TOXINS 2017
2017-01-05,Revance Provides Clinical Milestones And Financial Outlook For 2017
2016-12-12,Revance Announces Positive 24-Week Duration Of Effect In Interim Results From Phase 2 Cervical Dystonia Trial
2016-12-07,Revance Announces Initiation Of Subject Dosing In The SAKURA Phase 3 Clinical Program Of RT002 Injectable For The Treatment Of Glabellar (Frown) Lines
2016-11-17,Revance To Participate In The 28th Annual Piper Jaffray Healthcare Conference
2016-11-07,Revance To Participate In The Jefferies 2016 London Healthcare Conference
2016-11-03,Revance Releases Third Quarter 2016 Results
2016-11-03,Revance Announces Initiation Of Phase 2 Trial Of RT002 Injectable To Treat Plantar Fasciitis
2016-10-24,Revance Therapeutics To Release Third Quarter 2016 Financial Results Thursday, November 3, 2016
2016-10-04,Commit To Buy Revance Therapeutics At $10, Earn 10.1% Annualized Using Options
2016-08-30,Revance To Participate In The 2016 Wells Fargo Securities Healthcare Conference
2016-08-04,Revance Releases Second Quarter 2016 Results
2016-07-21,Revance Therapeutics To Release Second Quarter 2016 Financial Results Thursday, August 4, 2016
2016-07-15,These 5 Stocks Are Primed for Breakouts
2016-07-14,Revance Announces Completion Of Pre-Phase 3 Meeting With FDA For RT002 Injectable To Treat Glabellar Lines
2016-07-13,Short Interest In Revance Therapeutics Makes 16.2% Move
2016-07-05,Commit To Buy Revance Therapeutics At $10, Earn 15.2% Annualized Using Options
2016-07-05,Revance Appoints Industry Leader Julian S. Gangolli To Its Board Of Directors
2016-06-14,Revance Therapeutics Becomes Oversold (RVNC)
2016-06-14,Revance Therapeutics (RVNC) Stock Plunging on Drug Results
2016-06-13,Revance Reports Results For RT001 Topical Phase 3 Trial For Lateral Canthal Lines
2016-06-02,Revance Expands Botulinum Toxin Assets By Acquiring Intellectual Property (IP) Portfolio
2016-05-31,Revance To Participate In Upcoming Investor Conferences
2016-05-09,Revance Releases First Quarter 2016 Results
2016-04-25,Revance Therapeutics To Release First Quarter 2016 Financial Results Monday, May 9, 2016
2016-04-19,'Mad Money' Lightning Round: Ciena Is Dead
2016-04-18,Jim Cramer's 'Mad Money' Recap: Here Are Today's Top 10 Winning Stocks
2016-04-10,Allergan Could Buy These Drug Companies Now That the Pfizer Merger Is Scuttled
2016-04-05,Commit To Buy Revance Therapeutics At $17.50, Earn 51.6% Annualized Using Options
2016-03-14,Revance Therapeutics Expands Leadership Team, Appoints Roman G. Rubio, MD, MBA, As Senior Vice President Of Clinical Development
2016-03-05,Revance Announces Late-Breaking Podium Presentation Of Positive 6-Month Duration Results For BELMONT Phase 2 Active Comparator Study Of Injectable RT002 At The 74th Annual Meeting Of The American Academy Of Dermatology
2016-03-02,Revance Releases Fourth Quarter And Full Year 2015 Results
2016-02-29,5 Earnings Stocks Everyone Else Hates -- but You Should Love
2016-02-23,Revance To Participate In Upcoming Investor Conferences
2016-02-18,Oversold Conditions For Revance Therapeutics
2016-02-17,Revance Therapeutics To Release Fourth Quarter And Full Year 2015 Financial Results Wednesday, March 2, 2016
2016-01-07,Revance Specifies 2016 Clinical Program Milestones
2016-01-07,Revance Therapeutics Becomes Oversold (RVNC)
2016-01-07,Revance Therapeutics (RVNC) Highlighted As Weak On High Volume
2016-01-05,Commit To Buy Revance Therapeutics At $22.50, Earn 22% Annualized Using Options
2015-12-24,Revance Therapeutics (RVNC) Stock: Weak On High Volume Today
2015-12-23,Revance Announces Positive Phase 2 Results For RT001 Botulinum Toxin Type A Topical Gel To Treat Axillary Hyperhidrosis
2015-12-14,Revance Appoints Abhay Joshi, PhD, As Chief Operating Officer
2015-11-24,Interesting RVNC Put And Call Options For July 2016
2015-11-23,Revance Therapeutics (RVNC) Strong On High Relative Volume Today
2015-11-20,Revance Therapeutics (RVNC) Weak On High Volume Today
2015-11-19,Revance Therapeutics To Present In The 27th Annual Piper Jaffray Healthcare Conference
2015-11-13,'Mad Money' Lightning Round: Forget Revance, I Want Allergan
2015-11-12,Jim Cramer's 'Mad Money' Recap: There's Negative, and There's Too Negative
2015-11-11,New Lifetime High Reached By Revance Therapeutics (RVNC)
2015-11-09,Revance Therapeutics Releases Third Quarter 2015 Results
2015-11-09,Revance Therapeutics Announces Closing Of Public Offering Of Common Stock
2015-11-04,Revance Therapeutics To Present At Credit Suisse 24th Annual Healthcare Conference
2015-11-04,Revance Therapeutics To Release Third Quarter 2015 Financial Results Monday, November 9, 2015
2015-11-04,Revance Therapeutics (RVNC) Is Today's Pre-Market Mover With Heavy Volume Stock
2015-11-04,Revance Therapeutics Announces Pricing Of Public Offering Of Common Stock
2015-11-02,Revance Therapeutics Announces Proposed Public Offering Of Common Stock
2015-10-30,Trade-Ideas: Revance Therapeutics (RVNC) Is Today's "Perilous Reversal" Stock
2015-10-29,Jim Cramer -- Revance's Drug Results Are Better Than Allergan's Botox
2015-10-29,Revance Reports Positive 6-Month Duration In BELMONT Study
2015-10-21,Ratings Changes Today
2015-09-29,Revance Therapeutics Initiates Phase 2 Clinical Study Of Its Unique Botulinum Toxin Type A For Injection To Treat Cervical Dystonia
2015-09-28,Revance Therapeutics Initiates Phase 3 Clinical Trial Of Botulinum Toxin Type A Topical Gel To Treat Lateral Canthal Lines
2015-09-09,Revance Therapeutics Initiates Phase 2 Clinical Trial Of Botulinum Toxin Type A Topical Gel To Treat Axillary Hyperhidrosis
2015-08-18,Commit To Purchase Revance Therapeutics At $30, Earn 47.8% Annualized Using Options
2015-08-06,Revance Therapeutics Releases Second Quarter 2015 Results
2015-07-23,Revance Therapeutics To Release Second Quarter 2015 Financial Results Thursday, August 6, 2015
2015-07-02,Revance Therapeutics Announces Change In Role Of Jacob Waugh, M.D.
2015-06-03,Revance Therapeutics (RVNC) Is Strong On High Volume Today
2015-06-03,Revance Therapeutics To Initiate Two Key Trials For RT001, Its Topical Botulinum Toxin Type A Investigational Drug Product Candidate
2015-05-21,Revance To Participate In Upcoming Investor Conferences
2015-05-19,First Week Of RVNC January 2016 Options Trading
2015-05-15,Trade-Ideas: Revance Therapeutics (RVNC) Is Today's Strong On High Relative Volume Stock
2015-05-13,Revance Therapeutics Releases First Quarter 2015 Financial Results
2015-05-11,4 Big-Volume Stocks to Trade for Breakouts
2015-04-29,Revance Therapeutics To Release First Quarter 2015 Financial Results Wednesday, May 13, 2015
2015-04-10,Ratings Changes Today
2015-03-16,4 Stocks Spiking on Big Volume: Arista Networks and More
2015-03-09,Ratings Changes Today
2015-03-02,Revance Therapeutics Releases Fourth Quarter And Full Year 2014 Financial Results And Reiterates 2015 Outlook
2015-02-26,Revance Appoints Dr. Philip Vickers To Its Board Of Directors
2015-02-17,Revance Therapeutics, Inc. Announces Participation In Cowen 35th Annual Health Care Conference
2015-02-12,Revance Therapeutics To Release Fourth Quarter And Full Year 2014 Financial Results And Host Conference Call On Monday, March 2, 2015
2015-01-23,Commit To Purchase Revance Therapeutics At $15, Earn 13.2% Annualized Using Options
2015-01-12,Revance Therapeutics Defines Clinical Program Milestones And Provides Financial Guidance For 2015
2015-01-08,Revance Therapeutics Announces Publication Of Positive Results From RT002 Phase 1/2 Study
2015-01-05,Revance Therapeutics Announces Initiation Of BELMONT Phase 2 Active Comparator Trial Of Injectable RT002
2014-12-18,Revance Therapeutics Added To NASDAQ Biotechnology Index
2014-11-20,Revance Therapeutics, Inc. Announces Participation In 26th Annual Piper Jaffray Healthcare Conference
2014-11-12,Revance Therapeutics Releases Third Quarter 2014 Results
2014-11-12,5 Earnings Short-Squeeze Plays: Weibo, Kohl's and More
2014-11-04,Revance Therapeutics, Inc. Announces Participation In Credit Suisse 2014 Healthcare Conference
2014-10-29,Revance Therapeutics To Release Third Quarter 2014 Financial Results And Host Conference Call On Wednesday, November 12, 2014
2014-10-01,Revance Therapeutics Provides Update On RT001 Clinical Program For The Lead Indication For Crow's Feet Lines
2014-09-22,Revance Therapeutics Announces The Appointment Of Azita Nejad As Vice President Of Quality
2014-09-19,Revance Therapeutics Becomes Oversold (RVNC)
2014-09-02,Revance Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2014-08-12,Revance Therapeutics Releases Second Quarter 2014 Financial Results
2014-08-12,Revance Therapeutics Appoints Industry Veteran Arthur P. Bertolino, M.D., Ph.D., M.B.A. As Chief Medical Officer
2014-08-06,RSI Alert: Revance Therapeutics (RVNC) Now Oversold
2014-07-29,Revance Therapeutics To Release Second Quarter 2014 Financial Results And Host Conference Call On Tuesday, August 12, 2014
,
,
2017-03-22,RXi Pharmaceuticals To Present At The 5th Annual Cancer BioPartnering & Investment Forum
2017-03-21,RXi Pharmaceuticals To Present At The 2nd Annual Oligonucleotide And Peptide Therapeutics Conference
2017-03-16,RXi Pharmaceuticals To Webcast Fourth Quarter And Year End 2016 Financial Results On Thursday, March 30, 2017
2017-02-14,RXi Pharmaceuticals Appoints Medical Oncology Expert, Dr. James Griffin, To Scientific Advisory Board
2017-02-08,RXi Pharmaceuticals To Present At Leading Investor And Healthcare Conferences
2017-02-07,RXi Pharmaceuticals Appoints Leading Oncology Expert, Dr. Rolf Kiessling, To Scientific Advisory Board
2017-01-09,RXi Pharmaceuticals Completes Acquisition Of MirImmune Inc. And Appoints New Chief Business Officer
2016-12-26,RXi Pharmaceuticals To Present At The 9th Annual Biotech Showcase™
2016-12-21,RXi Pharmaceuticals Announces Closing Of $11.5 Million Underwritten Public Offering And Full Exercise Of Over-allotment Option
2016-12-16,RXi Pharmaceuticals Announces Pricing Of $10 Million Underwritten Public Offering
2016-12-13,RXi Pharmaceuticals Provides Year End Update On Its Business Development And Clinical Programs
2016-11-28,RXi Pharmaceuticals Corporation Discusses Competitive Advantage, Goals And Milestones For 2016-2017 In New SNNLive Newscast On StockNewsNow.com
2016-10-27,RXi Pharmaceuticals To Webcast Third Quarter 2016 Financial Results On Thursday, November 10, 2016
2016-10-12,RXi Pharmaceuticals Plans To Conduct Securities Offering
2016-10-12,RXi Pharmaceuticals Enters Into Exclusive Option Agreement To Acquire MirImmune Inc.
2016-10-11,RXi Pharmaceuticals To Present At The 15th Annual BIO Investor Forum
2016-09-19,RXi Pharmaceuticals To Present At The 16th Annual Biotech In Europe Forum For Global Partnering And Investment Conference
2016-09-12,RXi Pharmaceuticals To Present At The 4th Targeting Ocular Disorders Conference
2016-09-07,RXi Pharmaceuticals Corporation Selected to Present at Cavendish Global Health Impact Forum
2016-09-06,RXi Pharmaceuticals to Present at the 9th Annual BioPharm America™ Conference
2016-07-28,RXi Pharmaceuticals To Webcast Second Quarter 2016 Financial Results On Thursday, August 11, 2016
2016-07-21,RXi Pharmaceuticals To Present At The 2016 Summer Meeting Of The American Academy Of Dermatology
2016-05-10,RXi Pharmaceuticals Provides Strategic Update
2016-05-04,RXi Pharmaceuticals To Present An Update On Its Consumer Health Programs At The Society For Investigative Dermatology 75th Annual Meeting
2016-05-03,RXi Pharmaceuticals And Thera Neuropharma Enter Into An Exclusive License Agreement For RXi's Self-Delivering RNAi (sd-rxRNA®) Platform Targeting SOD1 To Develop Therapeutics For Neurodegenerative Diseases, Such As ALS (Lou Gehrig's Disease)
2016-05-02,RXi Pharmaceuticals Secures European Patent For Novel RNAi Platform
2016-04-28,RXi Pharmaceuticals Announces Advancement Of Its Ophthalmology Franchise With Successful Topical Delivery Of Sd-rxRNA To The Cornea In An In Vivo Corneal Wound Model
2016-04-27,RXi Pharmaceuticals To Webcast First Quarter 2016 Financial Results On Thursday, May 12, 2016
2016-04-26,RXi Pharmaceuticals Announces 'Biotech Spotlight' Presentation At The BioNetwork Partnering Summit
2016-04-25,RXi Pharmaceuticals To Present At 18th Annual TIDES: Oligonucleotide And Peptides Therapeutics Conference
2016-04-19,RXi Pharmaceuticals Fortifies Its Novel RNAi Patent Portfolio With Notice Of Allowance For Lead Clinical Candidate RXI-109
2016-04-18,RXi Pharmaceuticals To Present At The Association For Research In Vision And Ophthalmology 2016 Annual Meeting
2016-04-15,RXi Pharmaceuticals Announces Reverse Stock Split
2016-03-31,RXi Pharmaceuticals Strengthens Intellectual Property Portfolio For Dermal Indications
2016-03-28,RXi Pharmaceuticals To Present At The Oligonucleotide Therapeutics And Delivery Conference
2016-03-16,RXi Pharmaceuticals To Webcast Fourth Quarter And Year End 2015 Financial Results On Wednesday, March 30, 2016
2016-01-26,RXi Pharmaceuticals To Present At The 18th Annual BIO CEO & Investor Conference
2015-12-21,RXi Pharmaceuticals Announces The Initiation Of A Phase 2 Trial In Dermatology With Samcyprone For Cutaneous Warts
2015-12-14,RXi Pharmaceuticals To Present At The 8th Annual Biotech Showcase 2016
2015-11-05,RXi Pharmaceuticals Announces The Initiation Of A Phase 1/2 Trial In Ophthalmology With RXI-109 For Retinal Scarring
2015-10-29,RXi Pharmaceuticals To Webcast Third Quarter 2015 Financial Results On Thursday, November 12, 2015
2015-10-21,RXi Pharmaceuticals Announces Compound Selection For Cosmetic Product Development With Its Novel Self-delivering RNAi Platform
2015-10-20,RXi Pharmaceuticals Announces Remarkable And Positive Results With Its Novel Self-Delivering RNAi Platform: Potent Reduction Of Long Non-coding RNAs Demonstrated In Collaboration With Biogazelle
2015-10-15,RXi Pharmaceuticals Announces Positive Interim Results In Phase 2a Dermatology Program With RXI-109
2015-10-12,RXi Pharmaceuticals To Present At Premier Scientific Plastic Surgery Meeting
2015-10-07,RXi Pharmaceuticals To Present At 14th Annual BIO Investor Forum
2015-10-05,RXi Pharmaceuticals Bolsters Protection For Its Novel Self-Delivering RNAi Platform With Notice Of Allowance From USPTO
2015-09-29,RXi Pharmaceuticals To Present At Dawson James Securities Growth Stock Conference
2015-09-28,RXi Pharmaceuticals Granted Patent In China For Lead Clinical Candidate RXI-109
2015-09-15,RXi Pharmaceuticals To Present At The 15th Annual Biotech In Europe Forum For Global Partnering And Investment Conference
2015-09-08,RXi Pharmaceuticals Strengthens Intellectual Property Portfolio For Ocular Indications
2015-08-31,RXi Pharmaceuticals Announces Advancements In Its Ophthalmology Clinical Program With RXI-109
2015-07-29,RXi Pharmaceuticals To Webcast Second Quarter 2015 Financial Results On Wednesday, August 12, 2015
2015-06-04,3 Stocks Under $10 to Trade for Breakouts
2015-06-03,RXi Pharmaceuticals Granted Notice Of Allowance For Patent Covering Lead Compound, RXI-109, For Use In The Eye
2015-06-02,RXi Pharmaceuticals To Present At The 23rd World Congress Of Dermatology
2015-05-28,RXi Pharmaceuticals Announces $10 Million Public Offering Of Common Stock And Warrants
2015-05-27,RXi Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrants
2015-05-27,RXi Pharmaceuticals Provides An Update On Series A And Series A-1 Preferred Stock
2015-05-26,RXi Pharmaceuticals To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-11,RXi Pharmaceuticals Presented Promising New Data With Self-delivering RNAi Compounds Targeting Tyrosinase And Collagenase
2015-04-29,RXi Pharmaceuticals To Webcast First Quarter 2015 Financial Results On Wednesday, May 13, 2015
2015-04-27,RXi Pharmaceuticals Announces Upcoming Presentations At Leading Partnering And Scientific Conferences
2015-04-17,RXi Pharmaceuticals Receives Orphan Drug Designation For Samcyprone™ From The U.S. FDA For The Treatment Of Malignant Melanoma Stage IIb To IV
2015-03-27,RXi Pharmaceuticals And MirImmune LLC Enter Into An Exclusive Licensing Agreement For RXi's Self-Delivering RNAi (sd-rxRNA) Technology To Develop Cell-based Immunotherapies To Treat Cancer
2015-03-23,RXi Pharmaceuticals Reports Positive Advancements In Its Dermatology Programs At The Occasion Of The 73rd Annual Meeting Of The American Academy Of Dermatology
2015-03-16,RXi Pharmaceuticals To Webcast Fourth Quarter And Year End 2014 Financial Results On Monday, March 30, 2015
2015-03-11,RXi Pharmaceuticals To Present At The 73rd Annual Meeting Of The American Academy Of Dermatology
2015-02-05,RXi Pharmaceuticals Announces Closing Of The Exclusive Global Licensing Agreement To Samcyprone™ With Hapten Pharmaceuticals
2015-02-03,RXi Pharmaceuticals Strengthens Intellectual Property Portfolio For Ocular Indications
2015-02-02,RXi Pharmaceuticals To Present At The 17th Annual BIO CEO & Investor Conference
2015-01-26,Insider Trading Alert - RXII, MA And SWN Traded By Insiders
2015-01-05,RXi Pharmaceuticals To Present At The 7th Annual Biotech Showcase™
2014-12-22,RXi Pharmaceuticals Issues Open Letter To Shareholders
2014-12-19,RXi Pharmaceuticals Expands Its Clinical Pipeline With An Exclusive Global License For A Second Phase 2 Clinical Compound
2014-10-07,RXi Pharmaceuticals To Present New Data In Its First Phase 2a Clinical Trial With RXI-109
2014-09-29,RXi Pharmaceuticals To Present At The 13th Annual BIO Investor Forum
2014-09-18,RXi Pharmaceuticals To Present At The 7th Annual BioPharm America Conference
2014-09-17,RXi Pharmaceuticals Strengthens Intellectual Property Portfolio
2014-09-11,RXi Pharmaceuticals Presented An Update On The Company's Dermatology And Ophthalmology Franchises
2014-09-09,RXi Pharmaceuticals (RXII) Is Strong On High Volume Today
2014-09-03,RXi Pharmaceuticals To Present At The Rodman & Renshaw 16th Annual Global Investment Conference
2014-08-04,RXi Pharmaceuticals To Ring The NASDAQ Stock Market Closing Bell
2014-07-30,RXi Pharmaceuticals Expands Clinical Program With Initiation Of Third Phase 2a Study With RXI-109 For Treatment Of Hypertrophic Scars
2014-07-07,RXi Pharmaceuticals Appoints Peter Campochiaro M.D. To Its Scientific Advisory Board
2014-06-25,RXi Pharmaceuticals Set To Join Russell Microcap Index
2014-05-27,RXi Pharmaceuticals To Present At The Jefferies 2014 Global Healthcare Conference
2014-05-22,RXi Pharmaceuticals Granted US Notice Of Allowance Covering Self-Delivering (sd-rxRNA) Technology Platform
2014-05-02,RXi Pharmaceuticals Announces Positive Results With RXI?109 In The Eyes Of Cynomolgus Monkeys As Part Of A Dose Range Finding Study
2014-04-29,RXi Pharmaceuticals Announces Initiation Of Phase 2a Keloid Study
2014-04-28,RXi Pharmaceuticals To Present At ARVO 2014 Annual Meeting
2014-04-22,RXi Pharmaceuticals Enters Into Financing Facility With Lincoln Park Capital
2014-03-14,RXi Pharmaceuticals Announces Upcoming Presentations
2014-03-05,RXi Pharmaceuticals Granted Key Patent Related To Self-Delivering Technology For The Treatment Of Fibrotic Disorders
2014-03-04,RXi Pharmaceuticals To Present At The 26th Annual ROTH Conference
2014-02-24,RXi Pharmaceuticals To Present At The 24th Annual Wall Street Analyst Forum
2014-02-12,Ratings Changes Today
2014-02-11,OTC Markets Group Congratulates RXI Pharmaceuticals On NASDAQ Listing
2014-02-11,RXi Pharmaceuticals Announces Listing On NASDAQ Capital Market
2014-02-03,RXi Pharmaceuticals To Present At The 16th Annual BIO CEO & Investor Conference
2014-01-14,RXi Pharmaceuticals Receives US Notice Of Allowance For A Key Patent Relating To Its Self-Delivering Technology With Sd-rxRNAs Targeting CTGF, Including RXI-109, For The Treatment Of Fibrotic Disorders
2014-01-06,RXi Pharmaceuticals To Present At The Biotech Showcase&#8482; 2014
2013-12-04,RXi Pharmaceuticals Announces MRNA Data Of An Additional Cohort In The Second Phase 1 Multi-Dose Study With RXI-109, Extending The Dose Response Following Treatment In The Initial 2-week Period
2013-11-27,RXi Pharmaceuticals To Present At The Piper Jaffray 25th Annual Healthcare Conference
2013-11-18,RXi Pharmaceuticals Corporation And Ethicor Ltd. Announce The Signing Of A Distribution Agreement For RXI-109 In The European Union Under The "Specials" Provision
2013-11-13,RXi Pharmaceuticals Announces The Start Of Their First Phase 2 Study With RXI-109 For Treatment Of Hypertrophic Scars In Conjunction With Scar Revision Surgery
2013-09-17,RXi Pharmaceuticals To Present At The 12th Annual BIO Investor Forum
2013-07-22,RXi Pharmaceuticals Announces Application For NASDAQ Capital Market Listing And Reverse Stock Split
2013-07-18,RXi Pharmaceuticals Announces CEO Interview
2013-07-12,RXi Pharmaceuticals Announces Positive Data In Second Phase 1 Multi-Dose Study
2013-06-19,RXi Pharmaceuticals Corporation Begins Trading On OTCQX®
2013-06-06,RXi Pharmaceuticals Announces Positive Results In Its First Double Blind Study In Healthy Volunteers With RXI-109
2013-05-20,RXi Pharmaceuticals To Present At The Jefferies 2013 Global Healthcare Conference
2013-05-09,RXi Pharmaceuticals To Present At IBC's 15th Annual TIDES: Oligonucleotide And Peptide Therapeutics Conference
2013-03-12,RXi Pharmaceuticals To Present At The 25th Annual ROTH Conference
2013-03-07,RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock
2013-03-07,RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock
2013-03-07,RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets
2013-03-07,RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets
2013-02-19,RXi Pharmaceuticals Announces Upcoming Presentations
2013-02-04,RXi Pharmaceuticals To Present At 15th Annual BIO CEO &amp; Investor Conference
2013-01-30,RXi Pharmaceuticals Announces Completion Of Enrollment In Second Phase 1 Trial For RXI-109 Program
2013-01-03,RXi Pharmaceuticals To Webcast Presentation At Biotech Showcase&#8482; 2013
2012-12-19,RXi Pharmaceuticals To Present At Biotech Showcase&#8482; 2013
2012-12-05,RXi Pharmaceuticals Announces Initiation Of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109
2012-11-15,RXi Pharmaceuticals Announces Pharmacokinetic Results Of Its Single Dose Phase 1 Study With RXI-109 In Healthy Volunteers
2012-11-14,RXi Pharmaceuticals Reports Financial Results For The Third Quarter Of 2012
2012-10-16,RXi Pharmaceuticals To Present At 12th Annual Biotech Symposium
2012-10-04,RXi Pharmaceuticals Awarded NCI SBIR Funding To Advance Self-Delivering RNAi Technology
2012-10-02,RXi Pharmaceuticals To Present At 11th Annual BIO Investor Forum
2012-09-24,RXi Pharmaceuticals Announces Completion Of Dosing In Phase 1 Trial For RXI-109 Program
2012-08-15,RXi Pharmaceuticals Reports Financial Results For The Second Quarter Of 2012
2012-07-13,RXi Pharmaceuticals Appoints Jeannette Graf MD And Leroy Young MD To Its Scientific Advisory Board
2012-06-26,RXi Pharmaceuticals Announces Initiation Of&#160;First Clinical Trial
2012-06-21,RXi Pharmaceuticals Appoints Robert Bitterman And Keith Brownlie To Board Of Directors
2012-05-31,RXi Pharmaceuticals Receives FDA Clearance To Begin Clinical Trial With RXI-109
2012-05-10,RXi Pharmaceuticals Appoints Industry Veteran Dr. Geert Cauwenbergh As President And Chief Executive Officer
2011-11-10,Emerging Biotech Companies Discuss What&#8217;s In The Pipeline At NYSSA Conference
2011-08-02,Generex Provides Corporate Update
2011-07-13,RXi Pharmaceuticals Strengthens NeuVax&#8482; (E75) Patent Portfolio
2011-06-24,RXi Pharmaceuticals To Present At BIO International Convention
2011-06-08,RXi Pharmaceuticals Presents Additional Positive Phase 2 Efficacy Results For Combination Of NeuVaxTM (E75) And Trastuzumab Breast Cancer At ASCO
2011-06-06,RXi Pharmaceuticals Announces Positive NeuVaxTM (E75) Phase 2 Efficacy Results After 36 Months Of Follow-Up
2011-05-19,RXi Pharmaceuticals Presents Updated NeuVax&#8482; (E75) Data At ASCO
2011-05-17,RXi Pharmaceuticals Reports Financial Results For The First Quarter Of 2011
2011-04-28,RXi Pharmaceuticals And The University Of Massachusetts Medical School Announce Massachusetts Life Sciences Center Cooperative Research Grant For RNAi Therapeutics For ALS
2011-04-26,RXi Pharmaceuticals Awarded $580,000 In NIH Grants To Advance RNAi Therapeutics
2011-04-15,RXi Pharmaceuticals Prices $12 Million Public Offering Of Common Stock And Warrants
2011-04-14,RXi Pharmaceuticals Announces Public Offering Of Common Stock And Warrants
2011-04-14,RXi Pharmaceuticals Completes Apthera Acquisition
2011-04-07,RXi Pharmaceuticals To Webcast Presentation At BioCentury Future Leaders In The Biotech Industry Conference
2011-04-01,Biotech Stock Mailbag: Avanir Pharma
2011-03-31,RXi Pharmaceuticals Aggressively Moves Into Late-Stage Clinical Development With The Agreement To Acquire Apthera, Inc.
2011-03-21,RXi Pharmaceuticals Presents New Preclinical RNAi Data At The Keystone Mechanism And Biology Of Silencing Conference
2011-03-01,RXi Pharmaceuticals Prices $8.1 Million Public Offering Of Common Stock And Warrants
2011-02-28,RXi Pharmaceuticals Announces Public Offering Of Common Stock And Warrants
2011-02-08,RXi Pharmaceuticals To Webcast Presentation At The 13th Annual BIO CEO &amp; Investor Conference
2011-02-03,RXi Pharmaceuticals Initiates Development Program For Dermal Anti-Scarring Product Candidate
2011-01-27,RXi Pharmaceuticals Announces Positive Initial Results In MicroRNA Therapeutics
2011-01-06,Generex And RXi Pharmaceuticals Announce Positive Research Data Using RNAi Technology In The Development Of Therapeutic Vaccines For Cancer
2011-01-04,RXi Pharmaceuticals To Webcast Presentation At The Biotech Showcase Conference
2010-12-17,RXi Pharmaceuticals Nominates Dermal Anti-Scarring RNAi Product Candidate To Advance Into Development
2010-11-15,RXi Pharmaceuticals Reports Financial Results For The Third Quarter Of 2010
2010-11-10,RXi Pharmaceuticals To Webcast Presentation At The Lazard Capital Markets Annual Healthcare Conference
2010-11-02,RXi Pharmaceuticals Awarded $1 Million In IRS Grants To Advance RNAi Therapeutics
2010-09-30,RXi Pharmaceuticals To Webcast Presentation At The 9th Annual BIO Investor Forum
2010-09-22,RXi Pharmaceuticals And EyeGate Pharma Announce Collaboration Focused On Non-Invasive Ocular Delivery Of RNAi Therapeutics
2010-09-15,Rodman Rambles: Promising Biotechs
2010-09-07,RXi Pharmaceuticals To Webcast Presentation At The Rodman &amp; Renshaw Global Investment Conference
2010-08-11,RXi Pharmaceuticals Reports Financial Results For The Second Quarter Of 2010
2010-08-05,RXi Pharmaceuticals To Host Second Quarter 2010 Conference Call On Wednesday, August 11, 2010
2010-07-13,RXi Pharmaceuticals Receives $600,000 Grant
2010-07-13,RXi Pharmaceuticals Awarded NIH Grant To Advance RNAi Therapeutics
2010-06-10,RXi Pharmaceuticals Announces New Focused Therapeutic Strategy For Its Next Generation RNAi Technology
2010-06-03,Philips And RXi Pharmaceuticals Sign Agreement To Jointly Research Innovative Image-Guided Therapy Concepts Based On RNAi
2010-06-02,RXi Pharmaceuticals CEO To Present At The Jefferies 2010 Global Life Sciences Conference
2010-05-17,RXi Pharmaceuticals Reports Financial Results For The First Quarter Of 2010
2010-05-11,RXi Pharmaceuticals CEO To Present At The Rodman &amp; Renshaw Annual Global Healthcare Conference
2010-05-04,RXi Demonstrates Robust In Vivo Uptake And Significant Silencing Using Its Self-Delivering RxRNA&#8482; Compounds Administered To Mouse Retinal Cells
2010-04-23,RXi Pharmaceuticals To Deliver Presentations At Upcoming Conferences Outlining The Development And Progression Of Its Next Generation RxRNA&#8482; Therapeutic Platform
2017-03-22,RXi Pharmaceuticals To Present At The 5th Annual Cancer BioPartnering & Investment Forum
2017-03-21,RXi Pharmaceuticals To Present At The 2nd Annual Oligonucleotide And Peptide Therapeutics Conference
2017-03-16,RXi Pharmaceuticals To Webcast Fourth Quarter And Year End 2016 Financial Results On Thursday, March 30, 2017
2017-02-14,RXi Pharmaceuticals Appoints Medical Oncology Expert, Dr. James Griffin, To Scientific Advisory Board
2017-02-08,RXi Pharmaceuticals To Present At Leading Investor And Healthcare Conferences
2017-02-07,RXi Pharmaceuticals Appoints Leading Oncology Expert, Dr. Rolf Kiessling, To Scientific Advisory Board
2017-01-09,RXi Pharmaceuticals Completes Acquisition Of MirImmune Inc. And Appoints New Chief Business Officer
2016-12-26,RXi Pharmaceuticals To Present At The 9th Annual Biotech Showcase™
2016-12-21,RXi Pharmaceuticals Announces Closing Of $11.5 Million Underwritten Public Offering And Full Exercise Of Over-allotment Option
2016-12-16,RXi Pharmaceuticals Announces Pricing Of $10 Million Underwritten Public Offering
2016-12-13,RXi Pharmaceuticals Provides Year End Update On Its Business Development And Clinical Programs
2016-11-28,RXi Pharmaceuticals Corporation Discusses Competitive Advantage, Goals And Milestones For 2016-2017 In New SNNLive Newscast On StockNewsNow.com
2016-10-27,RXi Pharmaceuticals To Webcast Third Quarter 2016 Financial Results On Thursday, November 10, 2016
2016-10-12,RXi Pharmaceuticals Plans To Conduct Securities Offering
2016-10-12,RXi Pharmaceuticals Enters Into Exclusive Option Agreement To Acquire MirImmune Inc.
2016-10-11,RXi Pharmaceuticals To Present At The 15th Annual BIO Investor Forum
2016-09-19,RXi Pharmaceuticals To Present At The 16th Annual Biotech In Europe Forum For Global Partnering And Investment Conference
2016-09-12,RXi Pharmaceuticals To Present At The 4th Targeting Ocular Disorders Conference
2016-09-07,RXi Pharmaceuticals Corporation Selected to Present at Cavendish Global Health Impact Forum
2016-09-06,RXi Pharmaceuticals to Present at the 9th Annual BioPharm America™ Conference
2016-07-28,RXi Pharmaceuticals To Webcast Second Quarter 2016 Financial Results On Thursday, August 11, 2016
2016-07-21,RXi Pharmaceuticals To Present At The 2016 Summer Meeting Of The American Academy Of Dermatology
2016-05-10,RXi Pharmaceuticals Provides Strategic Update
2016-05-04,RXi Pharmaceuticals To Present An Update On Its Consumer Health Programs At The Society For Investigative Dermatology 75th Annual Meeting
2016-05-03,RXi Pharmaceuticals And Thera Neuropharma Enter Into An Exclusive License Agreement For RXi's Self-Delivering RNAi (sd-rxRNA®) Platform Targeting SOD1 To Develop Therapeutics For Neurodegenerative Diseases, Such As ALS (Lou Gehrig's Disease)
2016-05-02,RXi Pharmaceuticals Secures European Patent For Novel RNAi Platform
2016-04-28,RXi Pharmaceuticals Announces Advancement Of Its Ophthalmology Franchise With Successful Topical Delivery Of Sd-rxRNA To The Cornea In An In Vivo Corneal Wound Model
2016-04-27,RXi Pharmaceuticals To Webcast First Quarter 2016 Financial Results On Thursday, May 12, 2016
2016-04-26,RXi Pharmaceuticals Announces 'Biotech Spotlight' Presentation At The BioNetwork Partnering Summit
2016-04-25,RXi Pharmaceuticals To Present At 18th Annual TIDES: Oligonucleotide And Peptides Therapeutics Conference
2016-04-19,RXi Pharmaceuticals Fortifies Its Novel RNAi Patent Portfolio With Notice Of Allowance For Lead Clinical Candidate RXI-109
2016-04-18,RXi Pharmaceuticals To Present At The Association For Research In Vision And Ophthalmology 2016 Annual Meeting
2016-04-15,RXi Pharmaceuticals Announces Reverse Stock Split
2016-03-31,RXi Pharmaceuticals Strengthens Intellectual Property Portfolio For Dermal Indications
2016-03-28,RXi Pharmaceuticals To Present At The Oligonucleotide Therapeutics And Delivery Conference
2016-03-16,RXi Pharmaceuticals To Webcast Fourth Quarter And Year End 2015 Financial Results On Wednesday, March 30, 2016
2016-01-26,RXi Pharmaceuticals To Present At The 18th Annual BIO CEO & Investor Conference
2015-12-21,RXi Pharmaceuticals Announces The Initiation Of A Phase 2 Trial In Dermatology With Samcyprone For Cutaneous Warts
2015-12-14,RXi Pharmaceuticals To Present At The 8th Annual Biotech Showcase 2016
2015-11-05,RXi Pharmaceuticals Announces The Initiation Of A Phase 1/2 Trial In Ophthalmology With RXI-109 For Retinal Scarring
2015-10-29,RXi Pharmaceuticals To Webcast Third Quarter 2015 Financial Results On Thursday, November 12, 2015
2015-10-21,RXi Pharmaceuticals Announces Compound Selection For Cosmetic Product Development With Its Novel Self-delivering RNAi Platform
2015-10-20,RXi Pharmaceuticals Announces Remarkable And Positive Results With Its Novel Self-Delivering RNAi Platform: Potent Reduction Of Long Non-coding RNAs Demonstrated In Collaboration With Biogazelle
2015-10-15,RXi Pharmaceuticals Announces Positive Interim Results In Phase 2a Dermatology Program With RXI-109
2015-10-12,RXi Pharmaceuticals To Present At Premier Scientific Plastic Surgery Meeting
2015-10-07,RXi Pharmaceuticals To Present At 14th Annual BIO Investor Forum
2015-10-05,RXi Pharmaceuticals Bolsters Protection For Its Novel Self-Delivering RNAi Platform With Notice Of Allowance From USPTO
2015-09-29,RXi Pharmaceuticals To Present At Dawson James Securities Growth Stock Conference
2015-09-28,RXi Pharmaceuticals Granted Patent In China For Lead Clinical Candidate RXI-109
2015-09-15,RXi Pharmaceuticals To Present At The 15th Annual Biotech In Europe Forum For Global Partnering And Investment Conference
2015-09-08,RXi Pharmaceuticals Strengthens Intellectual Property Portfolio For Ocular Indications
2015-08-31,RXi Pharmaceuticals Announces Advancements In Its Ophthalmology Clinical Program With RXI-109
2015-07-29,RXi Pharmaceuticals To Webcast Second Quarter 2015 Financial Results On Wednesday, August 12, 2015
2015-06-04,3 Stocks Under $10 to Trade for Breakouts
2015-06-03,RXi Pharmaceuticals Granted Notice Of Allowance For Patent Covering Lead Compound, RXI-109, For Use In The Eye
2015-06-02,RXi Pharmaceuticals To Present At The 23rd World Congress Of Dermatology
2015-05-28,RXi Pharmaceuticals Announces $10 Million Public Offering Of Common Stock And Warrants
2015-05-27,RXi Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrants
2015-05-27,RXi Pharmaceuticals Provides An Update On Series A And Series A-1 Preferred Stock
2015-05-26,RXi Pharmaceuticals To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-11,RXi Pharmaceuticals Presented Promising New Data With Self-delivering RNAi Compounds Targeting Tyrosinase And Collagenase
2015-04-29,RXi Pharmaceuticals To Webcast First Quarter 2015 Financial Results On Wednesday, May 13, 2015
2015-04-27,RXi Pharmaceuticals Announces Upcoming Presentations At Leading Partnering And Scientific Conferences
2015-04-17,RXi Pharmaceuticals Receives Orphan Drug Designation For Samcyprone™ From The U.S. FDA For The Treatment Of Malignant Melanoma Stage IIb To IV
2015-03-27,RXi Pharmaceuticals And MirImmune LLC Enter Into An Exclusive Licensing Agreement For RXi's Self-Delivering RNAi (sd-rxRNA) Technology To Develop Cell-based Immunotherapies To Treat Cancer
2015-03-23,RXi Pharmaceuticals Reports Positive Advancements In Its Dermatology Programs At The Occasion Of The 73rd Annual Meeting Of The American Academy Of Dermatology
2015-03-16,RXi Pharmaceuticals To Webcast Fourth Quarter And Year End 2014 Financial Results On Monday, March 30, 2015
2015-03-11,RXi Pharmaceuticals To Present At The 73rd Annual Meeting Of The American Academy Of Dermatology
2015-02-05,RXi Pharmaceuticals Announces Closing Of The Exclusive Global Licensing Agreement To Samcyprone™ With Hapten Pharmaceuticals
2015-02-03,RXi Pharmaceuticals Strengthens Intellectual Property Portfolio For Ocular Indications
2015-02-02,RXi Pharmaceuticals To Present At The 17th Annual BIO CEO & Investor Conference
2015-01-26,Insider Trading Alert - RXII, MA And SWN Traded By Insiders
2015-01-05,RXi Pharmaceuticals To Present At The 7th Annual Biotech Showcase™
2014-12-22,RXi Pharmaceuticals Issues Open Letter To Shareholders
2014-12-19,RXi Pharmaceuticals Expands Its Clinical Pipeline With An Exclusive Global License For A Second Phase 2 Clinical Compound
2014-10-07,RXi Pharmaceuticals To Present New Data In Its First Phase 2a Clinical Trial With RXI-109
2014-09-29,RXi Pharmaceuticals To Present At The 13th Annual BIO Investor Forum
2014-09-18,RXi Pharmaceuticals To Present At The 7th Annual BioPharm America Conference
2014-09-17,RXi Pharmaceuticals Strengthens Intellectual Property Portfolio
2014-09-11,RXi Pharmaceuticals Presented An Update On The Company's Dermatology And Ophthalmology Franchises
2014-09-09,RXi Pharmaceuticals (RXII) Is Strong On High Volume Today
2014-09-03,RXi Pharmaceuticals To Present At The Rodman & Renshaw 16th Annual Global Investment Conference
2014-08-04,RXi Pharmaceuticals To Ring The NASDAQ Stock Market Closing Bell
2014-07-30,RXi Pharmaceuticals Expands Clinical Program With Initiation Of Third Phase 2a Study With RXI-109 For Treatment Of Hypertrophic Scars
2014-07-07,RXi Pharmaceuticals Appoints Peter Campochiaro M.D. To Its Scientific Advisory Board
2014-06-25,RXi Pharmaceuticals Set To Join Russell Microcap Index
2014-05-27,RXi Pharmaceuticals To Present At The Jefferies 2014 Global Healthcare Conference
2014-05-22,RXi Pharmaceuticals Granted US Notice Of Allowance Covering Self-Delivering (sd-rxRNA) Technology Platform
2014-05-02,RXi Pharmaceuticals Announces Positive Results With RXI?109 In The Eyes Of Cynomolgus Monkeys As Part Of A Dose Range Finding Study
2014-04-29,RXi Pharmaceuticals Announces Initiation Of Phase 2a Keloid Study
2014-04-28,RXi Pharmaceuticals To Present At ARVO 2014 Annual Meeting
2014-04-22,RXi Pharmaceuticals Enters Into Financing Facility With Lincoln Park Capital
2014-03-14,RXi Pharmaceuticals Announces Upcoming Presentations
2014-03-05,RXi Pharmaceuticals Granted Key Patent Related To Self-Delivering Technology For The Treatment Of Fibrotic Disorders
2014-03-04,RXi Pharmaceuticals To Present At The 26th Annual ROTH Conference
2014-02-24,RXi Pharmaceuticals To Present At The 24th Annual Wall Street Analyst Forum
2014-02-12,Ratings Changes Today
2014-02-11,OTC Markets Group Congratulates RXI Pharmaceuticals On NASDAQ Listing
2014-02-11,RXi Pharmaceuticals Announces Listing On NASDAQ Capital Market
2014-02-03,RXi Pharmaceuticals To Present At The 16th Annual BIO CEO & Investor Conference
2014-01-14,RXi Pharmaceuticals Receives US Notice Of Allowance For A Key Patent Relating To Its Self-Delivering Technology With Sd-rxRNAs Targeting CTGF, Including RXI-109, For The Treatment Of Fibrotic Disorders
2014-01-06,RXi Pharmaceuticals To Present At The Biotech Showcase&#8482; 2014
2013-12-04,RXi Pharmaceuticals Announces MRNA Data Of An Additional Cohort In The Second Phase 1 Multi-Dose Study With RXI-109, Extending The Dose Response Following Treatment In The Initial 2-week Period
2013-11-27,RXi Pharmaceuticals To Present At The Piper Jaffray 25th Annual Healthcare Conference
2013-11-18,RXi Pharmaceuticals Corporation And Ethicor Ltd. Announce The Signing Of A Distribution Agreement For RXI-109 In The European Union Under The "Specials" Provision
2013-11-13,RXi Pharmaceuticals Announces The Start Of Their First Phase 2 Study With RXI-109 For Treatment Of Hypertrophic Scars In Conjunction With Scar Revision Surgery
2013-09-17,RXi Pharmaceuticals To Present At The 12th Annual BIO Investor Forum
2013-07-22,RXi Pharmaceuticals Announces Application For NASDAQ Capital Market Listing And Reverse Stock Split
2013-07-18,RXi Pharmaceuticals Announces CEO Interview
2013-07-12,RXi Pharmaceuticals Announces Positive Data In Second Phase 1 Multi-Dose Study
2013-06-19,RXi Pharmaceuticals Corporation Begins Trading On OTCQX®
2013-06-06,RXi Pharmaceuticals Announces Positive Results In Its First Double Blind Study In Healthy Volunteers With RXI-109
2013-05-20,RXi Pharmaceuticals To Present At The Jefferies 2013 Global Healthcare Conference
2013-05-09,RXi Pharmaceuticals To Present At IBC's 15th Annual TIDES: Oligonucleotide And Peptide Therapeutics Conference
2013-03-12,RXi Pharmaceuticals To Present At The 25th Annual ROTH Conference
2013-03-07,RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock
2013-03-07,RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock
2013-03-07,RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets
2013-03-07,RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets
2013-02-19,RXi Pharmaceuticals Announces Upcoming Presentations
2013-02-04,RXi Pharmaceuticals To Present At 15th Annual BIO CEO &amp; Investor Conference
2013-01-30,RXi Pharmaceuticals Announces Completion Of Enrollment In Second Phase 1 Trial For RXI-109 Program
2013-01-03,RXi Pharmaceuticals To Webcast Presentation At Biotech Showcase&#8482; 2013
2012-12-19,RXi Pharmaceuticals To Present At Biotech Showcase&#8482; 2013
2012-12-05,RXi Pharmaceuticals Announces Initiation Of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109
2012-11-15,RXi Pharmaceuticals Announces Pharmacokinetic Results Of Its Single Dose Phase 1 Study With RXI-109 In Healthy Volunteers
2012-11-14,RXi Pharmaceuticals Reports Financial Results For The Third Quarter Of 2012
2012-10-16,RXi Pharmaceuticals To Present At 12th Annual Biotech Symposium
2012-10-04,RXi Pharmaceuticals Awarded NCI SBIR Funding To Advance Self-Delivering RNAi Technology
2012-10-02,RXi Pharmaceuticals To Present At 11th Annual BIO Investor Forum
2012-09-24,RXi Pharmaceuticals Announces Completion Of Dosing In Phase 1 Trial For RXI-109 Program
2012-08-15,RXi Pharmaceuticals Reports Financial Results For The Second Quarter Of 2012
2012-07-13,RXi Pharmaceuticals Appoints Jeannette Graf MD And Leroy Young MD To Its Scientific Advisory Board
2012-06-26,RXi Pharmaceuticals Announces Initiation Of&#160;First Clinical Trial
2012-06-21,RXi Pharmaceuticals Appoints Robert Bitterman And Keith Brownlie To Board Of Directors
2012-05-31,RXi Pharmaceuticals Receives FDA Clearance To Begin Clinical Trial With RXI-109
2012-05-10,RXi Pharmaceuticals Appoints Industry Veteran Dr. Geert Cauwenbergh As President And Chief Executive Officer
2011-11-10,Emerging Biotech Companies Discuss What&#8217;s In The Pipeline At NYSSA Conference
2011-08-02,Generex Provides Corporate Update
2011-07-13,RXi Pharmaceuticals Strengthens NeuVax&#8482; (E75) Patent Portfolio
2011-06-24,RXi Pharmaceuticals To Present At BIO International Convention
2011-06-08,RXi Pharmaceuticals Presents Additional Positive Phase 2 Efficacy Results For Combination Of NeuVaxTM (E75) And Trastuzumab Breast Cancer At ASCO
2011-06-06,RXi Pharmaceuticals Announces Positive NeuVaxTM (E75) Phase 2 Efficacy Results After 36 Months Of Follow-Up
2011-05-19,RXi Pharmaceuticals Presents Updated NeuVax&#8482; (E75) Data At ASCO
2011-05-17,RXi Pharmaceuticals Reports Financial Results For The First Quarter Of 2011
2011-04-28,RXi Pharmaceuticals And The University Of Massachusetts Medical School Announce Massachusetts Life Sciences Center Cooperative Research Grant For RNAi Therapeutics For ALS
2011-04-26,RXi Pharmaceuticals Awarded $580,000 In NIH Grants To Advance RNAi Therapeutics
2011-04-15,RXi Pharmaceuticals Prices $12 Million Public Offering Of Common Stock And Warrants
2011-04-14,RXi Pharmaceuticals Announces Public Offering Of Common Stock And Warrants
2011-04-14,RXi Pharmaceuticals Completes Apthera Acquisition
2011-04-07,RXi Pharmaceuticals To Webcast Presentation At BioCentury Future Leaders In The Biotech Industry Conference
2011-04-01,Biotech Stock Mailbag: Avanir Pharma
2011-03-31,RXi Pharmaceuticals Aggressively Moves Into Late-Stage Clinical Development With The Agreement To Acquire Apthera, Inc.
2011-03-21,RXi Pharmaceuticals Presents New Preclinical RNAi Data At The Keystone Mechanism And Biology Of Silencing Conference
2011-03-01,RXi Pharmaceuticals Prices $8.1 Million Public Offering Of Common Stock And Warrants
2011-02-28,RXi Pharmaceuticals Announces Public Offering Of Common Stock And Warrants
2011-02-08,RXi Pharmaceuticals To Webcast Presentation At The 13th Annual BIO CEO &amp; Investor Conference
2011-02-03,RXi Pharmaceuticals Initiates Development Program For Dermal Anti-Scarring Product Candidate
2011-01-27,RXi Pharmaceuticals Announces Positive Initial Results In MicroRNA Therapeutics
2011-01-06,Generex And RXi Pharmaceuticals Announce Positive Research Data Using RNAi Technology In The Development Of Therapeutic Vaccines For Cancer
2011-01-04,RXi Pharmaceuticals To Webcast Presentation At The Biotech Showcase Conference
2010-12-17,RXi Pharmaceuticals Nominates Dermal Anti-Scarring RNAi Product Candidate To Advance Into Development
2010-11-15,RXi Pharmaceuticals Reports Financial Results For The Third Quarter Of 2010
2010-11-10,RXi Pharmaceuticals To Webcast Presentation At The Lazard Capital Markets Annual Healthcare Conference
2010-11-02,RXi Pharmaceuticals Awarded $1 Million In IRS Grants To Advance RNAi Therapeutics
2010-09-30,RXi Pharmaceuticals To Webcast Presentation At The 9th Annual BIO Investor Forum
2010-09-22,RXi Pharmaceuticals And EyeGate Pharma Announce Collaboration Focused On Non-Invasive Ocular Delivery Of RNAi Therapeutics
2010-09-15,Rodman Rambles: Promising Biotechs
2010-09-07,RXi Pharmaceuticals To Webcast Presentation At The Rodman &amp; Renshaw Global Investment Conference
2010-08-11,RXi Pharmaceuticals Reports Financial Results For The Second Quarter Of 2010
2010-08-05,RXi Pharmaceuticals To Host Second Quarter 2010 Conference Call On Wednesday, August 11, 2010
2010-07-13,RXi Pharmaceuticals Receives $600,000 Grant
2010-07-13,RXi Pharmaceuticals Awarded NIH Grant To Advance RNAi Therapeutics
2010-06-10,RXi Pharmaceuticals Announces New Focused Therapeutic Strategy For Its Next Generation RNAi Technology
2010-06-03,Philips And RXi Pharmaceuticals Sign Agreement To Jointly Research Innovative Image-Guided Therapy Concepts Based On RNAi
2010-06-02,RXi Pharmaceuticals CEO To Present At The Jefferies 2010 Global Life Sciences Conference
2010-05-17,RXi Pharmaceuticals Reports Financial Results For The First Quarter Of 2010
2010-05-11,RXi Pharmaceuticals CEO To Present At The Rodman &amp; Renshaw Annual Global Healthcare Conference
2010-05-04,RXi Demonstrates Robust In Vivo Uptake And Significant Silencing Using Its Self-Delivering RxRNA&#8482; Compounds Administered To Mouse Retinal Cells
2010-04-23,RXi Pharmaceuticals To Deliver Presentations At Upcoming Conferences Outlining The Development And Progression Of Its Next Generation RxRNA&#8482; Therapeutic Platform
2017-03-22,RXi Pharmaceuticals To Present At The 5th Annual Cancer BioPartnering & Investment Forum
2017-03-21,RXi Pharmaceuticals To Present At The 2nd Annual Oligonucleotide And Peptide Therapeutics Conference
2017-03-16,RXi Pharmaceuticals To Webcast Fourth Quarter And Year End 2016 Financial Results On Thursday, March 30, 2017
2017-02-14,RXi Pharmaceuticals Appoints Medical Oncology Expert, Dr. James Griffin, To Scientific Advisory Board
2017-02-08,RXi Pharmaceuticals To Present At Leading Investor And Healthcare Conferences
2017-02-07,RXi Pharmaceuticals Appoints Leading Oncology Expert, Dr. Rolf Kiessling, To Scientific Advisory Board
2017-01-09,RXi Pharmaceuticals Completes Acquisition Of MirImmune Inc. And Appoints New Chief Business Officer
2016-12-26,RXi Pharmaceuticals To Present At The 9th Annual Biotech Showcase™
2016-12-21,RXi Pharmaceuticals Announces Closing Of $11.5 Million Underwritten Public Offering And Full Exercise Of Over-allotment Option
2016-12-16,RXi Pharmaceuticals Announces Pricing Of $10 Million Underwritten Public Offering
2016-12-13,RXi Pharmaceuticals Provides Year End Update On Its Business Development And Clinical Programs
2016-11-28,RXi Pharmaceuticals Corporation Discusses Competitive Advantage, Goals And Milestones For 2016-2017 In New SNNLive Newscast On StockNewsNow.com
2016-10-27,RXi Pharmaceuticals To Webcast Third Quarter 2016 Financial Results On Thursday, November 10, 2016
2016-10-12,RXi Pharmaceuticals Plans To Conduct Securities Offering
2016-10-12,RXi Pharmaceuticals Enters Into Exclusive Option Agreement To Acquire MirImmune Inc.
2016-10-11,RXi Pharmaceuticals To Present At The 15th Annual BIO Investor Forum
2016-09-19,RXi Pharmaceuticals To Present At The 16th Annual Biotech In Europe Forum For Global Partnering And Investment Conference
2016-09-12,RXi Pharmaceuticals To Present At The 4th Targeting Ocular Disorders Conference
2016-09-07,RXi Pharmaceuticals Corporation Selected to Present at Cavendish Global Health Impact Forum
2016-09-06,RXi Pharmaceuticals to Present at the 9th Annual BioPharm America™ Conference
2016-07-28,RXi Pharmaceuticals To Webcast Second Quarter 2016 Financial Results On Thursday, August 11, 2016
2016-07-21,RXi Pharmaceuticals To Present At The 2016 Summer Meeting Of The American Academy Of Dermatology
2016-05-10,RXi Pharmaceuticals Provides Strategic Update
2016-05-04,RXi Pharmaceuticals To Present An Update On Its Consumer Health Programs At The Society For Investigative Dermatology 75th Annual Meeting
2016-05-03,RXi Pharmaceuticals And Thera Neuropharma Enter Into An Exclusive License Agreement For RXi's Self-Delivering RNAi (sd-rxRNA®) Platform Targeting SOD1 To Develop Therapeutics For Neurodegenerative Diseases, Such As ALS (Lou Gehrig's Disease)
2016-05-02,RXi Pharmaceuticals Secures European Patent For Novel RNAi Platform
2016-04-28,RXi Pharmaceuticals Announces Advancement Of Its Ophthalmology Franchise With Successful Topical Delivery Of Sd-rxRNA To The Cornea In An In Vivo Corneal Wound Model
2016-04-27,RXi Pharmaceuticals To Webcast First Quarter 2016 Financial Results On Thursday, May 12, 2016
2016-04-26,RXi Pharmaceuticals Announces 'Biotech Spotlight' Presentation At The BioNetwork Partnering Summit
2016-04-25,RXi Pharmaceuticals To Present At 18th Annual TIDES: Oligonucleotide And Peptides Therapeutics Conference
2016-04-19,RXi Pharmaceuticals Fortifies Its Novel RNAi Patent Portfolio With Notice Of Allowance For Lead Clinical Candidate RXI-109
2016-04-18,RXi Pharmaceuticals To Present At The Association For Research In Vision And Ophthalmology 2016 Annual Meeting
2016-04-15,RXi Pharmaceuticals Announces Reverse Stock Split
2016-03-31,RXi Pharmaceuticals Strengthens Intellectual Property Portfolio For Dermal Indications
2016-03-28,RXi Pharmaceuticals To Present At The Oligonucleotide Therapeutics And Delivery Conference
2016-03-16,RXi Pharmaceuticals To Webcast Fourth Quarter And Year End 2015 Financial Results On Wednesday, March 30, 2016
2016-01-26,RXi Pharmaceuticals To Present At The 18th Annual BIO CEO & Investor Conference
2015-12-21,RXi Pharmaceuticals Announces The Initiation Of A Phase 2 Trial In Dermatology With Samcyprone For Cutaneous Warts
2015-12-14,RXi Pharmaceuticals To Present At The 8th Annual Biotech Showcase 2016
2015-11-05,RXi Pharmaceuticals Announces The Initiation Of A Phase 1/2 Trial In Ophthalmology With RXI-109 For Retinal Scarring
2015-10-29,RXi Pharmaceuticals To Webcast Third Quarter 2015 Financial Results On Thursday, November 12, 2015
2015-10-21,RXi Pharmaceuticals Announces Compound Selection For Cosmetic Product Development With Its Novel Self-delivering RNAi Platform
2015-10-20,RXi Pharmaceuticals Announces Remarkable And Positive Results With Its Novel Self-Delivering RNAi Platform: Potent Reduction Of Long Non-coding RNAs Demonstrated In Collaboration With Biogazelle
2015-10-15,RXi Pharmaceuticals Announces Positive Interim Results In Phase 2a Dermatology Program With RXI-109
2015-10-12,RXi Pharmaceuticals To Present At Premier Scientific Plastic Surgery Meeting
2015-10-07,RXi Pharmaceuticals To Present At 14th Annual BIO Investor Forum
2015-10-05,RXi Pharmaceuticals Bolsters Protection For Its Novel Self-Delivering RNAi Platform With Notice Of Allowance From USPTO
2015-09-29,RXi Pharmaceuticals To Present At Dawson James Securities Growth Stock Conference
2015-09-28,RXi Pharmaceuticals Granted Patent In China For Lead Clinical Candidate RXI-109
2015-09-15,RXi Pharmaceuticals To Present At The 15th Annual Biotech In Europe Forum For Global Partnering And Investment Conference
2015-09-08,RXi Pharmaceuticals Strengthens Intellectual Property Portfolio For Ocular Indications
2015-08-31,RXi Pharmaceuticals Announces Advancements In Its Ophthalmology Clinical Program With RXI-109
2015-07-29,RXi Pharmaceuticals To Webcast Second Quarter 2015 Financial Results On Wednesday, August 12, 2015
2015-06-04,3 Stocks Under $10 to Trade for Breakouts
2015-06-03,RXi Pharmaceuticals Granted Notice Of Allowance For Patent Covering Lead Compound, RXI-109, For Use In The Eye
2015-06-02,RXi Pharmaceuticals To Present At The 23rd World Congress Of Dermatology
2015-05-28,RXi Pharmaceuticals Announces $10 Million Public Offering Of Common Stock And Warrants
2015-05-27,RXi Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrants
2015-05-27,RXi Pharmaceuticals Provides An Update On Series A And Series A-1 Preferred Stock
2015-05-26,RXi Pharmaceuticals To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-11,RXi Pharmaceuticals Presented Promising New Data With Self-delivering RNAi Compounds Targeting Tyrosinase And Collagenase
2015-04-29,RXi Pharmaceuticals To Webcast First Quarter 2015 Financial Results On Wednesday, May 13, 2015
2015-04-27,RXi Pharmaceuticals Announces Upcoming Presentations At Leading Partnering And Scientific Conferences
2015-04-17,RXi Pharmaceuticals Receives Orphan Drug Designation For Samcyprone™ From The U.S. FDA For The Treatment Of Malignant Melanoma Stage IIb To IV
2015-03-27,RXi Pharmaceuticals And MirImmune LLC Enter Into An Exclusive Licensing Agreement For RXi's Self-Delivering RNAi (sd-rxRNA) Technology To Develop Cell-based Immunotherapies To Treat Cancer
2015-03-23,RXi Pharmaceuticals Reports Positive Advancements In Its Dermatology Programs At The Occasion Of The 73rd Annual Meeting Of The American Academy Of Dermatology
2015-03-16,RXi Pharmaceuticals To Webcast Fourth Quarter And Year End 2014 Financial Results On Monday, March 30, 2015
2015-03-11,RXi Pharmaceuticals To Present At The 73rd Annual Meeting Of The American Academy Of Dermatology
2015-02-05,RXi Pharmaceuticals Announces Closing Of The Exclusive Global Licensing Agreement To Samcyprone™ With Hapten Pharmaceuticals
2015-02-03,RXi Pharmaceuticals Strengthens Intellectual Property Portfolio For Ocular Indications
2015-02-02,RXi Pharmaceuticals To Present At The 17th Annual BIO CEO & Investor Conference
2015-01-26,Insider Trading Alert - RXII, MA And SWN Traded By Insiders
2015-01-05,RXi Pharmaceuticals To Present At The 7th Annual Biotech Showcase™
2014-12-22,RXi Pharmaceuticals Issues Open Letter To Shareholders
2014-12-19,RXi Pharmaceuticals Expands Its Clinical Pipeline With An Exclusive Global License For A Second Phase 2 Clinical Compound
2014-10-07,RXi Pharmaceuticals To Present New Data In Its First Phase 2a Clinical Trial With RXI-109
2014-09-29,RXi Pharmaceuticals To Present At The 13th Annual BIO Investor Forum
2014-09-18,RXi Pharmaceuticals To Present At The 7th Annual BioPharm America Conference
2014-09-17,RXi Pharmaceuticals Strengthens Intellectual Property Portfolio
2014-09-11,RXi Pharmaceuticals Presented An Update On The Company's Dermatology And Ophthalmology Franchises
2014-09-09,RXi Pharmaceuticals (RXII) Is Strong On High Volume Today
2014-09-03,RXi Pharmaceuticals To Present At The Rodman & Renshaw 16th Annual Global Investment Conference
2014-08-04,RXi Pharmaceuticals To Ring The NASDAQ Stock Market Closing Bell
2014-07-30,RXi Pharmaceuticals Expands Clinical Program With Initiation Of Third Phase 2a Study With RXI-109 For Treatment Of Hypertrophic Scars
2014-07-07,RXi Pharmaceuticals Appoints Peter Campochiaro M.D. To Its Scientific Advisory Board
2014-06-25,RXi Pharmaceuticals Set To Join Russell Microcap Index
2014-05-27,RXi Pharmaceuticals To Present At The Jefferies 2014 Global Healthcare Conference
2014-05-22,RXi Pharmaceuticals Granted US Notice Of Allowance Covering Self-Delivering (sd-rxRNA) Technology Platform
2014-05-02,RXi Pharmaceuticals Announces Positive Results With RXI?109 In The Eyes Of Cynomolgus Monkeys As Part Of A Dose Range Finding Study
2014-04-29,RXi Pharmaceuticals Announces Initiation Of Phase 2a Keloid Study
2014-04-28,RXi Pharmaceuticals To Present At ARVO 2014 Annual Meeting
2014-04-22,RXi Pharmaceuticals Enters Into Financing Facility With Lincoln Park Capital
2014-03-14,RXi Pharmaceuticals Announces Upcoming Presentations
2014-03-05,RXi Pharmaceuticals Granted Key Patent Related To Self-Delivering Technology For The Treatment Of Fibrotic Disorders
2014-03-04,RXi Pharmaceuticals To Present At The 26th Annual ROTH Conference
2014-02-24,RXi Pharmaceuticals To Present At The 24th Annual Wall Street Analyst Forum
2014-02-12,Ratings Changes Today
2014-02-11,OTC Markets Group Congratulates RXI Pharmaceuticals On NASDAQ Listing
2014-02-11,RXi Pharmaceuticals Announces Listing On NASDAQ Capital Market
2014-02-03,RXi Pharmaceuticals To Present At The 16th Annual BIO CEO & Investor Conference
2014-01-14,RXi Pharmaceuticals Receives US Notice Of Allowance For A Key Patent Relating To Its Self-Delivering Technology With Sd-rxRNAs Targeting CTGF, Including RXI-109, For The Treatment Of Fibrotic Disorders
2014-01-06,RXi Pharmaceuticals To Present At The Biotech Showcase&#8482; 2014
2013-12-04,RXi Pharmaceuticals Announces MRNA Data Of An Additional Cohort In The Second Phase 1 Multi-Dose Study With RXI-109, Extending The Dose Response Following Treatment In The Initial 2-week Period
2013-11-27,RXi Pharmaceuticals To Present At The Piper Jaffray 25th Annual Healthcare Conference
2013-11-18,RXi Pharmaceuticals Corporation And Ethicor Ltd. Announce The Signing Of A Distribution Agreement For RXI-109 In The European Union Under The "Specials" Provision
2013-11-13,RXi Pharmaceuticals Announces The Start Of Their First Phase 2 Study With RXI-109 For Treatment Of Hypertrophic Scars In Conjunction With Scar Revision Surgery
2013-09-17,RXi Pharmaceuticals To Present At The 12th Annual BIO Investor Forum
2013-07-22,RXi Pharmaceuticals Announces Application For NASDAQ Capital Market Listing And Reverse Stock Split
2013-07-18,RXi Pharmaceuticals Announces CEO Interview
2013-07-12,RXi Pharmaceuticals Announces Positive Data In Second Phase 1 Multi-Dose Study
2013-06-19,RXi Pharmaceuticals Corporation Begins Trading On OTCQX®
2013-06-06,RXi Pharmaceuticals Announces Positive Results In Its First Double Blind Study In Healthy Volunteers With RXI-109
2013-05-20,RXi Pharmaceuticals To Present At The Jefferies 2013 Global Healthcare Conference
2013-05-09,RXi Pharmaceuticals To Present At IBC's 15th Annual TIDES: Oligonucleotide And Peptide Therapeutics Conference
2013-03-12,RXi Pharmaceuticals To Present At The 25th Annual ROTH Conference
2013-03-07,RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock
2013-03-07,RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock
2013-03-07,RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets
2013-03-07,RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets
2013-02-19,RXi Pharmaceuticals Announces Upcoming Presentations
2013-02-04,RXi Pharmaceuticals To Present At 15th Annual BIO CEO &amp; Investor Conference
2013-01-30,RXi Pharmaceuticals Announces Completion Of Enrollment In Second Phase 1 Trial For RXI-109 Program
2013-01-03,RXi Pharmaceuticals To Webcast Presentation At Biotech Showcase&#8482; 2013
2012-12-19,RXi Pharmaceuticals To Present At Biotech Showcase&#8482; 2013
2012-12-05,RXi Pharmaceuticals Announces Initiation Of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109
2012-11-15,RXi Pharmaceuticals Announces Pharmacokinetic Results Of Its Single Dose Phase 1 Study With RXI-109 In Healthy Volunteers
2012-11-14,RXi Pharmaceuticals Reports Financial Results For The Third Quarter Of 2012
2012-10-16,RXi Pharmaceuticals To Present At 12th Annual Biotech Symposium
2012-10-04,RXi Pharmaceuticals Awarded NCI SBIR Funding To Advance Self-Delivering RNAi Technology
2012-10-02,RXi Pharmaceuticals To Present At 11th Annual BIO Investor Forum
2012-09-24,RXi Pharmaceuticals Announces Completion Of Dosing In Phase 1 Trial For RXI-109 Program
2012-08-15,RXi Pharmaceuticals Reports Financial Results For The Second Quarter Of 2012
2012-07-13,RXi Pharmaceuticals Appoints Jeannette Graf MD And Leroy Young MD To Its Scientific Advisory Board
2012-06-26,RXi Pharmaceuticals Announces Initiation Of&#160;First Clinical Trial
2012-06-21,RXi Pharmaceuticals Appoints Robert Bitterman And Keith Brownlie To Board Of Directors
2012-05-31,RXi Pharmaceuticals Receives FDA Clearance To Begin Clinical Trial With RXI-109
2012-05-10,RXi Pharmaceuticals Appoints Industry Veteran Dr. Geert Cauwenbergh As President And Chief Executive Officer
2011-11-10,Emerging Biotech Companies Discuss What&#8217;s In The Pipeline At NYSSA Conference
2011-08-02,Generex Provides Corporate Update
2011-07-13,RXi Pharmaceuticals Strengthens NeuVax&#8482; (E75) Patent Portfolio
2011-06-24,RXi Pharmaceuticals To Present At BIO International Convention
2011-06-08,RXi Pharmaceuticals Presents Additional Positive Phase 2 Efficacy Results For Combination Of NeuVaxTM (E75) And Trastuzumab Breast Cancer At ASCO
2011-06-06,RXi Pharmaceuticals Announces Positive NeuVaxTM (E75) Phase 2 Efficacy Results After 36 Months Of Follow-Up
2011-05-19,RXi Pharmaceuticals Presents Updated NeuVax&#8482; (E75) Data At ASCO
2011-05-17,RXi Pharmaceuticals Reports Financial Results For The First Quarter Of 2011
2011-04-28,RXi Pharmaceuticals And The University Of Massachusetts Medical School Announce Massachusetts Life Sciences Center Cooperative Research Grant For RNAi Therapeutics For ALS
2011-04-26,RXi Pharmaceuticals Awarded $580,000 In NIH Grants To Advance RNAi Therapeutics
2011-04-15,RXi Pharmaceuticals Prices $12 Million Public Offering Of Common Stock And Warrants
2011-04-14,RXi Pharmaceuticals Announces Public Offering Of Common Stock And Warrants
2011-04-14,RXi Pharmaceuticals Completes Apthera Acquisition
2011-04-07,RXi Pharmaceuticals To Webcast Presentation At BioCentury Future Leaders In The Biotech Industry Conference
2011-04-01,Biotech Stock Mailbag: Avanir Pharma
2011-03-31,RXi Pharmaceuticals Aggressively Moves Into Late-Stage Clinical Development With The Agreement To Acquire Apthera, Inc.
2011-03-21,RXi Pharmaceuticals Presents New Preclinical RNAi Data At The Keystone Mechanism And Biology Of Silencing Conference
2011-03-01,RXi Pharmaceuticals Prices $8.1 Million Public Offering Of Common Stock And Warrants
2011-02-28,RXi Pharmaceuticals Announces Public Offering Of Common Stock And Warrants
2011-02-08,RXi Pharmaceuticals To Webcast Presentation At The 13th Annual BIO CEO &amp; Investor Conference
2011-02-03,RXi Pharmaceuticals Initiates Development Program For Dermal Anti-Scarring Product Candidate
2011-01-27,RXi Pharmaceuticals Announces Positive Initial Results In MicroRNA Therapeutics
2011-01-06,Generex And RXi Pharmaceuticals Announce Positive Research Data Using RNAi Technology In The Development Of Therapeutic Vaccines For Cancer
2011-01-04,RXi Pharmaceuticals To Webcast Presentation At The Biotech Showcase Conference
2010-12-17,RXi Pharmaceuticals Nominates Dermal Anti-Scarring RNAi Product Candidate To Advance Into Development
2010-11-15,RXi Pharmaceuticals Reports Financial Results For The Third Quarter Of 2010
2010-11-10,RXi Pharmaceuticals To Webcast Presentation At The Lazard Capital Markets Annual Healthcare Conference
2010-11-02,RXi Pharmaceuticals Awarded $1 Million In IRS Grants To Advance RNAi Therapeutics
2010-09-30,RXi Pharmaceuticals To Webcast Presentation At The 9th Annual BIO Investor Forum
2010-09-22,RXi Pharmaceuticals And EyeGate Pharma Announce Collaboration Focused On Non-Invasive Ocular Delivery Of RNAi Therapeutics
2010-09-15,Rodman Rambles: Promising Biotechs
2010-09-07,RXi Pharmaceuticals To Webcast Presentation At The Rodman &amp; Renshaw Global Investment Conference
2010-08-11,RXi Pharmaceuticals Reports Financial Results For The Second Quarter Of 2010
2010-08-05,RXi Pharmaceuticals To Host Second Quarter 2010 Conference Call On Wednesday, August 11, 2010
2010-07-13,RXi Pharmaceuticals Receives $600,000 Grant
2010-07-13,RXi Pharmaceuticals Awarded NIH Grant To Advance RNAi Therapeutics
2010-06-10,RXi Pharmaceuticals Announces New Focused Therapeutic Strategy For Its Next Generation RNAi Technology
2010-06-03,Philips And RXi Pharmaceuticals Sign Agreement To Jointly Research Innovative Image-Guided Therapy Concepts Based On RNAi
2010-06-02,RXi Pharmaceuticals CEO To Present At The Jefferies 2010 Global Life Sciences Conference
2010-05-17,RXi Pharmaceuticals Reports Financial Results For The First Quarter Of 2010
2010-05-11,RXi Pharmaceuticals CEO To Present At The Rodman &amp; Renshaw Annual Global Healthcare Conference
2010-05-04,RXi Demonstrates Robust In Vivo Uptake And Significant Silencing Using Its Self-Delivering RxRNA&#8482; Compounds Administered To Mouse Retinal Cells
2010-04-23,RXi Pharmaceuticals To Deliver Presentations At Upcoming Conferences Outlining The Development And Progression Of Its Next Generation RxRNA&#8482; Therapeutic Platform
2017-03-22,RXi Pharmaceuticals To Present At The 5th Annual Cancer BioPartnering & Investment Forum
2017-03-21,RXi Pharmaceuticals To Present At The 2nd Annual Oligonucleotide And Peptide Therapeutics Conference
2017-03-16,RXi Pharmaceuticals To Webcast Fourth Quarter And Year End 2016 Financial Results On Thursday, March 30, 2017
2017-02-14,RXi Pharmaceuticals Appoints Medical Oncology Expert, Dr. James Griffin, To Scientific Advisory Board
2017-02-08,RXi Pharmaceuticals To Present At Leading Investor And Healthcare Conferences
2017-02-07,RXi Pharmaceuticals Appoints Leading Oncology Expert, Dr. Rolf Kiessling, To Scientific Advisory Board
2017-01-09,RXi Pharmaceuticals Completes Acquisition Of MirImmune Inc. And Appoints New Chief Business Officer
2016-12-26,RXi Pharmaceuticals To Present At The 9th Annual Biotech Showcase™
2016-12-21,RXi Pharmaceuticals Announces Closing Of $11.5 Million Underwritten Public Offering And Full Exercise Of Over-allotment Option
2016-12-16,RXi Pharmaceuticals Announces Pricing Of $10 Million Underwritten Public Offering
2016-12-13,RXi Pharmaceuticals Provides Year End Update On Its Business Development And Clinical Programs
2016-11-28,RXi Pharmaceuticals Corporation Discusses Competitive Advantage, Goals And Milestones For 2016-2017 In New SNNLive Newscast On StockNewsNow.com
2016-10-27,RXi Pharmaceuticals To Webcast Third Quarter 2016 Financial Results On Thursday, November 10, 2016
2016-10-12,RXi Pharmaceuticals Plans To Conduct Securities Offering
2016-10-12,RXi Pharmaceuticals Enters Into Exclusive Option Agreement To Acquire MirImmune Inc.
2016-10-11,RXi Pharmaceuticals To Present At The 15th Annual BIO Investor Forum
2016-09-19,RXi Pharmaceuticals To Present At The 16th Annual Biotech In Europe Forum For Global Partnering And Investment Conference
2016-09-12,RXi Pharmaceuticals To Present At The 4th Targeting Ocular Disorders Conference
2016-09-07,RXi Pharmaceuticals Corporation Selected to Present at Cavendish Global Health Impact Forum
2016-09-06,RXi Pharmaceuticals to Present at the 9th Annual BioPharm America™ Conference
2016-07-28,RXi Pharmaceuticals To Webcast Second Quarter 2016 Financial Results On Thursday, August 11, 2016
2016-07-21,RXi Pharmaceuticals To Present At The 2016 Summer Meeting Of The American Academy Of Dermatology
2016-05-10,RXi Pharmaceuticals Provides Strategic Update
2016-05-04,RXi Pharmaceuticals To Present An Update On Its Consumer Health Programs At The Society For Investigative Dermatology 75th Annual Meeting
2016-05-03,RXi Pharmaceuticals And Thera Neuropharma Enter Into An Exclusive License Agreement For RXi's Self-Delivering RNAi (sd-rxRNA®) Platform Targeting SOD1 To Develop Therapeutics For Neurodegenerative Diseases, Such As ALS (Lou Gehrig's Disease)
2016-05-02,RXi Pharmaceuticals Secures European Patent For Novel RNAi Platform
2016-04-28,RXi Pharmaceuticals Announces Advancement Of Its Ophthalmology Franchise With Successful Topical Delivery Of Sd-rxRNA To The Cornea In An In Vivo Corneal Wound Model
2016-04-27,RXi Pharmaceuticals To Webcast First Quarter 2016 Financial Results On Thursday, May 12, 2016
2016-04-26,RXi Pharmaceuticals Announces 'Biotech Spotlight' Presentation At The BioNetwork Partnering Summit
2016-04-25,RXi Pharmaceuticals To Present At 18th Annual TIDES: Oligonucleotide And Peptides Therapeutics Conference
2016-04-19,RXi Pharmaceuticals Fortifies Its Novel RNAi Patent Portfolio With Notice Of Allowance For Lead Clinical Candidate RXI-109
2016-04-18,RXi Pharmaceuticals To Present At The Association For Research In Vision And Ophthalmology 2016 Annual Meeting
2016-04-15,RXi Pharmaceuticals Announces Reverse Stock Split
2016-03-31,RXi Pharmaceuticals Strengthens Intellectual Property Portfolio For Dermal Indications
2016-03-28,RXi Pharmaceuticals To Present At The Oligonucleotide Therapeutics And Delivery Conference
2016-03-16,RXi Pharmaceuticals To Webcast Fourth Quarter And Year End 2015 Financial Results On Wednesday, March 30, 2016
2016-01-26,RXi Pharmaceuticals To Present At The 18th Annual BIO CEO & Investor Conference
2015-12-21,RXi Pharmaceuticals Announces The Initiation Of A Phase 2 Trial In Dermatology With Samcyprone For Cutaneous Warts
2015-12-14,RXi Pharmaceuticals To Present At The 8th Annual Biotech Showcase 2016
2015-11-05,RXi Pharmaceuticals Announces The Initiation Of A Phase 1/2 Trial In Ophthalmology With RXI-109 For Retinal Scarring
2015-10-29,RXi Pharmaceuticals To Webcast Third Quarter 2015 Financial Results On Thursday, November 12, 2015
2015-10-21,RXi Pharmaceuticals Announces Compound Selection For Cosmetic Product Development With Its Novel Self-delivering RNAi Platform
2015-10-20,RXi Pharmaceuticals Announces Remarkable And Positive Results With Its Novel Self-Delivering RNAi Platform: Potent Reduction Of Long Non-coding RNAs Demonstrated In Collaboration With Biogazelle
2015-10-15,RXi Pharmaceuticals Announces Positive Interim Results In Phase 2a Dermatology Program With RXI-109
2015-10-12,RXi Pharmaceuticals To Present At Premier Scientific Plastic Surgery Meeting
2015-10-07,RXi Pharmaceuticals To Present At 14th Annual BIO Investor Forum
2015-10-05,RXi Pharmaceuticals Bolsters Protection For Its Novel Self-Delivering RNAi Platform With Notice Of Allowance From USPTO
2015-09-29,RXi Pharmaceuticals To Present At Dawson James Securities Growth Stock Conference
2015-09-28,RXi Pharmaceuticals Granted Patent In China For Lead Clinical Candidate RXI-109
2015-09-15,RXi Pharmaceuticals To Present At The 15th Annual Biotech In Europe Forum For Global Partnering And Investment Conference
2015-09-08,RXi Pharmaceuticals Strengthens Intellectual Property Portfolio For Ocular Indications
2015-08-31,RXi Pharmaceuticals Announces Advancements In Its Ophthalmology Clinical Program With RXI-109
2015-07-29,RXi Pharmaceuticals To Webcast Second Quarter 2015 Financial Results On Wednesday, August 12, 2015
2015-06-04,3 Stocks Under $10 to Trade for Breakouts
2015-06-03,RXi Pharmaceuticals Granted Notice Of Allowance For Patent Covering Lead Compound, RXI-109, For Use In The Eye
2015-06-02,RXi Pharmaceuticals To Present At The 23rd World Congress Of Dermatology
2015-05-28,RXi Pharmaceuticals Announces $10 Million Public Offering Of Common Stock And Warrants
2015-05-27,RXi Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrants
2015-05-27,RXi Pharmaceuticals Provides An Update On Series A And Series A-1 Preferred Stock
2015-05-26,RXi Pharmaceuticals To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-11,RXi Pharmaceuticals Presented Promising New Data With Self-delivering RNAi Compounds Targeting Tyrosinase And Collagenase
2015-04-29,RXi Pharmaceuticals To Webcast First Quarter 2015 Financial Results On Wednesday, May 13, 2015
2015-04-27,RXi Pharmaceuticals Announces Upcoming Presentations At Leading Partnering And Scientific Conferences
2015-04-17,RXi Pharmaceuticals Receives Orphan Drug Designation For Samcyprone™ From The U.S. FDA For The Treatment Of Malignant Melanoma Stage IIb To IV
2015-03-27,RXi Pharmaceuticals And MirImmune LLC Enter Into An Exclusive Licensing Agreement For RXi's Self-Delivering RNAi (sd-rxRNA) Technology To Develop Cell-based Immunotherapies To Treat Cancer
2015-03-23,RXi Pharmaceuticals Reports Positive Advancements In Its Dermatology Programs At The Occasion Of The 73rd Annual Meeting Of The American Academy Of Dermatology
2015-03-16,RXi Pharmaceuticals To Webcast Fourth Quarter And Year End 2014 Financial Results On Monday, March 30, 2015
2015-03-11,RXi Pharmaceuticals To Present At The 73rd Annual Meeting Of The American Academy Of Dermatology
2015-02-05,RXi Pharmaceuticals Announces Closing Of The Exclusive Global Licensing Agreement To Samcyprone™ With Hapten Pharmaceuticals
2015-02-03,RXi Pharmaceuticals Strengthens Intellectual Property Portfolio For Ocular Indications
2015-02-02,RXi Pharmaceuticals To Present At The 17th Annual BIO CEO & Investor Conference
2015-01-26,Insider Trading Alert - RXII, MA And SWN Traded By Insiders
2015-01-05,RXi Pharmaceuticals To Present At The 7th Annual Biotech Showcase™
2014-12-22,RXi Pharmaceuticals Issues Open Letter To Shareholders
2014-12-19,RXi Pharmaceuticals Expands Its Clinical Pipeline With An Exclusive Global License For A Second Phase 2 Clinical Compound
2014-10-07,RXi Pharmaceuticals To Present New Data In Its First Phase 2a Clinical Trial With RXI-109
2014-09-29,RXi Pharmaceuticals To Present At The 13th Annual BIO Investor Forum
2014-09-18,RXi Pharmaceuticals To Present At The 7th Annual BioPharm America Conference
2014-09-17,RXi Pharmaceuticals Strengthens Intellectual Property Portfolio
2014-09-11,RXi Pharmaceuticals Presented An Update On The Company's Dermatology And Ophthalmology Franchises
2014-09-09,RXi Pharmaceuticals (RXII) Is Strong On High Volume Today
2014-09-03,RXi Pharmaceuticals To Present At The Rodman & Renshaw 16th Annual Global Investment Conference
2014-08-04,RXi Pharmaceuticals To Ring The NASDAQ Stock Market Closing Bell
2014-07-30,RXi Pharmaceuticals Expands Clinical Program With Initiation Of Third Phase 2a Study With RXI-109 For Treatment Of Hypertrophic Scars
2014-07-07,RXi Pharmaceuticals Appoints Peter Campochiaro M.D. To Its Scientific Advisory Board
2014-06-25,RXi Pharmaceuticals Set To Join Russell Microcap Index
2014-05-27,RXi Pharmaceuticals To Present At The Jefferies 2014 Global Healthcare Conference
2014-05-22,RXi Pharmaceuticals Granted US Notice Of Allowance Covering Self-Delivering (sd-rxRNA) Technology Platform
2014-05-02,RXi Pharmaceuticals Announces Positive Results With RXI?109 In The Eyes Of Cynomolgus Monkeys As Part Of A Dose Range Finding Study
2014-04-29,RXi Pharmaceuticals Announces Initiation Of Phase 2a Keloid Study
2014-04-28,RXi Pharmaceuticals To Present At ARVO 2014 Annual Meeting
2014-04-22,RXi Pharmaceuticals Enters Into Financing Facility With Lincoln Park Capital
2014-03-14,RXi Pharmaceuticals Announces Upcoming Presentations
2014-03-05,RXi Pharmaceuticals Granted Key Patent Related To Self-Delivering Technology For The Treatment Of Fibrotic Disorders
2014-03-04,RXi Pharmaceuticals To Present At The 26th Annual ROTH Conference
2014-02-24,RXi Pharmaceuticals To Present At The 24th Annual Wall Street Analyst Forum
2014-02-12,Ratings Changes Today
2014-02-11,OTC Markets Group Congratulates RXI Pharmaceuticals On NASDAQ Listing
2014-02-11,RXi Pharmaceuticals Announces Listing On NASDAQ Capital Market
2014-02-03,RXi Pharmaceuticals To Present At The 16th Annual BIO CEO & Investor Conference
2014-01-14,RXi Pharmaceuticals Receives US Notice Of Allowance For A Key Patent Relating To Its Self-Delivering Technology With Sd-rxRNAs Targeting CTGF, Including RXI-109, For The Treatment Of Fibrotic Disorders
2014-01-06,RXi Pharmaceuticals To Present At The Biotech Showcase&#8482; 2014
2013-12-04,RXi Pharmaceuticals Announces MRNA Data Of An Additional Cohort In The Second Phase 1 Multi-Dose Study With RXI-109, Extending The Dose Response Following Treatment In The Initial 2-week Period
2013-11-27,RXi Pharmaceuticals To Present At The Piper Jaffray 25th Annual Healthcare Conference
2013-11-18,RXi Pharmaceuticals Corporation And Ethicor Ltd. Announce The Signing Of A Distribution Agreement For RXI-109 In The European Union Under The "Specials" Provision
2013-11-13,RXi Pharmaceuticals Announces The Start Of Their First Phase 2 Study With RXI-109 For Treatment Of Hypertrophic Scars In Conjunction With Scar Revision Surgery
2013-09-17,RXi Pharmaceuticals To Present At The 12th Annual BIO Investor Forum
2013-07-22,RXi Pharmaceuticals Announces Application For NASDAQ Capital Market Listing And Reverse Stock Split
2013-07-18,RXi Pharmaceuticals Announces CEO Interview
2013-07-12,RXi Pharmaceuticals Announces Positive Data In Second Phase 1 Multi-Dose Study
2013-06-19,RXi Pharmaceuticals Corporation Begins Trading On OTCQX®
2013-06-06,RXi Pharmaceuticals Announces Positive Results In Its First Double Blind Study In Healthy Volunteers With RXI-109
2013-05-20,RXi Pharmaceuticals To Present At The Jefferies 2013 Global Healthcare Conference
2013-05-09,RXi Pharmaceuticals To Present At IBC's 15th Annual TIDES: Oligonucleotide And Peptide Therapeutics Conference
2013-03-12,RXi Pharmaceuticals To Present At The 25th Annual ROTH Conference
2013-03-07,RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock
2013-03-07,RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock
2013-03-07,RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets
2013-03-07,RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets
2013-02-19,RXi Pharmaceuticals Announces Upcoming Presentations
2013-02-04,RXi Pharmaceuticals To Present At 15th Annual BIO CEO &amp; Investor Conference
2013-01-30,RXi Pharmaceuticals Announces Completion Of Enrollment In Second Phase 1 Trial For RXI-109 Program
2013-01-03,RXi Pharmaceuticals To Webcast Presentation At Biotech Showcase&#8482; 2013
2012-12-19,RXi Pharmaceuticals To Present At Biotech Showcase&#8482; 2013
2012-12-05,RXi Pharmaceuticals Announces Initiation Of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109
2012-11-15,RXi Pharmaceuticals Announces Pharmacokinetic Results Of Its Single Dose Phase 1 Study With RXI-109 In Healthy Volunteers
2012-11-14,RXi Pharmaceuticals Reports Financial Results For The Third Quarter Of 2012
2012-10-16,RXi Pharmaceuticals To Present At 12th Annual Biotech Symposium
2012-10-04,RXi Pharmaceuticals Awarded NCI SBIR Funding To Advance Self-Delivering RNAi Technology
2012-10-02,RXi Pharmaceuticals To Present At 11th Annual BIO Investor Forum
2012-09-24,RXi Pharmaceuticals Announces Completion Of Dosing In Phase 1 Trial For RXI-109 Program
2012-08-15,RXi Pharmaceuticals Reports Financial Results For The Second Quarter Of 2012
2012-07-13,RXi Pharmaceuticals Appoints Jeannette Graf MD And Leroy Young MD To Its Scientific Advisory Board
2012-06-26,RXi Pharmaceuticals Announces Initiation Of&#160;First Clinical Trial
2012-06-21,RXi Pharmaceuticals Appoints Robert Bitterman And Keith Brownlie To Board Of Directors
2012-05-31,RXi Pharmaceuticals Receives FDA Clearance To Begin Clinical Trial With RXI-109
2012-05-10,RXi Pharmaceuticals Appoints Industry Veteran Dr. Geert Cauwenbergh As President And Chief Executive Officer
2011-11-10,Emerging Biotech Companies Discuss What&#8217;s In The Pipeline At NYSSA Conference
2011-08-02,Generex Provides Corporate Update
2011-07-13,RXi Pharmaceuticals Strengthens NeuVax&#8482; (E75) Patent Portfolio
2011-06-24,RXi Pharmaceuticals To Present At BIO International Convention
2011-06-08,RXi Pharmaceuticals Presents Additional Positive Phase 2 Efficacy Results For Combination Of NeuVaxTM (E75) And Trastuzumab Breast Cancer At ASCO
2011-06-06,RXi Pharmaceuticals Announces Positive NeuVaxTM (E75) Phase 2 Efficacy Results After 36 Months Of Follow-Up
2011-05-19,RXi Pharmaceuticals Presents Updated NeuVax&#8482; (E75) Data At ASCO
2011-05-17,RXi Pharmaceuticals Reports Financial Results For The First Quarter Of 2011
2011-04-28,RXi Pharmaceuticals And The University Of Massachusetts Medical School Announce Massachusetts Life Sciences Center Cooperative Research Grant For RNAi Therapeutics For ALS
2011-04-26,RXi Pharmaceuticals Awarded $580,000 In NIH Grants To Advance RNAi Therapeutics
2011-04-15,RXi Pharmaceuticals Prices $12 Million Public Offering Of Common Stock And Warrants
2011-04-14,RXi Pharmaceuticals Announces Public Offering Of Common Stock And Warrants
2011-04-14,RXi Pharmaceuticals Completes Apthera Acquisition
2011-04-07,RXi Pharmaceuticals To Webcast Presentation At BioCentury Future Leaders In The Biotech Industry Conference
2011-04-01,Biotech Stock Mailbag: Avanir Pharma
2011-03-31,RXi Pharmaceuticals Aggressively Moves Into Late-Stage Clinical Development With The Agreement To Acquire Apthera, Inc.
2011-03-21,RXi Pharmaceuticals Presents New Preclinical RNAi Data At The Keystone Mechanism And Biology Of Silencing Conference
2011-03-01,RXi Pharmaceuticals Prices $8.1 Million Public Offering Of Common Stock And Warrants
2011-02-28,RXi Pharmaceuticals Announces Public Offering Of Common Stock And Warrants
2011-02-08,RXi Pharmaceuticals To Webcast Presentation At The 13th Annual BIO CEO &amp; Investor Conference
2011-02-03,RXi Pharmaceuticals Initiates Development Program For Dermal Anti-Scarring Product Candidate
2011-01-27,RXi Pharmaceuticals Announces Positive Initial Results In MicroRNA Therapeutics
2011-01-06,Generex And RXi Pharmaceuticals Announce Positive Research Data Using RNAi Technology In The Development Of Therapeutic Vaccines For Cancer
2011-01-04,RXi Pharmaceuticals To Webcast Presentation At The Biotech Showcase Conference
2010-12-17,RXi Pharmaceuticals Nominates Dermal Anti-Scarring RNAi Product Candidate To Advance Into Development
2010-11-15,RXi Pharmaceuticals Reports Financial Results For The Third Quarter Of 2010
2010-11-10,RXi Pharmaceuticals To Webcast Presentation At The Lazard Capital Markets Annual Healthcare Conference
2010-11-02,RXi Pharmaceuticals Awarded $1 Million In IRS Grants To Advance RNAi Therapeutics
2010-09-30,RXi Pharmaceuticals To Webcast Presentation At The 9th Annual BIO Investor Forum
2010-09-22,RXi Pharmaceuticals And EyeGate Pharma Announce Collaboration Focused On Non-Invasive Ocular Delivery Of RNAi Therapeutics
2010-09-15,Rodman Rambles: Promising Biotechs
2010-09-07,RXi Pharmaceuticals To Webcast Presentation At The Rodman &amp; Renshaw Global Investment Conference
2010-08-11,RXi Pharmaceuticals Reports Financial Results For The Second Quarter Of 2010
2010-08-05,RXi Pharmaceuticals To Host Second Quarter 2010 Conference Call On Wednesday, August 11, 2010
2010-07-13,RXi Pharmaceuticals Receives $600,000 Grant
2010-07-13,RXi Pharmaceuticals Awarded NIH Grant To Advance RNAi Therapeutics
2010-06-10,RXi Pharmaceuticals Announces New Focused Therapeutic Strategy For Its Next Generation RNAi Technology
2010-06-03,Philips And RXi Pharmaceuticals Sign Agreement To Jointly Research Innovative Image-Guided Therapy Concepts Based On RNAi
2010-06-02,RXi Pharmaceuticals CEO To Present At The Jefferies 2010 Global Life Sciences Conference
2010-05-17,RXi Pharmaceuticals Reports Financial Results For The First Quarter Of 2010
2010-05-11,RXi Pharmaceuticals CEO To Present At The Rodman &amp; Renshaw Annual Global Healthcare Conference
2010-05-04,RXi Demonstrates Robust In Vivo Uptake And Significant Silencing Using Its Self-Delivering RxRNA&#8482; Compounds Administered To Mouse Retinal Cells
2010-04-23,RXi Pharmaceuticals To Deliver Presentations At Upcoming Conferences Outlining The Development And Progression Of Its Next Generation RxRNA&#8482; Therapeutic Platform
2017-03-24,Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk
2017-03-02,Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2017-02-23,Sage Therapeutics Announces Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update
2017-02-17,Sage Therapeutics Leads Biotech Movers on False Takeout Rumors
2017-02-17,Sage Therapeutics To Report Fourth Quarter And Full Year 2016 Financial Results On Thursday, February 23, 2017
2017-02-16,Sage Therapeutics Not In M&A Discussions: STATEMENT
2017-02-13,Sage Therapeutics Lifts Investor Spirits With Sliver of Depression Drug Data
2017-02-13,Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics
2017-02-13,Sage Therapeutics Advances SAGE-217 Into Placebo-Controlled Phase 2 Clinical Trial In Major Depressive Disorder
2017-02-07,Sage Therapeutics To Participate In Upcoming February Investor Conferences
2017-01-03,Sage Therapeutics To Present At J.P. Morgan Healthcare Conference On Tuesday, January 10, 2017
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2017-01-02,Starbucks, Allergan, Amazon: Doug Kass' Views
2016-12-29,Sage Therapeutics To Participate In Goldman Sachs Healthcare Conference
2016-12-19,Sage Therapeutics Announces Initiation Of Phase 2 Clinical Development For SAGE-217 In Mood Disorders
2016-12-19,Allergan, Apple, Oakland Capital: Doug Kass' Views
2016-12-13,Sage Therapeutics Announces Initiation Of Phase 2 Clinical Development For SAGE-217 In Movement Disorders
2016-12-12,Facebook, Apple, Starbucks: Doug Kass' Views
2016-12-07,Sage Therapeutics To Webcast R&D Day On December 13, 2016
2016-12-06,Sage Announces Expedited Development Plan For SAGE-547 In The Treatment Of Postpartum Depression Based On FDA Breakthrough Therapy Meeting
2016-12-05,Apple, Starbucks, Cisco: Doug Kass' Views
2016-12-01,Sage Therapeutics To Present At American Epilepsy Society 70th Annual Meeting
2016-11-28,Home Depot, Lowe's, Best Buy: Doug Kass' Views
2016-11-25,Apple Continues to Underperform; the Market Is Resistant: Best of Kass
2016-11-21,Facebook, Home Depot, Disney: Doug Kass' Views
2016-11-16,SAGE-547 Granted PRIME Designation By EMA For The Treatment Of Postpartum Depression
2016-11-14,Allergan, Macy's, Apple: Doug Kass' Views
2016-11-10,Sage Therapeutics To Present At Society For Neuroscience 2016 Annual Meeting
2016-11-09,Sage Therapeutics To Present At The Stifel 2016 Healthcare Conference
2016-11-07,Cisco, Allergan, Facebook: Doug Kass' Views
2016-11-04,Friday Wasn't Bad; Amazon-Induced Woes: Best of Kass
2016-11-03,Sage Therapeutics Announces Third Quarter 2016 Financial Results And Provides SRSE European Update
2016-10-27,Sage Therapeutics To Report Third Quarter 2016 Financial Results On Thursday, November 3, 2016
2016-09-27,Sage Reports Additional Positive Data On Secondary Endpoints From Phase 2 Clinical Trial Of SAGE-547 In Severe Postpartum Depression At The Marcé Society For Perinatal Mental Health Biennial Scientific Meeting
2016-09-21,Sage Therapeutics To Present At The Leerink Partners Rare Disease Roundtable
2016-09-16,Sage Therapeutics To Present At The Neurocritical Care Society 14th Annual Meeting
2016-09-08,Sage Therapeutics Announces Pricing Of Public Offering Of Common Stock
2016-09-08,'Mad Money' Lightning Round: I Believe in Walt Disney
2016-09-07,Jim Cramer's 'Mad Money' Recap: The Perils of Competition
2016-09-07,Sage Therapeutics Announces Proposed Public Offering Of Common Stock
2016-09-06,Sage Receives FDA Breakthrough Therapy Designation For SAGE-547 For The Treatment Of Postpartum Depression
2016-08-30,Sage Therapeutics And Collaborators Announce Publication Highlighting Epidemiology And Burden Of Illness For Super-Refractory Status Epilepticus In Journal Of Medical Economics
2016-08-10,Short Interest In Sage Therapeutics Expands By 12.7%
2016-08-09,SAGE Therapeutics (SAGE) Stock Closes Sharply Lower on 2Q Loss
2016-08-09,Sage Therapeutics Announces Second Quarter 2016 Financial Results And Provides Corporate Update
2016-08-03,Sage Therapeutics To Present At The Canaccord Genuity 36th Annual Growth Conference
2016-08-02,Sage Therapeutics To Report Second Quarter 2016 Financial Results On Tuesday, August 9, 2016
2016-07-22,Biogen Should Either a Buyer or a Seller Be
2016-07-19,Sage Appoints Geno Germano To Company's Board Of Directors
2016-07-12,Sage Therapeutics (SAGE) CEO Jonas Tells CNBC He's 'Very Excited' By Positive Drug Results
2016-07-12,SAGE Shares Surge After Postpartum Depression Drug Shows Promise
2016-07-12,Jim Cramer -- Sage Therapeutics Posts 'Remarkable Results'
2016-07-12,Sage Therapeutics Drug Eliminates Postpartum Depression in Mid-Stage Trial
2016-07-12,Sage Reports Positive Top-line Results Including Demonstration Of 30-Day Durability From Phase 2 Clinical Trial Of SAGE-547 In Severe Postpartum Depression
2016-06-27,A Biotech Stock Turnaround Requires an Alzheimer's Drug Miracle
2016-06-27,First Week of SAGE February 2017 Options Trading
2016-06-07,Sage Therapeutics' Approach To GABA Receptor Drug Development
2016-06-01,Sage Therapeutics To Present At The Goldman Sachs 37th Annual Global Healthcare Conference
2016-05-27,Biotech Stock Mailbag: Sage Therapeutics, Minerva
2016-05-26,Sage Therapeutics Announces Completion Of Enrollment For Phase 2 Proof-of-Concept Trial Of SAGE-547 In Severe Postpartum Depression
2016-05-24,First Week of SAGE July 15th Options Trading
2016-05-16,Monsanto, Amazon and Apple: Doug Kass' Views
2016-05-05,Sage Therapeutics Announces First Quarter 2016 Financial Results
2016-04-28,Sage Therapeutics To Report First Quarter 2016 Financial Results On Thursday, May 5, 2016
2016-04-17,Sage Therapeutics Expands Scientific, Clinical And Burden Of Illness Data For SAGE-547 In SRSE And Essential Tremor At The 2016 American Academy Of Neurology Annual Meeting
2016-04-11,Facebook, Ford and General Motors: Doug Kass' Views
2016-03-28,Sage Therapeutics To Present Data At The Society Of Biological Psychiatry 71st Annual Scientific Meeting
2016-03-24,First Week of SAGE November 18th Options Trading
2016-03-23,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Sage Therapeutics, Inc. - SAGE
2016-03-23,EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Sage Therapeutics, Inc. - SAGE
2016-03-23,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Sage Therapeutics, Inc. (SAGE)
2016-03-23,Here&rsquo;s Why Sage Therapeutics (SAGE) Stock is Tumbling Today
2016-03-07,Tesla, Amazon and Netflix: Doug Kass' Views
2016-03-03,Sage Therapeutics To Present SAGE-547 Clinical Data And SRSE Health Economic Data In Five Abstracts At The American Academy Of Neurology 2016 Annual Meeting
2016-02-29,Sage Therapeutics To Present At The Cowen & Co. 36th Annual Health Care Conference
2016-02-24,Sage Therapeutics Announces Fourth Quarter And Full Year 2015 Financial Results
2016-02-19,What Carl Icahn Is Doing; Biotech Breakout: Best of Kass
2016-02-17,Sage Therapeutics To Report Fourth Quarter And Full Year 2015 Financial Results On Wednesday, February 24, 2016
2016-02-15,JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views
2016-02-15,General Motors, MetLife and Tesla: Doug Kass' Views
2016-02-11,Sage Therapeutics Stock Sees Short Interest Jump 12%
2016-02-03,Sage Therapeutics To Present At The 2016 Leerink Global Healthcare Conference
2016-02-01,Biotech String: Assessing the January Damage, Gilead's Bottoming P/E, Sarepta Panel Date?
2016-01-06,Sage Therapeutics Announces Pricing Of Public Offering Of Common Stock
2016-01-05,Sage Therapeutics Announces Proposed Public Offering Of Common Stock
2016-01-04,Sage Therapeutics To Present At The 34th Annual J.P. Morgan Healthcare Conference
2015-12-15,SAGE Updates Guidance For Top-Line Results Of Phase 3 STATUS Trial Of SAGE-547
2015-12-02,SAGE To Present Three Poster Presentations At The American Epilepsy Society 69th Annual Meeting
2015-11-24,SAGE To Present At The Piper Jaffray 27th Annual Healthcare Conference
2015-11-05,SAGE Announces Third Quarter 2015 Financial Results And Recent Pipeline Progress
2015-11-03,SAGE Announces Presentations At Upcoming November Investor Conferences
2015-10-29,SAGE To Report Third Quarter 2015 Financial Results On Thursday, November 5, 2015
2015-10-08,SAGE To Present Data At Upcoming Scientific Conferences
2015-10-06,SAGE Announces Initiation Of Phase 1 And First Dosing Of SAGE-217
2015-09-23,SAGE Therapeutics To Participate In The 4th Annual Leerink Partners Rare Disease Roundtable
2015-09-21,SAGE Therapeutics Expands Leadership Team With Key Appointments
2015-09-03,Sage Psychiatric Drug Shows Activity Hint in Small Muscle Tremor Study
2015-09-03,SAGE Therapeutics Announces Results From Successful Exploratory Trial In Essential Tremor
2015-08-17,SAGE Announces First Patient Treated In Phase 3 STATUS Trial Of SAGE-547 In Super-Refractory Status Epilepticus
2015-08-12,SAGE Therapeutics Announces Second Quarter 2015 Financial Results And Highlights Recent Progress
2015-08-06,SAGE Receives Special Protocol Assessment For Phase 3 STATUS Trial Of SAGE-547 In Super-Refractory Status Epilepticus
2015-08-05,SAGE Therapeutics To Present At The Canaccord Genuity 35th Annual Growth Conference
2015-06-09,SAGE Therapeutics Announces Positive Top-Line Data In Exploratory Trial Of SAGE-547 In Postpartum Depression
2015-06-03,Where the Money Was Made the Last 5 Years
2015-06-03,SAGE Therapeutics To Participate In The Goldman Sachs 36th Annual Global Healthcare Conference
2015-05-14,SAGE Therapeutics Announces SAGE-547 Progress And First Quarter 2015 Financial Results
2015-05-14,SAGE Therapeutics Achieves 77 Percent Response Rate In Completed Phase 1/2 Clinical Trial Of SAGE-547 In Super-Refractory Status Epilepticus
2015-05-12,SAGE Therapeutics To Present At UBS Global Healthcare Conference
2015-05-07,SAGE Therapeutics To Report First Quarter 2015 Financial Results On Thursday, May 14
2015-04-21,SAGE Therapeutics Announces Closing Of $138 Million Public Offering Of Common Stock Including Full Exercise Of Option To Purchase Additional Shares
2015-04-20,SAGE Therapeutics Announces First Patient Treated Under Phase 3 Expanded Access Protocol To Evaluate SAGE-547 In Patients With Super-Refractory Status Epilepticus
2015-04-14,SAGE Therapeutics Announces Pricing Of Public Offering Of Common Stock
2015-04-13,SAGE Therapeutics Announces Proposed Public Offering Of Common Stock
2015-04-09,SAGE Therapeutics Announces Presentations At Upcoming Scientific Conferences
2015-04-02,SAGE Therapeutics Announces Positive End-of-Phase 2 Meeting With FDA And Planned Initiation Of SAGE-547 Global Phase 3 Trial In Mid-2015
2015-02-27,SAGE Therapeutics Reports Fourth Quarter And Full Year 2014 Financial Results
2015-02-13,SAGE Therapeutics Appoints New Vice Presidents To Lead Key Organizational Functions
2015-01-28,SAGE Therapeutics Announces Participation In February Conferences
2015-01-12,SAGE Therapeutics Initiates Phase 2a Trial Of SAGE-547 In Postpartum Depression
2015-01-09,SAGE Therapeutics Reports Updated Data From Ongoing Clinical Trial And Emergency Use Program Of SAGE-547 In Patients With Super-Refractory Status Epilepticus
2015-01-05,SAGE Therapeutics To Present At 33rd Annual J.P. Morgan Healthcare Conference
2014-12-17,SAGE Therapeutics Added To NASDAQ Biotechnology Index
2014-11-11,SAGE Therapeutics Reports Third Quarter 2014 Results
2014-11-10,SAGE Therapeutics Reports Positive Top-Line Phase 2 Data Of SAGE-547 In Patients With Super-Refractory Status Epilepticus
2014-11-10,Severe Epileptic Patients in Coma Respond to Sage Therapeutics Experimental Drug
2014-11-07,SAGE Therapeutics Announces Six Scientific Presentations At Neuroscience 2014, The Society For Neuroscience's 44th Annual Meeting
2014-11-05,SAGE To Present At Credit Suisse 23rd Annual Healthcare Conference
2014-11-03,First Evaluation Of SAGE-547 To Treat Super-Refractory Status Epilepticus In Children Published In Annals Of Neurology
2014-10-23,SAGE Therapeutics Initiates Exploratory Study Of SAGE-547 In Essential Tremor
2014-09-25,SAGE Therapeutics To Participate In The 2014 Leerink Partners Rare Disease Roundtable
2014-09-16,SAGE Therapeutics Appoints Michael F. Cola To The Company's Board Of Directors
2014-09-02,SAGE Therapeutics Presents New Preclinical Data On SAGE-217 At Eilat Conference On New Anti-Epileptic Drugs
2014-08-14,SAGE Therapeutics Reports Second Quarter 2014 Financial Results
2014-08-07,SAGE Therapeutics To Present At Canaccord Genuity 34th Annual Growth Conference
2014-07-23,SAGE Therapeutics Announces Closing Of Initial Public Offering
2014-07-22,SAGE Therapeutics Receives Fast Track Designation For Lead Compound SAGE-547 To Treat Status Epilepticus
2014-07-21,SAGE Therapeutics Announces Full Exercise Of Over-Allotment Option
2014-07-18,Sage Therapeutics (SAGE) Stock Soars on First Trading Day After IPO
,
2017-03-15,Sucampo Pharmaceuticals Announces Webcast Of Its Presentation At The Oppenheimer 27th Annual Healthcare Conference
2017-03-08,SCMP Crosses Above Key Moving Average Level
2017-03-08,Biotech Premarket Movers: Sucampo, Intellia, Cytokinetics
2017-03-08,Sucampo Reports Fourth Quarter And Full Year 2016 Financial Results
2017-02-23,Sucampo Announces Fourth Quarter And Full Year 2016 Earnings Call
2017-02-09,Sucampo Pharmaceuticals Announces Webcast Of Its Presentation At The 2017 Leerink Global Healthcare Conference
2017-01-24,First Week of September 15th Options Trading For Sucampo Pharmaceuticals (SCMP)
2017-01-17,Relative Strength Alert For Sucampo Pharmaceuticals
2016-12-28,Short Interest Jumps 37.4% For SCMP
2016-12-21,Sucampo Announces Pricing Of $260.0 Million 3.25% Convertible Senior Notes Due 2021
2016-12-20,First Week of February 2017 Options Trading For Sucampo Pharmaceuticals (SCMP)
2016-12-19,Sucampo Announces Proposed Convertible Senior Note Offering
2016-12-19,Big-Cap Tech Names, Biotechs, Oils Lifting Market
2016-11-29,The Pockets of Speculative Action Have Dried Up
2016-11-28,Shark Bites: Entry Points Are Scarce
2016-11-09,Sucampo Reports Third Quarter 2016 Financial Results
2016-11-03,Interesting SCMP Call Options For November 18th
2016-10-28,Sucampo Announces Third Quarter 2016 Earnings Call
2016-09-27,Commit To Purchase Sucampo Pharmaceuticals At $10, Earn 16% Annualized Using Options
2016-08-03,Sucampo Reports Second Quarter 2016 Financial Results
2016-07-29,Paul Edick Joins Sucampo's Board Of Directors
2016-07-20,Sucampo Announces Second Quarter 2016 Earnings Call
2016-07-11,Sucampo Provides Update On Cobiprostone Development Program
2016-07-08,Sucampo Pharmaceuticals Announces Webcast Of Its Presentation At Cantor Fitzgerald's 2nd Annual Healthcare Conference
2016-05-31,Weak On High Volume: Sucampo Pharmaceuticals (SCMP)
2016-05-31,Sucampo Pharmaceuticals Announces Webcast Of Its Presentation At The Jefferies 2016 Healthcare Conference
2016-05-17,Sucampo Pharmaceuticals Announces Webcast Of Its Presentation At The 2016 UBS Global Healthcare Conference
2016-05-12,Jim Cramer's 'Mad Money' Recap: These Stocks Went From Trash to Treasure
2016-05-04,Sucampo Reports Strong Results For First Quarter Of 2016
2016-05-03,Sucampo Pharmaceuticals Announces Webcast Of Its Presentation At The Bank Of America Merrill Lynch 2016 Healthcare Conference
2016-04-28,Sucampo Standardizes On Veeva Vault For A Single Source Of Truth Enterprise-wide
2016-04-20,Sucampo Announces First Quarter 2016 Earnings Call
2016-04-19,Sucampo Reports Top-Line Data From Phase 2a Study Of Cobiprostone In Patients With PPI-Refractory Non-Erosive Reflux Disease (NERD) And Symptomatic Gastroesophageal Reflux Disease (sGERD)
2016-04-08,Bearish Bets: 5 Stocks That Look Good Short
2016-04-06,Ratings Changes Today
2016-03-16,RSI Alert: Sucampo Pharmaceuticals (SCMP) Now Oversold
2016-03-09,Sucampo (SCMP) Stock Plunges Despite Strong Q4 Results
2016-03-09,Trade-Ideas: Sucampo Pharmaceuticals (SCMP) Is Today's Weak On High Relative Volume Stock
2016-03-09,Sucampo Pharmaceuticals Announces Webcast Of Its Presentation At The 28th Annual ROTH Conference
2016-03-08,Sucampo Pharmaceuticals (SCMP) Flagged As Strong On High Volume
2016-03-08,Sucampo Reports Continued Strong Performance For Fourth Quarter And Full Year 2015
2016-02-23,Sucampo Announces Fourth Quarter And Full Year 2015 Earnings Call
2016-02-09,Interesting SCMP Put And Call Options For September 16th
2016-02-04,Sucampo Pharmaceuticals Becomes Oversold (SCMP)
2016-02-04,Sucampo Pharmaceuticals Announces Webcast Of Its Presentation At The 2016 Leerink Global Healthcare Conference
2016-01-25,Commit To Purchase Sucampo Pharmaceuticals At $10, Earn 19% Annualized Using Options
2016-01-11,Sucampo Enters Into Exclusive Option And Collaboration Agreement With Cancer Prevention Pharmaceuticals For Development Of Late-Stage CPP-1X/Sulindac Combination For Familial Adenomatous Polyposis
2016-01-07,Sucampo Provides Update To 2015 And Confirms 2016 Financial Guidance Post Closing Of R-Tech Ueno Acquisition
2015-12-18,5 Stocks Ready for Breakouts
2015-12-15,Sucampo CEO Peter Greenleaf Appointed Chairman Of The Board Of Directors
2015-12-07,Sucampo Completes Acquisition Of R-Tech Ueno
2015-11-25,Sucampo Announces Webcast of Its Presentation at Piper Jaffray 27th Annual Healthcare Conference
2015-11-19,Insider Trading Alert - TWOU, SCMP And ESNT Traded By Insiders
2015-11-09,Mast Therapeutics Announces Appointment Of Peter Greenleaf To Board Of Directors
2015-11-04,SCMP Crosses Below Key Moving Average Level
2015-11-04,Sucampo Reports Third Quarter 2015 Financial Results And Provides Corporate Update
2015-10-30,Trade-Ideas: Sucampo Pharmaceuticals (SCMP) Is Today's "Dead Cat Bounce" Stock
2015-10-22,Sucampo Closes $250 Million Credit Facility
2015-10-21,Interesting SCMP Put And Call Options For June 2016
2015-10-21,Sucampo Announces Third Quarter 2015 Earnings Call
2015-10-15,Sucampo Pharmaceuticals (SCMP) Marked As A Dead Cat Bounce Stock
2015-10-14,Sucampo Announces Results Of Tender Offer For R-Tech Ueno
2015-10-13,Timothy P. Walbert Joins Sucampo's Board Of Directors
2015-10-05,Perilous Reversal Watch: Sucampo Pharmaceuticals (SCMP)
2015-09-30,10 Best Nasdaq Biotech Stocks in the Third Quarter
2015-09-23,Sucampo Pharmaceuticals (SCMP) Showing Signs Of A Dead Cat Bounce Today
2015-09-18,Sucampo Pharmaceuticals (SCMP) In A Perilous Reversal
2015-09-09,Sucampo Pharmaceuticals (SCMP) Strong On High Relative Volume Today
2015-09-04,Sucampo Pharmaceuticals (SCMP) Is Today's Dead Cat Bounce Stock
2015-09-03,Today's Perilous Reversal Stock: Sucampo Pharmaceuticals (SCMP)
2015-09-02,John Carter Markets Analysis: Don't Fight the Tape
2015-08-31,Interesting SCMP Put And Call Options For October 16th
2015-08-28,Trade-Ideas: Sucampo Pharmaceuticals (SCMP) Is Today's Strong On High Relative Volume Stock
2015-08-27,Trade-Ideas: Sucampo Pharmaceuticals (SCMP) Is Today's New Lifetime High Stock
2015-08-26,Sucampo Launches Tender Offer To Acquire R-Tech Ueno
2015-08-20,Today's Perilous Reversal Stock: Sucampo Pharmaceuticals (SCMP)
2015-08-18,New Lifetime High For Sucampo Pharmaceuticals (SCMP)
2015-08-05,Sucampo Reports Second Quarter 2015 Financial Results And Corporate Update
2015-07-29,Sucampo Pharmaceuticals (SCMP) Weak On High Volume Today
2015-07-27,Stock To Watch: Sucampo Pharmaceuticals (SCMP) In Perilous Reversal
2015-07-24,Today's Dead Cat Bounce Stock: Sucampo Pharmaceuticals (SCMP)
2015-07-22,Sucampo Announces Second Quarter 2015 Earnings Call
2015-07-21,Sucampo Pharmaceuticals (SCMP): Today's Weak On High Volume Stock
2015-07-20,Sucampo Pharmaceuticals (SCMP) Hits New Lifetime High Today
2015-07-17,Trade-Ideas: Sucampo Pharmaceuticals (SCMP) Is Today's Strong On High Relative Volume Stock
2015-07-15,Strong And Under The Radar Today: Sucampo Pharmaceuticals (SCMP)
2015-07-01,Sucampo Announces Webcast Of Its Presentation At Cantor Fitzgerald's Inaugural Healthcare Conference
2015-06-25,Commit To Buy Sucampo Pharmaceuticals At $12.50, Earn 11.6% Annualized Using Options
2015-06-25,Sucampo Pharmaceuticals (SCMP) Is Weak On High Volume Today
2015-06-16,Buy These 6 Risky Pharmaceutical Stocks for Big Upside Potential
2015-06-15,China Food And Drug Administration Accepts IND For Pivotal Study Of AMITIZA(R) (lubiprostone)
2015-06-05,Sucampo Pharmaceuticals (SCMP) Stock: Weak On High Volume Today
2015-05-27,Sucampo Announces Webcast Of Its Presentation At The Jefferies 2015 Healthcare Conference
2015-05-15,Sucampo Announces Clinical Data On Lubiprostone To Be Presented At Digestive Disease Week
2015-05-13,Sucampo Announces Webcast Of Its Presentation At The 2015 UBS Global Healthcare Conference
2015-05-11,Sucampo And Harbin Gloria Pharmaceuticals Enter Into Licensing Agreement For AMITIZA(R) (lubiprostone) In China
2015-05-07,FDA Grants Fast Track Designation To Sucampo's Cobiprostone For Oral Mucositis
2015-05-06,Sucampo Pharmaceuticals (SCMP) Strong On High Relative Volume Today
2015-05-06,Sucampo Reports First Quarter 2015 Financial Results And Corporate Update
2015-04-22,Sucampo Announces First Quarter 2015 Earnings Call
2015-04-21,Trade-Ideas: Sucampo Pharmaceuticals (SCMP) Is Today's New Lifetime High Stock
2015-04-07,Sucampo Announces Webcast Of Its Presentation At The 14th Annual Needham Healthcare Conference
2015-04-06,Insider Trading Alert - SCMP, SE And CNC Traded By Insiders
2015-03-27,Interesting SCMP Put And Call Options For May 15th
2015-03-26,Sucampo Prices Public Offering Of Common Stock By Selling Stockholders
2015-03-25,Sucampo Announces Proposed Public Offering By Selling Stockholders
2015-03-09,Sucampo To Return All Licenses For Unoprostone Isopropyl To R-Tech Ueno
2015-03-04,Sucampo Reports Fourth Quarter And Full Year 2014 Financial Results And Corporate Update
2015-03-03,Sucampo Announces Webcast Of Its Presentation At The 27th Annual ROTH Conference
2015-03-02,Sucampo Pharmaceuticals (SCMP) Weak On High Volume
2015-02-22,Sucampo Announces Webcast Of Its Presentation At The 2015 Cowen And Company Healthcare Conference
2015-02-18,Sucampo Pharmaceuticals, Inc. Announces Fourth Quarter And Full Year 2014 Earnings Call
2015-02-11,Sucampo Announces Resolution Of Par Pharmaceutical's ANDA For RESCULA(R)
2015-02-09,Commit To Buy Sucampo Pharmaceuticals At $12.50, Earn 23.6% Annualized Using Options
2015-02-05,Sucampo Pharmaceuticals Announces Webcast Of Its Presentation At The 2015 Leerink Global Healthcare Conference
2015-01-30,Sucampo Appoints Andrew Smith, FCMA, CGMA As CFO
2015-01-30,AMITIZA(R) (lubiprostone) Mutual Recognition Procedure Closes With Recommendation For Approval In European Countries
2015-01-21,Robert J. Spiegel, M.D., FACP Joins Sucampo's Board Of Directors
2015-01-20,Strong On High Volume: Sucampo Pharmaceuticals (SCMP)
2014-12-30,Sucampo Announces Acceptance Of New Drug Submission For AMITIZA(R) (lubiprostone) By Health Canada
2014-12-15,Sucampo Appoints John H. Johnson To Board Of Directors
2014-12-05,Sucampo Pharmaceuticals (SCMP) Strong On High Relative Volume Today
2014-11-25,Sucampo Pharmaceuticals Announces Webcast Of Its Presentation At The 26th Annual Piper Jaffray Healthcare Conference
2014-11-12,Sucampo Files Patent Infringement Lawsuit Against Dr. Reddy's
2014-11-11,Sucampo Pharmaceuticals Announces Webcast Of Its Presentation At The Stifel 2014 Healthcare Conference
2014-11-10,Commit To Purchase Sucampo Pharmaceuticals At $7.50, Earn 11% Annualized Using Options
2014-11-06,Sucampo Announces Third Quarter 2014 Financial Results
2014-11-05,Sucampo Pharmaceuticals Announces Webcast Of Its Presentation At The 2014 Credit Suisse Global Healthcare Conference
2014-10-29,Sucampo Pharmaceuticals (SCMP) Upgraded From Hold to Buy
2014-10-28,Ratings Changes Today
2014-10-24,Sucampo Pharmaceuticals, Inc. Announces Third Quarter 2014 Earnings Call
2014-10-23,Sucampo Solidifies Leadership Team With Additions Of CSO And Heads Of Business Development, Regulatory Affairs
2014-10-21,Takeda And Sucampo Enter Into Global Licensing Agreement For AMITIZA(R) (lubiprostone)
2014-10-14,Sucampo Announces Extension Of AMITIZA(R) (lubiprostone) License And Collaboration Agreement With Takeda
2014-10-13,Clinical Data For AMITIZA(R) Lubiprostone To Be Presented At The American College Of Gastroenterology 2014 Annual Scientific Meeting
2014-10-06,Sucampo Announces Departure Of Chief Financial Officer
2014-09-29,Sucampo And Takeda Launch Direct-to-Consumer Advertising Campaign For AMITIZA(R) (lubiprostone) For Chronic Idiopathic Constipation
2014-08-21,Sucampo Announces New Exclusive Global Manufacturing And Supply Agreement For Lubiprostone
2014-08-05,Sucampo Reports Second Quarter 2014 Financial Results And Corporate Update
2014-07-23,Sucampo Announces Publication Of NICE Recommendation For AMITIZA(R) (Lubiprostone)
2014-07-22,Sucampo Pharmaceuticals, Inc. Announces Second Quarter 2014 Financial Results And Corporate Update Teleconference And Webcast On August 5
2014-07-16,Sucampo Pharmaceuticals Enters Oversold Territory (SCMP)
2014-07-07,Swissmedic Approves AMITIZA(R) (Lubiprostone) For The Treatment Of Opioid-Induced Constipation
2014-06-17,AMITIZA(R) (Lubiprostone) Receives NICE Recommendation
2014-06-12,Sucampo Issues Statement Regarding Anesthetic And Analgesic Drug Products Advisory Committee Meeting's Vote
2014-05-29,Sucampo Announces Webcast Of Its Presentation At 2014 Jefferies Global Healthcare Conference
2014-05-13,Sucampo Announces Webcast Of Its Presentation At The 2014 UBS Global Healthcare Conference
2014-05-07,Sucampo Pharmaceuticals, Inc., Reports First Quarter 2014 Financial And Operating Results
2014-05-06,Sucampo Announces New Data On AMITIZA And Opioid-Induced Constipation Published Online In Pain Medicine Journal
2014-05-01,Sucampo Announces Clinical Data On Lubiprostone To Be Presented At Two Upcoming Scientific Conferences
2014-04-30,Sucampo Pharmaceuticals Announces First Quarter 2014 Results And Operating Highlights Teleconference And Webcast
2014-04-25,Preclinical Data For Lubiprostone And Unoprostone Isopropyl To Be Presented At Experimental Biology Conference 2014
2014-03-28,Sucampo Pharmaceuticals Becomes Oversold (SCMP)
2014-03-25,VLP Therapeutics Appoints Dr. Ryuji Ueno As Chair And Chief Medical Officer
2014-03-25,Sucampo Co-Founder And Chairman Emeritus, Dr. Ryuji Ueno, To Receive Visionary Award From The Foundation Fighting Blindness
2014-03-14,Sucampo And Takeda Announce Update On Liquid Formulation Program For AMITIZA(R) (lubiprostone)
2014-03-12,Sucampo Receives Notice That Second Indication For AMITIZA For Opioid-Induced Constipation Is Not Approved By Medicines And Healthcare Products Regulatory Agency In U.K.
2014-03-05,Sucampo Pharmaceuticals Announces Webcast Of Its Presentation At The 2014 ROTH Conference
2014-03-04,Sucampo And National Cherry Blossom Festival Announce Sucampo As Host And 'Step Into Spring' Program Sponsor For 2014
2014-02-26,Sucampo Pharmaceuticals, Inc. Reports Fourth Quarter And Full Year 2013 Financial And Operating Results
2014-02-12,Sucampo Pharmaceuticals Announces Fourth Quarter And Full Year 2013 Results And Operating Highlights Teleconference And Webcast
2014-02-10,Sucampo Names Peter Greenleaf Chief Executive Officer
2014-02-06,All Physicians In Switzerland Are Now Able To Prescribe Sucampo's AMITIZA(R) For Chronic Idiopathic Constipation
2014-02-05,Sucampo Pharmaceuticals Becomes Oversold (SCMP)
2014-02-05,Sucampo Pharmaceuticals Announces Webcast Of Its Presentation At The 2014 Leerink Global Healthcare Conference
2014-01-14,First Week of SCMP February 22nd Options Trading
2013-12-23,Sucampo Reports Results From Phase 2a Study Of Intravenous Ion Channel Activator For Lumbar Spinal Stenosis
2013-12-17,Sucampo And Takeda Initiate Global Pivotal Phase 3 Program Of Lubiprostone In Pediatric Functional Constipation
2013-11-06,Sucampo Pharmaceuticals Announces Webcast Of Its Presentation At The 2013 Credit Suisse Healthcare Conference
2013-11-05,Sucampo Pharmaceuticals, Inc. Reports Third Quarter And Nine Months 2013 Financial And Operating Results
2013-10-23,Sucampo And Takeda Initiate Pivotal Trial Of Lubiprostone Liquid Formulation In Adults With Chronic Idiopathic Constipation
2013-10-22,Sucampo Pharmaceuticals Announces Third Quarter And Nine Months 2013 Results And Operating Highlights Teleconference And Webcast
2013-10-21,Sucampo Announces Completion Of Patient Enrollment In A Phase 3 Clinical Study Of Unoprostone Isopropyl For Retinitis Pigmentosa
2013-10-11,Sucampo Announces Presentation Of Results On AMITIZA(R) (lubiprostone) In Opioid-Induced Constipation At Two Upcoming Scientific Conferences
2013-10-10,Sucampo Announces Presentation Of Results On Lubiprostone In Pediatric Functional Constipation At NASPGHAN 2013
2013-10-08,Clinical Data Show That Lubiprostone Is Efficacious And Well Tolerated In Children And Adolescents With Functional Constipation
2013-09-27,Commit To Purchase Sucampo Pharmaceuticals At $5, Earn 16.6% Annualized
2013-09-27,Sucampo To Present Data On AMITIZA(R) (Lubiprostone) In Opioid-Induced Constipation At 24th Annual AAPM Meeting
2013-09-26,5 Stocks Under $10 Set to Soar
2013-09-20,Sucampo Pharmaceuticals Announces Webcast Of Its Presentation At BioCentury(R) NewsMakers In The Biotech Industry 2013 Conference
2017-03-26,How I'd Play Biotech Buyout Rumors
2017-03-24,How I'd Play Biotech Buyout Rumors
2017-03-14,Synergy Pharmaceuticals To Present At Oppenheimer 27th Annual Healthcare Conference
2017-03-01,Synergy Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results And Business Update
2017-02-15,Biotech Buoyed by Deal Talk
2017-02-08,Synergy Pharmaceuticals To Present At Leerink Partners 6th Annual Global Healthcare Conference
2017-02-07,Pivotal Phase 3 Data Results For TRULANCE™ (plecanatide) In The Treatment Of Chronic Idiopathic Constipation (CIC) Published In American Journal Of Gastroenterology
2017-02-03,Synergy, Portola Still in My Sights
2017-02-01,How to Trade Hot Stocks Apple, Seadrill, Advanced Micro Devices
2017-02-01,Premarket Biotech Movers: Synergy, Arrowhead, BioCryst
2017-02-01,Synergy Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2017-01-31,Synergy Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2017-01-30,7 Things to Watch in Biotech Now
2017-01-29,The Next Target in Biotech Land
2017-01-27,The Next Target in Biotech Land
2017-01-24,First Week of SGYP March 17th Options Trading
2017-01-23,Bristol-Myers Squibb, Merck, Synergy Pharmaceuticals: Doug Kass' Views
2017-01-20,Synergy Pharmaceuticals Secures Approval for Linzess Competitor
2017-01-19,Futures, Asia Mixed as Investors Ponder the New President
2017-01-19,Synergy Pharmaceuticals' TRULANCE™ (Plecanatide) Receives U.S. FDA Approval For The Treatment Of Adults With Chronic Idiopathic Constipation
2017-01-17,Biotech Sector to See M&amp;A, Earnings Action
2017-01-07,Western Digital, Twilio, AT&amp;T: 'Mad Money' Lightning Round (Friday 1/6/17)
2017-01-06,Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17)
2016-12-27,Biotech Poised for Rebound
2016-12-27,Biotech Poised for Rebound
2016-12-24,How to Trade the Week's Most Active Stocks -- Micron, Nvidia, Synergy Pharma and More
2016-12-22,Futures Mixed Ahead of Holiday Weekend; Asia Opened Lower
2016-12-22,Synergy Pharmaceuticals Announces Positive Results In Second Phase 3 Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
2016-12-20,First Week of February 2017 Options Trading For Synergy Pharmaceuticals (SGYP)
2016-12-09,Synergy Pharmaceuticals Announces Positive Results In First Phase 3 Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
2016-11-22,4 Promising Small Biotechs to Watch in 2017
2016-11-22,First Week of July 2017 Options Trading For Synergy Pharmaceuticals (SGYP)
2016-11-10,Synergy Pharmaceuticals To Present At Jefferies 2016 London Healthcare Conference
2016-11-09,Synergy Pharmaceuticals Reports Third Quarter 2016 Financial Results And Business Update
2016-11-02,Synergy Pharmaceuticals Becomes Oversold (SGYP)
2016-11-01,Drug Makers Stocks Under Scanner -- Pernix Therapeutics, Novo Nordisk, Synergy Pharma, And Apricus Biosciences
2016-10-26,Short Interest Makes 10.6% Move For SGYP
2016-10-25,First Week of SGYP December 16th Options Trading
2016-10-17,Synergy Pharmaceuticals Presents Long-Term Data For Plecanatide In Chronic Idiopathic Constipation At The American College Of Gastroenterology (ACG) Annual Scientific Meeting
2016-10-13,Lack of Catalysts Keeps Analysts Away From Pfizer
2016-10-05,Synergy Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2016-09-28,Synergy Pharmaceuticals Announces New Plecanatide Data Presentations At Upcoming Scientific Meeting And Provides Update On IBS-C Program
2016-09-23,Synergy Pharmaceuticals To Present At OctoberINVESTfest 2016
2016-09-20,First Week of SGYP November 18th Options Trading
2016-09-15,Bought Aerie Earlier? Congratulations
2016-09-15,7 Stocks Under $10 Making Big Moves Higher
2016-09-14,Here's a Reason Why Synergy Pharma (SGYP) Stock Is Rallying Today
2016-09-12,Interesting SGYP Put And Call Options For January 2019
2016-09-07,Synergy Pharmaceuticals To Present At 18th Annual Rodman & Renshaw Global Investment Conference
2016-08-23,'Mad Money' Lightning Round: JetBlue Has No Upside
2016-08-22,Jim Cramer's 'Mad Money' Recap: I'm Watching Best Buy, PVH, Yellen This Week
2016-08-22,SGYP April 2017 Options Begin Trading
2016-08-08,Synergy Pharmaceuticals Reports Second Quarter 2016 Financial Results And Business Update
2016-08-04,Bullish Two Hundred Day Moving Average Cross - SGYP
2016-08-01,Synergy Pharmaceuticals To Present At Canaccord Genuity 36th Annual Growth Conference
2016-07-31,5 Small-Cap Biotechs With Big Potential
2016-07-29,5 Small-Cap Biotechs With Big Potential
2016-07-22,Biogen Should Either a Buyer or a Seller Be
2016-07-22,Synergy Pharma Offers Lots of Synergies
2016-07-21,Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal
2016-07-21,Investors Scour Big Pharma M&amp;A Scene for Next Big Takeover
2016-07-21,'Mad Money' Lightning Round: Avoid Monsanto Now
2016-07-20,Jim Cramer's 'Mad Money' Recap: 3 Stocks With Very Different Risks, Rewards
2016-07-18,SGYP September 16th Options Begin Trading
2016-07-15,Synergy Pharmaceuticals (SGYP) Stock Slides Despite FDA Updates
2016-07-15,Synergy Pharmaceuticals Provides Update On Ongoing FDA Review Of Plecanatide CIC NDA And IBS-C Clinical Development Program
2016-06-30,2 Small Biotech Stocks With Big Milestones
2016-06-28,'Mad Money' Lightning Round: You're in Good Shape With Charter Communications
2016-06-27,Jim Cramer's 'Mad Money' Recap: 'Brexit' Is the Dumbest Financial Mistake Ever
2016-06-21,First Week of SGYP August 19th Options Trading
2016-06-17,'Mad Money' Lightning Round: Broadcom Is One of the Best
2016-06-16,Jim Cramer's 'Mad Money' Recap: An Epic Battle of 'Brexit' vs. Oil
2016-06-09,'Mad Money' Lightning Round: Take American Electric Power Over Calpine
2016-06-08,Jim Cramer's 'Mad Money' Recap: These Stocks Matter More Than Others
2016-06-02,4 Possible Acquisition Targets in Biotech
2016-05-24,Synergy Pharmaceuticals Presents New In Vitro Data Showing The PH-Dependent Activity Of Plecanatide Replicates That Of Naturally Occurring GI Peptide Uroguanylin
2016-05-22,Synergy Pharmaceuticals Presents New Plecanatide Phase 3 Data In Chronic Idiopathic Constipation At Digestive Disease Week
2016-05-21,Synergy Pharmaceuticals Presents Additional Phase 3 Plecanatide Data In Chronic Idiopathic Constipation At Digestive Disease Week
2016-05-16,Synergy Pharmaceuticals To Present New Plecanatide Data At Digestive Disease Week 2016
2016-05-10,Synergy Pharmaceuticals Reports First Quarter 2016 Financial Results And Business Update
2016-05-10,Cramer Sees More Upside in Allergan
2016-05-09,Synergy Pharmaceuticals Inc. Announces Closing Of $89.8 Million Registered Direct Offering Of Common Stock
2016-05-05,Synergy Pharmaceuticals Inc. Announces $89.8 Million Registered Direct Offering Of Common Stock
2016-04-27,Synergy Pharmaceuticals Announces Resignation Of Chief Financial Officer
2016-04-26,Synergy Pharmaceuticals To Present At The Deutsche Bank Health Care Conference
2016-04-25,Is Now the Time to Jump on Allergan?
2016-04-20,These 7 Stocks Under $10 Are Breaking Out
2016-04-20,'Mad Money' Lightning Round: Take Apple Over Pandora Media
2016-04-19,Jim Cramer's 'Mad Money' Recap: These Stocks Are Too Cheap to Ignore
2016-04-19,Synergy Pharmaceuticals Soars After FDA Filing Accepted
2016-04-19,First Week of June 17th Options Trading For Synergy Pharmaceuticals (SGYP)
2016-04-19,Synergy Pharmaceuticals Announces Acceptance Of New Drug Application For Plecanatide, A Novel Uroguanylin Analog, In Chronic Idiopathic Constipation
2016-04-18,All Eyes on Allergan and Potential Targets
2016-04-13,Short Interest Moves 36.6% Lower For SGYP
2016-04-08,5 Stocks Poised for Breakouts
2016-03-28,Synergy Pharmaceuticals Announces Closing Of Convertible Notes Exchanges
2016-03-22,Interesting SGYP Put And Call Options For May 20th
2016-03-21,Synergy Pharmaceuticals' Exchange Agreements To Reduce 50% Of Senior Notes Outstanding
2016-03-11,7 Stocks Under $10 Making Big Moves Higher
2016-03-10,Marino Garcia, EVP And Chief Strategy Officer Synergy Pharmaceuticals Inc. (Photo: Business Wire)
2016-03-08,Synergy Pharmaceuticals To Present At The 28th Annual ROTH Conference
2016-03-04,8 Stocks Under $10 to Trade for Big Gains
2016-02-25,Synergy Pharmaceuticals Reports 2015 Fourth Quarter, Full-Year Financial Results And Business Update
2016-02-02,Synergy Pharmaceuticals To Present At The Leerink Partners Global Healthcare Conference
2016-01-29,Synergy Pharmaceuticals Files New Drug Application For Plecanatide In Chronic Idiopathic Constipation
2016-01-22,First Week of March 18th Options Trading For Synergy Pharmaceuticals (SGYP)
2016-01-15,3 Biotech Stocks Under $10 to Trade for Big Gains
2016-01-11,Synergy Pharmaceuticals Announces Positive Trial Results With Dolcanatide In Patients With Ulcerative Colitis, Confirming The Role Of Uroguanylin In Inflammatory Bowel Disease
2016-01-05,Commit To Purchase Synergy Pharmaceuticals At $3, Earn 26.7% Using Options
2015-12-13,4 Biotech Stocks Under $10 to Trade for Big Breakouts
2015-11-24,First Week of July 2016 Options Trading For Synergy Pharmaceuticals (SGYP)
2015-11-19,Gilead Leads a Biotech Rally
2015-11-19,Gilead Leads a Biotech Rally
2015-11-16,Gary Sender Executive Vice President And Chief Financial Officer, Synergy Pharmaceuticals(Photo: Business Wire)
2015-11-09,Synergy Pharmaceuticals Reports Third Quarter 2015 Financial Results And Business Update
2015-10-29,5 Stocks Under $10 Set to Soar Higher
2015-10-21,First Week of December 18th Options Trading For Synergy Pharmaceuticals (SGYP)
2015-09-28,Synergy Pharmaceuticals Stock Sees Short Interest Jump 14.7%
2015-09-28,Oversold Conditions For Synergy Pharmaceuticals (SGYP)
2015-09-09,Synergy Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
2015-08-28,Interesting SGYP Put And Call Options For April 2016
2015-08-25,'Mad Money' Lightning Round: Buy, Buy, Buy Constellation Brands
2015-08-24,Jim Cramer's 'Mad Money' Recap: Want to Profit From Market Panic? Keep Your Head
2015-08-10,Synergy Pharmaceuticals Reports Second Quarter And First Half 2015 Financial Results And Business Update
2015-08-04,Synergy Pharmaceuticals To Present At The Canaccord Genuity Growth Conference
2015-07-31,These 2 Small Caps Enjoy Strong Growth
2015-07-30,Synergy Pharmaceuticals Announces Positive Results In The Second Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation (CIC)
2015-07-29,Short Interest In Synergy Pharmaceuticals Moves 15.5% Higher
2015-07-21,First Week Of SGYP September 18th Options Trading
2015-07-08,Synergy Pharmaceuticals Appoints Troy Hamilton As Chief Commercial Officer
2015-07-01,10 Best Biotech Stocks in the NASDAQ
2015-07-01,Synergy Pharmaceuticals Appoints Timothy Callahan And Richard Daly To Board Of Directors
2015-06-30,Synergy Pharmaceuticals To Present At The Cantor Fitzgerald Healthcare Conference
2015-06-23,First Week Of SGYP August 21st Options Trading
2015-06-23,Synergy Pharmaceuticals Initiates Second Phase 3 Clinical Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation
2015-06-18,Synergy Pharmaceuticals (SGYP) Stock Price Target Hiked at Cantor Fitzgerald
2015-06-18,June 18 Premarket Briefing: 10 Things You Should Know
2015-06-17,5 Stocks on Traders' Radars -- and What You Should Do With Them
2015-06-17,Synergy Jumps on Positive Results; Stocks Climb Ahead of Fed
2015-06-17,Synergy Rises on Positive Results from Constipation Drug Study
2015-06-17,Synergy Pharmaceutical (SGYP) Stock Spikes on Positive Results of Gastrointestinal Tests
2015-06-17,Synergy A Potential Takeover Target After Constipation Drug Data
2015-06-17,Synergy Pharmaceuticals Announces Positive Results In The First Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation (CIC)
2015-05-29,2 Small Biotechs Worth Considering
2015-05-25,FireEye, Gilead Sciences, and Aeropostale: Doug Kass' Views
2015-05-22,Synergy Pharmaceutical (SGYP) Stock Gains After Coverage Initiation
2015-05-21,5 Stocks Under $10 Set to Soar
2015-05-19,First Week Of SGYP January 2016 Options Trading
2015-05-18,Synergy Pharmaceuticals (SGYP) Stock Higher in After-Hours Trading Following Paulson Investment
2015-05-11,Synergy Pharmaceuticals Reports 2015 First Quarter Results And Business Update
2015-05-04,Synergy Pharmaceuticals To Present At The UBS Global Healthcare Conference
2015-04-30,Chief Scientific Officer Of Synergy Pharmaceuticals To Give Keynote Presentation At The 17th Annual TIDES Summit
2015-03-25,First Week Of May 15th Options Trading For Synergy Pharmaceuticals (SGYP)
2015-03-16,Synergy Pharmaceuticals Reports 2014 Fourth Quarter And Full-Year Financial Results
2015-02-26,5 Stocks Under $10 Set to Soar: Sportsman's Warehouse and More
2015-02-25,First Week Of SGYP October 16th Options Trading
2015-02-03,Synergy Pharmaceuticals To Present At Two Upcoming Investment Conferences
2015-01-29,Synergy Pharmaceuticals Completes Patient Enrollment For The Second Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation
2015-01-13,Synergy Pharmaceuticals Stock Sees Short Interest Move 16% Lower
2015-01-13,ContraVir Pharmaceuticals Appoints John Sullivan-Bolyai, M.D., MPH, As Chief Medical Officer
2015-01-08,ContraVir Pharmaceuticals Adds Renu Gupta, M.D., To Scientific Advisory Board
2015-01-08,Synergy Pharmaceuticals Completes Patient Enrollment For The First Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation
2014-12-18,Chimerix And ContraVir Pharmaceuticals Establish Strategic Collaboration For Antiviral Drug Candidate CMX157
2014-12-18,Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation
2014-12-16,ContraVir Pharmaceuticals Appoints Nathaniel Katz, M.D., Chairman Of New Scientific Advisory Board
2014-12-12,Updating a Small Speculative Play
2014-12-11,ContraVir Pharmaceuticals' CEO Issues Letter To Shareholders Highlighting Significant Progress
2014-11-19,Synergy Pharmaceuticals Announces Positive Results Of SP-333 Phase 2 Trial In Patients With Opioid-Induced Constipation
2014-11-10,Synergy Pharmaceuticals Reports Third Quarter 2014 Financial Results
2014-11-05,Synergy Pharmaceuticals To Present At Credit Suisse 2014 Healthcare Conference
2014-11-03,Synergy Pharmaceuticals Inc. Announces Issuance Of $200 Million Of 7.50% Convertible Senior Notes
2014-10-30,Synergy Pharmaceuticals Inc. Announces Full Exercise Of Over-Allotment Option
2014-10-29,Synergy Pharmaceuticals Inc. Announces Pricing Of Private Offering Of $175 Million Of 7.50% Convertible Senior Notes
2014-10-28,Synergy Pharmaceuticals Inc. Announces Private Offering Of Convertible Senior Notes
2014-10-21,Synergy Pharmaceuticals Presents Positive Phase 2b Study Results For Plecanatide In Patients With Irritable Bowel Syndrome With Constipation
2014-10-07,Synergy Pharmaceuticals To Present Additional Positive Phase 2b Study Results For Plecanatide In Patients With Irritable Bowel Syndrome With Constipation At ACG 2014 Annual Scientific Meeting
2014-09-24,First Week of November 22nd Options Trading For Synergy Pharmaceuticals (SGYP)
2014-09-18,Synergy Pharmaceuticals Reaches Halfway Mark For Second Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation
2014-08-20,Interesting SGYP Put And Call Options For April 2015
2014-08-11,Synergy Pharmaceuticals Reports Second Quarter And First Half 2014 Financial Results
2017-03-26,How I'd Play Biotech Buyout Rumors
2017-03-24,How I'd Play Biotech Buyout Rumors
2017-03-14,Synergy Pharmaceuticals To Present At Oppenheimer 27th Annual Healthcare Conference
2017-03-01,Synergy Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results And Business Update
2017-02-15,Biotech Buoyed by Deal Talk
2017-02-08,Synergy Pharmaceuticals To Present At Leerink Partners 6th Annual Global Healthcare Conference
2017-02-07,Pivotal Phase 3 Data Results For TRULANCE™ (plecanatide) In The Treatment Of Chronic Idiopathic Constipation (CIC) Published In American Journal Of Gastroenterology
2017-02-03,Synergy, Portola Still in My Sights
2017-02-01,How to Trade Hot Stocks Apple, Seadrill, Advanced Micro Devices
2017-02-01,Premarket Biotech Movers: Synergy, Arrowhead, BioCryst
2017-02-01,Synergy Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2017-01-31,Synergy Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2017-01-30,7 Things to Watch in Biotech Now
2017-01-29,The Next Target in Biotech Land
2017-01-27,The Next Target in Biotech Land
2017-01-24,First Week of SGYP March 17th Options Trading
2017-01-23,Bristol-Myers Squibb, Merck, Synergy Pharmaceuticals: Doug Kass' Views
2017-01-20,Synergy Pharmaceuticals Secures Approval for Linzess Competitor
2017-01-19,Futures, Asia Mixed as Investors Ponder the New President
2017-01-19,Synergy Pharmaceuticals' TRULANCE™ (Plecanatide) Receives U.S. FDA Approval For The Treatment Of Adults With Chronic Idiopathic Constipation
2017-01-17,Biotech Sector to See M&amp;A, Earnings Action
2017-01-07,Western Digital, Twilio, AT&amp;T: 'Mad Money' Lightning Round (Friday 1/6/17)
2017-01-06,Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17)
2016-12-27,Biotech Poised for Rebound
2016-12-27,Biotech Poised for Rebound
2016-12-24,How to Trade the Week's Most Active Stocks -- Micron, Nvidia, Synergy Pharma and More
2016-12-22,Futures Mixed Ahead of Holiday Weekend; Asia Opened Lower
2016-12-22,Synergy Pharmaceuticals Announces Positive Results In Second Phase 3 Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
2016-12-20,First Week of February 2017 Options Trading For Synergy Pharmaceuticals (SGYP)
2016-12-09,Synergy Pharmaceuticals Announces Positive Results In First Phase 3 Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
2016-11-22,4 Promising Small Biotechs to Watch in 2017
2016-11-22,First Week of July 2017 Options Trading For Synergy Pharmaceuticals (SGYP)
2016-11-10,Synergy Pharmaceuticals To Present At Jefferies 2016 London Healthcare Conference
2016-11-09,Synergy Pharmaceuticals Reports Third Quarter 2016 Financial Results And Business Update
2016-11-02,Synergy Pharmaceuticals Becomes Oversold (SGYP)
2016-11-01,Drug Makers Stocks Under Scanner -- Pernix Therapeutics, Novo Nordisk, Synergy Pharma, And Apricus Biosciences
2016-10-26,Short Interest Makes 10.6% Move For SGYP
2016-10-25,First Week of SGYP December 16th Options Trading
2016-10-17,Synergy Pharmaceuticals Presents Long-Term Data For Plecanatide In Chronic Idiopathic Constipation At The American College Of Gastroenterology (ACG) Annual Scientific Meeting
2016-10-13,Lack of Catalysts Keeps Analysts Away From Pfizer
2016-10-05,Synergy Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2016-09-28,Synergy Pharmaceuticals Announces New Plecanatide Data Presentations At Upcoming Scientific Meeting And Provides Update On IBS-C Program
2016-09-23,Synergy Pharmaceuticals To Present At OctoberINVESTfest 2016
2016-09-20,First Week of SGYP November 18th Options Trading
2016-09-15,Bought Aerie Earlier? Congratulations
2016-09-15,7 Stocks Under $10 Making Big Moves Higher
2016-09-14,Here's a Reason Why Synergy Pharma (SGYP) Stock Is Rallying Today
2016-09-12,Interesting SGYP Put And Call Options For January 2019
2016-09-07,Synergy Pharmaceuticals To Present At 18th Annual Rodman & Renshaw Global Investment Conference
2016-08-23,'Mad Money' Lightning Round: JetBlue Has No Upside
2016-08-22,Jim Cramer's 'Mad Money' Recap: I'm Watching Best Buy, PVH, Yellen This Week
2016-08-22,SGYP April 2017 Options Begin Trading
2016-08-08,Synergy Pharmaceuticals Reports Second Quarter 2016 Financial Results And Business Update
2016-08-04,Bullish Two Hundred Day Moving Average Cross - SGYP
2016-08-01,Synergy Pharmaceuticals To Present At Canaccord Genuity 36th Annual Growth Conference
2016-07-31,5 Small-Cap Biotechs With Big Potential
2016-07-29,5 Small-Cap Biotechs With Big Potential
2016-07-22,Biogen Should Either a Buyer or a Seller Be
2016-07-22,Synergy Pharma Offers Lots of Synergies
2016-07-21,Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal
2016-07-21,Investors Scour Big Pharma M&amp;A Scene for Next Big Takeover
2016-07-21,'Mad Money' Lightning Round: Avoid Monsanto Now
2016-07-20,Jim Cramer's 'Mad Money' Recap: 3 Stocks With Very Different Risks, Rewards
2016-07-18,SGYP September 16th Options Begin Trading
2016-07-15,Synergy Pharmaceuticals (SGYP) Stock Slides Despite FDA Updates
2016-07-15,Synergy Pharmaceuticals Provides Update On Ongoing FDA Review Of Plecanatide CIC NDA And IBS-C Clinical Development Program
2016-06-30,2 Small Biotech Stocks With Big Milestones
2016-06-28,'Mad Money' Lightning Round: You're in Good Shape With Charter Communications
2016-06-27,Jim Cramer's 'Mad Money' Recap: 'Brexit' Is the Dumbest Financial Mistake Ever
2016-06-21,First Week of SGYP August 19th Options Trading
2016-06-17,'Mad Money' Lightning Round: Broadcom Is One of the Best
2016-06-16,Jim Cramer's 'Mad Money' Recap: An Epic Battle of 'Brexit' vs. Oil
2016-06-09,'Mad Money' Lightning Round: Take American Electric Power Over Calpine
2016-06-08,Jim Cramer's 'Mad Money' Recap: These Stocks Matter More Than Others
2016-06-02,4 Possible Acquisition Targets in Biotech
2016-05-24,Synergy Pharmaceuticals Presents New In Vitro Data Showing The PH-Dependent Activity Of Plecanatide Replicates That Of Naturally Occurring GI Peptide Uroguanylin
2016-05-22,Synergy Pharmaceuticals Presents New Plecanatide Phase 3 Data In Chronic Idiopathic Constipation At Digestive Disease Week
2016-05-21,Synergy Pharmaceuticals Presents Additional Phase 3 Plecanatide Data In Chronic Idiopathic Constipation At Digestive Disease Week
2016-05-16,Synergy Pharmaceuticals To Present New Plecanatide Data At Digestive Disease Week 2016
2016-05-10,Synergy Pharmaceuticals Reports First Quarter 2016 Financial Results And Business Update
2016-05-10,Cramer Sees More Upside in Allergan
2016-05-09,Synergy Pharmaceuticals Inc. Announces Closing Of $89.8 Million Registered Direct Offering Of Common Stock
2016-05-05,Synergy Pharmaceuticals Inc. Announces $89.8 Million Registered Direct Offering Of Common Stock
2016-04-27,Synergy Pharmaceuticals Announces Resignation Of Chief Financial Officer
2016-04-26,Synergy Pharmaceuticals To Present At The Deutsche Bank Health Care Conference
2016-04-25,Is Now the Time to Jump on Allergan?
2016-04-20,These 7 Stocks Under $10 Are Breaking Out
2016-04-20,'Mad Money' Lightning Round: Take Apple Over Pandora Media
2016-04-19,Jim Cramer's 'Mad Money' Recap: These Stocks Are Too Cheap to Ignore
2016-04-19,Synergy Pharmaceuticals Soars After FDA Filing Accepted
2016-04-19,First Week of June 17th Options Trading For Synergy Pharmaceuticals (SGYP)
2016-04-19,Synergy Pharmaceuticals Announces Acceptance Of New Drug Application For Plecanatide, A Novel Uroguanylin Analog, In Chronic Idiopathic Constipation
2016-04-18,All Eyes on Allergan and Potential Targets
2016-04-13,Short Interest Moves 36.6% Lower For SGYP
2016-04-08,5 Stocks Poised for Breakouts
2016-03-28,Synergy Pharmaceuticals Announces Closing Of Convertible Notes Exchanges
2016-03-22,Interesting SGYP Put And Call Options For May 20th
2016-03-21,Synergy Pharmaceuticals' Exchange Agreements To Reduce 50% Of Senior Notes Outstanding
2016-03-11,7 Stocks Under $10 Making Big Moves Higher
2016-03-10,Marino Garcia, EVP And Chief Strategy Officer Synergy Pharmaceuticals Inc. (Photo: Business Wire)
2016-03-08,Synergy Pharmaceuticals To Present At The 28th Annual ROTH Conference
2016-03-04,8 Stocks Under $10 to Trade for Big Gains
2016-02-25,Synergy Pharmaceuticals Reports 2015 Fourth Quarter, Full-Year Financial Results And Business Update
2016-02-02,Synergy Pharmaceuticals To Present At The Leerink Partners Global Healthcare Conference
2016-01-29,Synergy Pharmaceuticals Files New Drug Application For Plecanatide In Chronic Idiopathic Constipation
2016-01-22,First Week of March 18th Options Trading For Synergy Pharmaceuticals (SGYP)
2016-01-15,3 Biotech Stocks Under $10 to Trade for Big Gains
2016-01-11,Synergy Pharmaceuticals Announces Positive Trial Results With Dolcanatide In Patients With Ulcerative Colitis, Confirming The Role Of Uroguanylin In Inflammatory Bowel Disease
2016-01-05,Commit To Purchase Synergy Pharmaceuticals At $3, Earn 26.7% Using Options
2015-12-13,4 Biotech Stocks Under $10 to Trade for Big Breakouts
2015-11-24,First Week of July 2016 Options Trading For Synergy Pharmaceuticals (SGYP)
2015-11-19,Gilead Leads a Biotech Rally
2015-11-19,Gilead Leads a Biotech Rally
2015-11-16,Gary Sender Executive Vice President And Chief Financial Officer, Synergy Pharmaceuticals(Photo: Business Wire)
2015-11-09,Synergy Pharmaceuticals Reports Third Quarter 2015 Financial Results And Business Update
2015-10-29,5 Stocks Under $10 Set to Soar Higher
2015-10-21,First Week of December 18th Options Trading For Synergy Pharmaceuticals (SGYP)
2015-09-28,Synergy Pharmaceuticals Stock Sees Short Interest Jump 14.7%
2015-09-28,Oversold Conditions For Synergy Pharmaceuticals (SGYP)
2015-09-09,Synergy Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
2015-08-28,Interesting SGYP Put And Call Options For April 2016
2015-08-25,'Mad Money' Lightning Round: Buy, Buy, Buy Constellation Brands
2015-08-24,Jim Cramer's 'Mad Money' Recap: Want to Profit From Market Panic? Keep Your Head
2015-08-10,Synergy Pharmaceuticals Reports Second Quarter And First Half 2015 Financial Results And Business Update
2015-08-04,Synergy Pharmaceuticals To Present At The Canaccord Genuity Growth Conference
2015-07-31,These 2 Small Caps Enjoy Strong Growth
2015-07-30,Synergy Pharmaceuticals Announces Positive Results In The Second Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation (CIC)
2015-07-29,Short Interest In Synergy Pharmaceuticals Moves 15.5% Higher
2015-07-21,First Week Of SGYP September 18th Options Trading
2015-07-08,Synergy Pharmaceuticals Appoints Troy Hamilton As Chief Commercial Officer
2015-07-01,10 Best Biotech Stocks in the NASDAQ
2015-07-01,Synergy Pharmaceuticals Appoints Timothy Callahan And Richard Daly To Board Of Directors
2015-06-30,Synergy Pharmaceuticals To Present At The Cantor Fitzgerald Healthcare Conference
2015-06-23,First Week Of SGYP August 21st Options Trading
2015-06-23,Synergy Pharmaceuticals Initiates Second Phase 3 Clinical Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation
2015-06-18,Synergy Pharmaceuticals (SGYP) Stock Price Target Hiked at Cantor Fitzgerald
2015-06-18,June 18 Premarket Briefing: 10 Things You Should Know
2015-06-17,5 Stocks on Traders' Radars -- and What You Should Do With Them
2015-06-17,Synergy Jumps on Positive Results; Stocks Climb Ahead of Fed
2015-06-17,Synergy Rises on Positive Results from Constipation Drug Study
2015-06-17,Synergy Pharmaceutical (SGYP) Stock Spikes on Positive Results of Gastrointestinal Tests
2015-06-17,Synergy A Potential Takeover Target After Constipation Drug Data
2015-06-17,Synergy Pharmaceuticals Announces Positive Results In The First Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation (CIC)
2015-05-29,2 Small Biotechs Worth Considering
2015-05-25,FireEye, Gilead Sciences, and Aeropostale: Doug Kass' Views
2015-05-22,Synergy Pharmaceutical (SGYP) Stock Gains After Coverage Initiation
2015-05-21,5 Stocks Under $10 Set to Soar
2015-05-19,First Week Of SGYP January 2016 Options Trading
2015-05-18,Synergy Pharmaceuticals (SGYP) Stock Higher in After-Hours Trading Following Paulson Investment
2015-05-11,Synergy Pharmaceuticals Reports 2015 First Quarter Results And Business Update
2015-05-04,Synergy Pharmaceuticals To Present At The UBS Global Healthcare Conference
2015-04-30,Chief Scientific Officer Of Synergy Pharmaceuticals To Give Keynote Presentation At The 17th Annual TIDES Summit
2015-03-25,First Week Of May 15th Options Trading For Synergy Pharmaceuticals (SGYP)
2015-03-16,Synergy Pharmaceuticals Reports 2014 Fourth Quarter And Full-Year Financial Results
2015-02-26,5 Stocks Under $10 Set to Soar: Sportsman's Warehouse and More
2015-02-25,First Week Of SGYP October 16th Options Trading
2015-02-03,Synergy Pharmaceuticals To Present At Two Upcoming Investment Conferences
2015-01-29,Synergy Pharmaceuticals Completes Patient Enrollment For The Second Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation
2015-01-13,Synergy Pharmaceuticals Stock Sees Short Interest Move 16% Lower
2015-01-13,ContraVir Pharmaceuticals Appoints John Sullivan-Bolyai, M.D., MPH, As Chief Medical Officer
2015-01-08,ContraVir Pharmaceuticals Adds Renu Gupta, M.D., To Scientific Advisory Board
2015-01-08,Synergy Pharmaceuticals Completes Patient Enrollment For The First Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation
2014-12-18,Chimerix And ContraVir Pharmaceuticals Establish Strategic Collaboration For Antiviral Drug Candidate CMX157
2014-12-18,Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation
2014-12-16,ContraVir Pharmaceuticals Appoints Nathaniel Katz, M.D., Chairman Of New Scientific Advisory Board
2014-12-12,Updating a Small Speculative Play
2014-12-11,ContraVir Pharmaceuticals' CEO Issues Letter To Shareholders Highlighting Significant Progress
2014-11-19,Synergy Pharmaceuticals Announces Positive Results Of SP-333 Phase 2 Trial In Patients With Opioid-Induced Constipation
2014-11-10,Synergy Pharmaceuticals Reports Third Quarter 2014 Financial Results
2014-11-05,Synergy Pharmaceuticals To Present At Credit Suisse 2014 Healthcare Conference
2014-11-03,Synergy Pharmaceuticals Inc. Announces Issuance Of $200 Million Of 7.50% Convertible Senior Notes
2014-10-30,Synergy Pharmaceuticals Inc. Announces Full Exercise Of Over-Allotment Option
2014-10-29,Synergy Pharmaceuticals Inc. Announces Pricing Of Private Offering Of $175 Million Of 7.50% Convertible Senior Notes
2014-10-28,Synergy Pharmaceuticals Inc. Announces Private Offering Of Convertible Senior Notes
2014-10-21,Synergy Pharmaceuticals Presents Positive Phase 2b Study Results For Plecanatide In Patients With Irritable Bowel Syndrome With Constipation
2014-10-07,Synergy Pharmaceuticals To Present Additional Positive Phase 2b Study Results For Plecanatide In Patients With Irritable Bowel Syndrome With Constipation At ACG 2014 Annual Scientific Meeting
2014-09-24,First Week of November 22nd Options Trading For Synergy Pharmaceuticals (SGYP)
2014-09-18,Synergy Pharmaceuticals Reaches Halfway Mark For Second Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation
2014-08-20,Interesting SGYP Put And Call Options For April 2015
2014-08-11,Synergy Pharmaceuticals Reports Second Quarter And First Half 2014 Financial Results
2017-03-15,Summit Therapeutics To Present At The Oppenheimer 27th Annual Healthcare Conference
2017-02-28,Summit Therapeutics Recognises 10th Annual Rare Disease Day
2017-02-02,Summit Therapeutics To Participate In February Investor Conferences
2017-02-01,Summit Outlines Phase 3 Programme For Novel CDI Antibiotic Ridinilazole Following FDA And EMA Regulatory Meetings
2017-01-18,Summit Appoints Dr David Roblin As Chief Operating Officer And President Of Research & Development
2016-12-15,Summit Therapeutics Reports Financial Results For The Third Quarter Ended 31 October 2016 And Operational Progress
2016-12-13,Summit Therapeutics To Report Financial Results For The Third Quarter Ended 31 October 2016 On 15 December 2016
2016-11-16,Summit Enrols Patients In The United States Into PhaseOut DMD, A Phase 2 Clinical Trial Of Ezutromid In Patients With DMD
2016-10-06,Summit Therapeutics Presents Preclinical DMD Data At The 21st International Congress Of The World Muscle Society
2016-10-04,Trending Tickers: SDRL, P, SMMT, SRPT
2016-10-04,Summit Therapeutics Soars on Sarepta Deal
2016-10-04,Summit Therapeutics (SMMT) Stock Spikes on Sarepta Licensing Deal
2016-10-04,Summit To Host Conference Call To Discuss Exclusive License And Collaboration Agreement With Sarepta Therapeutics For European Rights To Summit's Utrophin Modulator Pipeline For The Treatment Of Duchenne Muscular Dystrophy
2016-10-04,Sarepta Therapeutics And Summit Enter Into Exclusive License And Collaboration Agreement For European Rights To Summit's Utrophin Modulator Pipeline For The Treatment Of Duchenne Muscular Dystrophy
2016-09-27,Summit Receives Rare Pediatric Disease Designation From US FDA For Ezutromid In Treatment Of Duchenne Muscular Dystrophy
2016-09-26,Summit Receives Fast Track Designation From US FDA For Ezutromid In The Treatment Of Duchenne Muscular Dystrophy
2016-09-12,Summit Launches Online Resource On Utrophin Modulation For The Duchenne Muscular Dystrophy Community
2016-09-08,Summit Therapeutics Reports Financial Results For The Second Quarter Ended 31 July 2016 And Operational Progress
2016-09-07,Summit Therapeutics To Present At 18th Annual Rodman & Renshaw Global Investment Conference
2016-09-05,Summit Therapeutics To Report Financial Results For The Second Quarter Ended 31 July 2016 On 8 September 2016
2016-08-09,Summit Reports Positive Phase 1 New Formulation Data And Outlines Route To Market Strategy For DMD Candidate Ezutromid
2016-08-05,Summit Therapeutics To Present At Canaccord Genuity Growth Conference
2016-06-20,Summit's Ridinilazole Preserves Microbiome During Treatment Of C. Difficile Infection
2016-06-17,First Patient Enrolled In Summit's PhaseOut DMD, A Phase 2 Clinical Trial Of Ezutromid In Boys With DMD
2016-06-16,Summit Therapeutics To Present At JMP Securities Life Sciences Conference
2016-06-08,Summit Therapeutics To Host Utrophin R&D Day 15 June 2016
2016-06-02,Summit Therapeutics Reports Financial Results For The First Quarter Ended 30 April 2016 And Operational Progress
2016-05-31,Summit Therapeutics To Report Financial Results For The First Quarter Ended 30 April 2016 On 2 June 2016
2016-05-23,Summit To Present Phase 2 CoDIFy Trial Data Highlighting Ridinilazole's Preservation Of The Microbiome In CDI Patients At ASM Microbe 2016
2016-05-11,Ratings Changes Today
2016-05-10,Summit Therapeutics Reports Financial Results For The Fourth Quarter And Fiscal Year Ended 31 January 2016
2016-05-06,Summit Therapeutics Provides Notice Of Financial Results For The Fourth Quarter And Fiscal Year Ended 31 January 2016
2016-04-28,Summit Announces Further US Patent Granted For CDI Antibiotic Ridinilazole
2016-04-26,Summit's IND Cleared By FDA Allowing Expansion Of PhaseOut DMD, A Phase 2 Clinical Trial Of Ezutromid (SMT C1100), Into The US
2016-04-11,Positive Results From Summit's Phase 2 CoDIFy Trial Highlight Potential Of Ridinilazole In The Treatment Of C. Difficile Infection
2016-04-06,Summit Therapeutics To Present At 15th Annual Needham Healthcare Conference
2016-03-30,Summit Reports Positive Interim Data From Ongoing Phase 1 Clinical Trial Testing A New Formulation Of SMT C1100 In Patients With DMD
2016-03-29,Summit To Present Additional Data From Phase 2 CoDIFy Trial Showing Ridinilazole's Statistical Superiority Over Vancomycin In Sustained Clinical Response Was Driven By Marked Reduction In Recurrence Of C. Difficile Infection
2016-03-15,Summit Announces Publication On Biomarkers To Quantify Utrophin Protein And Regeneration Of Muscle Fibres In DMD
2016-03-07,Summit Announces Ridinilazole Preserves The Gut Microbiome Of Patients With C. Difficile Infection In Phase 2 Trial
2016-02-29,Summit Therapeutics Supports Ninth Annual Rare Disease Day
2016-02-24,Summit Therapeutics Announces Publication Of Preclinical Data Showing Ridinilazole Outperformed Standard Of Care In Reducing C. Difficile Toxins That Drive Disease Symptoms
2016-02-17,Summit Therapeutics To Participate In SunTrust Robinson Humphrey's 2016 Orphan Drug Day
2016-02-03,Summit Therapeutics To Present At 18th Annual BIO CEO & Investor Conference
2016-01-21,Summit Therapeutics Receives Regulatory Approval To Initiate PhaseOut DMD, A Phase 2 Clinical Trial Of SMT C1100 In Patients With DMD
2016-01-19,Summit Therapeutics Granted Key European Patent For Novel Antibiotic Ridinilazole For Treatment Of C. Difficile Infection
2015-12-17,Summit Therapeutics Reports Financial Results For The Third Quarter Ended 31 October 2015 And Operational Progress
2015-12-14,Summit Therapeutics To Report Financial Results For The Third Quarter Ended 31 October 2015 On 17 December 2015
2015-12-10,Summit Therapeutics To Participate In The JMP Securities DMD Forum
2015-12-03,Summit Therapeutics To Present At The 26th Annual Oppenheimer Healthcare Conference
2015-12-02,Summit Therapeutics Announces First Milestone Achieved In Strategic Alliance With University Of Oxford For Future Generation Utrophin Modulators For Treatment Of DMD
2015-11-25,Summit Therapeutics To Present At The Piper Jaffray 27th Annual Healthcare Conference
2015-11-23,Summit Therapeutics Announces Novel Antibiotic Ridinilazole (SMT19969) Achieves Statistical Superiority Over Vancomycin In CoDIFy Phase 2 Clinical Trial For C. Difficile Infection
2015-11-17,Summit Therapeutics And The University Of Oxford Announce Multi-Year Extension Of Strategic Alliance For Development Of Utrophin Modulators For DMD
2015-11-02,Oversold Conditions For Summit Therapeutics (SMMT)
2015-09-30,Summit Therapeutics Presents Additional Data From Phase 1b Modified Diet Clinical Trial Of SMT C1100 In DMD Patients At WMS
2015-09-29,Summit Therapeutics Becomes Oversold (SMMT)
2015-09-24,Summit Therapeutics To Present Phase 1b Clinical And Preclinical DMD Data At The 20th International Congress Of The World Muscle Society
2015-09-18,Summit Therapeutics Presents New Positive Preclinical Data On Novel C. Difficile Antibiotic SMT19969 At ICAAC 2015
2015-09-10,Summit Therapeutics Completes Targeted Enrolment For SMT19969 Phase 2 Trial For C. Difficile Infection
2015-09-02,Summit Therapeutics Appoints Ralf Rosskamp, MD, As Chief Medical Officer
2015-08-27,Summit Therapeutics Reports Financial Results For The Second Quarter Ended 31 July 2015 And Operational Progress
2015-08-24,Summit Therapeutics To Report Second Quarter 2015 Financial Results On 27 August 2015
2015-08-17,Summit Therapeutics Announces Phase 1b Modified Diet Clinical Trial Achieves Primary Objective In Duchenne Muscular Dystrophy
2015-07-14,Summit Therapeutics Plc Annual General Meeting Statement
2015-07-13,Summit Therapeutics Publishes Preclinical Data On Disease-Modifying Potential Of Utrophin Modulation In DMD
2015-07-08,Summit Therapeutics Receives FDA Fast Track Designation For Novel Antibiotic SMT19969 In The Treatment Of C. Difficile Infection
2015-07-07,Summit Therapeutics Granted Key Patent By European Patent Office For Utrophin Modulator SMT C1100 In The Treatment Of DMD
2015-06-19,Summit Therapeutics To Present New Preclinical Data On Utrophin Modulator Programme At PPMD Connect Conference
2015-06-15,Summit To Present At JMP Securities Life Sciences Conference
2015-06-11,Summit Therapeutics Reports First Quarter Results For The Three Months Ended 30 April 2015
2015-06-05,Summit Therapeutics To Report First Quarter 2015 Financial Results On 11 June 2015
2015-05-06,Summit Therapeutics Reports Financial Results For The Fiscal Year Ended 31 January 2015
2015-05-01,Summit Therapeutics Provides Notice Of Full Year Financial Results
2015-04-30,Summit Therapeutics Granted Key Patent For Novel Antibiotic SMT19969 For The Treatment Of C. Difficile Infection
2015-04-17,IPO Market 'Has Been a Lonely Place' but Pace Is Picking Up
2015-04-07,Summit To Present At Needham And Company's Annual Healthcare Conference
2015-03-18,Summit Therapeutics Announces Exercise Of Over-Allotment Option
2015-03-10,Summit Therapeutics Announces Closing Of Its U.S. Initial Public Offering
,
,
,
2017-03-15,Soligenix To Present Data On Dusquetide In Combating Antibiotic-Resistant Infections At The 19th Annual Superbugs & Superdrugs Conference
2017-03-10,Soligenix To Present Results From Its Ricin Toxin Vaccine Program At The Society Of Toxicology 56th Annual Meeting
2017-02-22,Soligenix Receives European Patent For Formulation Of Synthetic Hypericin To Treat Psoriasis
2017-02-02,Soligenix Announces SGX301 Receives Promising Innovative Medicine Designation From The UK Medicines And Healthcare Products Regulatory Agency
2017-01-06,Soligenix To Present At 9th Annual Biotech Showcase Conference
2017-01-05,Soligenix Receives Positive Scientific Advice From The European Medicines Agency For SGX942 In The Treatment Of Oral Mucositis In Head And Neck Cancer Patients
2017-01-03,Soligenix Announces Extension Of Development Agreement With Emergent BioSolutions
2016-12-20,Soligenix Advances Collaboration With IDT Biologika
2016-12-16,Soligenix Announces Closing Of Public Offering
2016-12-13,Soligenix, Inc. Prices $5,277,000 Public Offering And Completes Listing On Nasdaq
2016-12-12,Soligenix Announces SGX942 Receives Promising Innovative Medicine Designation From The UK Medicines And Healthcare Products Regulatory Agency
2016-12-08,Soligenix Announces Investor Webcast Event: Origins Of Innate Defense Regulators And Review Of The SGX942 Phase 2 Study Results In Oral Mucositis
2016-12-08,Soligenix Announces Positive Long-Term Follow-up Results From Its Phase 2 Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients
2016-11-10,Soligenix Announces Recent Accomplishments And Third Quarter 2016 Financial Results Highlighted By Revenues Of $3.0 Million
2016-10-11,Soligenix Announces Poster Presentation Of Its Ricin Vaccine And Dusquetide Orphan Programs At The 2016 NORD Rare Diseases And Orphan Products Breakthrough Summit
2016-10-07,Soligenix Announces Reverse-Split In Preparation For Proposed Up-Listing Of Its Common Stock To The NASDAQ Capital Market
2016-09-15,Soligenix To Present At 2016 Aegis Growth Conference
2016-09-12,Soligenix And SciClone Establish Regional Licensing Agreement For SGX942, A Novel Product Candidate For Oral Mucositis
2016-09-06,Soligenix Announces Issuance of New Composition of Matter Patent for Dusquetide Analogs
2016-08-18,FDA Grants Soligenix Orphan Drug Designation For Dusquetide For Treatment Of Macrophage Activation Syndrome
2016-08-11,Soligenix Announces Recent Accomplishments And Second Quarter 2016 Financial Results Highlighted By Revenues Of $3.2 Million
2016-07-25,Soligenix Receives Additional BARDA And NIAID Funding To Advance Development Of OrbeShield® In GI ARS
2016-07-18,Soligenix Announces Presentation Of Positive Preliminary Results Of A Heat Stable Ebola Vaccine Formulation
2016-06-20,Soligenix Appoints Karen Krumeich, As Chief Financial Officer
2016-06-06,Soligenix Announces Presentation Of Phase 2 Oral Mucositis Clinical Trial Results At The 2016 Multinational Association For Supportive Care In Cancer Conference
2016-05-31,OTCQX And OTCQB Companies To Present At 2016 Marcum MicroCap Conference
2016-05-31,FDA Grants Soligenix "Fast Track" Designation For SGX943 For The Treatment Of Melioidosis
2016-05-26,Soligenix To Present At The 2016 Marcum MicroCap Conference
2016-05-25,Soligenix Receives Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine
2016-05-12,Soligenix Announces Recent Accomplishments And First Quarter 2016 Financial Results
2016-05-05,Soligenix Receives Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine
2016-04-14,Soligenix Announces Issuance Of New Patents For Dusquetide
2016-03-29,Soligenix Announces Publication Of Preclinical Efficacy Results With Dusquetide In Infectious Disease
2016-03-24,Soligenix Announces Recent Accomplishments And Year-End 2015 Financial Results
2016-03-17,Soligenix Receives Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine
2016-02-02,Soligenix To Present At Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
2016-01-26,Soligenix Provides 2016 Business Outlook
2015-12-16,Soligenix Will Host A Conference Call To Update Shareholders On Recent Positive Clinical Results And Company Development Milestones
2015-12-16,Soligenix Announces Positive Preliminary Results From Its Phase 2 Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients
2015-12-14,Soligenix Announces Initiation of its Pivotal Phase 3 Clinical Trial of SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma
2015-12-09,Soligenix Receives $490,000 In Non-Dilutive Financing From New Jersey's Technology Business Tax Certificate Transfer Program
2015-12-04,Soligenix Provides Clinical Program Updates For December 2015
2015-11-12,Soligenix Announces Recent Highlights And Third Quarter 2015 Financial Results
2015-10-05,Soligenix To Present At The 3rd Annual BioNJ CEO Summit
2015-08-31,Soligenix Announces Completion Of Patient Enrollment Into Its Phase 2 Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients
2015-08-27,Soligenix Receives Additional NIAID Funding To Advance Development Of OrbeShield™ In GI ARS
2015-08-19,Soligenix Receives Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine
2015-08-12,Soligenix Announces Recent Highlights And Second Quarter 2015 Financial Results
2015-08-04,Soligenix Receives Orphan Drug Designation From The European Commission For SGX301 As A Treatment For Cutaneous T-Cell Lymphoma
2015-08-03,Soligenix Enters Into A $10 Million Equity Purchase Agreement
2015-06-23,Soligenix Announces Collaboration With The National Organization For Rare Disorders And The Cutaneous Lymphoma Foundation In Advancing Its Phase 3 Study Of SGX301 For The Treatment Of Cutaneous T-Cell Lymphoma
2015-06-02,Soligenix Announces Publication Of Successful Application Of Its Heat Stabilization Technology To A Human Papillomavirus Vaccine
2015-05-28,Soligenix Announces Collaboration With The University Of Hawai'i At Manoa And Hawaii Biotech To Develop Heat Stable Ebola Vaccine
2015-05-14,Soligenix Announces First Quarter 2015 Highlights And Financial Results
2015-05-13,Soligenix Announces Development Agreement With Emergent BioSolutions
2015-05-04,Soligenix Announces Presentation And Poster At The 2015 Chemical And Biological Defense Science And Technology Conference In St. Louis, MO
2015-04-14,Soligenix Announces FDA Protocol Clearance Of Pivotal Phase 3 Clinical Trial Of SGX203 In Pediatric Crohn's Disease
2015-03-24,Soligenix Announces Recent Accomplishments And Year-End 2014 Financial Results
2015-03-11,Soligenix Announces Publication Of Successful Preclinical Efficacy And Immunogenicity Results For Ricin Toxin Vaccine
2015-03-05,Soligenix To Present At The 27th Annual ROTH Conference
2015-03-03,Soligenix Announces Positive Recommendation By Data Review Committee On Its Phase 2 Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients
2015-02-13,Ricin Toxin Vaccine Poster Presented At The 2015 ASM Biodefense And Emerging Diseases Research Meeting In Washington, DC
2015-02-11,Preclinical Melioidosis Results Presented At The 2015 ASM Biodefense And Emerging Diseases Research Meeting In Washington, DC
2015-02-05,Soligenix To Present At The 17th Annual BIO CEO & Investor Conference In New York City
2015-02-02,Soligenix Announces Presentation And Poster At The 2015 ASM Biodefense And Emerging Diseases Research Meeting In Washington, DC
2015-01-29,Soligenix Announces Publication Successfully Demonstrating Enhanced Immunogenicity Of Its Heat-Stable Anthrax Vaccine
2015-01-07,FDA Grants Soligenix "Fast Track" Designation For SGX301 For The First-Line Treatment Of Cutaneous T-Cell Lymphoma
2015-01-05,Soligenix Announces Positive Preliminary Nonclinical Results In Macrophage Activation Syndrome
2014-12-29,Soligenix Announces Publication Of Combination Ricin/Anthrax Vaccine Data
2014-12-24,Soligenix Announces Closing Of Public Offering Of Units
2014-12-19,Soligenix Announces Pricing Of Public Offering Of Units
2014-12-11,Soligenix Receives $617,000 In Non-Dilutive Financing From New Jersey's Technology Business Tax Certificate Transfer Program
2014-11-17,Soligenix Announces Formation Of Cutaneous T-Cell Lymphoma Medical Advisory Board
2014-11-10,Soligenix Reports Third Quarter 2014 Financial Results, Highlighted With The Acquisition Of SGX301, Synthetic Hypericin, For The Treatment Of Cutaneous T-Cell Lymphoma
2014-09-23,Soligenix Appoints Rasappa Arumugham, PhD, As Vice President Of Biopharmaceutical Development
2014-09-19,Soligenix Awarded NIAID Contract Valued Up To $24.7 Million For The Development Of Heat Stable RiVax™ Vaccine
2014-09-17,Soligenix Announces FDA Clearance Of Phase 3 Clinical Protocol Of SGX301 In Cutaneous T-Cell Lymphoma
2014-09-09,Soligenix Announces Issuance Of US Patent For ThermoVax™ Technology
2014-09-08,Soligenix To Present At The 16th Annual Rodman & Renshaw Global Investment Conference In New York City
2014-09-05,Soligenix Expands Pipeline With Acquisition Of Phase 3-Ready Oncology Clinical Program
2014-09-02,Soligenix Announces Positive Survival Results With Heat Stable Ricin Toxin Vaccine
2014-08-11,Soligenix Reports Second Quarter 2014 Financial Results, And Highlights Recent Accomplishments
2014-08-07,Soligenix Advances Development Of A Heat Stable Rapidly Acting Anthrax Vaccine VeloThrax™
2014-08-01,Soligenix Receives Additional NIAID Funding To Advance Development Of OrbeShield™ In GI ARS
2014-07-09,Soligenix Announces Combination Vaccine For Ricin And Anthrax Achieves Simultaneous Protection
2014-05-12,Soligenix Reports First Quarter 2014 Financial Results, And Highlights Recent Accomplishments
2014-04-07,Soligenix Announces $200,000 NIDCR SBIR Grant Award Supporting Phase 2 Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer
2014-03-26,Soligenix Reports Year-End 2013 Financial Results And Highlights Recent Accomplishments
2014-03-11,Soligenix To Present At 2014 World Vaccine Congress In Washington, DC
2014-02-14,Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation Of SGX943 As A Treatment For Melioidosis
2014-02-05,Soligenix To Present At The 16th Annual BIO CEO & Investor Conference In New York City
2014-01-16,Soligenix Receives $750,000 In Non-Dilutive Financing From New Jersey's Technology Business Tax Certificate Transfer Program
2014-01-15,Soligenix Announces Positive One-Year High-Temperature Stability Results With ThermoVax&#8482; Vaccine Heat Stabilization Technology
2014-01-09,Soligenix To Present At The 2014 Biotech Showcase In San Francisco
2014-01-06,Soligenix Appoints Richard Straube, MD, As Chief Medical Officer
2013-12-05,Soligenix Announces Initiation Of A Phase 2 Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients
2013-12-02,Soligenix Announces Initiation Of A Phase 2 Clinical Trial Of OrBecA® For The Treatment Of Chronic GI GVHD
2013-11-21,Soligenix Announces Initial $600,000 Investment And Up To $10.6 Million Common Stock Purchase Agreement With Lincoln Park Capital Fund, LLC
2013-11-12,Soligenix Reports Third Quarter 2013 Financial Results, And Highlights Recent Accomplishments
2013-10-31,Soligenix Submits NIAID Contract Proposal For Development Of A Thermostable Ricin Vaccine
2013-10-28,Soligenix To Host Conference Call And Webcast Discussion On Oral Mucositis
2013-10-21,Soligenix Announces Appointment Of Marco Maria Brughera To Its Board Of Directors
2013-10-17,Soligenix Announces Formation Of International Melioidosis Scientific Advisory Board
2013-10-03,Soligenix Appoints Oreola Donini, PhD, As Vice President Of Preclinical Research And Development
2013-09-25,Soligenix Awarded NIAID Contract Valued Up To $6.4 Million For The Development Of OrbeShield™ In GI ARS
2013-09-19,Soligenix Awarded BARDA Contract Valued Up To $26.3 Million For Advanced Development Of OrbeShield™ In GI ARS
2013-09-16,FDA Grants Soligenix Orphan Drug Designation For SGX94 For Treatment Of Acute Radiation Syndrome
2013-09-05,Soligenix To Present At The 15th Annual Rodman & Renshaw Global Investment Conference In New York City
2013-08-12,Soligenix Reports Second Quarter 2013 Financial Results, And Highlights Recent Accomplishments
2013-07-08,Soligenix Announces Commercial Collaboration With SciClone Pharmaceuticals In China For SGX942 In The Treatment Of Oral Mucositis
2013-06-28,Soligenix Completes Phase 1 Clinical Study With SGX203 For The Treatment Of Pediatric Crohn's Disease
2013-06-26,Soligenix Closes $7.1 Million Public Offering
2013-06-21,Soligenix Announces Pricing Of Public Offering Of Common Stock And Warrants
2013-06-03,FDA Grants Soligenix "Fast Track" Designation For SGX942 For The Treatment Of Oral Mucositis In Patients With Head And Neck Cancer
2013-05-22,Soligenix Announces Issuance Of US Patent For Its ThermoVax™ Technology
2013-05-15,Soligenix Initiates Phase 1 Clinical Study With SGX203 For The Treatment Of Pediatric Crohn's Disease
2013-05-03,Soligenix Reports First Quarter 2013 Financial Results And Highlights Recent Accomplishments
2013-05-01,Soligenix And Intrexon Pursue Melioidosis Therapy Through Worldwide Exclusive Collaboration
2013-04-16,Soligenix To Present At World Vaccine Congress & Expo
2013-03-27,Soligenix Receives IND Clearance From FDA To Initiate Clinical Program To Evaluate SGX942 For The Treatment Of Oral Mucositis
2013-03-19,Soligenix Announces Significant Progress With ThermoVax™ Towards The Development Of Heat Stable Vaccines
2013-02-26,Soligenix Reports Year-End 2012 Financial Results And Highlights Recent Accomplishments
2013-02-20,Soligenix Submits BARDA Contract Proposal For Development Of OrbeShield™ In GI ARS
2013-02-08,Soligenix To Present At 15th Annual BIO CEO & Investor Conference
2013-02-04,Soligenix Announces Formation Of Oral Mucositis Medical Advisory Board
2013-01-29,FDA Grants Soligenix Fast Track Designation For OrbeShield(TM) For The Reduction Of Mortality Associated With Gastrointestinal Acute Radiation Syndrome (GI ARS)
2013-01-07,BARDA Invites Soligenix To Submit Contract Proposal For Development Of OrbeShield™ In GI ARS
2013-01-04,Soligenix Receives IND Clearance From FDA To Initiate Program Evaluating OrbeShieldTM As A Therapy For Gastrointestinal Acute Radiation Syndrome
2013-01-02,FDA Grants Soligenix Orphan Drug Designation For OrbeShield™ For Treatment After Exposure To A Radiological Disaster
2012-12-28,Soligenix Receives $521,000 In Non-Dilutive Financing From New Jersey's Technology Business Tax Certificate Transfer Program
2012-12-27,Soligenix Regains North American And European Commercial Rights To Oral BDP
2012-12-18,Soligenix Expands Pipeline With Acquisition Of Novel Innate Defense Regulator Clinical Program
2012-11-14,Soligenix Reports Third Quarter 2012 Financial Results And Highlights Recent Accomplishments
2012-11-08,FDA Grants Soligenix Fast Track Designation For SGX203 For The Treatment Of Pediatric Crohn's Disease
2012-10-03,Soligenix Announces Formation Of Acute Radiation Syndrome Scientific Advisory Board
2012-10-01,Soligenix Announces Presentation Of OrbeShield™ Data At Annual Radiation Research Society Meeting
2012-09-13,Soligenix Announces Issuance Of US Patent For Topically Active Steroids To Treat Inflammatory Gastrointestinal Disorders
2012-09-06,Soligenix Receives IND Clearance From FDA To Initiate Clinical Program To Evaluate SGX203 As Therapy For Pediatric Crohn's Disease
2012-09-04,Soligenix Announces $300,000 NCI SBIR Grant Award Supporting A Phase 2 Trial Of OrBec® As A Treatment For Chronic GI GVHD
2012-08-30,Soligenix Announces Positive Phase 1B Clinical Results With RiVax™, Its Vaccine Against Ricin Toxin Exposure
2012-08-10,Soligenix Reports Second Quarter 2012 Financial Results And Highlights Recent Accomplishments
2012-07-17,Soligenix Announces $600,000 NIAID SBIR Grant Award Supporting Further Evaluation Of OrbeShield™ As A Treatment For Acute Radiation Syndrome
2012-06-27,Soligenix Announces Collaboration With Infectious Disease Research Institute To Develop Thermostabilized Biodefense Vaccines Utilizing Novel Adjuvants
2012-03-27,Soligenix Reports Year-End 2011 Financial Results And Highlights Recent Accomplishments
2012-02-01,Soligenix Announces 1 For 20 Reverse-Split Of Its Common Stock
2012-01-31,Soligenix Announces 1 For 20 Reverse-Split Of Its Common Stock
2012-01-26,Soligenix Receives $574,000 In Non-Dilutive Financing From New Jersey's Technology Business Tax Certificate Transfer Program
2011-12-15,Soligenix Initiates Next Generation Anthrax Vaccine Development Program Under Agreement With Harvard University
2011-12-12,Soligenix Announces Publication Of Results Of Its Phase 2 Clinical Trial Of OrBec® In The Prevention Of Acute GVHD
2011-11-14,Soligenix Reports Third Quarter 2011 Financial Results
2011-10-11,Soligenix Announces Formation Of Pediatric Crohn's Disease Medical Advisory Board
2011-09-15,Soligenix Announces Results Of Recent Data Safety Monitoring Board Review For Phase 3 OrBec® Study In Acute GI GVHD
2011-08-12,Soligenix Reports Second Quarter 2011 Financial Results And Reviews Accomplishments
2011-07-28,Soligenix Announces Expansion Of Partnership With Sigma-Tau Pharmaceuticals For OrBec® In Europe
2011-06-27,Soligenix Announces Appointment Of Jerome Zeldis, MD, PhD And Keith Brownlie, CPA To Its Board Of Directors
2011-06-02,Soligenix Appoints Joseph Warusz As Vice President Of Administration And Controller
2011-05-13,Soligenix Reports First Quarter 2011 Financial Results And Reviews Accomplishments
2011-03-29,Soligenix Reports Year-End 2010 Financial Results And Highlights Recent Accomplishments
2011-02-09,Soligenix To Present At 13th Annual BIO CEO & Investor Conference
2011-02-01,Soligenix Appoints Kevin Horgan, MD, As Chief Medical Officer
2011-01-27,Soligenix Executes Exclusive License With The University Of Colorado For Vaccine Thermostabilization Technology
2011-01-25,Soligenix Receives $245,810 In Non-Dilutive Financing From New Jersey's Technology Business Tax Certificate Transfer Program
2011-01-20,Soligenix Receives FDA Orphan Drug Designation For RiVax™ For The Prevention Of Ricin Intoxication
2011-01-18,Soligenix Announces Positive Preliminary Results Of SGX202 In Radiation Injury
2010-11-22,Soligenix Announces Issuance Of United States Patent For RiVax™, Its Vaccine Against Ricin Toxin
2010-11-12,Soligenix Reports Third Quarter 2010 Financial Results And Reviews Accomplishments
2010-11-03,Soligenix Receives Award Totaling $244,479 For OrBec® Program From Qualifying Therapeutic Discovery Project
2010-11-02,Soligenix Announces Completion Of Enrollment And Preliminary Safety Results Of A Phase 1B Clinical Trial For RiVax™
2010-10-25,Soligenix Announces Preliminary Results Of Its Phase 2 Clinical Trial Of OrBec® In The Prevention Of Acute GVHD
2010-09-27,Soligenix Provides Corporate Update
2010-09-13,Soligenix To Present At The Rodman & Renshaw Healthcare Conference On September 15, 2010 At 10AM EDT
2010-09-02,Soligenix Announces Publication Of Article Identifying Domains Within The Ricin Toxin A Subunit As Targets Of Protective Antibodies
2010-08-23,Soligenix Announces Award Of $1.2 Million FDA Orphan Products Development Grant
2010-08-13,Soligenix Reports Second Quarter 2010 Financial Results And Reviews Accomplishments
2010-06-29,Soligenix To Present At The OneMedForum Conference On Wednesday, June 30 At 2PM EDT
2010-06-25,Soligenix Announces Publication Of Positive Data Describing Protection From Mucosal And Systemic Ricin Intoxication By Intradermal RiVax™ Administration
2010-06-23,EMC Buys $6.4M More of VMware
2010-06-16,Soligenix Announces Private Equity Financing Of $5.16 Million With Its Partner Sigma-Tau And Other Institutional Investors
2010-06-03,Soligenix Announces Grant Of European Patent For The Treatment Of GVHD And Leukemia With Oral Beclomethasone Dipropionate
2010-05-19,Soligenix Announces Grant Of US Patent For The Treatment Of Irritable Bowel Syndrome With Oral Beclomethasone Dipropionate
2017-03-21,First Week Of November 17th Options Trading For Spectrum Pharmaceuticals (SPPI)
2017-03-09,Biotech Premarket Movers: Spectrum, BioCryst, Curis
2017-03-08,Spectrum Pharmaceuticals Reports Fourth Quarter 2016 And Full Year 2016 Financial Results And Pipeline Update
2017-03-01,Spectrum Pharmaceuticals Announces Fourth Quarter And Full Year 2016 Financial Results Teleconference And Webcast
2017-02-22,First Week of SPPI April 21st Options Trading
2017-02-16,Spectrum Pharmaceuticals To Present Corporate Update At The 2017 RBC Capital Markets Global Healthcare Conference On February 23rd
2016-12-23,Commit To Purchase Spectrum Pharmaceuticals At $3, Earn 16.6% Annualized Using Options
2016-12-08,Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib In Lung Cancer At The 17th IASLC World Conference On Lung Cancer
2016-12-06,Spectrum Pharmaceuticals Highlights Survival Advantage In A Case Match Control Analysis Of The PROPEL Study With FOLOTYN® (pralatrexate Injection) at The 58th Annual Meeting Of The American Society Of Hematology (ASH)
2016-12-05,Spectrum Pharmaceuticals Highlights Five Abstracts On ROLONTIS™ (eflapegrastim) And Poziotinib At The San Antonio Breast Cancer Symposium (SABCS) In San Antonio, Texas, December 6-10, 2016
2016-12-02,Spectrum Pharmaceuticals Highlights Four Abstracts At The 58th Annual Meeting Of The American Society Of Hematology (ASH) In San Diego, California, December 3-6, 2016
2016-11-18,SPPI UPCOMING DEADLINE: The Law Offices Of Vincent Wong Reminds Shareholders Of A Class Action Involving Spectrum Pharmaceuticals, Inc. And A Lead Plaintiff Deadline Of November 21, 2016
2016-11-17,Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of The Upcoming November 21st Deadline In The Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc.
2016-11-17,Spectrum Pharmaceuticals Announces Poziotinib Data Presentation At The 17th IASLC World Conference On Lung Cancer In Vienna, Austria, December 4-7, 2016
2016-11-14,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Spectrum Pharmaceuticals, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of November 21, 2016
2016-11-14,INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm
2016-11-14,Spectrum Pharmaceuticals Provides Third Quarter Financial Update
2016-11-09,SPPI SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Shareholders Of A Class Action Involving Spectrum Pharmaceuticals, Inc. And A Lead Plaintiff Deadline Of November 21, 2016
2016-11-08,SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm
2016-11-04,SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm
2016-11-03,Spectrum Pharmaceuticals Provides Third Quarter Financial And Pipeline Update
2016-10-31,GPM Reminds Investors Of The November 21st Deadline In The Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm
2016-10-31,Tax-Loss Selling Offers Stock-Picking Opportunities
2016-10-27,Spectrum Pharmaceuticals Announces Third Quarter 2016 Financial Results Teleconference And Webcast
2016-10-20,Cohen Milstein Sellers & Toll PLLC Announces Investigation Of Spectrum Pharmaceuticals, Inc.
2016-10-18,Spectrum Pharmaceuticals Announces Appointment Of Luigi Lenaz, M.D., As Lead Director
2016-10-14,Spectrum Pharmaceuticals Becomes Oversold (SPPI)
2016-10-11,SPPI LOSS NOTICE: Rosen Law Firm Reminds Spectrum Pharmaceuticals, Inc. Investors Of Important Deadline In Class Action Filed By Firm - SPPI
2016-10-10,Lifshitz & Miller Law Firm Announces Investigation Of Inteliquent, Inc., Isle Of Capri Casinos, Inc., Janus Capital Group, Inc., MGT Capital Investments, Inc., MoneyGram International Inc., Neos Therapeutics, Inc., Spectrum Pharmaceuticals, Inc. And Twitter, Inc.
2016-10-10,Johnson & Weaver, LLP Initiates Investigations Of Puma Biotechnology, Inc., Virtus Investment Partners, Inc., AAC Holdings, Inc. And Spectrum Pharmaceuticals, Inc.; Encourages Long-Term Investors To Contact The Firm Regarding Their Legal Rights
2016-10-06,SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Spectrum Pharmaceuticals, Inc. For Potential Breaches Of Fiduciary Duty By Its Board Of Directors
2016-10-03,Spectrum Pharmaceuticals Sued For Securities Fraud With Expanded Class Period By Block & Leviton LLP After Company Revealed It Concealed Discouraging Advice From The FDA
2016-09-30,SECURITIES NOTICE: Rosen Law Firm Reminds Spectrum Pharmaceuticals, Inc. Investors Of Important Deadline In Class Action Filed By Firm- SPPI
2016-09-22,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against Spectrum Pharmaceuticals Inc. (SPPI) And Lead Plaintiff Deadline: November 21, 2016
2016-09-21,SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Spectrum Pharmaceuticals, Inc. To Contact The Firm
2016-09-21,EQUITY ALERT: Rosen Law Firm Files Securities Class Action Against Spectrum Pharmaceuticals, Inc. - SPPI
2016-09-20,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By Spectrum Pharmaceuticals, Inc.
2016-09-20,First Week of SPPI May 2017 Options Trading
2016-09-20,SPECTRUM PHARMACEUTICALS NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Spectrum Pharmaceuticals, Inc. To Contact The Firm
2016-09-19,EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Spectrum Pharmaceuticals, Inc.
2016-09-19,IMPORTANT INVESTOR ALERT: Lundin Law PC Announces An Investigation Of Spectrum Pharmaceuticals, Inc. And Advises Investors With Losses To Contact The Firm
2016-09-19,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Spectrum Pharmaceuticals Inc. (SPPI)
2016-09-16,Block & Leviton LLP Investigates Spectrum Pharmaceuticals After Revelation That Company Concealed Discouraging Advice From FDA
2016-09-16,Spectrum Pharma, FDA and the Buried Truth About a Bladder Cancer Drug Meeting
2016-09-14,Spectrum Pharmaceuticals (SPPI) Stock Slumps on FDA Ruling
2016-09-14,FDA Advisory Committee Votes That Qapzola™ (apaziquone) Has Not Shown Substantial Evidence Of A Treatment Effect Over Placebo
2016-08-25,Spectrum Pharmaceuticals Stock Sees Short Interest Decline 15%
2016-08-22,October 21st Options Now Available For Spectrum Pharmaceuticals (SPPI)
2016-08-10,RSI Alert: Spectrum Pharmaceuticals (SPPI) Now Oversold
2016-08-09,Spectrum Pharmaceuticals Reports Second Quarter 2016 Financial Results And Pipeline Update
2016-08-02,Spectrum Pharmaceuticals Announces Second Quarter 2016 Financial Results Teleconference And Webcast
2016-07-19,Spectrum Pharmaceuticals Becomes Oversold (SPPI)
2016-07-13,Spectrum Pharmaceuticals Settles FOLOTYN® (pralatrexate Injection) ANDA Patent Litigation
2016-07-06,Spectrum Pharmaceuticals To Present Corporate Update At The Cantor Fitzgerald's 2nd Annual Healthcare Conference On July 13th
2016-06-24,Spectrum Pharmaceuticals Enters Oversold Territory (SPPI)
2016-06-22,First Week of February 2017 Options Trading For Spectrum Pharmaceuticals (SPPI)
2016-06-01,Spectrum Pharmaceuticals To Present Corporate Update At The Jefferies 2016 Healthcare Conference On June 8th
2016-05-06,Spectrum Pharmaceuticals Highlights An Oral Presentation On Apaziquone At The 2016 Annual Meeting Of The American Urological Association Education And Research Inc. (AUA) In San Diego, California, May 6-10, 2016
2016-05-05,Spectrum Pharmaceuticals Reports First Quarter 2016 Financial Results And Pipeline Update
2016-05-03,Spectrum Pharmaceuticals To Present Corporate Update At The Bank Of America Merrill Lynch 2016 Healthcare Conference On May 10th
2016-04-28,Spectrum Pharmaceuticals Announces First Quarter 2016 Financial Results Teleconference And Webcast
2016-04-20,FDA Grants Orphan Drug Exclusivity To EVOMELA™ (melphalan) For Injection, Indicated For Multiple Myeloma
2016-04-13,Spectrum Pharmaceuticals Stock Sees Short Interest Fall 12.5%
2016-03-22,First Week of November 18th Options Trading For Spectrum Pharmaceuticals (SPPI)
2016-03-15,FDA Grants Spectrum Pharmaceuticals Approval Of EVOMELA™ (melphalan) For Injection
2016-03-11,Weak On High Volume: Spectrum Pharmaceuticals (SPPI)
2016-03-09,Spectrum Pharmaceuticals Reports Fourth Quarter 2015 And Full Year 2015 Financial Results And Pipeline Update
2016-03-07,Spectrum Pharmaceuticals Initiates Phase 2 Breast Cancer Trial For Poziotinib, A Novel Pan-HER Inhibitor
2016-03-02,Spectrum Pharmaceuticals Announces Fourth Quarter And Full Year 2015 Financial Results Teleconference And Webcast
2016-02-22,Spectrum Pharmaceuticals To Present Corporate Update At 2016 RBC Capital Markets' Global Healthcare Conference On February 24
2016-02-19,Spectrum Pharmaceuticals Announces FDA's Acceptance Of NDA Filing For EOquin® (apaziquone For Intravesical Instillation)
2016-02-09,Spectrum Pharmaceuticals Becomes Oversold (SPPI)
2016-02-01,Weak On High Volume: Spectrum Pharmaceuticals (SPPI)
2016-01-29,Spectrum Pharmaceuticals Begins Enrolling Patients In Registrational Trial Of SPI-2012, A Novel, Long Acting G-CSF In Patients With Breast Cancer
2016-01-26,First Week of March 18th Options Trading For Spectrum Pharmaceuticals (SPPI)
2016-01-11,Spectrum Pharmaceuticals Signs A Strategic Partnership With Servier Canada
2015-12-16,Spectrum Pharmaceuticals Announces Agreement With FDA On The Special Protocol Assessment (SPA) For The Registrational Trial Of SPI-2012, A Novel, Long Acting G-CSF In Patients With Breast Cancer
2015-12-15,TheGrantLawFirm, PLLC Withdraws Action on Behalf of Spectrum Pharmaceuticals, Inc. Purchasers
2015-12-10,Marqibo® Made Available To Acute Lymphoblastic Leukemia Patients Through Global MyTomorrows Platform
2015-12-09,INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Spectrum Pharmaceuticals, Inc. Of Pendency Of Class Action Lawsuit And A Lead Plaintiff Deadline Of January 4, 2016 - SPPI
2015-12-09,Spectrum Pharmaceuticals, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors
2015-12-08,Spectrum Pharmaceuticals Highlights Four Abstracts On SPI-2012 And Poziotinib At The San Antonio Breast Cancer Symposium (SABCS)
2015-12-06,Spectrum Pharmaceuticals And Onxeo Announce Complete Response In 67% Of Patients With Peripheral T-Cell Lymphoma In Combination Of Belinostat (Beleodaq®) And Standard CHOP
2015-12-04,Spectrum Pharmaceuticals Highlights 18 Abstracts At The 57th Annual Meeting Of The American Society Of Hematology (ASH) In Orlando, Florida, December 5-8, 2015
2015-11-24,First Week of SPPI January 2016 Options Trading
2015-11-20,Spectrum Pharmaceuticals Submits Phase 2 Breast Cancer Protocol To FDA As Part Of An Investigational New Drug (IND) Application For Poziotinib
2015-11-18,Spectrum Pharmaceuticals Divests Rights To ZEVALIN® (ibritumomab Tiuxetan) In Japan And Select Other Ex-US Countries To Mundipharma
2015-11-17,TheGrantLawFirm, PLLC Files Class Action On Behalf Of Spectrum Pharmaceuticals, Inc. Securities Purchasers
2015-11-13,Short Interest Moves 14.3% Lower For SPPI
2015-11-12,INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Spectrum Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2015-11-10,Lifshitz & Miller Law Firm Announces Investigation Of Applied DNA Sciences Inc., Barrett Business Services Inc., First Niagara Financial Group, Fidelity & Guaranty Life, SORL Auto Parts, Inc., Spectrum Pharmaceuticals, And 6D Global Technologies, Inc.
2015-11-04,Eagle Pharmaceuticals And Spectrum Pharmaceuticals Announce Co-Promotion Agreement
2015-11-04,Spectrum Pharmaceuticals Reports Third Quarter 2015 Financial Results And Pipeline Update
2015-11-04,TheGrantLawFirm, PLLC Files Class Action On Behalf Of Spectrum Pharmaceuticals, Inc. Securities Purchasers
2015-11-02,Spectrum Pharmaceuticals Announces Third Quarter 2015 Financial Results Teleconference And Webcast
2015-10-26,Spectrum Pharmaceuticals Initiates Apaziquone Pivotal Trial For The Treatment Of Non-Muscle Invasive Bladder Cancer (NMIBC) Following SPA Agreement
2015-10-23,SHAREHOLDER ALERT: L & K Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By Spectrum Pharmaceuticals, Inc. And Certain Officers And Directors
2015-10-23,Spectrum Pharmaceuticals Investigated By Block & Leviton LLP Following FDA's Denial Of Spectrum's New Drug Application For EVOMELA
2015-10-23,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Spectrum Pharmaceuticals, Inc.
2015-10-23,Spectrum Pharmaceuticals Receives Complete Response Letter (CRL) From U.S. Food And Drug Administration (FDA) For EVOMELA™ (melphalan) For Injection
2015-09-03,Spectrum Pharmaceuticals (SPPI) Marked As A Dead Cat Bounce Stock
2015-09-03,Spectrum Pharmaceuticals To Present Corporate Update At The Rodman & Renshaw 17th Annual Global Investment Conference On September 10th
2015-09-02,Spectrum Pharmaceuticals Announces Publication Of Pivotal EVOMELA™ (melphalan Hydrochloride) For Injection Data In The Biology Of Blood And Marrow Transplantation Journal
2015-08-27,Spectrum Pharmaceuticals (SPPI) Strong On High Relative Volume Today
2015-08-17,Spectrum Pharmaceuticals Announces Agreement With FDA On The Special Protocol Assessment (SPA) For The Upcoming Apaziquone Phase 3 Trial In Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)
2015-08-06,Spectrum Pharmaceuticals Reports Second Quarter 2015 Financial Results And Pipeline Update
2015-07-30,Spectrum Pharmaceuticals Announces Second Quarter 2015 Financial Results Teleconference And Webcast
2015-07-21,First Week Of September 18th Options Trading For Spectrum Pharmaceuticals (SPPI)
2015-06-26,Spectrum Pharmaceuticals Stock Sees Short Interest Expand By 13.5%
2015-06-24,Spectrum Pharmaceuticals Announces Publication Of Beleodaq® Data Selected As A Rapid Communication In The Journal Of Clinical Oncology
2015-06-23,First Week Of SPPI February 2016 Options Trading
2015-05-29,Spectrum Pharmaceuticals Highlights Five Abstracts Of Clinical Data At The 2015 American Society Of Clinical Oncology (ASCO) Annual Meeting In Chicago, Illinois, May 29-June 2, 2015
2015-05-28,Spectrum Pharmaceuticals To Present Corporate Update At The Jefferies Global Healthcare Conference In New York City On June 3rd
2015-05-19,First Week Of July 17th Options Trading For Spectrum Pharmaceuticals (SPPI)
2015-05-14,Spectrum Pharmaceuticals Commits To Review Shareholder Proposal
2015-05-12,Spectrum Pharmaceuticals (SPPI) Is Today's Strong On High Volume Stock
2015-05-07,Spectrum Pharmaceuticals Reports Continued Advancement Of Robust, Late-Stage Pipeline And First Quarter 2015 Financial Results
2015-05-01,Spectrum Pharmaceuticals (SPPI) Is Strong On High Volume Today
2015-04-30,Spectrum Pharmaceuticals Announces First Quarter 2015 Financial Results Teleconference And Webcast
2015-04-08,Spectrum Stock Alert: Schubert Firm Investigates Company's Top Executives
2015-04-07,Spectrum Pharmaceuticals Is Now Oversold (SPPI)
2015-03-30,Spectrum Pharmaceuticals Presents New Data On EVOMELATM (CE-Melphalan), At The Annual Meeting Of The American Pharmacists Association (APhA) In San Diego, Highlighting Stability
2015-03-25,Interesting SPPI Put And Call Options For November 20th
2015-03-13,Spectrum Pharmaceuticals Reports Robust Clinical Data And Strong 2014 Financial Results
2015-03-11,Four Oncology Key Opinion Leaders To Present At Spectrum Pharmaceuticals' Analyst Day On Friday, March 13th
2015-03-09,Spectrum Pharmaceuticals Announces FDA's Acceptance Of NDA Filing For Captisol-Enabled™ (Propylene Glycol-Free) Melphalan
2015-03-04,Spectrum Pharmaceuticals In-Licenses Poziotinib, A Novel Pan-HER Inhibitor With Clinical Activity In Several Solid Tumors, From Hanmi Pharmaceuticals
2015-02-23,Spectrum Pharmaceuticals (SPPI) Stock Plunges to One-Year Low on Court's Fusilev Patent Ruling
2015-02-20,Spectrum Pharmaceuticals To Present Corporate Update At The 2015 RBC Capital Markets' Global Healthcare Conference On February 24th
2015-02-19,Spectrum Pharmaceuticals (SPPI) Shares Cross Above 200 DMA
2015-02-17,Spectrum Pharmaceuticals Announces Fourth Quarter 2014 Financial Results And Analyst Day
2015-02-12,Spectrum Pharmaceuticals Highlights Clinical Data For Captisol-Enabled™ (Propylene Glycol-Free) Melphalan At The 2015 BMT Tandem Meeting
2015-01-23,First Week Of SPPI March 20th Options Trading
2014-12-26,Spectrum Pharmaceuticals Files A New Drug Application With The FDA For Captisol-Enabled™ (Propylene Glycol-Free) Melphalan
2014-12-05,Spectrum Pharmaceuticals Highlights 11 Abstracts At The 56th Annual Meeting Of The American Society Of Hematology (ASH) In San Francisco, California, December 6-9, 2014
2014-11-14,Biotech Stock Mailbag: Spectrum, Intercept, Orexigen, Amarin, MannKind
2014-11-12,Spectrum Pharmaceuticals To Present Corporate Update At The Jefferies 2014 Global London Healthcare Conference On November 19th
2014-11-06,Spectrum Pharmaceuticals Reports Strong Product Sales For The Third Quarter 2014; Sales Of $47.9 Million Up 15.6% Over Last Year
2014-10-30,Spectrum Pharmaceuticals Announces Third Quarter 2014 Financial Results Teleconference And Webcast
2014-10-06,SPPI Makes Notable Cross Below Critical Moving Average
2014-09-18,5 Breakout Stocks Under $10 Set to Soar Higher
2014-09-18,Spectrum Pharmaceuticals Out-Licenses Rights For Greater China To CASI Pharmaceuticals For Three Of Its Drugs
2014-09-16,Spectrum Pharmaceuticals Announces Issue Of A New Patent For Beleodaq™ (belinostat) For Injection With Patent Term Adjustment Till 2027
2014-09-12,5 Stocks Under $10 Soaring Higher
2014-09-09,Spectrum Pharmaceuticals Makes Decision To Advance SPI-2012, A Novel Long-Acting GCSF, To Phase 3 Due To Positive Phase 2 Results In Its Collaboration Program With Hanmi Pharm. Co.
2014-09-02,Spectrum Pharmaceuticals To Present Corporate Update At The Morgan Stanley Global Healthcare Conference In New York City On September 9th
2014-08-19,Interesting SPPI Put And Call Options For October 18th
2014-08-18,SPPI Crosses Above Key Moving Average Level
2014-08-18,Why Spectrum Fell on Beleodaq Approval but Will Rocket on Melphalan Approval
2014-08-07,Spectrum Pharmaceuticals Reports 45% Sales Growth In The Second Quarter, Launches Fifth Product And Moves Closer To A Decision On A Potential Blockbuster
2014-07-31,Spectrum Pharmaceuticals Announces Second Quarter 2014 Financial Results Teleconference And Webcast
2014-07-25,Spectrum Pharmaceuticals Becomes Oversold (SPPI)
2014-07-22,First Week of September 20th Options Trading For Spectrum Pharmaceuticals (SPPI)
2014-07-07,Why Spectrum Pharmaceuticals (SPPI) Stock Is Higher This Morning
2014-07-07,FDA Grants Spectrum Pharmaceuticals Accelerated Approval Of Beleodaq&#8482; (belinostat) For Injection
2014-07-01,Spectrum Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for SPPI
2014-06-25,First Week Of SPPI February 2015 Options Trading
2014-06-09,SPPI Crosses Above Key Moving Average Level
2014-05-30,Spectrum Pharmaceuticals To Present Corporate Update At The Jefferies Global Healthcare Conference In New York City On June 3rd
2014-05-28,Spectrum Pharmaceuticals Completes Enrollment In Phase 2 Trial Of SPI-2012 - A Novel Long-Acting Granulocyte Colony Stimulating Factor (GCSF) To Treat Chemotherapy-induced Neutropenia
2014-05-20,First Week of SPPI July 19th Options Trading
2014-05-15,SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Spectrum Pharmaceuticals, Inc. Regarding Possible Breaches Of Fiduciary Duty
2014-05-09,Spectrum Pharmaceuticals To Present Corporate Update At The Bank Of America Merrill Lynch 2014 Health Care Conference In Las Vegas On May 13th
2014-05-08,Spectrum Pharmaceuticals Reports Financial Results For First Quarter 2014
2014-05-01,Spectrum Pharmaceuticals Announces First Quarter 2014 Financial Results Teleconference And Webcast
2014-04-23,Spectrum Pharmaceuticals&#8217; Pivotal Trial Of Captisol-Enabled&#8482; (Propylene Glycol-Free) Melphalan Meets Primary Endpoint
2014-04-21,Spectrum Pharmaceuticals Promotes And Appoints Joseph Turgeon As President And Chief Operating Officer
2014-04-15,RSI Alert: Spectrum Pharmaceuticals (SPPI) Now Oversold
2014-04-07,Spectrum Pharmaceuticals Inc Stock Downgraded (SPPI)
2014-04-04,Ratings Changes Today
2014-03-26,First Week of SPPI November 22nd Options Trading
2014-03-12,First Week of SPPI May 17th Options Trading
2014-03-07,Spectrum Pharmaceuticals Enters Oversold Territory (SPPI)
2014-03-07,Spectrum Pharmaceuticals To Present Corporate Update At The 26th Annual ROTH Conference In Laguna Niguel On March 11th
2014-03-06,Spectrum Pharmaceuticals Reports Fourth And Full Year 2013 Financial Results
2014-02-27,Spectrum Pharmaceuticals Announces Fourth Quarter 2013 Financial Results Teleconference And Webcast
2014-02-24,The 10 Most Heavily Shorted Bio-Pharma Stocks
2014-02-20,Biotech Stock 'Hate' Mailbag: Readers Riot Over Galena, Prana
2014-02-06,Spectrum Pharmaceuticals Announces FDA&#8217;s Acceptance Of NDA Filing For Beleodaq&#8482; (belinostat) For Injection, A Novel Pan-HDAC Inhibitor
2014-01-31,SPPI Makes Notable Cross Below Critical Moving Average
2017-03-24,Shark Bites: Even Without Health Care Vote, Market's Feeling Better
2017-03-07,Supernus Announces Settlement With Actavis On Trokendi XR® Patent Litigation
2017-03-06,Supernus Announces Settlement With Zydus On Trokendi XR® Patent Litigation
2017-03-01,4 Smaller Biotech Names Worth Researching
2017-02-28,Supernus Announces Record Fourth Quarter And Full Year 2016 Financial Results
2017-02-27,Supernus To Present At Cowen Health Care Conference In March
2017-02-13,Supernus To Host Fourth Quarter And Full Year 2016 Earnings Conference Call
2017-02-08,Supernus Announces Issuance Of Eighth U.S. Patent Protecting Trokendi XR®
2017-01-30,Supernus Announces Issuance Of Seventh U.S. Patent Protecting Trokendi XR®
2017-01-23,Supernus Files Form 10-Q For Third Quarter 2016 And Is Now Current With All Financial Filings
2017-01-11,4 Blue-Chip Health-Care Picks on Sale (and the Portfolio Is Up 163% Since 2006)
2017-01-03,Supernus To Present At The 2017 J.P. Morgan Healthcare Conference
2016-12-20,The Bulls Don't Have Enough Juice for 20,000
2016-12-20,Rev's Forum: Can the Market Find a Second Wind?
2016-12-19,Big-Cap Tech Names, Biotechs, Oils Lifting Market
2016-12-12,Supernus Wins Appeal Case On Oxtellar XR®
2016-11-17,Supernus Receives Nasdaq Non-Compliance Notice
2016-11-14,Supernus Provides Business Update
2016-11-12,'Mad Money' Lightning Round: 'Health Care Is All Over the Map'
2016-11-11,Jim Cramer's 'Mad Money' Recap: Markets Pivot From Shocked to Bullish
2016-11-11,Supernus To Host A Business Update Call
2016-11-07,Supernus To Present At Three November Healthcare Conferences
2016-11-03,Supernus Pharmaceuticals (SUPN) Shares Cross Below 200 DMA
2016-11-03,Relative Strength Alert For Supernus Pharmaceuticals
2016-11-01,Small Biotechs on My Shopping List
2016-10-13,Supernus Offers Super Small-Cap Potential
2016-10-11,Supernus Announces Positive Results From Phase IIb Clinical Trial For SPN-812 In Children With ADHD
2016-10-10,Supernus Schedules Conference Call To Present Results Of Phase IIb Clinical Trial Of SPN-812 In Children With ADHD
2016-09-23,A Pullback Drops Major Indices
2016-09-19,Seeing the Same Old Patterns Ahead of Fed News
2016-09-16,Shark Bites: 5 Stocks I Am Playing in This Choppy Action
2016-08-19,Supernus Receives FDA Tentative Approval For Expanded Label Of Trokendi XR® To Include Migraine Prophylaxis In Adults
2016-08-12,Supernus Announces Resignation Of Dr. James Barrett From Board Of Directors; Charles W. Newhall, III Elected Chairman
2016-08-03,Supernus Pharmaceuticals (SUPN) Reaches New Lifetime High Today
2016-08-02,Supernus Announces Second Quarter 2016 Financial Results
2016-07-27,Supernus Pharmaceuticals (SUPN) Is Today's Strong And Under The Radar Stock
2016-07-20,Supernus To Host Second Quarter 2016 Earnings Conference Call
2016-07-12,Today's Strong And Under The Radar Stock Is Supernus Pharmaceuticals (SUPN)
2016-07-12,Supernus Pharmaceuticals Founder And CEO Jack Khattar Joins ScPharmaceuticals Board Of Directors
2016-07-07,Supernus Pharmaceuticals (SUPN) Is Today's Perilous Reversal Stock
2016-06-22,Supernus Announces Issuance Of Seventh U.S. Patent Protecting Oxtellar XR®
2016-06-17,Supernus Pharmaceuticals (SUPN): Today's Weak On High Volume Stock
2016-06-16,Supernus Provides Update On Trokendi XR® Migraine SNDA And Reiterates Guidance
2016-06-02,Supernus Announces Issuance Of Sixth U.S. Patent Protecting Oxtellar XR®
2016-06-01,Commit To Purchase Supernus Pharmaceuticals At $15, Earn 13.5% Annualized Using Options
2016-05-24,Supernus To Present At June Jefferies Healthcare Conference
2016-05-10,Supernus Enters Into Partial Settlement Agreement With Actavis On Oxtellar XR®
2016-05-04,Supernus Pharmaceuticals (SUPN) Shares Cross Below 200 DMA
2016-05-03,Supernus Announces First Quarter 2016 Financial Results
2016-04-19,Supernus To Host First Quarter 2016 Earnings Conference Call
2016-04-01,SUPN Crosses Above Key Moving Average Level
2016-03-30,Ratings Changes Today
2016-03-10,Strong On High Relative Volume: Supernus Pharmaceuticals (SUPN)
2016-03-02,Supernus Announces Record Fourth Quarter And Full Year 2015 Financial Results
2016-03-01,First Week of SUPN April 15th Options Trading
2016-02-25,Supernus To Present At March Cowen Health Care Conference
2016-02-18,Supernus To Host Fourth Quarter And Full Year 2015 Earnings Conference Call
2016-02-08,Supernus Prevails In Oxtellar XR® ANDA Litigation
2016-01-29,Strong On High Relative Volume: Supernus Pharmaceuticals (SUPN)
2016-01-22,First Week of September 16th Options Trading For Supernus Pharmaceuticals (SUPN)
2016-01-08,Supernus Pharmaceuticals is Now Oversold (SUPN)
2015-12-14,Oversold Conditions For Supernus Pharmaceuticals (SUPN)
2015-12-04,Supernus Announces Distribution Of Common Stock By NEA
2015-12-02,Supernus To Attend Guggenheim Securities Boston Healthcare Conference
2015-11-13,Today's Dead Cat Bounce Stock Is Supernus Pharmaceuticals (SUPN)
2015-11-12,Supernus Announces Distribution Of Common Stock By NEA
2015-11-09,Supernus To Present At Two Investor Conferences
2015-11-09,Insider Trading Alert - MXL, SCOR And SUPN Traded By Insiders
2015-11-03,Supernus Announces Third Quarter 2015 Financial Results And Raises 2015 Guidance
2015-10-22,Supernus Announces FDA Acceptance Of SNDA To Add Migraine To Trokendi XR(R) Label
2015-10-21,First Week Of SUPN June 2016 Options Trading
2015-10-20,Supernus To Host Third Quarter 2015 Earnings Conference Call
2015-10-20,Perilous Reversal Stock: Supernus Pharmaceuticals (SUPN)
2015-10-15,Supernus Pharmaceuticals (SUPN) Strong On High Relative Volume Today
2015-10-15,Supernus Announces Settlement With Par On Trokendi XR(R) Patent Litigation
2015-09-29,Notable Two Hundred Day Moving Average Cross - SUPN
2015-09-28,Supernus Pharmaceuticals is Now Oversold (SUPN)
2015-09-22,Supernus Pharmaceuticals (SUPN) Showing Signs Of A Dead Cat Bounce Today
2015-09-10,Today's Dead Cat Bounce Stock Is Supernus Pharmaceuticals (SUPN)
2015-09-02,Supernus Announces Issuance Of Fifth U.S. Patent Protecting Oxtellar XR(R)
2015-08-28,Interesting SUPN Put And Call Options For October 16th
2015-08-27,Supernus To Attend FBR Healthcare Conference On September 9th
2015-08-19,Trade-Ideas: Supernus Pharmaceuticals (SUPN) Is Today's "Dead Cat Bounce" Stock
2015-08-18,Today's Perilous Reversal Stock: Supernus Pharmaceuticals (SUPN)
2015-08-06,Trade-Ideas: Supernus Pharmaceuticals (SUPN) Is Today's "Dead Cat Bounce" Stock
2015-08-05,New Lifetime High Reached By Supernus Pharmaceuticals (SUPN)
2015-08-04,Supernus Announces Second Quarter 2015 Financial Results
2015-07-28,New Lifetime High For Supernus Pharmaceuticals (SUPN)
2015-07-21,First Week Of March 2016 Options Trading For Supernus Pharmaceuticals (SUPN)
2015-07-20,Supernus To Host Second Quarter 2015 Earnings Conference Call
2015-07-20,Supernus Pharmaceuticals (SUPN) Reaches New Lifetime High Today
2015-07-15,Insider Trading Alert - VHI, SNX And SUPN Traded By Insiders
2015-07-15,Insider Trading Alert - VHI, SNX And SUPN Traded By Insiders
2015-06-23,First Week Of SUPN August 21st Options Trading
2015-06-19,Perilous Reversal Stock: Supernus Pharmaceuticals (SUPN)
2015-06-18,Today's Dead Cat Bounce Stock Is Supernus Pharmaceuticals (SUPN)
2015-06-17,Supernus Corrects Earlier Statement Regarding Distribution Of Common Stock By NEA
2015-06-17,Supernus Announces Distribution Of Common Stock By NEA
2015-06-16,Insider Trading Alert - GFN, SCOR And SUPN Traded By Insiders
2015-06-15,Insider Trading Alert - ALXN, SUPN And WLDN Traded By Insiders
2015-06-12,New Lifetime High For Supernus Pharmaceuticals (SUPN)
2015-06-10,Supernus Pharmaceuticals (SUPN) Weak On High Volume Today
2015-06-08,Supernus Announces Webcast Of Investor Day On June 17, 2015
2015-06-01,Today's Weak On High Volume Stock: Supernus Pharmaceuticals (SUPN)
2015-05-19,Supernus To Present At June Jefferies Healthcare Conference
2015-05-06,Supernus Pharmaceuticals (SUPN) Weak On High Volume Today
2015-05-05,Supernus Announces First Quarter 2015 Financial Results
2015-04-21,Supernus To Host First Quarter 2015 Earnings Conference Call
2015-04-02,Supernus Announces Issuance Of Sixth U.S. Patent Protecting Trokendi XR(R)
2015-03-25,First Week Of May 15th Options Trading For Supernus Pharmaceuticals (SUPN)
2015-03-23,Georges Gemayel, Ph.D., Joins Supernus Board Of Directors
2015-03-11,Supernus Pharmaceuticals (SUPN) Stock Is Up Today on Earnings Beat
2015-03-10,Supernus Announces Fourth Quarter And Full Year 2014 Results
2015-02-18,Supernus To Present At March Cowen Conference
2015-02-17,Supernus To Host Fourth Quarter And Full Year 2014 Earnings Conference Call
2015-01-21,Supernus Sues TWi For Infringement Of Oxtellar XR(R) Patents
2015-01-16,Supernus Sues Par For Infringement Of Trokendi XR(R) Patents
2015-01-14,Supernus Pharmaceuticals (SUPN) Is Strong On High Volume Today
2015-01-13,Short Interest Makes 30.7% Move For SUPN
2015-01-06,Interesting SUPN Put And Call Options For February 20th
2014-12-10,Supernus Announces Paragraph IV ANDA Filing For Oxtellar XR(R)
2014-12-09,Supernus Announces Paragraph IV ANDA Filing For Trokendi XR(R)
2014-11-24,Supernus Announces Issuance Of Fifth U.S. Patent Protecting Trokendi XR(R)
2014-11-21,Supernus Sues Zydus For Infringement Of Trokendi XR(R) Patents
2014-11-11,Supernus Announces Third Quarter 2014 Results
2014-11-07,Supernus Announces Issuance Of Fourth U.S. Patent Protecting Trokendi XR(R)
2014-11-04,Supernus To Present At Two Investor Conferences
2014-10-29,Supernus To Host Third Quarter 2014 Earnings Conference Call
2014-10-14,Supernus Announces Paragraph IV ANDA Filing For Trokendi XR(R)
2014-10-02,Supernus Sues Actavis For Infringement Of Trokendi XR(R) Patents
2014-09-26,Commit To Buy Supernus Pharmaceuticals At $7, Earn 16.4% Annualized Using Options
2014-09-22,Supernus Provides Business Update
2014-09-10,Supernus Pharmaceuticals (SUPN) Is Today's Strong On High Volume Stock
2014-09-04,Supernus Announces Issuance Of Fourth US Patent Protecting Oxtellar XR(R)
2014-08-21,Supernus Announces Paragraph IV ANDA Filing For Trokendi XR(R)
2014-08-19,Supernus To Attend FBR HealthCare Conference In September
2014-08-14,Supernus Receives FDA Fast Track Designation For SPN-810
2014-08-11,Supernus Announces Second Quarter 2014 Results
2014-07-31,Supernus Pharmaceuticals Enters Oversold Territory (SUPN)
2014-07-29,Supernus To Host Second Quarter 2014 Earnings Conference Call
2014-07-24,Ratings Changes Today
2014-07-08,Supernus To Receive $30 Million In Non-Dilutive Royalty Deal
2014-06-25,Interesting SUPN Put And Call Options For August 16th
2014-05-21,Supernus To Present At Jefferies Healthcare Conference In June
2014-05-20,Supernus Receives $2 Million Milestone For United Therapeutics' Launch Of Orenitram(TM)
2014-05-20,First Week of July 19th Options Trading For Supernus Pharmaceuticals (SUPN)
2014-05-12,Supernus Announces First Quarter 2014 Results
2014-04-29,Supernus To Host First Quarter 2014 Earnings Conference Call
2014-04-15,Oversold Conditions For Supernus Pharmaceuticals (SUPN)
2014-03-17,4 Stocks Under $10 Making Big Moves
2014-03-12,Supernus Announces Fourth Quarter And Full Year 2013 Results
2014-03-12,Supernus Announces Issuance Of Third US Patent Protecting Trokendi XR&#8482;
2014-02-25,Supernus To Host Fourth Quarter And Full Year 2013 Earnings Conference Call
2014-02-20,Supernus To Present At Cowen And Company Healthcare Conference In March
2014-02-12,Short Interest Moves 13% Lower For SUPN
2014-02-07,Supernus At Citibank And RBC Global Healthcare Conferences In February
2014-02-03,Supernus Announces Publication Of Phase III Study (PROSPER) Results On Oxtellar XR&#174;
2014-01-27,Supernus Announces Issuance Of First Use Patents Protecting SPN-812 As A Novel Non-Stimulant ADHD Product
2014-01-07,Supernus Announces Issuance Of Third US Patent Protecting Oxtellar XR(R)
2013-12-24,Supernus Announces Resignation Of Board Member
2013-12-23,Supernus Announces FDA Approval Of Its Partner's Product, Orenitram(TM)
2013-12-12,Supernus Posts Exciting Clinical Data Regarding Trokendi XR(TM) And Oxtellar XR(TM) On The Company Website
2013-12-06,5 Stocks Under $10 Moving Higher
2013-11-27,Supernus Pharmaceuticals Stock Sees Short Interest Decline 11.3%
2013-11-21,Supernus To Present At Piper Jaffray Healthcare Conference In December
2013-11-12,Supernus Pharmaceuticals Reports Third Quarter 2013 Financial Results
2013-11-11,Interesting SUPN Put Options For January 2016
2013-11-08,January 2015 Options Now Available For Supernus Pharmaceuticals (SUPN)
2013-11-06,Supernus Announces Third Quarter 2013 Earnings Conference Call And Webcast
2013-11-06,Supernus Announces Release Of Exciting New Clinical Data On Trokendi XR(TM)
2013-10-22,Supernus Pharmaceuticals Is Now Oversold (SUPN)
2013-09-20,5 Biotech Stocks Under $10 on the Move
2013-09-05,Supernus Launches Trokendi XR(TM) In The United States
2013-08-29,Supernus To Present At Two Investor Conferences In September
2013-08-19,Supernus Announces Final FDA Approval And Upcoming Launch Of Trokendi XR(TM)
2013-08-13,Supernus Pharmaceuticals Reports Second Quarter 2013 Financial Results
2013-08-07,Supernus Sues Watson For Infringement Of Oxtellar XR(TM) Patents
2013-08-06,Supernus Announces Second Quarter 2013 Earnings Conference Call And Webcast
2013-07-25,Short Interest In Supernus Pharmaceuticals Increases 12.2%
2013-07-02,SUPN: Insiders Vs. Shorts
2017-03-07,Synthetic Biologics To Present At The 29th Annual ROTH Conference
2017-02-21,Synthetic Biologics To Report 2016 Year End Operational Highlights And Financial Results On March 2, 2017
2017-02-03,Synthetic Biologics To Present At The 2017 BIO CEO & Investor Conference
2017-01-18,Synthetic Biologics Confirms Key Features Of Pivotal Phase 2b/3 Trial Of SYN-010 Pursuant To Consultations With FDA
2017-01-05,Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint In Phase 2b Trial For C. Difficile Infection (CDI)
2017-01-03,Synthetic Biologics To Present At The Biotech Showcase™ 2017 Conference
2016-12-13,Synthetic Biologics Announces Granting Of U.S. Composition Of Matter Patent For SYN-005, Designed For The Treatment And Prevention Of Pertussis (Whooping Cough)
2016-12-01,Synthetic Biologics Announces Participation In Two Upcoming Investor Conferences
2016-11-18,Synthetic Biologics Announces Closing Of Public Offering Of Common Stock And Warrants
2016-11-15,Synthetic Biologics Announces Pricing Of Public Offering Of Common Stock And Warrants
2016-11-14,Synthetic Biologics Announces Commencement Of Public Offering Of Common Stock And Warrants
2016-10-25,Synthetic Biologics To Report Third Quarter 2016 Operational Highlights And Financial Results On November 1, 2016
2016-10-06,Synthetic Biologics Awarded Research Contract From Centers For Disease Control And Prevention (CDC) For Microbiome Assessment And Intervention To Address Antibiotic Resistance
2016-09-20,Synthetic Biologics Announces Completion Of Enrollment For Phase 2b Proof-of-Concept Clinical Trial For SYN-004 (ribaxamase) For The Prevention Of Clostridium Difficile Infection, Antibiotic-Associated Diarrhea And The Emergence Of Antibiotic-Resistant Organisms
2016-09-15,7 Stocks Under $10 Making Big Moves Higher
2016-09-08,5 Stocks Under $10 That Could Make You a Lot of Money
2016-08-22,European Markets Slide as Oil Prices Fall
2016-08-22,European Markets Up; Syngenta Surges on ChemChina Security Approval
2016-08-02,Synthetic Biologics Announces Completion Of End Of Phase 2 Meeting With FDA For SYN-010, Intended For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)
2016-07-12,Synthetic Biologics Announces Granting Of European And U.S. Composition Of Matter Patents For Ribaxamase
2016-07-07,Synthetic Biologics Receives USAN Approval For Generic Name Ribaxamase For Phase 2 Drug Candidate SYN-004
2016-07-06,Synthetic Biologics To Present At The 2nd Annual Cantor Fitzgerald Healthcare Conference
2016-05-23,Synthetic Biologics Announces Detailed Data From Two SYN-010 Phase 2 Clinical Trials For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)
2016-05-17,Synthetic Biologics To Host Post-DDW 2016® Conference Call To Recap SYN-010 Phase 2 Clinical Trial Results For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)
2016-05-16,Synthetic Biologics Announces Positive Topline Results From Second Phase 2a Clinical Trial Of SYN-004 For The Prevention Of C. Difficile Infection And Antibiotic-Associated Diarrhea
2016-05-11,Isaac J. Bright, MD, Joins Synthetic Biologics As Vice President, Corporate Development
2016-05-09,Synthetic Biologics Appoints Deb Mathews, PharmD, As Vice President, Medical Affairs
2016-04-26,Synthetic Biologics To Report First Quarter 2016 Operational Highlights And Financial Results On May 5, 2016
2016-04-21,Syncordia Announces Sponsorship & Participation In 24/7 Run Across America
2016-03-09,Synthetic Biologics To Present At The 28th Annual ROTH Conference
2016-03-03,Synthetic Biologics To Report 2015 Year End Results On March 10, 2016
2016-03-01,Synthetic Biologics Announces Further U.S. Patent Successes Covering SYN-004 Intended For The Prevention Of C. Difficile Infection And Antibiotic-Associated Diarrhea
2016-02-17,Synthetic Biologics Announces The Allowance Of Key U.S. Patent Covering SYN-010 Intended For The Novel Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)
2016-02-16,Synthetic Biologics To Participate In Fireside Chat At RBC Capital Markets' Global Healthcare Conference
2016-02-03,Synthetic Biologics To Present At The 2016 BIO CEO & Investor Conference
2016-02-02,Synthetic Biologics Reports Results Of Independent Third Party Evaluations Of Trimesta™ Data From Investigator-Sponsored Phase 2 Clinical Trial For Relapsing-Remitting Multiple Sclerosis
2016-01-19,Synthetic Biologics Reports Positive Topline Data From Second Phase 2 Clinical Trial Of SYN-010 In Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
2016-01-06,Synthetic Biologics To Present At The Biotech Showcase™ 2016 Conference
2015-12-24,4 Great Stock-ing Stuffers for 2016
2015-12-10,Synthetic Biologics Targeting IBS Cause, Not Just Treatment
2015-12-10,2016 Will Be Big in Battle Against IBS Says Synthetic Biologics CEO
2015-12-08,Synthetic Biologics' SYN-010 Lowered Breath Methane And Improved Stool Frequency In A Phase 2 Four Week Study In Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
2015-12-07,Synthetic Biologics To Webcast Microbiome Clinical Program Seminar
2015-12-01,Synthetic Biologics Announces Positive Topline Results From First Phase 2a Clinical Trial Of SYN-004, The Company's Candidate For The Prevention Of C. Difficile Infection
2015-11-25,Synthetic Biologics Reports That Data From The Phase 2 Trimesta™ Clinical Trial For Relapsing-Remitting Multiple Sclerosis Were Published By Lead Principal Investigator
2015-11-24,Synthetic Biologics Announces Issuance Of First Key U.S. Patent Directly Covering SYN-010, The Company's Novel Candidate For Irritable Bowel Syndrome With Constipation (IBS-C)
2015-11-19,Synthetic Biologics To Host Microbiome Clinical Program Seminar In New York City
2015-10-21,Grant Awarded To Synthetic Biologics' Academic Collaborator To Fund Further Evaluation Of Monoclonal Antibody For The Prevention Of Whooping Cough (Pertussis)
2015-10-20,Synthetic Biologics' Novel Irritable Bowel Syndrome With Constipation (IBS-C) Program Featured In American College Of Gastroenterology Poster
2015-10-19,Synthetic Biologics To Report Third Quarter Results On November 5, 2015
2015-10-09,Syncordia Technologies And Healthcare Solutions, Corp. To Present At StableView Asset Management Tech15 Conference
2015-10-08,Synthetic Biologics Initiates Second SYN-010 Phase 2 Clinical Trial Intended To Treat Irritable Bowel Syndrome With Constipation (IBS-C)
2015-10-01,Synthetic Biologics Appoints Raymond Stapleton, PhD, As Senior Vice President, Manufacturing
2015-09-28,Synthetic Biologics Initiates SYN-004 Phase 2b Proof-of-Concept Clinical Trial
2015-09-21,Synthetic Biologics Reports First Analysis Demonstrating SYN-004's Ability To Protect The Microbiome From Damage Caused By IV Antibiotics In A Humanized Pig Model
2015-08-10,Intrexon And Synthetic Biologics Enter ECC To Develop Novel Biotherapeutics For Treatment Of Phenylketonuria
2015-07-29,Synthetic Biologics To Report Second Quarter Results On August 10, 2015
2015-07-21,Synthetic Biologics Announces Closing Of Recent Equity Offering And Exercise In Full Of Underwriters' Over-Allotment Option
2015-07-16,Synthetic Biologics (SYN) Stock Tanks After Pricing Secondary Offering
2015-07-16,Synthetic Biologics Announces Pricing Of $40.0 Million Public Offering
2015-07-15,Synthetic Biologics Announces Public Offering Of Common Stock
2015-07-07,IIROC Trading Resumption - SYN
2015-06-29,Synthetic Biologics' Initiates SYN-010 Phase 2 Clinical Trial To Treat Irritable Bowel Syndrome With Constipation (IBS-C)
2015-06-08,Stocks Move Off Lows; Apple Announces Streaming Service
2015-06-08,Stocks Are Slightly Lower; Casino Stocks Sell Off
2015-06-08,Stock Futures Are Slightly Lower as China's Exports Fall
2015-06-03,Synthetic Biologics Presents Initial Data Validating Platform Expansion To Cover Carbapenem Antibiotics
2015-06-02,Synthetic Biologics Expands Clinical & Regulatory Leadership Team With Addition Of Klaus Gottlieb, MD, FACG
2015-06-01,Synthetic Biologics To Host Microbiome Analyst & Investor Meeting
2015-05-19,Synthetic Biologics' SYN-004 Microbiome-Protecting Preclinical Data Highlighted In Late-Breaking Poster At Digestive Disease Week® 2015
2015-05-18,Synthetic Biologics' Novel SYN-010 Preclinical Data Featured In Digestive Disease Week® Poster
2015-05-07,Maureen Early Named Vice President, Commercial Of Synthetic Biologics
2015-05-04,Steven Shallcross Named Chief Financial Officer Of Synthetic Biologics
2015-04-30,Synthetic Biologics To Host First Quarter 2015 Investor Conference Call
2015-04-27,Posters At ECCMID 2015 Highlight Preclinical Data From Synthetic Biologics' Novel SYN-005 Monoclonal Antibody Combination For The Treatment And Prophylaxis Of Whooping Cough (Pertussis)
2015-04-01,Synthetic Biologics' SYN-004 Clinical Data For Protection Of Microbiome Selected For Poster Presentation At American Society Of Microbiology 2015
2015-03-30,Synthetic Biologics Initiates Phase 2a Clinical Trial Of SYN-004 To Protect The Microbiome And Prevent C. Difficile
2015-03-19,Synthetic Biologics Announces Positive Pharmacokinetics Data From Phase 1a And 1b Trials Of SYN-004 To Protect The Microbiome And Prevent C. Difficile Infection
2015-03-09,Synthetic Biologics To Report Year End 2014 Financial Results
2015-03-03,Synthetic Biologics To Present At The 27th Annual ROTH Conference
2015-03-02,Synthetic Biologics Announces Two Poster Presentations Of Novel Monoclonal Antibody Combination For Treatment Of Whooping Cough (Pertussis) At ECCMID 2015
2015-02-10,Synthetic Biologics Announces Positive Topline Results From Phase 1b Trial Of SYN-004 To Protect The Microbiome And Prevent C. Difficile Infection
2015-02-03,Synthetic Biologics To Present At The 2015 BIO CEO & Investor Conference
2015-01-07,Synthetic Biologics To Present At The Biotech Showcase™ 2015 Conference
2014-12-30,Synthetic Biologics Announces First Patient Dosed In Phase 1b Clinical Trial Of SYN-004 For The Prevention Of C. Difficile Infection
2014-12-22,Synthetic Biologics Announces Positive Topline Results From Phase 1a Trial Of SYN-004 For The Prevention Of C. Difficile Infection
2014-12-02,Synthetic Biologics Announces First Patient Dosed In Phase 1a Clinical Trial Of SYN-004 For The Prevention Of C. Difficile Infection
2014-12-01,5 Under-$10 Stocks Setting Up to Trade Higher: Must-See Charts
2014-11-06,Synthetic Biologics To Report Third Quarter 2014 Financial Results
2014-10-15,Synthetic Biologics Appoints Prominent Gastrointestinal (GI) Key Opinion Leaders To Irritable Bowel Syndrome (IBS) Clinical Advisory Board
2014-10-10,Synthetic Biologics To Raise $20.7 Million In Registered Direct Offering
2014-09-16,Synthetic Biologics' Statin-Class Candidate For Constipation-Predominant Irritable Bowel Syndrome Detailed At Company's Investor Day
2014-09-12,Synthetic Biologics Receives Orphan Drug Designation For SYN-005 Treatment For Whooping Cough (Pertussis)
2014-09-11,Synthetic Biologics To Host Phase II Trimesta™ For Multiple Sclerosis Conference Call
2014-09-10,Synthetic Biologics To Webcast September 16, 2014 Irritable Bowel Syndrome (IBS) Investor Day
2014-09-08,Synthetic Biologics Highlights SYN-005 Data Presented At The 54th ICAAC From Novel Whooping Cough (Pertussis) Program
2014-09-07,Synthetic Biologics Highlights New Data From C. Difficile Program Presented At The 54th ICAAC
2014-09-03,Synthetic Biologics To Present At The 16th Annual Rodman & Renshaw Global Investment Conference In New York City
2014-09-02,Synthetic Biologics To Initiate Clinical Trials Of SYN-004 In 4Q 2014 To Prevent Potentially Deadly C. Difficile Infections
2014-08-28,Synthetic Biologics And FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement In API Manufacturing Of SYN-004 For The Prevention Of C. Difficile
2014-08-26,Synthetic Biologics Announces Presentation Of Poster For SYN-004 C. Difficile Program At IDWeek 2014™
2014-08-19,Synthetic Biologics Announces Late-Breaking Poster Presentation For C. Difficile Program At 54th ICAAC
2014-08-13,Synthetic Biologics To Host Irritable Bowel Syndrome (IBS) Investor Day
2014-08-12,Synthetic Biologics' Academic Collaborator To Present Novel Monoclonal Antibody Combination For Treatment Of Whooping Cough (Pertussis) At 54th ICAAC
2014-08-07,Synthetic Biologics To Report Second Quarter 2014 Financial Results
2014-08-05,Synthetic Biologics On Track To Initiate Clinical Program For SYN-004 To Protect Against C. Difficile
2014-07-31,Expanded Data On Disability And Cognitive Improvements In Phase II Study Of Synthetic Biologics' Trimesta™ In Multiple Sclerosis To Be Presented At 2014 Joint ACTRIMS-ECTRIMS Meeting
2014-07-29,Synthetic Biologics, Inc. States That Its Policy Is Not To Comment On Unusual Market Activity
2014-07-21,Synthetic Biologics' Academic Collaborator To Present Novel Monoclonal Antibody Combination For Treating Whooping Cough (Pertussis) At Gordon Research Conference
2014-06-30,Synthetic Biologics Forms Clinical Advisory Board To Support Novel C. Difficile Preventative Program
2014-06-25,Synthetic Biologics Reports That Licensor Cedars-Sinai Finds Eradication Of Gut Methane Improves Insulin Sensitivity And Lipid Profiles In Study Of Pre-Diabetic, Obese Patients
2014-06-10,Synthetic Biologics And Enterome Bioscience Collaborate On Microbiome Research To Support Synthetic Biologics' C. Difficile Program
2014-06-10,Synthetic Biologics And Enterome Bioscience Collaborate On Microbiome Research To Support Synthetic Biologics' C. Difficile Program
2014-05-20,Synthetic Biologics To Present At The 3rd Annual Marcum LLP MicroCap Conference
2014-05-15,Why Synthetic Biologics (SYN) Stock Is Surging Today
2014-05-09,Synthetic Biologics To Report First Quarter 2014 Financial Results
2014-05-08,Synthetic Biologics Announces Recent International Patents That Bolster Its C. Difficile Program
2014-04-30,Synthetic Biologics To Discuss Phase II Results Of Oral Estriol Candidate Trimesta&#8482; For Relapsing-Remitting Multiple Sclerosis In Women
2014-04-29,Synthetic Biologics Reports UCLA Announcement Of Preliminary Positive Topline Efficacy And Safety Results From Investigator-Led Phase II Study Of Trimesta&#8482; For Relapsing-Remitting Multiple Sclerosis
2014-04-23,Synthetic Biologics' Reports Preclinical Data To Support Clinical Development Of Novel Pertussis Therapeutic
2014-04-14,Synthetic Biologics Appoints Mark Pimentel, M.D., Chairman Of New Irritable Bowel Syndrome Clinical Advisory Board
2014-03-25,Synthetic Biologics To Report Year End 2013 Financial Results
2014-03-18,4 Stocks Under $10 to Trade for Breakouts
2014-03-10,Synthetic Biologics Announces Issuance Of U.S. Patent Adding Another Layer Of Protection For The Use Of Oral Estriol Candidate, Trimesta&#8482;, For Multiple Sclerosis
2014-03-05,Synthetic Biologics To Present At The 26th Annual ROTH Conference
2014-02-26,Synthetic Biologics' Board Of Directors Accepts Resignation Of Long-Standing Founder And Board Member
2014-02-13,Synthetic Biologics, Inc. States That Its Policy Is Not To Comment On Unusual Market Activity
2014-02-10,Synthetic Biologics Announces Rhonda Voskuhl, M.D., To Present Trimesta&#8482; Phase II Multiple Sclerosis Clinical Trial Results At The 2014 AAN Annual Meeting
2014-02-04,Synthetic Biologics To Present At The 2014 BIO CEO & Investor Conference
2014-01-27,Synthetic Biologics Strengthens Clinical & Regulatory Team To Support Expanding Pipeline Of Infectious Disease Programs
2014-01-08,Synthetic Biologics To Present At The Biotech Showcase&#8482; 2014 Conference
2014-01-08,Synthetic Biologics To Present At The 7th Annual OneMedForum San Francisco 2014 Conference
2013-12-17,Synthetic Biologics Announces Closing Of Public Offering Of Common Stock
2013-12-13,Synthetic Biologics Announces Exercise Of Underwriters' Over-Allotment Option
2013-12-11,Synthetic Biologics Announces Pricing Of Public Offering Of Common Stock
2013-12-11,Synthetic Biologics Announces Proposed Public Offering Of Common Stock
2013-12-09,Synthetic Biologics And Intrexon Corporation Initiate Development Of Novel Biologics For A Subset Of Patients Suffering From Irritable Bowel Syndrome (IBS)
2013-12-09,Synthetic Biologics' Webcast Conference Call Set For 9:00 A.m. EST This Morning, December 9th
2013-12-07,Synthetic Biologics Enters Into License With Cedars-Sinai Medical Center To Develop Novel Anti-infective Approaches For Irritable Bowel Syndrome (IBS), Obesity And Diabetes
2013-12-02,Synthetic Biologics To Present At The LD MICRO VI: Main Event Conference In Los Angeles
2013-11-14,Synthetic Biologics' SYN-004 For The Prevention Of C. Difficile Infections Named A "Top Project To Watch" By Elsevier Business Intelligence
2013-11-07,Synthetic Biologics To Report Third Quarter 2013 Financial Results
2013-10-15,Synthetic Biologics Initiates Manufacturing Of SYN-004 For Use In Preclinical And Clinical Trials To Target The Prevention Of C. Difficile Infections
2013-09-20,Synthetic Biologics Responds To Recent CDC Report On Threat Of "Super Bugs"
2013-09-10,Synthetic Biologics To Present At The First Global Life Sciences Conference In Warsaw, Poland
2013-09-03,Synthetic Biologics To Present At The 15th Annual Rodman & Renshaw Global Investment Conference In New York City
2013-08-08,Synthetic Biologics To Report Second Quarter 2013 Financial Results
2013-08-06,Former Pfizer/Wyeth Global Infectious Disease Pharmaceutical Executive, Lewis Barrett, Appointed Senior Vice President, Commercial Strategy Of Synthetic Biologics, Inc.
2013-07-18,Synthetic Biologics Initiates Manufacturing Process For C. Difficile Infectious Disease Program
2013-06-19,Synthetic Biologics To Present At OneMedForum New York 2013
2013-06-13,Synthetic Biologics To Host Multiple Sclerosis-Estriol Investor Day In New York City On June 25, 2013
2013-05-21,Synthetic Biologics To Present At The 2nd Annual Marcum LLP MicroCap Conference
2013-04-19,Synthetic Biologics Reiterates That The Infectious Disease Collaboration With Intrexon Remains In Effect
2013-04-04,Synthetic Biologics Announces Issuance Of U.S. Patent Covering Combination Of Estriol And Copaxone® For Multiple Sclerosis
2013-03-12,Synthetic Biologics To Present At The 25th Annual ROTH Conference
2013-02-26,Infectious Disease Specialist, Brad Spellberg, M.D., Joins Synthetic Biologics' Scientific Advisory Board
2013-02-22,Synthetic Biologics Reports That Flupirtine Sublicensee, Meda AB, To Initiate Phase II Fibromyalgia Clinical Trial In U.S.
2013-02-07,3 Biotech Stocks Under $5 Moving Higher
2013-02-05,Synthetic Biologics To Present At The 2013 BIO CEO & Investor Conference
2013-01-07,Synthetic Biologics To Present At OneMedForum San Francisco 2013
2012-12-20,Synthetic Biologics And Intrexon Corporation Initiate Development Of Monoclonal Antibodies For Whooping Cough (Pertussis)
2012-12-03,Synthetic Biologics Closes Deal For Acquisition Of C. Difficile Infectious Disease Program
2012-11-30,Synthetic Biologics To Present At The Fifth Annual LD MICRO Conference In Los Angeles
2012-11-12,Synthetic Biologics To Acquire Clinical-Stage C. Difficile Infectious Disease Program
2012-10-31,Synthetic Biologics Completes $10.8 Million Private Placement Financing
2012-10-29,Synthetic Biologics Announces $10.8 Million Financing
2012-10-23,Synthetic Biologics Strengthens Research & Development Team To Support Expanding Pipeline Of Infectious Disease Therapies And Synthetic Biologics Programs
2012-10-09,Charles B. Shoemaker, Ph.D., Joins Synthetic Biologics' Scientific Advisory Board
2012-09-18,Synthetic Biologics Initiates Development Of Monoclonal Antibodies For Treatment Of Acinetobacter Infections
2012-08-08,Synthetic Biologics And Intrexon Corporation Enter Worldwide Exclusive Collaboration For Infectious Diseases
2012-07-13,5 Stocks Poised for Breakouts
2012-05-11,Synthetic Biologics Appoints Jeffrey J. Kraws As Independent Chairman
2012-04-26,Synthetic Biologics Launches Free Investor Relations Mobile Application
2012-01-24,Watching for a Short-Side Entry
2009-12-02,BB&T, SunTrust Upgraded At Credit Suisse
2009-09-14,Synovus To Raise $350M in Stock Offer
2008-07-22,Regions' Profit Stung by Fla. Real Estate
2007-11-21,Stock Upgrades, Downgrades from TheStreet.com Ratings
2007-10-01,Cramer's 'Mad Money Lightning Round': Best BuyBuyBuy
2002-11-14,Neurocrine Says Sleeping Pill Data Are Good
2017-02-17,Theravance Biopharma Presents Positive Clinical Data On TD-1473 At The 12th Congress Of The European Crohn's And Colitis Organization
2017-02-15,Theravance Biopharma To Report Fourth Quarter And Full Year 2016 Financial Results On February 27, 2017
2017-02-13,Theravance Biopharma Reaches Analyst Target Price
2017-02-02,Theravance Biopharma To Present At The Leerink Partners 6th Annual Global Healthcare Conference
2017-01-23,Theravance Biopharma Reports New Data From Ongoing TOUR™ Observational Patient Registry In Oral Presentation At SCCM Critical Care Congress
2016-12-19,Theravance Biopharma Highlights Initiation Of Phase 3 Study Of The Closed Triple In Patients With Asthma By GlaxoSmithKline And Innoviva
2016-12-12,Theravance Biopharma Reaches Analyst Target Price
2016-12-06,Theravance Biopharma Receives FDA Fast Track Designation For Velusetrag (TD-5108) For Idiopathic And Diabetic Gastroparesis
2016-12-05,Theravance Biopharma Highlights Filing Of EU Regulatory Submission For The Closed Triple In COPD By GlaxoSmithKline And Innoviva
2016-11-28,Short Interest In Theravance Biopharma Increases 60.2%
2016-11-22,Theravance Biopharma To Present At The 28th Annual Piper Jaffray Healthcare Conference
2016-11-21,Theravance Biopharma Highlights Filing Of U.S. New Drug Application For The Closed Triple In COPD By GlaxoSmithKline And Innoviva
2016-11-18,Ratings Changes Today
2016-11-11,TBPH Crosses Above Average Analyst Target
2016-11-01,Theravance Biopharma To Report Third Quarter 2016 Financial Results On November 8, 2016
2016-11-01,New Data For VIBATIV® (telavancin) Reported In Presentations At IDWeek™ 2016
2016-10-31,Theravance Biopharma Presents Interim Data From Ongoing Telavancin Observational Use Registry (TOUR™) At IDWeek™ 2016
2016-10-28,Theravance Biopharma Announces Pricing Of Public Offerings Of 3,850,000 Ordinary Shares And $200 Million Of 3.25% Convertible Senior Notes Due 2023
2016-10-26,Theravance Biopharma Announces Proposed Public Offerings Of $100 Million Of Ordinary Shares And $150 Million Of Convertible Senior Notes
2016-10-25,Theravance Biopharma Announces Positive Results Including Biomarker Data From Phase 1 Multiple-Ascending Dose Study Of TD-0714, An Inhibitor Of Neprilysin (NEP)
2016-10-20,Theravance Biopharma And Mylan Announce Positive Results From Two Pivotal Phase 3 Studies Of Revefenacin (TD-4208) For The Treatment Of Chronic Obstructive Pulmonary Disease (COPD)
2016-08-01,TBPH Crosses Above Average Analyst Target
2016-06-08,Takeda Licenses Global Rights To Theravance Biopharma's TD-8954, A Novel 5-HT4 Agonist And Motility Agent For Gastrointestinal Motility Disorders
2016-05-02,Short Interest In Theravance Biopharma Decreases By 11.6%
2016-04-28,Commit To Purchase Theravance Biopharma At $17.50, Earn 13% Annualized Using Options
2016-03-22,Ratings Changes Today
2016-01-28,Commit To Buy Theravance Biopharma At $12.50, Earn 14.5% Annualized Using Options
2016-01-11,Theravance Biopharma Becomes Oversold (TBPH)
2015-12-18,Ratings Changes Today
2015-11-05,Ratings Changes Today
2015-11-04,Commit To Buy Theravance Biopharma At $12.50, Earn 12.9% Annualized Using Options
2015-11-03,Theravance Biopharma (TBPH) Stock Boasts a 35% Upside
2015-09-14,Theravance Biopharma And Mylan Initiate Phase 3 Program For Revefenacin (TD-4208) For Treatment Of Chronic Obstructive Pulmonary Disease (COPD)
2015-08-06,Commit To Purchase Theravance Biopharma At $10, Earn 16.2% Annualized Using Options
2015-06-17,Ratings Changes Today
2015-05-07,Commit To Buy Theravance Biopharma At $12.50, Earn 21.8% Annualized Using Options
2015-02-02,Theravance Biopharma, Inc. And Mylan Partner To Develop And Commercialize A Novel LAMA Compound, TD-4208, For COPD
,
,
,
,
2017-03-14,TRACON Pharmaceuticals Announces $21 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC
2017-03-06,TRACON Pharmaceuticals To Present At The 29th Annual Roth Conference
2017-02-28,TRACON Pharmaceuticals Reports Fourth Quarter And Year-End 2016 Financial Results And Provides Corporate Update
2017-02-21,TRACON To Report Fourth Quarter And Full Year 2016 Company Highlights And Financial Results On February 28, 2017
2017-02-16,TRACON Pharmaceuticals Announces First Patient Dosed In Phase 3 TAPPAS Trial Of TRC105 In Angiosarcoma
2017-02-09,TRACON Pharmaceuticals Announces Top-line Results From NCI-Sponsored Phase 2 Trial Of TRC105 In Recurrent Glioblastoma
2017-01-03,TRACON Pharmaceuticals Receives Special Protocol Assessment (SPA) Agreement From FDA For Phase 3 Clinical Trial Of TRC105 In Angiosarcoma
2016-11-29,TRACON Pharmaceuticals Announces Closing Of Public Offering And Full Exercise Of Option To Purchase Additional Shares
2016-11-23,TRACON Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2016-11-22,TRACON Pharmaceuticals To Host Key Opinion Leader Luncheon For Investors Focused On Angiosarcoma And Prostate Cancer On December 1 In New York City
2016-11-22,TRACON Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2016-11-13,TRACON Pharmaceuticals Presents Clinical And Preclinical Data From Models Of NASH And Liver Fibrosis At The 2016 AASLD Annual Meeting
2016-11-11,TRACON Pharmaceuticals Announces Presentation Of Updated Data From Phase 1b/2 Study Of TRC105 And Votrient® In Patients With Angiosarcoma
2016-11-08,TRACON Pharmaceuticals Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-11-07,TRACON Pharmaceuticals To Present At Upcoming Investment Conferences
2016-11-03,TRACON Pharmaceuticals Announces Clinical Data Presentation At Upcoming Connective Tissue Oncology Society (CTOS) 2016 Annual Meeting
2016-11-01,TRACON To Report Third Quarter 2016 Company Highlights And Financial Results On November 8, 2016
2016-10-20,TRACON Pharmaceuticals Reports Granting Of Inducement Awards
2016-10-09,TRACON Pharmaceuticals Presents Final Updated Phase 1b Results For TRC105 In Combination With Inlyta® In Renal Cell Carcinoma At The ESMO 2016 Congress
2016-10-03,TRACON Pharmaceuticals Announces Successful Meetings With FDA And EMA For TRC105 (carotuximab) In Angiosarcoma
2016-09-28,TRACON Pharmaceuticals Announces A Strategic Licensing Collaboration For Two Janssen Oncology Assets And A $5 Million Equity Investment From Johnson & Johnson Innovation - JJDC, Inc.
2016-08-31,TRACON Pharmaceuticals To Present At Upcoming Investment Conferences
2016-08-10,TRACON Pharmaceuticals Reports Second Quarter 2016 Financial Results And Provides Corporate Update
2016-08-03,TRACON To Report Second Quarter 2016 Company Highlights And Financial Results On August 10, 2016
2016-06-06,TRACON Pharmaceuticals Announces Positive Results From TRC105 And TRC102 Clinical Trials At American Society Of Clinical Oncology (ASCO) 2016 Annual Meeting
2016-05-31,TRACON Pharmaceuticals To Present At Upcoming Investment Conferences
2016-05-20,TRACON Pharmaceuticals Reports Granting Of Inducement Award
2016-05-18,TRACON Pharmaceuticals Initiates Dosing In Phase 1b/2 Study Of TRC105 In Patients With Hepatocellular Carcinoma
2016-05-16,TRACON Pharmaceuticals To Present At The UBS Global Healthcare Conference
2016-05-11,TRACON Pharmaceuticals Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-05-09,TRACON Pharmaceuticals Announces Initiation Of Dosing In A Phase 1/2 Neoadjuvant Study Of TRC105 In Patients With Breast Cancer
2016-05-04,TRACON To Report First Quarter 2016 Company Highlights And Financial Results On May 11, 2016
2016-05-04,TRACON Announces EMA Orphan Drug Designation For TRC105 In Soft Tissue Sarcoma
2016-04-21,TRACON Announces Clinical Data Presentations At Upcoming ASCO Annual Meeting
2016-04-11,TRACON Pharmaceuticals Announces TRC105 Clinical Data Presentation At Upcoming AACR Annual Meeting
2016-04-05,TRACON Pharmaceuticals To Present At The 15th Annual Needham Healthcare Conference
2016-03-28,Ratings Changes Today
2016-03-21,TRACON Pharmaceuticals Reports Updated Positive Data On Ongoing Complete Response In Choriocarcinoma Patient Treated With TRC105
2016-03-14,TRACON Pharmaceuticals Initiates Phase 1b Study Of TRC105 In Patients With Lung Cancer
2016-03-07,TRACON Pharmaceuticals Reports Granting Of Inducement Awards
2016-03-07,TRACON Pharmaceuticals To Present At The 28th Annual Roth Conference
2016-02-18,TRACON Pharmaceuticals Reports Fourth Quarter And Year-End 2015 Financial Results And Provides Corporate Update
2016-02-11,TRACON To Report Fourth Quarter And Full Year 2015 Company Highlights And Financial Results On February 18, 2016
2016-01-27,TRACON Pharmaceuticals Announces Initiation Of TRC102 Phase 2 Clinical Trial In Glioblastoma
2016-01-25,TRACON Announces FDA Orphan Drug Designation For TRC105 In Soft Tissue Sarcoma
2015-12-02,TRACON Pharmaceuticals To Present At The Oppenheimer 26th Annual Healthcare Conference
2015-11-11,TRACON Pharmaceuticals To Present At The Stifel 2015 Healthcare Conference
2015-11-06,TRACON Pharmaceuticals Presents Positive Updated Phase 1b Results For TRC105 In Combination With Inlyta® At The 2015 Kidney Cancer Association Meeting
2015-11-05,TRACON Pharmaceuticals Presents Positive Interim Results From TRC105 Trial In Sarcoma At The Connective Tissue Oncology Society (CTOS) 2015 Annual Meeting
2015-11-04,TRACON Pharmaceuticals To Host Investor Meeting Featuring Key Opinion Leaders On November 13 In New York City
2015-11-03,TRACON Pharmaceuticals Reports Third Quarter 2015 Results And Provides Corporate Update
2015-10-29,TRACON Pharmaceuticals Announces Clinical Data Presentations At Upcoming Medical Meetings
2015-10-27,TRACON To Report Third Quarter 2015 Company Highlights And Financial Results On November 3, 2015
2015-10-12,TRACON Pharmaceuticals Announces Initiation Of TRC102 Combination Phase 1b/2 Trial
2015-10-06,TRACON Pharmaceuticals Announces Appointment Of Ronald Shazer, M.D., M.B.A., As Chief Medical Officer
2015-09-18,Market News: Freeport-McMoRan, La Quinta, TRACON Pharmaceuticals
2015-09-18,TRACON Pharmaceuticals Reports Ongoing Complete Response In Choriocarcinoma Patient Treated With Company's TRC105 In Compassionate Use Phase 2 Clinical Trial Conducted At Dana-Farber Cancer Institute
2015-09-02,TRACON Pharmaceuticals To Present At Upcoming Investment Conferences
2015-08-05,TRACON Pharmaceuticals Reports Second Quarter 2015 Financial Results And Provides Corporate Update
2015-07-29,TRACON To Report Second Quarter 2015 Company Highlights And Financial Results On August 5, 2015
2015-07-01,TRACON Pharmaceuticals Announces IND Filing Of DE-122 (TRC105) For The Treatment Of Wet Age-Related Macular Degeneration By Santen Pharmaceutical
2015-06-18,UPDATE -- TRACON Pharmaceuticals To Present At The JMP Securities Life Science Conference
2015-06-17,TRACON Pharmaceuticals To Present At The JMP Securities Life Science Conference
2015-06-01,TRACON Pharmaceuticals Announces Positive Results Of TRC105 Clinical Trials In Sarcoma And Liver Cancer At The American Society Of Clinical Oncology (ASCO) 2015 Annual Meeting
2015-05-15,6 Stocks Spiking on Big Volume
2015-05-14,TRACON's TRC105 Receives FDA Fast Track Designation
2015-05-13,TRACON Announces Clinical Data Presentations At Upcoming ASCO Annual Meeting
2015-05-13,TRACON Pharmaceuticals Reports First Quarter 2015 Financial Results And Provides Corporate Update
2015-05-11,TRACON Pharmaceuticals To Present At The UBS Global Healthcare Conference
2015-05-06,TRACON To Report First Quarter 2015 Company Highlights And Financial Results On May 13, 2015
2015-04-13,TRACON Pharmaceuticals Announces Data Presentations At Upcoming AACR Annual Meeting
2015-04-08,TRACON Pharmaceuticals Expands License Agreement And Signs Research Agreement With Case Western Reserve University
2015-04-07,TRACON Pharmaceuticals To Present At The 14th Annual Needham Healthcare Conference
2015-03-10,TRACON Pharmaceuticals Reports 2014 Year-End Financial Results And Recent Corporate Highlights
2015-03-02,Market News: TRACON Pharmaceuticals, NXP Semiconductor, Omeros
2015-02-28,TRACON Pharmaceuticals Announces Positive Phase 1b Results For TRC105 In Combination With Inlyta(R) (axitinib) At The American Society Of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium
2015-02-27,TRACON Pharmaceuticals Appoints Stephen Worland To Its Board Of Directors
2015-02-24,Market News: Tesla Motors, TRACON Pharmaceuticals, Qorvo
2015-02-19,TRACON Pharmaceuticals Announces Upcoming Presentation Of Results From A Clinical Trial Of TRC105 In Patients With Renal Cell Carcinoma At The American Society Of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium
2015-01-30,IPO Roundup: Shake Shack Shares More Than Double Out of Gate
,
,
,
2017-03-21,Tenax Therapeutics Announces Year-End 2016 Financial Results And Provides Corporate Update
2017-03-15,Tenax Therapeutics To Discuss Year-End 2016 Financial Results And Provide Business Update
2017-02-02,These 5 Stocks Under $10 Could Light Up Soon
2017-01-31,Tenax Therapeutics Announces Top-Line Results From Phase 3 LEVO-CTS Trial In Cardiac Surgery
2016-11-18,Tenax Therapeutics Announces Completion Of Enrollment For Phase 3 LEVO-CTS Trial In Cardiac Surgery
2016-11-10,Tenax Therapeutics Announces Third Quarter 2016 Financial Results And Provides Corporate Update
2016-11-03,Tenax Therapeutics To Discuss Third Quarter 2016 Financial Results And Provide Business Update
2016-10-05,Tenax Therapeutics Provides Clinical Update For Lead Candidate Levosimendan
2016-08-11,Tenax Therapeutics Announces Second Quarter 2016 Financial Results And Provides Corporate Update
2016-08-03,Tenax Therapeutics To Discuss Second Quarter 2016 Financial Results And Provide Business Update
2016-05-19,Tenax Therapeutics Announces First Quarter 2016 Financial Results And Provides Corporate Update
2016-05-10, Tenax Therapeutics To Discuss First Quarter 2016 Financial Results And Provide Business Update
2016-03-16,Tenax Therapeutics Announces 2015 Transitional Report And Provides Corporate Update
2016-03-09,Tenax Therapeutics To Provide 2015 Transitional Report And Business Update
2016-03-01,Tenax Therapeutics To Present At Cowen And Company 36th Annual Health Care Conference
2016-02-04,Tenax Therapeutics To Present At Leerink Partners 5th Annual Global Healthcare Conference
2016-02-01,Tenax Therapeutics Provides Update of Phase 3 LEVO-CTS Trial for LCOS
2015-12-22,Tenax Therapeutics Highlights Completion Of Enrollment For LeoPARDS Trial By Imperial College London
2015-12-15,Tenax Therapeutics Announces Second Quarter Fiscal Year 2016 Financial Results
2015-12-08,Tenax Therapeutics To Provide Corporate Update And Discuss Second Quarter Fiscal Year 2016 Financial Results On December 15, 2015
2015-10-08,Tenax Therapeutics Provides Clinical Update For Lead Candidate Levosimendan
2015-09-22,Tenax Therapeutics To Present At Ladenburg Thalmann 2015 Healthcare Conference
2015-09-14,Tenax Therapeutics Announces First Quarter Fiscal Year 2016 Financial Results
2015-09-10,Tenax Therapeutics Partners With Sepsis Alliance To Raise Awareness Of Sepsis And Septic Shock
2015-09-08,Tenax Therapeutics To Provide Corporate Update And Discuss First Quarter Fiscal Year 2016 Financial Results On September 14, 2015
2015-08-18,Tenax Therapeutics Announces Nomination Of James Mitchum To Board Of Directors
2015-08-05,Tenax Therapeutics To Present At 2015 Wedbush PacGrow Healthcare Conference
2015-07-16,Tenax Therapeutics Announces Fourth Quarter And Fiscal Year 2015 Financial Results
2015-07-09,Tenax Therapeutics To Provide Corporate Update And Discuss Fourth Quarter And Fiscal Year 2015 Financial Results On July 16, 2015
2015-07-01,Tenax Therapeutics Spotlights Academic Publication On Levosimendan In Cardiac Surgery
2015-06-16,Tenax Therapeutics Highlights New Scientific Publication Regarding The Potential Mortality Benefits Of Levosimendan In Septic Shock Patients
2015-04-15,Tenax Therapeutics Provides Clinical And Corporate Update
2015-03-31,Tenax Therapeutics Announces Analyst Day And Webcast On April 13, 2015
2015-03-18,Tenax Therapeutics Announces Third Quarter Fiscal Year 2015 Financial Results
2015-03-11,Tenax Therapeutics To Provide Corporate Update And Discuss Third Quarter Fiscal Year 2015 Financial Results On March 18, 2015
2015-03-05,Tenax Therapeutics Highlights Recent Scientific Publications On Levosimendan
2015-02-23,Tenax Therapeutics To Present At Cowen & Company 35th Annual Health Care Conference
2015-02-20,Tenax Therapeutics Issues Employment Inducement Award With Appointment Of Paula Bokesch, M.D., As Chief Medical Officer
2015-02-03,Tenax Therapeutics Announces Appointment Of Paula Bokesch, M.D., As Chief Medical Officer
2014-12-17,Tenax Therapeutics Announces Second Quarter Fiscal Year 2015 Financial Results
2014-12-10,Tenax Therapeutics To Provide Corporate Update And Discuss Second Quarter Fiscal Year 2015 Financial Results On December 17, 2014
2014-11-25,Small Cap IR Issues Tenax Therapeutics Analyst Report: Large Validated Market Opportunity Inspires $12 Price Target
2014-09-24,Tenax Therapeutics Announces First Quarter Fiscal Year 2015 Financial Results
2014-09-22,Tenax Therapeutics Announces First Patients Enrolled In Phase 3 LEVO-CTS Clinical Trial Of Levosimendan
2014-09-19,Tenax Therapeutics To Provide Corporate Update And Discuss First Quarter Fiscal Year 2015 Financial Results On September 24, 2014
,
,
,
,
2017-03-20,TG Therapeutics, Inc. Announces Preclinical Data Presentation At The 2017 American Association For Cancer Research (AACR) Annual Meeting
2017-03-17,TG Therapeutics, Inc. To Present At The 27th Annual Oppenheimer Healthcare Conference
2017-03-13,TG Therapeutics, Inc. To Present At The 29th Annual ROTH Conference
2017-03-10,Biotech Stock Mailbag: Puma's Rebound Explained, TG Therapeutics Approval Debate, Aurinia Next Steps
2017-03-10,TG Therapeutics, Inc. Announces Fourth Quarter And Year-End 2016 Financial Results And Business Update
2017-03-09,TG Therapeutics, Inc. To Host Conference Call On Fourth Quarter And Year-End 2016 Financial Results And Business Update
2017-03-09,TG Therapeutics, Inc. Announces Pricing Of $50 Million Public Offering Of Common Stock
2017-03-08,TG Therapeutics Announces Proposed Public Offering Of Common Stock
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-08,Could These 9 Drugs Gain FDA Approval in the Age of Trump?
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-08,Treehouse Foods, Arconic, Kinder Morgan, Chesapeake Energy: 'Mad Money' Lightning Round
2017-03-08,Trump's Tweet Creates Opportunity in Pharma: Cramer's 'Mad Money' Recap (Tuesday 2/7/17)
2017-03-07,DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Investors It Has Filed A Class Action Lawsuit Against TG Therapeutics, Inc. And Announces A Lead Plaintiff Deadline Of March 7, 2017 - TGTX
2017-03-06,How to Trade Monday's Most Active Stocks - Snap, GM, TG Therapeutics and More
2017-03-06,Notable Monday Option Activity: TGTX, OMED, KMB
2017-03-06,TG Therapeutics Announces Positive Topline Data From Phase 3 GENUINE Study Of TG-1101 In Combination With Ibrutinib In Patients With High Risk Chronic Lymphocytic Leukemia (CLL)
2017-03-03,TG Therapeutics, Inc. Announces Data Presentation At The Upcoming American Academy Of Neurology 69th Annual Meeting
2017-02-27,DEADLINE ALERT: Brower Piven Reminds Investors Of The March 7, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess Of $100,000 From Investment In TG Therapeutics, Inc. To Contact The Firm
2017-02-21,INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed A Class Action Lawsuit Against TG Therapeutics, Inc. And Announces A Lead Plaintiff Deadline Of March 7, 2017
2017-02-21,TG Therapeutics, Inc. Announces Publication of Clinical Data From The Phase 1/2 Trial Of TG-1101 (ublituximab) Monotherapy In The British Journal Of Haematology
2017-02-16,URGENT: Monteverde & Associates PC Encourages TG Therapeutics, Inc. Shareholders With Losses To Contact The Firm Immediately - TGTX
2017-02-15,TGTX SHAREHOLDER REMINDER: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving TG Therapeutics, Inc. And A Lead Plaintiff Deadline Of March 7, 2017
2017-02-14,Bragar Eagel & Squire, P.C. Reminds Investors That A Class Action Lawsuit Has Been Filed Against TG Therapeutics, Inc. (TGTX) And Encourages Investors With Losses To Contact The Firm
2017-02-10,TGTX UPCOMING DEADLINE: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving TG Therapeutics, Inc. And A Lead Plaintiff Deadline Of March 7, 2017
2017-02-09,TG Therapeutics, Inc. To Present At The 2017 BIO CEO & Investor Conference
2017-02-06,Bragar Eagel & Squire, P.C. Announces That A Class Action Lawsuit Has Been Filed Against TG Therapeutics, Inc. (TGTX) And Encourages Investors To Contact The Firm
2017-02-06,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed A Class Action Lawsuit Against TG Therapeutics, Inc. And Announces A Lead Plaintiff Deadline Of March 7, 2017
2017-02-03,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In TG Therapeutics, Inc. Of Class Action Lawsuit And Upcoming Deadline - TGTX
2017-02-01,TGTX SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving TG Therapeutics, Inc. And A Lead Plaintiff Deadline Of March 7, 2017
2017-01-30,SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In TG Therapeutics, Inc. To Contact The Firm Before Lead Plaintiff Deadline
2017-01-24,TG Therapeutics Enters Oversold Territory (TGTX)
2017-01-24,TG Therapeutics Announces Orphan Drug Designation For The Combination Of TG-1101 And TGR-1202 For The Treatment Of Diffuse Large B-cell Lymphoma
2017-01-17,INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In TG Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2017-01-12,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against TG Therapeutics, Inc. (TGTX) And Lead Plaintiff Deadline: March 13, 2017
2017-01-11,TG Therapeutics Announces Completion Of Enrollment And B-cell Depletion Data From Part 1 Of Ongoing Phase 2 Multiple Sclerosis Study
2017-01-09,TG Therapeutics Announces Orphan Drug Designation For The Combination Of TG-1101 And TGR-1202 For Treatment Of Chronic Lymphocytic Leukemia
2017-01-09,TG Therapeutics, Inc. To Present At The 35th Annual J.P. Morgan Healthcare Conference
2017-01-04,TG Therapeutics, Inc. Announces Investigator Initiated Trial At The University Of Nebraska Medical Center To Study TGR-1202 In Combination With Ibrutinib In Patients With Relapsed Or Refractory Diffuse Large B-cell Lymphoma
2016-12-20,First Week of August 2017 Options Trading For TG Therapeutics (TGTX)
2016-12-16,TG Therapeutics, Inc. Announces Publication Of Clinical Data From The Phase 2 Trial Of TG-1101 (ublituximab) In Combination With Ibrutinib In The British Journal Of Haematology
2016-12-06,TG Therapeutics, Inc. Announces Double & Triple Combination Therapy Data Presentations At The 58th American Society Of Hematology Annual Meeting
2016-12-06,TG Therapeutics, Inc. Announces That The GENUINE Phase 3 Study Has Reached Target Enrollment
2016-12-05,TG Therapeutics, Inc. Announces Oral Data Presentation For TGR-1202 In Combination With Ibrutinib In Patients With Relapsed Or Refractory CLL Or MCL At The 58th American Society Of Hematology Annual Meeting
2016-12-05,TG Therapeutics, Inc. Announces Preclinical Data Presentations For TGR-1202 At The 58th American Society Of Hematology Annual Meeting
2016-12-02,TG Therapeutics, Inc. Recaps Schedule Of Data Presentations At The 58th American Society Of Hematology Annual Meeting
2016-11-23,First Week of January 2017 Options Trading For TG Therapeutics (TGTX)
2016-11-22,TG Therapeutics Announces Positive DSMB Recommendation For Continuation Of The UNITY-CLL Phase 3 Trial
2016-11-07,TG Therapeutics, Inc. Provides Business Update And Reports Third Quarter 2016 Financial Results
2016-11-03,TG Therapeutics, Inc. To Host Conference Call On Third Quarter 2016 Financial Results And Business Update
2016-11-03,TG Therapeutics, Inc. Announces Data Presentations At The Upcoming 58th American Society Of Hematology Annual Meeting
2016-10-31,Lifshitz & Miller Law Firm Announces Investigation Of Electronics For Imaging, Inc., Ferrellgas Partners LP, Fusion Pharm, Inc., Humana Inc., KemPharm, Inc., National Beverage Corp., Puma Biotechnology, Inc., And TG Therapeutics, Inc.
2016-10-31,Interesting TGTX Put And Call Options For December 16th
2016-10-27,TG Therapeutics, Inc. Announces Publication in Blood Describing A Novel Complimentary Mechanism Of The PI3K-delta Inhibitor, TGR-1202
2016-10-20,TG Therapeutics, Inc. Announces The Launch Of The Phase 1/2 Study Of TGR-1202 And Carfilzomib In Patients With Relapsed Or Refractory Lymphoma
2016-10-19,IMPORTANT INVESTOR ALERT: Lundin Law PC Announces An Investigation Of TG Therapeutics, Inc. And Advises Investors With Losses To Contact The Firm
2016-10-19,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of TG Therapeutics, Inc. (TGTX)
2016-10-14,INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of TG Therapeutics, Inc. And Advises Investors With Losses To Contact The Firm
2016-10-14,INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Securities Fraud Violations By TG Therapeutics, Inc. And Certain Officers And Directors
2016-10-13,TG Therapeutics (TGTX) Stock Slumps on Trial Amendment
2016-10-13,Pardon Me, but I Have a Few Things to Say... Seattle Genetics, Biomarin, Sarepta, TG Therapeutics
2016-10-13,TG Therapeutics, Inc. Amends The GENUINE Phase 3 Clinical Trial To Accelerate Study Completion By Revising Primary Endpoint To Overall Response Rate
2016-10-12,TG Therapeutics, Inc. To Host Conference Call To Provide An Update On The GENUINE Phase 3 Trial
2016-10-03,Commit To Buy TG Therapeutics At $7.50, Earn 29.9% Annualized Using Options
2016-09-23,TG Therapeutics, Inc. To Present At The Ladenburg Thalmann 2016 Healthcare Conference
2016-09-16,TG Therapeutics, Inc. Announces Presentation Of Data From A Phase Ib Clinical Trial Of TG-1101 In Patients With Neuromyelitis Optica (NMO) At The 32nd Congress Of The European Committee For Treatment And Research In Multiple Sclerosis
2016-08-31,TG Therapeutics, Inc. Announces Clinical Data Presentation At The Upcoming 32nd Congress Of The European Committee For Treatment And Research In Multiple Sclerosis
2016-08-30,2 Biotechs to Watch Ahead of the Election
2016-08-26,TG Therapeutics Announces Orphan Drug Designation For TG-1101 For The Treatment Of Neuromyelitis Optica And Neuromyelitis Optica Spectrum Disorder
2016-08-24,TG Therapeutics Announces Orphan Drug Designation For TGR-1202 For Treatment Of Chronic Lymphocytic Leukemia
2016-08-12,TG Therapeutics Looks Like a Healthy Play
2016-08-08,TG Therapeutics, Inc. Announces Second Quarter 2016 Financial Results And Business Update
2016-08-04,TG Therapeutics, Inc. To Host Conference Call On Second Quarter 2016 Financial Results And Business Update
2016-07-19,Relative Strength Alert For TG Therapeutics
2016-06-22,First Week of TGTX February 2017 Options Trading
2016-06-10,TG Therapeutics, Inc. Announces Data From TGR-1202 In Combination With Ibrutinib As Well As Recaps Long-Term Safety And Efficacy Data Of TGR-1202 In CLL And NHL At The 21st European Hematology Association Annual Congress
2016-06-09,TG Therapeutics, Inc. To Present At The Jefferies 2016 Healthcare Conference
2016-06-07,Weak On High Volume: TG Therapeutics (TGTX)
2016-06-07,5 Small-Cap Favorites Are Moving on Up
2016-06-07,TG Therapeutics, Inc. Announces First Patient Enrolled In The Registration-Directed UNITY-DLBCL Phase 2b Trial
2016-06-06,TG Therapeutics, Inc. Announces Long-Term Follow-up Of TGR-1202 Demonstrates A Differentiated Safety Profile And High Response Rates In CLL And NHL In Data Presented At The 52nd Annual Meeting Of The American Society Of Clinical Oncology
2016-06-02,TG Therapeutics, Inc. Recaps Schedule Of Clinical Data Presentations At The 52nd Annual Meeting Of The American Society Of Clinical Oncology
2016-05-27,TG Therapeutics Enters Into A Global Collaboration To Develop And Commercialize Novel BET Inhibitors Developed By Jubilant Biosys For The Treatment Of Hematological Malignancies
2016-05-20,TG Therapeutics, Inc. Announces Clinical Data Presentations At The Upcoming 21st European Hematology Association Annual Congress
2016-05-18,TG Therapeutics, Inc. Announces Clinical Data Presentation At The Upcoming 52nd Annual Meeting Of The American Society Of Clinical Oncology
2016-05-12,RSI Alert: TG Therapeutics (TGTX) Now Oversold
2016-05-12,Profiting on Small-Cap Biotech Earnings
2016-05-10,TG Therapeutics, Inc. Announces First Quarter 2016 Financial Results And Business Update
2016-05-09,TG Therapeutics, Inc. To Host Conference Call On First Quarter 2016 Financial Results And Business Update
2016-05-03,TG Therapeutics, Inc. Launches First Clinical Trial In Multiple Sclerosis (MS) For TG-1101 (Ublituximab)
2016-04-27,'Mad Money' Lightning Round: Get Ready to Buy Palo Alto Networks
2016-04-26,Jim Cramer's 'Mad Money' Recap: Stay Positive, Stay Focused, Ignore Apple
2016-04-22,Commit To Purchase TG Therapeutics At $7.50, Earn 16.2% Annualized Using Options
2016-04-21,Insider Trading Alert - BLOX, ILMN And TGTX Traded By Insiders
2016-04-18,TG Therapeutics, Inc. Announces Pre-Clinical Data Presentation On TGR-1202 Demonstrating Differentiated Effects On T-Cells
2016-04-13,TG Therapeutics, Inc. Announces Issuance Of Composition Of Matter Patent For TG-1101 In The United States
2016-03-30,7 Stocks Under $10 to Trade for Breakout Gains
2016-03-17,TG Therapeutics, Inc. Announces Pre-Clinical Data Presentation On TGR-1202 At The 2016 American Association For Cancer Research (AACR) Annual Meeting
2016-03-11,TG Therapeutics, Inc. To Present At The 28th Annual ROTH Conference
2016-03-07,TG Therapeutics, Inc. Announces Fourth Quarter And Year-End 2015 Financial Results And Business Update
2016-03-07,TG Therapeutics, Inc. To Present At Upcoming Investment Conferences
2016-03-04,TG Therapeutics, Inc. To Host Conference Call On Fourth Quarter And Year-End 2015 Financial Results And Business Update
2016-02-23,TG Therapeutics, Inc. Announces Issuance Of Composition Of Matter Patent For TGR-1202 In The United States
2016-02-03,TG Therapeutics, Inc. To Present At The 18th Annual BIO CEO & Investor Conference
2016-01-29,8 Stocks Under $10 Making Big Moves Higher
2016-01-26,TG Therapeutics (TGTX) Highlighted As Weak On High Volume
2016-01-22,First Week of TGTX March 18th Options Trading
2016-01-19,TG Therapeutics, Inc. Sets Corporate Goals And Objectives For 2016
2016-01-12,TG Therapeutics (TGTX) Is Strong On High Volume Today
2016-01-11,TG Therapeutics, Inc. To Present At The 34th Annual J.P. Morgan Healthcare Conference
2016-01-07,TG Therapeutics is Now Oversold (TGTX)
2015-12-07,TG Therapeutics, Inc. Announces Oral Presentation Of Novel Pre-Clinical Combinations With TGR-1202 By Investigators At Columbia University At The 57th American Society Of Hematology Annual Meeting
2015-12-07,TG Therapeutics, Inc. Announces Data Presentations For TGR-1202 And TG-1101 In Combination With Ibrutinib At The 57th American Society Of Hematology Annual Meeting
2015-12-06,TG Therapeutics, Inc. Announces Data Presentations At The 57th American Society Of Hematology Annual Meeting From Ongoing Clinical Studies In Patients With Non-Hodgkins Lymphoma (NHL) And Chronic Lymphocytic Leukemia (CLL)
2015-12-04,TG Therapeutics, Inc. Recaps Schedule Of Data Presentations At The 57th American Society Of Hematology Annual Meeting
2015-12-01,Trade-Ideas: TG Therapeutics (TGTX) Is Today's Strong On High Relative Volume Stock
2015-11-09,TG Therapeutics, Inc. Announces Third Quarter 2015 Financial Results And Business Update
2015-11-05,TG Therapeutics, Inc. Announces Data Presentations At The Upcoming 57th American Society Of Hematology Annual Meeting
2015-11-04,TG Therapeutics, Inc. To Host Conference Call On Third Quarter 2015 Financial Results And Business Update
2015-10-06,Jim Cramer's Top Takeaways: TG Therapeutics, Mallinckrodt, General Electric
2015-10-05,Jim Cramer's 'Mad Money' Recap: Here's Where the Bear Tide Is Turning
2015-10-05,4 Unusual-Volume Stocks to Trade for Breakouts
2015-09-25,TG Therapeutics, Inc. To Present At The Ladenburg Thalmann 2015 Healthcare Conference
2015-09-17,TG Therapeutics (TGTX) Is Strong On High Volume Today
2015-09-17,TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement With The FDA For The First Phase 3 Clinical Trial Of Its Proprietary Combination Regimen Of TG-1101 (ublituximab) In Combination With TGR-1202 For Patients With Chronic Lymphocytic Leukemia (CLL)
2015-09-10,Strong On High Relative Volume: TG Therapeutics (TGTX)
2015-09-09,TG Therapeutics, Inc. Launches Phase 1/2 "Triple-Therapy" Study With TGR-1202 + TG-1101 + The PD-1 Checkpoint Inhibitor Pembrolizumab In Patients With Advanced Chronic Lymphocytic Leukemia (CLL) At The University Of Pennsylvania's Abramson Cancer Center
2015-09-08,TG Therapeutics, Inc. To Participate In Upcoming Investment Conferences In September
2015-08-28,First Week Of TGTX October 16th Options Trading
2015-08-21,Relative Strength Alert For TG Therapeutics
2015-08-10,TG Therapeutics, Inc. Announces Second Quarter 2015 Financial Results And Business Update
2015-08-05,TG Therapeutics, Inc. To Host Conference Call On Second Quarter 2015 Financial Results And Business Update
2015-07-03,Insider Trading Alert - PRAA, KIRK And TGTX Traded By Insiders
2015-06-23,Interesting TGTX Put And Call Options For February 2016
2015-06-22,TG Therapeutics (TGTX) Is Strong On High Volume Today
2015-06-18,Updated Results From Phase 2 Clinical Trial Of TG-1101 (Ublituximab) In Combination With Ibrutinib Confirms Robust Clinical Activity With A Favorable Safety Profile In Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL)
2015-06-11,TG Therapeutics To Present Clinical Data On TG-1101 And TGR-1202 At The 20th Congress Of The European Hematology Association And The 13th International Congress On Malignant Lymphoma
2015-06-10,'Mad Money' Lightning Round: Wells Fargo Is World's Best Financial
2015-06-09,Jim Cramer's 'Mad Money' Recap: Why You Need Common Sense in This Market
2015-06-02,TG Therapeutics, Inc. To Present At The Jefferies 2015 Healthcare Conference
2015-06-01,TG Therapeutics Announces The Triple Combination Of TG-1101, TGR-1202 And Ibrutinib Is Safe And Highly Active In Patients With Advanced B-Cell Malignancies
2015-05-31,TG Therapeutics, Inc. Announces Presentations Of Its Proprietary Combination Of TG-1101 Plus TGR-1202 As Well As TGR-1202 As A Single Agent In Ongoing Phase I/Ib Dose Escalation Clinical Studies
2015-05-29,TG Therapeutics, Inc. Recaps Schedule Of Clinical Data Presentations At The 51st Annual Meeting Of The American Society Of Clinical Oncology
2015-05-13,TG Therapeutics, Inc. Announces Clinical Data Presentations At The Upcoming 51st Annual Meeting Of The American Society Of Clinical Oncology
2015-05-11,The US Stock Market's Mood Shift
2015-05-05,TG Therapeutics Enters Oversold Territory (TGTX)
2015-05-04,TG Therapeutics, Inc. Announces First Quarter 2015 Financial Results And Business Update
2015-05-02,'Mad Money' Lightning Round: Buy Blackstone and MasterCard
2015-05-01,Jim Cramer's 'Mad Money' Recap: Warren Buffett Is Part of Next Week's Game Plan
2015-05-01,TG Therapeutics, Inc. To Present At The Deutsche Bank 40th Annual Health Care Conference
2015-04-30,TG Therapeutics, Inc. To Host Conference Call On First Quarter 2015 Financial Results And Business Update
2015-04-28,First Week Of TGTX June 19th Options Trading
2015-04-20,TG Therapeutics, Inc. Presents Pre-clinical Data On IRAK4 Compounds At The American Association For Cancer Research (AACR) Annual Meeting
2015-04-14,'Mad Money' Lightning Round: I Like Phillips 66, Don't Sell It
2015-04-13,Jim Cramer's 'Mad Money' Recap: Don't Leave Gains on the Table
2015-03-25,First Week Of November 20th Options Trading For TG Therapeutics (TGTX)
2015-03-23,Today's Weak On High Volume Stock: TG Therapeutics (TGTX)
2015-03-20,TG Therapeutics (TGTX) Showing Signs Of Perilous Reversal Today
2015-03-18,'Mad Money' Lightning Round: I Don't Like Caterpillar, Buy TG Therapeutics
2015-03-17,Jim Cramer's 'Mad Money' Recap: This Maddening Market Can't Make Up Its Mind
2015-03-13,Trade-Ideas: TG Therapeutics (TGTX) Is Today's Strong On High Relative Volume Stock
2015-03-11,TG Therapeutics, Inc. Announces Fourth Quarter And Year-End 2014 Financial Results And Business Update
2015-03-11,Short Interest In TG Therapeutics Moves 16.7% Lower
2015-03-10,TG Therapeutics, Inc. To Host Conference Call On Fourth Quarter And Year-End 2014 Financial Results And Business Update
2015-03-06,TG Therapeutics, Inc. To Present At The 27th Annual ROTH Conference
2015-03-04,TG Therapeutics Enters Into A Global Collaboration With Checkpoint Therapeutics To Develop And Commercialize Novel Immuno-Oncology Targeted Antibodies
2015-03-02,TG Therapeutics, Inc. To Present At The Cowen And Company 35th Annual Health Care Conference
2015-02-27,FireEye, 3 More Are Hot Momentum Stocks Despite Overheated Market
2015-02-06,'Mad Money' Lightning Round: Buy, Buy, Buy GlaxoSmithKline and Box
2015-02-05,Jim Cramer's 'Mad Money' Recap: Cheap Stocks Aren't Bad Stocks
2015-02-04,TG Therapeutics, Inc. To Present At The 17th Annual BIO CEO & Investor Conference
2015-01-24,McDonald's and UPS Deserve Better; Bob Dylan Was Right: Jim Cramer's Best Blogs
2015-01-23,First Week Of March 20th Options Trading For TG Therapeutics (TGTX)
2015-01-22,Jim Cramer's Top Stock Picks: NFLX FOLD TGTX
2015-01-15,TG Therapeutics, Inc. To Provide An Update On Its Clinical Programs And Corporate Goals For 2015 At The 33rd Annual J.P. Morgan Healthcare Conference
2015-01-08,TG Therapeutics, Inc. To Present At The 33rd Annual J.P. Morgan Healthcare Conference
2015-01-06,Jim Cramer's 'Mad Money' Recap: Knowing Where to Look for Bargains
2015-01-06,Interesting TGTX Put And Call Options For August 21st
2014-12-29,Commit To Buy TG Therapeutics At $15, Earn 31.1% Annualized Using Options
2014-12-17,TG Therapeutics, Inc. Announces Appointment Of Kenneth Hoberman To Board Of Directors
,
,
,
,
,
,
2017-03-17,Threshold Pharmaceuticals And Molecular Templates Agree To Combine
2017-01-26,Research Reports Coverage On Biotech Stocks -- OncoGenex Pharma, INSYS Therapeutics, Threshold Pharma, And AmpliPhi Biosciences
2017-01-13,Hurry! These 5 Stocks Are About to Break Out Explosively
2016-12-19,Threshold Pharmaceuticals And National Cancer Institute To Collaborate On Drug Candidate TH-3424
2016-11-15,Threshold Pharmaceuticals Announces Presentation And Webcast At The Stifel Healthcare Conference 2016
2016-11-07,Threshold Pharmaceuticals Reports Third Quarter Financial Results
2016-10-25,Caris Life Sciences And Threshold Pharmaceuticals Collaborate To Utilize Caris' ADAPT Biotargeting System In The Development Program For Evofosfamide
2016-09-29,Threshold Pharmaceuticals Announces Interim Results From Tarloxotinib Program And Its Plans To Focus On Evofosfamide And Earlier-Stage Opportunities
2016-08-22,One Reason Why Threshold Pharma (THLD) Stock Is Jumping Today
2016-08-18,5 Breakout Stocks Under $10 Set to Soar
2016-08-01,Threshold Pharmaceuticals Reports Second Quarter Financial Results
2016-06-06,Threshold Pharmaceuticals Highlights Multiple Presentations At The 2016 ASCO Annual Meeting
2016-06-01,Threshold Pharmaceuticals To Present At Jefferies 2016 Healthcare Conference
2016-05-10,CytRx Bear Thesis Explained: Why Sarcoma Drug Trial Will Fail
2016-05-05,Threshold Pharmaceuticals Reports First Quarter Financial Results
2016-03-21,Threshold Pharmaceuticals Appoints Stew Kroll As Chief Operating Officer
2016-03-10,Threshold Pharmaceuticals Provides Corporate Update And Reports Fourth Quarter And Year-End 2015 Financial Results
2016-03-01,Threshold Pharmaceuticals Announces Presentation And Webcast At The Cowen And Company 36th Annual Health Care Conference
2015-12-28,Short Interest Moves 50% Lower For THLD
2015-12-08,2 'Rules of the Road' for Biotech Investing
2015-12-04,Why Relypsa Is a New 'Best Idea'
2015-12-03,Threshold Pharmaceuticals (THLD) Weak On High Volume
2015-12-02,Biotech Stock Mailbag: Anavex, Northwest Bio, Threshold Therapeutics
2015-11-24,First Week of THLD January 2016 Options Trading
2015-09-21,Threshold Pharmaceuticals (THLD) Is Weak On High Volume Today
2015-09-12,My Wall Street Fantasy Football League
2015-09-08,Strong On High Volume: Threshold Pharmaceuticals (THLD)
2015-07-21,First Week Of THLD March 2016 Options Trading
2015-05-12,Threshold Pharmaceuticals (THLD) Stock Soars on FDA Fast Track Designation
2015-03-20,Take Aim at Threshold Pharmaceuticals
2015-03-11,Threshold Pharmaceuticals Stock Sees Short Interest Drop 21.8%
2015-01-29,3 Biotech Stocks Under $10 in Breakout Territory: TrovaGene and More
2014-08-22,Biotech Stock Mailbag: Threshold, Galena, CytRx
2014-08-11,5 Stocks Ready for Breakouts
2014-08-01,4 Biotech Stocks Under $10 to Trade for Breakouts
2014-06-11,Interesting THLD Call Options For July 19th
2014-03-27,First Week Of THLD May 17th Options Trading
2014-01-23,First Week Of September 20th Options Trading For Threshold Pharmaceuticals (THLD)
2014-01-17,2 Biotech Stocks Under $10 to Watch
2014-01-13,Top Insider Trades: LOV THLD NHF MBRG
2014-01-06,First Week of February 22nd Options Trading For Threshold Pharmaceuticals (THLD)
2013-10-14,2 Small Cap Biotechs to Bet On
2013-10-09,Interesting THLD Call For November 16th
2013-09-27,Commit To Buy Threshold Pharmaceuticals At $2.50, Earn 8%
2013-08-16,Threshold Pharmaceuticals Enters Oversold Territory (THLD)
2013-07-17,Top Insider Trades: THLD FUND OPK FSFR
2013-05-24,Commit To Buy Threshold Pharmaceuticals At $2.50, Earn 16%
2013-05-15,10 ASCO '13 Abstracts You Can Read Right Now
2013-04-03,SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Directors Of Threshold Pharmaceuticals Inc.
2013-03-01,5 Stocks Poised for Breakouts
2013-02-20,4 Biotech Stocks Under $10 Moving Higher
2013-02-12,3 Biotech Stocks Under $10 Moving Higher
2013-01-25,Stocks Continue to Climb as Companies Exceed Expectations
2013-01-25,Biotech Stock Mailbag: Keryx, Sangamo, Threshold and Amarin
2013-01-22,Celgene's Abraxane: Two Month Survival Boost In Pancreatic Cancer Trial
2013-01-08,4 Biotech Stocks Spiking on Unusual Volume
2012-11-27,10 Best-Performing Biopharma Stocks of 2012 and Their 2013 Outlook
2012-11-26,Nate Sadeghi's 2012 Biotech Stock Report Card
2012-11-12,Celgene: Abraxane Boosts Pancreatic Cancer Survival
2012-10-25,Stocks Under $5: Blossoming Biotech Play
2012-10-15,Making The Call: Celgene's Abraxane Will Work in Pancreatic Cancer
2012-10-01,Threshold's Pancreatic Cancer Drug May be Obsolete Before Launch
2012-10-01,Threshold Pharma Seeks to Erase Doubts About Pancreatic Cancer Drug
2012-10-01,Celgene's Abraxane Is Talk of European Cancer Confab
2012-09-25,Celgene CVR: Upside Into Abraxane Pancreatic Cancer Trial Data
2012-09-17,Nasdaq Stocks Posting Largest Percentage Decreases
2012-09-17,Nasdaq Stocks Posting Largest Percentage Decreases
2012-09-17,Threshold's Pancreatic Cancer Drug Boosts Survival -- With an Asterisk
2012-09-14,Biotech Stock Mailbag: Navidea, Celsion, Raptor and Threshold
2012-07-18,Insiders Trading FOLD, THLD, EMMS, MSM
2012-07-16,Cramer's 'Mad Money' Recap: Things Are Better Than You Think
2012-05-30,Threshold Pharmaceuticals Inc. (THLD): Today's Featured Drugs Winner
2012-04-26,Hitting the Ceiling
2012-04-13,5 Stocks Under $10 Poised for Gains
2012-04-05,Biotech Stock Mailbag: Ampio, Cel-Sci and Ziopharm
2012-03-29,3 Stocks Under $10 Moving Higher
2012-03-27,Energy Stocks Look Heavy
2012-03-19,'Mad Money Lightning Round: Freeport-McMoRan Will Surprise
2012-02-27,Clovis Oncology: Like the Story, Not the Stock
2012-02-24,Insiders Trading GHDX, THLD, RVBD
2012-02-23,'Mad Money Lightning Round': Go for American Capital Agency
2012-02-21,Threshold Drug Delays Pancreatic Cancer
2012-02-03,5 Stocks Under $10 Poised for Big Upside
2011-12-23,Biotech Stock Mailbag: Most Important Events for 2012
2011-08-04,Threshold Pharmaceuticals Reports Second Quarter 2011 Financial And Operational Results
2011-07-25,Threshold Pharmaceuticals Announces Initiation Of Clinical Trial Evaluating TH-302 In Combination With Bevacizumab At University Of Texas At San Antonio
2011-07-12,More Hot Biotech Trades for Second Half 2011
2011-07-06,Threshold Pharmaceuticals Announces National Comprehensive Cancer Network (NCCN) Grant For Phase 1 Trial Of TH-302 In Combination With Pazopanib
2011-06-29,Threshold Pharmaceuticals Initiates Clinical Trial Evaluating TH-302 In Combination With Sunitinib
2011-06-22,Threshold Pharmaceuticals To Present At OneMedForum Conference
2011-06-21,Threshold Pharmaceuticals Announces Completion Of Patient Recruitment For Phase 2 TH-302 Pancreatic Cancer Study
2011-03-24,Threshold Pharmaceuticals Reports Fourth Quarter And Year End 2010 Financial Results
2011-03-17,Threshold Pharmaceuticals Completes $30 Million Registered Direct Offering
2011-03-11,Threshold Pharmaceuticals Announces Registered Direct Offering Of $30 Million
2011-02-16,Dean Foods, La-Z Boy: Small-Cap Winners
2011-02-16,Threshold Pharmaceuticals Announces Agreement With The FDA On A Special Protocol Assessment For Planned Phase 3 TH-302 Combination Trial In Advanced Soft Tissue Sarcoma
2011-01-24,Threshold Pharmaceuticals' TH-302 Continues To Demonstrate Promising Activity In Pancreatic Cancer Phase 1/2 Clinical Trial
2010-12-22,Threshold Pharmaceuticals Announces Promising Early Phase 1 Clinical Trial Results In Patients With Advanced Leukemias
2010-11-18,Follow-up Data From Threshold Pharmaceuticals' Phase 1/2 Clinical Trials Of TH-302 Demonstrate Broad Activity In All Combinations Against Multiple Tumor Types
2010-11-12,Threshold Pharmaceuticals Presents Promising Data From A Phase 1/2 Clinical Trial Of TH-302 At International Sarcoma Meeting
2010-11-09,Threshold Pharmaceuticals Announces Additional Medical And Investor Conference Presentations
2010-11-04,Threshold Pharmaceuticals Reports Third Quarter 2010 Financial And Operational Results
2010-11-03,Threshold Pharmaceuticals Awarded $488,958 In Grants Under Qualifying Therapeutic Discovery Project Program
2010-10-12,Threshold Pharmaceuticals Presents Follow-Up Data From A Phase 1/2 Clinical Trial Of TH-302 In Solid Tumors
2010-09-08,Threshold To Present At Rodman & Renshaw Healthcare Conference
2010-08-05,Threshold Pharmaceuticals Reports Second Quarter 2010 Financial And Operational Results
2010-07-13,MBIA, L-1 Identity: Volume Movers
2010-07-12,Threshold Pharmaceuticals Presents Preclinical Results In Two Scientific Presentations At AACR Translational Cancer Medicine Meeting
2010-06-30,Threshold Pharmaceuticals Initiates A Randomized, Controlled, Phase 2 Clinical Trial Evaluating TH-302 In Patients With Advanced Pancreatic Cancer
2010-06-29,Threshold Pharmaceuticals Initiates A Clinical Trial Evaluating TH-302 In Patients With Advanced Leukemias
2010-06-07,Threshold Pharmaceuticals Presents Promising Clinical Trial Results Demonstrating Broad Anti-Tumor Activity
2010-06-03,Threshold Pharmaceuticals Announces A Presentation At The 2010 American Society Of Clinical Oncology (ASCO) Annual Meeting
2010-05-12,Threshold Pharmaceuticals Appoints Dr. David R. Parkinson To Board Of Directors
2010-05-06,Threshold Announces New Vice President Of Corporate Development
2010-01-26,Dynavax, Matrixx: Early Volume Plays
2009-11-06,Threshold Pharmaceuticals 3Q Loss Widens On Costs
2009-10-15,Early Movers: Pump Up the Volume
2009-10-09,Movers Roundup: Callaway Golf, Supervalu
2009-10-09,Threshold Shares Rise On Selected Study Data
2009-10-08,Shareholder Matlinpatterson Sells $31.8M Worth of Huntsman
2007-03-08,Thursday's Early Winners & Losers
2007-03-04,Feuerstein's Biotech Mailbag
2007-02-27,Tuesday's Health Winners & Losers
2007-02-27,Tuesday's Early Winners & Losers
2007-01-30,Tuesday's Early Winners & Losers
2006-12-28,Thursday's Health Winners & Losers
2006-12-28,Thursday's Early Winners & Losers
2006-09-20,Wednesday's Health Winners & Losers
2006-07-17,Monday's Health Winners & Losers
2006-06-02,Friday's Health Winners & Losers
2006-06-02,Friday's Early Winners & Losers
2006-05-19,Take Lessons From Biotech Blowups
2006-05-12,Today's Health Winners and Losers
2006-05-12,Today's Early Winners and Losers
2006-01-05,Medical IPOs Hunt for Cure
2005-11-13,This Week on RealMoney
2005-11-10,On the Threshold of Relief for Older Men
2005-10-12,Health Stocks in Motion
2005-08-19,IPOs for Financial Fashionistas
2005-05-30,Medical IPOs Coming Out Cheap
,
2017-03-17,Threshold Pharmaceuticals And Molecular Templates Agree To Combine
2017-01-26,Research Reports Coverage On Biotech Stocks -- OncoGenex Pharma, INSYS Therapeutics, Threshold Pharma, And AmpliPhi Biosciences
2017-01-13,Hurry! These 5 Stocks Are About to Break Out Explosively
2016-12-19,Threshold Pharmaceuticals And National Cancer Institute To Collaborate On Drug Candidate TH-3424
2016-11-15,Threshold Pharmaceuticals Announces Presentation And Webcast At The Stifel Healthcare Conference 2016
2016-11-07,Threshold Pharmaceuticals Reports Third Quarter Financial Results
2016-10-25,Caris Life Sciences And Threshold Pharmaceuticals Collaborate To Utilize Caris' ADAPT Biotargeting System In The Development Program For Evofosfamide
2016-09-29,Threshold Pharmaceuticals Announces Interim Results From Tarloxotinib Program And Its Plans To Focus On Evofosfamide And Earlier-Stage Opportunities
2016-08-22,One Reason Why Threshold Pharma (THLD) Stock Is Jumping Today
2016-08-18,5 Breakout Stocks Under $10 Set to Soar
2016-08-01,Threshold Pharmaceuticals Reports Second Quarter Financial Results
2016-06-06,Threshold Pharmaceuticals Highlights Multiple Presentations At The 2016 ASCO Annual Meeting
2016-06-01,Threshold Pharmaceuticals To Present At Jefferies 2016 Healthcare Conference
2016-05-10,CytRx Bear Thesis Explained: Why Sarcoma Drug Trial Will Fail
2016-05-05,Threshold Pharmaceuticals Reports First Quarter Financial Results
2016-03-21,Threshold Pharmaceuticals Appoints Stew Kroll As Chief Operating Officer
2016-03-10,Threshold Pharmaceuticals Provides Corporate Update And Reports Fourth Quarter And Year-End 2015 Financial Results
2016-03-01,Threshold Pharmaceuticals Announces Presentation And Webcast At The Cowen And Company 36th Annual Health Care Conference
2015-12-28,Short Interest Moves 50% Lower For THLD
2015-12-08,2 'Rules of the Road' for Biotech Investing
2015-12-04,Why Relypsa Is a New 'Best Idea'
2015-12-03,Threshold Pharmaceuticals (THLD) Weak On High Volume
2015-12-02,Biotech Stock Mailbag: Anavex, Northwest Bio, Threshold Therapeutics
2015-11-24,First Week of THLD January 2016 Options Trading
2015-09-21,Threshold Pharmaceuticals (THLD) Is Weak On High Volume Today
2015-09-12,My Wall Street Fantasy Football League
2015-09-08,Strong On High Volume: Threshold Pharmaceuticals (THLD)
2015-07-21,First Week Of THLD March 2016 Options Trading
2015-05-12,Threshold Pharmaceuticals (THLD) Stock Soars on FDA Fast Track Designation
2015-03-20,Take Aim at Threshold Pharmaceuticals
2015-03-11,Threshold Pharmaceuticals Stock Sees Short Interest Drop 21.8%
2015-01-29,3 Biotech Stocks Under $10 in Breakout Territory: TrovaGene and More
2014-08-22,Biotech Stock Mailbag: Threshold, Galena, CytRx
2014-08-11,5 Stocks Ready for Breakouts
2014-08-01,4 Biotech Stocks Under $10 to Trade for Breakouts
2014-06-11,Interesting THLD Call Options For July 19th
2014-03-27,First Week Of THLD May 17th Options Trading
2014-01-23,First Week Of September 20th Options Trading For Threshold Pharmaceuticals (THLD)
2014-01-17,2 Biotech Stocks Under $10 to Watch
2014-01-13,Top Insider Trades: LOV THLD NHF MBRG
2014-01-06,First Week of February 22nd Options Trading For Threshold Pharmaceuticals (THLD)
2013-10-14,2 Small Cap Biotechs to Bet On
2013-10-09,Interesting THLD Call For November 16th
2013-09-27,Commit To Buy Threshold Pharmaceuticals At $2.50, Earn 8%
2013-08-16,Threshold Pharmaceuticals Enters Oversold Territory (THLD)
2013-07-17,Top Insider Trades: THLD FUND OPK FSFR
2013-05-24,Commit To Buy Threshold Pharmaceuticals At $2.50, Earn 16%
2013-05-15,10 ASCO '13 Abstracts You Can Read Right Now
2013-04-03,SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Directors Of Threshold Pharmaceuticals Inc.
2013-03-01,5 Stocks Poised for Breakouts
2013-02-20,4 Biotech Stocks Under $10 Moving Higher
2013-02-12,3 Biotech Stocks Under $10 Moving Higher
2013-01-25,Stocks Continue to Climb as Companies Exceed Expectations
2013-01-25,Biotech Stock Mailbag: Keryx, Sangamo, Threshold and Amarin
2013-01-22,Celgene's Abraxane: Two Month Survival Boost In Pancreatic Cancer Trial
2013-01-08,4 Biotech Stocks Spiking on Unusual Volume
2012-11-27,10 Best-Performing Biopharma Stocks of 2012 and Their 2013 Outlook
2012-11-26,Nate Sadeghi's 2012 Biotech Stock Report Card
2012-11-12,Celgene: Abraxane Boosts Pancreatic Cancer Survival
2012-10-25,Stocks Under $5: Blossoming Biotech Play
2012-10-15,Making The Call: Celgene's Abraxane Will Work in Pancreatic Cancer
2012-10-01,Threshold's Pancreatic Cancer Drug May be Obsolete Before Launch
2012-10-01,Threshold Pharma Seeks to Erase Doubts About Pancreatic Cancer Drug
2012-10-01,Celgene's Abraxane Is Talk of European Cancer Confab
2012-09-25,Celgene CVR: Upside Into Abraxane Pancreatic Cancer Trial Data
2012-09-17,Nasdaq Stocks Posting Largest Percentage Decreases
2012-09-17,Nasdaq Stocks Posting Largest Percentage Decreases
2012-09-17,Threshold's Pancreatic Cancer Drug Boosts Survival -- With an Asterisk
2012-09-14,Biotech Stock Mailbag: Navidea, Celsion, Raptor and Threshold
2012-07-18,Insiders Trading FOLD, THLD, EMMS, MSM
2012-07-16,Cramer's 'Mad Money' Recap: Things Are Better Than You Think
2012-05-30,Threshold Pharmaceuticals Inc. (THLD): Today's Featured Drugs Winner
2012-04-26,Hitting the Ceiling
2012-04-13,5 Stocks Under $10 Poised for Gains
2012-04-05,Biotech Stock Mailbag: Ampio, Cel-Sci and Ziopharm
2012-03-29,3 Stocks Under $10 Moving Higher
2012-03-27,Energy Stocks Look Heavy
2012-03-19,'Mad Money Lightning Round: Freeport-McMoRan Will Surprise
2012-02-27,Clovis Oncology: Like the Story, Not the Stock
2012-02-24,Insiders Trading GHDX, THLD, RVBD
2012-02-23,'Mad Money Lightning Round': Go for American Capital Agency
2012-02-21,Threshold Drug Delays Pancreatic Cancer
2012-02-03,5 Stocks Under $10 Poised for Big Upside
2011-12-23,Biotech Stock Mailbag: Most Important Events for 2012
2011-08-04,Threshold Pharmaceuticals Reports Second Quarter 2011 Financial And Operational Results
2011-07-25,Threshold Pharmaceuticals Announces Initiation Of Clinical Trial Evaluating TH-302 In Combination With Bevacizumab At University Of Texas At San Antonio
2011-07-12,More Hot Biotech Trades for Second Half 2011
2011-07-06,Threshold Pharmaceuticals Announces National Comprehensive Cancer Network (NCCN) Grant For Phase 1 Trial Of TH-302 In Combination With Pazopanib
2011-06-29,Threshold Pharmaceuticals Initiates Clinical Trial Evaluating TH-302 In Combination With Sunitinib
2011-06-22,Threshold Pharmaceuticals To Present At OneMedForum Conference
2011-06-21,Threshold Pharmaceuticals Announces Completion Of Patient Recruitment For Phase 2 TH-302 Pancreatic Cancer Study
2011-03-24,Threshold Pharmaceuticals Reports Fourth Quarter And Year End 2010 Financial Results
2011-03-17,Threshold Pharmaceuticals Completes $30 Million Registered Direct Offering
2011-03-11,Threshold Pharmaceuticals Announces Registered Direct Offering Of $30 Million
2011-02-16,Dean Foods, La-Z Boy: Small-Cap Winners
2011-02-16,Threshold Pharmaceuticals Announces Agreement With The FDA On A Special Protocol Assessment For Planned Phase 3 TH-302 Combination Trial In Advanced Soft Tissue Sarcoma
2011-01-24,Threshold Pharmaceuticals' TH-302 Continues To Demonstrate Promising Activity In Pancreatic Cancer Phase 1/2 Clinical Trial
2010-12-22,Threshold Pharmaceuticals Announces Promising Early Phase 1 Clinical Trial Results In Patients With Advanced Leukemias
2010-11-18,Follow-up Data From Threshold Pharmaceuticals' Phase 1/2 Clinical Trials Of TH-302 Demonstrate Broad Activity In All Combinations Against Multiple Tumor Types
2010-11-12,Threshold Pharmaceuticals Presents Promising Data From A Phase 1/2 Clinical Trial Of TH-302 At International Sarcoma Meeting
2010-11-09,Threshold Pharmaceuticals Announces Additional Medical And Investor Conference Presentations
2010-11-04,Threshold Pharmaceuticals Reports Third Quarter 2010 Financial And Operational Results
2010-11-03,Threshold Pharmaceuticals Awarded $488,958 In Grants Under Qualifying Therapeutic Discovery Project Program
2010-10-12,Threshold Pharmaceuticals Presents Follow-Up Data From A Phase 1/2 Clinical Trial Of TH-302 In Solid Tumors
2010-09-08,Threshold To Present At Rodman & Renshaw Healthcare Conference
2010-08-05,Threshold Pharmaceuticals Reports Second Quarter 2010 Financial And Operational Results
2010-07-13,MBIA, L-1 Identity: Volume Movers
2010-07-12,Threshold Pharmaceuticals Presents Preclinical Results In Two Scientific Presentations At AACR Translational Cancer Medicine Meeting
2010-06-30,Threshold Pharmaceuticals Initiates A Randomized, Controlled, Phase 2 Clinical Trial Evaluating TH-302 In Patients With Advanced Pancreatic Cancer
2010-06-29,Threshold Pharmaceuticals Initiates A Clinical Trial Evaluating TH-302 In Patients With Advanced Leukemias
2010-06-07,Threshold Pharmaceuticals Presents Promising Clinical Trial Results Demonstrating Broad Anti-Tumor Activity
2010-06-03,Threshold Pharmaceuticals Announces A Presentation At The 2010 American Society Of Clinical Oncology (ASCO) Annual Meeting
2010-05-12,Threshold Pharmaceuticals Appoints Dr. David R. Parkinson To Board Of Directors
2010-05-06,Threshold Announces New Vice President Of Corporate Development
2010-01-26,Dynavax, Matrixx: Early Volume Plays
2009-11-06,Threshold Pharmaceuticals 3Q Loss Widens On Costs
2009-10-15,Early Movers: Pump Up the Volume
2009-10-09,Movers Roundup: Callaway Golf, Supervalu
2009-10-09,Threshold Shares Rise On Selected Study Data
2009-10-08,Shareholder Matlinpatterson Sells $31.8M Worth of Huntsman
2007-03-08,Thursday's Early Winners & Losers
2007-03-04,Feuerstein's Biotech Mailbag
2007-02-27,Tuesday's Health Winners & Losers
2007-02-27,Tuesday's Early Winners & Losers
2007-01-30,Tuesday's Early Winners & Losers
2006-12-28,Thursday's Health Winners & Losers
2006-12-28,Thursday's Early Winners & Losers
2006-09-20,Wednesday's Health Winners & Losers
2006-07-17,Monday's Health Winners & Losers
2006-06-02,Friday's Health Winners & Losers
2006-06-02,Friday's Early Winners & Losers
2006-05-19,Take Lessons From Biotech Blowups
2006-05-12,Today's Health Winners and Losers
2006-05-12,Today's Early Winners and Losers
2006-01-05,Medical IPOs Hunt for Cure
2005-11-13,This Week on RealMoney
2005-11-10,On the Threshold of Relief for Older Men
2005-10-12,Health Stocks in Motion
2005-08-19,IPOs for Financial Fashionistas
2005-05-30,Medical IPOs Coming Out Cheap
,
2017-03-16,Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split
2017-03-15,Tonix Pharmaceuticals To Present Breakthrough Therapy Designated-PTSD Program At Oppenheimer's 27th Annual Healthcare Conference
2017-03-14,Tonix Pharmaceuticals Receives Notice Of Allowance For New U.S. Patent Covering Composition And Manufacture Of TNX-102 SL
2017-03-07,Tonix Pharmaceuticals To Present Breakthrough Therapy Designated-PTSD Program And Corporate Update At The 29th Annual ROTH Conference
2017-03-02,Tonix Pharmaceuticals Announces Demonstrated Vaccine Activity In First-Ever Synthesized Chimeric Horsepox Virus
2017-02-28,Tonix Pharmaceuticals To Present Breakthrough Therapy Designated-PTSD Program And Corporate Update At The Cowen And Company 37th Annual Health Care Conference
2017-02-09,Tonix Pharmaceuticals To Present Breakthrough Therapy Designated-PTSD Program And Corporate Update At The 2017 BIO CEO & Investor Conference
2017-01-24,Tonix Pharmaceuticals To Present Breakthrough Therapy Designated-PTSD Program And Corporate Update At NobleCon13
2017-01-10,Tonix Pharmaceuticals Presented Details Of Newly Expanded Product Development Pipeline At 9th Annual Biotech Showcase Conference
2017-01-03,Tonix Pharmaceuticals To Present Breakthrough Therapy Designated-PTSD Program And Corporate Update At 9th Annual Biotech Showcase Conference
2016-12-19,Tonix Pharmaceuticals' PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation By The FDA
2016-12-08,Tonix Pharmaceuticals Presented New Clinical Results From Sub-Group Analysis Of Phase 2 AtEase Study In Military-Related Posttraumatic Stress Disorder (PTSD)
2016-12-02,Tonix Pharmaceuticals To Present Clinical Data At The 55th Annual Meeting Of The American College Of Neuropsychopharmacology (ACNP)
2016-11-30,Tonix Pharmaceuticals To Present At 9th Annual LD Micro Main Event Investor Conference
2016-11-10,Tonix Pharmaceuticals Reports Third Quarter 2016 Financial Results
2016-11-10,Tonix Pharmaceuticals To Present New Clinical Results From Retrospective Analysis Of Phase 2 AtEase Study In Military-Related PTSD
2016-11-07,Tonix Pharmaceuticals To Present Clinical Data At The International Society For Traumatic Stress Studies (ISTSS) 32nd Annual Meeting
2016-11-02,Tonix Pharmaceuticals To Present At 22nd Annual BIO-Europe® International Partnering Conference
2016-11-01,Tonix Pharmaceuticals To Present Clinical Data At The 2016 Neuroscience Education Institute (NEI) Psychopharmacology Congress
2016-10-31,Tonix Pharmaceuticals Completes $5.2 Million Underwritten Public Offering
2016-10-27,Tonix Pharmaceuticals To Present Clinical Data At CNS Summit 2016
2016-10-26,Tonix Pharmaceuticals Prices $5.2 Million Underwritten Public Offering
2016-10-25,Tonix Pharmaceuticals Announces Proposed Underwritten Public Offering Of Common Stock And Warrants
2016-10-20,5 Stocks Poised for Major Breakouts
2016-10-19,Tonix Pharmaceuticals To Host Posttraumatic Stress Disorder (PTSD) Awareness Day
2016-10-18,UPDATE -- Tonix Pharmaceuticals To Present At Dawson James Securities 2016 Small Cap Growth Stock Conference
2016-10-13,Tonix Pharmaceuticals To Present At Dawson James Securities 2016 Small Cap Growth Stock Conference
2016-09-26,Tonix Pharmaceuticals To Present At 16th Annual Sachs Biotech In Europe Forum
2016-09-07,Tonix Pharmaceuticals To Present At Rodman & Renshaw 18th Annual Global Investment Conference
2016-09-06,Tonix Pharmaceuticals Reports Topline Results From Phase 3 AFFIRM Study Of TNX-102 SL In Fibromyalgia And Provides Corporate Update
2016-08-29,Tonix Pharmaceuticals Announces Successful End-of-Phase 2 Meeting With FDA For TNX-102 SL In Post-Traumatic Stress Disorder
2016-08-15,Tonix Pharmaceuticals Presents Poster On The Development Of TNX-102 SL For Post-Traumatic Stress Disorder (PTSD) At The 2016 Military Health System Research Symposium
2016-08-08,Tonix Pharmaceuticals Reports Second Quarter 2016 Financial Results And Provides Programs Update
2016-07-26,Tonix Pharmaceuticals Initiates Second Pivotal Phase 3 Clinical Study Of TNX-102 SL In Fibromyalgia
2016-07-12,Tonix Pharmaceuticals Announces Full Exercise And Closing Of Underwriters' Over-Allotment Option
2016-07-07,Tonix Pharmaceuticals To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference
2016-06-22,Can You Catch These 6 Stocks Under $10 on Their Way Up?
2016-06-21,Tonix Pharmaceuticals Completes $10 Million Public Offering Of Common Stock
2016-06-17,Tonix Pharmaceuticals To Present At The JMP Securities Life Sciences Conference
2016-06-16,Tonix Pharmaceuticals Prices Underwritten Public Offering Of Common Stock
2016-06-15,Tonix Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2016-06-09,Tonix Pharmaceuticals Presents At EULAR Results Of A Retrospective Analysis From The Phase 2b BESTFIT Clinical Study Of TNX-102 SL In Fibromyalgia
2016-06-03,Tonix Pharmaceuticals To Present At The 2016 BIO International Convention
2016-05-31,Tonix Pharmaceuticals Presents Positive Results From Phase 2 AtEase Study Of TNX-102 SL In Post-Traumatic Stress Disorder (PTSD) At The American Society Of Clinical Psychopharmacology (ASCP) 2016 Annual Meeting
2016-05-26,Tonix Pharmaceuticals To Present Positive Results From Phase 2 AtEase Study Of TNX-102 SL In Post-Traumatic Stress Disorder At The ASCP 2016 Annual Meeting
2016-05-19,Tonix Pharmaceuticals Reports Positive Topline Results From Phase 2 AtEase Study Of TNX-102 SL In Post-Traumatic Stress Disorder (PTSD)
2016-05-13,6 Stocks Under $10 Making Big Moves Higher
2016-05-09,Tonix Pharmaceuticals Reports First Quarter 2016 Financial Results And Provides Programs Update
2016-05-02,Tonix Pharmaceuticals Completes Enrollment In Phase 3 Clinical Trial Of TNX-102 SL In Fibromyalgia
2016-04-15,Trade These 5 Breakout Stocks for Big Gains
2016-03-29,Tonix Pharmaceuticals To Present At The 10th Annual BIO Europe Spring Conference
2016-03-09,Tonix Pharmaceuticals Presents Pharmacokinetic Data On TNX-102 SL As A Potential Treatment For The Management Of Fibromyalgia And Treatment Of Post-Traumatic Stress Disorder At The ASCPT 2016 Annual Meeting
2016-03-08,Tonix Pharmaceuticals To Present At The 28th Annual ROTH Conference
2016-03-04,Tonix Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results And Provides Programs Update
2016-03-03,Tonix Pharmaceuticals To Present At Two Investor Conferences In March 2016
2016-02-25,Tonix Pharmaceuticals Appoints Chief Financial Officer
2016-02-16,Tonix Pharmaceuticals Reports Top Line Results From Phase 2 Proof-of-Concept Clinical Study Of TNX-201 In Episodic Tension-Type Headache
2016-02-02,Tonix Pharmaceuticals To Present At The 18th Annual BIO CEO & Investor Conference
2016-01-08,Tonix Pharmaceuticals Announces Management Change
2016-01-05,Tonix Pharmaceuticals To Present At Biotech Showcase 2016
2015-12-23,Tonix Pharmaceuticals Completes Enrollment In Phase 2 Clinical Trial Of TNX-102 SL In Post-Traumatic Stress Disorder (PTSD)
2015-12-08,Tonix Pharmaceuticals Completes Enrollment In Phase 2 Clinical Study Of TNX-201 In Episodic Tension-Type Headache
2015-12-07,Tonix Pharmaceuticals And U.S. Department Of Defense Military Developer In Partnership To Expand Efforts To Examine TNX-102 SL For Post-Traumatic Stress Disorder
2015-12-01,Tonix Pharmaceuticals To Participate In Fireside Chat At The Oppenheimer 26th Annual Healthcare Conference
2015-11-10,Tonix Pharmaceuticals Presents Additional Data On Tonmya(TM) Demonstrating Improvements In Sleep, Pain, And Other Outcomes In Fibromyalgia At 2015 ACR/ARHP Annual Meeting
2015-11-09,Tonix Pharmaceuticals Reports Third Quarter 2015 Financial Results And Provides Programs Update
2015-10-01,Tonix Pharmaceuticals Announces Acceptance Of Three Abstracts To Be Presented At The 2015 ACR/ARHP Annual Meeting
2015-09-24,Tonix Pharmaceuticals To Present At The 15th Annual Biotech In Europe Forum For Global Partnering And Investment
2015-09-08,Tonix Pharmaceuticals To Present At The Rodman & Renshaw Global Investment Conference
2015-08-18,Tonix Pharmaceuticals Presents On The Development Of TNX-102 SL For Post-Traumatic Stress Disorder (PTSD) At The 2015 Military Health System Research Symposium
2015-08-10,Tonix Pharmaceuticals Reports Second Quarter 2015 Financial Results And Provides Program Update
2015-07-21,Tonix Pharmaceuticals Appoints Mark T. Edgar, PhD As Senior Vice President Of Product Development
2015-07-17,Tonix Pharmaceuticals Closes $20.1 Million Public Offering Of Common Stock
2015-07-14,Tonix Pharmaceuticals (TNXP) Stock Falls After Pricing Public Offering
2015-07-14,Tonix Pharmaceuticals Prices Underwritten Public Offering Of Common Stock
2015-07-13,Tonix Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2015-06-22,Tonix Pharmaceuticals Presents Non-clinical Data On TNX-201 At The 57th Annual Scientific Meeting Of The American Headache Society
2015-06-17,Tonix Pharmaceuticals Announces Conditional Acceptance Of Tonmya As Proposed Brand Name For Cyclobenzaprine HCl Sublingual Tablets, 2.8 Mg
2015-06-16,Tonix Pharmaceuticals Initiates Phase 2 Clinical Study Of TNX-201 In Episodic Tension-Type Headache
2015-06-11,Tonix Pharmaceuticals Presents Additional Data From Phase 2b BESTFIT Clinical Study At EULAR
2015-05-28,Tonix Pharmaceuticals To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-26,Tonix Pharmaceuticals Announces Acceptance Of Two Abstracts For Presentation At EULAR
2015-05-20,Tonix Pharmaceuticals To Present Additional Data From Completed Phase 2b Study Of TNX-102 SL In Fibromyalgia At EULAR
2015-05-15,Tonix Pharmaceuticals Presents Data At The Annual Meeting Of The Society For Biological Psychiatry
2015-05-13,Tonix Pharmaceuticals Launches Phase 3 Clinical Study Of TNX-102 SL In Fibromyalgia
2015-05-11,Tonix Pharmaceuticals Reports First Quarter 2015 Financial Results And Clinical Update
2015-03-20,Tonix Pharmaceuticals To Present At The 12th Annual BIO Asia International Conference
2015-03-04,Tonix Pharmaceuticals To Present At The 27th Annual ROTH Conference
2015-03-03,Tonix Pharmaceuticals Reports Fourth Quarter And Full Year 2014 Financial Results
2015-03-02,Tonix Pharmaceuticals To Present At The 8th Annual European Life Sciences CEO Forum
2015-02-09,Tonix Pharmaceuticals Announces Closing Of $28.7 Million Public Offering Of Common Stock
2015-02-05,Tonix Pharmaceuticals To Present At The BIO CEO & Investor Conference
2015-02-04,Tonix Pharmaceuticals Prices Underwritten Public Offering Of Common Stock
2015-02-03,Tonix Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2015-01-15,Tonix Pharmaceuticals Commences Phase 2 Trial Of TNX-102 SL In Post-Traumatic Stress Disorder
2015-01-14,Tonix Pharmaceuticals To Present At The Noble Financial Annual Investor Conference
2015-01-09,Tonix Pharmaceuticals Announces Clinical Progress On Potential Treatment For Headache
2015-01-06,Tonix Pharmaceuticals Provides Clinical And Regulatory Update On Its Continued Development Of TNX-102 SL In Fibromyalgia
2014-11-25,Tonix Pharmaceuticals To Present At The LD Micro Investor Conference
2014-11-10,Tonix Pharmaceuticals Reports Third Quarter 2014 Financial Results
2014-10-21,Tonix Pharmaceuticals Receives IND Clearance For TNX-201 In Episodic Tension-Type Headache
2014-09-29,Why Tonix Pharmaceuticals (TNXP) Stock Is Plummeting Today
2014-09-29,Oversold Conditions For Tonix Pharmaceuticals Holding (TNXP)
2014-09-29,Tonix Pharmaceuticals Reports Top Line Results From Phase 2b BESTFIT Trial Of TNX-102 SL In Patients With Fibromyalgia
2014-09-19,Tonix Pharmaceuticals To Present At The BioCentury NewsMakers Conference
2014-09-03,Tonix Pharmaceuticals To Present At The Rodman & Renshaw Global Investment Conference
2014-08-26,3 Big-Volume Biotech Stocks to Trade for Breakouts
2014-08-11,Tonix Pharmaceuticals Announces Transfer To The NASDAQ Global Market
2014-08-08,Tonix Pharmaceuticals Reports Second Quarter 2014 Financial Results
2014-08-06,Tonix Pharmaceuticals To Present At Two Investor Conferences In August
2014-07-11,Tonix Pharmaceuticals Announces Registered Direct Offering Of $7.8 Million
2014-06-30,Tonix Pharmaceuticals Joins Russell Microcap Index
2014-06-26,Tonix Pharmaceuticals Appoints Ronald R. Notvest, Ph.D. As Senior Vice President Of Commercial Planning And Development
2014-06-24,3 Big-Volume Stocks to Trade for Breakouts
2014-06-10,Tonix Pharmaceuticals Receives IND Clearance From U.S. Food And Drug Administration For TNX-102 SL In Post-Traumatic Stress Disorder
2014-06-04,4 Under-$10 Stocks to Trade for Breakouts
2014-06-03,Tonix Appoints Gregory M. Sullivan, M.D. As Chief Medical Officer
2014-05-29,Tonix Pharmaceuticals To Present At The Jefferies 2014 Global Healthcare Conference
2014-05-29,Tonix Pharmaceuticals To Present At The LD Micro Invitational Conference
2014-05-28,Tonix Pharmaceuticals To Be Added To The MSCI Global Micro Cap Index
2014-05-28,3 Stocks Under $10 Making Big Moves
2014-05-20,Tonix Pharmaceuticals To Present At The MIXiii Biomed Conference In Israel
2014-05-13,Tonix Pharmaceuticals Reports First Quarter 2014 Financial Results
2014-05-12,Tonix Pharmaceuticals Completes Enrollment In BESTFIT Trial Of TNX-102 SL For Fibromyalgia
2014-04-09,Tonix Pharmaceuticals Spotlighted In April 7 Issue Of BioCentury
2014-04-01,Tonix Pharmaceuticals Appoints Donald J. Kellerman Senior Vice President, Clinical Development And Regulatory Affairs
2014-03-31,Tonix Pharmaceuticals Reports Fourth Quarter And Full Year 2013 Financial Results
2014-03-05,Tonix Pharmaceuticals To Present At The ROTH Conference
2014-03-03,Tonix Pharmaceuticals Completes Pre-IND Meeting With FDA On TNX-201 For Episodic Tension-Type Headache: Clinical Development To Begin In 4Q 2014
2014-02-21,Tonix Pharmaceuticals Spotlighted In Three Media Outlets In February
2014-02-14,Tonix CEO: Investors Seeing Value in Reformulation Strategy
2014-02-04,Tonix Pharmaceuticals To Present At The BIO CEO Conference
2014-01-29,Tonix Pharmaceuticals Announces Closing Of $43.5 Million Public Offering Of Common Stock
2014-01-24,Tonix Pharmaceuticals Prices Underwritten Public Offering Raising $43.5 Million
2014-01-23,Tonix Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2013-12-27,5 Stocks Rising on Unusual Volume
2013-12-10,Tonix Pharmaceuticals Announces The Enrollment Of Completers From The BESTFIT Trial Into A 12-Month Open-Label Extension Study
2013-11-26,Tonix Pharmaceuticals To Present At The Oppenheimer Healthcare Conference
2013-11-21,Tonix Pharmaceuticals To Present At The LD Micro Conference
2013-11-13,Tonix Pharmaceuticals Reports Third Quarter 2013 Financial Results
2013-01-18,(Graphic: Business Wire)
2012-08-16,Tonix Pharmaceuticals CEO Dr. Seth Lederman Describes Potential Treatment For Fibromyalgia, Post-Traumatic Stress Disorder And Traumatic Brain Injury
2012-08-14,Tonix Pharmaceuticals Reports That Sublingual Formulation Of Fibromyalgia Drug Reduces Production Of A Psychoactive Metabolite, Improving Suitability For Long-Term, Chronic Treatment
2012-07-30,Tonix Pharmaceuticals Announces Completion Of Clinical Trial Of Sublingual TNX-102
2012-07-09,Tonix Pharmaceuticals Reports Positive Preclinical Data On Sublingual TNX-102
2012-06-27,Tonix Pharmaceuticals To Present At LHA Life Sciences &amp; Medical Technologies Virtual Conference On June 28
2012-06-27,Tonix Pharmaceuticals Receives Health Canada Clearance To Study A Novel Treatment For Fibromyalgia
2012-06-19,Tonix Pharmaceuticals To Present At Marcum MicroCap Conference
2012-06-14,Tonix Pharmaceuticals Featured On GLX-TV OpenCEOLive Series
2012-05-23,Tonix Pharmaceuticals CEO Interviewed On CEOLive.TV
2012-05-10,Tonix Pharmaceuticals Appoints Dr. Samuel Saks To Its Board Of Directors
2012-04-30,TONIX Pharmaceuticals To Present At Three Investor Conferences In May
2017-03-24,Lifshitz & Miller LLP Announces Investigation Of Argos Therapeutics, Inc., Avid Technology, Inc., HMS Holdings Corp., Invuity, Inc., SITO Mobile, Ltd., Trevena, Inc., USANA Health Sciences, Inc. And VAALCO Energy, Inc.
2017-03-22,Regenxbio Leads Biotech Movers Ahead of Market's Open
2017-03-21,First Week Of TRVN May 19th Options Trading
2017-03-17,2 Questions From the Biotech Mailbag
2017-03-15,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Trevena, Inc. (TRVN)
2017-03-15,TREVENA (TRVN) Alert: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation Of Trevena, Inc.; Investors Encouraged To Contact Firm
2017-03-15,INVESTOR ALERT: Investigation Of Trevena Announced By Holzer & Holzer, LLC
2017-03-14,Trevena To Present At The Oppenheimer 27th Annual Healthcare Conference
2017-03-10,Trevena To Present At The 2017 Barclays Global Healthcare Conference
2017-03-08,Trevena Reports Full Year 2016 Earnings
2017-03-02,Trevena To Host Conference Call On March 8th To Discuss Full Year 2016 Financial Results
2017-02-24,Why Cara Therapeutics Is Up, Trevena Down
2017-02-23,Will Insiders Be Tempted To Buy More TRVN At The New 52-Week Low?
2017-02-22,First Week of April 21st Options Trading For Trevena
2017-02-22,Argos Plummets 72%, Leads Biotech Movers
2017-02-21,Trevena Enters Oversold Territory
2017-02-21,Sarepta Leads Biotech Movers on Voucher Deal News
2017-02-21,Trevena Makes Case for Better Post-Surgical Opioid with New Study Data
2017-02-21,What You Should Know About Trevena's New Painkiller
2017-02-21,Trevena Announces Positive Top-line Results From Two Phase 3 Pivotal Efficacy Studies Of Intravenous Oliceridine In Moderate-to-Severe Acute Pain
2017-02-16,Notable Thursday Option Activity: TRVN, MIDD, ANET
2017-02-02,Market Is Leaving a Sour Taste
2017-01-09,When Will the Market Take a Dive?
2017-01-04,Trevena Completes Enrollment Of Phase 3 APOLLO Pivotal Efficacy Trials Of Oliceridine For Moderate-to-Severe Acute Pain
2016-12-20,First Week of TRVN February 2017 Options Trading
2016-12-02,Get Addicted to Trevena
2016-11-22,First Week of January 2017 Options Trading For Trevena (TRVN)
2016-11-18,No to Closed-End Muni Bond Funds; Cara on a Run: Best of Kass
2016-11-11,TRVN: Insiders vs. Shorts
2016-11-10,Interesting TRVN Call Options For November 18th
2016-11-03,Trevena Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-10-19,Commit To Purchase Trevena At $5, Earn 24.5% Annualized Using Options
2016-10-17,Trevena To Webcast Thought Leader Symposium On Acute Pain Management And Present At The 2016 Annual Meeting Of The American Society Of Anesthesiologists
2016-10-06,Trevena Becomes Oversold (TRVN)
2016-08-10,Trevena To Present At The 2016 Wedbush Pacgrow Healthcare Conference
2016-08-05,Company Profile For Trevena, Inc.
2016-08-04,Trevena Reports Second Quarter 2016 Financial Results And Provides Corporate Update
2016-07-19,Commit To Buy Trevena At $5, Earn 16.7% Annualized Using Options
2016-06-20,Ratings Changes Today
2016-06-16,Trevena To Present At The JMP Life Sciences Conference
2016-06-08,Trevena, Inc. Announces First Patients Enrolled In The APOLLO-1 And APOLLO-2 Phase 3 Pivotal Efficacy Studies Of Oliceridine In Acute Pain
2016-06-01,Trevena To Present At The Jefferies 2016 Healthcare Conference
2016-05-16,Trevena is Now Oversold (TRVN)
2016-05-16,Trevena Reports TRV027 Did Not Achieve Primary Or Secondary Endpoints In BLAST-AHF Phase 2b Trial In Acute Heart Failure
2016-05-13,Ratings Changes Today
2016-05-11,Trevena Announces Presentations At The 35th Annual Scientific Meeting Of The American Pain Society
2016-05-05,Trevena Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-05-02,Trevena Announces Successful End-of-Phase 2 Meeting With FDA And Outlines Phase 3 Program For Oliceridine
2016-04-25,Noteworthy Monday Option Activity: TRVN, BLMN, CAVM
2016-04-20,First Week of December 16th Options Trading For Trevena (TRVN)
2016-04-07,Trevena To Present At The Needham & Company 15th Annual Healthcare Conference
2016-03-31,Trevena Announces Presentations At The 41st Annual Regional Anesthesiology And Acute Pain Medicine Meeting
2016-03-30,First Week of May 20th Options Trading For Trevena (TRVN)
2016-03-09,Trevena Reports Full Year 2015 Financial Results
2016-03-03,Trevena To Present At Three Upcoming Investor Events In March
2016-03-02,Trevena To Host Conference Call On March 9th To Discuss Full Year 2015 Financial Results
2016-02-26,Short Interest In Trevena Drops 16.4%
2016-02-22,Trevena Pain Drug Anointed 'Breakthrough Therapy' by FDA
2016-02-22,Trevena, Inc. Receives FDA Breakthrough Therapy Designation For Oliceridine For The Management Of Moderate-to-Severe Acute Pain
2016-02-17,Trevena To Present At The 2016 RBC Capital Markets' Global Healthcare Conference
2016-02-03,Trevena To Present At The 18th Annual BIO CEO & Investor Conference
2016-01-20,Commit To Purchase Trevena At $5, Earn 22.1% Annualized Using Options
2016-01-19,Trevena, Inc. Announces Initiation Of Oliceridine Phase 3 Clinical Program With Multi-Procedure Safety And Tolerability Study
2016-01-11,Trevena Becomes Oversold (TRVN)
2015-12-16,Trevena, Inc. Added To NASDAQ Biotechnology Index (NBI)
2015-12-03,Trevena Announces FDA Grant Of Fast Track Designation To Oliceridine (TRV130) For The Management Of Moderate-to-Severe Acute Pain
2015-12-03,Trevena Granted Key Composition Of Matter And Use Patent For TRV027 In Europe
2015-12-02,Trevena To Present At The Oppenheimer 26th Annual Healthcare Conference
2015-12-01,Commit To Buy Trevena At $10, Earn 33.8% Annualized Using Options
2015-11-12,Trevena CEO To Present At The Jefferies 2015 Global Healthcare Conference
2015-11-10,Trevena Reports Third Quarter 2015 Financial Results And Provides Corporate Update
2015-10-28,Trevena Hosts Investor And Analyst Day
2015-10-23,5 Stocks Poised for Breakouts
2015-10-21,Trevena To Host Analyst And Investor Day On October 28, 2015
2015-10-16,Trevena: Friday's Small-Cap Focus Stock
2015-09-29,Trevena Announces Publication Of TRV130 Phase 2 Bunionectomy Data In The Journal PAIN®
2015-09-16,Trevena, Inc. Announces Closing Of Public Offering Of Common Stock, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-09-11,Trevena, Inc. Announces Pricing Of Underwritten Offering Of Common Stock
2015-09-10,Trevena, Inc. Announces Proposed Underwritten Offering Of Common Stock
2015-09-08,Trevena Announces Presentations At PAINWeek® 2015
2015-09-04,2 Issues Keeping Buyers on the Sidelines Today
2015-08-31,Trevena Announces Positive Results From Phase 2b Study Of TRV130 In Acute Postoperative Pain
2015-08-11,Trevena Reports Second Quarter 2015 Financial Results And Provides A Corporate Update
2015-08-04,Trevena CEO To Present At The 2015 Wedbush PacGrow Healthcare Conference
2015-07-28,Short Interest Surges 277.7% For TRVN
2015-07-20,Trevena Appoints Yacoub Habib As Senior Vice President, Business Development And Corporate Planning
2015-06-29,Oversold Conditions For Trevena (TRVN)
2015-06-29,Trevena Added To Russell 3000®, Russell 2000®, And Russell Global Indexes
2015-06-18,Trevena Announces Poster Presentation Of Data For Delta Receptor Compound TRV250 At American Headache Society 57th Annual Scientific Meeting
2015-06-17,Trevena CEO To Present At The 2015 JMP Securities Life Sciences Conference
2015-06-02,Trevena Granted Key U.S. Composition Of Matter Patent For TRV734
2015-05-28,Trevena CEO To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-14,Trevena Announces Presentation Of Preclinical Data For Delta Receptor Compound TRV250 At International Headache Congress
2015-05-07,Trevena Reports First Quarter 2015 Financial Results And Provides A Corporate Update
2015-05-04,Trevena Appoints Carrie Bourdow As Chief Commercial Officer
2015-04-08,Trevena CEO To Present At The 14th Annual Needham Healthcare Conference
2015-03-18,Trevena CMO To Present At The BioCentury 22nd Annual Future Leaders In The Biotech Industry Conference
2015-03-18,Trevena Reports Full Year 2014 Financial Results
2015-03-11,Trevena To Host Conference Call On March 18th To Discuss Full Year 2014 Financial Results
2015-03-09,Trevena Completes Interim Analysis And Announces Plans For Ongoing Phase 2b BLAST-AHF Trial Of TRV027 In Acute Heart Failure
2015-03-06,5 Stocks Poised for Breakouts: Trevena, Inventergy and More
2015-03-04,Trevena CEO To Present At The Barclays Global Healthcare Conference
2015-02-24,Trevena CEO To Present At The Cowen And Company 35th Annual Health Care Conference
2015-02-23,Symic Biomedical Announces Appointment Of Barbara Yanni And Bill Newell As Independent Directors To Its Board
2015-02-09,Trevena Announces Positive Results From Phase 1 Multiple Ascending Dose Study Of TRV734 For Moderate To Severe Acute And Chronic Pain
2015-02-03,Trevena CEO To Present At The 17th Annual BIO CEO & Investor Conference
2015-02-03,TRV027 Phase 2b BLAST-AHF Trial Design Published In Journal Of The American College Of Cardiology: Heart Failure
2015-01-06,Trevena Initiates Second Phase 2b Study Of TRV130 For Acute Postoperative Pain
2014-12-17,Trevena Appoints Anne M. Phillips To The Board Of Directors
2014-12-10,Trevena Announces Closing Of Public Offering And Partial Exercise Of Underwriters' Option To Purchase Additional Shares
2014-12-04,Trevena Announces Pricing Of Public Offering
2014-12-01,Trevena Announces Commencement Of Public Offering
2014-11-17,Trevena Announces Positive Top-Line Results From Phase 2a/b Study Of TRV130 In Acute Postoperative Pain
2014-11-11,Trevena Reports Third Quarter 2014 Financial Results And Provides A Corporate Update
2014-10-13,RSI Alert: Trevena (TRVN) Now Oversold
2014-10-08,Trevena Announces Early Completion Of Enrollment Of Phase 2a/b Study Of TRV130 In Postoperative Pain
2014-09-22,Trevena Enters Into $35 Million Tranched Term Loan Credit Facility
2014-09-18,Trevena Appoints Adam M. Koppel To The Board Of Directors
2014-09-16,Trevena Granted Key U.S. Composition Of Matter Patent For TRV130
2014-08-13,4 Stocks Under $10 Making Big Moves
2014-08-12,Trevena Reports Second Quarter 2014 Financial Results
2014-08-07,Trevena CEO To Present At The Canaccord Genuity 34th Annual Growth Conference
2014-08-06,Trevena Initiates Phase 1 Multiple Ascending Dose Study Of TRV734 For Acute And Chronic Pain
2014-08-05,Trevena To Host Conference Call To Discuss Second Quarter 2014 Results On August 12
2014-08-05,Trevena Granted Key U.S. Method Of Use Patent For TRV027
,
2017-03-14,AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results
2017-03-13,Tesaro Announces Presentation Of Niraparib Phase 3 ENGOT-OV16/NOVA Trial Secondary Endpoint Results During SGO
2017-03-12,TESARO Announces Niraparib Data Presentations At The 2017 SGO Annual Meeting On Women's Cancer
2017-03-10,Incyte Pops on Continued Gilead Takeout Speculation
2017-03-01,Invest Like a Venture Capitalist With These 4 Stocks
2017-03-01,Forget the Snapchat IPO--Invest Like a Venture Capitalist With These 4 Stocks
2017-02-28,TESARO Announces Fourth-Quarter 2016 Operating Results
2017-02-27,TESARO Receives Positive CHMP Opinion For VARUBY®
2017-02-21,TESARO Announces Participation At Two Investor Conferences
2017-02-20,Your Burning Biotech Questions Answered
2017-02-17,Clovis, Tesaro Soar on Astrazeneca Phase Three News
2017-02-17,Your Burning Biotech Questions Answered
2017-02-15,Biotech Buoyed by Deal Talk
2017-02-14,Tesaro To Announce Fourth-Quarter 2016 Financial Results On February 28, 2017
2017-02-13,Morgan Stanley, Twitter, Tesaro: Doug Kass' Views
2017-02-10,Analysts' Actions -- Ford, Intel, Twitter, Viacom and More
2017-02-08,Notable Wednesday Option Activity: TSRO, PRLB, SPSC
2017-02-08,Biotech Tesaro Climbs on Takeout Reports
2017-02-02,Tesaro Announces Participation At Two Investor Conferences
2017-01-17,Tesaro Announces Opening Of Niraparib Expanded Access Program For U.S. Patients With Ovarian Cancer
2017-01-12,These 3 Biotech Stocks Are Already Moving Wildly on Thursday
2017-01-11,TESARO Receives Complete Response Letter For Rolapitant IV From U.S. FDA
2017-01-05,3 Biotechs Screaming 'Takeover Target'
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2016-12-20,Tesaro Announces Priority Review Designation For Niraparib NDA
2016-11-30,Analysts' Actions -- Goldman Sachs, Celanese, SBA Communications and More
2016-11-29,Ratings Changes Today
2016-11-21,Tesaro Announces Participation In Three Investor Conferences
2016-11-17,Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!
2016-11-15,TESARO Announces Pricing Of Public Offering Of Common Stock
2016-11-14,TESARO Announces Proposed Public Offering Of Common Stock
2016-11-03,TESARO Announces Third-Quarter 2016 Operating Results
2016-11-01,Tesaro Announces Submission Of Niraparib New Drug Application For Platinum-Sensitive, Recurrent Ovarian Cancer
2016-10-31,TESARO Announces Presentation Of Niraparib Data At The 2016 IGCS Biennial Meeting
2016-10-27,TESARO Announces Acceptance For Review Of Niraparib Marketing Authorization Application By EMA
2016-10-26,AstraZeneca Is Now a Competitive Threat to Tesaro in Ovarian Cancer Maintenance Therapy
2016-10-24,TESARO Announces Participation In Three Investor Conferences
2016-10-20,Tesaro To Announce Third-Quarter 2016 Financial Results On November 3, 2016
2016-10-10,Closing Bell: Stocks Lifted by Oil Prices; Facebook Launches Work-Friendly Social Network
2016-10-10,Stocks Buoyed by Higher Oil Prices; Investors Await Third-Quarter Earnings
2016-10-10,Stocks Maintain Gains as Oil Rallies
2016-10-10,Trending Tickers: MRK, BMY, TSRO, TWLO, CRM
2016-10-10,Even High-Flying Tesaro and Its Ovarian Cancer Drug Has a Bear Thesis. Here It Is, Explained
2016-10-10,Tesaro (TSRO) Stock Soars on Ovarian Cancer Trial Success, Upgraded
2016-10-10,Rev's Forum: News Flow Works Against the Bears Once More
2016-10-10,Analysts' Actions -- American Eagle, Mattel, Netflix, Tesaro and More
2016-10-08,Tesaro Drug Delays Recurrence of Ovarian Cancer, New Clinical Trial Shows
2016-10-08,TESARO And ENGOT Announce Presentation Of Successful Niraparib Phase 3 ENGOT-OV16/NOVA Trial Results During ESMO 2016
2016-10-04,Investor's Guide to This Week's Clovis, Tesaro Ovarian Cancer Drug Updates
2016-09-29,TESARO And Zai Lab Announce Collaboration, Development And License Agreement
2016-09-21,Is Tesaro Another M&amp;A Target? The Charts Say It Is
2016-09-12,TESARO Receives FDA Fast Track Designation For Niraparib And Initiates Rolling NDA Submission
2016-09-06,Is Bad News Necessarily a Bad Thing?
2016-09-06,TESARO Announces Six Data Presentations At The 2016 European Society For Medical Oncology (ESMO) Annual Meeting
2016-08-24,TESARO Announces Participation At Four Investor Conferences
2016-08-23,Healthy Market Action Takes an Unhealthy Turn
2016-08-22,Here's a Reason Why Tesaro (TSRO) Stock Climbed Today
2016-08-22,Medivation Scores Premium in Sale to Pfizer
2016-08-22,Facebook Stands Out and FormFactor Has a Good Start
2016-08-22,Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation
2016-08-17,Nice Recovery, But Momentum Is Missing
2016-08-09,It May Be Dull, but That's No Reason to Be Negative
2016-08-04,Tesaro Announces Second-Quarter 2016 Operating Results
2016-07-27,In the Red, and Breadth Is Steadily Slipping
2016-07-21,TESARO To Announce Second-Quarter 2016 Financial Results On August 4, 2016
2016-07-20,Market Momentum Is on the Move
2016-07-14,'Mad Money' Lightning Round: I'm Not Turning My Back on Blackstone
2016-07-13,Jim Cramer's 'Mad Money' Recap: Is the Bull Resting or Out the Gate?
2016-07-12,I Am Watching Some Momentum Names
2016-07-08,ENGOT And TESARO Partnership Generates Positive Data From ENGOT-OV16/NOVA Phase 3 Trial
2016-07-07,TESARO Announces Closing Of Public Offering Of Common Stock And Exercise Of Option By Underwriters
2016-07-07,Price Patterns Never Lie
2016-07-06,The Market Mood Is Sour
2016-07-05,Summer Trading at Its Finest
2016-06-30,TESARO Announces Pricing Of Public Offering Of Common Stock
2016-06-30,5 Hot Stocks to Watch Right Now
2016-06-30,Protect Gains Into the Holiday Weekend
2016-06-30,Dr. Marc Siegel Explains Why Tesaro (TSRO) Cancer Drug Is a Big Deal
2016-06-30,Tesaro (TSRO) Stock Slumps on Public Offering, Leerink Lifts Price Target
2016-06-30,Analysts' Actions -- General Mills, Priceline, Pulte, Yelp and More
2016-06-30,TESARO Announces Proposed Public Offering Of Common Stock
2016-06-29,What Tesaro's Cancer Drug Success Means for Medivation
2016-06-29,Tesaro (TSRO) Stock Skyrockets on Success of Ovarian Cancer Drug
2016-06-29,2 Big-Volume Stocks to Add to Your Buy List -- Plus 5 Risky Ones to Avoid
2016-06-29,16 Biopharma Companies Besides Medivation That Are Attractive Targets
2016-06-29,TESARO's Niraparib Significantly Improved Progression-Free Survival For Patients With Ovarian Cancer In Both Cohorts Of The Phase 3 NOVA Trial
2016-06-23,TESARO Announces Rolapitant Data Presentations At The 2016 MASCC/ISOO Annual Meeting On Supportive Care In Cancer
2016-06-04,TESARO Provides Pipeline Update At ASCO Investor Briefing
2016-05-21,5 Stocks to Sell in May Before They Destroy Your Portfolio
2016-05-18,TESARO Announces Five Abstracts To Be Presented At The 2016 American Society Of Clinical Oncology (ASCO) Annual Meeting
2016-05-05,TESARO Announces First-Quarter 2016 Operating Results
2016-04-25,TESARO Announces Submission Of Investigational New Drug Application For Anti-TIM-3 Antibody TSR-022 To The U.S. FDA
2016-04-22,5 Toxic Stocks You Should Sell Now
2016-04-21,TESARO To Announce First Quarter 2016 Financial Results On May 5, 2016
2016-04-06,TESARO Announces Global Prostate Cancer Collaboration And Licensing Agreement With Janssen
2016-04-04,TESARO Announces Appointment Of Dr. Kavita Patel To Board Of Directors
2016-03-29,TESARO Announces Enrollment Of First Patient In Phase 1 Clinical Trial Of TSR-042
2016-03-29,TESARO And MD Anderson Cancer Center Announce Immuno-Oncology Collaboration And Exclusive License Agreement
2016-03-23,TESARO Announces Validation Of Marketing Authorisation Application For Oral Rolapitant By The European Medicines Agency
2016-03-21,Ally Bridge Group (ABG) Completes Its Investment In TESARO, Inc. (TSRO)
2016-03-18,TESARO Announces Closing Of $155 Million Private Placement
2016-03-14,TESARO Submits New Drug Application For Intravenous Rolapitant To The U.S. Food And Drug Administration
2016-02-25,TESARO Announces Fourth-Quarter 2015 Operating Results
2016-02-25,TESARO Announces Definitive Agreement For $155 Million Private Placement
2016-02-11,Tesaro To Announce Fourth Quarter 2015 Financial Results On February 25, 2016
2016-02-03,TESARO To Present At The Leerink Partners 5th Annual Global Healthcare Conference
2016-01-11,TESARO Outlines Business Priorities And Strategic Outlook For 2016
2015-12-14,TESARO Added To The NASDAQ Biotechnology Index
2015-11-16,TESARO Announces The Launch Of VARUBI(TM) (Rolapitant) In The United States
2015-11-16,TESARO Announces The Launch Of VARUBI™ (rolapitant) In The United States
2015-11-06,TESARO Announces Data Presentations For Niraparib At The 2015 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
2015-10-29,TESARO Announces Third-Quarter 2015 Operating Results
2015-10-22,TESARO Announces Participation In Three Investor Conferences
2015-10-15,TESARO To Announce Third-Quarter Financial Results On October 29, 2015
2015-09-25,First Week of TSRO November 20th Options Trading
2015-09-24,TESARO Announces Inclusion Of VARUBI(TM) (rolapitant) In NCCN(R) Antiemesis Guidelines
2015-09-21,TESARO Appoints Martin Huber, M.D., As Senior Vice President And Chief Medical Officer
2015-09-03,First Week of TSRO October 16th Options Trading
2015-09-02,TESARO Announces U.S. FDA Approval Of VARUBI(TM) (rolapitant) For Nausea And Vomiting Associated With Cancer Chemotherapy
2015-09-01,TESARO Announces Participation At Three Investor Conferences
2015-08-06,TESARO Announces Second-Quarter 2015 Operating Results
2015-07-30,Tesaro And Jiangsu Hengrui Medicine Announce Rolapitant License Agreement For China
2015-07-23,TESARO To Announce Second-Quarter Financial Results On August 6, 2015
2015-07-13,TESARO Appoints Grant C. Bogle As Senior Vice President And Chief Commercial Officer
2015-06-29,TESARO Appoints Jeffrey H. Hanke, Ph.D., As Executive Vice President, Research & Development, And Chief Scientific Officer
2015-06-25,TESARO Announces Six Abstracts To Be Presented At The 2015 Multinational Association Of Supportive Care In Cancer Annual Meeting
2015-05-30,TESARO Announces Successful Completion Of Rolapitant Bioequivalence Study
2015-05-30,TESARO And Merck To Collaborate On A Combination Study Of Niraparib And KEYTRUDA(R) (Pembrolizumab)
2015-05-29,Fly Watch: Several Names That May Move Following ASCO Meeting
2015-05-20,TESARO Announces Webcast Of Presentation At The Jefferies 2015 Global Healthcare Conference
2015-05-14,TESARO Announces Election Of Garry A. Nicholson To Board Of Directors And Results Of Annual Stockholder Meeting
2015-05-13,TESARO Announces Seven Abstracts To Be Presented At The 2015 American Society Of Clinical Oncology (ASCO) Annual Meeting
2015-04-30,TESARO Announces Completion Of Targeted Enrollment In Phase 3 NOVA Trial And Initiation Of The QUADRA Trial Of Niraparib
2015-04-30,TESARO Announces First-Quarter 2015 Operating Results
2015-04-23,TESARO Launches Campaign To Raise Awareness Of Chemotherapy-Induced Nausea And Vomiting Among Patients With Cancer
2015-04-22,TESARO Announces Participation At Three Investor Conferences
2015-04-16,TESARO To Announce First-Quarter Financial Results On April 30, 2015
2015-04-14,TESARO Announces Upcoming Immuno-Oncology Presentations
2015-04-09,TESARO Announces Nomination Of Garry A. Nicholson For Election To Board Of Directors
2015-03-31,TESARO Appoints Joseph Farmer, As Senior Vice President, General Counsel And Secretary
2015-03-17,TSRO: Insiders Vs. Shorts
2015-03-09,TESARO Announces Closing Of Public Offering Of Common Stock And Exercise Of Over-Allotment Option By Underwriters
2015-03-05,TESARO To Present At The Barclays Global Healthcare Conference
2015-03-03,TESARO Announces Pricing Of Public Offering Of Common Stock
2015-03-02,TESARO Announces Proposed Public Offering Of Common Stock
2015-02-26,18.5% Of XBI Holdings Seeing Recent Insider Buys
2015-02-19,TESARO Announces Fourth-Quarter 2014 Operating Results
2015-02-05,TESARO To Announce Fourth-Quarter 2014 Financial Results On February 19, 2015
2015-02-05,TESARO To Present At The Leerink Global Healthcare Conference
2015-01-12,CORRECTING And REPLACING -- TESARO Announces Expansion Of Niraparib Clinical Program And Outlines Late-Stage Program Milestones For 2015
2015-01-12,TESARO Announces Expansion Of Niraparib Clinical Program And Outlines Late-Stage Program Milestones For 2015
2014-12-16,TSRO: Insiders Vs. Shorts
2014-12-02,TESARO And AnaptysBio Expand Immuno-Oncology Collaboration To Include Novel Bispecific Antibody Candidate
2014-11-25,TESARO To Present At The 2014 Deutsche Bank BioFEST
2014-11-25,TESARO To Present At The Nasdaq 31st Investor Program
2014-11-15,'Fast Money' Recap: Was Friday the Start of a Bull Rally in Gold?
2014-11-12,TESARO To Present At The Jefferies 2014 Global Healthcare Conference
2014-11-05,TESARO Announces Third-Quarter 2014 Operating Results
2014-10-27,Short Interest Jumps 17.3% For TSRO
2014-10-22,Tesaro To Announce Third-Quarter 2014 Financial Results On November 5, 2014
2014-09-29,TESARO Announces Closing Of $201.25 Million Public Offering Of 3.00% Convertible Senior Notes Due 2021, Including Full Exercise Of The Underwriters' Option To Purchase Additional Notes
2014-09-23,TESARO Announces Pricing Of $175 Million Of 3.00% Convertible Senior Notes Due 2021
2014-09-22,TESARO Announces Offering Of $165 Million Of Convertible Senior Notes Due 2021
2014-09-08,OPKO Licensee TESARO Submits New Drug Application For Rolapitant
2014-09-08,TESARO Announces Submission Of Rolapitant New Drug Application (NDA) To U.S. Food And Drug Administration
2014-08-25,Tesaro (TSRO) Shares Cross Above 200 DMA
2014-08-21,TESARO Announces Participation At Several Upcoming Investor Conferences
2014-07-24,TESARO Announces Second-Quarter 2014 Operating Results
2014-07-24,TESARO Appoints Mary Lynne Hedley, Ph.D., As Chief Operating Officer
2014-07-10,TESARO To Announce Second-Quarter 2014 Financial Results On July 24, 2014
2014-07-09,3 Big Stocks on Traders' Radars
2014-07-09,'Fast Money' Recap: Waiting for the Dust to Settle
2014-06-27,TESARO Summarizes Rolapitant Data Presented At The 2014 MASCC/ISOO International Symposium On Supportive Care In Cancer
2014-06-25,Short Interest In Tesaro Increases 13.7%
2014-06-01,Tesaro Summarizes Phase 3 Rolapitant Data Presented At The 2014 American Society Of Clinical Oncology (ASCO) Annual Meeting And Provides An Update On Niraparib Development Strategy
2014-05-27,TESARO Appoints Tim Pearson As Chief Financial Officer
2014-05-27,TESARO Announces Webcast Of Investor & Analyst Briefing At ASCO
2014-05-16,TESARO Announces Election Of Earl M. (Duke) Collier, Jr. To Board Of Directors And Results Of Annual Stockholder Meeting
2014-05-14,TESARO Announces Six Abstracts To Be Presented At The 2014 American Society Of Clinical Oncology (ASCO) Annual Meeting
2014-05-14,TESARO To Present At The UBS 2014 Global Healthcare Conference
2017-03-23,Outcomes Data From Over 950 Severe Burn Patients Treated With Epicel Presented At The 49th Annual Meeting Of The American Burn Association
2017-03-10,Vericel Reports Fourth-Quarter And Year-End 2016 Financial Results
2017-03-03,Vericel To Host Fourth-Quarter 2016 Earnings Webcast And Conference Call On March 10, 2017
2017-02-27,Vericel To Present At Multiple Upcoming Investor Conferences
2017-02-21,Vericel Receives FDA Fast Track Designation For Ixmyelocel-T, An Investigational Product For The Treatment Of Patients With Advanced Heart Failure Due To Ischemic Dilated Cardiomyopathy
2017-02-01,Vericel Announces First MACI Implant In The United States For The Treatment Of Symptomatic Cartilage Defects Of The Knee
2017-01-24,First Week of VCEL March 17th Options Trading
2016-12-21,Vericel Corporation Announces Exercise Of Underwriters' Over-Allotment Option And Closing Of $20 Million Offering Of Common Stock
2016-12-16,Vericel Corporation Prices $17 Million Public Offering Of Common Stock
2016-12-15,Vericel Corporation Announces Proposed Public Offering Of Common Stock
2016-12-14,FDA Approves MACI For The Treatment Of Symptomatic Cartilage Defects Of The Knee In Adults
2016-11-22,Vericel To Present At 28th Annual Piper Jaffray Healthcare Conference
2016-11-14,Additional Pre-Specified Secondary Results On The Reduction Of Ventricular Arrhythmias Presented At AHA From Vericel's Positive Phase 2b IxCELL-DCM Clinical Trial Of Ixmyelocel-T
2016-11-07,Vericel Reports Third-Quarter 2016 Financial Results
2016-10-31,Vericel To Host Third-Quarter 2016 Earnings Webcast And Conference Call On November 7, 2016
2016-09-26,Vericel To Present At 2016 Cell & Gene Meeting On The Mesa
2016-09-21,Vericel To Present At Ladenburg Thalmann Healthcare Conference
2016-09-12,Vericel Enters Into Expanded $20 Million Credit Facility And Term Loan With Silicon Valley Bank And MidCap Financial Services
2016-09-07,Vericel To Present Data At The American Heart Association's Scientific Sessions 2016 On The Reduction Of Ventricular Arrhythmias With Ixmyelocel-T In The IxCELL-DCM Clinical Trial
2016-08-08,Vericel Reports Second-Quarter 2016 Financial Results
2016-08-01,Vericel To Host Second-Quarter 2016 Earnings Webcast And Conference Call On August 8, 2016
2016-07-06,Vericel To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference
2016-05-10,Vericel Reports First-Quarter 2016 Financial Results
2016-04-27,Vericel To Host First-Quarter 2016 Earnings Webcast And Conference Call On May 10, 2016
2016-04-08,Vericel To Present At 15th Annual Needham Healthcare Conference
2016-04-06,Strong On High Volume: Vericel (VCEL)
2016-04-05,Vericel (VCEL) Is Weak On High Volume Today
2016-04-04,Results From Vericel's Positive Phase 2b IxCELL-DCM Clinical Trial Of Ixmyelocel-T Presented Today At ACC And Published In The Lancet
2016-03-29,Vericel To Host Review Of Positive Phase 2b IxCELL-DCM Trial Results Following American College Of Cardiology 65th Annual Scientific Sessions
2016-03-28,Trade-Ideas: Vericel (VCEL) Is Today's "Perilous Reversal" Stock
2016-03-28,Vericel Announces Publication Of Clinical Trial Rationale And Study Design For The Phase 2b IxCELL-DCM Trial Of Ixmyelocel-T In Patients With Heart Failure Due To Ischemic Dilated Cardiomyopathy
2016-03-22,Interesting VCEL Put And Call Options For May 20th
2016-03-22,Vericel (VCEL) Flagged As Strong On High Volume
2016-03-15,Vericel (VCEL) Flagged As Strong On High Volume
2016-03-14,Vericel (VCEL) Stock Falling on Q4 Results
2016-03-14,Trade-Ideas: Vericel (VCEL) Is Today's "Perilous Reversal" Stock
2016-03-14,Vericel Reports Fourth-Quarter And Year-End 2015 Financial Results
2016-03-11,Vericel (VCEL) Is Today's Pre-Market Mover With Heavy Volume Stock
2016-03-10,Vericel (VCEL) Stock Soars on Positive Phase 2 Trial Results
2016-03-10,Vericel Announces Positive Top-Line Results From Phase 2b IxCELL-DCM Clinical Trial Of Ixmyelocel-T In Patients With Heart Failure Due To Ischemic Dilated Cardiomyopathy
2016-03-09,Vericel Enters Into $10 Million Credit Facility And $5 Million Term Loan Agreement With Silicon Valley Bank
2016-03-08,Vericel To Present At 28th Annual ROTH Conference
2016-03-07,Vericel Announces FDA Acceptance For Filing Of BLA For MACI For The Treatment Of Symptomatic Cartilage Defects In The Knee
2016-02-26,Vericel To Host Fourth-Quarter 2015 Earnings Webcast And Conference Call On March 14, 2016
2016-02-24,Vericel To Present At Canaccord Genuity Investor Conference
2016-02-22,Vericel Announces FDA Approval Of Epicel HDE Supplement
2016-01-04,Vericel Submits Biologics License Application To The FDA For MACI For The Treatment Of Cartilage Defects In The Knee
2015-12-08,Vericel Submits HDE Supplement To The FDA To Revise The Labeled Indications For Use And Add Pediatric Labeling For Epicel
2015-11-13,Vericel Reports Third-Quarter 2015 Financial Results
2015-11-03,Vericel To Host Third-Quarter 2015 Earnings Webcast And Conference Call On November 13, 2015
2015-09-23,Vericel To Present At Upcoming Investor Conferences
2015-08-12,Vericel Reports Second-Quarter 2015 Financial Results
2015-07-29,Vericel To Host Second-Quarter 2015 Earnings Webcast And Conference Call On August 12, 2015
2015-07-14,Vericel Announces Plan To Submit HDE Supplement To The FDA To Revise The Labeled Indications For Use And Add Pediatric Labeling For Epicel
2015-06-10,Vericel Announces Plan To Submit Biologics License Application To FDA By Year-End 2015 For MACI For The Treatment Of Cartilage Defects In The Knee
2015-05-14,Vericel Reports First-Quarter 2015 Financial Results
2015-04-30,Vericel To Host First-Quarter 2015 Earnings Webcast And Conference Call On May 14, 2015
2015-04-08,Vericel To Present At Needham Healthcare Conference
2015-03-25,Vericel Reports Three-Year Follow-Up Results From Phase 3 SUMMIT Extension Study Of MACI(TM) Implant
2015-03-24,Vericel (VCEL) Stock Gains Today on Better Than Expected Quarter
2015-03-23,Vericel Reports Fourth-Quarter And Year-End 2014 Financial Results
2015-03-18,Vericel To Present At Canaccord Genuity And ARM Investor Conferences
2015-03-12,Vericel To Host Fourth-Quarter 2014 Earnings Call On March 23, 2015
2015-03-06,Vericel To Present At 27th Annual ROTH Conference
2015-01-29,Vericel Completes Patient Enrollment In Phase 2b IxCELL-DCM Clinical Study Of Ixmyelocel-T
,
,
,
2017-03-10,Vical To Provide Company Update At The 29th Annual ROTH Conference
2017-03-09,Vical To Provide Company Update At BIO Asia International Conference
2017-03-09,Vical Reports Fourth Quarter 2016 Financial Results
2017-03-02,Vical Announces News Release And Conference Call Schedule For Fourth Quarter 2016 Financial Results
2017-02-24,Vical Provides Company Update At Biocom's Global Life Science Partnering Conference
2017-02-07,Vical Provides Company Update At BIO CEO And Investor Conference
2016-11-03,Vical Reports Third Quarter 2016 Financial Results
2016-10-27,Vical Announces News Release And Conference Call Schedule For Third Quarter 2016 Financial Results
2016-09-26,Vical Announces Initiation Of A Phase 2 Trial Of Its HSV-2 Therapeutic DNA Vaccine For Genital Herpes
2016-09-19,Vical And Astellas Announce Topline Results From A Phase 2 Study Of Investigational Cytomegalovirus (CMV) Vaccine (ASP0113) In Kidney Transplant Patients
2016-09-02,Vical To Present At The 18th Annual Rodman & Renshaw Global Investment Conference
2016-08-09,Vical Reports Second Quarter 2016 Financial Results
2016-08-02,Vical Announces News Release And Conference Call Schedule For Second Quarter 2016 Financial Results
2016-08-01,Vical Announces $7.8 Million Equity Investment By Partner, AnGes MG
2016-06-20,Vical's Phase 1/2 Trial Data Presented At ASM 2016 Shows Bivalent Vaccine Imparts Reduction In Genital Herpes Lesions Durable To 9 Months
2016-06-13,Vical To Present HSV-2 Phase 1/2 Data At June ASM Microbe/ICAAC 2016 Conference
2016-05-31,Vical Provides VL-2397 Updates At BIO International Convention
2016-05-09,Vical Reports First Quarter 2016 Financial Results
2016-05-02,Vical Announces News Release And Conference Call Schedule For First Quarter 2016 Financial Results
2016-03-30,FDA Grants Vical Fast Track Designation For VL-2397 For The Treatment Of Invasive Aspergillosis
2016-03-14,Vical Reports Fourth Quarter 2015 Financial Results
2016-03-09,Vical To Present At The 28th Annual ROTH Conference
2016-03-07,Vical Announces News Release And Conference Call Schedule For Fourth Quarter 2015 Financial Results
2016-03-07,Vical Initiates Phase 1 Trial Of Novel Antifungal Compound VL-2397
2016-03-04,Insider Trading Alert - TREE, VRNS And VICL Traded By Insiders
2016-01-14,Insider Trading Alert - VICL, PF And KRO Traded By Insiders
2016-01-11,Insider Trading Alert - ASFI, ICE And VICL Traded By Insiders
2016-01-06,FDA Grants Vical Orphan Drug Designation For VL-2397 For The Treatment Of Invasive Aspergillosis
2015-12-21,Vical Appoints Dr. Thomas Shenk To Board Of Directors
2015-11-29,4 Stocks Under $10 to Trade for Big Breakouts
2015-11-11,Vical To Present At The Stifel Healthcare Conference 2015
2015-11-04,4 Stocks Under $10 to Trade for Big Breakouts
2015-10-29,Vical Reports Third Quarter 2015 Financial Results And Progress In Key Development Programs
2015-10-28,Insider Trading Alert - VICL, JNPR And GSBC Traded By Insiders
2015-10-22,Vical Announces News Release And Conference Call Schedule For Third Quarter 2015 Financial Results
2015-10-15,Insider Trading Alert - VICL, HEAR And SCOR Traded By Insiders
2015-09-15,Vical To Present Preclinical Data At ICAAC 2015 Meeting For Its Novel Antifungal Drug Candidate VL-2397
2015-09-03,Vical To Present At The Rodman & Renshaw 17th Annual Global Investment Conference
2015-08-19,FDA Grants Qualified Infectious Disease Product (QIDP) Designation To VL-2397, Vical's Antifungal Product Candidate
2015-07-30,Vical Reports Second Quarter 2015 Financial Results And Progress In Key Development Programs
2015-06-22,Vical Reports Top-Line Results From Phase 1/2 Trial Of Therapeutic Genital Herpes Vaccine
2015-06-02,Vical (VICL) Stock Jumps on Positive Coverage Initiation
2015-05-21,Vical Announces Completion Of Enrollment In Phase 2 Clinical Trial Of Investigational CMV Vaccine In Kidney Transplant Recipients
2015-05-08,Vical Reports First Quarter 2015 Financial Results And Progress In Key Development Programs
2015-05-01,Vical Announces News Release And Conference Call Schedule For First Quarter 2015 Financial Results
2015-04-22,Vical To Manufacture HIV Vaccines For Clinical Evaluation By Public-Private Partnership Initiative
2015-04-21,Vical Announces Presentation Of Preclinical Data For Congenital CMV DNA Vaccine At International Conference
2015-04-02,Insider Trading Alert - VICL, ARC And KIRK Traded By Insiders
2015-03-25,Vical Expands Infectious Disease Portfolio With Novel Antifungal From Astellas
2015-03-05,Vical To Present At The 27th Annual ROTH Conference
2015-02-26,Vical Reports Fourth Quarter 2014 Financial Results And Progress In Key Development Programs
2015-02-19,Vical Announces News Release And Conference Call Schedule For Fourth Quarter 2014 Financial Results
2015-02-09,Vical To Present At The Leerink Global Healthcare Conference
2015-01-23,Insider Trading Alert - VICL, AGX And GUID Traded By Insiders
2015-01-15,Insider Trading Alert - VICL, TIPT And HSP Traded By Insiders
2015-01-14,Vical And AnGes Announce Collaboration To Develop Therapy For Ebola Virus Disease
2014-12-11,Vical Completes Enrollment In Its Therapeutic HSV-2 Vaccine Clinical Trial
2014-11-25,Vical To Present At The Piper Jaffray 26th Annual Healthcare Conference
2014-11-11,Vical To Present At The Stifel 2014 Healthcare Conference
2014-10-31,Interesting VICL Put Options For June 2015
2014-10-30,Vical Reports Third Quarter 2014 Financial Results And Progress In Key Development Programs
2014-10-23,Vical Announces News Release And Conference Call Schedule For Third Quarter 2014 Financial Results
2014-10-08,Vical Granted Six U.S. Patents For HSV-2 Vaccines
2014-09-04,Vical To Present At The Rodman And Renshaw 16th Annual Global Investment Conference
2014-07-31,Vical Reports Second Quarter 2014 Financial Results And Progress In Key Development Programs
2014-07-24,Vical Announces News Release And Conference Call Schedule For Second Quarter 2014 Financial Results
2014-07-18,5 Stocks Under $10 Set to Soar
2014-06-18,Vical To Present At The JMP Securities Annual Healthcare Conference
2014-05-30,4 Stocks Under $10 Making Big Moves
2014-05-27,Provectus Executive Actions Worthy of FDA, SEC Investigations
2014-05-01,Vical Reports First Quarter 2014 Financial Results And Progress In Key Development Programs
2014-04-23,Vical Announces News Release And Conference Call Schedule For First Quarter 2014 Financial Results
2014-03-21,3 Stocks Under $10 Moving Higher
2014-03-05,Vical To Present At The ROTH Capital Partners 26th Annual Growth Stock Conference
2014-02-26,Vical To Present At The 34th Annual Cowen Health Care Conference
2014-02-12,Vical Reports 2013 Financial Results And Progress In Key Development Programs
2014-02-07,Vical To Present At The 2014 Leerink Global Healthcare Conference
2014-02-05,Vical Announces News Release And Conference Call Schedule For 2013 Financial Results
2014-01-22,Interesting VICL Put And Call Options For September 20th
2014-01-15,5 Stocks With Big Insider Buying
2014-01-15,Top Insider Trades: VICL SBCF RSE DY
2014-01-10,5 Stocks Poised for Breakouts
2013-12-26,Vical Stock Sees Short Interest Decline 22.2%
2013-12-17,The Worst Biotech CEO of 2013 Is...
2013-12-17,Vical Announces Initiation Of Phase 1/2 Trial Of A Therapeutic HSV-2 Vaccine For Genital Herpes
2013-12-12,Your Vote Counts: Who Is the Worst Biotech CEO of 2013?
2013-12-10,Astellas And Vical Announce Initiation Of Phase 2 Trial Of ASP0113, A Cytomegalovirus Vaccine, In Solid Organ Transplant Recipients
2013-12-05,SHAREHOLDER ALERT: Brower Piven Encourages Investors With More Than $100,000 In Losses From Investment In Vical Incorporated To Contact Brower Piven Before The December 31, 2013 Lead Plaintiff Deadline
2013-11-27,SHAREHOLDER ALERT: Pomerantz Law Firm Has Filed A Class Action Against Vical Incorporated And Certain Officers - VICL
2013-11-19,Two Drugs, Designed To Help Patients, Actually Hurt Them
2013-11-18,Presentation Of Vical's Allovectin(R) Phase 3 Results Scheduled At Society For Melanoma Research Meeting
2013-11-14,Attention Vical Incorporated Investors: Vical Misled Investors According To A Newly Filed Class Action
2013-11-08,SHAREHOLDER ALERT: Brower Piven Encourages Investors With More Than $100,000 In Losses From Investment In Vical Incorporated To Contact Brower Piven Before The December 31, 2013 Lead Plaintiff Deadline
2013-11-06,Harwood Feffer LLP Announces Investigation Of Vical Incorporated
2013-11-06,SHAREHOLDER ALERT: Investors With More Than $50,000 In Losses From Investments In Vical Incorporated Are Encouraged To Contact Wolf Haldenstein Before The December 31, 2013 Lead Plaintiff Deadline
2013-11-06,Vical To Present At 2013 Credit Suisse Healthcare Conference
2013-10-31,Vical Reports Third Quarter 2013 Financial Results And Progress In Key Development Programs
2013-10-24,Vical Reviews Herpes Simplex Vaccine Progress At 2nd International Conference And Exhibition On Cell & Gene Therapy
2013-10-24,Vical Announces News Release And Conference Call Schedule For Third Quarter 2013 Financial Results
2013-10-18,5 Stocks Under $10 to Trade for Breakouts
2013-10-03,Vical Publication Highlights Milestone In Vaccine Development
2013-09-06,Vical To Present At September Investor Conferences
2013-08-27,Short Interest Decreases By 30% For VICL
2013-08-23,Biotech Stock Mailbag: MannKind, Osiris, BioCryst, Vical, Amarin
2013-08-22,Vical Announces Restructuring And Staff Reduction
2013-08-14,4 Biotech Stocks Under $10 Making Big Moves
2013-08-12,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Vical Incorporated
2013-08-12,Vical Phase 3 Trial Of Allovectin(R) Fails To Meet Efficacy Endpoints
2013-08-11,Vical Announces Conference Call And Webcast To Discuss Allovectin(R) Phase 3 Results
2013-08-09,Biotech Stock Mailbag: Sarepta, Inovio, FDA Calendar, Ken Luskin's Angry Vical Voice Mail
2013-08-04,MannKind, Vical, GTx: Investors Predict Pivotal Clinical Trial Results
2013-08-01,Vical Reports Second Quarter 2013 Financial Results, Projects Phase 3 Data Release In August And Establishes Quiet Period
2013-07-25,Vical Announces News Release And Conference Call Schedule For Second Quarter 2013 Financial Results
2013-07-23,First Week Of March 2014 Options Trading For Vical (VICL)
2013-07-17,Worried About Credit Risk? Check Out These 5 Cash-Rich Companies
2013-07-03,Vical To Present At JMP Securities Healthcare Conference
2013-06-25,Vical And Astellas Announce Initiation Of Phase 3 Trial Of ASP0113 Cytomegalovirus Vaccine
2013-06-12,Vical To Present At Wells Fargo Securities Healthcare Conference
2013-05-23,Vical Appoints Richard M. Beleson And Stephen A. Sherwin, M.D., To Board Of Directors
2013-05-20,Interesting VICL Put And Call For July
2013-05-17,Biotech Stock Mailbag: Vical, Sangamo, Spectrum Pharma
2013-05-10,Short Interest In Vical Moves 21.2% Higher
2013-05-09,Vical Reports First Quarter 2013 Financial Results And Progress In Key Development Programs
2013-05-07,Vical To Present At May Investor Conferences
2013-05-06,Vaxfectin(R) Enhances Preclinical Immune Responses To Baxter's Cell Culture-Derived Influenza Vaccines
2013-05-02,Vical Announces News Release And Conference Call Schedule For First Quarter 2013 Financial Results
2013-04-22,Vical CEO To Participate In Cancer Immunotherapy Panel At BIO International Convention
2013-04-04,6 Stocks Under $10 Spiking Higher
2013-03-26,16 Stocks Under $5 Trading At Discounts To Target Price
2013-02-27,Vical To Present At March Investor Conferences
2013-02-06,Vical Reports 2012 Financial Results And Progress In Key Development Programs
2013-02-05,Vical To Present At February Investor Conferences
2013-02-04,Vical Announces Publication Of Herpes Simplex Vaccine Guinea Pig Study Data
2013-01-30,Vical Announces News Release And Conference Call Schedule For 2012 Financial Results
2013-01-15,3 Pharma Stocks Under $5 Trading Higher
2013-01-03,Vical To Present At 31st Annual J.P. Morgan Healthcare Conference
2013-01-02,Vical Named To NASDAQ Global Select Market
2012-11-09,Biotech Stock Mailbag: Sarepta, Acadia, Vical and a Hep C Preview
2012-11-09,Vical Incorporated Stock Downgraded (VICL)
2012-11-05,21 Most Volatile Biopharma Stocks Closing Out 2012
2012-10-16,Vical Appoints George J. Morrow To Board Of Directors
2012-09-27,Vical To Present At 3rd Annual Cancer Immunotherapy Conference
2012-09-13,Stocks Soar as Fed Delivers QE3
2012-09-13,Vical Licenses DNA Immunization Technology And Vaxfectin(R) Adjuvant To Bristol-Myers Squibb For Use In Antibody Production
2012-08-29,Vical To Present At September Investor Conferences
2012-08-01,Vical's CEO Discusses Q2 2012 Results - Earnings Call Transcript
2012-05-22,22 Biopharma Stocks With Breakout Potential in 2012
2012-05-16,Vical's CEO Presents At Bank Of America Merrill Lynch Health Care Conference Call (Transcript)
2012-05-04,Vical Incorporated Stock Upgraded (VICL)
2012-05-02,Vical's CEO Discusses Q1 2012 Results - Earnings Call Transcript
2012-02-28,Vical's CEO Hosts At Citi 2012 Global Health Care Conference (Transcript)
2012-02-10,Vical Incorporated Stock Downgraded (VICL)
2012-02-08,Vical's CEO Discusses Q4 2011 Results - Earnings Call Transcript
2012-01-27,Biotech Stock Mailbag: Vical, Hep C Drugs
2012-01-12,5 Stocks With Big Insider Buying
2012-01-10,Insiders Trading VICL, RAX, RAS, MIG
2012-01-06,Vical Stock Falls On Unusually High Volume (VICL)
2012-01-05,Vical, RF Micro: After-Hours Trading
2011-12-23,Biotech Stock Mailbag: Most Important Events for 2012
2011-12-20,10 Biotech Stock Predictions for 2012
2011-12-15,Biotech Stock Live Chat: 2012 Preview
2011-12-05,10 Best-Performing Stocks Under $5 in 2011
2011-11-16,Vical Incorporated At Credit Suisse Group Healthcare Conference Call Transcript
2011-11-03,Vical Incorporated Stock Upgraded (VICL)
2011-11-01,Vical Incorporated's CEO Discusses Q3 2011 Results - Earnings Call Transcript
2011-09-30,Biotech Stock Mailbag: Research Backs Shorting Micro-Cap Cancer Drug Stocks
2011-08-03,Vical's CEO Discusses Q2 2011 Results - Earnings Call Transcript
2011-05-19,ASCO: Cancer Stock Winners, Losers
2011-05-19,ASCO: Traders Love Speculative Cancer Stocks
2011-05-05,Vical's CEO Discusses Q1 2011 Results - Earnings Call Transcript
2011-04-14,11 Stocks to Watch: Fairchild, Goldman
2011-03-14,Vical To Present At ROTH Growth Stock Conference
2011-03-02,Vical Receives Positive Scientific Advice From EMA For TransVax(TM) Phase 3 Trial
2011-02-24,Vical To Present At Upcoming Investor Conferences
2011-02-22,Vical Extends Collaboration With U.S. Government For Emerging Disease Vaccines
2011-02-16,Vical Receives U.S. Patent For Cytomegalovirus Vaccines
2011-02-14,Vical's Allovectin-7(R) Phase 3 Trial Receives Positive Review From Safety Monitoring Board
2011-02-10,Vical CEO Discusses Q4 2010 Results - Earnings Call Transcript
2011-02-10,Vical Reports 2010 Financial Results And Progress In Key Development Programs
2011-02-08,Vical And The University Of Washington Receive U.S. Patent For Herpes Simplex Vaccine
2017-03-26,Why Concert Pharmaceuticals Is Music to Investors' Ears
2017-03-06,What You Must Know About Cystic Fibrosis Drug CTP-656
2017-03-06,Vertex Pharma Acquires Long-Acting Version of Cystic Fibrosis Drug From Concert Pharma
2017-03-06,Vertex To Acquire CTP-656 From Concert Pharmaceuticals For The Treatment Of Cystic Fibrosis
2017-03-02,Vertex To Present At The Cowen Healthcare Conference On March 6
2017-02-21,Activist Investors Shake Up the Boards at Tiffany &amp; Bristol-Myers Squibb
2017-01-31,Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence
2017-01-27,Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen
2017-01-25,Vertex Reports Full-Year And Fourth-Quarter 2016 Financial Results
2017-01-11,Merck KGaA, Darmstadt, Germany Licenses Four Oncology Research And Development Programs From Vertex
2017-01-09,Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference
2017-01-09,Vertex Pharmaceuticals to Rely on Acquisitions to Diversify Its Business
2017-01-09,Vertex Pharma Will Use Deals to Diversify Beyond Cystic Fibrosis
2017-01-09,Vertex Pharmaceuticals Sees Sales of Cystic Fibrosis Drug Lower Than Expected
2017-01-08,Vertex View into Cystic Fibrosis Sales Growth Still Limited by European Reimbursement
2017-01-08,Vertex Provides Update On Business And Financial Performance And Research And Development Programs
2017-01-07,Here Are 6 Things to Watch Out for at J.P. Morgan's Healthcare Conference Next Week
2017-01-05,Here's What to Look for at the J.P. Morgan Healthcare Conference
2017-01-05,What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017
2017-01-04,Vertex Announces Upcoming Presentation At The J.P. Morgan Healthcare Conference And Date Of Fourth Quarter And Full Year 2016 Financial Results
2017-01-03,Cramer's 'Mad Money' Recap (Tuesday 1/3/17): Better Buying Opportunities Are Lurking
2017-01-03,Cramer: Reviewing S&amp;P's Hit-and-Miss Parade
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2016-12-19,Vertex Announces German Reimbursement Agreement For ORKAMBI® (Lumacaftor/Ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People Ages 12 And Older With Two Copies Of The F508del Mutation
2016-12-12,Vertex Pharmaceuticals Becomes #42 Most Shorted Nasdaq 100 Component, Replacing Cerner
2016-12-09,Broadcom Call Should 'Make You Feel Better About Owning Apple': More Squawk From Jim Cramer
2016-11-29,More Base Building Ahead for Vertex Pharmaceuticals
2016-11-29,Analysts' Actions -- Goldman Sachs, Johnson & Johnson, Pfizer and More
2016-11-17,Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!
2016-11-14,Bullish and Bearish Chart Reversals
2016-11-13,Six Thoughts on President Trump and the Durability of the Biotech Stock Rally
2016-11-10,5 Health Care Stocks Set to Bounce
2016-11-07,Positive Phase 3 Study Of ORKAMBI® In Children With Cystic Fibrosis Ages 6-11 Who Have Two Copies Of The F508del Mutation Supports A Submission To The European Medicines Agency In The First Half Of 2017
2016-11-02,Vertex To Present At The Credit Suisse Healthcare Conference On November 8
2016-10-27,Vertex Pharmaceuticals Enters Oversold Territory
2016-10-27,ProQR Cystic Fibrosis Drug Passes First, Early Efficacy Test
2016-10-27,Vertex Presents Long-Term Data Demonstrating That ORKAMBI® (lumacaftor/ivacaftor) And KALYDECO® (ivacaftor) Show The Potential To Modify The Progression Of CF
2016-10-26,Vertex Pharma (VRTX) Stock Lower on Q3 Miss
2016-10-26,Pardon Me, but I Have a Few Things to Say... Vertex, Biogen, Ariad, Sarepta
2016-10-25,Vertex Pharma Moves Next-Generation Cystic Fibrosis Drugs Into New Clinical Trials
2016-10-25,Vertex Reports Third Quarter 2016 Financial Results
2016-10-25,Table 1 (Graphic: Vertex)
2016-10-11,Illumina Leads Healthcare Selloff, Abbott and Zimmer Also Fall
2016-10-07,Vertex To Announce Third Quarter 2016 Financial Results On October 25
2016-10-05,When Does Vertex Pharmaceuticals Become a Buy?
2016-09-28,U.S. Food And Drug Administration Approves ORKAMBI® (lumacaftor/ivacaftor) For Use In Children With Cystic Fibrosis Ages 6 Through 11 Who Have Two Copies Of The F508del Mutation
2016-09-09,Vertex To Present At Upcoming Investor Conferences
2016-08-25,Vertex Pharmaceuticals Takes Over #81 Spot From Starbucks
2016-08-15,Vertex Provides Update On Ongoing Phase 3 Program For VX-661 In Combination With Ivacaftor For The Treatment Of Cystic Fibrosis
2016-08-07,Listen Up and Pay Attention to the Utes
2016-08-01,Could a Spin-off of its Hepatitis C Division be in Gilead's Future?
2016-07-28,Ratings Changes Today
2016-07-27,Vertex Reports Second Quarter 2016 Financial Results
2016-07-27,A 'Semi-Charmed' Kind of NXPI Call Spread
2016-07-14,Vertex To Announce Second Quarter 2016 Financial Results On July 27
2016-07-13,3 Stocks Pushing The Health Care Sector Lower
2016-07-06,Wall Street Closes Higher as Fed Doves Make Case for Waiting on Rates
2016-07-06,Stocks Add to Gains as Fed Stresses Prudence in Policy-Making
2016-07-06,Vertex And Moderna Establish Exclusive Collaboration To Discover And Develop MRNA Therapeutics™ For Cystic Fibrosis
2016-07-01,Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here
2016-06-27,The New #41 Most Shorted Nasdaq 100 Component: Vertex Pharmaceuticals
2016-06-10,Vertex Announces Presentations Of Data For KALYDECO® (ivacaftor) And ORKAMBI® (lumacaftor/ivacaftor) At European Cystic Fibrosis Society (ECFS) Conference
2016-06-10,Biotech Stock Mailbag: Sarepta! Always More Sarepta. And Gilead, Too
2016-06-09,3 Stocks Pulling The Health Care Sector Downward
2016-05-31,Vertex To Present At The Goldman Sachs Healthcare Conference On June 7
2016-05-31,U.S. FDA Accepts For Priority Review Supplemental New Drug Application For The Use Of ORKAMBI® (lumacaftor/ivacaftor) In Children With Cystic Fibrosis Ages 6 To 11 Who Have Two Copies Of The F508del Mutation
2016-05-25,Vertex Pharmaceuticals Becomes #243 Most Shorted S&P 500 Component, Replacing Coach
2016-05-09,Cramer: How Did the Stock Market Get So Unwieldy?
2016-04-27,Vertex Forecasts Billion-Dollar Sales for Cystic Fibrosis Drug in '16
2016-04-27,Post-Market Activity Shows Vertex Pharmaceuticals (VRTX) Down
2016-04-27,Vertex Reports First Quarter 2016 Financial Results
2016-04-27,Charts Say Vertex Could Recover
2016-04-22,3 Compelling Reasons to Buy This Undervalued Biotechnology Stock
2016-04-22,5 Toxic Stocks You Should Sell Now
2016-04-18,Enterome In-licenses Novel Compounds From Vertex Pharmaceuticals To Treat Microbiome-related Inflammatory Bowel Diseases
2016-04-18,Strong On High Relative Volume: Vertex Pharmaceuticals (VRTX)
2016-04-15,Vertex To Announce First Quarter 2016 Financial Results On April 27
2016-04-12,Vertex Pharma (VRTX) Stock Price Target Cut at Credit Suisse
2016-04-07,Perilous Reversal Watch: Vertex Pharmaceuticals (VRTX)
2016-04-07,Vertex Pharmaceuticals (VRTX) Stock Receives &lsquo;Market Perform&rsquo; Rating at BMO Capital
2016-04-06,Vertex Pharmaceuticals (VRTX) Stock Price Target Reduced at Jefferies
2016-04-04,Reasons for Vertex's Stock Slump Since Last Summer Center on Orkambi Launch
2016-03-29,3 Stocks Pushing The Drugs Industry Downward
2016-03-27,5 Stocks That Could Be Toxic to Your Portfolio in 2016
2016-03-23,NVO, VRTX And ILMN, Pushing Health Care Sector Downward
2016-03-10,Vertex To Present At The Barclays Healthcare Conference On March 15
2016-03-10,3 Stocks Pulling The Drugs Industry Downward
2016-03-08,Vertex Receives Australian Approval For ORKAMBI® (lumacaftor/ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People Ages 12 And Older With Two Copies Of The F508del Mutation
2016-03-06,JPMorgan's 7 Best Stock Picks With Near-Term Catalysts
2016-03-02,3 Stocks Advancing The Drugs Industry
2016-02-25,3 Stocks Pushing The Drugs Industry Downward
2016-02-24,Vertex Awards $1 Million In Grants To 18 Non-profit Organizations To Advance Initiatives For People Living With Cystic Fibrosis
2016-02-20,10 Big CEOs Who Make Way Too Much Money
2016-02-09,Vertex To Present At Upcoming Investor Conferences
2016-02-05,Vertex Receives Complete Response Letter From U.S. FDA For Use Of KALYDECO® (ivacaftor) In People With Cystic Fibrosis Ages 2 And Older With One Of 23 Residual Function Mutations
2016-02-01,Analysts' Actions -- Bristol-Myers, Chipotle, Monster Beverage, Vertex Pharmaceuticals and More
2016-02-01,Biotech String: Assessing the January Damage, Gilead's Bottoming P/E, Sarepta Panel Date?
2016-01-29,Here Are the 5 Worst-Performing Stocks in the S&amp;P 500 in 2016
2016-01-27,Vertex Pharmaceuticals (VRTX) Is Today's Post-Market Loser Stock
2016-01-27,Vertex Reports Full-Year And Fourth Quarter 2015 Financial Results
2016-01-26,Health Canada Approves PrORKAMBI® (lumacaftor/ivacaftor) - The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis For People Ages 12 And Older With Two Copies Of The F508del Mutation
2016-01-25,Biotech String: Editas IPO Terms, Rooting for Shkreli in DC
2016-01-15,Vertex Pharmaceuticals (VRTX) Showing Signs Of Perilous Reversal Today
2016-01-14,Here Are the 10 Worst S&P 500 Stocks So Far in 2016
2016-01-12,3 Stocks Pulling The Drugs Industry Downward
2016-01-11,A Lack of News and Buzz at 'JPM16' Sinks Biotech Stocks
2016-01-10,Vertex Takes a Pass on 2016 Orkambi Cystic Fibrosis Sales Guidance
2016-01-10,Vertex Outlines 2016 Business Priorities To Support The Discovery And Development Of New Transformative Medicines For The Treatment Of Cystic Fibrosis And Other Serious Diseases
2016-01-09,5 Toxic Stocks to Sell in January
2016-01-05,Vertex Announces Upcoming Presentation At The J.P. Morgan Healthcare Conference And Date Of Fourth Quarter And Full Year 2015 Financial Results
2015-12-26,Sell These 6 Biotech Stocks Now Before It's Too Late
2015-12-08,J.P. Morgan's 53 Top Stock Picks for 2016
2015-12-04,Today's Dead Cat Bounce Stock Is Vertex Pharmaceuticals (VRTX)
2015-12-03,3 Drugs Stocks Dragging The Industry Down
2015-12-01,'Mad Money' Lightning Round: Buy Kroger, It's Terrific
2015-11-30,Jim Cramer's 'Mad Money' Recap: These Retailers Will Survive the Amazon Express
2015-11-23,Vertex To Present At The Piper Jaffray Healthcare Conference On December 1
2015-11-23,Vertex Appoints Michael J. Parini As Executive Vice President And Chief Legal Officer
2015-11-20,Vertex Receives EU Approval For ORKAMBI® (lumacaftor/ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People Ages 12 And Older With Two Copies Of The F508del Mutation
2015-11-18,Vertex Receives Two EU Approvals For KALYDECO® (ivacaftor) For People With Cystic Fibrosis
2015-11-13,3 Stocks Raising The Drugs Industry Higher
2015-11-04,Vertex To Present At The Credit Suisse Healthcare Conference On November 10
2015-10-30,Analysts' Actions -- Vertex, LinkedIn, BE/Aerospace, DreamWorks, Starbucks
2015-10-28,Vertex Reports Third Quarter 2015 Financial Results
2015-10-28,Trade-Ideas: Vertex Pharmaceuticals (VRTX) Is Today's "Perilous Reversal" Stock
2015-10-28,3 Stocks Underperforming Today In The Health Care Sector
2015-10-26,Vertex And CRISPR Therapeutics Establish Collaboration To Use CRISPR-Cas9 Gene Editing Technology To Discover And Develop New Treatments For Genetic Diseases
2015-10-13,3 Stocks Pulling The Drugs Industry Downward
2015-10-09,Vertex To Announce Third Quarter 2015 Financial Results On October 28
2015-10-08,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Breaches Of Fiduciary Duty By The Board Of Vertex Pharmaceuticals Incorporated -- VRTX
2015-10-08,Vertex to Test New Cystic Fibrosis Drugs, Seeking Broader, More Effective Treatments
2015-10-08,Vertex Announces Significant Progress In Its Development Efforts To Treat The Cause Of Cystic Fibrosis In The Vast Majority Of People With The Disease
2015-10-07,Supplemental New Drug Application For Use Of KALYDECO® (ivacaftor) In People With Cystic Fibrosis Ages 2 And Older Who Have One Of 23 Residual Function Mutations Accepted For Priority Review By U.S. FDA
2015-10-02,Morgan Stanley Says These 9 Health Care Stocks Are Best-Positioned, Despite Rising Drug Prices
2015-10-02,Analysts' Actions -- Google, Gilead, AIG and More
2015-10-01,10 Worst Health Care Stocks in the Third Quarter
2015-09-30,Strong On High Relative Volume: Vertex Pharmaceuticals (VRTX)
2015-09-25,Vertex Receives CHMP Positive Opinions For ORKAMBI™ (lumacaftor/ivacaftor) And KALYDECO® (ivacaftor) In The European Union
2015-09-23,3 Stocks Dragging The Health Care Sector Downward
2015-09-22,Analysts Say Buy Select Biotech Stocks Ahead Of Clinton Drug Plan
2015-09-22,Clinton Drug Plan Cuts Market Exclusivity, Sets Mandatory R&D Spending
2015-09-18,Roof Leaker To Watch: Vertex Pharmaceuticals (VRTX)
2015-09-18,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Breaches Of Fiduciary Duty By The Board Of Vertex Pharmaceuticals Incorporated -- VRTX
2015-09-16,3 Stocks Underperforming Today In The Drugs Industry
2015-09-14,Analysts' Actions -- Marvell, Dow Chemical, Other Calls
2015-09-08,Vertex To Present At The Morgan Stanley Healthcare Conference On September 16
2015-08-26,Vertex Pharmaceuticals (VRTX) Is Strong On High Volume Today
2015-08-24,Biotech Stocks Recover From Early-Morning Flash Crash
2015-08-19,Vertex Awards Two Boston Public High School Students The Vertex Science Leaders Scholarship To The University Of Massachusetts
2015-08-14,50 Stocks to Watch for Good Plays: Jim Cramer's Best Blogs
2015-08-14,Expect Bumpy Ride When 'Unicorn' Tech Bubble Pops, Says Avalon Founder
2015-08-04,3 Stocks Boosting The Drugs Industry Higher
2015-07-30,3 Drugs Stocks Pushing Industry Growth
2015-07-29,Trade-Ideas: Vertex Pharmaceuticals (VRTX) Is Today's Post-Market Leader Stock
2015-07-29,Vertex Reports Second Quarter 2015 Financial Results
2015-07-20,Apple's Earnings Could Coincide with an Overbought Reading
2015-07-15,Vertex Pharmaceuticals (VRTX) Is Strong On High Volume Today
2015-07-14,Vertex To Announce Second Quarter 2015 Financial Results On July 29
2015-07-02,Vertex Wins U.S. Approval for New Cystic Fibrosis Drug
2015-07-02,FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis For People Ages 12 And Older With Two Copies Of The F508del Mutation
2015-07-02,Vertex Pharmaceuticals (VRTX) Is Today's Unusual Social Activity Stock
2015-06-29,Vertex Profits Hinge on FDA Approving New Cystic Fibrosis Drug This Week
2015-06-29,Vertex Pharmaceuticals Becomes #232 Most Shorted S&P 500 Component, Replacing Exxon Mobil
2015-06-25,Trade-Ideas: Vertex Pharmaceuticals (VRTX) Is Today's Post-Market Leader Stock
2015-06-23,3 Stocks Raising The Health Care Sector Higher
2015-06-18,Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board Of Directors
2015-06-11,Vertex Announces Data Presentations At European Cystic Fibrosis Society (ECFS) Conference
2015-06-04,Vertex And Parion Sciences Establish Collaboration To Develop Epithelial Sodium Channel (ENaC) Inhibitors In Cystic Fibrosis And Other Pulmonary Diseases
2015-06-03,Vertex To Present At The Goldman Sachs Healthcare Conference On June 11
2015-06-03,Corbus Focused on Research and in No Hurry for Partnerships, Says CEO
2015-06-03,Corbus Ready to Take Cystic Fibrosis Drug the Distance Says CEO
2015-05-22,Biotech Stock Mailbag: ASCO Preview, CAR-T stocks, MannKind, Hate Mail!
2015-05-20,10 S&P 500 Companies to Have the Most Revenue Growth in 2015
2015-05-19,Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest
2015-05-17,New England Journal Of Medicine Publishes Data From Two Phase 3 Studies Of ORKAMBITM (lumacaftor/ivacaftor) in People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation
2015-05-13,Vertex To Present At The UBS Healthcare Conference On May 19
2015-05-13,Vertex Pharmaceuticals (VRTX) Stock Climbs Following FDA Advisory Panel Aprroval
2015-05-13,Cramer: I Like Receptos and Radius, as Well as the Four Horsemen
2015-05-13,Vertex Pharmaceuticals (VRTX) Showing Unusual Social Activity Today
2015-05-12,Food And Drug Administration Advisory Panel Voted 12 To 1 To Recommend Approval Of ORKAMBI™ (lumacaftor/ivacaftor) To Treat People With Cystic Fibrosis Ages 12 And Older Who Have Two Copies Of The F508del Mutation
2017-03-23,Versartis To Host Conference Call To Review Data From ENDO 2017 On Long-Acting Somavaratan For Growth Hormone Deficiency
2017-03-15,Versartis Appoints Tracy Woody As Chief Commercial Officer
2017-03-02,Versartis Announces Data On Long-Acting Somavaratan For Growth Hormone Deficiency To Be Featured In Late-Breaker Presentation At ENDO 2017
2017-03-01,Versartis To Present At Cowen & Co. Annual Healthcare Conference And Barclays Global Healthcare Conference
2017-02-21,Versartis Reports Fourth Quarter 2016 Financial Results
2017-02-15,Twitter Is One of Five Stocks Insiders Really Love Right Now
2017-01-31,Versartis Promotes Joshua T. Brumm To Chief Operating Officer And Paul Westberg To Chief Business Officer
2017-01-30,Versartis' Long-Acting Somavaratan For Growth Hormone Deficiency To Be Featured In Multiple Oral And Poster Presentations At ENDO 2017
2017-01-13,Versartis' Pipeline Holds Big Promise
2017-01-13,Versartis' Pipeline Holds Big Promise
2017-01-08,Don't Tell Anyone: Insiders Are Buying These Stocks Like Crazy
2016-12-01,Commit To Buy Versartis At $10, Earn 46.5% Annualized Using Options
2016-11-07,Versartis Presents Safety, Efficacy And IGF-I Data For Somavaratan In Pediatric Growth Hormone Deficiency At The 2016 Congress Of The GRS & IGF Society
2016-11-03,Versartis Reports Third Quarter 2016 Financial Results
2016-11-02,Versartis Enters Oversold Territory (VSAR)
2016-10-31,Versartis To Present At Two Investor Conferences In November
2016-10-04,Shark Bites: Versartis Is a Biotech Worth Tracking
2016-09-28,Versartis Announces Pricing Of Follow-On Offering
2016-09-27,Versartis Announces Proposed Offering Of Common Stock
2016-09-27,Short Interest Decreases By 26.6% For VSAR
2016-09-26,Versartis Initiates Phase 3 Trial Of Somavaratan In Japan For Children With Growth Hormone Deficiency Following Completion Of Phase 2
2016-09-12,Versartis Presents Data From Up To 30 Months Of Somavaratan Treatment For Pediatric Growth Hormone Deficiency At The 2016 ESPE Annual Meeting
2016-09-06,Versartis To Present At The Morgan Stanley Global Healthcare Conference
2016-09-06,Versartis To Host Investor Symposium Featuring Leading Experts In Growth Hormone Deficiency
2016-09-02,Versartis Presents Efficacy, Safety, Metabolic And Adherence Data For Somavaratan In Oral Session At The International Congress Of Endocrinology
2016-08-22,Versartis Announces Completion Of Enrollment In Phase 3 VELOCITY Trial Of Somavaratan In Pediatric GHD
2016-08-09,Teijin Limited And Versartis Enter Strategic Alliance For Commercialization Of Somavaratan Long-Acting Growth Hormone In Japan
2016-08-04,Versartis To Present At The Canaccord Genuity 36th Annual Growth Conference
2016-07-28,Versartis Reports Second Quarter 2016 Financial Results
2016-06-29,16 Biopharma Companies Besides Medivation That Are Attractive Targets
2016-04-28,Versartis Reports First Quarter 2016 Financial Results
2016-04-04,Versartis Presents Confirmatory Year Two Data From Ongoing Somavaratan Extension Study At Late-Breaker Session At ENDO Annual Meeting
2016-04-01,Versartis Presents Confirmatory 18-Month Adherence Data From Ongoing Somavaratan Extension Study At Late-Breaker Session At ENDO Annual Meeting
2016-03-30,Versartis Appoints Colin Hislop, M.D., As Chief Medical Officer
2016-03-20,8 Biotech Stocks Under $10 Making Big Moves Higher
2016-03-14,Versartis Announces Two Abstracts From Ongoing Pediatric Extension Study Of Somavaratan Selected For Late-Breaker Presentations At The Endocrine Society's 98th Annual Meeting
2016-03-08,RSI Alert: Versartis (VSAR) Now Oversold
2016-03-08,Capella Bioscience Completes Series A Financing Of £11 Million ($15.5 Million) To Progress Antibody Pipeline
2016-03-01,Versartis To Present At The Cowen And Company 36th Annual Health Care Conference
2016-02-18,Versartis Reports Fourth Quarter And Full Year 2015 Financial Results
2016-02-17,VSAR: Insiders vs. Shorts
2016-02-02,Versartis Reports Confirmatory Top-Line Two-Year Data From Ongoing Extension Study Of Somavaratan In GHD Children
2016-02-02,Medicxi Ventures, Formerly Index Ventures Life Sciences, Launches As An Independent Venture Capital Firm And Announces Closing Of A €210m Fund Including GSK And Johnson & Johnson Innovation
2016-01-28,Versartis To Host Conference Call To Review Two-Year Top-Line Data From Ongoing Extension Study Of Somavaratan
2015-12-16,Versartis' VRS-317 6-Month Data Published In The Journal Of Clinical Endocrinology & Metabolism
2015-11-16,VSAR: Insiders vs. Shorts
2015-11-03,Versartis To Present At The Credit Suisse 24th Annual Healthcare Conference
2015-10-29,Versartis Reports Third Quarter 2015 Financial Results
2015-10-01,Versartis Presents Confirmatory 18-Month Data From Ongoing Somavaratan Extension Study At Late-Breaker Session At ESPE Annual Meeting
2015-09-18,Versartis Announces Confirmatory 18-Month Data From Ongoing Extension Study Of Somavaratan In GHD Children
2015-09-10,Versartis Appoints Lars Ekman, MD, PhD, As Global Development Advisor
2015-09-10,Versartis Initiates Phase 2 Trial (VITAL) Of Monthly Somavaratan In Adults With Growth Hormone Deficiency
2015-09-08,Versartis Announces Agenda And Event Details For Investor Symposium Featuring Global Opinion Leaders In Pediatric Human Growth Hormone Deficiency (GHD)
2015-09-08,Versartis To Present At Upcoming Investor Conferences
2015-08-11,Versartis To Host Investor Symposium Featuring Global Opinion Leaders In Pediatric Human Growth Hormone Deficiency
2015-08-04,Versartis To Present At The Canaccord Genuity 35th Annual Growth Conference
2015-08-04,Versartis Abstract Accepted For Late-Breaker Presentation At The 54th Annual Meeting Of The European Society For Paediatric Endocrinology
2015-08-04,Versartis Reports Second Quarter 2015 Financial Results
2015-07-06,Versartis Price Gains on Drug Approval, eHealth Rises: Tech Winners & Losers
2015-07-06,Market News: Aetna, Versartis, Agile Therapeutics
2015-07-06,Versartis Announces Removal Of FDA Partial Clinical Hold And Continuation Of VRS-317 Phase 3 Clinical Trial
2015-07-01,10 Worst Biotech Stocks in the NASDAQ
2015-05-07,Versartis Becomes Oversold (VSAR)
2015-05-06,Versartis To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference
2015-05-06,Versartis Provides Update On Clinical Programs And Reports First Quarter 2015 Financial Results
2015-05-06,Versartis Appoints Jay Shepard As President And Chief Executive Officer
2015-04-13,Versartis Initiates Phase 2/3 Trial Of VRS-317 In Japan For Children With Growth Hormone Deficiency
2015-03-06,Versartis Presents 12-Month Data For VRS-317 At Late-Breaker Session At Endocrine Society's Annual Meeting
2015-03-04,Versartis To Present At The Barclays Global Healthcare Conference
2015-02-23,Versartis To Present At The Cowen And Company 35th Annual Health Care Conference
2015-02-12,Versartis Reports Fourth Quarter And Full Year 2014 Financial Results
2015-02-02,Versartis To Present At The 2015 BIO CEO & Investor Conference
2015-01-21,Versartis Announces Pricing Of Follow-On Offering
2015-01-20,Versartis Announces Proposed Offering Of Common Stock
2015-01-08,Versartis Initiates Global Phase 3 Study Of VRS-317 In Children With Growth Hormone Deficiency
2015-01-05,Versartis Announces Positive 12 Month Data For VRS-317 From Ongoing Extension Study
2014-12-29,Versartis To Hold Conference Call To Discuss VRS-317 Clinical Update From Ongoing Extension Study
2014-11-24,Versartis To Present At The 26th Annual Piper Jaffray Health Care Conference
2014-11-06,Versartis Reports Third Quarter 2014 Financial Results
2014-11-06,Keith Lui Joins Versartis To Lead Global Marketing Efforts
2014-11-05,Versartis To Present At The 2014 Credit Suisse Healthcare Conference
2014-10-30,Versartis Schedules Conference Call To Discuss Plans For Phase 3 Trial For VRS-317 In Pediatric Growth Hormone Deficiency Patients
2014-09-02,Versartis To Present At The Morgan Stanley 2014 Global Healthcare Conference
2014-08-05,Versartis To Present At The Canaccord Genuity 34th Annual Growth Conference
2014-08-05,Versartis Reports Second Quarter 2014 Financial Results
2014-06-30,4 Stocks Rising on Unusual Volume
2014-03-21,Versartis (VSAR) Surges on First Trading Day
,
,
,
2017-01-11,Allergan Shifts Strategy to Focus on Growth
2017-01-10,Allergan Hints It Is Ready to Make a Splash for More Near-term Growth
2017-01-09,Allergan Continues Down 'Stepping Stone' Path With Two Deals
2016-12-20,Allergan Takes Biggest Step Yet in 'Stepping Stone' Strategy, Signs $2.9 Billion Breast Cancer Deal
2016-10-17,Allergan And Vitae Pharmaceuticals Announce Expiration Of HSR Waiting Period For Allergan's Proposed Acquisition Of Vitae
2016-09-23,VITAE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces The Investigation Of Vitae Pharmaceuticals, Inc. (VTAE) Over The Proposed Sale Of The Company To Allergan Plc
2016-09-23,Allergan's Vitae Buy Could Spark More Interest in Kadmon
2016-09-21,Stocks Hold Higher as Fed's Yellen Says Economy Picking Up
2016-09-21,Stocks Hold Higher in Wait for Fed, Crude Jumps on Supply Drop
2016-09-21,Stock Futures Rise as Bank of Japan Tackles Deflation
2016-09-15,INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Vitae Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional Information
2016-09-15,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Regarding The Fairness Of The Sale Of Vitae Pharmaceuticals, Inc. To Allergan Plc For $21.00 Per Share
2016-09-15,Vitae Pharmaceuticals (VTAE) Stock Downgraded at BMO Capital
2016-09-15,VTAE Crosses Above Average Analyst Target
2016-09-14,SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Vitae Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information
2016-09-14,Harwood Feffer LLP Announces Investigation Of Vitae Pharmaceuticals, Inc.
2016-09-14,Vitae Pharmaceuticals (VTAE) Stock Downgraded on $639 Million Allergan Deal
2016-09-14,Allergan's Dealmaking Continues With Vitae Takeout
2016-09-14,Stocks Waver as Oil Tumbles but Apple Lifts Nasdaq
2016-09-14,4 Big Stocks to Add to Your Buy List -- Plus 3 to Avoid
2016-09-14,Fear of Being Left Out Is Lifting Indices
2016-09-14,VITAE PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
2016-09-14,Allergan Is Doing All the Right Things
2016-09-14,Stocks Add to Gains as Apple Boosts Dow, Crude Fluctuates
2016-09-14,Vitae Pharmaceuticals (VTAE) Stock Soars on $639 Million Allergan Deal
2016-09-14,Stock Futures Edge Higher After a Rocky Three Days
2016-09-14,Allergan To Acquire Vitae Pharmaceuticals Adding Innovative Development Programs For Dermatologic Conditions
2016-09-01,Vitae Pharmaceuticals To Present At Wells Fargo Healthcare Conference
2016-08-11,Vitae Pharmaceuticals To Present At Wedbush PacGrow Healthcare Conference
2016-08-10,Vitae Pharmaceuticals Appoints Scott Applebaum As General Counsel And Corporate Secretary
2016-08-04,Vitae Pharmaceuticals Enters Oversold Territory (VTAE)
2016-08-03,Vitae Pharmaceuticals Reports Second Quarter 2016 Operating And Financial Results
2016-08-01,Vitae Pharmaceuticals To Announce Second Quarter 2016 Financial Results On August 3, 2016
2016-07-27,Vitae Pharmaceuticals Appoints Daniel M. Junius To Board Of Directors
2016-07-06,Commit To Buy Vitae Pharmaceuticals At $10, Earn 31.3% Annualized Using Options
2016-06-17,Vitae Pharmaceuticals (VTAE) Is Weak On High Volume Today
2016-06-14,Vitae Pharmaceuticals To Present At JMP Securities Life Sciences Conference
2016-06-06,Vitae Pharmaceuticals Announces Appointment Of Carole Sable, M.D., As Chief Medical Officer
2016-05-10,Vitae Pharmaceuticals Reports First Quarter 2016 Operating And Financial Results
2016-05-09,Vitae Pharmaceuticals To Present At IMMUNOLOGY 2016
2016-05-03,Vitae Pharmaceuticals To Announce First Quarter 2016 Financial Results On May 10, 2016
2016-04-14,5 Stocks Under $10 Set to Soar
2016-04-12,Vitae Pharma (VTAE) Stock Gets &lsquo;Outperform&rsquo; Rating at BMO Capital
2016-03-30,Vitae Pharmaceuticals Closes Public Offering Of Common Stock
2016-03-24,Vitae Pharmaceuticals Prices Public Offering Of Common Stock
2016-03-23,Vitae Pharmaceuticals Proposes Public Offering Of Common Stock
2016-03-21,Trade-Ideas: Vitae Pharmaceuticals (VTAE) Is Today's "Perilous Reversal" Stock
2016-03-18,Vitae Pharmaceuticals (VTAE) Stock Continues to Gain on Positive Trial Results
2016-03-17,Vitae Pharmaceuticals (VTAE) Stock Skyrockets on Positive Trial Results
2016-03-17,Pre-Market Activity Shows Heavy Volume And Movement For Vitae Pharmaceuticals (VTAE)
2016-03-16,Vitae Pharmaceuticals Achieves Proof-of-Concept With First-in-Class RORyt Inhibitor In Moderate To Severe Psoriasis
2016-03-14,7 Breakout Stocks Spiking on Big Volume
2016-03-04,RSI Alert: Vitae Pharmaceuticals (VTAE) Now Oversold
2016-03-04,Vitae (VTAE) Stock Plunges on Q4 Loss
2016-03-03,Vitae Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Operating And Financial Results
2016-02-25,Vitae Pharmaceuticals To Announce Fourth Quarter And Full Year 2015 Financial Results On March 3, 2016
2015-12-29,Vitae Pharmaceuticals Doses First Patients In Phase 2a Proof-of-Concept Trial Of VTP-38543 In Atopic Dermatitis
2015-12-17,Vitae Pharmaceuticals Reports Top-Line Results From Remaining Monotherapy Arm Of Phase 2 Clinical Trial Of BI187004 In Overweight Type 2 Diabetes Patients
2015-12-14,Vitae Pharmaceuticals Announces Addition To The NASDAQ Biotechnology Index
2015-12-10,Vitae Pharmaceuticals Opens Phase 2a Proof-of-Concept Trial Of VTP-38543 In Atopic Dermatitis Patients
2015-11-24,Vitae Pharmaceuticals To Present At 27th Annual Piper Jaffray Healthcare Conference
2015-11-18,Vitae Pharmaceuticals Announces Positive Top-Line Results From A Phase 1 Multiple Ascending Dose Trial Of VTP-43742
2015-11-12,REMINDER: Vitae Pharmaceuticals To Host Analyst And Investor Briefing
2015-11-10,Vitae Pharmaceuticals To Present At Stifel 2015 Healthcare Conference
2015-11-09,Ratings Changes Today
2015-11-05,Vitae Pharmaceuticals Reports Third Quarter 2015 Operating And Financial Results
2015-11-02,Vitae Pharmaceuticals To Announce Third Quarter 2015 Financial Results On November 5, 2015
2015-10-20,Vitae Pharmaceuticals To Host Analyst And Investor Briefing
2015-09-30,Vitae Pharmaceuticals Appoints Dr. Karen Bernstein To Board Of Directors
2015-09-29,Vitae Pharmaceuticals Initiates Second Part Of A Phase 1 Multiple Ascending Dose Study Of VTP-43742 In Psoriatic Patients
2015-09-22,Vitae Pharmaceuticals To Ring The NASDAQ Stock Market Closing Bell
2015-09-09,Market News: Apple, Netflix, Vitae Pharmaceuticals
2015-09-08,Vitae Pharmaceuticals Announces Positive Top-Line Results From Initial Phase 1 Study Of First-in-Class RORyt Inhibitor VTP-43742 In Autoimmune Disorders
2015-09-01,4 Biotech Stocks Under $10 to Trade for Breakouts
2015-08-10,Vitae Pharmaceuticals Announces Initiation Of A Phase 1 Multiple Ascending Dose Study Of VTP-43742 In Autoimmune Disorders
2015-08-05,Vitae Pharmaceuticals To Present At Wedbush PacGrow Healthcare Conference
2015-08-04,Vitae Pharmaceuticals Reports Second Quarter 2015 Operating And Financial Results
2015-07-29,Vitae Pharmaceuticals Appoints Dr. John M. Leonard To Board Of Directors
2015-07-28,Vitae Pharmaceuticals To Announce Second Quarter 2015 Financial Results On August 4, 2015
2015-07-27,Vitae Pharmaceuticals And Boehringer Ingelheim To End Collaboration And License Agreement For BACE Inhibitors
2015-06-29,Vitae Pharmaceuticals Announces Top-Line Results From Metformin Arm Of Ongoing Phase 2 Clinical Trial Of BI187004/VTP-34072 In Overweight Type 2 Diabetics
2015-06-29,Vitae Pharmaceuticals Announces Initiation Of A Phase 1 Single Ascending Dose Study Of VTP-43742 In Autoimmune Disorders
2015-06-16,Vitae Pharmaceuticals To Present At JMP Securities Life Sciences Conference
2015-05-13,Vitae Pharmaceuticals To Present At UBS Global Healthcare Conference
2015-05-12,Vitae Pharmaceuticals Reports First Quarter 2015 Operating And Financial Results
2015-05-06,Vitae Pharmaceuticals To Present At Upcoming Meetings
2015-05-05,Vitae Pharmaceuticals To Announce First Quarter 2015 Financial Results On May 12, 2015
2015-04-16,Vitae Pharmaceuticals To Present At Keystone Symposia On Mechanisms Of Pro-Inflammatory Diseases
2015-03-31,Vitae Pharmaceuticals Reports Fourth Quarter And Full Year 2014 Operating And Financial Results
2015-03-27,Vitae Pharmaceuticals to Announce Fourth Quarter and Full Year 2014 Financial Results on March 31, 2015
2015-03-02,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Vitae Pharmaceuticals, Inc.
2015-02-27,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Vitae Pharmaceuticals, Inc. - VTAE
2015-02-27,EQUITY ALERT: The Rosen Law Firm Announces Investigation Of Securities Claims Against Vitae Pharmaceuticals, Inc. - VTAE
2015-02-27,Vitae Pharmaceuticals To Present At Cowen And Company 35th Annual Health Care Conference
2015-02-26,BACE Inhibitor BI 1181181 Voluntarily Put On Temporary Clinical Hold For Safety Evaluation
2015-01-28,Vitae Pharmaceuticals Announces Exercise Of Underwriters' Option To Purchase Additional Shares And Closing Of Follow-on Public Offering Of Common Stock
2015-01-23,Vitae Pharmaceuticals Announces Pricing Of Follow-on Public Offering Of Common Stock
2015-01-20,Vitae Pharmaceuticals Launches Proposed Follow-on Public Offering Of Common Stock
2015-01-08,The Best And Worst Analyst Recommendations Of 2014
2014-12-23,Vitae Pharmaceuticals Added To Russell 2000(R) And Russell 3000(R) Indexes
2014-12-08,Vitae Pharmaceuticals Among 2014 Best Places To Work In PA
2014-11-12,Vitae Pharmaceuticals Reports Third Quarter 2014 Operating And Financial Results
2014-11-12,Vitae Pharmaceuticals To Present At Stifel 2014 Healthcare Conference
2014-11-05,Vitae Pharmaceuticals To Announce Third Quarter 2014 Financial Results On November 12, 2014
2014-10-27,Market News: Apple Inc, Vitae Pharmaceuticals, Alexza Pharmaceuticals
2014-10-27,Vitae Pharmaceuticals Announces Exercise Of Underwriters' Option To Purchase Additional Shares Of Initial Public Offering
2014-10-23,Positive Top-Line Results Achieved From Two Phase 1 Clinical Trials Of BACE Inhibitor BI1181181/VTP-37948 In Alzheimer's Disease
2014-09-29,Vitae Pharmaceuticals Announces Closing of Initial Public Offering
2014-09-24,Vitae Pharmaceuticals Announces Pricing Of Initial Public Offering
,
,
2017-03-10,VTv Therapeutics To Present At Two Upcoming Annual Investor Conferences
2017-02-27,VTv Therapeutics Reports 2016 Fourth Quarter And Full Year Financial And Operational Results And Recent Highlights
2016-12-14,VTv Therapeutics Announces Positive Topline Results From Phase 2 Study Of TTP273 In Type 2 Diabetes
2016-11-16,New Pre-Clinical Data On A VTv Therapeutics Small Molecule Drug Candidate Against Parkinson's Disease To Be Presented At The Society For Neuroscience 2016 Meeting In San Diego
2016-11-10,VTv Therapeutics To Participate In Upcoming Mizuho, Stifel And Piper Jaffray Conferences
2016-11-02,VTv Therapeutics Reports Third Quarter Financial And Operational Results And Recent Highlights
2016-10-24,VTv Therapeutics To Present At Peptide Therapeutics Symposium
2016-10-03,VTv Therapeutics To Present At Neuro Advance Boston
2016-09-08,VTv Therapeutics To Present At The Rodman & Renshaw Global Investment Conference
2016-09-07,VTv Therapeutics Completes Enrollment Of Part A Of Pivotal Phase 3 Trial Evaluating Azeliragon For The Treatment Of Patients With Mild Alzheimer's Disease
2016-09-02,VTv Therapeutics To Present At The International Psychogeriatric Association International Congress
2016-08-16,VTv Therapeutics Completes Enrollment Of Phase 2 Trial Evaluating TTP273 For The Treatment Of Type 2 Diabetes
2016-08-10,VTv Therapeutics Announces Positive Initial Topline Results From Phase 2b Study Of Glucokinase Activator TTP399 In Type 2 Diabetes
2016-07-27,VTv Therapeutics Announces Presentation Of Phase 2b Azeliragon Results At The 2016 Alzheimer's Association International Conference (AAIC)
2016-07-14,VTv Therapeutics Announces Phase 2b Azeliragon Data Selected For Oral Presentation At The 2016 Alzheimer's Association International Conference
2016-07-06,VTv Therapeutics To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference
2016-06-14,VTv Therapeutics Presents Positive Results From A Pilot Study Of Its Glucokinase Activator At American Diabetes Association 76th Scientific Sessions
2016-05-12,VTv Therapeutics Reports First Quarter Financial And Operational Results
2016-04-20,VTv Therapeutics Presents Data On Two Diabetes Candidates At Keystone Symposia On New Therapeutics For Diabetes And Obesity
2016-04-13,5 Stocks With Big Insider Buying
2016-04-12,VTv Therapeutics Announces Presentations On Its Diabetes Product Candidates TTP273 And TTP399 At The Keystone Symposia On New Therapeutics For Diabetes And Obesity
2016-04-06,VTv Therapeutics To Present At The 15th Annual Needham Healthcare Conference
2016-03-04,VTv Therapeutics To Present At Two Investor Conferences In March
2016-03-01,VTv Therapeutics Reports Fourth Quarter And Full Year 2015 Financial And Operational Results And Recent Highlights
2016-02-22,VTv Therapeutics Reports Preclinical And Clinical Results On Its Diabetes Candidate TTP273
2016-02-09,VTv Therapeutics Completes Enrollment Of Phase 2b Trial Evaluating TTP399 For The Treatment Of Type 2 Diabetes
2016-01-28,VTv Therapeutics To Present At The 18th Annual BIO CEO & Investor Conference
2016-01-21,VTv Therapeutics Initiates Phase 2 Trial Evaluating TTP273 For The Treatment Of Type 2 Diabetes
2016-01-07,5 Stocks Under $10 Set to Soar
2015-12-02,VTv Therapeutics Announces Larry Altstiel To Serve As Chief Medical Officer
2015-11-24,VTv Therapeutics To Participate In Fireside Chat At Piper Jaffray 27th Annual Healthcare Conference
2015-11-13,VTv Therapeutics To Present At Stifel 2015 Healthcare Conference
2015-11-12,VTv Therapeutics Reports Financial Results For The Third Quarter Ended September 30, 2015
2015-10-22,VTv Therapeutics To Present At The 8th Clinical Trials On Alzheimer's Disease (CTAD) Conference
2015-09-23,VTv Therapeutics To Present At Ladenburg Thalmann 2015 Healthcare Conference
2015-09-04,5 Stocks Ready for Breakouts
2015-09-01,3 Breakout Biotech Stocks Trading for Under $10
,
,
,
,
2017-03-15,Voyager Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results And Corporate Highlights
2017-03-08,Voyager Therapeutics To Host Fourth Quarter And Full Year 2016 Financial Results Conference Call
2017-02-28,Voyager Therapeutics Supports Rare Disease Day® And Global Movement To Raise Awareness For Rare Diseases
2017-02-13,Voyager Therapeutics Announces Lead Clinical Candidate Selection For Monogenic Form Of Amyotrophic Lateral Sclerosis (ALS)
2017-02-02,Voyager Therapeutics To Attend Upcoming Investor Conferences
2017-01-25,Voyager Therapeutics Announces Publication Of Vectored Anti-Tau Monoclonal Antibody Study In The Journal Of Neuroscience
2017-01-20,Voyager Therapeutics Announces Updates From Phase 1b Trial Of VY-AADC01 For Advanced Parkinson's Disease
2017-01-05,Voyager Therapeutics Elects Wendy Dixon, Ph.D. And Glenn Pierce, M.D., Ph.D. To Board Of Directors
2017-01-03,Voyager Therapeutics Appoints Jane Pritchett Henderson As Chief Financial Officer
2016-12-13,Ratings Changes Today
2016-12-09,Voyager Therapeutics To Attend Upcoming Investor Conference
2016-12-07,Voyager Gene Therapy Shows Early, Promising Motor Function Improvements for Parkinson's Patients
2016-12-07,Voyager Therapeutics Announces Positive Interim Results From Phase 1b Trial Of VY-AADC01 For Advanced Parkinson's Disease
2016-11-29,Voyager Therapeutics And REGENXBIO Announce Exercise Of Options For Rights To NAV Vectors
2016-11-10,Voyager Therapeutics Provides Third Quarter 2016 Investor Update
2016-11-01,Voyager Therapeutics To Host Third Quarter 2016 Investor Update Call
2016-10-18,Voyager Therapeutics Announces Planned Transition Process For Chief Financial Officer
2016-09-29,Voyager Therapeutics is Now Oversold (VYGR)
2016-09-15,Voyager Therapeutics Licenses Novel Gene Therapy Capsids From The California Institute Of Technology
2016-09-12,Voyager Therapeutics And CHDI Foundation Collaborate To Develop Novel Gene Therapy For Huntington's Disease
2016-08-12,Voyager Therapeutics To Attend Upcoming Investor Conferences
2016-08-11,Voyager Therapeutics Provides Second Quarter 2016 Investor Update
2016-08-09,Voyager Therapeutics Initiates Third Cohort In Ongoing Phase 1b Clinical Trial Of VY-AADC01 In Advanced Parkinson's Disease
2016-08-04,Voyager Therapeutics To Host Second Quarter 2016 Investor Update Call
2016-06-22,Voyager Therapeutics Announces Interim Phase 1b Surgical Results For VY-AADC01 In Advanced Parkinson's Disease
2016-05-12,Voyager Therapeutics Provides First Quarter 2016 Investor Update
2016-05-11,Voyager Therapeutics To Present At Upcoming Investor Conferences
2016-05-05,Voyager Therapeutics To Host First Quarter 2016 Investor Update Call
2016-04-29,Voyager Therapeutics Highlights Programs In Parkinson's Disease And ALS; Announces Expansion Of CNS Pipeline At R&D Day
2016-04-14,Voyager Therapeutics To Host R&D Day And Webcast On April 29, 2016
2016-03-17,Voyager Therapeutics Provides Fourth Quarter And Full Year 2015 Investor Update
2016-03-14,Voyager Therapeutics To Present At Alliance For Regenerative Medicine's 4th Annual Cell & Gene Therapy Investor Day
2016-03-10,Voyager Therapeutics To Host Fourth Quarter And Full Year 2015 Investor Update Call
2016-02-29,Voyager Therapeutics To Present At Cowen And Company 36th Annual Health Care Conference
2016-02-04,Oversold Conditions For Voyager Therapeutics (VYGR)
2016-02-02,Voyager Therapeutics Promotes Jeff Goater To Chief Financial Officer
2015-12-18,Voyager Therapeutics Added To Russell 2000®, 3000® And Global Indexes
2015-12-17,Voyager Therapeutics Reports Third Quarter 2015 Financial Results
2015-11-16,Voyager Therapeutics Announces Closing Of Initial Public Offering, Including Full Exercise Of Option To Purchase Additional Shares
,
,
,
,
2017-02-16,Windtree Therapeutics' Aerosolized KL4 Surfactant Reduces Lung Inflammation And Improves Survival In A High-Pathogen Avian Influenza Preclinical Study
2017-02-15,Windtree Therapeutics Completes $10.5 Million Private Offering
2017-02-15,Windtree Therapeutics To Host A Conference Call And Webcast At 8:00 AM On Thursday, February 16, 2017 To Provide Clinical And Financial Updates
2016-12-01,Windtree Therapeutics Announces Upcoming Presentations At Hot Topics In Neonatology
2016-11-28,Windtree Therapeutics' AEROSURF® (lucinactant For Inhalation) Phase 2a Data Presented At The 2016 International Congress Of Union Of European Neonatal And Perinatal Societies
2016-11-08,Windtree Therapeutics To Present At Stifel 2016 Healthcare Conference
2016-11-03,Windtree Therapeutics Preclinical Study Results Show Potential For KL4 Surfactant As Possible Medical Countermeasure To Radiation Exposure
2016-10-24,Windtree Releases Data From Lung Deposition Study In Non-Human Primates Demonstrating Uniform Distribution Of Aerosolized KL4 Surfactant In All Regions Of The Lung
2016-10-20,Windtree Therapeutics To Host Conference Call And Webcast On Tuesday, October 25, 2016 To Provide A Business Update
2016-09-19,Windtree Therapeutics Announces FDA Fast Track Designation For AEROSURF®
2016-08-08,Windtree Receives $2.6 Million SBIR Grant To Support AEROSURF® Phase 2b Clinical Trial
2016-07-14,Windtree Awarded $1.0 Million SBIR Grant In Continuing Support Of The Development Of Aerosolized KL4 Surfactant To Address Radiation-Induced Lung Injury
2016-06-07,Windtree Therapeutics To Host Key Opinion Leader Meeting On Respiratory Distress Syndrome
2016-05-03,Windtree Therapeutics To Report First Quarter 2016 Financial Results And Host Conference Call On Thursday, May 12, 2016
2016-04-28,Windtree Therapeutics To Present At 2016 Pediatric Academic Societies Meeting
,
,
,
,
,
2017-02-16,Windtree Therapeutics' Aerosolized KL4 Surfactant Reduces Lung Inflammation And Improves Survival In A High-Pathogen Avian Influenza Preclinical Study
2017-02-15,Windtree Therapeutics Completes $10.5 Million Private Offering
2017-02-15,Windtree Therapeutics To Host A Conference Call And Webcast At 8:00 AM On Thursday, February 16, 2017 To Provide Clinical And Financial Updates
2016-12-01,Windtree Therapeutics Announces Upcoming Presentations At Hot Topics In Neonatology
2016-11-28,Windtree Therapeutics' AEROSURF® (lucinactant For Inhalation) Phase 2a Data Presented At The 2016 International Congress Of Union Of European Neonatal And Perinatal Societies
2016-11-08,Windtree Therapeutics To Present At Stifel 2016 Healthcare Conference
2016-11-03,Windtree Therapeutics Preclinical Study Results Show Potential For KL4 Surfactant As Possible Medical Countermeasure To Radiation Exposure
2016-10-24,Windtree Releases Data From Lung Deposition Study In Non-Human Primates Demonstrating Uniform Distribution Of Aerosolized KL4 Surfactant In All Regions Of The Lung
2016-10-20,Windtree Therapeutics To Host Conference Call And Webcast On Tuesday, October 25, 2016 To Provide A Business Update
2016-09-19,Windtree Therapeutics Announces FDA Fast Track Designation For AEROSURF®
2016-08-08,Windtree Receives $2.6 Million SBIR Grant To Support AEROSURF® Phase 2b Clinical Trial
2016-07-14,Windtree Awarded $1.0 Million SBIR Grant In Continuing Support Of The Development Of Aerosolized KL4 Surfactant To Address Radiation-Induced Lung Injury
2016-06-07,Windtree Therapeutics To Host Key Opinion Leader Meeting On Respiratory Distress Syndrome
2016-05-03,Windtree Therapeutics To Report First Quarter 2016 Financial Results And Host Conference Call On Thursday, May 12, 2016
2016-04-28,Windtree Therapeutics To Present At 2016 Pediatric Academic Societies Meeting
,
,
,
,
,
2017-03-24,Xenon Pharmaceuticals Becomes Oversold (XENE)
2017-03-24,Xenon Pharmaceuticals Announces XEN801 Did Not Meet Efficacy Endpoints In Phase 2 Clinical Trial In Patients With Moderate To Severe Acne
2017-03-08,Xenon Pharmaceuticals Reports 2016 Financial Results And Provides Corporate Update
2017-03-01,Xenon Pharmaceuticals To Host Conference Call And Webcast To Discuss 2016 Financial Results And Provide Corporate Update
2017-01-08,Xenon Pharmaceuticals Outlines Key Milestones For 2017
2016-11-08,Xenon Pharmaceuticals To Present At The Stifel 2016 Healthcare Conference
2016-11-03,Xenon Pharmaceuticals Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-10-27,Xenon Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2016 Financial Results And Provide Corporate Update
2016-09-27,Xenon Pharmaceuticals Appoints Dawn Svoronos To Its Board Of Directors
2016-09-13,Xenon Pharmaceuticals Announces Exercise In Full Of Option To Purchase Additional Shares And Closing Of $34.5 Million Public Offering
2016-09-08,Xenon Pharmaceuticals Announces Pricing Of $30 Million Public Offering Of Common Shares
2016-09-07,Xenon Pharmaceuticals Announces Proposed Public Offering Of Common Shares
2016-08-03,Xenon Pharmaceuticals Reports Second Quarter 2016 Financial Results And Provides Corporate Update
2016-08-02,Xenon Pharmaceuticals To Present At The Canaccord Genuity 36th Annual Growth Conference
2016-07-25,Xenon Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2016 Financial Results And Provide Corporate Update
2016-06-08,Xenon Pharmaceuticals Presents Corporate Update And Highlights Its Proprietary Therapeutic Programs At The Jefferies 2016 Healthcare Conference
2016-06-02,Xenon Pharmaceuticals To Present At The Jefferies 2016 Healthcare Conference
2016-05-10,Xenon Pharmaceuticals Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-05-02,Xenon Pharmaceuticals To Host Conference Call And Webcast To Discuss First Quarter 2016 Financial Results And Provide Corporate Update
2016-04-04,Xenon Names Dr. Raymond J. Winquist As Head, Translational Research
2016-03-31,Xenon Pharmaceuticals To Provide Business And Milestone Update At Needham Healthcare Conference
2016-03-15,Xenon And Genentech Extend Collaborations Focused On Pain
2016-03-08,Xenon Pharmaceuticals Reports 2015 Financial Results And Provides Corporate Update
2016-03-01,Xenon Pharmaceuticals To Host Conference Call And Webcast To Discuss 2015 Financial Results And Provide Corporate Update
2016-02-10,Xenon Initiates Phase 2 Clinical Trial Of XEN801 To Treat Moderate To Severe Acne
2016-02-09,Xenon Names Dr. James R. Empfield Senior Vice President, Drug Discovery
2016-01-11,Xenon Outlines Key Milestones For 2016
2015-12-17,Xenon And Genentech Publish In Science The 3-D Crystal Structure Of A Novel Nav1.7 Compound Binding Site Enabling The Development Of Potent Selective Inhibitors To Treat Pain
2015-12-08,Ratings Changes Today
2015-11-12,Xenon Pharmaceuticals To Present At The Stifel 2015 Healthcare Conference
2015-11-10,Xenon Pharmaceuticals Reports Third Quarter 2015 Financial Results And Provides Corporate Update
2015-11-05,Xenon Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2015 Financial Results And Provide Corporate Update
2015-10-22,Xenon Announces Its Partner Genentech Has Advanced GDC-0310, A Second Nav1.7 Inhibitor For Pain, Into Clinical Development
2015-09-24,Xenon Pharmaceuticals Announces Initiation Of XEN801 Phase 1 Clinical Trial
2015-09-21,Xenon Pharmaceuticals Achieves Milestone In Genentech Collaboration To Discover Novel Pain Targets
2015-09-03,Xenon Pharmaceuticals To Present At The 10th Annual Wells Fargo Healthcare Conference
2015-08-10,Xenon Pharmaceuticals Reports Second Quarter 2015 Financial Results And Provides Corporate Update
2015-08-07,Xenon Pharmaceuticals is Now Oversold (XENE)
2015-08-06,Xenon Pharmaceuticals To Present At The Canaccord Genuity 35th Annual Growth Conference
2015-08-05,Xenon Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2015 Financial Results And Provide Corporate Update
2015-07-08,9 Investments Wilbur Ross Is Making That Aren't Greece
2015-07-01,Xenon Pharmaceuticals To Host Conference Call And Webcast Today At 9:00 A.m. Eastern Time To Discuss TV-45070 Phase 2b Study In Osteoarthritis Pain
2015-07-01,Teva And Xenon Provide Update On TV-45070 Phase 2b Study In Osteoarthritis Pain
2015-07-01,Teva And Xenon Provide Update On TV-45070 Phase 2b Study In Osteoarthritis Pain
2015-05-28,Xenon Pharmaceuticals To Provide Business And Milestone Update At Jefferies 2015 Global Healthcare Conference
2015-05-22,Xenon Pharmaceuticals Appoints Steven Gannon To Its Board Of Directors
2015-05-20,Relative Strength Alert For Xenon Pharmaceuticals
2015-05-12,Xenon Pharmaceuticals Reports First Quarter 2015 Financial Results And Provides Corporate Update
2015-05-07,Xenon Pharmaceuticals To Host Conference Call And Webcast To Discuss First Quarter 2015 Financial Results And Provide Corporate Update
2015-04-21,Oversold Conditions For Xenon Pharmaceuticals (XENE)
2015-04-02,Voltari Corp. Dips After Icahn-Driven Surge
2015-04-02,Teva And Xenon Announce Enrollment Of First Patient In A Phase 2b Study Evaluating TV-45070 For Postherpetic Neuralgia (PHN)
2015-03-16,Xenon Pharmaceuticals Appoints Dr. Richard H. Scheller To Its Board Of Directors
2015-03-12,Xenon Pharmaceuticals Reports 2014 Financial Results And Provides Corporate Update
2015-03-09,Xenon Pharmaceuticals To Host Conference Call And Webcast To Discuss 2014 Financial Results And Provide Corporate Update
2015-02-23,15 Biggest Buys Buffett, Icahn and Other Big Investors Made Last Quarter
2015-02-20,4 Stocks Spiking on Big Volume: Xenon, Opus Bank and More
2015-02-19,Xenon Pharmaceuticals' Partner Teva To Initiate Phase 2b Clinical Trial Of TV-45070 In Post-Herpetic Neuralgia
2015-01-08,Xenon Pharmaceuticals Outlines Key Anticipated Milestones For 2015
2014-12-29,Market News: Manitowoc, Xenon Pharmaceuticals, USMD Holdings
2014-12-15,Xenon Pharmaceuticals Reports Third Quarter 2014 Financial Results
2014-11-04,Xenon Pharmaceuticals Announces Pricing Of Initial Public Offering
,
,
,
2017-03-08,Intersect ENT Submits New Drug Application To FDA For Office-Based RESOLVE Steroid Releasing Implant For Recurrent Chronic Sinus Disease
2017-02-28,Intersect ENT Reports Fourth Quarter And Full Year 2016 Results
2017-02-24,Intersect ENT's PROPEL® Contour Steroid Releasing Sinus Implant (Photo: Business Wire)
2017-02-21,SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Intersect ENT, Inc. For Potential Breaches Of Fiduciary Duty By Its Board Of Directors
2017-02-03,Intersect ENT To Report Fourth Quarter And Year 2016 Financial Results
2017-02-01,Intersect ENT To Present At LEERINK Partners Global Healthcare Conference
2017-01-09,Intersect ENT Reports Preliminary Q4 And Year 2016 Revenue
2016-12-30,Commit To Buy Intersect ENT At $10, Earn 16.3% Annualized Using Options
2016-12-20,Intersect ENT To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-11-16,Notable Wednesday Option Activity: XENT, FRO, NAT
2016-11-15,Intersect ENT To Present At The Piper Jaffray 28th Annual Healthcare Conference
2016-11-04,Noteworthy Friday Option Activity: XENT, W, DTSI
2016-11-03,Intersect ENT To Present At The Canaccord Genuity Medical Technology & Diagnostics Forum
2016-11-02,Intersect ENT Reports Third Quarter 2016 Results
2016-10-18,Intersect ENT Schedules Third Quarter 2016 Earnings Release And Conference Call For November 2, 2016
2016-10-17,Intersect ENT's Investigational RESOLVE Steroid Releasing Implant (Photo: Business Wire)
2016-09-19,Intersect ENT Announces American Rhinologic Society Endorsement Of The Use Of Drug Eluting Sinus Implants
2016-08-29,Intersect ENT Announces Positive Coverage Decision By CareFirst BlueCross BlueShield To Expand Access To PROPEL Steroid Releasing Implants To More Patients
2016-08-02,Intersect ENT Reports Second Quarter 2016 Results
2016-08-01,Intersect ENT Announces FDA Submission Of NOVA Bioabsorbable Steroid Releasing Implant For Patients With Chronic Sinus Disease
2016-07-19,Intersect ENT Schedules Second Quarter 2016 Earnings Release And Conference Call For August 2, 2016
2016-07-18,Strong On High Volume: Intersect ENT (XENT)
2016-07-18,Intersect ENT Announces Preliminary Q2 Revenue And Business Update
2016-07-11,Intersect ENT Announces Publication Of PROGRESS Study Of Steroid Releasing Implant In Patients With Frontal Sinus Disease
2016-07-07,Notable Thursday Option Activity: XENT, LPCN, JWN
2016-06-02,Intersect ENT To Present At William Blair & Company 36th Annual Growth Stock Conference
2016-06-01,Intersect ENT Announces Completion Of Enrollment In RESOLVE II Clinical Trial Of New In-Office Implant For Recurrent Chronic Sinusitis
2016-05-16,Intersect ENT Announces Positive Clinical Results From Pivotal Study Of Newest Steroid Releasing Sinus Implant
2016-05-06,Intersect ENT is Now Oversold (XENT)
2016-05-05,Intersect ENT Reports First Quarter 2016 Results
2016-04-26,Intersect ENT To Present At Bank Of America Merrill Lynch 2016 Health Care Conference
2016-04-19,Intersect ENT Schedules First Quarter 2016 Earnings Release And Conference Call For May 5, 2016
2016-04-08,Commit To Purchase Intersect ENT At $17.50, Earn 25.5% Annualized Using Options
2016-03-23,Intersect ENT Announces FDA Approval Of Additional Indication For PROPEL® Mini Sinus Implant
2016-02-23,Intersect ENT Reports Fourth Quarter And Year 2015 Results
2016-02-22,David Lehman, General Counsel, Intersect ENT (Photo: Business Wire)
2016-02-12,Intersect ENT To Report Fourth Quarter And Year 2015 Financial Results
2016-02-01,Intersect ENT To Present At LEERINK Partners Global Healthcare Conference
2016-01-29,Intersect ENT Announces NUB Status 1 Designation For PROPEL Sinus Implant In Germany
2016-01-25,Insider Trading Alert - TRUP, XENT And EA Traded By Insiders
2016-01-11,Intersect ENT Reports Preliminary Q4 And Year 2015 Revenue
2015-12-16,Intersect ENT To Present At The 34th Annual J.P. Morgan Healthcare Conference
2015-11-17,Intersect ENT Recognized For Gender Diversity By Watermark And UC Davis
2015-11-12,Intersect ENT To Present At Piper Jaffray Conference
2015-11-10,Intersect ENT Announces Data Further Demonstrating Health Economic Value Of PROPEL Steroid Releasing Implants
2015-11-04,Intersect ENT Reports Third Quarter 2015 Results
2015-11-02,Intersect ENT To Present At The Canaccord Genuity Medical Technology & Diagnostics Forum
2015-10-21,Intersect ENT Announces Publication Of Position Statement From AAO-HNS On Use Of Biomaterials
2015-10-20,Intersect ENT To Announce Third Quarter Financial Results
2015-10-02,Trade-Ideas: Intersect ENT (XENT) Is Today's "Dead Cat Bounce" Stock
2015-09-29,Intersect ENT (XENT) Strong On High Relative Volume Today
2015-09-29,Intersect ENT Announces FDA Submission To Seek Expanded Indication Of PROPEL Mini Steroid Releasing Implant To Treat Patients With Frontal Sinus Disease
2015-09-28,Intersect ENT Announces Positive Clinical Results From Three Studies Evaluating Steroid Releasing Implants Placed In The Physician's Office
2015-09-21,Strong On High Volume: Intersect ENT (XENT)
2015-09-09,Intersect ENT is Now Oversold (XENT)
2015-08-25,Ratings Changes Today
2015-08-17,Intersect ENT Announces Positive Preliminary Clinical Results For The PROPEL Mini Steroid Releasing Implant In Patients With Frontal Sinus Disease
2015-08-05,Intersect ENT Reports Second Quarter 2015 Results
2015-07-23,Intersect ENT To Present At The Wedbush PacGrow Life Sciences And Canaccord Genuity Conferences
2015-07-21,Intersect ENT To Announce Second Quarter Financial Results
2015-07-08,Intersect ENT Enrolls First Patient In Pivotal Study To Evaluate The NOVA Sinus Implant
2015-07-02,Intersect ENT To Present At Cantor Fitzgerald's Inaugural Healthcare Conference
2015-06-30,Analysts' Actions -- Abercrombie, Fitbit, Lowe's and More
2015-06-29,Nevro Appoints Lisa Earnhardt To Its Board Of Directors
2015-06-03,Intersect ENT To Present At The William Blair & Company 35th Annual Growth Stock Conference
2015-06-03,Intersect ENT (XEXT) Stock Gains After Upsizing Secondary Offering
2015-06-02,Intersect ENT Announces Upsizing And Pricing Of Public Offering
2015-06-01,Intersect ENT Commences Public Offering
2015-05-20,Intersect ENT Files S-1 Registration Statement For Proposed Public Offering
2015-05-06,Intersect ENT Reports First Quarter 2015 Results
2015-05-04,Intersect ENT Announces Positive Coverage Decision By Health Care Service Corporation
2015-04-22,Intersect ENT To Announce First Quarter Financial Results
2015-04-09,Intersect ENT Appoints Kieran Gallahue And Tony Vernon To Board Of Directors
2015-02-26,Intersect ENT Reports Fourth Quarter And Year 2014 Results
2015-02-23,Intersect ENT To Present At The 27th Annual ROTH Conference
2015-02-10,Intersect ENT To Announce Fourth Quarter And Year 2014 Financial Results
2015-02-02,Intersect ENT Appoints Chas McKhann As Chief Commercial Officer
2015-01-22,Intersect ENT To Present At Leerink Partners Global Healthcare Conference 2015
2015-01-12,Intersect ENT Announces Preliminary 2014 Financial Results
2014-12-29,Intersect ENT Announces Enrollment Of First Patient In Phase III Study Of In-Office Treatment For Recurrent Chronic Sinusitis
2014-12-18,Intersect ENT To Present At J.P. Morgan Healthcare Conference
2014-12-10,Intersect ENT Announces Changes To Board Of Directors
2014-11-11,Intersect ENT To Present At Canaccord Genuity And Piper Jaffray Conferences
2014-11-05,Intersect ENT Reports Third Quarter 2014 Results
2014-10-21,Intersect ENT To Announce Third Quarter Financial Results
2014-10-08,Intersect ENT Announces Publication Of Positive Data From Three Studies Of Company's Drug-Eluting Sinus Implants
2014-10-01,Intersect ENT Added To Russell 2000 Index
2014-09-22,Photo Release -- Intersect ENT Announces Positive Data From Clinical Trial Of New In-Office Implant For Recurrent Chronic Sinusitis
2014-09-17,Intersect ENT Enrolls First Patient In Clinical Study To Expand Access To PROPEL Treatment To Broader Patient Population
2014-09-03,Intersect ENT Reports Second Quarter 2014 Results
2014-08-22,Intersect ENT To Announce Second Quarter Financial Results
2014-08-11,Study Indicates Cost Effectiveness Of Intersect ENT's PROPEL Implant For Chronic Sinusitis
2014-07-29,Intersect ENT Announces Closing Of Its Initial Public Offering
2014-07-24,Intersect ENT (XENT) Stock Pops on First Trading Day After IPO
2014-07-24,Intersect ENT Announces Pricing Of Its Initial Public Offering
,
,
2017-03-16,Acceleron Announces Plans To Initiate A Phase 2 Trial Of ACE-083 In Charcot-Marie-Tooth Neuromuscular Disease And Host Educational Webinar
2017-03-02,Acceleron Pharma Price Target Raised by Leerink
2017-03-01,Acceleron Reports Fourth Quarter And Year Ended 2016 Operational And Financial Results
2017-02-28,Acceleron To Participate In Two Healthcare Investor Conferences In March
2017-02-22,Acceleron Pharma To Webcast Conference Call Of Fourth Quarter And Year Ended 2016 Financial Results On March 1, 2017
2017-02-01,Acceleron To Participate In Two Healthcare Investor Conferences In February
2017-01-19,Acceleron Pharma Enters Oversold Territory (XLRN)
2017-01-06,Acceleron Outlines Corporate Goals And Priorities For 2017
2017-01-04,Acceleron To Webcast Presentation At 35th Annual J.P. Morgan Healthcare Conference
2016-12-22,Acceleron Announces First Patient Treated In Phase 2 Trial Of ACE-083 In Facioscapulohumeral Muscular Dystrophy
2016-12-07,Trump's Drug Pricing Comment Sends Biotech Stocks Into Free-Fall
2016-12-05,Acceleron And Celgene Announce Updated Results From Phase 2 Studies Of Luspatercept In Beta-Thalassemia Presented At The 58th Annual Meeting Of The American Society Of Hematology
2016-12-05,Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting
2016-12-05,Acceleron And Celgene Announce Preliminary Results From An Investigator Initiated Phase 2 Study Of Sotatercept In Myelofibrosis At The 58th Annual Meeting Of The American Society Of Hematology
2016-12-04,Acceleron, Celgene Seek to Replace Entrenched Anti-Anemia Drugs in MDS Treatment
2016-12-04,Acceleron And Celgene Announce Updated Results From Ongoing Phase 2 Studies Of Luspatercept In Myelodysplastic Syndromes At The 58th Annual Meeting Of The American Society Of Hematology
2016-11-30,Acceleron Pharma To Host Conference Call And Webcast To Review Data Presented At The 58th American Society Of Hematology Annual Meeting And Exposition
2016-11-03,Acceleron Pharma Reports Third Quarter 2016 Financial And Operational Results
2016-11-03,RSI Alert: Acceleron Pharma (XLRN) Now Oversold
2016-11-03,Acceleron Announces New Data Presentations At The 58th American Society Of Hematology Annual Meeting And Exposition
2016-11-02,Acceleron To Present At Credit Suisse Healthcare Conference Monday, November 7, 2016
2016-10-27,Acceleron Pharma To Webcast Conference Call Of Third Quarter 2016 Financial Results On November 3, 2016
2016-10-13,Acceleron To Host Educational Webcast On Facioscapulohumeral Muscular Dystrophy (FSHD) With Leading Researcher And Provide Overview Of ACE-083 Phase 2 Trial
2016-09-27,Acceleron Announces Retirement Of John Knopf As President And CEO; Habib Dable Named As Successor
2016-08-31,Acceleron To Participate In Three Healthcare Investor Conferences In September
2016-08-04,Acceleron Pharma Reports Second Quarter 2016 Financial And Operational Results
2016-07-28,Acceleron Pharma To Webcast Conference Call Of Second Quarter 2016 Financial Results On August 4, 2016
2016-07-25,Acceleron Pharma Appoints Thomas McCourt To Its Board Of Directors
2016-07-08,Acceleron Announces ACE-083 Phase 1 Results At The 14th International Congress On Neuromuscular Diseases
2016-07-07,Acceleron Pharma (XLRN) Showing Signs Of Perilous Reversal Today
2016-07-06,Acceleron Pharma (XLRN) Marked As A Dead Cat Bounce Stock
2016-06-29,Acceleron Announces Presentation Of ACE-083 Phase 1 Healthy Volunteer Data At The 14th International Congress On Neuromuscular Disease
2016-06-28,Brexit Bargain Buys: 14 More Stocks Picked by Morgan Stanley
2016-06-20,Acceleron Pharma (XLRN) Is Today's Dead Cat Bounce Stock
2016-06-10,Acceleron And Celgene Announce Updated Results From An Ongoing Phase 2 Study Of Luspatercept In Beta-Thalassemia Presented At The 21st Congress Of The European Hematology Association
2016-06-10,Acceleron And Celgene Announce Updated Results From An Ongoing Phase 2 Study Of Luspatercept In Myelodysplastic Syndromes At The 21st Congress Of The European Hematology Association
2016-06-07,Acceleron Pharma To Host Conference Call And Webcast To Review Updated Luspatercept Results Presented At The 21st Congress Of The European Hematology Association
2016-06-01,Acceleron Pharma To Participate In Two Healthcare Investor Conferences In June
2016-05-19,Acceleron Announces Data Presentations With Luspatercept At The 21st Congress Of The European Hematology Association
2016-05-05,Acceleron Pharma Reports First Quarter 2016 Financial And Operational Results
2016-04-28,Acceleron Pharma To Host First Quarter 2016 Financial Results
2016-04-26,Acceleron Pharma To Participate In Two Healthcare Investor Conferences In May
2016-04-25,Trade-Ideas: Acceleron Pharma (XLRN) Is Today's Strong On High Relative Volume Stock
2016-03-01,Acceleron Pharma To Participate In Four Healthcare Investor Conferences In March
2016-02-25,Acceleron Pharma Reports Fourth Quarter And Year Ended 2015 Financial And Operational Results And Recent Highlights
2016-02-21,19 Charts to Calm Your Recession Fears
2016-02-18,Acceleron Pharma To Host Fourth Quarter And Year Ended 2015 Financial Results
2016-02-14,19 Stocks You Should Own if the U.S. Falls Into a Recession
2016-02-03,Acceleron Pharma Enters Oversold Territory (XLRN)
2016-02-01,Acceleron Pharma To Participate In Two Healthcare Investor Conferences In February
2016-01-15,5 Stocks to Trade for Breakout Gains
2016-01-12,Insider Trading Alert - XLRN, TTMI And AGX Traded By Insiders
2016-01-09,2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks
2016-01-06,Acceleron Pharma (XLRN) Trading With Heavy Volume Before Market Open
2016-01-05,Acceleron Announces Pricing Of Public Offering Of Common Stock
2016-01-04,Acceleron Announces Proposed Public Offering Of Common Stock
2015-12-07,Celgene And Acceleron Announce New Results From An Investigational Study With Luspatercept In Beta-Thalassemia Presented At The 57th American Society Of Hematology (ASH) Annual Meeting And Exposition
2015-12-07,FDA Fast Track Designation Granted To Luspatercept For The Treatment Of Patients With Lower-Risk Myelodysplastic Syndromes
2015-12-07,Investors Remain Skeptical about Bluebird Gene Therapy for Blood Disease
2015-12-05,Celgene And Acceleron Announce New Results From An Investigational Study With Luspatercept In Myelodysplastic Syndromes Presented At The 57th American Society Of Hematology (ASH) Annual Meeting And Exposition
2015-12-01,Acceleron Announces Oral Plenary Presentation For ACE-083 In The Late Breaking Clinical Trials Session At The 8th International Conference On Cachexia, Sarcopenia And Muscle Wasting
2015-11-24,Acceleron Pharma To Present At Piper Jaffray 27th Annual Healthcare Conference
2015-11-05,Acceleron Announces New Data Presentations At The 2015 American Society Of Hematology Annual Meeting
2015-11-04,Acceleron Pharma Reports Third Quarter 2015 Financial And Operational Results
2015-11-02,Acceleron Pharma To Present At Upcoming Investor Conferences In November
2015-10-29,Acceleron Pharma To Host Third Quarter 2015 Financial Results Conference Call And Webcast On November 4, 2015
2015-10-23,Acceleron Highlights Phase 3 Studies, New Clinical Results And Research Strategies At Research And Development Day Event
2015-10-15,Acceleron To Host Research And Development Day On October 23
2015-10-05,Commit To Buy Acceleron Pharma At $20, Earn 24% Annualized Using Options
2015-10-02,Acceleron Announces Presentation Of Sotatercept Data At The American Society Of Nephrology Kidney Week 2015
2015-10-01,Acceleron Presents Preclinical Data For ACE-083 And ACE-2494 At The 20th International Annual Congress Of The World Muscle Society
2015-09-24,Trade-Ideas: Acceleron Pharma (XLRN) Is Today's Weak On High Relative Volume Stock
2015-09-02,Acceleron Pharma To Present At Upcoming Investor Conferences In September
2015-08-14,Acceleron Pharma (XLRN) Highlighted As Weak On High Volume
2015-08-06,Acceleron Pharma Reports Second Quarter 2015 Financial And Operational Results
2015-07-29,Acceleron Pharma To Host Second Quarter 2015 Financial Results Conference Call And Webcast On August 6, 2015
2015-07-06,Commit To Purchase Acceleron Pharma At $25, Earn 14.1% Annualized Using Options
2015-06-15,Acceleron Announces Publication In Cancer Research Demonstrating Dalantercept Prevents Metastases In Preclinical Studies Of Breast Cancer
2015-06-12,Acceleron Announces New Luspatercept Phase 2 Clinical Results At The 20th Congress Of The European Hematology Association
2015-06-09,Acceleron Pharma To Host Conference Call And Webcast To Review New Luspatercept Data Presented At The 20th Congress Of The European Hematology Association
2015-05-27,Acceleron Pharma To Present At Upcoming Investor Conferences In June
2015-05-21,Acceleron To Present Luspatercept Clinical Trials At The 20th Congress Of The European Hematology Association
2015-05-18,(Graphic: Business Wire)
2015-05-14,Trade-Ideas: Acceleron Pharma (XLRN) Is Today's Weak On High Relative Volume Stock
2015-05-13,Acceleron To Present Dalantercept Clinical Data At The 2015 American Society Of Clinical Oncology (ASCO) Annual Meeting
2015-05-07,Acceleron Pharma Reports First Quarter 2015 Financial And Operational Results
2015-05-02,Luspatercept Data Presented At The 13th International Symposium On Myelodysplastic Syndromes
2015-04-30,Celgene And Acceleron Select Luspatercept To Advance To Phase 3 In Myelodysplastic Syndromes
2015-04-28,Acceleron Pharma To Host First Quarter 2015 Financial Results Conference Call And Webcast On May 7, 2015
2015-04-27,Oversold Conditions For Acceleron Pharma
2015-04-23,Acceleron Pharma To Present At Upcoming Investor Conferences In May
2015-04-07,Acceleron Announces Oral Presentations Of Luspatercept And Sotatercept Data At The 13th International Symposium On Myelodysplastic Syndromes
2015-04-06,Interesting XLRN Put And Call Options For August 21st
2015-04-06,Acceleron Pharma Appoints Dr. Francois Nader As Chairman Of Its Board Of Directors
2015-03-06,Acceleron Pharma Announces Executive Appointments And Promotions
2015-03-02,Acceleron Pharma Reports Fourth Quarter And Year Ended 2014 Financial And Operational Results
2015-02-28,Acceleron Presents Encouraging Response Rates And Progression-Free Survival Data In Patients With Advanced Renal Cell Carcinoma At The American Society Of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium
2015-02-26,Acceleron Pharma To Present At Upcoming Investor Conferences In March
2015-02-24,Acceleron Pharma To Host Fourth Quarter And Year Ended 2014 Financial Results Conference Call And Webcast On March 2, 2015
2015-02-19,Acceleron To Present New Dalantercept Clinical Data At The American Society Of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium
2015-01-28,Acceleron Pharma To Present At Upcoming Investor Conferences In February
2015-01-14,Insider Trading Alert - XLRN, MOH And PF Traded By Insiders
2015-01-12,Celgene Has 2020 Vision for Long-Term Growth but Plays Safe for 2017
2015-01-12,Insider Trading Alert - EXA, CVV And XLRN Traded By Insiders
2015-01-12,Acceleron Pharma Outlines Corporate Objectives For 2015
2014-12-24,Commit To Purchase Acceleron Pharma At $30, Earn 16.7% Annualized Using Options
2014-12-15,Acceleron Pharma Added To NASDAQ Biotechnology Index
2014-12-12,Acceleron Pharma Appoints Dr. Francois Nader To Its Board Of Directors
2014-12-10,Luspatercept Data On Myelodysplastic Syndromes Selected For "Best Of ASH" By The American Society Of Hematology
2014-12-08,New Data In Myelodysplastic Syndromes Presented At The 56th American Society Of Hematology (ASH) Annual Meeting And Exposition
2014-12-08,Acceleron Pharma (XLRN) Strong On High Relative Volume Today
2014-12-08,The 7 Most Important Drug-Stock Lessons From This Weekend's Blood Cancer Meeting
2014-12-07,Acceleron Drugs Reduce Anemia Caused by Rare Blood Disorders
2014-12-07,New Data From Luspatercept Phase 2 Clinical Trial In Beta-Thalassemia Presented At The 56th American Society Of Hematology (ASH) Annual Meeting And Exposition
2014-11-24,Acceleron Pharma To Present At Upcoming Investor Conferences In December
2014-11-13,Sotatercept Data From The Phase 2a Clinical Trial In Hemodialysis Patients Presented At The American Society Of Nephrology Kidney Week 2014
2014-11-11,Ratings Changes Today
2014-11-07,Acceleron Pharma Reports Third Quarter 2014 Financial And Operational Results
2014-11-06,Acceleron Announces New Clinical Data Presentations At The 2014 American Society Of Hematology Annual Meeting
2014-10-30,Acceleron Pharma To Host Third Quarter 2014 Financial Results Conference Call And Webcast On November 7, 2014
2014-10-29,Acceleron Pharma To Present At Upcoming Investor Conferences In November
2014-10-23,Acceleron Collaboration Partner Celgene To Present Data At The American Society Of Nephrology Kidney Week 2014
2014-10-22,Acceleron Announces Educational Webcast On Chronic Kidney Disease - Mineral And Bone Disorder
2014-10-14,Acceleron Initiates Phase 1 Clinical Trial With Innovative Muscle Drug ACE-083
2014-10-02,Acceleron Hit Over Competitive Concerns, but Investors Overlook Rest of Pipeline
2014-10-01,Acceleron To Host Educational Webcast On Beta-thalassemia
2014-09-29,Acceleron To Webcast Presentation At Leerink Partners Rare Disease Roundtable
2014-09-23,Acceleron Provides Update On Externally Sponsored Clinical Trial Of Dalantercept Monotherapy In Ovarian Cancer
2014-09-16,Acceleron To Host Educational Webcast Series With Clinical Thought Leaders
2014-08-27,Acceleron Pharma To Present At Upcoming Investor Conferences In September
2014-08-12,Acceleron Pharma Reports Second Quarter 2014 Financial Results
2014-08-05,Acceleron Pharma To Host Second Quarter 2014 Financial Results
2014-07-17,Acceleron Pharma Enters Oversold Territory (XLRN)
2014-07-14,Acceleron Pharma Appoints Terrence C. Kearney To Its Board Of Directors
2014-06-19,Acceleron Pharma To Present At JMP Securities Healthcare Conference
2014-06-14,Studies Presented At 19th European Hematology Association Annual Congress Evaluate Activin Receptor Ligand Trap Programs In Beta-Thalassemia
2014-06-10,3 Stocks Spiking on Unusual Volume
2014-05-29,Acceleron Pharma To Present At Upcoming Investor And Medical Conferences In June
2014-05-21,Acceleron Announces New Interim Phase 2 Data On Sotatercept And ACE-536 To Be Reported At Three Oral Presentations At The 19th Annual Congress Of The European Hematology Association
2014-05-15,Acceleron Pharma Reports First Quarter 2014 Financial Results
2014-05-14,Acceleron To Report New Encouraging Interim Clinical Data From Phase 2 Trial Of Dalantercept In Renal Cell Carcinoma At The 50th Annual Meeting Of The American Society Of Clinical Oncology
2014-05-12,Acceleron To Present At 2014 UBS Global Healthcare Conference
2014-05-08,Acceleron Pharma To Host First Quarter 2014 Financial Results Conference Call And Webcast On May 15, 2014
2014-04-23,Acceleron And Celgene Announce Interim Clinical Data For Sotatercept Demonstrating Dose Dependent Increases In Hemoglobin In Patients With End Stage Renal Disease On Hemodialysis
2014-03-28,'Fast Money' Recap: Downward Pressure
2014-03-24,Acceleron, Celgene And Collaborators Announce Two Publications In Nature Medicine Describing Sotatercept And ACE-536 Therapeutic Potential In Beta-thalassemia And Myelodysplastic Syndromes
2014-03-20,Acceleron To Present At The 21st Annual Future Leaders In The Biotech Industry Conference
2014-03-17,Acceleron And Celgene Announce Interim Clinical Data For Sotatercept In Patients With End Stage Renal Disease On Hemodialysis At The 2014 National Kidney Foundation Spring Clinical Meeting
2014-02-27,Acceleron To Present At Cowen And Company 34th Annual Health Care Conference
2014-02-26,Acceleron Pharma Reports Fourth Quarter And Year Ended 2013 Financial Results
2014-02-19,Acceleron Pharma To Host Fourth Quarter And Year Ended 2013 Financial Results Conference Call And Webcast On February 26, 2014
2014-02-05,Acceleron To Present At 2014 Leerink Global Healthcare Conference
2014-01-30,Top Insider Trades: XLRN AYR SVVC OPK
2014-01-28,Acceleron Announces Closing Of Public Offering And Full Exercise Of Underwriters&#8217; Option To Purchase Additional Shares
2014-01-23,The State of Gene Therapy in a Biogen Idec World: Sangamo, Bluebird and Acceleron
2014-01-22,Acceleron Announces Pricing Of Public Offering Of Common Stock
2014-01-21,Acceleron Commences Proposed Public Offering Of Common Stock
2014-01-09,Acceleron Files Registration Statement For Proposed Public Offering Of Common Stock
2013-12-23,3 Biotech Stocks Spiking on Big Volume
2013-12-20,Acceleron Pharma To Be Added To Russell 2000&#174; Index
2013-12-18,Acceleron Earns $7 Million Milestone Payment For Celgene&#8217;s Initiation Of Sotatercept Phase 2 Clinical Trial In Patients With End Stage Renal Disease On Hemodialysis
2013-12-09,Acceleron And Celgene Report New Interim Clinical Data From Phase 2 Trial Of Sotatercept In Beta-Thalassemia At 2013 American Society Of Hematology Annual Meeting
2013-12-03,Acceleron Pharma Provides Update On Clinical Pipeline At Piper Jaffray Healthcare Conference
2013-12-02,Acceleron Announces New Interim Phase 2 Sotatercept Clinical Data In Beta-Thalassemia To Be Presented At 2013 American Society Of Hematology Annual Meeting
2013-11-25,Acceleron To Present At Piper Jaffray Healthcare Conference In December
2013-11-06,Acceleron Pharma Reports Third Quarter 2013 Financial Results
2013-11-05,Acceleron Pharma To Ring The NASDAQ Stock Market Closing Bell On November 5, 2013
2013-10-30,Acceleron Pharma To Host Third Quarter 2013 Financial Results Conference Call And Webcast On November 6, 2013
2013-10-22,Flagship VentureLabs™ Launches Pronutria To Prevent And Treat Diseases With Novel Protein Nutrients
2013-09-27,Top Insider Trades: NSH KAR XLRN IMH
2013-09-24,Acceleron Announces Closing Of Initial Public Offering And Full-Exercise Of Over-Allotment Option
2013-09-18,BioTech IPOs With Big Partners
2017-03-16,Acceleron Announces Plans To Initiate A Phase 2 Trial Of ACE-083 In Charcot-Marie-Tooth Neuromuscular Disease And Host Educational Webinar
2017-03-02,Acceleron Pharma Price Target Raised by Leerink
2017-03-01,Acceleron Reports Fourth Quarter And Year Ended 2016 Operational And Financial Results
2017-02-28,Acceleron To Participate In Two Healthcare Investor Conferences In March
2017-02-22,Acceleron Pharma To Webcast Conference Call Of Fourth Quarter And Year Ended 2016 Financial Results On March 1, 2017
2017-02-01,Acceleron To Participate In Two Healthcare Investor Conferences In February
2017-01-19,Acceleron Pharma Enters Oversold Territory (XLRN)
2017-01-06,Acceleron Outlines Corporate Goals And Priorities For 2017
2017-01-04,Acceleron To Webcast Presentation At 35th Annual J.P. Morgan Healthcare Conference
2016-12-22,Acceleron Announces First Patient Treated In Phase 2 Trial Of ACE-083 In Facioscapulohumeral Muscular Dystrophy
2016-12-07,Trump's Drug Pricing Comment Sends Biotech Stocks Into Free-Fall
2016-12-05,Acceleron And Celgene Announce Updated Results From Phase 2 Studies Of Luspatercept In Beta-Thalassemia Presented At The 58th Annual Meeting Of The American Society Of Hematology
2016-12-05,Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting
2016-12-05,Acceleron And Celgene Announce Preliminary Results From An Investigator Initiated Phase 2 Study Of Sotatercept In Myelofibrosis At The 58th Annual Meeting Of The American Society Of Hematology
2016-12-04,Acceleron, Celgene Seek to Replace Entrenched Anti-Anemia Drugs in MDS Treatment
2016-12-04,Acceleron And Celgene Announce Updated Results From Ongoing Phase 2 Studies Of Luspatercept In Myelodysplastic Syndromes At The 58th Annual Meeting Of The American Society Of Hematology
2016-11-30,Acceleron Pharma To Host Conference Call And Webcast To Review Data Presented At The 58th American Society Of Hematology Annual Meeting And Exposition
2016-11-03,Acceleron Pharma Reports Third Quarter 2016 Financial And Operational Results
2016-11-03,RSI Alert: Acceleron Pharma (XLRN) Now Oversold
2016-11-03,Acceleron Announces New Data Presentations At The 58th American Society Of Hematology Annual Meeting And Exposition
2016-11-02,Acceleron To Present At Credit Suisse Healthcare Conference Monday, November 7, 2016
2016-10-27,Acceleron Pharma To Webcast Conference Call Of Third Quarter 2016 Financial Results On November 3, 2016
2016-10-13,Acceleron To Host Educational Webcast On Facioscapulohumeral Muscular Dystrophy (FSHD) With Leading Researcher And Provide Overview Of ACE-083 Phase 2 Trial
2016-09-27,Acceleron Announces Retirement Of John Knopf As President And CEO; Habib Dable Named As Successor
2016-08-31,Acceleron To Participate In Three Healthcare Investor Conferences In September
2016-08-04,Acceleron Pharma Reports Second Quarter 2016 Financial And Operational Results
2016-07-28,Acceleron Pharma To Webcast Conference Call Of Second Quarter 2016 Financial Results On August 4, 2016
2016-07-25,Acceleron Pharma Appoints Thomas McCourt To Its Board Of Directors
2016-07-08,Acceleron Announces ACE-083 Phase 1 Results At The 14th International Congress On Neuromuscular Diseases
2016-07-07,Acceleron Pharma (XLRN) Showing Signs Of Perilous Reversal Today
2016-07-06,Acceleron Pharma (XLRN) Marked As A Dead Cat Bounce Stock
2016-06-29,Acceleron Announces Presentation Of ACE-083 Phase 1 Healthy Volunteer Data At The 14th International Congress On Neuromuscular Disease
2016-06-28,Brexit Bargain Buys: 14 More Stocks Picked by Morgan Stanley
2016-06-20,Acceleron Pharma (XLRN) Is Today's Dead Cat Bounce Stock
2016-06-10,Acceleron And Celgene Announce Updated Results From An Ongoing Phase 2 Study Of Luspatercept In Beta-Thalassemia Presented At The 21st Congress Of The European Hematology Association
2016-06-10,Acceleron And Celgene Announce Updated Results From An Ongoing Phase 2 Study Of Luspatercept In Myelodysplastic Syndromes At The 21st Congress Of The European Hematology Association
2016-06-07,Acceleron Pharma To Host Conference Call And Webcast To Review Updated Luspatercept Results Presented At The 21st Congress Of The European Hematology Association
2016-06-01,Acceleron Pharma To Participate In Two Healthcare Investor Conferences In June
2016-05-19,Acceleron Announces Data Presentations With Luspatercept At The 21st Congress Of The European Hematology Association
2016-05-05,Acceleron Pharma Reports First Quarter 2016 Financial And Operational Results
2016-04-28,Acceleron Pharma To Host First Quarter 2016 Financial Results
2016-04-26,Acceleron Pharma To Participate In Two Healthcare Investor Conferences In May
2016-04-25,Trade-Ideas: Acceleron Pharma (XLRN) Is Today's Strong On High Relative Volume Stock
2016-03-01,Acceleron Pharma To Participate In Four Healthcare Investor Conferences In March
2016-02-25,Acceleron Pharma Reports Fourth Quarter And Year Ended 2015 Financial And Operational Results And Recent Highlights
2016-02-21,19 Charts to Calm Your Recession Fears
2016-02-18,Acceleron Pharma To Host Fourth Quarter And Year Ended 2015 Financial Results
2016-02-14,19 Stocks You Should Own if the U.S. Falls Into a Recession
2016-02-03,Acceleron Pharma Enters Oversold Territory (XLRN)
2016-02-01,Acceleron Pharma To Participate In Two Healthcare Investor Conferences In February
2016-01-15,5 Stocks to Trade for Breakout Gains
2016-01-12,Insider Trading Alert - XLRN, TTMI And AGX Traded By Insiders
2016-01-09,2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks
2016-01-06,Acceleron Pharma (XLRN) Trading With Heavy Volume Before Market Open
2016-01-05,Acceleron Announces Pricing Of Public Offering Of Common Stock
2016-01-04,Acceleron Announces Proposed Public Offering Of Common Stock
2015-12-07,Celgene And Acceleron Announce New Results From An Investigational Study With Luspatercept In Beta-Thalassemia Presented At The 57th American Society Of Hematology (ASH) Annual Meeting And Exposition
2015-12-07,FDA Fast Track Designation Granted To Luspatercept For The Treatment Of Patients With Lower-Risk Myelodysplastic Syndromes
2015-12-07,Investors Remain Skeptical about Bluebird Gene Therapy for Blood Disease
2015-12-05,Celgene And Acceleron Announce New Results From An Investigational Study With Luspatercept In Myelodysplastic Syndromes Presented At The 57th American Society Of Hematology (ASH) Annual Meeting And Exposition
2015-12-01,Acceleron Announces Oral Plenary Presentation For ACE-083 In The Late Breaking Clinical Trials Session At The 8th International Conference On Cachexia, Sarcopenia And Muscle Wasting
2015-11-24,Acceleron Pharma To Present At Piper Jaffray 27th Annual Healthcare Conference
2015-11-05,Acceleron Announces New Data Presentations At The 2015 American Society Of Hematology Annual Meeting
2015-11-04,Acceleron Pharma Reports Third Quarter 2015 Financial And Operational Results
2015-11-02,Acceleron Pharma To Present At Upcoming Investor Conferences In November
2015-10-29,Acceleron Pharma To Host Third Quarter 2015 Financial Results Conference Call And Webcast On November 4, 2015
2015-10-23,Acceleron Highlights Phase 3 Studies, New Clinical Results And Research Strategies At Research And Development Day Event
2015-10-15,Acceleron To Host Research And Development Day On October 23
2015-10-05,Commit To Buy Acceleron Pharma At $20, Earn 24% Annualized Using Options
2015-10-02,Acceleron Announces Presentation Of Sotatercept Data At The American Society Of Nephrology Kidney Week 2015
2015-10-01,Acceleron Presents Preclinical Data For ACE-083 And ACE-2494 At The 20th International Annual Congress Of The World Muscle Society
2015-09-24,Trade-Ideas: Acceleron Pharma (XLRN) Is Today's Weak On High Relative Volume Stock
2015-09-02,Acceleron Pharma To Present At Upcoming Investor Conferences In September
2015-08-14,Acceleron Pharma (XLRN) Highlighted As Weak On High Volume
2015-08-06,Acceleron Pharma Reports Second Quarter 2015 Financial And Operational Results
2015-07-29,Acceleron Pharma To Host Second Quarter 2015 Financial Results Conference Call And Webcast On August 6, 2015
2015-07-06,Commit To Purchase Acceleron Pharma At $25, Earn 14.1% Annualized Using Options
2015-06-15,Acceleron Announces Publication In Cancer Research Demonstrating Dalantercept Prevents Metastases In Preclinical Studies Of Breast Cancer
2015-06-12,Acceleron Announces New Luspatercept Phase 2 Clinical Results At The 20th Congress Of The European Hematology Association
2015-06-09,Acceleron Pharma To Host Conference Call And Webcast To Review New Luspatercept Data Presented At The 20th Congress Of The European Hematology Association
2015-05-27,Acceleron Pharma To Present At Upcoming Investor Conferences In June
2015-05-21,Acceleron To Present Luspatercept Clinical Trials At The 20th Congress Of The European Hematology Association
2015-05-18,(Graphic: Business Wire)
2015-05-14,Trade-Ideas: Acceleron Pharma (XLRN) Is Today's Weak On High Relative Volume Stock
2015-05-13,Acceleron To Present Dalantercept Clinical Data At The 2015 American Society Of Clinical Oncology (ASCO) Annual Meeting
2015-05-07,Acceleron Pharma Reports First Quarter 2015 Financial And Operational Results
2015-05-02,Luspatercept Data Presented At The 13th International Symposium On Myelodysplastic Syndromes
2015-04-30,Celgene And Acceleron Select Luspatercept To Advance To Phase 3 In Myelodysplastic Syndromes
2015-04-28,Acceleron Pharma To Host First Quarter 2015 Financial Results Conference Call And Webcast On May 7, 2015
2015-04-27,Oversold Conditions For Acceleron Pharma
2015-04-23,Acceleron Pharma To Present At Upcoming Investor Conferences In May
2015-04-07,Acceleron Announces Oral Presentations Of Luspatercept And Sotatercept Data At The 13th International Symposium On Myelodysplastic Syndromes
2015-04-06,Interesting XLRN Put And Call Options For August 21st
2015-04-06,Acceleron Pharma Appoints Dr. Francois Nader As Chairman Of Its Board Of Directors
2015-03-06,Acceleron Pharma Announces Executive Appointments And Promotions
2015-03-02,Acceleron Pharma Reports Fourth Quarter And Year Ended 2014 Financial And Operational Results
2015-02-28,Acceleron Presents Encouraging Response Rates And Progression-Free Survival Data In Patients With Advanced Renal Cell Carcinoma At The American Society Of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium
2015-02-26,Acceleron Pharma To Present At Upcoming Investor Conferences In March
2015-02-24,Acceleron Pharma To Host Fourth Quarter And Year Ended 2014 Financial Results Conference Call And Webcast On March 2, 2015
2015-02-19,Acceleron To Present New Dalantercept Clinical Data At The American Society Of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium
2015-01-28,Acceleron Pharma To Present At Upcoming Investor Conferences In February
2015-01-14,Insider Trading Alert - XLRN, MOH And PF Traded By Insiders
2015-01-12,Celgene Has 2020 Vision for Long-Term Growth but Plays Safe for 2017
2015-01-12,Insider Trading Alert - EXA, CVV And XLRN Traded By Insiders
2015-01-12,Acceleron Pharma Outlines Corporate Objectives For 2015
2014-12-24,Commit To Purchase Acceleron Pharma At $30, Earn 16.7% Annualized Using Options
2014-12-15,Acceleron Pharma Added To NASDAQ Biotechnology Index
2014-12-12,Acceleron Pharma Appoints Dr. Francois Nader To Its Board Of Directors
2014-12-10,Luspatercept Data On Myelodysplastic Syndromes Selected For "Best Of ASH" By The American Society Of Hematology
2014-12-08,New Data In Myelodysplastic Syndromes Presented At The 56th American Society Of Hematology (ASH) Annual Meeting And Exposition
2014-12-08,Acceleron Pharma (XLRN) Strong On High Relative Volume Today
2014-12-08,The 7 Most Important Drug-Stock Lessons From This Weekend's Blood Cancer Meeting
2014-12-07,Acceleron Drugs Reduce Anemia Caused by Rare Blood Disorders
2014-12-07,New Data From Luspatercept Phase 2 Clinical Trial In Beta-Thalassemia Presented At The 56th American Society Of Hematology (ASH) Annual Meeting And Exposition
2014-11-24,Acceleron Pharma To Present At Upcoming Investor Conferences In December
2014-11-13,Sotatercept Data From The Phase 2a Clinical Trial In Hemodialysis Patients Presented At The American Society Of Nephrology Kidney Week 2014
2014-11-11,Ratings Changes Today
2014-11-07,Acceleron Pharma Reports Third Quarter 2014 Financial And Operational Results
2014-11-06,Acceleron Announces New Clinical Data Presentations At The 2014 American Society Of Hematology Annual Meeting
2014-10-30,Acceleron Pharma To Host Third Quarter 2014 Financial Results Conference Call And Webcast On November 7, 2014
2014-10-29,Acceleron Pharma To Present At Upcoming Investor Conferences In November
2014-10-23,Acceleron Collaboration Partner Celgene To Present Data At The American Society Of Nephrology Kidney Week 2014
2014-10-22,Acceleron Announces Educational Webcast On Chronic Kidney Disease - Mineral And Bone Disorder
2014-10-14,Acceleron Initiates Phase 1 Clinical Trial With Innovative Muscle Drug ACE-083
2014-10-02,Acceleron Hit Over Competitive Concerns, but Investors Overlook Rest of Pipeline
2014-10-01,Acceleron To Host Educational Webcast On Beta-thalassemia
2014-09-29,Acceleron To Webcast Presentation At Leerink Partners Rare Disease Roundtable
2014-09-23,Acceleron Provides Update On Externally Sponsored Clinical Trial Of Dalantercept Monotherapy In Ovarian Cancer
2014-09-16,Acceleron To Host Educational Webcast Series With Clinical Thought Leaders
2014-08-27,Acceleron Pharma To Present At Upcoming Investor Conferences In September
2014-08-12,Acceleron Pharma Reports Second Quarter 2014 Financial Results
2014-08-05,Acceleron Pharma To Host Second Quarter 2014 Financial Results
2014-07-17,Acceleron Pharma Enters Oversold Territory (XLRN)
2014-07-14,Acceleron Pharma Appoints Terrence C. Kearney To Its Board Of Directors
2014-06-19,Acceleron Pharma To Present At JMP Securities Healthcare Conference
2014-06-14,Studies Presented At 19th European Hematology Association Annual Congress Evaluate Activin Receptor Ligand Trap Programs In Beta-Thalassemia
2014-06-10,3 Stocks Spiking on Unusual Volume
2014-05-29,Acceleron Pharma To Present At Upcoming Investor And Medical Conferences In June
2014-05-21,Acceleron Announces New Interim Phase 2 Data On Sotatercept And ACE-536 To Be Reported At Three Oral Presentations At The 19th Annual Congress Of The European Hematology Association
2014-05-15,Acceleron Pharma Reports First Quarter 2014 Financial Results
2014-05-14,Acceleron To Report New Encouraging Interim Clinical Data From Phase 2 Trial Of Dalantercept In Renal Cell Carcinoma At The 50th Annual Meeting Of The American Society Of Clinical Oncology
2014-05-12,Acceleron To Present At 2014 UBS Global Healthcare Conference
2014-05-08,Acceleron Pharma To Host First Quarter 2014 Financial Results Conference Call And Webcast On May 15, 2014
2014-04-23,Acceleron And Celgene Announce Interim Clinical Data For Sotatercept Demonstrating Dose Dependent Increases In Hemoglobin In Patients With End Stage Renal Disease On Hemodialysis
2014-03-28,'Fast Money' Recap: Downward Pressure
2014-03-24,Acceleron, Celgene And Collaborators Announce Two Publications In Nature Medicine Describing Sotatercept And ACE-536 Therapeutic Potential In Beta-thalassemia And Myelodysplastic Syndromes
2014-03-20,Acceleron To Present At The 21st Annual Future Leaders In The Biotech Industry Conference
2014-03-17,Acceleron And Celgene Announce Interim Clinical Data For Sotatercept In Patients With End Stage Renal Disease On Hemodialysis At The 2014 National Kidney Foundation Spring Clinical Meeting
2014-02-27,Acceleron To Present At Cowen And Company 34th Annual Health Care Conference
2014-02-26,Acceleron Pharma Reports Fourth Quarter And Year Ended 2013 Financial Results
2014-02-19,Acceleron Pharma To Host Fourth Quarter And Year Ended 2013 Financial Results Conference Call And Webcast On February 26, 2014
2014-02-05,Acceleron To Present At 2014 Leerink Global Healthcare Conference
2014-01-30,Top Insider Trades: XLRN AYR SVVC OPK
2014-01-28,Acceleron Announces Closing Of Public Offering And Full Exercise Of Underwriters&#8217; Option To Purchase Additional Shares
2014-01-23,The State of Gene Therapy in a Biogen Idec World: Sangamo, Bluebird and Acceleron
2014-01-22,Acceleron Announces Pricing Of Public Offering Of Common Stock
2014-01-21,Acceleron Commences Proposed Public Offering Of Common Stock
2014-01-09,Acceleron Files Registration Statement For Proposed Public Offering Of Common Stock
2013-12-23,3 Biotech Stocks Spiking on Big Volume
2013-12-20,Acceleron Pharma To Be Added To Russell 2000&#174; Index
2013-12-18,Acceleron Earns $7 Million Milestone Payment For Celgene&#8217;s Initiation Of Sotatercept Phase 2 Clinical Trial In Patients With End Stage Renal Disease On Hemodialysis
2013-12-09,Acceleron And Celgene Report New Interim Clinical Data From Phase 2 Trial Of Sotatercept In Beta-Thalassemia At 2013 American Society Of Hematology Annual Meeting
2013-12-03,Acceleron Pharma Provides Update On Clinical Pipeline At Piper Jaffray Healthcare Conference
2013-12-02,Acceleron Announces New Interim Phase 2 Sotatercept Clinical Data In Beta-Thalassemia To Be Presented At 2013 American Society Of Hematology Annual Meeting
2013-11-25,Acceleron To Present At Piper Jaffray Healthcare Conference In December
2013-11-06,Acceleron Pharma Reports Third Quarter 2013 Financial Results
2013-11-05,Acceleron Pharma To Ring The NASDAQ Stock Market Closing Bell On November 5, 2013
2013-10-30,Acceleron Pharma To Host Third Quarter 2013 Financial Results Conference Call And Webcast On November 6, 2013
2013-10-22,Flagship VentureLabs™ Launches Pronutria To Prevent And Treat Diseases With Novel Protein Nutrients
2013-09-27,Top Insider Trades: NSH KAR XLRN IMH
2013-09-24,Acceleron Announces Closing Of Initial Public Offering And Full-Exercise Of Over-Allotment Option
2013-09-18,BioTech IPOs With Big Partners
2017-03-23,XOMA Announces Four Presentations At The 2017 ENDO Meeting
2017-03-22,XOMA Announces Full Repayment Of Hercules Technology Growth Capital Debt Obligation
2017-03-16,XOMA Reports Fourth Quarter And Full Year 2016 Financial Results
2017-03-14,XOMA To Announce Fourth Quarter And Full Year 2016 Financial Results And Host Conference Call Focused On Its New Strategic Direction On March 16, 2017
2017-02-28,XOMA To Present New Strategic Initiatives At The Cowen And Company 37th Annual Health Care Conference
2017-02-16,XOMA Appoints Matthew Perry To Its Board Of Directors
2017-02-13,XOMA Announces Pricing Of $25 Million Registered Offering Of Common Stock And Convertible Preferred Stock
2017-01-31,XOMA Establishes Proof-of-Concept For 358 In Congenital Hyperinsulinism And Hypoglycemia Post-Bariatric Surgery
2016-12-21,XOMA Announces Up To $22 Million Generated From Sale Of Royalty Streams From Two License Agreements To HealthCare Royalty Partners And Provides Corporate Update
2016-11-09,XOMA Reports Third Quarter 2016 Achievements And Financial Results
2016-11-08,New XOMA Antibodies Unveiled At The Society For Immunotherapy Of Cancer 31st Annual Meeting
2016-10-19,XOMA Reaches Analyst Target Price
2016-10-19,XOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study For XOMA 358 In Children With Congenital Hyperinsulinism
2016-10-14,XOMA Announces Reverse Stock Split
2016-09-15,XOMA Provides Update From Ongoing Phase 2 XOMA 358 Clinical Studies
2016-09-06,XOMA To Host XOMA 358 Clinical Update Webcast And Conference Call On September 15, 2016
2016-08-11,XOMA To Present At The 2016 Wedbush PacGrow Healthcare Conference
2016-08-03,XOMA Reports Second Quarter 2016 Achievements And Financial Results
2016-07-20,XOMA Receives Orphan Drug Designation In The European Union For XOMA 358 For Treatment Of Congenital Hyperinsulinism
2016-07-05,XOMA To Present At The Cantor Fitzgerald Healthcare Conference
2016-06-28,XOMA Initiates Phase 2 Proof-of-Concept Study Of XOMA 213
2016-06-02,XOMA To Present At The Jefferies Global Healthcare Conference
2016-05-04,XOMA Reports First Quarter 2016 Operational Achievements And Financial Results
2016-04-27,XOMA Initiates XOMA 358 Proof-of-Concept Study In Patients With Hypoglycemia Post Gastric Bypass Surgery
2016-04-04,XOMA Presented First Data From Novel Antibody Fragment To Address Severe Acute Hypoglycemia At The ENDO Meeting
2016-03-11,XOMA (XOMA) Weak On High Volume
2016-03-10,Xoma Stock Soaring on Q4 Earnings Beat
2016-03-09,Xoma Stock Surges in After-Hours Trading on Q4 Results
2016-03-09,XOMA Reports Fourth Quarter And Full-Year 2015 Financial Results
2016-03-02,XOMA To Present At The Cowen & Company Health Care Conference
2016-02-24,XOMA To Announce Fourth Quarter And Full Year 2015 Financial Results And Host Webcast On March 9
2015-12-11,Friday Small-Cap Focus: Xoma
2015-12-01,Xoma Stock Surges, Sells Diabetes Treatment to Novo Nordisk for $295 Million
2015-12-01,XOMA Announces License Agreement With Novo Nordisk For XMetA Program In Diabetes
2015-11-12,XOMA To Present At Two Upcoming Investor Conferences
2015-11-09,Strong On High Volume: XOMA (XOMA)
2015-11-05,XOMA Announces The Sale Of Its Manufacturing Facilities To Agenus
2015-11-05,XOMA Provides Corporate Update And Reports Financial Results For Third Quarter 2015
2015-10-29,XOMA To Announce Third Quarter 2015 Financial Results And Host Webcast On November 5
2015-10-26,XOMA Initiates Proof-of-Concept Study For XOMA 358 In Patients With Congenital Hyperinsulinism
2015-10-01,XOMA Announces Development And Commercialization Agreement For First-in-Class Anti-TGF-beta Antibody Program In Immuno-Oncology
2015-09-30,10 Worst NASDAQ Biotech Stocks in the Third Quarter
2015-09-08,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors Of Class Action Against XOMA Corporation And Lead Plaintiff Deadline September 22, 2015
2015-08-18,TRADING ALERT: The Rosen Law Firm Reminds Xoma Corporation Investors Of Important Deadline In Class Action - XOMA
2015-08-07,XOMA To Present At The 2015 Wedbush PacGrow Healthcare Conference
2015-08-06,XOMA Reports Financial Results For Second Quarter 2015
2015-08-03,Robbins Arroyo LLP: XOMA Corporation (XOMA) Misled Shareholders According To A Recently Filed Class Action
2015-07-30,SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against XOMA Corporation
2015-07-30,Ride 'Shotgun' to Avoid Investing Mistakes
2015-07-30,EQUITY ALERT: The Rosen Law Firm Announces The Filing Of A Securities Class Action Lawsuit Against Xoma Corporation
2015-07-23,XOMA SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Xoma Corporation
2015-07-22,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of XOMA Corporation.
2015-07-22,Xoma Is a Biotech Zombie in Need of a Kill Shot to the Head
2015-07-22,XOMA Announces Results From Phase 3 EYEGUARD(TM)-B Study
2015-07-17,XOMA (XOMA) Showing Signs Of Perilous Reversal Today
2015-07-16,XOMA To Announce Second Quarter 2015 Financial Results And Host Webcast On August 6
2015-07-10,XOMA Stock Closed in the Green Following Upbeat Piper Note
2015-07-10,Stock To Watch: XOMA (XOMA) In Perilous Reversal
2015-07-09,Trade-Ideas: XOMA (XOMA) Is Today's "Dead Cat Bounce" Stock
2015-07-01,Trade-Ideas: XOMA (XOMA) Is Today's Weak On High Relative Volume Stock
2015-06-30,XOMA (XOMA) Showing Signs Of A Dead Cat Bounce Today
2015-06-26,'Mad Money' Lightning Round: Stay Away From Las Vegas Sands
2015-06-25,Jim Cramer's 'Mad Money' Recap: Supreme Court Almost Makes Market Forget Greece
2015-06-23,Interesting XOMA Put And Call Options For August 21st
2015-06-23,XOMA (XOMA) Is Weak On High Volume Today
2015-06-22,XOMA (XOMA) Is Strong On High Volume Today
2015-06-16,XOMA Receives Orphan Drug Designation For XOMA 358 From U.S. FDA For Treatment Of Congenital Hyperinsulinism (HI)
2015-06-11,5 Stocks Under $10 Set to Soar
2015-06-11,XOMA (XOMA) Is Today's Strong On High Volume Stock
2015-05-28,XOMA Stock Gains After Reaching Necessary Number of Events to Analyze Behcets Disease Drug Study
2015-05-28,XOMA Announces Phase 3 EYEGUARD(TM)-B Study Reaches Target Exacerbation Event
2015-05-19,First Week Of July 17th Options Trading For XOMA
2015-05-07,XOMA Reports First Quarter 2015 Achievements And Financial Results
2015-05-04,XOMA To Present At Credit Suisse Antibody Day 2015
2015-04-30,XOMA To Announce First Quarter 2015 Financial Results And Host Conference Call On May 7
2015-04-21,First Week Of XOMA December 18th Options Trading
2015-04-01,Servier Initiates Phase 2 Study Of Gevokizumab In Patients With Diabetic Nephropathy
2015-03-25,First Week Of May 15th Options Trading For XOMA
2015-03-24,4 Biotech Stocks Under $10 to Trade for Breakouts
2015-03-23,XOMA (XOMA): Today's Weak On High Volume Stock
2015-03-17,4 Stocks Under $10 Making Big Moves Into Breakout Territory
2015-03-11,XOMA Highlights Recent Achievements And Reports Fourth Quarter And Full-Year 2014 Financial Results
2015-03-10,4 Stocks Under $10 to Trade for Big Breakouts
2015-03-07,XOMA Presents Positive Phase 1 XOMA 358 Data At The ENDO Meeting
2015-03-05,XOMA Will Present XOMA 358 Phase 1 Data At ENDO 2015
2015-03-03,XOMA Announces Retirement Of Fred Kurland And Appointment Of Thomas Burns As Chief Financial Officer
2015-02-26,XOMA To Announce Fourth Quarter And Full Year 2014 Financial Results And Host Webcast On March 11
2015-02-24,First Week Of April 17th Options Trading For XOMA
2015-02-18,XOMA To Present At Upcoming Investor Conferences
2015-01-23,First Week Of September 18th Options Trading For XOMA
2015-01-23,XOMA (XOMA) Weak On High Volume
2015-01-06,Stock To Watch: XOMA (XOMA) In Perilous Reversal
2014-12-24,XOMA (XOMA) Is Today's Dead Cat Bounce Stock
2014-12-09,Today's Perilous Reversal Stock: XOMA (XOMA)
2014-12-09,XOMA Announces Pricing Of $40.0 Million Registered Offering Of Common Stock And Warrants
2014-12-05,Strong On High Relative Volume: XOMA (XOMA)
2014-12-03,XOMA (XOMA) Stock: Weak On High Volume Today
2014-11-24,XOMA To Present At The Piper Jaffray Healthcare Conference
2014-11-20,Trade-Ideas: XOMA (XOMA) Is Today's Strong On High Relative Volume Stock
2014-11-17,Interesting XOMA Call Options For January 2017
2014-11-10,XOMA To Present At Upcoming Investor Conferences
2014-11-07,XOMA (XOMA) Stock: Weak On High Volume Today
2014-11-06,XOMA Highlights Recent Achievements And Reports Financial Results For The Third Quarter Of 2014
2014-11-04,XOMA Initiates Pivotal Phase 3 Gevokizumab Study In Patients With Pyoderma Gangrenosum
2014-10-27,XOMA To Announce Third Quarter 2014 Financial Results And Host Webcast On November 6
2014-10-09,XOMA Launches XOMA 358 Clinical Development
2014-10-06,The Texas A&M University System And XOMA License Innovative Manufacturing Technology
2014-09-30,XOMA Initiates U.S. Clinical Trial Of Gevokizumab In Patients With Behcet's Disease Uveitis - EYEGUARD(TM)-US
2014-09-12,4 Under-$10 Stocks to Trade for Breakouts
2014-08-27,3 Stocks Under $10 Making Big Moves
2014-08-26,Your September Biotech Back-to-School Calendar
2014-08-19,First Week of October 18th Options Trading For XOMA
2014-08-15,4 Under-$10 Stocks Making Big Moves
2014-08-11,5 Stocks Ready for Breakouts
2014-08-07,XOMA Highlights Recent Achievements And Reports Financial Results For Second Quarter 2014
2014-08-06,XOMA To Present At Two Upcoming Investor Conferences
2014-07-30,XOMA To Announce Second Quarter 2014 Financial Results And Host Webcast On August 7
2014-07-22,First Week of March 2015 Options Trading For XOMA
2014-07-11,XOMA Corp Stock Sees Short Interest Drop 27.6%
2014-07-02,4 Biotech Stocks Under $10 to Watch for Breakout Trades
2014-06-30,XOMA Call Today At 4:30pm ET/1:30pm PT To Confirm Communication Plan For EYEGUARD(TM)-B Clinical Program
2014-06-24,Interesting XOMA Put And Call Options For August 16th
2014-06-13,3 Stocks Under $10 in Breakout Territory
2014-05-28,XOMA To Present At The Jefferies Global Healthcare Conference
2014-05-22,5 Stocks Under $10 Set to Soar
2014-05-19,Taking a Cautious Dose of Small Biotech
2014-05-16,Insider Trading Alert - ITMN, WAC And XOMA Traded By Insiders
2014-05-12,XOMA To Present At The Bank Of America Merrill Lynch Health Care Conference
2014-05-07,XOMA Reports First Quarter 2014 Operational Highlights And Financial Results
2014-04-30,XOMA To Announce First Quarter 2014 Financial Results And Host Webcast On May 7
2014-04-29,Why XOMA (XOMA) Stock Is Surging Today
2014-04-28,XOMA Finalizes Plans For Gevokizumab Phase 3 Clinical Program In Pyoderma Gangrenosum
2014-04-22,First Week of December 20th Options Trading For XOMA
2014-04-15,The Recent Performance of 'Baker Brother Biotech Stocks' is Awful
2014-03-21,Insider Trading Alert - SFY, XOMA And SNI Traded By Insiders
2014-03-07,XOMA Corp Stock Downgraded (XOMA)
2014-03-06,July 19th Options Now Available For XOMA
2014-03-06,XOMA (XOMA) Marked As A Dead Cat Bounce Stock
2014-03-05,Ratings Changes Today
2014-03-05,Why XOMA Corporation (XOMA) Is Plunging Today
2014-03-05,XOMA (XOMA) Showing Signs Of Perilous Reversal Today
2014-03-04,XOMA Reports 2013 Operational Highlights And Fourth Quarter And Full-Year 2013 Financial Results
2014-03-04,XOMA Provides Update On Gevokizumab Proof-of-Concept Program
2014-02-25,First Week of XOMA April 19th Options Trading
2014-02-24,XOMA Receives Orphan Drug Designation From U.S. FDA For Pyoderma Gangrenosum
2014-02-20,XOMA To Present At Upcoming Investor Conferences
2014-01-22,Interesting XOMA Put And Call Options For September 20th
2014-01-11,'Mad Money' Lightning Round: I Don't Like Amgen
2014-01-10,Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
2013-12-26,Short Interest In XOMA Drops 19.7%
2013-12-18,XOMA Announces Closing Of The Offering And Exercise Of Option
2013-12-16,Today's Dead Cat Bounce Stock Is XOMA (XOMA)
2013-12-13,XOMA Announces Pricing Of Approximately $50.0 Million Offering Of Common Stock
2013-12-12,XOMA Announces Proposed Public Offering Of Common Stock
2013-12-05,Ratings Changes Today
2013-11-26,XOMA To Present At The Piper Jaffray Healthcare Conference
2013-11-20,XOMA Awarded Key Flexible Manufacturing Patent
2013-11-19,First Week Of January 2014 Options Trading For XOMA
2013-11-18,Why I Remain Bullish On EZchip Semiconductor
2013-11-11,XOMA January 2016 Options Begin Trading
2013-11-08,Interesting XOMA Put And Call Options For January 2015
2013-11-07,XOMA Highlights Recent Achievements And Reports Financial Results For Third Quarter 2013
2013-11-06,XOMA To Present At The Credit Suisse Healthcare Conference
2013-10-31,XOMA To Announce Third Quarter 2013 Financial Results And Host Webcast On November 7
2013-10-30,Results From Two Phase 2 Studies In XOMA's Gevokizumab Proof-of-Concept Program Are Very Encouraging And Compelling
2013-10-25,Short Interest In XOMA Falls 31.6%
2013-10-25,5 Biotech Stocks Under $10 for Your Watch List
2013-10-01,Interesting XOMA Call For November 16th
2013-09-05,XOMA To Present At The Morgan Stanley Healthcare Conference
2013-08-23,XOMA Announces Closing Of The Offering And Exercise Of Over-Allotment Option
2013-08-20,XOMA Announces Pricing Of $27.5 Million Offering Of Common Stock
2013-08-08,XOMA To Present At Two Upcoming Investor Conferences
2013-08-07,XOMA Highlights Recent Achievements And Reports Financial Results For Second Quarter 2013
2013-07-25,XOMA To Announce Second Quarter 2013 Financial Results And Host Webcast On August 7
2013-07-22,XOMA Completes Enrollment In Phase 2 Proof-of-Concept Gevokizumab Trial In Patients With Erosive Osteoarthritis Of The Hand
2013-07-14,Sizing Up My Small Cap Strategy
2013-07-12,Short Interest Moves 10.7% Lower For XOMA
2013-07-03,XOMA Transfers Perindopril Franchise Rights To Symplmed
2013-07-02,XOMA To Present At The JMP Securities Healthcare Conference
2013-06-25,XOMA's Development Partner SERVIER Launches Proof-of-Concept Clinical Program For Gevokizumab
2017-03-23,XOMA Announces Four Presentations At The 2017 ENDO Meeting
2017-03-22,XOMA Announces Full Repayment Of Hercules Technology Growth Capital Debt Obligation
2017-03-16,XOMA Reports Fourth Quarter And Full Year 2016 Financial Results
2017-03-14,XOMA To Announce Fourth Quarter And Full Year 2016 Financial Results And Host Conference Call Focused On Its New Strategic Direction On March 16, 2017
2017-02-28,XOMA To Present New Strategic Initiatives At The Cowen And Company 37th Annual Health Care Conference
2017-02-16,XOMA Appoints Matthew Perry To Its Board Of Directors
2017-02-13,XOMA Announces Pricing Of $25 Million Registered Offering Of Common Stock And Convertible Preferred Stock
2017-01-31,XOMA Establishes Proof-of-Concept For 358 In Congenital Hyperinsulinism And Hypoglycemia Post-Bariatric Surgery
2016-12-21,XOMA Announces Up To $22 Million Generated From Sale Of Royalty Streams From Two License Agreements To HealthCare Royalty Partners And Provides Corporate Update
2016-11-09,XOMA Reports Third Quarter 2016 Achievements And Financial Results
2016-11-08,New XOMA Antibodies Unveiled At The Society For Immunotherapy Of Cancer 31st Annual Meeting
2016-10-19,XOMA Reaches Analyst Target Price
2016-10-19,XOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study For XOMA 358 In Children With Congenital Hyperinsulinism
2016-10-14,XOMA Announces Reverse Stock Split
2016-09-15,XOMA Provides Update From Ongoing Phase 2 XOMA 358 Clinical Studies
2016-09-06,XOMA To Host XOMA 358 Clinical Update Webcast And Conference Call On September 15, 2016
2016-08-11,XOMA To Present At The 2016 Wedbush PacGrow Healthcare Conference
2016-08-03,XOMA Reports Second Quarter 2016 Achievements And Financial Results
2016-07-20,XOMA Receives Orphan Drug Designation In The European Union For XOMA 358 For Treatment Of Congenital Hyperinsulinism
2016-07-05,XOMA To Present At The Cantor Fitzgerald Healthcare Conference
2016-06-28,XOMA Initiates Phase 2 Proof-of-Concept Study Of XOMA 213
2016-06-02,XOMA To Present At The Jefferies Global Healthcare Conference
2016-05-04,XOMA Reports First Quarter 2016 Operational Achievements And Financial Results
2016-04-27,XOMA Initiates XOMA 358 Proof-of-Concept Study In Patients With Hypoglycemia Post Gastric Bypass Surgery
2016-04-04,XOMA Presented First Data From Novel Antibody Fragment To Address Severe Acute Hypoglycemia At The ENDO Meeting
2016-03-11,XOMA (XOMA) Weak On High Volume
2016-03-10,Xoma Stock Soaring on Q4 Earnings Beat
2016-03-09,Xoma Stock Surges in After-Hours Trading on Q4 Results
2016-03-09,XOMA Reports Fourth Quarter And Full-Year 2015 Financial Results
2016-03-02,XOMA To Present At The Cowen & Company Health Care Conference
2016-02-24,XOMA To Announce Fourth Quarter And Full Year 2015 Financial Results And Host Webcast On March 9
2015-12-11,Friday Small-Cap Focus: Xoma
2015-12-01,Xoma Stock Surges, Sells Diabetes Treatment to Novo Nordisk for $295 Million
2015-12-01,XOMA Announces License Agreement With Novo Nordisk For XMetA Program In Diabetes
2015-11-12,XOMA To Present At Two Upcoming Investor Conferences
2015-11-09,Strong On High Volume: XOMA (XOMA)
2015-11-05,XOMA Announces The Sale Of Its Manufacturing Facilities To Agenus
2015-11-05,XOMA Provides Corporate Update And Reports Financial Results For Third Quarter 2015
2015-10-29,XOMA To Announce Third Quarter 2015 Financial Results And Host Webcast On November 5
2015-10-26,XOMA Initiates Proof-of-Concept Study For XOMA 358 In Patients With Congenital Hyperinsulinism
2015-10-01,XOMA Announces Development And Commercialization Agreement For First-in-Class Anti-TGF-beta Antibody Program In Immuno-Oncology
2015-09-30,10 Worst NASDAQ Biotech Stocks in the Third Quarter
2015-09-08,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors Of Class Action Against XOMA Corporation And Lead Plaintiff Deadline September 22, 2015
2015-08-18,TRADING ALERT: The Rosen Law Firm Reminds Xoma Corporation Investors Of Important Deadline In Class Action - XOMA
2015-08-07,XOMA To Present At The 2015 Wedbush PacGrow Healthcare Conference
2015-08-06,XOMA Reports Financial Results For Second Quarter 2015
2015-08-03,Robbins Arroyo LLP: XOMA Corporation (XOMA) Misled Shareholders According To A Recently Filed Class Action
2015-07-30,SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against XOMA Corporation
2015-07-30,Ride 'Shotgun' to Avoid Investing Mistakes
2015-07-30,EQUITY ALERT: The Rosen Law Firm Announces The Filing Of A Securities Class Action Lawsuit Against Xoma Corporation
2015-07-23,XOMA SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Xoma Corporation
2015-07-22,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of XOMA Corporation.
2015-07-22,Xoma Is a Biotech Zombie in Need of a Kill Shot to the Head
2015-07-22,XOMA Announces Results From Phase 3 EYEGUARD(TM)-B Study
2015-07-17,XOMA (XOMA) Showing Signs Of Perilous Reversal Today
2015-07-16,XOMA To Announce Second Quarter 2015 Financial Results And Host Webcast On August 6
2015-07-10,XOMA Stock Closed in the Green Following Upbeat Piper Note
2015-07-10,Stock To Watch: XOMA (XOMA) In Perilous Reversal
2015-07-09,Trade-Ideas: XOMA (XOMA) Is Today's "Dead Cat Bounce" Stock
2015-07-01,Trade-Ideas: XOMA (XOMA) Is Today's Weak On High Relative Volume Stock
2015-06-30,XOMA (XOMA) Showing Signs Of A Dead Cat Bounce Today
2015-06-26,'Mad Money' Lightning Round: Stay Away From Las Vegas Sands
2015-06-25,Jim Cramer's 'Mad Money' Recap: Supreme Court Almost Makes Market Forget Greece
2015-06-23,Interesting XOMA Put And Call Options For August 21st
2015-06-23,XOMA (XOMA) Is Weak On High Volume Today
2015-06-22,XOMA (XOMA) Is Strong On High Volume Today
2015-06-16,XOMA Receives Orphan Drug Designation For XOMA 358 From U.S. FDA For Treatment Of Congenital Hyperinsulinism (HI)
2015-06-11,5 Stocks Under $10 Set to Soar
2015-06-11,XOMA (XOMA) Is Today's Strong On High Volume Stock
2015-05-28,XOMA Stock Gains After Reaching Necessary Number of Events to Analyze Behcets Disease Drug Study
2015-05-28,XOMA Announces Phase 3 EYEGUARD(TM)-B Study Reaches Target Exacerbation Event
2015-05-19,First Week Of July 17th Options Trading For XOMA
2015-05-07,XOMA Reports First Quarter 2015 Achievements And Financial Results
2015-05-04,XOMA To Present At Credit Suisse Antibody Day 2015
2015-04-30,XOMA To Announce First Quarter 2015 Financial Results And Host Conference Call On May 7
2015-04-21,First Week Of XOMA December 18th Options Trading
2015-04-01,Servier Initiates Phase 2 Study Of Gevokizumab In Patients With Diabetic Nephropathy
2015-03-25,First Week Of May 15th Options Trading For XOMA
2015-03-24,4 Biotech Stocks Under $10 to Trade for Breakouts
2015-03-23,XOMA (XOMA): Today's Weak On High Volume Stock
2015-03-17,4 Stocks Under $10 Making Big Moves Into Breakout Territory
2015-03-11,XOMA Highlights Recent Achievements And Reports Fourth Quarter And Full-Year 2014 Financial Results
2015-03-10,4 Stocks Under $10 to Trade for Big Breakouts
2015-03-07,XOMA Presents Positive Phase 1 XOMA 358 Data At The ENDO Meeting
2015-03-05,XOMA Will Present XOMA 358 Phase 1 Data At ENDO 2015
2015-03-03,XOMA Announces Retirement Of Fred Kurland And Appointment Of Thomas Burns As Chief Financial Officer
2015-02-26,XOMA To Announce Fourth Quarter And Full Year 2014 Financial Results And Host Webcast On March 11
2015-02-24,First Week Of April 17th Options Trading For XOMA
2015-02-18,XOMA To Present At Upcoming Investor Conferences
2015-01-23,First Week Of September 18th Options Trading For XOMA
2015-01-23,XOMA (XOMA) Weak On High Volume
2015-01-06,Stock To Watch: XOMA (XOMA) In Perilous Reversal
2014-12-24,XOMA (XOMA) Is Today's Dead Cat Bounce Stock
2014-12-09,Today's Perilous Reversal Stock: XOMA (XOMA)
2014-12-09,XOMA Announces Pricing Of $40.0 Million Registered Offering Of Common Stock And Warrants
2014-12-05,Strong On High Relative Volume: XOMA (XOMA)
2014-12-03,XOMA (XOMA) Stock: Weak On High Volume Today
2014-11-24,XOMA To Present At The Piper Jaffray Healthcare Conference
2014-11-20,Trade-Ideas: XOMA (XOMA) Is Today's Strong On High Relative Volume Stock
2014-11-17,Interesting XOMA Call Options For January 2017
2014-11-10,XOMA To Present At Upcoming Investor Conferences
2014-11-07,XOMA (XOMA) Stock: Weak On High Volume Today
2014-11-06,XOMA Highlights Recent Achievements And Reports Financial Results For The Third Quarter Of 2014
2014-11-04,XOMA Initiates Pivotal Phase 3 Gevokizumab Study In Patients With Pyoderma Gangrenosum
2014-10-27,XOMA To Announce Third Quarter 2014 Financial Results And Host Webcast On November 6
2014-10-09,XOMA Launches XOMA 358 Clinical Development
2014-10-06,The Texas A&M University System And XOMA License Innovative Manufacturing Technology
2014-09-30,XOMA Initiates U.S. Clinical Trial Of Gevokizumab In Patients With Behcet's Disease Uveitis - EYEGUARD(TM)-US
2014-09-12,4 Under-$10 Stocks to Trade for Breakouts
2014-08-27,3 Stocks Under $10 Making Big Moves
2014-08-26,Your September Biotech Back-to-School Calendar
2014-08-19,First Week of October 18th Options Trading For XOMA
2014-08-15,4 Under-$10 Stocks Making Big Moves
2014-08-11,5 Stocks Ready for Breakouts
2014-08-07,XOMA Highlights Recent Achievements And Reports Financial Results For Second Quarter 2014
2014-08-06,XOMA To Present At Two Upcoming Investor Conferences
2014-07-30,XOMA To Announce Second Quarter 2014 Financial Results And Host Webcast On August 7
2014-07-22,First Week of March 2015 Options Trading For XOMA
2014-07-11,XOMA Corp Stock Sees Short Interest Drop 27.6%
2014-07-02,4 Biotech Stocks Under $10 to Watch for Breakout Trades
2014-06-30,XOMA Call Today At 4:30pm ET/1:30pm PT To Confirm Communication Plan For EYEGUARD(TM)-B Clinical Program
2014-06-24,Interesting XOMA Put And Call Options For August 16th
2014-06-13,3 Stocks Under $10 in Breakout Territory
2014-05-28,XOMA To Present At The Jefferies Global Healthcare Conference
2014-05-22,5 Stocks Under $10 Set to Soar
2014-05-19,Taking a Cautious Dose of Small Biotech
2014-05-16,Insider Trading Alert - ITMN, WAC And XOMA Traded By Insiders
2014-05-12,XOMA To Present At The Bank Of America Merrill Lynch Health Care Conference
2014-05-07,XOMA Reports First Quarter 2014 Operational Highlights And Financial Results
2014-04-30,XOMA To Announce First Quarter 2014 Financial Results And Host Webcast On May 7
2014-04-29,Why XOMA (XOMA) Stock Is Surging Today
2014-04-28,XOMA Finalizes Plans For Gevokizumab Phase 3 Clinical Program In Pyoderma Gangrenosum
2014-04-22,First Week of December 20th Options Trading For XOMA
2014-04-15,The Recent Performance of 'Baker Brother Biotech Stocks' is Awful
2014-03-21,Insider Trading Alert - SFY, XOMA And SNI Traded By Insiders
2014-03-07,XOMA Corp Stock Downgraded (XOMA)
2014-03-06,July 19th Options Now Available For XOMA
2014-03-06,XOMA (XOMA) Marked As A Dead Cat Bounce Stock
2014-03-05,Ratings Changes Today
2014-03-05,Why XOMA Corporation (XOMA) Is Plunging Today
2014-03-05,XOMA (XOMA) Showing Signs Of Perilous Reversal Today
2014-03-04,XOMA Reports 2013 Operational Highlights And Fourth Quarter And Full-Year 2013 Financial Results
2014-03-04,XOMA Provides Update On Gevokizumab Proof-of-Concept Program
2014-02-25,First Week of XOMA April 19th Options Trading
2014-02-24,XOMA Receives Orphan Drug Designation From U.S. FDA For Pyoderma Gangrenosum
2014-02-20,XOMA To Present At Upcoming Investor Conferences
2014-01-22,Interesting XOMA Put And Call Options For September 20th
2014-01-11,'Mad Money' Lightning Round: I Don't Like Amgen
2014-01-10,Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
2013-12-26,Short Interest In XOMA Drops 19.7%
2013-12-18,XOMA Announces Closing Of The Offering And Exercise Of Option
2013-12-16,Today's Dead Cat Bounce Stock Is XOMA (XOMA)
2013-12-13,XOMA Announces Pricing Of Approximately $50.0 Million Offering Of Common Stock
2013-12-12,XOMA Announces Proposed Public Offering Of Common Stock
2013-12-05,Ratings Changes Today
2013-11-26,XOMA To Present At The Piper Jaffray Healthcare Conference
2013-11-20,XOMA Awarded Key Flexible Manufacturing Patent
2013-11-19,First Week Of January 2014 Options Trading For XOMA
2013-11-18,Why I Remain Bullish On EZchip Semiconductor
2013-11-11,XOMA January 2016 Options Begin Trading
2013-11-08,Interesting XOMA Put And Call Options For January 2015
2013-11-07,XOMA Highlights Recent Achievements And Reports Financial Results For Third Quarter 2013
2013-11-06,XOMA To Present At The Credit Suisse Healthcare Conference
2013-10-31,XOMA To Announce Third Quarter 2013 Financial Results And Host Webcast On November 7
2013-10-30,Results From Two Phase 2 Studies In XOMA's Gevokizumab Proof-of-Concept Program Are Very Encouraging And Compelling
2013-10-25,Short Interest In XOMA Falls 31.6%
2013-10-25,5 Biotech Stocks Under $10 for Your Watch List
2013-10-01,Interesting XOMA Call For November 16th
2013-09-05,XOMA To Present At The Morgan Stanley Healthcare Conference
2013-08-23,XOMA Announces Closing Of The Offering And Exercise Of Over-Allotment Option
2013-08-20,XOMA Announces Pricing Of $27.5 Million Offering Of Common Stock
2013-08-08,XOMA To Present At Two Upcoming Investor Conferences
2013-08-07,XOMA Highlights Recent Achievements And Reports Financial Results For Second Quarter 2013
2013-07-25,XOMA To Announce Second Quarter 2013 Financial Results And Host Webcast On August 7
2013-07-22,XOMA Completes Enrollment In Phase 2 Proof-of-Concept Gevokizumab Trial In Patients With Erosive Osteoarthritis Of The Hand
2013-07-14,Sizing Up My Small Cap Strategy
2013-07-12,Short Interest Moves 10.7% Lower For XOMA
2013-07-03,XOMA Transfers Perindopril Franchise Rights To Symplmed
2013-07-02,XOMA To Present At The JMP Securities Healthcare Conference
2013-06-25,XOMA's Development Partner SERVIER Launches Proof-of-Concept Clinical Program For Gevokizumab
2017-03-15,Zogenix To Participate In The Oppenheimer 27th Annual Healthcare Conference
2017-03-13,August 18th Options Now Available For Zogenix (ZGNX)
2017-03-10,Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix
2017-03-09,Zogenix Provides Corporate Update And Reports Fourth Quarter And Full-Year 2016 Financial Results
2017-03-02,Zogenix To Release Fourth Quarter And Full-Year 2016 Financial Results And Host Conference Call And Webcast On March 9
2017-03-01,Zogenix Receives Orphan Drug Designation In The European Union For ZX008 In Lennox Gastaut Syndrome
2017-02-17,Notable Friday Option Activity: ZGNX, EPM, STZ
2017-02-15,Zogenix To Participate In The 2017 RBC Capital Markets Healthcare Conference
2017-02-13,Zogenix Announces Initiation Of Clinical Efficacy Portion Of Study 1504 For ZX008 In Dravet Syndrome
2017-02-08,Zogenix To Participate In The Leerink Partners 6th Annual Global Healthcare Conference
2017-02-02,These 5 Stocks Under $10 Could Light Up Soon
2017-01-30,Zogenix Announces Issuance Of U.S. Patent For ZX008 In Dravet Syndrome
2017-01-05,Zogenix Announces CFO Transition
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2016-12-05,Zogenix Announces New Efficacy And Safety Data For ZX008 In Treatment Of Seizures In Lennox Gastaut Syndrome & Dravet Syndrome
2016-11-22,New Data On Zogenix's ZX008 For Lennox Gastaut Syndrome & Dravet Syndrome To Be Presented At 70th Annual American Epilepsy Society Meeting
2016-11-22,Zogenix To Participate In Oppenheimer Life Sciences Summit 2016
2016-11-08,Depomed Reports Dip in Earnings, Reduces Revenue Guidance
2016-11-08,Zogenix To Participate In Stifel 2016 Healthcare Conference
2016-11-07,Zogenix Provides Corporate Update And Reports Third Quarter 2016 Financial Results
2016-10-31,Zogenix To Release Third Quarter 2016 Financial Results And Host Conference Call And Webcast On November 7
2016-10-12,Humana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday
2016-09-20,Zogenix To Participate In Two Upcoming Investor Conferences
2016-09-08,Zogenix To Have Significant Presence At 12th European Congress On Epileptology
2016-08-09,Zogenix Provides Corporate Update And Reports Second Quarter 2016 Financial Results
2016-08-02,Zogenix To Release Second Quarter 2016 Financial Results And Host Conference Call And Webcast On August 9
2016-07-13,Commit To Buy Zogenix At $5, Earn 9.6% Annualized Using Options
2016-06-27,Zogenix Becomes Oversold (ZGNX)
2016-06-21,Zogenix Announces Agreement To Refinance Debt, Further Increasing Company's Expected 2017 Cash Balance
2016-06-07,Zogenix Announces Initiation Of Multi-National Phase 3 Clinical Trial For ZX008 In Dravet Syndrome
2016-05-31,Zogenix To Participate In Jefferies 2016 Healthcare Conference
2016-05-10,Zogenix Provides Corporate Update And Reports First Quarter 2016 Financial Results
2016-05-05,Zogenix Announces New Efficacy And Safety Data On ZX008 For Treatment Of Seizures In Dravet Syndrome
2016-05-03,Zogenix To Release First Quarter 2016 Financial Results And Host Conference Call And Webcast On May 10
2016-04-21,New Data On Zogenix's ZX008 For Dravet Syndrome To Be Presented At 14th International Child Neurology Congress
2016-03-17,ZGNX: Insiders vs. Shorts
2016-03-17,Zogenix (ZGNX): Today's Weak On High Volume Stock
2016-03-10,Zogenix Provides Corporate Update And Reports Fourth Quarter And Full-Year 2015 Financial Results
2016-03-04,Zogenix To Release Fourth Quarter And Full-Year 2015 Financial Results And Host Conference Call And Webcast On March 10
2016-02-03,Zogenix To Participate In LEERINK Partners 5th Annual Global Healthcare Conference
2016-01-19,Zogenix Receives Fast Track Designation From FDA For Development Of ZX008 In Dravet Syndrome
2016-01-11,Commit To Buy Zogenix At $8, Earn 23.1% Using Options
2016-01-11,Zogenix Announces Initiation Of Phase 3 Program For ZX008 In Dravet Syndrome
2015-12-17,Insider Trading Alert - SCVL, ZGNX And FRME Traded By Insiders
2015-12-14,Zogenix Announces FDA Acceptance Of Investigational New Drug Application For ZX008 Phase 3 Clinical Trial In Dravet Syndrome
2015-12-09,Insider Trading Alert - RNST, AMPH And ZGNX Traded By Insiders
2015-12-07,Zogenix Announces New Efficacy And Safety Data On ZX008 For Treatment Of Seizures In Dravet Syndrome
2015-11-25,New Data On Zogenix's ZX008 For Dravet Syndrome To Be Presented At 69th Annual American Epilepsy Society Meeting
2015-11-11,Zogenix To Participate In Stifel 2015 Healthcare Conference
2015-11-09,Zogenix Provides Corporate Update And Reports Third Quarter 2015 Financial Results
2015-11-02,Zogenix To Release Third Quarter 2015 Financial Results And Host Conference Call & Webcast On November 9
2015-10-19,Zogenix Provides Regulatory Update For ZX008
2015-10-09,A Small Pharma Stock With Big Potential
2015-10-09,5 Stocks Ready for Breakouts
2015-09-30,Zogenix Reports Positive Top-Line Results From Relday(TM) Phase 1b Multi-Dose Clinical Trial
2015-09-23,Zogenix To Participate In The Leerink Partners 4th Annual Rare Disease Roundtable
2015-09-17,Fed's Non-Move Causes Whipsaw Action
2015-09-03,Zogenix To Participate In The Wells Fargo 2015 Healthcare Conference
2015-08-11,Ratings Changes Today
2015-08-10,Zogenix Provides Corporate Update And Reports Second Quarter 2015 Financial Results
2015-08-05,Zogenix Announces Closing Of Public Offering Of Common Stock, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-08-03,Zogenix To Release Second Quarter 2015 Financial Results And Host Conference Call & Webcast On August 10
2015-07-30,Pre-Market Activity Shows Heavy Volume And Movement For Zogenix (ZGNX)
2015-07-30,Zogenix Prices Public Offering Of Common Stock
2015-07-28,Zogenix Announces Proposed Public Offering Of 3,800,000 Shares Of Common Stock
2015-07-16,Zogenix (ZGNX) Flagged As Strong On High Volume
2015-07-07,Zogenix To Host Key Opinion Leader Meeting Tuesday, July 14, In New York City
2015-07-06,Zogenix Expands Senior Leadership Team To Further Drive Strategic Focus On CNS Disorders And Orphan Drug Development
2015-07-06,Zogenix To Participate In Cantor Fitzgerald Healthcare Conference
2015-07-02,Today's Weak On High Volume Stock: Zogenix (ZGNX)
2015-06-29,Ratings Changes Today
2015-06-26,5 Stocks Ready for Breakouts
2015-06-25,Zogenix (ZGNX) Flagged As Strong On High Volume
2015-06-18,Zogenix Announces Shareholders And Board Of Directors Approve Reverse Stock Split
2015-05-29,Strong On High Volume: Zogenix (ZGNX)
2015-05-27,Zogenix Announces New Efficacy Data From A Long-Term Study Of Low-Dose Fenfluramine For Treatment Of Dravet Syndrome
2015-05-11,Zogenix Provides Corporate Update And Reports First Quarter 2015 Financial Results
2015-05-04,Zogenix To Release First Quarter 2015 Financial Results And Host Conference Call & Webcast On May 11
2015-04-27,Dr. Stephen Farr Appointed As CEO Of Zogenix To Lead New Strategic Focus And Advance Late-Stage CNS Product Pipeline
2015-04-24,Zogenix Closes Sale Of Zohydro(R) ER Business To Pernix
2015-04-02,Interesting ZGNX Put And Call Options For January 2017
2015-03-26,Zogenix Announces First Patient Dosed In Relday Multi-Dose Clinical Study
2015-03-21,Betting the Underdog Can Be Profitable
2015-03-12,How to Trade the Market's Most-Active Stocks
2015-03-11,Stocks Struggle to Recover but Fed Rate Hike Worries Persist
2015-03-11,Stocks Trying -- and Failing -- to Recover From Tuesday's Brutal Selloff
2015-03-11,Stocks Mixed as Crude Supplies Climb More Than Forecast
2015-03-11,Zogenix (ZGNX) Stock Declines Today Following Sale of Zohydro
2015-03-11,Zogenix (ZGNX) Highlighted As Weak On High Volume
2015-03-11,Stock Futures Prepare to Bounce Back After Tuesday's Selloff
2015-03-10,Zogenix Announces Agreement Of Sale Of Zohydro(R) ER Business To Pernix For $100 Million At Closing Plus Potential Milestones Of $283.5 Million
2015-03-10,Zogenix Reports Fourth Quarter And Full Year 2014 Financial Results
2015-03-02,Zogenix Announces Conference Call And Webcast To Present Fourth Quarter And Full Year 2014 Financial Results
2015-02-10,Zogenix Appoints Industry Veteran Renee Tannenbaum To Its Board Of Directors
2015-02-06,Zogenix an Odd Winner at the Ballot Box
2015-02-05,Zogenix To Participate In Leerink Global Healthcare Conference
2015-02-02,Zogenix (ZGNX) Stock Rises Today on Zohydro FDA Approval
2015-01-30,Zogenix Receives FDA Approval Of New Formulation Of Zohydro(R) ER
2015-01-12,Zogenix Provides Business Update
2014-12-30,Zogenix (ZGNX) Stock Gets a Boost Today From This Coverage Initiation
2014-12-03,Zogenix To Participate In Oppenheimer 25th Annual Healthcare Conference
2014-12-01,Results Of Long-Term, Open-Label Study Published In The Journal Of Pain Research Demonstrate The Safety, Tolerability And Effectiveness Of Zohydro(R) ER
2014-11-14,Shotgun Investing in Biotech
2014-11-12,Zogenix To Participate In Stifel 2014 Healthcare Conference
2014-11-06,Zogenix Reports Third Quarter 2014 Financial Results
2014-10-31,Zogenix And Purdue Pharma Exchange Waivers Of Regulatory Exclusivity For Extended-Release Hydrocodone Products
2014-10-30,Zogenix Announces Conference Call And Webcast To Present Third Quarter 2014 Financial Results
2014-10-27,Zogenix Acquires U.K.-Based Brabant Pharma
2014-10-03,5 Breakout Stocks Under $10 Set to Soar
2014-10-01,Zogenix Submits Modified Formulation Of Zohydro(R) ER With Potential Abuse Deterrent Properties For FDA Review
2014-09-18,New Data Shows Zohydro(R) ER Reduced Pain And Improved Function In People With Chronic Pain
2014-09-04,Education, Patient-Focused Approach To Treating Chronic Pain Are Keys To Preventing Opioid Abuse, Say Experts, Patients
2014-09-02,Zogenix To Participate In Morgan Stanley Global Healthcare Conference 2014
2014-09-02,Zohydro(R) ER Demonstrates Sustained 12-Hour Pain Relief
2014-08-19,First Week of April 2015 Options Trading For Zogenix (ZGNX)
2014-08-12,Zogenix Stock Sees Short Interest Move 13% Higher
2014-08-05,Zogenix Reports Second Quarter 2014 Financial Results
2014-08-01,Zogenix Announces Departure Of Chief Commercial Officer, Scott Shively
2014-07-22,Zogenix Announces Conference Call And Webcast To Present Second Quarter 2014 Financial Results
2014-07-17,Zogenix Announces Appointment Of David Brushwood, J.D., R.Ph., To External Safe Use Board
2014-07-14,Zogenix Announces New Patent Valid Through 2032 For DosePro(R) Needle-Free Delivery System
2014-07-09,Zogenix Reports Positive Development On U.S. District Court Ruling
2014-07-08,Why Zogeniz (ZGNX) Stock Is Tumbling Today
2014-07-02,Zogenix Provides Update On Development Of Abuse Deterrent Formulations Of Zohydro(R) ER
2014-06-16,Zogenix To Present At Two Upcoming Conferences
2014-06-02,Zogenix Reports Granting Of Inducement Awards
2014-06-02,Zogenix Officers To Report Withholding Of Shares
2014-05-30,Zogenix To Present At Jefferies 2014 Global Healthcare Conference
2014-05-19,Zogenix Closes Sale Of SUMAVEL(R) DosePro(R) Migraine Therapy To Endo International
2014-05-08,Zogenix Reports First Quarter 2014 Financial Results
2014-05-02,Zogenix Reports Granting Of Inducement Awards
2014-04-30,Zogenix Announces Conference Call And Webcast To Present First Quarter 2014 Financial Results
2014-04-24,Zogenix Announces Sale Of SUMAVEL(R) DosePro(R) Migraine Therapy To Endo International
2014-04-23,First Week of ZGNX June 21st Options Trading
2014-04-17,Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings
2014-04-16,Why Zogenix (ZGNX) Stock is Up Today
2014-04-11,Let's Get The Facts Straight About Zohydro&#8482; ER--and The Important Patient Need It Fills
2014-04-08,Zogenix Update On Legal Action
2014-04-07,Zogenix Takes Legal Action In Federal Court To Block Massachusetts Improper Ban On Zohydro&#8482; ER
2014-04-04,FDA, HHS Reaffirm Support For Chronic Pain Patients Amid Zohydro ER Debate
2014-04-02,Zogenix Statement: Let's Get The Facts Straight About Zohydro ER
2014-04-02,Zogenix Reports Granting Of Inducement Awards
2014-03-27,Zogenix Statement: Massachusetts Denies Patients A Legitimate Option For Severe Chronic Pain
2014-03-27,First Week Of May 17th Options Trading For Zogenix (ZGNX)
2014-03-26,Zogenix Appoints James Breitmeyer To Its Board Of Directors
2014-03-14,Why Zogenix (ZGNX) Is Down Today
2014-03-13,Why Zogenix (ZGNX) Is Down In After Market Close
2014-03-13,Why Zogenix (ZGNX) Is Up Today
2014-03-12,Why Zogenix (ZGNX) Is Down Big Today
2014-03-12,Perilous Reversal Stock: Zogenix (ZGNX)
2014-03-07,Trade-Ideas: Zogenix (ZGNX) Is Today's "Dead Cat Bounce" Stock
2014-03-07,Dr. Marsha Stanton Receives 2014 American Academy Of Pain Medicine Distinguished Service Award
2014-03-06,'Mad Money' Lightning Round: Steer Clear of Tesla
2014-03-05,Jim Cramer's 'Mad Money' Recap: Beware the Bears
2014-03-05,Zogenix Reports Fourth Quarter And Full Year 2013 Financial Results
2014-03-05,Zogenix Reports Granting Of Inducement Awards
2014-02-27,Zogenix Announces Conference Call And Webcast To Present Fourth Quarter And Full Year 2013 Financial Results
2014-02-26,First Week of ZGNX October 18th Options Trading
2014-02-13,Data From Zohydro(TM) ER (hydrocodone Bitartrate) Phase 3 Clinical Trial Published In Pain Medicine Demonstrates Its Benefit As A Therapeutic Option For The Management Of Pain Severe Enough To Require Daily, Around-the-Clock, Long-Term Opioid Treatment And For Which Alternative Treatment Options Are Inadequate
2014-02-12,Zogenix Establishes External Safe-Use Board
2014-02-11,Zogenix Provides Update On Zohydro(TM) ER (hydrocodone Bitartrate) Launch Readiness Plans
2014-02-06,5 Stocks Under $10 Set to Soar
2014-02-04,Zogenix To Present At Leerink Swann 2014 Global Healthcare Conference
2014-02-04,Zogenix Reports Granting Of Inducement Awards
2014-01-23,First Week Of ZGNX March 22nd Options Trading
2014-01-13,Zogenix Announces Preliminary Fourth Quarter 2013 Gross Product Sales
2014-01-09,Zogenix And Mallinckrodt Agree To End Co-Promotion For SUMAVEL(R) DosePro(R) Effective January 31, 2014
2014-01-07,Zogenix Reports Granting Of Inducement Awards
2013-12-26,Zogenix Stock Sees Short Interest Jump 12.5%
2013-12-20,Zogenix Reports Granting Of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2013-12-17,Zogenix Appoints Chief Medical Officer And Expands Medical Leadership Team
2013-12-11,Zogenix Reports Granting Of Inducement Awards
2013-12-10,Zogenix Announces FDA Approval Of 4 Mg SUMAVEL(R) DosePro(R) (sumatriptan Injection) Needle-Free Delivery System
2013-12-04,Zogenix To Present At The Oppenheimer 24th Annual Healthcare Conference
2013-12-03,Zogenix And Battelle Expand DosePro Technology Business Agreement
2013-11-27,4 Stocks Under $10 Making Big Moves
2013-11-12,Zogenix Announces Closing Of Public Offering Of Common Stock, Including Full Exercise Of Over-Allotment Option By Underwriters
2013-11-05,Zogenix Prices Public Offering Of Common Stock
2013-11-04,Zogenix Announces Proposed Public Offering Of Common Stock
2013-11-04,Zogenix Reports Third Quarter 2013 Financial Results
2017-03-22,Zosano Announces Closing Of Public Offering Of Common Stock And Exercise Of Underwriters' Over-Allotment Option
2017-03-17,Zosano Announces Pricing Of Public Offering Of Common Stock
2017-03-01,Zosano Pharma Reports Fourth Quarter And Fiscal 2016 Financial Results And Business Update
2017-02-13,Fear of Missing Out Is Building
2017-02-13,Zosano Pharma Announces 3.8mg Dose Of M207, Its Novel Transdermal Therapeutic, Meets Both Co-primary Endpoints In The ZOTRIP Pivotal Efficacy Trial In Migraine
2017-01-31,Trading Action Has Improved, Here's What I Am Playing
2017-01-23,Zosano Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2017-01-05,Zosano Pharma Announces Last Subject Treated In Its Migraine Pivotal Trial
2016-11-22,Zosano Pharma Announces Sale Of Non-Strategic Asset
2016-11-09,Zosano Pharma Reports Third Quarter 2016 Financial Results
2016-11-08,Zosano Pharma Announces Completion Of Enrollment In Pivotal Efficacy Trial For M207 For Acute Migraine
2016-09-09,Zosano Announces Inducement Grant For Georgia Erbez, Chief Business Officer
2016-09-08,Zosano Appoints Georgia Erbez As Chief Business Officer
2016-08-31,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Shareholders of Zosano Pharma Corporation - ZSAN
2016-08-26,ALERT: Rosen Law Firm Continues To Investigate Securities Claims Against Zosano Pharma Corporation
2016-08-16,Zosano Pharma Announces Pricing Of Private Placement Of Common Stock And Warrants
2016-08-10,Zosano Pharma Reports Second Quarter 2016 Financial Results
2016-07-25,First Subject Treated In Zosano Pharma's Pivotal Efficacy Trial For M207 Patch For Acute Migraine
2016-06-17,Zosano Pharma Enrolls First Subject In Pivotal Clinical Trial For ZP-Triptan Patch Program For Treatment Of Migraine
2016-05-17,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Zosano Pharma Corporation (ZSAN)
2016-05-12,INVESTOR ALERT: Investigation Of Zosano Pharma Corporation Announced By The Law Firm Goldman Scarlato & Penny, P.C.; Investors Encouraged To Contact The Firm
2016-05-12,Zosano Pharma Reports First Quarter 2016 Financial Results
2016-05-09,Zosano Announces Appointment Of John P. Walker As Chairman Of The Board
2016-05-02,Zosano Pharma To Report First Quarter 2016 Financial Results
2016-04-15,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Shareholders Of Zosano Pharma Corporation - ZSAN
2016-04-15,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Violations Of Federal Securities Laws By The Board Of Zosano Pharma Corporation -- ZSAN
2016-04-14,EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Zosano Pharma Corporation
2016-04-14,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Zosano Pharma Corporation (ZSAN)
2016-04-08,ZOSANO NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Zosano Pharma Corporation To Contact The Firm
2016-04-08,IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Claims Against Zosano Pharma Corporation And Advises Investors With Losses To Contact The Firm
2016-04-07,Scott + Scott, LLP Announces Investigation Of Zosano Pharma Corp (ZSAN), Encourages Investors With Losses To Contact Firm
2016-03-29,Zosano Pharma Reports Fourth Quarter And 2015 Financial Results And Business Update
2016-03-21,Zosano Pharma To Report Fourth Quarter And 2015 Financial Results and To Provide A Corporate Update
2016-03-09,Zosano Pharma To Present At The 28th Annual ROTH Conference
2016-03-01,Ratings Changes Today
2016-02-25,Lifshitz & Miller Law Firm Announces Investigation Of Ashford Hospitality Prime, Inc., Cobalt International Energy, Inc., Inovalon Holdings, Inc., Ooma, Inc., OvaScience, Inc., Swift Transportation Company, And Zosano Pharma Corporation
2016-02-09,INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Violations Of Federal Securities Laws By The Board Of Zosano Pharma Corporation -- ZSAN
2016-02-09,ZOSANO PHARMA SHAREHOLDER ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Continues Its Investigation Of Zosano Pharma Corporation; Encourages Investors To Contact The Firm For Information Concerning Their Legal Rights
2016-01-21,Harwood Feffer LLP Announces Investigation Of Zosano Pharma Corporation
2016-01-21,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Violations Of Federal Securities Laws By The Board Of Zosano Pharma Corporation
2016-01-20,Robbins Arroyo LLP Is Investigating The Officers And Directors Of Zosano Pharma Corporation (ZSAN) On Behalf Of Shareholders
2016-01-07,Zosano Pharma Announces Appointment Of Konstantinos Alataris, Ph.D. As President And Chief Executive Officer
2016-01-06,ZOSANO PHARMA SHAREHOLDER ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation Of Zosano Pharma Corporation; Encourages Investors To Contact The Firm For Information Concerning Their Legal Rights
2015-11-10,Zosano Pharma To Present At The Stifel 2015 Healthcare Conference
2015-11-09,Zosano Pharma Reports Third Quarter 2015 Financial Results
2015-11-03,Zosano Pharma To Announce Third Quarter 2015 Financial Results, Host Conference Call And Live Webcast On November 9, 2015
2015-11-02,Zosano Pharma Announces Positive Phase 1 Results For Its ZP-Triptan Patch Program For Treatment Of Migraine
2015-10-13,Zosano Pharma Announces Positive Phase 2 Results For Its ZP-Glucagon Patch Program For Treatment Of Severe Hypoglycemia
2015-09-28,Zosano Pharma Resumes Development Of Weekly ZP-PTH Treatment For Severe Osteoporosis
2015-09-23,Zosano Pharma To Present At The Ladenburg Thalmann 2015 Healthcare Conference
2015-09-08,Zosano Pharma Announces New Executive Appointment And Management Change
2015-09-01,Zosano Pharma Completes Enrollment In Phase 1 Study For Microneedle Patch Delivery Of Zolmitriptan For The Treatment Of Migraine
2015-08-12,Zosano Pharma Reports Second Quarter 2015 Financial Results
2015-07-13,Zosano Pharma Expands Clinical & Regulatory Teams With Three Strategic Hires
2015-07-06,Zosano Pharma Announces Discontinuation Of Novo Nordisk GLP-1 Patch Collaboration
2015-06-29,Zosano Pharma To Present At The Cantor Fitzgerald Inaugural Healthcare Conference
2015-06-29,Zosano Announces $15 Million Debt Financing
2015-06-23,Zosano Pharma Completes Enrollment In Phase 2 Trial For ZP-Glucagon, Its Microneedle Patch For Treatment Of Severe Hypoglycemia
2015-05-27,Zosano Pharma Appoints Joseph P. Hagan To Board Of Directors
2015-05-11,Zosano Pharma Reports First Quarter 2015 Financial Results
2015-04-30,Zosano Pharma Appoints New CMO, Fills Two New Operations Management Positions To Bolster Leadership Team
2015-03-25,Zosano Pharma Reports 2014 Financial Results
2015-03-03,Zosano Pharma To Present At The 27th Annual ROTH Conference
2015-01-27,Zosano Pharma Announces Pricing Of Initial Public Offering
,
,
,
